FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Joubert, C
   Monchal, T
   Junca-Laplace, C
   Sellier, A
   Beucler, N
   Fesselet, J
   Balandraud, P
   Dagain, A
AF Joubert, Christophe
   Monchal, Tristan
   Junca-Laplace, Camille
   Sellier, Aurore
   Beucler, Nathan
   Fesselet, Jacques
   Balandraud, Paul
   Dagain, Arnaud
TI Management of Chyloretroperitoneum After Lumbar Surgery by Anterior
   Approach
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior approach; Chyloretroperitoneum; Computed tomography-guided
   drainage; Laparoscopic fenestration; Lumbar spine; Lymphocele
ID INTERBODY FUSION; RETROPERITONEAL LYMPHOCELE; CATHETER DRAINAGE; CHYLOUS
   LEAKAGE; POVIDONE-IODINE; SPINAL SURGERY; SCLEROTHERAPY; SCLEROSIS;
   DIAGNOSIS; REVISION
AB BACKGROUND: Anterior lumbar approach, routinely used in spinal surgery, provides many advantages, specifically avoidance of manipulation and potential injury to nervous system structures; it also provides indirect central and foramina! decompression, with a complication rate of 1%-3%. Chyloretroperitoneum is a rare complication of spinal procedures using anterior lumbar approach. The aim of this study was to discuss diagnosis, treatment, and management of chyloretroperitoneum based on review of the international literature through 2017.
   METHODS: The literature review was conducted using the terms "chyloretroperitoneum," "spinal surgery," and "Iymphocele." Additionally, an illustrative case of chyloretroperitoneum following anterior retroperitoneal lumbar approach was presented,
   RESULTS: In 33 cases, including the present case, clinical symptoms appeared after discharge in 75.8% = 25) and reflected direct mass effect. Abdominopelvic computed tomography permitted assessment of the fluid collection observed as a hypodense collection around the psoas muscle. In 24 cases, drainage of the chyloretroperitoneum was maintained for a mean duration of 2.9 days. Surgery vitas performed in 14 patients (42.4%) owing to lymphatic collection. In 5 cases, surgery was performed for direct lymphatic vessel treatment. Laparoscopic marsupialization of the collection and peritoneal fenestration were performed, especially after percutaneous drainage failure,
   CONCLUSIONS: Computed tomography was the most useful imaging modality for diagnosis and assessment of associated complications. If puncture alone is not sufficient and should be avoided, percutaneous computed tomography guided drainage with sclerosing agent administration appears to be a safe and efficient first-line treatment. Laparoscopic fenestration should be used in cases of complicated or recurrent lymphoceles.
C1 [Joubert, Christophe; Sellier, Aurore; Beucler, Nathan; Fesselet, Jacques; Dagain, Arnaud] St Anne Mil Hosp, Dept Neurosurg, Toulon, France.
   [Monchal, Tristan; Balandraud, Paul] St Anne Mil Hosp, Dept Oncol & Gen Surg, Toulon, France.
   [Junca-Laplace, Camille] St Anne Mil Hosp, Dept Radiol, Toulon, France.
   [Balandraud, Paul; Dagain, Arnaud] Ecole Val De Grace, French Mil Hlth Serv Acad, Paris, France.
RP Joubert, C (reprint author), St Anne Mil Hosp, Dept Neurosurg, Toulon, France.
EM christophe.joubert@neurochirurgie.fr
OI Sellier, Aurore/0000-0003-2655-8515
CR Akhan O, 2007, CARDIOVASC INTER RAD, V30, P237, DOI 10.1007/s00270-006-0180-y
   Alago W, 2013, CARDIOVASC INTER RAD, V36, P466, DOI 10.1007/s00270-012-0375-3
   Allain J, 2011, ORTHOP TRAUMATOL-SUR, V97, P541, DOI 10.1016/j.otsr.2011.06.003
   Atray NK, 2004, CLIN TRANSPLANT, V18, P46, DOI 10.1111/j.1399-0012.2004.00217.x
   Bateman DK, 2015, SPINE J, V15, P1118, DOI 10.1016/j.spinee.2015.02.040
   Bhat A L, 1997, Eur Spine J, V6, P270, DOI 10.1007/BF01322450
   Bryant AS, 2014, ANN THORAC SURG, V98, P232, DOI 10.1016/j.athoracsur.2014.03.003
   Cannon L, 1997, EUR J VASC ENDOVASC, V14, P505, DOI 10.1016/S1078-5884(97)80133-5
   Ching KC, 2014, CARDIOVASC INTER RAD, V37, P1103, DOI 10.1007/s00270-013-0811-z
   Clemens RKJ, 2012, VASA, V41, P149, DOI 10.1024/0301-1526/a000179
   Cordes BM, 2007, OTOLARYNG HEAD NECK, V137, P962, DOI 10.1016/j.otohns.2007.08.013
   Czerwein JK, 2011, J AM ACAD ORTHOP SUR, V19, P251, DOI 10.5435/00124635-201105000-00002
   DEHART MM, 1994, SPINE, V19, P716
   Ghezzi F, 2012, ANN SURG ONCOL, V19, P259, DOI 10.1245/s10434-011-1854-5
   Hanson D, 1998, SPINE, V23, P956, DOI 10.1097/00007632-199804150-00023
   Hey HWD, 2017, EUR SPINE J, V26, pS36, DOI 10.1007/s00586-016-4678-y
   Hsieh PC, 2007, J NEUROSURG-SPINE, V7, P379, DOI 10.3171/SPI-07/10/379
   Hussain NS, 2012, J NEUROSURG-SPINE, V17, P415, DOI 10.3171/2012.8.SPINE12243
   Jagannathan J, 2008, SPINE, V33, pE852, DOI 10.1097/BRS.0b013e3181891791
   Karcaaltincaba M, 2005, EUR J RADIOL, V55, P340, DOI 10.1016/j.ejrad.2005.03.007
   Kerlan RK, 1997, J VASC INTERV RADIOL, V8, P885, DOI 10.1016/S1051-0443(97)70678-X
   Khoueir P, 2008, NEUROSURGERY, V63, pA117, DOI 10.1227/01.NEU.0000320385.27734.CB
   Kim Y, 2017, TAIWAN J OBSTET GYNE, V56, P477, DOI 10.1016/j.tjog.2016.10.002
   Landmann E, 2006, J PEDIATR-US, V149, P425, DOI 10.1016/j.jpeds.2006.05.034
   Lee EW, 2014, KOREAN J RADIOL, V15, P724, DOI 10.3348/kjr.2014.15.6.724
   Lehman RA, 2011, SPINE J, V11, P684, DOI 10.1016/j.spinee.2011.05.012
   Leibovitch I, 2002, J UROLOGY, V167, P449, DOI 10.1016/S0022-5347(01)69064-5
   Levi ADO, 1999, NEUROSURGERY, V45, P658, DOI 10.1097/00006123-199909000-00047
   Lv SL, 2017, ONCOTARGET, V8, P69062, DOI 10.18632/oncotarget.17297
   Mobbs Ralph J, 2015, J Spine Surg, V1, P2, DOI 10.3978/j.issn.2414-469X.2015.10.05
   Mohapatra Bibhudendu, 2010, SAS J, V4, P87, DOI 10.1016/j.esas.2010.01.006
   Nagai H, 1997, SPINE, V22, P2766, DOI 10.1097/00007632-199712010-00013
   Patel AA, 2008, SPINE, V33, pE648, DOI 10.1097/BRS.0b013e31817c6ced
   Pee YH, 2007, J NEUROSURG-SPINE, V7, P566, DOI 10.3171/SPI-07/11/566
   PROPSTPROCTOR SL, 1983, SPINE, V8, P787, DOI 10.1097/00007632-198310000-00017
   Schizas C, 2009, EUR SPINE J, V18, pS228, DOI 10.1007/s00586-009-0893-0
   SHEN YS, 1989, J BONE JOINT SURG AM, V71A, P1250, DOI 10.2106/00004623-198971080-00020
   Steinmetz M P, 2001, Neurosurg Focus, V11, pe2
   Su IC, 2007, EUR SPINE J, V16, pS332, DOI 10.1007/s00586-007-0305-2
   Tasar M, 2005, CLIN IMAG, V29, P109, DOI 10.1016/j.clinimag.2004.04.028
   Thaler M, 2010, J SPINAL DISORD TECH, V23, P146, DOI 10.1097/BSD.0b013e3181a60b29
   Unno N, 2014, SURG TODAY, V44, P436, DOI 10.1007/s00595-013-0548-y
   Upadhyaya CD, 2007, J NEUROSURG-SPINE, V7, P562, DOI 10.3171/SPI-07/11/562
   Vaccaro AR, 2001, SPINE, V26, pS111, DOI 10.1097/00007632-200112151-00019
   VALENZUELARENDON J, 1990, AM J PHYSIOL, V258, pH1524
   Wagner WH, 2006, J VASC SURG, V44, P1266, DOI 10.1016/j.jvs.2006.07.046
   Zeidan S, 2008, J PEDIATR GASTR NUTR, V46, P478, DOI 10.1097/MPG.0b013e31815ce5be
NR 47
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1211
EP E1221
DI 10.7076/j.wneu.2018.71.018
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100147
PM 30447468
DA 2020-05-12
ER

PT J
AU Jung, J
   Lavrador, JP
   Patel, S
   Giamouriadis, A
   Lam, J
   Bhangoo, R
   Ashkan, K
   Vergani, F
AF Jung, Josephine
   Lavrador, Jose-Pedro
   Patel, Sabina
   Giamouriadis, Anastasios
   Lam, Jordan
   Bhangoo, Ranjeev
   Ashkan, Keyoumars
   Vergani, Francesco
TI First United Kingdom Experience of Navigated Transcranial Magnetic
   Stimulation in Preoperative Mapping of Brain Tumors
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain tumor; DES; Direct electrical stimulation; Glioma; Intraoperative
   neuromonitoring; IOM; Mapping; Navigated brain stimulation; NBS;
   Transcranial magnetic stimulation; TMS
ID DIRECT CORTICAL STIMULATION; MOTOR CORTEX; ELECTRICAL-STIMULATION;
   LANGUAGE LOCALIZATION; CEREBRAL-CORTEX; GLIOMA SURGERY; IMPROVES; AREA;
   HEMISPHERE; RESECTION
AB BACKGROUND: Surgery for lesions in eloquent brain areas remains challenging owing to the risk of permanent neurological deficits. To date, direct electrical stimulation (DES) and intraoperative neuromonitoring represent the reference standard. Recently, navigated transcranial magnetic stimulation (nTMS) has emerged as a mapping tool to optimize surgical planning. Our aim was to correlate nTMS with the intraoperative findings and assess its effects on surgical decision-making.
   METHODS: We retrospectively reviewed our series of patients who had undergone craniotomy for removal of a brain tumor at our institution with preoperative nTMS, intraoperative neuromonitoring, and DES from February 2017 to February 2018. Demographic data, tumor entity and location, extent of resection, change in surgical approach, and neurological outcome were collected.
   RESULTS: Of 35 patients, 24 (68.6%) had undergone preoperative motor mapping and 11 (31.4%) had undergone mapping for language. Histopathological examination demonstrated glioma in 88.6% (high grade, n = 24; low grade, n = 6), metastasis (n = 2), epidermoid cyst (n = 1), and cavernoma (n = 1). nTMS resulted in change in the surgical strategy in 31.5% (craniotomy size, n = 7; access pathway, n = 3; surgical indication, n = 1). The specificity of nTMS for language was 66.7%, with a negative predictive value of 74.1%. nTMS motor mapping correlated with DES in all cases, with a mean abductor pollicis brevis hotspot distance of 3.50 +/- 0.66 mm (n = 9).
   CONCLUSIONS: nTMS is a safe, noninvasive adjunctive tool for preoperative mapping of brain tumors in eloquent areas. Furthermore, nTMS can influence the surgical decisions in up to one third of patients in our experience.
C1 [Jung, Josephine; Lavrador, Jose-Pedro; Patel, Sabina; Giamouriadis, Anastasios; Bhangoo, Ranjeev; Ashkan, Keyoumars; Vergani, Francesco] Kings Coll Hosp London, Dept Neurosurg, London, England.
   [Jung, Josephine; Ashkan, Keyoumars] Kings Coll Hosp London, Dept Neurosci, Clin Trials Unit, London, England.
   [Lam, Jordan] Univ Leicester, Coll Med Biol Sci & Psychol, Leicester, Leics, England.
RP Jung, J (reprint author), Kings Coll Hosp London, Dept Neurosurg, London, England.; Jung, J (reprint author), Kings Coll Hosp London, Dept Neurosci, Clin Trials Unit, London, England.
EM Josephine.Jung@nhs.net
OI Lam, Jordan/0000-0003-3955-9031
CR ANNETT M, 1972, BRIT J PSYCHOL, V63, P343, DOI 10.1111/j.2044-8295.1972.tb01282.x
   BARKER AT, 1985, LANCET, V1, P1106
   Bello L, 2008, NEUROIMAGE, V39, P369, DOI 10.1016/j.neuroimage.2007.08.031
   BERGER MS, 1994, CANCER, V74, P1784, DOI 10.1002/1097-0142(19940915)74:6<1784::AID-CNCR2820740622>3.0.CO;2-D
   BERGER MS, 1992, STEREOT FUNCT NEUROS, V58, P153, DOI 10.1159/000098989
   Carrabba G, 2007, J Neurosurg Sci, V51, P45
   Corina DP, 2010, BRAIN LANG, V115, P101, DOI 10.1016/j.bandl.2010.04.001
   Dell'Acqua F, 2012, CURR OPIN NEUROL, V25, P375, DOI 10.1097/WCO.0b013e328355d544
   Devlin JT, 2007, BRAIN, V130, P610, DOI 10.1093/brain/awl331
   Duffau H, 2007, NEUROPHYSIOL CLIN, V37, P373, DOI 10.1016/j.neucli.2007.09.003
   Duffau H, 2003, NEUROIMAGE, V20, P1903, DOI 10.1016/S1053-8119(03)00203-9
   Duffau H, 2005, J NEUROL NEUROSUR PS, V76, P845, DOI 10.1136/jnnp.2004.048520
   Epstein CM, 1998, J CLIN NEUROPHYSIOL, V15, P325, DOI 10.1097/00004691-199807000-00004
   Frey D, 2014, NEURO-ONCOLOGY, V16, P1365, DOI 10.1093/neuonc/nou110
   Giussani C, 2010, NEUROSURGERY, V66, P113, DOI 10.1227/01.NEU.0000360392.15450.C9
   Hauck T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125298
   Hernandez-Pavon JC, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00660
   Ille S, 2016, ACTA NEUROCHIR, V158, P2265, DOI 10.1007/s00701-016-2968-0
   Ille S, 2015, J NEUROSURG, V123, P212, DOI 10.3171/2014.9.JNS14929
   Jbabdi S, 2011, BRAIN CONNECT, V1, P169, DOI 10.1089/brain.2011.0033
   Kallioniemi E, 2016, J NEUROSCI METH, V273, P138, DOI 10.1016/j.jneumeth.2016.09.002
   Krieg SM, 2014, NEURO-ONCOLOGY, V16, P1274, DOI 10.1093/neuonc/nou007
   Krieg SM, 2012, J NEUROSURG, V116, P994, DOI 10.3171/2011.12.JNS111524
   Lefaucheur JP, 2016, NEUROPHYSIOL CLIN, V46, P125, DOI 10.1016/j.neucli.2016.05.001
   Lorca-Puls DL, 2017, BRAIN, V140, P1729, DOI 10.1093/brain/awx087
   Maier-Hein KH, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01285-x
   Mandonnet E, 2010, ACTA NEUROCHIR, V152, P185, DOI 10.1007/s00701-009-0469-0
   Muthuraman M, 2016, CLIN NEUROPHYSIOL, V127, P1762, DOI 10.1016/j.clinph.2015.12.006
   OJEMANN G, 1989, J NEUROSURG, V71, P316, DOI 10.3171/jns.1989.71.3.0316
   OJEMANN GA, 1978, BRAIN LANG, V6, P239, DOI 10.1016/0093-934X(78)90061-5
   OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014
   Penfield W, 1937, BRAIN, V60, P389, DOI 10.1093/brain/60.4.389
   Picht T, 2016, J NEURO-ONCOL, V126, P535, DOI 10.1007/s11060-015-1993-9
   Picht T, 2013, NEUROSURGERY, V72, P808, DOI 10.1227/NEU.0b013e3182889e01
   Picht T, 2012, NEUROSURGERY, V70, P1248, DOI 10.1227/NEU.0b013e318243881e
   Picht T, 2011, NEUROSURGERY, V69, P581, DOI 10.1227/NEU.0b013e3182181b89
   Picht T, 2009, NEUROSURGERY, V65, P93, DOI 10.1227/01.NEU.0000348009.22750.59
   Pirotte B, 2008, NEUROSURGERY, V62, P941, DOI [10.1227/01.neu.0000333762.38500.ac, 10.1227/01.NEU.0000144837.31665.29]
   Reiss M, 1999, WIEN KLIN WOCHENSCHR, V111, P1009
   Rosenstock T, 2017, J NEUROSURG, V126, P1227, DOI 10.3171/2016.4.JNS152896
   Rossini PM, 2015, CLIN NEUROPHYSIOL, V126, P1071, DOI 10.1016/j.clinph.2015.02.001
   Ruohonen J, 2002, HDB MAGNETIC STIMULA
   Sacko O, 2011, NEUROSURGERY, V68, P1192, DOI 10.1227/NEU.0b013e31820c02a3
   Sanai N, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2009.12.FOCUS09266
   Sarubbo S, 2015, HUM BRAIN MAPP, V36, P3117, DOI 10.1002/hbm.22832
   SARVAS J, 1987, PHYS MED BIOL, V32, P11, DOI 10.1088/0031-9155/32/1/004
   Sollmann N, 2018, NEUROSURG FOCUS, V44, DOI [10.3171/2018.3.FOCUS1838, 10.3171/2018.10.FocusVid.1873]
   Sollmann N, 2017, BRAIN IMAGING BEHAV, V11, P1192, DOI 10.1007/s11682-016-9574-x
   Sollmann N, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-94
   Szelenyi A, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2009.12.FOCUS09237
   Takahashi S, 2013, NEUROSURG FOCUS, V34, DOI 10.3171/2013.1.FOCUS133
   Tarapore PE, 2013, NEUROIMAGE, V82, P260, DOI 10.1016/j.neuroimage.2013.05.018
   Tarapore PE, 2012, J NEUROSURG, V117, P354, DOI 10.3171/2012.5.JNS112124
   Tarkiainen A, 2003, CLIN NEUROPHYSIOL, V114, P1977, DOI 10.1016/S1388-2457(03)00195-0
   Tate MC, 2014, BRAIN, V137, P2773, DOI 10.1093/brain/awu168
   Tharin S, 2007, NEUROSURGERY, V60, P185, DOI 10.1227/01.0000255386.95464.52
   Tie YM, 2014, HUM BRAIN MAPP, V35, P1018, DOI 10.1002/hbm.22231
   Yousry TA, 1997, BRAIN, V120, P141, DOI 10.1093/brain/120.1.141
NR 58
TC 6
Z9 6
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1578
EP E1587
DI 10.1016/j.wneu.2018.11.114
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100194
PM 30476661
DA 2020-05-12
ER

PT J
AU Kang, MS
   Kim, KH
   Park, JY
   Kuh, SU
   Chin, DK
   Jin, BH
   Cho, YE
   Kim, KS
AF Kang, Moo Sung
   Kim, Kyung Hyun
   Park, Jeong Yoon
   Kuh, Sung Uk
   Chin, Dong Kyu
   Jin, Byung Ho
   Cho, Yong Eun
   Kim, Keun Su
TI Comparison of Endovascular Embolization and Surgery in the Treatment of
   Spinal Intradural Dorsal Arteriovenous Fistulas
SO WORLD NEUROSURGERY
LA English
DT Article
DE Arteriovenous; Embolization; Endovascular; Fistula; Intradural; Surgery
ID LONG-TERM; SURGICAL-TREATMENT; CLINICAL-FEATURES; EXPERIENCE;
   MANAGEMENT; OUTCOMES
AB BACKGROUND: We compared the outcomes of endovascular embolization and surgery and investigated the factors affecting the clinical outcomes of spinal intradural dorsal arteriovenous fistulas (SIDAVFs).
   METHODS: The medical records of 26 patients who had undergone endovascular embolization or surgery for SIDAVFs from 2004 to 2014 were retrospectively reviewed. The recurrence rate and clinical outcomes for each treatment modality were compared. Multivariate analysis was used to identify significant factors influencing the clinical outcomes using the Aminoff and Logue (AL) score.
   RESULTS: Of the 26 patients, 14 (56%) had undergone endovascular embolization and 11 (44%) had undergone surgery as the initial treatment. Embolization was applied as the primary treatment for most patients. Surgery was chosen for patients with difficult superselection (n = 5), multiple feeders (n = 2), or easy surgical accessibility (n = 4). Of the 14 patients who had undergone embolization as initial treatment, 5 (36%) had developed a recurrence within an average of 29.6 months (range, 2-87). One patient with recurrent SIDAVF was treated with repeat embolization and four with surgery. None of patients in the surgical group developed recurrence. Embolization as the initial treatment resulted in significantly greater recurrence compared with surgery (odds ratio, 2.222; 95% confidence interval, 1.369-3.608; P = 0.046). Surgery resulted in better clinical outcomes than embolization (P = 0.021). The final AL score was also strongly affected by the preoperative AL score, micturition score, and recurrence (P = 0.000, P = 0.000, and P = 0.011, respectively).
   CONCLUSIONS: Our results have shown that surgery results in a low recurrence rate and superior clinical outcomes. A multidisciplinary and ordered decision is crucial for the treatment choice to ensure better outcomes, especially for patients with a definite neurologic deficit at diagnosis.
C1 [Kang, Moo Sung; Kim, Kyung Hyun; Park, Jeong Yoon; Kuh, Sung Uk; Chin, Dong Kyu; Cho, Yong Eun; Kim, Keun Su] Yonsei Univ, Gangnam Severance Hosp, Coll Med, Dept Neurosurg,Spine & Spinal Cord Inst, Seoul, South Korea.
   [Kang, Moo Sung; Jin, Byung Ho] Catholic Kwandong Univ, Coll Med, Int St Marys Hosp, Dept Neurosurg, Incheon, South Korea.
RP Kim, KS (reprint author), Yonsei Univ, Gangnam Severance Hosp, Coll Med, Dept Neurosurg,Spine & Spinal Cord Inst, Seoul, South Korea.
EM spinekks@yuhs.ac
OI kim, kyunghyun/0000-0002-1338-5523; kim, keun su/0000-0002-3384-5638;
   Chin, Dong Kyu/0000-0002-9835-9294; CHO, Yong-Eun/0000-0001-9815-2720;
   Park, Jeong Yoon/0000-0002-3728-7784; KUH, Sunguk/0000-0003-2566-3209
CR Andres RH, 2008, NEURORADIOLOGY, V50, P869, DOI 10.1007/s00234-008-0425-3
   Bakker NA, 2015, NEUROSURGERY, V77, P137, DOI 10.1227/NEU.0000000000000727
   Cecchi PC, 2008, ACTA NEUROCHIR, V150, P563, DOI 10.1007/s00701-008-1560-7
   Cenzato M, 2012, NEUROSURG FOCUS, V32, DOI 10.3171/2012.2.FOCUS1218
   Chibbaro S, 2015, J CLIN NEUROSCI, V22, P180, DOI 10.1016/j.jocn.2014.07.024
   Clark S, 2013, BRIT J NEUROSURG, V27, P465, DOI 10.3109/02688697.2012.752433
   Elsberg CA, 1916, AM J MED SCI, V151, P642
   Eskandar EN, 2002, J NEUROSURG, V96, P162, DOI 10.3171/spi.2002.96.2.0162
   Gaupp J, 1888, BEITR PATHOL, V2, P516
   Gokhale Sankalp, 2014, Surg Neurol Int, V5, P7, DOI 10.4103/2152-7806.125628
   Hebold O., 1885, ARCH PSYCHIAT NERVEN, V16, P813
   Hetts SW, 2012, J NEUROSURG-SPINE, V16, P433, DOI 10.3171/2012.1.SPINE11643
   Jellema K, 2003, J NEUROL NEUROSUR PS, V74, P1438, DOI 10.1136/jnnp.74.10.1438
   Koch C, 2003, ROFO-FORTSCHR RONTG, V175, P1071
   Krause F., 1911, CHIRURG GEHIRNS RUCK
   Krings T, 2009, AM J NEURORADIOL, V30, P639, DOI 10.3174/ajnr.A1485
   Muralidharan R, 2013, SPINE, V38, P1188, DOI 10.1097/BRS.0b013e31828b2e10
   Nagata S, 2006, SURG NEUROL, V65, P563, DOI 10.1016/j.surneu.2005.09.018
   Narvid J, 2008, NEUROSURGERY, V62, P159, DOI 10.1227/01.NEU.0000311073.71733.C4
   NICHOLS DA, 1992, AM J NEURORADIOL, V13, P933
   OMMAYA AK, 1969, J NEUROSURG, V30, P25, DOI 10.3171/jns.1969.30.1.0025
   Pillai SK, 2011, BMJ CASE REP, V2011
   Qi XQ, 2014, INT J CLIN EXP MED, V7, P3062
   Rashad S, 2014, CLIN NEUROL NEUROSUR, V125, P81, DOI 10.1016/j.clineuro.2014.07.028
   Ruiz-Juretschke F, 2011, J CLIN NEUROSCI, V18, P1662, DOI 10.1016/j.jocn.2011.03.008
   Sasamori T, 2016, EUR SPINE J, V25, P748, DOI 10.1007/s00586-015-3887-0
   Sherif C, 2008, NEURORADIOLOGY, V50, P67, DOI 10.1007/s00234-007-0303-4
   Shin DA, 2015, YONSEI MED J, V56, P397, DOI 10.3349/ymj.2015.56.2.397
   Song JK, 2001, J NEUROSURG, V94, P199, DOI 10.3171/spi.2001.94.2.0199
   Steinmetz MP, 2004, NEUROSURGERY, V55, P77, DOI 10.1227/01.NEU.0000126878.95006.0F
   Yen PPW, 2014, J NEUROSURG-SPINE, V21, P837, DOI 10.3171/2014.7.SPINE13797
NR 31
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1519
EP E1527
DI 10.1016/j.wneu.2018.11.093
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100186
PM 30468927
DA 2020-05-12
ER

PT J
AU Kato, S
   Murakami, H
   Demura, S
   Yoshioka, K
   Yokogawa, N
   Yonezawa, N
   Shimizu, T
   Oku, N
   Kitagawa, R
   Tsuchiya, H
AF Kato, Satoshi
   Murakami, Hideki
   Demura, Satoru
   Yoshioka, Katsuhito
   Yokogawa, Noriaki
   Yonezawa, Noritaka
   Shimizu, Takaki
   Oku, Norihiro
   Kitagawa, Ryo
   Tsuchiya, Hiroyuki
TI Kidney and Thyroid Cancer-Specific Treatment Algorithm for Spinal
   Metastases: A Validation Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Kidney cancer; Spinal metastases; Thyroid cancer; Treatment algorithm;
   Validation study
ID RENAL-CELL CARCINOMA; PROGNOSTIC SCORING SYSTEMS; BONE METASTASES;
   IMPACT; SURVIVAL; CLASSIFICATION; GUIDELINES; MODALITIES; TUMORS
AB BACKGROUND: Spinal metastases (SMs) from kidney and thyroid cancers have several common features suggesting that excisional surgery for isolated and removable SMs can improve survival. We propose a simple treatment algorithm for SMs from these cancers. Our study aimed to evaluate the efficacy of the algorithm.
   METHODS: We performed a retrospective analysis of the data of 69 consecutive patients (48 with kidney and 21 with thyroid cancers) who underwent excisional surgery for SMs between 1995 and 2014. The patients were retrospectively classified into an indicated group for excisional SM surgery and a nonindicated group according to our algorithm, and the Tokuhashi and Tomita scoring systems. Patients in the indicated group were expected to survive >= 2 years postoperatively, whereas those in the nonindicated group were not. The positive predictive value and negative predictive value (NPV) were calculated using the predicted versus actual survival times of the patients. Survival was defined as the time from the first excisional surgery for the spinal lesion to death or the last follow-up of >= 2 years.
   RESULTS: For patients with kidney cancer, the 2- and 5-year survival rates were 85.4% and 60.4%, respectively. For patients with thyroid cancer, the 2- and 5-year survival rates were 100% and 83.8%, respectively. Our algorithm had a compatible high positive predictive value (95.5%) and NPV (100%), whereas the Tokuhashi and Tomita scoring systems had low NPVs of 15.8% and 13.3%, respectively.
   CONCLUSIONS: Our treatment algorithm of SMs from kidney and thyroid cancers is useful for determining an adequate treatment including excisional surgery.
C1 [Kato, Satoshi; Murakami, Hideki; Demura, Satoru; Yoshioka, Katsuhito; Yokogawa, Noriaki; Yonezawa, Noritaka; Shimizu, Takaki; Oku, Norihiro; Kitagawa, Ryo; Tsuchiya, Hiroyuki] Kanazawa Univ, Grad Sch Med Sci, Dept Orthopaed Surg, Kanazawa, Ishikawa, Japan.
RP Kato, S (reprint author), Kanazawa Univ, Grad Sch Med Sci, Dept Orthopaed Surg, Kanazawa, Ishikawa, Japan.
EM skato323@gmail.com
RI DEMURA, Satoru/X-8589-2019
OI Kato, Satoshi/0000-0003-4762-5932
CR Alt AL, 2011, CANCER-AM CANCER SOC, V117, P2873, DOI 10.1002/cncr.25836
   Bernier MO, 2001, J CLIN ENDOCR METAB, V86, P1568, DOI 10.1210/jc.86.4.1568
   Beuselinck B, 2011, ANN ONCOL, V22, P794, DOI 10.1093/annonc/mdq554
   Eggener SE, 2008, J UROLOGY, V180, P873, DOI 10.1016/j.juro.2008.05.006
   Farooki A, 2012, J CLIN ENDOCR METAB, V97, P2433, DOI 10.1210/jc.2012-1169
   Gregory TM, 2013, SPINE, V38, P965, DOI 10.1097/BRS.0b013e3182609d38
   Haugen BR, 2016, THYROID, V26, P1, DOI 10.1089/thy.2015.0020
   Jung ST, 2003, CLIN ORTHOP RELAT R, P223, DOI 10.1097/01.blo.0000059580.08469.3e
   Kato S, 2016, CANCER MED-US, V5, P2343, DOI 10.1002/cam4.823
   Kato S, 2016, J SURG ONCOL, V113, P587, DOI 10.1002/jso.24186
   Kim JY, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477-7819-12-245
   Kume H, 2011, J UROLOGY, V185, P1611, DOI 10.1016/j.juro.2010.12.037
   Kushchayeva YS, 2014, THYROID, V24, P1443, DOI 10.1089/thy.2013.0634
   Lee BH, 2013, ANN SURG ONCOL, V20, P40, DOI 10.1245/s10434-012-2644-4
   Leibovich BC, 2005, J UROLOGY, V174, P1759, DOI 10.1097/01.ju.0000177487.64651.3a
   Leithner A, 2008, EUR SPINE J, V17, P1488, DOI 10.1007/s00586-008-0763-1
   Ljungberg B, 2015, EUR UROL, V67, P913, DOI 10.1016/j.eururo.2015.01.005
   Luksanapruksa P, 2017, SPINE J, V17, P689, DOI 10.1016/j.spinee.2016.12.003
   Mckay RR, 2014, EUR UROL, V65, P577, DOI 10.1016/j.eururo.2013.08.012
   Naito S, 2010, EUR UROL, V57, P317, DOI 10.1016/j.eururo.2008.12.026
   Nixon IJ, 2012, THYROID, V22, P884, DOI 10.1089/thy.2011.0535
   Pittas AG, 2000, THYROID, V10, P261, DOI 10.1089/thy.2000.10.261
   Song HJ, 2015, EUR J ENDOCRINOL, V173, P399, DOI 10.1530/EJE-15-0296
   Tokuhashi Y, 2005, SPINE, V30, P2186, DOI 10.1097/01.brs.0000180401.06919.a5
   Tokuhashi Y, 2017, SPINE SURG RELAT RES, V1, P44, DOI 10.22603/ssrr.1.2016-0021
   Tomita K, 2006, J ORTHOP SCI, V11, P3, DOI 10.1007/s00776-005-0964-y
   Tomita K, 2001, SPINE, V26, P298, DOI 10.1097/00007632-200102010-00016
   Toyoda Y, 2007, EUR UROL, V52, P163, DOI 10.1016/j.eururo.2006.10.060
   van der Poel HG, 1999, EUR UROL, V35, P197, DOI 10.1159/000019849
   Wibmer C, 2011, SPINE, V36, P1977, DOI 10.1097/BRS.0b013e3182011f84
NR 30
TC 2
Z9 2
U1 0
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1305
EP E1311
DI 10.1016/j.wneu.2018.11.040
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100159
PM 30448587
DA 2020-05-12
ER

PT J
AU Kellner, CP
   Moore, F
   Arginteanu, MS
   Steinberger, AA
   Yao, K
   Scaggiante, J
   Mocco, J
   Gologorsky, Y
AF Kellner, Christopher P.
   Moore, Frank
   Arginteanu, Marc S.
   Steinberger, Alfred A.
   Yao, Kevin
   Scaggiante, Jacopo
   Mocco, J.
   Gologorsky, Yakov
TI Minimally Invasive Evacuation of Spontaneous Cerebellar Intracerebral
   Hemorrhage
SO WORLD NEUROSURGERY
LA English
DT Article
DE Craniectomy; Evacuation; Infratentorial; Intracerebral hemorrhage;
   Minimally invasive
ID CRANIECTOMY; CRANIOTOMY; EFFICACY; SAFETY
AB OBJECTIVE: Spontaneous cerebellar intracerebral hemorrhage (scICH) constitutes similar to 10% of all cases of spontaneous ICH, with a mortality of 20%-50%. Suboccipital craniectomy (SOC) is commonly performed for scICH causing brainstem compression or hydrocephalus. However, SOC requires long anesthesia times and results in a high complication rate. We present a series of patients who minimally invasive scICH evacuation as an alternative to traditional SOC.
   METHODS: We retrospectively reviewed the operative records for patients presenting to a single center from January 1, 2009 to March 1, 2017. All patients who had undergone evacuation of scICH were included in the present study. Clinical and radiographic variables were collected, including admission and postoperative Glasgow coma scale (GCS) scores, preoperative and postoperative hematoma volumes, and modified Rankin scale (mRS) scores at long-term follow-up.
   RESULTS: We identified 10 patients who had presented with scICH requiring surgery. All scICH evacuations were performed through a minicraniectomy positioned in the suboccipital area as close to the hematoma as possible. The mean patient age was 64.1 years. The mean presenting GCS score was 8.6, the mean initial hematoma volume was 25.4 mL, the mean procedure time was 57 minutes, and the mean postoperative hematoma volume was 2.8 mL. The mortality rate was 10% and mean long-term follow-up mRS score was 2.
   CONCLUSIONS: Minimally invasive scICH hematoma evacuation is a feasible alternative to SOC with numerous advantages that could lead to improved radiographic and clinical results.
C1 [Kellner, Christopher P.; Moore, Frank; Arginteanu, Marc S.; Steinberger, Alfred A.; Yao, Kevin; Scaggiante, Jacopo; Mocco, J.; Gologorsky, Yakov] Icahn Sch Med Mt Sinai, Dept Neurosurg, New York, NY 10029 USA.
   [Moore, Frank; Arginteanu, Marc S.; Steinberger, Alfred A.; Yao, Kevin; Gologorsky, Yakov] Englewood Hosp & Med Ctr, Dept Neurosurg, Englewood, NJ USA.
RP Kellner, CP (reprint author), Icahn Sch Med Mt Sinai, Dept Neurosurg, New York, NY 10029 USA.
EM christopher.kellner@mountsinai.org
RI Scaggiante, Jacopo/AAJ-4748-2020
OI Scaggiante, Jacopo/0000-0002-9531-9131; Kellner,
   Christopher/0000-0003-4604-8205
FU Arminio; Penumbra
FX This research was supported in part by a grant from Arminio and Lucyna
   Fraga and by a grant from Mr and Mrs. Durkovic. C.K. is the director of
   a continuing medical education course, "Endoscopic Minimally Invasive
   Intracerebral Hemorrhage Evacuation," funded by Penumbra. J.M. is the
   principal investigator of the INVEST trial funded by Penumbra and has
   financial interest in Rebound Therapeutics.
CR Bauer AM, 2017, OPER NEUROSURG, V13, P69, DOI 10.1227/NEU.0000000000001258
   BRENNAN RW, 1977, NEUROLOGY, V27, P527, DOI 10.1212/WNL.27.6.527
   DOI E, 1982, Neurologia Medico-Chirurgica, V22, P461, DOI 10.2176/nmc.22.461
   Fiorella D, 2016, NEUROSURGERY S1, V63, P1
   Flaherty ML, 2005, STROKE, V36, P934, DOI 10.1161/01.STR.0000160756.72109.95
   Hanley DF, 2016, LANCET NEUROL, V15, P1226, DOI 10.1016/S1474-4422(16)30234-4
   Hemphill JC, 2015, STROKE, V46, P2032, DOI 10.1161/STR.0000000000000069
   Legnani FG, 2013, ACTA NEUROCHIR, V155, P2281, DOI 10.1007/s00701-013-1882-y
   MOHADJER M, 1990, J NEUROSURG, V73, P217, DOI 10.3171/jns.1990.73.2.0217
   Smith Eric E, 2006, Magn Reson Imaging Clin N Am, V14, P127, DOI 10.1016/j.mric.2006.06.002
   Sporns PB, 2017, STROKE, V48, P131, DOI 10.1161/STROKEAHA.116.014068
   Tamaki T, 2004, NEUROL MED-CHIR, V44, P578, DOI 10.2176/nmc.44.578
   Tokimura H, 2010, NEUROL MED-CHIR, V50, P367, DOI 10.2176/nmc.50.367
   Urday S, 2015, STROKE, V46, P1116, DOI 10.1161/STROKEAHA.114.007565
   Yamamoto T, 2006, MINIM INVAS NEUROSUR, V49, P173, DOI 10.1055/s-2006-944242
NR 15
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1
EP E9
DI 10.1016/j.wneu.2018.07.145
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100002
PM 30292039
DA 2020-05-12
ER

PT J
AU Kennamer, BT
   Arginteanu, MS
   Moore, FM
   Steinberger, AA
   Yao, KC
   Gologorsky, Y
AF Kennamer, Brooke T.
   Arginteanu, Marc S.
   Moore, Frank M.
   Steinberger, Alfred A.
   Yao, Kevin C.
   Gologorsky, Yakov
TI Complications of Poor Cervical Alignment in Patients Undergoing
   Posterior Cervicothoracic Laminectomy and Fusion
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cervical kyphosis; Cervicothoracic fusion; Cervicothoracic junction;
   Multilevel posterior cervical fusion; Posterior cervical fusion;
   Sagittal vertical axis
ID RISK-FACTORS; PSEUDOARTHROSIS; DECOMPRESSION; ANTERIOR
AB OBJECTIVE: This study sought to determine whether a relationship exists between caudal instrumented level and revision rates, neck disability index scores, and cervical alignment in patients undergoing multilevel posterior cervical fusion.
   METHODS: This study examined a dataset of all patients undergoing posterior cervical decompression and fusion at >= 3 levels, terminating between C4 and T4, between January 2010 and December 2015, with at least 12 months of clinical follow-up. Patients were separated into cohorts based on caudal level of the fusion: C6 (or more cranial), C7, T1, or T2 (or more caudal). Revision rate, neck disability index score, sagittal vertical axis, T1 slope, and cervical lordosis were recorded. Linear regression and multivariate analysis were performed to identify independent predictors of patient outcomes and disparities between ending constructs in the cervical and the thoracic spine.
   RESULTS: The overall revision rate was 10.8% (n = 24). No statistically significant difference in the revision rate was identified between fusions terminating at C6 or cranial, C7, T1, or T2 and caudal (P = 0.74). Revision correlated strongly with increased sagittal vertical axis (P = 0.002) and T1 slope (P = 0.04). Increased neck disability index score correlated with revision rate (P = 0.01), cervical kyphosis (P < 0.001), and increased sagittal vertical axis (P = 0.04).
   CONCLUSIONS: This study suggests that constructs terminating in the proximal thoracic spine have similar revision rates, postoperative neck disability index scores, and radiographic measurements as those terminating in the cervical spine. Poor cervical alignment, as evidenced by increased sagittal vertical axis, cervical kyphosis and T1 slope, predicts need for revision and of poorer clinical outcomes.
C1 [Kennamer, Brooke T.; Arginteanu, Marc S.; Moore, Frank M.; Steinberger, Alfred A.; Yao, Kevin C.; Gologorsky, Yakov] Englewood Hosp & Med Ctr, Englewood, NJ 07631 USA.
   [Arginteanu, Marc S.; Moore, Frank M.; Steinberger, Alfred A.; Yao, Kevin C.; Gologorsky, Yakov] Mt Sinai Med Ctr, New York, NY 10029 USA.
RP Kennamer, BT (reprint author), Englewood Hosp & Med Ctr, Englewood, NJ 07631 USA.
EM brookekennamer@gmail.com
CR Ames CP, 2013, SPINE, V38, pS149, DOI 10.1097/BRS.0b013e3182a7f449
   An HS, 1999, J SPINAL DISORD, V12, P519
   Auerbach J, 2014, 37 ANN M CERV SPIN R
   Coe JD, 2006, SPINE, V31, P345, DOI 10.1097/01.brs.0000197188.76369.13
   Fehlings MG, 2013, SPINE, V38, P2247, DOI 10.1097/BRS.0000000000000047
   Gilad R, 2008, SPINE J, V8, P911, DOI 10.1016/j.spinee.2007.10.035
   Hann S, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2014.3.FOCUS1429
   Harrison DE, 2000, SPINE, V25, P2072, DOI 10.1097/00007632-200008150-00011
   Hyun SJ, 2016, SPINE, V41, pE396, DOI 10.1097/BRS.0000000000001264
   Ikenaga M, 2006, SPINE, V31, P1568, DOI 10.1097/01.brs.0000221985.37468.0f
   Juul T, 2016, J CLIN EPIDEMIOL, V79, P31, DOI 10.1016/j.jclinepi.2016.03.015
   Kong LD, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004171
   Leven D, 2016, ASIAN SPINE J, V10, P776, DOI 10.4184/asj.2016.10.4.776
   Ondra Stephen L, 2004, Clin Neurosurg, V51, P30
   Passias PG, 2016, SPINE, V41, pE1096, DOI 10.1097/BRS.0000000000001640
   Scheer JK, 2013, J NEUROSURG-SPINE, V19, P141, DOI 10.3171/2013.4.SPINE12838
   Schroeder GD, 2016, SPINE, V41, P1845, DOI 10.1097/BRS.0000000000001864
   Sekhon LHS, 2006, J CLIN NEUROSCI, V13, P23, DOI 10.1016/j.jocn.2005.02.006
   Tang JA, 2012, NEUROSURGERY, V71, P662, DOI 10.1227/NEU.0b013e31826100c9
   Truumees E, 2017, SPINE J, V17, P43
   Vaccaro AR, 2005, SPINE, V30, P2325, DOI 10.1097/01.brs.0000182986.43345.cb
   Wagner PJ, 2014, CERV SPIN RES SOC 42
   Yang JS, 2015, SPINE, V40, pE613, DOI 10.1097/BRS.0000000000000868
NR 23
TC 4
Z9 4
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E408
EP E414
DI 10.1016/j.wneu.2018.10.062
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100048
PM 30342267
DA 2020-05-12
ER

PT J
AU Kessler, RA
   Benzil, DL
   Loewenstern, J
   Chen, S
   Bhammar, A
   Kohli, KM
   Hadjipanayis, CG
   Scarrow, A
   Bederson, J
   Shrivastava, RK
AF Kessler, Remi A.
   Benzil, Deborah L.
   Loewenstern, Joshua
   Chen, Sabrina
   Bhammar, Ansh
   Kohli, Karan M.
   Hadjipanayis, Constantinos G.
   Scarrow, Alan
   Bederson, Joshua
   Shrivastava, Raj K.
TI Malpractice Litigation in Brain Tumor Surgery: A 31-Year Analysis of
   Causative Factors in the United States from the Westlaw Database
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain tumors; Litigation; Medical malpractice; Medicolegal
ID MEDICAL MALPRACTICE; RISK
AB BACKGROUND: Medical malpractice litigation is an issue of major concern in neurosurgery, with 19.1% of neurosurgeons facing a claim annually. Neurosurgery possesses the greatest risk of malpractice of any specialty, likely owing to the complex clinical environment and disease severity. In the present study, we have characterized such litigation to determine the common factors that compel plaintiffs to file these claims.
   METHODS: WestLawNext, a prominent legal database, was used to identify all cases from 1985 to 2016 related to brain tumors. A total of 225 cases were identified, and each was analyzed for the cause of litigation (multiple causes were permitted). Because many had >1 ground for litigation, the reported percentages were based on the total counts of litigation rather than the number of cases. Additional information was collected from each case, including location, tumor type, and physician specialty.
   RESULTS: The cases were distributed across 36 states and U.S. territories: California (n = 42; 20%) and New York (n = 28; 13%) had the greatest number of cases. The top reasons for litigation were failure to diagnose (n = 109; 28%), failure to treat (n = 72; 18%), procedural error (n = 63; 16%), and failure to refer for diagnostic tests (n = 55; 14%). The most common diagnoses included pituitary adenoma (n = 26; 12%), acoustic neuroma (n = 27; 12%), and meningioma (n = 23; 10%).
   CONCLUSIONS: Malpractice litigation contributes to high overhead and physician burnout and escalates the cost of patient care. We found that benign brain tumors were the most common in litigation and that surgical issues accounted for only a small percentage.
C1 [Kessler, Remi A.; Loewenstern, Joshua; Kohli, Karan M.; Hadjipanayis, Constantinos G.; Bederson, Joshua; Shrivastava, Raj K.] Icahn Sch Med Mt Sinai, Dept Neurosurg, New York, NY 10029 USA.
   [Benzil, Deborah L.] Cleveland Clin Fdn, Dept Neurosurg, Cleveland, OH 44195 USA.
   [Chen, Sabrina; Bhammar, Ansh] Johns Hopkins Univ, Baltimore, MD USA.
   [Scarrow, Alan] Mercy Hlth Syst, Springfield, MO USA.
RP Kessler, RA (reprint author), Icahn Sch Med Mt Sinai, Dept Neurosurg, New York, NY 10029 USA.
EM remi.kessler@icahn.mssm.edu
CR Agarwal N, 2018, SPINE, V43, P984, DOI 10.1097/BRS.0000000000002510
   American Association for Justice, 2011, MED NEGL ROL AM CIV
   American Association of Medical Colleges, 2017 STAT PHYS WORKF
   American Medical Association, CAPS ON DAM
   Balch CM, 2011, J AM COLL SURGEONS, V213, P657, DOI 10.1016/j.jamcollsurg.2011.08.005
   Castellucci M, 2018, HLTH AFFAIRS
   Daniels AH, 2017, J NEUROSURG-SPINE, V27, P470, DOI 10.3171/2016.11.SPINE16646
   Dobson R, 2002, BMJ-BRIT MED J, V325, P736
   Eloy JA, 2014, J NEUROSURG, V120, P185, DOI 10.3171/2013.8.JNS13584
   Emery RT, ALBANY LAW REV
   Engelhard SB, 2018, CORNEA, V37, P537, DOI 10.1097/ICO.0000000000001534
   Ho RW, 2015, J KOREAN NEUROSURG S, V57, P23, DOI 10.3340/jkns.2015.57.1.23
   Hong SS, 2014, LARYNGOSCOPE, V124, P896, DOI 10.1002/lary.24377
   Jena AB, 2011, NEW ENGL J MED, V365, P629, DOI 10.1056/NEJMsa1012370
   Mello MM, 2010, HEALTH AFFAIR, V29, P1569, DOI 10.1377/hlthaff.2009.0807
   Nahed BV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039237
   Sampath P, 1997, J NEUROSURG, V87, P60, DOI 10.3171/jns.1997.87.1.0060
   Schencker E, 2014, MED LIABILITY PREMIU
   Studdert DM, 2005, JAMA-J AM MED ASSOC, V293, P2609, DOI 10.1001/jama.293.21.2609
   Therattil Paul J, 2017, Eplasty, V17, pe30
   Thomas R, 2018, WORLD NEUROSURG, V110, pE552, DOI 10.1016/j.wneu.2017.11.051
   Thomas Ravi, 2002, Indian Journal of Ophthalmology, V50, P127
   U. S. Census Bureau, CENS BUR REP
   Waxman DA, 2014, NEW ENGL J MED, V371, P1518, DOI 10.1056/NEJMsa1313308
   Wheeler RE, 2011, LAW LIBR J, V103, P359
NR 25
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1570
EP E1577
DI 10.1016/j.wneu.2018.11.112
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100193
PM 30476665
DA 2020-05-12
ER

PT J
AU Kim, BS
   Kim, ST
   Kim, JH
   Seol, HJ
   Nam, DH
   Shin, HJ
   Lee, JI
   Kong, DS
AF Kim, Byung Sup
   Kim, Sung Tae
   Kim, Joon Hyung
   Seol, Ho Jun
   Nam, Do-Hyun
   Shin, Hyung Jin
   Lee, Jung-Il
   Kong, Doo-Sik
TI Apparent Diffusion Coefficient as a Predictive Biomarker for Survival in
   Patients with Treatment-Naive Glioblastoma Using Quantitative
   Multiparametric Magnetic Resonance Profiling
SO WORLD NEUROSURGERY
LA English
DT Article
DE ADC; Glioblastoma; Oncology; Radiomics; Survival
ID MGMT PROMOTER METHYLATION; RADIATION-THERAPY; PROGNOSTIC VALUE;
   BRAIN-TUMOR; TEMOZOLOMIDE; GLIOMA; RADIOMICS; EDEMA; GRADE; MRI
AB BACKGROUND: The purpose of the present study was to investigate whether quantitative radiomic profiles extracted from multiparametric magnetic resonance (MR) profiles can predict the clinical outcomes for patients with newly diagnosed glioblastoma (GBM) before therapy.
   METHODS: MR images from 93 treatment-naive patients with newly diagnosed GBM were analyzed. Through tumor segmentation, we selected 36 radiomic features. Using the unsupervised clustering method, we classified our patients into 2 groups and investigated their overall survival (OS) using Kaplan-Meier analyses.
   RESULTS: Among the 36 radiomic features, the apparent diffusion coefficient (ADC) histogram parameters demonstrated a significant association with OS (P < 0.05). To validate this finding, unsupervised clustering analysis revealed 3 clusters with similar radiomic expression patterns. Clusters 1 and 2 showed a significant correlation with the radiomic features representing the tumor volume, and cluster 2 also showed a significant correlation with relative cerebral blood volume values. In contrast, cluster 3 showed an inverse relationship with cluster 2, mainly representing the radiomic features indicating the ADC and mean transit time. Although no statistically significant difference was found in OS between cluster 1 plus 2 and cluster 3, cluster 3 showed a trend toward longer OS compared with cluster 1 plus 2 (P = 0.067). After stratification by methylation status and radiomic feature clustering, patients with methylated O-6-methylguanine DNA methyltransferase and those included in cluster 3 had significantly longer OS (P = 0.029).
   CONCLUSIONS: ADC histogram parameters are feasible prognostic biomarkers to predict the survival of patients with treatment-naive GBM. Quantitative MR profiles can predict the clinical outcomes of patients with GBM before therapy.
C1 [Kim, Byung Sup] Kosin Univ, Dept Neurosurg, Gospel Hosp, Coll Med, Busan, South Korea.
   [Kim, Sung Tae] Sungkyunkwan Univ, Dept Radiol, Samsung Med Ctr, Sch Med, Seoul, South Korea.
   [Kim, Joon Hyung; Seol, Ho Jun; Nam, Do-Hyun; Shin, Hyung Jin; Lee, Jung-Il; Kong, Doo-Sik] Sungkyunkwan Univ, Dept Neurosurg, Samsung Med Ctr, Sch Med, Seoul, South Korea.
RP Kong, DS (reprint author), Sungkyunkwan Univ, Dept Neurosurg, Samsung Med Ctr, Sch Med, Seoul, South Korea.
EM kds026@skku.edu
OI Kim, Byung Sup/0000-0001-6814-6194
CR Aerts HJWL, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5006
   Akbari H, 2014, RADIOLOGY, V273, P502, DOI 10.1148/radiol.14132458
   Bag AK, 2014, J NEURO-ONCOL, V120, P361, DOI 10.1007/s11060-014-1560-9
   Bammer R, 2003, EUR J RADIOL, V45, P169, DOI 10.1016/S0720-048X(02)00303-0
   Baris MM, 2016, CLIN NEUROL NEUROSUR, V148, P67, DOI 10.1016/j.clineuro.2016.07.008
   Bian W, 2014, NEURORADIOLOGY, V56, P91, DOI 10.1007/s00234-013-1297-8
   Carrillo JA, 2012, AM J NEURORADIOL, V33, P1349, DOI 10.3174/ajnr.A2950
   Choi YS, 2016, RADIOLOGY, V281, P175, DOI 10.1148/radiol.2016151913
   Coban G, 2015, AM J NEURORADIOL, V36, P1247, DOI 10.3174/ajnr.A4284
   Ellingson BM, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-014-0506-0
   Esteller M, 2000, NEW ENGL J MED, V343, P1350, DOI 10.1056/NEJM200011093431901
   Esteller M, 2004, ONCOGENE, V23, P1, DOI 10.1038/sj.onc.1207316
   Gatenby RA, 2013, RADIOLOGY, V269, P8, DOI 10.1148/radiol.13122697
   Gevaert O, 2015, RADIOLOGY, V276, P313, DOI 10.1148/radiol.2015154019
   Gillies RJ, 2016, RADIOLOGY, V278, P563, DOI 10.1148/radiol.2015151169
   Gooya A, 2012, IEEE T MED IMAGING, V31, P1941, DOI 10.1109/TMI.2012.2210558
   Gupta RK, 2000, J NEURO-ONCOL, V50, P215, DOI 10.1023/A:1006431120031
   Gutman DA, 2013, RADIOLOGY, V267, P560, DOI 10.1148/radiol.13120118
   Hartmann C, 2013, CLIN CANCER RES, V19, P5146, DOI 10.1158/1078-0432.CCR-13-0017
   Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331
   Higano S, 2006, RADIOLOGY, V241, P839, DOI 10.1148/radiol.2413051276
   Hilario A, 2014, AM J NEURORADIOL, V35, P1096, DOI 10.3174/ajnr.A3837
   Kong Doo-Sik, 2018, Oncotarget, V9, P6336, DOI 10.18632/oncotarget.23975
   Kumar V, 2012, MAGN RESON IMAGING, V30, P1234, DOI 10.1016/j.mri.2012.06.010
   Li QH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14753-7
   Mazurowski MA, 2014, J NEURO-ONCOL, V120, P483, DOI 10.1007/s11060-014-1580-5
   Mazurowski MA, 2013, NEURO-ONCOLOGY, V15, P1389, DOI 10.1093/neuonc/nos335
   Murakami R, 2007, RADIOLOGY, V243, P493, DOI 10.1148/radiol.2432060450
   Ostrom QT, 2015, NEURO-ONCOLOGY, V17, P1, DOI 10.1093/neuonc/nov189
   Parker NR, 2016, SCI REP-UK, V6, DOI 10.1038/srep22477
   Pope WB, 2011, AM J NEURORADIOL, V32, P882, DOI 10.3174/ajnr.A2385
   Pope WB, 2015, NEUROIMAG CLIN N AM, V25, P105, DOI 10.1016/j.nic.2014.09.006
   Provenzale JM, 2006, RADIOLOGY, V239, P632, DOI 10.1148/radiol.2393042031
   Romano A, 2013, EUR RADIOL, V23, P513, DOI 10.1007/s00330-012-2601-4
   Saksena S, 2010, J MAGN RESON IMAGING, V32, P788, DOI 10.1002/jmri.22304
   Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7
   Sugahara T, 1999, JMRI-J MAGN RESON IM, V9, P53, DOI 10.1002/(SICI)1522-2586(199901)9:1<53::AID-JMRI7>3.0.CO;2-2
   van Nifterik KA, 2010, BRIT J CANCER, V103, P29, DOI 10.1038/sj.bjc.6605712
   Weller M, 2010, NAT REV NEUROL, V6, P39, DOI 10.1038/nrneurol.2009.197
   Wen QT, 2015, J NEURO-ONCOL, V121, P331, DOI 10.1007/s11060-014-1636-6
   Wick W, 2014, NAT REV NEUROL, V10, P372, DOI 10.1038/nrneurol.2014.100
   Zulfiqar M, 2013, AM J ROENTGENOL, V200, P624, DOI 10.2214/AJR.12.8679
NR 42
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E812
EP E820
DI 10.1016/j.wneu.2018.10.151
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100098
PM 30391622
DA 2020-05-12
ER

PT J
AU Kim, JH
   Kang, HI
AF Kim, Jae Hoon
   Kang, Hee In
TI Intraoperative Ventriculostomy Using K Point in Surgical Management of
   Aneurysmal Subarachnoid Hemorrhage
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm; Subarachnoid hemorrhage; Ventriculostomy
AB BACKGROUND: Intraoperative ventriculostomy in the surgical management of aneurysmal subarachnoid hemorrhage (SAH) is frequently performed to reduce increased intracranial pressure. The previously suggested ventriculostomy points have some limitations because the dura mater must be opened to be accessed and it is difficult to measure the exact entry point in patients with brain edema. We propose a new intraoperative ventriculostomy point (K point) for use in the surgical management of aneurysmal SAH patient with severe brain edema.
   METHODS: We performed intraoperative ventriculostomy using the K point on 155 patients with aneurysmal SAH between January 2012 and August 2016. Before opening the dura mater following standard pterional craniotomy, we inserted the ventricular catheter through a small dural incision perpendicular to the middle frontal gyrus toward the ipsilateral medial epicanthus. We simulated the catheter trajectory using a commercial navigation system on 2 patients with brain tumor.
   RESULTS: Ventriculostomy related hemorrhage occurred in 12 patients (7.7%), but there were no large hemorrhages causing neurologic deterioration or requiring evacuation. No language impairment was observed in these patients. Analysis using the navigation system revealed that the trajectory of K point ventriculostomy avoided critical periventricular brain structures and passed through the space between the genu of the corpus callosum and head of the caudate nucleus.
   CONCLUSIONS: K point ventriculostomy allows for easy access to a target point and protects the brain during opening of the dura mater and drilling of the sphenoid bone.
C1 [Kim, Jae Hoon; Kang, Hee In] Eulji Univ, Eulji Hosp, Dept Neurosurg, Seoul, South Korea.
RP Kang, HI (reprint author), Eulji Univ, Eulji Hosp, Dept Neurosurg, Seoul, South Korea.
EM khi2303@eulji.ac.kr
OI KIM, JAEHOON/0000-0002-9179-8569
CR D'Angelo Vincenzo A, 2005, Neurosurgery, V56, P36
   Hyun SJ, 2007, ACTA NEUROCHIR, V149, P1049, DOI 10.1007/s00701-007-1281-3
   Lehto H, 2009, NEUROSURGERY, V64, P430, DOI 10.1227/01.NEU.0000338433.81852.75
   Menovsky T, 2006, J NEUROSURG, V105, P485, DOI 10.3171/jns.2006.105.3.485
   PAINE JT, 1988, NEUROSURGERY, V22, P1107, DOI 10.1227/00006123-198806010-00027
   Park J, 2008, SURG NEUROL, V70, P503, DOI 10.1016/j.surneu.2007.09.018
   Yasargil MG, 2008, NEUROSURGERY, V62, P1029, DOI [10.1227/01.NEU.0000316427.57165.01, 10.1227/01.neu.0000333768.12951.9a]
NR 7
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E248
EP E252
DI 10.1016/j.wneu.2018.09.228
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100027
PM 30312820
DA 2020-05-12
ER

PT J
AU Kim, S
   Lee, H
   Lee, Y
   Lee, J
   Yang, J
   Lee, M
   Yang, H
AF Kim, SooJung
   Lee, HyeYeon
   Lee, YoungHan
   Lee, JiHyun
   Yang, JaeHoon
   Lee, MoonKyu
   Yang, HeeJun
TI Blood Supply by the Superior Cerebellar Artery and Posterior Inferior
   Cerebellar Artery to the Motor and Nonmotor Domains of the Human Dentate
   Nucleus
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anatomy; Cognition; Deep nucleus; Diffusion image; fMRI
ID COGNITIVE FUNCTION
AB BACKGROUND: The human cerebellum plays an important role in motor and nonmotor coordination. Any functional loss of the dentate nucleus can result in interruption of the cerebellar efferent pathway based on its somatotopy. However, understanding of the vascular supply to the dentate nucleus remains inadequate.
   METHODS: The origin of the perforators to the dentate nucleus was investigated by microscopic anatomic dissection of 14 human cerebellar hemispheres. The dentate nuclei were divided dorsoventrally, rostrocaudally, and mediolaterally to identify which cerebellar artery dominated which part of the dentate nucleus.
   RESULTS: The average number of perforators from the superior cerebellar artery (SCA) to the dentate nucleus was 2.2 +/- 0.9. The average number of perforators from the posterior inferior cerebellar artery (PICA) was 1.8 +/- 0.7. The anterior inferior cerebellar artery did not provide perforators to the dentate nucleus. The dorsal, rostral, and lateral halves of the dentate nucleus were more frequently dominated by the SCA than by the PICA. The ventral and medial halves of the dentate nucleus were more frequently dominated by the PICA than by the SCA. The dorsal rostrolateral and the ventral caudomedial sections were mainly supplied by the SCA and PICA, respectively.
   CONCLUSIONS: These findings in combination with findings of previous imaging studies suggest that the SCA is mainly associated with the motor activity and the PICA is mainly associated with the nonmotor activity of the dentate nucleus.
C1 [Kim, SooJung; Lee, JiHyun; Yang, HeeJun] Gachon Univ, Coll Med, Dept Anat, Incheon, South Korea.
   [Lee, HyeYeon] Yonsei Univ, Coll Med, Dept Anat, Seoul, South Korea.
   [Lee, YoungHan] Yonsei Univ, Coll Med, Dept Radiol, Seoul, South Korea.
   [Yang, JaeHoon] Doo Neurol Clin, Cheonan Si, Chungcheongnam, South Korea.
   [Lee, MoonKyu] GangNeung Asan Hosp, Dept Neurol, Kangnung, Gangwon Do, South Korea.
RP Yang, H (reprint author), Gachon Univ, Coll Med, Dept Anat, Incheon, South Korea.
EM yangmdphd@gachon.ac.kr
OI Yang, Hee-Jun/0000-0002-4983-6365; Lee, Young Han/0000-0002-5602-391X;
   Lee, Hye-Yeon/0000-0001-6945-1967
FU Gachon University [GCU 2015-5110]
FX This work was supported by the Gachon University research fund of 2015
   [GCU 2015-51101
CR Akakin A, 2014, NEUROSURGERY, V74, P401, DOI 10.1227/NEU.0000000000000293
   Bond KM, 2017, AM J NEURORADIOL, V38, P1467, DOI 10.3174/ajnr.A5138
   Buckner RL, 2013, NEURON, V80, P807, DOI 10.1016/j.neuron.2013.10.044
   Fellows SJ, 2001, CLIN NEUROPHYSIOL, V112, P1793, DOI 10.1016/S1388-2457(01)00623-X
   ICARDO JM, 1982, ACTA ANAT, V113, P108
   Ito Y, 2010, NEUROL MED-CHIR, V50, P135, DOI 10.2176/nmc.50.135
   Kuper M, 2011, NEUROIMAGE, V54, P2612, DOI 10.1016/j.neuroimage.2010.11.028
   Kuper M, 2012, HUM BRAIN MAPP, V33, P2741, DOI 10.1002/hbm.21400
   Matsumoto Masato, 2007, Fukushima J Med Sci, V53, P85
   Nicolson RI, 1999, LANCET, V353, P1662, DOI 10.1016/S0140-6736(98)09165-X
   Reeber SL, 2013, FRONT SYST NEUROSCI, V7, DOI 10.3389/fnsys.2013.00083
   Rhoton AL, 2000, NEUROSURGERY, V47, pS29, DOI 10.1097/00006123-200009001-00010
   Schmahmann JD, 1998, BRAIN, V121, P561, DOI 10.1093/brain/121.4.561
   Steele CJ, 2017, CEREB CORTEX, V27, P4537, DOI 10.1093/cercor/bhw258
   Sultan F, 2010, NEUROSCIENCE, V167, P965, DOI 10.1016/j.neuroscience.2010.03.007
   Voogd J, 2016, GRAYS ANATOMY, P331
NR 16
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E606
EP E611
DI 10.1016/j.wneu.2018.10.111
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100074
PM 31108077
DA 2020-05-12
ER

PT J
AU Kim, YI
   Lee, DH
   Cho, CB
   Yang, SH
   Kim, IS
   Hong, JT
   Sung, JH
   Jeun, SS
AF Kim, Young Il
   Lee, Dong Hoon
   Cho, Chul Bum
   Yang, Seung Ho
   Kim, Il Sup
   Hong, Jae Taek
   Sung, Jae Hoon
   Jeun, Sin Soo
TI The Usefulness of Dual-Volume Visualization (Three-Dimensional Digital
   Subtraction Angiography and Cross-Sectional Imaging) for Surgical
   Planning in Treating Intracranial Meningiomas: A Case Series and
   Technical Report
SO WORLD NEUROSURGERY
LA English
DT Article
DE Computer-assisted surgery; Digital subtraction angiography; Meningioma;
   Three-dimensional imaging
ID FUSION; ANGIOARCHITECTURE; VEINS
AB OBJECTIVE: In presurgical planning for intracranial meningiomas, the relationship between tumors and adjacent vasculature must be identified. The purpose of this study was to evaluate the usefulness of 3-dimensional digital subtraction angiography (3D-DSA) with dual-volume visualization (DVV).
   METHODS: Between February 2013 and April 2016, 26 patients with intracranial meningiomas enrolled in this study. Two or 3 days before surgery, 3D-DSA with DVV was performed for presurgical planning. If necessary, the tumor was simultaneously embolized.
   RESULTS: Vascular supply and disfiguration observed by preoperative 3D-DSA with DVV closely resembled those actually observed during surgery. All but 2 patients had total tumor resection (Simpson grade 1 or 2). Three of 26 patients had new neurologic deficits.
   CONCLUSIONS: 3D-DSA with DVV may be useful for preoperative planning by allowing the surgeon to identify the relationship between a tumor and peritumoral vasculature before meningioma surgery. Young neurosurgeons with little experience may benefit most from this technique.
C1 [Kim, Young Il; Lee, Dong Hoon; Cho, Chul Bum; Yang, Seung Ho; Kim, Il Sup; Hong, Jae Taek; Sung, Jae Hoon] Catholic Univ Korea, St Vincents Hosp, Coll Med, Dept Neurosurg, Suwon, South Korea.
   [Jeun, Sin Soo] Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Neurosurg, Seoul, South Korea.
RP Jeun, SS (reprint author), Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Neurosurg, Seoul, South Korea.
EM ssjeun@catholic.ac.kr
OI Sung, Jae Hoon/0000-0003-3738-6413; Lee, Dong Hoon/0000-0002-3796-8707
CR Adeeb N, 2016, INTERV NEURORADIOL, V22, P687, DOI 10.1177/1591019916663469
   Besharati TL, 2015, J NEUROSURG, V123, P206, DOI DOI 10.3171/2014.9.JNS141001
   Ferroli P, 2010, NEUROSURGERY, V67, P79, DOI 10.1227/01.NEU.0000383133.01993.96
   Fukuda K, 2016, WORLD NEUROSURG, V85, P353, DOI 10.1016/j.wneu.2015.08.075
   Gu SX, 2011, CLIN NEUROL NEUROSUR, V113, P889, DOI 10.1016/j.clineuro.2011.06.008
   Huang CT, 2017, WORLD NEUROSURG, V101, DOI 10.1016/j.wneu.2017.03.080
   Kashimura H, 2008, NEUROL MED-CHIR, V48, P418, DOI 10.2176/nmc.48.418
   Kin T, 2017, NEUROL MED-CHIR, V57, P513, DOI 10.2176/nmc.ra.2016-0320
   Kin T, 2011, NEUROSURGERY, V69, P40, DOI 10.1227/NEU.0b013e318211019a
   Li ZF, 2015, CLIN NEUROL NEUROSUR, V128, P56, DOI 10.1016/j.clineuro.2014.11.002
   Low D, 2010, BRIT J NEUROSURG, V24, P69, DOI 10.3109/02688690903506093
   Mert A, 2012, NEUROSURGERY, V71, P286, DOI 10.1227/NEU.0b013e31826a8a75
   Oishi M, 2011, NEUROL MED-CHIR, V51, P201, DOI 10.2176/nmc.51.201
   Pandolfo I, 2007, EUR RADIOL, V17, P1584, DOI 10.1007/s00330-006-0519-4
   Schoenegger K, 2009, EUR J NEUROL, V16, P874, DOI 10.1111/j.1468-1331.2009.02613.x
   Shimizu S, 2003, AM J NEURORADIOL, V24, P2011
   Yin TK, 2017, WORLD NEUROSURG, V104, P220, DOI 10.1016/j.wneu.2017.04.145
NR 17
TC 0
Z9 0
U1 1
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E59
EP E66
DI 10.1016/j.wneu.2018.09.046
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100007
PM 30240858
DA 2020-05-12
ER

PT J
AU Kimura, H
   Hayashi, K
   Taniguchi, M
   Hosoda, K
   Fujita, A
   Seta, T
   Tomiyama, A
   Kohmura, E
AF Kimura, Hidehito
   Hayashi, Kosuke
   Taniguchi, Masaaki
   Hosoda, Kohkichi
   Fujita, Atsushi
   Seta, Takeshi
   Tomiyama, Akio
   Kohmura, Eiji
TI Detection of Hemodynamic Characteristics Before Growth in Growing
   Cerebral Aneurysms by Analyzing Time-of-Flight Magnetic Resonance
   Angiography Images Alone: Preliminary Results
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebral aneurysm; Computational fluid dynamics; Enlargement; Growing;
   Magnetic resonance angiography
ID UNRUPTURED INTRACRANIAL ANEURYSMS; COMPUTATIONAL FLUID-DYNAMICS;
   LATTICE-BOLTZMANN METHOD; RUPTURE; RISK; POPULATION; LOCATION; PATIENT;
   ARTERY; SIZE
AB OBJECTIVE: Cerebral aneurysm growth often precedes rupture. Definite contributors to aneurysm growth have not been determined even by means of recently developed commercially available computational fluid dynamics (CFD) software. We developed an original CFD tool that can analyze data from time-of-flight magnetic resonance angiography (TOF-MRA) before growth in the growing aneurysms and investigate possible factors for aneurysm growth in the near future.
   METHODS: We retrospectively reviewed unruptured aneurysms that were treated at our institute because of aneurysm growth (growing group) between April 2013 and March 2017. Stable aneurysms that had demonstrated no growth for more than 5 years were selected (stable group). TOF-MRA data of these aneurysms were retrospectively converted to 3-dimensional vessel geometric data; 3 hemodynamic indices including streamline, wall shear stress (WSS), and oscillatory shear index were calculated by our original CFD tool using the lattice Boltzmann method to quantitatively compare the 2 groups.
   RESULTS: Six growing aneurysms and 6 stable aneurysms were analyzed. Of the 6 growing aneurysms, WSS on the focal aneurysmal sac increased temporally in the vicinity of the constant low WSS area at the peak systolic phase. By contrast, WSS did not increase during any part of the cardiac cycle in 3 of the 6 stable aneurysms. The peak values of WSS were significantly different between the 2 groups.
   CONCLUSIONS: A focal increase in WSS in the peak systolic phase may be a risk factor for aneurysm enlargement in the near future.
C1 [Kimura, Hidehito; Taniguchi, Masaaki; Fujita, Atsushi; Kohmura, Eiji] Kobe Univ, Grad Sch Med, Dept Neurosurg, Kobe, Hyogo, Japan.
   [Hayashi, Kosuke; Tomiyama, Akio] Kobe Univ, Grad Sch Med, Kobe, Hyogo, Japan.
   [Hosoda, Kohkichi] Kobe City Nishi Kobe Med Ctr, Dept Neurosurg, Kobe, Hyogo, Japan.
   [Seta, Takeshi] Univ Toyama, Grad Sch Sci & Engn Res, Toyama, Japan.
RP Kimura, H (reprint author), Kobe Univ, Grad Sch Med, Dept Neurosurg, Kobe, Hyogo, Japan.
EM hkimura@med.kobe-u.ac.jp
RI Taniguchi, Masaaki/AAM-4198-2020; Fujita, Atsushi/Q-6619-2019; Hosoda,
   Kohkichi/AAF-1949-2020
OI Taniguchi, Masaaki/0000-0003-4678-2573; Fujita,
   Atsushi/0000-0003-1294-6584; Hosoda, Kohkichi/0000-0002-0419-9497
CR Abas A, 2016, COMPUT MATH METHOD M, DOI 10.1155/2016/6143126
   Aidun CK, 2010, ANNU REV FLUID MECH, V42, P439, DOI 10.1146/annurev-fluid-121108-145519
   Boussel L, 2008, STROKE, V39, P2997, DOI 10.1161/STROKEAHA.108.521617
   Brinjikji W, 2017, J NEUROINTERV SURG, V9, P376, DOI 10.1136/neurintsurg-2016-012327
   Chen S, 1998, ANNU REV FLUID MECH, V30, P329, DOI 10.1146/annurev.fluid.30.1.329
   Connolly ES, 2012, STROKE, V43, P1711, DOI 10.1161/STR.0b013e3182587839
   Fisher C, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3148470
   Funazaki K-I, FLOW STRUCTURE COUPL
   Hashimoto T, 2006, NEUROL RES, V28, P372, DOI 10.1179/016164106X14973
   Hayashi K, 2006, CFD J, V15, P225
   Imbesi SG, 1999, AM J NEURORADIOL, V20, P1703
   Isoda H, 2010, NEURORADIOLOGY, V52, P921, DOI 10.1007/s00234-009-0635-3
   Isoda H, 2010, NEURORADIOLOGY, V52, P913, DOI 10.1007/s00234-009-0634-4
   Le WJ, 2013, BMC NEUROL, V13, DOI 10.1186/1471-2377-13-166
   Mantha A, 2006, AM J NEURORADIOL, V27, P1113
   Marzo A, 2011, ANN BIOMED ENG, V39, P884, DOI 10.1007/s10439-010-0187-z
   Maurits NM, 2007, J BIOMECH, V40, P427, DOI 10.1016/j.jbiomech.2005.12.008
   Meng H, 2014, AM J NEURORADIOL, V35, P1254, DOI 10.3174/ajnr.A3558
   Meng H, 2007, STROKE, V38, P1924, DOI 10.1161/STROKEAHA.106.481234
   Morita A, 2005, J NEUROSURG, V102, P601, DOI 10.3171/jns.2005.102.4.0601
   Naito T, 2012, ACTA NEUROCHIR, V154, P993, DOI 10.1007/s00701-012-1305-5
   Ohta M, 2011, J NON-NEWTON FLUID, V166, P404, DOI 10.1016/j.jnnfm.2011.01.011
   Russell JH, 2013, NEUROSURGERY, V73, P1061, DOI 10.1227/NEU.0000000000000137
   Sano T, 2017, WORLD NEUROSURG, V98, DOI 10.1016/j.wneu.2016.12.047
   Sforza DM, 2016, J NEUROINTERV SURG, V8, P407, DOI 10.1136/neurintsurg-2014-011339
   Shiue I, 2011, CEREBROVASC DIS, V31, P573, DOI 10.1159/000324938
   Steinman DA, 2002, ANN BIOMED ENG, V30, P483, DOI 10.1114/1.1467679
   Sugiyama SI, 2012, WORLD NEUROSURG, V78, P462, DOI 10.1016/j.wneu.2011.09.023
   Tsuji M, 2017, J NEUROSURG, V126, P1566, DOI 10.3171/2016.3.JNS152264
   Weichert F, 2013, COMPUT MATH METHOD M, DOI 10.1155/2013/527654
   Wermer MJH, 2007, STROKE, V38, P1404, DOI 10.1161/01.STR.0000260955.51401.cd
   Wiebers D, 2003, LANCET, V362, P103, DOI 10.1016/S0140-6736(03)13860-3
   Xiang J, 2014, AM J NEURORADIOL, V35, P1849, DOI 10.3174/ajnr.A3710
   Yamaguchi T, MULTISCALE COMPUTATI
NR 34
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1439
EP E1448
DI 10.1016/j.wneu.2018.11.081
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100177
PM 30465954
DA 2020-05-12
ER

PT J
AU Kocaman, U
   Yilmaz, H
AF Kocaman, Umit
   Yilmaz, Hakan
TI Description of a Modified Technique (mini craniotomy-basal membranotomy)
   for Chronic Subdural Hematoma Surgery and Evaluation of the Contribution
   of Basal Membranotomy Performed as Part of This Technique to Cerebral
   Expansion
SO WORLD NEUROSURGERY
LA English
DT Article
DE Basal membranotomy; Chronic; Subdural hematoma
ID SURGICAL-TREATMENT; MEMBRANECTOMY; RECURRENCE
AB OBJECTIVE: To determine the effectiveness of basal membranotomy performed to ensure cerebral expansion in patients operated for chronic subdural hematoma.
   METHODS: Patients who were operated for unilateral chronic subdural hematoma and underwent basal membranotomy in addition to hematoma drainage were included in the first phase of the study. After the superficial membranous structures were excised, the maximum perpendicular distance between the internal tabula and the cerebral surface was measured after subdural hematoma evacuation. Subsequently, basal membranotomy was performed, the maximum perpendicular distance between the internal tabula and the cerebral surface was measured again, and the improvement in cerebral expansion was statistically calculated. The improvement of cerebral expansion in the patients who had undergone double burr hole drainage was statistically calculated in the second stage of the study.
   RESULTS: The cerebral expansion after the basal membrane excision was 41.1% in those with a 1.5- to 2-cm hematoma, 43.1% in those with a 2.1- to 3-cm hematoma, 43.5% in those with a 3.1- to 4-cm hematoma, and 45.4% in those with a hematoma thicker than 4 cm on average. No recurrence was seen during the 6-month follow-up in any patient. Double burr hole drainage revealed similar values for cerebral expansion increase with a mean value of 10%. The burr hole drainage was repeated because of recurrence in 5 patients during the 2-month follow-up.
   CONCLUSIONS: The mini craniotomy-basal membranotomy technique provided statistically significantly better cerebral expansion in patients with chronic subdural hematoma when compared with the double burr hole drainage technique.
C1 [Kocaman, Umit] Izmir Cigli Reg Educ & Res Hosp, Dept Neurosurg, Izmir, Turkey.
   [Yilmaz, Hakan] Usak Univ, Dept Neurosurg, Educ & Res Hosp, Usak, Turkey.
RP Yilmaz, H (reprint author), Usak Univ, Dept Neurosurg, Educ & Res Hosp, Usak, Turkey.
EM dr_hakanyilmaz@hotmail.com
CR Callovini GM, 2014, NEUROL MED-CHIR, V54, P349, DOI 10.2176/nmc.oa2013-0099
   de Araujo Silva Danilo Otavio, 2012, Surg Neurol Int, V3, P150, DOI 10.4103/2152-7806.104744
   Gelabert-Gonzalez M, 2005, CLIN NEUROL NEUROSUR, V107, P223, DOI 10.1016/j.clineuro.2004.09.015
   Gurelik M, 2007, CAN J NEUROL SCI, V34, P84, DOI 10.1017/S0317167100005849
   Kim JH, 2011, J KOREAN NEUROSURG S, V50, P103, DOI 10.3340/jkns.2011.50.2.103
   Lee JK, 2009, J KOREAN NEUROSURG S, V46, P210, DOI 10.3340/jkns.2009.46.3.210
   Lee JY, 2004, SURG NEUROL, V61, P523, DOI 10.1016/j.surneu.2003.10.026
   Mohamed EEHH, 2003, BRIT J NEUROSURG, V17, P244, DOI 10.1080/0268869031000153134
   Mondorf Y, 2009, BRIT J NEUROSURG, V23, P612, DOI 10.3109/02688690903370297
   Mori K, 2001, NEUROL MED-CHIR, V41, P371, DOI 10.2176/nmc.41.371
   Muzii V F, 2005, J Neurosurg Sci, V49, P41
   Muzii VF, 2005, J NEUROSURG SCI, V49, P6
   Rocchi G, 2007, SURG NEUROL, V67, P374, DOI 10.1016/j.surneu.2006.08.066
   Tanikawa M, 2001, ACTA NEUROCHIR, V143, P613, DOI 10.1007/s007010170067
   Wilberger JE, 2000, NEUROSURG CLIN N AM, V11, P435, DOI 10.1016/S1042-3680(18)30105-0
   Yamashima T, 2000, NEUROSURG CLIN N AM, V11, P413, DOI 10.1016/S1042-3680(18)30103-7
NR 16
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1002
EP E1006
DI 10.1016/j.wneu.2018.10.196
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100121
PM 30404056
DA 2020-05-12
ER

PT J
AU Koffie, RM
   Yanamadala, V
   Coumans, JV
AF Koffie, Robert M.
   Yanamadala, Vijay
   Coumans, Jean-Valery
TI High Sacral Endplate Inclination Vector Forces Are Associated with Pars
   Fracture-Mediated Lumbosacral Spondylolisthesis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Arthropathy; Facet; Pars fracture; Sacral slope; Spondylolisthesis
ID DEGENERATIVE LUMBAR SPONDYLOLISTHESIS; SAGITTAL ALIGNMENT; PELVIC
   INCIDENCE; SPINAL STENOSIS; FUSION; DECOMPRESSION
AB OBJECTIVE:Lumbar spondylolisthesis can be related to facet arthropathy and disc degeneration or to a fracture of the pars interarticularis, but the mechanistic underpinnings of spondylolisthesis remain unclear. We posit that high sacral slope and body weight increase sacral inclination vector forces, which leads to pars fractures and exacerbates risk for spondylolisthesis.
   METHODS:To investigate this hypothesis, we measured the sacral slope, body weight, and S1 endplate vector forces for patients who underwent L5-S1 fusion for grade I spondylolisthesis. Patients were stratified based on presence of pars fractures versus facet arthropathy, and statistical analyses were performed to determine whether high sacral endplate inclination vector force is associated with pars fracture-mediated spondylolisthesis.
   RESULTS:We identified 131 patients who had L5-S1 fusion for spondylolisthesis. The mean age was 56 years, and 57% were female. The body weight of patients ranged from 45.4 to 141.9 kg with an average of 83.8 kg; 32 patients had single-level L5-S1 spondylolisthesis secondary to bilateral L5 pars interarticularis fractures, whereas 99 patients had L5-S1 spondylolisthesis due to facet arthropathy. Patients with pars fractures had steeper sacral slopes (43.2 +/- 10.1 degrees) compared with those without pars fractures (36.8 +/- 8.1 degrees) (P = 0.0007, odds ratio 2.71). Despite having no significant differences in weight (82.7 +/- 17.2 vs. 87.3 +/- 17.2 kg, P = 0.189), patients with pars fractures had 49% greater sacral inclination vector forces compared with those without pars fractures (586 +/- 158 N vs. 394 +/- 90 N, P < 0.0001).
   CONCLUSIONS:These data suggest that high sacral endplate inclination vector force is a risk factor for developing pars fracture-mediated spondylolisthesis.
C1 [Koffie, Robert M.; Yanamadala, Vijay; Coumans, Jean-Valery] Harvard Med Sch, Dept Neurosurg, Boston, MA 02115 USA.
RP Coumans, JV (reprint author), Harvard Med Sch, Dept Neurosurg, Boston, MA 02115 USA.
EM jcoumans@mgh.harvard.edu
CR Blumenthal C, 2013, J NEUROSURG-SPINE, V18, P340, DOI 10.3171/2013.1.SPINE12537
   Boulay C, 2006, EUR SPINE J, V15, P415, DOI 10.1007/s00586-005-0984-5
   Forsth P, 2016, NEW ENGL J MED, V374, P1413, DOI 10.1056/NEJMoa1513721
   Ghogawala Z, 2016, NEW ENGL J MED, V374, P1424, DOI 10.1056/NEJMoa1508788
   HERKOWITZ HN, 1991, J BONE JOINT SURG AM, V73A, P802, DOI 10.2106/00004623-199173060-00002
   Hollenberg GM, 2002, SPINE, V27, P181, DOI 10.1097/00007632-200201150-00012
   Kelleher MO, 2010, SPINE, V35, pE981, DOI 10.1097/BRS.0b013e3181c46fb4
   Labelle H, 2004, SPINE, V29, P2049, DOI 10.1097/01.brs.0000138279.53439.cc
   Lim JK, 2014, J KOREAN NEUROSURG S, V55, P331, DOI 10.3340/jkns.2014.55.6.331
   Mehta Vivek A, 2015, Neurosurgery, V76 Suppl 1, pS42, DOI 10.1227/01.neu.0000462077.50830.1a
   Rampersaud YR, 2014, CAN J SURG, V57, pE126, DOI 10.1503/cjs.032213
   Resnick DK, 2014, J NEUROSURG-SPINE, V21, P54, DOI 10.3171/2014.4.SPINE14274
   Roussouly P, 2006, SPINE, V31, P2484, DOI 10.1097/01.brs.0000239155.37261.69
   Sahin MS, 2015, SPINE, V40, pE1058, DOI 10.1097/BRS.0000000000001070
   Weinstein JN, 2007, NEW ENGL J MED, V356, P2257, DOI 10.1056/NEJMoa070302
NR 15
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E790
EP E794
DI 10.1016/j.wneu.2018.10.148
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100095
PM 30391597
DA 2020-05-12
ER

PT J
AU Kong, DS
   Kim, YH
   Kim, YH
   Hur, KY
   Kim, JH
   Kim, MS
   Paek, SH
   Kwon, DH
   Kim, DK
   Lee, JI
AF Kong, Doo-Sik
   Kim, Young-Hoon
   Kim, Yong Hwy
   Hur, Kyu Yeon
   Kim, Jung Hee
   Kim, Min-Seon
   Paek, Sun Ha
   Kwon, Do-Hoon
   Kim, Dong-Kyu
   Lee, Jung-Il
TI Long-Term Efficacy and Tolerability of Gamma Knife Radiosurgery for
   Growth Hormone-Secreting Adenoma: A Retrospective Multicenter Study
   (MERGE-001)
SO WORLD NEUROSURGERY
LA English
DT Article
DE Acromegaly; Gamma knife radiosurgery; Long-term efficacy; Multicenter;
   Tolerability
ID STEREOTACTIC RADIOSURGERY; IGF-I; RADIOTHERAPY; GENDER
AB OBJECTIVE: Little is known about the long-term efficacy, prognostic factors, and tolerability of gamma knife radiosurgery (GKS) for acromegaly. The aim of this study was to investigate long-term hormonal effects, prognostic factors, and tolerability of GKS in patients with growth hormone-secreting adenoma.
   METHODS: A retrospective multicenter study over 25 years with a median follow-up of 85.2 months was performed. A total of 138 patients from 3 tertiary referral centers in South Korea were included in this study between 1991 and 2017. Main outcome measures were endocrine remission, endocrine control under somatostatin analogues, and hypopituitarism.
   RESULTS: With a mean follow-up period of 85.2 months (range, 12-304 months), overall median time to the endocrine remission and control under long-acting somatostatin analogues was 138 months and 96 months, respectively. Female sex, normal age-adjusted insulin growth factor-1 (IGF-1) <= 2, and GKS as an adjuvant treatment were significantly favorable factors for remission (P = 0.004, P = 0.001, P = 0.010, respectively). The early response group had a significantly lower proportion of normal age-adjusted IGF-1 levels >2 than did the late response group (22.2% vs. 51.7%, P = 0.035); also, the early response group had lower radiation dose than the late response group (24.3 Gy vs. 27.0 Gy, P = 0.003). The incidence of GKS-induced hypopituitarism (1 or more) was 12 of 138 patients (8.6%) at the last follow-up.
   CONCLUSIONS: In acromegalic patients, women with normal age-adjusted IGF-1 <= 2 and GKS as an adjuvant treatment have a better response to GKS. We should take into account the variability of radiosensitivity of the tumor according to the gender and IGF-1 level.
C1 [Kong, Doo-Sik; Lee, Jung-Il] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Endocrinol,Dept Neurosurg, Seoul, South Korea.
   [Hur, Kyu Yeon] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Endocrinol,Dept Internal Med, Seoul, South Korea.
   [Kim, Young-Hoon; Kwon, Do-Hoon] Univ Ulsan, Coll Med, Asan Med Ctr, Div Endocrinol,Dept Neurosurg, Ulsan, South Korea.
   [Kim, Min-Seon] Univ Ulsan, Coll Med, Asan Med Ctr, Div Endocrinol,Dept Internal Med, Ulsan, South Korea.
   [Kim, Yong Hwy; Paek, Sun Ha; Kim, Dong-Kyu] Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Div Endocrinol & Metab,Dept Neurosurg, Seoul, South Korea.
   [Kim, Jung Hee] Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Div Endocrinol & Metab,Dept Internal Med, Seoul, South Korea.
RP Lee, JI (reprint author), Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Endocrinol,Dept Neurosurg, Seoul, South Korea.
EM jilee@skku.edu
OI Kim, Young-Hoon/0000-0002-8852-6503
FU Ministry of Health and Welfare, Republic of KoreaMinistry of Health &
   Welfare, Republic of Korea; National Research Foundation of Korea by the
   Ministry of Science, ICT, and Future Planning (MSIP) of Korea; National
   Research Foundation - MSIP of Korea [NRF-2015M3A9A7029740,
   NRF-2015M3C9A1044522, NRF-2015M3A9B5053642]; Samsung Medical Center
   grant
FX This study was supported by the Ministry of Health and Welfare, Republic
   of Korea, from National Research Foundation of Korea by the Ministry of
   Science, ICT, and Future Planning (MSIP) of Korea and a grant
   (NRF-2015M3A9A7029740, NRF-2015M3C9A1044522, and NRF-2015M3A9B5053642)
   of the National Research Foundation funded by MSIP of Korea, and by a
   Samsung Medical Center grant.
CR Adeberg S, 2012, INT J RADIAT ONCOL, V83, P859, DOI 10.1016/j.ijrobp.2011.08.010
   Arosio M, 2012, EUR J ENDOCRINOL, V167, P189, DOI 10.1530/EJE-12-0084
   Attanasio R, 2003, J CLIN ENDOCR METAB, V88, P3105, DOI 10.1210/jc.2002-021663
   Castinetti F, 2005, J CLIN ENDOCR METAB, V90, P4483, DOI 10.1210/jc.2005-0311
   Cohen-Inbar O, 2016, CLIN ENDOCRINOL, V84, P524, DOI 10.1111/cen.12938
   Colao A, 2005, CLIN ENDOCRINOL, V63, P342, DOI 10.1111/j.1365-2265.2005.02351.x
   Colao A, 2002, J ENDOCRINOL INVEST, V25, P532, DOI 10.1007/BF03345496
   Epaminonda P, 2001, CLIN ENDOCRINOL, V55, P183, DOI 10.1046/j.1365-2265.2001.01294.x
   Franzin A, 2012, INT J ENDOCRINOL, DOI 10.1155/2012/342034
   Freda P U, 2001, Pituitary, V4, P163, DOI 10.1023/A:1015314906972
   Jagannathan J, 2008, NEUROSURGERY, V62, P1262, DOI 10.1227/01.neu.0000333297.41813.3d
   Jezkova J, 2006, CLIN ENDOCRINOL, V64, P588, DOI 10.1111/j.1365-2265.2006.02513.x
   Landolt AM, 2000, J CLIN ENDOCR METAB, V85, P1287, DOI 10.1210/jc.85.3.1287
   Lee CC, 2014, J CLIN ENDOCR METAB, V99, P1273, DOI 10.1210/jc.2013-3743
   Liu XM, 2012, J NEURO-ONCOL, V109, P71, DOI 10.1007/s11060-012-0862-z
   Losa M, 2008, J CLIN ENDOCR METAB, V93, P2546, DOI 10.1210/jc.2008-0135
   Oldfield EH, 2017, J NEUROSURG, V126, P1959, DOI 10.3171/2016.8.JNS161123
   Pollock BE, 2007, J NEUROSURG, V106, P833, DOI 10.3171/jns.2007.106.5.833
   Ronchi CL, 2009, CLIN ENDOCRINOL, V71, P846, DOI 10.1111/j.1365-2265.2009.03589.x
   Schaller Bernhard, 2002, Pituitary, V5, P247, DOI 10.1023/A:1025329900839
   Tanaka S, 2010, ENDOCR J, V57, P477, DOI 10.1507/endocrj.K09E-342
   TSANG RW, 1994, INT J RADIAT ONCOL, V30, P557, DOI 10.1016/0360-3016(92)90941-A
   Vik-Mo EO, 2007, EUR J ENDOCRINOL, V157, P255, DOI 10.1530/EJE-07-0189
NR 23
TC 2
Z9 3
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1291
EP E1299
DI 10.1016/j.wneu.2018.11.038
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100157
PM 30448582
DA 2020-05-12
ER

PT J
AU Krzyzewski, RM
   Klis, KM
   Kwinta, BM
   Gackowska, M
   Stachura, K
   Starowicz-Filip, A
   Thompson, A
   Gasowski, J
AF Krzyzewski, Roger M.
   Klis, Kornelia M.
   Kwinta, Borys M.
   Gackowska, Malgorzata
   Stachura, Krzysztof
   Starowicz-Filip, Anna
   Thompson, Ashley
   Gasowski, Jerzy
TI Analysis of Anterior Cerebral Artery Tortuosity: Association with
   Anterior Communicating Artery Aneurysm Rupture
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior cerebral artery; Subarachnoid hemorrhage; Tortuosity
ID WALL SHEAR-STRESS; RISK-FACTORS; FLOW
AB BACKGROUND: Many researchers have found a correlation between tortuous arteries and development of aneurysms in cerebral arteries. However, there are no studies analyzing the impact of tortuosity on risk of subarachnoid hemorrhage (SAH) occurrence. Therefore, we decided to determine whether tortuosity of the anterior cerebral artery can be related to the rupture of anterior communicating artery aneurysm and to severity and treatment outcome of SAH.
   METHODS: We retrospectively analyzed anterior cerebral artery anatomy of 121 patients with anterior communicating artery aneurysms. From patients' medical records, we obtained their history including previous and current diseases and medications. For each patient we calculated relative length, sum of angle metrics, triangular index, product of angle distance, and inflection count metrics.
   RESULTS: Patients with SAH had significantly higher relative length (0.70 +/- 0.19 vs. 0.63 +/- 0.22; P = 0.03) and significantly lower inflection count metrics (0.10 +/- 0.08 vs. 0.16 +/- 0.19; P < 0.01), respectively. In multivariate logistic regression analysis, after adjustment of all possible confounders, diabetes mellitus (odds ratio [OR], 0.154; 95% confidence interval [CI], 0.032-0.553; P < 0.01) and higher inflection count metrics (OR, 0.604; 95% CI, 0.357-0.909; P = 0.042) remained independently associated with lower risk of SAH. We also found an independent correlation between aneurysm dome size (R = -0.289; P = 0.02) and triangular index (R = 0.273; P = 0.03) and Glasgow Coma Scale score on admission.
   CONCLUSIONS: Higher anterior cerebral artery tortuosity might be a protective factor against anterior communicating artery aneurysm rupture.
C1 [Krzyzewski, Roger M.; Kwinta, Borys M.; Stachura, Krzysztof; Starowicz-Filip, Anna] Jagiellonian Univ, Med Coll, Dept Neurosurg & Neurotraumatol, Krakow, Poland.
   [Gasowski, Jerzy] Jagiellonian Univ, Med Coll, Dept Internal Med & Gerontol, Krakow, Poland.
   [Krzyzewski, Roger M.; Klis, Kornelia M.; Gasowski, Jerzy] Jagiellonian Univ, Med Coll, TENSOR Team NeuroSurg Oriented Res, Krakow, Poland.
   [Klis, Kornelia M.; Gackowska, Malgorzata; Thompson, Ashley] Jagiellonian Univ, Med Coll, Fac Med, Krakow, Poland.
   [Klis, Kornelia M.] AGH Univ Sci & Technol, Fac Comp Sci Elect & Telecommun, Krakow, Poland.
RP Krzyzewski, RM (reprint author), Jagiellonian Univ, Med Coll, Dept Neurosurg & Neurotraumatol, Krakow, Poland.; Krzyzewski, RM (reprint author), Jagiellonian Univ, Med Coll, TENSOR Team NeuroSurg Oriented Res, Krakow, Poland.
EM roger.krzyzewski@gmail.com
RI K, Kornelia/AAJ-9526-2020; Krzyzewski, Roger M./AAD-3383-2019
OI Gasowski, Jerzy/0000-0002-8025-5323
FU National Science Center-Poland [2014/15/N/NZ4/01062]
FX This study was funded by the National Science Center-Poland
   (2014/15/N/NZ4/01062) to R. M. Krzyewski.
CR Annunziata R, 2016, IEEE J BIOMED HEALTH, V20, P1129, DOI 10.1109/JBHI.2015.2440091
   Baharoglu MI, 2010, STROKE, V41, P1423, DOI 10.1161/STROKEAHA.109.570770
   Can A, 2016, NEUROSURGERY, V78, P510, DOI 10.1227/NEU.0000000000001083
   Cebral JR, 2010, AM J NEURORADIOL, V31, P304, DOI 10.3174/ajnr.A1819
   DOBRIN PB, 1988, SURGERY, V104, P568
   Han HC, 2012, J VASC RES, V49, P185, DOI 10.1159/000335123
   Hassan T, 2005, J NEUROSURG, V103, P662, DOI 10.3171/jns.2005.103.4.0662
   Hoi YM, 2011, ANN BIOMED ENG, V39, P1414, DOI 10.1007/s10439-011-0255-z
   Hughes AD, 2006, J HYPERTENS, V24, P889, DOI 10.1097/01.hjh.0000222759.61735.98
   Inagawa T, 2010, WORLD NEUROSURG, V73, P155, DOI 10.1016/j.surneu.2009.03.007
   Klis KM, 2019, J NEUROSURG, V130, P1478, DOI 10.3171/2017.12.JNS172114
   Kono AK, 2010, JPN J RADIOL, V28, P273, DOI 10.1007/s11604-010-0420-6
   Labeyrie PE, 2017, INT J STROKE, V12, P549, DOI 10.1177/1747493016687577
   Li Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024232
   Majeski J, 1998, SOUTHERN MED J, V91, P949, DOI 10.1097/00007611-199810000-00010
   Meng H, 2014, AM J NEURORADIOL, V35, P1254, DOI 10.3174/ajnr.A3558
   Miura Y, 2013, STROKE, V44, P519, DOI 10.1161/STROKEAHA.112.675306
   Morales HG, 2015, J BIOMECH, V48, P585, DOI 10.1016/j.jbiomech.2015.01.016
   Owen Christopher G, 2008, Ophthalmology, V115, pe27, DOI 10.1016/j.ophtha.2008.02.009
   Perez EA, 2016, CHEM ENGINEER TRANS, V49, P73, DOI 10.3303/CET1649013
   Rikhtegar F, 2012, ATHEROSCLEROSIS, V221, P432, DOI 10.1016/j.atherosclerosis.2012.01.018
   Russell JH, 2013, NEUROSURGERY, V73, P1061, DOI 10.1227/NEU.0000000000000137
   Sasongko MB, 2011, DIABETOLOGIA, V54, P2409, DOI 10.1007/s00125-011-2200-y
   Shojima M, 2004, STROKE, V35, P2500, DOI 10.1161/01.STR.0000144648.89172.0f
   Vorobtsova N, 2016, ANN BIOMED ENG, V44, P2228, DOI 10.1007/s10439-015-1492-3
   Wang GX, 2016, YONSEI MED J, V57, P1178, DOI 10.3349/ymj.2016.57.5.1178
   Xie XZ, 2014, J BIOMECH ENG-T ASME, V136, DOI 10.1115/1.4028052
   Yin Y, 2013, COMPUT MATH METHOD M, DOI 10.1155/2013/260410
   Zegers ES, 2007, NETH HEART J, V15, P191, DOI 10.1007/BF03085979
   Zhang Y, 2013, SCI WORLD J, DOI 10.1155/2013/508131
NR 30
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E480
EP E486
DI 10.1016/j.wneu.2018.10.086
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100058
PM 30366144
DA 2020-05-12
ER

PT J
AU Lai, PMR
   See, AP
   Silva, MA
   Gormley, WB
   Frerichs, KU
   Aziz-Sultan, MA
   Du, R
AF Lai, Pui Man Rosalind
   See, Alfred Pokmeng
   Silva, Michael A.
   Gormley, William B.
   Frerichs, Kai U.
   Aziz-Sultan, M. Ali
   Du, Rose
TI Noninfectious Fever in Aneurysmal Subarachnoid Hemorrhage: Association
   with Cerebral Vasospasm and Clinical Outcome
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebral vasospasm; Delayed cerebral infarction; Delayed cerebral
   ischemia; Delayed ischemic neurologic deficits; Fever; Subarachnoid
   hemorrhage
ID TEMPERATURE; COMPLICATIONS; PREDICTORS; IMPACT; DIAGNOSIS
AB OBJECTIVE: The purpose of this study was to evaluate the association between noninfectious fever onset and radiographic vasospasm, delayed ischemic neurologic deficit (DIND), delayed cerebral infarction (DCI), and clinical outcome in patients with aneurysmal subarachnoid hemorrhage.
   METHODS: We evaluated 44 patients for the association between noninfectious fever (greater than 101.5 degrees F) and the development of radiographic vasospasm by digital subtraction angiography (DSA) and transcranial Doppler (TCD), DIND, DCI, and modified Rankin scale outcome score at 6 months to 2 years. Multivariate logistic regression analyses were performed to account for patient age, sex, admission Hunt and Hess grade, and Fisher grade. TCD was additionally used for temporal analysis.
   RESULTS: Noninfectious fever was significantly associated with radiographic vasospasm using both DSA (odds ratio [OR], 2.2; 95% confidence interval [CI], 1.2-4.5; P = 0.02) and TCD (OR, 2.4; 95% CI, 1.2-5.6; P = 0.02), but it was not associated with DIND, DCI, or outcome. The maximum cross correlation between TCD velocity and temperature occurred for temperatures taken 1 day prior to TCD velocity measurement. A quadratic mixed-effects model demonstrated that TCD velocity was significantly associated with temperature from 1 day prior to TCD velocity measurement (beta = 13.5; 95% CI, 0.83-8.79, P = 0.01), posthemorrhage day (beta = 20.1; 95% CI, 2.14-7.52; P < 0.001), and (posthemorrhage day)(2) (beta = -0.72; 95% CI, -0.26 to -0.11; P < 0.001).
   CONCLUSIONS: Noninfectious fever was associated with the development of radiographic vasospasm but not with DIND, DCI, or clinical outcome. Furthermore, there is a temporal association between the onset of noninfectious fever and radiographic vasospasm by 1 day. Fever independent of patient's infectious profile may be an early marker for the development of radiographic vasospasm.
C1 [Du, Rose] Brigham & Womens Hosp, Dept Neurosurg, 75 Francis St, Boston, MA 02115 USA.
   Harvard Med Sch, Boston, MA USA.
RP Du, R (reprint author), Brigham & Womens Hosp, Dept Neurosurg, 75 Francis St, Boston, MA 02115 USA.
EM rdu@bwh.harvard.edu
RI Du, Rose/AAJ-2873-2020; Du, Rose/I-5402-2012
OI Du, Rose/0000-0003-2641-6496
CR CREISSARD P, 1995, ACTA NEUROCHIR, V136, P181, DOI 10.1007/BF01410623
   Dhar R, 2008, NEUROCRIT CARE, V8, P253, DOI 10.1007/s12028-007-9020-4
   Douds GL, 2012, NEUROL RES INT, V2012, DOI 10.1155/2012/479865
   Dumont AS, 2003, NEUROSURGERY, V53, P123, DOI 10.1227/01.NEU.0000068863.37133.9E
   Fernandez A, 2007, NEUROLOGY, V68, P1013, DOI 10.1212/01.wnl.0000258543.45879.f5
   da Silva IRF, 2016, J STROKE CEREBROVASC, V25, P2886, DOI 10.1016/j.jstrokecerebrovasdis.2016.07.051
   Hanafy KA, 2010, J CLIN NEUROSCI, V17, P22, DOI 10.1016/j.jocn.2009.09.003
   Kaufmann TJ, 2007, RADIOLOGY, V243, P812, DOI 10.1148/radiol.2433060536
   Kirkness CJ, 2008, NEUROCRIT CARE, V8, P380, DOI 10.1007/s12028-007-9034-y
   Kramer CL, 2016, NEUROCRIT CARE, V26, P41
   Macdonald RL, 2014, NAT REV NEUROL, V10, P44, DOI 10.1038/nrneurol.2013.246
   Mees SMD, 2008, STROKE, V39, P2141, DOI 10.1161/STROKEAHA.107.509851
   MOHR G, 1983, J NEUROSURG, V58, P482, DOI 10.3171/jns.1983.58.4.0482
   Naidech AM, 2008, NEUROSURGERY, V63, P212, DOI 10.1227/01.NEU.0000320453.61270.0F
   Oliveira J, 2001, NEUROLOGY, V56, P1299, DOI 10.1212/WNL.56.10.1299
   Pegoli M, 2015, J NEUROSURG, V122, P414, DOI 10.3171/2014.10.JNS14290
   R Core Team, 2018, R LANG ENV STAT COMP
   Rabinstein AA, 2007, J NEUROL NEUROSUR PS, V78, P1278, DOI 10.1136/jnnp.2006.112730
   ROUSSEAUX P, 1980, SURG NEUROL, V14, P459
   Schwarz S, 2000, NEUROLOGY, V54, P354, DOI 10.1212/WNL.54.2.354
   SINDOU M, 1990, PRESSE MED, V19, P411
   SLOAN MA, 1989, NEUROLOGY, V39, P1514, DOI 10.1212/WNL.39.11.1514
   Suehiro E, 2016, J STROKE CEREBROVASC, V25, P1482, DOI 10.1016/j.jstrokecerebrovasdis.2016.01.053
   Tam AKH, 2010, NEUROCRIT CARE, V13, P182, DOI 10.1007/s12028-010-9402-x
   Todd MM, 2009, NEUROSURGERY, V64, P897, DOI 10.1227/01.NEU.0000341903.11527.2F
   Wartenberg KE, 2006, CRIT CARE MED, V34, P617, DOI 10.1097/01.CCM.0000201903.46435.35
   WEIR B, 1989, NEUROSURGERY, V25, P161, DOI 10.1227/00006123-198908000-00002
   Wiebers D, 1998, NEW ENGL J MED, V339, P1725, DOI 10.1056/nejm199812103392401
   Yin L, 2011, ACTA NEUROCHIR SUPPL, V110, P175, DOI 10.1007/978-3-7091-0356-2_32
   Zhang GH, 2011, ACTA NEUROCHIR SUPPL, V110, P239, DOI 10.1007/978-3-7091-0353-1_42
NR 30
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1014
EP E1019
DI 10.1016/j.wneu.2018.10.203
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100123
PM 30414522
DA 2020-05-12
ER

PT J
AU Laing, R
   Timofeev, I
   Colasanti, R
   Dean, A
   Di Rienzo, A
AF Laing, Rodney
   Timofeev, Ivan
   Colasanti, Roberto
   Dean, Andrew
   Di Rienzo, Alessandro
TI Cord Splitting Access to Ventral Intradural Cysts of Cervicothoracic
   Junction and Thoracic Spine
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebrospinal fluid; Cyst; Hydrocephalus; Neuroenteric; Spinal cord
ID ARACHNOID CYSTS; DIAGNOSIS
AB OBJECTIVE: Surgical treatment of ventrally located intradural cysts is difficult and controversial. Laminectomy with division of the denticulate ligaments and gentle cord mobilization remains the standard approach but risks further neurologic deterioration secondary to cord manipulation. Our purpose is to evaluate the safety and effectiveness of a midline cord-splitting approach as an alternative for treating ventral thoracic intradural cysts.
   METHODS: We describe 2 patients who were treated for ventral intradural cysts causing progressive and severe myelopathy. Under general anesthesia and continuous neurophysiologic monitoring, laminectomy, durotomy, and cord splitting through a midline approach gave direct access to both lesions. Cyst drainage was supplemented by a cystopleural shunt in 1 case.
   RESULTS: Cyst collapse and cord reexpansion were documented in both patients with a magnetic resonance imaging scan 1 week after surgery. In both cases there was a significant neurologic improvement, which was maintained 2 years postoperatively. Intraoperative monitoring recorded no loss of somatosensory or motor potentials during surgery. Follow-up magnetic resonance imaging scans 2 years postoperatively showed no evidence of cyst recurrence, and both patients remained neurologically improved and stable.
   CONCLUSIONS: We have been able to drain 2 ventral intradural cysts using a cord-splitting technique. This has allowed safe access to purely ventrally located lesions, which were inaccessible dorsally or dorsolaterally. By using this method we have been able to avoid a more invasive ventral transthoracic approach necessitating vertebrectomy and reconstruction and risking serious complications.
C1 [Laing, Rodney; Timofeev, Ivan] Addenbrookes Univ Hosp, Dept Neurosurg, Cambridge, England.
   [Dean, Andrew] Addenbrookes Univ Hosp, Dept Histopathol, Cambridge, England.
   [Colasanti, Roberto; Di Rienzo, Alessandro] Univ Politecn Marche, Dept Neurosurg, Ancona, Italy.
RP Colasanti, R (reprint author), Univ Politecn Marche, Dept Neurosurg, Ancona, Italy.
EM roberto.colasanti@gmail.com
RI Timofeev, Ivan/AAE-7019-2019; Colasanti, Roberto/P-5574-2018
OI Colasanti, Roberto/0000-0001-5026-8089
CR AARABI B, 1979, J NEUROSURG, V50, P826, DOI 10.3171/jns.1979.50.6.0826
   ALVISI C, 1987, J NEUROSURG, V67, P333, DOI 10.3171/jns.1987.67.3.0333
   ANDREWS BT, 1988, J NEUROSURG, V68, P544, DOI 10.3171/jns.1988.68.4.0544
   Bassiouni H, 2004, NEUROSURGERY, V55, P1352, DOI 10.1227/01.NEU.0000143031.98237.6D
   Caruso G, 1999, Neurosurg Focus, V6, pe8
   CILLUFFO JM, 1982, ACTA NEUROCHIR, V65, P199, DOI 10.1007/BF01405846
   Endo T, 2010, J NEUROSURG-SPINE, V12, P641, DOI 10.3171/2009.12.SPINE09577
   Engelhardt J, 2016, EUR SPINE J, V25, pS19, DOI 10.1007/s00586-015-4026-7
   FORTUNA A, 1983, ACTA NEUROCHIR, V68, P289, DOI 10.1007/BF01401186
   GALZIO RJ, 1982, SURG NEUROL, V17, P388, DOI 10.1016/0090-3019(82)90321-4
   Kizilay Zahir, 2015, Open Access Maced J Med Sci, V3, P135, DOI 10.3889/oamjms.2015.026
   LESOIN F, 1985, ACTA NEUROCHIR, V76, P125, DOI 10.1007/BF01418473
   Mohindra S, 2010, BRIT J NEUROSURG, V24, P679, DOI 10.3109/02688697.2010.504052
   Muhammedrezai S, 2008, TURK NEUROSURG, V18, P241
   Nayak Raghavendra, 2017, Asian J Neurosurg, V12, P321, DOI 10.4103/1793-5482.150004
   OSENBACH RK, 1992, NEUROSURGERY, V30, P35, DOI 10.1227/00006123-199201000-00007
   PALMER JJ, 1974, J NEUROSURG, V41, P728, DOI 10.3171/jns.1974.41.6.0728
   PERRET G, 1962, RADIOLOGY, V79, P425, DOI 10.1148/79.3.425
   Peruzzotti-Jametti L, 2010, SPINE, V35, pE322, DOI 10.1097/BRS.0b013e3181c8a40a
   Petridis AK, 2010, EUR SPINE J, V19, pS124, DOI 10.1007/s00586-009-1156-9
   RABB CH, 1992, J NEUROSURG, V77, P369, DOI 10.3171/jns.1992.77.3.0369
   Sasani M, 2007, SPINE J, V7, P720, DOI 10.1016/j.spinee.2006.12.010
   Shukla M, 2015, ACTA NEUROCHIR, V157, P1601, DOI 10.1007/s00701-015-2484-7
   Wang MY, 2003, SURG NEUROL, V60, P49, DOI 10.1016/S0090-3019(03)00149-6
NR 24
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E168
EP E175
DI 10.1016/j.wneu.2018.09.188
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100018
PM 30292666
DA 2020-05-12
ER

PT J
AU Lamba, N
   Cagney, DN
   Brigell, RH
   Martin, AM
   Besse, LA
   Catalano, PJ
   Phillips, JG
   Pashtan, IM
   Bi, WL
   Claus, EB
   Golby, AJ
   Dunn, IF
   Smith, TR
   Tanguturi, SK
   Haas-Kogan, DA
   Alexander, BM
   Aizer, AA
AF Lamba, Nayan
   Cagney, Daniel N.
   Brigell, Rachel H.
   Martin, Allison M.
   Besse, Luke A.
   Catalano, Paul J.
   Phillips, John G.
   Pashtan, Itai M.
   Bi, Wenya Linda
   Claus, Elizabeth B.
   Golby, Alexandra J.
   Dunn, Ian F.
   Smith, Timothy R.
   Tanguturi, Shyam K.
   Haas-Kogan, Daphne A.
   Alexander, Brian M.
   Aizer, Ayal A.
TI Neurosurgical Resection and Stereotactic Radiation Versus Stereotactic
   Radiation Alone in Patients with a Single or Solitary Brain Metastasis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain metastasis; Radiation; Resection; Single; Solitary; Surgery;
   Survival
ID SURGICAL RESECTION; RADIOSURGERY SRS; RADIOTHERAPY; MANAGEMENT; SURGERY;
   THERAPY; EPIDEMIOLOGY
AB BACKGROUND: Brain metastases commonly manifest in patients with cancer, with similar to 20%-50% presenting with 1 intracranial lesion. Among patients with 1, small brain metastasis and controlled or absent extracranial disease, it remains unclear whether aggressive intracranial management using neurosurgical resection plus cavity stereotactic radiosurgery/stereotactic radiotherapy (SRS/SRT) rather than SRS/SRT alone is beneficial. In patients with controlled or absent extracranial disease and 1 brain metastasis <= 2 cm in size, we evaluated the effect of surgery plus SRS/SRT compared with SRS/SRT on oncologic outcomes, including overall survival.
   METHODS: We retrospectively identified 86 patients with controlled or absent extracranial disease and 1 brain metastasis <= 2 cm in size who had been treated from 2000 to 2015 at our institution. We examined differences in the rates of local and distant failure, use of salvage treatment, and other oncologic outcomes, including all-cause mortality.
   RESULTS: The baseline characteristics were similar between the 2 cohorts. The median follow-up period for the surviving patients was 38 months. On multivariable analysis, surgical resection plus cavity SRS/SRT was associated with a lower risk of all-cause mortality (hazard ratio, 0.44; 95% confidence interval, 0.19-1.00; P = 0.05) compared with SRS/SRT alone. The 1- and 2-year rates of overall survival were 100% and 88% versus 74% and 52% for surgery plus cavity SRS/SRT versus SRS/SRT alone, respectively.
   CONCLUSIONS: Aggressive, local therapy, including neurosurgical resection, might benefit patients with 1 brain metastasis in the context of controlled or absent systemic disease, even if the lesion in question is small. Further studies are needed to evaluate these associations.
C1 [Lamba, Nayan] Harvard Med Sch, Boston, MA USA.
   [Cagney, Daniel N.; Brigell, Rachel H.; Martin, Allison M.; Besse, Luke A.; Phillips, John G.; Pashtan, Itai M.; Tanguturi, Shyam K.; Haas-Kogan, Daphne A.; Alexander, Brian M.; Aizer, Ayal A.] Harvard Med Sch, Dept Radiat Oncol, Dana Farber Brigham & Womens Canc Ctr, Boston, MA 02115 USA.
   [Catalano, Paul J.] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA USA.
   [Catalano, Paul J.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
   [Bi, Wenya Linda; Claus, Elizabeth B.; Golby, Alexandra J.; Dunn, Ian F.; Smith, Timothy R.] Brigham & Womens Hosp, Dept Neurosurg, 75 Francis St, Boston, MA 02115 USA.
   [Claus, Elizabeth B.] Yale Univ, Sch Publ Hlth, New Haven, CT USA.
RP Cagney, DN (reprint author), Harvard Med Sch, Dept Radiat Oncol, Dana Farber Brigham & Womens Canc Ctr, Boston, MA 02115 USA.
EM dcagney@bwh.harvard.edu
CR Andrews DW, 2004, LANCET, V363, P1665, DOI 10.1016/S0140-6736(04)16250-8
   Aoyama H, 2006, JAMA-J AM MED ASSOC, V295, P2483, DOI 10.1001/jama.295.21.2483
   Brown PD, 2017, LANCET ONCOL, V18, P1049, DOI 10.1016/S1470-2045(17)30441-2
   Christ Sebastian M, 2015, Surg Neurol Int, V6, pS355, DOI 10.4103/2152-7806.163315
   Gavrilovic IT, 2005, J NEURO-ONCOL, V75, P5, DOI 10.1007/s11060-004-8093-6
   Hatiboglu MA, 2013, ECANCERMEDICALSCIENC, V7, DOI 10.3332/ecancer.2013.308
   International Radiosurgery Association, 2008, 508 INT RAD ASS
   Ippen FM, 2015, J ONCOL, DOI 10.1155/2015/636918
   Kocher M, 2011, J CLIN ONCOL, V29, P134, DOI 10.1200/JCO.2010.30.1655
   Lin XL, 2015, J CLIN ONCOL, V33, P3475, DOI 10.1200/JCO.2015.60.9503
   Mintz A, 2007, Curr Oncol, V14, P131, DOI 10.3747/co.2007.129
   Muldoon LL, 2007, J CLIN ONCOL, V25, P2295, DOI 10.1200/JCO.2006.09.9861
   Nayak L, 2012, CURR ONCOL REP, V14, P48, DOI 10.1007/s11912-011-0203-y
   Nussbaum ES, 1996, CANCER-AM CANCER SOC, V78, P1781, DOI 10.1002/(SICI)1097-0142(19961015)78:8<1781::AID-CNCR19>3.0.CO;2-U
   Park HS, 2012, INT J RADIAT ONCOL, V83, P1365, DOI 10.1016/j.ijrobp.2011.10.025
   PATCHELL RA, 1990, NEW ENGL J MED, V322, P494, DOI 10.1056/NEJM199002223220802
   Pessina F, 2017, WORLD NEUROSURG, V105, P184, DOI [10.1016/j.wneu.2017.05.131, 10.1016/j.wneu.2017.05.13]
   Prabhu RS, 2017, INT J RADIAT ONCOL, V99, P459, DOI 10.1016/j.ijrobp.2017.04.006
   Quigley MR, 2015, NEUROSURGERY, V76, P707, DOI 10.1227/NEU.0000000000000707
   Soliman H, 2016, ONCOTARGET, V7, P12318, DOI 10.18632/oncotarget.7131
   Taggar A, 2016, CUREUS, V8, DOI 10.7759/cureus.612
   Tsao M, 2012, CANCER-AM CANCER SOC, V118, P2486, DOI 10.1002/cncr.26515
   Tsao MN, 2012, PRACT RADIAT ONCOL, V2, P210, DOI 10.1016/j.prro.2011.12.004
   VECHT CJ, 1993, ANN NEUROL, V33, P583, DOI 10.1002/ana.410330605
   Wagner AE, 2014, J RADIOSURGERY SBRT, V3, P111
NR 25
TC 3
Z9 3
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1557
EP E1561
DI 10.1016/j.wneu.2018.11.100
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100191
PM 30471438
DA 2020-05-12
ER

PT J
AU Lan, ZB
   Huang, YM
   Xu, WH
AF Lan, Zhibin
   Huang, Yuming
   Xu, Weihong
TI Relationship Between TI Slope Minus C2-7 Lordosis and Cervical Alignment
   Parameters After Adjacent 2-Level Anterior Cervical Diskectomy and
   Fusion of Lower Cervical Spine
SO WORLD NEUROSURGERY
LA English
DT Article
ID SAGITTAL BALANCE; T1 SLOPE; SURGERY
AB OBJECTIVE: To investigate the relationships between sagittal alignment parameters and Neck Disability Index (NDI) scores after adjacent 2-level anterior cervical diskectomy and fusion (ACDF) and to study the impact of the T1 slope (T1s) minus C2-7 lordosis (T1s-CL).
   METHODS: In total, 76 patients after adjacent 2-level ACDF were retrospectively analyzed. Radiographic measurements included Tis, C2-7 lordosis, Tls-CL, segment angle (SA), and C2-7 sagittal vertical axis (SVA). NDI scores were used to evaluate clinical prognosis. Pearson correlation coefficient was calculated between radio-graphic measures. Linear regression analysis was used to analyze the relationships between follow-up cervical sagittal parameters and NM.
   RESULTS: Delta T1s was positively correlated with Delta C2-7 lordosis (r = 0.466, P< 0.001), Delta T1s-CL (r = 0.337, P = 0.003), Delta C2-7 SVA (r = 0238, P< 0.05), and Delta SA (r = 0.654, P< 0.001). Delta C2-7 lordosis was positively correlated with Delta SA (r P< 0.001) and negatively correlated with 1T1s-CL (r= -0.676, P< 0.001) and Delta C2-7 SVA (r = -0.418, P< 0.001). Delta T1s-CL was positively correlated with Delta C2-7 SVA (r = 0.644, P < 0.001). The pre- and postoperative SAs were significantly different (P< 0.05), increasing from 3.71 degrees +/- 8.92 degrees to 9.63 +/- 420 degrees Preoperative NM was positively correlated with preoperative C2-7 SVA (r = 0.325, P = 0.004) and Tls-CL (r = 0.498, P< 0.001). Follow-up NDI was positively correlated with follow-up T1s)r = 0.359, P = 0.001), C2-7 SVA (r = 0.613, P < 0.001), and Tls-CL (r = 0.696, P < 0.001) and negatively correlated with C2-7 lordosis (r = 0.491, P < 0.001). The linear regression model showed that when preoperative IlsCL was greater than 21.43 the NDI score was greater than 25/4 = 0248, P < 0.001), and when follow-up Tls-CL was greater than 28.07 the NW score was greater than 25 (R-2 = 0.484, P < 0.001).
   CONCLUSIONS: Changes in cervical sagittal parameters after 2-level ACDF were associated with quality of life. A greater T1S-CL mismatch was related to a greater degree of cervical malalignment. Tls-CL may be a more important predictor of cervical malalignment than C2-7 SVA. Specifically, a mismatch greater than 28.07 corresponded to positive cervical sagittal malalignment, defined as an NDI score greater than 25.
C1 [Lan, Zhibin; Huang, Yuming; Xu, Weihong] Fujian Med Univ, Affiliated Hosp 1, Dept Spine Surg, Fuzhou, Fujian, Peoples R China.
RP Xu, WH (reprint author), Fujian Med Univ, Affiliated Hosp 1, Dept Spine Surg, Fuzhou, Fujian, Peoples R China.
EM xuweihong815@126.com
OI Huang, Yuming/0000-0002-7693-6417; Lan, Zhibin/0000-0001-8610-7244
CR Benzel EC, 2013, NEUROSURG FOCUS, V35
   Burkhardt JK, 2013, NEUROSURG FOCUS, V35, DOI 10.3171/2013.3.FOCUS1396
   Hyun SJ, 2016, SPINE, V41, pE396, DOI 10.1097/BRS.0000000000001264
   Iyer S, 2016, SPINE, V41, P371, DOI 10.1097/BRS.0000000000001221
   Jenkins L A, 1994, Orthop Rev, VSuppl, P13
   Kawakami M, 1999, J SPINAL DISORD, V12, P50
   Lee SH, 2012, J SPINAL DISORD TECH, V25, pE41, DOI 10.1097/BSD.0b013e3182396301
   Lin SR, 2015, EUR SPINE J, V24, P127, DOI 10.1007/s00586-014-3605-3
   Park MS, 2014, SPINE J, V14, P1228, DOI 10.1016/j.spinee.2013.09.043
   Scheer JK, 2013, J NEUROSURG-SPINE, V19, P141, DOI 10.3171/2013.4.SPINE12838
   Smith JS, 2012, J NEUROSURG-SPINE, V17, P300, DOI 10.3171/2012.6.SPINE1250
   Smith JS, 2012, SPINE, V37, P845, DOI 10.1097/BRS.0b013e31823b0892
   Tang Jessica A, 2015, Neurosurgery, V76 Suppl 1, pS14, DOI 10.1227/01.neu.0000462074.66077.2b
   Weng C, 2016, SPINE, V41, P185, DOI 10.1097/BRS.0000000000001353
   Young WF, 2000, AM FAM PHYSICIAN, V62, P1064
   Zheng BL, 2017, BMC SURG, V17, DOI 10.1186/s12893-017-0316-9
NR 16
TC 2
Z9 2
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1195
EP E1201
DI 10.1016/j.wneu.2018.11.016
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100145
PM 30447441
DA 2020-05-12
ER

PT J
AU Lee, HJ
   Kim, JH
   Kim, IS
   Hong, JT
AF Lee, Ho Jin
   Kim, Jung Hee
   Kim, Il Sup
   Hong, Jae Taek
TI Physiologic Cervical Alignment Change Between Whole Spine Radiographs
   and Normal Standing Cervical Radiographs
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cervical spine radiograph; Horizontal gaze; Sagittal alignment; Thoracic
   kyphosis; Whole spine radiograph
ID NATURAL HEAD POSTURE; SAGITTAL BALANCE; VALIDATION; SEVERITY; SLOPE
AB BACKGROUND: The objective of this study was to evaluate the physiologic change of cervical spine (CS) alignment between 2 radiographs (whole spine [WS] and CS).
   METHODS: Multilevel cervical segmental angles (horizontal gaze, C2 slope, C7 slope, and T1 slope) were measured, and C0-2 angle, C0-7 angle, and C2-7 angle were also calculated.The relative translation statuses of C2-7 sagittal vertical axis and C0-7 sagittal vertical axis were measured,
   RESULTS: Generally, statistically significant differences were found for occipitalslope (Delta 7.1 degrees) and C7 slope (Delta 2,1 degrees), and these results induced a significant C0-2 angle (Delta 4.6 degrees) and nonsignificant C2-7 angle (Delta 1.2 degrees) change between the 2 types of radiographs. In the fixed horizontal gaze group analysis, C7 slope and C2-7 angle were significantly different between WS and CS radiographs. In the nonfixed horizontal gaze group analysis, C7 slope exhibited significant upward movement (Delta 3.7), and C7 slope did not showed significant change (Delta 0.1 degrees), which caused the constant value of cervical lordosis (C2-7 angle) between the 2 radiographs (P = 0.084),
   CONCLUSIONS: Horizontal gaze fixation may induce untruthful results of cervical lordosis (C2-7 angle) and a nonphysiologic distribution ratio of cervical lordosis (C0-2 angle, 92% vs. C2-7 angle, 8%), However, if the horizontal gaze is not controlled, WS radiographs exhibit a constant value of the C7 slope compared with CS radiographs, which may induce the unchanged state of cervical lordosis and physiologic distribution ratio of cervical lordosis (C0-2 angle, 74% vs. C2-7 angle, 26%).
C1 [Lee, Ho Jin] Catholic Univ Korea, Incheon St Marys Hosp, Dept Neurosurg, Incheon, South Korea.
   [Lee, Ho Jin; Kim, Il Sup; Hong, Jae Taek] Catholic Univ Korea, St Vincents Hosp, Dept Neurosurg, Seoul, South Korea.
   [Kim, Jung Hee] Seoul Med Ctr, Dept Neurosurg, Seoul, South Korea.
   [Hong, Jae Taek] Catholic Univ Korea, Eun Pyeong St Marys Hosp, Dept Neurosurg, Seoul, South Korea.
RP Hong, JT (reprint author), Catholic Univ Korea, St Vincents Hosp, Dept Neurosurg, Seoul, South Korea.; Hong, JT (reprint author), Catholic Univ Korea, Eun Pyeong St Marys Hosp, Dept Neurosurg, Seoul, South Korea.
EM jatagi15@gmail.com
CR Bao HD, 2017, SPINE, V42, P1375, DOI 10.1097/BRS.0000000000002144
   Cacho-Rodrigues P, 2016, SPINE, V41, pE791, DOI 10.1097/BRS.0000000000001386
   Fard BS, 2016, EUR SPINE J, V25, P3577, DOI 10.1007/s00586-015-4254-x
   Inami S, 2016, EUR SPINE J, V25, P3638, DOI 10.1007/s00586-016-4563-8
   Iyer S, 2016, SPINE, V41, P371, DOI 10.1097/BRS.0000000000001221
   Lafage R, 2016, NEUROSURGERY, V79, P108, DOI 10.1227/NEU.0000000000001193
   Lau KT, 2010, MANUAL THER, V15, P457, DOI 10.1016/j.math.2010.03.009
   Lee SH, 2012, J SPINAL DISORD TECH, V25, pE41, DOI 10.1097/BSD.0b013e3182396301
   Nunez-Pereira S, 2015, J NEUROSURG-SPINE, V23, P16, DOI 10.3171/2014.11.SPINE14368
   Park SM, 2015, EUR SPINE J, V24, P57, DOI 10.1007/s00586-014-3525-2
   Patwardhan AG, 2018, EUR SPINE J, V27, pS25, DOI 10.1007/s00586-017-5367-1
   Schwab F, 2012, SPINE, V37, P1077, DOI 10.1097/BRS.0b013e31823e15e2
   Smith JS, 2012, J NEUROSURG-SPINE, V17, P300, DOI 10.3171/2012.6.SPINE1250
   WATSON DH, 1993, CEPHALALGIA, V13, P272, DOI 10.1046/j.1468-2982.1993.1304272.x
   Yip CHT, 2008, MANUAL THER, V13, P148, DOI 10.1016/j.math.2006.11.002
NR 15
TC 1
Z9 1
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1222
EP E1227
DI 10.1016/j.wneu.2018.11.019
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100148
PM 30447457
DA 2020-05-12
ER

PT J
AU Lee, MH
   Hong, SD
   Woo, KI
   Kim, YD
   Choi, JW
   Seol, HJ
   Lee, JI
   Shin, HJ
   Nam, DH
   Kong, DS
AF Lee, Min Ho
   Hong, Sang Duk
   Woo, Kyung In
   Kim, Yoon-Duck
   Choi, Jung Won
   Seol, Ho Jun
   Lee, Jung-Il
   Shin, Hyung Jin
   Nam, Do-Hyun
   Kong, Doo-Sik
TI Endoscopic Endonasal Versus Transorbital Surgery for Middle Cranial
   Fossa Tumors: Comparison of Clinical Outcomes Based on Surgical
   Corridors
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cavernous sinus; Endonasal transpterygoid; Endoscopic surgery; Middle
   fossa tumors; Transorbital
ID GAMMA-KNIFE SURGERY; CAVERNOUS SINUS SURGERY; MENINGO-ORBITAL BAND;
   TERM-FOLLOW-UP; OCULOCARDIAC REFLEX; MANAGEMENT; REPAIR; COMPLICATIONS;
   PROGRESSION; PARASELLAR
AB BACKGROUND: Based on our experience with the endoscopic endonasal approach (EEA) and transorbital approach (TOA) for middle cranial fossa tumors, we evaluated the efficacy and limitations of visualization and the clinical outcomes associated with the approaches depending on the surgical corridors. In addition, we determined the optimal strategy for each approach.
   METHODS: Between September 2015 and May 2018, we retrospectively reviewed clinical outcomes in 21 patients who underwent minimally invasive endoscopic surgery for middle cranial fossa tumors involving the cavernous sinus. We classified the endoscopic approaches into 4 groups: endonasal quadrangular transcavernous (type I), endonasal infratemporal (type II), transclival medial-to-lateral (type III), and transorbital (type IV) routes. Displacement of the internal carotid artery, extent of tumor involvement, and the surgical corridor to the tumor direction were the primary determinants of the approach.
   RESULTS: The study enrolled 21 patients. Based on the classification of approaches, 6 patients underwent surgery via type I, 5 via type II, 1 via type III, 7 via type IV, and 2 via a combined approach. Among the 21 patients, gross total resection was performed in 12 (57.1%), subtotal resection in 6, and partial resection in 3. Comparison of the type I (EEA) with the type 4 (TOA) route showed that the gross total resection rate with the EEA was 33.3% compared with 71.4% with the TOA (P = 0.286).
   CONCLUSIONS: Endoscopic surgery can be considered an alternative with acceptable sequelae and reduced morbidity for the management of middle cranial fossa tumors. Surgeons should be aware of the strengths and weaknesses of each surgical corridor and select the optimal approach for each patient based on the tumor.
C1 [Lee, Min Ho; Choi, Jung Won; Seol, Ho Jun; Lee, Jung-Il; Shin, Hyung Jin; Nam, Do-Hyun; Kong, Doo-Sik] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Neurosurg, Seoul, South Korea.
   [Hong, Sang Duk] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Otorhinolaryngol Head & Neck Surg, Seoul, South Korea.
   [Woo, Kyung In; Kim, Yoon-Duck] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Ophthalmol, Seoul, South Korea.
RP Kong, DS (reprint author), Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Neurosurg, Seoul, South Korea.
EM neurokong@gmail.com
OI Lee, Min Ho/0000-0001-6174-7579
FU National Research Foundation of KoreaNational Research Foundation of
   Korea; Ministry of Science,ICT and Future Planning of Korea; National
   Research Foundation - Ministry of Science,ICT and Future Planning of
   Korea [NRF-2015M3A9A7029740, NRF-2015M3C9A1044522,
   NRF-2015M3A985053642]; Samsung Medical Center
FX This study is supported by the National Research Foundation of Korea,
   Ministry of Science,ICT and Future Planning of Korea and a grant
   (NRF-2015M3A9A7029740, NRF-2015M3C9A1044522, and NRF-2015M3A985053642)
   from the National Research Foundation funded by the Ministry of
   Science,ICT and Future Planning of Korea, as well as a grant from the
   Samsung Medical Center.
CR Bly RA, 2014, J NEUROL SURG PART B, V75, P11, DOI 10.1055/s-0033-1353363
   Cavallo Luigi Maria, 2005, Neurosurgery, V56, P379, DOI 10.1227/01.NEU.0000156548.30011.D4
   Ceylan S, 2010, J NEUROSURG, V112, P99, DOI 10.3171/2009.4.JNS09182
   Dallan I, 2018, J NEUROSURG SCI, V62, P369, DOI 10.23736/S0390-5616.16.03850-9
   Dallan I, 2017, J NEUROSURG, V127, P622, DOI 10.3171/2016.8.JNS16465
   DeJesus O, 1996, NEUROSURGERY, V39, P915, DOI 10.1097/00006123-199611000-00005
   DOLENC V, 1983, J NEUROSURG, V58, P824, DOI 10.3171/jns.1983.58.6.0824
   Forer B, 2010, J NEUROSURG, V112, P444, DOI 10.3171/2009.7.JNS09306
   Frank G, 2006, FRONT HORM RES, V34, P64, DOI 10.1159/000091573
   Fukuda H, 2014, J NEUROL SURG PART B, V75, P125, DOI 10.1055/s-0033-1359302
   Gardner PA, 2010, NEUROSURGERY, V66, DOI 10.1227/NEU.0b013e3181faaa70
   Gilani Syed Mushtaq, 2005, J Ayub Med Coll Abbottabad, V17, P57
   Golbin DA, 2017, J NEUROL SURG PART B, V78, P75, DOI 10.1055/s-0036-1584895
   Hardesty DA, 2018, J NEUROSURG SCI, V62, P332, DOI 10.23736/S0390-5616.18.04330-8
   Hasegawa T, 2007, J NEUROSURG, V107, P745, DOI 10.3171/JNS-07/10/0745
   Jeon CM, 2017, J CLIN NEUROSCI, V45, P227, DOI 10.1016/j.jocn.2017.07.012
   Kasemsiri P, 2013, LARYNGOSCOPE, V123, P811, DOI 10.1002/lary.23697
   Kassam AB, 2008, J NEUROSURG, V108, P177, DOI 10.3171/JNS/2008/108/01/0177
   Knosp E, 1996, NEUROSURGERY, V38, P434, DOI 10.1097/00006123-199603000-00003
   Koutourousiou M, 2017, WORLD NEUROSURG, V103, P713, DOI 10.1016/j.wneu.2017.04.096
   Lim JH, 2012, J NEUROL SURG PART B, V73, P394, DOI 10.1055/s-0032-1329617
   Lobo B, 2015, NEUROSURG CLIN N AM, V26, P389, DOI 10.1016/j.nec.2015.03.004
   Moe KS, 2011, LARYNGOSCOPE, V121, P13, DOI 10.1002/lary.21280
   Moe KS, 2010, NEUROSURGERY, V67, P16, DOI 10.1227/01.NEU.0000373431.08464.43
   Patrona A, 2017, J NEUROSURG, V126, P880, DOI 10.3171/2015.8.JNS15275
   PERNECZKY A, 1988, ACTA NEUROCHIR, V92, P76, DOI 10.1007/BF01401976
   Priddy BH, 2017, OPER NEUROSURG, V13, P614, DOI 10.1093/ons/opx042
   Ramakrishna R, 2016, J CLIN NEUROSCI, V24, P99, DOI 10.1016/j.jocn.2015.07.021
   Sajedi P, 2013, INT J PREVENTIVE MED, V4, P1258
   SEKHAR LN, 1989, NEUROSURGERY, V24, P18, DOI 10.1227/00006123-198901000-00004
   SEKHAR LN, 1986, J NEUROSURG, V64, P879, DOI 10.3171/jns.1986.64.6.0879
   Singh J, 2010, INT J OPHTHALMOL-CHI, V3, P14, DOI 10.3980/j.issn.2222-3959.2010.01.04
   Skeie BS, 2010, NEUROSURGERY, V66, P661, DOI 10.1227/01.NEU.0000366112.04015.E2
   Sonig A, 2013, WORLD NEUROSURG, V80, P810, DOI 10.1016/j.wneu.2012.07.024
   Williams BJ, 2017, J NEUROSURG, V127, P92, DOI 10.3171/2011.1.JNS091939
   Woodworth GF, 2014, J NEUROSURG, V120, P1086, DOI 10.3171/2014.1.JNS131228
   Zhang QH, 2012, J CLIN NEUROSCI, V19, P862, DOI 10.1016/j.jocn.2011.09.023
   Zhou B, 2016, J NEUROSURG, V124, P1068, DOI 10.3171/2015.3.JNS132702
NR 38
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1491
EP E1504
DI 10.1016/j.wneu.2018.11.090
PG 14
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100183
PM 30468930
DA 2020-05-12
ER

PT J
AU Lee, SH
   Park, YS
   Nam, TK
   Kwon, JT
AF Lee, Shin-Heon
   Park, Yong-Sook
   Nam, Taek-Kyun
   Kwon, Jeong-Taik
TI Psychopathological Influence of Middle Fossa Arachnoid Cysts in Young
   Men: Analysis of Korean Conscription Data
SO WORLD NEUROSURGERY
LA English
DT Article
DE Arachnoid cysts; Neuropsychiatry; Personality inventory; Young adult
ID TEMPORAL-LOBE; BRAIN VOLUME; SCHIZOPHRENIA; DISORDER; ABNORMALITIES;
   PSYCHOSIS; ATTENTION; STRESS; MALES; LIFE
AB BACKGROUND: A few reported studies have documented psychotic syndromes secondary to a middle fossa arachnoid cyst (AC). However, the association between middle fossa ACs and psychopathological symptoms remains to be determined. The present study investigated the psychopathological effects of middle fossa ACs in young men.
   METHODS: We reviewed military personal inventory test profiles and baseline demographic data of 19-year-old conscription examinees from February 2013 to December 2016. In total, 132 examinees with middle fossa ACs and 350 examinees with normal findings were enrolled in the present study. Two separate comparisons were performed. First, we compared the middle fossa AC group with the control group. Second, the middle fossa AC group was divided into 2 groups according to cyst size and compared with the control group.
   RESULTS: Faking bad response behavior, infrequency, inconsistency, depression, schizophrenia, paranoia, and personality disorder cluster A scales were significantly associated with the presence of a middle fossa AC. Abnormal responses to the military personal inventory were significantly and positively correlated with cyst size. The prediction rate to show abnormal psychological results with the presence of an AC was estimated to be 60.7%-68.8%.
   CONCLUSIONS: The presence of ACs and cyst size were associated with psychopathology in this select group of young men. The size-dependent psychopathological effects of ACs appear to result from a local mass effect on the brain.
C1 [Lee, Shin-Heon; Park, Yong-Sook; Nam, Taek-Kyun; Kwon, Jeong-Taik] Chung Ang Univ, Dept Neurosurg, Coll Med, Seoul, South Korea.
RP Park, YS (reprint author), Chung Ang Univ, Dept Neurosurg, Coll Med, Seoul, South Korea.
EM cuttage@cau.ac.kr
CR Al-Holou WN, 2013, J NEUROSURG, V118, P222, DOI 10.3171/2012.10.JNS12548
   Baquero G A, 2014, Open Neuroimag J, V8, P1, DOI 10.2174/1874440001408010001
   Bechter K, 2010, PSYCHIAT RES-NEUROIM, V184, P196, DOI 10.1016/j.pscychresns.2010.03.009
   Brody A L, 2001, Semin Clin Neuropsychiatry, V6, P102, DOI 10.1053/scnp.2001.21837
   Choi K, 2013, SOC PSYCH PSYCH EPID, V48, P1767, DOI 10.1007/s00127-012-0647-x
   Choi KH, 2009, UNO72699 KOR I DEF A
   CLAVEL M, 1985, ACTA NEUROCHIR, V78, P28, DOI 10.1007/BF01809237
   Gelabert-Gonzalez M, 2004, REV NEUROLOGIA, V39, P1161, DOI 10.33588/rn.3912.2004400
   Gundersen H, 2007, J NEUROL, V254, P60, DOI 10.1007/s00415-006-0280-2
   Ha TH, 2004, PSYCHIAT RES-NEUROIM, V132, P251, DOI 10.1016/j.pscychresns.2004.05.001
   Hund-Georgiadis M, 2002, NEUROLOGY, V59, P1935, DOI 10.1212/01.WNL.0000038745.98689.6B
   Kawasaki Y, 2004, EUR ARCH PSY CLIN N, V254, P406, DOI 10.1007/s00406-004-0522-1
   Kim SH, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000949
   Koolschijn PCMP, 2009, HUM BRAIN MAPP, V30, P3719, DOI 10.1002/hbm.20801
   Krzyzowski J, 1998, Neurol Neurochir Pol, V32, P433
   KUHNLEY EJ, 1981, J CLIN PSYCHIAT, V42, P167
   LANCZIK M, 1989, PSYCHIAT RES, V29, P421, DOI 10.1016/0165-1781(89)90109-1
   LANG W, 1985, EUR ARCH PSY CLIN N, V235, P38, DOI 10.1007/BF00380967
   Lawrie SM, 2002, BRIT J PSYCHIAT, V181, P138
   Lee JG, 2006, KOREAN PSYCHOL, V6, P464
   Lee JG, 2006, KOREAN PSYCHOL, V6, P466
   Martinez-Lage JF, 2006, CHILD NERV SYST, V22, P1091, DOI 10.1007/s00381-006-0043-5
   Millichap JG, 1997, NEUROLOGY, V48, P1435, DOI 10.1212/WNL.48.5.1435
   Oh CH, 2013, NEUROL SCI, V34, P949, DOI 10.1007/s10072-012-1166-y
   Pantelis C, 2003, LANCET, V361, P281, DOI 10.1016/S0140-6736(03)12323-9
   Park DE, 2004, J KOREAN MILIT MED A, V35, P157
   Park YS, 2009, CHILD NERV SYST, V25, P1071, DOI 10.1007/s00381-009-0872-0
   Raeder MB, 2005, NEUROLOGY, V64, P160, DOI 10.1212/01.WNL.0000148724.61966.A4
   SHENTON ME, 1992, NEW ENGL J MED, V327, P604, DOI 10.1056/NEJM199208273270905
   Spansdahl T, 2007, ACTA NEUROCHIR, V149, P1025, DOI 10.1007/s00701-007-1272-4
   SWAYZE VW, 1992, BIOL PSYCHIAT, V31, P221, DOI 10.1016/0006-3223(92)90046-3
   Vakis AF, 2006, BRIT J NEUROSURG, V20, P156, DOI 10.1080/02688690600776986
   van Tol MJ, 2010, ARCH GEN PSYCHIAT, V67, P1002, DOI 10.1001/archgenpsychiatry.2010.121
   WESTER K, 1995, J NEUROL NEUROSUR PS, V59, P293, DOI 10.1136/jnnp.59.3.293
   Wester K, 2008, J NEUROL, V255, P1113, DOI 10.1007/s00415-008-0011-y
   Wolf EJ, 2008, PSYCHOL ASSESSMENT, V20, P327, DOI 10.1037/a0012948
   Zaatreh MM, 2002, PEDIATR NEUROL, V26, P134, DOI 10.1016/S0887-8994(01)00379-4
   Zeegers M, 2006, BRAIN DEV-JPN, V28, P495, DOI 10.1016/j.braindev.2006.02.006
NR 38
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E530
EP E539
DI 10.1016/j.wneu.2018.10.095
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100064
PM 30889776
DA 2020-05-12
ER

PT J
AU Li, H
   Zhang, YS
   Zhang, GB
   Zhang, GJ
   Wang, B
   Li, D
   Wu, Z
   Zhang, JT
AF Li, Huan
   Zhang, Yun-Sheng
   Zhang, Guo-Bin
   Zhang, Gui-Jun
   Wang, Bo
   Li, Da
   Wu, Zhen
   Zhang, Jun-Ting
TI Treatment Protocol, Long-Term Follow-Up, and Predictors of Mortality in
   302 Cases of Atypical Meningioma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Atypical meningioma; Extent of resection; Invasiveness; Postoperative
   radiotherapy
ID GROSS-TOTAL RESECTION; BRAIN INVASION; ANAPLASTIC MENINGIOMAS; ADJUVANT
   RADIOTHERAPY; MALIGNANT MENINGIOMAS; RECURRENCE; GRADE; SURVIVAL; BENIGN
AB OBJECTIVE: Because of the paucity of relevant data, treatment and outcomes in intracranial atypical meningioma (AM) remain unclear. The aim of this study was to find useful factors predicting survival and to evaluate the role of postoperative radiation after surgery.
   METHODS: Data were obtained from 302 patients with AM who underwent surgery between January 2008 and December 2015.
   RESULTS: A series of 302 patients, including 166 female and 136 male, underwent surgery at our institution. Gross total resection (GTR) was achieved in 201 (66.6%) patients. Seventy-five patients (24.8%) underwent postoperative radiation after surgery. For the entire cohort, there were 131 (43.4%) recurrences, 1 (0.33%) metastasis, and 56 (18.5%) mortalities during a median follow-up duration of 41.6 months. The median recurrence-free survival (RFS) was 55.2 months after the date of the first AM surgery, with 1-year, 3-year, and 5-year RFS rates of 87.6%, 63.3% and 47.7%, respectively. The median overall survival (OS) for patients was 99.8 months, and the actuarial OS rates from the time of the first AM surgery at 1, 3, and 5 years were 97.0%, 90.6%, and 78.8%, respectively. In multivariate analysis, preoperative Karnofsky Performance Scale score (>= 80), primary tumor, tumor invasiveness, and GTR were associated with increased RFS, whereas preoperative Karnofsky Performance Scale score (>= 80), primary tumor, supratentorial location, lack of peritumoral edema, radiotherapy, and GTR were associated with increased OS.
   CONCLUSIONS: GTR is the first choice for patients with AM. We recommend that patients with secondary tumors receive radiotherapy after surgery.
C1 [Li, Huan; Zhang, Guo-Bin; Zhang, Gui-Jun; Wang, Bo; Li, Da; Wu, Zhen; Zhang, Jun-Ting] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing, Peoples R China.
   [Li, Huan; Zhang, Yun-Sheng; Zhang, Guo-Bin; Zhang, Gui-Jun; Wang, Bo; Li, Da; Wu, Zhen; Zhang, Jun-Ting] China Natl Clin Res Ctr Neurol Dis, Beijing, Peoples R China.
   [Li, Huan; Zhang, Yun-Sheng; Zhang, Guo-Bin; Zhang, Gui-Jun; Wang, Bo; Li, Da; Wu, Zhen; Zhang, Jun-Ting] Beijing Inst Brain Disorders, Ctr Brain Tumor, Beijing, Peoples R China.
   [Li, Huan; Zhang, Yun-Sheng; Zhang, Guo-Bin; Zhang, Gui-Jun; Wang, Bo; Li, Da; Wu, Zhen; Zhang, Jun-Ting] Beijing Key Lab Brain Tumor, Beijing, Peoples R China.
   [Zhang, Yun-Sheng] Beijing Neurosurg Inst, Beijing, Peoples R China.
   [Zhang, Yun-Sheng] Peking Univ, Civil Aviat Gen Hosp, Dept Neurosurg, Beijing, Peoples R China.
RP Zhang, JT (reprint author), Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing, Peoples R China.; Zhang, JT (reprint author), China Natl Clin Res Ctr Neurol Dis, Beijing, Peoples R China.; Zhang, JT (reprint author), Beijing Inst Brain Disorders, Ctr Brain Tumor, Beijing, Peoples R China.; Zhang, JT (reprint author), Beijing Key Lab Brain Tumor, Beijing, Peoples R China.
EM zhangjunting2003@aliyun.com
CR Adeberg S, 2012, INT J RADIAT ONCOL, V83, P859, DOI 10.1016/j.ijrobp.2011.08.010
   Aghi MK, 2009, NEUROSURGERY, V64, P56, DOI 10.1227/01.NEU.0000330399.55586.63
   Aizer AA, 2014, NEURO-ONCOLOGY, V16, P1547, DOI 10.1093/neuonc/nou098
   Bagshaw HP, 2017, J NEUROSURG, V126, P1822, DOI 10.3171/2016.5.JNS152809
   Baumgarten P, 2016, ACTA NEUROPATHOL, V132, P479, DOI 10.1007/s00401-016-1598-1
   Champeaux C, 2016, J NEURO-ONCOL, V129, P337, DOI 10.1007/s11060-016-2181-2
   Choi CYH, 2010, NEUROSURGERY, V67, P1180, DOI 10.1227/NEU.0b013e3181f2f427
   Cohen N, 2007, NEUROPATHOL APPL NEU, V33, P710, DOI DOI 10.1111/J.1365-2990.2007.00905.X
   Cushing H, 1978, JAMA-J AM MED ASSOC, V112, P185
   Detti B, 2013, J NEURO-ONCOL, V115, P421, DOI 10.1007/s11060-013-1239-7
   Gabeau-Lacet D, 2009, J NEUROSURG, V111, P464, DOI 10.3171/2009.2.JNS08877
   Hasan S, 2015, WORLD NEUROSURG, V83, P808, DOI 10.1016/j.wneu.2014.12.037
   Jenkinson MD, 2016, J CLIN NEUROSCI, V28, P87, DOI 10.1016/j.jocn.2015.09.021
   Jo K, 2010, J CLIN NEUROSCI, V17, P1362, DOI 10.1016/j.jocn.2010.03.036
   KLEIHUES P, 2000, WHO CLASSIFICATION T
   Komotar RJ, 2012, J NEUROSURG, V117, P679, DOI 10.3171/2012.7.JNS112113
   Krayenbuhl N, 2007, NEUROSURGERY, V61, P495, DOI 10.1227/01.NEU.0000280009.79813.DE
   Krayenbuhl N, 2007, NEUROSURGERY, V61, P503
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Mantle RE, 1999, J NEUROSURG, V91, P375, DOI 10.3171/jns.1999.91.3.0375
   Modha A, 2005, NEUROSURGERY, V57, P538, DOI 10.1227/01.NEU.0000170980.47582.A5
   Nowak A, 2015, NEUROL NEUROCHIR POL, V49, P1, DOI 10.1016/j.pjnns.2014.11.003
   Park HJ, 2013, J NEURO-ONCOL, V115, P241, DOI 10.1007/s11060-013-1219-y
   Pearson BE, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/5/E3
   Perry A, 1997, AM J SURG PATHOL, V21, P1455, DOI 10.1097/00000478-199712000-00008
   Pizem J, 2014, CLIN NEUROPATHOL, V33, P354, DOI 10.5414/NP300750
   Spille DC, 2016, WORLD NEUROSURG, V93, P346, DOI 10.1016/j.wneu.2016.06.055
   Vranic A, 2010, NEUROSURGERY, V67, P1124, DOI 10.1227/NEU.0b013e3181eb95b7
   Wang CY, 2017, NEURO-ONCOLOGY, V19, P1263, DOI 10.1093/neuonc/nox007
   Wang YC, 2015, CLIN NEUROL NEUROSUR, V128, P112, DOI 10.1016/j.clineuro.2014.11.009
   Yang SY, 2008, J NEUROL NEUROSUR PS, V79, P574, DOI 10.1136/jnnp.2007.121582
   Zaher A, 2013, WORLD NEUROSURG, V80, P549, DOI 10.1016/j.wneu.2013.07.001
NR 32
TC 1
Z9 1
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1275
EP E1284
DI 10.1016/j.wneu.2018.11.032
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100155
PM 30447439
DA 2020-05-12
ER

PT J
AU Li, HM
   Zhang, RJ
   Shen, CL
AF Li, Hui-Min
   Zhang, Ren-Jie
   Shen, Cai-Liang
TI Radiographic and Clinical Outcomes of Oblique Lateral Interbody Fusion
   Versus Minimally Invasive Transforaminal Lumbar Interbody Fusion for
   Degenerative Lumbar Disease
SO WORLD NEUROSURGERY
LA English
DT Article
DE Degenerative lumbar disease; Lumbar fusion; Lumbar spine; MI-TLIF; OLIF
ID RADIOLOGICAL OUTCOMES; PERIOPERATIVE COMPLICATIONS; SPONDYLOLISTHESIS;
   DECOMPRESSION
AB BACKGROUND: The effects of oblique lateral interbody fusion (OLIF) and minimally invasive transforaminal lumbar interbody fusion (MI-TLIF) have not been compared by a meta-analysis. The present study aimed to summarize the radiographic and clinical outcomes of OLIF and MI-TLIF for degenerative lumbar disease.
   METHODS: We performed a systematic review of related studies and report the outcomes of OLIF and MI-TLIF for degenerative lumbar disease. The radiographic outcomes measures included disc height, segmental lordotic angle, lumbar lordotic angle, and fusion. The clinical and functional outcomes included operative blood loss, operative time, length of hospital stay, complications, visual analog scale, and Oswestry disability index. Data pooling and meta-analysis with the random effects model were performed to evaluate the results.
   RESULTS: A total of 47 studies met the inclusion criteria. Similar changes in terms of disc height, segmental lordotic angle, lumbar lordotic angle, length of hospital stay, visual analog scale, Oswestry disability index, and radiological evidence of fusion of >90% were observed between the 2 groups. The OLIF group showed less operative blood loss and operative time. The incidence of intraoperative and postoperative complications was 9.5% and 19.9% for the OLIF group and 3.5% and 8.5% for the MI-TLIF group, respectively.
   CONCLUSIONS: The radiographic and functional outcomes and length of hospital stay were similar between the 2 groups. The OLIF group showed advantages in operative blood loss and operative time; however, the incidence of complications in this technique was greater than that in the MI-TLIF group.
C1 [Li, Hui-Min; Zhang, Ren-Jie; Shen, Cai-Liang] Anhui Med Univ, Affiliated Hosp 1, Dept Orthoped & Spine Surg, Hefei, Anhui, Peoples R China.
RP Shen, CL (reprint author), Anhui Med Univ, Affiliated Hosp 1, Dept Orthoped & Spine Surg, Hefei, Anhui, Peoples R China.
EM shencailiang1616@163.com
FU University Nature Scientific Research Project of Anhui Province
   [KJ2017A832]; Program for Science and Technology Development of Anhui
   Province [1704a0802158]; Natural Science Foundation Project of Anhui
   Province [14080850H174]
FX This work was supported by the University Nature Scientific Research
   Project of Anhui Province (grant KJ2017A832) and the Program for Science
   and Technology Development of Anhui Province (grant 1704a0802158), and
   the Natural Science Foundation Project of Anhui Province (grant
   14080850H174).
CR Abbasi H, 2017, CUREUS, V9, DOI 10.7759/cureus.1389
   Abbasi H, 2015, CUREUS, V7, DOI 10.7759/cureus.351
   Abe K, 2017, SPINE, V42, P55, DOI 10.1097/BRS.0000000000001650
   [Anonymous], 2017, Eur Spine J, V26, P292, DOI 10.1007/s00586-017-5226-0
   Chen Y L, 2018, Zhonghua Yi Xue Za Zhi, V98, P1990, DOI 10.3760/cma.j.issn.0376-2491.2018.25.005
   Choi WS, 2017, GLOB SPINE J, V7, p190S
   DiGiorgio AM, 2017, NEUROSURG FOCUS, V43, DOI 10.3171/2017.5.FOCUS17168
   Fan G, 2016, BIOMED RES INT, V2016, P9540298
   Foley Kevin T, 2002, Clin Neurosurg, V49, P499
   Fujibayashi S, 2015, SPINE, V40, pE175, DOI 10.1097/BRS.0000000000000703
   Giorgi H, 2018, EUR SPINE J, V27, P1933, DOI 10.1007/s00586-017-5452-5
   Gu GF, 2014, INT ORTHOP, V38, P817, DOI 10.1007/s00264-013-2169-x
   Heo DH, 2017, NEUROSURG FOCUS, V43, DOI 10.3171/2017.5.FOCUS17196
   Hey HWD, 2015, ASIAN SPINE J, V9, P185, DOI 10.4184/asj.2015.9.2.185
   Hur JW, 2017, GLOB SPINE J, V7, p2S
   Jin CZ, 2018, J ORTHOP SURG RES, V13, DOI 10.1186/s13018-018-0740-2
   Jin J, 2018, CLIN SPINE SURG, V31, P31, DOI 10.1097/BSD.0000000000000474
   Kim CW, 2016, WORLD NEUROSURG, V90, P228, DOI 10.1016/j.wneu.2016.02.075
   Kim Jin-Sung, 2016, Neurosurgery, V63 Suppl 1, P190, DOI 10.1227/01.neu.0000489803.65103.84
   Kim MC, 2011, ASIAN SPINE J, V5, P111, DOI 10.4184/asj.2011.5.2.111
   Lau D, 2013, J CLIN NEUROSCI, V20, P80, DOI 10.1016/j.jocn.2012.07.004
   Lee HJ, 2016, BIOMED RES INT, V2016
   Lee KH, 2012, EUR SPINE J, V21, P2265, DOI 10.1007/s00586-012-2281-4
   Lee WC, 2016, WORLD NEUROSURG, V85, P236, DOI 10.1016/j.wneu.2015.09.009
   Lo WL, 2015, BIOMED RES INT, V2015
   Min SH, 2013, EUR SPINE J, V22, P1164, DOI 10.1007/s00586-012-2619-y
   Miscusi M, 2018, EUR SPINE J, V27, P222, DOI 10.1007/s00586-018-5596-y
   Ohtori S, 2015, YONSEI MED J, V56, P1051, DOI 10.3349/ymj.2015.56.4.1051
   Park Y, 2014, CLIN ORTHOP RELAT R, V472, P1813, DOI 10.1007/s11999-013-3241-y
   Park Y, 2011, ASIAN SPINE J, V5, P228, DOI 10.4184/asj.2011.5.4.228
   Parker SL, 2012, WORLD NEUROSURG, V78, DOI 10.1016/j.wneu.2011.09.013
   Razak HRBA, 2017, ASIAN SPINE J, V11, P204, DOI 10.4184/asj.2017.11.2.204
   Sato J, 2017, EUR SPINE J, V26, P671, DOI 10.1007/s00586-015-4170-0
   Schizas C, 2009, INT ORTHOP, V33, P1683, DOI 10.1007/s00264-008-0687-8
   Silvestre C, 2012, ASIAN SPINE J, V6, P89, DOI 10.4184/asj.2012.6.2.89
   Singh K, 2014, SPINE J, V14, P1694, DOI 10.1016/j.spinee.2013.10.053
   Sulaiman WAR, 2014, OCHSNER J, V14, P32
   Tsahtsarlis A, 2012, J CLIN NEUROSCI, V19, P858, DOI 10.1016/j.jocn.2011.10.007
   Wang HW, 2017, ORTHOP SURG, V9, P277, DOI 10.1111/os.12345
   Wang J, 2014, SPINE J, V14, P2078, DOI 10.1016/j.spinee.2013.12.016
   Wang JA, 2010, EUR SPINE J, V19, P1780, DOI 10.1007/s00586-010-1404-z
   Wang MY, 2018, NEUROSURGERY, V83, P827, DOI 10.1093/neuros/nyx400
   Woods K, 2017, CUREUS, V9, DOI 10.7759/cureus.1980
   Woods KRM, 2017, SPINE J, V17, P545, DOI 10.1016/j.spinee.2016.10.026
   Wu AM, 2018, ANN TRANSL MED, V6, DOI 10.21037/atm.2018.02.11
   Yang Y, 2015, INT J CLIN EXP MED, V8, P21319
   Zeng ZY, 2018, ORTHOP SURG, V10, P98, DOI 10.1111/os.12380
   Zhao YF, 2018, J ORTHOP SURG RES, V13, DOI 10.1186/s13018-018-0764-7
NR 48
TC 3
Z9 3
U1 2
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E627
EP E638
DI 10.1016/j.wneu.2018.10.115
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100077
PM 31108079
DA 2020-05-12
ER

PT J
AU Li, J
   Hu, ZS
   Tseng, CC
   Zhao, ZH
   Yuan, YW
   Zhu, ZZ
   Qiu, Y
   Liu, Z
AF Li, Jie
   Hu, Zongshan
   Tseng, Changchun
   Zhao, Zhihui
   Yuan, Yiwen
   Zhu, Zezhang
   Qiu, Yong
   Liu, Zhen
TI Radiographic and Clinical Outcomes of Surgical Correction of
   Poliomyelitis-Related Spinal Deformities: A Comparison Among Three Types
   of Pelvic Instrumentations
SO WORLD NEUROSURGERY
LA English
DT Article
DE Pelvic fixation; Poliomyelitis; Postpolio syndrome; Spinal deformity
ID LEARNING-CURVE; SCOLIOSIS; COMPLICATIONS; SURGERY; FUSION; FIXATION
AB BACKGROUND: We compared the clinical and radiographic outcomes of corrective surgery in patients with poliomyelitis-related spinal deformity (PSD) using 3 types of pelvic fixation and investigated the incidence and risk factors for complications.
   METHODS: We reviewed the data from 42 patients with PSD who had undergone spinopelvic reconstruction at a single institution from 2000 to 2016. Of the 42 patients, 15 had been treated with the Galveston technique, 13 with iliac screw fixation, and 14 with S2-alar-iliac (S2AI) screw fixation. Demographic data, radiographic parameters, and complications were analyzed. Health-related quality of life was determined using Scoliosis Research Society (SRS) 22-item questionnaires and the Oswestry Disability Index scores.
   RESULTS: After surgery, the correction rate of the main curve was 51.7%, 57.8%, and 52.1% in the 3 groups, with significant improvement in regional kyphosis, coronal balance, and pelvic obliquity (PO) (P < 0.05). The correction of PO was similar among the 3 types of pelvic fixation; however, the patients treated with S2AI fixation required significantly less operative time (P < 0.05) and blood loss (P < 0.006). The overall complication rate was 40.5%, with a major complication rate of 23.8%. Age at surgery (P = 0.006) and grade > 2 SRS-Schwab osteotomy (P = 0.036) were significant risk factors for complications. Significant improvement was found in the SRS-22 and Oswestry Disability Index scores at the final follow-up examination in the 3 groups.
   CONCLUSIONS: The present study showed satisfactory correction of spinopelvic deformity for 42 patients with PSD. Compared with the Galveston technique and iliac screw fixation, the use of S2AI significantly decrease the operative time and estimated blood loss and obtained similar correction of PO. Patient age at surgery and grade > 2 SRS-Schwab osteotomy were significant risk factors for complications.
C1 [Li, Jie; Tseng, Changchun; Zhao, Zhihui; Zhu, Zezhang; Qiu, Yong; Liu, Zhen] Nanjing Univ, Sch Med, Affiliated Drum Tower Hosp, Dept Spine Surg, Nanjing, Jiangsu, Peoples R China.
   [Hu, Zongshan] Chinese Univ Hong Kong, Dept Orthopaed & Traumatol, Hong Kong, Peoples R China.
   [Yuan, Yiwen] Nanjing Med Univ, Drum Tower Hosp, Clin Coll, Dept Spine Surg, Nanjing, Jiangsu, Peoples R China.
RP Liu, Z (reprint author), Nanjing Univ, Sch Med, Affiliated Drum Tower Hosp, Dept Spine Surg, Nanjing, Jiangsu, Peoples R China.
EM drliuzhen@163.com
FU Jiangsu Health and Family Planning Commission [0201510]; Natural Science
   Foundation of Jiangsu ProvinceJiangsu Planned Projects for Postdoctoral
   Research FundsNatural Science Foundation of Jiangsu Province
   [BK20171116]
FX This work was supported by the Jiangsu Health and Family Planning
   Commission (grant 0201510) and Natural Science Foundation of Jiangsu
   Province (grant BK20171116).
CR Awwad W., 2015, EUR J ORTHOP SURG TR, V25, P233
   BROOM MJ, 1989, J BONE JOINT SURG AM, V71A, P32, DOI 10.2106/00004623-198971010-00007
   Cawley DT, 2015, SPINE J, V15, P2166, DOI 10.1016/j.spinee.2015.06.008
   Dayer R, 2012, CURR REV MUSCULOSKE, V5, P91, DOI 10.1007/s12178-012-9122-2
   Garg Sumeet, 2014, Spine Deform, V2, P214, DOI 10.1016/j.jspd.2014.01.002
   Glassman SD, 2007, SPINE, V32, P2764, DOI 10.1097/BRS.0b013e31815a7644
   Godzik J, 2014, SPINE, V39, P1211, DOI 10.1097/BRS.0000000000000375
   Gonzalez H, 2010, LANCET NEUROL, V9, P634, DOI 10.1016/S1474-4422(10)70095-8
   Halawi MJ, 2015, ORTHOPEDICS, V38, pE452, DOI 10.3928/01477447-20150603-50
   Howard RS, 2005, BMJ-BRIT MED J, V330, P1314, DOI 10.1136/bmj.330.7503.1314
   Hyun SJ, 2018, WORLD NEUROSURG, V110, pE129, DOI 10.1016/j.wneu.2017.10.109
   Jones KB, 2003, J PEDIATR ORTHOPED, V23, P143, DOI 10.1097/00004694-200303000-00002
   Kim DY, 2016, CLIN SPINE SURG, V29, pE413, DOI 10.1097/BSD.0b013e318294368e
   Lee DY, 1997, J BONE JOINT SURG BR, V79B, P190, DOI 10.1302/0301-620X.79B2.7052
   Lee MC, 2018, SPINE J, V18, P648, DOI 10.1016/j.spinee.2017.08.253
   LEONG JCY, 1981, J BONE JOINT SURG AM, V63, P726, DOI 10.2106/00004623-198163050-00007
   Master DL, 2011, SPINE, V36, P564, DOI 10.1097/BRS.0b013e3181e193e9
   MAYER PJ, 1981, SPINE, V6, P573, DOI 10.1097/00007632-198111000-00008
   Moon ES, 2011, SPINE, V36, P146, DOI 10.1097/BRS.0b013e3181cd2a55
   Obid P, 2013, ORTHOP REV, V5, P1, DOI 10.4081/or.2013.e1
   OBRIEN JP, 1975, CLIN ORTHOP RELAT R, P81
   Palisano R, 1997, DEV MED CHILD NEUROL, V39, P214, DOI 10.1111/j.1469-8749.1997.tb07414.x
   Pavon S J, 1970, J Bone Joint Surg Br, V52, P420
   Ryu KJ, 2016, BONE JOINT J, V98B, P679, DOI 10.1302/0301-620X.98B5.36356
   Schwab F, 2014, NEUROSURGERY, V74, P112, DOI 10.1227/NEU.0000000000000182o
   Shabtai L, 2017, J PEDIATR ORTHOPED, V37, pE470, DOI 10.1097/BPO.0000000000000720
   Turturro F, 2017, EUR SPINE J, V26, P539, DOI 10.1007/s00586-017-5034-6
   Yazici M, 2000, J BONE JOINT SURG AM, V82A, P524, DOI 10.2106/00004623-200004000-00008
NR 28
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1111
EP E1119
DI 10.1016/j.wneu.2018.10.238
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100136
PM 30439526
DA 2020-05-12
ER

PT J
AU Li, JH
   Zhang, S
   Wang, QG
   Cheng, J
   Deng, XY
   Wang, YC
   Hui, XH
AF Li, Jiuhong
   Zhang, Si
   Wang, Qiguang
   Cheng, Jian
   Deng, Xueyun
   Wang, Yanchao
   Hui, Xuhui
TI Spinal Clear Cell Meningioma: Clinical Study with Long-Term Follow-Up in
   12 Patients
SO WORLD NEUROSURGERY
LA English
DT Article
DE Clear cell meningioma; Management; Prognosis; Spinal
ID MR-IMAGING FINDINGS; PROGNOSTIC-FACTORS; FEATURES; VARIANT;
   CLASSIFICATION; RESECTION; TUMORS; CT
AB BACKGROUND: Clear cell meningioma (CCM) is a rare histologic subtype of meningioma. The features of CCMs have commonly been based on intracranial cases. However, CCMs in the spinal cord are even rarer, and their natural history, management, and prognosis remain ill-defined.
   METHODS: From January 2006 to January 2018, 12 patients with spinal CCM were treated in our hospital. The clinical features, radiologic findings, diagnosis, treatment, and outcome of these patients were analyzed retrospectively. Additionally, we performed a review of the reported data on spinal CCMs.
   RESULTS: CCMs accounted for 2.8% of all the spinal meningiomas treated in our hospital. The most common localization of this disease was the lumbar region (7 of 12). The mean age at diagnosis was significantly younger than that of patients with spinal meningiomas (28.8 +/- 13.4 years vs. 54.0 +/- 14.4 years). During the follow-up period, 5 patients (41.7%) experienced tumor recurrence. Kaplan-Meier analysis showed that younger patients had a significantly shorter progression-free survival time than older patients. The review of the reported data showed that 55 cases of spinal CCMs had been reported. Nineteen patients (38.0%) had developed local recurrence, with a 5-year progression-free survival rate of 33.3%.
   CONCLUSIONS: Spinal CCMs are extremely rare tumors with a predilection to affect younger patients and have a high recurrence rate. Although gross total resection is considered to be the optimal treatment, radiotherapy could be considered for patients who had undergone subtotal resection or for younger patients, regardless of the extent of removal. Close follow-up of the entire neuraxis for years is crucial.
C1 [Li, Jiuhong; Zhang, Si; Wang, Qiguang; Cheng, Jian; Wang, Yanchao; Hui, Xuhui] Sichuan Univ, Dept Neurosurg, West China Hosp, Chengdu, Sichuan, Peoples R China.
   [Deng, Xueyun] North Sichuan Med Coll, Dept Neurosurg, Nanchong Cent Hosp, Clin Med Coll 2, Nanchong, Peoples R China.
RP Hui, XH (reprint author), Sichuan Univ, Dept Neurosurg, West China Hosp, Chengdu, Sichuan, Peoples R China.
EM huixuhuiwc@126.com
OI Li, Jiuhong/0000-0001-9115-7246
CR ADEGBITE AB, 1983, J NEUROSURG, V58, P51, DOI 10.3171/jns.1983.58.1.0051
   Alameda F, 1999, ULTRASTRUCT PATHOL, V23, P51
   Balogun JA, 2013, PEDIATR NEUROSURG, V49, P311, DOI 10.1159/000366452
   Boet R, 2004, J CLIN NEUROSCI, V11, P432, DOI 10.1016/j.jocn.2003.10.014
   Cances C, 1998, ARCH PEDIATRIE, V5, P758, DOI 10.1016/S0929-693X(98)80062-6
   Carra S, 2001, PEDIATR NEUROSURG, V34, P264, DOI 10.1159/000056035
   Chamberlain MC, 2005, CANCER-AM CANCER SOC, V103, P1427, DOI 10.1002/cncr.20926
   Colen CB, 2009, J NEUROSURG-PEDIATR, V3, P57, DOI 10.3171/2008.10.17668
   Dhall SS, 2005, J NEUROSURG, V103, P559, DOI 10.3171/jns.2005.103.3.0559
   Dubois A, 1998, NEURORADIOLOGY, V40, P743, DOI 10.1007/s002340050676
   Gerkes EH, 2016, NEUROGENETICS, V17, P83, DOI 10.1007/s10048-015-0472-y
   Gottfried Oren N, 2003, Neurosurg Focus, V14, pe2, DOI 10.3171/foc.2003.14.6.2
   Heth JA, 2000, J NEUROSURG, V93, P317, DOI 10.3171/spi.2000.93.2.0317
   Holtzman RNN, 1996, J NEUROSURG, V84, P264, DOI 10.3171/jns.1996.84.2.0264
   Jain D, 2007, J NEURO-ONCOL, V81, P315, DOI 10.1007/s11060-006-9237-7
   Jallo GI, 2001, NEUROSURGERY, V48, P218, DOI 10.1097/00006123-200101000-00042
   Lee W, 2000, AM J NEURORADIOL, V21, P130
   Li P, 2016, ACTA NEUROCHIR, V158, P67, DOI 10.1007/s00701-015-2635-x
   Liu PI, 2005, SURG NEUROL, V63, P285, DOI 10.1016/j.surneu.2004.03.013
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Mallya V, 2012, INDIAN J PATHOL MICR, V55, P262, DOI 10.4103/0377-4929.97904
   MANIVEL JC, 1990, PATHOL ANNU, V25, P159
   Matsui H, 1998, NEUROSURG REV, V21, P171, DOI 10.1007/BF02389326
   Maxwell M, 1998, J NEUROSURG, V88, P562, DOI 10.3171/jns.1998.88.3.0562
   Ohba S, 2010, NEUROSURGERY, V67, pE870, DOI 10.1227/01.NEU.0000374857.06732.CD
   Oviedo A, 2005, PEDIATR DEVEL PATHOL, V8, P386, DOI 10.1007/s10024-005-0119-3
   Park HC, 2000, CHILD NERV SYST, V16, P607, DOI 10.1007/PL00007302
   Park SH, 2006, ACTA NEUROCHIR, V148, P463, DOI 10.1007/s00701-005-0695-z
   Pimentel J, 1998, CLIN NEUROPATHOL, V17, P141
   Prayson RA, 2010, APPL IMMUNOHISTO M M, V18, P422, DOI 10.1097/PAI.0b013e3181dd35d2
   Prinz Marco, 1996, General and Diagnostic Pathology, V141, P261
   Raco A, 2017, NEUROSURGERY, V80, P602, DOI 10.1093/neuros/nyw092
   Sachdev S, 2011, NEUROSURGERY, V69, P533, DOI 10.1227/NEU.0b013e318218db23
   Schollenberg E, 2013, INT J SURG PATHOL, V21, P411, DOI 10.1177/1066896912470165
   Smith MJ, 2017, HISTOPATHOLOGY, V70, P814, DOI 10.1111/his.13135
   Smith MJ, 2014, J PATHOL, V234, P436, DOI 10.1002/path.4427
   SOLERO CL, 1989, NEUROSURGERY, V25, P153, DOI 10.1227/00006123-198908000-00001
   Tao XG, 2018, WORLD NEUROSURG, V111, pE880, DOI 10.1016/j.wneu.2017.12.173
   Vural M, 2007, CHILD NERV SYST, V23, P225, DOI 10.1007/s00381-006-0181-9
   Wang XQ, 2014, J COMPUT ASSIST TOMO, V38, P200, DOI 10.1097/RCT.0000000000000018
   Whittle IR, 2004, LANCET, V363, P1535, DOI 10.1016/S0140-6736(04)16153-9
   Wu TT, 2010, PATHOL RES PRACT, V206, P349, DOI 10.1016/j.prp.2009.06.015
   Ye JL, 2016, J NEURO-ONCOL, V128, P349, DOI 10.1007/s11060-016-2119-8
   Yin SL, 2015, TURK NEUROSURG, V25, P976, DOI 10.5137/1019-5149.JTN.11847-14.1
   Yu KB, 2002, KOREAN J RADIOL, V3, P125, DOI 10.3348/kjr.2002.3.2.125
   Zhang H, 2017, WORLD NEUROSURG, V97, P693, DOI 10.1016/j.wneu.2016.10.010
   ZORLUDEMIR S, 1995, AM J SURG PATHOL, V19, P493, DOI 10.1097/00000478-199505000-00001
NR 47
TC 1
Z9 1
U1 2
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E415
EP E426
DI 10.1016/j.wneu.2018.10.064
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100049
PM 30342264
DA 2020-05-12
ER

PT J
AU Li, J
   Wang, C
   Zou, SL
   Liu, YD
   Qu, LF
AF Li, Jun
   Wang, Chao
   Zou, Sili
   Liu, Yandong
   Qu, Lefeng
TI Hybrid Surgery for Nontaper or Nonstump Lesions in Symptomatic Subacute
   or Chronic Internal Carotid Occlusion: A Better Solution
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endovascular; Hybrid surgery; Nonstump; Nontaper; Symptomatic chronic
   internal carotid occlusion
ID ARTERY OCCLUSION; BLOOD-PRESSURE; ENDOVASCULAR RECANALIZATION;
   CEREBRAL-ISCHEMIA; ENDARTERECTOMY; RISK
AB BACKGROUND: Internal carotid artery occlusion (ICAO) causes transient ischemic attack and cerebral infarction. ICAO management remains clinically challenging. We discuss a hybrid treatment combining carotid endarterectomy and endovascular intervention (E-I) for patients with nontaper or nonstump lesions of symptomatic ICAO.
   METHODS: We treated 32 patients with consecutive nontaper or nonstump ICAO with neurological symptoms with hybrid treatment or E-I. We analyzed the epidemiology, symptoms, angiographic morphology, technical success rate, and perioperative complications.
   RESULTS: Of the 32 patients, 17 were treated with hybrid surgery and 15, E-I. The demographic data and lesion characteristics were similar between the 2 groups. The overall recanalization success rate was 71.9%. The rate for hybrid surgery was better than that for E-I (88.2% vs. 53.3%). The postoperative cerebral hyperperfusion rate showed no difference between the 2 groups (11.8% vs. 6.7%). Ipsilateral cerebral perfusion improved after treatment. The mean transition time and time to peak were greater than normal (normal values, <6 seconds and <8 seconds, respectively). Both increased significantly after treatment (mean transition time, 11.30 seconds vs. 7.25 seconds; time to peak, 19.30 seconds vs. 15.50 seconds). The incidence of perioperative complications from hybrid surgery was less than that with E-I (5.9% vs. 40.0%). Recurrent cerebrovascular events (5.9% vs. 13.3%) and the 3-month modified Rankin scale score (2.76 +/- 0.66 vs. 2.93 +/- 0.70) did not differ between the 2 groups.
   CONCLUSIONS: Recanalization of nontaper or nonstump ICAO with hybrid treatment was more successful than that with E-I, with fewer perioperative complications. The carotid endarterectomy procedure enables easier wire crossing across the occlusion and reduces potential technology-related complications by requiring a shorter lesion and fewer dissections and minimizing the effect of calcification.
C1 [Li, Jun; Wang, Chao; Zou, Sili; Liu, Yandong; Qu, Lefeng] Second Mil Med Univ, Changzheng Hosp, Dept Vasc & Endovasc Surg, Shanghai, Peoples R China.
RP Qu, LF (reprint author), Second Mil Med Univ, Changzheng Hosp, Dept Vasc & Endovasc Surg, Shanghai, Peoples R China.
EM qulefeng@smmu.edu.cn
OI Qu, lefeng/0000-0002-6122-2569
CR Altinbas A, 2011, STROKE, V42, P3491, DOI 10.1161/STROKEAHA.111.624478
   Brown K, 2015, J VASC SURG, V61, P119, DOI 10.1016/j.jvs.2014.06.008
   Chang CH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019886
   Chen YH, 2016, JACC-CARDIOVASC INTE, V9, P1825, DOI 10.1016/j.jcin.2016.06.015
   Dalyai RT, 2013, WORLD NEUROSURG, V79, P143, DOI 10.1016/j.wneu.2012.08.017
   Danek BA, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.116.004272
   Flaherty ML, 2004, STROKE, V35, pE349, DOI 10.1161/01.STR.0000135024.54608.3f
   Grubb RL, 2013, J NEUROSURG, V118, P25, DOI 10.3171/2012.9.JNS12551
   HARRISON MJG, 1977, BRIT J SURG, V64, P511, DOI 10.1002/bjs.1800640717
   Hasan D, 2019, J NEUROSURG, V130, P1468, DOI 10.3171/2018.1.JNS172858
   John S, 2017, J NEUROINTERV SURG, V9, P455, DOI 10.1136/neurintsurg-2016-012369
   Kawamata T, 2009, NEUROSURGERY, V64, P447, DOI 10.1227/01.NEU.0000339110.73385.8A
   Malhotra K, 2017, CURR ATHEROSCLER REP, V19, DOI 10.1007/s11883-017-0677-7
   Marino M, 2014, ANN VASC SURG, V28
   Michel P, 2012, NEURORADIOLOGY, V54, P139, DOI 10.1007/s00234-011-0868-9
   Namba K, 2012, INTERV NEURORADIOL, V18, P288, DOI 10.1177/159101991201800307
   Paraskevas KI, 2018, EUR J VASC ENDOVASC, V55, P290, DOI 10.1016/j.ejvs.2017.12.010
   Persoon S, 2011, J NEUROL NEUROSUR PS, V82, P521, DOI 10.1136/jnnp.2010.208330
   Persoon S, 2009, J NEUROL, V256, P1728, DOI 10.1007/s00415-009-5194-3
   Powers WJ, 2011, JAMA-J AM MED ASSOC, V306, P1983, DOI 10.1001/jama.2011.1610
   Powers WJ, 2000, NEUROLOGY, V54, P878, DOI 10.1212/WNL.54.4.878
   Reichmann BL, 2013, EUR J VASC ENDOVASC, V46, P411, DOI 10.1016/j.ejvs.2013.07.002
   Schneider JR, 2015, J VASC SURG, V61, P1216, DOI 10.1016/j.jvs.2015.01.049
   Shih YT, 2013, NEUROSURGERY, V73, P117, DOI 10.1227/NEU.0b013e31827fca6c
   Shojima M, 2010, AM J NEURORADIOL, V31, P481, DOI 10.3174/ajnr.A1843
   Terada T, 2005, J NEUROSURG, V102, P558, DOI 10.3171/jns.2005.102.3.0558
   Thomas AJ, 2007, AM J NEURORADIOL, V28, P168
   THOMPSON JE, 1986, SURG CLIN N AM, V66, P233
   van Laar PJ, 2008, STROKE, V39, P3003, DOI 10.1161/STROKEAHA.108.514265
NR 29
TC 1
Z9 2
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1416
EP E1425
DI 10.1016/j.wneu.2018.11.075
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100174
PM 30458323
DA 2020-05-12
ER

PT J
AU Li, XY
   Zhang, HQ
   Ling, F
   He, C
   Ren, J
AF Li, Xiaoyu
   Zhang, Hong-Qi
   Ling, Feng
   He, Chuan
   Ren, Jian
TI Differences in the Electrophysiological Monitoring Results of Spinal
   Cord Arteriovenous and Intramedullary Spinal Cord Cavernous
   Malformations
SO WORLD NEUROSURGERY
LA English
DT Article
DE Arteriovenous malformation; Evoked potentials; Intraoperative
   monitoring; Spinal cord; Vascular malformations
ID SOMATOSENSORY-EVOKED-POTENTIALS; SURGERY; MOTOR
AB OBJECTIVE: Spinal arteriovenous malformations (SAVMs) and intramedullary spinal cord cavernous malformations (ISCCMs) have a very low incidence of disease. The purpose of this study was to compare the differences in electrophysiologic monitoring in these 2 surgeries.
   METHODS: The study included 109 patients (SAVMs, n = 55; ISCCMs, n = 54) recruited from November 2012 to January 2016. All patients underwent electrophysiologic monitoring during the entire operation, including somato-sensory-evoked potentials, motor-evoked potentials, and electromyography. We used an amplitude reduction of >80% as warning criterion for motor-evoked potentials and an amplitude reduction of more than 50% and latency prolongation of more than 10% as warning criteria for somatosensory-evoked potentials.
   RESULTS: In our study, the sensitivity and specificity of intraoperative monitoring during SAVM surgery were 77.3% and 87.1%, respectively. The sensitivity and specificity of intraoperative monitoring during ISCCM surgery were 68.8% and 83.3%, respectively. We found that 21 patients with SAVM showed permanent changes, 17 had immediate postoperative impairment, 8 recovered before discharge, and 5 showed neurologic deficits at long-term follow-up. Of the 17 patients with ISCCMs showing permanent changes, 11 had immediate postoperative impairment, 5 recovered before discharge, and 2 had long-term residual neurologic deficits.
   CONCLUSIONS: Electrophysiological monitoring provides effective guidance during operation on spinal vascular malformations. Electrophysiologic monitoring revealed that surgical resection of SAVMs resulted in more permanent changes and postoperative dysfunction when compared with ISCCMs. The incidence of both false-positive and -negative results suggests that electrophysiologic monitoring cannot fully predict the complete function of the patients.
C1 [Li, Xiaoyu; Zhang, Hong-Qi; Ling, Feng; He, Chuan; Ren, Jian] Capital Med Univ, China INI, Xuanwu Hosp, Dept Neurosurg, Beijing, Peoples R China.
RP Zhang, HQ (reprint author), Capital Med Univ, China INI, Xuanwu Hosp, Dept Neurosurg, Beijing, Peoples R China.
EM xwzhanghq@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81171165, 81671202]; Beijing Municipal
   Administration of Hospital Clinical Medicine Development Project
   [ZY201309]; Beijing Municipal Science and Technology CommissionBeijing
   Municipal Science & Technology Commission [D161100003816001]
FX This work was supported by the National Natural Science Foundation of
   China (81171165, 81671202), the Beijing Municipal Administration of
   Hospital Clinical Medicine Development Project (ZY201309), and the
   Beijing Municipal Science and Technology Commission (D161100003816001).
CR Chaloupka JC, 2002, SEMIN CEREBROVASC DI, V2, P245
   COSGROVE GR, 1988, J NEUROSURG, V68, P31, DOI 10.3171/jns.1988.68.1.0031
   ENGLER GL, 1978, J BONE JOINT SURG AM, V60, P528, DOI 10.2106/00004623-197860040-00016
   Gross BA, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.6.FOCUS10144
   Hilibrand A.S., 2004, SPINE J, V3, P73
   Jasper HH, 1957, ELECTROENCEPHALOGR C, V10
   Jellinger K, 1978, SPINAL ANGIOMAS, P18
   Korn A, 2015, ACTA NEUROCHIR, V157, P819, DOI 10.1007/s00701-014-2307-2
   Kramer Christopher L, 2018, Continuum (Minneap Minn), V24, P407, DOI 10.1212/CON.0000000000000595
   Kurokawa R, 2018, OPER NEUROSURG, V14, P279, DOI 10.1093/ons/opx113
   Langeloo DD, 2003, SPINE, V28, P1043, DOI 10.1097/00007632-200305150-00017
   LESSER RP, 1986, ANN NEUROL, V19, P22, DOI 10.1002/ana.410190105
   Li XY, 2018, CLIN NEUROL NEUROSUR, V165, P29, DOI 10.1016/j.clineuro.2017.12.016
   MacDonald DB, 2017, J CLIN NEUROPHYSIOL, V34, P4, DOI 10.1097/WNP.0000000000000302
   Ohashi Masayuki, 2017, Spinal Cord Ser Cases, V3, P17053, DOI 10.1038/scsandc.2017.53
   Park T, 2017, ANN REHABIL MED-ARM, V41, P610, DOI 10.5535/arm.2017.41.4.610
   Pelosi L, 1999, J NEUROL NEUROSUR PS, V66, P662, DOI 10.1136/jnnp.66.5.662
   Spetzler RF, 2002, J NEUROSURG, V96, P145, DOI 10.3171/spi.2002.96.2.0145
   Sutter M, 2007, EUR SPINE J, V16, pS153, DOI 10.1007/s00586-007-0417-8
   ZORNOW MH, 1990, ELECTROEN CLIN NEURO, V77, P137, DOI 10.1016/0168-5597(90)90028-C
NR 20
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E315
EP E324
DI 10.1016/j.wneu.2018.10.032
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100037
PM 30339909
DA 2020-05-12
ER

PT J
AU Li, ZH
   Wu, Z
   Zhang, JT
   Zhang, LW
AF Li, Zong-Hao
   Wu, Zhen
   Zhang, Jun-Ting
   Zhang, Li-Wei
TI Surgical Management and Outcomes of Cavernous Sinus Hemangiomas: A
   Single-Institution Series of 47 Patients
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cavernous sinus hemangioma; Extent of resection; Morbidity; Risk factor;
   Surgical management
ID EXTRADURAL TRANSCAVERNOUS APPROACH; STEREOTACTIC RADIOSURGERY;
   EXPERIENCE; DIAGNOSIS; SURGERY
AB OBJECTIVE: The purpose of this study was to analyze the outcomes of cavernous sinus hemangiomas (CSHs) treated surgically, and to investigate factors that affect the gross total resection (GTR), newly developed or deteriorated cranial nerve injury (NDDCNI), and follow-up neurologic performance, and to further discuss the optimal treatment for CSHs.
   METHODS: Clinical data of 47 patients with CSHs treated surgically at our institution between 2012-2018 were retrospectively reviewed.
   RESULTS: GTR was achieved in 26 (55.3%) patients. Significant relations were identified between the invasion of the sella turcica (odds ratio [OR] = 0.012; 95% confidence interval [CI], 0.001-0.213; P = 0.002), skull base ward (OR [27.838; 95% CI, 2.995-258.748; P = 0.003), and GTR. The preoperative Karnofsky Performance Scale (KPS) score (OR = 2.966, per 10 score increase; 95% CI, 1.136-7.743; P = 0.026) and the invasion of the sella turcica (OR = 7.137; 95% CI, 1.282-39.726; P = 0.025) were factors that significantly affected the incidence of NDDCNI. The average follow-up KPS score, which increased significantly compared with the pre (P < 0.001) and postoperative KPS scores (P < 0.001), was 89.1. Increased tumor size (OR = 0.044, per 1cm increase; 95% CI, 0.004-0.477; P = 0.010) was a risk factor for unfavorable follow-up KPS score.
   CONCLUSIONS: Being treated by an experienced skull base surgeon favors the total removal of CSHs, whereas the invasion of the sella turcica does just the opposite. Increased tumor size is a risk factor for unfavorable followup KPS score. The invasion of the sella turcica was related to NDDCNI and unfavorable follow-up KPS score.
C1 [Li, Zong-Hao; Wu, Zhen; Zhang, Jun-Ting; Zhang, Li-Wei] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing, Peoples R China.
   [Li, Zong-Hao; Wu, Zhen; Zhang, Jun-Ting; Zhang, Li-Wei] China Natl Clin Res Ctr Neurol Dis, Beijing, Peoples R China.
   [Li, Zong-Hao; Wu, Zhen; Zhang, Jun-Ting; Zhang, Li-Wei] Beijing Inst Brain Disorders, Ctr Brain Tumor, Beijing, Peoples R China.
   [Li, Zong-Hao; Wu, Zhen; Zhang, Jun-Ting; Zhang, Li-Wei] Beijing Key Lab Brain Tumor, Beijing, Peoples R China.
   [Li, Zong-Hao] Cangzhou Cent Hosp, Dept Neurosurg, Cangzhou, Hebei, Peoples R China.
RP Zhang, LW (reprint author), Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing, Peoples R China.; Zhang, LW (reprint author), China Natl Clin Res Ctr Neurol Dis, Beijing, Peoples R China.; Zhang, LW (reprint author), Beijing Inst Brain Disorders, Ctr Brain Tumor, Beijing, Peoples R China.; Zhang, LW (reprint author), Beijing Key Lab Brain Tumor, Beijing, Peoples R China.
EM zhangliweitt@aliyun.com
CR Al-Sharydah AM, 2018, INT J SURG CASE REP, V42, P161, DOI 10.1016/j.ijscr.2017.12.006
   Bal E, 2016, WORLD NEUROSURG, V94, P375, DOI 10.1016/j.wneu.2016.07.004
   Bansal S, 2014, J CLIN NEUROSCI, V21, P968, DOI 10.1016/j.jocn.2013.09.008
   Chang AR, 2017, RADIAT ONCOL J, V35, P25, DOI 10.3857/roj.2016.01984
   Chibbaro S, 2018, J CLIN NEUROSCI, V52, P135, DOI 10.1016/j.jocn.2018.03.021
   Das S, 2018, CLIN NEUROPATHOL, V37, P64, DOI 10.5414/NP301012
   Dou YH, 2010, ARTIF CELL BLOOD SUB, V38, P109, DOI 10.3109/10731191003634851
   Goel A, 2003, NEUROL MED-CHIR, V43, P112, DOI 10.2176/nmc.43.112
   Gonzalez L Fernando, 2006, Neurosurg Focus, V21, pe6
   Hori S, 2010, NEUROL MED-CHIR, V50, P330, DOI 10.2176/nmc.50.330
   Iwai Y, 1999, NEUROL MED-CHIR, V39, P288, DOI 10.2176/nmc.39.288
   Lee CC, 2017, J NEUROSURG, V126, P1498, DOI 10.3171/2016.4.JNS152097
   Li MH, 2015, CLIN NEUROL NEUROSUR, V136, P110, DOI 10.1016/j.clineuro.2015.06.004
   LINSKEY ME, 1992, NEUROSURGERY, V30, P101, DOI 10.1227/00006123-199201000-00018
   Ohata K, 1999, J NEUROSURG, V90, P702, DOI 10.3171/jns.1999.90.4.0702
   Park CK, 2016, ACTA NEUROCHIR, V158, P313, DOI 10.1007/s00701-015-2657-4
   Prajapati Hanuman Prasad, 2018, Asian J Neurosurg, V13, P217, DOI 10.4103/ajns.AJNS_160_16
   Srinivas D, 2017, J NEUROL SURG PART B, V78, P399, DOI 10.1055/s-0037-1602790
   Suri A, 2007, NEUROSURGERY, V60, P483, DOI 10.1227/01.NEU.0000255333.95532.13
   Tang XQ, 2015, ACTA NEUROCHIR, V157, P961, DOI 10.1007/s00701-015-2417-5
   Wang X, 2018, J NEUROSURG, V128, P60, DOI 10.3171/2016.10.JNS16693
   Wang X, 2012, J NEURO-ONCOL, V107, P239, DOI 10.1007/s11060-011-0753-8
   Wang Y, 2016, WORLD NEUROSURG, V94, P18, DOI 10.1016/j.wneu.2016.06.094
   Yin YH, 2013, J CLIN NEUROSCI, V20, P128, DOI 10.1016/j.jocn.2012.01.050
   Zhou LF, 2003, SURG NEUROL, V60, P31, DOI 10.1016/S0090-3019(03)00190-3
NR 25
TC 1
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1181
EP E1194
DI 10.1016/j.wneu.2018.11.015
PG 14
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100144
PM 30447442
DA 2020-05-12
ER

PT J
AU Linder, LKB
   Birgersson, U
   Lundgren, K
   Illies, C
   Engstrand, T
AF Linder, Lars Kihlstrom Burenstam
   Birgersson, Ulrik
   Lundgren, Kalle
   Illies, Christopher
   Engstrand, Thomas
TI Patient-Specific Titanium-Reinforced Calcium Phosphate Implant for the
   Repair and Healing of Complex Cranial Defects
SO WORLD NEUROSURGERY
LA English
DT Article
DE 3-Dimensional; Bone regeneration; Calcium phosphate; Ceramic; Cranial;
   Cranioplasty
ID CRANIOPLASTY; CEMENT; POLYETHERETHERKETONE; HYDROXYAPATITE;
   COMPLICATIONS; RESORPTION; OUTCOMES
AB BACKGROUND: The reconstruction of complex cranial defects is challenging and is associated with a high complication rate. The development of a patient-specific, titanium-reinforced, calcium phosphate-based (CaP-Ti) implant with bone regenerative properties has previously been described in 2 case studies with the hypothesis that the implant may improve clinical outcome.
   OBJECTIVE: To identify whether the introduction of CaP-Ti implant has the potential to improve clinical outcome.
   METHODS: A retrospective review of all patients having undergone CaP-Ti cranioplasty was conducted. Comprehensive clinical data were collected from the hospital computer database and patient records. Bone formation and osseointegration were analyzed in a single retrieval specimen.
   RESULTS: Fifty patients, with 52 cranial defects, met the inclusion criteria. The patient cohort displayed a previous failure rate of 64% (32/50) with autologous bone, alloplastic materials, or both. At a median follow-up time of 25 months, the explantation rate due to either early postoperative infection or persistent wound dehiscence was 1.9% (1/53) or 3.8% (2/53), respectively. Surgical intervention with local wound revision was required in 2 patients without the need of implant removal. One patient had a brain tumor recurrence, and the implant was explanted 31 months after implantation. Histologic examination showed that the entire implant was partly yet evenly transformed into vascularized compact bone.
   CONCLUSION: In the present study the CaP-Ti implant appears to have improved the clinical outcomes in a cohort of patients with a high rate of previous cranioplasty failures. The bone regenerative effect may in particular have an impact on the long-term success rate of the implant.
C1 [Linder, Lars Kihlstrom Burenstam] Karolinska Univ Hosp, Dept Neurosurg, Clin Neurosci, Stockholm, Sweden.
   [Linder, Lars Kihlstrom Burenstam; Lundgren, Kalle] Karolinska Inst, Stockholm, Sweden.
   [Birgersson, Ulrik] Karolinska Inst, Div Imaging & Technol, Dept Clin Sci Intervent & Technol, Huddinge, Sweden.
   [Lundgren, Kalle] Karolinska Univ Hosp, Dept Mol Med & Surg, Unit Craniofacial Dis, Stockholm, Sweden.
   [Illies, Christopher] Karolinska Univ Hosp, Dept Clin Pathol, Stockholm, Sweden.
   [Engstrand, Thomas] Uppsala Univ, Dept Surg Sci, Uppsala, Sweden.
RP Linder, LKB (reprint author), Karolinska Univ Hosp, Dept Neurosurg, Clin Neurosci, Stockholm, Sweden.; Linder, LKB (reprint author), Karolinska Inst, Stockholm, Sweden.
EM lars.kihlstrom-burenstam-linder@sll.se
FU Eurostars-2 Joint Programme; European Union's Horizon 2020 research and
   innovation programme [El 9741]
FX This project received funding from the Eurostars-2 Joint Programme with
   cofunding from the European Union's Horizon 2020 research and innovation
   programme (Project number El 9741). Dr Engstrand has direct ownership in
   OssDsign, the manufacturer of the implant that is the subject of this
   study. Drs Kihlstrom, Birgersson, and Engstrand have consulting
   agreements with OssDsign. The remaining authors have no conflicts to
   report. Part of this report was presented as a digital poster at the
   Congress of Neurological Surgeons 2017 Annual Meeting in Boston,
   Massachusetts.
CR Aberg J, 2013, United States patent, Patent No. [9913931B2, 9913931]
   Bonda DJ, 2015, NEUROSURGERY, V77, P814, DOI 10.1227/NEU.0000000000000899
   Corliss B, 2016, WORLD NEUROSURG, V96, P510, DOI 10.1016/j.wneu.2016.09.025
   Coulter IC, 2014, ACTA NEUROCHIR, V156, P1361, DOI 10.1007/s00701-014-2081-1
   Dorozhkin Sergey V, 2011, Biomatter, V1, P3, DOI 10.4161/biom.1.1.16782
   Durham SR, 2003, NEUROSURGERY, V52, P842, DOI 10.1227/01.NEU.0000054220.01290.8E
   Engstrand T, 2015, PRS-GLOB OPEN, V3, DOI 10.1097/GOX.0000000000000467
   Engstrand T, 2014, J NEUROSURG, V120, P273, DOI 10.3171/2013.6.JNS1360
   Fan MC, 2018, WORLD NEUROSURG, V109, pE853, DOI 10.1016/j.wneu.2017.10.112
   Foster KA, 2016, WORLD NEUROSURG, V95, P414, DOI 10.1016/j.wneu.2016.02.071
   Giese H, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-009273
   Grover LM, 2013, BIOMATERIALS, V34, P6631, DOI 10.1016/j.biomaterials.2013.05.001
   Kim J, 2012, J BIOMED MATER RES B, V100B, P1170, DOI 10.1002/jbm.b.31920
   Kolias AG, 2014, BRIT J NEUROSURG, V28, P310, DOI 10.3109/02688697.2013.859657
   Korhonen TK, 2019, J NEUROSURG, V130, P312, DOI 10.3171/2017.8.JNS171857
   Larsson S, 2010, J ORTHOP TRAUMA, V24, pS41, DOI 10.1097/BOT.0b013e3181cec472
   Li A, 2017, WORLD NEUROSURG, V102, P209, DOI 10.1016/j.wneu.2017.03.022
   Lindner D, 2017, J NEUROSURG, V126, P175, DOI 10.3171/2015.10.JNS151245
   Marion DW, 2006, NEUROSURGERY, V58, P655
   Moles A, 2018, WORLD NEUROSURG, V111, pE388, DOI 10.1016/j.wneu.2017.12.082
   Neovius E, 2010, J PLAST RECONSTR AES, V63, P1615, DOI 10.1016/j.bjps.2009.06.003
   Posti JP, 2016, J MECH BEHAV BIOMED, V55, P191, DOI 10.1016/j.jmbbm.2015.10.030
   Punchak M, 2017, J CLIN NEUROSCI, V41, P30, DOI 10.1016/j.jocn.2017.03.028
   Renth AN, 2012, TISSUE ENG PART B-RE, V18, P341, DOI 10.1089/ten.teb.2012.0080
   Saringer W, 2002, ACTA NEUROCHIR, V144, P1193, DOI 10.1007/s00701-002-0995-5
   Satyarthee GD, 2017, WORLD NEUROSURG, V103, P937, DOI 10.1016/j.wneu.2017.02.077
   Schwarz F, 2016, J NEUROSURG, V124, P710, DOI 10.3171/2015.4.JNS159
   Stefini R, 2015, J APPL BIOMATER FUNC, V13, pE136, DOI 10.5301/jabfm.5000211
   Tamimi F, 2012, ACTA BIOMATER, V8, P474, DOI 10.1016/j.actbio.2011.08.005
   Tang D, 2016, BIOMATERIALS, V83, P363, DOI 10.1016/j.biomaterials.2016.01.024
   Thien A, 2015, WORLD NEUROSURG, V83, P176, DOI 10.1016/j.wneu.2014.06.003
   van de Vijfeijken SECM, 2018, WORLD NEUROSURG, V117, P443, DOI 10.1016/j.wneu.2018.05.193
   Wiggins A, 2013, NEUROSURGERY, V72, P248, DOI 10.1227/NEU.0b013e31827b98f3
   Xu HHK, 2001, J MATER SCI-MATER M, V12, P57, DOI 10.1023/A:1026753020208
   Yuan HP, 2010, P NATL ACAD SCI USA, V107, P13614, DOI 10.1073/pnas.1003600107
   Zanotti B, 2016, J CRANIOFAC SURG, V27, P2061, DOI 10.1097/SCS.0000000000003025
   Zhang JT, 2014, ACTA BIOMATER, V10, P1035, DOI 10.1016/j.actbio.2013.11.001
NR 37
TC 3
Z9 3
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E399
EP E407
DI 10.1016/j.wneu.2018.10.061
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100047
PM 30342265
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Liu, J
   Tang, J
   Zhang, Y
   Gu, ZC
   Yu, SH
AF Liu, Jin
   Tang, Jing
   Zhang, Yu
   Gu, Zu-chao
   Yu, Sheng-hui
TI Percutaneous Vertebral Augmentation for Osteoporotic Vertebral
   Compression Fracture in the Midthoracic Vertebrae (T5-8): A
   Retrospective Study of 101 Patients with 111 Fractured Segments
SO WORLD NEUROSURGERY
LA English
DT Article
DE Distribution of bone cement; Midthoracic; Osteoporotic vertebral
   compression fracture (OVCF); Percutaneous kyphoplasty (PKP);
   Percutaneous vertebroplasty (PVP)
ID CONSERVATIVE TREATMENT; RISK-FACTORS; CEMENT DISTRIBUTION;
   VERTEBROPLASTY; KYPHOPLASTY; METAANALYSIS; VOLUME
AB OBJECTIVE: Data reporting percutaneous vertebroplasty (PVP) or percutaneous balloon kyphoplasty (PKP) application to the midthoracic vertebrae remain limited. This study aimed to summarize our experiences and explore the efficacy and safety of PVP or PKP in dealing with osteoporotic vertebral compression fracture (OVCF) in the midthoracic vertebrae.
   METHODS: Patients receiving PVP or PKP for midthoracic OVCF in our institution from January 2015 to January 2018 were retrospectively enrolled. All patients were grouped according to cement augmentation procedure types, surgical approaches, and puncture routes. All patients underwent a postoperative follow-up of 2-36 months. Visual analog scale (VAS) and ECOG Scale of Performance Status scores were evaluated pre- and post-operatively. Cement distribution and rate of cement leakage were assessed by radiographs. Associations of these variables and clinical scores and radiographic indices were analyzed.
   RESULTS: A total of 101 consecutive patients with 111 fractured centrums were enrolled. Both VAS and ECOG Scale of Performance Status scores of all patients decreased significantly after the operation, and progressively decreased at the final follow-up. The cement distribution of the bipedicular group was significantly better than the unipedicular group, but the total leakage rate of the former (71.7%) was significantly higher than the latter (43.1%). The rate of epidural cement leakage in the PKP group (5.4%) was significantly lower than that of the PVP group (20.3%), whereas the left puncture group (28.6%) was significantly higher than that of the right puncture group (2.7%).
   CONCLUSIONS: PKP and a bipedicular approach can help improve cement distribution and reduce the epidural cement leakage rate and therefore should be preferred over PVP or a unipedicular approach in OVCF of the midthoracic vertebrae.
C1 [Liu, Jin; Zhang, Yu; Gu, Zu-chao; Yu, Sheng-hui] Chengdu First Peoples Hosp, Dept Orthopaed, Chengdu, Sichuan, Peoples R China.
   [Tang, Jing] Sichuan Univ, West China Hosp, Dept Radiol, Chengdu, Sichuan, Peoples R China.
RP Zhang, Y (reprint author), Chengdu First Peoples Hosp, Dept Orthopaed, Chengdu, Sichuan, Peoples R China.
EM zy424516@163.com
CR Alexandru Daniela, 2012, Perm J, V16, P46
   Andrei D, 2017, INT ORTHOP, V41, P963, DOI 10.1007/s00264-017-3409-2
   Ballane G, 2017, OSTEOPOROSIS INT, V28, P1531, DOI 10.1007/s00198-017-3909-3
   Buccheri G, 1996, EUR J CANCER, V32A, P1135, DOI 10.1016/0959-8049(95)00664-8
   Chang X, 2015, INT ORTHOP, V39, P491, DOI 10.1007/s00264-014-2525-5
   Chen AT, 2013, J BONE JOINT SURG AM, V95A, P1729, DOI 10.2106/JBJS.K.01649
   Chen QY, 2018, ORTHOPADE, V47, P585, DOI 10.1007/s00132-018-3527-6
   Chevalier Y, 2008, SPINE, V33, P1722, DOI 10.1097/BRS.0b013e31817c750b
   Dong RB, 2013, INT ORTHOP, V37, P83, DOI 10.1007/s00264-012-1709-0
   Dong RB, 2009, INT ORTHOP, V33, P1689, DOI 10.1007/s00264-008-0680-2
   Gaughen JR, 2002, AM J NEURORADIOL, V23, P1657
   Han KR, 2005, ACTA RADIOL, V46, P280, DOI 10.1080/02841850510021058
   Johnell O, 2005, OSTEOPOROSIS INT, V16, pS3, DOI 10.1007/s00198-004-1702-6
   Kallmes DF, 2002, AM J NEURORADIOL, V23, P1117
   Landham PR, 2015, SPINE J, V15, P721, DOI 10.1016/j.spinee.2014.11.017
   Laratta Joseph L, 2017, J Spine Surg, V3, P364, DOI 10.21037/jss.2017.08.02
   Liebschner MAK, 2001, SPINE, V26, P1547, DOI 10.1097/00007632-200107150-00009
   Pourtaheri S, 2018, CLIN SPINE SURG, V31, P339, DOI 10.1097/BSD.0000000000000670
   Schofer MD, 2009, ARCH ORTHOP TRAUM SU, V129, P1391, DOI 10.1007/s00402-009-0901-1
   Si L, 2015, OSTEOPOROSIS INT, V26, P1929, DOI 10.1007/s00198-015-3093-2
   Steindler Arthur, 2006, Clin Orthop Relat Res, V443, P3, DOI 10.1097/01.blo.0000200246.45178.fe
   Sun HB, 2018, WORLD NEUROSURG, V114, pE677, DOI 10.1016/j.wneu.2018.03.050
   Teyssedou S, 2014, ORTHOP TRAUMATOL-SUR, V100, pS169, DOI 10.1016/j.otsr.2013.11.005
   Xie L, 2017, INT J SURG, V47, P25, DOI 10.1016/j.ijsu.2017.09.021
   Xu RM, 1999, SPINE, V24, P451, DOI 10.1097/00007632-199903010-00008
   Yang EZ, 2016, SPINE, V41, P653, DOI 10.1097/BRS.0000000000001298
   Yang LY, 2013, PAIN PHYSICIAN, V16, P277
   Ye LQ, 2018, PAIN PHYSICIAN, V21, pE33
   Yu WB, 2018, WORLD NEUROSURG, V111, P119, DOI 10.1016/j.wneu.2017.12.019
   Zhan Y, 2017, WORLD NEUROSURG, V101, P633, DOI 10.1016/j.wneu.2017.01.124
NR 30
TC 2
Z9 2
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1381
EP E1387
DI 10.1016/j.wneu.2018.11.062
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100169
PM 30465955
DA 2020-05-12
ER

PT J
AU Liu, LX
   Zhang, CW
   Lin, S
   Wu, C
   Wang, T
   Zhou, LX
   Wang, CH
   Xie, XD
AF Liu, Lun-Xin
   Zhang, Chang-Wei
   Lin, Sen
   Wu, Cong
   Wang, Ting
   Zhou, Liang-Xue
   Wang, Chao-Hua
   Xie, Xiao-Dong
TI Application of the Willis Covered Stent in the Treatment of Ophthalmic
   Artery Segment Aneurysms: A Single-Center Experience
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm; Covered stent; Endovascular; Internal carotid artery;
   Ophthalmic artery
ID INTERNAL CAROTID-ARTERY; INTRACRANIAL ANEURYSMS; FLOW-DIVERSION;
   NATURAL-HISTORY; PSEUDOANEURYSMS; EMBOLIZATION; TERRITORIES; MANAGEMENT;
   RUPTURE
AB OBJECTIVE: The purpose of this study is to introduce our initial experience with the evaluation of the feasibility of using Willis covered stents (WCSs) in the treatment of complicated ophthalmic artery (OA) segment aneurysms.
   METHODS: Of the 162 patients with OA segment aneurysms treated by endovascular techniques in West China Hospital from January 2015 to August 2017, a total of 26 patients treated with WCSs were included in the study.
   RESULTS: Twenty-six patients with 26 aneurysms were included (mean age, 57.0 years; range, 22-76 years). The cohort had 20 patients with large or giant aneurysms, 3 patients with blood blister aneurysms, and 3 patients with pseudoaneurysms. Ten aneurysms were OA type, and 16 were internal carotid artery (ICA) type. Twenty-four patients were treated with 1 stent, and 2 patients were treated with 2 stents. Among the 26 patients, 2 patients had minimal endoleak, and 24 patients had complete occlusion after immediate postoperative angiography. One patient who had complete occlusion experienced contrast agent extravasation, and this phenomenon disappeared by balloon compression during the procedure. The 3- to 15-month angiographic follow-up showed that all patients experienced complete occlusion, including 2 patients with minimal endoleak during immediate postprocedural angiography. Two patient showed signs of in-stent stenosis. Clinical follow-up demonstrated that no delayed thromboembolic or ischemic events were recorded in the stent-grafted vascular region and no bleeding occurred in any of the patients (except 1 patient who experienced subarachnoid hemorrhage, left frontal lobe hemorrhage, and hydrocephalus 10 days after the procedure).
   CONCLUSIONS: WCSs may provide an alternative solution for treating complex OA segment aneurysms by reconstruction and preservation of the ICA. Our study also confirms the safety, efficacy, and midterm durability of WCSs for complex OA segment aneurysms.
C1 [Liu, Lun-Xin; Zhang, Chang-Wei; Lin, Sen; Wu, Cong; Wang, Ting; Zhou, Liang-Xue; Wang, Chao-Hua; Xie, Xiao-Dong] Sichuan Univ, Dept Neurosurg, West China Hosp, Chengdu, Sichuan, Peoples R China.
RP Xie, XD (reprint author), Sichuan Univ, Dept Neurosurg, West China Hosp, Chengdu, Sichuan, Peoples R China.
EM 13708005179@163.com
OI Wu, Cong/0000-0002-9596-5344
FU National Natural Scientific Fund of ChinaNational Natural Science
   Foundation of China [81372446]
FX Supported by the National Natural Scientific Fund of China (81372446).
CR Almandoz JED, 2013, J NEUROINTERV SURG
   Biondi A, 2007, NEUROSURGERY, V61, P460, DOI 10.1227/01.NEU.0000290890.62201.A9
   DRAKE CG, 1968, J NEUROSURG, V29, P24, DOI 10.3171/jns.1968.29.1.0024
   Drake RL, 2009, ANAT SCI EDUC, V2, P253, DOI 10.1002/ase.117
   Feekes JA, 2005, ANN NEUROL, V58, P18, DOI 10.1002/ana.20505
   Fiorella D, 2006, NEUROSURGERY, V59, P34, DOI 10.1227/01.NEU.0000219853.56553.71
   Frosen J, 2004, STROKE, V35, P2287, DOI 10.1161/01.STR.0000140636.30204.da
   Geibprasert S, 2009, AM J NEURORADIOL, V30, P1459, DOI 10.3174/ajnr.A1500
   Ghica J, 1990, ARCH NEUROL-CHICAGO, V47, P1097
   Hamoir XL, 2004, EUR RADIOL, V14, P417, DOI 10.1007/s00330-003-2220-1
   Kan P, 2016, J NEUROINTERV SURG, V8, P945, DOI 10.1136/neurintsurg-2015-011959
   Kattner KA, 1998, SURG NEUROL, V49, P471, DOI 10.1016/S0090-3019(97)00374-1
   Kipshidze N, 2004, J AM COLL CARDIOL, V44, P733, DOI 10.1016/j.jacc.2004.04.048
   Kulcsar Z, 2011, AM J NEURORADIOL, V32, P20, DOI 10.3174/ajnr.A2370
   Lanzino G, 2012, AM J NEURORADIOL, V33, P2158, DOI 10.3174/ajnr.A3207
   LASJAUNIAS P, 1975, NEURORADIOLOGY, V9, P87, DOI 10.1007/BF00341426
   Li MH, 2007, AM J NEURORADIOL, V28, P1579, DOI 10.3174/ajnr.A0668
   Li MH, 2009, RADIOLOGY, V253, P470, DOI 10.1148/radiol.2532090037
   LOCKSLEY HB, 1966, J NEUROSURG, V25, P321, DOI 10.3171/jns.1966.25.3.0321
   Madaelil TP, 2017, AM J NEURORADIOL, V38, P590, DOI 10.3174/ajnr.A5030
   Perrini P, 2007, J NEUROSURG, V106, P142, DOI 10.3171/jns.2007.106.1.142
   Prabhakaran S, 2008, AM J NEURORADIOL, V29, P281, DOI 10.3174/ajnr.A0818
   Roy D, 1997, AM J NEURORADIOL, V18, P1207
   Saatci I, 2004, AM J NEURORADIOL, V25, P1742
   Tan HQ, 2011, CEREBROVASC DIS, V31, P154, DOI 10.1159/000321735
   Tatu L, 1998, NEUROLOGY, V50, P1699, DOI 10.1212/WNL.50.6.1699
   Wang W, 2011, J TRAUMA, V70, P816, DOI 10.1097/TA.0b013e3181f892af
NR 27
TC 0
Z9 0
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E546
EP E552
DI 10.1016/j.wneu.2018.10.098
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100066
PM 30889778
DA 2020-05-12
ER

PT J
AU Liu, LX
   Lim, J
   Zhang, CW
   Lin, S
   Wu, C
   Wang, T
   Xie, XD
   Zhou, LX
   Wang, CH
AF Liu, Lun-Xin
   Lim, Jaims
   Zhang, Chang-Wei
   Lin, Sen
   Wu, Cong
   Wang, Ting
   Xie, Xiao-Dong
   Zhou, Liang-Xue
   Wang, Chao-Hua
TI Application of the Willis Covered Stent in the Treatment of
   Carotid-Cavernous Fistula: A Single-Center Experience
SO WORLD NEUROSURGERY
LA English
DT Article
DE Carotid-cavernous fistula; Complication; Covered stent; Endovascular
ID ENDOVASCULAR TREATMENT; ARTERIOVENOUS-FISTULAS; BALLOON CATHETERIZATION;
   COIL EMBOLIZATION; DETACHABLE COILS; SINUS FISTULAS; FOLLOW-UP; ARTERY;
   MANAGEMENT; ANEURYSMS
AB BACKGROUND: The purpose of the present study was to describe our single-institutional experience of treating direct carotid-cavernous fistulas (DCCFs) with Willis covered stents (WCSs).
   METHODS: Of a total of 31 DCCFs, 10 were treated with WCSs (Microport, Shanghai, China) at West China Hospital from January 2015 to December 2016. The indications for treatment, perioperative findings, and postoperative and follow-up results were collected and analyzed.
   RESULTS: All 10 patients had successful deployment of WCSs. Complete exclusion of the fistula was achieved in 6 patients immediately after deployment of 1 stent. Endoleak was observed in 4 patients (patients 2, 4, 5, and 9). Thus, repeat dilation of the stent with greater pressure was performed, which resolved the endoleak in 2 patients (patients 2 and 9). The endoleak of the other 2 patients persisted after repeat dilation of the balloon. Hence, a second stent was deployed in these 2 patients (patients 4 and 5), which eliminated the endoleak in patient 4. However, patient 5 continued to have a minimal endoleak. Nine patients had fistulas successfully occluded by WCSs during the follow-up period. One patient experienced recurrence of a DCCF at the 10-day follow-up point. We chose coil embolization to address this DCCF. No stenosis of the internal carotid artery or DCCF recurrence, except that in the abovementioned patient, was observed.
   CONCLUSIONS: WCS was proved to be an alternative treatment method for complex DCCFs through reconstruction and preservation of the internal carotid artery. Our study also confirmed the safety, efficacy, and midterm durability of WCSs for complex DCCFs without any serious delayed complications.
C1 [Liu, Lun-Xin; Zhang, Chang-Wei; Lin, Sen; Wu, Cong; Wang, Ting; Xie, Xiao-Dong; Zhou, Liang-Xue; Wang, Chao-Hua] Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu, Sichuan, Peoples R China.
   [Lim, Jaims] Univ Buffalo, Dept Neurol Surg, Buffalo, NY USA.
RP Wang, CH (reprint author), Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu, Sichuan, Peoples R China.
EM wangchaohuaHX@163.com
OI Wu, Cong/0000-0002-9596-5344
CR Ahn JY, 2003, J CLIN NEUROSCI, V10, P96, DOI 10.1016/S0967-5868(02)00266-7
   Arat A, 2004, NEURORADIOLOGY, V46, P1012, DOI 10.1007/s00234-004-1244-9
   Archondakis E, 2007, AM J NEURORADIOL, V28, P342
   BARROW DL, 1985, J NEUROSURG, V62, P248, DOI 10.3171/jns.1985.62.2.0248
   Bartorelli Antonio L, 2001, Int J Cardiovasc Intervent, V4, P195
   Bavinzski G, 1997, NEURORADIOLOGY, V39, P81, DOI 10.1007/s002340050371
   DEBRUN G, 1981, J NEUROSURG, V55, P678, DOI 10.3171/jns.1981.55.5.0678
   Elhammady MS, 2010, J NEUROSURG, V112, P589, DOI 10.3171/2009.6.JNS09132
   Felber S, 2004, NEUROSURGERY, V55, P631, DOI 10.1227/01.NEU.0000134455.02947.1F
   Gomez F, 2007, AM J NEURORADIOL, V28, P1762, DOI 10.3174/ajnr.A0636
   Gupta AK, 2006, NEURORADIOLOGY, V48, P831, DOI 10.1007/s00234-006-0132-x
   HALBACH VV, 1991, AM J NEURORADIOL, V12, P429
   HIGASHIDA RT, 1989, AM J ROENTGENOL, V153, P577, DOI 10.2214/ajr.153.3.577
   Hoit DA, 2008, NEUROSURGERY, V62, P380, DOI [10.1227/01.NEU.0000335088.85470.FC, 10.1227/01.NEU.0000297138.40345.25]
   Jansen O, 1999, NEURORADIOLOGY, V41, P951, DOI 10.1007/s002340050875
   Kobayashi N, 2003, AM J NEURORADIOL, V24, P1789
   Lewis AI, 1996, J NEUROSURG, V84, P400, DOI 10.3171/jns.1996.84.3.0400
   Li J, 2010, WORLD NEUROSURG, V73, P514, DOI 10.1016/j.wneu.2010.02.062
   Li MH, 2007, AM J NEURORADIOL, V28, P1579, DOI 10.3174/ajnr.A0668
   Li MH, 2009, RADIOLOGY, V253, P470, DOI 10.1148/radiol.2532090037
   Lin CJ, 2009, J CLIN NEUROSCI, V16, P1663, DOI 10.1016/j.jocn.2009.02.026
   Liu LX, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006101
   Lukito G, 2000, ACTA CARDIOL, V55, P255, DOI 10.2143/AC.55.4.2005748
   Luo CB, 2006, AM J NEURORADIOL, V27, P1535
   Luo CB, 2004, J TRAUMA, V56, P1214, DOI 10.1097/01.TA.0000131213.93205.57
   Madan A, 2006, J NEUROSURG, V104, P969, DOI 10.3171/jns.2006.104.6.969
   Mathis JM, 1997, NEURORADIOLOGY, V39, P90, DOI 10.1007/s002340050373
   Moreno R, 2004, J AM COLL CARDIOL, V43, P1964, DOI 10.1016/j.jacc.2004.01.039
   Moron FE, 2005, AM J NEURORADIOL, V26, P1399
   Ogino H, 2004, CARDIOVASC INTER RAD, V27, P68, DOI 10.1007/s00270-003-2727-5
   Redekop G, 2001, J NEUROSURG, V95, P412, DOI 10.3171/jns.2001.95.3.0412
   Serbinenko FA, 2007, J NEUROSURG, V107, P685, DOI 10.3171/JNS-07/09/0685
   SERBINENKO FA, 1974, J NEUROSURG, V41, P125, DOI 10.3171/jns.1974.41.2.0125
   Suzuki S, 2006, AM J NEURORADIOL, V27, P1346
   Uysal E, 2010, J CLIN NEUROSCI, V17, P392, DOI 10.1016/j.jocn.2009.06.020
   van Rooij WJ, 2006, AM J NEURORADIOL, V27, P185
   Wang C, 2009, AM J NEURORADIOL, V30, P1342, DOI 10.3174/ajnr.A1583
   Wang W, 2016, NEUROSURGERY, V79, P794, DOI 10.1227/NEU.0000000000001266
   Wang W, 2011, J TRAUMA, V70, P816, DOI 10.1097/TA.0b013e3181f892af
   Wang W, 2011, J CLIN NEUROSCI, V18, P24, DOI 10.1016/j.jocn.2010.06.008
   Wang YL, 2012, INTERV NEURORADIOL, V18, P172, DOI 10.1177/159101991201800208
   Wang YL, 2012, NEUROL INDIA, V60, P180, DOI 10.4103/0028-3886.96397
   Wendl CM, 2017, CLIN NEURORADIOL, V27, P493, DOI 10.1007/s00062-016-0511-6
   Zenteno M, 2010, J NEUROSURG, V112, P595, DOI 10.3171/2009.6.JNS09440
NR 44
TC 2
Z9 2
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E390
EP E398
DI 10.1016/j.wneu.2018.10.060
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100046
PM 30352308
DA 2020-05-12
ER

PT J
AU Ma, XJ
   Meng, GL
   Wang, K
   Li, D
   Wang, L
   Li, H
   Zhang, JT
   Zhang, LW
   Wu, Z
AF Ma, Xiujian
   Meng, Guolu
   Wang, Ke
   Li, Da
   Wang, Liang
   Li, Huan
   Zhang, Junting
   Zhang, Liwei
   Wu, Zhen
TI The Differences Between Intracranial Mesenchymal Chondrosarcoma and
   Conventional Chondrosarcoma in Clinical Features and Outcomes
SO WORLD NEUROSURGERY
LA English
DT Article
DE Clinical characteristics; Conventional chondrosarcoma; Mesenchymal
   chondrosarcoma; Prognosis
ID SKULL-BASE; PROTON THERAPY; RESECTION; CHORDOMA; RADIOSURGERY; SURGERY
AB OBJECTIVE: To report differences in clinical features and outcomes between intracranial mesenchymal chondrosarcoma (MCS) and conventional chondrosarcoma (CCS).
   METHODS: Clinical data of patients with primary intracranial MCS and CCS were retrospectively extracted and analyzed to compare differences between MCS and CCS.
   RESULTS: Seventy-four patients with intracranial chondrosarcoma (61 cases with MCS and 13 cases with CCS) were included. Compared with patients with CCS, patients with MCS presented at a younger mean age (21.1 years vs. 34.5 years, P < 0.001) and had a poor mean preoperative Karnofsky performance scale score (64.6 vs. 77.8, P = 0.014). Compared with CCS, MCS was less often located in the skull base (38.5% vs. 96.7%, P < 0.001) and had a larger tumor volume (87.8 cm(3) vs. 26.7 cm(3), P < 0.001). Rates of gross total resection in MCS and CCS subgroups were 41.1% (n = 25) and 46.2% (n = 6), respectively; rates of adjuvant radiotherapy postoperatively were 44.2% (n = 27) and 46.2% (n = 6), respectively. After mean follow-up of 41.7 months, 1-year, 3-year, and 5-year overall survival and progression-free survival of MCS were significantly shorter than overall survival and progression-free survival of CCS. Multivariate analysis revealed that tumor pathology and extent of surgery were independent predictors for tumor recurrence.
   CONCLUSIONS: Clinical features of MCS are quite different from CCS. Treatment strategies used for CCS do not yield satisfactory outcomes for MCS. Treatment of MCS should be aggressive and individualized.
C1 [Ma, Xiujian; Wang, Ke; Li, Da; Wang, Liang; Li, Huan; Zhang, Junting; Zhang, Liwei; Wu, Zhen] Beijing Tiantan Hosp, Dept Neurosurg, Beijing, Peoples R China.
   [Meng, Guolu] Capital Med Univ, Xuanwu Hosp, Dept Neurosurg, Beijing, Peoples R China.
RP Wu, Z (reprint author), Beijing Tiantan Hosp, Dept Neurosurg, Beijing, Peoples R China.
EM wz_ttyy@163.com
OI Wu, Zhen/0000-0002-3329-6448
FU Natural Science Foundation of ChinaNational Natural Science Foundation
   of China [814742370, 81672506]; Special Fund for the Talents of Beijing
   [20160000214696212]
FX This work was supported in part by the Natural Science Foundation of
   China (Grant No. 814742370 to J.Z. and Grant No. 81672506to Z.W) and
   Special Fund for the Talents of Beijing (Grant No. 20160000214696212 to
   K.W)
CR BERSON AM, 1988, INT J RADIAT ONCOL, V15, P559, DOI 10.1016/0360-3016(88)90295-7
   Bloch O, 2013, NEUROSURG CLIN N AM, V24, P89, DOI 10.1016/j.nec.2012.08.002
   Bloch OG, 2010, SKULL BASE-INTERD AP, V20, P149, DOI 10.1055/s-0029-1246218
   Bloch OG, 2009, J CLIN NEUROSCI, V16, P1547, DOI 10.1016/j.jocn.2009.05.003
   Feuvret L, 2016, INT J RADIAT ONCOL, V95, P312, DOI 10.1016/j.ijrobp.2015.12.016
   Folbe AJ, 2017, OTOLARYNG CLIN N AM, V50, P315, DOI 10.1016/j.otc.2016.12.008
   Kan ZS, 2012, BRIT J NEUROSURG, V26, P912, DOI 10.3109/02688697.2012.697219
   Kano H, 2015, J NEUROSURG, V123, P1268, DOI 10.3171/2014.12.JNS132580
   Kano H, 2013, NEUROSURG CLIN N AM, V24, P553, DOI 10.1016/j.nec.2013.05.009
   Kim JH, 2014, J NEUROSURG, V121, P188, DOI 10.3171/2014.7.GKS141213
   Koch BB, 2000, HEAD NECK-J SCI SPEC, V22, P408, DOI 10.1002/1097-0347(200007)22:4<408::AID-HED15>3.0.CO;2-H
   Laghari AA, 2017, WORLD NEUROSURG, V99, DOI 10.1016/j.wneu.2016.12.086
   Li D, 2018, WORLD NEUROSURG, V109, pE517, DOI 10.1016/j.wneu.2017.10.013
   Oakley GJ, 2008, MODERN PATHOL, V21, P1461, DOI 10.1038/modpathol.2008.144
   Raza SM, 2017, NEUROSURGERY, V81, P520, DOI 10.1093/neuros/nyx042
   Rosenberg AE, 1999, AM J SURG PATHOL, V23, P1370, DOI 10.1097/00000478-199911000-00007
   Sadashiva N, 2016, WORLD NEUROSURG, V95, DOI 10.1016/j.wneu.2016.08.049
   Shakked RJ, 2012, ARCH PATHOL LAB MED, V136, P61, DOI 10.5858/arpa.2010-0362-OA
   Tzortzidis F, 2006, NEUROSURGERY, V58, P1090, DOI 10.1227/01.NEU.0000215892.65663.54
   Wanebo JE, 2006, NEUROSURGERY, V58, P249, DOI 10.1227/01.NEU.0000194834.74873.FB
   Wang K, 2018, WORLD NEUROSURG, V116, pE691, DOI 10.1016/j.wneu.2018.05.069
   Weber DC, 2016, NEURO-ONCOLOGY, V18, P236, DOI 10.1093/neuonc/nov154
   Yan J, 2015, INT J CLIN EXP MED, V8, P4697
NR 23
TC 0
Z9 0
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1078
EP E1082
DI 10.1016/j.wneu.2018.10.230
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100132
PM 30415056
DA 2020-05-12
ER

PT J
AU Majmundar, N
   Sarris, C
   Shastri, D
   Doran, J
   Gandhi, C
   Assina, R
AF Majmundar, Neil
   Sarris, Christina
   Shastri, Darshan
   Doran, Joseph
   Gandhi, Chirag
   Assina, Rachid
TI Hemorrhagic Complications of External Ventriculostomy in the Aspirin and
   P2Y12 Response Assay Era
SO WORLD NEUROSURGERY
LA English
DT Article
DE Catheter-induced hemorrhage (CIH); External ventricular drain (EVD);
   External ventriculostomy; Platelet inhibition assay; VerifyNow assay
ID PLATELET TRANSFUSION; ANTIPLATELET AGENTS; INTRACEREBRAL HEMORRHAGE;
   ANTICOAGULANT-THERAPY; DRAIN PLACEMENT; BLOOD-PRESSURE; RATES;
   INHIBITION; REACTIVITY; INSERTION
AB OBJECTIVE: Hemorrhagic complications reported from external ventricular drain (EVD) placement range from 10% to 44%. There remains limited literature investigating the incidence, risk factors, and mechanisms to prevent its occurrence, especially in the setting of antiplatelet agent use. We investigated EVD-related hemorrhagic complications after the implementation of VerifyNow platelet inhibition assays at our institution.
   METHODS: Medical records from 445 patients requiring EVD placement during a 2-year period during which our institution used the assays were reviewed. In total 345 patients were included, and 208 of them underwent assay testing. Indications for EVD included complications of cerebrovascular disease (n = 215), traumatic brain injury (n = 74), primary hydrocephalus (n = 23), and tumor (n = 33). Hemorrhage was defined as any new area of hyperdensity adjacent to or immediately along the catheter trajectory on computed tomography.
   RESULTS: There was no significant decrease in catheter-induced hemorrhage (CIH) between patients who underwent the VerifyNow assay and those who did not. Platelet transfusion did not significantly decrease the risk of CIH. CIH occurred in 17.7% of patients, significantly decreased when compared with our previously published incidence of 33% before platelet inhibition assay use (P < 0.05). Patients with cerebrovascular disease complications exhibited a significant decrease in CIH, 20% versus 39%, before assay use (P < 0.01).
   CONCLUSIONS: The incidence of hemorrhage is lower in our new cohort when compared with that of our previously published cohort. Despite the overall decreased rate of hemorrhage, there was no significant difference in hemorrhage rates between patients who did or did not undergo the assay. Platelet transfusion did not decrease the incidence of hemorrhage in patients with inhibited platelet function.
C1 [Majmundar, Neil; Doran, Joseph; Assina, Rachid] Rutgers New Jersey Med Sch, Dept Neurol Surg, Newark, NJ 07103 USA.
   [Sarris, Christina] St Josephs Hosp, Barrow Neurol Inst, Dept Neurosurg, Phoenix, AZ USA.
   [Shastri, Darshan] Univ N Carolina, Dept Neurosurg, Chapel Hill, NC 27515 USA.
   [Gandhi, Chirag] NY Med Coll, Westchester Med Ctr, Dept Neurosurg, Valhalla, NY USA.
RP Assina, R (reprint author), Rutgers New Jersey Med Sch, Dept Neurol Surg, Newark, NJ 07103 USA.
EM assinara@njms.rutgers.edu
OI Doran, Joseph/0000-0001-6341-6714; Majmundar, Neil/0000-0001-5910-6094;
   Shastri, Darshan/0000-0001-7062-2786
CR Batchelor JS, 2012, BRIT J NEUROSURG, V26, P525, DOI 10.3109/02688697.2011.650736
   Bauer DF, 2011, J TRAUMA, V70, P1112, DOI 10.1097/TA.0b013e3181e7c2ae
   Binz DD, 2009, NEUROCRIT CARE, V10, P253, DOI 10.1007/s12028-009-9193-0
   Butcher K, 2003, J CLIN NEUROSCI, V10, P158, DOI 10.1016/S0967-5868(02)00324-7
   Choi PA, 2017, NEUROSURGERY, V80, P98, DOI 10.1227/NEU.0000000000001401
   Dey M, 2012, CURR NEUROL NEUROSCI, V12, P24, DOI 10.1007/s11910-011-0231-x
   Gardner PA, 2009, J NEUROSURG, V110, P1021, DOI 10.3171/2008.9.JNS17661
   GRATZ I, 1992, J THORAC CARDIOV SUR, V104, P1417
   Husted SE, 2006, EUR HEART J, V27, P913, DOI 10.1093/eurheartj/ehi714
   Ko JK, 2014, NEUROL MED-CHIR, V54, P545, DOI 10.2176/nmc.oa.2013-0178
   Kung DK, 2011, J NEUROSURG, V114, P1021, DOI 10.3171/2010.9.JNS10445
   Maniker AH, 2006, NEUROSURGERY, V59, P419, DOI 10.1227/01.NEU.0000222817.99752.E6
   Maruishi M, 2001, NEUROL MED-CHIR, V41, P300, DOI 10.2176/nmc.41.300
   McMillian WD, 2009, J TRAUMA, V66, P942, DOI 10.1097/TA.0b013e3181978e7b
   Moon HH, 2009, J KOREAN NEUROSURG S, V46, P215, DOI 10.3340/jkns.2009.46.3.215
   Muller A, 2018, NEUROCRIT CARE, V29, P23, DOI 10.1007/s12028-017-0492-6
   Naidech AM, 2012, NEUROCRIT CARE, V16, P82, DOI 10.1007/s12028-011-9619-3
   Ohm C, 2005, J TRAUMA, V58, P518, DOI 10.1097/01.TA.0000151671.35280.8B
   Pakala R, 2011, CARDIOVASC REVASCULA, V12, P312, DOI 10.1016/j.carrev.2010.09.005
   Park YG, 2011, J KOREAN NEUROSURG S, V50, P317, DOI 10.3340/jkns.2011.50.4.317
   Parry PV, 2017, NEUROSURGERY, V80, P92, DOI 10.1227/NEU.0000000000001406
   Patal R, 2012, HAREFUAH, V151, P61
   Patal R, 2012, HAREFUAH, V151, P62
   Powner DJ, 2005, NEUROSURGERY, V57, P823, DOI 10.1227/01.NEU.0000179915.74429.b2
   Ranucci M, 2007, J CARDIOTHOR VASC AN, V21, P851, DOI 10.1053/j.jvca.2007.05.009
   Rasool AHG, 2004, J HUM HYPERTENS, V18, P187, DOI 10.1038/sj.jhh.1001647
   Rehman T, 2012, CLIN NEUROL NEUROSUR, V114, P651, DOI 10.1016/j.clineuro.2011.12.040
   Rowe AS, 2018, BMC NEUROL, V18, DOI 10.1186/s12883-018-1030-7
   Sussman ES, 2014, J NEUROSURG, V120, P931, DOI 10.3171/2013.12.JNS131685
   Taylor G, 2013, J TRAUMA ACUTE CARE, V74, P1367, DOI 10.1097/TA.0b013e31828cca61
   Wiesmann M, 2001, J CLIN NEUROSCI, V8, P126, DOI 10.1054/jocn.2000.0749
   Yuen J, 2018, ANN ROY COLL SURG, V100, P221, DOI 10.1308/rcsann.2017.0221
   Zhu X, 2017, J NEUROSURG SCI, V61, P53
NR 33
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E961
EP E968
DI 10.1016/j.wneu.2018.10.181
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100116
PM 30439521
DA 2020-05-12
ER

PT J
AU Malik, AT
   Kim, J
   Yu, E
   Khan, SN
AF Malik, Azeem Tariq
   Kim, Jeffery
   Yu, Elizabeth
   Khan, Safdar N.
TI Discharge to Inpatient Care Facility After Anterior Lumbar Interbody
   Fusion: Incidence, Predictors, and Postdischarge Outcomes
SO WORLD NEUROSURGERY
LA English
DT Article
DE ALIF; Anterior lumbar interbody fusion; Discharge destination; Inpatient
   facility; NSQIP; Postdischarge
ID BUNDLED PAYMENTS; RISK-FACTORS; COMPLICATIONS; ARTHROPLASTY; HIP
AB BACKGROUND: Despite a significant number of patients being discharged to inpatient care facilities after anterior lumbar interbody fusion (ALIF), the current literature remains limited regarding the predictors associated with a nonhome discharge and the impact of continued inpatient care in a facility on postdischarge outcomes.
   METHODS: The 2013-2016 American College of Surgeons National Surgical Quality Improvement Program was queried using Current Procedural Terminology (CPT) codes for ALIF (CPT-22558) and additional level fusions (CPT-22585). Discharge to inpatient care facilities included discharge to skilled care facilities and/or inpatient rehabilitation units.
   RESULTS: Independent predictors of an inpatient care facility discharge were age older than 45 years (P < 0.001), female sex (P < 0.001), more than 10% body weight loss in the last 6 months prior to surgery (P = 0.012), American Society of Anesthesiologists grade greater than II (P = 0.005), undergoing a 2-level (P < 0.001) or more than 2-level fusion (P = 0.017), a length of stay greater than 3 days (P < 0.001), and the occurrence of any predischarge complication (P < 0.001). After adjustment for differences in clinical and baseline characteristics between the 2 groups, discharge to an inpatient care facility after ALIF was independently associated with higher odds of any postdischarge complication (P = 0.010), postdischarge wound complication (P = 0.005), and postdischarge septic complications (P = 0.011). No significant impact was seen on 30-day readmissions (P = 0.943), 30-day reoperations (P = 0.228), and 30-day mortality (P = 0.913).
   CONCLUSIONS: With an increasing focus toward minimizing costs associated with postacute care, providers should understand the need of appropriate preoperative risk stratification and construction of care pathways aimed at a home discharge to reduce the occurrence and/or risk of experiencing postdischarge complications.
C1 [Malik, Azeem Tariq; Kim, Jeffery; Yu, Elizabeth; Khan, Safdar N.] Ohio State Univ, Wexner Med Ctr, Columbus, OH 43210 USA.
RP Khan, SN (reprint author), Ohio State Univ, Wexner Med Ctr, Columbus, OH 43210 USA.
EM Safdar.Khan@osumc.edu
CR Abt NB, 2016, CLIN NEUROL NEUROSUR, V143, P126, DOI 10.1016/j.clineuro.2016.02.024
   Burns BH, 1933, LANCET, V1, P1233
   Choy W, 2017, GLOB SPINE J, V7, P141, DOI 10.1177/2192568217694009
   Deleuran T, 2015, ACTA ORTHOP, V86, P108, DOI 10.3109/17453674.2014.961397
   Fu MC, 2017, J ARTHROPLASTY, V32, pS144, DOI 10.1016/j.arth.2017.03.044
   Garcia RM, 2016, J CLIN NEUROSCI, V32, P104, DOI 10.1016/j.jocn.2016.04.003
   Halawi MJ, 2015, J ARTHROPLASTY, V30, P539, DOI 10.1016/j.arth.2014.10.031
   Hardin L, 2017, J NURS ADMIN, V47, P313, DOI 10.1097/NNA.0000000000000492
   Jones SL, 2016, JT COMM J QUAL PATIE, V42, P122, DOI 10.1016/S1553-7250(16)42015-5
   Kahn EN, 2018, J NEUROSURG-SPINE, V29, P214, DOI 10.3171/2017.12.SPINE17674
   Kimball CC, 2018, J ARTHROPLASTY, V33, P3130, DOI 10.1016/j.arth.2018.06.020
   Malik AT, 2018, CLIN SPINE SURG, V31, pE453, DOI 10.1097/BSD.0000000000000700
   Malik Azeem Tariq, 2018, J Spine Surg, V4, P264, DOI 10.21037/jss.2018.05.25
   McLawhorn AS, 2017, J ARTHROPLASTY, V32, pS113, DOI 10.1016/j.arth.2017.01.039
   Norton RP, 2015, SPINE, V40, P1219, DOI 10.1097/BRS.0000000000000987
   Pfuntner A, 2006, HEALTHCARE COST UTIL
   Phan K, 2017, SPINE J, V17, P538, DOI 10.1016/j.spinee.2016.10.023
   Schoenfeld AJ, 2014, SPINE J, V14, P2793, DOI 10.1016/j.spinee.2014.07.002
   Shih T, 2015, CIRCULATION, V131, P2151, DOI 10.1161/CIRCULATIONAHA.114.010393
   Yoshihara H, 2015, SPINE J, V15, P265, DOI 10.1016/j.spinee.2014.09.026
NR 20
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E584
EP E590
DI 10.1016/j.wneu.2018.10.108
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100071
PM 31108074
DA 2020-05-12
ER

PT J
AU Ortega, AJM
   Venegas-Moreno, E
   Dios, E
   Ruiz, PJR
   Rivas, FJM
   Valdepenas, EC
   Kaen, AM
   Cano, DA
   Soto-Moreno, A
AF Martinez Ortega, Antonio Jesus
   Venegas-Moreno, Eva
   Dios, Elena
   Remon Ruiz, Pablo Jesus
   Marquez Rivas, Francisco Javier
   Cardenas Valdepenas, Eugenio
   Matias Kaen, Ariel
   Cano, David A.
   Soto-Moreno, Alfonso
TI Surgical Outcomes and Comorbidities in Cushing Disease: 30 Years of
   Experience in a Referral Center
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cushing disease; Pituitary; Radiotherapy; Transsphenoidal surgery
ID TRANSSPHENOIDAL SURGERY; SINGLE-CENTER; DIAGNOSIS
AB OBJECTIVE: Cushing disease (CD) is a rare, poorly understood entity. Our aim was to add our clinical experience of >30 years in a multidisciplinary specialized unit to the global knowledge of CD.
   METHODS: This descriptive retrospective study included all patients admitted to the Endocrinology and Nutrition Department of the Virgen del Rocio University Hospital, Seville, Spain, from January 1980 to May 2016. All patients had a definitive diagnosis of CD.
   RESULTS: Total sample included 119 patients; 100 (84%) were female. Median age at diagnosis was 37.97 years (interquartile range [IQR]: 25.89-45.07 years). Median follow-up was 88 months (IQR: 45.50-157.00 months). Most tumors were microadenomas (62/95) (5.1 mm [IQR: 4.0-7.0 mm]) without sinus invasion. Surgical procedures were conventional transsphenoidal surgery (CTSS) (101/108; cured 70 after first attempt) and expanded endoscopic transsphenoidal surgery (EETSS) (7/108; cured 5 after first attempt); 11 patients did not receive surgical treatment. Fourteen patients received radiotherapy after a first surgery and 5 patients after a second surgical removal attempt. In 13 patients (12.04%), CD relapse was demonstrated after initial CTSS (median disease-free period 65 months [IQR: 45-120 months]). Ten patients developed panhypopituitarism owing to the surgical procedure (CTSS); 8 patients developed panhypopituitarism after adjuvant radiotherapy.
   CONCLUSIONS: We observed slightly inferior cure rate after first surgery compared with moderately better relapse rates and time to relapse. Radiotherapy after surgery failure seemed to be more effective than CTSS; however, EETSS may be a valid alternative. Postoperative panhypopituitarism rate after first surgery was lower than expected; after radiotherapy, our results were comparable to other series.
C1 [Martinez Ortega, Antonio Jesus; Venegas-Moreno, Eva; Dios, Elena; Remon Ruiz, Pablo Jesus; Cano, David A.; Soto-Moreno, Alfonso] Virgen Rocio Univ Hosp, Endocrinol & Clin Nutr Dept, Inst Biomed Seville IBIS, Seville, Spain.
   [Marquez Rivas, Francisco Javier; Cardenas Valdepenas, Eugenio; Matias Kaen, Ariel] Univ Seville, Virgen RocUo Univ Hosp, Neurosurg Dept, CSIC Super Council Sci Invest, Seville, Spain.
RP Soto-Moreno, A (reprint author), Virgen Rocio Univ Hosp, Endocrinol & Clin Nutr Dept, Inst Biomed Seville IBIS, Seville, Spain.
EM alfonsom.soto.sspa@juntadeandalucia.es
RI kaen, ariel/G-3786-2015; Cano, David A./B-8013-2015; Martinez Ortega,
   Antonio Jesus/F-9450-2014; Marquez-Rivas, Javier/C-8940-2015
OI Cano, David A./0000-0001-6264-3288; Remon-Ruiz,
   Pablo/0000-0002-4551-8159; Martinez Ortega, Antonio
   Jesus/0000-0002-2878-4017; Marquez-Rivas, Javier/0000-0002-5136-4723
FU ISCIII-Subdireccion General de Evaluacion y Fomento de la Investacion;
   Fondos FEDER, SpainEuropean Union (EU) [P113/02043, P116/00175]; Junta
   de Andalucia, SpainJunta de Andalucia [A-0023-2015, A-0003-2016,
   C-0015-2014]
FX This research received funding from the ISCIII-Subdireccion General de
   Evaluacion y Fomento de la Investacion co-funded with Fondos FEDER,
   Spain (grant numbers P113/02043 to A. Soto-Moreno and P116/00175 to A.
   Soto-Moreno and a A. Cano) and Junta de Andalucia, Spain (grant numbers
   A-0023-2015 and A-0003-2016 to A. Soto-Moreno and C-0015-2014 to a A.
   Cano).
CR Alexandraki KI, 2013, EUR J ENDOCRINOL, V168, P639, DOI 10.1530/EJE-12-0921
   American Diabetes Association, 2018, Diabetes Care, V41, pS13, DOI 10.2337/dc18-S002
   Castinetti F, 2014, J CLIN ENDOCR METAB, V99, P1623, DOI 10.1210/jc.2013-3628
   Castinetti F, 2012, ORPHANET J RARE DIS, V7, DOI 10.1186/1750-1172-7-41
   Chandler WF, 2016, NEUROSURGERY, V78, P216, DOI 10.1227/NEU.0000000000001011
   Dekkers OM, 2013, J CLIN ENDOCR METAB, V98, P2277, DOI 10.1210/jc.2012-3582
   Elamin MB, 2008, J CLIN ENDOCR METAB, V93, P1553, DOI 10.1210/jc.2008-0139
   Findling JW, 2005, ENDOCRIN METAB CLIN, V34, P385, DOI 10.1016/j.ecl.2005.02.001
   Guignat L, 2010, EUR J ENDOCRINOL, V163, P9, DOI 10.1530/EJE-09-0627
   Hassan-Smith ZK, 2012, J CLIN ENDOCR METAB, V97, P1194, DOI 10.1210/jc.2011-2957
   Hofmann BM, 2008, J NEUROSURG, V108, P9, DOI 10.3171/JNS/2008/108/01/0009
   KNOSP E, 1993, NEUROSURGERY, V33, P610, DOI 10.1227/00006123-199310000-00008
   Leal-Cerro Alfonso, 2009, Endocrinol Nutr, V56, P187, DOI 10.1016/S1575-0922(09)70983-0
   Newell-Price J, 2009, BEST PRACT RES CL EN, V23, pS5, DOI 10.1016/S1521-690X(09)70003-X
   Nieman LK, 2008, J CLIN ENDOCR METAB, V93, P1526, DOI 10.1210/jc.2008-0125
   Owald A, 2014, EUR J ENDOCRINOL, V171, P209, DOI 10.1530/EJE-14-0214
   Rollin G, 2007, ARQ BRAS ENDOCRINOL, V51, P1355, DOI 10.1590/S0004-27302007000800022
   Rutkowski MJ, 2015, NEUROSURG FOCUS, V38, DOI 10.3171/2014.11.FOCUS14703
   Swearingen B, 2004, J CLIN ENDOCR METAB, V89, P3752, DOI 10.1210/jc.2003-032249
   Valassi E, 2011, EUR J ENDOCRINOL, V165, P383, DOI 10.1530/EJE-11-0272
NR 20
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E436
EP E442
DI 10.1016/j.wneu.2018.10.067
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100051
PM 31108069
DA 2020-05-12
ER

PT J
AU Matsunaga, S
   Shuto, T
   Kobayashi, N
AF Matsunaga, Shigeo
   Shuto, Takashi
   Kobayashi, Natsuki
TI Gamma Knife Radiosurgery for Metastatic Brain Tumors from Cancer of
   Unknown Primary
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain metastases; Gamma knife; Stereotactic radiosurgery; Unknown
   primary
ID STEREOTACTIC RADIOSURGERY
AB OBJECTIVE: We retrospectively analyzed treatment efficacy and identified prognostic factors impacting tumor control and survival in patients with brain metastases from cancer of unknown primary (CUP) treated with gamma knife radiosurgery (GKRS).
   METHODS: We retrospectively reviewed the medical records of 87 patients with 520 tumors who underwent GKRS for brain metastases from CUP.
   RESULTS: The median overall survival time after initial GKRS was 6 months. The 6- and 12-month overall survival rates were 79.3% and 14.9%, respectively. Older age (P = 0.002), lower Karnofsky Performance Status Index score (P = 0.026), extracranial metastases (P = 0.013), and multiple brain metastases (P = 0.007) were significantly correlated with shorter survival periods. The 6- and 12-month neurologic death rates were 25.3% and 32.2%, respectively. The 6- and 12-month neurologic deterioration rates were 24.1% and 27.6%, respectively. The 6- and 12-month distant brain control failure rates were 21.8% and 24.1%, respectively. The median tumor volume was 1.7 cm(3). The median marginal prescription dose was 18 Gy. The 6- and 12-month tumor recurrence rates were 5.1% and 15.7%, respectively. Larger tumor volume (P < 0.0001) and lower prescription dose (P = 0.001) were significantly correlated with local tumor control failure. Seven patients had symptomatic radiation injury. The 6- and 12-month GKRS-related complication rates were both 6.9%.
   CONCLUSIONS: Our findings suggest that GKRS is a relatively effective and safe treatment for control of tumor progression in patients with brain metastases from CUP. Overall and neurologic survivals were short, but we recommend GKRS treatment to prevent early neurologic dysfunction and death in patients with CUP.
C1 [Matsunaga, Shigeo] Yokohama Rosai Hosp, Dept Neurosurg, Yokohama, Kanagawa, Japan.
   Yokohama Rosai Hosp, Stereotact Radiotherapy Ctr, Yokohama, Kanagawa, Japan.
RP Matsunaga, S (reprint author), Yokohama Rosai Hosp, Dept Neurosurg, Yokohama, Kanagawa, Japan.
EM shigeo-m@yokohamah.johas.go.jp
CR Agazzi S, 2004, ACTA NEUROCHIR, V146, P153, DOI 10.1007/s00701-003-0188-x
   Bartelt S, 2003, J NEURO-ONCOL, V64, P249, DOI 10.1023/A:1025621819250
   D'Ambrosio Anthony L, 2007, Neurosurg Focus, V22, pE7
   Dziggel L, 2018, ANTICANCER RES, V38, P565, DOI 10.21873/anticanres.12260
   Han Hyun Jin, 2016, Brain Tumor Res Treat, V4, P107
   Kyritsis AP, 2012, CANCER CHEMOTH PHARM, V69, P1, DOI 10.1007/s00280-011-1775-9
   Maesawa S, 2000, CANCER, V89, P1095, DOI 10.1002/1097-0142(20000901)89:5<1095::AID-CNCR19>3.0.CO;2-H
   Matsunaga S, 2013, INT J RADIAT ONCOL, V85, P47, DOI 10.1016/j.ijrobp.2012.03.008
   Minamimoto R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132515
   Niranjan A, 2010, INT J RADIAT ONCOL, V77, P1457, DOI 10.1016/j.ijrobp.2009.07.012
   Rades D, 2007, STRAHLENTHER ONKOL, V183, P631, DOI 10.1007/s00066-007-1763-5
   Ruda R, 2001, J NEUROL, V248, P394, DOI 10.1007/s004150170180
   Yamamoto M, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2014.08.008
   Yamamoto M, 2014, LANCET ONCOL, V15, P387, DOI 10.1016/S1470-2045(14)70061-0
NR 14
TC 1
Z9 1
U1 16
U2 40
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1465
EP E1471
DI 10.1016/j.wneu.2018.11.086
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100180
PM 30468925
DA 2020-05-12
ER

PT J
AU Mazzoni, A
   Cazzador, D
   d'Avella, D
   Zanoletti, E
AF Mazzoni, Antonio
   Cazzador, Diego
   d'Avella, Domenico
   Zanoletti, Elisabetta
TI Large Intradural Tympanojugular Paragangliomas. A Contribution on
   Surgery and Management
SO WORLD NEUROSURGERY
LA English
DT Article
DE Fisch classification; Intradural growth; Jugular foramen; Skull base
   tumors; Treatment strategy; Tympanojugular paraganglioma
ID GLOMUS-JUGULARE; SURGICAL-MANAGEMENT; NECK PARAGANGLIOMAS; SKULL BASE;
   TUMORS; RADIOTHERAPY; HEAD; OUTCOMES
AB OBJECTIVE: Large intradural growth of tympanojugular paragangliomas (TJ-PGs) into the cerebellopontine angle is an infrequent condition that can determine an extensive involvement of vessels and brainstem, representing a surgical challenge. The current classifications lack accuracy for defining large intradural TJ-PGs and assessing their operability. This study aims to retrospectively reappraise the management of a large intradural TJ-PGs surgical series, discussing operability criteria, treatment strategies, and resection techniques.
   METHODS: Over a series of 63 class D TJ-PGs operated on between 1973 and 2008, patients with large intradural tumors were retrospectively reviewed. Surgical techniques and outcomes with long-term follow-up were analyzed.
   RESULTS: Seven patients presented with large intradural tumors, ranging from 4 cm to 5.5 cm in diameter. These cases were treated either via a petro-occipital transsigmoid approach in a single-stage resection (4 patients) or via a petro-occipital approach as a second-stage surgery after a previous infratemporal fossa approach on the extradural tumor (3 patients). Complete tumor resection was obtained in 5 cases through wide removal of the petro-occipital skull base and exposure of the dural root of the tumor, which carries its main blood supply and allows preemptive hemostasis. No new postoperative cranial nerve losses were observed. The surgical procedure was aborted in 2 cases because of cerebellar edema and carotid artery tear, respectively.
   CONCLUSIONS: Large intradural TJ-PGs can be effectively surgically managed with an appropriate technique combined with relevant nonsurgical strategies. Thus, operability criteria for these lesions can be extended. To share objective experience on large intradural TJ-PGs, a redefinition of Di3 tumors is recalled.
C1 [Mazzoni, Antonio; Cazzador, Diego; Zanoletti, Elisabetta] Univ Padua, Operat Unit Otorhinolaryngol, Dept Neurosci, Padua, Italy.
   [d'Avella, Domenico] Univ Padua, Acad Neurosurg, Dept Neurosci, Padua, Italy.
RP Cazzador, D (reprint author), Univ Padua, Operat Unit Otorhinolaryngol, Dept Neurosci, Padua, Italy.
EM gkmcaz@hotmail.it
CR Boedeker Carsten Christof, 2011, GMS Curr Top Otorhinolaryngol Head Neck Surg, V10, pDoc03, DOI 10.3205/cto000076
   Briner HR, 1999, LARYNGOSCOPE, V109, P577, DOI 10.1097/00005537-199904000-00011
   Carlson ML, 2015, OTOLARYNG HEAD NECK, V152, P98, DOI 10.1177/0194599814555839
   Carlson ML, 2012, J NEUROL SURG PART B, V73, P197, DOI 10.1055/s-0032-1312707
   Cosetti M, 2008, LARYNGOSCOPE, V118, P270, DOI 10.1097/MLG.0b013e318158194b
   FISCH U, 1982, ANN OTO RHINOL LARYN, V91, P474, DOI 10.1177/000348948209100502
   Gilbo P, 2014, CANCER-AM CANCER SOC, V120, P3738, DOI 10.1002/cncr.28923
   HAWTHORNE MR, 1988, LARYNGOSCOPE, V98, P325
   Hinerman RW, 2008, HEAD NECK-J SCI SPEC, V30, P1431, DOI 10.1002/hed.20885
   Huy PTB, 2009, SKULL BASE-INTERD AP, V19, P83, DOI 10.1055/s-0028-1103125
   Jackson CG, 2001, OTOLARYNG CLIN N AM, V34, P941, DOI 10.1016/S0030-6665(05)70356-X
   JACKSON CG, 1993, LARYNGOSCOPE, V103, P17
   Krych AJ, 2006, INT J RADIAT ONCOL, V65, P1063, DOI 10.1016/j.ijrobp.2006.02.020
   Li D, 2016, J NEUROSURG, V125, P1143, DOI 10.3171/2015.10.JNS151875
   MAZZONI A, 1995, SKULL BASE SURG, V5, P157, DOI 10.1055/s-2008-1058930
   Mazzoni A, 2016, EUR ARCH OTO-RHINO-L, V273, P635, DOI 10.1007/s00405-015-3605-x
   Mazzoni A, 2009, SKULL BASE-INTERD AP, V19, P48, DOI 10.1055/s-0028-1103127
   Moe KS, 1999, SKULL BASE SURG, V9, P185, DOI 10.1055/s-2008-1058145
   Prasad SC, 2014, OTOL NEUROTOL, V35, P922, DOI 10.1097/MAO.0000000000000386
   Puranik AD, 2015, EUR J NUCL MED MOL I, V42, P1223, DOI 10.1007/s00259-015-3029-2
   Shin SH, 2012, AUDIOL NEURO-OTOL, V17, P92, DOI 10.1159/000330724
   Tomasello F, 2015, WORLD NEUROSURG, V83, P756, DOI 10.1016/j.wneu.2014.09.013
   VANDERMEY AGL, 1992, ANN OTO RHINOL LARYN, V101, P635, DOI 10.1177/000348949210100802
   Wanna GB, 2014, OTOLARYNG HEAD NECK, V151, P991, DOI 10.1177/0194599814552060
   Zanoletti E, 2014, ACTA OTORHINOLARYNGO, V34, P184
NR 25
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1482
EP E1490
DI 10.1016/j.wneu.2018.11.089
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100182
PM 30468922
DA 2020-05-12
ER

PT J
AU Mehbodniya, AH
   Moghavvemi, M
   Narayanan, V
   Waran, V
AF Mehbodniya, Amir H.
   Moghavvemi, Mahmoud
   Narayanan, Vairavan
   Waran, Vicknes
TI Frequency and Causes of Line of Sight Issues During Neurosurgical
   Procedures Using Optical Image-Guided Systems
SO WORLD NEUROSURGERY
LA English
DT Article
DE Line of sight issue; Optical image-guided surgery; Surgical navigation
ID NEURONAVIGATION; NEUROENDOSCOPY; NAVIGATION
AB BACKGROUND: Navigation (image guidance) is an essential tool in modern neurosurgery, and most surgeons use an optical tracking system. Although the technology is accurate and reliable, one often is confronted by line of sight issues that interrupt the flow of an operation. There has been feedback on the matter, but the actual problem has not been accurately quantified, therefore making this the primary aim of this study. It is particularly important given that robotic technology is gradually making its way into neurosurgery and most of these devices depend on optical navigation when procedures are being conducted.
   METHODS: In this study, the frequency and causes of line of sight issues is assessed using recordings of Navigation probe locations and its synchronised video recordings.
   RESULTS: The mentioned experiment conducted for a series of 15 neurosurgical operations. This issue occured in all these surgeries except one. Maximum duration of issue presisting reached up to 56% of the navigation usage time.
   CONCLUSIONS: The arrangment of staff and equipment is a key factor in avoiding this issue.
C1 [Mehbodniya, Amir H.; Moghavvemi, Mahmoud] Univ Malaya, Dept Elect Engn, Fac Engn, Ctr Res Appl Elect, Kuala Lumpur, Malaysia.
   [Narayanan, Vairavan; Waran, Vicknes] Univ Malaya, Fac Med, Dept Surg, Kuala Lumpur, Malaysia.
   [Moghavvemi, Mahmoud] Univ Sci & Culture, Tehran, Iran.
RP Waran, V (reprint author), Univ Malaya, Fac Med, Dept Surg, Kuala Lumpur, Malaysia.
EM cmvwaran@gmail.com
RI Moghavvemi, Mahmoud/B-8912-2010; NARAYANAN, VAIRAVAN/B-9191-2010
OI Moghavvemi, Mahmoud/0000-0001-6447-4203; NARAYANAN,
   VAIRAVAN/0000-0002-1118-5042
FU University of Malaya, Malaysia High Impact Research [HIR
   -UM.C/625/1/HIR- MOHE/CHAN/12]; Ministry of Science and Innovation
   Malaysia [03-01-03-SF1219]
FX This work was supported by the University of Malaya, Malaysia High
   Impact Research (HIR -UM.C/625/1/HIR- MOHE/CHAN/12) and a ScienceFund
   grant from the Ministry of Science and Innovation Malaysia
   (03-01-03-SF1219).
CR Choi KY, 2013, J KOREAN NEUROSURG S, V53, P161, DOI 10.3340/jkns.2013.53.3.161
   Esposito F, 2013, WORLD NEUROSURG, V80, P709, DOI 10.1016/j.wneu.2013.05.011
   Grunert P, 2003, NEUROSURG REV, V26, P73, DOI 10.1007/s10143-003-0262-0
   Guo ZY, 2018, WORLD NEUROSURG, V116, P77, DOI 10.1016/j.wneu.2018.04.155
   Keereweer S, 2011, MOL IMAGING BIOL, V13, P199, DOI 10.1007/s11307-010-0373-2
   McMillen JL, 2010, CHILD NERV SYST, V26, P871, DOI 10.1007/s00381-009-1074-5
   Mezger U, 2013, LANGENBECK ARCH SURG, V398, P501, DOI 10.1007/s00423-013-1059-4
   Miner RC, 2017, J MED IMAGING RADIAT, V48, P328, DOI 10.1016/j.jmir.2017.06.005
   Orringer DA, 2012, EXPERT REV MED DEVIC, V9, P491, DOI [10.1586/ERD.12.42, 10.1586/erd.12.42]
   Rohde V, 2012, NEUROSURG REV, V35, P351, DOI 10.1007/s10143-011-0369-7
   Sangra M, 2009, J NEUROSURG-PEDIATR, V3, P325, DOI 10.3171/2008.12.PEDS0888
   Tokuda J, 2009, INT J MED ROBOT COMP, V5, P423, DOI 10.1002/rcs.274
NR 12
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E449
EP E454
DI 10.1016/j.wneu.2018.10.069
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100053
PM 30347306
DA 2020-05-12
ER

PT J
AU Meleis, A
   Jhawar, SR
   Weiner, JP
   Majmundar, N
   Mahtabfar, A
   Lin, Y
   Jabbour, S
   Danish, S
   Goyal, S
AF Meleis, Ahmed
   Jhawar, Sachin R.
   Weiner, Joseph P.
   Majmundar, Neil
   Mahtabfar, Aria
   Lin, Yong
   Jabbour, Salma
   Danish, Shabbar
   Goyal, Sharad
TI Stereotactic Body Radiation Therapy in Nonsurgical Patients with
   Metastatic Spinal Disease and Epidural Compression: A Retrospective
   Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Epidural disease; Malignant spinal cord compression (MSCC); Spinal
   metastases; Stereotactic ablative body radiotherapy (SABR); Stereotactic
   body radiation therapy (SBRT)
ID CORD; RADIOTHERAPY; MANAGEMENT; RADIOSURGERY
AB BACKGROUND: In the setting of spinal metastases with epidural cord compression, radiosurgery is often only considered when there is sufficient separation between the epidural disease and the spinal cord. However, in patients who are nonsurgical candidates or those who prefer nonoperative management, there may be a benefit from stereotactic body radiation therapy, even when the epidural target is closer than the traditionally referenced 3 mm distance from the spinal cord. The purpose of this retrospective study is to evaluate our institution's experience in treating 20 such patients.
   METHODS: We reviewed records of all patients treated with stereotactic body radiation therapy for spinal metastases at our institution from January 2010 to January 2016, with follow-up through December 2016. The primary end point was local progression of disease. Local progression was defined as clear radiographic disease growth on follow- up imaging or worsening clinical symptoms in the absence of evidence for radiation myelopathy.
   RESULTS: Local control was obtained in 55% of patients meeting these criteria without a single case of radiation myelitis. Most patients with disease progression were able to undergo additional local treatment.
   CONCLUSIONS: Although local control was less than expected when compared with spine radiosurgery with adequate separation between the target and spinal cord, this treatment appears to be a viable option in the nonsurgical candidate.
C1 [Meleis, Ahmed; Majmundar, Neil] Rutgers New Jersey Med Sch, Dept Neurol Surg, Newark, NJ 07103 USA.
   [Jhawar, Sachin R.; Weiner, Joseph P.; Jabbour, Salma] Rutgers Canc Inst New Jersey, Dept Radiat Oncol, New Brunswick, NJ USA.
   [Mahtabfar, Aria; Danish, Shabbar] Rutgers Robert Wood Johnson Med Sch, Dept Neurosurg, New Brunswick, NJ USA.
   [Lin, Yong] Rutgers Sch Publ Hlth, Dept Biostat, Piscataway, NJ USA.
   [Goyal, Sharad] George Washington Univ, Ctr Canc, Dept Radiat Oncol, Washington, DC USA.
RP Meleis, A (reprint author), Rutgers New Jersey Med Sch, Dept Neurol Surg, Newark, NJ 07103 USA.
EM meleisah@njms.rutgers.edu
RI Majmundar, Neil/AAH-9695-2020; Jhawar, Sachin R/M-1587-2017
OI Majmundar, Neil/0000-0001-5910-6094; Jhawar, Sachin
   R/0000-0001-8604-4757; Goyal, Sharad/0000-0002-6475-7411; Mahtabfar,
   Aria/0000-0002-4026-7821
CR Al-Omair A, 2013, NEURO-ONCOLOGY, V15, P1413, DOI 10.1093/neuonc/not101
   Bentzen SM, 2012, RADIOTHER ONCOL, V105, P266, DOI 10.1016/j.radonc.2012.10.006
   Bilsky MH, 2010, J NEUROSURG-SPINE, V13, P324, DOI 10.3171/2010.3.SPINE09459
   Chan MW, 2016, J NEUROSURG-SPINE, V24, P652, DOI 10.3171/2015.6.SPINE15294
   Cole JS, 2008, LANCET NEUROL, V7, P459, DOI 10.1016/S1474-4422(08)70089-9
   Cox BW, 2012, INT J RADIAT ONCOL, V83, pE597, DOI 10.1016/j.ijrobp.2012.03.009
   DALE RG, 1985, BRIT J RADIOL, V58, P515, DOI 10.1259/0007-1285-58-690-515
   Garg AK, 2011, CANCER-AM CANCER SOC, V117, P3509, DOI 10.1002/cncr.25918
   Jin Ryan, 2009, J Exp Ther Oncol, V8, P35
   Laufer I, 2013, J NEUROSURG-SPINE, V18, P207, DOI 10.3171/2012.11.SPINE12111
   Lee I, 2014, J RADIOSURGERY SBRT, V3, P51
   Loblaw DA, 2012, INT J RADIAT ONCOL, V84, P312, DOI 10.1016/j.ijrobp.2012.01.014
   Mahadevan A, 2011, INT J RADIAT ONCOL, V81, P1500, DOI 10.1016/j.ijrobp.2010.08.012
   Ricardi U, 2016, J RADIAT RES, V57, pI58, DOI 10.1093/jrr/rrw006
   Ryu S, 2007, CANCER, V109, P628, DOI 10.1002/cncr.22442
   Ryu S, 2010, CANCER-AM CANCER SOC, V116, P2250, DOI 10.1002/cncr.24993
   Ryu Samuel, 2018, IMAGE GUIDED RADIOSU
   Sahgal A, 2013, LANCET ONCOL, V14, pE310, DOI 10.1016/S1470-2045(13)70101-3
   Shiue K, 2010, EXPERT REV ANTICANC, V10, P697, DOI [10.1586/era.10.47, 10.1586/ERA.10.47]
   Thibault I, 2014, J NEUROSURG-SPINE, V21, P711, DOI 10.3171/2014.7.SPINE13895
   Timmerman RD, 2008, SEMIN RADIAT ONCOL, V18, P215, DOI 10.1016/j.semradonc.2008.04.001
   Versteeg AL, 2016, SPINE, V41, pS231, DOI 10.1097/BRS.0000000000001822
   Wang XS, 2012, LANCET ONCOL, V13, P395, DOI 10.1016/S1470-2045(11)70384-9
NR 23
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E198
EP E205
DI 10.1016/j.wneu.2018.09.210
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100021
PM 30308345
DA 2020-05-12
ER

PT J
AU Miekisiak, G
   Latka, D
   Jarmuzek, P
   Zaluski, R
   Urbanski, W
   Janusz, W
AF Miekisiak, Grzegorz
   Latka, Dariusz
   Jarmuzek, Pawel
   Zaluski, Rafal
   Urbanski, Wiktor
   Janusz, Witold
TI Steroids in Acute Spinal Cord Injury: All But Gone Within 5 Years
SO WORLD NEUROSURGERY
LA English
DT Article
DE Methylprednisolone; Spinal cord injury; Steroids; Survey
ID HIGH-DOSE METHYLPREDNISOLONE; PHARMACOLOGICAL THERAPY; EARLY
   COMPLICATIONS; SODIUM SUCCINATE; FOLLOW-UP; NALOXONE; STANDARD
AB BACKGROUND: Spinal cord injury (SCI) is a devastating event often leading to poor neurologic outcomes. One of the most widely practiced treatments has been the administration of methylprednisolone. However, today its use has been called into question over concerns of efficacy and safety. The present study evaluated the changes in the practice of steroid administration in acute SCI among members of the National Spinal Society in Poland in comparison with the results of the survey conducted in 2013.
   METHODS: The questionnaire, comprising 5 questions, was distributed among 240 spinal surgeons, members of the Polish Society of Spinal Surgery; of these, 97 (40%) responded. The results were compared with data from the previous survey conducted in 2013.
   RESULTS: Over a period of 5 years, the prevalence of steroid administration in acute SCI has completely reversed; the proportion of steroid users declined from 73% to 27%. The main rationale for using it was belief in efficacy, rather than fear of litigation. The differences between specialization and age groups were not statistically significant in both administrations.
   CONCLUSIONS: A significant decrease was observed in the number of surgeons using steroids in the acute SCI, similar to that reported in the literature. The critical appraisal of the existing clinical evidence, as well as the formulation of guidelines by professional organizations, exerted a profound impact on the practice pattern.
C1 [Miekisiak, Grzegorz; Latka, Dariusz] Univ Hosp, Dept Neurosurg, Opole, Poland.
   [Jarmuzek, Pawel] Univ Zielona Gora, Dept Neurosurg, Zielona Gora, Poland.
   [Zaluski, Rafal] Wroclaw Med Univ, Dept Neurosurg, Wroclaw, Poland.
   [Urbanski, Wiktor] Wroclaw Med Univ, Dept Orthoped & Traumatol, Wroclaw, Poland.
   [Janusz, Witold] Med Univ, Dept Neurosurg & Pediat Neurosurg, Lublin, Poland.
RP Miekisiak, G (reprint author), Univ Hosp, Dept Neurosurg, Opole, Poland.
EM gmiekisiak@gmail.com
RI Latka, Dariusz/X-2332-2018
OI Latka, Dariusz/0000-0003-3958-2477; Jarmuzek, Pawel/0000-0001-5645-9513;
   Miekisiak, Grzegorz/0000-0001-6781-7013
CR Bowers CA, 2016, NEURAL REGEN RES, V11, P882, DOI 10.4103/1673-5374.184450
   BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001
   BRACKEN MB, 1992, J NEUROSURG, V76, P23, DOI 10.3171/jns.1992.76.1.0023
   Coleman WP, 2000, J SPINAL DISORD, V13, P185, DOI 10.1097/00002517-200006000-00001
   Druschel C, 2013, SPINE, V38, pE669, DOI 10.1097/BRS.0b013e31828e4dce
   Eck JC, 2006, SPINE, V31, pE250, DOI 10.1097/01.brs.0000214886.21265.8c
   Fehlings MG, 2017, GLOB SPINE J, V7, p203S, DOI 10.1177/2192568217703085
   Hadley MN, 2002, NEUROSURGERY, V50, pS63
   Hugenholtz H, 2003, CAN MED ASSOC J, V168, P1145
   Hurlbert RJ, 2008, CAN J NEUROL SCI, V35, P41, DOI 10.1017/S031716710000754X
   Hurlbert R John, 2015, Neurosurgery, V76 Suppl 1, pS71, DOI 10.1227/01.neu.0000462080.04196.f7
   Hurlbert RJ, 2013, NEUROSURGERY, V72, P93, DOI 10.1227/NEU.0b013e31827765c6
   Hurlbert RJ, 2002, CAN J NEUROL SCI, V29, P236, DOI 10.1017/S0317167100002006
   Hurlbert RJ, 2000, J NEUROSURG, V93, P1, DOI 10.3171/spi.2000.93.1.0001
   Ito Y, 2009, SPINE, V34, P2121, DOI 10.1097/BRS.0b013e3181b613c7
   Matsumoto T, 2001, SPINE, V26, P426, DOI 10.1097/00007632-200102150-00020
   Miekisiak G, 2013, J SPINE SURG, V5, P11
   Molano MD, 2002, J NEUROSURG, V96, P267, DOI 10.3171/spi.2002.96.3.0267
   Qian T, 2005, SPINAL CORD, V43, P199, DOI 10.1038/sj.sc.3101681
   Suberviola B, 2008, INJURY, V39, P748, DOI 10.1016/j.injury.2007.12.005
   (UK) NCGC, 2016, SPIN INJ ASS IN MAN
   Werndle MC, 2012, J NEUROTRAUM, V29, P880, DOI 10.1089/neu.2011.2038
NR 22
TC 0
Z9 1
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E467
EP E471
DI 10.1016/j.wneu.2018.09.239
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100056
PM 30366138
DA 2020-05-12
ER

PT J
AU Molina, ES
   van Eck, ATCJ
   Sauerland, C
   Schipmann, S
   Horstmann, G
   Stummer, W
   Brokinkel, B
AF Molina, Eric Suero
   van Eck, Albertus T. C. J.
   Sauerland, Cristina
   Schipmann, Stephanie
   Horstmann, Gerhard
   Stummer, Walter
   Brokinkel, Benjamin
TI Local Tumor Control and Clinical Symptoms After Gamma Knife Radiosurgery
   for Residual and Recurrent Vestibular Schwannomas
SO WORLD NEUROSURGERY
LA English
DT Article
DE Gamma Knife radiosurgery; Microsurgery; Neuroma, acoustic; Schwannoma,
   vestibular
ID ACOUSTIC NEUROMA; FOLLOW-UP; SURGERY; MANAGEMENT; MICROSURGERY;
   RESECTION; EXPERIENCE; OUTCOMES
AB BACKGROUND: The use of Gamma Knife radiosurgery (GKRS) for recurrent or residual vestibular schwarmorna (VS) after microsurgery (MS) has been investigated in several retrospective studies. The purpose of this study vvas to identify potential risk factors for both neurologic deterioration and tumor progression after GKRS for previously operated VSs in a prospective setting.
   METHODS: Patients who underwent GKRS for previously operated and his topathologically confirmed VS between 1998 and 2015 vvere prospectively followed-up. Risk factors for therapy side effects and predictors for tumor control were investigated in uni- and multivariate analyses.
   RESULTS: A total of 160 individuals with a median age of 55 years were included. Median tumor, volume prior to GKRS was 1.40 cm(3) (range, 0.06-35.80 cm(3)). After a median follow-up of 36 months, hearing and facial nerve function were serviceable (modified Gardner-Robertson and HouseBrackmann grades I and II) in 7 (5%) and 82 (55%) patients, respectively. Deterioration to a nonserviceable facial nerve function after GKRS was found in 3% (3/89) and tended to increase with rising tumor volume (odds ratio, 1.65 per cm(3); 95% confidence interval, 1.00-2.71; P = 0.051). Median tumor volume prior to GKRS was higher in patients with radiologic (P = 0.020) or clinical tumor progression (P < 0.001). Critical tumor volume prior to GKRS to predict clinical and radiologic tumor progression was 1.30 cm(3) (P< 0.001) and 3.30 cm(3) (P = 0.019), respectively. However, in multivariate analyses, none of the analyzed variables were found to independently predict tumor progression.
   CONCLUSIONS: Intended submaximal resection followed by GKRS is as viable treatment for VS. Because tumor remnant size after MS is an important predictor for recurrence after adjuvant GKRS, both brainstem and cerebellar decompression and maximal safely achievable resection should remain major goals of microsurgery.
C1 [Molina, Eric Suero; Schipmann, Stephanie; Stummer, Walter; Brokinkel, Benjamin] Univ Hosp Munster, Dept Neurosurg, Munster, Germany.
   [van Eck, Albertus T. C. J.; Horstmann, Gerhard] Gamma Knife Ctr Krefeld, Krefeld, Germany.
   [Sauerland, Cristina] Univ Munster, Inst Biostat & Clin Res, Munster, Germany.
RP Brokinkel, B (reprint author), Univ Hosp Munster, Dept Neurosurg, Munster, Germany.
EM benjamin.brokinkel@ukmuenster.de
RI Stummer, Walter/AAA-3319-2020; Sauerland, Maria Cristina/A-4154-2014;
   Stummer, Walter/AAF-9043-2019
OI Brokinkel, Benjamin/0000-0003-3462-3479
CR Bloch DC, 2004, OTOLARYNG HEAD NECK, V130, P104, DOI 10.1016/S0194-5998(03)01598-5
   Bloch O, 2011, J NEURO-ONCOL, V102, P281, DOI 10.1007/s11060-010-0315-5
   Brokinkel B, 2014, J CLIN NEUROSCI, V21, P2077, DOI 10.1016/j.jocn.2014.03.037
   Conley GS, 2010, CURR OPIN OTOLARYNGO, V18, P351, DOI 10.1097/MOO.0b013e32833c71a2
   El-Kashlan HK, 2000, AM J OTOL, V21, P389, DOI 10.1016/S0196-0709(00)80049-6
   Falcioni M, 2011, J NEUROSURG, V115, P820, DOI 10.3171/2011.5.JNS101597
   Flickinger JC, 2004, INT J RADIAT ONCOL, V60, P225, DOI 10.1016/j.ijrobp.2004.02.019
   Freeman SRM, 2007, OTOL NEUROTOL, V28, P1076, DOI 10.1097/MAO.0b013e318159e76a
   Fu VX, 2018, J NEUROSURG, V129, P137, DOI 10.3171/2017.3.JNS162033
   Gerganov VM, 2012, WORLD NEUROSURG, V77, P627, DOI 10.1016/j.wneu.2011.10.008
   Godefroy WP, 2009, OTOL NEUROTOL, V30, P629, DOI 10.1097/MAO.0b013e3181a8651f
   Hasegawa T, 2013, J NEUROSURG, V118, P557, DOI 10.3171/2012.10.JNS12523
   Hong BJ, 2014, OTOL NEUROTOL, V35, P171, DOI 10.1097/MAO.0000000000000174
   HOUSE JW, 1985, OTOLARYNG HEAD NECK, V93, P146, DOI 10.1177/019459988509300202
   KAMEYAMA S, 1994, ACTA NEUROCHIR, V129, P127, DOI 10.1007/BF01406491
   Klijn S, 2016, J NEUROSURG, V124, P1619, DOI 10.3171/2015.4.JNS142415
   Kondziolka D, 1998, NEW ENGL J MED, V339, P1426, DOI 10.1056/NEJM199811123392003
   Lee CC, 2014, J NEUROSURG, V121, P150, DOI 10.3171/2014.8.GKS141312
   Liscak R, 2009, ACTA NEUROCHIR, V151, P317, DOI 10.1007/s00701-009-0254-0
   Lobato-Polo J, 2009, NEUROSURGERY, V65, P294, DOI 10.1227/01.NEU.0000345944.14065.35
   Lunsford LD, 2005, J NEUROSURG, V102, P195, DOI 10.3171/jns.2005.102.s_supplement.0195
   Magliulo G, 2000, J OTOLARYNGOL, V29, P344
   Matthies C, 1997, NEUROSURGERY, V40, P469, DOI 10.1097/00006123-199703000-00009
   Matthies C, 1997, NEUROSURGERY, V40, P1
   Matthies C, 1997, NEUROSURGERY, V40, P481
   Milligan BD, 2012, J NEUROSURG, V116, P598, DOI 10.3171/2011.11.JNS11811
   Nagano O, 2008, J NEUROSURG, V109, P811, DOI 10.3171/JNS/2008/109/11/0811
   Nakamura H, 2000, AM J NEURORADIOL, V21, P1540
   Nonaka Y, 2013, NEUROSURGERY, V72, P103, DOI 10.1227/NEU.0b013e3182752b05
   Pan HC, 2012, J NEUROSURG, V117, P69, DOI 10.3171/2012.6.GKS12697
   Petit JH, 2001, NEUROSURGERY, V49, P1299, DOI 10.1097/00006123-200112000-00003
   Pollock BE, 1998, J NEUROSURG, V89, P944, DOI 10.3171/jns.1998.89.6.0944
   Pollock BE, 1998, J NEUROSURG, V89, P949, DOI 10.3171/jns.1998.89.6.0949
   Pollock Bruce E, 2013, J Neurosurg, V119 Suppl, P949
   Pollock Bruce E, 2008, Prog Neurol Surg, V21, P163, DOI 10.1159/000156904
   Prasad D, 2000, J NEUROSURG, V92, P745, DOI 10.3171/jns.2000.92.5.0745
   Rinaldi V, 2012, J NEUROL SURG PART B, V73, P21, DOI 10.1055/s-0032-1304559
   Roberson JB, 1996, AM J OTOL, V17, P307
   Roche Pierre-Hugues, 2008, Prog Neurol Surg, V21, P152, DOI 10.1159/000156902
   Samii M, 1997, NEUROSURGERY, V40, P11, DOI 10.1097/00006123-199701000-00002
   Samii M, 1997, NEUROSURGERY, V40, P29
   Samii M, 2016, J NEUROSURG, V125, P1198, DOI 10.3171/2015.8.JNS151350
   Timmer FCA, 2011, LARYNGOSCOPE, V121, P1359, DOI 10.1002/lary.21763
   Unger F, 2002, ACTA NEUROCHIR, V144, P671, DOI 10.1007/s00701-002-0950-5
   van de Langenberg R, 2009, NEURORADIOLOGY, V51, P517, DOI 10.1007/s00234-009-0529-4
   van Eck ATCJ, 2005, J NEUROSURG, V102, P204, DOI 10.3171/jns.2005.102.s_supplement.0204
   Yang SY, 2008, J NEUROL NEUROSUR PS, V79, P431, DOI 10.1136/jnnp.2007.119602
NR 47
TC 1
Z9 1
U1 2
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1240
EP E1246
DI 10.1016/j.wneu.2018.11.022
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100150
PM 30447443
DA 2020-05-12
ER

PT J
AU Morone, PJ
   Shah, KJ
   Hendricks, BK
   Cohen-Gadol, AA
AF Morone, Peter J.
   Shah, Kushal J.
   Hendricks, Benjamin K.
   Cohen-Gadol, Aaron A.
TI Virtual, 3-Dimensional Temporal Bone Model and Its Educational Value for
   Neurosurgical Trainees
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anatomy; Neurosurgery; Temporal bone; Three-dimensional; Virtual reality
AB OBJECTIVE: Learning complex neuroanatomy is an arduous yet important task for every neurosurgical trainee. As technology has advanced, various modalities have been created to aid our understanding of anatomy. This study sought to assess the educational value of a virtual, 3-dimensional (3D) temporal bone model.
   METHODS: The 3D temporal bone model was created with assistance of computer graphic designers and published online. Its educational value as a teaching was tool was assessed by querying 73 neurosurgery residents at 4 institutions and was compared with that of a standard, 2-dimensional (2D) temporal bone resource. Data were collected via a survey, and significance among responses was analyzed via a univariate chi-square test.
   RESULTS: The survey response rate was 37%. Greater than 90% of residents preferred to study with the 3D model compared with the 2D resource and felt that the 3D model allowed them understand the anatomy more realistically (P = 0.001). Moreover, >90% of residents believed that reviewing the 3D model before an actual surgery could lead to improved operative efficiency and safety (P = 0.001).
   CONCLUSIONS: This study demonstrates the utility of a novel, 3D temporal bone model as a teaching tool for neurosurgery residents. The model contains accurate anatomic structures and allows user interaction via a virtual, immersive environment.
C1 [Morone, Peter J.] Vanderbilt Univ, Med Ctr, Dept Neurol Surg, Nashville, TN USA.
   [Shah, Kushal J.] Univ Kansas, Med Ctr, Dept Neurosurg, Kansas City, KS 66103 USA.
   [Hendricks, Benjamin K.] Barrow Neurol Inst, Dept Neurol Surg, Phoenix, AZ 85013 USA.
   [Cohen-Gadol, Aaron A.] Indiana Univ Sch Med, Dept Neurol Surg, Indianapolis, IN 46202 USA.
RP Cohen-Gadol, AA (reprint author), Indiana Univ Sch Med, Dept Neurol Surg, Indianapolis, IN 46202 USA.
EM acohenmd@gmail.com
RI Hendricks, Benjamin/AAI-6544-2020
OI Hendricks, Benjamin/0000-0002-7123-4387; Cohen-Gadol,
   Aaron/0000-0002-4946-1524
CR [Anonymous], 2014, ATLAS HUMAN ANATOMY
   Brodel M, 1941, JAMA-J AM MED ASSOC, V117, P668
   BURTON HE, 1945, J OPT SOC AM, V35, P357, DOI 10.1364/JOSA.35.000357
   Chan S, 2013, NEUROSURGERY, V72, pA154, DOI 10.1227/NEU.0b013e3182750d26
   Cullen TS, 1945, B MED LIB ASS, V33
   D'Urso PS, 1999, SURG NEUROL, V52, P490, DOI 10.1016/S0090-3019(99)00143-3
   Ellis H, 1994, J Med Biogr, V2, P71
   Gmeiner M, 2018, WORLD NEUROSURG, V112, pE313, DOI 10.1016/j.wneu.2018.01.042
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Martins C, 2015, J NEUROSURG, V123, P1077, DOI 10.3171/2014.10.JNS13542
   Matsushima T, 2017, NEUROSURG REV, P140
   Matsushima T, 2018, J NEUROSURG, P1
   Morone PJ, 2017, OPER NEUROSURG, V13, P603, DOI 10.1093/ons/opx022
   Netter FH, 2018, TEMPORAL BONE DEEP S
   Patel SK, 2011, J NEUROSURG, V115, P182, DOI 10.3171/2011.1.JNS101094
   Robertson Jon H, 2011, World Neurosurg, V76, P492, DOI 10.1016/j.wneu.2011.10.027
   Sampson HW, 1991, ATLAS HUMAN SKULL
   Scholz M, 2010, HEAD NECK ONCOL, V2, DOI 10.1186/1758-3284-2-16
   Schuenke M, 2016, HEAD NECK NEUROANATO
   Shah KJ, 2016, OPER NEUROSURG, V12, P326, DOI 10.1227/NEU.0000000000001127
   SUGAR O, 1992, SURG NEUROL, V38, P464, DOI 10.1016/0090-3019(92)90116-5
   Triarhou LC, 2011, EUR NEUROL, V65, P10, DOI 10.1159/000322500
   Tucker AM, 2017, OPER NEUROSURG HAGER, P1
   Wanibuchi M, 2016, WORLD NEUROSURG, V91, P66, DOI [10.1016/J.WNEU.2016.03.084, 10.1016/j.wneu.2016.03.084]
NR 24
TC 4
Z9 4
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1412
EP E1415
DI 10.1016/j.wneu.2018.11.074
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100173
PM 30471440
DA 2020-05-12
ER

PT J
AU Motiwala, M
   Ajmera, S
   Akinduro, O
   Wallace, D
   Norrdahl, SP
   Schultz, A
   Fraser, B
   Saad, H
   Justo, M
   Dave, P
   Nguyen, V
   Vaughn, B
   Michael, LM
   Klimo, P
AF Motiwala, Mustafa
   Ajmera, Sonia
   Akinduro, Olutomi
   Wallace, David
   Norrdahl, Sebastian P.
   Schultz, Andrew
   Fraser, Brittany
   Saad, Hassan
   Justo, Melissa
   Dave, Pooja
   Nguyen, Vincent
   Vaughn, Brandy
   Michael, L. Madison
   Klimo, Paul, Jr.
TI How Does the Media Portray Neurosurgeons?
SO WORLD NEUROSURGERY
LA English
DT Article
DE Criminal; Malpractice; Media; Negative; Neurosurgeon; Neurosurgery;
   News; Positive
ID SOCIAL MEDIA; MENTAL-ILLNESS; MASS-MEDIA; RISK
AB BACKGROUND: It is not unusual to find neurosurgeons in the news and entertainment. The present study examined the portrayal of neurosurgeons by major print and online media sources.
   METHODS: Two search strategies identified articles from October 1, 2012 to October 1, 2017 containing the keyword "neurosurgeon." The top 25 newspapers in the United States, determined by their circulation, were searched using the LexisNexis Academic or NewsBank databases; a layman's Google News search was used to collect online stories. Each identified article was evaluated to confirm the relevance and then examined for content. Relevant characteristics for each article and neurosurgeon were determined and analyzed.
   RESULTS: Our searches returned 1005 articles comprising 561 unique stories about 203 different neurosurgeons. One particular neurosurgeon had 459 reports (45.7%). More articles were reported in 2015 (405; 40.3%) than any other single year. Most articles featured male neurosurgeons (879; 87.1%) and neurosurgeons who had been practicing for >20 years (636; 63.0%), with just 10 institutions accounting for the training of most of them (733; 72.6%). The articles were classified as positive (270; 26.9%), negative (356; 35.4%), or neutral (379; 37.7%) in terms of their reflection on the field of neurosurgery. The odds of a negative story were greater for male neurosurgeons, within 10 years of residency completion, and in a nonacademic position.
   CONCLUSIONS: Neurosurgeons are naturally subject to media coverage, and we must be cognizant that this predilection can serve as both an occupational advantage and an occupational hazard.
C1 [Motiwala, Mustafa; Ajmera, Sonia; Akinduro, Olutomi; Wallace, David; Norrdahl, Sebastian P.; Schultz, Andrew; Fraser, Brittany; Justo, Melissa] Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA.
   [Saad, Hassan] CHI St Vincent Infirm, Arkansas Neurosci Inst, Little Rock, AR USA.
   [Dave, Pooja] Rhodes Coll, Memphis, TN 38112 USA.
   [Nguyen, Vincent; Michael, L. Madison; Klimo, Paul, Jr.] Univ Tennessee, Ctr Hlth Sci, Dept Neurosurg, Memphis, TN 38163 USA.
   [Vaughn, Brandy; Klimo, Paul, Jr.] Le Bonheur Childrens Hosp, Memphis, TN 38103 USA.
   [Michael, L. Madison; Klimo, Paul, Jr.] Semmes Murphey, Memphis, TN 38120 USA.
RP Klimo, P (reprint author), Univ Tennessee, Ctr Hlth Sci, Dept Neurosurg, Memphis, TN 38163 USA.; Klimo, P (reprint author), Le Bonheur Childrens Hosp, Memphis, TN 38103 USA.; Klimo, P (reprint author), Semmes Murphey, Memphis, TN 38120 USA.
EM pklimo@semmes-murphey.com
CR Alotaibi NM, 2017, WORLD NEUROSURG, V98, P456, DOI 10.1016/j.wneu.2016.11.085
   Alotaibi NM, 2016, WORLD NEUROSURG, V93, P449, DOI 10.1016/j.wneu.2016.06.134
   Alotaibi NM, 2016, WORLD NEUROSURG, V90, P574, DOI 10.1016/j.wneu.2016.01.087
   Alotaibi NM, 2016, WORLD NEUROSURG, V88, P619, DOI 10.1016/j.wneu.2015.11.011
   [Anonymous], 2012, ALLIANCE AUDITED MED
   Ban VS, 2016, WORLD NEUROSURG, V91, P609, DOI 10.1016/j.wneu.2016.02.117
   Berger J, 2012, J MARKETING RES, V49, P192, DOI 10.1509/jmr.10.0353
   Coverdale J, 2002, AUST NZ J PSYCHIAT, V36, P697, DOI 10.1046/j.1440-1614.2002.00998.x
   Elkarim GA, 2017, J NEUROSURG-PEDIATR, V20, P119, DOI 10.3171/2017.3.PEDS16552
   Fan DP, 1996, SUBST USE MISUSE, V31, P1413, DOI 10.3109/10826089609063984
   Greerand J. D., 2011, NEWSPAPER RES J, V32, P83, DOI 10.1080/21670811.2012.714928
   Jena AB, 2011, NEW ENGL J MED, V365, P629, DOI 10.1056/NEJMsa1012370
   Kim C, 2018, WORLD NEUROSURG, V113, pE172, DOI 10.1016/j.wneu.2018.01.210
   Linzey JR, 2018, J NEUROSURG, V129, P1093, DOI 10.3171/2018.2.JNS172817
   Mata-Gomez J, 2018, NEUROCIRUGIA, V29, P109, DOI [10.1016/j.neucir.2018.01.001, 10.1016/j.neucie.2018.01.001]
   Nahed BV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039237
   Samuel N, 2017, WORLD NEUROSURG, V105, P394, DOI 10.1016/j.wneu.2017.05.111
   Serani Deborah, 2008, PSYCHOANALYSIS PSYCH, V4, P240, DOI [10.3200/ PSYC.24.4.240-250, DOI 10.3200/PSYC.24.4.240-250]
   Smith TR, 2015, NEUROSURGERY, V76, P105, DOI 10.1227/NEU.0000000000000576
   Soroka S, 2013, J HEALTH POLIT POLIC, V38, P893, DOI 10.1215/03616878-2334656
   WADE S, 1969, PUBLIC OPIN QUART, V33, P197, DOI 10.1086/267691
   WAHL OF, 1992, J COMMUNITY PSYCHOL, V20, P343, DOI 10.1002/1520-6629(199210)20:4<343::AID-JCOP2290200408>3.0.CO;2-2
NR 22
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E598
EP E605
DI 10.1016/j.wneu.2018.10.110
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100073
PM 31108076
DA 2020-05-12
ER

PT J
AU Mu, XP
   Wei, JX
   Wang, CL
   Ou, YF
   Yin, D
   Liang, B
   Qiu, DZ
   Li, ZH
AF Mu, Xiaoping
   Wei, Jianxun
   Wang, Chenglong
   Ou, Yufu
   Yin, Dong
   Liang, Bin
   Qiu, Dezan
   Li, Zhuhai
TI Intravenous Administration of Tranexamic Acid Significantly Reduces
   Visible and Hidden Blood Loss Compared with Its Topical Administration
   for Double-Segment Posterior Lumbar Interbody Fusion: A Single-Center,
   Placebo-Controlled, Randomized Trial
SO WORLD NEUROSURGERY
LA English
DT Article
DE Hidden blood loss; Intravenous and topical administrations; Posterior
   lumbar interbody fusion; Tranexamic acid; Visible blood loss
ID SPINE SURGERY; EFFICACY; SAFETY
AB OBJECTIVE: Tranexamic acid (TXA) significantly reduces the visible and hidden blood loss associated with joint replacement. At present, many studies have examined the safety and effectiveness of the intravenous or topical administration of TXA after posterior lumbar surgery. However, randomized and controlled trials examining the presence of differences in the effect of TXA on the visible and hidden blood loss between these 2 modes of administration are lacking. The current study investigated the effects of intravenous and topical administrations of TXA on the visible and hidden blood loss of patients undergoing posterior lumbar interbody fusion (PLIF).
   METHODS: In a single-center, placebo-controlled, randomized design, a total of 150 patients with lumbar degenerative disease who underwent PLIF between September 2015 and August 2017 volunteered for this study. Of these patients, 126 fulfilled the inclusion criteria and were randomly assigned to 1 of 3 groups: the intravenous administration group (n = 45, group A), the topical administration group (n = 39, group B), or the placebo group (n = 42, group C). SPSS, version 17.0, was used to analyze the patient data, their blood biochemical indices, blood loss, and the number of blood transfusions across the 3 groups during the perioperative period.
   RESULTS: The postoperative drainage volume, number of blood transfusions, length of hospital stay, and extubation time significantly differed between group C and both groups A and B (P < 0.05); however, no significant differences were noted between groups A and B (P > 0.05). Intraoperative blood loss and visible or hidden blood loss as well as the levels of postoperative hemoglobin and hematocrit significantly differed among the 3 groups (P < 0.01). The results of the visual analogue scale, prothrombin time, and fibrinogen content did not significantly differ among the 3 groups (P > 0.05).
   CONCLUSIONS: For patients undergoing double-segment PLIF, both administrations of TXA can reduce blood loss, extubation time, and the length of hospital stay. Moreover, intravenous administration can reduce both visible and hidden blood loss more efficiently.
C1 [Mu, Xiaoping; Wei, Jianxun; Ou, Yufu; Yin, Dong; Liang, Bin; Qiu, Dezan; Li, Zhuhai] Peoples Hosp Guangxi Zhuang Autonomous Reg, Dept Orthopaed, Nanning, Guangxi, Peoples R China.
   [Wang, Chenglong] Guangxi Univ Chinese Med, Grad Sch, Nanning, Guangxi, Peoples R China.
RP Ou, YF (reprint author), Peoples Hosp Guangxi Zhuang Autonomous Reg, Dept Orthopaed, Nanning, Guangxi, Peoples R China.
EM Ou.YF1972@gmail.com
RI Mu, Xiaoping/AAA-2394-2020
FU Scientific Research Project of Guangxi Health and Family Planning
   Commission [Z2016625]; Guangxi Natural Science Foundation
   ProgramNational Natural Science Foundation of Guangxi Province
   [2016GXNSFAA380058]; Guangxi Medical and Health Research Fund Inc
   [Z2011106]
FX This work is supported by the Scientific Research Project of Guangxi
   Health and Family Planning Commission (Z2016625), Guangxi Natural
   Science Foundation Program (2016GXNSFAA380058), and Guangxi Medical and
   Health Research Fund Inc (Z2011106).
CR Alajmi Turki, 2017, J Spine Surg, V3, P531, DOI 10.21037/jss.2017.08.17
   ASTEDT B, 1978, ANN CHIR GYNAECOL FE, V67, P203
   Benoni G, 1997, THROMB RES, V85, P195, DOI 10.1016/S0049-3848(97)00004-2
   Colomina MJ, 2017, BRIT J ANAESTH, V118, P380, DOI 10.1093/bja/aew434
   Endres S, 2011, BMC SURG, V11, DOI 10.1186/1471-2482-11-29
   Farrokhi MR, 2011, J NEUROSURG ANESTH, V23, P290, DOI 10.1097/ANA.0b013e31822914a1
   GROSS JB, 1983, ANESTHESIOLOGY, V58, P277, DOI 10.1097/00000542-198303000-00016
   Hui SY, 2018, SPINE J, V18, P1325, DOI 10.1016/j.spinee.2017.11.017
   Kim KT, 2017, EUR SPINE J, V26, P2851, DOI 10.1007/s00586-017-5230-4
   Lin CM, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005344
   Luo W, 2018, J ORTHOP SURG RES, V13, DOI 10.1186/s13018-018-0815-0
   NADLER SB, 1962, SURGERY, V51, P224
   Ou YF, 2018, SURG INNOV, V25, P128, DOI 10.1177/1553350617751449
   Raksakietisak M, 2015, SPINE, V40, pE1257, DOI 10.1097/BRS.0000000000001063
   Ren ZN, 2017, SPINE, V42, P1779, DOI 10.1097/BRS.0000000000002231
   Ren ZN, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008233
   Shi HY, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000005718
   Smorgick Y, 2013, SPINE J, V13, P877, DOI 10.1016/j.spinee.2013.02.008
   Tengborn L, 2015, THROMB RES, V135, P231, DOI 10.1016/j.thromres.2014.11.012
   Wang WT, 2018, SPINE, V43, pE734, DOI 10.1097/BRS.0000000000002491
   Wong J, 2008, ANESTH ANALG, V107, P1479, DOI 10.1213/ane.0b013e3181831e44
   Xu DR, 2017, J ORTHOP SURG RES, V12, DOI 10.1186/s13018-017-0672-2
   Yang ZG, 2012, J BONE JOINT SURG AM, V94A, P1153, DOI 10.2106/JBJS.K.00873
   Zamani A, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-143
NR 24
TC 3
Z9 4
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E821
EP E827
DI 10.1016/j.wneu.2018.10.154
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100099
PM 30391759
DA 2020-05-12
ER

PT J
AU Narata, AP
   Janot, K
   Bibi, R
   Herbreteau, D
   Perrault, C
   Marzo, A
   Cottier, JP
AF Narata, Ana Paula
   Janot, Kevin
   Bibi, Richard
   Herbreteau, Denis
   Perrault, Cecile
   Marzo, Alberto
   Cottier, Jean-Philippe
TI Reversible Brain Edema Associated with Flow Diverter Stent Procedures: A
   Retrospective Single-Center Study to Evaluate Frequency, Clinical
   Evolution, and Possible Mechanism
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain edema; Flow diverter stent; Intracranial aneurysm
ID CEREBRAL HYPERPERFUSION; INTRACRANIAL ANEURYSMS; HEMORRHAGE; DIVERSION
AB BACKGROUND: Hemorrhage and ischemia after flow diverter stent (FDS) procedures for intracranial aneurysms are the most common complications and have been extensively described. Temporary brain edema (TBE) is an unknown complication that could be associated with particular FDS procedures.
   OBJECTIVE: To estimate the frequency, clinical presentation, imaging findings, and possible mechanisms associating TBE with FDS.
   METHODS: Unruptured aneurysms treated with FDS implantation performed in our service from June 2015 to March 2018 were reviewed. Medical antecedents, endovascular procedure, clinical assessments before and after treatment, aneurysm characteristics, and image records were collected. Artery diameters of patients in whom TEB developed were also calculated to investigate any correlation between TBE and anatomic descriptors.
   RESULTS: A total of 179 FDS procedures in 176 patients were reviewed. Six patients (3.4%) presented with symptomatic TBE, and all TBE patients had undergone FDS implantation from the middle cerebral artery (MCA) to the internal carotid artery (ICA). A Pearson product-moment correlation coefficient (PPCC) found smaller MCA diameters and MCA/ICA ratios in these 6 patients (respectively PPCC = -0.619, P < 0.04; PPCC = -0.647, P < 0.03). Hemorrhagic and ischemic complications were less frequent than TBE (2.3% and 1.1% vs. 3.4%).
   CONCLUSIONS: TBE was more frequent than ischemic or hemorrhagic complications after FDS in this study. TBE seemed to be associated with a particular FDS positioning in small arteries, inducing flow changes and disruption of the blood-brain barrier.
C1 [Narata, Ana Paula; Janot, Kevin; Bibi, Richard; Herbreteau, Denis; Cottier, Jean-Philippe] Univ Hosp Tours, Dept Radiol & Neuroradiol, Tours, France.
   [Perrault, Cecile; Marzo, Alberto] Univ Sheffield, Mech Engn Dept, Sheffield, S Yorkshire, England.
RP Narata, AP (reprint author), Univ Hosp Tours, Dept Radiol & Neuroradiol, Tours, France.
EM apnarata@gmail.com
RI ; Perrault, Cecile M./A-2982-2011
OI Janot, Kevin/0000-0002-7305-3125; Perrault, Cecile
   M./0000-0003-2230-6994
CR Abou-Chebl A, 2004, J AM COLL CARDIOL, V43, P1596, DOI 10.1016/j.jacc.2003.12.039
   Ballabh P, 2004, NEUROBIOL DIS, V16, P1, DOI 10.1016/j.nbd.2003.12.016
   Brinjikji W, 2015, AM J NEURORADIOL, V36, P2308, DOI 10.3174/ajnr.A4443
   Brinjikji W, 2013, STROKE, V44, P442, DOI 10.1161/STROKEAHA.112.678151
   Chiu AHY, 2013, J NEUROINTERV SURG, V5, pE48, DOI 10.1136/neurintsurg-2012-010479.rep
   Di Marco LY, 2015, NEUROBIOL DIS, V82, P593, DOI 10.1016/j.nbd.2015.08.014
   Gascou G, 2015, AM J NEURORADIOL, V36, P725, DOI 10.3174/ajnr.A4191
   Guimaraens L, 2010, CARDIOVASC INTER RAD, V33, P383, DOI 10.1007/s00270-009-9609-4
   HALEY EC, 1984, ANN NEUROL, V15, P100, DOI 10.1002/ana.410150118
   Hussein AE, 2017, INTERV NEURORADIOL, V23, P357, DOI 10.1177/1591019917701100
   Karapanayiotides T, 2005, STROKE, V36, P21, DOI 10.1161/01.STR.0000149946.86087.e5
   Losif C, 2015, J NEUROSURG, V122, P627, DOI 10.3171/2014.10.JNS132566
   Mitha AP, 2015, HEART LUNG CIRC, V24, P824, DOI 10.1016/j.hlc.2015.02.001
   Narata AP, 2019, NEUROSURGERY, V84, P77, DOI 10.1093/neuros/nyy002
   Spina R, 2017, CATHETER CARDIO INTE, V90, P257, DOI 10.1002/ccd.26871
   van Mook WNKA, 2005, LANCET NEUROL, V4, P877, DOI 10.1016/S1474-4422(05)70251-9
NR 16
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E569
EP E576
DI 10.1016/j.wneu.2018.10.103
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100069
PM 30394357
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Navone, SE
   Doniselli, FM
   Summers, P
   Guarnaccia, L
   Rampini, P
   Locatelli, M
   Campanella, R
   Marfia, G
   Costa, A
AF Navone, Stefania Elena
   Doniselli, Fabio Martino
   Summers, Paul
   Guarnaccia, Laura
   Rampini, Paolo
   Locatelli, Marco
   Campanella, Rolando
   Marfia, Giovanni
   Costa, Antonella
TI Correlation of Preoperative Von Willebrand Factor with Magnetic
   Resonance Imaging Perfusion and Permeability Parameters as Predictors of
   Prognosis in Glioblastoma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Angiogenesis; GBM; K-ep; K-trans; MRI; VWF
ID CEREBRAL BLOOD-VOLUME; MALIGNANT GLIOMAS; K-TRANS; CONTRAST; GRADE; MRI;
   ENHANCEMENT; MECHANISMS; SURVIVAL; TIME
AB BACKGROUND: Angiogenesis has been shown to be strictly related to tumor malignancy. Glioblastoma (GBM) is highly vascularized and von Willebrand Factor (VWF) plays a potent proangiogenic role. Dynamic contrast-enhanced and dynamic susceptibility contrast magnetic resonance imaging (MRI) represent a widely accepted method to assess GBM microvasculature. Our aim was to investigate the correlation between plasma VWF: Ag, permeability, and perfusion MRI parameters and examine their potential in predicting GBM patient prognosis.
   METHODS: We retrospectively analyzed preoperative dynamic contrast-enhanced, dynamic susceptibility contrast MRI, and VWF: Ag level of 26 patients with GBM. We assessed the maximum values of relative cerebral blood flow and volume, volume transfer constant K-trans, plasma volume (V-p) and reflux rate constant between fractional volume of the extravascular space and blood plasma (K-ep). Nonparametric Mann-Whitney test and Kaplan-Meier survival analyses were conducted and a P value < 0.05 was considered statistically significant.
   RESULTS: The median VWF: Ag value was 248 IU/dL and the median follow-up duration was about 13 months. We divided patients according to low-VWF: Ag and high-VWF: Ag and we found significant differences in the median follow-up duration (19 months vs. 10 months; P = 0.04) and in K-trans (0.31/minute vs. 0.53/minute; P = 0.02), and K-ep (1.79/minute vs. 3.89/minute; P = 0.005) values. The cumulative 1-year survival was significantly shorter in patients with high-VWF: Ag and high-K-ep compared with patients with low-VWF: Ag and low-K-ep (37.5% vs. 68%; P = 0.05).
   CONCLUSIONS: These findings, in a small group of patients, suggest a role for VWF: Ag, similar to K-trans, and Kep as a prognostic indicator of postoperative survival of patients with GBM.
C1 [Navone, Stefania Elena; Guarnaccia, Laura; Rampini, Paolo; Locatelli, Marco; Campanella, Rolando; Marfia, Giovanni] Univ Milan, Neurosurg Unit, Lab Expt Neurosurg & Cell Therapy, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy.
   [Doniselli, Fabio Martino] Univ Milan, Postgrad Sch Radiodiagnost, Milan, Italy.
   [Summers, Paul; Costa, Antonella] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dept Neuroradiol, Milan, Italy.
RP Marfia, G (reprint author), Univ Milan, Neurosurg Unit, Lab Expt Neurosurg & Cell Therapy, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy.; Costa, A (reprint author), Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dept Neuroradiol, Milan, Italy.
EM giovanni.marfia@policlinico.mi.it; antonella.costa@policlinico.mi.it
RI navone, stefania/Y-4779-2019; Marfia, Giovanni/AAB-8702-2020; Summers,
   Paul E/D-5211-2016; Campanella, Rolando/AAB-8998-2019; Guarnaccia,
   Laura/K-7854-2016; navone, stefania elena/K-7264-2016
OI Marfia, Giovanni/0000-0002-5849-7000; Summers, Paul
   E/0000-0002-5085-1095; Guarnaccia, Laura/0000-0002-5909-0165; navone,
   stefania elena/0000-0002-0097-9146; Doniselli, Fabio
   Martino/0000-0002-2272-7855
FU Associazione Amici della Clinica Neurochirurgica
FX We thank Associazione Amici della Clinica Neurochirurgica for
   financially supporting our research activity and A-Tono, The World in
   Your Hand for the precious collaboration in disseminating our research
   with a first-rate communication program.
CR Ahmed R, 2014, CANCER MANAG RES, V6, P149, DOI 10.2147/CMAR.S54726
   Alcaide-Leon P, 2015, AM J NEURORADIOL, V36, P871, DOI 10.3174/ajnr.A4231
   Bisdas S, 2009, AM J NEURORADIOL, V30, P681, DOI 10.3174/ajnr.A1465
   Boxerman JL, 2006, AM J NEURORADIOL, V27, P859
   Cao Y, 2006, INT J RADIAT ONCOL, V64, P876, DOI 10.1016/j.ijrobp.2005.09.001
   Cha S, 2006, AM J NEURORADIOL, V27, P409
   Choyke PL, 2003, J MAGN RESON IMAGING, V17, P509, DOI 10.1002/jmri.10304
   Guarnaccia L, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27116-7
   Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7
   Hardee ME, 2012, AM J PATHOL, V181, P1126, DOI 10.1016/j.ajpath.2012.06.030
   Henderson E, 2000, J MAGN RESON IMAGING, V12, P991, DOI 10.1002/1522-2586(200012)12:6<991::AID-JMRI26>3.3.CO;2-T
   Hirai T, 2008, AM J NEURORADIOL, V29, P1505, DOI 10.3174/ajnr.A1121
   Jung SC, 2014, AM J NEURORADIOL, V35, P1103, DOI 10.3174/ajnr.A3825
   Kim R, 2017, EUR RADIOL, V27, P1176, DOI 10.1007/s00330-016-4464-6
   Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304
   Law M, 2008, RADIOLOGY, V247, P490, DOI 10.1148/radiol.2472070898
   Mao JM, 2015, BIOMARK RES, V3, DOI 10.1186/s40364-015-0034-3
   Marfia G, 2016, CANCER MED-US, V5, P1783, DOI 10.1002/cam4.747
   Mills SJ, 2006, AM J NEURORADIOL, V27, P853
   Nguyen TB, 2015, AM J NEURORADIOL, V36, P2017, DOI 10.3174/ajnr.A4398
   Patankar TF, 2005, AM J NEURORADIOL, V26, P2455
   Randi AM, 2013, MEDITERR J HEMATOL I, V5, DOI 10.4084/MJHID.2013.060
   SPORN LA, 1986, CELL, V46, P185, DOI 10.1016/0092-8674(86)90735-X
   Stupp R, 2009, ANN ONCOL, V20, P126, DOI 10.1093/annonc/mdp151
   Tofts PS, 1999, J MAGN RESON IMAGING, V10, P223, DOI 10.1002/(SICI)1522-2586(199909)10:3<223::AID-JMRI2>3.0.CO;2-S
   Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126
   Yang J, 2017, ONCOTARGET, V9, P11964
   Yang X, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1083-6
   Zaki HS, 2004, ACTA NEUROCHIR, V146, P841, DOI 10.1007/s00701-004-0282-8
NR 29
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E226
EP E234
DI 10.1016/j.wneu.2018.09.216
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100024
PM 30312827
DA 2020-05-12
ER

PT J
AU Ng, S
   Boetto, J
   Poulen, G
   Berthet, JP
   Marty-Ane, C
   Lonjon, N
AF Ng, Sam
   Boetto, Julien
   Poulen, Gaetan
   Berthet, Jean-Philippe
   Marty-Ane, Charles
   Lonjon, Nicolas
TI Partial Vertebrectomies without Instrumented Stabilization During En
   Bloc Resection of Primary Bronchogenic Carcinomas Invading the Spine:
   Feasibility Study and Results on Spine Balance
SO WORLD NEUROSURGERY
LA English
DT Article
DE Lung cancers; Non-small-cell lung cancers; Pancoast tumors; Primary
   bronchogenic carcinomas; Spine deformity; Vertebral resection;
   Vertebrectomies
ID SUPERIOR SULCUS TUMORS; ADVANCED PANCOAST TUMORS; LUNG-CANCER; PULMONARY
   SULCUS; RECONSTRUCTION; MANAGEMENT; BONE
AB OBJECTIVE: It is unknown whether spinal instrumentation is required to prevent deformity after partial vertebrectomy in the treatment of primary bronchogenic carcinomas invading the spine (PBCIS). In this study, we focus on the postoperative spine deformity in patients who underwent operation for partial vertebrectomies without instrumentation during en bloc PBCIS resection. Our objective was to determine whether deformity depends on the type of vertebral resection and if any vertebral resection threshold can be observed to justify additional spinal instrumentation.
   METHODS: This is a retrospective study, including all patients with PBCIS operated without spinal instrumentation from 2009 to 2018. Partial vertebrectomies were classified into categories A, B, and C depending on vertebral resection. Patients had long-term radiologic follow-up to assess the spine deformity evolution.
   RESULTS: Eighteen patients were included. The median follow-up was 27 months. Four patients underwent a secondary posterior instrumentation surgical procedure due to progressive spinal deformity. A low-risk group of deformation was characterized as type A resection and type B resection on less than 3 vertebrae.
   CONCLUSIONS: There are no validated criteria to justify a systematic spinal instrumentation when performing a partial vertebrectomy during en bloc resection of PBCIS. Performed alone without spine instrumentation, both type A and type B resections on less than 3 resected vertebrae were not subject to sagittal and coronal deformity even after a long follow-up, emphasizing that a systematic stabilization is not needed in this low-risk group. These results could help to reduce the perioperative morbidity of these procedures that are usually long and complex.
C1 [Ng, Sam; Boetto, Julien; Poulen, Gaetan; Lonjon, Nicolas] Montpellier Univ, Med Ctr, Hop Gui de Chauliac, Dept Neurosurg, Montpellier, France.
   [Berthet, Jean-Philippe] Nice Univ, Med Ctr, Hop Pasteur, Dept Thorac Surg, Nice, France.
   [Marty-Ane, Charles] Montpellier Univ, Med Ctr, Hop Arnaud de Villeneuve, Dept Thorac Surg, Montpellier, France.
   [Lonjon, Nicolas] Univ Montpellier, INSERM U1198, Montpellier, France.
RP Ng, S (reprint author), Montpellier Univ, Med Ctr, Hop Gui de Chauliac, Dept Neurosurg, Montpellier, France.
EM s-ng@chu-montpellier.fr
CR Anraku M, 2009, J THORAC CARDIOV SUR, V137, P441, DOI 10.1016/j.jtcvs.2008.09.035
   Bilsky MH, 2002, J NEUROSURG, V97, P301, DOI 10.3171/spi.2002.97.3.0301
   Bolton WD, 2009, J THORAC CARDIOV SUR, V137, P1379, DOI 10.1016/j.jtcvs.2009.01.015
   Boriani S, 1997, SPINE, V22, P1036, DOI 10.1097/00007632-199705010-00020
   Collaud S, 2013, J THORAC ONCOL, V8, P1538, DOI 10.1097/01.JTO.0000437419.31348.a4
   Fadel E, 2011, ANN THORAC SURG, V92, P1024, DOI 10.1016/j.athoracsur.2011.04.100
   Farray D, 2005, J CLIN ONCOL, V23, P3257, DOI 10.1200/JCO.2005.03.008
   Fisher CG, 2005, SPINE, V30, P1899, DOI 10.1097/01.brs.0000174114.90657.74
   Gandhi S, 1999, ANN THORAC SURG, V68, P1778, DOI 10.1016/S0003-4975(99)01068-1
   Gokaslan ZL, 1999, NEUROSURGICAL OPERAT, V8, P253
   Grunenwald DH, 2002, J THORAC CARDIOV SUR, V123, P271, DOI 10.1067/mtc.2002.119333
   Jain S, 2008, J NEUROSURG-SPINE, V9, P71, DOI 10.3171/SPI/2008/9/7/071
   Komaki R, 2000, INT J RADIAT ONCOL, V48, P347, DOI 10.1016/S0360-3016(00)00736-7
   Mazel C, 2003, SPINE, V28, P782, DOI 10.1097/00007632-200304150-00010
   Pancoast HK, 1932, J AMER MED ASSOC, V99, P1391, DOI 10.1001/jama.1932.02740690001001
   Rami-Porta R, 2014, J THORAC ONCOL, V9, P1618, DOI 10.1097/JTO.0000000000000334
   Rusch VW, 2007, J CLIN ONCOL, V25, P313, DOI 10.1200/JCO.2006.08.2826
   SARTORI F, 1992, J THORAC CARDIOV SUR, V104, P679
   Schirren J, 2011, EUR J CARDIO-THORAC, V40, P647, DOI 10.1016/j.ejcts.2010.12.046
   Stamatis G, 2002, EUR J CARDIO-THORAC, V22, P292, DOI 10.1016/S1010-7940(02)00266-X
   Stamatis Georgios, 2008, Thorac Surg Clin, V18, P71, DOI 10.1016/j.thorsurg.2007.11.004
   Stoker GE, 2013, SPINE J, V13, P68, DOI 10.1016/j.spinee.2012.11.026
   Tobias JW, 1932, REV MED LAT AM, V17, P1522
   Tomita K, 1997, SPINE, V22, P324, DOI 10.1097/00007632-199702010-00018
   Yokomise H, 2007, EUR J CARDIO-THORAC, V31, P788, DOI 10.1016/j.ejcts.2007.01.062
   York JE, 1999, J NEUROSURG, V91, P74, DOI 10.3171/spi.1999.91.1.0074
   Zairi F, 2016, ASIAN SPINE J, V10, P1047, DOI 10.4184/asj.2016.10.6.1047
NR 27
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1542
EP E1550
DI 10.1016/j.wneu.2018.11.098
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100189
PM 30471449
DA 2020-05-12
ER

PT J
AU Ni, W
   Yang, H
   Xu, B
   Xu, F
   Jiang, HQ
   Lei, Y
   Su, JB
   Gu, YX
   Mao, Y
AF Ni, Wei
   Yang, Heng
   Xu, Bin
   Xu, Feng
   Jiang, Hanqiang
   Lei, Yu
   Su, Jiabin
   Gu, Yuxiang
   Mao, Ying
TI Proximal Middle Cerebral Artery Aneurysms: Microsurgical Management and
   Therapeutic Results
SO WORLD NEUROSURGERY
LA English
DT Article
DE Microsurgical strategy; Proximal middle cerebral aneurysm;
   Revascularization
ID EXTRACRANIAL-INTRACRANIAL BYPASS; ANTERIOR TEMPORAL ARTERY;
   TERM-FOLLOW-UP; SACCULAR ANEURYSMS; OUTCOMES; SURGERY; SEGMENT
AB BACKGROUND: Management of proximal (M1) middle cerebral artery (MCA) aneurysms can be challenging. Because of the diversity of aneurysm morphology and location of M1 aneurysms, the surgical strategy should be tailored to each individual case, especially for complex cases. We assessed the safety and efficacy of an algorithmic strategy for the management of M1 aneurysms.
   METHODS: A prospective single-center study of M1 aneurysms treated with microsurgery was performed. Our algorithmic strategy was determined by the location and complexity (e.g., size, shape) of the aneurysms. The surgical modalities included neck clipping, aneurysm resection and/or trapping, and proximal occlusion with revascularization. The clinical and radiographic data were analyzed.
   RESULTS: From January 2007 to March 2017, 92 proximal MCA aneurysms in 92 patients were treated microsurgically. Aneurysm treatment techniques included clipping in 55, proximal occlusion in 21, aneurysm resection in 11, and trapping in 4. Bypass techniques included 2 anterior temporal artery reconstructions, 5 middle cerebral bifurcation reconstructions, 4 parent artery reanastomoses, 2 interpositional bypasses, 25 high-flow bypasses, and 7 medium-flow bypasses. Overall, good outcomes (modified Rankin scale score, 0-2) were seen in 49 of 92 patients (53.3%) at discharge and in 79 of 91 (86.8%) at the last follow-up visit. On the latest angiogram, 78 of 90 aneurysms (86.7%) had been completely occluded without a remnant. Bypass patency was confirmed in 38 of 43 bypass procedures.
   CONCLUSIONS: Our present treating strategy might provide a benefit for patients with proximal MCA aneurysms.
C1 [Ni, Wei; Yang, Heng; Xu, Bin; Xu, Feng; Jiang, Hanqiang; Lei, Yu; Su, Jiabin; Gu, Yuxiang; Mao, Ying] Fudan Univ, Huashan Hosp, Dept Neurosurg, Div Cerebrovasc Surg & Intervent Neuroradiol, Shanghai, Peoples R China.
RP Gu, YX (reprint author), Fudan Univ, Huashan Hosp, Dept Neurosurg, Div Cerebrovasc Surg & Intervent Neuroradiol, Shanghai, Peoples R China.
EM guyuxiang1972@126.com
OI Gu, Yuxiang/0000-0002-4580-2205
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81500987, 81771237]; National Ministry of Science
   and Technology [2016YFC1301704]; Science and Technology Commission of
   Shanghai MunicipalityScience & Technology Commission of Shanghai
   Municipality (STCSM) [18511102800]
FX The present study was supported by the National Natural Science
   Foundation of China (grants grant 81500987 and 81771237), National
   Ministry of Science and Technology (grant 2016YFC1301704), and Science
   and Technology Commission of Shanghai Municipality (grant 18511102800).
   The content is solely the responsibility of the authors and does not
   necessarily represent the official views of the National Natural Science
   Foundation of China, National Ministry of Science and Technology, or
   Science and Technology Commission of Shanghai Municipality.
CR Amin-Hanjani S, 2006, ACTA NEUROCHIR, V148, P227, DOI 10.1007/s00701-005-0691-3
   Choi Seung Won, 2012, J Cerebrovasc Endovasc Neurosurg, V14, P289, DOI 10.7461/jcen.2012.14.4.289
   GREENE KA, 1993, J NEUROSURG, V78, P974, DOI 10.3171/jns.1993.78.6.0974
   HOSODA K, 1995, NEUROSURGERY, V36, P441, DOI 10.1227/00006123-199503000-00001
   Iwama T, 2004, ACTA NEUROCHIR, V146, P967, DOI 10.1007/s00701-004-0325-1
   Jafar JJ, 2002, NEUROSURGERY, V51, P138, DOI 10.1097/00006123-200207000-00021
   Jones JE, 2013, NEUROSURGERY, V73, P1018, DOI 10.1227/NEU.0000000000000145
   Kalani MYS, 2013, NEUROSURGERY, V72, P428, DOI 10.1227/NEU.0b013e3182804381
   Kivipelto L, 2014, J NEUROSURG, V120, P398, DOI 10.3171/2013.10.JNS13738
   Liu DZ, 2014, NEURORADIOLOGY, V56, P1023, DOI 10.1007/s00234-014-1422-3
   Meybodi AT, 2017, J NEUROSURG, V127, P740, DOI 10.3171/2016.8.JNS161225
   Meybodi AT, 2017, J NEUROSURG, V127, P463, DOI 10.3171/2016.7.JNS16772
   Nanda Anil, 2014, J La State Med Soc, V166, P160
   O'Shaughnessy Brian A, 2003, Neurosurg Focus, V14, pe4, DOI 10.3171/foc.2003.14.3.5
   Park DH, 2008, CLIN NEUROL NEUROSUR, V110, P544, DOI 10.1016/j.clineuro.2008.02.014
   Paulo Marques-Sanches, 2010, Asian J Neurosurg, V5, P57
   Pia HW, 2012, CEREBRAL ANEURYSMS A
   SCOTT RM, 1982, NEUROSURGERY, V10, P600
   Stoodley MA, 1998, NEUROSURG CLIN N AM, V9, P823, DOI 10.1016/S1042-3680(18)30231-6
   UMANSKY F, 1984, J NEUROSURG, V61, P458, DOI 10.3171/jns.1984.61.3.0458
   van Dijk JMC, 2011, ACTA NEUROCHIR, V153, P2111, DOI 10.1007/s00701-011-1139-6
   Zhou Y, 2012, ACTA NEUROCHIR, V154, P1835, DOI 10.1007/s00701-012-1453-7
   Zhu W, 2013, ACTA NEUROCHIR, V155, P1481, DOI 10.1007/s00701-013-1751-8
   Zhu W, 2011, WORLD NEUROSURG, V75, P476, DOI 10.1016/j.wneu.2010.07.043
NR 24
TC 0
Z9 0
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E907
EP E916
DI 10.1016/j.wneu.2018.10.174
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100109
PM 30404066
DA 2020-05-12
ER

PT J
AU Nikitin, PV
   Ryzhova, MV
   Shishkina, LV
   Shugay, SV
   Zubova, IV
AF Nikitin, Pavel V.
   Ryzhova, Marina V.
   Shishkina, Lyudmila V.
   Shugay, Svetlana V.
   Zubova, Irina V.
TI Study of Simple Immunohistochemical Cytocolorimetric Assay Application
   for More Accurate Assessment of Prognosis in Patients with Pituitary
   Adenomas
SO WORLD NEUROSURGERY
LA English
DT Article
DE Immunohistochemical cytocolorimetric index; Immunohistochemistry; Ki-67;
   Pituitary adenoma
ID DIGITAL-IMAGE-ANALYSIS; KI-67 LABELING INDEX; PROLIFERATION; SERIES
AB BACKGROUND: Immunohistochemistry is a basic diagnostic technique. Immunohistochemical examination results reflect mainly qualitative and less quantitative characteristics of proteomic status of cells. A combined approach with complex quantitative evaluation of marker expression using colorimetric analysis and computer technologies can expand the diagnostic capabilities of immunohistochemistry. We studied such an approach developed by using expression of the proliferative marker Ki-67 in pituitary adenomas.
   METHODS: A retrospective, blind, randomized, comparative study was performed of Ki-67 expression activity in pituitary adenomas using the traditional Ki-67 labeling index and a simple immunohistochemical cytocolorimetric analysis developed by us with immunohistochemical cytocolorimetric index (ICI) estimation as predictors of relapse, assessing the relationships of these indicators with the time before relapse.
   RESULTS: Mean Ki-67 labeling index was 3.87% +/- 0.29% in the relapse-free group and 4.01% +/- 0.29% in the relapse group; the difference was not statistically significant. The average Ki-67 ICI was 24.16% +/- 0.51% in the relapse-free group and 30.68% +/- 0.64% in the relapse group; the difference was statistically significant. The correlation coefficient of ICI values and time before relapse was -0.302, indicating the presence of a weak negative correlation.
   CONCLUSIONS: We successfully tested an ICI estimation method developed by us to assess Ki-67 expression in pituitary adenomas. The ICI technique can be used both as a prognostic factor for relapse and, in combination with other modern proteomic and genetic methods, as the basis for creation of new multimodal analyzing systems for functional state assessment of cells and tissues.
C1 [Nikitin, Pavel V.; Ryzhova, Marina V.; Shishkina, Lyudmila V.; Shugay, Svetlana V.; Zubova, Irina V.] NN Burdenko Inst Neurosurg, Dept Neuropathol & Mol Diagnost, Moscow, Russia.
RP Nikitin, PV (reprint author), NN Burdenko Inst Neurosurg, Dept Neuropathol & Mol Diagnost, Moscow, Russia.
EM nikitinpaul@yandex.com
OI Nikitin, Pavel/0000-0003-3223-4584; Ryzhova, Marina/0000-0001-7206-6365
CR Acs B, 2018, PATHOL ONCOL RES, V24, P115, DOI 10.1007/s12253-017-0220-8
   Asoklis R, 2014, ONCOL LETT, V8, P1482, DOI 10.3892/ol.2014.2366
   Ayad E, 2018, DIAGN PATHOL, V13, DOI 10.1186/s13000-018-0735-7
   Bodhinayake I, 2014, CLIN NEUROL NEUROSUR, V119, P75, DOI 10.1016/j.clineuro.2014.01.020
   Chiloiro S, 2014, PITUITARY, V17, P267, DOI 10.1007/s11102-013-0500-6
   Cho HJ, 2014, J KOREAN MED SCI, V29, P405, DOI 10.3346/jkms.2014.29.3.405
   Dabbs DJ., 2010, DIAGNOSTIC IMMUNOHIS, P763
   De Caro MD, 2017, NEUROSURG REV, V40, P105, DOI 10.1007/s10143-016-0740-9
   Di Ieva A, 2014, NAT REV ENDOCRINOL, V10, P423, DOI 10.1038/nrendo.2014.64
   Kim JS, 2016, J PATHOL TRANSL MED, V50, P419, DOI 10.4132/jptm.2016.06.30
   Kushnarev V. A., 2018, Arkhiv Patologii, V80, P38, DOI 10.17116/patol201880238-42
   MacCallum DE, 2000, J PATHOL, V191, P286
   Niikura N, 2016, BREAST CANCER-TOKYO, V23, P92, DOI 10.1007/s12282-014-0536-0
   Polley MYC, 2015, MODERN PATHOL, V28, P778, DOI 10.1038/modpathol.2015.38
   Polley MYC, 2013, JNCI-J NATL CANCER I, V105, P1897, DOI 10.1093/jnci/djt306
   Roge R, 2016, BREAST CANCER RES TR, V158, P11, DOI 10.1007/s10549-016-3852-6
   Stathopoulos GP, 2014, ANTI-CANCER DRUG, V25, P950, DOI 10.1097/CAD.0000000000000123
   Taylor CR, 2015, CELL TISSUE RES, V360, P109, DOI 10.1007/s00441-014-2089-0
   Yamazaki Y, 2016, HUM PATHOL, V53, P41, DOI 10.1016/j.humpath.2015.10.017
   Yeo MK, 2017, J CLIN PATHOL, V70, P715, DOI 10.1136/jclinpath-2016-204162
   Zizzi A, 2013, J BIOL REG HOMEOS AG, V27, P913
NR 21
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1047
EP E1051
DI 10.1016/j.wneu.2018.10.225
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100128
PM 30415039
DA 2020-05-12
ER

PT J
AU Niu, F
   Dong, JQ
   Xu, XJ
   Zhang, B
   Liu, BY
AF Niu, Fei
   Dong, Jinqian
   Xu, Xiaojian
   Zhang, Bin
   Liu, Baiyun
TI Mitochondrial Division Inhibitor 1 Prevents Early-Stage Induction of
   Mitophagy and Accelerated Cell Death in a Rat Model of Moderate
   Controlled Cortical Impact Brain Injury
SO WORLD NEUROSURGERY
LA English
DT Article
DE Drp1; Mitochondrial fission; Mitophagy; TBI
ID CEREBRAL-ISCHEMIA; OXIDATIVE STRESS; NEURONAL INJURY; AUTOPHAGY;
   DYSFUNCTION; DEFICITS; INFLAMMATION; DEGRADATION; APOPTOSIS; DYNAMICS
AB BACKGROUND: Increasing evidence has implicated dysfunctional mitochondria in the pathophysiology of neurodegenerative disorders. Selective degradation of dysfunctional mitochondria has been termed mitophagy and constitutes a pivotal component of mitochondrial quality control to maintain cellular homeostasis. Mitochondrial fission plays a prominent role in controlling mitochondrial shape and function. However, it is unclear whether mitochondrial fission in the context of eliminating damaged mitochondria is involved in traumatic brain injury (TBI). We examined the role of mitochondrial division inhibitor 1 (Mdivi1), a small-molecule inhibitor of dynamin-related protein (Drp1), in general autophagy and mitophagy after controlled cortical impact (CCI).
   METHODS: Mitophagy and the role of Drp1 in this process after CCI were examined using Western blotting, electron microscopy, double immunofluorescence staining, neurological severity scores, and hematoxylin and eosin staining. Statistical analysis was performed using 1-way analysis of variance, followed by the least significant difference test or the Games-Howell test.
   RESULTS: The rats exposed to CCI exhibited induction of mitophagy and fragmentation of mitochondria. When fission was blocked with Mdivi1, the mitochondria became excessively long and interconnected. Inhibition of Drp1 blocked the induction of mitophagy specifically, which aggravated neurological manifestations and neuronal apoptosis. Mdivi1 activated caspase-3 and caspase-9, implying that selective degradation of damaged mitochondria by autophagy markedly decreased cell apoptosis induced by TBI and, thus, promoted cell survival.
   CONCLUSIONS: The findings from the present study support the hypothesis that Drp1-dependent mitochondrial fission contributes to mitophagy in TBI, and further understanding of the regulatory mechanisms of Drp1 will provide opportunities to develop novel strategies against TBI.
C1 [Niu, Fei; Xu, Xiaojian; Liu, Baiyun] Beijing Neurosurg Inst, Neurotrauma Lab, Beijing, Peoples R China.
   [Dong, Jinqian; Zhang, Bin; Liu, Baiyun] Capital Med Univ, Beijing Tian Tan Hosp, Dept Neurosurg, Beijing, Peoples R China.
   [Liu, Baiyun] Beijing Inst Brain Disorders, Nerve Injury & Repair Ctr, Beijing, Peoples R China.
   [Liu, Baiyun] China Natl Clin Res Ctr Neurol Dis, Beijing, Peoples R China.
   [Liu, Baiyun] Beijing Key Lab Cent Nervous Syst Injury, Beijing, Peoples R China.
RP Liu, BY (reprint author), Beijing Neurosurg Inst, Neurotrauma Lab, Beijing, Peoples R China.; Liu, BY (reprint author), Capital Med Univ, Beijing Tian Tan Hosp, Dept Neurosurg, Beijing, Peoples R China.; Liu, BY (reprint author), Beijing Inst Brain Disorders, Nerve Injury & Repair Ctr, Beijing, Peoples R China.; Liu, BY (reprint author), China Natl Clin Res Ctr Neurol Dis, Beijing, Peoples R China.; Liu, BY (reprint author), Beijing Key Lab Cent Nervous Syst Injury, Beijing, Peoples R China.
EM liubaiyun1212@163.com
FU Beijing Neurosurgical Institute Youth Programme [2016002]; National
   Natural Science Foundation of ChinaNational Natural Science Foundation
   of China [81471238, 81771327]
FX This study was supported by the Beijing Neurosurgical Institute Youth
   Programme (grant 2016002) and the National Natural Science Foundation of
   China (grants 81471238 and 81771327).
CR Bilgen M, 2005, NEUROREHAB NEURAL RE, V19, P219, DOI 10.1177/1545968305278635
   Cavallucci V, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.511
   Chen H, 2016, CLIN EXP PHARMACOL P, V43, P1107, DOI 10.1111/1440-1681.12650
   Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367
   Decuypere JP, 2011, BBA-MOL CELL RES, V1813, P1003, DOI 10.1016/j.bbamcr.2010.11.023
   Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003
   Fimia GM, 2013, CELL DEATH DIFFER, V20, P1, DOI 10.1038/cdd.2012.97
   Gajavelli S, 2015, J BIOENERG BIOMEMBR, V47, P133, DOI 10.1007/s10863-014-9589-1
   Goemans CG, 2008, CELL DEATH DIFFER, V15, P545, DOI 10.1038/sj.cdd.4402290
   Gozuacik D, 2007, CURR TOP DEV BIOL, V78, P217, DOI 10.1016/S0070-2153(06)78006-1
   Guarente L, 2008, CELL, V132, P171, DOI 10.1016/j.cell.2008.01.007
   Hiebert JB, 2015, AM J MED SCI, V350, P132, DOI 10.1097/MAJ.0000000000000506
   Jin SK, 2006, AUTOPHAGY, V2, P80, DOI 10.4161/auto.2.2.2460
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kanki T, 2008, J BIOL CHEM, V283, P32386, DOI 10.1074/jbc.M802403200
   Komatsu M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035
   Kubli DA, 2012, CIRC RES, V111, P1208, DOI 10.1161/CIRCRESAHA.112.265819
   Kukat A, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn124
   Labrousse AM, 1999, MOL CELL, V4, P815, DOI 10.1016/S1097-2765(00)80391-3
   Larson BE, 2012, J SURG RES, V173, pE73, DOI 10.1016/j.jss.2011.09.056
   Lin C, 2016, J PINEAL RES, V61, P177, DOI 10.1111/jpi.12337
   Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292
   Liu K, 2016, AUTOPHAGY, V12, P2000, DOI 10.1080/15548627.2016.1212786
   Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021
   Melser S, 2013, CELL METAB, V17, P719, DOI 10.1016/j.cmet.2013.03.014
   Miller DM, 2015, EXP NEUROL, V264, P103, DOI 10.1016/j.expneurol.2014.11.008
   Motori E, 2013, CELL METAB, V18, P844, DOI 10.1016/j.cmet.2013.11.005
   Pivtoraiko VN, 2009, ANTIOXID REDOX SIGN, V11, P481, DOI 10.1089/ARS.2008.2263
   Purnell PR, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-86
   Rao W, 2015, BBA-MOL BASIS DIS, V1852, P2402, DOI 10.1016/j.bbadis.2015.08.014
   Santos RX, 2010, J ALZHEIMERS DIS, V20, pS401, DOI 10.3233/JAD-2010-100666
   Shi J, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.278
   Smirnova E, 2001, MOL BIOL CELL, V12, P2245, DOI 10.1091/mbc.12.8.2245
   Vives-Bauza C, 2011, TRENDS MOL MED, V17, P158, DOI 10.1016/j.molmed.2010.11.002
   Wang HM, 2009, HUM MOL GENET, V18, P737, DOI 10.1093/hmg/ddn404
   Waterham HR, 2007, NEW ENGL J MED, V356, P1736, DOI 10.1056/NEJMoa064436
   Wei WT, 2015, NEUROCHEM INT, V87, P85, DOI 10.1016/j.neuint.2015.06.003
   Wen YD, 2008, AUTOPHAGY, V4, P762, DOI 10.4161/auto.6412
   Wu Q, 2018, INT J BIOCHEM CELL B, V94, P44, DOI 10.1016/j.biocel.2017.11.007
   Yu SS, 2016, NEUROSCI LETT, V628, P24, DOI 10.1016/j.neulet.2016.06.012
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   Zhang XN, 2013, AUTOPHAGY, V9, P1321, DOI 10.4161/auto.25132
   Zhang Yan-Bo, 2008, Neurosci Bull, V24, P143, DOI 10.1007/s12264-008-1108-0
   Zuo W, 2014, NEUROPHARMACOLOGY, V86, P103, DOI 10.1016/j.neuropharm.2014.07.002
NR 44
TC 2
Z9 2
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1090
EP E1101
DI 10.1016/j.wneu.2018.10.236
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100134
PM 30439527
DA 2020-05-12
ER

PT J
AU Nouri, N
   Ferrigno, M
   Personnic, T
   Bala, F
   Bretzner, M
   Estrade, L
   Pruvo, JP
   Henon, H
   Kazemi, A
   Bricout, N
AF Nouri, Nasreddine
   Ferrigno, Marc
   Personnic, Thomas
   Bala, Fouzi
   Bretzner, Martin
   Estrade, Laurent
   Pruvo, Jean-Pierre
   Henon, Hilde
   Kazemi, Apolline
   Bricout, Nicolas
TI Real-World Thrombectomy Using the Sofia Catheter
SO WORLD NEUROSURGERY
LA English
DT Article
DE Catheter; Stroke; Thrombectomy
ID ACUTE ISCHEMIC-STROKE; ENDOVASCULAR TREATMENT; TRIAL; MANAGEMENT;
   THERAPY
AB OBJECTIVE: To study the safety and performance of real-world thrombectomy using the SOFIA Catheter in our comprehensive stroke center.
   METHODS: We conducted a cohort study from a prospective clinical registry of consecutive stroke patients treated by mechanical thrombectomy between March 2016 and September 2017. Baseline clinical and imaging characteristics, recanalization rates, complications, and clinical outcomes were analyzed.
   RESULTS: Among the 140 patients included, 54 were treated using aspiration first, 64 were treated using aspiration and stent-retriever straightaway, and 22 were treated with SOFIA as a rescue device. Successful recanalization (Modified Thrombolysis In Cerebral Infarction score 2b/3) was achieved in 82.1% patients and good outcomes in 34.3%. Symptomatic intracranial hemorrhage occurred in 7.1% and mortality in 25%.
   CONCLUSIONS: In our single-center experience, thrombectomy using the SOFIA as an intermediate or aspiration catheter provided high recanalization rates under everyday conditions.
C1 [Nouri, Nasreddine; Personnic, Thomas; Bala, Fouzi; Bretzner, Martin; Estrade, Laurent; Pruvo, Jean-Pierre; Kazemi, Apolline; Bricout, Nicolas] Univ Lille, CHU Lille, Dept Intervent Neuroradiol, Lille, France.
   [Ferrigno, Marc; Henon, Hilde] Univ Lille, CHU Lille, Stroke Unit, Dept Vasc Neurol, Lille, France.
   [Ferrigno, Marc; Bretzner, Martin; Pruvo, Jean-Pierre; Henon, Hilde] INSERM, U117, Dept Degenerat & Vasc Cognit Disorders, Lille, France.
RP Bricout, N (reprint author), Univ Lille, CHU Lille, Dept Intervent Neuroradiol, Lille, France.
EM bricout.nicolas@gmail.com
OI Bricout, Nicolas/0000-0003-1469-3613; BRETZNER,
   Martin/0000-0002-7594-4159
CR ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35
   Berkhemer OA, 2015, NEW ENGL J MED, V372, P11, DOI 10.1056/NEJMoa1411587
   Campbell BCV, 2015, NEW ENGL J MED, V372, P1009, DOI 10.1056/NEJMoa1414792
   Fahed R, 2016, CEREBROVASC DIS, V41, P298, DOI 10.1159/000444068
   Ferrigno M, 2018, STROKE, V49, P1377, DOI 10.1161/STROKEAHA.118.020490
   Hacke W, 1998, LANCET, V352, P1245, DOI 10.1016/S0140-6736(98)08020-9
   Lapergue B, 2018, INT J STROKE, V13, P87, DOI 10.1177/1747493017711948
   Lars N, 2013, CEREBROVASC DIS EXTR, V3, P103, DOI 10.1159/000354371
   Massari F, 2016, INTERV NEURORADIOL, V22, P325, DOI 10.1177/1591019916632369
   Maus V, 2018, CLIN NEURORADIOL, V28, P327, DOI 10.1007/s00062-017-0566-z
   Mohlenbruch MA, 2017, J NEUROINTERV SURG, V9, P1223, DOI 10.1136/neurintsurg-2016-012812
   Powers WJ, 2015, STROKE, V46, P3020, DOI 10.1161/STR.0000000000000074
   Sandercock P, 2012, LANCET, V379, P2352, DOI 10.1016/S0140-6736(12)60768-5
   Shallwani H, 2018, NEUROSURGERY, V82, P312, DOI 10.1093/neuros/nyx169
   Stampfl S, 2016, J NEUROINTERV SURG, V8, DOI 10.1136/neurintsurg-2015-011801
   Turk AS, 2014, J NEUROINTERV SURG, V6, P260, DOI 10.1136/neurintsurg-2014-011125
   VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604
   Zaidat OO, 2013, STROKE, V44, P2650, DOI 10.1161/STROKEAHA.113.001972
NR 18
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1247
EP E1251
DI 10.1016/j.wneu.2018.11.023
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100151
PM 30447455
DA 2020-05-12
ER

PT J
AU Nunno, A
   Li, Y
   Pieters, TA
   Towner, JE
   Schmidt, T
   Shi, M
   Walter, K
   Li, YM
AF Nunno, Andrew
   Li, Yan
   Pieters, Thomas A.
   Towner, James E.
   Schmidt, Tyler
   Shi, Meichuanzi
   Walter, Kevin
   Li, Yan Michael
TI Risk Factors and Associated Complications of Symptomatic Venous
   Thromboembolism in Patients with Craniotomy for Meningioma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Craniotomy; Deep venous thromboembolism; Meningioma; NSQIP; Pulmonary
   embolism; Venous thromboembolism
ID DEEP-VEIN THROMBOSIS; SINGLE-CENTER; BRAIN-TUMORS; SURGERY
AB OBJECTIVE: Patients undergoing surgical resection of meningioma are at increased risk for developing venous thromboembolism (VTE). The aim of this study was to assess occurrence of VTE in patients who underwent surgical resection of meningioma to determine risk factors and associated complications of VTE.
   METHODS: The American College of Surgeons National Surgical Quality Improvement Project database from 2012 to 2015 was reviewed for patients who had undergone meningioma resection according to primary Current Procedural Terminology codes and International Classification of Diseases, Ninth Revision.
   RESULTS: The study included 5036 patients with meningioma. Rate of VTE was 3.38%, with pulmonary embolism rate of 1.47% and deep venous thrombosis rate of 2.42%. During the first 30 days after surgery, patients with VTE had a mortality rate of 5.88% compared with 1.15% for patients without VTE. Multivariate binary logistic regression analysis determined 5 risk factors for VTE,: age >= 60 years, American Society of Anesthesiologists classification III, operative time >= 310 minutes, ventilator dependence, and preoperative transfusions. Univariate analysis revealed a number of complications significantly associated with VTE occurrence, including unplanned intubation, ventilator use for >48 hours, stroke, sepsis, septic shock, pneumonia, urinary tract infection, and transfusions.
   CONCLUSIONS: Risk factors of VTE and associated complications were identified. Understanding these risk factors provides physicians with further insight in managing this subgroup of patients in a personalized fashion in the perioperative period to minimize the incidence and morbidity of VTE.
C1 [Nunno, Andrew; Li, Yan; Pieters, Thomas A.; Towner, James E.; Schmidt, Tyler; Shi, Meichuanzi; Walter, Kevin; Li, Yan Michael] Univ Rochester, Med Ctr, Dept Neurosurg, Rochester, NY 14642 USA.
   [Li, Yan] Univ Nanjing Med Univ, Dept Bioinformat, Nanjing, Jiangsu, Peoples R China.
RP Li, YM (reprint author), Univ Rochester, Med Ctr, Dept Neurosurg, Rochester, NY 14642 USA.
EM yanm_li@urmc.rochester.edu
CR Anderson FA, 2003, CIRCULATION, V107, pI9, DOI 10.1161/01.CIR.0000078469.07362.E6
   Carrabba G, 2018, J NEURO-ONCOL, V138, P401, DOI 10.1007/s11060-018-2810-z
   Eisenring CV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079170
   FAUNO P, 1990, THROMB RES, V60, P185, DOI 10.1016/0049-3848(90)90179-G
   Gangireddy C, 2007, J VASC SURG, V45, P335, DOI 10.1016/j.jvs.2006.10.034
   Gerber DE, 2007, CANCER, V109, P300, DOI 10.1002/cncr.22405
   Grosse SD, 2016, THROMB RES, V137, P3, DOI 10.1016/j.thromres.2015.11.033
   HART RG, 1995, STROKE, V26, P1471, DOI 10.1161/01.STR.26.8.1471
   Hoefnagel D, 2014, CLIN NEUROL NEUROSUR, V123, P150, DOI 10.1016/j.clineuro.2014.06.001
   Ingraham Angela M, 2010, Adv Surg, V44, P251
   Karhade AV, 2017, J NEURO-ONCOL, V131, P59, DOI 10.1007/s11060-016-2262-2
   Kim JYS, 2015, JAMA SURG, V150, P110, DOI 10.1001/jamasurg.2014.1841
   Kimmell KT, 2014, J NEURO-ONCOL, V120, P567, DOI 10.1007/s11060-014-1587-y
   LEVI ADO, 1991, NEUROSURGERY, V28, P859, DOI 10.1227/00006123-199106000-00012
   Moussa WMM, 2016, CLIN NEUROL NEUROSUR, V144, P1, DOI 10.1016/j.clineuro.2016.02.040
   Ostrom QT, 2013, NEURO-ONCOLOGY, V15, P1, DOI 10.1093/neuonc/not151
   Piper K, 2017, J NEUROSURG-SPINE, V26, P90, DOI 10.3171/2016.6.SPINE1656
   SAWAYA R, 1992, J NEURO-ONCOL, V14, P119
   Sjavik K, 2016, WORLD NEUROSURG, V88, P320, DOI 10.1016/j.wneu.2015.12.077
   Smalberg JH, 2011, ARTERIOSCL THROM VAS, V31, P485, DOI 10.1161/ATVBAHA.110.213371
   Smith TR, 2015, J CLIN NEUROSCI, V22, P519, DOI 10.1016/j.jocn.2014.10.003
   Smith TR, 2014, J NEURO-ONCOL, V120, P347, DOI 10.1007/s11060-014-1557-4
NR 22
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1505
EP E1510
DI 10.1016/j.wneu.2018.11.091
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100184
PM 30468929
DA 2020-05-12
ER

PT J
AU Nyam, TTE
   Lim, SW
   Ho, CH
   Liao, JC
   Wang, JJ
   Chio, CC
   Kuo, JR
   Wang, CC
AF Nyam, Tee-Tau Eric
   Lim, Sher-Wei
   Ho, Chung-Han
   Liao, Jen-Chieh
   Wang, Jhi-Joung
   Chio, Chung-Ching
   Kuo, Jinn-Rung
   Wang, Che-Chuan
TI In-Hospital Mortality After Spinal Surgery in Hemodialysis Patients: An
   11-Year Population-Based Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Age; Comorbidity; End-stage renal disease; Hemodialysis; Hospital
   mortality; Spinal surgery
ID STAGE RENAL-DISEASE; DIALYSIS-DEPENDENT PATIENTS;
   CARDIOVASCULAR-DISEASE; CLINICAL-OUTCOMES; MORBIDITY; FUSION;
   EPIDEMIOLOGY; TAIWAN; TRENDS; RISK
AB BACKGROUND: Patients with end-stage renal disease (ESRD) are at an increased risk of surgical mortality. We aimed to investigate the factors associated with in-hospital mortality in patients with ESRD who underwent spinal surgery, which remains to be determined.
   MATERIAL AND METHODS: An age-and sex-matched cohort study was conducted using the Taiwan Longitudinal Health Insurance Database between January 2000 and December 2012. Kaplane-Meier curves were plotted with log-rank test to compare the differences between these 2 groups. The Cox proportional hazard model was used to estimate the hazard ratio of in-hospital mortality adjusted with potential confounding.
   RESULTS: In total, 4109 participants with pre-existing ESRD and 8218 patients without ESRD were included. The in-hospital mortality in ESRD (10.17%) was greater than without ESRD (1.39%). Spinal surgery patients with preexisting ESRD had a 6.78-fold increase in-hospital mortality risk compared with those without ESRD. Spinal surgery patients with ESRD of any age, male or female, and comorbidities experienced a greater incidence of hospital mortality. In patients with ESRD, operations on spinal cords and spinal canal structures had the greatest hospital mortality (14.87%) compared with spinal fusion (3.46%) or excision or destruction of intervertebral disc (3.01%). Kaplane-Meier survival curves showed that patients with ESRD experienced greater hospital mortality than patients without ESRD in all 3 spinal surgery methods (log rank P < 0.0001).
   CONCLUSIONS: Spinal surgery patients with ESRD have greater in-hospital mortality than patients without ESRD. Age, sex, history of comorbidities, and types of surgical methods were associated with greater in-hospital mortality among patients with ESRD.
C1 [Nyam, Tee-Tau Eric; Lim, Sher-Wei; Liao, Jen-Chieh; Chio, Chung-Ching; Kuo, Jinn-Rung; Wang, Che-Chuan] Chi Mei Med Ctr, Dept Neurosurg, Tainan, Taiwan.
   [Ho, Chung-Han; Wang, Jhi-Joung; Kuo, Jinn-Rung] Chi Mei Med Ctr, Dept Med Res, Tainan, Taiwan.
   [Lim, Sher-Wei] Min Hwei Coll Hlth Care Management, Dept Nursing, Tainan, Taiwan.
   [Ho, Chung-Han] Chia Nan Univ Pharm & Sci, Dept Hosp & Hlth Care Adm, Tainan, Taiwan.
   [Kuo, Jinn-Rung] Southern Taiwan Univ Sci & Technol, Dept Biotechnol, Tainan, Taiwan.
   [Wang, Che-Chuan] Southern Taiwan Univ Sci & Technol, Ctr Gen Educ, Tainan, Taiwan.
RP Kuo, JR (reprint author), Chi Mei Med Ctr, Dept Neurosurg, Tainan, Taiwan.; Kuo, JR (reprint author), Chi Mei Med Ctr, Dept Med Res, Tainan, Taiwan.; Kuo, JR (reprint author), Southern Taiwan Univ Sci & Technol, Dept Biotechnol, Tainan, Taiwan.
EM kuojinnrung@gmail.com
OI Ho, Chung-Han/0000-0001-5925-8477
CR Brakoniecki K, 2017, AM J SURG, V213, P395, DOI 10.1016/j.amjsurg.2016.03.009
   Chae JW, 2011, NEPHRON CLIN PRACT, V117, pC379, DOI 10.1159/000321525
   Chen LH, 2010, EUR SPINE J, V19, P2223, DOI 10.1007/s00586-010-1501-z
   Cherng YG, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191155
   Chikawa T, 2013, J SPINAL DISORD TECH, V26, P321, DOI 10.1097/BSD.0b013e318246af73
   Chikuda H, 2012, J BONE JOINT SURG AM, V94A, P433, DOI 10.2106/JBJS.K.00183
   Collins Allan J, 2012, Am J Kidney Dis, V59, pe1, DOI 10.1053/j.ajkd.2011.11.015
   Ramos RD, 2016, WORLD NEUROSURG, V95, P480, DOI 10.1016/j.wneu.2016.06.096
   Foley RN, 1998, AM J KIDNEY DIS, V32, pS112, DOI 10.1053/ajkd.1998.v32.pm9820470
   Han IH, 2009, SPINE, V34, P1990, DOI 10.1097/BRS.0b013e3181abbdff
   Hoffmann F, 2011, NEPHROL DIAL TRANSPL, V26, P1634, DOI 10.1093/ndt/gfq609
   Jardine AG, 2011, LANCET, V378, P1419, DOI 10.1016/S0140-6736(11)61334-2
   Kuo HW, 2007, AM J KIDNEY DIS, V49, P46, DOI 10.1053/j.ajkd.2006.10.007
   Lad SP, 2009, SURG NEUROL, V71, P66, DOI 10.1016/j.surneu.2008.02.045
   Li G, 2008, SPINE, V33, P1250, DOI 10.1097/BRS.0b013e3181714a44
   Liao JQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084941
   Lin SY, 2016, EUR J INTERN MED, V31, P68, DOI 10.1016/j.ejim.2016.02.012
   Maruo K, 2017, J ORTHOP SCI, V22, P248, DOI 10.1016/j.jos.2016.12.003
   Musallam KM, 2011, LANCET, V378, P1396, DOI 10.1016/S0140-6736(11)61381-0
   National Health Insurance Administration, 2000, NAT HLTH INS ANN STA
   Naughton CA, 2008, AM FAM PHYSICIAN, V78, P743
   Ponnusamy KE, 2015, J BONE JOINT SURG AM, V97A, P1326, DOI 10.2106/JBJS.N.01301
   Qunibi WY, 2015, SEMIN DIALYSIS, V28, P345, DOI 10.1111/sdi.12375
   Schmitges J, 2012, BJU INT, V110, pE183, DOI 10.1111/j.1464-410X.2012.10936.x
   Shen HN, 2012, PANCREAS, V41, P696, DOI 10.1097/MPA.0b013e31823db941
   U.S. Renal Data System, 2012, USRDS 2012 ANN DAT R
   Visconti L, 2016, J CLIN TRANSL ENDOCR, V6, P8, DOI 10.1016/j.jcte.2016.08.002
   Yamada T, 2016, ORTHOPEDICS, V39, pE863, DOI 10.3928/01477447-20160509-06
   Yang WC, 2008, NEPHROL DIAL TRANSPL, V23, P3977, DOI 10.1093/ndt/gfn406
   Yu SC, 2017, WORLD NEUROSURG, V105, P462, DOI 10.1016/j.wneu.2017.06.009
NR 30
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E667
EP E675
DI 10.1016/j.wneu.2018.10.119
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100081
PM 31108081
DA 2020-05-12
ER

PT J
AU Nyam, TTE
   Ho, CH
   Chio, CC
   Lim, SW
   Wang, JJ
   Chang, CH
   Kuo, JR
   Wang, CC
AF Nyam, Tee-Tau Eric
   Ho, Chung-Han
   Chio, Chung-Ching
   Lim, Sher-Wei
   Wang, Jhi-Joung
   Chang, Ching-Hung
   Kuo, Jinn-Rung
   Wang, Che-Chuan
TI Traumatic Brain Injury Increases the Risk of Major Adverse
   Cardiovascular and Cerebrovascular Events: A 13-Year, Population-Based
   Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE ACCI; Cardiovascular; Mortality; MACCE; Stroke; Traumatic brain injury
ID ISCHEMIC-STROKE; DYSFUNCTION; OUTCOMES; MACCE
AB BACKGROUND: Previous studies have indicated traumatic brain injury (TBI) as a risk factor for stroke and myocardial injury. Whether TBI increases new onset of major adverse cardiovascular and cerebrovascular events (MACCE) is not well established.
   METHODS: Patients with a diagnosis of TBI from 2000 to 2012 were 1: 2 age-, sex-, and age-adjusted comorbidities matched with normal population cohorts. The MACCE, which included coronary artery disease, heart failure and arrhythmia, ischemic and hemorrhagic stroke, and death, was defined as one inpatient admission with MACCE diagnosis. The maximum follow-up duration to MACCE after the initial TBI diagnosis was 5 years. The baseline comorbidities before TBI, including hypertension, diabetes mellitus, renal disease, and liver disease, also were considered to estimate the risk of MACCE.
   RESULTS: In total, 16,211 patients with TBI and 32,422 people from the control group were enrolled in the current study. Our results showed that patients with TBI had a 2.77-fold risk of MACCE, 1.72-fold risk of cardiovascular disease, 2.10-fold risk of ischemic stroke, 6.02-fold risk of hemorrhagic stroke, and 3.13-fold risk of mortality compared with the control group (all P < 0.0001) after adjusting the confounding factors. In addition, the trend of cumulated incidence risk among MACCE, cardiovascular disease, ischemic and hemorrhagic stroke, and mortality presented the greatest incidence within the first year after diagnosis and persisted during the 5 years of follow-up.
   CONCLUSIONS: Our results showed that patients with TBI have a significantly greater risk of MACCE than the control group. We hope this information will remind critical-care physicians and neurosurgeons to keep in mind the long-term effects of TBI on MACCE.
C1 [Nyam, Tee-Tau Eric; Chio, Chung-Ching; Lim, Sher-Wei; Chang, Ching-Hung; Kuo, Jinn-Rung; Wang, Che-Chuan] Chi Mei Med Ctr, Dept Neurosurg, Tainan, Taiwan.
   [Ho, Chung-Han; Wang, Jhi-Joung; Kuo, Jinn-Rung] Chi Mei Med Ctr, Dept Med Res, Tainan, Taiwan.
   [Ho, Chung-Han] Chia Nan Univ Pharm & Sci, Dept Hosp & Hlth Care Adm, Tainan, Taiwan.
   [Kuo, Jinn-Rung] Southern Taiwan Univ Sci & Technol, Dept Biotechnol, Tainan, Taiwan.
   [Wang, Che-Chuan] Southern Taiwan Univ Sci & Technol, Ctr Gen Educ, Tainan, Taiwan.
RP Kuo, JR (reprint author), Chi Mei Med Ctr, Dept Neurosurg, Tainan, Taiwan.; Kuo, JR (reprint author), Chi Mei Med Ctr, Dept Med Res, Tainan, Taiwan.; Kuo, JR (reprint author), Southern Taiwan Univ Sci & Technol, Dept Biotechnol, Tainan, Taiwan.
EM kuojinnrung@gmail.com
OI Ho, Chung-Han/0000-0001-5925-8477
FU ChiMei Foundation Hospital Research [CMFHR10682]
FX This research was funded by ChiMei Foundation Hospital Research
   (CMFHR10682) grants.
CR Albrecht JS, 2015, J HEAD TRAUMA REHAB, V30, pE62, DOI 10.1097/HTR.0000000000000035
   Bahloul M, 2006, AM J CRIT CARE, V15, P462
   Bijuklic K, 2017, WIEN KLIN WOCHENSCHR, V129, P243, DOI 10.1007/s00508-016-1148-9
   Burke JF, 2013, NEUROLOGY, V81, P33, DOI 10.1212/WNL.0b013e318297eecf
   Chang WT, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.005466
   Chen YH, 2011, STROKE, V42, P2733, DOI 10.1161/STROKEAHA.111.620112
   Cheng CY, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001468
   Cheng CL, 2011, PHARMACOEPIDEM DR S, V20, P236, DOI 10.1002/pds.2087
   Cheng PL, 2014, SCAND J TRAUMA RESUS, V22, DOI 10.1186/1757-7241-22-7
   Chiu WT, 1997, NEUROL RES, V19, P261, DOI 10.1080/01616412.1997.11740811
   de Groot B, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009598
   Faul M. M., 2010, TRAUMATIC BRAIN INJU
   Fu TS, 2015, J TRAUMA ACUTE CARE, V79, P449, DOI 10.1097/TA.0000000000000733
   Fu WW, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175868
   Glenn MB, 2010, J HEAD TRAUMA REHAB, V25, P68, DOI 10.1097/HTR.0b013e3181be1eab
   Hasanin A, 2016, SCAND J TRAUMA RESUS, V24, DOI 10.1186/s13049-016-0246-z
   Koppie TM, 2008, CANCER-AM CANCER SOC, V112, P2384, DOI 10.1002/cncr.23462
   Kowalski RG, 2017, STROKE, V48, P1802, DOI 10.1161/STROKEAHA.117.017327
   Krishnamoorthy V, 2016, CHEST, V149, P1325, DOI 10.1016/j.chest.2015.12.014
   Kwon Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147065
   Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006
   Lee YK, 2014, SCAND J TRAUMA RESUS, V22, DOI 10.1186/s13049-014-0066-y
   Liao CC, 2014, MAYO CLIN PROC, V89, P163, DOI 10.1016/j.mayocp.2013.09.019
   Liao JQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084941
   Liu SW, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14030230
   Lu DY, 2004, J NEUROTRAUM, V21, P1756, DOI 10.1089/0897715042664885
   Mammo DF, 2017, CARDIOVASC REVASCULA, V18, pS18, DOI 10.1016/j.carrev.2017.03.023
   Mantha S, 2011, J THROMB THROMBOLYS, V32, P334, DOI 10.1007/s11239-011-0609-2
   O'Donnell MJ, 2010, LANCET, V376, P112, DOI 10.1016/S0140-6736(10)60834-3
   Padhy S, 2017, J CLIN DIAGN RES, V11, pUC13, DOI 10.7860/JCDR/2017/27428.10616
   PARSONS LS, 2004, SAS USERS GROUP INT, V29, P1
   Prathep S, 2014, CRIT CARE MED, V42, P142, DOI 10.1097/CCM.0b013e318298a890
   Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455
   Sabate S, 2011, BRIT J ANAESTH, V107, P879, DOI 10.1093/bja/aer268
   Serri K, 2016, SCAND J TRAUMA RESUS, V24, DOI 10.1186/s13049-016-0217-4
   Shen HN, 2012, PANCREAS, V41, P696, DOI 10.1097/MPA.0b013e31823db941
   Xia JG, 2017, CLIN CHIM ACTA, V466, P162, DOI 10.1016/j.cca.2017.01.022
NR 37
TC 3
Z9 3
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E740
EP E753
DI 10.1016/j.wneu.2018.10.130
PG 14
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100089
PM 30391613
DA 2020-05-12
ER

PT J
AU Okuma, Y
   Wake, H
   Teshigawara, K
   Takahashi, Y
   Hishikawa, T
   Yasuhara, T
   Mori, S
   Takahashi, HK
   Date, I
   Nishibori, M
AF Okuma, Yu
   Wake, Hidenori
   Teshigawara, Kiyoshi
   Takahashi, Yu
   Hishikawa, Tomohito
   Yasuhara, Takao
   Mori, Shuji
   Takahashi, Hideo K.
   Date, Isao
   Nishibori, Masahiro
TI Anti-High Mobility Group Box 1 Antibody Therapy May Prevent Cognitive
   Dysfunction After Traumatic Brain Injury
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cognitive dysfunction; Electroencephalography; High mobility group box
   1; Traumatic brain injury
ID RECEPTOR; EPIDEMIOLOGY; INFLAMMATION; ISCHEMIA; MEDIATOR; PROFILE;
   CORTEX; BLOOD; HMG-1; RISK
AB BACKGROUND: High mobility group box 1 (HMGB1) protein plays a key role in triggering inflammatory responses in many diseases. Our previous study showed that HMGB1 is found upstream of secondary damage in traumatic brain injury (TBI). We found that anti-HMGB1 monoclonal antibody (mAb) effectively decreased acute brain damage, including the disruption of the blood-brain barrier, brain edema, and neurologic dysfunction. This effect of anti-HMGB1 mAb lasts for at least 1 week. In this study, we explored subacute effects of anti-HMGB1 mAb after TBI.
   METHODS: TBI was induced in rats by fluid percussion. Anti-HMGB1 mAb or control mAb was given intravenously after TBI. Histochemical staining, plasma levels of HMGB1, motor activity and memory, and video electroencephalography monitoring were evaluated 2 weeks after fluid percussion injury.
   RESULTS: Anti-HMGB1 mAb remarkably attenuated accumulation of activated microglia in the rat cortex in the ipsilateral hemisphere after TBI. Anti-HMGB1 mAb also prevented neuronal death in the hippocampus in the ipsilateral hemisphere after TBI. Treatment of rats with anti-HMGB1 mAb inhibited HMGB1 translocation and suppressed impairment of motor function. The beneficial effects of anti-HMGB1 mAb on motor and cognitive function persisted for 14 days after injury. Treatment with anti-HMGB1 mAb also had positive effects on electroencephalography activity.
   CONCLUSIONS: The beneficial effects of anti-HMGB1 mAb continued during the subacute postinjury phase, suggesting that anti-HMGB1 mAb may prevent cognitive dysfunction after TBI.
C1 [Okuma, Yu; Wake, Hidenori; Teshigawara, Kiyoshi; Takahashi, Yu; Nishibori, Masahiro] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Pharmacol, Okayama, Japan.
   [Okuma, Yu; Takahashi, Yu; Hishikawa, Tomohito; Yasuhara, Takao; Date, Isao] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Neurol Surg, Okayama, Japan.
   [Mori, Shuji] Shujitsu Univ, Sch Pharm, Dept Pharmacol, Okayama, Japan.
   [Takahashi, Hideo K.] Kinki Univ, Dept Pharmacol, Sch Med, Osaka, Japan.
   [Okuma, Yu] Hiroshima City Hiroshima Citizens Hosp, Dept Neurol Surg, Hiroshima, Japan.
RP Nishibori, M (reprint author), Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Pharmacol, Okayama, Japan.
EM mbori@md.okayama-u.ac.jp
OI Okuma, Yu/0000-0003-4769-8111
FU Japan Society for the Promotion of Science KAKENHIMinistry of Education,
   Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for
   the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)
   [18K08909]
FX This work was supported in part by the Japan Society for the Promotion
   of Science KAKENHI Grants-in-Aid for Scientific Research (C), Grant
   Number 18K08909.
CR Abraham E, 2000, J IMMUNOL, V165, P2950, DOI 10.4049/jimmunol.165.6.2950
   Aneja RK, NEUROTRAUMA, DOI [10.1089/neu.2018.5664, DOI 10.1089/NEU.2018.5664]
   BAKER CC, 1980, AM J SURG, V140, P144, DOI 10.1016/0002-9610(80)90431-6
   D'Ambrosio R, 2013, ANN NEUROL, V73, P199, DOI 10.1002/ana.23764
   Demetriades D, 2004, J AM COLL SURGEONS, V198, P20, DOI 10.1016/j.jamcollsurg.2003.09.003
   Eastman CL, 2011, J PHARMACOL EXP THER, V336, P779, DOI 10.1124/jpet.110.175133
   Flores-Rio de la Loza LJ, 2005, REV NEUROLOGIA, V41, P22, DOI 10.33588/rn.4101.2004442
   Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668
   Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316
   Haruma J, 2016, SCI REP-UK, V6, DOI 10.1038/srep37755
   Hayashi K, 2011, EPILEPSIA, V52, P1010, DOI 10.1111/j.1528-1167.2011.03046.x
   HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752
   Hyder AA, 2007, NEUROREHABILITATION, V22, P341
   Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322
   Kobayashi M, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1168-7
   Liu K, 2007, FASEB J, V21, P3904, DOI 10.1096/fj.07-8770com
   MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4
   Muhammad S, 2008, J NEUROSCI, V28, P12023, DOI 10.1523/JNEUROSCI.2435-08.2008
   Nishibori M, 2009, ACTA MED OKAYAMA, V63, P65
   Nosaka N, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0983-9
   Okuma Y, 2014, NEUROPHARMACOLOGY, V85, P18, DOI 10.1016/j.neuropharm.2014.05.007
   Okuma Y, 2013, NEUROSCI LETT, V554, P156, DOI 10.1016/j.neulet.2013.08.058
   Okuma Y, 2012, ANN NEUROL, V72, P373, DOI 10.1002/ana.23602
   Otani N, 2002, J NEUROTRAUM, V19, P1587, DOI 10.1089/089771502762300247
   Park JS, 2006, AM J PHYSIOL-CELL PH, V290, pC917, DOI 10.1152/ajpcell.00401.2005
   Reid AY, 2016, EPILEPSIA, V57, P1558, DOI 10.1111/epi.13486
   SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11
   Seichepine DR, 2013, J NEUROTRAUM, V30, P1299, DOI 10.1089/neu.2012.2690
   SHACKFORD SR, 1993, ARCH SURG-CHICAGO, V128, P571, DOI 10.1001/archsurg.1993.01420170107016
   Shojo H, 2010, NEUROSCIENCE, V171, P1273, DOI 10.1016/j.neuroscience.2010.10.018
   Silver JM, 2009, AM J PSYCHIAT, V166, P653, DOI 10.1176/appi.ajp.2009.08111676
   Sugihara M, 2016, AM J SURG, V211, P179, DOI 10.1016/j.amjsurg.2015.06.025
   Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248
   Yang LY, 2016, NEUROBIOL DIS, V96, P216, DOI 10.1016/j.nbd.2016.08.012
   Yu M, 2006, SHOCK, V26, P174, DOI 10.1097/01.shk.0000225404.51320.82
   Zhang JY, 2011, STROKE, V42, P1420, DOI 10.1161/STROKEAHA.110.598334
NR 36
TC 5
Z9 6
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E864
EP E871
DI 10.1016/j.wneu.2018.10.164
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100104
PM 30391757
DA 2020-05-12
ER

PT J
AU Ozcan-Eksi, EE
   Eksi, MS
   Akcal, MA
AF Ozcan-Eksi, Emel Ece
   Eksi, Murat Sakir
   Akcal, Mehmet Akif
TI Severe Lumbar Intervertebral Disc Degeneration Is Associated with Modic
   Changes and Fatty Infiltration in the Paraspinal Muscles at all Lumbar
   Levels, Except for L1-L2: A Cross-Sectional Analysis of 50 Symptomatic
   Women and 50 Age-Matched Symptomatic Men
SO WORLD NEUROSURGERY
LA English
DT Article
DE Degeneration; Disc; End-plate; Erector spinae; Multifidus; Paraspinal;
   Psoas
ID LOW-BACK-PAIN; MULTIFIDUS MUSCLE; CLASSIFICATION; DISEASE; MORPHOLOGY;
   RELIABILITY; PREVALENCE; GOUTALLIER; HERNIATION; ASYMMETRY
AB BACKGROUND: Low back pain is a common public health problem associated with lumbar intervertebral disc degeneration. It is still unclear, however, whether intervertebral disc degeneration is an isolated process or accompanied by other degenerative events. We analyzed whether disc degeneration was associated with vertebral end-plate changes and fatty infiltration in the paraspinal muscles. We also aimed to identify whether the severity of disc degeneration influenced this association.
   METHODS: Intervertebral disc degeneration, vertebral end-plate changes, and fatty infiltration in the multifidus, erector spinae, and psoas muscles at all lumbar intervertebral disc levels were evaluated on lumbar spine magnetic resonance images of 50 symptomatic women and 50 age-matched symptomatic men.
   RESULTS: The women had greater lumbar intervertebral disc degeneration scores at L4-L5 and L5-S1 and in total. The women had more fatty infiltration in the multifidus and erector spinae muscles at L4-L5 and L5-S1. The men had more fatty infiltration in the psoas muscle at L5-S1. Patients with severe intervertebral disc degeneration were more likely to have increased fatty infiltration in the multifidus and erector spinae muscles. The rate of vertebral end-plate changes was also greater in the patients with severe intervertebral disc degeneration.
   CONCLUSIONS: Severe disc degeneration in the lumbar spine is closely associated with Modic changes and fatty infiltration in the multifidus and erector spinae muscles. We suggest that disc degeneration is not an isolated event but, rather, a continuum of events that could more clearly be shown in future prospective, large sample-size studies.
C1 [Ozcan-Eksi, Emel Ece] Bahcesehir Univ, Sch Med, Dept Phys Med & Rehabil, Istanbul, Turkey.
   [Eksi, Murat Sakir] Acibadem Mehmet Ali Aydinlar Univ, Sch Med, Dept Neurosurg, Istanbul, Turkey.
   [Akcal, Mehmet Akif] Antalya Ataturk State Hosp, Orthoped Surg Clin, Antalya, Turkey.
RP Eksi, MS (reprint author), Acibadem Mehmet Ali Aydinlar Univ, Sch Med, Dept Neurosurg, Istanbul, Turkey.
EM muratsakireksi@gmail.com
RI Eksi, Murat Sakir/I-3699-2012; Ozcan-Eksi, Emel Ece/F-3343-2014
OI Eksi, Murat Sakir/0000-0002-3036-0061; Ozcan-Eksi, Emel
   Ece/0000-0001-5704-7019
CR Altinkaya N, 2016, SKELETAL RADIOL, V45, P73, DOI 10.1007/s00256-015-2252-z
   Battaglia PJ, 2014, J MANIP PHYSIOL THER, V37, P190, DOI 10.1016/j.jmpt.2013.12.010
   Battie MC, 2012, SPINE J, V12, P932, DOI 10.1016/j.spinee.2012.08.020
   Boos N, 2002, SPINE, V27, P2631, DOI 10.1097/00007632-200212010-00002
   Chen YY, 2014, EUR SPINE J, V23, P999, DOI 10.1007/s00586-013-3148-z
   D'hooge R, 2012, MANUAL THER, V17, P584, DOI 10.1016/j.math.2012.06.007
   Engelken F, 2014, J ARTHROPLASTY, V29, P149, DOI 10.1016/j.arth.2013.04.045
   Fortin M, 2015, SCAND J MED SCI SPOR, V25, P880, DOI 10.1111/sms.12301
   Fortin M, 2016, EUR SPINE J, V25, P1452, DOI 10.1007/s00586-016-4503-7
   GOUTALLIER D, 1994, CLIN ORTHOP RELAT R, P78
   Gruber HE, 2014, INT J MED SCI, V11, P748, DOI 10.7150/ijms.8770
   Hicks GE, 2009, SPINE, V34, P1301, DOI 10.1097/BRS.0b013e3181a18263
   Hodges P, 2006, SPINE, V31, P2926, DOI 10.1097/01.brs.0000248453.51165.0b
   Kader DF, 2000, CLIN RADIOL, V55, P145, DOI 10.1053/crad.1999.0340
   Kanna RM, 2014, SPINE J, V14, P300, DOI 10.1016/j.spinee.2013.10.042
   Kjaer P, 2007, BMC MED, V5, DOI 10.1186/1741-7015-5-2
   Kuisma M, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471-2474-9-51
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Luoma K, 2000, SPINE, V25, P487, DOI 10.1097/00007632-200002150-00016
   MacDonald D, 2010, SPINE, V35, P818, DOI 10.1097/BRS.0b013e3181bc98f1
   MacDonald D, 2009, PAIN, V142, P183, DOI 10.1016/j.pain.2008.12.002
   Macdonald DA, 2011, J ORTHOP SPORT PHYS, V41, P155, DOI 10.2519/jospt.2011.3410
   Manson NA, 2006, ORTHOP CLIN N AM, V37, P549, DOI 10.1016/j.ocl.2006.08.001
   Mengiardi B, 2006, RADIOLOGY, V240, P786, DOI 10.1148/radiol.2403050820
   MODIC MT, 1988, RADIOLOGY, V168, P177, DOI 10.1148/radiology.168.1.3289089
   MODIC MT, 1988, RADIOLOGY, V166, P193, DOI 10.1148/radiology.166.1.3336678
   Pfirrmann CWA, 2001, SPINE, V26, P1873, DOI 10.1097/00007632-200109010-00011
   Rajasekaran S, 2004, SPINE, V29, P2654, DOI 10.1097/01.brs.0000148014.15210.64
   Sencan S, 2018, ANN PHYS REHABIL MED, V61, P33, DOI 10.1016/j.rehab.2017.09.005
   Siemionow K, 2011, SPINE, V36, P1333, DOI 10.1097/BRS.0b013e3181f2a177
   Teichtahl AJ, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891-016-1297-z
   THOMPSON JP, 1990, SPINE, V15, P411, DOI 10.1097/00007632-199005000-00012
   WADDELL G, 1987, SPINE, V12, P632, DOI 10.1097/00007632-198709000-00002
   Wang YXJ, 2011, OSTEOPOROSIS INT, V22, P91, DOI 10.1007/s00198-010-1200-y
   West W, 2010, W INDIAN MED J, V59, P192
   Yoshihara K, 2001, SPINE, V26, P622, DOI 10.1097/00007632-200103150-00012
   Yu LP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048074
   Zhao WP, 2000, SPINE, V25, P2191, DOI 10.1097/00007632-200009010-00009
NR 38
TC 3
Z9 3
U1 1
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1069
EP E1077
DI 10.1016/j.wneu.2018.10.229
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100131
PM 30415054
DA 2020-05-12
ER

PT J
AU Panwar, N
   Agrawal, M
   Sinha, VD
AF Panwar, Naresh
   Agrawal, Manish
   Sinha, Virendra D.
TI Postcranioplasty Quantitative Assessment of Intracranial Fluid Dynamics
   and Its Impact on Neurocognition Cranioplasty Effect: A Pilot Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebrovascular hemodynamics; Cine phase cardiac gated MRI;
   Cranioplasty; CSF hydrodynamics; CT perfusion; MoCA score;
   Neurocognitive improvement
ID CEREBRAL-BLOOD-FLOW; DECOMPRESSIVE CRANIECTOMY; HEMODYNAMICS
AB BACKGROUND: This study was done to evaluate the effects of cranioplasty on cerebrohemodynamics (cerebral blood flow [CBF] and mean transient time [MTT]) and cerebrospinal fluid (CSF) hydrodynamics (flow velocities) by using computed tomography perfusion and cardiacgated cine phase magnetic resonance imaging (MRI) (phase contrast [PC] MRI), respectively. It also aims to determine the co-relation between changes in CBF, MTT, and CSF flow dynamics with neurocognitive outcome.
   RESULTS: The mean values of ipsilateral CBF were 27.58 and 41.66 mL/min/100 g in pre- and postcranioplasty patients, respectively (P=0.04). Contralateral CBF also showed improvement from 38.76 to 60.44 mL/min/100 g (P=0.03). Mean values of MTT were found to be decreased in the bilateral hemisphere after cranioplasty. On evaluation of CSF flow velocities by PC MRI, the means of the maximum velocity and peak velocity at the aqueduct of Sylvius were increased from pre-to postcranioplasty as 2.36 to 3.84 cm/s (P=0.048) and 1.21 to 3.50 cm/s (P < 0.001), respectively. Cognitive evaluation showed a significant improvement at 1 (P=0.035) and 6 months (P= 0.002) postcranioplasty.
   METHODS: All cases were subjected to precranioplasty cine phase cardiac gated contrast MRI for CSF dynamics and computed tomography perfusion for cerebrovascular hemodynamic parameters. CBF and related indices were calculated at different regions of interest with the help of the manufacturer's software package of computed tomography perfusion in the ipsilateral hemisphere and simultaneously on the contralateral side. Cine cardiac gated phase contrast MRI was also done for CSF flow velocity at the aqueduct of Sylvius and median aperture (foramen of Magendie). Both studies were again performed on postcranioplasty day 5-7.
   CONCLUSIONS: Cranioplasty can remarkably improve cortical perfusion for both the ipsilateral and contralateral hemispheres. Postoperative increased CSF velocities suggest improved rapid turnover of CSF in a circuit and possibly play a role in good neurologic outcome. Our study shows there is improvement in CSF flow at the aqueduct of Sylvius after cranioplasty. We propose that improvement in CSF circulation along with changes in CBF co-relate well with cognitive outcome (Montreal Cognitive Assessment score).
C1 [Panwar, Naresh; Agrawal, Manish; Sinha, Virendra D.] SMS Med Coll & Hosp, Dept Neurosurg, Jaipur, Rajasthan, India.
RP Agrawal, M (reprint author), SMS Med Coll & Hosp, Dept Neurosurg, Jaipur, Rajasthan, India.
EM manishagrawal30@gmail.com
CR Alvis-Miranda Hernando, 2013, Bull Emerg Trauma, V1, P60
   Chibbaro S, 2013, REV NEUROL-FRANCE, V169, P240, DOI 10.1016/j.neurol.2012.06.016
   Coelho F, 2014, NEUROPSYCH DIS TREAT, V10, P695, DOI 10.2147/NDT.S52875
   Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077
   Decaminada N, 2008, NEURORADIOL J, V21, P459, DOI 10.1177/197140090802100402
   Di Muzio B., MEAN TRANSIT TIME MT
   Erdogan E, 2003, NEUROL INDIA, V51, P479
   Fantini S, 2016, NEUROPHOTONICS, V3, DOI 10.1117/1.NPh.3.3.031411
   Grant FC, 1939, ANN SURG, V110, P488, DOI 10.1097/00000658-193910000-00002
   Halani SH, 2017, NEUROSURGERY, V81, P204, DOI 10.1093/neuros/nyx054
   Hutchinson PJ, 2016, NEW ENGL J MED, V375, P1119, DOI 10.1056/NEJMoa1605215
   Lee JH, 2004, KOREAN J RADIOL, V5, P81, DOI 10.3348/kjr.2004.5.2.81
   Maekawa M, 1999, NEUROL SURG TOKYO, V27, P717
   Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x
   RICHAUD J, 1985, NEUROCHIRURGIE, V31, P183
   Sakamoto S, 2006, CLIN NEUROL NEUROSUR, V108, P583, DOI 10.1016/j.clineuro.2005.03.012
   Schiffer J, 1997, SURG NEUROL, V47, P231, DOI 10.1016/S0090-3019(96)00376-X
   Schirmer CM, 2008, NEUROCRIT CARE, V8, P456, DOI 10.1007/s12028-008-9082-y
   SEGAL DH, 1994, NEUROSURGERY, V34, P729, DOI 10.1227/00006123-199404000-00024
   Stelling H, 2011, BRIT J NEUROSURG, V25, P407, DOI 10.3109/02688697.2011.566385
   Stocchetti N, 2014, NEW ENGL J MED, V370, P2121, DOI 10.1056/NEJMra1208708
   SUZUKI N, 1993, ACTA NEUROCHIR, V122, P49, DOI 10.1007/BF01446986
   Tameem A, 2013, BJA EDUC, V13, P113, DOI 10.1093/bjaceaccp/mkt001
   Winkler P A, 2000, Neurosurg Focus, V8, pe9
   YAMAURA A, 1977, Neurologia Medico-Chirurgica, V17, P43, DOI 10.2176/nmc.17pt1.43
NR 25
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E96
EP E107
DI 10.1016/j.wneu.2018.09.108
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100011
PM 30261402
DA 2020-05-12
ER

PT J
AU Park, SM
   Kim, HJ
   Kim, GU
   Choi, MH
   Chang, BS
   Lee, CK
   Yeom, JS
AF Park, Sang-Min
   Kim, Ho-Joong
   Kim, Gang-Un
   Choi, Min-Ho
   Chang, Bong-Soon
   Lee, Choon-Ki
   Yeom, Jin S.
TI Learning Curve for Lumbar Decompressive Laminectomy in Biportal
   Endoscopic Spinal Surgery Using the Cumulative Summation Test for
   Learning Curve
SO WORLD NEUROSURGERY
LA English
DT Article
DE Biportal endoscopic spinal surgery; Degenerative spine; Lumbar spine;
   Spinal stenosis
ID BILATERAL-DECOMPRESSION; UNILATERAL-LAMINOTOMY; STENOSIS; COMPLICATIONS;
   FUSION; STATE
AB OBJECTIVE: The purpose of the present study was to determine the learning curve for biportal endoscopic spinal surgery (BESS) for decompressive laminectomy in lumbar spinal stenosis using a learning curve cumulative summation test (LC-CUSUM).
   METHODS: The surgeon was proficient in open and microscopic decompressive laminectomy in lumbar spinal stenosis but did not have any experience with BESS or other endoscopic surgery techniques. The learning curve of BESS was investigated using LC-CUSUM analysis. Procedure success was defined as an operative time <75 minutes, the mean operative time with microscopic decompression laminectomy.
   RESULTS: The present study included the first 60 patients who had undergone single-level decompressive laminectomy using BESS by a single orthopedic surgeon. The mean operative time for decompressive laminectomy by BESS was 83.8 +/- 37.9 minutes. The mean operative time in the early learning period (<= 30 cases) and late learning period (second 30 cases) was 105.3 +/- 39.7 minutes and 62.4 +/- 19.9 minutes, respectively. The overall complication rate was similar to 10%. The LC-CUSUM signaled competency for surgery at the 58th operation, indicating that sufficient evidence had accumulated to prove that the surgeon was competent. Thus, a trainee with no experience with BESS had reached adequate performance at 58 cases.
   CONCLUSIONS: The results of the present study have demonstrated that a substantial learning period could be needed before adequate performance can be achieved with lumbar decompressive laminectomy using BESS.
C1 [Park, Sang-Min; Kim, Ho-Joong; Kim, Gang-Un; Choi, Min-Ho; Yeom, Jin S.] Seoul Natl Univ, Coll Med, Spine Ctr, Seongnam, South Korea.
   [Park, Sang-Min; Kim, Ho-Joong; Kim, Gang-Un; Choi, Min-Ho; Yeom, Jin S.] Seoul Natl Univ, Coll Med, Dept Orthoped Surg, Seongnam, South Korea.
   [Park, Sang-Min; Kim, Ho-Joong; Kim, Gang-Un; Choi, Min-Ho; Yeom, Jin S.] Seoul Natl Univ, Bundang Hosp, Seongnam, South Korea.
   [Chang, Bong-Soon; Lee, Choon-Ki] Seoul Natl Univ, Coll Med, Dept Orthoped Surg, Seoul, South Korea.
   [Chang, Bong-Soon; Lee, Choon-Ki] Seoul Natl Univ Hosp, Seoul, South Korea.
RP Yeom, JS (reprint author), Seoul Natl Univ, Coll Med, Spine Ctr, Seongnam, South Korea.; Yeom, JS (reprint author), Seoul Natl Univ, Coll Med, Dept Orthoped Surg, Seongnam, South Korea.; Yeom, JS (reprint author), Seoul Natl Univ, Bundang Hosp, Seongnam, South Korea.
EM highcervical@gmail.com
OI Yeom, Jin S/0000-0002-8241-5335
CR Arai Y, 2014, SPINE, V39, P332, DOI 10.1097/BRS.0000000000000136
   Biau D, 2010, ANAESTHESIA, V65, P755, DOI 10.1111/j.1365-2044.2010.06399.x
   Biau DJ, 2008, BRIT J SURG, V95, P925, DOI 10.1002/bjs.6056
   Biau DJ, 2010, STAT MED, V29, P1900, DOI 10.1002/sim.3947
   Birkenmaier C, 2013, PAIN PHYSICIAN, V16, P335
   Choi CM, 2016, ACTA NEUROCHIR, V158, P459, DOI 10.1007/s00701-015-2670-7
   Choi DJ, 2016, ASIAN SPINE J, V10, P624, DOI 10.4184/asj.2016.10.4.624
   Costa F, 2007, J NEUROSURG-SPINE, V7, P579, DOI 10.3171/SPI-07/12/579
   DeAntoni DJ, 1996, ARTHROSCOPY, V12, P330, DOI 10.1016/S0749-8063(96)90069-9
   Demirayak M, 2015, ASIAN SPINE J, V9, P713, DOI 10.4184/asj.2015.9.5.713
   Dohzono S, 2017, ASIAN SPINE J, V11, P285, DOI 10.4184/asj.2017.11.2.285
   Eum JH, 2016, J NEUROSURG-SPINE, V24, P602, DOI 10.3171/2015.7.SPINE15304
   Forsth P, 2016, NEW ENGL J MED, V374, P1413, DOI 10.1056/NEJMoa1513721
   Hsu HT, 2013, EUR SPINE J, V22, P727, DOI 10.1007/s00586-012-2540-4
   Katz JN, 2008, NEW ENGL J MED, V358, P818, DOI 10.1056/NEJMcp0708097
   Lee YK, 2014, J ARTHROPLASTY, V29, P586, DOI 10.1016/j.arth.2013.07.023
   Mobbs RJ, 2014, J NEUROSURG-SPINE, V21, P179, DOI 10.3171/2014.4.SPINE13420
   Polikandriotis JA, 2013, J ORTHOP, V10, P13, DOI 10.1016/j.jor.2013.01.006
   Sairyo K, 2010, MINIM INVAS NEUROSUR, V53, P175, DOI 10.1055/s-0030-1262814
   Torudom Y, 2016, ASIAN SPINE J, V10, P335, DOI 10.4184/asj.2016.10.2.335
   Uehara M, 2014, ASIAN SPINE J, V8, P768, DOI 10.4184/asj.2014.8.6.768
   Wang HW, 2013, CLIN NEUROL NEUROSUR, V115, P1987, DOI 10.1016/j.clineuro.2013.06.008
   WILLIAMS SM, 1992, BRIT MED J, V304, P1359, DOI 10.1136/bmj.304.6838.1359
   Wong AP, 2012, MINIM INVASIVE SURG, V2012, DOI 10.1155/2012/325095
NR 24
TC 8
Z9 8
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1007
EP E1013
DI 10.1016/j.wneu.2018.10.197
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100122
PM 30404053
DA 2020-05-12
ER

PT J
AU Pokorny, G
   Marchi, L
   Amaral, R
   Jensen, R
   Pimenta, L
AF Pokorny, Gabriel
   Marchi, Luis
   Amaral, Rodrigo
   Jensen, Rubens
   Pimenta, Luiz
TI Lumbar Total Disc Replacement by the Lateral Approach-Up to 10 Years
   Follow-Up
SO WORLD NEUROSURGERY
LA English
DT Article
DE DDD; Heterotopic ossification; Lumbar disc arthroplasty; XL-TDR
ID ANTERIOR LONGITUDINAL LIGAMENT; LOW-BACK-PAIN; HETEROTOPIC OSSIFICATION;
   ARTIFICIAL DISC; MINIMUM; DEGENERATION; EXPERIENCE; MOTION; OUTCOMES;
   FUSION
AB OBJECTIVE: This study aimed to analyze radiologic and clinical results with a minimum 5 years follow-up (FUP) of lateral lumbar total disc replacement for the treatment of symptomatic lumbar degenerative disc disease.
   METHODS: We performed a prospective, single-center, clinical, and radiologic study. Patients were treated with lumbar total disc replacement (extreme lateral total disc replacement) by a lateral transpsoas approach. From 2005 to 2012, 60 patients were enrolled (31 male, 29 female; total, 66 levels; average age, 42.8 years [standard deviation (SD), 9.7 years, range, 22-64 years]; mean body mass index, 26.0 [SD, 3.4]). Clinical end points included visual analog scale and Oswestry Disability Index questionnaires, complications, and reoperation. Radiographic end points included heterotopic ossification (McAfee classification), adjacent level disease, and prosthesis migration or subluxation.
   RESULTS: The mean surgical duration was 122 minutes (SD, 45 minutes) with mean 58 mL (SD, 21 mL) of estimated blood loss. No intraoperative complication occurred. The exceptions were 1 patient with postanesthesia apnea and 2 patients with quadriceps motor deficit (resolved within 4 months with physiotherapy). Of 60 patients, 9 were missed to FUP and 51 (85%) were enrolled in the study, with mean FUP of 92 months (range, 60-122 months). In total, 5 levels (9%; 5 of 55) required to be fused. Both removal of the prostheses and interbody fusion were performed by the lateral transpsoas approach. One patient experienced CrCo allergy (at 2 months); 4 experienced persistent pain from different causes (at 7, 9, 24, and 88 months). Five patients (10%) presented with progression at adjacent levels and 2 (4%) required surgery. One patient required sacroiliac fusion at 63 months. There were no complications during the retrieval surgeries. One partial disc migration occurred but the patient refused retrieval. There was no bone bridging in 9% of the discs (grade 0 heterotopic ossification): grade I, 22%; grade II, 31%; grade III, 20%; grade IV (fusion), 18%. Most heterotopic ossification cases (93%) occurred in the lateral aspect of the disc space, and mostly at the contralateral side of the surgical approach. Patient-reported outcomes significantly improved (P < 0.01) at the last FUP. Visual analog scale back pain score was preoperatively 8.5, early postoperatively 2.5, and at last FUP 3.1. Oswestry Disability Index was preoperatively 55%, early postoperatively 31%, and at last FUP 21%.
   CONCLUSIONS: This study presents mid-term to long-term results of extreme lateral total disc replacement artificial disc for the treatment of lumbar degenerative disease, with fast mobilization, sustained pain relief, and improved physical function. Despite the low rate of ALDis, some discs evolved to ankyloses and others were retrieved. Lumbar artificial disc replacement by the lateral approach seems to be a safe and effective treatment.
C1 [Pokorny, Gabriel; Marchi, Luis; Amaral, Rodrigo; Jensen, Rubens; Pimenta, Luiz] IPC, Sao Paulo, SP, Brazil.
   [Pimenta, Luiz] Univ Calif San Diego, San Diego, CA USA.
RP Pokorny, G (reprint author), IPC, Sao Paulo, SP, Brazil.
EM ghpokorny@gmail.com
RI Pokorny, Gabriel H. O./P-5599-2014; Marchi, Luis/G-2861-2011; Pokorny,
   Gabriel/Q-4745-2017
OI Marchi, Luis/0000-0002-3447-0399; Pokorny, Gabriel/0000-0002-7907-8032
CR Aoki Y, 2004, SPINE, V29, P2621, DOI 10.1097/01.brs.0000146051.11574.b4
   Barbagallo Giuseppe M, 2010, Evid Based Spine Care J, V1, P15, DOI 10.1055/s-0028-1100888
   Buttner-Janz K, 2014, INT J SPINE SURG, V8, DOI 10.14444/1012
   Cheng WK, 2011, J NEUROSURG-SPINE, V14, P466, DOI 10.3171/2010.12.SPINE09429
   Cinotti G, 1996, SPINE, V21, P995, DOI 10.1097/00007632-199604150-00015
   Clavel P, 2017, CLIN NEUROL NEUROSUR, V160, P119, DOI 10.1016/j.clineuro.2017.07.007
   Coutinho T, 2012, COLUNA-COLUMNA, V11, P135
   DePalma MJ, 2011, PAIN MED, V12, P224, DOI 10.1111/j.1526-4637.2010.01045.x
   Dreyer SJ, 1996, ARCH PHYS MED REHAB, V77, P290, DOI 10.1016/S0003-9993(96)90115-X
   Guyer RD, 2016, SPINE, V41, P3, DOI 10.1097/BRS.0000000000001168
   Haefeli M, 2006, SPINE, V31, P1522, DOI 10.1097/01.brs.0000222032.52336.8e
   Huang RC, 2005, SPINE, V30, P1407, DOI 10.1097/01.brs.0000166528.67425.0e
   Kim SW, 2016, SPINE J, V16, P470, DOI 10.1016/j.spinee.2015.07.436
   Laugesen LA, 2017, SPINE, V42, P1657, DOI 10.1097/BRS.0000000000002174
   Lemaire JP, 2005, J SPINAL DISORD TECH, V18, P353, DOI 10.1097/01.bsd.0000172361.07479.6b
   Lu SB, 2015, EUR SPINE J, V24, P2056, DOI 10.1007/s00586-015-3939-5
   Malham GM, 2017, J CLIN NEUROSCI, V39, P176, DOI 10.1016/j.jocn.2017.01.033
   Marchi L, 2012, INT J SPINE SURG, V6, P18, DOI 10.1016/j.ijsp.2011.09.002
   McAfee P.C., 2012, SEMIN SPINE SURG, V34, P37
   McAfee PC, 2003, J SPINAL DISORD TECH, V16, P384, DOI 10.1097/00024720-200308000-00010
   Mehren C, 2006, SPINE, V31, P2802, DOI 10.1097/01.brs.0000245852.70594.d5
   Mobbs RJ, 2017, ASIAN SPINE J, V11, P943, DOI 10.4184/asj.2017.11.6.943
   Moisi M, 2015, CUREUS, V7, DOI 10.7759/cureus.268
   Moreau PE, 2016, ORTHOP TRAUMATOL-SUR, V102, P759, DOI 10.1016/j.otsr.2016.03.012
   Ozgur Burak M, 2006, Spine J, V6, P435, DOI 10.1016/j.spinee.2005.08.012
   Park HJ, 2018, SPINE J, V18, P762, DOI 10.1016/j.spinee.2017.09.003
   Park SJ, 2011, INT ORTHOP, V35, P1197, DOI 10.1007/s00264-010-1095-4
   Patel AA, 2008, SPINE, V33, P1276, DOI 10.1097/BRS.0b013e3181714a1d
   Pimenta L, 2006, J NEUROSURG-SPINE, V5, P556, DOI 10.3171/spi.2006.5.6.556
   Pimenta L, 2015, J NEUROL SURG PART A, V76, P133, DOI 10.1055/s-0034-1394187
   Pimenta L, 2011, J NEUROSURG-SPINE, V14, P38, DOI 10.3171/2010.9.SPINE09865
   Putzier M, 2006, EUR SPINE J, V15, P183, DOI 10.1007/s00586-005-1022-3
   Regan JJ, 2005, ORTHOP CLIN N AM, V36, P323, DOI 10.1016/j.ocl.2005.03.005
   Saavedra-Pozo FM, 2014, OCHSNER J, V14, P78
   Schmidt R, 2010, EUR SPINE J, V19, P1534, DOI 10.1007/s00586-010-1432-8
   Siepe CJ, 2014, SPINE J, V14, P1417, DOI 10.1016/j.spinee.2013.08.028
   Tohmeh AG, 2015, EUR SPINE J, V24, pS331, DOI 10.1007/s00586-015-3843-z
   Tortolani PJ, 2007, J BONE JOINT SURG AM, V89A, P82, DOI 10.2106/JBJS.F.00432
   Uribe Enrique Vargas, 2015, Coluna/Columna, V14, P286, DOI 10.1590/S1808-185120151404152741
   Wuertinger C, 2018, SPINE J, V18, P72, DOI 10.1016/j.spinee.2017.06.035
   Zigler JE, 2012, J NEUROSURG-SPINE, V17, P504, DOI 10.3171/2012.9.SPINE11717
NR 41
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E325
EP E333
DI 10.1016/j.wneu.2018.10.033
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100038
PM 30326312
DA 2020-05-12
ER

PT J
AU Policicchio, D
   Dipellegrini, G
   Muggianu, G
   Pintus, A
   Sgaramella, E
   Santonio, FV
   Boccaletti, R
AF Policicchio, Domenico
   Dipellegrini, Giosue
   Muggianu, Giampiero
   Pintus, Adriana
   Sgaramella, Enrico
   Santonio, Filippo Veneziani
   Boccaletti, Riccardo
TI Flexible Fiber CO2 Laser in Microsurgical Treatment of Intraventricular
   Tumors: Usefulness and Limitations
SO WORLD NEUROSURGERY
LA English
DT Article
DE CO2 laser; Microsurgery; Neurosurgery; OmniGuide; Ventricular tumors
ID CARBON-DIOXIDE LASER; CORPUS CALLOSOTOMY; RESECTION; SAFETY
AB OBJECTIVE: To assess usefulness and limitations of flexible fiber carbon dioxide (CO2) laser in the microsurgical treatment of intraventricular tumors.
   METHODS: We reviewed a series of 9 patients treated with microsurgical resection of intraventricular tumors using a flexible fiber CO2 laser. The lesions involved the third ventricle (8) and the frontal horn of the right lateral ventricle (1). Histology revealed 6 craniopharyngiomas, 1 pituitary macroadenoma, 1 subependymoma, and 1 neurocytoma. In all cases, an interhemispheric transcallosal approach was performed. The laser was used during callosotomy, fornix column sectioning, tumor debulking, and to facilitate tumor dissection. We used a 5-tiered score system to assess laser's efficacy in each surgical step (approach, dissection, debulking): grade 1: laser was not at all helpful, grade 5: laser was extremely helpful. Limits of the instrument also are discussed.
   RESULTS: Gross total resection was achieved in 6 cases and subtotal resection in the remaining 3. Three patients had pulmonary complications treated without clinical sequelae. No laser-related complication was described. Mean utility score observed was 4.2 (range 3-5) during approach, 2.8 (range 2-4) during tumor dissection; and 3.3 (range 2-5) during tumor debulking. Main limits were low hemostatic effect and inefficiency versus calcified and highly vascularized tumors.
   CONCLUSIONS: The CO2 laser proved to be a useful and safe tool that could be used for intraventricular pathology; its design is suitable for narrow surgical corridors like interhemispheric fissure and foramen of Monro; its mainutility is the ability to create precise and relatively bloodless cut (callosotomy, tumor debulking); low hemostatic effect is its main limit.
C1 [Policicchio, Domenico; Dipellegrini, Giosue; Muggianu, Giampiero; Sgaramella, Enrico; Santonio, Filippo Veneziani] Azienda Osped Univ Sassari, Dept Neurosurg, Sassari, Italy.
   [Pintus, Adriana] Azienda Osped Univ Sassari, Dept Anat Pathol, Sassari, Italy.
   [Boccaletti, Riccardo] IRCCS Natl Canc Inst Regina Elena, Dept Neurosurg, Rome, Italy.
RP Policicchio, D (reprint author), Azienda Osped Univ Sassari, Dept Neurosurg, Sassari, Italy.
EM domenico.policicchio@aousassari.it
RI Policicchio, Domenico/AAM-5991-2020
OI Policicchio, Domenico/0000-0003-2031-3808; BOCCALETTI,
   Riccardo/0000-0002-9327-6393
CR Browd SR, 2009, J NEUROSURG-PEDIATR, V4, P280, DOI 10.3171/2009.4.PEDS08349
   Choudhri O, 2015, J NEUROSURG-PEDIATR, V15, P321, DOI 10.3171/2014.10.PEDS13498
   Choudhri O, 2014, OPER NEUROSURG, V10, P34, DOI 10.1227/NEU.0000000000000212
   Consiglieri GD, 2013, WORLD NEUROSURG, V79, P714, DOI 10.1016/j.wneu.2011.12.088
   Falowski S, 2012, STEREOT FUNCT NEUROS, V90, P137, DOI 10.1159/000336337
   Hussain NS, 2016, CUREUS, V8, DOI 10.7759/cureus.628
   Ibrahim TF, 2015, ACTA NEUROCHIR, V157, P2157, DOI 10.1007/s00701-015-2602-6
   Jayarao M, 2011, WORLD NEUROSURG, V76, P149, DOI 10.1016/j.wneu.2010.10.038
   Kassam AB, 2008, J NEUROSURG, V108, P715, DOI 10.3171/JNS/2008/108/4/0715
   Killory BD, 2010, NEUROSURGERY, V66, P1187, DOI 10.1227/01.NEU.0000369195.17553.F3
   Malone HR, 2012, WORLD NEUROSURG, V78, DOI 10.1016/j.wneu.2011.04.031
   Mastronardi L, 2016, CLIN NEUROL NEUROSUR, V145, P35, DOI 10.1016/j.clineuro.2016.03.019
   Rhoton AL, 2002, NEUROSURGERY, V51, pS207, DOI 10.1227/01.NEU.0000028161.91504.4F
   Ryan RW, 2010, J NEUROSURG, V112, P434, DOI 10.3171/2009.7.JNS09356
   Ryan RW, 2009, NEUROSURG FOCUS, V27, DOI 10.3171/2009.6.FOCUS09125
   Schwartz MS, 2018, NEUROSURG FOCUS, V44, DOI 10.3171/2017.12.FOCUS17592
   Takizawa T, 1984, Neurosurg Rev, V7, P135, DOI 10.1007/BF01780696
   Temelkuran B, 2002, NATURE, V420, P650, DOI 10.1038/nature01275
   Araujo JLV, 2017, J NEUROSURG, V127, P209, DOI 10.3171/2016.8.JNS16403
NR 19
TC 0
Z9 0
U1 0
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E427
EP E435
DI 10.1016/j.wneu.2018.10.065
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100050
PM 30342263
DA 2020-05-12
ER

PT J
AU Post, AF
   Dai, JB
   Li, AY
   Maniya, AY
   Haider, S
   Sobotka, S
   Germano, IM
   Choudhri, TF
AF Post, Alexander F.
   Dai, Jennifer B.
   Li, Adam Y.
   Maniya, Akbar Y.
   Haider, Syed
   Sobotka, Stanislaw
   Germano, Isabelle M.
   Choudhri, Tanvir F.
TI Workforce Analysis of Spine Surgeons Involved with Neurological and
   Orthopedic Surgery Residency Training
SO WORLD NEUROSURGERY
LA English
DT Article
DE Academic neurosurgery; Academic orthopedic surgery; Bibliometrics;
   Gender; h-Index; Spine surgery; Workforce analysis
ID HEALTH-CARE EXPENDITURES; UNITED-STATES; TRENDS; WOMEN; REQUIREMENTS;
   NEUROSURGERY; FUTURE
AB OBJECTIVE: Spinal surgery is taught and practiced within 2 different surgical disciplines: neurological surgery and orthopedic surgery. We have provided a unified analysis of spine-focused faculty at U.S. residency programs.
   METHODS: A total of 278 Accreditation Council for Graduate Medical Education training programs were assessed to identify 923 full-time faculty members with a spinal surgery designation, defined by spine fellowship training or surgeon case volume >75% spine surgeries. Faculty were assessed with respect to parent discipline, years of fellowship training, academic rank, gender, and academic productivity (h-index).
   RESULTS: The spine-teaching workforce contains 55% orthopedic surgeons and 45% neurosurgeons with wide gender asymmetry overall and at all faculty ranks. Of the female spine surgeons, those with neurosurgical training (64.44%) nearly doubled the number with orthopedic training (35.56%). Academic productivity increased with academic rank similarly for both genders and subspecialties. Orthopedic spine surgeons had a greater mean fellowship number compared with the neurological spine surgeons. Fellowship time of completion (intraresidency/infolded vs. postresidency) did not significantly affect the h-indexes. Addition of fellowship conferred academic productivity benefit for orthopedic surgeons only.
   CONCLUSIONS: Neurological and orthopedic spine surgery showed similar patterns for the spread of faculty across academic ranks and trends in academic productivity. Marked gender disparity was seen in both neurosurgical and orthopedic surgery, with fewer female spine surgeons seen at every academic rank. Orthopedic spine surgeons had a greater mean fellowship number than did their neurosurgical counterparts, and a lack of fellowship correlated with lower academic productivity in orthopedic, but not neurological, spine surgery.
C1 [Post, Alexander F.; Dai, Jennifer B.; Li, Adam Y.; Maniya, Akbar Y.; Haider, Syed; Sobotka, Stanislaw; Germano, Isabelle M.; Choudhri, Tanvir F.] Icahn Sch Med Mt Sinai, Dept Neurosurg, New York, NY 10029 USA.
RP Post, AF (reprint author), Icahn Sch Med Mt Sinai, Dept Neurosurg, New York, NY 10029 USA.
EM alexander.farber.post@gmail.com
OI Li, Adam/0000-0001-7654-1469
CR American Association of Neurological Surgeons, C NEUR SURG SOC NEUR
   Association of American Medical Colleges, 2016, 2016 PHYS SPEC DAT R
   Association of American Medical Colleges, 2012 PHYS SPEC DAT B
   Baumhauer JF, 2014, FOOT ANKLE INT, V35, P949, DOI 10.1177/1071100714534183
   Bean J, 2008, J NEUROSURG, V109, P377, DOI 10.3171/JNS/2008/109/9/0377
   Benzil DL, 2008, J NEUROSURG, V109, P378, DOI 10.3171/JNS/2008/109/9/0378
   Bernstein J, 2013, CLIN ORTHOP RELAT R, V471, P1754, DOI 10.1007/s11999-013-2978-7
   Chen PR, 2006, NEUROSURGERY, V59, P58
   Cote DJ, 2016, J CLIN NEUROSCI, V31, P106, DOI 10.1016/j.jocn.2016.02.014
   Dall T, 2018, 2018 UPDATE COMPLEXI
   Day CS, 2010, J BONE JOINT SURG AM, V92A, P2328, DOI 10.2106/JBJS.I.01482
   Durham SR, 2008, J NEUROSURG-PEDIATR, V1, P429, DOI 10.3171/PED/2008/1/6/429
   Durham SR, 2009, J NEUROSURG-PEDIATR, V3, P1, DOI 10.3171/2008.10.PEDS08255
   Dvorak MF, 2006, SPINE, V31, P831, DOI 10.1097/01.brs.0000207238.48446.ce
   Farley FA, 2007, J AM ACAD ORTHOP SUR, V15, P268, DOI 10.5435/00124635-200705000-00004
   Gottfried ON, 2005, J NEUROSURG, V102, P202, DOI 10.3171/jns.2005.102.2.0202
   Haralson RH, 2009, JAMA-J AM MED ASSOC, V302, P1586, DOI 10.1001/jama.2009.1489
   Hirsch JE, 2005, P NATL ACAD SCI USA, V102, P16569, DOI 10.1073/pnas.0507655102
   Institute of Medicine (I0M) Report, 2008, RET AG AM BUILD HLTH
   Iorio R, 2008, J BONE JOINT SURG AM, V90A, P1598, DOI 10.2106/JBJS.H.00067
   Jolliff L, WOMEN US ACAD MED SC
   Khan NR, 2014, J NEUROSURG, V120, P746, DOI 10.3171/2013.11.JNS131708
   Lee PP, 1998, J BONE JOINT SURG AM, V80A, P313, DOI 10.2106/00004623-199803000-00002
   Martin BI, 2009, SPINE, V34, P2077, DOI 10.1097/BRS.0b013e3181b1fad1
   O'Lynnger TM, 2015, NEUROSURGERY, V77, pS136, DOI 10.1227/NEU.0000000000000945
   Popp AJ, 2000, AANS B, P7
   Rohde RS, 2016, CLIN ORTHOP RELAT R, V474, P1950, DOI 10.1007/s11999-016-4827-y
   Salsberg ES, 2008, J BONE JOINT SURG AM, V90A, P1143, DOI 10.2106/JBJS.G.01305
   Sawyer JR, 2017, J PEDIATR ORTHOPED, V37, P59, DOI 10.1097/BPO.0000000000000666
   SCHWARTZ WB, 1988, NEW ENGL J MED, V318, P892, DOI 10.1056/NEJM198804073181405
   Schwend RM, 2009, J PEDIATR ORTHOPED, V29, P653, DOI 10.1097/BPO.0b013e3181b76906
   Sielatycki JA, 2016, J ORTHOP TRAUMA, V30, P278, DOI 10.1097/BOT.0000000000000540
   Watkins-Castillo S, 2006, ORTHOPAEDIC PRACTICE
   Weinstein JN, 1998, J BONE JOINT SURG AM, V80A, P327, DOI 10.2106/00004623-199803000-00003
   Zipfel GJ, 2006, NEUROSURGERY S3, V59
   Zipfel Gregory J, 2006, Neurosurgery, V59, pS261
   ZUIDEMA GD, 1977, J NEUROSURG, V46, P135, DOI 10.3171/jns.1977.46.2.0135
NR 37
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E147
EP E155
DI 10.1016/j.wneu.2018.09.152
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100016
PM 30300715
DA 2020-05-12
ER

PT J
AU Qi, YM
   Zeng, YW
   Jiang, CZ
   Liang, B
   Sui, JS
   Zhao, L
   Wang, DL
AF Qi, Yimin
   Zeng, Yiwen
   Jiang, Chunzhi
   Liang, Bin
   Sui, Jisheng
   Zhao, Lei
   Wang, Dalin
TI Comparison of Percutaneous Kyphoplasty Versus Modified Percutaneous
   Kyphoplasty for Treatment of Osteoporotic Vertebral Compression
   Fractures
SO WORLD NEUROSURGERY
LA English
DT Article
DE Balloon; Distraction; Modified percutaneous kyphoplasty; Osteoporotic
   vertebral compression fractures; Percutaneous kyphoplasty; Restoration
ID RISK-FACTORS; VERTEBROPLASTY; POLYMERIZATION; CEMENT; TEMPERATURE;
   PAINFUL
AB BACKGROUND: Although percutaneous kyphoplasty (PKP) is performed to restore the vertebral body height and kyphosis in osteoporotic vertebral compression fractures (OVCFs), the regained height may be lost on balloon deflation. This study compares PKP with modified percutaneous kyphoplasty (MPKP) in terms of the clinical outcomes in treating OVCFs.
   METHODS: Between May 2014 and March 2016, 76 patients with OVCFs were randomly assigned to 2 groups according to the procedure chosen: the PKP group (n = 36) and MPKP group (n = 40). Perioperative parameters, radiologic data, and other clinical parameters were compared between the groups.
   RESULTS: Of the 76 patients, 68 were followed-up for an average of 16 months. Both groups showed similar degrees of postoperative improvement on the visual analog scale, without any significant intergroup difference. However, the MPKP group showed greater improvement in vertebral body height and recovery of the Cobb angle compared with the PKP group. Additionally, the volume of bone cement and operative time were significantly higher in the MPKP group than in the PKP group, whereas the Oswestry Disability Index at the last follow-up was significantly lower in the MPKP group than in the PKP group. The cement leakage ratio and incidence of recurrent vertebral fractures did not differ significantly between the groups.
   CONCLUSIONS: MPKP prevents the loss of vertebral height observed with PKP during balloon deflation in addition to providing greater height, Cobb angle recovery, and quality of life compared with PKP in cases of OVCF.
C1 [Qi, Yimin] Nanjing Med Univ, Dept Grad Sch, Nanjing, Jiangsu, Peoples R China.
   [Zeng, Yiwen; Jiang, Chunzhi; Liang, Bin; Sui, Jisheng; Zhao, Lei; Wang, Dalin] Nanjing Med Univ, Nanjing Hosp 1, Dept Orthopaed Surg, Nanjing, Jiangsu, Peoples R China.
RP Zeng, YW (reprint author), Nanjing Med Univ, Nanjing Hosp 1, Dept Orthopaed Surg, Nanjing, Jiangsu, Peoples R China.
EM 654468946@qq.com
CR Albrecht A, 1999, EUR RADIOL, V9, P1901, DOI 10.1007/s003300050945
   Bae JS, 2017, WORLD NEUROSURG, V99, P387, DOI 10.1016/j.wneu.2016.12.038
   Boonen S, 2011, OSTEOPOROSIS INT, V22, P2915, DOI 10.1007/s00198-011-1639-5
   Chavali R, 2003, AM J NEURORADIOL, V24, P545
   Deramond H, 1999, BONE, V25, p17S, DOI 10.1016/S8756-3282(99)00127-1
   Feldmann I, 2007, ANGLE ORTHOD, V77, P578, DOI 10.2319/062506-257.1
   Fu ZY, 2016, DOSE-RESPONSE, V14, DOI 10.1177/1559325816682867
   Gajewski V, 1990, RUBBER WORLD, V202, P15
   He SC, 2017, PAIN PHYSICIAN, V20, P69
   [何仕诚 He Shicheng], 2002, [中华放射学杂志, Chinese Journal of Radiology], V36, P362
   JEFFERISS CD, 1975, J BONE JOINT SURG BR, V57, P511
   Klezl Z, 2011, INJURY, V42, P1038, DOI 10.1016/j.injury.2011.04.006
   Lamy O, 2014, OSTEOPOROSIS INT, V25, P807, DOI 10.1007/s00198-013-2574-4
   Liu Y, 2017, J PRACT ORTHOPAEDICS, V12, P1116
   Manchikanti L, 2004, BMC MUSCULOSKEL DIS, V5, DOI 10.1186/1471-2474-5-15
   MIGLIARESI C, 1994, BIOMATERIALS, V15, P875, DOI 10.1016/0142-9612(94)90110-4
   Nakashima H, 2015, SPINE, V40, pE831, DOI 10.1097/BRS.0000000000000917
   Old JL, 2004, AM FAM PHYSICIAN, V69, P111
   Pluijm SMF, 2000, J BONE MINER RES, V15, P1564, DOI 10.1359/jbmr.2000.15.8.1564
   Rao RD, 2003, J BONE JOINT SURG AM, V85A, P2010, DOI 10.2106/00004623-200310000-00024
   SENDIJAREVIC A, 1991, J ELASTOM PLAST, V23, P192, DOI 10.1177/009524439102300304
   Shah S, 2017, J BACK MUSCULOSKELET, V30, P1103, DOI 10.3233/BMR-169728
   Svensson HK, 2016, OSTEOPOROSIS INT, V27, P1729, DOI 10.1007/s00198-015-3445-y
   Tan QC, 2015, J SPINAL SURG, V13, P176
   Wang DL, 2018, SPINE, V43, pE341, DOI 10.1097/BRS.0000000000002317
   Xiao Y, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-1754-z
   [徐宝山 Xu Baoshan], 2002, [中华骨科杂志, Chinese Journal of Orthopedics], V22, P323
   Yang HL, 2007, J SPINAL DISORD TECH, V20, P221, DOI 10.1097/01.bsd.0000211273.74238.0e
   Zhan Y, 2017, WORLD NEUROSURG, V101, P633, DOI 10.1016/j.wneu.2017.01.124
   [张亮 Zhang Liang], 2014, [中国组织工程研究, Chinese Journal of Tissue Engineering Research], V18, P2722
   邓忠良, 2003, [中国脊柱脊髓杂志, Chinese Journal of Spine and Spinal Cord], V13, P98
NR 31
TC 1
Z9 2
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1020
EP E1027
DI 10.1016/j.wneu.2018.10.205
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100124
PM 30414526
OA Other Gold
DA 2020-05-12
ER

PT J
AU Rajpal, S
   Burneikiene, S
AF Rajpal, Sharad
   Burneikiene, Sigita
TI Minimally Invasive Sacroiliac Joint Fusion with Cylindrical Threaded
   Implants Using Intraoperative Stereotactic Navigation
SO WORLD NEUROSURGERY
LA English
DT Article
DE Arthrodesis; Minimally invasive surgery; Sacroiliac joint; SI joint
   fusion
ID LOW-BACK-PAIN; OUTCOMES; LUMBAR
AB BACKGROUND: Significant progress in hardware and surgical techniques for sacroiliac joint (SIJ) fusion surgeries has facilitated safer and more efficacious procedures for patients. Triangular-shaped implants for SIJ fusions are the most-studied devices and have demonstrated good short-term and long-term clinical outcomes. Reports on cylindrical threaded implants are very limited. Owing to biomechanical differences in the implants and the surgical techniques required for their placement, previously reported results may not be applicable to cylindrical threaded implants. The aim of this study was to report preliminary clinical experience with minimally invasive SIJ fusion using intraoperative stereotactic navigation and the Rialto SI Fusion System.
   METHODS: We retrospectively reviewed 24 patients who underwent SIJ fusions between May 2015 and October 2017 performed by a single surgeon.
   RESULTS: Mean total satisfaction score was 89.0% +/- 27.6%. A statistically significant reduction (P = 0.0028) in low back pain scores was noted from an average baseline score of 6.6 +/- 2.4 to 3.7 +/- 3.3 postoperatively. Leg pain scores decreased from 4.8 +/- 3.8 to 1.5 +/- 2.9 (P = 0.0034). Mean surgical time was 53.0 +/- 13.9 minutes. It took significantly longer (P = 0.0089) to perform the initial 13 cases (59.9 +/- 15.2 minutes) compared with subsequent cases (45.4 +/- 7.3 minutes). Estimated blood loss was minimal (10.4 +/- 5.2 mL).
   CONCLUSIONS: Minimally invasive SI joint fusion using cylindrical threaded implants can be safely performed with minimal morbidity and good clinical outcomes.
C1 [Rajpal, Sharad] Boulder Neurosurg Associates, Boulder, CO 80303 USA.
   Justin Parker Neurol Inst, Boulder, CO USA.
RP Rajpal, S (reprint author), Boulder Neurosurg Associates, Boulder, CO 80303 USA.
EM rajpal@bnasurg.com
OI Burneikiene, Sigita/0000-0002-6508-4140
CR Beck CE, 2015, CUREUS, V7, DOI 10.7759/cureus.260
   Bruna-Rosso C, 2016, INT J SPINE SURG, V10, DOI 10.14444/3016
   Cross William W, 2018, Open Orthop J, V12, P7, DOI 10.2174/1874325001812010007
   Darr E, 2018, MED DEVICES-EVID RES, V11, P113, DOI 10.2147/MDER.S160989
   Dengler J, 2017, PAIN PHYSICIAN, V20, P537
   DePalma MJ, 2011, PAIN MED, V12, P732, DOI 10.1111/j.1526-4637.2011.01098.x
   Duhon BS, 2016, INT J SPINE SURG, V10, DOI 10.14444/3013
   Ha KY, 2008, SPINE, V33, P1192, DOI 10.1097/BRS.0b013e318170fd35
   Kancherla VK, 2017, ASIAN SPINE J, V11, P120, DOI 10.4184/asj.2017.11.1.120
   Kube Richard A, 2016, Open Orthop J, V10, P679, DOI 10.2174/1874325001610010679
   Lee DJ, 2016, J BIOMED RES, V30, P162, DOI 10.7555/JBR.30.20150090
   Lindsey DP, 2018, WORLD J ORTHOP, V9, P14, DOI 10.5312/wjo.v9.i3.14
   Polly DW, 2016, INT J SPINE SURG, V10, DOI 10.14444/3028
   Rappoport LH, 2017, WORLD NEUROSURG, V101, P493, DOI 10.1016/j.wneu.2017.02.046
   Rudolf Leonard, 2014, Open Orthop J, V8, P375, DOI 10.2174/1874325001408010375
   Rudolf Leonard, 2013, Open Orthop J, V7, P163, DOI 10.2174/1874325001307010163
   Sachs D, 2016, MED DEVICES-EVID RES, V9, P213, DOI 10.2147/MDER.S109276
   Sachs D, 2014, MED DEVICES-EVID RES, V7, P299, DOI 10.2147/MDER.S56491
   Schutz Uwe, 2006, Acta Orthop Belg, V72, P296
   Sembrano JN, 2009, SPINE, V34, pE27, DOI 10.1097/BRS.0b013e31818b8882
   Smith Arnold Graham, 2013, Ann Surg Innov Res, V7, P14, DOI 10.1186/1750-1164-7-14
   Whang P, 2015, INT J SPINE SURG, V9, DOI 10.14444/2006
   Wise CL, 2008, J SPINAL DISORD TECH, V21, P579, DOI 10.1097/BSD.0b013e31815ecc4b
   Yoshihara H, 2012, EUR SPINE J, V21, P1788, DOI 10.1007/s00586-012-2350-8
NR 24
TC 3
Z9 3
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1588
EP E1591
DI 10.1016/j.wneu.2018.11.116
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100195
PM 30476656
DA 2020-05-12
ER

PT J
AU Ramhmdani, S
   Ishida, W
   Perdomo-Pantoja, A
   Witham, TF
   Lo, SFL
   Bydon, A
AF Ramhmdani, Seba
   Ishida, Wataru
   Perdomo-Pantoja, Alexander
   Witham, Timothy F.
   Lo, Sheng-Fu L.
   Bydon, Ali
TI Synovial Cyst as a Marker for Lumbar Instability: A Systematic Review
   and Meta-Analysis
SO WORLD NEUROSURGERY
LA English
DT Review
DE Degenerative disc disease; Facet arthropathy; Lumbar spondylosis;
   Spondylolisthesis; Synovial cyst
ID SURGICAL-TREATMENT; DEGENERATIVE SPONDYLOLISTHESIS; 10-YEAR EXPERIENCE;
   JUXTAFACET CYST; FACET CYSTS; SPINE; DIAGNOSIS; MANAGEMENT; RESECTION;
   RUPTURE
AB BACKGROUND: The pathogenesis of synovial cysts is largely unknown; however, they have been increasingly thought of as markers of spinal facet instability and typically associated with degenerative spondylosis. We specifically investigated the incidence of concomitant synovial cysts with underlying degenerative spondylolisthesis.
   METHODS: A literature search was performed using 4 online databases to assess the association between lumbar synovial cysts and degenerative spinal pathological features. Meta-analyses were performed on the prevalence rates of coexisting degenerative spinal pathological entities and treatment modalities. A random effects model was used to calculate the mean and 95% confidence intervals.
   RESULTS: A total of 17 studies encompassing 824 cases met the inclusion criteria. The pooled prevalence rates of concurrent spondylolisthesis, facet arthropathy, and degenerative disc disease at the same level of the synovial cysts were 42.5% (range, 39.0%-46.1%), 89.3% (range, 79.0%-94.8%), and 48.8% (range, 43.8%-53.9%), respectively. Among these, patients with coexisting spondylolisthesis were more likely to undergo spinal fusion surgery (vs. laminectomy alone) and reoperation than were patients without spondylolisthesis with a pooled odds ratio of 11.5 (95% confidence interval, 4.5-29.1; P < 0.0001) and 2.0 (95% confidence interval, 0.9-4.2; P = 0.088), respectively.
   CONCLUSIONS: Patients with a combination of synovial cysts and degenerative spondylolisthesis are more likely to undergo spinal fusion surgery than laminectomy alone compared with patients with synovial cysts and no preoperative spondylolisthesis. Furthermore, patients with synovial cysts and spondylolisthesis are more likely to require additional fusion surgery. The results from the present review lend credence to the argument that synovial cyst herniation might be a manifestation of an unstable spinal level.
C1 [Ramhmdani, Seba; Bydon, Ali] Johns Hopkins Univ, Sch Med, Spinal Column Biomech & Surg Outcomes Lab, Baltimore, MD 21218 USA.
   [Ramhmdani, Seba; Ishida, Wataru; Perdomo-Pantoja, Alexander; Witham, Timothy F.; Lo, Sheng-Fu L.; Bydon, Ali] Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA.
RP Bydon, A (reprint author), Johns Hopkins Univ, Sch Med, Spinal Column Biomech & Surg Outcomes Lab, Baltimore, MD 21218 USA.; Bydon, A (reprint author), Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA.
EM abydon1@jhmi.edu
RI Ishida, Wataru/J-6566-2019; Perdomo-Pantoja, Alexander/N-9161-2019
OI Ishida, Wataru/0000-0001-7015-3027; Perdomo-Pantoja,
   Alexander/0000-0002-4981-8132
CR ABDULLAH AF, 1984, J NEUROSURG, V60, P617, DOI 10.3171/jns.1984.60.3.0617
   Allen TL, 2009, SPINE J, V9, P387, DOI 10.1016/j.spinee.2008.08.008
   Ayberk G, 2008, NEUROL MED-CHIR, V48, P298, DOI 10.2176/nmc.48.298
   Boviatsis EJ, 2008, EUR SPINE J, V17, P831, DOI 10.1007/s00586-007-0563-z
   Bydon A, 2010, SPINE J, V10, P820, DOI 10.1016/j.spinee.2010.04.010
   Chazen JL, 2018, CLIN IMAG, V49, P7, DOI 10.1016/j.clinimag.2017.10.013
   Deinsberger R, 2006, J SPINAL DISORD TECH, V19, P155, DOI 10.1097/01.bsd.0000188660.31212.83
   Doyle AJ, 2004, SPINE, V29, P874, DOI 10.1097/00007632-200404150-00010
   Duval S, 2000, J AM STAT ASSOC, V95, P89, DOI 10.2307/2669529
   Epstein Nancy E, 2012, Surg Neurol Int, V3, pS157, DOI 10.4103/2152-7806.98576
   Epstein NE, 2004, SPINE, V29, P1049, DOI 10.1097/00007632-200405010-00018
   Farrokh D, 1998, J Belge Radiol, V81, P275
   Fujiwara A, 2000, J SPINAL DISORD, V13, P444, DOI 10.1097/00002517-200010000-00013
   Ganau M, 2013, NEUROL MED-CHIR, V53, P95, DOI 10.2176/nmc.53.95
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Howington JU, 1999, J NEUROSURG, V91, P193, DOI 10.3171/spi.1999.91.2.0193
   HSU KY, 1995, SPINE, V20, P80, DOI 10.1097/00007632-199501000-00015
   Indar R, 2004, SURG-J R COLL SURG E, V2, P141, DOI 10.1016/S1479-666X(04)80074-X
   James A, 2012, J SPINAL DISORD TECH, V25, pE13, DOI 10.1097/BSD.0b013e31822ac4e5
   Jankowski R, 2012, NEUROL NEUROCHIR POL, V46, P456, DOI 10.5114/ninp.2012.31356
   Khan AM, 2005, J SPINAL DISORD TECH, V18, P127, DOI 10.1097/01.bsd.0000156830.68431.70
   LIU SS, 1990, AM J ROENTGENOL, V154, P163, DOI 10.2214/ajr.154.1.2104702
   Lyons MK, 2000, J NEUROSURG, V93, P53, DOI 10.3171/spi.2000.93.1.0053
   Mattei TA, 2013, NEUROSURG REV, V36, P495, DOI 10.1007/s10143-012-0443-9
   Metellus P, 2006, ACTA NEUROCHIR, V148, P47, DOI 10.1007/s00701-005-0650-z
   Oertel JM, 2017, WORLD NEUROSURG, V103, P122, DOI 10.1016/j.wneu.2017.02.075
   Orwin RG, 1983, J ED STAT, V8, P157, DOI DOI 10.2307/1164923
   Parlier-Cuau C, 1999, RADIOLOGY, V210, P509, DOI 10.1148/radiology.210.2.r99fe60509
   REUST P, 1988, ARTHRITIS RHEUM-US, V31, P288, DOI 10.1002/art.1780310220
   Rosenberg A., 2013, TUMORS TUMOR LIKE LE, V2
   Sabo RA, 1996, J NEUROSURG, V85, P560, DOI 10.3171/jns.1996.85.4.0560
   Salmon B, 2001, ACTA NEUROCHIR, V143, P129, DOI 10.1007/s007010170117
   Sandhu FA, 2004, NEUROSURGERY, V54, P107, DOI 10.1227/01.NEU.0000097269.79994.2F
   Sehati Nouzhan, 2006, Neurosurg Focus, V20, pE2
   Shuang F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111695
   Szekanecz Z, 2001, Curr Rheumatol Rep, V3, P53, DOI 10.1007/s11926-001-0051-0
   Tillich M, 2001, NEURORADIOLOGY, V43, P1070, DOI 10.1007/s002340100682
   Trummer M, 2001, J NEUROL NEUROSUR PS, V70, P74, DOI 10.1136/jnnp.70.1.74
   Weiner Bradley K, 2007, J Orthop Surg Res, V2, P5, DOI 10.1186/1749-799X-2-5
   Xu RS, 2010, SPINE, V35, P1044, DOI 10.1097/BRS.0b013e3181bdafed
NR 40
TC 3
Z9 3
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1059
EP E1068
DI 10.1016/j.wneu.2018.10.228
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100130
PM 30415048
DA 2020-05-12
ER

PT J
AU Ramos, RD
   Longo, M
   Gelfand, Y
   Echt, M
   Diebo, BG
   Shah, NV
   Kessler, RA
   Passias, PG
   Yassari, R
AF Ramos, Rafael De la Garza
   Longo, Michael
   Gelfand, Yaroslav
   Echt, Murray
   Diebo, Bassel G.
   Shah, Neil V.
   Kessler, Remi A.
   Passias, Peter G.
   Yassari, Reza
TI Weekend versus Weekday Admission in Spinal Cord Injury and Its Effect on
   Timing of Surgical Intervention
SO WORLD NEUROSURGERY
LA English
DT Article
DE Complications; Outcomes; Spinal cord injury; Spinal fracture; Weekend
ID MORTALITY; OUTCOMES; IMPACT
AB OBJECTIVE: We sought to compare timing of intervention for patients with spinal cord injury (SCI) requiring surgical procedures during weekend versus weekday admissions.
   METHODS: The National Inpatient Sample database from 2012 to 2014 was queried to identify patients with SCI who underwent surgical treatment (decompression with or without stabilization) as an emergent/urgent procedure. Timing of intervention, inpatient morbidity, and inpatient mortality were compared between patients admitted during the weekend versus a weekday. Multiple logistic regression analyses were also performed.
   RESULTS: A total of 9390 patients were identified (mean age 55 years, 73.2% male) from the database, with 34.1% admitted during the weekend and 65.9% during a weekday. The average day of intervention for the entire cohort was 2.8 (SD 3.9, interquartile range 1-4); day 2.7 (standard deviation [SD] 4.0) versus day 2.8 ([SD] 3.9) for patients admitted in a weekend versus weekday (P = 0.418). After controlling for patient age, sex, and injury severity score on multiple logistic regression analysis, weekend admission was not significantly associated with early intervention (odds ratio [OR] 0.99; 95% confidence interval [CI], 0.82-1.21; P = 0.993), complication occurrence (OR 1.09; 95% CI, 0.86-1.38; P = 0.476), or inpatient mortality (OR 0.83; 95% CI, 0.44-1.56; P = 0.563). Patients with complete/American Spinal Injury Association A injuries were more likely to undergo early intervention (OR 2.09; 95% CI, 1.31-3.31; P = 0.002).
   CONCLUSION: In this national study, patients with SCI who were admitted during the weekend received surgical intervention as early as patients admitted during a weekday. Furthermore, no differences in complication or mortality rates between groups were found.
C1 [Ramos, Rafael De la Garza; Longo, Michael; Gelfand, Yaroslav; Echt, Murray; Yassari, Reza] Montefiore Med Ctr, Albert Einstein Coll Med, Spine Res Grp, Bronx, NY 10467 USA.
   [Ramos, Rafael De la Garza; Gelfand, Yaroslav; Echt, Murray; Yassari, Reza] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Neurol Surg, Bronx, NY 10467 USA.
   [Diebo, Bassel G.; Shah, Neil V.] Suny Downstate Med Ctr, Dept Orthopaed, Brooklyn, NY 11203 USA.
   [Kessler, Remi A.] Icahn Sch Med Mt Sinai, Dept Neurosurg, New York, NY 10029 USA.
   [Passias, Peter G.] NYU, Dept Orthopaed, Langone Orthoped Hosp, New York, NY USA.
RP Ramos, RD (reprint author), Montefiore Med Ctr, Albert Einstein Coll Med, Spine Res Grp, Bronx, NY 10467 USA.; Ramos, RD (reprint author), Montefiore Med Ctr, Albert Einstein Coll Med, Dept Neurol Surg, Bronx, NY 10467 USA.
EM rafdelag@gmail.com
RI Shah, Neil V./K-1839-2019; longo, michael/N-7338-2019
OI Shah, Neil V./0000-0002-3439-3071; longo, michael/0000-0002-2462-6118
CR Attenello FJ, 2015, J CLIN NEUROSCI, V22, P1349, DOI 10.1016/j.jocn.2015.02.022
   Bell CM, 2001, NEW ENGL J MED, V345, P663, DOI 10.1056/NEJMsa003376
   Dasenbrock HH, 2012, NEUROSURGERY, V70, P586, DOI 10.1227/NEU.0b013e318232d1ee
   DEVIVO MJ, 1987, ARCH NEUROL-CHICAGO, V44, P872, DOI 10.1001/archneur.1987.00520200074023
   DEVIVO MJ, 1990, ARCH NEUROL-CHICAGO, V47, P687, DOI 10.1001/archneur.1990.00530060101026
   El Tecle NE, 2018, J NEUROSURG-SPINE, V28, P436, DOI 10.3171/2017.7.SPINE17107
   Fassett DR, 2007, J NEUROSURG-SPINE, V7, P277, DOI 10.3171/SPI-07/09/277
   Fawcett JW, 2007, SPINAL CORD, V45, P190, DOI 10.1038/sj.sc.3102007
   Fehlings MG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032037
   Jabbour Pascal, 2008, Neurosurg Focus, V25, pE16, DOI 10.3171/FOC.2008.25.11.E16
   Kostis WJ, 2007, NEW ENGL J MED, V356, P1099, DOI 10.1056/NEJMoa063355
   Nandyala SV, 2013, SPINE, V38, P2178, DOI 10.1097/BRS.0000000000000020
   Pandey AS, 2017, NEUROSURGERY, V81, P87, DOI 10.1093/neuros/nyx015
   ter Wengel PV, 2019, J NEUROTRAUM, V36, P835, DOI 10.1089/neu.2018.5974
   Turner M, 2016, J NEUROL NEUROSUR PS, V87, P138, DOI 10.1136/jnnp-2015-311273
   Wilson JR, 2017, GLOB SPINE J, V7, p95S, DOI 10.1177/2192568217701716
NR 16
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E754
EP E758
DI 10.1016/j.wneu.2018.10.133
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100090
PM 30391609
DA 2020-05-12
ER

PT J
AU Ravindran, K
   Kumar, NG
   Englot, DJ
   Wilson, TJ
   Zuckerman, SL
AF Ravindran, Krishnan
   Kumar, Nishant Ganesh
   Englot, Dario J.
   Wilson, Thomas J.
   Zuckerman, Scott L.
TI Deep Brain Stimulation Versus Peripheral Denervation for Cervical
   Dystonia: A Systematic Review and Meta-Analysis
SO WORLD NEUROSURGERY
LA English
DT Review
DE Cervical dystonia; Deep brain stimulation; Selective peripheral
   degeneration
ID PALLIDAL STIMULATION; SPASMODIC TORTICOLLIS; RATING-SCALES; BENEFIT
AB BACKGROUND: Cervical dystonia is a disabling medical condition that drastically decreases quality of life. Surgical treatment consists of peripheral nerve denervation procedures with or without myectomies or deep brain stimulation (DBS). The current objective was to compare the efficacy of peripheral denervation versus DBS in improving the severity of cervical dystonia through a systematic review and meta-analysis.
   METHODS: A search of PubMed, MEDLINE, EMBASE, and Web of Science electronic databases was conducted in accordance with PRISMA guidelines. Preoperative and postoperative Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) total scores were used to generate standardized mean differences and 95% confidence intervals (CIs), which were combined in a random-effects model. Both mean percentage and absolute reduction in TWSTRS scores were calculated. Absolute reduction was used for forest plots.
   RESULTS: Eighteen studies met the inclusion criteria, comprising 870 patients with 180 (21%) undergoing DBS and 690 (79%) undergoing peripheral denervation procedures. The mean follow-up time was 31.5 months (range, 12-38 months). In assessing the efficacy of each intervention, forest plots revealed significant absolute reduction in total postoperative TWSTRS scores for both peripheral denervation (standardized mean difference 1.54; 95% CI 1.42-1.66) and DBS (standardized mean difference 2.07; 95% CI 1.43-2.71). On subgroup analysis, DBS therapy was significantly associated with improvement in postoperative TWSTRS severity (standardized mean difference 2.08; 95% CI 1.66-2.50) and disability (standardized mean difference 2.12; 95% CI 1.57-2.68) but not pain (standardized mean difference 1.18; 95% CI 0.80-1.55).
   CONCLUSIONS: Both peripheral denervation and DBS are associated with a significant reduction in absolute TWSTRS total score, with no significant difference in the magnitude of reduction observed between the 2 treatments. Further comparative data are needed to better evaluate the long-term results of both interventions.
C1 [Ravindran, Krishnan; Englot, Dario J.; Zuckerman, Scott L.] Vanderbilt Univ, Med Ctr Sch, Dept Neurosurg, Nashville, TN 37235 USA.
   [Kumar, Nishant Ganesh] Univ Michigan, Dept Surg, Sect Plast Surg, Ann Arbor, MI 48109 USA.
   [Wilson, Thomas J.] Stanford Univ, Dept Neurosurg, Stanford, CA 94305 USA.
RP Zuckerman, SL (reprint author), Vanderbilt Univ, Med Ctr Sch, Dept Neurosurg, Nashville, TN 37235 USA.
EM scott.zuckerman@vumc.org
RI Englot, Dario/C-3656-2013
OI Englot, Dario/0000-0001-8373-690X
FU NINDS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Neurological
   Disorders & Stroke (NINDS) [R00 NS097618]
CR Albanese A, 2013, MOVEMENT DISORD, V28, P874, DOI 10.1002/mds.25579
   Andrews C, 2010, J NEUROL NEUROSUR PS, V81, P1383, DOI 10.1136/jnnp.2010.207993
   Bergenheim AT, 2015, J NEUROL NEUROSUR PS, V86, P1307, DOI 10.1136/jnnp-2014-307959
   BERTRAND CM, 1993, SURG NEUROL, V40, P96, DOI 10.1016/0090-3019(93)90118-K
   Cacciola F, 2010, NEUROSURGERY, V67, P957, DOI 10.1227/NEU.0b013e3181ec49c7
   CHAN J, 1991, MOVEMENT DISORD, V6, P119, DOI 10.1002/mds.870060206
   Chung M, 2015, ACTA NEUROCHIR, V157, P435, DOI 10.1007/s00701-014-2291-6
   Cohen-Gadol AA, 2003, J NEUROSURG, V98, P1247, DOI 10.3171/jns.2003.98.6.1247
   Contarino MF, 2014, J NEUROL, V261, P300, DOI 10.1007/s00415-013-7188-4
   Defazio G, 2004, LANCET NEUROL, V3, P673, DOI 10.1016/S1474-4422(04)00907-X
   Defazio Giovanni, 2013, Tremor Other Hyperkinet Mov (N Y), V3, DOI 10.7916/D80C4TGJ
   Fox MD, 2015, JAMA NEUROL, V72, P713, DOI 10.1001/jamaneurol.2015.51
   Huh R, 2010, STEREOT FUNCT NEUROS, V88, P234, DOI 10.1159/000314359
   Hung SW, 2007, NEUROLOGY, V68, P457, DOI 10.1212/01.wnl.0000252932.71306.89
   JANKOVIC J, 1991, NEUROLOGY, V41, P1088, DOI 10.1212/WNL.41.7.1088
   JANKOVIC J, 1995, NEUROLOGY, V45, P1743, DOI 10.1212/WNL.45.9.1743
   Jeong SG, 2009, J KOREAN NEUROSURG S, V46, P346, DOI 10.3340/jkns.2009.46.4.346
   Jost WH, 2013, J NEURAL TRANSM, V120, P487, DOI 10.1007/s00702-012-0887-7
   Kessler KR, 1999, J NEUROL, V246, P265, DOI 10.1007/s004150050345
   Kiss ZHT, 2007, BRAIN, V130, P2879, DOI 10.1093/brain/awm229
   Krauss JK, 1997, J NEUROL NEUROSUR PS, V63, P642, DOI 10.1136/jnnp.63.5.642
   Moro E, 2009, EUR J NEUROL, V16, P506, DOI 10.1111/j.1468-1331.2008.02520.x
   Munchau A, 2001, BRAIN, V124, P769, DOI 10.1093/brain/124.4.769
   Ostrem JL, 2017, NEUROLOGY, V88, P25, DOI 10.1212/WNL.0000000000003451
   Ostrem JL, 2014, PARKINSONISM RELAT D, V20, P432, DOI 10.1016/j.parkreldis.2013.12.012
   Patel S, 2013, BEHAV NEUROL, V26, P275, DOI [10.1155/2013/817426, 10.3233/BEN-2012-120270]
   Sadnicka A, 2013, MOVEMENT DISORD, V28, P1874, DOI 10.1002/mds.25581
   Schjerling L, 2013, J NEUROSURG, V119, P1537, DOI 10.3171/2013.8.JNS13844
   Steeves TD, 2012, MOVEMENT DISORD, V27, P1789, DOI 10.1002/mds.25244
   Tarsy D, 1997, MOVEMENT DISORD, V12, P100, DOI 10.1002/mds.870120117
   Volkmann J, 2014, LANCET NEUROL, V13, P875, DOI 10.1016/S1474-4422(14)70143-7
   Walsh RA, 2013, BRAIN, V136, P761, DOI 10.1093/brain/awt009
   Wang JW, 2015, ACTA NEUROCHIR, V157, P427, DOI 10.1007/s00701-015-2348-1
   Warnke PC, 2015, J NEUROL NEUROSUR PS, V86, P1283, DOI 10.1136/jnnp-2015-310962
   Wilson TJ, 2018, OPER NEUROSURG, V14, P546, DOI 10.1093/ons/opx147
   Witt JL, 2013, MOVEMENT DISORD, V28, P1451, DOI 10.1002/mds.25560
   Yamada K, 2013, NEUROMODULATION, V16, P219, DOI 10.1111/j.1525-1403.2012.00464.x
   Yianni J, 2003, MOVEMENT DISORD, V18, P436, DOI 10.1002/mds.10380
NR 38
TC 2
Z9 2
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E940
EP E946
DI 10.1016/j.wneu.2018.10.178
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100113
PM 30419402
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Rennert, RC
   Martin, JR
   Brandel, MG
   Steinberg, JA
   Santiago-Dieppa, DR
   Wali, AR
   Costantini, TW
   Khalessi, AA
AF Rennert, Robert C.
   Martin, Joel R.
   Brandel, Michael G.
   Steinberg, Jeffrey A.
   Santiago-Dieppa, David R.
   Wali, Arvin R.
   Costantini, Todd W.
   Khalessi, Alexander A.
TI Risk Factors for Venous Thromboembolism After Admission for Traumatic
   Subdural Hematoma at Level I Trauma Center: Large Single-Institution
   Series
SO WORLD NEUROSURGERY
LA English
DT Article
DE Neurosurgical outcomes; Neurotrauma; Subdural hematoma; Thromboembolism
ID BRAIN-INJURY; PROPHYLAXIS; THROMBOSIS; MORTALITY
AB BACKGROUND: Traumatic subdural hematomas (tSDHs) have high morbidity and mortality and often require neurosurgical intervention. The risk of venous thromboembolism (VTE) after tSDH ranges from 1%-20%, yet a consensus chemoprophylaxis protocol does not exist. An increased understanding of VTE risk factors following tSDH may inform development of prophylaxis guidelines.
   METHODS: Retrospective analysis of a prospective, single-institution Level I trauma center database identified the incidence and risk factors for deep venous thrombosis (DVT) and pulmonary embolism (PE) in consecutive tSDH patients from 1990-2015. Univariate and multivariate analyses were used.
   RESULTS: Of 3024 tSDH patients, 682 (22.6%) required neurosurgical intervention in the form of an intracranial pressure monitor, external ventricular drain (EVD), or craniotomy/craniectomy. Overall, 129 (4.3%) and 20 (0.7%) patients were diagnosed with a DVT or PE. Risk factors for DVT included age >= 60 (odds ratio [OR] = 1.5, P = 0.039), preexisting endocrine disorder (OR = 4.1, P = 0.001), hospital length of stay >= 7 days (OR = 4.7, P < 0.001), intensive care unit length of stay >= 7 days (OR = 3.6, P < 0.001), and lower extremity fracture (OR = 2.1, P = 0.004); GCS >3 was associated with a reduced DVT risk (OR = 0.6, P = 0.020). Risk factors for PE included intensive care unit length of stay >= 7 days (OR = 9.7, P < 0.001) and lower extremity fracture (OR = 4.7, P = 0.002). Neurosurgical intervention did not independently increase VTE risk but was associated with increased hospital length of stay (P < 0.001).
   CONCLUSIONS: While overall VTE risk is low following tSDH, elderly patients and those with severe injuries requiring prolonged hospitalizations have increased thrombotic risk. Development of tiered VTE prophylaxis regimens based on early postinjury thrombotic risk profiles warrants future study.
C1 [Rennert, Robert C.; Martin, Joel R.; Brandel, Michael G.; Steinberg, Jeffrey A.; Santiago-Dieppa, David R.; Wali, Arvin R.; Khalessi, Alexander A.] Univ Calif San Diego, Dept Neurol Surg, La Jolla, CA 92093 USA.
   [Costantini, Todd W.] Univ Calif San Diego, Dept Surg, La Jolla, CA 92093 USA.
RP Khalessi, AA (reprint author), Univ Calif San Diego, Dept Neurol Surg, La Jolla, CA 92093 USA.
EM akhalessi@ucsd.edu
OI Santiago-Dieppa, David/0000-0003-4429-0030
CR Abdel-Aziz H, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0814-z
   Abdel-Razeq H, 2010, ANN THORAC MED, V5, P195, DOI 10.4103/1817-1737.69104
   Brakenridge SC, 2013, J TRAUMA ACUTE CARE, V74, P1231, DOI 10.1097/TA.0b013e31828cc9a0
   Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432
   Daley MJ, 2015, AM SURGEON, V81, P207
   Gearhart MM, 2000, SURGERY, V128, P631, DOI 10.1067/msy.2000.108224
   Hamada SR, 2017, ANN INTENSIVE CARE, V7, DOI 10.1186/s13613-017-0315-0
   Knudson MM, 2004, ANN SURG, V240, P490, DOI 10.1097/01.sla.0000137138.40116.6c
   Koc RK, 1997, NEUROSURG REV, V20, P239, DOI 10.1007/BF01105894
   Kumar DR, 2010, CLIN MED RES, V8, P168, DOI 10.3121/cmr.2009.866
   Kwiatt ME, 2012, J TRAUMA ACUTE CARE, V73, P625, DOI 10.1097/TA.0b013e318265cab9
   Laroche M, 2012, NEUROSURGERY, V70, P1334, DOI 10.1227/NEU.0b013e31824d179b
   Leonard Jan, 2016, Trauma Surg Acute Care Open, V1, pe000003, DOI 10.1136/tsaco-2016-000003
   Meizoso JP, 2017, J SURG RES, V207, P138, DOI 10.1016/j.jss.2016.08.072
   Mohseni Shahin, 2012, J Emerg Trauma Shock, V5, P11, DOI 10.4103/0974-2700.93102
   Ryan CG, 2012, J TRAUMA ACUTE CARE, V73, P1348, DOI 10.1097/TA.0b013e31826fcb30
   Scudday T, 2011, J AM COLL SURGEONS, V213, P148, DOI 10.1016/j.jamcollsurg.2011.02.027
   WILBERGER JE, 1990, J TRAUMA, V30, P733, DOI 10.1097/00005373-199006000-00014
NR 18
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E619
EP E626
DI 10.1016/j.wneu.2018.10.114
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100076
PM 31108078
DA 2020-05-12
ER

PT J
AU Ricciardi, L
   Sturiale, CL
   Pucci, R
   Reale, G
   Stifano, V
   Izzo, A
   Perna, A
   Proietti, L
   Forcato, S
   Perla, KMR
   El Boustany, S
   Olivi, A
   Polli, FM
AF Ricciardi, Luca
   Sturiale, Carmelo Lucio
   Pucci, Resi
   Reale, Gabriele
   Stifano, Vito
   Izzo, Alessandro
   Perna, Andrea
   Proietti, Luca
   Forcato, Stefano
   Perla, Krissia M. Rivera
   El Boustany, Stefano
   Olivi, Alessandro
   Polli, Filippo Maria
TI Patient-Oriented Aesthetic Outcome After Lumbar Spine Surgery: A 1-Year
   Follow-Up Prospective Observational Study Comparing Minimally Invasive
   and Standard Open Procedures
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aesthetic; Lumbar spine; Minimally invasive; Patient oriented; Patient
   outcomes; Quality of life
ID QUALITY-OF-LIFE; DEGENERATIVE DISEASE; FUSION PROCEDURES; GUIDELINE
   UPDATE; SPONDYLOLISTHESIS; PERFORMANCE; STENOSIS; SPONDYLOLYSIS;
   FIXATION; RETURN
AB BACKGROUND: Despite recent treatment developments, back pain and related disabilities still represent a challenge for practitioners. Among the available surgical techniques, many different features and outcomes have been investigated; however, aesthetic result was missing among them. The present investigation was designed to prospectively compare patient-oriented aesthetic results after minimally invasive surgery (MIS) and standard open surgery (SOS) for the lumbar spine.
   METHODS: This was a prospective observational study with 1-year follow-up. Patients who underwent SOS were assigned to group 1 and MIS to group 2. Patient-oriented aesthetic result evaluation was collected using a dedicated visual aesthetic analogue scale. The Vancouver Scar Scale was used to exclude objective underlying influencing factors. The Oswestry Disability Index and a 10-point itemized visual analogue scale for back pain were administered to assess the clinical and functional status. Follow-up data were collected before discharge at 1, 6, and 12 months. Statistical analysis was conducted, and P < 0.05 was considered as significant.
   RESULTS: We enrolled 74 patients, 44 in group 1 and 30 in group 2. The 2 groups were homogeneous for demographic and clinical data. No clinical or functional differences were measured at the end of follow-up. Visual aesthetic analogue scale reported greater mean values in group 1 at every follow-up time.
   CONCLUSIONS: Patients seem to prefer the aesthetic result from a single midline incision after SOS compared with MIS. The use of specific techniques could be considered if there is scientific evidence reporting greater aesthetic outcome, having similar clinical and functional ones.
C1 [Ricciardi, Luca; Sturiale, Carmelo Lucio; Stifano, Vito; Izzo, Alessandro; Perna, Andrea; Proietti, Luca; Olivi, Alessandro; Polli, Filippo Maria] Fdn Policlin Univ A Gemelli IRCCS, Rome, Italy.
   [Ricciardi, Luca; Izzo, Alessandro] Mayo Clin, Dept Neurosurg, Jacksonville, FL 32224 USA.
   [Ricciardi, Luca; Stifano, Vito; Izzo, Alessandro; Olivi, Alessandro] Univ Cattolica Sacro Cuore, Ist Neurochirurg, Rome, Italy.
   [Perna, Andrea; Proietti, Luca] Univ Cattolica Sacro Cuore, Ist Ortopedia, Rome, Italy.
   [Pucci, Resi; Reale, Gabriele] Sapienza Univ Roma, Dipartimento Sci Odontostomatol & Maxillo Faccial, Rome, Italy.
   [Forcato, Stefano] Osped Tricase, Pia Fdn Pan, Unita Operat Neurochirurg, Tricase, LE, Italy.
   [Perla, Krissia M. Rivera] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA.
   [El Boustany, Stefano] Univ La Sapienza, ICOT, Unita Operat Ortopedia, Latina, Italy.
RP Ricciardi, L (reprint author), Fdn Policlin Univ A Gemelli IRCCS, Rome, Italy.; Ricciardi, L (reprint author), Mayo Clin, Dept Neurosurg, Jacksonville, FL 32224 USA.; Ricciardi, L (reprint author), Univ Cattolica Sacro Cuore, Ist Neurochirurg, Rome, Italy.
EM ricciardi.lu@gmail.com
RI Stifano, Vito/I-9032-2019; Perna, Andrea/Q-6472-2019; Ricciardi,
   Luca/L-5405-2019; Sturiale, Carmelo Lucio/K-6412-2016
OI Stifano, Vito/0000-0002-5509-9592; Perna, Andrea/0000-0002-2475-1955;
   Ricciardi, Luca/0000-0001-5110-8386; Sturiale, Carmelo
   Lucio/0000-0002-4080-2492
CR Akinduro OO, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.7.FOCUS15269
   Barone M, 2017, EUR ARCH OTO-RHINO-L, V274, P1807, DOI 10.1007/s00405-016-4359-9
   Brundtland GH, 2003, WHO TECH REP SER, V919, P1
   Chang F, 2017, ANN ACAD MED SINGAP, V46, P124
   Chiarotto A, 2018, J CLIN EPIDEMIOL, V102, P23, DOI 10.1016/j.jclinepi.2018.05.006
   Clancy C, 2017, J BACK MUSCULOSKELET, V30, P395, DOI 10.3233/BMR-150318
   de Kunder SL, 2017, SPINE J, V17, P1712, DOI 10.1016/j.spinee.2017.06.018
   Draaijers LJ, 2004, PLAST RECONSTR SURG, V113, P1960, DOI 10.1097/01.PRS.0000122207.28773.56
   Eck JC, 2014, J NEUROSURG-SPINE, V21, P42, DOI 10.3171/2014.4.SPINE14270
   Fearmonti Regina, 2010, Eplasty, V10, pe43
   Freburger JK, 2009, ARCH INTERN MED, V169, P251, DOI 10.1001/archinternmed.2008.543
   Ghogawala Z, 2016, NEW ENGL J MED, V374, P1424, DOI 10.1056/NEJMoa1508788
   Heil J, 2010, BREAST, V19, P470, DOI 10.1016/j.breast.2010.05.004
   Hoy D, 2010, BEST PRACT RES CL RH, V24, P155, DOI 10.1016/j.berh.2009.11.002
   Imada AO, 2017, CUREUS, V9, DOI 10.7759/cureus.1488
   Jacobs WCH, 2013, EUR SPINE J, V22, P1936, DOI 10.1007/s00586-013-2823-4
   Kaiser MG, 2014, J NEUROSURG-SPINE, V21, P2, DOI 10.3171/2014.4.SPINE14257
   Keorochana G, 2017, WORLD NEUROSURG, V102, P340, DOI 10.1016/j.wneu.2017.03.010
   Kim HJ, 2018, INT J MED ROBOT COMP, V14, DOI 10.1002/rcs.1917
   Klassen A, 1996, BRIT J PLAST SURG, V49, P433, DOI 10.1016/S0007-1226(96)90025-9
   Kolcun JPG, 2017, ASIAN SPINE J, V11, P832, DOI 10.4184/asj.2017.11.5.832
   Lau D, 2014, SPINE, V39, P2093, DOI 10.1097/BRS.0000000000000627
   Lee Low Yong, 2017, Asian J Neurosurg, V12, P620, DOI 10.4103/ajns.AJNS_331_16
   Lu VM, 2018, WORLD NEUROSURG, V112, pE859, DOI 10.1016/j.wneu.2018.01.176
   Lu VM, 2017, SPINE, V42, pE177, DOI 10.1097/BRS.0000000000001731
   Miscusi M, 2015, J NEUROSURG-SPINE, V22, P518, DOI 10.3171/2014.10.SPINE131201
   Mundy LR, 2016, AESTHET PLAST SURG, V40, P792, DOI 10.1007/s00266-016-0642-9
   Ng KKM, 2017, J ORTHOP SURG-HONG K, V25, P1, DOI 10.1177/2309499017716254
   Omidi-Kashani F, 2014, ASIAN SPINE J, V8, P856, DOI 10.4184/asj.2014.8.6.856
   Oxland TR, 2000, EUR SPINE J, V9, pS95, DOI 10.1007/PL00010028
   Radcliff KE, 2015, SPINE J, V15, P336, DOI 10.1016/j.spinee.2014.09.022
   Resnick DK, 2014, J NEUROSURG-SPINE, V21, P62, DOI 10.3171/2014.4.SPINE14275
   Ricciardi L, 2018, WORLD NEUROSURG, V120, P153, DOI 10.1016/j.wneu.2018.08.204
   Ricciardi L, 2018, WORLD NEUROSURG, V115, pE659, DOI 10.1016/j.wneu.2018.04.126
   Schulte TL, 2016, EUR SPINE J, V25, P2359, DOI 10.1007/s00586-015-4177-6
   Sclafani JA, 2014, CLIN ORTHOP RELAT R, V472, P1711, DOI 10.1007/s11999-014-3495-z
   Siasios Ioannis, 2018, J Spine Surg, V4, P130, DOI 10.21037/jss.2018.03.10
   Tamburrelli FC, 2018, EUR SPINE J, V27, P237, DOI 10.1007/s00586-018-5627-8
   Tan JH, 2018, EUR SPINE J, V27, P1877, DOI 10.1007/s00586-018-5630-0
   Uribe JS, 2017, NEUROSURGERY, V80, P489, DOI 10.1093/neuros/nyw072
   Vercelli S, 2009, DISABIL REHABIL, V31, P2055, DOI [10.3109/09638280902874196a, 10.3109/09638280902874196]
   Wahmann MS, 2018, AESTHET PLAST SURG, V42, P1635, DOI 10.1007/s00266-018-1199-6
   Wang JC, 2012, SPINE, V37, pS133, DOI 10.1097/BRS.0b013e31826cadf2
   Wang X, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2398-6
   Yavin D, 2017, NEUROSURGERY, V80, P701, DOI 10.1093/neuros/nyw162
   Zanirato A, 2018, EUR SPINE J, V27, P2272, DOI 10.1007/s00586-018-5535-y
NR 46
TC 2
Z9 2
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1041
EP E1046
DI 10.1016/j.wneu.2018.10.208
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100127
PM 30415051
DA 2020-05-12
ER

PT J
AU Rieder, MD
   Oses, JP
   Kutchak, FM
   Sartor, M
   Cecchini, A
   Rodolphi, MS
   Wiener, CD
   Kopczynski, A
   Muller, AP
   Strogulski, NR
   Carteri, RB
   Hansel, G
   Bianchin, MM
   Portela, LV
AF Rieder, Marcelo de Mello
   Oses, Jean Pierre
   Kutchak, Fernanda Machado
   Sartor, Monia
   Cecchini, Andre
   Rodolphi, Marcelo Salimen
   Wiener, Carolina David
   Kopczynski, Afonso
   Muller, Alexandre Pastoris
   Strogulski, Nathan Ryzewski
   Carteri, Randhall B.
   Hansel, Gisele
   Bianchin, Marino Muxfeldt
   Portela, Luis Valmor
TI Serum Biomarkers and Clinical Outcomes in Traumatic Spinal Cord Injury:
   Prospective Cohort Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE GDNF; IL-6; NGF; NSE; Serum biomarkers; Spinal cord injury
ID NEURON-SPECIFIC ENOLASE; CEREBROSPINAL-FLUID; SEVERITY; PROTEIN;
   INTERLEUKIN-1-BETA; NEUROPROTECTION; REGENERATION; EXPRESSION;
   ELEVATION; CYTOKINES
AB BACKGROUND: A plethora of reactive cellular responses emerge immediately after a traumatic spinal cord injury (SCI) and may influence the patient's outcomes. We investigated whether serum concentrations of neuronspecific enolase, interleukin-6, glial-derived neurotrophic factor, and neurotrophic growth factor reflect the acute-phase responses to different etiologies of SCI and may serve as predictive biomarkers of neurologic and functional outcomes.
   METHODS: Fifty-two patients were admitted to the intensive care unit after SCI due to traffic accidents, falls, and firearm wounds and had blood samples collected within 48 hours and 7 days after SCI. Thirty-six healthy subjects with no history of SCI were included as controls. Neurologic and functional status was evaluated on the basis of American Spinal Injury Association and Functional Independence Measure scores over a period of 48 hours and 6 months after SCI.
   RESULTS: Serum NSE increased significantly 48 hours and 7 days after SCI compared with controls, while interleukin-6 increased only at 48 hours. In contrast, the neurotrophic growth factor level significantly decreased 48 hours and 7 days after SCI. Serum glial-derived neurotrophic factor level did not differ from control at any time point. Also, there was no significant difference in biomarker concentrations between the etiologies of SCI or the level of spinal injury. There were no correlations between biomarker levels at 48 hours with neurologic or functional outcomes 7 days and 6 months after SCI.
   CONCLUSIONS: Our results suggest expansive axonal damage coupled with an acute proinflammatory response after SCI. However, in our study biomarker concentration did not correlate with short- or long-term prognosis, such as survival rate or sensory and motor function.
C1 [Rieder, Marcelo de Mello; Kutchak, Fernanda Machado; Bianchin, Marino Muxfeldt] Univ Fed Rio Grande do Sul, Postgrad Program Med Sci, Porto Alegre, RS, Brazil.
   [Rieder, Marcelo de Mello; Kutchak, Fernanda Machado; Bianchin, Marino Muxfeldt] HCPA, BRAIN Ctr Expt Res, Porto Alegre, RS, Brazil.
   [Sartor, Monia; Rodolphi, Marcelo Salimen; Kopczynski, Afonso; Strogulski, Nathan Ryzewski; Carteri, Randhall B.; Portela, Luis Valmor] Univ Fed Rio Grande do Sul, Postgrad Program Biochem, Lab Neurotrauma & Biomarkers, Dept Biochem,ICBS, Porto Alegre, RS, Brazil.
   [Rieder, Marcelo de Mello; Kutchak, Fernanda Machado; Cecchini, Andre] Hosp Cristo Redentor, Porto Alegre, RS, Brazil.
   [Oses, Jean Pierre; Wiener, Carolina David] Univ Catolica Pelotas, Postgrad Program Hlth & Behav, Pelotas, Brazil.
   [Cecchini, Andre] Univ Luterana Brazil, Dept Legal Med & Neurol, Canoas, RS, Brazil.
   [Muller, Alexandre Pastoris; Hansel, Gisele] Univ Extremo Sul Catarinense, Lab Exercise Biochem & Physiol, Santa Catarina, SC, Brazil.
   [Hansel, Gisele] Univ Penn, Penn Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA.
   [Hansel, Gisele] Univ Penn, Perelman Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA.
RP Portela, LV (reprint author), Univ Fed Rio Grande do Sul, Postgrad Program Biochem, Lab Neurotrauma & Biomarkers, Dept Biochem,ICBS, Porto Alegre, RS, Brazil.
EM roskaportela@gmail.com
RI Bianchin, Marino/V-5956-2019; Hansel, Gisele/A-9150-2015; Carteri,
   Randhall/A-9015-2017
OI Hansel, Gisele/0000-0001-5048-1293; Carteri,
   Randhall/0000-0003-4124-9470; Oses, Jean Pierre/0000-0002-2012-273X
FU FAPERGSFoundation for Research Support of the State of Rio Grande do Sul
   (FAPERGS) [1010267]; PPSUS-FAPERGS [17/2551-0001];
   FAPERGS/PRONEXFoundation for Research Support of the State of Rio Grande
   do Sul (FAPERGS) [16/2551-0000499-4]; CAPESCAPES [PNPD 1663]; Program
   Science without Borders CNPQ [4011645/2012-6]; CNPqNational Council for
   Scientific and Technological Development (CNPq) [INNT 5465346/2014-6]
FX This research was funded by resources from Brazilian Agencies FAPERGS
   1010267, PPSUS-FAPERGS 17/2551-0001, FAPERGS/PRONEX 16/2551-0000499-4,
   CAPES PNPD 1663, Program Science without Borders CNPQ 4011645/2012-6,
   and CNPq INNT 5465346/2014-6. No competing financial conflicts of
   interest exist.
CR Ahadi R, 2015, SPINE, V40, pE823, DOI 10.1097/BRS.0000000000000654
   Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812
   Bohmer AE, 2011, NEUROSURGERY, V68, P1624, DOI 10.1227/NEU.0b013e318214a81f
   Bradbury EJ, 2006, NAT REV NEUROSCI, V7, P644, DOI 10.1038/nrn1964
   Brisby H, 1999, SPINE, V24, P742, DOI 10.1097/00007632-199904150-00003
   Cao F, 2008, J CLIN NEUROSCI, V15, P541, DOI 10.1016/j.jocn.2007.05.014
   Chiaretti A, 2014, EUR REV MED PHARMACO, V18, P894
   Chiaretti A, 2008, J NEUROTRAUM, V25, P1477, DOI 10.1089/neu.2008.0638
   Cordaro M, 2017, J NEUROTRAUM, V34, P3027, DOI 10.1089/neu.2016.4678
   Donnelly DJ, 2008, EXP NEUROL, V209, P378, DOI 10.1016/j.expneurol.2007.06.009
   Dumont RJ, 2001, CLIN NEUROPHARMACOL, V24, P254, DOI 10.1097/00002826-200109000-00002
   Elkabes S, 2014, EXP NEUROL, V259, P28, DOI 10.1016/j.expneurol.2014.01.008
   Fu ES, 2005, J NEUROSURG ANESTH, V17, P82, DOI 10.1097/01.ana.0000163199.10365.38
   Fumagalli F, 2008, EUR J PHARMACOL, V578, P19, DOI 10.1016/j.ejphar.2007.09.021
   Haque A, 2016, METAB BRAIN DIS, V31, P487, DOI 10.1007/s11011-016-9801-6
   Keefe KM, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030548
   Kirshblum SC, 2011, J SPINAL CORD MED, V34, P547, DOI 10.1179/107902611X13186000420242
   Kwon BK, 2017, J NEUROTRAUM, V34, P567, DOI 10.1089/neu.2016.4435
   Kwon BK, 2010, J NEUROTRAUM, V27, P669, DOI 10.1089/neu.2009.1080
   Lee BB, 2014, SPINAL CORD, V52, P110, DOI 10.1038/sc.2012.158
   Loy DN, 2005, NEUROSURGERY, V56, P391, DOI 10.1227/01.NEU.0000148906.83616.D2
   Mukaino M, 2010, EXP NEUROL, V224, P403, DOI 10.1016/j.expneurol.2010.04.020
   Murakami Y, 2002, J NEUROL SCI, V198, P63, DOI 10.1016/S0022-510X(02)00080-1
   Ota T, 1996, SPINAL CORD, V34, P531, DOI 10.1038/sc.1996.96
   Oyinbo CA, 2011, ACTA NEUROBIOL EXP, V71, P281
   Popovich PG, 2002, J NEUROPATH EXP NEUR, V61, P623, DOI 10.1093/jnen/61.7.623
   Popovich PG, 2003, TRENDS PHARMACOL SCI, V24, P13, DOI 10.1016/S0165-6147(02)00006-8
   Pouw MH, 2014, SPINAL CORD, V52, P428, DOI 10.1038/sc.2014.26
   Pouw MH, 2009, SPINAL CORD, V47, P519, DOI 10.1038/sc.2008.176
   Ramer MS, 2000, NATURE, V403, P312, DOI 10.1038/35002084
   Santos D, 2016, NEURAL PLAST, V2016, DOI 10.1155/2016/4969523
   Silva NA, 2014, PROG NEUROBIOL, V114, P25, DOI 10.1016/j.pneurobio.2013.11.002
   Singh A, 2014, CLIN EPIDEMIOL, V6, P309, DOI 10.2147/CLEP.S68889
   Stefani MA, 2017, ANN CLIN TRANSL NEUR, V4, P392, DOI 10.1002/acn3.416
   Wiener CD, 2017, J NEUROIMMUNOL, V307, P33, DOI 10.1016/j.jneuroim.2017.03.003
   Yang LQ, 2004, SPINE, V29, P966, DOI 10.1097/00007632-200405010-00004
   Zhang HY, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-130
NR 37
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1028
EP E1036
DI 10.1016/j.wneu.2018.10.206
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100125
PM 30414523
DA 2020-05-12
ER

PT J
AU Salgado-Lopez, L
   de Quintana-Schmidt, C
   Nieto, RB
   Arnall, CR
   Rodriguez, RR
   Holzapfel, MJA
   Molet-Teixido, J
AF Salgado-Lopez, Laura
   de Quintana-Schmidt, Cristian
   Belvis Nieto, Robert
   Roig Arnall, Carles
   Rodriguez Rodriguez, Rodrigo
   Alvarez Holzapfel, Maria Jesus
   Molet-Teixido, Joan
TI Efficacy of Sphenopalatine Ganglion Radiofrequency in Refractory Chronic
   Cluster Headache
SO WORLD NEUROSURGERY
LA English
DT Article
DE Chronic cluster headache; Pulsed radiofrequency; Radiofrequency
   ablation; Refractory; Sphenopalatine ganglion
ID DEEP-BRAIN-STIMULATION; PULSED RADIOFREQUENCY; TOMOGRAPHY; MANAGEMENT;
   ABLATION; BLOCK
AB BACKGROUND: In the literature, there are only short series of radiofrequency of the sphenopalatine ganglion (SPG) to treat chronic refractory cluster headache (CCHr) with variable results. Furthermore, there is no consensus on which methodology to use: radiofrequency ablation (RFA) or pulsed radiofrequency (PRF).
   METHODS: We conducted a prospective analysis of 37 patients with CCHr who underwent RFA or PRF of the SPG in our center between 2004 and 2015.
   RESULTS: The mean age of the patients was 40 years (range, 26-59 years). PRF was performed in 24 patients, and RFA was performed in 13 patients. A total of 5 patients (13.5%) experienced complete clinical relief of both pain and parasympathetic symptoms, 21 patients (56.8%) had partial and transient relief, and 11 patients (29.7%) did not improve. There was no evidence of significant superiority of one radiofrequency modality over the other (P = 0.48). There were no complications associated with the technique. The passage of time tended to decrease the efficacy of both techniques (P < 0.001). The mean follow-up was 68.1 months (range, 15-148 months). To our knowledge, this is the series with the largest number of patients and the longest follow-up period published in the literature.
   CONCLUSIONS: Radiofrequency of the SPG is a safe, fast, and partially effective method for the treatment of CCHr. Given its low rate of complications and its low economic cost, we think it should be one of the first invasive treatment options, prior to techniques with greater morbidity and mortality, such as neuromodulation.
C1 [Salgado-Lopez, Laura; de Quintana-Schmidt, Cristian; Rodriguez Rodriguez, Rodrigo; Alvarez Holzapfel, Maria Jesus; Molet-Teixido, Joan] Univ Hosp Santa Creu & St Pau, Dept Neurosurg, Barcelona, Spain.
   [Belvis Nieto, Robert; Roig Arnall, Carles] Univ Hosp Santa Creu & St Pau, Dept Neurol, Barcelona, Spain.
RP Salgado-Lopez, L (reprint author), Univ Hosp Santa Creu & St Pau, Dept Neurosurg, Barcelona, Spain.
EM lsalgado@santpau.cat
CR Bes A, 2013, CEPHALALGIA, V33, P629, DOI 10.1177/0333102413485658
   Chua NHL, 2011, PAIN PRACT, V11, P439, DOI 10.1111/j.1533-2500.2010.00445.x
   Bendersky DC, 2015, PAIN PRACT, V15, pE40, DOI 10.1111/papr.12288
   Cook N, 1978, Res Clin Stud Headache, V5, P86
   de Quintana-Schmidt C, 2010, REV NEUROLOGIA, V51, P19, DOI 10.33588/rn.5101.2009484
   Filippini-De Moor GPG, 1999, PAIN CLINIC, V11, P285
   Gaul C, 2011, CEPHALALGIA, V31, P1664, DOI 10.1177/0333102411425866
   Jurgens TP, 2009, PAIN, V146, P84, DOI 10.1016/j.pain.2009.07.006
   Lad SP, 2007, NEUROSURGERY, V60, P580, DOI 10.1227/01.NEU.0000255348.33582.DE
   Leone M, 2009, NEUROL SCI, V30, pS43, DOI 10.1007/s10072-009-0057-3
   Leone M, 2012, CEPHALALGIA, V32, P267, DOI 10.1177/0333102411436123
   Loomba V, 2016, PAIN PHYSICIAN, V19, pE1093
   Luo F, 2016, CEPHALALGIA, V36, P106, DOI 10.1177/0333102415580113
   MEYER JS, 1970, ARCHIV OTOLARYNGOL, V92, P475
   Mitsikostas DD, 2014, J HEADACHE PAIN, V15, DOI 10.1186/1129-2377-15-79
   Narouze S, 2009, HEADACHE, V49, P571, DOI 10.1111/j.1526-4610.2008.01226.x
   Narouze SN, 2010, CURR PAIN HEADACHE R, V14, P160, DOI 10.1007/s11916-010-0100-3
   Pedersen JL, 2013, CEPHALALGIA, V33, P1179, DOI 10.1177/0333102413489040
   Pipolo C, 2010, NEUROL SCI, V31, P197, DOI 10.1007/s10072-010-0325-2
   Placentino M, 2014, WORLD NEUROSURG, V81
   Robbins MS, 2016, HEADACHE, V56, P240, DOI 10.1111/head.12729
   Rozen Todd D, 2002, Curr Pain Headache Rep, V6, P57, DOI 10.1007/s11916-002-0025-6
   SALAR G, 1987, ACTA NEUROCHIR, V84, P24, DOI 10.1007/BF01456346
   Sanders M, 1997, J NEUROSURG, V87, P876, DOI 10.3171/jns.1997.87.6.0876
   Strahle J, 2014, WORLD NEUROSURG, V81, P306, DOI 10.1016/j.wneu.2013.03.006
   Tepper SJ, 2017, HEADACHE, V57, P14, DOI 10.1111/head.13035
   Tepper SJ, 2013, HEADACHE, V53, P1183, DOI 10.1111/head.12148
   Torkamani M, 2015, HEADACHE, V55, P287, DOI 10.1111/head.12486
   van Kleef M, 2009, PAIN PRACT, V9, P435, DOI 10.1111/j.1533-2500.2009.00331.x
   WALDMAN SD, 1993, REGION ANESTH, V18, P274
NR 30
TC 2
Z9 3
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E262
EP E269
DI 10.1016/j.wneu.2018.10.007
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100029
PM 30315985
DA 2020-05-12
ER

PT J
AU Scagnelli, RJ
   Patel, V
   Peris-Celda, M
   Kenning, TJ
   Pinheiro-Neto, CD
AF Scagnelli, Robert J.
   Patel, Varun
   Peris-Celda, Maria
   Kenning, Tyler J.
   Pinheiro-Neto, Carlos D.
TI Implementation of Free Mucosal Graft Technique for Sellar Reconstruction
   After Pituitary Surgery: Outcomes of 158 Consecutive Patients
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebrospinal fluid leak; Free mucosal graft; Nasoseptal flap; Pituitary
   surgery; Sellar reconstruction
ID ENDOSCOPIC ENDONASAL APPROACH; NASOSEPTAL FLAP; MORBIDITY; ADENOMAS
AB BACKGROUND: Cerebrospinal fluid (CSF) leak is a common complication after surgeries involving sellar reconstruction. Various techniques, including the nasoseptal flap, have been developed to limit postoperative CSF leak. However, the nasoseptal flap causes complications owing to donor site morbidity. A free mucosal graft may be just as effective in reducing CSF leaks as well as reducing postoperative nasal discomfort. This study aimed to assess operative outcomes of free mucosal graft after pituitary resection.
   METHODS: A retrospective chart review was performed for patients who underwent endoscopic endonasal resection of pituitary adenomas. The following data were collected: demographic data, intraoperative CSF leak, postoperative CSF leak, other complications, and mucosal graft healing at 1 month. Also, the Sinonasal Outcome Test-22 was administered preoperatively and 1 month and 3 months postoperatively.
   RESULTS: Charts of 158 patients were reviewed, including patients who underwent no mucosal reconstruction, free mucosal graft reconstruction, and nasoseptal flap reconstruction. There was a 7.4% postoperative CSF leak rate in patients who underwent no reconstruction (n = 27), whereas postoperative CSF leak rate was 0.82% in patients undergoing free mucosal graft reconstruction (n = 122) (P < 0.05). Sinonasal Outcome Test-22 scores for patients with free mucosal graft reconstruction showed no significant worsening postoperatively.
   CONCLUSIONS: The free mucosal graft is a simple and effective means of sellar reconstruction in patients undergoing endonasal endoscopic pituitary resection, and its efficacy is similar to nasoseptal flaps. The free mucosal graft technique does not worsen sinonasal morbidity postoperatively.
C1 [Scagnelli, Robert J.] Albany Med Coll, Albany, NY 12208 USA.
   [Patel, Varun; Pinheiro-Neto, Carlos D.] Albany Med Ctr, Div Otolaryngol Head & Neck Surg, Dept Surg, Albany, NY 12208 USA.
   [Peris-Celda, Maria; Kenning, Tyler J.] Albany Med Ctr, Dept Neurosurg, Albany, NY USA.
RP Pinheiro-Neto, CD (reprint author), Albany Med Ctr, Div Otolaryngol Head & Neck Surg, Dept Surg, Albany, NY 12208 USA.
EM pinheic@amc.edu
CR Dadgostar A, 2017, AM J RHINOL ALLERGY, V31, P196, DOI 10.2500/ajra.2017.31.4430
   Dehdashti AR, 2008, NEUROSURGERY, V62, P1006, DOI 10.1227/01.neu.0000325862.83961.12
   Fishpool SJC, 2017, EUR ARCH OTO-RHINO-L, V274, P837, DOI 10.1007/s00405-016-4287-8
   Hadad G, 2006, LARYNGOSCOPE, V116, P1882, DOI 10.1097/01.mlg.0000234933.37779.e4
   Jakimovski D, 2014, WORLD NEUROSURG, V82, pE513, DOI 10.1016/j.wneu.2013.06.005
   Jang JH, 2016, WORLD NEUROSURG, V96, P545, DOI 10.1016/j.wneu.2016.09.051
   Kassam AB, 2011, J NEUROSURG, V114, P1544, DOI 10.3171/2010.10.JNS09406
   Kimple AJ, 2012, LARYNGOSCOPE, V122, P1920, DOI 10.1002/lary.23325
   Kuan EC, 2018, J NEUROL SURG PART B, V79, P177, DOI 10.1055/s-0037-1606293
   Paluzzi A, 2014, PITUITARY, V17, P307, DOI 10.1007/s11102-013-0502-4
   Peris-Celda M, 2017, WORLD NEUROSURG, V101, P180, DOI 10.1016/j.wneu.2017.01.102
   Roxbury CR, 2017, INT FORUM ALLERGY RH, V7, P1178, DOI 10.1002/alr.22019
   Sanders-Taylor C, 2015, J NEUROL SURG PART B, V76, P281, DOI 10.1055/s-0034-1544118
   Schuss P, 2018, NEUROSURG REV, V41, P1053, DOI 10.1007/s10143-018-0949-x
   Soudry E, 2015, LARYNGOSCOPE, V125, P80, DOI 10.1002/lary.24863
   Suh JD, 2012, ANN OTO RHINOL LARYN, V121, P91, DOI 10.1177/000348941212100203
   Yoo F, 2017, J NEUROL SURG PART B, V78, P201, DOI 10.1055/s-0036-1597086
NR 17
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E506
EP E511
DI 10.1016/j.wneu.2018.10.090
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100061
PM 30368014
DA 2020-05-12
ER

PT J
AU Schuhmann, MU
   Kural, C
   Lalla, L
   Ebner, FH
   Bock, C
   Ludwig, HC
AF Schuhmann, Martin U.
   Kural, Cahit
   Lalla, Lisanne
   Ebner, Florian H.
   Bock, Christoph
   Ludwig, Hans-Christoph
TI Two-Micron Continuous-Wave Laser-Assisted Neuroendoscopy: Clinical
   Experience of Two Institutions in 524 Procedures
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cyst fenestration; Endoscopic third ventriculostomy; Laser;
   Neuroendoscopy; Septostomy
ID ENDOSCOPIC 3RD VENTRICULOSTOMY; ND-YAG LASER; COLLOID CYSTS; CONTACT
   LASER; DIODE-LASER; 3RD-VENTRICLE; COMPLICATIONS; SERIES
AB OBJECTIVE: To present the clinical experience of 2 neurosurgical centers with the use of a 2-micron continuous-wave laser (2 mu-cwL) system as standard tool in neuroendoscopic procedures and to discuss the safety and efficacy of this system.
   METHODS: In total, 469 patients underwent neuroendoscopic procedures using 2 mu-cwL between September 2009 and January 2015. All patient data were retrospectively reviewed. In total, 241 (51%) patients were children and 228 (49%) adults. Mean age was 27.5 years (range: 3 days to 83 years). Intraoperative ultrasonography or neuronavigation were used to guide ventricular or cyst puncture and for intraventricular or intracystic orientation if necessary.
   RESULTS: A total of 524 neuroendoscopic procedures using 2 mu-cwL were performed. Laser-assisted endoscopic third ventriculostomy was the most common procedure in 302 (64%) patients. Cyst fenestration was performed in 124 (26%), septostomy in 45, tumor biopsy in 41, tumor resection in 8, and choroid plexus coagulation in 3 patients. There was no intraoperative complication directly attributable to the use of laser and an overall procedural complication rate of 4.8%.
   CONCLUSIONS: This large series of 2 mu-cwL as a routine tool in neuroendoscopic procedures demonstrates that 2 mu-cwL is safe for endoscopic third ventriculostomy, septostomy, cyst fenestration, and intraventricular tumor biopsy or resection. As a cutting and coagulation tool, it combines the action of mechanical tools like forceps, balloons, and scissors plus those of electric tools. It therefore renders neuroendoscopic procedures more straightforward with a minimum need to change tools.
C1 [Schuhmann, Martin U.; Kural, Cahit; Lalla, Lisanne; Ebner, Florian H.] Eberhard Karls Univ Hosp Tubingen, Dept Neurosurgery, Div Pediat Neurosurg, Tubingen, Germany.
   [Kural, Cahit] Hlth Sci Univ, Gulhane Educ & Res Hosp, Dept Neurosurg, Ankara, Turkey.
   [Bock, Christoph; Ludwig, Hans-Christoph] Georg August Univ Hosp Gottingen, Dept Neurosurg, Div Pediat Neurosurg, Gottingen, Germany.
RP Kural, C (reprint author), Eberhard Karls Univ Hosp Tubingen, Dept Neurosurgery, Div Pediat Neurosurg, Tubingen, Germany.; Kural, C (reprint author), Hlth Sci Univ, Gulhane Educ & Res Hosp, Dept Neurosurg, Ankara, Turkey.
EM cahitkural23@gmail.com
CR Abtin K, 1998, PEDIATR NEUROSURG, V28, P35, DOI 10.1159/000028616
   Aref M, 2017, WORLD NEUROSURG, V104, P554, DOI 10.1016/j.wneu.2017.05.052
   Calisto A, 2014, J NEUROSURG-PEDIATR, V14, P563, DOI 10.3171/2014.8.PEDS13586
   CERULLO LJ, 1984, SURG CLIN N AM, V64, P995
   Devaux BC, 2004, LASER SURG MED, V34, P368, DOI 10.1002/lsm.20045
   Devaux BC, 1998, SURG NEUROL, V50, P33, DOI 10.1016/S0090-3019(98)00042-1
   Di Rocco C, 2006, CHILD NERV SYST, V22, P1573, DOI 10.1007/s00381-006-0194-4
   Ebner FH, 2012, ACTA NEUROCHIR SUPPL, V113, P143, DOI 10.1007/978-3-7091-0923-6_29
   GAMACHE FW, 1993, NEUROSURGERY, V32, P100, DOI 10.1227/00006123-199301000-00015
   Pinto FCG, 2009, ARQ NEURO-PSIQUIAT, V67, P1082, DOI 10.1590/S0004-282X2009000600023
   Hellwig D, 2003, NEUROSURGERY, V52, P525, DOI 10.1227/01.NEU.0000047671.27057.55
   JACK CR, 1989, AM J NEURORADIOL, V10, P515
   Ludwig HC, 2007, NEUROSURG REV, V30, P195, DOI 10.1007/s10143-007-0078-4
   McLaughlin MR, 1997, NEUROSURGERY, V41, P1400, DOI 10.1097/00006123-199712000-00034
   MERIENNE L, 1992, NEUROCHIRURGIE, V38, P245
   Nagatani T, 1997, MINIM INVAS NEUROSUR, V40, P98, DOI 10.1055/s-2008-1053425
   Passacantilli E, 2011, PHOTOMED LASER SURG, V29, P437, DOI 10.1089/pho.2010.2809
   Reis RC, 2016, J NEUROSURG, V124, P368, DOI 10.3171/2014.12.JNS141561
   Roux FX, 1999, DIODE LASERS NEUROSU, V86, P2
   Schroeder HWS, 2002, J NEUROSURG, V96, P1032, DOI 10.3171/jns.2002.96.6.1032
   Siomin V, 2001, CHILD NERV SYST, V17, P551, DOI 10.1007/s003810100475
   Beijnum J, 2008, NEUROSURGERY, V62, P437, DOI [10.1227/01.NEU.0000297058.27777.07, 10.1227/01.neu.0000316011.13174.b1]
   Vandertop WP, 1998, J NEUROSURG, V88, P82, DOI 10.3171/jns.1998.88.1.0082
   Willems PWA, 2001, LASER SURG MED, V28, P324, DOI 10.1002/lsm.1057
   Wuttipong T, 2004, CHILD NERV SYST, V20, P842
   Zimmermann M, 2004, ACTA NEUROCHIR, V146, P697, DOI 10.1007/s00701-004-0267-7
NR 26
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E81
EP E88
DI 10.1016/j.wneu.2018.09.064
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100009
PM 30244186
DA 2020-05-12
ER

PT J
AU Segal, DN
   Grabel, ZJ
   Wilson, JM
   Milby, AH
   Shi, WLJ
   Hutton, WC
   Rhee, JM
AF Segal, Dale N.
   Grabel, Zachary J.
   Wilson, Jacob M.
   Milby, Andrew H.
   Shi, Weilong J.
   Hutton, William C.
   Rhee, John M.
TI Total Disk Replacement Adjacent to a Multilevel Fusion in the Cervical
   Spine: A Biomechanical Motion Analysis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Disk adjacent to fusion; Disk arthroplasty; TDR; Total disk replacement
ID INTERBODY FUSION; FOLLOW-UP; ARTHROPLASTY; SURGERY; 2-LEVEL
AB OBJECTIVE: Cervical total disk replacement (TDR) has emerged as a motion-preserving alternative to anterior cervical diskectomy fusion (ACDF). Biomechanical studies have demonstrated that the TDR preserves motion at the diseased segment and minimizes motion and stress at adjacent segments compared with fusion. There has been growing interest in performing a TDR adjacent to a cervical fusion. The purpose of this study was to investigate the kinematics of a TDR after sequentially fusing adjacent segments.
   METHODS: Seven fresh-frozen human cadaveric cervical spine specimens from C1-T1 were used (average age, 56.2 +/- 7.3 years). The effect on cervical flexion-extension motion, by instrumenting a TDR above or below a 1-, 2-, or 3-level fusion, was measured. The protocol consisted of taking fluoroscopic images of each cervical specimen obtained at maximal angular displacement in flexion and extension during force application. Cobb angles were measured on digital radiographs to determine flexion-extension range of motion (ROM).
   RESULTS: Segmental ROM of the C6-7 TDR in the unfused spine was 11.3 degrees +/- 1.9 degrees. After performing a 3-level fusion at C3-6, the motion of the C6-7 TDR increased to 12.9 degrees +/- 1.3 degrees (P = 0.33). ROM of the C2-3 TDR in the unfused spine was 5.0 degrees +/- 1.1 degrees. After performing a 3-level fusion of C3-6, the C2-3 TDR segmental motion was 6.1 degrees +/- 1.3 degrees (P = 0.09).
   CONCLUSIONS: Biomechanically performing a cervical TDR adjacent to a long-segment fusion did not subject the implant to significantly greater motion than when the TDR was instrumented alone.
C1 [Segal, Dale N.; Grabel, Zachary J.; Wilson, Jacob M.; Shi, Weilong J.; Hutton, William C.; Rhee, John M.] Emory Univ, Dept Orthopaed, Atlanta, GA 30322 USA.
   [Milby, Andrew H.] Univ Penn, Dept Orthopaed, Philadelphia, PA 19104 USA.
RP Segal, DN (reprint author), Emory Univ, Dept Orthopaed, Atlanta, GA 30322 USA.
EM Dsegal2@emory.edu
CR BRAUNSTEIN EM, 1980, CLIN RADIOL, V31, P201, DOI 10.1016/S0009-9260(80)80160-7
   DiAngelo Denis J, 2004, Neurosurg Focus, V17, pE7
   DiAngelo DJ, 2003, J SPINAL DISORD TECH, V16, P314, DOI 10.1097/00024720-200308000-00002
   Diggle PJ, 1994, EXPLORING LONGITUDIN, P68
   Eck JC, 2002, SPINE, V27, P2431, DOI 10.1097/00007632-200211150-00003
   Goffin J, 2004, J SPINAL DISORD TECH, V17, P79, DOI 10.1097/00024720-200404000-00001
   Hacker RJ, 2000, J NEUROSURG, V93, P222, DOI 10.3171/spi.2000.93.2.0222
   Heller JG, 2009, SPINE, V34, P101, DOI 10.1097/BRS.0b013e31818ee263
   Hilibrand AS, 1999, J BONE JOINT SURG AM, V81A, P519, DOI 10.2106/00004623-199904000-00009
   Horton WC, 2005, SPINE, V30, P2014, DOI 10.1097/01.brs.0000180478.96494.88
   Lee MJ, 2011, SPINE, V36, P1932, DOI 10.1097/BRS.0b013e3181fc1aff
   Lee SB, 2017, CLIN NEUROL NEUROSUR, V162, P59, DOI 10.1016/j.clineuro.2017.08.001
   Martin S, 2011, SPINE, V36, P1359, DOI 10.1097/BRS.0b013e318222d4ad
   Park DH, 2007, J NEUROSURG-SPINE, V7, P336, DOI 10.3171/SPI-07/09/336
   Park MS, 2014, GLOB SPINE J, V4, P151, DOI 10.1055/s-0034-1378140
   Patwardhan AG, 2000, SPINE, V25, P1548, DOI 10.1097/00007632-200006150-00015
   Phillips FM, 2009, SPINE, V34, P556, DOI 10.1097/BRS.0b013e31819b061c
   Pickett GE, 2005, SPINE, V30, P1949, DOI 10.1097/01.brs.0000176320.82079.ce
   Rajakumar DV, 2017, NEUROSURG FOCUS, V42, DOI 10.3171/2016.11.FOCUS16412
   Schwab JS, 2006, SPINE, V31, P2439, DOI 10.1097/01.brs.0000239125.54761.23
NR 20
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E881
EP E889
DI 10.1016/j.wneu.2018.10.170
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100106
PM 30391767
DA 2020-05-12
ER

PT J
AU Shah, KJ
   Cohen-Gadol, AA
AF Shah, Kushal J.
   Cohen-Gadol, Aaron A.
TI The Application of FLOW 800 ICG Videoangiography Color Maps for
   Neurovascular Surgery and Intraoperative Decision Making
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain arteriovenous malformations; Cerebral aneurysm; Dural
   arteriovenous fistula; FLOW 800; Indocyanine green; Ligation;
   Videoangiography
ID INDOCYANINE GREEN VIDEOANGIOGRAPHY; ARTERIOVENOUS-MALFORMATIONS;
   SURGICAL-MANAGEMENT; HEMODYNAMIC-CHANGES; VIDEO ANGIOGRAPHY;
   LIMITATIONS; IDENTIFICATION; PERFUSION; EFFICACY; LOCATION
AB BACKGROUND: Indocyanine green (ICG) video-angiography can assess cerebral blood flow, but results are primarily qualitative. FLOW 800 software measures fluorescence dynamics and creates a semiquantitative color delay map for assessment of relative sequence of blood flow within the vasculature.
   METHODS: We retrospectively reviewed 23 consecutive patients for whom FLOW 800 ICG videoangiography was used. They harbored aneurysms, arteriovenous malformations (AVMs), dural arteriovenous fistula (dAVF), or hemangioblastoma. Patients' characteristics, FLOW 800 data, and clinical findings were recorded. Color map data were readily available intraoperatively and guided surgery.
   RESULTS: The cohort included 10 patients with AVMs, 11 with aneurysms, 1 with dAVF, and 1 with hemangioblastoma. Approximately two thirds of patients underwent intraoperative angiography. FLOW 800 data provided semiquantitative data regarding localization, flow status in major feeding arteries, and dominance of the arterialized draining veins for AVMs, more than data from ICG videoangiography alone. For complex aneurysms, color maps confirmed relative adequate flow in parent and branching vessels. For the foramen magnum dAVF, the location of the dominant transdural connection was appreciated only via flow analysis. Flow analysis created the blood flow map of a large complex solid brainstem hemangioblastoma and guided devascularization. All FLOW 800 findings agreed with intraoperative and postoperative angiography.
   CONCLUSIONS: ICG videoangiography with FLOW 800 analysis can provide semiquantitative and relative flow magnitude data that are efficient and noninvasive. This process helps identify early arterialized veins and their flow status during AVM and dAVF surgery and can confirm adequate relative flow within branching vessels during aneurysm surgery when clip-induced stenosis is suspected.
C1 [Shah, Kushal J.] Univ Kansas, Dept Neurosurg, Kansas City, KS USA.
   [Cohen-Gadol, Aaron A.] Goodman Campbell Brain & Spine, Dept Neurol Surg, Indianapolis, IN 46260 USA.
   [Cohen-Gadol, Aaron A.] Indiana Univ, Indianapolis, IN 46204 USA.
RP Cohen-Gadol, AA (reprint author), Goodman Campbell Brain & Spine, Dept Neurol Surg, Indianapolis, IN 46260 USA.; Cohen-Gadol, AA (reprint author), Indiana Univ, Indianapolis, IN 46204 USA.
EM acohenmd@gmail.com
OI Cohen-Gadol, Aaron/0000-0002-4946-1524
CR Abla AA, 2014, WORLD NEUROSURG, V82, pE585, DOI 10.1016/j.wneu.2014.08.019
   Acerbi F, 2018, NEUROSURG FOCUS, V44, DOI 10.3171/2018.3.FOCUS1862
   Benedetto N, 2013, BRIT J NEUROSURG, V27, P847, DOI 10.3109/02688697.2013.798863
   de Oliveira JG, 2008, NEUROSURGERY, V62, P1300, DOI [10.1227/01.NEU.0000279982.48426.A1, 10.1227/01.neu.0000333795.21468.d4]
   Feng SY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05913-w
   Ferroli P, 2011, J NEUROSURG, V115, P18, DOI 10.3171/2011.3.JNS10620
   Fischer G, 2010, ACTA NEUROCHIR, V152, P1519, DOI 10.1007/s00701-010-0723-5
   Fukuda K, 2015, WORLD NEUROSURG, V83, P203, DOI 10.1016/j.wneu.2014.07.012
   Fusco MR, 2014, OPER NEUROSURG, V10, P251, DOI 10.1227/NEU.0000000000000318
   Hanggi D, 2010, NEUROSURGERY, V67, P1094, DOI 10.1227/NEU.0b013e3181eb5049
   Hardesty DA, 2014, J CLIN NEUROSCI, V21, P1377, DOI 10.1016/j.jocn.2014.02.006
   Holling M, 2013, NEUROSURGERY, V73, P93, DOI 10.1227/NEU.0b013e31828772a4
   Jhawar SS, 2011, J CLIN NEUROSCI, V18, P1556, DOI 10.1016/j.jocn.2011.01.041
   Kalyvas J, 2015, WORLD NEUROSURG, V83, P147, DOI 10.1016/j.wneu.2014.09.010
   Kamp MA, 2012, NEUROSURGERY, V70, DOI 10.1227/NEU.0b013e31822f7d7c
   Kato Y, 2011, NEUROL INDIA, V59, P829, DOI 10.4103/0028-3886.91359
   KOGURE K, 1970, ARCH OPHTHALMOL-CHIC, V83, P209
   Kono K, 2013, TURK NEUROSURG, V23, P676, DOI 10.5137/1019-5149.JTN.6420-12.0
   Ng YP, 2013, J CLIN NEUROSCI, V20, P224, DOI 10.1016/j.jocn.2011.12.038
   Okawa M, 2014, ACTA NEUROCHIR SUPPL, V119, P97, DOI 10.1007/978-3-319-02411-0_17
   Prinz V, 2014, OPER NEUROSURG, V10, P231, DOI 10.1227/NEU.0000000000000277
   Raabe A, 2003, NEUROSURGERY, V52, P132, DOI 10.1097/00006123-200301000-00017
   Schuette AJ, 2010, NEUROSURGERY, V67, P658, DOI 10.1227/01.NEU.0000374721.84406.7F
   Sharma M, 2014, WORLD NEUROSURG, V82, pE607, DOI 10.1016/j.wneu.2014.05.033
   Shi W, 2015, J CLIN NEUROSCI, V22, P1155, DOI 10.1016/j.jocn.2015.01.024
   Spiotta AM, 2011, J NEUROINTERV SURG, V3, P182, DOI 10.1136/jnis.2010.003210
   Takagi Y, 2012, NEUROSURGERY, V70, DOI 10.1227/NEU.0b013e31822d9749
   Uchino H, 2013, ACTA NEUROCHIR, V155, P599, DOI 10.1007/s00701-012-1575-y
   Ueba T, 2013, J NEUROSURG, V118, P632, DOI 10.3171/2012.11.JNS121113
   Ueba T, 2012, J NEUROSURG-PEDIATR, V9, P428, DOI 10.3171/2011.12.PEDS11286
   Ye X, 2013, CHINESE MED J-PEKING, V126, P4232, DOI 10.3760/cma.j.issn.0366-6999.20131649
NR 31
TC 5
Z9 6
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E186
EP E197
DI 10.1016/j.wneu.2018.09.195
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100020
PM 30292668
DA 2020-05-12
ER

PT J
AU Shao, ZX
   Yan, YZ
   Pan, XX
   Chen, SQ
   Fang, X
   Chen, XB
   Wu, AM
   Wang, XY
AF Shao, Zhen-Xuan
   Yan, Ying-Zhao
   Pan, Xiang-Xiang
   Chen, Shao-Qing
   Fang, Xia
   Chen, Xi-Bang
   Wu, Ai-Min
   Wang, Xiang-Yang
TI Factors Associated with Cervical Spine Alignment in an Asymptomatic
   Population: A Preliminary Analysis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Asymptomatic individuals; Cervical parameters; Cervical sagittal
   balance; Prediction
ID SAGITTAL ALIGNMENT; RADIOGRAPHIC ANALYSIS; BALANCE; DEFORMITY;
   PARAMETERS; OSTEOTOMY; LORDOSIS; SLOPE; AGE
AB BACKGROUND: Cervical sagittal imbalance compromises health-related quality of life and can lead to myriad incapacitating symptoms through compression of the spinal cord. Questions regarding which parameters play primary roles in the progression of cervical sagittal imbalance and which might be compensatory factors remain unanswered.
   METHODS: This study enrolled 246 asymptomatic volunteers from July 2016 to June 2018. After demographic and radiologic parameters were measured, the data were analyzed using correlation coefficient test and multiple regression analysis. A predictive equation was assessed with variance analysis, residual analysis, collinearity analysis, and a paired t test.
   RESULTS: Average values are as follows: orbital tilt, 64 +/- 6 degrees; orbital slope (OS), 15 +/- 6 degrees; C0-C2 lordosis (C0C2), 28 +/- 8 degrees; cervical lordosis (CL), 5 +/- 11 degrees; C2-C7 sagittal vertical axis (C2C7SVA), 15 +/- 8 mm; T1 slope (TS), 17 +/- 6 degrees; thoracic inlet angle, 69 +/- 8 degrees; thoracic kyphosis, 34 +/- 9 degrees; lumbar lordosis, 50 +/- 10 degrees; sacral slope, 38 +/- 7 degrees; pelvic index, 48 +/- 9 degrees; sagittal vertical axis, 10 +/- 19 mm. Correlations of C2C7SVA were observed with body mass index (BMI), OS, C0C2, CL, and TS. The validated predictive equation was: C2C7SVA = 0.38 x BMI - 0.73 x OS + 0.73 x C0C2 + 0.15 x CL + 0.18 x TS - 6.53.
   CONCLUSIONS: BMI, OS, C0C2, CL, and TS were primary influencers in the progression of cervical sagittal imbalance and established a predictive equation of asymptomatic population, which can provide clinical advice and remind surgeons of the primary influencers of reconstructive surgery for better prognoses.
C1 [Shao, Zhen-Xuan; Yan, Ying-Zhao; Pan, Xiang-Xiang; Chen, Shao-Qing; Fang, Xia; Chen, Xi-Bang; Wu, Ai-Min; Wang, Xiang-Yang] Wenzhou Med Univ, Affiliated Hosp 2, Dept Orthopaed Surg, Wenzhou, Peoples R China.
   [Shao, Zhen-Xuan; Yan, Ying-Zhao; Pan, Xiang-Xiang; Chen, Shao-Qing; Fang, Xia; Chen, Xi-Bang; Wu, Ai-Min; Wang, Xiang-Yang] Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou, Peoples R China.
   [Shao, Zhen-Xuan; Yan, Ying-Zhao; Pan, Xiang-Xiang; Chen, Shao-Qing; Fang, Xia; Chen, Xi-Bang] Wenzhou Med Univ, Sch Med 2, Wenzhou, Peoples R China.
RP Wu, AM; Wang, XY (reprint author), Wenzhou Med Univ, Affiliated Hosp 2, Dept Orthopaed Surg, Wenzhou, Peoples R China.; Wu, AM; Wang, XY (reprint author), Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou, Peoples R China.
EM aiminwu@163.com; xiangyangwang@wmu.edu.cn
FU National Nature Science Foundation of ChinaNational Natural Science
   Foundation of China [81371988, 81501933]; Major Science and Technology
   Program for Medical and Health of Zhejiang Province [WKJ-ZJ-1527]
FX This work is supported by Grant from National Nature Science Foundation
   of China (grant numbers 81371988 and 81501933) and a Major Science and
   Technology Program for Medical and Health of Zhejiang Province (grant
   number WKJ-ZJ-1527). The funders had no role in the design, execution,
   or writing of the study.
CR Amabile C, 2018, EUR SPINE J, V27, P458, DOI 10.1007/s00586-016-4830-8
   Ames CP, 2013, SPINE, V38, pS149, DOI 10.1097/BRS.0b013e3182a7f449
   Barrey C, 2007, EUR SPINE J, V16, P1459, DOI 10.1007/s00586-006-0294-6
   Belanger TA, 2005, J BONE JOINT SURG AM, V87A, P1732, DOI 10.2106/JBJS.C.01472
   Belsley D.A., 1991, CONDITIONING DIAGNOS
   Chen YW, 2017, EUR SPINE J, V26, P2363, DOI 10.1007/s00586-017-5209-1
   Deviren V, 2011, J NEUROSURG-SPINE, V15, P174, DOI 10.3171/2011.3.SPINE10536
   Etame Arnold B, 2010, Neurosurg Focus, V28, pE14, DOI 10.3171/2010.1.FOCUS09272
   Faro FD, 2004, SPINE, V29, P2284, DOI 10.1097/01.brs.0000142224.46796.a7
   Glassman SD, 2005, SPINE, V30, P682, DOI 10.1097/01.brs.0000155425.04536.f7
   GORE DR, 1986, SPINE, V11, P521, DOI 10.1097/00007632-198607000-00003
   Gwinn DE, 2009, J NEUROSURG-SPINE, V11, P667, DOI 10.3171/2009.7.SPINE08656
   Harrison DD, 2004, SPINE, V29, P2485, DOI 10.1097/01.brs.0000144449.90741.7c
   Iyer S, 2016, SPINE, V41, P1837, DOI 10.1097/BRS.0000000000001644
   Iyer S, 2016, SPINE, V41, P371, DOI 10.1097/BRS.0000000000001221
   Le Huec JC, 2015, EUR SPINE J, V24, P63, DOI 10.1007/s00586-014-3632-0
   Lee SH, 2015, SPINE J, V15, P705, DOI 10.1016/j.spinee.2013.06.059
   McAviney J, 2005, J MANIP PHYSIOL THER, V28, P187, DOI 10.1016/j.jmpt.2005.02.015
   Nojiri K, 2003, J NEUROSURG, V99, P80, DOI 10.3171/spi.2003.99.1.0080
   Oe S, 2016, SPINE, V41, pE1168, DOI 10.1097/BRS.0000000000001578
   Oe S, 2015, SPINE, V40, P1487, DOI 10.1097/BRS.0000000000001071
   Paholpak P, 2017, SPINE J, V17, P1272, DOI 10.1016/j.spinee.2017.04.026
   Patwardhan AG, 2018, EUR SPINE J, V27, pS25, DOI 10.1007/s00586-017-5367-1
   Pigge RR, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/1/E7
   Protopsaltis TS, 2015, J NEUROSURG-SPINE, V23, P153, DOI 10.3171/2014.11.SPINE1441
   Scheer JK, 2013, J NEUROSURG-SPINE, V19, P141, DOI 10.3171/2013.4.SPINE12838
   Suk KS, 2003, SPINE, V28, P2001, DOI 10.1097/01.BRS.0000083239.06023.78
   Tamai K, 2018, SPINE, V43, P520, DOI 10.1097/BRS.0000000000002371
   Tang Jessica A, 2015, Neurosurgery, V76 Suppl 1, pS14, DOI 10.1227/01.neu.0000462074.66077.2b
   Uchida K, 2009, J NEUROSURG-SPINE, V11, P521, DOI 10.3171/2009.2.SPINE08385
   Vialle R, 2005, J BONE JOINT SURG AM, V87A, P260, DOI 10.2106/JBJS.D.02043
   Yang MY, 2017, SPINE, V42, pE219, DOI 10.1097/BRS.0000000000001782
   Yoshimoto H, 2004, SPINE, V29, P175, DOI 10.1097/01.BRS.0000107225.97653.CA
   Youn MS, 2016, EUR SPINE J, V25, P3114, DOI 10.1007/s00586-016-4488-2
NR 34
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E48
EP E58
DI 10.1016/j.wneu.2018.09.036
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100006
PM 30236812
DA 2020-05-12
ER

PT J
AU Sharma, BS
   Sawarkar, DP
   Verma, SK
AF Sharma, Bhawani Shanker
   Sawarkar, Dattaraj Paramanand
   Verma, Satish Kumar
TI Endoscopic Management of Fourth Ventricle Neurocysticercosis:
   Description of the New Technique in a Case Series of 5 Cases and Review
   of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Catheter; Endoscopy; Excision; Fourth ventricular; Neurocysticercosis
ID 4TH VENTRICULAR NEUROCYSTICERCOSIS; TRANSAQUEDUCTAL REMOVAL
AB BACKGROUND: Around 7%-33% of cases of neurocysticercosis (NCC) have intraventricular involvement, and the fourth ventricle is the most frequent site. Medical management and various surgical approaches have been described for treating this disease. The objective of this study was to describe technical modification for endoscopic fourth ventricular NCC removal in a series of 5 cases.
   METHODS: In this study (January 1, 2016, to December 31, 2017), all cases of fourth ventricular NCC which were treated with a special technique (endoscopic transcortical transforaminal transaqueductal approach) using a rigid endoscope system and 6-French infant feeding tube (IFT) were included in the study. The IFT was passed through the main channel, the cyst was engaged at the tip by applying gentle suction with a 20 cm(3) syringe, and the cyst was removed along with the whole endoscopic assembly. Patient's clinical, radiologic, and follow-up data were retrieved from the department database records.
   RESULTS: Five patients (3 men, 2 women; mean age, 20 years; range, 11-27 years) were enrolled. All patients had features of raised intracranial pressure. Two patients also had drop attacks, and one presented with altered sensorium and one had upgaze palsy. Duration of symptoms ranged from 3 months to 3 years. All patients had isolated fourth ventricular NCC with obstructive hydrocephalus. Complete removal of the neurocysticercal cyst could be performed in all patients without any injury to the periaqueductal region or fornix. There was no intraoperative rupture of the neurocysticercal cyst. On follow-up (range, 12-28 months; mean, 19.4 months), all patients had relief of symptoms and imaging showed no cyst and hydrocephalus.
   CONCLUSIONS: We conclude that our endoscopic approach is safe, simple, cost-effective, and allows minimally invasive removal of the fourth ventricle cyst and treatment of hydrocephalus without any morbidity.
C1 [Sawarkar, Dattaraj Paramanand] All India Inst Med Sci, Dept Neurosurg, New Delhi, India.
   All India Inst Med Sci, Gamma Knife Ctr, New Delhi, India.
   [Sharma, Bhawani Shanker] Mahatma Gandhi Univ Med Sci & Technol, Dept Neurosurg, Jaipur, Rajasthan, India.
RP Sawarkar, DP (reprint author), All India Inst Med Sci, Dept Neurosurg, New Delhi, India.
EM dattaraja@gmail.com
CR Anandh B, 2001, MINIM INVAS NEUROSUR, V44, P194, DOI 10.1055/s-2001-19928
   APUZZO MLJ, 1984, J NEUROSURG, V60, P400, DOI 10.3171/jns.1984.60.2.0400
   Bergsneider M, 1999, J NEUROSURG, V91, P340, DOI 10.3171/jns.1999.91.2.0340
   Ceja-Espinosa A, 2017, Surg Neurol Int, V8, P232, DOI 10.4103/sni.sni_251_17
   Chen GQ, 2015, TURK NEUROSURG, V25, P488, DOI 10.5137/1019-5149.JTN.10153-13.1
   Citow Jonathan Stuart, 2002, Neurosurg Focus, V12, pe6
   Cuetter Albert C, 2002, Neurosurg Focus, V12, pe5
   Das KK, 2017, WORLD NEUROSURG, V102, DOI 10.1016/j.wneu.2017.04.067
   Goel RK, 2008, J CLIN NEUROSCI, V15, P1096, DOI 10.1016/j.jocn.2007.10.004
   Hopf NJ, 1998, NEUROSURGERY, V43, P1330, DOI 10.1097/00006123-199812000-00037
   Husain M, 2007, ACTA NEUROCHIR, V149, P341, DOI 10.1007/s00701-006-1059-z
   Husain M, 2007, NEUROSURGERY, V60, P249, DOI 10.1227/01.NEU.0000255382.72593.81
   Kaif M, 2019, TURK NEUROSURG, V29, P59, DOI 10.5137/1019-5149.JTN.21389-17.3
   Khalid Saifullah, 2016, Surg Neurol Int, V7, pS952, DOI 10.4103/2152-7806.195232
   Kotha Vamshi Krishna, 2013, Asian J Neurosurg, V8, P54, DOI 10.4103/1793-5482.110282
   Proano JV, 2009, CHILD NERV SYST, V25, P1467, DOI 10.1007/s00381-009-0933-4
   Psarros TG, 2003, SOUTH MED J, V96, P1019, DOI 10.1097/01.SMJ.0000076706.09204.40
   Rajshekhar V, 2010, INT J SURG, V8, P100, DOI 10.1016/j.ijsu.2009.12.006
   Rangel-Castilla L, 2009, AM J TROP MED HYG, V80, P373, DOI 10.4269/ajtmh.2009.80.373
   Schroeder HWS, 1999, NEUROSURGERY, V45, P508, DOI 10.1097/00006123-199909000-00020
   Sharma BS, 1998, NEUROL INDIA, V46, P177
   Sinha S, 2012, BRIT J NEUROSURG, V26, P305, DOI 10.3109/02688697.2011.635820
   Sinha S, 2009, J CLIN NEUROSCI, V16, P867, DOI 10.1016/j.jocn.2008.10.030
   Suri A, 2008, J NEUROS-PEDIATR, V1, P35, DOI 10.3171/PED-08/01/035
   Zymberg ST, 2013, WORLD NEUROSURG, V79, DOI 10.1016/j.wneu.2012.02.019
   Zymberg ST, 2003, ARQ NEURO-PSIQUIAT, V61, P204, DOI 10.1590/S0004-282X2003000200009
NR 26
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E647
EP E654
DI 10.1016/j.wneu.2018.10.117
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100079
PM 30814022
DA 2020-05-12
ER

PT J
AU Silva, SR
   Gliniewicz, A
   Martin, B
   Prabhu, VC
   Germanwala, AV
   Melian, E
   Jones, GA
   Solanki, AA
AF Silva, Scott R.
   Gliniewicz, Adam
   Martin, Brendan
   Prabhu, Vikram C.
   Germanwala, Anand V.
   Melian, Edward
   Jones, G. Alex
   Solanki, Abhishek A.
TI Oligometastatic Disease State Is Associated with Improved Local Control
   in Patients Undergoing Three or Five Fraction Spine Stereotactic Body
   Radiotherapy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Local control of spinal metastases; Oligometastatic disease state;
   Spinal metastases; Stereotactic body radiotherapy
ID VERTEBRAL COMPRESSION FRACTURE; INTENSITY-MODULATED RADIOTHERAPY;
   RADIATION-THERAPY; SINGLE-FRACTION; BONE METASTASES; RADIOSURGERY;
   OUTCOMES; MODEL
AB BACKGROUND: The objective of our study was to describe the local control (LC) outcomes with 3- or 5-fraction stereotactic body radiotherapy (SBRT) to the spine in patients with oligometastatic (<= 5 systemic metastases) versus polymetastatic disease (>5 metastases).
   METHODS: We retrospectively reviewed the outcomes of patients who had undergone SBRT for spinal metastases. No patients had undergone previous surgical intervention or had spinal cord compression. All patients were treated with 3- fraction (median dose, 27 Gy; range, 24-30 Gy) or 5-fraction (median dose, 35 Gy; range, 25-40 Gy) SBRT. The Kaplan-Meier method and Spine Response Assessment in Neuro-Oncology criteria were used to determine LC.
   RESULTS: We included 61 patients with a total of 72 distinct SBRT targets who had been treated from August 2007 to June 2017. The median follow-up period was 13.58 months. We treated 20 targets and 52 targets with 3 and 5 fractions, respectively. Thirteen patients (18.1%) had undergone previous RT to the SBRT area. Twenty patients (35% of the distinct SBRT targets) had an oligometastatic disease state. The 1-year LC rate was 83% for the entire cohort. On univariable analysis, polymetastases (1-year LC, 73.8% vs. 100%; P = 0.07) showed a trend toward worse LC. On multivariable analysis, patients with an oligometastatic state (hazard ratio, 0.21; P = 0.04) had improved LC.
   CONCLUSIONS: Our study was hypothesis-generating in that patients with an oligometastatic disease state appear to have improved LC after SBRT, suggesting a biological advantage exists with local therapy for this group of patients not seen for patients with polymetastatic disease.
C1 [Silva, Scott R.] Univ Louisville, James Graham Brown Canc Ctr, Dept Radiat Oncol, Louisville, KY 40292 USA.
   [Gliniewicz, Adam; Melian, Edward; Solanki, Abhishek A.] Loyola Univ Med Ctr, Stritch Sch Med, Dept Radiat Oncol, Maywood, IL 60153 USA.
   [Martin, Brendan] Loyola Univ Med Ctr, Stritch Sch Med, Clin Res Off, Maywood, IL 60153 USA.
   [Prabhu, Vikram C.; Germanwala, Anand V.; Jones, G. Alex] Loyola Univ Med Ctr, Stritch Sch Med, Dept Neurol Surg, Maywood, IL 60153 USA.
RP Solanki, AA (reprint author), Loyola Univ Med Ctr, Stritch Sch Med, Dept Radiat Oncol, Maywood, IL 60153 USA.
EM abhishek.solanki@lumc.edu
RI Martin, Brendan/AAG-6147-2020
OI Jones, G. Alexander/0000-0002-0009-5463
CR Ahmed KA, 2015, INT J RADIAT ONCOL, V92, P837, DOI 10.1016/j.ijrobp.2015.01.036
   Ahmed KA, 2012, INT J RADIAT ONCOL, V82, pE803, DOI 10.1016/j.ijrobp.2011.11.036
   Allemani C, 2015, LANCET, V385, P977, DOI 10.1016/S0140-6736(14)62038-9
   Boehling NS, 2012, J NEUROSURG-SPINE, V16, P379, DOI 10.3171/2011.11.SPINE116
   Chang JH, 2016, SPINE, V41, pS238, DOI 10.1097/BRS.0000000000001823
   Chow E, 2007, J CLIN ONCOL, V25, P1423, DOI 10.1200/JCO.2006.09.5281
   Chow E, 2014, LANCET ONCOL, V15, P164, DOI 10.1016/S1470-2045(13)70556-4
   Cox D. R., 1984, ANAL SURVIVAL DATA
   Cunha MVR, 2012, INT J RADIAT ONCOL, V84, pE343, DOI 10.1016/j.ijrobp.2012.04.034
   De Bari B, 2016, CRIT REV ONCOL HEMAT, V98, P147, DOI 10.1016/j.critrevonc.2015.11.002
   Folkert MR, 2017, ADV DRUG DELIVER REV, V109, P3, DOI 10.1016/j.addr.2016.11.005
   Folkert MR, 2014, INT J RADIAT ONCOL, V88, P1085, DOI 10.1016/j.ijrobp.2013.12.042
   Gerszten PC, 2007, SPINE, V32, P193, DOI 10.1097/01.brs.0000251863.76595.a2
   Ghia AJ, 2016, J NEUROSURG-SPINE, V24, P829, DOI 10.3171/2015.8.SPINE15844
   Greco C, 2015, REP PRACT ONCOL RADI, V20, P454, DOI 10.1016/j.rpor.2015.03.004
   Hashmi A, 2016, J NEUROSURG-SPINE, V25, P646, DOI 10.3171/2016.4.SPINE151523
   HELLMAN S, 1995, J CLIN ONCOL, V13, P8, DOI 10.1200/JCO.1995.13.1.8
   Heron DE, 2012, J NEUROSURG-SPINE, V17, P11, DOI 10.3171/2012.4.SPINE11902
   Husain ZA, 2017, J NEUROSURG-SPINE, V27, P295, DOI 10.3171/2017.1.SPINE16684
   Katsoulakis E, 2017, SEMIN RADIAT ONCOL, V27, P209, DOI 10.1016/j.semradonc.2017.03.004
   LIN DY, 1993, BIOMETRIKA, V80, P557, DOI 10.2307/2337177
   Lussier YA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050141
   McClelland S, 2017, J CLIN NEUROSCI, V46, P109, DOI 10.1016/j.jocn.2017.08.007
   Milano MT, 2008, CANCER-AM CANCER SOC, V112, P650, DOI 10.1002/cncr.23209
   Moussazadeh N, 2015, INT J RADIAT ONCOL, V93, P361, DOI 10.1016/j.ijrobp.2015.05.035
   Nelson JW, 2009, INT J RADIAT ONCOL, V73, P1369, DOI 10.1016/j.ijrobp.2008.06.1949
   Nguyen J, 2011, CLIN ONCOL-UK, V23, P485, DOI 10.1016/j.clon.2011.01.507
   Potters L, 2010, INT J RADIAT ONCOL, V76, P326, DOI 10.1016/j.ijrobp.2009.09.042
   Rose PS, 2009, J CLIN ONCOL, V27, P5075, DOI 10.1200/JCO.2008.19.3508
   Sahgal A, 2013, J CLIN ONCOL, V31, P3426, DOI 10.1200/JCO.2013.50.1411
   Sahgal A, 2011, J NEUROSURG-SPINE, V14, P151, DOI 10.3171/2010.9.SPINE091005
   Salama JK, 2012, CANCER-AM CANCER SOC, V118, P2962, DOI 10.1002/cncr.26611
   Scott JG, 2017, LANCET ONCOL, V18, P202, DOI 10.1016/S1470-2045(16)30648-9
   Sze WM, 2004, COCHRANE DB SYST REV, V2, pCD004721, DOI DOI 10.1002/14651858.CD004721
   Thibault I, 2015, LANCET ONCOL, V16, pE595, DOI 10.1016/S1470-2045(15)00166-7
   Wang XS, 2012, LANCET ONCOL, V13, P395, DOI 10.1016/S1470-2045(11)70384-9
   Yamada Y, 2008, INT J RADIAT ONCOL, V71, P484, DOI 10.1016/j.ijrobp.2007.11.046
   Zelefsky MJ, 2012, INT J RADIAT ONCOL, V82, P1744, DOI 10.1016/j.ijrobp.2011.02.040
NR 38
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E342
EP E348
DI 10.1016/j.wneu.2018.10.044
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100040
PM 30326310
DA 2020-05-12
ER

PT J
AU Sindeev, S
   Prothmann, S
   Frolov, S
   Zimmer, C
   Liepsch, D
   Berg, P
   Kirschke, JS
   Friedrich, B
AF Sindeev, Sergey
   Prothmann, Sascha
   Frolov, Sergey
   Zimmer, Claus
   Liepsch, Dieter
   Berg, Philipp
   Kirschke, Jan Stefan
   Friedrich, Benjamin
TI Intimal Hyperplasia After Aneurysm Treatment by Flow Diversion
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebral aneurysm; Computational fluid dynamics; Flow diverter; Intimal
   hyperplasia; Virtual stenting
ID INTRACRANIAL ANEURYSMS; EMBOLIZATION DEVICE; STENT APPOSITION;
   HEMODYNAMICS
AB BACKGROUND: Flow diverter stents have become a useful tool for treatment of complex intracranial aneurysms. A serious complication is incomplete wall apposition after flow diverter placement. The aim of this study was to present a comprehensive investigation of hemodynamic changes induced by incomplete expansion of a flow diverter.
   METHODS: A case of a patient treated for an internal carotid artery aneurysm by flow diversion with incomplete wall apposition was virtually investigated. The effect of incomplete flow diverter expansion was studied using image-based blood flow simulations under physiologically relevant flow conditions based on patient-specific clinical data.
   RESULTS: The numerical results revealed that incomplete expansion at the proximal end of the stent had minimal impact on the intra-aneurysmal blood flow alteration. A region of nonphysiologically high wall shear stress was observed near the contact area between the incompletely expanded proximal end of the flow diverter and the parent artery, which caused an intimal hyperplasia in this region. These simulation results were consistent with the real-life clinical course and outcome.
   CONCLUSIONS: The results of this study can be considered during treatment planning of complex cases where the risk of incomplete flow diverter expansion exists. Further studies are required before results can also be used to support the decision process about antiplatelet therapy and additional interventions to improve wall apposition.
C1 [Sindeev, Sergey; Frolov, Sergey] Tambov State Tech Univ, Dept Biomed Engn, Tambov, Russia.
   [Prothmann, Sascha] Helios Klinikum Munchen West, Dept Neuroradiol, Munich, Germany.
   [Prothmann, Sascha; Zimmer, Claus; Kirschke, Jan Stefan; Friedrich, Benjamin] Tech Univ Munich, Dept Neuroradiol, Munich, Germany.
   [Liepsch, Dieter] Munich Univ Appl Sci, Dept Bldg Serv Engn Chem Engn Paper & Packaging P, Munich, Germany.
   [Berg, Philipp] Univ Magdeburg, Dept Fluid Dynam & Tech Flows, Magdeburg, Germany.
RP Sindeev, S (reprint author), Tambov State Tech Univ, Dept Biomed Engn, Tambov, Russia.
EM ssindeev@yandex.ru
RI Kirschke, Jan/E-2550-2012; Frolov, Sergey S.V./E-8654-2014; Sindeev,
   Sergey/E-5772-2014
OI Kirschke, Jan/0000-0002-7557-0003; Frolov, Sergey
   S.V./0000-0003-2917-535X; Sindeev, Sergey/0000-0002-6494-0785
FU Russian Science FoundationRussian Science Foundation (RSF) [16-15-10327]
FX This work was supported by the Russian Science Foundation (Project
   16-15-10327).
CR Adeeb N, 2017, WORLD NEUROSURG, V105, P232, DOI 10.1016/j.wneu.2017.05.128
   Balasso A, 2014, BIORHEOLOGY, V51, P341, DOI 10.3233/BIR-14019
   Berg P, 2017, ELS MIC SOC BOOK SER, P371, DOI 10.1016/B978-0-12-811018-8.00014-X
   Berg P, 2016, J BIOMECH, V49, P4, DOI 10.1016/j.jbiomech.2015.10.047
   Bhogal P, 2017, J NEUROINTERV SURG, V9, P283, DOI 10.1136/neurintsurg-2016-012648
   Briganti F, 2016, J NEUROINTERV SURG, V8, P287, DOI 10.1136/neurintsurg-2014-011460
   Burrows AM, 2015, J NEUROINTERV SURG, V7, P646, DOI 10.1136/neurintsurg-2014-011184
   Chien S, 2007, AM J PHYSIOL-HEART C, V292, pH1209, DOI 10.1152/ajpheart.01047.2006
   DAVIES PF, 1995, PHYSIOL REV, V75, P519
   Ding D, 2014, J CLIN NEUROSCI, V21, P1981, DOI 10.1016/j.jocn.2014.04.003
   Dolan JM, 2011, ANN BIOMED ENG, V39, P1620, DOI 10.1007/s10439-011-0267-8
   Foin N, 2014, CIRC-CARDIOVASC INTE, V7, P180, DOI 10.1161/CIRCINTERVENTIONS.113.000931
   Frolov SV, 2016, TECHNOL HEALTH CARE, V24, P317, DOI 10.3233/THC-161132
   Hoskins PR, 2009, BRIT J RADIOL, V82, pS3, DOI 10.1259/bjr/96847348
   Janiga G, 2013, BIOMED ENG-BIOMED TE, V58, P303, DOI 10.1515/bmt-2012-0119
   Kim Byung Moon, 2016, Neurointervention, V11, P10, DOI 10.5469/neuroint.2016.11.1.10
   King RM, 2018, J NEUROINTERV SURG, V10, P697, DOI 10.1136/neurintsurg-2017-013502
   Liepsch D, 2017, SER BIOMECH, V31, P3
   Lv XL, 2016, NEURORADIOL J, V29, P66, DOI 10.1177/1971400915621321
   Marzo A, 2011, ANN BIOMED ENG, V39, P884, DOI 10.1007/s10439-010-0187-z
   Park MS, 2015, J NEUROINTERV SURG, V7, P652, DOI 10.1136/neurintsurg-2014-011265
   Rouchaud A, 2016, AM J NEURORADIOL, V37, P2087, DOI 10.3174/ajnr.A4848
   Saatci I, 2012, AM J NEURORADIOL, V33, P1436, DOI 10.3174/ajnr.A3246
   Tomasello A, 2016, NEUROL RES, V38, P381, DOI 10.1080/01616412.2016.1155335
   van der Marel K, 2016, J NEUROINTERV SURG, V8, P847, DOI 10.1136/neurintsurg-2015-011843
   Walcott BP, 2016, JAMA NEUROL, V73, P1002, DOI 10.1001/jamaneurol.2016.0609
   Xiang JP, 2012, J NEUROINTERV SURG, V4, DOI 10.1136/neurintsurg-2011-010089
   Yamaguchi R, 2016, INT J NEUROL NEUROTH, V3
   Zanaty M, 2014, STROKE, V45, P2656, DOI 10.1161/STROKEAHA.114.006247
   Zarrinkoob L, 2015, J CEREBR BLOOD F MET, V35, P648, DOI 10.1038/jcbfm.2014.241
NR 30
TC 3
Z9 3
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E577
EP E583
DI 10.1016/j.wneu.2018.10.107
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100070
PM 31108073
DA 2020-05-12
ER

PT J
AU Soliman, H
   Fridley, J
   Telfeian, A
   Choi, DB
   Galgano, M
   Kosztowski, T
   Gokaslan, ZL
   Oyelese, AA
AF Soliman, Hesham
   Fridley, Jared
   Telfeian, Albert
   Choi, David B.
   Galgano, Michael
   Kosztowski, Thomas
   Gokaslan, Ziya L.
   Oyelese, Adetokunbo A.
TI Minimally Invasive, Far Lateral Lumbar Microdiscectomy with
   Intraoperative Computed Tomography Navigational Assistance and
   Electrophysiological Monitoring
SO WORLD NEUROSURGERY
LA English
DT Article
DE Airo intraoperative CT imaging system; Extraforaminal disc herniation;
   Far lateral discectomy; Image-guided spine surgery; Kambin's triangle;
   Minimally invasive spine surgery; 0-arm
ID PERCUTANEOUS ENDOSCOPIC DISKECTOMY; DISC HERNIATIONS;
   RADIATION-EXPOSURE; MANAGEMENT; PLACEMENT; ANATOMY; SURGEON
AB BACKGROUND: Patients with far lateral disc herniation (FLDH) experience more severe pain and sensory symptoms compared with those with paracentral disc herniation. In addition, surgical intervention has both been more challenging and resulted in poorer outcomes,
   METHODS: We report our experience with a operative computed tomography (CT) navigation-assisted minimally invasive tubular microdiscectomy via a paramedian approach with electrophysiological monitoring for precise 3-dimensional anatomical localization and early electrophysiological identification of the exiting nerve.
   RESULTS: Five patients presenting with weakness and pain refractory to conservative management underwent iCT navigation surgery for lumbar FLDH with electrophysiological monitoring. The mean decrease in the visual analog scale pain score was 7.1 and the modified MacNab criteria outcomes were good in 1 patient and excellent in 4 patients.
   CONCLUSIONS: These results from a small group of patients suggest this is a safe approach with the potential for improved outcomes in the surgical treatment of FLDH.
C1 [Soliman, Hesham] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA.
   [Fridley, Jared; Telfeian, Albert; Choi, David B.; Galgano, Michael; Kosztowski, Thomas; Gokaslan, Ziya L.; Oyelese, Adetokunbo A.] Brown Univ, Rhode Isl Hosp, Alpert Med Sch, Dept Neurosurg, Providence, RI 02912 USA.
RP Oyelese, AA (reprint author), Brown Univ, Rhode Isl Hosp, Alpert Med Sch, Dept Neurosurg, Providence, RI 02912 USA.
EM aoyelese@lifespan.org
RI Soliman, Hesham/AAL-3811-2020
CR ABDULLAH AF, 1988, NEUROSURGERY, V22, P648, DOI 10.1227/00006123-198804000-00005
   ABDULLAH AF, 1974, J NEUROSURG, V41, P229, DOI 10.3171/jns.1974.41.2.0229
   Ahn Y, 2003, J NEUROSURG, V99, P320, DOI 10.3171/spi.2003.99.3.0320
   Ahn Y, 2013, SPINE, V38, P617, DOI 10.1097/BRS.0b013e318275ca58
   Akinduro OO, 2017, WORLD NEUROSURG, V108, P924, DOI 10.1016/j.wneu.2017.08.025
   Bae JS, 2016, J KOREAN NEUROSURG S, V59, P143, DOI 10.3340/jkns.2016.59.2.143
   Chang SB, 2006, SPINE, V31, P1163, DOI 10.1097/01.brs.0000216431.69359.91
   Choi G, 2007, SPINE, V32, pE93, DOI 10.1097/01.brs.0000252093.31632.54
   DARDEN BV, 1995, SPINE, V20, P1500, DOI 10.1097/00007632-199507000-00011
   Epstein Nancy E, 2018, Surg Neurol Int, V9, P87, DOI 10.4103/sni.sni_66_18
   EPSTEIN NE, 1995, J NEUROSURG, V83, P648, DOI 10.3171/jns.1995.83.4.0648
   EPSTEIN NE, 1990, SPINE, V15, P534, DOI 10.1097/00007632-199006000-00019
   Foley K T, 1999, Neurosurg Focus, V7, pe5
   Houten JK, 2012, NEUROSURGERY, V70, P990, DOI 10.1227/NEU.0b013e318237a829
   Iprenburg M, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2015.11.FOCUS15485
   Jenis L G, 2001, Am J Orthop (Belle Mead NJ), V30, P205
   Kakarla UK, 2010, WORLD NEUROSURG, V74, P606, DOI 10.1016/j.wneu.2010.03.028
   KAMBIN P, 1987, CLIN ORTHOP RELAT R, P145
   Marquardt G, 2012, EUR SPINE J, V21, P660, DOI 10.1007/s00586-011-2123-9
   Mendelsohn D, 2016, SPINE J, V16, P343, DOI 10.1016/j.spinee.2015.11.020
   Navarro-Ramirez R, 2017, WORLD NEUROSURG, V100, P325, DOI 10.1016/j.wneu.2017.01.025
   OHara LJ, 1997, J BONE JOINT SURG BR, V79B, P943, DOI 10.1302/0301-620X.79B6.7876
   Oyelese A, 2018, WORLD NEUROSURG, V115, P29, DOI 10.1016/j.wneu.2018.03.188
   Oyelese AA, 2018, J NEUROSURG-SPINE, V29, P46, DOI 10.3171/2017.11.SPINE17509
   Ozer AF, 2017, WORLD NEUROSURG, V100, P498, DOI 10.1016/j.wneu.2017.01.057
   Park Hyun Wook, 2013, Korean J Spine, V10, P155, DOI 10.14245/kjs.2013.10.3.155
   Phan Kevin, 2016, J Spine Surg, V2, P59, DOI 10.21037/jss.2016.03.02
   Porchet F, 1999, J NEUROSURG, V90, P59, DOI 10.3171/spi.1999.90.1.0059
   Ryang YM, 2005, J NEUROL NEUROSUR PS, V76, P971, DOI 10.1136/jnnp.2004.051102
   Sasani M, 2007, MINIM INVAS NEUROSUR, V50, P91, DOI 10.1055/s-2007-984383
   Siu TLT, 2016, J CLIN NEUROSCI, V33, P129, DOI 10.1016/j.jocn.2016.02.040
   Srinivasan D, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2014.07.041
   Viswanathan R, 2002, J NEUROSURG, V96, P206, DOI 10.3171/spi.2002.96.2.0206
   WILTSE LL, 1988, SPINE, V13, P696
NR 34
TC 0
Z9 0
U1 2
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1228
EP E1239
DI 10.1016/j.iwneu.2018.11.020
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100149
PM 30447467
DA 2020-05-12
ER

PT J
AU Son, S
   Kim, WK
   Lee, SG
   Ahn, Y
AF Son, Seong
   Kim, Woo Kyung
   Lee, Sang Gu
   Ahn, Yong
TI Long-Term Outcomes After Microscopic Anterior Cervical Foraminotomy with
   a Minimum 10-Year Follow-Up
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cervical radiculopathy; Foraminotomy; Intervertebral disc
ID DISC; MICROFORAMINOTOMY; RADICULOPATHY; DECOMPRESSION; ARTHROPLASTY;
   SPINE
AB BACKGROUND: Microscopic anterior cervical foraminotomy (MACF) is a surgical technique for unilateral cervical radiculopathy that preserves segmental motion and avoids adjacent segmental degeneration, but little is known of its long-term outcomes.
   METHODS: A retrospective minimum 10-year follow-up study was conducted on patients treated by 1 surgeon. Clinical outcomes were assessed using a visual analog scale of neck and arm pain, Neck Disability Index, and Odom criteria. Surgical outcomes were assessed using additional procedure rates. Radiologic outcomes were estimated by measuring disc heights, segmental angles, and range of motion at the surgical level and adjacent segments, and so on.
   RESULTS: Of the 94 patients who underwent MACF between January 2000 and December 2004 by 1 surgeon, 69 were enrolled in this study. Median follow-up period was 11.9 years (range, 10.0-14.5 years).
   Visual analog scales for neck or arm pain and Neck Disability Index improved significantly during follow-up period (P < 0.001). Also, according to the Odom criteria, an excellent or good outcome was achieved in 62 patients (89.9%) at final follow-up.
   An additional procedure was performed in 10 patients (14.5%) for symptom recurrence during the follow-up period. The only risk factor found to be related to the need for an additional procedure was a small preoperative range of motion at the surgical level (P = 0.018).
   Although mean disc height at the surgical level decreased significantly (from 6.23 +/- 1.10 to 5.17 +/- 1.12 mm; P = 0.004), adjacent discs were not significantly affected.
   CONCLUSIONS: Although some radiologic results have shortcomings, the results of this study suggest that MACF has favorable long-term outcomes.
C1 [Son, Seong; Kim, Woo Kyung; Lee, Sang Gu; Ahn, Yong] Gachon Univ, Gil Med Ctr, Coll Med, Dept Neurosurg, Incheon, South Korea.
RP Kim, WK (reprint author), Gachon Univ, Gil Med Ctr, Coll Med, Dept Neurosurg, Incheon, South Korea.
EM wkkim@gilhospital.com
OI Son, Seong/0000-0002-2815-9908
CR Aydin Y, 2005, SURG NEUROL, V63, P210, DOI 10.1016/j.surneu.2004.07.001
   Balasubramanian C, 2008, MINIM INVAS NEUROSUR, V51, P258, DOI 10.1055/s-0028-1082320
   Bydon M, 2014, J NEUROSURG-SPINE, V21, P727, DOI 10.3171/2014.7.SPINE131110
   Cho Tack Geun, 2014, Korean J Spine, V11, P1, DOI 10.14245/kjs.2014.11.1.1
   Choi G, 2010, MINIM INVAS NEUROSUR, V53, P127, DOI 10.1055/s-0030-1249681
   Cornelius JF, 2007, NEUROSURGERY, V61, P972, DOI 10.1227/01.neu.0000303193.64802.8f
   Hacker RJ, 2003, J NEUROSURG, V98, P126, DOI 10.3171/spi.2003.98.2.0126
   Han C, 2014, J KOREAN NEUROSURG S, V56, P200, DOI 10.3340/jkns.2014.56.3.200
   Hong WJ, 2006, MINIM INVAS NEUROSUR, V49, P296, DOI 10.1055/s-2006-954828
   Hu Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149312
   Jho HD, 1996, J NEUROSURG, V84, P155, DOI 10.3171/jns.1996.84.2.0155
   Jho HD, 2002, NEUROSURGERY, V51, pS54, DOI 10.1227/01.NEU.0000031015.31389.01
   Jho HD, 2002, NEUROSURGERY, V51, pS46, DOI 10.1227/01.NEU.0000030982.31694.2A
   Johnson JP, 2000, SPINE, V25, P905, DOI 10.1097/00007632-200004150-00002
   Kim MH, 2013, SPINE, V38, P1812, DOI 10.1097/BRS.0b013e31827ddd9e
   Kim SD, 2014, J KOREAN NEUROSURG S, V56, P114, DOI 10.3340/jkns.2014.56.2.114
   Kotani Y, 1998, SPINE, V23, P1559, DOI 10.1097/00007632-199807150-00011
   Kotil K, 2008, J CLIN NEUROSCI, V15, P749, DOI 10.1016/j.jocn.2007.04.013
   Lee JY, 2006, ACTA NEUROCHIR, V148, P951, DOI 10.1007/s00701-006-0812-7
   Li GL, 2015, J CLIN NEUROSCI, V22, P460, DOI 10.1016/j.jocn.2014.09.010
   Matz PG, 2009, J NEUROSURG-SPINE, V11, P174, DOI 10.3171/2009.3.SPINE08720
   Meisel HJ, 2016, J NEUROSURG-SPINE, V25, P556, DOI 10.3171/2016.3.SPINE15810
   ODOM GL, 1958, JAMA-J AM MED ASSOC, V166, P23, DOI 10.1001/jama.1958.02990010025006
   Park YK, 2013, EUR SPINE J, V22, P1489, DOI 10.1007/s00586-013-2712-x
   Pechlivanis I, 2008, MINIM INVAS NEUROSUR, V51, P211, DOI 10.1055/s-2008-1080914
   SMITH GW, 1958, J BONE JOINT SURG AM, V40, P607, DOI 10.2106/00004623-195840030-00009
   Umebayashi D, 2013, EUR SPINE J, V22, P2884, DOI 10.1007/s00586-013-2974-3
   VERNON H, 1991, J MANIP PHYSIOL THER, V14, P409
   White BD, 2007, BRIT J NEUROSURG, V21, P370, DOI 10.1080/02688690701441340
   Yi S, 2009, SURG NEUROL, V71, P677, DOI 10.1016/j.surneu.2008.06.017
NR 30
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E67
EP E80
DI 10.1016/j.wneu.2018.09.049
PG 14
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100008
PM 30240855
DA 2020-05-12
ER

PT J
AU Sorimachi, T
   Osada, T
   Hirayama, A
   Shigematsu, H
   Srivatanakul, K
   Matsumae, M
AF Sorimachi, Takatoshi
   Osada, Takahiro
   Hirayama, Akihiro
   Shigematsu, Hideaki
   Srivatanakul, Kittipong
   Matsumae, Mitsunori
TI Preservation of Anterior Choroidal Artery Blood Flow During Trapping of
   the Internal Carotid Artery for a Ruptured Blood Blister-Like Aneurysm
   with High-Flow Bypass
SO WORLD NEUROSURGERY
LA English
DT Article
DE Bypass; Cerebral infarction; Complications; Internal carotid artery
   aneurysm; Subarachnoid hemorrhage
ID SUBARACHNOID HEMORRHAGE; BALLOON OCCLUSION; ENCIRCLING CLIP; GRAFT;
   MANAGEMENT; REPAIR; WALL
AB BACKGROUND: The ideal surgery for a blood blister-like aneurysm (BBA) in the internal carotid artery (ICA) involves complete termination of blood flow into the BBA by trapping of the ICA at sites both proximal and distal to the BBA. In the present report, we describe a clipping method with ICA trapping for prevention of anterior choroidal artery ischemia, a major problem in ICA trapping with reconstruction surgery using external carotid artery-middle cerebral artery high-flow bypass (HFB).
   METHODS: The data from patients with a ruptured BBA treated by the combination of ICA trapping and blood flow reconstruction from 2008 to 2018 were retrospectively evaluated.
   RESULTS: Fifteen patients had been treated with the combination surgery. Clip placement for ICA trapping depended on the relationship between the distal neck of the BBA and the posterior communicating artery. In the case of the BBA distal neck located at the same level or distal to the posterior communicating artery, oblique placement of a distal clip to the ICA was mandatory to maintain blood flow of the anterior choroidal artery. No patients developed recurrence of the BBA after trapping. The outcomes were assessed using the modified Rankin scale score, with a score of 0 or 1 in 12 of the 15 patients (80%).
   CONCLUSIONS: A complete shutdown of blood flow to the BBA by ICA trapping is essential for the permanent prevention of BBA recurrence. In cases of a BBA distal neck located distal to the posterior communicating artery, the oblique clipping technique applied to the ICA is useful to prevent ischemic complications of the anterior choroidal artery.
C1 [Sorimachi, Takatoshi; Osada, Takahiro; Hirayama, Akihiro; Shigematsu, Hideaki; Srivatanakul, Kittipong; Matsumae, Mitsunori] Tokai Univ, Dept Neurosurg, Hiratsuka, Kanagawa, Japan.
RP Sorimachi, T (reprint author), Tokai Univ, Dept Neurosurg, Hiratsuka, Kanagawa, Japan.
EM sorimachi@tokai-u.jp
CR Aydin K, 2015, J NEUROINTERV SURG, V7, P202, DOI 10.1136/neurintsurg-2013-011090
   Baskaya MK, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/2/E13
   Fujimura M, 2013, SURG CEREBRAL STROKE, V41, P201
   FUJITSU K, 1994, J NEUROSURG, V80, P336, DOI 10.3171/jns.1994.80.2.0336
   Hall R, 2011, ANESTH ANALG, V112, P292, DOI 10.1213/ANE.0b013e318203f38d
   ISHIKAWA T, 1995, SURG NEUROL, V43, P500, DOI 10.1016/0090-3019(95)80098-2
   Kalani MYS, 2013, NEUROSURGERY, V73, P1026, DOI 10.1227/NEU.0000000000000147
   Kamijo K, 2010, J NEUROSURG, V113, P781, DOI 10.3171/2009.10.JNS09970
   Kawashima A, 2008, J CLIN NEUROSCI, V15, P797, DOI 10.1016/j.jocn.2007.03.012
   Kazumata K, 2014, OPER NEUROSURG, V10, P66, DOI 10.1227/NEU.0000000000000076
   Kikkawa Y, 2017, WORLD NEUROSURG, V105, P470, DOI 10.1016/j.wneu.2017.06.033
   Kotowski A, 2011, ENVIRON PROT ENG, V37, P105
   Kubo Y, 2006, J NEUROSURG, V105, P785, DOI 10.3171/jns.2006.105.5.785
   Lang ST, 2017, J NEUROINTERV SURG, V9, pE16, DOI 10.1136/neurintsurg-2016-012506.rep
   Lee JW, 2009, ACTA NEUROCHIR, V151, P125, DOI 10.1007/s00701-008-0165-5
   Liu YT, 2012, BRIT J NEUROSURG, V26, P378, DOI 10.3109/02688697.2011.631617
   Meling TR, 2008, J NEUROSURG, V108, P662, DOI 10.3171/JNS/2008/108/4/0662
   Murai Y, 2012, WORLD NEUROSURG, V77, P166, DOI 10.1016/j.wneu.2011.05.020
   NAKAGAWA F, 1986, J NEUROSURG, V65, P303, DOI 10.3171/jns.1986.65.3.0303
   Nakano S, 2000, SURG NEUROL, V53, P330, DOI 10.1016/S0090-3019(00)00177-4
   Ogawa A, 2000, NEUROSURGERY, V47, P578, DOI 10.1097/00006123-200009000-00008
   Ohkuma H, 2002, J NEUROSURG, V97, P576, DOI 10.3171/jns.2002.97.3.0576
   Okudaira Y, 1996, STROKE, V27, P617, DOI 10.1161/01.STR.27.4.617
   Park JH, 2007, J NEUROSURG, V106, P812, DOI 10.3171/jns.2007.106.5.812
   Peschillo S, 2016, AM J NEURORADIOL, V37, P856, DOI 10.3174/ajnr.A4606
   Princiotta C, 2011, INTERV NEURORADIOL, V17, P365, DOI 10.1177/159101991101700314
   Sekula RF, 2006, NEUROSURGERY, V59, P168, DOI 10.1227/01.NEU.0000220058.17532.B5
   Senbokuya N, 2013, J NEUROSURG, V118, P121, DOI 10.3171/2012.9.JNS12492
   Sorimachi T, 2013, SURG CEREB STROKE, V41, P43
   Sugawara Y, 2002, J NUCL MED, V43, P1616
   Yanagisawa T, 2004, J NEUROSURG, V100, P146, DOI 10.3171/jns.2004.100.1.0146
   Yanaka K, 2002, NEUROSURGERY, V50, P218, DOI 10.1097/00006123-200201000-00037
   Yoon JW, 2014, NEUROSURGERY, V75, P419, DOI 10.1227/NEU.0000000000000487
NR 33
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E847
EP E855
DI 10.1016/j.wneu.2018.10.162
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100102
PM 30391762
DA 2020-05-12
ER

PT J
AU Still, MEH
   Venturini, S
   Vycheth, I
   Nang, S
   Vuthy, D
   Park, KB
AF Still, Megan E. H.
   Venturini, Sara
   Vycheth, Iv
   Nang, Sam
   Vuthy, Din
   Park, Kee B.
TI Predictive Factors of Spine Surgery Complications at a Major Government
   Hospital in Cambodia
SO WORLD NEUROSURGERY
LA English
DT Article
DE Complications; Low- and middle-income countries; Risk factors; Spine
   complications; Spine surgery
ID CORD-INJURY; RISK; CHALLENGE; MORTALITY
AB BACKGROUND: Spine pathology is a common reason for admission to neurosurgical units in low- and middle-income countries (LMICs) and can have high morbidity rates from lack of specialized institutes. However, good surgical outcomes and quality-of-life scores have been reported in LMICs.
   This study details the complication rates and predictive factors from spine surgery at a large hospital in Cambodia, aiming to identify high-risk patients to improve surgeon understanding of these complications for improved preoperative planning and patient counseling.
   METHODS: This is a retrospective review of patients admitted for spine conditions to Preah Kossamak Hospital in Phnom Penh, Cambodia (2013-2017). Univariate analysis was conducted on potential predictive factors; variables with P < 0.1 were entered into multivariate logistic regression models.
   RESULTS: Seven hundred seventy-three patients were included. Forty-six patients had complications including wrong level surgery, hardware failure, and infection. On multivariate analysis, patients from the provinces of Kratie (P = 0.009) or Sihanoukville (P = 0.036), and those that delayed seeking care for more than 1 year after injury (P = 0.027), were significant predictive factors of postoperative complications, and American Spinal Injury Association grade A injury (P = 0.020) was a predictive factor of poor outcome.
   CONCLUSIONS: Many factors play a role in spine surgery complications in LMICs, including limited access to intra-operative technology, low follow-up rates, and minimal physiotherapy and rehabilitation capabilities. Patients with long delays in presentation, American Spinal Injury Association grade A injuries, and lumbar-level surgery may be especially susceptible to complications and postoperative morbidity. Despite this, institutions have reported encouraging spine trauma outcomes, and spine surgeries are becoming more accepted and safe operations in many LMICs.
C1 [Still, Megan E. H.] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA.
   [Still, Megan E. H.; Venturini, Sara; Vycheth, Iv; Nang, Sam; Vuthy, Din; Park, Kee B.] Preah Kossamak Hosp, Dept Neurosurg, Phnom Penh, Cambodia.
   [Venturini, Sara] Univ Leicester, Leicester Med Sch, Leicester, Leics, England.
   [Park, Kee B.] Harvard Med Sch, Dept Global Hlth & Social Med, Program Global Surg & Social Change, Boston, MA USA.
RP Still, MEH (reprint author), Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA.; Still, MEH (reprint author), Preah Kossamak Hosp, Dept Neurosurg, Phnom Penh, Cambodia.
EM Megan.Still@UTSouthwestern.edu
CR Brasil AVB, 1998, SPINAL CORD, V36, P353, DOI 10.1038/sj.sc.3100630
   Burns AS, 2012, J SPINAL CORD MED, V35, P3, DOI 10.1179/2045772311Y.0000000043
   Chua MH, 2018, WORLD NEUROSURG, V114, P375, DOI 10.1016/j.wneu.2018.03.057
   Farshad M, 2018, SPINE J, V18, P1625, DOI 10.1016/j.spinee.2018.02.003
   Gosselin RA, 2005, INT ORTHOP, V29, P330, DOI 10.1007/s00264-005-0665-3
   Goz V, 2013, SPINE, V38, P1970, DOI 10.1097/BRS.0b013e3182a62527
   Jang HD, 2018, SPINE J, V18, P285, DOI 10.1016/j.spinee.2017.07.168
   Kpelao E, 2013, NEUROCHIRURGIE, V59, P111, DOI 10.1016/j.neuchi.2013.04.008
   Kumar R, 2018, WORLD NEUROSURG, V113, pE345, DOI 10.1016/j.wneu.2018.02.033
   Laudato PA, 2018, SPINE, V43, pE373, DOI 10.1097/BRS.0000000000002449
   Lehre MA, 2015, J NEUROSURG-SPINE, V23, P772, DOI 10.3171/2015.3.SPINE141282
   Li G, 2010, EUR SPINE J, V19, P1576, DOI 10.1007/s00586-010-1316-y
   Peeters S, 2017, WORLD NEUROSURG, V97, P580, DOI 10.1016/j.wneu.2016.09.127
   Schoenfeld AJ, 2013, SPINE J, V13, P1171, DOI 10.1016/j.spinee.2013.02.071
   Schoenfeld AJ, 2011, J BONE JOINT SURG AM, V93A, P1577, DOI 10.2106/JBJS.J.01048
   Venturini S, 2018, WORLD NEUROSURG, V109, P98, DOI 10.1016/j.wneu.2017.09.117
NR 16
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1172
EP E1180
DI 10.1016/j.wneu.2018.11.014
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100143
PM 30447437
DA 2020-05-12
ER

PT J
AU Stone, JJ
   Adamo, DA
   Khan, DZ
   Packard, AT
   Broski, SM
   Nathan, MA
   Howe, BM
   Spinner, RJ
AF Stone, Jonathan J.
   Adamo, Daniel A.
   Khan, Danyal Z.
   Packard, Ann T.
   Broski, Stephen M.
   Nathan, Mark A.
   Howe, B. Matthew
   Spinner, Robert J.
TI Multimodal Imaging Aids in the Diagnosis of Perineural Spread of
   Prostate Cancer
SO WORLD NEUROSURGERY
LA English
DT Article
DE Lumbosacral plexus; MRI; Magnetic resonance imaging; PET; Perineural
   spread; Positron emission tomography; Prostate cancer; Sciatic nerve
ID LUMBOSACRAL PLEXOPATHY
AB BACKGROUND: The perineural spread of prostate cancer into pelvic peripheral nerves is a rare, but increasingly recognized, entity. This form of metastasis invades the lumbosacral plexus via the splanchnic nerves innervating the prostate. The prevalence of perineural spread is likely underappreciated, and further imaging-based studies are needed to elucidate its true frequency.
   METHODS: A retrospective review was performed using an institutional radiology database. Medical reports from patients with prostate cancer who had undergone positron emission tomography (PET) imaging were queried for terms suggestive of perineural spread. PET and magnetic resonance imaging (MRI) from the identified patients were blindly reviewed for peripheral nerve involvement by 2 nuclear medicine and 2 musculoskeletal radiologists.
   RESULTS: A total of 22 patients were identified. After review by the radiologists, 16 patients had positive findings of perineural spread found on PET and 15 had abnormalities found on MRI involving lumbosacral plexus neural elements. All patients with biopsy-proven neoplastic perineural spread (including 1 patient with malignant peripheral nerve sheath tumor) had positive findings on both PET and MRI. All patients with biopsy-proven inflammatory lesions had negative PET and variable MRI findings.
   CONCLUSIONS: The perineural spread of prostate cancer might be more common than previously thought. The use of multimodal imaging for patients suspected of having perineural spread should be a part of the treatment algorithm. Targeted fascicular biopsy might be indicated for patients with progressive neurological deficit and an unclear diagnosis.
C1 [Stone, Jonathan J.; Khan, Danyal Z.; Spinner, Robert J.] Mayo Clin, Dept Neurol Surg, Rochester, MN 55905 USA.
   [Adamo, Daniel A.; Packard, Ann T.; Broski, Stephen M.; Nathan, Mark A.; Howe, B. Matthew] Mayo Clin, Dept Radiol, Rochester, MN USA.
RP Spinner, RJ (reprint author), Mayo Clin, Dept Neurol Surg, Rochester, MN 55905 USA.
EM spinner.robert@mayo.edu
CR Aguilera Navarro J M, 1993, Neurologia, V8, P271
   Babu MA, 2013, ABDOM IMAGING, V38, P1155, DOI 10.1007/s00261-013-9991-x
   Bartels AL, 2009, CASES J, V3, P1
   Bashir Muhammad Naeem, 2015, Asian Pac J Cancer Prev, V16, P5137
   Capek S, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.7.FOCUS15209
   Capek S, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.6.FOCUS15213
   Capek S, 2015, SKELETAL RADIOL, V44, P1365, DOI 10.1007/s00256-015-2143-3
   Capek S, 2015, J NEUROSURG, V122, P778, DOI 10.3171/2014.12.JNS141339
   Crush AB, 2014, RADIOGRAPHICS, V34, P1987, DOI 10.1148/rg.347130129
   Hebert-Blouin MN, 2010, ACTA NEUROCHIR, V152, P1567, DOI 10.1007/s00701-010-0682-x
   JAECKLE KA, 1985, NEUROLOGY, V35, P8, DOI 10.1212/WNL.35.1.8
   Ladha SS, 2006, MUSCLE NERVE, V34, P659, DOI 10.1002/mus.20597
   Liu YY, 2010, ANTICANCER RES, V30, P369
   Rauscher I., 2014, J NUCL MED, V55, P1
   Reinicke K, 2012, J CELL BIOCHEM, V113, P553, DOI 10.1002/jcb.23379
   Stone Jonathan J, 2018, Neurosurg Focus, V44, pV7, DOI 10.3171/2018.1.FocusVid.17580
   Taylor BV, 1997, MAYO CLIN PROC, V72, P823, DOI 10.4065/72.9.823
   THOMAS JE, 1985, NEUROLOGY, V35, P1
   Wallitt KL, 2017, RADIOGRAPHICS, V37, P1512, DOI 10.1148/rg.2017170035
   Weber WA, 2014, J NUCL MED, V55, p56S, DOI 10.2967/jnumed.113.129270
   Wetter A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101571
NR 21
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E235
EP E240
DI 10.1016/j.wneu.2018.09.221
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100025
PM 30312825
DA 2020-05-12
ER

PT J
AU Sun, KQ
   Wang, SM
   Sun, JC
   Guo, YF
   Huan, L
   Xu, XM
   Sun, XF
   Zhang, B
   Wang, Y
   Shi, JG
AF Sun, Kaiqiang
   Wang, Shunmin
   Sun, Jingchuan
   Guo, Yongfei
   Huan, Le
   Xu, Ximing
   Sun, Xiaofei
   Zhang, Bin
   Wang, Yuan
   Shi, Jiangang
TI Analysis of the Correlation Between Cerebrospinal Fluid Space and
   Outcomes of Anterior Controllable Antedisplacement and Fusion for
   Cervical Myelopathy Due to Ossification of the Posterior Longitudinal
   Ligament
SO WORLD NEUROSURGERY
LA English
DT Article
DE ACAF; Anterior controllable antedisplacement and fusion; CSF space;
   Radiological parameters; Surgical outcomes; T2-weighed MRI
ID SPINAL-CORD COMPRESSION; SPONDYLOTIC MYELOPATHY; DECOMPRESSIVE SURGERY;
   SIGNAL INTENSITY; FLOW; CORPECTOMY
AB OBJECTIVE: We investigated whether the cerebrospinal fluid (CSF) space on magnetic resonance imaging (MRI) correlates with the outcomes of anterior controllable antedisplacement and fusion (ACAF) for ossification of the posterior longitudinal ligament (OPLL).
   METHODS: A total of 53 patients with OPLL who had undergone ACAF were enrolled. The Japanese Orthopaedic Association (JOA) scale, visual analog scale, and neck disability index were used to evaluate the clinical outcomes. The area of CSF space and spinal cord on T2-weighted MRI, the occupying rate of the CSF space and spinal cord, and the postoperative MRI score of the CSF space were measured. The patients were divided into 2 groups according to the JOA score improvement rate (IR). The relationship between the postoperative MRI score and the JOA score IR was analyzed.
   RESULTS: The patients in group A experienced better recovery compared with those in group B regarding the JOA, visual analog scale, and neck disability index score at the final follow-up visit. On both axial and sagittal T2-weighed MRI, patients in group A experienced lower improvement of the area of the spinal cord than in group B (P > 0.05). However, the mean improvement in the CSF space in group A was better than that in group B (62.86 +/- 30.05 mm(2) vs. -6.36 +/- 24.58 mm(2); P < 0.05), with a greater occupying rate of CSF space in group A at the final visit. A strong correlation was noted between the JOA score IR and postoperative CSF space score (P < 0.01).
   CONCLUSION: These results suggest that ACAF could provide good decompression of the spinal cord and neurological improvement. Also, recovery of the CSF space correlated closely with the surgical ACAF outcomes for cervical myelopathy due to OPLL.
C1 [Sun, Kaiqiang; Wang, Shunmin; Sun, Jingchuan; Guo, Yongfei; Huan, Le; Xu, Ximing; Sun, Xiaofei; Zhang, Bin; Wang, Yuan; Shi, Jiangang] Changzheng Hosp, Dept Spine Surg 2, Shanghai, Peoples R China.
RP Shi, JG (reprint author), Changzheng Hosp, Dept Spine Surg 2, Shanghai, Peoples R China.
EM changzhengspine@smmu.edu.cn
CR ALMEFTY O, 1988, J NEUROSURG, V68, P217, DOI 10.3171/jns.1988.68.2.0217
   Chatley A, 2009, J NEUROSURG-SPINE, V11, P562, DOI 10.3171/2009.6.SPINE091
   Chen ZH, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2016.3.FOCUS15596
   GRIFFITHS IR, 1978, NEUROLOGY, V28, P1145, DOI 10.1212/WNL.28.11.1145
   Gu YF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136042
   Ito K, 2016, SPINE, V42, pE98
   Iwasaki M, 2007, SPINE, V32, P647, DOI 10.1097/01.brs.0000257560.91147.86
   Kawano O, 2014, SPINE, V39, P1108, DOI 10.1097/BRS.0000000000000361
   KOYANAGI T, 1993, SPINE, V18, P1958, DOI 10.1097/00007632-199310001-00006
   Levy L M, 1999, Magn Reson Imaging Clin N Am, V7, P573
   Liu HC, 2013, EUR SPINE J, V22, P1480, DOI 10.1007/s00586-013-2707-7
   Liu XZ, 2014, EUR SPINE J, V23, P362, DOI 10.1007/s00586-013-3043-7
   Mizuno J, 2003, J NEUROSURG, V99, P162, DOI 10.3171/spi.2003.99.2.0162
   Naderi S, 1998, NEUROSURGERY, V43, P43, DOI 10.1097/00006123-199807000-00028
   OHSHIO I, 1993, SPINE, V18, P1140, DOI 10.1097/00007632-199307000-00005
   Rajshekhar V, 2005, NEUROSURGERY, V56, P1279, DOI 10.1227/01.NEU.0000159713.20597.0F
   Shibuya R, 2002, SPINE, V27, P1087, DOI 10.1097/00007632-200205150-00015
   Shin JJ, 2010, ACTA NEUROCHIR, V152, P1687, DOI 10.1007/s00701-010-0692-8
   Shou FY, 2015, EUR SPINE J, V24, P2724, DOI 10.1007/s00586-015-4186-5
   Sun JC, 2018, WORLD NEUROSURG, V113, pE101, DOI 10.1016/j.wneu.2018.01.181
   Sun JC, 2018, WORLD NEUROSURG, V116, pE118, DOI 10.1016/j.wneu.2018.04.128
   Sun JC, 2018, WORLD NEUROSURG, V120, pE1098, DOI 10.1016/j.wneu.2018.08.233
   Sun JC, 2018, EUR SPINE J, V27, P1469, DOI 10.1007/s00586-017-5437-4
   Sun QZ, 2011, EUR SPINE J, V20, P1466, DOI 10.1007/s00586-011-1813-7
   Tominaga T, 2002, NEUROSURGERY, V50, P791, DOI 10.1097/00006123-200204000-00020
   Vavasour IM, 2014, SPINE J, V14, P2344, DOI 10.1016/j.spinee.2014.01.036
   Vedantam A, 2014, SPINE, V39, P1458, DOI 10.1097/BRS.0000000000000440
   Vedantam A, 2011, J NEUROSURG-SPINE, V15, P660, DOI 10.3171/2011.8.SPINE11452
   Watabe N, 1999, NEUROSURGERY, V44, P779, DOI 10.1097/00006123-199904000-00052
   Yang H, 2018, WORLD NEUROSURG, V38, P205
   Yang HS, 2018, WORLD NEUROSURG, V115, pE501, DOI 10.1016/j.wneu.2018.04.078
   Yun JB, 2016, EUR SPINE J, V26, P1
NR 32
TC 2
Z9 2
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E358
EP E366
DI 10.1016/j.wneu.2018.10.051
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100042
PM 30326311
DA 2020-05-12
ER

PT J
AU Swong, K
   Johans, S
   Molefe, A
   Hofler, RC
   Wemhoff, M
   Kuo, P
   Germanwala, A
AF Swong, Kevin
   Johans, Stephen
   Molefe, Ayrin
   Hofler, Ryan C.
   Wemhoff, Michael
   Kuo, Paul
   Germanwala, Anand
TI Unintended Consequences After Postoperative Ileus in Spinal Fusion
   Patients
SO WORLD NEUROSURGERY
LA English
DT Article
DE Database; Ileus; Length of stay; Spinal fusion
ID LUMBAR SPINE; RISK-FACTORS; SURGERY; COMPLICATIONS; ANTERIOR; MORBIDITY;
   POSTERIOR
AB BACKGROUND: Postoperative ileus is not uncommon after spinal surgery. Although previous research has focused on the frequency of ileus formation, little has been done to investigate the clinical sequelae after development. We investigated the effect of postoperative ileus on patients' length of stay and rates of deep vein thrombosis (DVT) formation, myocardial infarction (MI), aspiration pneumonia, sepsis, and death.
   METHODS: The Healthcare Cost and Utilization Project National Inpatient Sample was queried to identify adult patients who underwent any spinal fusion procedure. Patient characteristics and outcomes for discharges involving spinal fusion surgery were compared between patients with and without postoperative ileus. The Rao-Scott chi(2) test of association was used for categorical variables, and a t test for equality of means was used for continuous variables. Among discharges with postoperative ileus, a multivariate linear regression model was used to assess how fusion approach and fusion length were associated with length of hospital stay, controlling for sex, age, and race.
   RESULTS: A total of 250,221 patients were included. The mean length of stay was 3.75 days for patients without postoperative ileus and 9.40 days for patients with postoperative ileus. Patients with postoperative ileus are more likely to have DVT (4.1% vs. 20.8%, P < 0.001), MI (2.5% vs. 7.1%, P < 0.001), aspiration pneumonia (6.6% vs. 34.3%, P < 0.001), sepsis (5.7% vs. 35.7%, P < 0.001), and death (2.6% vs. 11.4%, P < 0.001).
   CONCLUSIONS: This study demonstrates that patients with postoperative ileus are significantly more likely to have DVT, experience MI, acquire aspiration pneumonia, develop sepsis, and die.
C1 [Swong, Kevin; Johans, Stephen; Hofler, Ryan C.; Wemhoff, Michael; Germanwala, Anand] Loyola Univ, Med Ctr, Dept Neurol Surg, Maywood, IL 60153 USA.
   [Kuo, Paul] Loyola Univ, Med Ctr, Dept Surg, Maywood, IL 60153 USA.
   [Molefe, Ayrin] Loyola Univ Chicago, Biostat Collaborat Core, Clin Res Off, Maywood, IL USA.
RP Germanwala, A (reprint author), Loyola Univ, Med Ctr, Dept Neurol Surg, Maywood, IL 60153 USA.
EM agermanwala@gmail.com
CR Al Maaieh MA, 2014, SPINE, V39, P688, DOI 10.1097/BRS.0000000000000238
   Althausen PL, 2001, J SPINAL DISORD, V14, P541, DOI 10.1097/00002517-200112000-00014
   Asgeirsson T, 2010, J AM COLL SURGEONS, V210, P228, DOI 10.1016/j.jamcollsurg.2009.09.028
   Bennett-Guerrero E, 1999, ANESTH ANALG, V89, P514, DOI 10.1097/00000539-199908000-00050
   Coe JD, 2006, SPINE, V31, P345, DOI 10.1097/01.brs.0000197188.76369.13
   Daubs MD, 2007, SPINE, V32, P2238, DOI 10.1097/BRS.0b013e31814cf24a
   Doorly MG, 2012, SURG CLIN N AM, V92, P259, DOI 10.1016/j.suc.2012.01.010
   Durand WM, 2018, WORLD NEUROSURG, V116, pE806, DOI 10.1016/j.wneu.2018.05.099
   FACISZEWSKI T, 1995, SPINE, V20, P1592, DOI 10.1097/00007632-199507150-00007
   Fineberg SJ, 2014, SPINE J, V14, P1680, DOI 10.1016/j.spinee.2013.10.015
   FUJIMAKI A, 1982, CLIN ORTHOP RELAT R, P164
   Gruskay JA, 2015, SPINE J, V15, P1188, DOI 10.1016/j.spinee.2013.10.022
   Kiely PD, 2016, INT ORTHOP, V40, P1067, DOI 10.1007/s00264-016-3148-9
   Mobbs RJ, 2012, J CLIN NEUROSCI, V19, P829, DOI 10.1016/j.jocn.2011.10.004
   Pannell WC, 2015, SPINE J, V15, P1719, DOI 10.1016/j.spinee.2013.10.014
   Rajaraman V, 1999, J NEUROSURG, V91, P60, DOI 10.3171/spi.1999.91.1.0060
   Senagore AJ, 2007, AM J HLTH SYST P S13, V64, P3
NR 17
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E512
EP E515
DI 10.1016/j.wneu.2018.10.093
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100062
PM 31060199
DA 2020-05-12
ER

PT J
AU Takai, K
   Komori, T
   Taniguchi, M
AF Takai, Keisuke
   Komori, Takashi
   Taniguchi, Makoto
TI Angioarchitecture of Filum Terminale Arteriovenous Fistulas:
   Relationship with a Tethered Spinal Cord
SO WORLD NEUROSURGERY
LA English
DT Article
DE Arteriovenous shunt; Endovascular treatment; Outcome; Perimedullary;
   Surgical treatment; Vascular anatomy; Vascular malformation
ID ENDOVASCULAR TREATMENT; SACRAL LIPOMA; NEURAL-TUBE; MALFORMATION;
   SHUNTS; ADAMKIEWICZ; ARTERY
AB OBJECTIVE:Spinal arteriovenous fistulas at the filum terminale (filum AVFs) are rare. Treatment strategies have not yet been established, particularly for cases of filum AVF with lipoma.
   METHODS:We report 7 cases of filum AVF with (n = 3) or without (n = 4) a tethered spinal cord by sacral terminal lipoma, with a focus on angiographic and operative findings.
   RESULTS:All 7 patients (median age, 73 years; range, 40-84 years; men: n = 5) presented with slowly progressive paraparesis, lower extremity sensory disturbances, and bladder/bowel disturbances. Filum AVFs were fed by the filum artery, the distal segment of the anterior spinal artery supplied from the artery of Adamkiewicz. The arteriovenous shunt was located at the filum terminale and drained via the ascending filum vein. In 3 patients with filum AVFs without lipoma, the artery of Adamkiewicz originated from the thoracic segmental artery. In contrast, in 3 patients with filum AVFs with lipoma, the artery of Adamkiewicz originated from the lower lumber or sacral artery because of low-lying conus medullaris. In all patients, filum AVFs were completely obliterated by microsurgical resection of the filum terminale including the arteriovenous fistula. Recurrence was not reported in the follow-up period (median, 64 months), except for 1 patient who required additional surgery because of complex neurovascular structures.
   CONCLUSIONS:Caution is needed when identifying the spinal level of occlusion of the fistula, particularly in cases of a tethered spinal cord by lipoma, because the feeding artery is associated with the artery of Adamkiewicz, which supplies the low-lying spinal cord in the sacral region.
C1 [Takai, Keisuke; Taniguchi, Makoto] Tokyo Metropolitan Neurol Hosp, Dept Neurosurg, Tokyo, Japan.
   [Komori, Takashi] Tokyo Metropolitan Neurol Hosp, Dept Lab Med & Pathol, Tokyo, Japan.
RP Takai, K (reprint author), Tokyo Metropolitan Neurol Hosp, Dept Neurosurg, Tokyo, Japan.
EM takai-nsu@umin.ac.jp
CR Alleyne CH, 1998, J NEUROSURG, V89, P791, DOI 10.3171/jns.1998.89.5.0791
   AMINOFF MJ, 1974, BRAIN, V97, P211, DOI 10.1093/brain/97.1.211
   Bley TA, 2010, RADIOLOGY, V255, P873, DOI 10.1148/radiol.10091304
   Brockstein B, 1994, Ann Vasc Surg, V8, P394, DOI 10.1007/BF02133005
   Chanthanaphak E, 2013, J NEUROSURG-SPINE, V19, P49, DOI 10.3171/2013.4.SPINE12685
   CHAPMAN PH, 1993, PEDIATR NEUROSURG, V19, P267, DOI 10.1159/000120743
   CHAPMAN PH, 1982, CHILD BRAIN, V9, P37
   Cheung AC, 2005, NEUROSURGERY, V57, P598, DOI 10.1227/01.NEU.0000171028.96829
   DJINDJIAN M, 1989, J NEUROSURG, V71, P768, DOI 10.3171/jns.1989.71.5.0768
   Erdogan C, 2007, Br J Radiol, V80, pe98, DOI 10.1259/bjr/61517865
   Giordan E, 2018, AM J NEURORADIOL, V39, P597, DOI 10.3174/ajnr.A5498
   Giordan E, 2018, J NEUROINTERV SURG, V10, P191, DOI 10.1136/neurintsurg-2017-013309
   Hong T, 2017, AM J NEURORADIOL, V38, P403, DOI 10.3174/ajnr.A5001
   Krisht KM, 2015, CASE REP NEUROL MED, V2015, P1
   Lee JH, 2000, AM J NEURORADIOL, V21, P595
   Lim SM, 2011, AM J NEURORADIOL, V32, P1846, DOI 10.3174/ajnr.A2612
   Macht S, 2012, NEURORADIOLOGY, V54, P517, DOI 10.1007/s00234-011-0899-2
   Mavani SB, 2014, J NEUROSURG-SPINE, V21, P489, DOI 10.3171/2014.5.SPINE13670
   MOURIER KL, 1993, NEUROSURGERY, V32, P885, DOI 10.1227/00006123-199306000-00001
   MULLER F, 1987, ANAT EMBRYOL, V176, P413, DOI 10.1007/BF00310083
   PierreKahn A, 1997, CHILD NERV SYST, V13, P298, DOI 10.1007/s003810050090
   Rajeev K, 2005, J NEUROSURG-SPINE, V3, P386, DOI 10.3171/spi.2005.3.5.0386
   Rodesch G, 2002, NEUROSURGERY, V51, P374, DOI 10.1097/00006123-200208000-00013
   Saitsu H, 2004, ANAT EMBRYOL, V209, P107, DOI 10.1007/s00429-004-0421-2
   Sato M, 2013, NEUROL MED-CHIR, V53, P107, DOI 10.2176/nmc.53.107
   Takai K, 2018, WORLD NEUROSURG, V111, pE819, DOI 10.1016/j.wneu.2017.12.162
   Takai K, 2017, NEUROL MED-CHIR, V57, P356, DOI 10.2176/nmc.ra.2016-0316
   Takai K, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2015.12.FOCUS15574
   Takai K, 2015, ACTA NEUROCHIR, V157, P1659, DOI 10.1007/s00701-015-2531-4
   Takai K, 2013, J NEUROSURG-SPINE, V18, P398, DOI 10.3171/2013.1.SPINE12305
   Weon YC, 2005, NEURORADIOLOGY, V47, P774, DOI 10.1007/s00234-005-1336-1
NR 31
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E795
EP E804
DI 10.1016/j.wneu.2018.10.149
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100096
PM 30391599
DA 2020-05-12
ER

PT J
AU Tavares, WM
   Tustumi, F
   Leite, CD
   Gamarra, LF
   Amaro, E
   Texeira, MJ
   de Franca, SA
   Fonoff, ET
AF Tavares, Wagner Malago
   Tustumi, Francisco
   Leite, Claudia da Costa
   Gamarra, Lionel Fernel
   Amaro Junior, Edson
   Texeira, Manoel Jacobsen
   de Franca, Sabrina Araujo
   Fonoff, Erich Talamoni
TI Distortion Correction Protocol for 3T Stereotactic Magnetic Resonance
   Imaging: A Clinical Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Clinical protocol; Distortion; Inverted sequence; Magnetic resonance;
   Stereotactic technique
ID GEOMETRIC DISTORTION; MRI SYSTEMS; FIELD; RADIOTHERAPY; IMAGES
AB BACKGROUND: With application of 3T magnetic resonance imaging (MRI) to functional neurosurgery procedures and given the inherent requirement of millimetric precision, the need to develop a method for correction of geometric image distortion emerged. The aim of this study was to demonstrate clinical safety and practical viability of a correction protocol in patients scheduled to undergo stereotactic procedures using 3T MRI.
   METHODS: This prospective study comprised 20 patients scheduled to undergo computed tomography (CT) stereotactic functional procedures or encephalic brain lesion biopsies. The CT images were references for MRI geometric accuracy calculations. For each scan, 2 images were obtained: normal and reversed images. Eight distinct points on CT and MRI were selected summing 152 points that were based on a power analysis calculation value >0.999. One patient was excluded because of the inability to find reliable common landmark points on CT and MRI.
   RESULTS: The distortion range was 0-5.6 mm and increased proportionally with stereotactic isocenter distance, meaning the distortion was greater in the periphery. After correction, the minimum and maximum distortion found was 0 mm and 3.5 mm, respectively. There was no significant difference between CT and MRI corrected x-coordinates (P > 0.05).
   CONCLUSIONS: The proposed method can satisfactorily correct geometric distortions in clinical 3T MRI studies. Clinical use of the technique can be practical and efficient after software automation of the process. The method can be applied to all spin-echo MRI sequences.
C1 [Tavares, Wagner Malago; Tustumi, Francisco; Texeira, Manoel Jacobsen; Fonoff, Erich Talamoni] Univ Sao Paulo, Inst Neurol, Div Funct Neurosurg, Sao Paulo, Brazil.
   [Leite, Claudia da Costa; Gamarra, Lionel Fernel; Amaro Junior, Edson] Univ Sao Paulo, Inst Radiol, Dept Radiol, Sao Paulo, Brazil.
   [Tavares, Wagner Malago; de Franca, Sabrina Araujo] Inst Paulista Saude Alta Complexidade, Santo Andre, Brazil.
   [Gamarra, Lionel Fernel] Albert Einstein Israelita Hosp, Sao Paulo, Brazil.
RP de Franca, SA (reprint author), Inst Paulista Saude Alta Complexidade, Santo Andre, Brazil.
EM ipspac.saude@gmail.com
RI Gamarra, Lionel fernel/AAA-9638-2020; GAMARRA, LIONEL/AAF-7201-2020;
   Fonoff, Erich Talamoni/E-4327-2012; Tustumi, Francisco/K-4992-2017
OI Gamarra, Lionel fernel/0000-0002-3910-0047; Fonoff, Erich
   Talamoni/0000-0001-7831-9941; Tustumi, Francisco/0000-0001-6695-0496
CR Alvarez-Linera J, 2008, EUR J RADIOL, V67, P415, DOI 10.1016/j.ejrad.2008.02.045
   BAKKER CJG, 1992, MAGN RESON IMAGING, V10, P597, DOI 10.1016/0730-725X(92)90011-N
   Baldwin LN, 2007, MED PHYS, V34, P388, DOI 10.1118/1.2402331
   CHANG H, 1992, IEEE T MED IMAGING, V11, P319, DOI 10.1109/42.158935
   Chen LL, 2004, INT J RADIAT ONCOL, V60, P636, DOI 10.1016/j.ijrobp.2004.05.068
   Clare S., 1997, THESIS
   Dong S., 1992, Proceedings. Fifth Annual IEEE Symposium on Computer-Based Medical Systems (Cat. No.92CH3117-9), P181, DOI 10.1109/CBMS.1992.244949
   Doran SJ, 2005, PHYS MED BIOL, V50, P1343, DOI 10.1088/0031-9155/50/7/001
   FEIG E, 1986, PHYS MED BIOL, V31, P1091, DOI 10.1088/0031-9155/31/10/002
   Fransson A, 2001, STRAHLENTHER ONKOL, V177, P59, DOI 10.1007/PL00002385
   HUTCHISON JMS, 1978, J PHYS E SCI INSTRUM, V11, P217, DOI 10.1088/0022-3735/11/3/012
   LAI CM, 1983, PHYS MED BIOL, V28, P925, DOI 10.1088/0031-9155/28/8/005
   Lee YK, 2003, RADIOTHER ONCOL, V66, P203, DOI 10.1016/S0167-8140(02)00440-1
   Maciunas RJ, 1996, STEREOT FUNCT NEUROS, V66, P137, DOI 10.1159/000099680
   ODONNELL M, 1985, MED PHYS, V12, P20, DOI 10.1118/1.595732
   Schmitz BL, 2005, AM J NEURORADIOL, V26, P2229
   SEKIHARA K, 1987, MED PHYS, V14, P1087, DOI 10.1118/1.595989
   SUMANAWEERA T, 1994, MAGNET RESON MED, V31, P40, DOI 10.1002/mrm.1910310106
   SUMANAWEERA TS, 1994, NEUROSURGERY, V35, P696, DOI 10.1227/00006123-199410000-00016
   Tavares WM, 2014, NEUROSURGERY, V74, P121, DOI 10.1227/NEU.0000000000000178
   Vaughan JT, 2001, MAGNET RESON MED, V46, P24, DOI 10.1002/mrm.1156
   von Elm E, 2007, BMJ-BRIT MED J, V335, P806
   Wang D, 2004, MAGN RESON IMAGING, V22, P1211, DOI 10.1016/j.mri.2004.08.012
   Wang D, 2004, MAGN RESON IMAGING, V22, P1223, DOI 10.1016/j.mri.2004.08.014
   Wang DM, 2004, MAGN RESON IMAGING, V22, P529, DOI 10.1016/j.mri.2004.01.008
NR 25
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E690
EP E699
DI 10.1016/j.wneu.2018.10.123
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100084
PM 30394358
DA 2020-05-12
ER

PT J
AU Todnem, N
   Ward, A
   Nahhas, M
   Vender, JR
   Alleyne, CH
   Rahimi, SY
AF Todnem, Nathan
   Ward, Ayobami
   Nahhas, Michael
   Vender, John R.
   Alleyne, Cargill H.
   Rahimi, Scott Y.
TI A Retrospective Cohort Analysis of Hemorrhagic Arteriovenous
   Malformations Treated with Combined Endovascular Embolization and Gamma
   Knife Stereotactic Radiosurgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Arteriovenous malformation; Embolization; Endovascular; Gamma knife;
   Radiosurgery; Spetzler-Martin; Stereotactic
ID GRADING SYSTEM; BRAIN; MANAGEMENT; MULTICENTER; OUTCOMES; SURGERY;
   DESIGN
AB BACKGROUND: The management of brain arteriovenous malformations (AVMs) remains a controversial topic. Given the relatively low incidence, high heterogeneity, and high morbidity and mortality of these lesions, consensus on treatment strategies is an issue of concern to organized neurosurgery. The present retrospective analysis examined and quantified the outcomes of patients with an initial presentation of intracranial hemorrhage from a Spetzler-Martin grade III or IV AVM, later ruled out as surgical candidates.
   METHODS: A total of 16 patients (5 females; 11 males) had presented with symptomatic hemorrhage confirmed by non-contrast-enhanced computed tomography and were deemed to not be surgical candidates owing to AVM location and/or architecture. The patients underwent combined endovascular embolization and gamma knife stereotactic radiosurgery (SRS). The modified Rankin scale was used to measure the clinical outcomes, comparing the scores at presentation, gamma knife treatment, and the last known follow-up examination. A radiographic evaluation was used to determine the level of AVM nidus involution after the procedure.
   RESULTS: The present study identified 16 patients with ruptured high-grade AVMs of high surgical risk. All the patients had undergone immediate embolization with delayed SRS for treatment of the hemorrhage and nidus of the AVM. A statistically significant proportion of patients showed marked improvement in the modified Rankin scale scores. No subsequent repeat hemorrhage or any associated complications after embolization occurred in any patient.
   CONCLUSION: These findings warrant consideration of endovascular embolization with adjuvant SRS as a powerful treatment option for cases with high surgical morbidity due to AVM characteristics.
C1 [Todnem, Nathan; Ward, Ayobami; Vender, John R.; Rahimi, Scott Y.] Augusta Univ, Med Coll Georgia, Dept Neurosurg, Augusta, GA 30904 USA.
   [Nahhas, Michael] Augusta Univ, Med Coll Georgia, Dept Neurol, Augusta, GA USA.
   [Alleyne, Cargill H.] Augusta Back Neurosci Ctr, Augusta, GA USA.
RP Rahimi, SY (reprint author), Augusta Univ, Med Coll Georgia, Dept Neurosurg, Augusta, GA 30904 USA.
EM srahmi@augusta.edu
CR Ajiboye N, 2014, SCI WORLD J, V2014
   Alexander MD, 2016, INTERV NEURORADIOL, V22, P445, DOI 10.1177/1591019916641316
   Andreou A, 2008, J NEUROSURG, V109, P1091, DOI 10.3171/JNS.2008.109.12.1091
   AUGER RG, 1992, NEUROSURGERY, V30, P561
   Berman MF, 2000, NEUROSURGERY, V47, P389, DOI 10.1097/00006123-200008000-00023
   Bervini D, 2014, J NEUROSURG, V121, P878, DOI 10.3171/2014.7.JNS132691
   Bitaraf Mohammad Ali, 2017, Asian J Neurosurg, V12, P159, DOI 10.4103/1793-5482.145121
   Bruno CA, 2012, INTERV NEUROL, V1, P109, DOI 10.1159/000346927
   Chung WY, 2008, J NEUROSURG, V109, P65, DOI 10.3171/JNS/2008/109/12/S11
   Cockroft KM, 2012, STROKE, V43, P1979, DOI 10.1161/STROKEAHA.112.652032
   Cohen-Inbar O, 2016, J CLIN NEUROSCI, V24, P37, DOI 10.1016/j.jocn.2015.11.006
   Ding DL, 2017, J NEUROSURG, V126, P859, DOI 10.3171/2016.1.JNS152564
   Flickinger JC, 2002, RADIOTHER ONCOL, V63, P347, DOI 10.1016/S0167-8140(02)00103-2
   Gross BA, 2013, J NEUROSURG, V118, P437, DOI 10.3171/2012.10.JNS121280
   Gross BA, 2012, J CLIN NEUROSCI, V19, P1087, DOI 10.1016/j.jocn.2011.12.005
   Hongo K, 2000, J CLIN NEUROSCI, V7, P88
   Iyer A, 2018, J NEUROSURG SCI, V62, P514, DOI 10.23736/S0390-5616.18.04425-9
   Katsaridis V, 2008, NEURORADIOLOGY, V50, P589, DOI 10.1007/s00234-008-0382-x
   Kim EJ, 2014, TRANSL CANCER RES, V3, P399, DOI 10.3978/j.issn.2218-676X.2014.07.07
   Kim H, 2015, NEUROSURGERY, V76, P25, DOI 10.1227/NEU.0000000000000556
   Kretzer RM, 2010, J NEUROSURG, V112, P1182, DOI 10.3171/2009.7.JNS09737
   Lawton MT, 2010, NEUROSURGERY, V66, P702, DOI 10.1227/01.NEU.0000367555.16733.E1
   MCCORMICK WF, 1973, STROKE, V4, P946, DOI 10.1161/01.STR.4.6.946
   MCCORMICK WF, 1966, J NEUROSURG, V24, P807, DOI 10.3171/jns.1966.24.4.0807
   Mendelow AD, 2013, LANCET, V382, P397, DOI 10.1016/S0140-6736(13)60986-1
   Mohr JP, 2014, LANCET, V383, P614, DOI 10.1016/S0140-6736(13)62302-8
   Oermann EK, 2015, NEUROSURGERY, V77, P406, DOI 10.1227/NEU.0000000000000772
   Potts MB, 2015, J NEUROSURG, V122, P912, DOI 10.3171/2014.12.JNS14938
   Solomon RA, 2017, NEW ENGL J MED, V376, P1859, DOI 10.1056/NEJMra1607407
   SPETZLER RF, 1986, J NEUROSURG, V65, P476, DOI 10.3171/jns.1986.65.4.0476
   Stapf C, 2003, STROKE, V34, pE29, DOI 10.1161/01.STR.0000068784.36838.19
   Starke RM, 2017, J NEUROSURG, V126, P36, DOI 10.3171/2015.9.JNS151311
   Starke RM, 2009, STROKE, V40, P2783, DOI 10.1161/STROKEAHA.108.539775
   Szajner M, 2013, POL J RADIOL, V78, P35, DOI 10.12659/PJR.889120
   Valavanis A, 2005, INTERV NEURORADIOL, V11, P37, DOI 10.1177/15910199050110S107
   van Beijnum J, 2011, JAMA-J AM MED ASSOC, V306, P2011, DOI 10.1001/jama.2011.1632
   Weber W, 2007, NEUROSURGERY, V61, P244, DOI 10.1227/01.NEU.0000255473.60505.84
NR 37
TC 2
Z9 2
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E713
EP E722
DI 10.1016/j.wneu.2018.10.125
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100086
PM 30394359
DA 2020-05-12
ER

PT J
AU Uzunoglu, I
   Kaya, I
   Sucu, HK
   Kizmazoglu, C
   Sevin, IE
   Aydin, HE
   Rezanko, TA
   Yuceer, N
AF Uzunoglu, Inan
   Kaya, Ismail
   Sucu, Hasan Kamil
   Kizmazoglu, Ceren
   Sevin, Ismail Ertan
   Aydin, Hasan Emre
   Rezanko, Turkan Atasever
   Yuceer, Nurullah
TI Evaluation of Incidentally Detected Pathology Results of Patients with
   Vertebral Fracture Treated by Vertebroplasty and Kyphoplasty: A
   Retrospective Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Biopsy; Incidental; Infection; Kyphoplasty; Malignancy; Vertebroplasty
ID QUALITY-OF-LIFE; COMPRESSION FRACTURES; HISTOLOGICAL-EVALUATION; GUIDED
   BIOPSY; BONE-BIOPSY; SPINE; MORTALITY; IMPACT
AB BACKGROUND: Vertebroplasty and kyphoplasty are minimally invasive techniques used to treat vertebral compression fractures. The etiology of vertebral compression fractures varies among patients. Although osteoporosis and trauma are major etiologic factors in patients with a vertebral compression fracture, unexpected results were found in 11 patients in the present study. The aim of the present retrospective study was to determine the incidentally detected pathology results of patients with vertebral fracture treated by vertebroplasty and kyphoplasty.
   METHODS: From February 2010 to November 2015, 616 patients with a vertebral compression fracture were treated by kyphoplasty and vertebroplasty at our institution. Vertebral biopsies were obtained from 533 patients during a vertebral augmentation technique. The average patient age was 62.4 years. Of the 616 patients, 388 were female and 228 were male. Histological evaluation of the biopsy specimens from the vertebral compression fractures was performed.
   RESULTS: The biopsy results of 505 patients showed various stages of bone healing. Among these patients, malignancy was identified in 23 patients, and 43 patients had a history of malignancy. In 6 patients, an unsuspected malignancy was found, and 1 patient had Paget's disease. Infection was detected in 4 patients. In our study, the rate of unsuspected malignancy was 1.1%.
   CONCLUSIONS: Tissue examination is useful and could reveal pathologic fractures. An incidentally detected biopsy result could change the treatment of patients; however, bone biopsy should be reserved for those patients whose preoperative radiological diagnosis raises suspicion of a nonosteoporotic etiology.
C1 [Uzunoglu, Inan; Sucu, Hasan Kamil; Sevin, Ismail Ertan; Yuceer, Nurullah] Izmir Katip Celebi Univ, Ataturk Res & Training Hosp, Dept Neurosurg, Izmir, Turkey.
   [Kaya, Ismail; Aydin, Hasan Emre] Kutahya Med Sci Univ, Dept Neurosurg, Kutahya, Turkey.
   [Kizmazoglu, Ceren] Dokuz Eylul Univ, Sch Med, Dept Neurosurg, Izmir, Turkey.
   [Rezanko, Turkan Atasever] Izmir Katip Celebi Univ, Ataturk Training & Res Hosp, Dept Pathol, Izmir, Turkey.
RP Uzunoglu, I (reprint author), Izmir Katip Celebi Univ, Ataturk Res & Training Hosp, Dept Neurosurg, Izmir, Turkey.
EM dr_inan_uzunoglu@hotmail.com
RI Kaya, Ismail/A-7270-2018; Uzunoglu, Inan/S-4158-2019
CR Allen RT, 2009, SPINE, V34, P1486, DOI 10.1097/BRS.0b013e3181a55539
   Cauley JA, 2000, OSTEOPOROSIS INT, V11, P556, DOI 10.1007/s001980070075
   COOPER C, 1993, AM J EPIDEMIOL, V137, P1001, DOI 10.1093/oxfordjournals.aje.a116756
   COOPER C, 1992, J BONE MINER RES, V7, P221, DOI 10.1002/jbmr.5650070214
   Garfin SR, 2006, SPINE, V31, P2213, DOI 10.1097/01.brs.0000232803.71640.ba
   Gold DT, 1996, BONE, V18, pS185, DOI 10.1016/8756-3282(95)00500-5
   Hoshino M, 2009, EUR SPINE J, V18, P1279, DOI 10.1007/s00586-009-1041-6
   Johnell O, 2004, OSTEOPOROSIS INT, V15, P38, DOI 10.1007/s00198-003-1490-4
   Lasocki A, 2017, NEURORADIOL J, V30, P259, DOI 10.1177/1971400917699426
   Li Q, 2014, PLOS ONE, V9
   Lis E, 2004, AM J NEURORADIOL, V25, P1583
   LYLES KW, 1993, AM J MED, V94, P595, DOI 10.1016/0002-9343(93)90210-G
   Magerl F, 1994, Eur Spine J, V3, P184, DOI 10.1007/BF02221591
   Mazzie JP, 2014, NEUROIMAG CLIN N AM, V24, P365, DOI 10.1016/j.nic.2014.01.003
   Minart D, 2001, NEURORADIOLOGY, V43, P409, DOI 10.1007/s002340000423
   Muijs SPJ, 2009, SPINE, V34, P2395, DOI 10.1097/BRS.0b013e3181b8707e
   Pneumaticos SG, 2010, EUR SPINE J, V19, P1894, DOI 10.1007/s00586-010-1388-8
   Schoenfeld AJ, 2008, INJURY, V39, P327, DOI 10.1016/j.injury.2007.06.019
   Shen MS, 2006, BULL HOSP JT DIS, V64, P106
   Shindle MK, 2006, J BONE JOINT SURG AM, V88A, P2721, DOI 10.2106/JBJS.F.00100
   Sucu HK, 2006, JOINT BONE SPINE, V73, P532, DOI 10.1016/j.jbspin.2006.01.013
   Theodorou DJ, 2011, AM J ROENTGENOL, V196, pS64, DOI 10.2214/AJR.10.7222
   Togawa D, 2005, SPINE, V30, P781, DOI 10.1097/01.brs.0000157478.03349.57
   van Schoor NM, 2005, OSTEOPOROSIS INT, V16, P749, DOI 10.1007/s00198-004-1744-9
   Wardlaw D, 2009, LANCET, V373, P1016, DOI 10.1016/S0140-6736(09)60010-6
   Zhang L, 2013, ONCOL LETT, V5, P135, DOI 10.3892/ol.2012.944
NR 26
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E639
EP E646
DI 10.1016/j.wneu.2018.10.116
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100078
PM 31108080
DA 2020-05-12
ER

PT J
AU Vahtera, AS
   Junttila, EK
   Jalkanen, LV
   Huhtala, HS
   Katanandova, KV
   Helen, PT
   Kuitunen, AH
AF Vahtera, Annukka S.
   Junttila, Eija K.
   Jalkanen, L. Ville
   Huhtala, Heini S.
   Katanandova, Ksenia V.
   Helen, Pauli T.
   Kuitunen, Anne H.
TI Activation of Blood Coagulation After Aneurysmal Subarachnoid
   Hemorrhage: A Prospective Observational Trial of Rotational
   Thromboelastometry
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysmal subarachnoid hemorrhage; Blood coagulation; Intensive care
   unit; Neurosurgery; Thromboelastometry
ID DELAYED CEREBRAL-ISCHEMIA; EARLY BRAIN-INJURY; ANTIPLATELET THERAPY;
   FIBRINOLYTIC SYSTEM; PLATELET ACTIVATION; VENOUS THROMBOSIS; VASOSPASM;
   RISK; TIME; HYPERCOAGULABILITY
AB OBJECTIVE: Aneurysmal subarachnoid hemorrhage (aSAH) has been reported to actuate blood coagulation. Rotational thromboelastometry (ROTEM) is a dynamic hemostatic test that can differentiate various coagulation abnormalities. For example, increased coagulation activity can be detected as a wider amplitude of tracing (maximal clot firmness [MCF]). ROTEM had not been used to evaluate coagulation changes after aSAH. We evaluated the ongoing coagulation process in patients with aSAH in a prospective, observational study to compare their ROTEM assay results with the control values obtained from patients undergoing clipping of nonruptured aneurysms.
   METHODS: ROTEM analyses were performed at 12, 24, 48, and 72 hours after the onset of aSAH and compared with the preoperative analyses from the control group. A total of 17 patients with aSAH treated in the intensive care unit and 16 control patients were enrolled.
   RESULTS: At 72 hours, EXTEM-MCF was significantly greater in patients with aSAH compared with the baseline values of the control group (68.0 mm [interquartile range (IQR), 66.0-71.0] versus 64.5 mm [IQR, 59.5-66.8]; P = 0.024). This was mainly due to increased fibrin formation and fibrin polymerization. The same comparison in the FIBTEM-MCF analysis yielded similar results (aSAH group, 23.0 mm [IQR, 19.0-25.0] vs. control group, 15.4 mm [IQR, 12.5-17.8], respectively; P = 0.001).
   CONCLUSIONS: Blood coagulation is activated at 72 hours after aSAH onset, which can be detected by ROTEM EXTEM-MCF analysis. Also, the FIBTEM-MCF was elevated, implying that the relative contribution of fibrin formation and fibrin polymerization is essential.
C1 [Vahtera, Annukka S.; Jalkanen, L. Ville; Kuitunen, Anne H.] Tampere Univ Hosp, Dept Intens Care Med, Tampere, Finland.
   [Junttila, Eija K.] Tampere Univ Hosp, Dept Anaesthesia, Tampere, Finland.
   [Katanandova, Ksenia V.] Tampere Univ Hosp, Dept Radiol, Tampere, Finland.
   [Helen, Pauli T.] Tampere Univ Hosp, Dept Neurosurg, Tampere, Finland.
   [Huhtala, Heini S.] Univ Tampere, Fac Social Sci, Tampere, Finland.
RP Vahtera, AS (reprint author), Tampere Univ Hosp, Dept Intens Care Med, Tampere, Finland.
EM annukka.vahtera@pshp.fi
FU CSL Behring Research Grant; Finnish Intensive Care Society Research
   Grant
FX This work was supported by a small project grant the CSL Behring
   Research Grant. The additional ultrasound scans were provided by a
   project grant from the Finnish Intensive Care Society Research Grant.
CR Ahn SH, 2018, NEUROSURGERY, V83, P137, DOI 10.1093/neuros/nyx364
   Akay OM, 2009, MED ONCOL, V26, P358, DOI 10.1007/s12032-008-9129-0
   BRODERICK JP, 1994, STROKE, V25, P1342, DOI 10.1161/01.STR.25.7.1342
   Dai Y, 2009, ANESTH ANALG, V108, P734, DOI 10.1213/ane.0b013e31818f8907
   de Rooij NK, 2007, J NEUROL NEUROSUR PS, V78, P1365, DOI 10.1136/jnnp.2007.117655
   Diringer MN, 2011, NEUROCRIT CARE, V15, P211, DOI 10.1007/s12028-011-9605-9
   ETTINGER M G, 1970, Stroke, V1, P139
   FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001
   Frontera JA, 2017, NEUROCRIT CARE, V26, P48, DOI 10.1007/s12028-016-0292-4
   Frontera JA, 2009, STROKE, V40, P1963, DOI 10.1161/STROKEAHA.108.544700
   Fujii M, 2013, TRANSL STROKE RES, V4, P432, DOI 10.1007/s12975-013-0257-2
   Fujii Y, 1997, J NEUROSURG, V86, P594, DOI 10.3171/jns.1997.86.4.0594
   Harr JN, 2013, J TRAUMA ACUTE CARE, V74, P756, DOI 10.1097/TA.0b013e3182826d7e
   HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014
   Ilveskero S, 2005, NEUROSURGERY, V57, P16, DOI 10.1227/01.NEU.0000163085.48999.D6
   Ji Y, 2014, NEUROL MED-CHIR, V54, P457, DOI 10.2176/nmc.oa2013-0006
   Juvela S, 2006, STROKE, V37, P1451, DOI 10.1161/01.STR.0000221710.55467.33
   Korja M, 2016, NEUROLOGY, V87, P1118, DOI 10.1212/WNL.0000000000003091
   Korja M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073760
   Korja M, 2013, NEUROLOGY, V80, P481, DOI 10.1212/WNL.0b013e31827f0fb5
   Kornblith LZ, 2014, J TRAUMA ACUTE CARE, V76, P255, DOI 10.1097/TA.0000000000000108
   Larsen CC, 2012, THROMB RES, V129, pE229, DOI 10.1016/j.thromres.2012.01.016
   Lilly CM, 2014, CHEST, V146, P51, DOI 10.1378/chest.13-2160
   Macdonald RL, 2014, NAT REV NEUROL, V10, P44, DOI 10.1038/nrneurol.2013.246
   Mees SMD, 2003, STROKE, V34, P2285, DOI 10.1161/01.STR.0000083621.44269.3E
   Miao W, 2018, WORLD NEUROSURG, V110, pE46, DOI 10.1016/j.wneu.2017.09.200
   Nagahama Y, 2018, J NEUROSURG, V129, P702, DOI 10.3171/2017.5.JNS17831
   Nagler M, 2013, THROMB RES, V131, P249, DOI 10.1016/j.thromres.2013.01.009
   Nina P, 2001, SURG NEUROL, V55, P197, DOI 10.1016/S0090-3019(01)00402-5
   Nyquist P, 2016, NEUROCRIT CARE, V24, P47, DOI 10.1007/s12028-015-0221-y
   Ogawa S, 2012, ANESTH ANALG, V115, P16, DOI 10.1213/ANE.0b013e31824d523b
   Park MS, 2009, J TRAUMA, V67, P266, DOI 10.1097/TA.0b013e3181ae6f1c
   Perez P, 2018, BMC NEUROL, V18, DOI 10.1186/s12883-018-1062-z
   Ramchand P, 2016, WORLD NEUROSURG, V96, P215, DOI 10.1016/j.wneu.2016.04.002
   Ray WZ, 2009, J NEUROSURG, V110, P1010, DOI 10.3171/2008.9.JNS08107
   Rowland MJ, 2012, BRIT J ANAESTH, V109, P315, DOI 10.1093/bja/aes264
   Siironen J, 2003, J NEUROSURG, V99, P953, DOI 10.3171/jns.2003.99.6.0953
   Sivula M, 2009, BLOOD COAGUL FIBRIN, V20, P419, DOI 10.1097/MBC.0b013e32832a76e1
   Steiner T, 2013, CEREBROVASC DIS, V35, P93, DOI 10.1159/000346087
   Turner CL, 2015, NEUROSURGERY, V77, P786, DOI 10.1227/NEU.0000000000000963
   Vergouwen MDI, 2010, STROKE, V41, P2391, DOI 10.1161/STROKEAHA.110.589275
   Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573
NR 42
TC 2
Z9 2
U1 2
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E334
EP E341
DI 10.1016/j.wneu.2018.10.035
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100039
PM 30339910
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Vetrano, IG
   Prada, F
   Perin, A
   Casali, C
   DiMeco, F
   Saini, M
AF Vetrano, Ignazio G.
   Prada, Francesco
   Perin, Alessandro
   Casali, Cecilia
   DiMeco, Francesco
   Saini, Marco
TI Piezosurgery for Infra- and Supratentorial Craniotomies in Brain Tumor
   Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain tumors; Craniotomy; Dural sinuses; Piezosurgery; Ultrasonic
   surgery
ID PIEZOELECTRIC BONE SURGERY; COMPLICATIONS; OSTEOTOMY; EXPERIENCE;
   RESECTION; IMPLANTS; SINUS
AB OBJECTIVE: Piezoelectric surgery represents an innovative technique to perform safe and effective osteotomies and is an alternative to traditional bony tissue management using rotating or perforating instruments. We evaluated the safety and feasibility of craniotomies using an ultrasonic device that allows the selective cut of mineralized structures, avoiding damages to the vascular, dural, and parenchymal structures.
   METHODS: We analyzed a series of 300 patients (age range, 1-81 years; SD +/- 15.2) who underwent elective cranial surgery for brain tumors, in which the craniotomy was performed using a piezoelectric device. Pre- and postoperative imaging, clinical notes, and intraoperative details were collected.
   RESULTS: There were 197 patients (66%) who underwent surgery for supratentorial tumors; the remaining 103 patients (34%) underwent surgery for infratentorial ones. Tumors involved the skull base in 125 cases. Meningiomas, gliomas, and schwannomas represented the most common histotypes. Duraplasty for dural damages was not necessary in all cases; no venous sinuses or parenchymal injuries were reported during bone work. We noted in 13 cases (4.3%) a minor dural tear, requiring only direct sutures. Bone flaps were always intact after craniotomy. No subgaleal cerebrospinal fluid (CSF) collection or CSF leak was recorded. Because of the minimal bone gap, we always achieved correct bone flap ossification. No reabsorption or mobilization of bone flap was noted.
   CONCLUSIONS: We illustrate the feasibility and safety of a piezosurgical cutter to perform craniotomies. This alternative technique appears to be safe, with excellent cosmetic effects, adding another tool to the neurosurgical armamentarium.
C1 [Vetrano, Ignazio G.; Prada, Francesco; Perin, Alessandro; Casali, Cecilia; DiMeco, Francesco; Saini, Marco] Fdn IRCCS Ist Neurol Carlo Besta, Dept Neurosurg, Milan, Italy.
   [Prada, Francesco] Univ Virginia, Hlth Sci Ctr, Dept Neurol Surg, Charlottesville, VA 22908 USA.
   [Perin, Alessandro] Fdn IRCCS Ist Neurol Carlo Besta, Besta NeuroSim Ctr, Milan, Italy.
   [Perin, Alessandro] Univ Trieste, Dept Life Sci, Trieste, Italy.
   [DiMeco, Francesco] Johns Hopkins Univ, Dept Neurosurg, Baltimore, MD USA.
   [DiMeco, Francesco] Univ Milan, Dept Pathophysiol & Transplantat, Milan, Italy.
RP Vetrano, IG (reprint author), Fdn IRCCS Ist Neurol Carlo Besta, Dept Neurosurg, Milan, Italy.
EM ignazio.vetrano@istituto-besta.it
RI Perin, Alessandro/AAC-1316-2019; Casali, Cecilia/AAC-1626-2019; DiMeco,
   Francesco/Z-5431-2019; vetrano, ignazio/J-1573-2017
OI Perin, Alessandro/0000-0002-6697-9835; Casali,
   Cecilia/0000-0002-9176-8589; vetrano, ignazio/0000-0003-0664-9700
CR Acharya AN, 2015, OTOL NEUROTOL, V36, P444, DOI 10.1097/MAO.0000000000000645
   Beziat JL, 2007, REV STOMATOL CHIR, V108, P101, DOI 10.1016/j.stomax.2006.03.004
   Caird JD, 2003, BRIT J NEUROSURG, V17, P509, DOI 10.1080/02688690310001627722
   DiMeco F, 2004, ACTA NEUROCHIR, V146, P995, DOI 10.1007/s00701-004-0322-4
   DiMeco F, 2008, NEUROSURGERY, V62, P1124, DOI [10.1227/01.NEU.0000143373.74160.F2, 10.1227/01.neu.0000333779.73940.c4]
   Eggers G, 2004, BRIT J ORAL MAX SURG, V42, P451, DOI 10.1016/j.bjoms.2004.04.006
   Franzini A, 2018, WORLD NEUROSURG, V114, P58, DOI [10.1016/J.WNEU.2018.03.026, 10.1016/j.wneu.2018.03.026]
   Goodrich JT, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2014.2.FOCUS13543
   Grauvogel J, 2018, OPER NEUROSURG, V15, P664, DOI 10.1093/ons/opx272
   Grauvogel J, 2011, ACTA NEUROCHIR, V153, P1941, DOI 10.1007/s00701-011-1092-4
   Jung SH, 2011, CRANIOMAX TRAUM REC, V4, P193, DOI 10.1055/s-0031-1286113
   Iacoangeli M, 2015, J NEUROL SURG PART A, V76, P112, DOI 10.1055/s-0034-1368685
   Kotrikova B, 2006, INT J ORAL MAX SURG, V35, P461, DOI 10.1016/j.ijom.2005.12.006
   Lassen B, 2012, NEUROSURGERY, V70, P936, DOI 10.1227/NEU.0b013e31823bcc61
   Legnani FG, 2013, ACTA NEUROCHIR, V155, P2281, DOI 10.1007/s00701-013-1882-y
   Lopez Pinero JM, 1999, LANCET S, V354, pSIV35
   Malekpour M, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2014.2.FOCUS13580
   Martini M, 2017, J CRANIO MAXILL SURG, V45, P395, DOI 10.1016/j.jcms.2016.12.018
   OGILVY CS, 1993, J NEUROSURG, V78, P508, DOI 10.3171/jns.1993.78.3.0508
   Ormond DR, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2014.2.FOCUS13548
   Pellegrino G, 2017, INT J ORAL MAX IMPL, V32, pE161, DOI 10.11607/jomi.5800
   Preti G, 2007, J PERIODONTOL, V78, P716, DOI 10.1902/jop.2007.060285
   Ramieri V, 2015, J CRANIOFAC SURG, V26, P840, DOI 10.1097/SCS.0000000000001574
   Salami A, 2008, ACTA OTO-LARYNGOL, V128, P530, DOI 10.1080/00016480701635175
   Salami A, 2007, OTOLARYNG HEAD NECK, V136, P484, DOI 10.1016/j.otohns.2006.10.045
   Salami A, 2010, OTOLARYNG HEAD NECK, V142, P120, DOI 10.1016/j.otohns.2009.10.013
   Salami A, 2009, OTOLARYNG HEAD NECK, V140, P412, DOI 10.1016/j.otohns.2008.11.013
   Schaller BJ, 2005, NEUROSURGERY, V57, DOI 10.1227/01.NEU.0000176700.77461.C9
   Schlee Markus, 2006, Implant Dent, V15, P334, DOI 10.1097/01.id.0000247859.86693.ef
   Shen WM, 2017, ANN PLAS SURG, V78, P511, DOI 10.1097/SAP.0000000000000939
   Pereira CCS, 2014, J ORAL IMPLANTOL, V40, P401, DOI 10.1563/AAID-JOI-D-11-00196
   Solero CL, 2000, NEUROSURGERY, V47, P1296, DOI 10.1097/00006123-200012000-00007
   Stacchi C, 2013, CLIN IMPLANT DENT R, V15, P188, DOI 10.1111/j.1708-8208.2011.00341.x
   Vercellotti T, 2000, INT J PERIODONT REST, V20, P359
   Vercellotti T, 2005, INT J PERIODONT REST, V25, P543
   Vercellotti T, 2004, Minerva Stomatol, V53, P207
   Vercellotti T, 2001, INT J PERIODONT REST, V21, P561
   Vercellotti T, 2014, INT J PERIODONT REST, V34, P11, DOI 10.11607/prd.1860
   Vogel TW, 2011, J NEUROSURG, V115, P570, DOI 10.3171/2011.3.JNS101310
   Walcott BP, 2014, J NEUROSURG, V120, P278, DOI 10.3171/2013.8.JNS13703
   WILKINS RH, 1962, J NEUROSURG, V19, P1007, DOI 10.3171/jns.1962.19.11.1007
NR 41
TC 2
Z9 2
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1398
EP E1404
DI 10.1016/j.wneu.2018.11.064
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100171
PM 30458322
DA 2020-05-12
ER

PT J
AU Vetter, M
   Iwanaga, J
   Choi, PJ
   Yilmaz, E
   Oskouian, RJ
   Tubbs, RS
AF Vetter, Marc
   Iwanaga, Joe
   Choi, Paul J.
   Yilmaz, Emre
   Oskouian, Rod J.
   Tubbs, R. Shane
TI A Novel Microsurgical Procedure for Revascularization of the Vertebral
   Artery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anatomy; Bypass graft; Deep cervical artery; Posterior cervical
   triangle; Subclavian artery; Vertebral artery
ID ANTERIOR CERVICAL-SPINE; BYPASS; ANATOMY; MANAGEMENT; OCCLUSION;
   EXPOSURE; SURGERY; INJURY
AB OBJECTIVE: A broad armamentarium of microsurgical techniques affords flexibility to surgeons when choosing a procedure that is best tailored to fit the anatomy of an individual. Herein, we report on the feasibility of using the deep cervical artery (DCA) to revascularize the vertebral artery (VA) via a DCA-V3 bypass graft.
   METHODS: Fourteen DCAs from 7 injected cadaveric heads were located and traced. The diameter of the main trunk of the DCA was measured bilaterally at the C3 level. The proximal vertebral branches of each DCA were then severed and the main trunk of the DCA was transposed superiorly onto the V3 segment of the VA, which was also exposed bilaterally.
   RESULTS: The DCA was identified and traced bilaterally on all specimens. The diameter of the main trunk of the DCA at the C3 level ranged from 1.03 to 2.79 mm. The mean diameter of the main trunk of the DCA at this level was found to be 1.52 +/- 0.60 mm for the right side and 1.46 +/- 0.54 mm for the left side. After releasing the proximal vertebral branches of the DCA, all arteries were able to be transposed to the ipsilateral VA.
   CONCLUSIONS: Based on the mean diameter of the DCA reported in extant literature and this study, the blood flow volume of the DCA makes it a viable candidate to bypass the proximal VA.
C1 [Vetter, Marc; Iwanaga, Joe; Choi, Paul J.; Oskouian, Rod J.; Tubbs, R. Shane] Seattle Sci Fdn, Seattle, WA 98122 USA.
   [Iwanaga, Joe] Kurume Univ, Sch Med, Dept Anat, Div Gross & Clin Anat, Kurume, Fukuoka, Japan.
   [Yilmaz, Emre] Swedish Med Ctr, Swedish Neurosci Inst, Seattle, WA USA.
   [Tubbs, R. Shane] Dept Anat Sci, True Blue Point, Grenada.
RP Iwanaga, J (reprint author), Seattle Sci Fdn, Seattle, WA 98122 USA.; Iwanaga, J (reprint author), Kurume Univ, Sch Med, Dept Anat, Div Gross & Clin Anat, Kurume, Fukuoka, Japan.
EM joei@seattlesciencefoundation.org
RI Choi, Paul J./O-9311-2018
OI Choi, Paul J./0000-0003-3654-3106
CR Abd el-Bary TH, 1995, SURG NEUROL, V44, P400
   Arslan M, 2018, TURK NEUROSURG, V28, P234, DOI 10.5137/1019-5149.JTN.19469-16.1
   Baikoussis NG, 2014, J CARDIOL, V63, P321, DOI 10.1016/j.jjcc.2013.11.016
   BERGUER R, 1976, ARCH SURG-CHICAGO, V111, P976
   BERGUER R, 1985, J VASC SURG, V2, P621, DOI 10.1067/mva.1985.avs0020621
   Berguer R, 1999, J VASC SURG, V30, P344, DOI 10.1016/S0741-5214(99)70146-1
   Brasiliense LBC, 2014, NEUROSURGERY, V74, pS102, DOI 10.1227/NEU.0000000000000218
   Coleman DM, 2013, J VASC SURG, V58, P152, DOI 10.1016/j.jvs.2012.12.067
   DONALDSON MC, 1985, J VASC SURG, V2, P917
   ElBary THA, 1995, SURG NEUROL, V44, P392, DOI 10.1016/0090-3019(95)00033-X
   Evans JJ, 2004, NEUROSURGERY, V55, P1036, DOI 10.1227/01.NEU.0000140822.64362.C6
   Flossmann E, 2003, BRAIN, V126, P1940, DOI 10.1093/brain/awg197
   Guan Q, 2017, WORLD NEUROSURG, V106, P715, DOI 10.1016/j.wneu.2017.07.027
   Haddad FA, 2018, CLIN ANAT, V31, P314, DOI 10.1002/ca.23051
   Iwanaga J, 2018, WORLD NEUROSURG, V112, pE662, DOI 10.1016/j.wneu.2018.01.118
   Keser N, 2018, WORLD NEUROSURG, V112, pE534, DOI 10.1016/j.wneu.2018.01.073
   Kubota H, 2014, WORLD NEUROSURG, V81, DOI 10.1016/j.wneu.2013.01.025
   Mammen T, 2013, J NEUROINTERV SURG, V5, pE44, DOI 10.1136/neurintsurg-2012-010363
   Melgar MA, 2005, J NEUROSURG, V103, P170, DOI 10.3171/jns.2005.103.1.0170
   Nagasawa Shiro, 1994, Neurologia Medico-Chirurgica, V34, P311, DOI 10.2176/nmc.34.311
   Nourbakhsh A, 2017, CLIN ANAT, V30, P492, DOI 10.1002/ca.22858
   Oktar SO, 2006, AM J NEURORADIOL, V27, P363
   Pait TG, 1996, NEUROSURGERY, V39, P769, DOI 10.1097/00006123-199610000-00026
   Raheja A, 2018, OPER NEUROSURG, V14, P312, DOI 10.1093/ons/opx130
   Rojas S, 2018, CLIN ANAT, V31, P1137, DOI 10.1002/ca.23213
   ROON AJ, 1979, AM J SURG, V138, P29, DOI 10.1016/0002-9610(79)90238-1
   Saito N, 2016, NEUROSURG REV, V39, P289, DOI 10.1007/s10143-015-0686-3
   Saito N, 2014, NEUROL MED-CHIR, V54, P189, DOI 10.2176/nmc.cr.2012-0216
   Sanchis-Gimeno JA, 2017, CLIN ANAT, V30, P761, DOI 10.1002/ca.22897
   Shin KJ, 2018, CLIN ANAT, V31, P1058, DOI 10.1002/ca.23210
   Shoja MM, 2018, CLIN ANAT, V31, P466, DOI 10.1002/ca.23049
   Shoja MM, 2018, CLIN ANAT, V31, P488, DOI 10.1002/ca.23048
   Standring S, 2016, GRAYS ANATOMY ANATOM
   Tardieu GG, 2017, CLIN ANAT, V30, P811, DOI 10.1002/ca.22923
   TATSUMI T, 1965, J NEUROL NEUROSUR PS, V28, P235, DOI 10.1136/jnnp.28.3.235
   Tessler O, 2017, PLAST RECONSTR SURG, V139, p745E, DOI 10.1097/PRS.0000000000003085
   Tubbs RS, 2006, J NEUROSURG-SPINE, V5, P320, DOI 10.3171/spi.2006.5.4.320
   WILKINSON IM, 1972, ARCH NEUROL-CHICAGO, V27, P392, DOI 10.1001/archneur.1972.00490170024004
   Yeom JS, 2013, SPINE J, V13, P775, DOI 10.1016/j.spinee.2013.04.005
NR 39
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E302
EP E306
DI 10.1016/j.wneu.2018.10.026
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100035
PM 30321685
DA 2020-05-12
ER

PT J
AU Vlachogiannis, P
   Hillered, L
   Khalil, F
   Enblad, P
   Ronne-Engstrom, E
AF Vlachogiannis, Pavlos
   Hillered, Lars
   Khalil, Fattema
   Enblad, Per
   Ronne-Engstrom, Elisabeth
TI Interleukin-6 Levels in Cerebrospinal Fluid and Plasma in Patients with
   Severe Spontaneous Subarachnoid Hemorrhage
SO WORLD NEUROSURGERY
LA English
DT Article
DE Inflammatory response; Interleukin-6; Neuroinflammation; SAH;
   Subarachnoid hemorrhage
ID SYSTEMIC INFLAMMATORY RESPONSE; ENDOTHELIAL CELL-INTERACTIONS; CEREBRAL
   VASOSPASM; IL-6; INTERVENTION; ACTIVATION; CYTOKINES; SURVIVAL; CARE;
   CSF
AB BACKGROUND: Inflammatory processes play a key role in the pathophysiology of subarachnoid hemorrhage (SAH). This study evaluated whether different temporal patterns of intrathecal and systemic inflammation could be identified in the acute phase after SAH. The intensity of the inflammation was also assessed in clinical subgroups.
   METHODS: Cerebrospinal fluid (CSF) and blood samples were collected at days 1, 4, and 10 after ictus in 44 patients with severe SAH. Interleukin-6 (IL-6) was analyzed by a routine monoclonal antibody-based method. Median IL-6 values for each day were calculated. Day 4 IL-6 values were compared in dichotomized groups (age, sex, World Federation of Neurosurgical Societies [WFNS] grade, Fisher scale grade, outcome, vasospasm, central nervous system infection and systemic infections).
   RESULTS: CSF IL-6 levels were significantly elevated from day 1 to days 4 and 10, whereas plasma IL-6 showed a different trend at lower levels. Median CSF IL-6 concentrations for days 1, 4, and 10 were 876.5, 3361, and 1567 ng/L, whereas plasma was 26, 27.5, and 15.9 ng/L, respectively. No significant differences in CSF concentrations were observed between the subgroups, with the most prominent one being in day 4 IL-6 in the WFNS subgroups (grades 1-3 vs. 4-5, 1158.5 vs. 5538 ng/L; P = 0.056). Patients with systemic infection had significantly higher plasma IL-6 concentrations than patients without infection (31 vs. 16.05 ng/L, respectively; P = 0.028).
   CONCLUSIONS: Distinctly different inflammatory patterns could be seen intrathecally compared with the systemic circulation. In plasma, a significant difference in the intensity of the inflammation was seen in cases with systemic infection. No other subgroup showed statistically significant differences.
C1 [Vlachogiannis, Pavlos; Hillered, Lars; Khalil, Fattema; Enblad, Per; Ronne-Engstrom, Elisabeth] Uppsala Univ, Dept Neurosci Neurosurg, Uppsala, Sweden.
   [Khalil, Fattema] Karolinska Inst, Dept Neurosci, Stockholm, Sweden.
RP Vlachogiannis, P (reprint author), Uppsala Univ, Dept Neurosci Neurosurg, Uppsala, Sweden.
EM Pavlos.vlachogiannis@neuro.uu.se
FU Uppsala University Hospital (ALF funds); Uppsala Country Council (Region
   Uppsala)
FX This research was supported financially by the Uppsala University
   Hospital (ALF funds) and the Uppsala Country Council (Region Uppsala).
CR Acalovschi D, 2003, STROKE, V34, P1864, DOI 10.1161/01.STR.0000079815.38626.44
   Bro-Jeppesen J, 2016, RESUSCITATION, V98, P1, DOI 10.1016/j.resuscitation.2015.10.009
   Carpenter KLH, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00026
   Cesarini KG, 1999, J NEUROSURG, V90, P664, DOI 10.3171/jns.1999.90.4.0664
   Chaichana KL, 2010, WORLD NEUROSURG, V73, P22, DOI 10.1016/j.surneu.2009.05.027
   Dhar R, 2008, NEUROCRIT CARE, V8, P253, DOI 10.1007/s12028-007-9020-4
   Dumont AS, 2003, NEUROSURGERY, V53, P123, DOI 10.1227/01.NEU.0000068863.37133.9E
   Eisenhut M, 2014, INT J INFLAMM, DOI 10.1155/2014/509707
   Fassbender K, 2001, J NEUROL NEUROSUR PS, V70, P534, DOI 10.1136/jnnp.70.4.534
   FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001
   Gaetani P, 1998, NEUROL RES, V20, P337, DOI 10.1080/01616412.1998.11740528
   Gallia GL, 2006, NEUROL RES, V28, P750, DOI 10.1179/016164106X152025
   Graetz D, 2010, NEUROL RES, V32, P728, DOI 10.1179/016164109X12464612122650
   Gruber A, 1999, CRIT CARE MED, V27, P505, DOI 10.1097/00003246-199903000-00026
   Hanafy KA, 2010, J NEUROL SCI, V291, P69, DOI 10.1016/j.jns.2009.12.023
   Hendryk S, 2004, NEUROENDOCRINOL LETT, V25, P141
   Hillman J, 2007, J NEUROSURG, V106, P820, DOI 10.3171/jns.2007.106.5.820
   HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014
   JENNETT B, 1975, LANCET, V1, P480
   Johansson M, 2001, STROKE, V32, P2845, DOI 10.1161/hs1201.099416
   Kao HW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132115
   KIKUCHI T, 1995, NEUROL RES, V17, P106, DOI 10.1080/01616412.1995.11740296
   Lucke-Wold BP, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17040497
   MATHIESEN T, 1993, J NEUROSURG, V78, P562, DOI 10.3171/jns.1993.78.4.0562
   Miller BA, 2014, BIOMED RES INT, DOI 10.1155/2014/384342
   Molyneux AJ, 2005, LANCET, V366, P809, DOI 10.1016/S0140-6736(05)67214-5
   Naredi S, 2006, INTENS CARE MED, V32, P1955, DOI 10.1007/s00134-006-0408-y
   Osuka K, 1998, ACTA NEUROCHIR, V140, P943, DOI 10.1007/s007010050197
   Pavle G, 2010, HEPATO-GASTROENTEROL, V57, P349
   Persson L, 1999, ACT NEUR S, V72, P73
   Rodriguez-Rodriguez A, 2014, J NEUROL SCI, V341, P119, DOI 10.1016/j.jns.2014.04.020
   Ronne-Engstrom E, 2014, UPSALA J MED SCI, V119, P38, DOI 10.3109/03009734.2013.849781
   Rosengart AJ, 2007, STROKE, V38, P2315, DOI 10.1161/STROKEAHA.107.484360
   Ryttlefors M, 2007, NEUROSURGERY, V61, P704, DOI 10.1227/01.NEU.0000298898.38979.E3
   Sarrafzadeh A, 2010, NEUROCRIT CARE, V13, P339, DOI 10.1007/s12028-010-9432-4
   Schoch B, 2007, NEUROSURGERY, V60, P828, DOI 10.1227/01.NEU.0000255440.21495.80
   Sercombe R, 2002, JPN J PHARMACOL, V88, P227, DOI 10.1254/jjp.88.227
   Takizawa T, 2001, NEUROL RES, V23, P724, DOI 10.1179/016164101101199243
   TEASDALE G, 1974, LANCET, V2, P81
   TEASDALE GM, 1988, J NEUROL NEUROSUR PS, V51, P1457, DOI 10.1136/jnnp.51.11.1457
   Volpin G, 2014, INT ORTHOP, V38, P1303, DOI 10.1007/s00264-013-2261-2
   Wostrack M, 2014, NEUROCRIT CARE, V21, P78, DOI 10.1007/s12028-014-9991-x
   Wu W, 2016, MOL NEUROBIOL, V53, P3277, DOI 10.1007/s12035-015-9268-1
   Yoshimoto Y, 2001, STROKE, V32, P1989, DOI 10.1161/hs0901.095646
   Zeiler FA, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00379
NR 45
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E612
EP E618
DI 10.1016/j.wneu.2018.10.113
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100075
PM 30814021
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Vorbau, C
   Baldauf, J
   Oertel, J
   Gaab, MR
   Schroeder, HWS
AF Vorbau, Christina
   Baldauf, Joerg
   Oertel, Joachim
   Gaab, Michael R.
   Schroeder, Henry W. S.
TI Long-Term Results After Endoscopic Resection of Colloid Cysts
SO WORLD NEUROSURGERY
LA English
DT Article
DE Colloid cyst; Endoscopic resection; Long-term result; Neuroendoscopy;
   Neuronavigation
ID LATERAL TRANSCALLOSAL APPROACH; MICROSURGICAL TREATMENT; FORNIX DAMAGE;
   3RD-VENTRICLE; EXPERIENCE; MANAGEMENT; REMOVAL; ANTEROGRADE; AMNESIA
AB BACKGROUND: Endoscopic resection of colloid cysts is a widely accepted treatment option instead of microsurgery. However, there is still a debate about a potentially higher rate of incomplete resections and recurrence.
   OBJECTIVE: The aim of this retrospective study was to evaluate long-term results after endoscopic removal of colloid cysts.
   METHODS: Twenty patients underwent endoscopic treatment in our department. Eighteen patients agreed to follow-up examinations. In 17 patients, magnetic resonance images were obtained.
   RESULTS: Total cyst resection was achieved in 16 procedures. In 1 patient, only plexus coagulation and widening of the ipsilateral foramen of Monro were performed. In 3 patients, small remnants of the cyst membrane were left behind. Conversion to microsurgery became necessary in 1 patient. Mild temporary complications occurred in 6 patients. Preoperative symptoms were completely relieved in 16 patients and improved in 2 patients. The average follow-up period was 188 months. In the patient with plexus coagulation, the cyst did not change. Recurrence occurred in 2 of 3 patients with cyst remnants. To date, no cyst remnant or recurrence has caused any symptoms or required surgical treatment.
   CONCLUSIONS: Our results indicate that endoscopic treatment of colloid cysts is a safe and effective treatment option that provides excellent long-term results. However, we determined that a significant risk for recurrence exists when even small parts of the cyst capsule were left behind. Therefore, we advocate an attempt at total endoscopic cyst resection.
C1 [Vorbau, Christina; Baldauf, Joerg; Schroeder, Henry W. S.] Univ Med Greifswald, Dept Neurosurg, Greifswald, Germany.
   [Oertel, Joachim] Univ Hosp Saarland, Dept Neurosurg, Homburg, Germany.
   [Gaab, Michael R.] Spine Ctr Hannover & Hildesheim, Hannover, Germany.
RP Vorbau, C (reprint author), Univ Med Greifswald, Dept Neurosurg, Greifswald, Germany.
EM vorbauc@uni-greifswald.de
CR Abdou MS, 1998, J NEUROSURG, V89, P1062, DOI 10.3171/jns.1998.89.6.1062
   Acerbi F, 2007, J Neurosurg Sci, V51, P53
   ANTUNES JL, 1980, NEUROSURGERY, V7, P450, DOI 10.1227/00006123-198011000-00004
   Boogaarts HD, 2011, NEUROSURGERY, V68, P179, DOI 10.1227/NEU.0b013e3181ffae71
   CAMACHO A, 1989, NEUROSURGERY, V24, P693, DOI 10.1227/00006123-198905000-00006
   Cohen-Gadol A A, 2013, WORLD NEUROSURG, V79
   Decq P, 1998, NEUROSURGERY, V42, P1288, DOI 10.1097/00006123-199806000-00051
   DEINSBERGER W, 1994, MINIM INVAS NEUROSUR, V37, P12, DOI 10.1055/s-2008-1053442
   Desai KI, 2002, SURG NEUROL, V57, P295, DOI 10.1016/S0090-3019(02)00701-2
   El-Ghandour NMF, 2009, NEUROSURG REV, V32, P395, DOI 10.1007/s10143-009-0208-2
   Fliessbach K, 2006, FORTSCHR NEUROL PSYC, V74, P643, DOI 10.1055/s-2006-932162
   GARCIABENGOCHEA F, 1987, SURG NEUROL, V27, P361, DOI 10.1016/0090-3019(87)90012-7
   Greenlee JDW, 2008, NEUROSURGERY, V63, P51, DOI [10.1227/01.NEU.0000297004.20222.ED, 10.1227/01.neu.0000317373.00018.6f]
   Grondin RT, 2007, CAN J NEUROL SCI, V34, P197, DOI 10.1017/S0317167100006041
   Hellwig D, 2008, NEUROSURGERY, V62, P1101, DOI [10.1227/01.NEU.0000047671.27057.55, 10.1227/01.neu.0000333776.89187.0e]
   Hernesniemi J, 2008, SURG NEUROL, V69, P447, DOI 10.1016/j.surneu.2007.11.005
   Hernesniemi J, 2008, SURG NEUROL, V69, P455, DOI 10.1016/j.surneu.2007.12.004
   HODGES JR, 1991, J NEUROL NEUROSUR PS, V54, P633, DOI 10.1136/jnnp.54.7.633
   Hoffman CE, 2013, NEUROSURGERY, V73, P233, DOI 10.1227/01.neu.0000430300.10338.71
   Horn EM, 2008, NEUROSURGERY, V62, P1076, DOI [10.1227/01.NEU.0000255409.61398.EA, 10.1227/01.neu.0000333773.43445.7b]
   Horvath Z, 2000, ACTA NEUROCHIR, V142, P539, DOI 10.1007/s007010050466
   JEEVES MA, 1979, J NEUROL NEUROSUR PS, V42, P134, DOI 10.1136/jnnp.42.2.134
   Jeffree RL, 2001, J CLIN NEUROSCI, V8, P328, DOI 10.1054/jocn.2000.0800
   Kehler U, 2001, MINIM INVAS NEUROSUR, V44, P121, DOI 10.1055/s-2001-18122
   KELLY R, 1951, BRAIN, V74, P23, DOI 10.1093/brain/74.1.23
   Lajara-Nanson W A, 2000, W V Med J, V96, P512
   Levine NB, 2007, MINIM INVAS NEUROSUR, V50, P313, DOI 10.1055/s-2007-993215
   LEWIS AI, 1994, J NEUROSURG, V81, P174, DOI 10.3171/jns.1994.81.2.0174
   LOBOSKY JM, 1984, J NEUROL NEUROSUR PS, V47, P1075, DOI 10.1136/jnnp.47.10.1075
   Longatti P, 2006, CHILD NERV SYST, V22, P1263, DOI 10.1007/s00381-006-0105-8
   Longatti P, 2000, MINIM INVAS NEUROSUR, V43, P118, DOI 10.1055/s-2000-8331
   Margetis K, 2013, WORLD NEUROSURG, V79, DOI 10.1016/j.wneu.2012.02.021
   Mathiesen T, 1997, J NEUROSURG, V86, P5, DOI 10.3171/jns.1997.86.1.0005
   MCKISSOCK W, 1951, BRAIN, V74, P1, DOI 10.1093/brain/74.1.1
   MCMACKIN D, 1995, ACTA NEUROCHIR, V135, P12, DOI 10.1007/BF02307408
   Poreh A, 2006, NEUROPSYCHOLOGIA, V44, P2241, DOI 10.1016/j.neuropsychologia.2006.05.020
   Rodziewicz GS, 2000, NEUROSURGERY, V46, P655, DOI 10.1097/00006123-200003000-00025
   Sampath R, 2010, NEUROSURGERY, V66, P368, DOI 10.1227/01.NEU.0000363858.17782.82
   Schroeder HWS, 2008, NEUROSURGERY, V62, P489, DOI 10.1227/01.neu.0000316017.43668.6c
   Schroeder HWS, 2002, NEUROSURGERY, V51, P1441, DOI 10.1097/00006123-200212000-00014
   Teo C, 1999, Neurosurg Focus, V6, pe9
   Tirakotai W, 2004, CHILD NERV SYST, V20, P842, DOI 10.1007/s00381-004-0941-3
   UPADHYAYA AK, 1988, BRIT J PSYCHIAT, V152, P567, DOI 10.1192/bjp.152.4.567
NR 43
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E176
EP E185
DI 10.1016/j.wneu.2018.09.190
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100019
PM 30292657
DA 2020-05-12
ER

PT J
AU Vourla, E
   Filis, A
   Cornelius, JF
   Bostelmann, R
   Turowski, B
   Kalakoti, P
   Rubbert, C
   Suresh, MP
   Tortora, A
   Steiger, HJ
   Petridis, AK
AF Vourla, Eleni
   Filis, Andreas
   Cornelius, Jan F.
   Bostelmann, Richard
   Turowski, Bernd
   Kalakoti, Piyush
   Rubbert, Christian
   Suresh, Marian Preetham
   Tortora, Angelo
   Steiger, Hans Jakob
   Petridis, Athanasios K.
TI Natural History of De Novo Aneurysm Formation in Patients with Treated
   Aneurysmatic Subarachnoid Hemorrhage: A Ten-Year Follow-Up
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebral aneurysm; Cerebrovascular; De novo aneurysm; Endovascular
   coiling; Microsurgical clipping; Subarachnoid haemorrhage
ID LONG-TERM; RECURRENCE; RISK
AB BACKGROUND: De novo aneurysm formation after completely occluded aneurysms via clipping or coiling has not been well studied. Although known to occur several years after initial aneurysm management, the natural history of de novo aneurysms is obscure. We investigated the formation of new aneurysms in patients who had previously undergone treatment of intracranial aneurysms.
   METHODS: In a retrospective, single-institutional series, eligible patients who had undergone treatment of ruptured cerebral aneurysms from 2000 to 2011 were included. The primary outcome measure was the development of de novo aneurysms during long-term follow-up.
   RESULTS: Overall, 130 patients (63% women) who had undergone microsurgical clipping (n = 63; 48.5%) or endovascular coiling (n = 67%; 51.5%) for ruptured aneurysms were included. The average follow-up time for our cohort was 10 +/- 2.7 years. De novo aneurysms occurred in 10 of 130 patients (7.7%), with a mean time of 7.9 years for aneurysm detection. No association between the formation of de novo aneurysms and the location of the treated aneurysms, smoking status, hypertension, age, or gender was found. Follow-up imaging studies were performed every 2 years. De novo aneurysms had formed in 2 patients within 2-5 years, 7 patients after 5-10 years, and 1 patient after 10 years of follow-up. In 2 of 10 patients, the de novo aneurysm had ruptured and led to subarachnoid haemorrhage.
   CONCLUSION: The rate of de novo aneurysm occurrence was 7.6%, with a mean time to development of 7.9 years. This underscores the significance of long-term monitoring of patients with intracranial aneurysms. In our series, most new aneurysms had occurred after 5 years of follow-up.
C1 [Vourla, Eleni; Cornelius, Jan F.; Bostelmann, Richard; Suresh, Marian Preetham; Tortora, Angelo; Steiger, Hans Jakob; Petridis, Athanasios K.] Univ Hosp Duesseldorf, Dept Neurosurg, Dusseldorf, Germany.
   [Turowski, Bernd; Rubbert, Christian] Univ Hosp Duesseldorf, Inst Neuroradiol, Dusseldorf, Germany.
   [Filis, Andreas] Imland Klin Rendsburg, Dept Neurosurg, Rendsburg, Germany.
   [Kalakoti, Piyush] Louisiana State Univ, Hlth Sci Ctr, Dept Neurosurg, Shreveport, LA 71105 USA.
RP Filis, A (reprint author), Imland Klin Rendsburg, Dept Neurosurg, Rendsburg, Germany.
EM andreasfilis79@yahoo.de
RI Kalakoti, Piyush/J-5269-2015; Bostelmann, Richard/AAI-7162-2020
OI Kalakoti, Piyush/0000-0002-9169-7418; 
CR Briganti F, 2002, NEURORADIOLOGY, V44, P604, DOI 10.1007/s00234-001-0732-4
   Brown MA, 2017, J NEUROSURG, V126, P819, DOI 10.3171/2016.2.JNS152059
   Bruneau M, 2011, NEUROSURG REV, V34, P485, DOI 10.1007/s10143-011-0332-7
   Burkhardt JK, 2017, WORLD NEUROSURG, V106, P74, DOI [10.1016/j.WNEU.2017.06.110, 10.1016/j.wneu.2017.06.110]
   Consoli A, 2012, INTERV NEURORADIOL, V18, P5, DOI 10.1177/159101991201800101
   Giordan E, 2019, J NEUROSURG, V131, P1024, DOI 10.3171/2018.5.JNS1875
   Hu S, 2019, NEUROSURGERY, V85, P454, DOI 10.1093/neuros/nyy332
   Juvela S, 2001, STROKE, V32, P485, DOI 10.1161/01.STR.32.2.485
   Leblanc R, 1999, NEUROSURGERY, V44, P871, DOI 10.1097/00006123-199904000-00110
   Long B, 2017, EMERG MED CLIN N AM, V35, P803, DOI 10.1016/j.emc.2017.07.001
   Rahmah NN, 2011, NEUROSURGERY, V69, pE761, DOI 10.1227/NEU.0b013e3182196489
   SAKAKI T, 1993, NEUROSURGERY, V32, P512
   Zali A, 2014, WORLD NEUROSURG, V82, P722, DOI 10.1016/j.wneu.2013.06.008
NR 13
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E291
EP E295
DI 10.1016/j.wneu.2018.10.022
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100033
PM 30321678
DA 2020-05-12
ER

PT J
AU Wang, A
   Tenner, MS
   Schmidt, MH
   Bowers, C
AF Wang, Arthur
   Tenner, Michael S.
   Schmidt, Meic H.
   Bowers, Christian
TI Placement of Ommaya Reservoirs Using Electromagnetic Neuronavigation and
   Neuroendoscopy: A Retrospective Study with Cost-Benefit Analysis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cost-benefit analysis; Electromagnetic neuronavigation; Frameless
   stereotaxy; Neuroendoscopy; Ommaya reservoir; Ventricular catheter
ID VENTRICULAR CATHETER PLACEMENT; FRAMELESS; SHUNT; INSERTION;
   CHEMOTHERAPY; NAVIGATION; ACCURACY
AB BACKGROUND: Placement of intraventricular catheters in oncology patients is associated with high complication rates. Placing Ommaya reservoirs with the zero-error precision protocol (ZEPP), a combination of neuronavigation (AxiEM stereotactic navigation) and direct verification of catheter tip placement with a flexible neuroendoscope, is associated with decreased complication rates as a result of increased catheter placement accuracy. However, the ZEPP costs more than traditional methods of catheter placement, and the question of whether this increased accuracy with the ZEPP is cost-effective is unknown.
   METHODS: We performed a single-center retrospective chart review of 50 consecutive ommaya reservoir patient placements between 2010 and 2017. Twenty-five ventricular catheters were placed using the ZEPP protocol, and 25 ventricular catheters were placed using only AxiEM stealth navigation. Postoperative catheter accuracy and complication rates were assessed. A cost-benefit analysis was then conducted to determine if the overall cost for placing Ommaya reservoirs with the ZEPP was effective compared with the alternative method of using neuro-navigation alone.
   RESULTS: In the non-ZEPP cohort, 10 of 25 catheters were placed within the optimal location compared with 25 of 25 catheters placed in the ZEPP cohort. Three complications occurred in the non-ZEPP cohort: 2 catheters required surgical revision and 1 catheter-related hemorrhage resulted in a prolonged stay in the intensive care unit. No complications occurred in the ZEPP cohort. A cost-benefit analysis showed $4784 savings per patient with ZEPP utilization because of the high complication-associated costs.
   CONCLUSIONS: Implementation of the ZEPP for verifying ventricular catheter placement in Ommaya reservoirs improved catheter tip accuracy, resulted in lower complication rates, and was more cost-effective when compared with the non-ZEPP cohort, which used only neuronavigation. The ZEPP can be used for ventricular shunt catheter placement to decrease complications and verify catheter tip accuracy in Ommaya or standard ventriculoperitoneal shunts.
C1 [Wang, Arthur; Schmidt, Meic H.; Bowers, Christian] New York Med Coll, Westchester Med Ctr, Dept Neurol Surg, Valhalla, NY 10595 USA.
   [Tenner, Michael S.] New York Med Coll, Dept Radiol, Westchester, NY USA.
RP Schmidt, MH (reprint author), New York Med Coll, Westchester Med Ctr, Dept Neurol Surg, Valhalla, NY 10595 USA.
EM meic.schmidt@wmchealth.org
CR Al-Anazi A, 2000, J NEUROSURG, V92, P1050, DOI 10.3171/jns.2000.92.6.1050
   Azeem SS, 2007, NEUROSURGERY, V60, P243, DOI 10.1227/01.NEU.0000255387.03088.53
   Barszcz S, 2007, NEUROL NEUROCHIR POL, V41, P122
   Chamberlain MC, 1997, J NEUROSURG, V87, P694, DOI 10.3171/jns.1997.87.5.0694
   Clark S, 2008, J NEUROSURG-PEDIATR, V2, P430, DOI 10.3171/PED.2008.2.12.430
   DEWAAL R, 1993, J NEURO-ONCOL, V15, P269, DOI 10.1007/BF01050074
   Greenfield JP, 2008, STEREOT FUNCT NEUROS, V86, P101, DOI 10.1159/000112431
   HAGEN NA, 1987, J NEURO-ONCOL, V5, P273, DOI 10.1007/BF00151231
   Hermann EJ, 2012, J NEUROSURG-PEDIATR, V10, P327, DOI 10.3171/2012.7.PEDS11369
   Kennedy BC, 2016, J CLIN NEUROSCI, V27, P44, DOI 10.1016/j.jocn.2015.11.005
   Levitt MR, 2012, J NEUROSURG-PEDIATR, V10, P112, DOI 10.3171/2012.3.PEDS122
   LEVY WJ, 1981, NEUROSURGERY, V9, P559, DOI 10.1227/00006123-198111000-00012
   MCDERMOTT MW, 1995, CAN J NEUROL SCI, V22, P235, DOI 10.1017/S0317167100039913
   Morgenstern PF, 2016, WORLD NEUROSURG, V93, P154, DOI 10.1016/j.wneu.2016.04.090
   Sandberg DI, 2000, NEUROSURGERY, V47, P49, DOI 10.1097/00006123-200007000-00011
   Shamir RR, 2011, NEUROSURGERY, V68, DOI 10.1227/NEU.0b013e31820828d9
   Stieglitz LH, 2010, NEUROSURGERY, V67, P131, DOI 10.1227/01.NEU.0000382964.72262.9A
   Villavicencio AT, 2003, SURG NEUROL, V59, P375, DOI 10.1016/S0090-3019(03)00070-3
   Wang A, 2016, WORLD NEUROSURG, V96, P195, DOI 10.1016/j.wneu.2016.08.127
   Weiner GM, 2015, CLIN NEUROL NEUROSUR, V130, P61, DOI 10.1016/j.clineuro.2014.12.018
   Woodworth GF, 2005, STEREOT FUNCT NEUROS, V83, P12, DOI 10.1159/000084059
   Xu LW, 2016, CLIN NEUROL NEUROSUR, V147, P46, DOI 10.1016/j.clineuro.2016.05.024
NR 22
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E723
EP E728
DI 10.1016/j.wneu.2018.10.127
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100087
PM 30404054
DA 2020-05-12
ER

PT J
AU Wang, SX
   Wang, HL
   Lin, KY
   Bian, C
   Sun, C
   Dong, J
AF Wang, Sheng-Xing
   Wang, Hou-Lei
   Lin, Kai-Yuan
   Bian, Chong
   Sun, Chi
   Dong, Jian
TI Surgical Outcomes and Prognostic Factors for Metastatic Spine
   Hepatocellular Carcinoma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Excisional surgery; Hepatocellular carcinoma; Spinal metastases;
   Survival analysis; Tokuhashi score; Total en bloc spondylectomy
ID EN-BLOC SPONDYLECTOMY; PREOPERATIVE EVALUATION; SCORING SYSTEM; TUMORS;
   SURVIVAL; SURGERY
AB BACKGROUND: We evaluated the surgical outcomes of metastatic spine hepatocellular carcinoma (HCC) and determined the factors that might influence the outcomes of metastatic HCC of the spine.
   METHODS: From 2010 to 2017, 72 patients with HCC-derived metastatic spine tumors were treated in our department. For each patient, we recorded the pre- and postoperative visual analog scale score, Frankel grade, perioperative complications, and mortality. Univariate and multivariate analyses were used to explore a range of factors that might influence postoperative survival.
   RESULTS: The mean postoperative survival was 10.8 +/- 5.4 months. The concordance rate between a Tokuhashi score of 0-8 and a life expectancy of <6 months was only 19.2%. The mean postoperative survival for patients undergoing excisional surgery was 14.7 +/- 6.5 months, and the mean survival of those receiving palliative surgery was 8.5 +/- 2.6 months. Pain had significantly improved in both patient groups (P < 0.001). Paralysis did not change significantly in the excisional surgery group (P = 0.641) or palliative surgery group (P = 0.912). Univariate analysis showed that the preoperative Frankel score, Tomita score, Tokuhashi score, blood loss, multilevel metastases, and operative type were independent prognostic factors for postoperative survival time. Multivariate analysis showed that operation type was an independent factor for prognosis, just as were the Tomita score and Tokuhashi score.
   CONCLUSIONS: Our results have challenged previously reported estimates of the life expectancy correlating with the Tokuhashi score. Our results showed that excisional surgery resulted in better clinical outcomes compared with palliative surgery.
C1 [Wang, Sheng-Xing; Wang, Hou-Lei; Lin, Kai-Yuan; Bian, Chong; Sun, Chi; Dong, Jian] Fudan Univ, Zhongshan Hosp, Dept Orthopaed Surg, Shanghai, Peoples R China.
RP Dong, J (reprint author), Fudan Univ, Zhongshan Hosp, Dept Orthopaed Surg, Shanghai, Peoples R China.
EM dong.jian@zs-hospital.sh.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81572629, 81772855]; Science and Technology
   Commission of Shanghai MunicipalityScience & Technology Commission of
   Shanghai Municipality (STCSM) [17411950302]
FX The present study was supported by the National Natural Science
   Foundation of China (grants 81572629 and 81772855) and Science and
   Technology Commission of Shanghai Municipality (17411950302). The
   funding agencies had no role in the study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Abbas A, 2014, DIGEST DIS SCI, V59, P2813, DOI 10.1007/s10620-014-3229-9
   Arrigo RT, 2011, NEUROSURGERY, V68, P674, DOI 10.1227/NEU.0b013e318207780c
   Boriani S, 1997, SPINE, V22, P1036, DOI 10.1097/00007632-199705010-00020
   Chen H, 2010, SPINE, V35, P1339
   Chi JH, 2008, NEUROSURG CLIN N AM, V19, P111, DOI 10.1016/j.nec.2007.10.004
   Doval DC, 2006, WORLD J GASTROENTERO, V12, P5247
   Fehlings MG, 2010, J NEUROSURG-SPINE, V13, P411, DOI 10.3171/2009.11.SPINE09786
   Forner A, 2018, LANCET, V391, P1301, DOI 10.1016/S0140-6736(18)30010-2
   IARC, FACT SHEETS POP GLOB
   Jemal A, 2010, CANCER EPIDEM BIOMAR, V19, P1893, DOI 10.1158/1055-9965.EPI-10-0437
   Kawahara N, 2011, SPINE, V36, P74, DOI 10.1097/BRS.0b013e3181cded6c
   Kodama H, 2007, ONCOLOGY-BASEL, V72, P285, DOI 10.1159/000113040
   Lee MH, 2015, J KOREAN NEUROSURG S, V58, P448, DOI 10.3340/jkns.2015.58.5.448
   Sohn S, 2016, J KOREAN NEUROSURG S, V59, P37, DOI 10.3340/jkns.2016.59.1.37
   Sundaresan N, 2009, SPINE, V34, pS7, DOI 10.1097/BRS.0b013e3181bac476
   Tokuhashi Y, 2005, SPINE, V30, P2186, DOI 10.1097/01.brs.0000180401.06919.a5
   Tokuhashi Y, 2009, SPINE, V34, P69, DOI 10.1097/BRS.0b013e3181913f19
   Tomita K, 1997, SPINE, V22, P324, DOI 10.1097/00007632-199702010-00018
   Tomita K, 2006, J ORTHOP SCI, V11, P3, DOI 10.1007/s00776-005-0964-y
   Tomita K, 2001, SPINE, V26, P298, DOI 10.1097/00007632-200102010-00016
   Uei H, 2018, INT J CLIN ONCOL, V23, P886, DOI 10.1007/s10147-018-1277-4
   Uei H, 2017, SPINE, V42, pE1446, DOI 10.1097/BRS.0000000000002382
   Uy GL, 2017, LEUKEMIA, V31, P872, DOI 10.1038/leu.2016.282
   YOUNG RF, 1980, J NEUROSURG, V53, P741, DOI 10.3171/jns.1980.53.6.0741
   Zhang D, 2013, SPINE, V38, pE1090, DOI 10.1097/BRS.0b013e3182983bf8
NR 25
TC 0
Z9 0
U1 2
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1052
EP E1058
DI 10.1016/j.wneu.2018.10.226
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100129
PM 30415045
DA 2020-05-12
ER

PT J
AU Wang, X
   Gao, J
   Wang, TY
   Li, ZM
   Li, YN
AF Wang, Xin
   Gao, Jun
   Wang, Tianyu
   Li, Zhimin
   Li, Yongning
TI Clinical Significance of Variable Clivus Gradients in Patients with
   Chiari Malformation Type I After Surgical Decompression: A Retrospective
   Analysis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Chiari malformation type I; Chicago Chiari Outcome Scale; Clivus
   gradients; Syringomyelia
ID POSTERIOR CRANIAL FOSSA; FEATURES; MRI
AB OBJECTIVE: Previous studies have shown that the clivus angle gradient is significantly decreased in patients with Chiari malformation type I (CMI) with an associated syrinx compared with patients with CMI only and a healthy population. To date, the relationship between the clivus gradient and clinical outcomes has remained unclear. The objective of the present study was to investigate whether different clivus gradients (angle alpha) in CMI after posterior fossa decompression will lead to different clinical outcomes.
   METHODS: A total of 86 patients who had undergone surgical decompression at our institution from 2010 to 2016 were retrospectively divided into 2 groups: group A, with a gradient angle >44 degrees, and group B, with an angle <= 44 degrees. The patients' outcomes were determined using the Chicago Chiari Outcome Scale (CCOS).
   RESULTS: Direct comparisons were made between the 2 groups. No statistically significant differences were found between the 2 groups in demographic data, preoperative symptoms, postoperative complications, or radiographic characteristics (P > 0.05), except for the length of the postoperative hospital stay (P = 0.006). The mean overall CCOS score was 12.80 +/- 2.08. The total CCOS score was significantly different statistically between the 2 groups (P < 0.05). Moreover, group A demonstrated significantly better postoperative improvements compared with group B in the clinical outcome measures using the CCOS (P = 0.021).
   CONCLUSIONS: A direct comparison between the 2 groups revealed that a decreased clivus gradient was related to unsatisfactory clinical outcomes. Thus, clivus gradients might emerge as a predictor of clinical outcomes after surgical decompression in patients with CMI.
C1 [Li, Yongning] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Neurosurg, Beijing, Peoples R China.
   Peking Union Med Coll, Beijing, Peoples R China.
RP Li, YN (reprint author), Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Neurosurg, Beijing, Peoples R China.
EM wangxin0967@163.com
FU Independent Innovation Project of Capital Health Research [2016-2-4014]
FX The authors declare that the article content was composed in the absence
   of any commercial or financial relationships that could be construed as
   a potential conflict of interest. This work was funded by Independent
   Innovation Project of Capital Health Research (2016-2-4014).
CR Aliaga L, 2012, NEUROSURGERY, V70, P656, DOI 10.1227/NEU.0b013e31823200a6
   Alkoc OA, 2015, J KOREAN NEUROSURG S, V58, P454, DOI 10.3340/jkns.2015.58.5.454
   APPLEGATE GR, 1992, NEURORADIOLOGY, V34, P217, DOI 10.1007/BF00596340
   Arnautovic A, 2015, J NEUROSURG-PEDIATR, V15, P161, DOI 10.3171/2014.10.PEDS14295
   Fernandez AA, 2009, BMC MUSCULOSKEL DIS, V10, DOI 10.1186/1471-2474-10-S1-S1
   Botelho RV, 2013, NEUROSURG REV, V36, P603, DOI 10.1007/s10143-013-0471-0
   Chotai S, 2014, CLIN NEUROL NEUROSUR, V125, P182, DOI 10.1016/j.clineuro.2014.07.027
   Driver CJ, 2013, VET J, V198, P551, DOI 10.1016/j.tvjl.2013.07.014
   Dufton JA, 2011, CAN J NEUROL SCI, V38, P452, DOI 10.1017/S0317167100011860
   El-Ghandour NMF, 2012, NEUROSURG REV, V35, P537, DOI 10.1007/s10143-012-0387-0
   Ferreira Janio A, 2015, Surg Neurol Int, V6, P118, DOI 10.4103/2152-7806.160322
   Heiss JD, 2012, J NEUROSURG-SPINE, V17, P367, DOI 10.3171/2012.8.SPINE111059
   HUANG PP, 1994, J NEUROSURG, V80, P1099, DOI 10.3171/jns.1994.80.6.1099
   Hwang HS, 2013, J KOREAN NEUROSURG S, V54, P405, DOI 10.3340/jkns.2013.54.5.405
   Karagoz F, 2002, ACTA NEUROCHIR, V144, P165, DOI 10.1007/s007010200020
   Khalsa SSS, 2018, J NEUROSURG-PEDIATR, V21, P65, DOI 10.3171/2017.8.PEDS17345
   Klekamp J, 2012, NEUROSURGERY, V71, P365, DOI 10.1227/NEU.0b013e31825c3426
   McGirt MJ, 2008, CHILD NERV SYST, V24, P1333, DOI 10.1007/s00381-008-0651-3
   McVige JW, 2015, CURR PAIN HEADACHE R, V19, DOI 10.1007/s11916-015-0491-2
   Pomeraniec IJ, 2016, J NEUROSURG-PEDIATR, V17, P343, DOI 10.3171/2015.7.PEDS1594
   Sweeney KJ, 2013, J NEUROSURG-PEDIATR, V11, P154, DOI 10.3171/2012.10.PEDS12177
   Vernooij MW, 2007, NEW ENGL J MED, V357, P1821, DOI 10.1056/NEJMoa070972
   Wu YW, 1999, NEUROLOGY, V53, P1271, DOI 10.1212/WNL.53.6.1271
   Yan H, 2016, EUR SPINE J, V25, P2202, DOI 10.1007/s00586-016-4410-y
NR 24
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E443
EP E448
DI 10.1016/j.wneu.2018.10.068
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100052
PM 30347304
DA 2020-05-12
ER

PT J
AU Wang, YQ
   Wang, C
   Yan, M
AF Wang, Yongqiang
   Wang, Chao
   Yan, Ming
TI Clinical Outcomes of Atlantoaxial Dislocation Combined with High-Riding
   Vertebral Artery Using C2 Translaminar Screws
SO WORLD NEUROSURGERY
LA English
DT Article
DE Atlantoaxial dislocation; Atlantoaxial fusion; High-riding vertebral
   artery; Revision; Translaminar screw
ID FIXATION; PEDICLE; FUSION; INJURY; REDUCTION; PLATE; SPINE; RISK; C1
AB OBJECTIVE: Atlantoaxial stabilization procedures in high-riding vertebral artery (HRVA) cases are challenging. C2 translaminar screws are rigid and pose no risk to the vertebral artery. The aim of this study was to present clinical outcomes of atlantoaxial dislocation combined with HRVA using C2 translaminar screws.
   METHODS: Cases of atlantoaxial dislocation combined with HRVA surgically treated in our institution from 2007 to 2015 were retrospectively reviewed. Atlantodental interval and clivus-axial angle were measured. The Japanese Orthopaedic Association scale was used to evaluate neurologic status.
   RESULTS: There were 58 patients enrolled: 15 with instability and 43 with dislocation, 13 of which were irreducible. Incidence of bilateral HRVA was 5.2%. C1-C2 fixation was performed in 26 cases; atlantodental interval decreased from 9.9 +/- 3.7 mm to 1.0 +/- 1.7 mm (P < 0.05). C0-C2 fixation was performed in 32 cases; clivus-axial angle increased from 125 degrees +/- 13 degrees to 150 degrees +/- 15 degrees (P < 0.05). Preoperative and postoperative Japanese Orthopaedic Association scores of 56 patients with myelopathy were 11.9 +/- 2.8 and 14.6 +/- 2.4, respectively (P < 0.05). Fusion rate was 93.1% (54/58) and at 4-month follow-up was 81% (47/58). In 14 cases of redislocation, final fusion was achieved; 3 of 14 required odontoidectomy. Four cases lacking bony fusion also required revision surgery. Redislocation rate was 31% (18/58), and reoperation rate was 12.1% (7/58).
   CONCLUSIONS: Surgical results of C2 translaminar screws are unsatisfactory, with high redislocation and reoperation rates in atlantoaxial dislocation cases. New treatment methods should be investigated to facilitate clinical outcomes. Extending fixed segments should be considered.
C1 [Wang, Yongqiang; Wang, Chao; Yan, Ming] Peking Univ, Hosp 3, Dept Orthoped, Beijing, Peoples R China.
RP Wang, C (reprint author), Peking Univ, Hosp 3, Dept Orthoped, Beijing, Peoples R China.
EM drwangpku@bjmu.edu.cn
CR Daentzer D, 2009, ARCH ORTHOP TRAUM SU, V129, P177, DOI 10.1007/s00402-008-0620-z
   Farey ID, 1999, CLIN ORTHOP RELAT R, P126, DOI 10.1097/00003086-199902000-00013
   Goel A, 2002, NEUROSURGERY, V51, P1351, DOI 10.1097/00006123-200212000-00004
   Gorek J, 2005, SPINE, V30, P1513, DOI 10.1097/01.brs.0000167827.84020.49
   Harms J, 2001, SPINE, V26, P2467, DOI 10.1097/00007632-200111150-00014
   Hoh DJ, 2010, J NEUROSURG-SPINE, V12, P602, DOI 10.3171/2009.12.SPINE09543
   Lapsiwala SB, 2006, NEUROSURGERY, V58, P516, DOI 10.1227/01.NEU.0000197222.05299.31
   Lee JH, 2007, J SPINAL DISORD TECH, V20, P499, DOI 10.1097/BSD.0b013e318031af51
   Lehman RA, 2008, SPINE, V33, P960, DOI 10.1097/BRS.0b013e31816c915b
   Madawi AA, 1997, J NEUROSURG, V86, P961, DOI 10.3171/jns.1997.86.6.0961
   MAGERL F, 1987, CERVICAL SPINE, V1, P322
   Meyer D, 2012, NEUROSURG REV, V35, P255, DOI 10.1007/s10143-011-0358-x
   Neo M, 2003, SPINE, V28, P666, DOI 10.1097/00007632-200304010-00009
   Padua MRA, 2013, SPINE J, V13, P1455, DOI 10.1016/j.spinee.2013.05.036
   Park YS, 2010, J KOREAN NEUROSURG S, V48, P367, DOI 10.3340/jkns.2010.48.4.367
   Rajinda P, 2017, EUR SPINE J, V26, P1064, DOI 10.1007/s00586-016-4829-1
   Sim HB, 2011, SPINE, V36, pE401, DOI 10.1097/BRS.0b013e31820611ba
   Song GS, 1997, J NEUROSURG, V87, P851, DOI 10.3171/jns.1997.87.6.0851
   Tan LA, 2019, BRIT J NEUROSURG, V33, P422, DOI 10.1080/02688697.2017.1346170
   Wang C, 2006, SPINE, V31, pE306, DOI 10.1097/01.brs.0000217686.80327.e4
   Wang C, 2007, SPINE, V32, P643, DOI 10.1097/01.brs.0000257539.75693.cc
   Wang SL, 2013, SPINE, V38, pE1348, DOI 10.1097/BRS.0b013e3182a1e5e4
   Wright NM, 1998, J NEUROSURG, V88, P634, DOI 10.3171/jns.1998.88.4.0634
   Wright NM, 2004, J SPINAL DISORD TECH, V17, P158, DOI 10.1097/00024720-200404000-00014
   Yeom JS, 2013, SPINE J, V13, P775, DOI 10.1016/j.spinee.2013.04.005
   Yin QS, 2005, SPINE, V30, pE375, DOI 10.1097/01.brs.0000168374.84757.d5
   Yoshida M, 2006, SPINE, V31, pE513, DOI 10.1097/01.brs.0000224516.29747.52
NR 27
TC 0
Z9 1
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1511
EP E1518
DI 10.1016/j.wneu.2018.11.092
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100185
PM 30468926
DA 2020-05-12
ER

PT J
AU Wang, ZH
   Guo, XP
   Gao, L
   Feng, CZ
   Lian, W
   Deng, K
   Bao, XJ
   Feng, M
   Wang, RZ
   Xing, B
AF Wang, Zihao
   Guo, Xiaopeng
   Gao, Lu
   Feng, Chenzhe
   Lian, Wei
   Deng, Kan
   Bao, Xinjie
   Feng, Ming
   Wang, Renzhi
   Xing, Bing
TI Delayed Remission of Growth Hormone-Secreting Pituitary Adenoma After
   Transsphenoidal Adenectomy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Acromegaly; Growth hormone; Pituitary surgery; Remission;
   Transsphenoidal surgery
ID IGF-1 LEVELS; SURGERY
AB OBJECTIVE: To investigate the clinical characteristics of delayed remission (DR) of growth hormone (GH)-secreting pituitary adenoma after transsphenoidal adenectomy and inform follow-up treatments.
   METHODS: We retrospectively reviewed 87 patients who had undergone transsphenoidal surgery for acromegaly. Demographic, radiological, and endocrinological data were reviewed before, immediately after, 3 months after, and in the long term (2.4 +/- 1.1 years) after surgery. The definition of DR was that patients did not achieve GH remission immediately, 3 months, or later after surgery, but did so in the long term without any additional postoperative treatment.
   RESULTS: Fifty-one patients (58.6%) achieved long-term GH remission. There were 24 (27.6%) DR patients immediately postoperatively and 9 (10.3%) DR patients 3 months postoperatively. On average, the 24 DR patients achieved remission at 10.2 (range, 3-32) months. Immediate postoperative random and nadir GH after an oral glucose load were significantly lower in the DR group than in the non-remission group (2.73 +/- 3.17 and 2.03 +/- 2.59 vs. 8.05 +/- 10.35 and 5.55 +/- 5.91 mu g/L, respectively). Three-month postoperative nadir GH was significantly lower in the DR group than in the nonremission group (1.63 +/- 2.82 vs. 3.48 +/- 4.25 mu g/L, P = 0.007). Immediate postoperative random GH effectively predicted long-term remission (Spearman's rho = 0.513, area under the curve = 0.905 > 0.90). However, the best predictor of long-term remission was 3-month postoperative nadir GH (Spearman's rho = 0.728, area under the curve = 0.944 > 0.90), with 76.5% sensitivity and 97.2% specificity.
   CONCLUSIONS: For certain groups of patients likely to achieve DR, additional treatments should not be performed early after surgery. Prolonged follow-up and close observation could help determine the therapeutic effect of surgery and guide postoperative treatments.
C1 [Wang, Zihao; Guo, Xiaopeng; Gao, Lu; Feng, Chenzhe; Lian, Wei; Deng, Kan; Bao, Xinjie; Feng, Ming; Wang, Renzhi; Xing, Bing] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Neurosurg, Beijing, Peoples R China.
   [Wang, Zihao; Guo, Xiaopeng; Gao, Lu; Feng, Chenzhe; Lian, Wei; Deng, Kan; Bao, Xinjie; Feng, Ming; Wang, Renzhi; Xing, Bing] Peking Union Med Coll, Beijing, Peoples R China.
   [Wang, Zihao; Guo, Xiaopeng; Gao, Lu; Feng, Chenzhe; Lian, Wei; Deng, Kan; Bao, Xinjie; Feng, Ming; Wang, Renzhi; Xing, Bing] Chinese Pituitary Adenoma Cooperat Grp, China Pituitary Dis Registry Ctr, Beijing, Peoples R China.
RP Xing, B (reprint author), Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Neurosurg, Beijing, Peoples R China.; Xing, B (reprint author), Peking Union Med Coll, Beijing, Peoples R China.; Xing, B (reprint author), Chinese Pituitary Adenoma Cooperat Grp, China Pituitary Dis Registry Ctr, Beijing, Peoples R China.
EM xingbingemail@aliyun.com
RI Wang, Zihao/I-9307-2018
OI Gao, Lu/0000-0003-1632-5101
CR Brzana JA, 2012, PITUITARY, V15, P562, DOI 10.1007/s11102-011-0369-1
   Erfe JM, 2017, J NEUROSURG, V13, P1
   Giustina A, 2010, J CLIN ENDOCR METAB, V95, P3141, DOI 10.1210/jc.2009-2670
   Katznelson L, 2014, J CLIN ENDOCR METAB, V99, P3933, DOI 10.1210/jc.2014-2700
   Kim EH, 2012, NEUROSURGERY, V70, P1106, DOI 10.1227/NEU.0b013e31823f5c16
   Mayberg M, 2017, J NEUROSURG, P1
   Melmed S, 2006, NEW ENGL J MED, V355, P2558, DOI 10.1056/NEJMra062453
   Oldfield EH, 2017, J NEUROSURG, V126, P1959, DOI 10.3171/2016.8.JNS161123
   Shin MS, 2013, NEUROSURGERY, V73, P473, DOI 10.1227/01.neu.0000431480.87160.84
   Zeinalizadeh M, 2015, PITUITARY, V18, P48, DOI 10.1007/s11102-014-0556-y
   Zhang S, 2018, J FORMOS MED ASSOC, V117, P34, DOI 10.1016/j.jfma.2017.02.014
NR 11
TC 2
Z9 2
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1137
EP E1145
DI 10.1016/j.wneu.2018.11.004
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100139
PM 30447463
DA 2020-05-12
ER

PT J
AU Wu, J
   Kim, C
   Bai, HX
   Tang, L
   Wang, YY
   Li, XJ
   Zhang, ZS
   Karakousis, G
   Huang, R
   Zhang, PJ
   Xiao, B
   Yang, L
AF Wu, Jing
   Kim, Casey
   Bai, Harrison X.
   Tang, Lei
   Wang, Yinyan
   Li, Xuejun
   Zhang, Zishu
   Karakousis, Giorgos
   Huang, Raymond
   Zhang, Paul J.
   Xiao, Bo
   Yang, Li
TI Comparison of Radiation Therapy Alone and Chemotherapy Alone for
   Low-Grade Gliomas without Surgical Resection
SO WORLD NEUROSURGERY
LA English
DT Article
DE Chemotherapy; Low-grade glioma; Overall survival; Radiotherapy
ID TERM-FOLLOW-UP; BRAIN-TUMORS; RADIOTHERAPY; RISK; PROCARBAZINE;
   VINCRISTINE; TEMOZOLOMIDE; MANAGEMENT; LOMUSTINE; DIFFUSE
AB BACKGROUND: The combined use of chemotherapy (CT) and radiotherapy (RT) is becoming increasingly common in the treatment of surgically resected low-grade gliomas. However, whether RT or CT is associated with improved overall survival (OS) for low-grade gliomas without surgical resection is less clear.
   METHODS: The U.S. National Cancer Data Base was used to identify patients with histologically confirmed World Health Organization (WHO) grade 2 gliomas who received either RT alone or CT alone but did not undergo surgical resection from 2004 to 2013. OS was evaluated with Kaplan-Meier analysis, multivariable Cox proportional hazard regression, and propensity score-matched analysis.
   RESULTS: In total, 1126 patients with WHO grade 2 gliomas were included, among whom 715 (63.5%) received RT alone and 411 (36.5%) CT alone. CT alone was associated with significantly longer OS when compared to RT alone on multivariable analysis and propensity-score matched analysis. Age less than 60 years and time from diagnosis to start of adjuvant therapy (RT or CT) greater than 30 days were also associated with longer OS. In subgroup analysis based on age, the survival advantage of CT alone over RT alone persisted in both age subgroups (< 60 years and >60 years). In subgroup analyses based on histology of glioma, CT alone was associated with longer OS in the astrocytoma and oligodendroglioma group, but not in the oligoastrocytoma group.
   CONCLUSIONS: Our results suggest that CT alone was independently associated with longer OS when compared with RT alone in patients with low-grade glioma but without surgical resection. This survival advantage persisted in both age subgroups, but it varied by histology of glioma.
C1 [Wu, Jing; Xiao, Bo] Cent S Univ, Xiangya Hosp, Dept Neurol, Changsha, Hunan, Peoples R China.
   [Kim, Casey] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Bai, Harrison X.] Hosp Univ Penn, Dept Radiol, 3400 Spruce St, Philadelphia, PA 19104 USA.
   [Tang, Lei; Yang, Li] Cent S Univ, Xiangya Hosp 2, Dept Neurol, Changsha, Hunan, Peoples R China.
   [Wang, Yinyan] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing, Peoples R China.
   [Li, Xuejun] Cent S Univ, Xiangya Hosp, Dept Neurosurg, Changsha, Hunan, Peoples R China.
   [Zhang, Zishu] Cent S Univ, Xiangya Hosp 2, Dept Radiol, Changsha, Hunan, Peoples R China.
   [Karakousis, Giorgos] Hosp Univ Penn, Dept Surg, 3400 Spruce St, Philadelphia, PA 19104 USA.
   [Huang, Raymond] Brigham & Womens Hosp, Dept Radiol, 75 Francis St, Boston, MA 02115 USA.
   [Zhang, Paul J.] Hosp Univ Penn, Dept Pathol & Lab Med, 3400 Spruce St, Philadelphia, PA 19104 USA.
RP Yang, L (reprint author), Cent S Univ, Xiangya Hosp 2, Dept Neurol, Changsha, Hunan, Peoples R China.
EM yangli762@csu.edu.cn
RI Wang, Yinyan/AAJ-1160-2020
FU Natural Science Foundation of Human ProvinceNatural Science Foundation
   of Hunan Province [2018JJ3709]; Shenghua Yuying Project of Central South
   University [81472594]
FX This work was supported by Natural Science Foundation of Human Province
   (2018JJ3709 to Li Yang), Shenghua Yuying Project of Central South
   University to Li Yang and Natural Science Foundation of China (81472594
   to Xuejun Li).
CR Bandopadhayay P, 2014, PEDIATR BLOOD CANCER, V61, P1173, DOI 10.1002/pbc.24958
   Baumert BG, 2016, LANCET ONCOL, V17, P1521, DOI 10.1016/S1470-2045(16)30313-8
   Buckner JC, 2016, NEW ENGL J MED, V374, P1344, DOI 10.1056/NEJMoa1500925
   Cahill DP, 2015, J NEURO-ONCOL, V125, P531, DOI 10.1007/s11060-015-1909-8
   Cairncross JG, 2014, J CLIN ONCOL, V32, P783, DOI 10.1200/JCO.2013.49.3726
   DANOFF BF, 1982, CANCER, V48, P1580, DOI 10.1002/1097-0142(19820415)49:8<1580::AID-CNCR2820490810>3.0.CO;2-7
   Douw L, 2009, LANCET NEUROL, V8, P810, DOI 10.1016/S1474-4422(09)70204-2
   Friedman DL, 2010, JNCI-J NATL CANCER I, V102, P1083, DOI 10.1093/jnci/djq238
   Howell Rebecca, 2012, Med Phys, V39, P7729, DOI 10.1118/1.4765651
   Liu R, 2009, NEURO-ONCOLOGY, V11, P330, DOI 10.1215/15228517-2008-093
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Merchant TE, 2009, J CLIN ONCOL, V27, P3691, DOI 10.1200/JCO.2008.21.2738
   Huynh-Le MP, 2016, CHILD NERV SYST, V32, P1425, DOI 10.1007/s00381-016-3100-8
   Rotta J, 2017, ACTA NEUROL BELG, V117, P235, DOI 10.1007/s13760-016-0657-7
   Runzer-Colmenares FM, 2017, MED CLIN-BARCELONA, V149, P325, DOI 10.1016/j.medcli.2017.02.022
   Sanai N, 2011, J NEUROSURG, V115, P948, DOI [10.3171/2011.7.JNS101238, 10.3171/2011.7.JNS10238]
   Scott AS, 2009, RADIOTHER ONCOL, V90, P163, DOI 10.1016/j.radonc.2008.12.019
   Smith GL, 2008, J CLIN ONCOL, V26, P5119, DOI 10.1200/JCO.2008.16.6546
   Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330
   Tsang DS, 2017, J NEURO-ONCOL, V134, P317, DOI 10.1007/s11060-017-2525-6
   van den Bent MJ, 2013, J CLIN ONCOL, V31, P344, DOI 10.1200/JCO.2012.43.2229
   Williams NL, 2018, AM J CLIN ONCOL-CANC, V41, P307, DOI 10.1097/COC.0000000000000267
   Youland RS, 2017, J NEURO-ONCOL, V135, P535, DOI 10.1007/s11060-017-2599-1
NR 23
TC 1
Z9 1
U1 6
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E108
EP E120
DI 10.1016/j.wneu.2018.09.109
PG 13
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100012
PM 30261385
DA 2020-05-12
ER

PT J
AU Xie, Q
   Liu, M
   Yan, YF
   Shen, X
   Wang, ES
AF Xie, Qiang
   Liu, Meng
   Yan, Yu-Feng
   Shen, Xiao
   Wang, Er-Song
TI Exogenous Tetranectin Protects Against 1-Methyl-4-Phenylpyridine-Induced
   Neurotoxicity by Inhibiting Apoptosis and Autophagy Through Ribosomal
   Protein S6 Kinase Beta-1
SO WORLD NEUROSURGERY
LA English
DT Article
DE 1-Methyl-4-phenylpyridine; Neurotoxicity; p70S6K1; Parkinson disease;
   Tetranectin
ID CEREBROSPINAL-FLUID; PARKINSONS-DISEASE; PLASMA TETRANECTIN; SERUM
   TETRANECTIN; PROGNOSTIC MARKER; EXPRESSION; CANCER; IMMUNOREACTIVITY;
   ACTIVATION
AB BACKGROUND: Tetranectin is a secreted homotrimeric protein belonging to the C-type lectin family. Our previous studies found that tetranectin was not only related to, but also played a protective role in, Parkinson disease. In this study, we aim to illustrate the molecular mechanism of the secreted tetranectin.
   METHODS: We used exogenous tetranectin to investigate the function and molecular mechanism of secreted tetranectin in a 1-methyl-4-phenylpyridine (MPP+)-induced SH-SY5Y cell model. Cell viability and reactive oxygen species were measured to assess the protective effects of tetranectin against MPPD. Apoptosis was measured in several aspects, including Bcl-2/Bax expression, caspase-3/7 activity, annexin V staining, and nuclear morphology. Autophagy was measured as LC3 expression and autophagy flux. Moreover, we used cell immunofluorescence to detect the transport of tetranectin. Western blotting was performed to measure the phosphorylation level of ribosomal protein S6 kinase beta-1 (p70S6K1), and co-immunoprecipitation was applied to confirm the interaction between tetranectin and p70S6K1.
   RESULTS: The data showed exogenous tetranectin alleviated MPPD-induced toxicity, high reactive oxygen species levels, apoptosis, and autophagy and changed the phosphorylation level of p70S6K1. Immunofluorescence images suggested exogenous tetranectin could be taken into SH-SY5Y cells, and the co-immunoprecipitation experiment indicated tetranectin interacted with p70S6K1.
   CONCLUSIONS: Exogenous tetranectin protects against MPP+-induced neurotoxicity by promoting p70S6K1 phosphorylation once taken into SH-SY5Y cells.
C1 [Xie, Qiang; Liu, Meng; Yan, Yu-Feng; Shen, Xiao; Wang, Er-Song] Fudan Univ, Jinshan Hosp, Dept Neurosurg, Shanghai, Peoples R China.
   [Xie, Qiang] Fudan Univ, Huashan Hosp, Dept Neurosurg, Shanghai, Peoples R China.
RP Wang, ES (reprint author), Fudan Univ, Jinshan Hosp, Dept Neurosurg, Shanghai, Peoples R China.
EM wersong@aliyun.com
CR BORREGAARD N, 1990, J CLIN INVEST, V85, P408, DOI 10.1172/JCI114453
   Brunner A, 2007, VIRCHOWS ARCH, V450, P659, DOI 10.1007/s00428-007-0409-4
   Chen GH, 2017, FRONT PHARMACOL, V8, DOI [10.3389/frhar.2017.00775, 10.3389/fphar.2017.00775]
   Chen ZF, 2015, BIOCHEM BIOPH RES CO, V468, P400, DOI 10.1016/j.bbrc.2015.10.118
   CHRISTENSEN L, 1987, HISTOCHEMISTRY, V87, P195, DOI 10.1007/BF00492409
   CHRISTENSEN L, 1989, HISTOCHEMISTRY, V92, P29, DOI 10.1007/BF00495012
   CLEMMENSEN I, 1986, EUR J BIOCHEM, V156, P327, DOI 10.1111/j.1432-1033.1986.tb09586.x
   Gao N, 2004, AM J PHYSIOL-CELL PH, V287, pC281, DOI 10.1152/ajpcell.00422.2003
   HOGDALL CK, 1993, CANCER, V72, P2415
   HOGDALL CK, 1993, ACTA ONCOL, V32, P631, DOI 10.3109/02841869309092443
   HOGDALL CK, 1993, SCAND J CLIN LAB INV, V53, P741, DOI 10.3109/00365519309092579
   Hogdall CK, 2002, APMIS, V110, P630, DOI 10.1034/j.1600-0463.2002.1100906.x
   IBA K, 1995, FEBS LETT, V373, P1, DOI 10.1016/0014-5793(95)00992-I
   Jiang BH, 2013, CURR CANCER DRUG TAR, V13, P233, DOI 10.2174/1568009611313030001
   Kamper EF, 1998, ANN CLIN BIOCHEM, V35, P400, DOI 10.1177/000456329803500309
   Li XJ, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3329-y
   Marzec M, 2007, ONCOGENE, V26, P5606, DOI 10.1038/sj.onc.1210346
   NIELSEN H, 1993, SCAND J IMMUNOL, V37, P39, DOI 10.1111/j.1365-3083.1993.tb01662.x
   Obeso JA, 2017, MOVEMENT DISORD, V32, P1264, DOI 10.1002/mds.27115
   Rousseaux Maxime W C, 2017, F1000Res, V6, P1121, DOI 10.12688/f1000research.11820.1
   Shen SY, 2014, INT J BIOL SCI, V10, P212, DOI 10.7150/ijbs.8056
   Stoevring B, 2006, SCAND J CLIN LAB INV, V66, P577, DOI 10.1080/00365510600863929
   Stoevring B, 2005, CLIN CHIM ACTA, V359, P65, DOI 10.1016/j.cccn.2005.03.034
   Thougaard AV, 2001, COMP BIOCHEM PHYS B, V128, P625, DOI 10.1016/S1096-4959(00)00329-8
   Vega F, 2006, CANCER RES, V66, P6589, DOI 10.1158/0008-5472.CAN-05-3018
   Vinayagam A, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001699
   Wang ES, 2010, ACTA NEUROL SCAND, V122, P350, DOI 10.1111/j.1600-0404.2009.01318.x
   Wang ES, 2014, CELL PHYSIOL BIOCHEM, V34, P277, DOI 10.1159/000362998
   Wang ES, 2013, CELL PHYSIOL BIOCHEM, V31, P625, DOI 10.1159/000350082
   Wang L, 2010, CLIN CHIM ACTA, V411, P581, DOI 10.1016/j.cca.2010.01.022
   Xiao F, 2009, BRAIN RES, V1255, P180, DOI 10.1016/j.brainres.2008.12.008
   Yao AJ, 2015, BIOCHEM BIOPH RES CO, V465, P696, DOI 10.1016/j.bbrc.2015.08.049
NR 32
TC 1
Z9 1
U1 1
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E375
EP E382
DI 10.1016/j.wneu.2018.10.058
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100044
PM 30342268
DA 2020-05-12
ER

PT J
AU Xu, KH
   Wan, W
   Li, B
   Li, JL
   Huang, Q
   Liu, YJ
   Jiang, DJ
   Xu, YD
   Xiao, JR
AF Xu, Kehan
   Wan, Wei
   Li, Bo
   Li, Jialin
   Huang, Quan
   Liu, Yujie
   Jiang, Dongjie
   Xu, Yuduo
   Xiao, Jianru
TI Prognostic Significance of Preoperative Plasma D-Dimer Level and
   Clinical Factors in Patients with Spinal Giant Cell Tumor: Retrospective
   Analysis of 153 Patients in a Single Center
SO WORLD NEUROSURGERY
LA English
DT Article
DE D-dimer; Disease-free survival; Giant cell tumor; Prognosis; Spine
ID ZOLEDRONIC ACID; BONE; RECURRENCE; EXPERIENCE; BIOMARKER; RESECTION;
   CANCER
AB BACKGROUND: Giant cell tumor (GCT) of the spine is a benign tumor with local aggressiveness and potential for recurrence. No published study has discussed the prognostic role of preoperative D-dimer (D-D) level in spinal GCT. The purpose of this retrospective study was to evaluate the prognostic value of preoperative plasma D-D level and clinical factors.
   METHODS: Routine clinical parameters and plasma D-D level were analyzed preoperatively. The disease-free survival (DFS) rate was estimated using Kaplan-Meier analysis. Variables with P value <0.1 were subjected to multivariate analysis by Cox regression analysis. P values <0.05 were considered statistically significant.
   RESULTS: The recurrence rate of spinal GCT was 21.6% in our series. A total of 153 patients were stratified into 2 groups by preoperative D-D level of <= 0.5 mu g/mL or >0.5 mu g/mL. We found that several clinicopathologic features were associated with the D-D level, including tumor location, the segment involved, Jaffe grade, and recurrence (P < 0.05). Multivariate analysis indicated that the treatment history, resection mode, bisphosphonate treatment, and preoperative D-D level were prognostic factors of DFS (all P < 0.05). In addition, the Jaffe grading system stratified by preoperative plasma D-D level was correlated with DFS of patients with spinal GCT (P < 0.05).
   CONCLUSIONS: Our study demonstrated that preoperative plasma D-D level, total spondylectomy, bisphosphonate treatment, and treatment history were powerful independent prognostic factors for DFS of patients with spinal GCT, suggesting that preoperative plasma D-D level may be a useful biomarker for predicting recurrence and prognosis of spinal GCT.
C1 [Xu, Kehan; Wan, Wei; Li, Bo; Li, Jialin; Huang, Quan; Liu, Yujie; Jiang, Dongjie; Xu, Yuduo; Xiao, Jianru] Second Mil Med Univ, Dept Orthoped Oncol, Changzheng Hosp, Shanghai, Peoples R China.
RP Xiao, JR (reprint author), Second Mil Med Univ, Dept Orthoped Oncol, Changzheng Hosp, Shanghai, Peoples R China.
EM jianruxiao83@smmu.edu.cn
CR Bardakhchyan S, 2017, ITAL J PEDIATR, V43, DOI 10.1186/s13052-017-0353-0
   Batschauer APB, 2010, ANN ONCOL, V21, P1267, DOI 10.1093/annonc/mdp474
   CAMPANACCI M, 1987, J BONE JOINT SURG AM, V69A, P106, DOI 10.2106/00004623-198769010-00018
   Cao JL, 2017, WORLD J SURG ONCOL, V15, DOI 10.1186/s12957-017-1104-9
   Charest-Morin R, 2017, SPINE, V42, P1383, DOI 10.1097/BRS.0000000000002094
   Chen GJ, 2015, WORLD J SURG ONCOL, V13, DOI 10.1186/s12957-015-0438-4
   Chien MC, 2015, J PEDIAT HEMATOL ONC, V37, pe399, DOI 10.1097/MPH.0000000000000380
   Frankel H L, 1969, Paraplegia, V7, P179
   Fukumoto K, 2015, SURG TODAY, V45, P63, DOI 10.1007/s00595-014-0894-4
   Gao ZH, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471-2474-15-330
   GOLDENBERG RR, 1970, J BONE JOINT SURG AM, VA 52, P619, DOI 10.2106/00004623-197052040-00001
   Gupta R, 2008, ANN DIAGN PATHOL, V12, P239, DOI 10.1016/j.anndiagpath.2007.09.002
   Huang P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183835
   Kaseda K, 2017, J CARDIOTHORAC SURG, V12, DOI 10.1186/s13019-017-0676-3
   Komurcuoglu B, 2011, TUMORI, V97, P743, DOI 10.1700/1018.11091
   Kundu ZS, 2018, INDIAN J ORTHOP, V52, P45, DOI 10.4103/ortho.IJOrtho_216_17
   Li JL, 2017, ONCOTARGET, V8, P86934, DOI 10.18632/oncotarget.21168
   Li YT, 2016, CANCER RES, V76, P4002, DOI 10.1158/0008-5472.CAN-15-3189
   Liu ZK, 2017, HEPATOL RES, V47, P1108, DOI 10.1111/hepr.12848
   Ma YF, 2016, EUR SPINE J, V25, P4033, DOI 10.1007/s00586-015-4348-5
   Mattei TA, 2014, SPINE J, V14, pE15, DOI 10.1016/j.spinee.2014.02.019
   Motavaf E, 2014, INT J COLORECTAL DIS, V29, P1427, DOI 10.1007/s00384-014-2000-1
   Nakka M, 2017, ONCOTARGET, V8, P96738, DOI 10.18632/oncotarget.18236
   Pabinger I, 2009, ARTERIOSCL THROM VAS, V29, P332, DOI 10.1161/ATVBAHA.108.182188
   SANERKIN NG, 1980, CANCER, V46, P1641, DOI 10.1002/1097-0142(19801001)46:7<1641::AID-CNCR2820460725>3.0.CO;2-Z
   SANJAY BKS, 1993, J BONE JOINT SURG BR, V75, P148
   SAVINI R, 1983, J BONE JOINT SURG AM, V65, P1283, DOI 10.2106/00004623-198365090-00009
   Suega Ketut, 2011, Acta Med Indones, V43, P162
   von Borstel D, 2017, SKELETAL RADIOL, V46, P571, DOI 10.1007/s00256-017-2588-7
   Watanabe A, 2016, ANN SURG ONCOL, V23, pS886, DOI 10.1245/s10434-016-5422-x
   Wu ZP, 2011, SPINE, V36, pE1385, DOI 10.1097/BRS.0b013e31820e60b2
   Xu W, 2017, J NEUROSURG-SPINE, V26, P716, DOI 10.3171/2016.10.SPINE151197
   Xu W, 2013, ANN SURG ONCOL, V20, P804, DOI 10.1245/s10434-012-2707-6
   Yamamoto M, 2012, ONCOLOGY-BASEL, V83, P10, DOI 10.1159/000338329
   Yin HB, 2015, J NEURO-ONCOL, V124, P275, DOI 10.1007/s11060-015-1835-9
   Yonezawa N, 2017, EUR SPINE J, V26, pS236, DOI 10.1007/s00586-017-5086-7
   Zheng K, 2017, ORTHOP SURG, V9, P252, DOI 10.1111/os.12333
NR 37
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E872
EP E880
DI 10.1016/j.wneu.2018.10.169
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100105
PM 30391765
DA 2020-05-12
ER

PT J
AU Yamamoto, S
   Kashiwazaki, D
   Akioka, N
   Kuwayama, N
   Noguchi, K
   Kuroda, S
AF Yamamoto, Shusuke
   Kashiwazaki, Daina
   Akioka, Naoki
   Kuwayama, Naoya
   Noguchi, Kyo
   Kuroda, Satoshi
TI Progressive Shrinkage of Involved Arteries in Parallel with Disease
   Progression in Moyamoya Disease
SO WORLD NEUROSURGERY
LA English
DT Article
DE 3D-CISS; Moyamoya disease; Outer diameter
ID MIDDLE CEREBRAL-ARTERIES; CONSTRUCTIVE INTERFERENCE; GROWTH-FACTOR;
   VASOSPASM; SURGERY
AB OBJECTIVE: Recent three-dimensional constructive interference in steady state (3D-CISS) studies have shown that the involved arteries decrease not only their own luminal caliber but also outer diameter in moyamoya disease (MMD). This study was aimed to clarify how the outer diameter of the involved arteries serially change during disease progression in MMD using qunatitaive 3D-CISS imaging.
   METHODS: This study included 8 hemispheres of 7 patients with MMD whose Suzuki angiographic stage spontaneously progressed during follow-up. Using 3D-CISS, the outer diameter was quantified serially in supraclinoid portion of internal carotid artery (C1), the horizontal portion of middle and anterior cerebral arteries (M1 and A1, respectively) before and after the spontaneous disease progression, and also 3-12 months later.
   RESULTS: In 7 hemispheres with early disease stage (stage 1-3) at initial presentation, the involved arteries decreased in their outer dimater in parallel with luminal stenosis during spontaneous disease progression in the C1 (P = 0.005), M1 (P < 0.0001), and A1 portions (P = 0.0048). In the remaining 1 hemisphere with stage 4 at initial presentation, 3D-CISS imaging showed no significant change in the outer diameter of C1, M1, and A1 segments during disease progression.
   CONCLUSIONS: Using quantitative 3D-CISS imaging, this study clearly shows that the involved arteries serially decrease in their own outer diameter in parallel with luminal stenosis during spontaneous disease progression in early stages of MMD (stage 1-3). This phenomenon has not been reported previously and may result from the pathognomic mechanisms underlying the development of MMD.
C1 [Yamamoto, Shusuke; Kashiwazaki, Daina; Akioka, Naoki; Kuwayama, Naoya; Kuroda, Satoshi] Univ Toyama, Grad Sch Med & Pharmaceut Sci, Dept Neurosurg, Toyama, Japan.
   [Noguchi, Kyo] Univ Toyama, Grad Sch Med & Pharmaceut Sci, Dept Radiol, Toyama, Japan.
RP Yamamoto, S (reprint author), Univ Toyama, Grad Sch Med & Pharmaceut Sci, Dept Neurosurg, Toyama, Japan.
EM s.yamamoto1007@gmail.com
FU Research Committee on Moyamoya Disease; Ministry of Health, Labor, and
   Welfare of JapanMinistry of Health, Labour and Welfare, Japan
FX This study was supported by a grant from the Research Committee on
   Moyamoya Disease, sponsored by the Ministry of Health, Labor, and
   Welfare of Japan.
CR COAKHAM HB, 1979, J NEUROL NEUROSUR PS, V42, P289, DOI 10.1136/jnnp.42.4.289
   Cui HK, 2014, MOL MED REP, V10, P1416, DOI 10.3892/mmr.2014.2350
   Gaetani P, 1997, ACTA NEUROCHIR, V139, P319, DOI 10.1007/BF01808827
   Gao J, 2006, NEUROCRIT CARE, V4, P25, DOI 10.1385/NCC:4:1:025
   HALTIA M, 1982, CLIN NEUROPATHOL, V1, P11
   Houkin K, 2004, CHILD NERV SYST, V20, P734, DOI 10.1007/s00381-004-0971-x
   Kaku Y, 2012, ACTA NEUROCHIR, V154, P2151, DOI 10.1007/s00701-012-1472-4
   Kim YJ, 2013, EUR J NEUROL, V20, P1311, DOI 10.1111/ene.12202
   Kuroda S, 2005, STROKE, V36, P2148, DOI 10.1161/01.STR.0000182256.32489.99
   Kuroda S, 2015, NEUROL MED-CHIR, V55, P796, DOI 10.2176/nmc.oa.2015-0044
   Kuroda S, 2010, NEUROSURGERY, V66, P1093, DOI 10.1227/01.NEU.0000369606.00861.91
   Lad SP, 2012, J STROKE CEREBROVASC, V21, P30, DOI 10.1016/j.jstrokecerebrovasdis.2010.04.004
   Leclerc JL, 2015, P NATL ACAD SCI USA, V112, P1155, DOI 10.1073/pnas.1412833112
   Miyawaki S, 2013, STROKE, V44, P2894, DOI 10.1161/STROKEAHA.113.002477
   Miyawaki S, 2012, STROKE, V43, P3371, DOI 10.1161/STROKEAHA.112.663864
   Research Committee on the Pathology and Treatment of Spontaneous Occlusion of the Circle of Willis, 2012, Neurol Med Chir (Tokyo), V52, P245
   Ryoo S, 2014, STROKE, V45, P2457, DOI 10.1161/STROKEAHA.114.004761
   SAKAKI T, 1979, Neurologia Medico-Chirurgica, V19, P1085, DOI 10.2176/nmc.19.1085
   SUZUKI J, 1969, ARCH NEUROL-CHICAGO, V20, P288, DOI 10.1001/archneur.1969.00480090076012
   Takagi Y, 2006, NEUROSURGERY, V58, P943
   Takagi Y, 2006, NEUROSURGERY, V59, P894, DOI 10.1227/01.NEU.0000232771.80339.15
   Uchida Y, 2011, AM J PHYSIOL-HEART C, V300, pH423, DOI 10.1152/ajpheart.00959.2010
   Yamamoto S, 2016, J STROKE CEREBROVASC, V25, P1509, DOI 10.1016/j.jstrokecerebrovasdis.2016.02.029
   Yanamoto H, 2012, EUR NEUROL, V68, P329, DOI 10.1159/000341336
NR 24
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E253
EP E261
DI 10.1016/j.wneu.2018.10.001
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100028
PM 30315975
DA 2020-05-12
ER

PT J
AU Yang, JS
   Chu, L
   Deng, R
   Chen, CM
   Wang, XF
   Xie, PG
   Yu, KX
   Rong, LM
   Hao, DJ
   Wei, JM
   Deng, ZL
AF Yang, Jun-Song
   Chu, Lei
   Deng, Rui
   Chen, Chien-Min
   Wang, Xiang-Fu
   Xie, Pei-Gen
   Yu, Ke-Xiao
   Rong, Li-Min
   Hao, Ding-Jun
   Wei, Jian-Min
   Deng, Zhong-Liang
TI Treatment of Single-Level Thoracic Tuberculosis by Percutaneous
   Endoscopic Debridement and Allograft via the Transforaminal Approach
   Combined with Percutaneous Pedicle Screw Fixation: A Multicenter Study
   with a Median Follow-Up of 36 Months
SO WORLD NEUROSURGERY
LA English
DT Article
DE Bone graft; Debridement; Minimally invasive spine surgery; Percutaneous
   endoscopy; Percutaneous pedicle screw; Thoracic tuberculosis
ID POSTERIOR INSTRUMENTATION; ANTERIOR DEBRIDEMENT; SPINAL TUBERCULOSIS;
   MANAGEMENT; OUTCOMES; FUSION
AB OBJECTIVE: To examine effects of percutaneous endoscopic debridement and allograft via the transforaminal approach combined with percutaneous pedicle screw fixation as treatment for single-level thoracic tuberculosis.
   METHODS: This multicenter retrospective analysis included 75 patients with single-level thoracic tuberculosis who underwent percutaneous endoscopic debridement and allograft via the transforaminal approach combined with percutaneous pedicle screw fixation and were followed for >36 months between January 2012 and December 2014.
   RESULTS: Follow-up was 36-48 months (average 41.1 +/- 2.2 months). Intraoperative blood loss was low (average 30.5 +/- 7.9 mL), and bed rest time was short (average 1.5 +/- 0.3 days). No recurrence was observed in all 75 patients. Except for 3 patients, almost all patients (96%) achieved grade I or II fusion in interbody bone grafting. Segmental Cobb angle was 13.5 degrees +/- 4.1 degrees before surgery, 10.5 degrees +/- 3.7 degrees immediately after surgery, and 11.7 degrees +/- 3.9 degrees at 36 months of follow-up. All patients achieved complete recovery of neurologic function (American Spinal Injury Association grade E), including 15 patients with spinal cord injury (American Spinal Injury Association grade D) before surgery. The visual analog scale and 36-Item Short-Form Health Survey scores significantly improved at 1, 3, 12, and 36 months of follow-up. No complications related to internal fixation occurred within the follow-up period; complication rate was 9.0%.
   CONCLUSIONS: Median follow-up clinical experience with percutaneous endoscopic debridement and allograft via the transforaminal approach combined with percutaneous pedicle screw fixation indicates that the technique is safe, effective, feasible, and minimally invasive.
C1 [Yang, Jun-Song; Hao, Ding-Jun] Xi An Jiao Tong Univ, Honghui Hosp, Dept Spine Surg, Xian, Shaanxi, Peoples R China.
   [Chu, Lei; Deng, Rui; Yu, Ke-Xiao; Deng, Zhong-Liang] Chongqing Med Univ, Affiliated Hosp 2, Dept Orthopaed, Chongqing, Peoples R China.
   [Chen, Chien-Min] Changhua Christian Hosp, Dept Neurosurg, Changhua, Taiwan.
   [Chen, Chien-Min] Kaohsiung Med Univ, Sch Med, Kaohsiung, Taiwan.
   [Chen, Chien-Min] Dayeh Univ, Coll Nursing & Hlth Sci, Changhua, Taiwan.
   [Wang, Xiang-Fu] Gansu Prov Hosp Tradit Chinese Med, Dept Spinal Minimally Invas Surg, Lanzhou, Gansu, Peoples R China.
   [Xie, Pei-Gen; Rong, Li-Min] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Spine Surg, Guangzhou, Guangdong, Peoples R China.
   [Wei, Jian-Min] Baoji City Hosp Tradit Chinese Med, Dept Spine Surg, Baoji, Shaanxi, Peoples R China.
RP Hao, DJ (reprint author), Xi An Jiao Tong Univ, Honghui Hosp, Dept Spine Surg, Xian, Shaanxi, Peoples R China.
EM dingjun.hao@qq.com
OI Yu, Ke-Xiao/0000-0002-6221-144X
FU Key Project of Medical Research of Chongqing Municipal Healthy Bureau
   [2016ZDXM007]; Chinese National Natural Science FoundationNational
   Natural Science Foundation of China [81772357]
FX This research was supported by the Key Project of Medical Research of
   Chongqing Municipal Healthy Bureau (Grant No. 2016ZDXM007 to Zhong-Liang
   Deng) and Chinese National Natural Science Foundation (Grant No.
   81772357 for Ding-Jun Hao).
CR D'souza AR, 2017, CLIN SPINE SURG, V30, pE1426, DOI 10.1097/BSD.0000000000000498
   Eck KR, 2000, J SPINAL DISORD, V13, P501, DOI 10.1097/00002517-200012000-00006
   Gan FP, 2018, BMC MUSCULOSKEL DIS, V19, DOI 10.1186/s12891-018-2187-3
   Garg N, 2014, CLIN ORTHOP RELAT R, V472, P1855, DOI 10.1007/s11999-014-3472-6
   Guzey FK, 2005, J NEUROSURG-SPINE, V3, P450, DOI 10.3171/spi.2005.3.6.0450
   Hardin Carolyn A, 2013, Asian J Neurosurg, V8, P153, DOI 10.4103/1793-5482.121687
   Huang Y, 2017, J ORTHOP SURG RES, V12, DOI 10.1186/s13018-017-0650-8
   Jain AK, 2010, J BONE JOINT SURG BR, V92B, P905, DOI 10.1302/0301-620X.92B7.24668
   Jia LS, 2007, ORTHOP J CHINA, V15, P516
   Kim M, 2018, BIOMED RES INT, DOI 10.1155/2018/9073460
   Klockner C, 2003, SPINE, V28, P1036, DOI 10.1097/00007632-200305150-00016
   Li Lu, 2002, Zhonghua Yufang Yixue Zazhi, V36, P109
   Liu LH, 2014, J HUAZHONG U SCI-MED, V34, P907, DOI 10.1007/s11596-014-1372-3
   Liu P, 2011, SPINE, V36, pE1290, DOI 10.1097/BRS.0b013e31820beae3
   Lu GH, 2012, EUR SPINE J, V21, P463, DOI 10.1007/s00586-011-2038-5
   Ma YZ, 2013, SPINAL TUBERCULOSIS, P53
   Mlyavykh S, 2018, J NEUROSURG-SPINE, V29, P241, DOI 10.3171/2017.11.SPINE16664
   Prasad Rajendra, 2007, Indian J Tuberc, V54, P3
   Qu DB, 2008, CHIN J SPINE SPINAL, V18, P565
   [瞿东滨 Qu Dongbin], 2005, [中华骨科杂志, Chinese Journal of Orthopedics], V25, P74
   Sun XY, 2017, EUR SPINE J, V26, P1418, DOI 10.1007/s00586-016-4818-4
   Technical Guidance Group of the Fifth National TB Epidemiological Survey The Office of the Fifth National TB Epidemiological Survey, 2012, CHIN J ANTITUBERC, V34, P485
   Wang B, 2004, FOREIGN MED SCI PHYS, V24, P103
   Yang SC, 2014, EUR SPINE J, V23, P846, DOI 10.1007/s00586-013-3157-y
   Zhang PH, 2016, BRIT J NEUROSURG, V30, P666, DOI 10.1080/02688697.2016.1206182
   Zhang ZH, 2016, J ORTHOP SURG RES, V11, DOI 10.1186/s13018-016-0385-y
   Zhong WY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119759
NR 27
TC 2
Z9 2
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1472
EP E1481
DI 10.1016/j.wneu.2018.11.087
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100181
PM 30465947
DA 2020-05-12
ER

PT J
AU Yang, WY
   Luksik, AS
   Jiang, BW
   Feghali, J
   Caplan, JM
   Tamargo, RJ
   Huang, J
AF Yang, Wuyang
   Luksik, Andrew S.
   Jiang, Bowen
   Feghali, James
   Caplan, Justin M.
   Tamargo, Rafael J.
   Huang, Judy
TI Venous Stenosis and Hemorrhage After Radiosurgery for Cerebral
   Arteriovenous Malformations
SO WORLD NEUROSURGERY
LA English
DT Article
DE Arteriovenous malformations; Hemorrhage; Radiosurgery; Venous stenosis
ID GAMMA-KNIFE RADIOSURGERY; NATURAL-HISTORY; STEREOTACTIC RADIOSURGERY;
   OCCLUSIVE HYPEREMIA; RANDOMIZED-TRIAL; DRAINAGE SYSTEM; LATENCY PERIOD;
   BRAIN; RISK; ARUBA
AB BACKGROUND: The risk of hemorrhage remains after radiosurgery for patients with arteriovenous malformations (AVMs), especially during the latency period. The effect of venous outflow stenosis on postradiosurgery AVM hemorrhage has been understudied. The present study sought to clarify the effect of venous stenosis on postradiation hemorrhage.
   METHODS: We retrospectively reviewed the records of patients with AVM seen at our institution from 1990 to 2015. Patients who had undergone radiosurgery were included, and those without sufficient data were excluded. We performed multivariable Cox regression to evaluate the predictors of postradiosurgery hemorrhage, with specific emphasis on venous stenosis. Patients were censored from the first radiosurgery to hemorrhage or the last follow-up visit. The baseline and angiographic characteristics were compared between those with venous stenosis and those without to address potential confounders.
   RESULTS: The present study included 240 patients, of whom 29 (12.1%) had venous stenosis. The venous stenosis cohort included more patients with venous varices (P = 0.009) and fewer with deep venous drainage (P = 0.048) compared with those without venous stenosis. Most patients had grade III or higher AVMs (63.2%), with an obliteration rate of 32.9%. In an all-inclusive multivariable Cox regression, hemorrhage risk was associated with venous stenosis (hazard ratio [HR], 3.70; P = 0.034), age (HR, 1.05; P = 0.002), AVM volume (HR, 1.04; P = 0.004), and hemorrhage before treatment (HR, 4.11; P = 0.014). Male gender was protective (HR, 0.31; P = 0.036) against hemorrhage.
   CONCLUSIONS: We identified statistically significant risk factors for postradiosurgery AVM hemorrhage, which included advanced age, female gender, the presence of venous stenosis, a larger AVM volume, and previous hemorrhage. We recommend cautious selection of patients for radiosurgery with close follow-up after treatment, especially for patients with these risk factors.
C1 [Yang, Wuyang; Luksik, Andrew S.; Jiang, Bowen; Feghali, James; Caplan, Justin M.; Tamargo, Rafael J.; Huang, Judy] Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21218 USA.
RP Huang, J (reprint author), Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21218 USA.
EM jhuang24@jhmi.edu
OI Huang, Judy/0000-0002-0675-1935
CR ALBERT P, 1990, ACTA NEUROCHIR, V103, P30, DOI 10.1007/BF01420189
   Atkinson RP, 2001, STROKE, V32, P1430
   Bose R, 2015, NEUROSURGERY, V76, P623, DOI 10.1227/NEU.0000000000000660
   Brown RD, 1996, J NEUROSURG, V85, P29, DOI 10.3171/jns.1996.85.1.0029
   BROWN RD, 1988, J NEUROSURG, V68, P352, DOI 10.3171/jns.1988.68.3.0352
   Chapman PH, 2004, NEUROSURGERY, V55, P228, DOI 10.1227/01.NEU.0000126950.67029.F8
   Cockroft KM, 2012, STROKE, V43, P1979, DOI 10.1161/STROKEAHA.112.652032
   Cohen-Inbar O, 2017, J NEUROSURG, V127, P503, DOI 10.3171/2016.7.JNS161194
   CRAWFORD PM, 1986, J NEUROL NEUROSUR PS, V49, P1, DOI 10.1136/jnnp.49.1.1
   da Costa L, 2009, STROKE, V40, P100, DOI 10.1161/STROKEAHA.108.524678
   Ding D, 2016, STROKE, V47, P342, DOI 10.1161/STROKEAHA.115.011400
   Ding D, 2015, WORLD NEUROSURG, V84, DOI 10.1016/j.wneu.2015.04.064
   Ding D, 2015, WORLD NEUROSURG, V84, DOI 10.1016/j.wneu.2015.05.012
   Ding D, 2015, WORLD NEUROSURG, V84, DOI 10.1016/j.wneu.2015.02.039
   Ding D, 2015, CEREBROVASC DIS, V39, P53, DOI 10.1159/000369959
   Ding D, 2014, J NEUROSURG, V121, P470, DOI 10.3171/2014.2.JNS131605
   Duong DH, 1999, NEW ENGL J MED, V340, P1812
   Fennell VS, 2017, WORLD NEUROSURG, V98, DOI 10.1016/j.wneu.2016.11.007
   Fleetwood IG, 2002, LANCET, V359, P863, DOI 10.1016/S0140-6736(02)07946-1
   Friedman WA, 1996, J NEUROSURG, V84, P912, DOI 10.3171/jns.1996.84.6.0912
   FULTS D, 1984, NEUROSURGERY, V15, P658, DOI 10.1227/00006123-198411000-00003
   GRAF CJ, 1983, J NEUROSURG, V58, P331, DOI 10.3171/jns.1983.58.3.0331
   Gross BA, 2013, J NEUROSURG, V118, P437, DOI 10.3171/2012.10.JNS121280
   Hademenos GJ, 1996, STROKE, V27, P1072, DOI 10.1161/01.STR.27.6.1072
   Hernesniemi JA, 2008, NEUROSURGERY, V63, P823, DOI 10.1227/01.NEU.0000330401.82582.5E
   Hung AL, 2017, NEUROSURGERY, V81, P441, DOI 10.1093/neuros/nyw140
   Kano H, 2017, STROKE, V48, P84, DOI 10.1161/STROKEAHA.116.014825
   Karlsson B, 2001, INT J RADIAT ONCOL, V49, P1045, DOI 10.1016/S0360-3016(00)01432-2
   Lawton MT, 2003, NEUROSURGERY, V52, P740, DOI 10.1227/01.NEU.0000053220.02268.9C
   MARKS MP, 1990, RADIOLOGY, V176, P807, DOI 10.1148/radiology.176.3.2389040
   Maruyama K, 2005, NEW ENGL J MED, V352, P146, DOI 10.1056/NEJMoa040907
   MIYASAKA Y, 1992, J NEUROSURG, V76, P239, DOI 10.3171/jns.1992.76.2.0239
   Mohr JP, 2014, LANCET, V383, P614, DOI 10.1016/S0140-6736(13)62302-8
   Parkhutik V, 2012, STROKE, V43, P1247, DOI 10.1161/STROKEAHA.111.635789
   Patibandla MR, 2019, J NEUROSURG, V130, P579, DOI 10.3171/2017.8.JNS171336
   Pollock BE, 1996, STROKE, V27, P1, DOI 10.1161/01.STR.27.1.1
   Pollock BE, 1996, NEUROSURGERY, V38, P652, DOI 10.1227/00006123-199604000-00004
   QUISLING RG, 1989, AM J NEURORADIOL, V10, P411
   Russin J, 2014, NEUROSURGERY, V75, pE96, DOI 10.1227/NEU.0000000000000357
   Rutledge WC, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.7.FOCUS14242
   Sahlein DH, 2014, STROKE, V45, P1964, DOI 10.1161/STROKEAHA.114.005170
   Schneider BF, 1997, J NEUROSURG, V87, P352, DOI 10.3171/jns.1997.87.3.0352
   Shimizu S, 2001, NEUROL MED-CHIR, V41, P599, DOI 10.2176/nmc.41.599
   SPETZLER RF, 1986, J NEUROSURG, V65, P476, DOI 10.3171/jns.1986.65.4.0476
   Starke RM, 2013, J NEUROSURG, V119, P981, DOI 10.3171/2013.5.JNS1311
   STEINER L, 1992, J NEUROSURG, V77, P1, DOI 10.3171/jns.1992.77.1.0001
   Teo M, 2015, BRIT J NEUROSURG, V29, P635, DOI 10.3109/02688697.2015.1096909
   Beijnum J, 2009, BRAIN, V132, P537, DOI 10.1093/brain/awn318
   VINUELA F, 1985, J NEUROSURG, V63, P180, DOI 10.3171/jns.1985.63.2.0180
   WILSON CB, 1993, J NEUROSURG, V78, P165, DOI 10.3171/jns.1993.78.2.0165
   Yang WY, 2018, NEUROSURGERY, V82, P481, DOI 10.1093/neuros/nyx230
   Yang WY, 2016, WORLD NEUROSURG, V94, P64, DOI 10.1016/j.wneu.2016.06.082
   Yang WY, 2016, NEUROSURGERY, V78, P684, DOI 10.1227/NEU.0000000000001103
   Yang WY, 2015, WORLD NEUROSURG, V84, P461, DOI 10.1016/j.wneu.2015.03.050
   Yen CP, 2011, STROKE, V42, P1691, DOI 10.1161/STROKEAHA.110.602706
   Yen CP, 2010, NEUROSURGERY, V67, P1293, DOI 10.1227/NEU.0b013e3181f2b396
NR 56
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1615
EP E1625
DI 10.1016/j.wneu.2018.11.193
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100199
PM 30500592
DA 2020-05-12
ER

PT J
AU Yecies, D
   Azad, TD
   Esparza, R
   Quon, JL
   Forkert, ND
   MacEachern, SJ
   Bruckert, L
   Maleki, M
   Edwards, MSB
   Grant, GA
   Yeom, KW
AF Yecies, Derek
   Azad, Tej D.
   Esparza, Rogelio
   Quon, Jennifer L.
   Forkert, Nils D.
   MacEachern, Sarah J.
   Bruckert, Lisa
   Maleki, Maryam
   Edwards, Michael S. B.
   Grant, Gerald A.
   Yeom, Kristen W.
TI Long-Term Supratentorial Radiologic Effects of Surgery and Local
   Radiation in Children with Infratentorial Ependymoma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Ependymoma; Late effects; Pediatric limits; Retrospective; Small sample
   size; Treatment effects
ID POSTERIOR-FOSSA; MULTICENTER REPRODUCIBILITY; PEDIATRIC-PATIENTS; HUMAN
   BRAIN; PHASE-II; CHEMOTHERAPY; THERAPY; IRRADIATION; PERFUSION;
   RADIOTHERAPY
AB BACKGROUND: Current standard of care for children with infratentorial ependymoma includes maximal safe resection and local radiation of 54-59 Gray. High-dose local radiation has been associated with declines in multiple cognitive domains. The anatomic and physiologic correlates of this cognitive decline remain undefined, and there have been no radiographic studies on the long-term effects of this treatment paradigm.
   METHODS: A comprehensive database of pediatric brain tumor patients treated at Stanford Children's from 2004-2016 was queried. Seven patients with posterior fossa ependymoma who were treated with surgery and local radiation alone, who had no evidence of recurrent disease, and had imaging suitable for analysis were identified. Diffusion-weighted magnetic resonance imaging datasets were used to calculate apparent diffusion coefficient maps for each subject, while arterial spin labeling datasets were used to calculate maps of cerebral blood flow. Diffusion-weighted imaging and arterial spin labeling datasets of 52 age-matched healthy children were analyzed in the same fashion to enable group comparisons.
   RESULTS: Several statistically significant differences were detected between the 2 groups. Cerebral blood flow was lower in the caudate and pallidum and higher in the nucleus accumbens in the ependymoma cohort compared with controls. Apparent diffusion coefficient was increased in the thalamus and trended toward decreased in the amygdala.
   CONCLUSIONS: Surgery and local radiation for posterior fossa ependymoma are associated with supratentorial apparent diffusion coefficient and cerebral blood flow alterations, which may represent an anatomic and physiologic correlate to the previously published decline in neurocognitive outcomes in this population.
C1 [Yecies, Derek; Azad, Tej D.; Quon, Jennifer L.; Edwards, Michael S. B.; Grant, Gerald A.] Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA.
   [Esparza, Rogelio] NYU Sch Med, Dept Neurosurg, New York, NY USA.
   [Forkert, Nils D.; MacEachern, Sarah J.] Univ Calgary, Dept Radiol, Calgary, AB, Canada.
   [Forkert, Nils D.; MacEachern, Sarah J.] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada.
   [Bruckert, Lisa] Stanford Univ, Sch Med, Div Dev Behav Pediat, Stanford, CA 94305 USA.
   [Maleki, Maryam; Yeom, Kristen W.] Stanford Univ, Sch Med, Dept Radiol, Stanford, CA 94305 USA.
RP Yecies, D (reprint author), Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA.
EM dyecies@stanford.edu
RI Forkert, Nils Daniel/K-6273-2012
OI Forkert, Nils Daniel/0000-0003-2556-3224; Azad, Tej/0000-0001-7823-4294;
   Yecies, Derek/0000-0001-8534-4651; Bruckert, Lisa/0000-0002-3472-3675
CR Buxton RB, 1998, MAGNET RESON MED, V40, P383, DOI 10.1002/mrm.1910400308
   Combs SE, 2008, INT J RADIAT ONCOL, V71, P972, DOI 10.1016/j.ijrobp.2007.12.036
   Conklin HM, 2008, J CLIN ONCOL, V26, P3965, DOI 10.1200/JCO.2007.15.9970
   Dai WY, 2008, MAGN RESON MED, V60, P1488, DOI 10.1002/mrm.21790
   Forkert ND, 2016, AM J NEURORADIOL, P1
   Garvin JH, 2012, PEDIATR BLOOD CANCER, V59, P1183, DOI 10.1002/pbc.24274
   Gevers S, 2009, AM J NEURORADIOL, V30, P968, DOI 10.3174/ajnr.A1454
   Gevers S, 2011, J CEREBR BLOOD F MET, V31, P1706, DOI 10.1038/jcbfm.2011.10
   Grech-Sollars M, 2015, NMR BIOMED, V28, P468, DOI 10.1002/nbm.3269
   Grill J, 2001, J CLIN ONCOL, V19, P1288, DOI 10.1200/JCO.2001.19.5.1288
   HOPPEHIRSCH E, 1995, CHILD NERV SYST, V11, P340, DOI 10.1007/BF00301666
   Li MD, 2017, J PEDIATR-US, V185, P173, DOI 10.1016/j.jpeds.2017.01.019
   Massimino M, 2016, NEURO-ONCOLOGY, V18, P1451, DOI 10.1093/neuonc/now108
   Massimino M, 2011, INT J RADIAT ONCOL, V80, P807, DOI 10.1016/j.ijrobp.2010.02.048
   MAZZIOTTA JC, 1995, NEUROIMAGE, V2, P89, DOI 10.1006/nimg.1995.1012
   Merchant TE, 2015, INT J RADIAT ONCOL, V93, pS1, DOI 10.1016/j.ijrobp.2015.07.009
   Merchant TE, 2004, J NEUROSURG, V101, P159, DOI 10.3171/ped.2004.101.2.0159
   Merchant TE, 2005, INT J RADIAT ONCOL, V63, P1546, DOI 10.1016/j.ijrobp.2005.05.028
   Merchant TE, 2016, INT J RADIAT ONCOL, V90, P547
   Merchant TE, 2010, INT J RADIAT ONCOL, V76, P496, DOI 10.1016/j.ijrobp.2009.01.079
   Merchant TE, 2009, LANCET ONCOL, V10, P258, DOI 10.1016/S1470-2045(08)70342-5
   Morris EB, 2009, J NEURO-ONCOL, V94, P391, DOI 10.1007/s11060-009-9866-8
   Netson KL, 2012, INT J RADIAT ONCOL, V84, P217, DOI 10.1016/j.ijrobp.2011.10.043
   Pajtler KW, 2017, ACTA NEUROPATHOL, V133, P5, DOI 10.1007/s00401-016-1643-0
   Puget S, 2009, CANCER-AM CANCER SOC, V115, P1338, DOI 10.1002/cncr.24150
   Steen RG, 2001, INT J RADIAT ONCOL, V49, P79, DOI 10.1016/S0360-3016(00)01351-1
   Timmermann B, 2000, INT J RADIAT ONCOL, V46, P287, DOI 10.1016/S0360-3016(99)00414-9
   Timmermann B, 2005, RADIOTHER ONCOL, V77, P278, DOI 10.1016/j.radonc.2005.10.016
   von Hoff K, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-15
   Willard VW, 2014, INT J RADIAT ONCOL, V88, P814, DOI 10.1016/j.ijrobp.2013.12.006
NR 30
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1300
EP E1304
DI 10.1016/j.wneu.2018.11.039
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100158
PM 30448581
DA 2020-05-12
ER

PT J
AU Yoon, HK
   Lee, HC
   Kim, YH
   Lim, YJ
   Park, HP
AF Yoon, Hyun-Kyu
   Lee, Hyung-Chul
   Kim, Yong Hwy
   Lim, Young-Jin
   Park, Hee-Pyoung
TI Predictive Factors for Delayed Hyponatremia After Endoscopic
   Transsphenoidal Surgery in Patients with Nonfunctioning Pituitary
   Tumors: A Retrospective Observational Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Delayed hyponatremia; Pituitary tumor; Transsphenoidal surgery
ID POSTOPERATIVE HYPONATREMIA; SYMPTOMATIC HYPONATREMIA; READMISSION;
   PREVALENCE; MANAGEMENT; ADENOMA; VASOPRESSIN; OUTCOMES; SODIUM
AB OBJECTIVE: Delayed hyponatremia can occur after transsphenoidal pituitary tumor surgery, resulting in unexpected readmission. Predictive factors for delayed hyponatremia after this type of surgery are not well established. In this retrospective study, predictive factors for delayed hyponatremia were investigated in patients undergoing transsphenoidal pituitary tumor surgery.
   METHODS: Preoperative data (demographics, comorbidities, and hormonal assessment), preoperative, intraoperative, and immediate postoperative sodium concentrations, the nadir sodium concentration on postoperative day (POD) 1-2, characteristics of pituitary tumor (size, cell type, optic chiasm compression, and cavernous sinus invasion), and intraoperative data (operation time and fluid balance) were retrospectively collected from 234 patients undergoing endoscopic transsphenoidal surgery for removal of nonfunctioning pituitary tumors. Delayed hyponatremia was defined as serum sodium concentration <135 mEq/L on POD 3 or later, and after discharge, postoperative sodium concentration was measured on POD 7-10.
   RESULTS: Delayed hyponatremia was observed in 53 patients (22.6%). Of these patients, 5 (9.4%) were readmitted because of delayed hyponatremia. In binary logistic regression analysis, age >60 years (odds ratio [OR], 2.22; 95% confidence interval [CI], 1.16-4.26; P = 0.017), the nadir sodium concentration on POD 1-2 (OR, 0.88; 95% CI, 0.77-0.99; P = 0.034), and operation time (OR, 1.01; 95% CI, 1.00-1.02; P = 0.018) were independent risk factors for delayed hyponatremia after endoscopic transsphenoidal pituitary surgery.
   CONCLUSIONS: The incidence of delayed hyponatremia in patients with nonfunctioning pituitary tumor who underwent endoscopic transsphenoidal surgery was 22.6%. Old age, low sodium concentration on POD 1-2, and long operation time were associated with the development of delayed hyponatremia in such patients.
C1 [Yoon, Hyun-Kyu; Lee, Hyung-Chul; Lim, Young-Jin; Park, Hee-Pyoung] Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Dept Anesthesiol & Pain Med, Seoul, South Korea.
   [Kim, Yong Hwy] Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Dept Neurosurg, Seoul, South Korea.
RP Park, HP (reprint author), Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Dept Anesthesiol & Pain Med, Seoul, South Korea.
EM hppark@snu.ac.kr
RI Lee, Hyung-Chul/U-1910-2019
OI Lee, Hyung-Chul/0000-0003-0048-7958; Park,
   Hee-Pyoung/0000-0002-4772-0780; Yoon, hyun-kyu/0000-0001-5424-3559
CR Barber SM, 2014, J CLIN MED, V3, P1199, DOI 10.3390/jcm3041199
   Bohl MA, 2018, NEUROSURGERY, V82, P110, DOI 10.1093/neuros/nyx151
   Bohl MA, 2016, NEUROSURGERY, V78, P84, DOI 10.1227/NEU.0000000000001003
   Burke WT, 2018, PITUITARY, V21, P25, DOI 10.1007/s11102-017-0843-5
   Ciric I, 1997, NEUROSURGERY, V40, P225, DOI 10.1097/00006123-199702000-00001
   Cote DJ, 2017, J AM COLL SURGEONS, V224, P971, DOI 10.1016/j.jamcollsurg.2017.02.015
   Cote DJ, 2016, WORLD NEUROSURG, V88, P1, DOI 10.1016/j.wneu.2016.01.022
   CUSICK JF, 1984, NEW ENGL J MED, V311, P36, DOI 10.1056/NEJM198407053110107
   HELDERMAN JH, 1978, J GERONTOL, V33, P39, DOI 10.1093/geronj/33.1.39
   Hendricks BL, 2016, OTOLARYNG HEAD NECK, V154, P359, DOI 10.1177/0194599815617130
   Hensen J, 1999, CLIN ENDOCRINOL, V50, P431, DOI 10.1046/j.1365-2265.1999.00666.x
   Hussain NS, 2013, J NEUROSURG, V119, P1453, DOI 10.3171/2013.8.JNS13411
   Il Lee J, 2008, NEUROL MED-CHIR, V48, P489
   Jahangiri A, 2013, J NEUROSURG, V119, P1478, DOI 10.3171/2013.7.JNS13273
   KELLY DF, 1995, J NEUROSURG, V83, P363, DOI 10.3171/jns.1995.83.2.0363
   Kim JH, 2018, WORLD NEUROSURG, V109, pE409, DOI 10.1016/j.wneu.2017.09.194
   Kinoshita Y, 2011, ENDOCR J, V58, P373, DOI 10.1507/endocrj.K10E-352
   Kristof RA, 2009, J NEUROSURG, V111, P555, DOI 10.3171/2008.9.JNS08191
   Krogh J, 2018, EUR J ENDOCRINOL, V178, P247, DOI 10.1530/EJE-17-0879
   Lane N, 1999, BMJ-BRIT MED J, V318, P1363, DOI 10.1136/bmj.318.7195.1363
   LEE JI, 2008, NEUROL MED CHIR TOKY, V48, P492
   MITCH WE, 1982, AM J MED, V72, P536, DOI 10.1016/0002-9343(82)90523-X
   ROWE JW, 1982, J CLIN ENDOCR METAB, V54, P661, DOI 10.1210/jcem-54-3-661
   Sata A, 2006, NEUROENDOCRINOLOGY, V83, P117, DOI 10.1159/000094725
   Spasovski G, 2014, EUR J ENDOCRINOL, V170, pG1, DOI 10.1530/EJE-13-1020
   Staiger RD, 2013, BRIT J NEUROSURG, V27, P63, DOI 10.3109/02688697.2012.714013
   TAYLOR SL, 1995, NEUROSURGERY, V37, P649, DOI 10.1227/00006123-199510000-00007
   Tohti M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119621
   Zada G, 2007, J NEUROSURG, V106, P66, DOI 10.3171/jns.2007.106.1.66
NR 29
TC 4
Z9 4
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1457
EP E1464
DI 10.1016/j.wneu.2018.11.085
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100179
PM 30465961
DA 2020-05-12
ER

PT J
AU Yoshihara, H
   Margalit, A
   Yoneoka, D
AF Yoshihara, Hiroyuki
   Margalit, Adam
   Yoneoka, Daisuke
TI Incidence of C5 Palsy: Meta-Analysis and Potential Etiology
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior cervical surgery; C5 palsy; Cervical decompression; Etiology;
   Incidence; Meta-analysis; Myelopathy; Pathomechanism; Posterior cervical
   surgery; Radiculopathy
ID OPEN-DOOR LAMINOPLASTY; POSTERIOR LONGITUDINAL LIGAMENT; NERVE ROOT
   PALSY; CERVICAL SPONDYLOTIC MYELOPATHY; SEGMENTAL MOTOR PARALYSIS; UPPER
   EXTREMITY PALSY; LONG-TERM OUTCOMES; ANTERIOR DECOMPRESSION; EXPANSIVE
   LAMINOPLASTY; PLATE FIXATION
AB BACKGROUND: Among the proposed hypotheses for C5 palsy, the most acceptable etiologies have been the tethering effect of the spinal nerve or reperfusion injury of the spinal cord. We performed a meta-analysis to determine a potential etiology of C5 palsy.
   METHODS: The PubMed, Embase, Web of Science, and Cochrane Library databases were searched up to 2017 for relevant studies of the incidence of C5 palsy after cervical decompression surgery. Relevant incident estimates of C5 palsy stratified by the surgical approach and underlying diagnosis were calculated using an appropriate meta-analysis.
   RESULTS: A total of 107 studies were included for our meta-analysis. The pooled incidence of C5 palsy was 0.00 (95% confidence interval [CI], 0.00-0.01) for anterior decompression in patients with radiculopathy, 0.04 (95% CI, 0.03-0.05) for anterior decompression and 0.07 (95% CI, 0.06-0.08) for posterior decompression in patients with myelopathy. A two-tailed t test with unequal variance accepted the null hypothesis of no differences in the incidence between anterior and posterior decompression in patients with myelopathy (P = 0.999) and rejected the hypothesis of no differences in the incidence between the patients with radiculopathy and myelopathy in anterior decompression (P < 0.001).
   CONCLUSIONS: With no significant difference found in the incidence of C5 palsy between anterior and posterior cervical decompression in patients with myelopathy, the tethering effect of the spinal nerve might not be a plausible etiology for C5 palsy. In contrast, we found a significantly greater incidence of C5 palsy in patients with myelopathy compared with those with radiculopathy undergoing anterior decompression, which might support the reperfusion injury of the spinal cord as the etiology of C5 palsy.
C1 [Yoshihara, Hiroyuki] Suny Downstate Med Ctr, Dept Orthopaed Surg & Rehabil Med, Brooklyn, NY 11203 USA.
   [Yoshihara, Hiroyuki] Nagoya City Univ, Dept Orthopaed Surg, Grad Sch Med Sci, Nagoya, Aichi, Japan.
   [Margalit, Adam] Johns Hopkins Univ, Dept Orthopaed Surg, Baltimore, MD USA.
   [Yoneoka, Daisuke] Univ Tokyo, Dept Med, Tokyo, Japan.
RP Yoshihara, H (reprint author), Suny Downstate Med Ctr, Dept Orthopaed Surg & Rehabil Med, Brooklyn, NY 11203 USA.; Yoshihara, H (reprint author), Nagoya City Univ, Dept Orthopaed Surg, Grad Sch Med Sci, Nagoya, Aichi, Japan.
EM hiroyoshihara55@yahoo.co.jp
RI Yoshihara, Hiroyuki/P-8444-2014; Yoneoka, Daisuke/A-9336-2016
OI Yoneoka, Daisuke/0000-0002-3525-5092
CR Alvin MD, 2016, CLIN SPINE SURG, V29, pE67, DOI 10.1097/BSD.0000000000000099
   Ashkenazi E, 2005, J NEUROSURG-SPINE, V3, P205, DOI 10.3171/spi.2005.3.3.0205
   Baba S, 2016, ASIAN SPINE J, V10, P298, DOI 10.4184/asj.2016.10.2.298
   Basaran R, 2016, EUR SPINE J, V25, P2050, DOI 10.1007/s00586-016-4567-4
   Bhalodia VM, 2013, J NEUROSURG-SPINE, V19, P395, DOI 10.3171/2013.6.SPINE12355
   Blizzard DJ, 2017, EUR SPINE J, V26, P85, DOI 10.1007/s00586-016-4746-3
   Blizzard DJ, 2015, J ORTHOP SURG RES, V10, DOI 10.1186/s13018-015-0297-2
   Bu GY, 2016, WORLD NEUROSURG, V94, P507, DOI 10.1016/j.wneu.2016.06.051
   Bydon M, 2014, NEUROSURGERY, V74, P604
   Bydon M, 2014, NEUROSURGERY, V74, P595, DOI 10.1227/NEU.0000000000000322
   Chang PY, 2013, J CHIN MED ASSOC, V76, P378, DOI 10.1016/j.jcma.2013.03.008
   Chaudhary SK, 2017, J ORTHOP SURG-HONG K, V25, DOI 10.1177/2309499017731446
   Chen GD, 2012, ORTHOPEDICS, V35, pE543, DOI 10.3928/01477447-20120327-24
   Chen H, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004666
   Chen H, 2015, CLIN NEUROL NEUROSUR, V138, P188, DOI 10.1016/j.clineuro.2015.09.004
   Chen Y, 2007, J SPINAL DISORD TECH, V20, P533, DOI 10.1097/BSD.0b013e318042b655
   Chen Y, 2014, J SPINAL DISORD TECH, V27, P240, DOI 10.1097/BSD.0b013e31825c6e2f
   Chen Y, 2013, ARCH ORTHOP TRAUM SU, V133, P171, DOI 10.1007/s00402-012-1658-5
   Chen Y, 2012, ARCH ORTHOP TRAUM SU, V132, P1219, DOI 10.1007/s00402-012-1540-5
   Chen Y, 2012, ORTHOPEDICS, V35, pE1231, DOI 10.3928/01477447-20120725-25
   Chen Y, 2011, J SPINAL DISORD TECH, V24, P24, DOI 10.1097/BSD.0b013e3181c7e91e
   Cheng ZH, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001171
   Cherian J, 2016, NEUROSURGERY, V79, P816, DOI 10.1227/NEU.0000000000001199
   Chiba K, 2002, SPINE, V27, P2108, DOI 10.1097/00007632-200210010-00006
   Chiba K, 2006, SPINE, V31, P2998, DOI 10.1097/01.brs.0000250307.78987.6b
   Chugh AJ, 2015, ORTHOPEDICS, V38, pE830, DOI 10.3928/01477447-20150902-63
   Chugh AJS, 2017, CLIN SPINE SURG, V30, pE1256, DOI 10.1097/BSD.0000000000000462
   Dai LY, 1998, J BONE JOINT SURG BR, V80B, P846, DOI 10.1302/0301-620X.80B5.8580
   Dalbayrak S, 2010, J NEUROSURG-SPINE, V12, P33, DOI 10.3171/2009.7.SPINE08965
   Du W, 2014, SPINE J, V14, P57, DOI 10.1016/j.spinee.2013.06.017
   Edwards CC, 2000, SPINE, V25, P1788, DOI 10.1097/00007632-200007150-00009
   Epstein N, 2001, SURG NEUROL, V55, P313, DOI 10.1016/S0090-3019(01)00464-5
   Eskander MS, 2012, J BONE JOINT SURG AM, V94A, P1605, DOI 10.2106/JBJS.K.00664
   Fan DP, 2002, SPINE, V27, P2499, DOI 10.1097/00007632-200211150-00014
   Fujimoto Y, 2002, SPINE, V27, P715, DOI 10.1097/00007632-200204010-00008
   Fujiwara Y, 2016, CLIN SPINE SURG, V29, pE188, DOI 10.1097/BSD.0000000000000311
   Greiner-Perth R, 2005, NEUROSURG REV, V28, P137, DOI 10.1007/s10143-004-0352-7
   Gu YF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101933
   Guo QF, 2011, EUR SPINE J, V20, P1539, DOI 10.1007/s00586-011-1735-4
   Guo QF, 2011, ARCH ORTHOP TRAUM SU, V131, P631, DOI 10.1007/s00402-010-1181-5
   Guzman JZ, 2014, BONE JOINT J, V96B, P950, DOI 10.1302/0301-620X.96B7.33665
   Hasegawa K, 2007, SPINE, V32, pE197, DOI 10.1097/01.brs.0000257576.84646.49
   Hashimoto M, 2010, EUR SPINE J, V19, P1702, DOI 10.1007/s00586-010-1427-5
   HERKOWITZ HN, 1990, SPINE, V15, P1026, DOI 10.1097/00007632-199015100-00009
   Higgins J, 2011, COCHRANE COLLAB, V5, P1, DOI DOI 10.1002/9780470712184
   Hirabayashi K, 1999, CLIN ORTHOP RELAT R, P35
   Hu W, 2014, ORTHOPEDICS, V37, pE71, DOI 10.3928/01477447-20131219-20
   Huang RC, 2003, J SPINAL DISORD TECH, V16, P123, DOI 10.1097/00024720-200304000-00002
   Ikegami S, 2014, SPINE, V39, P463, DOI 10.1097/BRS.0000000000000175
   Ikenaga M, 2005, J NEUROSURG-SPINE, V3, P210, DOI 10.3171/spi.2005.3.3.0210
   Imagama S, 2010, J BONE JOINT SURG BR, V92B, P393, DOI 10.1302/0301-620X.92B3.22786
   Jiang LJ, 2012, ORTHOPEDICS, V35, pE225, DOI 10.3928/01477447-20120123-07
   Kanchiku T, 2014, ARCH ORTHOP TRAUM SU, V134, P1045, DOI 10.1007/s00402-014-2017-5
   Kaner T, 2009, TURK NEUROSURG, V19, P121
   Kaneyama S, 2010, SPINE, V35, pE1553, DOI 10.1097/BRS.0b013e3181ce873d
   Katonis P, 2011, J SPINAL DISORD TECH, V24, P415, DOI 10.1097/BSD.0b013e3182024c06
   Katsumi K, 2013, J SPINAL DISORD TECH, V26, P177, DOI 10.1097/BSD.0b013e31823db346
   Katsumi K, 2012, SPINE, V37, P748, DOI 10.1097/BRS.0b013e3182326957
   Kim K, 2011, NEUROL MED-CHIR, V51, P108, DOI 10.2176/nmc.51.108
   Kim S, 2014, J SPINAL DISORD TECH, V27, P436, DOI 10.1097/BSD.0b013e31826a10b0
   Komagata M, 2002, J JPN SPINE RES SOC, V131, P237
   Komagata Masashi, 2004, Spine J, V4, P650, DOI 10.1016/j.spinee.2004.03.022
   Kotil K, 2011, TURK NEUROSURG, V21, P606, DOI [10.5137/1019-5149.JTN .4739-11.2, 10.5137/1019-5149.JTN.4739-11.2]
   Kurakawa T, 2016, EUR SPINE J, V25, P2060, DOI 10.1007/s00586-016-4548-7
   Lee CH, 2016, CLIN SPINE SURG, V29, pE9, DOI 10.1097/BSD.0000000000000058
   Lee DG, 2013, J SPINAL DISORD TECH, V26, pE198, DOI 10.1097/BSD.0b013e31828bb296
   Lee SE, 2013, J SPINAL DISORD TECH, V26, pE101, DOI 10.1097/BSD.0b013e3182706b69
   Li Z, 2017, SPINE, V42, pE575, DOI 10.1097/BRS.0000000000001907
   Lim CH, 2017, EUR SPINE J, V26, P1101, DOI 10.1007/s00586-016-4664-4
   Liu K, 2013, CLIN ORTHOP RELAT R, V471, P2219, DOI 10.1007/s11999-013-2889-7
   Liu T, 2010, ORTHOPEDICS, V33, P8
   Liu TL, 2016, TURK NEUROSURG, V26, P280, DOI 10.5137/1019-5149.JTN.7476-12.1
   Liu Y, 2012, EUR SPINE J, V21, P2428, DOI 10.1007/s00586-012-2323-y
   Lubelski D, 2014, SPINE J, V14, P1895, DOI 10.1016/j.spinee.2013.10.038
   Minamide A, 2010, EUR SPINE J, V19, P487, DOI 10.1007/s00586-009-1233-0
   Minoda Y, 2003, SPINE, V28, P1123, DOI 10.1097/00007632-200306010-00008
   Moher D, 2010, INT J SURG, V8, P336, DOI 10.1016/j.ijsu.2010.02.007
   Nakamae T, 2012, J SPINAL DISORD TECH, V25, P92, DOI 10.1097/BSD.0b013e318211fc4e
   Nakashima H, 2014, SPINE, V39, P642, DOI 10.1097/BRS.0000000000000252
   Nakashima H, 2012, J NEUROSURG-SPINE, V17, P103, DOI 10.3171/2012.4.SPINE11255
   Odate S, 2016, CLIN SPINE SURG, V29, P226, DOI 10.1097/BSD.0b013e31827ada34
   Odate S, 2013, SPINE, V38, P2184, DOI 10.1097/BRS.0000000000000019
   Okada M, 2009, SPINE, V34, P1119, DOI 10.1097/BRS.0b013e31819c3b61
   Park JH, 2012, J SPINAL DISORD TECH, V25, pE224, DOI 10.1097/BSD.0b013e31825dda6b
   Qian L, 2014, J ORTHOP SURG RES, V9, DOI 10.1186/s13018-014-0063-x
   Ruetten S, 2008, SPINE, V33, P940, DOI 10.1097/BRS.0b013e31816c8b67
   Sakaura H, 2003, SPINE, V28, P2447, DOI 10.1097/01.BRS.0000090833.96168.3F
   Sakaura H, 2005, SPINE, V30, P756, DOI 10.1097/01.brs.0000157415.79713.7e
   SATOMI K, 1994, SPINE, V19, P507, DOI 10.1097/00007632-199403000-00003
   Seichi A, 2004, SPINE, V29, P1478, DOI 10.1097/01.BRS.0000128757.32816.19
   Selvanathan SK, 2015, ACTA NEUROCHIR, V157, P1595, DOI 10.1007/s00701-015-2491-8
   Shibuya S, 2010, SPINAL CORD, V48, P214, DOI 10.1038/sc.2009.114
   Shiozaki T, 2009, SPINE, V34, P274, DOI 10.1097/BRS.0b013e318194e275
   Shou FY, 2015, EUR SPINE J, V24, P2724, DOI 10.1007/s00586-015-4186-5
   Sieh Koon-Man, 2009, J Orthop Surg Res, V4, P24, DOI 10.1186/1749-799X-4-24
   Spitz S, 2015, EUR SPINE J, V24, P2866, DOI 10.1007/s00586-015-4252-z
   Su N, 2016, THER CLIN RISK MANAG, V12, P1329, DOI 10.2147/TCRM.S110340
   Takemitsu M, 2008, J SPINAL DISORD TECH, V21, P267, DOI 10.1097/BSD.0b013e31812f6f54
   Takenaka S, 2016, BONE JOINT J, V98B, P117, DOI 10.1302/0301-620X.98B1.36042
   Tanaka N, 2006, SPINE, V31, P3013, DOI 10.1097/01.brs.0000250303.17840.96
   Tsuzuki N, 1996, SPINE, V21, P203, DOI 10.1097/00007632-199601150-00008
   Tsuzuki N, 1993, Eur Spine J, V2, P197, DOI 10.1007/BF00299446
   Tumialan LM, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.1.FOCUS09305
   Tung KL, 2015, J ORTHOP SURG-HONG K, V23, P174, DOI 10.1177/230949901502300211
   Uematsu Y, 1998, SPINE, V23, P2057, DOI 10.1097/00007632-199810010-00004
   Wada E, 2001, SPINE, V26, P1443, DOI 10.1097/00007632-200107010-00011
   Wang HY, 2015, INT J CLIN EXP MED, V8, P3983
   Wang T, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008560
   Wu FL, 2014, SPINE J, V14, P909, DOI 10.1016/j.spinee.2013.07.445
   Xia G, 2011, ORTHOPEDICS, V34, P968, DOI 10.3928/01477447-20111021-03
   Xia YP, 2011, J SPINAL DISORD TECH, V24, P514, DOI 10.1097/BSD.0b013e3182064632
   Yanase M, 2010, J SPINAL DISORD TECH, V23, P170, DOI 10.1097/BSD.0b013e31819e91b4
   Yang LL, 2013, ORTHOPEDICS, V36, pE79, DOI 10.3928/01477447-20121217-23
   Yeh KT, 2016, BIOMED RES INT, DOI 10.1155/2016/8069354
   Yeh KT, 2015, J FORMOS MED ASSOC, V114, P1225, DOI 10.1016/j.jfma.2014.10.005
   Yeh KT, 2014, J ORTHOP SURG RES, V9, DOI 10.1186/s13018-014-0049-8
   YONENOBU K, 1991, SPINE, V16, P1277, DOI 10.1097/00007632-199111000-00006
   Yoshihara H, 2010, EUR SPINE J, V19, P1702
   Yoshihara H, 2011, EUR SPINE J, V20, P1188, DOI 10.1007/s00586-010-1674-5
   Yuan W, 2015, CLIN NEUROL NEUROSUR, V134, P17, DOI 10.1016/j.clineuro.2015.04.004
   Yue B, 2015, INT J CLIN EXP MED, V8, P9565
   Zhang H, 2015, J SPINAL DISORD TECH, V28, P89, DOI 10.1097/BSD.0b013e3182695295
   Zhao XT, 2012, ARCH ORTHOP TRAUM SU, V132, P203, DOI 10.1007/s00402-011-1420-4
NR 123
TC 3
Z9 3
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E828
EP E837
DI 10.1016/j.wneu.2018.10.159
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100100
PM 30391764
DA 2020-05-12
ER

PT J
AU Yoshimoto, T
   Maruichi, K
   Itoh, Y
   Takamiya, S
   Kaneko, T
AF Yoshimoto, Tetsuyuki
   Maruichi, Katsuhiko
   Itoh, Yasuhiro
   Takamiya, Soichiro
   Kaneko, Tetsuya
TI Monitoring Corticocortical Evoked Potentials During Intracranial
   Vascular Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Bypass; CCEP; Clipping; Ischemia; Speech function
ID CEREBRAL ANEURYSM SURGERY; FUNCTIONAL CONNECTIVITY; ASYMMETRY; NETWORK;
   SYSTEM
AB BACKGROUND: Monitoring of corticocortical evoked potentials (CCEPs) during brain tumor surgery of patients under anesthesia was recently reported to be effective in assisting in preservation of speech function. The aim of this study was to investigate whether CCEPs can be reproducibly measured between the frontal and temporal lobes during standard intracranial vascular surgery under general anesthesia; whether dynamic changes in CCEPs caused by reduced focal cerebral blood flow can be measured; and whether CCEPs can be used to monitor speech function, particularly associated with the left side of the brain.
   METHODS: We monitored CCEPs during 58 vascular surgeries (42 clipping procedures; 15 bypasses, 1 of which overlapped with clipping; and 2 hematoma removals from the left frontal and temporal lobe) at Kashiwaba Neurosurgical Hospital from October 2016 to January 2018.
   RESULTS: CCEPs could be reproducibly and routinely monitored in bilateral vascular surgeries. None of the patients experienced any postoperative symptoms or showed any ischemic lesions on postoperative magnetic resonance imaging; however, 5 patients temporarily demonstrated reduced CCEPs intraoperatively that were caused by transient obstructions of blood flow. Motor evoked potentials and somatosensory evoked potentials were simultaneously monitored intraoperatively and did not show any changes.
   CONCLUSIONS: The results of our pilot study show that CCEPs can be routinely monitored during bilateral intracranial vascular surgery and that they are sensitive to ischemia. CCEPs on the left side could serve as unique intraoperative monitoring of speech function under anesthesia.
C1 [Yoshimoto, Tetsuyuki; Maruichi, Katsuhiko; Takamiya, Soichiro] Kashiwaba Neurosurg Hosp, Dept Neurosurg, Sapporo, Hokkaido, Japan.
   [Kaneko, Tetsuya] Kashiwaba Neurosurg Hosp, Dept Neurophysiol, Sapporo, Hokkaido, Japan.
   [Itoh, Yasuhiro] Hokkaido Univ, Sch Med, Dept Neurosurg, Sapporo, Hokkaido, Japan.
   [Yoshimoto, Tetsuyuki] Hokkaido Neurosurg Mem Hosp, Sapporo, Hokkaido, Japan.
RP Yoshimoto, T (reprint author), Kashiwaba Neurosurg Hosp, Dept Neurosurg, Sapporo, Hokkaido, Japan.; Yoshimoto, T (reprint author), Hokkaido Neurosurg Mem Hosp, Sapporo, Hokkaido, Japan.
EM yossikamer@me.com
CR Abdulrauf SI, 2017, J NEUROSURG, V127, P311, DOI 10.3171/2015.12.JNS152140
   Araki K, 2015, CLIN NEUROPHYSIOL, V126, P682, DOI 10.1016/j.clinph.2014.07.020
   Catani M, 2012, CORTEX, V48, P273, DOI 10.1016/j.cortex.2011.12.001
   Enatsu R, 2016, J NEUROSURG, V125, P90, DOI 10.3171/2015.6.JNS15622
   Entz L, 2014, HUM BRAIN MAPP, V35, P5736, DOI 10.1002/hbm.22581
   Guo LJ, 2011, CLIN NEUROPHYSIOL, V122, P648, DOI 10.1016/j.clinph.2010.09.001
   Horiuchi K, 2005, J NEUROSURG, V103, P275, DOI 10.3171/jns.2005.103.2.0275
   Keller CJ, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0528
   Kunieda T, 2015, NEUROL MED-CHIR, V55, P374, DOI 10.2176/nmc.ra.2014-0388
   Matsumoto R, 2004, BRAIN, V127, P2316, DOI 10.1093/brain/awh246
   Matsumoto R, 2007, BRAIN, V130, P181, DOI 10.1093/brain/awl257
   Neuloh G, 2004, J NEUROSURG, V100, P389, DOI 10.3171/jns.2004.100.3.0389
   Nucifora PGP, 2005, NEUROREPORT, V16, P791, DOI 10.1097/00001756-200505310-00002
   Rodrigo S, 2007, AM J NEURORADIOL, V28, P1526, DOI 10.3174/ajnr.A0584
   Saito T, 2014, J NEUROSURG, V121, P827, DOI 10.3171/2014.4.JNS131195
   Szelenyi A, 2006, J NEUROSURG, V105, P675, DOI 10.3171/jns.2006.105.5.675
   Tanabe Jun, 2017, Surg Neurol Int, V8, P79, DOI 10.4103/sni.sni_410_16
   Terada K, 2012, HUM BRAIN MAPP, V33, P14, DOI 10.1002/hbm.21189
   Trebaul L, 2016, J NEUROSCI METH, V264, P94, DOI 10.1016/j.jneumeth.2016.03.002
   Umeoka S, 2009, NEUROSURGERY, V64, P847, DOI 10.1227/01.NEU.0000344001.26669.92
   Yamao Y, 2017, HUM BRAIN MAPP, V38, P1977, DOI 10.1002/hbm.23498
   Yamao Y, 2014, HUM BRAIN MAPP, V35, P4345, DOI 10.1002/hbm.22479
NR 22
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E947
EP E954
DI 10.1016/j.wneu.2018.10.179
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100114
PM 30408608
DA 2020-05-12
ER

PT J
AU Yu, JYH
   Fridley, J
   Gokaslan, Z
   Telfeian, A
   Oyelese, AA
AF Yu, James Y. H.
   Fridley, Jared
   Gokaslan, Ziya
   Telfeian, Albert
   Oyelese, Adetokunbo A.
TI Minimally Invasive Thoracolumbar Corpectomy and Stabilization for
   Unstable Burst Fractures Using Intraoperative Computed Tomography and
   Computer-Assisted Spinal Navigation
SO WORLD NEUROSURGERY
LA English
DT Article
DE Airo; Burst fracture; Computer-assisted navigation; Extreme lateral
   interbody fusion corpectomy; Image guidance; Intraoperative CT;
   Mini-open lateral approach thoracolumbar corpectomy
ID LATERAL INTERBODY FUSION; PEDICLE SCREW PLACEMENT; MINI-OPEN; ANTERIOR
   CORPECTOMY; TRANSPSOAS APPROACH; SURGERY; OUTCOMES; INSTRUMENTATION;
   COMPLICATIONS; DECOMPRESSION
AB BACKGROUND: Minimally invasive surgery using a mini-open lateral retropleural or retroperitoneal approach for corpectomy is a well-described procedure for treating unstable thoracolumbar burst fractures. Most surgeons have incorporated fluoroscopy for localization and determination of hardware placement accuracy; however, the utility of computer-assisted image-guided spinal navigation has not been well described. We report a series of mini-open lateral approach thoracolumbar corpectomy cases using either fluoroscopy or intraoperative computed tomography (iCT) with computer-assisted navigation and discuss the technical nuances and advantages of using iCT with navigation versus fluoroscopy.
   METHODS: A retrospective review and analysis was performed of the cases of 20 patients with thoracolumbar burst fractures surgically managed via mini-open lateral corpectomy with fluoroscopy (2013-2015) or iCT navigation (2015-2017). The surgical outcomes were evaluated by the estimated blood loss, operative time, hospital stay, and need for revision. The clinical outcomes were evaluated using the numerical rating scale pain score. Radiographic outcomes were assessed with follow-up CT scans. The results were statistically analyzed using the Wilcoxon-Mann-Whitney test.
   RESULTS: The mean follow-up period was 13.4 months for the fluoroscopy group and 14.7 months for the iCT group. No surgical complications developed and no revisions were required. No statistically significant differences were found between the groups in surgical or clinical outcomes. However, the radiation exposure to the surgeons was significantly less with the iCT group (P < 0.003).
   CONCLUSIONS: The use of iCT with spinal navigation for mini-open lateral corpectomy for thoracolumbar burst fractures yields perioperative and clinical outcomes comparable to those using traditional fluoroscopy, with decreased radiation exposure to surgeons.
C1 [Yu, James Y. H.; Fridley, Jared; Gokaslan, Ziya; Telfeian, Albert; Oyelese, Adetokunbo A.] Brown Univ, Dept Neurosurg, Warren Alpert Med Sch, Providence, RI 02912 USA.
   [Fridley, Jared; Gokaslan, Ziya; Telfeian, Albert; Oyelese, Adetokunbo A.] Rhode Isl Hosp, Norman Prince Neurosci Inst, Providence, RI 02903 USA.
RP Oyelese, AA (reprint author), Brown Univ, Dept Neurosurg, Warren Alpert Med Sch, Providence, RI 02912 USA.; Oyelese, AA (reprint author), Rhode Isl Hosp, Norman Prince Neurosci Inst, Providence, RI 02903 USA.
EM aoyelese@lifespan.org
CR Adkins DE, 2013, J CLIN NEUROSCI, V20, P1289, DOI 10.1016/j.jocn.2012.09.051
   Avanzi O, 2015, REV BRAS ORTOP, V45, P236
   Baaj AA, 2013, CLIN NEUROL NEUROSUR, V115, P342, DOI 10.1016/j.clineuro.2012.05.007
   Baaj AA, 2012, J CLIN NEUROSCI, V19, P1265, DOI 10.1016/j.jocn.2012.01.026
   Blattert TR, 2011, EUR J TRAUMA EMERG S, V37, P127, DOI 10.1007/s00068-011-0082-9
   Blizzard DJ, 2015, J CLIN NEUROSCI, V22, P1758, DOI 10.1016/j.jocn.2015.05.021
   Comer GC, 2012, SPINE J, V12, P881, DOI 10.1016/j.spinee.2012.09.040
   Costa F, 2016, J NEUROSURG-SPINE, V25, P654, DOI 10.3171/2016.3.SPINE151139
   Drazin D, 2013, J CLIN NEUROSCI, V20, P1438, DOI 10.1016/j.jocn.2012.12.028
   Formica M, 2017, EUR SPINE J, V26, P464, DOI 10.1007/s00586-017-5115-6
   Gandhoke GS, 2015, EUR SPINE J, V24, pS353, DOI 10.1007/s00586-015-3880-7
   Hecht N, 2016, EUR SPINE J, V25, P716, DOI 10.1007/s00586-015-3814-4
   Houten JK, 2012, NEUROSURGERY, V70, P990, DOI 10.1227/NEU.0b013e318237a829
   Jarvers JS, 2011, EUR J TRAUMA EMERG S, V37, P109, DOI 10.1007/s00068-011-0098-1
   Joseph JR, 2016, J NEUROSURG-SPINE, V25, P339, DOI 10.3171/2016.2.SPINE151295
   Kim TT, 2016, BIOMED RES INT, DOI 10.1155/2016/5716235
   Kim TT, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2014.1.FOCUS13531
   Lang G, 2017, WORLD NEUROSURG, V101, P99, DOI 10.1016/j.wneu.2017.01.080
   Lau D, 2013, J NEUROSURG-SPINE, V18, P356, DOI 10.3171/2013.1.SPINE12882
   Lee CY, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000757
   Malham GM, 2015, J NEUROL SURG PART A, V76, P240, DOI 10.1055/s-0034-1368094
   Ozgur Burak M, 2006, Spine J, V6, P435, DOI 10.1016/j.spinee.2005.08.012
   Patel NB, 2015, J CLIN NEUROSCI, V22, P1753, DOI 10.1016/j.jocn.2015.03.061
   Puvanesarajah V, 2016, TURK NEUROSURG, V26, P646, DOI 10.5137/1019-5149.JTN.15271-15.1
   Reinshagen C, 2015, J CLIN NEUROSCI, V22, P1484, DOI 10.1016/j.jocn.2015.03.019
   Rienmuller A, 2017, BONE JOINT J, V99B, P1373, DOI 10.1302/0301-620X.99B10.BJJ-2016-1283.R1
   Smith WD, 2018, SPINE, V43, pE118, DOI 10.1097/BRS.0000000000002244
   Sulaiman OAR, 2017, WORLD NEUROSURG, V99, P295, DOI 10.1016/j.wneu.2016.11.075
   Tang JS, 2014, J BIOMED RES, V28, P228, DOI 10.7555/JBR.28.20130159
   Theologis AA, 2016, J NEUROSURG-SPINE, V24, P60, DOI 10.3171/2015.4.SPINE14944
   Thomas KC, 2006, J NEUROSURG-SPINE, V4, P351, DOI 10.3171/spi.2006.4.5.351
   Vaccaro AR, 2006, J SPINAL DISORD TECH, V19, P1, DOI 10.1097/01.bsd.0000180080.59559.45
   Walker CT, 2018, ANN TRANSL MED, V6, DOI 10.21037/atm.2018.02.10
   Xiao R, 2017, J NEUROSURG-SPINE, V26, P628, DOI 10.3171/2016.10.SPINE16373
   Yen CP, 2018, CLIN SPINE SURG, V31, P14, DOI 10.1097/BSD.0000000000000580
NR 35
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1266
EP E1274
DI 10.1016/j.wneu.2018.11.027
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100154
PM 30447453
DA 2020-05-12
ER

PT J
AU Yu, KX
   Chu, L
   Yang, JS
   Deng, R
   Chen, L
   Shi, L
   Hao, DJ
   Deng, ZL
AF Yu, Ke-Xiao
   Chu, Lei
   Yang, Jun-Song
   Deng, Rui
   Chen, Liang
   Shi, Lei
   Hao, Ding-Jun
   Deng, Zhong-Liang
TI Anterior Transcorporeal Approach to Percutaneous Endoscopic Cervical
   Diskectomy for Single-Level Cervical Intervertebral Disk Herniation:
   Case Series with 2-Year Follow-Up
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cervical diskectomy; Endoscopes; Percutaneous; Transcorporeal approach
ID HEALTH SURVEY SF-36; FUSION; RADICULOPATHY; MICROFORAMINOTOMY; SPINE
AB OBJECTIVE: To examine the effects of anterior transcorporeal percutaneous endoscopic cervical diskectomy (ATPECD) for the treatment of single-level cervical intervertebral disk herniation (CIDH) with a focus on its safety, feasibility, clinical efficacy, and specific possible complications.
   METHODS: A series of 35 patients with symptomatic single-level CIDH were enrolled to be treated with ATPECD. Neck and arm pain was measured using the visual analog scale. Quality of life was measured using the bodily pain and physical function on the SF-36. The average disk height and vertical vertebral body height were recorded. Bone healing was evaluated on the basis of postoperative computed tomography.
   RESULTS: Successful removal of the herniated disk was confirmed in all 35 cases. At 2 years, the patients showed a significant treatment effect in the visual analog scale and body pain and physical function portions of the SF-36 (1.14 +/- 0.60 vs. 7.62 +/- 0.61, 63.92 +/- 6.74 vs. 32.55 +/- 6.80, and 82.14 +/- 6.22 vs. 34.43 +/- 4.50, respectively, P < 0.01). Mean preoperative disk height was 6.79 +/- 0.37 mm, which decreased to 6.34 +/- 0.46 mm 2 years post operation (6.6% decrease). Preoperative surgical vertebral body height also decreased from preoperation (15.79 +/- 0.52 mm) to 2 years post operation (15.12 +/- 0.38 mm) (4.2% decrease). Three surgery-related complications were observed (8.6%).
   CONCLUSIONS: Preliminary clinical experience with ATPECD shows that it is safe, effective, feasible, and minimally invasive. Although it has some disadvantages, such as the need for repeated fluoroscopy, some minor complications, and nonsymptomatic disk height decreases, ATPECD can supplement minimally invasive surgeries in selected cases of CIDH.
C1 [Yu, Ke-Xiao; Chu, Lei; Deng, Rui; Chen, Liang; Shi, Lei; Deng, Zhong-Liang] Chongqing Med Univ, Affiliated Hosp 2, Dept Orthopaed, Chongqing, Peoples R China.
   [Yang, Jun-Song; Hao, Ding-Jun] Xi An Jiao Tong Univ, Honghui Hosp, Dept Spine Surg, Xian, Shaanxi, Peoples R China.
RP Deng, ZL (reprint author), Chongqing Med Univ, Affiliated Hosp 2, Dept Orthopaed, Chongqing, Peoples R China.
EM zhongliang.deng@yahoo.com
OI Yu, Ke-Xiao/0000-0002-6221-144X
FU Key Project of Medical Research of Chongqing Municipal Healthy Bureau
   [2016ZDXM007]; Chongqing graduate student research innovation project
   [CYB17122]; Chinese National Natural Science FoundationNational Natural
   Science Foundation of China [81772357]
FX The Key Project of Medical Research of Chongqing Municipal Healthy
   Bureau (2016ZDXM007 for Zhong-Liang Deng), Chongqing graduate student
   research innovation project. (CYB17122 for Ke-Xiao Yu) and Chinese
   National Natural Science Foundation (81772357 for Ding-Jun Hao) provided
   grants.
CR Ahn Y, 2005, PHOTOMED LASER SURG, V23, P362, DOI 10.1089/pho.2005.23.362
   Ahn Y, 2004, NEURORADIOLOGY, V46, P378, DOI 10.1007/s00234-004-1197-z
   Ahn Y, 2016, EXPERT REV MED DEVIC, V13, P601, DOI 10.1080/17434440.2016.1180245
   BOHLMAN HH, 1993, J BONE JOINT SURG AM, V75A, P1298, DOI 10.2106/00004623-199309000-00005
   Chaudhary SK, 2017, J ORTHOP SURG-HONG K, V25, DOI 10.1177/2309499017731446
   Chen Y, 2009, INT ORTHOP, V33, P477, DOI 10.1007/s00264-008-0542-y
   Choi G, 2010, MINIM INVAS NEUROSUR, V53, P127, DOI 10.1055/s-0030-1249681
   Choi G, 2007, EUR SPINE J, V16, P1387, DOI 10.1007/s00586-006-0286-6
   Deng ZL, 2016, SPINE J, V16, P659, DOI 10.1016/j.spinee.2016.01.187
   Fountas KN, 2007, SPINE, V32, P2310, DOI 10.1097/BRS.0b013e318154c57e
   Fraser JF, 2007, J NEUROSURG-SPINE, V6, P298, DOI 10.3171/spi.2007.6.4.298
   GEORGE B, 1993, NEUROCHIRURGIE, V39, P171
   HAKUBA A, 1976, J NEUROSURG, V45, P284, DOI 10.3171/jns.1976.45.3.0284
   Hjermstad MJ, 2011, J PAIN SYMPTOM MANAG, V41, P1073, DOI 10.1016/j.jpainsymman.2010.08.016
   Hsieh AH, 2009, SPINE, V34, P998, DOI 10.1097/BRS.0b013e31819c09c4
   Jagannathan J, 2008, J NEUROSURG-SPINE, V8, P420, DOI 10.3171/SPI/2008/8/5/420
   Jeon JK, 2014, SPINE, V39, P275, DOI 10.1097/BRS.0000000000000140
   Jho HD, 2002, NEUROSURGERY, V51, pS46, DOI 10.1227/01.NEU.0000030982.31694.2A
   Kim JS, 2011, EUR SPINE J, V20, pS147, DOI 10.1007/s00586-010-1454-2
   Lee JH, 2014, PHOTOMED LASER SURG, V32, P663, DOI 10.1089/pho.2014.3806
   Lee SH, 2007, ORTHOP CLIN N AM, V38, P327, DOI 10.1016/j.ocl.2007.02.007
   Maiman DJ, 1999, BIO-MED MATER ENG, V9, P27
   MCHORNEY CA, 1994, MED CARE, V32, P40, DOI 10.1097/00005650-199401000-00004
   Ruetten S, 2008, SPINE, V33, P940, DOI 10.1097/BRS.0b013e31816c8b67
   Ruetten S, 2009, INT ORTHOP, V33, P1677, DOI 10.1007/s00264-008-0684-y
   Suk KS, 2006, INT ORTHOP, V30, P290, DOI 10.1007/s00264-005-0072-9
   Tureyen K, 2003, ACTA NEUROCHIR, V145, P565, DOI 10.1007/s00701-003-0050-1
   Tzaan WC, 2011, J SPINAL DISORD TECH, V24, P421, DOI 10.1097/BSD.0b013e31820ef328
   WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002
   Wu WK, 2018, WORLD NEUROSURG, V114, pE199, DOI 10.1016/j.wneu.2018.02.140
   Yang JS, 2014, SPINE, V39, P1743, DOI 10.1097/BRS.0000000000000508
NR 31
TC 1
Z9 1
U1 2
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1345
EP E1353
DI 10.1016/j.wneu.2018.11.045
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100164
PM 30448574
DA 2020-05-12
ER

PT J
AU Yu, LB
   Fang, ZJ
   Yang, XJ
   Zhang, D
AF Yu, Le-Bao
   Fang, Zhi-Jun
   Yang, Xin-Jian
   Zhang, Dong
TI Management of Residual and Recurrent Aneurysms After Clipping or
   Coiling: Clinical Characteristics, Treatments, and Follow-Up Outcomes
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endovascular coiling; Microsurgical clipping; Recurrent aneurysm
ID RUPTURED INTRACRANIAL ANEURYSMS; ENDOVASCULAR TREATMENT; REMNANTS;
   TRIAL; ISAT
AB BACKGROUND: Recurrent intracranial aneurysms (RAs) remain a daunting challenge for neurosurgeons. This study aimed to explore a potential optimal management strategy of RAs by reviewing the characteristics and management outcomes of 117 RAs.
   METHODS: A total of 117 patients with RAs were treated in a single neurosurgical center from January 2011 to January 2017. The demographic and angiographic characteristics of the patients, treatment approaches, and follow-up outcomes were evaluated.
   RESULTS: Of the 117 patients with RAs, 16 (13.7%) and 101 (86.3%) initially underwent microsurgical clipping and endovascular coiling, respectively. Coil embolization was used in 75 cases, microsurgical clipping was used in 32 cases, and conservative treatment occurred in 10 cases. Complete clipping was achieved in all 32 aneurysms by microsurgery, and remnants were observed in 25 aneurysms after coiling (33.3%, P < 0.001). Operation-related cerebral infarction occurred in 4 cases (12.5%) with complex and large RA in the clipping group and in 1.3% (1/75) of patients treated with coiling (P = 0.027). Follow-up found similar favorable outcomes in patients after coiling, clipping, and conservative treatment (90.3% vs. 86.7% vs. 80%, respectively; P = 0.711). Follow-up rates of recurrence were significantly higher in the coiling group than the clipping group (26% vs. 0%, respectively; P = 0.003).
   CONCLUSIONS: The follow-up outcomes appeared to be acceptable and comparable between the 2 groups. However, in large or giant recurrent aneurysms, sound judgment and the careful selection of treatment are strongly suggested because direct microsurgery has a higher morbidity, even in experienced hands, whereas endovascular coiling is complicated with a higher incomplete occlusion rate.
C1 [Yu, Le-Bao; Zhang, Dong] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing, Peoples R China.
   [Yu, Le-Bao; Zhang, Dong] China Natl Clin Res Ctr Neurol Dis, Beijing, Peoples R China.
   [Yu, Le-Bao; Zhang, Dong] Beijing Inst Brain Disorders, Ctr Stroke, Beijing, Peoples R China.
   [Yu, Le-Bao; Zhang, Dong] Beijing Key Lab Translat Med Cerebrovasc Dis, Beijing, Peoples R China.
   [Fang, Zhi-Jun] Capital Med Univ, Dept Neurosurg, Peoples Hosp Beijing Daxing Dist, Beijing, Peoples R China.
   [Yang, Xin-Jian] Beijing Neurosurg Inst, Dept Intervent Neuroradiol, Beijing, Peoples R China.
   [Yang, Xin-Jian] Capital Med Univ, Beijing Tiantan Hosp, Beijing, Peoples R China.
RP Zhang, D (reprint author), Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing, Peoples R China.; Zhang, D (reprint author), China Natl Clin Res Ctr Neurol Dis, Beijing, Peoples R China.; Zhang, D (reprint author), Beijing Inst Brain Disorders, Ctr Stroke, Beijing, Peoples R China.; Zhang, D (reprint author), Beijing Key Lab Translat Med Cerebrovasc Dis, Beijing, Peoples R China.
EM zhangdong0660@aliyun.com
FU China National Clinical Research Center for Neurosurgical Diseases
   [2015BAI12804]
FX This study was funded by The China National Clinical Research Center for
   Neurosurgical Diseases (2015BAI12804).
CR Rubino PA, 2014, WORLD NEUROSURG, V82, pE203, DOI 10.1016/j.wneu.2013.09.016
   Boet R, 2001, ACTA NEUROCHIR, V143, P1093, DOI 10.1007/s007010100001
   Chung J, 2010, NEURORADIOLOGY, V52, P1143, DOI 10.1007/s00234-010-0695-4
   Debrun GM, 2000, SURG NEUROL, V53, P150, DOI 10.1016/S0090-3019(99)00194-9
   Dorfer C, 2012, NEUROSURGERY, V70, P537, DOI 10.1227/NEU.0b013e3182350da5
   El Beltagy M, 2010, WORLD NEUROSURG, V74, P472, DOI 10.1016/j.wneu.2010.06.036
   Gawlitza M, 2018, J NEUROINTERV SURG, V10, P629, DOI 10.1136/neurintsurg-2017-013287
   GIANNOTTA SL, 1995, J NEUROSURG, V83, P387, DOI 10.3171/jns.1995.83.3.0387
   Gross BA, 2017, J NEUROINTERV SURG, V9, P169, DOI 10.1136/neurintsurg-2016-012625
   GUGLIELMI G, 1991, J NEUROSURG, V75, P1, DOI 10.3171/jns.1991.75.1.0001
   Hayakawa M, 2000, J NEUROSURG, V93, P561, DOI 10.3171/jns.2000.93.4.0561
   Johnston SC, 2006, STROKE, V37, P1437, DOI 10.1161/01.STR.0000221331.01830.ce
   Kashimura H, 2007, J NEUROSURG, V107, P881, DOI 10.3171/JNS-0711010881
   Kim BM, 2010, NEUROSURGERY, V66, P1128, DOI 10.1227/01.NEU.0000367998.33743.D6
   Lejeune JP, 2008, NEUROSURGERY, V63, P684, DOI 10.1227/01.NEU.0000325499.82876.6D
   Lin N, 2012, J NEUROINTERV SURG, V4, P182, DOI 10.1136/jnis.2011.004978
   Mangiafico S, 2005, INTERV NEURORADIOL, V11, P41, DOI 10.1177/159101990501100106
   Molyneux A, 2002, LANCET, V360, P1267, DOI 10.1016/S0140-6736(02)11314-6
   Molyneux AJ, 2005, LANCET, V366, P809, DOI 10.1016/S0140-6736(05)67214-5
   Molyneux AJ, 2009, LANCET NEUROL, V8, P427, DOI 10.1016/S1474-4422(09)70080-8
   Qureshi AI, 2011, J NEUROSURG, V114, P834, DOI 10.3171/2010.6.JNS091486
   Raftopoulos C, 2007, ACTA NEUROCHIR, V149, P11, DOI 10.1007/s00701-006-1046-4
   Raymond J, 2003, STROKE, V34, P1398, DOI 10.1161/01.STR.0000073841.88563.E9
   Raymond J, 1997, NEUROSURGERY, V41, P1235, DOI 10.1097/00006123-199712000-00002
   Raymond J, 2006, NEUROIMAGING CLIN N, V16, P513
   SAKAKI T, 1994, J NEUROSURG, V80, P58, DOI 10.3171/jns.1994.80.1.0058
   Sanai N, 2012, NEUROSURGERY, V71, P285, DOI 10.1227/NEU.0b013e318256c3eb
   Spiotta AM, 2013, NEUROSURGERY, V72, P65, DOI 10.1227/NEU.0b013e318276b46b
NR 28
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E838
EP E846
DI 10.1016/j.wneu.2018.10.160
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100101
PM 30391763
DA 2020-05-12
ER

PT J
AU Yuan, J
   Qu, JX
   Zhang, D
   Liu, XJ
   Li, JX
   Wu, CX
   Gao, PY
AF Yuan, Jing
   Qu, Jianxun
   Zhang, Dong
   Liu, Xingju
   Li, Jiaxi
   Wu, Chunxue
   Gao, Peiyi
TI Cerebral Perfusion Territory Changes After Direct Revascularization
   Surgery in Moyamoya Disease: A Territory Arterial Spin Labeling Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Computed tomography angiography; Magnetic resonance imaging; Moyamoya
   disease; Perfusion imaging; Revascularization; Territory arterial spin
   labeling
AB OBJECTIVE: To use territory arterial spin labeling (T-ASL) in the early postoperative period to evaluate the revascularization area (RA) obtained by superficial temporal artery-to-middle cerebral artery bypass and to evaluate subsequent perfusion territory changes of the major cerebral arteries.
   METHODS: Thirty patients with moyamoya disease treated via unilateral superficial temporal artery-to-middle cerebral artery bypass were included. T-ASL was performed preoperatively and within 1 week postoperatively. The RA was examined by labeling the superficial temporal artery-to-middle cerebral artery bypass postoperatively. Preoperative and postoperative perfusion territories of the bilateral internal carotid arteries, bilateral external carotid arteries, and basilar artery were also examined and compared. Postoperative computed tomography angiography was performed and compared with T-ASL results.
   RESULTS: In 14 of 30 patients (46.7%), T-ASL demonstrated the presence of an RA (RA-positive), whereas 16 patients (53.3%) had no RA (RA-negative). In the RA-positive group, mean volume of the RA was 80.32 +/- 8.13 mL (range, 34.95-142.50 mL). Postoperative perfusion territory changes of the major cerebral arteries differed between the RA-positive group and the RA-negative group. The incidence of preoperative external carotid artery compensation was significantly higher in the RA-negative group than the RA-positive group (F = 0.011, df = 1, P < 0.05). There was good intermodality agreement between T-ASL and computed tomography angiography (kappa = 0.780).
   CONCLUSIONS: T-ASL can demonstrate the RA obtained by direct revascularization and postoperative perfusion territory changes of the major cerebral arteries. T-ASL is a promising technique in postoperative evaluation of patients with moyamoya disease.
C1 [Yuan, Jing; Wu, Chunxue; Gao, Peiyi] Capital Med Univ, Beijing Neurosurg Inst, Beijing Tiantan Hosp, Dept Radiol, Beijing, Peoples R China.
   [Zhang, Dong; Liu, Xingju; Li, Jiaxi] Capital Med Univ, Beijing Neurosurg Inst, Beijing Tiantan Hosp, Dept Neurosurg, Beijing, Peoples R China.
   [Qu, Jianxun] GE Healthcare China, Shanghai, Peoples R China.
RP Gao, PY (reprint author), Capital Med Univ, Beijing Neurosurg Inst, Beijing Tiantan Hosp, Dept Radiol, Beijing, Peoples R China.
EM gaopeiyittyy@163.com
OI Li, Jiaxi/0000-0002-2007-6366
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81371292]; China National Clinical Research Center
   for Neurosurgical Diseases [2015BA112804]
FX This work was supported by the National Natural Science Foundation of
   China (Grant No. 81371292) and the China National Clinical Research
   Center for Neurosurgical Diseases (Grant No. 2015BA112804).
CR Acker G, 2018, STROKE, V49, P476, DOI 10.1161/STROKEAHA.117.018563
   Alsop DC, 2015, MAGN RESON MED, V73, P102, DOI 10.1002/mrm.25197
   Bang JS, 2012, NEUROSURGERY, V70, P625, DOI 10.1227/NEU.0b013e3182333c47
   Bang OY, 2015, STROKE, V46, P3302, DOI 10.1161/STROKEAHA.115.010508
   Cho WS, 2014, STROKE, V45, P3025, DOI 10.1161/STROKEAHA.114.005624
   Hartkamp NS, 2013, NMR BIOMED, V26, P901, DOI 10.1002/nbm.2836
   Hong JM, 2016, NEUROL SCI, V37, P1969, DOI 10.1007/s10072-016-2700-0
   Kitajima M, 2010, JPN J RADIOL, V28, P746, DOI 10.1007/s11604-010-0507-0
   Liebeskind DS, 2003, STROKE, V34, P2279, DOI 10.1161/01.STR.0000086465.41263.06
   Research Committee on the Pathology and Treatment of Spontaneous Occlusion of the Circle of Willis, 2012, Neurol Med Chir (Tokyo), V52, P245
   Robertson RL, 1997, AM J NEURORADIOL, V18, P837
   Saida T, 2012, J COMPUT ASSIST TOMO, V36, P143, DOI 10.1097/RCT.0b013e31824150dd
   Scott RM, 2009, NEW ENGL J MED, V360, P1226, DOI 10.1056/NEJMra0804622
   Storey A, 2017, J NEUROSURG-PEDIATR, V19, P289, DOI 10.3171/2016.9.PEDS16161
   Tian B, 2013, EUR J RADIOL, V82, P2342, DOI 10.1016/j.ejrad.2013.09.006
   Zaharchuk G, 2011, STROKE, V42, P2485, DOI 10.1161/STROKEAHA.111.616466
NR 16
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1128
EP E1136
DI 10.1016/j.wneu.2018.11.002
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100138
PM 30447461
DA 2020-05-12
ER

PT J
AU Zhang, LM
   Li, R
   Zhao, XC
   Wang, ML
   Fu, Y
AF Zhang, Li-Min
   Li, Rui
   Zhao, Xiao-Chun
   Wang, Ming-Li
   Fu, Yue
TI The Relationship Between Colloid Transfusion During Surgical
   Decompression Hemicraniectomy Period and Postoperative Pneumonia or
   Long-Term Outcome After Space-Occupying Cerebral Infarction: A
   Retrospective Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Colloid; Modified Rankin Scale; Pneumonia; Space-occupying cerebral
   infarction
ID ARTERY INFARCTION; HYDROXYETHYL STARCH; OLDER PATIENTS; INJURY; EDEMA;
   FLUID; COMPLICATIONS; MANAGEMENT; MORTALITY
AB BACKGROUND: Colloid transfusion during surgical decompressive hemicraniectomy (DHC) to treat space-occupying cerebral infarction induced by middle cerebral artery (MCA) is controversial. A multicenter retrospective study was conducted to determine whether an increased colloid transfusion during surgery is associated with a lower incidence of postoperative pneumonia and better long-term outcomes after space-occupying cerebral infarction.
   METHODS: Data from surgical DHC within 48 hours to treat space-occupying cerebral infarction that took place between November 30, 2013, and March 30, 2016, were collected in a multicenter chart. Univariate analysis, Spearman correlation, chi(2) test, and bivariate and multivariate logistic regression were performed to account for the associations between colloid transfusion and post-operative pneumonia or long-term outcomes (indicated by modified Rankin Scale [mRS] scores).
   RESULTS: Univariate analysis showed that surgical duration and mRS were significantly different between the subjects older and younger than 60 years who underwent surgical DHC (P < 0.05). In the entire population studied, increased National Institutes of Health Stroke Scale was associated with a greater incidence of postoperative pneumonia (odds ratio [OR] 1.255, P = 0.003) and increased mRS (OR 1.229, P = 0.014). In the population older than 60 years, it was revealed that increased colloid transfusion was associated with a lower incidence of postoperative pneumonia (OR 0.761, P = 0.030) or better outcomes, as indicated with lower mRS (OR 0.837, P = 0.045).
   CONCLUSIONS: Our retrospective study demonstrated that there is a robust association between increased perioperative colloid transfusion and lower incidence of postoperative pneumonia and better outcomes among the patients older than 60 years after space-occupying cerebral infarction.
C1 [Zhang, Li-Min; Li, Rui] Cangzhou Cent Hosp, Dept Anesthesiol, Cangzhou, Peoples R China.
   [Zhao, Xiao-Chun] Shengjing Hosp, Dept Anesthesiol, Shenyang, Liaoning, Peoples R China.
   [Wang, Ming-Li] Cangzhou Peoples Hosp, Dept Anesthesiol, Cangzhou, Peoples R China.
   [Fu, Yue] Cangzhou Second Peoples Hosp, Dept Anesthesiol, Cangzhou, Peoples R China.
RP Zhang, LM (reprint author), Cangzhou Cent Hosp, Dept Anesthesiol, Cangzhou, Peoples R China.
EM azai2010@126.com
FU Programs of Science and Technology Commission Foundation of Hebei
   Province [172777117]
FX Funded by the Programs of Science and Technology Commission Foundation
   of Hebei Province (NO. 172777117).
CR Albrecht NA, 2016, BMC VET RES, V12, DOI 10.1186/s12917-016-0767-8
   Arac A, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0958
   Arslantas MK, 2015, J THORAC CARDIOV SUR, V149, P314, DOI 10.1016/j.jtcvs.2014.08.071
   Berrouschot J, 1998, INTENS CARE MED, V24, P620, DOI 10.1007/s001340050625
   Bruening T, 2015, J STROKE CEREBROVASC, V24, P1724, DOI 10.1016/j.jstrokecerebrovasdis.2015.03.045
   Critchley LAH, 2000, INTENS CARE MED, V26, P679, DOI 10.1007/s001340051232
   Dalfino L, 2011, CRIT CARE, V15, DOI 10.1186/cc10284
   Dasenbrock HH, 2016, NEUROCRIT CARE, V25, P1
   Datar S, 2018, NEUROCRIT CARE, V4, P1
   Dessap AM, 2014, CHEST, V146, P58, DOI 10.1378/chest.13-2564
   Diaper John, 2008, J Clin Monit Comput, V22, P367, DOI 10.1007/s10877-008-9144-x
   Dinevski N, 2017, WORLD NEUROSURG, V103, P275, DOI 10.1016/j.wneu.2017.03.093
   Ducci DP, 2017, NEUROLOG RES, V40, P1
   Frank JI, 2014, STROKE, V45, P781, DOI 10.1161/STROKEAHA.113.003200
   Hofmeijer J, 2009, LANCET NEUROL, V8, P326, DOI 10.1016/S1474-4422(09)70047-X
   Honeybul S, 2015, STROKE, V46, P2695, DOI 10.1161/STROKEAHA.115.010078
   Juttler E, 2014, NEW ENGL J MED, V370, P1091, DOI 10.1056/NEJMoa1311367
   Kim BD, 2014, SPINE, V39, P510, DOI 10.1097/BRS.0000000000000163
   Kim H, 2015, J CLIN NEUROSCI, V22, P554, DOI 10.1016/j.jocn.2014.08.021
   Leberle R, 2015, INJURY, V46, P105, DOI 10.1016/j.injury.2014.08.039
   Lindroos AC, 2014, J ANESTH, V28, P189, DOI 10.1007/s00540-013-1711-8
   Momeni M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186403
   Montravers P, 2002, CRIT CARE MED, V30, P368, DOI 10.1097/00003246-200202000-00017
   Nerva JD, 2015, WORLD NEUROSURG, V83, P397, DOI 10.1016/j.wneu.2015.01.007
   Nilsson CU, 2016, PERIOPER MED, V5, DOI 10.1186/s13741-016-0046-z
   Park J, 2016, WORLD NEUROSURG, V93, P104, DOI 10.1016/j.wneu.2016.05.079
   Payen D, 2011, ANESTH ANALG, V112, P17, DOI 10.1213/ANE.0b013e31820324f3
   Pranesh MB, 2003, J NEUROL NEUROSUR PS, V74, P800, DOI 10.1136/jnnp.74.6.800
   Qin C, 2015, INT J SURG, V20, P107, DOI 10.1016/j.ijsu.2015.05.051
   Robinson JS, 2010, WORLD NEUROSURG, V74, P294, DOI 10.1016/j.wneu.2010.02.059
   Sedy J, 2008, PHYSIOL RES, V57, P499
   Tan PG, 2011, EMERG MED AUSTRALAS, V23, P665, DOI 10.1111/j.1742-6723.2011.01455.x
   Vlachou E, 2010, BURNS, V36, P984, DOI 10.1016/j.burns.2010.04.001
   Walid M Sami, 2011, J Vasc Interv Neurol, V4, P29
   Walz B, 2002, J NEUROL, V249, P1183, DOI 10.1007/s00415-002-0798-x
   Zhang LM, 2018, SHOCK, V50, P421, DOI 10.1097/SHK.0000000000001095
   Zhang LM, 2017, WORLD NEUROSURG, V104, P381, DOI 10.1016/j.wneu.2017.04.140
   Zhang LM, 2017, WORLD NEUROSURG, V98, P140, DOI 10.1016/j.wneu.2016.10.115
NR 38
TC 0
Z9 1
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1312
EP E1320
DI 10.1016/j.wneu.2018.11.041
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100160
PM 30448584
DA 2020-05-12
ER

PT J
AU Zhang, P
   Selim, MH
   Wang, HY
   Kuang, W
   Wu, MJ
   Ji, CX
   Hu, GW
   Wu, L
   Zhu, XG
   Guo, H
AF Zhang, Pei
   Selim, M. Helmy
   Wang, Haiyan
   Kuang, Wei
   Wu, Miaojing
   Ji, Chenxing
   Hu, Guowen
   Wu, Lei
   Zhu, Xingen
   Guo, Hua
TI Intraoperative Measuring of the Offending Vessel's Pressure on the
   Facial Nerve at Root Exit Zone in Patients with Hemifacial Spasm During
   Microvascular Decompression: A Prospective Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cohen scores; Functional neurosurgery; Hemifacial spasm; Microvascular
   decompression; Neurovascular compression; REZ
ID QUALITY-OF-LIFE; CHRONIC ELECTRICAL-STIMULATION; NEUROVASCULAR
   COMPRESSION; VASCULAR COMPRESSION; TRIGEMINAL NEURALGIA; HYPERACTIVITY;
   IMPROVEMENT; SURGERY; SAFETY
AB OBJECTIVE: The compression of the offending vessel on the facial nerve at root exit zone is considered as the leading cause of hemifacial spasm (HFS). However, the correlation between the severity of spasm and the pressure of neurovascular compression (NVC) has not yet been investigated. The aim of this study was to investigate the clinical correlation between the severity of HFS and the pressure of NVC.
   METHODS: A prospective study was performed, which included 52 of 151 patients who underwent microvascular decompression. We classified the preoperative spasm severity according to the Cohen scores. Codman intracranial pressure monitoring system was used to measure the NVC pressure at the root exit zone during microvascular decompression. All patients were followed up for 12-24 months.
   RESULTS: Herein, the intraoperative pressure readings of NVC were in the range of 21-63 mmHg. The means of the pressure of NVC that corresponded to the Cohen scores (1-4) were 23.00 +/- 1.83, 34.91 +/- 12.42, 46.50 +/- 9.40, and 55.40 +/- 3.03 mmHg, respectively. The Spearman's rank correlation established a strong positive correlation between the pressure and the Cohen scores (r = 0.689, P < 0.0001). The simple linear analysis indicated that sex (P = 0.132), duration (P = 0.304), and delayed relief (P = 0.158) were not significantly associated with the pressure. However, a substantial correlation was determined between the pressure values and the time until the complete recovery (r = 0.949, P < 0.0001) of the delayed healing population.
   CONCLUSIONS: The severity of HFS exhibited a strong positive correlation with the intraoperative offending vessel's pressure values. Thus, the neurovascular pressure is a significant factor in the pathogenesis of HFS.
C1 [Zhang, Pei; Kuang, Wei; Wu, Miaojing; Ji, Chenxing; Hu, Guowen; Wu, Lei; Zhu, Xingen; Guo, Hua] Nanchang Univ, Affiliated Hosp 2, Dept Neurosurg, Nanchang, Jiangxi, Peoples R China.
   [Selim, M. Helmy] Nanchang Univ, Nanchang, Jiangxi, Peoples R China.
   [Wang, Haiyan] Nanchang Univ, Affiliated Hosp 2, Dept Operat, Nanchang, Jiangxi, Peoples R China.
RP Wu, L; Zhu, XG; Guo, H (reprint author), Nanchang Univ, Affiliated Hosp 2, Dept Neurosurg, Nanchang, Jiangxi, Peoples R China.
EM doctorleiming@163.com; zxg2008vip@163.com; 750758089@qq.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81560411]; Technical Projection Foundation of the
   Second Affiliated Hospital of Nanchang University [2014YNLC12015]
FX The study was supported by National Natural Science Foundation of China
   (No.81560411) and Technical Projection Foundation of the Second
   Affiliated Hospital of Nanchang University (2014YNLC12015).
CR Campos-Benitez M, 2008, J NEUROSURG, V109, P416, DOI 10.3171/JNS/2008/109/9/0416
   Cheng J, 2017, WORLD NEUROSURG, V107, P549, DOI 10.1016/j.wneu.2017.08.044
   COHEN DA, 1986, CLIN NEUROPHARMACOL, V9, P415, DOI 10.1097/00002826-198610000-00002
   Deep NL, 2016, J NEUROL SURG PART B, V77, P503, DOI 10.1055/s-0036-1584196
   Goto Y, 2002, NEUROL RES, V24, P296, DOI 10.1179/016164102101199774
   Guclu B, 2011, ACTA NEUROCHIR, V153, P2365, DOI 10.1007/s00701-011-1168-1
   Illingworth RD, 1996, J NEUROL NEUROSUR PS, V60, P72, DOI 10.1136/jnnp.60.1.72
   Jiang CR, 2017, ACTA NEUROCHIR, V159, P259, DOI 10.1007/s00701-016-3006-y
   Kim YG, 2016, ACTA NEUROCHIR, V158, P1397, DOI 10.1007/s00701-016-2822-4
   KUROKI A, 1994, ACTA NEUROCHIR, V126, P149, DOI 10.1007/BF01476426
   KUROKI A, 1994, NEUROL RES, V16, P284
   Li CS, 2005, ACTA NEUROCHIR, V147, P617, DOI 10.1007/s00701-005-0492-8
   Lu Alex Y, 2014, ScientificWorldJournal, V2014, P349319, DOI 10.1155/2014/349319
   McLaughlin MR, 1999, J NEUROSURG, V90, P1, DOI 10.3171/jns.1999.90.1.0001
   Miller LE, 2012, BRIT J NEUROSURG, V26, P438, DOI 10.3109/02688697.2011.641613
   Montava M, 2016, ACTA OTORHINOLARYNGO, V36, P220, DOI 10.14639/0392-100X-899
   Niwa Y, 1996, Rinsho Shinkeigaku, V36, P544
   Poungvarin Niphon, 1995, Journal of the Medical Association of Thailand, V78, P281
   Ray DK, 2010, STEREOT FUNCT NEUROS, V88, P383, DOI 10.1159/000319883
   Rudzinska M, 2014, NEUROL NEUROCHIR POL, V48, P383, DOI 10.1016/j.pjnns.2014.09.006
   Rudzinska M, 2012, NEUROL NEUROCHIR POL, V46, P121, DOI 10.5114/ninp.2012.28254
   SAITO S, 1993, NEUROL RES, V15, P225
   Sindou M, 2018, NEUROCHIRURGIE, V64, P106, DOI 10.1016/j.neuchi.2018.01.001
   Suzuki M, 2015, OR SURG OR MED OR PA, V119, P113, DOI 10.1016/j.oooo.2014.09.013
   TASH R, 1991, AM J NEURORADIOL, V12, P839
   Wu YC, 2010, J NEUROL SCI, V298, P61, DOI 10.1016/j.jns.2010.08.017
   Xia L, 2014, J CRANIOFAC SURG, V25, P1413, DOI 10.1097/SCS.0000000000000984
   Yamakami I, 2007, J CLIN NEUROSCI, V14, P459, DOI 10.1016/j.jocn.2006.04.010
   Ziyal Ibrahim M, 2007, Neurosurgery, V60, pE582, DOI 10.1227/01.NEU.0000255367.19228.C4
NR 29
TC 1
Z9 1
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E89
EP E95
DI 10.1016/j.wneu.2018.09.080
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100010
PM 30261393
DA 2020-05-12
ER

PT J
AU Zhang, Y
   Deng, K
   Zhu, HJ
   Lu, L
   Pan, H
   Ma, WB
   Wang, RZ
   Yao, Y
AF Zhang, Yi
   Deng, Kan
   Zhu, Huijuan
   Lu, Lin
   Pan, Hui
   Ma, Wenbin
   Wang, Renzhi
   Yao, Yong
TI Delays in Diagnosis of Pediatric Histologically Confirmed Sellar Germ
   Cell Tumors in China: A Retrospective Risk Factor Analysis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Delayed diagnosis; Histological confirmation; Pediatric sellar germ cell
   tumors; Risk factors
ID CENTRAL DIABETES-INSIPIDUS; PITUITARY-STALK LESIONS; BRAIN-TUMORS;
   LONG-TERM; INTRACRANIAL GERMINOMA; SYMPTOM ONSET; YOUNG-ADULTS;
   CHILDREN; CHILDHOOD; CANCER
AB BACKGROUND: Sellar germ cell tumors (GCTs) occur more frequently in childhood. Some will present as malignancy with infiltration and metastasis. However, the association between the timeliness of diagnosis and outcome has been controversial. We investigated the clinical risk factors associated with a diagnostic delay in patients with sellar GCTs in China.
   METHODS: The data from 53 patients aged <18 years with histologically confirmed sellar GCTs at Peking Union Medical College Hospital treated from January 2008 to December 2016 were reviewed retrospectively.
   RESULTS: The median interval between symptom onset and diagnosis was 25 months. Of the 53 patients, 44 (83%) had a delayed diagnosis. Most patients (86%) with a delayed diagnosis presented with polyuria or polydipsia. Of the 53 patients, 48 (91%) exhibited changes in the pituitary stalk. Patients with a germinoma (odds ratio, 4.1; 95% confidence interval, 2.4-6.9) and slow growth (odds ratio, 5.3; 95% confidence interval, 1.2-24.5) were more likely to have a delayed diagnosis. The overwhelming majority of patients with a delayed diagnosis (96%) had been seen by >1 doctor. No statistically significant differences were found in the mean survival time (P = 0.21) or mean progression-free survival time (P = 0.36) between patients with and without delay in diagnosis, respectively.
   CONCLUSIONS: A significant proportion of patients with sellar GCTs will experience a delay in the time to diagnosis. Although a delay in diagnosis did not reduce the survival time or progression-free survival time for patients with sellar GCTs, it might increase the risk of short stature. Thus, a detailed medical history and an immediate radiological examination are important for the early diagnosis of sellar GCTs in childhood.
C1 [Zhang, Yi; Deng, Kan; Ma, Wenbin; Wang, Renzhi; Yao, Yong] Peking Union Med Coll Hosp, Dept Neurosurg, Beijing, Peoples R China.
   [Zhu, Huijuan; Lu, Lin; Pan, Hui] Peking Union Med Coll Hosp, Dept Endocrinol, Beijing, Peoples R China.
RP Yao, Y (reprint author), Peking Union Med Coll Hosp, Dept Neurosurg, Beijing, Peoples R China.
EM tigerfreeyy@126.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81372414]; Leading Synergic Innovative Project of
   Chinese Academy of Medical Sciences [2016-I2M-1-002]
FX The present study was supported by the National Natural Science
   Foundation of China (grant 81372414) and Leading Synergic Innovative
   Project of Chinese Academy of Medical Sciences (grant 2016-I2M-1-002).
CR Brasme JF, 2012, LANCET ONCOL, V13, pE445, DOI 10.1016/S1470-2045(12)70361-3
   Catford S, 2016, CLIN ENDOCRINOL, V85, P507, DOI 10.1111/cen.13058
   Cho KT, 2002, CHILD NERV SYST, V18, P30, DOI 10.1007/s00381-001-0547-y
   Chovanec M, 2018, ADV UROL, V2018, DOI 10.1155/2018/3718165
   Crawford JR, 2007, NEUROLOGY, V68, P1668, DOI 10.1212/01.wnl.0000261908.36803.ac
   De Buyst J, 2007, EUR J PEDIATR, V166, P43, DOI 10.1007/s00431-006-0206-0
   DEARNALEY DP, 1990, INT J RADIAT ONCOL, V18, P773, DOI 10.1016/0360-3016(90)90396-2
   Di Iorgi N, 2014, J CLIN ENDOCR METAB, V99, P1264, DOI 10.1210/jc.2013-3724
   Dobrovoljac M, 2002, EUR J PEDIATR, V161, P663, DOI 10.1007/s00431-002-1088-4
   Dorner L, 2007, CHILD NERV SYST, V23, P887, DOI 10.1007/s00381-007-0323-8
   Edgeworth J, 1996, ARCH DIS CHILD, V74, P148, DOI 10.1136/adc.74.2.148
   FLORES LE, 1986, AM J DIS CHILD, V140, P684, DOI 10.1001/archpedi.1986.02140210082031
   Furtado SV, 2012, NEUROL INDIA, V60, P90, DOI 10.4103/0028-3886.93611
   GJERRIS F, 1978, ACTA NEUROL SCAND, V57, P445
   Haimi M, 2004, PEDIATR HEMAT ONCOL, V21, P37, DOI 10.1080/08880010490263579
   Hardenbergh PH, 1997, INT J RADIAT ONCOL, V39, P419, DOI 10.1016/S0360-3016(97)00330-1
   Hargrave D, 2009, BRIT J NEUROSURG, V23, P351, DOI 10.1080/02688690903158809
   JAMES HE, 1985, CANCER, V56, P1800, DOI 10.1002/1097-0142(19851001)56:7+<1800::AID-CNCR2820561315>3.0.CO;2-K
   JENNINGS MT, 1985, J NEUROSURG, V63, P155, DOI 10.3171/jns.1985.63.2.0155
   Ji JG, 2018, INT J CANCER, V143, P591, DOI 10.1002/ijc.31340
   Jian FF, 2014, ENDOCRINE, V47, P325, DOI 10.1007/s12020-014-0184-3
   Kyritsis AP, 2010, J NEURO-ONCOL, V96, P143, DOI 10.1007/s11060-009-9951-z
   Maghnie M, 2000, NEW ENGL J MED, V343, P998, DOI 10.1056/NEJM200010053431403
   Maghnie M, 2006, CLIN ENDOCRINOL, V65, P470, DOI 10.1111/j.1365-2265.2006.02616.x
   Marinoff AE, 2017, J NEURO-ONCOL, V135, P201, DOI 10.1007/s11060-017-2568-8
   Matsutani M, 2001, J NEURO-ONCOL, V54, P311, DOI 10.1023/A:1012743707883
   Mehta V, 2002, NEUROSURGERY, V51, P365, DOI 10.1227/01.NEU.0000019779.27789.AC
   Mootha SL, 1997, J CLIN ENDOCR METAB, V82, P1362, DOI 10.1210/jc.82.5.1362
   Murray MJ, 2015, LANCET ONCOL, V16, pE470, DOI 10.1016/S1470-2045(15)00244-2
   Neglia JP, 2001, J NATL CANCER I, V93, P618, DOI 10.1093/jnci/93.8.618
   Ostrom QT, 2015, NEUROONCOL S4
   Phi JH, 2013, CHILD NERV SYST, V29, P1871, DOI 10.1007/s00381-013-2164-y
   Reulecke BC, 2008, J CHILD NEUROL, V23, P178, DOI 10.1177/0883073807308692
   Sethi RV, 2013, J PEDIATR-US, V163, P1448, DOI 10.1016/j.jpeds.2013.06.024
   Shay V, 2012, CHILD NERV SYST, V28, P93, DOI 10.1007/s00381-011-1564-0
   Shin JH, 2001, KOREAN J RADIOL, V2, P222, DOI 10.3348/kjr.2001.2.4.222
   Turcu AF, 2013, J CLIN ENDOCR METAB, V98, P1812, DOI 10.1210/jc.2012-4171
   Wisoff JH, 1998, J NEUROSURG, V89, P52, DOI 10.3171/jns.1998.89.1.0052
   Wong TT, 2005, CANCER, V104, P2156, DOI 10.1002/cncr.21430
   Zeltzer PM, 1999, J CLIN ONCOL, V17, P832, DOI 10.1200/JCO.1999.17.3.832
NR 40
TC 2
Z9 2
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E472
EP E479
DI 10.1016/j.wneu.2018.10.082
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100057
PM 30366141
DA 2020-05-12
ER

PT J
AU Zhang, YQ
   Wang, JW
   Wang, YP
   Zhang, XH
   Li, JP
AF Zhang, Yu-Qing
   Wang, Jia-Wei
   Wang, Yun-Peng
   Zhang, Xiao-Hua
   Li, Ji-Ping
TI Thalamus Stimulation for Myoclonus Dystonia Syndrome: Five Cases and
   Long-Term Follow-up
SO WORLD NEUROSURGERY
LA English
DT Article
DE Deep brain stimulation; Myoclonic dystonia syndrome; Ventral
   intermediate nucleus
ID DEEP-BRAIN-STIMULATION; GLOBUS-PALLIDUS; PATIENT; NUCLEUS
AB BACKGROUND: Myoclonic dystonia syndrome (MDS) is a rare inherited movement disorder characterized by the coexistence of myoclonic jerks and dystonia. Deep brain stimulation (DBS) is a promising treatment for patients with MDS that targets the globus pallidus internus or ventral intermediate nucleus (Vim) of the thalamus. However, there are few studies regarding the long-term effects of Vim DBS in patients with MDS and even fewer in those without gene mutations.
   METHODS: Two positive and three negative SGCE mutation patients presenting with predominant myoclonus underwent Vim DBS. The Unified Myoclonus Rating Scale and the Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS) were assessed pre- and postoperation.
   RESULTS: Over an average follow-up period of 50 months, the myoclonus improvement rate was 92.7%. The average improvement in the BFMDRS motor score was 71.4% and the average improvement in the BFMDRS disabling score was 75.8%.
   CONCLUSIONS: This study suggests that Vim DBS can be a safe and effective treatment option for patients with MDS. Vim DBS alone may be preferable for patients with myoclonus-dominated MDS regardless of the identification of an SGCE mutation. Additional globus pallidus internus DBS may be used for progressive dystonia after Vim DBS.
C1 [Zhang, Yu-Qing; Wang, Yun-Peng; Zhang, Xiao-Hua; Li, Ji-Ping] Capital Med Univ, Xuanwu Hosp, Dept Funct Neurosurg, Beijing, Peoples R China.
   [Wang, Jia-Wei] Chinese Acad Med Sci, Canc Hosp, Dept Neurosurg, Beijing, Peoples R China.
   [Wang, Jia-Wei] Peking Union Med Coll, Beijing, Peoples R China.
RP Li, JP (reprint author), Capital Med Univ, Xuanwu Hosp, Dept Funct Neurosurg, Beijing, Peoples R China.
EM yhljp89@163.com
FU Project of Citizen Healthy,Beijing Science and Technology Commission
   [Z161100000116059]
FX This work was supported by the Project of Citizen Healthy,Beijing
   Science and Technology Commission (Grant Z161100000116059). The authors
   declare that the article content was composed in the absence of any
   commercial or financial relationships that could be construed as a
   potential conflict of interest.
CR Asahi T, 2014, STEREOT FUNCT NEUROS, V92, P405, DOI 10.1159/000366004
   Azoulay-Zyss J, 2011, ARCH NEUROL-CHICAGO, V68, P94, DOI 10.1001/archneurol.2010.338
   Beukers R J, 2012, Front Neurol, V3, P22, DOI 10.3389/fneur.2012.00022
   Contarino MF, 2011, ARCH NEUROL-CHICAGO, V68, P1087, DOI 10.1001/archneurol.2011.180
   Fernandez-Pajarin G, 2016, ACTA NEUROCHIR, V158, P2023, DOI 10.1007/s00701-016-2904-3
   Foncke EMJ, 2007, MOVEMENT DISORD, V22, P369, DOI 10.1002/mds.21284
   Fukaya C, 2007, J NEUROSURG, V107, P977, DOI 10.3171/JNS-07/11/0977
   Ghika J, 2002, NEUROLOGY, V58, P311, DOI 10.1212/WNL.58.2.311
   Gruber D, 2010, MOVEMENT DISORD, V25, P1733, DOI 10.1002/mds.23312
   Grunewald A, 2008, HUM MUTAT, V29, P331, DOI 10.1002/humu.9521
   Guo CJ, 2015, TRANSL NEUROSCI, V6, P271, DOI 10.1515/tnsci-2015-0030
   Hedera P, 2013, PARKINSONISM RELAT D, V19, P684, DOI 10.1016/j.parkreldis.2013.03.010
   Jog M, 2009, MOVEMENT DISORD, V24, P1547, DOI 10.1002/mds.22551
   Kim JH, 2014, NEUROMODULATION, V17, P724, DOI 10.1111/ner.12162
   Kinugawa K, 2009, MOVEMENT DISORD, V24, P479, DOI 10.1002/mds.22425
   Kuhn AA, 2014, J CHILD NEUROL, V29, pNP149, DOI 10.1177/0883073813513071
   Kuncel AM, 2009, CLIN NEUROL NEUROSUR, V111, P303, DOI 10.1016/j.clineuro.2008.10.015
   Kurtis MM, 2010, CLIN NEUROL NEUROSUR, V112, P149, DOI 10.1016/j.clineuro.2009.10.001
   Liu XG, 2002, MOVEMENT DISORD, V17, P346, DOI 10.1002/mds.10038
   Long LL, 2015, NEUROPSYCH DIS TREAT, V11, P485, DOI 10.2147/NDT.S77910
   Magarinos-Ascone CM, 2005, J NEUROL NEUROSUR PS, V76, P989, DOI 10.1136/jnnp.2004.039248
   Multani N, 2016, NEUROCASE, V22, P215, DOI 10.1080/13554794.2015.1120312
   Mure H, 2014, STEREOT FUNCT NEUROS, V92, P393, DOI 10.1159/000365577
   Nardocci N, 2007, MOVEMENT DISORD, V23, P28
   Oropilla JQL, 2010, J NEUROSURG, V112, P1267, DOI 10.3171/2009.10.JNS091062
   Papuc E, 2014, MOVEMENT DISORD, V29, pE3, DOI 10.1002/mds.23783
   Rocha H, 2016, J CLIN NEUROSCI, V27, P17, DOI 10.1016/j.jocn.2015.08.034
   Roze E, 2015, MOVEMENT DISORD, V30, P871, DOI 10.1002/mds.26215
   Rughani AI, 2013, MOVEMENT DISORD, V28, P282, DOI 10.1002/mds.25326
   Sidiropoulos C, 2014, PARKINSONISM RELAT D, V20, P915, DOI 10.1016/j.parkreldis.2014.04.017
   Taira T, 2003, STEREOT FUNCT NEUROS, V80, P88, DOI 10.1159/000075165
   Trottenberg T, 2001, MOVEMENT DISORD, V16, P769, DOI 10.1002/mds.1119
   Uruha A, 2014, CASE REP NEUROL MED, DOI 10.1155/2014/937095
   Vercueil L, 2001, J NEUROL, V248, P695, DOI 10.1007/s004150170116
   Wang SY, 2006, J NEUROSURG, V105, P21, DOI 10.3171/jns.2006.105.1.21
   Yianni J, 2003, MOVEMENT DISORD, V18, P436, DOI 10.1002/mds.10380
NR 36
TC 1
Z9 2
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E933
EP E939
DI 10.1016/j.wneu.2018.10.177
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100112
PM 30419400
DA 2020-05-12
ER

PT J
AU Zhao, F
   Zhang, S
   Du, J
   Chen, Y
   Wang, B
   Zhang, J
   He, QY
   Lin, L
   Zhang, L
   Yu, YB
   Liu, PA
AF Zhao, Fu
   Zhang, Shun
   Du, Jiang
   Chen, Yang
   Wang, Bo
   Zhang, Jing
   He, Qiyang
   Lin, Luo
   Zhang, Li
   Yu, Yanbing
   Liu, Pinan
TI Comparison of Clinical, Histopathological, and Genomic Features Between
   Malignant Peripheral Nerve Sheath Tumors and Cellular Schwannomas of the
   Eighth Cranial Nerve: A Case Series
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cellular schwannoma; Copy number variation; Cranial nerve;
   Histopathology; Malignant peripheral nerve sheath tumor
ID PROLIFERATION; DIAGNOSIS; SURVIVAL; BENIGN; NF1
AB BACKGROUND: Malignant peripheral nerve sheath tumors (MPNSTs) and cellular schwannomas (CSs) of the eighth cranial nerve are exceedingly rare. The purpose of the present study was to evaluate clinical and genetic characterization of these rare tumors.
   METHODS: The clinical and radiological features were analyzed retrospectively. The histopathological characteristics were assessed by hematoxylin and eosin staining and immunohistochemistry. Genomic abnormalities were evaluated using array comparative genomic hybridization.
   RESULTS: Of the 1287 surgeries for vestibular schwannomas from 2014 to 2017, 2 were for MPNSTs and 5 were for CSs. The mean age at diagnosis was older for patients with MPNSTs (57.0 +/- 4.2 years) than that of patients with CS (35.8 +/- 9.4 years; P = 0.03). Two patients with MPNST died of tumor recurrence. None of the patients with CS died. The 2-year overall and progression-free survival of patients with MPNSTs were worse than those for patients with CSs (overall survival, 50.0% +/- 35.4% vs. 100%, P = 0.027; progression-free survival, 0% vs. 100%; P = 0.012). The Ki67 index for the MPNSTs (29.0% +/- 3.5%) was greater than that for the CSs (10.3% +/- 3.1%; P = 0.001). The common alterations in MPNSTs mainly included gains of chromosomes 7p, 8p, 9q, 12, and 17 and loss of heterozygosity of 1p, 6 and 9p. The common alterations in CSs included gain of 4p16.3, loss of heterozygosity of 2p15-14, and 22q11.1-13.3.
   CONCLUSIONS: To the best of our knowledge, the present study is the first high-resolution genomic analysis of MPNSTs and CSs of the eighth cranial nerve and has shown a significant difference that might be more accurate to distinguish between these 2 types of rare tumors.
C1 [Zhao, Fu; Zhang, Li; Yu, Yanbing; Liu, Pinan] Capital Med Univ, Beijing Neurosurg Inst, Neural Reconstruct Dept, Beijing, Peoples R China.
   [Zhao, Fu; Zhang, Shun; Liu, Pinan] Capital Med Univ, Beijing Tian Tan Hosp, Dept Neurosurg, Beijing, Peoples R China.
   [Du, Jiang; Lin, Luo] Capital Med Univ, Beijing Neurosurg Inst, Dept Pathol, Beijing, Peoples R China.
   [Zhao, Fu; Wang, Bo; Zhang, Jing] Peking Univ, China Japan Friendship Sch Clin Med, Neurosurg Dept, Beijing, Peoples R China.
   [Chen, Yang; He, Qiyang] Peking Union Med Coll, Inst Med Biotechnol, Beijing, Peoples R China.
   [Chen, Yang; He, Qiyang] Chinese Acad Med Sci, Beijing, Peoples R China.
RP Liu, PA (reprint author), Capital Med Univ, Beijing Neurosurg Inst, Neural Reconstruct Dept, Beijing, Peoples R China.; Liu, PA (reprint author), Capital Med Univ, Beijing Tian Tan Hosp, Dept Neurosurg, Beijing, Peoples R China.
EM pinanliu@ccmu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81372715, 8150110473, 61671187]; Beijing Natural
   Science FoundationBeijing Natural Science Foundation [7162057]
FX This work was supported by the National Natural Science Foundation of
   China (grants 81372715, 8150110473, and 61671187 to PL.) and Beijing
   Natural Science Foundation (grant 7162057 to PL.).
CR Anghileri M, 2006, CANCER-AM CANCER SOC, V107, P1065, DOI 10.1002/cncr.22098
   Carlson ML, 2016, J NEUROSURG, V125, P1120, DOI 10.3171/2015.7.JNS151056
   CASADEI GP, 1995, CANCER, V75, P1109, DOI 10.1002/1097-0142(19950301)75:5<1109::AID-CNCR2820750510>3.0.CO;2-M
   Chen L, 2008, NEUROSURGERY, V62, P825, DOI 10.1227/01.neu.0000318167.97966.f3
   Cichowski K, 2001, CELL, V104, P593, DOI 10.1016/S0092-8674(01)00245-8
   Endo M, 2013, CLIN CANCER RES, V19, P450, DOI 10.1158/1078-0432.CCR-12-1067
   Ferner RE, 2002, CANCER RES, V62, P1573
   Foster JM, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920-015-0079-z
   Gousias K, 2010, RADIAT ONCOL, V5, DOI 10.1186/1748-717X-5-114
   Guerrant W, 2016, CANCER RES, V76, P3507, DOI 10.1158/0008-5472.CAN-15-1144
   Hanabusa K, 2001, J NEUROSURG, V95, P518, DOI 10.3171/jns.2001.95.3.0518
   Hunter SM, 2011, CLIN CANCER RES, V17, P7273, DOI 10.1158/1078-0432.CCR-11-2080
   Khu KJ, 2016, WORLD NEUROSURG, V94, P566, DOI 10.1016/j.wneu.2016.07.054
   Ki DH, 2017, ONCOGENE, V36, P1058, DOI 10.1038/onc.2016.269
   King AA, 2000, AM J MED GENET, V93, P388, DOI 10.1002/1096-8628(20000828)93:5<388::AID-AJMG8>3.0.CO;2-#
   L'Heureux-Lebeau B, 2013, ONCOTARGETS THER, V6, P459, DOI 10.2147/OTT.S41397
   Mantripragada KK, 2008, CLIN CANCER RES, V14, P1015, DOI 10.1158/1078-0432.CCR-07-1305
   Pekmezci M, 2015, MODERN PATHOL, V28, P187, DOI 10.1038/modpathol.2014.109
   Ren XH, 2013, J NEUROSURG, V119, P695, DOI 10.3171/2013.5.JNS122119
   Rodriguez FJ, 2012, ACTA NEUROPATHOL, V123, P295, DOI 10.1007/s00401-012-0954-z
   Rohrich M, 2016, ACTA NEUROPATHOL, V131, P877, DOI 10.1007/s00401-016-1540-6
   Scheithauer BW, 2009, AM J SURG PATHOL, V33, P325, DOI 10.1097/PAS.0b013e31818d6470
   Stucky CCH, 2012, ANN SURG ONCOL, V19, P878, DOI 10.1245/s10434-011-1978-7
   van den Munckhof P, 2011, NEUROSURGERY, V68, pE1152, DOI 10.1227/NEU.0b013e31820a1599
   Warren C, 2003, J MED GENET, V40, P802, DOI 10.1136/jmg.40.11.802
   WHITE W, 1990, CANCER, V66, P1266, DOI 10.1002/1097-0142(19900915)66:6<1266::AID-CNCR2820660628>3.0.CO;2-E
   Wu LMN, 2018, CANCER CELL, V33, P292, DOI 10.1016/j.ccell.2018.01.005
   Yamanaka R, 2017, WORLD NEUROSURG, V105, P961, DOI 10.1016/j.wneu.2017.06.010
   Yang JL, 2011, CLIN CANCER RES, V17, P7563, DOI 10.1158/1078-0432.CCR-11-1707
   Yu JS, 2011, CLIN CANCER RES, V17, P1924, DOI 10.1158/1078-0432.CCR-10-1551
   Zhao F, 2018, WORLD NEUROSURG, V117, pE269, DOI 10.1016/j.wneu.2018.06.010
NR 31
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E487
EP E497
DI 10.1016/j.wneu.2018.10.087
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100059
PM 30366145
DA 2020-05-12
ER

PT J
AU Zhao, QP
   Yin, CY
   Yuan, Y
   Zhang, HT
   Teng, L
AF Zhao, Qingping
   Yin, Changyou
   Yuan, Yuan
   Zhang, Hongtao
   Teng, Lu
TI Down-Regulation of Mir-145 Improves Learning and Memory Abilities in
   Epileptic Rats by Regulating Hippocampal Neuron Apoptosis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Apoptosis; Caspase-9; Epilepsy; Learning and memory abilities; miR-45
ID CASPASE-9
AB OBJECTIVES: To investigate effect of miR-145 on learning and memory ability in rats with epilepsy.
   METHODS: Rats with epilepsy were induced by lithium chloride-pilocarpine. miR-145 antagomir and antagomir-control were injected into epileptic brains by the stereotactic technique, respectively. Then, rats were divided into a normal group (N), epilepsy group (Ep), miR-145 antagomir group (A) and antagomir-control group (C). After 1 and 7 days of treatment, the expression of miR-145 and Caspase-9 were detected, and the apoptosis of hippocampal neurons in CA1 of hippocampus was detected. After 7 days of treatment, the learning and memory abilities of rats was measured by using the Morris water maze test.
   RESULTS: The rat epilepsy model was successfully constructed. Compared with the N group, the target quadrant time and platform crossing times were reduced and the expression of miR-145 and Caspase-9 was increased in the epilepsy groups (P < 0.05). Compared with the Ep and C groups, the target quadrant time and platform crossing times were increased and the expression of miR-145 and Caspase-9 was down-regulated in the A group (P < 0.05). The number of apoptotic hippocampal neurons in the hippocampal CAl area of the Ep group was more than that in the N group and in the A group was less than that in the C group at 1 and 7 days after modeling respectively (P < 0.05).
   CONCLUSIONS: Down-regulated miR-145 improved the apoptosis of hippocampal neurons by reducing the Caspase-9 expression in hippocampus and further affected learning and memory abilities of rats with epilepsy.
C1 [Zhao, Qingping; Yin, Changyou; Yuan, Yuan; Zhang, Hongtao; Teng, Lu] Qingdao Univ, Affiliated Yantai Yuhuangding Hosp, Dept Neurosurg, Yantai, Shandong, Peoples R China.
RP Teng, L (reprint author), Qingdao Univ, Affiliated Yantai Yuhuangding Hosp, Dept Neurosurg, Yantai, Shandong, Peoples R China.
EM tenglu286@163.com
OI Teng, Lu/0000-0002-0780-9895
CR Anton L, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03217-7
   Du Y, 2017, ONCOTARGET, V8, P61510, DOI 10.18632/oncotarget.18604
   Fujikawa DG, 2010, EPILEPSIA, V41, P981
   Gan Y, 2012, PLOS ONE, V7
   Gao FC, 2014, MED RECAPITULATE, V20, P1068
   Hu K, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-115
   Kanno T, 2011, J CELL PHYSIOL, V226, P2329, DOI 10.1002/jcp.22571
   Li SZ, 2016, AM J TRANSL RES, V8, P993
   Liu YJ, 2007, NEUROL RES, V29, P855, DOI 10.1179/016164107X223575
   Ma HM, 2016, MOL MED REP, V13, P4814, DOI 10.3892/mmr.2016.5132
   Ma J, 2016, AM J TRANSL RES, V8, P1895
   Matsushita R, 2016, J UROLOGY, V195, pE924, DOI 10.1016/j.juro.2016.02.1484
   McKiernan RC, 2012, EXP NEUROL, V237, P346, DOI 10.1016/j.expneurol.2012.06.029
   Ostenfeld M, 2009, CANC RES, V69
   Pan Y, 2018, ONCOL LETT, V15, P4337, DOI 10.3892/ol.2018.7863
   Qin SD, 2013, CANCER BIOTHER RADIO, V28, P177, DOI 10.1089/cbr.2012.1261
   Ren L, 2016, GENET MOL RES, V15
   Wang Y J, 2017, Beijing Da Xue Xue Bao Yi Xue Ban, V49, P310
   Wei D, 2017, MOL VIS, V23, P385
   Wen X, 2018, J CELL BIOCHEM, V119, P5821, DOI 10.1002/jcb.26769
   WILDER BJ, 1977, ANN NEUROL, V1, P511, DOI 10.1002/ana.410010602
   Yang L, 2014, J MED POSTGRAD, V27, P793
   [杨晓青 Yang Xiaoqing], 2018, [中国实验方剂学杂志, Chinese Journal of Experimental Traditional Medical Formulae], V24, P144
   Yun-Heng HE, 2008, LIAONING J TRADITION, V35, P1600
   Zhang B, 2017, SYNAPSE, V71, DOI 10.1002/syn.21945
   Zheng M, 2016, TUMOR BIOL, V37, P1
   Zhu HY, 2011, MOL CANCER RES, V9, P960, DOI 10.1158/1541-7786.MCR-10-0531
NR 27
TC 0
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1432
EP E1438
DI 10.1016/j.wneu.2018.11.080
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100176
PM 30465949
DA 2020-05-12
ER

PT J
AU Zhao, XC
   Moreira, LB
   Cavallo, C
   Belykh, E
   Gandhi, S
   Labib, MA
   Meybodi, AT
   Mulholland, CB
   Liebelt, BD
   Lee, M
   Nakaji, P
   Preul, MC
AF Zhao, Xiaochun
   Moreira, Leandro Borba
   Cavallo, Claudio
   Belykh, Evgenii
   Gandhi, Sirin
   Labib, Mohamed A.
   Meybodi, Ali Tayebi
   Mulholland, Celene B.
   Liebelt, Brandon D.
   Lee, Michaela
   Nakaji, Peter
   Preul, Mark C.
TI Quantitative Endoscopic Comparison of Contralateral Interhemispheric
   Transprecuneus and Supracerebellar Transtentorial Transcollateral Sulcus
   Approaches to the Atrium
SO WORLD NEUROSURGERY
LA English
DT Article
DE Atrium of lateral ventricle; Endoscopic assistant surgery;
   Transcollateral sulcus approach; Transprecuneus approach
ID LATERAL VENTRICLE; TEMPORAL-LOBE; ANATOMICAL ANALYSIS; OPTIC RADIATIONS;
   BRIDGING VEINS; TRIGONE; SURGERY; REGION
AB OBJECTIVE: The contralateral interhemispheric transprecuneus approach (CITP) and the supracerebellar transtentorial transcollateral sulcus approach (STTC) are 2 novel approaches to access the atrium of the lateral ventricle. We quantitatively compared the 2 approaches.
   METHODS: Both approaches were performed in 6 sides of fixed and color-injected cadaver heads. We predefined the 6 targets in the atrium for measurement and standardization of the approaches. Using a navigation system, we quantitatively measured the working distance, cortical transgression, angle of attack, area of exposure, and surgical freedom.
   RESULTS: The distances from the craniotomy edge to the posterior pole of the choroid plexus of the CITP (mean +/- standard deviation, 67 +/- 5.3 mm) and STTC (mean, 57 +/- 4.0 mm) differed significantly (P < 0.01). Cortical transgression with the CITP (mean, 27 +/- 2.8 mm) was significantly greater than that with the STTC (mean, 21 +/- 6.7 mm; P = 0.03). The CITP showed a significantly wider rostrocaudal angle of attack than that with the STTC (P = 0.01). The STTC showed a significantly wider mediolateral angle (P < 0.01). No significant difference was found for surgical freedom of any target except for point E, for which the CITP was larger. The exposure area did not differ significantly between the 2 approaches (P = 0.07).
   CONCLUSIONS: Both approaches were feasible for accessing the atrium. The STTC provided a shorter working distance and wider mediolateral angle, CITP provided a wider rostrocaudal angle of attack and better exposure and maneuverability to the anterior and superior atrium. In contrast, the STTC was more favorable for the inferior and posterior regions.
C1 [Zhao, Xiaochun; Moreira, Leandro Borba; Cavallo, Claudio; Belykh, Evgenii; Gandhi, Sirin; Labib, Mohamed A.; Meybodi, Ali Tayebi; Mulholland, Celene B.; Liebelt, Brandon D.; Lee, Michaela; Nakaji, Peter; Preul, Mark C.] St Josephs Hosp, Barrow Neurol Inst, Dept Neurosurg, Phoenix, AZ 85013 USA.
   [Belykh, Evgenii] Irkutsk State Med Univ, Dept Neurosurg, Irkutsk, Russia.
RP Preul, MC (reprint author), St Josephs Hosp, Barrow Neurol Inst, Dept Neurosurg, Phoenix, AZ 85013 USA.
EM Neuropub@barrowneuro.org
RI Belykh, Evgenii/O-8279-2017
OI Belykh, Evgenii/0000-0003-2060-5739; Liebelt,
   Brandon/0000-0001-8707-9329
FU Newsome Chair in Neurosurgery Research; Barrow Neurological Foundation
FX This study was supported by funds from the Newsome Chair in Neurosurgery
   Research held by Dr. Preul and the Barrow Neurological Foundation. The
   authors thank the staff of Neuroscience Publications at Barrow
   Neurological Institute for assistance with manuscript preparation.
CR BARROW DL, 1994, NEUROSURGERY, V35, P1046, DOI 10.1227/00006123-199412000-00005
   Belykh E, 2018, J NEUROSURG, V128, P1492, DOI 10.3171/2017.1.JNS161338
   Bohnstedt BN, 2015, J NEUROSURG, V123, P1045, DOI 10.3171/2015.3.JNS14847
   Cappabianca P, 2008, NEUROSURGERY S2, V62, P597
   Cappabianca P, 2008, NEUROSURGERY, V62, P575, DOI [10.1227/01.NEU.0000297107.42131.DF, 10.1227/01.neu.0000316262.74843.dd]
   Cappahianea P, 2008, NEUROSURGERY S2, V62, P578
   D'Angelo Vincenzo A, 2005, Neurosurgery, V56, P36
   EBELING U, 1988, ACTA NEUROCHIR, V92, P29, DOI 10.1007/BF01401969
   Erdener T, 1986, NEUROSURGERY, V19, P685
   FLETCHER PC, 1995, NEUROIMAGE, V2, P195, DOI 10.1006/nimg.1995.1025
   Hopf NJ, 1999, MINIM INVAS NEUROSUR, V42, P27, DOI 10.1055/s-2008-1053364
   Huntgeburth SC, 2012, EUR J NEUROSCI, V35, P1295, DOI 10.1111/j.1460-9568.2012.08031.x
   Izci Y, 2009, SURG NEUROL, V72, P509, DOI 10.1016/j.surneu.2009.01.025
   Jeelani Y, 2017, J NEUROSURG, V126, P1246, DOI 10.3171/2016.3.JNS151289
   Kalani MY, 2016, NEUROSURG FOCUS S1, V40
   Kawashima M, 2006, SURG NEUROL, V65, P436, DOI 10.1016/j.surneu.2005.09.033
   KEMPE LG, 1976, ACTA NEUROCHIR, V35, P233, DOI 10.1007/BF01406119
   Lou HC, 2004, P NATL ACAD SCI USA, V101, P6827, DOI 10.1073/pnas.0400049101
   Mahaney KB, 2008, NEUROSURGERY, V63, P195, DOI 10.1227/01.NEU.0000313121.58694.4A
   Marcus HJ, 2013, NEUROSURGERY S, V73
   Marcus HJ, 2013, NEUROSURGERY S, V73
   Mortazavi MM, 2013, CHILD NERV SYST, V29, P1073, DOI 10.1007/s00381-013-2054-3
   Nayar VV, 2010, CLIN NEUROL NEUROSUR, V112, P400, DOI 10.1016/j.clineuro.2010.02.005
   Nayar VV, 2009, J NEUROSURG, V110, P740, DOI 10.3171/2008.6.17606
   Novak K, 2002, J NEUROSURG, V96, P464, DOI 10.3171/jns.2002.96.3.0464
   Park P, 2005, AM J NEURORADIOL, V26, P1475
   Rhoton AL, 2002, NEUROSURGERY, V51, pS1, DOI 10.1227/01.NEU.0000028086.48597.4F
   Sincoff EH, 2004, J NEUROSURG, V101, P739, DOI 10.3171/jns.2004.101.5.0739
   SMITH KA, 1995, J NEUROSURG, V82, P940, DOI 10.3171/jns.1995.82.6.0940
   SPETZLER RF, 1986, J NEUROSURG, V65, P476, DOI 10.3171/jns.1986.65.4.0476
   STRUGAR J, 2000, [No title captured], P837
   Suh D Y, 2001, Neurosurg Focus, V10, pE4, DOI 10.3171/foc.2001.10.6.5
   Sun CJ, 2014, J CLIN NEUROSCI, V21, P1968, DOI 10.1016/j.jocn.2014.03.030
   Tokunaga K, 2006, SURG NEUROL, V65, P167, DOI 10.1016/j.surneu.2005.06.036
   Ueyama T, 1998, NEUROSURGERY, V43, P1137, DOI 10.1097/00006123-199811000-00068
   Araujo JLV, 2017, J NEUROSURG, V127, P209, DOI 10.3171/2016.8.JNS16403
   Wang S, 2010, J NEUROSURG, V113, P949, DOI 10.3171/2010.1.JNS091169
   Xie T, 2017, WORLD NEUROSURG, V105, P805, DOI 10.1016/j.wneu.2017.06.093
   Xie T, 2015, OPER NEUROSURG, V11, P110, DOI 10.1227/NEU.0000000000000643
   Yagmurlu K, 2017, J NEUROSURG, V127, P646, DOI 10.3171/2016.6.JNS16306
   Yasargil MG, 1996, MICRONEUROSURGERY MI
   Yasargil MG, 2008, NEUROSURGERY, V62, DOI DOI 10.1227/01.NEU.0000316427.57165.01
   Zaidi HA, 2015, WORLD NEUROSURG, V84, P257, DOI 10.1016/j.wneu.2015.03.009
NR 43
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E215
EP E225
DI 10.1016/j.wneu.2018.09.214
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100023
PM 30308340
DA 2020-05-12
ER

PT J
AU Zheng, SF
   Zhang, YB
   He, YY
   Shang-Guan, HC
   Kang, DZ
   Chen, GR
   Lin, YX
   Yao, PS
AF Zheng, Shu-Fa
   Zhang, Yi-Bin
   He, Yan-Yan
   Shang-Guan, Huang-Cheng
   Kang, De-Zhi
   Chen, Guo-Rong
   Lin, Yuan-Xiang
   Yao, Pei-Sen
TI Cerebellopontine Angle Tumors Are Associated with a Greater Incidence of
   Unruptured Intracranial Aneurysms
SO WORLD NEUROSURGERY
LA English
DT Article
DE Arteriosclerosis; Cerebral aneurysm; Intracranial tumors; Neuro-oncology
ID SUBARACHNOID HEMORRHAGE; BRAIN; GROWTH; MANAGEMENT; SCHWANNOMA; FLOW; CT
AB OBJECTIVE: We tested the hypothesis that cerebellopontine angle (CPA) tumors are associated with a greater incidence of unruptured intracranial aneurysms (IAs).
   METHODS: Patients with intracranial tumors (ITs) undergoing computed tomography angiography and magnetic resonance imaging were enrolled in an observational cohort study that prospectively collected age, sex, hypertension, diabetes, cerebral arteriosclerosis, tumor type, tumor location, hydrocephalus, smoking, alcohol intake, CPA tumor size, cerebral aneurysms, and cerebral arteriosclerosis. Patients with the coexistence of IA and IT were classified as group II, whereas the others with IT as group I.
   RESULTS: We included 1218 patients with IT for analysis. The incidence of IA was 7.1% (86/1218). A total of 31% of patients with aneurysms had CPA tumors. In a multivariate logistic regression model, a greater incidence of IA was found in female patients (odds ratio [OR] 1.726, 95% confidence interval [CI] 1.050-2.836, P = 0.031) and in patients with CPA tumors (OR 3.002, 95% CI 1.822-4.947, P = 0.000) after adjustment for tumor type, cerebral arteriosclerosis, and age. In female patients, CPA tumors were a unique independent risk factor of a greater incidence of IA (OR 2.270, 95% CI 1.194-4.317, P = 0.012). Furthermore, cerebral arteriosclerosis was a unique independent risk factor of IA in patients with CPA tumors (OR 7.626, 95% CI 2.928-19.860, P = 0.000).
   CONCLUSIONS: These data support the hypothesis that CPA tumors are associated with a greater incidence of unruptured IAs, especially in female patients. Cerebral arteriosclerosis contributed to elevated risk of IA in patients with CPA tumors.
C1 [Zheng, Shu-Fa; Kang, De-Zhi; Chen, Guo-Rong; Lin, Yuan-Xiang; Yao, Pei-Sen] Fujian Med Univ, Affiliated Hosp 1, Dept Neurosurg, Fuzhou, Fujian, Peoples R China.
   [Shang-Guan, Huang-Cheng] Fujian Med Univ, Affiliated Hosp 1, Dept Crit Care Med, Fuzhou, Fujian, Peoples R China.
   [Zhang, Yi-Bin] Dehua Cty Hosp, Dept Neurosurg, Quanzhou, Peoples R China.
   [He, Yan-Yan] Affiliated Peoples Fujian Univ Tradit Chinese Med, Dept Radiol, Fuzhou, Fujian, Peoples R China.
RP Yao, PS (reprint author), Fujian Med Univ, Affiliated Hosp 1, Dept Neurosurg, Fuzhou, Fujian, Peoples R China.
EM peisen.yao@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81802492]; Young and Middle-aged Backbone Key
   Research Project of National Health and Family Planning Commission of
   Fujian Province [2017-ZQN-46]; National Science Foundation of Fujian
   Province [2018J01175, 2018J01176]; key clinical specialty discipline
   construction program of Fujian, P.R.C.; major project of Fujian
   Provincial Department of Science and Technology [2014YZ0003, 2014YZ01]
FX The study was supported by the National Natural Science Foundation of
   China (no. 81802492 to Pei-Sen Yao), Young and Middle-aged Backbone Key
   Research Project of National Health and Family Planning Commission of
   Fujian Province (no. 2017-ZQN-46 to Pei-Sen Yao), National Science
   Foundation of Fujian Province (no. 2018J01175 to Pei-Sen Yao and no.
   2018J01176 to Shu-Fa Zheng), key clinical specialty discipline
   construction program of Fujian, P.R.C, and major project of Fujian
   Provincial Department of Science and Technology (no. 2014YZ0003 and no.
   2014YZ01 to De-Zhi Kang).
CR ACQUI M, 1988, ITAL J NEUROL SCI, V9, P365, DOI 10.1007/BF02334000
   Bian LG, 2007, SKULL BASE-INTERD AP, V17, P145, DOI 10.1055/s-2006-953515
   Brady KM, 2009, ANESTH ANALG, V108, P1278, DOI 10.1213/ane.0b013e3181964848
   Chiu JJ, 2003, J BIOMECH, V36, P1883, DOI 10.1016/S0021-9290(03)00210-0
   De Paulis Danilo, 2016, J Med Case Rep, V10, P78, DOI 10.1186/s13256-016-0869-8
   Feigin VL, 2005, STROKE, V36, P2773, DOI 10.1161/01.STR.0000190838.02954.e8
   Fischer BR, 2009, CLIN NEUROL NEUROSUR, V111, P647, DOI 10.1016/j.clineuro.2009.05.016
   Griffiths PD, 1996, NEURORADIOLOGY, V38, P25, DOI 10.1007/BF00593211
   HORI T, 1982, SURG NEUROL, V18, P108, DOI 10.1016/0090-3019(82)90366-4
   JAKUBOWSKI J, 1978, J NEUROL NEUROSUR PS, V41, P972, DOI 10.1136/jnnp.41.11.972
   Juvela S, 2001, STROKE, V32, P485, DOI 10.1161/01.STR.32.2.485
   Kassab MY, 2009, CEREBROVASC DIS, V28, P45, DOI 10.1159/000219296
   Kim YH, 2015, J NEUROSURG, V123, P357, DOI 10.3171/2014.10.JNS14710
   KODAMA T, 1987, Surgical Neurology, V27, P77, DOI 10.1016/0090-3019(87)90112-1
   Kohler BA, 2011, J NATL CANCER I, V103, P714, DOI 10.1093/jnci/djr077
   KOSIERKIEWICZ TA, 1994, J NEUROPATH EXP NEUR, V53, P399, DOI 10.1097/00005072-199407000-00012
   Kulseng B, 2006, INT ANGIOL, V25, P433
   Malek AM, 1999, JAMA-J AM MED ASSOC, V282, P2035, DOI 10.1001/jama.282.21.2035
   Morimoto M, 2002, STROKE, V33, P1911, DOI 10.1161/01.STR.0000021000.19637.3D
   Nguyen-Huynh MN, 2008, STROKE, V39, P1184, DOI 10.1161/STROKEAHA.107.502906
   Oh MC, 2012, J NEUROSURG, V116, P942, DOI 10.3171/2011.12.JNS11875
   Oshino S, 2013, PITUITARY, V16, P195, DOI 10.1007/s11102-012-0404-x
   Paisley AN, 2006, J CLIN ENDOCR METAB, V91, P4635, DOI 10.1210/jc.2005-2589
   Pant B, 1997, NEUROSURG REV, V20, P13, DOI 10.1007/BF01390519
   Park KY, 2016, KOREAN J RADIOL, V17, P931, DOI 10.3348/kjr.2016.17.6.931
   PIA HW, 1973, ACTA NEUROCHIR, V27, P189
   Steiner T, 2013, CEREBROVASC DIS, V35, P93, DOI 10.1159/000346087
   Sugiyama S, 2013, NEUROSURGERY, V73, P767, DOI 10.1227/NEU.0000000000000096
   TSUCHIDA T, 1983, SURG NEUROL, V20, P67, DOI 10.1016/0090-3019(83)90110-6
   Vernooij MW, 2007, NEW ENGL J MED, V357, P1821, DOI 10.1056/NEJMoa070972
   Vlak MHM, 2011, LANCET NEUROL, V10, P626, DOI 10.1016/S1474-4422(11)70109-0
   Zairi F, 2011, ACTA NEUROCHIR, V153, P353, DOI 10.1007/s00701-010-0863-7
   Zhong ZH, 2013, NEUROSURG REV, V36, P645, DOI 10.1007/s10143-013-0477-7
NR 33
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E561
EP E568
DI 10.1016/j.wneu.2018.10.100
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100068
PM 31108072
DA 2020-05-12
ER

PT J
AU Zhi, M
   Girvigian, MR
   Miller, MJ
   Chen, JC
   Schumacher, AJ
   Rahimian, J
   Lodin, K
AF Zhi, Ming
   Girvigian, Michael R.
   Miller, Michael J.
   Chen, Joseph C.
   Schumacher, Andrew J.
   Rahimian, Javad
   Lodin, Kenneth
TI Long-Term Outcomes of Newly Diagnosed Resected Atypical Meningiomas and
   the Role of Adjuvant Radiotherapy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Atypical meningioma; Brain; Progression; Radiotherapy; Recurrence;
   Surgery; Tumor
ID GROSS-TOTAL RESECTION; SIMPSON GRADE I; INTRACRANIAL MENINGIOMAS;
   CRANIAL MENINGIOMAS; PROGNOSTIC-FACTORS; RECURRENCE; RADIATION;
   MANAGEMENT; SURGERY; CLASSIFICATION
AB OBJECTIVE: The role of adjuvant radiotherapy (ART) in patients with World Health Organization Grade II atypical meningiomas (AMs) remains controversial.
   METHODS: We retrospectively reviewed 149 patients with newly diagnosed resected AMs from 2000 to 2012. Gross total resection (GTR) was defined as Simpson Grades I-III and subtotal resection (STR) as Grades IV and V. Kaplan-Meier analyses of local control (LC), progression-free survival (PFS), and overall survival were performed with the log-rank test, and risk factors for progression/recurrence (P/R) were analyzed with multivariate Cox regression.
   RESULTS: Median follow-up was 74.2 months. GTR was achieved in 98 patients and STR in 51 patients. Fifty-three (35%) patients received ART. Overall, 46 patients (31%) experienced P/R with a median time to P/R of 32.4 months. ART was associated with a trend toward improved PFS (P = 0.0669) in the GTR subset but significantly improved LC (P = 0.0183) and PFS (P = 0.0034) in the STR subset. Age, tumor size, and STR were significant risk factors for worse PFS, whereas receiving ART was associated with improved PFS on multivariate analyses. Thirty-nine of the 46 progressive/recurrent patients underwent salvage therapy with only 22 patients experiencing long-term control. Five patients experienced transformation to World Health Organization Grade III malignant meningioma.
   CONCLUSIONS: Patients who undergo STR for newly diagnosed AM should receive ART based on improvements in LC and PFS. GTR patients should be considered for ART, but active surveillance is a reasonable management approach with the recognition that progressive/recurrent disease can act aggressively. Prospective, randomized trials are currently underway to evaluate the role of ART.
C1 [Zhi, Ming; Girvigian, Michael R.; Miller, Michael J.; Schumacher, Andrew J.; Rahimian, Javad; Lodin, Kenneth] Kaiser Permanente Los Angeles Med Ctr, Dept Radiat Oncol, Los Angeles, CA 90027 USA.
   [Chen, Joseph C.] Kaiser Permanente Los Angeles Med Ctr, Dept Neurosurg, Los Angeles, CA USA.
RP Zhi, M (reprint author), Kaiser Permanente Los Angeles Med Ctr, Dept Radiat Oncol, Los Angeles, CA 90027 USA.
EM ming.zhi@kp.org
CR Aghi MK, 2009, NEUROSURGERY, V64, P56, DOI 10.1227/01.NEU.0000330399.55586.63
   Aizer AA, 2014, NEURO-ONCOLOGY, V16, P1547, DOI 10.1093/neuonc/nou098
   Bagshaw HP, 2017, J NEUROSURG, V126, P1822, DOI 10.3171/2016.5.JNS152809
   Condra KS, 1997, INT J RADIAT ONCOL, V39, P427, DOI 10.1016/S0360-3016(97)00317-9
   Coskun M, 2013, RADIAT ONCOL, V8, DOI 10.1186/1748-717X-8-23
   Goyal LK, 2000, INT J RADIAT ONCOL, V46, P57, DOI 10.1016/S0360-3016(99)00349-1
   Hammouche S, 2014, ACTA NEUROCHIR, V156, P1475, DOI 10.1007/s00701-014-2156-z
   Hardesty DA, 2013, J NEUROSURG, V119, P475, DOI 10.3171/2012.12.JNS12414
   Hasseleid BF, 2012, J NEUROSURG, V117, P999, DOI 10.3171/2012.9.JNS12294
   Heald JB, 2014, ACTA NEUROCHIR, V156, P383, DOI 10.1007/s00701-013-1923-6
   Hwang WL, 2016, NEURO-ONCOLOGY, V18, P863, DOI 10.1093/neuonc/nov285
   Jenkinson MD, 2016, J CLIN NEUROSCI, V28, P87, DOI 10.1016/j.jocn.2015.09.021
   Jenkinson MD, 2015, TRIALS, V16, DOI 10.1186/s13063-015-1040-3
   Jo K, 2010, J CLIN NEUROSCI, V17, P1362, DOI 10.1016/j.jocn.2010.03.036
   KALLIO M, 1992, NEUROSURGERY, V31, P2, DOI 10.1227/00006123-199207000-00002
   Kaur G, 2014, NEURO-ONCOLOGY, V16, P628, DOI 10.1093/neuonc/nou025
   Komotar RJ, 2012, J NEUROSURG, V117, P679, DOI 10.3171/2012.7.JNS112113
   Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Mair R, 2011, J NEUROSURG, V115, P811, DOI 10.3171/2011.5.JNS11112
   Marcus HJ, 2008, BRIT J NEUROSURG, V22, P520, DOI 10.1080/02688690802308687
   Oya S, 2012, J NEUROSURG, V117, P121, DOI 10.3171/2012.3.JNS111945
   Palma L, 1997, Neurosurg Focus, V2, pe3
   Park HJ, 2013, J NEURO-ONCOL, V115, P241, DOI 10.1007/s11060-013-1219-y
   Pearson BE, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/5/E3
   Rogers L, 2018, J NEUROSURG, V129, P35, DOI 10.3171/2016.11.JNS161170
   Rogers L, 2015, J NEUROSURG, V122, P4, DOI 10.3171/2014.7.JNS131644
   Simon M, 2006, J NEUROL NEUROSUR PS, V77, P767, DOI 10.1136/jnnp.2005.077974
   SIMPSON D, 1957, J NEUROL NEUROSUR PS, V20, P22, DOI 10.1136/jnnp.20.1.22
   Stafford SL, 1998, MAYO CLIN PROC, V73, P936, DOI 10.4065/73.10.936
   Stessin AM, 2012, J NEUROSURG, V117, P669, DOI 10.3171/2012.7.JNS111439
   Sughrue ME, 2010, J NEUROSURG, V113, P1029, DOI 10.3171/2010.3.JNS091971
   Sun SQ, 2014, NEUROSURGERY, V75, P356, DOI 10.1227/NEU.0000000000000462
   Sun SQ, 2014, NEUROSURGERY, V75, P347, DOI 10.1227/NEU.0000000000000461
   Talacchi A, 2016, WORLD NEUROSURG, V87, P565, DOI 10.1016/j.wneu.2015.10.013
   Vernooij MW, 2007, NEW ENGL J MED, V357, P1821, DOI 10.1056/NEJMoa070972
   Weber DC, 2018, RADIOTHER ONCOL, V128, P260, DOI 10.1016/j.radonc.2018.06.018
   Wiemels J, 2010, J NEURO-ONCOL, V99, P307, DOI 10.1007/s11060-010-0386-3
   Willis J, 2005, NEUROPATH APPL NEURO, V31, P141, DOI 10.1111/j.1365-2990.2004.00621.x
   Yang SY, 2008, J NEUROL NEUROSUR PS, V79, P574, DOI 10.1136/jnnp.2007.121582
   Yoon H, 2015, J CANCER RES THER, V11, P59, DOI 10.4103/0973-1482.148708
NR 41
TC 4
Z9 4
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1153
EP E1161
DI 10.1016/j.wneu.2018.11.006
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100141
PM 30447464
DA 2020-05-12
ER

PT J
AU Zhong, WY
   Zhang, J
   Shen, J
   Su, WD
   Wang, DH
   Zhang, P
   Wang, YY
AF Zhong, Weiying
   Zhang, Ji
   Shen, Jie
   Su, Wandong
   Wang, Donghai
   Zhang, Ping
   Wang, Yunyan
TI Dural Arteriovenous Fistulas at the Craniocervical Junction: A Series
   Case Report
SO WORLD NEUROSURGERY
LA English
DT Article
DE Craniocervical junction; Dura arteriovenous fistula; Myelopathy;
   Subarachnoid hemorrhage
ID SUBARACHNOID HEMORRHAGE
AB BACKGROUND: Craniocervical junction dural arteriovenous fistulas (CJDAVFs) are rare vascular malformations with unclear clinical characteristics. This study investigated the clinical characteristics and outcomes of patients with CJDAVFs.
   METHODS: Thirty-eight patients with CJDAVFs who had undergone either conservative or surgical treatment were retrospectively analyzed.
   RESULTS: Eleven (28.9%) patients were women and 27 (71.1%) were men (median age, 52.5 years). Two (5.3%) had myelopathy, and 36 (94.7%) had subarachnoid hemorrhage (SAH). Three patients had SAH recurrence before treatment. Five patients (13.9%) with SAH initially had negative results on angiography, which may have been due to a low-flow fistula without varicose veins (P = 0.034) and acute hydrocephalus (P = 0.084). Coincidental vascular lesions were noted in 5 patients (13.2%). Caudal drainage was mainly found in patients with myelopathy, whereas superolateral drainage was frequently observed in patients with SAH (P = 0.021). Thirty-six (94.7%) patients underwent microsurgery; of these, 33 (91.7%) had favorable outcomes and 3 (8.3%) had unfavorable outcomes. The main neurosurgical complications included acute hydrocephalus in 4 (10.5%) and new-onset mild persistent myelopathy in 6 (15.7%). According to the univariate analysis, the presence of myelopathy predicted poor outcomes, whereas SAH predicted favorable outcomes (P = 0.004). However, the multivariate analysis did not show statistical significance.
   CONCLUSIONS: SAH is a common presenting sign of CJDAVF that may be overlooked on initial cerebral angiography, especially in patients with acute hydrocephalus and a low-flow fistula without varicose veins. Microsurgery involving disconnecting the draining vein is effective and beneficial. Further studies should be performed to investigate predictive factors influencing the prognosis.
C1 [Zhong, Weiying; Shen, Jie; Su, Wandong; Wang, Donghai; Zhang, Ping; Wang, Yunyan] Shandong Univ, Qilu Hosp, Dept Neurosurg, Jinan, Shandong, Peoples R China.
   [Zhong, Weiying; Shen, Jie; Su, Wandong; Wang, Donghai; Zhang, Ping; Wang, Yunyan] Shandong Univ, Inst Brain & Brain Inspired Sci, Jinan, Shandong, Peoples R China.
   [Zhang, Ji] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Dept Neurosurg,Canc Ctr, Guangzhou, Guangdong, Peoples R China.
RP Wang, YY (reprint author), Shandong Univ, Qilu Hosp, Dept Neurosurg, Jinan, Shandong, Peoples R China.; Wang, YY (reprint author), Shandong Univ, Inst Brain & Brain Inspired Sci, Jinan, Shandong, Peoples R China.
EM wangyunyan0618@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81701160]
FX This work was supported by a grant from the National Natural Science
   Foundation of China (no. 81701160).
CR Aviv RI, 2004, AM J NEURORADIOL, V25, P854
   Beynon C, 2012, CLIN NEUROL NEUROSUR, V114, P696, DOI 10.1016/j.clineuro.2011.11.022
   Cecchi PC, 2009, SURG NEUROL, V72, P257, DOI 10.1016/j.surneu.2009.03.010
   Germans MR, 2015, NEUROLOGY, V84, P1337, DOI 10.1212/WNL.0000000000001423
   Guo LM, 2010, EUR J NEUROL, V17, P684, DOI 10.1111/j.1468-1331.2009.02895.x
   Hetts SW, 2013, INTERV NEURORADIOL, V19, P483, DOI 10.1177/159101991301900413
   Hillier CEM, 2000, J NEUROL NEUROSUR PS, V68, P218, DOI 10.1136/jnnp.68.2.218
   Jablawi F, 2018, WORLD NEUROSURG, V114, pE698, DOI 10.1016/j.wneu.2018.03.061
   Jablawi F, 2017, WORLD NEUROSURG, V103, P360, DOI 10.1016/j.wneu.2017.04.050
   Ibanez FAL, 2011, WORLD NEUROSURG, V75, P709, DOI 10.1016/j.wneu.2010.11.010
   Oishi H, 1999, NEURORADIOLOGY, V41, P463, DOI 10.1007/s002340050785
   Oshita J, 2011, NEUROSURGERY, V69, pE1166, DOI 10.1227/NEU.0b013e318223bab5
   Sato K, 2013, J NEUROSURG, V118, P451, DOI 10.3171/2012.10.JNS121028
   Sato K, 2012, J NEUROSURG-SPINE, V16, P441, DOI 10.3171/2012.2.SPINE11500
   Shinoyama M, 2010, WORLD NEUROSURG, V73, P401, DOI 10.1016/j.wneu.2010.01.003
   Sorenson TJ, 2017, ACTA NEUROCHIR, V159, P1489, DOI 10.1007/s00701-017-3200-6
   TERADA T, 1994, J NEUROSURG, V80, P884, DOI 10.3171/jns.1994.80.5.0884
   Wang JY, 2015, J CLIN NEUROSCI, V22, P1701, DOI 10.1016/j.jocn.2015.05.014
   Zhao JJ, 2016, J NEUROINTERV SURG, V8, P648, DOI 10.1136/neurintsurg-2015-011775
   Zhong WY, 2014, TURK NEUROSURG, V24, P327, DOI 10.5137/1019-5149.JTN.7253-12.1
NR 20
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E700
EP E712
DI 10.1016/j.wneu.2018.10.124
PG 13
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100085
PM 30385361
DA 2020-05-12
ER

PT J
AU Zhou, JJ
   Mooney, MA
   Farber, SH
   Bohl, MA
   Little, AS
   Nakaji, P
AF Zhou, James J.
   Mooney, Michael A.
   Farber, S. Harrison
   Bohl, Michael A.
   Little, Andrew S.
   Nakaji, Peter
TI Bedside Iohexol Ventriculography for Patients with Obstructive Colloid
   Cysts: A Protocol to Identify Auto-Fenestration of the Septum Pellucidum
SO WORLD NEUROSURGERY
LA English
DT Article
DE Auto-fenestration; Colloid cyst; External ventricular drain;
   Hydrocephalus; Intraventricular; Iohexol; Septum pellucidum;
   Ventriculography
AB OBJECTIVE: Patients with hydrocephalus secondary to third ventricular colloid cysts can require bilateral external ventricular drain (EVD) placement while awaiting surgery. However, some patients could develop auto-fenestration of the septum pellucidum (AFSP) and only require 1 EVD. We evaluated our experience with bedside iohexol ventriculography and staged EVD placement for patients with obstructive hydrocephalus.
   METHODS: We retrospectively identified 34 patients who had been treated for third ventricular colloid cysts (2013-2016). The preoperative and postoperative data, including age, sex, colloid cyst size, preoperative hydrocephalus, preoperative EVD placement, preoperative iohexol ventriculography, operative approach, intraoperative findings, and postoperative ventriculoperitoneal shunt requirements, were reviewed.
   RESULTS: Hydrocephalus was found in 23 patients (68%) on initial presentation. Nine patients (26%) had EVDs placed before surgery. Six patients (18%) underwent iohexol ventriculography after insertion of a right-sided EVD. Five patients (15%) demonstrated no evidence of ventricular communication. Four patients (67%) required left-sided EVD placement. One patient (17%) had robust communication between the lateral ventricles after intraventricular iohexol injection, which was managed with a single EVD. AFSP was observed during surgical resection of this patient's colloid cyst. One other patient who did not undergo preoperative EVD placement was noted to have AFSP intraoperatively, resulting in 2 of 34 patients (6%) with AFSP in our series.
   CONCLUSIONS: A subset of patients with obstruction at the foramina of Monro can develop AFSP. Iohexol ventriculography after unilateral EVD placement allows clinicians to assess for the presence of AFSP and identify patients who can be treated with a single EVD before surgery.
C1 [Zhou, James J.; Mooney, Michael A.; Farber, S. Harrison; Bohl, Michael A.; Little, Andrew S.; Nakaji, Peter] St Josephs Hosp, Barrow Neurol Inst, Dept Neurosurg, Phoenix, AZ 85013 USA.
RP Nakaji, P (reprint author), St Josephs Hosp, Barrow Neurol Inst, Dept Neurosurg, Phoenix, AZ 85013 USA.
EM Neuropub@barrowneuro.org
OI Farber, S. Harrison/0000-0002-0171-6516
CR ANTUNES JL, 1980, NEUROSURGERY, V7, P450, DOI 10.1227/00006123-198011000-00004
   Friede R, 1975, DEV NEUROPATHOLOGY
   Greenberg MS, 2016, HDB NEUROSURGERY
   Hamer PCD, 2002, J NEUROSURG, V96, P1041, DOI 10.3171/jns.2002.96.6.1041
   Humphries Roger L, 2011, J Emerg Med, V40, pe5, DOI 10.1016/j.jemermed.2007.11.110
   Kakarla UK, 2008, NEUROSURGERY, V63, P162, DOI 10.1227/01.NEU.0000312390.83127.7F
   Kakarla UK, 2008, NEUROSURGERY S1, V63
   Maniker AH, 2006, OPER NEUROSURG S4, V59
   Maniker AH, 2006, OPER NEUROSURG S4, V59
   Mathiesen T, 1997, J NEUROSURG, V86, P5, DOI 10.3171/jns.1997.86.1.0005
   Muralidharan Rajanandini, 2015, Surg Neurol Int, V6, pS271, DOI 10.4103/2152-7806.157620
   Ngo QN, 2009, PEDIATR CRIT CARE ME, V10, P346, DOI 10.1097/PCC.0b013e3181a320cd
   Pollock BE, 2000, NEUROSURGERY, V46, P1077, DOI 10.1097/00006123-200005000-00010
   Punt J, 2004, PEDIATRIC HYDROCEPHALUS, P389
   Ravnik J, 2014, BOSNIAN J BASIC MED, V14, P132, DOI 10.17305/bjbms.2014.3.38
   SARWAR M, 1989, AM J NEURORADIOL, V10, P989
NR 16
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E279
EP E284
DI 10.1016/j.wneu.2018.10.020
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100031
PM 30321679
DA 2020-05-12
ER

PT J
AU Zoccoli, C
   Li, CF
   Black, D
   Smith, DB
   Sheehan, J
   Harbaugh, RE
   Glantz, M
AF Zoccoli, Christina
   Li, Christina F.
   Black, David
   Smith, Don B.
   Sheehan, Jonas
   Harbaugh, Robert E.
   Glantz, Michael
TI The Honest Palm Sign: Detecting Incomplete Effort on Physical
   Examination
SO WORLD NEUROSURGERY
LA English
DT Article; Proceedings Paper
CT 66th Annual Meeting of the American-Academy-of-Neurology
CY APR 26-MAY 03, 2014
CL Philadelphia, PA
SP Amer Acad Neurol
DE Chronic pain; Incomplete effort; Motor examination; MRC grading scale;
   Neurological examination
ID FIBROMYALGIA; VALIDITY; PERFORMANCE
AB BACKGROUND: We investigated a simple, novel diagnostic test for detecting incomplete effort during the motor portion of the neurological examination.
   METHODS: The results from the honest palm sign (HPS) were evaluated for 162 consecutive neuro-oncology patients who had undergone upper extremity strength testing. Deltoid, bicep, and wrist extensor strength was assessed in all patients. During the examination, patients were repeatedly encouraged to "try as hard as possible" and to "resist with all your strength." The absence of nail prints on the palms constituted a positive HPS test result (i.e., indicative of incomplete effort). The presence of nail prints constituted a negative HPS test result (i.e., indicative of full effort).
   RESULTS: A total of 162 patients were tested. Their mean age was 55.5 +/- 14.9 years, the median Karnofsky performance scale score was 80 (range, 60-100), and 63 patients (39%) were men. Of the 162 patients, 102 (63%) had malignant gliomas, 28 (17%) had brain metastases, 21 (13%) had other primary brain tumors, and 11 (6.8%) had primary central nervous system lymphomas. Of the 162 patients, 48 (30%) had positive HPS test results. The test sensitivity (84.6%), specificity (75.2%), positive likelihood ratio (3.41), and negative likelihood ratio (0.205) were good. After excluding 33 patients with characteristics that rendered them unsuitable for testing, the results from the remaining 129 patients were analyzed. The sensitivity was unchanged (84.6%), but the specificity (96.6%), positive likelihood ratio (24.5), and negative likelihood ratio (0.16) improved dramatically.
   CONCLUSIONS: The HPS test is a simple, sensitive, and very specific test for detecting incomplete effort during the motor portion of neurological evaluations.
C1 [Zoccoli, Christina] Emory Univ, Sch Med, Atlanta, GA 30322 USA.
   [Li, Christina F.] Kaiser Permanente Oakland Med Ctr, Oakland, CA USA.
   [Black, David; Harbaugh, Robert E.; Glantz, Michael] Penn State Milton S Hershey Med Ctr, Dept Neurosurg, Hershey, PA 17033 USA.
   [Smith, Don B.] Univ Colorado, Sch Med, Dept Neurol, Denver, CO 80202 USA.
   [Sheehan, Jonas] Geisinger Hlth Syst, Camp Hill, PA USA.
RP Glantz, M (reprint author), Penn State Milton S Hershey Med Ctr, Dept Neurosurg, Hershey, PA 17033 USA.
EM mglantz@pennstatehealth.psu.edu
CR Aronoff Gerald M, 2007, Pain Pract, V7, P178, DOI 10.1111/j.1533-2500.2007.00126.x
   Belenguer-Prieto R, 2013, CLIN EXP RHEUMATOL, V31, pS86
   Bigler ED, 2014, BRAIN INJURY, V28, P1623, DOI 10.3109/02699052.2014.947627
   Carone DA, 2015, NEUROREHABILITATION, V36, P387, DOI 10.3233/NRE-151228
   Chafetz M, 2013, ARCH CLIN NEUROPSYCH, V28, P633, DOI 10.1093/arclin/act038
   Fishbain DA, 1999, CLIN J PAIN, V15, P244, DOI 10.1097/00002508-199912000-00002
   Gervais RO, 2001, J RHEUMATOL, V28, P1892
   Hertzman PA, 2001, ARCH INTERN MED, V161, P2301, DOI 10.1001/archinte.161.19.2301
   Kalfon TBO, 2016, J PSYCHOSOM RES, V87, P30, DOI 10.1016/j.jpsychores.2016.06.004
   Medical Research Council of the United Kingdom, 1978, 45 MED RES COUNC UK
   Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379
   Oddsdottir GL, 2015, PHYSIOTHER THEOR PR, V31, P403, DOI 10.3109/09593985.2015.1024299
   Paternostro-Sluga T, 2008, J REHABIL MED, V40, P665, DOI 10.2340/16501977-0235
   Patterson DC, 2018, BULL HOSP JT DIS, V76, P123
   Reitsma JB, 2009, J CLIN EPIDEMIOL, V62, P797, DOI 10.1016/j.jclinepi.2009.02.005
   Rutjes A W S, 2007, Health Technol Assess, V11, pix
   Silver JM, 2015, NEUROREHABILITATION, V36, P463, DOI 10.3233/NRE-151234
   Zasler ND, 2015, NEUROREHABILITATION, V36, P401, DOI 10.3233/NRE-151229
   Zubera A, 2015, ACAD PSYCHIATR, V39, P233, DOI 10.1007/s40596-014-0253-1
NR 19
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E1354
EP E1358
DI 10.1016/j.wneu.2018.11.047
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100165
PM 30448572
DA 2020-05-12
ER

PT J
AU Zou, F
   Yang, S
   Lu, FZ
   Ma, XS
   Xia, XL
   Jiang, JY
AF Zou, Fei
   Yang, Shuo
   Lu, Feizhou
   Ma, Xiaosheng
   Xia, Xinlei
   Jiang, Jianyuan
TI Factors Affecting the Surgical Outcomes of Hirayama Disease: A
   Retrospective Analysis of Preoperative Magnetic Resonance Imaging
   Features of the Cervical Spine
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cervical spine; Follow-up; Hirayama disease; Image study; Retrospective
   study; Surgical treatment
ID JUVENILE MUSCULAR-ATROPHY; DURAL SAC; FLEXION; DECOMPRESSION;
   DURAPLASTY; FUSION; CORD
AB OBJECTIVE: We explored the factors affecting the surgical outcomes of Hirayama disease (HD).
   METHODS: We enrolled 40 patients with a diagnosis of HD in the present study. Cervical spine magnetic resonance imaging (MRI) was performed before surgery with the neck in the cervical neutral and flexion positions. Fusion surgery was performed at the most severely compressed 2 levels according to the flexion sagittal MRI findings. The patients were divided into improvement and no-improvement groups according to Odom's scale 6 months after surgery. The axial MRI parameters in the neutral and flexion positions at the most severely compressed segment were measured. P values < 0.05 were considered statistically significant.
   RESULTS: The average age was 18.4 +/- 2.27 years, and the average disease duration was 1.8 +/- 1.2 years. The main symptomatic side of HD statistically matched the atrophied side of the spinal cord (P < 0.001). Based on the pathophysiology of spinal cord flattening with flexion, the parameters indicating atrophy of the spinal cord and the ability of the spinal cord to recover from flattening were significantly larger in the improvement group (P < 0.05). Receiver operating characteristic curves showed good prognostic capacity for these parameters (P < 0.05).
   CONCLUSIONS: The main side of the symptoms in patients with HD corresponded with ipsilateral spinal cord atrophy found on MRI. Also, atrophy of the spinal cord in the neutral position MRI study and the ability of the spinal cord to recover were significantly related to the surgical outcome. These factors might be used as potential indications for surgery of HD.
C1 [Zou, Fei; Yang, Shuo; Lu, Feizhou; Ma, Xiaosheng; Xia, Xinlei; Jiang, Jianyuan] Fudan Univ, Huashan Hosp, Dept Orthopaed, Shanghai, Peoples R China.
RP Jiang, JY (reprint author), Fudan Univ, Huashan Hosp, Dept Orthopaed, Shanghai, Peoples R China.
EM dr_jiangjianyuan@126.com
FU General Program of National Natural Science Foundation of ChinaNational
   Natural Science Foundation of China [81601914]
FX This work was supported by the General Program of National Natural
   Science Foundation of China (grant 81601914).
CR Arrese I, 2009, NEUROCIRUGIA, V20, P555
   Brandicourt P, 2018, NEUROCHIRURGIE, V64, P303, DOI 10.1016/j.neuchi.2018.04.004
   Fu Y, 2016, Zhonghua Yi Xue Za Zhi, V96, P3485, DOI 10.3760/cma.j.issn.0376-2491.2016.43.009
   Fujimoto Y, 2002, EUR SPINE J, V11, P276, DOI 10.1007/s005860100344
   Goel A, 2017, WORLD NEUROSURG, V99, P186, DOI 10.1016/j.wneu.2016.11.143
   Guo X, 2014, J SPINAL DISORD TECH, V27, pE241, DOI 10.1097/BSD.0000000000000098
   HIRABUKI N, 1991, EUR J RADIOL, V13, P215, DOI 10.1016/0720-048X(91)90033-R
   Hirayama K, 2000, NEUROLOGY, V54, P1922, DOI 10.1212/WNL.54.10.1922
   Hirayama K, 1959, PSYCHIATR NEUROL JAP, V61, P2190
   Ito H, 2014, J NEUROSURG-SPINE, V21, P743, DOI 10.3171/2014.7.SPINE13955
   Lai V, 2011, EUR J RADIOL, V80, P724, DOI 10.1016/j.ejrad.2010.07.021
   Liao MF, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004210
   Lu FZ, 2013, J NEUROSURG-SPINE, V19, P412, DOI 10.3171/2013.4.SPINE12575
   Nascimento OJM, 2000, ARQ NEURO-PSIQUIAT, V58, P814, DOI 10.1590/S0004-282X2000000500004
   ODOM GL, 1958, JAMA-J AM MED ASSOC, V166, P23, DOI 10.1001/jama.1958.02990010025006
   Paredes I, 2014, J NEUROSURG-SPINE, V20, P191, DOI 10.3171/2013.10.SPINE13508
   Song J, 2017, WORLD NEUROSURG, V105, P69, DOI 10.1016/j.wneu.2017.05.097
   Sun Y, 2017, Beijing Da Xue Xue Bao Yi Xue Ban, V49, P1019
   Wang HL, 2018, WORLD NEUROSURG, V114, pE433, DOI 10.1016/j.wneu.2018.03.004
   Xu XJ, 2011, EUR J RADIOL, V78, P82, DOI 10.1016/j.ejrad.2010.08.012
   Yang G, 2014, J CHILD NEUROL, V29, P509, DOI 10.1177/0883073813482770
NR 21
TC 1
Z9 2
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E296
EP E301
DI 10.1016/j.wneu.2018.10.025
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100034
PM 30321675
DA 2020-05-12
ER

PT J
AU Zuckerman, SL
   Lim, J
   Lakomkin, N
   Than, KD
   Smith, JS
   Shaffrey, CI
   Devin, CJ
AF Zuckerman, Scott L.
   Lim, Jaims
   Lakomkin, Nikita
   Than, Khoi D.
   Smith, Justin S.
   Shaffrey, Christopher I.
   Devin, Clinton J.
TI Effect of Resident and Fellow Involvement in Adult Spinal Deformity
   Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adult spinal deformity; Complications; Resident fellow training; Spine
   outcomes
ID 30-DAY COMPLICATIONS; RISK-FACTORS; IMPACT; MORBIDITY; MORTALITY;
   FUSION; MULTICENTER; RATES; AIS
AB BACKGROUNG: Adult spinal deformity (ASD) operations are complex and often require a multisurgeon team. Simultaneously, it is the responsibility of academic spine surgeons to train future complex spine surgeons. Our objective was to assess the effect of resident and fellow involvement (RFI) on ASD surgery in 4 areas: 1) perioperative outcomes, 2) length of stay (LOS), 3) discharge status, and 4) complications.
   METHODS: Adults undergoing thoracolumbar spinal deformity correction from 2008 to 2014 were identified in the National Surgical Quality Improvement Program database. Cases were divided into those with RFI and those with attendings only. Outcomes were operative time, transfusions, LOS, discharge status, and complications. Univariate and multivariable regression modeling was used. Covariates included preoperative comorbidities, specialty, and levels undergoing instrumentation.
   RESULTS: A total of 1471 patients underwent ASD surgery with RFI in 784 operations (53%). After multivariable regression modeling, RFI was independently associated with longer operations (beta = 66.01 minutes; 95% confidence interval [CI], 35.8296.19; P < 0.001), increased odds of transfusion (odds ratio, 2.80; 95% CI, 1.814.32; P < 0.001), longer hospital stay (beta = 1.76 days; 95% CI, 0.183.34; P = 0.030), and discharge to an inpatient rehabilitation or a skilled nursing facility (odds ratio, 2.02; 95% CI, 1.343.05; P < 0.001). However, RFI was not associated with any increase in major or minor complications.
   CONCLUSION: RFI in ASD surgery was associated with increased operative time, the need for additional transfusions, longer LOS, and nonhome discharge. However, no increase in major, minor, or severe complications occurred. These data support the continued training of future deformity and complex spine surgeons without fear of worsening complications; however, areas of improvement exist.
C1 [Zuckerman, Scott L.; Lim, Jaims; Devin, Clinton J.] Vanderbilt Univ, Dept Neurol Surg, 221 Kirkland Hall, Nashville, TN 37235 USA.
   [Lakomkin, Nikita] Icahn Sch Med Mt Sinai, Dept Neurosurg, New York, NY 10029 USA.
   [Than, Khoi D.] Oregon Hlth & Sci Univ, Dept Neurol Surg, Portland, OR 97201 USA.
   [Smith, Justin S.; Shaffrey, Christopher I.] Univ Virginia, Dept Neurosurg, Charlottesville, VA USA.
   [Devin, Clinton J.] Orthopaed Steamboat Springs, Steamboat Springs, CO USA.
RP Zuckerman, SL (reprint author), Vanderbilt Univ, Dept Neurol Surg, 221 Kirkland Hall, Nashville, TN 37235 USA.
EM scott.zuckerman@vumc.org
CR Acaroglu E, 2017, ACTA ORTHOP TRAUMATO, V51, P181, DOI 10.1016/j.aott.2017.03.003
   Ames Christopher P, 2016, Spine Deform, V4, P310, DOI 10.1016/j.jspd.2015.12.009
   Ames Christopher P, 2013, Spine Deform, V1, P51, DOI 10.1016/j.jspd.2012.10.004
   Auerbach JD, 2008, SPINE, V33, P1113, DOI 10.1097/BRS.0b013e31816f69cf
   Badlani N, 2013, SPINE, V38, P1288, DOI 10.1097/BRS.0b013e318291b752
   Bydon M, 2015, J NEUROSURG, V122, P955, DOI 10.3171/2014.11.JNS14890
   Di Capua J, 2017, SPINE, V42, P595, DOI 10.1097/BRS.0000000000001840
   Drazin D, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.7.FOCUS11145
   Eastlack RK, 2017, SPINE J S, V17, pS189
   Gomez JA, 2017, SPINE, V42, P992, DOI 10.1097/BRS.0000000000002071
   Halanski MA, 2013, J ORTHOP, V10, P54, DOI 10.1016/j.jor.2013.03.001
   Iglehart JK, 2002, NEW ENGL J MED, V346, P1924, DOI 10.1056/NEJMhpr020324
   Kothari P, 2017, GLOB SPINE J, V7, P39, DOI 10.1055/s-0036-1583946
   Kothari P, 2016, SPINE, V41, P1296, DOI 10.1097/BRS.0000000000001522
   Kothari P, 2016, SPINE, V41, P1133, DOI 10.1097/BRS.0000000000001499
   Kwan MK, 2017, SPINE J, V17, P224, DOI 10.1016/j.spinee.2016.09.005
   Leven DM, 2016, SPINE, V41, pE1394, DOI 10.1097/BRS.0000000000001886
   Pateder DB, 2008, SPINE, V33, P1224, DOI 10.1097/BRS.0b013e3181714a66
   Phan K, 2017, GLOB SPINE J, V7, P664, DOI 10.1177/2192568217701110
   Scheer JK, 2017, SPINE, V42, P932, DOI 10.1097/BRS.0000000000002070
   Scheer JK, 2015, J NEUROSURG-SPINE, V22, P540, DOI 10.3171/2014.10.SPINE14475
   Scheer JK, 2013, J NEUROSURG-SPINE, V19, P464, DOI 10.3171/2013.7.SPINE12901
   Schoenfeld AJ, 2013, ARCH ORTHOP TRAUM SU, V133, P1483, DOI 10.1007/s00402-013-1841-3
   Schwab FJ, 2012, EUR SPINE J, V21, P2603, DOI 10.1007/s00586-012-2370-4
   Shiloach M, 2010, J AM COLL SURGEONS, V210, P6, DOI 10.1016/j.jamcollsurg.2009.09.031
   Smith JS, 2009, NEUROSURGERY, V65, P93, DOI DOI 10.1227/01.NEU.0000347005.35282.6C
   Smith JS, 2016, J NEUROSURG-SPINE, V25, P1, DOI 10.3171/2015.11.SPINE151036
   Smith JS, 2009, NEUROSURGERY, V65, P86, DOI 10.1227/01.NEU.0000347005.35282.6C
   Yadla S, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2009.12.FOCUS09254
   Yoshida G, 2017, SPINE, V42, P411, DOI 10.1097/BRS.0000000000001770
NR 30
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2019
VL 122
BP E759
EP E764
DI 10.1016/j.wneu.2018.10.135
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HJ6UM
UT WOS:000457328100091
PM 30391619
DA 2020-05-12
ER

PT J
AU D'Agostino, PM
   Boundy, MJ
   Harwood, TD
   Carmichael, WW
   Neilan, BA
   Wood, SA
AF D'Agostino, Paul M.
   Boundy, Michael J.
   Harwood, Tim D.
   Carmichael, Wayne W.
   Neilan, Brett A.
   Wood, Susanna A.
TI Re-evaluation of paralytic shellfish toxin profiles in cyanobacteria
   using hydrophilic interaction liquid chromatography-tandem mass
   spectrometry
SO TOXICON
LA English
DT Article
DE Saxitoxin; Paralytic shellfish toxins; Hydrophilic interaction liquid
   chromatography-tandem mass spectrometry (HILIC-MS/MS); Cyanobacteria;
   Saxitoxin profiles
ID FRESH-WATER CYANOBACTERIUM; ANABAENA-CIRCINALIS;
   CYLINDROSPERMOPSIS-RACIBORSKII; SAXITOXIN ANALOGS;
   APHANIZOMENON-GRACILE; NONTOXIC STRAIN; IDENTIFICATION; GENE;
   QUANTITATION; RAPHIDIOPSIS
AB To date Paralytic shellfish toxin (PST) variants in cyanobacteria have primarily been characterized using high performance liquid chromatography coupled with fluorescence detection. In this study we re-evaluated the PST profiles of five cyanobacterial cultures (Dolichospermum circinale AWQC131C, Aphanizomenon sp. NH-5, Raphidiopsis raciborskii T3, Scytonema cf. crispum CAWBG524 and CAWBG72) and one environmental sample (Microseria wollei) using hydrophilic interaction liquid chromatography coupled with electrospray ionization tandem mass spectrometry. A total of 35 different PST variants were detected. D. circinale contained the highest number of variants (23), followed by S. cf. crispum CAWBG72 (21). Many of the variants detected in the cultures/environmental sample had not been reported from these strains previously: D. circinale (14 variants), S. cf. crispum CAWBG72 (16), S. cf. crispum CAWBG524 (9), Aphanizomenon sp. (9), R. raciborskii (7), and M. wollei (7). Of particular interest was the detection of M-toxins (Aphanizomenon sp., R. raciborskii, D. circinale). These have previously only been identified from shellfish where they were thought to be metabolites. Well-characterized PST variant profiles are essential for research investigating the genetic basis of PST production, and given that the toxicity of each variants differs, it will assist in refining risk assessments.
C1 [D'Agostino, Paul M.; Neilan, Brett A.] Univ New South Wales, Sch Biotechnol & Biomol Sci, Kensington, NSW 2052, Australia.
   [D'Agostino, Paul M.] Tech Univ Munich, Dept Chem, Biosyst Chem, Lichtenbergstr 4, D-85748 Garching, Germany.
   [D'Agostino, Paul M.] Tech Univ Munich, Ctr Integrated Prot Sci Munich CIPSM, Lichtenbergstr 4, D-85748 Garching, Germany.
   [Boundy, Michael J.; Harwood, Tim D.; Wood, Susanna A.] Cawthron Inst, 98 Halifax St East,Private Bag 2, Nelson 7010, New Zealand.
   [Carmichael, Wayne W.] Wright State Univ, Dept Biol Sci, Dayton, OH 45435 USA.
   [Neilan, Brett A.] Univ Newcastle, Sch Environm & Life Sci, Newcastle, NSW, Australia.
RP D'Agostino, PM (reprint author), Tech Univ Munich, Dept Chem, Biosyst Chem, Lichtenbergstr 4, D-85748 Garching, Germany.; D'Agostino, PM (reprint author), Tech Univ Munich, Ctr Integrated Prot Sci Munich CIPSM, Lichtenbergstr 4, D-85748 Garching, Germany.
EM p.dagostino@tum.de; tim.harwood@cawthron.org.nz;
   wayne.carmichael@wright.edu; brett.neilan@newcastle.edu.au;
   susie.wood@cawthron.org.nz
RI D'Agostino, Paul M/B-9890-2015
OI D'Agostino, Paul M/0000-0002-8323-5416; Wood,
   Susanna/0000-0003-1976-8266
FU New Zealand Ministry of Business, Innovation and EmploymentNew Zealand
   Ministry of Business, Innovation and Employment (MBIE) [UOWX1503,
   CAWX1317]; Australian Research Council Discovery Grant schemeAustralian
   Research Council
FX S.A.W., T.D.H. and M.J.B. thank the New Zealand Ministry of Business,
   Innovation and Employment (UOWX1503; Enhancing the health and resilience
   of New Zealand lakes', CAWX1317; Safe New Zealand Seafood). PMD and BAN
   thank funding by the Australian Research Council Discovery Grant scheme.
CR Aguilera A, 2018, PHYCOLOGIA, V57, P130, DOI 10.2216/17-2.1
   Baker TR, 2003, TOXICON, V41, P339, DOI 10.1016/S0041-0101(02)00314-8
   Ballot A, 2010, APPL ENVIRON MICROB, V76, P1173, DOI 10.1128/AEM.02285-09
   Bolch CJS, 1996, J APPL PHYCOL, V8, P5, DOI 10.1007/BF02186215
   Boundy MJ, 2015, J CHROMATOGR A, V1387, P1, DOI 10.1016/j.chroma.2015.01.086
   Carmichael WW, 1997, APPL ENVIRON MICROB, V63, P3104, DOI 10.1128/AEM.63.8.3104-3110.1997
   Cho Y, 2015, HARMFUL ALGAE, V49, P58, DOI 10.1016/j.hal.2015.09.003
   Chun SW, 2018, J AM CHEM SOC, V140, P2430, DOI 10.1021/jacs.7b13297
   Cullen A, 2018, ACS CHEM BIOL, V13, P3107, DOI 10.1021/acschembio.8b00608
   D'Agostino PM, 2014, TOXINS AND BIOLOGICALLY ACTIVE COMPOUNDS FROM MICROALGAE, VOL 1: ORIGIN, CHEMISTRY AND DETECTION, P251
   D'Agostino PM, 2016, ENVIRON MICROBIOL, V18, P461, DOI 10.1111/1462-2920.13131
   D'Agostino PM, 2014, J PROTEOME RES, V13, P1474, DOI 10.1021/pr401007k
   Dell'Aversano C, 2005, J CHROMATOGR A, V1081, P190, DOI 10.1016/j.chroma.2005.05.056
   Dell'Aversano C, 2008, J NAT PROD, V71, P1518, DOI 10.1021/np800066r
   Dias E, 2002, J PHYCOL, V38, P705, DOI 10.1046/j.1529-8817.2002.01146.x
   Epstein-Barash H, 2009, P NATL ACAD SCI USA, V106, P7125, DOI 10.1073/pnas.0900598106
   Foss AJ, 2012, TOXICON, V60, P1148, DOI 10.1016/j.toxicon.2012.07.009
   Hackett JD, 2013, MOL BIOL EVOL, V30, P70, DOI 10.1093/molbev/mss142
   Halme M, 2012, J CHROMATOGR B, V880, P50, DOI 10.1016/j.jchromb.2011.11.015
   Kellmann R, 2008, APPL ENVIRON MICROB, V74, P4044, DOI 10.1128/AEM.00353-08
   KOEHN FE, 1981, BIOORG CHEM, V10, P412, DOI 10.1016/0045-2068(81)90053-5
   Lagos N, 1999, TOXICON, V37, P1359, DOI 10.1016/S0041-0101(99)00080-X
   Lawrence JF, 2005, J AOAC INT, V88, P1714
   LeDoux M, 2000, J AOAC INT, V83, P305
   Li RH, 2000, HYDROBIOLOGIA, V438, P99, DOI 10.1023/A:1004166029866
   Li RH, 2003, J PHYCOL, V39, P814, DOI 10.1046/j.1529-8817.2003.02199.x
   Liu YM, 2006, ENVIRON TOXICOL, V21, P289, DOI 10.1002/tox.20182
   Llewellyn LE, 2006, NAT PROD REP, V23, P200, DOI 10.1039/b501296c
   Llewellyn LE, 2001, ENVIRON SCI TECHNOL, V35, P1445, DOI 10.1021/es001575z
   Lukowski AL, 2018, J AM CHEM SOC, V140, P11863, DOI 10.1021/jacs.8b08901
   MAHMOOD NA, 1986, TOXICON, V24, P175, DOI 10.1016/0041-0101(86)90120-0
   McGregor GB, 2015, J PHYCOL, V51, P109, DOI 10.1111/jpy.12256
   McLaughlin Joseph B., 2011, Morbidity and Mortality Weekly Report, V60, P1554
   Mihali TK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014657
   Mihali Troco K, 2009, BMC Biochem, V10, P8, DOI 10.1186/1471-2091-10-8
   NEGRI AP, 1995, TOXICON, V33, P1321, DOI 10.1016/0041-0101(95)00068-W
   Ongley SE, 2016, ENVIRON MICROBIOL, V18, P427, DOI 10.1111/1462-2920.13048
   Onodera Hideyuki, 1997, Natural Toxins, V5, P146
   Orr RJS, 2013, APPL ENVIRON MICROB, V79, P2128, DOI 10.1128/AEM.03279-12
   OSHIMA Y, 1993, MAR BIOL, V116, P471, DOI 10.1007/BF00350064
   OSHIMA Y, 1995, J AOAC INT, V78, P528
   Pereira P, 2004, EUR J PHYCOL, V39, P361, DOI 10.1080/09670260410001714723
   Pereyra JPA, 2017, TOXICON, V138, P68, DOI 10.1016/j.toxicon.2017.08.006
   Plominsky AM, 2009, LETT APPL MICROBIOL, V49, P332, DOI 10.1111/j.1472-765X.2009.02665.x
   Pomati F, 2000, J PHYCOL, V36, P553, DOI 10.1046/j.1529-8817.2000.99181.x
   Smith FMJ, 2012, PHYCOLOGIA, V51, P542, DOI 10.2216/11-84.1
   Smith FMJ, 2011, TOXICON, V57, P566, DOI 10.1016/j.toxicon.2010.12.020
   Soto-Liebe K, 2012, TOXICON, V60, P1324, DOI 10.1016/j.toxicon.2012.09.001
   Soto-Liebe K, 2010, TOXICON, V56, P1350, DOI 10.1016/j.toxicon.2010.07.022
   Steffensen D, 1999, ENVIRON TOXICOL, V14, P183, DOI 10.1002/(SICI)1522-7278(199902)14:1<183::AID-TOX24>3.0.CO;2-G
   Steffensen DA, 2008, ADV EXP MED BIOL, V619, P855, DOI 10.1007/978-0-387-75865-7_37
   Stevens M, 2011, FRONT PHARMACOL, V2, DOI 10.3389/fphar.2011.00071
   Stucken K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009235
   Stuken A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020096
   Thomas KM, 2017, ANAL BIOANAL CHEM, V409, P5675, DOI 10.1007/s00216-017-0507-3
   Tsuchiya S, 2017, ANGEW CHEM INT EDIT, V56, P5327, DOI 10.1002/anie.201612461
   Tsuchiya S, 2016, SCI REP-UK, V6, DOI 10.1038/srep20340
   Tsuchiya S, 2015, CHEM-EUR J, V21, P7835, DOI 10.1002/chem.201500064
   Tsuchiya S, 2014, ORG BIOMOL CHEM, V12, P3016, DOI 10.1039/c4ob00071d
   Turnbull A, 2013, COMMUN DIS INTELL, V37, pE52
   Turner AD, 2015, J AOAC INT, V98, P609, DOI 10.5740/jaoacint.14-275
   Vale P, 2010, PHYTOCHEM REV, V9, P525, DOI 10.1007/s11101-010-9196-7
   Vale P, 2010, TOXICON, V55, P162, DOI 10.1016/j.toxicon.2009.07.010
   van de Riet J, 2011, J AOAC INT, V94, P1154
   Wang DZ, 2016, J PROTEOMICS, V135, P132, DOI 10.1016/j.jprot.2015.08.008
   Wiese M, 2010, MAR DRUGS, V8, P2185, DOI 10.3390/md8072185
   Willis A, 2016, TOXICON, V119, P307, DOI 10.1016/j.toxicon.2016.07.005
NR 67
TC 4
Z9 4
U1 9
U2 15
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD FEB
PY 2019
VL 158
BP 1
EP 7
DI 10.1016/j.toxicon.2018.11.301
PG 7
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HL3EP
UT WOS:000458596000001
PM 30471380
DA 2020-05-12
ER

PT J
AU Blanshan, N
   Mahowald, ML
   Dorman, C
   Frizelle, S
   Krug, HE
AF Blanshan, Nicole
   Mahowald, Maren L.
   Dorman, Christopher
   Frizelle, Sandra
   Krug, Hollis E.
TI The analgesic effect of intraarticular OnabotulinumtoxinA in a female
   murine model of collagenase induced chronic degenerative monoarthritis
SO TOXICON
LA English
DT Article
DE Botox (TM); Osteoarthritis; Mouse; Pain; Neurotoxins
ID BOTULINUM-TOXIN-A; ARTHROSCOPIC SURGERY; RHEUMATIC CONDITIONS;
   CONTROLLED-TRIAL; PAIN; OSTEOARTHRITIS; ARTHRITIS; PREVALENCE;
   NEUROTOXINS; MECHANISM
AB Purpose: We previously reported the efficacy of intraarticular (IA) rimabotulinumtoxinB (BoNT/B) in a murine model of chronic degenerative arthritis pain. This study aimed to measure the analgesic effects of onabotulinumtoxinA (BoNT/A) on collagenase induced chronic degenerative arthritis joint pain.
   Methods: Chronic degenerative arthritis was produced by IA injection of 10 I collagenase (Col) (10 IU) into the left knee of C57BL/6J female mice 4 weeks prior to pain assessment. IA BoNT/A was injected 3 days before testing. Arthritis pain was measured as evoked pain scores (EPS) and spontaneous pain behaviors with an advanced dynamic weight bearing (ADWB) device. EPS was a tally of fights and vocalizations exhibited in one minute with knee palpation. Percent body weight and percent time spent on each limb was quantified. All mice were 12 weeks old at the time of examination.
   Results: IA Col increased EPS and reduced ADWB measures of percent weight bearing on the left hind limb compared to naive mice. BoNT/A treatment reduced EPS and increased weight bearing on the left hind limb. The improvements were not significant compared to the Col group. There was no significant difference in time spent on the left hind limb between any treatment groups. Forelimb ADWB measures of percent weight and time in arthritic mice significantly increased compared to nonarthritic animals. Treatment with BoNT/A in the arthritic limb decreased this offloading; however, statistical analysis only showed significance in weightbearing.
   Conclusion: IA Col monoarthritis increased evoked and spontaneous pain behaviors in female mice after four weeks. Treatment with IA BoNT/A decreased pain behaviors but only forelimb weight bearing showed a significant improvement. This led us to conclude that treatment with BoNT/A is not an effective analgesic for the treatment of chronic degenerative knee arthritis in murine models.
C1 [Blanshan, Nicole; Mahowald, Maren L.; Dorman, Christopher; Frizelle, Sandra; Krug, Hollis E.] Vet Affairs Med Ctr, Rheumatol Dept, Minneapolis, MN USA.
   [Mahowald, Maren L.; Krug, Hollis E.] Univ Minnesota, Dept Med, Box 736 UMHC, Minneapolis, MN 55455 USA.
RP Krug, HE (reprint author), Rheumatol 111R,One Vet Dr, Minneapolis, MN 55417 USA.
EM nicole.blanshan@va.gov; mahow001@gmail.com; christopher.dorman@va.gov;
   sandra.frizelle@va.gov; hollis.krug@va.gov
FU Merit Review AwardUS Department of Veteran Affairs [RX000379-05]; US
   Department of Veterans Affairs Rehabilitation Research and Development
   ServiceUS Department of Veteran Affairs
FX This work was supported by Merit Review Award #RX000379-05 from the US
   Department of Veterans Affairs Rehabilitation Research and Development
   Service. The contents do not represent the views of the US department of
   Veterans Affairs or the United States Government.
CR Abdullah M, 2016, J PAIN RES, V9, P563, DOI 10.2147/JPR.S107385
   Anderson Stephanie, 2010, J Pain Res, V3, P161, DOI 10.2147/JPR.S12520
   Aoki KR, 2008, J NEURAL TRANSM, V115, P567, DOI 10.1007/s00702-007-0758-9
   Aoki KR, 2005, NEUROTOXICOLOGY, V26, P785, DOI 10.1016/j.neuro.2005.01.017
   Aoki KR, 2001, EUR J NEUROL, V8, P21, DOI 10.1046/j.1468-1331.2001.00035.x
   Berntsson RPA, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3058
   Bert J., 2016, INT MED REV, V2016, P89
   Burstein R, 2014, CEPHALALGIA, V34, P853, DOI 10.1177/0333102414527648
   Centers for Disease Control and Prevention (CDC), 2010, MMWR Morb Mortal Wkly Rep, V59, P1261
   Conaghan PG, 2012, RHEUMATOL INT, V32, P1491, DOI 10.1007/s00296-011-2263-6
   Cui ML, 2004, PAIN, V107, P125, DOI 10.1016/j.pain.2003.10.008
   Doherty M, 2011, ANN RHEUM DIS, V70, P1534, DOI 10.1136/ard.2011.154047
   Dolly JO, 2006, EUR J NEUROL, V13, P1, DOI 10.1111/j.1468-1331.2006.01648.x
   Dorman HW, 2014, J PAIN RES, V7, P25, DOI 10.2147/JPR.S52195
   Favre-Guilmard C, 2017, EUR J PAIN, V21, P927, DOI 10.1002/ejp.995
   Fischer A, 2007, J BIOL CHEM, V282, P29604, DOI 10.1074/jbc.M703619200
   Glasson SS, 2010, OSTEOARTHR CARTILAGE, V18, pS17, DOI 10.1016/j.joca.2010.05.025
   Griffioen MA, 2015, NURS RES, V64, P81, DOI 10.1097/NNR.0000000000000082
   Hootman JM, 2016, ARTHRITIS RHEUMATOL, V68, P1582, DOI 10.1002/art.39692
   Hootman JM, 2006, ARTHRITIS RHEUM-US, V54, P226, DOI 10.1002/art.21562
   Kirkley A, 2008, NEW ENGL J MED, V359, P1097, DOI 10.1056/NEJMoa0708333
   Kotlarz H, 2010, J OCCUP ENVIRON MED, V52, P263, DOI 10.1097/JOM.0b013e3181cf00aa
   Lam FFY, 2004, INT IMMUNOPHARMACOL, V4, P299, DOI 10.1016/j.intimp.2004.01.009
   Lawrence RC, 2008, ARTHRITIS RHEUM, V58, P26, DOI 10.1002/art.23176
   Malfait AM, 2010, OSTEOARTHR CARTILAGE, V18, P572, DOI 10.1016/j.joca.2009.11.013
   Malfait AM, 2013, NAT REV RHEUMATOL, V9, P654, DOI 10.1038/nrrheum.2013.138
   Marinelli S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047977
   Mense S, 2004, J NEUROL, V251, P1, DOI 10.1007/s00415-004-1102-z
   Meziane H, 2007, GENES BRAIN BEHAV, V6, P192, DOI 10.1111/j.1601-183X.2006.00249.x
   Miller RE, 2014, CYTOKINE, V70, P185, DOI 10.1016/j.cyto.2014.06.019
   Mogil JS, 2009, NAT REV NEUROSCI, V10, P283, DOI 10.1038/nrn2606
   Moseley JB, 2002, NEW ENGL J MED, V347, P81, DOI 10.1056/NEJMoa013259
   National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals, 2011, GUIDE CARE USE LAB A
   Neogi T, 2013, OSTEOARTHR CARTILAGE, V21, P1145, DOI 10.1016/j.joca.2013.03.018
   Oh HM, 2015, TOXINS, V7, P3127, DOI 10.3390/toxins7083127
   Pellizzari R, 1999, PHILOS T ROY SOC B, V354, P259, DOI 10.1098/rstb.1999.0377
   Pirazzini M, 2017, PHARMACOL REV, V69, P200, DOI 10.1124/pr.116.012658
   Restani L, 2011, J NEUROSCI, V31, P15650, DOI 10.1523/JNEUROSCI.2618-11.2011
   Rummel A, 2017, CURR TOP MICROBIOL, V406, P1, DOI 10.1007/82_2016_48
   Schaible FG, 2006, ADV DRUG DELIVER REV, V58, P323, DOI 10.1016/j.addr.2006.01.011
   Stern D, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007048
   Strotmeier J, 2014, FEBS LETT, V588, P1087, DOI 10.1016/j.febslet.2014.02.034
   Theis KA, 2007, ARTHRIT RHEUM-ARTHR, V57, P355, DOI 10.1002/art.22622
   VANDERKRAAN PM, 1990, J EXP PATHOL, V71, P19
   Verderio C, 2007, TRAFFIC, V8, P142, DOI 10.1111/j.1600-0854.2006.00520.x
   Wenham CYJ, 2013, AGE AGEING, V42, P272, DOI 10.1093/ageing/aft043
   Yelin E, 2007, ARTHRITIS RHEUM-US, V56, P1397, DOI 10.1002/art.22565
   Zanetti G, 2015, BIOCHEM PHARMACOL, V98, P522, DOI 10.1016/j.bcp.2015.09.023
   Zhang W, 2010, OSTEOARTHR CARTILAGE, V18, P476, DOI 10.1016/j.joca.2010.01.013
   Ziv NY, 2016, EXP NEUROL, V275, P133, DOI 10.1016/j.expneurol.2015.09.020
NR 50
TC 0
Z9 0
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD FEB
PY 2019
VL 158
BP 8
EP 15
DI 10.1016/j.toxicon.2018.11.307
PG 8
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HL3EP
UT WOS:000458596000002
PM 30471381
OA Other Gold
DA 2020-05-12
ER

PT J
AU Siigur, J
   Aaspollu, A
   Siigur, E
AF Siigur, Jun
   Aaspollu, Anu
   Siigur, Ene
TI Biochemistry and pharmacology of proteins and peptides purified from the
   venoms of the snakes Macrovipera lebetina subspecies
SO TOXICON
LA English
DT Review
DE Vipera lebetina (Levantine viper); Macrovipera lebetina cemovi;
   Macrovipera lebetina lebetina; Macrovipera lebetina obtusa; Macrovipera
   lebetina transmediterranea; Macrovipera lebetina turanica; Snake; Venom;
   Blood coagulation; Cancer; Angiogenesis; Apoptosis
ID C-TYPE LECTIN; AMINO-ACID-SEQUENCE; NERVE GROWTH-FACTOR; ACTING
   FIBRINOLYTIC ENZYME; SERINE-PROTEASE INHIBITOR; V ACTIVATING ENZYME;
   CANCER CELL-GROWTH; FACTOR-X ACTIVATOR; VIPERA-LEBETINA; IN-VITRO
AB The isolation and characterization of individual snake venom components is important for a deeper understanding of the pathophysiology of envenomations, for improving the therapeutic procedures of patients, and it also opens possibilities for the discovery of novel toxins that might be useful as tools for understanding cellular and molecular processes. This review provides a summary of the different toxins that have been isolated and characterized from the venoms of Vipera lebetina (Macrovipera lebetina) subspecies Macrovipera lebetina cernovi, Macrovipera lebetina lebetina, Macrovipera lebetina obtusa, Macrovipera lebetina transmediterranea, Macrovipera lebetina turanica, the snake species causing the majority of human envenomings in Central Asia (Middle East) and North Africa. The venoms of these snakes contain proteins belonging to different families: Zn2+- metalloproteinases, serine proteinases, L-amino acid oxidase, 5'-nucleotidase, phosphodiesterase, phosphomonoesterase, nucleases, hyaluronidase, phospholipase A2, C-type lectin-like protein, disintegrin, DC-fragment, cystein-rich secretory protein, proteinase inhibitors, nerve growth factor (NGF), vascular endothelial growth factor (VEGF), low molecular weight peptides. Their main biochemical properties, toxic and pharmacological actions have been described. In this review we will provide an overview of the proteins and peptides from the venoms of M. lebetina subspecies, their biochemical, pharmacological and structural features and their role in snake venom toxinology. A lot of contributions have been made for better understandings of these venomous snakes, their venom, and their pharmacological effects. Many of these components are also fascinating models for drug design.
C1 [Siigur, Jun] NICPB, Lab Environm Toxicol, Akad Tee 23, EE-12618 Tallinn, Estonia.
   [Aaspollu, Anu] Natl Inst Hlth Dev, Tallinn, Estonia.
   [Siigur, Ene] NICPB, Tallinn, Estonia.
RP Siigur, J (reprint author), NICPB, Lab Environm Toxicol, Akad Tee 23, EE-12618 Tallinn, Estonia.
EM juri.siigur@kbfi.ee
RI Siigur, Juri/A-8660-2011
FU Estonian Science Foundation [1515, 3842, 4228, 5938, 7251, 9458,
   SF0690063s08]; NIH, USAUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [5R 37GM 15591]
FX We thank all colleagues and collaborators that have contributed to the
   study of M. L turanica venom at National Institute of Chemical Physics
   and Biophysics as well as prof. Anthony Tu from Colorado State
   University and prof. Nisse Kalkkinen from Helsinki University. Many of
   the studies reviewed in this work have been supported by Estonian
   Science Foundation grants 1515, 3842, 4228, 5554, 5938, 7251, 8899,
   9458, SF0690063s08 and NIH 5R 37GM 15591, USA, grants.
CR Aaspollu A, 2005, TOXICON, V46, P591, DOI 10.1016/j.toxicon.2005.07.001
   Aloui Z, 2009, BIOCHEM BIOPH RES CO, V389, P10, DOI 10.1016/j.bbrc.2009.08.068
   Amel KS, 2015, J BIOCHEM MOL TOXIC, V29, P388, DOI 10.1002/jbt.21709
   ARUMAE U, 1987, MOL IMMUNOL, V24, P1295, DOI 10.1016/0161-5890(87)90124-6
   BABKINA G. T., 1964, BIOKHIMIYA, V29, P268
   Barbouche R, 1998, TOXICON, V36, P1939, DOI 10.1016/S0041-0101(98)00118-4
   Barbouche R, 1996, FEBS LETT, V392, P6, DOI 10.1016/0014-5793(96)00774-0
   Bazaa A, 2005, PROTEOMICS, V5, P4223, DOI 10.1002/pmic.200402024
   Bazaa A, 2007, J MOL EVOL, V64, P261, DOI 10.1007/s00239-006-0161-4
   Bazaa A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010124
   Bazaa A, 2009, MATRIX BIOL, V28, P188, DOI 10.1016/j.matbio.2009.03.007
   Bazan-Socha S, 2004, BIOCHEMISTRY-US, V43, P1639, DOI 10.1021/bi035853t
   Bennacef-Heffar N, 2003, CAN J PHYSIOL PHARM, V81, P1110, DOI [10.1139/y03-112, 10.1139/Y03-112]
   Bennacef-Heffar N, 2017, ACTA TROP, V171, P226, DOI 10.1016/j.actatropica.2017.04.012
   Black RA, 1998, CURR OPIN CELL BIOL, V10, P654, DOI 10.1016/S0955-0674(98)80042-2
   Boumaiza S, 2016, BIOLOGICALS, V44, P1, DOI 10.1016/j.biologicals.2015.11.002
   Brown MC, 2008, INT J CANCER, V123, P2195, DOI 10.1002/ijc.23777
   Brown MC, 2009, BIOCHEM J, V417, P95, DOI 10.1042/BJ20081403
   Calvete JJ, 2005, TOXICON, V45, P1063, DOI 10.1016/j.toxicon.2005.02.024
   Calvete JJ, 2005, CURR PHARM DESIGN, V11, P829, DOI 10.2174/1381612053381783
   Calvete JJ, 2003, BIOCHEM J, V372, P725, DOI 10.1042/BJ20021739
   Calvete JJ, 2017, BIOCHEM J, V474, P611, DOI 10.1042/BCJ20160577
   Carbajo RJ, 2015, FEBS J, V282, P341, DOI 10.1111/febs.13138
   Casewell NR, 2014, P NATL ACAD SCI USA, V111, P9205, DOI 10.1073/pnas.1405484111
   Clemetson KJ, 2009, J THROMB HAEMOST, V7, P360, DOI 10.1111/j.1538-7836.2008.03233.x
   Clemetson KJ, 2010, TOXICON, V56, P1236, DOI 10.1016/j.toxicon.2010.03.011
   COHEN S, 1956, P NATL ACAD SCI USA, V42, P571, DOI 10.1073/pnas.42.9.571
   COHEN S, 1954, P NATL ACAD SCI USA, V40, P1014, DOI 10.1073/pnas.40.10.1014
   Daidone I, 2013, BIOPOLYMERS, V99, P47, DOI 10.1002/bip.22138
   Doley Robin, 2010, P173
   Eble JA, 2003, J BIOL CHEM, V278, P26488, DOI 10.1074/jbc.M301860200
   Fatehi-Hassanabad Z, 2004, TOXICON, V43, P385, DOI 10.1016/j.toxicon.2004.01.010
   Fox JW, 2008, FEBS J, V275, P3016, DOI 10.1111/j.1742-4658.2008.06466.x
   Fox JW, 2013, TOXICON, V62, P75, DOI 10.1016/j.toxicon.2012.09.009
   Fox Jay W., 2010, P95
   Fox JW, 2005, TOXICON, V45, P969, DOI 10.1016/j.toxicon.2005.02.012
   Gasmi A, 2002, J BIOL CHEM, V277, P29992, DOI 10.1074/jbc.M202202200
   Gasmi A, 2001, BBA-PROTEIN STRUCT M, V1547, P51, DOI 10.1016/S0167-4838(01)00168-6
   Gasmi A, 2000, BIOCHEM BIOPH RES CO, V268, P69, DOI 10.1006/bbrc.2000.2078
   Gasmi A, 1997, THROMB RES, V86, P233, DOI 10.1016/S0049-3848(97)00066-2
   GASMI A, 1991, TOXICON, V29, P827, DOI 10.1016/0041-0101(91)90219-H
   Gasmi A, 2000, BBA-PROTEIN STRUCT M, V1481, P209, DOI 10.1016/S0167-4838(00)00128-X
   Gasmi Ammar, 1994, Natural Toxins, V2, P44, DOI 10.1002/nt.2620020109
   Ghazaryan NA, 2015, EUR J PHARMACOL, V764, P340, DOI 10.1016/j.ejphar.2015.07.011
   Ghazaryan NA, 2015, BBA-BIOMEMBRANES, V1848, P463, DOI 10.1016/j.bbamem.2014.10.037
   Hammouda MB, 2018, BBA-GEN SUBJECTS, V1862, P600, DOI 10.1016/j.bbagen.2017.11.019
   Hammouda MB, 2016, TOXINS, V8, DOI 10.3390/toxins8070206
   Hamza L, 2010, TOXICON, V56, P381, DOI 10.1016/j.toxicon.2010.04.001
   Hamza L, 2010, BIOCHIMIE, V92, P797, DOI 10.1016/j.biochi.2010.02.025
   Harrison RA, 2007, GENE, V392, P22, DOI 10.1016/j.gene.2006.10.026
   Igci N, 2012, ARCH TOXICOL, V86, P441, DOI 10.1007/s00204-011-0763-5
   Jebali J, 2014, TOXICON, V86, P16, DOI 10.1016/j.toxicon.2014.04.010
   Jebali J, 2012, BIOTECHNOL PROGR, V28, P1560, DOI 10.1002/btpr.1632
   Jebali J, 2009, TOXICON, V53, P228, DOI 10.1016/j.toxicon.2008.11.006
   Kakanj M, 2015, IRAN J PHARM RES, V14, P109
   Kollipara PS, 2014, BIOMOL THER, V22, P106, DOI 10.4062/biomolther.2013.103
   Kurtovic T, 2014, TOXICON, V78, P103, DOI 10.1016/j.toxicon.2013.12.004
   Lamb T, 2017, CLIN TOXICOL, V55, P557, DOI 10.1080/15563650.2017.1300261
   LATIFI M, 1984, TOXICON, V22, P373, DOI 10.1016/0041-0101(84)90081-3
   Lee HL, 2016, ARCH TOXICOL, V90, P463, DOI 10.1007/s00204-014-1393-5
   Lee HL, 2015, ONCOTARGET, V6, P22139, DOI 10.18632/oncotarget.4192
   Leonardi A, 2014, TOXICON, V77, P141, DOI 10.1016/j.toxicon.2013.11.009
   LEVIMONTALCINI R, 1954, CANCER RES, V14, P49
   Limam I, 2010, MATRIX BIOL, V29, P117, DOI 10.1016/j.matbio.2009.09.009
   Lopp A, 2010, MAR DRUGS, V8, P235, DOI 10.3390/md8020235
   MAHAR A, 1987, BIOCHIM BIOPHYS ACTA, V925, P272, DOI 10.1016/0304-4165(87)90192-9
   Makran B, 2012, J PROTEOMICS, V75, P2431, DOI 10.1016/j.jprot.2012.02.022
   Marcinkiewicz C, 2003, CANCER RES, V63, P2020
   Markland FS, 2013, TOXICON, V62, P3, DOI 10.1016/j.toxicon.2012.09.004
   Marrakchi N, 2001, HAEMOSTASIS, V31, P207
   McLane MA, 1998, P SOC EXP BIOL MED, V219, P109, DOI 10.3181/00379727-219-44322
   Monleon D, 2003, J BIOL CHEM, V278, P45570, DOI 10.1074/jbc.M307030200
   Montassar F, 2017, FASEB J, V31, P1107, DOI 10.1096/fj.201600351R
   Moreno-Murciano MP, 2003, J MOL BIOL, V329, P135, DOI 10.1016/S0022-2836(03)00371-1
   Moreno-Murciano MP, 2003, PROTEIN SCI, V12, P366, DOI 10.1110/ps.0230203
   Morjen M, 2018, INT J BIOL MACROMOL, V117, P790, DOI 10.1016/j.ijbiomac.2018.05.230
   Morjen M, 2014, MICROVASC RES, V95, P149, DOI 10.1016/j.mvr.2014.08.006
   Morjen M, 2013, MATRIX BIOL, V32, P52, DOI 10.1016/j.matbio.2012.11.015
   Nalbantsoy A, 2012, J VENOM ANIM TOXINS, V18, P208, DOI 10.1590/S1678-91992012000200011
   NIKOL'SKAYA I. I., 1965, BIGKHIMIYA, V30, P1236
   NIKOLSKAJA II, 1962, BIOCHIM BIOPHYS ACTA, V64, P197, DOI 10.1016/0006-3002(62)90780-1
   NIKOLSKAYA II, 1963, BIOCHEMISTRY-MOSCOW+, V28, P759
   Oghalaie Akbar, 2017, J Family Med Prim Care, V6, P780, DOI 10.4103/jfmpc.jfmpc_208_17
   Olfa KZ, 2005, LAB INVEST, V85, P1507, DOI 10.1038/labinvest.3700350
   Ozen MO, 2015, FRONT LIFE SCI, V8, P363, DOI 10.1080/21553769.2015.1055862
   PAALME VA, 1988, DOKL AKAD NAUK SSSR+, V301, P754
   Paalme V, 2009, TOXICON, V54, P329, DOI 10.1016/j.toxicon.2009.05.001
   Park MH, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-228
   Park MH, 2009, ARCH PHARM RES, V32, P1545, DOI 10.1007/s12272-009-2106-0
   Pilorget A, 2007, J CELL PHYSIOL, V211, P307, DOI 10.1002/jcp.20935
   Pla D, 2017, BBA-GEN SUBJECTS, V1861, P814, DOI 10.1016/j.bbagen.2017.01.020
   RANDOLPH A, 1992, PROTEIN SCI, V1, P590, DOI 10.1002/pro.5560010505
   Rosenow Felix, 2008, Neoplasia, V10, P168, DOI 10.1593/neo.07898
   Rosing J, 2001, HAEMOSTASIS, V31, P241
   SAARMA MI, 1984, DOKL AKAD NAUK SSSR+, V277, P1267
   Saidi N, 1999, BBA-PROTEIN STRUCT M, V1434, P94, DOI 10.1016/S0167-4838(99)00164-8
   SAKHIBOV DN, 1972, BIOCHEMISTRY-USSR+, V37, P841
   Samel M, 2002, TOXICON, V40, P51, DOI 10.1016/S0041-0101(01)00187-8
   Samel M, 2013, TOXINS, V5, P203, DOI 10.3390/toxins5020203
   Samel M, 2012, TOXICON, V60, P648, DOI 10.1016/j.toxicon.2012.03.023
   Sanz L, 2006, BIOCHEM J, V395, P385, DOI 10.1042/BJ20051678
   Sanz L, 2008, J PROTEOMICS, V71, P198, DOI [10.1016/j.jprot.2008.05.003, 10.1016/j.jprot.2008.03.001]
   Sanz-Soler R, 2016, INTEGR COMP BIOL, V56, P989, DOI 10.1093/icb/icw031
   Sanz-Soler R, 2012, TOXICON, V60, P665, DOI 10.1016/j.toxicon.2012.05.010
   Sarray S, 2004, LAB INVEST, V84, P573, DOI 10.1038/labinvest.3700088
   Sarray S, 2003, BBA-PROTEINS PROTEOM, V1651, P30, DOI 10.1016/S1570-9639(03)00232-2
   Sarray S, 2001, HAEMOSTASIS, V31, P173
   Sarray S, 2007, MATRIX BIOL, V26, P306, DOI 10.1016/j.matbio.2007.01.001
   Sarray S, 2009, CANCER LETT, V285, P174, DOI 10.1016/j.canlet.2009.05.012
   Sebia-Amrane F, 2013, INFLAMMATION, V36, P434, DOI 10.1007/s10753-012-9563-1
   Sharma LR, 2008, WILD ENVIRON MED, V19, P195, DOI 10.1580/07-WEME-CR-175.1
   SIIGUR E, 1991, TOXICON, V29, P107, DOI 10.1016/0041-0101(91)90043-Q
   Siigur E, 1998, BBA-PROTEIN STRUCT M, V1429, P239, DOI 10.1016/S0167-4838(98)00232-5
   Siigur E, 1999, BIOCHEM BIOPH RES CO, V262, P328, DOI 10.1006/bbrc.1999.1200
   Siigur E, 2000, COMP BIOCHEM PHYS B, V126, P377, DOI 10.1016/S0305-0491(00)00187-5
   Siigur E, 2004, BBA-PROTEINS PROTEOM, V1702, P41, DOI 10.1016/j.bbapap.2004.07.007
   Siigur E, 2003, THROMB HAEMOSTASIS, V89, P826
   Siigur E, 1996, BIOCHEM BIOPH RES CO, V224, P229, DOI 10.1006/bbrc.1996.1012
   SIIGUR E, 1985, COMP BIOCHEM PHYS B, V81, P211, DOI 10.1016/0305-0491(85)90185-3
   Siigur E, 2001, BBA-GEN SUBJECTS, V1568, P90, DOI 10.1016/S0304-4165(01)00206-9
   Siigur E., 1983, Eesti NSV Teaduste Akadeemia Toimetised Keemia, V32, P58
   SIIGUR E, 1991, BIOCHIM BIOPHYS ACTA, V1074, P223, DOI 10.1016/0304-4165(91)90156-B
   Siigur E, 2001, GENE, V263, P199, DOI 10.1016/S0378-1119(00)00571-0
   Siigur E., 2011, 17 C EUR SECT INT SO, P157
   Siigur E., 1990, 9 EUR S AN PLANT MIC, P57
   SIIGUR E P, 1982, Biokhimiya, V47, P1730
   Siigur E, 2011, BIOCHIMIE, V93, P321, DOI 10.1016/j.biochi.2010.10.004
   SIIGUR J, 1987, COMP BIOCHEM PHYS B, V87, P329, DOI 10.1016/0305-0491(87)90147-7
   Siigur J, 2005, PATHOPHYSIOL HAEMO T, V34, P209, DOI 10.1159/000092426
   Siigur J, 1996, TOXICON, V34, P608, DOI 10.1016/0041-0101(95)00165-4
   Siigur J, 1998, THROMB RES, V90, P39, DOI 10.1016/S0049-3848(98)00009-7
   Siigur J, 2001, HAEMOSTASIS, V31, P123
   Siigur J, 2013, HANDBOOK OF PROTEOLYTIC ENZYMES, VOLS 1 AND 2, 3RD EDITION, P1054, DOI 10.1016/B978-0-12-382219-2.00236-2
   Son DJ, 2007, MOL CANCER THER, V6, P675, DOI 10.1158/1535-7163.MCT-06-0328
   Song JK, 2012, ARCH PHARM RES, V35, P867, DOI 10.1007/s12272-012-0512-1
   Suzergoz F, 2016, UHOD-ULUSLAR HEMATOL, V26, P37, DOI 10.4999/uhod.161104
   Takeda S, 2012, BBA-PROTEINS PROTEOM, V1824, P164, DOI 10.1016/j.bbapap.2011.04.009
   TAKEYA H, 1992, J BIOL CHEM, V267, P14109
   Tasoulis T, 2017, TOXINS, V9, DOI 10.3390/toxins9090290
   Titma T, 2014, TOXICOL LETT, V229, pS234, DOI 10.1016/j.toxlet.2014.06.784
   Tonismagi K, 2006, TOXICON, V48, P227, DOI 10.1016/j.toxicon.2006.05.004
   Tourki B, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162632
   Trummal K, 2005, TOXICON, V46, P46, DOI 10.1016/j.toxicon.2005.03.008
   Trummal K, 2000, BBA-PROTEIN STRUCT M, V1476, P331, DOI 10.1016/S0167-4838(99)00236-8
   Trummal K, 2016, TOXICON, V119, P39, DOI 10.1016/j.toxicon.2016.05.004
   Trummal K, 2015, TOXICON, V93, P155, DOI 10.1016/j.toxicon.2014.11.234
   Trummal K, 2014, BIOCHIMIE, V106, P48, DOI 10.1016/j.biochi.2014.07.020
   Trummal K, 2011, TOXICON, V58, P363, DOI 10.1016/j.toxicon.2011.07.005
   VASSILENKO SK, 1963, BIOCHEMISTRY-MOSCOW+, V28, P602
   Vija H, 2009, TOXICON, V54, P429, DOI 10.1016/j.toxicon.2009.05.010
   Vija H, 2009, COMP BIOCHEM PHYS B, V153, P253, DOI 10.1016/j.cbpb.2009.03.002
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   Yee KT, 2018, TOXICON, V146, P31, DOI 10.1016/j.toxicon.2018.03.005
   YUKELSON LY, 1991, TOXICON, V29, P491, DOI 10.1016/0041-0101(91)90023-K
   Zakraoui O, 2017, MOL CARCINOGEN, V56, P18, DOI 10.1002/mc.22470
   Zolfagharian H, 2015, HUM VACC IMMUNOTHER, V11, P2734, DOI 10.4161/21645515.2014.985492
   Zouari-Kessentini R, 2013, BIOMED RES INT, DOI 10.1155/2013/391389
NR 157
TC 2
Z9 2
U1 4
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD FEB
PY 2019
VL 158
BP 16
EP 32
DI 10.1016/j.toxicon.2018.11.294
PG 17
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HL3EP
UT WOS:000458596000003
PM 30472110
DA 2020-05-12
ER

PT J
AU Herzig, V
AF Herzig, Volker
TI Arthropod assassins: Crawling biochemists with diverse toxin
   pharmacopeias
SO TOXICON
LA English
DT Editorial Material
ID VENOM COMPONENTS; SPIDER VENOMS; SCORPION; EVOLUTION; WEB
AB The millions of extant arthropod species are testament to their evolutionary success that can at least partially be attributed to venom usage, which evolved independently in at least 19 arthropod lineages. While some arthropods primarily use venom for predation (e.g., spiders and centipedes) or defense (e.g., bees and caterpillars), it can also have more specialised functions (e.g. in parasitoid wasps to paralyse arthropods for their brood to feed on) or even a combination of functions (e.g. the scorpion Parabuthus transvaalicus can deliver a prevenom for predator deterrence and a venom for predation). Most arthropod venoms are complex cocktails of water, salts, small bioactive molecules, peptides, enzymes and larger proteins, with peptides usually comprising the majority of toxins. Some spider venoms have been reported to contain > 1000 peptide toxins, which function as combinatorial libraries to provide an evolutionary advantage. The astounding diversity of venomous arthropods multiplied by their enormous toxin arsenals results in an almost infinite resource for novel bioactive molecules. The main challenge for exploiting this resource is the small size of most arthropods, which can be a limitation for current venom extraction techniques. Fortunately, recent decades have seen an incredible improvement in transcriptomic and proteomic techniques that have provided increasing sensitivity while reducing sample requirements. In turn, this has provided a much larger variety of arthropod venom compounds for potential applications such as therapeutics, molecular probes for basic research, bioinsecticides or anti-parasitic drugs. This special issue of Toxicon aims to cover the breadth of arthropod venom research, including toxin evolution, pharmacology, toxin discovery and characterisation, toxin structures, clinical aspects, and potential applications.
C1 [Herzig, Volker] Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia.
RP Herzig, V (reprint author), Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia.
EM v.herzig@uq.edu.au
CR dos Santos-Pinto JRA, 2018, TOXICON, V148, P172, DOI 10.1016/j.toxicon.2018.04.029
   Berkov A, 2008, NATURWISSENSCHAFTEN, V95, P257, DOI 10.1007/s00114-007-0316-1
   Cabezas-Cruz A, 2014, FRONT ZOOL, V11, DOI 10.1186/1742-9994-11-47
   Cid-Uribe JI, 2018, TOXICON, V151, P47, DOI 10.1016/j.toxicon.2018.06.085
   da Silva CN, 2018, TOXICON, V150, P280, DOI 10.1016/j.toxicon.2018.06.073
   Daly NL, 2018, TOXICON, V152, P46, DOI 10.1016/j.toxicon.2018.07.018
   Escoubas P, 2006, TOXICON, V47, P650, DOI 10.1016/j.toxicon.2006.01.018
   Escoubas P, 2006, MOL DIVERS, V10, P545, DOI 10.1007/s11030-006-9050-4
   Foelix RF, 1992, BIOL DER SPINNEN
   Giribet G, 2012, ANNU REV ENTOMOL, V57, P167, DOI 10.1146/annurev-ento-120710-100659
   Guo SD, 2018, TOXICON, V150, P297, DOI 10.1016/j.toxicon.2018.06.077
   Hauke TJ, 2017, TOXICON, V138, P173, DOI 10.1016/j.toxicon.2017.08.024
   Herzig V, 2019, TOXICON, V158, P33, DOI 10.1016/j.toxicon.2018.11.312
   Ikonomopoulou MP, 2016, TOXICON, V123, P62, DOI 10.1016/j.toxicon.2016.10.013
   Inceoglu B, 2003, P NATL ACAD SCI USA, V100, P922, DOI 10.1073/pnas.242735499
   Jerusalem K, 2018, TOXICON, V156, P7, DOI 10.1016/j.toxicon.2018.10.304
   Laxme R. R. S., 2019, TOXICON, V158, P84
   Moreau SJM, 2015, TOXINS, V7, P2385, DOI 10.3390/toxins7072385
   Murienne J, 2008, MOL PHYLOGENET EVOL, V49, P170, DOI 10.1016/j.ympev.2008.06.002
   Ombati R, 2018, TOXICON, V154, P60, DOI 10.1016/j.toxicon.2018.09.008
   Ombati R, 2018, TOXICON, V148, P56, DOI 10.1016/j.toxicon.2018.04.011
   Ortiz E, 2018, TOXICON, V150, P17, DOI 10.1016/j.toxicon.2018.04.032
   Ortiz E, 2015, TOXICON, V93, P125, DOI 10.1016/j.toxicon.2014.11.233
   Palma MS, 2005, TOXIN REV, V24, P209, DOI 10.1081/TXR-200057857
   Peigneur S, 2018, TOXICON, V151, P96, DOI 10.1016/j.toxicon.2018.07.008
   Perez-Riverol A, 2017, J PROTEOMICS, V161, P88, DOI 10.1016/j.jprot.2017.04.016
   Pienaar R., 2018, VET SCI, V5
   POLIS GA, 1986, OECOLOGIA, V71, P111, DOI 10.1007/BF00377328
   Rein 10, 2018, SCORPION FILES
   Robinson SD, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aau4640
   Robinson SD, 2017, EXPERT REV PROTEOMIC, V14, P931, DOI 10.1080/14789450.2017.1377613
   Saez NJ, 2019, TOXICON, V158, P109, DOI 10.1016/j.toxicon.2018.11.298
   Santibanez-Lopez C, 2018, TOXINS, V10
   Schmidt JO, 2018, TOXICON, V150, P96, DOI 10.1016/j.toxicon.2018.05.013
   Sousa SR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182848
   Touchard A, 2016, TOXINS, V8, DOI 10.3390/toxins8010030
   Undheim EAB, 2016, EXPERT OPIN DRUG DIS, V11, P1139, DOI 10.1080/17460441.2016.1235155
   Undheim EAB, 2015, TOXINS, V7, P679, DOI 10.3390/toxins7030679
   Vetter RS, 2018, TOXICON, V152, P65, DOI 10.1016/j.toxicon.2018.07.021
   Villas-Boas IM, 2018, TOXICON, V153, P39, DOI 10.1016/j.toxicon.2018.08.007
   von Reumont BM, 2014, MOL BIOL EVOL, V31, P48, DOI 10.1093/molbev/mst199
   von Reumont BM, 2014, TOXINS, V6, P3488, DOI 10.3390/toxins6123488
   Walker AA, 2018, TOXICON, V154, P15, DOI 10.1016/j.toxicon.2018.09.004
   Walker AA, 2018, CELL MOL LIFE SCI, V75, P3215, DOI 10.1007/s00018-018-2768-1
   Walker AA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03091-5
   Walker AA, 2016, TOXINS, V8, DOI 10.3390/toxins8020043
   Ward MJ, 2018, TOXICON, V152, P137, DOI 10.1016/j.toxicon.2018.07.026
   Ward MJ, 2018, TOXICON, V151, P137, DOI 10.1016/j.toxicon.2018.07.007
   World Spider Catalog, 2018, NAT HIST MUS BERN
   Wullschleger B, 2004, P NATL ACAD SCI USA, V101, P11251, DOI 10.1073/pnas.0402226101
   Yigit N, 2008, J VENOM ANIM TOXINS, V14, P466, DOI 10.1590/S1678-91992008000300007
NR 51
TC 3
Z9 3
U1 1
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD FEB
PY 2019
VL 158
BP 33
EP 37
DI 10.1016/j.toxicon.2018.11.312
PG 5
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HL3EP
UT WOS:000458596000004
PM 30496730
DA 2020-05-12
ER

PT J
AU Monzavi, SM
   Afshari, R
   Khoshdel, AR
   Mahmoudi, M
   Salarian, AA
   Samieimanesh, F
   Shirmast, E
   Mihandoust, A
AF Monzavi, Seyed Mostafa
   Afshari, Reza
   Khoshdel, Ali Reza
   Mahmoudi, Mahmoud
   Salarian, Amir Ahmad
   Samieimanesh, Farhad
   Shirmast, Elham
   Mihandoust, Azam
TI Analysis of effectiveness of Iranian snake antivenom on Viper venom
   induced effects including analysis of immunologic biomarkers in the
   Echis carinatus sochureki envenomed victims
SO TOXICON
LA English
DT Article
DE Antivenins; Acute-phase reaction; Complement system proteins; Cytokines;
   Snake bite
ID NECROSIS-FACTOR-ALPHA; BOTHROPS-ASPER; CLINICAL-EXPERIENCES;
   COMPLEMENT-SYSTEM; CYTOKINE RELEASE; OVINE FAB; INFLAMMATION;
   METALLOPROTEINASES; POLYVALENT; EFFICACY
AB Snakebite is an important toxicologic emergency with the potential of triggering local and systemic inflammation. Antivenom has remained the mainstay of treatment for snakebite envenomation. In this study we sought to investigate the effectiveness of Iranian antivenom in a series of 44 viper envenomed patients through analysis of changes in clinical severity and the levels of inflammatory markers. Clinical envenomation severity assessed by snakebite severity score (SSS) and laboratory exams of the patients were recorded before (baseline visit) and after antivenom therapy. During 12-h antivenom therapy, the median (range) score of SSS significantly decreased from 3.5 (2-10) on admission to 1 (0-5) in the last visit (P < 0.001). Moreover, a significant decrease in prothrombin time and international normalized ratio was found (P = 0.006 and 0.008; respectively). Plasma concentrations of interleukin (IL) 1-beta, IL-6, IL-8, tumor necrosis factor alpha (TNF-alpha), complement hemolytic activity (CH50) were also measured in 10 severely Echis carinatus sochureki envenomed victims and 10 age and gender matched healthy controls. Except IL-8, the baseline levels of IL-1 beta, IL-6 and TNF-alpha in victims were significantly higher than healthy controls (P = 0.005, < 0.001 and < 0.001, respectively). Moreover, the baseline level of CH50 was significantly lower in the patients compared to healthy controls (P < 0.001). After 12-h antivenom therapy, the plasma levels of IL-1 beta, IL-6 and TNF-alpha significantly decreased (P = 0.032, 0.006 and 0.003, respectively), the levels of IL-8 remained relatively unchanged and the CH50 significantly increased (P = 0.011). Iranian snake antivenom was effective in treating viper bite envenomation as it reversed clinical venom effects and restored near normal underlying inflammatory status. This study is the first to ascertain and report the effectiveness of this antivenom in human subjects.
C1 [Monzavi, Seyed Mostafa; Afshari, Reza; Mihandoust, Azam] Mashhad Univ Med Sci, Sch Med, Imam Reza Hosp, Med Toxicol Ctr, Mashhad, Iran.
   [Khoshdel, Ali Reza] AJA Univ Med Sci, Sch Med, Dept Epidemiol, Tehran, Iran.
   [Mahmoudi, Mahmoud] Mashhad Univ Med Sci, Immunol Res Ctr, Sch Med, Mashhad 9196773117, Iran.
   [Mahmoudi, Mahmoud; Samieimanesh, Farhad; Shirmast, Elham] Mashhad Univ Med Sci, Sch Med, Imam Reza Hosp, Cent Lab, Mashhad, Iran.
   [Salarian, Amir Ahmad] AJA Univ Med Sci, Toxin Res Ctr, Tehran, Iran.
RP Mahmoudi, M (reprint author), Mashhad Univ Med Sci, Immunol Res Ctr, Sch Med, Mashhad 9196773117, Iran.; Salarian, AA (reprint author), AJA Univ Med Sci, Toxin Res Ctr, Tehran, Iran.
EM mahmoudim@mums.ac.ir; amir.salarian@gmail.com
RI Monzavi, Seyed Mostafa/R-5765-2019
OI Monzavi, Seyed Mostafa/0000-0002-1631-1626
FU Mashhad University of medical Sciences; AJA University of Medical
   Sciences
FX The whole research project was supported by the Mashhad University of
   medical Sciences and AJA University of Medical Sciences.
CR Acikalin A, 2011, EMERG MED J, V28, P208, DOI 10.1136/emj.2009.078428
   Afshari R, 2004, J TOXICOL-CLIN TOXIC, V42, P965, DOI 10.1081/CLT-200042550
   Afshari R., 2016, AFSHARIS CLIN TOXICO, P221
   Atkinson AJ, 2001, CLIN PHARMACOL THER, V69, P89, DOI 10.1067/mcp.2000.113989
   Avila-Aguero ML, 2001, PEDIATR EMERG CARE, V17, P425, DOI 10.1097/00006565-200112000-00006
   Ayres LR, 2015, J VENOM ANIM TOXINS, V21, DOI 10.1186/s40409-015-0026-7
   Baldo C, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000727
   BARRAVIERA B, 1994, TOXICON, V32, P861, DOI 10.1016/0041-0101(94)90364-6
   Barraviera B., 1995, Journal of Venomous Animals and Toxins, V1, P11
   Barros SF, 1998, MEDIAT INFLAMM, V7, P339, DOI 10.1080/09629359890866
   Bradley JR, 2008, J PATHOL, V214, P149, DOI 10.1002/path.2287
   Casewell NR, 2014, P NATL ACAD SCI USA, V111, P9205, DOI 10.1073/pnas.1405484111
   Chaves F, 2005, TOXICON, V45, P171, DOI 10.1016/j.toxicon.2004.10.005
   Clissa PB, 2001, TOXICON, V39, P1567, DOI 10.1016/S0041-0101(01)00131-3
   Corris PA, 2005, CLIN EXP IMMUNOL, V139, P176, DOI 10.1111/j.1365-2249.2005.02711.x
   Cruz AH, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/874962
   Dadpour B, 2012, ASIA PAC J MED TOXIC, V1, P27
   Dadpour B, 2012, HONG KONG J EMERG ME, V19, P443
   Dart RC, 1997, ANN EMERG MED, V30, P33, DOI 10.1016/S0196-0644(97)70107-0
   Dart RC, 1996, ANN EMERG MED, V27, P321, DOI 10.1016/S0196-0644(96)70267-6
   Dart RC, 2001, ANN EMERG MED, V37, P181, DOI 10.1067/mem.2001.113372
   de Silva HA, 2016, BRIT J CLIN PHARMACO, V81, P446, DOI 10.1111/bcp.12739
   Dehghani R, 2014, TOXICON, V90, P291, DOI 10.1016/j.toxicon.2014.08.063
   Delafontaine M, 2018, J IMMUNOL RES, DOI 10.1155/2018/3462136
   Escalante T, 2011, J PROTEOMICS, V74, P1781, DOI 10.1016/j.jprot.2011.03.026
   Farsky SHP, 2000, MEDIAT INFLAMM, V9, P213, DOI 10.1080/09629350020025728
   Gasmi Ammar, 1994, Natural Toxins, V2, P44, DOI 10.1002/nt.2620020109
   GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0
   Guerranti R, 2010, PROTEOMICS, V10, P3712, DOI 10.1002/pmic.201000055
   Habib AG, 2013, TOXICON, V69, P82, DOI 10.1016/j.toxicon.2013.01.002
   Isbister GK, 2010, TOXICOLOGY, V268, P148, DOI 10.1016/j.tox.2009.09.013
   KarlsonStiber C, 1997, J INTERN MED, V241, P53, DOI 10.1046/j.1365-2796.1997.80896000.x
   Kashani TM, 2012, IRAN J PHARM RES, V11, P1183
   Khadem-Rezaiyan M., 2018, IRAN J TOXICOL, V12, P27
   Kishimoto T, 2010, INT IMMUNOL, V22, P347, DOI 10.1093/intimm/dxq030
   Kulmatycki KM, 2001, CYTOKINE, V14, P1, DOI 10.1006/cyto.2000.0827
   Laing GD, 2003, EUR J IMMUNOL, V33, P3458, DOI 10.1002/eji.200324475
   Lalloo DG, 2003, J TOXICOL-CLIN TOXIC, V41, P277, DOI 10.1081/CLT-120021113
   LOMONTE B, 1993, INFLAMMATION, V17, P93, DOI 10.1007/BF00916097
   Luna KPO, 2011, INT J INTERF CYTOK M, V2011, P9, DOI DOI 10.2147/IJICMR.S14331
   Maduwage K, 2016, SCI REP-UK, V6, DOI 10.1038/srep26778
   Gutierrez JM, 2018, TOXICON, V150, P11, DOI 10.1016/j.toxicon.2018.05.003
   Gutierrez JM, 2013, TOXICON, V62, P27, DOI 10.1016/j.toxicon.2012.09.006
   Gutierrez JM, 2010, TOXICON, V56, P1223, DOI 10.1016/j.toxicon.2009.11.020
   Markland FS, 2013, TOXICON, V62, P3, DOI 10.1016/j.toxicon.2012.09.004
   Meyer WP, 1997, AM J TROP MED HYG, V56, P291, DOI 10.4269/ajtmh.1997.56.291
   Mitrmoonpitak C, 2013, TOXICON, V61, P47, DOI 10.1016/j.toxicon.2012.10.017
   Monastero RN, 2017, INT J INFLAMM, DOI 10.1155/2017/4309485
   Monzavi SM, 2015, WILD ENVIRON MED, V26, P115, DOI 10.1016/j.wem.2014.09.011
   Monzavi SM, 2014, J RES MED SCI, V19, P153
   Moura-Da-Silva AM, 2007, CURR PHARM DESIGN, V13, P2893, DOI 10.2174/138161207782023711
   MouradaSilva AM, 1996, EUR J IMMUNOL, V26, P2000, DOI 10.1002/eji.1830260905
   Offerman SR, 2002, PEDIATRICS, V110, P968, DOI 10.1542/peds.110.5.968
   Otero-Patino R, 2012, TOXICON, V59, P344, DOI 10.1016/j.toxicon.2011.11.017
   Patrao-Neto FC, 2013, TOXICON, V69, P55, DOI 10.1016/j.toxicon.2013.01.023
   Petricevich Vera L., 2004, Current Drug Targets - Inflammation and Allergy, V3, P325, DOI 10.2174/1568010043343642
   Petricevich VL, 2000, TOXICON, V38, P1253, DOI 10.1016/S0041-0101(99)00227-5
   Rucavado A, 2002, MEDIAT INFLAMM, V11, P121, DOI 10.1080/09629350220131980
   Ruha AM, 2002, ANN EMERG MED, V39, P609, DOI 10.1067/mem.2002.123698
   Sanz L, 2008, J PROTEOMICS, V71, P198, DOI [10.1016/j.jprot.2008.05.003, 10.1016/j.jprot.2008.03.001]
   Schattner M, 2005, BIOL CHEM, V386, P369, DOI 10.1515/BC.2005.044
   Setubal SD, 2013, TOXICON, V76, P143, DOI 10.1016/j.toxicon.2013.09.019
   Slagboom J, 2017, BRIT J HAEMATOL, V177, P947, DOI 10.1111/bjh.14591
   Stone SF, 2014, BRIT J CLIN PHARMACO, V78, P1, DOI 10.1111/bcp.12297
   Stone SF, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002326
   Szold O, 2001, INTENS CARE MED, V27, P884, DOI 10.1007/s001340100875
   Tarrant JM, 2010, TOXICOL SCI, V117, P4, DOI 10.1093/toxsci/kfq134
   Teixeira C, 2009, TOXICON, V54, P988, DOI 10.1016/j.toxicon.2009.05.026
   Teixeira CFP, 2003, TOXICON, V42, P947, DOI 10.1016/j.toxicon.2003.11.006
   THEAKSTON RDG, 1991, TOXICON, V29, P1419, DOI 10.1016/0041-0101(91)90002-9
   THEAKSTON RDG, 1992, AM J TROP MED HYG, V47, P593, DOI 10.4269/ajtmh.1992.47.593
   Wanderley CWS, 2014, TOXICON, V90, P134, DOI 10.1016/j.toxicon.2014.08.001
   Warrell DA, 2010, LANCET, V375, P77, DOI 10.1016/S0140-6736(09)61754-2
   White J, 2005, TOXICON, V45, P951, DOI 10.1016/j.toxicon.2005.02.030
   WHITESIDE TL, 1994, J CLIN IMMUNOL, V14, P327, DOI 10.1007/BF01546317
   Williams DJ, 2018, TOXICON, V150, P1, DOI 10.1016/j.toxicon.2018.05.001
   Yamamoto C, 2001, PHARMACOL TOXICOL, V89, P188, DOI 10.1111/j.0901-9928.2001.890408.x
   Yamashita KM, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002814
   Yeretssian G, 2008, CYTOKINE, V43, P380, DOI 10.1016/j.cyto.2008.07.015
   Zamuner SR, 2005, TOXICON, V46, P806, DOI 10.1016/j.toxicon.2005.08.011
NR 80
TC 1
Z9 1
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD FEB
PY 2019
VL 158
BP 38
EP 46
DI 10.1016/j.toxicon.2018.11.293
PG 9
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HL3EP
UT WOS:000458596000005
PM 30452924
DA 2020-05-12
ER

PT J
AU Lima, SC
   Godoy, KCS
   Leal, PV
   Lee, ST
   Pfister, JA
   Souza, AI
   de Barros, CSL
   de Lemos, RAA
AF Lima, Stephanie C.
   Godoy, Kelly C. S.
   Leal, Paula, V
   Lee, Stephen T.
   Pfister, James A.
   Souza, Alda, I
   de Barros, Claudio S. L.
   de Lemos, Ricardo A. A.
TI Toxicity of the different vegetative stages of Amorimia pubiflora to
   sheep
SO TOXICON
LA English
DT Article
DE Toxic plants; Monofluoroacetate; Amorimia pubiflora; Sudden death; Sheep
ID SODIUM MONOFLUOROACETATE; PALICOUREA-MARCGRAVII; SEPTENTRIONALIS;
   FLUOROACETATE; RESISTANCE; FIBROSIS; CATTLE; GOATS
AB Toxic plants containing monofluoroacetate (MFA) cause sudden death in livestock in Australia, South Africa and Brazil, causing economic losses to producers. The objective of this study was to determine the amount of MFA present in young leaves, mature leaves, senescent leaves, and seeds of Amorimia pubiflora harvested at different times of the year and to determine their toxic effect on sheep. Samples of Amorimia pubiflora were collected during April, August and December of 2015 and March of 2016, separated according to the vegetative stage (young leaves, seeds, mature leaves, and senescent leaves), dried in an oven, and administered in daily doses of 5 g/kg/body weight (bw) of fresh leaves to sheep through ruminal cannulae. The experiment was divided into four stages according to the time of collection of the plant so that each sheep received a different vegetative stage of the plant (young leaves, mature leaves, and senescent leaves). Only in the second stage of the experiment was it possible to collect A. pubifiora seeds, which were administered using the same method used for the administration of the leaves. The sheep were dosed with the plant until they showed clinical signs of toxicosis or until the plant was no longer available. Aliquots of leaves and seeds of A. pubiflora were analyzed for MFA concentration. The seeds and young leaves had higher concentrations of MFA than did the mature (harvested in August and December) and senescent (harvested in December) leaves. However, all vegetative stages of the plant were toxic and caused fatal poisoning. The results of our study showed that A. pubiflora is toxic to sheep even when MFA concentrations are low, demonstrating that the presence of this substance is a risk factor for the occurrence of poisoning. Knowing the toxic principle and its variations allow us to determine the conditions for the occurrence of plant toxicosis as well as possible treatment, control, and prophylaxis methods, contributing significantly to the reduction of economic losses on farms due to plant poisoning.
C1 [Lima, Stephanie C.; Godoy, Kelly C. S.; Leal, Paula, V] Univ Fed Mato Grosso do Sul UFMS, Fac Med Vet & Zootecnia FAMEZ, Programa Posgrad Ciencias Vet, Av Senador Felinto Muller 2443, BR-79070900 Campo Grande, MS, Brazil.
   [Lee, Stephen T.; Pfister, James A.] ARS, Poisonous Plant Res Lab, USDA, 1150 E 1400 N, Logan, UT 84341 USA.
   [Souza, Alda, I; de Barros, Claudio S. L.; de Lemos, Ricardo A. A.] Univ Fed Mato Grosso do Sul, FAMEZ, Lab Patal Clin Vet, Av Senador Felinto Muller 2443, BR-79070900 Campo Grande, MS, Brazil.
RP Lima, SC (reprint author), Univ Fed Mato Grosso do Sul UFMS, Fac Med Vet & Zootecnia FAMEZ, Programa Posgrad Ciencias Vet, Av Senador Felinto Muller 2443, BR-79070900 Campo Grande, MS, Brazil.
EM stephanie_k_lima@hotmail.com; k.c.s.godoy@gmail.com;
   paulavleal@hotmail.com; stephen.Lee@ars.usda.gov;
   jim.pfister@ars.usda.gov; alda.izabel@ufms.br;
   claudioslbarros@uol.com.br; ricardo.lemos@ufms.br
FU Fundacao de Apoio ao Desenvolvimento do Ensino, Ciencia e Tecnologia do
   Estado de Mato Grosso do Sul (FUNDECT/CNPq)Fundect; FUNDECTFundect
   [8/2015, 3/2017]; CAPESCAPES [101/2015]; Coordenacao de Aperfeicoamento
   de Pessoal de Nivel Superior-Brasil (CAPES)CAPES [001]
FX This work was funded by the Fundacao de Apoio ao Desenvolvimento do
   Ensino, Ciencia e Tecnologia do Estado de Mato Grosso do Sul
   (FUNDECT/CNPq). The authors K.C.S. Godoy and P.V. Leal are funded by
   fellowship from FUNDECT (No 8/2015 and No 3/2017) and S.C. Lima by CAPES
   (No 101/2015). This study was financed in part by the Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior-Brasil (CAPES) - Finance
   code 001.
CR Albuquerque SSC, 2014, PESQUI VET BRASIL, V34, P433, DOI 10.1590/S0100-736X2014000500008
   Barbosa EDG, 2015, PESQUI VET BRASIL, V35, P209, DOI 10.1590/S0100-736X2015000300001
   Becker M, 2016, CIENC RURAL, V46, P674, DOI 10.1590/0103-8478cr20141484
   Becker M, 2013, PESQUI VET BRASIL, V33, P1049, DOI 10.1590/S0100-736X2013000900001
   da Silva LCA, 2016, TOXICON, V111, P65, DOI 10.1016/j.toxicon.2015.12.016
   de Oliveira MD, 2013, PESQUI VET BRASIL, V33, P731
   Duarte ALL, 2014, J APPL TOXICOL, V34, P220, DOI 10.1002/jat.2860
   KELLERMAN TS, 2005, PLANT POISONINGS MYC
   KREBS HC, 1994, TOXICON, V32, P909, DOI 10.1016/0041-0101(94)90369-7
   Lee ST, 2014, J AGR FOOD CHEM, V62, P7345, DOI 10.1021/jf500563h
   Lee ST, 2012, TOXICON, V60, P791, DOI 10.1016/j.toxicon.2012.05.029
   Nogueira VA, 2010, PESQUI VET BRASIL, V30, P533, DOI 10.1590/S0100-736X2010000700004
   Peixoto TC, 2010, PESQUI VET BRASIL, V30, P1021, DOI 10.1590/S0100-736X2010001200004
   Pessoa DAN, 2015, PESQUI VET BRASIL, V35, P125, DOI 10.1590/S0100-736X2015000200005
   Santos AC, 2014, PESQUI VET BRASIL, V34, P649, DOI 10.1590/S0100-736X2014000700007
   Schons SV, 2011, TOXICON, V57, P781, DOI 10.1016/j.toxicon.2011.02.012
   SCHULTZ RA, 1982, ONDERSTEPOORT J VET, V49, P237
   Shokry E, 2017, TOXICON, V137, P54, DOI 10.1016/j.toxicon.2017.07.014
   Soares MP, 2011, J VET DIAGN INVEST, V23, P1226, DOI 10.1177/1040638711425586
   Tokarnia C. H., 2012, PLANTAS TOXICAS BRAS
NR 20
TC 2
Z9 2
U1 2
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD FEB
PY 2019
VL 158
BP 47
EP 50
DI 10.1016/j.toxicon.2018.11.306
PG 4
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HL3EP
UT WOS:000458596000006
PM 30471379
DA 2020-05-12
ER

PT J
AU Facey, JA
   Steele, JR
   Violi, JP
   Mitrovic, SM
   Cranfield, C
AF Facey, Jordan A.
   Steele, Joel R.
   Violi, Jake P.
   Mitrovic, Simon M.
   Cranfield, Charles
TI An examination of microcystin-LR accumulation and toxicity using
   tethered bilayer lipid membranes (tBLMs)
SO TOXICON
LA English
DT Article
DE Microcystin-LR; Biomagnification; Tethered bilayer lipid membrane;
   Cyanobacteria
ID ANTIMICROBIAL PEPTIDE; KALATA B1; BIOACCUMULATION; CYANOBACTERIA; LAKE;
   SELECTIVITY; TISSUES; TOXINS; RISK; FISH
AB Microcystin-LR (MC-LR) is a potent cyanobacterial toxin responsible for animal and human poisonings world-wide. MC-LR is found in organisms throughout the foodweb, however there is conjecture regarding whether it biomagnifies. Few studies have investigated how MC-LR interacts with lipid membranes, a determinant of biomagnification potential. We tested whether 1 mu M MC-LR irreversibly associates with lipid bilayers or causes the creation of pore defects upon short and long-term exposure. Using tethered bilayer lipid membranes (tBLMs), we observed an increase in membrane conduction in tBLMs, representing an interaction of microcystin-LR with the lipid bilayer and a change in membrane packing properties. However, there were minimal changes in membrane capacitance upon short and long-term exposure, and MC-LR exhibited a rapid off-rate. Upon 24 h exposure to the toxin, no lipophilic multimeric complexes were detected capable of altering the toxin's off-rate. There was no evidence of the creation of new pores. This study demonstrates that MC-LR does not irreversibly imbed itself into lipids membranes after short or long-term exposure and suggests MC-LR does not biomagnify through the food web via lipid storage.
C1 [Facey, Jordan A.; Steele, Joel R.; Violi, Jake P.; Mitrovic, Simon M.; Cranfield, Charles] Univ Technol Sydney, Sch Life Sci, POB 123, Broadway, NSW 2000, Australia.
RP Facey, JA (reprint author), Univ Technol Sydney, Sch Life Sci, POB 123, Broadway, NSW 2000, Australia.
EM Jordan.Facey@uts.edu.au
OI Cranfield, Charles/0000-0003-3608-5440
FU Australian Government Research Training Program StipendAustralian
   Government; Jumbunna Postgraduate Research Scholarship; University of
   Technology Sydney's Research Excellence Scholarship
FX J.R.S. and J.P.V. are recipients of the Australian Government Research
   Training Program Stipend. J.R.S is also the recipient of the Jumbunna
   Postgraduate Research Scholarship and the University of Technology
   Sydney's Research Excellence Scholarship. We would like to acknowledge
   Adj Prof Bruce Cornell from SDx Tethered Membranes Pty Ltd for his
   valuable discussions concerning the data and Dr Anne Colville for her
   critical reading of the manuscript.
CR Al Khamici H, 2016, MEMBRANES, V6, DOI 10.3390/membranes6040051
   Amiard J.-C., 2015, AQUATIC ECOTOXICOLOG, P25, DOI [10.1016/B978-0-12-800949-9.00002-4, DOI 10.1016/B978-0-12-800949-9.00002-4]
   Azevedo SMFO, 2002, TOXICOLOGY, V181, P441, DOI 10.1016/S0300-483X(02)00491-2
   Bagu JR, 1997, J BIOL CHEM, V272, P5087, DOI 10.1074/jbc.272.8.5087
   Barda I, 2015, ENVIRON POLLUT, V196, P313, DOI 10.1016/j.envpol.2014.10.024
   Boopathi T, 2014, TOXINS, V6, P1951, DOI 10.3390/toxins6071951
   Carmichael WW, 2001, HUM ECOL RISK ASSESS, V7, P1393, DOI 10.1080/20018091095087
   Chorus I, 2001, CYANOTOXINS OCCURREN
   Chorus I., 1999, TOXIC CYANOBACTERIA
   Cranfield C, 2015, METHODS MOL BIOL, V1232, P45, DOI 10.1007/978-1-4939-1752-5_4
   Cranfield CG, 2017, LANGMUIR, V33, P6630, DOI 10.1021/acs.langmuir.7b01642
   Cranfield CG, 2016, LANGMUIR, V32, P10725, DOI 10.1021/acs.langmuir.6b01988
   Cranfield CG, 2015, LANGMUIR, V31, P292, DOI 10.1021/la504057z
   Cranfield CG, 2014, BIOPHYS J, V106, P182, DOI 10.1016/j.bpj.2013.11.1121
   de Figueiredo DR, 2004, ECOTOX ENVIRON SAFE, V59, P151, DOI 10.1016/j.ecoenv.2004.04.006
   Drobac D, 2013, ARH HIG RADA TOKSIKO, V64, P305, DOI 10.2478/10004-1254-64-2013-2320
   Dyble J, 2011, MAR DRUGS, V9, P2553, DOI 10.3390/md9122553
   Henriques ST, 2011, J BIOL CHEM, V286, P24231, DOI 10.1074/jbc.M111.253393
   Ibelings BW, 2005, MICROB ECOL, V49, P487, DOI 10.1007/s00248-004-0014-x
   Ito E, 2000, TOXICON, V38, P37, DOI 10.1016/S0041-0101(99)00084-7
   Kozlowsky-Suzuki B, 2012, HARMFUL ALGAE, V18, P47, DOI 10.1016/j.hal.2012.04.002
   Krishna G, 2003, LANGMUIR, V19, P2294, DOI 10.1021/la026238d
   Kuppusamy R, 2018, EUR J MED CHEM, V143, P1702, DOI 10.1016/j.ejmech.2017.10.066
   Lance E, 2008, HARMFUL ALGAE, V7, P464, DOI 10.1016/j.hal.2007.10.004
   Lei HH, 2008, ENVIRON TOXICOL CHEM, V27, P1167, DOI 10.1897/07-522.1
   McLellan NL, 2017, TOXICOL RES-UK, V6, P391, DOI [10.1039/c7tx00043j, 10.1039/C7TX00043J]
   Miller M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009057
   Mitrovic SM, 2005, ECOTOX ENVIRON SAFE, V61, P345, DOI 10.1016/j.ecoenv.2004.11.003
   Mowe MAD, 2015, J LIMNOL, V74, P205, DOI 10.4081/jlimnol.2014.1005
   Nizalapur S, 2016, ORG BIOMOL CHEM, V14, P3623, DOI 10.1039/c6ob00298f
   Orr PT, 1998, LIMNOL OCEANOGR, V43, P1604, DOI 10.4319/lo.1998.43.7.1604
   Paerl HW, 2006, ECOL STU AN, V189, P95, DOI 10.1007/978-3-540-32210-8_8
   Paerl HW, 2011, SCI TOTAL ENVIRON, V409, P1739, DOI 10.1016/j.scitotenv.2011.02.001
   Palmer M, 2001, TOXICON, V39, P1681, DOI 10.1016/S0041-0101(01)00155-6
   Papadimitriou T, 2012, ECOTOXICOLOGY, V21, P1155, DOI 10.1007/s10646-012-0870-y
   Petersen G., 1998, ENVIRON TOXICOL CHEM, V17, P1395
   PETROV AG, 1991, EUR BIOPHYS J, V20, P17
   Quiblier C, 2013, WATER RES, V47, P5464, DOI 10.1016/j.watres.2013.06.042
   Rastogi R, 2015, ENV HLTH IMPACT MITI, V6, P1, DOI DOI 10.3389/FMICB.2015.01254
   Schmidt JR, 2014, TOXINS, V6, P3354, DOI 10.3390/toxins6123354
   Tokodi N, 2018, SCI TOTAL ENVIRON, V635, P1047, DOI 10.1016/j.scitotenv.2018.04.177
   Turner J, 1998, ANTIMICROB AGENTS CH, V42, P2206, DOI 10.1128/AAC.42.9.2206
   van der Merwe D, 2012, J VET DIAGN INVEST, V24, P679, DOI 10.1177/1040638712445768
   Vasconcelos JF, 2013, EGYPT J AQUATIC RES, V39, P185, DOI DOI 10.1016/j.ejar.2013.11.002
   Vesterkvist PSM, 2012, TOXINS, V4, P1008, DOI 10.3390/toxins4111008
   Vesterkvist PSM, 2003, TOXICON, V41, P349, DOI 10.1016/S0041-0101(02)00315-X
   Wang Q, 2008, TOXICON, V52, P721, DOI 10.1016/j.toxicon.2008.08.004
   White Susan H., 2005, Lakes & Reservoirs Research and Management, V10, P25, DOI 10.1111/j.1440-1770.2005.00258.x
   WHO, 2017, GUID DRINK WAT QUAL
   Xie LQ, 2005, ENVIRON TOXICOL, V20, P293, DOI 10.1002/tox.20120
   Xie LQ, 2004, ENVIRON POLLUT, V127, P431, DOI 10.1016/j.envpol.2003.08.011
   Zurawell RW, 2005, J TOXICOL ENV HEAL B, V8, P1, DOI 10.1080/10937400590889412
NR 52
TC 1
Z9 1
U1 3
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD FEB
PY 2019
VL 158
BP 51
EP 56
DI 10.1016/j.toxicon.2018.11.432
PG 6
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HL3EP
UT WOS:000458596000007
PM 30521837
OA Green Published
DA 2020-05-12
ER

PT J
AU Khanian, M
   Karimi-Torshizi, MA
   Allameh, A
AF Khanian, Maryam
   Karimi-Torshizi, Mohammad-Amir
   Allameh, Abdolamir
TI Alleviation of aflatoxin-related oxidative damage to liver and
   improvement of growth performance in broiler chickens consumed
   Lactobacillus plantarum 299v for entire growth period
SO TOXICON
LA English
DT Article
DE Broiler chicken; Aflatoxin-binder; Probiotic; Antioxidant capacity;
   Oxidative stress; Growth
ID SERUM BIOCHEMISTRY; HISTOPATHOLOGICAL CHANGES; PROBIOTICS; PARAMETERS;
   MYCOTOXINS; POULTRY; ENZYME; FEED; B-1
AB Growing broiler chicks on a diet contaminated with aflatoxins (200 or 2000 ppb) for entire growth period resulted in increased oxidative stress and liver damage markers. The toxicity was subsided in broilers received a specific aflatoxin-binding probiotic i.e., Lactobacillus plantarum 299v (Lp299v). There was a substantial (30-90%) increase in antioxidant activity of plasma, which was suppressed due to dietary aflatoxins. Probiotic also reduced serum lactate dehydrogenase and alanine amino transferase together with lipid peroxidation products in liver, which were elevated due to aflatoxin. Because of Lp299v consumption, there was similar to 20-55% recovery in body weight gain in broilers intoxicated with aflatoxins. Comparison of the Lp299v effects with that of a commercial aflatoxin binder revealed that, improved antioxidant activity of the chicks was associated with growth performance. These data suggest that aflatoxin-binding probiotics are beneficial with multi-functional effects and can efficiently help reducing aflatoxins in food chain associated with poultry industry.
C1 [Khanian, Maryam; Karimi-Torshizi, Mohammad-Amir] Tarbiat Modares Univ, Fac Agr, Dept Poultry Sci, Tehran, Iran.
   [Allameh, Abdolamir] Tarbiat Modares Univ, Fac Med Sci, Dept Clin Biochem, Tehran, Iran.
RP Allameh, A (reprint author), Tarbiat Modares Univ, Fac Med Sci, Dept Clin Biochem, Tehran, Iran.
EM Allameha@modares.ac.ir
RI Allameh, Abdolamir/O-2293-2019
OI Allameh, Abdolamir/0000-0003-0757-9572
FU Iran National Science Foundation (INSF)Iran National Science Foundation
   (INSF) [93037128]
FX This study was supported by a grant (Research project #93037128)
   provided by Iran National Science Foundation (INSF).
CR Allameh A, 2005, ANIM FEED SCI TECH, V122, P289, DOI 10.1016/j.anifeedsci.2005.03.005
   Allameh A., 2018, IRAN J BIOTECHNOL
   Barati M, 2017, J APPL ANIM RES, V46, P707, DOI 10.1080/09712119.2017.1388243
   Benzie IFF, 1996, ANAL BIOCHEM, V239, P70, DOI 10.1006/abio.1996.0292
   Binder EM, 2007, ANIM FEED SCI TECH, V137, P265, DOI 10.1016/j.anifeedsci.2007.06.005
   BOTSOGLOU NA, 1994, J AGR FOOD CHEM, V42, P1931, DOI 10.1021/jf00045a019
   DALVI RR, 1986, VET RES COMMUN, V10, P429, DOI 10.1007/BF02214006
   Denli M, 2009, POULTRY SCI, V88, P1444, DOI 10.3382/ps.2008-00341
   Diaz DE, 2003, MYCOPATHOLOGIA, V156, P223, DOI 10.1023/A:1023388321713
   Eaton D. L., 2013, TOXICOLOGY AFLATOXIN
   Fan Y, 2015, TOXINS, V7, P3330, DOI 10.3390/toxins7083330
   Huang L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170109
   Isolauri E, 2001, AM J CLIN NUTR, V73, p444S, DOI 10.1093/ajcn/73.2.444s
   Kasmani FB, 2012, POULTRY SCI, V91, P1846, DOI 10.3382/ps.2011-01830
   Kolosova A, 2012, FOOD ADDIT CONTAM A, V29, P1959, DOI 10.1080/19440049.2012.720035
   Magnoli AP, 2011, POULTRY SCI, V90, P48, DOI 10.3382/ps.2010-00971
   Magnoli A. P., 2011, POULTRY SCI, V1, P90
   Mishra V, 2015, J AGR FOOD CHEM, V63, P3615, DOI 10.1021/jf506326t
   Namazi M., 2002, ACTA POLONIAE TOXICO, V1, P65
   Peng Q, 2016, POULTRY SCI, V95, P893, DOI 10.3382/ps/pev435
   Rawal S, 2010, RES VET SCI, V89, P325, DOI 10.1016/j.rvsc.2010.04.011
   Razzaghi-Abyaneh M, 2005, MYCOPATHOLOGIA, V159, P565, DOI 10.1007/s11046-005-4332-4
   Razzaghi-Abyaneh M, 2006, TOXICON, V48, P1075, DOI 10.1016/j.toxicon.2006.09.002
   *SAS I, 1990, SAS STAT US GUID VER
   SHOTWELL OL, 1966, APPL MICROBIOL, V14, P425, DOI 10.1128/AEM.14.3.425-428.1966
   Tessari ENC, 2006, BRIT POULTRY SCI, V47, P357, DOI 10.1080/00071660600756071
   Verma J, 2004, BRIT POULTRY SCI, V45, P512, DOI 10.1080/00071660412331286226
   Zuo RY, 2013, FOOD CHEM TOXICOL, V59, P470, DOI 10.1016/j.fct.2013.06.044
NR 28
TC 7
Z9 8
U1 1
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD FEB
PY 2019
VL 158
BP 57
EP 62
DI 10.1016/j.toxicon.2018.11.431
PG 6
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HL3EP
UT WOS:000458596000008
PM 30529382
DA 2020-05-12
ER

PT J
AU Botelho, AFM
   Pierezan, F
   Soto-Blanco, B
   Melo, MM
AF Botelho, Ana Flavia M.
   Pierezan, Felipe
   Soto-Blanco, Benito
   Melo, Marilia Martins
TI A review of cardiac glycosides: Structure, toxicokinetics, clinical
   signs, diagnosis and antineoplastic potential
SO TOXICON
LA English
DT Review
DE Digoxin; Ouabain; Oleandrin; Bufalin; Pharmacokinetics;
   Pharmacodynamics; Cardiotoxicity
ID NERIUM-OLEANDER; HYDROALCOHOLIC EXTRACT; ENDOGENOUS OUABAIN;
   PHARMACOKINETICS; INTOXICATION; DIGOXIN; TOXICITY; PHARMACOLOGY;
   APOCYNACEAE; COMPOUND
AB Cardiac glycosides (CGs) are secondary compounds found in plants and amphibians and are widely distributed in nature with potential cardiovascular action. Their mechanism is based on the blockage of the heart's sodium potassium ATPase, with a positive inotropic effect. Some of the most well-known CGs are digoxin, ouabain, oleandrin, and bufalin. They have similar chemical structures: a lactone ring, steroid ring, and sugar moiety. Digoxin, ouabain, and oleandrin are classified as cardenolides, consisting of a lactone ring with five carbons, while bufalin is classified as bufodienolides, with a six-carbon ring. Small structural differences determine variations in the toxicokinetics and toxicodynamics of such substances. Most case reports of poisoning caused by CGs are associated with cardiovascular toxicity, causing a variety of arrhythmias and lesions in the heart tissue. Experimental studies also describe important similarities among different CGs, especially regarding species sensitivity. Recent studies furthermore focus on their antineoplastic potential, with controversial results. Data from research studies and case reports were reviewed to identify the main characteristics of the CGs, including toxicokinetics, toxicodynamics, clinical signs, electrocardiographic, pathological findings, antineoplastic potential and the main techniques used for diagnostic purposes.
C1 [Botelho, Ana Flavia M.; Pierezan, Felipe; Soto-Blanco, Benito; Melo, Marilia Martins] Univ Fed Minas Gerais, Vet Coll, Dept Vet Clin & Surg, Ave Antonio Carlos 6627, BR-30123970 Belo Horizonte, MG, Brazil.
RP Soto-Blanco, B (reprint author), Univ Fed Minas Gerais, Vet Coll, Dept Vet Clin & Surg, Ave Antonio Carlos 6627, BR-30123970 Belo Horizonte, MG, Brazil.
EM benito@ufmg.br
RI Soto-Blanco, Benito/A-5817-2010
OI Soto-Blanco, Benito/0000-0003-3861-1838
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico,
   CNPqNational Council for Scientific and Technological Development (CNPq)
   [424241/2016-01]; Fundacao de Amparo a Pesquisa do Estado de Minas
   Gerais, FAPEMIGMinas Gerais State Research Foundation (FAPEMIG)
   [APQ-03578-16]; Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior, CAPESCAPES [001]
FX This study was supported by the Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico, CNPq (Grant 424241/2016-01), Fundacao de
   Amparo a Pesquisa do Estado de Minas Gerais, FAPEMIG (Grant
   APQ-03578-16) and Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior, CAPES (Finance Code 001).
CR Aslani MR, 2007, IRAN J VETERINARY RE, V8, P58
   Aslani MS, 2004, VET RES COMMUN, V28, P609, DOI 10.1023/B:VERC.0000042870.30142.56
   Atkins C, 2009, J VET INTERN MED, V23, P1142, DOI 10.1111/j.1939-1676.2009.0392.x
   Bandara V, 2010, TOXICON, V56, P273, DOI 10.1016/j.toxicon.2010.03.026
   Barbosa RR, 2008, RES VET SCI, V85, P279, DOI 10.1016/j.rvsc.2007.10.004
   Bocchi EA, 2009, ARQ BRAS CARDIOL, V93, P1, DOI 10.1590/S0066-782X2009002000001
   BOURDOIS PS, 1982, ARCH TOXICOL, V51, P273, DOI 10.1007/BF00317006
   Braga FC, 1997, QUIM NOVA, V20, P481, DOI 10.1590/S0100-40421997000500008
   BROWN L, 1986, N-S ARCH PHARMACOL, V332, P98, DOI 10.1007/BF00633205
   Calderon-Montano JM, 2014, ONCOGENE, V33, P2947, DOI 10.1038/onc.2013.229
   Camplesi A. C., 2013, SCI J ANIMAL SCI, V29, P323, DOI [10.1590/S1678, DOI 10.1590/S1678]
   Cao Y, 2007, J CHROMATOGR B, V853, P227, DOI 10.1016/j.jchromb.2007.03.018
   CASSELS BK, 1985, J ETHNOPHARMACOL, V14, P273, DOI 10.1016/0378-8741(85)90094-7
   CHEUNG K, 1989, CLIN CHEM, V35, P295
   Cornelius F, 2013, J BIOL CHEM, V288, P6602, DOI 10.1074/jbc.M112.442137
   D'Urso G, 2004, J CARDIOVASC PHARM, V43, P657, DOI 10.1097/00005344-200405000-00007
   Davel AP, 2014, HORM MOL BIOL CLIN I, V18, P113, DOI 10.1515/hmbci-2013-0058
   DOHERTY JE, 1975, ANNU REV MED, V26, P159, DOI 10.1146/annurev.me.26.020175.001111
   DOHERTY JE, 1978, PROG CARDIOVASC DIS, V21, P141, DOI 10.1016/0033-0620(78)90020-8
   Galey FD, 1996, J VET DIAGN INVEST, V8, P358, DOI 10.1177/104063879600800314
   Germiniani H., 1995, RELAMPA, V8, P77
   GLANTZ SA, 1976, CIRC RES, V39, P407, DOI 10.1161/01.RES.39.3.407
   GOTO A, 1990, BIOCHEM BIOPH RES CO, V173, P1093, DOI 10.1016/S0006-291X(05)80898-8
   GOTTLIEB SS, 1992, CIRCULATION, V86, P420, DOI 10.1161/01.CIR.86.2.420
   Gowda R M, 2003, Heart, V89, pe14, DOI 10.1136/heart.89.4.e14
   GUPTA RS, 1986, J CELL PHYSIOL, V127, P197, DOI 10.1002/jcp.1041270202
   HAASS A, 1972, EUR J PHARMACOL, V19, P366, DOI 10.1016/0014-2999(72)90103-3
   Hamlyn JM, 1996, J HYPERTENS, V14, P151, DOI 10.1097/00004872-199602000-00002
   HAMLYN JM, 1991, P NATL ACAD SCI USA, V88, P6259, DOI 10.1073/pnas.88.14.6259
   HAYNES BE, 1985, ANN EMERG MED, V14, P350, DOI 10.1016/S0196-0644(85)80103-7
   Huang HM, 2015, J ETHNOPHARMACOL, V161, P175, DOI 10.1016/j.jep.2014.07.056
   Joost A., 2010, MED INT, V4, P77
   Kanji S, 2012, CRIT CARE CLIN, V28, P527, DOI 10.1016/j.ccc.2012.07.005
   Kucukdurmaz Z, 2012, TURK KARDIYOL DERN A, V40, P168, DOI 10.5543/tkda.2012.01703
   Kuo H., 2007, EMERG MED J BCR, V11
   Langford SD, 1996, TOXICOLOGY, V109, P1, DOI 10.1016/0300-483X(95)03296-R
   LAREDO J, 1994, ENDOCRINOLOGY, V135, P794, DOI 10.1210/en.135.2.794
   Le Couteur DG, 2002, J TOXICOL-CLIN TOXIC, V40, P523
   Li J., 2013, QUIM NOVA, V36, DOI [10.1590/S0100-40422013000500013.686-680, DOI 10.1590/S0100-40422013000500013.686-680]
   LISALO E, 1977, CLIN PHARMACOKINET, V2, P1
   Botelho AFM, 2017, J ETHNOPHARMACOL, V206, P170, DOI 10.1016/j.jep.2017.05.031
   Calderon-Montano JM, 2014, BIOMED RES INT, DOI 10.1155/2014/794930
   Calderon-Montano JM, 2013, PLANTA MED, V79, P1017, DOI 10.1055/s-0032-1328715
   Mijatovic T, 2007, BBA-REV CANCER, V1776, P32, DOI 10.1016/j.bbcan.2007.06.002
   Mitchell A., 2010, BMJ CASE REP, DOI [10.1136/bcr.01.2010.2633.bcr0120102633, DOI 10.1136/BCR.01.2010.2633.BCR0120102633]
   NARUSE K, 1994, HYPERTENSION, V23, pI102, DOI 10.1161/01.HYP.23.1_Suppl.I102
   Newman RA, 2008, MOL INTERV, V8, P36, DOI 10.1124/mi.8.1.8
   Newman RA, 2006, J EXP THER ONCOL, V5, P167
   Ni Dan, 2002, J Exp Ther Oncol, V2, P278, DOI 10.1046/j.1359-4117.2002.01052.x
   Gadelha ICN, 2014, SCI WORLD J, DOI 10.1155/2014/851473
   Osman MH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178611
   PAGE E, 1955, CIRC RES, V3, P501, DOI 10.1161/01.RES.3.5.501
   Papi L, 2012, AM J FOREN MED PATH, V33, P93, DOI 10.1097/PAF.0b013e31822d33d4
   Pedroso PMO, 2009, PESQUI VET BRASIL, V29, P404, DOI 10.1590/S0100-736X2009000500008
   Pedroza HD, 2015, CIENC RURAL, V45, P864, DOI 10.1590/0103-8478cr20140885
   Petschenka G, 2015, P ROY SOC B-BIOL SCI, V282, DOI 10.1098/rspb.2015.1865
   Peymani P, 2011, IRAN RED CRESCENT ME, V13, P219
   Prassas I, 2008, NAT REV DRUG DISCOV, V7, P926, DOI 10.1038/nrd2682
   Princi T, 2000, PHARMACOL RES, V42, P355, DOI 10.1006/phrs.2000.0698
   PROPPE D, 1975, CLIN EXP PHARMACOL P, V2, P489, DOI 10.1111/j.1440-1681.1975.tb01854.x
   Ramirez-Ortega M, 2007, EUR J PHARMACOL, V566, P34, DOI 10.1016/j.ejphar.2007.03.033
   Roberts DM, 2016, BRIT J CLIN PHARMACO, V81, P488, DOI 10.1111/bcp.12814
   SCHONFELD W, 1985, N-S ARCH PHARMACOL, V329, P414, DOI 10.1007/BF00496377
   Senthilkumaran S, 2011, J ELECTROCARDIOL, V44, P470, DOI 10.1016/j.jelectrocard.2010.12.002
   SMITH TW, 1985, J AM COLL CARDIOL, V5, pA43, DOI 10.1016/S0735-1097(85)80462-9
   SMITH TW, 1982, NEW ENGL J MED, V307, P1357, DOI 10.1056/NEJM198211253072201
   Sonne L, 2008, CIENC RURAL, V38, P1787, DOI 10.1590/S0103-84782008000600050
   Soto-Blanco B, 2006, TROP ANIM HEALTH PRO, V38, P451, DOI 10.1007/s11250-006-4400-x
   TYMIAK AA, 1993, P NATL ACAD SCI USA, V90, P8189, DOI 10.1073/pnas.90.17.8189
NR 69
TC 5
Z9 5
U1 8
U2 27
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD FEB
PY 2019
VL 158
BP 63
EP 68
DI 10.1016/j.toxicon.2018.11.429
PG 6
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HL3EP
UT WOS:000458596000009
PM 30529380
DA 2020-05-12
ER

PT J
AU Knight, RB
   Dvorcakova, S
   Luptakova, L
   Vdoviakova, K
   Petrilla, V
   Petrovova, E
AF Knight, R. B.
   Dvorcakova, S.
   Luptakova, L.
   Vdoviakova, K.
   Petrilla, V
   Petrovova, E.
TI Evaluation of vasoactivity after haemotoxic snake venom administration
SO TOXICON
LA English
DT Article
DE CAM assay; Chick embryo; Snake venom; Vasoactivity
ID EMBRYO CHORIOALLANTOIC MEMBRANE; CHICK-EMBRYO; IN-VIVO; MODEL
AB The chick chorioallantoic membrane (CAM) is a widely used model in medical research and fulfils the requirements laid out in the 3 R's. The CAM, contains a dense network of blood vessels, essential for embryo development but also makes the chick embryo an invaluable resource for the study of angiogenesis and the haemotoxicity of substances. Non-neurotoxic snake venom is responsible worldwide for numerous deaths but also has been found to have a vast range of medicinal benefit. This study combines evaluating the time of onset and intensity of effects of three whole viper venoms (Bitis aritans, Crotalus viridis, Agkistrodon contortrix) at varying concentrations. They were applied onto the CAM, using the Luepke grading system as one method of determining their rapid irritation potential. Regarding the principles of 3 R's, this method helps to evaluate the haemotoxic effect of venom as an alternative method to the rodent tests. The information provided from these results can be used as a rapid tool for both medical management of snakebite wounds and the potential use of snake venom in medical treatments. Then, Luepke grading system can help to evaluate the haemotoxic effect of venom in combination with other appropriate methods.
C1 [Knight, R. B.] Head & Head Vet Practice Ltd, Helston TR13 0LW, Cornwall, England.
   [Vdoviakova, K.; Petrilla, V; Petrovova, E.] Univ Vet Med & Pharm, Dept Anat Histol & Physiol, Komenskeho 73, Kosice 04181, Slovakia.
   [Dvorcakova, S.; Luptakova, L.] Univ Vet Med & Pharm, Dept Biol & Genet, Komenskeho 73, Kosice 04181, Slovakia.
RP Petrovova, E (reprint author), Univ Vet Med & Pharm, Dept Anat Histol & Physiol, Komenskeho 73, Kosice 04181, Slovakia.
EM eva.petrovova@uvlf.sk
RI Petrovova, Eva/AAC-4113-2019; Luptakova, Lenka/AAC-4094-2019
OI Petrovova, Eva/0000-0002-9141-4211; Luptakova, Lenka/0000-0002-1214-1746
FU Operational Program "Research and Development" through the European
   Regional Development Fund [26220120066]; Ministry of Education
   VEGAVedecka grantova agentura MSVVaS SR a SAV (VEGA) [1/0046/16]
FX This work was realized within the framework of the project ITMS No.
   26220120066 "Centre of excellence for biomedical technologies", which is
   supported by the Operational Program "Research and Development" financed
   through the European Regional Development Fund and the project of
   Ministry of Education VEGA No. 1/0046/16.
CR AUSPRUNK DH, 1974, DEV BIOL, V38, P237, DOI 10.1016/0012-1606(74)90004-9
   Bellairs R., 2014, ATLAS CHICK DEV, V692
   Bocian A., 2016, TOXINS, V8, pE372
   Boviatsis EJ, 2003, AM J TROP MED HYG, V68, P253, DOI 10.4269/ajtmh.2003.68.253
   Calzia D, 2011, J BIOCHEM MOL TOXIC, V25, P377, DOI 10.1002/jbt.20404
   Campbell J. A., 2004, VENOMOUS REPTILES W, V976
   Djonov V, 2000, CIRC RES, V86, P286, DOI 10.1161/01.RES.86.3.286
   Doke SK, 2015, SAUDI PHARM J, V23, P223, DOI 10.1016/j.jsps.2013.11.002
   Eagle H, 1937, J EXP MED, V65, P613, DOI 10.1084/jem.65.5.613
   Fasoli E, 2010, J PROTEOMICS, V73, P932, DOI 10.1016/j.jprot.2009.12.006
   Flecknell P, 2002, ALTEX-ALTERN TIEREXP, V19, P73
   Gutierrez JM, 2016, TOXINS, V8, DOI 10.3390/toxins8040093
   IACUC, 2012, IACUC POL PROC US CH
   Kain KH, 2014, DEV DYNAM, V243, P216, DOI 10.1002/dvdy.24093
   Kue CS, 2015, EXP ANIM TOKYO, V64, P129, DOI 10.1538/expanim.14-0059
   LUEPKE NP, 1985, FOOD CHEM TOXICOL, V23, P287, DOI 10.1016/0278-6915(85)90030-4
   Mackessy S. P., 2010, HDB VENOMS TOXINS RE, V528
   Mackessy SP, 2006, ZOOL ANZ, V245, P147, DOI 10.1016/j.jcz.2006.01.003
   Mackessy SP, 2010, TOXICON, V55, P1463, DOI 10.1016/j.toxicon.2010.02.028
   Palmeira-de-Oliveira R, 2018, ALTEX-ALTERN ANIM EX, V35, P495, DOI 10.14573/altex.1710091
   Petrovova E, 2009, J ENVIRON SCI HEAL B, V44, P383, DOI 10.1080/03601230902801091
   Psychoyos D, 2008, BIRTH DEFECTS RES B, V83, P477, DOI 10.1002/bdrb.20166
   Rashidi H, 2009, BIOESSAYS, V31, P459, DOI 10.1002/bies.200800168
   Ribatti D, 2016, MECH DEVELOP, V141, P70, DOI 10.1016/j.mod.2016.05.003
   Ribatti D, 2010, PHARMACEUTICALS, V3, P482, DOI 10.3390/ph3030482
   Richardson Mary, 2003, Current Drug Targets - Cardiovascular & Haematological Disorders, V3, P155, DOI 10.2174/1568006033481492
   Rosenbruch M., 1997, ALTEX, V14, P111
   Schedel A, 2016, PLATELETS, V27, P43, DOI 10.3109/09537104.2015.1026803
   Sells PG, 1998, TOXICON, V36, P985, DOI 10.1016/S0041-0101(98)00004-X
   Sells PG, 2001, TOXICON, V39, P665, DOI 10.1016/S0041-0101(00)00191-4
   Tay SLM, 2012, J PHARM PHARMACOL, V64, P1128, DOI 10.1111/j.2042-7158.2012.01506.x
   Valdes TI, 2002, J BIOMED MATER RES, V62, P273, DOI 10.1002/jbm.10152
   Vonk FJ, 2008, NATURE, V454, P630, DOI 10.1038/nature07178
NR 33
TC 1
Z9 1
U1 0
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD FEB
PY 2019
VL 158
BP 69
EP 76
DI 10.1016/j.toxicon.2018.11.430
PG 8
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HL3EP
UT WOS:000458596000010
PM 30529379
DA 2020-05-12
ER

PT J
AU Fox, EGP
   Wu, XQ
   Wang, L
   Chen, L
   Lu, YY
   Xu, YJ
AF Fox, Eduardo G. P.
   Wu, Xiaoqing
   Wang, Lei
   Chen, Li
   Lu, Yong-Yue
   Xu, Yijuan
TI Queen venom isosolenopsin A delivers rapid incapacitation of fire ant
   competitors
SO TOXICON
LA English
DT Article
DE Myrmecology; Zoochemistry; Nitrogenous amines; Natural insecticide;
   Paralytic toxin
ID SOLENOPSIS-INVICTA HYMENOPTERA; COLONIES
AB Fire ant venom contains insecticidal alkaloids named 'solenopsins'. Whilst species-specific differences are reported, little attention has been given to caste-specific venom adaptations. The venom of fire ant queens has remained particularly poorly studied, though studies have shown it to be strikingly similar across different species, in being primarily composed of the alkaloid isosolenopsin A, regardless of the chemical configuration in workers. We predict that this is the evolutionary outcome of stabilising selection, implying that a shared mechanism is responsible for the conserved venom composition among fire ant queens. The present investigation tests whether venom plays a role in nest founding, when queens must succeed in isolation in the field against competitor species. Here, we report that fire ant queen venom and isosolenopsin A are faster to incapacitate alien ants than the venom of fire ant workers. Representative sympatric competitor ant species were selected and exposed on their heads to the venom of workers and queens of the invasive fire ant species Solenopsis invicta and S. geminate. Queen venom was found to incapacitate rival foragers quicker than worker venom. The effects were reproduced using synthetic solenopsins, establishing that solenopsin A analogues are particularly effective contact neurotoxins. Overall, the venom of S. invicta is more lethal than of S. geminate, regardless of the incapacitation speed. We believe these are fundamental aspects of the chemical ecology of the invasive ants which remain overlooked, and emphasise the need for further studies into the venom biology of founding queens.
C1 [Fox, Eduardo G. P.] Univ Fed Rio de Janeiro, Ctr Ciencias Saude, Inst Biofis Carlos Chagas Filho, Rio De Janeiro, Brazil.
   [Wang, Lei; Lu, Yong-Yue; Xu, Yijuan] South China Agr Univ, Red Imported Fire Ant Res Ctr, Guangzhou 510642, Guangdong, Peoples R China.
   [Wu, Xiaoqing; Chen, Li] Chinese Acad Sci, Inst Zool, Zool State Key Lab Integrated Management Pest Ins, Beijing 100101, Peoples R China.
RP Fox, EGP (reprint author), Univ Fed Rio de Janeiro, Ctr Ciencias Saude, Inst Biofis Carlos Chagas Filho, Rio De Janeiro, Brazil.
EM ofoxofox@gmail.com
RI Fox, Eduardo/A-3702-2008
OI Fox, Eduardo/0000-0001-6141-255X
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [31772540]
FX Wen-Wei Tang, HuiJu Zhang, Meng Xu, Mu-Yang He, Dong-Qiang-Zeng provided
   invaluable support in collecting fire ant colonies in the field. Kevin
   Haight provided useful insights into venom manipulation. Useful comments
   were provided by Laurent Keller and Edward LeBrun. Field trips were
   partially supported by the National Natural Science Foundation of China
   (Grant No. 31772540). Comments from three anonymous reviewers have
   provided relevant suggestions. Kate Ridout kindly linguistically
   polished the final version of this manuscript.
CR BLUM MS, 1988, ACS SYM SER, V380, P438
   BRAND JM, 1973, INSECT BIOCHEM, V3, P45, DOI 10.1016/0020-1790(73)90017-6
   BRAND JM, 1973, TOXICON, V11, P325, DOI 10.1016/0041-0101(73)90029-9
   Fox E.G.P., 2014, VENOM GENOMICS PROTE, P1, DOI DOI 10.1007/978-94-007-6649-5_38-1
   Fox E. G. P., 2018, MENDELEY DATA V1, DOI [10.17632/s8x82r464b.1, DOI 10.17632/S8X82R464B.1]
   Fox Eduardo Goncalves Paterson, 2012, Psyche (Cambridge), V2012, P1
   Greenberg L, 2008, ANN ENTOMOL SOC AM, V101, P1162, DOI 10.1603/0013-8746-101.6.1162
   Herath HMTB, 2008, J HETEROCYCLIC CHEM, V45, P129
   Lai LC, 2010, SOCIOBIOLOGY, V56, P653
   LeBrun EG, 2014, SCIENCE, V343, P1014, DOI 10.1126/science.1245833
   MARKIN GP, 1972, ANN ENTOMOL SOC AM, V65, P1053, DOI 10.1093/aesa/65.5.1053
   Fox EGP, 2013, TOXICON, V65, P5, DOI 10.1016/j.toxicon.2012.12.009
   Pianaro A, 2012, TETRAHEDRON-ASYMMETR, V23, P635, DOI 10.1016/j.tetasy.2012.05.005
   Pitts JP, 2005, ZOOL SCR, V34, P493, DOI 10.1111/j.1463-6409.2005.00203.x
   Rao A, 2004, ENVIRON ENTOMOL, V33, P587, DOI 10.1603/0046-225X-33.3.587
   Shi QH, 2015, FRONT ECOL EVOL, V3, DOI 10.3389/fevo.2015.00076
   Touchard A, 2016, TOXINS, V8, DOI 10.3390/toxins8010030
   Tschinkel W.R., 2006, FIRE ANTS
   Vinson SB, 2004, ENVIRON ENTOMOL, V33, P1626, DOI 10.1603/0046-225X-33.6.1626
NR 19
TC 2
Z9 3
U1 3
U2 16
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD FEB
PY 2019
VL 158
BP 77
EP 83
DI 10.1016/j.toxicon.2018.11.428
PG 7
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HL3EP
UT WOS:000458596000011
PM 30529381
DA 2020-05-12
ER

PT J
AU Laxme, RRS
   Suranse, V
   Sunagar, K
AF Laxme, R. R. Senji
   Suranse, Vivek
   Sunagar, Kartik
TI Arthropod venoms: Biochemistry, ecology and evolution
SO TOXICON
LA English
DT Review
DE Arthropoda; Venom; Biochemistry; Ecology; Evolution
ID ROBBER FLIES DIPTERA; RESISTANT STAPHYLOCOCCUS-AUREUS;
   DIVISION-OF-LABOR; D-AMINO-ACID; BRADYKININ-POTENTIATING PEPTIDE;
   LIPOLYSIS ACTIVATING PEPTIDE; CATERPILLAR BRISTLE EXTRACT;
   SPHINGOMYELINASE D ACTIVITY; TICK ORNITHODOROS-SAVIGNYI; WASP
   NASONIA-VITRIPENNIS
AB Comprising of over a million described species of highly diverse invertebrates, Arthropoda is amongst the most successful animal lineages to have colonized aerial, terrestrial, and aquatic domains. Venom, one of the many fascinating traits to have evolved in various members of this phylum, has underpinned their adaptation to diverse habitats. Over millions of years of evolution, arthropods have evolved ingenious ways of delivering venom in their targets for self-defence and predation. The morphological diversity of venom delivery apparatus in arthropods is astounding, and includes extensively modified pedipalps, tail (telson), mouth parts (hypostome), fangs, appendages (maxillulae), proboscis, ovipositor (stinger), and hair (urticating bristles). Recent investigations have also unravelled an astonishing venom biocomplexity with molecular scaffolds being recruited from a multitude of protein families. Venoms are a remarkable bioresource for discovering lead compounds in targeted therapeutics. Several components with prospective applications in the development of advanced lifesaving drugs and environment friendly bio-insecticides have been discovered from arthropod venoms. Despite these fascinating features, the composition, bioactivity, and molecular evolution of venom in several arthropod lineages remains largely understudied. This review highlights the prevalence of venom, its mode of toxic action, and the evolutionary dynamics of venom in Arthropoda, the most speciose phylum in the animal kingdom.
C1 [Laxme, R. R. Senji; Suranse, Vivek; Sunagar, Kartik] Indian Inst Sci, Ctr Ecol Sci, Evolutionary Venom Lab, Bangalore 560012, Karnataka, India.
RP Sunagar, K (reprint author), Indian Inst Sci, Ctr Ecol Sci, Evolutionary Venom Lab, Bangalore 560012, Karnataka, India.
EM ksunagar@iisc.ac.in
OI Senji Laxme, R R/0000-0002-9151-7771
FU Department of Science and Technology (DST) INSPIRE Faculty Award
   [DST/INSPIRE/04/2017/000071]; DBT-IISc Partnership Program
FX This work is supported by the Department of Science and Technology (DST)
   INSPIRE Faculty Award (DST/INSPIRE/04/2017/000071) to KS and the
   DBT-IISc Partnership Program. The authors would like to thank the
   reviewers and Mr Bharat Ahuja for their valuable suggestions that
   significantly improved the overall quality of the manuscript.
CR Aguiar NO, 1998, J ARACHNOL, V26, P452
   Akef HM, 2018, TOXICOL RES-UK, V7, P381, DOI 10.1039/c8tx00022k
   Alarcon-Chaidez FJ, 2009, PARASITE IMMUNOL, V31, P210, DOI 10.1111/j.1365-3024.2009.01095.x
   Almaaytah A, 2014, PEPTIDES, V51, P35, DOI 10.1016/j.peptides.2013.10.021
   Almaaytah A, 2013, INT J PEPT RES THER, V19, P281, DOI 10.1007/s10989-013-9350-3
   AMARANT T, 1991, BIOCHIM BIOPHYS ACTA, V1079, P214, DOI 10.1016/0167-4838(91)90128-M
   Amin R., 2013, SCORPION STING ENVEN, P1
   Aminetzach YT, 2009, CURR BIOL, V19, P1925, DOI 10.1016/j.cub.2009.09.022
   dos Santos-Pinto JRA, 2018, TOXICON, V148, P172, DOI 10.1016/j.toxicon.2018.04.029
   Arbuckle K, 2017, TOXINOLOGY, P3, DOI 10.1007/978-94-007-6458-3_16
   AROCHAPINANGO CL, 1969, LANCET, V1, P810
   Asgari S, 2011, ANNU REV ENTOMOL, V56, P313, DOI 10.1146/annurev-ento-120709-144849
   Askew R.R., 1986, Symposia of the Royal Entomological Society of London, P225
   ATKINS JA, 1958, AM J TROP MED HYG, V7, P165, DOI 10.4269/ajtmh.1958.7.165
   Auvynet C, 2009, FEBS J, V276, P6497, DOI 10.1111/j.1742-4658.2009.07360.x
   Bansal PS, 2008, J BIOL CHEM, V283, P8969, DOI 10.1074/jbc.M709762200
   Baptist BA, 1941, Q J MICROSC SCI, V83, P91
   Baracchi D, 2011, TOXICON, V58, P550, DOI 10.1016/j.toxicon.2011.08.017
   Baron A, 2013, TOXICON, V75, P187, DOI 10.1016/j.toxicon.2013.04.008
   BEARD RL, 1963, ANNU REV ENTOMOL, V8, P1, DOI 10.1146/annurev.en.08.010163.000245
   Beck M, 2000, J INSECT PHYSIOL, V46, P1275, DOI 10.1016/S0022-1910(00)00048-2
   Beckage NE, 2004, ANNU REV ENTOMOL, V49, P299, DOI 10.1146/annurev.ento.49.061802.123324
   Bedford G. J. P., 1931, NUTTALLIELLA NAMAQUA, V23, P230
   BEIER M., 1948, OESTERREICH ZOOL ZEITSCHR, V1, P441
   Benton MJ, 1999, BIOESSAYS, V21, P1043
   BERG CO, 1953, J PARASITOL, V39, P630, DOI 10.2307/3274083
   Bernard C, 2001, BIOCHEMISTRY-US, V40, P12795, DOI 10.1021/bi015537j
   Beshers SN, 2001, ANNU REV ENTOMOL, V46, P413, DOI 10.1146/annurev.ento.46.1.413
   BETTICHER DC, 1995, ONCOGENE, V11, P1005
   Bhere KV, 2014, FEBS LETT, V588, P3891, DOI 10.1016/j.febslet.2014.08.034
   Billen B, 2010, J BIOL CHEM, V285, P18545, DOI 10.1074/jbc.M110.125211
   Binford GJ, 2005, TOXICON, V45, P547, DOI 10.1016/j.toxicon.2004.11.011
   Binford GJ, 2003, COMP BIOCHEM PHYS B, V135, P25, DOI 10.1016/S1096-4959(03)00045-9
   Binford GJ, 2009, MOL BIOL EVOL, V26, P547, DOI 10.1093/molbev/msn274
   Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720
   BLACK WC, 1994, P NATL ACAD SCI USA, V91, P10034, DOI 10.1073/pnas.91.21.10034
   BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x
   Bonato L, 2010, ZOOKEYS, P17, DOI 10.3897/zookeys.69.737
   BONAVITACOUGOURDAN A, 1985, BEHAV PROCESS, V11, P425, DOI 10.1016/0376-6357(85)90007-5
   Bond JE, 2014, CURR BIOL, V24, P1765, DOI 10.1016/j.cub.2014.06.034
   Bowman CL, 2007, TOXICON, V49, P249, DOI 10.1016/j.toxicon.2006.09.030
   BRAND JM, 1972, TOXICON, V10, P259, DOI 10.1016/0041-0101(72)90011-6
   BRAYDEN JE, 1992, SCIENCE, V256, P532, DOI 10.1126/science.1373909
   BROOKS HK, 1955, J PALEONTOL, V29, P852
   BROWN AWA, 1958, INSECTICIDE RESISTAN
   Brown BV, 2018, COMMUN BIOL, V1, DOI 10.1038/s42003-018-0022-x
   Brust A, 2013, MOL CELL PROTEOMICS, V12, P1488, DOI [10.1074/mcp.A112.023135, 10.1074/mcp.M112.023135]
   Buczek O, 2005, CELL MOL LIFE SCI, V62, P3067, DOI 10.1007/s00018-005-5283-0
   BULET P, 1992, EUR J BIOCHEM, V209, P977, DOI 10.1111/j.1432-1033.1992.tb17371.x
   Burke GR, 2014, MOL ECOL, V23, P890, DOI 10.1111/mec.12648
   Bybee SM, 2004, MOL PHYLOGENET EVOL, V30, P789, DOI 10.1016/S1055-7903(03)00253-7
   Cabezas-Cruz A, 2014, FRONT ZOOL, V11, DOI 10.1186/1742-9994-11-47
   Cahalan MD, 2001, J CLIN IMMUNOL, V21, P235, DOI 10.1023/A:1010958907271
   Cao ZJ, 2006, TOXICON, V47, P348, DOI 10.1016/j.toxicon.2005.11.013
   Cao ZJ, 2006, J BIOCHEM MOL TOXIC, V20, P1, DOI 10.1002/jbt.20111
   Cao ZJ, 2005, IUBMB LIFE, V57, P513, DOI 10.1080/15216540500149870
   Carapelli A, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-S2-S8
   Carpenter JH, 1999, CRUSTACEANA, V72, P979, DOI 10.1163/156854099503889
   Carrijo-Carvalho LC, 2007, TOXICON, V49, P741, DOI 10.1016/j.toxicon.2006.11.033
   Casewell NR, 2013, TRENDS ECOL EVOL, V28, P219, DOI 10.1016/j.tree.2012.10.020
   Casewell NR, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2065
   Casewell NR, 2011, MOL BIOL EVOL, V28, P2637, DOI 10.1093/molbev/msr091
   CATTERALL WA, 1986, ANNU REV BIOCHEM, V55, P953, DOI 10.1146/annurev.biochem.55.1.953
   CATTERALL WA, 1975, P NATL ACAD SCI USA, V72, P1782, DOI 10.1073/pnas.72.5.1782
   Chen J, 2015, J BIOCHEM MOL TOXIC, V29, P207, DOI 10.1002/jbt.21686
   Chen JJ, 2008, TOXICON, V52, P794, DOI 10.1016/j.toxicon.2008.08.003
   Chippaux JP, 2008, ACTA TROP, V107, P71, DOI 10.1016/j.actatropica.2008.05.021
   Chopra I, 2008, LANCET INFECT DIS, V8, P133, DOI 10.1016/S1473-3099(08)70018-5
   Cid-Uribe JI, 2018, TOXICON, V151, P47, DOI 10.1016/j.toxicon.2018.06.085
   COCIANCICH S, 1993, BIOCHEM BIOPH RES CO, V194, P17, DOI 10.1006/bbrc.1993.1778
   COHEN AC, 1995, ANNU REV ENTOMOL, V40, P85, DOI 10.1146/annurev.en.40.010195.000505
   Colgrave ML, 2004, BIOCHEMISTRY-US, V43, P5965, DOI 10.1021/bi049711q
   Colinet D., 2010, ORIGIN INTRASPECIFIC, V6
   Colinet D, 2009, DEV COMP IMMUNOL, V33, P681, DOI 10.1016/j.dci.2008.11.013
   Colinet D, 2007, PLOS PATHOG, V3, P2029, DOI 10.1371/journal.ppat.0030203
   Colinet D, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-342
   Colinet D, 2013, INSECT BIOCHEM MOLEC, V43, P601, DOI 10.1016/j.ibmb.2013.03.010
   Conde R, 2000, FEBS LETT, V471, P165, DOI 10.1016/S0014-5793(00)01384-3
   COOPER TA, 1985, J BIOL CHEM, V260, P1140
   Cordes MHJ, 2006, BIOINFORMATICS, V22, P264, DOI 10.1093/bioinformatics/bti811
   Cracraft J., 2004, ASSEMBLING TREE LIFE
   Cranston P.S., 2009, ENCY INSECTS, P780
   Cranston P. S., 2009, PHYLOGENY INSECTS EN, P780
   CUSHMAN DW, 1977, BIOCHEMISTRY-US, V16, P5484, DOI 10.1021/bi00644a014
   Macoris MDD, 2014, REV SOC BRAS MED TRO, V47, P573, DOI 10.1590/0037-8682-0141-2014
   da Silva PH, 2004, TOXICON, V44, P693, DOI 10.1016/j.toxicon.2004.07.012
   Daix V, 2007, INSECT MOL BIOL, V16, P155, DOI 10.1111/j.1365-2583.2006.00710.x
   Danforth BN, 2013, CURR BIOL, V23, pR1011, DOI 10.1016/j.cub.2013.10.026
   Danneels EL, 2010, TOXINS, V2, P494, DOI 10.3390/toxins2040494
   Dantas AE, 2016, TOXICON, V120, P97, DOI 10.1016/j.toxicon.2016.08.002
   Dantas-Torres F, 2012, TRENDS PARASITOL, V28, P437, DOI 10.1016/j.pt.2012.07.003
   de Graaf DC, 2010, INSECT MOL BIOL, V19, P11, DOI 10.1111/j.1365-2583.2009.00914.x
   DEBIN JA, 1993, AM J PHYSIOL, V264, pC361
   Dehghani R, 2012, TOXICON, V60, P919, DOI 10.1016/j.toxicon.2012.06.002
   DEJONG MCJM, 1982, TOXICON, V20, P477, DOI 10.1016/0041-0101(82)90011-3
   Del-Claro K, 2009, ACTA ETHOL, V12, P13, DOI 10.1007/s10211-009-0052-y
   Dennis D. Steve, 2007, Journal of the Entomological Research Society, V9, P23
   Dennis DS, 2012, J ENTOMOL RES SOC, V14, P65
   Dennis DS, 2010, J ENTOMOL RES SOC, V12, P27
   Diaz P, 2009, TOXICON, V54, P802, DOI 10.1016/j.toxicon.2009.06.014
   Diego-Garcia E, 2008, CELL MOL LIFE SCI, V65, P187, DOI 10.1007/s00018-007-7370-x
   Diego-Garcia E, 2005, TOXICON, V45, P273, DOI 10.1016/j.toxicon.2004.10.014
   Dikow T, 2009, ORG DIVERS EVOL, V9, P165, DOI 10.1016/j.ode.2009.02.004
   Dobson SJ, 1999, MOL PHYLOGENET EVOL, V11, P288, DOI 10.1006/mpev.1998.0565
   Dongol Y., 2014, INTECH
   Pinto JRAD, 2012, J PROTEOME RES, V11, P4643, DOI 10.1021/pr300451g
   dos Santos WF, 2006, J BIOCHEM MOL TOXIC, V20, P27, DOI 10.1002/jbt.20113
   Drukewitz SH, 2018, TOXINS, V10, DOI 10.3390/toxins10010029
   Duan ZG, 2006, COMP BIOCHEM PHYS B, V145, P350, DOI 10.1016/j.cbpb.2006.08.006
   Duarte AC, 1996, LANCET, V348, P1033, DOI 10.1016/S0140-6736(05)64961-6
   DUCANCEL F, 1993, J BIOL CHEM, V268, P3052
   Duckert P, 2004, PROTEIN ENG DES SEL, V17, P107, DOI 10.1093/protein/gzh013
   Dugon MM, 2012, ARTHROPOD STRUCT DEV, V41, P231, DOI 10.1016/j.asd.2012.02.001
   Dugon MM, 2012, EVOL DEV, V14, P128, DOI 10.1111/j.1525-142X.2011.00527.x
   Dunlop JA, 2010, ARTHROPOD STRUCT DEV, V39, P124, DOI 10.1016/j.asd.2010.01.003
   Dutertre S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4521
   Dutertre S, 2010, J BIOL CHEM, V285, P13315, DOI 10.1074/jbc.R109.076596
   Earl STH, 2006, PROTEOMICS, V6, P6554, DOI 10.1002/pmic.200600263
   Edgecombe GD, 2007, ANNU REV ENTOMOL, V52, P151, DOI 10.1146/annurev.ento.52.110405.091326
   Edstrom A., 1992, VENOMOUS POISONOUS A
   EDWARDS JS, 1961, J EXP BIOL, V38, P61
   ELAYEB M, 1985, TOXICON, V23, P755, DOI 10.1016/0041-0101(85)90005-4
   Escoubas P, 2006, TOXICON, V47, P650, DOI 10.1016/j.toxicon.2006.01.018
   Estrada G, 2007, NAT PROD REP, V24, P145, DOI 10.1039/b603083c
   Fan Z, 2011, ANTIMICROB AGENTS CH, V55, P5220, DOI 10.1128/AAC.00369-11
   Fernandes-Pedrosa MD, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-279
   FERREIRA LAF, 1993, TOXICON, V31, P941, DOI 10.1016/0041-0101(93)90253-F
   FET V, 2000, CATALOG SCORPIONS WO
   Fletcher JI, 1997, STRUCTURE, V5, P1525, DOI 10.1016/S0969-2126(97)00301-8
   Foelix R. F, 2011, BIOL SPIDERS
   Foottit R.G., 2009, INSECT BIODIVERSITY
   Froy O, 2003, TOXICON, V42, P549, DOI 10.1016/S0041-0101(03)00236-8
   Froy O, 1999, J MOL EVOL, V48, P187, DOI 10.1007/PL00006457
   Fry B., 2015, VENOMOUS REPTILES TH
   Fry BG, 2010, MOL CELL PROTEOMICS, V9, P2369, DOI 10.1074/mcp.M110.001370
   Fry BG, 2010, MOL BIOL EVOL, V27, P395, DOI 10.1093/molbev/msp251
   Fry BG, 2009, ANNU REV GENOM HUM G, V10, P483, DOI 10.1146/annurev.genom.9.081307.164356
   Gal R, 2005, ARCH INSECT BIOCHEM, V60, P198, DOI 10.1002/arch.20092
   Gal R, 2008, CURR BIOL, V18, P877, DOI 10.1016/j.cub.2008.04.076
   Gao B, 2013, BIOSCIENCE REP, V33, P513, DOI 10.1042/BSR20130052
   Gao B, 2009, FASEB J, V23, P1230, DOI 10.1096/fj.08-122317
   Garb JE, 2004, MOL PHYLOGENET EVOL, V31, P1127, DOI 10.1016/j.ympev.2003.10.012
   Garb JE, 2013, MOL BIOL EVOL, V30, P999, DOI 10.1093/molbev/mst011
   Gendreau KL, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-3551-7
   Georghiou G. P., 1983, Pest resistance to pesticides, P1
   Ghosh A., 2018, INT J PEPT RES THER, P1
   GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001
   Giribet G, 2000, CLADISTICS, V16, P204, DOI 10.1111/j.1096-0031.2000.tb00353.x
   Giribet G, 1998, MOL PHYLOGENET EVOL, V9, P481, DOI 10.1006/mpev.1998.0494
   Godfray H.C.J., 1994, PARASITOIDS BEHAV EV
   Goetghebeur M, 2007, CAN J INFECT DIS MED, V18, P27, DOI 10.1155/2007/253947
   Gokay S. S., 2018, RELATIONSHIP CLIN LA
   Gonzalez-Morales L, 2009, TOXICON, V54, P8, DOI 10.1016/j.toxicon.2009.03.003
   Gordon D, 2003, TOXICON, V41, P125, DOI 10.1016/S0041-0101(02)00294-5
   Gordon D, 2007, TOXICON, V49, P452, DOI 10.1016/j.toxicon.2006.11.016
   Gordon RJ, 2008, CLIN INFECT DIS, V46, pS350, DOI 10.1086/533591
   Gouveia AID, 2005, TOXICON, V45, P403, DOI 10.1016/j.toxicon.2004.11.008
   Grishin EV, 1998, TOXICON, V36, P1693, DOI 10.1016/S0041-0101(98)00162-7
   Grisley MS, 1996, J EXP MAR BIOL ECOL, V202, P225, DOI 10.1016/0022-0981(96)00035-4
   Grolleau F, 2001, J EXP BIOL, V204, P711
   Gullan P.J., 2014, INSECTS OUTLINE ENTO
   Guo XX, 2013, BIOCHIMIE, V95, P1784, DOI 10.1016/j.biochi.2013.06.003
   Hall-Mendelin S, 2011, ANN TROP MED PARASIT, V105, P95, DOI 10.1179/136485911X12899838413628
   Hancock REW, 2000, TRENDS MICROBIOL, V8, P402, DOI 10.1016/S0966-842X(00)01823-0
   Harada Susumu, 2005, Arerugi, V54, P1279
   Harrison PL, 2014, TOXICON, V88, P115, DOI 10.1016/j.toxicon.2014.06.006
   Harvey MS, 2013, ZOOTAXA, V3703, P34
   He YW, 2013, J PROTEOMICS, V89, P1, DOI 10.1016/j.jprot.2013.06.007
   HECK SD, 1994, SCIENCE, V266, P1065, DOI 10.1126/science.7973665
   Heinen TE, 2011, TOXICON, V57, P497, DOI 10.1016/j.toxicon.2011.01.002
   Hemingway J, 2002, SCIENCE, V298, P96, DOI 10.1126/science.1078052
   Hemingway J, 2000, ANNU REV ENTOMOL, V45, P371, DOI 10.1146/annurev.ento.45.1.371
   Herzig V, 2015, TOXINS, V7, P4366, DOI 10.3390/toxins7104366
   Holding ML, 2016, P ROY SOC B-BIOL SCI, V283, DOI 10.1098/rspb.2015.2841
   Hynes TM, 2014, BIOCONTROL SCI TECHN, V24, P1077, DOI 10.1080/09583157.2014.912259
   Inceoglu B, 2003, P NATL ACAD SCI USA, V100, P922, DOI 10.1073/pnas.242735499
   Ip SW, 2008, ANTICANCER RES, V28, P833
   Isbister GK, 2003, MED J AUSTRALIA, V179, P88, DOI 10.5694/j.1326-5377.2003.tb05442.x
   Ishiwata K, 2011, MOL PHYLOGENET EVOL, V58, P169, DOI 10.1016/j.ympev.2010.11.001
   JACKMAN R, 1983, SCIENCE, V222, P515, DOI 10.1126/science.222.4623.515
   Jang MH, 2003, J PHARMACOL SCI, V91, P95, DOI 10.1254/jphs.91.95
   Jansa SA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020997
   Jenssen H, 2006, CLIN MICROBIOL REV, V19, P491, DOI 10.1128/CMR.00056-05
   Jeram A. J., 1997, P 17 EUR C AR, P17
   Jeyaprakash A, 2009, EXP APPL ACAROL, V47, P1, DOI 10.1007/s10493-008-9203-5
   Jilek A, 2005, P NATL ACAD SCI USA, V102, P4235, DOI 10.1073/pnas.0500789102
   Jilek A, 2008, MONATSH CHEM, V139, P1, DOI 10.1007/s00706-007-0780-5
   Jilek A, 2012, AMINO ACIDS, V42, P1757, DOI 10.1007/s00726-011-0890-6
   Jimenez EC, 1996, J BIOL CHEM, V271, P28002, DOI 10.1074/jbc.271.45.28002
   JOHANSSON B, 1991, INT J LEGAL MED, V104, P99, DOI 10.1007/BF01626039
   Jones S, 2012, BIOCONJUGATE CHEM, V23, P47, DOI 10.1021/bc2002924
   Joubert AM, 1998, EXP APPL ACAROL, V22, P603, DOI 10.1023/A:1006198713791
   JOVER E, 1980, BIOCHEM BIOPH RES CO, V95, P1607, DOI 10.1016/S0006-291X(80)80082-9
   JOVER E, 1980, BIOCHEMISTRY-US, V19, P463, DOI 10.1021/bi00544a010
   KAHAN D, 1964, ISRAEL J ZOOL, V13, P47
   Kalam H, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006236
   Kalapothakis E, 2007, TOXICON, V50, P938, DOI 10.1016/j.toxicon.2007.07.001
   KATSU T, 1990, BIOCHIM BIOPHYS ACTA, V1027, P185, DOI 10.1016/0005-2736(90)90083-Z
   Kazimirova M, 2013, FRONT CELL INFECT MI, V3, DOI 10.3389/fcimb.2013.00043
   Keirans J.E., 1992, P1
   Kesavan K., 2009, J BIOL CHEM
   Khvotchev M, 2000, EMBO J, V19, P3250, DOI 10.1093/emboj/19.13.3250
   Kim SJ, 2011, J ATHEROSCLER THROMB, V18, P1117, DOI 10.5551/jat.8474
   King G., 2013, AUST BIOCH, V44, P931
   King GF, 2004, TOXICON, V43, P471, DOI 10.1016/j.toxicon.2004.02.001
   King GF, 2013, ANNU REV ENTOMOL, V58, P475, DOI 10.1146/annurev-ento-120811-153650
   KING TP, 1976, ARCH BIOCHEM BIOPHYS, V172, P661, DOI 10.1016/0003-9861(76)90121-1
   Kivaria FM, 2006, TROP ANIM HEALTH PRO, V38, P291, DOI 10.1007/s11250-006-4181-2
   KIYATKIN NI, 1995, EUR J BIOCHEM, V230, P854, DOI 10.1111/j.1432-1033.1995.tb20628.x
   KIYATKIN NI, 1990, FEBS LETT, V270, P127, DOI 10.1016/0014-5793(90)81250-R
   Kjellesvig-Waering E. N., 1986, RESTUDY FOSSIL SCORP
   Klompen JSH, 1996, ANNU REV ENTOMOL, V41, P141, DOI 10.1146/annurev.en.41.010196.001041
   Knysak I, 1998, REV SAUDE PUBL, V32, P514, DOI 10.1590/S0034-89101998000600003
   Koenemann S, 2010, ARTHROPOD STRUCT DEV, V39, P88, DOI 10.1016/j.asd.2009.10.003
   Koludarov I, 2012, J MOL EVOL, V75, P168, DOI 10.1007/s00239-012-9529-9
   Kong Y, 2013, INT J PEPT RES THER, V19, P303, DOI 10.1007/s10989-013-9353-0
   Kozlov SA, 2007, TOXICON, V49, P721, DOI 10.1016/j.toxicon.2006.11.007
   Kozminsky-Atias A, 2012, FASEB J, V26, P576, DOI 10.1096/fj.11-187179
   Kozminsky-Atias A, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-333
   Krenn HW, 2012, ARTHROPOD STRUCT DEV, V41, P101, DOI 10.1016/j.asd.2011.12.001
   KURPIEWSKI G, 1981, BIOCHIM BIOPHYS ACTA, V678, P467, DOI 10.1016/0304-4165(81)90128-8
   Labrada L, 2002, J VIROL, V76, P7932, DOI 10.1128/JVI.76.16.7932-7941.2002
   Lajoie DM, 2015, J BIOL CHEM, V290, P10994, DOI 10.1074/jbc.M115.636951
   Lajoie DM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072372
   LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113
   Lee H. S., 2016, TOXINS, V8
   Lee S, 2005, BIOCHEM J, V391, P317, DOI 10.1042/BJ20050043
   Lewis J, 2006, BIOL CENTIPEDES
   Lewis RJ, 2003, NAT REV DRUG DISCOV, V2, P790, DOI 10.1038/nrd1197
   Li B, 2006, ONKOLOGIE, V29, P367, DOI 10.1159/000094711
   Liang SP, 2004, TOXICON, V43, P575, DOI 10.1016/j.toxicon.2004.02.005
   LIPPENS G, 1995, BIOCHEMISTRY-US, V34, P13, DOI 10.1021/bi00001a003
   [刘辉 Liu Hui], 2005, [武汉大学学报. 理学版, Journal of Wuhan University. Natural Science Edition], V51, P477
   Liu XF, 1999, BIOCHEM BIOPH RES CO, V264, P833, DOI 10.1006/bbrc.1999.1595
   Loomis E.C., 1984, TICKS CALIFORNIA ACA
   Ma YB, 2012, J PROTEOMICS, V75, P1563, DOI 10.1016/j.jprot.2011.11.029
   MacCarthy T, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-213
   Malta MB, 2008, TOXICON, V52, P255, DOI 10.1016/j.toxicon.2008.05.012
   Mans BJ, 2008, INSECT BIOCHEM MOLEC, V38, P42, DOI 10.1016/j.ibmb.2007.09.003
   Mans BJ, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00413
   Mans BJ, 2016, TICKS TICK-BORNE DIS, V7, P509, DOI 10.1016/j.ttbdis.2016.02.002
   Mans BJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049461
   Mans BJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023675
   Mans BJ, 2002, MOL BIOL EVOL, V19, P1695, DOI 10.1093/oxfordjournals.molbev.a003992
   Mans BJ, 2004, INSECT BIOCHEM MOLEC, V34, P1, DOI 10.1016/j.ibmb.2003.09.002
   Mans BJ, 2002, J BIOL CHEM, V277, P21371, DOI 10.1074/jbc.M112060200
   Manton S. M., 1970, P1
   Manzoni-de-Almeida D, 2018, MOL IMMUNOL, V94, P45, DOI 10.1016/j.molimm.2017.12.009
   Mario P, 1995, EUR J BIOCHEM, V230, P322
   Martin-Eauclaire M, 1995, NEUROL DIS THER, V36, P688
   Martinson EO, 2017, CURR BIOL, V27, P2007, DOI 10.1016/j.cub.2017.05.032
   Martinson EO, 2016, MOL BIOL EVOL, V33, P1042, DOI 10.1093/molbev/msv348
   Mazzuca M, 2007, NAT NEUROSCI, V10, P943, DOI 10.1038/nn1940
   McCowan C, 2014, GENE, V536, P366, DOI 10.1016/j.gene.2013.11.054
   MEKI ARMA, 1995, PEPTIDES, V16, P1359, DOI 10.1016/0196-9781(95)02036-5
   Minelli A, 2000, EVOL DEV, V2, P35, DOI 10.1046/j.1525-142x.2000.00030.x
   Misof B, 2014, SCIENCE, V346, P763, DOI 10.1126/science.1257570
   Miyazawa H, 2014, SCI REP-UK, V4, DOI 10.1038/srep04127
   Moran Y, 2008, MOL BIOL EVOL, V25, P737, DOI 10.1093/molbev/msn021
   Moran Y, 2012, MOL BIOL EVOL, V29, P2223, DOI 10.1093/molbev/mss089
   Moreno M, 2015, TOXINS, V7, P1126, DOI 10.3390/toxins7041126
   Mortimer NT, 2013, FLY, V7, P242, DOI 10.4161/fly.26484
   Mosbah A, 2000, PROTEINS, V40, P436, DOI 10.1002/1097-0134(20000815)40:3&lt;436::AID-PROT90&gt;3.0.CO;2-9
   Mouhat S, 2008, CURR PHARM DESIGN, V14, P2503, DOI 10.2174/138161208785777441
   Moura-da-Silva AM, 2016, TOXINS, V8, DOI 10.3390/toxins8060183
   Muchmore W. B, 1971, ROCHESTER ACAD SCI P
   MULLER GJ, 1993, S AFR MED J, V83, P399
   Murakami MT, 2006, BIOCHEM BIOPH RES CO, V342, P323, DOI 10.1016/j.bbrc.2006.01.123
   Murienne J, 2008, MOL PHYLOGENET EVOL, V49, P170, DOI 10.1016/j.ympev.2008.06.002
   Murienne J, 2010, MOL PHYLOGENET EVOL, V57, P301, DOI 10.1016/j.ympev.2010.06.022
   Murphy WJ, 2001, NATURE, V409, P614, DOI 10.1038/35054550
   Nascimento DG, 2006, TOXICON, V47, P628, DOI 10.1016/j.toxicon.2006.01.015
   Naug D, 1998, BEHAV ECOL SOCIOBIOL, V42, P37, DOI 10.1007/s002650050409
   Naug D, 1999, J THEOR BIOL, V197, P123, DOI 10.1006/jtbi.1998.0862
   Nei M, 2005, ANNU REV GENET, V39, P121, DOI 10.1146/annurev.genet.39.073003.112240
   Neiber MT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019627
   NELSON MT, 1995, AM J PHYSIOL-CELL PH, V268, pC799
   NEWLANDS G, 1988, S AFR MED J, V73, P235
   Nicholson GM, 2004, TOXICON, V43, P587, DOI 10.1016/j.toxicon.2004.02.006
   Nienaber J, 1999, EXP PARASITOL, V93, P82, DOI 10.1006/expr.1999.4448
   Nishida R, 2014, BIOSCI BIOTECH BIOCH, V78, P1, DOI 10.1080/09168451.2014.877836
   NISHIMURA K, 1993, EVOL ECOL, V7, P199, DOI 10.1007/BF01239388
   Nowicki S., 1983, Psyche (Cambridge), V90, P119, DOI 10.1155/1983/54806
   OLIVER JH, 1989, ANNU REV ECOL SYST, V20, P397, DOI 10.1146/annurev.es.20.110189.002145
   Oller-Salvia B, 2013, BIOPOLYMERS, V100, P675, DOI 10.1002/bip.22257
   Orlova EV, 2000, NAT STRUCT BIOL, V7, P48, DOI 10.1038/71247
   Ortiz E, 2015, TOXICON, V93, P125, DOI 10.1016/j.toxicon.2014.11.233
   Osnaya-Romero N, 2001, TOXICON, V39, P781, DOI 10.1016/S0041-0101(00)00204-X
   Owsley William B., 1946, ANN ENT SOC AMERICA, V39, P33
   Page R.D., 2009, MOL EVOLUTION PHYLOG
   Palagi A, 2013, J PROTEOMICS, V80, P292, DOI 10.1016/j.jprot.2013.01.002
   Palma MS, 2012, STUD NAT PROD CHEM, V36, P27, DOI 10.1016/B978-0-444-53836-9.00019-0
   Park SP, 2008, PAIN, V137, P208, DOI 10.1016/j.pain.2008.02.013
   Parkinson N, 2002, INSECT BIOCHEM MOLEC, V32, P729, DOI 10.1016/S0965-1748(01)00155-2
   Parkinson NM, 2004, INSECT BIOCHEM MOLEC, V34, P565, DOI 10.1016/j.ibmb.2004.03.003
   Escalona MP, 2013, FRONT BIOSCI-LANDMRK, V18, P572, DOI 10.2741/4121
   Peng KF, 2010, TOXICON, V55, P274, DOI 10.1016/j.toxicon.2009.07.040
   Peters RS, 2017, CURR BIOL, V27, P1013, DOI 10.1016/j.cub.2017.01.027
   PETERSEN OH, 1984, NATURE, V307, P693, DOI 10.1038/307693a0
   Petkov GV, 2012, NAT REV UROL, V9, P30, DOI 10.1038/nrurol.2011.194
   PFEIFFER DR, 1995, J BIOL CHEM, V270, P4923, DOI 10.1074/jbc.270.9.4923
   Pineda SS, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-177
   Pineda SS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043699
   Pinto AFM, 2010, TOXICON, V56, P1103, DOI 10.1016/j.toxicon.2010.01.013
   Poinar George O. Jr., 1998, Acta Arachnologica, V47, P79, DOI 10.2476/asjaa.47.79
   Poirie M, 2014, CURR OPIN INSECT SCI, V6, P52, DOI 10.1016/j.cois.2014.10.004
   Possani LD, 2001, METHOD PHARMACOL TOX, P145
   Possani LD, 1999, EUR J BIOCHEM, V264, P287, DOI 10.1046/j.1432-1327.1999.00625.x
   Possani LD, 2000, BIOCHIMIE, V82, P861, DOI 10.1016/S0300-9084(00)01167-6
   Quicke D. L. J, 2009, ENCY INSECTS, P473
   QUINN DM, 1987, CHEM REV, V87, P955, DOI 10.1021/cr00081a005
   Quintero-Hernandez V, 2013, TOXICON, V76, P328, DOI 10.1016/j.toxicon.2013.07.012
   Rajput Zahid Iqbal, 2006, J Zhejiang Univ Sci B, V7, P912, DOI 10.1631/jzus.2006.B0912
   Rash LD, 2002, TOXICON, V40, P225, DOI 10.1016/S0041-0101(01)00199-4
   Rates B, 2007, TOXICON, V49, P810, DOI 10.1016/j.toxicon.2006.12.001
   Readio P. A. J. K. U. s. b, 1927, STUDIES BIOL REDUVII, V17
   Regier JC, 2010, NATURE, V463, P1079, DOI 10.1038/nature08742
   Regier JC, 2008, SYST BIOL, V57, P920, DOI 10.1080/10635150802570791
   Rehm P, 2011, MOL PHYLOGENET EVOL, V61, P880, DOI 10.1016/j.ympev.2011.09.003
   Reis CV, 2006, BIOCHEM J, V398, P295, DOI 10.1042/BJ20060325
   Renault S, 2002, J INSECT PHYSIOL, V48, P297, DOI 10.1016/S0022-1910(01)00174-3
   Renault S, 2005, J INSECT PHYSIOL, V51, P137, DOI 10.1016/j.jinsphys.2004.08.002
   Rholam M, 2009, CELL MOL LIFE SCI, V66, P2075, DOI 10.1007/s00018-009-0007-5
   Ribeiro JMC, 2012, PSYCHE, V2012, P16
   Ribeiro JMC, 2017, TICKS TICK-BORNE DIS, V8, P201, DOI 10.1016/j.ttbdis.2016.08.011
   Rocha T, 2007, TOXICON, V50, P589, DOI 10.1016/j.toxicon.2007.05.003
   Rosenberg Joerg, 2006, Norwegian Journal of Entomology, V53, P119
   Ruder T, 2013, J MOL EVOL, V76, P192, DOI 10.1007/s00239-013-9552-5
   Runham N. W., 1997, Scientia Marina, V61, P67
   Saez NJ, 2010, TOXINS, V2, P2851, DOI 10.3390/toxins2122851
   Safavi-Hemami H, 2018, J PROTEOMICS, V190, P2
   Santibanez-Lopez C, 2018, TOXINS, V10
   SCHEER H, 1984, J PHYSIOLOGY PARIS, V79, P216
   Schmidt J. O., 1990, INSECT DEFENSES ADAP
   SCHMIDT JO, 1982, ANNU REV ENTOMOL, V27, P339, DOI 10.1146/annurev.en.27.010182.002011
   Schram F.R., 1989, Crustacean Issues, V6, P115
   Seibert CS, 2006, BIOCHEM BIOPH RES CO, V342, P1027, DOI 10.1016/j.bbrc.2006.02.071
   Seibert CS, 2004, TOXICON, V44, P793, DOI 10.1016/j.toxicon.2004.08.019
   Seibert CS, 2003, TOXICON, V41, P831, DOI 10.1016/S0041-0101(03)00040-0
   SHEAR WA, 1989, NATURE, V341, P527, DOI 10.1038/341527a0
   Siigur E, 2001, GENE, V263, P199, DOI 10.1016/S0378-1119(00)00571-0
   Sim AD, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2924-7
   Smith CR, 2008, NAT REV GENET, V9, P735, DOI 10.1038/nrg2429
   Smith JJ, 2013, CELL MOL LIFE SCI, V70, P3665, DOI 10.1007/s00018-013-1315-3
   Smith JJ, 2011, P NATL ACAD SCI USA, V108, P10478, DOI 10.1073/pnas.1103501108
   SNELSON JT, 1975, FAO PLANT PROTECT B, V23, P103
   Sollod BL, 2005, PEPTIDES, V26, P131, DOI 10.1016/j.peptides.2004.07.016
   Soman NR, 2009, J CLIN INVEST, V119, P2830, DOI 10.1172/JCI38842
   Sonenshine DE, 2013, BIOL TICKS
   Soudani N, 2005, BBA-PROTEINS PROTEOM, V1747, P47, DOI 10.1016/j.bbapap.2004.09.020
   Spears T, 1998, CRUSTACEAN PHYLOGENY, P169
   Stankiewicz M, 1999, TOXICON, V37, P1431, DOI 10.1016/S0041-0101(99)00089-6
   Strugatsky D, 2005, BIOCHEMISTRY-US, V44, P9179, DOI 10.1021/bi050235t
   Sunagar K, 2013, TOXINS, V5
   Sunagar K, 2016, TOXINOLOGY, P1, DOI 10.1007/978-94-007-6416-3_27
   Sunagar K, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005596
   Sunagar K, 2013, TOXINS, V5, P2456, DOI 10.3390/toxins5122456
   Supakthanasiri P., 2004, Journal of Allergy and Clinical Immunology, V113, pS244, DOI 10.1016/j.jaci.2004.01.341
   Suranse V, 2018, ANIMAL VENOMS ORIGIN
   Szeto TH, 2000, FEBS LETT, V470, P293, DOI 10.1016/S0014-5793(00)01339-9
   Tambourgi DV, 1998, BIOCHEM BIOPH RES CO, V251, P366, DOI 10.1006/bbrc.1998.9474
   Terra W. R, 2009, DIGESTIVE SYSTEM ENC, P273
   Thistle A. B, 1989, FUNCTIONAL MORPHOLOG
   Torres AM, 2007, AMINO ACIDS, V32, P63, DOI 10.1007/s00726-006-0346-6
   Torres AM, 2006, FEBS LETT, V580, P1587, DOI 10.1016/j.febslet.2006.01.089
   TREMPE JP, 1988, J VIROL, V62, P3356, DOI 10.1128/JVI.62.9.3356-3363.1988
   Tripplehorn C. A., 2005, BORROR DELONGS INTRO
   Tytgat J, 2000, BIOPHYS J, V78, p172A
   Undheim A. E, 2015, TOXINS, V7
   Undheim A. E, 2013, TOXINS, V5
   Undheim EAB, 2015, STRUCTURE, V23, P1283, DOI 10.1016/j.str.2015.05.003
   Undheim EAB, 2015, P NATL ACAD SCI USA, V112, P4026, DOI 10.1073/pnas.1424068112
   Undheim EAB, 2014, J PROTEOMICS, V102, P1, DOI 10.1016/j.jprot.2014.02.024
   Undheim EAB, 2011, TOXICON, V57, P512, DOI 10.1016/j.toxicon.2011.01.004
   Ushkaryov YA, 2004, TOXICON, V43, P527, DOI 10.1016/j.toxicon.2004.02.008
   Valdez-Cruz NA, 2004, BIOCHIMIE, V86, P387, DOI 10.1016/j.biochi.2004.05.005
   Valdivia HH, 1998, TRENDS CARDIOVAS MED, V8, P111, DOI 10.1016/S1050-1738(97)00138-2
   Valenzuela JG, 1996, INSECT BIOCHEM MOLEC, V26, P557, DOI 10.1016/S0965-1748(96)00041-0
   van der Ham JL, 2007, J CRUSTACEAN BIOL, V27, P1, DOI 10.1651/S-2778.1
   Van Der Ham JL, 2007, CRUSTACEANA, V80, P755, DOI 10.1163/156854007781360603
   van Meeteren L. A, 2004, SPIDER BACTERIAL SPH
   vandeLocht A, 1996, EMBO J, V15, P6011, DOI 10.1002/j.1460-2075.1996.tb00989.x
   Veiga SS, 2000, TOXICON, V38, P825, DOI 10.1016/S0041-0101(99)00197-X
   Veiseh M, 2007, CANCER RES, V67, P6882, DOI 10.1158/0008-5472.CAN-06-3948
   Veraldi S, 2014, INT J DERMATOL, V53, P869, DOI 10.1111/ijd.12434
   Vetter RS, 2008, ANNU REV ENTOMOL, V53, P409, DOI 10.1146/annurev.ento.53.103106.093503
   Vinson S. Bradleigh, 1997, American Entomologist, V43, P23
   von Reumont BM, 2014, MOL BIOL EVOL, V31, P48, DOI 10.1093/molbev/mst199
   von Reumont BM, 2017, TOXINS, V9, DOI 10.3390/toxins9080234
   von Reumont M. B, 2014, TOXINS, V6
   Vonk FJ, 2013, P NATL ACAD SCI USA, V110, P20651, DOI 10.1073/pnas.1314702110
   Vontas J, 2012, PESTIC BIOCHEM PHYS, V104, P126, DOI 10.1016/j.pestbp.2012.05.008
   Walker A. A, 2018, CELL MOL LIFE SCI, P1
   Walker AA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03091-5
   Walker AA, 2017, MOL CELL PROTEOMICS, V16, P552, DOI [10.1074/mcp.M116.063321, 10.1074/mcp.m116.063321]
   Walker AA, 2016, TOXINS, V8, DOI 10.3390/toxins8020043
   Wang XH, 1999, EUR J BIOCHEM, V264, P488, DOI 10.1046/j.1432-1327.1999.00646.x
   Wang YH, 2016, CLADISTICS, V32, P390, DOI 10.1111/cla.12137
   Warf B, 2010, ENCY GEOGRAPHY
   WAXMAN L, 1990, SCIENCE, V248, P593, DOI 10.1126/science.2333510
   Wei AZ, 1998, J MOL BIOL, V283, P147, DOI 10.1006/jmbi.1998.2069
   Weinberger H, 2010, MOL BIOL EVOL, V27, P1025, DOI 10.1093/molbev/msp310
   Weygoldt P., 1969, BIOL PSEUDOSCORPIONS
   WHEELER KP, 1983, PFLUG ARCH EUR J PHY, V397, P164, DOI 10.1007/BF00582058
   Whitfield FGS, 1925, P ZOOL SOC LOND, V1925, P599
   Whitfield JB, 1998, ANNU REV ENTOMOL, V43, P129, DOI 10.1146/annurev.ento.43.1.129
   Willems J, 2002, TOXICON, V40, P1679, DOI 10.1016/S0041-0101(02)00183-6
   Woodard SH, 2011, P NATL ACAD SCI USA, V108, P7472, DOI 10.1073/pnas.1103457108
   World Spider Catalog, 2018, NAT HIST MUS BERN
   Wu TM, 1999, INT J TISSUE REACT, V21, P35
   YAGER J, 1981, Journal of Crustacean Biology, V1, P328, DOI 10.2307/1547965
   Yamamoto T, 2014, FEBS J, V281, P3933, DOI 10.1111/febs.12930
   Yan ZC, 2016, SCI REP-UK, V6, DOI 10.1038/srep19604
   Yang H, 2008, TOXICON, V51, P289, DOI 10.1016/j.toxicon.2007.10.003
   Yang SL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9297
   Yang S, 2012, MOL CELL PROTEOMICS, V11, P640, DOI 10.1074/mcp.M112.018853
   Yeates DK, 2016, CURR OPIN INSECT SCI, V13, P16, DOI 10.1016/j.cois.2015.10.007
   You WK, 2004, INSECT BIOCHEM MOLEC, V34, P239, DOI 10.1016/j.ibmb.2003.10.003
   Yuan WY, 2010, PEPTIDES, V31, P22, DOI 10.1016/j.peptides.2009.10.008
   Zaki TI, 2003, TOXICON, V41, P109, DOI 10.1016/S0041-0101(02)00242-8
   Zamudio FZ, 1997, FEBS LETT, V405, P385, DOI 10.1016/S0014-5793(97)00227-5
   Zeh D. W, 1992, B BRIT ARACHNOLOGICA
   ZEH DW, 1992, J INSECT BEHAV, V5, P37, DOI 10.1007/BF01049156
   ZEH DW, 1991, J ARACHNOL, V19, P153
   ZEH JA, 1990, J ARACHNOL, V18, P307
   Zeng XC, 2006, PEPTIDES, V27, P675, DOI 10.1016/j.peptides.2005.07.016
   Zeng XC, 2005, IUBMB LIFE, V57, P13, DOI 10.1080/15216540500058899
   Zeng XC, 2000, TOXICON, V38, P1009, DOI 10.1016/S0041-0101(99)00212-3
   Zeng XC, 2000, IUBMB LIFE, V49, P207, DOI 10.1080/152165400306214
   Zeng XC, 2012, PEPTIDES, V33, P44, DOI 10.1016/j.peptides.2011.11.012
   Zerachia T, 1972, INT S AN PLANT TOX D
   Zhang GM, 2006, DEV COMP IMMUNOL, V30, P756, DOI 10.1016/j.dci.2005.11.001
   Zhang L, 2015, J PROTEOMICS, V128, P231, DOI 10.1016/j.jprot.2015.07.030
   Zhang Yun, 2015, Zoological Research, V36, P183, DOI 10.13918/j.issn.2095-8137.2015.4.183
   Zhao YP, 2015, TOXINS, V7, P1749, DOI 10.3390/toxins7051749
   Zhao ZH, 2009, ANTIMICROB AGENTS CH, V53, P3472, DOI 10.1128/AAC.01436-08
   Zhu S, 2006, FEBS LETT, V580, P6825, DOI 10.1016/j.febslet.2006.11.040
   Zhu S, 2005, CELL MOL LIFE SCI, V62, P2257, DOI 10.1007/s00018-005-5200-6
   Zhu S, 2004, CELL MOL LIFE SCI, V61, P1751, DOI 10.1007/s00018-004-4149-1
   Zhu SY, 2000, IUBMB LIFE, V50, P57, DOI 10.1080/15216540050176601
   Zhu SY, 2004, J MOL EVOL, V58, P145, DOI 10.1007/s00239-003-2534-2
   Zhu SY, 2003, FASEB J, V17, P1765, DOI 10.1096/fj.02-1044fje
   Zimmerman G, 2006, CELL TISSUE RES, V326, P655, DOI 10.1007/s00441-006-0239-8
NR 443
TC 5
Z9 5
U1 6
U2 33
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD FEB
PY 2019
VL 158
BP 84
EP 103
DI 10.1016/j.toxicon.2018.11.433
PG 20
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HL3EP
UT WOS:000458596000012
PM 30529476
DA 2020-05-12
ER

PT J
AU Fu, XY
   Gao, YH
   Yang, YM
   Zou, N
   Wang, KW
   Yan, P
   Sun, DJ
AF Fu, Xiaoyan
   Gao, Yanhui
   Yang, Yanmei
   Zou, Ning
   Wang, Kewei
   Yan, Pan
   Sun, Dianjun
TI Induced lesion and inhibited Ihh-PTHrP signalling pathway activity in
   the articular cartilage of rats caused by T-2 toxin
SO TOXICON
LA English
DT Article
DE Lesion; Ihh-PTHrP; Articular cartilage; T-2 toxin
AB This study aims to investigate the role of Ihh-PTHrP signalling pathway in the articular cartilage injury of rats caused by T-2 toxin. Sixty male Wistar rats were randomly divided into four groups: group A, normal diet; group B, normal diet plus the dissolvent (0.9% sodium chloride sterile aqueous solution containing ethanol); group C, normal diet plus low T-2 toxin (0.1 mg/kg BW/day) and group D, normal diet plus high T-2 toxin (0.2 mg/kg BW/day) by intragastric administration daily for 4 weeks. Histological changes in articular cartilage were assessed by HE staining and scanning electron microscopy. The expression of Ihh and PTHrP in cartilage was assessed by immunohistochemistry. There is a significant difference in average weight gain between group A and group D P < 0.01, groups A and D P < 0.001, respectively. The result of scanning electron microscopy and HE staining showed that the damage of articular cartilage was much severe with the increase of T-2 toxin. Immunohistochemical analysis indicated that the expression of Ihh in group A and group B was higher than that of group C and group D (P < 0.05, < 0.01, respectively). However, the expression of PTHrP was lower in group A and group B than that of group C and group D (P < 0.001, < 0.001, respectively). These results indicated that T-2 toxin can cause the damage to articular cartilage and weight loss in rats. The effect of T-2 toxin on articular cartilage of rat may be related to the Ihh-PTHrP pathway.
C1 [Fu, Xiaoyan; Gao, Yanhui; Yang, Yanmei; Zou, Ning; Wang, Kewei; Yan, Pan; Sun, Dianjun] Harbin Med Univ, Chinese Ctr Dis Control & Prevent, Ctr Endem Dis Control, Harbin 150081, Heilongjiang, Peoples R China.
   [Fu, Xiaoyan; Gao, Yanhui; Yang, Yanmei; Zou, Ning; Wang, Kewei; Yan, Pan; Sun, Dianjun] Educ Bur Heilongjiang Prov, Key Lab Etiol & Epidemiol, Harbin 150081, Heilongjiang, Peoples R China.
   [Fu, Xiaoyan; Gao, Yanhui; Yang, Yanmei; Zou, Ning; Wang, Kewei; Yan, Pan; Sun, Dianjun] Minist Hlth, Harbin 150081, Heilongjiang, Peoples R China.
RP Sun, DJ (reprint author), Harbin Med Univ, Chinese Ctr Dis Control & Prevent, Ctr Endem Dis Control, Harbin 150081, Heilongjiang, Peoples R China.
EM hrbmusdj@hrbmu.edu.cn
FU Young Teacher Research and development Fund of Endemic Disease Control
   Center of Harbin Medical University, China
FX This research was funded by the Young Teacher Research and development
   Fund of Endemic Disease Control Center of Harbin Medical University,
   China (2013).
CR [安永会 An Yongkuai], 2010, [中国地质, Geology of China], V37, P563
   Beaupre GS, 2000, J REHABIL RES DEV, V37, P145
   Borjesson AE, 2012, BONE, V50, pS59, DOI 10.1016/j.bone.2012.02.163
   Cao J., 2009, OSTEOARTHR CARTIL S1, V17, pS143
   Cao J., 1995, CHIN J CONTR ENDEM D, V2, P69
   Hi H., 2001, J XIAN MED U, V22, P308
   Kang P, 2013, OSTEOARTHR CARTILAGE, V21, P1108, DOI 10.1016/j.joca.2013.05.005
   National Kashin-Beck Disease Surveillance Group, 2006, CHIN J ENDEMIOL, V25, P670
NR 8
TC 0
Z9 0
U1 2
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD FEB
PY 2019
VL 158
BP 104
EP 108
DI 10.1016/j.toxicon.2018.12.001
PG 5
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HL3EP
UT WOS:000458596000013
PM 30550741
DA 2020-05-12
ER

PT J
AU Saez, NJ
   Herzig, V
AF Saez, Natalie J.
   Herzig, Volker
TI Versatile spider venom peptides and their medical and agricultural
   applications
SO TOXICON
LA English
DT Article
DE Spider; Venom-based drug discovery; Therapeutics; Insecticidal spider
   venom peptide; Bioinsecticide; Arachnid; Arthropod; Toxins
ID CALCIUM-CHANNEL BLOCKER; GATED SODIUM-CHANNELS; ACUTE PAIN MODEL;
   PHONEUTRIA-NIGRIVENTER; LYCOSIN-I; ANTIMICROBIAL PEPTIDE; SNOWDROP
   LECTIN; DISULFIDE-RICH; PERIPHERAL ANTINOCICEPTION; INSECTICIDAL TOXIN
AB Spiders have been evolving complex and diverse repertoires of peptides in their venoms with vast pharmacological activities for more than 300 million years. Spiders use their venoms for prey capture and defense, hence they contain peptides that target both prey (mainly arthropods) and predators (other arthropods or vertebrates). This includes peptides that potently and selectively modulate a range of targets such as ion channels, receptors and signaling pathways involved in physiological processes. The contribution of these targets in particular disease pathophysiologies makes spider venoms a valuable source of peptides with potential therapeutic use. In addition, peptides with insecticidal activities, used for prey capture, can be exploited for the development of novel bioinsecticides for agricultural use. Although we have already reviewed potential applications of spider venom peptides as therapeutics (in 2010) and as bioinsecticides (in 2012), a considerable number of research articles on both topics have been published since, warranting an updated review. Here we explore the most recent research on the use of spider venom peptides for both medical and agricultural applications.
C1 [Saez, Natalie J.; Herzig, Volker] Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia.
RP Saez, NJ; Herzig, V (reprint author), Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia.
EM n.saez@uq.edu.au; v.herzig@uq.edu.au
CR Abdulqawi R, 2015, LANCET, V385, P1198, DOI 10.1016/S0140-6736(14)61255-1
   Adams ME, 2004, TOXICON, V43, P509, DOI 10.1016/j.toxicon.2004.02.004
   Alcaino C, 2017, CHANNELS, V11, P245, DOI 10.1080/19336950.2017.1279370
   Almeida AP, 2011, TOXICON, V57, P217, DOI 10.1016/j.toxicon.2010.11.013
   Almeida FD, 2018, CURR DRUG DELIV, V15, P1064, DOI 10.2174/1567201815666180108170206
   Andrade E, 2008, BJU INT, V102, P835, DOI 10.1111/j.1464-410X.2008.07762.x
   Arenas I, 2016, MOLECULES, V21, DOI 10.3390/molecules21020225
   Ayroza G, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00324
   Bae C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051516
   Bae C, 2011, BIOCHEMISTRY-US, V50, P6295, DOI 10.1021/bi200770q
   Bagal SK, 2015, CHANNELS, V9, P360, DOI 10.1080/19336950.2015.1079674
   Baron A, 2013, TOXICON, V75, P187, DOI 10.1016/j.toxicon.2013.04.008
   Bastianelli G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021812
   Bende NS, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5350
   Berkut AA, 2015, J BIOL CHEM, V290, P492, DOI 10.1074/jbc.M114.595678
   Bilgo E, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03399-0
   Binda NS, 2016, TOXINS, V8, DOI 10.3390/toxins8030070
   Bishop HI, 2015, J NEUROSCI, V35, P14922, DOI 10.1523/JNEUROSCI.1897-15.2015
   Bladen C, 2014, MOL BRAIN, V7, DOI 10.1186/1756-6606-7-36
   Blaustein M. B., 2014, AKASHI THERAPEUTICS
   Bohlen CJ, 2010, CELL, V141, P834, DOI 10.1016/j.cell.2010.03.052
   Bomgardner M, 2017, CHEM ENG NEWS, V95, P30
   Ferreira FRB, 2016, TOXICON, V122, P119, DOI 10.1016/j.toxicon.2016.09.019
   Bosmans F, 2006, MOL PHARMACOL, V69, P419, DOI 10.1124/mol.105.015941
   Bowman CL, 2007, TOXICON, V49, P249, DOI 10.1016/j.toxicon.2006.09.030
   Bravo A, 2011, INSECT BIOCHEM MOLEC, V41, P423, DOI 10.1016/j.ibmb.2011.02.006
   Budagavi DP, 2018, EUR J PHARM SCI, V115, P43, DOI 10.1016/j.ejps.2018.01.015
   Burnett Arthur L, 2006, J Clin Hypertens (Greenwich), V8, P53
   Burnstock G, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00661
   Cao CW, 2010, J INSECT SCI, V10, DOI 10.1673/031.010.20001
   Cardoso FC, 2015, MOL PHARMACOL, V88, P291, DOI 10.1124/mol.115.098178
   Catterall WA, 2018, CURR OPIN PHYSIOL, V2, P42, DOI 10.1016/j.cophys.2017.12.007
   Chao RY, 2018, J NEUROCHEM, V144, P483, DOI 10.1111/jnc.14282
   Chassagnon IR, 2017, P NATL ACAD SCI USA, V114, P3750, DOI 10.1073/pnas.1614728114
   Chen C, 2018, ORG CHEM FRONT, V5, P2143, DOI 10.1039/c8qo00415c
   Chernov-Rogan T, 2018, P NATL ACAD SCI USA, V115, pE792, DOI 10.1073/pnas.1713701115
   Choi SJ, 2004, FEBS LETT, V572, P109, DOI 10.1016/j.febslet.2004.07.019
   Clement H, 2015, J VENOM ANIM TOXINS, V21, DOI 10.1186/s40409-015-0018-7
   Combes A, 2009, EUR J MASS SPECTROM, V15, P517, DOI 10.1255/ejms.1000
   Consuegra J, 2013, J PERIODONTOL, V84, P1858, DOI 10.1902/jop.2013.120679
   Copp SW, 2016, J PHYSIOL-LONDON, V594, P641, DOI 10.1113/JP271714
   Corzo G, 2002, J BIOL CHEM, V277, P23627, DOI 10.1074/jbc.M200511200
   Cristofori-Armstrong B, 2017, NEUROPHARMACOLOGY, V127, P173, DOI 10.1016/j.neuropharm.2017.04.042
   Olivo EAC, 2017, J PERIODONTOL, V88, pE88, DOI 10.1902/jop.2016.160438
   Culliney TW, 2014, INTEGRATED PEST MANA, V3, P201, DOI DOI 10.1007/978-94-007-7796-5_8
   da Silva JF, 2015, TOXICON, V108, P53, DOI 10.1016/j.toxicon.2015.09.043
   Dai BB, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102125
   Dalmolin Gerusa D, 2017, Pain Rep, V2, pe610, DOI 10.1097/PR9.0000000000000610
   Dalmolin GD, 2011, PAIN, V152, P2224, DOI 10.1016/j.pain.2011.04.015
   De Jonghe P, 2011, DEV MED CHILD NEUROL, V53, P7, DOI 10.1111/j.1469-8749.2011.03965.x
   de Oliveira LC, 2015, TOXICON, V104, P73, DOI 10.1016/j.toxicon.2015.07.010
   de Souza AH, 2011, TOXICON, V58, P626, DOI 10.1016/j.toxicon.2011.09.008
   Deng MC, 2014, NEUROPHARMACOLOGY, V79, P657, DOI 10.1016/j.neuropharm.2014.01.017
   Deuis J. R., 2016, TOXINS BASEL, V8
   Deuis JR, 2017, SCI REP-UK, V7, DOI 10.1038/srep40883
   DiMilia T., 2017, AKASHI THERAPEUTICS
   dos Santos NB, 2019, J CELL PHYSIOL, V234, P1398, DOI 10.1002/jcp.26935
   Down RE, 2006, PEST MANAG SCI, V62, P77, DOI 10.1002/ps.1119
   Drenth JPH, 2007, J CLIN INVEST, V117, P3603, DOI 10.1172/JCI33297
   Duan B, 2011, J NEUROSCI, V31, P2101, DOI 10.1523/JNEUROSCI.4351-10.2011
   Dubovskii PV, 2015, CELL MOL LIFE SCI, V72, P4501, DOI 10.1007/s00018-015-2016-x
   Emir TLR., 2017, NEUROBIOLOGY TRP CHA
   Er SY, 2017, NEUROPHARMACOLOGY, V127, P185, DOI 10.1016/j.neuropharm.2017.03.020
   Escoubas P, 2000, BIOCHIMIE, V82, P893, DOI 10.1016/S0300-9084(00)01166-4
   Escoubas P, 2000, J BIOL CHEM, V275, P25116, DOI 10.1074/jbc.M003643200
   Escoubas P, 2002, MOL PHARMACOL, V62, P48, DOI 10.1124/mol.62.1.48
   Estrada G, 2016, TOXICON, V119, P152, DOI 10.1016/j.toxicon.2016.06.001
   Fernandez-Rojo MA, 2018, CELL DEATH DISCOV, V4, DOI 10.1038/s41420-018-0030-0
   Fitches E, 2004, J INSECT PHYSIOL, V50, P61, DOI 10.1016/j.jinsphys.2003.09.010
   Fitches EC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039389
   Ford AP, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00267
   Fosgerau K, 2015, DRUG DISCOV TODAY, V20, P122, DOI 10.1016/j.drudis.2014.10.003
   Freitas ACN, 2017, NITRIC OXIDE-BIOL CH, V64, P31, DOI 10.1016/j.niox.2017.01.004
   Freitas ACN, 2016, BRIT J PHARMACOL, V173, P1491, DOI 10.1111/bph.13448
   Freitas ACN, 2018, TOXINS, V10, DOI 10.3390/toxins10010043
   Garcia F, 2013, J ANTIBIOT, V66, P3, DOI 10.1038/ja.2012.87
   Gartrell BA, 2015, EUR UROL, V68, P850, DOI 10.1016/j.eururo.2015.06.039
   Ginnetti AT, 2018, BIOORG MED CHEM LETT, V28, P1392, DOI 10.1016/j.bmcl.2018.02.039
   Gleeson MP, 2011, J MOL MODEL, V17, P769, DOI 10.1007/s00894-010-0732-6
   Gnanasambandam R, 2017, BIOPHYS J, V112, P31, DOI 10.1016/j.bpj.2016.11.013
   Gomes GM, 2013, TOXICON, V76, P23, DOI 10.1016/j.toxicon.2013.08.059
   Gomez MV, 2016, TOXINS, V8, DOI 10.3390/toxins8090253
   Grishin EV, 2010, ANN NEUROL, V67, P680, DOI 10.1002/ana.21949
   Guo SD, 2018, TOXICON, V150, P297, DOI 10.1016/j.toxicon.2018.06.077
   Hardy KC., 2013, PLOS ONE, V8
   Hardy Margaret C, 2014, Insects, V5, P227, DOI 10.3390/insects5010227
   Hauke TJ, 2017, TOXICON, V138, P173, DOI 10.1016/j.toxicon.2017.08.024
   Hefti FF, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-S3-S7
   Herzig V., 2010, INSECT PHARM, P119
   Herzig V, 2018, BIOMEDICINES, V6, DOI 10.3390/biomedicines6030090
   Herzig V, 2016, TOXINS, V8, DOI 10.3390/toxins8090252
   Herzig V, 2016, SCI REP-UK, V6, DOI 10.1038/srep29538
   Herzig V, 2015, TOXINS, V7, P4366, DOI 10.3390/toxins7104366
   Herzig V, 2014, ADV INSECT PHYSIOL, V47, P389, DOI 10.1016/B978-0-12-800197-4.00008-7
   Holford M, 2018, SCIENCE, V361, P842, DOI 10.1126/science.aau7761
   Honigsperger C, 2017, J PHYSIOL-LONDON, V595, P739, DOI 10.1113/JP273024
   Huang XH, 2010, J ADV RES, V1, P13, DOI 10.1016/j.jare.2010.02.002
   Ikonomopoulou MP, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0885-2
   Ikonomopoulou MP, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29826-4
   Ikonomopoulou MP, 2016, TOXICON, V123, P62, DOI 10.1016/j.toxicon.2016.10.013
   Jin L, 2017, AMINO ACIDS, V49, P1237, DOI 10.1007/s00726-017-2425-2
   Kabanova NV, 2012, BBA-BIOMEMBRANES, V1818, P2868, DOI 10.1016/j.bbamem.2012.07.016
   Kamolkijkarn P, 2010, PEPTIDES, V31, P533, DOI 10.1016/j.peptides.2010.01.001
   Khan SA, 2006, TRANSGENIC RES, V15, P349, DOI 10.1007/s11248-006-0007-2
   Kikuchi Kyoko, 2015, Int J Pept, V2015, P537508, DOI 10.1155/2015/537508
   Kim Hunmin, 2011, Korean J Pediatr, V54, P473, DOI 10.3345/kjp.2011.54.11.473
   King GF, 2013, ANNU REV ENTOMOL, V58, P475, DOI 10.1146/annurev-ento-120811-153650
   Klint JK, 2015, BRIT J PHARMACOL, V172, P2445, DOI 10.1111/bph.13081
   Klint JK, 2012, TOXICON, V60, P478, DOI 10.1016/j.toxicon.2012.04.337
   Kozlov SA, 2006, J BIOL CHEM, V281, P20983, DOI 10.1074/jbc.M602168200
   Kroemer JA, 2015, VIRUSES-BASEL, V7, P422, DOI 10.3390/v7010422
   Kuhn-Nentwig L, 2012, J BIOL CHEM, V287, P25640, DOI 10.1074/jbc.M112.339051
   Kuhn-Nentwig L, 2011, ADV INSECT PHYSIOL, V40, P1, DOI 10.1016/B978-0-12-387668-3.00001-5
   Kuhn-Nentwig L, 2011, AMINO ACIDS, V40, P69, DOI 10.1007/s00726-009-0471-0
   Kuzmenkov AI, 2018, NEUROSCI LETT, V679, P15, DOI 10.1016/j.neulet.2017.10.050
   Kwong K, 2015, CURR OPIN PHARMACOL, V22, P131, DOI 10.1016/j.coph.2015.04.007
   Lajoie DM, 2015, J BIOL CHEM, V290, P10994, DOI 10.1074/jbc.M115.636951
   Lau JL, 2018, BIOORGAN MED CHEM, V26, P2700, DOI 10.1016/j.bmc.2017.06.052
   Lazarev VN, 2013, ARCH MICROBIOL, V195, P173, DOI 10.1007/s00203-012-0863-5
   Lazarev VN, 2011, ANTIMICROB AGENTS CH, V55, P5367, DOI 10.1128/AAC.00449-11
   Lei Q, 2015, TOXINS, V7, P886, DOI 10.3390/toxins7030886
   Leite KRM, 2012, TOXICON, V60, P797, DOI 10.1016/j.toxicon.2012.06.006
   Lhouvum K, 2015, MED CHEM RES, V24, P1527, DOI 10.1007/s00044-014-1232-5
   Li XY, 2018, INFLAMM RES, V67, P455, DOI 10.1007/s00011-018-1138-7
   Li XY, 2013, J PHARMACOL EXP THER, V344, P407, DOI 10.1124/jpet.112.199083
   LIANG SP, 1993, TOXICON, V31, P969, DOI 10.1016/0041-0101(93)90256-I
   Lin SH, 2015, NEUROPHARMACOLOGY, V94, P99, DOI 10.1016/j.neuropharm.2014.12.011
   Liu PW, 2014, J NEUROSCI, V34, P4991, DOI 10.1523/JNEUROSCI.1925-13.2014
   Liu Z, 2012, CURR MOL MED, V12, P1350, DOI 10.2174/156652412803833643
   LOPESMARTINS RAB, 1994, BRIT J PHARMACOL, V113, P81, DOI 10.1111/j.1476-5381.1994.tb16177.x
   Lorenzini DM, 2003, INSECT BIOCHEM MOLEC, V33, P1011, DOI 10.1016/S0965-1748(03)00115-2
   Ma BB, 2018, PEPTIDES, V99, P108, DOI 10.1016/j.peptides.2017.12.011
   Maciel IS, 2014, NEUROSCIENCE, V277, P794, DOI 10.1016/j.neuroscience.2014.07.065
   Mannikko R, 2018, P NATL ACAD SCI USA, V115, P4495, DOI 10.1073/pnas.1720185115
   Mao HF, 2017, NEURAL REGEN RES, V12, P596, DOI 10.4103/1673-5374.205099
   Maretic Z., 1954, Bulletin of the World Health Organization, V11, P1007
   Matsubara FH, 2017, INSECT MOL BIOL, V26, P25, DOI 10.1111/imb.12268
   Mazzuca M, 2007, NAT NEUROSCI, V10, P943, DOI 10.1038/nn1940
   McCarthy CA, 2015, NEUROPHARMACOLOGY, V99, P650, DOI 10.1016/j.neuropharm.2015.08.040
   Mikov AN, 2015, SCI REP-UK, V5, DOI 10.1038/srep17232
   Moran MM, 2018, BRIT J PHARMACOL, V175, P2185, DOI 10.1111/bph.14044
   Morgenstern D, 2013, TOXICON, V63, P120, DOI 10.1016/j.toxicon.2012.11.022
   Mukherjee AK, 2006, TOXICON, V47, P182, DOI 10.1016/j.toxicon.2005.10.011
   Murray JK, 2015, BIOORG MED CHEM LETT, V25, P4866, DOI 10.1016/j.bmcl.2015.06.033
   Murray JK, 2015, J MED CHEM, V58, P2299, DOI 10.1021/jm501765v
   Nakasu E., 2014, P R SOC B, V281
   Nakasu EYT, 2014, FRONT PLANT SCI, V5, DOI 10.3389/fpls.2014.00673
   Nanou E, 2018, NEURON, V98, P466, DOI 10.1016/j.neuron.2018.03.017
   NENTWIG W, 1993, TOXICON, V31, P233, DOI 10.1016/0041-0101(93)90140-E
   Nicoletti NF, 2017, TOXICON, V129, P58, DOI 10.1016/j.toxicon.2017.02.001
   Norton RS, 2017, NEUROPHARMACOLOGY, V127, P124, DOI 10.1016/j.neuropharm.2017.07.002
   Oliveira SM, 2016, PFLUG ARCH EUR J PHY, V468, P881, DOI 10.1007/s00424-016-1801-1
   Oparin PB, 2016, BIOCHEM J, V473, P3113, DOI 10.1042/BCJ20160573
   Osteen JD, 2016, NATURE, V534, P494, DOI 10.1038/nature17976
   Pacheco DD, 2016, J VENOM ANIM TOXINS, V22, DOI 10.1186/s40409-016-0091-6
   Palhares MR, 2017, LIFE SCI, V182, P122, DOI 10.1016/j.lfs.2017.06.018
   Pascale M, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3617-6
   Peigneur S, 2018, TOXICON, V151, P96, DOI 10.1016/j.toxicon.2018.07.008
   Pennington MW, 2018, BIOORGAN MED CHEM, V26, P2738, DOI 10.1016/j.bmc.2017.09.029
   Ardisson-Araujo DMP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084404
   Pignataro G, 2007, BRAIN, V130, P151, DOI 10.1093/brain/awl325
   Pimentel C, 2006, PROTEIN SCI, V15, P628, DOI 10.1110/ps.051860606
   Polina NF, 2012, PROBIOTICS ANTIMICRO, V4, P208, DOI 10.1007/s12602-012-9108-9
   Polyansky AA, 2009, FEBS LETT, V583, P2425, DOI 10.1016/j.febslet.2009.06.044
   Ponnappan N, 2017, EUR J PHARM BIOPHARM, V114, P145, DOI 10.1016/j.ejpb.2017.01.012
   Raposo Catarina, 2017, J Clin Transl Res, V3, P233
   Reis PVM, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00667
   Renukuntla J, 2013, INT J PHARMACEUT, V447, P75, DOI 10.1016/j.ijpharm.2013.02.030
   Richards KL, 2018, P NATL ACAD SCI USA, V115, pE8077, DOI 10.1073/pnas.1804764115
   Rigo FK, 2017, SCAND J PAIN, V17, P203, DOI 10.1016/j.sjpain.2017.09.019
   Rigo FK, 2017, TOXICON, V133, P145, DOI 10.1016/j.toxicon.2017.05.018
   Rigo FK, 2013, CANCER SCI, V104, P1226, DOI 10.1111/cas.12209
   Rosa F, 2014, ANESTH ANALG, V119, P196, DOI 10.1213/ANE.0000000000000249
   Rothan FLA., 2015, PLOS ONE, V10
   Rothan HA, 2014, BMC MICROBIOL, V14, DOI 10.1186/1471-2180-14-140
   Sachkova MY, 2014, INSECT MOL BIOL, V23, P527, DOI 10.1111/imb.12097
   Sachs Frederick, 2015, World J Neurol, V5, P74, DOI 10.5316/wjn.v5.i3.74
   Saez NJ, 2017, METHODS MOL BIOL, V1586, P155, DOI 10.1007/978-1-4939-6887-9_10
   Saez NJ, 2010, TOXINS, V2, P2851, DOI 10.3390/toxins2122851
   Salari A, 2016, SCI REP-UK, V6, DOI 10.1038/srep23894
   Santos DM, 2010, AMINO ACIDS, V39, P135, DOI 10.1007/s00726-009-0385-x
   Santos DM, 2016, TOXINOLOGY, P361, DOI 10.1007/978-94-007-6389-0_19
   Schmalhofer WA, 2008, MOL PHARMACOL, V74, P1476, DOI 10.1124/mol.108.047670
   Shcherbatko A, 2016, J BIOL CHEM, V291, P13974, DOI 10.1074/jbc.M116.725978
   Shen HW, 2018, EXP BIOL MED, V243, P725, DOI 10.1177/1535370218772802
   Siemens J, 2006, NATURE, V444, P208, DOI 10.1038/nature05285
   Silva CN, 2015, J UROLOGY, V194, P1481, DOI 10.1016/j.juro.2015.06.081
   Silva JF, 2017, DATA BRIEF, V14, P440, DOI 10.1016/j.dib.2017.07.059
   Silva RBM, 2015, BRIT J PHARMACOL, V172, P924, DOI 10.1111/bph.12966
   Silva RBM, 2018, MOL NEUROBIOL, V55, P9307, DOI 10.1007/s12035-018-1049-1
   Siveen KS, 2014, BBA-REV CANCER, V1845, P136, DOI 10.1016/j.bbcan.2013.12.005
   Smith JJ, 2017, TOXINS, V9, DOI 10.3390/toxins9050155
   Smith JJ, 2013, CELL MOL LIFE SCI, V70, P3665, DOI 10.1007/s00018-013-1315-3
   Sousa SR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182848
   Souza AH, 2008, PAIN, V140, P115, DOI 10.1016/j.pain.2008.07.014
   Sternberg D, 2001, BRAIN, V124, P1091, DOI 10.1093/brain/124.6.1091
   Suchyna TM, 2017, PROG BIOPHYS MOL BIO, V130, P244, DOI 10.1016/j.pbiomolbio.2017.07.011
   Tan H, 2013, CURR MOL MED, V13, P900, DOI 10.2174/15665240113139990045
   Tan HX, 2017, THERANOSTICS, V7, P3168, DOI 10.7150/thno.19780
   Titaux-Delgado G, 2018, PROTEIN SCI, V27, P692, DOI 10.1002/pro.3363
   Tonello R, 2017, BRIT J PHARMACOL, V174, P57, DOI 10.1111/bph.13652
   Tonello R, 2014, J PAIN, V15, P619, DOI 10.1016/j.jpain.2014.02.007
   Turchetto J, 2017, MICROB CELL FACT, V16, DOI 10.1186/s12934-016-0617-1
   Upert G, 2014, CHEM COMMUN, V50, P8408, DOI [10.1039/C4CC02679A, 10.1039/c4cc02679a]
   Vassilevski AA, 2009, BIOCHEMISTRY-MOSCOW+, V74, P1505, DOI 10.1134/S0006297909130069
   Vassilevski AA, 2008, BIOCHEM J, V411, P687, DOI [10.1042/BJ20071123, 10.1042/bj20071123]
   Vassilevski AA, 2013, FEBS J, V280, P6247, DOI 10.1111/febs.12547
   Vassilevski AA, 2010, J BIOL CHEM, V285, P32293, DOI 10.1074/jbc.M110.104265
   Vetter I, 2017, PHARMACOL THERAPEUT, V172, P73, DOI 10.1016/j.pharmthera.2016.11.015
   Vieira LB, 2005, J PHARMACOL EXP THER, V314, P1370, DOI 10.1124/jpet.105.087023
   Wang B, 2018, NAT ECOL EVOL, V2, P614, DOI 10.1038/s41559-017-0449-3
   Wang GS, 2010, ANTIMICROB AGENTS CH, V54, P1343, DOI 10.1128/AAC.01448-09
   Wang JL, 2016, J MOL CELL CARDIOL, V98, P83, DOI 10.1016/j.yjmcc.2016.07.005
   Wang L, 2014, ANTIMICROB AGENTS CH, V58, P6999, DOI 10.1128/AAC.03279-14
   Wang Y, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0229-y
   Windley MJ, 2012, TOXINS, V4, P191, DOI 10.3390/toxins4030191
   World Health Organization, 2017, WORLD MALARIA REPORT
   World Spider Catalog, 2018, WORLD SPIDER CATALOG
   Wu J, 2017, TRENDS BIOCHEM SCI, V42, P57, DOI 10.1016/j.tibs.2016.09.004
   Xiao Z, 2018, TOXINS, V10, DOI 10.3390/toxins10060233
   Xiong ZG, 2004, CELL, V118, P687, DOI 10.1016/j.cell.2004.08.026
   Yang S, 2014, INSECT BIOCHEM MOLEC, V47, P1, DOI 10.1016/j.ibmb.2014.01.007
   Yang ZJ, 2011, NEUROBIOL DIS, V43, P446, DOI 10.1016/j.nbd.2011.04.018
   Yans LZ, 1998, J BIOL CHEM, V273, P2059, DOI 10.1074/jbc.273.4.2059
   Ye MY, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-17344-8
   Yeung EW, 2005, J PHYSIOL-LONDON, V562, P367, DOI 10.1113/jphysiol.2004.075275
   Zamponi GW, 2015, PHARMACOL REV, V67, P821, DOI 10.1124/pr.114.009654
   Zhang P, 2017, ORG BIOMOL CHEM, V15, P9379, DOI 10.1039/c7ob02233f
   Zhao HW, 2011, J PEPT SCI, V17, P540, DOI 10.1002/psc.1370
   Zhong YQW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098850
   Zhou RP, 2018, GENE, V642, P230, DOI 10.1016/j.gene.2017.11.034
   Zobel-Thropp PA, 2012, TOXICON, V60, P265, DOI 10.1016/j.toxicon.2012.04.350
NR 232
TC 4
Z9 4
U1 3
U2 23
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD FEB
PY 2019
VL 158
BP 109
EP 126
DI 10.1016/j.toxicon.2018.11.298
PG 18
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HL3EP
UT WOS:000458596000014
PM 30543821
DA 2020-05-12
ER

PT J
AU Gnanakumar, ES
   Chandran, N
   Kozhevnikov, IV
   Grau-Atienza, A
   Fernandez, EVR
   Sepulveda-Escribano, A
   Shiju, NR
AF Gnanakumar, Edwin S.
   Chandran, Narendraraj
   Kozhevnikov, Ivan V.
   Grau-Atienza, Aida
   Ramos Fernandez, Enrique V.
   Sepulveda-Escribano, Antonio
   Shiju, N. Raveendran
TI Highly efficient nickel-niobia composite catalysts for hydrogenation of
   CO2 to methane
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Niobia; CO2 utilisation; Methanation; Nickel; Heterogeneous catalysis;
   Methane
ID POWER-TO-GAS; CARBON-DIOXIDE; CLIMATE-CHANGE; NANOPARTICLES;
   DEACTIVATION; CONVERSION; OXIDATION; PROGRESS; CAPTURE; SILICA
AB We studied the catalytic hydrogenation of CO2 to methane using nickel-niobia composite catalysts. Catalysts containing 10-70 wt% Ni were synthesized by wet impregnation and tested for CO 2 hydrogenation in a flow reactor. 40 wt% was found to be the optimum Ni loading, which resulted in CO2 conversion of 81% at 325 degrees C. We also calcined the Nb2O5 support at different temperatures to study the influence of calcination temperature on the catalytic performance. 40 wt% Ni loaded on Nb-2 O-5, which was calcined at 700 degrees C gave higher methanation activity (91% conversion of CO2). Time on stream study for 50 h showed a stable activity and selectivity; thus confirming the scope for practical application. (C) 2018 Published by Elsevier Ltd.
C1 [Gnanakumar, Edwin S.; Shiju, N. Raveendran] Univ Amsterdam, Vant Hoff Inst Mol Sci, POB 94157, NL-1090 GD Amsterdam, Netherlands.
   [Chandran, Narendraraj] Indian Inst Sci, Ctr Nano Sci & Engn, Bangalore, Karnataka, India.
   [Kozhevnikov, Ivan V.] Univ Liverpool, Dept Chem, Liverpool L69 7ZD, Merseyside, England.
   [Grau-Atienza, Aida; Ramos Fernandez, Enrique V.; Sepulveda-Escribano, Antonio] Univ Alicante, Lab Mat Avanzados, Inst Univ Mat Alicante, Dept Quim Inorgan, Apartado 99, E-03080 Alicante, Spain.
RP Shiju, NR (reprint author), Univ Amsterdam, Vant Hoff Inst Mol Sci, POB 94157, NL-1090 GD Amsterdam, Netherlands.
EM n.r.shiju@uva.nl
RI Ramos-Fernandez, Enrique V./B-8407-2011
OI Ramos-Fernandez, Enrique V./0000-0001-6357-0383
FU NWO CAPITA project [732.013.002]; MINECO [MAT-2013-45008-P,
   MAT2016-81732-ERC, RyC-2012-11427]; University of Alicante [GRE-13-31];
   Generalitat ValencianaGeneralitat Valenciana [PROMETEOII/ 2014/004]
FX E.S.G. and N.R.S acknowledge the financial support from NWO CAPITA
   project (732.013.002). ASE acknowledges the financial support from the
   MINECO projects MAT-2013-45008-P and MAT2016-81732-ERC. EVRF gratefully
   acknowledge support from MINECO for his Ramon y Cajal grant
   (RyC-2012-11427) and University of Alicante for the project GRE-13-31.
   Generalitat Valenciana is also acknowledged for financial support
   (PROMETEOII/ 2014/004).
CR Aziz MAA, 2015, GREEN CHEM, V17, P2647, DOI 10.1039/c5gc00119f
   BAJPAI PK, 1982, CAN J CHEM ENG, V60, P4, DOI 10.1002/cjce.5450600102
   Barrientos J, 2014, APPL CATAL A-GEN, V486, P143, DOI 10.1016/j.apcata.2014.08.021
   Batyrev ED, 2012, J PHYS CHEM C, V116, P19335, DOI 10.1021/jp3051438
   Cai W, 2013, CATAL COMMUN, V39, P30, DOI 10.1016/j.catcom.2013.04.025
   Chary KVR, 2004, J MOL CATAL A-CHEM, V223, P353, DOI 10.1016/j.molcata.2003.09.049
   Crowley TJ, 2000, SCIENCE, V289, P270, DOI 10.1126/science.289.5477.270
   Davis SJ, 2010, SCIENCE, V329, P1330, DOI 10.1126/science.1188566
   Daza YA, 2016, RSC ADV, V6, P49675, DOI 10.1039/c6ra05414e
   Jardim ED, 2015, APPL CATAL A-GEN, V502, P129, DOI 10.1016/j.apcata.2015.05.033
   den Otter JH, 2016, J CATAL, V340, P270, DOI 10.1016/j.jcat.2016.05.025
   den Otter J, 2014, TOP CATAL, V57, P445, DOI 10.1007/s11244-013-0200-5
   Friedlingstein P, 2010, NAT GEOSCI, V3, P811, DOI 10.1038/ngeo1022
   Frontera P, 2017, CATALYSTS, V7, DOI 10.3390/catal7020059
   Frydman A, 1999, J CATAL, V188, P1, DOI 10.1006/jcat.1999.2579
   Gao JJ, 2012, RSC ADV, V2, P2358, DOI 10.1039/c2ra00632d
   Gotz M, 2016, RENEW ENERG, V85, P1371, DOI 10.1016/j.renene.2015.07.066
   Inui T, 1991, CATAL TODAY, V10, P95, DOI 10.1016/0920-5861(91)80077-M
   Junaedi C., 2011, 41 INT C ENV SYST PO
   Khorsand K, 2007, PETROL COAL, V49, P46
   Lu HL, 2014, INT J HYDROGEN ENERG, V39, P18894, DOI 10.1016/j.ijhydene.2014.09.076
   Marakatti VS, 2016, CATAL SCI TECHNOL, V6, P2268, DOI 10.1039/c5cy01252j
   Meehl GA, 2005, SCIENCE, V307, P1769, DOI 10.1126/science.1106663
   Mejia C. H., 2016, CATAL SCI TECHNOL, V6, P577
   Mozer TS, 2011, INT J HYDROGEN ENERG, V36, P13369, DOI 10.1016/j.ijhydene.2011.08.011
   Nair GS, 2012, CATAL SCI TECHNOL, V2, P1173, DOI 10.1039/c2cy00335j
   Nie WX, 2017, CATALYSTS, V7, DOI 10.3390/catal7040104
   Nowak I, 1999, CHEM REV, V99, P3603, DOI 10.1021/cr9800208
   Polanski J, 2017, APPL CATAL B-ENVIRON, V206, P16, DOI 10.1016/j.apcatb.2017.01.017
   Porosoff MD, 2016, ENERG ENVIRON SCI, V9, P62, DOI 10.1039/c5ee02657a
   Rockstrom J, 2017, SCIENCE, V355, P1269, DOI 10.1126/science.aah3443
   Rojas E, 2009, CATAL COMMUN, V10, P1555, DOI 10.1016/j.catcom.2009.04.016
   Saeidi S, 2014, J CO2 UTIL, V5, P66, DOI 10.1016/j.jcou.2013.12.005
   Shiju NR, 2010, TOP CATAL, V53, P1217, DOI 10.1007/s11244-010-9566-9
   Tada S, 2012, INT J HYDROGEN ENERG, V37, P5527, DOI 10.1016/j.ijhydene.2011.12.122
   Wachs IE, 2005, CATAL TODAY, V100, P79, DOI 10.1016/j.cattod.2004.12.019
   Wang W, 2011, FRONT CHEM SCI ENG, V5, P2, DOI 10.1007/s11705-010-0528-3
   Wang W, 2011, CHEM SOC REV, V40, P3703, DOI 10.1039/c1cs15008a
   Wojcieszak R, 2006, J MOL CATAL A-CHEM, V256, P225, DOI 10.1016/j.molcata.2006.04.053
   Yang HQ, 2008, J ENVIRON SCI, V20, P14, DOI 10.1016/S1001-0742(08)60002-9
   Yu KMK, 2008, CHEMSUSCHEM, V1, P893, DOI 10.1002/cssc.200800169
   Zhang XJ, 2017, APPL ENERG, V190, P326, DOI 10.1016/j.apenergy.2016.12.098
   Zhou L, 2015, CATAL LETT, V145, P612, DOI 10.1007/s10562-014-1426-y
NR 43
TC 10
Z9 10
U1 4
U2 92
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 2
PY 2019
VL 194
SI SI
BP 2
EP 9
DI 10.1016/j.ces.2018.08.038
PG 8
WC Engineering, Chemical
SC Engineering
GA HC6NG
UT WOS:000451917900002
DA 2020-05-12
ER

PT J
AU Ma, HB
   Ma, K
   Ji, JY
   Tang, SY
   Liu, CJ
   Jiang, W
   Yue, HR
   Liang, B
AF Ma, Haibin
   Ma, Kui
   Ji, Junyi
   Tang, Siyang
   Liu, Changjun
   Jiang, Wei
   Yue, Hairong
   Liang, Bin
TI Graphene intercalated Ni-SiO2/GO-Ni-foam catalyst with enhanced
   reactivity and heat-transfer for CO2 methanation
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Metal-structured nanomaterials; Graphene intercalation; Ni-based
   catalysts; CO2 methanation; DFT investigation
ID ULTRATHIN-GRAPHITE FOAM; CARBON-DIOXIDE; FUNDAMENTAL CHALLENGES; CH4;
   PSEUDOPOTENTIALS; HYDROGENATION; OPPORTUNITIES; DISSOCIATION; INTERFACE;
   SILICA
AB The fabrication of stable Ni active species over the high heat-transfer support is essential for the Ni-based catalysts in CO2 methanation to resist sintering and remove the reaction heat. A metal-structured Ni-SiO2/GO-Ni-foam catalyst was synthesized via intercalation of graphene oxide (GO) to facilitate the synthesis of stable nickel silicates on Ni-foam, which exhibited excellent activity and stability in the high-temperature (e.g., 470 degrees C) CO2 methanation. Characterization results suggested that the intercalated graphene over the Ni-foam contributed to a stronger metal-support interaction on the metal-structured catalyst due to the connective function of GO between the Ni-foam and nickel silicates. The formation of nickel silicates on GO lead to high dispersion of Ni sites and high amount of surface OH groups for elimination of carbon deposition. Density functional theory study revealed that the graphene modified the electronic structure of surface Ni, and contributed to an increase of CO2 adsorption energy, Ni-4 binding energy with support, and a decrease of H-2 and CO2 dissociation energy, and thus led to a high reactivity for CO2 methanation. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Ma, Haibin; Ma, Kui; Ji, Junyi; Tang, Siyang; Liu, Changjun; Jiang, Wei; Yue, Hairong; Liang, Bin] Sichuan Univ, Sch Chem Engn, Multiphases Mass Transfer & React Engn Lab, Chengdu 610065, Sichuan, Peoples R China.
   [Liu, Changjun; Yue, Hairong; Liang, Bin] Sichuan Univ, Inst New Energy & Low Carbon Technol, Chengdu 610207, Sichuan, Peoples R China.
RP Yue, HR (reprint author), Sichuan Univ, Sch Chem Engn, Multiphases Mass Transfer & React Engn Lab, Chengdu 610065, Sichuan, Peoples R China.
EM hryue@scu.edu.cn
OI Jiang, Wei/0000-0002-5560-0885
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21576169, 21306118]; Research Fund for the Doctoral
   Program of Higher Education of ChinaResearch Fund for the Doctoral
   Program of Higher Education of China (RFDP)Specialized Research Fund for
   the Doctoral Program of Higher Education (SRFDP) [20130181120065];
   Outstanding young scholar fund of Sichuan University [2015SCU04A10]
FX The authors are grateful for the support from the National Natural
   Science Foundation of China (21576169, 21306118), Research Fund for the
   Doctoral Program of Higher Education of China (20130181120065) and
   Outstanding young scholar fund of Sichuan University (2015SCU04A10).
CR Abello S, 2013, FUEL, V113, P598, DOI 10.1016/j.fuel.2013.06.012
   Aziz MAA, 2015, GREEN CHEM, V17, P2647, DOI 10.1039/c5gc00119f
   Aziz MAA, 2014, APPL CATAL B-ENVIRON, V147, P359, DOI 10.1016/j.apcatb.2013.09.015
   BARTHOLOMEW CH, 1982, CATAL REV, V24, P67, DOI 10.1080/03602458208079650
   BERGNER A, 1993, MOL PHYS, V80, P1431, DOI 10.1080/00268979300103121
   Burattin P, 1998, J PHYS CHEM B, V102, P2722, DOI 10.1021/jp980018k
   Burattin P, 2000, J PHYS CHEM B, V104, P10482, DOI 10.1021/jp0003151
   Castro Neto AH, 2009, REV MOD PHYS, V81, P109, DOI 10.1103/RevModPhys.81.109
   Fan YJ, 2016, J CO2 UTIL, V16, P150, DOI 10.1016/j.jcou.2016.07.001
   Frey M, 2015, CR CHIM, V18, P283, DOI 10.1016/j.crci.2015.01.002
   Ganesh I, 2014, RENEW SUST ENERG REV, V31, P221, DOI 10.1016/j.rser.2013.11.045
   Gaskell KJ, 2007, J PHYS CHEM C, V111, P13912, DOI 10.1021/jp073590x
   Geim AK, 2007, NAT MATER, V6, P183, DOI 10.1038/nmat1849
   Gong C, 2012, ACS NANO, V6, P5381, DOI 10.1021/nn301241p
   Guo M, 2014, CATAL COMMUN, V54, P55, DOI 10.1016/j.catcom.2014.05.022
   GUPTA RP, 1975, PHYS REV B, V12, P15, DOI 10.1103/PhysRevB.12.15
   He HY, 2016, J PHYS CHEM C, V120, P16732, DOI 10.1021/acs.jpcc.6b04526
   He S, 2013, CHEM MATER, V25, P1040, DOI 10.1021/cm303517z
   Hwang S, 2012, CATAL LETT, V142, P860, DOI 10.1007/s10562-012-0842-0
   Ji HX, 2012, NANO LETT, V12, P2446, DOI 10.1021/nl300528p
   Ji JY, 2013, ACS NANO, V7, P6237, DOI 10.1021/nn4021955
   Jones G, 2007, J AM CHEM SOC, V130, P14483
   Li JD, 2013, J PHYS CHEM C, V117, P16907, DOI 10.1021/jp402421q
   Li YK, 2016, APPL CATAL A-GEN, V510, P216, DOI 10.1016/j.apcata.2015.11.034
   Liu B, 2009, J PHYS CHEM C, V113, P13715, DOI 10.1021/jp9003196
   Liu DP, 2009, APPL CATAL A-GEN, V358, P110, DOI 10.1016/j.apcata.2008.12.044
   Mitsui T, 2003, NATURE, V422, P705, DOI 10.1038/nature01557
   MONKHORST HJ, 1976, PHYS REV B, V13, P5188, DOI 10.1103/PhysRevB.13.5188
   Montebelli A, 2014, CATAL SCI TECHNOL, V4, P2846, DOI 10.1039/c4cy00179f
   Muroyama H, 2016, J CATAL, V343, P178, DOI 10.1016/j.jcat.2016.07.018
   Ortalan V, 2010, NAT NANOTECHNOL, V5, P506, DOI [10.1038/NNANO.2010.92, 10.1038/nnano.2010.92]
   Park JN, 2009, J CATAL, V266, P92, DOI 10.1016/j.jcat.2009.05.018
   Peck MA, 2012, CHEM MATER, V24, P4483, DOI 10.1021/cm300739y
   PERDEW JP, 1992, PHYS REV B, V46, P6671, DOI 10.1103/PhysRevB.46.6671
   Reddy BM, 1997, J PHYS CHEM B, V101, P1769, DOI 10.1021/jp963091o
   Simon F, 1998, COLLOID POLYM SCI, V276, P930, DOI 10.1007/s003960050330
   Sivaiah MV, 2010, CATAL TODAY, V157, P397, DOI 10.1016/j.cattod.2010.04.042
   Sun KQ, 2006, PHYS CHEM CHEM PHYS, V8, P1731, DOI 10.1039/b513319j
   Swalus C, 2012, APPL CATAL B-ENVIRON, V125, P41, DOI 10.1016/j.apcatb.2012.05.019
   VANDERBILT D, 1990, PHYS REV B, V41, P7892, DOI 10.1103/PhysRevB.41.7892
   Wang SG, 2009, SURF SCI, V603, P2600, DOI 10.1016/j.susc.2009.06.009
   Westermann A, 2015, APPL CATAL B-ENVIRON, V174, P120, DOI 10.1016/j.apcatb.2015.02.026
   Yan Z, 2005, J AM CHEM SOC, V127, P1604, DOI 10.1021/ja043652m
   Younas M, 2016, ENERG FUEL, V30, P8815, DOI 10.1021/acs.energyfuels.6b01723
   Zhang CX, 2013, CHEM COMMUN, V49, P9383, DOI 10.1039/c3cc43895c
   Zhang CX, 2013, ACS SUSTAIN CHEM ENG, V1, P161, DOI 10.1021/sc300081q
   Zhang QF, 2016, ACS CATAL, V6, P6236, DOI 10.1021/acscatal.6b01226
   Zhen WL, 2015, CHEM COMMUN, V51, P1728, DOI 10.1039/c4cc08733j
   Zhu HW, 2013, AICHE J, V59, P2567, DOI 10.1002/aic.14026
NR 49
TC 8
Z9 8
U1 14
U2 111
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 2
PY 2019
VL 194
SI SI
BP 10
EP 21
DI 10.1016/j.ces.2018.05.019
PG 12
WC Engineering, Chemical
SC Engineering
GA HC6NG
UT WOS:000451917900003
DA 2020-05-12
ER

PT J
AU Zhou, R
   Cao, XX
   Jia, XY
   Wang, JJ
   Liu, CJ
AF Zhou, Rui
   Cao, Xinxiang
   Jia, Xinyu
   Wang, Jiajun
   Liu, Chang-jun
TI On the reactivity of carbon formed from CO CVD over Ni(111)/TiO2
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Carbon; Ni(111); Graphene; TiO2; Methanation
ID REDUCED GRAPHENE OXIDE; CATALYST PREPARATION; NI CATALYST; METHANATION;
   HYDROGEN; DIOXIDE; NI/SIO2; NI/TIO2; SURFACE; PLASMA
AB The formation and reactivity of carbon on the supported nickel catalyst is a key issue for the low temperature activity and stability with methanation, reforming and other reactions. In this work, Ni(1 1 1)/TiO2 was prepared and applied as the catalyst to deposit carbon using low temperature chemical vapor deposition (CVD) of carbon monoxide. It was found that the CVD temperature could significantly affect the formation of carbon. With the CVD temperature decreasing, the disorder of the carbon increased, while the degree of graphitization was reduced. As a result, graphene-like films can be obtained at low CVD temperatures (from 300 to 350 degrees C). Such carbon films show a significantly improved reactivity with hydrogen and carbon dioxide. This explains the excellent low temperature activity and stability for CO2 or CO methanation over Ni catalysts with Ni(1 1 1). (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Zhou, Rui; Cao, Xinxiang; Jia, Xinyu; Wang, Jiajun; Liu, Chang-jun] Tianjin Univ, Sch Chem Engn & Technol, Tianjin Coinnovat Ctr Chem Sci & Engn, Tianjin 300072, Peoples R China.
RP Liu, CJ (reprint author), Tianjin Univ, Sch Chem Engn & Technol, Tianjin Coinnovat Ctr Chem Sci & Engn, Tianjin 300072, Peoples R China.
EM coronacj@tju.edu.cn
OI Liu, Chang-jun/0000-0001-9918-1638
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21536008, 21476157]
FX The support from the National Natural Science Foundation of China (under
   contracts #21536008 and # 21476157) is appreciated. The authors thank
   Dr. Brian M. Tackett and Dr. Zhenhua Xie from Columbia University for
   their help in the correction of the use of English.
CR Belkhalfa H, 2016, SENSOR ACTUAT B-CHEM, V237, P693, DOI 10.1016/j.snb.2016.06.132
   Bian ZF, 2017, J CO2 UTIL, V18, P345, DOI 10.1016/j.jcou.2016.12.014
   BIBBY DM, 1986, J CATAL, V97, P493, DOI 10.1016/0021-9517(86)90020-5
   Chen C, 2017, DIAM RELAT MATER, V72, P7, DOI 10.1016/j.diamond.2016.12.013
   Chen YG, 1997, APPL CATAL A-GEN, V161, pL11, DOI 10.1016/S0926-860X(97)00106-3
   Chou CC, 2015, ENERGY, V90, P1973, DOI 10.1016/j.energy.2015.07.023
   Choudhary TV, 2000, J CATAL, V192, P316, DOI 10.1006/jcat.2000.2853
   Fan ZG, 2015, J ENERGY CHEM, V24, P655, DOI 10.1016/j.jechem.2015.09.004
   Ferrari AC, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.187401
   Jin Y. L., 2016, CHEM ENG SCI, V152, P754
   Kho ET, 2016, CHEM ENG SCI, V140, P161, DOI 10.1016/j.ces.2015.10.021
   Kim S, 2015, APPL CATAL B-ENVIRON, V168, P212, DOI 10.1016/j.apcatb.2014.12.027
   Le TA, 2017, CATAL TODAY, V293, P89, DOI 10.1016/j.cattod.2016.12.036
   Li WH, 2018, RSC ADV, V8, P7651, DOI 10.1039/c7ra13546g
   Li Y, 2017, FUEL, V189, P23, DOI 10.1016/j.fuel.2016.10.047
   Li ZJ, 2016, ELECTROCHIM ACTA, V212, P390, DOI 10.1016/j.electacta.2016.07.020
   Liu CJ, 2011, CHEMCATCHEM, V3, P529, DOI 10.1002/cctc.201000358
   MCCARTY JG, 1979, J CATAL, V57, P406, DOI 10.1016/0021-9517(79)90007-1
   NIELSEN JR, 1977, J CATAL, V48, P155
   Pan YX, 2008, CATAL LETT, V123, P96, DOI 10.1007/s10562-008-9400-1
   Ping D, 2017, INT J HYDROGEN ENERG, V42, P15551, DOI 10.1016/j.ijhydene.2017.04.285
   Rai AK, 2013, ELECTROCHIM ACTA, V100, P63, DOI 10.1016/j.electacta.2013.03.140
   Tada S, 2014, J POWER SOURCES, V264, P59, DOI 10.1016/j.jpowsour.2014.04.075
   Tao L, 2013, J PHYS CHEM C, V117, P10079, DOI 10.1021/jp312075v
   TSIPOURIARI VA, 1994, CATAL TODAY, V21, P579, DOI 10.1016/0920-5861(94)80182-7
   Wang CZ, 2016, INT J HYDROGEN ENERG, V41, P19014, DOI 10.1016/j.ijhydene.2016.08.128
   Wang D, 2016, APPL CATAL A-GEN, V527, P60, DOI 10.1016/j.apcata.2016.08.027
   Wang Z, 2018, ACS CATAL, V8, P2093, DOI 10.1021/acscatal.7b03723
   Yan XL, 2017, TOP CATAL, V60, P890, DOI 10.1007/s11244-017-0754-8
   Yan XL, 2015, CATAL TODAY, V256, P29, DOI 10.1016/j.cattod.2015.04.045
   Yan XL, 2013, INT J HYDROGEN ENERG, V38, P2283, DOI 10.1016/j.ijhydene.2012.12.024
   Yan XL, 2013, DIAM RELAT MATER, V31, P50, DOI 10.1016/j.diamond.2012.11.001
   Zeller P, 2016, SURF SCI, V653, P143, DOI 10.1016/j.susc.2016.06.014
   Zhang Y, 2015, CATAL TODAY, V256, P130, DOI 10.1016/j.cattod.2015.01.016
   Zhao BR, 2013, IND ENG CHEM RES, V52, P8182, DOI 10.1021/ie400688y
   Zhen WL, 2017, J CATAL, V348, P200, DOI 10.1016/j.jcat.2017.02.031
   Zhou R, 2016, INT J HYDROGEN ENERG, V41, P22017, DOI 10.1016/j.ijhydene.2016.08.093
   Zhu DT, 2017, CARBON, V120, P274, DOI 10.1016/j.carbon.2017.05.032
   Zhu XL, 2008, APPL CATAL B-ENVIRON, V81, P132, DOI 10.1016/j.apcatb.2007.11.042
NR 39
TC 1
Z9 1
U1 4
U2 32
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 2
PY 2019
VL 194
SI SI
BP 22
EP 28
DI 10.1016/j.ces.2018.08.040
PG 7
WC Engineering, Chemical
SC Engineering
GA HC6NG
UT WOS:000451917900004
DA 2020-05-12
ER

PT J
AU Dong, H
   Zhang, L
   Yang, PP
   Chang, XX
   Zhu, WJ
   Ren, XH
   Zhao, ZJ
   Gong, JL
AF Dong, Hao
   Zhang, Lei
   Yang, Piaoping
   Chang, Xiaoxia
   Zhu, Wenjin
   Ren, Xiaohong
   Zhao, Zhi-Jian
   Gong, Jinlong
TI Facet design promotes electroreduction of carbon dioxide to carbon
   monoxide on palladium nanocrystals
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Pd nanocrystal; Concave structure; Electrochemical carbon dioxide
   reduction; Facet effect
ID CO2 REDUCTION; FORMIC-ACID; ELECTROCATALYTIC REDUCTION; PD;
   NANOPARTICLES; NANOWIRES; EFFICIENCY; CATALYST
AB Highly selective electrochemical carbon dioxide reduction to valuable chemical products is a crucial approach to alleviate the energy crisis. To date, some noble metal based heterogeneous catalysts such as Pd exhibit high activity for electrochemical carbon dioxide reduction. However, few systematic studies of the active reaction site of these catalysts have been reported. This paper describes the facet effect on Pd nanocrystals with the same size for CO2 electroreduction. The surface structure of Pd catalysts enclosed with {3 1 0}, {1 0 0} and {1 1 1} facets can be precisely controlled. The Pd concave cubes enclosed with high-index {3 1 0} facets show the highest CO Faradaic efficiency (FE) of 90.6%, compared with Pd cubes enclosed with {1 0 0} facets and Pd octahedrons enclosed with {1 1 1} facets. Density functional theory calculations reveal that the {3 1 0} facets of concave cubes boost the catalytic activity by facilitating the COOH* formation and the desorption of CO*. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Dong, Hao; Zhang, Lei; Yang, Piaoping; Chang, Xiaoxia; Zhu, Wenjin; Zhao, Zhi-Jian; Gong, Jinlong] Tianjin Univ, Collaborat Innovat Ctr Chem Sci & Engn, Sch Chem Engn & Technol, Key Lab Green Chem Technol,Minist Educ, Tianjin 300072, Peoples R China.
   [Ren, Xiaohong] Tianjin Univ Technol, Sch Chem & Chem Engn, Tianjin 300384, Peoples R China.
RP Zhao, ZJ; Gong, JL (reprint author), Tianjin Univ, Collaborat Innovat Ctr Chem Sci & Engn, Sch Chem Engn & Technol, Key Lab Green Chem Technol,Minist Educ, Tianjin 300072, Peoples R China.
EM zjzhao@tju.edu.cn; jlgong@tju.edu.cn
RI Zhao, Zhi-Jian/C-8965-2009; Gong, Jinlong/B-6783-2009
OI Zhao, Zhi-Jian/0000-0002-8856-5078; Gong, Jinlong/0000-0001-7263-318X
FU National Key R&D Program of China [2016YFB0600901]; National Natural
   Science Foundation of ChinaNational Natural Science Foundation of China
   [U1463205, U1662111, 21525626, 21606169, 21761132023]; Program of
   Introducing Talents of Discipline to Universities [B06006]; State Key
   Laboratory of Fine Chemicals of Dalian University of Technology [KF1516]
FX We acknowledge the National Key R&D Program of China (2016YFB0600901),
   the National Natural Science Foundation of China (U1463205, U1662111,
   21525626, 21606169, and 21761132023) for financial support, and the
   Program of Introducing Talents of Discipline to Universities (B06006)
   for financial support. X.R. thanks the support by the State Key
   Laboratory of Fine Chemicals of Dalian University of Technology
   (KF1516).
CR BLOCHL PE, 1994, PHYS REV B, V50, P17953, DOI 10.1103/PhysRevB.50.17953
   Cao SW, 2017, J CATAL, V349, P208, DOI 10.1016/j.jcat.2017.02.005
   Chen YH, 2012, J AM CHEM SOC, V134, P19969, DOI 10.1021/ja309317u
   Fu QQ, 2016, SCI CHINA MATER, V59, P112, DOI 10.1007/s40843-016-0123-0
   Gao DF, 2015, J AM CHEM SOC, V137, P4288, DOI 10.1021/jacs.5b00046
   Gao S, 2016, NATURE, V529, P68, DOI 10.1038/nature16455
   HICKS RF, 1984, J CATAL, V89, P498, DOI 10.1016/0021-9517(84)90326-9
   Huang HW, 2017, ANGEW CHEM INT EDIT, V56, P3594, DOI 10.1002/anie.201612617
   Huang XQ, 2009, J AM CHEM SOC, V131, P4602, DOI 10.1021/ja9009343
   Jin MS, 2012, ENERG ENVIRON SCI, V5, P6352, DOI 10.1039/c2ee02866b
   Jin MS, 2011, ANGEW CHEM INT EDIT, V50, P7850, DOI 10.1002/anie.201103002
   Jin MS, 2011, NANO RES, V4, P83, DOI 10.1007/s12274-010-0051-3
   Kim C, 2015, J AM CHEM SOC, V137, P13844, DOI 10.1021/jacs.5b06568
   Klinkova A, 2016, ACS CATAL, V6, P8115, DOI 10.1021/acscatal.6b01719
   Kortlever R, 2015, ACS CATAL, V5, P3916, DOI 10.1021/acscatal.5b00602
   Kresse G, 1996, COMP MATER SCI, V6, P15, DOI 10.1016/0927-0256(96)00008-0
   Liu HZ, 2017, SCI CHINA MATER, V60, P1215, DOI 10.1007/s40843-017-9128-4
   Lu Q, 2016, NANO ENERGY, V29, P439, DOI 10.1016/j.nanoen.2016.04.009
   Lu WL, 2017, SCI CHINA MATER, V60, P929, DOI 10.1007/s40843-017-9112-4
   Lu YZ, 2017, SCI CHINA MATER, V60, P1109, DOI 10.1007/s40843-017-9029-5
   Luc W, 2017, J AM CHEM SOC, V139, P1885, DOI 10.1021/jacs.6b10435
   Mazumder V, 2009, J AM CHEM SOC, V131, P4588, DOI 10.1021/ja9004915
   Mistry H, 2014, J AM CHEM SOC, V136, P16473, DOI 10.1021/ja508879j
   MONKHORST HJ, 1976, PHYS REV B, V13, P5188, DOI 10.1103/PhysRevB.13.5188
   Niu WX, 2015, ANGEW CHEM INT EDIT, V54, P8271, DOI 10.1002/anie.201503148
   Reske R, 2014, J AM CHEM SOC, V136, P6978, DOI 10.1021/ja500328k
   Shao MH, 2011, CHEM COMMUN, V47, P6566, DOI 10.1039/c1cc11004g
   Song JF, 2017, SCI CHINA MATER, V60, P1179, DOI 10.1007/s40843-017-9120-6
   Sun ZQ, 2017, SCI CHINA MATER, V60, P1, DOI 10.1007/s40843-016-5117-0
   Wellendorff J, 2012, PHYS REV B, V85, DOI 10.1103/PhysRevB.85.235149
   Wu Y, 2016, SCI CHINA MATER, V59, P938, DOI 10.1007/s40843-016-5112-0
   Xia TY, 2017, SCI CHINA MATER, V60, P57, DOI 10.1007/s40843-016-5139-y
   Xiao L, 2009, J AM CHEM SOC, V131, P602, DOI 10.1021/ja8063765
   Xu JQ, 2017, ANGEW CHEM INT EDIT, V56, P9121, DOI 10.1002/anie.201704928
   Yang HC, 2017, SCI CHINA MATER, V60, P1121, DOI 10.1007/s40843-017-9035-8
   Zhang H, 2013, ACCOUNTS CHEM RES, V46, P1783, DOI 10.1021/ar300209w
   Zhang L, 2017, ANGEW CHEM INT EDIT, V56, P11326, DOI 10.1002/anie.201612214
   Zhang L, 2016, CHEM SOC REV, V45, P3916, DOI 10.1039/c5cs00958h
   Zheng Z, 2016, SCI CHINA MATER, V59, P200, DOI 10.1007/s40843-016-5026-4
   Zhu WL, 2014, J AM CHEM SOC, V136, P16132, DOI 10.1021/ja5095099
   Zhu WL, 2013, J AM CHEM SOC, V135, P16833, DOI 10.1021/ja409445p
NR 41
TC 7
Z9 7
U1 21
U2 126
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 2
PY 2019
VL 194
SI SI
BP 29
EP 35
DI 10.1016/j.ces.2018.03.029
PG 7
WC Engineering, Chemical
SC Engineering
GA HC6NG
UT WOS:000451917900005
DA 2020-05-12
ER

PT J
AU Chen, XF
   Liang, Y
   Wan, L
   Xie, ZL
   Easton, CD
   Bourgeois, L
   Wang, ZY
   Bao, QL
   Zhu, YG
   Tao, SW
   Wang, HT
AF Chen, Xiaofang
   Liang, Yan
   Wan, Li
   Xie, Zongli
   Easton, Christopher D.
   Bourgeois, Laure
   Wang, Ziyu
   Bao, Qiaoliang
   Zhu, Yonggang
   Tao, Shanwen
   Wang, Huanting
TI Construction of porous N-doped graphene layer for efficient oxygen
   reduction reaction
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Microporous N-doped graphene; Oxygen reduction reaction; Nitrogen
   doping; Electrocatalytic activity; g-C3N4
ID RAMAN-SPECTROSCOPY; GRAPHITE
AB Graphitic carbon materials have shown great potential for use as high-performance catalysts for electrochemical reactions and devices. In this work, we developed a simple and versatile method for synthesis of porous N-doped graphene layers (NGS) by high-temperature treatment of chitosan film deposited on the graphitic carbon nitride (g-C3N4) nanosheets. In the sandwiched chitosan/g-C3N4/chitosan structure, the g-C3N4 nanosheet served as a substrate for chitosan film. The pyrolysis of this substrate, g-C3N4 nanosheet, prevented the severe agglomeration of as-carbonized chitosan sheets and resulted the porous structure. The BET surface area, micropore volume, nitrogen content and graphitic level of result sample highly depended on the heat-treatment temperature. The NGS synthesized at 1000 degrees C (NGS-1000) exhibited an ultrahigh specific surface area (1183 m(2) g( 1)) and high nitrogen content (4.12%). Importantly, NGS-1000 exhibited a higher limiting current density (5.8 mA cm( 2)) and a greater stability than the commercial Pt/C electrocatalyst in alkaline media for oxygen reduction reaction (ORR). Such excellent electrocatalytic performance can be explained by a balanced combination of appropriate nitrogen doping level, the degree of graphitization, porous structure, and high specific surface area. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Chen, Xiaofang; Liang, Yan; Wan, Li; Tao, Shanwen; Wang, Huanting] Monash Univ, Dept Chem Engn, Clayton, Vic 3800, Australia.
   [Chen, Xiaofang; Xie, Zongli; Easton, Christopher D.] CSIRO Mfg, Private Bag 10, Clayton, Vic 3169, Australia.
   [Bourgeois, Laure] Monash Univ, Dept Mat Sci & Engn, Monash Ctr Electron Microscopy, Clayton, Vic 3800, Australia.
   [Wang, Ziyu; Bao, Qiaoliang] Monash Univ, Dept Mat Sci & Engn, Clayton, Vic 3800, Australia.
   [Zhu, Yonggang] RMIT Univ Melbourne, Sch Sci, Melbourne, Vic 3001, Australia.
RP Wang, HT (reprint author), Monash Univ, Dept Chem Engn, Clayton, Vic 3800, Australia.
EM huanting.wang@monash.edu
RI Bao, Qiaoliang/A-6383-2009; Zhu, Yonggang/B-3362-2012; Xie,
   Zongli/G-9393-2013; Wang, Huanting/G-8399-2011
OI Bao, Qiaoliang/0000-0002-6971-789X; Zhu, Yonggang/0000-0002-5419-9508;
   Xie, Zongli/0000-0002-4610-0758; Wang, Huanting/0000-0002-9887-5555;
   Easton, Christopher/0000-0002-1981-3779; Bourgeois,
   Laure/0000-0003-3961-5099; Chen, Xiaofang/0000-0001-5848-4413
FU Australian Research CouncilAustralian Research Council [LE110100223]
FX This work was in part supported by the Australian Research Council
   (project no. DP150100765). The authors acknowledge use of facilities
   within the Monash Centre for Electron Microscopy and in particular
   equipment funded by the Australian Research Council grant LE110100223.
CR Ajlani H, 2016, SUPERLATTICE MICROST, V90, P96, DOI 10.1016/j.spmi.2015.12.009
   Avouris P, 2007, NAT NANOTECHNOL, V2, P605, DOI 10.1038/nnano.2007.300
   Balandin AA, 2008, NANO LETT, V8, P902, DOI 10.1021/nl0731872
   Chen XF, 2016, APPL CATAL B-ENVIRON, V188, P342, DOI 10.1016/j.apcatb.2016.02.012
   Chen ZP, 2011, NAT MATER, V10, P424, DOI [10.1038/NMAT3001, 10.1038/nmat3001]
   Choi IA, 2017, APPL CATAL B-ENVIRON, V211, P235, DOI 10.1016/j.apcatb.2017.04.039
   Cong HP, 2014, NANO ENERGY, V3, P55, DOI 10.1016/j.nanoen.2013.10.010
   Cooper AI, 2003, ADV MATER, V15, P1049, DOI 10.1002/adma.200300380
   Davis ME, 2002, NATURE, V417, P813, DOI 10.1038/nature00785
   Ferrari AC, 2007, SOLID STATE COMMUN, V143, P47, DOI 10.1016/j.ssc.2007.03.052
   Ferrero GA, 2016, J MATER CHEM A, V4, P2581, DOI 10.1039/c5ta10063a
   Gammon WJ, 2003, CARBON, V41, P1917, DOI 10.1016/S0008-6223(03)00170-2
   Geng DS, 2011, ENERG ENVIRON SCI, V4, P760, DOI 10.1039/c0ee00326c
   Guo BD, 2010, NANO LETT, V10, P4975, DOI 10.1021/nl103079j
   Guo DH, 2016, SCIENCE, V351, P361, DOI 10.1126/science.aad0832
   Han S, 2014, ADV MATER, V26, P849, DOI 10.1002/adma.201303115
   Hao GP, 2013, ADV ENERGY MATER, V3, P1421, DOI 10.1002/aenm.201300383
   Hao P, 2015, NANO ENERGY, V15, P9, DOI 10.1016/j.nanoen.2015.02.035
   He WH, 2014, ANGEW CHEM INT EDIT, V53, P9503, DOI 10.1002/anie.201404333
   Hellgren N, 2016, CARBON, V108, P242, DOI 10.1016/j.carbon.2016.07.017
   JANSEN RJJ, 1995, CARBON, V33, P1021, DOI 10.1016/0008-6223(95)00030-H
   Jeon IY, 2011, CHEM MATER, V23, P3987, DOI 10.1021/cm201542m
   Jin ZY, 2014, ADV MATER, V26, P3700, DOI 10.1002/adma.201306273
   Jorio A, 2013, SOLID STATE COMMUN, V175, P3, DOI 10.1016/j.ssc.2013.08.008
   Klingele M, 2016, FUEL CELLS, V16, P522, DOI 10.1002/fuce.201600113
   Kurak KA, 2009, J PHYS CHEM C, V113, P6730, DOI 10.1021/jp811518e
   Lai LF, 2012, ENERG ENVIRON SCI, V5, P7936, DOI 10.1039/c2ee21802j
   Lee KR, 2010, ELECTROCHEM COMMUN, V12, P1052, DOI 10.1016/j.elecom.2010.05.023
   Li XH, 2012, ANGEW CHEM INT EDIT, V51, P9689, DOI 10.1002/anie.201203207
   Liu MK, 2014, ACS APPL MATER INTER, V6, P4214, DOI 10.1021/am405900r
   Mateo D, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11819
   Matter PH, 2006, J CATAL, V239, P83, DOI 10.1016/j.jcat.2006.01.022
   Nicholls RJ, 2013, ACS NANO, V7, P7145, DOI 10.1021/nn402489v
   Niu WH, 2016, SMALL, V12, P1900, DOI 10.1002/smll.201503542
   Pandiselvi K, 2014, IONICS, V20, P551, DOI 10.1007/s11581-013-1020-0
   Parvez K, 2012, ACS NANO, V6, P9541, DOI 10.1021/nn302674k
   Peng HJ, 2014, ADV FUNCT MATER, V24, P2772, DOI 10.1002/adfm.201303296
   Presser V, 2011, ADV FUNCT MATER, V21, P810, DOI 10.1002/adfm.201002094
   Primo A, 2012, CHEM COMMUN, V48, P9254, DOI 10.1039/c2cc34978g
   Qie L, 2013, ENERG ENVIRON SCI, V6, P2497, DOI 10.1039/c3ee41638k
   Scardamaglia M, 2014, CARBON, V73, P371, DOI 10.1016/j.carbon.2014.02.078
   Sheng ZH, 2011, ACS NANO, V5, P4350, DOI 10.1021/nn103584t
   Suenaga K, 2010, NATURE, V468, P1088, DOI 10.1038/nature09664
   Tang YF, 2009, J AM CHEM SOC, V131, P13200, DOI 10.1021/ja904595t
   Terrones M, 2010, NANO TODAY, V5, P351, DOI 10.1016/j.nantod.2010.06.010
   Wang HB, 2012, ACS CATAL, V2, P781, DOI 10.1021/cs200652y
   Wang MM, 2017, CHEM COMMUN, V53, P8372, DOI 10.1039/c7cc03558f
   Wei J, 2015, ADV FUNCT MATER, V25, P5768, DOI 10.1002/adfm.201502311
   Wen ZH, 2012, ADV MATER, V24, P5610, DOI 10.1002/adma.201201920
   Wu G, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8258
   Wu JX, 2014, ACTA CHIM SINICA, V72, P301, DOI 10.6023/A13090936
   Xiao J, 2011, NANO LETT, V11, P5071, DOI 10.1021/nl203332e
   Xu ZX, 2016, ADV MATER, V28, P1981, DOI 10.1002/adma.201505131
   Zhang LL, 2012, NANO LETT, V12, P1806, DOI 10.1021/nl203903z
   Zhang LP, 2011, J PHYS CHEM C, V115, P11170, DOI 10.1021/jp201991j
   Zhang YJ, 2011, ENERG ENVIRON SCI, V4, P4517, DOI 10.1039/c1ee01400e
   Zheng, 2005, ADV MATER, V27, P5388
   Zheng Y, 2011, J AM CHEM SOC, V133, P20116, DOI 10.1021/ja209206c
   Zhu YW, 2011, SCIENCE, V332, P1537, DOI 10.1126/science.1200770
   Zhuang, 2017, ANGEW CHEM INT EDIT, V2018, P496
NR 60
TC 10
Z9 10
U1 15
U2 154
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 2
PY 2019
VL 194
SI SI
BP 36
EP 44
DI 10.1016/j.ces.2018.04.004
PG 9
WC Engineering, Chemical
SC Engineering
GA HC6NG
UT WOS:000451917900006
DA 2020-05-12
ER

PT J
AU Zhai, LF
   Kong, SY
   Zhang, HY
   Tian, WJ
   Sun, M
   Sun, HQ
   Wang, SB
AF Zhai, Lin-Feng
   Kong, Shi-Yu
   Zhang, Huayang
   Tian, Wenjie
   Sun, Min
   Sun, Hongqi
   Wang, Shaobin
TI Facile synthesis of Co-N-rGO composites as an excellent electrocatalyst
   for oxygen reduction reaction
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Oxygen reduction reaction; Co-N codoping; Electrocatalyst;
   Low-temperature hydrothermal; Graphene
ID NITROGEN-DOPED GRAPHENE; METAL-FREE ELECTROCATALYSTS; FUEL-CELL
   CONDITIONS; COBALT PHTHALOCYANINE; CATALYTIC-ACTIVITY; CATHODE
   CATALYSTS; RECENT PROGRESS; CARBON; OXIDE; FE
AB Cobalt and nitrogen co-doped reduced graphene oxide (Co-N-rGO) composites are prepared by a facile low-temperature hydrothermal method. Structure characterization reveals that cobalt and nitrogen are co-ordinately attached to the rGO sheets with the formation of covalent C-N and Co-O-C linkages. Cyclic voltammetry and linear sweep voltammetry show that the Co-N-rGO composite possesses higher electrocatalytic activity and four-electron selectivity for oxygen reduction reaction (ORR) as compared to the rGO, Co-rGO and N-rGO. In addition, the Co-N-rGO composite presents excellent stability and durability in alkaline medium comparable to commercial Pt/C. The edge plane CoN2/C, CoN4/C, and basal plane macrocyclic CoN4/C species within the Co-N-rGO structure are proposed to be the active sites performing catalysis in the ORR. The strong covalent linkages between the cobalt/nitrogen and rGO not only enable potent synergy of cobalt, nitrogen and rGO in catalysis, but also ensure structure stability of the composite. Due to the superior ORR activity of Co-N-rGO, high-temperature heat treatment is not able to improve its activity any more. The low-temperature hydrothermal method is anticipated to be used as a low-cost and facile preparation approach for ORR catalysts, and the superb ORR performance of Co-N-rGO endow it with great application potential in fuel cells, metal-air batteries and other ORR-related electrochemical industries. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Zhai, Lin-Feng; Kong, Shi-Yu; Sun, Min] Hefei Univ Technol, Sch Chem & Chem Engn, Hefei 230009, Anhui, Peoples R China.
   [Zhai, Lin-Feng; Zhang, Huayang; Tian, Wenjie; Wang, Shaobin] Curtin Univ, Dept Chem Engn, GPO Box U1987, Perth, WA 6845, Australia.
   [Sun, Hongqi] Edith Cowan Univ, Sch Engn, Joondalup, WA 6027, Australia.
RP Zhai, LF; Wang, SB (reprint author), Hefei Univ Technol, Sch Chem & Chem Engn, Hefei 230009, Anhui, Peoples R China.
EM linfengzhai@hfut.edu.cn; shaobin.wang@curtin.edu.au
RI Wang, Shaobin/AAL-9581-2020; Wang, Shaobin/C-5507-2008; Zhang,
   Huayang/AAF-3983-2020; Sun, Hongqi/B-3128-2014
OI Wang, Shaobin/0000-0002-1751-9162; Wang, Shaobin/0000-0002-1751-9162;
   Sun, Hongqi/0000-0003-0907-5626
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51378166, 51478157]; Program for New Century
   Excellent Talents in UniversityProgram for New Century Excellent Talents
   in University (NCET) [NCET-13-0767]; Australian Research
   CouncilAustralian Research Council [DP150103026]
FX This work was supported by the National Natural Science Foundation of
   China [No. 51378166, 51478157]; the Program for New Century Excellent
   Talents in University [No. NCET-13-0767]. We also acknowledge the
   support from the Australian Research Council (DP150103026).
CR Aravinda LS, 2013, ELECTROCHIM ACTA, V95, P119, DOI 10.1016/j.electacta.2013.02.027
   Arechederra RL, 2010, ACS APPL MATER INTER, V2, P3295, DOI 10.1021/am100724v
   BECK F, 1977, J APPL ELECTROCHEM, V7, P239, DOI 10.1007/BF00618991
   Bezerra CWB, 2008, ELECTROCHIM ACTA, V53, P4937, DOI 10.1016/j.electacta.2008.02.012
   Chao SJ, 2015, CARBON, V82, P77, DOI 10.1016/j.carbon.2014.10.034
   Chen RR, 2009, J PHYS CHEM C, V113, P20689, DOI 10.1021/jp906408y
   Chen S, 2013, ANGEW CHEM INT EDIT, V52, P13567, DOI 10.1002/anie.201306166
   Cheng S, 2006, ENVIRON SCI TECHNOL, V40, P364, DOI 10.1021/es0512071
   Ferrari AC, 2000, PHYS REV B, V61, P14095, DOI 10.1103/PhysRevB.61.14095
   Fuge GM, 2003, DIAM RELAT MATER, V12, P1049, DOI 10.1016/S0925-9635(02)00357-6
   Gao W, 2009, NAT CHEM, V1, P403, DOI [10.1038/NCHEM.281, 10.1038/nchem.281]
   Gasteiger HA, 2005, APPL CATAL B-ENVIRON, V56, P9, DOI 10.1016/j.apcatb.2004.06.021
   Geng DS, 2011, ENERG ENVIRON SCI, V4, P760, DOI 10.1039/c0ee00326c
   Gojkovic SL, 1998, J ELECTROCHEM SOC, V145, P3493, DOI 10.1149/1.1838833
   Gomez-Navarro C, 2007, NANO LETT, V7, P3499, DOI 10.1021/nl072090c
   HUMMERS WS, 1958, J AM CHEM SOC, V80, P1339, DOI 10.1021/ja01539a017
   Jang JW, 2004, APPL PHYS LETT, V84, P2877, DOI 10.1063/1.1697624
   JASINSKI R, 1965, J ELECTROCHEM SOC, V112, P526, DOI 10.1149/1.2423590
   Jiang S, 2013, J MATER CHEM A, V1, P3593, DOI 10.1039/c3ta01682j
   Kattel S, 2013, J MATER CHEM A, V1, P10790, DOI 10.1039/c3ta12142a
   Kim H, 2011, PHYS CHEM CHEM PHYS, V13, P17505, DOI 10.1039/c1cp21665a
   Kim KS, 2009, NATURE, V457, P706, DOI 10.1038/nature07719
   Kim SK, 2012, ELECTROCHEM COMMUN, V22, P141, DOI 10.1016/j.elecom.2012.06.018
   Kong XK, 2014, CHEM SOC REV, V43, P2841, DOI 10.1039/c3cs60401b
   Kramm UI, 2011, J ELECTROCHEM SOC, V158, pB69, DOI 10.1149/1.3499621
   Kumar NA, 2012, ACS NANO, V6, P1715, DOI 10.1021/nn204688c
   Lai LF, 2012, ENERG ENVIRON SCI, V5, P7936, DOI 10.1039/c2ee21802j
   Lee JS, 2013, J MATER CHEM A, V1, P9603, DOI 10.1039/c3ta12520c
   Lee SU, 2009, SMALL, V5, P1769, DOI 10.1002/smll.200801938
   Lefevre M, 2005, J PHYS CHEM B, V109, P16718, DOI 10.1021/jp0529265
   Lefevre M, 2002, J PHYS CHEM B, V106, P8705, DOI 10.1021/jp020267f
   Medard C, 2006, ELECTROCHIM ACTA, V51, P3202, DOI 10.1016/j.electacta.2005.09.012
   Qiao XC, 2015, CATALYSTS, V5, P981, DOI 10.3390/catal5020981
   Qu LT, 2010, ACS NANO, V4, P1321, DOI 10.1021/nn901850u
   Schulenburg H, 2003, J PHYS CHEM B, V107, P9034, DOI 10.1021/jp030349j
   Sheng ZH, 2011, ACS NANO, V5, P4350, DOI 10.1021/nn103584t
   Shinozaki K, 2015, J ELECTROCHEM SOC, V162, pF1384, DOI 10.1149/2.0551512jes
   Sidik RA, 2006, J PHYS CHEM B, V110, P1787, DOI 10.1021/jp055150g
   Wang HB, 2012, ACS CATAL, V2, P781, DOI 10.1021/cs200652y
   Wang SY, 2011, ANGEW CHEM INT EDIT, V50, P11756, DOI 10.1002/anie.201105204
   Wang YY, 2011, J MATER CHEM, V21, P3779, DOI 10.1039/c0jm03567j
   Wei J, 2015, ADV FUNCT MATER, V25, P5768, DOI 10.1002/adfm.201502311
   Wu G, 2013, ACCOUNTS CHEM RES, V46, P1878, DOI 10.1021/ar400011z
   Wu G, 2011, J MATER CHEM, V21, P11392, DOI 10.1039/c0jm03613g
   Wu JJ, 2012, J POWER SOURCES, V198, P122, DOI 10.1016/j.jpowsour.2011.10.007
   Xu JX, 2013, CHEMSUSCHEM, V6, P493, DOI 10.1002/cssc.201200564
   Xu ZW, 2011, J MOL CATAL A-CHEM, V335, P89, DOI 10.1016/j.molcata.2010.11.018
   Xue YH, 2012, ANGEW CHEM INT EDIT, V51, P12124, DOI 10.1002/anie.201207277
   Yang JH, 2013, J PHYS CHEM C, V117, P3785, DOI 10.1021/jp311051g
   Yang LJ, 2011, ANGEW CHEM INT EDIT, V50, P7132, DOI 10.1002/anie.201101287
   Zhang LP, 2011, J PHYS CHEM C, V115, P11170, DOI 10.1021/jp201991j
   Zheng Y., 2013, ANGEW CHEM, V125, P3192, DOI DOI 10.1002/ANGE.201209548
   Zhu CZ, 2013, NANOSCALE, V5, P1753, DOI 10.1039/c2nr33839d
   Zhu YW, 2010, ADV MATER, V22, P3906, DOI 10.1002/adma.201001068
NR 54
TC 8
Z9 8
U1 20
U2 149
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 2
PY 2019
VL 194
SI SI
BP 45
EP 53
DI 10.1016/j.ces.2018.05.020
PG 9
WC Engineering, Chemical
SC Engineering
GA HC6NG
UT WOS:000451917900007
DA 2020-05-12
ER

PT J
AU Guo, XM
   Zhu, YZ
   Han, WW
   Fan, XB
   Li, Y
   Zhang, FB
   Zhang, GL
   Peng, WC
   Wang, SB
AF Guo, Xiaomeng
   Zhu, Yuanzhi
   Han, Weiwei
   Fan, Xiaobin
   Li, Yang
   Zhang, Fengbao
   Zhang, Guoliang
   Peng, Wenchao
   Wang, Shaobin
TI Nitrogen-doped graphene quantum dots decorated graphite foam as
   ultra-high active free-standing electrode for electrochemical hydrogen
   evolution and phenol degradation
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Graphene quantum dots; N-doping; Graphite foam; Electrochemical hydrogen
   evolution; Peroxymonosulfate activation; Degradation
ID WALLED CARBON NANOTUBES; METHYLENE-BLUE; CATALYST; REMOVAL;
   NANOCOMPOSITE; ACTIVATION; OXIDE; DYES
AB In this study, nitrogen-doped graphene quantum dots (N-GQDs, similar to 5 nm) were synthesized and supported on graphite foam (GF) by a facile hydrothermal route. The obtained N-GQDs/GF composite demonstrates as an ultra-active free-standing electrode for electrochemical hydrogen evolution and activation of peroxymonosulfate to degrade phenol pollutant. An overpotential in the electrochemical hydrogen evolution is only -72 mV vs. RHE at 10 mA/cm(2) with a Tafel slope of 84 mV/Dec. The N-GQDs/GF electrode can also achieve 100% phenol removal in short time in electrochemical degradation. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Guo, Xiaomeng; Zhu, Yuanzhi; Han, Weiwei; Fan, Xiaobin; Li, Yang; Zhang, Fengbao; Zhang, Guoliang; Peng, Wenchao] Tianjin Univ, Sch Chem Engn & Technol, Tianjin 300350, Peoples R China.
   [Wang, Shaobin] Curtin Univ, Dept Chem Engn, GPO Box U1987, Perth, WA 6845, Australia.
RP Peng, WC (reprint author), Tianjin Univ, Sch Chem Engn & Technol, Tianjin 300350, Peoples R China.; Wang, SB (reprint author), Curtin Univ, Dept Chem Engn, GPO Box U1987, Perth, WA 6845, Australia.
EM wenchao.peng@tju.edu.cn; shaobin.wang@curtin.edu.au
RI Wang, Shaobin/C-5507-2008; Peng, Wenchao/O-2264-2015; Wang,
   Shaobin/AAL-9581-2020
OI Wang, Shaobin/0000-0002-1751-9162; Peng, Wenchao/0000-0002-1515-8287;
   Wang, Shaobin/0000-0002-1751-9162
FU National Natural Science Foundation of China (NSFC)National Natural
   Science Foundation of China [21506158]; Australian Research
   CouncilAustralian Research Council [DP150103026]
FX This research was supported by a project (No. 21506158) from the
   National Natural Science Foundation of China (NSFC) and a discovery
   project (DP150103026) from the Australian Research Council.
CR Ali I, 2004, INT J ENVIRON AN CH, V84, P947, DOI 10.1080/03067310410001729637
   Ali I, 2012, INT J ELECTROCHEM SC, V7, P1898
   Asfaram A, 2015, RSC ADV, V5, P18438, DOI 10.1039/c4ra15637d
   Duan XG, 2015, CHEM COMMUN, V51, P15249, DOI 10.1039/c5cc05101k
   Duan XG, 2015, ACS CATAL, V5, P553, DOI 10.1021/cs5017613
   Ghaedi M, 2015, CHEM ENG J, V268, P28, DOI 10.1016/j.cej.2014.12.090
   Gupta VK, 2014, J COLLOID INTERF SCI, V417, P420, DOI 10.1016/j.jcis.2013.11.067
   Hussain H, 2013, CHEM REV, V113, P3329, DOI 10.1021/cr3004373
   Ito Y, 2015, ANGEW CHEM INT EDIT, V54, P2131, DOI 10.1002/anie.201410050
   Ji JY, 2015, ACS NANO, V9, P8609, DOI 10.1021/acsnano.5b03888
   Jia Y, 2016, ADV MATER, V28, P9532, DOI 10.1002/adma.201602912
   Karthikeyan S, 2012, J MOL LIQ, V173, P153, DOI 10.1016/j.molliq.2012.06.022
   Li DG, 2017, CARBON, V115, P649, DOI 10.1016/j.carbon.2017.01.058
   Li YG, 2011, J AM CHEM SOC, V133, P7296, DOI 10.1021/ja201269b
   Morales-Guio CG, 2014, CHEM SOC REV, V43, P6555, DOI 10.1039/c3cs60468c
   Navalon S, 2014, CHEM REV, V114, P6179, DOI 10.1021/cr4007347
   Qu D, 2013, NANOSCALE, V5, P12272, DOI 10.1039/c3nr04402e
   Robati D, 2016, CHEM ENG J, V284, P687, DOI 10.1016/j.cej.2015.08.131
   Saravanan R, 2015, J COLLOID INTERF SCI, V452, P126, DOI 10.1016/j.jcis.2015.04.035
   Saravanan R, 2015, RSC ADV, V5, P34645, DOI 10.1039/c5ra02557e
   Saravanan R, 2013, MAT SCI ENG C-MATER, V33, P4725, DOI 10.1016/j.msec.2013.07.034
   Saravanan R, 2013, MAT SCI ENG C-MATER, V33, P2235, DOI 10.1016/j.msec.2013.01.046
   Saravanan R, 2013, J MOL LIQ, V177, P394, DOI 10.1016/j.molliq.2012.10.018
   Sau TK, 2010, ADV MATER, V22, P1805, DOI 10.1002/adma.200902557
   Song HR, 2018, WATER RES, V128, P393, DOI 10.1016/j.watres.2017.10.018
   Sun HQ, 2013, CHEM COMMUN, V49, P9914, DOI 10.1039/c3cc43401j
   Yan XC, 2016, CHEM COMMUN, V52, P8156, DOI 10.1039/c6cc03687b
   Zheng J, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1501602
NR 28
TC 9
Z9 10
U1 17
U2 120
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 2
PY 2019
VL 194
SI SI
BP 54
EP 57
DI 10.1016/j.ces.2018.04.072
PG 4
WC Engineering, Chemical
SC Engineering
GA HC6NG
UT WOS:000451917900008
DA 2020-05-12
ER

PT J
AU He, TW
   Zhang, CM
   Du, AJ
AF He, Tianwei
   Zhang, Chunmei
   Du, Aijun
TI Single-atom supported on graphene grain boundary as an efficient
   electrocatalyst for hydrogen evolution reaction
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Grain boundary; Single atom; Hydrogen evolution reaction; Density
   function theory
ID TOTAL-ENERGY CALCULATIONS; CATALYSTS; CO; NANOSHEETS; MECHANISM;
   TRANSPORT; OXIDATION; EXCHANGE; SULFIDE; DEFECT
AB Embedding a single atom into the supported catalysts is the most effective way to maximize the catalytic efficiency, holding promise for developing low-cost electrocatalysts. Grain boundaries in graphene display unique structures and have attracted great research efforts in electronic properties, catalysis and sensors. By using density function theory (DFT) calculations, we systematically investigated the potential of a single transition metal (TM) atom (TM = Sc, Ti, V, Cr, Mn, Fe, Co, Ni, Cu, Zn, Ag, Au, Pt) supported on the experimentally realised 558 grain boundary (GB), as a highly efficient electrocatalyst for hydrogen evolution reaction (HER). We find that the Fe, Co, Ni and V atom anchored on 558 GB can substantially tune the free energy of hydrogen adsorption to a more optimal value, especially for the V atom (Delta G H = -0.01 eV), which is very close to, or even better than the most active Pt and MoS2 catalysts. This feature is attributed to the charge transfer between TM atom and the adsorbed H atom, which significantly promotes the proton adsorption and the reduction of kinetics. In addition, a large number of electronic states near the Fermi level ensure efficient electron transfer. Our study may provide a new cost-effective, highly active and earth-abundant HER electrocatalyst for hydrogen production. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [He, Tianwei; Zhang, Chunmei; Du, Aijun] Queensland Univ Technol, Sch Chem Phys & Mech Engn, Gardens Point Campus, Brisbane, Qld 4001, Australia.
RP Du, AJ (reprint author), Queensland Univ Technol, Sch Chem Phys & Mech Engn, Gardens Point Campus, Brisbane, Qld 4001, Australia.
EM aijun.du@qut.edu.au
RI Du, Aijun/C-5759-2009
OI Du, Aijun/0000-0002-3369-3283
FU Australian GovernmentAustralian Government; Government of Western
   Australia; Australian Research CouncilAustralian Research Council
   [DP130102420, DP170103598]
FX We acknowledge generous grants of high-performance computer resources
   provided by NCI National Facility and The Pawsey Supercomputing Centre
   through the National Computational Merit Allocation Scheme supported by
   the Australian Government and the Government of Western Australia. A. D.
   also greatly appreciates the financial support by Australian Research
   Council under Discovery Project (DP130102420 and DP170103598).
CR Alexandre SS, 2012, NANO LETT, V12, P5097, DOI 10.1021/nl3017434
   Back S, 2017, CHEM SCI, V8, P1090, DOI 10.1039/c6sc03911a
   Bader R., 1990, A QUANTUM THEORY
   Bandarenka AS, 2012, ANGEW CHEM INT EDIT, V51, P11845, DOI 10.1002/anie.201205314
   Banhart F, 2011, ACS NANO, V5, P26, DOI 10.1021/nn102598m
   Benck JD, 2014, ACS CATAL, V4, P3957, DOI 10.1021/cs500923c
   BLOCHL PE, 1994, PHYS REV B, V50, P17953, DOI 10.1103/PhysRevB.50.17953
   Bu X., 2017, ANGEW CHEM
   Gao G., 2016, ACS CATAL
   Gao GP, 2016, J AM CHEM SOC, V138, P6292, DOI 10.1021/jacs.6b02692
   Gao GP, 2015, J PHYS CHEM C, V119, P13124, DOI 10.1021/acs.jpcc.5b04658
   GAO MR, 2015, NAT COMMUN, V6
   Gao W, 2013, ANGEW CHEM INT EDIT, V52, P14237, DOI 10.1002/anie.201305001
   Grantab R, 2010, SCIENCE, V330, P946, DOI 10.1126/science.1196893
   Greeley J, 2006, NAT MATER, V5, P909, DOI 10.1038/nmat1752
   Grimme S, 2006, J COMPUT CHEM, V27, P1787, DOI 10.1002/jcc.20495
   He TW, 2017, J CATAL, V354, P231, DOI 10.1016/j.jcat.2017.08.025
   Hinnemann B, 2005, J AM CHEM SOC, V127, P5308, DOI 10.1021/ja0504690
   Huang PY, 2011, NATURE, V469, P389, DOI 10.1038/nature09718
   Jiang QG, 2013, PHYS CHEM CHEM PHYS, V15, P21016, DOI 10.1039/c3cp52976b
   Karunadasa HI, 2010, NATURE, V464, P1329, DOI 10.1038/nature08969
   Kresse G, 1996, PHYS REV B, V54, P11169, DOI 10.1103/PhysRevB.54.11169
   Kresse G, 1996, COMP MATER SCI, V6, P15, DOI 10.1016/0927-0256(96)00008-0
   Lahiri J, 2010, NAT NANOTECHNOL, V5, P326, DOI [10.1038/nnano.2010.53, 10.1038/NNANO.2010.53]
   Li H, 2016, NAT MATER, V15, P48, DOI [10.1038/NMAT4465, 10.1038/nmat4465]
   Ling CY, 2016, CHEM MATER, V28, P9026, DOI 10.1021/acs.chemmater.6b03972
   Liu T., 2017, ADV ENERGY MAT
   Liu TH, 2011, CARBON, V49, P2306, DOI 10.1016/j.carbon.2011.01.063
   Liu YY, 2010, NANO LETT, V10, P2178, DOI 10.1021/nl100988r
   Norskov JK, 2005, J ELECTROCHEM SOC, V152, pJ23, DOI 10.1149/1.1856988
   Ophus C, 2015, PHYS REV B, V92, DOI 10.1103/PhysRevB.92.205402
   Perdew JP, 1996, J CHEM PHYS, V105, P9982, DOI 10.1063/1.472933
   Perdew JP, 1996, PHYS REV LETT, V77, P3865, DOI 10.1103/PhysRevLett.77.3865
   Popczun EJ, 2013, J AM CHEM SOC, V135, P9267, DOI 10.1021/ja403440e
   Qiao BT, 2011, NAT CHEM, V3, P634, DOI [10.1038/NCHEM.1095, 10.1038/nchem.1095]
   Qiu HJ, 2015, ANGEW CHEM INT EDIT, V54, P14031, DOI 10.1002/anie.201507381
   Qiu SY, 2016, ACS CATAL, V6, P5541, DOI 10.1021/acscatal.6b01359
   Ran JR, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13907
   Robertson AW, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2141
   Schlapbach L, 2009, NATURE, V460, P809, DOI 10.1038/460809a
   Smirnova AA, 2011, ZOOL ZH, V90, P803
   Subbaraman R, 2011, SCIENCE, V334, P1256, DOI 10.1126/science.1211934
   Sultana UK, 2017, RSC ADV, V7, P54995, DOI 10.1039/c7ra10394h
   Tang Q, 2016, ACS CATAL, V6, P4953, DOI 10.1021/acscatal.6b01211
   Tang YA, 2012, PHYS CHEM CHEM PHYS, V14, P16566, DOI 10.1039/c2cp41441d
   Tsai C, 2014, NANO LETT, V14, P1381, DOI 10.1021/nl404444k
   Tsen AW, 2012, SCIENCE, V336, P1143, DOI 10.1126/science.1218948
   Turner JA, 2004, SCIENCE, V305, P972, DOI 10.1126/science.1103197
   Voiry D, 2016, NAT MATER, V15, P1003, DOI [10.1038/nmat4660, 10.1038/NMAT4660]
   Voiry D, 2013, NAT MATER, V12, P850, DOI [10.1038/NMAT3700, 10.1038/nmat3700]
   Wang ZL, 2015, J AM CHEM SOC, V137, P15070, DOI 10.1021/jacs.5b09021
   Wang ZY, 2016, INT J HYDROGEN ENERG, V41, P22034, DOI 10.1016/j.ijhydene.2016.08.102
   Warner JH, 2013, NANO LETT, V13, P4937, DOI 10.1021/nl402902q
   Yang M, 2014, SCIENCE, V346, P1498, DOI 10.1126/science.1260526
   Yasaei P, 2015, NANO LETT, V15, P4532, DOI 10.1021/acs.nanolett.5b01100
   Yazyev OV, 2014, NAT NANOTECHNOL, V9, P755, DOI [10.1038/nnano.2014.166, 10.1038/NNANO.2014.166]
   Yazyev OV, 2010, NAT MATER, V9, P806, DOI [10.1038/NMAT2830, 10.1038/nmat2830]
   Zhang ZH, 2015, ADV FUNCT MATER, V25, P367, DOI 10.1002/adfm.201403024
   Zheng Y, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4783
   Zheng Y, 2011, J AM CHEM SOC, V133, P20116, DOI 10.1021/ja209206c
NR 60
TC 24
Z9 24
U1 69
U2 427
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 2
PY 2019
VL 194
SI SI
BP 58
EP 63
DI 10.1016/j.ces.2018.03.028
PG 6
WC Engineering, Chemical
SC Engineering
GA HC6NG
UT WOS:000451917900009
DA 2020-05-12
ER

PT J
AU Wang, L
   Rawal, A
   Aguey-Zinsou, KF
AF Wang, Lei
   Rawal, Aditya
   Aguey-Zinsou, Kondo-Francois
TI Hydrogen storage properties of nanoconfined aluminium hydride (AlH3)
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Hydrogen storage; Alane; Nanoconfinement; Nanosizing; Reversibility
ID MECHANOCHEMICAL SYNTHESIS; THERMAL-DECOMPOSITION; ALANE; SURFACE; ALPHA
AB AlH3 (alane) is considered as an ideal one-off compact hydrogen storage material thanks to its high storage capacity and moderate decomposition temperature. However, application has been hindered by the lack of direct hydrogen reversibility, i.e. regeneration of AlH3 directly from the reaction of spent Al with hydrogen under mild conditions. Herein, we investigated the effect of nanoconfinement on the properties of AlH(3 )and the potential of this approach toward the direct release and uptake of hydrogen by nanosized Al. AlH(3 )was confined within the mesopores of a high surface area graphite (HSAG). The decomposition of the nanoconfined AlH(3 )was detected 50 degrees C lower than the bulk, showing some effect of nanoconfinement on the overall temperature for hydrogen release. Some hydrogen uptake was also observed at 150 degrees C and 60 bar hydrogen pressure, and this indicates that reversible release of hydrogen with alane under moderate conditions of pressure and temperature may be possible. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Wang, Lei; Aguey-Zinsou, Kondo-Francois] Univ New South Wales, Sch Chem Engn, Merlin Grp, Sydney, NSW 2052, Australia.
   [Rawal, Aditya] Univ New South Wales, Mark Wainwright Analyt Ctr, Sydney, NSW 2052, Australia.
RP Aguey-Zinsou, KF (reprint author), Univ New South Wales, Sch Chem Engn, Merlin Grp, Sydney, NSW 2052, Australia.
EM f.aguey@unsw.edu.au
RI Rawal, Aditya/G-2451-2015
FU UNSW Internal Research Grant program; Australian Research Council (ARC)
   - Linkage, Infrastructure, Equipment and Facilities (LIEF)Australian
   Research Council
FX Financial support by UNSW Internal Research Grant program is gratefully
   acknowledged. We appreciate the use of instruments in the Mark
   Wainwright Analytical Centre at UNSW as well as equipment funded by the
   Australian Research Council (ARC) -Linkage, Infrastructure, Equipment
   and Facilities (LIEF). We thank Dr James Hook for supporting access to
   the NMR Facility.
CR Adhikari S, 2008, J ELECTROCHEM SOC, V155, pC16, DOI 10.1149/1.2800770
   Alpatova N. M., 1968, RUSS CHEM REV, V37, P99
   BROWER FM, 1976, J AM CHEM SOC, V98, P2450, DOI 10.1021/ja00425a011
   Chaudhuri S, 2005, J PHYS CHEM B, V109, P6952, DOI 10.1021/jp050558z
   CHIZINSKY G, 1955, J AM CHEM SOC, V77, P3164, DOI 10.1021/ja01616a092
   Clasen H, 1962, Germany Patent:, Patent No. 114162315
   de Jongh PE, 2013, MRS BULL, V38, P488, DOI 10.1557/mrs.2013.108
   de Jongh PE, 2010, CHEMSUSCHEM, V3, P1332, DOI 10.1002/cssc.201000248
   FINHOLT AE, 1947, J AM CHEM SOC, V69, P1199, DOI 10.1021/ja01197a061
   Graetz J, 2011, J ALLOY COMPD, V509, pS517, DOI 10.1016/j.jallcom.2010.11.115
   Graetz J, 2012, ISRN MAT SCI, V2012
   Graetz J, 2007, J PHYS CHEM C, V111, P19148, DOI 10.1021/jp076804j
   Graetz J, 2007, SCRIPTA MATER, V56, P835, DOI 10.1016/j.scriptamat.2007.01.007
   Graetz J, 2006, J ALLOY COMPD, V424, P262, DOI 10.1016/j.jallcom.2005.11.086
   Gupta S, 2014, GREEN CHEM, V16, P4378, DOI 10.1039/c4gc00998c
   Humphries TD, 2013, INT J HYDROGEN ENERG, V38, P4577, DOI 10.1016/j.ijhydene.2013.01.096
   Hwang S-J, 2011, MRS P, V927
   KONOVALOV SK, 1995, INORG CHEM, V34, P172, DOI 10.1021/ic00105a029
   Lacina D, 2011, J PHYS CHEM C, V115, P3789, DOI 10.1021/jp1106263
   Lacina D, 2010, ENERG ENVIRON SCI, V3, P1099, DOI 10.1039/c002064h
   McCormick PG, 2001, ADV MATER, V13, P1008, DOI 10.1002/1521-4095(200107)13:12/13<1008::AID-ADMA1008>3.0.CO;2-Q
   McGrady G. S, 2011, US Patent:, Patent No. 20080241
   Ngene P, 2010, CHEM COMMUN, V46, P8201, DOI 10.1039/c0cc03218b
   Ni CB, 2013, J PHYS CHEM C, V117, P2628, DOI 10.1021/jp310848u
   Nielsen TK, 2011, NANOSCALE, V3, P2086, DOI 10.1039/c0nr00725k
   Oumellal Y, 2014, NANOSCALE, V6, P14459, DOI 10.1039/c4nr03444a
   Paskevicius M, 2009, J ALLOY COMPD, V487, P370, DOI 10.1016/j.jallcom.2009.07.124
   Paskevicius M., 2009, NANOSTRUCTURAL INVES
   Puri P, 2007, J PHYS CHEM C, V111, P11776, DOI 10.1021/jp0724774
   Saitoh H, 2010, J PHYS CONF SER, V215, DOI 10.1088/1742-6596/215/1/012127
   Saitoh H, 2010, J ALLOY COMPD, V496, pL25, DOI 10.1016/j.jallcom.2010.02.112
   Saitoh H, 2008, APPL PHYS LETT, V93, DOI 10.1063/1.3002374
   Saitoh H, 2009, APPL PHYS LETT, V94, DOI 10.1063/1.3120559
   Sandrock G, 2005, APPL PHYS A-MATER, V80, P687, DOI 10.1007/s00339-004-3105-0
   Sandrock G, 2006, J ALLOY COMPD, V421, P185, DOI 10.1016/j.jallcom.2005.09.081
   Sartori S, 2009, INT J HYDROGEN ENERG, V34, P6350, DOI 10.1016/j.ijhydene.2009.06.019
   Sun J, 2007, THERMOCHIM ACTA, V463, P32, DOI 10.1016/j.tca.2007.07.007
   Sun YH, 2018, ENERGY STORAGE MATER, V10, P168, DOI 10.1016/j.ensm.2017.01.010
   Tkacz M, 1983, Z PHYS CHEM, P27
   Wang L, 2017, INT J HYDROGEN ENERG, V42, P14144, DOI 10.1016/j.ijhydene.2017.04.104
   Wang L, 2016, INT J HYDROGEN ENERG, V41, P18088, DOI 10.1016/j.ijhydene.2016.07.073
   Wiench JW, 2004, J SOLID STATE CHEM, V177, P648, DOI 10.1016/j.jssc.2003.08.006
   Xu B, 2014, VACUUM, V99, P127, DOI 10.1016/j.vacuum.2013.05.009
   Zidan R, 2009, CHEM COMMUN, P3717, DOI 10.1039/b901878f
   Zlotea C, 2013, COLLOID SURFACE A, V439, P117, DOI 10.1016/j.colsurfa.2012.11.043
NR 45
TC 10
Z9 12
U1 8
U2 64
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 2
PY 2019
VL 194
SI SI
BP 64
EP 70
DI 10.1016/j.ces.2018.02.014
PG 7
WC Engineering, Chemical
SC Engineering
GA HC6NG
UT WOS:000451917900010
DA 2020-05-12
ER

PT J
AU Pan, YX
   Zhuang, HQ
   Ma, H
   Cheng, J
   Song, J
AF Pan, Yun-Xiang
   Zhuang, Hua-Qiang
   Ma, Hui
   Cheng, Jin
   Song, Jie
TI Tungsten carbide hollow spheres flexible for charge separation and
   transfer for enhanced visible-light-driven photocatalysis
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Tungsten carbide; Photocatalysis; Charge separation; H-2; Hollow spheres
ID CDS QUANTUM DOTS; HYDROGEN EVOLUTION; H-2 EVOLUTION; DECORATED GRAPHENE;
   METAL-FREE; EFFICIENT; WATER; OXIDE; TIO2; DEGRADATION
AB As a promising green chemical technology, solar-energy-driven photocatalysis has attracted great attentions. Herein, tungsten carbide (WC) hollow spheres with a surface area of 396.3 m(2) g(-1) were successfully fabricated, and used to support CdS nanoparticles (similar to 5 nm) to form a noble-metal-free CdS/WC photocatalyst. CdS/WC exhibits high abilities in absorbing visible light which is the main part of the sunlight (44%) and in separating the photogenerated electron-hole pairs. The H-2 evolution rate in the visible-light-driven photocatalytic H2O splitting on CdS/WC (1331.7 mu mol h(-1)) is much higher than those on the photocatalysts formed by combining the CdS nanoparticles with WC nanoparticles (739.6 mu mol h(-1)) and with Pt nanoparticles (556.3 mu mol h(-1)). The enhanced electron-hole separation and subsequent transfer of the charge carriers on CdS/WC is responsible for the higher H-2 evolution rate on CdS/WC. These results are helpful for preparing noble-metal-free photocatalysts for more efficient photocatalysis. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Pan, Yun-Xiang; Cheng, Jin; Song, Jie] Shanghai Jiao Tong Univ, Inst Nano Biomed & Engn, Sch Elect Informat & Elect Engn, Dept Instrument Sci & Engn, Shanghai 200240, Peoples R China.
   [Zhuang, Hua-Qiang] Quanzhou Normal Univ, Coll Chem Engn & Mat Sci, Quanzhou 362000, Fujian, Peoples R China.
   [Ma, Hui] Juhai Co, Cangzhou Dahua Grp Co Ltd, Cangzhou 061000, Hebei, Peoples R China.
RP Pan, YX; Song, J (reprint author), Shanghai Jiao Tong Univ, Inst Nano Biomed & Engn, Sch Elect Informat & Elect Engn, Dept Instrument Sci & Engn, Shanghai 200240, Peoples R China.
EM tjupyx@hfut.edu.cn; sjie@sjtu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [U1662138, 21503062, 21605102, 11761141006]
FX This work is supported by the National Natural Science Foundation of
   China (Grant No. U1662138, 21503062, 21605102, 11761141006).
CR Chortos A, 2017, ACS NANO, V11, P5660, DOI 10.1021/acsnano.7b01076
   Fang JJ, 2017, APPL CATAL B-ENVIRON, V217, P100, DOI 10.1016/j.apcatb.2017.05.069
   Fang Z, 2013, NANOSCALE, V5, P9830, DOI 10.1039/c3nr03043a
   Gao XH, 2017, SOL ENERG MAT SOL C, V164, P63, DOI 10.1016/j.solmat.2017.02.009
   Goh TW, 2015, CHEM ENG SCI, V124, P45, DOI 10.1016/j.ces.2014.08.052
   Guayaquil-Sosa F, 2017, APPL CATAL B-ENVIRON, V211, P337, DOI 10.1016/j.apcatb.2017.04.029
   Ijaz S, 2016, MATER DESIGN, V107, P178, DOI 10.1016/j.matdes.2016.06.031
   Jiang LB, 2017, APPL CATAL B-ENVIRON, V217, P388, DOI 10.1016/j.apcatb.2017.06.003
   Jiang M, 2016, APPL CATAL B-ENVIRON, V198, P180, DOI 10.1016/j.apcatb.2016.05.055
   Kisch H, 2017, ACCOUNTS CHEM RES, V50, P1002, DOI 10.1021/acs.accounts.7b00023
   Krasovskii PV, 2015, APPL SURF SCI, V339, P46, DOI 10.1016/j.apsusc.2015.02.152
   Lee SK, 2017, CHEM SOC REV, V46, P4877, DOI 10.1039/c7cs00136c
   Li Q, 2011, J AM CHEM SOC, V133, P10878, DOI 10.1021/ja2025454
   Lingampalli SR, 2013, ENERG ENVIRON SCI, V6, P3589, DOI 10.1039/c3ee42623h
   Liu JK, 2013, ANGEW CHEM INT EDIT, V52, P3241, DOI 10.1002/anie.201209363
   Liu J, 2017, ADV MATER, V29, DOI 10.1002/adma.201605349
   Liu XQ, 2017, ENERG ENVIRON SCI, V10, P402, DOI 10.1039/c6ee02265k
   Mao XL, 2013, CHEM ENG J, V218, P73, DOI 10.1016/j.cej.2012.12.031
   Moreira J, 2012, CHEM ENG SCI, V78, P186, DOI 10.1016/j.ces.2012.04.033
   Nandiyanto ABD, 2013, CHEM ENG SCI, V101, P523, DOI 10.1016/j.ces.2013.06.049
   Pan YX, 2017, ACS SUSTAIN CHEM ENG, V5, P5449, DOI 10.1021/acssuschemeng.7b00787
   Pan YX, 2016, CATAL SCI TECHNOL, V6, P2206, DOI 10.1039/c5cy01634g
   Pan YX, 2014, CHEMSUSCHEM, V7, P2537, DOI 10.1002/cssc.201402334
   Peng R, 2013, CHEM COMMUN, V49, P3221, DOI 10.1039/c3cc41362d
   Peng Y, 2017, INT J HYDROGEN ENERG, V42, P14409, DOI 10.1016/j.ijhydene.2017.04.204
   Ranjith KS, 2017, CHEM ENG J, V325, P588, DOI 10.1016/j.cej.2017.05.105
   Rey A, 2015, CHEM ENG SCI, V126, P80, DOI 10.1016/j.ces.2014.12.016
   Schaidle JA, 2010, J CATAL, V272, P235, DOI 10.1016/j.jcat.2010.04.004
   Vrubel H, 2012, ANGEW CHEM INT EDIT, V51, P12703, DOI 10.1002/anie.201207111
   Wan C, 2014, ANGEW CHEM INT EDIT, V53, P6407, DOI 10.1002/anie.201402998
   Wang B, 2017, APPL SURF SCI, V391, P449, DOI 10.1016/j.apsusc.2016.07.056
   Wang XQ, 2015, NANO ENERGY, V12, P9, DOI 10.1016/j.nanoen.2014.12.007
   Wu KF, 2014, J AM CHEM SOC, V136, P7708, DOI 10.1021/ja5023893
   Wu KF, 2012, J AM CHEM SOC, V134, P10337, DOI 10.1021/ja303306u
   Xing Z, 2013, CHEM ENG SCI, V104, P125, DOI 10.1016/j.ces.2013.08.039
   Yan Y, 2013, CHEM COMMUN, V49, P4884, DOI 10.1039/c3cc41031e
   Yang Y, 2017, CARBON, V122, P1, DOI 10.1016/j.carbon.2017.06.033
   Zha DW, 2016, INT J HYDROGEN ENERG, V41, P17370, DOI 10.1016/j.ijhydene.2016.07.227
   Zhou XF, 2015, CATAL SCI TECHNOL, V5, P2798, DOI 10.1039/c4cy01757a
NR 39
TC 4
Z9 4
U1 15
U2 81
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 2
PY 2019
VL 194
SI SI
BP 71
EP 77
DI 10.1016/j.ces.2018.01.022
PG 7
WC Engineering, Chemical
SC Engineering
GA HC6NG
UT WOS:000451917900011
DA 2020-05-12
ER

PT J
AU Cerdan, K
   Ouyang, WY
   Colmenares, JC
   Munoz-Batista, MJ
   Luque, R
   Balu, AM
AF Cerdan, Kenneth
   Ouyang, Weiyi
   Colmenares, Juan C.
   Munoz-Batista, Mario J.
   Luque, Rafael
   Balu, Alina M.
TI Facile mechanochemical modification of g-C3N4 for selective
   photo-oxidation of benzyl alcohol
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Photo-catalysis; Graphitic carbon nitride; Mechanochemical; Benzyl
   alcohol; ZnO; Fe2O3
ID PHOTOCATALYTIC ACTIVITY; COMPOSITE; OXIDATION; PERFORMANCE; TOLUENE;
   PHOTODEGRADATION; GRAPHENE; TIO2; ZNO; UV
AB Graphitic carbon nitride (CN) enriched with ZnO or Fe2O3 were synthesized using a simple one-pot mechanochemical method. By using this method, composite samples were synthetized without the production of any potentially hazardous waste. Synthesized materials were used as catalysts during selective photo-oxidation of benzyl alcohol. Both composite materials displayed an enhancement of activity and benzaldehyde selectivity with respect to the pure CN. The most active catalyst was Fe2O3/g-C3N4(Fe/CN). Conversion and benzaldehyde selectivity of this sample were 20 and 70%, respectively. It showed a considerable increase of benzaldehyde selectivity compared to the pure CN and TiO2 P25 commercial reference. A complete structural and electronic characterization using Scanning Electron Microscopy-Energy Dispersive (SEM-EDX), BET measurements, X-ray diffraction (XRD), X-ray Photoelectron (XPS), and UV-visible spectroscopies was carried out. The characterization analysis pointed out the leading role of the crystallinity and surface concentration over the activity and benzaldehyde selectivity of the reaction. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Cerdan, Kenneth; Ouyang, Weiyi; Munoz-Batista, Mario J.; Luque, Rafael; Balu, Alina M.] Univ Cordoba, Dept Quim Organ, Edificio Marie Curie C-3,Ctra Nnal 4-A,Km 396, E-14014 Cordoba, Spain.
   [Colmenares, Juan C.] Polish Acad Sci, Inst Phys Chem, Kasprzaka 44-52, PL-01224 Warsaw, Poland.
   [Luque, Rafael] Peoples Friendship Univ Russia, RUDN Univ, 6 Miklukho Maklaya Str, Moscow 117198, Russia.
RP Luque, R; Balu, AM (reprint author), Univ Cordoba, Dept Quim Organ, Edificio Marie Curie C-3,Ctra Nnal 4-A,Km 396, E-14014 Cordoba, Spain.
EM rafael.luque@uco.es
RI Munoz-Batista, Mario J./U-4555-2019; Cerdan Gomez, Kenneth/R-9979-2018;
   Ouyang, Weiyi/H-2539-2015
OI Munoz-Batista, Mario J./0000-0002-1419-0592; Cerdan Gomez,
   Kenneth/0000-0002-4444-1401; Ouyang, Weiyi/0000-0002-7317-6651
FU European UnionEuropean Union (EU) [641861]; MINECO [FJCI-2016-29014];
   RUDN University Program 5-100
FX Rafael Luque funding from the European Union's Horizon 2020 research and
   innovation programme under the Marie Sklodowska-Curie grant agreement
   No. 641861 (for funding Weyi Ouyang Ph.D studies). Mario J.
   Munoz-Batista gratefully acknowledges MINECO for a JdC contract (Ref.
   FJCI-2016-29014). The publication has been prepared with support of RUDN
   University Program 5-100.
CR Augugliaro V, 2008, CHEM-EUR J, V14, P4640, DOI 10.1002/chem.200702044
   Bertolini GR, 2018, APPL CATAL B-ENVIRON, V225, P100, DOI 10.1016/j.apcatb.2017.11.055
   Boyle DS, 2002, CHEM COMMUN, P80, DOI 10.1039/b110079n
   Colmenares JC, 2009, MATERIALS, V2, P2228, DOI 10.3390/ma2042228
   Dong GP, 2014, J PHOTOCH PHOTOBIO C, V20, P33, DOI 10.1016/j.jphotochemrev.2014.04.002
   Evgenidou E, 2005, APPL CATAL B-ENVIRON, V59, P81, DOI 10.1016/j.apcatb.2005.01.005
   Fontelles-Carceller O, 2016, ACS APPL MATER INTER, V8, P2617, DOI 10.1021/acsami.5b10434
   Ge L, 2012, J PHYS CHEM C, V116, P13708, DOI 10.1021/jp3041692
   He YM, 2015, APPL CATAL B-ENVIRON, V168, P1, DOI 10.1016/j.apcatb.2014.12.017
   He YM, 2015, ENVIRON SCI TECHNOL, V49, P649, DOI 10.1021/es5046309
   Hu SZ, 2014, RSC ADV, V4, P24863, DOI 10.1039/c4ra03290j
   Jo WK, 2015, CHEM ENG J, V281, P549, DOI 10.1016/j.cej.2015.06.120
   Kakuta S, 2009, J MATER SCI, V44, P2890, DOI 10.1007/s10853-009-3382-2
   Kim JS, 2017, INT J HYDROGEN ENERG, V42, P5485, DOI 10.1016/j.ijhydene.2016.08.077
   Kuang PY, 2015, APPL SURF SCI, V358, P296, DOI 10.1016/j.apsusc.2015.08.066
   Kubacka A, 2012, CHEM REV, V112, P1555, DOI 10.1021/cr100454n
   Li K, 2015, ACS APPL MATER INTER, V7, P9023, DOI 10.1021/am508505n
   Li LL, 2007, J PHYS CHEM C, V111, P2123, DOI 10.1021/jp066664y
   Li XH, 2012, ACS CATAL, V2, P2082, DOI 10.1021/cs300413x
   Li XZ, 2015, CHEMCATCHEM, V7, P2047, DOI 10.1002/cctc.201500009
   Lisowski P, 2017, ACS SUSTAIN CHEM ENG, V5, P6274, DOI 10.1021/acssuschemeng.7b01251
   Liu Y, 2014, INT J HYDROGEN ENERG, V39, P9105, DOI 10.1016/j.ijhydene.2014.03.248
   Magdziarz A, 2017, ULTRASON SONOCHEM, V38, P189, DOI 10.1016/j.ultsonch.2017.03.012
   Mamba G, 2016, APPL CATAL B-ENVIRON, V198, P347, DOI 10.1016/j.apcatb.2016.05.052
   Martin A, 1999, CATAL LETT, V59, P61, DOI 10.1023/A:1019083429551
   Miranda C, 2013, J PHOTOCH PHOTOBIO A, V253, P16, DOI 10.1016/j.jphotochem.2012.12.014
   Munoz-Batista MJ, 2014, CATAL SCI TECHNOL, V4, P2006, DOI 10.1039/c4cy00226a
   Munoz-Batista MJ, 2017, APPL CATAL B-ENVIRON, V203, P663, DOI 10.1016/j.apcatb.2016.10.044
   Munoz-Batista MJ, 2016, APPL CATAL B-ENVIRON, V183, P86, DOI 10.1016/j.apcatb.2015.10.024
   Munoz-Batista MJ, 2015, APPL CATAL B-ENVIRON, V176, P687, DOI 10.1016/j.apcatb.2015.04.051
   Munoz-Batista MJ, 2015, APPL CATAL B-ENVIRON, V164, P261, DOI 10.1016/j.apcatb.2014.09.037
   Munoz-Batista MJ, 2014, J CATAL, V309, P428, DOI 10.1016/j.jcat.2013.10.021
   Obregon S, 2014, APPL CATAL B-ENVIRON, V144, P775, DOI 10.1016/j.apcatb.2013.07.034
   Ouyang WY, 2016, NANOMATERIALS-BASEL, V6, DOI 10.3390/nano6050093
   Theerthagiri J, 2014, RSC ADV, V4, P38222, DOI 10.1039/c4ra04266b
   Wang W, 2017, CHEMPHOTOCHEM, V1, P35, DOI 10.1002/cptc.201600021
   Wang YJ, 2011, ENERG ENVIRON SCI, V4, P2922, DOI 10.1039/c0ee00825g
   Wanger C.D., 1979, HDB XRAY PHOTOELECTR
   Xu CP, 2015, CHEM COMMUN, V51, P6698, DOI 10.1039/c4cc09876e
   Xu Q, 2018, INT J GREEN ENERGY, V15, P181, DOI 10.1080/15435075.2018.1431547
   Yan SC, 2009, LANGMUIR, V25, P10397, DOI 10.1021/la900923z
   Yang MQ, 2013, PHYS CHEM CHEM PHYS, V15, P19102, DOI 10.1039/c3cp53325e
   Yoon T. P, 2011, SCIENCE, V334, P1114, DOI [10.1126/science.1213920, DOI 10.1126/SCIENCE.1213920]
   Zhang GG, 2012, J MATER CHEM, V22, P8083, DOI 10.1039/c2jm00097k
   Zhang N, 2015, CHEM REV, V115, P10307, DOI 10.1021/acs.chemrev.5b00267
   Zhang N, 2014, ACS NANO, V8, P623, DOI 10.1021/nn405242t
   Zhang YH, 2013, ACS SUSTAIN CHEM ENG, V1, P1258, DOI 10.1021/sc400116k
   Zhang YJ, 2013, SCI REP-UK, V3, DOI 10.1038/srep02163
   Zhao ZW, 2015, NANOSCALE, V7, P15, DOI 10.1039/c4nr03008g
   Zhou JW, 2015, PHYS CHEM CHEM PHYS, V17, P3647, DOI 10.1039/c4cp05173d
NR 50
TC 17
Z9 17
U1 19
U2 158
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 2
PY 2019
VL 194
SI SI
BP 78
EP 84
DI 10.1016/j.ces.2018.04.001
PG 7
WC Engineering, Chemical
SC Engineering
GA HC6NG
UT WOS:000451917900012
DA 2020-05-12
ER

PT J
AU Tan, HL
   Du, AJ
   Amal, R
   Ng, YH
AF Tan, Hui Ling
   Du, Aijun
   Amal, Rose
   Ng, Yun Hau
TI Decorating platinum on nitrogen-doped graphene sheets: Control of the
   platinum particle size distribution for improved photocatalytic H-2
   generation
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Graphene; Nitrogen doping; Catalyst support; Photocatalysis; Hydrogen
   generation
ID GRAPHITIC CARBON NITRIDE; SUPPORTED PLATINUM; OXIDE; CATALYST;
   PERFORMANCE; NANOPARTICLES; EVOLUTION; COMPOSITES; DEPOSITION; NANOTUBES
AB Nitrogen doping of graphene with systematically controlled dopant content and distribution of nitrogen species is demonstrated to improve the size distribution of the deposited platinum (Pt) nanoparticles. While the dopant content can be tuned by varying the urea dosage, the doped nitrogen species (namely pyridinic N, pyrrolic N, and graphitic N) can be controlled through the annealing temperature. Chemically reduced Pt nanoparticles were found to be evenly distributed on the nitrogen-doped graphene sheets (NRGO) with particle size centred at 2.7 nm. In comparison, the decoration of Pt on the non-doped graphene (RGO) yielded a composite material with larger Pt (7.8 nm) and poorer size distribution. The loading of Pt nanoparticles is shown to correlate with the concentration of the nitrogen dopant, in particular that of the graphitic N species. Owing to the smaller and better distributed Pt nanoparticles which facilitated more active sites for reaction, the Pt-loaded NRGO photocatalytically generated H-2 gas ten times higher than that of Pt-loaded RGO when coupled with photoactive graphitic carbon nitride (g-C3N4). (C) 2017 Elsevier Ltd. All rights reserved.
C1 [Tan, Hui Ling; Amal, Rose; Ng, Yun Hau] Univ New South Wales, Sch Chem Engn, Particles & Catalysis Res Grp, Sydney, NSW 2052, Australia.
   [Du, Aijun] Queensland Univ Technol, Sch Chem Phys & Mech Engn, Fac Sci & Engn, Garden Point Campus, Brisbane, Qld 4001, Australia.
RP Ng, YH (reprint author), Univ New South Wales, Sch Chem Engn, Particles & Catalysis Res Grp, Sydney, NSW 2052, Australia.
EM yh.ng@unsw.edu.au
RI Ng, Yun Hau/B-4716-2009; Du, Aijun/C-5759-2009
OI Ng, Yun Hau/0000-0001-9142-2126; Du, Aijun/0000-0002-3369-3283; Amal,
   Rose/0000-0001-9561-4918; Tan, Hui Ling/0000-0001-6156-2857
FU Australian Research Council (ARC)Australian Research Council
   [DP130102420]
FX The authors thank the Australian Research Council (ARC) for its
   financial support through Discovery Project (DP130102420).
CR Arico AS, 2001, APPL SURF SCI, V172, P33, DOI 10.1016/S0169-4332(00)00831-X
   Bell NJ, 2011, J PHYS CHEM C, V115, P6004, DOI 10.1021/jp1113575
   Chen JY, 2004, J AM CHEM SOC, V126, P10854, DOI 10.1021/ja0468224
   Harada T, 2008, ADV FUNCT MATER, V18, P2190, DOI 10.1002/adfm.200701442
   Hong WJ, 2010, J PHYS CHEM C, V114, P1822, DOI 10.1021/jp9101724
   HUMMERS WS, 1958, J AM CHEM SOC, V80, P1339, DOI 10.1021/ja01539a017
   Jafri RI, 2010, J MATER CHEM, V20, P7114, DOI 10.1039/c0jm00467g
   Jiang LQ, 2003, CARBON, V41, P2923, DOI 10.1016/S0008-6223(03)00339-7
   KOZLOWSKI C, 1987, CARBON, V25, P751, DOI 10.1016/0008-6223(87)90146-1
   Lee SU, 2009, SMALL, V5, P1769, DOI 10.1002/smll.200801938
   Li H, 2010, CHEM COMMUN, V46, P6243, DOI 10.1039/c0cc01098g
   Li WZ, 2003, J PHYS CHEM B, V107, P6292, DOI 10.1021/jp022505c
   Li XL, 2009, J AM CHEM SOC, V131, P15939, DOI 10.1021/ja907098f
   Li YJ, 2010, CARBON, V48, P1124, DOI 10.1016/j.carbon.2009.11.034
   Liang YM, 2006, J CATAL, V238, P468, DOI 10.1016/j.jcat.2006.01.005
   Lin ZY, 2012, PHYS CHEM CHEM PHYS, V14, P3381, DOI 10.1039/c2cp00032f
   Liu JB, 2010, J AM CHEM SOC, V132, P7279, DOI 10.1021/ja100938r
   Lv RT, 2011, ADV FUNCT MATER, V21, P999, DOI 10.1002/adfm.201001602
   Ma TY, 2014, ANGEW CHEM INT EDIT, V53, P7281, DOI 10.1002/anie.201403946
   Moon GH, 2011, CARBON, V49, P3454, DOI 10.1016/j.carbon.2011.04.042
   Mou ZG, 2011, APPL SURF SCI, V258, P1704, DOI 10.1016/j.apsusc.2011.10.019
   Muszynski R, 2008, J PHYS CHEM C, V112, P5263, DOI 10.1021/jp800977b
   Ng YH, 2008, CHEM COMMUN, P3181, DOI 10.1039/b803912g
   Ng YH, 2008, LANGMUIR, V24, P6307, DOI 10.1021/la800045u
   Ng YH, 2008, CHEM MATER, V20, P1154, DOI 10.1021/cm702034w
   PELS JR, 1995, CARBON, V33, P1641, DOI 10.1016/0008-6223(95)00154-6
   Qiu JD, 2012, CHEM-EUR J, V18, P7950, DOI 10.1002/chem.201200258
   Seger B, 2009, J PHYS CHEM C, V113, P7990, DOI 10.1021/jp900360k
   Seo MH, 2011, ELECTROCHEM COMMUN, V13, P182, DOI 10.1016/j.elecom.2010.12.008
   Shim JW, 2001, CARBON, V39, P1635, DOI 10.1016/S0008-6223(00)00290-6
   Singh V, 2011, PROG MATER SCI, V56, P1178, DOI 10.1016/j.pmatsci.2011.03.003
   Sun L, 2012, RSC ADV, V2, P4498, DOI 10.1039/c2ra01367c
   Tan HL, 2016, SMALL, V12, P5295, DOI 10.1002/smll.201601536
   Wakeland S, 2010, CARBON, V48, P3463, DOI 10.1016/j.carbon.2010.05.043
   Wang DW, 2010, ELECTROCHEM COMMUN, V12, P1423, DOI 10.1016/j.elecom.2010.07.037
   Wang XC, 2009, J AM CHEM SOC, V131, P1680, DOI 10.1021/ja809307s
   Wang XC, 2009, NAT MATER, V8, P76, DOI 10.1038/NMAT2317
   Wei DC, 2009, NANO LETT, V9, P1752, DOI 10.1021/nl803279t
   Wiley B, 2005, CHEM-EUR J, V11, P454, DOI 10.1002/chem.200400927
   Xiang QJ, 2011, J PHYS CHEM C, V115, P7355, DOI 10.1021/jp200953k
   Xin YC, 2012, ELECTROCHIM ACTA, V60, P354, DOI 10.1016/j.electacta.2011.11.062
   Xu C, 2008, J PHYS CHEM C, V112, P19841, DOI 10.1021/jp807989b
   Yang SY, 2012, ELECTROCHEM COMMUN, V14, P39, DOI 10.1016/j.elecom.2011.10.028
   Ng YH, 2012, ENERG ENVIRON SCI, V5, P9307, DOI 10.1039/c2ee22128d
   Ng YH, 2011, CATAL TODAY, V164, P353, DOI 10.1016/j.cattod.2010.10.090
   Zhang JS, 2010, ANGEW CHEM INT EDIT, V49, P441, DOI 10.1002/anie.200903886
   Zhang LS, 2010, PHYS CHEM CHEM PHYS, V12, P12055, DOI 10.1039/c0cp00789g
   Zheng SF, 2007, J PHYS CHEM C, V111, P11174, DOI 10.1021/jp0727042
NR 48
TC 10
Z9 10
U1 5
U2 57
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 2
PY 2019
VL 194
SI SI
BP 85
EP 93
DI 10.1016/j.ces.2017.12.042
PG 9
WC Engineering, Chemical
SC Engineering
GA HC6NG
UT WOS:000451917900013
DA 2020-05-12
ER

PT J
AU Stanley, JNG
   Garcia-Garcia, I
   Perfrement, T
   Lovell, EC
   Schmidt, TW
   Scott, J
   Amal, R
AF Stanley, Jessica N. G.
   Garcia-Garcia, Iker
   Perfrement, Tom
   Lovell, Emma C.
   Schmidt, Timothy W.
   Scott, Jason
   Amal, Rose
TI Plasmonic effects on CO2 reduction over bimetallic Ni-Au catalysts
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE CO2 reduction; Nickel-gold; Bimetallic interactions; Localised surface
   plasmonic resonance
ID LOW-TEMPERATURE; CARBON-DIOXIDE; RUTHENIUM NANOPARTICLES; RU
   NANOPARTICLES; HYDROGENATION; METHANATION; METALS; ALLOY; SIZE;
   NANOPLASMONICS
AB The anthropogenic rise of carbon emissions has led to increased interest in the innovative utilisation of CO2. CO2 reduction via the Sabatier reaction presents a thermodynamically favourable pathway to reduce CO2; however, to date, there has been a lack of understanding of how plasmonic enhancement may be utilised for this reaction particularly with respect to the role of bimetallic catalysts. In this study, the effect of laser light illumination on Ni-Au/SiO2 , at 520 nm and 660 nm, was studied for CO2 reduction over a temperature range of 150 degrees C to 450 degrees C, with the catalytic performance being assessed by CO2 conversion along with CH4 and CO selectivity. Under laser light illumination, at 520 nm and 450 degrees C, CO2 conversion for Ni-Au/SiO2 increased by 79% whilst simultaneously lowering CH4 selectivity, which was attributed to localised surface plasmon resonance effects and promotion of the reverse water-gas shift reaction by the Au. Laser light illumination at 660 nm also introduced a mild conversion increase, however not to the same extent as for 520 nm. XPS analysis of Ni-Au/SiO2 implied that the observed photo-enhancement could be due to plasmonic mediated electron charge transfer from the Au deposits to the Ni deposits. Monometallic Ni and Au samples were examined and compared with the bimetallic system to elucidate the origin of the photo enhancement and to understand the plasmonic and catalytic interactions. The Au/SiO2 and Ni/SiO2 samples demonstrated that the photo-enhancement arose from the presence of the Au, with the increase in CO2 conversion at 520 nm increasing with increasing Au content; Au (similar to 110%) > NiAu (similar to 80%) > Ni (similar to 21%). However, the overall better performance of the Ni/SiO2 sample, facilitating high CO2 conversion and CH4 selectivity emphasises that, while plasmonic metal inclusion can induce synergistic effects, the benefits can be muted if it is unable to promote the target reaction. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Stanley, Jessica N. G.; Perfrement, Tom; Lovell, Emma C.; Scott, Jason; Amal, Rose] Univ New South Wales, Sch Chem Engn, Sydney, NSW 2052, Australia.
   [Garcia-Garcia, Iker] Univ Basque Country, Fac Engn, Plaza Ingn Torres Quevedo 1, Bilbao 48013, Spain.
   [Schmidt, Timothy W.] Univ New South Wales, Sch Chem, ARC Ctr Excellence Exciton Sci, Sydney, NSW 2052, Australia.
RP Lovell, EC; Amal, R (reprint author), Univ New South Wales, Sch Chem Engn, Sydney, NSW 2052, Australia.
EM e.lovell@unsw.edu.au; r.amal@unsw.edu.au
RI Lovell, Emma/C-7212-2019; Stanley, Jessica/AAB-8390-2020
OI Lovell, Emma/0000-0002-9027-0316; Amal, Rose/0000-0001-9561-4918;
   Schmidt, Timothy/0000-0001-6691-1438; Scott, Jason/0000-0003-2395-2058
FU Australian Research CouncilAustralian Research Council [FL140100081,
   FT130100177]; Australian Research Council Centre of Excellence in
   Exciton Science [CE170100026]
FX This work was supported by the Australian Research Council under the
   Laureate Fellowship Scheme - FL140100081. The authors acknowledge the
   use of facilities within the UNSW Mark Wainwright Analytical Centre.
   T.W.S. acknowledges the Australian Research Council for a Future
   Fellowship (FT130100177). T.W.S. was supported by the Australian
   Research Council Centre of Excellence in Exciton Science (CE170100026).
CR Aziz MAA, 2015, GREEN CHEM, V17, P2647, DOI 10.1039/c5gc00119f
   Aziz MAA, 2014, APPL CATAL B-ENVIRON, V147, P359, DOI 10.1016/j.apcatb.2013.09.015
   Baffou G, 2014, CHEM SOC REV, V43, P3898, DOI 10.1039/c3cs60364d
   Beuls A, 2012, APPL CATAL B-ENVIRON, V113, P2, DOI 10.1016/j.apcatb.2011.02.033
   Bian L, 2015, J NAT GAS SCI ENG, V27, P1189, DOI 10.1016/j.jngse.2015.09.066
   Bumajdad A, 2014, PHYS CHEM CHEM PHYS, V16, P7146, DOI 10.1039/c3cp54411g
   Chiang IC, 2009, J ALLOY COMPD, V468, P237, DOI 10.1016/j.jallcom.2008.01.063
   Chiu HK, 2009, J NANOPART RES, V11, P1137, DOI 10.1007/s11051-008-9506-9
   Erola MOA, 2015, J SOLID STATE CHEM, V230, P209, DOI 10.1016/j.jssc.2015.06.036
   Hou WB, 2013, ADV FUNCT MATER, V23, P1612, DOI 10.1002/adfm.201202148
   Jin RX, 2013, DALTON T, V42, P7888, DOI 10.1039/c2dt32590j
   Karelovic A, 2013, J CATAL, V301, P141, DOI 10.1016/j.jcat.2013.02.009
   Karelovic A, 2012, APPL CATAL B-ENVIRON, V113, P237, DOI 10.1016/j.apcatb.2011.11.043
   KOLB DM, 1974, J ELECTROANAL CHEM, V54, P25, DOI 10.1016/S0022-0728(74)80377-3
   Kwak JH, 2013, ACS CATAL, V3, P2094, DOI 10.1021/cs4001392
   Kwak JH, 2013, ACS CATAL, V3, P2449, DOI 10.1021/cs400381f
   Lin QQ, 2014, CATAL SCI TECHNOL, V4, P2058, DOI 10.1039/c4cy00030g
   Linic S, 2015, NAT MATER, V14, P567, DOI [10.1038/NMAT4281, 10.1038/nmat4281]
   Liu HZ, 2012, J NAT GAS CHEM, V21, P703, DOI 10.1016/S1003-9953(11)60422-2
   Lovell EC, 2015, MOLECULES, V20, P4594, DOI 10.3390/molecules20034594
   Martins J, 2015, CATAL COMMUN, V58, P11, DOI 10.1016/j.catcom.2014.08.027
   Matsubu JC, 2015, J AM CHEM SOC, V137, P3076, DOI 10.1021/ja5128133
   Nishikawa H, 2013, J CATAL, V307, P254, DOI 10.1016/j.jcat.2013.07.027
   Ocampo F, 2009, APPL CATAL A-GEN, V369, P90, DOI 10.1016/j.apcata.2009.09.005
   Pan QS, 2014, CATAL COMMUN, V45, P74, DOI 10.1016/j.catcom.2013.10.034
   Rivero-Mendoza DE, 2016, CATALYSTS, V6, DOI 10.3390/catal6110170
   Ro I, 2016, APPL CATAL A-GEN, V521, P182, DOI 10.1016/j.apcata.2015.11.021
   Rodriguez JA, 1996, SURF SCI REP, V24, P225, DOI 10.1016/0167-5729(96)00004-0
   Roldan L, 2015, CHEMCATCHEM, V7, P1347, DOI 10.1002/cctc.201500016
   She HD, 2012, J MATER CHEM, V22, P2757, DOI 10.1039/c1jm14479k
   Srisawad N, 2012, REACT KINET MECH CAT, V107, P179, DOI 10.1007/s11144-012-0459-8
   Stanley JNG, 2014, RSC ADV, V4, P28062, DOI 10.1039/c4ra03474k
   Stanley JNG, 2013, APPL CATAL A-GEN, V454, P46, DOI 10.1016/j.apcata.2013.01.002
   Stanley JNG, 2011, CATAL TODAY, V178, P164, DOI 10.1016/j.cattod.2011.09.014
   Stockman MI, 2011, OPT EXPRESS, V19, P22029, DOI 10.1364/OE.19.022029
   Tada S, 2012, INT J HYDROGEN ENERG, V37, P5527, DOI 10.1016/j.ijhydene.2011.12.122
   Tan T. H., 2016, ACS CATAL
   Upadhye AA, 2015, CATAL SCI TECHNOL, V5, P2590, DOI 10.1039/c4cy01183j
   Wang CJ, 2013, NANOSCALE, V5, P6968, DOI 10.1039/c3nr02001k
   Wang F, 2014, RSC ADV, V4, P10834, DOI 10.1039/c3ra47076h
   Wang W, 2011, CHEM SOC REV, V40, P3703, DOI 10.1039/c1cs15008a
   Wu H, 2011, GREEN CHEM, V13, P651, DOI 10.1039/c0gc00843e
   Yang MH, 2015, CATAL SCI TECHNOL, V5, P5095, DOI 10.1039/c5cy01361e
   Yoo SM, 2015, APPL CATAL A-GEN, V499, P47, DOI 10.1016/j.apcata.2015.04.003
NR 44
TC 5
Z9 5
U1 15
U2 119
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 2
PY 2019
VL 194
SI SI
BP 94
EP 104
DI 10.1016/j.ces.2018.04.003
PG 11
WC Engineering, Chemical
SC Engineering
GA HC6NG
UT WOS:000451917900014
DA 2020-05-12
ER

PT J
AU Chen, XY
   Kuo, DH
   Saragih, AD
   Wu, ZY
   Abdullah, H
   Lin, JG
AF Chen, Xiaoyun
   Kuo, Dong-Hau
   Saragih, Albert Daniel
   Wu, Zong-Yan
   Abdullah, Hairus
   Lin, Jinguo
TI The effect of the Cu+/Cu2+ ratio on the redox reactions by nanoflower
   CuNiOS catalysts
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Bimetal oxysulfide; Inorganic catalysts; Cu2+/Cu+ ratio; Dark
ID DRIVEN PHOTOCATALYTIC REDUCTION; X-RAY PHOTOELECTRON; TITANIUM-DIOXIDE;
   SOLVOTHERMAL SYNTHESIS; HIGH-PERFORMANCE; METHYLENE-BLUE; DYE
   DEGRADATION; TIO2 PHOTOCATALYST; METHANOL SYNTHESIS; LIGHT IRRADIATION
AB CuNiOS bimetal oxysulfide catalysts with catalytic activity in the dark were synthesized by a feasible solution method below 100 degrees C. It has a hexagonal CuS covellite structure with the Cu+/(Cu++Cu2+) molar ratio above 0.6. S6+ was formed to balance the deficiency in positive charge due to a high Cu+ content. The effect of hydrazine (N2H4) amount added during the CuNiOS synthesis on the redox reactions was evaluated. The N2H4-free CuNiOS showed the fast methylene blue (MB) degradation capability and the [N2H4]-high CuNiOS had the high Cr(VI) reduction capability all in the dark condition. The adjustable redox reactions by the CuNiOS catalyst system are demonstrated and explained. The catalytic reaction mechanism is elucidated, depending upon the Cu+/Cu2+ ratio for different charge transports. CuNiOS also exhibited relatively good stability and durability during its reusability tests. The catalytic reactions under the mild conditions without heat and electrical and thermal energies are encouraging for green synthesis. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Chen, Xiaoyun; Kuo, Dong-Hau; Saragih, Albert Daniel; Wu, Zong-Yan; Abdullah, Hairus] Natl Taiwan Univ Sci & Technol, Dept Mat Sci & Engn, Taipei 10607, Taiwan.
   [Chen, Xiaoyun; Lin, Jinguo] Fujian Agr & Forestry Univ, Coll Mat Engn, Fuzhou 350002, Peoples R China.
RP Kuo, DH (reprint author), Natl Taiwan Univ Sci & Technol, Dept Mat Sci & Engn, Taipei 10607, Taiwan.
EM dhkuo@mail.ntust.edu.tw
RI Kuo, Dong-Hau/J-5283-2012
OI Kuo, Dong-Hau/0000-0001-9300-8551; Abdullah, Hairus/0000-0002-1775-535X
FU MOST of the Republic of China [106-2633-E-011-002]; Strait Postdoctoral
   Program [1323H0005]
FX This work was supported by MOST of the Republic of China under the grant
   No. 106-2633-E-011-002. Dr. X. Y. Chen was supported by the Strait
   Postdoctoral Program under the grant No. 1323H0005.
CR Abdullah H, 2017, INT J HYDROGEN ENERG, V42, P5638, DOI 10.1016/j.ijhydene.2016.11.137
   Ajmal A, 2014, RSC ADV, V4, P37003, DOI 10.1039/c4ra06658h
   Asahi R, 2001, SCIENCE, V293, P269, DOI 10.1126/science.1061051
   Atchudan R, 2017, J PHOTOCH PHOTOBIO A, V333, P92, DOI 10.1016/j.jphotochem.2016.10.021
   Barreca D, 2011, J PHYS CHEM C, V115, P10510, DOI 10.1021/jp202449k
   Barreca D, 2011, LANGMUIR, V27, P6409, DOI 10.1021/la200698t
   Chen CC, 2010, CHEM SOC REV, V39, P4206, DOI 10.1039/b921692h
   Chen P, 2016, MATER LETT, V163, P130, DOI 10.1016/j.matlet.2015.10.064
   Chen X, 2007, CHEM REV, V107, P2891, DOI 10.1021/cr0500535
   Chen X, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10705-3
   Chen XY, 2017, ACS SUSTAIN CHEM ENG, V5, P4133, DOI 10.1021/acssuschemeng.7b00107
   Chen XY, 2017, SCI REP-UK, V7, DOI 10.1038/srep41194
   Chen XY, 2016, CHEM ENG J, V295, P192, DOI 10.1016/j.cej.2016.03.047
   Chen XY, 2016, MICROPOR MESOPOR MAT, V223, P145, DOI 10.1016/j.micromeso.2015.11.005
   Chu HP, 2016, SCI REP-UK, V6, DOI 10.1038/srep35304
   Chu HP, 2016, APPL CATAL A-GEN, V521, P19, DOI 10.1016/j.apcata.2016.01.022
   DePuccio DP, 2015, ACS APPL MATER INTER, V7, P1987, DOI 10.1021/am507806a
   Dinda D, 2013, J MATER CHEM A, V1, P11221, DOI 10.1039/c3ta12504a
   Dozzi MV, 2016, APPL CATAL B-ENVIRON, V186, P157, DOI 10.1016/j.apcatb.2016.01.004
   El-Sheikh SM, 2014, J HAZARD MATER, V280, P723, DOI 10.1016/j.jhazmat.2014.08.038
   FUJISHIMA A, 1972, NATURE, V238, P37, DOI 10.1038/238037a0
   Graciani J, 2014, SCIENCE, V345, P546, DOI 10.1126/science.1253057
   HABER J, 1978, J SOLID STATE CHEM, V25, P207, DOI 10.1016/0022-4596(78)90105-6
   Khanchandani S, 2016, ACS SUSTAIN CHEM ENG, V4, P1487, DOI 10.1021/acssuschemeng.5b01460
   KHAWAJA EE, 1989, J NON-CRYST SOLIDS, V110, P33, DOI 10.1016/0022-3093(89)90179-8
   KLEIN JC, 1984, APPL SPECTROSC, V38, P729, DOI 10.1366/0003702844555016
   Kumar DR, 2015, ELECTROCHIM ACTA, V176, P514, DOI 10.1016/j.electacta.2015.07.034
   Kuo DH, 2016, APPL CATAL B-ENVIRON, V184, P191, DOI 10.1016/j.apcatb.2015.11.032
   Li HH, 2012, ENVIRON SCI TECHNOL, V46, P7741, DOI 10.1021/es300987s
   Li JY, 2016, CATAL COMMUN, V77, P26, DOI 10.1016/j.catcom.2016.01.011
   Li Z, 2012, CRYSTENGCOMM, V14, P3965, DOI 10.1039/c2ce00018k
   Lin JD, 2013, J MATER SCI, V48, P5509, DOI 10.1007/s10853-013-7345-2
   Lin WY, 2005, J AM CHEM SOC, V127, P1610, DOI 10.1021/ja040162l
   Liu LF, 2013, NANOSCALE, V5, P11615, DOI 10.1039/c3nr03533f
   Liu SX, 2007, J HAZARD MATER, V141, P315, DOI 10.1016/j.jhazmat.2006.07.006
   Liu SX, 2008, J HAZARD MATER, V152, P48, DOI 10.1016/j.jhazmat.2007.06.062
   Ma D., 2014, APPL CATAL B-ENVIRON, V14, P749
   McManamon C, 2015, J MOL CATAL A-CHEM, V406, P51, DOI 10.1016/j.molcata.2015.05.002
   Meng XY, 2013, CRYSTENGCOMM, V15, P5144, DOI 10.1039/c3ce40195b
   Molla A, 2016, SCI REP-UK, V6, DOI 10.1038/srep26034
   Molla A, 2015, J MATER CHEM A, V3, P15616, DOI 10.1039/c5ta02888d
   OREGAN B, 1991, NATURE, V353, P737, DOI 10.1038/353737a0
   Park S, 2017, J IND ENG CHEM, V45, P206, DOI 10.1016/j.jiec.2016.09.024
   Pelaez M, 2012, APPL CATAL B-ENVIRON, V125, P331, DOI 10.1016/j.apcatb.2012.05.036
   PERRY DL, 1986, J MATER SCI LETT, V5, P384, DOI 10.1007/BF01672333
   Prasanna VL, 2015, LANGMUIR, V31, P9155, DOI 10.1021/acs.langmuir.5b02266
   Qiu XQ, 2012, ACS NANO, V6, P1609, DOI 10.1021/nn2045888
   Randorn C, 2010, J MATER CHEM, V20, P8700, DOI 10.1039/c0jm01370f
   Rico-Santacruz M, 2017, APPL CATAL B-ENVIRON, V200, P93, DOI 10.1016/j.apcatb.2016.06.061
   Riha SC, 2011, J AM CHEM SOC, V133, P1383, DOI 10.1021/ja106254h
   Roman E, 1997, VACUUM, V48, P597, DOI 10.1016/S0042-207X(97)00074-2
   Shaham-Waldmann N, 2013, CHEM ENG J, V231, P49, DOI 10.1016/j.cej.2013.07.021
   Shu QW, 2015, CRYSTENGCOMM, V17, P1374, DOI 10.1039/c4ce02120g
   STROHMEIER BR, 1985, J CATAL, V94, P514, DOI 10.1016/0021-9517(85)90216-7
   Swesi AT, 2016, ENERG ENVIRON SCI, V9, P1771, DOI 10.1039/c5ee02463c
   Tang YC, 2007, PROG CHEM, V19, P225
   Tong ZW, 2015, CHEM ENG J, V260, P117, DOI 10.1016/j.cej.2014.08.072
   Trandafilovic LV, 2017, APPL CATAL B-ENVIRON, V203, P740, DOI 10.1016/j.apcatb.2016.10.063
   Vaiano V, 2016, APPL CATAL B-ENVIRON, V188, P134, DOI 10.1016/j.apcatb.2016.02.001
   Wang Q, 2016, J HAZARD MATER, V317, P8, DOI 10.1016/j.jhazmat.2016.05.044
   Wang Q, 2014, IND ENG CHEM RES, V53, P643, DOI 10.1021/ie403402q
   Wang TX, 2014, MATER LETT, V123, P153, DOI 10.1016/j.matlet.2014.02.109
   Wang WG, 2012, APPL CATAL B-ENVIRON, V119, P109, DOI 10.1016/j.apcatb.2012.02.035
   Wu JG, 1998, CATAL TODAY, V45, P215, DOI 10.1016/S0920-5861(98)00218-1
   Wu JM, 2016, ADV MATER, V28, P3718, DOI 10.1002/adma.201505785
   Xiao D, 2015, APPL SURF SCI, V358, P181, DOI 10.1016/j.apsusc.2015.09.042
   Xu ZH, 2016, MATER CHEM PHYS, V171, P386, DOI 10.1016/j.matchemphys.2016.01.037
   Xu ZH, 2015, ENVIRON ENG SCI, V32, P497, DOI 10.1089/ees.2014.0404
   Yamashita H, 2002, J PHOTOCH PHOTOBIO A, V148, P257, DOI 10.1016/S1010-6030(02)00051-5
   Yoon M, 2005, CHEM MATER, V17, P6069, DOI 10.1021/cm0515855
   Yu H, 2010, J PHYS CHEM C, V114, P16481, DOI 10.1021/jp1071956
   Zelekew OA, 2017, APPL SURF SCI, V393, P110, DOI 10.1016/j.apsusc.2016.10.016
   Zhang GS, 2014, APPL CATAL B-ENVIRON, V144, P614, DOI 10.1016/j.apcatb.2013.07.058
   Zhang N, 2016, J AM CHEM SOC, V138, P8928, DOI 10.1021/jacs.6b04629
   Zhang YC, 2013, APPL CATAL B-ENVIRON, V142, P249, DOI 10.1016/j.apcatb.2013.05.023
   Zhang YC, 2012, APPL CATAL B-ENVIRON, V123, P18, DOI 10.1016/j.apcatb.2012.04.018
   Zhang YC, 2011, ENVIRON SCI TECHNOL, V45, P9324, DOI 10.1021/es202012b
   Zhang YC, 2015, SEP PURIF TECHNOL, V142, P251, DOI 10.1016/j.seppur.2014.12.041
   Zhao JH, 2017, APPL CATAL B-ENVIRON, V202, P509, DOI 10.1016/j.apcatb.2016.09.065
NR 79
TC 20
Z9 20
U1 15
U2 98
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 2
PY 2019
VL 194
SI SI
BP 105
EP 115
DI 10.1016/j.ces.2018.02.016
PG 11
WC Engineering, Chemical
SC Engineering
GA HC6NG
UT WOS:000451917900015
HC Y
HP N
DA 2020-05-12
ER

PT J
AU Gagrani, A
   Tsuzuki, T
AF Gagrani, Ankita
   Tsuzuki, Takuya
TI Calcium manganese oxides as biomimetic catalysts in energy applications:
   A short review
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Review
DE Calcium manganese oxide; Catalyst; Water oxidation; Energy
ID OXYGEN-EVOLVING COMPLEX; PHOTOSYNTHETIC WATER OXIDATION; CYANOBACTERIAL
   PHOTOSYSTEM-II; HETEROGENEOUS BASE CATALYSTS; VISIBLE-LIGHT-DRIVEN;
   MAGNETIC-PROPERTIES; CRYSTAL-STRUCTURE; ARTIFICIAL PHOTOSYNTHESIS;
   PHOTOCATALYTIC DEGRADATION; SYNECHOCOCCUS-ELONGATUS
AB Calcium manganese oxides have captured strong scientific interest in recent years due to exceptional catalytic activities, inexpensive synthesis methods, and constitution of earth abundant and environmentally benign elements. In particular, the catalytic properties of Ca-Mn-O systems have been recognised as a potentially useful new tool in addressing energy and environmental problems. This article presents an overview of new developments in the research on Ca-Mn-O catalyst materials. The article begins with the discussion about the CaMn4O5(H2O)(4) cluster which is situated within Photosystem II proteins in plant cells and is responsible for the natural water-splitting reaction. It then focuses on the crystal structures and synthesis routes of various Ca-Mn-O systems, followed by a critical discussion on the applications in catalytic water oxidation. Other known applications of Ca-Mn-O systems in the energy and environmental sectors are also discussed. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Gagrani, Ankita; Tsuzuki, Takuya] Australian Natl Univ, Res Sch Engn, Canberra, ACT 2601, Australia.
RP Tsuzuki, T (reprint author), Australian Natl Univ, Res Sch Engn, Canberra, ACT 2601, Australia.
EM takuya.tsuzuki@anu.edu.au
RI Tsuzuki, Takuya/A-7058-2009
OI Tsuzuki, Takuya/0000-0002-2002-3758
CR Akpan UG, 2009, J HAZARD MATER, V170, P520, DOI 10.1016/j.jhazmat.2009.05.039
   ANSELL GB, 1982, ACTA CRYSTALLOGR B, V38, P1795, DOI 10.1107/S0567740882007201
   Arnold DC, 2007, CHEMPHYSCHEM, V8, P1694, DOI 10.1002/cphc.200700308
   Artero V, 2011, ANGEW CHEM INT EDIT, V50, P7238, DOI 10.1002/anie.201007987
   Baktash E, 2013, DALTON T, V42, P16920, DOI 10.1039/c3dt51693h
   Barber J, 2016, BIOCHEMISTRY-US, V55, P5901, DOI 10.1021/acs.biochem.6b00794
   Barrier N, 2005, J MATER CHEM, V15, P386, DOI 10.1039/b417239f
   Barrocas B, 2016, APPL SURF SCI, V360, P798, DOI 10.1016/j.apsusc.2015.11.070
   Barrocas B, 2014, J PHYS CHEM C, V118, P24127, DOI 10.1021/jp507070u
   Biesiadka J, 2004, PHYS CHEM CHEM PHYS, V6, P4733, DOI 10.1039/b406989g
   Birkner N, 2013, P NATL ACAD SCI USA, V110, P8801, DOI 10.1073/pnas.1306623110
   Bourajoini H, 2016, MATER RES BULL, V79, P133, DOI 10.1016/j.materresbull.2016.03.018
   Britt RD, 2004, BBA-BIOENERGETICS, V1655, P158, DOI 10.1016/j.bbabio.2003.11.009
   Bruce PG, 2012, NAT MATER, V11, P19, DOI [10.1038/nmat3191, 10.1038/NMAT3191]
   Christensen J, 2012, J ELECTROCHEM SOC, V159, pR1, DOI 10.1149/2.086202jes
   Cui HJ, 2015, GEOCHEM T, V16, DOI 10.1186/s12932-015-0024-2
   Currao A, 2007, CHIMIA, V61, P815, DOI 10.2533/chimia.2007.815
   Daneshvar N, 2003, J PHOTOCH PHOTOBIO A, V157, P111, DOI 10.1016/S1010-6030(03)00015-7
   Dau H, 2010, CHEMCATCHEM, V2, P724, DOI 10.1002/cctc.201000126
   de Muro IG, 2005, J SOLID STATE CHEM, V178, P928, DOI 10.1016/j.jssc.2004.06.052
   Dias JM, 2013, ENERG CONVERS MANAGE, V65, P647, DOI 10.1016/j.enconman.2012.09.016
   Dompablo M. E. A., 2016, CHEM MATER, V28, P6886
   Du J, 2014, INORG CHEM, V53, P9106, DOI 10.1021/ic501631h
   Du J, 2012, J MATER CHEM, V22, P15812, DOI 10.1039/c2jm32564k
   Duan LL, 2012, NAT CHEM, V4, P418, DOI [10.1038/NCHEM.1301, 10.1038/nchem.1301]
   Ferreira KN, 2004, SCIENCE, V303, P1831, DOI 10.1126/science.1093087
   Frey CE, 2014, DALTON T, V43, P4370, DOI 10.1039/c3dt52604f
   Fukabori A, 2008, CHEM LETT, V37, P978, DOI 10.1246/cl.2008.978
   Gagrani A, 2018, CERAM INT, V44, P4694, DOI 10.1016/j.ceramint.2017.12.050
   Giesber HG, 2001, ACTA CRYSTALLOGR C, V57, P329, DOI 10.1107/S0108270100011367
   Girishkumar G, 2010, J PHYS CHEM LETT, V1, P2193, DOI 10.1021/jz1005384
   GLAUNSINGER WS, 1980, J SOLID STATE CHEM, V35, P187, DOI 10.1016/0022-4596(80)90492-2
   Grewe T, 2016, CHEM-ASIAN J, V11, P22, DOI 10.1002/asia.201500723
   Guskov A, 2009, NAT STRUCT MOL BIOL, V16, P334, DOI 10.1038/nsmb.1559
   Hadermann J, 2006, CHEM MATER, V18, P5530, DOI 10.1021/cm0618998
   Han XP, 2013, CHEM SCI, V4, P368, DOI 10.1039/c2sc21475j
   Han XP, 2014, ADV MATER, V26, P2047, DOI 10.1002/adma.201304867
   Han XP, 2014, CHEM COMMUN, V50, P1497, DOI 10.1039/c3cc48207c
   Hartmann P, 2013, NAT MATER, V12, P228, DOI [10.1038/nmat3486, 10.1038/NMAT3486]
   HOROWITZ HS, 1978, MATER RES BULL, V13, P1359, DOI 10.1016/0025-5408(78)90127-7
   Hu YX, 2015, J MATER CHEM A, V3, P3320, DOI 10.1039/c4ta06287f
   Jorge MEM, 2001, INT J INORG MATER, V3, P915
   Kamiya N, 2003, P NATL ACAD SCI USA, V100, P98, DOI 10.1073/pnas.0135651100
   Kanady JS, 2014, J AM CHEM SOC, V136, P14373, DOI 10.1021/ja508160x
   Kanady JS, 2011, SCIENCE, V333, P733, DOI 10.1126/science.1206036
   Kawakami K, 2011, J PHOTOCH PHOTOBIO B, V104, P9, DOI 10.1016/j.jphotobiol.2011.03.017
   Kawashima A, 2008, BIORESOURCE TECHNOL, V99, P3439, DOI 10.1016/j.biortech.2007.08.009
   Kesic Z, 2016, FUEL PROCESS TECHNOL, V143, P162, DOI 10.1016/j.fuproc.2015.11.018
   Khanahmadzadeh S, 2017, J MATER SCI-MATER EL, V28, P4521, DOI 10.1007/s10854-016-6087-8
   Kim J, 2014, J AM CHEM SOC, V136, P14646, DOI 10.1021/ja506254g
   Kim TW, 2014, SCIENCE, V343, P990, DOI 10.1126/science.1246913
   Kotzabasaki V, 2011, INORG CHEM COMMUN, V14, P213, DOI 10.1016/j.inoche.2010.10.025
   Kouzu M, 2008, FUEL, V87, P2798, DOI 10.1016/j.fuel.2007.10.019
   Kraytsberg A, 2011, J POWER SOURCES, V196, P886, DOI 10.1016/j.jpowsour.2010.09.031
   Kudo A, 2009, CHEM SOC REV, V38, P253, DOI 10.1039/b800489g
   Lee SY, 2014, CHEMSUSCHEM, V7, P3442, DOI 10.1002/cssc.201402533
   Li YL, 2013, CHEM COMMUN, V49, P11731, DOI 10.1039/c3cc46606j
   Ling CD, 2001, J SOLID STATE CHEM, V160, P167, DOI 10.1006/jssc.2001.9214
   Liu W, 2013, CHEM COMMUN, V49, P1951, DOI 10.1039/c3cc00085k
   Liu XJ, 2007, SOLID STATE COMMUN, V142, P525, DOI 10.1016/j.ssc.2007.03.021
   Loll B, 2005, NATURE, V438, P1040, DOI 10.1038/nature04224
   Luo SL, 2015, APPL CATAL B-ENVIRON, V164, P92, DOI 10.1016/j.apcatb.2014.09.008
   Maeda K, 2005, J AM CHEM SOC, V127, P8286, DOI 10.1021/ja0518777
   Mazario-Fernandez A, 2017, INORG CHEM, V56, P11753, DOI 10.1021/acs.inorgchem.7b01728
   Mishra A, 2005, CHEM COMMUN, P54, DOI 10.1039/b413680b
   Mukherjee S, 2012, P NATL ACAD SCI USA, V109, P2257, DOI 10.1073/pnas.1115290109
   Najafpour MM, 2014, J PHOTOCH PHOTOBIO B, V133, P124, DOI 10.1016/j.jphotobiol.2014.03.005
   Najafpour MM, 2013, DALTON T, V42, P12173, DOI 10.1039/c3dt51345a
   Najafpour MM, 2012, J R SOC INTERFACE, V9, P2383, DOI 10.1098/rsif.2012.0412
   Najafpour MM, 2012, DALTON T, V41, P4799, DOI 10.1039/c2dt12189a
   Najafpour MM, 2011, DALTON T, V40, P9374, DOI 10.1039/c1dt11048a
   Najafpour MM, 2011, DALTON T, V40, P9076, DOI 10.1039/c1dt10746a
   Najafpour MM, 2011, J PHOTOCH PHOTOBIO B, V104, P111, DOI 10.1016/j.jphotobiol.2010.12.009
   Najafpour MM, 2011, ORIGINS LIFE EVOL B, V41, P237, DOI 10.1007/s11084-010-9224-z
   Najafpour MM, 2011, DALTON T, V40, P3805, DOI 10.1039/c1dt00006c
   Najafpour MM, 2011, DALTON T, V40, P3793, DOI 10.1039/c0dt01109f
   Najafpour MM, 2010, ANGEW CHEM INT EDIT, V49, P2233, DOI 10.1002/anie.200906745
   Nakhowong R, 2016, MATER LETT, V163, P222, DOI 10.1016/j.matlet.2015.10.081
   Nayak S, 2011, DALTON T, V40, P2699, DOI 10.1039/c0dt01463j
   Ni M, 2007, RENEW SUST ENERG REV, V11, P401, DOI 10.1016/j.rser.2005.01.009
   Nield J, 2000, J BIOL CHEM, V275, P27940
   Park YJ, 2006, SOLID STATE IONICS, V177, P893, DOI 10.1016/j.ssi.2006.02.001
   Park YJ, 2011, J AM CHEM SOC, V133, P9258, DOI 10.1021/ja203458d
   Pecoraro VL, 1998, PURE APPL CHEM, V70, P925, DOI 10.1351/pac199870040925
   Persson K., 2016, MAT DATA CA2MN308 SG
   Persson K., 2014, MAT DATA CAMN204 SG
   Persson K., 2016, MAT DATA CAMN306 SG
   POEPPELMEIER KR, 1982, J SOLID STATE CHEM, V45, P71, DOI 10.1016/0022-4596(82)90292-4
   Raabe S, 2012, ADV FUNCT MATER, V22, P3378, DOI 10.1002/adfm.201103173
   Ramirez A, 2012, NANO ENERGY, V1, P282, DOI 10.1016/j.nanoen.2011.10.003
   Renger G, 2001, BBA-BIOENERGETICS, V1503, P210, DOI 10.1016/S0005-2728(00)00227-9
   Robinson DM, 2013, J AM CHEM SOC, V135, P3494, DOI 10.1021/ja310286h
   Rong F, 2016, J MATER CHEM A, V4, P6585, DOI 10.1039/c5ta08217j
   Shen JR, 2015, ANNU REV PLANT BIOL, V66, P23, DOI 10.1146/annurev-arplant-050312-120129
   Shinde A, 2017, ACS ENERGY LETT, V2, P2307, DOI 10.1021/acsenergylett.7b00607
   Sivula K, 2011, CHEMSUSCHEM, V4, P432, DOI 10.1002/cssc.201000416
   Spooren J, 2005, J SOLID STATE CHEM, V178, P1683, DOI 10.1016/j.jssc.2005.03.006
   Suryaputra W, 2013, RENEW ENERG, V50, P795, DOI 10.1016/j.renene.2012.08.060
   Tachibana Y, 2012, NAT PHOTONICS, V6, P511, DOI 10.1038/nphoton.2012.175
   Tang C., 2015, ANGEW CHEM INT EDIT, V127, P9483, DOI DOI 10.1002/ANGE.201503407
   Umena Y, 2011, NATURE, V473, P55, DOI 10.1038/nature09913
   Varela A, 2009, J AM CHEM SOC, V131, P8660, DOI 10.1021/ja901963m
   Vrettos JS, 2001, BBA-BIOENERGETICS, V1503, P229, DOI 10.1016/S0005-2728(00)00214-0
   Walter MG, 2010, CHEM REV, V110, P6446, DOI 10.1021/cr1002326
   Wang YX, 2016, CATAL SCI TECHNOL, V6, P2918, DOI 10.1039/c5cy01967b
   Wang ZK, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12033
   White BD, 2008, J CRYST GROWTH, V310, P3325, DOI 10.1016/j.jcrysgro.2008.04.005
   White BD, 2009, PHYS REV B, V79, DOI 10.1103/PhysRevB.79.104427
   WHITE TR, 1979, J SOLID STATE CHEM, V29, P205, DOI 10.1016/0022-4596(79)90225-1
   Wiechen M, 2012, CHEM SCI, V3, P2330, DOI 10.1039/c2sc20226c
   Yano J, 2006, SCIENCE, V314, P821, DOI 10.1126/science.1128186
   Yu JY, 2012, DALTON T, V41, P10286, DOI 10.1039/c2dt30624g
   Zaharieva I, 2011, ENERG ENVIRON SCI, V4, P2400, DOI 10.1039/c0ee00815j
   Zahran ZN, 2017, J MATER CHEM A, V5, P15167, DOI 10.1039/c7ta03665e
   Zeng Z, 1999, PHYS REV B, V59, P8784, DOI 10.1103/PhysRevB.59.8784
   Zhang CX, 2015, SCIENCE, V348, P690, DOI 10.1126/science.aaa6550
   Zhang FP, 2011, PHYSICA B, V406, P1258, DOI 10.1016/j.physb.2011.01.011
   Zhou QD, 2006, J PHYS CHEM SOLIDS, V67, P1595, DOI 10.1016/j.jpcs.2006.02.011
   Zouni A, 2001, NATURE, V409, P739, DOI 10.1038/35055589
NR 119
TC 3
Z9 3
U1 14
U2 71
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 2
PY 2019
VL 194
SI SI
BP 116
EP 126
DI 10.1016/j.ces.2018.06.059
PG 11
WC Engineering, Chemical
SC Engineering
GA HC6NG
UT WOS:000451917900016
DA 2020-05-12
ER

PT J
AU Da, PF
   Wu, MY
   Qiu, KW
   Yan, DY
   Li, YJ
   Mao, J
   Dong, CK
   Ling, T
   Qiao, SZ
AF Da, Pengfei
   Wu, Mengying
   Qiu, Kangwen
   Yan, Dongyang
   Li, Yuejiao
   Mao, Jing
   Dong, Cunku
   Ling, Tao
   Qiao, Shizhang
TI Realizing large-scale and controllable fabrication of active cobalt
   oxide nanorod catalysts for zinc-air battery
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Electrocatalysis; Zn-air battery; CoO; Nanomaterials
ID OXYGEN REDUCTION ELECTROCATALYST; METAL; SURFACE
AB Driven by the intensified demand for energy storage systems with high-energy density and safety, allsolid-state zinc (Zn) air batteries have drawn extensive attentions. However, the development of non-precious metals with high catalytic activity as the air electrode is still a big challenge. In this work, we realize the large-scale fabrication of single-crystal CoO nanorods with high active facets and abundant oxygen vacancies in-situ on conductive substrate, which exhibits superior electrocatalytic activity in both oxygen reduction reaction and oxygen evolution reaction. The all-solid-state Zn-air batteries assembled with such free-standing CoO NRs show low charge/discharge overpotentials, a high energy density and a high cyclic stability. Our work indicates that the rational structure design of catalysts can pave a new route to next generation efficient and durable electrochemical devices. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Da, Pengfei; Wu, Mengying; Qiu, Kangwen; Yan, Dongyang; Li, Yuejiao; Mao, Jing; Dong, Cunku; Ling, Tao] Tianjin Univ, Sch Mat Sci & Engn, Key Lab Adv Ceram & Machining Technol, Minist Educ, Tianjin 300072, Peoples R China.
   [Qiao, Shizhang] Univ Adelaide, Sch Chem Engn, Adelaide, SA 5005, Australia.
RP Mao, J; Dong, CK; Ling, T (reprint author), Tianjin Univ, Sch Mat Sci & Engn, Key Lab Adv Ceram & Machining Technol, Minist Educ, Tianjin 300072, Peoples R China.
EM maojingwmf@163.com; ckdong@tju.edu.cn; lingt04@tju.edu.cn
RI Qiao, Shizhang/A-6057-2010
OI Qiao, Shizhang/0000-0002-4568-8422; Ling, Tao/0000-0002-8830-4492
CR Chen X, 2017, ADV ENERGY MATER, V7, DOI 10.1002/aenm.201700779
   Chen XY, 2012, NANOSCALE, V4, P5602, DOI 10.1039/c2nr31018j
   Chen Z, 2012, NANO LETT, V12, P1946, DOI 10.1021/nl2044327
   Chen Z, 2011, J POWER SOURCES, V196, P3673, DOI 10.1016/j.jpowsour.2010.12.047
   Fominykh K, 2014, ADV FUNCT MATER, V24, P3123, DOI 10.1002/adfm.201303600
   Jian B., 2015, ANGEW CHEM, V127, P7507, DOI DOI 10.1002/ange.201502226
   JIMENEZ VM, 1995, J ELECTRON SPECTROSC, V71, P61, DOI 10.1016/0368-2048(94)02238-0
   Jin MJ, 2012, NANOTECHNOLOGY, V23, DOI 10.1088/0957-4484/23/48/485401
   Kakati N, 2014, CHEM REV, V114, P12397, DOI 10.1021/cr400389f
   Koza JA, 2012, CHEM MATER, V24, P3567, DOI 10.1021/cm3012205
   Lee DU, 2014, ADV ENERGY MATER, V4, DOI 10.1002/aenm.201301389
   Lee JS, 2011, ADV ENERGY MATER, V1, P34, DOI 10.1002/aenm.201000010
   Li YG, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2812
   Li YB, 2018, ADV MATER, V30, DOI 10.1002/adma.201703657
   Liang HW, 2015, NANO ENERGY, V11, P366, DOI 10.1016/j.nanoen.2014.11.008
   Liang YY, 2012, J AM CHEM SOC, V134, P15849, DOI 10.1021/ja305623m
   Ling T, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01872-y
   Ling T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12876
   Meng C, 2017, ADV MATER, V29, DOI 10.1002/adma.201604607
   Morozan A, 2011, ENERG ENVIRON SCI, V4, P1238, DOI 10.1039/c0ee00601g
   Ng JWD, 2014, ENERG ENVIRON SCI, V7, P2017, DOI 10.1039/c3ee44059a
   Prabu M, 2014, NANOSCALE, V6, P3173, DOI 10.1039/c3nr05835b
   Qiu KW, 2017, J MATER CHEM A, V5, P5820, DOI 10.1039/c7ta00506g
   Qu SX, 2017, NANO ENERGY, V39, P101, DOI 10.1016/j.nanoen.2017.06.045
   Roginskaya YE, 1997, LANGMUIR, V13, P4621, DOI 10.1021/la9609128
   Wang YC, 2014, ADV ENERGY MATER, V4, DOI 10.1002/aenm.201400696
   Wang ZL, 2014, CHEM SOC REV, V43, P7746, DOI 10.1039/c3cs60248f
   Yin J, 2017, ACS NANO, V11, P2275, DOI 10.1021/acsnano.7b00417
   Zhang L, 2015, SCIENCE, V349, P412, DOI 10.1126/science.aab0801
   Zhang T, 2018, NANO ENERGY, V43, P103, DOI 10.1016/j.nanoen.2017.11.015
   Zhou ZY, 2011, CHEM SOC REV, V40, P4167, DOI 10.1039/c0cs00176g
NR 31
TC 7
Z9 7
U1 12
U2 108
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 2
PY 2019
VL 194
SI SI
BP 127
EP 133
DI 10.1016/j.ces.2018.05.022
PG 7
WC Engineering, Chemical
SC Engineering
GA HC6NG
UT WOS:000451917900017
DA 2020-05-12
ER

PT J
AU Meng, XH
   Deng, D
AF Meng, Xinghua
   Deng, Da
TI Bio-inspired synthesis of 3-D network of NiO-Ni nanowires on carbonized
   eggshell membrane for lithium-ion batteries
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Bio-inspired; Bio-template; Nanowire; Composite; Membrane; Electrode;
   Battery
ID GAS-SENSING PROPERTIES; ANODE MATERIALS; POROUS NIO; HYDROTHERMAL
   SYNTHESIS; UREA HYDROLYSIS; PERFORMANCE; ARCHITECTURES; NANO;
   NANOSTRUCTURES; NANOCOMPOSITE
AB Composite nanowires incorporating both metal oxide and metal nanoparticles as the basic building units are attracting much attention recently. We report here a facile approach to synthesize 3D networks of 1D nanowires of formed by both NiO and Ni nanoparticle. The composite nanowires were in-situ synthesized on carbonized eggshell membrane. Here, alpha-Ni(OH)(2) nanowire precursor was synthesized on eggshell membrane under mild conditions in a diaphragm-assisted reactor first. Then the precursor was transformed into composite of NiO-Ni nanowires on carbonized eggshell membrane under heat treatment in argon. The eggshell membrane played multiple roles as the substrate to collect the alpha-Ni(OH)(2) nanowire precursor and then as the source of reducing agents to partially reduce to Ni2+ to Ni-0. When tested for lithium-ion batteries, the composite of 3D networks NiO-Ni nanowires attached on carbonized eggshell membrane demonstrated impressively improved rate and cycling performances, as compared to that of bare NiO nanowires. The idea and method outline here based on bio-inspired synthesis using bio-template to prepare composites could be applied to synthesize other functional materials. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Meng, Xinghua; Deng, Da] Wayne State Univ, Dept Chem Engn & Mat Sci, 5050 Anthony Wayne Dr, Detroit, MI 48202 USA.
RP Deng, D (reprint author), Wayne State Univ, Dept Chem Engn & Mat Sci, 5050 Anthony Wayne Dr, Detroit, MI 48202 USA.
EM da.deng@wayne.edu
RI meng, xinghua/Q-1700-2019
CR Alberti G, 2001, J MEMBRANE SCI, V185, P73, DOI 10.1016/S0376-7388(00)00635-9
   Arico AS, 2005, NAT MATER, V4, P366, DOI 10.1038/nmat1368
   Cheng J, 2006, J POWER SOURCES, V159, P734, DOI 10.1016/j.jpowsour.2005.07.095
   Dixit M, 1996, J MATER CHEM, V6, P1429, DOI 10.1039/jm9960601429
   Gao T, 2013, J PHYS CHEM C, V117, P17294, DOI 10.1021/jp405149d
   GERMS AC, 1973, J SCI FOOD AGR, V24, P7, DOI 10.1002/jsfa.2740240103
   Gogotsi Y, 2014, ACS NANO, V8, P5369, DOI 10.1021/nn503164x
   Goswami A, 2001, J PHYS CHEM B, V105, P9196, DOI 10.1021/jp010529y
   Haubold HG, 2001, ELECTROCHIM ACTA, V46, P1559, DOI 10.1016/S0013-4686(00)00753-2
   Huang XH, 2006, J POWER SOURCES, V161, P541, DOI 10.1016/j.jpowsour.2006.03.039
   Jayalakshmi M, 2005, J POWER SOURCES, V150, P272, DOI 10.1016/j.jpowsour.2005.02.022
   KASARDA DD, 1968, BIOPOLYMERS, V6, P1001, DOI 10.1002/bip.1968.360060712
   Kim S, 2013, ADV FUNCT MATER, V23, P10, DOI 10.1002/adfm.201201994
   KOH WH, 1983, J MEMBRANE SCI, V13, P279, DOI 10.1016/S0376-7388(00)81561-6
   Kong CS, 2013, ADV FUNCT MATER, V23, P4585, DOI 10.1002/adfm.201203882
   Lang JW, 2008, CHEM COMMUN, P4213, DOI 10.1039/b800264a
   Laruelle S, 2002, J ELECTROCHEM SOC, V149, pA627, DOI 10.1149/1.1467947
   Li JT, 2011, NANOSCALE, V3, P5103, DOI 10.1039/c1nr10802f
   Li QY, 2008, J COLLOID INTERF SCI, V320, P254, DOI 10.1016/j.jcis.2007.11.006
   Li XW, 2012, J MATER CHEM, V22, P14276, DOI 10.1039/c2jm32559d
   Li XF, 2011, J POWER SOURCES, V196, P9625, DOI 10.1016/j.jpowsour.2011.06.097
   Liang H, 2010, CRYST RES TECHNOL, V45, P661, DOI 10.1002/crat.200900732
   Liu BH, 2006, J PHYS CHEM B, V110, P4039, DOI 10.1021/jp055970t
   Liu B, 2011, SENSOR ACTUAT B-CHEM, V156, P251, DOI 10.1016/j.snb.2011.04.028
   Liu H, 2011, J MATER CHEM, V21, P3046, DOI 10.1039/c0jm03132a
   Liu JH, 2012, ADV MATER, V24, P4097, DOI 10.1002/adma.201104993
   Liu KS, 2013, PROG MATER SCI, V58, P503, DOI 10.1016/j.pmatsci.2012.11.001
   Liu LX, 2013, ELECTROCHIM ACTA, V114, P42, DOI 10.1016/j.electacta.2013.09.152
   Liu XG, 2013, CARBON, V60, P215, DOI 10.1016/j.carbon.2013.04.014
   Lu ZY, 2011, NANO RES, V4, P658, DOI 10.1007/s12274-011-0121-1
   Luo YY, 2006, NANOTECHNOLOGY, V17, P4278, DOI 10.1088/0957-4484/17/16/046
   Luo ZJ, 2012, MATER CHEM PHYS, V132, P387, DOI 10.1016/j.matchemphys.2011.11.041
   Luo ZJ, 2011, CRYSTENGCOMM, V13, P7108, DOI 10.1039/c1ce05936j
   Magasinski A, 2010, NAT MATER, V9, P353, DOI [10.1038/NMAT2725, 10.1038/nmat2725]
   Mallampati R, 2013, NANOSCALE, V5, P3395, DOI 10.1039/c3nr34221b
   Meng XH, 2016, CHEM MATER, V28, P3897, DOI 10.1021/acs.chemmater.6b01142
   Meng XH, 2016, J MATER CHEM A, V4, P6919, DOI 10.1039/c5ta09329e
   Miot J, 2014, ENERG ENVIRON SCI, V7, P451, DOI 10.1039/c3ee41767k
   Needham SA, 2006, J POWER SOURCES, V159, P254, DOI 10.1016/j.jpowsour.2006.04.025
   Poizot P, 2000, NATURE, V407, P496, DOI 10.1038/35035045
   Rahman MM, 2010, SOLID STATE IONICS, V180, P1646, DOI 10.1016/j.ssi.2009.10.018
   Ren Y, 2010, J AM CERAM SOC, V93, P3560, DOI 10.1111/j.1551-2916.2010.04090.x
   Rhee YW, 2003, J POWER SOURCES, V117, P35, DOI 10.1016/S0378-7753(03)00352-5
   Schmidt-Rohr K, 2008, NAT MATER, V7, P75, DOI 10.1038/nmat2074
   Song NN, 2012, MICRO NANO LETT, V7, P943, DOI 10.1049/mnl.2012.0631
   Song XF, 2008, J AM CERAM SOC, V91, P4105, DOI 10.1111/j.1551-2916.2008.02762.x
   Sun XL, 2014, NANO ENERGY, V9, P168, DOI 10.1016/j.nanoen.2014.06.022
   Tang B, 2005, INORG CHEM, V44, P2568, DOI 10.1021/ic049195s
   Tong GX, 2012, CRYSTENGCOMM, V14, P5963, DOI 10.1039/c2ce25622c
   Varghese B, 2008, CHEM MATER, V20, P3360, DOI 10.1021/cm703512k
   Wang C, 2010, J POWER SOURCES, V195, P7432, DOI 10.1016/j.jpowsour.2010.04.090
   Wang MM, 2013, J NANOPART RES, V15, DOI 10.1007/s11051-013-1849-1
   Wang Y, 2012, J MATER SCI, V47, P2182, DOI 10.1007/s10853-011-6021-7
   Wang ZY, 2012, ADV MATER, V24, P1903, DOI 10.1002/adma.201200469
   Wen W, 2013, J MATER CHEM A, V1, P3881, DOI 10.1039/c3ta01626a
   Xia YN, 2003, ADV MATER, V15, P353, DOI 10.1002/adma.200390087
   Xiao JW, 2012, J MATER CHEM, V22, P12253, DOI 10.1039/c2jm31057k
   Xie D, 2013, ELECTROCHIM ACTA, V92, P87, DOI 10.1016/j.electacta.2013.01.008
   Xu ZP, 1999, CHEM MATER, V11, P67, DOI 10.1021/cm980420b
   Yan J, 2012, ADV FUNCT MATER, V22, P2632, DOI 10.1002/adfm.201102839
   YEO RS, 1983, J ELECTROCHEM SOC, V130, P533, DOI 10.1149/1.2119746
   Yu L., 2013, J NANOPART RES, V15
   Yue GH, 2015, ELECTROCHIM ACTA, V152, P315, DOI 10.1016/j.electacta.2014.11.177
   Zhang CQ, 2007, J ELECTROCHEM SOC, V154, pA65, DOI 10.1149/1.2400609
   Zhang K, 2009, J PHYS CHEM C, V113, P142, DOI 10.1021/jp808280z
   Zhu LP, 2009, NANOSCALE RES LETT, V4, P550, DOI 10.1007/s11671-009-9279-9
NR 66
TC 6
Z9 6
U1 17
U2 136
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 2
PY 2019
VL 194
SI SI
BP 134
EP 141
DI 10.1016/j.ces.2018.06.038
PG 8
WC Engineering, Chemical
SC Engineering
GA HC6NG
UT WOS:000451917900018
DA 2020-05-12
ER

PT J
AU Zhou, ZB
   Zhang, YM
   Chen, P
   Wu, YT
   Yang, HC
   Ding, HR
   Zhang, Y
   Wang, ZZ
   Du, X
   Liu, N
AF Zhou, Zhubo
   Zhang, Yamin
   Chen, Peng
   Wu, Yutong
   Yang, Haochen
   Ding, Haoran
   Zhang, Yi
   Wang, Zhongzhen
   Du, Xu
   Liu, Nian
TI Graphene oxide-modified zinc anode for rechargeable aqueous batteries
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Aqueous batteries; Rechargeable; Graphene oxide; Passivation;
   Dissolution; Surface modification
ID LI; MEMBRANES; NA
AB Li-based batteries are intrinsically unsafe because of their use of flammable organic electrolyte. Great efforts are being made to develop solid electrolytes or safer alternative battery chemistries, among which Zn-based batteries stand out for their high energy density and good compatibility with aqueous electrolyte. Theoretically, Zn-air batteries have very high volumetric energy density, which is similar to 85% of that of Li-S batteries. However, Zn anodes have poor cycling performance because of their passivation (insulating discharge product ZnO) and dissolution (soluble zinc species in alkaline electrolytes) problems.
   In this work, we overcome these problems by modifying Zn anode with graphene oxide (Zn@GO) by a facile solution casting method. The GO layers on the Zn surface can deliver electrons across insulating ZnO, slow down the Zn intermediates from dissolving into the electrolyte, and thereby enhance the utilization and rechargeability of Zn anodes. As a result, the Zn@GO anode containing only 1.92 wt% GO showed improved cycling performance compared to that of the unmodified Zn mesh. The accumulated areal discharge capacity of the Zn@GO anode is 128% of that of the unmodified Zn mesh. The Zn@GO anode reported here can potentially be paired with oxygen cathode to form safe high-energy rechargeable batteries, and be used in large scale applications, ranging from electric vehicles, to grid-scale energy storage. The surface modification method reported here can also potentially be applied to other high-capacity electrodes that undergo passivation or dissolution issues. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Zhou, Zhubo; Zhang, Yamin; Chen, Peng; Wu, Yutong; Yang, Haochen; Ding, Haoran; Zhang, Yi; Wang, Zhongzhen; Du, Xu; Liu, Nian] Georgia Inst Technol, Sch Chem & Biomol Engn, Atlanta, GA 30332 USA.
   [Chen, Peng] Northeastern Univ, Sch Met, Shenyang 110819, Liaoning, Peoples R China.
   [Ding, Haoran] Tianjin Univ, Sch Chem Engn & Technol, Tianjin 300072, Peoples R China.
   [Zhang, Yi] Nanjing Tech Univ, Coll Energy, Nanjing 211816, Jiangsu, Peoples R China.
   [Zhang, Yi] Nanjing Tech Univ, Inst Electrochem Energy Storage, Nanjing 211816, Jiangsu, Peoples R China.
RP Liu, N (reprint author), Georgia Inst Technol, Sch Chem & Biomol Engn, Atlanta, GA 30332 USA.
EM nian.liu@chbe.gatech.edu
RI Liu, Nian/AAF-2407-2019; Zhang, Yamin/AAF-4800-2020; Du, Xu/S-3543-2019
OI Liu, Nian/0000-0002-5966-0244; Du, Xu/0000-0003-3200-4391; Zhang,
   Yi/0000-0002-1603-8623; Wang, Zhongzhen/0000-0001-9763-5077
FU National Science FoundationNational Science Foundation (NSF)
   [ECCS-1542174]; Georgia Institute of Technology
FX This work was performed in part at the Georgia Tech Institute for
   Electronics and Nanotechnology, a member of the National Nanotechnology
   Coordinated Infrastructure, which is supported by the National Science
   Foundation (Grant ECCS-1542174). Nian Liu acknowledges support from
   faculty startup funds from the Georgia Institute of Technology. The
   authors thank Prof. Sankar Nair and Prof. Yulin Deng for helpful
   discussions on the synthesis of graphene oxide. Dexmet Corporation is
   acknowledged for providing Zn MicroGrid (R) Metals.
CR Chu S, 2017, NAT MATER, V16, P16, DOI 10.1038/nmat4834
   Dikin DA, 2007, NATURE, V448, P457, DOI 10.1038/nature06016
   Fan XB, 2008, ADV MATER, V20, P4490, DOI 10.1002/adma.200801306
   Fu J, 2017, ADV MATER, V29, DOI 10.1002/adma.201604685
   Kim H, 2014, CHEM REV, V114, P11788, DOI 10.1021/cr500232y
   Li YG, 2014, CHEM SOC REV, V43, P5257, DOI 10.1039/c4cs00015c
   Li YG, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2812
   Liang YL, 2017, NAT MATER, V16, P841, DOI [10.1038/NMAT4919, 10.1038/nmat4919]
   Lu ZD, 2015, ACS NANO, V9, P2540, DOI 10.1021/nn505410q
   Marcano DC, 2010, ACS NANO, V4, P4806, DOI 10.1021/nn1006368
   Mi BX, 2014, SCIENCE, V343, P740, DOI 10.1126/science.1250247
   Obama B, 2017, SCIENCE, V355, P126, DOI 10.1126/science.aam6284
   Parker JF, 2017, SCIENCE, V356, P414, DOI 10.1126/science.aak9991
   Rashidi F, 2017, ACS SUSTAIN CHEM ENG, V5, P1002, DOI 10.1021/acssuschemeng.6b02321
   Sun YM, 2016, NAT ENERGY, V1, DOI [10.1038/nenergy.2016.71, 10.1038/NENERGY.2016.71]
   Wood KN, 2016, ACS CENTRAL SCI, V2, P790, DOI 10.1021/acscentsci.6b00260
   Xu K, 2014, CHEM REV, V114, P11503, DOI 10.1021/cr500003w
   Zhang HW, 2017, ADV FUNCT MATER, V27, DOI 10.1002/adfm.201606023
   Zhang YM, 2017, CHEM MATER, V29, P9589, DOI 10.1021/acs.chemmater.7b03839
NR 19
TC 21
Z9 21
U1 21
U2 139
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 2
PY 2019
VL 194
SI SI
BP 142
EP 147
DI 10.1016/j.ces.2018.06.048
PG 6
WC Engineering, Chemical
SC Engineering
GA HC6NG
UT WOS:000451917900019
HC Y
HP N
DA 2020-05-12
ER

PT J
AU Hong, XD
   Liang, J
   Tang, XN
   Yang, HC
   Li, F
AF Hong, Xiaodong
   Liang, Ji
   Tang, Xiaonan
   Yang, Huicong
   Li, Feng
TI Hybrid graphene album with polysulfides adsorption layer for Li-S
   batteries
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Graphitic carbon nitride; Graphene album; Self-assembly; Lithium-sulfur
   battery
ID NITROGEN-DOPED GRAPHENE; SULFUR; PERFORMANCE; IMPROVEMENT; ELECTRODES;
   CATHODE; SPHERES; REDOX; OXIDE; HOST
AB Lithium-sulfur (Li-S) battery is a promising candidate for the next-generation power sources due to their low-cost and high energy density. However, the shuttle effect of the dissolved polysulfides in the electrolyte solvents has hindered the commercialization of Li-S batteries. In order to effectively suppress the shuttle effect, we design and prepare a bybrid graphene album structure as an efficient polysulfides-trapped host for Li-S battery. In this composite, the graphene album structure is stacked by graphene layer by layer through a bottom-up assembly, which provides a hierarchical porous structure, easy mass transport and excellent conductivity for the cathode host of Li-S batteries. The uniform g-C3N4 layer was in-situ generated on each graphene by hydrothermal treatment and heat polycondensation. The orderly bybrid graphene album (coded as g-C3N4@n-G) achieves the two-dimensional surface adsorption interaction for imobilizing soluble polysulfides, and the multilayer barriers also effectively prevent the escape of polysulfides to enhance the long cycling stability of Li-S batteries. As a result, an extremely low capacity decay of 0.028% cycle(-1) and a high initial capacity of 1252 mA h g(-1) have been achieved at 0.2 C. Furthermore, this kind of unique design and preparation method for hybrid graphene album also opens an opportunity for the construction of other album-like graphene-based hybrids. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Hong, Xiaodong; Liang, Ji; Tang, Xiaonan; Yang, Huicong; Li, Feng] Chinese Acad Sci, Inst Met Res, 72 Wenhua Rd, Shenyang 110016, Peoples R China.
   [Hong, Xiaodong] Liaoning Tech Univ, Coll Mat Sci & Engn, Fuxing 123000, Peoples R China.
   [Tang, Xiaonan] Shandong Univ Technol, Sch Chem Engn, Zibo 255000, Peoples R China.
RP Li, F (reprint author), Chinese Acad Sci, Inst Met Res, 72 Wenhua Rd, Shenyang 110016, Peoples R China.
EM fli@imr.ac.cn
OI LI, Feng/0000-0002-2213-9914; Yang, Huicong/0000-0002-0122-1193
FU Ministry of Science and Technology of ChinaMinistry of Science and
   Technology, China [2016YFA0200100, 2016YFB0100100, 2014CB932402];
   Natural Science Foundation of ChinaNational Natural Science Foundation
   of China [51525206, 51521091, 51372253, 51403094, U1401243]; "Strategic
   Priority Research Program" of the Chinese Academy of SciencesChinese
   Academy of Sciences [XDA09010104]; Key Research Program of the Chinese
   Academy of SciencesChinese Academy of Sciences [KGZD-EW-T06]; CAS/SAFEA
   International Partnership Program for Creative Research TeamsChinese
   Academy of Sciences
FX This work was supported by the Ministry of Science and Technology of
   China (2016YFA0200100, 2016YFB0100100 and 2014CB932402), Natural Science
   Foundation of China (Nos. 51525206, 51521091, 51372253, 51403094 and
   U1401243), "Strategic Priority Research Program" of the Chinese Academy
   of Sciences (XDA09010104), the Key Research Program of the Chinese
   Academy of Sciences (Grant No. KGZD-EW-T06), and the CAS/SAFEA
   International Partnership Program for Creative Research Teams.
CR Elazari R, 2011, ADV MATER, V23, P5641, DOI 10.1002/adma.201103274
   Fan CY, 2016, ACS APPL MATER INTER, V8, P16108, DOI 10.1021/acsami.6b04578
   Fu YS, 2014, NANOSCALE, V6, P12555, DOI 10.1039/c4nr03145h
   Han K, 2014, CHEMSUSCHEM, V7, P2545, DOI 10.1002/cssc.201402329
   Han Q, 2015, ANGEW CHEM INT EDIT, V54, P11433, DOI 10.1002/anie.201504985
   Hu GJ, 2016, ADV MATER, V28, P1603, DOI 10.1002/adma.201504765
   Ji LW, 2011, ENERG ENVIRON SCI, V4, P5053, DOI 10.1039/c1ee02256c
   Ji XL, 2009, NAT MATER, V8, P500, DOI [10.1038/NMAT2460, 10.1038/nmat2460]
   Jiang J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9622
   Li L, 2016, CARBON, V108, P120, DOI 10.1016/j.carbon.2016.07.008
   Li QT, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6780
   Li XL, 2011, J MATER CHEM, V21, P16603, DOI 10.1039/c1jm12979a
   Li Z, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13065
   Liang J, 2016, ACS APPL MATER INTER, V8, P25193, DOI 10.1021/acsami.6b05647
   Liang J, 2016, ENERGY STORAGE MATER, V2, P76, DOI 10.1016/j.ensm.2015.09.007
   Liao KM, 2016, J MATER CHEM A, V4, P5406, DOI 10.1039/c6ta00054a
   Long DH, 2010, LANGMUIR, V26, P16096, DOI 10.1021/la102425a
   Niu SZ, 2015, J POWER SOURCES, V295, P182, DOI 10.1016/j.jpowsour.2015.06.122
   Pang Q, 2016, ACS NANO, V10, P4111, DOI 10.1021/acsnano.5b07347
   Pang Q, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5759
   Peng HJ, 2016, ADV MATER, V28, P9551, DOI 10.1002/adma.201603401
   Schuster J, 2012, ANGEW CHEM INT EDIT, V51, P3591, DOI 10.1002/anie.201107817
   Xu GY, 2014, J MATER CHEM A, V2, P12662, DOI 10.1039/c4ta02097a
   Yin YX, 2013, ANGEW CHEM INT EDIT, V52, P13186, DOI 10.1002/anie.201304762
   Yuan Z, 2016, NANO LETT, V16, P519, DOI 10.1021/acs.nanolett.5b04166
   Zhang B, 2010, ENERG ENVIRON SCI, V3, P1531, DOI 10.1039/c002639e
   Zhang CF, 2012, ANGEW CHEM INT EDIT, V51, P9592, DOI 10.1002/anie.201205292
   Zhang J, 2014, J POWER SOURCES, V270, P1, DOI 10.1016/j.jpowsour.2014.07.089
   Zhang SS, 2012, J POWER SOURCES, V200, P77, DOI 10.1016/j.jpowsour.2011.10.076
   Zhang Y. J, 2016, ENERG ENVIRON SCI, V4, P4517
   Zhou GM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8760
   Zhou GM, 2012, ACS NANO, V6, P3214, DOI 10.1021/nn300098m
   Zhou WD, 2013, J AM CHEM SOC, V135, P16736, DOI 10.1021/ja409508q
NR 33
TC 6
Z9 6
U1 13
U2 128
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 2
PY 2019
VL 194
SI SI
BP 148
EP 155
DI 10.1016/j.ces.2018.03.027
PG 8
WC Engineering, Chemical
SC Engineering
GA HC6NG
UT WOS:000451917900020
DA 2020-05-12
ER

PT J
AU Li, XB
   Rafie, A
   Smolin, YY
   Simotwo, S
   Kalra, V
   Lau, KKS
AF Li, Xiaobo
   Rafie, Ayda
   Smolin, Yuriy Y.
   Simotwo, Silas
   Kalra, Vibha
   Lau, Kenneth K. S.
TI Engineering conformal nanoporous polyaniline via oxidative chemical
   vapor deposition and its potential application in supercapacitors
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Oxidative chemical vapor deposition; Polyaniline; Nanoporous;
   Electrospinning; Carbon nanofibers; Supercapacitors
ID SYNTHESIZED CONDUCTING POLYANILINE; POROUS CARBON NANOFIBERS; MESOPOROUS
   POLYANILINE; THIN-FILMS; ELECTROCHEMICAL PROPERTIES; ENHANCED
   PERFORMANCE; ELECTRODE MATERIALS; FACILE SYNTHESIS; POLYMER; CAPACITANCE
AB Oxidative chemical vapor deposition (oCVD) offers unique advantages in synthesizing and integrating conducting polymers, like polyaniline (PANI), over conventional solution-based techniques, among them its ability to achieve thin films, conformal and uniform coatings, and coatings on topologically complex substrates. In this work, PANI was synthesized by oCVD via oxidative polymerization using aniline monomer and antimony pentachloride oxidant. Fourier transform infrared (FTIR) and X-ray photoelectron spectroscopy (XPS) confirm the formation of PANI. Uniquely, as evidenced by scanning electron microscopy (SEM) and atomic force microscopy (AFM), oCVD PANI shows a rough nanoporous morphology with pore openings of around 20 nm, while maintaining the conformality and uniformity of the coating. This nanoscale porosity leads to greater surface area that enhanced the energy storage capacity of nonporous electrospun carbon nanofibers (CNFs). With a coating thickness of similar to 160 nm on CNFs, the oCVD PANI-CNF composite shows high specific capacitance and excellent cycling stability, and demonstrates the potential for porous oCVD PANI to enhance supercapacitor energy storage and power density. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Li, Xiaobo; Rafie, Ayda; Smolin, Yuriy Y.; Simotwo, Silas; Kalra, Vibha; Lau, Kenneth K. S.] Drexel Univ, Dept Chem & Biol Engn, Philadelphia, PA 19104 USA.
RP Kalra, V; Lau, KKS (reprint author), Drexel Univ, Dept Chem & Biol Engn, Philadelphia, PA 19104 USA.
EM vk99@drexel.edu; klau@drexel.edu
FU National Science FoundationNational Science Foundation (NSF)
   [CMMI-1463170]
FX National Science Foundation (CMMI-1463170).
CR Abdiryim T, 2005, MATER CHEM PHYS, V90, P367, DOI 10.1016/j.matchemphys.2004.10.036
   Amadei CA, 2014, ACS APPL MATER INTER, V6, P4705, DOI 10.1021/am405159f
   Bhadra S, 2009, PROG POLYM SCI, V34, P783, DOI 10.1016/j.progpolymsci.2009.04.003
   Bissett MA, 2015, ACS APPL MATER INTER, V7, P17388, DOI 10.1021/acsami.5b04672
   BURROUGHES JH, 1990, NATURE, V347, P539, DOI 10.1038/347539a0
   Castro-Carranza A, 2016, J POLYM SCI POL PHYS, V54, P1537, DOI 10.1002/polb.24049
   Tran C, 2015, J POWER SOURCES, V293, P373, DOI 10.1016/j.jpowsour.2015.05.054
   Tran C, 2013, J POWER SOURCES, V235, P289, DOI 10.1016/j.jpowsour.2013.01.080
   Tran C, 2013, SOFT MATTER, V9, P846, DOI 10.1039/c2sm25976a
   Chelawat H, 2010, CHEM MATER, V22, P2864, DOI 10.1021/cm100092c
   Chen W, 2013, J MATER CHEM A, V1, P3315, DOI 10.1039/c3ta00499f
   Cho S, 2012, J MATER CHEM, V22, P12164, DOI 10.1039/c2jm30594a
   Cong HP, 2013, ENERG ENVIRON SCI, V6, P1185, DOI 10.1039/c2ee24203f
   Dai XL, 2014, NATURE, V515, P96, DOI 10.1038/nature13829
   Danesh E, 2014, ANAL CHEM, V86, P8951, DOI 10.1021/ac501908c
   Daraei P, 2012, J MEMBRANE SCI, V415, P250, DOI 10.1016/j.memsci.2012.05.007
   DUIC L, 1995, ELECTROCHIM ACTA, V40, P1681, DOI 10.1016/0013-4686(95)00086-T
   Facchetti A, 2011, CHEM MATER, V23, P733, DOI 10.1021/cm102419z
   Fan W, 2013, ACS APPL MATER INTER, V5, P3382, DOI 10.1021/am4003827
   Fang Y, 2010, SENSOR ACTUAT A-PHYS, V158, P121, DOI 10.1016/j.sna.2009.12.012
   Feast WJ, 1996, POLYMER, V37, P5017, DOI 10.1016/0032-3861(96)00439-9
   Fonseca CP, 2015, POLIMEROS, V25, P425, DOI 10.1590/0104-1428.1804
   FURUKAWA Y, 1988, MACROMOLECULES, V21, P1297, DOI 10.1021/ma00183a020
   Ghalei B, 2017, J MATER CHEM A, V5, P4686, DOI 10.1039/c6ta09181d
   Gigot A, 2018, MATERIALS, V11, DOI 10.3390/ma11010057
   Golczak S, 2008, SOLID STATE IONICS, V179, P2234, DOI 10.1016/j.ssi.2008.08.004
   Guo F, 2015, RSC ADV, V5, P94008, DOI 10.1039/c5ra19478d
   Han JP, 2014, J MATER CHEM A, V2, P5352, DOI 10.1039/c3ta15271e
   Han MG, 2002, SYNTHETIC MET, V126, P53, DOI 10.1016/S0379-6779(01)00494-5
   Howden R. M, 2015, CVD POLYM FABRICATIO, P233
   Huang JX, 2003, J AM CHEM SOC, V125, P314, DOI 10.1021/ja028371y
   Huang XL, 2012, J MATER CHEM, V22, P22488, DOI 10.1039/c2jm34340a
   Im SG, 2008, ACS NANO, V2, P1959, DOI 10.1021/nn800380e
   Jo WJ, 2016, ADV MATER, V28, P6399, DOI 10.1002/adma.201601221
   Khdary NH, 2014, J ELECTROCHEM SOC, V161, pG63, DOI 10.1149/2.0441409jes
   Kulkarni MV, 2004, J POLYM SCI POL CHEM, V42, P2043, DOI 10.1002/pola.11030
   KUMAR SN, 1990, SURF INTERFACE ANAL, V15, P531, DOI 10.1002/sia.740150906
   KUMAR SN, 1990, SYNTHETIC MET, V36, P111, DOI 10.1016/0379-6779(90)90240-L
   Li J, 2011, J POWER SOURCES, V196, P10775, DOI 10.1016/j.jpowsour.2011.08.105
   Li ZH, 2016, SENSOR ACTUAT B-CHEM, V226, P553, DOI 10.1016/j.snb.2015.10.062
   Liu C, 2018, INORG CHEM FRONT, V5, P835, DOI 10.1039/c8qi00010g
   Liu H, 2015, ELECTROCHIM ACTA, V167, P132, DOI 10.1016/j.electacta.2015.03.151
   Liu TY, 2014, NANO LETT, V14, P2522, DOI 10.1021/nl500255v
   Liu ZY, 2017, SMALL, V13, DOI 10.1002/smll.201603388
   Lizarraga L, 2004, J ELECTROANAL CHEM, V561, P127, DOI 10.1016/j.jelechem.2003.07.026
   Lock JP, 2006, MACROMOLECULES, V39, P5326, DOI 10.1021/ma060113o
   Lota K, 2004, J PHYS CHEM SOLIDS, V65, P295, DOI 10.1016/j.jpcs.2003.10.051
   Ma GF, 2018, ROY SOC OPEN SCI, V5, DOI 10.1098/rsos.171186
   MACDIARMID AG, 1987, SYNTHETIC MET, V18, P285, DOI 10.1016/0379-6779(87)90893-9
   Nejati S, 2015, NANOSCI NANOTECH LET, V7, P50, DOI 10.1166/nnl.2015.1907
   Nejati S, 2014, ACS NANO, V8, P5413, DOI 10.1021/nn500007c
   Nejati S, 2011, LANGMUIR, V27, P15223, DOI 10.1021/la203318f
   NEOH KG, 1991, J POLYM SCI POL CHEM, V29, P759, DOI 10.1002/pola.1991.080290518
   OHSAKA T, 1984, J ELECTROANAL CHEM, V161, P399, DOI 10.1016/0368-1874(84)83662-X
   Pan LJ, 2012, P NATL ACAD SCI USA, V109, P9287, DOI 10.1073/pnas.1202636109
   Pauliukaite R, 2004, ELECTROCHIM ACTA, V50, P159, DOI 10.1016/j.electacta.2004.07.034
   Peng C, 2011, CHEM COMMUN, V47, P4105, DOI 10.1039/c1cc10675a
   Quillard S, 1997, SYNTHETIC MET, V84, P805, DOI 10.1016/S0379-6779(96)04155-0
   Santiago EI, 1998, SYNTHETIC MET, V98, P87, DOI 10.1016/S0379-6779(98)00149-0
   Santino LM, 2016, ACS APPL MATER INTER, V8, P29452, DOI 10.1021/acsami.6b09779
   Simotwo SK, 2016, ACS APPL MATER INTER, V8, P21261, DOI 10.1021/acsami.6b03463
   Skotheim T. A., 2007, HDB CONDUCTING POLYM
   Smolin YY, 2017, BEILSTEIN J NANOTECH, V8, P1266, DOI 10.3762/bjnano.8.128
   Smolin YY, 2017, IND ENG CHEM RES, V56, P6221, DOI 10.1021/acs.iecr.7b00441
   Smolin YY, 2017, ADV MATER INTERFACES, V4, DOI 10.1002/admi.201601201
   Snook GA, 2011, J POWER SOURCES, V196, P1, DOI 10.1016/j.jpowsour.2010.06.084
   Stejskal J, 2012, POLYM INT, V61, P240, DOI 10.1002/pi.3179
   STILLWAGON LE, 1987, J ELECTROCHEM SOC, V134, P2030, DOI 10.1149/1.2100813
   TAN KL, 1989, PHYS REV B, V39, P8070, DOI 10.1103/PhysRevB.39.8070
   TANG JS, 1988, SYNTHETIC MET, V24, P231, DOI 10.1016/0379-6779(88)90261-5
   Tenhaeff WE, 2008, ADV FUNCT MATER, V18, P979, DOI 10.1002/adfm.200701479
   Tian H, 2017, ACS APPL MATER INTER, V9, P43975, DOI 10.1021/acsami.7b13666
   Tiwari A, 2015, INTELLIGENT COATINGS
   Trchova M, 2004, POLYM DEGRAD STABIL, V86, P179, DOI 10.1016/j.polymdegradstab.2004.04.011
   Vaddiraju S, 2008, ADV FUNCT MATER, V18, P1929, DOI 10.1002/adfm.200800196
   Vaddiraju S, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/12/125503
   Vilaro I, 2017, ACS APPL MATER INTER, V9, P1057, DOI 10.1021/acsami.6b12119
   Wang K, 2013, ADV MATER, V25, P1494, DOI 10.1002/adma.201204598
   Wang Q, 2014, J POWER SOURCES, V247, P197, DOI 10.1016/j.jpowsour.2013.08.076
   Wang YG, 2006, ADV MATER, V18, P2619, DOI 10.1002/adma.200600445
   Wu ZQ, 2013, SENSOR ACTUAT B-CHEM, V178, P485, DOI 10.1016/j.snb.2013.01.014
   Xing J, 2017, PHYS CHEM CHEM PHYS, V19, P14030, DOI 10.1039/c7cp02016c
   Yang R, 2012, LANGMUIR, V28, P12266, DOI 10.1021/la302059s
   Yang R, 2011, CHEM MATER, V23, P1263, DOI 10.1021/cm1031392
   Yoon SB, 2011, J POWER SOURCES, V196, P10791, DOI 10.1016/j.jpowsour.2011.08.107
   Zaharias GA, 2006, THIN SOLID FILMS, V501, P341, DOI 10.1016/j.tsf.2005.07.145
   Zeng XR, 1998, POLYMER, V39, P1187, DOI 10.1016/S0032-3861(97)00381-9
   Zequine C., 2016, SCI REP, V6, P31074
   Zhai DY, 2013, ACS NANO, V7, P3540, DOI 10.1021/nn400482d
   Zhang JT, 2012, J PHYS CHEM C, V116, P5420, DOI 10.1021/jp211474e
   Zhang K, 2010, CHEM MATER, V22, P1392, DOI 10.1021/cm902876u
   Zhang KQ, 2009, POLYM ADVAN TECHNOL, V20, P689, DOI 10.1002/pat.1333
   Zhao S, 2011, J MEMBRANE SCI, V385, P251, DOI 10.1016/j.memsci.2011.10.006
   Zhou JS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9503
   Zuo FM, 2017, SENSOR ACTUAT B-CHEM, V244, P282, DOI 10.1016/j.snb.2017.01.001
NR 95
TC 6
Z9 6
U1 12
U2 87
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 2
PY 2019
VL 194
SI SI
BP 156
EP 164
DI 10.1016/j.ces.2018.06.053
PG 9
WC Engineering, Chemical
SC Engineering
GA HC6NG
UT WOS:000451917900021
DA 2020-05-12
ER

PT J
AU Healy, SA
   Fried, M
   Richie, T
   Bok, K
   Little, M
   August, A
   Riley, L
   Swamy, GK
   Wylie, BJ
   Menendez, C
   Muehlenbachs, A
   Doumbo, O
   Greenwood, B
   Billingsley, PF
   Hoffman, SL
   Duffy, PE
AF Healy, Sara A.
   Fried, Michal
   Richie, Thomas
   Bok, Karin
   Little, Maggie
   August, Allison
   Riley, Laura
   Swamy, Geeta K.
   Wylie, Blair J.
   Menendez, Clara
   Muehlenbachs, Atis
   Doumbo, Ogobara
   Greenwood, Brian
   Billingsley, Peter F.
   Hoffman, Stephen L.
   Duffy, Patrick E.
TI Malaria vaccine trials in pregnant women: An imperative without
   precedent
SO VACCINE
LA English
DT Article
DE Malaria; Pregnant women; Plasmodium falciparum; PfSPZ vaccine
ID PLASMODIUM-FALCIPARUM; PYRIMETHAMINE; EFFICACY
AB Pregnant women are highly susceptible to Plasmodium falciparum malaria, leading to substantial maternal, perinatal, and infant mortality. While malaria vaccine development has made significant progress in recent years, no trials of malaria vaccines have ever been conducted in pregnant women. In December 2016, an expert meeting was convened at NIAID, NIH, in Rockville, Maryland to deliberate on the rationale and design of malaria vaccine trials in pregnant women. The discussions highlighted the progress made over recent years in the field of maternal immunization for other infectious diseases, and the evolving regulatory and ethical environment, all of which support a new emphasis on testing malaria vaccines that offer direct benefits to pregnant women. Initial safety and immunogenicity studies of malaria vaccines will be conducted in non-pregnant adult volunteers. Subsequently, efficacy trials involving pregnant women will likely be conducted in malaria-endemic and often resource-poor environments where sufficiently high malaria incidence will allow vaccine activity to be measured. Such trials will need to meet all international standards to ensure the safety of mother and offspring, under oversight of appropriate ethical and regulatory bodies. The convened experts drafted a clinical development plan to test a malaria vaccine product during pregnancy, using as a case study PfSPZ Vaccine being developed by Sanaria Inc. that is currently in phase 2 testing. Following the expert recommendations, a pregnancy registry has been initiated in Ouelessebougou, Mali, to provide baseline information on maternal and fetal outcomes as a context for evaluating PfSPZ Vaccine safety in the future, and new regimens are being assessed that will be suitable for evaluation in pregnant women.
C1 [Healy, Sara A.; Fried, Michal; Duffy, Patrick E.] NIAID, Lab Malaria Immunol & Vaccinol, NIH, Rockville, MD 20852 USA.
   [Fried, Michal; Billingsley, Peter F.; Hoffman, Stephen L.] Sanaria Inc, Rockville, MD USA.
   [Bok, Karin] Off Assistant Secretary Hlth, NVPO, Washington, DC USA.
   [Little, Maggie] Georgetown Univ, Kennedy Inst Eth, Washington, DC 20057 USA.
   [August, Allison] Moderna Therapeut, Clin Dev, Cambridge, MA USA.
   [Riley, Laura] Massachusetts Gen Hosp, Obstet, Boston, MA 02114 USA.
   [Swamy, Geeta K.] Duke Univ, Dept Obstet & Gynecol, Durham, NC USA.
   [Wylie, Blair J.] Beth Israel Deaconess Med Ctr, Maternal Fetal Med, Boston, MA 02215 USA.
   [Menendez, Clara] Univ Barcelona, Hosp Clin, Barcelona Inst Global Hlth ISGlobal, Barcelona, Spain.
   [Muehlenbachs, Atis] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Doumbo, Ogobara] Univ Bamako, Malaria Res & Training Ctr, Bamako, Mali.
   [Greenwood, Brian] London Sch Hyg & Trop Med, London, England.
RP Duffy, PE (reprint author), NIAID, Lab Malaria Immunol & Vaccinol, NIH, Rockville, MD 20852 USA.
EM patrick.duffy@nih.gov
RI Menendez, Clara/Q-3446-2016
OI Menendez, Clara/0000-0002-2641-6907
FU Intramural Research Program of the National Institute of Allergy and
   Infectious Diseases, National Institutes of HealthUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
FX The Expert Meeting received support for participant travel from Noble
   Energy, Inc. as part of its Corporate and Social Responsibility Program.
   J. Patrick Gorres contributed to writing and editing the manuscript.
   Sara A. Healy, Michal Fried, and Patrick E. Duffy are supported by the
   Intramural Research Program of the National Institute of Allergy and
   Infectious Diseases, National Institutes of Health.
CR ACOG, 2015, ETH CONS INCL WOM RE
   CIOMS, 2016, NEW CIOMS GUID RES P
   COHEN P, 1946, J PEDIATR-US, V29, P609, DOI 10.1016/S0022-3476(46)80128-8
   Duffy PE, 2003, INFECT IMMUN, V71, P6620, DOI 10.1128/IAI.71.11.6620-6623.2003
   Filler SJ, 2006, J INFECT DIS, V194, P286, DOI 10.1086/505080
   Parise ME, 1998, AM J TROP MED HYG, V59, P813, DOI 10.4269/ajtmh.1998.59.813
   Sissoko MS, 2017, LANCET INFECT DIS, V17, P498, DOI [10.1016/s1473-3099(17)30104-4, 10.1016/S1473-3099(17)30104-4]
   WHO, 2016, ZIK ETH CONS ETH GUI
   World Health Organization, 2017, WORLD MALARIA REPORT
NR 9
TC 3
Z9 3
U1 2
U2 9
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 4
PY 2019
VL 37
IS 6
BP 763
EP 770
DI 10.1016/j.vaccine.2018.12.025
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HK9WH
UT WOS:000458343100001
PM 30621913
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Souto, FJD
   de Brito, WI
   Fontes, CJF
AF Dutra Souto, Francisco Jose
   de Brito, Wagner Izidoro
   Fernandes Fontes, Cor Jesus
TI Impact of the single-dose universal mass vaccination strategy against
   hepatitis A in Brazil
SO VACCINE
LA English
DT Article
DE Hepatitis A virus; Hepatitis A vaccines; Incidence; Epidemiology; Public
   health; Outbreak
ID IMMUNIZATION; CHILDREN
AB Universal vaccination of children against hepatitis A was introduced in 2014 in Brazil as a single-dose schedule. We analyzed the numbers of reported cases of hepatitis A virus infection (HAV) from 2010 to 2017 to evaluate the initial impact of that intervention. Data were assessed and has been freely available on the Brazilian Ministry of Health website. The HAV incidence was steady around 6000 cases per year until 2014. Between 2014 and 2016, there was a 85.5% cumulative drop, independent of gender and geographical macroregions. The fall was especially significant among toddlers (96.8%). In 2017, cases increased due to an outbreak among male adults in Sao Paulo. Decrease in incidence continued to occur for females and for those under 15 years of age. Data show that there was a significant decrease in HAV cases number in Brazil from 2015 after the introduction of single-dose HAV vaccine program. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Dutra Souto, Francisco Jose; Fernandes Fontes, Cor Jesus] Univ Fed Mato Grosso, Hosp Univ Julio Muller, Fac Med, Dept Clin Med, Cuiaba, Mato Grosso, Brazil.
   [de Brito, Wagner Izidoro] Univ Fed Mato Grosso, Nucl Vigilcincia Epidemiol Hosp, Cuiaba, Mato Grosso, Brazil.
RP Souto, FJD (reprint author), Hosp Univ Julio Muller, Rua Luiz Philippe Pereira Leite S-N, BR-78048902 Cuiaba, Mato Grosso, Brazil.
EM fsouto@terra.com.br
CR Aggarwal R, 2015, CURR OPIN INFECT DIS, V28, P488, DOI 10.1097/QCO.0000000000000188
   Bordi L, 2012, J CLIN VIROL, V54, P26, DOI 10.1016/j.jcv.2012.01.009
   Curran D, 2016, HUM VACC IMMUNOTHER, V12, P2765, DOI 10.1080/21645515.2016.1203495
   CUZICK J, 1985, STAT MED, V4, P87, DOI 10.1002/sim.4780040112
   Dagan R, 2005, JAMA-J AM MED ASSOC, V294, P202, DOI 10.1001/jama.294.2.202
   Ximenes RAD, 2008, INT J EPIDEMIOL, V37, P852, DOI 10.1093/ije/dyn114
   de Brito WI, 2018, BRAZ J INFECT DIS, V22, P166, DOI 10.1016/j.bjid.2018.04.001
   Kury CM, 2016, CAD SAUDE PUBLICA, V32, DOI [10.1590/0102-311X00175614, 10.1590/0102-311x00175614]
   Rivas V, 2018, EUROSURVEILLANCE, V23, P14, DOI 10.2807/1560-7917.ES.2018.23.9.18-00060
   Secretaria de Estado de Saude de Sao Paulo, SURT DE HEP A
   Vitral CL, 2006, MEM I OSWALDO CRUZ, V101, P119, DOI 10.1590/S0074-02762006000200001
   Vitral CL, 2012, MEM I OSWALDO CRUZ, V107, P652, DOI 10.1590/S0074-02762012000500012
   Vizzotti C, 2014, PEDIATR INFECT DIS J, V33, P84, DOI 10.1097/INF.0000000000000042
   Wasley Annemarie, 2007, MMWR Surveill Summ, V56, P1
   Werber D, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.5.30457
   World Health Organization, 2017, HEP A
NR 16
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 4
PY 2019
VL 37
IS 6
BP 771
EP 775
DI 10.1016/j.vaccine.2018.12.054
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HK9WH
UT WOS:000458343100002
PM 30639462
DA 2020-05-12
ER

PT J
AU Oliveira, TL
   Rizzi, C
   da Cunha, CEP
   Dorneles, J
   Neto, ACPS
   Amaral, MG
   Hartwig, DD
   Dellagostin, OA
AF Oliveira, Thais Larre
   Rizzi, Caroline
   Pouey da Cunha, Carlos Eduardo
   Dorneles, Jessica
   Pinto Seixas Neto, Amilton Clair
   Amaral, Marta Goncalves
   Hartwig, Daiane Drawanz
   Dellagostin, Odir Antonio
TI Recombinant BCG strains expressing chimeric proteins derived from
   Leptospira protect hamsters against leptospirosis
SO VACCINE
LA English
DT Article
DE Leptospirosis; Recombinant vaccine; Chimera; Bacillus Calmette-Guerin
ID VACCINE; CANDIDATE; IMMUNITY; ANTIGEN; CATTLE; HOST
AB Leptospirosis is a zoonosis that is responsible for one million human cases per year. Fusing multiple immunogenic antigens represents a promising approach to delivering an effective vaccine against leptospirosis. Mycobacterium bovis bacillus Calmette-Guerin (BCG) is a potential vaccine vector due to its adjuvant properties and safety. Two chimeric genes based on genic sequences of ligANI, ligBrep, lipL32, and lemA, were individually cloned into five BioBrick vectors with different promoters (pAN, Hsp60, 18 kDa, Ag85B and Ag85B plus signal sequence) for antigen expression in BCG. Groups of ten hamsters were vaccinated with recombinant BCG (rBCG) strains in two doses of 10(6) CFU and challenged with 5 x LD50 of L. interrogans serovar Copenhageni. All rBCG vaccines expressing chimera 1, based on antigens LipL32, LigANI, and LemA, under the control of any promoter, protected 80-100% of the hamsters from challenge (P < 0.05) and four of them also protected from renal carrier status; for chimera 2, based on LigANI and LigBrep antigens, the only vaccine that afforded survival rates statistically different from the control was the vaccine that incorporated the pAN promoter (60% of survival). A single vaccine dose was sufficient to induce significant IgG levels by all vaccine compositions evaluated; however, humoral response was not related to protection. These findings suggest that the combination of potential vaccine candidates in chimeric antigens and the use of BCG as a live vector are promising strategies by which it is possible to obtain an effective and sterilizing vaccine against leptospirosis. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Oliveira, Thais Larre; Rizzi, Caroline; Pouey da Cunha, Carlos Eduardo; Dorneles, Jessica; Pinto Seixas Neto, Amilton Clair; Amaral, Marta Goncalves; Hartwig, Daiane Drawanz; Dellagostin, Odir Antonio] Univ Fed Pelotas, Ctr Desenvolvimento Tecnol, Programa Posgrad Biotecnol, Pelotas, RS, Brazil.
   [Hartwig, Daiane Drawanz] Univ Fed Pelotas, Inst Biol, Dept Microbiol & Parasitol, Pelotas, RS, Brazil.
RP Dellagostin, OA (reprint author), Univ Fed Pelotas, Ctr Desenvolvimento Tecnol, Nucl Biotecnol, Campus Univ,Caixa Postal 354, BR-96010900 Pelotas, RS, Brazil.
EM odirad@ufpel.edu.br
RI Rizzi, Caroline/H-1014-2014; Rizzi, Caroline/M-7187-2019; Oliveira,
   Thais/P-5974-2019
OI Rizzi, Caroline/0000-0001-5810-9592; Rizzi,
   Caroline/0000-0001-5810-9592; 
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); CAPESCAPES; FAPERGSFoundation for Research Support of the State
   of Rio Grande do Sul (FAPERGS)
FX We are grateful to Michele dos Santos for the technical assistance
   provided during this study. This work was funded by grants from CNPq,
   CAPES and FAPERGS, Brazilian Research Funding Agencies.
CR Adler B, 2015, CURR TOP MICROBIOL, V387, P251, DOI 10.1007/978-3-662-45059-8_10
   Adler B, 2010, VET MICROBIOL, V140, P287, DOI 10.1016/j.vetmic.2009.03.012
   Babiuk LA, 2000, VET IMMUNOL IMMUNOP, V76, P1, DOI 10.1016/S0165-2427(00)00198-7
   Bastos RG, 2009, VACCINE, V27, P6495, DOI 10.1016/j.vaccine.2009.08.044
   Bolin CA, 2001, AM J VET RES, V62, P995, DOI 10.2460/ajvr.2001.62.995
   Cameron CE, 2015, CURR TOP MICROBIOL, V387, P21, DOI 10.1007/978-3-662-45059-8_3
   Chagas AD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032712
   Conrad NL, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005441
   Costa F, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003898
   Coutinho ML, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001422
   Dellagostin OA, 2011, HUM VACCINES, V7, P1215, DOI 10.4161/hv.7.11.17944
   Eddine AN, 2005, MICROBES INFECT, V7, P939, DOI 10.1016/j.micinf.2005.03.012
   Edelman R, 1999, VACCINE, V17, P904, DOI 10.1016/S0264-410X(98)00276-X
   Ellis WA, 2015, CURR TOP MICROBIOL, V387, P99, DOI 10.1007/978-3-662-45059-8_6
   Fernandes LGV, 2017, INT J INFECT DIS, V57, P61, DOI 10.1016/j.ijid.2017.01.032
   Garba B, 2018, MICROB PATHOGENESIS, V124, P136, DOI 10.1016/j.micpath.2018.08.028
   Grassmann AA, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00463
   Haake DA, 2015, CURR TOP MICROBIOL, V387, P187, DOI 10.1007/978-3-662-45059-8_8
   Haake DA, 2015, CURR TOP MICROBIOL, V387, P65, DOI 10.1007/978-3-662-45059-8_5
   Hartwig DD, 2013, CLIN VACCINE IMMUNOL, V20, P747, DOI 10.1128/CVI.00034-13
   Kaufmann SHE, 1999, IMMUNOL LETT, V65, P81, DOI 10.1016/S0165-2478(98)00128-X
   Ko AI, 2009, NAT REV MICROBIOL, V7, P736, DOI 10.1038/nrmicro2208
   Lilenbaum W, 2014, TRANSBOUND EMERG DIS, V61, P63, DOI 10.1111/tbed.12233
   Lin X, 2016, BMC MICROBIOL, V16, DOI 10.1186/s12866-016-0852-y
   Maciel EAP, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000154
   Medeiros MA, 2002, MICROBIOL-SGM, V148, P1999, DOI 10.1099/00221287-148-7-1999
   Naiman BM, 2001, INFECT IMMUN, V69, P7550, DOI 10.1128/IAI.69.12.7550-7558.2001
   Oliveira TL, 2017, APPL MICROBIOL BIOTE
   Parish T, 1995, Methods Mol Biol, V47, P237
   Reis RB, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000228
   Seixas FK, 2007, VACCINE, V26, P88, DOI 10.1016/j.vaccine.2007.10.052
   Shetty Reshma P, 2008, J Biol Eng, V2, P5, DOI 10.1186/1754-1611-2-5
   Silva EF, 2007, VACCINE, V25, P6277, DOI 10.1016/j.vaccine.2007.05.053
   Torgerson PR, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004122
   Zuerner RL, 2015, CURR TOP MICROBIOL, V387, P223, DOI 10.1007/978-3-662-45059-8_9
NR 35
TC 3
Z9 3
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 4
PY 2019
VL 37
IS 6
BP 776
EP 782
DI 10.1016/j.vaccine.2018.12.050
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HK9WH
UT WOS:000458343100003
PM 30630695
DA 2020-05-12
ER

PT J
AU Prasert, K
   Patumanond, J
   Praphasiri, P
   Siriluk, S
   Ditsungnoen, D
   Chittaganpich, M
   Dawood, FS
   Mott, JA
   Lindblade, KA
AF Prasert, Kriengkrai
   Patumanond, Jayanton
   Praphasiri, Prabda
   Siriluk, Supakit
   Ditsungnoen, Darunee
   Chittaganpich, Malinee
   Dawood, Fatimah S.
   Mott, Joshua A.
   Lindblade, Kim A.
TI Effectiveness of trivalent inactivated influenza vaccine among
   community-dwelling older adults in Thailand: A two-year prospective
   cohort study
SO VACCINE
LA English
DT Article
DE Older adults; Seasonal influenza vaccine; Vaccine effectiveness;
   Thailand
ID CLINICAL CASE DEFINITIONS; VULNERABLE ELDERS SURVEY; SEASONAL INFLUENZA;
   UNITED-STATES; SURVEILLANCE; HOSPITALIZATION; INFECTION; VALIDITY;
   VIRUSES
AB Background: We conducted a two-year prospective cohort study to measure the effectiveness of trivalent inactivated influenza vaccine (IIV3) to prevent laboratory-confirmed influenza among community-dwelling Thai adults aged >= 65 years during 2015-16 and 2016-17 influenza seasons.
   Methods: In 2015, we enrolled a cohort of 3220 participants. Trained health volunteers collected baseline data and followed participants for two years with weekly surveillance for new or worsened cough with self-collection of nasal swabs. Vaccine effectiveness (VE) was estimated as 100% x (1- rate ratio of rRT-PCR-confirmed influenza) among vaccinated versus unvaccinated participants. Propensity score stratification was used to reduce differences between vaccinated and unvaccinated participants associated with access to and receipt of IIV3.
   Findings: During 2015-16 and 2016-17, 1666 (52%) and 1498 (48%) participants received IIV3, respectively. The overall incidence of influenza during the two seasons was 14.3/1000 person-years among vaccinated participants and 20.2/1000 person-years among unvaccinated participants. VE was -4% (95% confidence interval [CI], -83%-40%) during 2015-16 when there was poor antigenic match between the dominant circulating A/H3N2 viruses and the vaccine strain, and 50% (95% CI, 12-71%) during 2016-17 when circulating and vaccine strains were well-matched. Of all three influenza subtypes in both years, significant protection was observed only against Influenza A/H3N2 during 2016-17 (VE, 49%; 95% CI, 3-73%).
   Interpretation: During a season with well-matched circulating and vaccine strains, IIV3 was moderately effective against laboratory-confirmed influenza among older adults in Thailand. Published by Elsevier Ltd.
C1 [Prasert, Kriengkrai] Nakhon Phanom Prov Hosp, Nakhon Phanom, Thailand.
   [Prasert, Kriengkrai; Patumanond, Jayanton] Thammasat Univ, Pathum Thani, Thailand.
   [Praphasiri, Prabda; Ditsungnoen, Darunee; Mott, Joshua A.; Lindblade, Kim A.] Thailand MOPH US CDC Collaborat, Influenza Program, Nonthaburi, Thailand.
   [Siriluk, Supakit] Thai Minist Publ Hlth, Hlth Tech Off, Nonthaburi, Thailand.
   [Chittaganpich, Malinee] Thai Minist Publ Hlth, Natl Inst Hlth, Nonthaburi, Thailand.
   [Dawood, Fatimah S.; Mott, Joshua A.; Lindblade, Kim A.] US Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA.
RP Praphasiri, P (reprint author), Thailand MOPH US CDC Collaborat, Minist Publ Hlth, DDC Bldg 7,4th Fl,Soi 4,Tivanon Rd, Nonthaburi 11000, Thailand.
EM hpu3@cdc.gov
FU US Centers for Disease Control and PreventionUnited States Department of
   Health & Human ServicesCenters for Disease Control & Prevention - USA;
   Ministry of Public Health, Thailand
FX US Centers for Disease Control and Prevention and Ministry of Public
   Health, Thailand.
CR Andrew MK, 2017, J INFECT DIS, V216, P405, DOI 10.1093/infdis/jix282
   [Anonymous], 2012, Wkly Epidemiol Rec, V87, P461
   Baxter R, 2010, J INFECT DIS, V201, P186, DOI 10.1086/649568
   Bedford T, 2015, NATURE, V523, P217, DOI 10.1038/nature14460
   Bureau of Epidemiology MoPH, 2018, 506 BUR EP MOPH
   Chittaganpitch M, 2012, INFLUENZA OTHER RESP, V6, P276, DOI 10.1111/j.1750-2659.2011.00302.x
   Dawood FS, 2014, INFLUENZA OTHER RESP, V8, P463, DOI 10.1111/irv.12233
   Desai RJ, 2017, EPIDEMIOLOGY, V28, P249, DOI 10.1097/EDE.0000000000000595
   Falsey AR, 2015, INFLUENZA OTHER RESP, V9, P23, DOI 10.1111/irv.12316
   Flannery B, 2017, MMWR-MORBID MORTAL W, V66, P167, DOI 10.15585/mmwr.mm6606a3
   Fleiss J. L., 2004, STAT METHODS RATES P, P64
   Goyal S, 2017, INFLUENZA OTHER RESP, V11, P412, DOI 10.1111/irv.12471
   Grohskopf LA, 2017, MMWR RECOMM REP, V66, P3, DOI 10.15585/mmwr.rr6602a1
   Gupta V, 2013, INFLUENZA OTHER RESP, V7, P321, DOI 10.1111/j.1750-2659.2012.00401.x
   Hirve S, 2016, INFLUENZA OTHER RESP, V10, P254, DOI 10.1111/irv.12374
   Jackson ML, 2017, NEW ENGL J MED, V377, P534, DOI [10.1056/NEJMoa1700153, 10.1056/nejmoa1700153]
   Jefferson T, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004876.pub3
   Lipsitch M, 2016, INT J EPIDEMIOL, V45, P2060, DOI 10.1093/ije/dyw124
   Min LC, 2006, J AM GERIATR SOC, V54, P507, DOI 10.1111/j.1532-5415.2005.00615.x
   Osterholm MT, 2012, LANCET INFECT DIS, V12, P36, DOI 10.1016/S1473-3099(11)70295-X
   Owusu JT, 2015, VACCINE, V33, P742, DOI 10.1016/j.vaccine.2014.10.029
   Plasai Valaikanya, 2006, Southeast Asian J Trop Med Public Health, V37 Suppl 3, P140
   Praditsuwan Rungnirand, 2005, Journal of the Medical Association of Thailand, V88, P256
   Prakongsai P, 2006, APPL ASSET INDEX MEA
   Praphasiri P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188422
   Remschmidt C, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1154-y
   Restivo V, 2018, HUM VACC IMMUNOTHER, V14, P724, DOI 10.1080/21645515.2017.1321722
   Rondy M, 2017, EUROSURVEILLANCE, V22, P8, DOI 10.2807/1560-7917.ES.2017.22.41.17-00645
   ROSENBAUM PR, 1984, J AM STAT ASSOC, V79, P516, DOI 10.2307/2288398
   Russell K, 2018, VACCINE, V36, P1272, DOI 10.1016/j.vaccine.2018.01.045
   Saliba D, 2001, J AM GERIATR SOC, V49, P1691, DOI 10.1046/j.1532-5415.2001.49281.x
   Simmerman JM, 2006, VACCINE, V24, P4417, DOI 10.1016/j.vaccine.2005.12.060
   Simmerman JM, 2009, PLOS ONE, V4, pA107, DOI 10.1371/journal.pone.0007776
   Skowronski DM, 2017, EUROSURVEILLANCE, V22, P2, DOI [10.2807/1560-7917.es.2017.22.6.30460, 10.2807/1560-7917.ES.2017.22.6.30460]
   Surichan S, 2011, VACCINE, V29, pA29, DOI 10.1016/j.vaccine.2011.04.120
   Wang RXE, 2010, EXPERT REV ANTI-INFE, V8, P517, DOI [10.1586/eri.10.24, 10.1586/ERI.10.24]
   Williamson EJ, 2014, RESPIROLOGY, V19, P625, DOI 10.1111/resp.12312
NR 37
TC 3
Z9 3
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 4
PY 2019
VL 37
IS 6
BP 783
EP 791
DI 10.1016/j.vaccine.2018.12.047
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HK9WH
UT WOS:000458343100004
PM 30616956
OA Other Gold
DA 2020-05-12
ER

PT J
AU Shen, A
   Khavjou, O
   King, G
   Bates, L
   Zhou, FJ
   Leidner, AJ
   Yarnoff, B
AF Shen, Angela
   Khavjou, Olga
   King, Grant
   Bates, Laurel
   Zhou, Fangjun
   Leidner, Andrew J.
   Yarnoff, Benjamin
TI Provider time and costs to vaccinate adult patients: Impact of time
   counseling without vaccination
SO VACCINE
LA English
DT Article
DE Adult vaccination; Time-motion; Vaccination; Vaccine counseling
ID UNITED-STATES; INFLUENZA
AB Amid provider reports of financial barriers as an impediment to adult immunization, this study explores the time and costs of vaccination in adult provider practices. Both a Vaccination Time-Motion Study and Vaccine Practice Management Survey were conducted (March - October 2017) in a convenience sample of 19 family medicine (FM), internal medicine (IM), and obstetrician-gynecology (OBGYN) practices, in nine states. Practices were directly observed during a one week period; estimates were collected of time spent on activities that could not be directly observed. Cost estimates were calculated by converting staff time for performed activities. In the time-motion study, FM and IM practices spent similar time conducting vaccination activities (median = 5 min per vaccination), while OBGYN practices spent more time (median = 29 min per vaccination). Combining results from the time-motion study and the practice management survey, the median costs of vaccination remained similar for FM practices and IM practices at $7 and $8 per vaccination, respectively, but was substantially higher for OBGYN practices at $43 per vaccination. Factors that contributed to higher costs among OBGYN practices were the increased time to counsel patients, administer vaccines, and to plan and manage vaccine supplies. In addition, 68% of OBGYN patients who were offered and counseled to receive vaccines declined to receive them. Counseling patients who ultimately do not go on to receive a vaccine may be an important cost factor. Lower costs of vaccination services may be achieved by increasing efficiencies in workflow or the volume of vaccinations. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Shen, Angela] US Dept HHS, Off Assistant Secretary Hlth, Natl Vaccine Program Off, Washington, DC 20201 USA.
   [Khavjou, Olga; King, Grant; Bates, Laurel; Yarnoff, Benjamin] RTI Int, Raleigh, NC USA.
   [Zhou, Fangjun] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA.
   [Leidner, Andrew J.] Berry Technol Solut, Atlanta, GA USA.
RP Yarnoff, B (reprint author), 3040 E Cornwallis Rd, Res Triangle Pk, NC 27709 USA.
EM byarnoff@rti.org
OI Leidner, Andrew/0000-0001-8869-5561; Shen, Angela/0000-0003-3761-0016;
   Bates, Laurel/0000-0003-0142-4975
FU National Vaccine Program Office [HHSP23320150039I]
FX This study was supported by the National Vaccine Program Office
   (contract number HHSP23320150039I). The opinions expressed in this
   manuscript are those of the authors and not intended to represent the
   opinions of the National Vaccine Program Office or the Centers for
   Disease Control and Prevention.
CR American Academy of Family Physicians, COD TOB SCREEN CESS
   [Anonymous], 2012, PUBLIC HEALTH REP, V127, P1
   Bhatt A, 2014, PUBLIC HEALTH REP, V129, P115
   Bridges CB, 2015, VACCINE, V33, pD114, DOI 10.1016/j.vaccine.2015.09.054
   Bureau of Labor Statistics, CPI ROS 2 4 PERC 12
   Bureau of Labor Statistics, 2018, EMPL COSTS EMPL COMP
   Bureau of Labor Statistics, 2016, METR NONM AR OCC EMP
   Coleman MS, 2005, VACCINE, V23, P915, DOI 10.1016/j.vaccine.2004.07.028
   Community Preventive Services Task Force, GUID COMM PREV SERV
   Cowan AE, 2016, VACCINE, V34, P5060, DOI 10.1016/j.vaccine.2016.08.080
   Glazner JE, 2004, PEDIATRICS, V113, P1582, DOI 10.1542/peds.113.6.1582
   Glazner Judith E, 2009, Pediatrics, V124 Suppl 5, pS492, DOI 10.1542/peds.2009-1542H
   Lu PJ, 2018, VACCINE, V36, P890, DOI 10.1016/j.vaccine.2017.12.016
   Orenstein WA, 2015, PUBLIC HEALTH REP, V130, P573
   Singleton JA, 2005, AM J PREV MED, V29, P412, DOI 10.1016/j.amepre.2005.08.012
   Williams WW, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6611a1
   Yoo Byung-Kwang, 2009, Pediatrics, V124 Suppl 5, pS499, DOI 10.1542/peds.2009-1542I
NR 17
TC 3
Z9 3
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 4
PY 2019
VL 37
IS 6
BP 792
EP 797
DI 10.1016/j.vaccine.2018.12.045
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HK9WH
UT WOS:000458343100005
PM 30639460
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Lusvan, ME
   Debellut, F
   Clark, A
   Demberelsuren, S
   Otgonbayar, D
   Batjargal, T
   Purevsuren, S
   Groman, D
   Tate, J
   Pecenka, C
AF Lusvan, Munkh-Erdene
   Debellut, Frederic
   Clark, Andrew
   Demberelsuren, Sodbayar
   Otgonbayar, Dashpagam
   Batjargal, Tselkhaasuren
   Purevsuren, Sugarmaa
   Groman, Devin
   Tate, Jacqueline
   Pecenka, Clint
TI Projected impact, cost-effectiveness, and budget implications of
   rotavirus vaccination in Mongolia
SO VACCINE
LA English
DT Article
DE Rotavirus; Vaccination; Cost-effectiveness; DALY; ICER; Mongolia
ID DISEASE; VACCINES; BURDEN; MODEL
AB Introduction: Rotavirus disease in Mongolia is estimated to cause more than 50 deaths yearly and many more cases and hospitalizations. Mongolia must self-finance new vaccines and does not automatically access Gavi prices for vaccines. Given the country's limited resources for health, it is critical to assess potential new vaccine programs. This evaluation estimates the impact, cost-effectiveness, and budget implications associated with a nationwide rotavirus vaccine introduction targeting infants as part of the national immunization program in Mongolia, in order to inform decision-making around introduction.
   Methods: The analysis examines the use of the two-dose vaccine ROTARIX (R), and three-dose vaccines ROTAVAC (R) and RotaTeq (R) compared to no vaccination from the government and the societal perspective. We use a modelling approach informed by local data and published literature to analyze the impact and cost-effectiveness of rotavirus vaccination over a ten-year time period starting in 2019, using a 3% discount rate. Our main outcome measure is the incremental cost-effectiveness ratio (ICER) expressed as US dollar per DALY averted. We assessed uncertainty around a series of parameters through univariate sensitivity analysis.
   Results: Rotavirus vaccination in Mongolia could avert more than 95,000 rotavirus cases and 271 deaths, over 10 years. Averted visits and hospitalizations represent US$2.4 million in health care costs saved by the government. The vaccination program cost ranges from $6 to $11 million depending on vaccine choice. From the governmental perspective, ICER ranged from $412 to $1050 and from $77 to $715 when considering the societal perspective. Sensitivity analysis highlights vaccine price as the main driver of uncertainty.
   Conclusion: Introduction of rotavirus vaccination is likely to be highly cost-effective in Mongolia, with ICERs estimated at only a fraction of Mongolia's per capita GDP. From an economic standpoint, ROTAVAC (R) is the least costly and most cost-effective product choice. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Lusvan, Munkh-Erdene; Purevsuren, Sugarmaa] Mongolian Natl Univ Med Sci, Sch Publ Hlth, Rm 334,S Zorig St, Ulaanbaatar, Mongolia.
   [Debellut, Frederic] PATH, Rue Varembe 7, CH-1202 Geneva, Switzerland.
   [Clark, Andrew] London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England.
   [Demberelsuren, Sodbayar] WHO, Representat Off Mongolia, Govt Bldg 8,Olymp St 2, Ulaanbaatar 14210, Mongolia.
   [Otgonbayar, Dashpagam; Batjargal, Tselkhaasuren] Minist Hlth, Natl Ctr Communicable Dis, Govt Bldg 8,Olymp St 2, Ulaanbaatar 14210, Mongolia.
   [Groman, Devin; Pecenka, Clint] PATH, 2201 Westlake Ave,Suite 200, Seattle, WA 98121 USA.
   [Tate, Jacqueline] Ctr Dis Control & Prevent, Atlanta, GA USA.
RP Debellut, F (reprint author), PATH, Rue Varembe 7, CH-1202 Geneva, Switzerland.
EM fdebellut@path.org
OI Debellut, Frederic/0000-0002-3027-2838
FU Bill & Melinda Gates Foundation, Seattle, WAGates Foundation
   [OPP1147721]
FX This work was supported by the Bill & Melinda Gates Foundation, Seattle,
   WA [grant number OPP1147721].
CR Andrus JK, 2007, PUBLIC HEALTH REP, V122, P811
   [Anonymous], 2013, Wkly Epidemiol Rec, V88, P49
   [Anonymous], COMMUNICATION
   Bertram MY, 2016, B WORLD HEALTH ORGAN, V94, P925, DOI 10.2471/BLT.15.164418
   Bhandari N, 2014, LANCET, V383, P2136, DOI 10.1016/S0140-6736(13)62630-6
   Bilcke J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006060
   Center for Disease Control and Prevention (CDC), PINK BOOK
   Center for Health development, 2015, HLTH IND
   Clark A, 2017, PLOS ONE, V12, DOI [10.1371/journal.pone.0183397e0183392, DOI 10.1371/JOURNAL.PONE.0183397E0183392]
   Clark A, EFFICACY ROTAVIRUS V
   Clark A, 2013, VACCINE, V31, pC19, DOI 10.1016/j.vaccine.2013.05.045
   Flem ET, 2009, J INFECT DIS, V200, pS195, DOI 10.1086/605040
   Gavi the vaccine alliance, TRANS PROC
   Gavi the vaccine alliance, DET PROD PROF
   Gavi the vaccine alliance, 2016, VACC PRIC COMM MAN
   Gavi the vaccine alliance, 2016, FAQ GLAXOSMITHKLINE
   Gherghita S, IMPACT ROTAVIRUS VAC
   Immunization Costing Action Network (ICAN), 2018, UN COST REP IMM DEL
   Immunization Division. Ministry of Health Family and Welfare. Government of India, 2015, OP GUID INTR ROT VAC
   Kotirum S, 2017, VACCINE, V35, P3364, DOI 10.1016/j.vaccine.2017.04.051
   Latipov R, 2011, INT J INFECT DIS, V15, pE464, DOI 10.1016/j.ijid.2011.03.014
   Management Sciences for Health, INT MED PROD PRIC GU
   Mongolian Statistical Information Service, POP MONG AG GROUP SE
   National Center for Communicable Diseases, 2011, COMPR MULT PLAN IMM
   National Statistical Office of Mongolia, 2015, MONG SOC IND SAMPL S
   NCHD, 2015, HLTH IND 2014 REP
   NCHD, 2014, HLTH IND 2013 REP
   NCHD, 2016, HLTH IND 2015 REP
   NCHD, 2017, HLTH IND 2016 REP
   NCHD, 2013, HLTH IND 2012 REP
   Pecenka C, 2018, VACCINE, V36, P7472, DOI 10.1016/j.vaccine.2018.10.068
   Salomon JA, 2015, LANCET GLOB HEALTH, V3, pE712, DOI 10.1016/S2214-109X(15)00069-8
   Samdan A, 2018, VACCINE, V36, P7883, DOI 10.1016/j.vaccine.2018.02.010
   Sanderson CFB, 2017, ANAL DHS MICS UNPUB
   Sundaram N, 2017, VACCINE, V35, P1055, DOI 10.1016/j.vaccine.2016.12.070
   Tate JE, 2016, CLIN INFECT DIS, V62, pS96, DOI 10.1093/cid/civ1013
   WHO, MONG NAT IMM PROGR I
   *WHO, WHO UNICEF EST IMM C
   World Health Organization, 2016, FACT SHEET VACC PRIC
   World Health Organization, 2003, MAKING CHOICES HLTH
   World Health Organization, VACC PROD PRIC PROC
   Yen C, ROTAVIRUS VACCINES C
   Zaman K, 2010, LANCET, V376, P615, DOI 10.1016/S0140-6736(10)60755-6
NR 43
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 4
PY 2019
VL 37
IS 6
BP 798
EP 807
DI 10.1016/j.vaccine.2018.12.056
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HK9WH
UT WOS:000458343100006
PM 30639458
OA Other Gold, Green Accepted, Green Published
DA 2020-05-12
ER

PT J
AU Baker, SM
   Pociask, D
   Clements, JD
   McLachlan, JB
   Morici, LA
AF Baker, Sarah M.
   Pociask, Derek
   Clements, John D.
   McLachlan, James B.
   Morici, Lisa A.
TI Intradermal vaccination with a Pseudomonas aeruginosa vaccine adjuvanted
   with a mutant bacterial ADP-ribosylating enterotoxin protects against
   acute pneumonia
SO VACCINE
LA English
DT Article
DE Pseudomonas aeruginosa; Bacteria; Intradermal; Vaccine; dmLT; Lung
ID HEAT-LABILE ENTEROTOXIN; OUTER-MEMBRANE PROTEIN; INTRANASAL
   IMMUNIZATION; MUCOSAL VACCINATION; LUNG INFECTION; TH17 RESPONSES; I
   VACCINE; OPRF-OPRI; T-CELLS; IMMUNITY
AB Respiratory infections are a leading cause of morbidity and mortality globally. This is partially due to a lack of effective vaccines and a clear understanding of how vaccination route and formulation influence protective immunity in mucosal tissues such as the lung. Pseudomonas aeruginosa is an opportunistic pathogen capable of causing acute pulmonary infections and is a leading cause of hospital-acquired and ventilator-associated pneumonia. With multidrug-resistant P. aeruginosa infections on the rise, the need for a vaccine against this pathogen is critical. Growing evidence suggests that a successful P. aeruginosa vaccine may require mucosal antibody and Th1- and Th17-type CD4(+) T cells to prevent pulmonary infection. Intradermal immunization with adjuvants, such as the bacterial ADP-Ribosylating Enterotoxin Adjuvant (BARE) double mutant of E. coli heat-labile toxin (dmLT), can direct protective immune responses to mucosal tissues, including the lungs. We reasoned that intradermal immunization with P. aeruginosa outer membrane proteins (OMPs) adjuvanted with dmLT could drive neutralizing antibodies and migration of CD4(+) T cells to the lungs and protect against P. aeruginosa pneumonia in a murine model. Here we show that mice immunized with OMPs and dmLT had significantly more antigen-specific IgG and TH1- and Th17-type CD4(+) memory T cells in the pulmonary environment compared to control groups of mice. Furthermore, OMPs and dmLT immunized mice were significantly protected against an otherwise lethal lung infection. Protection was associated with early IFN-gamma and IL-17 production in the lungs of immunized mice. These results indicate that intradermal immunization with dmLT can drive protective immunity to the lung mucosa and may be a viable vaccination strategy for a multitude of respiratory pathogens. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Baker, Sarah M.; Clements, John D.; McLachlan, James B.; Morici, Lisa A.] Tulane Univ, Sch Med, Dept Microbiol & Immunol, 1430 Tulane Ave, New Orleans, LA 70112 USA.
   [Pociask, Derek] Tulane Univ, Sch Med, Dept Med, 1430 Tulane Ave, New Orleans, LA 70112 USA.
RP Morici, LA (reprint author), 1430 Tulane Ave, New Orleans, LA 70112 USA.
EM lmorici@tulane.edu
OI Baker, Sarah/0000-0002-0177-8135
FU Tulane University Carol Lavin Bernick Faculty Grant
FX This work was supported by a Tulane University Carol Lavin Bernick
   Faculty Grant to L.M.
CR Baldwin SL, 2009, VACCINE, V27, P3063, DOI 10.1016/j.vaccine.2009.03.018
   Baumann U, 2004, VACCINE, V22, P840, DOI 10.1016/j.vaccine.2003.11.029
   Baumann U, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-57
   Bowe F, 2004, INFECT IMMUN, V72, P4052, DOI 10.1128/IAI.72.7.4052-4060.2004
   Centers for Disease Control and Prevention, 2013, ANT RES THREATS US
   Centers for Disease Control and Prevention, 2015, EPIDEMIOLOGY PREVENT
   Chen K, 2011, IMMUNITY, V35, P997, DOI 10.1016/j.immuni.2011.10.018
   Conti P, 2001, ALLERGY ASTHMA PROC, V22, P133, DOI 10.2500/108854101778148737
   DANDREA A, 1993, J EXP MED, V178, P1041, DOI 10.1084/jem.178.3.1041
   Dudda JC, 2004, TRENDS IMMUNOL, V25, P417, DOI 10.1016/j.it.2004.05.008
   Dufour JH, 2002, J IMMUNOL, V168, P3195, DOI 10.4049/jimmunol.168.7.3195
   FINKE M, 1990, INFECT IMMUN, V58, P2241, DOI 10.1128/IAI.58.7.2241-2244.1990
   Frederick DR, 2018, MUCOSAL IMMUNOL, V11, P549, DOI 10.1038/mi.2017.70
   Gocke K, 2003, FEMS IMMUNOL MED MIC, V37, P167, DOI 10.1016/S0928-8244(03)00094-4
   Hancock R.E.W., HANCOCK LAB METHODS
   Hartl D, 2006, J ALLERGY CLIN IMMUN, V117, P204, DOI 10.1016/j.jaci.2005.09.023
   Hassan R, 2018, J MICROBIOL IMMUNOL, V51, P312, DOI 10.1016/j.jmii.2016.08.014
   Heine SJ, 2014, J IMMUNOL, V192, P1630, DOI 10.4049/jimmunol.1302743
   Jakobsen H, 2002, INFECT IMMUN, V70, P1443, DOI 10.1128/IAI.70.3.1443-1452.2002
   Kamei A, 2013, J INFECT DIS, V207, P39, DOI 10.1093/infdis/jis657
   Kamei A, 2011, INFECT IMMUN, V79, P1289, DOI 10.1128/IAI.01139-10
   Knapp B, 1999, VACCINE, V17, P1663, DOI 10.1016/S0264-410X(98)00420-4
   Kumar P, 2013, CURR OPIN IMMUNOL, V25, P373, DOI 10.1016/j.coi.2013.03.011
   Lakatos HF, 2006, EXP LUNG RES, V32, P181, DOI 10.1080/01902140600817465
   Larbig M, 2001, VACCINE, V19, P2291, DOI 10.1016/S0264-410X(00)00550-8
   Larena M, 2015, J IMMUNOL, V194, P3829, DOI 10.4049/jimmunol.1401633
   Leach S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051718
   Lu YJ, 2010, CLIN VACCINE IMMUNOL, V17, P1005, DOI 10.1128/CVI.00036-10
   Lundgren A, 2013, VACCINE, V31, P1163, DOI 10.1016/j.vaccine.2012.12.063
   Mahler M, 2014, LAB ANIM-UK, V48, P178, DOI 10.1177/0023677213516312
   Mansouri E, 2003, FEMS IMMUNOL MED MIC, V37, P161, DOI 10.1016/S0928-8244(03)00072-5
   Merakou C, 2018, SURG INFECT, V19, P757, DOI 10.1089/sur.2018.233
   Moser C, 2002, CLIN EXP IMMUNOL, V127, P206, DOI 10.1046/j.1365-2249.2002.01731.x
   Norton EB, 2015, VACCINE, V33, P1909, DOI 10.1016/j.vaccine.2015.02.069
   Norton EB, 2012, INFECT IMMUN, V80, P2426, DOI 10.1128/IAI.00181-12
   Novotny LA, 2011, MUCOSAL IMMUNOL, V4, P456, DOI 10.1038/mi.2011.6
   Novotny LA, 2013, VACCINE, V31, P3417, DOI 10.1016/j.vaccine.2012.10.033
   Priebe GP, 2008, J IMMUNOL, V181, P4965, DOI 10.4049/jimmunol.181.7.4965
   Priebe GP, 2014, EXPERT REV VACCINES, V13, P507, DOI 10.1586/14760584.2014.890053
   Ryan EJ, 1999, INFECT IMMUN, V67, P6270
   Scharton-Kersten T, 2000, INFECT IMMUN, V68, P5306, DOI 10.1128/IAI.68.9.5306-5313.2000
   Shindo Y, 2017, J LEUKOCYTE BIOL, V101, P543, DOI 10.1189/jlb.4A1215-581R
   Sievert DM, 2013, INFECT CONT HOSP EP, V34, P1, DOI 10.1086/668770
   Sorichter S, 2009, VACCINE, V27, P2755, DOI 10.1016/j.vaccine.2009.03.010
   Sornasse T, 1996, J EXP MED, V184, P473, DOI 10.1084/jem.184.2.473
   Tozuka M, 2016, J DERMATOL SCI, V82, P38, DOI 10.1016/j.jdermsci.2015.11.008
   Tufail S, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00254
   Unsinger J, 2010, J IMMUNOL, V184, P3768, DOI 10.4049/jimmunol.0903151
   Weber DJ, 2007, INFECT CONT HOSP EP, V28, P825, DOI 10.1086/518460
   Wojnarowski C, 1999, EUR RESPIR J, V14, P1136, DOI 10.1183/09031936.99.14511369
   Woolard MD, 2008, INFECT IMMUN, V76, P2651, DOI 10.1128/IAI.01412-07
   Yang F, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04029-5
NR 52
TC 2
Z9 2
U1 1
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 4
PY 2019
VL 37
IS 6
BP 808
EP 816
DI 10.1016/j.vaccine.2018.12.053
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HK9WH
UT WOS:000458343100007
PM 30638799
DA 2020-05-12
ER

PT J
AU Mooij, P
   Grodeland, G
   Koopman, G
   Andersen, TK
   Mortier, D
   Nieuwenhuis, IG
   Verschoor, EJ
   Fagrouch, Z
   Bogers, WM
   Bogen, B
AF Mooij, Petra
   Grodeland, Gunnveig
   Koopman, Gerrit
   Andersen, Tor Kristian
   Mortier, Daniella
   Nieuwenhuis, Ivonne G.
   Verschoor, Ernst J.
   Fagrouch, Zahra
   Bogers, Willy M.
   Bogen, Bjarne
TI Needle-free delivery of DNA: Targeting of hemagglutinin to MHC class II
   molecules protects rhesus macaques against H1N1 influenza
SO VACCINE
LA English
DT Article
DE Influenza; DNA vaccine; Antigen presenting cell; APC-targeted antigen;
   Non-human primates
ID ANTIGEN-PRESENTING CELLS; NONHUMAN-PRIMATES; IN-VIVO; VACCINE;
   RESPONSES; IMMUNOGENICITY; LYMPHOCYTES; EFFICACY; INSIGHTS
AB Conventional influenza vaccines are hampered by slow and limited production capabilities, whereas DNA vaccines can be rapidly produced for global coverage in the event of an emerging pandemic. However, a drawback of DNA vaccines is their generally low immunogenicity in non-human primates and humans. We have previously demonstrated that targeting of influenza hemagglutinin to human HLA class II molecules can increase antibody responses in larger animals such as ferrets and pigs. Here, we extend these observations by immunizing non-human primates (rhesus macaques) with a DNA vaccine encoding a bivalent fusion protein that targets influenza virus hemagglutinin (HA) to Mamu class II molecules. Such immunization induced neutralizing antibodies and antigen-specific T cells. The DNA was delivered by pain- and needle-free jet injections intradermally. No adverse effects were observed. Most importantly, the immunized rhesus macaques were protected against a challenge with influenza virus. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Mooij, Petra; Koopman, Gerrit; Mortier, Daniella; Nieuwenhuis, Ivonne G.; Verschoor, Ernst J.; Fagrouch, Zahra; Bogers, Willy M.] Biomed Primate Res Ctr, Rijswijk, Netherlands.
   [Grodeland, Gunnveig; Andersen, Tor Kristian; Bogen, Bjarne] Univ Oslo, Inst Clin Med, KG Jebsen Ctr Influenza Vaccine Res, N-0027 Oslo, Norway.
   [Grodeland, Gunnveig; Andersen, Tor Kristian; Bogen, Bjarne] Oslo Univ Hosp, N-0027 Oslo, Norway.
RP Grodeland, G (reprint author), Univ Oslo, Inst Clin Med, KG Jebsen Ctr Influenza Vaccine Res, N-0027 Oslo, Norway.; Grodeland, G (reprint author), Oslo Univ Hosp, N-0027 Oslo, Norway.
EM gunnveig.grodeland@medisin.uio.no
OI Grodeland, Gunnveig/0000-0001-6285-3162
FU K.G. Jebsen Foundation, Norway; Biomedical Primate Research Center,
   Rijswijk, The Netherlands; EUPRIM-Net under the EU of the 7th Framework
   Programme [262443]
FX We thank Pharmajet Inc. for providing the apparatus for jet injections,
   and Dr. Y. Li and Dr. G. Kobinger from the Public Health Agency of
   Canada, National Microbiology Laboratory, Canadian Science Centre for
   Human and Animal Health, Winnipeg, MB, Canada for providing the
   influenza A/Mexico/InDRE4487/2009 (H1N1) (Mex4487) virus. The technical
   help of H. Niphuis, Dr. I. Kondova, A.G.M. Haaksma, Dr. G Doxiadis, and
   F. van Hassel (all from the Biomedical Primate Research Center,
   Rijswijk, The Netherlands), is gratefully acknowledged. This study was
   funded by the K.G. Jebsen Foundation, Norway, the Biomedical Primate
   Research Center, Rijswijk, The Netherlands, and part of this work has
   been supported by EUPRIM-Net under the EU contract 262443 of the 7th
   Framework Programme. The funders had no role in study design, data
   collection and interpretation, or the decision to submit the work for
   publication.
CR Black APB, 2007, EUR J IMMUNOL, V37, P1485, DOI 10.1002/eji.200636915
   CARAYANNIOTIS G, 1987, NATURE, V327, P59, DOI 10.1038/327059a0
   Daniel S, 1997, J IMMUNOL, V159, P2350
   Daza-Vamenta R, 2004, GENOME RES, V14, P1501, DOI 10.1101/gr.2134504
   Dominguez A, 2016, EXPERT REV VACCINES, P1
   Engelke L, 2015, VACCINE, V33, P4663, DOI 10.1016/j.vaccine.2015.05.012
   Fossum E, 2015, EUR J IMMUNOL, V45, P624, DOI 10.1002/eji.201445080
   Fredriksen AB, 2006, MOL THER, V13, P776, DOI 10.1016/j.ymthe.2005.10.019
   Fredriksen AB, 2007, BLOOD, V110, P1797, DOI 10.1182/blood-2006-06-032938
   Grodeland G, 2016, J IMMUNOL, V197, P3575, DOI 10.4049/jimmunol.1600893
   Grodeland G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080008
   Grodeland G, 2013, J IMMUNOL, V191, P3221, DOI 10.4049/jimmunol.1300504
   KAWAMURA H, 1986, J IMMUNOL, V136, P58
   Kim BS, 2009, J INVEST DERMATOL, V129, P2805, DOI 10.1038/jid.2009.176
   Koday MT, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189780
   Koopman G, 2016, J VIROL, V90, P1023, DOI 10.1128/JVI.02757-15
   Kuroda MJ, 1999, J VIROL, V73, P1573, DOI 10.1128/JVI.73.2.1573-1579.1999
   Laddy DJ, 2009, J VIROL, V83, P4624, DOI 10.1128/JVI.02335-08
   Ledgerwood JE, 2015, CLIN TRIALS
   Liang F, 2017, MOL THER, V25, P2635, DOI 10.1016/j.ymthe.2017.08.006
   Loudon PT, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011021
   Lovas TO, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108069
   McAllister L, 2014, LANCET, V384, P674, DOI 10.1016/S0140-6736(14)60524-9
   McClain MT, 2016, CLIN EXP IMMUNOL, V183, P441, DOI 10.1111/cei.12736
   Mooij P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126132
   NICKOLOFF BJ, 1994, IMMUNOL TODAY, V15, P464, DOI 10.1016/0167-5699(94)90190-2
   Osterholm MT, 2012, LANCET INFECT DIS, V12, P36, DOI 10.1016/S1473-3099(11)70295-X
   Peng BW, 2007, VACCINE, V25, P2064, DOI 10.1016/j.vaccine.2006.11.042
   Poon LLM, 2009, CLIN CHEM, V55, P1555, DOI 10.1373/clinchem.2009.130229
   Rivera-Hernandez T, 2014, DISCOV MED, V18, P313
   Safronetz D, 2011, J VIROL, V85, P1214, DOI 10.1128/JVI.01848-10
   SLIERENDREGT BL, 1994, J IMMUNOL, V152, P2298
   Slukvin II, 2001, J REPROD IMMUNOL, V50, P57, DOI 10.1016/S0165-0378(00)00090-5
   SNIDER DP, 1987, J IMMUNOL, V139, P1609
   Thompson EA, 2017, CURR OPIN IMMUNOL, V47, P1, DOI 10.1016/j.coi.2017.06.006
NR 35
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 4
PY 2019
VL 37
IS 6
BP 817
EP 826
DI 10.1016/j.vaccine.2018.12.049
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HK9WH
UT WOS:000458343100008
PM 30638800
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Khan, AI
   Islam, MS
   Islam, MT
   Ahmed, A
   Chowdhury, MI
   Chowdhury, F
   Siddik, MAU
   Clemens, JD
   Qadri, F
AF Khan, Ashraful Islam
   Islam, Muhammad Shariful
   Islam, Md. Taufiqul
   Ahmed, Azimuddin
   Chowdhury, Mohiul Islam
   Chowdhury, Fahima
   Siddik, Md. Ashraf Uddin
   Clemens, John D.
   Qadri, Firdausi
TI Oral cholera vaccination strategy: Self-administration of the second
   dose in urban Dhaka, Bangladesh
SO VACCINE
LA English
DT Article
DE Oral cholera vaccine; Self-administration; Urban; Bangladesh
ID COVERAGE
AB Cholera remains a major public health problem in many developing countries including Bangladesh. The oral cholera vaccine (OCV) is now considered a key component of the public health response to cholera. Although maintaining cold chain and organizing human resource are the major challenges of vaccine delivery to the community. Here we applied an innovative approach to second dose OCV delivery to minimize financial and logistic burdens. The purpose of this study was to assess the feasibility and compliance of second dose self-administration when the second dose was provided in a plastic bag to first dose vaccine recipients as OCV is stable for up to 42 days at ambient temperatures. We aimed to deploy vaccines (N = 112,000) left over from other studies to 56,000 people aged >= one year living in Mirpur, Dhaka to see the feasibility of self-administration strategy. During vaccination, the first OCV dose (OCV1) was given from fixed sites and the second dose (OCV2) was provided in a plastic zip-lock bag for the participant to take the vaccine two weeks later at home. Participants were instructed to keep the vaccine away from light and in a dry cool place. Empty vials were collected following the end date of the scheduled second vaccination. Of the targeted population, 41,694 (74%) received the first OCV dose whereas an estimated 38,852 (93% of those receiving the first dose) received the second dose which represents a 7% drop out rate from OCV1 to OCV2. However the average two dose coverage was 69%. A survey of a subsample 2990 (from 8551) randomly selected households revealed that almost all respondents (98.75%) appreciated this new self-administration strategy and considered the strategy to be more practical and convenient than the usual method. This simplified, self-administered delivery strategy provides an ideal alternative for second-dose OCV delivery in hard-to-reach populations and resource-poor settings. (C) 2019 International Centre for Diarrhoea, Disease Research, Bangladesh. Published by Elsevier Ltd.
C1 [Khan, Ashraful Islam; Islam, Muhammad Shariful; Islam, Md. Taufiqul; Ahmed, Azimuddin; Chowdhury, Mohiul Islam; Chowdhury, Fahima; Siddik, Md. Ashraf Uddin; Clemens, John D.; Qadri, Firdausi] Int Ctr Diarrheal Dis Res Bangladesh Icddr b, Dhaka, Bangladesh.
RP Qadri, F (reprint author), Icddr b, 68 Shaheed Tajuddin Ahmed Sharani, Dhaka 1212, Bangladesh.
EM fqadri@icddrb.org
RI Al, Mamun M./AAF-5850-2019; Qadri, Firdausi/AAF-4583-2019
FU Gavi [CP65621217A2]
FX This study was supported partly by the Gavi (USD 70,000), contract
   number CP65621217A2. The study was also supported by core grants to the
   icddr,b.
CR ALBERT MJ, 1993, LANCET, V342, P387
   Ali M, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003832
   [Anonymous], 2017, Wkly Epidemiol Rec, V92, P301
   Bhattacharya S, 2013, LANCET INFECT DIS, V13, P1050, DOI 10.1016/S1473-3099(13)70273-1
   Chowdhury F, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000999
   Ciglenecki I, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001512
   EPI D MoHFW, 2015, BANGL EPI COV EV SUR
   Hardt K, 2016, VACCINE, V34, P6691, DOI 10.1016/j.vaccine.2016.10.078
   Ivers LC, 2013, AM J TROP MED HYG, V89, P617, DOI 10.4269/ajtmh.13-0183
   Kar SK, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002629
   Khan IA, 2013, VACCINE, V31, P6058, DOI 10.1016/j.vaccine.2013.10.021
   Mohiuddin H, 2014, 5 INT C ENV ASP BANG
   mondiale de la Sante O Organization WH., 2017, WEEKLY EPIDEMIOLOGIC, V92, P477
   Msyamboza KP, 2016, PAN AFRIC MED J, V23
   Organization WH, 2010, OR CHOL VACC MASS IM
   Pugliese-Garcia M, 2018, VACCINE, V36, P5617, DOI [10.1016/j.vaccine.2018.07.042, 10.1016/j.vaccine.2017.10.108]
   Qadri F, 2018, LANCET INFECT DIS, V18, P666, DOI 10.1016/S1473-3099(18)30108-7
   Qadri F, 2015, LANCET, V386, P1362, DOI 10.1016/S0140-6736(15)61140-0
   Saha A, 2016, VACCINE, V34, P1551, DOI 10.1016/j.vaccine.2016.02.020
   Sauvageot D, 2017, VACCINE, V35, P5194, DOI 10.1016/j.vaccine.2017.07.104
   Sur D, 2009, LANCET, V374, P1694, DOI 10.1016/S0140-6736(09)61297-6
   WHO, 2018, WHO PREQ VACC
NR 22
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 4
PY 2019
VL 37
IS 6
BP 827
EP 832
DI 10.1016/j.vaccine.2018.12.048
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HK9WH
UT WOS:000458343100009
PM 30639459
OA Other Gold
DA 2020-05-12
ER

PT J
AU Jalloh, MF
   Bennett, SD
   Alam, D
   Kouta, P
   Lourenco, D
   Alamgir, M
   Feldstein, LR
   Ehlman, DC
   Abad, N
   Kapil, N
   Vandenent, M
   Conklin, L
   Wolff, B
AF Jalloh, Mohamed F.
   Bennett, Sarah D.
   Alam, Didarul
   Kouta, Paryss
   Lourenco, Dalia
   Alamgir, Mohammad
   Feldstein, Leora R.
   Ehlman, Daniel C.
   Abad, Neetu
   Kapil, Neha
   Vandenent, Maya
   Conklin, Laura
   Wolff, Brent
TI Rapid behavioral assessment of barriers and opportunities to improve
   vaccination coverage among displaced Rohingyas in Bangladesh, January
   2018
SO VACCINE
LA English
DT Article
DE Rohingya; Diphtheria; Vaccine; Barriers; Hesitancy; Demand
ID HESITANCY CAUSES; STRATEGIES; COMMUNICATION; INTERVENTIONS;
   CONSEQUENCES; ACCEPTANCE; ZIMBABWE; REFUSAL; CALL
AB Background: In November 2017, the World Health Organization received initial reports of suspected diphtheria cases in camps established for displaced Rohingyas in Cox's Bazar district, Bangladesh. By January 11, 2018, over 4,000 suspected cases of diphtheria and 30 deaths were reported. The Bangladesh government and partners implemented a diphtheria vaccination campaign in December 2017. Outbreak response staff reported anecdotal evidence of vaccine hesitancy. Our assessment aimed to understand vaccination barriers and opportunities to enhance vaccine demand among displaced Rohingyas in Bangladesh.
   Methods: In January 2018, we conducted a qualitative assessment consisting of nine focus group discussions and 15 key informant interviews with displaced Rohingyas in three camps. Participants included mothers and fathers with under five-year-old children, community volunteers, majhis (camp leaders), Islamic religious leaders, traditional and spiritual healers, and teachers. We recruited participants using purposive sampling, and analyzed the data thematically.
   Results: Across focus groups and in-depth interviews, trusted information sources cited by participants included religious leaders, elders, village doctors, pharmacists, majhis, and mothers trained by non-governmental organizations to educate caregivers. Treatment of diphtheria and measles was usually sought from multiple sources including traditional and spiritual healers, village doctors, pharmacies, and health clinics. Major barriers to vaccination included: various beliefs about vaccination causing people to become Christian; concerns about multiple vaccines being received on the same day; worries about vaccination side effects; and, lack of sensitivity to cultural gender norms at the vaccination sites.
   Conclusion: Although vaccination was understood as an important intervention to prevent childhood diseases, participants reported numerous barriers to vaccination. Strengthening vaccine demand and acceptance among displaced Rohingyas can be enhanced by improving vaccination delivery practices and engaging trusted leaders to address religious and cultural barriers using community-based channels. Published by Elsevier Ltd.
C1 [Jalloh, Mohamed F.; Bennett, Sarah D.; Feldstein, Leora R.; Ehlman, Daniel C.; Abad, Neetu; Conklin, Laura; Wolff, Brent] US Ctr Dis Control & Prevent, Immunizat Syst Branch, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA 30329 USA.
   [Alam, Didarul; Kouta, Paryss; Alamgir, Mohammad] UNICEF Field Off, Coxs Bazar, Bangladesh.
   [Kouta, Paryss] Commun Communities, Coxs Bazar, Bangladesh.
   [Lourenco, Dalia] WHO, Field Off, Coxs Bazar, Bangladesh.
   [Kapil, Neha; Vandenent, Maya] UNICEF Country Off, Dhaka, Bangladesh.
RP Jalloh, MF (reprint author), US Ctr Dis Control & Prevent, Immunizat Syst Branch, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA 30329 USA.
EM yum8@cdc.gov
OI Ehlman, Daniel/0000-0001-6817-2739
FU World Health OrganizationWorld Health Organization [001]
CR Butler R, 2015, VACCINE, V33, P4176, DOI 10.1016/j.vaccine.2015.04.038
   Chan EYY, 2018, INT J INFECT DIS, V68, P39, DOI 10.1016/j.ijid.2018.01.001
   Domachowske JB, 2013, HUM VACC IMMUNOTHER, V9, P2654, DOI 10.4161/hv.26783
   Dube E, 2018, VACCINE, V36, P1509, DOI 10.1016/j.vaccine.2017.12.012
   Dube E, 2015, VACCINE, V33, P4191, DOI 10.1016/j.vaccine.2015.04.041
   Dube E, 2015, EXPERT REV VACCINES, V14, P99, DOI 10.1586/14760584.2015.964212
   Dube E, 2014, VACCINE, V32, P6649, DOI 10.1016/j.vaccine.2014.09.039
   Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657
   Edwards KM, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-2146
   Eskola J, 2015, VACCINE, V33, P4215, DOI 10.1016/j.vaccine.2015.04.043
   Forbes TA, 2015, HUM VACC IMMUNOTHER, V11, P2895, DOI 10.1080/21645515.2015.1070997
   FRIEDRICH MJ, 2018, JAMA-J AM MED ASSOC, V319, P648, DOI DOI 10.1001/JAMA.2018.0964
   Gerede R, 2017, J RELIG HEALTH, V56, P1692, DOI 10.1007/s10943-017-0435-8
   Goldstein S, 2015, VACCINE, V33, P4212, DOI 10.1016/j.vaccine.2015.04.042
   Handy LK, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180759
   Jarrett C, 2015, VACCINE, V33, P4180, DOI 10.1016/j.vaccine.2015.04.040
   Kaufman J, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4320-x
   Kestenbaum LA, 2015, PEDIATR ANN, V44, pE71, DOI 10.3928/00904481-20150410-07
   Kriss JL, 2016, PAN AFR MED J, V24, DOI 10.11604/pamj.2016.24.47.8663
   Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081
   MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036
   Machekanyanga Z, 2017, J RELIG HEALTH, V56, P1683, DOI 10.1007/s10943-017-0428-7
   McClure CC, 2017, CLIN THER, V39, P1550, DOI 10.1016/j.clinthera.2017.07.003
   Odone A, 2015, HUM VACC IMMUNOTHER, V11, P72, DOI 10.4161/hv.34313
   Oku A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186733
   Oku A, 2016, GLOBAL HEALTH ACTION, V9, DOI 10.3402/gha.v9.30337
   Patel PR, 2013, HUM VACC IMMUNOTHER, V9, P2649, DOI 10.4161/hv.26224
   Peprah D, 2016, VACCINE, V34, P3823, DOI 10.1016/j.vaccine.2016.05.038
   Sadaf A, 2013, VACCINE, V31, P4293, DOI 10.1016/j.vaccine.2013.07.013
   Salmon DA, 2015, VACCINE, V33, pD66, DOI 10.1016/j.vaccine.2015.09.035
   Salmon DA, 2015, AM J PREV MED, V49, pS391, DOI 10.1016/j.amepre.2015.06.009
   Schmid P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170550
   Smith MJ, 2015, INFECT DIS CLIN N AM, V29, P759, DOI 10.1016/j.idc.2015.07.004
   Smith TC, 2017, OPEN FORUM INFECT DI, V4, DOI 10.1093/ofid/ofx146
   Taylor S, 2017, VACCINE, V35, P6438, DOI 10.1016/j.vaccine.2017.09.075
   Translators Without Borders, 2017, ROH ZUB
   UNICEF, 2018, 22 UNICEF
   United Nations, 2017, FORC DISPL MYANM NAT
   WHO, 2018, BANGL ROH REF CRIS 2
   WHO, 2017, DIPHTH COXS BAZ BANG
   Williams SE, 2014, HUM VACC IMMUNOTHER, V10, P2584, DOI 10.4161/hv.28596
   World Health Organization, 2015, DIPHTH
NR 42
TC 3
Z9 3
U1 1
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 4
PY 2019
VL 37
IS 6
BP 833
EP 838
DI 10.1016/j.vaccine.2018.12.042
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HK9WH
UT WOS:000458343100010
PM 30642728
DA 2020-05-12
ER

PT J
AU Wang, XL
   Tang, QX
   Qiu, L
   Yang, ZQ
AF Wang, Xinglong
   Tang, Qiuxia
   Qiu, Li
   Yang, Zengqi
TI Penton-dodecahedron of fowl adenovirus serotype 4 as a vaccine candidate
   for the control of related diseases
SO VACCINE
LA English
DT Article
DE Adenovirus; Penton-dodecahedron; Immunization; Protection
ID VIRUS-LIKE PARTICLES; HYDROPERICARDIUM SYNDROME; PROTEIN TRANSDUCTION;
   PROTECTIVE EFFICACY; SOLUBLE COMPONENTS; IMMUNE-RESPONSES;
   HEPARAN-SULFATE; INTERNALIZATION; INFECTIONS; ATTACHMENT
AB In some serotypes of adenovirus (Ad), the penton base and attached trimeric fiber assemble into dodecameric virus-like particles called penton-dodecahedron (Pt-Dd), which can be internalized and used to deliver the vaccine antigens and drugs. Fowl adenovirus serotype 4 (FAdV-4) is an important pathogen, causing seriously economic loss to poultry industry in China and other counties. Pt-Dd particles from FAdV-4 infected cells, as well as in those infected with recombinant human Ad expressing fiber-1, fiber-2, and penton base of FAdV-4, were visualized by transmission electron microscopy. For the first time, we proved that FAdV-4 produced Pt-Dd in infected cells. Pt-Dd can also be assembled by the over expressed recombinant proteins fiber-1, fiber-2, and penton base. Pt-Dd, as well as the recombinant proteins fiber-1, fiber-2, and penton base, were then used to immunize chickens. The humoral immune response, expression of selected immune molecules and challenge results were used to evaluate the immune efficacy of the vaccine candidates. Pt-Dd induced the highest level of enzyme-linked immunosorbent assay antibodies and significant high levels (p < 0.05) of interferon gamma, interleukin-4, and major histocompatibility complex II expression in peripheral blood mononuclear cells at 48 h post-infection. The challenge results showed that Pt-Dd, inactivated FAdV-4 vaccine, and fiber-1 induced the best protection (100%), followed by fiber-2 (80%) and penton base (67%). The present study showed that FAdV-4-Pt-Dd and recombinant fiber-1 are promising FAdV-4 vaccine candidates and could be used to replace the tissue-sourced inactivated FAdV-4 vaccine. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Wang, Xinglong; Tang, Qiuxia; Qiu, Li; Yang, Zengqi] Northwest A&F Univ, Coll Vet Med, Yangling 712100, Shaanxi, Peoples R China.
RP Wang, XL; Yang, ZQ (reprint author), Northwest A&F Univ, Coll Vet Med, Yangling 712100, Shaanxi, Peoples R China.
EM wxlong@nwsauf.edu.cn; yzq1106@nwsuaf.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [31672581]
FX This work was supported by the National Natural Science Foundation of
   China (No. 31672581).
CR ANJUM AD, 1990, AVIAN PATHOL, V19, P655, DOI 10.1080/03079459008418721
   [Anonymous], 1966, VIROLOGY, V28, P236
   BOULANGER PA, 1976, INTERVIROLOGY, V7, P126, DOI 10.1159/000149946
   Davison AJ, 2003, J GEN VIROL, V84, P2895, DOI 10.1099/vir.0.19497-0
   Fender P, 1997, NAT BIOTECHNOL, V15, P52, DOI 10.1038/nbt0197-52
   Fender P, 2005, VIROLOGY, V340, P167, DOI 10.1016/j.virol.2005.06.030
   Fender P, 2003, J VIROL, V77, P4960, DOI 10.1128/JVI.77.8.4960-4964.2003
   Fender P, 2008, VIROLOGY, V371, P155, DOI 10.1016/j.virol.2007.09.026
   Garcel A, 2006, J GENE MED, V8, P524, DOI 10.1002/jgm.862
   Gelderblom H, 1967, J Gen Virol, V1, P553, DOI 10.1099/0022-1317-1-4-553
   Gupta A, 2017, VACCINE, V35, P2716, DOI 10.1016/j.vaccine.2017.03.075
   Hess M, 2000, AVIAN PATHOL, V29, P195, DOI 10.1080/03079450050045440
   Jia LJ, 2013, KOREAN J PARASITOL, V51, P247, DOI 10.3347/kjp.2013.51.2.247
   Kajon AE, 2016, EMERG INFECT DIS, V22, P730, DOI 10.3201/eid2204.151403
   Kang X, 2015, CANCER BIOL MED, V12, P362, DOI 10.7497/j.issn.2095-3941.2015.0063
   KARAYAN L, 1994, VIROLOGY, V202, P782, DOI 10.1006/viro.1994.1400
   Kim MS, 2014, VACCINE, V32, P3564, DOI 10.1016/j.vaccine.2014.03.015
   Kumar R, 1997, TROP ANIM HEALTH PRO, V29, P158, DOI 10.1007/BF02633014
   Li CJ, 2016, VET MICROBIOL, V197, P62, DOI 10.1016/j.vetmic.2016.11.005
   Liew MWO, 2012, BIOCHEM ENG J, V67, P88, DOI 10.1016/j.bej.2012.05.007
   Lion T, 2014, CLIN MICROBIOL REV, V27, P441, DOI 10.1128/CMR.00116-13
   Mansoor MK, 2011, TROP ANIM HEALTH PRO, V43, P331, DOI 10.1007/s11250-010-9694-z
   MCCRACKEN R M, 1976, Avian Pathology, V5, P325, DOI 10.1080/03079457608418202
   Naskalska A, 2009, VACCINE, V27, P7385, DOI 10.1016/j.vaccine.2009.09.021
   NORRBY E, 1968, J GEN VIROL, V2, P135, DOI 10.1099/0022-1317-2-1-135
   NORRBY E, 1968, VIROLOGY, V36, P201, DOI 10.1016/0042-6822(68)90137-2
   Pan Q, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01005
   Reddy VS, P NATL ACAD SCI US, P11715
   Martin CS, 2012, VIRUSES-BASEL, V4, P847, DOI 10.3390/v4050847
   Schachner A, 2014, VACCINE, V32, P1086, DOI 10.1016/j.vaccine.2013.12.056
   Schonewille E, 2010, AVIAN DIS, V54, P905, DOI 10.1637/8999-072309-Reg.1
   Shah MS, 2012, VACCINE, V30, P7153, DOI 10.1016/j.vaccine.2012.10.013
   Silva AC, 2010, CURR GENE THER, V10, P437
   Song LZ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002257
   Szolajska E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046075
   Turner RL, 2014, VIROLOGY, V456, P205, DOI 10.1016/j.virol.2014.03.010
   Villegas-Mendez A, 2010, MOL THER, V18, P1046, DOI 10.1038/mt.2010.16
   Vives RR, 2004, VIROLOGY, V321, P332, DOI 10.1016/j.virol.2004.01.015
   Wang X, 2017, VIRUS RES, V245, P1
   Wang XW, 2017, J INTERF CYTOK RES, V37, P467, DOI 10.1089/jir.2017.0043
   Wang XL, 2018, VIRUS RES, V245, P1, DOI 10.1016/j.virusres.2017.12.003
   Wang XL, 2012, VET IMMUNOL IMMUNOP, V145, P277, DOI 10.1016/j.vetimm.2011.11.014
   WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E
   WILCOX WC, 1963, J EXP MED, V118, P307, DOI 10.1084/jem.118.2.307
   Wold WSM, 2013, CURR GENE THER, V13, P421
   Xia J, 2017, EMERG MICROBES INFEC, V6, DOI 10.1038/emi.2017.91
   Zhang T, 2016, VIROL J, V13, DOI 10.1186/s12985-016-0644-x
   Zochowska M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005569
   Zubieta C, 2005, MOL CELL, V17, P121, DOI 10.1016/j.molcel.2004.11.041
NR 49
TC 2
Z9 2
U1 1
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 4
PY 2019
VL 37
IS 6
BP 839
EP 847
DI 10.1016/j.vaccine.2018.12.041
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HK9WH
UT WOS:000458343100011
PM 30642730
DA 2020-05-12
ER

PT J
AU Wallace, AS
   Wannemuehler, K
   Bonsu, G
   Wardle, M
   Nyaku, M
   Amponsah-Achiano, K
   Dadzie, JF
   Sarpong, FO
   Orenstein, WA
   Rosenberg, ES
   Omer, SB
AF Wallace, Aaron S.
   Wannemuehler, Kathleen
   Bonsu, George
   Wardle, Melissa
   Nyaku, Mawuli
   Amponsah-Achiano, Kwame
   Dadzie, John F.
   Sarpong, Frederick O.
   Orenstein, Walter A.
   Rosenberg, Eli S.
   Omer, Saad B.
TI Development of a valid and reliable scale to assess parents' beliefs and
   attitudes about childhood vaccines and their association with
   vaccination uptake and delay in Ghana
SO VACCINE
LA English
DT Article
DE Vaccine hesitancy; Vaccine acceptance; Ghana; Vaccination delay; Factor
   analysis
ID PUBLISHED LITERATURE; IMMUNIZATION STATUS; CONFIDENCE SCALE; HESITANCY;
   CHILDREN; SAFETY
AB Background: Parents' attitudes and beliefs in vaccination are important to understand for shaping vaccine acceptance and demand interventions. Little research has focused on developing a validated scale to measure parents' attitudes towards vaccinations in low and middle-income countries; Ghana provided an opportunity develop a caregiver vaccination attitudes scale (CVAS) validated against childhood vaccine compliance.
   Methods: We conducted a cluster survey of 373 households with children aged 12-35 months of age from Northern Region, Ghana. Caregivers responded to 22 vaccination behavior and belief survey items and provided the child's vaccination status. In exploratory factor analysis (EFA) to assess CVAS content validity, we used parallel analysis to guide the number of factors to extract and principal axis factor analysis for factor extraction. Reliability of the scale was assessed using McDonald's Omega coefficient. Criterion validity of scale and subscales was assessed against receipt of vaccinations by 12 months of age and vaccination delay, using number of days undervaccinated.
   Results: EFA of CVAS responses resulted in removing 11 of 22 survey items due to loadings <0.30 and development of a 5-factor structure with subscales for Vaccine-Preventable Disease (VPD) Awareness, Vaccine Benefits, Past Behavior, Vaccine Efficacy and Safety, and Trust. The 5 factors accounted for 69% of the common variance and omega coefficients were >0.73 for all subscales. Validity analysis indicated that for every unit increase in the parent's scale score, the odds of the child being vaccinated decreased by 0.58 (95% confidence interval [Cl]: 0.37, 0.68) and the number of days under-vaccinated increased by 86 (95%Cl: 28,143). The final 3-factor scale included Vaccine Benefits, Past Behavior, and Vaccine Efficacy and Safety.
   Discussion: The final CVAS included three factors associated with vaccine compliance in Ghana, although several survey items suggested for use in vaccine acceptance scales were dropped. Replicating this study in several country settings will provide additional evidence to assist in refining a tool for use in routine vaccine acceptance and demand surveillance efforts. Published by Elsevier Ltd.
C1 [Wallace, Aaron S.] Emory Univ, Dept Epidemiol, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA.
   [Wallace, Aaron S.; Wannemuehler, Kathleen; Wardle, Melissa; Nyaku, Mawuli; Omer, Saad B.] US Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
   [Bonsu, George; Amponsah-Achiano, Kwame; Dadzie, John F.; Sarpong, Frederick O.] Ghana Hlth Serv, Accra, Ghana.
   [Orenstein, Walter A.] Emory Univ, Sch Med, Div Infect Dis, Atlanta, GA 30322 USA.
   [Rosenberg, Eli S.] SUNY Albany, Sch Publ Hlth, Dept Epidemiol & Biostat, Albany, NY 12222 USA.
   [Omer, Saad B.] Emory Univ, Dept Global Hlth, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA.
RP Wallace, AS (reprint author), 1600 Clifton Rd, Atlanta, GA 30033 USA.
EM awallace@cdc.gov
OI Wannemuehler, Kathleen/0000-0001-9535-6277
FU United States Centers for Disease Control and PreventionUnited States
   Department of Health & Human ServicesCenters for Disease Control &
   Prevention - USA
FX This study was funded by the United States Centers for Disease Control
   and Prevention.
CR Akmatov MK, 2012, J EPIDEMIOL COMMUN H, V66, DOI 10.1136/jech.2010.124651
   Azizi FSM, 2017, VACCINE, V35, P2955, DOI 10.1016/j.vaccine.2017.04.010
   Baglin J., 2014, PRACTICAL ASSESSMENT, V19, P2
   Clark LA, 1995, PSYCHOL ASSESSMENT, V7, P309, DOI 10.1037/1040-3590.7.3.309
   Cooper S, 2018, HUM VACCINES IMMUNOT
   CURETON EE, 1975, PSYCHOMETRIKA, V40, P183, DOI 10.1007/BF02291565
   Domek GJ, 2018, VACCINE, V36, P5273, DOI 10.1016/j.vaccine.2018.07.046
   Furr M, 2011, SCALE CONSTRUCTION P
   Gilkey MB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159087
   Gilkey MB, 2016, ACAD PEDIATR, V16, P42, DOI 10.1016/j.acap.2015.06.007
   Gilkey MB, 2014, VACCINE, V32, P6259, DOI 10.1016/j.vaccine.2014.09.007
   Gust D, 2005, AM J HEALTH BEHAV, V29, P81, DOI 10.5993/AJHB.29.1.7
   Gust DA, 2004, PEDIATRICS, V114, pE16, DOI 10.1542/peds.114.1.e16
   Gust DA, 2005, AM J PREV MED, V29, P105, DOI 10.1016/j.amepre.2005.04.010
   Gust DA, 2008, PEDIATRICS, V122, P718, DOI 10.1542/peds.2007-0538
   Kennedy AM, 2005, PUBLIC HEALTH REP, V120, P252, DOI 10.1177/003335490512000306
   Larson HJ, 2015, VACCINE, V33, P4165, DOI 10.1016/j.vaccine.2015.04.037
   Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081
   Larson HJ, 2015, PLOS CURR
   Lorenzo-Seva U, 2017, FACTOR COMPUTER PROG
   Luman ET, 2005, JAMA-J AM MED ASSOC, V293, P1204, DOI 10.1001/jama.293.10.1204
   MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036
   McNeish D., 2017, THANKS COEFFICIENT A
   McRee AL, 2010, SEX TRANSM DIS, V37, P234, DOI 10.1097/OLQ.0b013e3181c37e15
   Munoz DC, 2015, INT J PUBLIC HEALTH, V60, P767, DOI 10.1007/s00038-015-0715-6
   Nyaku M, 2017, PAN AFR MED J S3, V27
   Opel DJ, 2013, JAMA PEDIATR, V167, P1065, DOI 10.1001/jamapediatrics.2013.2483
   Opel DJ, 2011, VACCINE, V29, P6598, DOI 10.1016/j.vaccine.2011.06.115
   Opel DJ, 2011, HUM VACCINES, V7, P419, DOI 10.4161/hv.7.4.14120
   Holgado-Tello FP, 2010, QUAL QUANT, V44, P153, DOI 10.1007/s11135-008-9190-y
   Perez S, 2016, SEX TRANSM DIS, V43, P626, DOI 10.1097/OLQ.0000000000000506
   Prislin R, 1998, AM J PUBLIC HEALTH, V88, P1821, DOI 10.2105/AJPH.88.12.1821
   Rainey JJ, 2011, VACCINE, V29, P8215, DOI 10.1016/j.vaccine.2011.08.096
   Revelle W., 2017, PSYCH PROCEDURES PER
   Roberts JR, 2015, VACCINE, V33, P1748, DOI 10.1016/j.vaccine.2015.01.068
   Salmon DA, 2015, VACCINE, V33, pD66, DOI 10.1016/j.vaccine.2015.09.035
   Salmon Daniel A, 2009, WMJ, V108, P17
   Shui IM, 2006, AM J PREV MED, V31, P244, DOI 10.1016/j.amepre.2006.04.006
   Thomas TL, 2013, J NURS MEAS, V21, P96, DOI 10.1891/1061-3749.21.1.96
   Trizano-Hermosilla I, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.00769
   TVERSKY A, 1973, COGNITIVE PSYCHOL, V5, P207, DOI 10.1016/0010-0285(73)90033-9
   World Health Organization, 2014, REP SAGE WORK GROUP
NR 42
TC 3
Z9 3
U1 0
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 4
PY 2019
VL 37
IS 6
BP 848
EP 856
DI 10.1016/j.vaccine.2018.12.055
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HK9WH
UT WOS:000458343100012
PM 30642731
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Arora, G
   Lehman, D
   Charlu, S
   Ross, N
   Ardy, A
   Gordon, B
   Pannaraj, PS
AF Arora, Gitanjli
   Lehman, Deborah
   Charlu, Sandhya
   Ross, Nicole
   Ardy, Adriana
   Gordon, Bahareh
   Pannaraj, Pia S.
TI Vaccine health beliefs and educational influences among pediatric
   residents
SO VACCINE
LA English
DT Article
DE Vaccinations; Vaccine hesitancy; Medical education
ID PHYSICIAN COMMUNICATION; HPV VACCINATION; HESITANCY; SAFETY;
   ASSOCIATION; MEASLES; IMPACT; RATES
AB Objective: A pilot study of pediatric residents to describe perceived benefits and effects of vaccines and educational influences on vaccine practice among pediatric residents.
   Study design: Eighty-seven residents, from two institutions in a region with relatively high vaccine hesitancy, responded to a survey conducted in 2014-2015.
   Results: Residents identified professional experiences with vaccine preventable diseases (VPDs) and observing pediatricians as most impactful to their vaccine beliefs. Residents who had observed pediatric faculty agreeing to alternative or delayed vaccinations were more likely to believe this to be acceptable vaccine practice (70.1% vs. 21.1%, chi(2) = 17.778, p < 0.001). Most residents (68 [79.1%]) reported feeling confident in their ability to discuss vaccines.
   Conclusions: Pediatricians must be equipped with accurate vaccine health beliefs to impact parental vaccine hesitancy. This study identifies important gaps in medical education, with pediatric residents reporting limitations in their professional experience with VPDs and high rates of observing alternative vaccination practice. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Arora, Gitanjli; Charlu, Sandhya; Ross, Nicole; Ardy, Adriana; Pannaraj, Pia S.] Childrens Hosp Los Angeles, Dept Pediat, 4650 Sunset Blvd 170, Los Angeles, CA 90027 USA.
   [Lehman, Deborah; Gordon, Bahareh] Univ Calif Los Angeles, Dept Pediat, Los Angeles, CA 90024 USA.
   [Pannaraj, Pia S.] Univ Southern Calif, Dept Mol Microbiol & Immunol, Los Angeles, CA 90089 USA.
RP Arora, G (reprint author), Childrens Hosp Los Angeles, Dept Pediat, 4650 Sunset Blvd 170, Los Angeles, CA 90027 USA.
EM garora@chla.usc.edu
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [K23 HD072774-02]; MedImmuneAstraZeneca
FX Pia S. Pannaraj receives funding from NIH K23 HD072774-02 and MedImmune.
   The other others have no financial disclosures and no conflicts of
   interest relevant to this article to disclose.
CR Brewer NT, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-1764
   Butteris SM, 2015, PEDIATRICS, V136, P458, DOI 10.1542/peds.2015-0792
   CAMPBELL JR, 1994, ARCH PEDIAT ADOL MED, V148, P926, DOI 10.1001/archpedi.1994.02170090040005
   Centers for Disease Control and Prevention, 10 GREAT PUBL HLTH A
   Centers for Disease Control and Prevention, MEASL CAS OUTBR
   Chung Y, 2017, MATERN CHILD HLTH J
   Corace KM, 2016, VACCINE, V34, P3235, DOI 10.1016/j.vaccine.2016.04.071
   Cordrey K, 2018, CLIN PEDIATR, V57, P327, DOI 10.1177/0009922817727465
   Dempsey AF, 2018, JAMA PEDIAT, V172
   Dube E, 2015, VACCINE, V33, P4191, DOI 10.1016/j.vaccine.2015.04.041
   Edwards KM, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-2146
   England L, 1997, CLIN PEDIATR, V36, P129, DOI 10.1177/000992289703600302
   Gilkey MB, 2016, VACCINE, V34, P1187, DOI 10.1016/j.vaccine.2016.01.023
   Gilkey MB, 2015, CANCER EPIDEM BIOMAR, V24, P1673, DOI 10.1158/1055-9965.EPI-15-0326
   Gowda C, 2013, HUM VACC IMMUNOTHER, V9, P1755, DOI 10.4161/hv.25085
   Henrikson NB, 2015, PEDIATRICS, V136, P70, DOI 10.1542/peds.2014-3199
   Hough-Telford C, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-2127
   Jacobson Robert M, 2013, Minn Med, V96, P49
   Kempe A, 2015, PEDIATRICS, V135, P666, DOI 10.1542/peds.2014-3474
   Kundi M, 2015, CURR DRUG SAF, V10, P16, DOI 10.2174/157488631001150407104320
   Lo NC, 2017, JAMA PEDIAT
   Mergler MJ, 2013, VACCINES, V1, P154, DOI 10.3390/vaccines1020154
   Nyhan B, 2014, PEDIATRICS, V133, pE835, DOI 10.1542/peds.2013-2365
   Olive JK, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002578
   Opel DJ, 2013, PEDIATRICS, V132, P1037, DOI 10.1542/peds.2013-2037
   Perkins RB, 2015, VACCINE, V33, P1223, DOI 10.1016/j.vaccine.2014.11.021
   Phadke VK, 2016, JAMA-J AM MED ASSOC, V315, P1149, DOI 10.1001/jama.2016.1353
   ROSENSTOCK IM, 1974, HEALTH EDUC QUART, V2, P328, DOI 10.1177/109019817400200403
   Sarnquist C, 2013, J PUBLIC HEALTH MAN, V19, P40, DOI 10.1097/PHH.0b013e3182495776
   Seither R, 2015, MMWR-MORBID MORTAL W, V64, P897, DOI 10.15585/mmwr.mm6433a2
   Smith PJ, 2006, PEDIATRICS, V118, pE1287, DOI 10.1542/peds.2006-0923
   Suryadevara M, 2015, VACCINE, V33, P6629, DOI 10.1016/j.vaccine.2015.10.096
   Williams SE, 2014, VACCINE, V32, P3175, DOI 10.1016/j.vaccine.2014.04.001
   World Health Organization, MEASL CAS HIT REC HI
   Yang YT, 2015, JAMA-J AM MED ASSOC, V314, P1229, DOI 10.1001/jama.2015.9579
   Ziegheimat F, 2016, J ED HLTH PROMOT, V5
   Zimmerman RK, 1997, ARCH PEDIAT ADOL MED, V151, P657, DOI 10.1001/archpedi.1997.02170440019004
NR 37
TC 0
Z9 0
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 4
PY 2019
VL 37
IS 6
BP 857
EP 862
DI 10.1016/j.vaccine.2018.12.038
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HK9WH
UT WOS:000458343100013
PM 30611603
DA 2020-05-12
ER

PT J
AU Vannice, KS
   Cassetti, MC
   Eisinger, RW
   Hombach, J
   Knezevic, I
   Marston, HD
   Wilder-Smith, A
   Cavaleri, M
   Krause, PR
AF Vannice, Kirsten S.
   Cassetti, M. Cristina
   Eisinger, Robert W.
   Hombach, Joachim
   Knezevic, Ivana
   Marston, Hilary D.
   Wilder-Smith, Annelies
   Cavaleri, Marco
   Krause, Philip R.
TI Demonstrating vaccine effectiveness during a waning epidemic: A WHO/NIH
   meeting report on approaches to development and licensure of Zika
   vaccine candidates
SO VACCINE
LA English
DT Article
DE Zika vaccine; Vaccine licensure; Immunogenicity; Human challenge trials
ID VIRUS; PROTECTION; EFFICACY; IMMUNITY; TRIALS; DENGUE; ASIA
AB Since its peak in early 2016, the incidence of Zika virus (ZIKV) cases has declined to such low levels that Phase 3 field efficacy trials may be infeasible. While great progress was made to rapidly advance several vaccine candidates into Phase 1 and 2 clinical trials, in the absence of sustained viral transmission it may be difficult to evaluate the effectiveness of ZIKV vaccine candidates by conducting traditional clinical disease endpoint efficacy studies. However, ZIKV is still circulating at low levels in some areas and is likely to re-emerge in naive populations or in sites of prior epidemics once population immunity wanes. Therefore, the public health need for a ZIKV vaccine remains. To facilitate continued ZIKV vaccine development efforts, the World Health Organization's Initiative for Vaccine Research and the National Institutes of Health's National Institute of Allergy and Infectious Diseases co-hosted a meeting of experts in March 2018 to identify strategies to demonstrate vaccine effectiveness in view of waning ZIKV disease incidence. This paper outlines points for consideration for developers, regulators, and other stakeholders working towards a licensed ZIKV vaccine. These deliberations may also be applicable to development of vaccines for other emerging infections where the size, unpredictability, and ephemeral nature of outbreaks makes clinical disease endpoint efficacy trials to demonstrate vaccine effectiveness infeasible. (C) 2019 Published by Elsevier Ltd.
C1 [Vannice, Kirsten S.; Hombach, Joachim; Wilder-Smith, Annelies] WHO, Dept Immunizat Vaccines & Biol, Geneva, Switzerland.
   [Cassetti, M. Cristina; Eisinger, Robert W.; Marston, Hilary D.] NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
   [Knezevic, Ivana] WHO, Dept Essential Med & Hlth Prod, Geneva, Switzerland.
   [Cavaleri, Marco] European Med Agcy, London, England.
   [Krause, Philip R.] US FDA, Ctr Biol Evaluat & Res, Rockville, MD 20857 USA.
RP Vannice, KS (reprint author), WHO, Dept Immunizat Vaccines & Biol, Geneva, Switzerland.
EM kirsten.vannice@gmail.com
OI Krause, Philip/0000-0002-1045-7536; Knezevic, Ivana/0000-0002-6441-7601
FU World Health OrganizationWorld Health Organization [001]
CR Abbink P, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aao4163
   Abbink P, 2016, SCIENCE, V353, P1129, DOI 10.1126/science.aah6157
   Aliota MT, 2017, ANTIVIR RES, V144, P223, DOI 10.1016/j.antiviral.2017.06.001
   [Anonymous], BLOOD PROD REL BIOL
   Bogoch II, 2016, LANCET INFECT DIS, V16, P1237, DOI 10.1016/S1473-3099(16)30270-5
   Chung AW, 2015, CELL, V163, P988, DOI 10.1016/j.cell.2015.10.027
   Darton TC, 2015, LANCET INFECT DIS, V15, P840, DOI 10.1016/S1473-3099(15)00068-7
   Durbin AP, 2017, J INFECT DIS, V216, pS971, DOI 10.1093/infdis/jix491
   Espinosa D, 2018, EBIOMEDICINE, V27, P61, DOI 10.1016/j.ebiom.2017.12.010
   Food and Drug Administration, 2016, SUMM BAS REG ACT VAX
   Glaesser D, 2017, J TRAVEL MED, V24, DOI 10.1093/jtm/tax007
   Goncalves A, 2018, J INFECT DIS, V217, P1060, DOI 10.1093/infdis/jix678
   Goodfellow FT, 2016, STEM CELLS DEV, V25, P1691, DOI 10.1089/scd.2016.0231
   Gruber MF, 2017, J INFECT DIS, V216, pS964, DOI 10.1093/infdis/jix433
   Hirsch AJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02499-9
   Kumar M, 2017, VIROL J, V14, DOI 10.1186/s12985-017-0750-4
   Larocca RA, 2016, NATURE, V536, P474, DOI 10.1038/nature18952
   Marshall V, 2011, PEDIATRICS, V127, pS23, DOI 10.1542/peds.2010-1722E
   Martinot AJ, 2018, CELL, V173, P1111, DOI 10.1016/j.cell.2018.03.019
   Modjarrad K, 2018, LANCET, V391, P563, DOI 10.1016/S0140-6736(17)33106-9
   Mohr EL, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190617
   Montoya M, 2018, J INFECT DIS, V218, P536, DOI 10.1093/infdis/jiy164
   Moodie Z, 2018, J INFECT DIS, V217, P742, DOI 10.1093/infdis/jix609
   Paixao ES, 2018, OPEN FORUM INFECT DI, V5, DOI 10.1093/ofid/ofy073
   Paz-Bailey G, 2018, NEW ENGL J MED, V379, P1234, DOI 10.1056/NEJMoa1613108
   Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10
   Quam MB, 2016, J TRAVEL MED, V23, DOI 10.1093/jtm/taw059
   Rice ME, 2018, MMWR-MORBID MORTAL W, V67, P858, DOI 10.15585/mmwr.mm6731e1
   Richner JM, 2017, CELL, V170, P273, DOI 10.1016/j.cell.2017.06.040
   Shah SK, ETHICAL CONSIDERATIO
   Shan C, 2017, NAT MED, V23, P763, DOI 10.1038/nm.4322
   WHO, LIST BLUEPR PRIOR DI
   WHO, 2018, ZIK VACC DEV TECHN R
   WHO Expert Committee on Biological Standardization, 2017, TECH REP SER, V1004
   WHO Expert Committee on Biological Standardization, 2017, TECHNICAL REPORT SER, V1004
   Wilder-Smith A, 2018, J TRAVEL MED, V25, DOI 10.1093/jtm/tay044
   Wilder-Smith A, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1067-x
   World Health Organization, ZIK VIR DIS
   World Health Organization, EFF TRIALS ZIKV VACC
   World Health Organization, IND PART DAT MET ZIK
   World Health Organization, 2018, MAIN OUTC M WHO EXP
   World Health Organization, WHO GLOB CONS RES RE
NR 42
TC 10
Z9 10
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 4
PY 2019
VL 37
IS 6
BP 863
EP 868
DI 10.1016/j.vaccine.2018.12.040
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HK9WH
UT WOS:000458343100014
PM 30639461
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Vu, M
   Luu, M
   Haardorfer, R
   Berg, CJ
   Escoffery, C
   Bednarczyk, RA
AF Vu, Milkie
   Minh Luu
   Haardorfer, Regine
   Berg, Carla J.
   Escoffery, Cam
   Bednarczyk, Robert A.
TI A multilevel analysis of factors influencing the inaccuracy of parental
   reports of adolescent HPV vaccination status
SO VACCINE
LA English
DT Article
DE Adolescent health; HPV vaccine; Vaccine policy; Health disparities
ID HUMAN-PAPILLOMAVIRUS VACCINATION; IMMUNIZATION SURVEY-TEEN; AGED 13-17
   YEARS; UNITED-STATES; SCHOOL-ENTRY; COVERAGE; VALIDITY
AB Background: Parental reports are commonly used for adolescent HPV vaccination status but may be subjected to bias. Guided by the Socioecological Framework, our study explores potential multilevel factors influencing the inaccuracy of parental reports of adolescent HPV vaccination status.
   Methods: Data from parents of 19,683 adolescents with provider-verified data were analyzed using multilevel modeling. Correlates included adolescent characteristics, parent/household factors, number of providers seen, state-level median income, and state-level HPV vaccine policy. Outcomes included inaccuracy in reporting: vaccine initiation (>= 1 dose), completion (3 doses), and number of doses.
   Results: 24% and 25% of parents reported initiation and completion inaccurately; 28% under-reported and 11% over-reported number of doses. All adolescent characteristics, parent/household factors, and number of healthcare providers seen were associated with the outcomes. Of note, compared to parents of White adolescents, parents of racial/ethnic minority adolescents were more likely to inaccurately report all outcomes (aOR ranges from 1.43 to 1.76 for initiation, 1.45-1.75 for completion, 1.98-2.05 for under-reporting, and 1.17-1.41 for over-reporting). Households with higher maternal education (aOR = 0.70, 0.92, 0.79, and 0.80) and income (aOR = 0.54, 0.62, 0.50, and 0.70) were less likely to inaccurately report initiation, report completion, under-report, and over-report, respectively. Those having seen more providers were less likely to inaccurately report initiation and completion but more likely to over-report number of vaccine doses.
   Discussion: Being parents of females, older adolescents, and racial/ethnic minority adolescents, having lower material education, and poverty status were associated with higher odds of inaccurately reporting HPV vaccination status. These results have implications for estimates drawn from self-reports. Future research can examine sources of inaccuracies (e.g., social desirability or health literacy); they could also explore solutions (e.g., access to vaccine records) that can help parents accurately report vaccination status. State policy does not appear to have an impact on report accuracy. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Vu, Milkie; Minh Luu; Haardorfer, Regine; Berg, Carla J.; Escoffery, Cam] Emory Univ, Rollins Sch Publ Hlth, Dept Behav Sci & Hlth Educ, Atlanta, GA 30322 USA.
   [Berg, Carla J.; Escoffery, Cam; Bednarczyk, Robert A.] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
   [Bednarczyk, Robert A.] Emory Univ, Rollins Sch Publ Hlth, Hubert Dept Global Hlth, Atlanta, GA 30322 USA.
RP Vu, M (reprint author), Rollins Sch Publ Hlth, Dept Behav Sci & Hlth Educ, 1518 Clifton Rd NE, Atlanta, GA 30322 USA.
EM milkie.vu@emory.edu
RI Bednarczyk, Robert/L-9403-2017; Escoffery, Cam/F-8030-2011
OI Bednarczyk, Robert/0000-0002-6812-0928; Vu, Milkie/0000-0003-0230-473X;
   Escoffery, Cam/0000-0003-4445-009X; Luu, Minh/0000-0001-7909-7842
FU National Institute for Allergy and Infectious Diseases, National
   Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [K01AI106961]
FX Dr. Bednarczyk is supported by a grant (K01AI106961) from the National
   Institute for Allergy and Infectious Diseases, National Institutes of
   Health. Any analyses, interpretations, or conclusions reached are those
   of the authors and not to the National Center for Immunization and
   Respiratory Diseases, which is responsible only for the initial data.
CR Allen JD, 2010, CANCER EPIDEM BIOMAR, DOI [10.1158/1055-9965.EP1-10-0217, DOI 10.1158/11055-9965.EP1-10-0217]
   Anonymous, 2010, Morbidity and Mortality Weekly Report, V59, P630
   Attanasio L, 2014, PUBLIC HEALTH REP, V129, P237, DOI 10.1177/003335491412900305
   Boakye EA, 2017, AM J PREV MED, V52, P742, DOI 10.1016/j.amepre.2016.10.016
   Centers for Disease Control and Prevention, 2010, MMWR MORB MORTAL WKL
   Centers for Disease Control and Prevention, WHAT IS HPV QUEST AN
   Centers for Disease Control and Prevention, 2017, NAT IMM SURV TEEN US
   Centers for Disease Control and Prevention, 2018, NAT IMM SURV NIS
   Centers for Disease Control and Prevention, 2016, CDC REC ONL 2 HPV SH
   Dorell CG, 2011, PUBLIC HEALTH REP, V126, P60, DOI 10.1177/00333549111260S208
   Hirth J, 2016, VACCINE, V34, P4415, DOI 10.1016/j.vaccine.2016.07.014
   Hirth JM, 2018, VACCINE, V36, P1032, DOI 10.1016/j.vaccine.2018.01.037
   Keim-Malpass J, 2017, RISK MANAG HEALTHC P, V10, P29, DOI 10.2147/RMHP.S128247
   Kroger Andrew T., 2006, Morbidity and Mortality Weekly Report, V55, P1
   Laugesen MJ, 2014, J ADOLESCENT HEALTH, DOI [10.1016/j.jadohealth.2014.04.015, DOI 10.1016/JJADOHEALTH.2014.04.01.]
   Luman ET, 2009, VACCINE, V27, P2534, DOI 10.1016/j.vaccine.2008.10.002
   MCLEROY KR, 1988, HEALTH EDUC QUART, V15, P351, DOI 10.1177/109019818801500401
   Office of Disease Prevention and Health Promotion, IMM INF DIS
   Ojha RP, 2013, ANN EPIDEMIOL, DOI [10.1016/jannepidem201302.002, DOI 10.1016/JANNEPIDEM201302.002]
   Perkins RB, 2016, HUM VACC IMMUNOTHER, V12, P1615, DOI 10.1080/21645515.2016.1150394
   Reagan-Steiner S, 2016, MMWR-MORBID MORTAL W, V65, P850, DOI 10.15585/mmwr.mm6533a4
   Roberts MC, 2018, AM J PUBLIC HEALTH, V108, P493, DOI [10.2105/AJPH.2017.304263, 10.2105/ajph.2017.304263]
   Thompson EL, 2018, AM J PUBLIC HEALTH, V108, P1421, DOI 10.2105/AJPH.2018.304552
   Walker TY, 2017, MMWR-MORBID MORTAL W, DOI [10.15585/mmwr.mm6613a7, DOI 10.15585/MMWR.MM6613A7]
NR 24
TC 2
Z9 2
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 4
PY 2019
VL 37
IS 6
BP 869
EP 876
DI 10.1016/j.vaccine.2018.12.032
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HK9WH
UT WOS:000458343100015
PM 30626532
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Nawa, N
   Fujiwara, T
AF Nawa, Nobutoshi
   Fujiwara, Takeo
TI Association between social capital and second dose of measles
   vaccination in Japan: Results from the A-CHILD study
SO VACCINE
LA English
DT Article
DE Measles-containing vaccines; Social capital; Low vaccination rate; Low
   immunization rate; Vaccine hesitancy; Vaccine acceptance
ID STRONG COMMUNITIES; OLDER-PEOPLE; IMMUNIZATION; MULTILEVEL; ELIMINATION
AB Background and Objectives: Measles vaccination is important to prevent outbreak, and social capital can be an important preventive factor. However, there have been very few studies that investigated the association between social capital and measles vaccination, especially the second dose, which is more likely to be suboptimal. This study aimed to investigate the association between social capital and second dose of measles vaccine.
   Methods: Data were derived from a population-based study of first-grade elementary school children (6-7 years old) in Adachi City, Tokyo. Caregivers were asked to complete a questionnaire, and 4291 of them provided a valid response (response rate: 80.1%). Among these 4291 valid responses, 69 responses were excluded since variables for social capital measures were missing, which resulted in analytic sample size of 4222. We analyzed the association between measles vaccination and social capital including social ties, social trust and mutual aid by multilevel logistic regression analysis with a random intercept model.
   Results: About 8.9% of the children did not receive a second dose of measles-containing vaccines. After covariates adjustments, increase of one-standard-deviation of poor individual-level social ties showed 11% lower odds of receiving measles-containing vaccines (OR: 0.89, 95% CI: 0.80-0.99). By contrast, no significant association between community-level social ties and measles vaccination was found. Regarding social trust, no significant association between individual-level social trust and measles vaccination was found. However, increase of one-standard-deviation of poor community-level social trust showed 11% lower odds of receiving measles-containing vaccines (OR: 0.89, 95% CI: 0.79-0.998). There was no association between mutual aid and measles vaccination.
   Conclusion: Social ties and social trust were associated with second dose of measles vaccination. Fostering social capital may be effective in raising the low rate of second dose of measles vaccine. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Nawa, Nobutoshi; Fujiwara, Takeo] Tokyo Med & Dent Univ, Dept Global Hlth Promot, Tokyo, Japan.
   [Nawa, Nobutoshi] Tokyo Med & Dent Univ, Inst Educ, Tokyo, Japan.
RP Fujiwara, T (reprint author), TMDU, Dept Global Hlth Promot, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.
EM fujiwara.hlth@tmd.ac.jp
FU Japanese Ministry of Health, Labour and WelfareMinistry of Health,
   Labour and Welfare, Japan [H27-Jyunkankito-ippan-002]; Japan Society for
   the Promotion of Science (JSPS KAKENHI)Ministry of Education, Culture,
   Sports, Science and Technology, Japan (MEXT)Japan Society for the
   Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)
   [16H03276, 16K21669, 16J11423]; St. Luke's Life Science InstituteSt.
   Luke's Life Science Institute (SLLSI); Japan Health FoundationJapan
   Health Foundation
FX We are particularly grateful to the staff members and central office of
   Adachi City Hall for conducting the survey. We would like to thank
   everyone who participated in the surveys. In particular, we would also
   like to thank Mayor Yayoi Kondo, Mr. Syuichiro Akiu, Mr. Hideaki Otaka,
   and Ms. Yuko Baba of Adachi City Hall, all of whom contributed
   significantly to completion of this study. This study was supported by a
   Health Labour Sciences Research Grant, Comprehensive Research on
   Lifestyle Disease from the Japanese Ministry of Health, Labour and
   Welfare (H27-Jyunkankito-ippan-002), and Grants-in-Aid for Scientific
   Research from the Japan Society for the Promotion of Science (JSPS
   KAKENHI Grant Number 16H03276, 16K21669 and 16J11423), St. Luke's Life
   Science Institute Grants, and the Japan Health Foundation Grants.
CR Aida J, 2009, SOC SCI MED, V69, P512, DOI 10.1016/j.socscimed.2009.06.003
   Chuang YC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122970
   Coleman J., 1990, FDN SOCIAL THEORY
   Doi S, 2018, FRONT PSYCHIATRY, V9, DOI 10.3389/fpsyt.2018.00192
   Doi S, 2018, SLEEP MED, V45, P62, DOI 10.1016/j.sleep.2017.12.015
   Fujiwara T, 2017, SOC SCI MED, V182, P45, DOI 10.1016/j.socscimed.2017.04.008
   Gay NJ, 2004, J INFECT DIS, V189, pS27, DOI 10.1086/381592
   Gomi H, 2004, LANCET, V364, P328, DOI 10.1016/S0140-6736(04)16715-9
   Inaida S, 2017, EPIDEMIOL INFECT, V145, P2374, DOI 10.1017/S0950268817001248
   Jung M, 2013, VACCINE, V31, P4860, DOI 10.1016/j.vaccine.2013.07.068
   Kimbrough-Melton RJ, 2015, CHILD ABUSE NEGLECT, V41, P67, DOI 10.1016/j.chiabu.2015.02.015
   Kinoshita R, 2017, VACCINE, V35, P3309, DOI 10.1016/j.vaccine.2017.05.011
   Kumar S, 2012, HEALTH EDUC BEHAV, V39, P229, DOI 10.1177/1090198111415105
   Matsuyama Y, 2018, COMMUN DENT ORAL EPI
   McDonell JR, 2015, CHILD ABUSE NEGLECT, V41, P79, DOI 10.1016/j.chiabu.2014.11.016
   MCLEROY KR, 1988, HEALTH EDUC QUART, V15, P351, DOI 10.1177/109019818801500401
   Ministry of Health Labour and Welfare, 2016, COMPR SURV LIV COND
   Ministry of Health Labour and Welfare Japan, HLTH PAR CHILDR 21
   Ministry of Health Labour and Welfare Japan, MEASL AND RUB
   Ministry of Health Labour and Welfare Japan and National Institute of Infectious Diseases Japan, 2017, NAT IMM RAT MEASL RU
   Miyamoto K, 2015, GLOB HEALTH PROMOT, V22, P5, DOI 10.1177/1757975914547547
   Nagaoka K, 2012, VACCINE, V30, P7481, DOI 10.1016/j.vaccine.2012.10.055
   National Institute of Infectious Diseases Japan, 2018, INF DIS WEEKL REP ID
   National Institute of Infectious Diseases Japan. Measles February 2018, 2018, INFECT AGENTS SURVEI, V39, P49
   National Institute of Infetious Diseases [NIID] and Tuberculosis and Infectious Disease Control Division Ministry of Health Labor and Welfare [MHLW], 2017, INFECT AGENTS SURVEI, V38, P45
   Nawa N, 2018, SOC PSYCHIAT PSYCHIA
   Nezlek JB, 2008, SOC PERSONAL PSYCHOL, V2, P842, DOI 10.1111/j.1751-9004.2007.00059.x
   Ronnerstrand B, 2014, PUBLIC HEALTH, V128, P709, DOI 10.1016/j.puhe.2014.05.015
   Ronnerstrand B, 2016, SSM-POPUL HLTH, V2, P632, DOI 10.1016/j.ssmph.2016.08.004
   Ronnerstrand B, 2013, SCAND J PUBLIC HEALT, V41, P853, DOI 10.1177/1403494813494975
   Saito M, 2017, J EPIDEMIOL, V27, P221, DOI 10.1016/j.je.2016.06.005
   Sampson RJ, 1997, SCIENCE, V277, P918, DOI 10.1126/science.277.5328.918
   Story WT, 2014, HEALTH PLACE, V28, P73, DOI 10.1016/j.healthplace.2014.03.011
   Tani Y, 2018, FRONT PEDIATR, V6, DOI 10.3389/fped.2018.00134
   Townsend P., 1979, POVERTY UK
   Vikram K, 2012, SOC SCI MED, V75, P331, DOI 10.1016/j.socscimed.2012.02.043
NR 36
TC 1
Z9 1
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 4
PY 2019
VL 37
IS 6
BP 877
EP 881
DI 10.1016/j.vaccine.2018.12.037
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HK9WH
UT WOS:000458343100016
PM 30611602
DA 2020-05-12
ER

PT J
AU Pham, MA
   Bednarczyk, RA
   Becker, ER
   Orenstein, WA
   Omer, SB
AF Pham, Matthew A.
   Bednarczyk, Robert A.
   Becker, Edmund R.
   Orenstein, Walter A.
   Omer, Saad B.
TI Trends in US Community hospitalizations due to herpes zoster: 2001-2015
SO VACCINE
LA English
DT Article
DE Epidemiology; Herpes zoster; Varicella; Trends; Nationwide inpatient
   sample; Policy; Hospitalization
ID VARICELLA VACCINE; IMMUNIZATION PRACTICES; ADVISORY-COMMITTEE;
   UNITED-STATES; OLDER-ADULTS; RECOMMENDATIONS; PREVENTION; COVERAGE;
   CHILDREN; EXPENDITURES
AB Background: In 2007, based on decisions by the U.S. Advisory Committee on Immunization Practices, the CDC recommended a booster dose at 4-6 years in the varicella vaccine schedule. In 2008, a herpes zoster vaccine was recommended for use in persons age >= 60 years. The purpose of this study was to examine trends in herpes zoster hospitalization rates and assess the impact of both policy recommendations using U.S. hospital discharge data.
   Methods: Nationwide Inpatient Sample discharge data from 2001 to 2015 were used to identify primary or secondary herpes zoster diagnoses. Trends in annual total and age-specific herpes zoster hospitalization rates and average length of stay were examined. Average annual rates for the pre (2001-2005) and post (2012-2015)-zoster vaccine policy eras were compared. Absolute change in herpes zoster hospitalizations were calculated.
   Results: The rate difference of U.S. herpes zoster hospitalizations in the post vs. pre-zoster vaccine policy era was -1.9 per 100,000 population (6,200 fewer hospitalizations in 2015 than expected). Key age group rate differences: 0-3 years (-0.4 per 100,000; 50 fewer), 4-6 years (-0.6 per 100,000; 50 fewer), 7-14 years (-1.3 per 100,000; 400 fewer), 50-59 years (0.7 per 100,000; 300 more), 60-69 years (-2.5 per 100,000; 900 fewer), 70-79 years (-10.2 per 100,000; 2,000 fewer), 80+ years (-29.9 per 100,000; 3,600 fewer).
   Conclusions: Reduction of wild-type varicella due to the 2-dose varicella vaccination recommendation may have impacted declining herpes zoster hospitalization rates among children <= 14 years. The 2008 herpes zoster vaccine may have impacted declining herpes zoster hospitalization rates for adults age >60 years despite vaccination coverage <31% by 2015. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Pham, Matthew A.; Bednarczyk, Robert A.; Omer, Saad B.] Emory Univ, Dept Epidemiol, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA.
   [Bednarczyk, Robert A.; Omer, Saad B.] Emory Univ, Rollins Sch Publ Hlth, Hubert Dept Global Hlth, Atlanta, GA 30322 USA.
   [Becker, Edmund R.] Emory Univ, Rollins Sch Publ Hlth, Dept Hlth Policy & Management, Atlanta, GA 30322 USA.
   [Orenstein, Walter A.] Emory Univ, Sch Med, Dept Med, Div Infect Dis, Atlanta, GA 30322 USA.
RP Pham, MA (reprint author), Emory Univ, Rollins Sch Publ Hlth, 1518 Clifton Rd NE, Atlanta, GA 30322 USA.
EM mapham@alumni.emory.edu
RI Bednarczyk, Robert/L-9403-2017
OI Bednarczyk, Robert/0000-0002-6812-0928
CR Black S, 1999, PEDIATR INFECT DIS J, V18, P1041, DOI 10.1097/00006454-199912000-00003
   Chao DY, 2012, EPIDEMIOL INFECT, V140, P1131, DOI 10.1017/S0950268811001786
   Davis MM, 2004, PEDIATRICS, V114, P786, DOI 10.1542/peds.2004-0012
   Dooling KL, 2018, AM J TRANSPLANT, V18, P756, DOI 10.1111/ajt.14683
   Dooling KL, 2018, MMWR-MORBID MORTAL W, V67, P103, DOI 10.15585/mmwr.mm6703a5
   Evolution of varicella surveillance-selected states, 2012, MMWR-MORBID MORTAL W, V61, P609
   Gerberding J, 2012, POPUL HEALTH MANAG, V15, P382, DOI 10.1089/pop.2012.1561
   Hales Craig M, 2014, MMWR Morb Mortal Wkly Rep, V63, P729
   Harpaz R, 2008, MMWR RECOMM REP, V57, P1
   Harpaz Rafael, 2007, Morbidity and Mortality Weekly Report, V57, P1
   Harrison C, 2015, PLOS ONE, V10, DOI DOI 10.1371/JOURNAL.PONE.0125025
   Holmes SJ, 1996, MMWR-MORBID MORTAL W, pi
   Humes EA, 2015, OPEN FORUM INFECT DI, V2, DOI 10.1093/ofid/ofv001
   Kilgore Paul E., 2003, Journal of Medical Virology, V70, pS111, DOI 10.1002/jmv.10364
   Kuter B, 2004, PEDIATR INFECT DIS J, V23, P132, DOI 10.1097/01.inf.0000109287.97518.67
   Liesegang TJ, 1999, MAYO CLIN PROC, V74, P983
   Lopez AS, 2006, PEDIATRICS, V117, pE1070, DOI 10.1542/peds.2005-2085
   Marin Mona, 2007, Morbidity and Mortality Weekly Report, V56, P1
   Nguyen HQ, 2005, NEW ENGL J MED, V352, P450, DOI 10.1056/NEJMoa042271
   Oxman MN, 2005, NEW ENGL J MED, V352, P2271, DOI 10.1056/NEJMoa051016
   Patel MS, 2008, INFECT CONT HOSP EP, V29, P1157, DOI 10.1086/591975
   Russell ML, 2014, VACCINE, V32, P6319, DOI 10.1016/j.vaccine.2013.09.018
   Schmader KE, 2012, CLIN INFECT DIS, V55, P1320, DOI 10.1093/cid/cis638
   Schmader KE, 2012, CLIN INFECT DIS, V54, P922, DOI 10.1093/cid/cir970
   Seward JF, 2002, JAMA-J AM MED ASSOC, V287, P606, DOI 10.1001/jama.287.5.606
   Tseng HF, 2011, JAMA-J AM MED ASSOC, V305, P160, DOI 10.1001/jama.2010.1983
   Weinmann S, 2013, J INFECT DIS, V208, P1859, DOI 10.1093/infdis/jit405
   White CJ, 1996, INFECT DIS CLIN N AM, V10, P595
   Williams WW, 2013, MMWR-MORBID MORTAL W, V62, P66
   Williams WW, 2017, MMWR SURVEILL SUMMAR, V66
   Zhang DM, 2017, AM J PREV MED, V52, pE17, DOI 10.1016/j.amepre.2016.08.029
NR 31
TC 3
Z9 3
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 4
PY 2019
VL 37
IS 6
BP 882
EP 888
DI 10.1016/j.vaccine.2018.12.034
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HK9WH
UT WOS:000458343100017
PM 30616954
DA 2020-05-12
ER

PT J
AU Chen, W
   Zhao, Y
   Xie, X
   Liu, JH
   Li, JR
   Zhao, C
   Wang, SM
   Liao, XY
   Shou, Q
   Zheng, MH
   Saah, AJ
   Wei, LH
   Qiao, YL
AF Chen, Wen
   Zhao, Yun
   Xie, Xing
   Liu, Jihong
   Li, Jingran
   Zhao, Chao
   Wang, Shaoming
   Liao, Xueyan
   Shou, Qiong
   Zheng, Minghuan
   Saah, Alfred J.
   Wei, Lihui
   Qiao, Youlin
TI Safety of a quadrivalent human papillomavirus vaccine in a Phase 3,
   randomized, double-blind, placebo-controlled clinical trial among
   Chinese women during 90 months of follow-up
SO VACCINE
LA English
DT Article
DE Safety; Quadrivalent human papillomavirus vaccine; Randomised controlled
   trial
ID HPV VACCINATION; INFANT OUTCOMES; PREGNANCY; MISCARRIAGE; RISK
AB Background: A quadrivalent human papillomavirus (qHPV) vaccine (HPV6/11/16/18) has demonstrated efficacy and acceptable safety in international studies. However, these studies did not include participants from mainland China, which has a substantial burden of HPV-related disease. This is the first safety report with a follow-up period of up to 90 months from a randomized, double-blind, placebo-controlled trial of qHPV vaccine in Chinese women 20-45 years of age.
   Methods: Participants were randomized 1:1 to receive three doses of qHPV vaccine or placebo (Day 1, Month 2, and Month 6). Efficacy outcomes are reported elsewhere. Injection-site and systemic adverse events (AEs) were collected using vaccination report cards (VRCs) for 15 days following each vaccination. Serious AEs (SAES), pregnancy outcomes, new medical conditions, and fetal/infant SAES were collected during the entire study.
   Results: Of 3006 participants randomized, AEs were reported by 926 (61.8%) qHPV vaccine recipients and 856 (57.1%) placebo recipients over the entire study. Four participants (two in each group) discontinued the study vaccination due to AEs that were considered vaccination-related. Within 15 days following any vaccination, injection-site AEs prompted for on the VRC were more frequent among qHPV vaccine recipients (37.6% vs 27.8%), and systemic AEs prompted for on the VRC were similar in frequency between qHPV vaccine and placebo groups (46.8% vs 45.1%). Thirty-eight and 43 participants reported SAES in qHPV vaccine and placebo groups, respectively. No SAE was considered qHPV vaccine-related. Pregnancy outcomes, fetal/infant SAES, and new medical conditions were generally similar in frequency between the qHPV vaccine and placebo groups, and within normal ranges.
   Conclusion: The qHPV vaccine was well tolerated and demonstrated a favorable safety profile in Chinese women 20-45 years of age, consistent with findings from global trials and safety surveillance studies. (C) 2018 Published by Elsevier Ltd.
C1 [Chen, Wen; Wang, Shaoming; Qiao, Youlin] Chinese Acad Med Sci, Natl Clin Res Ctr Canc, Dept Canc Epidemiol, Natl Canc Ctr,Canc Hosp, 17 South Panjiayuan Lane, Beijing 100021, Peoples R China.
   [Chen, Wen; Wang, Shaoming; Qiao, Youlin] Peking Union Med Coll, 17 South Panjiayuan Lane, Beijing 100021, Peoples R China.
   [Zhao, Yun; Li, Jingran; Zhao, Chao; Wei, Lihui] Peking Univ, Peoples Hosp, Dept Obstet & Gynecol, 11 Xizhimen South St, Beijing 100044, Peoples R China.
   [Xie, Xing] Zhejiang Univ, Sch Med, Womens Hosp, Dept Gynecol Oncol, 1 Xueshi Rd, Hangzhou 310006, Zhejiang, Peoples R China.
   [Liu, Jihong] Sun Yat Sen Univ, Dept Gynecol Oncol, Canc Ctr, 651 Dongfeng Rd East, Guangzhou 510060, Guangdong, Peoples R China.
   [Liao, Xueyan; Shou, Qiong; Zheng, Minghuan] MSD R&D China, 21 Rongda Rd, Beijing 100012, Peoples R China.
   [Saah, Alfred J.] Merck & Co Inc, 2000 Galloping Hill Rd, Kenilworth, NJ 07033 USA.
RP Qiao, YL (reprint author), 17 South Panjiayuan Lane, Beijing 100021, Peoples R China.; Wei, LH (reprint author), 11 Xizhimen South St, Beijing 100044, Peoples R China.
EM chenwen@cicams.ac.cn; xiex@zju.edu.cn; liujh@sysucc.org.cn;
   wangshaoming@cicams.ac.cn; Xue.yan.liao@merck.com; qiong.shou@merck.com;
   Ming.huan.zheng@merck.com; alfred_saah@merck.com; weilhpku@163.com;
   qiaoy@cicams.ac.cn
RI Qiao, You-Lin/B-4139-2012
OI Qiao, You-Lin/0000-0001-6380-0871
FU Merck Sharp & Dohme Corp of Merck & Co., Inc., Kenilworth, NJ, USA
FX This work was supported by Merck Sharp & Dohme Corp, a subsidiary of
   Merck & Co., Inc., Kenilworth, NJ, USA. Authors and others employed by
   the study sponsor, together with the academic authors, participated in
   study design; in the collection, analysis and interpretation of data; in
   the writing of the report; and in the decision to submit the article for
   publication.
CR [Anonymous], 2017, WKLY EPIDEMIOL REC, V92, P241, DOI DOI 10.1016/j.vaccine.2017.05.069
   [Anonymous], 2012, GLOBOCAN 2012 EST CA
   Block SL, 2010, PEDIATR INFECT DIS J, V29, P95, DOI 10.1097/INF.0b013e3181b77906
   Bruni L, 2017, HUMAN PAPILLOMAVIRUS
   de Martel C, 2017, INT J CANCER, V141, P664, DOI 10.1002/ijc.30716
   de Sanjose S, 2010, LANCET ONCOL, V11, P1048, DOI 10.1016/S1470-2045(10)70230-8
   Garcia-Enguidanos A, 2002, EUR J OBSTET GYN R B, V102, P111, DOI 10.1016/S0301-2115(01)00613-3
   Garland SM, 2016, CLIN INFECT DIS, V63, P519, DOI 10.1093/cid/ciw354
   Garland SM, 2009, OBSTET GYNECOL, V114, P1179, DOI 10.1097/AOG.0b013e3181c2ca21
   Garland SM, 2009, J INFECT DIS, V199, P805, DOI 10.1086/597071
   Global Advisory Committee on Vaccine Safety (World Health Organization), 2015, STAT SAF HPV VACC
   Goss MA, 2015, VACCINE, V33, P3422, DOI 10.1016/j.vaccine.2015.04.014
   Hanley SJB, 2015, LANCET, V385, P2571, DOI 10.1016/S0140-6736(15)61152-7
   Kharbanda EO, 2018, OBSTET GYNECOL, V132, P35, DOI [10.1097/AOG.0000000000002694, 10.1097/aog.0000000000002694]
   Koutsky Laura, 1997, American Journal of Medicine, V102, P3
   Li RC, 2012, VACCINE, V30, P4284, DOI 10.1016/j.vaccine.2012.02.079
   Lipkind HS, 2017, OBSTET GYNECOL, V130, P599, DOI 10.1097/AOG.0000000000002191
   Lohstroh PN, 2005, FERTIL STERIL, V83, P1000, DOI 10.1016/j.fertnstert.2004.10.038
   Markowitz LE, 2014, MMWR RECOMM REP, V63, P1
   Munoz N, 2009, LANCET, V373, P1949, DOI 10.1016/S0140-6736(09)60691-7
   Scheller NM, 2017, NEW ENGL J MED, V376, P1223, DOI 10.1056/NEJMoa1612296
   Schiller JT, 2012, VACCINE, V30, pF123, DOI 10.1016/j.vaccine.2012.04.108
   Sy LS, 2018, HUM VACC IMMUNOTHER, V14, P412, DOI 10.1080/21645515.2017.1403702
   Tanaka Y, 2016, LANCET ONCOL, V17, P868, DOI 10.1016/S1470-2045(16)00147-9
   Vichnin M, 2015, PEDIATR INFECT DIS J, V34, P983, DOI 10.1097/INF.0000000000000793
   Wang XB, 2003, FERTIL STERIL, V79, P577, DOI 10.1016/S0015-0282(02)04694-0
   Wei L, 2018, VACCINE
   WILCOX AJ, 1988, NEW ENGL J MED, V319, P189, DOI 10.1056/NEJM198807283190401
   World Health Organization, 2016, WKLY EPIDEMIOL REC, V91, P21
   World Health Organization (WHO), 2016, GUID INTR HPV VACC N
   World Health Organization (WHO), 2017, M GLOB ADV COMM VACC
   Zhao FH, 2012, INT J CANCER, V131, P2929, DOI 10.1002/ijc.27571
NR 32
TC 3
Z9 3
U1 1
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 4
PY 2019
VL 37
IS 6
BP 889
EP 897
DI 10.1016/j.vaccine.2018.12.030
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HK9WH
UT WOS:000458343100018
PM 30638797
DA 2020-05-12
ER

PT J
AU Lalsiamthara, J
   Senevirathne, A
   Lee, JH
AF Lalsiamthara, Jonathan
   Senevirathne, Amal
   Lee, John Hwa
TI Partial protection induced by Salmonella based Brucella vaccine
   candidate in pregnant guinea pigs
SO VACCINE
LA English
DT Article
DE Brucella vaccine; Rough Salmonella vaccine vector; Pregnant guinea pig
   model; Brucellosis; Abortion
ID MICE; PROLIFERATION; GAMMA
AB Residual virulence is a major drawback in current Brucella vaccines. Live vaccines induce abortions in pregnant animals. Hence, a novel anti-Brucella vaccine was developed utilizing rough Salmonella delivering four Brucella antigens. Safety implications during pregnancy, humoral immune responses, and protective efficacy against wild type Brucella was investigated in guinea pig model. The vaccine did not induce abortions or severe complications in pregnant guinea pigs when administered 4 x 10(8) CFU via intraperitoneal route. Systemic IgG determination against antigen components reveals induction of immunity via the Salmonella delivery. Protection efficacy against abortions was 33.3% (2/6) when midterm sow challenged with virulent Brucella 544 strain while none was protected in control group. Lower Brucella recovery in spleen and liver and reduced histopathological burden were also noticed. Although abortion induced by Brucella challenge was not completely prevented, the vaccine candidate may perform better with optimization of vaccination such as inoculation dose optimization. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Lalsiamthara, Jonathan; Senevirathne, Amal; Lee, John Hwa] Chonbuk Natl Univ, Coll Vet Med, Iksan Campus, Iksan 570752, South Korea.
RP Lee, JH (reprint author), Chonbuk Natl Univ, Coll Vet Med, Iksan Campus, Iksan 570752, South Korea.
EM johnhlee@jbnu.ac.kr
RI Senevirathne, Amal/AAH-1318-2019
OI Senevirathne, Amal/0000-0001-6949-5011
FU Korea Health Technology R&D Project through the Korea Health Industry
   Development Institute (KHIDI) - Ministry of Health & Welfare, Republic
   of Korea [HI16C2130]
FX This research was supported by a grant of the Korea Health Technology
   R&D Project through the Korea Health Industry Development Institute
   (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea
   [grant number: HI16C2130].
CR BRAUDE AI, 1951, J INFECT DIS, V89, P87, DOI 10.1093/infdis/89.1.87
   Corbel M. J., 2006, BRUCELLOSIS HUMANS A
   Garcia-Carrillo C., 1990, Animal brucellosis., P423
   Grillo MJ, 2012, VET RES, V43, DOI 10.1186/1297-9716-43-29
   Lalsiamthara J, 2018, ONCOTARGET, DOI [10.18632/oncotarger.25192, DOI 10.18632/ONCOTARGER.25192]
   Lalsiamthara J, 2018, VACCINE, V36, P1837, DOI 10.1016/j.vaccine.2018.02.069
   Lalsiamthara J, 2017, J VET SCI, V18, P281, DOI 10.4142/jvs.2017.18.S1.281
   Lalsiamthara J, 2017, VET MICROBIOL, V205, P84, DOI 10.1016/j.vetmic.2017.05.012
   Lalsiamthara J, 2017, VACCINE, V35, P767, DOI 10.1016/j.vaccine.2016.12.042
   Neta AVC, 2010, VET J, V184, P146, DOI 10.1016/j.tvjl.2009.04.010
   Nymo IH, 2011, VET RES, V42, DOI 10.1186/1297-9716-42-93
   Oliveira SC, 1996, CELL IMMUNOL, V172, P262, DOI 10.1006/cimm.1996.0241
   Olsen S, 2010, VET CLIN N AM-FOOD A, V26, P15, DOI 10.1016/j.cvfa.2009.10.006
   Schurig GG, 2002, VET MICROBIOL, V90, P479, DOI 10.1016/S0378-1135(02)00255-9
   Silva TMA, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/518323
NR 15
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 8
PY 2019
VL 37
IS 7
BP 899
EP 902
DI 10.1016/j.vaccine.2019.01.020
PG 4
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HK9WA
UT WOS:000458342400001
PM 30661832
DA 2020-05-12
ER

PT J
AU Yung, BS
   Pugh, H
   Generotti, AA
   Phanhthilath, N
   Schultheis, K
   Muthumani, K
   Broderick, KE
   Smith, TRF
AF Yung, Bryan S.
   Pugh, Holly
   Generotti, Alison A.
   Phanhthilath, Nikki
   Schultheis, Katherine
   Muthumani, Kar
   Broderick, Kate E.
   Smith, Trevor R. F.
TI Novel IFN-gamma ELISpot reveals robust T cell responses elicited after
   influenza nucleoprotein DNA vaccination in New Zealand White rabbits
SO VACCINE
LA English
DT Article
DE DNA vaccine; T cell; Rabbit; ELISpot
ID INTERFERON-GAMMA; TUMOR-CELLS; PROTECTION; IMMUNITY; DISEASE; MODELS;
   MICE; INFECTION; VACCINES; INVIVO
AB The New Zealand White rabbit is a highly accessible animal model which is regularly employed in biomedical research. However, the paucity of rabbit-specific reagents available limits its use in certain fields. Specifically, the lack of a reliable T cell assay has limited its employment in immune prophylactic and therapeutic studies. To address this inadequacy, we have developed an ELISpot assay to detect cellular immune responses (IFN-gamma production) after antigenic stimulation. We have applied this assay to model the T cell responses elicited by a DNA vaccine. Immunization with an influenza nucleoprotein (NP) DNA vaccine revealed strong antigen-specific T cell responses in the peripheral blood mononuclear cell population. We believe this is the first report of such an assay in rabbit species, and it will become a useful tool to monitor in vivo responses to vaccines and permit the wider adoption of this model to measure immunological responses. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Yung, Bryan S.; Pugh, Holly; Generotti, Alison A.; Phanhthilath, Nikki; Schultheis, Katherine; Broderick, Kate E.; Smith, Trevor R. F.] Inovio Pharmaceut Inc, 10480 Wateridge Circle, San Diego, CA 92121 USA.
   [Muthumani, Kar] Wistar Inst Anat & Biol, Vaccine & Immunotherapy Ctr, 3601 Spruce St, Philadelphia, PA 19104 USA.
RP Smith, TRF (reprint author), Inovio Pharmaceut Inc, 10480 Wateridge Circle, San Diego, CA 92121 USA.
EM tsmith@inovio.com
CR Amanna IJ, 2011, VIROLOGY, V411, P206, DOI 10.1016/j.virol.2010.12.016
   Bosze Z, 2003, TRANSGENIC RES, V12, P541, DOI 10.1023/A:1025816809372
   Camacho P, 2016, AM J CARDIOVASC DIS, V6, P70
   Cao JF, 2015, OCUL ONCOL PATHOL, V1, P141, DOI 10.1159/000370152
   Crotty S, 2015, NAT REV IMMUNOL, V15, P185, DOI 10.1038/nri3803
   Darwich L, 2009, IMMUNOLOGY, V126, P386, DOI 10.1111/j.1365-2567.2008.02905.x
   del Amo EM, 2018, EXP EYE RES, V169, P60, DOI 10.1016/j.exer.2018.01.006
   DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539
   Duranthon V, 2012, TRANSGENIC RES, V21, P699, DOI 10.1007/s11248-012-9599-x
   EICHELBERGER M, 1991, J EXP MED, V174, P875, DOI 10.1084/jem.174.4.875
   Epstein SL, 1998, J IMMUNOL, V160, P322
   Fan JL, 2003, PHARMACOL THERAPEUT, V99, P261, DOI 10.1016/S0163-7258(03)00069-X
   Gillis PA, 2014, VACCINE, V32, P3963, DOI 10.1016/j.vaccine.2014.05.011
   Graur D, 1996, NATURE, V379, P333, DOI 10.1038/379333a0
   Hayward AC, 2015, AM J RESP CRIT CARE, V191, P1422, DOI 10.1164/rccm.201411-1988OC
   Hoos A, 2010, JNCI-J NATL CANCER I, V102, P1388, DOI 10.1093/jnci/djq310
   Hung K, 1998, J EXP MED, V188, P2357, DOI 10.1084/jem.188.12.2357
   Laddy DJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002517
   Laddy DJ, 2009, J VIROL, V83, P4624, DOI 10.1128/JVI.02335-08
   Lillie PJ, 2012, CLIN INFECT DIS, V55, P19, DOI 10.1093/cid/cis327
   LIN YL, 1981, J EXP MED, V154, P225, DOI 10.1084/jem.154.2.225
   LUKACHER AE, 1984, J EXP MED, V160, P814, DOI 10.1084/jem.160.3.814
   McElhaney JE, 2006, J IMMUNOL, V176, P6333, DOI 10.4049/jimmunol.176.10.6333
   MCMICHAEL AJ, 1983, NEW ENGL J MED, V309, P13, DOI 10.1056/NEJM198307073090103
   MELIEF CJM, 1992, ADV CANCER RES, V58, P143, DOI 10.1016/S0065-230X(08)60294-8
   Mohr E, 2010, P NATL ACAD SCI USA, V107, P17292, DOI 10.1073/pnas.1004879107
   Nakajima C, 2001, CANCER RES, V61, P3399
   Ogi C, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.26012
   Overacre-Delgoffe AE, 2017, CELL, V169, P1130, DOI 10.1016/j.cell.2017.05.005
   Peng XW, 2015, COMPARATIVE MED, V65, P499
   Rimmelzwaan GF, 2009, VACCINE, V27, P6363, DOI 10.1016/j.vaccine.2009.01.016
   Sant AJ, 2012, J EXP MED, V209, P1391, DOI 10.1084/jem.20121517
   Schultheis K, 2017, VACCINE, V35, P61, DOI 10.1016/j.vaccine.2016.11.052
   Sercan O, 2010, J IMMUNOL, V184, P2855, DOI 10.4049/jimmunol.0902708
   Sridhar S, 2013, NAT MED, V19, P1305, DOI 10.1038/nm.3350
   Tewari K, 2007, J IMMUNOL, V179, P2115, DOI 10.4049/jimmunol.179.4.2115
   Wang ZF, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7833
   WEBSTER RG, 1980, EUR J IMMUNOL, V10, P396, DOI 10.1002/eji.1830100515
   Wilkinson TM, 2012, NAT MED, V18, P274, DOI 10.1038/nm.2612
   Yanni AE, 2004, LAB ANIM-UK, V38, P246, DOI 10.1258/002367704323133628
   YAP KL, 1978, NATURE, V273, P238, DOI 10.1038/273238a0
NR 41
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 8
PY 2019
VL 37
IS 7
BP 903
EP 909
DI 10.1016/j.vaccine.2019.01.006
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HK9WA
UT WOS:000458342400002
PM 30661837
OA Other Gold
DA 2020-05-12
ER

PT J
AU Smith, GP
   Jain-Gupta, N
   Alqublan, H
   Dorneles, EMS
   Boyle, SM
   Sriranganathan, N
AF Smith, G. P.
   Jain-Gupta, N.
   Alqublan, H.
   Dorneles, E. M. S.
   Boyle, S. M.
   Sriranganathan, N.
TI Development of an auxotrophic, live-attenuated Brucella suis vaccine
   strain capable of expressing multimeric GnRH
SO VACCINE
LA English
DT Article
DE Brucella suis; Feral swine; Live-attenuated vaccine;
   Immuno-contraception
ID FERAL SWINE; ROUGH STRAIN; WBOA GENE; RB51
AB Feral swine cost around $1.5 billion each year in agricultural, environmental, and personal property damages. They are also the most widespread carriers of the zoonotic disease brucellosis, which threatens both livestock bio-security and public health. Currently, there is no approved vaccine against brucellosis in pigs. This is a preliminary report on the development of a live-attenuated B. suis vaccine that could be employed to deliver heterologous antigens to control swine populations. An attenuated vaccine strain provided significant protection against B. suis challenge in mice. Leucine auxotrophy in the vaccine strain allowed the over-expression of heterologous antigens without the use of antibiotic resistant markers. Vaccinated mice showed the development of antibodies against expressed antigen. Further evaluation is required to assess its ability to cause infertility using the mouse model prior to further testing for use as a tool for feral swine population and disease control. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Smith, G. P.; Jain-Gupta, N.; Alqublan, H.; Boyle, S. M.; Sriranganathan, N.] Virginia Tech, Virginia Maryland Coll Vet Med, Ctr Hlth Res 1, Blacksburg, VA 24061 USA.
   [Dorneles, E. M. S.] Univ Fed Lavras, Dept Med Vet, Lavras, MG, Brazil.
RP Sriranganathan, N (reprint author), Virginia Tech, Virginia Maryland Coll Vet Med, Ctr Hlth Res 1, Blacksburg, VA 24061 USA.
EM nathans@vt.edu
RI Dorneles, Elaine/V-2816-2019
OI Dorneles, Elaine/0000-0002-2753-1296; Jain Gupta,
   Neelu/0000-0003-4885-1827
FU Virginia APHIS-USDA [422319]
FX This research project was funded by Virginia APHIS-USDA (422319).
CR Gelfand MS, 2014, INFECT DIS CLIN PRAC, DOI [10.1097/IPC.0000000000000160, DOI 10.1097/IPC.0000000000000160]
   Gupta JC, 2004, PROTEIN EXPRES PURIF, V37, P1, DOI 10.1016/j.pep.2004.03.018
   Killian G, 2006, AM J REPROD IMMUNOL, V55, P378, DOI 10.1111/j.1600-0897.2006.00379.x
   Marx CJ, 2002, BIOTECHNIQUES, V33, P1062, DOI 10.2144/02335rr01
   Meng XJ, 2009, PHILOS T R SOC B, V364, P2697, DOI 10.1098/rstb.2009.0086
   Miller LA, 2006, P 22 VERT PEST C, P106
   Miller LA, 2008, AM J REPROD IMMUNOL, V60, P214, DOI 10.1111/j.1600-0897.2008.00616.x
   Pimental D., 2007, ENV EC COSTS VERTEBR
   Rajasekaran P, 2008, APPL ENVIRON MICROB, V74, P7051, DOI 10.1128/AEM.01511-08
   Rajasekaran P, 2011, VACCINE, V29, P3106, DOI 10.1016/j.vaccine.2011.02.054
   Sandfoss MR, 2012, J WILDLIFE DIS, V48, P462, DOI 10.7589/0090-3558-48.2.462
   SCHURIG GG, 1991, VET MICROBIOL, V28, P171, DOI 10.1016/0378-1135(91)90091-S
   Seleem MN, 2010, VET MICROBIOL, V140, P392, DOI 10.1016/j.vetmic.2009.06.021
   Stoffregen WC, 2007, J VET DIAGN INVEST, V19, P227, DOI 10.1177/104063870701900301
   Stoffregen WC, 2006, AM J VET RES, V67, P1802, DOI 10.2460/ajvr.67.10.1802
   Stoffregen WC, 2013, RES VET SCI, V95, P451, DOI 10.1016/j.rvsc.2013.04.014
   Talwar GP, 2004, VACCINE, V22, P3713, DOI 10.1016/j.vaccine.2004.03.014
   Vemulapalli R, 1999, CLIN DIAGN LAB IMMUN, V6, P760, DOI 10.1128/CDLI.6.5.760-764.1999
   Vemulapalli R, 2000, INFECT IMMUN, V68, P3927, DOI 10.1128/IAI.68.7.3927-3932.2000
   Winter AJ, 1996, AM J VET RES, V57, P677
NR 20
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 8
PY 2019
VL 37
IS 7
BP 910
EP 914
DI 10.1016/j.vaccine.2018.12.070
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HK9WA
UT WOS:000458342400003
PM 30655173
DA 2020-05-12
ER

PT J
AU Boccalini, S
   Tacconi, FM
   Lai, PL
   Bechini, A
   Bonanni, P
   Panatto, D
AF Boccalini, S.
   Tacconi, F. Manda
   Lai, Piero Luigi
   Bechini, A.
   Bonanni, P.
   Panatto, D.
TI Appropriateness and preferential use of different seasonal influenza
   vaccines: A pilot study on the opinion of vaccinating physicians in
   Italy
SO VACCINE
LA English
DT Article
DE Influenza; Vaccination; Policy
AB In Italy, several types of influenza vaccine are on the market. Available evidence suggests that no single vaccine type is universally appropriate; rather, different types may be more appropriate for different population strata. However, while the concept of appropriateness/preferential use of single vaccines is usually adopted at the central level, little is known about the attitudes of physicians on the matter. A pilot survey of Italian physicians (N = 372) revealed that most (about 90%) were aware that the available vaccines were different, and that particular vaccines were more appropriate for specific groups. The availability of explicit guidelines on which vaccine to administer to a given population group was deemed desirable by 93.2% of respondents. The results were consistent with the 2018 Italian and UK normative documents, which indicate adjuvanted vaccines as the most appropriate choice for the elderly, and quadrivalent formulations for the younger age-classes. Public health policy implications are discussed. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Boccalini, S.; Tacconi, F. Manda; Bechini, A.; Bonanni, P.] Univ Florence, Dept Hlth Sci, Viale Morgagni 48, I-50134 Florence, Italy.
   [Lai, Piero Luigi; Panatto, D.] Univ Genoa, Dept Hlth Sci, Genoa, Italy.
   [Panatto, D.] Interuniv Res Ctr Influenza & Other Transmissible, Genoa, Italy.
RP Boccalini, S (reprint author), Univ Florence, Dept Hlth Sci, Viale Morgagni 48, I-50134 Florence, Italy.
EM sara.boccalini@unifi.it
RI Bonanni, Paolo/AAB-9823-2019
OI Bonanni, Paolo/0000-0003-2875-3744; Panatto,
   Donatella/0000-0002-2677-0551; Boccalini, Sara/0000-0002-9695-7549;
   Bechini, Angela/0000-0002-6013-8779
FU Seqirus srl
FX An unconditional grant from Seqirus srl enabled the study to be
   conducted.
CR [Anonymous], 2012, Wkly Epidemiol Rec, V87, P461
   Barbieri M, 2017, J Prev Med Hyg, V58, pE279, DOI 10.15167/2421-4248/jpmh2017.58.4.867
   Bonanni P, PUBLIC HLTH ENGLAND
   Bonanni P, 2018, HUM VACC IMMUNOTHER, V14, P699, DOI 10.1080/21645515.2017.1388480
   Cartabellotta A, 2015, EVIDENCE, V7
   Development Core R Team R, 2008, LANG ENV STAT COMP
   Italian Ministry of Health, INFL VACC COV
   Italian Ministry of Health, 2017, NAT IMM PREV PLAN
   Italian Ministry of Health, 2018, PREV CONTR INFL REC
   Italian Ministry of Health, 2017, PREV CONTR INFL REC
   Kohlhammer Y, 2007, PUBLIC HEALTH, V121, P742, DOI 10.1016/j.puhe.2007.02.011
   Levi M, 2018, HUM VACC IMMUNOTHER, P1, DOI [10.1080/21645515.2018.1410543, DOI 10.1080/21645515.2018.1410543]
   Public Health England (PHE), GUID SUMM DAT SUPP C
   Superior Institute of Health, SURV PASS
   World Health Organization (WHO), 2000, APPR HEALTHC SERV WH
NR 15
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 8
PY 2019
VL 37
IS 7
BP 915
EP 918
DI 10.1016/j.vaccine.2018.12.057
PG 4
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HK9WA
UT WOS:000458342400004
PM 30651199
OA Green Published
DA 2020-05-12
ER

PT J
AU Strijbos, E
   Tannemaat, MR
   Alleman, I
   de Meel, RHP
   Bakker, JA
   van Beek, R
   Kroon, FP
   Rimmelzwaan, GF
   Verschuuren, JJGM
AF Strijbos, Ellen
   Tannemaat, Martijn R.
   Alleman, Iris
   de Meel, Robert H. P.
   Bakker, Jaap A.
   van Beek, Ruud
   Kroon, Frank P.
   Rimmelzwaan, Guus F.
   Verschuuren, Jan J. G. M.
TI A prospective, double-blind, randomized, placebo-controlled study on the
   efficacy and safety of influenza vaccination in myasthenia gravis
SO VACCINE
LA English
DT Article
DE Influenza; Vaccination; Autoimmune disease; Myasthenia gravis;
   Immunosuppression; Antibodies
ID ANTIBODY
AB Objective: To investigate the efficacy and safety of an influenza vaccination in patients with myasthenia gravis with acetylcholine receptor antibodies (AChR MG).
   Methods: An influenza vaccination or placebo was administered to 47 AChR MG patients. Before and 4 weeks after administration blood samples and clinical outcome scores were obtained. Antibodies to the vaccine strains A/California/7/2009 (H1N1)pdm09, A/Hong Kong/4801/14 (H3N2) and B/Brisbane/060/08 were measured using the hemagglutination-inhibition (HI) assay and disease-specific AChR antibody titers were measured with a radio-immunoprecipitation assay. Forty-seven healthy controls (HC) were vaccinated with the same influenza vaccine to compare antibody titers.
   Results: A post-vaccination, seroprotective titer (HI >= 1:40) was achieved in 89.4% of MG patients vs. 93.6% in healthy controls for the H3N2 strain, 95.7% vs 97.9% for the H1N1 strain and 46.8 vs 51% for the B-strain. A seroprotective titer for all three strains of the seasonal influenza vaccine was reached in 40.4% (19/47) of the MG group and in 51% (24/47) of the HC group. Immunosuppressive medication did not significantly influence post geomean titers (GMT). The titers of disease-specific AChR antibodies were unchanged 4 weeks after vaccination. The clinical outcome scores showed no exacerbation of MG symptoms.
   Conclusion: The antibody response to an influenza vaccination in patients with AChR MG was not different from that in healthy subjects, even in AChR MG patients using immunosuppressive medication. Influenza vaccination does not induce an immunological or clinical exacerbation of AChR MG.
C1 [Strijbos, Ellen; Tannemaat, Martijn R.; de Meel, Robert H. P.; Verschuuren, Jan J. G. M.] Leiden Univ, Med Ctr, Dept Neurol, Leiden, Netherlands.
   [Alleman, Iris] Leiden Univ, Med Ctr, Dept Physiotherapy, Leiden, Netherlands.
   [Bakker, Jaap A.] Leiden Univ, Med Ctr, Dept Clin Chem & Lab Med, Leiden, Netherlands.
   [Kroon, Frank P.] Leiden Univ, Med Ctr, Dept Infect Dis, Leiden, Netherlands.
   [Rimmelzwaan, Guus F.] Univ Vet Med, Res Ctr Emerging Infect & Zoonoses, Hannover, Germany.
   [van Beek, Ruud] Erasmus MC, Dept Virosci, Rotterdam, Netherlands.
RP Strijbos, E (reprint author), Albinusdreef 2, NL-2333 ZA Leiden, Netherlands.
EM e.strijbos@lumc.nl
RI ; Tannemaat, Martijn/S-3445-2016
OI de Meel, Robert/0000-0002-4374-3715; Verschuuren,
   Jan/0000-0002-4572-1501; Tannemaat, Martijn/0000-0003-2929-0390
CR Abu-Shakra M, 2002, J RHEUMATOL, V29, P2555
   Auriel E, 2011, MUSCLE NERVE, V43, P893, DOI 10.1002/mus.22077
   Barohn RJ, 1998, ANN NY ACAD SCI, V841, P769, DOI 10.1111/j.1749-6632.1998.tb11015.x
   Bedlack RS, 2005, NEUROLOGY, V64, P1968, DOI 10.1212/01.WNL.0000163988.28892.79
   Burns TM, 2010, NEUROLOGY, V74, P1434, DOI 10.1212/WNL.0b013e3181dc1b1e
   Burns TM, 2008, MUSCLE NERVE, V38, P1553, DOI 10.1002/mus.21185
   Carr AS, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-46
   Gilhus NE, 2018, J NEUROL
   Gilhus NE, 2015, LANCET NEUROL, V14, P1023, DOI 10.1016/S1474-4422(15)00145-3
   Holvast A, 2006, ANN RHEUM DIS, V65, P913, DOI 10.1136/ard.2005.043943
   Kassianos George, 2016, Drugs Context, V5, P212293, DOI 10.7573/dic.212293
   Klinkenberg Roselke E, 2014, Ned Tijdschr Geneeskd, V158, pA7574
   Meyer-Olson D, 2011, NAT REV RHEUMATOL, V7, P198, DOI 10.1038/nrrheum.2011.14
   Muppidi S, 2012, ANN NY ACAD SCI, V1274, P114, DOI 10.1111/j.1749-6632.2012.06817.x
   Seok HY, 2017, J CLIN NEUROL, V13, P325, DOI 10.3988/jcn.2017.13.4.325
   Strijbos E, 2017, VACCINE, V35, P6290, DOI 10.1016/j.vaccine.2017.09.078
   Tackenberg B, 2018, EBIOMEDICINE
   VINCENT A, 1985, J NEUROL NEUROSUR PS, V48, P1246, DOI 10.1136/jnnp.48.12.1246
   Vogtlander NPJ, 2004, VACCINE, V22, P2199, DOI 10.1016/j.vaccine.2003.11.046
   Westra J, 2015, NAT REV RHEUMATOL, V11, P135, DOI 10.1038/nrrheum.2014.206
   Zinman L, 2009, MUSCLE NERVE, V40, P947, DOI 10.1002/mus.21440
NR 21
TC 1
Z9 1
U1 1
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 8
PY 2019
VL 37
IS 7
BP 919
EP 925
DI 10.1016/j.vaccine.2019.01.007
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HK9WA
UT WOS:000458342400005
PM 30660402
DA 2020-05-12
ER

PT J
AU Mo, FZ
   Xue, DB
   Duan, SL
   Liu, AQ
   Yang, XM
   Hou, XQ
   Lu, XL
AF Mo, Fengzhen
   Xue, Dabing
   Duan, Siliang
   Liu, Aiqun
   Yang, Xiaomei
   Hou, Xiaoqiong
   Lu, Xiaoling
TI Novel fusion cells derived from tumor cells expressing the heterologous
   alpha-galactose epitope and dendritic cells effectively target cancer
SO VACCINE
LA English
DT Article
DE Tumor cells; Dendritic cells; Fusion cells; alpha-galactose; Cancer
   immunotherapy
ID ANTI-GAL ANTIBODY; INTRATUMORAL INJECTION; IMMUNOTHERAPY; VACCINES; IGG;
   XENOTRANSPLANTATION; COMBINATION; RECOGNITION; INDUCTION; MELANOMA
AB Tumor cells/dendritic cells (DCs) fusion cells (tumor/DC) represent a promising immunotherapeutic strategy but are still under performed in clinical trials for cancer treatment. To further boost their anticancer efficacy, here we developed a novel design for fusing dendritic cells with MDA-MB-231 cells expressing the heterologous alpha-galactose (alpha-gal) epitope and assessed its anticancer activities both in vitro and in vivo. The high expression of alpha-gal in MDA-MB-231 (Gal(+)/DC correlated with enhanced DC activation. When applied to T cells, MDA-MB-231 (Gal(+)/DC significantly stimulated T-cell proliferation and activation, promoted productions of cytokines IL-2 and IFN-gamma, and enhanced T-cell-mediated cytotoxicity against MDA-MB-231 cells. MDA-MB-231 (Gal(+)/DC inhibited proliferation and promoted apoptosis of tumor cells in vivo, prolonged mouse survival, and significantly boosted anticancer immunity by increasing CD4(+) and CD8(+) T cells systemically and elevating serum levels of cytokines and IgG. These results suggested that fusing dendritic cells with tumor cells expressing the heterologous alpha-gal epitope provides a novel therapeutic strategy for cancer treatment. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Mo, Fengzhen; Xue, Dabing; Duan, Siliang; Yang, Xiaomei; Hou, Xiaoqiong; Lu, Xiaoling] Guangxi Med Univ, Sch Preclin Med, Nanning 530021, Guangxi, Peoples R China.
   [Mo, Fengzhen; Xue, Dabing; Duan, Siliang; Liu, Aiqun; Yang, Xiaomei; Hou, Xiaoqiong; Lu, Xiaoling] Guangxi Med Univ, Int Nanobody Res Ctr Guangxi, Nanning 530021, Guangxi, Peoples R China.
   [Mo, Fengzhen] Guangxi Med Univ, Pharmaceut Coll, Nanning 530021, Guangxi, Peoples R China.
   [Lu, Xiaoling] Guangxi Med Univ, Natl Ctr Int Res Biol Targeting Diag & Therapy, Nanning 530021, Guangxi, Peoples R China.
RP Lu, XL (reprint author), Guangxi Med Univ, Int Nanobody Res Ctr Guangxi, Nanning 530021, Guangxi, Peoples R China.
EM luxiaoling@gxmu.edu.cn
FU Programs for Changjiang Scholars and Innovative Research Team in
   UniversityProgram for Changjiang Scholars & Innovative Research Team in
   University (PCSIRT) [IRT_15R13]; International Cooperation Project of
   the Misnistry of Science and Technology of China [2015DFA31320]; Project
   for Innovative Research Team in Guangxi Natural Science Foundation
   [2015GXNSFFA139001]; Project of National Natural Scientific Foundation
   of ChinaNational Natural Science Foundation of China [81773254]; project
   for International Nanobody Research Center of Guangxi [GuiKe-AD17195001]
FX I thank all researchers from our laboratory and collaborators all over
   the world for sharing their exciting data and contribution to progress.
   This work was supported by grants from Programs for Changjiang Scholars
   and Innovative Research Team in University (No.IRT_15R13); International
   Cooperation Project of the Misnistry of Science and Technology of China
   (No. 2015DFA31320); the Project for Innovative Research Team in Guangxi
   Natural Science Foundation (2015GXNSFFA139001); Project of National
   Natural Scientific Foundation of China (No. 81773254), and the project
   for International Nanobody Research Center of Guangxi
   (No.GuiKe-AD17195001).
CR Abdel-Motal UM, 2009, CANCER IMMUNOL IMMUN, V58, P1545, DOI 10.1007/s00262-009-0662-2
   Abdel-Motal UM, 2009, VACCINE, V27, P3072, DOI 10.1016/j.vaccine.2009.03.019
   Avigan D, 2012, SEMIN ONCOL, V39, P287, DOI 10.1053/j.seminoncol.2012.02.003
   Baxevanis CN, 2014, EXPERT REV VACCINES, V13, P131, DOI 10.1586/14760584.2014.852961
   Chagpar Anees B, 2007, J Ky Med Assoc, V105, P559
   Chi HY, 2012, ANIM SCI J, V83, P88, DOI 10.1111/j.1740-0929.2011.00964.x
   Ferlazzo G, 2004, P NATL ACAD SCI USA, V101, P16606, DOI 10.1073/pnas.0407522101
   Galili U, 2005, IMMUNOL CELL BIOL, V83, P674, DOI 10.1111/j.1440-1711.2005.01366.x
   Galili U, 2003, GYNECOL ONCOL, V90, P100, DOI 10.1016/S0090-8258(03)00148-3
   GALILI U, 1987, J EXP MED, V165, P693, DOI 10.1084/jem.165.3.693
   GALILI U, 1984, J EXP MED, V160, P1519, DOI 10.1084/jem.160.5.1519
   GALILI U, 1985, J EXP MED, V162, P573, DOI 10.1084/jem.162.2.573
   Galili U, 2007, J IMMUNOL, V178, P4676, DOI 10.4049/jimmunol.178.7.4676
   Gong JL, 1997, NAT MED, V3, P558, DOI 10.1038/nm0597-558
   He J, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1361094
   Heufler C, 1996, EUR J IMMUNOL, V26, P659, DOI 10.1002/eji.1830260323
   Higano CS, 2009, CANCER-AM CANCER SOC, V115, P3670, DOI 10.1002/cncr.24429
   Kajihara M, 2015, IMMUNOTHERAPY-UK, V7, P1111, DOI 10.2217/imt.15.73
   Kalinski P, 1997, J IMMUNOL, V159, P28
   Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294
   Koido S, 2007, ARCH IMMUNOL THER EX, V55, P281, DOI 10.1007/s00005-007-0034-6
   Koido S, 2007, J IMMUNOL, V178, P613, DOI 10.4049/jimmunol.178.1.613
   Koido S, 2015, METHODS MOL BIOL, P185, DOI 10.1007/978-1-4939-2703-6_13
   Koido S, 2009, CLIN DEV IMMUNOL, DOI 10.1155/2009/657369
   Lai CH, 2014, J BIOMED NANOTECHNOL, V10, P3576, DOI 10.1166/jbn.2014.2051
   Manches O, 2005, HAEMATOLOGICA, V90, P625
   Misganaw A, 2017, POPUL HEALTH METR, V15, DOI 10.1186/s12963-017-0145-1
   Nazarpour R, 2012, INT J MOL CELL MED, V1, P88
   Oju Y, 2011, WORLD J GASTROENTERO, V17, P5260, DOI [10.3748/wjg.v17.i48.5260, DOI 10.3748/WIG.V17.J48.5260]
   Palucka K, 2012, NAT REV CANCER, V12, P265, DOI 10.1038/nrc3258
   Papaioannou NE, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.04.01
   Pizzurro GA, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00091
   Qiu Y, 2016, CYTOTHERAPY, V18, P91, DOI 10.1016/j.jcyt.2015.09.012
   Qiu Y, 2013, INT J CLIN ONCOL, V18, P657, DOI 10.1007/s10147-012-0434-4
   Rossi GR, 2005, CANCER RES, V65, P10555, DOI 10.1158/0008-5472.CAN-05-0627
   Rossi GR, 2005, CANCER IMMUNOL IMMUN, V54, P999, DOI 10.1007/s00262-005-0667-4
   Saito H, 2017, CANCER GENE THER, V24, P289, DOI 10.1038/cgt.2017.21
   Schmidt SV, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00274
   Sharma P, 2011, NAT REV CANCER, V11, P805, DOI 10.1038/nrc3153
   Shultz LD, 2012, NAT REV IMMUNOL, V12, P786, DOI 10.1038/nri3311
   Szekely B, 2011, EUR J GYNAECOL ONCOL, V32, P636
   Tanemura M, 2015, WORLD J GASTROENTERO, V21, P11396, DOI 10.3748/wjg.v21.i40.11396
   Tanida T, 2015, INT J ONCOL, V46, P78, DOI 10.3892/ijo.2014.2717
   Teneberg S, 1996, GLYCOBIOLOGY, V6, P599, DOI 10.1093/glycob/6.6.599
   Vinay DS, 2015, SEMIN CANCER BIOL, V35, pS185, DOI 10.1016/j.semcancer.2015.03.004
   Whalen GF, 2012, ANTICANCER RES, V32, P3861
   Xue DB, 2016, ONCOL REP, V36, P2843, DOI 10.3892/or.2016.5128
   Yao XF, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1973-7
NR 48
TC 0
Z9 0
U1 2
U2 10
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 8
PY 2019
VL 37
IS 7
BP 926
EP 936
DI 10.1016/j.vaccine.2019.01.004
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HK9WA
UT WOS:000458342400006
PM 30661833
DA 2020-05-12
ER

PT J
AU Fereig, RM
   Abdelbaky, HH
   Kuroda, Y
   Nishikawa, Y
AF Fereig, Ragab M.
   Abdelbaky, Hanan H.
   Kuroda, Yasuhiro
   Nishikawa, Yoshifumi
TI Critical role of TLR2 in triggering protective immunity with cyclophilin
   entrapped in oligomannose-coated liposomes against Neospora caninum
   infection in mice
SO VACCINE
LA English
DT Article
DE Neospora caninum; NcCyp; Vaccination; Neosporosis; Cyclophilin
ID CUTTING EDGE; BALB/C MICE; IMMUNIZATION; RECOGNITION; ACTIVATION;
   RESPONSES; CELLS; IL-12
AB Neospora caninum is an intracellular protozoan parasite closely related to Toxoplasma gondii. N. caninum is thought to be a major cause of abortion in cattle worldwide. Given the current situation of drastic economic losses and a lack of efficient control strategies against such parasites, the challenge to develop potent vaccine candidates and technologies remains. We investigated the immune stimulating activity of N. caninum cyclophilin (NcCyp) with and without a formulation with oligomannose-coated-liposomes (OML) as the potential adjuvant. NcCyp-OML activated NF-kappa B in RAW 264.7 cells and triggered interleukin (IL)-12p40 production from murine peritoneal macrophages. In BALB/c mice, immunization with NcCyp-OML was associated with the production of specific antibodies (IgGI and IgG2a). The specific antibody (IgG1) against naked NcCyp was also observed after the challenge infection, but it was significantly lower than those of NcCyp-OML. Moreover, significant cellular immune responses were induced, including spleen cell proliferation and interferon-gamma production. The immunization of mice with NcCyp-OML, and to lesser extent with naked NcCyp, induced significant protection against challenge with a lethal dose of N. caninum compared with the PBS control group. This protection was associated with a higher survival rate, slight changes in body weight, and lower clinical score of mice. In addition, the significant protective efficacy of NcCyp-OML was confirmed in another mouse strain, male C57BL/6 mice. The current study revealed the marked contribution of Toll-like receptor 2 (TLR2) to the protective immunity triggered by NcCyp-OML because higher numbers of TLR2(-/-) mice succumbed to a lethal dose of N. caninum compared with C57BL/6 mice. Moreover, prominent spleen cell proliferation and IFN-gamma production was induced in NcCyp-OML-immunized mice by a TLR2-dependent mechanism. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Fereig, Ragab M.; Abdelbaky, Hanan H.; Nishikawa, Yoshifumi] Obihiro Univ Agr & Vet Med, Natl Res Ctr Protozoan Dis, Inada Cho, Obihiro, Hokkaido 0808555, Japan.
   [Fereig, Ragab M.] South Valley Univ, Fac Vet Med, Dept Anim Med, Qena City 83523, Qena, Egypt.
   [Kuroda, Yasuhiro] Tokai Univ, Dept Appl Biochem, Hiratsuka, Kanagawa 2591292, Japan.
RP Nishikawa, Y (reprint author), Obihiro Univ Agr & Vet Med, Natl Res Ctr Protozoan Dis, Inada Cho, Obihiro, Hokkaido 0808555, Japan.
EM kuro@keyaki.cc.u-tokai.ac.jp; nisikawa@obihiro.ac.jp
FU Ministry of Education, Culture, Sports, Science and Technology
   KAKENHIMinistry of Education, Culture, Sports, Science and Technology,
   Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for
   Scientific Research (KAKENHI) [15H04589, 18H02335]
FX This research was supported by a Grant-in-Aid for Scientific Research
   (B) from the Ministry of Education, Culture, Sports, Science and
   Technology KAKENHI (15H04589, 18H02335).
CR Abe C, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-014-0620-5
   Abe C, 2014, CLIN VACCINE IMMUNOL, V21, P1185, DOI 10.1128/CVI.00082-14
   Aguado-Martinez A, 2017, INT J PARASITOL, V47, P723, DOI 10.1016/j.ijpara.2017.09.001
   Aguado-Martinez A, 2016, PARASITOLOGY, V143, P606, DOI 10.1017/S0031182016000056
   Basto AP, 2014, J IMMUNOL RES, DOI 10.1155/2014/619410
   Chen X, 2005, J LEUKOCYTE BIOL, V78, P114, DOI 10.1189/jlb.0604341
   Dubey JP, 2011, VET PARASITOL, V180, P90, DOI 10.1016/j.vetpar.2011.05.031
   Ferreira BL, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00553
   Gibson J., 2010, Immunology Endocrine & Metabolic Agents in Medicinal Chemistry, V10, P11
   Halliday A, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1381-0
   Hawiger J, 2001, IMMUNOL RES, V23, P99, DOI 10.1385/IR:23:2-3:099
   Innes EA, 2000, ANN NY ACAD SCI, V916, P93, DOI 10.1111/j.1749-6632.2000.tb05278.x
   Kameyama K, 2012, PARASITOLOGY, V139, P294, DOI 10.1017/S0031182011002022
   Kato C, 2008, BIOCHEM BIOPH RES CO, V372, P898, DOI 10.1016/j.bbrc.2008.05.151
   Kato C, 2010, GLYCOCONJUGATE J, V27, P525, DOI 10.1007/s10719-010-9298-x
   Kim WS, 2016, ONCOTARGET, V7, P24962, DOI 10.18632/oncotarget.8771
   Liu T, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.23
   Matsuoka Y, 2016, IMMUNOL LETT, V178, P61, DOI 10.1016/j.imlet.2016.07.016
   Mineo TWP, 2010, IMMUNOL CELL BIOL, V88, P825, DOI 10.1038/icb.2010.52
   Mun HS, 2003, INT IMMUNOL, V15, P1081, DOI 10.1093/intimm/dxg108
   Nishikawa Y, 2003, VET PARASITOL, V116, P175, DOI 10.1016/j.vetpar.2003.07.001
   Nishikawa Y, 2017, J VET MED SCI, V79, P1374, DOI 10.1292/jvms.17-0285
   Nishikawa Y, 2009, CLIN VACCINE IMMUNOL, V16, P792, DOI 10.1128/CVI.00032-09
   Nishimura M, 2013, VACCINE, V31, P3528, DOI 10.1016/j.vaccine.2013.05.083
   O'Garra A, 2009, NAT IMMUNOL, V10, P929, DOI 10.1038/ni0909-929
   Rahman MM, 2011, NAT REV MICROBIOL, V9, P291, DOI 10.1038/nrmicro2539
   Scanga CA, 2002, J IMMUNOL, V168, P5997, DOI 10.4049/jimmunol.168.12.5997
   Scotland RS, 2011, BLOOD, V118, P5918, DOI 10.1182/blood-2011-03-340281
   Shepardson KM, 2017, MBIO, V8, DOI 10.1128/mBio.01356-17
   Shimizu Y, 2007, PARASITE IMMUNOL, V29, P229, DOI 10.1111/j.1365-3024.2007.00937.x
   Takeuchi O, 2000, J IMMUNOL, V165, P5392, DOI 10.4049/jimmunol.165.10.5392
   Tuo WB, 2011, VACCINE, V29, P2392, DOI 10.1016/j.vaccine.2011.01.041
   VanLeeuwen JA, 2011, VET PARASITOL, V175, P372, DOI 10.1016/j.vetpar.2010.10.016
   Wang S, 2011, J IMMUNOL, V187, P141, DOI 10.4049/jimmunol.1003740
   Weber FH, 2013, CLIN VACCINE IMMUNOL, V20, P99, DOI 10.1128/CVI.00225-12
   Zhang GL, 2001, J CLIN INVEST, V107, P13, DOI 10.1172/JCI11837
   Zhang HS, 2010, EXP PARASITOL, V125, P130, DOI 10.1016/j.exppara.2010.01.008
NR 37
TC 2
Z9 2
U1 2
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 8
PY 2019
VL 37
IS 7
BP 937
EP 944
DI 10.1016/j.vaccine.2019.01.005
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HK9WA
UT WOS:000458342400007
PM 30660401
DA 2020-05-12
ER

PT J
AU Degarege, A
   Krupp, K
   Fennie, K
   Srinivas, V
   Li, T
   Stephens, DP
   Madhivanan, P
AF Degarege, Abraham
   Krupp, Karl
   Fennie, Kristopher
   Srinivas, Vijaya
   Li, Tan
   Stephens, Dionne P.
   Madhivanan, Purnima
TI An integrative behavior theory derived model to assess factors affecting
   HPV vaccine acceptance using structural equation modeling
SO VACCINE
LA English
DT Article
DE HPV vaccine; Acceptance; Daughter; Parent; India
ID HUMAN-PAPILLOMAVIRUS VACCINATION; CERVICAL-CANCER; ADOLESCENT GIRLS;
   INDIAN ACADEMY; ACCEPTABILITY; PARENTS; ATTITUDES; IMMUNIZATION;
   KNOWLEDGE; MYSORE
AB The study examined factors that affect parental intention-to-vaccinate adolescent daughters with HPV vaccine in Mysore district, India. A cross-sectional study was conducted among 1609 parents of adolescent girls attending schools in Mysore District between February 2010 and October 2011. A validated questionnaire was used to assess parental attitudes, beliefs related with HPV infection, cervical cancer, HPV vaccine and vaccination in general. Structural equation modeling was used to estimate parameters and assess whether a model based on the integrative behavior theory would fit the current data. More than two-thirds (78.0%) of parents would accept vaccinating their daughters with HPV vaccine. Intention to HPV vaccination significantly increased with increase in the perception of parents about the benefits (standardized regression coefficient (beta) = 0.39) or sources of information about HPV vaccine (beta = 0.24), but intention decreased significantly with an increase in the perception about barriers to HPV vaccination beta = -0.44). The effect of beliefs about severity of HPV infection or cervical cancer (beta = 0.20), and beliefs about benefits (beta = 0.20) or barriers (beta = -0.25) to vaccination in general on intention to HPV vaccination were significantly mediated by parental attitudes and source of information about the vaccine. Geographical location significantly moderated the awareness about HPV on beliefs about severity of HPV infection or cervical cancer (beta = 0.33), and the effect of religion on norms related to HPV vaccination (beta = 0.19). Fit of the model to the data was acceptable. This study identified modifiable parental attitudes about HPV vaccine and beliefs related with HPV infection, cervical cancer and vaccination, which predicted parental intention-to-vaccinate their daughters with HPV vaccine in India. Health education interventions tailored to counter parental negative attitudes and beliefs about HPV vaccine and vaccination in general would be important for the community to promote HPV vaccination. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Degarege, Abraham; Fennie, Kristopher; Madhivanan, Purnima] Florida Int Univ, Robert Stempel Coll Publ Hlth & Social Work, Dept Epidemiol, 11200 SW 8th St, Miami, FL 33199 USA.
   [Degarege, Abraham] Addis Ababa Univ, Aklilu Lemma Inst Pathobiol, Addis Ababa, Ethiopia.
   [Krupp, Karl] Florida Int Univ, Robert Stempel Coll Publ Hlth & Social Work, Dept Hlth Promot & Dis Prevent, Miami, FL 33199 USA.
   [Krupp, Karl; Srinivas, Vijaya; Madhivanan, Purnima] Publ Hlth Res Inst India, Mysore, Karnataka, India.
   [Li, Tan] Florida Int Univ, Robert Stempel Coll Publ Hlth & Social Work, Dept Biostat, Miami, FL 33199 USA.
   [Stephens, Dionne P.] Florida Int Univ, Dept Psychol, Coll Arts Sci & Educ, Miami, FL 33199 USA.
RP Madhivanan, P (reprint author), Florida Int Univ, Robert Stempel Coll Publ Hlth & Social Work, Dept Epidemiol, 11200 SW 8th St, Miami, FL 33199 USA.
EM pmadhiva@fiu.edu
RI Madhivanan, Purnima/AAH-4849-2019
OI Madhivanan, Purnima/0000-0001-7818-3394; Stephens,
   Dionne/0000-0002-6636-6625; Degarege, Abraham/0000-0002-5738-0521;
   Degarege, Abraham/0000-0002-1537-6639
FU Merck & Co., Inc, United States; Florida International University,
   United States; Fogarty International CenterUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   Fogarty International Center (FIC); National Heart Lung and Blood
   Institutes at National Institute for Health, United States [D43
   TW010540]
FX This study was funded by an Investigator Initiated Award from Merck &
   Co., Inc, United States. AD is funded by a Dissertation Year Fellowship
   from Florida International University, United States. KK was a Global
   Health Equity Scholar funded by the Fogarty International Center and
   National Heart Lung and Blood Institutes at National Institute for
   Health, United States under Award Number D43 TW010540. The funders had
   no role in the study design, data collection, analysis, interpretation
   or publication of the manuscript.
CR [Anonymous], VACC NAT IMM PROGR U
   [Anonymous], THE ASIAN AGE
   [Anonymous], INDIAN EXPRESS
   Arora S, 2017, RES REV J IMMUNOL, V7, P2349
   Azur MJ, 2011, INT J METH PSYCH RES, V20, P40, DOI 10.1002/mpr.329
   Basu P, 2011, J OBSTET GYNAECOL RE, V37, P393, DOI 10.1111/j.1447-0756.2010.01371.x
   BENTLER PM, 1987, SOCIOL METHOD RES, V16, P78, DOI 10.1177/0049124187016001004
   Bobdey S, 2016, INDIAN J MED PAEDIAT, V37, P278, DOI 10.4103/0971-5851.195751
   Byrne B, 2011, STRUCTURAL EQUATION
   Carmines EG, 1981, SOCIAL MEASUREMENT C, P80
   Charakorn C, 2011, ASIA-PAC J CLIN ONCO, V7, P160, DOI 10.1111/j.1743-7563.2011.01392.x
   Chatterjee Sharmila, 2016, Asian Pac J Cancer Prev, V17, P3663
   Das D., 2012, INT J ADV RES TECHNO, V1, P1
   Das M, 2018, LANCET ONCOL, V19, pE84, DOI 10.1016/S1470-2045(18)30018-4
   Degarege A, 2018, J PEDIATR ADOL GYNEC, V31, P583, DOI 10.1016/j.jpag.2018.07.008
   Degarege A, 2018, J PEDIATR ADOL GYNEC, V31, P494, DOI 10.1016/j.jpag.2018.03.008
   Dikshit R, 2012, LANCET, V379, P1807, DOI 10.1016/S0140-6736(12)60358-4
   Eberhardt MS, 2004, AM J PUBLIC HEALTH, V94, P1682, DOI 10.2105/AJPH.94.10.1682
   Fernandez ME, 2010, ANNU REV PUBL HEALTH, V31, P235, DOI 10.1146/annurev.publhealth.012809.103609
   Fishbein M, 2000, AIDS CARE, V12, P273, DOI 10.1080/09540120050042918
   Grandahl M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193054
   Hanley SJB, 2012, VACCINE, V30, P5740, DOI 10.1016/j.vaccine.2012.07.003
   Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118
   Jaspers L, 2011, VACCINE, V29, P7785, DOI 10.1016/j.vaccine.2011.07.107
   Juntasopeepun P, 2018, INT J GYNECOL OBSTET, V142, P343, DOI 10.1002/ijgo.12539
   LaMontagne DS, 2013, LANCET ONCOL, V14, pE492, DOI 10.1016/S1470-2045(13)70476-5
   Madhivanan P, 2014, PREV MED, V64, P69, DOI 10.1016/j.ypmed.2014.04.002
   Madhivanan P, 2009, VACCINE, V27, P5203, DOI 10.1016/j.vaccine.2009.06.073
   Marlow LAV, 2007, VACCINE, V25, P1945, DOI 10.1016/j.vaccine.2007.01.059
   MARSH HW, 1985, PSYCHOL BULL, V97, P562, DOI 10.1037/0033-2909.97.3.562
   Mishra GA, 2016, ONCOLOGY-BASEL, V91, P1, DOI 10.1159/000447575
   Montano DE, 2008, HLTH BEHAV HLTH ED T, P67, DOI DOI 10.1016/S0033-3506(49)81524-1
   Montgomery MP, 2015, J CANCER EDUC, V30, P130, DOI 10.1007/s13187-014-0745-4
   Muthen BO, ROBUST INFERENCE USI
   Muthen L. K., 1998, MPLUS USERS GUIDE
   Paul P, 2014, HEALTH CARE WOMEN IN, V35, P1148, DOI 10.1080/07399332.2012.740115
   Sabeena S, 2018, J OBSTET GYNAECOL RE, V44, P989, DOI 10.1111/jog.13634
   Sam IC, 2009, J ADOLESCENT HEALTH, V44, P610, DOI 10.1016/j.jadohealth.2008.11.014
   Santhanes D, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21912-x
   Saxena U, 2012, ASIAN PAC J CANCER P, V13, P1699, DOI 10.7314/APJCP.2012.13.4.1699
   Singhal T, 2008, INDIAN PEDIATR, V45, P635
   Vashishtha VM, 2014, INDIAN PEDIATR, V51, P785, DOI 10.1007/s13312-014-0504-y
   Wang LDL, 2017, PREV MED, V102, P24, DOI 10.1016/j.ypmed.2017.06.021
   Witte K, 1996, J Health Commun, V1, P317, DOI 10.1080/108107396127988
   Yu Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146741
NR 45
TC 0
Z9 0
U1 1
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 8
PY 2019
VL 37
IS 7
BP 945
EP 955
DI 10.1016/j.vaccine.2019.01.012
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HK9WA
UT WOS:000458342400008
PM 30655176
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Xu, LL
   Li, ZJ
   Su, ZG
   Yang, YL
   Ma, GH
   Yu, R
   Zhang, SP
AF Xu, Lingling
   Li, Zhengjun
   Su, Zhiguo
   Yang, Yanli
   Ma, Guanghui
   Yu, Rong
   Zhang, Songping
TI Development of meningococcal polysaccharide conjugate vaccine that can
   elicit long-lasting and strong cellular immune response with hepatitis B
   core antigen virus-like particles as a novel carrier protein
SO VACCINE
LA English
DT Article
DE Neisseria meningitidis; Conjugate vaccine; Hepatitis B core antigen;
   Virus-like particles
ID TETANUS TOXOID-CONJUGATE; QUANTITATIVE ESTIMATION; IMMUNOGENICITY;
   SEQUENCE; EPITOPE
AB Neisseria meningitidis caused meningitis is life-threatening acute infection with high fatality and high frequency of severe sequelae. Meningococcal capsular polysaccharides can be used to prevent meningococcal disease; while conjugating the polysaccharides to carrier protein was found necessary to improve the immunogenicity and induce memory responses in infants and young children. Nevertheless, repeated administration of glycoconjugate vaccines might lead to carrier-induced epitope suppression due to limited number of carrier proteins. Here in this study, full-length hepatitis B core antigen virus-like particles (HBc VLPs) was used as a novel potential carrier protein for conjugation of meningococcal group C polysaccharides (CPS) with heterobifunctional polyethylene glycol (PEG) of different length (2, 5 and 10 kDa) as linkers. The physiochemical properties of the CPS-PEG-HBc conjugate vaccines were fully characterized. The TEM, DLS, native agarose gel electrophoresis, and HPLC analyses all confirmed the successful conjugation. As compared to plain CPS and the physical mixture of CPS and HBc, the immunization with the conjugate vaccines can generate about 10 times increase in CPS specific IgG titers with a significant boosting effect. HBc conjugation induced a shift to a Th1 cellular immune type response, as assessed by the increased IgG2a subclass production. In addition, vaccination of the conjugate vaccines elicited much enhanced avidity functional antibody and long-lasting immunological memory. IgG titers elicited by CPS-P2k-HBc, CPS-P5k-HBc and CPS-PlOk-HBc at week 18 maintained 38.1%, 17.9% and 33.3% of their peak values. All these results demonstrated that HBc VLPs can be used as potential carrier protein to develop polysaccharide conjugate vaccines effective in eliciting long-lasting and strong cellular immune response. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Xu, Lingling; Yu, Rong] Sichuan Univ, West China Sch Pharm, Key Lab Drug Targeting & Drug Delivery Syst, Minist Educ, Chengdu 610041, Sichuan, Peoples R China.
   [Xu, Lingling; Li, Zhengjun; Su, Zhiguo; Yang, Yanli; Ma, Guanghui; Zhang, Songping] Chinese Acad Sci, Inst Proc Engn, State Key Lab Biochem Engn, Beijing 100190, Peoples R China.
   [Li, Zhengjun] Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
RP Yu, R (reprint author), Sichuan Univ, West China Sch Pharm, Key Lab Drug Targeting & Drug Delivery Syst, Minist Educ, Chengdu 610041, Sichuan, Peoples R China.; Zhang, SP (reprint author), Chinese Acad Sci, Inst Proc Engn, State Key Lab Biochem Engn, Beijing 100190, Peoples R China.
EM yurong@scu.edu.cn; spzhang@ipe.ac.cn
OI Zhang, Songping/0000-0001-5793-5286
FU National Key R & D Program of China [2016YFD0500800, 2016YFD0500809];
   National Natural Sciences Foundation of ChinaNational Natural Science
   Foundation of China [21821005, 81773623, 21808226]
FX Financial supports from the National Key R & D Program of China (No
   2016YFD0500800, 2016YFD0500809), National Natural Sciences Foundation of
   China (Nos. 21821005, 81773623, 21808226) are acknowledged.
CR ADAIR BM, 1989, AVIAN PATHOL, V18, P175, DOI 10.1080/03079458908418589
   Avci FY, 2011, NAT MED, V17, P1602, DOI 10.1038/nm.2535
   BEUVERY EC, 1983, INFECT IMMUN, V41, P609, DOI 10.1128/IAI.41.2.609-617.1983
   Buonaguro FM, 2009, EXPERT REV VACCINES, V8, P1379, DOI 10.1586/ERV.09.81
   Cuervo MLC, 2007, VACCINE, V25, P194, DOI 10.1016/j.vaccine.2005.05.041
   Christensen H, 2010, LANCET INFECT DIS, V10, P853, DOI 10.1016/S1473-3099(10)70251-6
   Chu XJ, 2016, INT J NANOMED, V11, P2417, DOI 10.2147/IJN.S102467
   CLARKE BE, 1987, NATURE, V330, P381, DOI 10.1038/330381a0
   Crum-Cianflone N, 2016, INFECT DIS THER, V5, P89, DOI 10.1007/s40121-016-0107-0
   Dagan R, 1998, INFECT IMMUN, V66, P2093, DOI 10.1128/IAI.66.5.2093-2098.1998
   Dagan R, 2010, VACCINE, V28, P5513, DOI 10.1016/j.vaccine.2010.06.026
   Donadei A, 2016, EUR J PHARM BIOPHARM, V107, P110, DOI 10.1016/j.ejpb.2016.07.004
   DONNELLY JJ, 1990, J IMMUNOL, V145, P3071
   GIANNINI G, 1984, NUCLEIC ACIDS RES, V12, P4063, DOI 10.1093/nar/12.10.4063
   Harrison LH, 2009, VACCINE, V27, pB51, DOI 10.1016/j.vaccine.2009.04.063
   Huang QR, 2013, J CONTROL RELEASE, V172, P382, DOI 10.1016/j.jconrel.2013.03.008
   Jumel K, 2002, BIOTECHNOL APPL BIOC, V36, P219, DOI 10.1042/BA20020066
   Lei QP, 2000, J PHARMACEUT BIOMED, V21, P1087, DOI 10.1016/S0731-7085(99)00183-1
   Lu Y, 2015, P NATL ACAD SCI USA, V112, P12360, DOI 10.1073/pnas.1510533112
   MACDONALD RA, 1988, J IMMUNOL METHODS, V106, P191, DOI 10.1016/0022-1759(88)90196-2
   Mohsen MO, 2017, SEMIN IMMUNOL, V34, P123, DOI 10.1016/j.smim.2017.08.014
   NEUMULLER C, 1954, NATURE, V174, P405, DOI 10.1038/174405a0
   Pobre K, 2014, VACCINE, V32, P1423, DOI 10.1016/j.vaccine.2014.01.047
   Prymula R, 2009, EXPERT REV VACCINES, V8, P1479, DOI 10.1586/ERV.09.113
   Pumpens P, 2016, MOL BIOL+, V50, P489, DOI 10.1134/S0026893316040099
   Pumpens P, 2001, INTERVIROLOGY, V44, P98, DOI 10.1159/000050037
   Roose K, 2013, EXPERT REV VACCINES, V12, P183, DOI [10.1586/erv.12.150, 10.1586/ERV.12.150]
   Schwarz K, 2005, EUR J IMMUNOL, V35, P816, DOI 10.1002/eji.200425755
   Silveira IAFB, 2007, VACCINE, V25, P7261, DOI 10.1016/j.vaccine.2007.07.037
   Stephens DS, 2007, LANCET, V369, P2196, DOI 10.1016/S0140-6736(07)61016-2
   SVENNERHOLM L, 1957, BIOCHIM BIOPHYS ACTA, V24, P604, DOI 10.1016/0006-3002(57)90254-8
   Tsybalova LM, 2015, VACCINE, V33, P3398, DOI 10.1016/j.vaccine.2015.04.073
   Vanlandschoot P, 2005, J GEN VIROL, V86, P75, DOI 10.1099/vir.0.80580-0
   Xu MF, 2015, VACCINE, V33, P5815, DOI 10.1016/j.vaccine.2015.09.021
   Yang YL, 2015, VACCINE, V33, P1143, DOI 10.1016/j.vaccine.2015.01.031
   Zhang TT, 2015, VACCINE, V33, P3208, DOI 10.1016/j.vaccine.2015.04.094
   Zhang YL, 2007, SCAND J IMMUNOL, V65, P320, DOI 10.1111/j.1365-3083.2007.01900.x
NR 37
TC 1
Z9 1
U1 7
U2 21
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 8
PY 2019
VL 37
IS 7
BP 956
EP 964
DI 10.1016/j.vaccine.2018.12.073
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HK9WA
UT WOS:000458342400009
PM 30655174
DA 2020-05-12
ER

PT J
AU Sharma, N
   Hanif, S
   Rana, R
   Upadhyay, D
   Chhikara, MK
AF Sharma, Nitya
   Hanif, Sarmad
   Rana, Rakesh
   Upadhyay, Dilip
   Chhikara, Manoj Kumar
TI Evaluation of impact of temperature and pH alterations on the size and
   antigenicity of meningococcal serogroup A and X polysaccharides and
   conjugates
SO VACCINE
LA English
DT Article
DE Neisseria meningitidis serogroup A and X; Inhibition ELISA;
   Antigenicity; Size
ID THERMAL-STABILITY; IMMUNOGENICITY; ASSAY
AB The changes in the recommended storage conditions of the glycoconjugate vaccines against Neisseria meningitidis (Men) serogroup A and serogroup X can affect its activity or potency. Elevated temperature and the change in pH may result in the physical instability leading to the size degradation of the polysaccharide (PS) and subsequent loss of PS epitopes. Moreover, high temperature may also result in protein aggregation and altered tertiary structure of the protein in the conjugate. Consequently, the construction of a potent glycoconjugate is dependent on optimal temperature and pH. The changes in both these conditions can also affect the production of a capsular polysaccharide (PS) and its conjugation to a protein carrier and may also affect the integrity of the vaccine molecule including the maintenance of the protective epitopes. In our study we have used inhibition ELISA as a tool to assess the impact of temperature and pH alterations on the antigenicity of N. meningitidis serogroup A and X, PS and conjugates and their correlation with the size distribution analysis using high pressure size exclusion chromatography. The studies on pH alterations from 5 to 9 led to minimal impact on size and antigenicity of all antigens, however, an elevated temperature adversely impacted the antigen size as well as antigenicity to varying extent. Results indicate the higher stability of MenX PS and conjugate as compared to that for MenA counterparts at elevated temperatures. Furthermore, both the MenA and MenX conjugates appears to be more stable as compared to the corresponding PSs. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Sharma, Nitya; Upadhyay, Dilip] Amity Univ, Amity Inst Virol & Immunol, Noida 201313, Uttar Pradesh, India.
   [Hanif, Sarmad; Rana, Rakesh; Chhikara, Manoj Kumar] Jamia Hamdard, MSD Wellcome Trust Hilleman Labs Pvt Ltd, 2nd Floor,Nanotechnol Bldg, New Delhi 110062, India.
RP Chhikara, MK (reprint author), Jamia Hamdard, MSD Wellcome Trust Hilleman Labs Pvt Ltd, 2nd Floor,Nanotechnol Bldg, New Delhi 110062, India.
EM manoj.kumar@hillemanlabs.org
RI Chhikara, Manoj Kumar/H-9985-2019
OI Chhikara, Manoj Kumar/0000-0002-7650-0306
FU SERB/CII Prime Minister's Fellowship
FX NS was awarded with SERB/CII Prime Minister's Fellowship for her PhD
   research work to be conducted at Hilleman Laboratories under supervision
   of MKC as her industry guide and DU as her University guide. All the
   resources required to conduct the project were provided by Hilleman
   Laboratories.
CR [Anonymous], 1976, World Health Organ Tech Rep Ser, P1
   Arakere G, 1999, J CLIN MICROBIOL, V37, P2564, DOI 10.1128/JCM.37.8.2564-2567.1999
   Bastos RC, 2018, GLYCOCONJUGATE J, V35, P3, DOI 10.1007/s10719-017-9787-2
   Beresford NJ, 2017, VACCINE, V35, P3598, DOI 10.1016/j.vaccine.2017.03.066
   Berti F, 2012, VACCINE, V30, P6409, DOI 10.1016/j.vaccine.2012.08.021
   Bolgiano B, 2001, VACCINE, V19, P3189, DOI 10.1016/S0264-410X(01)00024-X
   Frasch CE, 2009, VACCINE, V27, P6468, DOI 10.1016/j.vaccine.2009.06.013
   Gao F, 2014, HUM VACC IMMUNOTHER, V10, P2744, DOI 10.4161/hv.29696
   GOTSCHLICH EC, 1969, J EXP MED, V129, P1367, DOI 10.1084/jem.129.6.1367
   Ho MM, 2000, VACCINE, V19, P716, DOI 10.1016/S0264-410X(00)00261-9
   Ho MM, 2002, VACCINE, V20, P3509, DOI 10.1016/S0264-410X(02)00342-0
   McIntyre PB, 2012, LANCET, V380, P1703, DOI 10.1016/S0140-6736(12)61187-8
   Morefield GL, 2011, AAPS J, V13, P191, DOI 10.1208/s12248-011-9261-1
   Reyes F, 2014, J IMMUNOL METHODS, V407, P58, DOI 10.1016/j.jim.2014.03.020
   World Health Organization, REC ASS QUAL SAF EFF
   Xie O, 2012, VACCINE, V30, P5812, DOI 10.1016/j.vaccine.2012.07.032
   Xing DKL, 1996, VACCINE, V14, P1205, DOI 10.1016/S0264-410X(96)00032-1
NR 17
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 8
PY 2019
VL 37
IS 7
BP 965
EP 972
DI 10.1016/j.vaccine.2018.12.051
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HK9WA
UT WOS:000458342400010
PM 30651197
DA 2020-05-12
ER

PT J
AU Kole, S
   Qadiri, SSN
   Shin, SM
   Kim, WS
   Lee, J
   Jung, SJ
AF Kole, Sajal
   Qadiri, Syed Shariq Nazir
   Shin, Su-Mi
   Kim, Wi-Sik
   Lee, Jehee
   Jung, Sung-Ju
TI PLGA encapsulated inactivated-viral vaccine: Formulation and evaluation
   of its protective efficacy against viral haemorrhagic septicaemia virus
   (VHSV) infection in olive flounder (Paralichthys olivaceus) vaccinated
   by mucosal delivery routes
SO VACCINE
LA English
DT Article
DE Nanoencapsulation; VHSV; Paralichthys olivaceus; PLGA; Mucosal immunity
ID SALMO-SALAR L.; RAINBOW-TROUT; IMMUNE-RESPONSES; ONCORHYNCHUS-MYKISS;
   ORAL IMMUNIZATION; DNA VACCINES; B-CELLS; NANOPARTICLES; ANTIGEN; SYSTEM
AB Viral haemorrhagic septicaemia virus (VHSV), an OIE listed viral pathogen, is the etiological agent of a contagious disease, causing huge economic losses in farmed olive flounder (Paralichthys olivaceus) and significant mortalities among several other marine fish species in Korea, Japan, and China. In continuation with our previous work, where injection vaccination with inactivated VHSV mixed with squalene (as adjuvant) conferred higher protective immunity to olive flounder, the present study focused on replacing the injection route of vaccine delivery by immersion/oral route to overcome the limitations of the par enteral immunization method. Here, we encapsulated the inactivated VHSV vaccine with PLGA (poly lactic-co-glycolic acid) nanoparticles (PNPs-IV) and evaluated its ability to induce protective immunity in olive flounder (12.5 +/- 1.5 g) by initially immunizing the fishes by immersion route followed by a booster with the same dose two weeks later with half of the fish through immersion route and other half through oral route (incorporated into fish feed). Cumulative mortalities post-challenge (1 x 10(6) TCID50 virus/fish) with virulent VHSV-isolate, were lower in vaccinated fish and RPS of 60% and 73.3% were obtained for PNPs-IV (immersion/immersion) and PNPs-IV (immersion/oral) groups, respectively. In addition, specific (anti-VHSV) antibody titre in the fish sera, skin mucus and intestinal mucus of the immunized groups were significantly (p < 0.05) enhanced following vaccination. Furthermore, PNPs-IV immunized fish showed significant (p < 0.05) upregulation of different immune gene transcripts (IgM, IgT, plgR, MHC-I, MHC-II, IFN-gamma, and Caspase3) compared to controls, in both the systemic (kidney) and mucosal (skin and intestine) immune compartment of the host post immunization as well as post challenge. Thus it can be inferred that the adopted immunization strategy efficiently protected and transported the inactivated viral antigen to target immune organs and positively stimulated the protective immune response against VHSV in olive flounder. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Kole, Sajal; Qadiri, Syed Shariq Nazir; Shin, Su-Mi; Kim, Wi-Sik; Jung, Sung-Ju] Chonnam Natl Univ, Dept Aqualife Med, 50 Daehak Ro, Yeosu 59626, South Korea.
   [Lee, Jehee] Jeju Natl Univ, Dept Marine Life Sci, Jeju City, South Korea.
RP Jung, SJ (reprint author), Chonnam Natl Univ, Dept Aqualife Med, 50 Daehak Ro, Yeosu 59626, South Korea.
EM sungju@chonnam.ac.kr
OI Umasuthan, Navaneethaiyer/0000-0001-8851-6121
FU Ministry of Oceans and Fisheries, Korea
FX This research was supported by 'Fish Vaccine Research Center', funded by
   the Ministry of Oceans and Fisheries, Korea.
CR Adomako M, 2012, J FISH DIS, V35, P203, DOI 10.1111/j.1365-2761.2011.01338.x
   Ahmadivand S, 2017, DEV COMP IMMUNOL, V74, P178, DOI 10.1016/j.dci.2017.05.004
   Akagi T, 2012, ADV POLYM SCI, V247, P31, DOI 10.1007/12_2011_150
   Amend D., 1981, DEV BIOL STAND, V49, P447
   Avunje S, 2011, FISH SHELLFISH IMMUN, V31, P407, DOI 10.1016/j.fsi.2011.06.009
   Ballesteros NA, 2015, FISH SHELLFISH IMMUN, V45, P877, DOI 10.1016/j.fsi.2015.05.045
   Ballesteros NA, 2014, FISH SHELLFISH IMMUN, V37, P220, DOI 10.1016/j.fsi.2014.02.003
   Ballesteros NA, 2012, FISH SHELLFISH IMMUN, V33, P174, DOI 10.1016/j.fsi.2012.03.016
   Behera T, 2010, FISH SHELLFISH IMMUN, V28, P320, DOI 10.1016/j.fsi.2009.11.009
   de las Heras AI, 2010, FISH SHELLFISH IMMUN, V28, P562, DOI 10.1016/j.fsi.2009.12.006
   Delgado A, 1999, VACCINE, V17, P2927, DOI 10.1016/S0264-410X(99)00140-1
   Doggett T.A., 1991, Fish & Shellfish Immunology, V1, P213, DOI 10.1016/S1050-4648(10)80006-3
   Duy J, 2010, J NANOPART RES, V12, P2363, DOI 10.1007/s11051-010-9996-0
   Fredriksen BN, 2011, VACCINE, V29, P8338, DOI 10.1016/j.vaccine.2011.08.087
   Harikrishnan R, 2012, EXP PARASITOL, V131, P325, DOI 10.1016/j.exppara.2012.04.017
   Heppell J, 2000, ADV DRUG DELIVER REV, V43, P29, DOI 10.1016/S0169-409X(00)00075-2
   Illum L, 2001, ADV DRUG DELIVER REV, V51, P81, DOI 10.1016/S0169-409X(01)00171-5
   Isshiki T, 2001, DIS AQUAT ORGAN, V47, P87, DOI 10.3354/dao047087
   Jain RA, 2000, BIOMATERIALS, V21, P2475, DOI 10.1016/S0142-9612(00)00115-0
   Kai YH, 2014, FISH SHELLFISH IMMUN, V40, P563, DOI 10.1016/j.fsi.2014.08.005
   Kanchan V, 2007, BIOMATERIALS, V28, P5344, DOI 10.1016/j.biomaterials.2007.08.015
   Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863
   Kim WS, 2009, AQUACULTURE, V296, P165, DOI 10.1016/j.aquaculture.2009.07.019
   Kole S, 2018, VACCINE, V36, P2155, DOI 10.1016/j.vaccine.2018.02.099
   Koping-Hoggard M, 2001, GENE THER, V8, P1108, DOI 10.1038/sj.gt.3301492
   Lapatra S. E., 1993, Journal of Aquatic Animal Health, V5, P165, DOI 10.1577/1548-8667(1993)005&lt;0165:COTHRO&gt;2.3.CO;2
   Lavelle EC, 1997, VACCINE, V15, P1070, DOI 10.1016/S0264-410X(97)00013-3
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lorenzen N, 2005, REV SCI TECH OIE, V24, P201, DOI 10.20506/rst.24.1.1565
   Magnadottir B, 2010, MAR BIOTECHNOL, V12, P361, DOI 10.1007/s10126-010-9279-x
   Miller TA, 1998, DIS AQUAT ORGAN, V34, P13, DOI 10.3354/dao034013
   Munang'andu HM, 2012, VACCINE, V30, P4007, DOI 10.1016/j.vaccine.2012.04.039
   Munang'andu HM, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00427
   Parra D, 2016, DEV COMP IMMUNOL, V64, P150, DOI 10.1016/j.dci.2016.03.013
   Pierce LR, 2012, MOL PHYLOGENET EVOL, V63, P327, DOI 10.1016/j.ympev.2011.12.024
   Rauta PR, 2015, FISH SHELLFISH IMMUN, V44, P287, DOI 10.1016/j.fsi.2015.02.007
   Salinas Irene, 2015, Biology-Basel, V4, P525, DOI 10.3390/biology4030525
   Salinas I, 2011, DEV COMP IMMUNOL, V35, P1346, DOI 10.1016/j.dci.2011.11.009
   Taylor RC, 2008, NAT REV MOL CELL BIO, V9, P231, DOI 10.1038/nrm2312
   Tian JY, 2008, INT IMMUNOPHARMACOL, V8, P900, DOI 10.1016/j.intimp.2008.02.006
   Vandervoort J, 2002, INT J PHARM, V238, P77, DOI 10.1016/S0378-5173(02)00058-3
   Vinay TN, 2013, VACCINE, V31, P4603, DOI 10.1016/j.vaccine.2013.07.036
   Win KY, 2005, BIOMATERIALS, V26, P2713, DOI 10.1016/j.biomaterials.2004.07.050
   Yun S, 2017, VACCINE, V35, P3959, DOI 10.1016/j.vaccine.2017.06.005
   Zou J, 2005, J IMMUNOL, V175, P2484, DOI 10.4049/jimmunol.175.4.2484
NR 45
TC 7
Z9 7
U1 3
U2 14
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 8
PY 2019
VL 37
IS 7
BP 973
EP 983
DI 10.1016/j.vaccine.2018.12.063
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HK9WA
UT WOS:000458342400011
PM 30661835
DA 2020-05-12
ER

PT J
AU Bianco, A
   Mascaro, V
   Zucco, R
   Pavia, M
AF Bianco, Aida
   Mascaro, Valentina
   Zucco, Rossella
   Pavia, Maria
TI Parent perspectives on childhood vaccination: How to deal with vaccine
   hesitancy and refusal?
SO VACCINE
LA English
DT Article
DE Vaccine hesitancy; Vaccine refusal; Childhood vaccinations; Public
   health
ID ATTITUDES; ADOLESCENTS; BELIEFS; ONLINE
AB Background: The aims of the study are to evaluate attitudes about childhood vaccines and vaccine refusal or delay among parents and to assess the role played by the variables mapped as potential determinants to suggest strategies that could improve childhood vaccination rates.
   Methods: The cross-sectional study was intended for parents of kindergarteners. Parental attitudes were measured using the Parent Attitudes about Childhood Vaccines (PACV) survey, to screen for Vaccine Hesitancy (VH). In addition, selected factors have been grouped in three categories (contextual, individual and group and vaccine/vaccination-specific influences), and were explored as potential determinant of VH and vaccination refusal or delay.
   Results: 7.7% of subjects were defined as VH parents (VHPs) through PACV score, while 24.6% reported having refused or delayed at least one dose of vaccine for their child. VH was more common in those parents that decided not to vaccinate their child after having received information from mass-media, in those who did not agree with mandatory vaccinations, and in those who agreed with political leaders who oppose to vaccination. Vaccine refusing/delaying parents were more frequently those who agreed that infant vaccinations are primarily an economic business of pharmaceutical companies, and who disagreed that access to the kindergarten should only be allowed to children who had been vaccinated.
   Conclusion: The findings of the present study emphasize the importance of PACV as a tool to screen VHPs. Furthermore, results highlight important potential determinants of VH, such as communication and media environment, and attitudes about prevention. Health care providers could act as key components to improve the public trust to scientific and epidemiological evidence. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Bianco, Aida; Mascaro, Valentina; Zucco, Rossella; Pavia, Maria] Univ Catanzaro Magna Graecia, Dept Hlth Sci, Via Tommaso Campanella 115, I-88100 Catanzaro, Italy.
RP Pavia, M (reprint author), Univ Catanzaro Magna Graecia, Dept Hlth Sci, Via Tommaso Campanella 115, I-88100 Catanzaro, Italy.
EM pavia@unicz.it
CR Ajzen I, 2004, PERS SOC PSYCHOL B, V30, P1108, DOI 10.1177/0146167204264079
   Andre FE, VACCINATION GREATLY
   Benin AL, 2006, PEDIATRICS, V117, P1532, DOI 10.1542/peds.2005-1728
   Bianco A, 2014, HUM VACC IMMUNOTHER, V10, P2536, DOI 10.4161/21645515.2014.969614
   Bianco A, 2013, J MED INTERNET RES, V15, P268, DOI 10.2196/jmir.2752
   Bloom BR, 2014, SCIENCE, V344, P339, DOI 10.1126/science.1254834
   Chow MYK, 2017, AUST FAM PHYSICIAN, V46, P145
   Cooper LZ, 2008, PEDIATRICS, V122, P149, DOI 10.1542/peds.2008-0987
   Dube E, 2016, PLOS CURR, DOI [10.1371/currents.outbreaks.9e239605f4d320c6ad27ce2aea5aaad2, DOI 10.1371/CURRENRS.OUTBREAKS...9_E239605F4D320C6AD27CE2AEA5AAAD2]
   ECDC, VACC HES
   Esposito S, 2014, CLIN MICROBIOL INFEC, V20, P25, DOI 10.1111/1469-0691.12447
   Gilkey MB, 2013, PREV MED, V56, P202, DOI 10.1016/j.ypmed.2012.12.019
   Greenberg Joshua, 2017, PLoS Curr, V9, DOI 10.1371/currents.outbreaks.0561a011117a1d1f9596e24949e8690b
   Kata A, 2012, VACCINE, V30, P3778, DOI 10.1016/j.vaccine.2011.11.112
   Larson HJ, 2015, VACCINE, V33, P4165, DOI 10.1016/j.vaccine.2015.04.037
   Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081
   Larson HJ, 2011, LANCET, V378, P526, DOI 10.1016/S0140-6736(11)60678-8
   MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036
   Marti M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172310
   Mesch GS, 2015, AM J INFECT CONTROL, V43, P1161, DOI 10.1016/j.ajic.2015.06.031
   Ministero della Salute, VACC DAT 2016 CAL CO
   Ministero della Salute, COP VACC ET PED
   Napolitano F, 2018, HUM VACC IMMUNOTHER, V14, P1558, DOI 10.1080/21645515.2018.1463943
   Opel DJ, 2013, JAMA PEDIATR, V167, P1065, DOI 10.1001/jamapediatrics.2013.2483
   Opel DJ, 2011, VACCINE, V29, P6598, DOI 10.1016/j.vaccine.2011.06.115
   Paterson P, 2016, VACCINE, V34, P6700, DOI 10.1016/j.vaccine.2016.10.042
   Poland GA, 2010, VACCINE, V28, P2361, DOI 10.1016/j.vaccine.2010.02.052
   Smith PJ, 2011, PUBLIC HEALTH REP, V126, P135, DOI 10.1177/00333549111260S215
   Stata Corporation, 2009, STAT REF MAN REL 14
   Vannice KS, 2011, PEDIATRICS, V127, pS120, DOI 10.1542/peds.2010-1722R
   Verger P, 2016, EUROSURVEILLANCE, V21, P14, DOI 10.2807/1560-7917.ES.2016.21.47.30406
   World Health Organization, REP SAGE WORK GROUP
   World Health Organization (WHO), ADDR VACC HES
   Zucco R, 2018, INT J MED INFORM, V111, P131, DOI 10.1016/j.ijmedinf.2017.12.005
NR 34
TC 10
Z9 10
U1 2
U2 18
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 8
PY 2019
VL 37
IS 7
BP 984
EP 990
DI 10.1016/j.vaccine.2018.12.062
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HK9WA
UT WOS:000458342400012
PM 30655175
DA 2020-05-12
ER

PT J
AU Muzzi, A
   Brozzi, A
   Serino, L
   Bodini, M
   Abad, R
   Caugant, D
   Comanducci, M
   Lemos, AP
   Gorla, MC
   Krizova, P
   Mikula, C
   Mulhall, R
   Nissen, M
   Nohynek, H
   Simoes, MJ
   Skoczynska, A
   Stefanelli, P
   Taha, MK
   Toropainen, M
   Tzanakaki, G
   Vadivelu-Pechai, K
   Watson, P
   Vazquez, JA
   Rajam, G
   Rappuoli, R
   Borrow, R
   Medini, D
AF Muzzi, Alessandro
   Brozzi, Alessandro
   Serino, Laura
   Bodini, Margherita
   Abad, Raquel
   Caugant, Dominique
   Comanducci, Maurizio
   Lemos, Ana Paula
   Gorla, Maria Cecilia
   Krizova, Pavla
   Mikula, Claudia
   Mulhall, Robert
   Nissen, Michael
   Nohynek, Hanna
   Simoes, Maria Joao
   Skoczynska, Anna
   Stefanelli, Paola
   Taha, Muhamed-Kheir
   Toropainen, Maija
   Tzanakaki, Georgina
   Vadivelu-Pechai, Kumaran
   Watson, Philip
   Vazquez, Julio A.
   Rajam, Gowrisankar
   Rappuoli, Rino
   Borrow, Ray
   Medini, Duccio
TI Genetic Meningococcal Antigen Typing System (gMATS): A genotyping tool
   that predicts 4CMenB strain coverage worldwide
SO VACCINE
LA English
DT Article
DE Neisseria meningitidis serogroup B; 4CMenB vaccine; Strain coverage;
   gMATS; Genotyping
ID SEROGROUP-B VACCINE; MULTICOMPONENT VACCINE; DISEASE; MATS;
   STANDARDIZATION; ANTIBODY; ENGLAND; PROTEIN; NADA
AB Background: The Meningococcal Antigen Typing System (MATS) was developed to identify meningococcus group B strains with a high likelihood of being covered by the 4CMenB vaccine, but is limited by the requirement for viable isolates from culture-confirmed cases. We examined if antigen genotyping could complement MATS in predicting strain coverage by the 4CMenB vaccine.
   Methods: From a panel of 3912 MATS-typed invasive meningococcal disease isolates collected in England and Wales in 2007-2008, 2014-2015 and 2015-2016, and in 16 other countries in 2000-2015, 3481 isolates were also characterized by antigen genotyping. Individual associations between antigen genotypes and MATS coverage for each 4CMenB component were used to define a genetic MATS (gMATS). gMATS estimates were compared with England and Wales human complement serum bactericidal assay (hSBA) data and vaccine effectiveness (VE) data from England.
   Results: Overall, 81% of the strain panel had genetically predictable MATS coverage, with 92% accuracy and highly concordant results across national panels (Lin's accuracy coefficient, 0.98; root-mean square deviation, 6%). England and Wales strain coverage estimates were 72-73% by genotyping (66-73% by MATS), underestimating hSBA values after four vaccine doses (88%) and VE after two doses (83%). The gMATS predicted strain coverage in other countries was 58-88%.
   Conclusions: gMATS can replace MATS in predicting 4CMenB strain coverage in four out of five cases, without requiring a cultivable isolate, and is open to further improvement. Both methods underestimated VE in England. Strain coverage predictions in other countries matched or exceeded England and Wales estimates. (C) 2019 GlaxoSmithKline Biologicals SA. Published by Elsevier Ltd.
C1 [Muzzi, Alessandro; Brozzi, Alessandro; Serino, Laura; Bodini, Margherita; Comanducci, Maurizio; Rappuoli, Rino; Medini, Duccio] GSK, Via Fiorentina 1, Siena, Italy.
   [Abad, Raquel; Vazquez, Julio A.] Inst Hlth Carlos Ill, Natl Ctr Microbiol, Madrid, Spain.
   [Caugant, Dominique] Norwegian Inst Publ Hlth, Oslo, Norway.
   [Lemos, Ana Paula; Gorla, Maria Cecilia] Adolfo Lutz Inst, Sao Paulo, Brazil.
   [Krizova, Pavla] Natl Inst Publ Hlth, Prague, Czech Republic.
   [Mikula, Claudia] Austrian Agcy Hlth & Food Safety, Inst Med Microbiol & Hyg, Graz, Austria.
   [Mulhall, Robert] IMSRL, Dublin, Ireland.
   [Nissen, Michael] Univ Queensland, Lady Cilento Childrens Hosp, Childrens Hlth Res Ctr, Queensland Paediat Infect Dis Lab, South Brisbane, Qld, Australia.
   [Nohynek, Hanna; Toropainen, Maija] Natl Inst Hlth & Welf THL, Helsinki, Finland.
   [Simoes, Maria Joao] Natl Inst Hlth Dr Ricardo Jorge, Lisbon, Portugal.
   [Skoczynska, Anna] Natl Med Inst, Warsaw, Poland.
   [Stefanelli, Paola] Ist Super Sanita, Dept Infect Parasit & Immune Mediated Dis, Rome, Italy.
   [Taha, Muhamed-Kheir] Inst Pasteur, Paris, France.
   [Tzanakaki, Georgina] Natl Sch Publ Hlth, Natl Meningitis Reference Lab, Athens, Greece.
   [Vadivelu-Pechai, Kumaran; Watson, Philip] GSK, Rockville, MD USA.
   [Rajam, Gowrisankar] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Borrow, Ray] Manchester Royal Infirm, Publ Hlth England, Meningococcal Reference Unit, Manchester, Lancs, England.
   [Comanducci, Maurizio] Via L da Vinci 4, I-44042 Cento, FE, Italy.
   [Nissen, Michael] GSK Intercontinental, Res & Dev, 23 Rochester Pk, Singapore, Singapore.
   [Rajam, Gowrisankar] Merck & Co Inc, Lansdale, PA USA.
RP Medini, D (reprint author), GSK, Via Fiorentina 1, Siena, Italy.
EM alessandro.x.muzzi@gsk.com; alessandro.x.brozzi@gsk.com;
   laura.x.serino@gsk.com; margherita.x.bodini@gsk.com; rabad@isciii.es;
   Dominique.Caugant@fhi.no; ana.lemos@ial.sp.gov.br;
   maria.gorla@ial.sp.gov.br; pavla.krizova@szu.cz; claudia.mikula@ages.at;
   Robert.Mulhall@cuh.ie; michael.d.nissen@gsk.com; hanna.nohynek@thl.fi;
   njoao.Simoes@insa.min-saude.pt; skoczek@cis.edu.pl;
   paola.stefanelli@iss.it; muhamed-kheir.taha@pasteur.fr;
   maija.toropainen@thl.fi; gtzanakaki@esdy.edu.gr;
   kumaran.k.vadivelu-pechai@gsk.com; philip.s.watson@gsk.com;
   jvazquez@isciii.es; rino.r.rappuoli@gsk.com; Ray.Borrow@phe.gov.uk;
   duccio.x.medini@gsk.com
RI , dcaugant/AAH-6843-2019; Abad, Raquel/L-7595-2015; Medini,
   Duccio/Q-9556-2016
OI Abad, Raquel/0000-0002-8339-0950; Medini, Duccio/0000-0001-6041-2603;
   Muzzi, Alessandro/0000-0002-8635-6424; Skoczynska,
   Anna/0000-0002-2247-830X
FU GlaxoSmithKline Biologicals SAGlaxoSmithKline
FX This work was supported by GlaxoSmithKline Biologicals SA, including all
   costs associated with the development and publishing of the manuscript.
CR Abad R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150721
   Azzari C, 2016, EMERG INFECT DIS, V22, P469, DOI 10.3201/eid2203.150928
   Bai XL, 2010, EXPERT REV VACCINES, V9, P1203, DOI 10.1586/ERV.10.116
   Banzhoff Angelika, 2017, Ther Adv Vaccines, V5, P3, DOI 10.1177/2051013616681365
   Bettinger JA, 2013, VACCINE, V32, P124, DOI 10.1016/j.vaccine.2013.03.063
   Biagini M, 2016, P NATL ACAD SCI USA, V113, P2714, DOI 10.1073/pnas.1521142113
   Borrow R, 2006, VACCINE, V24, P5093, DOI 10.1016/j.vaccine.2006.03.091
   Brehony C, 2016, VACCINE, V34, P4690, DOI 10.1016/j.vaccine.2016.08.015
   Budroni S, 2016, VACCINE, V34, P2579, DOI 10.1016/j.vaccine.2016.04.009
   Cayrou C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197186
   Clark SA, 2018, INT J MED MICROBIOL, V308, P256, DOI 10.1016/j.ijmm.2017.11.004
   Clark SA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089921
   Donnelly J, 2010, P NATL ACAD SCI USA, V107, P19490, DOI 10.1073/pnas.1013758107
   Fagnocchi L, 2013, INFECT IMMUN, V81, P560, DOI 10.1128/IAI.01085-12
   Findlow J, 2017, PATHOG DIS, V75, DOI 10.1093/femspd/ftx025
   Findlow J, 2016, HUM VACC IMMUNOTHER, V12, P235, DOI 10.1080/21645515.2015.1091131
   Frosi G, 2013, VACCINE, V31, P4968, DOI 10.1016/j.vaccine.2013.08.006
   Giuliani M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22057-7
   Jolley KA, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-595
   Ladhani SN, 2016, ARCH DIS CHILD, V101, P91, DOI 10.1136/archdischild-2015-308928
   Lucidarme J, 2010, CLIN VACCINE IMMUNOL, V17, P919, DOI 10.1128/CVI.00027-10
   Medini D, 2015, VACCINE, V33, P2629, DOI 10.1016/j.vaccine.2015.04.015
   Mowlaboccus S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158315
   Parikh SR, 2017, LANCET INFECT DIS, V17, P754, DOI 10.1016/S1473-3099(17)30170-6
   Parikh SR, 2016, LANCET, V388, P2775, DOI 10.1016/S0140-6736(16)31921-3
   Partridge E, 2017, VACCINE, V35, P4236, DOI 10.1016/j.vaccine.2017.06.020
   Plikaytis BD, 2012, CLIN VACCINE IMMUNOL, V19, P1609, DOI 10.1128/CVI.00202-12
   R Core Team, 2013, R LANG ENV STAT COMP
   Rajam G, 2017, MSPHERE, V2, DOI [10.1128/mSphere.00261-17, 10.1128/msphere.00261-17]
   Rodrigues C, 2017, 14 C EMGM PRAG CZECH, P17
   Serruto D, 2012, VACCINE, V30, pB87, DOI 10.1016/j.vaccine.2012.01.033
   Simoes MJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176177
   Snape MD, 2012, VACCINE, V30, pB67, DOI 10.1016/j.vaccine.2011.12.126
   Stephens DS, 2007, LANCET, V369, P2196, DOI 10.1016/S0140-6736(07)61016-2
   Toropainen M, 2016, 20 INT PATH NEISS C, P279
   Tzanakaki G, 2014, BMC MICROBIOL, V14, DOI 10.1186/1471-2180-14-111
   Vogel U, 2013, LANCET INFECT DIS, V13, P416, DOI 10.1016/S1473-3099(13)70006-9
   Vogel U, 2012, VACCINE, V30, pB73, DOI 10.1016/j.vaccine.2011.12.061
   Wasko I, 2016, VACCINE, V34, P510, DOI 10.1016/j.vaccine.2015.11.070
   Yu Y, 2012, AGREEMENT STAT TOOLS
NR 40
TC 10
Z9 10
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 8
PY 2019
VL 37
IS 7
BP 991
EP 1000
DI 10.1016/j.vaccine.2018.12.061
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HK9WA
UT WOS:000458342400013
PM 30661831
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU McClenahan, SD
   Krause, PR
AF McClenahan, Shasta D.
   Krause, Philip R.
TI Towards dynamic monitoring of cell cultures using high throughput
   sequencing
SO VACCINE
LA English
DT Article
DE Adventitious agent; Virus; Degenerate PCR; High throughput sequencing
   (HTS)
ID VIRUS DETECTION
AB We used a combination of DOP-PCR with high throughput sequencing (HTS) to study infected cell cultures over time to assess the feasibility of using this technique to provide a read-out other than cytopathic effect in cell culture infectivity assays. Because DOP-PCR primers feature a short constant sequence at their 3' terminus, the procedure yields a reproducible representational library of products from a given PCR template, including viral nucleic acids. Using SV40- and MVM-infected cultures harvested at different times, we show that the number of viral matches among DOP-PCR products parallels the quantity of virus as shown by real-time PCR, and further show that HTS analysis of specific DOP-PCR products that increase in quantity over time could be used to identify the infecting virus with a sensitivity similar to that of typical cell-culture assays that rely on cytopathic effect. Published by Elsevier Ltd.
C1 [McClenahan, Shasta D.; Krause, Philip R.] US FDA, Ctr Biol Evaluat & Res, Silver Spring, MD USA.
   [McClenahan, Shasta D.] NOAA, Natl Marine Fisheries Serv, 1315 East West Highway,SSMC3 Room 13319, Silver Spring, MD USA.
RP Krause, PR (reprint author), WO71 RM 3234,HFM-457,10903 New Hampshire Ave, Silver Spring, MD 20993 USA.
EM Philip.krause@fda.hhs.gov
OI Krause, Philip/0000-0002-1045-7536
FU FDA/CBER intramural research program
FX The authors would like to thank Drs. Haru Murata and Keith Peden (FDA)
   for providing SV40 virus for these experiments, and Drs. Steven Rubin
   and Keith Peden for critical reading of the manuscript. This research
   was supported by the FDA/CBER intramural research program.
CR Garnick RL, 1996, DEV BIOL STAND, V88, P49
   McClenahan SD, 2014, VACCINE, V32, P7115, DOI 10.1016/j.vaccine.2014.10.022
   McClenahan SD, 2014, BIOLOGICALS, V42, P34, DOI 10.1016/j.biologicals.2013.11.002
   McClenahan SD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068777
   McClenahan SD, 2011, VACCINE, V29, P4745, DOI 10.1016/j.vaccine.2011.04.087
   Nanda S, 2008, J VIROL METHODS, V152, P18, DOI 10.1016/j.jviromet.2008.06.007
   Onions D, 2011, VACCINE, V29, P7117, DOI 10.1016/j.vaccine.2011.05.071
   SWEET BH, 1960, P SOC EXP BIOL MED, V105, P420, DOI 10.3181/00379727-105-26128
   Uhlenhaut C, 2012, TRANSPL INFECT DIS, V14, P79, DOI 10.1111/j.1399-3062.2011.00657.x
   Uhlenhaut C, 2009, J CLIN VIROL, V44, P337, DOI 10.1016/j.jcv.2009.01.011
   US Food and Drug Administration, GUID IND CHAR QUAL C
   Victoria JG, 2010, J VIROL, V84, P6033, DOI 10.1128/JVI.02690-09
NR 12
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 8
PY 2019
VL 37
IS 7
BP 1001
EP 1005
DI 10.1016/j.vaccine.2018.12.019
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HK9WA
UT WOS:000458342400014
PM 30642729
DA 2020-05-12
ER

PT J
AU Lyons, NA
   Knight-Jones, TJD
   Bartels, C
   Paton, DJ
   Ferrari, G
   Vermillion, MS
   Brooks, AW
   Motroni, R
   Parker, E
   Berquist, MLH
   Sumption, KJ
   Klement, E
AF Lyons, Nicholas A.
   Knight-Jones, Theodore J. D.
   Bartels, Chris
   Paton, David J.
   Ferrari, Giancarlo
   Vermillion, Meghan S.
   Brooks, Abdullah W.
   Motroni, Roxann
   Parker, Elizabeth
   Berquist, Melissa L. Hefferin
   Sumption, Keith J.
   Klement, Eyal
TI Considerations for design and implementation of vaccine field trials for
   novel foot-and-mouth disease vaccines
SO VACCINE
LA English
DT Article
DE Vaccine evaluation; Vaccine efficacy; Livestock; Foot-and-mouth disease
ID A24 SUBUNIT VACCINE; VIRUS SEROTYPE; TRANSMISSION; EFFICACY; ANTIBODY;
   CATTLE
AB Vaccines are commonly used to control Foot-and-Mouth Disease (FMD) in endemic regions and form an important part of contingency plans for FMD-free countries. Conventional FMD vaccines have numerous limitations, and the U.S. government supports the development of next-generation vaccines. In the U.S., vaccine efficacy is typically demonstrated through experimental vaccination and challenge of animals using the World Organization for Animal Health (OIE) standards. Although conventional challenge and immunogenicity studies provide useful information, they have limitations and results do not always accurately predict field performance. Consequently, there is a need to test next-generation vaccines under field conditions to gain a better understanding of field performance to inform policy decisions and support their viability as a commercial product.
   In June 2017, an expert consultation was organised to discuss and define an optimal field study design for novel FMD vaccines. Cattle were the primary species considered, although parallel strategies for swine and small ruminants were also discussed. Many methodological and logistical considerations in the study design were identified, including: (1) study site selection and the importance of baseline studies to understand exposure risk, (2) ethics of using a placebo and assessing equivalence with conventional vaccines, (3) merits of using individual randomised versus cluster randomised trials, (4) preventive versus reactive vaccination, and (5) methods of randomisation and blinding.
   The proposed optimal study design was a multicentre (i.e. farm), three-arm, double-blind randomised controlled trial comparing groups receiving the novel vaccine to a conventional vaccine group and a placebo group. Large farms in areas of high exposure risk were identified as ideal study sites, and the primary study outcome was susceptibility to disease or infection, during a six-month observation period, following a single dose of vaccine. This report provides a summary of the important issues to consider when designing a field efficacy study in livestock and proposes a study design that could be utilised for novel FMD vaccines.
C1 [Lyons, Nicholas A.; Bartels, Chris; Ferrari, Giancarlo; Sumption, Keith J.] Food & Agr United Nations, European Commiss Control Foot & Mouth Dis EuFMD, Rome, Italy.
   [Lyons, Nicholas A.; Paton, David J.] Pirbright Inst, Ash Rd, Woking GU24 0NF, Surrey, England.
   [Knight-Jones, Theodore J. D.] Howard Davis Fm, Dept Environm, Trinity, Jersey, England.
   [Ferrari, Giancarlo] Ist Zooprofilatt Sperimentale Lazio & Toscana M A, Via Appia Nuova 1411, I-00178 Rome, Italy.
   [Vermillion, Meghan S.] Johns Hopkins Bloomberg Sch Publ Hlth, W Harry Feinstone Dept Mol Microbiol & Immunol, 615 N Wolfe St, Baltimore, MD 21205 USA.
   [Brooks, Abdullah W.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, 615 N Wolfe St, Baltimore, MD 21205 USA.
   [Motroni, Roxann] US Dept Homeland Secur, Sci & Technol Directorate, HSARPA, Chem & Biol Def Div, Washington, DC USA.
   [Parker, Elizabeth; Berquist, Melissa L. Hefferin] Texas A&M Univ Syst, IIAD, College Stn, TX USA.
   [Klement, Eyal] Hebrew Univ Jerusalem, Robert H Smith Fac Agr Food & Environm Sci, Koret Sch Vet Med, POB 12, IL-76100 Rehovot, Israel.
RP Lyons, NA (reprint author), Food & Agr United Nations, European Commiss Control Foot & Mouth Dis EuFMD, Rome, Italy.
EM nicholas.lyons@fao.org
OI Lyons, Nick/0000-0002-5847-8707
FU U.S. Department of Homeland SecurityUnited States Department of Homeland
   Security (DHS) [HSHQDC-14-J-00335]
FX This material is based upon work supported by the U.S. Department of
   Homeland Security task order HSHQDC-14-J-00335. The views and
   conclusions contained in this document are those of the authors and
   should not be interpreted as necessarily representing the official
   policies, either expressed or implied, of the U.S. Department of
   Homeland Security.
CR Aanensen DM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006968
   [Anonymous], 2014, DIS RESP PLAN
   Barrera J, 2018, TRANSBOUND EMERG DIS, V65, P447, DOI 10.1111/tbed.12724
   Barrera J, 2018, VACCINE, V36, P1078, DOI 10.1016/j.vaccine.2018.01.026
   Carpenter TE, 2001, AM J VET RES, V62, P1582, DOI 10.2460/ajvr.2001.62.1582
   DAWE PS, 1994, VET REC, V134, P230, DOI 10.1136/vr.134.10.230
   Donken R, 2015, VACCINE, V33, P1426, DOI 10.1016/j.vaccine.2015.01.072
   GHENDON Y, 1994, B WORLD HEALTH ORGAN, V72, P973
   Halloran ME, 1997, AM J EPIDEMIOL, V146, P789
   HEDGER RS, 1970, J HYG-CAMB, V68, P53, DOI 10.1017/S0022172400028497
   Jones E, 1996, BMJ-BRIT MED J, V313, P36, DOI 10.1136/bmj.313.7048.36
   KITCHING RP, 1995, BRIT VET J, V151, P379, DOI 10.1016/S0007-1935(95)80127-8
   Knight-Jones TJD, 2013, PREV VET MED, V112, P161, DOI 10.1016/j.prevetmed.2013.07.013
   Moraes MP, 2002, VACCINE, V20, P1631, DOI 10.1016/S0264-410X(01)00483-2
   Parida S, 2009, EXPERT REV VACCINES, V8, P347, DOI 10.1586/14760584.8.3.347
   Paton DJ, 2006, VACCINE, V24, P6503, DOI 10.1016/j.vaccine.2006.06.032
   Paton DJ, 2018, CURR OPIN VIROL, V28, P85, DOI 10.1016/j.coviro.2017.11.013
   Paton DJ, 2009, PHILOS T R SOC B, V364, P2657, DOI 10.1098/rstb.2009.0100
   Paton DJ, 2005, REV SCI TECH OIE, V24, P981, DOI 10.20506/rst.24.3.1632
   Schutta C, 2016, VACCINE, V34, P3214, DOI 10.1016/j.vaccine.2015.12.018
   Spath EJ, 2007, VACCINE, V25, P3373, DOI [10.1016/j.vaccine.2006.12.049, DOI 10.1016/J.VACCINE.2006.12.049]
   Sumption K., 2012, PROGR CONTROL PATHWA
   Suresh Kp, 2011, J Hum Reprod Sci, V4, P8, DOI 10.4103/0974-1208.82352
   Vickers Andrew J, 2006, J Soc Integr Oncol, V4, P194, DOI 10.2310/7200.2006.023
NR 24
TC 1
Z9 1
U1 2
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 14
PY 2019
VL 37
IS 8
BP 1007
EP 1015
DI 10.1016/j.vaccine.2018.12.064
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HL4QW
UT WOS:000458709200001
PM 30685245
DA 2020-05-12
ER

PT J
AU Robertson, CA
   Hedrick, J
   Bassily, E
   Greenberg, DP
AF Robertson, Corwin A.
   Hedrick, James
   Bassily, Ehab
   Greenberg, David P.
TI Persistence of bactericidal antibodies 4 years after a booster dose of
   quadrivalent meningococcal diphtheria toxoid conjugate vaccine
   (MenACWY-D)
SO VACCINE
LA English
DT Article
ID IMMUNOGENICITY; DISEASE; SAFETY
AB One dose of quadrivalent meningococcal conjugate vaccine (MenACWY) was first recommended for US adolescents (ages 11-12 years) in 2005 to protect against invasive meningococcal disease (IMD). In 2010, after evidence emerged about waning protection within 5 years after MenACWY vaccination, the US Advisory Committee on Immunization Practices (ACIP) recommended a MenACWY booster at age 16 years. We used a serum bactericidal assay with human complement (hSBA) to evaluate antibody persistence after a MenACWY-D booster in a sample of 110 participants who received the booster 4 years earlier in a phase 2 study. High proportions (89.9-98.2%) of participants maintained hSBA titers (>= 1:4) associated with protection against IMD; a majority (81.7-97.2%) also had hSBA titers >= 1:8, a more conservative threshold. These findings support ACIP recommendations regarding MenACWY booster vaccination, which are aimed at protecting adolescents and young adults throughout the period in which they are at increased risk of IMD. (C) 2019 Sanofi Pasteur Inc. Published by Elsevier Ltd.
C1 [Robertson, Corwin A.; Bassily, Ehab; Greenberg, David P.] Sanofi Pasteur Inc, Discovery Dr, Swiftwater, PA 18370 USA.
   [Hedrick, James] Kentucky Pediat Adult Res, 201 South 5th St, Bardstown, KY 40004 USA.
   [Greenberg, David P.] Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15261 USA.
RP Robertson, CA (reprint author), Sanofi Pasteur Inc, Discovery Dr, Swiftwater, PA 18370 USA.
EM corey.robertson@sanofi.com; jhedrick@bard-stowncable.net;
   ehab.bassily@sanofi.com; greenbed@pitt.edu
FU Sanofi Pasteur Inc., Swiftwater, Pennsylvania, USA
FX This study was funded by Sanofi Pasteur Inc., Swiftwater, Pennsylvania,
   USA, which also funded the development and publication of this
   manuscript. All authors had full access to the data and participated in
   the drafting and finalization of the manuscript. The corresponding
   author had final responsibility for submission of the manuscript.
CR Anonymous, 2011, Morbidity and Mortality Weekly Report, V60, P72
   Baxter R, 2014, PEDIATR INFECT DIS J, V33, P1169, DOI 10.1097/INF.0000000000000438
   Bilukha Oleg O., 2005, Morbidity and Mortality Weekly Report, V54, P1
   Borrow R, 2005, VACCINE, V23, P2222, DOI 10.1016/j.vaccine.2005.01.051
   Centers for Disease Control and Prevention, 2015, MEN DIS EP PREV VACC, P231
   Cohn AC, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-2193
   Davis KL, 2011, HUM VACCINES, V7, P96, DOI 10.4161/hv.7.1.13692
   Granoff DM, 2005, VACCINE, V23, P4307, DOI 10.1016/j.vaccine.2005.03.031
   Granoff DM, 2004, PEDIATR INFECT DIS J, V23, P490, DOI 10.1097/01.inf.0000129686.12470.e6
   Harrison Lee H, 2011, Vaccine, V29, P3363, DOI 10.1016/j.vaccine.2011.02.058
   Hou VC, 2011, 11 EMGM C 2011 LJUBL, P169
   Keyserling H, 2005, ARCH PEDIAT ADOL MED, V159, P907, DOI 10.1001/archpedi.159.10.907
   MacNeil JR, 2017, CLIN INFECT DIS
   Martinon-Torres F, 2016, J ADOLESCENT HEALTH, V59, pS12, DOI 10.1016/j.jadohealth.2016.03.041
   Pace D, 2012, VACCINE, V30, pB3, DOI 10.1016/j.vaccine.2011.12.062
   Pina LM, 2012, PEDIATR INFECT DIS J, V31, P1173, DOI 10.1097/INF.0b013e318268dfe4
   Robertson CA, 2016, VACCINE, V34, P5273, DOI 10.1016/j.vaccine.2016.09.003
   US Food and Drug Administration, 2011, SUMM BAS REG ACT
   Vu DM, 2006, J INFECT DIS, V193, P821, DOI 10.1086/500512
   World Health Organization (WHO), 2018, MEN MEN FACT SHEET
NR 20
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 14
PY 2019
VL 37
IS 8
BP 1016
EP 1020
DI 10.1016/j.vaccine.2019.01.008
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HL4QW
UT WOS:000458709200002
PM 30670301
OA Other Gold
DA 2020-05-12
ER

PT J
AU Vadlamudi, NK
   Parhar, K
   Malana, KLA
   Kang, A
   Marra, F
AF Vadlamudi, Nirma Khatri
   Parhar, Kamalpreet
   Malana, Kim Lorenzo Altre
   Kang, Amy
   Marra, Fawziah
TI Immunogenicity and safety of the 13-valent pneumococcal conjugate
   vaccine compared to 23-valent pneumococcal polysaccharide in
   immunocompetent adults: A systematic review and meta-analysis
SO VACCINE
LA English
DT Review
DE Streptococcus pneumoniae; Pneumococcal conjugate vaccines; PCV13;
   Adults; Meta-analysis; Systematic review; Immunogenicity; Pneumococcal
   disease; OPA
ID INFANTS; IMMUNOSENESCENCE
AB Background: Despite the use of 23-valent pneumococcal polysaccharide vaccine (PPV23) in adults there is substantial morbidity and mortality in the elderly due to pneumococcal infections. Since 2010, the 13-valent pneumococcal conjugate vaccine (PCV13) is in use for infant immunization programs to reduce rates of pneumococcal disease, but is not routinely used in adults. Recent literature suggests PCV13 may be used in adult vaccination programs as well.
   Objective: To determine the immunogenicity and safety of PCV13 compared with the PPV23 in adults.
   Design: Systematic review and meta-analysis.
   Setting: Randomized controlled trials evaluating immunogenicity of a single dose of PCV13 and PPV23 in adults by the opsonophagocytic assay (OPA) geometric mean titer (GMT) response at 1-month post-vaccination were considered for inclusion.
   Results: Five randomized trials were included with 4561 subjects ranging 50-95.5 years, consisting of 51% females. The pooled OPA GMT ratio (GMTR) in the PCV13 arm was significantly higher for 10 of 13 serotypes (1, 4, 5, 6A, 6B, 9V, 18C, 19A, 19F and 23F) compared with the PPV23 arm. Overall, pooled risk ratios (RR) for local and systemic reactions did not differ between PCV13 and PPV23. Pneumococcal naive subjects experienced significantly higher local reactions in the PCV13 arm compared with the PPV23 arm (RR: 1.15, 95%Cl: 1.05-1.26, p = 0.0025).
   Conclusion: A single dose of PCV13 elicits a better immune response among adults compared with PPV23, while having a similar safety profile to PPV23. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Vadlamudi, Nirma Khatri; Parhar, Kamalpreet; Marra, Fawziah] Univ British Columbia, Fac Pharmaceut Sci, 2405 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.
   [Malana, Kim Lorenzo Altre] Univ British Columbia, Fac Med, Vancouver, BC, Canada.
   [Kang, Amy] Univ British Columbia, Fac Sci, Vancouver, BC, Canada.
RP Marra, F (reprint author), Univ British Columbia, Fac Pharmaceut Sci, 2405 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.
EM fawziah@mail.ubc.ca
FU PfizerPfizer
FX This research did not receive any specific grant from funding agencies
   in the public, commercial or not-for-profit sectors. NKV, KP, LM and AK
   did not have any financial support for this study; FM has received a
   grant from Pfizer within the last 5 years.
CR Altman DG, 2003, BMJ-BRIT MED J, V326, P219, DOI 10.1136/bmj.326.7382.219
   [Anonymous], 2017, PNEUM VACC WHAT YOU
   Chen WH, 2009, TRENDS IMMUNOL, V30, P351, DOI 10.1016/j.it.2009.05.002
   de Roux A, 2008, CLIN INFECT DIS, V46, P1015, DOI 10.1086/529142
   Duan K, 2017, INDIAN J PEDIATR, V84, P101, DOI 10.1007/s12098-016-2248-2
   Ewald H, 2016, DTSCH ARZTEBL INT, V113, P139, DOI 10.3238/arztebl.2016.0139
   Goldblatt D, 2009, CLIN INFECT DIS, V49, P1318, DOI 10.1086/606046
   Greenberg RN, 2014, VACCINE, V32, P2364, DOI 10.1016/j.vaccine.2014.02.002
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
   Jackson L, 2008, VACCINES
   Jackson LA, 2013, VACCINE, V31, P3577, DOI 10.1016/j.vaccine.2013.04.085
   Jackson LA, 2013, VACCINE, V31, P3585, DOI 10.1016/j.vaccine.2013.05.010
   Juergens C, 2014, HUM VACC IMMUNOTHER, V10, P1343, DOI 10.4161/hv.27998
   Kobayashi M, 2015, MMWR-MORBID MORTAL W, V64, P944, DOI 10.15585/mmwr.mm6434a4
   Moher D, 2010, INT J SURG, V8, P336, DOI 10.1016/j.ijsu.2010.02.007
   National Advisory Committee on Immunization (NACI), 2016, UPD US 13 VAL PNEUM
   New Zealand Ministry of Health, 2017, IMM HDB 2017, V2017, P405
   O'Brien KL, 2009, CLIN INFECT DIS, V49, P1326, DOI 10.1086/606047
   Ochoa-Gondar O, 2014, CLIN INFECT DIS, V58, P909, DOI 10.1093/cid/ciu002
   Papadatou I, 2014, CLIN INFECT DIS, V59, P862, DOI 10.1093/cid/ciu409
   Poland GA, 2014, CURR OPIN IMMUNOL, V29, P62, DOI 10.1016/j.coi.2014.04.005
   Robinson KA, 2001, JAMA-J AM MED ASSOC, V285, P1729, DOI 10.1001/jama.285.13.1729
   Ruiz-Aragon J, 2013, VACCINE, V31, P5349, DOI 10.1016/j.vaccine.2013.09.008
   Shiramoto M, 2015, HUM VACC IMMUNOTHER, V11, P2198, DOI 10.1080/21645515.2015.1030550
   Shiri T, 2017, LANCET GLOB HEALTH, V5, pE51, DOI 10.1016/S2214-109X(16)30306-0
   Sings HL, 2017, VACCINE, V35, P5406, DOI 10.1016/j.vaccine.2017.05.075
   Sterne JAC, 2001, J CLIN EPIDEMIOL, V54, P1046, DOI 10.1016/S0895-4356(01)00377-8
   Targonski PV, 2007, VACCINE, V25, P3066, DOI 10.1016/j.vaccine.2007.01.025
   Thompson A, 2013, VACCINE, V31, P5289, DOI 10.1016/j.vaccine.2013.08.025
   van der Linden M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131494
   World Health Organization, 2017, INT TRAV HLTH PNEUM
NR 31
TC 4
Z9 4
U1 3
U2 10
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 14
PY 2019
VL 37
IS 8
BP 1021
EP 1029
DI 10.1016/j.vaccine.2019.01.014
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HL4QW
UT WOS:000458709200003
PM 30685252
DA 2020-05-12
ER

PT J
AU Randi, BA
   Sejas, ONE
   Miyaji, KT
   Infante, V
   Lara, AN
   Ibrahim, KY
   Lopes, MH
   Sartori, AMC
AF Randi, Bruno A.
   Encinas Sejas, Odeli Nicole
   Miyaji, Karina T.
   Infante, Vanessa
   Lara, Amanda N.
   Ibrahim, Karim Y.
   Lopes, Marta H.
   Sartori, Ana Marli C.
TI A systematic review of adult tetanus-diphtheria-acellular (Tdap)
   coverage among healthcare workers
SO VACCINE
LA English
DT Review
DE Diphtheria-tetanus-pertussis vaccine; Bordetella pertussis; Health
   personnel; Immunization; Vaccination; Whooping cough
ID PERTUSSIS VACCINATION COVERAGE; UNITED-STATES; NOSOCOMIAL PERTUSSIS;
   IMMUNIZATION; OUTBREAK; SURVEILLANCE; POPULATIONS; HOSPITALS; INFLUENZA;
   PROVIDERS
AB During the last decades pertussis incidence raised globally. Several vaccination strategies targeting adults to reduce pertussis among young infants have been proposed, including vaccination of healthcare workers (HCWs). The aim of this study was to analyse, by performing a systematic review of literature, published papers that evaluated Tdap coverage among HCWs, variables associated with vaccine uptake and efforts implemented to raise vaccination rates. We searched the MedLine, Embase, SCOPUS, LILACS, Web of Science and Cochrane for full-text studies that evaluated Tdap coverage in HCW. Two independent reviewers screened the articles and extracted the data. Twenty-eight studies published from 2009 to 2018 were reviewed. Most studies were conducted in the USA. Initial Tdap coverage varied from 6.1% to 63.9%. USA and France are the only two countries with studies evaluating Tdap coverage within HCWs using national data. In the USA, Tdap coverage in HCWs raised from 6.1% to 45.1% from 2007 to 2015. In the analysis of French national data, a Tdap coverage of 63.9% was observed. Five studies used interventions to raise Tdap coverage in HCWs. Two intervention studies implemented mandatory vaccination and three used educational strategies. All of them achieved coverages over 86%. Only eleven studies analysed the association of Tdap vaccination with variables of interest. Previous immunization with other vaccines recommended for HCWs (like influenza, hepatitis B and MMR) was positively associated with Tdap uptake in four studies. In conclusion, overall Tdap coverage among HCWs is low, but seems to increase over the years after the vaccine introduction and with implementation of interventions to increase coverage. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Randi, Bruno A.; Encinas Sejas, Odeli Nicole; Miyaji, Karina T.; Infante, Vanessa; Lara, Amanda N.; Ibrahim, Karim Y.; Lopes, Marta H.; Sartori, Ana Marli C.] Hosp Clin Sao Paulo, Div Clin Molestias Infecciosas & Parasitarias, Ctr Referencia Imunobiol Especiais, Sao Paulo, Brazil.
   [Randi, Bruno A.; Miyaji, Karina T.; Infante, Vanessa; Lopes, Marta H.; Sartori, Ana Marli C.] Univ Sao Paulo, Fac Med, Dept Molestias Infecciosas & Parasitarias, Sao Paulo, Brazil.
RP Randi, BA (reprint author), Dr Ovidio Pires Campos St,225 Cerqueira Cesar, BR-05403010 Sao Paulo, SP, Brazil.
EM bruno_randi@usp.br
RI Lopes, Marta H/J-3285-2012; Sartori, Ana Marli Christovam/I-6663-2012;
   Lara, Amanda/AAA-9607-2019; Miyaji, Karina T/B-1319-2016
OI Sartori, Ana Marli Christovam/0000-0003-3777-0757; Miyaji, Karina
   T/0000-0003-2653-3975; Lara, Amanda/0000-0002-4294-0282
CR Baggett HC, 2007, INFECT CONT HOSP EP, V28, P537, DOI 10.1086/513497
   Baron-Epel O, 2013, HUM VACC IMMUNOTHER, V9, P100, DOI 10.4161/hv.22503
   Bohmer MM, 2013, DEUT MED WOCHENSCHR, V138, P1451, DOI 10.1055/s-0033-1343249
   Boulay BR, 2006, INFECT CONT HOSP EP, V27, P92, DOI 10.1086/500420
   Calderon TA, 2015, J PEDIAT INF DIS SOC, V4, P252, DOI 10.1093/jpids/piu056
   Calugar A, 2006, CLIN INFECT DIS, V42, P981, DOI 10.1086/500321
   Carande-Kulis VG, 2000, AM J PREV MED, V18, P75, DOI 10.1016/S0749-3797(99)00120-8
   Centers for Disease Control and Prevention (CDC), 2005, MMWR Morb Mortal Wkly Rep, V54, P67
   DEVILLE JG, 1995, CLIN INFECT DIS, V21, P639, DOI 10.1093/clinids/21.3.639
   Domenech de Celles M, 2016, P BIOL SCI, P283, DOI 10.1098/rspb.2015.309
   Duclos A, 2008, J EVAL CLIN PRACT, V14, P610, DOI 10.1111/j.1365-2753.2008.00946.x
   Eden J, 2011, FIND WHAT WORKS HLTH, P317
   Esolen LM, 2013, AM J INFECT CONTROL, V41, P740, DOI 10.1016/j.ajic.2012.10.012
   Forsyth K, 2015, PEDIATRICS, V135, pE1475, DOI 10.1542/peds.2014-3925
   Gabutti G, 2015, HUM VACC IMMUNOTHER, V11, P108, DOI 10.4161/hv.34364
   Haviari S, 2015, HUM VACC IMMUNOTHER, V11, P2522, DOI 10.1080/21645515.2015.1082014
   Hees L, 2009, ARCH PEDIATRIE, V16, P14, DOI 10.1016/j.arcped.2008.10.017
   Higgins JP, 2011, COCHRANE COLLABORATI, DOI DOI 10.1002/9780470712184
   Jiang CH, 2018, VACCINE, V36, P214, DOI 10.1016/j.vaccine.2017.11.071
   Kassianos George, 2015, Drugs Context, V4, P212268, DOI 10.7573/dic.212268
   La Torre G, 2017, HEALTHCARE-BASEL, V5, DOI 10.3390/healthcare5010013
   Leibu R, 2015, J OCCUP ENVIRON MED, V57, P58, DOI 10.1097/JOM.0000000000000294
   Loulergue P, 2009, VACCINE, V27, P4240, DOI 10.1016/j.vaccine.2009.03.039
   Loulergue P, 2013, VACCINE, V31, P2835, DOI 10.1016/j.vaccine.2013.04.004
   Lu PJ, 2014, VACCINE, V32, P572, DOI 10.1016/j.vaccine.2013.11.077
   MacDougall D, 2015, HUM VACC IMMUNOTHER, V11, P2167, DOI 10.1080/21645515.2015.1046662
   MacDougall DM, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-009062
   Maltezou HC, 2014, VACCINE, V32, P4876, DOI 10.1016/j.vaccine.2013.10.046
   Miller B. L., 2010, Morbidity and Mortality Weekly Report, V59, P1302
   Miller BL, 2011, VACCINE, V29, P3850, DOI 10.1016/j.vaccine.2011.03.058
   Nowalk MP, 2016, VACCINE, V34, P5026, DOI 10.1016/j.vaccine.2016.07.053
   O'Halloran AC, 2018, AM J PREV MED, V54, P119, DOI 10.1016/j.amepre.2017.09.017
   Paranthaman K, 2016, PUBLIC HEALTH, V137, P196, DOI 10.1016/j.puhe.2016.02.033
   Pascual FB, 2006, INFECT CONT HOSP EP, V27, P546, DOI 10.1086/506232
   Pulcini C, 2013, VACCINE, V31, P3943, DOI 10.1016/j.vaccine.2013.06.039
   Sandora TJ, 2008, CLIN MICROBIOL REV, V21, P426, DOI 10.1128/CMR.00003-08
   Seale H, 2009, VACCINE, V27, P3022, DOI 10.1016/j.vaccine.2009.03.038
   Srivastav A, 2017, AM J PREV MED, V53, P537, DOI 10.1016/j.amepre.2017.04.002
   Taddei C, 2014, HUM VACC IMMUNOTHER, V10, P2612, DOI 10.4161/21645515.2014.970879
   Tariq L, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-0800-8
   Teresa Aguado M, 2018, REP WHO M IMM OLD AD
   Tuckerman JL, 2015, HUM VACC IMMUNOTHER, V11, P704, DOI 10.1080/21645515.2015.1008886
   Vic P, 2011, ARCH PEDIATRIE, V18, P1339, DOI 10.1016/j.arcped.2011.09.029
   Walther K, 2015, VACCINE, V33, P2009, DOI 10.1016/j.vaccine.2015.03.013
   Williams WW, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6611a1
   Williams WW, 2016, MMWR SURVEILL SUMM, V65, P1, DOI 10.15585/mmwr.ss6501a1
   Williams WW, 2015, MMWR-MORBID MORTAL W, V64, P95
   Williams WW, 2014, MMWR-MORBID MORTAL W, V63, P95
   Williams WW, 2013, MMWR-MORBID MORTAL W, V62, P66
   Williams Walter W., 2012, Morbidity and Mortality Weekly Report, V61, P66
   Wright SW, 1999, INFECT CONT HOSP EP, V20, P120, DOI 10.1086/501593
NR 51
TC 1
Z9 1
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 14
PY 2019
VL 37
IS 8
BP 1030
EP 1037
DI 10.1016/j.vaccine.2018.12.046
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HL4QW
UT WOS:000458709200004
PM 30630694
DA 2020-05-12
ER

PT J
AU Coelho, CH
   Gazzinelli-Guimaraes, PH
   Howard, J
   Barnafo, E
   Alani, NAH
   Muratova, O
   McCormack, A
   Kelnhofer, E
   Urban, JF
   Narum, DL
   Anderson, C
   Langhorne, J
   Nutman, TB
   Duffy, PE
AF Coelho, Camila H.
   Gazzinelli-Guimaraes, Pedro Henrique
   Howard, Jennifer
   Barnafo, Emma
   Alani, Nada A. H.
   Muratova, Olga
   McCormack, Ashley
   Kelnhofer, Emily
   Urban, Joseph F., Jr.
   Narum, David L.
   Anderson, Charles
   Langhorne, Jean
   Nutman, Thomas B.
   Duffy, Patrick E.
TI Chronic helminth infection does not impair immune response to malaria
   transmission blocking vaccine Pfs230D1-EPA/Alhydrogel (R) in mice
SO VACCINE
LA English
DT Article
DE Malaria transmission blocking vaccine; H. polygyrus bakeri; Pfs230; P.
   falciparum; Helminth intestinal infection; Immunoregulation
ID HELIGMOSOMOIDES-POLYGYRUS; T-CELLS; B-CELLS; SUPPRESSION; MODEL
AB Introduction: Malaria transmission blocking vaccines (TBV) are innovative approaches that aim to induce immunity in humans against Plasmodium during mosquito stage, neutralizing the capacity of the infected vectors to transmit malaria. Pfs23001-EPA/Alhydrogel (R), a promising protein-protein conjugate malaria TBV, is currently being tested in human clinical trials in areas where P. falciparum malaria is coendemic with helminth parasites. Helminths are complex metazoans that share the master capacity to downregulate the host immune response towards themselves and also to bystander antigens, including vaccines. However, it is not known whether the activity of a protein-based malaria TBV may be affected by a chronic helminth infection.
   Methods: Using an experimental murine model for a chronic helminth infection (Heligmosomoides polygyrus bakeri - Hpb), we evaluated whether prior infection alters the activity of Pfs23001-EPA/Alhydrogel (R) TBV in mice.
   Results: After establishment of a chronic infection, characterized by a marked increase of parasite antigen-specific IgGI, IgA and IgE antibody responses, concomitant with an increase of systemic IL-10, IL-5 and IL-6 levels, the Hpb-infected mice were immunized with Pfs23001-EFA/Alhydrogel (R) and the vaccine-specific immune response was compared with that in non-infected immunized mice. TBV immunizations induced an elevated vaccine specific-antibody response, however Pfs23001 specific-IgG levels were similar between infected and uninfected mice at days 15, 25 and 35 post-vaccination. Absolute numbers of Pfs23001-activated B cells generated in response to the vaccine were also similar among the vaccinated groups. Finally, vaccine activity assessed by reduction of oocyst number in P. falciparum infected mosquitoes was similar between Hpb-infected and immunized mice with non-infected immunized mice.
   Conclusion: Pfs23001-EFA/Alhydrogel (R) efficacy is not impaired by a chronic helminth infection in mice. Published by Elsevier Ltd.
C1 [Coelho, Camila H.; Howard, Jennifer; Barnafo, Emma; Alani, Nada A. H.; Muratova, Olga; McCormack, Ashley; Kelnhofer, Emily; Narum, David L.; Anderson, Charles; Duffy, Patrick E.] NIAID, Lab Malaria Immunol & Vaccinol, NIH, 5640 Fishers Lane,Room 1111, Rockville, MD 20852 USA.
   [Gazzinelli-Guimaraes, Pedro Henrique; Nutman, Thomas B.] NIAID, Lab Parasit Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
   [Urban, Joseph F., Jr.] ARS, USDA, Beltsville Human Nutr Res Ctr, Diet Genom & Immunol Lab, Beltsville, MD USA.
   [Langhorne, Jean] Francis Crick Inst, London, England.
RP Duffy, PE (reprint author), NIAID, Lab Malaria Immunol & Vaccinol, NIH, 5640 Fishers Lane,Room 1111, Rockville, MD 20852 USA.
EM Patrick.duffy@nih.gov
RI Gazzinelli-Guimaraes, Pedro Henrique/E-7693-2013
OI Gazzinelli-Guimaraes, Pedro Henrique/0000-0003-4932-2206; Coelho,
   Camila/0000-0002-7885-9996; Narum, David/0000-0003-3041-5402
FU National Institute of Allergy and Infectious Diseases, National
   Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID); Francis Crick Institute - UK
   Medical Research Council; Cancer Research UKCancer Research UK; Wellcome
   TrustWellcome Trust [FC10101]
FX This work was supported by the Intramural Research Program of the
   National Institute of Allergy and Infectious Diseases, National
   Institutes of Health.; Jean Langhorne is supported by the Francis Crick
   Institute which receives its core funding from the UK Medical Research
   Council, Cancer Research UK, and the Wellcome Trust (FC10101).
CR Apiwattanakul N, 2014, VACCINE, V32, P5405, DOI 10.1016/j.vaccine.2014.07.107
   Babu S, 2016, TRENDS IMMUNOL, V37, P597, DOI 10.1016/j.it.2016.07.005
   Ben-Smith A, 2003, J HELMINTHOL, V77, P133, DOI 10.1079/JOH2003173
   Camberis Mali, 2003, Curr Protoc Immunol, VChapter 19, DOI 10.1002/0471142735.im1912s55
   Carter R, 2001, VACCINE, V19, P2309, DOI 10.1016/S0264-410X(00)00521-1
   Coelho CH, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0035-3
   Cooper PJ, 1998, J INFECT DIS, V178, P1133, DOI 10.1086/515661
   Finney CAM, 2007, EUR J IMMUNOL, V37, P1874, DOI 10.1002/eji.200636751
   Frantz FG, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000700
   Gazzinelli-Guimaraes PH, 2018, F1000RES, V7
   Hamilton JA, 2015, J IMMUNOL, V194, P5022, DOI 10.4049/jimmunol.1402335
   Harnett W, 2008, PARASITE IMMUNOL, V30, P447, DOI 10.1111/j.1365-3024.2008.01045.x
   Johnston CJC, 2015, JOVE-J VIS EXP, DOI 10.3791/52412
   MacDonald NJ, 2016, J BIOL CHEM, V291, P19913, DOI 10.1074/jbc.M116.732305
   Maizels RM, 2016, J ALLERGY CLIN IMMUN, V138, P666, DOI 10.1016/j.jaci.2016.07.007
   Maizels RM, 2012, EXP PARASITOL, V132, P76, DOI 10.1016/j.exppara.2011.08.011
   Metenou S, 2012, EUR J IMMUNOL, V42, P641, DOI 10.1002/eji.201141991
   Mitre E, 2008, J INFECT DIS, V197, P94, DOI 10.1086/524301
   Miura K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057909
   MONROY FG, 1992, PARASITOL TODAY, V8, P49, DOI 10.1016/0169-4758(92)90084-F
   Noland GS, 2010, VACCINE, V28, P2917, DOI 10.1016/j.vaccine.2010.02.055
   Nutman TB, 2015, PARASITE IMMUNOL, V37, P304, DOI 10.1111/pim.12194
   Reynolds LA, 2012, SEMIN IMMUNOPATHOL, V34, P829, DOI 10.1007/s00281-012-0347-3
   Sabin EA, 1996, J INFECT DIS, V173, P269, DOI 10.1093/infdis/173.1.269
   Setiawan T, 2007, INFECT IMMUN, V75, P4655, DOI 10.1128/IAI.00358-07
   Steenhard NR, 2009, VACCINE, V27, P5161, DOI 10.1016/j.vaccine.2009.05.075
   Su Z, 2006, INFECT IMMUN, V74, P2138, DOI 10.1128/IAI.74.4.2138-2144.2006
   Taylor JJ, 2012, J EXP MED, V209, P2065, DOI 10.1084/jem.20112272
   Urban JF, 2007, VET PARASITOL, V148, P14, DOI 10.1016/j.vetpar.2007.05.006
   Wajja A, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005440
   Wilson MS, 2005, J EXP MED, V202, P1199, DOI 10.1084/jem.20042572
   Wu YM, 2015, ADV PARASIT, V89, P109, DOI 10.1016/bs.apar.2015.04.001
   Yazdanbakhsh M, 2005, CURR OPIN ALLERGY CL, V5, P386, DOI 10.1097/01.all.0000182541.52971.eb
NR 33
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 14
PY 2019
VL 37
IS 8
BP 1038
EP 1045
DI 10.1016/j.vaccine.2019.01.027
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HL4QW
UT WOS:000458709200005
PM 30685251
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Lu, JH
   Luo, MY
   Yee, AZH
   Sheldenkar, A
   Lau, J
   Lwin, MO
AF Lu, Jiahui
   Luo, Meiyin
   Yee, Andrew Zi Han
   Sheldenkar, Anita
   Lau, Jerrald
   Lwin, May Oo
TI Do superstitious beliefs affect influenza vaccine uptake through shaping
   health beliefs?
SO VACCINE
LA English
DT Article
DE Influenza; Vaccine uptake; Superstition; Health belief model
ID RISK PERCEPTION; ANTI-VACCINATION; BEHAVIOR; DECISION; ADULTS; TRAIT;
   MODEL
AB Background: This study examined the impact of superstitious beliefs on influenza vaccine uptake and investigated the role of health beliefs as underlying psychological mechanisms. It is hypothesized that superstitious beliefs predict greater perceived risks in influenza and vaccines, which in turn affect influenza vaccine uptake.
   Methods: A cross-sectional survey of Singaporeans and Singapore Permanent Residents aged between 21 and 70 (N = 668) was conducted using computer-assisted telephone interviews. The survey covered beliefs in superstition, health beliefs in influenza and vaccines, and influenza vaccine uptake intention and behavior using the Health Belief Model. Path analysis was adopted to examine the hypothesized model.
   Results: Approximately 60% of the sample had never obtained influenza vaccination. The path analysis found that superstitious beliefs significantly predicted higher perceived barriers and lower perceived benefits of vaccines, which in turn predicted a lower intention to take influenza vaccine in the next year and/or a lower probability of ever taking influenza vaccine. In contrast, superstitious beliefs predicted higher perceived susceptibility and severity of influenza that in turn predicted higher influenza vaccine uptake intention and/or probability. Examining demographic variables and past experience on influenza as control and confounding factors did not significantly affect the results.
   Conclusion: The findings imply that beliefs in superstitions can have mixed effects on vaccine uptake and intention through shaping beliefs of the disease and vaccines. Significant implications in health education and persuasion on vaccine uptake are discussed. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Lu, Jiahui; Luo, Meiyin; Yee, Andrew Zi Han; Sheldenkar, Anita; Lwin, May Oo] Nanyang Technol Univ, Wee Kim Wee Sch Commun & Informat, 31 Nanyang Link, Singapore 637718, Singapore.
   [Lau, Jerrald] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore, Singapore.
RP Lu, JH (reprint author), Nanyang Technol Univ, Wee Kim Wee Sch Commun & Informat, 31 Nanyang Link, Singapore 637718, Singapore.
EM jhlu@ntu.edu.sg
OI Lu, Jiahui/0000-0003-2984-7435; Lau, Jerrald/0000-0002-3872-6371
FU Singapore Ministry of Health's Communicable Diseases Public Health
   Research Grant [MOH/CDPHRG/0017/2015]
FX This research is supported by the Singapore Ministry of Health's
   Communicable Diseases Public Health Research Grant MOH/CDPHRG/0017/2015.
   The funder had no involvement in study design, data collection,
   analysis, interpretation of data, writing of this manuscript or decision
   to submit for publication.
CR Ang LW, 2017, EPIDEMIOL INFECT, V145, P775, DOI 10.1017/S0950268816002491
   [Anonymous], 2016, STAND DEF FIN DISP C
   BECKER MH, 1974, HEALTH EDUC QUART, V2, P409, DOI 10.1177/109019817400200407
   Blue Carolyn L, 2002, AAOHN J, V50, P227
   Brewer NT, 2007, HEALTH PSYCHOL, V26, P136, DOI 10.1037/0278-6133.26.2.136
   Brewer NT, HLTH BEHAV HLTH ED T, P149
   Bryden GM, 2018, VACCINE, V36, P1227, DOI 10.1016/j.vaccine.2017.12.068
   Carlson BD, 2009, PSYCHOL MARKET, V26, P689, DOI 10.1002/mar.20295
   Champion V L, 1984, ANS Adv Nurs Sci, V6, P73
   Chapman GB, 1999, PREV MED, V29, P249, DOI 10.1006/pmed.1999.0535
   Coffman DL, 2005, MULTIVAR BEHAV RES, V40, P235, DOI 10.1207/s15327906mbr4002_4
   Department of Statistics  Singapore, 2016, POPULATION TRENDS
   Downs JS, 2008, VACCINE, V26, P1595, DOI 10.1016/j.vaccine.2008.01.011
   Hamerman EJ, 2013, J CONSUM RES, V40, P428, DOI 10.1086/670762
   Iwasa T, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-647
   Kata A, 2010, VACCINE, V28, P1709, DOI 10.1016/j.vaccine.2009.12.022
   Keinan G, 2002, PERS SOC PSYCHOL B, V28, P102, DOI 10.1177/0146167202281009
   Kouabenan DR, 1998, RISK ANAL, V18, P243, DOI 10.1111/j.1539-6924.1998.tb01291.x
   Kwong EWY, 2010, J ADV NURS, V66, P2297, DOI 10.1111/j.1365-2648.2010.05397.x
   Kwong Enid Wai-yung, 2008, Nurs Older People, V20, P29
   Mo PKH, 2015, HEALTH EDUC RES, V30, P706, DOI 10.1093/her/cyv038
   Mowen JC, 2003, PSYCHOL MARKET, V20, P1045, DOI 10.1002/mar.10108
   Peltzer K, 2003, ACCIDENT ANAL PREV, V35, P619, DOI 10.1016/S0001-4575(02)00035-0
   PETERSON C, 1978, J SOC PSYCHOL, V105, P305, DOI 10.1080/00224545.1978.9924131
   Reyna VF, 2012, VACCINE, V30, P3790, DOI 10.1016/j.vaccine.2011.11.070
   Risen JL, 2016, PSYCHOL REV, V123, P182, DOI 10.1037/rev0000017
   ROSENSTOCK IM, 1974, HEALTH EDUC QUART, V2, P354, DOI 10.1177/109019817400200405
   Rudski J, 2003, CURR PSYCHOL, V22, P306
   Schmid P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170550
   Shahrabani S, 2012, HEALTH EDUC BEHAV, V39, P612, DOI 10.1177/1090198111427411
   Shahrabani S, 2010, INT J ENV RES PUB HE, V7, P853, DOI 10.3390/ijerph7030853
   Shahrabani S, 2009, EUR J HEALTH ECON, V10, P227, DOI 10.1007/s10198-008-0124-3
   Strecher Victor J, 1997, CAMBRIDGE HDB PSYCHO, P113
   Tenkorang EY, 2011, CULT HEALTH SEX, V13, P1001, DOI 10.1080/13691058.2011.592218
   Tobacyk J. J., 2004, INT J TRANSPERSONAL, V23, P94, DOI DOI 10.24972/IJTS.2004.23.1.94
   Whitson JA, 2008, SCIENCE, V322, P115, DOI 10.1126/science.1159845
   Wiseman R, 2004, PERS INDIV DIFFER, V37, P1533, DOI 10.1016/j.paid.2004.02.009
   Witte K, 1996, J Health Commun, V1, P317, DOI 10.1080/108107396127988
   World Health Organization, 2018, INFLUENZA
   World Health Organization, 2016, BARR INFL VACC INT B
   Yang CH, 2008, SOC SCI MED, V66, P1990, DOI 10.1016/j.socscimed.2008.01.014
   Yeung MPS, 2016, J PUBLIC HEALTH-UK, V38, P746, DOI 10.1093/pubmed/fdv194
   Yuen CYS, 2014, VACCINE, V32, P4602, DOI 10.1016/j.vaccine.2014.06.067
NR 43
TC 0
Z9 0
U1 2
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 14
PY 2019
VL 37
IS 8
BP 1046
EP 1052
DI 10.1016/j.vaccine.2019.01.017
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HL4QW
UT WOS:000458709200006
PM 30683509
DA 2020-05-12
ER

PT J
AU Liu, C
   Luo, J
   Xue, RY
   Guo, L
   Nie, L
   Li, S
   Ji, L
   Ma, CJ
   Chen, DQ
   Miao, K
   Zou, QM
   Li, HB
AF Liu, Chang
   Luo, Jiao
   Xue, Ruo-Yi
   Guo, Ling
   Nie, Li
   Li, Sun
   Ji, Lu
   Ma, Cong-Jia
   Chen, Da-Qun
   Miao, Kuan
   Zou, Quan-Ming
   Li, Hai-Bo
TI The mucosal adjuvant effect of plant polysaccharides for induction of
   protective immunity against Helicobacter pylori infection
SO VACCINE
LA English
DT Article
DE Plant polysaccharides mucosal adjuvant effect; TLR2 activity;
   Helicobacter pylori
ID VACCINE ADJUVANTS; IMMUNIZATION; MICE; EFFICACY; TOXIN; CELLS
AB Some plant polysaccharides (PPSs) had been used as the adjuvants for systemic vaccination. In this study, we investigated whether PPSs could exhibit adjuvant effect at the mucosa. Groups of mice were intranasally immunized with Epimedium Polysaccharide (EPS), Trollius chinensis polysaccharide (TCPS), Siberian solomonseal rhizome polysaccharide (SSRPS) and Astragalus polysaccharides (APS) together with ovalbumin (OVA). Significantly higher levels of OVA-specific IgG in serum and secretory IgA in saliva, vaginal wash and intestinal lavage fluid were induced after immunization with OVA plus one of the four PPSs compared to OVA alone. Antigen absorption and TLR2 (Toll-like receptor 2) activation may be related to their mucosal adjuvant effect. Of note, when APS used as an adjuvant, intranasally vaccination with recombination UreB (rUreB, Urease subunit B) conferred more robust protection against Helicobacter pylori (H. pylori). Immunized with rUreB in combination APS resulted in mixed specific Th1 and Th17 immune response, which may contribute to the inhibition of H. pylori colonization. Though specific Th2-dominant responses were elicited when the other three PPS intranasally immunized with rUreB, no significant difference in the protective effect were found between those groups and rUreb alone group. Taken together, the four PPSs may be promising candidates for mucosal adjuvant, and APS could enhance rUreB-specific protective immunity against H. pylori infection. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Liu, Chang; Luo, Jiao; Xue, Ruo-Yi; Nie, Li; Li, Sun; Ji, Lu; Ma, Cong-Jia; Chen, Da-Qun; Miao, Kuan; Zou, Quan-Ming; Li, Hai-Bo] Third Mil Med Univ, Coll Pharm, Dept Microbiol & Biochem Pharm, Natl Engn Res Ctr Immunol Prod, Chongqing 400038, Peoples R China.
   [Guo, Ling] Chongqing Tech Ctr Drug Evaluat Certificat, Chongqing 400014, Peoples R China.
RP Zou, QM; Li, HB (reprint author), Third Mil Med Univ, Coll Pharm, Dept Microbiol & Biochem Pharm, Natl Engn Res Ctr Immunol Prod, Chongqing 400038, Peoples R China.
EM qmzou@tmmu.edu.cn; lihaibo@tmmu.edu.cn
FU Chinese National Natural Science Foundation ProjectNational Natural
   Science Foundation of China [31670936/81501722/31400788]
FX This work was supported by Chinese National Natural Science Foundation
   Project (No. 31670936/81501722/31400788).
CR Aoshi T, 2017, VIRAL IMMUNOL, V30, P463, DOI 10.1089/vim.2017.0026
   Awate S, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00114
   Banerjee S, 2002, GUT, V51, P634, DOI 10.1136/gut.51.5.634
   Chen ZS, 2009, J IMMUNOL, V182, P3503, DOI 10.4049/jimmunol.0802567
   Delyria ES, 2009, GASTROENTEROLOGY, V136, P247, DOI 10.1053/j.gastro.2008.09.017
   Ermak TH, 1998, J EXP MED, V188, P2277, DOI 10.1084/jem.188.12.2277
   Gellin BG, 2015, VACCINE, V33, pB44, DOI 10.1016/j.vaccine.2015.02.073
   Gong S, 2018, AIDS, V32, pF5, DOI [10.1097/qad.0000000000001857, 10.1097/QAD.0000000000001857]
   Gorrell RJ, 2013, INFECT IMMUN, V81, P3880, DOI 10.1128/IAI.01424-12
   HogenEsch H, 2002, VACCINE, V20, pS34, DOI 10.1016/S0264-410X(02)00169-X
   Hyun H, 2017, ACS BIOMATER SCI ENG, V3, P1853, DOI 10.1021/acsbiomaterials.7b00262
   Jimenez-Guardeno JM, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005215
   Kayamuro H, 2010, J VIROL, V84, P12703, DOI 10.1128/JVI.01182-10
   Lee SG, 2015, INT J BIOL MACROMOL, V79, P971, DOI 10.1016/j.ijbiomac.2015.06.023
   Lewis DJM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006999
   Li HB, 2012, VACCINE, V31, P120, DOI 10.1016/j.vaccine.2012.10.091
   Liang F, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal2094
   Lin KI, 2006, J BIOL CHEM, V281, P24111, DOI 10.1074/jbc.M601106200
   Longhi MP, 2009, J EXP MED, V206, P1589, DOI 10.1084/jem.20090247
   Maisonneuve C, 2014, P NATL ACAD SCI USA, V111, P12294, DOI 10.1073/pnas.1400478111
   Marciani DJ, 2018, TRENDS PHARMACOL SCI, V39, P573, DOI 10.1016/j.tips.2018.03.005
   MARINARO M, 1995, J IMMUNOL, V155, P4621
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Otczyk DC, 2010, HUM VACCINES, V6, P978, DOI 10.4161/hv.6.12.13142
   Paciello I, 2013, P NATL ACAD SCI USA, V110, pE4345, DOI 10.1073/pnas.1303641110
   Pi CC, 2014, VACCINE, V32, P401, DOI 10.1016/j.vaccine.2013.11.027
   Qiu Y, 2007, POULTRY SCI, V86, P2530, DOI 10.3382/ps.2007-00076
   Reed SG, 2013, NAT MED, V19, P1597, DOI 10.1038/nm.3409
   Robinson K, 2004, INFECT IMMUN, V72, P2753, DOI 10.1128/IAI.72.5.2753-2761.2004
   Roussel Y, 2005, J MICROBIOL METH, V62, P71, DOI 10.1016/j.mimet.2005.01.011
   Sayi A, 2009, J IMMUNOL, V182, P7085, DOI 10.4049/jimmunol.0803293
   Thompson AL, 2011, CLIN DEV IMMUNOL, DOI 10.1155/2011/289597
   Vajdy M, 2011, EXPERT OPIN BIOL TH, V11, P1501, DOI 10.1517/14712598.2011.623695
   Venkatesan P, 2011, BIOMATERIALS, V32, P3794, DOI 10.1016/j.biomaterials.2011.01.027
   Wagner A, 2011, J DRUG DELIV, DOI 10.1155/2011/591325
   Wang CL, 2012, BMC COMPLEM ALTERN M, P12
   Wang H, 2013, CURR MED CHEM, V20, P2899, DOI 10.2174/0929867311320230006
   Wienken CJ, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1093
   Xiang YX, 2017, REJUV RES, V20, P34, DOI 10.1089/rej.2016.1830
   Yang LS, 2008, VACCINE, V26, P4451, DOI 10.1016/j.vaccine.2008.06.075
   Yang WC, 2013, VACCINE, V31, P1204, DOI 10.1016/j.vaccine.2012.12.058
NR 41
TC 1
Z9 2
U1 6
U2 23
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 14
PY 2019
VL 37
IS 8
BP 1053
EP 1061
DI 10.1016/j.vaccine.2018.12.066
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HL4QW
UT WOS:000458709200007
PM 30665774
DA 2020-05-12
ER

PT J
AU Ledov, VA
   Golovina, ME
   Markina, AA
   Knirel, YA
   L'vov, VL
   Kovalchuk, AL
   Aparin, PG
AF Ledov, Vladimir A.
   Golovina, Marina E.
   Markina, Anna A.
   Knirel, Yuriy A.
   L'vov, Vyacheslav L.
   Kovalchuk, Alexander L.
   Aparin, Petr G.
TI Highly homogenous tri-acylated S-LPS acts as a novel clinically
   applicable vaccine against Shigella flexneri 2a infection
SO VACCINE
LA English
DT Article
DE Clinically applicable LPS; Vaccine; Antibody response; Homogenous pool;
   Mucosal immunity
ID CONJUGATE VACCINE; O-ANTIGEN; LIPOPOLYSACCHARIDE; RECOGNITION;
   RESPONSES; MICE; PROTECTION; ENDOTOXIN; ANTIBODY; MUTANTS
AB Shigellosis, a major cause of diarrhea worldwide, exhibits high morbidity and mortality in children. Specificity of Shigella immunity is determined by the structure of the main protective O-antigen polysaccharide component incorporated into the lipopolysaccharide (LPS) molecule. Endotoxicity, however, precludes LPS clinical use. Thus, there is still no vaccine against the most prevalent shigellosis species (serotype S. flexneri 2a), despite ongoing efforts focused on inducing serotype-specific immunity. As LPS is highly heterogenous, we hypothesized that more homogenous pools of LPS might be less toxic. We developed a method to generate a homogenous S. flexneri 2a LPS subfraction, Ac-3-S-LPS, containing long chain O-specific polysaccharide (S-LPS) and mainly tri-acylated lipid A, with no penta- and hexa-acylated, and rare tetra-acylated lipid A. Ac-3-S-LPS had dramatically reduced pyrogenicity and protected guinea pigs from shigellosis. In volunteers, 50 mu g of injected Ac-3-S-LPS vaccine was safe, with low pyrogenicity, no severe and few minor adverse events, and did not induce pro-inflammatory cytokines. In spite of the profound lipid A modification, the vaccine induced a prevalence of IgG and IgA antibodies. Thus, we have developed the first safe immunogenic LPS-based vaccine candidate for human administration. Homogenous underacetylated LPSs may also be useful for treating other LPS-driven human diseases. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Ledov, Vladimir A.; Golovina, Marina E.; Markina, Anna A.; Aparin, Petr G.] Fed Med Biol Agcy Russia, Inst Immunol, Natl Res Ctr, Lab Carbohydrate Vaccines, 24 Kashirskoe Shosse, Moscow 115478, Russia.
   [Knirel, Yuriy A.] Russian Acad Sci, ND Zelinsky Inst Organ Chem, 47 Leninsky Prospect, Moscow 117913, Russia.
   [L'vov, Vyacheslav L.] Fed Med Biol Agcy Russia, Inst Immunol, Natl Res Ctr, Lab Preparat Biochem, 24 Kashirskoe Shosse, Moscow 115478, Russia.
   [Kovalchuk, Alexander L.] NIAID, Virol & Cellular Immunol Sect, Lab Immunogenet, NIH, Rockville, MD 20852 USA.
RP Aparin, PG (reprint author), Natl Res Ctr, Inst Immunol, Lab Carbohydrate Vaccines, 24 Kashirskoe Shosse, Moscow 115478, Russia.
EM pg.aparin@nrcii.ru
RI Knirel, Yuriy A/E-2058-2014
FU Ministry of Education and Science of the Russian FederationMinistry of
   Education and Science, Russian Federation [02.522.11.2014]; Russian
   Science FundRussian Science Foundation (RSF) [14-14-01042,
   14-14-01042-P]; Intramural Research Program of the National Institute of
   Allergy and Infectious DiseasesUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID)
FX We are greatful to Drs Polly Matzinger and Herbert C Morse III from LIG,
   NIAID for critical review and editing the manuscript. Authors thank A.
   S. Shahskov and O. A. Chizhov for help with NMR spectroscopy and mass
   spectrometry, respectively. This work was supported by Ministry of
   Education and Science of the Russian Federation Grant No 02.522.11.2014
   (to P.G.A.); Russian Science Fund Grants 14-14-01042 and 14-14-01042-P
   (to Y.A.K.) and in part by the Intramural Research Program of the
   National Institute of Allergy and Infectious Diseases (A.L.K.).
CR ACHI R, 1994, SCAND J INFECT DIS, V26, P329, DOI 10.3109/00365549409011803
   [Anonymous], 2013, EUROPEAN PHARMACOPOE, V2013, P183
   Bainbridge BW, 2001, ACTA ODONTOL SCAND, V59, P131, DOI 10.1080/000163501750266710
   Barry EM, 2013, NAT REV GASTRO HEPAT, V10, P245, DOI 10.1038/nrgastro.2013.12
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   BRAHMBHATT HN, 1992, CURR TOP MICROBIOL, V180, P45
   Brandenburg K, 2009, CURR MED CHEM, V16, P2653, DOI 10.2174/092986709788682001
   CAMPREDON M, 1986, MAGN RESON CHEM, V24, P624, DOI 10.1002/mrc.1260240712
   Coats SR, 2011, INFECT IMMUN, V79, P203, DOI 10.1128/IAI.00937-10
   Cohen D, 1997, LANCET, V349, P155, DOI 10.1016/S0140-6736(96)06255-1
   Copeland S, 2005, CLIN DIAGN LAB IMMUN, V12, P60, DOI 10.1128/CDLI.12.1.60-67.2005
   Coster TS, 1999, INFECT IMMUN, V67, P3437, DOI 10.1128/IAI.67.7.3437-3443.1999
   Cross AS, 2014, VIRULENCE, V5, P219, DOI 10.4161/viru.25965
   Czerkinsky C, 2015, PHILOS T R SOC B, V370, DOI 10.1098/rstb.2015.0142
   DUBRAY G, 1982, ANAL BIOCHEM, V119, P325, DOI 10.1016/0003-2697(82)90593-0
   Haas KM, 2009, J IMMUNOL, V183, P3661, DOI 10.4049/jimmunol.0901218
   Herber DL, 2006, GLIA, V53, P382, DOI 10.1002/glia.20272
   Hougs L, 1999, J IMMUNOL, V162, P224
   Knirel YA, 2011, BACTERIAL LIPOPOLYSACCHARIDES: STRUCTURE, CHEMICAL SYNTHESIS, BIOGENESIS AND INTERACTION WITH HOST CELLS, P41, DOI 10.1007/978-3-7091-0733-1_3
   Konadu E, 1996, INFECT IMMUN, V64, P2709, DOI 10.1128/IAI.64.7.2709-2715.1996
   Kotloff KL, 1999, B WORLD HEALTH ORGAN, V77, P651
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Levine MM, 2007, NAT REV MICROBIOL, V5, P540, DOI 10.1038/nrmicro1662
   LINDBERG AA, 1991, REV INFECT DIS, V13, pS279
   Livio S, 2014, CLIN INFECT DIS, V59, P933, DOI 10.1093/cid/ciu468
   MUNFORD RS, 1986, SCIENCE, V234, P203, DOI 10.1126/science.3529396
   MYERS KR, 1990, Patent No. 4912094
   Noriega FR, 1999, INFECT IMMUN, V67, P782, DOI 10.1128/IAI.67.2.782-788.1999
   Nowotny A, 1971, MICROBIAL TOXINS, P309
   Paciello I, 2013, P NATL ACAD SCI USA, V110, pE4345, DOI 10.1073/pnas.1303641110
   Pauli NT, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00077
   Perepelov AV, 2009, CARBOHYD RES, V344, P687, DOI 10.1016/j.carres.2009.01.004
   PETERSON AA, 1985, J BACTERIOL, V162, P738, DOI 10.1128/JB.162.2.738-745.1985
   Raqib R, 2002, SCAND J IMMUNOL, V55, P414, DOI 10.1046/j.1365-3083.2002.01079.x
   Rietschel ET, 1996, CURR TOP MICROBIOL, V216, P39
   ROBBINS JB, 1995, J INFECT DIS, V171, P1387, DOI 10.1093/infdis/171.6.1387
   Robbins JB, 2009, P NATL ACAD SCI USA, V106, P7974, DOI 10.1073/pnas.0900891106
   SANDLIN RC, 1995, INFECT IMMUN, V63, P229, DOI 10.1128/IAI.63.1.229-237.1995
   Sansonetti P, 2002, GUT, V50, P2
   Sarlus H, 2017, J CLIN INVEST, V127, P3240, DOI 10.1172/JCI90606
   SERENY B, 1962, ACTA MICROBIOL HUNG, V9, P55
   SPIRIN A S, 1958, Biokhimiia, V23, P656
   Steimle A, 2016, INT J MED MICROBIOL, V306, P290, DOI 10.1016/j.ijmm.2016.03.001
   Teghanemt A, 2005, J IMMUNOL, V175, P4669, DOI 10.4049/jimmunol.175.7.4669
   Telepnev MV, 2009, J INFECT DIS, V200, P1694, DOI 10.1086/647986
   van der Ley P, 2001, INFECT IMMUN, V69, P5981, DOI 10.1128/IAI.69.10.5981-5990.2001
   Varela G, 2001, MICROB PATHOGENESIS, V31, P21, DOI 10.1006/mpat.2001.0443
   West NP, 2005, SCIENCE, V307, P1313, DOI 10.1126/science.1108472
   WESTPHAL O., 1965, METHOD CARBOHYD CHEM, V5, P83
   WHO, 1994, TECHNICAL REPORT SER, V840
NR 50
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 14
PY 2019
VL 37
IS 8
BP 1062
EP 1072
DI 10.1016/j.vaccine.2018.12.067
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HL4QW
UT WOS:000458709200008
PM 30670300
OA Other Gold, Green Accepted
DA 2020-05-12
ER

PT J
AU Sahin, Z
   Neeleman, R
   Haines, J
   Kayser, V
AF Sahin, Ziya
   Neeleman, Ronald
   Haines, Jonathan
   Kayser, Veysel
TI Preparation-free method can enable rapid surfactant screening during
   industrial processing of influenza vaccines
SO VACCINE
LA English
DT Article
DE Influenza split-virus vaccine; Rapid Triton X-100 screening; UV-Vis
   absorption spectroscopy; Biopharmaceutical formulation safety; Protein
   aggregation
ID ELECTRON-MICROSCOPY; IMMUNE-RESPONSE; TRITON X-100; PROTEIN; VIRUS;
   SPECTROSCOPY; ABSORPTION; STABILITY; IMMUNOGENICITY; FLUORESCENCE
AB Triton X-100 (TX-100) is the most common surfactant used to split viruses during the production of influenza split-virus vaccines. It is a mild surfactant not known to denature the viral proteins; this property makes TX-100 useful for maintaining antigen conformational structure, and, as an added benefit, for partially stabilizing vaccine formulations against protein aggregation. Despite its benefits, TX-100 needs to be filtered out after virus splitting has been achieved, due to its toxicity in large quantities. Accordingly, residual TX-100 presence in vaccine formulations has implications for both formulation stability and safety, necessitating both accurate screening during processing to guide decision-making about filtration repeats and accurate quantitation in the final product. Accurate HPLC-based methods are used successfully for the latter but their use for routine screening during processing is far from ideal because they often require extensive sample preparation and are fairly slow, complicated and costly. Here, "deconstruction" of UV-Vis absorption spectra into components corresponding to different absorbing "species" is demonstrated as a novel and viable method for routine TX-100 screening in vaccine samples from different industrial processing steps. This method is fairly accurate and, more importantly, preparation-free, rapid, simple/user-friendly and comparatively inexpensive. It is evaluated in depth in terms of applicability conditions, limitations and potential for high-throughput adaptation as well as generalization to other complex biopharmaceutical formulations. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Sahin, Ziya; Kayser, Veysel] Univ Sydney, Fac Med & Hlth, Sch Pharm, Sydney, NSW, Australia.
   [Neeleman, Ronald; Haines, Jonathan] Sanofi Pasteur, MTech, Viral Technol, Swiftwater, PA USA.
RP Kayser, V (reprint author), Univ Sydney, Sch Pharm, Sci Rd,Pharm & Bank Bldg A15,Rm S242, Sydney, NSW 2006, Australia.
EM ziya.sahin@sydney.edu.au; Ronald.Neeleman@sanofipasteur.com;
   Jonathan.Haines@sanofipasteur.com; veysel.kayser@sydney.edu.au
OI Kayser, Veysel/0000-0003-1310-9534
FU Sanofi-Pasteur; School of Pharmacy at the University of Sydney
FX The research was funded by Sanofi-Pasteur. ZS acknowledges the School of
   Pharmacy at the University of Sydney for the postgraduate research
   scholarship used during this study and others. Author contributions:
   study conception and design - ZS, RN, JH and VK; acquisition of data -
   ZS, RN and JH; analysis and interpretation of data - ZS, RN, JH and VK;
   drafting of manuscript - ZS and VK; critical revision - ZS, RN, JH and
   VK; final approval of version to be published - ZS, RN, JH and VK.
CR Babiuk S, 2004, J MED VIROL, V72, P138, DOI 10.1002/jmv.10540
   BALESTRIERI C, 1978, EUR J BIOCHEM, V90, P433, DOI 10.1111/j.1432-1033.1978.tb12622.x
   Belanger JM, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-72
   Braun A, 1997, PHARMACEUT RES, V14, P1472, DOI 10.1023/A:1012193326789
   CANTOR CR, 1970, BIOPOLYMERS, V9, P1059, DOI 10.1002/bip.1970.360090909
   Capelle Martinus A H, 2008, Drug Discov Today Technol, V5, pe71, DOI 10.1016/j.ddtec.2009.03.003
   Cavalluzzi M.J., 2004, NUCLEIC ACIDS RES, V32, P1
   CORNFORTH JW, 1951, NATURE, V168, P150, DOI 10.1038/168150a0
   Cox AJ, 2002, AM J PHYS, V70, P620, DOI 10.1119/1.1466815
   Demeule B, 2009, MABS-AUSTIN, V1, P142, DOI 10.4161/mabs.1.2.7632
   DRAKE RM, 1985, AM J PHYS, V53, P955, DOI 10.1119/1.14011
   Garman E, 2005, PROTEIN REV, V1, P247
   Heinig K, 1997, FRESEN J ANAL CHEM, V359, P202, DOI 10.1007/s002160050560
   HOROWITZ B, 1992, BLOOD, V79, P826
   HOYLE L, 1973, POSTGRAD MED J, V49, P193, DOI 10.1136/pgmj.49.569.193
   Huckriede A, 2005, VACCINE, V23, pS26, DOI 10.1016/j.vaccine.2005.04.026
   KALB VF, 1977, ANAL BIOCHEM, V82, P362, DOI 10.1016/0003-2697(77)90173-7
   Kallansrud G, 1996, ANAL BIOCHEM, V236, P134, DOI 10.1006/abio.1996.0141
   Kayser V, 2011, J PHARM SCI-US, V100, P2526, DOI 10.1002/jps.22493
   LEACH SJ, 1960, J AM CHEM SOC, V82, P4790, DOI 10.1021/ja01503a008
   Lee KKH, 2016, HUM VACC IMMUNOTHER, P1
   Li Y, 2011, J PHARM SCI-US, V100, P2120, DOI 10.1002/jps.22450
   MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G
   Maddux NR, 2014, J PHARM SCI-US, V103, P828, DOI 10.1002/jps.23849
   Mantele W, 2017, SPECTROCHIM ACTA A, V173, P965, DOI 10.1016/j.saa.2016.09.037
   MANNING MC, 1995, BIOTECHNOL BIOENG, V48, P506, DOI 10.1002/bit.260480513
   MULLER F, 1973, BIOCHEMISTRY-US, V12, P4654
   Murphy JH, 1996, ANAL BIOCHEM, V240, P273, DOI 10.1006/abio.1996.0357
   Patois E, 2011, VACCINE, V29, P7404, DOI 10.1016/j.vaccine.2011.07.067
   Pavlovic B, 2016, J AOAC INT, V99, P396, DOI 10.5740/jaoacint.15-0201
   Porterfield JZ, 2010, VIROLOGY, V407, P281, DOI 10.1016/j.virol.2010.08.015
   Purohit VS, 2006, J PHARM SCI-US, V95, P358, DOI 10.1002/jps.20529
   Rosenberg AS, 2006, AAPS J, V8, pE501
   RUIGROK RWH, 1989, VIROLOGY, V173, P311, DOI 10.1016/0042-6822(89)90248-1
   RUIGROK RWH, 1986, EMBO J, V5, P41, DOI 10.1002/j.1460-2075.1986.tb04175.x
   Sahin Z, 2017, VACCINE, V35, P3026, DOI 10.1016/j.vaccine.2017.04.066
   Sahin Z, 2016, EUR J PHARM SCI, V86, P115, DOI 10.1016/j.ejps.2016.03.007
   Schellekens H, 2002, NAT REV DRUG DISCOV, V1, P457, DOI 10.1038/nrd818
   SWITZER R, 1999, [No title captured]
   Tay T, 2015, HUM VACC IMMUNOTHER, V11, P1673, DOI 10.1080/21645515.2015.1034914
   VARKONYI Z, 1975, ACTA BIOCHIM BIOPHYS, V10, P129
   Wang W, 2005, INT J PHARMACEUT, V289, P1, DOI 10.1016/j.ijpharm.2004.11.014
   WEBSTER RG, 1977, J IMMUNOL, V119, P2073
NR 43
TC 0
Z9 0
U1 1
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 14
PY 2019
VL 37
IS 8
BP 1073
EP 1079
DI 10.1016/j.vaccine.2018.12.069
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HL4QW
UT WOS:000458709200009
PM 30685250
DA 2020-05-12
ER

PT J
AU Wouters, I
   Desmet, S
   Van Heirstraeten, L
   Blaizot, S
   Verhaegen, J
   Van Damme, P
   Malhotra-Kumar, S
   Theeten, H
   De Wilde, B
   De Meulemeester, M
   Azou, M
   Verghote, M
   Tuerlinckx, D
   Verlinden, R
   Cohen, R
   Finn, A
   Van Herck, K
   Goossens, H
AF Wouters, Ine
   Desmet, Stefanie
   Van Heirstraeten, Liesbet
   Blaizot, Stephanie
   Verhaegen, Jan
   Van Damme, Pierre
   Malhotra-Kumar, Surbhi
   Theeten, Heidi
   De Wilde, Barbara
   De Meulemeester, Marc
   Azou, Myriam
   Verghote, Marc
   Tuerlinckx, David
   Verlinden, Raf
   Cohen, Robert
   Finn, Adam
   Van Herck, Koen
   Goossens, Herman
CA NPcarriage Study Grp
TI Follow-up of serotype distribution and antimicrobial susceptibility of
   Streptococcus pneumoniae in child carriage after a PCV13-to-PCV10
   vaccine switch in Belgium
SO VACCINE
LA English
DT Article
DE Nasopharyngeal carriage; Streptococcus pneumoniae; Pneumococcal
   conjugate vaccines; Day-care; Acute otitis media; Children
ID PNEUMOCOCCAL CONJUGATE VACCINE; NASOPHARYNGEAL CARRIAGE;
   HAEMOPHILUS-INFLUENZAE; DISEASE; COLONIZATION; PREVALENCE; YOUNGER
AB Background: A three year pneumococcal carriage study was set up in Belgium when the vaccination programme switched from a 13-valent (PCV13) to a 10-valent (PCV10) vaccine. We compared the first follow-up period (October 2016 - June 2017, year 2, Y2) for nasopharyngeal carriage, serotype distribution and antimicrobial susceptibility of S. pneumoniae with the baseline (January July 2016, year 1, Y1).
   Materials/methods: A single nasopharyngeal swab was taken in children (6-30 months), either attending one of the 112 day-care centres (DCCs), or visiting one of the 21 physicians for an acute otitis media (AOM). S. pneumoniae were cultured, screened for antimicrobial susceptibility, and serotyped.
   Results: In Y2, 1218 samples were collected. The majority of the Y2-children (>85%) was vaccinated appropriately for their age. Children in Y2 received either PCV13 only (DCC: 23.5%; AOM: 24.6%), PCV10 only (DCC: 29.8%; AOM: 37.7%), or a mix of both vaccines (DCC: 31.9%; AOM: 25.4%). Pneumococcal carriage rates were high (Y2, DCC: 68.2%; AOM: 64.8%). Among carriers, prevalence of PCV13 serotypes was low (Y2 vs Y1, DCC: 3.5% vs 5.4%; AOM: 7.6% vs 7.7%). Although prevalence of PCV13-non-PCV10 serotypes did not increase significantly compared to Y1 (Y2 vs Y1, DCC: 1.6% vs 0.9%; Y2 vs Y1, AOM: 5.1% vs 0.0%), the proportion of serotypes 3, 6A, 19A among PCV13 serotype carriers in DCC was significantly higher in Y2 (46.2% vs Y1: 16.0%, p-value = 0.034). Serotypes 23B and 15B were the predominant non-vaccine serotypes (Y2). Among detected strains, non-susceptibility to at least one of five antibiotics tested (penicillin, tetracycline, erythromycin, levofloxacin, cotrimoxazole) was comparable to Y1 (Y2 vs Yl, DCC: 41.3% vs 42.4%; AOM: 49.4% vs 48.1%).
   Conclusion: After completion of the PCV13-to-PCV10 vaccine switch in Belgium, the proportion of PCV13-non-PCV10 serotypes (mainly 19A) significantly increased among PCV13 serotype carriers in DCC, stressing the need for strengthened surveillance as the PCV10-vaccinated population grows. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Wouters, Ine; Van Damme, Pierre; Theeten, Heidi] Univ Antwerp, Vaccine & Infect Dis Inst, Ctr Evaluat Vaccinat, Campus Drie Eiken,Univ Pl 1, B-2610 Antwerp, Belgium.
   [Desmet, Stefanie; Verhaegen, Jan] Univ Hosp Leuven, Reference Ctr Pneumococci, Campus Gasthuisberg,Herestr 49, B-3000 Leuven, Belgium.
   [Van Heirstraeten, Liesbet; Malhotra-Kumar, Surbhi] Univ Antwerp, Vaccine & Infect Dis Inst, Lab Med Microbiol, Campus Drie Eiken,Univ Pl 1, B-2610 Antwerp, Belgium.
   [Blaizot, Stephanie] Univ Antwerp, Ctr Hlth Econ Res & Modelling Infect Dis, Campus Drie Eiken,Univ Pl 1, B-2610 Antwerp, Belgium.
   [De Wilde, Barbara] AZ Maria Middelares, Ghent, Belgium.
   [Azou, Myriam] AZ Damiaan, Oostende, Belgium.
   [Tuerlinckx, David] Catholic Univ Louvain, CHU Dinant Godinne, Yvoir, Belgium.
   [Cohen, Robert] Univ Paris Est, GEMINI, IMRB, GRC, F-94000 Creteil, France.
   [Finn, Adam] Univ Bristol, Sch Cellular & Mol Med, Bristol, Avon, England.
   [Van Herck, Koen] Univ Ghent, Dept Publ Hlth, Ghent, Belgium.
   [Goossens, Herman] Univ Antwerp, Vaccine & Infect Dis Inst, Lab Med Microbiol, Antwerp, Belgium.
RP Wouters, I (reprint author), Univ Antwerp, Campus Drie Eiken,Bldg R 2nd Floor, Antwerp, Belgium.
EM ine.wouters@uantwerpen.be
RI Van Herck, Koen/L-2549-2019; Van Herck, Koen/G-5223-2013
OI Van Herck, Koen/0000-0003-0717-2406; Van Herck, Koen/0000-0003-0717-2406
FU Research Foundation Flanders (FWO Research Grant) [1150017N, 33341];
   Antwerp Study Centre for Infectious Diseases (ASCID); PfizerPfizer;
   University of Antwerp special research fund (BOF)
FX The study is supported by a research grant from Research Foundation
   Flanders (FWO Research Grant 1150017N, Antigoon ID 33341), the Antwerp
   Study Centre for Infectious Diseases (ASCID) and an
   investigator-initiated research grant from Pfizer. Stephanie Blaizot
   acknowledges support from the University of Antwerp special research
   fund (BOF).
CR Alberts N, 2016, NATL IMMUNISATION PR
   Balsells E, 2018, J INFECTION, V77, P368, DOI 10.1016/j.jinf.2018.06.004
   Brandileone MCC, 2018, VACCINE, V36, P2559, DOI 10.1016/j.vaccine.2018.04.010
   Chavanet P, 2011, MED MALADIES INFECT, V41, P307, DOI 10.1016/j.medmal.2011.02.001
   Cohen R, 2009, CLIN MICROBIOL INFEC, V15, P21, DOI 10.1111/j.1469-0691.2009.02727.x
   Deceuninck G, 2015, VACCINE, V33, P2684, DOI 10.1016/j.vaccine.2015.04.005
   Desmet S, 2018, LANCET INFECT DIS, V18, P830, DOI 10.1016/S1473-3099(18)30346-3
   Diawara I, 2015, INT J INFECT DIS, V40, P95, DOI 10.1016/j.ijid.2015.09.019
   Faden H, 1997, J INFECT DIS, V175, P1440, DOI 10.1086/516477
   Franco CM, 2010, PEDIATR INFECT DIS J, V29, P77, DOI 10.1097/INF.0b013e3181af7e90
   GRAY BM, 1980, J INFECT DIS, V142, P923, DOI 10.1093/infdis/142.6.923
   Jaakola S, 2017, INFECT DIS FINLAND 2
   Lindstrand A, 2016, VACCINE, V34, P4565, DOI 10.1016/j.vaccine.2016.07.031
   Loughlin AM, 2014, PEDIATR INFECT DIS J, V33, P504, DOI 10.1097/INF.0000000000000279
   Mendes da Costa E, 2016, INFECTIEZIEKTEN BIJ
   MILLAR MR, 1994, J HOSP INFECT, V27, P99, DOI 10.1016/0195-6701(94)90002-7
   Moore MR, 2016, LANCET RESP MED, V4, P399, DOI 10.1016/S2213-2600(16)00052-7
   Naucler P, 2017, CLIN INFECT DIS, V65, P1780, DOI 10.1093/cid/cix685
   Neves FPG, 2017, VACCINE, V35, P2794, DOI 10.1016/j.vaccine.2017.04.019
   O'Brien KL, 2009, LANCET, V374, P893, DOI 10.1016/S0140-6736(09)61204-6
   Principi N, 1999, PEDIATR INFECT DIS J, V18, P517, DOI 10.1097/00006454-199906000-00008
   Reichler MR, 1996, J INFECT DIS, V173, P374, DOI 10.1093/infdis/173.2.374
   Robert E, 2015, ENQUETE COUVERTURE V
   Sabbe M, 2011, PEDISURY JAARRAPPORT
   Setchanova L, 2017, BRAZ J INFECT DIS, V21, P433, DOI 10.1016/j.bjid.2017.03.011
   Simell B, 2012, EXPERT REV VACCINES, V11, P841, DOI [10.1586/erv.12.53, 10.1586/ERV.12.53]
   Steens A, 2015, PEDIATR INFECT DIS J, V34, P875, DOI 10.1097/INF.0000000000000751
   van Hoek AJ, 2014, VACCINE, V32, P4349, DOI 10.1016/j.vaccine.2014.03.017
   Vandermeulen C, 2017, STUDIE VACCINATIEGRA
   Verhaegen J, 2018, VERSLAG VOOR 2017
   Verhaegen J, 2016, 10 INT S PNEUM PNEUM
   Verhaegen J, 2017, VERSLAG VOOR 2016
   Vestrheim DF, 2008, J CLIN MICROBIOL, V46, P2508, DOI 10.1128/JCM.02296-07
   Wouters I, 2018, VACCINE, V36, P15, DOI 10.1016/j.vaccine.2017.11.052
   Zhou JY, 2015, INT J INFECT DIS, V39, P50, DOI 10.1016/j.ijid.2015.08.010
   Zuccotti G, 2014, VACCINE, V32, P527, DOI 10.1016/j.vaccine.2013.12.003
NR 36
TC 3
Z9 3
U1 1
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 14
PY 2019
VL 37
IS 8
BP 1080
EP 1086
DI 10.1016/j.vaccine.2018.12.068
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HL4QW
UT WOS:000458709200010
PM 30665775
DA 2020-05-12
ER

PT J
AU Zou, W
   Williams, D
   Cox, A
AF Zou, Wei
   Williams, Dean
   Cox, Andrew
TI Mitigating base-catalysed degradation of periodate-oxidized capsular
   polysaccharides: Conjugation by reductive amination in acidic media
SO VACCINE
LA English
DT Article
DE Polysaccharide; Degradation; Conjugate vaccine; Reductive amination;
   beta-Elimination
ID INFLUENZAE TYPE-B; GROUP-A; IMMUNOGENICITY; PROTEINS; VACCINES;
   OLIGOSACCHARIDES; ANTIBODIES
AB Reductive amination coupling an aldehyde-containing polysaccharide, generated by periodate oxidation, with the amino groups in protein has been widely used in the synthesis of glycoconjugate vaccines. The conjugation is often achieved under slightly basic conditions via a Schiffs base intermediate followed by its reduction with sodium cyanoborohydride. We observed that oxidized capsular polysaccharides such as Streptococcus pneumoniae type 6B (Pn-6B) and Haemophilus influenzae type a (HiA) underwent significant degradation during the conjugation in slightly basic media leading to sub-optimal glycoconjugates. Further study on oxidized Pn-3, Pn-6A, Pn-6C, Pn-2 polysaccharides and dextran provided evidence that the degradation is a result of base-catalysed 0-elimination. In contrast to HiA, Pn-2, Pn-3, Pn-6B polysaccharides and dextran, oxidized Pn-6A and Pn-6C polysaccharides were stable under basic conditions due to lack of the leaving group at the beta-position of the aldehyde. By performing conjugation of oxidized polysaccharides to bovine serum albumin (BSA) in phosphate buffer at pH 6.0, 6.8, 7.2 and 8.0, we concluded that the reductive amination proceeds best in slightly acidic media, particularly with those beta-elimination susceptible polysaccharides. Crown Copyright (C) 2019 Published by Elsevier Ltd. All rights reserved.
C1 [Zou, Wei; Williams, Dean; Cox, Andrew] Natl Res Council Canada, Human Hlth Therapeut Res Ctr, 100 Sussex Dr, Ottawa, ON K1A 0R6, Canada.
RP Zou, W (reprint author), Natl Res Council Canada, Human Hlth Therapeut Res Ctr, 100 Sussex Dr, Ottawa, ON K1A 0R6, Canada.
EM wei.zou@nrc-cnrc.gc.ca
OI Cox, Andrew/0000-0002-8397-9271
CR ANDERSON PW, 1986, J IMMUNOL, V137, P1181
   Angyal SJ, 2001, TOP CURR CHEM, V215, P1
   AXEN R, 1967, NATURE, V214, P1302, DOI 10.1038/2141302a0
   Carmenate T, 2004, FEMS IMMUNOL MED MIC, V40, P193, DOI 10.1016/S0928-8244(03)00346-8
   CHU CY, 1983, INFECT IMMUN, V40, P245, DOI 10.1128/IAI.40.1.245-256.1983
   CLAESSON BA, 1990, J PEDIATR-US, V116, P929, DOI 10.1016/S0022-3476(05)80655-9
   COSTANTINO P, 1992, VACCINE, V10, P691, DOI 10.1016/0264-410X(92)90091-W
   Cox AD, 2017, VACCINE, V35, P6129, DOI 10.1016/j.vaccine.2017.09.055
   Frasch CE, 2015, CLIN INFECT DIS, V61, pS404, DOI 10.1093/cid/civ595
   Hi Jennings, 1994, SYNTHETIC GLYCOCONJU, P325
   JENNINGS HJ, 1981, J IMMUNOL, V127, P1011
   KAGEDAL L, 1971, ACTA CHEM SCAND, V25, P1855, DOI 10.3891/acta.chem.scand.25-1855
   Laferriere CA, 1997, VACCINE, V15, P179, DOI 10.1016/S0264-410X(96)00148-X
   Lee CH, 2009, VACCINE, V27, P726, DOI 10.1016/j.vaccine.2008.11.065
   Lees A, 1996, VACCINE, V14, P190, DOI 10.1016/0264-410X(95)00195-7
   Paoletti LC, 2001, VACCINE, V20, P370, DOI 10.1016/S0264-410X(01)00364-4
   PATEL TP, 1994, METHOD ENZYMOL, V230, P57
   Prasad AK, 2011, US patent, Patent No. [7,955,605, 20117955605]
   ROBBINS JB, 1990, J INFECT DIS, V161, P821, DOI 10.1093/infdis/161.5.821
   SCHWARTZ BA, 1977, ARCH BIOCHEM BIOPHYS, V181, P542, DOI 10.1016/0003-9861(77)90261-2
   Smith M. B., 2007, MARCHS ADV ORGANIC C, P501
   Stroop CJM, 2002, CARBOHYD RES, V337, P335, DOI 10.1016/S0008-6215(01)00318-4
   Wang Z, 2003, J ORG CHEM, V68, P8097, DOI 10.1021/jo034446k
   WESSELS MR, 1993, INFECT IMMUN, V61, P4760, DOI 10.1128/IAI.61.11.4760-4766.1993
   Wessels MR, 1998, INFECT IMMUN, V66, P2186, DOI 10.1128/IAI.66.5.2186-2192.1998
   Zou W, 2009, PREPARATION BACTERIA, P55
NR 26
TC 0
Z9 0
U1 4
U2 17
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 14
PY 2019
VL 37
IS 8
BP 1087
EP 1093
DI 10.1016/j.vaccine.2018.12.072
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HL4QW
UT WOS:000458709200011
PM 30678850
DA 2020-05-12
ER

PT J
AU Milucky, J
   Carvalho, MD
   Rouphael, N
   Bennett, NM
   Talbot, HK
   Harrison, LH
   Farley, MM
   Walston, J
   Pimenta, F
   Lessa, FC
   Bower, M
   McNair, N
   Williams, S
   Presmanes, E
   Tunali, A
   Thomas, S
   Hollick, R
   Langdon, J
   Sepehri, AS
   Sharova, A
AF Milucky, Jennifer
   Carvalho, Maria de Gloria
   Rouphael, Nadine
   Bennett, Nancy M.
   Talbot, H. Keipp
   Harrison, Lee H.
   Farley, Monica M.
   Walston, Jeremy
   Pimenta, Fabiana
   Lessa, Fernanda C.
   Bower, Mary
   McNair, Nina
   Williams, Sabrina
   Presmanes, Emily
   Tunali, Amy
   Thomas, Stephanie
   Hollick, Rosemary
   Langdon, Jacqueline
   Sepehri, Amir Salar
   Sharova, Anna
CA Adult Pneumococcal Carriage Study
TI Streptococcus pneumoniae colonization after introduction of 13-valent
   pneumococcal conjugate vaccine for US adults 65 years of age and older,
   2015-2016
SO VACCINE
LA English
DT Article
DE Streptococcus pneumoniae; Pneumococcal conjugate vaccine; PCV13; Older
   adults; Pneumococcal carriage
ID NASOPHARYNGEAL CARRIAGE; POLYSACCHARIDE VACCINE; ADVISORY-COMMITTEE;
   INFECTED ADULTS; CHILDREN; DISEASE; RECOMMENDATIONS; SEROTYPES;
   COMMUNITY; LYTA
AB Background: Vaccination of children with 13-valent pneumococcal conjugate vaccine (PCV13) led to declines in vaccine-type pneumococcal nasopharyngeal carriage among adults through indirect effects. In August 2014, PCV13 immunization of all U.S. adults >= 65 years of age was recommended. This study sought to define prevalence and serotype distribution of pneumococcal carriage among adults >= 65 years of age and to describe risk factors for colonization soon after introduction of PCV13 in adults.
   Methods: A cross-sectional survey of non-institutionalized U.S. adults >= 65 years of age was conducted in four states in 2015-2016. Demographic information, risk factors for disease, PCV13 vaccination history, and nasopharyngeal (NP) and oropharyngeal (OP) swabs were collected. NP and OP swabs were processed separately and pneumococcal isolates were serotyped by Quellung reaction. Antimicrobial susceptibility of pneumococcal isolates was performed. NP swabs also underwent real-time PCR for pneumococcal detection and serotyping.
   Results: Of 2989 participants, 45.3% (1354/2989) had been vaccinated with PCV13. Fifty-five (1.8%) carried pneumococcus (45 identified by culture and 10 by real-time PCR only) and PCV13 serotypes were found in eight (0.3%) participants. Almost half (22/45) of pneumococcal isolates were not susceptible to at least one of the antibiotics tested. Vaccine-type carriage among vaccinated and unvaccinated individuals was similar (0.2% vs. 0.1%, respectively). Respiratory symptoms were associated with higher odds of pneumococcal colonization (adjusted OR: 2.1; 95% CI =1.1-3.8).
   Conclusions: Pneumococcal carriage among non-institutionalized adults >= 65 years of age was very low. Less than 0.5% of both vaccinated and unvaccinated individuals in our study carried vaccine-type serotypes. Over a decade of PCV vaccination of children likely led to indirect effects in adults. However, given the low vaccine-type carriage rates we observed in an already high PCV13 adult coverage setting, it is difficult to attribute our findings to the direct versus indirect effects of PCV13 on adult carriage. Published by Elsevier Ltd.
C1 [Milucky, Jennifer; Carvalho, Maria de Gloria; Pimenta, Fabiana; Lessa, Fernanda C.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Div Bacterial Dis, Atlanta, GA USA.
   [Rouphael, Nadine; Farley, Monica M.] Emory Univ, Sch Med, Dept Med, Atlanta, GA USA.
   [Rouphael, Nadine; Bower, Mary; McNair, Nina; Williams, Sabrina; Presmanes, Emily; Tunali, Amy; Thomas, Stephanie] Emory Univ, Hope Clin, Emory Vaccine Ctr, Decatur, GA USA.
   [Bennett, Nancy M.] Univ Rochester, Sch Med & Dent, Dept Med, Rochester, NY 14642 USA.
   [Talbot, H. Keipp] Vanderbilt Univ, Med Ctr, Nashville, TN USA.
   [Harrison, Lee H.; Hollick, Rosemary] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
   [Farley, Monica M.; McNair, Nina] Atlanta Vet Affairs Med Ctr, Atlanta, GA USA.
   [Walston, Jeremy; Langdon, Jacqueline; Sepehri, Amir Salar; Sharova, Anna] Johns Hopkins Univ, Sch Med, Div Geriatr Med & Gerontol, Baltimore, MD 21218 USA.
RP Milucky, J; Lessa, FC (reprint author), 1600 Clifton Rd,MS H24-6, Atlanta, GA 30329 USA.
EM wii7@cdc.gov; flessa@cdc.gov
FU EIP sites; Centers for Disease Control and PreventionUnited States
   Department of Health & Human ServicesCenters for Disease Control &
   Prevention - USA
FX This work was funded by the Emerging Infections Program (EIP)
   Cooperative Agreement between the four EIP sites and the Centers for
   Disease Control and Prevention.
CR Abdullahi O, 2008, PEDIATR INFECT DIS J, V27, P59, DOI 10.1097/INF.0b013e31814da70c
   Anonymous, 2010, Morbidity and Mortality Weekly Report, V59, P258
   Bennett Nancy M., 2012, Morbidity and Mortality Weekly Report, V61, P816
   Black CL, 2017, MMWR-MORBID MORTAL W, V66, P728, DOI 10.15585/mmwr.mm6627a4
   Bonten MJM, 2015, NEW ENGL J MED, V372, P1114, DOI 10.1056/NEJMoa1408544
   Branche AR, 2018, VACCINE, V36, P4304, DOI 10.1016/j.vaccine.2018.05.107
   Bresnitz E, 2001, JAMA-J AM MED ASSOC, V286, P1570
   Brooks LRK, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01366
   Bruce MG, 2015, VACCINE, V33, P4813, DOI 10.1016/j.vaccine.2015.07.080
   Carvalho MDG, 2013, PEERJ, V1, DOI 10.7717/peerj.97
   Carvalho MDS, 2007, J CLIN MICROBIOL, V45, P2460, DOI 10.1128/JCM.02498-06
   CDC, 2014, ACT BACT COR SURV RE
   CDC, 2013, PNEUM DIS SURV REP F, V3
   CDC, 2015, ACT BACT COR SURV RE
   Desai AP, 2015, PEDIATR INFECT DIS J, V34, P1168, DOI 10.1097/INF.0000000000000849
   Dewhirst FE, 2010, J BACTERIOL, V192, P5002, DOI 10.1128/JB.00542-10
   Donkor ES, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2224-0
   Dumyati G, 2017, CURR INFECT DIS REP, V19, DOI 10.1007/s11908-017-0576-7
   Feola TD, 2016, HUM VACC IMMUNOTHER, V12, P2441, DOI 10.1080/21645515.2016.1172758
   Grijalva CG, 2014, CLIN INFECT DIS, V58, P1369, DOI 10.1093/cid/ciu148
   Hamaluba M, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000335
   Institute CaLS, 2018, PERFORMANCE STANDARD
   Jain S, 2015, NEW ENGL J MED, V373, P415, DOI 10.1056/NEJMoa1500245
   Kim GB L, 2016, INT S PNEUM PNEUM DI
   Krone CL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119875
   Moore MR, 2015, LANCET INFECT DIS, V15, P301, DOI 10.1016/S1473-3099(14)71081-3
   Onwubiko C, 2008, J CLIN MICROBIOL, V46, P3621, DOI 10.1128/JCM.01245-08
   Pilishvili T, 2010, J INFECT DIS, V201, P32, DOI 10.1086/648593
   Pimenta FC, 2013, J CLIN MICROBIOL, V51, P647, DOI 10.1128/JCM.02927-12
   Regev-Yochay G, 2004, CLIN INFECT DIS, V38, P632, DOI 10.1086/381547
   Reisman J, 2014, J PEDIATR INFECT DIS, V3, P104, DOI 10.1093/jpids/pit069
   Simell B, 2012, EXPERT REV VACCINES, V11, P841, DOI [10.1586/erv.12.53, 10.1586/ERV.12.53]
   Simoes AS, 2016, DIAGN MICR INFEC DIS, V85, P141, DOI 10.1016/j.diagmicrobio.2016.03.018
   Surveillance ABC, 2016, EM INF PROGR N UNPUB
   Tomczyk S, 2014, MMWR-MORBID MORTAL W, V63, P822
   Williams WW, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6611a1
   Wunderink RG, 2018, CLIN INFECT DIS
NR 37
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 14
PY 2019
VL 37
IS 8
BP 1094
EP 1100
DI 10.1016/j.vaccine.2018.12.075
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HL4QW
UT WOS:000458709200012
PM 30685247
OA Green Accepted, Other Gold
DA 2020-05-12
ER

PT J
AU Jendrossek, M
   Edmunds, WJ
   Rohan, H
   Clifford, S
   Mooney, TA
   Eggo, RM
AF Jendrossek, Mario
   Edmunds, W. John
   Rohan, Hana
   Clifford, Samuel
   Mooney, Thomas A.
   Eggo, Rosalind M.
TI Health care worker vaccination against Ebola: Vaccine acceptance and
   employment duration in Sierra Leone
SO VACCINE
LA English
DT Article
DE Ebola virus disease; Health care workers; Vaccination; Mathematical
   modelling; Public health; Vaccine sentiment
ID VIRUS DISEASE; ATTITUDES; GUINEA
AB Health care workers (HCW) are at high risk of Ebola virus disease (EVD) infection during epidemics and may contribute to onward transmission, and therefore HCW-targeted prophylactic vaccination strategies are being considered as interventions. To assess the feasibility of preventive HCW vaccination, we conducted a pilot survey on staff turnover and vaccine acceptance amongst 305 HCW in Freetown and Kambia districts of Sierra Leone.
   Multivariable logistic regression demonstrated which demographic and behavioural factors were associated with acceptance of a hypothetical new vaccine. We quantified the duration of employment of HCW, and used multivariable gamma regression to detect associations with duration of employment in current or any health care position. Finally, we simulated populations of HCW, to determine the likely future immunisation coverage amongst HCW based on our estimates of vaccine acceptance and employment duration.
   Most HCW we surveyed had a positive opinion of EVD vaccination (76.3%). We found that being a volunteer HCW (vs being on the government payroll) was associated with increased vaccine acceptance. We found that HCW have stable employment, with a mean duration of employment in the health sector of 10.9 years (median 8.0 years). Older age and being on the government payroll (vs volunteer HCW) were associated with a longer duration of employment in the health sector. Assuming a single vaccine campaign, with 76.3% vaccine acceptance, 100% vaccine efficacy and no waning of vaccine-induced protection, immunisation coverage was sustained over 50% until 6 years after a vaccination campaign. If vaccine-induced immunity wanes at 10% per year, then the immunisation coverage among HCW would fall below 50% after 3 years.
   Vaccinating HCW against EVD could be feasible as employment appeared stable and vaccine acceptance high. However, even with high vaccine efficacy and long-lasting immunity, repeated campaigns or vaccination at employment start may be necessary to maintain high coverage. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Jendrossek, Mario; Edmunds, W. John; Clifford, Samuel; Eggo, Rosalind M.] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, Keppel St, London WC1E 7HT, England.
   [Jendrossek, Mario; Edmunds, W. John; Clifford, Samuel; Eggo, Rosalind M.] London Sch Hyg & Trop Med, Ctr Math Modelling Infect Dis, Keppel St, London WC1E 7HT, England.
   [Rohan, Hana] London Sch Hyg & Trop Med, UK Publ Hlth Rapid Support Team, London, England.
   [Rohan, Hana] Publ Hlth England, London, England.
   [Mooney, Thomas A.] London Sch Hyg & Trop Med, Dept Clin Res, Keppel St, London WC1E 7HT, England.
RP Eggo, RM (reprint author), London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, Keppel St, London WC1E 7HT, England.
EM r.eggo@lshtm.ac.uk
OI Eggo, Rosalind M/0000-0002-0362-6717
FU National Institute for Health Research through the Health Protection
   Research Unit in Immunisation at the London School of Hygiene & Tropical
   Medicine; Public Health England; HDR UK Innovation Fellowship
   [MR/S003975/1]; Innovative Medicines Initiative 2 (IMI2) Joint
   Undertaking [115854]; European Union Horizon 2020 Research and
   Innovation Programme; European Federation of Pharmaceutical Industries
   and Associations; United Kingdom Department of Health and Social Care; 
   [PR-OD-1017-20001]
FX Electronic data solutions were provided by LSHTM Open Research Kit
   (odk.lshtm.ac.uk) through the 'Electronic Data Capture to support rapid
   epidemiological research and response during epidemics' grant
   (PR-OD-1017-20001). RME acknowledges funding from the National Institute
   for Health Research through the Health Protection Research Unit in
   Immunisation (http://immunisation.hpru.nihr.ac.uk/) at the London School
   of Hygiene & Tropical Medicine in partnership with Public Health
   England, and from an HDR UK Innovation Fellowship (grant MR/S003975/1).
   MJ, WJE and TM acknowledge funding from the Innovative Medicines
   Initiative 2 (IMI2) Joint Undertaking under grant agreement EBOVACI
   (grant 115854). The IMI2 is supported by the European Union Horizon 2020
   Research and Innovation Programme and the European Federation of
   Pharmaceutical Industries and Associations. The UK Public Health Rapid
   Support Team is funded by the United Kingdom Department of Health and
   Social Care. The views expressed in this publication are those of the
   authors and not necessarily those of the National Health System, the
   National Institute for Health Research or the Department of Health and
   Social Care.
CR AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705
   ALEXANDER CS, 1978, PUBLIC OPIN QUART, V42, P93, DOI 10.1086/268432
   Aly HAA, 2015, WHO TECH REP SER, V994, P1
   [Anonymous], 2015, STAG PHAS 3 STUD ASS, DOI [10.1101/113506, DOI 10.1101/113506]
   [Anonymous], 2018, HLTH UM UGANDA VACCI
   [Anonymous], 2014, NATURE, V514, P15, DOI [10.1018/514015a, DOI 10.1018/514015A]
   Bertone Maria Paola, 2014, Confl Health, V8, P11, DOI 10.1186/1752-1505-8-11
   Brunette W, 2017, MOBISYS'17: PROCEEDINGS OF THE 15TH ANNUAL INTERNATIONAL CONFERENCE ON MOBILE SYSTEMS, APPLICATIONS, AND SERVICES, P440, DOI 10.1145/3081333.3081365
   Chambers J. M., 1992, STAT MODELS S
   Directorate of Human Resources for Health-Ministry of Health and Sanitation Government of Sierra Leone, 2016, HUM RES HLTH COUNTR
   Esangbedo DO, 2016, AM J TROP MED HYG, V95, P654, DOI 10.4269/ajtmh.16-0206
   FINCH J, 1987, SOCIOLOGY, V21, P105, DOI 10.1177/0038038587021001008
   Gesesew HA, 2016, ETHIOP J HEALTH SCI, V26, P331, DOI 10.4314/ejhs.v26i4.5
   Henao-Restrepo AM, 2017, LANCET, V389, P505, DOI 10.1016/S0140-6736(16)32621-6
   Huo X, 2016, VACCINE, V34, P1767, DOI 10.1016/j.vaccine.2016.02.046
   Irwin KL, 2017, VACCINE, V35, P6915, DOI 10.1016/j.vaccine.2017.06.026
   Maxmen A., 2017, NATURE, DOI [10.1038/nature.2017.22024, DOI 10.1038/NATURE.2017.22024]
   Ministry of Health and Sanitation Government of Sierra Leone, HUM RES HLTH STRAT 2
   Naburi H, 2017, HUM RESOUR HEALTH, V15, DOI 10.1186/s12960-017-0235-y
   Ramirez R, 2015, FUTURES, V71, P70, DOI 10.1016/j.futures.2015.06.006
   Robert A, 2017, BIORXIV, DOI [10.1101/113506, DOI 10.1101/113506]
   Shoman H, 2017, GLOBALIZATION HEALTH, V13, DOI 10.1186/s12992-016-0224-2
   Ughasoro MD, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003838
   Venables W.N., 2002, MODERN APPL STAT S
   WHO (World Health Organization), 2016, GLOB EB VACC IMPL TE
   Witter S, 2018, INT J HEALTH PLAN M, V33, P434, DOI 10.1002/hpm.2484
   Wurie H, 2014, STAFFING PUBLIC HLTH
NR 27
TC 1
Z9 1
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 14
PY 2019
VL 37
IS 8
BP 1101
EP 1108
DI 10.1016/j.vaccine.2018.12.060
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HL4QW
UT WOS:000458709200013
PM 30685246
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Mizuta, K
   Tanaka, S
   Komabayashi, K
   Aoki, Y
   Itagaki, T
   Matsushima, F
   Katsushima, Y
   Yoshida, H
   Ito, S
   Matsuzaki, Y
   Ikeda, T
AF Mizuta, Katsumi
   Tanaka, Shizuka
   Komabayashi, Kenichi
   Aoki, Yoko
   Itagaki, Tsutomu
   Matsushima, Fumio
   Katsushima, Yuriko
   Yoshida, Hiroshi
   Ito, Sueshi
   Matsuzaki, Yoko
   Ikeda, Tatsuya
TI Phylogenetic and antigenic analyses of coxsackievirus A6 isolates in
   Yamagata, Japan between 2001 and 2017
SO VACCINE
LA English
DT Article
DE Coxsackievirus A6; Herpangina; Hand-foot-and-mouth-disease; Molecular
   epidemiology; Antigenicity
ID MOUTH-DISEASE; ATYPICAL HAND; FOOT; INFECTIONS; CHILDREN; STRAINS;
   VACCINE
AB Although coxsackievirus A6 (CV-A6) is generally recognized as a causative agent of herpangina in children, CV-A6 infections globally emerged as a new and major cause of epidemic hand-foot-and-mouth-diseases (HFMDs) around 2008. To clarify the longitudinal epidemiology of CV-A6, we carried out sequence and phylogenetic analyses for the VP1 and partially for the VP4-3D regions as well as antigenic analysis using 115 CV-A6 isolates and 105 human sera in Yamagata, Japan between 2001 and 2017. Phylogenetic analysis revealed that CV-A6 isolates were clearly divided into two clusters; strains in circulation between 2001 and 2008 and those between 2010 and 2017. Neutralizing antibody titers of two rabbit antisera, which were immunized with Yamagata isolates in 2001 and 2015, respectively, against 28 Yamagata representative strains as well as the prototype Gdula strain were 1:2560-1:5120 and 1:160-1:640, respectively. The neutralizing antibody titers among residents in Yamagata against the above two strains were similar. Our analyses revealed that there were cross-antigenicities among all analyzed CV-A6 strains, although the newly emerged strains were introduced into Yamagata around 2010 and replaced the previous ones. With regard to control measures, these findings suggest that we can prevent CV-A6 infections through the development of a vaccine that effectively induces neutralizing antibodies against CV-A6, irrespective of genetic cluster. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Mizuta, Katsumi; Tanaka, Shizuka; Komabayashi, Kenichi; Aoki, Yoko; Ikeda, Tatsuya] Yamagata Prefectural Inst Publ Hlth, Dept Microbiol, Yamagata 1-6-6, Yamagata 9900031, Japan.
   [Itagaki, Tsutomu] Yamanobe Pediat Clin, Yamagata 9900301, Japan.
   [Matsushima, Fumio; Katsushima, Yuriko] Katsushima Pediat Clin, Yamagata 9902461, Japan.
   [Yoshida, Hiroshi; Ito, Sueshi] Tsuruoka Municipal Shonai Hosp, Dept Pediat, Yamagata 9909585, Japan.
   [Ito, Sueshi] Ito Clin, Dept Pediat, Hinode 1-17-8, Tsuruoka, Yamagata 9970025, Japan.
   [Matsuzaki, Yoko] Yamagata Univ, Dept Infect Dis, Fac Med, Yamagata 9909585, Japan.
RP Mizuta, K (reprint author), Yamagata Prefectural Inst Publ Hlth, Dept Microbiol, Tokamachi 1-6-6, Yamagata 9900031, Japan.
EM mizutak@pref.yamagata.jp
FU Association for Research on Lactic Acid Bacteria, Japan; Research
   Program on Emerging and Re-emerging Infectious Diseases from the Japan
   Agency for Medical Research and Development, AMEDJapan Agency for
   Medical Research and Development (AMED)
FX This work was partially supported by a grant from the Association for
   Research on Lactic Acid Bacteria, Japan and by the Research Program on
   Emerging and Re-emerging Infectious Diseases from the Japan Agency for
   Medical Research and Development, AMED.
CR Aswathyraj S, 2016, MED MICROBIOL IMMUN, V205, P397, DOI 10.1007/s00430-016-0465-y
   Chen YJ, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0052417e52432, DOI 10.1371/JOURNAL.PONE.0052417E52432]
   Cherry JD, 2014, FEIGIN CHERRYS TXB P, P2051
   Chung WH, 2013, J INFECT DIS, V208, P1968, DOI 10.1093/infdis/jit383
   Feder HM, 2014, LANCET INFECT DIS, V14, P83, DOI 10.1016/S1473-3099(13)70264-0
   Feng XB, 2015, SCI REP-UK, V5, DOI 10.1038/srep11700
   Fujii K, 2018, J VIROL, V92, DOI 10.1128/JVI.00682-18
   Fujimoto T, 2012, EMERG INFECT DIS, V18, P337, DOI 10.3201/eid1802.111147
   Gaunt E, 2015, J GEN VIROL, V96, P1067, DOI 10.1099/vir.0.000062
   Itagaki T, 2011, PEDIATR INFECT DIS J, V30, P680, DOI 10.1097/INF.0b013e31821608a8
   Kiyota N, 2013, INFECT AGENTS SUVEIL, V34, P233
   Li J, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00391
   Mirand A, 2012, CLIN MICROBIOL INFEC, V18, pE110, DOI 10.1111/j.1469-0691.2012.03789.x
   Mizuta K, 2003, J INFECTION, V47, P243, DOI 10.1016/S0163-4453(03)00081-1
   Mizuta K, 2009, VACCINE, V27, P3153, DOI 10.1016/j.vaccine.2009.03.060
   Mizuta K, 2008, JPN J INFECT DIS, V61, P196
   NIID, 2012, IASR, V33, P55
   NikNadia NMN, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004562
   Oberste MS, 2014, VIRAL INFECT HUMANS, P225
   Ogi M, 2017, J MED VIROL, V89, P1395, DOI 10.1002/jmv.24798
   Osterback R, 2009, EMERG INFECT DIS, V15, P1485, DOI 10.3201/eid1509.090438
   Pons-Salort M, 2018, SCIENCE, V361, P800, DOI 10.1126/science.aat6777
   Racaniello V., 2013, FIELDS VIROLOGY, P453
   Romero JR, 2015, MANDELL DOUGLAS BENN, P2080
   Shen CY, 2016, VACCINE, V34, P4025, DOI 10.1016/j.vaccine.2016.06.028
   Sinclair C, 2014, EUROSURVEILLANCE, V19, P6, DOI 10.2807/1560-7917.ES2014.19.12.20745
   Song Y, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05618-0
   Tanaka S, 2016, MICROBIOL IMMUNOL, V60, P854, DOI 10.1111/1348-0421.12456
   Yan X, 2015, BIOMED RES INT, DOI 10.1155/2015/802046
   Zeng HR, 2015, SCI REP-UK, V5, DOI 10.1038/srep10550
NR 30
TC 1
Z9 1
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 14
PY 2019
VL 37
IS 8
BP 1109
EP 1117
DI 10.1016/j.vaccine.2018.12.065
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HL4QW
UT WOS:000458709200014
PM 30683510
DA 2020-05-12
ER

PT J
AU Zhang, DC
   Jiang, N
   Chen, QJ
AF Zhang, Dongchao
   Jiang, Ning
   Chen, Qijun
TI Vaccination with recombinant adenoviruses expressing Toxoplasma gondii
   MIC3, ROP9, and SAG2 provide protective immunity against acute
   toxoplasmosis in mice
SO VACCINE
LA English
DT Article
DE Toxoplasma gondii; TgMIC3; TgSAG2; TgROP9; Recombinant adenoviruses;
   Vaccine candidates
ID PRIME-BOOST IMMUNIZATION; RHOPTRY PROTEIN; INNATE IMMUNITY;
   HEALTHY-ADULTS; EBOLA VACCINE; DOUBLE-BLIND; IFN-GAMMA; TNF-ALPHA;
   INFECTION; IMMUNOGENICITY
AB Toxoplasmosis is a worldwide zoonosis caused by the protozoan parasite Toxoplasma gondii, an obligate intracellular parasite. Currently, no viable vaccine or effective drug strategies exist to prevent and control toxoplasmosis. T. gondii microneme protein 3 (MIC3), rhoptry protein 9 (ROP9), and surface antigen 2 (SAG2) are related to active invasion of the parasite. Hence, we constructed recombinant adenoviruses expressing TgMIC3, TgSAG2, or TgROP9 and evaluated the recombinant adenoviruses as potential vaccines against acute T. gondii infection in BALB/c mice. Mice immunized with the recombinant adenoviruses were measured the antibody levels, percentages of lymphocytes and actived T lymphocytes, cytokine productions, and the survival rates and time to evaluate the protective efficacy. Results showed that immunization with the bivalent or trivalent recombiant adenoviruses could strongly stimulate humoral and cellular immune responses in mice, resulting in effective immune protections against lethal challenge with the tachyzoites of T. gondii RH. These results indicated that the divalent and trivalent adenoviruses, especially Ad-ROP9-MIC3-EGFP, may be promising vaccine candidates against acute T. gondii infection. (C) 2018 The Author(s). Published by Elsevier Ltd.
C1 [Zhang, Dongchao; Jiang, Ning; Chen, Qijun] Jilin Univ, Inst Zoonoses, Coll Vet Med, Key Lab Zoonosis Res,Minist Educ, Changchun 130062, Jilin, Peoples R China.
   [Jiang, Ning; Chen, Qijun] Shenyang Agr Univ, Key Lab Zoonosis, Shenyang 110866, Liaoning, Peoples R China.
RP Chen, QJ (reprint author), Shenyang Agr Univ, Key Lab Zoonosis, Shenyang 110866, Liaoning, Peoples R China.
EM qijunchen759@syau.edu.cn
FU National Key Research and Development Program of China [2017YFD0500400,
   2017YFD0501200]; National Natural Science Foundation of ChinaNational
   Natural Science Foundation of China [81420108023, 81772219]; Jilin
   province [2015Y033]
FX This work was supported by grants from the National Key Research and
   Development Program of China (Grant Numbers 2017YFD0500400,
   2017YFD0501200); the National Natural Science Foundation of China (Grant
   Numbers 81420108023, 81772219); and Jilin province grants (Grant Number
   2015Y033).
CR Akbar H, 2015, INFECT IMMUN, V83, P3601, DOI 10.1128/IAI.00217-15
   Beghetto E, 2005, J INFECT DIS, V191, P637, DOI 10.1086/427660
   Cabrera-Mora M, 2016, J IMMUNOL, V197, P2748, DOI 10.4049/jimmunol.1501926
   Caetano BC, 2006, HUM GENE THER, V17, P415, DOI 10.1089/hum.2006.17.415
   Cerede O, 2002, EMBO J, V21, P2526, DOI 10.1093/emboj/21.11.2526
   Chang ZG, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11537
   Chen J, 2014, EXP PARASITOL, V139, P42, DOI 10.1016/j.exppara.2014.02.016
   Ching X.T., 2016, FRONT MICROBIOL, V7
   Chuang SC, 2014, PARASITOLOGY, V18, P1
   Dobrowolski JM, 1996, CELL, V84, P933, DOI 10.1016/S0092-8674(00)81071-5
   Garg H, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10110631
   Gaud G, 2018, SCI SIGNAL, V11
   GAZZINELLI RT, 1992, J IMMUNOL, V148, P1792
   Guo JJ, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00163
   Guo Q, 2018, J INFECT DIS, V218, P365, DOI 10.1093/infdis/jiy187
   Hou N, 2016, J INFECT DIS, V214, P1547, DOI 10.1093/infdis/jiw428
   Hunter CA, 2012, NAT REV MICROBIOL, V10, P766, DOI 10.1038/nrmicro2858
   Jebbari H, 1998, PARASITE IMMUNOL, V20, P231, DOI 10.1046/j.1365-3024.1998.00152.x
   Kur J, 2009, EXPERT REV VACCINES, V8, P791, DOI 10.1586/ERV.09.27
   Lai MY, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2387-y
   Landrith TA, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00335
   Lee SH, 2018, VACCINE, V36, P5692, DOI 10.1016/j.vaccine.2018.08.016
   Li JX, 2017, LANCET GLOB HEALTH, V5, pE324, DOI [10.1016/S2214-109X(16)30367-9, 10.1016/s2214-109x(16)30367-9]
   Li XZ, 2016, INFECT GENET EVOL, V45, P447, DOI 10.1016/j.meegid.2016.10.006
   Li XZ, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-0815-1
   Liu JL, 2016, VIROL SIN, V31, P279, DOI 10.1007/s12250-016-3756-y
   Machado AV, 2010, VACCINE, V28, P3247, DOI 10.1016/j.vaccine.2010.02.003
   Maroof A, 2012, J INFECT DIS, V205, P853, DOI 10.1093/infdis/jir842
   Meira CS, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00492
   Meissner M, 2002, SCIENCE, V298, P837, DOI 10.1126/science.1074553
   Mendes EA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063201
   Miyata T, 2011, VACCINE, V29, P2720, DOI 10.1016/j.vaccine.2011.01.083
   Ni T, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aaq0762
   Nie H, 2011, VET PARASITOL, V181, P215, DOI 10.1016/j.vetpar.2011.04.039
   Ntumngia FB, 2018, J INFECT DIS, V218, P1110, DOI 10.1093/infdis/jiy273
   Qiu JF, 2016, SCI REP-UK, V6, DOI 10.1038/srep39407
   Qu DF, 2013, PARASITOL RES, V112, P2593, DOI 10.1007/s00436-013-3425-0
   Rauch S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01963
   Reichmann G, 2002, MOL BIOCHEM PARASIT, V119, P43, DOI 10.1016/S0166-6851(01)00397-8
   Rhee EG, 2011, J VIROL, V85, P315, DOI 10.1128/JVI.01597-10
   Wang B, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aat7061
   Wang T, 2017, PARASITE, V24, DOI 10.1051/parasite/2017013
   Wold WSM, 2013, CURR GENE THER, V13, P421
   Yamamoto Y, 2017, CANCER SCI, V108, P831, DOI 10.1111/cas.13228
   Yang XS, 2016, SCI REP-UK, V6, DOI 10.1038/srep31534
   Yarovinsky F, 2014, NAT REV IMMUNOL, V14, P109, DOI 10.1038/nri3598
   Zhang D, 2017, AVIAN PATHOL, V47, P213
   Zhang ZQ, 2018, J ASIA-PAC ENTOMOL, V21, P9, DOI 10.1016/j.aspen.2017.10.014
   Zheng B, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00216
   Zheng LN, 2017, ACTA TROP, V166, P336, DOI 10.1016/j.actatropica.2016.12.004
   Zhou J, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01733
   Zhu FC, 2017, LANCET, V389, P621, DOI [10.1016/s0140-6736(16)32617-4, 10.1016/S0140-6736(16)32617-4]
   Zhu FC, 2015, LANCET, V385, P2272, DOI 10.1016/S0140-6736(15)60553-0
NR 53
TC 0
Z9 0
U1 2
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 14
PY 2019
VL 37
IS 8
BP 1118
EP 1125
DI 10.1016/j.vaccine.2018.12.044
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HL4QW
UT WOS:000458709200015
PM 30670302
OA Other Gold
DA 2020-05-12
ER

PT J
AU Torisu, H
   Okada, K
AF Torisu, Hiroyuki
   Okada, Kenji
TI Vaccination-associated acute disseminated encephalomyelitis
SO VACCINE
LA English
DT Article
DE Encephalomyelitis; Vaccination-associated acute disseminated
   encephalomyelitis
ID PEDIATRIC MULTIPLE-SCLEROSIS; ACQUIRED DEMYELINATING SYNDROMES; CASE
   DEFINITIONS; ENCEPHALITIS; MYELITIS; CNS
AB While the basic definition of vaccination-associated acute disseminated encephalomyelitis (ADEM) is relatively clear and easily understandable, it is often difficult to diagnose ADEM based on clinical findings alone. ADEM is actually a heterogeneous clinical syndrome that can be approximately characterized by encephalomyelitis with multiple inflammatory demyelination, autoimmune causes, and relationship with a preceding infection or vaccination. The differential diagnosis of ADEM should exclude the possibility of infectious or other autoimmune encephalitis. The occurrence of vaccination-associated ADEM is influenced by several factors including the health and ethnic status of the vaccinated individual, vaccine components, and environment. Cases suspected of vaccination-associated ADEM should be analyzed cautiously from multi-disciplinary perspectives. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Torisu, Hiroyuki] Fukuoka Dent Coll, Sect Pediat, Dept Med, Sawara Ku, 2-15-1 Tamura, Fukuoka, Fukuoka 8140193, Japan.
   [Okada, Kenji] Fukuoka Nursing Coll, Div Basic Nursing, Sawara Ku, 2-15-1 Tamura, Fukuoka, Fukuoka 8140193, Japan.
RP Torisu, H (reprint author), Fukuoka Dent Coll, Sect Pediat, Dept Med, Sawara Ku, 2-15-1 Tamura, Fukuoka, Fukuoka 8140193, Japan.
EM torisu@college.fdcnet.ac.jp
CR Absoud M, 2013, MULT SCLER J, V19, P76, DOI 10.1177/1352458512445944
   Banwell B, 2009, NEUROLOGY, V72, P232, DOI 10.1212/01.wnl.0000339482.84392.bd
   Baxter AG, 2007, NAT REV IMMUNOL, V7, P904, DOI 10.1038/nri2190
   Gudbjornsson BT, 2015, PEDIATR NEUROL, V53, P503, DOI 10.1016/j.pediatrneurol.2015.08.020
   HEMACHUDHA T, 1987, NEW ENGL J MED, V316, P369, DOI 10.1056/NEJM198702123160703
   Ketelslegers IA, 2012, J NEUROL, V259, P1929, DOI 10.1007/s00415-012-6441-6
   Krupp LB, 2007, NEUROLOGY, V68, pS7, DOI 10.1212/01.wnl.0000259422.44235.a8
   Krupp LB, 2013, MULT SCLER J, V19, P1261, DOI 10.1177/1352458513484547
   Langer-Gould A, 2011, NEUROLOGY, V77, P1143, DOI 10.1212/WNL.0b013e31822facdd
   Leake JAD, 2004, PEDIATR INFECT DIS J, V23, P756, DOI 10.1097/01.inf.0000133048.75452.dd
   Ministry of Health, LAB WELF YOB SESSH H
   Nakayama T, 2007, VACCINE, V25, P570, DOI 10.1016/j.vaccine.2006.05.130
   Orgogozo JM, 2003, NEUROLOGY, V61, P46, DOI 10.1212/01.WNL.0000073623.84147.A8
   Pellegrino P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077766
   Pohl D, 2007, EUR J PEDIATR, V166, P405, DOI 10.1007/s00431-006-0249-2
   Rath B, 2010, VACCINE, V28, P3488, DOI 10.1016/j.vaccine.2010.02.053
   Sejvar JJ, 2007, VACCINE, V25, P5771, DOI 10.1016/j.vaccine.2007.04.060
   Torisu H, 2010, BRAIN DEV-JPN, V32, P454, DOI 10.1016/j.braindev.2009.10.006
   Xiong CH, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-111
   Yamaguchi Y, 2016, NEUROLOGY, V87, P2006, DOI 10.1212/WNL.0000000000003318
NR 20
TC 0
Z9 1
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 14
PY 2019
VL 37
IS 8
BP 1126
EP 1129
DI 10.1016/j.vaccine.2019.01.021
PG 4
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HL4QW
UT WOS:000458709200016
PM 30683508
DA 2020-05-12
ER

PT J
AU Warrell, MJ
AF Warrell, M. J.
TI Rabies post-exposure vaccination in 2 visits within a week: A 4-site
   intradermal regimen
SO VACCINE
LA English
DT Article
DE Rabies; Post-exposure; Intradermal; Economical; Off-label; Encephalitis;
   Immunosuppressed; Dog; 4 site
ID HUMAN-IMMUNODEFICIENCY-VIRUS; EMBRYO CELL VACCINE; ANTIBODY-RESPONSE;
   BOOSTER VACCINATION; INFLUENZA VACCINE; IMMUNE-RESPONSES;
   IMMUNOGENICITY; PROPHYLAXIS; SAFETY; IMMUNIZATION
AB Rabies is fatal in all unvaccinated patients bitten by dogs, and so post-exposure vaccine regimens must be robust enough to ensure their survival under all conditions. Treatment tends to be excessive for most people, but there is justified anxiety about reducing vaccine dosage and shortening regimens. Recently, World Health Organisation (WHO) recommended one week primary post-exposure intradermal regimens requiring 3 clinic visits, but these are unlikely to prove economical where rabies vaccination is most needed, in deprived rural areas of Africa and Asia.
   A highly immunogenic regimen involving two doses of intradermal vaccine given one week apart has advantages over other regimens. Anyone exposed to a possibly rabid animal would be given intradermal (ID) injections at 4 sites using a whole vial of vaccine. Those who had not been previously vaccinated would be given 2-site ID injections using half a vial one week later. Those who might be immunosuppressed could be given an optional single ID dose on day 28. The rationale for this regimen is discussed in the context of the recently revised WHO recommendations for rabies prophylaxis. (C) 2019 The Author. Published by Elsevier Ltd.
C1 [Warrell, M. J.] Univ Oxford, Churchill Hosp, Oxford Vaccine Grp, Ctr Clin Vaccinol & Trop Med, Old Rd, Oxford OX3 7LE, England.
RP Warrell, MJ (reprint author), Univ Oxford, Churchill Hosp, Oxford Vaccine Grp, Ctr Clin Vaccinol & Trop Med, Old Rd, Oxford OX3 7LE, England.
EM mary.warrell@ndm.ox.ac.uk
FU Hamish Ogsten Foundation
FX The Hamish Ogsten Foundation supported the open access publication.
CR Ambrozaitis A, 2006, VACCINE, V24, P4116, DOI 10.1016/j.vaccine.2006.02.036
   [Anonymous], 1984, IMMUNISATION INFECT
   [Anonymous], 2018, WHO TECHN REP SER, V1012
   Beran J, 2005, VACCINE, V23, P3902, DOI 10.1016/j.vaccine.2005.03.007
   Boonnak K, 2017, VACCINE, V35, P7339, DOI 10.1016/j.vaccine.2017.10.106
   Buchy Philippe, 2017, Trop Med Infect Dis, V2, DOI 10.3390/tropicalmed2030023
   Cramer JP, 2016, J TRAVEL MED, V23, DOI 10.1093/jtm/taw011
   Deshpande A, 2001, RABIES CONTROL IN ASIA, P58
   Dodet B, 2011, BIOLOGICALS, V39, P444, DOI 10.1016/j.biologicals.2011.08.002
   FISHBEIN DB, 1987, J INFECT DIS, V156, P50, DOI 10.1093/infdis/156.1.50
   Gelinck LBS, 2009, AIDS, V23, P2451, DOI 10.1097/QAD.0b013e328331a43b
   Gongal Gyanendra, 2011, Adv Prev Med, V2011, P383870, DOI 10.4061/2011/383870
   Hampson K, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000982
   Jaijaroensup W, 1999, J TRAVEL MED, V6, P234, DOI 10.1111/j.1708-8305.1999.tb00524.x
   Khawplod P, 2002, J TRAVEL MED, V9, P153, DOI 10.2310/7060.2002.23189
   Kositprapa C, 1997, CLIN INFECT DIS, V25, P614, DOI 10.1086/513760
   MADHUSUDANA SN, 1988, INDIAN J MED RES, V87, P1
   Madhusudana SN, 2001, NATL MED J INDIA, V14, P145
   Narayana A, 2015, HUM VACC IMMUNOTHER, V11, P1748, DOI 10.1080/21645515.2015.1048938
   Neels P, 2017, VACCINE, V35, P2329, DOI 10.1016/j.vaccine.2017.02.056
   PHANUPHAK P, 1987, ASIAN PAC J ALLERGY, V5, P33
   Seo YB, 2016, HUM VACC IMMUNOTHER, V12, P478, DOI 10.1080/21645515.2015.1076599
   Shantavasinkul P, 2010, CLIN INFECT DIS, V50, P56, DOI 10.1086/649211
   Sirikwin S, 2009, VACCINE, V27, P4350, DOI 10.1016/j.vaccine.2009.03.027
   Suraweera W, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001847
   Tantawichien T, 2001, CLIN INFECT DIS, V33, P2085, DOI 10.1086/338155
   Tantawichien T, 1999, CLIN INFECT DIS, V28, P1100, DOI 10.1086/514737
   Tantawichien T, 2001, CLIN INFECT DIS, V33, pE122, DOI 10.1086/324087
   Tarantola A, 2018, INTRADERMAL RABIES P, DOI [10.1016/j.vaccine2018.10.054.S0264-410X(18)31420-8, DOI 10.1016/J.VACCINE2018.10.054.S0264-410X(18)31420-8]
   Thisyakorn U, 2000, CLIN INFECT DIS, V30, P218, DOI 10.1086/313610
   TURNER GS, 1976, LANCET, V1, P1379
   Warrell MJ, 2018, REV SCI TECH OIE, V37, P629, DOI 10.20506/rst.37.2.2829
   Warrell MJ, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000224
   WARRELL MJ, 1984, LANCET, V1, P874
   WARRELL MJ, 1985, LANCET, V1, P1059
   WARRELL MJ, 1983, LANCET, V2, P301
   WHO, 2013, WHO TECH REP SER, V982, P1
   *WHO, 1997, WHOEMCZ00966
   WHO, 2017, BACKGR PAP PROP REV
   WHO Expert Consultation on rabies, 2005, TECH REP SER, V931
   WHO Human and dog rabies prevention and control, 2009, REP WHO BILL M GAT F, P21
   Wilde H, 2012, TRAVEL MED INFECT DI, V10, P162, DOI 10.1016/j.tmaid.2012.03.004
NR 42
TC 2
Z9 2
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 21
PY 2019
VL 37
IS 9
BP 1131
EP 1136
DI 10.1016/j.vaccine.2019.01.019
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HM9YN
UT WOS:000459841000001
PM 30691982
OA Other Gold
DA 2020-05-12
ER

PT J
AU Borras, E
   Urbiztondo, L
   Carmona, G
   Jane, M
   Barrabeig, I
   Sala, MR
   Balana, JPJ
   Company, M
   Parron, I
   Godoy, P
   Rius, C
   Soldevila, N
   Cabezas, C
   Dominguez, A
   Alseda, M
   Alvarez, J
   Arias, C
   Balana, PJ
   Camps, N
   Carol, M
   Farras, J
   Ferrus, G
   Follia, N
   Martinez, A
   Minguell, S
   Planas, C
   Rovira, A
   Sala, MR
   Torres, J
   Manzanares, S
AF Borras, Eva
   Urbiztondo, Luis
   Carmona, Gloria
   Jane, Mireia
   Barrabeig, Irene
   Rosa Sala, M.
   Jorgina Balana, J. P.
   Company, Maria
   Parron, Ignasi
   Godoy, Pere
   Rius, Cristina
   Soldevila, Nuria
   Cabezas, Carmen
   Dominguez, Angela
   Alseda, Miguel
   Alvarez, Josep
   Arias, Cesar
   Jorgina Balana, Pilar
   Camps, Neus
   Carol, Monica
   Farras, Joaquim
   Ferrus, Gloria
   Follia, Nuria
   Martinez, Anna
   Minguell, Sofia
   Planas, Caritat
   Rovira, Ariadna
   Rosa Sala, Maria
   Torres, Joan
   Manzanares, Sandra
CA Working Grp Study Hepatitis B Cata
TI Effectiveness and impact of the hepatitis B vaccination program in
   preadolescents in Catalonia 21 years after its introduction
SO VACCINE
LA English
DT Article
DE Vaccination effectiveness; Hepatitis B; Coverage; Vaccine failure;
   Population prevented fraction
ID UNIVERSAL VACCINATION; UNITED-STATES; IMPLEMENTATION; VARIANTS; MARKERS;
   VIRUS; AREAS
AB Hepatitis B is a viral disease of global importance. In Catalonia in the 1980s, the seroepidemiological pattern of HBV infection was low-intermediate. In 1990, the Expert Committee on Vaccinations of the Department of Health of the Generalitat of Catalonia evaluated the systematic introduction of hepatitis B vaccination in preadolescents, maintaining the vaccination of risk groups. The objective of this study was to estimate the effectiveness and impact of the systematic hepatitis B vaccination programme in preadolescents in Catalonia 21 years after its introduction. A retrospective cohort study was conducted, comparing the disease incidence in vaccinated and unvaccinated cohorts. Cases of hepatitis B were defined as those reported by the General Subdirectorate of Surveillance and Response to Public Health Emergencies between 2000 and 2014. The incidence rate was 2.5 per 100,000 persons in 1991 and 1.2 per 100,000 persons in 2014, a reduction of 52%. During the study period, 388 cases of hepatitis B infection were notified, of which three were classified as vaccine failures. Vaccine effectiveness was 99.30% (95% CI: 97.83-99.78) and the population prevented fraction in the cohorts of preadolescents studied was 64.56% (95% CI: 60.45-68.66). The effectiveness and impact of the hepatitis B vaccination program in preadolescents in Catalonia is high, with the consequent benefits for the population. (C) 2019 Published by Elsevier Ltd.
C1 [Borras, Eva; Urbiztondo, Luis; Carmona, Gloria; Jane, Mireia; Barrabeig, Irene; Rosa Sala, M.; Jorgina Balana, J. P.; Company, Maria; Parron, Ignasi; Godoy, Pere; Cabezas, Carmen] Generalitat Catalunya, Agencia Salut Publ Catalunya, Barcelona, Spain.
   [Borras, Eva; Jane, Mireia; Barrabeig, Irene; Godoy, Pere; Rius, Cristina; Soldevila, Nuria; Dominguez, Angela] CIBER Epidemiol & Salud Publ CIBERESP, Madrid, Spain.
   [Borras, Eva; Soldevila, Nuria; Dominguez, Angela] Univ Barcelona, Dept Med, Barcelona, Spain.
   [Rius, Cristina; Manzanares, Sandra] Agencia Salut Publ Barcelona, Barcelona, Spain.
   [Borras, Eva; Urbiztondo, Luis; Carmona, Gloria; Jane, Mireia; Barrabeig, Irene; Company, Maria; Parron, Ignasi; Godoy, Pere; Cabezas, Carmen; Alseda, Miguel; Alvarez, Josep; Arias, Cesar; Jorgina Balana, Pilar; Camps, Neus; Carol, Monica; Farras, Joaquim; Ferrus, Gloria; Follia, Nuria; Martinez, Anna; Minguell, Sofia; Planas, Caritat; Rovira, Ariadna; Rosa Sala, Maria; Torres, Joan] Agencia Salut Publ Catalunya, Barcelona, Spain.
   [Soldevila, Nuria; Dominguez, Angela] Univ Barcelona, Barcelona, Spain.
RP Borras, E (reprint author), Carrer Roc Boronat 81-95, Barcelona 08005, Spain.
EM eva.borras@gencat.cat
RI Sala, Maria/H-2562-2013
OI Sala, Maria/0000-0002-9955-8746; Urbiztondo, Luis/0000-0003-4371-4612;
   Barrabeig, Irene/0000-0003-4789-7620; Cabezas,
   Carmen/0000-0002-4291-0454; Godoy, Pere/0000-0002-2896-7286
FU CIBER of Epidemiology and Public Health (CIBERESP) of the Carlos III
   Health Institute; Catalan Agency for the Management of Grants for
   University Research (AGAUR) [2017/SGR 1342]
FX This work was partially funded by CIBER of Epidemiology and Public
   Health (CIBERESP) of the Carlos III Health Institute and the Catalan
   Agency for the Management of Grants for University Research (AGAUR Grant
   Number 2017/SGR 1342).
CR ALTER MJ, 1990, JAMA-J AM MED ASSOC, V263, P1218, DOI 10.1001/jama.263.9.1218
   [Anonymous], 2009, Wkly Epidemiol Rec, V84, P405
   Boccalini S, 2013, HUM VACC IMMUNOTHER, V9, P1119, DOI 10.4161/hv.23827
   Caligiuri P, 2016, WORLD J GASTROENTERO, V22, P145, DOI 10.3748/wjg.v22.i1.145
   Carmona G, 2005, B EPIDEMIOLOGIC CATA, V26, P59
   Chiang CJ, 2013, JAMA-J AM MED ASSOC, V310, P974, DOI 10.1001/jama.2013.276701
   Departament of Health, 2011, CAS DEF COMP REP DIS
   Huang ML, 2007, VACCINE, V25, P6326, DOI 10.1016/j.vaccine.2007.06.022
   Immunization practices advisory committee, 1985, MMWR MORB MORT WKLY, V34, P313
   Immunization practices advisory committee, 1985, MMWR-MORBID MORTAL W, V34, P329
   KANE MA, 1989, AM J MED, V87, pS11, DOI 10.1016/0002-9343(89)90524-X
   Kimberlin DW, 2015, RED BOOK 2015 REPORT, P391
   Kubba A K, 2003, Commun Dis Public Health, V6, P106
   Mele A, 2008, CLIN INFECT DIS, V46, P868, DOI 10.1086/528687
   Peto TJ, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-7
   Romano L, 2015, HUM VACC IMMUNOTHER, V11, P53, DOI 10.4161/hv.34306
   SALLERAS L, 1992, EUR J EPIDEMIOL, V8, P640, DOI 10.1007/BF00145377
   SALLERAS LI, 1994, GASTROENTEROL HEPATO, V17, P349
   SPASOFF RA, 1999, EPIDEMIOLOGIC METHOD
   Tosti ME, 2016, CLIN INFECT DIS, V62, P1412, DOI 10.1093/cid/ciw162
   Van Damme P, 2018, VACCINES, P342
   Wang J, 2017, VACCINE, V35, P5808, DOI 10.1016/j.vaccine.2017.09.030
   World Health Organization, 2016, COMB HEP B C REACH E
   World Health Organization, 2001, INTR HEP B VACC CHIL
   Yamani LN, 2015, J CLIN MICROBIOL, V53, P3165, DOI 10.1128/JCM.00602-15
NR 25
TC 2
Z9 2
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 21
PY 2019
VL 37
IS 9
BP 1137
EP 1141
DI 10.1016/j.vaccine.2019.01.024
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HM9YN
UT WOS:000459841000002
PM 30709729
DA 2020-05-12
ER

PT J
AU Rocha, JN
   Dangott, LJ
   Mwangi, W
   Alaniz, RC
   Bordin, AI
   Cywes-Bentley, C
   Lawhon, SD
   Pillai, SD
   Bray, JM
   Pier, GB
   Cohen, ND
AF Rocha, Joana N.
   Dangott, Lawrence J.
   Mwangi, Waithaka
   Alaniz, Robert C.
   Bordin, Angela, I
   Cywes-Bentley, Colette
   Lawhon, Sara D.
   Pillai, Suresh D.
   Bray, Jocelyne M.
   Pier, Gerald B.
   Cohen, Noah D.
TI PNAG-specific equine IgG(1) mediates significantly greater opsonization
   and killing of Prescottella equi (formerly Rhodococcus equi) than does
   IgG(4/7)
SO VACCINE
LA English
DT Article
DE Intracellular bacteria; Rhodoccus equi; IgG(1); IgG(4/7); Complement;
   Opsonization; Opsonophagocytic killing
ID CRYPTOCOCCUS-NEOFORMANS; IMMUNOGLOBULIN-G; MONOCLONAL-ANTIBODIES;
   GALLIUM MALTOLATE; T-LYMPHOCYTE; PROTEIN-A; INFECTION; VIRULENCE;
   PNEUMONIA; RESPONSES
AB Prescottella equi (formerly Rhodococcus equi) is a facultative intracellular bacterial pathogen that causes severe pneumonia in foals 1-6 months of age, whereas adult horses are highly resistant to infection. We have shown that vaccinating pregnant mares against the conserved surface polysaccharide capsule, beta-1 -> 6-linked poly-N-acetyl glucosamine (PNAG). elicits opsonic killing antibody that transfers via colostrum to foals and protects them against experimental infection with virulent.
   R. equi. We hypothesized that equine IgG(1) might be more important than IgG(4/7) for mediating protection against R. equi infection in foals. To test this hypothesis, we compared complement component 1 (C1) deposition and polymorphonuclear cell-mediated opsonophagocytic killing (OPK) mediated by IgG(1) or IgG(4/7) enriched from either PNAG hyperimmune plasma (HIP) or standard plasma. Subclasses IgG(1) and IgG(4/7) from PNAG HIP and standard plasma were precipitated onto a diethylaminoethyl ion exchange column, then further enriched using a protein G Sepharose column. We determined Cl deposition by enzyme-linked immunosorbent assay (ELISA) and estimated OPK by quantitative microbiologic culture. Anti-PNAG IgG(1) deposited significantly (P < 0.05) more Cl onto PNAG than did IgG(4/7) from PNAG HIP or subclasses IgG(1) and IgG(4/7) from standard plasma. In addition, IgG(1) from PNAG HIP mediated significantly (P < 0.05) greater OPK than lgG(4/7) from PNAG HIP or IgG(1) and IgG(4/7) from standard plasma. Our findings indicate that anti-PNAG IgG(1) is a correlate of protection against R. equi in foals, which has important implications for understanding the immunopathogenesis of R. equi pneumonia, and as a tool for assessing vaccine efficacy and effectiveness when challenge is not feasible. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Rocha, Joana N.; Bordin, Angela, I; Lawhon, Sara D.; Bray, Jocelyne M.; Cohen, Noah D.] Texas A&M Univ, Coll Vet Med & Biomed Sci, 660 Raymond Stotzer Pkwy, College Stn, TX 77843 USA.
   [Dangott, Lawrence J.] Texas A&M Univ, Prot Chem Lab, 300 Olsen Blvd, College Stn, TX 77843 USA.
   [Mwangi, Waithaka] Kansas State Univ, Dept Diagnost Med Pathobiol, 1800 Denison Ave, Manhattan, KS 66506 USA.
   [Alaniz, Robert C.] Texas A&M Univ, Hlth & Sci Ctr, Dept Microbial Pathogenesis & Immunol, 206 Olsen Blvd, College Stn, TX 77845 USA.
   [Cywes-Bentley, Colette; Pier, Gerald B.] Harvard Med Sch, Brigham & Womens Hosp, 181 Longwood Ave, Boston, MA 02115 USA.
   [Pillai, Suresh D.] Texas A&M Univ, Natl Ctr Electron Beam Res, IAEA Collaborat Ctr Electron Beam Technol, 400 Discovery Dr, College Stn, TX 77845 USA.
RP Cohen, ND (reprint author), Texas A&M Univ, Coll Vet Med & Biomed Sci, 660 Raymond Stotzer Pkwy, College Stn, TX 77843 USA.
EM jrocha@cvm.tamu.edu; dangott@tamu.edu; wmwangi@vet.k-state.edu;
   alaniz@medicine.tamhsc.edu; abordin@cvm.tamu.edu;
   ccywes@rics.bwh.harvard.edu; slawhon@cvm.tamu.edu; s-pillai@tamu.edu;
   gpier@bwh.harvard.edu; ncohen@cvm.tamu.edu
RI Lawhon, Sara D/G-5147-2011
OI Lawhon, Sara D/0000-0001-9154-8909; Pier, Gerald/0000-0002-9112-2331
FU Department of Large Animal Clinical Sciences, College of Veterinary
   Medicine & Biomedical Sciences, Texas AM University; ALOPEXX Enterprises
   LLCs, Concord, MA; Link Equine Research Endowment, Texas AM University
FX This work was supported by a grant from Department of Large Animal
   Clinical Sciences, College of Veterinary Medicine & Biomedical Sciences,
   Texas A&M University. Additional support was provided by ALOPEXX
   Enterprises LLCs, Concord, MA, and the Link Equine Research Endowment,
   Texas A&M University. The funders had no role in study design, data
   collection and interpretation, or the decision to submit the work for
   publication.
CR Achkar JM, 2015, IMMUNOL REV, V264, P167, DOI 10.1111/imr.12276
   BANKS KL, 1975, IMMUNOLOGY, V28, P581
   Bordin AI, 2018, VET MICROBIOL, V215, P18, DOI 10.1016/j.vetmic.2017.11.019
   BOWLES PM, 1989, VET IMMUNOL IMMUNOP, V22, P369, DOI 10.1016/0165-2427(89)90172-4
   Casadevall A, 2018, CURR OPIN IMMUNOL, V53, P74, DOI 10.1016/j.coi.2018.04.011
   Cauchard J, 2004, VET MICROBIOL, V104, P73, DOI 10.1016/j.vetmic.2004.09.006
   Chaffin MK, 2008, JAVMA-J AM VET MED A, V232, P1035, DOI 10.2460/javma.232.7.1035
   Chaffin MK, 2011, AM J VET RES, V72, P945, DOI 10.2460/ajvr.72.7.945
   Cohen ND, 2015, J VET INTERN MED, V29, P932, DOI 10.1111/jvim.12595
   Cohen ND, 2014, VET CLIN N AM-EQUINE, V30, P609, DOI 10.1016/j.cveq.2014.08.010
   Collins AM, 2016, IMMUNOL CELL BIOL, V94, P949, DOI 10.1038/icb.2016.65
   Cywes-Bentley C, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007160
   Edelson BT, 2001, IMMUNITY, V14, P503, DOI 10.1016/S1074-7613(01)00139-X
   Giguere S, 1999, INFECT IMMUN, V67, P3548
   Giguere S, 2011, J VET INTERN MED, V25, P1221, DOI 10.1111/j.1939-1676.2011.00804.x
   Giguere S, 2011, J VET INTERN MED, V25, P1209, DOI 10.1111/j.1939-1676.2011.00835.x
   Giguere S, 1999, INFECT IMMUN, V67, P5041
   Gonzalez-Iglesias P, 2014, VET MICROBIOL, V172, P256, DOI 10.1016/j.vetmic.2014.03.026
   Goodman LB, 2006, VACCINE, V24, P3636, DOI 10.1016/j.vaccine.2006.01.062
   Hamasur B, 2004, CLIN EXP IMMUNOL, V138, P30, DOI 10.1111/j.1365-2249.2004.02593.x
   HIETALA SK, 1987, VET MICROBIOL, V14, P307, DOI 10.1016/0378-1135(87)90118-0
   Hooper-McGrevy KE, 2003, CLIN DIAGN LAB IMMUN, V10, P345, DOI 10.1128/CDLI.10.3.345-351.2003
   JOHANSSON PJH, 1985, J VIROL, V56, P489, DOI 10.1128/JVI.56.2.489-494.1985
   Lewis MJ, 2008, MOL IMMUNOL, V45, P818, DOI 10.1016/j.molimm.2007.06.158
   Lopez AM, 2002, CLIN DIAGN LAB IMMUN, V9, P1270, DOI 10.1128/CDLI.9.6.1270-1276.2002
   Lu LL, 2016, CELL, V167, P433, DOI 10.1016/j.cell.2016.08.072
   MARTENS RJ, 1989, EQUINE VET J, V21, P249, DOI 10.1111/j.2042-3306.1989.tb02161.x
   McClelland EE, 2010, J CLIN INVEST, V120, P1355, DOI 10.1172/JCI38322
   McGuire TC, P 3 INT C EQ INF DIS, P364
   Nelson KM, 1998, VACCINE, V16, P1306, DOI 10.1016/S0264-410X(98)00009-7
   Netski D, 2002, INFECT IMMUN, V70, P2812, DOI 10.1128/IAI.70.6.2812-2819.2002
   NORDMANN P, 1992, ANTIMICROB AGENTS CH, V36, P1244, DOI 10.1128/AAC.36.6.1244
   NORDMANN P, 1992, INFECT IMMUN, V60, P2748, DOI 10.1128/IAI.60.7.2748-2752.1992
   Passwell JH, 2010, VACCINE, V28, P2231, DOI 10.1016/j.vaccine.2009.12.050
   Phumoonna T, 2008, VACCINE, V26, P2457, DOI 10.1016/j.vaccine.2008.03.015
   Power CA, 1998, INFECT IMMUN, V66, P5743, DOI 10.1128/IAI.66.12.5743-5750.1998
   Prados-Rosales R, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006250
   Ross TL, 1996, CAN J VET RES, V60, P186
   Sanz MG, 2016, EQUINE VET J, V48, P103, DOI 10.1111/evj.12363
   Shapiro S, 2002, INFECT IMMUN, V70, P2598, DOI 10.1128/IAI.70.5.2598-2604.2002
   SIDAK Z, 1967, J AM STAT ASSOC, V62, P626, DOI 10.2307/2283989
   Siggins MK, 2014, EUR J IMMUNOL, V44, P1093, DOI 10.1002/eji.201343529
   Sugiura T, 2000, J CHROMATOGR B, V742, P327, DOI 10.1016/S0378-4347(00)00177-8
   SURCEL HM, 1994, IMMUNOLOGY, V81, P171
   Takai S, 1999, FEMS IMMUNOL MED MIC, V24, P1
   Teitelbaum R, 1998, P NATL ACAD SCI USA, V95, P15688, DOI 10.1073/pnas.95.26.15688
   Vidarsson G, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00520
   Yuan RR, 1997, P NATL ACAD SCI USA, V94, P2483, DOI 10.1073/pnas.94.6.2483
   Zimmermann N, 2016, EMBO MOL MED, V8, P1325, DOI 10.15252/emmm.201606330
NR 49
TC 1
Z9 1
U1 3
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 21
PY 2019
VL 37
IS 9
BP 1142
EP 1150
DI 10.1016/j.vaccine.2019.01.028
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HM9YN
UT WOS:000459841000003
PM 30691984
DA 2020-05-12
ER

PT J
AU Addison, M
   Lazzaro, T
   Crawford, N
AF Addison, Mel
   Lazzaro, Teresa
   Crawford, Nigel
TI Injection site abscess (ISA) following an infant vaccine
SO VACCINE
LA English
DT Article
DE Vaccine; Safety; Abscess; Injection site
C1 [Addison, Mel; Lazzaro, Teresa; Crawford, Nigel] Royal Childrenss Hosp, Melbourne, Vic, Australia.
   [Addison, Mel; Crawford, Nigel] Murdoch Childrens Res Inst, SAEFVIC, Melbourne, Vic, Australia.
   [Crawford, Nigel] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia.
RP Addison, M (reprint author), Royal Childrenss Hosp, Melbourne, Vic, Australia.; Addison, M (reprint author), Murdoch Childrens Res Inst, SAEFVIC, Melbourne, Vic, Australia.
EM mel.addison@rch.org.au
OI CRAWFORD, NIGEL/0000-0003-1851-5080
CR Kohl KS, 2007, VACCINE, V25, P5821, DOI 10.1016/j.vaccine.2007.04.057
   World Heath Orgnisation (WHO), 2010, WHO BEST PRACT INJ R
NR 2
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 21
PY 2019
VL 37
IS 9
BP 1151
EP 1152
DI 10.1016/j.vaccine.2019.01.025
PG 2
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HM9YN
UT WOS:000459841000004
PM 30704820
DA 2020-05-12
ER

PT J
AU Smithson, MW
   Basinki, AJ
   Nuismer, SL
   Bull, JJ
AF Smithson, Mark W.
   Basinki, Andrew J.
   Nuismer, Scott L.
   Bull, James J.
TI Transmissible vaccines whose dissemination rates vary through time, with
   applications to wildlife
SO VACCINE
LA English
DT Article
DE Infectious vaccine; Gene therapy; Population dynamics
ID VECTORED IMMUNOCONTRACEPTION; MURINE CYTOMEGALOVIRUS; STRAINS; TRIAL
AB Transmission is a potential property of live viral vaccines that remains largely unexploited but may lie within the realm of many engineering designs. While likely unacceptable for vaccines of humans, transmission may be highly desirable for vaccines of wildlife, both to protect natural populations and also to limit zoonotic transmissions into humans. Defying intuition, transmission alone does not guarantee that a vaccine will perform well: the benefit of transmission over no transmission depends on and increases with the basic reproductive number of the vaccine, R-0. The R-0 of an infectious agent in a homogeneous population is typically considered to be a fixed number, but some evidence suggests that dissemination of transmissible vaccines may change through time. One obvious possibility is that transmission will be greater from hosts directly vaccinated than from hosts who acquire the vaccine passively, but other types of change might also accrue. Whenever transmission changes over time, the R-0 estimated from directly vaccinated hosts will not reflect the vaccine's long term impact. As there is no theory on the consequences of changing transmission rates for a vaccine, we derive conditions for a transmissible vaccine with varying transmission rates to protect a population from pathogen invasion. Being the first in the transmission chain, the R-0 from directly vaccinated hosts has a larger effect than those from later steps in the chain. This mathematical property reveals that a transmissible vaccine with low long term transmission may nonetheless realize a big impact if early transmission is high. Furthermore, there may be ways to artificially elevate early transmission, thereby achieving high herd immunity from transmission while ensuring that the vaccine will ultimately die out. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Smithson, Mark W.] Washington State Univ, Sch Biol Sci, Pullman, WA 99163 USA.
   [Basinki, Andrew J.; Nuismer, Scott L.] Univ Idaho, Sch Math, Moscow, ID 83843 USA.
   [Nuismer, Scott L.] Univ Idaho, Dept Biol Sci, Moscow, ID 83843 USA.
   [Bull, James J.] Univ Texas Austin, Dept Integrat Biol, Austin, TX 78712 USA.
   [Bull, James J.] Univ Texas Austin, Inst Cellular & Mol Biol, Austin, TX 78712 USA.
   [Bull, James J.] Univ Texas Austin, Ctr Computat Biol & Bioinformat, Austin, TX 78712 USA.
RP Bull, JJ (reprint author), Univ Texas Austin, Dept Integrat Biol, Austin, TX 78712 USA.
EM bull@austin.utexas.edu
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [GM 122079]
FX We thank Spencer Fox for insight about network models. Two anonymous
   reviewers helped us clarify the ms. Some figures were generated in R
   [26]. Supported by NIH GM 122079.
CR Barcena J, 2000, J VIROL, V74, P1114, DOI 10.1128/JVI.74.3.1114-1123.2000
   Barlow ND, 1997, REPROD FERT DEVELOP, V9, P51, DOI 10.1071/R96068
   BARLOW ND, 1994, J APPL ECOL, V31, P454, DOI 10.2307/2404442
   Basinski AJ, 2018, VACCINE, V36, P675, DOI 10.1016/j.vaccine.2017.12.037
   Braunstein LA, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.168701
   Bull JJ, 2018, TRENDS MICROBIOL, V26, P6, DOI 10.1016/j.tim.2017.09.007
   Farroway LN, 2005, EPIDEMIOL INFECT, V133, P701, DOI 10.1017/S0950268805003717
   Fooks AR, 2014, LANCET, V384, P1389, DOI 10.1016/S0140-6736(13)62707-5
   Georgescu MM, 1997, J VIROL, V71, P7758, DOI 10.1128/JVI.71.10.7758-7768.1997
   HILBINK FW, 1987, VET QUART, V9, P215, DOI 10.1080/01652176.1987.9694103
   Hood GM, 2000, J APPL ECOL, V37, P914, DOI 10.1046/j.1365-2664.2000.00544.x
   Keeling M. J., 2008, MODELING INFECT DIS
   KIM KS, 1971, J VIROL, V7, P720, DOI 10.1128/JVI.7.6.720-725.1971
   Lauring AS, 2010, NAT BIOTECHNOL, V28, P573, DOI 10.1038/nbt.1635
   Martinez-Sobrido L, 2016, EXPERT REV VACCINES, V15, P1113, DOI 10.1080/14760584.2016.1182024
   Metzger VT, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002015
   Monath TP, 2000, J VIROL, V74, P1742, DOI 10.1128/JVI.74.4.1742-1751.2000
   Murphy AA, 2016, EXPERT REV VACCINES, V15, P31, DOI 10.1586/14760584.2016.1106942
   Newman M., 2010, NETWORKS INTRO
   Nuismer SL, 2001, P ROY SOC B-BIOL SCI, V268, P1937, DOI 10.1098/rspb.2001.1760
   Pastor-Satorras R, 2015, REV MOD PHYS, V87, P925, DOI 10.1103/RevModPhys.87.925
   R Core Team, 2017, R LANG ENV STAT COMP
   Rupprecht CE, 2004, DEV BIOLOGICALS, V119, P173
   Torres JM, 2001, VACCINE, V19, P4536, DOI 10.1016/S0264-410X(01)00184-0
   TYNDALEBISCOE CH, 1994, REPROD FERT DEVELOP, V6, P281, DOI 10.1071/RD9940281
   Wang YX, 2017, HUM VACC IMMUNOTHER, V13, P153, DOI 10.1080/21645515.2016.1225637
NR 26
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 21
PY 2019
VL 37
IS 9
BP 1153
EP 1159
DI 10.1016/j.vaccine.2019.01.018
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HM9YN
UT WOS:000459841000005
PM 30686635
OA Green Accepted, Other Gold
DA 2020-05-12
ER

PT J
AU Suryadevara, M
   Bonville, CA
   Cibula, DA
   Domachowske, JB
   Suryadevara, AC
AF Suryadevara, Manika
   Bonville, Cynthia A.
   Cibula, Donald A.
   Domachowske, Joseph B.
   Suryadevara, Amar C.
TI Associations between population based voting trends during the 2016 US
   presidential election and adolescent vaccination rates
SO VACCINE
LA English
DT Article
DE HPV vaccine; Adolescent immunizations; Voting patterns
ID HUMAN-PAPILLOMAVIRUS VACCINATION; HPV VACCINE; UNITED-STATES; SOCIAL
   MEDIA; IMMUNIZATION; COVERAGE; RECOMMENDATION; EXPOSURE; POLITICS
AB Background: Politics play a role in the dissemination of public health information, including immunization-related issues. We aim to describe relationships between HPV vaccination rates and state voting patterns during the 2016 US presidential election.
   Methods: We classified each of the 50 states as either "Red" or "Blue," based on whether a higher proportion of the state's casted votes were for the Republican or Democratic nominee during the 2016 US presidential election. State-specific HPV, Tdap, and meningococcal vaccination rates were obtained from the 2016-National Immunization Survey-Teen. State socio-demographic factors and HPV vaccine legislation were obtained from the US Census Bureau and National Conference of State Legislatures. Vaccination rates and socio-demographic variables were compared using independent t-tests. Multiple linear regression compared vaccination rates between "Red" and "Blue" states, adjusting for percentage of both uninsured children and educational attainment.
   Results: Compared to "Blue" states, "Red" states had significantly lower unadjusted HPV vaccine series initiation (56% vs 66%, p < 0.05) and completion (39% vs 50%, p < 0.05) rates; yet had similar rates of Tdap (88% vs 89%, p > 0.05) and meningococcal (79% vs 83%, p > 0.05) vaccinations. After adjusting for potential confounders, the regression-adjusted mean rate for HPV vaccine initiation and completion remained significantly lower for "Red" states compared to "Blue" states (57% vs 65%, p < 0.05, and 41% vs 48%, p < 0.05, respectively).
   Conclusion: HPV vaccination rates are associated with statewide-level voting patterns. Future interventions aimed at improving HPV vaccination rates should consider engaging local and national elected leaders to be proactive in disseminating accurate and authoritative immunization information. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Suryadevara, Manika; Bonville, Cynthia A.; Domachowske, Joseph B.] SUNY Upstate Med Univ, Dept Pediat, 750 East Adams St, Syracuse, NY 13210 USA.
   [Cibula, Donald A.] SUNY Upstate Med Univ, Dept Publ Hlth & Prevent Med, Syracuse, NY 13210 USA.
   [Suryadevara, Amar C.] SUNY Upstate Med Univ, Dept Otolaryngol & Commun Sci, Syracuse, NY 13210 USA.
RP Suryadevara, M (reprint author), SUNY Upstate Med Univ, Dept Pediat, 750 East Adams St, Syracuse, NY 13210 USA.
EM suryadem@upstate.edu
RI Domachowske, Joseph/AAI-1797-2020
CR Abiola SE, 2013, J HEALTH POLIT POLIC, V38, P645, DOI 10.1215/03616878-2208567
   [Anonymous], 2011, CNN TEA PARTY REPUBL
   Averhoff F, 2004, AM J PUBLIC HEALTH, V94, P978, DOI 10.2105/AJPH.94.6.978
   Baumgaertner B, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191728
   Bernstein S, 2016, AM J PUBLIC HEALTH, V106, P1879, DOI 10.2105/AJPH.2016.303381
   Bugenske E, 2012, PEDIATRICS, V129, P1056, DOI 10.1542/peds.2011-2641
   Bynum SA, 2014, J ADOLESCENT HEALTH, V54, P190, DOI 10.1016/j.jadohealth.2013.08.006
   Centers for Disease Control and Prevention (CDC), 2001, MMWR Morb Mortal Wkly Rep, V50, P660
   Clark SJ, 2016, CLIN PEDIATR, V55, P701, DOI 10.1177/0009922815610629
   Daley EM, 2017, PAPILLOMAVIRUS RES, V3, P142, DOI 10.1016/j.pvr.2017.04.004
   Daley MF, 2010, PEDIATRICS, V126, P425, DOI 10.1542/peds.2009-3500
   Dunn AG, 2017, VACCINE, V35, P3033, DOI 10.1016/j.vaccine.2017.04.060
   Dunn AG, 2015, J MED INTERNET RES, V17, DOI 10.2196/jmir.4343
   Dvir-Gvirsman S, 2017, NEW MEDIA SOC, V19, P1072, DOI 10.1177/1461444815625945
   Frimer JA, 2017, J EXP SOC PSYCHOL, V72, P1, DOI 10.1016/j.jesp.2017.04.003
   Gargano LM, 2013, HUM VACC IMMUNOTHER, V9, P2627, DOI 10.4161/hv.25823
   Garland SM, 2018, J INFECT DIS, V218, P95, DOI 10.1093/infdis/jiy133
   Gollust SE, 2016, HUM VACC IMMUNOTHER, V12, P1430, DOI 10.1080/21645515.2015.1109169
   Hersh ED, 2016, P NATL ACAD SCI USA, V113, P11811, DOI 10.1073/pnas.1606609113
   Holman DM, 2014, JAMA PEDIATR, V168, P76, DOI 10.1001/jamapediatrics.2013.2752
   Kash N, 2015, J CLIN MED, V4, P614, DOI 10.3390/jcm4040614
   Mahoney L Meghan, 2015, JMIR Public Health Surveill, V1, pe2, DOI 10.2196/publichealth.3310
   Mesch GS, 2015, HEALTH PROMOT INT, V30, P213, DOI 10.1093/heapro/dau094
   Mulcahy N., BIOETHICISTS OFFER 1
   Perkins RB, 2014, PEDIATRICS, V134, pE666, DOI 10.1542/peds.2014-0442
   Perkins RB, 2013, J HEALTH CARE POOR U, V24, P828, DOI 10.1353/hpu.2013.0080
   Petrosky E, 2015, MMWR-MORBID MORTAL W, V64, P300
   Rand CM, 2011, CLIN PEDIATR, V50, P106, DOI 10.1177/0009922810379907
   Rodriguez JM, 2014, INT J EPIDEMIOL, V43, P818, DOI 10.1093/ije/dyt252
   Shin ME, 2013, PREV MED, V57, P721, DOI 10.1016/j.ypmed.2013.07.026
   Strickland AA, 2011, J HEALTH POLIT POLIC, V36, P935, DOI 10.1215/03616878-1460524
   Thomas TL, 2013, J ADOLESCENT HEALTH, V52, pS60, DOI 10.1016/j.jadohealth.2012.08.011
   Walker TY, 2017, MMWR-MORBID MORTAL W, V66, P874, DOI 10.15585/mmwr.mm6633a2
   Zucker RA, 2015, J HEALTH COMMUN, V20, P783, DOI 10.1080/10810730.2015.1018577
NR 34
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 21
PY 2019
VL 37
IS 9
BP 1160
EP 1167
DI 10.1016/j.vaccine.2019.01.036
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HM9YN
UT WOS:000459841000006
PM 30691983
DA 2020-05-12
ER

PT J
AU Quinn, SC
   Jamison, AM
   An, J
   Hancock, GR
   Freimuth, VS
AF Quinn, Sandra Crouse
   Jamison, Amelia M.
   An, Ji
   Hancock, Gregory R.
   Freimuth, Vicki S.
TI Measuring vaccine hesitancy, confidence, trust and flu vaccine uptake:
   Results of a national survey of White and African American adults
SO VACCINE
LA English
DT Article
DE Vaccine hesitancy; Vaccine confidence; Trust; Influenza vaccine; Adults;
   US
ID HEALTH-CARE WORKERS; GENERAL-PRACTITIONERS; QUALITATIVE-ANALYSIS;
   PARENTS; ATTITUDES
AB Introduction: Vaccine hesitancy (VH) has emerged as a factor in vaccine delay and refusal yet the measurement of the constructs within vaccine hesitancy remains a challenge. Outstanding questions include; should VH be measured as an attitude or a behavior? What is the role of key constructs including confidence, complacency, and convenience? What is the role of trust? Should measures be general or vaccine specific? Furthermore, much of the research has centered on parental acceptance of vaccines for their children.
   Methods: In March of 2015, we contracted with the GfK Group to conduct a nationally representative survey with 819 African American and 838 White, US born adults. Measures include general vaccine hesitancy and confidence, trust, and influenza vaccine specific measures of hesitancy, confidence and trust.
   Results: Factor analysis yielded a bi-factor structure for both general vaccine hesitancy and flu vaccine specific hesitancy. Greater hesitancy, both in general and specific to the flu vaccine, was associated with lower vaccine uptake. In the flu vaccine specific model, greater confidence was associated with higher vaccine uptake. Trust remained distinct from vaccine confidence in both the general and flu vaccine specific models.
   Conclusions: Clearly, there is value in the utilization of general vaccine hesitancy and confidence measures, as well as vaccine specific measures. Trust continues to provide additional insights apart of vaccine confidence and remains an important factor for inclusion in future research. Our set of measures can be tested and validated with other populations and applied to other vaccines for adults and children. (C) 2019 Published by Elsevier Ltd.
C1 [Quinn, Sandra Crouse] Univ Maryland, Dept Family Sci, College Pk, MD 20742 USA.
   [Quinn, Sandra Crouse; Jamison, Amelia M.] Univ Maryland, Ctr Hlth Equ, College Pk, MD 20742 USA.
   [An, Ji; Hancock, Gregory R.] Univ Maryland, Dept Human Dev & Quantitat Methods, College Pk, MD 20742 USA.
   [Freimuth, Vicki S.] Univ Georgia, Ctr Hlth & Risk Commun, Athens, GA 30602 USA.
RP Quinn, SC (reprint author), Univ Maryland, 1142L Sch Publ Hlth Bldg,4200 Valley Dr, College Pk, MD 20742 USA.
EM scquinn@umd.edu
FU Research Center of Excellence in Race, Ethnicity and Health Disparities
   Research [NIH-NIMHD: P20MD006737]
FX This research was supported by the Research Center of Excellence in
   Race, Ethnicity and Health Disparities Research (NIH-NIMHD: P20MD006737:
   PIs, Quinn and Thomas). The research was presented in this paper is that
   of the authors and does not reflect the policy of the NIH. (UMD IRB
   APPROVAL: 367080-16).
CR Bedford H, 2018, VACCINE, V36, P6556, DOI 10.1016/j.vaccine.2017.08.004
   Benin AL, 2006, PEDIATRICS, V117, P1532, DOI 10.1542/peds.2005-1728
   Cooper LZ, 2008, PEDIATRICS, V122, P149, DOI 10.1542/peds.2008-0987
   Dube E, 2016, QUAL HEALTH RES, V26, P411, DOI 10.1177/1049732315573207
   Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657
   Enkel SL, 2018, VACCINE, V36, P6459, DOI 10.1016/j.vaccine.2017.09.088
   Gowda C, 2013, HUM VACC IMMUNOTHER, V9, P430, DOI 10.4161/hv.22065
   Greenberg Joshua, 2017, PLoS Curr, V9, DOI 10.1371/currents.outbreaks.0561a011117a1d1f9596e24949e8690b
   Gust D, 2005, AM J HEALTH BEHAV, V29, P81, DOI 10.5993/AJHB.29.1.7
   Karafillakis E, 2016, VACCINE, V34, P5013, DOI 10.1016/j.vaccine.2016.08.029
   Keane MT, 2005, VACCINE, V23, P2486, DOI 10.1016/j.vaccine.2004.10.026
   Killian M, 2016, EUR J CLIN MICROBIOL, V35, P1837, DOI 10.1007/s10096-016-2735-4
   Larson HJ, 2019, HUM VACC IMMUNOTHER, V15, P625, DOI 10.1080/21645515.2018.1522468
   Larson Heidi J, 2015, PLoS Curr, V7, DOI 10.1371/currents.outbreaks.ce0f6177bc97332602a8e3fe7d7f7cc4
   Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081
   Larson HJ, 2013, LANCET INFECT DIS, V13, P606, DOI 10.1016/S1473-3099(13)70108-7
   MacDonald N, 2017, VACCINE
   MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036
   Mendel-Van Alstyne JA, 2018, VACCINE, V36, P6464, DOI 10.1016/j.vaccine.2017.09.007
   Moradi P, 2016, APPL SOFT COMPUT, V43, P117, DOI [10.1016/j.asoc.2016.01.044, 10.1177/0886260516669164]
   NICHTER M, 1995, SOC SCI MED, V41, P617, DOI 10.1016/0277-9536(95)00034-5
   Opel DJ, 2011, VACCINE, V29, P6598, DOI 10.1016/j.vaccine.2011.06.115
   Opel DJ, 2011, HUM VACCINES, V7, P419, DOI 10.4161/hv.7.4.14120
   Orr C, 2017, CLIN PEDIATR, V56, P784, DOI 10.1177/0009922816687328
   Paterson P, 2016, VACCINE, V34, P6700, DOI 10.1016/j.vaccine.2016.10.042
   Peretti-Watel P, 2015, PLOS CURR, V7
   Quinn Sandra, 2016, PLoS Curr, V8, DOI 10.1371/currents.outbreaks.3e4a5ea39d8620494e2a2c874a3c4201
   Quinn SC, 2017, VACCINE, V35, P1167, DOI 10.1016/j.vaccine.2016.12.046
   Ramanadhan S, 2015, VACCINES, V3, P556, DOI 10.3390/vaccines3030556
   Saada A, 2015, CLIN PEDIATR, V54, P236, DOI 10.1177/0009922814548838
   Sadaf A, 2013, VACCINE, V31, P4293, DOI 10.1016/j.vaccine.2013.07.013
   Shapiro GK, 2018, VACCINE, V36, P660, DOI 10.1016/j.vaccine.2017.12.043
   Streefland P, 1999, SOC SCI MED, V49, P1705, DOI 10.1016/S0277-9536(99)00239-7
   Suryadevara M, 2015, VACCINE, V33, P6629, DOI 10.1016/j.vaccine.2015.10.096
   Vallee-Tourangeau G, 2018, VACCINE, V36, P6540, DOI 10.1016/j.vaccine.2017.08.025
   Velan B, 2016, ISR J HEALTH POLICY, V5, DOI 10.1186/s13584-016-0071-x
   Verger P, 2015, EBIOMEDICINE, V2, P891, DOI 10.1016/j.ebiom.2015.06.018
   Wang E, 2015, VACCINE, V33, P6703, DOI 10.1016/j.vaccine.2015.10.090
   Williams SE, 2016, CLIN PEDIATR, V55, P537, DOI 10.1177/0009922815615823
   Wilson RJ, 2015, VACCINE, V33, P6420, DOI 10.1016/j.vaccine.2015.08.046
   World Health Organization, 2017, ADDR VACC HES SEC AD
NR 41
TC 5
Z9 5
U1 2
U2 9
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 21
PY 2019
VL 37
IS 9
BP 1168
EP 1173
DI 10.1016/j.vaccine.2019.01.033
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HM9YN
UT WOS:000459841000007
PM 30709722
DA 2020-05-12
ER

PT J
AU Padmanabha, N
   Kini, JR
   Alwani, AA
   Sardesai, A
AF Padmanabha, Nandan
   Kini, Jyoti Ramnath
   Alwani, Anam Anil
   Sardesai, Aashlesha
TI Acceptability of human papillomavirus vaccination among medical students
   in Mangalore, India
SO VACCINE
LA English
DT Article
DE Undergraduate Medical Education; Cervical neoplasms; Vaccination;
   Medical students
ID HPV; KNOWLEDGE; AWARENESS
AB Background: The highly prevalent cervical cancer can be prevented through a vaccine. However, the uptake of the Human Papillomavirus vaccine in the general population continues to be low. Medical students, as healthcare providers in the future, would be influential in affecting the community's views and thereby the uptake of the Human Papillomavirus vaccine. Hence, there is a need to promote the right attitude for prompt implementation of this vaccine among medical students. None of the studies in India have so far documented the proportion of vaccinated population among medical students or an intervention strategy to eliminate the barriers to Human Papillomavirus vaccine.
   Aims and objectives: To determine the proportion of vaccinated medical students and the barriers against HPV vaccination among non-vaccinated participants; and to test the efficacy of an information session on the barrier.
   Methodology: Data on barriers against the Human Papillomavirus vaccination was collected through a questionnaire-based survey. The barriers were reassessed after an intervention in the form of training session using audio-visual aids.
   Results: Out of the 263 participants, 46 (18%) had never heard of the vaccine against Human Papillomavirus and only 54 (21%) were vaccinated. Participants thought it was not essential to get vaccinated as they were not sexually active (28%). Lack of information about the vaccine (28%), its access (24%), and high cost (27%) were the other barriers. Following the information session, 59% of the previously non-vaccinated participants responded that they would get vaccinated while 34% were considering getting vaccinated. The most common reason for rejection of the vaccine post- intervention was high cost of the vaccine.
   Conclusion: Vaccine uptake is very low among medical students and amenable barriers exist against the vaccine. Urgent intervention in the form of information session is recommended targeted at the medical students, to eliminate the barriers of Human Papillomavirus vaccination. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Padmanabha, Nandan; Alwani, Anam Anil; Sardesai, Aashlesha] Manipal Acad Higher Educ, Kasturba Med Coll, Mangalore, India.
   [Kini, Jyoti Ramnath] Manipal Acad Higher Educ, Kasturba Med Coll, Dept Pathol, Mangalore, India.
RP Kini, JR (reprint author), Kasturba Med Coll & Hosp, Dept Pathol, Mangalore 575001, Karnataka, India.
EM kinijyoti@gmail.com
OI Padmanabha, Nandan/0000-0002-5836-3387
CR Allen JD, 2010, VACCINE, V28, P4027, DOI 10.1016/j.vaccine.2010.03.063
   Brewer NT, 2007, PREV MED, V45, P107, DOI 10.1016/j.ypmed.2007.05.013
   Bruni L, 2016, LANCET GLOB HEALTH, V4, pE453, DOI 10.1016/S2214-109X(16)30099-7
   Chesson HW, 2014, SEX TRANSM DIS, V41, P660, DOI 10.1097/OLQ.0000000000000193
   Cohen SA, 2007, GUTTMACHER POL REV, V10, P17
   Cooper SC, 2016, HEALTH EDUC J, V75, P610, DOI 10.1177/0017896915608884
   Dikshit R, 2012, LANCET, V379, P1807, DOI 10.1016/S0140-6736(12)60358-4
   Doshi Dolar, 2015, Asian Pac J Cancer Prev, V16, P5415
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Fernandez ME, 2010, ANNU REV PUBL HEALTH, V31, P235, DOI 10.1146/annurev.publhealth.012809.103609
   Gallagher KE, 2018, VACCINE, V36, P4761, DOI 10.1016/j.vaccine.2018.02.003
   Gonik B, 2000, OBSTET GYNECOL, V96, P81, DOI 10.1016/S0029-7844(00)00860-7
   Hwang LL, 2013, J CANCER EDUC, V28, P247, DOI 10.1007/s13187-013-0461-5
   Kavita RK, 2013, J OBSTET GYN INDIA, V63, P399, DOI 10.1007/s13224-013-0413-3
   Larson HJ, 2010, LANCET, V376, P572, DOI 10.1016/S0140-6736(10)60881-1
   Madhivanan P, 2014, PREV MED, V64, P69, DOI 10.1016/j.ypmed.2014.04.002
   Marlow LAV, 2013, VACCINE, V31, P763, DOI 10.1016/j.vaccine.2012.11.083
   Mehta Sumita, 2013, Indian J Community Med, V38, P92, DOI 10.4103/0970-0218.112438
   Muhammad H, 2015, BIOMED RES-INDIA, V26, P65
   Pandey D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040619
   Singhal T, 2008, INDIAN PEDIATR, V45, P635
   Trim K, 2012, OBSTET GYNECOL INT, V2012, DOI 10.1155/2012/921236
   Verma R, 2013, HUM VACC IMMUNOTHER, V9, P97, DOI 10.4161/hv.22063
NR 23
TC 0
Z9 0
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 21
PY 2019
VL 37
IS 9
BP 1174
EP 1181
DI 10.1016/j.vaccine.2019.01.032
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HM9YN
UT WOS:000459841000008
PM 30709724
DA 2020-05-12
ER

PT J
AU Wu, WD
   Liu, DW
   Nuorti, JP
   Li, KL
   Xu, DS
   Ye, JK
   Zheng, JS
   Cao, L
   Wang, HQ
AF Wu, Wendi
   Liu, Dawei
   Nuorti, J. Pekka
   Li, Keli
   Xu, Disha
   Ye, Jiakai
   Zheng, Jingshan
   Cao, Lei
   Wang, Huaqing
TI Deaths reported to national surveillance for adverse events following
   immunization in China, 2010-2015
SO VACCINE
LA English
DT Article
DE Adverse events following immunization; Deaths
ID VACCINATION; GUIDELINES; COLLECTION; SYSTEM; RATES
AB Background: The national Adverse Events Following Immunization (AEFI) surveillance system in China (CNAEFIS) has collected AEFI reports -including deaths following all vaccines used in China since 2008. Aims: To review reports of AEFI-associated death cases from 2010 to 2015 to assess potential vaccine safety issues.
   Methods: Descriptive analysis of epidemiologic characteristic of AEFI-associated death cases and standard causality assessment for reported causes of deaths. To estimate the risk of death after vaccination, we used population data, administered doses and live births to calculate denominators.
   Results: During 2010-2015, 753 deaths were reported to CNAEFIS from mainland China. Highest numbers were reported in 2013 and 2014 when reporting peak of AEFI-associated deaths occurred after media reports concerning "death following Hepatitis B vaccination" in China. About 95% of deaths were in children <5 years of age and males accounted for 60%. Most common vaccines associated with reports of fatal AEFIs were vaccines in national immunization schedule. In causality assessment, 120 (16.0%) deaths were classified as vaccine-associated reactions such as anaphylactic reactions and disseminated BCG infections; 594 (78.9%) deaths were identified as coincidental events. The main causes of death were asphyxia, and Sudden Infant Death Syndrome. The overall estimated AEFI-associated death rates were: 0.26 per million vaccination doses administered and 0.09 per million population. The neonatal AEFI death rate was 0.77 per million live births.
   Conclusions: These data provide reassuring information about the small risk of death following immunization. They also illustrate sensitivity of passive reporting to public information and that peaks in serious AEFI reports should be interpreted with caution. Continuous monitoring and scientific causality assessment for serious AEFIs, including AEFI-associated deaths is imperative to ensure public confidence in the immunization program. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Wu, Wendi; Liu, Dawei; Li, Keli; Xu, Disha; Ye, Jiakai; Zheng, Jingshan; Cao, Lei; Wang, Huaqing] Chinese Ctr Dis Control & Prevent, Natl Immunizat Programme, 27 Nanwei Rd, Beijing 100050, Peoples R China.
   [Wu, Wendi; Nuorti, J. Pekka] Univ Tampere, Fac Social Sci, Hlth Sci Unit, Tampere, Finland.
   [Nuorti, J. Pekka] Natl Inst Hlth & Welf THL, Dept Hlth Secur, Helsinki, Finland.
RP Li, KL; Wang, HQ (reprint author), Chinese Ctr Dis Control & Prevent, Natl Immunizat Programme, 27 Nanwei Rd, Beijing 100050, Peoples R China.
EM Likl@chinacdc.cn; Wanghq@chinacdc.cn
OI WU, Wendi/0000-0002-0327-6497
FU National Immunization Programme, Chinese Center for Diseases Control and
   Prevention, China; Health Sciences unit, Faculty of Social Sciences,
   University of Tampere, Finland
FX This work was sponsored by National Immunization Programme, Chinese
   Center for Diseases Control and Prevention, China. Wendi Wu was
   supported in part by Health Sciences unit, Faculty of Social Sciences,
   University of Tampere, Finland.
CR China Ministry of Health, 2014, BRIEF MED TEXT REC P
   China Ministry of Health, 2010, NAT GUID SURV ADV EV
   Chinese Center for Disease Control and Prevention, 2013, DEATH SURV DAT REP N
   Gold MS, 2016, VACCINE, V34, P212, DOI 10.1016/j.vaccine.2015.11.018
   Guo BA, 2013, VACCINE, V31, P603, DOI 10.1016/j.vaccine.2012.11.051
   Hauben M, 2003, DRUG SAFETY, V26, P159, DOI 10.2165/00002018-200326030-00003
   Hendriks J, 2010, HUM VACCINES, V6, P602, DOI 10.4161/hv.6.7.11933
   Larson HJ, MEASURING VACCINE CO, DOI [10.1016/s1473-3099(13)70108-7, DOI 10.1016/S1473-3099(13)70108-7]
   Li MN, 2014, HUM VACC IMMUNOTHER, V10, P2992, DOI 10.4161/21645515.2014.971643
   Liang XF, 2011, NEW ENGL J MED, V364, P638, DOI 10.1056/NEJMoa1008553
   Liu D-W, 2007, CHIN J VACCINES IMMU, V13, P505
   Liu DW, 2015, VACCINE, V33, P4041, DOI 10.1016/j.vaccine.2015.04.060
   McCarthy NL, 2013, AM J PREV MED, V45, P91, DOI 10.1016/j.amepre.2013.02.020
   Miller ER, 2015, VACCINE, V33, P3288, DOI 10.1016/j.vaccine.2015.05.023
   Moro PL, 2015, CLIN INFECT DIS, V61, P980, DOI 10.1093/cid/civ423
   Ren X, 2016, MATERN CHILD HLTH CA, V31, P1442
   Sejvar JJ, 2007, VACCINE, V25, P5771, DOI 10.1016/j.vaccine.2007.04.060
   Singleton JA, 1999, VACCINE, V17, P2908, DOI 10.1016/S0264-410X(99)00132-2
   Tapiainen T, 2007, VACCINE, V25, P5793, DOI 10.1016/j.vaccine.2007.04.058
   World Health Organization, 2018, CAUS ASS ADV EV FOLL
   Wu WD, 2013, CHIN J VAC IMMUN, V19, P97
   Wu WD, 2014, CHIN J VACCIN IMMUN, V20, P1
   Wu WD, 2012, CHIN J VAC IMMUN, V18, P402
   Yan J, 2015, CHIN J VACC IMMUN, V21, P147
   YE J K, 2015, CHIN J VAC IMMUN, V21, P121
   YE J K, 2016, CHIN J VAC IMMUN, V22, P125
   Ye J K, 2017, CHIN J VAC IMMUN, V23, P481
   Ye JL, 2012, CHIN WOMEN CHILD HLT, V392, P66
   Yu WZ, 2016, INT J EPIDEMIOL, V45, P441, DOI 10.1093/ije/dyv349
   Yue CY, 2012, CHINESE J VACCINE IM, V18, P246
   Zhang X, 2011, J CAPIT MED U, V32, P704
   Zheng JS, 2010, VACCINE, V28, pA84, DOI 10.1016/j.vaccine.2010.02.039
NR 32
TC 1
Z9 1
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 21
PY 2019
VL 37
IS 9
BP 1182
EP 1187
DI 10.1016/j.vaccine.2019.01.009
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HM9YN
UT WOS:000459841000009
PM 30709723
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Cohen, CC
   Badger, GJ
   McLean, KC
AF Cohen, Courtney C.
   Badger, Gary J.
   McLean, Kelley C.
TI Provider group type and Tdap coverage in pregnancy
SO VACCINE
LA English
DT Article
DE Tdap immunization; Pregnancy; Provider characteristics
ID IMMUNIZATION INFORMATION-SYSTEMS; PERTUSSIS-VACCINE TDAP; ACELLULAR
   PERTUSSIS; INFLUENZA VACCINATION; UNITED-STATES; MATERNAL TDAP; TETANUS;
   DIPHTHERIA; WOMEN; BARRIERS
AB Introduction: The Advisory Committee on Immunization Practices (ACIP) has focused on maternal Tdap immunization as an important means to protect neonates from pertussis infections. There is little published data on provider and/or clinic characteristics as predictors of maternal Tdap uptake. This study examined differences in maternal Tdap coverage in women delivering at a single academic institution, but cared for prenatally in different clinical settings, in 2013, 2014, and 2015. Additionally, the accuracy and utilization of Vermont's immunization information system (IIS) was assessed.
   Methods: This was a retrospective, multiple time-point cross-sectional analysis of annual maternal Tdap coverage in women delivering at a single academic institution in the 3 years following a fundamental change in national maternal Tdap vaccination guidelines. Tdap administration was examined across different obstetric groups using chart review and data from the state's IIS.
   Results: All obstetric care groups except the resident-staffed clinic significantly increased maternal Tdap coverage in 2014, compared to 2013 coverage, with no further increase in 2015. In contrast, there was no increase in maternal Tdap coverage in 2014 in the resident-staffed clinics, but then a statistically significant increase in 2015. Overall Tdap coverage in 2014 was 80.4%, with variation in Tdap coverage between clinics types. In the subset of women who were cared for by the University-based groups, there was significant variation in Tdap coverage between clinics, despite racial homogeneity, which persisted after adjustment for maternal age and insurance type. The state's IIS was found to be highly accurate, using individual chart review as the "gold standard."
   Discussion: While we demonstrated high maternal Tdap coverage in women delivering at our institution, differences in clinic type and provider training appeared to impact immunization rates, as well as how quickly evolving national recommendations were adopted. Additionally, the fidelity of the state's IIS data was verified. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Cohen, Courtney C.; McLean, Kelley C.] Univ Vermont, Dept Obstet Gynecol & Reprod Sci, Larner Coll Med, Burlington, VT 05401 USA.
   [Badger, Gary J.] Univ Vermont, Dept Med Biostat, Larner Coll Med, Burlington, VT 05401 USA.
   [Cohen, Courtney C.] Biltmore Ob GYN, 24 Med Pk Dr, Asheville, NC USA.
RP McLean, KC (reprint author), Univ Vermont, Med Ctr, Dept Ob GYN, Womens, 111 Colchester Ave,Smith 4, Burlington, VT 05401 USA.
EM kelley.mclean@uvmhealth.org
FU Vermont Agency of Human Services, Department of Health, Vermont
   Statewide Public and Private Partnership to Improve Maternal and Child
   Health [03420-6987S]
FX Grant number: 03420-6987S, Vermont Agency of Human Services, Department
   of Health, Vermont Statewide Public and Private Partnership to Improve
   Maternal and Child Health.
CR Becker-Dreps S, 2018, AM J PREV MED
   Bok K, 2017, PUBLIC HEALTH REP, V132, P271, DOI 10.1177/0033354917698118
   Butler AM, 2017, OBSTET GYNECOL, V129, P629, DOI 10.1097/AOG.0000000000001927
   Cardemil C, 2013, MMWR-MORBID MORTAL W, V62, P1005
   CDC, 2013, MORBIDITY MORTALITY
   CDC, 2017, AD IMM SCHED
   CDC, CLIN COMPL
   Dempsey AF, 2015, VACCINE, V33, pD106, DOI 10.1016/j.vaccine.2015.09.032
   Goldfarb IT, 2014, AM J OBSTET GYNECOL, V211, DOI 10.1016/j.ajog.2014.05.029
   Griffin JB, 2018, VACCINE, V36, P5173, DOI 10.1016/j.vaccine.2018.07.011
   Healy CM, 2015, VACCINE, V33, P4983, DOI 10.1016/j.vaccine.2015.07.018
   Kharbanda EO, 2014, JAMA-J AM MED ASSOC, V312, P1897, DOI 10.1001/jama.2014.14825
   Kharbanda EO, 2016, VACCINE, V34, P968, DOI 10.1016/j.vaccine.2015.12.046
   Koepke R, 2017, VACCINE, V35, P2298, DOI 10.1016/j.vaccine.2017.03.024
   Koepke R, 2015, MMWR-MORBID MORTAL W, V64, P746
   Koepke R, 2014, J INFECT DIS, V210, P942, DOI 10.1093/infdis/jiu322
   Koerner J, 2018, ANN PHARMACOTHER, V52, P655, DOI 10.1177/1060028018755454
   Kriss JL, 2017, VACCINE, V35, P1551, DOI 10.1016/j.vaccine.2017.01.037
   La EM, 2018, HUM VACC IMMUNOTHER, V14, P430, DOI 10.1080/21645515.2017.1403697
   Locht C, 2012, FEMS IMMUNOL MED MIC, V66, P121, DOI 10.1111/j.1574-695X.2012.00988.x
   Lutz CS, 2018, VACCINE, V36, P7445, DOI 10.1016/j.vaccine.2018.10.046
   Martin DW, 2015, J PUBLIC HEALTH MAN, V21, P296, DOI 10.1097/PHH.0000000000000040
   Miller BL, 2011, VACCINE, V29, P3850, DOI 10.1016/j.vaccine.2011.03.058
   Miller RM, 2015, J AM PHARM ASSOC, V55, P104, DOI 10.1331/JAPhA.2014.15503
   Morgan JL, 2015, OBSTET GYNECOL, V125, P1433, DOI 10.1097/AOG.0000000000000862
   Sevin AM, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3107-9
   Sukumaran L, 2015, OBSTET GYNECOL, V126, P1069, DOI 10.1097/AOG.0000000000001066
   Sukumaran L, 2015, JAMA-J AM MED ASSOC, V314, P1581, DOI 10.1001/jama.2015.12790
   Ventola C Lee, 2016, P T, V41, P492
   Yeung MPS, 2016, J PUBLIC HEALTH-UK, V38, P746, DOI 10.1093/pubmed/fdv194
NR 30
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 21
PY 2019
VL 37
IS 9
BP 1188
EP 1193
DI 10.1016/j.vaccine.2019.01.001
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HM9YN
UT WOS:000459841000010
PM 30665776
DA 2020-05-12
ER

PT J
AU Shen, AK
   Warnock, R
   Selna, W
   MaCurdy, TE
   Chu, S
   Kelman, JA
AF Shen, Angela K.
   Warnock, Rob
   Selna, Weston
   MaCurdy, Thomas E.
   Chu, Steve
   Kelman, Jeffrey A.
TI Vaccination among Medicare-fee-for service beneficiaries:
   Characteristics and predictors of vaccine receipt, 2014-2017
SO VACCINE
LA English
DT Article
DE Medicare; Vaccine; Immunization; Advisory committee on immunization
   practices; Influenza; Pneumococcal; Herpes zoster
ID ANNUAL WELLNESS VISIT; ADVISORY-COMMITTEE; IMMUNIZATION PRACTICES;
   INFLUENZA VACCINATION; ADULT IMMUNIZATION; UNITED-STATES;
   RECOMMENDATIONS; POPULATIONS
AB Background: Vaccination coverage rates for older adults are low. To better understand utilization of Medicare vaccination benefits we examined a retrospective cohort of more than 26 million Medicare fee-for-service beneficiaries age 65 years and older from 2014 to 2017.
   Methods: Multivariate logistic regression was used to obtain marginal effects (ME) describing the association between patient-level characteristics and the likelihood of vaccination. Vaccines routinely recommended by the Advisory Committee on Immunization Practices-seasonal influenza, 23-valent pneumococcal polysaccharide, 13-valent pneumococcal conjugate, and herpes zoster vaccines-were examined. Variables considered include demographics (e.g., age, sex, race), use of preventive services, frailty indicators, and co-morbidities.
   Results: The mean beneficiary age (SD) for each vaccine examined-seasonal influenza (2016-2017), pneumococcal, and herpes zoster-was 75.0 (7.9) years, 74.5 (7.5) years, 74.5 (7.4) years respectively; and 43.7%, 43.2%, and 39.5% were males respectively. Adjusted marginal effects showed that Black beneficiaries were less likely to receive any of the three vaccines compared to White beneficiaries, while North American Native beneficiaries were most likely to receive a pneumococcal vaccine. Trends by race and sex were similar across all ages. Beneficiaries utilizing preventive services, particularly cardiovascular disease screening (ME of 13.8%, 15.6% and 1.5% for influenza, pneumococcal and herpes zoster vaccine respectively), other vaccinations, and the Medicare Annual Wellness Visit (ME of 9.8%, 15.3% and 0.4% respectively) were predictors of vaccination for all three vaccines. For herpes zoster vaccines, beneficiaries in rural settings (ME of 1.0%) and those who are dual-eligible for Medicare and Medicaid insurance (ME of 1.7%) were more likely to receive herpes zoster vaccine than beneficiaries in urban settings and those not dual-eligible, respectively.
   Conclusion: Medicare beneficiaries of certain demographic with selected comorbid conditions are less likely to receive routinely-recommended vaccines. Strategies and interventions can target such sub-populations of Medicare beneficiaries by optimizing the utilization of preventive services. Published by Elsevier Ltd.
C1 [Shen, Angela K.] US Dept HHS, Natl Vaccine Program Off, Off Assistant Secretary Hlth, Washington, DC 20201 USA.
   [Warnock, Rob; Selna, Weston; MaCurdy, Thomas E.] Acumen LLC, Burlingame, CA USA.
   [Chu, Steve; Kelman, Jeffrey A.] Ctr Medicare & Medicaid Serv, Ctr Medicare, Baltimore, MD USA.
   [Shen, Angela K.] US PHS, Washington, DC 20201 USA.
   [Shen, Angela K.] Drexel Univ, Dornsife Sch Publ Hlth, Philadelphia, PA 19104 USA.
RP Shen, AK (reprint author), 200 Independence Ave SW Room 715H, Washington, DC 20201 USA.
EM aks352@drexel.edu
OI Shen, Angela/0000-0003-3761-0016
CR [Anonymous], 2012, PUBLIC HEALTH REP, V127, P1
   Avalere Health, 2016, AD VACC COV MED D
   Bhatt A, 2014, PUBLIC HEALTH REP, V129, P115
   Black CL, 2017, MMWR-MORBID MORTAL W, V66, P728, DOI 10.15585/mmwr.mm6627a4
   Castrodale L., 2009, Morbidity and Mortality Weekly Report, V58, P1341
   Center for Disease Control and Prevention (CDC), 2018, REC IMM SCHED AD AG
   Centers for Disease Control and Prevention, FLU HEART DIS STROK
   Centers for Disease Control and Prevention, 2017, NAT AM DIAB
   Centers for Medicare and Medicaid Services, YOUR MED COV
   Centers for Medicare & Medicaid Services, MED LEAN NETW ED TOO
   Centers for Medicare & Medicaid Services, MED PRESCR DRUG BE D
   Dooling KL, 2018, MMWR-MORBID MORTAL W, V67, P103, DOI 10.15585/mmwr.mm6703a5
   Ganguli I, 2017, JAMA-J AM MED ASSOC, V317, P2233, DOI 10.1001/jama.2017.4342
   Gellin BG, 2016, AM J PREV MED, V51, P1079, DOI 10.1016/j.amepre.2016.04.014
   Groom AV, 2014, AM J PUBLIC HEALTH, V104, pS460, DOI 10.2105/AJPH.2013.301740
   Indian Health Service, GPRA OTH NAT REP
   Izurieta HS, 2018, CLIN INFECT DIS, V67, P378, DOI 10.1093/cid/ciy100
   Jiang M, 2018, PREV MED, V116, P126, DOI 10.1016/j.ypmed.2018.08.035
   Keehan SP, 2016, HEALTH AFFAIR, V35, P1522, DOI 10.1377/hlthaff.2016.0459
   Lind KE, 2018, MED CARE, V56, P761, DOI 10.1097/MLR.0000000000000962
   Lu PJ, 2018, VACCINE, V36, P890, DOI 10.1016/j.vaccine.2017.12.016
   Lu PJ, 2014, VACCINE, V32, P3198, DOI 10.1016/j.vaccine.2014.04.003
   MaCurdy Bhattacharya J., 2014, CHALLENGES CONTROLLI
   Makaroff LA, 2014, ANN FAM MED, V12, P427, DOI 10.1370/afm.1689
   McCarthy D., 2015, MODELS CARE HIGH NEE
   Nguyen JL, 2016, JAMA CARDIOL, V1, P274, DOI 10.1001/jamacardio.2016.0433
   Ozawa S, 2016, HEALTH AFFAIR, V35, P2124, DOI 10.1377/hlthaff.2016.0462
   Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83
   Shen AK, 2001, PUBLIC HLTH REP
   Shen AK, 2018, VACCINE, V36, P4399, DOI 10.1016/j.vaccine.2018.06.020
   Shen AK, 2017, VACCINE, V35, P7302, DOI 10.1016/j.vaccine.2017.10.105
   Shen AK, 2017, VACCINE, V35, P6938, DOI 10.1016/j.vaccine.2017.10.055
   Shipman SA, 2011, PEDIATRICS, V127, P19, DOI 10.1542/peds.2010-0150
   Tao Guoyu, 2018, Prev Med Rep, V10, P210, DOI 10.1016/j.pmedr.2017.12.014
   U. S. Food and Drug Administration, ZOST
   U. S. Government Accountability Office, 2011, MED MAN FACT INCL D
   Weiser T, 2018, VACCINE, V36, P4952, DOI 10.1016/j.vaccine.2018.04.006
   Williams WW, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6611a1
NR 38
TC 2
Z9 2
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 21
PY 2019
VL 37
IS 9
BP 1194
EP 1201
DI 10.1016/j.vaccine.2019.01.010
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HM9YN
UT WOS:000459841000011
PM 30683507
DA 2020-05-12
ER

PT J
AU Garon, J
   Wuddhika, IV
   Sreenivasan, N
   Wannemuehler, K
   Vutthikol, Y
   Chhorvann, C
   Loharikar, A
AF Garon, Julie
   Wuddhika, In Vong
   Sreenivasan, Nandini
   Wannemuehler, Kathleen
   Vutthikol, Yong
   Chhorvann, Chhea
   Loharikar, Anagha
TI Community-based household assessment of human papillomavirus (HPV)
   vaccination coverage and acceptability - HPV vaccine demonstration
   program, Cambodia-2017
SO VACCINE
LA English
DT Article
DE Human papillomavirus vaccine; Immunization coverage survey; HPV; HPV
   vaccine demonstration program; Cambodia
ID STRATEGIES
AB Background: In 2017, the Cambodia Ministry of Health introduced human papillomavirus (HPV) vaccine through primarily school-based vaccination targeting 9-year-old girls. Vaccination with a two-dose series of HPV vaccine took place in six districts in two provinces as a demonstration program, to better understand HPV vaccine delivery in Cambodia.
   Methods: We conducted a community-based coverage survey using a one-stage sampling design to evaluate dose-specific vaccination coverage among eligible girls (those born in 2007 and residents in the areas targeted by the campaign). The household-level survey also assessed factors associated with vaccine acceptability and communication strategies. Trained data collectors interviewed caregivers and girls using a standard questionnaire; vaccination cards and health facility records were reviewed.
   Results: Of the 7594 households visited in the two provinces, 315 girls were enrolled in the survey (188 in Siem Reap; 127 in Svay Rieng). Documented two-dose HPV vaccination coverage was 84% (95% confidence interval [CI]: 78-88%) overall [85% (95% CI: 78-90%) in Siem Reap; 82% (95% CI: 73-88%) in Svay Rieng.) Almost all girls (>99%) were reported to be enrolled in school and over 90% of respondents reported receipt of vaccine in school. Knowledge of HPV infection and associated diseases was poor among caregivers and girls; however, 58% of caregivers reported "protection from cervical cancer" as the primary reason for the girl receiving vaccine. No serious adverse events after immunization were reported.
   Conclusions: The HPV vaccine demonstration program in Cambodia achieved high two-dose coverage among eligible girls in both provinces targeted for vaccination in 2017, through primarily school-based vaccination. High school enrollment and strong microplanning and coordination were seen throughout the campaign. Cambodia will use lessons learned from this demonstration program to prepare for national introduction of HPV vaccine. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Garon, Julie] CDC Fdn, 600 Peachtree St NE,Suite 1000, Atlanta, GA 30308 USA.
   [Wuddhika, In Vong; Chhorvann, Chhea] Cambodia Natl Inst Publ Hlth, Lot 80289 Samdach Penn Nouth St 289, Phnom Penh, Cambodia.
   [Sreenivasan, Nandini; Wannemuehler, Kathleen; Loharikar, Anagha] Ctr Dis Control & Prevent, Global Immunizat Div, 1600 Clifton Rd NE,MS H24-2, Atlanta, GA 30329 USA.
   [Vutthikol, Yong] Minist Hlth, Cambodia Natl Immunizat Program, 80 Samdach Penn Mouth Blvd 289,Sankat Beoungkak 2, Tuol Kork Dist, Phnom Penh, Cambodia.
RP Garon, J (reprint author), CDC Fdn, 600 Peachtree St NE,Suite 1000, Atlanta, GA 30308 USA.
EM jgaron@cdc.gov
OI Wannemuehler, Kathleen/0000-0001-9535-6277
FU Gavi, the Vaccine Alliance
FX The authors would like to thank the Cambodia Ministry of Health, the
   Cambodia National Institutes of Public Health and WHO Cambodia for their
   cooperation in the study. This project was supported by Gavi, the
   Vaccine Alliance.
CR [Anonymous], 2017, Wkly Epidemiol Rec, V92, P393
   [Anonymous], 2017, WKLY EPIDEMIOL REC, V92, P241, DOI DOI 10.1016/j.vaccine.2017.05.069
   Bartolini RM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048017
   Bonner K, 2018, VACCINE, V36, P191, DOI 10.1016/j.vaccine.2017.11.038
   Bosch FX, 2002, J CLIN PATHOL, V55, P244, DOI 10.1136/jcp.55.4.244
   Bosch-Capblanch X, 2009, TROP MED INT HEALTH, V14, P2, DOI 10.1111/j.1365-3156.2008.02181.x
   Campos NG, 2017, INT J GYNECOL OBSTET, V138, P47, DOI 10.1002/ijgo.12184
   Cover JK, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-629
   Dorji T, 2015, VACCINE, V33, P3726, DOI 10.1016/j.vaccine.2015.05.078
   Ferlay J, 2018, GLOBOCAN 2018 CANC I
   Gallagher KE, 2017, PLOS ONE, V12, DOI [10.1371jjournalpone0177771, DOI 10.1371/JOURNAL.PONE.0177771]
   Hanson CM, 2015, VACCINES-BASEL, V3, P408, DOI 10.3390/vaccines3020408
   International Agency for Research on Cancer, 2012, GLOBOCAN 2012 EST CA
   Islam JY, 2018, BMC WOMENS HEALTH, V18, DOI 10.1186/s12905-018-0510-7
   Kabakama S, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3517-8
   Ladner J, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-370
   LaMontagne DS, 2011, B WORLD HEALTH ORGAN, V89, P821, DOI [10.2471/BLT.11.08986, 10.2471/BLT.11.089862]
   National Institute of Statistics Directorate General for Health ICF International, 2015, CAMB DEM HLTH SURV 2
   Santhanes D, 2018, HUM VACC IMMUNOTHER, V14, P124, DOI 10.1080/21645515.2017.1381811
   Schlecht NF, 2001, JAMA-J AM MED ASSOC, V286, P3106, DOI 10.1001/jama.286.24.3106
   World Health Organization, 2017, DAT STAT GRAPH 2017
   Wuddhika In Vong Chhorvann Chhea, 2017, POSTINTRODUCTION EVA
NR 22
TC 0
Z9 0
U1 1
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 21
PY 2019
VL 37
IS 9
BP 1202
EP 1208
DI 10.1016/j.vaccine.2018.12.052
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HM9YN
UT WOS:000459841000012
PM 30686637
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Nolan, T
   Santolaya, ME
   de Looze, F
   Marshall, H
   Richmond, P
   Henein, S
   Rheault, P
   Heaton, K
   Perrett, KP
   Garfield, H
   Gupta, A
   Ferguson, M
   D'Agostino, D
   Toneatto, D
   O'Ryan, M
AF Nolan, Terry
   Elena Santolaya, Maria
   de Looze, Ferdinandus
   Marshall, Helen
   Richmond, Peter
   Henein, Sam
   Rheault, Paul
   Heaton, Ken
   Perrett, Kirsten P.
   Garfield, Hartley
   Gupta, Anil
   Ferguson, Murdo
   D'Agostino, Diego
   Toneatto, Daniela
   O'Ryan, Miguel
TI Antibody persistence and booster response in adolescents and young
   adults 4 and 7.5 years after immunization with 4CMenB vaccine
SO VACCINE
LA English
DT Article
DE 4-component serogroup B meningococcal vaccine; Adolescents; Persistence;
   Immunogenicity; Kinetics
ID MENINGOCOCCAL ACWY GLYCOCONJUGATE; OBSERVER-BLIND; BACTERICIDAL
   ANTIBODY; B VACCINE; PHASE-III; DISEASE; EPIDEMIOLOGY; INFANTS; IMPACT;
   IMMUNOGENICITY
AB Background: Data on duration of protection against invasive meningococcal disease post-vaccination with the recombinant, 4-component, meningococcal serogroup B vaccine (4CMenB) are limited. We evaluated bactericidal activity persistence in adolescents/young adults up to 7.5 years post-primary vaccination with 4CMenB, and response to a booster dose compared with vaccine-naive controls.
   Methods: This open-label, multicenter study (NCT02446743) enrolled 15-24 year-old-previously vaccinated participants from Canada, Australia (group Primed_4y) 4 years post-priming with 4CMenB (2 doses; 0,1-month schedule), and Chile (Primed_7.5y) 7.5 years after priming with 4CMenB (2 doses; 0,1/0,2/0,6-month schedule) and vaccine-naive participants of similar age (Naive_4y and Naive_7.5y groups). Primed participants received a booster dose; vaccine-naive participants received 2 catch-up doses of 4CMenB, 1 month apart. We evaluated antibody persistence and immune responses using hSBA in terms of geometric mean titers and percentages of participants with hSBA titers >= 4, the kinetics of bactericidal activity post-booster (previously vaccinated) or post-2 doses (vaccine-naive), and safety.
   Results: Antibody levels declined at 4 (Primed_4y) and 7.5 (Primed_7.5y) years post-primary vaccination, but remained higher than in vaccine-naive participants at baseline (<= 44% vs <= 13% [fHbp]; <= 84% vs <= 24% [NadA]; <= 29% vs <= 14% [Porn for all vaccine antigens except NHBA (<= 81% vs <= 79%). One month post-booster and post-second dose, 93-100% of primed and 79-100% of vaccine-naive participants had hSBA titers >= 4 for all antigens. Kinetics of the antibody response were similar across groups with an early robust response observed 7 days post-booster/second dose. No vaccine-related serious adverse event was reported.
   Conclusion: For all antigens except NHBA, a higher proportion of primed participants had hSBA titers >= 4, at 4 and 7.5 years post-vaccination, compared with vaccine-naive participants. A more robust immune response after booster compared to a first dose in vaccine-naive individuals, showed effective priming in an adolescent/young adult population. No safety or new reactogenicity issues were identified. (C) 2019 GlaxoSmithKline Biologicals SA. Published by Elsevier Ltd.
C1 [Nolan, Terry] Univ Melbourne, Vaccine & Immunisat Res Grp VIRGo, Sch Populat & Global Hlth, Melbourne, Vic, Australia.
   [Nolan, Terry] Murdoch Childrens Res Inst, Melbourne, Vic, Australia.
   [Elena Santolaya, Maria] Univ Chile, Fac Med, Dept Pediat, Hosp Dr Luis Calvo Mackenna, Santiago, Chile.
   [de Looze, Ferdinandus] Univ Queensland, Sch Med, Brisbane, Qld, Australia.
   [de Looze, Ferdinandus] AusTrials Pty Ltd, Brisbane, Qld, Australia.
   [Marshall, Helen] Univ Adelaide, Adelaide Med Sch, Adelaide, SA, Australia.
   [Marshall, Helen] Univ Adelaide, Robinson Res Inst, Adelaide, SA, Australia.
   [Marshall, Helen] Womens & Childrens Hlth Network, Vaccinol & Immunol Res Trials Unit, Adelaide, SA, Australia.
   [Richmond, Peter] Univ Western Australia, Wesfarmers Ctr Vaccines & Infect Dis, Div Paediat, Telethon Kids Inst,Princess Margaret Hosp Childre, Perth, WA, Australia.
   [Richmond, Peter] Univ Western Australia, Wesfarmers Ctr Vaccines & Infect Dis, Ctr Child Hlth Res, Telethon Kids Inst,Princess Margaret Hosp Childre, Perth, WA, Australia.
   [Henein, Sam] Univ Toronto, Toronto, ON, Canada.
   [Rheault, Paul; Heaton, Ken] Medicor Res Inc, Sudbury, ON, Canada.
   [Perrett, Kirsten P.] Univ Melbourne, Murdoch Childrens Res Inst, Melbourne, Vic, Australia.
   [Perrett, Kirsten P.] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Melbourne, Vic, Australia.
   [Perrett, Kirsten P.] Royal Childrens Hosp, Melbourne, Vic, Australia.
   [Garfield, Hartley; Gupta, Anil] Queens Univ, Univ Toronto, Dept Med, Toronto, ON, Canada.
   [Garfield, Hartley; Gupta, Anil] Hosp Sick Children, Toronto, ON, Canada.
   [Ferguson, Murdo] Colchester Res Grp, Truro, NS, Canada.
   [D'Agostino, Diego] GSK, Amsterdam, Netherlands.
   [Toneatto, Daniela] GSK, Siena, Italy.
   [O'Ryan, Miguel] Univ Chile, Microbiol & Mycol Program, Inst Biomed Sci, Fac Med, Santiago, Chile.
   [O'Ryan, Miguel] Univ Chile, Millennium Inst Immunol & Immunotherapy, Fac Med, Santiago, Chile.
RP O'Ryan, M (reprint author), Univ Chile, Microbiol & Mycol Program, Inst Biomed Sci, Fac Med, Santiago, Chile.; O'Ryan, M (reprint author), Univ Chile, Millennium Inst Immunol & Immunotherapy, Fac Med, Santiago, Chile.
EM moryan@med.uchile.cl
RI Nolan, Terry/A-2236-2008; Richmond, Peter C/G-3379-2012; perrett,
   kirsten/P-8813-2019
OI Nolan, Terry/0000-0001-6018-3863; Richmond, Peter C/0000-0001-7562-7228;
   perrett, kirsten/0000-0002-5683-996X
FU Novartis Vaccines and Diagnostics Inc., GSK group of companies
FX This study was funded by Novartis Vaccines and Diagnostics Inc., now
   part of the GSK group of companies. GlaxoSmithKline Biologicals SA took
   responsibility for all costs associated with the development and
   publishing of the present manuscript.
CR Ali A, 2014, PATHOG GLOB HEALTH, V108, P11, DOI 10.1179/2047773214Y.0000000126
   Archer BN, 2017, MED J AUSTRALIA, V207, P382, DOI 10.5694/mja16.01340
   Australian Government, 2017, INV MEN DIS NAT SURV
   Banzhoff Angelika, 2017, Ther Adv Vaccines, V5, P3, DOI 10.1177/2051013616681365
   de Salud Ministerio de Chile Gobierno. Departamento de Epidemiologia, 2015, ENF MEN INF EP
   De Wals P, 2017, CLIN INFECT DIS, V64, P1263, DOI 10.1093/cid/cix154
   Donnelly J, 2010, P NATL ACAD SCI USA, V107, P19490, DOI 10.1073/pnas.1013758107
   Santolaya ME, 2013, HUM VACC IMMUNOTHER, V9, P2304, DOI 10.4161/hv.25505
   Santolaya ME, 2012, LANCET, V379, P617, DOI 10.1016/S0140-6736(11)61713-3
   Frosi G, 2013, VACCINE, V31, P4968, DOI 10.1016/j.vaccine.2013.08.006
   GOLDSCHNEIDER I, 1969, J EXP MED, V129, P1307, DOI 10.1084/jem.129.6.1307
   Halperin SA, 2012, VACCINE, V30, pB26, DOI 10.1016/j.vaccine.2011.12.032
   Ibarz-Pavon AB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044102
   Levine OS, 1997, VACCINE, V15, P325, DOI 10.1016/S0264-410X(96)00161-2
   Mak PA, 2011, CLIN VACCINE IMMUNOL, V18, P1252, DOI 10.1128/CVI.05028-11
   Martinon-Torres F, 2018, J INFECTION, V76, P258, DOI 10.1016/j.jinf.2017.12.005
   Martinon-Torres F, 2017, VACCINE, V35, P3548, DOI 10.1016/j.vaccine.2017.05.023
   McIntosh EDG, 2015, VACCINE, V33, P4414, DOI 10.1016/j.vaccine.2015.07.019
   Nolan T, 2015, VACCINE, V33, P4437, DOI 10.1016/j.vaccine.2015.06.011
   Pan -Canadian Public Health Network Partners in Public Health, 2014, REC US MULT MEN B 4C
   Parikh SR, 2016, LANCET, V388, P2775, DOI 10.1016/S0140-6736(16)31921-3
   Pelton SI, 2016, J ADOLESCENT HEALTH, V59, pS3, DOI 10.1016/j.jadohealth.2016.04.012
   Perrett KP, 2015, VACCINE, V33, P5217, DOI 10.1016/j.vaccine.2015.06.103
   Read RC, 2017, VACCINE, V35, P427, DOI 10.1016/j.vaccine.2016.11.071
   Read RC, 2014, LANCET, V384, P2123, DOI 10.1016/S0140-6736(14)60842-4
   Safadi MA, 2015, EXPERT REV VACCINES, V14, P505, DOI 10.1586/14760584.2015.979799
   Toneatto D, 2017, EXPERT REV VACCINES, V16, P433, DOI 10.1080/14760584.2017.1308828
   Vetter V, 2016, EXPERT REV VACCINES, V15, P641, DOI 10.1586/14760584.2016.1130628
   Wang X, 2011, VACCINE, V29, P4739, DOI 10.1016/j.vaccine.2011.04.092
NR 29
TC 6
Z9 6
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 21
PY 2019
VL 37
IS 9
BP 1209
EP 1218
DI 10.1016/j.vaccine.2018.12.059
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HM9YN
UT WOS:000459841000013
PM 30691980
OA Other Gold
DA 2020-05-12
ER

PT J
AU Amador-Molina, A
   Trejo-Moreno, C
   Romero-Rodriguez, D
   Sada-Ovalle, BI
   Perez-Cardenas, E
   Lamoyi, E
   Moreno, J
   Lizano, M
AF Amador-Molina, Alfredo
   Trejo-Moreno, Cesar
   Romero-Rodriguez, Damaris
   Sada-Ovalle, Isabel B.
   Perez-Cardenas, Enrique
   Lamoyi, Edmundo
   Moreno, Jose
   Lizano, Marcela
TI Vaccination with human papillomavirus-18 E1 protein plus
   alpha-galactosyl-ceramide induces CD8(+) cytotoxic response and impairs
   the growth of E1-expressing tumors
SO VACCINE
LA English
DT Article
DE Human papillomavirus; E1 protein; alpha-galactosylceramide; Cytotoxic
   CD8+T cells; NK cells
ID B-SUBUNIT; T-CELLS; MUCOSAL CHALLENGE; IMMUNE-RESPONSES;
   CERVICAL-CANCER; DENDRITIC CELLS; IMMUNIZATION; EXPRESSION; ANTIGEN;
   IDENTIFICATION
AB CD8+ T cell-mediated immune response plays a major role in the clearance of virus-infected cells, including human papillomavirus (HPV). The effective treatment of women with normal cytology but persistent high risk-HPV infection or with low-grade intraepithelial lesions could take advantage of novel strategies based on vaccination with viral immunological targets with a wide spectrum of cross-protection. The helicase E1, expressed early during viral replication in HPV infection, is among the most conserved papillomavirus proteins, which makes it a good vaccine candidate. In the present study, we examined E1-specific CD8+ T cell and NK immune responses in a mouse model with alpha-galactosylceramide (alpha-GalCer) as an adjuvant. We found that mice immunized with El combined with alpha-GalCer elicited an E1-specific CD8+ T and NK cell cytotoxic responses, which correlated with growth inhibition of grafted melanoma B16-F0 cells expressing E1, both in prophylactic and therapeutic protocols. (C) 2018 The Authors. Published by Elsevier Ltd.
C1 [Amador-Molina, Alfredo; Trejo-Moreno, Cesar; Perez-Cardenas, Enrique; Lizano, Marcela] Inst Nacl Cancerol, Unidad Invest Biomed Canc, Av San Fernando 22,Col Secc 16, Ciudad De Mexico 14080, Mexico.
   [Romero-Rodriguez, Damaris; Sada-Ovalle, Isabel B.] Inst Nacl Enfermedades Resp Ismael Cosio Villegas, Lab Inmunol Integrat, Calzada Tlalpan 4502, Ciudad De Mexico 14080, Mexico.
   [Lamoyi, Edmundo] Univ Nacl Autonoma Mexico, Inst Invest Biomed, Dept Inmunol, Ciudad Univ, Ciudad De Mexico 04510, Mexico.
   [Moreno, Jose] Hosp Juarez Mexico, Direcc Invest, Ciudad De Mexico 07760, Mexico.
   [Lizano, Marcela] Univ Nacl Autonoma Mexico, Inst Invest Biomed, Dept Med Genom & Toxicol Ambiental, Ciudad Univ, Ciudad De Mexico 04510, Mexico.
RP Lizano, M (reprint author), Inst Nacl Cancerol, Unidad Invest Biomed Canc, Av San Fernando 22,Col Secc 16, Ciudad De Mexico 14080, Mexico.
EM lizano@unam.mx
RI Moreno, Jose/C-7319-2016
OI Moreno, Jose/0000-0002-8887-6087
FU Instituto Nacional de Cancerologia, Mexico [017/001/IBI]; Programa de
   Apoyo a Proyectos de Investigacion e Innovacion Tecnologica, Direccion
   General de Asuntos del Personal Academic, Universidad Nacional Autonoma
   de Mexico [PAPIIT-IN221810]
FX This work was supported by Instituto Nacional de Cancerologia, Mexico
   (017/001/IBI), and Programa de Apoyo a Proyectos de Investigacion e
   Innovacion Tecnologica, Direccion General de Asuntos del Personal
   Academic, Universidad Nacional Autonoma de Mexico (PAPIIT-IN221810).
CR Abbate EA, 2004, GENE DEV, V18, P1981, DOI 10.1101/gad.1220104
   Adotevi O, 2007, J IMMUNOL, V179, P3371, DOI 10.4049/jimmunol.179.5.3371
   Aktas E, 2009, CELL IMMUNOL, V254, P149, DOI 10.1016/j.cellimm.2008.08.007
   Betts MR, 2003, J IMMUNOL METHODS, V281, P65, DOI 10.1016/S0022-1759(03)00265-5
   Bosch FX, 2002, J CLIN PATHOL, V55, P244, DOI 10.1136/jcp.55.4.244
   Butterfield LH, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h988
   Chennamadhavuni D, 2018, CELL CHEM BIOL
   Clifford GM, 2003, BRIT J CANCER, V89, P101, DOI 10.1038/sj.bjc.6601024
   Clifford GM, 2003, BRIT J CANCER, V88, P63, DOI 10.1038/sj.bjc.6600688
   Cote-Martin A, 2008, J VIROL, V82, P1271, DOI 10.1128/JVI.01405-07
   Demeret C, 1998, VIROLOGY, V242, P378, DOI 10.1006/viro.1997.9023
   Dolen Y, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1068493
   Doorbar J, 2007, DIS MARKERS, V23, P297, DOI 10.1155/2007/613150
   Ellis JM, 2000, HUM IMMUNOL, V61, P334, DOI 10.1016/S0198-8859(99)00155-X
   Faustino-Rocha A, 2013, LAB ANIMAL, V42, P217, DOI 10.1038/laban.254
   Haicheur N, 2003, INT IMMUNOL, V15, P1161, DOI 10.1093/intimm/dxg118
   Haicheur N, 2000, J IMMUNOL, V165, P3301, DOI 10.4049/jimmunol.165.6.3301
   Han R, 1999, VACCINE, V17, P1558, DOI 10.1016/S0264-410X(98)00356-9
   Han R, 2000, VACCINE, V18, P2937, DOI 10.1016/S0264-410X(00)00110-9
   Ito H, 2015, ONCOTARGET, V6, P41863, DOI 10.18632/oncotarget.6172
   Johnston KB, 2005, VIROLOGY, V336, P208, DOI 10.1016/j.virol.2005.03.022
   Jung AC, 2013, INT J CANCER, V132, pE26, DOI 10.1002/ijc.27776
   Kim TJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6317
   KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P2541, DOI 10.1093/nar/21.11.2541
   Liang XZ, 2013, J VIROL, V87, P6051, DOI 10.1128/JVI.00375-13
   Magaldi TG, 2012, VIROLOGY, V422, P114, DOI 10.1016/j.virol.2011.10.012
   Melief CJM, 2015, J CLIN INVEST, V125, P3401, DOI 10.1172/JCI80009
   Miller JP, 2016, TOMOGRAPHY, V2, P17, DOI 10.18383/j.tom.2016.00100
   Moore RA, 2002, VIROLOGY, V304, P451, DOI 10.1006/viro.2002.1726
   Morrow MP, 2016, MOL THER-ONCOLYTICS, V3, DOI 10.1038/mto.2016.25
   Newell EW, 2012, IMMUNITY, V36, P142, DOI 10.1016/j.immuni.2012.01.002
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Pufnock JS, 2011, BLOOD, V117, P6542, DOI 10.1182/blood-2010-11-317966
   Ragonnaud E, 2017, J IMMUNOTHER, V40, P51, DOI 10.1097/CJI.0000000000000153
   Reche PA, 2002, HUM IMMUNOL, V63, P701, DOI 10.1016/S0198-8859(02)00432-9
   Remy-Ziller C, 2014, CLIN VACCINE IMMUNOL, V21, P147, DOI 10.1128/CVI.00678-13
   Ringvall M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014526
   ROMANCZUK H, 1992, P NATL ACAD SCI USA, V89, P3159, DOI 10.1073/pnas.89.7.3159
   Smyth MJ, 2002, BLOOD, V99, P1259, DOI 10.1182/blood.V99.4.1259
   Stanley MA, 2007, BIOCHEM SOC T, V35, P1456, DOI 10.1042/BST0351456
   Tindle RW, 2002, NAT REV CANCER, V2, P59, DOI 10.1038/nrc700
   van Duikeren S, 2012, J IMMUNOL, V189, P3397, DOI 10.4049/jimmunol.1201540
   Wang ZH, 2013, J IMMUNOL, V190, P2415, DOI 10.4049/jimmunol.1202535
   Wilson VG, 2002, VIRUS GENES, V24, P275, DOI 10.1023/A:1015336817836
   World Health Organization, HUM PAP HPV CERV CAN
   Yin WJ, 2016, CANCER IMMUNOL RES, V4, P823, DOI 10.1158/2326-6066.CIR-16-0128
   zurHausen H, 1996, BBA-REV CANCER, V1288, pF55
NR 47
TC 2
Z9 3
U1 1
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 21
PY 2019
VL 37
IS 9
BP 1219
EP 1228
DI 10.1016/j.vaccine.2018.12.036
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HM9YN
UT WOS:000459841000014
PM 30704821
OA Other Gold
DA 2020-05-12
ER

PT J
AU Landazabal, CS
   Moro, PL
   Lewis, P
   Omer, SB
AF Landazabal, Claudia S.
   Moro, Pedro L.
   Lewis, Paige
   Omer, Saad B.
TI Safety of 9-valent human papillomavirus vaccine administration among
   pregnant women: Adverse event reports in the Vaccine Adverse Event
   Reporting System (VAERS), 2014-2017
SO VACCINE
LA English
DT Article
DE Adverse event; Epidemiology; Human papillomavirus vaccine; Surveillance;
   Vaccine safety
ID ADVISORY-COMMITTEE; REPRODUCTIVE OUTCOMES; HPV VACCINATION;
   UNITED-STATES; RECOMMENDATIONS; GENERATION; SIGNAL
AB Introduction: 9-valent human papillomavirus vaccine (9vHPV) was approved by the Food and Drug Administration (FDA) in December 2014. 9vHPV is not recommended during pregnancy, but some women of childbearing age may be inadvertently exposed. This study aims to evaluate reports submitted to the Vaccine Adverse Event Reporting System (VAERS) of pregnant women exposed to 9vHPV.
   Methods: We searched the VAERS database, a national post-licensure vaccine safety surveillance system, for reports of pregnant women vaccinated with 9vHPV in the United States between December 10, 2014 and December 31, 2017. Disproportionate reporting of adverse events (AEs) was assessed using proportional reporting ratios (PRRs).
   Results: A total of 82 pregnancy reports were identified. Sixty reports (73.2%) did not describe an AE and were submitted only to report the vaccine exposure during pregnancy. The most frequently reported pregnancy-specific AE was spontaneous abortion (n = 3; 3.7%), followed by vaginal bleeding (n = 2; 2.4%). Among non-pregnancy-specific AEs, injection site reaction (n = 3; 3.7%) was most common. No disproportionate reporting of any AE was found.
   Discussion: No unexpected AEs were observed among these pregnancy reports. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Landazabal, Claudia S.; Omer, Saad B.] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, 1518 Clifton Rd, Atlanta, GA 30322 USA.
   [Moro, Pedro L.; Lewis, Paige] Ctr Dis Control & Prevent, Natl Ctr Zoonot & Emerging Infect Dis, Div Healthcare Qual Promot, Immunizat Safety Off, 1600 Clifton Rd, Atlanta, GA 30333 USA.
   [Omer, Saad B.] Emory Univ, Rollins Sch Publ Hlth, Hubert Dept Global Hlth, 1518 Clifton Rd, Atlanta, GA 30322 USA.
   [Omer, Saad B.] Emory Vaccine Ctr, 954 Gatewood Rd, Atlanta, GA 30329 USA.
RP Landazabal, CS (reprint author), Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, 1518 Clifton Rd, Atlanta, GA 30322 USA.
EM claudialandazabal@alumni.emory.edu; psm9@cdc.gov; fqv9@cdc.gov;
   somer@emory.edu
FU Centers for Disease Control and Prevention (CDC)United States Department
   of Health & Human ServicesCenters for Disease Control & Prevention - USA
FX The study was implemented by the Centers for Disease Control and
   Prevention (CDC). The only funds used were from CDC budgets. This study
   had no external sponsors.
CR ANANTH CV, 1994, PAEDIATR PERINAT EP, V8, P62, DOI 10.1111/j.1365-3016.1994.tb00436.x
   Arana J, 2018, M ADV COMM IMM PRACT
   Banks D, 2005, PHARMACOEPIDEM DR S, V14, P601, DOI 10.1002/pds.1107
   Broder KR, 2012, VACCINE, V30, P2032, DOI 10.1016/j.vaccine.2011.12.040
   Centers for Disease Control and Prevention, UND VACC ADV EV REP
   Centers for Disease Control and Prevention, 2016, HPV VACC INF CLIN
   Centers for Disease Control and Prevention, HUM PAP HPV VACC SAF
   Clark LR, 2013, J ADOLESCENT HEALTH, V52, P322, DOI 10.1016/j.jadohealth.2012.07.003
   Cunningham F.G., 2010, WILLIAMS OBSTET
   Ellenberg SS, 2001, PHARMACOEPIDEM DR S, V10, P411, DOI 10.1002/pds.616
   Evans SJW, 2001, PHARMACOEPIDEM DR S, V10, P483, DOI 10.1002/pds.677
   Fritzell B, 2001, VACCINE, V20, pS47, DOI 10.1016/S0264-410X(01)00291-2
   Goss MA, 2015, VACCINE, V33, P3422, DOI 10.1016/j.vaccine.2015.04.014
   Gruber MF., 2014, DECEMBTER 10 2014 AP
   Hartnell NR, 2004, PHARMACOTHERAPY, V24, P743, DOI 10.1592/phco.24.8.743.36068
   Health Resources and Services Administration, VACC INJ TABL
   Hibbs BF, 2015, VACCINE, V33, P3171, DOI 10.1016/j.vaccine.2015.05.006
   Institute of Medicine (US) Committee on Review of Priorities in the National Vaccine Plan, 2010, PRIOR NAT VACC PLAN
   Kharbanda EO, 2018, OBSTET GYNECOL, V132, P35, DOI [10.1097/AOG.0000000000002694, 10.1097/aog.0000000000002694]
   Lipkind HS, 2017, OBSTET GYNECOL, V130, P599, DOI 10.1097/AOG.0000000000002191
   Markowitz L., UPDATE RECOMMENDATIO
   Markowitz Lauri E., 2007, Morbidity and Mortality Weekly Report, V56, P1
   Markowitz LE, 2014, MMWR RECOMM REP, V63, P1
   Medical College of Wisconsin, PREGN DAT CALC
   Meites E, 2016, MMWR-MORBID MORTAL W, V65, P1405, DOI 10.15585/mmwr.mm6549a5
   Merck Sharp and Dohme Corp, 2006, HIGHL PRESCR INF GAR
   Merck Sharp & Dohme Corp. Highlights of Prescribing Information, 2014, HIGHL PRESCR INF GAR
   Moreira ED, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2015-4387
   Moro PL, 2015, VACCINE, V33, P519, DOI 10.1016/j.vaccine.2014.11.047
   Moro PL, 2011, AM J OBSTET GYNECOL, V205, DOI 10.1016/j.ajog.2011.06.047
   Petrosky E, 2015, MMWR-MORBID MORTAL W, V64, P300
   Scheller NM, 2017, NEW ENGL J MED, V376, P1223, DOI 10.1056/NEJMoa1612296
   Shimabukuro TT, 2015, VACCINE, V33, P4398, DOI 10.1016/j.vaccine.2015.07.035
   Singleton JA, 1999, VACCINE, V17, P2908, DOI 10.1016/S0264-410X(99)00132-2
   THOMAS DC, 1992, EPIDEMIOLOGY, V3, P32, DOI 10.1097/00001648-199201000-00007
   Varricchio F, 2004, PEDIATR INFECT DIS J, V23, P287, DOI 10.1097/00006454-200404000-00002
   WILCOX AJ, 1981, AM J EPIDEMIOL, V114, P548, DOI 10.1093/oxfordjournals.aje.a113220
NR 37
TC 0
Z9 0
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 21
PY 2019
VL 37
IS 9
BP 1229
EP 1234
DI 10.1016/j.vaccine.2018.11.077
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HM9YN
UT WOS:000459841000015
PM 30660400
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Meyers, JL
   Candrilli, SD
   Rausch, DA
   Yan, SK
   Patterson, BJ
   Levin, MJ
AF Meyers, Juliana L.
   Candrilli, Sean D.
   Rausch, Debora A.
   Yan, Songkai
   Patterson, Brandon J.
   Levin, Myron J.
TI Costs of herpes zoster complications in older adults: A cohort study of
   US claims database
SO VACCINE
LA English
DT Article
DE Zoster; Complications; Costs
ID COMORBIDITY INDEX; BURDEN; RATES
AB Background/Objectives: Herpes zoster (HZ) incidence increases with age, and the burden of HZ is expected to grow with aging of populations worldwide. We aim to determine the incremental healthcare resource utilization and associated costs of patients with common HZ-related complications other than postherpetic neuralgia (cutaneous, neurologic and ophthalmic) compared to uncomplicated HZ.
   Methods: We conducted a retrospective cohort study of commercial health insurance claims covering about 40 million immunocompetent individuals aged >= 50 years at study entry from all over the US, from 2008 to 2013, with follow-up for one year after HZ onset. All-cause healthcare resource utilization and direct healthcare costs were recorded and calculated from six months before until 12 months after HZ onset. The mean costs for HZ patients with complications were compared to the mean costs for patients with uncomplicated HZ. Multivariable regression analyses estimated mean incremental costs adjusted for demographics, comorbidities, type of complication and time period.
   Results: Over the five-year study period, 22,948 HZ patients (60% women, median age 62 years) who experienced at least one of the selected complications were compared to 213,232 patients (63% women, median age 61 years) with uncomplicated HZ. Overall, the mean annual incremental unadjusted costs for the patients with HZ-related complications were US$4716, ranging from US$2173 for ophthalmic to US $18,323 for neurologic complications. Most of the incremental costs associated with HZ complications were accrued during the first quarter after HZ onset. For each complication type the incremental costs increased with age up to, but not including the oldest group, aged >= 80 years.
   Conclusions: Approximately 10% of immunocompetent older patients with HZ develop complications which considerably increase the economic burden of HZ. Vaccination of older adults will offset some of the burden of HZ, including costs associated with HZ-related complications. (C) 2018 GlaxoSmithKline Biologicals SA. Published by Elsevier Ltd.
C1 [Meyers, Juliana L.; Candrilli, Sean D.] RTI Hlth Solut, Res Triangle Pk, NC USA.
   [Rausch, Debora A.; Yan, Songkai; Patterson, Brandon J.] GSK, 5 Crescent Dr, Philadelphia, PA 19112 USA.
   [Levin, Myron J.] Univ Colorado, Anschutz Med Campus, Aurora, CO USA.
   [Yan, Songkai] CSL Behring, King Of Prussia, PA USA.
RP Patterson, BJ (reprint author), GSK, 5 Crescent Dr, Philadelphia, PA 19112 USA.
EM jmeyers@rti.org; scandrilli@rti.org; debora.a.rausch@gsk.com;
   Songkai.Yan@cslbehring.com; brandon.j.patterson@gsk.com;
   myron.levin@ucdenver.edu
OI Patterson, Brandon/0000-0002-5319-9493
FU GlaxoSmithKline Biologicals S.A. (Rixensart, Belgium) [HO-15-15772]
FX GlaxoSmithKline Biologicals S.A. (Rixensart, Belgium) funded this study
   (GSK study identifier: HO-15-15772) and all costs related to the
   development of the related publications.
CR Advisory Committee on Immunization Practices, 2018, ZOST SHINGL ACIP VAC
   Basu A, 2005, BIOSTATISTICS, V6, P93, DOI 10.1093/biostatistics/kxh020
   Centers for Disease Control and Prevention (CDC), 2006, CDCS ADV COM REC SHI
   Charlson ME, 2008, J CLIN EPIDEMIOL, V61, P1234, DOI 10.1016/j.jclinepi.2008.01.006
   DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8
   Insinga RP, 2005, J GEN INTERN MED, V20, P748, DOI 10.1111/j.1525-1497.2005.0150.x
   Johnson RW, 2003, BMJ-BRIT MED J, V326, P748, DOI 10.1136/bmj.326.7392.748
   Kawai K, 2017, MAYO CLIN PROC, V92, P1806, DOI 10.1016/j.mayocp.2017.10.009
   Kawai K, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-004833
   Meyers JL, 2017, HUM VACC IMMUNOTHER, V13, P1861, DOI 10.1080/21645515.2017.1324373
   Panatto D, 2015, HUM VACC IMMUNOTHER, V11, P245, DOI 10.4161/hv.36160
   Pinchinat S, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-170
   Suaya JA, 2014, OPEN FORUM INFECT DI, V1, DOI 10.1093/ofid/ofu049
   Varghese L, 2017, BMC GERIATR, V17, DOI 10.1186/s12877-017-0420-9
   WEDDERBURN RWM, 1974, BIOMETRIKA, V61, P439, DOI 10.2307/2334725
   Yawn BP, 2007, MAYO CLIN PROC, V82, P1341, DOI 10.4065/82.11.1341
   Yawn BP, 2011, AM J EPIDEMIOL, V174, P1054, DOI 10.1093/aje/kwr206
   Yawn BP, 2009, MAYO CLIN PROC, V84, P787, DOI 10.1016/S0025-6196(11)60488-6
NR 18
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 21
PY 2019
VL 37
IS 9
BP 1235
EP 1244
DI 10.1016/j.vaccine.2018.11.079
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HM9YN
UT WOS:000459841000016
PM 30685248
OA Other Gold
DA 2020-05-12
ER

PT J
AU Munira, SL
   Hendriks, JT
   Atmosukarto, II
   Friede, MH
   Carter, LM
   Butler, JRG
   Clements, ACA
AF Munira, Syarifah Liza
   Hendriks, Jan T.
   Atmosukarto, Ines I.
   Friede, Martin H.
   Carter, Louise M.
   Butler, James R. G.
   Clements, Archie C. A.
TI A cost analysis of producing vaccines in developing countries
SO VACCINE
LA English
DT Article
DE Cost analysis; Vaccine; Vaccine production; Developing country
ID DRUG
AB Developing country vaccine manufacturers (DCVMs) supply over half of the vaccines used in developing country immunisation programs. Decisions by developing countries to establish vaccine manufacturing should be based on economic viability, however reliable assessments of vaccine production costs are lacking. This study aimed to quantify the cost of establishing vaccine manufacturing facilities and producing vaccines in developing countries.
   This study estimates vaccine production costs in developing countries based on twelve vaccines produced by eight DCVMs. The results were based on estimates of the capital and operating costs required to establish vaccine manufacturing facilities under three hypothetical scenarios of production scale and scope. Cost patterns were then compared to vaccine prices paid by countries in both industrialized and developing country markets.
   The cost of producing vaccines in developing countries was estimated to be on average US$ 2.18 per dose, ranging between US$ 0.98 and US$ 4.85 for different vaccine types and formulations. Vaccine costs-per-dose decrease as production scale and scope increase. Cost-per-dose is mainly driven by fixed costs, but at a scale of production over 20 million doses per year it becomes driven by variable costs. Under the three hypothetical scenarios used, costs-per-dose of vaccines produced by developing countries were around 47% lower than vaccine prices in developing-country markets and 84% lower than prices in industrialized-country markets.
   This study has found that local production of vaccines in developing countries exhibits both economies of scale and economies of scope. The lower costs relative to prices suggests that a producer surplus and potential profits may be attainable in both developing and developed country markets, supporting sustainable production. (C) 2018 World Health Organization. Published by Elsevier Ltd. All rights reserved.
C1 [Munira, Syarifah Liza] Univ Indonesia, Fac Econ & Business, Kota Depok, Jawa Barat, Indonesia.
   [Hendriks, Jan T.] Inst Translat Vaccinol Intravacc, Bilthoven, Netherlands.
   [Atmosukarto, Ines I.] Lipotek Pty Ltd, Acton, ACT, Australia.
   [Friede, Martin H.] WHO, Initiat Vaccine Res, Geneva, Switzerland.
   [Carter, Louise M.] Novartis, Primary Care, Macquarie Park, NSW, Australia.
   [Butler, James R. G.] Univ Canberra, Hlth Res Inst, Canberra, ACT, Australia.
   [Clements, Archie C. A.] Curtin Univ, Fac Hlth Sci, Bentley, WA, Australia.
RP Munira, SL (reprint author), Univ Indonesia, Fac Econ & Business, Kota Depok, Jawa Barat, Indonesia.
EM lizamunira@yahoo.com
FU Australian Department of Foreign Affairs and Trade Australia Leadership
   Award; Alison Sudradjat Prize; Australian National Health and Medical
   Research CouncilNational Health and Medical Research Council of
   Australia [1058878]
FX This work was supported by the Australian Department of Foreign Affairs
   and Trade Australia Leadership Award and Alison Sudradjat Prize
   (Munira). Australian National Health and Medical Research Council,
   Senior Research Fellowship (Clements, #1058878).
CR Alker S., 2000, J ENVIRON PLANN MAN, V43, P49, DOI DOI 10.1080/09640560010766
   Butler JRG, 1990, DAY SURG COST REDUCI
   Cerne K., 2009, EKON ISTRAZ, V22, P66
   Clendinen C, 2016, VACCINE, V34, P5984, DOI 10.1016/j.vaccine.2016.09.042
   DAVIDSON S, 1966, J ACCOUNTING RES, V4, P183, DOI 10.2307/2489953
   Denault J-F, 2008, BIOPROCESS INT
   DiMasi JA, 2003, J HEALTH ECON, V22, P151, DOI 10.1016/S0167-6296(02)00126-1
   Friede M., 2013, WORKSH BUS MOD SUST
   Gomez PL, 2012, VACCINE MANUFACTURIN
   Herlihy N, 2016, HEALTH AFFAIR, V35, P227, DOI 10.1377/hlthaff.2015.1411
   Jarrett SW, 2008, PUBLIC HEALTH ETH-UK, V1, P104, DOI 10.1093/phe/phn020
   Kaddar M., 2013, WORKSH BUS MOD SUST
   Levin HM, 1983, COST EFFECTIVENESS P
   LEVINE R, 2005, MAKING MARKETS VACCI
   Light DW, 2009, VACCINE, V27, P6627, DOI 10.1016/j.vaccine.2009.07.077
   Luter N, 2017, VACCINE, V35, P3897, DOI 10.1016/j.vaccine.2017.04.087
   Mahoney RT, 2012, VACCINE, V30, P4892, DOI 10.1016/j.vaccine.2012.02.064
   MAHONEY RT, 1990, VACCINE, V8, P397, DOI 10.1016/0264-410X(90)90101-Q
   *MERC MAN CONS, 2002, LESS LEARN NEW PROC
   Mercer Management Consulting, 2006, EXP CONS SER COMP PN
   Mestre-Ferrandiz J, 2012, R D COST NEW MED
   Milstien JB, 2010, M STRAT ADV GROUP EX
   PINDYCK R, 1989, MICROECONOMICS
   POST, 1998, BROWN PLEAS LAND
   Pronker ES, 2011, VACCINE, V29, P5846, DOI 10.1016/j.vaccine.2011.06.051
   Sinclair A, 2015, WILEY SER BIOTECHNOL, P413
   Struck MM, 1996, NAT BIOTECHNOL, V14, P591, DOI 10.1038/nbt0596-591
   Waye A, 2013, EXPERT REV VACCINES, V12, P1495, DOI 10.1586/14760584.2013.850035
   WHO, 2005, V3P
NR 29
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 21
PY 2019
VL 37
IS 9
BP 1245
EP 1251
DI 10.1016/j.vaccine.2018.11.050
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HM9YN
UT WOS:000459841000017
PM 30651198
DA 2020-05-12
ER

PT J
AU He, XL
   Wang, Z
   Pu, Y
   Wang, D
   Tang, RJ
   Cui, SM
   Wang, JX
   Chen, JF
AF He, Xianglei
   Wang, Zhi
   Pu, Yuan
   Wang, Dan
   Tang, Ruijie
   Cui, Simin
   Wang, Jie-Xin
   Chen, Jian-Feng
TI High-gravity-assisted scalable synthesis of zirconia nanodispersion for
   light emitting diodes encapsulation with enhanced light extraction
   efficiency
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Zirconia nanoparticles; Rotating packed bed; Hybrid nanocomposite; LED
   encapsulation
ID ROTATING PACKED-BED; ORGANIC-INORGANIC NANOCOMPOSITES; PROCESS
   INTENSIFICATION; NANOPARTICLES; PRECIPITATION; BEHAVIOR; HYBRIDS;
   FACILE; DESIGN; WATER
AB Zirconia-based hybrid polymers has become one of the ideal encapsulation material for light emitting diodes (LEDs) with high extraction efficiency due to their proper refractive index to those of semiconductor chips. However, the controlling of the dispersion for zirconia nanoparticles in polymeric hosts to obtain optically transparent hybrid nanocomposites has been one of the major challenges. Herein, we reported the synthesis of zirconia nanodispersion via high-gravity-assisted homogeneous precipitation in an internal circulation rotating packed bed (RPB) reactor followed by two-step modification. An alternative to conventional precipitation in batch stirred tank reactors (STR), the process intensification by high-gravity RPB results in homogeneous micromixing during the nucleation and growth of zirconia particles, which are benefit for continuous and reproducible production of ultrasmall zirconia nanoparticles. The obtained zirconia nanoparticles are purely cubic phase with narrow size-distribution in the range of 3-5 nm according to the X-ray diffraction and transmission electron microscopy characterization, which were similarity to that by the conventional methods. Nevertheless, the average hydrodynamic diameters of zirconia nanoparticles in aqueous solutions obtained by RPB methods were much smaller than those prepared in conventional STR, which enabled easy control and surface modification for highly dispersed nanodispersion in organic solvents and/or polymeric hosts. After two-step surface modification, zirconia nanoparticles with goal-directed structures were obtained, with highly dispersity in various organic solvents (e.g. toluene, trichloromethane, tetrahydrofuran, etc.) and aliphatic epoxy resin, forming transparent hybrid films with tunable refractive indexes. The preliminary applications of these zirconia nanodispersions for LEDs encapsulation were demonstrated. The light extraction efficiency of the LEDs devices packaged with zirconia/epoxy hybrid material increased by 10 percent when the doping content of zirconia nanoparticles was 0.2, compared to the devices encapsulated by original epoxy. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [He, Xianglei; Wang, Zhi; Pu, Yuan; Wang, Dan; Tang, Ruijie; Cui, Simin; Wang, Jie-Xin; Chen, Jian-Feng] Beijing Univ Chem Technol, State Key Lab Organ Inorgan Composites, Beijing 100029, Peoples R China.
   [He, Xianglei; Pu, Yuan; Wang, Dan; Tang, Ruijie; Cui, Simin; Wang, Jie-Xin; Chen, Jian-Feng] Beijing Univ Chem Technol, Minist Educ High Grav Engn & Technol, Res Ctr, Beijing 100029, Peoples R China.
RP Wang, D; Wang, JX (reprint author), Beijing Univ Chem Technol, State Key Lab Organ Inorgan Composites, Beijing 100029, Peoples R China.
EM wangdan@mail.buct.edu.cn; wangjx@mail.buct.edu.cn
RI Wang, Dan/B-9997-2013
OI Wang, Dan/0000-0002-3515-4590; He, Xianglei/0000-0003-4995-0085
FU National Key Research and Development Program of China
   [2017YFB0404302/2017YFB0404300]; National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China [21808009,
   21620102007, 21622601]; Beijing Natural Science FoundationBeijing
   Natural Science Foundation [2182051]
FX We are grateful for financial support from National Key Research and
   Development Program of China (2017YFB0404302/2017YFB0404300), the
   National Natural Science Foundation of China (21808009, 21620102007,
   21622601) and the Beijing Natural Science Foundation (2182051).
CR Althues H, 2007, CHEM SOC REV, V36, P1454, DOI 10.1039/b608177k
   ASPNES DE, 1982, AM J PHYS, V50, P704, DOI 10.1119/1.12734
   Caseri WR, 2006, MATER SCI TECH-LOND, V22, P807, DOI 10.1179/174328406X101256
   Chang Y, 2012, MATER RES BULL, V47, P527, DOI 10.1016/j.materresbull.2011.12.055
   Chau JLH, 2007, MATER LETT, V61, P2908, DOI 10.1016/j.matlet.2007.01.088
   Chen JF, 2017, ENGINEERING, V3, P279, DOI 10.1016/J.ENG.2017.03.028
   Chen LL, 2015, RSC ADV, V5, P65184, DOI 10.1039/c5ra10197b
   Chiang A.S.T., 2016, U.S. Patent Application, Patent No. [20160096738 A1, 20160096738]
   Chiang A.S.T, 2015, RECENT INNOV CHEM EN, V7, P76
   Chung PT, 2012, MATER CHEM PHYS, V136, P868, DOI 10.1016/j.matchemphys.2012.08.013
   Chung PT, 2016, ACS APPL MATER INTER, V8, P9986, DOI 10.1021/acsami.6b02082
   Enomoto K, 2018, ACS APPL MATER INTER, V10, P13985, DOI 10.1021/acsami.8b00422
   Enomoto K, 2017, MACROMOLECULES, V50, P9713, DOI 10.1021/acs.macromol.7b02155
   Enomoto K, 2015, KOBUNSHI RONBUNSHU, V72, P82, DOI 10.1295/koron.2014-0073
   Fujii T, 2004, APPL PHYS LETT, V84, P855, DOI 10.1063/1.1645992
   Garnweitner G, 2007, SMALL, V3, P1626, DOI 10.1002/smll.200700075
   Huang F, 2011, CRYSTENGCOMM, V13, P4500, DOI 10.1039/c1ce05306j
   Huang JH, 2015, J TAIWAN INST CHEM E, V46, P168, DOI 10.1016/j.jtice.2014.09.008
   Huang P, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05166-7
   Huang XJ, 2018, IND ENG CHEM RES, V57, P4253, DOI 10.1021/acs.iecr.7b04878
   Jiao WZ, 2017, CHEM ENG J, V321, P564, DOI 10.1016/j.cej.2017.03.141
   Kang F, 2018, POWDER TECHNOL, V325, P405, DOI 10.1016/j.powtec.2017.11.036
   Kuang YY, 2015, IND ENG CHEM RES, V54, P8157, DOI 10.1021/acs.iecr.5b01584
   Lee S, 2008, J MATER CHEM, V18, P1751, DOI 10.1039/b715338d
   Lei IA, 2014, MATER CHEM PHYS, V144, P41, DOI 10.1016/j.matchemphys.2013.12.009
   Leng JN, 2017, IND ENG CHEM RES, V56, P7977, DOI 10.1021/acs.iecr.7b02262
   Li WZ, 2008, LANGMUIR, V24, P8358, DOI 10.1021/la800370r
   Lin YT, 2018, MATER CHEM PHYS, V206, P136, DOI 10.1016/j.matchemphys.2017.12.011
   Lu CL, 2009, J MATER CHEM, V19, P2884, DOI 10.1039/b816254a
   Pu Y, 2018, POWDER TECHNOL, V340, P208, DOI 10.1016/j.powtec.2018.09.035
   Pu Y, 2018, IND ENG CHEM RES, V57, P1790, DOI 10.1021/acs.iecr.7b04836
   Singhal A, 1996, J AM CHEM SOC, V118, P11529, DOI 10.1021/ja9602399
   Su HW, 2008, MACROMOL CHEM PHYSIC, V209, P1778, DOI 10.1002/macp.200800174
   Tao P, 2013, J APPL POLYM SCI, V130, P3785, DOI 10.1002/app.39652
   Wang D, 2017, ENGINEERING, V3, P402, DOI 10.1016/J.ENG.2017.03.014
   Wenzel D, 2018, CHEM ENG J, V345, P492, DOI 10.1016/j.cej.2018.03.109
   Wu K, 2018, IND ENG CHEM RES, V57, P1903, DOI 10.1021/acs.iecr.7b04103
   Wu K, 2016, IND ENG CHEM RES, V55, P6753, DOI 10.1021/acs.iecr.6b00397
   Xia Y, 2018, LANGMUIR, V34, P6806, DOI 10.1021/acs.langmuir.8b00160
   Yamada N, 2000, J SOL-GEL SCI TECHN, V17, P123, DOI 10.1023/A:1008787200364
   Yang XC, 2017, CHEM ENG PROCESS, V120, P201, DOI 10.1016/j.cep.2017.07.019
   Yovcheva T, 2012, APPL OPTICS, V51, P7771, DOI 10.1364/AO.51.007771
   Zhao H, 2010, CHEM ENG J, V156, P588, DOI 10.1016/j.cej.2009.04.053
   Zhao ZJ, 2018, CHEM ENG PROCESS, V129, P77, DOI 10.1016/j.cep.2018.03.028
NR 44
TC 10
Z9 11
U1 10
U2 49
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 1
EP 10
DI 10.1016/j.ces.2018.11.036
PG 10
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500001
DA 2020-05-12
ER

PT J
AU Sommer, DE
   Kirchen, P
AF Sommer, David E.
   Kirchen, Patrick
TI Towards improved partial oxidation product yield in mixed
   ionic-electronic membrane reactors using CSTR and CFD modelling
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Ion transport membranes; Mixed ionic-electronic conducting membranes;
   Inorganic membrane; Reactor design; Oxidative coupling of methane
ID OXY-COMBUSTION CHARACTERISTICS; COMPUTATIONAL FLUID-DYNAMICS; TRANSPORT
   MEMBRANE; CERAMIC MEMBRANE; DEFECT-TRANSPORT; FUEL CONVERSION; METHANE;
   PERMEATION; PEROVSKITE; PERFORMANCE
AB Mixed ionic-electronic conducting (MIEC) membrane reactors are attractive for partial oxidation and oxidative coupling of methane (OCM) because of their ability to separate oxygen from air with a low energetic penalty, and introduce the oxygen into a reaction zone with spatial and temporal control. To facilitate design and optimization of such reactors, two numerical models for MIEC membrane reactors for methane reforming are introduced: a computationally inexpensive, coupled, two-chamber CSTR model, and a CFD model for reacting flow. The CFD model considers diffusive transport with a mixture averaged model, and was shown to agree well with previous experimental and modelling works. Both models utilize a detailed gas-phase chemical kinetic mechanism and a membrane oxygen permeation model that considers the local oxygen concentration. It is demonstrated that the CSTR model can be used to evaluate a large number of reactor parameters efficiently to identify optimal conditions for OCM. The most promising reactor operating points identified using the CSTR for a particular reactor size are further considered with spatial detail using the CFD model. It is shown that the coupling between oxygen permeation, gas phase chemical kinetics, and flow field can have a significant impact on the reactor performance. Here the flow direction in a typical button reactor was reversed, which resulted in a 40% increase in predicted C-2 yield. The increase is attributed to the shorter post-reaction residence time of the C-2 products in the reactor, thereby inhibiting deeper oxidation. This significant impact on the reactor performance can be utilized to improve the yield of partially oxidized products from membrane reactors. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Sommer, David E.; Kirchen, Patrick] Univ British Columbia, Dept Mech Engn, 2054-6250 Appl Sci Lane, Vancouver, BC V6T 1Z4, Canada.
RP Kirchen, P (reprint author), Univ British Columbia, Dept Mech Engn, 2054-6250 Appl Sci Lane, Vancouver, BC V6T 1Z4, Canada.
EM sommerd@mail.ubc.ca; pkirchen@mech.ubc.ca
OI Kirchen, Patrick/0000-0002-1154-8923
FU Natural Science and Engineering Research Council (NSERC)Natural Sciences
   and Engineering Research Council of Canada; University of British
   Columbia
FX The authors would like acknowledge the Natural Science and Engineering
   Research Council (NSERC) for their financial support through the PGS-D
   program, as well as the University of British Columbia for its financial
   support. We would also like to acknowledge Drs. Walter Merida and Anton
   Hunt, as well as Tilman Schlotter for the fruitful technical
   discussions.
CR Ahmed P, 2017, INT J ENERG RES, V41, P1049, DOI 10.1002/er.3696
   ASAMI K, 1987, IND ENG CHEM RES, V26, P2348, DOI 10.1021/ie00071a029
   Aseem A, 2018, CHEM ENG SCI, V175, P199, DOI 10.1016/j.ces.2017.09.035
   Assael M.J., 1996, THERMOPHYSICAL PROPE
   Behrouzifar A, 2012, CERAM INT, V38, P4797, DOI 10.1016/j.ceramint.2012.02.068
   Benguerba Y, 2017, KINET CATAL+, V58, P328, DOI 10.1134/S0023158417030028
   Bhatia S, 2009, CHEM ENG J, V148, P525, DOI 10.1016/j.cej.2009.01.008
   Bird B. R., 2007, TRANSPORT PHENOMENA
   Coroneo M, 2009, CHEM ENG SCI, V64, P1085, DOI 10.1016/j.ces.2008.10.065
   Cruellas A, 2017, CATAL REV, V59, P234, DOI 10.1080/01614940.2017.1348085
   Dimitrakopoulos G, 2016, J MEMBRANE SCI, V510, P209, DOI 10.1016/j.memsci.2016.03.004
   Euser B, 2016, J ELECTROCHEM SOC, V163, pF264, DOI 10.1149/2.1021603jes
   Fogler H. S., 2016, ELEMENTS CHEM REACTI
   Gambo Y, 2018, J IND ENG CHEM, V59, P218, DOI 10.1016/j.jiec.2017.10.027
   Geerts J. W. M. H, 1992, METHANE CONVERSION O, P259
   Geffroy PM, 2017, CHEM ENG SCI, V162, P245, DOI 10.1016/j.ces.2017.01.006
   Godini HR, 2012, IND ENG CHEM RES, V51, P7747, DOI 10.1021/ie202877r
   Gozalvez-Zafrilla JM, 2011, J MEMBRANE SCI, V378, P290, DOI 10.1016/j.memsci.2011.05.016
   Habib MA, 2013, J MEMBRANE SCI, V446, P230, DOI 10.1016/j.memsci.2013.06.035
   Hong J, 2015, J MEMBRANE SCI, V488, P1, DOI 10.1016/j.memsci.2015.04.006
   Hong JS, 2013, J MEMBRANE SCI, V428, P309, DOI 10.1016/j.memsci.2012.10.055
   Hong J, 2012, J MEMBRANE SCI, V407, P71, DOI 10.1016/j.memsci.2012.03.018
   Hunt A. S., 2015, THESIS
   Jin Y, 2016, INT J HYDROGEN ENERG, V41, P17399, DOI 10.1016/j.ijhydene.2016.07.076
   Karakaya C, 2016, PROG ENERG COMBUST, V55, P60, DOI 10.1016/j.pecs.2016.04.003
   Kee R.J., 2005, CHEM REACTING FLOW T
   Kee RJ, 2017, P COMBUST INST, V36, P51, DOI 10.1016/j.proci.2016.06.014
   KELLER GE, 1982, J CATAL, V73, P9, DOI 10.1016/0021-9517(82)90075-6
   Kirchen P, 2013, P COMBUST INST, V34, P3463, DOI 10.1016/j.proci.2012.07.076
   KROGER FA, 1956, SOLID STATE PHYS, V3, P307
   LAFARGA D, 1994, CHEM ENG SCI, V49, P2005, DOI 10.1016/0009-2509(94)80083-9
   Lee MR, 2012, FUEL PROCESS TECHNOL, V96, P175, DOI 10.1016/j.fuproc.2011.12.038
   Lu TF, 2008, COMBUST FLAME, V154, P761, DOI 10.1016/j.combustflame.2008.04.025
   Lu YP, 2000, CHEM ENG SCI, V55, P4901, DOI 10.1016/S0009-2509(00)00121-4
   Luo HX, 2010, J MEMBRANE SCI, V350, P154, DOI 10.1016/j.memsci.2009.12.023
   Mancini ND, 2011, ENERGY, V36, P4701, DOI 10.1016/j.energy.2011.05.023
   Mancini ND, 2011, ENERGY, V36, P4721, DOI 10.1016/j.energy.2011.05.024
   MLECZKO L, 1995, FUEL PROCESS TECHNOL, V42, P217, DOI 10.1016/0378-3820(94)00121-9
   Nemitallah MA, 2016, J NAT GAS SCI ENG, V28, P61, DOI 10.1016/j.jngse.2015.11.041
   Nemitallah MA, 2015, ENERGY, V84, P600, DOI 10.1016/j.energy.2015.03.022
   Poling B. E., 2001, PROPERTIES GASES LIQ, V5
   Quddus MR, 2010, IND ENG CHEM RES, V49, P6469, DOI 10.1021/ie900971p
   Salehi MS, 2016, IND ENG CHEM RES, V55, P3287, DOI 10.1021/acs.iecr.5b03292
   Smith G, 1999, GRI MECH 3 0
   Spallina V, 2017, ENERG CONVERS MANAGE, V154, P244, DOI 10.1016/j.enconman.2017.10.061
   Stansch Z, 1997, IND ENG CHEM RES, V36, P2568, DOI 10.1021/ie960562k
   Sunarso J, 2008, J MEMBRANE SCI, V320, P13, DOI 10.1016/j.memsci.2008.03.074
   Takahashi T., 1972, Journal of Applied Electrochemistry, V2, P97, DOI 10.1007/BF00609125
   Tonkovich ALY, 1996, CHEM ENG SCI, V51, P789, DOI 10.1016/0009-2509(95)00325-8
   Tuller H. L., 1981, NONSTOICHIOMETRIC OX, P271
   TUNG WY, 1992, IND ENG CHEM RES, V31, P1621, DOI 10.1021/ie00007a008
   Tye CT, 2002, CHEM ENG J, V87, P49, DOI 10.1016/S1385-8947(01)00191-7
   Wang B, 2017, CATAL TODAY, V285, P147, DOI 10.1016/j.cattod.2017.01.023
   WANG W, 1995, J MEMBRANE SCI, V103, P219, DOI 10.1016/0376-7388(95)00005-W
   Weller HG, 1998, COMPUT PHYS, V12, P620, DOI 10.1063/1.168744
   Xu SJ, 1999, CHEM ENG SCI, V54, P3839, DOI 10.1016/S0009-2509(99)00015-9
   Zanthoff H., 1993, P DGMK C SELECTIVE H, P227
   Zeng Y, 1998, J MEMBRANE SCI, V150, P87, DOI 10.1016/S0376-7388(98)00182-3
NR 58
TC 2
Z9 3
U1 8
U2 31
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 11
EP 22
DI 10.1016/j.ces.2018.11.033
PG 12
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500002
DA 2020-05-12
ER

PT J
AU Zhou, H
   Yu, X
   Jing, S
   Zhou, H
   Lan, WJ
   Li, SW
AF Zhou, Han
   Yu, Xiong
   Jing, Shan
   Zhou, Hao
   Lan, Wenjie
   Li, Shaowei
TI Measurement of droplet breakage in a pump-mixer
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Population balance model; Pump-mixer; Droplet breakup; Daughter droplet
   size distribution
ID FLUID PARTICLES; PULSED DISC; POPULATION BALANCES; THEORETICAL-MODEL;
   DOUGHNUT COLUMN; BUBBLE BREAKUP; STIRRED-TANK; LIQUID; SIMULATION; FLOW
AB The direct experimental data for droplet breakage frequency and daughter droplet size distribution is urgently required for the application of the population balance model. To meet this requirement, a method to directly measure the droplet breakage in the pump-mixer was developed using a high speed online camera. Two typical breakup patterns, tensile breakup and revolving breakup were observed and the number of the breakup fragments was determined. The multiple breakage was treated as a series of binary breakups. In order to precisely describe the daughter size distribution, these binary breakups were divided into three different types, i.e. the original tensile breakup, intermediate tensile breakup, and revolving breakup. The influences of the rotating speed and interfacial tension on the droplet breakup frequency and daughter droplet size distribution were then quantitatively investigated. Empirical correlations were proposed and good agreement was found between the prediction results and the experimental data. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Zhou, Han; Yu, Xiong; Jing, Shan; Zhou, Hao; Li, Shaowei] Tsinghua Univ, Collaborat Innovat Ctr Adv Nucl Energy Technol, Inst Nucl & New Energy Technol, Beijing 100084, Peoples R China.
   [Lan, Wenjie] China Univ Petr, State Key Lab Heavy Oil Proc, Beijing 102249, Peoples R China.
   [Li, Shaowei] Tsinghua Univ, State Key Lab Chem Engn, Beijing 100084, Peoples R China.
RP Jing, S; Li, SW (reprint author), Tsinghua Univ, Collaborat Innovat Ctr Adv Nucl Energy Technol, Inst Nucl & New Energy Technol, Beijing 100084, Peoples R China.
EM s-jing@tsinghua.edu.cn; lsw@tsinghua.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21576147, 21776151, 21376132]
FX We gratefully acknowledge the support of the National Natural Science
   Foundation of China (21576147, 21776151, 21376132).
CR Alopaeus V, 1999, CHEM ENG SCI, V54, P5887, DOI 10.1016/S0009-2509(99)00170-0
   Andersson R, 2006, AICHE J, V52, P2020, DOI 10.1002/aic.10831
   Andersson R, 2006, AICHE J, V52, P2031, DOI 10.1002/aic.10832
   Ayyappa SVN, 2016, CHEM ENG PROCESS, V105, P30, DOI 10.1016/j.cep.2016.04.005
   Baldi S, 2004, CHEM ENG SCI, V59, P2659, DOI 10.1016/j.ces.2004.03.021
   COULALOGLOU CA, 1977, CHEM ENG SCI, V32, P1289, DOI 10.1016/0009-2509(77)85023-9
   Falzone S., 2018, ADV CHEM ENG, V52, P125
   Fang Q, 2017, CHEM ENG SCI, V161, P274, DOI 10.1016/j.ces.2016.12.051
   Hagesaether L, 2002, CHEM ENG SCI, V57, P3251, DOI 10.1016/S0009-2509(02)00197-5
   Hartmann H, 2004, CHEM ENG SCI, V59, P2419, DOI 10.1016/j.ces.2004.01.065
   Kopriwa N, 2012, SOLVENT EXTR ION EXC, V30, P683, DOI 10.1080/07366299.2012.700598
   Liao YX, 2009, CHEM ENG SCI, V64, P3389, DOI 10.1016/j.ces.2009.04.026
   Luo H, 1996, AICHE J, V42, P1225, DOI 10.1002/aic.690420505
   Maass S, 2012, CHEM ENG SCI, V70, P146, DOI 10.1016/j.ces.2011.08.027
   Parvizi S, 2016, MIN PROC EXT MET REV, V37, P342, DOI 10.1080/08827508.2016.1218868
   Qin CP, 2016, CHEM ENG SCI, V155, P16, DOI 10.1016/j.ces.2016.07.034
   Ramachandran R, 2009, CHEM ENG RES DES, V87, P598, DOI 10.1016/j.cherd.2008.11.007
   RAO NVR, 1984, CAN J CHEM ENG, V62, P497, DOI 10.1002/cjce.5450620408
   Razzaghi K, 2016, AICHE J, V62, P4508, DOI 10.1002/aic.15314
   Reeve RN, 2002, CHEM ENG RES DES, V80, P864, DOI 10.1205/026387602321143408
   Solsvik J, 2016, IND ENG CHEM RES, V55, P2872, DOI 10.1021/acs.iecr.6b00591
   Solsvik J, 2015, CHEM ENG SCI, V131, P219, DOI 10.1016/j.ces.2015.03.059
   Solsvik J, 2014, CAN J CHEM ENG, V92, P234, DOI 10.1002/cjce.21876
   Srilatha C, 2008, CHEM ENG PROCESS, V47, P1678, DOI 10.1016/j.cep.2007.09.009
   Thakur RK, 2003, CHEM ENG RES DES, V81, P787, DOI 10.1205/026387603322302968
   van Delden ML, 2006, SOLVENT EXTR ION EXC, V24, P519, DOI 10.1080/07366290600760649
   Vonka M, 2015, AICHE J, V61, P2403, DOI 10.1002/aic.14831
   Wang TF, 2006, AICHE J, V52, P125, DOI 10.1002/aic.10611
   Wang TF, 2005, IND ENG CHEM RES, V44, P7540, DOI 10.1021/ie0489002
   Wang TF, 2003, CHEM ENG SCI, V58, P4629, DOI 10.1016/j.ces.2003.07.009
   Xing CT, 2013, CHEM ENG SCI, V95, P313, DOI 10.1016/j.ces.2013.03.022
   Zaccone A, 2007, CHEM ENG SCI, V62, P6297, DOI 10.1016/j.ces.2007.07.026
   Zhou H, 2017, AICHE J, V63, P4188, DOI 10.1002/aic.15742
NR 33
TC 2
Z9 2
U1 4
U2 17
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 23
EP 38
DI 10.1016/j.ces.2018.11.035
PG 16
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500003
DA 2020-05-12
ER

PT J
AU Nikku, M
   Daikeler, A
   Stroh, A
   Myohanen, K
AF Nikku, Markku
   Daikeler, Alexander
   Stroh, Alexander
   Myohanen, Kari
TI Comparison of solid phase closure models in Eulerian-Eulerian
   simulations of a circulating fluidized bed riser
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
ID NUMERICAL-SIMULATION; HYDRODYNAMIC MODELS; PARTICLE-TRANSPORT;
   VOLUME-FRACTION; FLOW; DRAG; FLUX; COEFFICIENT; EQUATIONS; FURNACE
AB In this work, computational fluid dynamics with Eulerian-Eulerian modeling approach is used in the investigation of the effect of the solid phase closure models on the hydrodynamics of a circulating fluidized bed riser. The studied models are the kinetic theory of granular flow and the powder modulus model. Computational performance and model prediction accuracy are investigated by performing transient simulations for three different cases and for different mesh sizes. The modeling results are compared with measured vertical pressure profile, external circulation mass flow rates, and particle velocity and concentration profiles obtained from a laboratory scale circulating fluidized bed unit. Additionally the computational times are compared to estimate the computational performance and to investigate if a simpler set of closures is computationally more affordable. The results indicate that both closure models can give good predictions for some quantities, while lacking in other quantities. The results indicate that the closure models for the solid phase have a noticeable effect on the model predictions, such as the vertical pressure profile and external circulation rate of the particles. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Nikku, Markku; Myohanen, Kari] Lappeenranta Univ Technol, LUT Energy, PL 20, FI-53851 Lappeenranta, Finland.
   [Daikeler, Alexander; Stroh, Alexander] Tech Univ Darmstadt, Inst Energy Syst & Technol, Otto Berndt Str 2, D-64287 Darmstadt, Germany.
RP Nikku, M (reprint author), Lappeenranta Univ Technol, LUT Energy, PL 20, FI-53851 Lappeenranta, Finland.
EM mnikku@lut.fi
FU Academy of FinlandAcademy of Finland [278641]
FX The authors would like to acknowledge the financial support for this
   research from the Academy of Finland under Grant No. 278641.
CR Adamczyk WP, 2014, PARTICUOLOGY, V16, P29, DOI 10.1016/j.partic.2013.10.007
   Adamczyk WP, 2014, PARTICUOLOGY, V15, P129, DOI 10.1016/j.partic.2013.06.008
   Alves JJN, 1998, COMPUT CHEM ENG, V22, pS763, DOI 10.1016/S0098-1354(98)00143-4
   Armstrong LM, 2010, CHEM ENG J, V160, P239, DOI 10.1016/j.cej.2010.02.032
   Chan CW, 2009, POWDER TECHNOL, V196, P318, DOI 10.1016/j.powtec.2009.08.019
   Chaouki J, 1997, IND ENG CHEM RES, V36, P4476, DOI 10.1021/ie970210t
   Cloete S, 2011, POWDER TECHNOL, V205, P103, DOI 10.1016/j.powtec.2010.08.072
   Daikeler A, 2019, CHEM ENG SCI, V195, P921, DOI 10.1016/j.ces.2018.10.037
   Dubrawski K, 2013, POWDER TECHNOL, V235, P203, DOI 10.1016/j.powtec.2012.10.031
   Ellis N, 2004, POWDER TECHNOL, V141, P124, DOI 10.1016/j.powtec.2004.03.001
   Enwald H, 1996, INT J MULTIPHAS FLOW, V22, P21, DOI 10.1016/S0301-9322(96)90004-X
   ERGUN S, 1952, CHEM ENG PROG, V48, P89
   Farzaneh M, 2015, POWDER TECHNOL, V270, P68, DOI 10.1016/j.powtec.2014.09.050
   Fox RO, 2014, J FLUID MECH, V742, P368, DOI 10.1017/jfm.2014.21
   Gidaspow  D., 1991, 7 INT C FLUID GOLD C
   Jalali P, 2018, POWDER TECHNOL, V339, P569, DOI 10.1016/j.powtec.2018.08.046
   Jalali P, 2013, IND ENG CHEM RES, V52, P4342, DOI 10.1021/ie302704j
   Jin BS, 2010, ENERG FUEL, V24, P3159, DOI 10.1021/ef100096c
   JOHNSON PC, 1990, J FLUID MECH, V210, P501, DOI 10.1017/S0022112090001380
   Johnsson H, 2001, POWDER TECHNOL, V115, P13, DOI 10.1016/S0032-5910(00)00270-9
   Lu BN, 2013, AICHE J, V59, P1108, DOI 10.1002/aic.13917
   Lu G, 2015, CHEM ENG SCI, V127, P425, DOI 10.1016/j.ces.2014.11.050
   LUN CKK, 1984, J FLUID MECH, V140, P223, DOI 10.1017/S0022112084000586
   LUN CKK, 1986, ACTA MECH, V63, P15, DOI 10.1007/BF01182538
   Magnusson A, 2005, POWDER TECHNOL, V151, P19, DOI 10.1016/j.powtec.2004.11.028
   Malcus S, 2000, CHEM ENG SCI, V55, P4129, DOI 10.1016/S0009-2509(00)00083-X
   MASSOUDI M, 1992, AICHE J, V38, P471, DOI 10.1002/aic.690380317
   Maurer S, 2015, INT J MULTIPHAS FLOW, V75, P237, DOI 10.1016/j.ijmultiphaseflow.2015.06.001
   Nikku M., 2017, P 12 INT C FLUID BED, P349
   Nikku M, 2016, CHEM ENG RES DES, V115, P77, DOI 10.1016/j.cherd.2016.09.023
   Nikolopoulos A, 2017, CHEM ENG SCI, V163, P189, DOI 10.1016/j.ces.2017.01.052
   Panday R, 2014, POWDER TECHNOL, V258, P370, DOI 10.1016/j.powtec.2014.02.010
   Passalacqua A, 2009, CHEM ENG SCI, V64, P2795, DOI 10.1016/j.ces.2009.03.005
   Patil DJ, 2005, CHEM ENG SCI, V60, P57, DOI 10.1016/j.ces.2004.07.059
   Patil DJ, 2005, CHEM ENG SCI, V60, P73, DOI 10.1016/j.ces.2004.07.058
   Peltola J., 2009, DYNAMICS CIRCULATING
   Pugsley T, 2003, CHEM ENG SCI, V58, P3923, DOI 10.1016/S0009-2509(03)00288-4
   Qiu XP, 2017, POWDER TECHNOL, V314, P299, DOI 10.1016/j.powtec.2016.09.002
   SAVAGE SB, 1988, J FLUID MECH, V194, P457, DOI 10.1017/S0022112088003064
   SCHAEFFER DG, 1987, J DIFFER EQUATIONS, V66, P19, DOI 10.1016/0022-0396(87)90038-6
   Shah MT, 2016, CHEM ENG RES DES, V111, P403, DOI 10.1016/j.cherd.2016.04.017
   Shah S, 2015, POWDER TECHNOL, V274, P239, DOI 10.1016/j.powtec.2015.01.019
   Shah S, 2015, PARTICUOLOGY, V18, P66, DOI 10.1016/j.partic.2014.05.008
   SINCLAIR JL, 1989, AICHE J, V35, P1473, DOI 10.1002/aic.690350908
   Syamlal M., 1993, MFIX DOCUMENTATION T, DOI [10.2172/10145548, DOI 10.2172/10145548]
   Tortora PR, 2008, POWDER TECHNOL, V180, P312, DOI 10.1016/j.powtec.2007.09.007
   Van de Velden M, 2008, POWDER TECHNOL, V183, P290, DOI 10.1016/j.powtec.2007.07.027
   van Wachem BGM, 2001, AICHE J, V47, P1035, DOI 10.1002/aic.690470510
   Weber JM, 2018, POWDER TECHNOL, V327, P524, DOI 10.1016/j.powtec.2017.12.094
   Wen C.Y., 1966, CHEM ENG PROGR S SER, V62, P100, DOI DOI 10.1016/S0032-0633(98)00014-2
   Wiesendorf V, 2000, POWDER TECHNOL, V110, P143, DOI 10.1016/S0032-5910(99)00276-4
   Yang DY, 2018, MEASUREMENT, V127, P227, DOI 10.1016/j.measurement.2018.05.076
   Ye S, 2009, CHEM ENG TECHNOL, V32, P580, DOI 10.1002/ceat.200800361
   Zhao YH, 2016, IND ENG CHEM RES, V55, P1439, DOI 10.1021/acs.iecr.5b03792
   Zhao YH, 2015, INT J MULTIPHAS FLOW, V71, P1, DOI 10.1016/j.ijmultiphaseflow.2014.12.002
   Zheng Y, 2001, CHEM ENG SCI, V56, P6813, DOI 10.1016/S0009-2509(01)00319-0
   Zhou XY, 2013, PARTICUOLOGY, V11, P556, DOI 10.1016/j.partic.2012.08.006
NR 57
TC 5
Z9 5
U1 3
U2 14
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 39
EP 50
DI 10.1016/j.ces.2018.11.031
PG 12
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500004
DA 2020-05-12
ER

PT J
AU Dai, CL
   Huang, YP
   Lyu, XY
   Li, L
   Sun, YP
   Zhao, MW
   Zhao, G
   Wu, YN
AF Dai, Caili
   Huang, Yongping
   Lyu, Xiaoying
   Li, Lin
   Sun, Yongpeng
   Zhao, Mingwei
   Zhao, Guang
   Wu, Yining
TI Solid-like film formed by nano-silica self-assembly at oil-water
   interface
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE NS-surfactant; Interfacial tension; Surface coverage; Self-assembled;
   Solid-like film
ID WETTABILITY ALTERATION; JANUS PARTICLES; NANOFLUIDS; NANOPARTICLES;
   SURFACTANTS; RECOVERY; BEHAVIOR; TENSION
AB Nanoparticles have been widely investigated in enhancing oil recovery for unique interfacial properties. Bare nano-silica (NS) cannot be easily adsorbed at the interface due to a large number of hydroxyls on its surface. In this study, NS was decorated by dodecyl trimethyl ammonium bromide (DTAB), forming NS-surfactant via electrostatic force. In order to investigate the interfacial behavior of NS-surfactant at the oil-water interface, experiments and molecular dynamics simulations were conducted. Results indicated that NS-surfactant can self-assemble at the oil-water interface and solid-like films were observed, which contributed to 10.4% oil recovery of NS-surfactant flooding relative to water flooding. DTAB concentration, pH and NaCl were used to regulate the interfacial behavior of NS-surfactant. Interfacial tension decreased and surface coverage increased with DTAB concentration increase due to more NS-surfactant arranged at oil-water interface. NS-surfactant could arrange at the oil-water interface more closely through increase zeta potential, which could be achieved by adjusting pH and adding NaCl. Lower interfacial tension and higher surface coverage was observed under weakly acidic conditions. The addition of NaCl could greatly reduce the interfacial tension and increase the surface coverage. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Dai, Caili; Huang, Yongping; Li, Lin; Sun, Yongpeng; Zhao, Mingwei; Zhao, Guang; Wu, Yining] China Univ Petr East China, State Key Lab Heavy Oil Proc, Sch Petr Engn, Qingdao 266580, Peoples R China.
   [Lyu, Xiaoying] Sinochem Quanzhou Energy Technol Co LTD, Quanzhou 362103, Peoples R China.
RP Dai, CL; Wu, YN (reprint author), China Univ Petr East China, State Key Lab Heavy Oil Proc, Sch Petr Engn, Qingdao 266580, Peoples R China.
OI Dai, Cai li/0000-0002-7477-8865; Zhao, Guang/0000-0002-2254-3511
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [U1663206, 51704313, 51425406]; Changjiang Scholars
   ProgramProgram for Changjiang Scholars & Innovative Research Team in
   University (PCSIRT) [T2014152]; Taishan Scholar Climbing Program in
   Shandong Province [tspd20161004]; Fundamental Research Funds for the
   Central UniversitiesFundamental Research Funds for the Central
   Universities [18CX02028A]
FX This work was supported by the National Natural Science Foundation of
   China (U1663206, 51704313, 51425406), Changjiang Scholars Program (No.
   T2014152), the Taishan Scholar Climbing Program in Shandong Province
   (tspd20161004) and the Fundamental Research Funds for the Central
   Universities (18CX02028A).
CR Al-Anssari S, 2016, J COLLOID INTERF SCI, V461, P435, DOI 10.1016/j.jcis.2015.09.051
   Barry MM, 2015, J PETROL SCI ENG, V127, P338, DOI 10.1016/j.petrol.2015.01.012
   Bera A, 2016, J NAT GAS SCI ENG, V34, P1284, DOI 10.1016/j.jngse.2016.08.023
   Bera A, 2014, J CHEM ENG DATA, V59, P2490, DOI 10.1021/je500274r
   Bera A, 2014, J CHEM ENG DATA, V59, P89, DOI 10.1021/je400850c
   Bera A, 2013, J SURFACTANTS DETERG, V16, P621, DOI 10.1007/s11743-012-1422-4
   Binks BP, 2002, CURR OPIN COLLOID IN, V7, P21, DOI 10.1016/S1359-0294(02)00008-0
   Gavrielatos I, 2017, J PETROL SCI ENG, V152, P664, DOI 10.1016/j.petrol.2016.12.040
   Giraldo J, 2013, ENERG FUEL, V27, P3659, DOI 10.1021/ef4002956
   Glaser N, 2006, LANGMUIR, V22, P5227, DOI 10.1021/la060693i
   Guo F, 2016, FUEL, V186, P430, DOI 10.1016/j.fuel.2016.08.058
   Jiang S, 2010, ADV MATER, V22, P1060, DOI 10.1002/adma.200904094
   Jiang YF, 2017, ACS APPL MATER INTER, V9, P33327, DOI 10.1021/acsami.7b10981
   Karimi A, 2012, ENERG FUEL, V26, P1028, DOI 10.1021/ef201475u
   Kondiparty K, 2011, LANGMUIR, V27, P3324, DOI 10.1021/la104204b
   Kondiparty K, 2012, LANGMUIR, V28, P14618, DOI 10.1021/la3027013
   Kuang WD, 2018, FUEL, V220, P849, DOI 10.1016/j.fuel.2018.01.102
   Lim S, 2016, J COLLOID INTERF SCI, V470, P22, DOI 10.1016/j.jcis.2016.02.044
   Liu KL, 2012, LANGMUIR, V28, P16274, DOI 10.1021/la302702g
   Liu XB, 2017, ANGEW CHEM INT EDIT, V56, P12594, DOI 10.1002/anie.201706839
   Luo D, 2016, P NATL ACAD SCI USA, V113, P7711, DOI 10.1073/pnas.1608135113
   Mao H, 2015, J PETROL SCI ENG, V129, P1, DOI 10.1016/j.petrol.2015.03.003
   Mo D., 2013, APPL NANOPARTICLE ST
   Nikolov A, 2010, LANGMUIR, V26, P7665, DOI 10.1021/la100928t
   Pei H. H., 2015, SPE CAN HEAV OIL TEC, P412
   Ragab A.M.S., 2015, SPE N AFR TECH C EXH
   Rubilar O, 2013, BIOTECHNOL LETT, V35, P1365, DOI 10.1007/s10529-013-1239-x
   Saidur R, 2011, RENEW SUST ENERG REV, V15, P1646, DOI 10.1016/j.rser.2010.11.035
   Salih AH, 2017, SPE W REG M
   Sarkar J, 2015, RENEW SUST ENERG REV, V43, P164, DOI 10.1016/j.rser.2014.11.023
   Sharma T, 2016, IND ENG CHEM RES, V55, P12387, DOI 10.1021/acs.iecr.6b03299
   Singh R., 2014, SPE IMPR OIL REC S 1
   Somasundaran P, 2006, J PETROL SCI ENG, V52, P198, DOI 10.1016/j.petrol.2006.03.022
   Suleimanov BA, 2011, J PETROL SCI ENG, V78, P431, DOI 10.1016/j.petrol.2011.06.014
   Toor A, 2018, ACS NANO, V12, P2365, DOI 10.1021/acsnano.7b07635
   Toor A, 2017, NANO LETT, V17, P3119, DOI 10.1021/acs.nanolett.7b00556
   Torsater O., 2012, IMPROVED OIL RECOVER
   Vryzas Z, 2017, ENERGIES, V10, DOI 10.3390/en10040540
   Walther A, 2008, SOFT MATTER, V4, P663, DOI 10.1039/b718131k
   Wasan D, 2011, CURR OPIN COLLOID IN, V16, P344, DOI 10.1016/j.cocis.2011.02.001
   Wei B., 2016, ENERGY FUELS, V30
   Wei B, 2017, LANGMUIR, V33, P5127, DOI 10.1021/acs.langmuir.7b00387
   Wu Y., 2018, LANGMUIR ACS J SURF
   Yu W, 2011, J NANOMATER, V2012, P1
   Zhang H., 2016, ENERGY FUELS, V30
   Zhang J., 2017, LANGMUIR, V33
   Zhang T., 2009, SPE INT S OILF CHEM
NR 47
TC 4
Z9 4
U1 11
U2 72
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 51
EP 61
DI 10.1016/j.ces.2018.11.042
PG 11
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500005
DA 2020-05-12
ER

PT J
AU Zha, L
   Shang, MJ
   Qiu, M
   Zhang, H
   Su, YH
AF Zha, Li
   Shang, Minjing
   Qiu, Min
   Zhang, Hong
   Su, Yuanhai
TI Process intensification of mixing and chemical modification for polymer
   solutions in microreactors based on gas-liquid two-phase flow
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Mixing; Microreactors; Process intensification; Flow patterns; Polymers;
   Chemical modification
ID HETEROGENEOUS CATALYSIS; SLUG FLOW; BUBBLES; SYSTEM; PERFORMANCE;
   TECHNOLOGY; REGIMES; WAKE
AB Inert gas was introduced into a capillary microreactor for intensifying the mixing and reaction of polymer solutions. Operational ranges regarding volumetric flow rates of the gas and liquid phases deserved to be carefully selected for ensuring the process stability. Formation of side-by-side bubble flow in microreactors relevant to special properties of polymer solutions was observed with the use of high-speed camera. The gas introduction obviously promoted the mixing of polymer solutions in microreactors, and accordingly the improvement on the micromixing performance was confirmed by a diazo-coupling reaction system. Various factors such as the gas volume fraction and introduction mode affected gas-liquid two-phase flow patterns and thus the mixing efficiency in microreactors. Simplified mathematic models were developed to evaluate the shear effect and to reveal intensification mechanisms within the gas-liquid slug flow and the annular flow in microreactors. Moreover, the effectiveness of such a mixing intensification strategy for polymer solutions was further demonstrated through the sulfonation of polystyrene (PS) in the capillary microreactor. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Zha, Li; Shang, Minjing; Qiu, Min; Zhang, Hong; Su, Yuanhai] Shanghai Jiao Tong Univ, Shanghai Electrochem Energy Devices Res Ctr, Sch Chem & Chem Engn, Dept Chem Engn, Shanghai 200240, Peoples R China.
   [Su, Yuanhai] Shanghai Jiao Tong Univ, Minist Educ, Key Lab Thin Film & Microfabricat, Shanghai 200240, Peoples R China.
RP Su, YH (reprint author), Shanghai Jiao Tong Univ, Shanghai Electrochem Energy Devices Res Ctr, Sch Chem & Chem Engn, Dept Chem Engn, Shanghai 200240, Peoples R China.
EM y.su@sjtu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21676164, 21706157]; China Postdoctoral Science
   FoundationChina Postdoctoral Science Foundation [2017M611565]
FX We would like to acknowledge financial support from the National Natural
   Science Foundation of China (Nos. 21676164 and 21706157) and China
   Postdoctoral Science Foundation (2017M611565).
CR Abiev RS, 2008, THEOR FOUND CHEM EN+, V42, P105, DOI 10.1134/S0040579508020012
   Abiev RS, 2013, CHEM ENG J, V227, P66, DOI 10.1016/j.cej.2012.10.009
   ACHARYA A, 1978, IND ENG CHEM FUND, V17, P230, DOI 10.1021/i160067a018
   Arratia PE, 2008, PHYS REV E, V77, DOI 10.1103/PhysRevE.77.036309
   BOURNE JR, 1985, CHEM ENG COMMUN, V37, P293, DOI 10.1080/00986448508911287
   BOURNE JR, 1992, IND ENG CHEM RES, V31, P949, DOI 10.1021/ie00003a042
   Chen WL, 2002, INT J MULTIPHAS FLOW, V28, P1235, DOI 10.1016/S0301-9322(02)00023-X
   Chiarello E, 2015, MICROMACHINES-BASEL, V6, P1825, DOI 10.3390/mi6121458
   Dong ZY, 2015, LAB CHIP, V15, P1145, DOI 10.1039/c4lc01431f
   Engler M, 2004, CHEM ENG J, V101, P315, DOI 10.1016/j.cej.2003.10.017
   Fu TT, 2015, CHEM ENG PROCESS, V91, P114, DOI 10.1016/j.cep.2015.03.020
   Fu TT, 2011, MICROFLUID NANOFLUID, V10, P1135, DOI 10.1007/s10404-010-0741-x
   Gutmann B, 2015, ANGEW CHEM INT EDIT, V54, P6688, DOI 10.1002/anie.201409318
   HASSAGER O, 1979, NATURE, V279, P402, DOI 10.1038/279402a0
   Hessel V, 2005, CHEM ENG SCI, V60, P2479, DOI 10.1016/j.ces.2004.11.033
   Husny J, 2006, J NON-NEWTON FLUID, V137, P121, DOI 10.1016/j.jnnfm.2006.03.007
   Jensen KF, 1999, AICHE J, V45, P2051, DOI 10.1002/aic.690451003
   Jensen KF, 2017, AICHE J, V63, P858, DOI 10.1002/aic.15642
   Katz J, 1996, INT J MULTIPHAS FLOW, V22, P239, DOI 10.1016/0301-9322(95)00081-X
   Kreutzer MT, 2005, CHEM ENG SCI, V60, P5895, DOI 10.1016/j.ces.2005.03.022
   Kuijpers KPL, 2017, REACT CHEM ENG, V2, P109, DOI 10.1039/c7re00024c
   Ley SV, 2015, ANGEW CHEM INT EDIT, V54, P10122, DOI 10.1002/anie.201501618
   Li GX, 2019, AICHE J, V65, P334, DOI 10.1002/aic.16211
   Li HZ, 1998, CHEM ENG SCI, V53, P2219, DOI 10.1016/S0009-2509(98)00048-7
   Lin TJ, 2005, INT J MULTIPHAS FLOW, V31, P239, DOI 10.1016/j.ijmultiphaseflow.2004.11.004
   Marre S, 2010, CHEM SOC REV, V39, P1183, DOI 10.1039/b821324k
   Nagaki A, 2004, J AM CHEM SOC, V126, P14702, DOI 10.1021/ja044879k
   Nagaki A, 2008, CHEM-ASIAN J, V3, P1558, DOI 10.1002/asia.200800081
   Noel T., 2015, TOP ORGANOMETAL CHEM, V9, P27
   Noel T, 2011, CHEM SOC REV, V40, P5010, DOI 10.1039/c1cs15075h
   Pu X, 2018, CHEM ENG SCI, V184, P200, DOI 10.1016/j.ces.2018.03.049
   Rebrov EV, 2010, THEOR FOUND CHEM EN+, V44, P355, DOI 10.1134/S0040579510040019
   Velez-Cordero JR, 2011, J NON-NEWTON FLUID, V166, P118, DOI 10.1016/j.jnnfm.2010.11.003
   Roumpea E, 2017, AICHE J, V63, P3599, DOI 10.1002/aic.15704
   Serizawa A, 2002, EXP THERM FLUID SCI, V26, P703, DOI 10.1016/S0894-1777(02)00175-9
   Shao N, 2009, CHEM ENG SCI, V64, P2749, DOI 10.1016/j.ces.2009.01.067
   Song H, 2003, J AM CHEM SOC, V125, P14613, DOI 10.1021/ja0354566
   Song Y, 2018, AICHE J, V64, P1828, DOI 10.1002/aic.16046
   Sontti SG, 2017, CHEM ENG J, V330, P245, DOI 10.1016/j.cej.2017.07.097
   Sousa RG, 2007, INT J MULTIPHAS FLOW, V33, P970, DOI 10.1016/j.ijmultiphaseflow.2007.03.009
   Steinbacher JL, 2006, J POLYM SCI POL CHEM, V44, P6505, DOI 10.1002/pola.21630
   Su YH, 2015, LAB CHIP, V15, P179, DOI 10.1039/c4lc00987h
   Su YH, 2014, IND ENG CHEM RES, V53, P390, DOI 10.1021/ie401924x
   Su YH, 2012, AICHE J, V58, P1660, DOI 10.1002/aic.12698
   Tanimu A, 2017, CHEM ENG J, V327, P792, DOI 10.1016/j.cej.2017.06.161
   Thandlam AK, 2017, HEAT MASS TRANSFER, V53, P1183, DOI 10.1007/s00231-016-1898-y
   Tonhauser C, 2012, MACROMOLECULES, V45, P9551, DOI 10.1021/ma301671x
   Watanabe S, 2017, CHEM ENG J, V313, P724, DOI 10.1016/j.cej.2016.12.118
   WILKE CR, 1955, AICHE J, V1, P264, DOI 10.1002/aic.690010222
   Wilms D, 2007, CHEM ENG TECHNOL, V30, P1519, DOI 10.1002/ceat.200700277
   Yue J, 2008, CHEM ENG SCI, V63, P4189, DOI 10.1016/j.ces.2008.05.032
   Zha L, 2018, AICHE J, V64, P3479, DOI 10.1002/aic.16188
NR 52
TC 2
Z9 2
U1 11
U2 57
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 62
EP 73
DI 10.1016/j.ces.2018.11.043
PG 12
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500006
DA 2020-05-12
ER

PT J
AU Liu, CY
   Carvalho, MS
   Kumar, S
AF Liu, Chen-Yu
   Carvalho, Marcio S.
   Kumar, Satish
TI Dynamic wetting failure in curtain coating: Comparison of model
   predictions and experimental observations
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Curtain coating; Dynamic wetting failure; Air entrainment; Surfactants
ID AIR ENTRAINMENT; HYDRODYNAMIC ASSIST; SURFACTANT; INSTABILITY;
   HYSTERESIS; SPEED; ONSET
AB In this work dynamic wetting failure of Newtonian liquids in a curtain coating geometry is studied using a hydrodynamic model developed in our prior work (Liu et al., 2016b). The model is used to predict the onset of wetting failure with curtain heights consistent with prior experimental setups. In the model, a Navier-slip boundary condition and constant contact angle are used to describe the dynamic contact line (DCL). The governing equations are solved with the Galerkin finite-element method and the critical substrate speed is identified at which wetting failure occurs. A boundary of a coating window is constructed which outlines the critical substrate speed for different flow rates of the liquid curtain. The model predictions are compared with prior experimental observations reported by Blake et al. (1999) and Marston et al. (2009). The model reproduces the non-monotonic behavior of the critical speed as the liquid flow rate increases. When surfactants are absent, our results suggest that the experimental observations can largely be explained with a model that uses the simplest boundary conditions at the DCL (Navier-slip and constant contact angle) and accounts for the air stresses there to accurately calculate interface shapes. When surfactants are present, our results suggest that a decrease in the equilibrium surface tension may not be the only mechanism responsible for changes in the shape of the coating window. In particular, Marangoni stresses may play an important role. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Liu, Chen-Yu; Kumar, Satish] Univ Minnesota, Dept Chem Engn & Mat Sci, Minneapolis, MN 55455 USA.
   [Carvalho, Marcio S.] Pontificia Univ Catolica Rio de Janeiro, Dept Mech Engn, BR-22451041 Rio De Janeiro, RJ, Brazil.
RP Kumar, S (reprint author), Univ Minnesota, Dept Chem Engn & Mat Sci, Minneapolis, MN 55455 USA.; Carvalho, MS (reprint author), Pontificia Univ Catolica Rio de Janeiro, Dept Mech Engn, BR-22451041 Rio De Janeiro, RJ, Brazil.
EM msc@puc-rio.br; kumar030@umn.edu
RI Kumar, Satish/A-1235-2007
FU National Science FoundationNational Science Foundation (NSF)
   [CBET-1434016]
FX This work is supported by the National Science Foundation under Grant
   No. CBET-1434016. C.-Y. L. acknowledges financial support from the
   Doctoral Dissertation Fellowship administered by the University of
   Minnesota. We are grateful to the Minnesota Supercomputing Institute
   (MSI) at the University of Minnesota for providing computational
   resources.
CR Blake T. D., 1995, US Patent, Patent No. 5391401
   Blake TD, 1999, PHYS FLUIDS, V11, P1995, DOI 10.1063/1.870063
   BLAKE TD, 1994, AICHE J, V40, P229, DOI 10.1002/aic.690400205
   Blake TD, 2004, J COLLOID INTERF SCI, V279, P198, DOI 10.1016/j.jcis.2004.06.057
   Campana D, 2004, INT J MULTIPHAS FLOW, V30, P431, DOI 10.1016/j.ijmultiphaseflow.2004.03.007
   Campana DM, 2011, PHYS FLUIDS, V23, DOI 10.1063/1.3589346
   CHANG CH, 1995, COLLOID SURFACE A, V100, P1, DOI 10.1016/0927-7757(94)03061-4
   Chang HK, 2012, POLYM ENG SCI, V52, P1, DOI 10.1002/pen.22031
   Dussan EB, 1976, J FLUID MECH, V77, P665, DOI DOI 10.1017/S0022112076002838
   HUH C, 1971, J COLLOID INTERF SCI, V35, P85, DOI 10.1016/0021-9797(71)90188-3
   Kumar S, 2004, PHYS FLUIDS, V16, P39, DOI 10.1063/1.1629128
   Lauga E., 2005, SPRINGER HDB EXPT FL, P1219
   Liu CY, 2017, J FLUID MECH, V825, P677, DOI 10.1017/jfm.2017.394
   Liu CY, 2016, J FLUID MECH, V808, P290, DOI 10.1017/jfm.2016.594
   Liu CY, 2016, J FLUID MECH, V789, P285, DOI 10.1017/jfm.2015.739
   Marston JO, 2006, J FLUID MECH, V569, P349, DOI 10.1017/S0022112006002886
   Marston JO, 2007, EXP FLUIDS, V42, P483, DOI 10.1007/s00348-007-0258-6
   Marston JO, 2009, EXP FLUIDS, V46, P549, DOI 10.1007/s00348-008-0580-7
   Miamoto K., 1997, LIQUID FILM COATING, P463
   Rame E, 2001, J FLUID MECH, V440, P205, DOI 10.1017/S0022112001004712
   Schunk P. R., 1997, LIQUID FILM COATING, P495
   SCRIVEN LE, 1960, NATURE, V187, P186, DOI 10.1038/187186a0
   Shikhmurzaev Y. D, 1993, MOVING CONTACT LINE
   Shikhmurzaev YD, 1997, J FLUID MECH, V334, P211, DOI 10.1017/S0022112096004569
   Sprittles JE, 2017, PHYS REV LETT, V118, DOI 10.1103/PhysRevLett.118.114502
   Sprittles JE, 2015, J FLUID MECH, V769, P444, DOI 10.1017/jfm.2015.121
   Tricot Y.-M., 1997, LIQUID FILM COATING, P99
   Vandre E, 2014, J FLUID MECH, V747, P119, DOI 10.1017/jfm.2014.110
   Vandre E, 2013, PHYS FLUIDS, V25, DOI 10.1063/1.4821193
   VANDRE E. A., 2013, THESIS
   Vandre E, 2012, J FLUID MECH, V707, P496, DOI 10.1017/jfm.2012.295
   Wilson M. C. T., 2001, IUTAM S FREE SURF FL, P345
   Wilson MCT, 2006, PHYS REV E, V73, DOI 10.1103/PhysRevE.73.041606
   Yamamura M, 2000, CHEM ENG SCI, V55, P931, DOI 10.1016/S0009-2509(99)00387-5
   Yamamura M, 2007, COLLOID SURFACE A, V311, P55, DOI 10.1016/j.colsurfa.2007.08.027
NR 35
TC 2
Z9 2
U1 0
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 74
EP 82
DI 10.1016/j.ces.2018.11.015
PG 9
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500007
DA 2020-05-12
ER

PT J
AU Sebastia-Saez, D
   Hernandez, L
   Arellano-Garcia, H
   Julia, JE
AF Sebastia-Saez, Daniel
   Hernandez, Leonor
   Arellano-Garcia, Harvey
   Enrique Julia, Jose
TI Numerical and experimental characterization of the hydrodynamics and
   drying kinetics of a barbotine slurry spray
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Spray drying; Multiphase drop; CFD; Laser Doppler anemometry; Ceramic
   powder
ID DROPLET; CFD; SIMULATION; AGGLOMERATION; PRODUCTS; SWIRL
AB Spray drying is a basic unit operation in several process industries such as food, pharmaceutical, ceramic, and others. In this work, a Eulerian-Lagrangian three-phase simulation is presented to study the drying process of barbotine slurry droplets for the production of ceramic tiles. To this end, the simulated velocity field produced by a spray nozzle located at the Institute of Ceramic Technology in Castello (Spain) is benchmarked against measurements obtained by means of laser Doppler anemometry in order to validate the numerical model. Also, the droplet size distribution generated by the nozzle is obtained at operating conditions by means of laser diffraction and the data obtained are compared qualitatively to those found in the literature. The characteristic Rosin-Rammler droplet size from the distribution is introduced thereafter in the three-phase simulation to analyse the drying kinetics of individual droplets. The model predicts the theoretical linear evolution of the square diameter (D-2-law), and the temperature and mass exchange with the environment. The proposed model is intended to support the design and optimization of industrial spray dryers. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Sebastia-Saez, Daniel; Arellano-Garcia, Harvey] Univ Surrey, Dept Chem & Proc Engn, Guildford GU2 7XH, Surrey, England.
   [Hernandez, Leonor; Enrique Julia, Jose] Jaume I Univ, Dept Mech Engn, Castellon de La Plana 12071, Spain.
   [Arellano-Garcia, Harvey] Brandenburgische Tech Univ Cottbus Senftenberg, LS Prozess & Anlagentech, D-03046 Cottbus, Germany.
RP Sebastia-Saez, D (reprint author), Univ Surrey, Dept Chem & Proc Engn, Guildford GU2 7XH, Surrey, England.
EM j.sebastiasaez@surrey.ac.uk
RI Hernandez, Leonor/K-6129-2014
OI Hernandez, Leonor/0000-0002-7897-2972; Arellano-Garcia,
   Harvey/0000-0002-8297-0232
FU Fundacio Caixa Castello-Bancaixa [P11B2006-37, P11B2009-27]; Consejo
   Superior de Investigaciones Cientificas (CSIC) in Zaragoza, Spain;
   Ceramic Technology Institute of Castello
FX The authors gratefully acknowledge the financial support from Fundacio
   Caixa Castello-Bancaixa (projects P11B2006-37 and P11B2009-27), the
   Ceramic Technology Institute of Castello for granting us access to the
   pilot-scale spray dryer, and the Consejo Superior de Investigaciones
   Cientificas (CSIC) in Zaragoza, Spain, for leasing the laser diffraction
   analysis equipment.
CR Ali M, 2015, PROCEDIA ENGINEER, V102, P1284, DOI 10.1016/j.proeng.2015.01.259
   Anandharamakrishnan C., 2002, 16 INT DRYING S HYD
   ASCER (Asociacion Espanola de Fabricantes de Azulejos y Pavimentos Ceramicos), 2018, CIFR SECT 2017
   Eckert C, 2017, LWT-FOOD SCI TECHNOL, V82, P176, DOI 10.1016/j.lwt.2017.04.045
   Fletcher D., 2016, APPL MATH MODEL, V30, P1281
   Guo BY, 2004, APPL MATH MODEL, V28, P273, DOI 10.1016/S0307-904X(03)00133-1
   Jaskulski M, 2018, ADV POWDER TECHNOL, V29, P1724, DOI 10.1016/j.apt.2018.04.007
   Jubaer H., DRYING TECHNOLOGY
   JUSLIN L, 1995, INT J PHARM, V123, P257, DOI 10.1016/0378-5173(95)00082-T
   Kavoshi L, 2015, CHEM ENG RES DES, V98, P157, DOI 10.1016/j.cherd.2015.04.023
   Kieviet F.G., 1997, THESIS
   Kuriakose R, 2010, TRENDS FOOD SCI TECH, V21, P383, DOI 10.1016/j.tifs.2010.04.009
   Langrish TAG, 2004, CHEM ENG RES DES, V82, P821, DOI 10.1205/0263876041596661
   Mezhericher M, 2010, CHEM ENG PROCESS, V49, P1205, DOI 10.1016/j.cep.2010.09.002
   RANZ WE, 1952, CHEM ENG PROG, V48, P141
   RANZ WE, 1952, CHEM ENG PROG, V48, P173
   Roustapour OR, 2009, J FOOD ENG, V90, P20, DOI 10.1016/j.jfoodeng.2008.05.031
   Salem A, 2011, J IND ENG CHEM, V17, P527, DOI 10.1016/j.jiec.2010.10.023
   Schmitz-Schug I, 2016, CHEM ENG SCI, V141, P315, DOI 10.1016/j.ces.2015.11.008
   Southwell DB, 2001, CHEM ENG RES DES, V79, P222, DOI 10.1205/026387601750281752
   Straatsma J, 1999, J FOOD ENG, V42, P67, DOI 10.1016/S0260-8774(99)00107-7
   Tran TTH, 2017, DRY TECHNOL, V35, P1571, DOI 10.1080/07373937.2016.1263204
   Woo MW, 2012, CHEM ENG RES DES, V90, P336, DOI 10.1016/j.cherd.2011.06.019
   Woo MW, 2008, CHEM ENG RES DES, V86, P1038, DOI 10.1016/j.cherd.2008.04.003
   Xiao J, 2018, PARTICUOLOGY, V38, P44, DOI 10.1016/j.partic.2017.04.008
   Chang YC, 2007, J AEROSOL SCI, V38, P39, DOI 10.1016/j.jaerosci.2006.09.003
   Zaitone B. A., 2009, THESIS
NR 27
TC 0
Z9 0
U1 1
U2 16
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 83
EP 94
DI 10.1016/j.ces.2018.11.040
PG 12
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500008
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Zainal-Abidin, MH
   Hayyan, M
   Ngoh, GC
   Wong, WF
AF Zainal-Abidin, Mohamad Hamdi
   Hayyan, Maan
   Ngoh, Gek Cheng
   Wong, Won Fen
TI From nanoengineering to nanomedicine: A facile route to enhance
   biocompatibility of graphene as a potential nano-carrier for targeted
   drug delivery using natural deep eutectic solvents
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Carbon nanomaterial; Reactive oxygen species; Superoxide ion;
   Nanotoxicology; Breast cancer; Ionic liquid
ID WALLED CARBON NANOTUBES; CONTROLLED-RELEASE; OXIDE; CYTOTOXICITY;
   FUNCTIONALIZATION; GENERATION; TOXICITY; SYSTEM; NANOPARTICLES;
   NANOMATERIALS
AB Graphene has attracted massive interest in numerous biomedical applications such as anti-cancer therapy, drug delivery, bio-imaging and gene delivery. Therefore, it is important to ensure that graphene is nontoxic, and that its cellular biological behavior is safe and biocompatible. Herein, a new route was used to enhance the biocompatibility of graphene, using several natural deep eutectic solvents (DESs) as functionalizing agents, owing to their capability to introduce various functional groups and surface modifications. Characterization of the physicochemical changes in DES-functionalized graphene were conducted by FESEM, FTIR, XRD, and Raman spectroscopy. There were considerable improvements in the cytotoxicity profile of DES-functionalized graphene compared to pristine graphene and oxidized graphene, as demonstrated by cell viability, cell cycle progression, and reactive oxygen species evaluation assays. We also studied the association between cellular toxicity of DES-functionalized graphene and their physicochemical properties. To the best of our knowledge, this is the first study on the cytotoxicity profile improvement of graphene using DESs as functionalizing agents, and its cellular biological behavior. The application of DESs as functionalizing agents, especially for DES choline chloride (ChCI):malonic acid (1:1), significantly reduced the cytotoxicity level of graphenes. DES ChCI:malonic acid (1:1) also demonstrated higher tamoxifen entrapment efficiency and loading capacity in comparison to the functionalization with DES ChCI: glucose (2:1), ChCI: fructose (2:1) and ChCI: sucrose (2:1). Therefore, DES ChCI:malonic acid (1:1) is considered the most promising nanocarrier for drug delivery applications, owing to its lower cytotoxicity and higher drug loading capacity. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Zainal-Abidin, Mohamad Hamdi; Hayyan, Maan; Ngoh, Gek Cheng] Univ Malaya, Dept Chem Engn, Kuala Lumpur, Malaysia.
   [Zainal-Abidin, Mohamad Hamdi; Hayyan, Maan] Univ Malaya, UMCiL, Kuala Lumpur, Malaysia.
   [Hayyan, Maan] Sohar Univ, Fac Engn, Dept Chem Engn, POB 44,PC 311, Sohar, Oman.
   [Wong, Won Fen] Univ Malaya, Fac Med, Dept Med Microbiol, Kuala Lumpur, Malaysia.
RP Hayyan, M (reprint author), Univ Malaya, Dept Chem Engn, Kuala Lumpur, Malaysia.; Hayyan, M (reprint author), Univ Malaya, UMCiL, Kuala Lumpur, Malaysia.; Hayyan, M (reprint author), Sohar Univ, Fac Engn, Dept Chem Engn, POB 44,PC 311, Sohar, Oman.
EM maan_hayyan@yahoo.com
RI Fen, Wong Won/D-3087-2012; Hayyan, Maan/A-1089-2011
OI Fen, Wong Won/0000-0003-1082-1956; Hayyan, Maan/0000-0002-2179-0801
FU University of MalayaUniversiti Malaya [UMRG (RP037B-15AET)]; Malaysia
   Toray Science Foundation
FX The authors would like to express their thanks to University of Malaya
   Grant no: UMRG (RP037B-15AET). This material is based upon work
   supported by the Malaysia Toray Science Foundation.
CR Abbott AP, 2004, J AM CHEM SOC, V126, P9142, DOI 10.1021/ja048266j
   Abo-Hamad A, 2017, CHEM ENG J, V311, P326, DOI 10.1016/j.cej.2016.11.108
   Abo-Hamad A, 2015, CHEM ENG J, V273, P551, DOI 10.1016/j.cej.2015.03.091
   Akhavan O, 2010, ACS NANO, V4, P5731, DOI 10.1021/nn101390x
   Akhtar MJ, 2017, CLIN CHIM ACTA, V469, P53, DOI 10.1016/j.cca.2017.03.020
   Becker S, 1996, TOXICOL APPL PHARM, V141, P637, DOI 10.1006/taap.1996.0330
   Bianco A, 2013, ANGEW CHEM INT EDIT, V52, P4986, DOI 10.1002/anie.201209099
   Bitounis D, 2013, ADV MATER, V25, P2258, DOI 10.1002/adma.201203700
   Chang YL, 2011, TOXICOL LETT, V200, P201, DOI 10.1016/j.toxlet.2010.11.016
   Chatterjee N, 2014, BIOMATERIALS, V35, P1109, DOI 10.1016/j.biomaterials.2013.09.108
   Chen KH, 2016, MAT SCI ENG C-MATER, V69, P1222, DOI 10.1016/j.msec.2016.08.036
   Chen M, 2009, ACS NANO, V3, P2016, DOI 10.1021/nn900480m
   Cheng C, 2017, CHEM REV, V117, P1826, DOI 10.1021/acs.chemrev.6b00520
   Dallavalle M, 2015, ACS APPL MATER INTER, V7, P4406, DOI 10.1021/am508938u
   Das S, 2013, PART PART SYST CHAR, V30, P148, DOI 10.1002/ppsc.201200066
   Depan D, 2011, MAT SCI ENG C-MATER, V31, P1305, DOI 10.1016/j.msec.2011.04.010
   Duch MC, 2011, NANO LETT, V11, P5201, DOI 10.1021/nl202515a
   Faraj F. L., 2014, SCI WORLD J, V2014, P15
   Ferrari AC, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.187401
   Fu PP, 2014, J FOOD DRUG ANAL, V22, P64, DOI 10.1016/j.jfda.2014.01.005
   Georgakilas V, 2012, CHEM REV, V112, P6156, DOI 10.1021/cr3000412
   Goenka S, 2014, J CONTROL RELEASE, V173, P75, DOI 10.1016/j.jconrel.2013.10.017
   Hajrezaie M, 2015, SCI REP-UK, V5, DOI 10.1038/srep09097
   Hamwi A, 1997, CARBON, V35, P723, DOI 10.1016/S0008-6223(97)00013-4
   Hayyan M, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-2575-9
   Hayyan M, 2016, CHEM REV, V116, P3029, DOI 10.1021/acs.chemrev.5b00407
   Hayyan M, 2015, NANOSCALE RES LETT, V10, DOI 10.1186/s11671-015-1004-2
   Hayyan M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117934
   Hayyan M, 2013, CHEMOSPHERE, V93, P455, DOI 10.1016/j.chemosphere.2013.05.013
   Hegab HM, 2016, CARBON, V105, P362, DOI 10.1016/j.carbon.2016.04.046
   Horev-Azaria L, 2013, PART FIBRE TOXICOL, V10, DOI 10.1186/1743-8977-10-32
   How CW, 2013, COLLOID SURFACE B, V112, P393, DOI 10.1016/j.colsurfb.2013.08.009
   Jones CF, 2009, ADV DRUG DELIVER REV, V61, P438, DOI 10.1016/j.addr.2009.03.005
   Kim S, 2009, TOXICOL IN VITRO, V23, P1076, DOI 10.1016/j.tiv.2009.06.001
   Lin MM, 2015, MAT SCI ENG C-MATER, V50, P300, DOI 10.1016/j.msec.2015.01.086
   Liu JQ, 2013, ACTA BIOMATER, V9, P9243, DOI 10.1016/j.actbio.2013.08.016
   Liu Z, 2008, J AM CHEM SOC, V130, P10876, DOI 10.1021/ja803688x
   Mahmoudi M, 2011, CHEM REV, V111, P3407, DOI 10.1021/cr1003166
   Matesanz MC, 2013, BIOMATERIALS, V34, P1562, DOI 10.1016/j.biomaterials.2012.11.001
   Miao ZA, 2010, RSC DRUG DISCOV, V1, P460
   Nel A, 2006, SCIENCE, V311, P622, DOI 10.1126/science.1114397
   Ou LL, 2016, PART FIBRE TOXICOL, V13, DOI 10.1186/s12989-016-0168-y
   Prolongo SG, 2013, COMPOS SCI TECHNOL, V86, P185, DOI 10.1016/j.compscitech.2013.06.020
   Ramirez C, 2013, J EUR CERAM SOC, V33, P471, DOI 10.1016/j.jeurceramsoc.2012.09.014
   Sasidharan A, 2012, SMALL, V8, P1251, DOI 10.1002/smll.201102393
   Sasidharan A, 2011, NANOSCALE, V3, P2461, DOI 10.1039/c1nr10172b
   Sayes CM, 2006, TOXICOL LETT, V161, P135, DOI 10.1016/j.toxlet.2005.08.011
   Sayes CM, 2004, NANO LETT, V4, P1881, DOI 10.1021/nl0489586
   Smith EL, 2014, CHEM REV, V114, P11060, DOI 10.1021/cr300162p
   Stankovich S, 2007, CARBON, V45, P1558, DOI 10.1016/j.carbon.2007.02.034
   Sun J, 2016, ACS APPL MATER INTER, V8, P10226, DOI 10.1021/acsami.6b02032
   Sun XM, 2008, NANO RES, V1, P203, DOI 10.1007/s12274-008-8021-8
   Talaeemashhadi S, 2013, CARBON, V59, P150, DOI 10.1016/j.carbon.2013.03.003
   Tang B, 2015, J SEP SCI, V38, P1053, DOI 10.1002/jssc.201401347
   Tu YS, 2013, NAT NANOTECHNOL, V8, P594, DOI [10.1038/NNANO.2013.125, 10.1038/nnano.2013.125]
   Walker DK, 2010, RSC DRUG DISCOV, V1, P168
   Wang GX, 2009, CARBON, V47, P1359, DOI 10.1016/j.carbon.2009.01.027
   Wang X, 2013, REACT FUNCT POLYM, V73, P854, DOI 10.1016/j.reactfunctpolym.2013.03.003
   Yan L, 2012, J MATER CHEM, V22, P8367, DOI 10.1039/c2jm30961k
   Yang K, 2013, SMALL, V9, P1492, DOI 10.1002/smll.201201417
   Yang K, 2013, CHEM SOC REV, V42, P530, DOI 10.1039/c2cs35342c
   Yang XY, 2008, J PHYS CHEM C, V112, P17554, DOI 10.1021/jp806751k
   Yazdanian M, 2004, PHARM RES-DORDR, V21, P293, DOI 10.1023/B:PHAM.0000016242.48642.71
   Zahedifard M, 2015, SCI REP-UK, V5, DOI 10.1038/srep11544
   Zhang XY, 2012, TOXICOL RES-UK, V1, P62, DOI 10.1039/c2tx20006f
   Zhang YB, 2010, ACS NANO, V4, P3181, DOI 10.1021/nn1007176
   Zhu YW, 2010, ADV MATER, V22, P3906, DOI 10.1002/adma.201001068
NR 67
TC 9
Z9 9
U1 11
U2 78
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 95
EP 106
DI 10.1016/j.ces.2018.11.013
PG 12
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500009
DA 2020-05-12
ER

PT J
AU Zhang, XB
   Liu, YX
   Luo, ZH
AF Zhang, Xi-Bao
   Liu, Yuan-Xing
   Luo, Zheng-Hong
TI Kinetic study of the aqueous Kolbe-Schmitt synthesis of 2,4-and
   2,6-dihydroxybenzoic acids
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Kolbe-Schmitt reaction; 2,4-Dihydroxybenzoic acid; 2,6-Dihydroxybenzoic
   acid; Kinetic model; Activation energy; Rate-determining step
ID CARBON-DIOXIDE; CARBOXYLATION; RESORCINOL; MECHANISM; CHEMISTRY;
   CATALYST; PHENOLS; REACTOR; CO2
AB The Kolbe-Schmitt reaction is the traditional method for preparing 2,4- and 2,6-dihydroxybenzoic acid (2,4- and 2,6-DHBA). In this work, accurate kinetic models for the Kolbe-Schmitt synthesis of 2,4- and 2,6-DHBA were successfully developed. The relative errors between the theoretical and experimental 2,4-DHBA equilibrium yields are less than 3.7% as T = 348-473 K, [C6H6O2] = 0.4-0.8 M and [KHCO3] = 1.2-4.0 M. The effects of reaction temperature, reaction time, KHCO3 and resorcinol (C6H6O2) concentrations on the formation rates and the yields of 2,4- and 2,6-DHBA were investigated by the developed models. Results show that the 2,4-DHBA equilibrium yield exhibits a strong dependence on the KHCO3 concentration, and the formation rate of 2,4-DHBA is strongly dependent on the reaction temperature. Furthermore, the reaction time is a critical factor in controlling the ratio of 2,4-DHBA to 2,6-DHBA as the reaction temperature varies from 433 to 473 K. Additionally, the results of the present work deepen the understanding of the reaction mechanism, e.g. the rate-determining step and main reaction pathway of 2,6-DHBA formation. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Zhang, Xi-Bao; Liu, Yuan-Xing; Luo, Zheng-Hong] Shanghai Jiao Tong Univ, Sch Chem & Chem Engn, Dept Chem Engn, State Key Lab Met Matrix Composites, Shanghai 200240, Peoples R China.
RP Luo, ZH (reprint author), Shanghai Jiao Tong Univ, Sch Chem & Chem Engn, Dept Chem Engn, State Key Lab Met Matrix Composites, Shanghai 200240, Peoples R China.
EM luozh@sjtu.edu.cn
FU National Ministry of Science and Technology of ChinaMinistry of Science
   and Technology, China [2017YFB0602401]; National Natural Science
   Foundation of ChinaNational Natural Science Foundation of China
   [21776173, 21625603]; Program of Shanghai Subject Chief Scientist
   [18XD1402000]
FX The authors thank the National Ministry of Science and Technology of
   China (No. 2017YFB0602401), the National Natural Science Foundation of
   China (No. 21776173 and 21625603), the Program of Shanghai Subject Chief
   Scientist (No. 18XD1402000) and the computational support from the
   Center for High Performance Computing, Shanghai Jiao Tong University for
   supporting this work.
CR Aguilar PG, 2018, IND ENG CHEM RES, V57, P4815, DOI 10.1021/acs.iecr.8b00227
   Barbarossa V, 2015, J CO2 UTIL, V10, P50, DOI 10.1016/j.jcou.2015.04.004
   Benaskar F, 2009, ORG PROCESS RES DEV, V13, P970, DOI 10.1021/op9000803
   Bie YW, 2015, IND ENG CHEM RES, V54, P11986, DOI 10.1021/acs.iecr.5b03232
   Dessimoz AL, 2012, CHEM ENG J, V200, P738, DOI 10.1016/j.cej.2012.04.099
   Eng AYS, 2017, ACS NANO, V11, P1789, DOI 10.1021/acsnano.6b07746
   Fogler H. S., 2004, ELEMENTS CHEM REACTI, P177
   Geng SL, 2018, IND ENG CHEM RES, V57, P8413, DOI 10.1021/acs.iecr.8b00662
   HALE DK, 1952, J CHEM SOC, P3503, DOI 10.1039/jr9520003503
   HALES JL, 1954, J CHEM SOC, P3145, DOI 10.1039/jr9540003145
   Hessel V, 2005, ORG PROCESS RES DEV, V9, P479, DOI 10.1021/op050045q
   HUNT SE, 1958, J CHEM SOC, P3152, DOI 10.1039/jr9580003152
   Jin P, 2018, IND ENG CHEM RES, V57, P4329, DOI 10.1021/acs.iecr.8b00250
   KHLEBNIKOV VN, 1991, KINET CATAL+, V32, P1
   KOLBE H, 1860, ANN CHEM PHARM, V113, P125, DOI DOI 10.1002/JLAC.18601130120
   Kosugi Y, 1998, STUD SURF SCI CATAL, V114, P487
   Kosugi Y, 2003, ORG BIOMOL CHEM, V1, P817, DOI 10.1039/b210793g
   Kosugi Y, 2000, APPL ORGANOMET CHEM, V14, P841, DOI 10.1002/1099-0739(200012)14:12<841::AID-AOC74>3.0.CO;2-P
   Kressirer S, 2013, ENVIRON SCI TECHNOL, V47, P5362, DOI 10.1021/es400085y
   Krtschil U, 2011, CHEM ENG J, V167, P510, DOI 10.1016/j.cej.2010.10.041
   Krtschil U, 2013, CHEM ENG TECHNOL, V36, P1010, DOI 10.1002/ceat.201200633
   Krtschil U, 2009, CHEM ENG TECHNOL, V32, P1774, DOI 10.1002/ceat.200900450
   Lei W., 2012, CHEM IND, V16, P86
   LINDSEY AS, 1957, CHEM REV, V57, P583, DOI 10.1021/cr50016a001
   Lopez J. S., 2011, SIMULTANEOUS PRODUCT
   Luo JF, 2016, CHEM-EUR J, V22, P6798, DOI 10.1002/chem.201601114
   Markovic S, 2015, THEOR CHEM ACC, V134, DOI 10.1007/s00214-015-1648-0
   Nierensterin M., 1943, ORG SYNTH, V2, P557
   Toro JCO, 2015, IND ENG CHEM RES, V54, P2311, DOI 10.1021/ie504763g
   Pesci L, 2015, FEBS J, V282, P1334, DOI 10.1111/febs.13225
   Schmitt R, 1885, J PRAKT CHEM, V31, P397, DOI DOI 10.1002/PRAC.18850310130
   Shanthi B, 2015, ULTRASON SONOCHEM, V27, P268, DOI 10.1016/j.ultsonch.2015.05.019
   Stanescu I, 2006, MOL SIMULAT, V32, P279, DOI 10.1080/08927020600615000
   Stanescu I, 2006, CHEM ENG SCI, V61, P6199, DOI 10.1016/j.ces.2006.05.025
   Stark A, 2009, CHEM ENG TECHNOL, V32, P1730, DOI 10.1002/ceat.200900331
   Sullivan F, 2018, IND ENG CHEM RES, V57, P1883, DOI 10.1021/acs.iecr.7b03818
   Sun WZ, 2015, IND ENG CHEM RES, V54, P3293, DOI 10.1021/acs.iecr.5b00113
   Sun WZ, 2011, IND ENG CHEM RES, V50, P2548, DOI 10.1021/ie1005993
   Wuensch C, 2013, J BIOTECHNOL, V168, P264, DOI 10.1016/j.jbiotec.2013.07.017
NR 39
TC 2
Z9 2
U1 1
U2 14
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 107
EP 119
DI 10.1016/j.ces.2018.11.045
PG 13
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500010
DA 2020-05-12
ER

PT J
AU Rismanian, M
   Saidi, MS
   Kashaninejad, N
AF Rismanian, Milad
   Saidi, Mohammad Said
   Kashaninejad, Navid
TI A new non-dimensional parameter to obtain the minimum mixing length in
   tree-like concentration gradient generators
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Concentration gradient generator; Mixing length; Peclet number;
   Micromixer
ID MICROFLUIDICS; CHEMOTAXIS
AB Microfluidic-based concentration gradient generators (CGGs) have a number of applications in chemical, biological and pharmaceutical studies. Thus, precise design of the microfluidic system is crucial to maintaining the desired concentration gradient in microchannels. One of the design considerations is the length of microchannels in the structure of a CGG. A CGG with a short length fails to provide the complete diffusive mixing, while the size of the microchip would unfavorably increase by incorporating a long CGG. Considering a CGG as a tree-like structure consisting of T-shaped micromixers, the mixing process of the species at a straight microchannel has been solved analytically. Herein, we define a new non-dimensional parameter (psi) as the ratio of the minimum length of the microchannel required for the desired fluid mixing to the product of the channel width and Peclet number. The numerically obtained values of psi (i.e., 0.22 and 0.17 for 95% mixing in straight and serpentine micromixers, respectively) are in good agreement with the experimental results. The numerical simulation also shows that the value of psi is the same for all micromixers in a CGG with the similar microchannel structure (e.g., straight or serpentine) and is independent of the channel size (width-to-depth ratio) and fluid velocity. Therefore, psi can be computed only once for any micromixer with different structures (e.g., zigzag, square wave, and so forth) and then considering this constant value of psi, the minimum required length of all other micromixers in a CGG with similar repetitive structures and dimensions at the specified flow rates could be designed quickly and precisely. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Rismanian, Milad; Saidi, Mohammad Said] Sharif Univ Technol, Dept Mech Engn, Tehran 111559567, Iran.
   [Kashaninejad, Navid] Univ Technol Sydney, Sch Math & Phys Sci, Sydney, NSW 2007, Australia.
RP Rismanian, M (reprint author), Sharif Univ Technol, Dept Mech Engn, Tehran 111559567, Iran.
RI Kashaninejad, Navid/L-9228-2016
OI Kashaninejad, Navid/0000-0002-4385-7771
CR Chiu DT, 2017, CHEM-US, V2, P201, DOI 10.1016/j.chempr.2017.01.009
   Chung BG, 2005, LAB CHIP, V5, P401, DOI 10.1039/b417651k
   Dertinger SKW, 2001, ANAL CHEM, V73, P1240, DOI 10.1021/ac001132d
   Duncombe TA, 2015, NAT REV MOL CELL BIO, V16, P554, DOI 10.1038/nrm4041
   Jeon NL, 2000, LANGMUIR, V16, P8311, DOI 10.1021/la000600b
   Jeon NL, 2002, NAT BIOTECHNOL, V20, P826, DOI 10.1038/nbt712
   Kashaninejad N, 2018, ADV BIOSYST, V2, DOI 10.1002/adbi.201700197
   Kashaninejad N, 2016, MICROMACHINES-BASEL, V7, DOI 10.3390/mi7080130
   Khademhosseini A, 2016, NAT PROTOC, V11, P1775, DOI 10.1038/nprot.2016.123
   Lee CY, 2011, INT J MOL SCI, V12, P3263, DOI 10.3390/ijms12053263
   Lin F, 2004, LAB CHIP, V4, P164, DOI 10.1039/b313600k
   Linshiz G, 2016, J BIOL ENG, V10, DOI 10.1186/s13036-016-0024-5
   Liu MY, 2011, CHEM ENG SCI, V66, P2211, DOI 10.1016/j.ces.2011.02.036
   Moghadas H., 2017, DRUG DELIV T RES
   Nguyen NT, 2013, ADV DRUG DELIVER REV, V65, P1403, DOI 10.1016/j.addr.2013.05.008
   Nimafar M, 2012, CHEM ENG SCI, V76, P37, DOI 10.1016/j.ces.2012.03.036
   Sackmann EK, 2014, NATURE, V507, P181, DOI 10.1038/nature13118
   Suh YK, 2010, MICROMACHINES-BASEL, V1, P82, DOI 10.3390/mi1030082
   Toh AGG, 2014, MICROFLUID NANOFLUID, V16, P1, DOI 10.1007/s10404-013-1236-3
   Walker GM, 2005, LAB CHIP, V5, P611, DOI 10.1039/b417245k
   WANG JH, 1965, J PHYS CHEM-US, V69, P4412, DOI 10.1021/j100782a510
   Wang L, 2012, CHEM ENG SCI, V81, P157, DOI 10.1016/j.ces.2012.07.004
   Wang SJ, 2004, EXP CELL RES, V300, P180, DOI 10.1016/j.yexcr.2004.06.030
   Wang X, 2017, RSC ADV, V7, P29966, DOI 10.1039/c7ra04494a
   Wang Y, 2006, J MICROMECH MICROENG, V16, P2128, DOI 10.1088/0960-1317/16/10/029
   Wu ZG, 2005, MICROFLUID NANOFLUID, V1, P208, DOI 10.1007/s10404-004-0011-x
   Wu ZG, 2004, J MICROMECH MICROENG, V14, P604, DOI 10.1088/0960-1317/14/4/022
   Zilionis R, 2017, NAT PROTOC, V12, DOI 10.1038/nprot.2016.154
NR 28
TC 4
Z9 4
U1 3
U2 17
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 120
EP 126
DI 10.1016/j.ces.2018.11.041
PG 7
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500011
DA 2020-05-12
ER

PT J
AU Xing, L
   Xu, YX
   Das, PK
   Mao, BD
   Xu, Q
   Su, HN
   Wu, X
   Shi, WD
AF Xing, Lei
   Xu, Yuanxiang
   Das, Prodip K.
   Mao, Baodong
   Xu, Qian
   Su, Huaneng
   Wu, Xu
   Shi, Weidong
TI Numerical matching of anisotropic transport processes in porous
   electrodes of proton exchange membrane fuel cells
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE PEM fuel cells; Anisotropy; Gas diffusion coefficient; Capillary
   diffusion coefficient; Electrode conductivity; Thermal conductivity
ID GAS-DIFFUSION LAYER; OXYGEN REDUCTION REACTION; WATER MANAGEMENT;
   CATALYST-LAYER; 2-PHASE FLOW; MASS-TRANSPORT; ELECTRICAL-CONDUCTIVITY;
   THERMAL-CONDUCTIVITY; AGGLOMERATE MODEL; IONOMER CONTENT
AB Owing to the spatial orientations of carbon fibers, the porous electrodes of proton exchange membrane (PEM) fuel cells exhibit strong structural anisotropy, which affects the transport of species, ions, electrons, liquid water, and heat along the in-plane and through-plane directions. To capture the anisotropies of species transport, charge migration, and heat transport for PEM fuel cells operated at various loads, a two-phase flow, non-isothermal, computational fluid dynamics (CFD) model was developed and experimentally validated. Various anisotropic parameters were separately studied, and their contributions to the overall cell performance at different loads were compared. The results indicated the significance of anisotropic transport processes inside the electrodes, as the isotropic electrode properties overpredicted the cell performance. Among all the studied parameters, the anisotropies of the ion conductivity and gas diffusivity deserve careful consideration due to their significant impact on the cell performance, especially at high current densities. The anisotropies of the electrode permeability for gas transport and thermal conductivity can be neglected because of their limited effects on the cell performance. The anisotropy of the electrode permeability for liquid-water transport under a capillary mechanism had a considerable influence on the cell performance owing to its impact on the water saturation within the electrode. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Xing, Lei; Xu, Yuanxiang] Jiangsu Univ, Inst Green Chem & Chem Technol, Zhenjiang 212013, Peoples R China.
   [Das, Prodip K.] Newcastle Univ, Sch Engn, Newcastle NE1 7RU, England.
   [Mao, Baodong; Shi, Weidong] Jiangsu Univ, Sch Chem & Chem Engn, Zhenjiang 212013, Peoples R China.
   [Xu, Qian; Su, Huaneng] Jiangsu Univ, Inst Energy Res, Zhenjiang 212013, Peoples R China.
   [Wu, Xu] Huazhong Univ Sci & Technol, Sch Environm Sci & Engn, Wuhan 430074, Hubei, Peoples R China.
RP Shi, WD (reprint author), Jiangsu Univ, Sch Chem & Chem Engn, Zhenjiang 212013, Peoples R China.
EM swd1978@ujs.edu.cn
RI XING, LEI/AAG-9775-2020; Das, Prodip K./G-5297-2012
OI XING, LEI/0000-0002-0360-8025; Das, Prodip K./0000-0001-9096-3721
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21522603]; Excellent Youth Foundation of Jiangsu
   Scientific Committee [BK20140011]; Natural Science Foundation of Jiangsu
   province of ChinaNatural Science Foundation of Jiangsu Province
   [BK20170530]; Innovation and Creation program of Jiangsu province of
   China [2016-32]; Jiangsu University [16JDG061]; EPSRC Supergen Fuel Cell
   ConsortiumEngineering & Physical Sciences Research Council (EPSRC)
   [G030995]
FX The authors acknowledge the National Natural Science Foundation of China
   (21522603), Excellent Youth Foundation of Jiangsu Scientific Committee
   (BK20140011), the Natural Science Foundation of Jiangsu province of
   China (BK20170530), the Innovation and Creation program of Jiangsu
   province of China (2016-32), and the start-up funding for young
   researchers of Jiangsu University (16JDG061). Grateful acknowledgment is
   also given to the EPSRC Supergen Fuel Cell Consortium (G030995).
CR Ahmed DH, 2008, INT J HYDROGEN ENERG, V33, P3767, DOI 10.1016/j.ijhydene.2008.04.024
   Anderson R, 2010, J POWER SOURCES, V195, P4531, DOI 10.1016/j.jpowsour.2009.12.123
   Andersson M, 2016, APPL ENERG, V180, P757, DOI 10.1016/j.apenergy.2016.08.010
   Banham D, 2015, J POWER SOURCES, V285, P334, DOI 10.1016/j.jpowsour.2015.03.047
   Bapat CJ, 2008, J POWER SOURCES, V179, P240, DOI 10.1016/j.jpowsour.2007.12.033
   Becker J, 2009, J ELECTROCHEM SOC, V156, pB1175, DOI 10.1149/1.3176876
   Cao TF, 2015, INT J HEAT MASS TRAN, V87, P544, DOI 10.1016/j.ijheatmasstransfer.2015.04.010
   Carton JG, 2017, ENERGY, V136, P185, DOI 10.1016/j.energy.2016.02.010
   Cindrella L, 2009, J POWER SOURCES, V194, P146, DOI 10.1016/j.jpowsour.2009.04.005
   Dang D, 2017, J POWER SOURCES, V355, P83, DOI 10.1016/j.jpowsour.2017.04.050
   Dang D, 2014, J POWER SOURCES, V260, P27, DOI 10.1016/j.jpowsour.2014.02.111
   Das PK, 2010, INT J HYDROGEN ENERG, V35, P2403, DOI 10.1016/j.ijhydene.2009.12.160
   Das PK, 2010, APPL ENERG, V87, P2785, DOI 10.1016/j.apenergy.2009.05.006
   Debe MK, 2012, NATURE, V486, P43, DOI 10.1038/nature11115
   Djilali N, 2002, INT J THERM SCI, V41, P29, DOI 10.1016/S1290-0729(01)01301-1
   Fishman Z, 2010, J ELECTROCHEM SOC, V157, pB1643, DOI 10.1149/1.3481443
   Gandomi YA, 2016, J ELECTROCHEM SOC, V163, pF933, DOI 10.1149/2.1331608jes
   Ismail MS, 2012, APPL ENERG, V95, P50, DOI 10.1016/j.apenergy.2012.02.003
   Ismail MS, 2010, J POWER SOURCES, V195, P2700, DOI 10.1016/j.jpowsour.2009.11.069
   Jayakumar A, 2015, IONICS, V21, P1, DOI 10.1007/s11581-014-1322-x
   Ji MB, 2009, ENERGIES, V2, P1057, DOI 10.3390/en20401057
   Jiao K, 2011, PROG ENERG COMBUST, V37, P221, DOI 10.1016/j.pecs.2010.06.002
   Khajeh-Hosseini-Dalasm N, 2010, INT J HYDROGEN ENERG, V35, P2417, DOI 10.1016/j.ijhydene.2009.12.111
   Kim JY, 2017, J POWER SOURCES, V365, P419, DOI 10.1016/j.jpowsour.2017.09.003
   Lee C, 2007, J POWER SOURCES, V164, P141, DOI 10.1016/j.jpowsour.2006.09.092
   Li H, 2008, J POWER SOURCES, V178, P103, DOI 10.1016/j.jpowsour.2007.12.068
   Li L, 2015, ENERGY, V88, P563, DOI 10.1016/j.energy.2015.05.085
   Liu XL, 2015, J POWER SOURCES, V299, P85, DOI 10.1016/j.jpowsour.2015.08.092
   Malko D, 2016, J POWER SOURCES, V323, P189, DOI 10.1016/j.jpowsour.2016.05.035
   Meng H, 2006, J POWER SOURCES, V161, P466, DOI 10.1016/j.jpowsour.2006.03.056
   Meyer Q, 2016, ELECTROCHIM ACTA, V211, P478, DOI 10.1016/j.electacta.2016.06.068
   Mougenot M, 2011, INT J HYDROGEN ENERG, V36, P8429, DOI 10.1016/j.ijhydene.2011.04.080
   Nam JH, 2003, INT J HEAT MASS TRAN, V46, P4595, DOI 10.1016/S0017-9310(03)00305-3
   Natarajan D, 2004, J POWER SOURCES, V135, P95, DOI 10.1016/j.jpowsour.2004.03.063
   Nie Y, 2015, CHEM SOC REV, V44, P2168, DOI 10.1039/c4cs00484a
   Nitta I, 2007, J POWER SOURCES, V171, P26, DOI 10.1016/j.jpowsour.2006.11.018
   Park JE, 2018, ELECTROCHIM ACTA, V265, P488, DOI 10.1016/j.electacta.2018.01.191
   Pasaogullari U, 2004, ELECTROCHIM ACTA, V49, P4359, DOI 10.1016/j.electacta.2004.04.027
   Pasaogullari U, 2007, J ELECTROCHEM SOC, V154, pB823, DOI 10.1149/1.2745714
   Peighambardoust SJ, 2010, INT J HYDROGEN ENERG, V35, P9349, DOI 10.1016/j.ijhydene.2010.05.017
   Pharoah JG, 2006, J POWER SOURCES, V161, P214, DOI 10.1016/j.jpowsour.2006.03.093
   Poling B. E., 2001, PROPERTIES GAS LIQUI
   Rama P, 2011, FUEL CELLS, V11, P274, DOI 10.1002/fuce.201000037
   Rostami L, 2016, ENERGY, V97, P400, DOI 10.1016/j.energy.2015.10.132
   Sadeghifar H, 2014, J POWER SOURCES, V248, P632, DOI 10.1016/j.jpowsour.2013.09.136
   Siegel C, 2008, ENERGY, V33, P1331, DOI 10.1016/j.energy.2008.04.015
   Sousa T, 2010, CHEM ENG SCI, V65, P2513, DOI 10.1016/j.ces.2009.12.038
   SPRINGER TE, 1991, J ELECTROCHEM SOC, V138, P2334, DOI 10.1149/1.2085971
   Sun W, 2005, ELECTROCHIM ACTA, V50, P3359, DOI 10.1016/j.electacta.2004.12.009
   Suzuki A, 2011, INT J HYDROGEN ENERG, V36, P2221, DOI 10.1016/j.ijhydene.2010.11.076
   Todd D, 2016, INT J HYDROGEN ENERG, V41, P6029, DOI 10.1016/j.ijhydene.2016.02.111
   Tomadakis MM, 2005, J COMPOS MATER, V39, P163, DOI 10.1177/00219983050464338
   TOMADAKIS MM, 1993, J CHEM PHYS, V99, P9820, DOI 10.1063/1.465464
   Wang Y, 2011, APPL ENERG, V88, P981, DOI 10.1016/j.apenergy.2010.09.030
   Weber AZ, 2006, J ELECTROCHEM SOC, V153, pA2205, DOI 10.1149/1.2352039
   Weber AZ, 2014, J ELECTROCHEM SOC, V161, pF1254, DOI 10.1149/2.0751412jes
   WILKE CR, 1950, J CHEM PHYS, V18, P517, DOI 10.1063/1.1747673
   Xiao ML, 2015, ADV MATER, V27, P2521, DOI 10.1002/adma.201500262
   Xing L, 2018, CHEM ENG SCI, V179, P198, DOI 10.1016/j.ces.2018.01.026
   Xing L, 2016, ENERGY, V106, P631, DOI 10.1016/j.energy.2016.03.105
   Xing L, 2016, CHEM ENG SCI, V146, P88, DOI 10.1016/j.ces.2016.02.029
   Xing L, 2016, ENERGY, V96, P80, DOI 10.1016/j.energy.2015.12.048
   Xing L, 2015, APPL ENERG, V138, P242, DOI 10.1016/j.apenergy.2014.10.011
   Xing L, 2014, ENERGY, V73, P618, DOI 10.1016/j.energy.2014.06.065
   Xing L, 2014, INT J HYDROGEN ENERG, V39, P9087, DOI 10.1016/j.ijhydene.2014.03.225
   Xing L, 2013, INT J HYDROGEN ENERG, V38, P14295, DOI 10.1016/j.ijhydene.2013.08.104
   Yan WM, 2004, J POWER SOURCES, V129, P127, DOI 10.1016/j.jpowsour.2003.11.028
   Yang WW, 2008, J POWER SOURCES, V185, P765, DOI 10.1016/j.jpowsour.2008.06.100
   Yang XG, 2011, INT J HYDROGEN ENERG, V36, P12524, DOI 10.1016/j.ijhydene.2011.07.014
   Zamel N, 2012, APPL ENERG, V93, P39, DOI 10.1016/j.apenergy.2011.08.037
   Zamel N, 2010, CHEM ENG SCI, V65, P3994, DOI 10.1016/j.ces.2010.03.047
   Zenyuk IV, 2016, J ELECTROCHEM SOC, V163, pF691, DOI 10.1149/2.1161607jes
   Zhou TH, 2006, J POWER SOURCES, V161, P444, DOI 10.1016/j.jpowsour.2006.04.106
NR 73
TC 7
Z9 7
U1 4
U2 54
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 127
EP 140
DI 10.1016/j.ces.2018.11.034
PG 14
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500012
DA 2020-05-12
ER

PT J
AU Bianchi, C
   Datt, AK
   Dughiero, F
AF Bianchi, C.
   Datt, A. K.
   Dughiero, F.
TI Mechanistic understanding of plasma arcing in microwave food processing
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Breakdown; Microwave plasma; Food processing; Discharge formation;
   Microwave oven
ID BREAKDOWN; DISCHARGE; ELECTRON; CORONA; MODE; AIR
AB While arcing during processing of food in a domestic microwave oven has been well known and has major safety implications, its mechanistic understanding is not available. A comprehensive multiphysics 3D numerical model was developed that couples electromagnetics, electrodynamics, heat transfer and moisture transfer. The model is multiscale with the electromagnetics and heat and moisture transfer at the oven cavity scale while electrodynamics at the smaller scale of the region around the food. The model was validated using calorimetric and temperature measurements and reproducibility of arcing. Time evolution of arcing, and factors affecting it, were identified by the model. In drier air, arcing occurs at a lower power level because the equilibrium between ionization and attachment is achieved at lower electric field magnitude than in moist air. Higher temperature leads to greater chances of arcing as higher temperature increases ionization more than it increases attachment. Small load of food also increases the chances of arcing. Sample geometry, orientation, and placement inside the oven are also significant factors. Conditions that lead to arcing were identified in terms of maximum electric field values and temperatures. These threshold conditions can be used to identify unsafe situations for domestic microwave ovens and other microwave devices for product and process designers. (C) 2018 Published by Elsevier Ltd.
C1 [Bianchi, C.; Dughiero, F.] Univ Padua, Elect Engn Div, Lab Electroheat, Via Gradenigo 6A, I-35131 Padua, PD, Italy.
   [Datt, A. K.] Cornell Univ, Dept Biol & Environm Engn, 208 Riley Robb Hall, Ithaca, NY 14853 USA.
RP Bianchi, C (reprint author), Univ Padua, Elect Engn Div, Lab Electroheat, Via Gradenigo 6A, I-35131 Padua, PD, Italy.
CR Abdel-Salam M, 2000, HIGH VOLTAGE ENG THE
   ABDELSALAM M, 1985, IEEE T IND APPL, V21, P35, DOI 10.1109/TIA.1985.349640
   Affandi M, 2013, PROCEDIA ENGINEER, V53, P722, DOI 10.1016/j.proeng.2013.02.095
   Anderson D, 1999, IEEE T MICROW THEORY, V47, P2547, DOI 10.1109/22.809005
   Anderson D. G., 1987, IEEE T MICROWAVE THE, V35
   Aria AK, 2009, OPT COMMUN, V282, P423, DOI 10.1016/j.optcom.2008.10.033
   Canadian Food Inspection Agency, 2016, WHY SPARKS OCC COOK
   Chabert P, 2011, PHYSICS OF RADIO-FREQUENCY PLASMAS, P1, DOI 10.1017/CBO9780511974342
   Chaudhury B, 2010, IEEE T PLASMA SCI, V38, P2281, DOI 10.1109/TPS.2010.2055893
   CHOI Y, 1986, PHYS CHEM PROPERTIES, P35
   DATTA AK, 2002, BIOL BIOENVIRONMENTA
   DOUGAL AA, 1958, PHYS REV, V109, P615, DOI 10.1103/PhysRev.109.615
   ELIASSON B, 1991, IEEE T PLASMA SCI, V19, P309, DOI 10.1109/27.106829
   Frigui K., 2007, 2007 International Microwave Symposium (IMS 2007), P2121, DOI 10.1109/MWSYM.2007.380307
   Frigui K, 2014, INT J RF MICROW C E, V24, P46, DOI 10.1002/mmce.20712
   Fujii S, 2015, AIP ADV, V5, DOI 10.1063/1.4939095
   General Electrics, 2016, MICR ARC CAV
   Held B, 1999, CZECHOSLOVAK J PHYS, V49
   Jawla SK, 2005, OPT COMMUN, V251, P346, DOI 10.1016/j.optcom.2005.03.019
   Kildal PS, 2003, APPL COMPUT ELECTROM, V18, P32
   Larsson A, 1998, J PHYS D APPL PHYS, V31, P1831, DOI 10.1088/0022-3727/31/15/011
   Lebedev YA, 2008, J PHYS D APPL PHYS, V41, DOI 10.1088/0022-3727/41/19/194001
   Lieberman MA, 2005, PRINCIPLES OF PLASMA DISCHARGES AND MATERIALS PROCESSING, 2ND EDITION, P1
   Lupi S., 2005, APPUNTI ELETTROTERMI
   LYMBEROPOULOS DP, 1995, J RES NATL INST STAN, V100, P473, DOI 10.6028/jres.100.036
   MacDonald A. D, 1966, MICROWAVE BREACKDOWN
   Malik H K, 2013, PHYS PLASMAS, V20
   Malik H. K., 2008, J APPL PHYS, V104
   Malik HK, 2010, J APPL PHYS, V108, DOI 10.1063/1.3452335
   Meredith R. J., 1995, IND MICROWAVE HEATIN
   NAKAMURA M, 1978, IEEE T MICROW THEORY, V26, P354, DOI 10.1109/TMTT.1978.1129387
   National Fire Protection Agency, 2016, HOM FIR INV COOK EQ
   National Institutes of Health, 2016, FIR SAF TIPS US MICR
   Olsson T, 2006, IEEE MTT S INT MICR, P1233, DOI 10.1109/MWSYM.2006.249433
   Paunska Ts., 2011, 30 INT C PHEN ION GA
   Peruani F, 2003, PHYS REV E, V67, DOI 10.1103/PhysRevE.67.066121
   Pozar D.M., 2011, MICROWAVE ENG
   Rasch J, 2010, J PHYS D APPL PHYS, V43, DOI 10.1088/0022-3727/43/32/325204
   RYZKO H, 1965, P PHYS SOC LOND, V85, P1283, DOI 10.1088/0370-1328/85/6/327
   Shibkov VM, 2009, J PROPUL POWER, V25, P123, DOI 10.2514/1.24803
   Shiffmann R. F, 2016, FIRES MICROWAVE RF H
   Sun J., 2016, APPL ENERG, V175, P494
   Tomala R, 2005, J PHYS D APPL PHYS, V38, P2378, DOI 10.1088/0022-3727/38/14/012
   Tomar SK, 2013, PHYS PLASMAS, V20, DOI 10.1063/1.4812455
   TULASIDAS TN, 1995, J MICROWAVE POWER EE, V30, P117
   VANBRUNT RJ, 1994, IEEE T DIELECT EL IN, V1, P761, DOI 10.1109/94.326651
   Wen XS, 2016, IEEE T PLASMA SCI, V44, P3386, DOI 10.1109/TPS.2016.2623805
   Wieser ME, 2006, PURE APPL CHEM, V78, P2051, DOI 10.1351/pac200678112051
   Wormeester G., 2011, 14 INT C ATM EL
   Wyatt W. T, 1967, COMPUTED ELECT DRIFT
NR 50
TC 2
Z9 2
U1 2
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 141
EP 158
DI 10.1016/j.ces.2018.10.006
PG 18
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500013
DA 2020-05-12
ER

PT J
AU La Forgia, N
   Hero, EH
   Solsvik, J
   Jakobsen, HA
AF La Forgia, Nicolas
   Hero, Eirik Helno
   Solsvik, Jannike
   Jakobsen, Hugo Atle
TI Dissipation rate estimation in a rectangular shaped test section with
   periodic structure at the walls
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Droplet breakage; Experimental investigation; Turbulence measurement;
   Dissipation rate
ID DROP SIZE DISTRIBUTIONS; ENERGY-SPECTRUM; BREAKUP MECHANISMS; FLUID
   PARTICLES; LOCAL-STRUCTURE; TURBULENCE; MODEL; PIV
AB An experimental study of turbulent flow concerning the characterization of turbulence by two-point correlation and estimations of the turbulent dissipation rate is presented. The fluid used is deionized water and the test section used was a square shaped channel of 24 mm by 30 mm on the cross section with a length of 1 m. The test section also presented periodic baffle structure at two of the walls for enhancing and maintaining turbulence. The study consisted in the measurement of the velocities at different positions of the channel using Laser Doppler Velocimetry instrument (LDV), the velocity measurement obtained were used for estimating two point correlations using the Taylor's frozen hypothesis. Finally, the results from the two-point correlation were used for estimating the turbulent dissipation rate. Considering the difference in the methods for calculating the dissipation rate, a comparison of the accuracy of each method is presented. It was found that the methods presented in this work showed similar results and trends of the dissipation rate with respect to changes in flow condition and distance to the channel walls. However, better accuracy was obtained by estimating the dissipation rate using the second order structure function and the Kolmogorov's two-third law. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [La Forgia, Nicolas; Hero, Eirik Helno; Solsvik, Jannike; Jakobsen, Hugo Atle] Norwegian Univ Sci & Technol NTNU, Dept Chem Engn, Trondheim, Norway.
RP La Forgia, N (reprint author), Norwegian Univ Sci & Technol NTNU, Dept Chem Engn, Trondheim, Norway.
EM nicolas.la-forgia@ntnu.no; eirik.h.hero@ntnu.no;
   jannike.solsvik@ntnu.no; hugo.a.jakobsen@ntnu.no
FU SUBPRO - Research Council of Norway; NTNU
FX This work was carried out as a part of SUBPRO, a Research-based
   Innovation Centre within Subsea Production and Processing. The authors
   gratefully acknowledge the financial support from SUBPRO, which is
   financed by the Research Council of Norway, major industry partners and
   NTNU.
CR Andersson R, 2006, AICHE J, V52, P2020, DOI 10.1002/aic.10831
   Andersson R, 2004, CHEM ENG SCI, V59, P4911, DOI 10.1016/j.ces.2004.07.084
   Andersson R, 2006, AICHE J, V52, P2031, DOI 10.1002/aic.10832
   Azizi F, 2011, CHEM ENG J, V166, P715, DOI 10.1016/j.cej.2010.11.050
   Bouaifi M, 2004, CHEM ENG RES DES, V82, P274, DOI 10.1205/026387604772992873
   COULALOGLOU CA, 1976, AICHE J, V22, P289, DOI 10.1002/aic.690220211
   Davidson P.A., 2015, TURBULENCE INTRO SCI
   de Jong J, 2009, EXP FLUIDS, V46, P499, DOI 10.1007/s00348-008-0576-3
   Gong SG, 2018, CHEM ENG SCI, V176, P377, DOI 10.1016/j.ces.2017.10.045
   Hakansson A, 2017, CHEM ENG SCI, V171, P625, DOI 10.1016/j.ces.2017.06.042
   Han LC, 2014, CHEM ENG SCI, V117, P55, DOI 10.1016/j.ces.2014.06.018
   Hero E. H, 2018, 6 INT C POP BAL MOD
   HINZE JO, 1975, TURBULENCE
   Iyer VA, 2005, AIAA J, V43, P512, DOI 10.2514/1.8283
   KOLMOGOROV AN, 1991, P ROY SOC LOND A MAT, V434, P9, DOI 10.1098/rspa.1991.0075
   KOLMOGOROV AN, 1962, J FLUID MECH, V13, P82, DOI 10.1017/S0022112062000518
   Lemenand T, 2017, CHEM ENG J, V314, P453, DOI 10.1016/j.cej.2016.12.001
   Lemenand T, 2013, CHEM ENG RES DES, V91, P2587, DOI 10.1016/j.cherd.2013.03.017
   Lemenand T, 2017, CHEM ENG SCI, V158, P41, DOI 10.1016/j.ces.2016.09.031
   Maass S., 2012, CHEM ENG RES DES, V85, P703
   Maass S, 2012, CHEM ENG SCI, V76, P140, DOI 10.1016/j.ces.2012.03.050
   Maass S, 2012, CHEM ENG SCI, V70, P146, DOI 10.1016/j.ces.2011.08.027
   Maass S, 2010, CHEM ENG J, V162, P792, DOI 10.1016/j.cej.2010.06.007
   Mortensen HH, 2018, CHEM ENG RES DES, V130, P52, DOI 10.1016/j.cherd.2017.12.006
   Pope S. B., 2000, TURBULENT FLOWS
   SAWFORD BL, 1986, J FLUID MECH, V165, P373, DOI 10.1017/S0022112086003142
   Sheng J, 2000, CHEM ENG SCI, V55, P4423, DOI 10.1016/S0009-2509(00)00039-7
   Shi J., 2017, 12 INT C CFD OIL GAS
   Smagorinsky J., 1963, MON WEATHER REV, V91, P99, DOI [10.1175/1520-0493(1963)091<0099:GCEWTP>2.3.CO;2, DOI 10.1175/1520-0493(1963)091<0099:GCEWTP>2.3.CO;2, 10.1175/1520-0493(1963)091, 10.1175/1520-0493(1963)091<less than>0099:GCEWTP<greater than>2.3.CO;2]
   Solsvik J, 2017, EUR J MECH B-FLUID, V61, P170, DOI 10.1016/j.euromechflu.2016.10.011
   Solsvik J, 2016, AICHE J, V62, P1795, DOI 10.1002/aic.15128
   Solsvik J, 2016, IND ENG CHEM RES, V55, P1449, DOI 10.1021/acs.iecr.5b04077
   Taylor GI, 1938, PROC R SOC LON SER-A, V164, P0476, DOI 10.1098/rspa.1938.0032
   Taylor GI, 1935, PROC R SOC LON SER-A, V151, P0421, DOI 10.1098/rspa.1935.0158
   Taylor J.R., 1997, INTRO ERROR ANAL
   Tennekes H., 1972, 1 COURSE TURBULENCE
   Vejrazka J, 2017, AICHE J, V64, P740
NR 37
TC 1
Z9 1
U1 3
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 159
EP 178
DI 10.1016/j.ces.2018.11.039
PG 20
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500014
DA 2020-05-12
ER

PT J
AU Arvajova, AB
   Boutikos, P
   Koci, P
AF Arvajova, Adela Buzkova
   Boutikos, Panagiotis
   Koci, Petr
TI Differentiation between O-2 and NO2 impact on PtOx formation in a diesel
   oxidation catalyst
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE NO oxidation; Automotive exhaust gas aftertreatment; Pt/gamma-Al2O3
   catalyst; Mathematical modeling; Deactivation
ID PLATINUM OXIDE FORMATION; REDUCTION; SCR; PT/AL2O3; HYSTERESIS;
   DISPERSION; MONOXIDE; SOOT
AB NO oxidation activity of platinum-based catalysts undergoes reversible changes during operation in oxidative atmosphere typical for Diesel engine exhaust gas due to platinum oxides (PtOx) formation and reduction. In recent years, these changes were studied mostly with the mixtures containing both O-2 and NO2 so that it was difficult to quantify individual impacts of the oxidants on PtOx formation. In this paper, Pt/Al2O3 catalyst deactivation and PtOx formation with O-2 and NO2 was examined separately by the means of transient isothermal experiments at 150, 175 and 200 degrees C with alternating deactivation and probe periods. The largest extent of deactivation was detected at 175 degrees C where the NO conversion in the isothermal experiment dropped from 85% (reduced catalyst) down to 10% (steady-state PtOx level) over 4 h. The experimental data were then utilized for parameter evaluation in global kinetic model of NO oxidation on a diesel oxidation catalyst extended by the reactions describing PtOx formation and reduction. Though the rate coefficient for PtOx formation with NO2 is higher than with O-2, the overall PtOx formation rate and the steady-state PtOx level are higher with O-2 at typical component concentrations (8% O-2 or 250 ppm NO2). Similar activation energies were observed for both PtOx formation reactions. Validity of the model was verified also at lower O-2 and NO2 concentrations (4% O-2 or 125 ppm NO2). The developed model is thus capable of sufficiently precise prediction of catalyst deactivation at various O-2 and NO2 concentrations relevant to diesel exhaust gas. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Arvajova, Adela Buzkova; Boutikos, Panagiotis; Koci, Petr] Univ Chem & Technol, Dept Chem Engn, Tech 5, Prague 16628, Czech Republic.
RP Koci, P (reprint author), Univ Chem & Technol, Dept Chem Engn, Tech 5, Prague 16628, Czech Republic.
EM petr.koci@vscht.cz
RI Koci, Petr/AAG-8076-2020
OI Koci, Petr/0000-0002-1310-6862
FU Czech Science FoundationGrant Agency of the Czech Republic [GA
   17-26018S]; specific university research (MSMT)Ministry of Education,
   Youth & Sports - Czech Republic [20-SVV/2018]
FX The work was financially supported by the Czech Science Foundation
   (project GA 17-26018S) and specific university research (MSMT No
   20-SVV/2018).
CR Arvajova A, 2017, CHEM ENG SCI, V158, P181, DOI 10.1016/j.ces.2016.10.011
   Arvajova A, 2016, APPL CATAL B-ENVIRON, V181, P644, DOI 10.1016/j.apcatb.2015.08.004
   Auvray X, 2013, APPL CATAL B-ENVIRON, V129, P517, DOI 10.1016/j.apcatb.2012.10.002
   CHATTERJEE D, 2006, [No title captured]
   Despres J, 2004, APPL CATAL B-ENVIRON, V50, P73, DOI 10.1016/j.apcatb.2003.12.020
   Dubbe H, 2016, TOP CATAL, V59, P1054, DOI 10.1007/s11244-016-0589-8
   Dubbe H., 2016, EMISSION CONTROL SCI, V2, P137, DOI DOI 10.1007/s40825-016-0038-y
   Dudak M., 2014, APPL CATAL B-ENVIRON, P446
   Getman RB, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.076101
   Guthenke A, 2008, ADV CHEM ENG, V33, P103, DOI 10.1016/S0065-2377(07)33003-2
   Hansen TK, 2017, TOP CATAL, V60, P1333, DOI 10.1007/s11244-017-0818-9
   Hauff K, 2013, APPL CATAL B-ENVIRON, V129, P273, DOI 10.1016/j.apcatb.2012.09.022
   Hauff K, 2012, APPL CATAL B-ENVIRON, V123, P107, DOI 10.1016/j.apcatb.2012.04.008
   Hauptmann W, 2009, APPL CATAL B-ENVIRON, V93, P22, DOI 10.1016/j.apcatb.2009.09.008
   Khazanchi R, 2017, CHEM ENG J, V314, P139, DOI 10.1016/j.cej.2016.12.042
   Koebel M, 2000, CATAL TODAY, V59, P335, DOI 10.1016/S0920-5861(00)00299-6
   Koebel M, 2002, J CATAL, V209, P159, DOI 10.1006/jcat.2002.3624
   Koebel M, 2001, IND ENG CHEM RES, V40, P52, DOI 10.1021/ie000551y
   Leskovjan M, 2018, CHEM ENG SCI, V189, P179, DOI 10.1016/j.ces.2018.05.031
   Li JH, 2015, CATAL TODAY, V258, P169, DOI 10.1016/j.cattod.2015.04.035
   Muller JO, 2012, CATAL TODAY, V191, P106, DOI 10.1016/j.cattod.2012.03.010
   Mulla SS, 2006, J CATAL, V241, P389, DOI 10.1016/j.jcat.2006.05.016
   Nova I, 2006, CATAL TODAY, V114, P3, DOI 10.1016/j.cattod.2006.02.012
   OH SH, 1982, IND ENG CHEM PROD RD, V21, P29, DOI 10.1021/i300005a006
   Olsson L, 2002, J CATAL, V210, P340, DOI 10.1006/jcat.2002.3698
   Olsson L, 2004, TOP CATAL, V30-1, P85, DOI 10.1023/B:TOCA.0000029733.75156.25
   Setiabudi A, 2004, APPL CATAL B-ENVIRON, V50, P185, DOI 10.1016/j.apcatb.2004.01.004
   Underwood GM, 1999, J PHYS CHEM A, V103, P6184, DOI 10.1021/jp991586i
   VOLTZ SE, 1973, IND ENG CHEM PROD RD, V12, P294, DOI 10.1021/i360048a006
   Wang HF, 2009, J PHYS CHEM C, V113, P18746, DOI 10.1021/jp904371f
NR 30
TC 1
Z9 1
U1 7
U2 27
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 179
EP 184
DI 10.1016/j.ces.2018.11.038
PG 6
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500015
DA 2020-05-12
ER

PT J
AU Mano, TB
   Guillen-Gosalbez, G
   Jimenez, L
   Ravagnani, MASS
AF Mano, Thiago B.
   Guillen-Gosalbez, Gonzalo
   Jimenez, Laureano
   Ravagnani, Mauro A. S. S.
TI Synthesis of heat exchanger networks with economic and environmental
   assessment using fuzzy-Analytic Hierarchy Process
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Eco-costs; Multi-objective optimization; Life cycle assessment;
   Fuzzy-AHP programming
ID DECISION-MAKING; STOCHASTIC OPTIMIZATION; GLOBAL OPTIMIZATION;
   GENERALIZED-METHOD; HEN SYNTHESIS; ECO-COSTS; ALGORITHM; MODEL
AB In the present paper we propose an optimization model based on fuzzy-Analytic Hierarchy Process (AHP) programming in which the external costs associated with the environmental impacts caused by energy generation and equipment construction were explicitly incorporated in the synthesis of Heat Exchanger Networks (HEN) using the eco-costs methodology. The damage categories that compose the environmental and economic objective functions were human health (HH), ecosystem quality (EQ), resources depletion (RD), greenhouse gases (GW) impacts and HEN cost. The inclusion of the impact in the optimal synthesis of HEN was performed considering the most used fuels in industries: hard coal, heavy and light fuel oil and natural gas. Boilers operating with each one of the cited fuels were considered, and three different technologies for boiler operating with natural gas were included (low NO x natural gas, modulating and non-modulating natural gas boilers). The weights were obtained through a questionnaire directed to a multidisciplinary group of specialists. A case study with two hot and one cold streams was used to test the efficiency of the model and results were compared to a single-objective model and to a model not considering impacts in the objective function. Results showed that the fuzzy-AHP programming model was not able to find HEN costs lower than those obtained by the single-objective model for HENs operating with heavy and light fuel oil. For the HENs operating with hard coal and natural gas, HEN costs were lower than those obtained by the single objective model. The same HEN configuration was obtained for all fuels considered. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Mano, Thiago B.; Ravagnani, Mauro A. S. S.] Univ Estadual Maringa, Chem Engn Dept, Av Colombo 5790, BR-87020900 Maringa, Parana, Brazil.
   [Guillen-Gosalbez, Gonzalo] Imperial Coll London, Ctr Proc Syst Engn, Dept Chem Engn, South Kensington Campus, London SW7 2AZ, England.
   [Guillen-Gosalbez, Gonzalo; Jimenez, Laureano] Univ Rovira & Virgili, Dept Enginyeria Quim, Av Paisos Catalans 26, Tarragona, Spain.
RP Ravagnani, MASS (reprint author), Univ Estadual Maringa, Chem Engn Dept, Av Colombo 5790, BR-87020900 Maringa, Parana, Brazil.
EM massravagnani@uem.br
RI Ravagnani, Mauro A S S/Q-3010-2018; Guillen-Gosalbez,
   Gonzalo/G-3531-2016
OI Ravagnani, Mauro A S S/0000-0002-2151-1534; Guillen-Gosalbez,
   Gonzalo/0000-0001-6074-8473
FU Spanish Ministry of Economy and Competitiveness [DPI2016-77968-C3-1-P];
   Coordination for the Improvement of Higher Education Personnel - CAPES
   (Brazil)CAPES [88881.171419/2018-01]; National Council for Scientific
   and Technological Development - CNPq (Brazil)National Council for
   Scientific and Technological Development (CNPq)
FX The authors would like to acknowledge the financial support received
   from the Spanish Ministry of Economy and Competitiveness
   (DPI2016-77968-C3-1-P, MINECO/FEDER), from the Coordination for the
   Improvement of Higher Education Personnel - CAPES Processo
   88881.171419/2018-01(Brazil) and the National Council for Scientific and
   Technological Development - CNPq (Brazil).
CR Adjiman CS, 1997, COMPUT CHEM ENG, V21, pS445
   Lopez-Maldonado LA, 2011, APPL THERM ENG, V31, P1099, DOI 10.1016/j.applthermaleng.2010.12.005
   [Anonymous], 2006, 14044 ISO
   Bergamini ML, 2007, IND ENG CHEM RES, V46, P1752, DOI 10.1021/ie061288p
   Bergamini ML, 2005, COMPUT CHEM ENG, V29, P1914, DOI 10.1016/j.compchemeng.2005.04.003
   Biegler L.T., 1997, SYSTEMATIC METHODS C
   BIT AK, 1992, FUZZY SET SYST, V50, P135, DOI 10.1016/0165-0114(92)90212-M
   Chan FTS, 2007, OMEGA-INT J MANAGE S, V35, P417, DOI 10.1016/j.omega.2005.08.004
   Chang DY, 1996, EUR J OPER RES, V95, P649, DOI 10.1016/0377-2217(95)00300-2
   DHINGRA AK, 1991, EUR J OPER RES, V53, P348
   FLOUDAS CA, 1986, AICHE J, V32, P276, DOI 10.1002/aic.690320215
   Goedkoop M, 2009, RECIPE 2008 LIFE CYC
   Holme R., 2000, CORPORATE SOCIAL REP, V3, P2000
   Javanbarg MB, 2012, EXPERT SYST APPL, V39, P960, DOI 10.1016/j.eswa.2011.07.095
   Ku CY, 2010, QUAL QUANT, V44, P623, DOI 10.1007/s11135-009-9223-1
   LEBERLING H, 1981, FUZZY SET SYST, V6, P105, DOI 10.1016/0165-0114(81)90019-1
   Lee AHI, 2009, EXPERT SYST APPL, V36, P2879, DOI 10.1016/j.eswa.2008.01.045
   Lewin DR, 1998, COMPUT CHEM ENG, V22, P1503, DOI 10.1016/S0098-1354(98)00220-8
   Lewin DR, 1998, COMPUT CHEM ENG, V22, P1387, DOI 10.1016/S0098-1354(98)00221-X
   Linnhoff B., 1983, CHEM ENG SCI, V38, P754
   Linnhoff B, 1982, USER GUIDE PROCESS I
   Luo X, 2009, COMPUT CHEM ENG, V33, P1169, DOI 10.1016/j.compchemeng.2008.12.003
   Mano TB, 2017, J CLEAN PROD, V162, P1502, DOI 10.1016/j.jclepro.2017.06.154
   Onishi VC, 2017, ENERG CONVERS MANAGE, V140, P192, DOI 10.1016/j.enconman.2017.02.074
   PAPOULIAS SA, 1983, COMPUT CHEM ENG, V7, P707, DOI 10.1016/0098-1354(83)85023-6
   Pavao LV, 2018, ENERGY, V142, P356, DOI 10.1016/j.energy.2017.09.147
   Pavao LV, 2017, ENERGY, V139, P98, DOI 10.1016/j.energy.2017.07.153
   Pavao LV, 2017, AICHE J, V63, P1582, DOI 10.1002/aic.15524
   Pavao LV, 2017, CHEM ENG SCI, V158, P96, DOI 10.1016/j.ces.2016.09.030
   Pavao LV, 2016, COMPUT CHEM ENG, V94, P370, DOI 10.1016/j.compchemeng.2016.08.009
   Peidro D, 2011, APPL SOFT COMPUT, V11, P2656, DOI 10.1016/j.asoc.2010.10.014
   QUESADA I, 1992, COMPUT CHEM ENG, V16, P937, DOI 10.1016/0098-1354(92)80028-8
   Ravagnani MASS, 2007, COMPUT CHEM ENG, V31, P1432, DOI 10.1016/j.compchemeng.2006.12.005
   Ravagnani MASS, 2005, APPL THERM ENG, V25, P1003, DOI 10.1016/j.applthermaleng.2004.06.024
   Ravagnani MASS, 2014, COMPUT-AIDED CHEM EN, V33, P1579
   SAATY RW, 1987, MATH MODELLING, V9, P161, DOI 10.1016/0270-0255(87)90473-8
   Shaw K, 2012, EXPERT SYST APPL, V39, P8182, DOI 10.1016/j.eswa.2012.01.149
   Silva AP, 2010, OPTIM ENG, V11, P459, DOI 10.1007/s11081-009-9089-z
   TIWARI RN, 1987, FUZZY SET SYST, V24, P27, DOI 10.1016/0165-0114(87)90111-4
   Vasant PM, 2005, INT J UNCERTAIN FUZZ, V13, P97, DOI 10.1142/S0218488505003321
   Vaskan P, 2012, APPL ENERG, V98, P149, DOI 10.1016/j.apenergy.2012.03.018
   Vogtlander JG, 2001, INT J LIFE CYCLE ASS, V6, P157, DOI 10.1065/lca2000.011.042
   YEE TF, 1990, COMPUT CHEM ENG, V14, P1165, DOI 10.1016/0098-1354(90)85010-8
   Zamora JM, 1998, COMPUT CHEM ENG, V22, P367, DOI 10.1016/S0098-1354(96)00346-8
   Zamora JM, 1997, COMPUT CHEM ENG, V21, pS65, DOI 10.1016/S0098-1354(97)87480-7
   Zhang CW, 2016, APPL THERM ENG, V107, P565, DOI 10.1016/j.applthermaleng.2016.07.009
   Zhou K, 2014, COMPUT CHEM ENG, V66, P290, DOI 10.1016/j.compchemeng.2013.11.009
   Zimmermann H.-J., 1978, Fuzzy Sets and Systems, V1, P45, DOI 10.1016/0165-0114(78)90031-3
NR 48
TC 7
Z9 7
U1 3
U2 39
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 185
EP 200
DI 10.1016/j.ces.2018.11.044
PG 16
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500016
DA 2020-05-12
ER

PT J
AU Azizian, P
   Azarmanesh, M
   Dejam, M
   Mohammadi, M
   Shamsi, M
   Sanati-Nezhad, A
   Mohamad, AA
AF Azizian, Pooya
   Azarmanesh, Milad
   Dejam, Morteza
   Mohammadi, Mehdi
   Shamsi, Milad
   Sanati-Nezhad, Amir
   Mohamad, Abdulmajeed A.
TI Electrohydrodynamic formation of single and double emulsions for low
   interfacial tension multiphase systems within microfluidics
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Multiphase flow; Emulsion; Electrohydrodynamic; Numerical simulation;
   Microfluidics
ID ADAPTIVE SOLVER; GENERATION
AB The feasibility of droplet formation from the dispersion of one viscous fluid within another immiscible viscous fluid with low interfacial tension is shown to be very limited. In this work, the process of emulsion formation for low interfacial tension multiphase systems (e.g. aqueous two-phase systems (ATPSs)) was simulated, where the liquids were exposed to an electric field within a microfluidic device. For the first time, the formation of double emulsion via electrohydrodynamic (EHD) force within microfluidics was investigated. A three dimensional (3D) numerical model was developed based on finite-volume discretization of the governing equations to simulate the EHD-based single and double emulsion formation for ATPSs within microfluidics. The dispersed viscous phase moving toward the active electrode is subjected to shear stress, producing instability on the two-phase interface and causing the formation of a necking area. Upon removal of the electric pulse, the dispersed phase moves in the opposite direction resulting in the formation of the droplet. The volume-of-fluid numerical method was applied to trace the two-phase interface, and a height function was imposed to deal with the 3D contact angles. The effect of capillary number and permittivity ratio of the phases on the size and shape of the droplets was assessed and compared with experimental data. Through controlling the interface between the phases, pressure contours, and volumetric charge density contours, it is possible to generate EHD-based single and double emulsions from viscous fluids within microfluidics with applications in drug delivery, tissue engineering and chemical and biological processes. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Azizian, Pooya] Babol Noshirvani Univ Technol, Dept Mech Engn, Shariati St, Babol Sar 4714871167, Iran.
   [Azizian, Pooya; Azarmanesh, Milad; Mohammadi, Mehdi; Shamsi, Milad; Sanati-Nezhad, Amir; Mohamad, Abdulmajeed A.] Univ Calgary, Dept Mech & Mfg Engn, Calgary, AB T2N 1N4, Canada.
   [Dejam, Morteza] Univ Wyoming, Coll Engn & Appl Sci, Dept Petr Engn, 1000 E Univ Ave, Laramie, WY 82071 USA.
   [Mohammadi, Mehdi; Shamsi, Milad; Sanati-Nezhad, Amir] Univ Calgary, Ctr Bioengn Res & Educ, Calgary, AB T2N 1N4, Canada.
RP Sanati-Nezhad, A; Mohamad, AA (reprint author), Univ Calgary, Dept Mech & Mfg Engn, Calgary, AB T2N 1N4, Canada.
EM amir.sanatinezhad@ucalgaiy.ca; mohamad@ucalgary.ca
RI mohammadi, mehdi/AAM-8412-2020; Dejam, Morteza/F-5313-2011; Azarmanesh,
   Milad/I-4839-2015
OI mohammadi, mehdi/0000-0001-8736-7259; Dejam,
   Morteza/0000-0002-3435-3838; Azizian, Pooya/0000-0002-6191-6800;
   Azarmanesh, Milad/0000-0003-1592-9464
FU Natural Sciences and Engineering Research Council of Canada
   (NSERC)Natural Sciences and Engineering Research Council of Canada;
   Canada Research ChairNatural Resources CanadaCanadian Forest
   ServiceCanada Research Chairs; CMC Canadian Microsystem
FX This work is funded in part by the Natural Sciences and Engineering
   Research Council of Canada (NSERC), Canada Research Chair, and CMC
   Canadian Microsystem.
CR Abate AR, 2011, LAB CHIP, V11, P253, DOI [10.1039/c0lc00236d, 10.1039/c01c00236d]
   Afkhami S, 2009, INT J NUMER METH FL, V61, P827, DOI 10.1002/fld.1974
   Afkhami S, 2009, J COMPUT PHYS, V228, P5370, DOI 10.1016/j.jcp.2009.04.027
   Azarmanesh M, 2016, MECCANICA, V51, P819, DOI 10.1007/s11012-015-0245-6
   Azarmanesh M, 2016, PHYS FLUIDS, V28, DOI 10.1063/1.4944058
   Azarmanesh M, 2015, INT J NUMER METHOD H, V25, P1705, DOI 10.1108/HFF-09-2014-0294
   BRACKBILL JU, 1992, J COMPUT PHYS, V100, P335, DOI 10.1016/0021-9991(92)90240-Y
   Bransky A, 2009, LAB CHIP, V9, P516, DOI 10.1039/b814810d
   Carneiro J, 2019, CHEM ENG SCI, V195, P442, DOI 10.1016/j.ces.2018.09.042
   Chen XD, 2014, J COMPUT PHYS, V269, P22, DOI 10.1016/j.jcp.2014.02.035
   Datta SS, 2011, PHYS REV E, V84, DOI 10.1103/PhysRevE.84.041404
   Diamond A D, 1992, Adv Biochem Eng Biotechnol, V47, P89
   Gupta A, 2016, PHYS REV E, V94, DOI 10.1103/PhysRevE.94.063302
   Hardt S, 2012, LAB CHIP, V12, P434, DOI 10.1039/c1lc20569b
   Hsu FY, 1999, BIOMATERIALS, V20, P1931
   Huebner A, 2008, LAB CHIP, V8, P1244, DOI 10.1039/b806405a
   Kovalchuk NM, 2018, CHEM ENG SCI, V176, P139, DOI 10.1016/j.ces.2017.10.026
   Laliberte M, 2007, J CHEM ENG DATA, V52, P321, DOI 10.1021/je0604075
   Liu HH, 2011, PHYS FLUIDS, V23, DOI 10.1063/1.3615643
   Lopez-Herrera JM, 2015, INT J MULTIPHAS FLOW, V71, P14, DOI 10.1016/j.ijmultiphaseflow.2014.12.005
   Lopez-Herrera JM, 2011, J COMPUT PHYS, V230, P1939, DOI 10.1016/j.jcp.2010.11.042
   Lu YC, 2011, MICROFLUID NANOFLUID, V10, P1079, DOI 10.1007/s10404-010-0736-7
   Nabavi SA, 2015, CHEM ENG SCI, V130, P183, DOI 10.1016/j.ces.2015.03.004
   Popinet S, 2003, J COMPUT PHYS, V190, P572, DOI 10.1016/S0021-9991(03)00298-5
   Popinet S, 2009, J COMPUT PHYS, V228, P5838, DOI 10.1016/j.jcp.2009.04.042
   Sauret A, 2012, APPL PHYS LETT, V100, DOI 10.1063/1.3702434
   Saville DA, 1997, ANNU REV FLUID MECH, V29, P27, DOI 10.1146/annurev.fluid.29.1.27
   Song Y, 2013, BIOMICROFLUIDICS, V7, DOI 10.1063/1.4827916
   Song Y, 2012, LANGMUIR, V28, P12054, DOI 10.1021/la3026599
   Song YS, 2007, J CHROMATOGR A, V1162, P180, DOI 10.1016/j.chroma.2007.06.032
   Thorsen T, 2001, PHYS REV LETT, V86, P4163, DOI 10.1103/PhysRevLett.86.4163
   Utada AS, 2007, MRS BULL, V32, P702, DOI 10.1557/mrs2007.145
   Vijayakumar K, 2010, CHEM SCI, V1, P447, DOI 10.1039/c0sc00229a
   Walter H., 1985, PARTITIONING AQUEOUS, DOI [10.1016/B978-0-12-733860-6, DOI 10.1016/B978-0-12-733860-6]
   Ziemecka I, 2011, SOFT MATTER, V7, P9878, DOI 10.1039/c1sm06517c
   Ziemecka I, 2011, LAB CHIP, V11, P620, DOI 10.1039/c0lc00375a
NR 36
TC 4
Z9 4
U1 5
U2 39
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 201
EP 207
DI 10.1016/j.ces.2018.11.050
PG 7
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500017
DA 2020-05-12
ER

PT J
AU Shang, H
   Wang, TY
   Zhang, WH
AF Shang, Hui
   Wang, Tianye
   Zhang, Wenhui
TI Sulfur vacancy formation at different MoS2 edges during
   hydrodesulfurization process: A DFT study
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Sulfur vacancy; Molybdenum sulfide; Hydrodesulfurization; DFT
ID DENSITY-FUNCTIONAL THEORY; ACTIVE 100 EDGE; THIOPHENE
   HYDRODESULFURIZATION; REACTION PATHWAYS; ADSORPTION; CATALYSTS;
   HYDROGENOLYSIS; MORPHOLOGY; CHEMISTRY; SITES
AB A periodic density functional theory study of the sulfur vacancy formation mechanism on different edges of MoS2 nanocrystallites was investigated from thermodynamics and kinetics points of views. Thermodynamics study shows that the generations of vacancies on the Mo edge and basal plane were found severely inhibited by the thermodynamic limitations. Whilst the formation on the S edge can be proceeded spontaneously. Homolysis dissociation of H-2 molecule was found more favorable than heterolytic dissociation on sulfur edge. The process of dissociated H atoms to form absorbed H2S was proved to be the rate controlling step. By comparing the distribution of charges and FuKui function before and after the vacancy formation, the contribution of sulfur vacancy to electrophilicity of Mo was clear, sulfur vacancies formed at the edges of Mo and S is favorable to the following hydrodesulfurization (HDS) reactions, whereas, the generation of sulfur vacancies on the basal plane inhibits the chemical reaction. The findings are critical to the development of highly active HDS catalysts. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Shang, Hui; Wang, Tianye; Zhang, Wenhui] China Univ Petr, State Key Lab Heavy Oil Proc, Beijing 102249, Peoples R China.
RP Shang, H (reprint author), China Univ Petr, State Key Lab Heavy Oil Proc, Beijing 102249, Peoples R China.
EM huishang@cup.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21476258]
FX This work was supported by the National Natural Science Foundation of
   China [grant Number 21476258] for funding this project.
CR Bollinger MV, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.085410
   Cristol S, 2004, J CATAL, V224, P138, DOI 10.1016/j.jcat.2004.02.008
   DELLEY B, 1990, J CHEM PHYS, V92, P508, DOI 10.1063/1.458452
   Delley B, 2000, J CHEM PHYS, V113, P7756, DOI 10.1063/1.1316015
   Dupont C, 2011, J CATAL, V279, P276, DOI 10.1016/j.jcat.2011.01.025
   Fuchtbauer HG, 2014, TOP CATAL, V57, P207, DOI 10.1007/s11244-013-0176-1
   HALGREN TA, 1977, CHEM PHYS LETT, V49, P225, DOI 10.1016/0009-2614(77)80574-5
   Hammer B, 1999, PHYS REV B, V59, P7413, DOI 10.1103/PhysRevB.59.7413
   Inada Y, 2008, J COMPUT CHEM, V29, P225, DOI 10.1002/jcc.20782
   Jaramillo TF, 2007, SCIENCE, V317, P100, DOI 10.1126/science.1141483
   Kibsgaard J, 2010, J CATAL, V272, P195, DOI 10.1016/j.jcat.2010.03.018
   Kumar N, 2015, J PHYS CHEM C, V119, P29157, DOI 10.1021/acs.jpcc.5b09712
   Lauritsen JV, 2015, J CATAL, V328, P49, DOI 10.1016/j.jcat.2014.12.034
   Lauritsen JV, 2004, J CATAL, V224, P94, DOI 10.1016/j.jcat.2004.02.009
   Lauritsen JV, 2003, NANOTECHNOLOGY, V14, P385, DOI 10.1088/0957-4484/14/3/306
   Maragakis P, 2002, J CHEM PHYS, V117, P4651, DOI 10.1063/1.1495401
   Moses PG, 2007, J CATAL, V248, P188, DOI 10.1016/j.jcat.2007.02.028
   Moses PG, 2009, J CATAL, V268, P201, DOI 10.1016/j.jcat.2009.09.016
   Nikulshin PA, 2014, J CATAL, V309, P386, DOI 10.1016/j.jcat.2013.10.020
   Paul JF, 2003, J PHYS CHEM B, V107, P4057, DOI 10.1021/jp027668f
   Prodhomme PY, 2011, J CATAL, V280, P178, DOI 10.1016/j.jcat.2011.03.017
   Rangarajan S, 2017, ACS CATAL, V7, P501, DOI 10.1021/acscatal.6b02735
   Rangarajan S, 2016, ACS CATAL, V6, P2904, DOI 10.1021/acscatal.6b00058
   Rangarajan S, 2015, AICHE J, V61, P4036, DOI 10.1002/aic.15025
   Raybaud P, 2007, APPL CATAL A-GEN, V322, P76, DOI 10.1016/j.apcata.2007.01.005
   Schweiger H, 2002, J CATAL, V207, P76, DOI 10.1006/jcat.2002.3508
   Todorova T, 2005, J CATAL, V236, P190, DOI 10.1016/j.jcat.2005.09.032
   Todorova T, 2007, J CATAL, V246, P109, DOI 10.1016/j.jcat.2006.11.023
   Topsoe NY, 2011, J CATAL, V279, P337, DOI 10.1016/j.jcat.2011.02.002
   Walton AS, 2013, J CATAL, V308, P306, DOI 10.1016/j.jcat.2013.08.017
   Wang T, 2012, J PHYS CHEM C, V116, P6340, DOI 10.1021/jp300422g
   Wang W., 2015, THESIS
   Wen XD, 2005, J PHYS CHEM B, V109, P18491, DOI 10.1021/jp051540r
   Zheng P, 2017, CHEM ENG SCI, V164, P292, DOI 10.1016/j.ces.2017.02.037
NR 34
TC 2
Z9 2
U1 10
U2 67
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 208
EP 217
DI 10.1016/j.ces.2018.11.049
PG 10
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500018
DA 2020-05-12
ER

PT J
AU Samain, S
   Leturia, M
   Mottelet, S
   Benali, M
   Saleh, K
AF Samain, Sophie
   Leturia, Mikel
   Mottelet, Stephane
   Benali, Mohammed
   Saleh, Khashayar
TI Characterization of caking for crystalline materials: Comparison and
   statistical analysis of three mechanical tests
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Caking; Sucrose; Shear test; Uniaxial compression; Diametrical
   compression; Kernel regression
ID TENSILE-STRENGTH; STORAGE-CONDITIONS; COHESIVE POWDERS; FLOWABILITY;
   HUMIDITY; COMPACTS; BEHAVIOR; SOLIDS
AB Undesired agglomeration of powders, known as caking, results in the loss of product quality and is unacceptable in many powder industries. Information on how ambient conditions influence the cake strength is essential to prevent caking. Although there are a lot of existing methods to form caked samples and even more to characterize them, there is still no consensus regarding these methods. Repeatability is rarely evaluated and the comparative studies remain infrequent. As a deliquescent powder, sucrose is characterized by a threshold Relative Humidity (RH), called Deliquescence Relative Humidity (DRH), above which it turns into an aqueous solution. Partially deliquesced crystals are linked by liquid bridges of aqueous solution. When the RH is decreased below the DRH, these liquid bridges recrystallize into solid bridges to form a hard cake. In this study, an accelerated caking device was developed to obtain homogeneous caked samples of sucrose under controlled conditions. Three mechanical tests were compared on the basis of their sensitivity and repeatability: the uniaxial compression test, the diametrical compression test (tensile test) and the shear test. The varying parameter was the amount of water uptaken before drying, and the data were fitted by cross-validated local linear nonparametric regression. The best mechanical test was found to be the shear test, giving a sharp failure of the cake along a predetermined failure surface and a linear relationship between the cake strength and the amount of water uptaken. (C) 2018 Published by Elsevier Ltd.
C1 [Samain, Sophie; Leturia, Mikel; Mottelet, Stephane; Benali, Mohammed; Saleh, Khashayar] Sorbonne Univ, Univ Technol Compiegne, EA TIMR 4297, F-60200 Compiegne, France.
RP Saleh, K (reprint author), Sorbonne Univ, Univ Technol Compiegne, EA TIMR 4297, F-60200 Compiegne, France.
EM khashayar.saleh@utc.fr
RI Leturia, Mikel/J-9296-2019
OI Leturia, Mikel/0000-0002-1474-6044; BENALI,
   Mohammed/0000-0003-2815-9091; Samain, Sophie/0000-0001-5895-629X
FU region Hauts-de-FranceRegion Hauts-de-France; FEDEREuropean Union (EU);
   Department "Particle Systems", Nestle Research Center, Lausanne,
   Switzerland
FX The authors would like to thank the region Hauts-de-France and the FEDER
   for their financial support to project Motamorph. Financial support
   provided by the Department "Particle Systems", Nestle Research Center,
   Lausanne, Switzerland, is also gratefully acknowledged.
CR ARINZE EA, 2001, [No title captured], V13, P45
   Calvert G, 2013, POWDER TECHNOL, V249, P323, DOI 10.1016/j.powtec.2013.08.037
   CHEN YL, 1993, POWDER TECHNOL, V77, P1, DOI 10.1016/0032-5910(93)85001-P
   Cleaver JAS, 2004, POWDER TECHNOL, V146, P93, DOI 10.1016/j.powtec.2004.07.005
   ELGINDY NA, 1982, INT J PHARM, V13, P35, DOI 10.1016/0378-5173(82)90140-5
   Fitzpatrick JJ, 2008, FOOD BIOPROD PROCESS, V86, P198, DOI 10.1016/j.fbp.2007.10.009
   Fitzpatrick JJ, 2007, INT DAIRY J, V17, P383, DOI 10.1016/j.idairyj.2006.04.010
   Fitzpatrick JJ, 2010, POWDER TECHNOL, V204, P131, DOI 10.1016/j.powtec.2010.07.029
   Freeman T, 2015, PROCEDIA ENGINEER, V102, P35, DOI 10.1016/j.proeng.2015.01.104
   Gao S., 2012, THESIS
   Hassanpour A, 2007, PART PART SYST CHAR, V24, P117, DOI 10.1002/ppsc.200601111
   Hondros G., 1959, Australian Journal of Applied Science, V10, P243
   Hou H, 2008, J PHARM SCI-US, V97, P4030, DOI 10.1002/jps.21288
   IRANI RR, 1959, IND ENG CHEM, V51, P1285, DOI 10.1021/ie50598a035
   KNIGHT PC, 1988, POWDER TECHNOL, V54, P279, DOI 10.1016/0032-5910(88)80058-5
   Leaper MC, 2003, P I MECH ENG E-J PRO, V217, P41, DOI 10.1243/09544080360562972
   LI LC, 1990, J PHARM PHARMACOL, V42, P272, DOI 10.1111/j.2042-7158.1990.tb05406.x
   Li Q, 2004, STAT SINICA, V14, P485
   Lloyd RJ, 1996, INT J FOOD SCI TECH, V31, P305, DOI 10.1046/j.1365-2621.1996.00352.x
   Mauer LJ, 2010, ANNU REV FOOD SCI T, V1, P41, DOI 10.1146/annurev.food.080708.100915
   Ozkan N, 2002, J FOOD ENG, V55, P293, DOI 10.1016/S0260-8774(02)00104-8
   Palzer S, 2011, FOOD ENG SER, P491, DOI 10.1007/978-1-4419-7475-4_19
   Pasha M, 2013, POWDER TECHNOL, V233, P80, DOI 10.1016/j.powtec.2012.08.017
   Pierrat P, 1997, POWDER TECHNOL, V91, P83, DOI 10.1016/S0032-5910(96)03179-8
   PIETSCH WB, 1969, CAN J CHEM ENG, V47, P403, DOI 10.1002/cjce.5450470419
   Procopio AT, 2003, J MATER SCI, V38, P3629, DOI 10.1023/A:1025681432260
   Rock M, 2005, POWDER TECHNOL, V157, P121, DOI 10.1016/j.powtec.2005.05.018
   Rondeau X, 2000, THESIS
   Rumpf H, 1974, J CHEM ENG JPN, V7, P294, DOI 10.1252/jcej.7.294
   SCHUBERT H, 1975, POWDER TECHNOL, V11, P107, DOI 10.1016/0032-5910(75)80036-2
   Schulze D., 2008, POWDERS BULK SOLIDS
   Schweiger A, 1999, POWDER TECHNOL, V101, P7, DOI 10.1016/S0032-5910(98)00117-X
   Smith RM, 2012, POWDER TECHNOL, V224, P189, DOI 10.1016/j.powtec.2012.02.053
   Sormoli ME, 2013, J FOOD ENG, V116, P873, DOI 10.1016/j.jfoodeng.2013.01.038
   Stoklosa AM, 2012, FOOD RES INT, V49, P783, DOI 10.1016/j.foodres.2012.09.034
   TAKENAKA H, 1981, CHEM PHARM BULL, V29, P2653
   Teunou E, 1999, J FOOD ENG, V42, P109, DOI 10.1016/S0260-8774(99)00087-4
   Tomas J., 2001, BULK SOLIDS HANDL, V21, P431
   Vyal' EY, 2002, POWDER METALL MET C+, V41, P249, DOI 10.1023/A:1020523129918
   Wahl M, 2008, POWDER TECHNOL, V188, P147, DOI 10.1016/j.powtec.2008.04.062
   WAKIYAMA N, 1992, INT J PHARM, V78, P95, DOI 10.1016/0378-5173(92)90361-5
   Walker GM, 1999, IND ENG CHEM RES, V38, P4100, DOI 10.1021/ie990204s
   Wang C, 2008, PARTICUOLOGY, V6, P282, DOI 10.1016/j.partic.2008.05.004
   Wang Y., 2006, CHARACTERIZATION CAK
   Weigl B, 2006, CHEM ENG TECHNOL, V29, P686, DOI 10.1002/ceat.200600083
   WU CFJ, 1986, ANN STAT, V14, P1261, DOI 10.1214/aos/1176350142
NR 46
TC 0
Z9 0
U1 0
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 218
EP 229
DI 10.1016/j.ces.2018.11.048
PG 12
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500019
DA 2020-05-12
ER

PT J
AU Ren, YX
   Peng, DD
   Wu, H
   Yang, LX
   Wu, XY
   Wu, YZ
   Wang, SF
   Jiang, ZY
AF Ren, Yanxiong
   Peng, Dongdong
   Wu, Hong
   Yang, Leixin
   Wu, Xingyu
   Wu, Yingzhen
   Wang, Shaofei
   Jiang, Zhongyi
TI Enhanced carbon dioxide flux by catechol-Zn2+ synergistic manipulation
   of graphene oxide membranes
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Graphene oxide membranes; Dopamine; Zinc ions; Synergistic manipulation;
   CO2 separation
ID MECHANICAL-PROPERTIES; ZINC ION; NANOSHEETS; ULTRATHIN; REDUCTION;
   ROBUST; FUNCTIONALIZATION; CHEMISTRY; TRANSPORT; FRAMEWORK
AB In this study, a kind of functionalized graphene oxide (GO) membranes was fabricated. GO nanosheets were pre-coated by polydopamine (PDA) via spontaneous polymerization of dopamine (DA) and then cross-linked with zinc ions (Zn2+) via dopamine-mediated complexation reaction. The PDA coating rendered GO nanosheets a large number of evenly distributed oxygen-containing functional groups, which are beneficial to bond zinc ions effectively and to create favorable microenvironments of the nanochannels in GO membranes. Both PDA and Zn2+ acted as cross-linkers to tune the interlayer spacing of GO nanosheets. Zinc ions also afforded facilitated transport ability towards CO2 in dry state. Taking CO2/CH4 separation as the model system, the GO-PDA-Zn2+ membrane exhibited significantly enhanced CO2 permeance of 175 GPU with CO2/CH4 selectivity of 19.1 in dry state owing to the large transport channels and facilitated transport carriers. Moreover, the GO-PDA-Zn2+ membrane exhibited high CO2/CH4 selectivity of 32.9 in wet state owing to the stable intergalleries and moderate interlayer spacing. It is envisioned that the synergistic manipulation of PDA and metal ions can be utilized to exploit a variety of 2D membranes with superior gas separation performance. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Ren, Yanxiong; Peng, Dongdong; Wu, Hong; Yang, Leixin; Wu, Xingyu; Wu, Yingzhen; Jiang, Zhongyi] Tianjin Univ, Sch Chem Engn & Technol, Key Lab Green Chem Technol, Minist Educ, Tianjin 300072, Peoples R China.
   [Ren, Yanxiong; Peng, Dongdong; Wu, Hong; Yang, Leixin; Wu, Xingyu; Wu, Yingzhen; Jiang, Zhongyi] Collaborat Innovat Ctr Chem Sci & Engn Tianjin, Tianjin 300072, Peoples R China.
   [Wang, Shaofei] KAUST, Biol & Environm Sci & Engn Div BESE, Thuwal 239556900, Saudi Arabia.
RP Jiang, ZY (reprint author), Tianjin Univ, Sch Chem Engn & Technol, Key Lab Green Chem Technol, Minist Educ, Tianjin 300072, Peoples R China.
EM zhyjiang@tju.edu.cn
RI Wang, Shaofei/C-4875-2017; Wang, Shaofei/L-1017-2019; Ren,
   Yanxiong/S-6389-2017
OI Wang, Shaofei/0000-0002-1790-7149; Wu, Yingzhen/0000-0003-0165-3970;
   Ren, Yanxiong/0000-0002-5356-8236
FU National Key RAMP;D Program of China [2017YFB0603400]; National Natural
   Science Foundation of ChinaNational Natural Science Foundation of China
   [21490583, 21621004]; State Key Laboratory of Organic-Inorganic
   Composites [oic-201701004]; National Science Fund for Distinguished
   Young ScholarsNational Natural Science Foundation of ChinaNational
   Science Fund for Distinguished Young Scholars [21125627]; State Key
   Laboratory of Separation Membranes and Membrane Processes (Tianjin
   Polytechnic University) [M1-201701, M1-201501]; Program of Introducing
   Talents of Discipline to UniversitiesMinistry of Education, China - 111
   Project [B06006]; National Key Laboratory of United Laboratory for
   Chemical Engineering [SKL-ChE-17B01]
FX The authors gratefully acknowledge the support from National Key R&D
   Program of China (2017YFB0603400), National Natural Science Foundation
   of China (No. 21490583 and 21621004), State Key Laboratory of
   Organic-Inorganic Composites (oic-201701004), National Science Fund for
   Distinguished Young Scholars (No. 21125627), State Key Laboratory of
   Separation Membranes and Membrane Processes (Tianjin Polytechnic
   University) (No. M1-201701 and No. M1-201501), the Program of
   Introducing Talents of Discipline to Universities (B06006), National Key
   Laboratory of United Laboratory for Chemical Engineering
   (SKL-ChE-17B01).
CR Abraham J, 2017, NAT NANOTECHNOL, V12, P546, DOI [10.1038/nnano.2017.21, 10.1038/NNANO.2017.21]
   Ammar MR, 2015, CARBON, V95, P364, DOI 10.1016/j.carbon.2015.07.095
   An Z, 2011, ADV MATER, V23, P3842, DOI 10.1002/adma.201101544
   Cheng J, 2015, J BIOACT COMPAT POL, V30, P289, DOI 10.1177/0883911515569918
   Chowdhury AD, 2016, ACS APPL MATER INTER, V8, P21002, DOI 10.1021/acsami.6b06266
   Cui W, 2014, ACS NANO, V8, P9511, DOI 10.1021/nn503755c
   Dresselhaus MS, 2010, NANO LETT, V10, P751, DOI 10.1021/nl904286r
   Eigler S, 2014, ANGEW CHEM INT EDIT, V53, P7720, DOI 10.1002/anie.201402780
   Gong SS, 2016, J MATER CHEM A, V4, P17073, DOI 10.1039/c6ta06893f
   He GW, 2015, ADV FUNCT MATER, V25, P7502, DOI 10.1002/adfm.201503229
   Hu YX, 2016, ANGEW CHEM INT EDIT, V55, P2048, DOI 10.1002/anie.201509213
   HUMMERS WS, 1958, J AM CHEM SOC, V80, P1339, DOI 10.1021/ja01539a017
   Hung WS, 2014, CHEM MATER, V26, P2983, DOI 10.1021/cm5007873
   Jia ZQ, 2016, J MEMBRANE SCI, V520, P139, DOI 10.1016/j.memsci.2016.07.042
   Jia ZQ, 2016, COLLOID SURFACE A, V494, P101, DOI 10.1016/j.colsurfa.2016.01.023
   Jia ZQ, 2016, CARBON, V101, P290, DOI 10.1016/j.carbon.2016.02.016
   Jia ZQ, 2015, J MATER CHEM A, V3, P4405, DOI 10.1039/c4ta06193d
   Karim MR, 2013, J AM CHEM SOC, V135, P8097, DOI 10.1021/ja401060q
   Karunakaran M, 2017, J MATER CHEM A, V5, P649, DOI 10.1039/c6ta08858a
   Kim HW, 2014, CHEM COMMUN, V50, P13563, DOI 10.1039/c4cc06207h
   Kim HW, 2013, SCIENCE, V342, P91, DOI 10.1126/science.1236098
   Lam DV, 2015, CHEM COMMUN, V51, P2671, DOI 10.1039/c4cc08896d
   Lee H, 2007, SCIENCE, V318, P426, DOI 10.1126/science.1147241
   Li H, 2013, SCIENCE, V342, P95, DOI 10.1126/science.1236686
   Li WB, 2018, ADV MATER INTERFACES, V5, DOI 10.1002/admi.201800032
   Li YF, 2012, J MATER CHEM, V22, P19617, DOI 10.1039/c2jm33238h
   Liu GP, 2016, ANGEW CHEM INT EDIT, V55, P13384, DOI 10.1002/anie.201600438
   Liu WP, 2013, J MATER CHEM A, V1, P3713, DOI 10.1039/c3ta00766a
   Lopez V, 2009, ADV MATER, V21, P4683, DOI 10.1002/adma.200901582
   Mi BX, 2014, SCIENCE, V343, P740, DOI 10.1126/science.1250247
   Mi YJ, 2012, J MATER CHEM, V22, P8036, DOI 10.1039/c2jm16656a
   Park S, 2008, ACS NANO, V2, P572, DOI 10.1021/nn700349a
   Peng DD, 2017, J MEMBRANE SCI, V522, P351, DOI 10.1016/j.memsci.2016.09.040
   Shen J, 2016, ACS NANO, V10, P3398, DOI 10.1021/acsnano.5b07304
   Shen J, 2015, ANGEW CHEM INT EDIT, V54, P578, DOI 10.1002/anie.201409563
   Stankovich S, 2007, CARBON, V45, P1558, DOI 10.1016/j.carbon.2007.02.034
   Su Y, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5843
   Suk JW, 2010, ACS NANO, V4, P6557, DOI 10.1021/nn101781v
   Sun PZ, 2013, ACS NANO, V7, P428, DOI 10.1021/nn304471w
   Wang SF, 2017, ANGEW CHEM INT EDIT, V56, P14246, DOI 10.1002/anie.201708048
   Wang SF, 2016, ENERG ENVIRON SCI, V9, P3107, DOI 10.1039/c6ee01984f
   Wu XY, 2017, J MEMBRANE SCI, V528, P273, DOI 10.1016/j.memsci.2017.01.042
   Wu YZ, 2018, J MEMBRANE SCI, V563, P229, DOI 10.1016/j.memsci.2018.05.075
   Xia SJ, 2015, DESALINATION, V371, P78, DOI 10.1016/j.desal.2015.06.005
   Xin QP, 2015, J MATER CHEM A, V3, P6629, DOI 10.1039/c5ta00506j
   Xu LQ, 2010, MACROMOLECULES, V43, P8336, DOI 10.1021/ma101526k
   Yang HC, 2015, J MEMBRANE SCI, V483, P42, DOI 10.1016/j.memsci.2015.02.027
   Yang LX, 2017, J MEMBRANE SCI, V543, P69, DOI 10.1016/j.memsci.2017.08.050
   Yeh CN, 2015, NAT CHEM, V7, P166, DOI [10.1038/NCHEM.2145, 10.1038/nchem.2145]
   Zhang N, 2018, J MEMBRANE SCI, V549, P670, DOI 10.1016/j.memsci.2017.10.054
   Zhang YY, 2016, CHEM SOC REV, V45, P2378, DOI 10.1039/c5cs00258c
   Zhang Z, 2013, NANOSCALE, V5, P118, DOI 10.1039/c2nr32092d
   Zhao J, 2014, PROG POLYM SCI, V39, P1668, DOI 10.1016/j.progpolymsci.2014.06.001
NR 53
TC 6
Z9 7
U1 17
U2 80
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 230
EP 238
DI 10.1016/j.ces.2018.11.055
PG 9
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500020
DA 2020-05-12
ER

PT J
AU Luo, C
AF Luo, Cheng
TI Determination of constant viscosity for a power-law melt flow inside a
   circular tube
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Power-law melt flow; Non-Newtonian fluid; Viscous heating; Capillary
   rheometry; Temperature-dependent viscosity; Constant viscosity
ID MOLTEN POLYMER FLOW; HEAT-TRANSFER
AB For a melt flow with viscous heating, a temperature-independent viscosity model is simple to use in estimating its temperature profile. In this model, a constant viscosity is chosen to represent a temperature-dependent one. However, it is still not clear about what value should be selected for the constant viscosity. In this short communication, we derive a relation to find it, followed by validation using existing numerical examples. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Luo, Cheng] Univ Texas Arlington, Dept Mech & Aerosp Engn, 500 W First St,Woolf Hall 226, Arlington, TX 76019 USA.
RP Luo, C (reprint author), Univ Texas Arlington, Dept Mech & Aerosp Engn, 500 W First St,Woolf Hall 226, Arlington, TX 76019 USA.
EM chengluo@uta.edu
FU University of Texas at Arlington
FX The author would like to thank the University of Texas at Arlington for
   a grant to support his faculty development leave (FDL). He also wants to
   thank Dr. Kalman Migler and Dr. Jonathan Seppala for their hospitality
   during his FDL in the NIST. One of very helpful discussions with Dr.
   Migler motivated the writing of this short communication.
CR AGUR EE, 1981, J APPL POLYM SCI, V26, P765, DOI 10.1002/app.1981.070260302
   Bird R. B., 1987, DYNAMICS POLYM LIQUI, V1, P218
   HIEBER CA, 1977, RHEOL ACTA, V16, P553, DOI 10.1007/BF01525656
   Laun HM, 2004, RHEOL ACTA, V43, P509, DOI 10.1007/s00397-004-0387-2
   LYCHE BC, 1956, CHEM ENG SCI, V6, P35, DOI 10.1016/0009-2509(56)80008-0
   Phan DD, 2018, J RHEOL, V62, P1097, DOI 10.1122/1.5022982
   Seppala JE, 2017, SOFT MATTER, V13, P6761, DOI 10.1039/c7sm00950j
   SUKANEK PC, 1971, CHEM ENG SCI, V26, P1775, DOI 10.1016/0009-2509(71)86068-2
   Turner BN, 2014, RAPID PROTOTYPING J, V20, P192, DOI 10.1108/RPJ-01-2013-0012
   Wei DM, 2003, INT J HEAT MASS TRAN, V46, P3097, DOI 10.1016/S0017-9310(03)00069-3
NR 10
TC 1
Z9 1
U1 2
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 239
EP 241
DI 10.1016/j.ces.2018.11.053
PG 3
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500021
DA 2020-05-12
ER

PT J
AU Ramji, S
   Pushpavanam, S
AF Ramji, Sundari
   Pushpavanam, S.
TI Liquid-liquid extraction in laminar two-phase stratified flows in
   capillary microchannels
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Mathematical model; Hydrodynamics; Mass transfer; Circular microchannel;
   Stratified flow; Bipolar cylindrical coordinates
ID MASS-TRANSFER; PLUG-FLOW; SLUG FLOW; HYDRODYNAMICS; MICROREACTOR;
   PERFORMANCE; SYSTEM
AB In this work, we study the mass transfer of a solute in laminar, two-phase, stratified flow in a circular microchannel. The model developed in our earlier work (Picardo et al., 2015) has been used. We adopt a semi-analytical approach to model liquid-liquid extraction in the circular channel with stratified flow. A bipolar cylindrical coordinate system is employed for an elegant description of the boundaries in the form of iso-coordinate surfaces.
   The model developed for the circular channel is computationally intensive. We present a methodology to estimate the mass transfer predictions for the 2D circular channel from a 2D channel of rectangular cross-section and a 1D channel i.e. flow between infinite parallel plates. This is analyzed for different carrier phase holdups and fluid properties. It is found that the 1D model can accurately predict the performance of the capillary. Further, we conclude that a more viscous carrier phase results in enhanced mass transfer. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Ramji, Sundari; Pushpavanam, S.] IIT, Dept Chem Engn, Madras 600036, Tamil Nadu, India.
RP Pushpavanam, S (reprint author), IIT, Dept Chem Engn, Madras 600036, Tamil Nadu, India.
EM spush@iitm.ac.in
CR Aljbour S., 2009, INT J CHEM MOL NUCL, V3, P267
   Aljbour S, 2010, TOP CATAL, V53, P694, DOI 10.1007/s11244-010-9507-7
   Asano Y, 2015, J CHEM ENG JPN, V48, P915, DOI 10.1252/jcej.14we328
   Biswas KG, 2015, CHEM ENG J, V262, P436, DOI 10.1016/j.cej.2014.09.122
   Brauner N, 1996, CHEM ENG COMMUN, V141, P103, DOI 10.1080/00986449608936412
   Burns JR, 1999, CHEM ENG RES DES, V77, P206, DOI 10.1205/026387699526106
   Fries DM, 2008, CHEM ENG TECHNOL, V31, P1182, DOI 10.1002/ceat.200800169
   Gupta R, 2013, CHEM ENG SCI, V92, P180, DOI 10.1016/j.ces.2013.01.013
   Hisamoto H, 2001, CHEM COMMUN, P2662, DOI 10.1039/b106494k
   Huh YS, 2011, KOREAN J CHEM ENG, V28, P633, DOI 10.1007/s11814-010-0533-8
   Jovanovic J, 2012, IND ENG CHEM RES, V51, P1015, DOI 10.1021/ie200715m
   Jovanovic J, 2011, CHEM ENG SCI, V66, P42, DOI 10.1016/j.ces.2010.09.040
   Kashid MN, 2011, CHEM ENG SCI, V66, P3876, DOI 10.1016/j.ces.2011.05.015
   Kashid MN, 2011, IND ENG CHEM RES, V50, P6906, DOI 10.1021/ie102200j
   Li Q, 2017, CHEM ENG J, V328, P717, DOI 10.1016/j.cej.2017.07.037
   Lu YC, 2011, MICROFLUID NANOFLUID, V10, P1079, DOI 10.1007/s10404-010-0736-7
   Malengier B, 2012, CHEM ENG SCI, V83, P2, DOI 10.1016/j.ces.2012.03.027
   Novak U, 2015, MICROFLUID NANOFLUID, V19, P75, DOI 10.1007/s10404-015-1550-z
   Novak U, 2012, SEP PURIF TECHNOL, V97, P172, DOI 10.1016/j.seppur.2012.01.033
   Okubo Y, 2008, CHEM ENG SCI, V63, P4070, DOI 10.1016/j.ces.2008.05.017
   Picardo JR, 2015, INDIAN CHEM ENG, V57, P322, DOI 10.1080/00194506.2015.1044027
   Sahu A, 2016, CHEM ENG PROCESS, V104, P190, DOI 10.1016/j.cep.2016.03.010
   Soares RRG, 2016, BIOTECHNOL J, V11, P1498, DOI 10.1002/biot.201600356
   Susanti, 2016, IND ENG CHEM RES, V55, P4691, DOI 10.1021/acs.iecr.5b04917
   Tusek AJ, 2017, SEP SCI TECHNOL, V52, P864, DOI 10.1080/01496395.2016.1273953
   Vir AB, 2014, MICROFLUID NANOFLUID, V16, P1057, DOI 10.1007/s10404-013-1269-7
   Vir AB, 2014, IND ENG CHEM RES, V53, P8171, DOI 10.1021/ie4041803
   Znidarsic-Plazl P, 2007, LAB CHIP, V7, P883, DOI 10.1039/b704432a
NR 28
TC 0
Z9 0
U1 2
U2 25
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 242
EP 249
DI 10.1016/j.ces.2018.11.060
PG 8
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500022
DA 2020-05-12
ER

PT J
AU Wang, G
   Gu, Y
   Zhao, LHB
   Xuan, J
   Zeng, GF
   Tang, ZY
   Sun, YH
AF Wang, Gang
   Gu, Yu
   Zhao, Luhaibo
   Xuan, Jin
   Zeng, Gaofeng
   Tang, Zhiyong
   Sun, Yuhan
TI Experimental and numerical investigation of fractal-tree-like heat
   exchanger manufactured by 3D printing
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Fractal-tree-like; Heat exchanger; Heat transfer; 3D printing;
   Computational Fluid Dynamics (CFD) simulation
ID PRESSURE-DROP; THERMAL-CHARACTERISTICS; LAMINAR-FLOW; LIQUID FLOW;
   FLUID-FLOW; MICROCHANNEL; DISTRIBUTOR; PERFORMANCE; NETWORKS; ROUGHNESS
AB The manufacturing difficulties of complex fractal-tree-like heat exchangers have limited their industrial applications, although many evidences have shown that they have significant advantages in heat transfer. Nevertheless, the emerging 3D printing technology has brought great opportunity for the development of complex structured device. In the present study, three-dimensional (3D) fractal-tree-like heat exchangers were designed and manufactured using 3D printing technology. Their performance was evaluated from both thermal and hydrodynamic perspectives, the flow characteristics were investigated in detail. The results show that a fractal-tree-like heat exchanger can improve hydrodynamic performance, reduce pressure drops and has great heat transfer ability. In general, the fractal-tree-like heat exchanger has a comprehensive advantage over the traditional spiral-tube exchangers as it has a higher value of coefficient of performance (COP). Furthermore, the 3D printing provides a visual, efficient, and precise approach in the present research. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Wang, Gang; Gu, Yu; Zhao, Luhaibo; Zeng, Gaofeng; Tang, Zhiyong; Sun, Yuhan] Chinese Acad Sci, SARI, CAS Key Lab Low Carbon Convers Sci & Engn, Shanghai 201210, Peoples R China.
   [Xuan, Jin] Heriot Watt Univ, Sch Engn & Phys Sci, Inst Mech Proc & Energy Engn, Edinburgh EH14 4AS, Midlothian, Scotland.
   [Zeng, Gaofeng; Tang, Zhiyong; Sun, Yuhan] ShanghaiTech Univ, Sch Phys Sci & Technol, Shanghai 201210, Peoples R China.
RP Tang, ZY; Sun, YH (reprint author), Chinese Acad Sci, SARI, CAS Key Lab Low Carbon Convers Sci & Engn, Shanghai 201210, Peoples R China.
EM tangzy@sari.ac.cn; sunyh@sari.ac.cn
RI Xuan, Jin/B-2973-2013
OI Xuan, Jin/0000-0002-6718-9018
FU Youth Innovation Promotion Association of Chinese Academy of Sciences;
   CAS Key Technology Talent Program; Ministry of Science and Technology of
   ChinaMinistry of Science and Technology, China [2016YFA0602603]
FX This work was supported by the Youth Innovation Promotion Association of
   Chinese Academy of Sciences and the CAS Key Technology Talent Program,
   the Ministry of Science and Technology of China (grant 2016YFA0602603).
CR Al-Kalbani H, 2016, APPL ENERG, V165, P1, DOI 10.1016/j.apenergy.2015.12.027
   Alharbi AY, 2004, J HEAT TRANS-T ASME, V126, P744, DOI 10.1115/1.1795236
   Bejan A, 1997, FRACTALS, V5, P685, DOI 10.1142/S0218348X97000553
   Bejan A, 2001, INT J HEAT MASS TRAN, V44, P699, DOI 10.1016/S0017-9310(00)00138-1
   Ben-Ner A, 2017, CALIF MANAGE REV
   Benoit B., 1983, FRACTAL GEOMETRY NAT
   Bhargava KC, 2014, P NATL ACAD SCI USA, V111, P15013, DOI 10.1073/pnas.1414764111
   Chen YP, 2010, AICHE J, V56, P2018, DOI 10.1002/aic.12135
   Chen YP, 2005, INT COMMUN HEAT MASS, V32, P931, DOI 10.1016/j.icheatmasstransfer.2005.02.001
   Chen YP, 2002, INT J HEAT MASS TRAN, V45, P2643, DOI 10.1016/S0017-9310(02)00013-3
   Cheng YQ, 2009, PHYS REV B, V80, DOI 10.1103/PhysRevB.80.064104
   Chu JC, 2012, EXP THERM FLUID SCI, V38, P171, DOI 10.1016/j.expthermflusci.2011.11.015
   Coppens MO, 2012, CURR OPIN CHEM ENG, V1, P281, DOI 10.1016/j.coche.2012.03.002
   Fan YL, 2008, AICHE J, V54, P2796, DOI 10.1002/aic.11597
   Gamrat G, 2008, J FLUID MECH, V594, P399, DOI 10.1017/S0022112007009111
   Guo XF, 2014, ENERGY, V69, P728, DOI 10.1016/j.energy.2014.03.069
   Guo XF, 2013, CHEM ENG J, V227, P116, DOI 10.1016/j.cej.2012.08.068
   Herwig H, 2008, J FLUID MECH, V613, P35, DOI 10.1017/S0022112008003534
   Huchet F, 2007, J APPL ELECTROCHEM, V37, P49, DOI 10.1007/s10800-006-9213-0
   Huchet F, 2008, CHEM ENG RES DES, V86, P1135, DOI 10.1016/j.cherd.2008.04.008
   IEA, 2015, CO2 EM FUEL COMB
   [IEA]-International Energy Agency, 2015, KEY WORLD EN STAT 20
   Kandlikar SG, 2005, PHYS FLUIDS, V17, DOI 10.1063/1.1896985
   Kulkarni AA, 2011, IND ENG CHEM RES, V50, P7667, DOI 10.1021/ie200301y
   Kumar R, 2012, INT J HEAT MASS TRAN, V55, P2707, DOI 10.1016/j.ijheatmasstransfer.2012.01.026
   Li KK, 2016, APPL ENERG, V165, P648, DOI 10.1016/j.apenergy.2015.12.109
   Li P, 2016, INT J HEAT MASS TRAN, V99, P372, DOI 10.1016/j.ijheatmasstransfer.2016.04.004
   Liu C, 2011, INT J HEAT MASS TRAN, V54, P3069, DOI 10.1016/j.ijheatmasstransfer.2011.02.030
   Luo L, 2007, APPL THERM ENG, V27, P1708, DOI 10.1016/j.applthermaleng.2006.07.018
   Luo LG, 2015, CHEM ENG SCI, V123, P542, DOI 10.1016/j.ces.2014.11.051
   McCabe Warren L, 1993, UNIT OPERATIONS CHEM, P101
   MOFFAT RJ, 1988, EXP THERM FLUID SCI, V1, P3, DOI 10.1016/0894-1777(88)90043-X
   Monzel WJ, 2015, IEEE T DIELECT EL IN, V22, P3543, DOI 10.1109/TDEI.2015.005199
   Murray CD, 1926, P NATL ACAD SCI USA, V12, P207, DOI 10.1073/pnas.12.3.207
   Sakai N, 2013, J HEAT TRANSF, V135, P216
   Senn SM, 2004, J POWER SOURCES, V130, P178, DOI 10.1016/j.jpowsour.2003.12.025
   Soulaine C, 2014, INT J HEAT MASS TRAN, V74, P88, DOI 10.1016/j.ijheatmasstransfer.2014.02.069
   Squires TM, 2005, REV MOD PHYS, V77, P977, DOI 10.1103/RevModPhys.77.977
   Toh KC, 2002, INT J HEAT MASS TRAN, V45, P5133, DOI 10.1016/S0017-9310(02)00223-5
   West GB, 1999, SCIENCE, V284, P1677, DOI 10.1126/science.284.5420.1677
   Xu SL, 2015, INT J HEAT MASS TRAN, V81, P33, DOI 10.1016/j.ijheatmasstransfer.2014.10.002
   Yu XF, 2012, INT J HEAT MASS TRAN, V55, P7499, DOI 10.1016/j.ijheatmasstransfer.2012.07.050
   Zhang CP, 2015, INT J HEAT MASS TRAN, V85, P723, DOI 10.1016/j.ijheatmasstransfer.2015.01.118
   2002, HDB CHEM PHYS
NR 44
TC 4
Z9 4
U1 10
U2 63
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 250
EP 261
DI 10.1016/j.ces.2018.07.021
PG 12
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500023
OA Green Published
DA 2020-05-12
ER

PT J
AU Chen, XM
   Lai, CY
   Fang, F
   Zhao, HP
   Dai, XH
   Ni, BJ
AF Chen, Xueming
   Lai, Chun-Yu
   Fang, Fang
   Zhao, He-Ping
   Dai, Xiaohu
   Ni, Bing-Jie
TI Model-based evaluation of selenate and nitrate reduction in
   hydrogen-based membrane biofilm reactor
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Hydrogen-based membrane biofilm reactor; Selenate; Nitrate; Mathematical
   modelling; Model calibration
ID AUTOTROPHIC NITROGEN REMOVAL; JOAQUIN DRAINAGE WATER; SULFATE REDUCTION;
   SELENIUM; PERCHLORATE; BIOREMEDIATION
AB A biofilm model was developed to describe the simultaneous NO3- and SeO42- reduction in a H-2-based membrane biofilm reactor (MBfR). Model calibration and validation was conducted using the experimental data of a reported H-2-based MBfR. With a good level of identifiability, the SeO42- affinity constant and the SeO32- affinity constant were estimated at 9.80 +/- 0.51 g Se m(-3) and 1.83 +/- 0.38 g Se m(-3), respectively. The model was then applied to evaluate the effects of key operating conditions on the single-stage H-2-based MBfR and the role of reactor configuration through comparing two-stage to single-stage MBfR systems. The results showed that (i) high SeO42- or low NO3- concentration in the influent favored the growth of selenate-reducing bacteria (SeRB) and therefore benefited the Se removal, (ii) the influent dissolved oxygen slightly inhibited the Se removal through enhancing the aerobic microbial respiration on H-2, (iii) the H-2 supply should be controlled at a proper level to avoid SeRB suppression and H-2 wastage, (iv) thin biofilm should be avoided to ensure a protected niche for SeRB and therefore a promising Se removal, and (v) the two-stage MBfR configuration offered relatively higher efficiency in removing Se and NO3- simultaneously under the same loading condition. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Chen, Xueming] Tech Univ Denmark, Proc & Syst Engn Ctr PROSYS, Dept Chem & Biochem Engn, DK-2800 Lyngby, Denmark.
   [Lai, Chun-Yu; Zhao, He-Ping] Zhejiang Univ, Coll Environm & Resource Sci, Hangzhou 310058, Zhejiang, Peoples R China.
   [Fang, Fang] Hohai Univ, Key Lab Integrated Regulat & Resource Dev Shallow, Minist Educ, Nanjing 210098, Jiangsu, Peoples R China.
   [Dai, Xiaohu; Ni, Bing-Jie] Tongii Univ, Coll Environm Sci & Engn, Shanghai Inst Pollut Control & Ecol Secur, State Key Lab Pollut Control & Resources Reuse, Shanghai 200092, Peoples R China.
RP Ni, BJ (reprint author), Tongii Univ, Coll Environm Sci & Engn, Shanghai Inst Pollut Control & Ecol Secur, State Key Lab Pollut Control & Resources Reuse, Shanghai 200092, Peoples R China.
EM bjni@tongji.edu.cn
RI ; Chen, Xueming/D-3208-2014
OI Ni, Bing-Jie/0000-0002-1129-7837; Chen, Xueming/0000-0003-4009-9810
FU Recruitment Program of Global Experts; National Natural Science
   Foundation of ChinaNational Natural Science Foundation of China
   [51578391]; Program for 100 Young Talents in Tongji University
FX This work was supported by the Recruitment Program of Global Experts,
   the National Natural Science Foundation of China (No. 51578391) and the
   Program for 100 Young Talents in Tongji University (Category A).
CR Batstone DJ, 2003, BIOTECHNOL BIOENG, V84, P195, DOI 10.1002/bit.10753
   Cannon H. L, 1964, GEOCHEMISTRY ROCKS R
   Cantafio AW, 1996, APPL ENVIRON MICROB, V62, P3298, DOI 10.1128/AEM.62.9.3298-3303.1996
   Chen XM, 2017, CHEM ENG J, V316, P82, DOI 10.1016/j.cej.2017.01.084
   Chung J, 2006, ENVIRON SCI TECHNOL, V40, P1664, DOI 10.1021/es051251g
   Di Capua F, 2015, CHEM ENG J, V280, P643, DOI 10.1016/j.cej.2015.05.131
   EPA, 2015, FED REG EFFL LIM GUI
   EPA (United States Environmental Protection Agency), 2009, 816F09004 EPA
   Fellowes JW, 2011, J HAZARD MATER, V189, P660, DOI 10.1016/j.jhazmat.2011.01.079
   Fesharaki PJ, 2010, BRAZ J MICROBIOL, V41, P461, DOI [10.1590/S1517-83822010000200028, 10.1590/S1517-838220100002000028]
   Ge HQ, 2010, WATER RES, V44, P123, DOI 10.1016/j.watres.2009.09.005
   GERHARDT MB, 1991, RES J WATER POLLUT C, V63, P799
   Kleerebezem R, 2010, CRIT REV ENV SCI TEC, V40, P1, DOI 10.1080/10643380802000974
   Knobeloch L, 2000, ENVIRON HEALTH PERSP, V108, P675, DOI 10.2307/3434890
   Lai CY, 2014, ENVIRON SCI TECHNOL, V48, P3395, DOI 10.1021/es4053939
   Lee E. W., 1989, Biotreatment of agricultural wastewater., P33
   Lemly A D., 2002, SELENIUM ASSESSMENT, P3
   MACY JM, 1993, APPL MICROBIOL BIOT, V40, P588
   Mal J, 2017, BIORESOURCE TECHNOL, V229, P11, DOI 10.1016/j.biortech.2016.12.112
   Ni BJ, 2013, J MEMBRANE SCI, V428, P163, DOI 10.1016/j.memsci.2012.10.049
   REICHERT P, 1998, AQUASIM 2 0 COMPUTER
   Rittmann BE, 2018, WATER SCI TECHNOL, V77, P1149, DOI 10.2166/wst.2018.021
   SQUIRES RC, 1989, J IRRIG DRAIN ENG, V115, P48, DOI 10.1061/(ASCE)0733-9437(1989)115:1(48)
   Tang Y, 2013, BIOTECHNOL BIOENG, V110, P763, DOI 10.1002/bit.24755
   Tang YN, 2012, ENVIRON SCI TECHNOL, V46, P1598, DOI 10.1021/es203129s
   Terada A, 2007, BIOTECHNOL BIOENG, V97, P40, DOI 10.1002/bit.21213
   World Health Organization (WHO), 2011, SEL DRINK WAT BACKGR
   Zhang YQ, 2003, J AGR FOOD CHEM, V51, P7073, DOI 10.1021/jf0304019
   Zhao HP, 2013, ENVIRON SCI TECHNOL, V47, P1565, DOI 10.1021/es303823n
NR 29
TC 3
Z9 3
U1 12
U2 56
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 262
EP 270
DI 10.1016/j.ces.2018.11.032
PG 9
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500024
DA 2020-05-12
ER

PT J
AU Frey, M
   Romero, T
   Roger, AC
   Edouard, D
AF Frey, Myriam
   Romero, Thierry
   Roger, Anne-Cecile
   Edouard, David
TI An intensification of the CO2 methanation reaction: Effect of carbon
   nanofiber network on the hydrodynamic, thermal and catalytic properties
   of reactors filled with open cell foams
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Residence time distribution; Platelet milli-reactors; Open cell foam;
   Carbon nanofibers; CO2 methanation; Thermal-infrared imaging
ID PERFORMANCE; SUPPORTS
AB The carbon dioxide methanation reaction is highly exothermal (Delta(r)H298K(0) = -165 kJ mol(-1)) and needs therefore an efficient process to evacuate the heat generated during the reaction. In this paper, a structured bed filled with an open cell foam was chosen due to the many advantages of this kind of reactor (high surface/volume ratio, low pressure drop, intensification of mass and heat transfer...). First we showed that the presence carbon nanofibers didn't have an influence on the hydrodynamic behaviour of the platelet milli-reactor. Then, we used in situ infrared thermography to measure the surface temperature of the catalytic foam during the methanation reaction. The thermal imaging allowed us to visualize the "ignition" of the reaction, as well as to show the presence or absence of hot spots and their temperature. In this paper, we directly show for the first time the positive effect of carbon nanofibers on the surface temperature of the catalytic foam. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Frey, Myriam; Romero, Thierry; Roger, Anne-Cecile] Univ Strasbourg, Grp Energy & Fuels Sustainable Environm, ICPEES, UMR CNRS 7515, 25 Rue Becquerel, F-67087 Strasbourg, France.
   [Edouard, David] Unive Claude Bernard Lyon 1, LAGEP, UMR CNRS 5007, 43 Blvd 11 Novembre 1918, F-69100 Villeurbanne, France.
RP Frey, M (reprint author), Univ Strasbourg, Grp Energy & Fuels Sustainable Environm, ICPEES, UMR CNRS 7515, 25 Rue Becquerel, F-67087 Strasbourg, France.; Edouard, D (reprint author), Unive Claude Bernard Lyon 1, LAGEP, UMR CNRS 5007, 43 Blvd 11 Novembre 1918, F-69100 Villeurbanne, France.
EM myriam.frey@univ-poitiers.fr; david.edouard@univ-lyon1.fr
FU ANRFrench National Research Agency (ANR) [ANR2010JCJC90401 SIMI9
   'Millimatrix']; Region AlsaceRegion Grand-Est; CNRS Emergence CO2 2014
   (CAMICOM project)
FX The authors would like to thank the ANR (project ANR2010JCJC90401 SIMI9
   'Millimatrix'), the Region Alsace and CNRS Emergence CO<INF>2</INF> 2014
   (CAMICOM project) for their financial support.
CR Bengaouer A, 2018, CAN J CHEM ENG, V96, P1937, DOI 10.1002/cjce.23140
   Dussud F.-X., 2015, REPERES CHIFFRES CLE
   E-cube Strategy Consultants-GRTgaz, 2013, AN ROL TRANSP GAZ NA, P16
   EE-Consultant HESPUL SOLAGRO, 2014, ET PORT HYDR METH CO, P238
   Frey M., 2013, ADV CHEM LETT, V1, P257
   Frey M, 2017, ENERGY TECHNOL-GER, V5, P2078, DOI 10.1002/ente.201700188
   Frey M, 2016, CATAL TODAY, V273, P83, DOI 10.1016/j.cattod.2016.03.016
   Frey M, 2015, CR CHIM, V18, P283, DOI 10.1016/j.crci.2015.01.002
   Giani L, 2005, IND ENG CHEM RES, V44, P4993, DOI 10.1021/ie0490886
   Hetsroni G, 2005, INT J HEAT MASS TRAN, V48, P3793, DOI 10.1016/j.ijheatmasstransfer.2005.02.040
   Hill CG, 1977, INTRO CHEM ENG KINET
   Ivanova S., 2008, Deshydratation Du Methanol En Dimethyl Ether Employant Des Catalyseurs a Base D'une Zeolithe Supportee Sur Du Carbure de Silicium, Patent No. [PCT/FR2007/002017, PCTFR2007002017]
   Jarrah NA, 2004, J MATER CHEM, V14, P1590, DOI 10.1039/b314585a
   Lalinde J. A. H., 2017, CATALYSTS, V86, P1
   Liu Y, 2013, CHEM ENG J, V222, P265, DOI 10.1016/j.cej.2013.02.066
   Liu Y, 2011, APPL CATAL A-GEN, V409, P113, DOI 10.1016/j.apcata.2011.09.035
   Pham-Huu C, 2001, J CATAL, V200, P400, DOI 10.1006/jcat.2001.3216
   Richardson J. T., 2009, APPL CATAL A-GEN, V250, P319
   Ronsch S, 2016, FUEL, V166, P276, DOI 10.1016/j.fuel.2015.10.111
   Saber M, 2012, IND ENG CHEM RES, V51, P15011, DOI 10.1021/ie3017829
   Solomon S, 2007, CLIMATE CHANGE 2007: THE PHYSICAL SCIENCE BASIS, P19
   Taha TJ, 2016, INT J THERM SCI, V105, P13, DOI 10.1016/j.ijthermalsci.2016.02.005
   Tuzovskaya I, 2012, INT J HEAT MASS TRAN, V55, P5769, DOI 10.1016/j.ijheatmasstransfer.2012.05.073
   Vanhaecke E, 2008, J MATER CHEM, V18, P4654, DOI 10.1039/b806785f
   Vieira R, 2004, APPL CATAL A-GEN, V274, P1, DOI 10.1016/j.apcata.2004.04.008
NR 25
TC 4
Z9 4
U1 1
U2 20
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 271
EP 280
DI 10.1016/j.ces.2018.11.028
PG 10
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500025
DA 2020-05-12
ER

PT J
AU Sochorakis, N
   Grifoll, J
   Rosell-Llompart, J
AF Sochorakis, Nikolas
   Grifoll, Jordi
   Rosell-Llompart, Joan
TI Scaling up of extractor-free electrosprays in linear arrays
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Aerosol; Electrohydrodynamic atomization; Electrospray; Electrostatic
   spraying; Multiplexing; Space charge
ID ELECTROHYDRODYNAMIC ATOMIZATION; EMITTER ARRAYS; CONE-JETS; GENERATION;
   FABRICATION; THROUGHPUT; PARTICLES; NOZZLES; GLYCOL; DEVICE
AB Electrospray offers unique atomization of liquids, whereby micro- or nano-droplets with very narrow size distributions are generated from electrified Taylor cones. To scale up this process, many electrospray emitters must be operated simultaneously, while the flow rate per emitter must remain low enough to preserve stability. To cope with the electrostatic repulsion between the various elements in the system, it is common to position the emitters very near a counter-electrode. Instead, we have studied the conditions leading to robust scalable spraying by using linear arrays of electrosprays in which the counter-electrode is far compared to the inter-emitter separation. In our design, a row of emitter tubes protrudes out of a backplate, and the counter-electrode is a flat collector plate (droplet collection plate set at a high negative electric potential). In addition, electrodes at both ends of the array enable uniform electrical field conditions, while preventing electrical gaseous discharges. Strong electrostatic interactions are expected between the spray plumes and the Taylor cones. Nonetheless, we show that this geometry is scalable without bound, both by electric field computations as by experiments performed under different geometrical configurations, liquid flow rates per emitter, and electrical conductivities of the liquid (mainly, NaCl/MEG solutions). The onset voltage necessary to stabilize the spraying at all emitter positions approaches a plateau as the number of operated emitters increases. Eventually, at high enough potential difference, the cones and sprays misalign, pointing in directions in consonance with minute zig-zag misalignments of the emitters, revealing the importance of small imbalances in the electrostatic forces at the Taylor cones. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Sochorakis, Nikolas; Grifoll, Jordi; Rosell-Llompart, Joan] Univ Rovira & Virgili, Dept Chem Engn, E-43007 Tarragona, Spain.
   [Rosell-Llompart, Joan] Catalan Inst Res & Adv Studies ICREA, E-08010 Barcelona, Spain.
RP Rosell-Llompart, J (reprint author), Univ Rovira & Virgili, Dept Chem Engn, E-43007 Tarragona, Spain.
EM joan.rosell@urv.cat
RI Grifoll, Jordi/C-3946-2011; ROSELL-LLOMPART, JOAN/I-4120-2015
OI Grifoll, Jordi/0000-0003-3067-2644; ROSELL-LLOMPART,
   JOAN/0000-0002-5288-9150
FU Spanish GovernmentSpanish Government [DPI2015-68969-P, BES-2013-064098];
   Catalan Government [2017SGR1516]; Universitat Rovira i Virgili (URV)
   (Spain) [2015PFRURV-B2-57]; URV
FX This work has been supported by the Spanish Government under grant
   DPI2015-68969-P (MINECO/FEDER), and the Catalan Government under grant
   2017SGR1516, and by Universitat Rovira i Virgili (URV) (Spain) through
   grant 2015PFRURV-B2-57. Nikolas Sochorakis also acknowledges
   scholarships from the URV and from the Spanish Government
   (BES-2013-064098). We also thank Mr. Jordi Mare from URV for printing
   the nanoammeter circuit boards.
CR Almekinders JC, 1999, J AEROSOL SCI, V30, P969, DOI 10.1016/S0021-8502(98)00755-1
   Almeria B, 2011, J CONTROL RELEASE, V154, P203, DOI 10.1016/j.jconrel.2011.05.018
   Almeria B, 2010, J COLLOID INTERF SCI, V343, P125, DOI 10.1016/j.jcis.2009.10.002
   Bhatnagar P, 2007, APPL PHYS LETT, V91, DOI 10.1063/1.2754642
   Bober DB, 2011, J FLUID MECH, V689, P552, DOI 10.1017/jfm.2011.453
   Bocanegra R, 2005, J AEROSOL SCI, V36, P1387, DOI 10.1016/j.jaerosci.2005.04.003
   Bock N, 2012, PROG POLYM SCI, V37, P1510, DOI 10.1016/j.progpolymsci.2012.03.002
   Bodnar E, 2018, J AEROSOL SCI, V125, P93, DOI 10.1016/j.jaerosci.2018.04.012
   Bodnar E, 2013, J COLLOID INTERF SCI, V407, P536, DOI 10.1016/j.jcis.2013.06.013
   CLOUPEAU M, 1989, J ELECTROSTAT, V22, P135, DOI 10.1016/0304-3886(89)90081-8
   Daerr A, 2016, J OPEN RES SOFTW, V4, pe3, DOI DOI 10.5334/J0RS.97
   DELAMORA JF, 1992, J FLUID MECH, V243, P561, DOI 10.1017/S0022112092002829
   DELAMORA JF, 1994, J FLUID MECH, V260, P155, DOI 10.1017/S0022112094003472
   Deng WW, 2007, P COMBUST INST, V31, P2239, DOI 10.1016/j.proci.2006.08.080
   Deng W, 2007, J AEROSOL SCI, V38, P1062, DOI 10.1016/j.jaerosci.2007.08.005
   Deng WW, 2006, J AEROSOL SCI, V37, P696, DOI 10.1016/j.jaerosci.2005.05.011
   Deng WW, 2011, INT J HEAT MASS TRAN, V54, P2270, DOI 10.1016/j.ijheatmasstransfer.2011.02.038
   Deng WW, 2009, J AEROSOL SCI, V40, P907, DOI 10.1016/j.jaerosci.2009.07.002
   Fenn JB, 2003, ANGEW CHEM INT EDIT, V42, P3871, DOI 10.1002/anie.200300605
   Ganan-Calvo AM, 2018, J AEROSOL SCI, V125, P32, DOI 10.1016/j.jaerosci.2018.05.002
   Ganan-Calvo AM, 1997, J AEROSOL SCI, V28, P249, DOI 10.1016/S0021-8502(96)00433-8
   Higuera FJ, 2013, J FLUID MECH, V734, P363, DOI 10.1017/jfm.2013.450
   Hogrefe O, 2004, AEROSOL SCI TECH, V38, P196, DOI 10.1080/02786820390229516
   Jackson J. D., 1998, CLASSICAL ELECTRODYN
   Jaworek A, 2018, J AEROSOL SCI, V125, P57, DOI 10.1016/j.jaerosci.2018.04.006
   Kawakami K, 2012, INT J PHARMACEUT, V433, P71, DOI 10.1016/j.ijpharm.2012.04.082
   Kelly RT, 2008, ANAL CHEM, V80, P143, DOI 10.1021/ac701647s
   Kelly RT, 2008, ANAL CHEM, V80, P5660, DOI 10.1021/ac800508q
   Kelly RT, 2007, ANAL CHEM, V79, P4192, DOI 10.1021/ac062417e
   Kempen L, 2016, PROCEDIA ENGINEER, V168, P1366, DOI 10.1016/j.proeng.2016.11.378
   Kim H, 2015, AEROSOL SCI TECH, V49, P11, DOI 10.1080/02786826.2014.989956
   Kim W, 2007, ANAL CHEM, V79, P3703, DOI 10.1021/ac070010j
   Krpoun R, 2009, J MICROMECH MICROENG, V19, DOI 10.1088/0960-1317/19/4/045019
   Kumar V, 2018, J MICROMECH MICROENG, V28, DOI 10.1088/1361-6439/aaa1d5
   Kyritsis DC, 2004, COMBUST FLAME, V139, P77, DOI 10.1016/j.combustflame.2004.06.010
   Larsen G, 2004, ADV MATER, V16, P166, DOI 10.1002/adma.200306021
   Lhernould MS, 2011, J ELECTROSTAT, V69, P313, DOI 10.1016/j.elstat.2011.04.006
   Lojewski B, 2013, AEROSOL SCI TECH, V47, P146, DOI 10.1080/02786826.2012.734936
   Mao P, 2011, ANAL CHEM, V83, P6082, DOI 10.1021/ac2011813
   Marijnissen J.C.M, 2003, J AER SCI P EUR AERO, V34, pS1269, DOI DOI 10.1016/S0021-8502(03)00171-X
   Mehta P, 2017, DRUG DISCOV TODAY, V22, P157, DOI 10.1016/j.drudis.2016.09.021
   Olvera-Trejo D, 2016, LAB CHIP, V16, P4121, DOI 10.1039/c6lc00729e
   Peltonen L, 2010, EXPERT OPIN DRUG DEL, V7, P705, DOI 10.1517/17425241003716802
   RIDDICK JA, 1986, ORGANIC SOLVENTS PHY
   Rosell-Llompart J, 2018, J AEROSOL SCI, V125, P2, DOI 10.1016/j.jaerosci.2018.04.008
   ROSELLLLOMPART J, 1994, J AEROSOL SCI, V25, P1093, DOI 10.1016/0021-8502(94)90204-6
   RULISON AJ, 1993, REV SCI INSTRUM, V64, P683, DOI 10.1063/1.1144197
   Sandengen K, 2006, J CHEM ENG DATA, V51, P443, DOI 10.1021/je0503711
   SMITH DPH, 1986, IEEE T IND APPL, V22, P527, DOI 10.1109/TIA.1986.4504754
   Steiner G, 2017, AEROSOL SCI TECH, V51, P946, DOI 10.1080/02786826.2017.1328103
   Tang J, 2015, J MATER CHEM A, V3, P7830, DOI 10.1039/c5ta00288e
   Tang J, 2017, J AEROSOL SCI, V113, P201, DOI 10.1016/j.jaerosci.2017.07.001
   Tran SBQ, 2010, J ELECTROSTAT, V68, P138, DOI 10.1016/j.elstat.2009.11.011
   Tsierkezos NG, 1998, J CHEM ENG DATA, V43, P989, DOI 10.1021/je9800914
   Velasquez-Garcia LF, 2006, J MICROELECTROMECH S, V15, P1260, DOI 10.1109/JMEMS.2006.879707
   Wang D, 2015, J EUR CERAM SOC, V35, P3475, DOI 10.1016/j.jeurceramsoc.2015.05.013
   Wang L, 2007, MICROELECTRON ENG, V84, P1190, DOI 10.1016/j.mee.2007.01.116
   Xie JW, 2015, CHEM ENG SCI, V125, P32, DOI 10.1016/j.ces.2014.08.061
   Yan WC, 2017, AICHE J, V63, P5303, DOI 10.1002/aic.15821
   Yang WW, 2012, J AEROSOL SCI, V46, P20, DOI 10.1016/j.jaerosci.2011.11.004
   Zhao XY, 2017, J AEROSOL SCI, V113, P108, DOI 10.1016/j.jaerosci.2017.07.013
   Zhou FL, 2009, POLYM INT, V58, P331, DOI 10.1002/pi.2521
NR 62
TC 0
Z9 0
U1 3
U2 16
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 281
EP 298
DI 10.1016/j.ces.2018.09.006
PG 18
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500026
DA 2020-05-12
ER

PT J
AU Shevchenko, EA
   Mitra, S
   Ermakov, SA
   Titov, AG
   Ermakov, AA
   Pattader, PSG
AF Shevchenko, Ekaterina A.
   Mitra, Shirsendu
   Ermakov, Sergei A.
   Titov, Anatolii G.
   Ermakov, Anatolii A.
   Pattader, Partho Sarathi Gooh
TI Joint mass transfer of two components associated with the spontaneous
   interfacial convection in the liquid-liquid extraction system
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Marangoni effect; Spontaneous interfacial convection; Interphase
   instability; Liquid-liquid extraction; Mass transfer
ID MARANGONI CONVECTION; THERMOCAPILLARY CONVECTION; CHEMICAL-REACTION;
   SELF-MOTION; FILM FLOWS; INSTABILITY; CAMPHOR; TURBULENCE; DIFFUSION;
   DROPLETS
AB This article focuses on the experimental work supported by theoretical model of the multicomponent mass transfer during extraction driven by spontaneous interfacial convection (SIC). The regularities of individual and joint unidirectional and reciprocal mass transfer of components with different surface-active properties in the benzene-water extraction system at a flat phase interface are considered. The article demonstrates that both the diffusion and convective hydrodynamics of the flow affect the intensity of unidirectional and counter-mass transfer of the components under the conditions of SIC. Marangoni instability at the interface causes local convection, which enhances the mass transfer rate considerably. Experimental studies have shown that the joint unidirectional mass transfer of acetic acid and iodine from organic phase to aqueous phase under the conditions of SIC can be characterised by an increase in the iodine mass transfer coefficient in comparison with its individual mass transfer. It has found that with the acetic acid the unidirectional mass transfer of iodine can be increased by more than 20 times compared to its mass transfer without acid. However in case of counter-transfer of acetic acid and iodine, both the acetic acid as well as iodine mass transfer coefficients decrease compared to their individual mass transfer situations. The experimental data are in accord with the theoretical justification. A simplistic semi empirical theoretical model is developed for joint mass transfer, to estimate the coefficient of mass transfer of the components. The satisfactory convergence of the experimental and calculated data are shown. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Shevchenko, Ekaterina A.; Ermakov, Sergei A.; Titov, Anatolii G.; Ermakov, Anatolii A.] Ural Fed Univ, Ekaterinburg 620002, Russia.
   [Mitra, Shirsendu; Pattader, Partho Sarathi Gooh] Indian Inst Technol Guwahati, Dept Chem Engn, Gauhati 781039, India.
   [Pattader, Partho Sarathi Gooh] Indian Inst Technol Guwahati, Ctr Nanotechnol, Gauhati 781039, India.
RP Shevchenko, EA (reprint author), Ural Fed Univ, Ekaterinburg 620002, Russia.; Pattader, PSG (reprint author), Indian Inst Technol Guwahati, Dept Chem Engn, Gauhati 781039, India.
EM eshevchenko@yandex.ru; psgp@iitg.ac.in
OI Titov, Anatolii/0000-0003-4511-627X
FU DST SERB [ECR/2015/000447]; RFBRRussian Foundation for Basic Research
   (RFBR); Ural Federal University, Russia; MeitY [5(9)/2012-NANO]
FX PSGP thanks DST SERB, Grant no. ECR/2015/000447 and MeitY grant no.
   5(9)/2012-NANO for financial aids. Ekaterina A. Shevchenko and Sergei A.
   Ermakov acknowledge RFBR and Ural Federal University, Russia for all the
   supports.
CR Ban T, 2000, CHEM ENG SCI, V55, P5385, DOI 10.1016/S0009-2509(00)00156-1
   Ban T, 2013, LANGMUIR, V29, P2554, DOI 10.1021/la3047164
   BYRON PR, 1986, INT J PHARM, V29, P103, DOI 10.1016/0378-5173(86)90107-9
   Celli M, 2015, PHYS REV E, V91, DOI 10.1103/PhysRevE.91.023006
   Craster RV, 2006, J FLUID MECH, V553, P85, DOI 10.1017/S0022112006008706
   Ding ZJ, 2018, CHEM ENG SCI, V177, P261, DOI 10.1016/j.ces.2017.11.039
   Duner G, 2016, J COLLOID INTERF SCI, V467, P105, DOI 10.1016/j.jcis.2016.01.011
   Duner G, 2016, J COLLOID INTERF SCI, V462, P75, DOI 10.1016/j.jcis.2015.09.042
   Engberg RE, 2014, CHEM ENG SCI, V116, P208, DOI 10.1016/j.ces.2014.04.023
   Ermakov SA, 2001, CHEM ENG J, V84, P321, DOI 10.1016/S1385-8947(00)00379-X
   GOLOVIN AA, 1992, CHEM ENG SCI, V47, P2069, DOI 10.1016/0009-2509(92)80323-5
   Huang HL, 2017, INT J THERM SCI, V118, P226, DOI 10.1016/j.ijthermalsci.2017.05.003
   Ikura YS, 2012, J PHYS CHEM B, V116, P992, DOI 10.1021/jp210990a
   Javadi A, 2014, COLLOID SURFACE A, V441, P846, DOI 10.1016/j.colsurfa.2012.10.032
   Khadamkar HP, 2017, CHEM ENG SCI, V170, P176, DOI 10.1016/j.ces.2017.02.016
   Khanwale MA, 2015, PHYS FLUIDS, V27, DOI 10.1063/1.4935231
   Kitahata H, 2004, PHYS CHEM CHEM PHYS, V6, P2409, DOI 10.1039/b315672a
   Kitahata H, 2017, COLLOID SURFACE A, V520, P436, DOI 10.1016/j.colsurfa.2017.01.048
   KOLEV N, 1991, CHEM ENG PROCESS, V29, P83, DOI 10.1016/0255-2701(91)87017-W
   KONSHIN YA, 1980, J APPL CHEM-USSR+, V53, P1445
   Liu R, 2017, INT J HEAT MASS TRAN, V112, P918, DOI 10.1016/j.ijheatmasstransfer.2017.05.030
   Lopes DG, 2017, INT J PHARMACEUT, V517, P403, DOI 10.1016/j.ijpharm.2016.12.040
   Matsuda Y, 2016, CHEM PHYS LETT, V654, P92, DOI 10.1016/j.cplett.2016.05.008
   Melnikov DE, 2014, INT J HEAT MASS TRAN, V74, P185, DOI 10.1016/j.ijheatmasstransfer.2014.02.058
   Melnikov DE, 2005, ADV SPACE RES-SERIES, V36, P43, DOI 10.1016/j.asr.2005.02.078
   Mostov LA, 2011, RUSS J APPL CHEM+, V84, P2051, DOI 10.1134/S1070427211120068
   Nakata S, 2015, COLLOID SURFACE A, V466, P40, DOI 10.1016/j.colsurfa.2014.10.041
   Nie ZH, 2008, NAT MATER, V7, P277, DOI 10.1038/nmat2109
   Nishino K, 2015, J CRYST GROWTH, V420, P57, DOI 10.1016/j.jcrysgro.2015.01.039
   Novev JK, 2017, CHEM ENG SCI, V171, P520, DOI 10.1016/j.ces.2017.06.016
   PANTALONI J, 1979, J NON-EQUIL THERMODY, V4, P201, DOI 10.1515/jnet.1979.4.4.201
   RUCKENSTEIN E, 1964, CHEM ENG SCI, V19, P329, DOI 10.1016/0009-2509(64)80002-6
   Sheng XY, 2008, J UNIV SCI TECHNOL B, V15, P385, DOI 10.1016/S1005-8850(08)60073-0
   Sinzato YZ, 2017, EXP THERM FLUID SCI, V85, P370, DOI 10.1016/j.expthermflusci.2017.03.011
   Skurygin EF, 2000, J FOOD ENG, V43, P125, DOI 10.1016/S0260-8774(99)00125-9
   Slavtchev S, 2006, COLLOID SURFACE A, V282, P37, DOI 10.1016/j.colsurfa.2006.01.029
   Sorensen T. S., 1979, DYNAMICS INSTABILITY, P276
   Stricker L, 2017, J COMPUT PHYS, V347, P467, DOI 10.1016/j.jcp.2017.07.007
   Takasu T, 1998, CAN METALL QUART, V37, P285, DOI 10.1016/S0008-4433(97)00038-4
   Tarasov VV, 2008, THEOR FOUND CHEM EN+, V42, P832, DOI 10.1134/S0040579508060055
   Tarasov VV, 2000, RUSS J PHYS CHEM+, V74, pS118
   Wang JF, 2011, AICHE J, V57, P2670, DOI 10.1002/aic.12494
   Wang ZH, 2013, AICHE J, V59, P4424, DOI 10.1002/aic.14161
   Weatherley LR, 2017, CHEM ENG J, V322, P115, DOI 10.1016/j.cej.2017.03.115
   Wegener M, 2014, INT J HEAT MASS TRAN, V71, P769, DOI 10.1016/j.ijheatmasstransfer.2013.11.027
   Wegener M, 2012, INT J HEAT MASS TRAN, V55, P1561, DOI 10.1016/j.ijheatmasstransfer.2011.11.011
   Yao X, 2012, SOFT MATTER, V8, P5988, DOI 10.1039/c2sm25153a
   You XY, 2014, J TAIWAN INST CHEM E, V45, P772, DOI 10.1016/j.jtice.2013.08.007
   Zhao GJ, 2012, J PHYS CHEM B, V116, P10960, DOI 10.1021/jp3057702
   Zheng HD, 2014, CHEM ENG SCI, V111, P278, DOI 10.1016/j.ces.2014.02.015
NR 50
TC 2
Z9 2
U1 1
U2 18
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 301
EP 311
DI 10.1016/j.ces.2018.09.018
PG 11
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500028
DA 2020-05-12
ER

PT J
AU Roloff, C
   Lukas, E
   van Wachem, B
   Thevenin, D
AF Roloff, Christoph
   Lukas, Eduard
   van Wachem, Berend
   Thevenin, Dominique
TI Particle dynamics investigation by means of shadow imaging inside an air
   separator
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Air separator; Zigzag classifier; Shadow imaging; Particles; Separation
ID SOLIDS; SYSTEM; FLOW; SIZE
AB A multicamera shadow imaging (shadowgraphy) system is developed to simultaneously capture particle dynamics at multiple locations inside a so called zigzag air separator which is used for separating fine from coarse particle fractions. The adaption of the shadowgraphy system to the specific requirements of the separator apparatus to measure particle sizes and velocities including calibration and particle size correction strategies is described. Measurements reveal the behaviour of glass beads ranging from 1 to 4 mm in diameter with variable particle mass loadings and air flow rates inside the zigzag channel. From the processing of the shadow data, particle flow morphologies and characteristic particle trajectories inside the channel stages are obtained. Furthermore, it is shown that particle mean velocities and particle fluctuation energies depend on the particle mass loading, the air flow rate and the location inside the zigzag channel. The results reveal novel quantitative insights into particle velocities in such an air separator which can be used to better understand the underlying particle mechanisms and foster the development of refined process models. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Roloff, Christoph; Thevenin, Dominique] Otto von Guericke Univ, Fluid Dynam & Tech Flows, Univ Pl 2, D-39106 Magdeburg, Germany.
   [Lukas, Eduard; van Wachem, Berend] Otto von Guericke Univ, Mech Proc Engn, Univ Pl 2, D-39106 Magdeburg, Germany.
RP Roloff, C (reprint author), Otto von Guericke Univ, Fluid Dynam & Tech Flows, Univ Pl 2, D-39106 Magdeburg, Germany.
EM christoph.roloff@ovgu.de
RI Thevenin, Dominique/E-6588-2013
OI Thevenin, Dominique/0000-0001-7599-9574
FU Deutsche Forschungsgemeinschaft (DFG), GermanyGerman Research Foundation
   (DFG) [SPP 1679]
FX This work is part of the German priority program SPP 1679 "Dynamische
   Simulation vernetzter Feststoffprozesse" ("Dynamic simulation of
   interconnected solids processes") that is financially supported by the
   Deutsche Forschungsgemeinschaft (DFG), Germany.
CR BERTOLLINI GP, 1985, OPT ENG, V24, P464, DOI 10.1117/12.7973508
   Bordas R, 2013, NEW J PHYS, V15, DOI 10.1088/1367-2630/15/4/045010
   Castanet G, 2013, EXP FLUIDS, V54, DOI 10.1007/s00348-013-1489-3
   COLON FJ, 1976, CONSERV RECYCLING, V1, P129, DOI 10.1016/0361-3658(76)90012-6
   FANTINI E, 1990, COMPUT CHEM ENG, V14, P1201, DOI 10.1016/0098-1354(90)80002-S
   Fastov B. N., 1975, CHEM PET ENG, V11, P477, DOI 10.1007/BF01152009
   Furchner B., 2012, ULLMANNS ENCY IND CH
   Georgi-Maschler T, 2012, J POWER SOURCES, V207, P173, DOI 10.1016/j.jpowsour.2012.01.152
   Gillandt I, 1996, FORSCH INGENIEURWES, V62, P315, DOI 10.1007/BF02601909
   Groger T., 1999, AUFBEREIT TECH, V40, P379
   HOWELL SG, 1992, J HAZARD MATER, V29, P143, DOI 10.1016/0304-3894(92)85066-A
   KAISER F, 1963, CHEM-ING-TECH, V35, P273
   Kerst K, 2017, CHEM ENG SCI, V165, P1, DOI 10.1016/j.ces.2017.01.068
   KIM KS, 1994, ATOMIZATION SPRAY, V4, P65, DOI 10.1615/AtomizSpr.v4.i1.30
   KOX WMA, 1982, RESOUR CONSERV, V8, P75, DOI 10.1016/0166-3097(82)90054-2
   Kussin J, 2002, EXP FLUIDS, V33, P143, DOI 10.1007/s00348-002-0485-9
   LaVision GmbH, 2014, PROD MAN PARTICLEMAS
   Lecuona A, 2000, MEAS SCI TECHNOL, V11, P1152, DOI 10.1088/0957-0233/11/8/309
   Mann H, 2016, THESIS
   Nishino K, 2000, MEAS SCI TECHNOL, V11, P633, DOI 10.1088/0957-0233/11/6/306
   Roloff C., 2015, C MOD FLUID FLOW 16, p[1, 1]
   Rosenbrand G. G, 1986, THESIS
   Schubert H., 1986, AUFBEREITUNGS TECHNI, V27, P295
   Senden M. M. G, 1979, THESIS
   Senden MMG, 1980, P 1980 WAST PROC C A, P351
   Skorych V, 2017, POWDER TECHNOL, V314, P665, DOI 10.1016/j.powtec.2017.01.061
   Stebbins A. H, 1930, AIR CLASSIFIER
   Tomas J, 2004, PARTICUL SCI TECHNOL, V22, P169, DOI 10.1080/02726350490457222
   VESILIND PA, 1981, RESOUR CONSERV, V6, P211, DOI 10.1016/0166-3097(81)90050-X
NR 29
TC 0
Z9 0
U1 3
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 312
EP 324
DI 10.1016/j.ces.2018.09.020
PG 13
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500029
DA 2020-05-12
ER

PT J
AU Gao, JB
   Wang, P
   Wang, ZK
   Li, CL
   Sun, SQ
   Hu, SQ
AF Gao, Jianbang
   Wang, Pei
   Wang, Zhikun
   Li, Chunling
   Sun, Shuangqing
   Hu, Songqing
TI Self-assembly of DCPD-loaded cross-linked micelle from triblock
   copolymers and its pH-responsive behavior: A dissipative particle
   dynamics study
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Self-assembly; pH-responsive micelles; Agent encapsulated;
   Cross-linking; Dissipative particle dynamics simulation
ID TUNABLE MEMBRANE-PERMEABILITY; DEMAND DRUG-DELIVERY; MOLECULAR-DYNAMICS;
   POLYMERIC MICELLES; MAGNETIC-RESONANCE; QUANTUM DOTS; SIMULATION;
   VESICLES; RELEASE; SYSTEM
AB Dissipative particle dynamics (DPD) simulations were applied to investigate the solution self-assembly and pH-responsive behavior of hydrophobic DCPD (dicyclopentadiene)-loaded microcapsules from triblock copolymers poly (1,2-ethanediol, homopolymer-b-2-Diethylaminoethylmethacrylate-b-methyl methacrylate) (PEG-b-PDMAEMA-b-PMMA). Results indicate that micelles with longer hydrophilic PEG blocks and shorter hydrophobic PMMA blocks were in favor of encapsulating hydrophobic DCPD. Cross-linking at the core/shell interface generates a chemically bonded network structure in the micelle and leads to a significant decrease of their thermodynamic mobility (i.e., the increase of stability). Both non cross-linked and cross-linked micelles show a good pH-responsive behavior. In particular, cross-linked micelles still have the ability to carry DCPD due to the incomplete dispersion even completely pro-tonation of PDMAEMA, which indicates that the cross-linked micelles could be expected to realize the slow release of encapsulated DCPD agent. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Gao, Jianbang; Wang, Zhikun; Li, Chunling; Sun, Shuangqing; Hu, Songqing] China Univ Petr East China, Sch Mat Sci & Engn, Qingdao 266580, Shandong, Peoples R China.
   [Gao, Jianbang; Wang, Zhikun; Li, Chunling; Sun, Shuangqing; Hu, Songqing] China Univ Petr, Inst Adv Mat, Qingdao 266580, Shandong, Peoples R China.
   [Wang, Pei] Luoyang Ship Mat Res Inst, Qingdao Branch, Qingdao 266101, Shandong, Peoples R China.
RP Sun, SQ (reprint author), China Univ Petr East China, Sch Mat Sci & Engn, Qingdao 266580, Shandong, Peoples R China.
EM sunshuangqing@upc.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51501226, 51201183, 51874331]; Shandong Provincial
   Natural Science Foundation, ChinaNatural Science Foundation of Shandong
   Province [ZR2014EL003, ZR2017MEE028]; Fundamental Research Funds for the
   Central UniversitiesFundamental Research Funds for the Central
   Universities [14CX02221A, 16CX05017A, 17CX05023]
FX The authors acknowledge funding support from the National Natural
   Science Foundation of China (51501226, 51201183 and 51874331), Shandong
   Provincial Natural Science Foundation, China (ZR2014EL003 and
   ZR2017MEE028), and Fundamental Research Funds for the Central
   Universities (14CX02221A, 16CX05017A and 17CX05023).
CR Barner-Kowollik C, 2011, ANGEW CHEM INT EDIT, V50, P60, DOI 10.1002/anie.201003707
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118
   Chang HY, 2012, MACROMOLECULES, V45, P4778, DOI 10.1021/ma3007366
   De Geest BG, 2007, MACROMOL RAPID COMM, V28, P88, DOI 10.1002/marc.200600631
   DECHER G, 1992, THIN SOLID FILMS, V210, P831, DOI 10.1016/0040-6090(92)90417-A
   Deng C, 2012, NANO TODAY, V7, P467, DOI 10.1016/j.nantod.2012.08.005
   Groot RD, 1998, J CHEM PHYS, V108, P8713, DOI 10.1063/1.476300
   Groot RD, 1999, J CHEM PHYS, V110, P9739, DOI 10.1063/1.478939
   Groot RD, 1997, J CHEM PHYS, V107, P4423, DOI 10.1063/1.474784
   Guo XD, 2010, MACROMOLECULES, V43, P7839, DOI 10.1021/ma101132n
   Harris TJ, 2006, ANGEW CHEM INT EDIT, V45, P3161, DOI 10.1002/anie.200600259
   Hoogerbrugge P. J, 2007, EPL, V21, P363
   HOOGERBRUGGE PJ, 1992, EUROPHYS LETT, V19, P155, DOI 10.1209/0295-5075/19/3/001
   Hruby M, 2005, J CONTROL RELEASE, V103, P137, DOI 10.1016/j.jconrel.2004.11.017
   Huang J, 2008, J PHYS CHEM B, V112, P6735, DOI 10.1021/jp710567f
   Huang X, 2012, ACS NANO, V6, P9718, DOI 10.1021/nn3031723
   Immesoete K., 2010, ADV MATER, V20, P3687
   Kim J, 2006, ANGEW CHEM INT EDIT, V45, P7754, DOI 10.1002/anie.200602471
   Kim YH, 2009, J CONTROL RELEASE, V134, P132, DOI 10.1016/j.jconrel.2008.10.020
   Kishimura A, 2007, ANGEW CHEM INT EDIT, V46, P6085, DOI 10.1002/anie.200701776
   Lee HJ, 2013, PHARM RES-DORDR, V30, P2077, DOI 10.1007/s11095-013-1060-1
   Lee JH, 2006, ANGEW CHEM INT EDIT, V45, P8160, DOI 10.1002/anie.200603052
   Li YP, 2014, ADV DRUG DELIVER REV, V66, P58, DOI 10.1016/j.addr.2013.09.008
   Luo ZL, 2016, MACROMOLECULES, V49, P6084, DOI 10.1021/acs.macromol.6b01211
   Luo ZL, 2012, J CONTROL RELEASE, V162, P185, DOI 10.1016/j.jconrel.2012.06.027
   Moeinzadeh S, 2012, J PHYS CHEM B, V116, P1536, DOI 10.1021/jp211056p
   Mohwald H, 2010, ADV FUNCT MATER, V17, P1451
   Mulder WJM, 2006, NANO LETT, V6, P1, DOI 10.1021/nl051935m
   Nie SY, 2014, ACS APPL MATER INTER, V6, P17668, DOI 10.1021/am503920m
   NOSE S, 1991, PROG THEOR PHYS SUPP, P1
   Nostrum van, 2011, SOFT MATTER, V7, P3246
   O'Reilly RK, 2006, CHEM SOC REV, V35, P1068, DOI 10.1039/b514858h
   Oliveira H, 2013, J CONTROL RELEASE, V169, P165, DOI 10.1016/j.jconrel.2013.01.013
   Owen SC, 2012, NANO TODAY, V7, P53, DOI 10.1016/j.nantod.2012.01.002
   Peyratout CS, 2003, ADV MATER, V15, P1722, DOI 10.1002/adma.200304999
   Pi PH, 2015, IND ENG CHEM RES, V54, P6123, DOI 10.1021/acs.iecr.5b00912
   Popescu MT, 2014, POLYMER, V55, P2943, DOI 10.1016/j.polymer.2014.04.034
   Rapoport N, 2007, PROG POLYM SCI, V32, P962, DOI 10.1016/j.progpolymsci.2007.05.009
   Read ES, 2007, CHEM COMMUN, P3021, DOI 10.1039/b701217a
   Salami-Kalajahi M, 2016, COLLOID POLYM SCI, V294, P1
   Shao Y, 2012, THER DELIV, V3, P1409, DOI [10.4155/tde.12.106, 10.4155/TDE.12.106]
   Shenogina NB, 2012, MACROMOLECULES, V45, P5307, DOI 10.1021/ma3007587
   Shi Y, 2015, ACS BIOMATER SCI ENG, V1, P393, DOI 10.1021/acsbiomaterials.5b00006
   Sun H, 1998, J PHYS CHEM B, V102, P7338, DOI 10.1021/jp980939v
   Wang WJ, 2012, J PHYS CHEM B, V116, P7213, DOI 10.1021/jp303840a
   Wang ZK, 2017, LANGMUIR, V33, P7288, DOI 10.1021/acs.langmuir.7b01586
   Wang ZK, 2016, ACS APPL MATER INTER, V8, P7499, DOI 10.1021/acsami.5b11810
   Wu CF, 2006, POLYMER, V47, P6004, DOI 10.1016/j.polymer.2006.06.025
   Xin J, 2007, J PHYS CHEM B, V111, P13675, DOI 10.1021/jp073173k
   Xu Y, 2013, POLYM SCI SER A+, V55, P198, DOI 10.1134/S0965545X13030103
   Zhao Y, 2010, LANGMUIR, V26, P8966, DOI 10.1021/la9047819
   Zhu DY, 2015, PROG POLYM SCI, V49-50, P175, DOI 10.1016/j.progpolymsci.2015.07.002
NR 52
TC 3
Z9 3
U1 8
U2 64
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 325
EP 334
DI 10.1016/j.ces.2018.09.028
PG 10
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500030
DA 2020-05-12
ER

PT J
AU Szilagyi, B
   Borsos, A
   Pal, K
   Nagy, ZK
AF Szilagyi, Botond
   Borsos, Akos
   Pal, Kanjakha
   Nagy, Zoltan K.
TI Experimental implementation of a Quality-by-Control (QbC) framework
   using a mechanistic PBM-based nonlinear model predictive control
   involving chord length distribution measurement for the batch cooling
   crystallization of L-ascorbic acid
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Ascorbic acid; DNC; Population balances; NMPC; Quality-by-Control; QbC
ID DIRECT NUCLEATION CONTROL; PARTICLE-SIZE DISTRIBUTION; POPULATION
   BALANCE MODELS; VITAMIN-C; L(+)-ASCORBIC ACID; NUMERICAL-SOLUTION;
   FEEDBACK-CONTROL; GROWTH; SHAPE; WATER
AB L-ascorbic acid is synthetized in large industrial scale from glucose and marketed as an immune system strengthening agent and anti-oxidant ingredient. The overall yield of conversion of the precursor glucose to L-ascorbic acid is limited, therefore the crystallization is a critically important step of the L-ascorbic acid production from economic point of view. It is widely accepted that the crystal size distribution (CSD) influences numerous relevant macroscopic properties of the final crystalline product and it also significantly affects the downstream operations. The present paper discusses the chord length distribution (CLD, which is directly related to the CSD) control, during the crystallization of L-ascorbic acid from aqueous solution. Batch crystallization process is employed, which is the classical, and still dominant, operation in fine chemical and pharmaceutical industries. A comparative experimental study of two state-of-the-art Quality-by-Control (QbC) based crystallization design approaches are presented: (1) a model-free QbC based on direct nucleation control (DNC) and (2) a model-based QbC using a novel nonlinear model predicative control (NMPC) framework. In the first investigation, the DNC, a process analytical technology based state-of-the-art model free control strategy, is applied. Although, DNC requires minimal preliminary system information and often provides robust process control, due to the unusual crystallization behavior of L-ascorbic acid, it leads to long batch times and oscillatory operation. In a second study the benefits of model-based QbC approach are demonstrated, based on using a NMPC approach. A population balance based crystallization process model is built and calibrated by estimating the nucleation and growth kinetics from concentration and CLD measurements. A projection based CSD to CLD forward transformation is used in the estimation of nucleation and growth kinetics. For robustness and adaptive behavior, the NMPC is coupled with a growing horizon state estimator, which is aimed to continuously improve the model by re-adjusting the kinetic constants. The study demonstrates that the model-based QbC framework can lead to rapid and robust crystallization process development with the NMPC system presenting good control behavior under significant plant model mismatch (PMM) conditions. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Szilagyi, Botond; Borsos, Akos; Nagy, Zoltan K.] Loughborough Univ, Dept Chem Engn, Loughborough LE11 3TU, Leics, England.
   [Szilagyi, Botond; Pal, Kanjakha] Purdue Univ, Sch Chem Engn, W Lafayette, IN 47907 USA.
   [Szilagyi, Botond] Babes Bolyai Univ, Dept Chem Engn, Arany Janos St 1, Cluj Napoca 400028, Romania.
RP Nagy, ZK (reprint author), Loughborough Univ, Dept Chem Engn, Loughborough LE11 3TU, Leics, England.
EM zknagy@purdue.edu
RI Szilagyi, Botond/AAD-8754-2020; Szilagyi, Botond/AAG-8819-2020
OI Nagy, Zoltan/0000-0003-4787-6678; Botond, Szilagyi/0000-0001-7777-9612
FU International Fine Particle Research Institution; European Research
   Council under the European Union's Seventh Framework Programme
   (FP7/2007-2013)/ERC [280106-CrySys]
FX The financial support of the International Fine Particle Research
   Institution is acknowledged gratefully. Funding from the European
   Research Council under the European Union's Seventh Framework Programme
   (FP7/2007-2013)/ERC grant agreement No. [280106-CrySys] is also
   acknowledged.
CR Aamir E, 2009, IND ENG CHEM RES, V48, P8575, DOI 10.1021/ie900430t
   Abu Bakar MR, 2009, CRYST GROWTH DES, V9, P1378, DOI 10.1021/cg800595v
   Acevedo D, 2015, IND ENG CHEM RES, V54, P2156, DOI 10.1021/acs.iecr.5b00173
   Agachi P.S., 2007, MODEL BASED CONTROL
   Agimelen OS, 2015, CHEM ENG SCI, V123, P629, DOI 10.1016/j.ces.2014.11.014
   Barrett M, 2010, CHEM ENG RES DES, V88, P1108, DOI 10.1016/j.cherd.2010.02.010
   Berg J. M., 2010, BIOCH BIOCH TXB
   Beuzelin-Ollivier M. G., 2012, FERMENTATIVE VITAMIN
   Botschi S, 2018, CRYST GROWTH DES, V18, P4470, DOI 10.1021/acs.cgd.8b00473
   Borsos A, 2017, ORG PROCESS RES DEV, V21, P511, DOI 10.1021/acs.oprd.6b00242
   Eggers J, 2009, CHEM ENG SCI, V64, P163, DOI 10.1016/j.ces.2008.09.025
   Grosch R, 2007, AICHE J, V53, P207, DOI 10.1002/aic.11041
   Gunawan R, 2004, AICHE J, V50, P2738, DOI 10.1002/aic.10228
   Hansen N, 2003, EVOL COMPUT, V11, P1, DOI 10.1162/106365603321828970
   Hukkanen EJ, 2003, SENSOR ACTUAT B-CHEM, V96, P451, DOI 10.1016/S0925-4005(03)00600-2
   HULBURT HM, 1964, CHEM ENG SCI, V19, P555, DOI 10.1016/0009-2509(64)85047-8
   Kacker R, 2016, CRYST GROWTH DES, V16, P440, DOI 10.1021/acs.cgd.5b01444
   Kail N, 2009, CHEM ENG SCI, V64, P984, DOI 10.1016/j.ces.2008.10.039
   LeVeque Randall J., 2002, FINITE VOLUME METHOD
   Li MZ, 2006, PART PART SYST CHAR, V23, P170, DOI 10.1002/ppsc.200601026
   Ma CY, 2012, J PROCESS CONTR, V22, P72, DOI 10.1016/j.jprocont.2011.10.007
   Majumder A, 2010, IND ENG CHEM RES, V49, P3862, DOI 10.1021/ie9016946
   McGraw R, 1997, AEROSOL SCI TECH, V27, P255, DOI 10.1080/02786829708965471
   Mersmann A, 2001, CRYSTALLIZATION TECH, DOI [10.1080/07373939508917003, DOI 10.1080/07373939508917003]
   Mesbah A, 2012, IEEE T CONTR SYST T, V20, P1188, DOI 10.1109/TCST.2011.2160945
   Mesbah A, 2011, AICHE J, V57, P1557, DOI 10.1002/aic.12366
   Mesbah A, 2011, J PROCESS CONTR, V21, P652, DOI 10.1016/j.jprocont.2010.11.013
   Mesbah A, 2009, CHEM ENG SCI, V64, P4262, DOI 10.1016/j.ces.2009.06.060
   Moldovanyi N, 2005, J CRYST GROWTH, V275, pE1349, DOI 10.1016/j.jcrysgro.2004.11.170
   Myerson A., 2002, HDB IND CRYSTALLIZAT, pxiii, DOI DOI 10.1016/B978-075067012-8/50002-1
   Nagy ZK, 2003, AICHE J, V49, P1776, DOI 10.1002/aic.690490715
   Nagy ZK, 2013, CHEM ENG RES DES, V91, P1903, DOI 10.1016/j.cherd.2013.07.018
   Nagy ZK, 2012, ANNU REV CHEM BIOMOL, V3, P55, DOI 10.1146/annurev-chembioeng-062011-081043
   Pappenberger G, 2014, ADV BIOCHEM ENG BIOT, V143, P143, DOI 10.1007/10_2013_243
   Suarez LAP, 2011, CHEM ENG RES DES, V89, P753, DOI 10.1016/j.cherd.2010.10.010
   Porru M, 2017, IND ENG CHEM RES, V56, P9578, DOI 10.1021/acs.iecr.7b00243
   Qin SJ, 2000, PROG SYST C, V26, P369
   Randolph A, 1973, THEORY PARTICULATE P
   Rawlings J. B, 2012, MODEL PREDICTIVE CON, DOI [10.1109/TBME.2009.2039571, DOI 10.1109/TBME.2009.2039571]
   Saleemi A, 2012, CRYSTENGCOMM, V14, P2196, DOI 10.1039/c2ce06288g
   Shalmashi A, 2008, J CHEM ENG DATA, V53, P1332, DOI 10.1021/je800056h
   Simone E, 2015, CRYST GROWTH DES, V15, P2908, DOI 10.1021/acs.cgd.5b00337
   Su QL, 2017, AICHE J, V63, P5007, DOI 10.1002/aic.15810
   Szilagyi B, 2018, IND ENG CHEM RES, V57, P3320, DOI 10.1021/acs.iecr.7b03964
   Szilagyi B, 2016, COMPUT CHEM ENG, V91, P167, DOI 10.1016/j.compchemeng.2016.03.023
   Uesaka H, 2002, J CRYST GROWTH, V237, P132, DOI 10.1016/S0022-0248(01)01892-9
   Wierzbowska B, 2008, CRYST RES TECHNOL, V43, P381, DOI 10.1002/crat.200711075
   Wierzbowska B, 2008, POL J CHEM TECHNOL, V10, P60, DOI 10.2478/v10026-008-0015-5
   Wierzbowska B, 2011, CRYST GROWTH DES, V11, P1557, DOI 10.1021/cg101521k
   Worlitschek J, 2005, PART PART SYST CHAR, V22, P81, DOI 10.1002/ppsc.200400872
   Yang Y, 2015, CRYST GROWTH DES, V15, P5839, DOI 10.1021/acs.cgd.5b01219
   Zhang GP, 2004, CHEM ENG COMMUN, V191, P356, DOI 10.1080/00986440490272546
NR 52
TC 6
Z9 6
U1 2
U2 22
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 335
EP 346
DI 10.1016/j.ces.2018.09.032
PG 12
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500031
DA 2020-05-12
ER

PT J
AU Braz, CG
   Mendes, A
   Rocha, J
   Alvim, R
   Matos, HA
AF Braz, Catarina G.
   Mendes, Adelio
   Rocha, Jorge
   Alvim, Ricardo
   Matos, Henrique A.
TI Model of an industrial multitubular reactor for methanol to formaldehyde
   oxidation in the presence of catalyst deactivation
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Formaldehyde; Dynamic modelling; Industrial data; Parameter estimation;
   Catalyst deactivation
ID IRON-MOLYBDATE CATALYST; SELECTIVE OXIDATION; KINETICS
AB In the present work, a first-principles model of methanol partial oxidation to formaldehyde in an industrial reactor was developed and the reaction kinetic and deactivation parameters estimated, taking advantage of the temperature profile established by the exothermic reaction. The catalyst deactivation was assigned primarily to hot-spot regions in the oxidation reactor. The exposure to high temperatures enhances solid-state reactions that produce volatile compounds and a consequential loss of catalyst active compounds that migrate downstream from the hot-spot. This phenomenon was modelled implementing a new method where, instead of time, the deactivation was integrated as a function of the total consumed reagent until the instant of interest. This approach allowed computing the activity of the catalyst at any instant without needing to solve the model for the whole operating history until the pertinent instant; for simulating industrial reactors, where the operating conditions are changing frequently, this feature is quite relevant. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Braz, Catarina G.; Matos, Henrique A.] Univ Lisbon, Ctr Recursos Nat & Ambiente, Inst Super Tecn, Ave Rovisco Pais 1, P-1049001 Lisbon, Portugal.
   [Mendes, Adelio] Univ Porto, Fac Engn, Lab Proc Engn Environm Biotechnol & Energy, R Dr Roberto Frias, P-4200464 Porto, Portugal.
   [Rocha, Jorge; Alvim, Ricardo] Ind Quim SA, Plataforma Ind Sines Lote Ind 1, EuroResinas, Uma Empresa Grp Sonae Arauco, 7520-064 Sines, P-7520064 Sines, Portugal.
RP Matos, HA (reprint author), Univ Lisbon, Ctr Recursos Nat & Ambiente, Inst Super Tecn, Ave Rovisco Pais 1, P-1049001 Lisbon, Portugal.
RI Matos, Henrique/A-4946-2012
OI Matos, Henrique/0000-0001-8128-7346; Braz, Ana
   Catarina/0000-0001-7859-2294
FU EuroResinas; FCTPortuguese Foundation for Science and Technology
   [UID/ECI/04028/2013, PD/BDE/113539/2015]
FX The authors greatly acknowledge EuroResinas and FCT financial support
   through the project UID/ECI/04028/2013 and the PhD grant number
   PD/BDE/113539/2015. Additionally, the authors would like to thank
   Perstorp for the insightful comments.
CR Andersson A, 2006, CATAL TODAY, V112, P40, DOI 10.1016/j.cattod.2005.11.052
   [Anonymous], 2014, FORM MARK AN APPL UF
   Bird RB, 2017, TRANSPORT PHENOMENA
   Burriesci N., 1980, STUD SURF SCI CATAL, P115, DOI DOI 10.1016/S0167-2991(08)65224-6
   Carbucicchio M., 1980, CATALYST DEACTIVATIO, P103, DOI 10.1016/S0167-2991(08)65223-4
   Cheng WH, 1996, J CATAL, V158, P477, DOI 10.1006/jcat.1996.0047
   Dazhuang L., 1997, REACTION KINETICS CA, V62, P347, DOI [10.1007/BF02475474, DOI 10.1007/BF02475474]
   Deshmukh SARK, 2005, APPL CATAL A-GEN, V289, P240, DOI 10.1016/j.apcata.2005.05.005
   Diakov V, 2002, CHEM ENG SCI, V57, P1563, DOI 10.1016/S0009-2509(02)00031-3
   EDWARDS J, 1977, J CATAL, V50, P24, DOI 10.1016/0021-9517(77)90005-7
   Evemenenko N. P, 1969, KINET CATAL, V10, P1071
   FORZATTI P, 1982, REACT KINET CATAL L, V20, P213, DOI 10.1007/BF02063612
   Gerberich HR, 2005, KIRK OTHMER ENCY CHE, V12, P929, DOI DOI 10.1002/0471238961.0615181307051802.A01
   Himmelblau D. M., 1970, PROCESS ANAL STAT ME
   Huang XM, 2004, CATAL LETT, V97, P185, DOI 10.1023/B:CATL.0000038582.88770.c9
   Ivanov KI, 2010, CATAL TODAY, V154, P250, DOI 10.1016/j.cattod.2010.03.051
   JIRU P, 1966, COLLECT CZECH CHEM C, V31, P674
   MA YH, 1988, J CATAL, V109, P132, DOI 10.1016/0021-9517(88)90191-1
   MACHIELS CJ, 1982, J CATAL, V76, P238, DOI 10.1016/0021-9517(82)90254-8
   Mars P., 1954, CHEM ENG SCI S, V3, P41, DOI DOI 10.1016/S0009-2509(54)80005-4
   PERNICON.N, 1969, J CATAL, V14, P293, DOI 10.1016/0021-9517(69)90319-4
   Pernicone N., 1991, CATAL TODAY, V11, P85, DOI DOI 10.1016/0920-5861(91)87009-C
   Poling B. E, 2001, PROPERTIES GASES LIQ, DOI [10.1036/0070116822, DOI 10.1036/0070116822]
   Rangarajan S, 2009, CHEM BUS, P31
   Reuss G., 2005, ULLMANNS ENCY IND CH, V15, P73, DOI [10.1002/14356007.a11, DOI 10.1002/14356007.A11]
   SANTACESARIA E, 1981, CHEM ENG SCI, V36, P909, DOI 10.1016/0009-2509(81)85045-2
   SCHWEDOCK MJ, 1989, CHEM ENG COMMUN, V78, P45, DOI 10.1080/00986448908940186
   Soares A. P. V., 2001, CATAL COMMUN, V2, P159, DOI 10.1016/S1566-7367(01)00026-7
   Soares APV, 2002, REACT KINET CATAL L, V75, P13, DOI 10.1023/A:1014833131133
   Tatibouet JM, 1997, APPL CATAL A-GEN, V148, P213, DOI 10.1016/S0926-860X(96)00236-0
NR 30
TC 4
Z9 4
U1 4
U2 19
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 347
EP 355
DI 10.1016/j.ces.2018.09.033
PG 9
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500032
DA 2020-05-12
ER

PT J
AU Xu, YP
   Li , TW
   Lu, LQ
   Tebianian, S
   Chaouki, J
   Leadbeater, TW
   Jafari, R
   Parker, DJ
   Seville, J
   Ellis, N
   Grace, JR
AF Xu, Yupeng
   Li, Tingwen
   Lu, Liqiang
   Tebianian, Sina
   Chaouki, Jamal
   Leadbeater, Thomas W.
   Jafari, Rouzben
   Parker, David J.
   Seville, Jonathan
   Ellis, Naoko
   Grace, John R.
TI Numerical and experimental comparison of tracer particle and averaging
   techniques for particle velocities in a fluidized bed
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Fluidized bed; Particle tracking; Particle velocity; Numerical
   simulation
ID MFIX-DEM SOFTWARE; DISCRETE PARTICLE; MODEL; VALIDATION; SIMULATION;
   FLOW
AB Particle tracking methods using emitted radiation are attractive for following motion in opaque systems such as granular materials. Leading examples are Positron Emission Particle Tracking (PEPT) and Radioactive Particle Tracking (RPT). The application of such techniques sometimes requires the use of tracer particles which differ in size, density and/or shape from the particles of interest. This study investigates the extent to which such differences affect the result of the study by using the open source MFIX-DEM software to model particle motion in the travelling fluidized bed experiments. The results are compared with previously reported experimental studies using both PEPT and RPT. Consistent numerical results were obtained for both PEPT and RPT tracer particles. In determining averaged velocities using such techniques, there is a choice to be made between averaging velocities of particles crossing a virtual plane over a period of time (the "face-average" approach) or those passing through a defined volume over time (the "volume-average" approach). The differences between results obtained with these two approaches are shown to be significant in this case, for both computation and experiment. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Xu, Yupeng; Li, Tingwen; Lu, Liqiang] US DOE, Natl Energy Technol Lab, Morgantown, WV USA.
   [Tebianian, Sina] IFP Energies Nouvelles, Proc Design & Modeling Div, Lyon, France.
   [Chaouki, Jamal; Jafari, Rouzben] Ecole Polytech, Dept Genie Chim, Montreal, PQ H3T 1J4, Canada.
   [Parker, David J.; Seville, Jonathan] Univ Birmingham, Positron Imaging Ctr, Birmingham B15 2TT, W Midlands, England.
   [Ellis, Naoko; Grace, John R.] Univ British Columbia, Dept Chem & Biol Engn, Vancouver, BC V6T 1Z3, Canada.
   [Li, Tingwen] AECOM, Morgantown, WV 26505 USA.
   [Leadbeater, Thomas W.] Univ Cape Town, Dept Phys, Cape Town, South Africa.
   [Xu, Yupeng] West Virginia Univ Res Corp, Morgantown, WV 26506 USA.
RP Li , TW (reprint author), SABIC Global Corp Res, 14100 Southwest Freeway Suite 600, Sugar Land, TX 77479 USA.
EM litingwen@gmail.com
OI Li, Tingwen/0000-0002-1900-308X; Xu, Yupeng/0000-0003-4641-0200; Lu,
   Liqiang/0000-0002-5101-1688
FU National Energy Technology Laboratory under RES [DE-FE0004000];
   DOEUnited States Department of Energy (DOE); Natural Sciences and
   Engineering Research Council of Canada (NSERC)Natural Sciences and
   Engineering Research Council of Canada
FX This technical paper was produced in support of the National Energy
   Technology Laboratory's ongoing research in advanced numerical
   simulation of multiphase flow under RES contract DE-FE0004000. This
   research was also supported in part by an appointment to the National
   Energy Technology Laboratory Research Participation Program, sponsored
   by DOE and administered by the Oak Ridge Institute for Science and
   Education. Financial support from the Natural Sciences and Engineering
   Research Council of Canada (NSERC) is also gratefully acknowledged.
CR Alobaid F, 2013, PARTICUOLOGY, V11, P514, DOI 10.1016/j.partic.2012.05.008
   Bi HT, 1996, CAN J CHEM ENG, V74, P811, DOI 10.1002/cjce.5450740534
   CUNDALL PA, 1979, GEOTECHNIQUE, V29, P47, DOI 10.1680/geot.1979.29.1.47
   Dietiker J. F., 2009, AICHE ANN M
   Dietiker J.F., 2015, MULTIPHASE FLOW INTE
   Dubrawski K, 2013, POWDER TECHNOL, V235, P203, DOI 10.1016/j.powtec.2012.10.031
   ELGHOBASHI S, 1994, APPL SCI RES, V52, P309, DOI 10.1007/BF00936835
   ELGHOBASHI S, 2004, FLUID MEC A, V81, P3, DOI DOI 10.1007/1-4020-4977-3_1
   Garg R, 2012, POWDER TECHNOL, V220, P122, DOI 10.1016/j.powtec.2011.09.019
   Gopalakrishnan P, 2013, POWDER TECHNOL, V235, P33, DOI 10.1016/j.powtec.2012.09.006
   Karri R. S. B, 2003, HDB FLUIDIZATION FLU
   Larachi F., 1997, NONINVASIVE MONITORI, P335, DOI DOI 10.1016/B978-044482521-6/50012-7
   Leadbeater TW, 2012, PARTICUOLOGY, V10, P146, DOI 10.1016/j.partic.2011.09.006
   Li TW, 2015, POWDER TECHNOL, V286, P817, DOI 10.1016/j.powtec.2015.09.033
   Li TW, 2012, POWDER TECHNOL, V220, P138, DOI 10.1016/j.powtec.2011.09.020
   Liu HD, 2014, POWDER TECHNOL, V259, P22, DOI 10.1016/j.powtec.2014.03.047
   Lu LQ, 2018, CHEM ENG SCI, V179, P53, DOI 10.1016/j.ces.2018.01.003
   Lu LQ, 2016, CHEM ENG SCI, V155, P314, DOI 10.1016/j.ces.2016.08.013
   Lu LQ, 2014, CHEM ENG SCI, V120, P67, DOI 10.1016/j.ces.2014.08.004
   PATIENCE GS, 1993, CHEM ENG SCI, V48, P3195, DOI 10.1016/0009-2509(93)80205-5
   Sakai M, 2014, CHEM ENG J, V244, P33, DOI 10.1016/j.cej.2014.01.029
   Syamlal M., 1993, MFIX DOCUMENTATION T
   Tebianian S, 2015, COMP ALTERNATIVE ADV
   Tebianian S, 2016, CHEM ENG J, V306, P306, DOI 10.1016/j.cej.2016.07.058
   Tebianian S, 2016, POWDER TECHNOL, V296, P45, DOI 10.1016/j.powtec.2015.08.040
   Tebianian S, 2015, CHEM ENG RES DES, V104, P191, DOI 10.1016/j.cherd.2015.08.006
   Tebianian S, 2015, CHEM ENG SCI, V127, P310, DOI 10.1016/j.ces.2015.01.049
   van der Hoef M.A., 2006, ADV CHEM ENG, P65, DOI DOI 10.1016/S0065-2377(06)31002-2
   Verma V, 2017, POWDER TECHNOL, V318, P282, DOI 10.1016/j.powtec.2017.05.037
   Verma V, 2013, CHEM ENG SCI, V102, P227, DOI 10.1016/j.ces.2013.08.002
   Xu Y, 2013, CHEM ENG SCI, V104, P201, DOI 10.1016/j.ces.2013.09.023
   Xu Y., 2017, POWDER TECHNOL, P318
   Xu Y., 2014, PHYS REV E, V90, P6
   Xu Y., 2017, IND ENG CHEM RES
   Xu YP, 2017, POWDER TECHNOL, V320, P304, DOI 10.1016/j.powtec.2017.07.047
NR 35
TC 3
Z9 3
U1 2
U2 12
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 356
EP 366
DI 10.1016/j.ces.2018.09.034
PG 11
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500033
DA 2020-05-12
ER

PT J
AU Sanchez-Delgado, S
   Marugan-Cruz, C
   Serrano, D
   Briongos, JV
AF Sanchez-Delgado, S.
   Marugan-Cruz, C.
   Serrano, D.
   Briongos, J., V
TI Distributor performance in a bubbling fluidized bed: Effects of multiple
   gas inlet jet and bubble generation
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Distributor performance; Fluidized beds; Bubble generation; Wavelet
   coherent analysis; Time dependent dynamics; Multiple gas jet
ID DIGITAL IMAGE-ANALYSIS; SIZE DISTRIBUTION; PART I; PRESSURE; FLOW;
   MALDISTRIBUTION; HYDRODYNAMICS; BEHAVIOR; DESIGN; SYSTEM
AB This study considers the role of the distributor effect during the bubble generation, growth and interaction within a bubbling fluidized bed. To characterize this effect, short-term and long-term dynamics are explored in time and frequency domains. Controversy occurs when inspecting what is actually known of the gas distribution mechanism in bubbling fluidized beds. To sustain discussion, classical and innovative techniques, such as Digital Image Analysis, DIA, and Wavelet Analysis WA, are used. As a result, the conclusion is that the distributor not only has no effect in the averaged long-term dynamics but also has no effect on the general bubble generation characteristic frequencies. The analysis performed on the bubble generation region concludes that the distributor design has a great influence at the short-term scale such as during the bubble generation process controlling the spatial distribution of the bubble nucleation sites over the distributor plate. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Sanchez-Delgado, S.; Marugan-Cruz, C.; Serrano, D.; Briongos, J., V] Carlos III Univ Madrid, Thermal & Fluid Engn Dept, Energy Syst Engn Res Grp, Leganes, Madrid, Spain.
RP Sanchez-Delgado, S (reprint author), Carlos III Univ Madrid, Thermal & Fluid Engn Dept, Energy Syst Engn Res Grp, Leganes, Madrid, Spain.
EM sergio.sanchez@uc3m.es
RI Marugan-Cruz, Carolina/H-8979-2015
OI VILLA BRIONGOS, JAVIER/0000-0002-1837-7135; Marugan-Cruz,
   Carolina/0000-0002-1288-1963; SERRANO, DANIEL/0000-0001-9004-6114
CR Adanez J, 2018, PROG ENERG COMBUST, V65, P6, DOI 10.1016/j.pecs.2017.07.005
   Agarwal G, 2011, POWDER TECHNOL, V214, P122, DOI 10.1016/j.powtec.2011.08.002
   Asegehegn TW, 2011, POWDER TECHNOL, V210, P248, DOI 10.1016/j.powtec.2011.03.025
   Bakshi A, 2017, AICHE J, V63, P4316, DOI 10.1002/aic.15801
   BLAKE TR, 1990, CHEM ENG SCI, V45, P365, DOI 10.1016/0009-2509(90)87022-K
   Bokkers GA, 2006, CHEM ENG SCI, V61, P5590, DOI 10.1016/j.ces.2006.04.009
   Briens CL, 1997, AICHE J, V43, P1904, DOI 10.1002/aic.690430725
   Briongos JV, 2006, CHEM ENG SCI, V61, P6963, DOI 10.1016/j.ces.2006.07.023
   Busciglio A, 2008, CHEM ENG J, V140, P398, DOI 10.1016/j.cej.2007.11.015
   Chen LM, 2017, POWDER TECHNOL, V322, P461, DOI 10.1016/j.powtec.2017.09.039
   Clemson P, 2016, P IEEE, V104, P223, DOI 10.1109/JPROC.2015.2491262
   Deen NG, 2007, CHEM ENG SCI, V62, P28, DOI 10.1016/j.ces.2006.08.014
   Donoho DL, 1995, J AM STAT ASSOC, V90, P1200, DOI 10.1080/01621459.1995.10476626
   Eow JS, 2003, POWDER TECHNOL, V138, P169, DOI 10.1016/j.powtec.2003.09.006
   Garcia-Gutierrez LM, 2014, POWDER TECHNOL, V263, P112, DOI 10.1016/j.powtec.2014.04.085
   GELDART D, 1985, POWDER TECHNOL, V42, P67, DOI 10.1016/0032-5910(85)80039-5
   GELDART D, 1973, POWDER TECHNOL, V7, P285, DOI 10.1016/0032-5910(73)80037-3
   Gomez-Hernandez J, 2017, POWDER TECHNOL, V316, P446, DOI 10.1016/j.powtec.2016.11.068
   Grinsted A, 2004, NONLINEAR PROC GEOPH, V11, P561, DOI 10.5194/npg-11-561-2004
   Haron NS, 2017, IOP CONF SER-MAT SCI, V243, DOI 10.1088/1757-899X/243/1/012038
   He YJ, 2009, AICHE J, V55, P2563, DOI 10.1002/aic.11878
   Helmi A, 2018, CHEM ENG SCI, V182, P146, DOI 10.1016/j.ces.2018.02.038
   Julian I, 2015, CHEM ENG SCI, V134, P238, DOI 10.1016/j.ces.2015.05.009
   Kanholy SK, 2017, CHEM ENG J, V328, P1009, DOI 10.1016/j.cej.2017.07.116
   Labat D, 2005, J HYDROL, V314, P275, DOI 10.1016/j.jhydrol.2005.04.003
   Lau YM, 2013, CHEM ENG SCI, V98, P203, DOI 10.1016/j.ces.2013.05.024
   Laverman J. A., 2008, CHEM ENG, V86
   Li G, 2018, INT J HYDROGEN ENERG, V43, P1980, DOI 10.1016/j.ijhydene.2017.12.049
   Li YN, 2018, CHEM ENG RES DES, V132, P1037, DOI 10.1016/j.cherd.2017.12.014
   Lim CN, 2007, CHEM ENG SCI, V62, P56, DOI 10.1016/j.ces.2006.08.034
   Lombardi G, 1997, POWDER TECHNOL, V94, P5, DOI 10.1016/S0032-5910(97)03256-7
   Lu XS, 1999, CHEM ENG J, V75, P113, DOI 10.1016/S1385-8947(99)00097-2
   Mallat S., 2008, WAVELET TOUR SIGNAL, DOI [10.1016/B978-0-12-374370-1.X0001-8, DOI 10.1016/B978-0-12-374370-1.X0001-8]
   Maraun D, 2007, PHYS REV E, V75, DOI 10.1103/PhysRevE.75.016707
   Marwan N, 2007, PHYS REP, V438, P237, DOI 10.1016/j.physrep.2006.11.001
   Maurer S, 2016, CHEM ENG J, V298, P17, DOI 10.1016/j.cej.2016.02.012
   Pannala S, 2004, CHAOS, V14, P487, DOI 10.1063/1.1752181
   QURESHI AE, 1979, POWDER TECHNOL, V22, P113, DOI 10.1016/0032-5910(79)85013-5
   Rees AC, 2006, CHEM ENG SCI, V61, P6002, DOI 10.1016/j.ces.2006.05.006
   Sanchez-Delgado S, 2013, POWDER TECHNOL, V235, P669, DOI 10.1016/j.powtec.2012.11.012
   Sanchez-Delgado S, 2010, POWDER TECHNOL, V200, P37, DOI 10.1016/j.powtec.2010.02.005
   Sanchez-Prieto J, 2014, POWDER TECHNOL, V261, P176, DOI 10.1016/j.powtec.2014.04.035
   Sasic S, 2005, POWDER TECHNOL, V153, P176, DOI 10.1016/j.powtec.2005.03.012
   Sasic S, 2004, IND ENG CHEM RES, V43, P5730, DOI 10.1021/ie049763b
   Sathiy Amoorthy D, 1979, POWDER TECHNOL, V24, P215, DOI [10.1016/0032-5910(79)87038-2, DOI 10.1016/0032-5910(79)87038-2]
   SATHIYAMOORTHY D, 1981, POWDER TECHNOL, V30, P139, DOI 10.1016/0032-5910(81)80006-X
   SATHIYAMOORTHY D, 1978, POWDER TECHNOL, V20, P47, DOI 10.1016/0032-5910(78)80007-2
   Sathiyamoorthy D, 2003, CHEM ENG J, V93, P151, DOI 10.1016/S1385-8947(02)00257-7
   SAXENA SC, 1979, POWDER TECHNOL, V22, P191, DOI 10.1016/0032-5910(79)80026-1
   Schreiber T, 1996, PHYS REV LETT, V77, P635, DOI 10.1103/PhysRevLett.77.635
   Shen LH, 2004, CHEM ENG SCI, V59, P2607, DOI 10.1016/j.ces.2004.01.063
   Sobrino C, 2009, INT J MULTIPHAS FLOW, V35, P970, DOI 10.1016/j.ijmultiphaseflow.2009.04.005
   Sobrino C, 2009, CHEM ENG SCI, V64, P2307, DOI 10.1016/j.ces.2009.01.046
   Thorpe RB, 2002, IND ENG CHEM RES, V41, P5878, DOI 10.1021/ie0203173
   Torrence C, 1998, B AM METEOROL SOC, V79, P61, DOI 10.1175/1520-0477(1998)079<0061:APGTWA>2.0.CO;2
   Torrence C, 1999, J CLIMATE, V12, P2679, DOI 10.1175/1520-0442(1999)012<2679:ICITEM>2.0.CO;2
   van der Schaaf J, 1998, POWDER TECHNOL, V95, P220, DOI 10.1016/S0032-5910(97)03341-X
   van der Schaaf J, 2002, INT J MULTIPHAS FLOW, V28, P865, DOI 10.1016/S0301-9322(01)00090-8
   Briongos JV, 2011, AICHE J, V57, P1733, DOI 10.1002/aic.12375
   Walker B., 1975, CHEM ENG J, V9, P49, DOI DOI 10.1016/0300-9467(75)88004-X
   Wu KQ, 2017, CHEM ENG J, V329, P4, DOI 10.1016/j.cej.2017.05.152
   Zunino L, 2007, PHYSICA A, V379, P503, DOI 10.1016/j.physa.2006.12.057
NR 62
TC 4
Z9 4
U1 0
U2 12
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 367
EP 380
DI 10.1016/j.ces.2018.09.035
PG 14
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500034
DA 2020-05-12
ER

PT J
AU Ma, YJ
   Luo, YQ
   Yuan, XG
AF Ma, Yingjie
   Luo, Yiqing
   Yuan, Xigang
TI Equation-oriented optimization of reactive distillation systems using
   pseudo-transient models
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Reactive distillation; Pseudo-transient continuation model; Equilibrium
   stage model; Process optimization; Bypass efficiency method; Reactive
   divided wall column
ID PROCESS INTENSIFICATION; OPTIMAL-DESIGN; PROCESS FLOWSHEETS; ACETATE;
   SIMULATION; FRAMEWORK
AB Reactive distillation has significant economic and environmental advantages compared to conventional processes. However, the optimal design of a reactive distillation system is far from mature. This work proposed a novel equation-oriented optimization framework based on a rigorous equilibrium stage model for the optimization of reactive distillation systems. A pseudo-transient continuation (PTC) reactive distillation model was developed to solve the convergence problem of simulations. The bypass efficiency method was incorporated into the PTC model to avoid the intractable mixed integer optimization. The developed model can be integrated well with a steady-state optimization algorithm assisted by PTC models. Two cases demonstrated that the proposed model and optimization framework were robust and fast. However, the bypass efficiency method caused physically meaningless solutions, but they were found to be convertible to physically meaningful solutions without influencing the accurate optimization of number of stages according to the intrinsic properties of the bypass efficiency method introduced in the current work. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Ma, Yingjie; Luo, Yiqing; Yuan, Xigang] Tianjin Univ, Chem Engn Res Ctr, Sch Chem Engn & Technol, Tianjin 300350, Peoples R China.
   [Yuan, Xigang] Tianjin Univ, State Key Lab Chem Engn, Tianjin 300350, Peoples R China.
   [Ma, Yingjie] Univ Manchester, Sch Chem Engn & Analyt Sci, Manchester, Lancs, England.
RP Luo, YQ (reprint author), Tianjin Univ, Chem Engn Res Ctr, Sch Chem Engn & Technol, Tianjin 300350, Peoples R China.
EM luoyq@tju.edu.cn
OI Luo, yiqing/0000-0003-2435-8659; Jia, Shengkun/0000-0003-4524-0588
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21676183]
FX The financial support is provided by the National Natural Science
   Foundation of China (No. 21676183).
CR Al-Arfaj MA, 2002, IND ENG CHEM RES, V41, P3784, DOI 10.1021/ie010432y
   Almeida-Rivera CP, 2004, COMPUT CHEM ENG, V28, P1997, DOI 10.1016/j.compchemeng.2004.03.014
   Avami A, 2012, CHEM ENG SCI, V71, P166, DOI 10.1016/j.ces.2011.12.021
   Barkmann S, 2008, CHEM-ING-TECH, V80, P107, DOI 10.1002/cite.200700143
   Biegler LT, 2004, COMPUT CHEM ENG, V28, P1169, DOI 10.1016/j.compchemeng.2003.11.003
   Bildea C. S., 2017, COMPUT CHEM ENG
   Bildea CS, 2015, J CHEM TECHNOL BIOT, V90, P992, DOI 10.1002/jctb.4683
   Burri JE, 2004, COMPUT CHEM ENG, V28, P2509, DOI 10.1016/j.compchemeng.2004.06.014
   Caballero JA, 2008, AICHE J, V54, P2633, DOI 10.1002/aic.11579
   Cardoso MF, 1997, COMPUT CHEM ENG, V21, P1349, DOI 10.1016/S0098-1354(97)00015-X
   Cardoso MF, 2000, CHEM ENG SCI, V55, P5059, DOI 10.1016/S0009-2509(00)00119-6
   CIRIC AR, 1994, AICHE J, V40, P1479, DOI 10.1002/aic.690400907
   Dejanovic I, 2010, CHEM ENG PROCESS, V49, P559, DOI 10.1016/j.cep.2010.04.001
   Domingues L, 2014, COMPUT CHEM ENG, V64, P81, DOI 10.1016/j.compchemeng.2014.01.014
   Dowling AW, 2015, COMPUT CHEM ENG, V72, P3, DOI 10.1016/j.compchemeng.2014.05.013
   Dowling AW, 2014, COMPUT-AIDED CHEM EN, V33, P55
   Frey T., 2000, COMPUT AIDED CHEM EN, V8, P115
   Segovia-Hernandez JG, 2015, CHEM ENG PROCESS, V97, P134, DOI 10.1016/j.cep.2015.09.004
   Gangadwala J, 2007, CHEM ENG PROCESS, V46, P107, DOI 10.1016/j.cep.2006.04.009
   Gomez JM, 2006, IND ENG CHEM RES, V45, P1373, DOI 10.1021/ie0504506
   Harmsen GJ, 2007, CHEM ENG PROCESS, V46, P774, DOI 10.1016/j.cep.2007.06.005
   Harwardt A, 2011, CHINESE J CHEM ENG, V19, P371, DOI 10.1016/S1004-9541(09)60223-8
   Huang KJ, 2006, AICHE J, V52, P2518, DOI 10.1002/aic.10885
   Huang KJ, 2010, CHEM ENG PROCESS, V49, P294, DOI 10.1016/j.cep.2010.02.008
   Jackson JR, 2001, COMPUT CHEM ENG, V25, P1661, DOI 10.1016/S0098-1354(01)00730-X
   Kamath RS, 2010, COMPUT CHEM ENG, V34, P1312, DOI 10.1016/j.compchemeng.2010.02.029
   Kiss AA, 2012, FUEL, V95, P352, DOI 10.1016/j.fuel.2011.12.064
   Lee JW, 2003, AICHE J, V49, P1471, DOI 10.1002/aic.690490611
   Lima RM, 2006, CHEM ENG SCI, V61, P1718, DOI 10.1016/j.ces.2005.10.009
   Luyben W. L., 2008, REACTIVE DISTILLATIO
   Luyben WL, 2011, PRINCIPLES CASE STUD
   Ma Y., 2018, IND ENG CHEM R UNPUB
   Ma YJ, 2018, COMPUT CHEM ENG, V108, P337, DOI 10.1016/j.compchemeng.2017.10.004
   Ma YJ, 2017, IND ENG CHEM RES, V56, P6266, DOI 10.1021/acs.iecr.7b00380
   Malone MF, 2000, IND ENG CHEM RES, V39, P3953, DOI 10.1021/ie000633m
   Niesbach A, 2013, CHEM ENG SCI, V100, P360, DOI 10.1016/j.ces.2013.01.035
   Okasinski MJ, 1998, IND ENG CHEM RES, V37, P2821, DOI 10.1021/ie9708788
   Pattison RC, 2017, COMPUT CHEM ENG, V105, P161, DOI 10.1016/j.compchemeng.2016.12.019
   Pattison RC, 2016, AICHE J, V62, P704, DOI 10.1002/aic.15060
   Pattison RC, 2015, AICHE J, V61, P1856, DOI 10.1002/aic.14766
   Pattison RC, 2014, AICHE J, V60, P4104, DOI 10.1002/aic.14567
   Qi ZW, 2002, CHEM ENG SCI, V57, P163, DOI 10.1016/S0009-2509(01)00353-0
   Qian X, 2015, CHEM ENG RES DES, V99, P176, DOI 10.1016/j.cherd.2015.03.029
   Rios LM, 2013, J GLOBAL OPTIM, V56, P1247, DOI 10.1007/s10898-012-9951-y
   Ryll O, 2013, CHEM ENG SCI, V104, P374, DOI 10.1016/j.ces.2013.09.012
   Silva HG, 2011, CHEM ENG SCI, V66, P1306, DOI 10.1016/j.ces.2011.01.001
   Sneesby Martin G, 2004, AICHE J, V44, P388
   Song W, 1997, NATURE, V388, P561, DOI 10.1038/41515
   Stankiewicz A, 2003, CHEM ENG PROCESS, V42, P137, DOI 10.1016/S0255-2701(02)00084-3
   Stankiewicz AI, 2000, CHEM ENG PROG, V96, P22
   Subawalla H, 1999, IND ENG CHEM RES, V38, P3696, DOI 10.1021/ie990008l
   Suo XM, 2017, IND ENG CHEM RES, V56, P5607, DOI 10.1021/acs.iecr.6b04354
   Taylor R, 2000, CHEM ENG SCI, V55, P5183, DOI 10.1016/S0009-2509(00)00120-2
   Tong LW, 2014, CHEM ENG SCI, V106, P190, DOI 10.1016/j.ces.2013.11.036
   Tsay C, 2017, AICHE J, V63, P3778, DOI 10.1002/aic.15705
NR 55
TC 3
Z9 3
U1 6
U2 20
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 381
EP 398
DI 10.1016/j.ces.2018.09.036
PG 18
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500035
DA 2020-05-12
ER

PT J
AU Gakis, GP
   Vergnes, H
   Scheid, E
   Vahlas, C
   Boudouvis, AG
   Caussat, B
AF Gakis, Georgios P.
   Vergnes, Hugues
   Scheid, Emmanuel
   Vahlas, Constantin
   Boudouvis, Andreas G.
   Caussat, Brigitte
TI Detailed investigation of the surface mechanisms and their interplay
   with transport phenomena in alumina atomic layer deposition from TMA and
   water
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE ALD; TMA; Surface mechanisms; CFD; Desorption; Alumina
ID QUARTZ-CRYSTAL MICROBALANCE; MODEL-BASED METHODOLOGY; THIN-FILM GROWTH;
   REACTOR; DESIGN; TRIMETHYLALUMINUM; CHEMISTRY; SILICA; OXIDE; H2O
AB The surface mechanisms involved in the Atomic Layer Deposition of Al2O3 from TMA and H2O are investigated by means of combined experimental and computational analyses. Reactant adsorption, desorption and surface reaction are taken into account by a surface chemistry model, coupled to a CFD model for an industrial reactor treating 200 mm substrates. Once the model validated by comparison with experimental deposition rates, the relative contribution of each surface phenomenon is quantitatively determined between 100 and 300 degrees C through original reaction probability calculations. It is revealed that the competition between surface reactions and desorption of H2O plays a crucial role in the ALD growth of alumina. The H2O desorption is the limiting factor for the growth at low process temperature whereas it is the OH group surface concentration at higher temperature. This integrated (surface chemistry/kinetics and CFD) model shows a direct link between transport phenomena, such as gas flow recirculation and low temperature zones in the reactor, and film uniformity. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Gakis, Georgios P.; Boudouvis, Andreas G.] Natl Tech Univ Athens, Sch Chem Engn, Athens, Greece.
   [Gakis, Georgios P.; Vergnes, Hugues; Caussat, Brigitte] Univ Toulouse, Lab Genie Chim, Toulouse, France.
   [Scheid, Emmanuel] Univ Toulouse, LAAS, Toulouse, France.
   [Vahlas, Constantin] Univ Toulouse, CIRIMAT, Toulouse, France.
RP Boudouvis, AG (reprint author), Natl Tech Univ Athens, Sch Chem Engn, Athens, Greece.
EM boudouvi@chemeng.ntua.gr
RI Vahlas, Constantin/F-7160-2019; Boudouvis, Andreas/B-2307-2010
OI Vahlas, Constantin/0000-0001-5911-0296; Boudouvis,
   Andreas/0000-0001-6651-7318
FU Toulouse Tech Inter Lab 2016 grant; NTUA Research Committee
FX This work was partly funded by a Toulouse Tech Inter Lab 2016 grant. GPG
   acknowledges the financial support by the NTUA Research Committee.
CR [Anonymous], 2013, CHEMKIN PRO 15131
   Aria AI, 2016, ACS APPL MATER INTER, V8, P30564, DOI 10.1021/acsami.6b09596
   CHEN JR, 1994, J VAC SCI TECHNOL A, V12, P1750, DOI 10.1116/1.579049
   Delabie A., 2012, J VAC SCI TECHNOL A, V30, P1
   DILLON AC, 1995, SURF SCI, V322, P230, DOI 10.1016/0039-6028(95)90033-0
   Elam JW, 2002, REV SCI INSTRUM, V73, P2981, DOI 10.1063/1.1490410
   Gakis GP, 2018, CHEM ENG RES DES, V132, P795, DOI 10.1016/j.cherd.2018.02.031
   George SM, 2010, CHEM REV, V110, P111, DOI 10.1021/cr900056b
   Groner MD, 2004, CHEM MATER, V16, P639, DOI 10.1021/cm0304546
   HAUKKA S, 1994, J PHYS CHEM-US, V98, P1695, DOI 10.1021/j100057a025
   Holmqvist A, 2014, CHEM ENG SCI, V117, P301, DOI 10.1016/j.ces.2014.07.002
   Holmqvist A, 2014, CHEM ENG SCI, V111, P15, DOI 10.1016/j.ces.2014.02.005
   Holmqvist A, 2013, CHEM ENG SCI, V96, P71, DOI 10.1016/j.ces.2013.03.061
   Holmqvist A, 2013, CHEM ENG SCI, V94, P316, DOI 10.1016/j.ces.2012.06.063
   Holmqvist A, 2012, CHEM ENG SCI, V81, P260, DOI 10.1016/j.ces.2012.07.015
   Johnson RW, 2014, MATER TODAY, V17, P236, DOI 10.1016/j.mattod.2014.04.026
   Jur JS, 2011, ACS APPL MATER INTER, V3, P299, DOI 10.1021/am100940g
   Murray C, 2013, ACS APPL MATER INTER, V5, P3704, DOI 10.1021/am400310p
   Ott AW, 1997, THIN SOLID FILMS, V292, P135, DOI 10.1016/S0040-6090(96)08934-1
   Pan DQ, 2015, J VAC SCI TECHNOL A, V33, DOI 10.1116/1.4905726
   Peltonen P, 2018, J VAC SCI TECHNOL A, V36, DOI 10.1116/1.5018475
   Puurunen RL, 2005, APPL SURF SCI, V245, P6, DOI 10.1016/j.apsusc.2004.10.003
   Puurunen RL, 2005, J APPL PHYS, V97, DOI 10.1063/1.1940727
   Remmers EM, 2015, CHEM ENG SCI, V127, P374, DOI 10.1016/j.ces.2015.01.051
   Shaeri MR, 2014, INT J HEAT MASS TRAN, V78, P1243, DOI 10.1016/j.ijheatmasstransfer.2014.07.079
   Travis CD, 2013, THEOR CHEM ACC, V133, DOI 10.1007/s00214-013-1414-0
   Travis CD, 2013, CHEM VAPOR DEPOS, V19, P4, DOI 10.1002/cvde.201206985
   Vandalon V, 2016, APPL PHYS LETT, V108, DOI 10.1063/1.4939654
   Vandalon V, 2017, J VAC SCI TECHNOL A, V35, DOI 10.1116/1.4993597
   Weckman T, 2015, PHYS CHEM CHEM PHYS, V17, P17322, DOI 10.1039/c5cp01912e
   Widjaja Y, 2002, APPL PHYS LETT, V80, P3304, DOI 10.1063/1.1473237
   Wind RA, 2010, J PHYS CHEM A, V114, P1281, DOI 10.1021/jp9049268
   Xie YY, 2015, CHEM ENG J, V259, P213, DOI 10.1016/j.cej.2014.07.105
   Zhuravlev LT, 2000, COLLOID SURFACE A, V173, P1, DOI 10.1016/S0927-7757(00)00556-2
NR 34
TC 6
Z9 6
U1 8
U2 33
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 399
EP 412
DI 10.1016/j.ces.2018.09.037
PG 14
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500036
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Kumar, U
   Paul, MC
AF Kumar, Umesh
   Paul, Manosh C.
TI CFD modelling of biomass gasification with a volatile break-up approach
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Downdraft gasifier; Biomass gasification; CFD modelling; DPM model
ID DOWNDRAFT GASIFIER; KINETIC-MODEL; SIMULATION
AB Gasification thermochemical processes of biomass in a 20 kW downdraft gasifier are investigated using a robust two-dimensional (2D) computational fluid dynamics (CFD) modelling method. The model includes all the four zones of the gasifier namely drying, pyrolysis, oxidation and reduction. A step-by-step approach is proposed to evaluate the composition of different gas species as a result of the volatile break-up during gasification. However, selecting suitable chemical reactions for the CFD modelling becomes challenging as the commonly used reactions in kinetic study showed discrepancy in predicting the synthesis gas compositions. A revised set of chemical mechanisms is therefore proposed in the study and the robustness of the approach is examined with results validated against data from literature. The study reports how the air equivalence ratio (ER) affects the gasifier temperature and also the composition of producer gases. The model is then applied to investigate the syngas production of various biomass feedstocks sourced from Scottish agricultural sites. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Kumar, Umesh; Paul, Manosh C.] Univ Glasgow, Sch Engn, Syst Power & Energy Res Div, Glasgow G12 8QQ, Lanark, Scotland.
RP Paul, MC (reprint author), Univ Glasgow, Sch Engn, Syst Power & Energy Res Div, Glasgow G12 8QQ, Lanark, Scotland.
EM Manosh.Paul@glasgow.ac.uk
OI Paul, Manosh/0000-0002-6510-456X
FU Innovate UK [132362, TS/N011686/1]; RAEng/The Leverhulme Trust Senior
   Research Fellowship support [LTSRF1718\14\45]
FX We gratefully acknowledge the Innovate UK (132362, TS/N011686/1) for
   their financial support. The second author (M.C. Paul) also acknowledges
   his RAEng/The Leverhulme Trust Senior Research Fellowship support
   (LTSRF1718\14\45).
CR ANSYS, 2013, 15 FLUENT THEOR GUID
   Aziz M, 2016, ENERGIES, V9, DOI 10.3390/en9030137
   Bissett M., 1992, METC GASIFIER ADV SI
   Chen CX, 2000, CHEM ENG SCI, V55, P3861, DOI 10.1016/S0009-2509(00)00030-0
   Di Blasi C, 2000, CHEM ENG SCI, V55, P2931, DOI 10.1016/S0009-2509(99)00562-X
   Dryer F., 1973, P COMBUST INST, V14, P987, DOI DOI 10.1016/S0082-0784(73)80090-6
   Gerun L, 2008, FUEL, V87, P1383, DOI 10.1016/j.fuel.2007.07.009
   Gomez-Barea A, 2010, PROG ENERG COMBUST, V36, P444, DOI 10.1016/j.pecs.2009.12.002
   Howard J, 1973, S INT COMBUST, V14, P975, DOI DOI 10.1016/S0082-0784(73)80089-X
   Huang HJ, 2009, APPL BIOCHEM BIOTECH, V154, P193, DOI 10.1007/s12010-008-8483-x
   Janajreh I, 2013, ENERG CONVERS MANAGE, V65, P783, DOI 10.1016/j.enconman.2012.03.009
   Jarungthammachote S, 2007, ENERGY, V32, P1660, DOI 10.1016/j.energy.2007.01.010
   Jayah TH, 2003, BIOMASS BIOENERG, V25, P459, DOI 10.1016/S0961-9534(03)00037-0
   Kumar U, 2017, ENRGY PROCED, V142, P822, DOI 10.1016/j.egypro.2017.12.132
   Melgar A, 2007, ENERG CONVERS MANAGE, V48, P59, DOI 10.1016/j.enconman.2006.05.004
   Nakod P., 2013, INT J CHEM PHYS SCI, V2, P2319
   Paul M. C., 2016, ENG TECHNOL, V4, P182
   Salem AM, 2018, ENERGY ENV SUSTAIN, P307, DOI 10.1007/978-981-10-7335-9_12
   Salem AM, 2018, BIOMASS BIOENERG, V109, P172, DOI 10.1016/j.biombioe.2017.12.030
   Sepe AM, 2016, ENERG CONVERS MANAGE, V129, P216, DOI 10.1016/j.enconman.2016.10.018
   Sharma AK, 2008, ENERG CONVERS MANAGE, V49, P832, DOI 10.1016/j.enconman.2007.06.025
   WANG Y, 1993, SOL ENERGY, V51, P19, DOI 10.1016/0038-092X(93)90037-O
   Xie J, 2012, BIORESOURCE TECHNOL, V121, P36, DOI 10.1016/j.biortech.2012.06.080
   Yetter R. A., 1988, S INT COMBUST, V21, P749
   Zainal ZA, 2001, ENERG CONVERS MANAGE, V42, P1499, DOI 10.1016/S0196-8904(00)00078-9
NR 25
TC 6
Z9 6
U1 0
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 413
EP 422
DI 10.1016/j.ces.2018.09.038
PG 10
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500037
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Magens, OM
   Hofmans, JFA
   Adriaenssens, Y
   Wilson, DI
AF Magens, Ole M.
   Hofmans, Jurgen F. A.
   Adriaenssens, Yves
   Wilson, D. Ian
TI Comparison of fouling of raw milk and whey protein solution on stainless
   steel and fluorocarbon coated surfaces: Effects on fouling performance,
   deposit structure and composition
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Milk fouling; Coating; Fluoropolymer; Pasteurisation;
   Beta-lactoglobulin; Calcium phosphate
ID HEAT-EXCHANGE APPARATUS; BETA-LACTOGLOBULIN; TEMPERATURE; STABILITY
AB Fouling from raw milk and from whey protein solutions mimicking the protein content of milk have been performed at two length scales, using a microfluidic heat transfer cell and a bench-scale device with hydraulic diameters 1.0 mm and 16.1 mm, respectively. The microfluidic cell allows raw milk to be studied in once-through mode and was used to identify polymer coated surfaces to test against stainless steel. Several of the fluorocarbon coated surfaces reduced the mass deposition but the pressure drop and thermal resistance did not match these directly, indicating that the nature and structure of the deposit is affected by the surface. A fluorinated ethylene propylene coating was identified as a promising candidate for large scale tests. At the interface with apolar surfaces, raw milk fouling layers were high in protein whereas a strongly attached mineral-rich layer was present at the interface with steel. The attraction of denatured protein towards apolar surfaces and the formation of a calcium phosphate layer on steel at later stages of fouling are explained with arguments based on the interfacial free energy of these materials in water. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Magens, Ole M.; Wilson, D. Ian] Dept Chem Engn & Biotechnol, Philippa Fawcett Dr, Cambridge CB3 0AS, England.
   [Hofmans, Jurgen F. A.; Adriaenssens, Yves] Chemours Belgium BVBA, A Spinoystr 6A, B-2800 Mechelen, Belgium.
RP Wilson, DI (reprint author), Dept Chem Engn & Biotechnol, Philippa Fawcett Dr, Cambridge CB3 0AS, England.
EM diw11@cam.ac.uk
OI Wilson, D Ian/0000-0003-3950-9165
CR AMJAD Z, 1998, CALCIUM PHOSPHATES B
   Bansal B, 2006, COMPR REV FOOD SCI F, V5, P27, DOI 10.1111/j.1541-4337.2006.tb00080.x
   Barish JA, 2013, FOOD BIOPROD PROCESS, V91, P352, DOI 10.1016/j.fbp.2013.01.003
   Barish JA, 2014, J FOOD ENG, V124, P143, DOI 10.1016/j.jfoodeng.2013.10.009
   Bergman T. L., 2011, FUNDAMENTALS HEAT MA
   Blanpain-Avet P, 2016, J DAIRY SCI, V99, P9611, DOI 10.3168/jds.2016-10957
   Boxler C, 2014, DAIRY SCI TECHNOL, V94, P17, DOI 10.1007/s13594-013-0142-5
   Davies TJ, 1997, FOOD BIOPROD PROCESS, V75, P106, DOI 10.1205/096030897531414
   Dupre M. A., 1869, THEORIE MECH CHALEUR
   FERNANDEZMARTIN F, 1972, J DAIRY RES, V39, P75, DOI 10.1017/S0022029900013868
   FOSTER CL, 1989, J DAIRY RES, V56, P201, DOI 10.1017/S002202990002642X
   FOSTER CL, 1990, J DAIRY RES, V57, P339, DOI 10.1017/S0022029900026996
   FOWKES FM, 1963, J PHYS CHEM-US, V67, P2538, DOI 10.1021/j100806a008
   da Cruz LG, 2015, FOOD BIOPROD PROCESS, V93, P343, DOI 10.1016/j.fbp.2014.05.003
   Gunning PA, 2004, FOOD HYDROCOLLOID, V18, P509, DOI 10.1016/j.foodhyd.2003.08.008
   Hagsten C, 2016, FOOD STRUCT-NETH, V7, P13, DOI 10.1016/j.foostr.2015.12.002
   Huang K, 2015, J FOOD ENG, V158, P22, DOI 10.1016/j.jfoodeng.2015.02.026
   Israelachvili JN, 2011, INTERMOLECULAR AND SURFACE FORCES, 3RD EDITION, P1
   Lefevre C, 1996, BIOCONJUGATE CHEM, V7, P482, DOI 10.1021/bc960034p
   LUEY JK, 1991, J COLLOID INTERF SCI, V143, P489, DOI 10.1016/0021-9797(91)90282-D
   Magens O. M., 2017, HEAT EXCH FOUL CLEAN, P140
   Merian T, 2012, J AGR FOOD CHEM, V60, P2943, DOI 10.1021/jf204741p
   Miriani M, 2014, PROTEINS, V82, P1272, DOI 10.1002/prot.24493
   O'Kennedy BT, 2006, J AGR FOOD CHEM, V54, P5637, DOI 10.1021/jf0607866
   Piepiorka-Stepuk J, 2016, CZECH J FOOD SCI, V34, P271, DOI 10.17221/466/2015-CJFS
   Rieke PC, 1997, J CRYST GROWTH, V182, P472, DOI 10.1016/S0022-0248(97)00357-6
   Rosmaninho R, 2007, EXP THERM FLUID SCI, V32, P375, DOI 10.1016/j.expthermflusci.2007.04.012
   Thomas D, 2000, CELL CALCIUM, V28, P213, DOI 10.1054/ceca.2000.0152
   Tuladhar TR, 2002, FOOD BIOPROD PROCESS, V80, P332, DOI 10.1205/096030802321154862
   van Oss CJ, 2003, J MOL RECOGNIT, V16, P177, DOI 10.1002/jmr.618
   VANOSS CJ, 1992, LANGMUIR, V8, P2877, DOI 10.1021/la00048a006
   VANOSS CJ, 1987, ADV COLLOID INTERFAC, V28, P35, DOI 10.1016/0001-8686(87)80008-8
   Visser J, 1997, EXP THERM FLUID SCI, V14, P407, DOI 10.1016/S0894-1777(96)00142-2
   Walstra P., 2005, DAIRY SCI TECHNOL, V2, DOI [10.1021/op0101005, DOI 10.1021/OP0101005]
   Wijayanti HB, 2014, COMPR REV FOOD SCI F, V13, P1235, DOI 10.1111/1541-4337.12105
   Wu WJ, 1997, J BIOMED MATER RES, V35, P93, DOI 10.1002/(SICI)1097-4636(199704)35:1<93::AID-JBM9>3.0.CO;2-H
   Wu WJ, 1998, PURE APPL CHEM, V70, P1867, DOI 10.1351/pac199870101867
NR 37
TC 0
Z9 0
U1 3
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 423
EP 432
DI 10.1016/j.ces.2018.09.039
PG 10
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500038
DA 2020-05-12
ER

PT J
AU Shang, XL
   Luo, ZY
   Bai, BF
AF Shang, Xinglong
   Luo, Zhengyuan
   Bai, Bofeng
TI Droplets trapped by a wetting surface with chemical defects in shear
   flows
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Wetting surface; Chemical defects; Droplet trapped; Triple-phase contact
   line; Shear flows; Front-tracking method
ID FRONT-TRACKING METHOD; PATTERNED SURFACES; WETTABLE GRADIENT;
   MANIPULATION; MOTION; DROPS; DYNAMICS; MODEL; WATER
AB With the development of techniques to control the wettability on solid surface, directional control of droplets on such surfaces exhibit promising applications in the design of microfluidic devices. The sliding droplet can even be trapped by the heterogeneous surface that is equipped with wetting defects. However, its detailed mechanism and general physical conditions required for trapping droplets displaced by another fluid have never been fully described. In this work, we present numerical simulations based on front-tracking method to investigate the trapping of droplets on a hydrophilic surface with a stripe-like chemical wetting defect displaced by another immiscible liquid. Three kind of equilibrium status are observed for trapped droplets based on the analysis on the dynamic of the contact line. We determine the transition conditions between trapping and escaping by mapping droplet dynamics as a function of nondimensional defect strength and capillary number. To reveal the underlying mechanism of droplets escaping, the deformation and motion including the dynamics of triple-phase contact line are explored as the droplet passing through the defect. It is found that the unbalanced Young's force acting the contact line could be a driving or resistance force, which is the key factor to dominate the critical condition of the trapping-to-escaping transition. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Shang, Xinglong; Luo, Zhengyuan; Bai, Bofeng] Xi An Jiao Tong Univ, State Key Lab Multiphase Flow Power Engn, Xian 710049, Shaanxi, Peoples R China.
RP Bai, BF (reprint author), Xi An Jiao Tong Univ, State Key Lab Multiphase Flow Power Engn, Xian 710049, Shaanxi, Peoples R China.
EM bfbai@mail.xjtu.edu.cn
RI bai, bofeng/C-7663-2011
FU BRICS STI Framework Programme of the Ministry of Science and Technology
   of China [2017YFE0100600]; National Science Fund for Distinguished Young
   Scholars of ChinaNational Natural Science Foundation of ChinaNational
   Science Fund for Distinguished Young Scholars [51425603]
FX Bofeng Bai acknowledges financial support from the BRICS STI Framework
   Programme of the Ministry of Science and Technology of China (Grant no.
   2017YFE0100600) and the National Science Fund for Distinguished Young
   Scholars of China (Grant no. 51425603).
CR Anantharaju N, 2009, J COLLOID INTERF SCI, V337, P176, DOI 10.1016/j.jcis.2009.04.095
   Beltrame P, 2009, EPL-EUROPHYS LETT, V86, DOI 10.1209/0295-5075/86/24006
   De Coninck J, 2017, PHYS REV E, V96, DOI 10.1103/PhysRevE.96.042804
   Feng S, 2015, SCI REP-UK, V5, DOI 10.1038/srep10067
   FERMIGIER M, 1991, J COLLOID INTERF SCI, V146, P226, DOI 10.1016/0021-9797(91)90020-9
   Gao ZH, 2013, GRAPH MODELS, V75, P23, DOI 10.1016/j.gmod.2012.10.007
   Hou YP, 2016, CHEM MATER, V28, P3625, DOI 10.1021/acs.chemmater.6b01544
   Huang DM, 2008, PHYS REV LETT, V101, DOI 10.1103/PhysRevLett.101.226101
   Kajiya T, 2016, SCI REP-UK, V6, DOI 10.1038/srep23687
   Kusumaatmaja H, 2007, LANGMUIR, V23, P956, DOI 10.1021/la062082w
   Kusumaatmaja H, 2006, EUROPHYS LETT, V73, P740, DOI 10.1209/epl/i2005-10452-0
   Li Q, 2016, LANGMUIR, V32, P9389, DOI 10.1021/acs.langmuir.6b01490
   Li Y, 2017, J PHYS CHEM B, V121, P6766, DOI 10.1021/acs.jpcb.7b05062
   Li Y, 2013, COMPUT METHOD APPL M, V257, P36, DOI 10.1016/j.cma.2013.01.009
   Lin JL, 2006, LANGMUIR, V22, P484, DOI 10.1021/la052011h
   Luo ZY, 2018, J FLUID MECH, V840, P656, DOI 10.1017/jfm.2018.88
   Luo ZY, 2016, PHYS FLUIDS, V28, DOI 10.1063/1.4965251
   Luo ZY, 2015, J FLUID MECH, V775, P77, DOI 10.1017/jfm.2015.286
   Luo ZY, 2013, SOFT MATTER, V9, P9651, DOI 10.1039/c3sm51823j
   Mettu S, 2008, LANGMUIR, V24, P10833, DOI 10.1021/la801380s
   Ni MJ, 2003, NUMER HEAT TR B-FUND, V44, P533, DOI 10.1080/10407790390231789
   Ouenzerfi S, 2016, LANGMUIR, V32, P2378, DOI 10.1021/acs.langmuir.5b04539
   Park JK, 2017, LAB CHIP, V17, P1793, DOI 10.1039/c6lc01354f
   Peskin CS, 2002, ACT NUMERIC, V11, P479, DOI 10.1017/S0962492902000077
   Pit AM, 2015, BIOMICROFLUIDICS, V9, DOI 10.1063/1.4928452
   QIAN T, 2003, COMMUN MATH SCI, V1, P333, DOI DOI 10.4310/CMS.2003.v1.n2.a7
   Qian TZ, 2003, PHYS REV E, V68, DOI 10.1103/PhysRevE.68.016306
   Semprebon C, 2016, SOFT MATTER, V12, P8268, DOI 10.1039/c6sm01077f
   Semprebon C, 2014, SOFT MATTER, V10, P3325, DOI 10.1039/c3sm51959g
   Shang XL, 2018, COMPUT FLUIDS, V172, P181, DOI 10.1016/j.compfluid.2018.06.021
   Song D, 2015, PHYS CHEM CHEM PHYS, V17, P13800, DOI 10.1039/c5cp01530h
   Sugiyama K, 2008, J ENG MATH, V62, P35, DOI 10.1007/s10665-007-9185-z
   't Mannetje D, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4559
   't Mannetje D, 2013, LANGMUIR, V29, P9944, DOI 10.1021/la4015724
   Thiele U, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.204501
   Tryggvason G, 2001, J COMPUT PHYS, V169, P708, DOI 10.1006/jcph.2000.6726
   Xue YH, 2010, ADV MATER, V22, P4814, DOI 10.1002/adma.201001898
   Yamamoto Y, 2016, PHYS FLUIDS, V28, DOI 10.1063/1.4961490
   Yamamoto Y, 2013, INT J MULTIPHAS FLOW, V51, P22, DOI 10.1016/j.ijmultiphaseflow.2012.12.002
   Yanashima R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045893
   Yang JT, 2008, LANGMUIR, V24, P9889, DOI 10.1021/la8004695
   Yu X, 2006, LANGMUIR, V22, P4483, DOI 10.1021/la053133c
   Zhang GY, 2014, ACS APPL MATER INTER, V6, P1729, DOI 10.1021/am404681y
   Zou L, 2018, COLLOID SURFACE A, V537, P139, DOI 10.1016/j.colsurfa.2017.09.052
NR 44
TC 2
Z9 2
U1 10
U2 33
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 433
EP 441
DI 10.1016/j.ces.2018.09.041
PG 9
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500039
DA 2020-05-12
ER

PT J
AU Carneiro, J
   Campos, JBLM
   Miranda, JM
AF Carneiro, J.
   Campos, J. B. L. M.
   Miranda, J. M.
TI High viscosity polymeric fluid droplet formation in a flow focusing
   microfluidic device - Experimental and numerical study
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Viscous fluids; Flow-focusing; Droplet microfluidics; Regime map;
   Surfactant
ID MASS-TRANSFER; BREAKUP DYNAMICS; TAYLOR BUBBLE; LEVEL SET; SIMULATION;
   GENERATION; VOLUME
AB Experimental and numerical studies concerning the formation of droplets of a viscous fluid in a less viscous immiscible one (viscosity ratio of 533), containing surfactant, were conducted in a flow-focusing square microchannel. Numerical and experimental data from three flow regimes were analysed: threading, dripping and jetting. The results were analysed qualitatively and quantitatively and also compared to correlations from the literature. The droplet sizes and the thread lengths obtained experimentally deviate from the ones obtained for surfactant free systems reported in the literature. The roles of the surfactant mass transport limitations and of the interface rheology are analysed and discussed. The numerical code, based on a coupled level-set and volume of fluid method, successfully predicts droplets sizes in surfactant free systems in almost all the conditions studied. The limits of the numerical code to accurately predict the size of the droplets, particularly in the monodispersed dripping regime, were established. If surfactant is present, the numerical code fails to predict the droplet size under certain flow conditions. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Carneiro, J.; Campos, J. B. L. M.; Miranda, J. M.] Univ Porto, Fac Engn, Transport Phenomena Res Ctr, Chem Engn Dept,CEFT, P-4050465 Porto, Portugal.
RP Miranda, JM (reprint author), Univ Porto, Fac Engn, Transport Phenomena Res Ctr, Chem Engn Dept,CEFT, P-4050465 Porto, Portugal.
EM jmiranda@fe.up.pt
OI Carneiro, Joao/0000-0002-1598-4554; Miranda, Joao/0000-0002-1830-0525;
   Campos, Joao/0000-0002-8113-7142
FU FEDER funds through COMPETE2020-Operational Programme for
   Competitiveness Factors (POCI); National Funds (PIDDAC) through FCT
   (Fundacao para a Ciencia e a Tecnologia) [PEst-OE/EME/UI0532, POCI-01-0
   145-FEDER-016861-PTDC/QEQ-FTT/4287/2014]
FX This work was funded by FEDER funds through COMPETE2020-Operational
   Programme for Competitiveness Factors (POCI) and National Funds (PIDDAC)
   through FCT (Fundacao para a Ciencia e a Tecnologia) under projects
   PEst-OE/EME/UI0532 and POCI-01-0
   145-FEDER-016861-PTDC/QEQ-FTT/4287/2014. J. Carneiro wants to thank
   Franscisco Pimenta for the MATLAB (R) custom code.
CR Abadie T, 2012, MICROFLUID NANOFLUID, V12, P355, DOI 10.1007/s10404-011-0880-8
   Abate AR, 2009, PHYS REV E, V80, DOI 10.1103/PhysRevE.80.026310
   Anna SL, 2006, PHYS FLUIDS, V18, DOI 10.1063/1.2397023
   Anna SL, 2016, ANNU REV FLUID MECH, V48, P285, DOI 10.1146/annurev-fluid-122414-034425
   Anna SL, 2003, APPL PHYS LETT, V82, P364, DOI 10.1063/1.1537519
   Bardin D, 2014, LAB CHIP, V14, P3978, DOI 10.1039/c4lc00424h
   Bardin D, 2011, LAB CHIP, V11, P3990, DOI 10.1039/c1lc20615j
   Baroud CN, 2010, LAB CHIP, V10, P2032, DOI 10.1039/c001191f
   Bo WRG, 2011, SIAM J SCI COMPUT, V33, P1505, DOI 10.1137/10079135X
   BRACKBILL JU, 1992, J COMPUT PHYS, V100, P335, DOI 10.1016/0021-9991(92)90240-Y
   Carneiro J, 2016, J MICROMECH MICROENG, V26, DOI 10.1088/0960-1317/26/10/105013
   Carneiro J., 2015, MICRONANOSYST, V7, P154, DOI [10.2174/1876402908666160106000558, DOI 10.2174/1876402908666160106000558]
   Champion JA, 2007, J CONTROL RELEASE, V121, P3, DOI 10.1016/j.jconrel.2007.03.022
   Chen YP, 2013, PHYS REV E, V87, DOI 10.1103/PhysRevE.87.013002
   Christopher GF, 2007, J PHYS D APPL PHYS, V40, pR319, DOI 10.1088/0022-3727/40/19/R01
   Cristini V, 2004, LAB CHIP, V4, P257, DOI 10.1039/b403226h
   Cubaud T, 2008, PHYS FLUIDS, V20, DOI 10.1063/1.2911716
   Day P, 2012, INTEGR ANAL SYST, P1, DOI 10.1007/978-1-4614-3265-4
   DEGENNES PG, 1985, REV MOD PHYS, V57, P827, DOI 10.1103/RevModPhys.57.827
   Dendukuri D, 2009, ADV MATER, V21, P4071, DOI 10.1002/adma.200803386
   Di Benedetto F, 2013, SOFT MATTER, V9, P2206, DOI 10.1039/c2sm27327f
   Du W, 2016, AICHE J, V62, P325, DOI 10.1002/aic.15043
   Fletcher DF, 2017, CHEM ENG SCI, V167, P334, DOI 10.1016/j.ces.2016.08.034
   Fu TT, 2012, CHEM ENG SCI, V84, P207, DOI 10.1016/j.ces.2012.08.039
   Garstecki P, 2006, LAB CHIP, V6, P693
   Glawdel T, 2012, PHYS REV E, V85, DOI 10.1103/PhysRevE.85.016322
   Herrada MA, 2010, J FLUID MECH, V649, P523, DOI 10.1017/S0022112010000443
   HIRT CW, 1981, J COMPUT PHYS, V39, P201, DOI 10.1016/0021-9991(81)90145-5
   Hosokawa S, 2017, INT J MULTIPHAS FLOW, V97, P157, DOI 10.1016/j.ijmultiphaseflow.2017.08.007
   HUERRE P, 1990, ANNU REV FLUID MECH, V22, P473, DOI 10.1146/annurev.fl.22.010190.002353
   Jensen MJ, 2006, PHYS FLUIDS, V18, DOI 10.1063/1.2214461
   Jia HW, 2016, CHEM ENG J, V285, P252, DOI 10.1016/j.cej.2015.09.102
   Jiang KQ, 2012, SOFT MATTER, V8, P923, DOI 10.1039/c2sm06685h
   Kamat PM, 2018, PHYS REV FLUIDS, V3, DOI 10.1103/PhysRevFluids.3.043602
   Kragel J, 2010, CURR OPIN COLLOID IN, V15, P246, DOI 10.1016/j.cocis.2010.02.001
   LAFAURIE B, 1994, J COMPUT PHYS, V113, P134, DOI 10.1006/jcph.1994.1123
   Lagus TP, 2013, J PHYS D APPL PHYS, V46, DOI 10.1088/0022-3727/46/11/114005
   Lee W, 2009, PHYS FLUIDS, V21, DOI 10.1063/1.3081407
   Li YH, 2015, SOFT MATTER, V11, P3884, DOI 10.1039/c5sm00252d
   Liu H., 2011, PHYS FLUIDS, V23
   Ma M, 2016, INT J MULTIPHAS FLOW, V85, P336, DOI 10.1016/j.ijmultiphaseflow.2016.06.021
   Ma M, 2015, PHYS FLUIDS, V27, DOI 10.1063/1.4930004
   Martin JD, 2011, ADV MATER, V23, P426, DOI 10.1002/adma.201001758
   Mata A, 2005, BIOMED MICRODEVICES, V7, P281, DOI 10.1007/s10544-005-6070-2
   Munoz-Sanchez BN, 2016, BIOMICROFLUIDICS, V10, DOI 10.1063/1.4943007
   Nie ZH, 2008, MICROFLUID NANOFLUID, V5, P585, DOI 10.1007/s10404-008-0271-y
   Nunes JK, 2013, J PHYS D APPL PHYS, V46, DOI 10.1088/0022-3727/46/11/114002
   Raimondi ND, 2014, CHEM ENG SCI, V105, P169, DOI 10.1016/j.ces.2013.11.009
   RAYLEIGH L, 1879, P R SOC LONDON, V29, P71, DOI DOI 10.1098/RSPL.1879.0015
   Seemann R, 2012, REP PROG PHYS, V75, DOI 10.1088/0034-4885/75/1/016601
   Seo M, 2005, LANGMUIR, V21, P11614, DOI 10.1021/la050519e
   Shi Y, 2014, COMPUT FLUIDS, V90, P155, DOI 10.1016/j.compfluid.2013.11.025
   SUSSMAN M, 1994, J COMPUT PHYS, V114, P146, DOI 10.1006/jcph.1994.1155
   Sussman M, 2000, J COMPUT PHYS, V162, P301, DOI 10.1006/jcph.2000.6537
   Tan YC, 2006, SENSOR ACTUAT B-CHEM, V114, P350, DOI 10.1016/j.snb.2005.06.008
   Teh SY, 2008, LAB CHIP, V8, P198, DOI 10.1039/b715524g
   Tomotika S., 1935, Proceedings of the Royal Society of London, Series A (Mathematical and Physical Sciences), V150, P322, DOI 10.1098/rspa.1935.0104
   Tryggvason G, 2016, NUCL SCI ENG, V184, P312, DOI 10.13182/NSE16-10
   Utada AS, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.094502
   van Baten JM, 2004, CHEM ENG SCI, V59, P2535, DOI 10.1016/j.ces.2004.03.010
   van Loo S, 2016, MICROFLUID NANOFLUID, V20, DOI 10.1007/s10404-016-1807-1
   Vu TV, 2013, INT J MULTIPHAS FLOW, V49, P58, DOI 10.1016/j.ijmultiphaseflow.2012.10.004
   Wan JD, 2012, POLYMERS-BASEL, V4, P1084, DOI 10.3390/polym4021084
   Ward T, 2005, ELECTROPHORESIS, V26, P3716, DOI 10.1002/elps.200500173
   Wu P, 2015, CHINESE J CHEM ENG, V23, P7, DOI 10.1016/j.cjche.2014.09.043
   Xu JH, 2012, LANGMUIR, V28, P9250, DOI 10.1021/la301363d
   Xu QB, 2009, SMALL, V5, P1575, DOI 10.1002/smll.200801855
   Yang LX, 2016, CHEM ENG SCI, V143, P364, DOI 10.1016/j.ces.2016.01.013
   Zhu PA, 2017, LAB CHIP, V17, P34, DOI 10.1039/c6lc01018k
NR 69
TC 7
Z9 7
U1 15
U2 56
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 442
EP 454
DI 10.1016/j.ces.2018.09.042
PG 13
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500040
DA 2020-05-12
ER

PT J
AU Yasuda, K
   Matsushima, H
   Asakura, Y
AF Yasuda, Keiji
   Matsushima, Hodaka
   Asakura, Yoshiyuki
TI Generation and reduction of bulk nanobubbles by ultrasonic irradiation
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Bulk nanobubbles; Ultrasound; Frequency; Ultrapure water; Number
   concentration; Ultrafine bubbles
ID ACOUSTIC CAVITATION SERIES; CONTRAST AGENTS; WATER; DELIVERY; BUBBLES
AB To develop a compact generator of bulk nanobubbles (ultrafine bubbles), ultrasound was irradiated to ultrapure water. Effects of ultrasonic power and frequency on nanobubble concentration and diameter were investigated. Nanobubbles with a diameter of 90-100 nm were generated. Number concentration of nanobubbles increased with time and approached asymptotically to an equilibrium value which was about 1.5 x 10(9) mL(-1). Nanobubble concentration increased with increasing ultrasonic power and decreasing frequency. For comparison, ultrasound was also irradiated to high concentration nanobubble water prepared by pressurized dissolution method. Reduction of nanobubbles was measured and nanobubble concentration decreased to the equilibrium value. Nanobubble concentration decreased with increasing ultrasonic power and frequency.
   Generation and reduction of nanobubbles by ultrasound was modeled to analyze experimental data. The generation rate coefficient of nanobubbles increased with decreasing frequency because cavitation collapse became stronger. The reduction rate constant of nanobubbles at 488 kHz and 1 MHz in high concentration nanobubble water became much higher than those in ultrapure water due to aggregation and floatation of nanobubbles. The equilibrium number concentration increased with decreasing frequency. The results calculated by our model were in good agreement with the experimental data. The nanobubble generator using ultrasound is compact, simple in operation and produce nanobubbles in a short time. This method is contamination-free because the liquid pump is unnecessary. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Yasuda, Keiji; Matsushima, Hodaka] Nagoya Univ, Dept Chem Syst Engn, Grad Sch Engn, Chikusa Ku, Furo Cho, Nagoya, Aichi 4648603, Japan.
   [Asakura, Yoshiyuki] Honda Elect Co Ltd, 20 Oyamazuka,Oiwa Cho, Toyohashi, Aichi 4413193, Japan.
RP Yasuda, K (reprint author), Nagoya Univ, Dept Chem Syst Engn, Grad Sch Engn, Chikusa Ku, Furo Cho, Nagoya, Aichi 4648603, Japan.
EM yasuda.keiji@material.nagoya-u.ac.jp
FU Japan Society for the Promotion of ScienceMinistry of Education,
   Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for
   the Promotion of Science [16H04560]
FX This work was supported by Grant-in-Aid for Scientific Research (B)
   Number 16H04560 from Japan Society for the Promotion of Science.
CR Agarwal A, 2011, CHEMOSPHERE, V84, P1175, DOI 10.1016/j.chemosphere.2011.05.054
   Alheshibri M, 2016, LANGMUIR, V32, P11086, DOI 10.1021/acs.langmuir.6b02489
   APFEL RE, 1984, ULTRASONICS, V22, P167, DOI 10.1016/0041-624X(84)90032-5
   Cai WB, 2015, SCI REP-UK, V5, DOI 10.1038/srep13725
   Chang FM, 2008, APPL PHYS LETT, V92, DOI 10.1063/1.2953703
   Cosgrove D, 2006, EUR J RADIOL, V60, P324, DOI 10.1016/j.ejrad.2006.06.022
   Devaud M, 2008, EUR J PHYS, V29, P1263, DOI 10.1088/0143-0807/29/6/014
   Ebina K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065339
   Grieser F, 2015, SONOCHEMISTRY AND THE ACOUSTIC BUBBLE, P251, DOI 10.1016/B978-0-12-801530-8.00011-6
   Jing H, 2016, COLLOID SURFACE B, V146, P387, DOI 10.1016/j.colsurfb.2016.06.037
   Kobayashi D, 2011, ULTRASON SONOCHEM, V18, P1193, DOI 10.1016/j.ultsonch.2010.11.005
   Kukizaki M, 2006, J MEMBRANE SCI, V281, P386, DOI 10.1016/j.memsci.2006.04.007
   Lee J, 2011, ULTRASON SONOCHEM, V18, P92, DOI 10.1016/j.ultsonch.2010.03.004
   LEIGHTON TG, 1994, ACOUSTIC BUBBLE
   Liu S, 2016, LANGMUIR, V32, P11295, DOI 10.1021/acs.langmuir.6b01621
   Liu S, 2013, CHEM ENG SCI, V93, P250, DOI 10.1016/j.ces.2013.02.004
   Lujan-Facundo MJ, 2016, ULTRASON SONOCHEM, V33, P18, DOI 10.1016/j.ultsonch.2016.04.018
   Maeda S, 2014, PROC SPIE, V9232, DOI 10.1117/12.2064810
   Mason T., 1988, THEORY APPL USES ULT
   Matsuno H, 2014, LANGMUIR, V30, P15238, DOI 10.1021/la5035883
   Miastkowska MA, 2017, J SURFACTANTS DETERG, V20, P233, DOI 10.1007/s11743-016-1887-7
   Minamikawa K, 2015, ENVIRON RES LETT, V10, DOI 10.1088/1748-9326/10/8/084012
   Minnaert M, 1933, PHILOS MAG, V16, P235
   Mogami K., 2013, Japanese patent, Patent No. [2013-086161, 2013086161]
   NEPPIRAS EA, 1984, ULTRASONICS, V22, P25, DOI 10.1016/0041-624X(84)90057-X
   Noguchi T, 2017, OSTEOPOROSIS INT, V28, P1063, DOI 10.1007/s00198-016-3830-1
   Oh SH, 2017, LANGMUIR, V33, P3818, DOI 10.1021/acs.langmuir.7b00510
   Oh SH, 2013, INT J HYDROGEN ENERG, V38, P14849, DOI 10.1016/j.ijhydene.2013.09.063
   Safonov VL, 2013, COLLOID SURFACE A, V436, P333, DOI 10.1016/j.colsurfa.2013.06.043
   Schenk HJ, 2015, TRENDS PLANT SCI, V20, P199, DOI 10.1016/j.tplants.2015.01.008
   SUSLICK KS, 1989, SCI AM, V260, P80, DOI 10.1038/scientificamerican0289-80
   Suzuki R, 2016, CANCER SCI, V107, P217, DOI 10.1111/cas.12867
   Nguyen TT, 2017, ULTRASON SONOCHEM, V39, P301, DOI 10.1016/j.ultsonch.2017.04.037
   Temesgen T, 2017, ADV COLLOID INTERFAC, V246, P40, DOI 10.1016/j.cis.2017.06.011
   Tran KVB, 2014, ULTRASON SONOCHEM, V21, P716, DOI 10.1016/j.ultsonch.2013.08.018
   Tsuji H, 2013, United states patent, Patent No. [8523151 B2, 8523151]
   Tuziuti T, 2018, ULTRASON SONOCHEM, V43, P272, DOI 10.1016/j.ultsonch.2018.01.015
   Ushida A, 2012, J SURFACTANTS DETERG, V15, P695, DOI 10.1007/s11743-012-1348-x
   VanOsdol J, 2017, J CONTROL RELEASE, V247, P55, DOI 10.1016/j.jconrel.2016.12.033
   Wang JP, 2017, ONCOTARGET, V8, P78153, DOI 10.18632/oncotarget.18155
   Wang QX, 2014, PHYS FLUIDS, V26, DOI 10.1063/1.4866772
   Watanabe H, 2014, J CHEM PHYS, V141, DOI 10.1063/1.4903811
   Wu ZH, 2008, J COLLOID INTERF SCI, V328, P10, DOI 10.1016/j.jcis.2008.08.064
   Yang H, 2015, J BIOMED NANOTECHNOL, V11, P2124, DOI 10.1166/jbn.2015.2168
   Yasui K, 2016, LANGMUIR, V32, P11101, DOI 10.1021/acs.langmuir.5b04703
   Zhu J, 2016, LANGMUIR, V32, P11203, DOI 10.1021/acs.langmuir.6b01004
NR 46
TC 9
Z9 9
U1 14
U2 53
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 455
EP 461
DI 10.1016/j.ces.2018.09.044
PG 7
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500041
DA 2020-05-12
ER

PT J
AU Xu, HJ
   Xing, ZB
   Wang, FQ
   Cheng, ZM
AF Xu, H. J.
   Xing, Z. B.
   Wang, F. Q.
   Cheng, Z. M.
TI Review on heat conduction, heat convection, thermal radiation and phase
   change heat transfer of nanofluids in porous media: Fundamentals and
   applications
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Review
DE Nanofluid; Porous media; Heat transfer; Convection; Thermal radiation;
   Phase change
ID NON-NEWTONIAN FLUIDS; NATURAL-CONVECTION; OPTICAL-PROPERTIES;
   MIXED-CONVECTION; PERFORMANCE ANALYSIS; ENTROPY GENERATION;
   FORCED-CONVECTION; SOLAR RECEIVER; MELTING/FREEZING CHARACTERISTICS;
   NONEQUILIBRIUM CONDITIONS
AB Increasing the heat transfer rate of heat transfer equipment is an ever-lasting topic in thermal engineering. Due to the advantages of light weight, high specific surface, high thermal conductivity, metal foam is a good extending surface for heat transfer enhancement. Nanofluid has a higher thermal conductivity than the traditional base fluid, so it can be used as an efficient heat transfer medium. This paper focuses on various flow and heat transfer modes of nanofluid, metal foam and the combination of the two, with the physical properties of nanofluid and metal foam summarized. The characteristics of flow and heat transfer are introduced. The motivation of this review paper is to arouse the researchers to pay attention to the basic transport understandings for the heat transfer enhancement of nanofluids in porous media. The knowledge reviewed in this paper is useful for improving the performance of compact heat exchangers, and heat sinks for cooling electronics with porous media and nanofluids. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Xu, H. J.] Shanghai Jiao Tong Univ, China UK Low Carbon Coll, Shanghai 200240, Peoples R China.
   [Wang, F. Q.; Cheng, Z. M.] Harbin Inst Technol Weihai, Sch New Energy, Weihai 264209, Peoples R China.
   [Xing, Z. B.] Zhongtong Bus Holding Co Ltd, Liaocheng 252000, Peoples R China.
RP Wang, FQ (reprint author), Harbin Inst Technol Weihai, Sch New Energy, Weihai 264209, Peoples R China.
EM wangfuqiang@hitwh.edu.cn
OI Fuqiang, Wang/0000-0002-5500-9649
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51876118, 51606239]; Initiative Program of New
   Youth Teachers in SJTU [WF220428001]; Fundamental Research Funds for the
   Central UniversitiesFundamental Research Funds for the Central
   Universities; NSRIF [201706]
FX This work is financially supported by National Natural Science
   Foundation of China (51876118, 51606239), Initiative Program of New
   Youth Teachers in SJTU (WF220428001) and Fundamental Research Funds for
   the Central Universities (HIT. NSRIF. 201706).
CR Al-Nimr MA, 2014, ENERGY, V68, P318, DOI 10.1016/j.energy.2014.03.023
   Albojamal A, 2017, INT J HEAT MASS TRAN, V114, P225, DOI 10.1016/j.ijheatmasstransfer.2017.06.030
   Amhalhel G., 1997, B INSTYTUTU TECHNIKI, V85
   An W, 2017, ENERG CONVERS MANAGE, V151, P23, DOI 10.1016/j.enconman.2017.08.080
   An W, 2016, APPL ENERG, V184, P197, DOI 10.1016/j.apenergy.2016.10.004
   Arisetty S, 2007, J POWER SOURCES, V165, P49, DOI 10.1016/j.jpowsour.2006.12.008
   Bai FW, 2010, INT J THERM SCI, V49, P2400, DOI 10.1016/j.ijthermalsci.2010.08.010
   Bang IC, 2005, INT J HEAT MASS TRAN, V48, P2407, DOI 10.1016/j.ijheatmasstransfer.2004.12.047
   Barber J, 2011, NANOSCALE RES LETT, V6, DOI 10.1186/1556-276X-6-280
   Beg OA, 2015, J MECH MED BIOL, V15, DOI 10.1142/S0219519415500712
   Bejan A, 1996, J APPL PHYS, V79, P1191, DOI 10.1063/1.362674
   Bhadauria BS, 2011, TRANSPORT POROUS MED, V88, P107, DOI 10.1007/s11242-011-9727-8
   Bhattacharya A, 2002, INT J HEAT MASS TRAN, V45, P1017, DOI 10.1016/S0017-9310(01)00220-4
   Bianco V, 2009, APPL THERM ENG, V29, P3632, DOI 10.1016/j.applthermaleng.2009.06.019
   Boomsma K, 2003, MECH MATER, V35, P1161, DOI 10.1016/j.mechmat.2003.02.001
   Boomsma K, 2001, INT J HEAT MASS TRAN, V44, P827, DOI 10.1016/S0017-9310(00)00123-X
   BRINKMAN HC, 1952, J CHEM PHYS, V20, P571, DOI 10.1063/1.1700493
   Buongiorno J, 2006, J HEAT TRANS-T ASME, V128, P240, DOI 10.1115/1.2150834
   Buongiorno J, 2009, J APPL PHYS, V106, DOI 10.1063/1.3245330
   Butt AS, 2016, ENERGY, V99, P237, DOI 10.1016/j.energy.2016.01.067
   Cai JC, 2017, INT J HEAT MASS TRAN, V105, P623, DOI 10.1016/j.ijheatmasstransfer.2016.10.011
   Calmidi VV, 1999, J HEAT TRANS-T ASME, V121, P466, DOI 10.1115/1.2826001
   Calmidi VV, 2000, J HEAT TRANS-T ASME, V122, P557, DOI 10.1115/1.1287793
   Calmidi VV, 1998, TRANSPORT PHENOMENA
   Chai JL, 2015, INT J THERM SCI, V91, P96, DOI 10.1016/j.ijthermalsci.2014.12.024
   Chala GT, 2018, J NON-NEWTON FLUID, V251, P69, DOI 10.1016/j.jnnfm.2017.11.008
   Chamkha AJ, 2014, INT J NUMER METHOD H, V24, P1471, DOI 10.1108/HFF-07-2012-0169
   Chen HS, 2007, NEW J PHYS, V9, DOI 10.1088/1367-2630/9/10/367
   CHEN HT, 1988, J HEAT TRANS-T ASME, V110, P257, DOI 10.1115/1.3250462
   CHEN HT, 1988, INT COMMUN HEAT MASS, V15, P605, DOI 10.1016/0735-1933(88)90051-6
   Chen X, 2018, SOL ENERGY, V162, P187, DOI 10.1016/j.solener.2018.01.032
   Chen X, 2018, ENERG CONVERS MANAGE, V158, P489, DOI 10.1016/j.enconman.2017.12.066
   Chen X, 2015, ENERG CONVERS MANAGE, V97, P282, DOI 10.1016/j.enconman.2015.03.066
   CHENG P, 1966, AIAA J, V4, P238, DOI 10.2514/3.3424
   Cheng Q. F., 2013, EXPT RES HEAT TRANSF
   Cheng Q, 2016, INT J THERM SCI, V105, P36, DOI 10.1016/j.ijthermalsci.2016.02.010
   Cheng ZM, 2017, INT J HYDROGEN ENERG, V42, P26626, DOI 10.1016/j.ijhydene.2017.09.044
   Choi S.U.S., 1995, ASME FLUIDS ENG DIV, V231, P99, DOI DOI 10.1063/1.1341218
   Chon CH, 2005, APPL PHYS LETT, V87, DOI 10.1063/1.2093936
   Corcione M., 2011, ENERGY CONVERS MANAG, V52
   Corcione M, 2011, INT J HEAT FLUID FL, V32, P65, DOI 10.1016/j.ijheatfluidflow.2010.08.004
   Das SK, 2003, J HEAT TRANS-T ASME, V125, P567, DOI 10.1115/1.1571080
   Delgado JMPQ, 2006, HEAT MASS TRANSFER, V42, P279, DOI 10.1007/s00231-005-0019-0
   DUPLESSIS P, 1994, CHEM ENG SCI, V49, P3545, DOI 10.1016/0009-2509(94)00170-7
   Eastman JA, 2001, APPL PHYS LETT, V78, P718, DOI 10.1063/1.1341218
   Ebrahimnia-Bajestan E, 2016, INT J HEAT MASS TRAN, V92, P1041, DOI 10.1016/j.ijheatmasstransfer.2015.08.107
   Einstein A, 1906, ANN PHYS-BERLIN, V19, P289, DOI 10.1002/andp.19063240204
   ERGUN S, 1952, CHEM ENG PROG, V48, P89
   Esfe M. H., 2016, INT J HEAT MASS TRAN, V66, P246
   FAND RM, 1986, INT J HEAT MASS TRAN, V29, P119, DOI 10.1016/0017-9310(86)90040-2
   Fourie JG, 2002, CHEM ENG SCI, V57, P2781
   Fu H. L., 2013, THEORETICAL STUDY TH
   Gao DY, 2017, INT J HEAT MASS TRAN, V110, P58, DOI 10.1016/j.ijheatmasstransfer.2017.03.014
   Gao L, 2006, PHYS LETT A, V348, P355, DOI 10.1016/j.physleta.2005.08.069
   Giani L, 2005, IND ENG CHEM RES, V44, P9078, DOI 10.1021/ie050598p
   Goharshadi EK, 2013, PHYS CHEM RES, V1, P1
   Goodarzi M, 2014, INT J THERM SCI, V75, P204, DOI 10.1016/j.ijthermalsci.2013.08.003
   Gorla RSR, 2013, J NANOFLUIDS, V2, P297, DOI 10.1166/jon.2013.1064
   Guo CX, 2011, ADV MATER RES-SWITZ, V150-151, P723, DOI 10.4028/www.scientific.net/AMR.150-151.723
   Guo L. Y., 2013, OPTIMAL ANAL EFFECT
   Guo S. S., 2006, RES THERMOPHYSICAL C
   Hadim H, 2005, INT J THERM SCI, V44, P33, DOI 10.1016/j.ijthermalsci.2004.04.016
   Hajipour M, 2014, EXP THERM FLUID SCI, V53, P49, DOI 10.1016/j.expthermflusci.2013.11.002
   He ZZ, 2015, INT J HYDROGEN ENERG, V40, P9952, DOI 10.1016/j.ijhydene.2015.06.041
   Holman J.P., 2002, HEAT TRANSFER
   Hong S. T., 2010, ADV ENG MATER, V9, P554
   Howell J.R., 2002, THERMAL RAD HEAT TRA
   Hsu PF, 1992, EXP HEAT TRANSFER, V5, P293, DOI 10.1080/08916159208946446
   HUNT ML, 1988, INT J HEAT MASS TRAN, V31, P301, DOI 10.1016/0017-9310(88)90013-0
   Izadi F, 2018, PHYSICA E, V98, P83, DOI 10.1016/j.physe.2017.12.031
   Jang SP, 2004, APPL PHYS LETT, V84, P4316, DOI 10.1063/1.1756684
   [贾涛 Jia Tao], 2015, [制冷学报, Journal of Refrigeration], V36, P35
   Jianhua Du, 2003, Heat Transfer-Asian Research, V32, P545, DOI 10.1002/htj.10107
   Jing DW, 2017, RENEW SUST ENERG REV, V78, P452, DOI 10.1016/j.rser.2017.04.084
   Keblinski P, 2002, INT J HEAT MASS TRAN, V45, P855, DOI 10.1016/S0017-9310(01)00175-2
   Kefayati GR, 2015, ADV POWDER TECHNOL, V26, P576, DOI 10.1016/j.apt.2015.01.005
   Khanafer K, 2018, RENEW ENERG, V123, P398, DOI 10.1016/j.renene.2018.01.097
   Khanafer K, 2011, INT J HEAT MASS TRAN, V54, P4410, DOI 10.1016/j.ijheatmasstransfer.2011.04.048
   Khodadadi JM, 2007, INT COMMUN HEAT MASS, V34, P534, DOI 10.1016/j.icheatmasstransfer.2007.02.005
   Kim SJ, 2006, APPL PHYS LETT, V89, DOI 10.1063/1.2360892
   Kim SJ, 2010, NUCL ENG DES, V240, P1186, DOI 10.1016/j.nucengdes.2010.01.020
   Kodama T, 2003, ENERG FUEL, V17, P13, DOI 10.1021/ef0200525
   Kribus A, 2014, SOL ENERGY, V110, P463, DOI 10.1016/j.solener.2014.09.035
   Kuwahara F, 1996, J HEAT TRANS-T ASME, V118, P756, DOI 10.1115/1.2822696
   Kuwahara F, 2001, INT J HEAT MASS TRAN, V44, P1153, DOI 10.1016/S0017-9310(00)00166-6
   Labib MN, 2013, INT J THERM SCI, V71, P163, DOI 10.1016/j.ijthermalsci.2013.04.003
   Lafdi K., 2007, APPL PHYS LETT, V102
   Lee J, 2007, INT J HEAT MASS TRAN, V50, P452, DOI 10.1016/j.ijheatmasstransfer.2006.08.001
   Lee JH, 2011, INT J MICRONANOSCALE, DOI [10.1260/1759-3093.1.4.269, DOI 10.1260/1759-3093.1.4.269]
   Lee S, 1999, J HEAT TRANS-T ASME, V121, P280, DOI 10.1115/1.2825978
   Li D, 2015, OPTIK, V126, P834, DOI 10.1016/j.ijleo.2015.02.062
   [李强 Li Qiang], 2002, [热能动力工程, Journal of Engineering for Thermal Energy and Power], V17, P568
   Li ZX, 2018, COMPUT METHOD APPL M, V339, P663, DOI 10.1016/j.cma.2018.05.015
   Liang HX, 2019, INT J HEAT MASS TRAN, V128, P668, DOI 10.1016/j.ijheatmasstransfer.2018.09.032
   Liang HX, 2017, INT J HYDROGEN ENERG, V42, P12133, DOI 10.1016/j.ijhydene.2017.03.194
   Lin LN, 2018, INT J HEAT MASS TRAN, V119, P91, DOI 10.1016/j.ijheatmasstransfer.2017.11.095
   Lipinski W, 2013, J THERM SCI ENG APPL, V5, DOI 10.1115/1.4024088
   Liu JF, 2006, EXP THERM FLUID SCI, V30, P329, DOI 10.1016/j.expthermflusci.2005.07.007
   Lu G, 2016, ADV COLLOID INTERFAC, V236, P43, DOI 10.1016/j.cis.2016.07.004
   Lu W, 2006, INT J HEAT MASS TRAN, V49, P2751, DOI 10.1016/j.ijheatmasstransfer.2005.12.012
   Ma CY, 2016, J QUANT SPECTROSC RA, V172, P146, DOI 10.1016/j.jqsrt.2015.08.002
   Ma LX, 2017, J QUANT SPECTROSC RA, V196, P94, DOI 10.1016/j.jqsrt.2017.03.039
   Ma LX, 2017, J QUANT SPECTROSC RA, V187, P255, DOI 10.1016/j.jqsrt.2016.09.025
   Ma LX, 2015, OPT EXPRESS, V23, P24274, DOI 10.1364/OE.23.024274
   Mahdy A, 2009, J NON-NEWTON FLUID, V161, P37, DOI 10.1016/j.jnnfm.2009.04.003
   Mahian O, 2013, INT J HEAT MASS TRAN, V65, P514, DOI 10.1016/j.ijheatmasstransfer.2013.06.010
   Maiga SE, 2005, INT J HEAT FLUID FL, V26, P530, DOI 10.1016/j.ijheatfluidflow.2005.02.004
   Mandi RA, 2015, RENEW SUST ENERG REV, V41, P715, DOI 10.1016/j.rser.2014.08.040
   Mao Y. B., 2015, REFRIGERATION, V34, P6
   Masuda H., 1993, NETSU BUSSEI, V7, P227, DOI DOI 10.2963/JJTP.7.227
   Matin MH, 2013, INT COMMUN HEAT MASS, V46, P134, DOI 10.1016/j.icheatmasstransfer.2013.05.001
   Maxwell J C, 1954, TREATISE ELECT MAGNE
   Maxwell J.C., 1873, TREATISE ELECT MAGNE
   Minkowycz WJ, 1999, INT J HEAT MASS TRAN, V42, P3373, DOI 10.1016/S0017-9310(99)00043-5
   Modest MF, 2013, RADIATIVE HEAT TRANSFER, 3RD EDITION, P1
   Moyne C, 1997, ADV WATER RESOUR, V20, P63, DOI 10.1016/S0309-1708(96)00023-1
   Nakayama A, 2006, J FLUID MECH, V563, P81, DOI 10.1017/S0022112006001078
   NAKAYAMA A, 1991, APPL SCI RES, V48, P55, DOI 10.1007/BF01998665
   Nakayama A, 2009, HEAT MASS TRANSFER, V45, P1365, DOI 10.1007/s00231-009-0513-x
   Nazari M, 2015, INT J THERM SCI, V88, P33, DOI 10.1016/j.ijthermalsci.2014.08.013
   Nield DA, 2009, INT J HEAT MASS TRAN, V52, P5796, DOI 10.1016/j.ijheatmasstransfer.2009.07.023
   Nield D.A., 2013, CONVECTION POROUS ME
   Nikkhah V, 2015, EXP THERM FLUID SCI, V60, P83, DOI 10.1016/j.expthermflusci.2014.08.009
   OUNIS H, 1991, J COLLOID INTERF SCI, V143, P266, DOI 10.1016/0021-9797(91)90458-K
   Paek JW, 2000, INT J THERMOPHYS, V21, P453, DOI 10.1023/A:1006643815323
   Pasquali M, 1996, AICHE J, V42, P532, DOI 10.1002/aic.690420222
   Patel HE, 2003, APPL PHYS LETT, V83, P2931, DOI 10.1063/1.1602578
   Pham NH, 2018, INT J HEAT MASS TRAN, V121, P477, DOI 10.1016/j.ijheatmasstransfer.2017.12.150
   Pourmehran O, 2015, J TAIWAN INST CHEM E, V55, P49, DOI 10.1016/j.jtice.2015.04.016
   Qu ZG, 2012, INT J HEAT MASS TRAN, V55, P7508, DOI 10.1016/j.ijheatmasstransfer.2012.07.048
   Qu Z. G., 2009, J XIAN JIAO TONG U, V43, P4
   Rashad AM, 2013, J APPL FLUID MECH, V6, P301
   Rashidi MM, 2010, HEAT TRANSF-ASIAN RE, V39, P575, DOI 10.1002/htj.20317
   Rashidi MM, 2010, INT J THERM SCI, V49, P2405, DOI 10.1016/j.ijthermalsci.2010.07.005
   Ren YT, 2016, INT COMMUN HEAT MASS, V77, P33, DOI 10.1016/j.icheatmasstransfer.2016.06.012
   Ren YT, 2015, OPT EXPRESS, V23, P19328, DOI 10.1364/OE.23.019328
   Said Z, 2015, NUMER HEAT TR A-APPL, V67, P1010, DOI 10.1080/10407782.2014.955344
   Saito MB, 2006, J HEAT TRANS-T ASME, V128, P444, DOI 10.1115/1.2175150
   Sakai F., 2014, INT HEAT TRANSF C
   Sarafraz MM, 2017, APPL THERM ENG, V123, P29, DOI 10.1016/j.applthermaleng.2017.05.056
   Sarafraz MM, 2017, APPL THERM ENG, V121, P388, DOI 10.1016/j.applthermaleng.2017.04.083
   Sarafraz MM, 2015, APPL THERM ENG, V82, P212, DOI 10.1016/j.applthermaleng.2015.02.070
   Sarafraz MM, 2014, INT COMMUN HEAT MASS, V53, P116, DOI 10.1016/j.icheatmasstransfer.2014.02.019
   SEGELSTEIN D, 1981, THESIS U MISSOURI KA
   Semenov SN, 2003, PHILOS MAG, V83, P2199, DOI 10.1080/0141861031000107917
   Shafahi M, 2010, INT J HEAT MASS TRAN, V53, P1438, DOI 10.1016/j.ijheatmasstransfer.2009.12.007
   Sheikholeslami M, 2018, INT J HEAT MASS TRAN, V127, P665, DOI 10.1016/j.ijheatmasstransfer.2018.06.087
   Sheikholeslami M, 2018, INT J HEAT MASS TRAN, V127, P614, DOI 10.1016/j.ijheatmasstransfer.2018.07.013
   Sheikholeslami M, 2018, J MOL LIQ, V266, P495, DOI 10.1016/j.molliq.2018.06.083
   Sheikholeslami M, 2018, INT J HEAT MASS TRAN, V126, P156, DOI 10.1016/j.ijheatmasstransfer.2018.05.128
   Sheikholeslami M, 2018, J MOL LIQ, V265, P347, DOI 10.1016/j.molliq.2018.05.132
   Sheikholeslami M, 2018, J MOL LIQ, V263, P472, DOI 10.1016/j.molliq.2018.04.111
   Sheikholeslami M, 2018, J MOL LIQ, V263, P489, DOI 10.1016/j.molliq.2018.04.147
   Sheikholeslami M, 2018, INT J HEAT MASS TRAN, V123, P418, DOI 10.1016/j.ijheatmasstransfer.2018.02.095
   Sheikholeslami M, 2018, INT J HEAT MASS TRAN, V122, P1264, DOI 10.1016/j.ijheatmasstransfer.2018.02.080
   Sheikholeslami M, 2017, PHYS LETT A, V381, P494, DOI 10.1016/j.physleta.2016.11.042
   Sheremet MA, 2015, INT J HEAT MASS TRAN, V82, P396, DOI 10.1016/j.ijheatmasstransfer.2014.11.066
   Sheremet MA, 2015, TRANSPORT POROUS MED, V106, P595, DOI 10.1007/s11242-014-0415-3
   Sheremet MA, 2014, TRANSPORT POROUS MED, V105, P411, DOI 10.1007/s11242-014-0375-7
   Sheremet MA, 2014, INT J HEAT MASS TRAN, V79, P137, DOI 10.1016/j.ijheatmasstransfer.2014.07.092
   Sheremet MA, 2014, J HEAT TRANS-T ASME, V136, DOI 10.1115/1.4027355
   Siahpush A., 2008, J HEAT TRANSFER, V130, P318
   Sivasankaran S, 2016, INT COMMUN HEAT MASS, V75, P86, DOI 10.1016/j.icheatmasstransfer.2016.03.016
   Sun Q, 2011, INT J THERM SCI, V50, P2141, DOI 10.1016/j.ijthermalsci.2011.06.005
   Sundarram SS, 2014, APPL THERM ENG, V64, P147, DOI 10.1016/j.applthermaleng.2013.11.072
   Sundarram SS, 2014, J MANUF SCI E-T ASME, V136, DOI 10.1115/1.4025418
   Suter S, 2014, INT J HEAT MASS TRAN, V78, P688, DOI 10.1016/j.ijheatmasstransfer.2014.07.020
   Tan He Ping, 1987, High Temperatures - High Pressures, V19, P417
   Tan JY, 2017, INT J HEAT MASS TRAN, V115, P1103, DOI 10.1016/j.ijheatmasstransfer.2017.07.127
   Tao YB, 2016, APPL THERM ENG, V93, P476, DOI 10.1016/j.applthermaleng.2015.10.016
   Teng KH, 2017, APPL THERM ENG, V110, P495, DOI 10.1016/j.applthermaleng.2016.08.181
   Tian Y, 2011, ENERGY, V36, P5539, DOI 10.1016/j.energy.2011.07.019
   Ting HW, 2015, ENERG CONVERS MANAGE, V105, P731, DOI 10.1016/j.enconman.2015.08.022
   Torabi M, 2017, INT J HEAT MASS TRAN, V114, P31, DOI 10.1016/j.ijheatmasstransfer.2017.06.021
   Torabi M, 2015, ENERGY, V87, P540, DOI 10.1016/j.energy.2015.05.009
   Vafai K., 2005, HDB POROUS MEDIA
   Wakao N., 1983, HEAT MASS TRANSFER P
   Wakao N., 1982, HEAT MASS TRANSFER P
   Wang BX, 2003, INT J HEAT MASS TRAN, V46, P2665, DOI 10.1016/S0017-9310(03)00016-4
   Wang FQ, 2017, RENEW SUST ENERG REV, V79, P1314, DOI 10.1016/j.rser.2017.05.174
   Wang FQ, 2017, RENEW SUST ENERG REV, V73, P935, DOI 10.1016/j.rser.2017.01.165
   Wang FQ, 2017, OPTIK, V131, P323, DOI 10.1016/j.ijleo.2016.11.052
   Wang FQ, 2015, ENERGY, V91, P645, DOI 10.1016/j.energy.2015.08.080
   Wang FQ, 2014, ENERG CONVERS MANAGE, V87, P956, DOI 10.1016/j.enconman.2014.08.003
   Wang FQ, 2014, SOL ENERGY, V108, P348, DOI 10.1016/j.solener.2014.07.016
   Wang FQ, 2014, INT J HEAT MASS TRAN, V78, P7, DOI 10.1016/j.ijheatmasstransfer.2014.06.035
   Wang FQ, 2013, SOL ENERGY, V93, P158, DOI 10.1016/j.solener.2013.04.004
   Wang FQ, 2013, INT J HEAT MASS TRAN, V62, P247, DOI 10.1016/j.ijheatmasstransfer.2013.03.003
   Wang JT, 2018, CHINESE J CHEM ENG, V26, P623, DOI 10.1016/j.cjche.2017.10.022
   Wang P, 2014, NUMER HEAT TR A-APPL, V65, P931, DOI 10.1080/10407782.2013.850917
   Wang WZ, 2015, OPT EXPRESS, V23, pA1010, DOI 10.1364/OE.23.0A1010
   Wang XZ, 2017, SOL ENERGY, V157, P35, DOI 10.1016/j.solener.2017.08.015
   Wang XZ, 2016, ENERG CONVERS MANAGE, V130, P176, DOI 10.1016/j.enconman.2016.10.049
   Weber M J, 2003, HDB OPTICAL MAT
   Wu SY, 2012, J THERM ANAL CALORIM, V110, P1127, DOI 10.1007/s10973-011-2080-x
   Wu SY, 2010, ENERG FUEL, V24, P1894, DOI 10.1021/ef9013967
   Wu ZY, 2011, SOL ENERGY, V85, P2374, DOI 10.1016/j.solener.2011.06.030
   Wu ZY, 2011, INT J HEAT MASS TRAN, V54, P1527, DOI 10.1016/j.ijheatmasstransfer.2010.11.037
   Xia XL, 2017, INT J HEAT MASS TRAN, V106, P83, DOI 10.1016/j.ijheatmasstransfer.2016.10.053
   Xie HQ, 2002, J APPL PHYS, V91, P4568, DOI 10.1063/1.1454184
   Xu HJ, 2016, APPL THERM ENG, V93, P15, DOI 10.1016/j.applthermaleng.2015.09.068
   Xu HJ, 2015, INT J THERM SCI, V95, P73, DOI 10.1016/j.ijthermalsci.2015.04.007
   Xu HJ, 2014, APPL THERM ENG, V66, P43, DOI 10.1016/j.applthermaleng.2014.01.053
   Xu HJ, 2011, J HEAT TRANS-T ASME, V133, DOI 10.1115/1.4004209
   Xu HJ, 2011, INT J HEAT MASS TRAN, V54, P3846, DOI 10.1016/j.ijheatmasstransfer.2011.04.044
   Xu HJ, 2018, EUR J MECH B-FLUID, V68, P1, DOI 10.1016/j.euromechflu.2017.10.009
   [徐会金 Xu Huijin], 2017, [热科学与技术, Journal of Thermal Science and Technology], V16, P287
   Xu HJ, 2017, INT COMMUN HEAT MASS, V89, P73, DOI 10.1016/j.icheatmasstransfer.2017.09.013
   Xu HJ, 2017, INT J THERM SCI, V120, P337, DOI 10.1016/j.ijthermalsci.2017.06.021
   Xu HJ, 2017, HEAT MASS TRANSFER, V53, P2663, DOI 10.1007/s00231-017-2011-x
   Xu HJ, 2017, APPL THERM ENG, V116, P516, DOI 10.1016/j.applthermaleng.2016.12.090
   Xu HJ, 2015, J HEAT TRANS-T ASME, V137, DOI 10.1115/1.4030905
   Xu HJ, 2015, INT J HEAT MASS TRAN, V83, P399, DOI 10.1016/j.ijheatmasstransfer.2014.12.024
   [徐会金 Xu Huijin], 2014, [工程热物理学报, Journal of Engineering Thermophysics], V35, P1586
   Xu HJ, 2014, INT J HEAT MASS TRAN, V76, P357, DOI 10.1016/j.ijheatmasstransfer.2014.04.034
   Xu ZG, 2016, APPL THERM ENG, V100, P68, DOI 10.1016/j.applthermaleng.2016.02.016
   Xuan YM, 2003, J HEAT TRANS-T ASME, V125, P151, DOI 10.1115/1.1532008
   Xuan YM, 2000, INT J HEAT MASS TRAN, V43, P3701, DOI 10.1016/S0017-9310(99)00369-5
   Xue Q, 2005, MATER CHEM PHYS, V90, P298, DOI 10.1016/j.matchemphys.2004.05.029
   Xue QZ, 2005, PHYSICA B, V368, P302, DOI 10.1016/j.physb.2005.07.024
   YAGI S, 1960, AICHE J, V6, P543, DOI 10.1002/aic.690060407
   Yang C, 2013, J HEAT TRANS-T ASME, V135, DOI 10.1115/1.4023539
   Yang C, 2013, INT J THERM SCI, V71, P249, DOI 10.1016/j.ijthermalsci.2013.04.007
   Yang C, 2010, INT J HEAT MASS TRAN, V53, P3222, DOI 10.1016/j.ijheatmasstransfer.2010.03.004
   Yang Y, 2005, INT J HEAT MASS TRAN, V48, P1107, DOI 10.1016/j.ijheatmasstransfer.2004.09.038
   You SM, 2003, APPL PHYS LETT, V83, P3374, DOI 10.1063/1.1619206
   Yu W, 2004, J NANOPART RES, V6, P355, DOI 10.1007/s11051-004-2601-7
   Yu W, 2010, COLLOID SURFACE A, V355, P109, DOI 10.1016/j.colsurfa.2009.11.044
   Yuan Y, 2017, J CATAL, V348, P246, DOI 10.1016/j.jcat.2016.12.022
   Zeng JL, 2010, J THERM ANAL CALORIM, V101, P385, DOI 10.1007/s10973-009-0472-y
   Zhang B, 2015, INT J HEAT MASS TRAN, V85, P300, DOI 10.1016/j.ijheatmasstransfer.2015.01.140
   Zhang H, 2018, J COLLOID INTERF SCI, V511, P48, DOI 10.1016/j.jcis.2017.09.067
   Zhang L, 2012, J QUANT SPECTROSC RA, V113, P1826, DOI 10.1016/j.jqsrt.2012.04.020
   Zhang W, 2015, J FLUID MECH, V769, P590, DOI 10.1017/jfm.2015.131
   Zhao CY, 2010, SOL ENERGY, V84, P1402, DOI 10.1016/j.solener.2010.04.022
   Zhao CY, 2006, INT J HEAT MASS TRAN, V49, P2762, DOI 10.1016/j.ijheatmasstransfer.2005.12.014
   Zheng K., 2012, ACTA PHYS SINICA, V61, P1
   [朱禹 Zhu Yu], 2011, [化工学报, Journal of Chemical Industry and Engineering (China)], V62, P329
   Zukauskas A., 1987, HDB SINGLE PHASE CON
NR 239
TC 29
Z9 31
U1 25
U2 105
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 462
EP 483
DI 10.1016/j.ces.2018.09.045
PG 22
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500042
HC Y
HP N
DA 2020-05-12
ER

PT J
AU Li, Q
   Zhu, XF
   Zhang, Y
   Fang, ZGZ
   Zheng, SL
   Sun, P
   Xia, Y
   Li, P
   Zhang, Y
   Zou, X
AF Li, Qing
   Zhu, Xiaofang
   Zhang, Ying
   Fang, Zhigang Zak
   Zheng, Shili
   Sun, Pei
   Xia, Yang
   Li, Ping
   Zhang, Yang
   Zou, Xing
TI An investigation of the reduction of TiO2 by Mg in H-2 atmosphere
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE TiO2 sintering; Mg reduction; Oxygen contents; Phase transformation;
   Morphology
ID ASSISTED MAGNESIOTHERMIC REDUCTION; TITANIUM-DIOXIDE; CALCIOTHERMIC
   REDUCTION; CAMBRIDGE PROCESS; POWDER; ELECTROLYSIS; METALLURGY; LIMIT
AB Hydrogen assisted magnesiothermic reduction (HAMR) of TiO2 is a promising new process developed recently to produce Ti metal with low cost and less energy consumption. This work focuses on the understanding and optimization of the reduction process to control the quality of the reduced product. TiO2 precursor particles with different relative densities were prepared, and the effects of the relative densities on reduction by Mg in H-2 were studied. The changes of oxygen contents vs. reduction time at various temperatures were investigated. The phase transformations during the reduction were analyzed both theoretically and experimentally. The relationship between the morphology of the reduced products and the relative densities of the TiO2 precursors was analyzed by SEM characterization and the likely reason for the morphology evolution was discussed. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Li, Qing; Zou, Xing] Univ Sci & Technol Beijing, Beijing 100083, Peoples R China.
   [Li, Qing; Zhu, Xiaofang; Zhang, Ying; Zheng, Shili; Li, Ping; Zhang, Yang] Chinese Acad Sci, Inst Proc Engn, Natl Engn Lab Hydromet Cleaner Prod Technol, Key Lab Green Proc & Engn, Beijing 100190, Peoples R China.
   [Fang, Zhigang Zak; Sun, Pei; Xia, Yang] Univ Utah, Dept Met Engn, Salt Lake City, UT 84112 USA.
RP Zhang, Y; Zheng, SL (reprint author), Chinese Acad Sci, Inst Proc Engn, Natl Engn Lab Hydromet Cleaner Prod Technol, Key Lab Green Proc & Engn, Beijing 100190, Peoples R China.
EM zhangying@ipe.ac.cn; slzheng@ipe.ac.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51771179]; US Department of Energy, Advanced
   Research Projects Agency - Energy, United States (ARPA-E) [DE-AR0000420]
FX This work was financially supported by the National Natural Science
   Foundation of China under Grant No. 51771179 and the US Department of
   Energy, Advanced Research Projects Agency - Energy, United States
   (ARPA-E), under contract number DE-AR0000420.
CR Abiko T., 2003, 10 WORLD C TIT HAMB
   Bolivar M. S. R., 2009, P EMS 2009 GERM
   Chen GZ, 2000, NATURE, V407, P361, DOI 10.1038/35030069
   Choi K, 2017, METALL MATER TRANS B, V48, P922, DOI 10.1007/s11663-016-0912-6
   COUGHLIN J.P., 1954, US BUR MINES B, V542
   Crowley G, 2003, ADV MATER PROCESS, V161, P25
   Eisen WB, 1998, POWDER METAL TECHNOL
   Fang ZGZ, 2018, INT MATER REV, V63, P407, DOI 10.1080/09506608.2017.1366003
   Feng La-Jun, 2003, Micronanoelectronic Technology, V40, P536
   Hall F. W, 2012, ALUMINOTHERMIC PROCE
   Hu D, 2018, JOM-US, V70, P129, DOI 10.1007/s11837-017-2664-4
   Jackson M, 2006, MATER SCI TECH-LOND, V22, P881, DOI 10.1179/174328406x111147
   Jacob KT, 2009, JOM-US, V61, P56, DOI 10.1007/s11837-009-0072-0
   Kikuchi T, 2014, J PHYS CHEM SOLIDS, V75, P1041, DOI 10.1016/j.jpcs.2014.04.016
   Kleespies E. K., 1964, Magnesium reduction of titanium oxides in a hydrogen atmosphere, Patent No. [US 3140170 A, 3140170A, 3140170a]
   Kroll W., 1940, Transactions of the Electrochemical Society, V78, P35, DOI 10.1149/1.3071290
   Kroll W, 1937, Z ANORG ALLG CHEM, V234, P42, DOI 10.1002/zaac.19372340105
   Mo W., 1998, TITANIUM METALLURGY
   Mohandas KS, 2004, T INDIAN I METALS, V57, P579
   Okabe TH, 2004, J ALLOY COMPD, V364, P156, DOI 10.1016/S0925-8388(03)00610-8
   ONO K, 1985, J JPN I MET, V49, P871, DOI 10.2320/jinstmet1952.49.10_871
   Ono K, 2002, JOM-J MIN MET MAT S, V54, P59, DOI 10.1007/BF02701078
   Park I, 2005, J PHYS CHEM SOLIDS, V66, P410, DOI 10.1016/j.jpcs.2004.06.052
   Reed T. B., 1971, FREE ENERGY FORMATIO
   Rostron D. W., 1958, US Patent, Patent No. [US2834667 A, 2834667]
   Stoephasius J. C., 2005, P EMC, P1429
   Suzuki RO, 2003, METALL MATER TRANS B, V34, P287, DOI 10.1007/s11663-003-0074-1
   Xia Y, 2017, MATER TRANS, V58, P355, DOI 10.2320/matertrans.MK201628
   Xia Y, 2017, J MATER SCI, V52, P4120, DOI 10.1007/s10853-016-0674-1
   Zhang Y, 2017, JOM-US, V69, P1861, DOI 10.1007/s11837-017-2481-9
   Zhang Y, 2017, CHEM ENG J, V327, P169, DOI 10.1016/j.cej.2017.06.060
   Zhang Y, 2017, CHEM ENG J, V308, P299, DOI 10.1016/j.cej.2016.09.066
   Zhang Y, 2016, J AM CHEM SOC, V138, P6916, DOI 10.1021/jacs.6b00845
   Zhang Y, 2016, CHEM ENG J, V286, P517, DOI 10.1016/j.cej.2015.10.090
NR 34
TC 2
Z9 2
U1 0
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 484
EP 493
DI 10.1016/j.ces.2018.09.047
PG 10
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500043
DA 2020-05-12
ER

PT J
AU Cao, XP
   Jia, SK
   Luo, YQ
   Yuan, XG
   Qi, ZW
   Yu, KT
AF Cao, Xuepu
   Jia, Shengkun
   Luo, Yiqing
   Yuan, Xigang
   Qi, Zhiwen
   Yu, Kuo-Tsong
TI Multi-objective optimization method for enhancing chemical reaction
   process
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Reaction process enhancement; Multi-objective optimization; Weight
   coefficient; Entropy generation; Viscous dissipation
ID MASS-TRANSFER ENHANCEMENT; ENTROPY PRODUCTION-RATE; GENERATION;
   COMBUSTION
AB An approach to enhancing the chemical reaction process based on flow pattern construction was proposed. We demonstrated that the entropy generation due to mass transfer, chemical reaction and the viscous dissipation tend to their extremums when the performance of the reaction is enhanced. Based on this finding, a multi-objective optimization problem was formulated. The weight coefficients of individual objectives (various entropy generations) were derived according to their relative importance. The final objective function was formulated by the linear combination of the entropy generations of mass transfer and chemical reaction. By minimization of the objective function, subject to a constraint of fixed viscous dissipation, through calculus of variations, a velocity field and associate body force field can be obtained, by which the reaction process was effectively enhanced. The flow pattern obtained by optimization calculation can be used to guide the design of the internal structures in the reactors. (C) 2018 Published by Elsevier Ltd.
C1 [Cao, Xuepu; Jia, Shengkun; Luo, Yiqing; Yuan, Xigang; Yu, Kuo-Tsong] Tianjin Univ, Sch Chem Engn & Technol, Tianjin 300072, Peoples R China.
   [Yuan, Xigang; Yu, Kuo-Tsong] Tianjin Univ, State Key Lab Chem Engn, Tianjin 300072, Peoples R China.
   [Qi, Zhiwen] East China Univ Sci & Technol, State Key Lab Chem Engn, Shanghai 200237, Peoples R China.
RP Yuan, XG (reprint author), Tianjin Univ, Sch Chem Engn & Technol, Tianjin 300072, Peoples R China.
EM yuanxg@tju.edu.cn
OI Qi, Zhiwen/0000-0003-2037-2234; Jia, Shengkun/0000-0003-4524-0588; Luo,
   yiqing/0000-0003-2435-8659
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [91434204]
FX Support by National Natural Science Foundation of China (Grant 91434204)
   is acknowledged.
CR Albini A, 2009, J AM CHEM SOC, V132, P16726
   Aravind GP, 2017, INT J HEAT MASS TRAN, V115, P809, DOI 10.1016/j.ijheatmasstransfer.2017.07.104
   Arjmandi HR, 2015, ENERGY, V81, P706, DOI 10.1016/j.energy.2014.12.077
   Bejan A, 1998, REV GEN THERM, V37, P165, DOI 10.1016/S0035-3159(97)83647-1
   Bejan A, 1997, ADV ENG THERMODYNAMI
   Bejan A., 1995, SOC PHOTOOPT INSTRUM, P174
   Bidi M, 2010, ENERGY, V35, P3483, DOI 10.1016/j.energy.2010.04.053
   Cao X., 2018, P 13 INT S PROC SYST
   CARRINGTON CG, 1991, INT J HEAT MASS TRAN, V34, P2767, DOI 10.1016/0017-9310(91)90235-7
   Chen Q, 2008, INT J HEAT MASS TRAN, V51, P2863, DOI 10.1016/j.ijheatmasstransfer.2007.09.024
   Finlayson B.A., 2013, METHOD WEIGHTED RESI
   Gavrilescu M, 2005, BIOTECHNOL ADV, V23, P471, DOI 10.1016/j.biotechadv.2005.03.004
   Ghermay Y, 2011, COMBUST FLAME, V158, P1491, DOI 10.1016/j.combustflame.2010.12.025
   Gutierrez F, 2012, ENERG CONVERS MANAGE, V55, P1, DOI 10.1016/j.enconman.2011.10.021
   Hikita H, 1976, CHEM ENG J, V11, P131, DOI DOI 10.1016/S0300-9467(76)80035-4
   Hirschfelder J. O., 1964, MOL THEORY GASES LIQ
   Jia SK, 2016, CHEM ENG SCI, V146, P26, DOI 10.1016/j.ces.2016.01.059
   Jia XQ, 2010, CHEM ENG J, V157, P451, DOI 10.1016/j.cej.2009.12.007
   Johannessen E, 2004, ENERGY, V29, P2403, DOI 10.1016/j.energy.2004.03.033
   Kjelstrup S., 2000, INT J THERMODYN, V3
   KLOOSTERMAN EG, 1987, IND ENG CHEM RES, V26, P2216, DOI 10.1021/ie00071a008
   Li Q, 2014, CHEM ENG SCI, V116, P806, DOI 10.1016/j.ces.2014.05.051
   Lior N, 2006, ENERGY, V31, P553, DOI 10.1016/j.energy.2005.05.009
   Lisboa KM, 2017, J POWER SOURCES, V359, P322, DOI 10.1016/j.jpowsour.2017.05.038
   Logist F, 2012, COMPUT CHEM ENG, V37, P191, DOI 10.1016/j.compchemeng.2011.11.002
   Martin C. A., 2016, J ADV OXID TECHNOL, V5, P164
   Miettinen K., 1999, NONLINEAR MULTIOBJEC
   Mitra K, 2011, CHEM ENG SCI, V66, P3471, DOI 10.1016/j.ces.2011.03.041
   Mitra K, 2009, CHEM ENG SCI, V64, P5043, DOI 10.1016/j.ces.2009.08.012
   Muller C, 2005, EUR J INORG CHEM, P4011, DOI 10.1002/ejic.200500466
   Nishimura T, 2000, INT J HEAT MASS TRAN, V43, P2365, DOI 10.1016/S0017-9310(99)00311-7
   Nummedal L, 2003, IND ENG CHEM RES, V42, P1044, DOI 10.1021/ie020319n
   Rana U, 2014, ENERGY, V68, P510, DOI 10.1016/j.energy.2014.02.070
   SAATY TL, 1977, J MATH PSYCHOL, V15, P234, DOI 10.1016/0022-2496(77)90033-5
   Sciacovelli A, 2015, RENEW SUST ENERG REV, V43, P1167, DOI 10.1016/j.rser.2014.11.104
   TAKEDA E, 1995, EUR J OPER RES, V86, P315, DOI 10.1016/0377-2217(95)00095-8
   Tang A, 2014, J POWER SOURCES, V248, P154, DOI 10.1016/j.jpowsour.2013.09.071
   Teng H, 1998, J ENERG RESOUR-ASME, V120, P226, DOI 10.1115/1.2795040
   Tondeur D., 2007, AM J OBSTET GYNECOL, V191, pS161
   Vallerio M, 2015, EXPERT SYST APPL, V42, P7710, DOI 10.1016/j.eswa.2015.05.038
   Yazid MNAWM, 2017, RENEW SUST ENERG REV, V80, P914, DOI 10.1016/j.rser.2017.05.192
   Zheng Q, 2016, J POWER SOURCES, V324, P402, DOI 10.1016/j.jpowsour.2016.05.110
NR 42
TC 3
Z9 3
U1 4
U2 24
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 494
EP 506
DI 10.1016/j.ces.2018.09.048
PG 13
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500044
DA 2020-05-12
ER

PT J
AU Roumpea, E
   Kovalchuk, NM
   Chinaud, M
   Nowak, E
   Simmons, MJH
   Angeli, P
AF Roumpea, Evangelia
   Kovalchuk, Nina M.
   Chinaud, Maxime
   Nowak, Emilia
   Simmons, Mark J. H.
   Angeli, Panagiota
TI Experimental studies on droplet formation in a flow-focusing
   microchannel in the presence of surfactants
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE mu-PIV; Surfactants; Flow-focusing microchannel; Droplet formation
ID BREAKUP DYNAMICS; DEVICES; PIV
AB The formation of an aqueous droplet in an organic continuous phase was studied experimentally inside a flow-focusing microchannel (190 mu m x 195 mu m: depth x width) in the presence of surfactants. A low viscosity silicone oil (0.0046 Pa s) was used as the continuous phase and a mixture of 48% w/w water and 52% w/w glycerol was the dispersed phase. Two ionic surfactants, C(12)TAB (50 mM) and C(16)TAB (5 mM) were added in the aqueous phase, at concentrations above the CMC values. Four regimes of drop formation were identified, namely squeezing, dripping, jetting and threading, whose boundaries changed when the surfactants were present. The drop formation process and the velocity profiles in both phases in the squeezing and dripping regimes were studied in more detail using a two-colour Particle Image Velocimetry technique. For all solutions studied, three distinct drop formation stages were identified, expansion, necking and pinch-off. The surfactant-laden solutions produced smaller drops. Considering the dynamic interfacial tension, rather than the equilibrium one, it was possible to explain differences in the drop formation between the two surfactant systems in the expansion stage. The forces acting on the forming drops were estimated and showed that the drag force overcomes the interfacial tension force at the transition between the expansion and necking stages. During this transition, the curvature of the neck changed while its thinning rate was increased. The transition from the necking to the pinch-off stage was signified by a flow reversal at the bottom part of the drop. (C) 2018 The Authors. Published by Elsevier Ltd.
C1 [Roumpea, Evangelia; Chinaud, Maxime; Angeli, Panagiota] UCL, Dept Chem Engn, ThAMeS Multiphase, Torrington Pl, London WC1E 7JE, England.
   [Kovalchuk, Nina M.; Simmons, Mark J. H.] Univ Birmingham, Sch Chem Engn, Birmingham B15 2TT, W Midlands, England.
   [Nowak, Emilia] Massey Univ, Auckland 0745, New Zealand.
RP Angeli, P (reprint author), UCL, Dept Chem Engn, ThAMeS Multiphase, Torrington Pl, London WC1E 7JE, England.
EM p.angeli@ucl.ac.uk
RI Kovalchuk, Nina/O-2579-2017; Simmons, Mark/M-9064-2015
OI Kovalchuk, Nina/0000-0002-6497-650X; Simmons, Mark/0000-0002-0655-3744;
   Angeli, Panagiota/0000-0001-9575-4259
FU UK Engineering and Physical Sciences Research Council (EPSRC) Programme
   Grant MEMPHISEngineering & Physical Sciences Research Council (EPSRC)
   [EP/K003976/1]
FX This project was funded by the UK Engineering and Physical Sciences
   Research Council (EPSRC) Programme Grant MEMPHIS (EP/K003976/1).
CR Anna SL, 2016, ANNU REV FLUID MECH, V48, P285, DOI 10.1146/annurev-fluid-122414-034425
   Baret JC, 2009, LANGMUIR, V25, P6088, DOI 10.1021/la9000472
   Carrier O, 2015, J MICROMECH MICROENG, V25, DOI 10.1088/0960-1317/25/8/084014
   Chen XM, 2015, MICROFLUID NANOFLUID, V18, P1341, DOI 10.1007/s10404-014-1533-5
   Chiarello E, 2017, PHYS REV FLUIDS, V2, DOI 10.1103/PhysRevFluids.2.123602
   Chinaud M, 2015, EXP THERM FLUID SCI, V69, P99, DOI 10.1016/j.expthermflusci.2015.07.022
   Christopher GF, 2008, PHYS REV E, V78, DOI 10.1103/PhysRevE.78.036317
   Cubaud T, 2008, PHYS FLUIDS, V20, DOI 10.1063/1.2911716
   Fu TT, 2016, CHEM ENG SCI, V144, P75, DOI 10.1016/j.ces.2015.12.031
   Fu TT, 2012, CHEM ENG SCI, V84, P207, DOI 10.1016/j.ces.2012.08.039
   Fu TT, 2009, CHEM ENG SCI, V64, P2392, DOI 10.1016/j.ces.2009.02.022
   Funfschilling D, 2009, PHYS REV E, V80, DOI 10.1103/PhysRevE.80.015301
   Garstecki P, 2006, LAB CHIP, V6, P693
   Garstecki P, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.164501
   Glawdel T, 2012, PHYS REV E, V86, DOI 10.1103/PhysRevE.86.026308
   Glawdel T, 2012, PHYS REV E, V85, DOI 10.1103/PhysRevE.85.016323
   Glawdel T, 2012, PHYS REV E, V85, DOI 10.1103/PhysRevE.85.016322
   Husny J, 2006, J NON-NEWTON FLUID, V137, P121, DOI 10.1016/j.jnnfm.2006.03.007
   Jin F, 2006, PHYS FLUIDS, V18, DOI 10.1063/1.2172003
   Kovalchuk NM, 2018, CHEM ENG SCI, V176, P139, DOI 10.1016/j.ces.2017.10.026
   Kovalchuk NM, 2016, LANGMUIR, V32, P5069, DOI 10.1021/acs.langmuir.6b01467
   Lee W, 2009, PHYS FLUIDS, V21, DOI 10.1063/1.3081407
   Liu HH, 2011, PHYS FLUIDS, V23, DOI 10.1063/1.3615643
   Riaud A, 2018, LANGMUIR, V34, P4980, DOI 10.1021/acs.langmuir.8b00123
   Seemann R, 2012, REP PROG PHYS, V75, DOI 10.1088/0034-4885/75/1/016601
   Timgren A, 2008, EXP FLUIDS, V44, P565, DOI 10.1007/s00348-007-0416-x
   Utada AS, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.094502
   van der Graaf S, 2006, LANGMUIR, V22, P4144, DOI 10.1021/la052682f
   van Steijn V, 2007, CHEM ENG SCI, V62, P7505, DOI 10.1016/j.ces.2007.08.068
   Wang K, 2009, LANGMUIR, V25, P2153, DOI 10.1021/la803049s
   Wonga VL, 2017, CHEM ENG SCI, V174, P157, DOI 10.1016/j.ces.2017.08.027
   Xu JH, 2008, MICROFLUID NANOFLUID, V5, P711, DOI 10.1007/s10404-008-0306-4
NR 32
TC 1
Z9 1
U1 2
U2 37
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 507
EP 518
DI 10.1016/j.ces.2018.09.049
PG 12
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500045
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Azzato, G
   De Marco, G
   Stellato, V
   Sun, Y
   Caravella, A
AF Azzato, Giulia
   De Marco, Giuseppe
   Stellato, Virgilio
   Sun, Yu
   Caravella, Alessio
TI Tortuosity and connectivity evaluation by CFD simulation for
   morphological characterization of membranes and catalytic structures.
   Case study: CaF2-like structure
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Connectivity; Tortuosity; Morphology map; CaF2 structure; Connection
   curve; Porous media
ID POROUS-MEDIA; PORE STRUCTURE; DIFFUSION; POROSITY; TRANSPORT;
   MICROSTRUCTURE; PERMEABILITY; DISPERSION; SIZE; 2D
AB A systematic methodology to characterise porous structure of membranes and catalysts in terms of tortuosity and connectivity is presented. The considered case study is the CaF2-like structure of bidisperse spherical particles (i.e., inner and outer particles with different diameters), which are allowed to overlap. Consequently, the morphology of the resulting structure is shown to be completely determined by two geometrical parameters (two degrees of freedom). For this investigation, a Morphology Map is developed, it being a plot mapping void connection as a function of the characteristic geometrical parameters. Within such a map, we introduce the so-called Minimum Connection Curve, which is a characteristic curve representing the boundary between the connected region and the disconnected one (zero connectivity). It is then found that the CaF2-like structure has three specific points where there is an abrupt change in the morphology behaviour, also correlated to the normalised surface area. Then, the structure tortuosity and connectivity are systematically evaluated in a wide range of geometrical conditions of the two parameters characterising the considered structure. As a result, it is shown that it is not possible to express these parameters as a unique function of porosity. However, both tortuosity and connectivity are found to be correlated with a good approximation in a certain range of porosity values with a geometrical parameter that we called Effective Porosity, which is the porosity available for diffusion at the minimum connection conditions. Convenient empirical correlations are eventually provided to allow readers to evaluate tortuosity and connectivity in a wide range of values. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Azzato, Giulia; Stellato, Virgilio; Caravella, Alessio] Univ Calabria, Dept Environm & Chem Engn DIATIC, Via P Bucci,Cubo 44A, I-87036 Arcavacata Di Rende, CS, Italy.
   [De Marco, Giuseppe] Univ Calabria, Informat Technol Ctr ICT, Via P Bucci,Cubo 22B, I-87036 Arcavacata Di Rende, CS, Italy.
   [Sun, Yu] Hokkaido Univ, Inst Int Collaborat, Sapporo, Hokkaido 0600815, Japan.
   [Sun, Yu] Hokkaido Univ, Fac Sci, Dept Chem, Kita Ku, N10W8, Sapporo, Hokkaido 0600810, Japan.
RP Caravella, A (reprint author), Univ Calabria, Dept Environm & Chem Engn DIATIC, Via P Bucci,Cubo 44A, I-87036 Arcavacata Di Rende, CS, Italy.
EM alessio.caravella@unical.it
OI Caravella, Alessio/0000-0002-9295-1414
FU Programma Per Giovani Ricercatori "Rita Levi Montalcini" - Ministero
   dell'Istruzione, dell'Universita e della Ricerca, MIUR [PGR12BV33A]
FX A. Caravella has received funding through the "Programma Per Giovani
   Ricercatori "Rita Levi Montalcini" granted by the "Ministero
   dell'Istruzione, dell'Universita e della Ricerca, MIUR" (Grant no.
   PGR12BV33A), which is gratefully acknowledged.
CR Alam P, 2006, NORD PULP PAP RES J, V21, P670, DOI 10.3183/npprj-2006-21-05-p670-675
   Annunziata R, 2016, MED IMAGE ANAL, V32, P216, DOI 10.1016/j.media.2016.04.006
   Anovitz LM, 2015, REV MINERAL GEOCHEM, V80, P61, DOI 10.2138/rmg.2015.80.04
   Bellini S, 2018, APPL SCI-BASEL, V8, DOI 10.3390/app8040573
   Berg CF, 2014, TRANSPORT POROUS MED, V103, P381, DOI 10.1007/s11242-014-0307-6
   Brun E., 2008, P CMDS11, P121
   Caravella A, 2016, MICROPOR MESOPOR MAT, V235, P87, DOI 10.1016/j.micromeso.2016.07.049
   Caravella A, 2012, CHEM ENG J, V210, P363, DOI 10.1016/j.cej.2012.08.101
   Caravella A, 2012, CHEM ENG SCI, V84, P351, DOI 10.1016/j.ces.2012.08.050
   Chen-Wiegart YCK, 2014, J POWER SOURCES, V249, P349, DOI 10.1016/j.jpowsour.2013.10.026
   Cieszko M, 2009, ARCH MECH, V61, P425
   Coleman SW, 2008, PHYS REV E, V78, DOI 10.1103/PhysRevE.78.016308
   Delarue A., 2003, IMAGE ANAL STEREOL, V22, P153
   Duda A, 2011, PHYS REV E, V84, DOI 10.1103/PhysRevE.84.036319
   Espinoza M, 2015, ECS TRANSACTIONS, V65, P59, DOI 10.1149/06501.0059ecst
   Farlenkov A.S., 2015, CHIMICA TECHNO ACTA, V2, P16, DOI [10.15826/chimtech.2015.2.1.002, DOI 10.15826/CHIMTECH.2015.2.1.002]
   FUKAI Y, 1984, J LESS-COMMON MET, V101, P1, DOI 10.1016/0022-5088(84)90084-5
   Gao HY, 2012, T NONFERR METAL SOC, V22, P2179, DOI 10.1016/S1003-6326(11)61446-5
   Gommes CJ, 2009, AICHE J, V55, P2000, DOI 10.1002/aic.11812
   Grisan E, 2008, IEEE T MED IMAGING, V27, P310, DOI 10.1109/TMI.2007.904657
   Guo PJ, 2012, TRANSPORT POROUS MED, V95, P285, DOI 10.1007/s11242-012-0043-8
   Herremans E, 2015, BMC PLANT BIOL, V15, DOI 10.1186/s12870-015-0650-y
   Khabbazi A.E., 2015, THESIS
   Kim AS, 2006, J MEMBRANE SCI, V279, P129, DOI 10.1016/j.memsci.2005.11.042
   KIM JH, 1987, TRANSPORT POROUS MED, V2, P327
   Kong W, 2015, INT J ELECTROCHEM SC, V10, P5800
   Landesfeind J, 2016, J ELECTROCHEM SOC, V163, pA1373, DOI 10.1149/2.1141607jes
   Le LH, 2010, ULTRASONICS, V50, P1, DOI 10.1016/j.ultras.2009.07.011
   Lichtner AZ, 2015, J EUR CERAM SOC, V35, P585, DOI 10.1016/j.jeurceramsoc.2014.09.030
   Manickam SS, 2014, J MEMBRANE SCI, V454, P549, DOI 10.1016/j.memsci.2013.11.044
   Matyka M, 2008, PHYS REV E, V78, DOI 10.1103/PhysRevE.78.026306
   Maude RJ, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-527
   Maxwell James Clerk, 1881, TREATISE ELECT MAGNE, V1
   Melo LF, 2005, WATER SCI TECHNOL, V52, P77
   Moh'd B.K, 2015, JORD J EARTH ENVIRON, V7, P71
   Moldrup P, 2001, SOIL SCI SOC AM J, V65, P613, DOI 10.2136/sssaj2001.653613x
   Moreau E, 1999, GEODERMA, V92, P55, DOI 10.1016/S0016-7061(99)00025-7
   Muraoka Y, 2014, INVEST OPHTH VIS SCI, V55, P134, DOI 10.1167/iovs.13-13201
   NEALE GH, 1973, AICHE J, V19, P112, DOI 10.1002/aic.690190116
   Nwaizu Charles, 2015, Canadian Biosystems Engineering, V57, DOI 10.7451/CBE.2015.57.3.13
   Pawlowski S, 2018, CHEM ENG J, V350, P757, DOI 10.1016/j.cej.2018.06.017
   Pisani L, 2011, TRANSPORT POROUS MED, V88, P193, DOI 10.1007/s11242-011-9734-9
   Promentilla MAB, 2009, CEMENT CONCRETE RES, V39, P548, DOI 10.1016/j.cemconres.2009.03.005
   QUINTARD M, 1993, CHEM ENG SCI, V48, P2537, DOI 10.1016/0009-2509(93)80266-S
   QUINTARD M, 1993, TRANSPORT POROUS MED, V11, P187, DOI 10.1007/BF01059634
   Ranachowski Z, 2015, ARCH METALL MATER, V60, P1115, DOI 10.1515/amm-2015-0140
   Rezanezhad F., 2009, HYDROL EARTH SYST SC, V6, P3835, DOI [10.5194/hessd-6-3835-2009., DOI 10.5194/HESSD-6-3835-2009]
   Sasongko M. B., 2015, CURR EYE RES, V41, P1, DOI DOI 10.3109/02713683.2015.1034371
   Schneemann A, 2014, CHEM SOC REV, V43, P6062, DOI 10.1039/c4cs00101j
   Shen L, 2007, CHEM ENG SCI, V62, P3748, DOI 10.1016/j.ces.2007.03.041
   Sobieski W, 2012, TRANSPORT POROUS MED, V93, P431, DOI 10.1007/s11242-012-9961-8
   Solorzano E., 2013, 1 INT C TOM MAT STRU, P71
   Sugiyama T., 2007, P 32 C OUR WORLD CON
   SUNAGAWA I, 1999, FORMA, V14, P147
   Szczepanski Z., 2010, NANOTECHNOL MAT, P90
   Vallavh R., 2009, THESIS
   Vogel HJ, 1997, EUR J SOIL SCI, V48, P365, DOI 10.1046/j.1365-2389.1997.00096.x
   Vogel HJ, 1998, EUR J SOIL SCI, V49, P547, DOI 10.1046/j.1365-2389.1998.4940547.x
   Wang Ping, 2014, MATH PROBL ENG, V2014, P1, DOI DOI 10.1155/2014/694350.ARTICLE
   WHITAKER S, 1977, ADV HEAT TRANSFER, V13, P119
   Wiedenmann D, 2013, AICHE J, V59, P1446, DOI 10.1002/aic.14094
   Yamashita T, 2009, MATER TRANS, V50, P373, DOI 10.2320/matertrans.MRA2008207
   Zalc JM, 2004, CHEM ENG SCI, V59, P2947, DOI 10.1016/j.ces.2004.04.028
NR 63
TC 0
Z9 0
U1 1
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 519
EP 530
DI 10.1016/j.ces.2018.09.051
PG 12
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500046
DA 2020-05-12
ER

PT J
AU Fazli-Abukheyli, R
   Darvishi, P
AF Fazli-Abukheyli, Ruhollah
   Darvishi, Parviz
TI Combination of axial dispersion and velocity profile in parallel
   tanks-in-series compartment model for prediction of residence time
   distribution in a wide range of non-ideal laminar flow regimes
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Non-ideal reactor; Laminar flow; RTD prediction; Tanks-in-series
   compartment model; Axial dispersion; Velocity profile
ID TUBULAR REACTORS; TAYLOR FLOW; DIFFUSION; FLUIDS; POWER
AB The residence time distribution is an important characteristic in the analysis of non-ideal reactors. In micro-reactors that operate predominantly under low Reynolds number, the axial dispersion is important. Since the channel length or residence time of fluid is usually not long enough, the axial dispersion model cannot predict an accurate RTD of the fluid in micro-reactors. In order to overcome this dilemma, a new model has been developed in the present work that combines the axial dispersion and velocity profile using the parallel tanks-in-series compartment model. The model comprises of two parameters, including the velocity profile exponent and Peclet number. It can be used for Newtonian and non-Newtonian fluid flow in the reactors with a wide range of Reynolds number and in all ranges of flow regime, including plug, laminar, perfectly mixed, and other profiles between these regimes. After verifying the model, the effects of velocity profile and Peclet number on the RTD of fluid in the tube for m-laminar and y-laminar velocity profiles were evaluated. Then, the RTDs of some previously reported systems such as straight Polytetrafluoroethylene (PTFE) tube, multi-laminated/elongational flow micro-mixer (MEFM-4) and standard T-junction micro-mixer (TjM) were adjusted to the proposed model. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Fazli-Abukheyli, Ruhollah; Darvishi, Parviz] Univ Yasuj, Sch Engn, Dept Chem Engn, Yasuj, Iran.
RP Darvishi, P (reprint author), Univ Yasuj, Sch Engn, Dept Chem Engn, Yasuj, Iran.
EM pdarvishi@yu.ac.ir
OI Fazli-Abukheyli, Ruhollah/0000-0002-7351-2993
CR Adeosun JT, 2010, CHEM ENG SCI, V65, P1865, DOI 10.1016/j.ces.2009.11.038
   Adeosun JT, 2009, CHEM ENG SCI, V64, P2422, DOI 10.1016/j.ces.2009.02.013
   Aubin J, 2009, CHEM ENG PROCESS, V48, P554, DOI 10.1016/j.cep.2008.08.004
   BOORAS GS, 1976, IND ENG CHEM FUND, V15, P249, DOI 10.1021/i160060a004
   Borovinskaya ES, 2013, MICROREACTORS IN PREPARATIVE CHEMISTRY: PRACTICAL ASPECTS IN BIOPROCESSING, NANOTECHNOLOGY, CATALYSIS AND MORE, P297
   Boskovic D, 2008, CHEM ENG J, V135, pS138, DOI 10.1016/j.cej.2007.07.058
   Boskovic D, 2011, CHEM ENG TECHNOL, V34, P361, DOI 10.1002/ceat.201000352
   Bosworth R. C. L., 1948, LOND EDINB DUBLIN PH, V39, P847
   CLELAND FA, 1956, AICHE J, V2, P489, DOI 10.1002/aic.690020414
   DANCKWERTS PV, 1953, CHEM ENG SCI, V2, P1, DOI 10.1016/0009-2509(53)80001-1
   Dantas JATA, 2014, INT J HEAT MASS TRAN, V71, P18, DOI 10.1016/j.ijheatmasstransfer.2013.12.003
   Delaplace G, 2008, CHEM ENG TECHNOL, V31, P231, DOI 10.1002/ceat.200700118
   DONG L, 1994, CHEM ENG SCI, V49, P3511, DOI 10.1016/0009-2509(94)00150-2
   Dong ZY, 2017, AICHE J, V63, P1404, DOI 10.1002/aic.15493
   Embry I, 2013, ISRN CHEM ENG, V2013, P1
   Erdogan S, 2013, CHEM ENG J, V227, P158, DOI 10.1016/j.cej.2012.08.057
   Erdogan S, 2012, CHEM ENG J, V200, P380, DOI 10.1016/j.cej.2012.06.062
   FAN LT, 1966, PROC R SOC LON SER-A, V292, P203, DOI 10.1098/rspa.1966.0129
   Farmer R, 2005, COMPUT CHEM ENG, V29, P2386, DOI 10.1016/j.compchemeng.2005.05.022
   Fillaudeau L, 2009, J FOOD ENG, V95, P489, DOI 10.1016/j.jfoodeng.2009.06.010
   Fogler H. S., 2005, ELEMENTS CHEM REACTI
   Garcia-Serna J, 2007, J SUPERCRIT FLUID, V41, P82, DOI 10.1016/j.supflu.2006.08.016
   Gavriilidis A, 2002, CHEM ENG RES DES, V80, P3, DOI 10.1205/026387602753393196
   Georget E, 2013, J FOOD ENG, V116, P910, DOI 10.1016/j.jfoodeng.2013.01.041
   Gutierrez CGCC, 2010, J FOOD ENG, V98, P248, DOI 10.1016/j.jfoodeng.2010.01.004
   Ham JH, 2004, CHEM ENG TECHNOL, V27, P1172, DOI 10.1002/ceat.200407038
   Hornung CH, 2009, CHEM ENG SCI, V64, P3889, DOI 10.1016/j.ces.2009.05.033
   Ji LJ, 2010, J IND ENG CHEM, V16, P646, DOI 10.1016/j.jiec.2009.09.071
   JOHNSON JL, 1971, IND ENG CHEM PROC DD, V10, P425, DOI 10.1021/i260040a001
   Kohler JM, 2010, CHEM ENG J, V160, P845, DOI 10.1016/j.cej.2010.02.028
   LEE JH, 1993, J FOOD ENG, V18, P413, DOI 10.1016/0260-8774(93)90055-O
   LEVENSPIEL O, 1998, CHEM REACTION ENG
   Levenspiel O., 2002, CHEM REACTOR OMNIBOO
   Lin L, 2014, APPL MATH COMPUT, V247, P494, DOI 10.1016/j.amc.2014.09.012
   Linge S., 2015, TEXTS COMPUTATIONAL
   Liu AL, 2018, TALANTA, V182, P544, DOI 10.1016/j.talanta.2018.02.028
   Lopes JM, 2002, INT J ENG EDUC, V18, P674
   Maloszewski P, 2006, J HYDROL, V331, P630, DOI 10.1016/j.jhydrol.2006.06.014
   MANSOUR AR, 1989, INT COMMUN HEAT MASS, V16, P603, DOI 10.1016/0735-1933(89)90063-8
   Martin AD, 2000, CHEM ENG SCI, V55, P5907, DOI 10.1016/S0009-2509(00)00108-1
   Nauman EB, 2005, IND ENG CHEM RES, V44, P5031, DOI 10.1021/ie049677b
   Ndoye FT, 2012, J FOOD ENG, V112, P158, DOI 10.1016/j.jfoodeng.2012.03.036
   NOVOSAD Z, 1966, CHEM ENG SCI, V21, P405, DOI 10.1016/0009-2509(66)85051-0
   OSBORNE FT, 1975, CHEM ENG SCI, V30, P159, DOI 10.1016/0009-2509(75)80001-7
   Pegoraro PR, 2012, CHEM ENG TECHNOL, V35, P1593, DOI 10.1002/ceat.201200057
   Platzer B, 1999, CHEM-ING-TECH, V71, P795, DOI 10.1002/cite.330710805
   Qi WK, 2013, CHEM ENG SCI, V104, P460, DOI 10.1016/j.ces.2013.09.035
   Salman W, 2004, CHEM ENG J, V101, P391, DOI 10.1016/j.cej.2003.10.027
   Supriyanto E, 2017, INDIAN J SCI TECHNOL, V10, P1
   TRIVEDI RN, 1974, CHEM ENG SCI, V29, P2291, DOI 10.1016/0009-2509(74)80005-9
   Wibel W, 2013, CHEM ENG J, V215, P449, DOI 10.1016/j.cej.2012.10.011
   Worner M, 2007, INT J HEAT FLUID FL, V28, P83, DOI 10.1016/j.ijheatfluidflow.2006.04.011
   Worner M, 2015, CHEM ENG SCI, V122, P555, DOI 10.1016/j.ces.2014.10.015
   Yao XJ, 2015, RENEW SUST ENERG REV, V47, P519, DOI 10.1016/j.rser.2015.03.078
   Zakharov MK, 2006, THEOR FOUND CHEM ENG, V40, P319, DOI 10.1134/S0040579506030134
NR 55
TC 2
Z9 2
U1 2
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 531
EP 540
DI 10.1016/j.ces.2018.09.052
PG 10
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500047
DA 2020-05-12
ER

PT J
AU Kreitz, B
   Wehinger, GD
   Turek, T
AF Kreitz, Bjarne
   Wehinger, Gregor D.
   Turek, Thomas
TI Dynamic simulation of the CO2 methanation in a micro-structured
   fixed-bed reactor
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Dynamic simulation; Methanation; Micro-structured reactor; Carbon
   dioxide; Reactor modeling; Periodic operation
ID POWER-TO-GAS; CARBON-MONOXIDE METHANATION; CATALYTIC METHANATION;
   TRANSIENT-BEHAVIOR; OPERATION; KINETICS; HYDROGENATION; DIOXIDE;
   SURFACE; NICKEL
AB The dynamic operation of methanation reactors is under discussion due to the increasing interest in power-to-gas technology. Here, hydrogen is supplied via a water electrolyzer which is powered by fluctuating renewable energy sources. With dynamic process modeling and simulation, the methanation reactor can be designed. Since the methanation reaction proceeds fast in the presence of an active catalyst and releases a large amount of reaction heat, the model has to account for the pellet phase in terms of energy, species mass and reaction. In this work, a dynamic 1D heterogeneous model is presented. The model describes a micro-structured fixed-bed reactor for the methanation of carbon dioxide under industrially relevant operating conditions with periodic oscillations of the inlet feed composition. The simulation shows that the hot spot temperature changes significantly during the periodic operation, both in position and magnitude. For high frequency changes the reactor behavior moves towards a thermally relaxed steady state. The outlet methane concentration in the dynamic operation does not reach the steady-state value. However, the model reveals interesting insights of the dynamic CO2 methanation, which will be accompanied with experiments in the future. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Kreitz, Bjarne; Wehinger, Gregor D.; Turek, Thomas] Tech Univ Clausthal, Inst Chem & Electrochem Proc Engn, Leibnizstr 17, D-38678 Clausthal Zellerfeld, Germany.
RP Kreitz, B (reprint author), Tech Univ Clausthal, Inst Chem & Electrochem Proc Engn, Leibnizstr 17, D-38678 Clausthal Zellerfeld, Germany.
EM kreitz@icvt.tu-clausthal.de
RI Turek, Thomas/E-1592-2011; Wehinger, Gregor D/AAF-1335-2020
OI Turek, Thomas/0000-0002-7415-1966; Wehinger, Gregor
   D/0000-0002-1774-3391; Kreitz, Bjarne/0000-0003-0158-9147
CR Abbas SZ, 2017, INT J HYDROGEN ENERG, V42, P2889, DOI 10.1016/j.ijhydene.2016.11.093
   Belimov M, 2017, AICHE J, V63, P120, DOI 10.1002/aic.15461
   Bremer J, 2017, AICHE J, V63, P23, DOI 10.1002/aic.15496
   Chein RY, 2016, FUEL, V185, P394, DOI 10.1016/j.fuel.2016.07.123
   Currie R, 2018, ISR J CHEM, V58, P762, DOI 10.1002/ijch.201700134
   De Falco M, 2007, INT J HYDROGEN ENERG, V32, P2902, DOI 10.1016/j.ijhydene.2007.04.014
   Ducamp J, 2017, CAN J CHEM ENG, V95, P241, DOI 10.1002/cjce.22706
   Eisfeld B, 2001, CHEM ENG SCI, V56, P4321, DOI 10.1016/S0009-2509(00)00533-9
   El Sibai A, 2015, COMPUT-AIDED CHEM EN, V37, P1157
   Elnashaie S. S. E. H., 1993, TOPICS CHEM ENG, V7
   Froment G. F., 1972, ADV CHEM SER, V109, P1, DOI 10.1021/ba-1972-0109.ch001
   FULLER EN, 1966, IND ENG CHEM, V58, P19, DOI 10.1021/ie50677a007
   Ghaib K, 2016, CHEM-ING-TECH, V88, P1102, DOI 10.1002/cite.201500180
   Gnielinski V, 2013, VDI HEAT ATLAS, P785, DOI DOI 10.1007/978-3-642-19981-3_42
   Gnielinski V., 2013, VDI WARMEATLAS, P839, DOI DOI 10.1007/978-3-642-19981-3_50
   Gotz M, 2016, RENEW ENERG, V85, P1371, DOI 10.1016/j.renene.2015.07.066
   Gruber M, 2018, CHEM-ING-TECH, V90, P615, DOI 10.1002/cite.201700160
   Guttel R, 2013, CHEM ENG TECHNOL, V36, P1675, DOI 10.1002/ceat.201300223
   Guettel R, 2009, CHEM ENG SCI, V64, P955, DOI 10.1016/j.ces.2008.10.059
   Harriott P, 1975, CHEM ENG J, V10, P65, DOI DOI 10.1016/0300-9467(75)88018-X
   Kang WR, 2013, KOREAN J CHEM ENG, V30, P1386, DOI 10.1007/s11814-013-0047-2
   Kiewidt L, 2015, CHEM ENG SCI, V132, P59, DOI 10.1016/j.ces.2015.03.068
   KLUSACEK K, 1995, CATAL TODAY, V25, P169, DOI 10.1016/0920-5861(95)00106-P
   Kopyscinski J, 2010, J CATAL, V271, P262, DOI 10.1016/j.jcat.2010.02.008
   Koschany F, 2016, APPL CATAL B-ENVIRON, V181, P504, DOI 10.1016/j.apcatb.2015.07.026
   Li XX, 2015, CHINESE J CHEM ENG, V23, P389, DOI 10.1016/j.cjche.2014.11.007
   Li XX, 2013, J PROCESS CONTR, V23, P1360, DOI 10.1016/j.jprocont.2013.09.003
   Linstrom P. J, 1997, 20899 MD NIST
   LUNDE PJ, 1974, IND ENG CHEM PROC DD, V13, P226, DOI 10.1021/i260051a007
   Marwood M, 1996, CAN J CHEM ENG, V74, P660, DOI 10.1002/cjce.5450740516
   MARWOOD M, 1994, CATAL TODAY, V20, P437, DOI 10.1016/0920-5861(94)80137-1
   Marwood M, 1997, APPL CATAL A-GEN, V151, P223, DOI 10.1016/S0926-860X(96)00267-0
   Matthischke S, 2016, FUEL PROCESS TECHNOL, V153, P87, DOI 10.1016/j.fuproc.2016.07.021
   Parlikkad NR, 2013, FUEL, V107, P254, DOI 10.1016/j.fuel.2013.01.024
   Perry R.H., 2008, PERRYS CHEM ENG HDB
   Poling B. E., 2001, PROPERTIES GASES LIQ
   Ronsch S, 2017, CHEM ENG TECHNOL, V40, P2314, DOI 10.1002/ceat.201700229
   Ronsch S, 2016, CHEM ENG TECHNOL, V39, P208, DOI 10.1002/ceat.201500327
   Ronsch S, 2016, FUEL, V166, P276, DOI 10.1016/j.fuel.2015.10.111
   Ronsch S, 2014, CHEM-ING-TECH, V86, P1198, DOI 10.1002/cite.201300046
   Rout KR, 2015, CAN J CHEM ENG, V93, P1222, DOI 10.1002/cjce.22202
   Schildhauer TJ, 2016, SYNTHETIC NATURAL GA, DOI [10.1002/9781119191339, DOI 10.1002/9781119191339]
   Schlereth D, 2014, CHEM ENG RES DES, V92, P702, DOI 10.1016/j.cherd.2013.11.014
   Sharma C. S, 1975, CHEM ENG J, V10, P73, DOI [10.1016/0300-9467(75)88019-1, DOI 10.1016/0300-9467(75)88019-1]
   Solsvik J, 2011, CHEM ENG SCI, V66, P1986, DOI 10.1016/j.ces.2011.01.060
   SOOMRO M, 1979, CAN J CHEM ENG, V57, P24, DOI 10.1002/cjce.5450570104
   STUCHLY V, 1993, J CATAL, V139, P62, DOI 10.1006/jcat.1993.1007
   Sudiro M, 2010, COMPUT-AIDED CHEM EN, V28, P691
   Tsotsas E., 2013, VDI WARMEATLAS, P1517, DOI [10.1007/978-3-642-19981-3_102, DOI 10.1007/978-3-642-19981-3_102]
   Ullrich C., 2013, VDI WARMEATLAS, P629, DOI DOI 10.1007/978-3-642-19981-3_28
   UNDERWOOD RP, 1984, J CATAL, V86, P245, DOI 10.1016/0021-9517(84)90370-1
   Ursua A, 2013, INT J HYDROGEN ENERG, V38, P14952, DOI 10.1016/j.ijhydene.2013.09.085
   VANDOESBURG H, 1976, CHEM ENG SCI, V31, P53, DOI 10.1016/0009-2509(76)85008-7
   VANDOESBURG H, 1976, CHEM ENG SCI, V31, P45, DOI 10.1016/0009-2509(76)85007-5
   Vesselli E, 2011, J PHYS CHEM C, V115, P1255, DOI 10.1021/jp106551r
   Witte J, 2018, ENERG CONVERS MANAGE, V171, P750, DOI 10.1016/j.enconman.2018.05.056
   XU JG, 1989, AICHE J, V35, P88, DOI 10.1002/aic.690350109
   YADAV R, 1990, CHEM ENG SCI, V45, P3221, DOI 10.1016/0009-2509(90)80214-Y
   YADAV R, 1992, IND ENG CHEM RES, V31, P502, DOI 10.1021/ie00002a009
NR 59
TC 6
Z9 6
U1 11
U2 38
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 541
EP 552
DI 10.1016/j.ces.2018.09.053
PG 12
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500048
DA 2020-05-12
ER

PT J
AU Mouallem, J
   Niaki, SRA
   Chavez-Cussy, N
   Milioli, CC
   Milioli, FE
AF Mouallem, Joseph
   Niaki, Seyed R. A.
   Chavez-Cussy, Norman
   Milioli, Christian C.
   Milioli, Fernando E.
TI Macro-scale effects over filtered and residual stresses in gas-solid
   riser flows
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Fluidization; Gas-particle flow; Two-fluid model; Filtered stresses;
   Residual stresses
ID PARTICLE FLOWS; EULERIAN APPROACH; 2-FLUID MODELS; 2-PHASE FLOW;
   SIMULATION; DRAG; TRANSPORT
AB Sub-grid models for filtered and residual stresses are required as closures in filtered two-fluid modeling of gas-solid fluidized flows. An approach for deriving such models consists of filtering over results from highly resolved simulations with microscopic two-fluid modeling, which are mostly performed under suspension like conditions as separation of scales is assumed. This means that no macro-scale effects are accounted for. In this work effects of flow macro-scale are evaluated by practicing conditions from suspensions up to pneumatic transport, under solid concentrations typical of risers, applying highly resolved simulations with microscopic two-fluid modeling in periodic domains. Results show that the domain average gas Reynolds number and the domain average solid volume fraction both considerably affect filtered and residual stresses of both phases. It becomes evident that accurate sub-grid models require macro-scale effects to be accounted for. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Mouallem, Joseph; Niaki, Seyed R. A.; Chavez-Cussy, Norman; Milioli, Christian C.; Milioli, Fernando E.] Univ Sao Paulo, Sch Engn Sao Carlos, Dept Mech Engn, BR-13566590 Sao Carlos, SP, Brazil.
RP Milioli, FE (reprint author), Univ Sao Paulo, Sch Engn Sao Carlos, Dept Mech Engn, BR-13566590 Sao Carlos, SP, Brazil.
EM milioli@sc.usp.br
RI Mouallem, Joseph/M-7853-2018
OI Mouallem, Joseph/0000-0003-2468-3056
FU State of Sao Paulo Research Foundation (FAPESP), BrazilFundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); National Council for
   Scientific and Technological Development (CNPq), BrazilNational Council
   for Scientific and Technological Development (CNPq); Coordination for
   the Improvement of Higher Level Personnel (CAPES), BrazilCAPES
FX This work was supported by The State of Sao Paulo Research Foundation
   (FAPESP), The National Council for Scientific and Technological
   Development (CNPq), and The Coordination for the Improvement of Higher
   Level Personnel (CAPES), all from Brazil.
CR Agrawal K, 2001, J FLUID MECH, V445, P151, DOI 10.1017/S0022112001005663
   Agrawal K, 2013, CHEM ENG SCI, V95, P291, DOI 10.1016/j.ces.2013.03.017
   ANDERSON TB, 1967, IND ENG CHEM FUND, V6, P527, DOI 10.1021/i160024a007
   Andrews AT, 2005, IND ENG CHEM RES, V44, P6022, DOI 10.1021/ie0492193
   Chavez-Cussy N, 2017, THESIS
   Enwald H, 1996, INT J MULTIPHAS FLOW, V22, P21, DOI 10.1016/S0301-9322(96)90004-X
   Fede P, 2006, PHYS FLUIDS, V18, DOI 10.1063/1.2189288
   Garzo V, 1999, PHYS REV E, V59, P5895, DOI 10.1103/PhysRevE.59.5895
   Gidaspow D., 1994, MULTIPHASE FLOW FLUI
   Igci Y, 2008, AICHE J, V54, P1431, DOI 10.1002/aic.11481
   Igci Y, 2011, IND ENG CHEM RES, V50, P13190, DOI 10.1021/ie200190q
   Igci Y, 2011, AICHE J, V57, P2691, DOI 10.1002/aic.12486
   Ishii M., 1975, THERMOFLUID DYNAMIC
   Jackson R., 2000, DYNAMICS FLUIDIZED P
   JENKINS JT, 1983, J FLUID MECH, V130, P187, DOI 10.1017/S0022112083001044
   JOHNSON PC, 1987, J FLUID MECH, V176, P67, DOI 10.1017/S0022112087000570
   Li J., 1994, PARTICLE FLUID 2 PHA
   LUN CKK, 1984, J FLUID MECH, V140, P223, DOI 10.1017/S0022112084000586
   Milioli CC, 2013, AICHE J, V59, P3265, DOI 10.1002/aic.14130
   Milioli CC, 2011, IND ENG CHEM RES, V50, P13538, DOI 10.1021/ie1020975
   Mouallem J, 2018, CHEM ENG SCI, V182, P200, DOI 10.1016/j.ces.2018.02.039
   Ozel A, 2013, INT J MULTIPHAS FLOW, V55, P43, DOI 10.1016/j.ijmultiphaseflow.2013.04.002
   Parmentier JF, 2012, AICHE J, V58, P1084, DOI 10.1002/aic.12647
   Qi HY, 2007, CHEM ENG SCI, V62, P1670, DOI 10.1016/j.ces.2005.07.002
   Sarkar A, 2016, CHEM ENG SCI, V152, P443, DOI 10.1016/j.ces.2016.06.023
   Schneiderbauer S, 2014, AICHE J, V60, P839, DOI 10.1002/aic.14321
   Sinclair J. L., 1997, CIRCULATING FLUIDIZE
   Sundaresan S, 2000, AICHE J, V46, P1102, DOI 10.1002/aic.690460602
   Syamlal M, 1998, DEAC2195MC31346
   Syamlal M, 1993, DOEMETC941004
   van der Hoef M.A., 2006, ADV CHEM ENG, P65, DOI DOI 10.1016/S0065-2377(06)31002-2
   Wang SA, 2011, POWDER TECHNOL, V208, P98, DOI 10.1016/j.powtec.2010.12.007
   Wang W, 2007, CHEM ENG SCI, V62, P208, DOI 10.1016/j.ces.2006.08.017
   Wen C.Y., 1966, CHEM ENG PROGR S SER, V62, P100, DOI DOI 10.1016/S0032-0633(98)00014-2
NR 34
TC 6
Z9 5
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 553
EP 564
DI 10.1016/j.ces.2018.09.054
PG 12
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500049
DA 2020-05-12
ER

PT J
AU Defrenne, Y
   Zhdankin, V
   Ramanna, S
   Ramaswamy, S
   Ramarao, BV
AF Defrenne, Y.
   Zhdankin, V
   Ramanna, S.
   Ramaswamy, S.
   Ramarao, B., V
TI The dual phase moisture conductivity of fibrous materials using random
   walk techniques in X-ray microcomputed tomographic structures
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Three dimensional structure; Porous materials; Simultaneous diffusion;
   Dual phase diffusion; Random walk method; Intrinsic diffusivity
ID COMPUTER-SIMULATION; DIFFUSION; PAPER; MICROTOMOGRAPHY; TRANSPORT;
   DIFFUSIVITIES
AB Molecular and energy transport in several porous materials can occur through both the pore space as well as the solid phase. In the case of paper and paperboard structures, moisture can be conducted via diffusion in the air through the pore space under low moisture conditions, but primarily through the fiber phase at high moisture contents. Prediction of the overall diffusivity or conductivity in such cases can become quite complex and the impact of the pore-fiber microstructure on transport is not possible. In the present work, a new method based on random walk inside the pore space allowing for a restricted walk inside the conducting fiber phases was applied to show the impact of this dual conduction on the overall transport of moisture (or analogously, heat). Model verification using periodic array of spheres showed the non-linear relationship between normalized effective diffusivity and porosity of the structure in correspondence with Archie's equation and agreeing reasonably well with literature. The structures of samples of paperboard were first assembled using X Ray Computed Tomographic (XR-CT) reconstruction after which a hybrid random walk algorithm was implemented. The walker was allowed to penetrate the fiber space in proportion to the conductivity ratio and also with an adjusted path length.
   Paper and fiber structures are strongly anisotropic, with the structure in the thickness dimension (z) being different from the in-plane dimensions (x, y). This is reflected in the anisotropy of the diffusivity tensor. Assuming fibers to be nonconductive, laboratory made paper fiber structures showed a nonlinear relationship between normalized effective diffusivity and porosity with in-plane direction being more conductive than the transverse direction. Since both the pore and fiber spaces are conductive to moisture, the diffusivity tensor has contributions from each space and can be assembled from the diffusivities in each of these phases individually. An important result from the present work is that initially anisotropic porous structures become more isotropic as the fiber phase becomes more conductive. Experimental diffusivity data and model simulations were compared showing the effect of structure on the anisotropic diffusion characteristics of paper. The results are presented in the form of a proposed 'effective diffusional tortuosity' and the intrinsic fiber diffusivity, as fundamental characteristics of cellulose fibers. With the development of new nanofibrous cellulosic materials, it is expected that net effective conduction parameters accounting for multiple phase random walks will be more prominent in controlling material properties. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Defrenne, Y.; Zhdankin, V; Ramanna, S.; Ramaswamy, S.] Univ Minnesota, Dept Bioprod & Biosyst Engn, St Paul, MN 55108 USA.
   [Ramarao, B., V] SUNY Coll Environm Sci & Forestry, Dept Paper & Bioproc Engn, Syracuse, NY 13210 USA.
RP Ramaswamy, S (reprint author), Univ Minnesota, Dept Bioprod & Biosyst Engn, St Paul, MN 55108 USA.
EM shri@umn.edu
OI Ramarao, Bandaru/0000-0002-1044-2393; /0000-0002-3362-953X
FU Minnesota Agriculture Experiment Station [43-060]; U.S. Department of
   Energy (DOE Project) [DE-FC07-00ID13873]
FX We would like to acknowledge the funding support provided by the
   Minnesota Agriculture Experiment Station (#43-060) and the U.S.
   Department of Energy (DOE Project DE-FC07-00ID13873).
CR Aaltosalmi U, 2004, J PULP PAP SCI, V30, P251
   AKANNI KA, 1987, CHEM ENG SCI, V42, P1945, DOI 10.1016/0009-2509(87)80141-0
   Archie G., 1942, T AIME SOC PETROLEUM
   Bandyopadhyay A, 2002, COLLOID SURFACE A, V206, P455, DOI 10.1016/S0927-7757(02)00067-5
   Bandyopadhyay A, 2000, IND ENG CHEM RES, V39, P219, DOI 10.1021/ie990279w
   Bird B. R., 2007, TRANSPORT PHENOMENA
   Chinga-Carrasco G, 2008, J PULP PAP SCI, V34, P13
   CUSSLER EL, 1997, DIFFUSION MASS TRANS
   Defrenne Y, 2009, ADVANCES IN PULP AND PAPER RESEARCH, OXFORD 2009, VOLS 1-3, P455
   Defrenne Y, 2017, TAPPI J, V16, P519
   du Roscoat SR, 2012, J MATER SCI, V47, P6517, DOI 10.1007/s10853-012-6575-z
   du Roscoat SR, 2005, J PHYS D APPL PHYS, V38, pA78, DOI 10.1088/0022-3727/38/10A/015
   Eitzman D, 1992, DIFFUSION FLAKE FILL
   Eitzman DM, 1996, AICHE J, V42, P2, DOI 10.1002/aic.690420103
   Goel A, 2003, NUMERICAL METHODS IM
   Goel A, 2000, STRUCTURE PERMEABILI
   Gommes CJ, 2009, AICHE J, V55, P2000, DOI 10.1002/aic.11812
   Gupta M. K., 2004, MODELING SIMULTANEOU
   Hwang S, 2012, PHYS REV LETT, V109, DOI 10.1103/PhysRevLett.109.088701
   Hyvaluoma J, 2007, PHYS REV E, V75, DOI 10.1103/PhysRevE.75.036301
   Koivu V, 2009, INT J COMPUT FLUID D, V23, P713, DOI 10.1080/10618561003727512
   KOPLIK J, 1984, J APPL PHYS, V56, P3127, DOI 10.1063/1.333872
   Kuang X, 2015, J ENVIRON ENG, V141, DOI 10.1061/(ASCE)EE.1943-7870.0000826
   LASO M, 1994, AICHE J, V40, P1297, DOI 10.1002/aic.690400804
   Lavrykov S, 2016, DRY TECHNOL, V34, P871, DOI 10.1080/07373937.2015.1057837
   Lavrykov SA, 2012, DRY TECHNOL, V30, P297, DOI 10.1080/07373937.2011.638148
   LINDSAY JD, 1993, TAPPI J, V76, P119
   Massoquete A, 2005, TAPPI J, V4, P3
   Massoquete A., 2003, 2003 International Paper Physics Conference. Preprints, P253
   Massoquete A, 2005, J PULP PAP SCI, V31, P121
   Matsumoto M., 1998, ACM Transactions on Modeling and Computer Simulation, V8, P3, DOI 10.1145/272991.272995
   Melkote R. R., 1990, MODELLING TRANSPORT
   MELKOTE RR, 1992, AICHE J, V38, P56, DOI 10.1002/aic.690380106
   Muter D, 2015, J PHYS CHEM C, V119, P10329, DOI 10.1021/jp5117867
   Nakashima Y, 2002, WATER RESOUR RES, V38, DOI 10.1029/2001WR000937
   Nakashima Y, 2004, J CONTAM HYDROL, V74, P253, DOI 10.1016/j.jconhyd.2004.03.002
   Ramanna S., 2017, C TRAD SHOW PAPERCON
   Ramarao BV, 2003, DRY TECHNOL, V21, P2007, DOI 10.1081/DRT-120027044
   du Roscoat SR, 2007, ACTA MATER, V55, P2841, DOI 10.1016/j.actamat.2006.11.050
   Samuelsen EJ, 2001, J PULP PAP SCI, V27, P50
   Shen L, 2007, CHEM ENG SCI, V62, P3748, DOI 10.1016/j.ces.2007.03.041
   SIEGEL RA, 1986, J COLLOID INTERF SCI, V109, P426, DOI 10.1016/0021-9797(86)90320-6
   Stauffer D., 1992, INTRO PERCOLATION TH
   STEIN M, 1987, TECHNOMETRICS, V29, P143, DOI 10.2307/1269769
   TAPPI (Techncial Association of the Pulp and Paper Industry), 1999, 227OM99 TAPPI, P1
   Tomadakis MM, 1996, J CHEM PHYS, V104, P6893, DOI 10.1063/1.471356
   TORQUATO S, 1989, APPL PHYS LETT, V55, P1847, DOI 10.1063/1.102184
   Watanabe Y, 2002, COMPUT GEOSCI-UK, V28, P583, DOI 10.1016/S0098-3004(01)00057-7
   Young IT., 1983, CYTOMETRY, V4, P184, DOI DOI 10.1002/CYT0.990040213
   Zalc JM, 2003, CHEM ENG SCI, V58, P4605, DOI 10.1016/j.ces.2003.07.008
   ZHENG LH, 1989, J CHEM PHYS, V90, P322, DOI 10.1063/1.456532
NR 51
TC 0
Z9 0
U1 1
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 565
EP 577
DI 10.1016/j.ces.2018.09.055
PG 13
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500050
DA 2020-05-12
ER

PT J
AU Hallett, WLH
   Busigin, MK
   Berdusco, D
   Wiens, E
AF Hallett, William L. H.
   Busigin, Marina K.
   Berdusco, Dana
   Wiens, Evan
TI Pressure loss in packed beds of binary mixtures of angular
   parallelepipeds
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Packed bed; Pressure drop; Particle mixtures; Non-spherical particles;
   Effective surface area
ID PARTICLE-SIZE DISTRIBUTION; FIXED-BEDS; FLOW-THROUGH; FLUID-FLOW; DROP;
   POROSITY; WALL; PACKING; PERMEABILITY; EQUATIONS
AB Pressure loss measurements for packed beds of binary mixtures of angular parallelepipedal particles are reported for a range of Reynolds numbers from 40 to 800. Mixture void fractions generally lay between values for beds of the individual particles, but in two cases were lower than either component void fraction. Particles were found to overlap to a considerable degree in the bed, resulting in a reduction of effective surface area by up to 33%. A modified version of the Nemec and Levec (2005) pressure loss correlation which accounts for particle interference was used to estimate the degree of overlap, and gave values which agreed well with those estimated from photographs of the bed. This provides the means to estimate the effective specific surface area of a particle mixture of known component properties. It is shown that the appropriate parameters to use for a mixture are the volume-surface or Sauter mean diameter and a similarly defined average particle sphericity. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Hallett, William L. H.; Busigin, Marina K.; Berdusco, Dana; Wiens, Evan] Univ Ottawa, Dept Mech Engn, Ottawa, ON, Canada.
RP Hallett, WLH (reprint author), Univ Ottawa, Dept Mech Engn, Ottawa, ON, Canada.
EM hallett@uottawa.ca
FU Natural Sciences and Engineering Research Council (Canada)Natural
   Sciences and Engineering Research Council of Canada [RGPIN/001650-2011];
   Faculty of Engineering, University of Ottawa
FX The authors are grateful for the financial support of the Natural
   Sciences and Engineering Research Council (Canada) through Discovery
   Grant RGPIN/001650-2011 to W. Hallett. M. Busigin received partial
   support through a student award from the Faculty of Engineering,
   University of Ottawa.
CR Allen KG, 2013, POWDER TECHNOL, V246, P590, DOI 10.1016/j.powtec.2013.06.022
   Bird R.B., 1960, TRANSPORT PHENOMENA
   Burke SP, 1928, IND ENG CHEM, V20, P1196, DOI 10.1021/ie50227a025
   Carman P.C., 1937, T I CHEM ENG-LOND, V15, P17, DOI [10.1016/S0263-8762(97)80003-2, DOI 10.1016/S0263-8762(97)80003-2]
   COMITI J, 1989, CHEM ENG SCI, V44, P1539, DOI 10.1016/0009-2509(89)80031-4
   DIXON AG, 1988, CAN J CHEM ENG, V66, P705, DOI 10.1002/cjce.5450660501
   Dorai F, 2015, CHEM ENG SCI, V129, P180, DOI 10.1016/j.ces.2015.01.070
   Eisfeld B, 2001, CHEM ENG SCI, V56, P4321, DOI 10.1016/S0009-2509(00)00533-9
   ERGUN S, 1952, CHEM ENG PROG, V48, P89
   ERGUN S, 1952, ANAL CHEM, V24, P388, DOI 10.1021/ac60062a033
   Finkers HJ, 1998, AICHE J, V44, P495, DOI 10.1002/aic.690440227
   GAMSON BW, 1951, CHEM ENG PROG, V47, P19
   GLASER MB, 1958, AICHE J, V4, P63, DOI 10.1002/aic.690040113
   Hamel S, 2012, BIOMASS BIOENERG, V46, P203, DOI 10.1016/j.biombioe.2012.08.025
   Hamel S, 2008, POWDER TECHNOL, V188, P55, DOI 10.1016/j.powtec.2008.03.011
   Harrison LD, 2013, AICHE J, V59, P703, DOI 10.1002/aic.14034
   JU CC, 1953, CHEM ENG PROG, V49, P141
   Lee H, 2014, J IND ENG CHEM, V20, P1397, DOI 10.1016/j.jiec.2013.07.024
   Lee QF, 2005, CAN J CHEM ENG, V83, P755
   Li LX, 2018, ANN NUCL ENERGY, V112, P62, DOI 10.1016/j.anucene.2017.09.031
   Luckos A, 2011, FUEL, V90, P917, DOI 10.1016/j.fuel.2010.09.020
   MACDONALD IF, 1979, IND ENG CHEM FUND, V18, P199, DOI 10.1021/i160071a001
   Mariani NJ, 2009, INT J CHEM REACT ENG, V7
   Mayerhofer M, 2011, POWDER TECHNOL, V205, P30, DOI 10.1016/j.powtec.2010.08.006
   McCabe W.L., 2005, UNIT OPERATIONS CHEM
   MEHTA D, 1969, IND ENG CHEM PROC DD, V8, P280, DOI 10.1021/i260030a021
   Montillet A, 2001, POWDER TECHNOL, V121, P138, DOI 10.1016/S0032-5910(01)00332-1
   Nemec D, 2005, CHEM ENG SCI, V60, P6947, DOI 10.1016/j.ces.2005.05.068
   Niven RK, 2002, CHEM ENG SCI, V57, P527, DOI 10.1016/S0009-2509(01)00371-2
   Pinto TCS, 2009, MINER METALL PROC, V26, P105, DOI 10.1007/BF03403426
   Rhodes M. J., 2008, INTRO PARTICLE TECHN
   ROBLEE LHS, 1958, AICHE J, V4, P460, DOI 10.1002/aic.690040415
   RUMPF H, 1971, CHEM-ING-TECH, V43, P367, DOI 10.1002/cite.330430610
   SOHN HY, 1968, CAN J CHEM ENG, V46, P162, DOI 10.1002/cjce.5450460305
   Trudel E, 2017, CHEM ENG SCI, V162, P209, DOI 10.1016/j.ces.2017.01.004
   Wang ZC, 2001, CHEM ENG PROCESS, V40, P209, DOI 10.1016/S0255-2701(00)00108-2
   Westman AER, 1936, J AM CERAM SOC, V19, P127, DOI 10.1111/j.1151-2916.1936.tb19809.x
   YOSHIDA F, 1962, AICHE J, V8, P5, DOI 10.1002/aic.690080106
   YU AB, 1993, J AM CERAM SOC, V76, P2813, DOI 10.1111/j.1151-2916.1993.tb04021.x
NR 39
TC 0
Z9 0
U1 1
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 578
EP 584
DI 10.1016/j.ces.2018.09.056
PG 7
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500051
DA 2020-05-12
ER

PT J
AU Hofer, G
   Marzinger, T
   Eder, C
   Proll, F
   Proll, T
AF Hofer, G.
   Maerzinger, T.
   Eder, C.
   Proell, F.
   Proell, T.
TI Particle mixing in bubbling fluidized bed reactors with continuous
   particle exchange
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Bubbling fluidized bed; Tracer experiment; Residence time distribution;
   Particle mixing; Fluidized bed hydrodynamics
ID RESIDENCE TIME DISTRIBUTION; BODENSTEIN NUMBER; SOLIDS; SYSTEM
AB This paper reports on experiments conducted with a cold flow model utilized for the investigation of the particle residence time distribution and mixing characteristics in a bubbling fluidized bed with continuous solids exchange. The investigated system is of a rectangular cross section (0.4 x 0.2 m) with a bed height of 0.17 m. A measurement device based on an alternating current bridge circuitry coupled with lock-in amplifier technology was built in the scope of quantifying the solids residence time distribution, whereby a pulse-injected ferromagnetic tracer creates the input signal. The implementation of a profound mathematical routine ensures the reproducible calculation of the particles mean residence time and characteristic values describing particle mixing phenomena. Therefore, the E-curve was modeled by mathematical convolution of the exit age distributions available for an ideally mixed continuous stirred tank reactor and a plug flow reactor with axial dispersion. It is shown that the in-bed mixing is highly dependent on the fluidization rate as well as on the solids circulation rate. Albeit the lowest superficial gas velocity equals a fluidization number of 4.7, the formation of dead spaces and short-circuit flows was observed under these conditions. Axial dispersion coefficients in the range of 5.10(-3) to 7.10(-1) m(-2) s(-1) were obtained. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Hofer, G.; Maerzinger, T.; Eder, C.; Proell, F.; Proell, T.] Univ Nat Resources & Life Sci, Inst Chem & Energy Engn, Peter Jordan Str 82, A-1190 Vienna, Austria.
RP Hofer, G (reprint author), Univ Nat Resources & Life Sci, Inst Chem & Energy Engn, Peter Jordan Str 82, A-1190 Vienna, Austria.
EM gerhard.hofer@boku.ac.at
OI Eder, Christoph/0000-0002-0057-8561; Proll, Tobias/0000-0001-6240-1916
FU Institute of Sanitary Engineering and Water Pollution Control (SIG)
FX The authors gratefully acknowledge the support by the Institute of
   Sanitary Engineering and Water Pollution Control (SIG), in particular
   the head of the institute Thomas Ertl for providing the lab facilities
   and Friedrich Kropitz for technical support.
CR AnalogDevices, 2015, BAL MOD DEM AD630 RE
   AVIDAN A, 1985, AICHE J, V31, P835, DOI 10.1002/aic.690310520
   Bachmann P, 2017, POWDER TECHNOL, V308, P378, DOI 10.1016/j.powtec.2016.11.025
   Bachmann P, 2016, POWDER TECHNOL, V301, P1067, DOI 10.1016/j.powtec.2016.07.045
   Bachmann P, 2015, PROCEDIA ENGINEER, V102, P790, DOI 10.1016/j.proeng.2015.01.190
   BELLGARDT D, 1986, POWDER TECHNOL, V48, P173, DOI 10.1016/0032-5910(86)80076-6
   Carpenter Technology, 2018, MAGN PROP STAINL STE
   Chen K, 2017, PARTICUOLOGY, V34, P134, DOI 10.1016/j.partic.2017.02.003
   Fitzgerald T., 1977, CIRCULATING FLUIDIZE, VV, P135
   Fogler H. S., 2015, ELEMENTS CHEM REACTI
   Gao YJ, 2012, POWDER TECHNOL, V228, P416, DOI 10.1016/j.powtec.2012.05.060
   GELDART D, 1973, POWDER TECHNOL, V7, P285, DOI 10.1016/0032-5910(73)80037-3
   Guio-Perez DC, 2013, CHEM ENG SCI, V104, P269, DOI 10.1016/j.ces.2013.08.047
   Guio-Perez DC, 2013, IND ENG CHEM RES, V52, P10732, DOI 10.1021/ie400211h
   Guio-Perez DC, 2013, POWDER TECHNOL, V239, P147, DOI 10.1016/j.powtec.2013.01.040
   Harris AT, 2003, CHEM ENG SCI, V58, P2181, DOI 10.1016/S0009-2509(03)00082-4
   Kong WB, 2018, CHEM ENG SCI, V187, P213, DOI 10.1016/j.ces.2018.04.073
   Kunii D., 1991, FLUIDIZATION ENG
   LEVENSPIEL O, 1998, CHEM REACTION ENG
   Nauman EB, 2008, IND ENG CHEM RES, V47, P3752, DOI 10.1021/ie071635a
   NILSSON L, 1988, CHEM ENG SCI, V43, P1153, DOI 10.1016/0009-2509(88)85075-9
   Proll T, 2016, CHEM ENG SCI, V141, P166, DOI 10.1016/j.ces.2015.11.005
   Sette E, 2015, FUEL PROCESS TECHNOL, V138, P368, DOI 10.1016/j.fuproc.2015.06.016
   Sette E, 2014, POWDER TECHNOL, V263, P74, DOI 10.1016/j.powtec.2014.04.091
   SYDENHAM P, 2005, HDB MEASURING SYSTEM
   YAGI S, 1961, CHEM ENG SCI, V16, P364, DOI 10.1016/0009-2509(61)80043-2
NR 26
TC 1
Z9 1
U1 2
U2 21
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 585
EP 597
DI 10.1016/j.ces.2018.10.001
PG 13
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500052
DA 2020-05-12
ER

PT J
AU Xu, HH
   Liu, FS
   Sun, SZ
   Meng, S
   Zhao, YJ
AF Xu, Huanhuan
   Liu, Fengshan
   Sun, Shaozeng
   Meng, Shun
   Zhao, Yijun
TI A systematic numerical study of the laminar burning velocity of
   iso-octane/syngas/air mixtures
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Laminar burning velocity; Iso-octane; Syngas; Pathway analysis
ID PRIMARY REFERENCE FUELS; FLAME SPEEDS; EMISSIONS PERFORMANCE; HYDROGEN
   ADDITION; ELEVATED PRESSURES; GASOLINE-ENGINE; H-2 ADDITION; AIR
   MIXTURES; N-HEPTANE; COMBUSTION
AB The laminar burning velocities of iso-octane/syngas/air mixtures were numerically investigated using a detailed reaction mechanism over a wide range of equivalence ratio (0.4-1.4) at atmospheric and elevated pressure at an initial temperature of 423 K. The mole fraction of syngas in the fuel mixture was varied from the entire range of 0 (pure iso-octane) to 1 (pure syngas). To take into account the large variations of syngas compositions, the following three syngas compositions are considered: 75%H-2-25% CO, 50%H-2-50%CO3 and 25%H-2-75%CO by volume. The results show that the laminar burning velocity of iso-octane/syngas/air mixtures increases with the content of syngas, especially for higher H-2 content in syngas and rich mixtures. The enhanced burning velocity is attributed to the chemical effects of H-2 in syngas. The burning velocity correlates linearly with the level of syngas dilution of the fuel mixture, regardless of how the syngas dilution ratio is defined when the dilution level is low. The linear correlation remains over a wide range of syngas dilution when the dilution ration is defined as that introduced by Yu et al. (1986). H-2 addition and CO addition affect the radical pool differently and H is found to be a kinetics indicator for the burning velocity of iso-octane/syngas/air mixtures under the current conditions. Detailed sensitivity and pathway analysis was also conducted to identify reactions that significantly affect the burning velocity of iso-octane/syngas/air mixtures and to illustrate the kinetics interactions between H-2, CO, and iso-octane in iso-octane/syngas/air mixtures. (C) 2018 Published by Elsevier Ltd.
C1 [Xu, Huanhuan] Shandong Univ, Sch Energy & Power Engn, Natl Engn Lab Coal Fired Pollut Emiss Reduct, Jinan 250061, Shandong, Peoples R China.
   [Xu, Huanhuan; Liu, Fengshan] Natl Res Council Canada, Measurement Sci & Stand, Bldg M-9,1200 Montreal Rd, Ottawa, ON K1A 0R6, Canada.
   [Sun, Shaozeng; Zhao, Yijun] Harbin Inst Technol, Combust Engn Res Inst, Sch Energy Sci & Engn, Harbin, Heilongjiang, Peoples R China.
   [Meng, Shun] Hefei Univ Technol, Sch Automot & Transportat Engn, Hefei, Anhui, Peoples R China.
RP Liu, FS (reprint author), Natl Res Council Canada, Measurement Sci & Stand, Bldg M-9,1200 Montreal Rd, Ottawa, ON K1A 0R6, Canada.; Zhao, YJ (reprint author), Harbin Inst Technol, Sch Energy Sci & Engn, 92 West Dazhi St, Harbin 150001, Heilongjiang, Peoples R China.
EM fengshan.liu@nrc-cnrc.gc.ca; zhaoyijun@hit.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51476048]; Foundation for Innovative Research
   Groups of the National Natural Science Foundation of ChinaNational
   Natural Science Foundation of China [51421063]
FX This work was supported by the National Natural Science Foundation of
   China under Grant No. 51476048 and the Foundation for Innovative
   Research Groups of the National Natural Science Foundation of China
   under Grant No. 51421063.
CR Bhattacharya A, 2017, COMBUST THEOR MODEL, V21, P228, DOI 10.1080/13647830.2016.1215533
   Bouvet N, 2013, INT J HYDROGEN ENERG, V38, P5949, DOI 10.1016/j.ijhydene.2013.02.098
   Cai LM, 2015, COMBUST FLAME, V162, P1623, DOI 10.1016/j.combustflame.2014.11.018
   Chaos M, 2007, INT J CHEM KINET, V39, P399, DOI 10.1002/kin.20253
   Cheng Y, 2015, INT J HYDROGEN ENERG, V40, P703, DOI 10.1016/j.ijhydene.2014.11.010
   Dai XX, 2012, INT J HYDROGEN ENERG, V37, P14624, DOI 10.1016/j.ijhydene.2012.07.039
   Di Sarli V, 2007, INT J HYDROGEN ENERG, V32, P637, DOI 10.1016/j.ijhydene.2006.05.016
   Di Sarli V, 2012, INT J HYDROGEN ENERG, V37, P16201, DOI 10.1016/j.ijhydene.2012.08.061
   Halter F, 2005, P COMBUST INST, V30, P201, DOI 10.1016/j.proci.2004.08.195
   Hassan MI, 1997, J PROPUL POWER, V13, P239, DOI 10.2514/2.5154
   Hu EJ, 2009, INT J HYDROGEN ENERG, V34, P6951, DOI 10.1016/j.ijhydene.2009.06.072
   Hu EJ, 2009, INT J HYDROGEN ENERG, V34, P4876, DOI 10.1016/j.ijhydene.2009.03.058
   Huang Y, 2004, COMBUST FLAME, V139, P239, DOI 10.1016/j.combustflame.2004.08.011
   Huang ZH, 2006, COMBUST FLAME, V146, P302, DOI 10.1016/j.combustflame.2006.03.003
   Ji CW, 2013, INT J HYDROGEN ENERG, V38, P11169, DOI 10.1016/j.ijhydene.2013.02.101
   Ji CW, 2010, INT J HYDROGEN ENERG, V35, P1453, DOI 10.1016/j.ijhydene.2009.11.051
   Ji CW, 2010, INT J HYDROGEN ENERG, V35, P346, DOI 10.1016/j.ijhydene.2009.10.074
   Ji CW, 2009, INT J HYDROGEN ENERG, V34, P7823, DOI 10.1016/j.ijhydene.2009.06.082
   Kee R. J., 1989, CHEMKIN 2 FORTRAN CH
   Kee R. J., 1985, PREMIX FORTRAN PROGR
   Kirwan J. E., 2002, 01487191 SAE
   Kohn MP, 2011, IND ENG CHEM RES, V50, P3570, DOI 10.1021/ie101937s
   Kumar K, 2007, J PROPUL POWER, V23, P428, DOI 10.2514/1.24391
   Law CK, 2004, INT J HYDROGEN ENERG, V29, P867, DOI 10.1016/j.ijhydene.2003.09.012
   Li ZS, 2015, FUEL, V158, P443, DOI 10.1016/j.fuel.2015.05.070
   Lieuwen T, 2009, SYNTHESIS GAS COMBUS
   Liguras DK, 2003, APPL CATAL B-ENVIRON, V43, P345, DOI 10.1016/S0926-3373(02)00327-2
   Ma FH, 2007, INT J HYDROGEN ENERG, V32, P5067, DOI 10.1016/j.ijhydene.2007.07.048
   Park C, 2010, FUEL, V89, P2118, DOI 10.1016/j.fuel.2010.03.018
   REFAEL S, 1989, COMBUST FLAME, V78, P326, DOI 10.1016/0010-2180(89)90021-7
   Ren JY, 2001, COMBUST FLAME, V124, P717, DOI 10.1016/S0010-2180(00)00205-4
   REVEL J, 1994, J CHIM PHYS PCB, V91, P365, DOI 10.1051/jcp/1994910365
   Shinagawa T., 2004, 01487191 SAE
   Sileghem L, 2014, FUEL, V115, P32, DOI 10.1016/j.fuel.2013.07.004
   Sileghem L, 2013, FUEL, V112, P355, DOI 10.1016/j.fuel.2013.05.049
   Subramanian G, 2007, COMBUST SCI TECHNOL, V179, P1937, DOI 10.1080/00102200701386065
   Sun SZ, 2016, INT J HYDROGEN ENERG, V41, P3272, DOI 10.1016/j.ijhydene.2015.11.120
   Sung CJ, 2001, COMBUST FLAME, V126, P1699, DOI 10.1016/S0010-2180(01)00284-X
   Tahtouh T, 2011, INT J HYDROGEN ENERG, V36, P985, DOI 10.1016/j.ijhydene.2010.08.148
   Takashi H, 2006, LAMINAR FLAME SPEEDS
   Tang CL, 2011, P COMBUST INST, V33, P921, DOI 10.1016/j.proci.2010.05.039
   Tang CL, 2008, INT J HYDROGEN ENERG, V33, P4906, DOI 10.1016/j.ijhydene.2008.06.063
   Tang CL, 2008, INT J HYDROGEN ENERG, V33, P7274, DOI 10.1016/j.ijhydene.2008.08.053
   Tomita E, 2007, CIMAC C
   Topinka J. A., 2004, 01487191 SAE
   van Lipzig JPJ, 2011, FUEL, V90, P2773, DOI 10.1016/j.fuel.2011.04.029
   Wu FJ, 2011, INT J HYDROGEN ENERG, V36, P13171, DOI 10.1016/j.ijhydene.2011.07.021
   Yamamoto K, 2009, P COMBUST INST, V32, P1227, DOI 10.1016/j.proci.2008.06.077
   YU G, 1986, COMBUST FLAME, V63, P339, DOI 10.1016/0010-2180(86)90003-9
   Zeng MR, 2017, COMBUST FLAME, V184, P41, DOI 10.1016/j.combustflame.2017.05.028
NR 50
TC 2
Z9 2
U1 0
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 598
EP 608
DI 10.1016/j.ces.2018.10.002
PG 11
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500053
DA 2020-05-12
ER

PT J
AU Pan, FS
   Wang, HJ
   Li, WD
   Zhang, SB
   Sun, J
   Yang, H
   Wang, MD
   Wang, MR
   Zhou, XD
   Liu, X
   Jiang, ZY
AF Pan, Fusheng
   Wang, Hongjian
   Li, Weidong
   Zhang, Shengbo
   Sun, Jie
   Yang, Hao
   Wang, Medi
   Wang, Manru
   Zhou, Xiaodi
   Liu, Xiao
   Jiang, Zhongyi
TI Constructing rapid diffusion pathways in ultrapermeable hybrid membranes
   by hierarchical porous nanotubes
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Hybrid membranes; Hierarchical porous structure; Organosilica nanotubes;
   Separation of organic mixtures; Pervaporation; Desulfurization
ID MIXED MATRIX MEMBRANES; WATER TRANSPORT; HYDRODYNAMICS
AB Constructing mass transfer highways in polymer membranes via fillers with hierarchical porous and/or hollow structure is an effective approach to enhance their separation performance. In this study, novel hierarchical porous organosilica nanotubes (HPSiNT) were designed and incorporated into Pebax matrix to fabricate hybrid membranes for organic solvent separation. The HPSiNT, with plenty of micropores (similar to 1.6 nm) on the wall of nanotubes and atomically smooth meso-inner channels (similar to 6 nm), offer abundant entrances and rapid diffusion pathways for penetrant molecules, thus endowing the hybrid membranes with superior separation performance. Employing thiophene/n-octane feed solution as a model system, the hybrid membrane that consists of 2 wt% HPSiNT exhibited a high permeation flux of 19.0 kg/(m(2) h) (increased by 66.8% compared with pure Pebax membrane) and thiophene/n-octane enrichment factor of 5.5 (increased by 11.7% compared with pure Pebax membrane), respectively. Introducing hierarchical nano-channels in polymeric matrices could open a new avenue to designing hybrid membranes with high permeation flux. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Pan, Fusheng; Wang, Hongjian; Li, Weidong; Zhang, Shengbo; Sun, Jie; Yang, Hao; Wang, Medi; Wang, Manru; Zhou, Xiaodi; Liu, Xiao; Jiang, Zhongyi] Tianjin Univ, Sch Chem Engn & Technol, Minist Educ, Key Lab Green Chem Technol, Tianjin 300072, Peoples R China.
   [Pan, Fusheng; Wang, Hongjian; Li, Weidong; Sun, Jie; Yang, Hao; Wang, Medi; Wang, Manru; Zhou, Xiaodi; Jiang, Zhongyi] Collaborat Innovat Ctr Chem Sci & Engn Tianjin, Tianjin 300072, Peoples R China.
   [Pan, Fusheng; Jiang, Zhongyi] Tianjin Polytech Univ, State Key Lab Separat Membranes & Membrane Proc, Tianjin 300387, Peoples R China.
   [Liu, Xiao] Cent China Normal Univ, Coll Chem, Minist Educ, Key Lab Pesticide & Chem Biol, Wuhan 430079, Hubei, Peoples R China.
RP Liu, X; Jiang, ZY (reprint author), Tianjin Univ, Sch Chem Engn & Technol, 92 Weijin Rd, Tianjin 300072, Peoples R China.
EM liuxiao71@tju.edu.cn; zhyjiang@tju.edu
RI Pan, Fusheng/E-1885-2018; Liu, Xiao/L-3213-2017
OI Pan, Fusheng/0000-0002-4941-1295; Liu, Xiao/0000-0001-6653-1582
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21490583, 21306131, 21621004]; National Science
   Fund for Distinguished Young ScholarsNational Natural Science Foundation
   of ChinaNational Science Fund for Distinguished Young Scholars
   [21125627]; Open Project Program of State Key Laboratory of Petroleum
   Pollution Control [PPC2017014]; CNPC Research Institute of Safety and
   Environmental Technology
FX This work was financially supported by the National Natural Science
   Foundation of China (No. 21490583, 21306131 and 21621004), the National
   Science Fund for Distinguished Young Scholars (21125627), the Open
   Project Program of State Key Laboratory of Petroleum Pollution Control
   (Grant No. PPC2017014), CNPC Research Institute of Safety and
   Environmental Technology.
CR Celebi K, 2014, SCIENCE, V344, P289, DOI 10.1126/science.1249097
   Cheng X., 2017, J MEMBR SCI, V541
   Cheng Y., 2017, J MEMBR SCI
   Corry B, 2008, J PHYS CHEM B, V112, P1427, DOI 10.1021/jp709845u
   Ding H, 2017, J MEMBRANE SCI, V526, P94, DOI 10.1016/j.memsci.2016.12.020
   Gai JG, 2014, J MATER CHEM A, V2, P4023, DOI 10.1039/c3ta14256f
   Geise GM, 2013, ACS APPL MATER INTER, V5, P10294, DOI 10.1021/am403207w
   Holt JK, 2006, SCIENCE, V312, P1034, DOI 10.1126/science.1126298
   Howorka S, 2017, NAT NANOTECHNOL, V12, P619, DOI [10.1038/nnano.2017.99, 10.1038/NNANO.2017.99]
   Hummer G, 2001, NATURE, V414, P188, DOI 10.1038/35102535
   Khayet M, 2011, ADV COLLOID INTERFAC, V164, P56, DOI 10.1016/j.cis.2010.09.005
   Konatham D, 2013, LANGMUIR, V29, P11884, DOI 10.1021/la4018695
   Li B, 2010, IND ENG CHEM RES, V49, P12444, DOI 10.1021/ie101142b
   Liu X, 2011, CHEM COMMUN, V47, P8073, DOI 10.1039/c1cc12136g
   Majumder M, 2005, NATURE, V438, P44, DOI 10.1038/43844a
   Mitra D, 2012, SEP PURIF REV, V41, P97, DOI 10.1080/15422119.2011.573044
   Mortaheb HR, 2012, CHEM ENG RES DES, V90, P409, DOI 10.1016/j.cherd.2011.07.019
   Pan F., 2018, J MEMBR SCI, V552
   Pan F., 2017, J MEMBR SCI, V545
   Park HB, 2017, SCIENCE, V356, DOI 10.1126/science.aab0530
   Park HG, 2014, CHEM SOC REV, V43, P565, DOI 10.1039/c3cs60253b
   Rezakazemi M, 2014, PROG POLYM SCI, V39, P817, DOI 10.1016/j.progpolymsci.2014.01.003
   Robeson LM, 2008, J MEMBRANE SCI, V320, P390, DOI 10.1016/j.memsci.2008.04.030
   Robeson LM, 2007, J MEMBRANE SCI, V302, P70, DOI 10.1016/j.memsci.2007.06.029
   Shen YX, 2015, P NATL ACAD SCI USA, V112, P9810, DOI 10.1073/pnas.1508575112
   Suk ME, 2013, RSC ADV, V3, P9365, DOI 10.1039/c3ra40661j
   Suk ME, 2010, J PHYS CHEM LETT, V1, P1590, DOI 10.1021/jz100240r
   Wang LD, 2017, NAT NANOTECHNOL, V12, P509, DOI [10.1038/nnano.2017.72, 10.1038/NNANO.2017.72]
   Wang ZG, 2016, ADV MATER, V28, P3399, DOI 10.1002/adma.201504982
   Werber JR, 2016, NAT REV MATER, V1, DOI 10.1038/natrevmats.2016.18
   Yang H, 2016, J MEMBRANE SCI, V520, P583, DOI 10.1016/j.memsci.2016.08.022
   Zhang S., 2017, APPL CATAL B, V220
   Zhu CQ, 2014, J CHEM PHYS, V141, DOI 10.1063/1.4898075
   Zhu YX, 2010, J MEMBRANE SCI, V349, P341, DOI 10.1016/j.memsci.2009.11.065
NR 34
TC 5
Z9 5
U1 9
U2 45
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 609
EP 618
DI 10.1016/j.ces.2018.10.003
PG 10
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500054
DA 2020-05-12
ER

PT J
AU Chen, ZY
   Feng, S
   Zhang, LZ
   Shi, Q
   Xu, ZM
   Zhao, SQ
   Xu, CM
AF Chen, Zhengyu
   Feng, Song
   Zhang, Linzhou
   Shi, Quan
   Xu, Zhiming
   Zhao, Suoqi
   Xu, Chunming
TI Molecular-level kinetic modelling of fluid catalytic cracking slurry oil
   hydrotreating
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE SLO hydrotreating; Kinetic model; QSRC; Trickle-bed reactor model
ID POLYNUCLEAR AROMATIC-HYDROCARBONS; COMPLEX-REACTION SYSTEMS; SIMULATION;
   HYDROCRACKING; HYDROGENATION; FEEDSTOCKS; REACTIVITY; CHEMISTRY
AB In this study, a molecular-level kinetic model of fluid catalytic cracking (FCC) slurry oil (SLO) hydrotreating in a trickle-bed reactor was developed. The physical and chemical properties of SLO were measured, and the data were used as input to tune the composition model parameters. A series of reaction rules were collected and established in terms of the reaction family according to the hydrotreating reaction mechanism. After applying the reaction rules on all the SLO molecules, a reaction network was generated containing 5,753 molecules and 15,830 reactions. The kinetic model was then built employing the Langmuir-Hinshelwood-Hougen-Watson (LHHW) formalism. The kinetic model parameters were reduced using the linear free energy relationship (LFER) and quantitative structure-reactivity correlations (QSRCs). The kinetic model was delivered to the trickle-bed reactor model, and the model parameters were tuned using experimental data obtained from a pilot hydrotreating unit. The obtained SLO hydrotreating model showed good agreement between the predicted and experimental product properties and composition under various processing conditions. The model was able to predict the concentration distribution of each species along the reactor. In addition, the influence of reaction temperature on the aromatic content and thiophene compound content was also evaluated. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Chen, Zhengyu; Feng, Song; Zhang, Linzhou; Shi, Quan; Xu, Zhiming; Zhao, Suoqi; Xu, Chunming] China Univ Petr, State Key Lab Heavy Oil Proc, Beijing 102249, Peoples R China.
RP Zhang, LZ (reprint author), China Univ Petr, State Key Lab Heavy Oil Proc, Beijing 102249, Peoples R China.
EM lzz@cup.edu.cn; sqzhao@cup.edu.cn
OI Zhang, Linzhou/0000-0002-8354-784X
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21506254]; Science Foundation of China University
   of Petroleum, Beijing [2462014YJRC020, 2462018BJC003]
FX This work was supported by National Natural Science Foundation of China
   (No. 21506254) and Science Foundation of China University of Petroleum,
   Beijing (No. 2462014YJRC020, 2462018BJC003).
CR Ahmed T. H., 1989, CONTRIBUTIONS PETROL
   Alvarez A, 2008, APPL CATAL A-GEN, V351, P148, DOI 10.1016/j.apcata.2008.09.010
   Alvarez-Majmutov A, 2017, IND ENG CHEM RES, V56, P6926, DOI 10.1021/acs.iecr.7b01743
   Alvarez-Majmutov A, 2016, ENERG FUEL, V30, P138, DOI [10.1021/acs.energyfuels.5b02084, 10.1021/acs.energyfuels.5b02082]
   Alvarez-Majmutov A, 2014, IND ENG CHEM RES, V53, P10566, DOI 10.1021/ie501032j
   Beauharnois ME, 2001, CARBON, V39, P2101, DOI 10.1016/S0008-6223(01)00045-8
   Becker PJ, 2015, FUEL, V139, P133, DOI 10.1016/j.fuel.2014.08.032
   Chen M, 2017, INT J CHEM ENG, DOI 10.1155/2017/4824376
   Choudhary T. V., 2006, ANGEW CHEM, V118, P3377
   Christensen G, 1999, CHEM ENG SCI, V54, P2753, DOI 10.1016/S0009-2509(99)00002-0
   Cooper BH, 1996, APPL CATAL A-GEN, V137, P203, DOI 10.1016/0926-860X(95)00258-8
   de Oliveira LP, 2014, CATAL TODAY, V220, P208, DOI 10.1016/j.cattod.2013.08.011
   de Oliveira LP, 2012, CHEM ENG J, V207, P94, DOI 10.1016/j.cej.2012.05.039
   Du HB, 2005, APPL CATAL A-GEN, V294, P1, DOI 10.1016/j.apcata.2005.06.033
   Evans M.G., 1935, PROG THEOR PHYS, V56, P1965
   Froment G.F., 1990, CHEM REACTOR ANAL DE
   Froment GF, 1999, CATAL TODAY, V52, P153, DOI 10.1016/S0920-5861(99)00073-5
   Ghosh P, 2009, ENERG FUEL, V23, P5743, DOI 10.1021/ef900632v
   GIRGIS MJ, 1991, IND ENG CHEM RES, V30, P2021, DOI 10.1021/ie00057a001
   GOTO S, 1975, AICHE J, V21, P706, DOI 10.1002/aic.690210410
   He S, 2017, ENERG FUEL, V31, P9881, DOI 10.1021/acs.energyfuels.7b01202
   Horton SR, 2015, IND ENG CHEM RES, V54, P4226, DOI 10.1021/ie5041572
   Hudebine D, 2004, CHEM ENG SCI, V59, P4755, DOI 10.1016/j.ces.2004.09.019
   Jarullah AT, 2011, FUEL, V90, P2165, DOI 10.1016/j.fuel.2011.01.025
   Jarullah AT, 2011, CHEM ENG SCI, V66, P859, DOI 10.1016/j.ces.2010.11.016
   Klein MT, 2005, MOL MODELING HEAVY H
   Korre S. C., 1994, QUANTITATIVE STRUCTU
   KORRE SC, 1994, CHEM ENG SCI, V49, P4191, DOI 10.1016/S0009-2509(05)80015-6
   KORRE SC, 1995, IND ENG CHEM RES, V34, P101, DOI 10.1021/ie00040a008
   Korre SC, 1997, IND ENG CHEM RES, V36, P2041, DOI 10.1021/ie9606808
   Korsten H, 1996, AICHE J, V42, P1350, DOI 10.1002/aic.690420515
   Kumar H, 2007, IND ENG CHEM RES, V46, P5881, DOI 10.1021/ie0704290
   Laxminarasimhan CS, 1996, AICHE J, V42, P2645, DOI 10.1002/aic.690420925
   Li WD, 2016, ENERG FUEL, V30, P10064, DOI 10.1021/acs.energyfuels.6b01132
   Liu JC, 2017, IND ENG CHEM RES, V56, P3568, DOI 10.1021/acs.iecr.7b00320
   MARTENS JA, 1986, APPL CATAL, V20, P239
   MOCHIDA I, 1988, CARBON, V26, P57, DOI 10.1016/0008-6223(88)90009-7
   MOCHIDA I, 1967, J CATAL, V7, P393, DOI 10.1016/0021-9517(67)90168-6
   NEUROCK M, 1990, CHEM ENG SCI, V45, P2083, DOI 10.1016/0009-2509(90)80080-X
   Nguyen TTH, 2017, ENERG FUEL, V31, P5673, DOI 10.1021/acs.energyfuels.7b00360
   Peng, 1999, MOL MODELLING PETROL
   QUANN RJ, 1992, IND ENG CHEM RES, V31, P2483, DOI 10.1021/ie00011a013
   Quann RJ, 1996, CHEM ENG SCI, V51, P1615, DOI 10.1016/0009-2509(96)00023-1
   Reid RC, 1987, PROPERTIES GASES LIQ
   Tian LD, 2012, IND ENG CHEM RES, V51, P3923, DOI 10.1021/ie2025272
   VRINAT ML, 1983, APPL CATAL, V6, P137, DOI 10.1016/0166-9834(83)80260-7
   Wu Y., 2010, MOL MANAGEMENT REFIN
   Zhang LZ, 2014, ENERG FUEL, V28, P1736, DOI 10.1021/ef402081x
NR 48
TC 5
Z9 5
U1 7
U2 35
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 619
EP 630
DI 10.1016/j.ces.2018.10.007
PG 12
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500055
DA 2020-05-12
ER

PT J
AU Faezian, A
   Yeganehzad, S
   Tighchi, HA
AF Faezian, Ali
   Yeganehzad, Samira
   Tighchi, Hashem Ahmadi
TI A simplified model to describe drainage of egg white powder foam
   containing additives
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Foam; Egg white powder; Additive; Drainage; Mathematical model
ID AQUEOUS FOAMS; STABILITY
AB This paper presents a theoretical model to describe liquid drainage of foams prepared from egg white powder with added an additive while reflecting the validity of the model. Having utilized some simplifying assumptions in the non-linear partial differential equation of the foam drainage, an analytical solution for free drainage was obtained. To compare the results of the theoretical model and the experimental approach, a number of experiments were conducted in order to measure the drainage of foams prepared from egg white powder with added sugar (10% and 30%), xanthan gum (0.01% and 0.05%) and Chubak extract (0.01% and 0.05%). First, an analysis was performed on the physical properties of the solutions, i.e. density, viscosity and surface tension so that the influence of the additive's presence would be examined. Moreover, the image analysis was applied to allow the assessment of the initial bubble size distributions. The experimental and theoretical drainage curves of different foams showed that foam drainage rate decreased due to the influences of the above-mentioned additives. According to the obtained results, the mathematical model can be adopted to estimate foam drainage rate. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Faezian, Ali] RIFST, Dept Food Machinery Design, POB 91895-157-356, Mashhad, Iran.
   [Yeganehzad, Samira] RIFST, Dept Food Proc, POB 91895-157-356, Mashhad, Iran.
   [Tighchi, Hashem Ahmadi] Shahrood Univ Technol, Dept Mech Engn, Shahrood, Iran.
RP Faezian, A (reprint author), RIFST, Dept Food Machinery Design, POB 91895-157-356, Mashhad, Iran.
EM a.faezian@rifst.ac.ir
RI yeganehzad, samira/Z-5435-2019
OI yeganehzad, samira/0000-0001-7467-4778; Ahmadi Tigh chi,
   Hashem/0000-0002-5000-7695; Faezian, Ali/0000-0002-6445-3055
CR Aghel N, 2007, IRAN J PHARM RES, V6, P167
   Alquran M, 2014, MATH SCI, V8, P153, DOI 10.1007/s40096-015-0141-1
   Anazadehsayed A, 2017, CHEM ENG SCI, V166, P11, DOI 10.1016/j.ces.2017.03.008
   CUNNINGHAM FE, 1976, POULTRY SCI, V55, P738, DOI 10.3382/ps.0550738
   Durand M, 2002, EUR PHYS J E, V7, P35, DOI 10.1140/epje/i200101092
   GERMICK RJ, 1994, J FOOD ENG, V23, P555, DOI 10.1016/0260-8774(94)90112-0
   Gol'dfarb I. I., 1988, Fluid Dynamics, V23, P244, DOI 10.1007/BF01051894
   Helal MA, 2007, APPL MATH COMPUT, V190, P599, DOI 10.1016/j.amc.2007.01.055
   Jun S, 2012, LANGMUIR, V28, P5323, DOI 10.1021/la300412u
   Koehler SA, 2000, LANGMUIR, V16, P6327, DOI 10.1021/la9913147
   Koehler SA, 1998, PHYS REV E, V58, P2097, DOI 10.1103/PhysRevE.58.2097
   Kraynik A. M, 1983, FOAM DRAINAGE
   Lomakina K, 2006, CZECH J FOOD SCI, V24, P110
   Magrabi SA, 2001, AICHE J, V47, P314, DOI 10.1002/aic.690470210
   Papara M, 2009, CHEM ENG SCI, V64, P1404, DOI 10.1016/j.ces.2008.11.021
   Pasban A, 2015, J FOOD PROCESS PRES, V39, P737, DOI 10.1111/jfpp.12283
   Pernell CW, 2002, COLLOID SURFACE A, V204, P9, DOI 10.1016/S0927-7757(01)01061-5
   Podual K, 1996, CHEM ENG SCI, V51, P1393, DOI 10.1016/0009-2509(95)00314-2
   Prins A, 1988, PRINCIPLES FOAM STAB
   Ptaszek P, 2015, J FOOD ENG, V144, P129, DOI 10.1016/j.jfoodeng.2014.07.017
   Raikos V, 2007, FOOD RES INT, V40, P347, DOI 10.1016/j.foodres.2006.10.008
   Sadahira MS, 2014, CARBOHYD POLYM, V103, P55, DOI 10.1016/j.carbpol.2013.11.070
   Sagis LMC, 2001, COLLOID SURFACE A, V180, P163, DOI 10.1016/S0927-7757(00)00734-2
   Saint-Jalmes A, 1999, EUR PHYS J B, V12, P67, DOI 10.1007/s100510050978
   Saint-Jalmes A, 2002, J PHYS-CONDENS MAT, V14, P9397, DOI 10.1088/0953-8984/14/40/325
   Stevenson P, 2007, FOOD HYDROCOLLOID, V21, P221, DOI 10.1016/j.foodhyd.2006.03.009
   Verbist G, 1996, J PHYS-CONDENS MAT, V8, P3715, DOI 10.1088/0953-8984/8/21/002
   Weaire D, 2003, J PHYS-CONDENS MAT, V15, pS65, DOI 10.1088/0953-8984/15/1/307
   Weaire D, 1997, ADV CHEM PHYS <D>, V102, P315, DOI 10.1002/9780470141618.ch5
   Zmudzinski D, 2014, J FOOD ENG, V121, P128, DOI 10.1016/j.jfoodeng.2013.08.020
NR 30
TC 0
Z9 0
U1 3
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 631
EP 641
DI 10.1016/j.ces.2018.10.008
PG 11
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500056
DA 2020-05-12
ER

PT J
AU Mema, I
   Mahajan, VV
   Fitzgerald, BW
   Padding, JT
AF Mema, Ivan
   Mahajan, Vinay V.
   Fitzgerald, Barry W.
   Padding, Johan T.
TI Effect of lift force and hydrodynamic torque on fluidisation of
   non-spherical particles
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE CFD-DEM; Fluidised bed; Gas-solid flow; Non-spherical particles; Lift
   force; Hydrodynamic torque
ID CFD-DEM SIMULATION; BED REACTOR; PARTICULATE SYSTEMS; DRAG COEFFICIENT;
   FLUID-FLOW; BIOMASS; GASIFICATION; PYROLYSIS; MODEL; SCALE
AB The aim of many industrial processes is to manipulate solid particle aggregates within gas suspensions. Prime examples of such processes include fluidised bed reactors, cyclone separators, and dust collectors. In recent years, fluidised bed reactors have been used in the gasification of biomass particles. When fluidised, these particles are subject to various hydrodynamic forces such as drag, lift and torque due to interactions with the fluid. Computational approaches, which can be used to replicate laboratory and industrial scale processes, offer a crucial method for the study of reactor design and for the formulation of optimal operating procedures. Until now, many computer models have assumed particles to be spherical whereas, in reality, biomass feedstocks typically consist of non-spherical particles. While lift and torque are of minimal importance for spherical particles, non-spherical particles experience varying lift force and torque conditions, depending on particle orientation relative to the direction of the fluid velocity. In this study, we present a numerical investigation on the effect of different lift force and torque correlations on fluidised spherocylindrical particles. We find that lift force has a significant influence on particle velocities parallel to the direction of gravity. On the other hand, particle orientation is dependent on hydrodynamic torque. Results from this numerical study provide new insight with regards to the dynamics of non-spherical particles that can be of paramount importance for industrial processes involving non-spherical particles. (C) 2018 The Authors. Published by Elsevier Ltd.
C1 [Mema, Ivan; Mahajan, Vinay V.; Fitzgerald, Barry W.; Padding, Johan T.] Delft Univ Technol, Dept Proc & Energy, Intensified React & Separat Syst, Leeghwaterstr 39, NL-2628 CB Delft, Netherlands.
RP Padding, JT (reprint author), Delft Univ Technol, Dept Proc & Energy, Intensified React & Separat Syst, Leeghwaterstr 39, NL-2628 CB Delft, Netherlands.
EM imema@tudelft.nl; j.t.padding@tudelft.nl
OI Mahajan, Vinay/0000-0002-9427-1164
FU European Research CouncilEuropean Research Council (ERC) [615096]; FP7
   Ideas: European Research Council [615096]
FX The authors thank the European Research Council for its financial
   support under its consolidator grant scheme, contract No. 615096
   (NonSphereFlow). FP7 Ideas: European Research Council, 615096
   (NonSphereFlow). We thank Sathish Sanjeevi for providing fitting
   coefficients listed in the Appendix and for useful discussions.
CR Aharonov E, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.051302
   Aharonov E, 1999, PHYS REV E, V60, P6890, DOI 10.1103/PhysRevE.60.6890
   Alauddin ZABZ, 2010, RENEW SUST ENERG REV, V14, P2852, DOI 10.1016/j.rser.2010.07.026
   Azema E, 2012, PHYS REV E, V85, DOI 10.1103/PhysRevE.85.031303
   Bridgwater AV, 2003, CHEM ENG J, V91, P87, DOI 10.1016/S1385-8947(02)00142-0
   Bridgwater T, 2006, J SCI FOOD AGR, V86, P1755, DOI 10.1002/jsfa.2605
   Buist KA, 2017, AICHE J, V63, P5335, DOI 10.1002/aic.15854
   Buist KA, 2014, AICHE J, V60, P3133, DOI 10.1002/aic.14512
   Cai WF, 2018, FUEL PROCESS TECHNOL, V171, P308, DOI 10.1016/j.fuproc.2017.12.001
   Chen GY, 2017, ENERG CONVERS MANAGE, V138, P556, DOI 10.1016/j.enconman.2017.02.036
   CUNDALL PA, 1979, GEOTECHNIQUE, V29, P47, DOI 10.1680/geot.1979.29.1.47
   Deen NG, 2007, CHEM ENG SCI, V62, P28, DOI 10.1016/j.ces.2006.08.014
   DIFELICE R, 1994, INT J MULTIPHAS FLOW, V20, P153, DOI 10.1016/0301-9322(94)90011-6
   Fitzgerald BW, 2014, PHYSICA A, V410, P582, DOI 10.1016/j.physa.2014.05.046
   Gan JQ, 2016, CHEM ENG SCI, V144, P201, DOI 10.1016/j.ces.2016.01.041
   GANSER GH, 1993, POWDER TECHNOL, V77, P143, DOI 10.1016/0032-5910(93)80051-B
   Gil M, 2014, FUEL, V116, P328, DOI 10.1016/j.fuel.2013.08.011
   Grace J. R., 1997, CIRCULATING FLUIDIZE
   HAIDER A, 1989, POWDER TECHNOL, V58, P63, DOI 10.1016/0032-5910(89)80008-7
   Haustein M, 2017, SOFTWAREX, V6, P118, DOI 10.1016/j.softx.2017.05.001
   Hilton JE, 2010, CHEM ENG SCI, V65, P1584, DOI 10.1016/j.ces.2009.10.028
   Holzer A, 2008, POWDER TECHNOL, V184, P361, DOI 10.1016/j.powtec.2007.08.021
   Holzer A, 2009, COMPUT FLUIDS, V38, P572, DOI 10.1016/j.compfluid.2008.06.001
   Kloss C, 2012, PROG COMPUT FLUID DY, V12, P140, DOI 10.1504/PCFD.2012.047457
   Kohler A, 2017, POWDER TECHNOL, V316, P492, DOI 10.1016/j.powtec.2016.12.093
   Kruggel-Emden H, 2016, PARTICUOLOGY, V29, P1, DOI 10.1016/j.partic.2016.01.004
   Kumar R, 2018, AICHE J, V64, P1986, DOI 10.1002/aic.16082
   Loth E, 2008, POWDER TECHNOL, V182, P342, DOI 10.1016/j.powtec.2007.06.001
   Ma H., 2018, ADV POWDER TECHNOL
   Ma H., 2018, POWDER TECHNOL
   Mahajan Vinay V., 2017, EPJ Web of Conferences, V140, DOI 10.1051/epjconf/201714006019
   Mahajan VV, 2018, CHEM ENG SCI, V192, P1105, DOI 10.1016/j.ces.2018.08.041
   Mahajan VV, 2018, AICHE J, V64, P1573, DOI 10.1002/aic.16078
   Mando M, 2010, POWDER TECHNOL, V202, P1, DOI 10.1016/j.powtec.2010.05.001
   Marschall T, 2018, PHYS REV E, V97, DOI 10.1103/PhysRevE.97.012905
   Mattisson T, 2018, FUEL PROCESS TECHNOL, V172, P1, DOI 10.1016/j.fuproc.2017.11.016
   McKendry P, 2002, BIORESOURCE TECHNOL, V83, P55, DOI 10.1016/S0960-8524(01)00120-1
   Mema I., 2017, P 12 INT C CFD OIL G
   Nikoo MB, 2008, BIOMASS BIOENERG, V32, P1245, DOI 10.1016/j.biombioe.2008.02.020
   Ouchene R, 2016, POWDER TECHNOL, V303, P33, DOI 10.1016/j.powtec.2016.07.067
   Ouchene R, 2015, COMPUT FLUIDS, V113, P53, DOI 10.1016/j.compfluid.2014.12.005
   Peng ZB, 2014, AICHE J, V60, P2000, DOI 10.1002/aic.14421
   Pournin L, 2005, GRANUL MATTER, V7, P119, DOI 10.1007/s10035-004-0188-4
   Richter A, 2013, POWDER TECHNOL, V249, P463, DOI 10.1016/j.powtec.2013.08.044
   Rong LW, 2013, CHEM ENG SCI, V99, P44, DOI 10.1016/j.ces.2013.05.036
   Rosendahl L, 2000, APPL MATH MODEL, V24, P11, DOI 10.1016/S0307-904X(99)00023-2
   Salikov V, 2015, POWDER TECHNOL, V270, P622, DOI 10.1016/j.powtec.2014.05.026
   Sanjeevi SKP, 2018, INT J MULTIPHAS FLOW, V106, P325, DOI 10.1016/j.ijmultiphaseflow.2018.05.011
   Sanjeevi SKP, 2017, J FLUID MECH, V820, DOI 10.1017/jfm.2017.239
   Son SR, 2006, IND ENG CHEM RES, V45, P2689, DOI 10.1021/ie050919x
   Stukowski A, 2010, MODEL SIMUL MATER SC, V18, DOI 10.1088/0965-0393/18/1/015012
   Tran-Cong S, 2004, POWDER TECHNOL, V139, P21, DOI 10.1016/j.powtec.2003.10.002
   TSUJI Y, 1993, POWDER TECHNOL, V77, P79, DOI 10.1016/0032-5910(93)85010-7
   VEGA C, 1994, COMPUT CHEM, V18, P55, DOI 10.1016/0097-8485(94)80023-5
   Vollmari K, 2016, POWDER TECHNOL, V291, P506, DOI 10.1016/j.powtec.2015.11.045
   Vorobiev N, 2017, FUEL, V210, P107, DOI 10.1016/j.fuel.2017.08.037
   Warnecke R, 2000, BIOMASS BIOENERG, V18, P489, DOI 10.1016/S0961-9534(00)00009-X
   Werther J., 2000, FLUIDIZED BED REACTO
   Williams PT, 1999, J ANAL APPL PYROL, V51, P107, DOI 10.1016/S0165-2370(99)00011-X
   Woytiuk K, 2017, RENEW ENERG, V101, P409, DOI 10.1016/j.renene.2016.08.071
   Xu BH, 1997, CHEM ENG SCI, V52, P2785, DOI 10.1016/S0009-2509(97)00081-X
   Xue Y, 2016, FUEL, V166, P227, DOI 10.1016/j.fuel.2015.10.125
   Zastawny M, 2012, INT J MULTIPHAS FLOW, V39, P227, DOI 10.1016/j.ijmultiphaseflow.2011.09.004
   Zhao JD, 2013, POWDER TECHNOL, V239, P248, DOI 10.1016/j.powtec.2013.02.003
   Zhu HP, 2007, CHEM ENG SCI, V62, P3378, DOI 10.1016/j.ces.2006.12.089
   Zhu HP, 2008, CHEM ENG SCI, V63, P5728, DOI 10.1016/j.ces.2008.08.006
NR 66
TC 3
Z9 3
U1 3
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 642
EP 656
DI 10.1016/j.ces.2018.10.009
PG 15
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500057
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Bandulasena, MV
   Vladisavljevic, GT
   Benyahia, B
AF Bandulasena, Monalie, V
   Vladisavljevic, Goran T.
   Benyahia, Brahim
TI Droplet-based microfluidic method for robust preparation of gold
   nanoparticles in axisymmetric flow focusing device
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Reaction droplets; Gold nanoparticles; Glass capillaries; Continuous
   production; Droplet-based micromixer; Droplet microfluidics
ID DOUBLE EMULSIONS; GENERATION; PARTICLES; SIZE
AB A novel microfluidic mixing strategy was developed and used to prepare polyvinylpyrrolidone (PVP) capped gold nanoparticles (AuNPs). In this process, 1 mM tetrachloroauric acid (HAuCl4) stream containing 1% (w/v) PVP was injected through the inner capillary tube and mixed with 20 mM L-ascorbic acid solution delivered co-currently through the outer coaxial capillary. The reaction mixture was hydrodynamically flow focused by the environmentally friendly oil Miglyol 840 delivered from the opposite side of the outer capillary, which resulted in the generation of reaction droplets in a tapered collection tube. The reactants were rapidly mixed within droplets by internal circulating flows induced by hydrodynamic interactions of fluids inside the droplets with the carrier oil. The size of the prepared AuNPs was measured by both dynamic light scattering and transmission electron microscopy and was found to decrease with decreasing the droplet size and increasing the difference in velocity between the two reactant streams, which improved mixing efficiency within droplets. The smallest nanoparticles were obtained when the outlet section of the injection tube was positioned at the entry section of the collection tube due to the highest shear at the liquid interface. The carrier oil formed a hydrophobic barrier between the droplets and the reactor walls preventing deposition of the synthesised particles. As a result, the size of the AuNPs was smaller than in the co-flow mixer operated with two continuous reactant streams. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Bandulasena, Monalie, V; Vladisavljevic, Goran T.; Benyahia, Brahim] Loughborough Univ, Dept Chem Engn, Loughborough LE11 3TU, Leics, England.
RP Vladisavljevic, GT; Benyahia, B (reprint author), Loughborough Univ, Dept Chem Engn, Loughborough LE11 3TU, Leics, England.
EM g.vladisavljevic@lboro.ac.uk; B.Benyalua@lboro.ac.uk
RI Benyahia, Brahim/AAG-5553-2020
OI Benyahia, Brahim/0000-0002-5397-1498; Vladisavljevic,
   Goran/0000-0002-8894-975X
FU EPSRC, UKEngineering & Physical Sciences Research Council (EPSRC)
   [EP/J020184/1]
FX The authors would like to thank Mr Jeff Nan for his assistance in
   experiments during his undergraduate research project and Dr Zhaoxia
   Zhou from the Loughborough Materials Characterization Centre (LMCC),
   Loughborough University, UK for her assistance in the TEM imaging. The
   microfluidic rig used in the project was purchased from the grant
   EP/J020184/1, funded by EPSRC, UK.
CR Bandulasena MV, 2017, CHEM ENG SCI, V171, P233, DOI 10.1016/j.ces.2017.05.035
   Bannock JH, 2014, MATER HORIZONS, V1, P373, DOI 10.1039/c4mh00054d
   Casadevall I, 2010, ANAL CHEM, V82, P3950, DOI [10.1021/ac100055g, DOI 10.1021/AC100055G]
   deMello AJ, 2006, NATURE, V442, P394, DOI 10.1038/nature05062
   Du K, 2010, LANGMUIR, V26, P12518, DOI 10.1021/la100497h
   Duraiswamy S, 2009, SMALL, V5, P2828, DOI 10.1002/smll.200901453
   Ekanem EE, 2017, LANGMUIR, V33, P8476, DOI 10.1021/acs.langmuir.7b02506
   Ellis E, 2017, J MATER CHEM B, V5, P4421, DOI 10.1039/c7tb00654c
   Filatov NA, 2016, J PHYS CONF SER, V741, DOI 10.1088/1742-6596/741/1/012052
   Fissan H, 2014, ANAL METHODS-UK, V6, P7324, DOI 10.1039/c4ay01203h
   Ganan-Calvo AM, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.274501
   Garstecki P., 2005, Bulletin of the Polish Academy of Sciences, Technical Sciences, V53, P361
   Grigoriev RO, 2006, LAB CHIP, V6, P1369, DOI 10.1039/b607003e
   Horikoshi S, 2013, MICROWAVES NANOPARTI, P1, DOI DOI 10.1002/9783527648122
   Huang D, 2003, J ELECTROCHEM SOC, V150, pG412, DOI 10.1149/1.1582466
   Iwakoshi A, 2005, GOLD BULL, V38, P107, DOI 10.1007/BF03215244
   Kaminski TS, 2017, CHEM SOC REV, V46, P6210, DOI 10.1039/c5cs00717h
   Khan S.A, 2010, MINIATURIXED SYSTEMS, P1181
   Kim DK, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2218
   Lee JS, 2010, GOLD BULL, V43, P189, DOI 10.1007/BF03214986
   Marre S, 2010, CHEM SOC REV, V39, P1183, DOI 10.1039/b821324k
   Nabavi SA, 2017, J COLLOID INTERF SCI, V505, P315, DOI 10.1016/j.jcis.2017.05.115
   Nabavi SA, 2015, CHEM ENG SCI, V130, P183, DOI 10.1016/j.ces.2015.03.004
   Nightingale A. M., 2014, NAT COMMUN, P5, DOI DOI 10.1038/NCOMMS4777.3777-1-8
   Othman R, 2015, CHEM ENG SCI, V137, P119, DOI 10.1016/j.ces.2015.06.025
   Phapal SM, 2013, CHEM PHYS LIPIDS, V172, P20, DOI 10.1016/j.chemphyslip.2013.04.006
   Pissuwan D, 2011, J CONTROL RELEASE, V149, P65, DOI 10.1016/j.jconrel.2009.12.006
   Rahman MT, 2014, PROCESSES, V2, P466, DOI 10.3390/pr2020466
   Raj Vidya, 2015, Sensing and Bio-Sensing Research, V5, P33, DOI 10.1016/j.sbsr.2015.05.004
   Rana S, 2012, LANGMUIR, V28, P2023, DOI 10.1021/la204017z
   Sarrazin F, 2007, CHEM ENG SCI, V62, P1042, DOI 10.1016/j.ces.2006.10.013
   Shestopalov I, 2004, LAB CHIP, V4, P316, DOI 10.1039/b403378g
   Song H, 2006, ANGEW CHEM INT EDIT, V45, P7336, DOI 10.1002/anie.200601554
   Song YJ, 2008, SMALL, V4, P698, DOI 10.1002/smll.200701029
   Stone ZB, 2005, PHYS FLUIDS, V17, DOI 10.1063/1.1929547
   Tice JD, 2003, LANGMUIR, V19, P9127, DOI 10.1021/la030090w
   Tyagi H, 2011, INT J NANOSCI, V10, P857, DOI 10.1142/S0219581X11009301
   Utada AS, 2005, SCIENCE, V308, P537, DOI 10.1126/science.1109164
   Vasilescu A, 2012, CURR ANAL CHEM, V8, P495, DOI 10.2174/157341112803216780
   Verma MS, 2014, BIOSENS BIOELECTRON, V61, P386, DOI 10.1016/j.bios.2014.05.045
   Vladisavljevic GT, 2014, COLLOID SURFACE A, V458, P168, DOI 10.1016/j.colsurfa.2014.03.016
   Vladisavljevic GT, 2012, LANGMUIR, V28, P12948, DOI 10.1021/la302092f
   Wagner J, 2004, CHEM ENG J, V101, P251, DOI 10.1016/j.cej.2003.11.021
   Wagner J, 2005, NANO LETT, V5, P685, DOI 10.1021/nl050097t
   Zhao SF, 2012, CHEM ENG J, V207, P267, DOI 10.1016/j.cej.2012.06.098
   Zhao YF, 2016, ADV HEALTHC MATER, V5, P928, DOI 10.1002/adhm.201500992
   Zheng B, 2005, ANGEW CHEM INT EDIT, V44, P2520, DOI 10.1002/anie.200462857
NR 47
TC 0
Z9 0
U1 6
U2 41
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 657
EP 664
DI 10.1016/j.ces.2018.10.010
PG 8
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500058
DA 2020-05-12
ER

PT J
AU Zhang, HX
   Jiang, H
   Xu, QC
   Hu, YJ
   Li, CZ
AF Zhang, Haoxuan
   Jiang, Hao
   Xu, Qiucheng
   Hu, Yanjie
   Li, Chunzhong
TI Rapid low-temperature synthesis of hollow CuS0.55 nanoparticles for
   efficient electrocatalytic water oxidation
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Copper sulfide; Hollow nanoparticles; Water oxidation; Electrocatalysts
ID OXYGEN EVOLUTION REACTION; HIGH-PERFORMANCE ELECTROCATALYSTS; OXIDES;
   NANOSHEETS; CU; HYDROXIDES; ARRAYS; COPPER; SITES; XPS
AB Developing low-cost and binder-free Cu-based electrocatalysts for high-performance oxygen evolution reactions (OER) is of great importance to promote their practical applications. Herein, we demonstrate the low-temperature and rapid synthesis of hollow CuS0.55 nanoparticles on a Cu foam as highly active OER electrocatalysts through an anodic oxidation electrodeposition technique. The large electrochemically active surface area and strong adsorption ability of Cu sites to targeted OOH* intermediates are beneficial for enhancing catalytic properties. As a consequence, the hollow CuS0.55 nanoparticles exhibit an ultralow overpotential of 386 mV to achieve a high current density of 100 mA cm(-2) in alkaline media with a very small Tafel slope of 33 mV dec(-1), which is among the best reported for Cu-based electrocatalysts. The turnover frequency (TOF) is approximately 6 times higher than those of the corresponding CuS0.57 and CuO catalysts. This work provides a simple and feasible approach that can be scaled up easily to construct low-cost and efficient Cu-based OER electrocatalysts. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Zhang, Haoxuan; Jiang, Hao; Xu, Qiucheng; Hu, Yanjie; Li, Chunzhong] East China Univ Sci & Technol, Key Lab Ultrafine Mat, Minist Educ, Sch Mat Sci & Engn, Shanghai 200237, Peoples R China.
RP Jiang, H; Li, CZ (reprint author), East China Univ Sci & Technol, Key Lab Ultrafine Mat, Minist Educ, Sch Mat Sci & Engn, Shanghai 200237, Peoples R China.
EM jianghao@ecust.edu.cn; czli@ecust.edu.cn
RI Hu, Yanjie/U-5465-2017; Li, Chunzhong/B-1103-2015
OI Hu, Yanjie/0000-0003-4531-8429; Li, Chunzhong/0000-0001-7897-5850
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21522602, 91534122, 91534202]; Social Development
   Program of Shanghai [17DZ1200900]; Shanghai Scientific and Technological
   Innovation Project [18JC1410600]; National Program for Support of
   Top-Notch Young Professionals; Fundamental Research Funds for the
   Central UniversitiesFundamental Research Funds for the Central
   Universities [222201718002]
FX This work was supported by the National Natural Science Foundation of
   China (21522602, 91534122 and 91534202), the Social Development Program
   of Shanghai (17DZ1200900), the Shanghai Scientific and Technological
   Innovation Project (18JC1410600), the National Program for Support of
   Top-Notch Young Professionals, and the Fundamental Research Funds for
   the Central Universities (222201718002).
CR An L, 2017, ADV FUNCT MATER, V27, DOI 10.1002/adfm.201703779
   ANTONIDES E, 1977, PHYS REV B, V15, P1669, DOI 10.1103/PhysRevB.15.1669
   Biesinger MC, 2017, SURF INTERFACE ANAL, V49, P1325, DOI 10.1002/sia.6239
   Biesinger MC, 2010, APPL SURF SCI, V257, P887, DOI 10.1016/j.apsusc.2010.07.086
   Cai PW, 2017, ANGEW CHEM INT EDIT, V56, P4858, DOI 10.1002/anie.201701280
   Chen SC, 2017, ACS CENTRAL SCI, V3, P1221, DOI 10.1021/acscentsci.7b00424
   Chen W, 2015, ACS CENTRAL SCI, V1, P244, DOI 10.1021/acscentsci.5b00227
   Deng YL, 2016, ACS CATAL, V6, P2473, DOI 10.1021/acscatal.6b00205
   Dou S, 2016, ENERG ENVIRON SCI, V9, P1320, DOI 10.1039/c6ee00054a
   Dupin JC, 2000, PHYS CHEM CHEM PHYS, V2, P1319, DOI 10.1039/a908800h
   Feng JX, 2016, ANGEW CHEM INT EDIT, V55, P3694, DOI 10.1002/anie.201511447
   Guan C, 2017, ADV MATER, V29, DOI 10.1002/adma.201704117
   Han L, 2016, ADV MATER, V28, P9266, DOI 10.1002/adma.201602270
   Henson MJ, 1999, J AM CHEM SOC, V121, P10332, DOI 10.1021/ja9918425
   Hu CL, 2018, ADV MATER, V30, DOI 10.1002/adma.201705538
   Hu CL, 2017, ADV MATER, V29, DOI 10.1002/adma.201701820
   Jin S, 2017, ACS ENERGY LETT, V2, P1937, DOI 10.1021/acsenergylett.7b00679
   Li Q, 2017, ACS NANO, V11, P12230, DOI 10.1021/acsnano.7b05606
   Li Y, 2018, ACS CATAL, V8, P1913, DOI 10.1021/acscatal.7b03949
   Liu YC, 2016, MATER HORIZ, V3, P402, DOI 10.1039/c6mh00075d
   McCrory CCL, 2015, J AM CHEM SOC, V137, P4347, DOI 10.1021/ja510442p
   Seh ZW, 2017, SCIENCE, V355, DOI 10.1126/science.aad4998
   Shamraiz U, 2016, J SOLID STATE CHEM, V238, P25, DOI 10.1016/j.jssc.2016.02.046
   Stevens M. B., 2016, CHEM MATER, V1, P120
   Subbaraman R, 2012, NAT MATER, V11, P550, DOI [10.1038/NMAT3313, 10.1038/nmat3313]
   Wu YY, 2016, ADV FUNCT MATER, V26, P4839, DOI 10.1002/adfm.201601315
   Xu H, 2017, ACS CATAL, V7, P986, DOI 10.1021/acscatal.6b02911
   Xu X, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12324
   Ye SH, 2018, ANGEW CHEM INT EDIT, V57, P2672, DOI 10.1002/anie.201712549
   Zhang HX, 2018, MATER CHEM FRONT, V2, P1462, DOI 10.1039/c8qm00178b
   Zhang HX, 2017, GREEN ENERGY ENVIRON, V2, P112, DOI 10.1016/j.gee.2016.12.004
   Zhang J, 2016, ENERG ENVIRON SCI, V9, P2789, DOI 10.1039/c6ee01786j
NR 32
TC 10
Z9 10
U1 10
U2 65
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 665
EP 670
DI 10.1016/j.ces.2018.10.011
PG 6
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500059
DA 2020-05-12
ER

PT J
AU Alexander, V
   Albazzaz, H
   Al-Dahhan, M
AF Alexander, Vineet
   Albazzaz, Hamza
   Al-Dahhan, Muthanna
TI Gas phase dispersion/mixing investigation in a representative geometry
   of gas-liquid upflow Moving Bed Hydrotreater Reactor (MBR) using
   developed gas tracer technique and method based on
   convolution/regression
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Residence Time Distribution (RTD); Moving Bed Reactor (MBR); Gas tracer;
   Gas dispersion coefficient; Peclet number; Axial Dispersion Model (ADM)
ID 3-PHASE FLUIDIZED-BED; AXIAL-DISPERSION; PACKED-BED; HOLD-UP; FLOW;
   HYDRODYNAMICS; DIFFUSION; RTD
AB Gas dispersion studies has been executed for the catalyst bed section of a representative geometry of scaled-down industrial Moving Bed Hydrotreater Reactor (MBR). The catalyst bed of MBR is modeled using Axial Dispersion Model (ADM) and its parameters gas dispersion coefficient (D-g) and Peclet number (Pe) are estimated using Residence Time Distribution (RTD) and implementing a methodology based on convolution and regression. Additionally, dimensionless variance (sigma(2)(D)) for the catalyst bed is also measured using RTDs first and second moments to compare with those findings of ADM model. This study is conducted at the varying flow rates of gas and liquid including scaled down operating conditions. The results of D-g, Pe, sigma(2)(D) and indicate that bed behaves as a packed bed for low liquid flow rate and moves towards three-phase fluidized bed for increasing liquid flow rate. Overall the gas phase behavior is seen to be in plug flow for all the operating conditions, with relatively high dispersion/mixing in packed bed state. Scaled down flow conditions is seen to be best in terms of gas dispersion/mixing and catalyst utilization. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Alexander, Vineet] Missouri Univ Sci & Technol, Dept Chem & Biochem Engn, Rolla, MO 65409 USA.
   [Albazzaz, Hamza] Kuwait Inst Sci Res, Safat, Kuwait.
   [Al-Dahhan, Muthanna] Cihan Univ, Erbil, Iraq.
RP Al-Dahhan, M (reprint author), Cihan Univ, Erbil, Iraq.
EM aldahhanm@mst.edu
FU Kuwait Institute for Scientific Research (KISR); Kuwait Petroleum
   Corporation (KPC); Kuwait National Petroleum Company (KNPC)
FX The authors like to acknowledge the financial and technical support
   given by Kuwait Institute for Scientific Research (KISR), Kuwait
   National Petroleum Company (KNPC) and Kuwait Petroleum Corporation
   (KPC). Authors also like to acknowledge Dr. Lu Han and Dr. Rahman
   Abdulmohsin, for their efforts in developing the methods and
   experimental setup related to gaseous tracer technique available at
   Department of Chemical Engineering, Missouri S&T.
CR Abdulmohsin RS, 2016, ANN NUCL ENERGY, V88, P100, DOI 10.1016/j.anucene.2015.10.038
   Beg SA, 1996, CHEM ENG J, V63, P93, DOI 10.1016/0923-0467(96)03080-1
   Benneker AH, 1996, CHEM ENG SCI, V51, P2099, DOI 10.1016/0009-2509(96)00067-X
   Briens LA, 2005, CHEM ENG SCI, V60, P6094, DOI 10.1016/j.ces.2005.04.005
   Bruce E. R., 1999, Gas pocket distributor for hydroprocessing a hydrocarbon feed stream. US Patent, Patent No. [US5885534A, 5885534A]
   CARLETON AJ, 1967, CHEM ENG SCI, V22, P1839, DOI 10.1016/0009-2509(67)80214-8
   Collins JHP, 2017, CHEM ENG SCI, V157, P2, DOI 10.1016/j.ces.2016.04.004
   DANCKWERTS PV, 1953, CHEM ENG SCI, V2, P1, DOI 10.1016/0009-2509(53)80001-1
   Delgado JMPQ, 2006, HEAT MASS TRANSFER, V42, P279, DOI 10.1007/s00231-005-0019-0
   EDWARDS MF, 1968, CHEM ENG SCI, V23, P109, DOI 10.1016/0009-2509(68)87056-3
   FAN LS, 1987, POWDER TECHNOL, V53, P285, DOI 10.1016/0032-5910(87)80101-8
   Fogler H. S., 2005, ELEMENTS CHEM REACTI
   GUNN DJ, 1969, TRANS INST CHEM ENG, V47, pT341
   Han LL, 2007, THESIS
   Iliuta I, 1998, CHEM ENG RES DES, V76, P64, DOI 10.1205/026387698524488
   Jena HM, 2008, CHEM ENG RES DES, V86, P1301, DOI 10.1016/j.cherd.2008.05.007
   Koh JH, 1998, IND ENG CHEM RES, V37, P228, DOI 10.1021/ie970337i
   Kumar S, 2012, PROCEDIA ENGINEER, V42, P782, DOI 10.1016/j.proeng.2012.07.470
   LEVENSPIEL O, 1957, CHEM ENG SCI, V6, P227, DOI 10.1016/0009-2509(57)85021-0
   Midoux N., 1972, Chemical Engineering Journal, V4, P287, DOI 10.1016/0300-9467(72)80026-1
   MUROYAMA K, 1985, AICHE J, V31, P1, DOI 10.1002/aic.690310102
   Pugliese L, 2012, WATER AIR SOIL POLL, V223, P4101, DOI 10.1007/s11270-012-1176-7
   Saroha AK, 2006, CHEM ENG PROCESS, V45, P455, DOI 10.1016/j.cep.2005.11.005
   SHAH YT, 1978, AICHE J, V24, P369, DOI 10.1002/aic.690240302
   Simcik M, 2012, CHEM ENG RES DES, V90, P1739, DOI 10.1016/j.cherd.2012.03.014
   Tang DH, 2004, CHEM ENG TECHNOL, V27, P866, DOI 10.1002/ceat.200402076
   Toukan A, 2017, CHEM ENG SCI, V168, P380, DOI 10.1016/j.ces.2017.04.028
   Valenz L, 2010, IND ENG CHEM RES, V49, P10016, DOI 10.1021/ie101092e
   Yun JX, 2005, CHEM ENG J, V109, P123, DOI 10.1016/j.cej.2005.03.015
NR 29
TC 1
Z9 2
U1 3
U2 15
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 671
EP 682
DI 10.1016/j.ces.2018.10.013
PG 12
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500060
DA 2020-05-12
ER

PT J
AU Zhang, N
   Yang, BY
   Huo, J
   Qi, WX
   Zhang, XP
   Ruan, XH
   Bao, JJ
   He, GH
AF Zhang, Ning
   Yang, Boyun
   Huo, Jun
   Qi, Wenxu
   Zhang, Xiaopeng
   Ruan, Xuehua
   Bao, Junjiang
   He, Gaohong
TI Hydration structures of vanadium/oxovanadium cations in the presence of
   sulfuric acid: A molecular dynamics simulation study
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Vanadium cation; Hydration size; Sulfonate acid; Proton; Molecular
   dynamics simulation
ID PARTICLE MESH EWALD; VANADIUM IONS; REDOX; ELECTROLYTE; TRANSPORT;
   MEMBRANES; PARAMETERS; CHEMISTRY; PROTON; WATER
AB Structure design of proton exchange membrane determines the performance of vanadium redox flow battery. Appropriate pore size of the membrane not only benefits the proton conduction but also blocks the cross contamination of the vanadium cations. For this purpose, hydration sizes of proton, vanadium (II) [V2+], vanadium(III) [V3+], oxovanadium(IV) [VO2+], and dioxovanadium(V) [VO2+] cations were estimated by molecular dynamics simulation based on all-atom force field. The local hydration structures of the vanadium cations were consistent with the previous reports, verifying the adopted force field. V2+, V3+, VO2+, VO2+, and proton exhibit the hydration sizes of 8.24, 8.14, 8.18, 8.34, and 4.12 angstrom in the aqueous mixtures of sulfuric acid and vanadium sulfate. Thus the pore size distribution from 4.12 to 8.14 angstrom was recommended for the membrane fabrication. SO42- prefers to distribute around the vanadium cations due to electrostatic interaction, thus weakening the hydration structures of the vanadium cations. Introducing sulfuric acid decreases the local distributions of SO42- around and V3+, but increases the local distributions of SO42- around VO2+ and VO2+. This work helps to understand the structure of the aqueous mixtures of sulfuric acid and vanadium sulfate. It also provides potential guidance for improving the membrane performance in vanadium redox flow battery. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Zhang, Ning; Yang, Boyun; Huo, Jun; Qi, Wenxu; Zhang, Xiaopeng; Ruan, Xuehua; Bao, Junjiang; He, Gaohong] Dalian Univ Technol, Sch Petr & Chem Engn, State Key Lab Fine Chem, Panjin 124221, Peoples R China.
RP Bao, JJ; He, GH (reprint author), Dalian Univ Technol, Sch Petr & Chem Engn, State Key Lab Fine Chem, Panjin 124221, Peoples R China.
EM baojj@dlut.edu.cn; hgaohong@dlut.edu.cn
OI Bao, Junjiang/0000-0002-0123-1252; Zhang, Ning/0000-0003-2893-5505
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21506019]; Fundamental Research Funds for the
   Central UniversitiesFundamental Research Funds for the Central
   Universities [DUT16RC (4) 80, DUT16QY43]; Program for Changjiang
   ScholarsProgram for Changjiang Scholars & Innovative Research Team in
   University (PCSIRT) [T2012049]
FX This research has been supported by National Natural Science Foundation
   of China (Grant No. 21506019), the Fundamental Research Funds for the
   Central Universities (Grant Nos. DUT16RC (4) 80, DUT16QY43), the Program
   for Changjiang Scholars (T2012049).
CR Bandyopadhyay B, 2012, CHEM PHYS LETT, V530, P10, DOI 10.1016/j.cplett.2012.01.048
   Bon M, 2016, J PHYS CHEM C, V120, P10791, DOI 10.1021/acs.jpcc.6b02642
   BONDI A, 1964, J PHYS CHEM-US, V68, P441, DOI 10.1021/j100785a001
   Buhl M, 2001, CHEM-EUR J, V7, P4487, DOI 10.1002/1521-3765(20011015)7:20<4487::AID-CHEM4487>3.0.CO;2-G
   CANNON WR, 1994, J PHYS CHEM-US, V98, P6225, DOI 10.1021/j100075a027
   Cao L, 2016, ENERGIES, V9, DOI 10.3390/en9121058
   Choi C, 2017, RENEW SUST ENERG REV, V69, P263, DOI 10.1016/j.rser.2016.11.188
   Cui ST, 2015, J PHYS CHEM C, V119, P12848, DOI 10.1021/acs.jpcc.5b02876
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   Darve E, 2008, J CHEM PHYS, V128, DOI 10.1063/1.2829861
   Eigen M., 1958, MATH PHYS ENG SCI, V247, P506
   Guo XJ, 2011, CHINESE J CHEM ENG, V19, P212, DOI 10.1016/S1004-9541(11)60156-0
   Gupta S, 2018, ELECTROCHIM ACTA, V270, P471, DOI 10.1016/j.electacta.2018.03.008
   Gupta S, 2016, J MOL LIQ, V215, P596, DOI 10.1016/j.molliq.2016.01.028
   Henin J, 2010, J CHEM THEORY COMPUT, V6, P35, DOI 10.1021/ct9004432
   Hinkle KR, 2014, J PHYS CHEM C, V118, P23803, DOI 10.1021/jp507155s
   Jang SS, 2004, J PHYS CHEM B, V108, P3149, DOI 10.1021/jp036842c
   Jiang Z, 2016, J CHEM PHYS, V145, DOI 10.1063/1.4962748
   Keshri S, 2016, CHEM PHYS, V476, P80, DOI 10.1016/j.chemphys.2016.08.003
   Koch D, 2018, MRS COMMUN, P1
   Koh P. W., 2014, VISIBLE LIGHT SCI EN, P45
   Krakowiak J, 2012, INORG CHEM, V51, P9598, DOI 10.1021/ic300202f
   Kritayakornupong C, 2009, J COMPUT CHEM, V30, P2777, DOI 10.1002/jcc.21278
   Lawton JS, 2013, J ELECTROCHEM SOC, V160, pA697, DOI 10.1149/2.004306jes
   Li PF, 2013, J CHEM THEORY COMPUT, V9, P2733, DOI 10.1021/ct400146w
   Liu Y.-Y., 2017, SCI CHINA CHEM, V59, P1
   Liu ZC, 2017, CHEMELECTROCHEM, V4, P2184, DOI 10.1002/celc.201700244
   MacKerell AD, 2001, BIOPOLYMERS, V56, P257
   Mai ZS, 2011, J POWER SOURCES, V196, P482, DOI 10.1016/j.jpowsour.2010.07.028
   Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289
   Rahman F, 2009, J POWER SOURCES, V189, P1212, DOI 10.1016/j.jpowsour.2008.12.113
   Roznyatovskaya NV, 2017, J POWER SOURCES, V363, P234, DOI 10.1016/j.jpowsour.2017.07.100
   Sepehr F, 2015, J PHYS CHEM A, V119, P5749, DOI 10.1021/acs.jpca.5b01794
   Sepehr F, 2013, CHEM PHYS LETT, V585, P53, DOI 10.1016/j.cplett.2013.08.089
   Shao Q, 2009, NANO LETT, V9, P989, DOI 10.1021/nl803044k
   Sun CX, 2010, J POWER SOURCES, V195, P890, DOI 10.1016/j.jpowsour.2009.08.041
   Vijayakumar M, 2010, J POWER SOURCES, V195, P7709, DOI 10.1016/j.jpowsour.2010.05.008
   Wernersson E, 2010, J CHEM THEORY COMPUT, V6, P3233, DOI 10.1021/ct100465g
   Xu Z, 2016, J PHYS CHEM C, V120, P26386, DOI 10.1021/acs.jpcc.6b09383
   Yang RD, 2015, J MEMBRANE SCI, V484, P1, DOI 10.1016/j.memsci.2015.03.012
   Yang RD, 2014, J MEMBRANE SCI, V450, P12, DOI 10.1016/j.memsci.2013.08.048
   Yang ZG, 2011, CHEM REV, V111, P3577, DOI 10.1021/cr100290v
   Zhang N, 2017, CHEM ENG SCI, V158, P234, DOI 10.1016/j.ces.2016.10.015
   Zhang N, 2016, PHYS CHEM CHEM PHYS, V18, P24198, DOI 10.1039/c6cp03012b
   Zhao Y, 2015, CHEM SOC REV, V44, P7968, DOI 10.1039/c5cs00289c
   Zhu YD, 2010, FLUID PHASE EQUILIBR, V297, P215, DOI 10.1016/j.fluid.2010.05.005
   Zielkiewicz J, 2005, J CHEM PHYS, V123, DOI 10.1063/1.2018637
NR 47
TC 4
Z9 4
U1 7
U2 58
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 683
EP 692
DI 10.1016/j.ces.2018.10.014
PG 10
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500061
DA 2020-05-12
ER

PT J
AU Hu, CS
   Luo, K
   Wang, S
   Sun, LY
   Fan, JR
AF Hu, Chenshu
   Luo, Kun
   Wang, Shuai
   Sun, Liyan
   Fan, Jianren
TI Influences of operating parameters on the fluidized bed coal
   gasification process: A coarse-grained CFD-DEM study
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Bubbling fluidized bed; Coal gasification; Gas back-mixing; Solids
   mixing; Coarse grained CFD-DEM
ID BIOMASS GASIFICATION; PARTICLE METHOD; KINETIC-THEORY; HEAT-TRANSFER;
   SIMULATION; MODEL; FLOW; GASIFIER; REACTOR; SEGREGATION
AB In the present study, a comprehensive coarse-grained computational fluid dynamics and discrete element method (CFD-DEM) is developed for modeling the fluidized bed gasifier. Based on the model validations against experimental measurements, a series of simulations are conducted to investigate the effects of different operating parameters on the coal gasification in a bubbling fluidized bed. This study offers new insights into the effects of gas-solid mixing on the gasification reaction. The results show the non-uniform spatial distributions of the gasification rate in both the horizontal and vertical directions, which reflects the preferential distribution of fuel particles. It is found that the gas back-mixing plays an important role in controlling of the pyrolysis gas combustion, which is undesired for producing gasification products. The results show that the sand particle size has the most remarkable effect on the gas back-mixing. Though the uniformity of the fuel particle distribution is not a key factor influencing the average product yields, the horizontal fuel particle mixing is found to be the main cause of the fluctuations of the gasification rate. Fundamentally, it is demonstrated that the fluctuations of the horizontal fuel mixing are mainly dominated by the bubble behaviors. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Hu, Chenshu; Luo, Kun; Wang, Shuai; Sun, Liyan; Fan, Jianren] Zhejiang Univ, State Key Lab Clean Energy Utilizat, Hangzhou 310027, Zhejiang, Peoples R China.
RP Luo, K (reprint author), Zhejiang Univ, State Key Lab Clean Energy Utilizat, Hangzhou 310027, Zhejiang, Peoples R China.
EM zjulk@zju.edu.cn
RI luo, kun/A-8039-2012
OI luo, kun/0000-0003-3644-9400
FU National Key Research and Development Program of China [2017YFB0601805];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51390493, 51621005]
FX The study was supported by the National Key Research and Development
   Program of China (2017YFB0601805) and the National Natural Science
   Foundation of China (Nos. 51390493, 51621005).
CR Armstrong LM, 2011, IND ENG CHEM RES, V50, P5959, DOI 10.1021/ie1023029
   Armstrong LM, 2013, AICHE J, V59, P1952, DOI 10.1002/aic.13997
   Askaripour H, 2015, CHEM ENG RES DES, V100, P377, DOI 10.1016/j.cherd.2015.05.041
   Ayeni OO, 2016, CHEM ENG J, V302, P395, DOI 10.1016/j.cej.2016.05.056
   Basu P., 2006, COMBUSTION GASIFICAT
   BATCHELOR GK, 1977, P ROY SOC LOND A MAT, V355, P313, DOI 10.1098/rspa.1977.0100
   Beetstra R, 2007, CHEM ENG SCI, V62, P246, DOI 10.1016/j.ces.2006.08.054
   Chen JH, 2017, ENERG CONVERS MANAGE, V148, P506, DOI 10.1016/j.enconman.2017.05.080
   Chen JH, 2016, J RENEW SUSTAIN ENER, V8, DOI 10.1063/1.4967717
   Chen JH, 2014, ENERG FUEL, V28, P6351, DOI 10.1021/ef501134e
   Chu KW, 2018, POWDER TECHNOL, V329, P47, DOI 10.1016/j.powtec.2018.01.058
   Chu KW, 2016, MINER ENG, V90, P43, DOI 10.1016/j.mineng.2016.01.020
   Cloete S, 2013, POWDER TECHNOL, V235, P735, DOI 10.1016/j.powtec.2012.11.041
   CUNDALL PA, 1979, GEOTECHNIQUE, V29, P47, DOI 10.1680/geot.1979.29.1.47
   Esmaili E, 2014, CAN J CHEM ENG, V92, P1714, DOI 10.1002/cjce.22041
   Gidaspow D., 1994, MULTIPHASE FLOW FLUI
   Gomez-Barea A, 2010, PROG ENERG COMBUST, V36, P444, DOI 10.1016/j.pecs.2009.12.002
   GUNN DJ, 1978, INT J HEAT MASS TRAN, V21, P467, DOI 10.1016/0017-9310(78)90080-7
   KAZARI M, 1995, P 2 INT C MULT FLOW
   Klimanek A, 2018, ENERGY
   Ku XK, 2017, CHEM ENG SCI, V168, P235, DOI 10.1016/j.ces.2017.04.050
   LACEY PMC, 1954, J APPL CHEM, V4, P257
   Li QJ, 2009, CAN J CHEM ENG, V87, P169, DOI 10.1002/cjce.20151
   Li TW, 2013, ENERG FUEL, V27, P7896, DOI 10.1021/ef401887r
   Li TW, 2012, POWDER TECHNOL, V220, P138, DOI 10.1016/j.powtec.2011.09.020
   Liu H, 2013, IND ENG CHEM RES, V52, P18162, DOI 10.1021/ie4024148
   Liu Z., 2013, USE SIMILARITIES CFD
   Lu LQ, 2018, CHEM ENG SCI, V179, P53, DOI 10.1016/j.ces.2018.01.003
   Lu LQ, 2017, IND ENG CHEM RES, V56, P7865, DOI 10.1021/acs.iecr.7b01862
   Lu LQ, 2017, INT J HEAT MASS TRAN, V111, P723, DOI 10.1016/j.ijheatmasstransfer.2017.04.040
   Lu LQ, 2016, CHEM ENG SCI, V155, P314, DOI 10.1016/j.ces.2016.08.013
   Lu LQ, 2016, IND ENG CHEM RES, V55, P10477, DOI 10.1021/acs.iecr.6b02688
   Ocampo A, 2003, FUEL, V82, P161, DOI 10.1016/S0016-2361(02)00253-3
   Olaofe OO, 2014, CHEM ENG SCI, V108, P258, DOI 10.1016/j.ces.2014.01.009
   Rong D., 1999, 2 INT C CFD MIN PROC, P65
   Sakai M, 2010, INT J NUMER METH FL, V64, P1319, DOI 10.1002/fld.2364
   Shen LH, 2007, CHEM ENG SCI, V62, P636, DOI 10.1016/j.ces.2006.09.033
   Syamlal M, 1992, METC GASIFIER ADV SI
   Verma V, 2017, POWDER TECHNOL, V318, P282, DOI 10.1016/j.powtec.2017.05.037
   Wahyudi H, 2016, INT J HEAT MASS TRAN, V97, P521, DOI 10.1016/j.ijheatmasstransfer.2016.02.038
   Wang S, 2018, POWDER TECHNOL, V333, P304, DOI 10.1016/j.powtec.2018.04.027
   Wang S, 2017, APPL THERM ENG, V111, P1523, DOI 10.1016/j.applthermaleng.2016.07.161
   Xie J, 2013, ADV POWDER TECHNOL, V24, P382, DOI 10.1016/j.apt.2012.09.001
   Yu L, 2007, FUEL, V86, P722, DOI 10.1016/j.fuel.2006.09.008
   Zhang YW, 2015, ASIA-PAC J CHEM ENG, V10, P307, DOI 10.1002/apj.1878
   Zhao LX, 2018, J SUPERCRIT FLUID, V131, P26, DOI 10.1016/j.supflu.2017.07.022
   Zhao YH, 2015, INT J MULTIPHAS FLOW, V71, P1, DOI 10.1016/j.ijmultiphaseflow.2014.12.002
   Zhou ZY, 2010, J FLUID MECH, V661, P482, DOI 10.1017/S002211201000306X
NR 48
TC 13
Z9 13
U1 7
U2 43
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 693
EP 706
DI 10.1016/j.ces.2018.10.015
PG 14
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500062
DA 2020-05-12
ER

PT J
AU Diaz, VHG
   von Stosch, M
   Willis, MJ
AF Diaz, Victor Hugo Grisales
   von Stosch, Moritz
   Willis, Mark J.
TI Butanol production via vacuum fermentation: An economic evaluation of
   operating strategies
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Butanol production; Heat pump; Dynamic modelling; Scheduling; Economic
   optimisation; Batch, fed-batch, continuous operation
ID TECHNOECONOMIC ANALYSIS; CLOSTRIDIUM-SACCHAROPERBUTYLACETONICUM;
   SIMULTANEOUS SACCHARIFICATION; ENERGY-REQUIREMENTS; N-BUTANOL; RECOVERY;
   ETHANOL; PERVAPORATION; PERMEATION; SIMULATION
AB Butanol production from corn stover via (acetone-butanol-ethanol) ABE fermentation under vacuum was studied in this work. The reactor operating strategies considered were batch, fed-batch and continuous. The integrated reactor and vacuum separation process includes energy integration by a heat-pump system as well. A mathematical model describing the dynamics of the integrated reactors and the network of compressors and heat exchangers has been developed. The dynamic process models were used to select the optimum production strategy using economic optimisation where a methodology to determine the effect of scheduling of parallel reactor operation on the sizing of the heat-pump system was developed. The results suggest that the optimal operating mode for the integrated reaction system was fed-batch. Although the fed-batch process had the highest economic potential (37.8 MM USD), the compressor work for batch process operation (36.6 MM USD) was the lowest (1.8 MJ/kg ABE, 18% lower than that of fedbatch). Continuous process operation demonstrated the lowest economic potential (23.8 MM USD) and the highest compression work (2.87 MJ/kg ABE). The energy requirements of the purification system, a double-effect distillation process, were found to be between 3.45 and 4.14 MJ/kg ABE. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Diaz, Victor Hugo Grisales; von Stosch, Moritz; Willis, Mark J.] Newcastle Univ, Sch Engn, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
RP Diaz, VHG (reprint author), Newcastle Univ, Sch Engn, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
EM victor.grisales-diaz@newcastle.ac.uk
RI Diaz, Victor Hugo Grisales/M-5265-2016
OI Diaz, Victor Hugo Grisales/0000-0002-6634-2199
CR Abdi HK, 2016, CAN J CHEM ENG, V94, P833, DOI 10.1002/cjce.22461
   Belaissaoui B, 2016, ENERGY, V95, P291, DOI 10.1016/j.energy.2015.12.006
   Cai D, 2016, CHEM ENG J, V287, P1, DOI 10.1016/j.cej.2015.11.024
   Claes S, 2012, J MEMBRANE SCI, V389, P265, DOI 10.1016/j.memsci.2011.10.035
   Diaz VHG, 2018, BIOCHEM ENG J, V137, P30, DOI 10.1016/j.bej.2018.05.011
   Diaz VHG, 2018, BIOPROC BIOSYST ENG, V41, P395, DOI 10.1007/s00449-017-1874-z
   Dubreuil MFS, 2013, J MEMBRANE SCI, V447, P134, DOI 10.1016/j.memsci.2013.07.032
   Fontalvo J, 2005, IND ENG CHEM RES, V44, P5259, DOI 10.1021/ie049225z
   Ghosh S, 2017, APPL ENERG, V198, P284, DOI 10.1016/j.apenergy.2016.12.091
   Diaz VHG, 2016, CHEM ENG PROCESS, V108, P117, DOI 10.1016/j.cep.2016.07.005
   Diaz VHG, 2016, BIORESOURCE TECHNOL, V218, P174, DOI 10.1016/j.biortech.2016.06.091
   Henley E.J., 2011, SEPARATION PROCESS P
   Hodge DB, 2008, BIORESOURCE TECHNOL, V99, P8940, DOI 10.1016/j.biortech.2008.05.015
   Humbird D, 2011, PROCESS DESIGN EC BI
   Quiroz-Ramirez JJ, 2018, CLEAN TECHNOL ENVIR, V20, P1663, DOI 10.1007/s10098-018-1486-6
   Kadam KL, 2004, BIOTECHNOL PROGR, V20, P698, DOI 10.1021/bp034316x
   Kiran B, 2012, ENERGY, V41, P443, DOI 10.1016/j.energy.2012.02.055
   Kujawska A, 2015, RENEW SUST ENERG REV, V48, P648, DOI 10.1016/j.rser.2015.04.028
   Lodi G, 2018, BIOMASS BIOENERG, V116, P227, DOI 10.1016/j.biombioe.2018.06.012
   Mariano AP, 2011, ENERG FUEL, V25, P2347, DOI 10.1021/ef200279v
   Mariano AP, 2012, RENEW ENERG, V47, P183, DOI 10.1016/j.renene.2012.04.041
   Mariano AP, 2012, J CHEM TECHNOL BIOT, V87, P334, DOI 10.1002/jctb.2717
   Matsumiya N, 2005, SEP PURIF TECHNOL, V46, P26, DOI 10.1016/j.seppur.2005.04.006
   MILESTONE NB, 1981, J CHEM TECHNOL BIOT, V31, P732, DOI 10.1002/jctb.280310198
   Morales-Rodriguez R, 2011, CHINESE J CHEM ENG, V19, P185, DOI 10.1016/S1004-9541(11)60152-3
   Mussatto SI, 2013, BIORESOURCE TECHNOL, V148, P302, DOI 10.1016/j.biortech.2013.08.046
   Oudshoorn A, 2010, PROCESS BIOCHEM, V45, P1605, DOI 10.1016/j.procbio.2010.07.003
   Oudshoorn A, 2009, IND ENG CHEM RES, V48, P7325, DOI 10.1021/ie900537w
   Pereira JPC, 2017, BIOTECHNOL J, V12, DOI 10.1002/biot.201600657
   Perkins J. D, 2007, J CHEM TECHNOL BIOT, V46, P249, DOI [10.1002/jctb.280460308, DOI 10.1002/JCTB.280460308]
   Qureshi N, 2005, BIOPROC BIOSYST ENG, V27, P215, DOI 10.1007/s00449-005-0402-8
   Qureshi N, 2014, BIORESOURCE TECHNOL, V154, P222, DOI 10.1016/j.biortech.2013.11.080
   Raganati F, 2016, CHEM ENG SCI, V152, P678, DOI 10.1016/j.ces.2016.06.059
   Ren C, 2010, METAB ENG, V12, P446, DOI 10.1016/j.ymben.2010.05.002
   Rohani AS, 2015, CAN J CHEM ENG, V93, P986, DOI 10.1002/cjce.22186
   Sander R, 2015, ATMOS CHEM PHYS, V15, P4399, DOI 10.5194/acp-15-4399-2015
   Servinsky MD, 2010, MICROBIOL-SGM, V156, P3478, DOI 10.1099/mic.0.037085-0
   Sreemahadevan S, 2018, BIOMASS BIOENERG, V110, P17, DOI 10.1016/j.biombioe.2018.01.008
   Tao L, 2014, BIOFUEL BIOPROD BIOR, V8, P342, DOI 10.1002/bbb.1462
   Vane LM, 2013, J CHEM TECHNOL BIOT, V88, P1436, DOI 10.1002/jctb.4087
   Xue C, 2016, BIORESOURCE TECHNOL, V219, P158, DOI 10.1016/j.biortech.2016.07.111
   Xue C, 2014, APPL MICROBIOL BIOT, V98, P3463, DOI 10.1007/s00253-014-5561-6
   Xue C, 2013, BIOTECHNOL ADV, V31, P1575, DOI 10.1016/j.biotechadv.2013.08.004
   Yao DF, 2017, FUEL, V208, P549, DOI 10.1016/j.fuel.2017.07.004
   Yaws CL, 2008, THERMOPHYSICAL PROPERTIES OF CHEMICALS AND HYDROCARBONS, P309
   Zauba, 2015, IND IMP EXP DAT
   Zheng J, 2015, J BIOSCI BIOENG, V119, P1, DOI 10.1016/j.jbiosc.2014.05.023
NR 47
TC 1
Z9 1
U1 6
U2 25
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 707
EP 719
DI 10.1016/j.ces.2018.10.016
PG 13
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500063
DA 2020-05-12
ER

PT J
AU Lu, H
   Xu, X
   Xie, LS
   Wang, HL
   Sun, GN
   Yang, Q
AF Lu, Hao
   Xu, Xiao
   Xie, Lin-sheng
   Wang, Hua-lin
   Sun, Gai-nai
   Yang, Qiang
TI Deformation and crawling of oil drop on solid substrates by shearing
   liquid
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Shearing fluid; Drop deformation; Force balance; Wettability
ID 3-DIMENSIONAL FLUID DROPLETS; PLANE WALL; IMMISCIBLE DROPLET; FLOW;
   DISPLACEMENT; DETACHMENT; SURFACES; MOTION; SIMULATION; DYNAMICS
AB We focused on the study of deformation and crawling of oil drops and the critical conditions for the incipient motion of a drop in a liquid shear flow. Through systematic experiments, the drop volume, drop physical properties, surface wettability, and flow rate were investigated. The deformation and motion were recorded by camera, and the main parameters were obtained by image processing. A force-balanced model was developed to explain the deformation of drops before incipient motion and the critical shear rate required for different systems by comparing the interfacial adhesion force of the contact line and the driving force of a shearing fluid. Experiments revealed that the critical shear rate required for the incipient motion of a drop mainly depended on system wettability and drop volume, and no detachment was observed unless in a low-wettability system. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Lu, Hao; Xu, Xiao; Xie, Lin-sheng; Wang, Hua-lin; Sun, Gai-nai; Yang, Qiang] East China Univ Sci & Technol, State Environm Protect Key Lab Environm Risk Asse, Shanghai 200237, Peoples R China.
RP Yang, Q (reprint author), State Environm Protect Key Lab Environm Risk Asse, 130 Meilong Rd, Shanghai 200237, Peoples R China.
EM qyang@ecust.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51208200, 51678238, 51722806]; Shanghai Rising-Star
   Program [16QA1401200]
FX This work was supported by the National Natural Science Foundation of
   China [51208200], [51678238], [51722806]; and Shanghai Rising-Star
   Program [16QA1401200].
CR Ahmadlouydarab M, 2014, J FLUID MECH, V746, P214, DOI 10.1017/jfm.2014.133
   Basu S, 1997, J COLLOID INTERF SCI, V190, P253, DOI 10.1006/jcis.1997.4856
   COX RG, 1986, J FLUID MECH, V168, P169, DOI 10.1017/S0022112086000332
   Dimitrakopoulos P, 2007, J FLUID MECH, V580, P451, DOI 10.1017/S0022112007005721
   Dimitrakopoulos P, 2001, J FLUID MECH, V435, P327, DOI 10.1017/S0022112001003883
   Dimitrakopoulos P, 1998, J FLUID MECH, V377, P189, DOI 10.1017/S0022112098002985
   Ding H, 2008, J FLUID MECH, V599, P341, DOI 10.1017/S0022112008000190
   Ding H, 2007, J FLUID MECH, V576, P287, DOI 10.1017/S0022112007004910
   Ding H, 2010, J FLUID MECH, V644, P217, DOI 10.1017/S0022112009992217
   DUSSAN EB, 1983, J FLUID MECH, V137, P1, DOI 10.1017/S002211208300227X
   DUSSAN EB, 1987, J FLUID MECH, V174, P381, DOI 10.1017/S002211208700017X
   Fan J, 2011, J COLLOID INTERF SCI, V356, P286, DOI 10.1016/j.jcis.2010.12.087
   Feigl K, 2007, CHEM ENG SCI, V62, P3242, DOI 10.1016/j.ces.2007.02.008
   Gupta AK, 2008, CHEM ENG SCI, V63, P5496, DOI 10.1016/j.ces.2008.07.027
   Hu HB, 2013, EXP THERM FLUID SCI, V49, P86, DOI 10.1016/j.expthermflusci.2013.04.005
   Lu H, 2016, SEP PURIF TECHNOL, V159, P50, DOI 10.1016/j.seppur.2015.12.049
   Lu H, 2016, CHEM ENG TECHNOL, V39, P255, DOI 10.1002/ceat.201400773
   Madani S, 2014, COLLOID SURFACE A, V441, P796, DOI 10.1016/j.colsurfa.2013.04.058
   MAHE M, 1988, J COLLOID INTERF SCI, V126, P329, DOI 10.1016/0021-9797(88)90126-9
   Mate A, 2000, CHEM ENG SCI, V55, P2073, DOI 10.1016/S0009-2509(99)00502-3
   Megias-Alguacil D, 2005, J NON-NEWTON FLUID, V126, P153, DOI 10.1016/j.jnnfm.2004.07.019
   ONEILL ME, 1968, CHEM ENG SCI, V23, P1293, DOI 10.1016/0009-2509(68)89039-6
   Pan DY, 2016, J HYDRODYN, V28, P702, DOI 10.1016/S1001-6058(16)60673-X
   Roisman, 2015, PHYS REV E, V92
   Schleizer AD, 1999, J FLUID MECH, V383, P29, DOI 10.1017/S0022112098003462
   Seevaratnam GK, 2010, CHEM ENG SCI, V65, P4523, DOI 10.1016/j.ces.2010.04.012
   SHAPIRA M, 1990, INT J MULTIPHAS FLOW, V16, P305, DOI 10.1016/0301-9322(90)90061-M
   Spelt PDM, 2006, J FLUID MECH, V561, P439, DOI 10.1017/S0022112006000954
   Sugiyama K, 2008, J ENG MATH, V62, P35, DOI 10.1007/s10665-007-9185-z
   Wang YL, 2012, EXP THER MED, V4, P26, DOI 10.3892/etm.2012.551
   Yon S, 1999, PHYS FLUIDS, V11, P1297, DOI 10.1063/1.869995
   Zhang J, 2006, PHYS FLUIDS, V18, DOI 10.1063/1.2222336
NR 32
TC 2
Z9 3
U1 14
U2 45
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 720
EP 729
DI 10.1016/j.ces.2018.10.017
PG 10
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500064
DA 2020-05-12
ER

PT J
AU Liu, YJ
   Zhu, JX
AF Liu, Yingjie
   Zhu, Jing-Xu (Jesse)
TI Hydrodynamics of a bubble-driven liquid-solid fluidized bed
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Liquid-solid fluidization; Bubble-driven; Loose velocity; Initial
   fluidization velocity; Flow regime; Flow mechanism
ID GAS-LIQUID; VELOCITY; FLOW; PRESSURE
AB A new fluidization system, the bubble-driven liquid-solid fluidized bed, adopting particles with a slightly higher density than the fluid, has been proposed. During the experiment process, air was introduced into the bottom of the column as driving force, and superficial gas velocity ranged from 0 to 28 mm/s and liquid was continuous phase but maintained at the stationary state. The variation of pressure drops in the bottom section near the gas distributor was measured to identify the demarcation of flow regimes and determine the loose velocity (U-loose) and initial fluidization velocity (U-in). It was found that U-loose and U-in both increase with the initial hydrostatic height but are independent of the initial liquid height. Moreover, solids holdup was analyzed using a photographic technique while gas holdup was calculated from the pressure drop variation and solids holdup. A non-uniform axial solids distribution exists for all gas velocities. Additionally, two fluidization mechanisms were proposed based on the experimental observations. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Liu, Yingjie; Zhu, Jing-Xu (Jesse)] Changzhou Univ, Jiangsu Key Lab Adv Catalyt Mat & Technol, Changzhou 213164, Peoples R China.
   [Liu, Yingjie; Zhu, Jing-Xu (Jesse)] Western Univ, Dept Chem & Biochem Engn, London, ON N6A 5B9, Canada.
RP Zhu, JX (reprint author), Western Univ, Dept Chem & Biochem Engn, London, ON N6A 5B9, Canada.
EM jzhu@uwo.ca
RI Zhu, Jesse/E-4048-2017
OI Zhu, Jesse/0000-0001-7749-8917
FU State Key Laboratory of Heavy Oil Processing [SKLOP20163001]; Jiangsu
   Key Laboratory of Advanced Catalytic Materials and Technology
   [BM2012110]; National Natural Science Foundation of ChinaNational
   Natural Science Foundation of China [21306014]; Natural Science and
   Engineering Council of Canada (NSERC)Natural Sciences and Engineering
   Research Council of Canada; foundation of Jiangsu Government Scholarship
   for Overseas Studies
FX The research is partially supported by State Key Laboratory of Heavy Oil
   Processing (SKLOP20163001), Jiangsu Key Laboratory of Advanced Catalytic
   Materials and Technology (BM2012110), National Natural Science
   Foundation of China (21306014) and Natural Science and Engineering
   Council of Canada (NSERC). Y. Liu also thanks the foundation of Jiangsu
   Government Scholarship for Overseas Studies.
CR Briens LA, 2005, CHEM ENG SCI, V60, P6094, DOI 10.1016/j.ces.2005.04.005
   Briens LA, 1997, CHEM ENG SCI, V52, P4231, DOI 10.1016/S0009-2509(97)88936-1
   CHEN RC, 1994, AICHE J, V40, P1093, DOI 10.1002/aic.690400702
   CHISTI MY, 1987, CHEM ENG COMMUN, V60, P195, DOI 10.1080/00986448708912017
   Cui Z, 2004, CHEM ENG SCI, V59, P1755, DOI 10.1016/j.ces.2004.01.031
   EPSTEIN N, 1981, CAN J CHEM ENG, V59, P649, DOI 10.1002/cjce.5450590601
   Fan L.S., 1989, GAS LIQUID SOLID FLU
   Felipe CAS, 2007, POWDER TECHNOL, V174, P104, DOI 10.1016/j.powtec.2007.01.015
   Huang J. Q., 2017, HYDRODYNAMICS GAS DR
   JEAN RH, 1987, CAN J CHEM ENG, V65, P881, DOI 10.1002/cjce.5450650601
   Jena HM, 2008, CHEM ENG J, V145, P50, DOI 10.1016/j.cej.2008.03.002
   Lee J. C., 1978, FLUIDIZATION, P184
   MATSUURA A, 1984, AICHE J, V30, P894, DOI 10.1002/aic.690300604
   MUROYAMA K, 1985, AICHE J, V31, P1, DOI 10.1002/aic.690310102
   Pjontek D, 2014, POWDER TECHNOL, V253, P657, DOI 10.1016/j.powtec.2013.12.030
   Sun X. L., 2017, BUBBLE INDUCED INVER
   VUNJAKNOVAKOVIC G, 1992, CHEM ENG SCI, V47, P3451, DOI 10.1016/0009-2509(92)85057-I
   Yang GQ, 2007, CHEM ENG SCI, V62, P2, DOI 10.1016/j.ces.2006.08.021
   ZHANG JP, 1995, CHEM ENG RES DES, V73, P347
   Zhang JP, 1997, CHEM ENG SCI, V52, P3979, DOI 10.1016/S0009-2509(97)00241-8
   Zheng Y, 1999, CAN J CHEM ENG, V77, P284, DOI 10.1002/cjce.5450770213
NR 21
TC 0
Z9 0
U1 5
U2 22
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 730
EP 736
DI 10.1016/j.ces.2018.10.018
PG 7
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500065
DA 2020-05-12
ER

PT J
AU Pan, ZH
   Yan, J
   Zhao, CY
AF Pan, Z. H.
   Yan, J.
   Zhao, C. Y.
TI Numerical analyses and optimization of tubular thermochemical heat
   storage reactors using axisymmetric thermal lattice Boltzmann model
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Axisymmetric thermal lattice Boltzmann method; MgO; Mg(OH)(2);
   Thermochemical heat storage
ID MAGNESIUM-HYDROXIDE; EXPANDED GRAPHITE; NATURAL-CONVECTION;
   CHEMICAL-REACTION; ENERGY-STORAGE; MAGNETIC-FIELD; POROUS CAVITY;
   PHASE-CHANGE; PACKED-BED; CONDUCTIVITY
AB Axisymmetric lattice Boltzmann (LB) model has gained great development in the field of fluid flow and heat transfer in recent decades. Compared with the standard LB method, the axisymmetric LB method can solve 3D axisymmetric problems with minimal meshes. This numerical method will be helpful in research on thermochemical heat storage, especially considering the profound understanding and optimization of reactor performance. In this study, we extended a previous axisymmetric LB model to simulate the charging/discharging processes of a MgO/Mg(OH)(2) thermochemical reactor. We derived a new evolution function by including an unstable heat source term out of a chemical reaction. New isothermal and heat flux boundary treatment approaches were proposed to maintain the precision of this axisymmetric LB model in the presence of the heat source term. In addition, a local method for transient conjugate heat transfer simulation without the utilization of temperature gradient information at the fluid-solid interface was developed to predict heat transfer between the reactor bed and heat transfer fluid. With the proposed axisymmetric thermal LB model, the charging/discharging processes of a tubular MgO/Mg(OH)(2) thermochemical reactor unit with a heat exchanger were simulated. Results showed that the average power output was maximized with a bed thickness of 1.0 cm. The length of the reactor unit should be considered by balancing power output and cost. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Pan, Z. H.; Yan, J.; Zhao, C. Y.] Shanghai Jiao Tong Univ, Sch Mech Engn, Minist Educ, Key Lab Power Machinery & Engn, Shanghai 200240, Peoples R China.
RP Zhao, CY (reprint author), Shanghai Jiao Tong Univ, Sch Mech Engn, Minist Educ, Key Lab Power Machinery & Engn, Shanghai 200240, Peoples R China.
EM changying.zhao@sjtu.edu.cn
FU National Basic Research Program of ChinaNational Basic Research Program
   of China [2013CB228303]; National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China [51706130]
FX This work was supported by the National Basic Research Program of China
   (Grant No. 2013CB228303) and the National Natural Science Foundation of
   China (Grant No. 51706130).
CR Chaise A, 2009, INT J HEAT MASS TRAN, V52, P4564, DOI 10.1016/j.ijheatmasstransfer.2009.03.052
   Chen S, 1998, ANNU REV FLUID MECH, V30, P329, DOI 10.1146/annurev.fluid.30.1.329
   Chen X, 2000, INT J HEAT FLUID FL, V21, P463, DOI 10.1016/S0142-727X(00)00028-X
   D'Orazio A, 2004, INT J THERM SCI, V43, P575, DOI 10.1016/j.ijthermalsci.2003.11.002
   FUJII I, 1985, SOL ENERGY, V34, P367, DOI 10.1016/0038-092X(85)90049-0
   Guo ZL, 2009, PHYS REV E, V79, DOI 10.1103/PhysRevE.79.046708
   Halliday I, 2001, PHYS REV E, V64, DOI 10.1103/PhysRevE.64.011208
   Ishitobi H, 2013, APPL THERM ENG, V50, P1639, DOI 10.1016/j.applthermaleng.2011.07.020
   Kato Y, 1996, APPL THERM ENG, V16, P853, DOI 10.1016/1359-4311(96)00009-9
   KATO Y, 1993, KAGAKU KOGAKU RONBUN, V19, P1213, DOI 10.1252/kakoronbunshu.19.1213
   Kato Y., 2006, PACKED BED REACTOR D
   Kato Y, 2009, INT J REFRIG, V32, P661, DOI 10.1016/j.ijrefrig.2009.01.032
   Lee TS, 2006, INT J MOD PHYS C, V17, P645, DOI 10.1142/S0129183106008923
   Li Q, 2016, PROG ENERG COMBUST, V52, P62, DOI 10.1016/j.pecs.2015.10.001
   Li Q, 2009, PHYS REV E, V80, DOI 10.1103/PhysRevE.80.037702
   Linder M, 2014, ENRGY PROCED, V49, P888, DOI 10.1016/j.egypro.2014.03.096
   Liu Q, 2015, PHYSICA A, V438, P94, DOI 10.1016/j.physa.2015.06.018
   Pan ZH, 2017, SCI BULL, V62, P256, DOI 10.1016/j.scib.2016.12.009
   Pan ZH, 2015, ENERGY, V82, P611, DOI 10.1016/j.energy.2015.01.070
   Reis T, 2007, PHYS REV E, V75, DOI 10.1103/PhysRevE.75.056703
   Rong FM, 2010, INT J HEAT MASS TRAN, V53, P5519, DOI 10.1016/j.ijheatmasstransfer.2010.07.005
   Ryu J, 2008, CHEM LETT, V37, P1140, DOI 10.1246/cl.2008.1140
   Sheikholeslami M, 2018, PHYSICA B, V542, P51, DOI 10.1016/j.physb.2018.03.036
   Sheikholeslami M, 2017, J MOL LIQ, V234, P364, DOI 10.1016/j.molliq.2017.03.104
   Sheikholeslami M, 2017, INT J HEAT MASS TRAN, V113, P106, DOI 10.1016/j.ijheatmasstransfer.2017.05.054
   Shen D, 2013, CHEM ENG SCI, V98, P273, DOI 10.1016/j.ces.2013.05.041
   Wang JK, 2007, INT J THERM SCI, V46, P228, DOI 10.1016/j.ijthermalsci.2006.04.012
   Wang MR, 2007, J COLLOID INTERF SCI, V311, P562, DOI 10.1016/j.jcis.2007.03.038
   Xin F, 2013, J THERM SCI, V22, P42, DOI 10.1007/s11630-013-0590-5
   Zamengo M, 2016, J CHEM ENG JPN, V49, P261, DOI 10.1252/jcej.14we292
   Zamengo M, 2015, ENRGY PROCED, V71, P293, DOI 10.1016/j.egypro.2014.11.882
   Zamengo M, 2014, APPL THERM ENG, V69, P29, DOI 10.1016/j.applthermaleng.2014.04.037
   Zamengo M, 2014, APPL THERM ENG, V64, P339, DOI 10.1016/j.applthermaleng.2013.12.036
   Zhang T, 2012, PHYS REV E, V85, DOI 10.1103/PhysRevE.85.016701
   Zheng L, 2010, COMPUT FLUIDS, V39, P945, DOI 10.1016/j.compfluid.2010.01.006
NR 35
TC 1
Z9 1
U1 2
U2 24
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 737
EP 747
DI 10.1016/j.ces.2018.10.019
PG 11
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500066
DA 2020-05-12
ER

PT J
AU Yuan, HL
   Kong, WJ
   Liu, FS
   Chen, DP
AF Yuan, Hongliang
   Kong, Wenjun
   Liu, Fengshan
   Chen, Dongping
TI Study on soot nucleation and growth from PAHs and some reactive species
   at flame temperatures by ReaxFF molecular dynamics
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE ReaxFF; Molecule dynamic; Soot; PAHs
ID POLYCYCLIC AROMATIC-HYDROCARBONS; ANGLE NEUTRON-SCATTERING; PREMIXED
   ETHYLENE; FORCE-FIELD; NANOPARTICLE FORMATION; DIFFUSION FLAMES;
   INCIPIENT SOOT; COUNTERFLOW; SIMULATIONS; PARTICLES
AB The transformations from polycyclic aromatic hydrocarbons (PAHs) to polymers and finally to young soot were simulated under different initial conditions at flame temperatures using Reax-FF MD. At low temperatures, PAH heterogeneous nucleation is mainly through physical interactions, but these clusters are not stable at higher temperatures. The molecular dynamics simulation results at 1450 K suggested that soot growth at intermediate temperature and low radical concentration conditions mainly controlled by chemical reactions involving carbon addition directly, without hydrogen abstraction. Some branched chains can be added to the PAH edges and small PAHs grow into dimers, trimers, or larger molecules through combination with unsaturated aliphatic hydrocarbons. At higher temperatures, radical-molecule reactions, such as via the HACA mechanism, reactions of aryl radicals and aryl-acetylene, and radical-radical reactions involving the combination of two aryl radicals, are dominant in soot formation because of high radical concentrations. Crown Copyright (C) 2018 Published by Elsevier Ltd. All rights reserved.
C1 [Yuan, Hongliang; Kong, Wenjun] Chinese Acad Sci, Inst Engn Thermophys, Key Lab Light Duty Gas Turbine, Beijing 100190, Peoples R China.
   [Yuan, Hongliang; Kong, Wenjun] Univ Chinese Acad Sci, Beijing 100039, Peoples R China.
   [Liu, Fengshan] CNR, Measurement Sci & Stand, Ottawa, ON K1A 0R6, Canada.
   [Chen, Dongping] Beijing Inst Technol, State Key Lab Explos Sci & Technol, Beijing 100081, Peoples R China.
RP Kong, WJ (reprint author), Chinese Acad Sci, Inst Engn Thermophys, Key Lab Light Duty Gas Turbine, Beijing 100190, Peoples R China.
EM wjkong@iet.cn
OI kong, wen jun/0000-0002-9949-7891
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [U1738113]; National Key Basic Research Program of
   ChinaNational Basic Research Program of China [2014CB239603]
FX This work is supported by National Natural Science Foundation of China
   (No. U1738113) and the National Key Basic Research Program of China (No.
   2014CB239603).
CR Abid AD, 2008, COMBUST FLAME, V154, P775, DOI 10.1016/j.combustflame.2008.06.009
   And P.W.A, 2000, J CHEM PHYS, V116, P8731
   Chenoweth K, 2008, J PHYS CHEM A, V112, P1040, DOI 10.1021/jp709896w
   Chung SH, 2007, CARBON, V45, P2400, DOI 10.1016/j.carbon.2007.07.003
   Chung SH, 2011, P COMBUST INST, V33, P693, DOI 10.1016/j.proci.2010.06.038
   D'Anna A, 2001, COMBUST FLAME, V127, P1995, DOI 10.1016/S0010-2180(01)00303-0
   DELLEY B, 1986, CHEM PHYS, V110, P329, DOI 10.1016/0301-0104(86)87089-6
   Elvati P, 2013, P COMBUST INST, V34, P1837, DOI 10.1016/j.proci.2012.07.030
   Fantauzzi D, 2014, PHYS CHEM CHEM PHYS, V16, P23118, DOI 10.1039/c4cp03111c
   Frenklach M., 2018, P COMBUST I
   Gale JD, 1997, J CHEM SOC FARADAY T, V93, P629, DOI 10.1039/a606455h
   Gale JD, 2011, PHYS CHEM CHEM PHYS, V13, P16666, DOI 10.1039/c1cp21034c
   Han S., 2017, ENERGY FUELS
   Herdman JD, 2008, J PHYS CHEM A, V112, P6249, DOI 10.1021/jp800483h
   Huang LL, 2012, PHYS CHEM CHEM PHYS, V14, P11327, DOI 10.1039/c2cp41511a
   Jin HF, 2014, COMBUST FLAME, V161, P657, DOI 10.1016/j.combustflame.2013.10.020
   Johansson KO, 2018, SCIENCE, V361, P997, DOI 10.1126/science.aat3417
   Kang KT, 1997, COMBUST FLAME, V109, P266, DOI 10.1016/S0010-2180(96)00163-0
   Kholghy M.R., 2018, PHYS CHEM CHEM PHYS
   Liu SB, 2016, ACTA PHYS-CHIM SIN, V32, P98, DOI 10.3866/PKU.WHXB201510302
   Lu K., 2017, PHYS CHEM CHEM PHYS, V20
   Mao Q, 2017, J CHEM PHYS, V147, DOI 10.1063/1.5000534
   Mao Q, 2017, CARBON, V121, P380, DOI 10.1016/j.carbon.2017.06.009
   Monge-Palacios M, 2017, PHYS CHEM CHEM PHYS, V19, P2175, DOI 10.1039/c6cp07029a
   MULLIKEN RS, 1955, J CHEM PHYS, V23, P1841, DOI 10.1063/1.1740589
   Omidvarborna H, 2015, RENEW SUST ENERG REV, V48, P635, DOI 10.1016/j.rser.2015.04.019
   Parr R.G., 1989, DENSITY FUNCTIONAL T
   Pascazio L, 2017, COMBUST FLAME, V185, P53, DOI 10.1016/j.combustflame.2017.07.003
   PERDEW JP, 1992, PHYS REV B, V45, P13244, DOI 10.1103/PhysRevB.45.13244
   Sabbah H., 2012, J PHYS CHEM LETT, V1, P1857
   Santamaria A, 2006, COMBUST FLAME, V146, P52, DOI 10.1016/j.combustflame.2006.04.008
   Schuetz CA, 2003, P COMBUST INST, V29, P2307, DOI 10.1016/S1540-7489(02)80281-4
   Sirignano M, 2012, COMBUST FLAME, V159, P1663, DOI 10.1016/j.combustflame.2011.11.005
   Slavinskaya NA, 2012, COMBUST FLAME, V159, P979, DOI 10.1016/j.combustflame.2011.10.005
   Srinivasan SG, 2015, J PHYS CHEM A, V119, P571, DOI 10.1021/jp510274e
   STEIN SE, 1985, J PHYS CHEM-US, V89, P3714, DOI 10.1021/j100263a027
   van Duin ACT, 2001, J PHYS CHEM A, V105, P9396, DOI 10.1021/jp004368u
   Vedal S, 1997, J AIR WASTE MANAGE, V47, P551, DOI 10.1080/10473289.1997.10463922
   Violi A, 2004, COMBUST FLAME, V139, P279, DOI 10.1016/j.combustflame.2004.08.013
   Violi A, 2001, COMBUST FLAME, V126, P1506, DOI 10.1016/S0010-2180(01)00268-1
   Wang H, 1997, COMBUST FLAME, V110, P173, DOI 10.1016/S0010-2180(97)00068-0
   Wang H, 2002, P COMBUST INST, V29, P2749, DOI 10.1016/S1540-7489(02)80335-2
   Wang H, 2011, P COMBUST INST, V33, P41, DOI 10.1016/j.proci.2010.09.009
   Wang Y, 2013, COMBUST FLAME, V160, P1667, DOI 10.1016/j.combustflame.2013.03.013
   Zhang CY, 2015, PHYS CHEM CHEM PHYS, V17, P11469, DOI 10.1039/c5cp00926j
   Zhang HB, 2016, J PHYS CHEM A, V120, P683, DOI 10.1021/acs.jpca.5b10306
   Zhao B, 2007, P COMBUST INST, V31, P851, DOI 10.1016/j.proci.2006.08.064
NR 47
TC 10
Z9 10
U1 6
U2 46
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 748
EP 757
DI 10.1016/j.ces.2018.10.020
PG 10
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500067
DA 2020-05-12
ER

PT J
AU Nebreda, AP
   Russo, V
   Di Serio, M
   Salmi, T
   Grenman, H
AF Nebreda, A. Perez
   Russo, V
   Di Serio, M.
   Salmi, T.
   Grenman, H.
TI Modelling of homogeneously catalyzed hemicelluloses hydrolysis in a
   laminar-flow reactor
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Laminar flow; Reactor modelling; Kinetics; Acid hydrolysis;
   Hemicelluloses; Sugars
ID AQUEOUS EXTRACTION; ACID-HYDROLYSIS; SPRUCE; KINETICS; HOT;
   OLIGOFRUCTOSE; CELLULOSE; INULIN; WOOD; MASS
AB Hydrolysis of hemicelluloses with acid catalysts yield different sugar monomers and oligomers, depending on the substrate as well as the process design. The hydrolysis kinetics are typically rather slow, which leads to requirements of long residence times, i.e. slow flow rates, in order to achieve adequate conversion. Hydrolysis experiments of two different polysaccharides - o-acetylgalactoglucomannan (GGM) and inulin - were conducted in an isothermal tubular continuous reactor in laboratory scale, working in the laminar flow regime. A dynamic mass balance-based reactor model was developed, including convection and molecular diffusion in axial and radial directions, as well as the self-accelerating kinetics of the reaction. The model gave a very satisfactory description of the experimental data. The behavior of the laminar flow reactor in the hemicellulose hydrolysis was further illustrated by numerical simulations. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Nebreda, A. Perez; Russo, V; Salmi, T.; Grenman, H.] Abo Akad Univ, Fac Sci & Engn, Johan Gadolin Proc Chem Ctr, Lab Ind Chem & React Engn, Biskopsgatan 8, FI-20500 Turku, Finland.
   [Russo, V; Di Serio, M.] Univ Naples Federico II, Chem Sci Dept, Via Cintia 4, IT-80126 Naples, Italy.
   [Grenman, H.] Abo Akad Univ, Mol Proc & Mat Technol, Biskopsgatan 8, SF-20500 Turku, Finland.
RP Grenman, H (reprint author), Abo Akad Univ, Fac Sci & Engn, Johan Gadolin Proc Chem Ctr, Lab Ind Chem & React Engn, Biskopsgatan 8, FI-20500 Turku, Finland.
EM henrik.grenman@abo.fi
RI Salmi, Tapio/U-5462-2019; Russo, Vincenzo/L-9658-2019; Di Serio,
   Martino/B-4166-2013
OI Russo, Vincenzo/0000-0002-1867-739X; Di Serio,
   Martino/0000-0003-4489-7115
FU Academy of FinlandAcademy of Finland; University of Naples "Federico
   II"; Abo Akademi University
FX Academy of Finland and the University of Naples "Federico II" are
   acknowledged for the financial support. Process System Enterprise (PSE)
   is acknowledged for providing licenses to enable this study. The work is
   a part of the activities of Johan Gadolin Process Chemistry Centre
   (PCC), a centre of Excellence financed by Abo Akademi University.
CR Fernandez MA, 2018, J SUPERCRIT FLUID, V133, P647, DOI 10.1016/j.supflu.2017.07.001
   Bird RB, 2007, TRANSPORT PHENOMENA
   Blecker C, 2002, J AGR FOOD CHEM, V50, P1602, DOI 10.1021/jf010905b
   Cherbut C, 2002, BRIT J NUTR, V87, pS159, DOI 10.1079/BJN2002532
   Delbecq F, 2018, FRONT CHEM, V6, DOI 10.3389/fchem.2018.00146
   Gallina G, 2018, J SUPERCRIT FLUID, V133, P716, DOI 10.1016/j.supflu.2017.10.001
   Grenman H, 2011, IND ENG CHEM RES, V50, P3818, DOI 10.1021/ie101946c
   Grenman H, 2010, IND ENG CHEM RES, V49, P9703, DOI 10.1021/ie101215a
   Haavisto A, 1995, MAOL TAULUKOT
   Kusema BT, 2013, CATAL SCI TECHNOL, V3, P116, DOI 10.1039/c2cy20314f
   Kusema BT, 2010, INT J CHEM REACT ENG, V8, DOI 10.2202/1542-6580.2118
   Liu J., 2015, BIOACTIVE CARBOHYDRA, V5, P31, DOI DOI 10.1016/J.BCDF.2014.12.001
   Lundqvist J, 2002, CARBOHYD POLYM, V48, P29, DOI 10.1016/S0144-8617(01)00210-7
   Maki-Arvela P, 2011, CHEM REV, V111, P5638, DOI 10.1021/cr2000042
   Nebreda AP, 2018, J CHEM TECHNOL BIOT, V93, P224, DOI 10.1002/jctb.5344
   Nebreda AP, 2016, HOLZFORSCHUNG, V70, P187, DOI 10.1515/hf-2014-0314
   Negahdar L, 2016, APPL CATAL B-ENVIRON, V184, P285, DOI 10.1016/j.apcatb.2015.11.039
   Perry R.H., 1997, PERRYS CHEM ENG HDB
   Pezoa-Conte R, 2017, BIOENERG RES, V10, P915, DOI 10.1007/s12155-017-9853-4
   Rissanen JV, 2016, BIORESOURCE TECHNOL, V199, P279, DOI 10.1016/j.biortech.2015.08.116
   Rissanen JV, 2015, CELL CHEM TECHNOL, V49, P449
   Rissanen JV, 2014, CHEMSUSCHEM, V7, P2947, DOI 10.1002/cssc.201402282
   Rissanen JV, 2014, IND ENG CHEM RES, V53, P6341, DOI 10.1021/ie500234t
   Ronkart SN, 2006, TALANTA, V70, P1006, DOI 10.1016/j.talanta.2006.02.024
   Salmi T.O., 2010, CHEM REACTION ENG RE
   Salmi T, 2014, AICHE J, V60, P1066, DOI 10.1002/aic.14311
   Sundberg A., 1996, NORD PULP PAP RES J, V11, P216, DOI DOI 10.3183/NPPRJ-1996-11-04-P216-219
   Werner K, 2014, J ANAL APPL PYROL, V110, P130, DOI 10.1016/j.jaap.2014.08.013
   Willfor S, 2003, TAPPI J, V2, P27
   Willfor S, 2003, CARBOHYD POLYM, V52, P175, DOI 10.1016/S0144-8617(02)00288-6
   Willfor S, 2009, IND CROP PROD, V29, P571, DOI 10.1016/j.indcrop.2008.11.003
   Woo KS, 2011, J MED FOOD, V14, P167, DOI 10.1089/jmf.2010.1166
   Xu CL, 2008, J AGR FOOD CHEM, V56, P2429, DOI 10.1021/jf703702y
   Xu WY, 2017, CHEMNANOMAT, V3, P109, DOI 10.1002/cnma.201600347
NR 34
TC 0
Z9 0
U1 1
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 758
EP 766
DI 10.1016/j.ces.2018.10.021
PG 9
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500068
DA 2020-05-12
ER

PT J
AU Wang, JQ
   Shen, BX
   Kang, DR
   Yuan, P
   Wu, CF
AF Wang, Jianqiao
   Shen, Boxiong
   Kang, Dongrui
   Yuan, Peng
   Wu, Chunfei
TI Investigate the interactions between biomass components during pyrolysis
   using in-situ DRIFTS and TGA
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE In-situ DRIFTS; Biomass pyrolysis; Cellulose; Xylan; Lignin
ID CELLULOSE-LIGNIN INTERACTIONS; DIFFERENT TEMPERATURES; MAJOR COMPONENTS;
   HEMICELLULOSE; ELUCIDATION; DEGRADATION; MECHANISMS; EVOLUTION; XYLAN
AB Biomass pyrolysis is a promising thermal chemical processing technology to produce renewable and sustainable energy materials. However, the interaction between biomass components (cellulose, hemicellulose and lignin) during pyrolysis process needed further investigation. In this work, an in-situ Reflectance Infrared Fourier Transform Spectroscopy (in-situ DRIFTS) reactor was introduced to investigate the interactions assisted with Thermogravimetric Analysis (TGA). The experiments demonstrate that there exist complicated interactions between the main components of biomass during pyrolysis. The results from TGA/DTG indicate that the interactions between cellulose and xylan introduce higher pyrolysis temperature, while the interactions between cellulose and lignin, xylan and lignin, resulte less weight loss. The increase of compression pressure for the mixture of main components changes the weight loss of the mixture. The results from in-situ DRIFTS show that the decomposition and aromatization of xylan are promoted when the cellulose is added. Cellulose will also hinder the accumulation of the benzene rings of the lignin. The in-situ DRIFTS experiment results also suggest that the contact pressure between the components conduct more residue solid, mainly because the dehydration reaction of the mixture samples was inhibited and the charring process was promoted, especially the reaction between cellulose and lignin. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Wang, Jianqiao; Shen, Boxiong; Kang, Dongrui; Yuan, Peng; Wu, Chunfei] Hebei Univ Technol, Sch Energy & Environm Engn, Tianjin, Peoples R China.
   [Wu, Chunfei] Queens Univ Belfast, Sch Chem & Chem Engn, Belfast BT7 1NN, Antrim, North Ireland.
RP Shen, BX; Wu, CF (reprint author), Hebei Univ Technol, Sch Energy & Environm Engn, Tianjin, Peoples R China.
EM shenbx@hebut.edu.cn; c.wu@hull.ac.uk
FU National Key Research and Development Program of China [2018YFB0605101];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21706050]; Key Project Natural Science Foundation
   of Tianjin [18JCZDJC39800]; Natural Science Foundation of Hebei
   ProvinceNatural Science Foundation of Hebei Province [E2018202180];
   European Union's Horizon 2020 research and innovation programme under
   the Marie Sklodowska-Curie grantEuropean Union (EU) [643322]
FX The project was supported by National Key Research and Development
   Program of China (2018YFB0605101), National Natural Science Foundation
   of China (21706050), Key Project Natural Science Foundation of Tianjin
   (18JCZDJC39800), Natural Science Foundation of Hebei Province (Project
   No. E2018202180) and European Union's Horizon 2020 research and
   innovation programme under the Marie Sklodowska-Curie grant agreement
   No. 643322 (FLEXI-PYROCAT).
CR Anca-Couce A, 2016, PROG ENERG COMBUST, V53, P41, DOI 10.1016/j.pecs.2015.10.002
   Candelier K, 2011, J ANAL APPL PYROL, V92, P376, DOI 10.1016/j.jaap.2011.07.010
   Collard FX, 2014, RENEW SUST ENERG REV, V38, P594, DOI 10.1016/j.rser.2014.06.013
   Couhert C, 2009, FUEL, V88, P408, DOI 10.1016/j.fuel.2008.09.019
   Fushimi C, 2009, J ANAL APPL PYROL, V86, P82, DOI 10.1016/j.jaap.2009.04.008
   Hilbers TJ, 2015, J ANAL APPL PYROL, V114, P197, DOI 10.1016/j.jaap.2015.05.020
   Kan T, 2016, RENEW SUST ENERG REV, V57, P1126, DOI 10.1016/j.rser.2015.12.185
   Lee HV, 2014, SCI WORLD J, DOI 10.1155/2014/631013
   Li SG, 2004, FUEL PROCESS TECHNOL, V85, P1201, DOI 10.1016/j.fuproc.2003.11.043
   Liu QA, 2011, J ANAL APPL PYROL, V90, P213, DOI 10.1016/j.jaap.2010.12.009
   Lu Q, 2011, J ANAL APPL PYROL, V92, P430, DOI 10.1016/j.jaap.2011.08.006
   McGrath TE, 2003, J ANAL APPL PYROL, V66, P51, DOI 10.1016/S0165-2370(02)00105-5
   McKendry P, 2002, BIORESOURCE TECHNOL, V83, P37, DOI 10.1016/S0960-8524(01)00118-3
   Nakamura T, 2008, J ANAL APPL PYROL, V81, P173, DOI 10.1016/j.jaap.2007.11.002
   Scheirs J, 2001, EUR POLYM J, V37, P933, DOI 10.1016/S0014-3057(00)00211-1
   Shao SS, 2017, J ANAL APPL PYROL, V127, P258, DOI 10.1016/j.jaap.2017.07.026
   Sharma RK, 2004, FUEL, V83, P1469, DOI 10.1016/j.fuel.2003.11.015
   Stefanidis SD, 2014, J ANAL APPL PYROL, V105, P143, DOI 10.1016/j.jaap.2013.10.013
   Svenson J, 2004, COMBUST SCI TECHNOL, V176, P977, DOI 10.1080/00102200490428585
   Uchimiya M, 2013, J ANAL APPL PYROL, V102, P53, DOI 10.1016/j.jaap.2013.03.014
   Van de Velden M, 2010, RENEW ENERG, V35, P232, DOI 10.1016/j.renene.2009.04.019
   Vorwerk S, 2004, TRENDS PLANT SCI, V9, P203, DOI 10.1016/j.tplants.2004.02.005
   Wang SR, 2017, PROG ENERG COMBUST, V62, P33, DOI 10.1016/j.pecs.2017.05.004
   Wang SR, 2011, J ANAL APPL PYROL, V91, P183, DOI 10.1016/j.jaap.2011.02.006
   Wang ZH, 2013, J ANAL APPL PYROL, V100, P56, DOI 10.1016/j.jaap.2012.11.017
   Williams PT, 1996, RENEW ENERG, V7, P233, DOI 10.1016/0960-1481(96)00006-7
   Wu CF, 2013, FUEL, V106, P697, DOI 10.1016/j.fuel.2012.10.064
   Wu SL, 2016, BIOMASS BIOENERG, V95, P55, DOI 10.1016/j.biombioe.2016.09.015
   Wu SL, 2016, BIOMASS BIOENERG, V90, P209, DOI 10.1016/j.biombioe.2016.04.012
   Xin SZ, 2013, FUEL, V113, P266, DOI 10.1016/j.fuel.2013.05.061
   Yang HP, 2007, FUEL, V86, P1781, DOI 10.1016/j.fuel.2006.12.013
   Yang HP, 2006, ENERG FUEL, V20, P388, DOI 10.1021/ef0580117
   Yu J, 2017, FUEL, V191, P140, DOI 10.1016/j.fuel.2016.11.057
   Zhang J, 2015, ACS SUSTAIN CHEM ENG, V3, P293, DOI 10.1021/sc500664h
   Zhao CX, 2017, J ENERGY INST, V90, P902, DOI 10.1016/j.joei.2016.08.004
NR 35
TC 9
Z9 9
U1 8
U2 46
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 767
EP 776
DI 10.1016/j.ces.2018.10.023
PG 10
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500069
DA 2020-05-12
ER

PT J
AU Amin, MT
   Khan, F
   Imtiaz, S
AF Amin, Md Tanjin
   Khan, Faisal
   Imtiaz, Syed
TI Fault detection and pathway analysis using a dynamic Bayesian network
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Process monitoring; Fault detection; Fault propagation pathway; Root
   cause diagnosis; Dynamic Bayesian network; Cause-effect relationship
ID ROOT CAUSE DIAGNOSIS; SYSTEMS; MODEL
AB A dynamic Bayesian network (DBN) based fault detection, root cause diagnosis, and fault propagation pathway identification scheme is proposed. The proposed methodology generates evidence from monitored process data and uses the information to update the DBN that captures the process knowledge. A new dynamic Bayesian anomaly index (DBAI) based control chart is proposed for detection purpose. Following the detection of the fault(s), root cause(s) is diagnosed using the smoothing inference of a DBN, and fault propagation pathway is identified from the cause-effect relationships among the process variables. The proposed methodology is applied to a binary distillation column and a continuous stirred tank heater (CSTH). The result shows that it can detect the fault and diagnose the root cause of the fault precisely. The result has been compared to the performance of the Shewhart control chart, principal component analysis (PCA) and static BN. The comparative study confirms that the proposed methodology is a more efficient fault detection and diagnosis (FDD) tool. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Amin, Md Tanjin; Khan, Faisal; Imtiaz, Syed] Mem Univ Newfoundland, C RISE, Fac Engn & Appl Sci, St John, NF A1B 3X5, Canada.
RP Imtiaz, S (reprint author), Mem Univ Newfoundland, C RISE, Fac Engn & Appl Sci, St John, NF A1B 3X5, Canada.
EM simtiaz@mun.ca
OI Khan, Faisal/0000-0002-5638-4299; Imtiaz, Syed/0000-0002-2715-9084
FU Natural Sciences and Engineering Research Council (NSERC), CanadaNatural
   Sciences and Engineering Research Council of Canada
FX Authors would like to thank the Natural Sciences and Engineering
   Research Council (NSERC), Canada for providing the financial support to
   conduct this research.
CR Amin M. T., 2017, 5 INT C CHEM ENG ICC, P461
   Amin MT, 2018, RELIAB ENG SYST SAFE, V178, P108, DOI 10.1016/j.ress.2018.05.017
   Amin MT, 2018, CHEM ENG SCI, V189, P191, DOI 10.1016/j.ces.2018.05.045
   Azhdari Maryam, 2010, 2010 International Conference on Chemistry and Chemical Engineering (ICCCE 2010), P92, DOI 10.1109/ICCCENG.2010.5560369
   Bakshi BR, 1998, AICHE J, V44, P1596, DOI 10.1002/aic.690440712
   Choi SW, 2004, CHEM ENG SCI, V59, P5897, DOI 10.1016/j.ces.2004.07.019
   Dey S, 2005, INT J MACH TOOL MANU, V45, P75, DOI 10.1016/j.ijmachtools.2004.06.018
   Gharahbagheri H, 2017, IND ENG CHEM RES, V56, P2054, DOI 10.1021/acs.iecr.6b01916
   Gharahbagheri H., 2015, IFAC - Papers Online, V48, P838, DOI 10.1016/j.ifacol.2015.09.631
   Gharahbagheri H, 2017, CAN J CHEM ENG, V95, P1497, DOI 10.1002/cjce.22852
   Gonzalez R, 2015, ISA T, V58, P330, DOI 10.1016/j.isatra.2015.04.001
   HOSKINS JC, 1991, AICHE J, V37, P137, DOI 10.1002/aic.690370112
   KRAMER MA, 1991, AICHE J, V37, P233, DOI 10.1002/aic.690370209
   KRESTA JV, 1991, CAN J CHEM ENG, V69, P35, DOI 10.1002/cjce.5450690105
   Kulkarni A, 2005, COMPUT CHEM ENG, V29, P2128, DOI 10.1016/j.compchemeng.2005.06.006
   Lupinska-Dubicka A., 2012, SCI B BIALYSTOK U TE, P77
   Mallick M. R., 2013, IFAC P, V46, P827
   Mehranbod N, 2005, J PROCESS CONTR, V15, P321, DOI 10.1016/j.jprocont.2004.06.009
   Mehranbod N, 2003, AICHE J, V49, P1787, DOI 10.1002/aic.690490716
   Mihajlovic V., 2001, DYNAMIC BAYESIAN NET
   Montgomery D. C., 2010, APPL STAT PROBABILIT
   Mrad A., 2015, APPL INTELL, V43, P802, DOI DOI 10.1007/S10489-015-0678-6
   Murphy K. P., 2002, THESIS, P1, DOI 10.1.1.129.7714
   Mylaraswamy D, 1997, COMPUT CHEM ENG, V21, pS935, DOI 10.1016/S0098-1354(97)00169-5
   Neapolitan R.E., 2004, LEARNING BAYESIAN NE
   NIMMO I, 1995, CHEM ENG PROG, V91, P36
   Nomikos P, 1995, CHEMOMETR INTELL LAB, V30, P97, DOI 10.1016/0169-7439(95)00043-7
   Pearl J, 1988, PROBABILISTIC REASON
   Qin SJ, 2012, ANNU REV CONTROL, V36, P220, DOI 10.1016/j.arcontrol.2012.09.004
   Shewhart WA, 1930, BELL SYST TECH J, V9, P364, DOI 10.1002/j.1538-7305.1930.tb00373.x
   Skogestad S, 1997, CHEM ENG RES DES, V75, P539, DOI 10.1205/026387697524092
   SPIEGELHALTER DJ, 1990, NETWORKS, V20, P579, DOI 10.1002/net.3230200507
   Thornhill NF, 2008, J PROCESS CONTR, V18, P347, DOI 10.1016/j.jprocont.2007.07.006
   Venkatasubramanian V, 2003, COMPUT CHEM ENG, V27, P327, DOI 10.1016/S0098-1354(02)00162-X
   Venkatasubramanian V, 2003, COMPUT CHEM ENG, V27, P313, DOI 10.1016/S0098-1354(02)00161-8
   Wang W, 2017, INT J CHEM ENG, DOI 10.1155/2017/5083086
   Weber P, 2012, ENG APPL ARTIF INTEL, V25, P671, DOI 10.1016/j.engappai.2010.06.002
   Yu HY, 2015, IND ENG CHEM RES, V54, P2724, DOI 10.1021/ie503530v
   Yu J, 2013, AICHE J, V59, P2348, DOI 10.1002/aic.14013
   Zadakbar O, 2013, IND ENG CHEM RES, V52, P809, DOI 10.1021/ie202880w
   Zhang ZD, 2014, CHEMOMETR INTELL LAB, V138, P30, DOI 10.1016/j.chemolab.2014.07.009
NR 41
TC 8
Z9 8
U1 14
U2 71
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 777
EP 790
DI 10.1016/j.ces.2018.10.024
PG 14
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500070
DA 2020-05-12
ER

PT J
AU Su, MJ
   Bai, S
   Luo, Y
   Chu, GW
   Sun, BC
   Le, Y
   Chen, JF
AF Su, Meng-Jun
   Bai, Shun
   Luo, Young
   Chu, Guang-Wen
   Sun, Bao-Chang
   Le, Yuan
   Chen, Jian-Feng
TI Controllable wettability on stainless steel substrates with highly
   stable coatings
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Controllable wettability; Stainless steel substrate; Structure-function
   relationship; Dynamic wettability; Stable coatings
ID ROTATING PACKED-BED; MASS-TRANSFER; WATER-REPELLENT; SURFACE;
   FABRICATION; LIQUID; SILICA; MESH; FLOW; INTENSIFICATION
AB A rotating packed bed (RPB) is one of the typical process intensification equipment and its performance can be influenced by the surface wettability of packings. However, tuning the surface wettability of the packing by the surface-modification method is still a challenge due to the extreme physical and chemical environment in RPBs. This work presents a facile strategy for controlling the surface wettability on the stainless steel substrate with a series of highly stable coatings. The water contact angles on the surfaces can be tuned from 75 degrees to 160 degrees. Based on the systematical analysis from the micro-characteristics (surface microstructure and surface free energy) to the macro-wettabilities (water contact angle) of the prepared coatings, the structure-function relationship of these coatings was revealed with wetting models. Application performance testing indicates that the coatings displayed strong adhesion, long-time corrosion resistance, and liquid impinging resistance under high-gravity conditions. This work opens a new avenue to produce highly stable coatings on stainless steel substrates with controllable wettability, which is very helpful to the wettability control for the stainless steel wire mesh packing of RPBs for industrial applications. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Su, Meng-Jun; Bai, Shun; Chu, Guang-Wen; Chen, Jian-Feng] Beijing Univ Chem Technol, Beijing Adv Innovat Ctr Soft Matter Sci & Engn, Beijing 100029, Peoples R China.
   [Su, Meng-Jun; Bai, Shun; Chu, Guang-Wen; Le, Yuan; Chen, Jian-Feng] Beijing Univ Chem Technol, State Key Lab Organ Inorgan Composites & Technol, Beijing 100029, Peoples R China.
   [Su, Meng-Jun; Bai, Shun; Luo, Young; Chu, Guang-Wen; Sun, Bao-Chang; Le, Yuan; Chen, Jian-Feng] Beijing Univ Chem Technol, Res Ctr, Minist Educ High Grav Engn Technol, Beijing 100029, Peoples R China.
RP Luo, Y; Chu, GW (reprint author), Beijing Univ Chem Technol, Res Ctr, Minist Educ High Grav Engn Technol, Beijing 100029, Peoples R China.
EM luoyong@mail.buct.edu.cn; chugw@mail.buct.edu.cn
RI Luo, Yong/E-7522-2016
OI Luo, Yong/0000-0001-8300-5277
FU National Key Research and Development Program of China [2017YFA0206801];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21676009, 21725601, 21436001]
FX This work was supported by the National Key Research and Development
   Program of China (No. 2017YFA0206801) and National Natural Science
   Foundation of China (Nos. 21676009, 21725601, and 21436001).
CR Alexander S, 2016, ACS APPL MATER INTER, V8, P660, DOI 10.1021/acsami.5b09784
   [Anonymous], 2017, D335917 ASTM
   Cao LL, 2007, LANGMUIR, V23, P4310, DOI 10.1021/la063572r
   Cassie ABD, 1944, T FARADAY SOC, V40, P0546, DOI 10.1039/tf9444000546
   Chen JF, 2000, IND ENG CHEM RES, V39, P948, DOI 10.1021/ie990549a
   Chen QY, 2016, IND ENG CHEM RES, V55, P11606, DOI 10.1021/acs.iecr.6b02630
   Chen YS, 2006, IND ENG CHEM RES, V45, P6846, DOI 10.1021/ie060399l
   Chu GW, 2015, IND ENG CHEM RES, V54, P1697, DOI 10.1021/ie504407a
   Cottin-Bizonne C, 2003, NAT MATER, V2, P237, DOI 10.1038/nmat857
   COUGHLIN RW, 1969, AICHE J, V15, P654, DOI 10.1002/aic.690150506
   Erbil HY, 2003, SCIENCE, V299, P1377, DOI 10.1126/science.1078365
   Fan WZ, 2016, CHEM PHYS LETT, V644, P261, DOI 10.1016/j.cplett.2015.12.010
   Feng L, 2004, ANGEW CHEM INT EDIT, V43, P2012, DOI 10.1002/anie.200353381
   Gao XF, 2004, NATURE, V432, P36, DOI 10.1038/432036a
   Guo F, 1997, CHEM ENG SCI, V52, P3853, DOI 10.1016/S0009-2509(97)00229-7
   Li XG, 2016, IND ENG CHEM RES, V55, P10095, DOI 10.1021/acs.iecr.6b02541
   Liu MJ, 2017, NAT REV MATER, V2, DOI 10.1038/natrevmats.2017.36
   Liu TY, 2014, SCIENCE, V346, P1096, DOI 10.1126/science.1254787
   Liu YH, 2014, NAT PHYS, V10, P515, DOI [10.1038/NPHYS2980, 10.1038/nphys2980]
   Luo Y, 2017, CHEM ENG SCI, V170, P347, DOI 10.1016/j.ces.2016.10.023
   Luo Y, 2012, IND ENG CHEM RES, V51, P16320, DOI 10.1021/ie302531j
   Luo Y, 2012, IND ENG CHEM RES, V51, P9164, DOI 10.1021/ie300466f
   Mousavi MA, 2013, APPL SURF SCI, V273, P205, DOI 10.1016/j.apsusc.2013.02.014
   Nakae H, 1998, ACTA MATER, V46, P2313, DOI 10.1016/S1359-6454(97)00387-X
   Neinhuis C, 1997, ANN BOT-LONDON, V79, P667, DOI 10.1006/anbo.1997.0400
   OWENS DK, 1969, J APPL POLYM SCI, V13, P1741, DOI 10.1002/app.1969.070130815
   Pan ZH, 2015, APPL SURF SCI, V324, P612, DOI 10.1016/j.apsusc.2014.10.146
   Parker AR, 2001, NATURE, V414, P33, DOI 10.1038/35102108
   Ramshaw C, 1981, U.S. Patent, Patent No. [4, 283, 255, 4]
   Reddy KJ, 2006, IND ENG CHEM RES, V45, P4270, DOI 10.1021/ie051382q
   Richard D, 2002, NATURE, V417, P811, DOI 10.1038/417811a
   Sandilya P, 2001, IND ENG CHEM RES, V40, P384, DOI 10.1021/ie0000818
   Sang L, 2017, CHEM ENG SCI, V158, P429, DOI 10.1016/j.ces.2016.10.044
   Shao N, 2009, CHEM ENG SCI, V64, P2749, DOI 10.1016/j.ces.2009.01.067
   Shen YZ, 2017, CHEM ENG J, V313, P47, DOI 10.1016/j.cej.2016.12.063
   STOBER W, 1968, J COLLOID INTERF SCI, V26, P62, DOI 10.1016/0021-9797(68)90272-5
   Su B, 2016, J AM CHEM SOC, V138, P1727, DOI 10.1021/jacs.5b12728
   Su MJ, 2018, IND ENG CHEM RES, V57, P4743, DOI 10.1021/acs.iecr.8b00269
   Tuteja A, 2007, SCIENCE, V318, P1618, DOI 10.1126/science.1148326
   Wang HY, 2015, APPL SURF SCI, V357, P229, DOI 10.1016/j.apsusc.2015.09.017
   WENZEL RN, 1949, J PHYS COLLOID CHEM, V53, P1466, DOI 10.1021/j150474a015
   Yan P, 2018, CHEM ENG SCI, V176, P220, DOI 10.1016/j.ces.2017.10.023
   Yang H, 2011, SURF COAT TECH, V205, P5387, DOI 10.1016/j.surfcoat.2011.05.049
   Young T., 1805, PHILOS T R SOC LONDO, V95, P65, DOI [10.1098/rst1.1805.0005, DOI 10.1098/RSTL.1805.0005]
   Zheng XH, 2016, CHEM ENG J, V285, P236, DOI 10.1016/j.cej.2015.09.083
NR 45
TC 6
Z9 6
U1 1
U2 24
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 791
EP 800
DI 10.1016/j.ces.2018.10.025
PG 10
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500071
DA 2020-05-12
ER

PT J
AU Zhao, Y
   Liao, ZJ
   Xiang, ZH
AF Zhao, Yun
   Liao, Zhijian
   Xiang, Zhonghua
TI Microfluidics for synthesis and morphology control of hierarchical
   porous covalent organic polymer monolith
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Droplet microfluidic system; Porous material; Hierarchical porous
   monolith; Massive producing; Microchemical engineering
ID CONTINUOUS-FLOW SYNTHESIS; FRAMEWORKS; CRYSTALLINE; CARBON; ULTRAFAST;
   DROPLET
AB The hierarchical porous monoliths are important in enhancing diffusion efficiency and reducing pressure drop in heterogeneous catalysis. Here, a practical way to synthesize hierarchical porous covalent organic polymer (COP) monolith by using droplet microfluidic is proposed. The interconnected macro pores (up to similar to 130 nm) were created within intrinsic microporous COP structures by the further condensation of COP particles in the confined microdroplets. Concentration, flow rate ratio, catalyst, etc., were screened to figure out the superior condition for producing different hierarchical porous COP monolith in microfluidic. Rod-like and spherical monolith with gradient sizes were controllable synthesized to satisfy the requirements of different packing density for practical applications. Significantly, our homemade single microreactor is able to produce the spherical hierarchical porous COP monolith with a high space-time yield of 413 kg.m(-3).day(-1) at optimized condition, which provides a promising scale-up method to synthesize COP monoliths for but not limit to industrial heterogeneous catalysis. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Zhao, Yun; Liao, Zhijian; Xiang, Zhonghua] Beijing Univ Chem Technol, State Key Lab Organ Inorgan Composites, Beijing 100029, Peoples R China.
RP Xiang, ZH (reprint author), Beijing Univ Chem Technol, State Key Lab Organ Inorgan Composites, Beijing 100029, Peoples R China.
EM xiangzh@mail.buct.edu.cn
OI Xiang, Zhonghua/0000-0002-0709-4527
FU National Key Research and Development Program of China [2017YFA0206500];
   NSF of ChinaNational Natural Science Foundation of China [51502012,
   21676020, 21620102007]; Beijing Natural Science FoundationBeijing
   Natural Science Foundation [17L20060, 2162032]; Young Elite Scientists
   Sponsorship Program by CAST [2017QNRC001]; Start-up fund for talent
   introduction of Beijing University of Chemical Technology [buctrc201420,
   buctrc201714]; Fundamental Research Funds for the Central Universities
   (China)Fundamental Research Funds for the Central Universities [ZY1811];
   Talent cultivation of State Key Laboratory of Organic-Inorganic
   Composites; Distinguished scientist program at BUCT [buctylkxj02]; "111"
   project of China [B14004]
FX This work was supported by the National Key Research and Development
   Program of China [2017YFA0206500]; NSF of China [51502012; 21676020;
   21620102007]; Beijing Natural Science Foundation [17L20060, 2162032];
   Young Elite Scientists Sponsorship Program by CAST [2017QNRC001]; The
   Start-up fund for talent introduction of Beijing University of Chemical
   Technology [buctrc201420; buctrc201714]; The research funding by the
   Fundamental Research Funds for the Central Universities ZY1811 (China).
   Talent cultivation of State Key Laboratory of Organic-Inorganic
   Composites; Distinguished scientist program at BUCT [buctylkxj02] and
   the "111" project of China [B14004].
CR Asthana A, 2009, LAB CHIP, V9, P1138, DOI 10.1039/b818987k
   Brivio M, 2006, LAB CHIP, V6, P329, DOI 10.1039/b510856j
   Campanati M, 2003, CATAL TODAY, V77, P299, DOI 10.1016/S0920-5861(02)00375-9
   Corma A, 2010, CHEM REV, V110, P4606, DOI 10.1021/cr9003924
   Cote AP, 2005, SCIENCE, V310, P1166, DOI 10.1126/science.1120411
   Cui JC, 2018, NANOSCALE, V10, P9192, DOI 10.1039/c8nr01219a
   Ding SY, 2013, CHEM SOC REV, V42, P548, DOI 10.1039/c2cs35072f
   Faustini M, 2013, J AM CHEM SOC, V135, P14619, DOI 10.1021/ja4039642
   Feng X, 2012, CHEM SOC REV, V41, P6010, DOI 10.1039/c2cs35157a
   Garstecki P, 2006, LAB CHIP, V6, P693
   Kandambeth S, 2012, J AM CHEM SOC, V134, P19524, DOI 10.1021/ja308278w
   Kikutani Y, 2002, LAB CHIP, V2, P193, DOI 10.1039/b208383n
   Lee J, 2009, CHEM SOC REV, V38, P1450, DOI 10.1039/b807080f
   Lee J, 2006, ADV MATER, V18, P2073, DOI 10.1002/adma.200501576
   Liang CD, 2008, ANGEW CHEM INT EDIT, V47, P3696, DOI 10.1002/anie.200702046
   Lopez-Orozco S, 2011, ADV MATER, V23, P2602, DOI 10.1002/adma.201100462
   Peng P, 2017, ACS ENERGY LETT, V2, P1308, DOI 10.1021/acsenergylett.7b00267
   Peng YW, 2016, CHEM MATER, V28, P5095, DOI 10.1021/acs.chemmater.6b01954
   Perez-Ramirez J, 2008, CHEM SOC REV, V37, P2530, DOI 10.1039/b809030k
   Hoang PH, 2011, J AM CHEM SOC, V133, P14765, DOI 10.1021/ja2054429
   Rodriguez-San-Miguel D, 2016, CHEM COMMUN, V52, P9212, DOI 10.1039/c6cc04013f
   Segura JL, 2016, CHEM SOC REV, V45, P5635, DOI 10.1039/c5cs00878f
   Shen K, 2018, SCIENCE, V359, P206, DOI 10.1126/science.aao3403
   Silverstein R. M., 2014, SPECTROMETRIC IDENTI
   Singh V, 2018, NPG ASIA MATER, V10, DOI 10.1038/am.2017.209
   Smith BJ, 2016, CHEM COMMUN, V52, P3690, DOI 10.1039/c5cc10221a
   SOHN HY, 1968, CAN J CHEM ENG, V46, P162, DOI 10.1002/cjce.5450460305
   Song H, 2003, ANGEW CHEM, V115, P792, DOI DOI 10.1002/ANGE.200390172
   Song Y, 2018, AICHE J, V64, P1828, DOI 10.1002/aic.16046
   Tice JD, 2004, ANAL CHIM ACTA, V507, P73, DOI 10.1016/j.aca.2003.11.024
   Tice JD, 2003, LANGMUIR, V19, P9127, DOI 10.1021/la030090w
   Valencia PM, 2012, NAT NANOTECHNOL, V7, P623, DOI 10.1038/nnano.2012.168
   van Donk S, 2003, CATAL REV, V45, P297, DOI 10.1081/CR-120023908
   Vyas VS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9508
   Wang DW, 2008, ANGEW CHEM INT EDIT, V47, P373, DOI 10.1002/anie.200702721
   Whitesides GM, 2006, NATURE, V442, P368, DOI 10.1038/nature05058
   Xiang ZH, 2016, CHEM MATER, V28, P8651, DOI 10.1021/acs.chemmater.6b03619
   Xiang ZH, 2014, ADV MATER, V26, P3315, DOI 10.1002/adma.201306328
   Xiang ZH, 2014, ANGEW CHEM INT EDIT, V53, P2433, DOI 10.1002/anie.201308896
   Xiang ZH, 2013, J MATER CHEM A, V1, P2691, DOI 10.1039/c2ta00063f
   Yang QQ, 2017, CHEM ENG SCI, V162, P33, DOI 10.1016/j.ces.2016.12.071
   Zhao Y, 2014, J FLOW CHEM, V4, P195, DOI 10.1556/JFC-D-14-00018
   Zhao Y, 2013, ADV MATER, V25, P4561, DOI 10.1002/adma.201300858
NR 43
TC 2
Z9 2
U1 16
U2 102
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 801
EP 809
DI 10.1016/j.ces.2018.10.026
PG 9
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500072
DA 2020-05-12
ER

PT J
AU Bensabath, T
   Monnier, H
   Glaude, PA
AF Bensabath, Tsilla
   Monnier, Hubert
   Glaude, Pierre-Alexandre
TI Acetylene pyrolysis in a jet-stirred-reactor for low pressure gas
   carburizing process - Experiments, kinetic modeling and mixing intensity
   investigations by CFD simulation
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Pyrolysis; Acetylene; Carburizing; Jet-stirred-reactor; Mixing; CFD
ID POLYCYCLIC AROMATIC-HYDROCARBONS; COMBUSTION; OXIDATION; CARBON; PAH
AB Low-pressure gas carburizing is used to harden steel, it has been shown to be a source of considerable PAH (Polycyclic Aromatic Hydrocarbon) pollution. Some PAH, like benzo[a]pyrene, are carcinogenic, and activities such as furnace maintenance and cleaning operations may thus represent a risk to workers. Occupational exposure during these operations should therefore be reduced. Benzene is a specific chemical marker of PAH, and the aim of the study was to understand its formation. Acetylene pyrolysis was experimentally performed in a jet-stirred-reactor in the laboratory, in conditions close to those encountered in industrial processes (1173 K and 8 kPa). Products of pyrolysis were analyzed by gas chromatography (TCD, FID) at the outlet from the reaction zone. The influence of residence time in the reactor was studied. A detailed kinetic model assuming an ideal continuous stirred tank reactor was used to describe the formation of chemical compounds and validate experimental data. CFD simulations were performed to characterize the reactor's hydrodynamics by applying the theory of the free jet. They allowed putting forward one explanation to understand the deviation between experiments and the kinetic model. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Bensabath, Tsilla; Monnier, Hubert] Inst Natl Rech & Secur, 1 Rue Morvan, F-54519 Vandoeuvre Les Nancy, France.
   [Bensabath, Tsilla; Glaude, Pierre-Alexandre] Univ Lorraine, Lab React & Genie Proc, CNRS, 1 Rue Grandville, F-54000 Nancy, France.
RP Monnier, H (reprint author), Inst Natl Rech & Secur, 1 Rue Morvan, F-54519 Vandoeuvre Les Nancy, France.
EM hubert.monnier@inrs.fr
OI MONNIER, HUBERT/0000-0002-6175-3247
CR Adeosun JT, 2009, CHEM ENG SCI, V64, P2422, DOI 10.1016/j.ces.2009.02.013
   [Anonymous], 2017, ANSYS FLUENT GETT ST
   Ayass WW, 2016, CHEM ENG RES DES, V111, P461, DOI 10.1016/j.cherd.2016.05.016
   AZAY P, 1979, IND ENG CHEM PROC DD, V18, P754, DOI 10.1021/i260072a030
   Bensabath T., 2017, THESIS
   Bensabath T, 2016, J ANAL APPL PYROL, V122, P342, DOI 10.1016/j.jaap.2016.09.007
   Bird R.B., 1960, TRANSPORT PHENOMENA
   Bush S. F, 1969, T I CHEM ENG-LOND, V47, P59
   Champmartin C, 2017, ANN WORK EXPOS HEAL, V61, P321, DOI 10.1093/annweh/wxw024
   Commenge JM, 2006, CHEM ENG SCI, V61, P597, DOI 10.1016/j.ces.2005.07.015
   Dai B, 1999, CHEM ENG SCI, V54, P957, DOI 10.1016/S0009-2509(98)00312-1
   DAVID R, 1975, CAN J CHEM ENG, V53, P297, DOI 10.1002/cjce.5450530309
   Dulcy J, 2007, THEORIE TRAITEMENTS
   Gavi E, 2007, CHEM ENG SCI, V62, P2228, DOI 10.1016/j.ces.2006.12.077
   Gil I, 2012, CHEM PROCESS ENG-INZ, V33, P397, DOI 10.2478/v10176-012-0035-9
   Herbinet O, 2015, CHEM ENG SCI, V131, P49, DOI 10.1016/j.ces.2015.03.026
   Herbinet O, 2013, GREEN ENERGY TECHNOL, P183, DOI 10.1007/978-1-4471-5307-8_8
   HIEP TV, 1973, CHEM ENG SCI, V28, P1951, DOI 10.1016/0009-2509(73)85039-0
   Hilgers A, 2001, FLUID DYN RES, V29, P345, DOI 10.1016/S0169-5983(01)00035-1
   HINZE JO, 1949, APPL SCI RES, V1, P435, DOI 10.1007/BF02120346
   Hognon C, 2018, CHEM ENG SCI, V181, P46, DOI 10.1016/j.ces.2018.01.038
   IARC (International Agency for Research on Cancer), 2012, MON EV CARC RISKS HU, p100F
   Iwata H., 2005, IHI ENG REV, V38, P83
   Kanaris AG, 2011, CHEM ENG SCI, V66, P5366, DOI 10.1016/j.ces.2011.07.044
   Kuwana K, 2006, CHEM ENG SCI, V61, P6718, DOI 10.1016/j.ces.2006.07.006
   Levenspiel O., 1962, CHEM REACTION ENG
   Liepmann H. W., 1947, 1257 NACA
   MATRAS D, 1973, CHEM ENG SCI, V28, P129, DOI 10.1016/0009-2509(73)85093-6
   Norinaga K, 2006, CARBON, V44, P1790, DOI 10.1016/j.carbon.2005.12.050
   Norinaga K, 2009, J ANAL APPL PYROL, V86, P148, DOI 10.1016/j.jaap.2009.05.001
   Patankar S.V., 1980, NUMERICAL HEAT TRANS
   ROTA R, 1994, CHEM ENG SCI, V49, P4211
   Sanchez NE, 2012, ENERG FUEL, V26, P4823, DOI 10.1021/ef300749q
   Violi A, 1999, CHEM ENG SCI, V54, P3433, DOI 10.1016/S0009-2509(98)00460-6
   Woldemariam M, 2016, CHEM ENG SCI, V152, P26, DOI 10.1016/j.ces.2016.05.030
   YAKHOT V, 1992, PHYS FLUIDS A-FLUID, V4, P1510, DOI 10.1063/1.858424
   Yan BH, 2012, CHEM ENG SCI, V84, P31, DOI 10.1016/j.ces.2012.08.005
NR 37
TC 2
Z9 2
U1 2
U2 17
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 810
EP 819
DI 10.1016/j.ces.2018.10.028
PG 10
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500073
DA 2020-05-12
ER

PT J
AU Yin, X
   Zarikos, I
   Karadimitriou, NK
   Raoof, A
   Hassanizadeh, SM
AF Yin, X.
   Zarikos, I
   Karadimitriou, N. K.
   Raoof, A.
   Hassanizadeh, S. M.
TI Direct simulations of two-phase flow experiments of different geometry
   complexities using Volume-of-Fluid (VOF) method
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Volume of Fluid (VOF) method; Two-phase flow; Porous media; Pore-scale
   simulations
ID POROUS-MEDIA; PORE-SCALE; MULTIPHASE FLOWS; SURFACE; MODEL; MICROMODEL
AB Two-phase flow in three porous media with different geometry complexities are simulated using the Volume-of-Fluid (VOF) method. The evolution of the flow pattern, as well as the dynamics involved are simulated and compared to experiments. For a simple geometry and smooth solid surface, like single capillary rise experiment, VOF simulation gives results which are in good agreement with the experiments. For a micromodel, with a relatively simple geometry, we can predict the flow pattern while we cannot effectively capture the dynamics of the process in terms of the temporal evolution of flow. With an increase in the geometry complexity in another micromodel, we fail to predict both the flow pattern and the flow dynamics. The reasons for this failure are discussed: interface modeling, pinning of contact line, 3D effects and the sensitivity of the system to initial and boundary conditions. More work regarding benchmarking of pore-scale methods in combination with experiments with different geometry complexities is needed. Also, possibilities and the potential to make better use of the porous media structure data from advanced visualization methods should be addressed. (C) 2018 The Author(s). Published by Elsevier Ltd.
C1 [Yin, X.; Zarikos, I; Raoof, A.; Hassanizadeh, S. M.] Univ Utrecht, Dept Earth Sci, Utrecht, Netherlands.
   [Karadimitriou, N. K.] Univ Stuttgart, Inst Mech CE, Stuttgart, Germany.
   [Yin, X.] Tsinghua Univ, Grad Sch Shenzhen, Engn Lab Functionalized Carbon Mat, Shenzhen, Peoples R China.
RP Yin, X (reprint author), Univ Utrecht, Dept Earth Sci, Utrecht, Netherlands.; Yin, X (reprint author), Tsinghua Univ, Grad Sch Shenzhen, Engn Lab Functionalized Carbon Mat, Shenzhen, Peoples R China.
EM xiaoguang.yin@sz.tsinghua.edu.cn; s.m.hassanizadeh@uu.nl
OI Zarikos, Ioannis/0000-0002-3171-2794; Yin, Xiaoguang/0000-0003-1428-2961
FU European Research Council (ERC)European Research Council (ERC);
   ERCEuropean Research Council (ERC) [341225]
FX S.M. Hassanizadeh would like to thank European Research Council (ERC)
   for the support received under the ERC Advanced Grant Agreement No.
   341225. Comments by anonymous reviewers, which led to the improvement of
   the article, are gratefully appreciated.
CR Berg S, 2016, ADV WATER RESOUR, V90, P24, DOI 10.1016/j.advwatres.2016.01.010
   Blunt MJ, 2001, CURR OPIN COLLOID IN, V6, P197, DOI 10.1016/S1359-0294(01)00084-X
   BRACKBILL JU, 1992, J COMPUT PHYS, V100, P335, DOI 10.1016/0021-9991(92)90240-Y
   Bultreys T, 2016, EARTH-SCI REV, V155, P93, DOI 10.1016/j.earscirev.2016.02.001
   deGennes P.-G., 2004, CAPILLARITY WETTING
   Deshpande Suraj S., 2012, Computational Science and Discovery, V5, DOI 10.1088/1749-4699/5/1/014016
   Dullien F. A. L., 1992, POROUS MEDIA FLUID T
   Fakhari A, 2018, ADV WATER RESOUR, V114, P119, DOI 10.1016/j.advwatres.2018.02.005
   Ferrari A, 2015, WATER RESOUR RES, V51, P1381, DOI 10.1002/2014WR016384
   Heshmati M, 2014, LANGMUIR, V30, P14151, DOI 10.1021/la501724y
   Hirschler M, 2016, J COMPUT PHYS, V307, P614, DOI 10.1016/j.jcp.2015.12.024
   Horgue P, 2013, CHEM ENG SCI, V102, P335, DOI 10.1016/j.ces.2013.08.031
   Kaestner A, 2008, ADV WATER RESOUR, V31, P1174, DOI 10.1016/j.advwatres.2008.01.022
   Kang QJ, 2002, PHYS REV E, V66, DOI 10.1103/PhysRevE.66.056307
   Karadimitriou NK, 2014, WATER RESOUR RES, V50, P8125, DOI 10.1002/2014WR015388
   Kunz P, 2018, TRANSPORT POROUS MED, V122, P253, DOI 10.1007/s11242-018-1002-9
   Kunz P, 2016, TRANSPORT POROUS MED, V114, P581, DOI 10.1007/s11242-015-0599-1
   Ling BW, 2017, ADV WATER RESOUR, V105, P29, DOI 10.1016/j.advwatres.2017.04.005
   Oren P. E., 1998, SPE J, V3, P324, DOI DOI 10.2118/52052-PA
   Raeini AQ, 2012, J COMPUT PHYS, V231, P5653, DOI 10.1016/j.jcp.2012.04.011
   Renardy Y, 2002, J COMPUT PHYS, V183, P400, DOI 10.1006/jcph.2002.7190
   Richards LA, 1931, PHYSICS-J GEN APPL P, V1, P318, DOI 10.1063/1.1745010
   Scardovelli R, 1999, ANNU REV FLUID MECH, V31, P567, DOI 10.1146/annurev.fluid.31.1.567
   Shams M, 2018, J COMPUT PHYS, V357, P159, DOI 10.1016/j.jcp.2017.12.027
   VANGENUCHTEN MT, 1980, SOIL SCI SOC AM J, V44, P892, DOI 10.2136/sssaj1980.03615995004400050002x
   Weller HG, 1998, COMPUT PHYS, V12, P620, DOI 10.1063/1.168744
   Worner M, 2012, MICROFLUID NANOFLUID, V12, P841, DOI 10.1007/s10404-012-0940-8
   WOODING RA, 1976, ANNU REV FLUID MECH, V8, P233, DOI 10.1146/annurev.fl.08.010176.001313
   Xu ZY, 2017, WATER RESOUR RES, V53, P3770, DOI 10.1002/2017WR020373
   Yin X., 2018, THESIS
   Zhmud BV, 2000, J COLLOID INTERF SCI, V228, P263, DOI 10.1006/jcis.2000.6951
NR 31
TC 3
Z9 4
U1 4
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 820
EP 827
DI 10.1016/j.ces.2018.10.029
PG 8
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500074
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Chen, M
   Xu, Q
AF Chen, Min
   Xu, Qiang
TI Upset-conscious scheduling for continuous parallel-process and
   performance decaying unit system
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Scheduling; MILP; Optimization; Modeling; Operability; Decoking policy
ID ETHYLENE CRACKING; FURNACE; OPERATIONS
AB Olefin plants employ multi-type cracking furnaces in parallel to convert various hydrocarbon feeds into products such as ethylene and propylene. The cracking process of each furnace is a performance-decaying batch operation, which needs periodic shutdowns for decoking operations and thus involves inherently frequent upsets to downstream process. Therefore, the furnace feed allocation, batch processing time and decoking sequence of the entire furnace system must be optimally scheduled to maximize the plant profitability; meanwhile, the induced upset of the main product yields also needs to be restricted within an appropriate range at any time for the sake of the plant operability. Facing this challenge, a new MILP (mixed-integer linear programming) model has been developed in this paper for the upset-conscious scheduling of cracking furnace systems. The study can not only benefit both profitability and operability for the entire olefin plant operation, but also be applied to other continuous parallel-process and performance-decaying unit systems. The efficacy of the developed scheduling model has been demonstrated by various case studies. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Chen, Min; Xu, Qiang] Lamar Univ, Dan F Smith Dept Chem Engn, Beaumont, DC 77710 USA.
RP Xu, Q (reprint author), Lamar Univ, Dan F Smith Dept Chem Engn, Beaumont, DC 77710 USA.
EM Qiang.xu@lamar.edu
FU President Visionary Project from Lamar University, United States; Anita
   Riddle Faculty Fellowship from Lamar University, United States
FX This work was partially supported by President Visionary Project and
   Anita Riddle Faculty Fellowship from Lamar University, United States.
CR Amghizar I, 2017, ENGINEERING-PRC, V3, P171, DOI 10.1016/J.ENG.2017.02.006
   Gao XD, 2008, COMPUT CHEM ENG, V32, P2801, DOI 10.1016/j.compchemeng.2008.01.005
   Jain V, 1998, AICHE J, V44, P1623
   Jiang P, 2017, CHINESE J CHEM ENG, V25, P992, DOI 10.1016/j.cjche.2017.03.040
   Kwon H, 2017, IND ENG CHEM RES, V56, P1267, DOI 10.1021/acs.iecr.6b03527
   Lagzi S, 2017, IND ENG CHEM RES, V56, P8940, DOI 10.1021/acs.iecr.7b01718
   Lagzi S, 2017, COMPUT CHEM ENG, V97, P135, DOI 10.1016/j.compchemeng.2016.11.012
   Lim H, 2006, IND ENG CHEM RES, V45, P5738, DOI 10.1021/ie050129n
   Lim H, 2009, IND ENG CHEM RES, V48, P3024, DOI 10.1021/ie800331z
   Liu CW, 2010, COMPUT CHEM ENG, V34, P544, DOI 10.1016/j.compchemeng.2009.10.008
   Schulz E., 2000, COMPUT AIDED CHEM EN, V8, P487
   Schulz EP, 2006, IND ENG CHEM RES, V45, P2748, DOI 10.1021/ie050341r
   Yu KJ, 2017, COMPUT CHEM ENG, V99, P314, DOI 10.1016/j.compchemeng.2017.01.024
   Zhang SJ, 2017, IND ENG CHEM RES, V56, P1327, DOI 10.1021/acs.iecr.6b02822
   Zhao CY, 2011, IND ENG CHEM RES, V50, P12026, DOI 10.1021/ie200318p
   Zhao CY, 2010, IND ENG CHEM RES, V49, P5765, DOI 10.1021/ie1001235
NR 16
TC 2
Z9 2
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 828
EP 840
DI 10.1016/j.ces.2018.10.030
PG 13
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500075
DA 2020-05-12
ER

PT J
AU Torkashvand, B
   Maier, L
   Hettel, M
   Schedlbauer, T
   Grunwaldt, JD
   Deutschmann, O
AF Torkashvand, Bentolhoda
   Maier, Lubow
   Hettel, Matthias
   Schedlbauer, Thomas
   Grunwaldt, Jan-Dierk
   Deutschmann, Olaf
TI On the challenges and constrains of ultra-low emission limits:
   Formaldehyde oxidation in catalytic sinusoidal-shaped channels
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Formaldehyde oxidation; Kinetic model; Metallic monolith; Mass transport
   limitation; CFD
ID NATURAL-GAS; MONOLITH CATALYSTS; WASHCOAT GEOMETRY; HEAT-TRANSFER;
   MASS-TRANSFER; INDOOR AIR; LEAN-BURN; COMBUSTION; REACTOR; PERFORMANCE
AB This paper presents the results of a study on kinetics and mass transfer in a catalytically coated metallic monolith converter with sinusoidal-shape channels. Hereby, experimental and modelling studies are performed on a commercial Pt-based oxidation catalyst for total oxidation of formaldehyde applicable in after-treatment system of lean-burn gas engines. For the description of flow field and mass transport inside the channel as well as species diffusion and chemical reaction inside the porous washcoat, a three-dimensional approach is applied and the calculations are performed, using ANSYS-FLUENT. Three different computational models representing different washcoat distribution are compared. The effects of washcoat distribution and mass transfer on kinetics and catalyst activity are investigated in detail and the numerically obtained results are compared with experimental data.
   Despite of a very high intrinsic reaction rate at operation temperature, the complete conversion of formaldehyde could not be achieved experimentally. All three models have shown to operate in mass transport limited regime, where the diffusion distance from bulk to catalyst surface as well as reactant concentration play a significant role. Thus, very low levels of formaldehyde emissions are technically hard to achieve and a long catalyst is required to overcome the low diffusion rate due to the small concentration gradient. The computational results indicate also that due to individual structure of each channel of metallic monolith in real applications, they can behave distinctly from each other and one channel does not represent the entire monolith. It is also evident from simulated data that the lack of knowledge of washcoat properties and distribution may bring about misleading results since apparent reaction rates can be highly sensitive to this parameter for particularly catalytic reactions under mass-transfer-controlled conditions. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Torkashvand, Bentolhoda; Hettel, Matthias; Schedlbauer, Thomas; Grunwaldt, Jan-Dierk; Deutschmann, Olaf] Karlsruhe Inst Technol, Inst Chem Technol & Polymer Chem ITCP, D-76131 Karlsruhe, Germany.
   [Maier, Lubow; Grunwaldt, Jan-Dierk; Deutschmann, Olaf] Karlsruhe Inst Technol, Inst Catalysis Res & Technol IKFT, D-76344 Eggenstein Leopoldshafen, Germany.
RP Deutschmann, O (reprint author), Karlsruhe Inst Technol, Inst Chem Technol & Polymer Chem ITCP, D-76131 Karlsruhe, Germany.
EM deutschmann@kit.edu
RI Deutschmann, Olaf/AAC-2652-2019; Grunwaldt, Jan-Dierk/L-9246-2013;
   Grunwaldt, Jan-Dierk/Q-5748-2019; Deutschmann, Olaf/B-4891-2015
OI Deutschmann, Olaf/0000-0001-9211-7529; Grunwaldt,
   Jan-Dierk/0000-0003-3606-0956; Grunwaldt, Jan-Dierk/0000-0003-3606-0956;
   Deutschmann, Olaf/0000-0001-9211-7529
FU German Research Association for Combustion Engines e.V. (FVV) [1187]
FX The German Research Association for Combustion Engines e.V. (FVV) is
   acknowledged for funding the project "Formaldehyde" (Project-Nr. 1187)
   chaired by Heinrich Baas. The authors would like to thank Dr. Christian
   Breuer (Heraeus Deutschland GmbH & Co. KG, a technology group
   headquartered in Hanau, Germany) for providing the catalyst. We
   gratefully thank Dr. Maria Casapu for very fruitful discussions
   concerning the results of this study.
CR Alzueta MU, 2003, ENVIRON SCI TECHNOL, V37, P4512, DOI 10.1021/es026144q
   Amneus P., 2007, 2007010049 SAE
   Arts JHE, 2006, REGUL TOXICOL PHARM, V44, P144, DOI 10.1016/j.yrtph.2005.11.006
   Arts JHE, 2008, REGUL TOXICOL PHARM, V52, P189, DOI 10.1016/j.yrtph.2008.08.009
   Chen JW, 2008, APPL CATAL A-GEN, V345, P1, DOI 10.1016/j.apcata.2008.04.010
   Colussi S, 2015, CATAL TODAY, V253, P163, DOI 10.1016/j.cattod.2015.02.028
   Correa SM, 2005, ATMOS ENVIRON, V39, P4513, DOI 10.1016/j.atmosenv.2005.03.042
   Day E. G. W., 2000, 2000010206 SAE
   Deutschmann O, 1996, TWENTY-SIXTH SYMPOSIUM (INTERNATIONAL) ON COMBUSTION, VOLS 1 AND 2, P1747
   Deutschmann O., 2001, STUD SURF SCI CATAL, P251, DOI DOI 10.1016/S0167-2991(01)80312-8
   Groppi G, 2005, CATAL TODAY, V105, P297, DOI 10.1016/j.cattod.2005.06.041
   Groppi G, 1997, CHEM ENG SCI, V52, P3521, DOI 10.1016/S0009-2509(97)00153-X
   Hayes RE, 2005, CHEM ENG SCI, V60, P2037, DOI 10.1016/j.ces.2004.11.041
   Hayes RE, 2004, CHEM ENG SCI, V59, P3169, DOI 10.1016/j.ces.2004.05.002
   HAYES RE, 1994, CHEM ENG SCI, V49, P3587, DOI 10.1016/0009-2509(94)00164-2
   Iwaniszyn M, 2015, CR CHIM, V18, P1030, DOI 10.1016/j.crci.2015.03.010
   Joshi SY, 2010, CHEM ENG SCI, V65, P1729, DOI 10.1016/j.ces.2009.11.021
   Joshi SY, 2009, CHEM ENG SCI, V64, P4976, DOI 10.1016/j.ces.2009.08.008
   Karavalakis G, 2016, FUEL, V175, P146, DOI 10.1016/j.fuel.2016.02.034
   Kolaczkowski ST, 2003, CATAL TODAY, V83, P85, DOI 10.1016/S0920-5861(03)00218-9
   Koop J, 2009, APPL CATAL B-ENVIRON, V91, P47, DOI 10.1016/j.apcatb.2009.05.006
   Kristensen P. G. E. R., 2007, COMBUST SCI TECHNOL, V157, P262
   Lang I, 2008, REGUL TOXICOL PHARM, V50, P23, DOI 10.1016/j.yrtph.2007.08.012
   Lemel M, 2005, SAE T, V114, P1347
   Mei H, 2007, CHEM ENG SCI, V62, P4294, DOI 10.1016/j.ces.2007.05.011
   Mitchell CE, 2000, J ENG GAS TURB POWER, V122, P603, DOI 10.1115/1.1290585
   Mladenov N, 2010, CHEM ENG SCI, V65, P812, DOI 10.1016/j.ces.2009.09.034
   More H, 2006, TOP CATAL, V37, P155, DOI 10.1007/s11244-006-0017-6
   Olsen D. B., 2011, ENERGY POWER ENG, V03, P574
   Owrang F., 2004, 2004011928 SAE
   Papadias D, 2000, CHEM ENG SCI, V55, P1447, DOI 10.1016/S0009-2509(99)00375-9
   Raja LL, 2000, CATAL TODAY, V59, P47, DOI 10.1016/S0920-5861(00)00271-6
   Reuss G., 2002, ULLMANNS ENCY IND CH, DOI [10.1002/14356007.a11_619, DOI 10.1002/14356007.A11_619]
   Rodriguez ML, 2016, CHEM ENG SCI, V143, P305, DOI 10.1016/j.ces.2015.12.010
   Roh HS, 2010, INT J HYDROGEN ENERG, V35, P1613, DOI 10.1016/j.ijhydene.2009.12.051
   Rumchev KB, 2002, EUR RESPIR J, V20, P403, DOI 10.1183/09031936.02.00245002
   Santos H, 2013, SAE INT J ENGINES, V6, P1846, DOI 10.4271/2013-24-0166
   Schedlbauer T, 2018, 2018015021 SAE
   Sekine Y, 2001, ATMOS ENVIRON, V35, P2001, DOI 10.1016/S1352-2310(00)00465-9
   Seyed-Reihani SA, 2004, CHEM ENG SCI, V59, P5937, DOI 10.1016/j.ces.2004.07.028
   Stutz MJ, 2008, CHEM ENG SCI, V63, P1761, DOI 10.1016/j.ces.2007.11.032
   Tilland A, 2015, CHEM ENG PROCESS, V95, P317, DOI 10.1016/j.cep.2015.07.003
   Tischer S, 2005, CATAL TODAY, V105, P407, DOI 10.1016/j.cattod.2005.06.061
   Torkashvand B, 2019, CHEM ENG J, V377, DOI 10.1016/j.cej.2018.08.186
   Yoon S, 2014, ATMOS ENVIRON, V83, P220, DOI 10.1016/j.atmosenv.2013.11.003
   Zhang C, 2007, CATAL TODAY, V126, P345, DOI 10.1016/j.cattod.2007.06.010
   Zhang CB, 2006, APPL CATAL B-ENVIRON, V65, P37, DOI 10.1016/j.apcatb.2005.12.010
NR 47
TC 1
Z9 1
U1 2
U2 26
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 841
EP 850
DI 10.1016/j.ces.2018.10.031
PG 10
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500076
DA 2020-05-12
ER

PT J
AU Krishna, R
AF Krishna, Rajamani
TI Diffusing uphill with James Clerk Maxwell and Josef Stefan
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Review
DE Phase transitions; Coupled diffusion; Transient overshoots; Serpentine
   trajectories; Asymmetrical kinetics; Thermodynamic non-idealities;
   Electro-neutrality
ID ACETONE PLUS WATER; TAYLOR DISPERSION MEASUREMENTS; BINARY-MIXTURE
   DIFFUSION; MASS-TRANSFER; TERNARY DIFFUSION; MULTICOMPONENT DIFFUSION;
   ION-EXCHANGE; SPONTANEOUS EMULSIFICATION; COMPOSITION TRAJECTORIES;
   MOLECULAR-DIFFUSION
AB The accurate description of molecular diffusion is important in the design and development of several processes of interest to chemical engineers. Most commonly, a component diffuses down the gradient of its concentration, and Fick's law provides an adequate description for calculation of the fluxes. The major objective of this review article is to highlight a wide variety of processes in which a component is transported uphill, requiring more rigorous models for describing diffusion.
   Uphill diffusion may occur in multicomponent mixtures in which the diffusion flux of any species is strongly coupled to that of partner species. Such coupling effects often arise from strong thermodynamic non-idealities; for a quantitative description we need to use the Maxwell-Stefan formulation with chemical potential gradients as driving forces. Thermodynamic non-idealities are of particular significance for operations close to phase transition regions. A careful and detailed analysis of multicomponent distillation, and extraction processes reveals that Murphree component efficiencies could be "unbounded", i.e. exhibit values less than zero or exceed unity. A characteristic signature of uphill diffusion is the occurrence of transient overshoots in the approach to steady-state; the equilibration trajectories in composition space follow serpentine trajectories. For mixtures of liquids, metals, alloys, ceramics and glasses the serpentine equilibration trajectories could cause forays into meta-stable composition zones; such forays could result in spontaneous emulsification, and the Ouzo effect.
   The transport of ionic species is invariably coupled with its partner ions because of the electroneutrality constraints; such constraints may accelerate or decelerate a specific ion resulting in uphill transport. The forward and reverse kinetics of uptake in ion-exchange resins are asymmetric.
   For mixture separations with microporous adsorbents, uphill diffusion can cause supra-equilibrium loadings to be achieved during transient uptake within crystals; this allows the possibility of overriding adsorption equilibrium for achieving difficult separations. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Krishna, Rajamani] Univ Amsterdam, Vant Hoff Inst Mol Sci, Sci Pk 904, NL-1098 XH Amsterdam, Netherlands.
RP Krishna, R (reprint author), Univ Amsterdam, Vant Hoff Inst Mol Sci, Sci Pk 904, NL-1098 XH Amsterdam, Netherlands.
EM r.krishna@contact.uva.nl
RI Krishna, Rajamani/A-1098-2012
OI Krishna, Rajamani/0000-0002-4784-8530
CR Agren J, 2012, METALL MATER TRANS A, V43A, P3453, DOI 10.1007/s11661-011-0863-0
   ALIMADADIAN A, 1976, CAN J CHEM ENG, V54, P208, DOI 10.1002/cjce.5450540315
   ARNOLD KR, 1967, AICHE J, V13, P909, DOI 10.1002/aic.690130518
   Bakker W. J. W, 1999, THESIS
   BART HJ, 2001, REACTIVE EXTRACTION
   BENJEBRIA A, 1987, INT J BIOMED COMPUT, V20, P97, DOI 10.1016/0020-7101(87)90018-3
   Binder T, 2015, IND ENG CHEM RES, V54, P8997, DOI 10.1021/acs.iecr.5b02163
   Boudin L, 2010, ESAIM Proceedings, V30, P90, DOI 10.1051/proc/2010008
   BRES M, 1977, PFLUG ARCH EUR J PHY, V371, P227, DOI 10.1007/BF00586262
   Buzatu D, 2007, J SOLUTION CHEM, V36, P1373, DOI 10.1007/s10953-007-9200-z
   CHANG HK, 1973, RESP PHYSIOL, V18, P370
   CHANG HK, 1975, RESP PHYSIOL, V23, P109, DOI 10.1016/0034-5687(75)90075-4
   CHANG YC, 1986, AICHE J, V32, P1567, DOI 10.1002/aic.690320919
   Chevrolet JC, 2001, CRIT CARE, V5, P179
   Chiappa GR, 2009, AM J RESP CRIT CARE, V179, P1004, DOI 10.1164/rccm.200811-1793OC
   CHRISTENSEN NH, 1977, J AM CERAM SOC, V60, P293, DOI 10.1111/j.1151-2916.1977.tb15544.x
   CLARK WM, 1985, INT J THERMOPHYS, V6, P631, DOI 10.1007/BF00500335
   Courthial L, 2013, AICHE J, V59, P959, DOI 10.1002/aic.13866
   CULLINAN HT, 1965, J PHYS CHEM-US, V69, P3941, DOI 10.1021/j100895a050
   CULLINAN HT, 1976, CAN J CHEM ENG, V54, P156, DOI 10.1002/cjce.5450540306
   DARKEN LS, 1949, T AM I MIN MET ENG, V180, P430
   de Villiers WE, 2002, CHEM ENG PROG, V98, P66
   Doherty MF, 2001, CONCEPTUAL DESIGN DI
   DUNCAN JB, 1962, AICHE J, V8, P38, DOI 10.1002/aic.690080112
   Enqvist Y, 2003, CHEM ENG RES DES, V81, P1354, DOI 10.1205/026387603771339564
   Fornasiero F, 2005, MACROMOLECULES, V38, P1364, DOI 10.1021/ma040133v
   FULLARTON D, 1986, CHEM ENG PROCESS, V20, P255, DOI 10.1016/0255-2701(86)80018-6
   FULLER EN, 1966, IND ENG CHEM, V58, P19, DOI 10.1021/ie50677a007
   Ganachaud F, 2005, CHEMPHYSCHEM, V6, P209, DOI 10.1002/cphc.200400527
   GARSIDE J, 1985, CHEM ENG SCI, V40, P3, DOI 10.1016/0009-2509(85)85043-0
   GEDDES RL, 1946, T AM INST CHEM ENG, V42, P79
   GEUS ER, 1993, MICROPOROUS MATER, V1, P131, DOI 10.1016/0927-6513(93)80019-Q
   Glicksman M. E., 2000, DIFFUSION SOLIDS FIE
   Grillo I, 2003, COLLOID SURFACE A, V225, P153, DOI 10.1016/S0927-7757(03)00331-5
   Grossmann T, 2005, J CHEM ENG DATA, V50, P1396, DOI 10.1021/je050082c
   Grossmann T, 2007, J CHEM ENG DATA, V52, P336, DOI 10.1021/je060258q
   Grossmann T, 2007, J CHEM ENG DATA, V52, P341, DOI 10.1021/je060259i
   GUPTA PK, 1971, PHYSICA, V54, P39, DOI 10.1016/0031-8914(71)90062-0
   Haase M. F., 2014, ANGEW CHEM, V126, P11987
   HABGOOD HW, 1958, CAN J CHEM, V36, P1384, DOI 10.1139/v58-204
   Haeberl M, 1999, CHEM ENG RES DES, V77, P647, DOI 10.1205/026387699526584
   Hansen N, 2010, CHEM ENG SCI, V65, P2472, DOI 10.1016/j.ces.2009.12.028
   Hansen N, 2009, J PHYS CHEM C, V113, P235, DOI 10.1021/jp8073046
   He P, 2018, J SUPERCRIT FLUID, V135, P105, DOI 10.1016/j.supflu.2017.12.040
   HEINTZ A, 1994, J MEMBRANE SCI, V89, P143, DOI 10.1016/0376-7388(93)E0222-6
   Helfferich F., 1983, MASS TRANSFER KINETI, P157, DOI DOI 10.1007/978-94-009-6899-8_6
   Jebria A. B, 1982, INT J BIOMED COMPUT, V13, P403
   JONES IL, 1993, IND ENG CHEM RES, V32, P117, DOI 10.1021/ie00013a016
   Kolvenbach R, 2011, CATAL TODAY, V168, P147, DOI 10.1016/j.cattod.2011.01.037
   Kooijman H. A, 2007, THE CHEMSEP BOOK
   KRISHNA R, 1985, CHEM ENG RES DES, V63, P312
   Krishna R, 2005, IND ENG CHEM RES, V44, P6939, DOI 10.1021/ie050146c
   KRISHNA R, 1985, CHEM ENG SCI, V40, P893, DOI 10.1016/0009-2509(85)85003-X
   Krishna R, 1997, CHEM ENG SCI, V52, P861, DOI 10.1016/S0009-2509(96)00458-7
   Krishna R, 2009, CHEM ENG SCI, V64, P3159, DOI 10.1016/j.ces.2009.03.047
   Krishna R, 2009, CHEM ENG SCI, V64, P870, DOI 10.1016/j.ces.2008.10.045
   KRISHNA R, 1977, T I CHEM ENG-LOND, V55, P178
   Krishna R, 2018, MICROPOR MESOPOR MAT, V267, P274, DOI 10.1016/j.micromeso.2018.03.013
   Krishna R, 2018, MICROPOR MESOPOR MAT, V258, P151, DOI 10.1016/j.micromeso.2017.09.014
   Krishna R, 2018, SEP PURIF TECHNOL, V191, P392, DOI 10.1016/j.seppur.2017.09.057
   Krishna R, 2017, J MEMBRANE SCI, V540, P261, DOI 10.1016/j.memsci.2017.06.062
   Krishna R, 2017, PHYS CHEM CHEM PHYS, V19, P20320, DOI 10.1039/c7cp04101b
   Krishna R, 2017, REACT CHEM ENG, V2, P324, DOI 10.1039/c7re00001d
   Krishna R, 2017, CHEM ENG SCI, V164, P63, DOI 10.1016/j.ces.2017.01.060
   Krishna R, 2016, POLYMER, V103, P124, DOI 10.1016/j.polymer.2016.09.051
   Krishna R, 2016, CHEM ENG RES DES, V114, P1, DOI 10.1016/j.cherd.2016.08.009
   Krishna R, 2016, CHEM ENG SCI, V153, P174, DOI 10.1016/j.ces.2016.07.025
   Krishna R, 2016, PHYS CHEM CHEM PHYS, V18, P15482, DOI 10.1039/c6cp00132g
   Krishna R, 2016, IND ENG CHEM RES, V55, P4749, DOI 10.1021/acs.iecr.6b00762
   Krishna R, 2016, IND ENG CHEM RES, V55, P1053, DOI 10.1021/acs.iecr.5b04236
   Krishna R, 2015, PHYS CHEM CHEM PHYS, V17, P27428, DOI 10.1039/c5cp04520g
   Krishna R, 2015, CHEM SOC REV, V44, P2812, DOI 10.1039/c4cs00440j
   Krishna R, 2013, J MEMBRANE SCI, V430, P113, DOI 10.1016/j.memsci.2012.12.004
   Krishna R, 2012, CHEM SOC REV, V41, P3099, DOI 10.1039/c2cs15284c
   Krishna R, 2011, MICROPOR MESOPOR MAT, V137, P83, DOI 10.1016/j.micromeso.2010.08.026
   Krishna R, 2010, LANGMUIR, V26, P10854, DOI 10.1021/la100737c
   Krishna R, 2010, LANGMUIR, V26, P3981, DOI 10.1021/la9033639
   Krishna R, 2009, J PHYS CHEM C, V113, P19756, DOI 10.1021/jp906879d
   Kuiken G.D.C., 1994, THERMODYNAMICS IRREV
   LAO MZ, 1989, CHEM ENG COMMUN, V86, P73, DOI 10.1080/00986448908940364
   Lauerer A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8697
   Leahy-Dios A, 2005, J CHEM PHYS, V122, DOI 10.1063/1.1924503
   LEVY SG, 1985, IND ENG CHEM FUND, V24, P463, DOI 10.1021/i100020a011
   Lightfoot EN, 1974, TRANSPORT PHENOMENA
   Lo P. Y., 1989, AICHE J, V35, P676
   Louhi-Kultanen M, 2001, CHEM ENG SCI, V56, P3505, DOI 10.1016/S0009-2509(01)00018-5
   Matsufuji T, 2000, IND ENG CHEM RES, V39, P2434, DOI 10.1021/ie000026z
   Matsufuji T, 2000, J MEMBRANE SCI, V178, P25, DOI 10.1016/S0376-7388(00)00462-2
   Maxwell JC, 1867, PHILOS T ROY SOC LON, V157, P49, DOI [DOI 10.1098/RSTL.1867.0004, 10.1098/rstl.1867.0004]
   MULDER MHV, 1984, J MEMBRANE SCI, V17, P289, DOI 10.1016/S0376-7388(00)83220-2
   Murphree EV, 1925, IND ENG CHEM, V17, P747, DOI 10.1021/ie50187a044
   MYERSON AS, 1984, AICHE J, V30, P1004, DOI 10.1002/aic.690300624
   NAKAGAKI M, 1976, B CHEM SOC JPN, V49, P1748, DOI 10.1246/bcsj.49.1748
   Newman J., 2004, ELECTROCHEMICAL SYST
   Price PE, 2003, AICHE J, V49, P309, DOI 10.1002/aic.690490204
   Ravi R, 2007, CHEM ENG COMMUN, V194, P170, DOI 10.1080/00986440600715953
   Rehfeldt S, 2010, FLUID PHASE EQUILIBR, V290, P1, DOI 10.1016/j.fluid.2009.12.009
   REID R, 1986, PROPERTIES GASES LIQ
   REUVERS AJ, 1987, J MEMBRANE SCI, V34, P67, DOI 10.1016/S0376-7388(00)80021-6
   Ribeiro CP, 2011, POLYMER, V52, P3970, DOI 10.1016/j.polymer.2011.06.042
   Rodriguez JF, 1998, IND ENG CHEM RES, V37, P2020, DOI 10.1021/ie970684s
   RUSCHAK KJ, 1972, IND ENG CHEM FUND, V11, P534, DOI 10.1021/i160044a017
   SABATIER JP, 1967, MEM ETUD SCI REV MET, V64, P225
   Saint Remi JC, 2013, J PHYS CHEM C, V117, P9758, DOI 10.1021/jp312287k
   Sandler S.I., 1999, CHEM BIOCH ENG THERM
   Seader J.D., 2011, SEPARATION PROCESS P
   SETHY A, 1975, AICHE J, V21, P571, DOI 10.1002/aic.690210321
   SHERWOOD TK, 1955, AICHE J, V1, P522, DOI 10.1002/aic.690010423
   SHERWOOD TK, 1975, MASS TRANSFER
   SHUCK FO, 1963, J PHYS CHEM-US, V67, P540, DOI 10.1021/j100797a002
   Singh N, 2011, J CHEM TECHNOL BIOT, V86, P1495, DOI 10.1002/jctb.2659
   Sirkar K.K., 2014, SEPARATION MOL MACRO
   Sitnikova NL, 2005, LANGMUIR, V21, P7083, DOI 10.1021/la046816l
   Solans C, 2016, CURR OPIN COLLOID IN, V22, P88, DOI 10.1016/j.cocis.2016.03.002
   Springer PAM, 2002, CHEM ENG RES DES, V80, P654, DOI 10.1205/026387602760312863
   Springer PAM, 2002, COMPUT CHEM ENG, V26, P1265, DOI 10.1016/S0098-1354(02)00039-X
   Springer PAM, 2002, SEP PURIF TECHNOL, V29, P1, DOI 10.1016/S1383-5866(01)00157-5
   Springer PAM, 2002, IND ENG CHEM RES, V41, P1621, DOI 10.1021/ie010388m
   STANDART GL, 1979, CHEM ENG COMMUN, V3, P277, DOI 10.1080/00986447908935866
   Stefan J., 1871, SITZBER AKAD WISS WI, P63
   Sun YL, 2014, IND ENG CHEM RES, V53, P3654, DOI 10.1021/ie4036862
   TAI RC, 1979, B MATH BIOL, V41, P591, DOI 10.1007/BF02458332
   Taveira P., 2000, CHEM ENG ED      WIN, P90
   Taylor R, 2003, CHEM ENG PROG, V99, P28
   TAYLOR R, 1993, MULTICOMPONENT MASS
   Titze T, 2014, J PHYS CHEM C, V118, P2660, DOI 10.1021/jp412526t
   TSAY CS, 1990, J POLYM SCI POL PHYS, V28, P1327, DOI 10.1002/polb.1990.090280810
   VANDENBERG GB, 1992, J MEMBRANE SCI, V73, P103, DOI 10.1016/0376-7388(92)80121-Y
   VARSHNEY.AK, 1972, J AM CERAM SOC, V55, P312, DOI 10.1111/j.1151-2916.1972.tb11293.x
   Vielzeuf D, 2011, CONTRIB MINERAL PETR, V161, P683, DOI 10.1007/s00410-010-0557-4
   VIGNES A, 1966, IND ENG CHEM FUND, V5, P189, DOI 10.1021/i160018a007
   VIGNES A, 1969, T METALL SOC AIME, V245, P1795
   VITAGLIANO V, 1978, J SOLUTION CHEM, V7, P605, DOI 10.1007/BF00646038
   Vitale SA, 2003, LANGMUIR, V19, P4105, DOI 10.1021/la026842o
   VRENTAS JS, 1979, AICHE J, V25, P1, DOI 10.1002/aic.690250102
   Wankat P. C, 2012, SEPARATION PROCESS E
   Wesselingh J.A., 2000, MASS TRANSFER MULTIC
   Yang YH, 2000, AICHE J, V46, P1177, DOI 10.1002/aic.690460610
   YOSHIDA H, 1987, IND ENG CHEM RES, V26, P1179, DOI 10.1021/ie00066a020
NR 139
TC 6
Z9 6
U1 3
U2 29
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 851
EP 880
DI 10.1016/j.ces.2018.10.032
PG 30
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500077
DA 2020-05-12
ER

PT J
AU Sherratt, A
   DeGroot, CT
   Straatman, AG
   Santoro, D
AF Sherratt, Anthony
   DeGroot, Christopher T.
   Straatman, Anthony G.
   Santoro, Domenico
TI Numerical modeling and control of solids separation using continuously
   moving fine mesh filters
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Filtration; Primary wastewater treatment; Solids separation; Control
ID WATER TREATMENT PLANTS; FILTRATION; IMPACT; SIEVES
AB This work presents a numerical model for solids separation using continuously moving, inclined fine mesh filters. One of the main difficulties in modeling fine mesh filters is the characterization of the cake resistance as the solids accumulate on the filter. It is proposed to model the cake resistance using a gravity drainage column experiment implementing continuous water level monitoring. Based on the drainage curve, an analytical formulation is developed for the cake resistance, as a function of the filtered volume per unit area, V. The removal efficiency is also correlated with V through a sieve test. With the cake resistance and removal efficiency functions determined, a one-dimensional filter model is developed. Since the total suspended solids concentration varies as a function of time, and will not always be the same as that tested, a technique of scaling the cake resistance is introduced. A PID control algorithm is also developed into the model, so that the filter rotation speed can be controlled to maintain a set water level upstream of the filter. Results for sizing curves are given, as well as results for the PID controller operation, and validation results based on full-scale pilot testing. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Sherratt, Anthony; DeGroot, Christopher T.; Straatman, Anthony G.] Univ Western Ontario, Dept Mech & Mat Engn, London, ON, Canada.
   [Santoro, Domenico] Trojan Technol, 3020 Gore Rd, London, ON, Canada.
RP DeGroot, CT (reprint author), Univ Western Ontario, Dept Mech & Mat Engn, London, ON, Canada.
EM cdegroo5@uwo.ca
RI Santoro, Domenico/AAL-1710-2020; DeGroot, Christopher/D-1150-2011
OI DeGroot, Christopher/0000-0002-2069-8253; Santoro,
   Domenico/0000-0002-9561-4894
FU Natural Science and Engineering Research Council (NSERC)Natural Sciences
   and Engineering Research Council of Canada [CRDPJ 488704-15, EGP
   496723-16]
FX This work was supported by the Natural Science and Engineering Research
   Council (NSERC) [CRDPJ 488704-15, 2016] and [EGP 496723-16, 2016].
CR Bai RB, 2005, CHEM ENG SCI, V60, P301, DOI 10.1016/j.ces.2004.08.008
   Behera CR, 2018, CHEM ENG J, V334, P1965, DOI 10.1016/j.cej.2017.11.091
   DeGroot C.T., 2016, P WAT ENV FED, V2016, P1158, DOI 10.2175/193864716819712791
   DeGroot C. T., 2015, P WAT ENV FED, V2015, P1249, DOI DOI 10.2175/193864715819556273
   Franchi A, 2015, WATER PRACT TECHNOL, V10, P319, DOI 10.2166/wpt.2015.038
   Franklin G. F., 2015, FEEDBACK CONTROL DYN
   Ho CC, 2000, J COLLOID INTERF SCI, V232, P389, DOI 10.1006/jcis.2000.7231
   Osterroth S, 2016, SEP PURIF TECHNOL, V165, P114, DOI 10.1016/j.seppur.2016.03.046
   Paulsrud B, 2014, WATER SCI TECHNOL, V69, P560, DOI 10.2166/wst.2013.737
   Rusten B, 2006, WATER SCI TECHNOL, V54, P31, DOI 10.2166/wst.2006.710
   Rusten B, 2017, WATER SCI TECHNOL, V75, P2598, DOI 10.2166/wst.2017.145
   Sherratt A, 2019, T CAN SOC MECH ENG, V43, P221, DOI 10.1139/tcsme-2018-0071
   Tchobanoglous G., 2014, WASTEWATER ENG TREAT
   Teklehaimanot GZ, 2015, ENVIRON MANAGE, V56, P984, DOI 10.1007/s00267-015-0564-3
   Teoh SK, 2006, AICHE J, V52, P3427, DOI 10.1002/aic.10952
   Tien C, 2012, PRINCIPLES OF FILTRATION, P1
   Tien C, 2003, CHEM ENG SCI, V58, P1323, DOI 10.1016/S0009-2509(02)00655-3
   Tien C, 2002, POWDER TECHNOL, V127, P1, DOI 10.1016/S0032-5910(02)00063-3
   Tien C, 2008, J MEMBRANE SCI, V319, P10, DOI 10.1016/j.memsci.2008.02.049
   Tien C, 2014, CHEM ENG SCI, V111, P421, DOI 10.1016/j.ces.2014.01.022
   Tien C, 2011, J MEMBRANE SCI, V383, P17, DOI 10.1016/j.memsci.2011.07.019
   VAFAI K, 1981, INT J HEAT MASS TRAN, V24, P195, DOI 10.1016/0017-9310(81)90027-2
   Ward JC, 1964, J HYDRAUL DIV ASCE, V90, P1
NR 23
TC 1
Z9 1
U1 3
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 881
EP 893
DI 10.1016/j.ces.2018.10.033
PG 13
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500078
DA 2020-05-12
ER

PT J
AU Son, Y
   Won, W
AF Son, Yongho
   Won, Wangyun
TI Liquid holdup and pressure drop in packed column with structured packing
   under offshore conditions
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Offshore; Floating liquefied natural gas; Electrical resistance
   tomography; Sloshing machine; CO2 absorption; Hydraulic model
ID PLANE ERT SYSTEM; MASS-TRANSFER; MODEL; PERFORMANCE; FLOW;
   HYDRODYNAMICS; DESIGN; TILT
AB In this study, we propose liquid holdup and pressure drop models for a packed column with structured packing, under offshore conditions. To improve the model performance, we conducted experiments for an air-water system under various conditions (i.e., liquid load, gas load, and permanent tilt angle). We used a column with an inner diameter of 0.6 m and a packed height of 4 m, which was installed on a sloshing machine that enabled us to simulate offshore conditions, and corrected the key parameters of the model based on the experimental data obtained. The result showed that in offshore column design, the rolling motion can be regarded as permanent tilt, by extracting the tilt angle data from the rolling motion characteristics. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Son, Yongho] Sogang Univ, Dept Chem & Biomol Engn, 35 Baekbeomro, Seoul 04107, South Korea.
   [Won, Wangyun] Changwon Natl Univ, Dept Chem Engn, 20 Changwondaehak Ro, Chang Won 51140, Gyeongnam, South Korea.
RP Won, W (reprint author), Changwon Natl Univ, Dept Chem Engn, 20 Changwondaehak Ro, Chang Won 51140, Gyeongnam, South Korea.
EM wwon@changwon.ac.kr
FU C1 Gas Refinery Program through the National Research Foundation of
   Korea (NRF) - Ministry of Science, ICT & Future Planning
   [2015M3D3A1A01064929]
FX This research was supported by C1 Gas Refinery Program through the
   National Research Foundation of Korea (NRF) funded by the Ministry of
   Science, ICT & Future Planning (2015M3D3A1A01064929).
CR BAKER SA, 1992, CHEM ENG RES DES, V70, P509
   Billet R, 1999, CHEM ENG RES DES, V77, P498, DOI 10.1205/026387699526520
   Bird RB, 2007, TRANSPORT PHENOMENA
   Bravo J. L., 1986, PRESSURE DROP STRUCT, P65
   Brunazzi E, 1997, AICHE J, V43, P317, DOI 10.1002/aic.690430205
   Cullinane J. T, 2011, EFFECTS TOWER MOTION
   Deng X, 2001, MEAS SCI TECHNOL, V12, P1024, DOI 10.1088/0957-0233/12/8/306
   Dong F, 2005, FLOW MEAS INSTRUM, V16, P191, DOI 10.1016/j.flowmeasinst.2005.02.010
   Gauthier P, 2016, INT PETR TECHN C
   Gorak A, 2014, DISTILLATION: OPERATION AND APPLICATIONS, pVII
   Heymes F, 2006, CHEM ENG SCI, V61, P5094, DOI 10.1016/j.ces.2006.03.037
   Jones G, 1941, J AM CHEM SOC, V63, P3262, DOI 10.1021/ja01857a007
   Kobayashi T., 1999, ISHIKAWAJIMA HARIMA, V39, P209
   Lee S, 2012, IND ENG CHEM RES, V51, P10021, DOI 10.1021/ie2029283
   Ljung L., 1999, SYSTEM IDENTIFICATIO
   NAWROCKI PA, 1991, CAN J CHEM ENG, V69, P1336, DOI 10.1002/cjce.5450690614
   Ozbek H., 1977, VISCOSITY AQUEOUS SO
   ROCHA JA, 1993, IND ENG CHEM RES, V32, P641, DOI 10.1021/ie00016a010
   Seader JD, 1998, SEPARATION PROCESS P
   SHULMAN HL, 1955, AICHE J, V1, P247, DOI 10.1002/aic.690010219
   Son Y, 2017, CHEM ENG SCI, V166, P168, DOI 10.1016/j.ces.2017.03.044
   Stichlmair J., 1989, GAS SEP PURIF, V3, P19, DOI DOI 10.1016/0950-4214(89)80016-7
   SUESS P, 1992, CHEM ENG PROCESS, V31, P119, DOI 10.1016/0255-2701(92)85005-M
   Tanner R. K., 1992, I CHEM ENG S SER, V128, pB111
   Tanner RK, 1996, CHEM ENG RES DES, V74, P177
   Tapp HS, 2003, SENSOR ACTUAT B-CHEM, V92, P17, DOI 10.1016/S0925-4005(03)00126-6
   TSAI R., 2010, THESIS
   Tsai RE, 2011, AICHE J, V57, P1173, DOI 10.1002/aic.12345
   VANSWAAIJ WP, 1969, CHEM ENG SCI, V24, P1083, DOI 10.1016/0009-2509(69)80080-1
   Waldie B., 2004, AICHE DIST M NEW ORL
   Weiss C., 2014, OFFSH TECHN C OFFSH
   White V., 2010, Patent US, Patent No. [7673857 B2, 7673857]
   Won W, 2017, COMPUT CHEM ENG, V96, P87, DOI 10.1016/j.compchemeng.2016.10.009
   Won W, 2014, KOREAN J CHEM ENG, V31, P732, DOI 10.1007/s11814-014-0047-x
   Won W, 2012, COMPUT CHEM ENG, V40, P223, DOI 10.1016/j.compchemeng.2012.01.019
   Won W, 2012, SEP PURIF TECHNOL, V85, P120, DOI 10.1016/j.seppur.2011.09.056
   Wongkia A, 2015, CHEM ENG SCI, V138, P256, DOI 10.1016/j.ces.2015.08.024
   Wu YX, 2005, CAN J CHEM ENG, V83, P37
   Yin FH, 2002, CHEM ENG PROCESS, V41, P473, DOI 10.1016/S0255-2701(01)00167-2
NR 39
TC 3
Z9 3
U1 3
U2 15
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 894
EP 903
DI 10.1016/j.ces.2018.10.034
PG 10
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500079
DA 2020-05-12
ER

PT J
AU Obermeier, A
   Windmeier, C
   Esche, E
   Repke, JU
AF Obermeier, Andreas
   Windmeier, Christoph
   Esche, Erik
   Repke, Jens-Uwe
TI A discrete-time scheduling model for power-intensive processes taking
   fatigue of equipment into consideration
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Scheduling; Fatigue; Mechanical limitations; Air separation; Demand side
   management
ID AIR SEPARATION PLANT; OPTIMAL-DESIGN; OPTIMIZATION; FRAMEWORK;
   OPERATIONS; AGILITY; PRICES
AB In the light of the growing renewable energy generation, matching of electricity supply and demand has become increasingly challenging. By participating in demand side management programs, industry can contribute to counter this challenge. However, the frequent adjustment of operation conditions according to volatile electricity prices leads to additional dynamic loads for the equipment. In this work, a mixed-integer linear programming based discrete-time model is proposed for scheduling of a single air separation unit, explicitly considering fatigue of equipment occurring during transient operation. Besides constraints for describing the feasible region and the process dynamics, the model includes constraints for considering mechanical fatigue of some selected key equipment in a simplified way. The resulting model is applied to investigate the impact of mechanical constraints on the potentials of demand side management. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Obermeier, Andreas; Windmeier, Christoph] Linde AG, R&D Proc Dev, Engn Div, Dr Carl von Linde Str 6-14, D-82049 Pullach, Germany.
   [Esche, Erik; Repke, Jens-Uwe] Tech Univ Berlin, Proc Dynam & Operat Grp, Sekr KWT 9,Str 17 Juni 135, D-10623 Berlin, Germany.
RP Obermeier, A (reprint author), Linde AG, R&D Proc Dev, Engn Div, Dr Carl von Linde Str 6-14, D-82049 Pullach, Germany.
EM andreas.obermeier@linde.com
OI Obermeier, Andreas/0000-0002-0110-3912; Esche, Erik/0000-0002-2223-1825
FU German Federal Ministry of Education and ResearchFederal Ministry of
   Education & Research (BMBF) [03SFK3X1]
FX The project on which this report is based was supported by funds from
   the German Federal Ministry of Education and Research, funding code
   03SFK3X1. Responsibility for the content of this publication is assumed
   by the author.
CR Cao YN, 2016, IND ENG CHEM RES, V55, P9956, DOI 10.1021/acs.iecr.6b02090
   Cao YA, 2016, AICHE J, V62, P1602, DOI 10.1002/aic.15164
   Cao YN, 2015, J PROCESS CONTR, V33, P37, DOI 10.1016/j.jprocont.2015.05.002
   Castro PM, 2009, IND ENG CHEM RES, V48, P6701, DOI 10.1021/ie900073k
   Charles River Associates, 2005, PRIM DEM SID MAN EMP
   DARYANIAN B, 1989, IEEE T POWER SYST, V4, P897, DOI 10.1109/59.32577
   Dias LS, 2018, COMPUT CHEM ENG, V113, P139, DOI 10.1016/j.compchemeng.2018.03.009
   Hart W. E., 2017, PYOMO OPTIMIZATION M, V67
   Hart WE, 2011, MATH PROGRAM COMPUT, V3, P219, DOI 10.1007/s12532-011-0026-8
   Ierapetritou MG, 2002, IND ENG CHEM RES, V41, P5262, DOI 10.1021/ie011012b
   Karwan MH, 2007, COMPUT OPER RES, V34, P848, DOI 10.1016/j.cor.2005.05.014
   Kelley MT, 2018, APPL ENERG, V222, P951, DOI 10.1016/j.apenergy.2017.12.127
   Manenti F, 2013, COMPUT CHEM ENG, V56, P128, DOI 10.1016/j.compchemeng.2013.05.018
   Miller J, 2008, IND ENG CHEM RES, V47, P394, DOI 10.1021/ie070975t
   Mitra S, 2014, COMPUT CHEM ENG, V65, P89, DOI 10.1016/j.compchemeng.2014.01.016
   Mitra S, 2013, ENERGY, V54, P194, DOI 10.1016/j.energy.2013.02.030
   Mitra S, 2012, COMPUT CHEM ENG, V38, P171, DOI 10.1016/j.compchemeng.2011.09.019
   Obermeier A, 2018, COMPUT-AIDED CHEM EN, V43, P955, DOI 10.1016/B978-0-444-64235-6.50168-6
   Pattison RC, 2016, IND ENG CHEM RES, V55, P4562, DOI 10.1021/acs.iecr.5b03499
   Pattison RC, 2014, COMPUT-AIDED CHEM EN, V34, P393
   RAMAN R, 1994, COMPUT CHEM ENG, V18, P563, DOI 10.1016/0098-1354(93)E0010-7
   Zhang Q, 2016, ALTERNATIVE ENERGY S, P383, DOI DOI 10.1007/978-3-319-28752-2_14
   Zhang Q, 2016, OPTIM ENG, V17, P289, DOI 10.1007/s11081-015-9288-8
   Zhang Q, 2016, COMPUT CHEM ENG, V86, P90, DOI 10.1016/j.compchemeng.2015.12.015
   Zhang Q, 2016, COMPUT CHEM ENG, V84, P382, DOI 10.1016/j.compchemeng.2015.09.019
   Zhang Q, 2015, AICHE J, V61, P1547, DOI 10.1002/aic.14730
   Zhou DY, 2017, SEP PURIF TECHNOL, V172, P178, DOI 10.1016/j.seppur.2016.08.009
   Zhu Y, 2010, COMPUT CHEM ENG, V34, P1377, DOI 10.1016/j.compchemeng.2010.02.007
NR 28
TC 4
Z9 4
U1 1
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 904
EP 920
DI 10.1016/j.ces.2018.10.036
PG 17
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500080
DA 2020-05-12
ER

PT J
AU Daikeler, A
   Strohle, J
   Epple, B
AF Daikeler, A.
   Stroehle, J.
   Epple, B.
TI Experimental flow structure analysis in a 1 MWth circulating fluidized
   bed pilot plant
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Circulating fluidized bed; 1 MWth CFB pilot plant; Solids volume
   concentration and velocity; Capacitance probe
ID CARBONATE LOOPING PROCESS; MODELS; COAL
AB A water-cooled dual-channel capacitance probe system was developed for in-furnace measurements of solids concentration and solids velocity in a 1 MWth dual fluidized bed pilot plant. Measurements were conducted in both reactors of the pilot plant during carbonate looping and combustion test campaigns. Solids velocities were derived by cross correlating the signals of the two channels of the capacitance probe. Thus, horizontal profiles of solids concentration and velocity were simultaneously determined in the reactors. These profiles show a strong core annulus flow structure in both reactors of the pilot plant. The influence of bed material characteristics, operating conditions as well as riser geometries on the particle flow structure is evaluated. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Daikeler, A.; Stroehle, J.; Epple, B.] Tech Univ Darmstadt, Inst Energy Syst & Technol, Otto Berndt Str 2, D-64287 Darmstadt, Germany.
RP Daikeler, A (reprint author), Tech Univ Darmstadt, Inst Energy Syst & Technol, Otto Berndt Str 2, D-64287 Darmstadt, Germany.
EM alexander.daikeler@est.tu-darmstadt.de
OI Strohle, Jochen/0000-0003-2092-326X
FU European Union's Seventh Framework Programme (FP7/2007-2013)European
   Union (EU) [608578]; German Federal Ministry of Economic Affairs and
   Energy [LISA2-FKZ: 03ET7018]; GE; RWE; Uniper; Steinmuller Babcock
   Engineering; Rheinkalk
FX This research received funding from the European Union's Seventh
   Framework Programme (FP7/2007-2013) under grant agreement no. 608578
   (SCARLET-www.project-scarlet.eu) and from the German Federal Ministry of
   Economic Affairs and Energy based on a resolution of the German
   Parliament (LISA2-FKZ: 03ET7018). The financial contributions of GE,
   RWE, Uniper, Steinmuller Babcock Engineering and Rheinkalk are
   gratefully acknowledged.
CR Adamczyk WP, 2018, ENERGY, V143, P219, DOI 10.1016/j.energy.2017.10.029
   Brereton C., 1987, THESIS
   Caloz Y. P, 2000, THESIS
   Grace JR, 2004, POWDER TECHNOL, V139, P99, DOI 10.1016/j.powtec.2003.10.006
   Hage B, 1997, POWDER TECHNOL, V93, P235, DOI 10.1016/S0032-5910(97)03276-2
   Hartge EU, 2005, Circulating Fluidized Bed Technology VIII, P675
   Herdel P, 2017, FUEL, V205, P286, DOI 10.1016/j.fuel.2017.05.058
   Hilz J, 2017, FUEL, V210, P892, DOI 10.1016/j.fuel.2017.08.105
   Johnsson F, 2003, 47 IEA FBC M
   Johnsson H, 2001, POWDER TECHNOL, V115, P13, DOI 10.1016/S0032-5910(00)00270-9
   Kraume M, 2012, TRANSPORTVORGANGE VE
   Kunii D., 1991, FLUIDIZATION ENG
   Louge M, 1997, CIRCULATING FLUIDIZE, P312
   Nikku M, 2019, CHEM ENG SCI, V195, P39, DOI 10.1016/j.ces.2018.11.031
   Noymer PD, 2000, CHEM ENG SCI, V55, P5283, DOI 10.1016/S0009-2509(00)00171-8
   Ohlemuller P, 2017, INT J GREENH GAS CON, V65, P149, DOI 10.1016/j.ijggc.2017.08.013
   Richtberg M, 2001, THESIS
   Riley C. Acree, 1989, PARTICUL SCI TECHNOL, V7, P51
   Rolfe A, 2018, INT J GREENH GAS CON, V75, P85, DOI 10.1016/j.ijggc.2018.05.020
   Strabel M, 2004, THESIS
   Strohle J, 2014, FUEL, V127, P13, DOI 10.1016/j.fuel.2013.12.043
   Strohle J, 2014, APPL ENERG, V113, P1490, DOI 10.1016/j.apenergy.2013.09.008
   Strohle J, 2009, CHEM ENG TECHNOL, V32, P435, DOI 10.1002/ceat.200800569
   Stroh A, 2019, CHEM ENG SCI, V196, P37, DOI 10.1016/j.ces.2018.11.052
   VonHippel A. R., 1954, DIELECTRIC MAT APPL
   Werther J, 1997, CIRCULATING FLUIDIZE, P119
   Wiesendorf V, 2000, POWDER TECHNOL, V110, P143, DOI 10.1016/S0032-5910(99)00276-4
   Wiesendorf V., 2000, THESIS
   YANG YL, 1992, POWDER TECHNOL, V73, P67, DOI 10.1016/0032-5910(92)87008-X
NR 29
TC 4
Z9 4
U1 2
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 921
EP 934
DI 10.1016/j.ces.2018.10.037
PG 14
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500081
DA 2020-05-12
ER

PT J
AU Nanda, S
   Rana, R
   Hunter, HN
   Fang, Z
   Dalai, AK
   Kozinski, JA
AF Nanda, Sonil
   Rana, Rachita
   Hunter, Howard N.
   Fang, Zhen
   Dalai, Ajay K.
   Kozinski, Janusz A.
TI Hydrothermal catalytic processing of waste cooking oil for hydrogen-rich
   syngas production
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Waste cooking oil; Gasification; Supercritical water; Hydrogen; Process
   parameters; Catalysis
ID SUPERCRITICAL WATER GASIFICATION; VEGETABLE-OIL; LIGNOCELLULOSIC
   BIOMASS; CHEMICAL-REACTIONS; BIODIESEL; GLYCEROL; PYROLYSIS; GLUCOSE;
   FUELS; ACID
AB Substantial amounts of waste cooking oil are obtained worldwide from household and catering enterprises because of deep-frying and other cooking activities. Supercritical water gasification is considered as an aqueous phase reforming process to produce hydrogen enriched syngas from biomass and other organic wastes. In this study, waste cooking oil was gasified at variable temperatures (375-675 degrees C), feed concentration (25-40 wt%) and reaction time (15-60 min) to investigate their effects on syngas yield and composition. Maximum yields of hydrogen (5.16 mol/kg) and total gases (10.5 mol/kg) were obtained at optimal temperature, feed concentration and reaction time of 675 degrees C, 25 wt% and 60 min, respectively. At 5 wt% loading, Ru/Al2O3 enhanced hydrogen yield (10.16 mol/kg) through water-gas shift reaction, whereas Ni/Si-Al2O3 improved methane yield (8.15 mol/kg) via methanation reaction. The trend of hydrogen production from catalytic supercritical water gasification of waste cooking oil at 675 degrees C, 25 wt% and 60 min decreased as Ru/Al2O3 > Ni/Si-Al2O3 > K2CO3 > Na2CO3. The results indicate the recycling potential of waste cooking oil for hydrogen production through hydrothermal gasification. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Nanda, Sonil] Univ Western Ontario, Dept Chem & Biochem Engn, London, ON, Canada.
   [Rana, Rachita; Dalai, Ajay K.] Univ Saskatchewan, Dept Chem & Biol Engn, Saskatoon, SK, Canada.
   [Hunter, Howard N.] York Univ, Dept Chem, Toronto, ON, Canada.
   [Fang, Zhen] Nanjing Agr Univ, Coll Engn, Nanjing, Jiangsu, Peoples R China.
   [Kozinski, Janusz A.] Univ Waterloo, Dept Chem Engn, Waterloo, ON, Canada.
RP Kozinski, JA (reprint author), Univ Waterloo, Dept Chem Engn, Waterloo, ON, Canada.
EM jkoziski@brocku.ca
RI Fang, Zhen/I-8323-2014; Nanda, Sonil/AAD-5541-2020
OI Fang, Zhen/0000-0002-7391-372X; Nanda, Sonil/0000-0001-6047-0846
FU Natural Sciences and Engineering Research Council (NSERC), CanadaNatural
   Sciences and Engineering Research Council of Canada; Canada Research
   Chair (CRC) programCanada Research ChairsAustralian GovernmentDepartment
   of Industry, Innovation and ScienceCooperative Research Centres (CRC)
   Programme
FX The authors acknowledge the funding support from the Natural Sciences
   and Engineering Research Council (NSERC), Canada and Canada Research
   Chair (CRC) program.
CR Akiya N, 2002, CHEM REV, V102, P2725, DOI 10.1021/cr000668w
   Altin R, 2001, ENERG CONVERS MANAGE, V42, P529, DOI 10.1016/S0196-8904(00)00080-7
   Avisha C, 2013, J CHEM TECHNOL BIOT, V88, P139, DOI 10.1002/jctb.3874
   Birouk M, 2015, COMBUST SCI TECHNOL, V187, P937, DOI 10.1080/00102202.2014.991867
   Bokade VV, 2007, PROCESS SAF ENVIRON, V85, P372, DOI 10.1205/psep06073
   Buhler W, 2002, J SUPERCRIT FLUID, V22, P37, DOI 10.1016/S0896-8446(01)00105-X
   Byrd AJ, 2008, FUEL, V87, P2956, DOI 10.1016/j.fuel.2008.04.024
   Byrd AJ, 2007, IND ENG CHEM RES, V46, P3574, DOI 10.1021/ie070241g
   Chen G, 2003, ENERG CONVERS MANAGE, V44, P1875, DOI 10.1016/S0196-8904(02)00188-7
   Chhetri AB, 2008, ENERGIES, V1, P3, DOI 10.3390/en1010003
   Cortright RD, 2002, NATURE, V418, P964, DOI 10.1038/nature01009
   Cvengros J, 2004, BIOMASS BIOENERG, V27, P173, DOI 10.1016/j.biombioe.2003.11.006
   de Leeuw D. W., 2017, THESIS
   Demirbas A, 2003, ENERG CONVERS MANAGE, V44, P2093, DOI 10.1016/S0196-8904(02)00234-0
   Dupain X, 2007, APPL CATAL B-ENVIRON, V72, P44, DOI 10.1016/j.apcatb.2006.10.005
   Gong M, 2017, CATAL TODAY, V291, P13, DOI 10.1016/j.cattod.2017.02.017
   Guo LJ, 2007, CATAL TODAY, V129, P275, DOI 10.1016/j.cattod.2007.05.027
   Guo SM, 2013, J SUPERCRIT FLUID, V78, P95, DOI 10.1016/j.supflu.2013.03.025
   Guo Y, 2010, RENEW SUST ENERG REV, V14, P334, DOI 10.1016/j.rser.2009.08.012
   Harry I, 2014, BIOMASS BIOENERG, V71, P381, DOI 10.1016/j.biombioe.2014.09.017
   KATIKANENI SPR, 1995, CAN J CHEM ENG, V73, P484, DOI 10.1002/cjce.5450730408
   KATIKANENI SPR, 1995, ENERG FUEL, V9, P599, DOI 10.1021/ef00052a005
   Kim SJ, 2012, IND ENG CHEM RES, V51, P1364, DOI 10.1021/ie201452y
   Kruse A, 2008, BIOFUEL BIOPROD BIOR, V2, P415, DOI 10.1002/bbb.93
   Kulkarni MG, 2006, IND ENG CHEM RES, V45, P2901, DOI 10.1021/ie0510526
   Lang X, 2001, BIORESOURCE TECHNOL, V80, P53, DOI 10.1016/S0960-8524(01)00051-7
   Lee IG, 2002, IND ENG CHEM RES, V41, P1182, DOI 10.1021/ie010066i
   Leung DYC, 2006, FUEL PROCESS TECHNOL, V87, P883, DOI 10.1016/j.fuproc.2006.06.003
   Lv PM, 2004, BIORESOURCE TECHNOL, V95, P95, DOI 10.1016/j.biortech.2004.02.003
   Maher KD, 2007, BIORESOURCE TECHNOL, V98, P2351, DOI 10.1016/j.biortech.2006.10.025
   Meng XM, 2008, FUEL PROCESS TECHNOL, V89, P851, DOI 10.1016/j.fuproc.2008.02.006
   Minowa T, 1998, CATAL TODAY, V45, P411, DOI 10.1016/S0920-5861(98)00277-6
   Mitsuoka K, 2011, FUEL PROCESS TECHNOL, V92, P26, DOI 10.1016/j.fuproc.2010.08.015
   Moghadam R. A., 2017, ENERG CONVERS MANAGE, V87, P670
   Mohammed MAA, 2011, ENERG CONVERS MANAGE, V52, P1555, DOI 10.1016/j.enconman.2010.10.023
   Muhizi T., 2014, Oriental Journal of Chemistry, V30, P643, DOI 10.13005/ojc/300233
   Naik M, 2008, BIOMASS BIOENERG, V32, P354, DOI 10.1016/j.biombioe.2007.10.006
   Nanda S, 2017, SUSTAIN ENERG FUELS, V1, P1232, DOI 10.1039/c7se00212b
   Nanda S, 2016, BIOMASS BIOENERG, V95, P378, DOI 10.1016/j.biombioe.2016.05.023
   Nanda S, 2016, ENERG CONVERS MANAGE, V110, P296, DOI 10.1016/j.enconman.2015.11.060
   Nanda S, 2015, RENEW SUST ENERG REV, V50, P925, DOI 10.1016/j.rser.2015.05.058
   Nanda S, 2013, BIOENERG RES, V6, P663, DOI 10.1007/s12155-012-9281-4
   Osada M, 2006, ENERG FUEL, V20, P930, DOI 10.1021/ef050398q
   Pavlovic I, 2013, J AGR FOOD CHEM, V61, P8003, DOI 10.1021/jf401008a
   Qadariyah L, 2011, BIORESOURCE TECHNOL, V102, P9267, DOI 10.1016/j.biortech.2011.06.066
   Rana R, 2018, J ENVIRON CHEM ENG, V6, P182, DOI 10.1016/j.jece.2017.11.036
   Reddy SN, 2014, INT J HYDROGEN ENERG, V39, P6912, DOI 10.1016/j.ijhydene.2014.02.125
   Resende FLP, 2008, ENERG FUEL, V22, P1328, DOI 10.1021/ef700574k
   Sahraei OAZ, 2017, APPL CATAL B-ENVIRON, V219, P183, DOI 10.1016/j.apcatb.2017.07.039
   Sanli H., 2011, BIOENERG TECHNOL, P479, DOI DOI 10.3384/ECP11057479
   Savage PE, 1999, CHEM REV, V99, P603, DOI 10.1021/cr9700989
   Sheikhdavoodi MJ, 2015, J ENERGY INST, V88, P450, DOI 10.1016/j.joei.2014.10.005
   Sinag A, 2003, IND ENG CHEM RES, V42, P3516, DOI 10.1021/ie030079r
   Statista, 2018, GLOB PROD VEG OILS 2
   Statista-The portal for statistics, 2018, COMS VEG OILS WORLDW
   Tilay A, 2014, ASIA-PAC J CHEM ENG, V9, P507, DOI 10.1002/apj.1779
   Vardon DR, 2014, GREEN CHEM, V16, P1507, DOI 10.1039/c3gc41798k
   Vlahov G, 1999, PROG NUCL MAG RES SP, V35, P341, DOI 10.1016/S0079-6565(99)00015-1
   Wang EP, 2014, BIOMASS BIOENERG, V66, P371, DOI 10.1016/j.biombioe.2014.03.022
   Wang Y, 2007, ENERG CONVERS MANAGE, V48, P184, DOI 10.1016/j.enconman.2006.04.016
   Xie QL, 2014, BIORESOURCE TECHNOL, V156, P291, DOI 10.1016/j.biortech.2014.01.057
   Xie QL, 2012, BIORESOURCE TECHNOL, V110, P603, DOI 10.1016/j.biortech.2012.01.028
   Yang HP, 2006, FUEL PROCESS TECHNOL, V87, P935, DOI 10.1016/j.fuproc.2006.07.001
   Yoshida T, 2004, BIOMASS BIOENERG, V26, P71, DOI 10.1016/S0961-9534(03)00063-1
   Youssef EA, 2011, INT J HYDROGEN ENERG, V36, P4830, DOI 10.1016/j.ijhydene.2011.01.116
NR 65
TC 15
Z9 15
U1 9
U2 42
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 935
EP 945
DI 10.1016/j.ces.2018.10.039
PG 11
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500082
DA 2020-05-12
ER

PT J
AU Ansoni, JL
   Santiago, PA
   Seleghim, P
AF Ansoni, Jonas Laerte
   Santiago, Patricia A.
   Seleghim, Paulo, Jr.
TI Multiobjective optimization of a flat-panel airlift reactor designed by
   computational fluid dynamics
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Flat-panel airlift reactor; Automatic multiobjective optimization; CFD;
   Hydrodynamics; Shape optimization
ID BUBBLE-COLUMN; MASS-TRANSFER; PHOTOBIOREACTORS; CULTIVATION; MODELS;
   VOLUME
AB The optimization and scale-up process of industrial reactors maintaining optimum and homogeneous reaction conditions is a great challenge to engineers. For each final product, process and facility is necessary elaborate suitable strategies in order to allow a comprehensive and detailed process characterization to identify the most relevant process parameters influencing product yield and quality. Despite several research efforts to develop ideal reactors, these studies usually focus on trial-and-error optimization approach. This work was aimed to propose a numerical multiobjective optimization method and its application to the design of a flat-panel airlift (FPA) reactor. A preliminary study of the hydrodynamics of the reactor was conducted in a 61L FPA reactor. Experiments and computational fluid dynamics (CFD) simulations were compared to demonstrate the viability of usage of the simplifications applied to CFD model in order to reduce the computational effort. The inner structure key parameters of a FPA reactor, including the ratio of the cross-section area of the downcomer to the cross-section area of the riser, are optimized vis-a-vis the flow aspects portrayed by the performance parameters, such as shear stress and residence time variations. An in-house computer package was used for the automatic CFD simulations and the optimization process. A Pareto-optimal front with possible solutions to the problem and a detailed investigation of the mixing performance of the possible optimal geometries were presented in the study herein. The results also showed the high influence of the geometric parameters on the hydrodynamics of the FPA reactor, that have to be taken in account in the scaling-up process. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Ansoni, Jonas Laerte; Santiago, Patricia A.; Seleghim, Paulo, Jr.] Univ Sao Paulo, Sao Carlos Sch Engn, Dept Mech Engn, Av Trabalhador Sao Carlense 400, BR-13566970 Sao Carlos, SP, Brazil.
RP Ansoni, JL (reprint author), Univ Sao Paulo, Sao Carlos Sch Engn, Dept Mech Engn, Av Trabalhador Sao Carlense 400, BR-13566970 Sao Carlos, SP, Brazil.
EM jonasansoni@sc.usp.br; seleghim@sc.usp.br
RI Santiago, Patricia Aparecida/D-1389-2012; Ansoni, Jonas/M-5639-2014
OI Ansoni, Jonas/0000-0002-7113-4765; Santiago,
   Patricia/0000-0002-9326-0674
FU CAPES (Coordination of Improvement of Higher Level Personnel), Brazil;
   FAPESP (Sao Paulo Research Foundation), BrazilFundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [2010/00442-5]
FX The authors are grateful to CAPES (Coordination of Improvement of Higher
   Level Personnel), Brazil and FAPESP (Sao Paulo Research Foundation,
   Proc. 2010/00442-5), Brazil for the financial support given to this
   research. The authors would also like to acknowledge Dr. Oscar M. H.
   Rodriguez for allowing us to use his high speed camera and LaVision PIV
   equipment.
CR Akhtar MA, 2007, CAN J CHEM ENG, V85, P290
   Ansoni JL, 2016, ADV ENG SOFTW, V91, P23, DOI 10.1016/j.advengsoft.2015.08.008
   Berberovic E, 2009, PHYS REV E, V79, DOI 10.1103/PhysRevE.79.036306
   Bitog JP, 2011, COMPUT ELECTRON AGR, V76, P131, DOI 10.1016/j.compag.2011.01.015
   Chisti Y, 1998, APPL MECH REV, V51, P33, DOI DOI 10.1115/1.3098989
   Contreras A, 1999, ENZYME MICROB TECH, V25, P820, DOI 10.1016/S0141-0229(99)00119-2
   Couvert A, 2004, CHEM ENG PROCESS, V43, P1381, DOI 10.1016/j.cep.2003.06.001
   Dean JA, 1990, MAT MANUF PROCESSES, V5, DOI DOI 10.1080/10426919008953291
   Deb K, 2002, IEEE T EVOLUT COMPUT, V6, P182, DOI 10.1109/4235.996017
   Deb K., 2001, MULTIOBJECTIVE OPTIM
   Fogler H. S., 2005, ELEMENTS CHEM REACTI
   Gamba IL, 2012, INT J CHEM REACT ENG, V10, DOI 10.1515/1542-6580.3057
   HIRT CW, 1981, J COMPUT PHYS, V39, P201, DOI 10.1016/0021-9991(81)90145-5
   Horvath A, 2009, CHEM ENGINEER TRANS, V18, P605, DOI 10.3303/CET0918098
   Huang JK, 2015, BIORESOURCE TECHNOL, V182, P151, DOI 10.1016/j.biortech.2015.01.067
   Kalitzin G, 2005, J COMPUT PHYS, V204, P265, DOI 10.1016/j.jcp.2004.10.018
   Lestinsky P, 2012, PROCEDIA ENGINEER, V42, P892, DOI 10.1016/j.proeng.2012.07.482
   Levenspiel O, 1999, IND ENG CHEM RES, V38, P4140, DOI 10.1021/ie990488g
   MAJEED JG, 1995, GAS SEP PURIF, V9, P101, DOI 10.1016/0950-4214(95)93947-I
   Menter F., 2001, 16 BRAZ C MECH ENG C
   MENTER FR, 1992, AIAA J, V30, P1657, DOI 10.2514/3.11115
   Merchuk J.C., 2002, ENCY BIOPROCESS TECH, DOI [10.1002/0471250589.EBT029, DOI 10.1002/0471250589.EBT029, 10.1002/0471250589.ebt029]
   Michels MHA, 2010, BIOPROC BIOSYST ENG, V33, P921, DOI 10.1007/s00449-010-0415-9
   Miron AS, 2000, AICHE J, V46, P1872
   OpenCFD, 2013, OPENFOAM OP SOURC CF
   Perner I, 2003, ENG LIFE SCI, V3, P287, DOI 10.1002/elsc.200302964
   Pruvost J, 2006, CHEM ENG SCI, V61, P4476, DOI 10.1016/j.ces.2006.02.027
   Richmond A, 2004, HYDROBIOLOGIA, V512, P33, DOI 10.1023/B:HYDR.0000020365.06145.36
   RUBIO FC, 2004, AIRLIFT BIOREACTORS, V59, P4369, DOI DOI 10.1016/J.CES.2004.06.037
   Rusche H., 2002, COMPUTATIONAL FLUID
   Shariff S, 2017, APPL ENERG, V185, P973, DOI 10.1016/j.apenergy.2015.12.033
   SHETH M, 1977, AICHE J, V23, P794, DOI 10.1002/aic.690230604
   Thevenin D, 2008, OPTIMIZATION AND COMPUTATIONAL FLUID DYNAMICS, P3, DOI 10.1007/978-3-540-72153-6_1
   Ugwu CU, 2008, BIORESOURCE TECHNOL, V99, P4021, DOI 10.1016/j.biortech.2007.01.046
   Ziegenhein T, 2016, CHEM ENG SCI, V150, P54, DOI 10.1016/j.ces.2016.04.039
NR 35
TC 1
Z9 1
U1 3
U2 21
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 946
EP 957
DI 10.1016/j.ces.2018.10.041
PG 12
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500083
DA 2020-05-12
ER

PT J
AU Qu, H
   Gong, JH
   Tan, XC
   Yuan, PQ
   Cheng, ZM
   Yuan, WK
AF Qu, Hao
   Gong, Jian-Hong
   Tan, Xue-Cai
   Yuan, Pei-Qing
   Cheng, Zhen-Min
   Yuan, Wei-Kang
TI Dissolution of polycyclic aromatic hydrocarbons in subcritical and
   supercritical Water: A molecular dynamics simulation study
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Supercritical water; Polycyclic aromatic hydrocarbons; Molecular
   dynamics simulation; Phase structure; Pyrolysis
ID GUDAO RESIDUAL OIL; UNSATURATED ALIPHATICS HYDROGENATION; HEAVY OIL;
   PETROLEUM RESIDUE; PARTIAL OXIDATION; RADICAL-ADDITION; AB-INITIO; PART
   II; KINETICS; PYROLYSIS
AB To get a better understanding of the upgrading of heavy oil under severe hydrothermal environment, a molecular dynamics simulation on the dissolution of oil droplets containing polycyclic aromatic hydrocarbons (PAHs) or PAH mixtures in subcritical or supercritical water (sub-CW/SCW) was applied. Being the representative of light PAHs, naphthalene dissolves readily into sub-CW/SCW. The dissolution of heavy PAHs, like benzo[alpha]pyrene and benzo[ghi]perylene however is sensitive to the thermodynamic state of water. During the dissolution of PAH mixtures, a preferential dissolution of light PAHs into the water phase occurs, leaving heavy PAHs concentrated in the oil droplets. With the simultaneous increase in water density and temperature, the miscibility of PAHs with sub-CW/SCW is improved by the enhanced attractive electrostatic interaction between PAHs and hydrothermal environment and the weakened interaction between PAHs. By the differences in heavy oil composition and the thermodynamic state of water, the upgrading of heavy oil in sub-CW/SCW could be run in the condensed emulsion or pseudo single-phase structure. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Qu, Hao; Tan, Xue-Cai; Yuan, Pei-Qing; Cheng, Zhen-Min; Yuan, Wei-Kang] East China Univ Sci & Technol, State Key Lab Chem Engn, 130 Meilong Rd, Shanghai 200237, Peoples R China.
   [Gong, Jian-Hong] Sinopec Res Inst Petr Proc, Beijing 100083, Peoples R China.
RP Yuan, PQ (reprint author), East China Univ Sci & Technol, State Key Lab Chem Engn, 130 Meilong Rd, Shanghai 200237, Peoples R China.
EM pqyuan@ecust.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21676084]
FX This work was supported by the National Natural Science Foundation of
   China (Grant No. 21676084).
CR Brunner E, 2006, J SUPERCRIT FLUID, V39, P160, DOI 10.1016/j.supflu.2005.12.003
   Cheng J, 2008, PETROL SCI TECHNOL, V26, P2088, DOI 10.1080/10916460802096162
   Cheng J, 2005, PETROL SCI TECHNOL, V23, P1453, DOI 10.1081/LFT-200038254
   Cheng J, 2006, PETROL SCI TECHNOL, V24, P1339, DOI 10.1081/LFT-200056751
   Cheng ZM, 2009, ENERG FUEL, V23, P3178, DOI 10.1021/ef900132z
   Chopra M, 2016, J MOL LIQ, V224, P599, DOI 10.1016/j.molliq.2016.09.118
   Fujisawa T, 2006, CHEM PHYS LETT, V430, P303, DOI 10.1016/j.cplett.2006.09.019
   Gai XK, 2016, FUEL PROCESS TECHNOL, V142, P315, DOI 10.1016/j.fuproc.2015.10.032
   Gascon G, 2017, ENERG FUEL, V31, P7783, DOI 10.1021/acs.energyfuels.7b00527
   Golmohammadi M, 2016, J SUPERCRIT FLUID, V113, P136, DOI 10.1016/j.supflu.2016.03.023
   [韩丽娜 HAN Lina], 2008, [燃料化学学报, Journal of Fuel Chemistry and Technology], V36, P1, DOI 10.1016/S1872-5813(08)60007-9
   He P, 2018, J SUPERCRIT FLUID, V135, P105, DOI 10.1016/j.supflu.2017.12.040
   He P, 2015, IND ENG CHEM RES, V54, P8809, DOI 10.1021/acs.iecr.5b02516
   Hemelsoet K, 2006, J PHYS CHEM A, V110, P8942, DOI 10.1021/jp061823z
   Henrikson JT, 2006, J PHYS CHEM A, V110, P3627, DOI 10.1021/jp057184u
   Hosseinpour M, 2016, J SUPERCRIT FLUID, V110, P75, DOI 10.1016/j.supflu.2015.12.014
   Hosseinpour M, 2016, J SUPERCRIT FLUID, V107, P278, DOI 10.1016/j.supflu.2015.08.004
   Jin H, 2018, J ENERG RESOUR-ASME, V140, DOI 10.1115/1.4037814
   Jin H, 2015, ENERG FUEL, V29, P6342, DOI 10.1021/acs.energyfuels.5b01558
   Kozhevnikov IV, 2010, J SUPERCRIT FLUID, V55, P217, DOI 10.1016/j.supflu.2010.08.009
   Lafrad F, 2017, J MOL LIQ, V239, P61, DOI 10.1016/j.molliq.2016.07.093
   Leininger JP, 2007, J PHYS CHEM A, V111, P3082, DOI 10.1021/jp0643956
   Liu J, 2018, IND ENG CHEM RES, V57, P867, DOI 10.1021/acs.iecr.7b04024
   Liu QK, 2017, ENERG FUEL, V31, P3620, DOI 10.1021/acs.energyfuels.6b03135
   Liu QK, 2016, AICHE J, V62, P207, DOI 10.1002/aic.14978
   Morimoto M, 2014, J JPN PETROL INST, V57, P11, DOI 10.1627/jpi.57.11
   Morimoto M, 2010, J SUPERCRIT FLUID, V55, P223, DOI 10.1016/j.supflu.2010.08.002
   Oka H, 2003, PHYS CHEM CHEM PHYS, V5, P2535, DOI 10.1039/b211848n
   Rana MS, 2007, FUEL, V86, P1216, DOI 10.1016/j.fuel.2006.08.004
   Sabbe MK, 2007, J PHYS CHEM A, V111, P8416, DOI 10.1021/jp072897t
   Sato T, 2003, FUEL, V82, P1231, DOI 10.1016/S0016-2361(03)00019-X
   Sato T, 2012, FUEL, V95, P347, DOI 10.1016/j.fuel.2011.10.016
   Savage PE, 2000, J ANAL APPL PYROL, V54, P109, DOI 10.1016/S0165-2370(99)00084-4
   Sawarkar AN, 2007, CAN J CHEM ENG, V85, P1, DOI 10.1002/cjce.5450850101
   Tan XC, 2015, AICHE J, V61, P857, DOI 10.1002/aic.14677
   Tanaka R, 2004, ENERG FUEL, V18, P1118, DOI 10.1021/ef034082z
   Van Speybroeck V, 2000, J PHYS CHEM A, V104, P10939, DOI 10.1021/jp002172o
   Van Speybroeck V, 2004, INT J QUANTUM CHEM, V96, P568, DOI 10.1002/qua.10758
   Wang Q, 2018, FUEL, V230, P319, DOI 10.1016/j.fuel.2018.05.031
   Watanabe M, 2000, AICHE J, V46, P843, DOI 10.1002/aic.690460417
   Watanabe M, 2010, J SUPERCRIT FLUID, V53, P48, DOI 10.1016/j.supflu.2009.11.013
   Xin SM, 2016, CHEM ENG SCI, V146, P115, DOI 10.1016/j.ces.2016.02.032
   Xu T, 2013, ENERG FUEL, V27, P3148, DOI 10.1021/ef400573p
   Zhang W, 2018, MOL SIMULAT, V44, P769, DOI 10.1080/08927022.2018.1450981
   Zhu CC, 2013, FUEL PROCESS TECHNOL, V111, P111, DOI 10.1016/j.fuproc.2013.02.003
NR 45
TC 7
Z9 7
U1 12
U2 56
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 958
EP 967
DI 10.1016/j.ces.2018.10.042
PG 10
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500084
DA 2020-05-12
ER

PT J
AU Colombo, M
   Fairweather, M
AF Colombo, Marco
   Fairweather, Michael
TI Influence of multiphase turbulence modelling on interfacial momentum
   transfer in two-fluid Eulerian-Eulerian CFD models of bubbly flows
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Bubbly flow; Two-fluid model; Multiphase turbulence; Reynolds stress
   turbulence; Elliptic blending; Void fraction distribution
ID VOID FRACTION CORRELATIONS; PHASE-DISTRIBUTION; 2-PHASE FLOW; SINGLE
   BUBBLES; BREAK-UP; SPHERICAL BUBBLES; VERTICAL PIPE; HEAT-TRANSFER;
   COALESCENCE; VELOCITY
AB Eulerian-Eulerian two-fluid computational fluid dynamic (CFD) models are increasingly used to predict bubbly flows at an industrial scale. In these approaches, interface transfer is modelled with closure models and correlations. Normally, the lateral void fraction distribution is considered to mainly result from a balance between the lift and wall lubrication forces. However, and despite the numerous models available that achieve, at least in pipe flows, a reasonable predictive accuracy, agreement on a broadly applicable and accurate modelling approach has not yet been reached. Additionally, the impact of turbulence modelling on the lateral void fraction distribution has not, in general, been examined in detail. In this work, an elliptic blending Reynolds stress model (EB-RSM), capable of resolving the turbulence field in the near-wall region and improved to account for the contribution of bubble-induced turbulence, is evaluated against best-practice k-epsilon and high-Reynolds second-moment turbulence closures. Lift and wall lubrication forces are initially deliberately neglected in the EB-RSM. Comparisons for flows in pipes and a square duct show that the EB-RSM reproduces the lateral void fraction distribution, including the peak in the void fraction in the near-wall region, and reaches an accuracy comparable to the other two models noted above. In rod bundles, even if none of the models considered performs with sufficient accuracy, the EB-RSM detects features of the flow that are not predicted by the other two approaches. Overall, the results demonstrate a much more prominent role of the turbulence structure and the induced cross-sectional pressure field on the lateral void fraction distribution than is normally considered. These effects need to be accounted for if more physically-consistent modelling of bubbly flows is to be achieved. The lift force is added to the EB-RSM in the final part of the paper, to provide a two-fluid formulation that can be used as the basis for additional developments aimed at improving the accuracy and general applicability of two-fluid CFD models. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Colombo, Marco; Fairweather, Michael] Univ Leeds, Sch Chem & Proc Engn, Leeds LS2 9JT, W Yorkshire, England.
RP Colombo, M (reprint author), Univ Leeds, Sch Chem & Proc Engn, Leeds LS2 9JT, W Yorkshire, England.
EM M.Colombo@leeds.ac.uk
FU EPSRCEngineering & Physical Sciences Research Council (EPSRC)
   [EP/K007777/1, EP/M018733/1]
FX The authors gratefully acknowledge the financial support of the EPSRC
   under grant EP/K007777/1, Thermal Hydraulics for Boiling and Passive
   Systems, and EP/M018733/1, Grace Time, part of the UK-India Civil
   Nuclear Collaboration.
CR ANTAL SP, 1991, INT J MULTIPHAS FLOW, V17, P635, DOI 10.1016/0301-9322(91)90029-3
   Behzadi A, 2004, CHEM ENG SCI, V59, P759, DOI 10.1016/j.ces.2003.11.018
   Besagni G, 2018, NUCL ENG DES, V331, P222, DOI 10.1016/j.nucengdes.2018.03.003
   BRUNDRETT E, 1964, J FLUID MECH, V19, P375, DOI 10.1017/S0022112064000799
   Burns A. D., 2004, 5 INT C MULT FLOWS Y
   CD-adapco, 2016, STAR CCM VERS 10 04
   Clift R., 1978, BUBBLES DROPS PARTIC
   Coddington P, 2002, NUCL ENG DES, V215, P199, DOI 10.1016/S0029-5493(01)00503-9
   Colombo M, 2016, CHEM ENG SCI, V146, P207, DOI 10.1016/j.ces.2016.02.034
   Colombo M, 2015, INT J MULTIPHAS FLOW, V77, P222, DOI 10.1016/j.ijmultiphaseflow.2015.09.003
   Dabiri S, 2015, CHEM ENG SCI, V122, P106, DOI 10.1016/j.ces.2014.09.006
   DALY BJ, 1970, PHYS FLUIDS, V13, P2634, DOI 10.1063/1.1692845
   DEBERTODANO ML, 1994, INT J MULTIPHAS FLOW, V20, P805
   DEBERTODANO ML, 1990, J FLUID ENG-T ASME, V112, P107, DOI 10.1115/1.2909357
   DREW DA, 1982, J FLUID MECH, V117, P91, DOI 10.1017/S0022112082001530
   Ervin EA, 1997, J FLUID ENG-T ASME, V119, P443, DOI 10.1115/1.2819153
   Feng JY, 2017, INT J MULTIPHAS FLOW, V93, P92, DOI 10.1016/j.ijmultiphaseflow.2017.04.003
   GOSMAN AD, 1992, AICHE J, V38, P1946, DOI 10.1002/aic.690381210
   Hassan Y. A., 2014, CASLU20140209000
   Hibiki T, 2007, CHEM ENG SCI, V62, P6457, DOI 10.1016/j.ces.2007.07.034
   Hosokawa S., 2003, T JSME, V69, P2214
   Hosokawa S, 2014, J NUCL SCI TECHNOL, V51, P220, DOI 10.1080/00223131.2013.862189
   Hosokawa S, 2009, CHEM ENG SCI, V64, P5308, DOI 10.1016/j.ces.2009.09.017
   JONES WP, 1972, INT J HEAT MASS TRAN, V15, P301, DOI 10.1016/0017-9310(72)90076-2
   KATAOKA I, 1989, INT J MULTIPHAS FLOW, V15, P843, DOI 10.1016/0301-9322(89)90045-1
   Kim M, 2016, EXP FLUIDS, V57, DOI 10.1007/s00348-016-2144-6
   Lahey RT, 2001, NUCL ENG DES, V204, P29, DOI 10.1016/S0029-5493(00)00337-X
   LAHEY RT, 1993, NUCL ENG DES, V141, P177, DOI 10.1016/0029-5493(93)90101-E
   Liao YX, 2015, CHEM ENG SCI, V122, P336, DOI 10.1016/j.ces.2014.09.042
   Liao YX, 2010, CHEM ENG SCI, V65, P2851, DOI 10.1016/j.ces.2010.02.020
   LIU TJ, 1993, INT J HEAT MASS TRAN, V36, P1049, DOI 10.1016/S0017-9310(05)80289-3
   LIU TJ, 1993, INT J HEAT MASS TRAN, V36, P1061, DOI 10.1016/S0017-9310(05)80290-X
   Lu JC, 2013, J FLUID MECH, V732, P166, DOI 10.1017/jfm.2013.397
   Lubchenko N, 2018, INT J MULTIPHAS FLOW, V98, P36, DOI 10.1016/j.ijmultiphaseflow.2017.09.003
   Lucas D, 2010, INT J THERM SCI, V49, P664, DOI 10.1016/j.ijthermalsci.2009.11.008
   Manceau R, 2002, PHYS FLUIDS, V14, P744, DOI 10.1063/1.1432693
   Manceau R, 2015, INT J HEAT FLUID FL, V51, P195, DOI 10.1016/j.ijheatfluidflow.2014.09.002
   Mimouni S, 2011, NUCL ENG DES, V241, P4523, DOI 10.1016/j.nucengdes.2010.12.028
   Mimouni S, 2010, NUCL ENG DES, V240, P2233, DOI 10.1016/j.nucengdes.2009.11.019
   OHKAWA K, 1980, NUCL ENG DES, V61, P245, DOI 10.1016/0029-5493(80)90052-7
   PRINCE MJ, 1990, AICHE J, V36, P1485, DOI 10.1002/aic.690361004
   Rzehak R, 2013, INT J MULTIPHAS FLOW, V55, P138, DOI 10.1016/j.ijmultiphaseflow.2013.04.007
   Santarelli C, 2016, INT J MULTIPHAS FLOW, V81, P27, DOI 10.1016/j.ijmultiphaseflow.2016.01.004
   Santarelli C, 2015, INT J MULTIPHAS FLOW, V75, P174, DOI 10.1016/j.ijmultiphaseflow.2015.05.007
   Serizawa A., 1975, International Journal of Multiphase Flow, V2, P221, DOI 10.1016/0301-9322(75)90011-7
   SPEZIALE CG, 1991, J FLUID MECH, V227, P245, DOI 10.1017/S0022112091000101
   Sugrue R, 2017, ANN NUCL ENERGY, V110, P79, DOI 10.1016/j.anucene.2017.05.059
   Sun HM, 2014, J NUCL SCI TECHNOL, V51, P267, DOI 10.1080/00223131.2014.863718
   Talley JD, 2015, INT J MULTIPHAS FLOW, V76, P223, DOI 10.1016/j.ijmultiphaseflow.2015.06.012
   Tomiyama A, 2002, CHEM ENG SCI, V57, P1849, DOI 10.1016/S0009-2509(02)00085-4
   Tomiyama A, 2002, INT J MULTIPHAS FLOW, V28, P1497, DOI 10.1016/S0301-9322(02)00032-0
   Tomiyama A, 1998, JSME INT J B-FLUID T, V41, P472, DOI 10.1299/jsmeb.41.472
   Troshko AA, 2001, INT J MULTIPHAS FLOW, V27, P1965, DOI 10.1016/S0301-9322(01)00043-X
   Ullrich M., 2014, 10 INT ERCOFTAC S EN
   Nguyen VT, 2013, INT J MULTIPHAS FLOW, V54, P31, DOI 10.1016/j.ijmultiphaseflow.2013.03.001
   Vasavada S, 2009, INT J MULTIPHAS FLOW, V35, P323, DOI 10.1016/j.ijmultiphaseflow.2009.01.006
   WANG SK, 1987, INT J MULTIPHAS FLOW, V13, P327, DOI 10.1016/0301-9322(87)90052-8
   WELLEK RM, 1966, AICHE J, V12, P854, DOI 10.1002/aic.690120506
   Woldesemayat MA, 2007, INT J MULTIPHAS FLOW, V33, P347, DOI 10.1016/j.ijmultiphaseflow.2006.09.004
   Yao W, 2004, INT J HEAT MASS TRAN, V47, P307, DOI 10.1016/j.ijheatmasstransfer.2003.06.004
   Yeoh GH, 2006, APPL MATH MODEL, V30, P1370, DOI 10.1016/j.apm.2006.03.010
NR 61
TC 2
Z9 2
U1 5
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 968
EP 984
DI 10.1016/j.ces.2018.10.043
PG 17
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500085
OA Green Published
DA 2020-05-12
ER

PT J
AU Wu, MY
   Leung, DYC
   Zhang, YG
   Huang, HB
   Xie, RJ
   Szeto, W
   Li, F
AF Wu, Muyan
   Leung, Dennis Y. C.
   Zhang, Yingguang
   Huang, Haibao
   Xie, Ruijie
   Szeto, Wai
   Li, Fang
TI Toluene degradation over Mn-TiO2/CeO2 composite catalyst under vacuum
   ultraviolet (VUV) irradiation
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Mn-TiO2; Mesoporous CeO2; VUV irradiation; VOCs degradation; Catalytic
   ozonation
ID PHOTOCATALYTIC OXIDATION; GASEOUS BENZENE; EFFICIENT DEGRADATION;
   GAS-PHASE; MODIFIED TIO2; OZONE; PERFORMANCE; CEO2; DECOMPOSITION;
   FORMALDEHYDE
AB Volatile organic compounds (VOCs) are attracting more and more attention among all the air pollutants. Photocatalytic oxidation under vacuum ultraviolet (VUV) irradiation presents a novel and promising process for VOC degradation while also generating ozone as a byproduct. To improve the degradation efficiency of VOCs and remove the residual ozone Mn-TiO2/mesoporous CeO2 composite catalysts were developed and used as a catalyst in a VUV-PCO system for toluene degradation. Characterizations including SEM, TEM, BET, XRD, XPS, Raman and H-2-TPR, were conducted to examine the physical and chemical features of the synthetic samples. Results of a toluene degradation test showed that the Mn-TiO2/CeO2 catalyst had superior activity in removing toluene and ozone to Mn-TiO2 and pure CeO2. The toluene removal efficiencies of the catalysts with a different molar ratio of Ti/Ce were found to be in the order of Mn-TiO2/CeO2 (1:1) > Mn-TiO2/CeO2 (1:2) > Mn-TiO2/CeO2 (2:1). The mineralization rate increased in the order of Mn-TiO2/CeO2 (1:1) > Mn-TiO2/CeO2 (2:1) approximate to Mn-TiO2 > Mn-TiO2/CeO2 (1:2) > CeO2 > VUV photolysis. High ozone removal rates of over 99.9% were obtained for all the doped samples with Mn, resulting in a residual ozone lower than 0.12 ppm. With the use of the scavenger tert-butanol (TBA) and the electron spin resonance (ESR) test, hydroxyl radicals ((OH)-O-center dot) were found to play a significant role in toluene oxidation in the VUV-PCO process and ozone is also involved in the formation of (OH)-O-center dot. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Wu, Muyan; Leung, Dennis Y. C.; Zhang, Yingguang; Szeto, Wai; Li, Fang] Univ Hong Kong, Dept Mech Engn, Pokfulam Rd, Hong Kong, Peoples R China.
   [Huang, Haibao; Xie, Ruijie] Sun Yat Sen Univ, Sch Environm Sci & Engn, Guangzhou 510275, Guangdong, Peoples R China.
RP Leung, DYC (reprint author), Univ Hong Kong, Dept Mech Engn, Pokfulam Rd, Hong Kong, Peoples R China.; Huang, HB (reprint author), Sun Yat Sen Univ, Sch Environm Sci & Engn, Guangzhou 510275, Guangdong, Peoples R China.
EM ycleung@hku.hk; seabao8@gmail.com
OI Leung, Dennis Y.C./0000-0002-8917-0916; Huang,
   Haibao/0000-0002-9259-7179
FU National Natural Science Foundation of China (NSFC)National Natural
   Science Foundation of China; Research Grants Council (RGC) of Hong Kong
   Joint Research Scheme [51561165015, N_HKU718/15]; NSFCNational Natural
   Science Foundation of China [21677179]; Guangdong Special Fund for
   Science & Technology Development (Hong Kong Technology Cooperation
   Funding Scheme) [2016A050503022, GHP/025/16GD, InP/272/16]; Innovation
   Platform Construction of Guangdong and Hong Kong [2017B050504001]; Key
   Fundamental Research Fund for the Central Universities [17lgjc17];
   National Key Research and Development Program of China [2016YFC0204800]
FX The authors gratefully acknowledge the financial supports from the
   National Natural Science Foundation of China (NSFC) and The Research
   Grants Council (RGC) of Hong Kong Joint Research Scheme (Nos.
   51561165015 and N_HKU718/15), NSFC (21677179), Guangdong Special Fund
   for Science & Technology Development (Hong Kong Technology Cooperation
   Funding Scheme) (No. 2016A050503022, GHP/025/16GD & InP/272/16),
   Innovation Platform Construction of Guangdong and Hong Kong (No.
   2017B050504001), the Key Fundamental Research Fund for the Central
   Universities (17lgjc17) and National Key Research and Development
   Program of China (No. 2016YFC0204800).
CR Antonello A, 2014, CATAL TODAY, V230, P35, DOI 10.1016/j.cattod.2013.12.033
   Braslavsky SE, 2007, PURE APPL CHEM, V79, P293, DOI 10.1351/pac200779030293
   Campbell CT, 2005, SCIENCE, V309, P713, DOI 10.1126/science.1113955
   CARPENTER R, 1983, GEOCHIM COSMOCHIM AC, V47, P875, DOI 10.1016/0016-7037(83)90153-9
   Chen FY, 2002, WATER RES, V36, P4203, DOI 10.1016/S0043-1354(02)00140-9
   Dutta G, 2006, CHEM MATER, V18, P3249, DOI 10.1021/cm060267i
   Einaga H, 2013, J CATAL, V305, P227, DOI 10.1016/j.jcat.2013.05.016
   Farhanian D, 2013, BUILD ENVIRON, V66, P148, DOI 10.1016/j.buildenv.2013.04.010
   Faria PCC, 2008, CATAL COMMUN, V9, P2121, DOI 10.1016/j.catcom.2008.04.009
   Fu PF, 2011, APPL CATAL B-ENVIRON, V105, P220, DOI 10.1016/j.apcatb.2011.04.021
   Guo T, 2008, APPL CATAL B-ENVIRON, V79, P171, DOI 10.1016/j.apcatb.2007.09.033
   Han ZN, 2013, CHEM ENG J, V218, P9, DOI 10.1016/j.cej.2012.12.025
   Hashem TM, 1997, WATER SCI TECHNOL, V35, P41, DOI 10.1016/S0273-1223(97)00007-3
   Huang HB, 2016, FRONT ENV SCI-SWITZ, V4, DOI 10.3389/fenvs.2016.00017
   Huang HB, 2017, APPL CATAL B-ENVIRON, V203, P870, DOI 10.1016/j.apcatb.2016.10.083
   Huang HB, 2017, CATAL TODAY, V281, P649, DOI 10.1016/j.cattod.2016.07.005
   Huang HB, 2017, APPL SURF SCI, V391, P662, DOI 10.1016/j.apsusc.2016.07.040
   Huang HB, 2015, CATAL TODAY, V258, P627, DOI 10.1016/j.cattod.2015.01.006
   Huang H, 2015, CHEM ENG J, V264, P24, DOI 10.1016/j.cej.2014.11.072
   Huang HB, 2015, CHEM ENG J, V259, P534, DOI 10.1016/j.cej.2014.08.057
   Huang HB, 2011, APPL CATAL B-ENVIRON, V102, P449, DOI 10.1016/j.apcatb.2010.12.025
   Huang HL, 2016, APPL CATAL B-ENVIRON, V186, P62, DOI 10.1016/j.apcatb.2015.12.055
   Jarnstrom H, 2006, ATMOS ENVIRON, V40, P7178, DOI 10.1016/j.atmosenv.2006.06.021
   Li X, 2015, APPL CATAL B-ENVIRON, V164, P352, DOI 10.1016/j.apcatb.2014.09.053
   Li YZ, 2010, CHEMCATCHEM, V2, P1082, DOI 10.1002/cctc.201000085
   Liu GY, 2018, APPL SURF SCI, V433, P329, DOI 10.1016/j.apsusc.2017.09.257
   Liu GY, 2017, CHEM ENG J, V324, P44, DOI 10.1016/j.cej.2017.04.105
   Liu Y, 2017, APPL CATAL A-GEN, V530, P102, DOI 10.1016/j.apcata.2016.11.028
   Ochiai T, 2012, J PHOTOCH PHOTOBIO C, V13, P247, DOI 10.1016/j.jphotochemrev.2012.07.001
   Organization W. H., 1989, IND AIR QUAL ORG POL
   Orge CA, 2011, APPL CATAL B-ENVIRON, V103, P190, DOI 10.1016/j.apcatb.2011.01.026
   Oyama ST, 2000, CATAL REV, V42, P279, DOI 10.1081/CR-100100263
   Qin HD, 2014, J CHEM TECHNOL BIOT, V89, P1402, DOI 10.1002/jctb.4222
   Reddy BJ, 2005, MINERAL MAG, V69, P155, DOI 10.1180/0026461056920243
   Shi WQ, 2013, J MATER CHEM A, V1, P728, DOI 10.1039/c2ta00504b
   Shiraishi F, 2009, CHEM ENG SCI, V64, P2466, DOI 10.1016/j.ces.2009.02.024
   Shu YJ, 2018, APPL CATAL B-ENVIRON, V220, P78, DOI 10.1016/j.apcatb.2017.08.019
   Sleiman M, 2009, APPL CATAL B-ENVIRON, V86, P159, DOI 10.1016/j.apcatb.2008.08.003
   Sundell J, 2004, INDOOR AIR, V14, P51, DOI 10.1111/j.1600-0668.2004.00273.x
   Pham TD, 2015, J HAZARD MATER, V300, P493, DOI 10.1016/j.jhazmat.2015.07.048
   TRUDEAU ML, 1995, SURF INTERFACE ANAL, V23, P219, DOI 10.1002/sia.740230405
   Wang B, 2009, IND ENG CHEM RES, V48, P440, DOI 10.1021/ie800725h
   Weschler CJ, 2009, ATMOS ENVIRON, V43, P153, DOI 10.1016/j.atmosenv.2008.09.044
   Yu KP, 2007, APPL CATAL B-ENVIRON, V75, P29, DOI 10.1016/j.apcatb.2007.03.006
   Yu QL, 2009, APPL CATAL B-ENVIRON, V92, P454, DOI 10.1016/j.apcatb.2009.09.004
   Zeng M, 2015, ACS CATAL, V5, P3278, DOI 10.1021/acscatal.5b00292
   Zhang PY, 2004, CHEM LETT, V33, P1242, DOI 10.1246/cl.2004.1242
   Zhang YH, 2003, CHEM MATER, V15, P4028, DOI 10.1021/cm034246p
   Zhong LX, 2015, BUILD ENVIRON, V91, P191, DOI 10.1016/j.buildenv.2015.01.033
   Zhong LX, 2013, J HAZARD MATER, V261, P130, DOI 10.1016/j.jhazmat.2013.07.014
   Zhong LX, 2013, BUILD ENVIRON, V62, P155, DOI 10.1016/j.buildenv.2013.01.009
   Zhu W, 2015, LANGMUIR, V31, P10822, DOI 10.1021/acs.langmuir.5b02232
NR 52
TC 14
Z9 14
U1 42
U2 253
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 985
EP 994
DI 10.1016/j.ces.2018.10.044
PG 10
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500086
DA 2020-05-12
ER

PT J
AU Motlagh, AHA
   Palanisamy, K
   Pougatch, K
   Salcudean, M
   Grace, JR
   Grecov, D
   McMillan, J
AF Motlagh, Amir H. Ahmadi
   Palanisamy, Karthikeyan
   Pougatch, Konstantin
   Salcudean, Martha
   Grace, John R.
   Grecov, Dana
   McMillan, Jennifer
TI Mechanistic model to simulate wet agglomerate breakage in a gas-solid
   fluidized bed
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
ID GRANULATION; IMPACT; GROWTH
AB A mathematical model that describes wet agglomerate breakage in a gas-solid fluidized bed was developed, utilizing the energy approach to assess agglomerate stability and the Kinetic Theory of Granular Flows (KTGF) to describe collisions between bed primary particles and agglomerates. Wet agglomerates are held together by liquid bridges that resist breakage due to capillary and viscous forces. The probability of breakage depends on the balance between the collisional energy and the energy required to break the necessary number of liquid bridges. The model considers two types of breakage: abrasion, characterized by individual primary particles being stripped from an agglomerate, and fragmentation, where an agglomerate breaks into two pieces, each containing multiple primary particles. Simulations were performed using the Eulerian-Eulerian method with either a monodispersed or a polydispersed approach to describe the size distribution of agglomerates during breakage. Comparison with available experimental data revealed good qualitative agreement between the predicted and measured abrasion and fragmentation rates, with some quantitative discrepancies that can be attributed to model limitations and experimental uncertainties. The effects of superficial gas velocity and liquid viscosity on agglomerate breakage are investigated in detail. The model can serve as a valuable tool to study breakage of wet agglomerates, and it can be extended to include agglomerate formation for a more comprehensive description of hydrodynamics of wet fluidized beds. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Motlagh, Amir H. Ahmadi; Grace, John R.] Univ British Columbia, Dept Chem & Biol Engn, Vancouver, BC V6T 1Z3, Canada.
   [Palanisamy, Karthikeyan; Salcudean, Martha; Grecov, Dana] Univ British Columbia, Dept Mech Engn, Vancouver, BC V6T 1Z4, Canada.
   [Pougatch, Konstantin] Coanda Res & Dev Corp, Vancouver, BC V3N 4A3, Canada.
   [McMillan, Jennifer] Syncrude Canada Ltd, Edmonton Res Ctr, Edmonton, AB T6N 1H4, Canada.
RP Motlagh, AHA (reprint author), Univ British Columbia, Dept Chem & Biol Engn, Vancouver, BC V6T 1Z3, Canada.
EM amirmotlagh@gmail.com
RI Motlagh, Amir Ahmadi/AAA-7462-2019
FU Natural Sciences and Engineering Research Council of Canada
   (NSERC)Natural Sciences and Engineering Research Council of Canada;
   Syncrude Canada Limited
FX The authors gratefully acknowledge funding by the Natural Sciences and
   Engineering Research Council of Canada (NSERC) and Syncrude Canada
   Limited.
CR ANSYS Inc, 2017, FLUENT 18 1 STUD VER
   Darabi P, 2011, THESIS
   Darabi P, 2009, CHEM ENG SCI, V64, P1868, DOI 10.1016/j.ces.2009.01.017
   Donahue CM, 2012, J FLUID MECH, V708, P128, DOI 10.1017/jfm.2012.297
   Ennis B. J., 1997, PERRYS CHEM ENG HDB
   ENNIS BJ, 1990, CHEM ENG SCI, V45, P3071, DOI 10.1016/0009-2509(90)80054-I
   Fries L, 2011, CHEM ENG SCI, V66, P2340, DOI 10.1016/j.ces.2011.02.038
   Galvin J. E, 2013, AICHE J, P1
   Gidaspow D, 1992, FLUIDIZATION, P75
   Gidaspow D., 1994, MULTIPHASE FLOW FLUI
   Girardi M, 2016, CHEM ENG SCI, V144, P224, DOI 10.1016/j.ces.2016.01.017
   Herminghaus S., 2013, WET GRANULAR MATTER
   Hrenya CM, 1997, AICHE J, V43, P853, DOI 10.1002/aic.690430402
   Kantak A. A, 2013, THESIS
   Kumar L, 2017, POWDER TECHNOL, V321, P499, DOI 10.1016/j.powtec.2017.08.016
   Landau Lev, 1986, THEORY ELASTICITY
   LUN CKK, 1984, J FLUID MECH, V140, P223, DOI 10.1017/S0022112084000586
   Motlagh AHA, 2014, CHEM ENG SCI, V120, P22, DOI 10.1016/j.ces.2014.08.042
   Palanisamy K, 2016, THESIS
   PAO YH, 1955, J APPL PHYS, V26, P1083, DOI 10.1063/1.1722155
   Parveen F, 2012, POWDER TECHNOL, V231, P102, DOI 10.1016/j.powtec.2012.07.055
   Pitois O, 2001, EUR PHYS J B, V23, P79, DOI 10.1007/s100510170084
   Pougatch K., 2011, THESIS, P1
   Reynolds GK, 2005, CHEM ENG SCI, V60, P3969, DOI 10.1016/j.ces.2005.02.029
   Salman AD, 2004, POWDER TECHNOL, V143, P19, DOI 10.1016/j.powtec.2004.04.005
   Salman AD, 2003, POWDER TECHNOL, V130, P359, DOI 10.1016/S0032-5910(02)00237-1
   Sen M, 2014, PROCESSES, V2, P89, DOI 10.3390/pr2010089
   Seville JPK, 2000, POWDER TECHNOL, V113, P261, DOI 10.1016/S0032-5910(00)00309-0
   SHAMLOU PA, 1994, CHEM ENG SCI, V49, P2647
   Subero J, 2001, POWDER TECHNOL, V120, P232, DOI 10.1016/S0032-5910(01)00276-5
   Syamlal M., 1987, DERIVATION DRAG COEF
   Thornton C, 1996, J PHYS D APPL PHYS, V29, P424, DOI 10.1088/0022-3727/29/2/021
   van Buijtenen MS, 2009, CAN J CHEM ENG, V87, P308, DOI 10.1002/cjce.20144
   Wang W, 2010, INT J MULTIPHAS FLOW, V36, P109, DOI 10.1016/j.ijmultiphaseflow.2009.01.008
   Weber S, 2011, POWDER TECHNOL, V209, P53, DOI 10.1016/j.powtec.2011.02.004
   Wen C.Y., 1966, CHEM ENG PROGR S SER, V62, P100, DOI DOI 10.1016/S0032-0633(98)00014-2
NR 36
TC 2
Z9 2
U1 4
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 995
EP 1009
DI 10.1016/j.ces.2018.10.045
PG 15
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500087
DA 2020-05-12
ER

PT J
AU Szilagyi, B
   Koswara, A
   Loren, BP
   Ferreira, CR
   Thompson, DH
   Nagy, ZK
AF Szilagyi, Botond
   Koswara, Andy
   Loren, Bradley P.
   Ferreira, Christina R.
   Thompson, David H.
   Nagy, Zoltan K.
TI Piezoelectric-based high performance spray solvent delivery system for
   desorption electrospray ionization mass spectrometry: Systematic design
   and case studies for high throughput screening of N-alkylation reactions
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE High throughput screening; DESI-MS; Solvent delivery system; Adaptive
   controller synthesis
ID CRYSTAL
AB Desorption electrospray ionization mass spectrometry (DESI-MS) is a powerful tool for ultra-high throughput chemical reaction screening having enormous scientific and practical implications. DESIMS enables considerably faster chemical reaction and/or product discovery than most current screening methods using very small amount of materials. It has the advantage of bringing the reagents in contact inside charged micro-droplets, that can accelerate reaction by compared to bulk or flow reaction approaches. Since both the desorption efficiency from the surface and the reaction kinetics can be significantly influenced by the DESI spray solvent flowrate and composition, these parameters are expected to play key roles in the overall performance of the ultrahigh-throughput screening. Syringe pumps are frequently used to deliver the DESI spray. They are robust, but inflexible and slow when it comes to manipulating solvent composition and varying flowrate setpoints. This study addresses the importance of designing a high performance, flexible solvent delivery system that enables more rapid solvent composition and flowrate setpoint changes than the routinely used syringe pumps. Our system utilizes a piezoelectric-based pressure controller and valve system employed with fine-tuned adaptive proportional-integrative-derivative (PID) controller. N-alkylation reactions were used to demonstrate the impact of spray-solvent composition and flowrate on the DESI-MS outcome. In particular, the results showed that ions resulting from solvent mixtures can induce reactions that would be otherwise unobserved when using the corresponding neat solvents. This further signifies the need for a flexible spray-solvent delivery system with fast dynamics in the context of ultra-high throughput DESI-MS analysis. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Szilagyi, Botond; Koswara, Andy; Nagy, Zoltan K.] Purdue Univ, Davidson Sch Chem Engn, W Lafayette, IN 47907 USA.
   [Loren, Bradley P.; Ferreira, Christina R.; Thompson, David H.] Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA.
RP Nagy, ZK (reprint author), Purdue Univ, Davidson Sch Chem Engn, W Lafayette, IN 47907 USA.
EM zknagy@purdue.edu
RI Ferreira, Christina R/F-4744-2012; Szilagyi, Botond/AAD-8754-2020;
   Szilagyi, Botond/AAG-8819-2020
OI Ferreira, Christina R/0000-0003-3988-6454; Botond,
   Szilagyi/0000-0001-7777-9612; Nagy, Zoltan/0000-0003-4787-6678
FU Department of Defense: Defense Advanced Research Projects Agency
   [W911NF-16-2-0020]
FX Financial Support is acknowledged from the Department of Defense:
   Defense Advanced Research Projects Agency (award no. W911NF-16-2-0020).
   We thank Graham R. Cooks for contributions to the larger study of which
   this work is a part.
CR Amaral LAN, 2004, CHEM ENG SCI, V59, P1653, DOI 10.1016/j.ces.2004.01.043
   Chang CE, 2010, NANO LETT, V10, P726, DOI 10.1021/nl9040719
   Cooks RG, 2006, SCIENCE, V311, P1566, DOI 10.1126/science.1119426
   DAVIS KA, 1989, ANAL CHEM, V61, P1227, DOI 10.1021/ac00186a010
   Eberlin LS, 2011, BBA-MOL CELL BIOL L, V1811, P946, DOI 10.1016/j.bbalip.2011.05.006
   FAWCETT NC, 1988, ANAL LETT, V21, P1099
   FENN JB, 1990, MASS SPECTROM REV, V9, P37, DOI 10.1002/mas.1280090103
   Jang LS, 2007, BIOMED MICRODEVICES, V9, P619, DOI 10.1007/s10544-007-9075-1
   Kalantarifard A, 2018, CHEM ENG SCI, V178, P238, DOI 10.1016/j.ces.2017.12.045
   Kuhn S, 2011, LAB CHIP, V11, P2488, DOI 10.1039/c1lc20337a
   Ladosz A, 2018, CHEM ENG SCI, V191, P398, DOI 10.1016/j.ces.2018.06.057
   Lucarelli F, 2008, ANAL CHIM ACTA, V609, P139, DOI 10.1016/j.aca.2007.12.035
   Medler D. A., 1998, NEURAL COMPUT SURVEY, V1, P18, DOI DOI 10.1007/BF01889762
   MURAMATSU H, 1988, ANAL CHIM ACTA, V215, P91, DOI 10.1016/S0003-2670(00)85269-1
   NGEHNGWAINBI J, 1990, BIOSENS BIOELECTRON, V5, P13, DOI 10.1016/0956-5663(90)80023-7
   PETERS KS, 1988, SCIENCE, V241, P1053, DOI 10.1126/science.3045967
   Randall CA, 2005, J ELECTROCERAM, V14, P177, DOI 10.1007/s10832-005-0956-5
   ROEDERER JE, 1983, ANAL CHEM, V55, P2333, DOI 10.1021/ac00264a030
   Skogestad S., 2001, J PROCESS CONTR, P1
   Starr MB, 2015, NANO ENERGY, V14, P296, DOI 10.1016/j.nanoen.2015.01.035
   Starr MB, 2012, ANGEW CHEM INT EDIT, V51, P5962, DOI 10.1002/anie.201201424
   Trachsel F, 2005, CHEM ENG SCI, V60, P5729, DOI 10.1016/j.ces.2005.04.039
   WARD MD, 1990, SCIENCE, V249, P1000, DOI 10.1126/science.249.4972.1000
   Wleklinski M, 2018, CHEM SCI, V9, P1647, DOI 10.1039/c7sc04606e
   Wleklinski M, 2016, EUR J ORG CHEM, V2016, P5480, DOI 10.1002/ejoc.201601270
   Yan X, 2016, ANGEW CHEM INT EDIT, V55, P12960, DOI 10.1002/anie.201602270
NR 26
TC 1
Z9 1
U1 2
U2 22
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 1010
EP 1020
DI 10.1016/j.ces.2018.10.046
PG 11
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500088
DA 2020-05-12
ER

PT J
AU Bazzano, M
   Marchisio, D
   Sangermano, M
   Worner, M
   Pisano, R
AF Bazzano, Marco
   Marchisio, Daniele
   Sangermano, Marco
   Woerner, Michael
   Pisano, Roberto
TI A molecular dynamics approach to nanostructuring of particles produced
   via aerosol cationic photopolymerization
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Molecular dynamics; Nanoparticles; Nano-structuring; Phase separation;
   Photopolymerization
ID POLYMER; PERSPECTIVES
AB Structuring of particles obtained by aerosol photopolymerization is here described from both the experimental and the simulation point of view. Transport phenomena occurring within aerosol droplets are studied in order to identify the key issues that must be carefully designed when considering particles structuring. In particular, phase separation and diffusion of the reacting species were evaluated using molecular dynamics simulations, allowing the identification of a series of formulation parameters such as the composition of a mixed solvent (hexadecane and 2-octanone) or the addition of a chain transfer reagent, which are crucial for the control of phase separation and, thus, of the final morphology of the microparticles. The results were compared with morphology analyses obtained from the experimental work. We also found that molecular simulations were useful for the decoupling of the effects of different solvents which were thus treated separately. The interplay between phase separation and gelation rates was also found to be crucial in the structuring process. For example, the ratio between hexadecane and a chain transfer reagent seemed to strongly affect the final morphology of micro-particles. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Bazzano, Marco; Marchisio, Daniele; Sangermano, Marco; Pisano, Roberto] Politecn Torino, Dept Appl Sci & Technol, 24 Corso Duca Abruzzi, I-10129 Turin, Italy.
   [Woerner, Michael] Karlsruhe Inst Technol, Proc Engn Life Sci, Karlsruhe, Germany.
RP Pisano, R (reprint author), Politecn Torino, Dept Appl Sci & Technol, 24 Corso Duca Abruzzi, I-10129 Turin, Italy.
EM roberto.pisano@polito.it
RI Marchisio, Daniele/I-2139-2013
OI Marchisio, Daniele/0000-0002-9104-0571
CR Ahlrichs P, 1999, J CHEM PHYS, V111, P8225, DOI 10.1063/1.480156
   Akgun E, 2015, MACROMOL MATER ENG, V300, P136, DOI 10.1002/mame.201400211
   Akgun E, 2014, MACROMOL MATER ENG, V299, P1316, DOI 10.1002/mame.201400032
   Akgun E, 2013, CHEM ENG SCI, V101, P248, DOI 10.1016/j.ces.2013.06.010
   Akgun E, 2014, COLLOID POLYM SCI, V292, P1241, DOI 10.1007/s00396-014-3175-2
   Bazzano M, 2017, J PHOTOCH PHOTOBIO A, V346, P364, DOI 10.1016/j.jphotochem.2017.06.009
   Di Pasquale N, 2014, J PHYS CHEM B, V118, P13258, DOI 10.1021/jp505348t
   Esen C, 1997, COLLOID POLYM SCI, V275, P131, DOI 10.1007/s003960050062
   Esen C, 1996, J COLLOID INTERF SCI, V179, P276, DOI 10.1006/jcis.1996.0214
   Flory P.J., 1953, PRINCIPLES POLYM CHE
   Gao ZQ, 2007, COLLOID POLYM SCI, V285, P847, DOI 10.1007/s00396-006-1625-1
   Godawat R, 2010, J PHYS CHEM B, V114, P2246, DOI 10.1021/jp906976q
   Jorgensen WL, 1996, J AM CHEM SOC, V118, P11225, DOI 10.1021/ja9621760
   Lavino AD, 2018, J PHYS CHEM B, V122, P5234, DOI 10.1021/acs.jpcb.8b01293
   Lide D. R., 2007, CRC HDB CHEM PHYS
   PALMER BJ, 1994, PHYS REV E, V49, P359, DOI 10.1103/PhysRevE.49.359
   Paradossi G., 2011, INT J PHARMACEUT, V309, P44
   Sherrington DC, 1998, CHEM COMMUN, P2275, DOI 10.1039/a803757d
   Tamai Y, 1996, MACROMOLECULES, V29, P6750, DOI 10.1021/ma951635z
   Vorderbruggen MA, 1996, CHEM MATER, V8, P1106, DOI 10.1021/cm9505254
   Yamamoto T, 2004, POLYMER, V45, P1357, DOI 10.1016/j.polymer.2003.04.006
   Zhou Y, 2011, J MOL MODEL, V17, P3015, DOI 10.1007/s00894-011-0977-8
NR 22
TC 1
Z9 1
U1 0
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2019
VL 195
BP 1021
EP 1027
DI 10.1016/j.ces.2018.10.047
PG 7
WC Engineering, Chemical
SC Engineering
GA HF3QB
UT WOS:000454148500089
DA 2020-05-12
ER

PT J
AU Bearson, SMD
   Bearson, BL
   Sylte, MJ
   Looft, T
   Kogut, MH
   Cai, GH
AF Bearson, Shawn M. D.
   Bearson, Bradley L.
   Sylte, Matthew J.
   Looft, Torey
   Kogut, Michael H.
   Cai, Guohong
TI Cross-protective Salmonella vaccine reduces cecal and splenic
   colonization of multidrug-resistant Salmonella enterica serovar
   Heidelberg
SO VACCINE
LA English
DT Article
DE Salmonella vaccine; Salmonella enterica serovar Heidelberg; Foodborne
   pathogen; Turkey; Colonization; Gene expression
ID DIVA VACCINE; EXPRESSION; OUTBREAK
AB Salmonella vaccine strategies for food-producing animals have typically focused on a specific serovar that either causes production losses due to morbidity/mortality or is an important food safety pathogen for a particular food commodity. The Salmonella enterica serovar Typhimurium BBS 866 vaccine strain was designed to reduce serovar specificity to provide cross-protection against diverse Salmonella serovars, thereby broadening its applicability for multiple animal and poultry species. We reported cross-protection of the BBS 866 vaccine in swine [Vaccine 34:1241-6]. In the current study, we extend the efficacy of the Salmonella vaccine to a poultry commodity by revealing significant reduction of multidrug-resistant Salmonella enterica serovar Heidelberg colonization of the cecum and systemic dissemination to the spleen in BBS 866-vaccinated turkeys. Transcriptional analysis of whole blood from BBS 866-vaccinated turkeys revealed down-regulation of metabolic and immune genes (KCNAB1, ACOD1, GPR17, ADOR2AB, and IL-17RD), suggesting limited leukocyte activation without an overt peripheral inflammatory response to vaccination. Published by Elsevier Ltd.
C1 [Bearson, Shawn M. D.; Sylte, Matthew J.; Looft, Torey; Cai, Guohong] ARS, USDA, Natl Anim Dis Ctr, Ames, IA 50010 USA.
   [Bearson, Bradley L.] ARS, USDA, Natl Lab Agr & Environm, Ames, IA 50010 USA.
   [Kogut, Michael H.] ARS, USDA, Food & Feed Safety Res, College Stn, TX USA.
   [Cai, Guohong] ARS, USDA, Crop Prod & Pest Control Res, W Lafayette, IN USA.
RP Bearson, SMD (reprint author), ARS, Food Safety & Enter Pathogens Res Unit, USDA, Natl Anim Dis Ctr, 1920 Dayton Ave,Room 1403, Ames, IA 50010 USA.
EM shawn.bearson@ars.usda.gov
RI Cai, Guohong/N-1274-2013; Kogut, Michael H./Z-3119-2019
OI Cai, Guohong/0000-0002-7700-6019; 
FU USDA, ARS CRIS funds;  [CVM41579]
FX The authors are greatly appreciative of the outstanding technical
   support of Kellie Winter, Jennifer Jones, and Margaret Walker. The
   authors thank David Alt for assistance with the DNA sequencing facility.
   Patrick McDermott at the FDA Center for Veterinary Medicine, Laurel, MD,
   USA, kindly provided MDR S. Heidelberg strain 2011 K-1138 (CVM41579).;
   This research was supported by USDA, ARS CRIS funds.
CR Bearson BL, 2017, FRONT VET SCI, V4, DOI [10.3389/fvets.2017.00156, 10.3333/fvets.2017.00156]
   Bearson BL, 2017, J MED MICROBIOL, V66, P651, DOI 10.1099/jmm.0.000482
   Bearson BL, 2016, VACCINE, V34, P1241, DOI 10.1016/j.vaccine.2016.01.036
   Cekic C, 2013, J EXP MED, V210, P2693, DOI 10.1084/jem.20130249
   Chandy KG, 2004, TRENDS PHARMACOL SCI, V25, P280, DOI 10.1016/j.tips.2004.03.010
   Dalloul RA, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000475
   Didelot X, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002191
   Ehrentraut H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032416
   Hoffmann M, 2012, J BACTERIOL, V194, P3274, DOI 10.1128/JB.00419-12
   Li YK, 2013, J BIOL CHEM, V288, P16225, DOI 10.1074/jbc.M113.454538
   Mellett M, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2127
   Nagy G, 2006, INFECT IMMUN, V74, P5914, DOI 10.1128/IAI.00619-06
   Pires SM, 2014, FOODBORNE PATHOG DIS, V11, P667, DOI 10.1089/fpd.2014.1744
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Routh JA, 2015, EPIDEMIOL INFECT, V143, P3227, DOI 10.1017/S0950268815000497
NR 15
TC 1
Z9 1
U1 1
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 28
PY 2019
VL 37
IS 10
BP 1255
EP 1259
DI 10.1016/j.vaccine.2018.12.058
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HO1ZU
UT WOS:000460712000001
PM 30718082
DA 2020-05-12
ER

PT J
AU Borgey, F
   Henry, L
   Lebeltel, J
   Lescure, P
   Le Coutour, X
   Vabret, A
   Verdon, R
   Thibon, P
AF Borgey, France
   Henry, Liliane
   Lebeltel, Josiane
   Lescure, Pascale
   Le Coutour, Xavier
   Vabret, Astrid
   Verdon, Renaud
   Thibon, Pascal
TI Effectiveness of an intervention campaign on influenza vaccination of
   professionals in nursing homes: A cluster-randomized controlled trial
SO VACCINE
LA English
DT Article
DE Seasonal influenza vaccination; Nursing homes; Intervention campaign;
   Professional vaccination
ID HEALTH-CARE WORKERS; PROGRAM; IMPACT; IMMUNIZATION; RESIDENTS;
   MORTALITY; OUTBREAKS; RATES; STAFF
AB Background: Seasonal influenza has a major individual and collective impact, especially among the elderly living in nursing homes. To prevent infection by influenza viruses, vaccination of residents and professionals is an essential measure. However, while the vaccination rates of residents are generally high (>85%), rates among professionals are generally approximately 20%. To evaluate the effectiveness of an intervention campaign on the improvement of the influenza vaccination rate of professionals, a regional intervention study was proposed for nursing homes during the 2014-15 season.
   Methods: Cluster-randomized controlled trial (with a nursing home representing a cluster). In the intervention group, a campaign on influenza vaccination was offered to staff, combining different teaching aids in a multimodal approach. In the control group, no intervention was proposed. The primary endpoint was the rate of influenza vaccination among staff. Before and after the study, professionals were asked to complete short questionnaires on their perceptions of influenza vaccination. A multilevel analysis was carried out to compare the vaccination rates between the 2 groups and their evolution before/after the winter period.
   Results: A total of 32 nursing homes were randomized, and 6 were excluded. Initial vaccination rates were 27.6% in the intervention group and 24.2% in the control group (p = 0.16). After the study, these rates increased to 33.7% and 22.9%, respectively, which was a relative difference of +22.1% in the intervention group compared to -5.4% in the control group, p = 0.0025.
   Conclusions: Despite professionals' reluctance to be vaccinate, participation in a promotional campaign with a pragmatic approach has increased the rate of influenza vaccination. The approach will be offered to all nursing homes in the region after revision of the tools to enhance their ease of use and pedagogical messages focused on the direct benefits to professionals. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Borgey, France; Henry, Liliane; Lebeltel, Josiane; Thibon, Pascal] CHU Caen, CPias Normandie, F-14000 Caen, France.
   [Lescure, Pascale] CHU Caen, Dept Filiere Geriatr Med, F-14000 Caen, France.
   [Le Coutour, Xavier] CHU Caen, Serv Hyg Hosp, F-14000 Caen, France.
   [Le Coutour, Xavier; Vabret, Astrid; Verdon, Renaud] Univ Caen Normandie, Med Sch, F-14000 Caen, France.
   [Vabret, Astrid] CHU Caen, Lab Virol, F-14000 Caen, France.
   [Verdon, Renaud] CHU Caen, Serv Malad Infect, F-14000 Caen, France.
RP Borgey, F (reprint author), CHU Caen, CPias Normandie, F-14033 Caen 9, France.
EM borgey-f@chu-caen.fr
OI VABRET, Astrid/0000-0002-8940-7645
CR [Anonymous], 2012, Wkly Epidemiol Rec, V87, P461
   Association paritaire pour la sante et la securite du travail du secteur des affaires sociales (ASSTSAS), IMPL CAMP VACC GRIPP
   Carman WF, 2000, LANCET, V355, P93, DOI 10.1016/S0140-6736(99)05190-9
   Centers for Disease Control and Prevention (CDC), PREV FLU VACC WHO SH
   Centre d'appui pour la prevention des infections associees aux soins (CPias), GRIPP SE VACC CEST P
   Dube E, 2014, AM J INFECT CONTROL, V42, pE55, DOI 10.1016/j.ajic.2014.01.006
   Elias C, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4556-5
   Equipes  de surveillance de la grippe, 2014, B EPIDEMIOL HEBD, V28, P460
   Gallagher N, 2018, J HOSP INFECT, V99, P175, DOI 10.1016/j.jhin.2017.08.020
   Gaspard P, 2011, MED MALADIES INFECT, V41, P253, DOI 10.1016/j.medmal.2010.12.008
   Gaspard P, 2015, PRESSE MED, V44, pE311, DOI 10.1016/j.lpm.2015.04.041
   Gasparini R, 2012, HUM VACC IMMUNOTHER, V8, P21, DOI 10.4161/hv.8.1.17622
   Goronzy JJ, 2013, NAT IMMUNOL, V14, P428, DOI 10.1038/ni.2588
   Guthmann JP, 2009, VACCINE, V2012, P35
   Hayward AC, 2006, BRIT MED J, V333, P1241, DOI 10.1136/bmj.39010.581354.55
   High Council of Public Health (France), 2014, EFFICACITE VACCINATI
   Hollmeyer H, 2013, INFLUENZA OTHER RESP, V7, P604, DOI 10.1111/irv.12002
   Lam PP, 2010, CAN MED ASSOC J, V182, pE542, DOI 10.1503/cmaj.091304
   Lemaitre M, 2009, J AM GERIATR SOC, V57, P1580, DOI 10.1111/j.1532-5415.2009.02402.x
   Looijmans-van den Akker I, 2010, VACCINE, V28, P5086, DOI 10.1016/j.vaccine.2010.05.003
   Ministere de la sante, 2014, 316 MIN SANT
   Music T, 2012, INT NURS REV, V59, P161, DOI 10.1111/j.1466-7657.2011.00961.x
   Nace DA, 2007, J AM MED DIR ASSOC, V8, P128, DOI 10.1016/j.jamda.2006.09.014
   Nace DA, 2012, J AM MED DIR ASSOC, V13, P806, DOI 10.1016/j.jamda.2012.08.016
   Potter J, 1997, J INFECT DIS, V175, P1, DOI 10.1093/infdis/175.1.1
   Rothan-Tondeur M, 2010, AGING CLIN EXP RES, V22, P450, DOI [10.1007/BF03337740, 10.3275/6708]
   Schmidt S, 2013, HUM VACC IMMUNOTHER, V9, P349, DOI 10.4161/hv.22736
   To KW, 2016, J HOSP INFECT, V94, P133, DOI 10.1016/j.jhin.2016.07.003
   Utsumi M, 2010, AGE AGEING, V39, P299, DOI 10.1093/ageing/afq029
   Vaux S, 2009, EUR J EPIDEMIOL, V24, P149, DOI 10.1007/s10654-009-9315-1
   World Health Organization, GUID IMPL WHO MULT H
NR 31
TC 1
Z9 1
U1 2
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 28
PY 2019
VL 37
IS 10
BP 1260
EP 1265
DI 10.1016/j.vaccine.2019.01.066
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HO1ZU
UT WOS:000460712000002
PM 30738645
DA 2020-05-12
ER

PT J
AU Roy, S
   Jaeson, MI
   Li, Z
   Mahboob, S
   Jackson, RJ
   Grubor-Bauk, B
   Wijesundara, DK
   Gowans, EJ
   Ranasinghe, C
AF Roy, S.
   Jaeson, M., I
   Li, Z.
   Mahboob, S.
   Jackson, R. J.
   Grubor-Bauk, B.
   Wijesundara, D. K.
   Gowans, E. J.
   Ranasinghe, C.
TI Viral vector and route of administration determine the ILC and DC
   profiles responsible for downstream vaccine-specific immune outcomes
SO VACCINE
LA English
DT Article
DE ILC; DC; Viral vector-based vaccines; IL-13; IFN-gamma; IL-17; Mucosal
   and systemic vaccination
ID INNATE LYMPHOID-CELLS; CD103(+) DENDRITIC CELLS; CD8 T-CELLS;
   INFLUENZA-VIRUS; ANTIGEN PRESENTATION; HIV-1 VACCINE; MUCOSAL; PRIME;
   IMMUNIZATION; AVIDITY
AB This study demonstrates that route and viral vector can significantly influence the innate lymphoid cells (ILC) and dendritic cells (DC) recruited to the vaccination site, 24 h post delivery. Intranasal (i.n.) vaccination induced ST2/IL-33R(+ )ILC2, whilst intramuscular (i.m.) induced IL-25R(+) and TSLPR+ (Thymic stromal lymphopoietin protein receptor) ILC2 subsets. However, in muscle a novel ILC subset devoid of the known ILC2 markers (IL-25R(-) IL-33R(-) TSLPR-) were found to express IL-13, unlike in lung. Different viral vectors also influenced the ILC-derived cytokines and the DC profiles at the respective vaccination sites. Both i.n. and i.m. recombinant fowlpox virus (rFPV) priming, which has been associated with induction of high avidity T cells and effective antibody differentiation exhibited low ILC2-derived IL-13, high NKp46(+) ILC1 /ILC3 derived-IFN-gamma and no IL-17A, together with enhanced CD11b(+) CD103(-) conventional DCs (cDC). In contrast, recombinant Modified Vaccinia Ankara (rMVA) and Influenza A vector priming, which has been linked to low avidity T cells, induced opposing ILC derived-cytokine profiles and enhanced cross-presenting DCs. These observations suggested that the former ILC/DC profiles could be a predictor of a balanced cellular and humoral immune outcome. In addition, following i.n. delivery Rhinovirus (RV) and Adenovius type 5 (Ad5) vectors that induced elevated ILC2-derived IL-13, NKp46(+) ILC1/ILC3-derived-IFN-gamma and no IL-17A, predominantly recruited CD11b(-) B220(+) plasmacytoid DCs (pDC). Knowing that pDC are involved in antibody differentiation, we postulate that i.n. priming with these vectors may favour induction of effective humoral immunity. Our data also revealed that vector-specific replication status and/or presence or absence of immune evasive genes can significantly alter the ILC and DC activity. Collectively, our findings suggest that understanding the route- and vector-specific ILC and DC profiles at the vaccination site may help tailor/design more efficacious viral vector-based vaccines, according to the pathogen of interest. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Roy, S.; Jaeson, M., I; Li, Z.; Mahboob, S.; Jackson, R. J.; Wijesundara, D. K.; Ranasinghe, C.] Australian Natl Univ, John Curtin Sch Med Res, Dept Immunol & Infect Dis, Mol Mucosal Vaccine Immunol Grp, Canberra, ACT 2601, Australia.
   [Grubor-Bauk, B.; Wijesundara, D. K.; Gowans, E. J.] Univ Adelaide, Basil Hetzel Inst Translat Hlth Res, Virol Grp, Adelaide, SA, Australia.
RP Ranasinghe, C (reprint author), Australian Natl Univ, John Curtin Sch Med Res, Dept Immunol & Infect Dis, Mol Mucosal Vaccine Immunol Grp, Canberra, ACT 2601, Australia.
EM Charani.Ranasinge@anu.edu.au
OI Grubor-Bauk, Branka/0000-0002-4642-105X; Li, Zheyi/0000-0002-1128-8631
FU Australian Centre for HIV and Hepatitis Virology Research (ACH2) grant;
   National Health and Medical Research Council (NHMRC)National Health and
   Medical Research Council of Australia [APP1093532, APP1136351]
FX The authors would like to thank Prof. Arno Mullbacher, JCSMR, ANU for
   the Influenza A and Adenovirus (Ad5) vectors; The Imaging and Cytometry
   facility for providing support with flow cytometry experiments; The
   Australian Phenomics Facility, ANU for maintenance and housing of mice
   used for the experiments. This work was supported by the Australian
   Centre for HIV and Hepatitis Virology Research (ACH2) grant, and
   National Health and Medical Research Council (NHMRC) Development grant
   APP1093532 and APP1136351 awarded to CR.
CR Artis D, 2015, NATURE, V517, P293, DOI 10.1038/nature14189
   Ashok D, 2014, EUR J IMMUNOL, V44, P1422, DOI 10.1002/eji.201344242
   Barouch DH, 2010, NAT MED, V16, P319, DOI 10.1038/nm.2089
   Belyakov IM, 2007, J IMMUNOL, V178, P7211, DOI 10.4049/jimmunol.178.11.7211
   Belyakov IM, 2009, J IMMUNOL, V182, P1779, DOI 10.4049/jimmunol.0990002
   Belyakov IM, 2006, BLOOD, V107, P3258, DOI 10.1182/blood-2005-11-4374
   Belyakov IM, 1950, J IMMUNOL, V182, P80
   Bernink JH, 2015, IMMUNITY, V43, P146, DOI 10.1016/j.immuni.2015.06.019
   Braciale TJ, 2013, IMMUNOL REV, V255, P5, DOI 10.1111/imr.12109
   Buchbinder SP, 2008, LANCET, V372, P1881, DOI 10.1016/S0140-6736(08)61591-3
   Cerutti A, 2005, IMMUNOL CELL BIOL, V83, P554, DOI 10.1111/j.1440-1711.2005.01389.x
   Coupar BEH, 2006, VACCINE, V24, P1378, DOI 10.1016/j.vaccine.2005.09.044
   Erbel C, 2014, J IMMUNOL, V193, P4344, DOI 10.4049/jimmunol.1400181
   Garber DA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005445
   Garcia-Arriaza J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012395
   Gasteiger G, 2015, SCIENCE, V350, P981, DOI 10.1126/science.aac9593
   GeurtsvanKessel CH, 2008, J EXP MED, V205, P1621, DOI 10.1084/jem.20071365
   GeurtsvanKessel CH, 2009, J EXP MED, V206, P2339, DOI 10.1084/jem.20090410
   Gherardi MM, 2003, J VIROL, V77, P7048, DOI 10.1128/JVI.77.12.7048-7057.2003
   Gladiator A, 2013, J IMMUNOL, V190, P521, DOI 10.4049/jimmunol.1202924
   Hamid MA, 2018, EUR J IMMUNOL
   Hansen SG, 2011, NATURE, V473, P523, DOI 10.1038/nature10003
   Harari A, 2008, J EXP MED, V205, P63, DOI 10.1084/jem.20071331
   Heath WR, 2009, NAT IMMUNOL, V10, P1237, DOI 10.1038/ni.1822
   Helft J, 2012, J CLIN INVEST, V122, P4037, DOI 10.1172/JCI60659
   Hildner K, 2008, SCIENCE, V322, P1097, DOI 10.1126/science.1164206
   Ho AWS, 2011, J IMMUNOL, V187, P6011, DOI 10.4049/jimmunol.1100987
   Huang YJ, 2017, J IMMUNOL, V198
   Huang YF, 2015, NAT IMMUNOL, V16, P161, DOI 10.1038/ni.3078
   Ibango HB, 2006, LANCET INFECT DIS, V6, P522, DOI 10.1016/S1473-3099(06)70552-7
   Ingulli E, 2009, J IMMUNOL, V182, P29, DOI 10.4049/jimmunol.182.1.29
   Jackson RJ, 2014, VACCINE, V32, P5703, DOI 10.1016/j.vaccine.2014.08.023
   Jirmo AC, 2009, J IMMUNOL, V182, P283, DOI 10.4049/jimmunol.182.1.283
   Keefer MC, 2011, VACCINE, V29, P1948, DOI 10.1016/j.vaccine.2010.12.104
   Kim BS, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005374
   Kim MC, 2017, ANTIVIR RES, V148, P43, DOI 10.1016/j.antiviral.2017.10.018
   Klose CSN, 2014, CELL, V157, P340, DOI 10.1016/j.cell.2014.03.030
   Lee J, 2017, J VIROL, V91
   Li ZY, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0048-6
   Lim AI, 2016, J EXP MED, V213, P569, DOI 10.1084/jem.20151750
   Lukens MV, 2009, J VIROL, V83, P7235, DOI 10.1128/JVI.00452-09
   Marthas ML, 2011, VACCINE, V29, P3124, DOI 10.1016/j.vaccine.2011.02.051
   Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900
   Newcomb DC, 2011, J ALLERGY CLIN IMMUN, V127, P1006, DOI 10.1016/j.jaci.2010.11.043
   Novick D, 1999, IMMUNITY, V10, P127, DOI 10.1016/S1074-7613(00)80013-8
   Provine NM, 2014, J IMMUNOL, V192, P5214, DOI 10.4049/jimmunol.1302806
   Ranasinghe C, 2013, MUCOSAL IMMUNOL, V6, P1068, DOI 10.1038/mi.2013.1
   Ranasinghe C, 2007, J IMMUNOL, V178, P2370, DOI 10.4049/jimmunol.178.4.2370
   Ranasinghe C, 2006, VACCINE, V24, P5881, DOI 10.1016/j.vaccine.2006.04.023
   Ranasinghe C, 2011, VACCINE, V29, P3008, DOI 10.1016/j.vaccine.2011.01.106
   Ravichandran J, 2015, J INTERF CYTOK RES, V35, P176, DOI 10.1089/jir.2014.0078
   Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492
   Roberts DM, 2006, NATURE, V441, P239, DOI 10.1038/nature04721
   Shiver JW, 2002, NATURE, V415, P331, DOI 10.1038/415331a
   Silver JS, 2016, NAT IMMUNOL, V17, P626, DOI 10.1038/ni.3443
   Spencer SP, 2014, SCIENCE, V343, P432, DOI 10.1126/science.1247606
   Staib C, 2005, J GEN VIROL, V86, P1997, DOI 10.1099/vir.0.80646-0
   Tan HX, 2016, VACCINE, V34, P1172, DOI 10.1016/j.vaccine.2016.01.030
   Tomusange K, 2016, SCI REP-UK, V6, DOI 10.1038/srep36658
   Tomusange K, 2015, VIRUS RES, V203, P72, DOI 10.1016/j.virusres.2015.04.002
   Trivedi S, 2014, VIROLOGY, V468, P479, DOI 10.1016/j.virol.2014.09.004
   Waithman J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066136
   Wijesundara DK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105366
   Yang TC, 2007, MOL THER, V15, P997, DOI 10.1038/sj.mt.6300130
   Yoneyama H, 2005, J EXP MED, V202, P425, DOI 10.1084/jem.20041961
NR 65
TC 0
Z9 0
U1 1
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 28
PY 2019
VL 37
IS 10
BP 1266
EP 1276
DI 10.1016/j.vaccine.2019.01.045
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HO1ZU
UT WOS:000460712000003
PM 30733092
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Shen, AK
   Groom, AV
   Leach, DL
   Bridges, CB
   Tsai, AY
   Tan, L
AF Shen, Angela K.
   Groom, Amy, V
   Leach, Diane L.
   Bridges, Carolyn B.
   Tsai, Alice Y.
   Tan, Litjen
TI A pathway to developing and testing quality measures aimed at improving
   adult vaccination rates in the United States
SO VACCINE
LA English
DT Article
DE Adult vaccination; HEDIS (R); Quality measurement; Composite
   measurement; Influenza, Tdap, Td, Pneumococcal, Zoster vaccines
ID ADVISORY-COMMITTEE; IMMUNIZATION; RECOMMENDATIONS; DISEASE
AB Despite recommendations for vaccinating adults and widespread availability of immunization services (e.g., pharmacy venues, workplace wellness clinics), vaccination rates in the United States remain low. The U.S. National Adult Immunization Plan identified the development of quality measures as a priority and key strategy to address low adult vaccination coverage rates. The use of quality measures can provide incentives for increased utilization of preventive services. To address the lack of adult immunization measures, the National Adult and Influenza Immunization Summit, a coalition of adult immunization partners led by the Immunization Action Coalition, Centers for Disease Control and Prevention, and National Vaccine Program Office, spearheaded efforts to (1) identify gaps and priorities in adult immunization quality performance measurement; (2) explore feasibility of data collection on adult immunizations through pilot testing and engaging stakeholders; and (3) develop and test quality measure specifications. This paper outlines the process by which a public-private partnership drove the development of two adult immunization performance measures-an adult immunization status measure for influenza, tetanus and diphtheria (Td) and/or tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap), herpes zoster and pneumococcal vaccines, and a prenatal immunization status measure for influenza and Tdap vaccinations in pregnant women. These measures have recently been added to the 2019 Healthcare Effectiveness Data and Information Set (HEDIS (R)), a widely used set of performance measures reportable by private health plans. Published by Elsevier Ltd.
C1 [Shen, Angela K.; Tsai, Alice Y.] US Dept HHS, Natl Vaccine Program Off, Off Assistant Secretary Hlth, Washington, DC 20201 USA.
   [Groom, Amy, V; Bridges, Carolyn B.] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Leach, Diane L.] Indian Hlth Serv, Rockville, MD USA.
   [Bridges, Carolyn B.] Berry Technol Solut LLC, Peachtree City, GA USA.
   [Tan, Litjen] Immunizat Act Coalit, St Paul, MN USA.
RP Shen, AK (reprint author), US Dept HHS, Natl Vaccine Program Off, Off Assistant Secretary Hlth, Washington, DC 20201 USA.
EM aks352@drexel.edu
OI Shen, Angela/0000-0003-3761-0016
CR Agency for healthcare research and quality, NAT QUAL STRAT
   [Anonymous], 2017, MEASURE APPL PARTNER
   Bach AT, 2015, INTEGR PHARM RES PRA, V4, P67, DOI 10.2147/IPRP.S63822
   Bardenheier BH, 2008, J ADOLESCENT HEALTH, V42, P137, DOI 10.1016/j.jadohealth.2007.08.030
   Bhatt A, 2014, PUBLIC HEALTH REP, V129, P115
   Bridges CB, 2015, VACCINE, V33, pD114, DOI 10.1016/j.vaccine.2015.09.054
   Bundy DG, 2012, PEDIATRICS, V129, P648, DOI 10.1542/peds.2011-3073
   Center for Disease Control and Prevention, 2017, NAT EARL SEAS FLU VA
   Centers for Medicare & Medicaid Services, 2018, ACC CAR ORG ACOS GEN
   Centers for Medicare & Medicaid Services, 2018, MACRA
   Centers for Medicare & Medicaid Services, 2018, 5 STAR QUAL RAT SYST
   Centers for Medicare & Medicaid Services, MEAN MEAS HUB
   CORTESE MM, 1992, ARCH INTERN MED, V152, P2277, DOI 10.1001/archinte.152.11.2277
   Gellin BG, 2016, AM J PREV MED, V51, P1079, DOI 10.1016/j.amepre.2016.04.014
   Groom AV, 2014, AM J PUBLIC HEALTH, V104, pS460, DOI 10.2105/AJPH.2013.301740
   Harpaz Rafael, 2007, Morbidity and Mortality Weekly Report, V57, P1
   Hennessy TW, 2016, EPIDEMIOL INFECT, V144, P315, DOI 10.1017/S0950268815001211
   Hung MC, 2016, VACCINATION COVERAGE
   Indian health service, 2018, GPRA OTHER NAT REP
   Institute of Medicine  Board on Health Care Services Staff Board on Health Care Services Committee on Redesigning Health Insurance Performance Measures Payment and Performance Improvement Programs & Institute of Medicine (U. S. ) Staff, 2006, PERF MEAS ACC IMPR, DOI [10.17226/11517, DOI 10.17226/11517]
   Kim D., 2017, ADULT NETCONFERENCE
   Kim DK, 2018, ANN INTERN MED, V168, P210, DOI 10.7326/M17-3439
   Kretsinger Katrina, 2006, Morbidity and Mortality Weekly Report, V55, P1
   L&M policy research, EV MED QUAL BON PAY
   Lu PJ, 2014, VACCINE, V32, P3198, DOI 10.1016/j.vaccine.2014.04.003
   Medicaid. gov, AD HLTH CAR QUAL MEA
   Medicaid. gov, CHILDR HLTH CAR QUAL
   National adult and influenza immunization summit, 2017, MIPS FACTSH
   National Committee for Quality Assurance, HEDIS PERF MEAS
   National Committee for Quality Assurance, 2019, NCQA UPD QUAL MEAS H
   National Quality Forum, PRIOR MEAS
   National Quality Forum, 2014, PRIOR SETT HEALTHC P
   National Vaccine Program Office, AD IMM PLANS
   Ng J, 2015, MMWR-MORBID MORTAL W, V64, P1185, DOI 10.15585/mmwr.mm6442a1
   Office of Disease Prevention and Health Promotion, HLTH PEOPL 2020 IMM
   Ozawa S, 2016, HEALTH AFFAIR, V35, P2124, DOI 10.1377/hlthaff.2016.0462
   Shen AK, 2017, NAIIS QUAL PERF MEAS
   Shen AK, 2018, AM J PREV MED, V55, P517, DOI 10.1016/j.amepre.2018.04.050
   Shen AK, 2017, VACCINE, V35, P7302, DOI 10.1016/j.vaccine.2017.10.105
   Shen AK, 2013, VACCINE, V31, P279, DOI 10.1016/j.vaccine.2012.11.033
   Tomczyk S, 2014, MMWR-MORBID MORTAL W, V63, P822
   U. S. office of personnel management, C BUDG JUST ANN PERF
   Weiser T, 2018, VACCINE, V36, P4952, DOI 10.1016/j.vaccine.2018.04.006
   Whitney CG, 2014, MMWR-MORBID MORTAL W, V63, P352
NR 44
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 28
PY 2019
VL 37
IS 10
BP 1277
EP 1283
DI 10.1016/j.vaccine.2019.01.044
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HO1ZU
UT WOS:000460712000004
PM 30738646
DA 2020-05-12
ER

PT J
AU Petrie, JG
   Martin, ET
   Truscon, R
   Johnson, E
   Cheng, CK
   McSpadden, EJ
   Malosh, RE
   Lauring, AS
   Lamerato, LE
   Eichelberger, MC
   Ferdinands, JM
   Monto, AS
AF Petrie, Joshua G.
   Martin, Emily T.
   Truscon, Rachel
   Johnson, Emileigh
   Cheng, Caroline K.
   McSpadden, E. J.
   Malosh, Ryan E.
   Lauring, Adam S.
   Lamerato, Lois E.
   Eichelberger, Maryna C.
   Ferdinands, Jill M.
   Monto, Arnold S.
TI Evaluation of correlates of protection against influenza A(H3N2) and A
   (H1N1)pdm09 infection: Applications to the hospitalized patient
   population
SO VACCINE
LA English
DT Article
DE Influenza; Hemagglutinin; Neuraminidase; Influenza vaccine; Serology;
   Correlates of protection; Inpatient
ID VACCINE EFFECTIVENESS; UNITED-STATES; VIRUS NEURAMINIDASE;
   ANTIBODY-RESPONSES; SEASONAL INFLUENZA; CANADA
AB Background: Influenza vaccines are important for prevention of influenza-associated hospitalization. However, the effectiveness of influenza vaccines can vary by year and influenza type and subtype and mechanisms underlying this variation are incompletely understood. Assessments of serologic correlates of protection can support interpretation of influenza vaccine effectiveness in hospitalized populations.
   Methods: We enrolled adults hospitalized for treatment of acute respiratory illnesses during the 2014-2015 and 2015-2016 influenza seasons whose symptoms began <10 days prior to enrollment. Influenza infection status was determined by RT-PCR. Influenza vaccination status was defined by selfreport and medical record/registry documentation. Serum specimens collected at hospital admission were tested in hemagglutination-inhibition (HAI) and neuraminidase-inhibition (NAI) assays. We evaluated how well antibody measured in these specimens represented pre-infection immune status, and measured associations between antibody and influenza vaccination and infection.
   Results: Serum specimens were retrieved for 315 participants enrolled during the 2014-2015 season and 339 participants during the 2015-2016 season. Specimens were collected within 3 days of illness onset from 65% of participants. Geometric mean titers (GMTs) did not vary by the number of days from illness onset to specimen collection among influenza positive participants suggesting that measured antibody was representative of pre-infection immune status rather than a de novo response to infection. In both seasons, vaccinated participants had higher HAI and NAI GMTs than unvaccinated. HAI titers against the 2014-2015 A(H3N2) vaccine strain did not correlate with protection from infection with antigenically-drifted A(H3N2) viruses that circulated that season. In contrast, higher HAI titers against the A(H1N1)pdm09 vaccine strain were associated with reduced odds of A(H1N1)pdm09 infection in 2015-2016.
   Conclusions: Serum collected shortly after illness onset at hospital admission can be used to assess correlates of protection against influenza infection. Broader implementation of similar studies would provide an opportunity to understand the successes and shortcomings of current influenza vaccines. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Petrie, Joshua G.; Martin, Emily T.; Truscon, Rachel; Johnson, Emileigh; Cheng, Caroline K.; McSpadden, E. J.; Malosh, Ryan E.; Monto, Arnold S.] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA.
   [Lauring, Adam S.] Univ Michigan, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA.
   [Lauring, Adam S.] Univ Michigan, Dept Internal Med, Div Infect Dis, Ann Arbor, MI 48109 USA.
   [Lamerato, Lois E.] Henry Ford Hlth Syst, Dept Publ Hlth Sci, Detroit, MI USA.
   [Eichelberger, Maryna C.] US FDA, Ctr Biol Evaluat & Res, Div Biol Stand & Qual Control, Silver Spring, MD USA.
   [Ferdinands, Jill M.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA.
RP Petrie, JG (reprint author), Univ Michigan, Sch Publ Hlth, 1415 Washington Hts, Ann Arbor, MI 48109 USA.
EM jpetrie@umich.edu
OI Petrie, Joshua/0000-0002-5696-965X
FU Centers for Disease Control and PreventionUnited States Department of
   Health & Human ServicesCenters for Disease Control & Prevention - USA
   [U01 IP000974, U01 IP000474]
FX This work was supported by the Centers for Disease Control and
   Prevention (U01 IP000974, U01 IP000474).
CR [Anonymous], 2016, Wkly Epidemiol Rec, V91, P121
   Appiah GD, 2015, MMWR-MORBID MORTAL W, V64, P583
   Belongia Edward A, 2017, Expert Rev Vaccines, V16, P1, DOI 10.1080/14760584.2017.1334554
   Belongia EA, 2016, LANCET INFECT DIS, V16, P942, DOI 10.1016/S1473-3099(16)00129-8
   Chung JR, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-3279
   Couch RB, 2013, J INFECT DIS, V207, P974, DOI 10.1093/infdis/jis935
   Couch RB, 2012, VACCINE, V31, P190, DOI 10.1016/j.vaccine.2012.10.065
   Couzens L, 2014, J VIROL METHODS, V210, P7, DOI 10.1016/j.jviromet.2014.09.003
   D'Mello T, 2015, MMWR-MORBID MORTAL W, V64, P206
   Davlin SL, 2016, MMWR-MORBID MORTAL W, V65, P567, DOI 10.15585/mmwr.mm6522a3
   Erbelding EJ, 2018, J INFECT DIS, V218, P347, DOI 10.1093/infdis/jiy103
   Flannery B, 2016, J INFECT DIS, V214, P1010, DOI 10.1093/infdis/jiw181
   Grohskopf LA, 2017, AM J TRANSPLANT, V17, P2970, DOI 10.1111/ajt.14511
   Huang KYA, 2014, J INFECT DIS, V209, P1354, DOI 10.1093/infdis/jit650
   Jackson ML, 2017, NEW ENGL J MED, V377, P534, DOI [10.1056/NEJMoa1700153, 10.1056/nejmoa1700153]
   Monto AS, 2015, J INFECT DIS, V212, P1191, DOI 10.1093/infdis/jiv195
   Nichols MK, 2018, VACCINE, V36, P2166, DOI 10.1016/j.vaccine.2018.02.093
   Ohmit SE, 2015, J INFECT DIS, V211, P1519, DOI 10.1093/infdis/jiu650
   Ohmit SE, 2014, CLIN INFECT DIS, V58, P319, DOI 10.1093/cid/cit736
   Paules CI, 2018, NEW ENGL J MED, V378, P7, DOI 10.1056/NEJMp1714916
   Petrie JG, 2016, CLIN INFECT DIS, V63, P1017, DOI 10.1093/cid/ciw432
   Petrie JG, 2015, J INFECT DIS, V212, P1914, DOI 10.1093/infdis/jiv313
   Puig-Barbera J, 2015, EURO SURVEILL B EUR, V20
   Qin Y, 2016, VACCINE, V34, P2329, DOI 10.1016/j.vaccine.2016.03.068
   Rolfes MA, 2018, J INFECT DIS, V217, P1078, DOI 10.1093/infdis/jiy013
   Skowronski DM, 2008, J INFECT DIS, V197, P490, DOI 10.1086/524146
   Skowronski DM, 2012, CLIN INFECT DIS, V55, P332, DOI 10.1093/cid/cis431
   Thompson WW, 2004, JAMA-J AM MED ASSOC, V292, P1333, DOI 10.1001/jama.292.11.1333
   Valenciano M, 2012, EUROSURVEILLANCE, V17, P39
NR 29
TC 2
Z9 2
U1 1
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 28
PY 2019
VL 37
IS 10
BP 1284
EP 1292
DI 10.1016/j.vaccine.2019.01.055
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HO1ZU
UT WOS:000460712000005
PM 30738647
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Rao, S
   Alishahi, M
   De Crescenzo, L
   Dempsey, AF
AF Rao, Suchitra
   Alishahi, Musheng
   De Crescenzo, Lauren
   Dempsey, Amanda F.
TI A population-based study of maternal and infant factors influencing
   influenza vaccination among young children born in Colorado from 2008 to
   2016
SO VACCINE
LA English
DT Article
DE Influenza vaccination; Vaccine uptake; Birth registry; Immunization
   registry
ID UNITED-STATES; VACCINES RECOMMENDATIONS; IMMUNIZATION PRACTICES;
   ADVISORY-COMMITTEE; SEASONAL INFLUENZA; PREVENTION; DETERMINANTS;
   ATTITUDES; COVERAGE; COHORT
AB Introduction: Influenza causes significant morbidity among young children, and vaccination remains the best strategy to prevent disease. Understanding factors influencing early influenza vaccination uptake are important to identify strategies to increase vaccination rates.
   Objective: To assess maternal and neonatal factors associated with influenza vaccination among firstborn children within the first two years of life.
   Methods: We conducted a retrospective population-based cohort study linking Colorado Birth Registry data and state immunization data of all live births between 2008 and 2016. The cohort was limited to singleton, first births. Multivariable logistic regression was used to assess associations between maternal and neonatal factors and influenza vaccination.
   Results: Among 126,763 births meeting criteria for inclusion, 50.2% were vaccinated against influenza by two years of age. Mothers of unvaccinated children were older (27 vs 26 years, p < 0.0001), married (67.8% vs 66.8%, p < 0.0001), with a college education (38.8% vs 37.2%, p < 0.0001). Influenza vaccination rates declined over time by birth year (30.5% in 2009 vs 6.8% in 2013, p < 0.0001). Children admitted to the NICU receiving oxygen with 72 h of birth were 20% less likely to be vaccinated (RR = 0.8, 95% CI: 0.670.96) after adjusting for maternal age, race/ethnicity, education and preterm birth. Conversely, premature births were associated with an increase in influenza vaccination by age two years (RR 1.1, 95%Cl: 1.05, 1.15).
   Conclusions: Among a large population based cohort of mother-infant pairs in Colorado using birth and immunization registry data, there were statistically significant differences in maternal factors between unvaccinated and vaccinated children with influenza in the first 2 years of life, but the differences were too small to be clinically significant. Children admitted to the NICU were 20% less likely to be vaccinated, highlighting the need to target influenza vaccination in this population once eligible. Ongoing studies are needed to explore factors associated with early influenza vaccination. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Rao, Suchitra] Univ Colorado, Dept Pediat, Sch Med, Infect Dis,Hosp Med,Epidemiol, Box 055,13123 E 16th Ave, Aurora, CO 80045 USA.
   [Rao, Suchitra; Dempsey, Amanda F.] Childrens Hosp Colorado, Box 055,13123 E 16th Ave, Aurora, CO 80045 USA.
   [Alishahi, Musheng; De Crescenzo, Lauren] Univ Colorado, Sch Publ Hlth, Dept Epidemiol, Aurora, CO 80045 USA.
   [Dempsey, Amanda F.] Univ Colorado, Sch Med, Dept Pediat, Aurora, CO 80045 USA.
   [Dempsey, Amanda F.] Adult & Child Ctr Hlth Outcomes Res & Delivery Sc, Aurora, CO USA.
RP Rao, S (reprint author), Univ Colorado, Dept Pediat, Sch Med, Infect Dis,Hosp Med,Epidemiol, Box 055,13123 E 16th Ave, Aurora, CO 80045 USA.; Rao, S (reprint author), Childrens Hosp Colorado, Box 055,13123 E 16th Ave, Aurora, CO 80045 USA.
EM suchitra.rao@childrenscolorado.org
CR [Anonymous], 2018, COLORADO DEP PUBLIC
   Gowda C, 2013, J ADOLESCENT HEALTH, V53, P498, DOI 10.1016/j.jadohealth.2013.07.022
   Grohskopf LA, 2017, MMWR RECOMM REP, V66, P3, DOI 10.15585/mmwr.rr6602a1
   Grohskopf LA, 2015, MMWR-MORBID MORTAL W, V64, P818, DOI [10.15585/mmwr.mm6430a3, 10.1111/ajt.13505]
   Grohskopf LA, 2014, MMWR-MORBID MORTAL W, V63, P691
   Hak E, 2005, VACCINE, V23, P3103, DOI 10.1016/j.vaccine.2005.01.074
   Hill Holly A, 2016, MMWR Morb Mortal Wkly Rep, V65, P1065, DOI 10.15585/mmwr.mm6539a4
   Jones TF, 2004, CLIN INFECT DIS, V39, P1824, DOI 10.1086/427153
   Lin CJ, 2013, BMC PEDIATR, V13, DOI 10.1186/1471-2431-13-180
   Lu PJ, 2013, MMWR SURVEILL SUMM, V62, P1
   O'Leary ST, 2015, J RURAL HEALTH, V31, P421, DOI 10.1111/jrh.12119
   Pati S, 2017, HUM VACC IMMUNOTHER, V13, P1141, DOI 10.1080/21645515.2016.1261771
   Poehling KA, 2010, PEDIATRICS, V126, P665, DOI 10.1542/peds.2009-2620
   Prevention CfDCa, 2018, EST FLU VACC COV CHI
   Salmon DA, 2015, VACCINE, V33, pD66, DOI 10.1016/j.vaccine.2015.09.035
   Santibanez TA, 2016, VACCINE, V34, P2671, DOI 10.1016/j.vaccine.2016.04.039
   Santibanez TA, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-3280
   Shefer A, 1999, EPIDEMIOL REV, V21, P96, DOI 10.1093/oxfordjournals.epirev.a017992
   Smith PJ, 2010, PUBLIC HEALTH REP, V125, P534, DOI 10.1177/003335491012500408
   Tozzi AE, 2014, VACCINE, V32, P793, DOI 10.1016/j.vaccine.2013.12.044
   Uwemedimo OT, 2012, J COMMUN HEALTH, V37, P663, DOI 10.1007/s10900-011-9497-9
   Wong KK, 2016, INFLUENZA OTHER RESP, V10, P421, DOI 10.1111/irv.12388
NR 22
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 28
PY 2019
VL 37
IS 10
BP 1293
EP 1298
DI 10.1016/j.vaccine.2019.01.054
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HO1ZU
UT WOS:000460712000006
PM 30723065
DA 2020-05-12
ER

PT J
AU Nolan, MB
   Schulman, ML
   Botha, AE
   Human, AM
   Roth, R
   Crampton, MC
   Bertschinger, HJ
AF Nolan, Margaret B.
   Schulman, Martin L.
   Botha, Alma E.
   Human, Anne-Marie
   Roth, Robyn
   Crampton, Michael C.
   Bertschinger, Henk J.
TI Serum antibody immunoreactivity and safety of native porcine and
   recombinant zona pellucida vaccines formulated with a non-Freund's
   adjuvant in horses
SO VACCINE
LA English
DT Article
DE Antibody titres; Zona pellucida proteins; Immunocontraception; Vaccine
   formulation; Horse
ID OVARIAN-FUNCTION; AFRICAN ELEPHANTS; IMMUNOCONTRACEPTION; POPULATIONS;
   PROTEINS; MODES
AB Commercial and regulatory limitations associated with native porcine zona pellucida (pZP) vaccines formulated with Freund's adjuvants may be overcome by developing effective recombinant ZP vaccines (reZP) and identifying alternative adjuvant formulations. A two-part preparatory study used 15 geldings and identified potentially effective alternative adjuvant formulations based on anti-pZP antibody response following treatment with pZP formulated with Addavax (AddaVax (TM), Invivogen), Quil A (Quil-A (R) Adjuvant, Invivogen), Quil A and Poly (I:C) (HMW VacciGrade (TM), Invivogen), Pet Gel A (Montanid (TM) Pet Gel A, Seppic) and Pet Gel A and Poly (I:C). Injection site reactions, rectal temperature and respiratory and heart rates were also monitored for three days post-treatment. Suitable anti-pZP antibody titres were seen in response to Pet Gel A and Pet Gel A and Poly (I:C). Subsequently in 31 mares, following administration of pZP, reZP and a combination of pZP and reZP proteins prepared in Pet Gel A and Poly (I:C), both serum anti-pZP and -reZP antibody responses were monitored. In addition, safety was assessed for up to seven days post-treatment by inspection and palpation of gluteal intramuscular injection sites and measurement of rectal temperature. The measured antibody titres in all treatment groups differed significantly to an adjuvant control group (P < 0.001). Temporal changes in both anti-pZP and -reZP antibody titres in all ZP treatment groups were similar to patterns reported previously in various species vaccinated with pZP formulated with Freund's adjuvants. There were no differences in anti-pZP antibody titres between the pZP and reZP treated groups (P > 0.05). Side effects were mild and transient in nature. This represents the first application of a reZP vaccine formulated with non-Freund's adjuvants evoking a similar antibody titre response to native pZP vaccination in mares. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Nolan, Margaret B.; Schulman, Martin L.; Botha, Alma E.; Bertschinger, Henk J.] Univ Pretoria, Fac Vet Sci, Dept Prod Anim Studies, Onderstepoort, South Africa.
   [Nolan, Margaret B.; Schulman, Martin L.; Human, Anne-Marie; Bertschinger, Henk J.] Univ Pretoria, Fac Vet Sci, Dept Prod Anim Studies, Vet Populat Management Lab, Onderstepoort, South Africa.
   [Roth, Robyn; Crampton, Michael C.] CSIR, Biomfg Technol, Biosci, Pretoria, South Africa.
RP Nolan, MB (reprint author), Univ Pretoria, Fac Vet Sci, Dept Prod Anim Studies, Vet Populat Management Lab, Onderstepoort, South Africa.
EM margaret.nolan@up.ac.za; martin.schulman@up.ac.za; ester.botha@up.ac.za;
   annemarie.human@up.ac.za; rroth@csir.co.za; mcrampton@csir.co.za;
   henkbert@tiscali.co.za
RI Nolan, Margaret Bethaline/K-1026-2017
OI Nolan, Margaret Bethaline/0000-0003-1755-853X; Roth,
   Robyn/0000-0002-6486-7549
FU Technology Innovation Agency, Pretoria, South Africa [TAHC12-0042]
FX This study was funded by the Technology Innovation Agency, Pretoria,
   South Africa. TAHC12-0042: Immunocontraception as a means of population
   control in wildlife and domestic animals.
CR Ambrosia R. L., 2017, Clinical Theriogenology, V9, P439
   [Anonymous], 2010, USDA TECHNICAL B
   Apostolico JD, 2016, J IMMUNOL RES, DOI 10.1155/2016/1459394
   Barber MR, 2000, J REPROD IMMUNOL, V46, P103, DOI 10.1016/S0165-0378(99)00063-7
   Bechert U, 2016, PACHYDERM, V57, P97
   Bechert U, 2013, J WILDLIFE MANAGE, V77, P1386, DOI 10.1002/jwmg.600
   Bertschinger H., 2012, 4 INT WILDL MAN C CO, P95
   Bertschinger HJ, 2018, BOTHALIA, V48, DOI 10.4102/abc.v48i2.2324
   Billiau A, 2001, J LEUKOCYTE BIOL, V70, P849
   Cauchard S, 2014, VET IMMUNOL IMMUNOP, V157, P164, DOI 10.1016/j.vetimm.2013.12.003
   CLAASSEN E, 1992, RES IMMUNOL, V143, P478, DOI 10.1016/0923-2494(92)80057-R
   Cox JC, 1997, VACCINE, V15, P248, DOI 10.1016/S0264-410X(96)00183-1
   Delsink AK, 2007, J S AFR VET ASSOC, V78, P25
   Fayrer-Hosken R, 2008, REPROD DOMEST ANIM, V43, P179, DOI 10.1111/j.1439-0531.2008.01159.x
   Fayrer-Hosken RA, 2000, NATURE, V407, P149, DOI 10.1038/35025136
   Frank KM, 2005, ZOO BIOL, V24, P349, DOI 10.1002/zoo.20060
   GOTO N, 1982, MICROBIOL IMMUNOL, V26, P1121, DOI 10.1111/j.1348-0421.1982.tb00261.x
   Gupta N, 2013, AM J REPROD IMMUNOL, V70, P139, DOI 10.1111/aji.12095
   Gupta Satish K., 2010, Reproductive Medicine and Biology, V9, P61, DOI 10.1007/s12522-009-0042-9
   HENNEKE DR, 1983, EQUINE VET J, V15, P371, DOI 10.1111/j.2042-3306.1983.tb01826.x
   Joone CJ, 2019, THERIOGENOLOGY, V126, P106, DOI 10.1016/j.theriogenology.2018.12.012
   Joone CJ, 2017, EQUINE VET J, V49, P189, DOI 10.1111/evj.12557
   Joone CJ, 2017, THERIOGENOLOGY, V89, P329, DOI 10.1016/j.theriogenology.2016.09.018
   Kirkpatrick JF, 2009, J REPROD IMMUNOL, V83, P151, DOI 10.1016/j.jri.2009.06.257
   Kirkpatrick JF, 2008, WILDLIFE RES, V35, P513, DOI 10.1071/WR07106
   KIRKPATRICK JF, 1990, WILDLIFE SOC B, V18, P326
   KIRKPATRICK JF, 1992, J REPROD FERTIL, V94, P437, DOI 10.1530/jrf.0.0940437
   Lee S, 2015, IMMUNE NETW, V15, P51, DOI 10.4110/in.2015.15.2.51
   Legastelois I, 2017, HUM VACC IMMUNOTHER, V13, P947, DOI 10.1080/21645515.2016.1260795
   LIU IKM, 1989, J REPROD FERTIL, V85, P19, DOI 10.1530/jrf.0.0850019
   Lloyd ML, 2010, J AUTOIMMUN, V35, P77, DOI 10.1016/j.jaut.2010.03.002
   Lou YH, 2000, J IMMUNOL, V164, P5251, DOI 10.4049/jimmunol.164.10.5251
   Lyda RO, 2005, J ZOO WILDLIFE MED, V36, P610, DOI 10.1638/04104.1
   MAHIBROWN CA, 1985, BIOL REPROD, V32, P761, DOI 10.1095/biolreprod32.4.761
   Mask TA, 2015, THERIOGENOLOGY, V84, P261, DOI 10.1016/j.theriogenology.2015.03.012
   McShea WJ, 1997, J WILDLIFE MANAGE, V61, P560, DOI 10.2307/3802615
   Nolan MB, 2018, THERIOGENOLOGY, V120, P111, DOI 10.1016/j.theriogenology.2018.07.044
   Olive C, 2012, EXPERT REV VACCINES, V11, P237, DOI [10.1586/ERV.11.189, 10.1586/erv.11.189]
   OWNBY CL, 1972, BIOL REPROD, V6, P310, DOI 10.1093/biolreprod/6.2.310
   Parker R, 2009, PROCEDIA VACCINOL, V1, P140, DOI 10.1016/j.provac.2009.07.026
   Paterson M, 1998, AM J REPROD IMMUNOL, V40, P198
   Prasad SV, 2000, CELLS TISSUES ORGANS, V166, P148, DOI 10.1159/000016730
   RHIM SH, 1992, J CLIN INVEST, V89, P28, DOI 10.1172/JCI115572
   Rutberg AT, 2008, WILDLIFE RES, V35, P494, DOI 10.1071/WR07128
   Sharma S, 2012, J PHARM BIOALLIED SC, V4, P258, DOI 10.4103/0975-7406.103231
   WASSARMAN PM, 1988, ANNU REV BIOCHEM, V57, P415, DOI 10.1146/annurev.bi.57.070188.002215
NR 46
TC 2
Z9 2
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 28
PY 2019
VL 37
IS 10
BP 1299
EP 1306
DI 10.1016/j.vaccine.2019.01.053
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HO1ZU
UT WOS:000460712000007
PM 30733089
DA 2020-05-12
ER

PT J
AU Dempsey, AF
   Pyrzanowski, J
   Campagna, EJ
   Lockhart, S
   O'Leary, ST
AF Dempsey, A. F.
   Pyrzanowski, J.
   Campagna, E. J.
   Lockhart, S.
   O'Leary, S. T.
TI Parent report of provider HPV vaccine communication strategies used
   during a randomized, controlled trial of a provider communication
   intervention
SO VACCINE
LA English
DT Article
DE Human papillomavirus; Adolescent; Vaccines; Provider recommendation;
   Health communication
ID RECOMMENDATION
AB Objective: To assess secondary, parent-reported outcomes from a randomized controlled trial (RCT) of a provider communication intervention aimed at improving adolescent HPV vaccination.
   Methods: A paper survey was provided to a random sample of 777 parents of adolescents from 8 control and 8 intervention clinics participating in the larger trial. Chi-square or Fisher's exact tests assessed associations between study arm and providers' HPV vaccine communication strategies, parents' vaccination attitudes and parent's HPV vaccine acceptance. Exploratory analyses assessed the association between receipt of 'very strong' or presumptive HPV vaccine recommendation (regardless of study arm) and parent's perceptions about their providers' vaccine communication, and parents' attitudes and acceptance of the HPV vaccine.
   Results: The response rate was 47%. There were no differences between study arms in parents' report of how their provider communicated about the HPV vaccine, parent vaccination attitudes, or uptake of the HPV vaccine. Receipt of a 'very strong' recommendation was associated with greater perceived urgency for getting vaccinated, greater trust in the information received from the provider, decreased vaccine hesitancy, and increased vaccine receipt. Receipt of a presumptive recommendation was associated with a lower likelihood of having concerns about the vaccine's safety, lower vaccine hesitancy, and an increased likelihood of vaccination. Neither recommendation strategy appeared to negatively impact parents' visit experience or trust in the information being provided. Similar results were found in sub-analyses of vaccine hesitant parents.
   Conclusions: Providing very strong, presumptive HPV vaccine recommendations is associated with improved parent vaccination attitudes and acceptance, and does not seem to have significant negative impacts, even among parents who are vaccine hesitant. Response bias in our sample could explain why there were no reported differences between study arms in parents' reports of how their adolescent's providers communicated about the HPV vaccine. (C) 2019 Elsevier Ltd. Ail rights reserved.
C1 [Dempsey, A. F.; Pyrzanowski, J.; Campagna, E. J.; Lockhart, S.; O'Leary, S. T.] Univ Colorado Denver, ACCORDS, Denver, CO 80204 USA.
RP Dempsey, AF (reprint author), 13199 East Montview Blvd,Suite 300, Aurora, CO 80045 USA.
EM Amanda.dempsey@ucdenver.edu
OI Lockhart, Steven/0000-0001-5528-1784
FU Centers for Disease Control and PreventionUnited States Department of
   Health & Human ServicesCenters for Disease Control & Prevention - USA
   [U01IP000801]
FX This work was funded by the Centers for Disease Control and Prevention
   (U01IP000801). The opinions expressed in this manuscript do not
   necessarily represent those of the funding agency.
CR Brewer NT, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-1764
   Darden PM, 2013, PEDIATRICS, V131, P645, DOI 10.1542/peds.2012-2384
   Dempsey A, 2016, PEDIAT ACAD SOC M 20
   Dempsey A, 2018, JAMA PEDIAT
   Dempsey AF, 2016, HUM VACC IMMUNOTHER, P1
   Dempsey AF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100193
   Gilkey M. B., 2015, CANC EPIDEMIOL BIOMA
   Gilkey MB, 2016, VACCINE, V34, P1187, DOI 10.1016/j.vaccine.2016.01.023
   Gilkey MB, 2016, ACAD PEDIATR, V16, P42, DOI 10.1016/j.acap.2015.06.007
   Gilkey MB, 2015, PREV MED, V77, P181, DOI 10.1016/j.ypmed.2015.05.024
   Lockhart S, 2018, ACAD PEDIAT
   Malo TL, 2018, IMPLEMENT SCI, V13, DOI 10.1186/s13012-018-0743-8
   Mohammed KA, 2016, J ADOLESCENT HEALTH, V59, P592, DOI 10.1016/j.jadohealth.2016.06.005
   Opel DJ, 2015, AM J PUBLIC HEALTH, V105, P1998, DOI 10.2105/AJPH.2014.302425
   Opel DJ, 2013, PEDIATRICS, V132, P1037, DOI 10.1542/peds.2013-2037
   Opel DJ, 2012, VACCINE, V30, P1269, DOI 10.1016/j.vaccine.2011.12.129
   Orenstein WA, 2015, PUBLIC HEALTH REP, V130, P10
   Reno JE, 2018, J HEALTH COMMUN, P1
   Walker TY, 2017, MMWR-MORBID MORTAL W, V66, P874, DOI 10.15585/mmwr.mm6633a2
NR 19
TC 3
Z9 3
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 28
PY 2019
VL 37
IS 10
BP 1307
EP 1312
DI 10.1016/j.vaccine.2019.01.051
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HO1ZU
UT WOS:000460712000008
PM 30733088
DA 2020-05-12
ER

PT J
AU Wildes, TJ
   Grippin, A
   Fasanya, H
   Dyson, KA
   Brantly, M
AF Wildes, Tyler J.
   Grippin, Adam
   Fasanya, Henrietta
   Dyson, Kyle A.
   Brantly, Mark
TI Effect of atorvastatin on humoral immune response to 23-valent
   pneumococcal polysaccharide vaccination in healthy volunteers: The
   StatVax randomized clinical trial
SO VACCINE
LA English
DT Article
DE Pneumococcal pneumonia; Atorvastatin; Vaccination; Healthy volunteers;
   Humoral immunity
ID STATIN THERAPY; UNITED-STATES; PNEUMONIA; ACTIVATION; ADULTS; CELLS;
   MORTALITY; DISEASE; RESISTANCE; EXPRESSION
AB Background: The immunomodulatory effects of statins on vaccine response remain uncertain. Therefore, the objective of this study was to determine if atorvastatin enhances pneumococcal-specific antibody titer following 23-valent pneumococcal polysaccharide vaccination.
   Methods: Double-blind, placebo-controlled, single-center randomized clinical trial entitled StatVax. Subjects were enrolled between June and July 2014 and followed up through September 2014. 33 healthy volunteers signed informed consent after volunteer sampling. 11 participants were excluded; 22 healthy volunteers without prior pneumococcal vaccination were enrolled and completed the study. Participants were randomized to receive a 28-day course of 40 mg atorvastatin (n = 12) or matching lactose placebo (n = 10). On day 7 of treatment, Pneumovax 23 was administered intramuscularly. The primary outcome was fold change in total pneumococcal-specific antibody titer determined by a ratio of post-vaccination titer over baseline titer. Secondary outcomes included serotype-specific pneumococcal antibody titer, seroconversion, complete blood counts (CBC), erythrocyte sedimentation rate (ESR), and serum cytokine analysis.
   Results: Of the 22 randomized patients (mean age, 23.86; SD, 4.121; 11 women [50%]), 22 completed the trial. Total anti-pneumococcal antibody titer in the atorvastatin group went from a baseline mean of 32.58 (SD, 15.96) to 147.7 (SD, 71.52) mu g/mL at 21 days post-vaccination while titer in the placebo group went from a mean of 30.81 (SD, 13.04) to 104.4 (SD, 45) mu g/mL. When comparing fold change between treatment groups, there was a significant increase in fold change of total anti-pneumococcal antibody titer in the atorvastatin group compared to the placebo group (2-way ANOVA, p = .0177).
   Conclusions: Atorvastatin enhances antigen-specific primary humoral immune response to a T cell-independent pneumonia vaccination. Pending confirmation by larger cohort studies of target populations, peri-vaccination conventional doses of statins can become a novel adjuvant for poorl-yimmunogenic polysaccharide-based vaccines. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Wildes, Tyler J.; Grippin, Adam; Fasanya, Henrietta; Dyson, Kyle A.; Brantly, Mark] Univ Florida, Coll Med, MD PhD Program, Gainesville, FL 32610 USA.
   [Wildes, Tyler J.; Grippin, Adam; Dyson, Kyle A.] Univ Florida, Preston A Wells Jr Ctr Brain Tumor Therapy, Brain Tumor Immunotherapy Program, McKnight Brain Inst,Lillian S Wells Dept Neurosur, POB 100265, Gainesville, FL 32610 USA.
   [Fasanya, Henrietta] Univ Florida, Hlth Canc Ctr, Dept Radiat Oncol, Gainesville, FL 32610 USA.
   [Brantly, Mark] Univ Florida, Div Pulm & Crit Care Med, Gainesville, FL 32610 USA.
RP Wildes, TJ (reprint author), Univ Florida, Preston A Wells Jr Ctr Brain Tumor Therapy, Brain Tumor Immunotherapy Program, McKnight Brain Inst,Lillian S Wells Dept Neurosur, POB 100265, Gainesville, FL 32610 USA.
EM twildes@ufl.edu
RI Brantly, Mark/AAH-2922-2020
OI Wildes, Tyler/0000-0001-8313-9144
FU NIH/NCATS Clinical and Translational Science AwardsUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [UL1TR001427]
FX This research was supported by the NIH/NCATS Clinical and Translational
   Science Awards to the University of Florida (UL1TR001427) and the
   University of Florida MD-PhD Program. The authors would like to thank
   the research nurses and staff at the University of Florida Clinical
   Research Center, as well as Ms. Teresa d'Angelo for her assistance and
   guidance in establishing this study. We also thank Ms. Joanna Nolte, who
   served as our head clinical trial nurse. Lastly, we thank Dr. Jon
   Shuster and the RDAP for developing the original statistical plan and
   generating the randomization.
CR Adedinsewo D, 2016, CLIN CARDIOL, V39, P491, DOI 10.1002/clc.22577
   Albert MA, 2001, JAMA-J AM MED ASSOC, V286, P64, DOI 10.1001/jama.286.1.64
   Ansell BJ, 2003, CIRCULATION, V108, P2751, DOI 10.1161/01.CIR.0000103624.14436.4B
   Arora M, 2006, P NATL ACAD SCI USA, V103, P7777, DOI 10.1073/pnas.0508492103
   Azor MH, 2011, CLIN EXP IMMUNOL, V166, P291, DOI 10.1111/j.1365-2249.2011.04473.x
   Chalmers JD, 2008, AM J MED, V121, P1002, DOI 10.1016/j.amjmed.2008.06.030
   Chou R, 2016, JAMA-J AM MED ASSOC, V316, P2008, DOI 10.1001/jama.2015.15629
   Chyu KY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092095
   Coward WR, 2006, J IMMUNOL, V176, P5284, DOI 10.4049/jimmunol.176.9.5284
   Fehr T, 2004, ATHEROSCLEROSIS, V175, P83, DOI 10.1016/j.atherosclerosis.2004.02.016
   Feikin DR, 2000, AM J PUBLIC HEALTH, V90, P223, DOI 10.2105/AJPH.90.2.223
   Griffin MR, 2013, NEW ENGL J MED, V369, P155, DOI 10.1056/NEJMoa1209165
   Jackson LA, 2003, NEW ENGL J MED, V348, P1747, DOI 10.1056/NEJMoa022678
   Kantor ED, 2015, JAMA-J AM MED ASSOC, V314, P1818, DOI 10.1001/jama.2015.13766
   Kim DK, 2018, ANN INTERN MED, V168, P210, DOI 10.7326/M17-3439
   Kolawole EM, 2016, J IMMUNOL, V196, P1461, DOI 10.4049/jimmunol.1501932
   Kuijk LM, 2008, MOL IMMUNOL, V45, P2158, DOI 10.1016/j.molimm.2007.12.008
   Kwak B, 2000, NAT MED, V6, P1399
   Lee PY, 2006, VACCINE, V24, P4035, DOI 10.1016/j.vaccine.2005.12.042
   Li SR, 2003, EUR J CLIN PHARMACOL, V59, P507, DOI 10.1007/s00228-003-0668-1
   Liang F, 2017, BIOMED RES INT, DOI 10.1155/2017/1279486
   Majlesi Y, 2003, J LEUKOCYTE BIOL, V73, P107, DOI 10.1189/jlb.0202075
   Manni G, 2018, J IMMUNOL, V200
   Maron DJ, 2000, CIRCULATION, V101, P207, DOI 10.1161/01.CIR.101.2.207
   Mausner-Fainberg K, 2008, ATHEROSCLEROSIS, V197, P829, DOI 10.1016/j.atherosclerosis.2007.07.031
   Min B, 2012, IMMUNOLOGY, V135, P192, DOI 10.1111/j.1365-2567.2011.03530.x
   Mitchell P, 2014, DIABETES, V63, P3569, DOI 10.2337/db14-1059
   O'Brien KL, 2009, LANCET, V374, P893, DOI 10.1016/S0140-6736(09)61204-6
   Orange JS, 2012, J ALLERGY CLIN IMMUN, V130, pS1, DOI 10.1016/j.jaci.2012.07.002
   Papazian L, 2013, JAMA-J AM MED ASSOC, V310, P1692, DOI 10.1001/jama.2013.280031
   Schlienger RG, 2007, PHARMACOTHERAPY, V27, P325, DOI 10.1592/phco.27.3.325
   Schramm R, 2007, IMMUNOLOGY, V120, P315, DOI 10.1111/j.1365-2567.2006.02505.x
   Thomsen RW, 2008, ARCH INTERN MED, V168, P2081, DOI 10.1001/archinte.168.19.2081
   Turco A, 2017, J IMMUNOL, V198
   Uddin S, 2006, VACCINE, V24, P5637, DOI 10.1016/j.vaccine.2006.03.088
   van de Garde EMW, 2006, THORAX, V61, P957, DOI 10.1136/thx.2006.062885
   Vandermeer ML, 2012, J INFECT DIS, V205, P13, DOI 10.1093/infdis/jir695
   Vinogradova Y, 2011, BRIT J GEN PRACT, V61, DOI 10.3399/bjgp11X606654
   Weinberger B, 2008, CLIN INFECT DIS, V46, P1078, DOI 10.1086/529197
   Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158
   Zeiser R, 2007, BLOOD, V110, P4588, DOI 10.1182/blood-2007-08-106005
NR 41
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 28
PY 2019
VL 37
IS 10
BP 1313
EP 1324
DI 10.1016/j.vaccine.2019.01.023
PG 12
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HO1ZU
UT WOS:000460712000009
PM 30686636
OA Other Gold, Green Accepted
DA 2020-05-12
ER

PT J
AU Xu, S
   Newcomer, SR
   Kulldorff, M
   Daley, MF
   Fireman, B
   Glanz, JM
AF Xu, Stanley
   Newcomer, Sophia R.
   Kulldorff, Martin
   Daley, Matthew F.
   Fireman, Bruce
   Glanz, Jason M.
TI Use of three summary measures of pediatric vaccination for studying the
   safety of the childhood immunization schedule
SO VACCINE
LA English
DT Article
DE Summary measures; Pediatric vaccination; Immunization safety;
   Collinearity; Variance inflation factor
ID POPULATION-BASED COHORT; UNITED-STATES; MULTICOLLINEARITY; DATALINK;
   EXPOSURE
AB Background: Summary measures such as number of vaccine antigens, number of vaccines, and vaccine aluminum exposure by the 2nd birth day are directly related to parents' concerns that children receive too many vaccines over a brief period. High correlation among summary measures could cause problems in regression models that examine their associations with outcomes.
   Objectives: To evaluate the performance of multiple regression models using summary measures as risk factors to simulated binary outcomes.
   Methods: We calculated summary measures for a cohort of 232,627 children born between 1/1/2003 and 9/31/2013. Correlation and variance inflation factors (VIFs) were calculated. We conducted simulations (1) to examine the extent to which an association can be detected using a summary measure other than the true risk factor; (2) to evaluate the performance of multiple regression models including true and redundant risk factors; (3) to evaluate the performance of multiple regression models when all three were risk factors; (4) to examine the performance of multiple regression models with incorrect relationship between risk factors and outcome.
   Results: These summary measures were highly correlated. VIFs were 7.14, 6.25 and 2.17 for number of vaccine antigens, number of vaccines, and vaccine aluminum exposure, respectively. In simulations, an association would be detected if a summary measure other than the true risk factor was used. The power to detect the association between the true risk factor and outcome significantly decreased if redundant risk factors were included. When all three were risk factors, multiple regression model was appropriate to detect the stronger risk factor. Correctly specifying the relationship between risk factors and the outcome was crucial.
   Conclusions: Multiple regression models can be used to examine the association between summary measures and outcome despite of high correlation among summary measures. It is important to correctly specify the relationship between risk factors and outcome. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Xu, Stanley; Daley, Matthew F.; Glanz, Jason M.] Kaiser Permanente Colorado, Inst Hlth Res, 2550 S Parker Rd,Suite 200, Aurora, CO 80014 USA.
   [Xu, Stanley; Glanz, Jason M.] Univ Colorado Denver, Sch Publ Hlth, Denver, CO USA.
   [Newcomer, Sophia R.] Univ Montana, Sch Publ & Community Hlth Sci, Missoula, MT 59812 USA.
   [Kulldorff, Martin] Brigham & Womens Hosp, Boston, MA 02115 USA.
   [Kulldorff, Martin] Harvard Med Sch, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02115 USA.
   [Daley, Matthew F.] Univ Colorado Denver, Sch Med, Dept Pediat, Denver, CO USA.
   [Fireman, Bruce] Kaiser Permanente Northern Calif, Div Res, Vaccine Study Ctr, Oakland, CA USA.
RP Xu, S (reprint author), Kaiser Permanente Colorado, Inst Hlth Res, 2550 S Parker Rd,Suite 200, Aurora, CO 80014 USA.
EM stan.xu@kp.org
OI Daley, Matthew/0000-0003-1309-4096
FU National Institutes of Health, National Institute of Allergy and
   Infectious DiseasesUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [NIH R01AI107721]; NIH/NCATS
   Colorado CTSA GrantUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS) [UL1 TR002535]
FX This study was funded by a grant from the National Institutes of Health,
   National Institute of Allergy and Infectious Diseases (NIH R01AI107721,
   "Methods for Safety Evaluation of Vaccine Schedules", Principal
   Investigator: Martin Kulldorff, PhD). Xu was also Supported by NIH/NCATS
   Colorado CTSA Grant Number UL1 TR002535.
CR Baggs J, 2011, PEDIATRICS, V127, pS45, DOI 10.1542/peds.2010-1722H
   FARRAR DE, 1967, REV ECON STAT, V49, P92, DOI 10.2307/1937887
   Glanz JM, 2018, JAMA-J AM MED ASSOC, V319, P906, DOI 10.1001/jama.2018.0708
   Glanz Jason M, 2016, Vaccine, V34 Suppl 1, pA1, DOI 10.1016/j.vaccine.2015.10.082
   Glanz JM, 2015, VACCINE, V33, P6736, DOI 10.1016/j.vaccine.2015.10.076
   Glanz JM, 2013, JAMA PEDIATR, V167, P274, DOI 10.1001/jamapediatrics.2013.502
   Hsieh FY, 1998, STAT MED, V17, P1623, DOI 10.1002/(SICI)1097-0258(19980730)17:14<1623::AID-SIM871>3.0.CO;2-S
   Institute of Medicine, 2013, CHILDH IMM SCHED SAF
   Kulldorff M., 2012, STUDY DESIGNS SAFETY
   KUMAR TK, 1975, REV ECON STAT, V57, P365, DOI 10.2307/1923925
   Kutner M.H., 2004, APPL LINEAR REGRESSI
   Luman ET, 2005, JAMA-J AM MED ASSOC, V293, P1204, DOI 10.1001/jama.293.10.1204
   McNeil MM, 2014, VACCINE, V32, P5390, DOI 10.1016/j.vaccine.2014.07.073
   Robinson CL, 2016, MMWR-MORBID MORTAL W, V65, P86, DOI 10.15585/mmwr.mm6504a4
   Simon TD, 2014, PEDIATRICS, V133, pE1647, DOI 10.1542/peds.2013-3875
NR 15
TC 1
Z9 1
U1 2
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 28
PY 2019
VL 37
IS 10
BP 1325
EP 1331
DI 10.1016/j.vaccine.2019.01.040
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HO1ZU
UT WOS:000460712000010
PM 30709727
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Shapiro, JR
   Hodgins, B
   Hendin, HE
   Patel, A
   Menassa, K
   Menassa, C
   Menassa, M
   Pereira, JA
   Ward, BJ
AF Shapiro, Janna R.
   Hodgins, Breanna
   Hendin, Hilary E.
   Patel, Aakash
   Menassa, Karim
   Menassa, Celine
   Menassa, Maurice
   Pereira, Jennifer A.
   Ward, Brian J.
TI Needle-free delivery of influenza vaccine using the Med-Jet (R) H4 is
   efficient and elicits the same humoral and cellular responses as
   standard IM injection: A randomized trial
SO VACCINE
LA English
DT Article
DE Jet injector; Needle-free immunization; Influenza vaccine; Humoral
   immunity; Cell-mediated immunity
ID CD4 T-CELLS; VIRUS; IMMUNOGENICITY; CHILDREN; SAFETY
AB Background: Needle-free vaccine delivery systems have many potential advantages including increased vaccine compliance and decreased risk of needlestick injuries and syringe reuse. The Med-Jet (R) H4 is a gas-powered, auto-disabling disposable syringe jet injector. The Med-Jet family of products are currently being used in dermatology, podiatry, pain management and veterinary practices. The objectives of this study were to assess patient attitudes, time-efficiency, safety and immunogenicity of the seasonal influenza vaccine delivered by Med-Jet compared to the traditional needle-and-syringe.
   Methods: A total of 80 patients were randomized 2:1:1 to receive a commercial trivalent vaccine by Med-Jet or needle injection from a single-dose or multi-dose vial. Patient attitudes were assessed pre-randomization and post-immunization. Safety data were collected for 21 days post-immunization. Efficiency of vaccine administration was measured through a time-and-motion study. Humoral and cellular responses were assessed on Days 0 and 21.
   Results: Overall, the participants readily accepted Med-Jet vaccination despite greater frequency of transient local reactions (eg: redness, swelling) immediately following immunization. Vaccine administration took slightly longer with the Med-Jet, but this difference decreased over time. Geometric mean hemag-glutination inhibition titers, seroconversion and seroprotection rates in the Med-Jet and needle groups were equivalent for all influenza strains in the vaccine. Microneutralization responses were also essentially identical. There were no significant differences between the groups in the frequency of functional CD4 + T cells, memory subset distribution or poly-functionality.
   Conclusions: These data suggest that the Med-Jet is an acceptable means of delivering seasonal influenza vaccine. The system was attractive to subjects, rapidly learned by skilled vaccine nurses and elicited both humoral and cellular responses that were indistinguishable from those elicited with needle injection. While other studies have assessed the humoral response to jet injection of influenza vaccine, to our knowledge, this study is the first to assess the cellular aspect of this response. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Shapiro, Janna R.; Hodgins, Breanna; Hendin, Hilary E.; Patel, Aakash; Ward, Brian J.] McGill Univ, Hlth Ctr, Res Inst, 1001 Decarie St, Montreal, PQ H4A 3J1, Canada.
   [Shapiro, Janna R.; Hendin, Hilary E.; Ward, Brian J.] McGill Univ, Dept Microbiol & Immunol, Montreal, PQ, Canada.
   [Hodgins, Breanna] McGill Univ, Dept Expt Med, Montreal, PQ, Canada.
   [Menassa, Karim; Menassa, Celine; Menassa, Maurice] MIT Canada, 1872 Beaulac St, St Laurent, PQ H4R 2E7, Canada.
   [Pereira, Jennifer A.] JRL Res & Consulting Inc, Toronto, ON, Canada.
   [Ward, Brian J.] McGill Univ, Vaccine Study Ctr, Hlth Ctr, Res Inst, Montreal, PQ, Canada.
RP Ward, BJ (reprint author), McGill Univ, Res Inst, Infect Dis & Immun Global Hlth Program, Hlth Ctr, 1001 Decarie Blvd,EM2-3219, Montreal, PQ H4A 3J1, Canada.
EM brian.ward@mcgill.ca
OI Ward, Brian/0000-0003-3251-958X
FU Mitacs Accelerate Canada [IT09303]; MEDTEQ-Innovation for Health [6-22];
   Medical International Technologies Canada Inc.
FX JS and BH received funding from Mitacs Accelerate Canada (reference
   number IT09303). The study was also supported by MEDTEQ-Innovation for
   Health (project #6-22, injecteur de vaccin, 2017) and Medical
   International Technologies Canada Inc.
CR Benohanian A, 2007, BRIT J DERMATOL, V156, P593, DOI 10.1111/j.1365-2133.2007.07691.x
   Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818
   Centers for Disease Control (CDC), 1986, MMWR Morb Mortal Wkly Rep, V35, P373
   He XS, 2006, J VIROL, V80, P11756, DOI 10.1128/JVI.01460-06
   Hendin HE, 2017, VACCINE, V35, P2592, DOI 10.1016/j.vaccine.2017.03.058
   Hodgins B, 2017, CLIN VACCINE IMMUNOL, V24, DOI 10.1128/CVI.00273-17
   Jackson LA, 2001, VACCINE, V19, P4703, DOI 10.1016/S0264-410X(01)00225-0
   Kannanganat S, 2007, J VIROL, V81, P8468, DOI 10.1128/JVI.00228-07
   Levine MM, 2003, NAT MED, V9, P99, DOI 10.1038/nm0103-99
   McAllister L, 2014, LANCET, V384, P674, DOI 10.1016/S0140-6736(14)60524-9
   McKinstry KK, 2012, J CLIN INVEST, V122, P2847, DOI 10.1172/JCI63689
   Nantel-Battista M, 2014, J CUTAN MED SURG, V18, P38, DOI 10.2310/7750.2013.13078
   Pillet S, 2016, CLIN IMMUNOL, V168, P72, DOI 10.1016/j.clim.2016.03.008
   Pruss-Ustun A, 2005, AM J IND MED, V48, P482, DOI 10.1002/ajim.20230
   Seidman PA, 1998, ANESTH ANALG, V87, P634, DOI 10.1097/00000539-199809000-00027
   Simon JK, 2011, VACCINE, V29, P9544, DOI 10.1016/j.vaccine.2011.09.097
   Taddio A, 2012, VACCINE, V30, P4807, DOI 10.1016/j.vaccine.2012.05.011
   Teijaro JR, 2010, J VIROL, V84, P9217, DOI 10.1128/JVI.01069-10
   Voelker R, 1999, JAMA-J AM MED ASSOC, V281, P1879, DOI 10.1001/jama.281.20.1879
   Weniger BG, 2013, 61 ALTERNATIVE VACCI, P1200
   Wilkinson TM, 2012, NAT MED, V18, P274, DOI 10.1038/nm.2612
   ZACHOVAL R, 1988, LANCET, V1, P189
   Zens KD, 2015, MEMORY CD4 T CELLS I, P399, DOI 10.1007/82_2014_401
NR 23
TC 1
Z9 1
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 28
PY 2019
VL 37
IS 10
BP 1332
EP 1339
DI 10.1016/j.vaccine.2019.01.039
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HO1ZU
UT WOS:000460712000011
PM 30709725
DA 2020-05-12
ER

PT J
AU Montesino, R
   Gutierrez, N
   Camacho, F
   Farnos, O
   Andrades, S
   Gonzalez, A
   Acosta, J
   Cortez-San Martin, M
   Sanchez, O
   Ruiz, A
   Toledo, JR
AF Montesino, R.
   Gutierrez, N.
   Camacho, F.
   Farnos, O.
   Andrades, S.
   Gonzalez, A.
   Acosta, J.
   Cortez-San Martin, M.
   Sanchez, O.
   Ruiz, A.
   Toledo, J. R.
TI Multi-antigenic recombinant subunit vaccine against Lawsonia
   intracellularis: The etiological agent of porcine proliferative
   enteropathy
SO VACCINE
LA English
DT Article
DE Lawsonia intracellularis; Recombinant vaccine; Proliferative
   enteropathy; Pig immune response
ID EARLY FULL PROTECTION; B-CELL EPITOPES; HUMORAL IMMUNITY;
   NEURAL-NETWORKS; IN-VITRO; PROTEIN; PREDICTION; PIGS; EXPRESSION;
   REDUCTION
AB Proliferative enteropathy, caused by Lawsonia intracellularis, represents a threat for swine industry. Current vaccines are effective but difficult to obtain and scaled up, because of demanding bacterial culture conditions. In this work, a subunit vaccine candidate against L intracellularis was developed and its efficacy was evaluated in vivo, alone or co-formulated with pig recombinant IFN-alpha.
   The vaccine formulation contains three chimeric antigens: two outer membrane proteins and a secreted one, which were engineered by adding T epitopes using bioinformatics tools. After simultaneously expressing the three antigens in E. coli, its immunogenicity was tested in mice and pigs. Antigens co-formulated with porcine IFN-alpha were also assayed in the last species. Immune response was assessed by ELISA and qPCR, and histopathological studies of intestinal epithelial tissue were performed after challenge.
   Mice and pigs showed an increased IgG response against chimeric antigens. Particularly, there were significant differences in the antibody response when porcine IFN-alpha was co-administrated with L intracellularis antigens. Besides, mRNAs from il12 and cd4 marker were detected during the first week after immunization of pigs, suggesting a Th1-type cellular immune response. The significant enhancement of oast gene expression indicates the effect exerted by porcine IFN-alpha. Post-mortem histopathological analysis post-challenge revealed damage only into epithelial cells of the gastrointestinal tract from animals of the negative control group. Injuries were related to atrophy of the intestinal villi, where a decrease of globet cells and a greater migration of lymphocytes were observed.
   Overall, our results demonstrated that the vaccine candidate elicited significant humoral and cellular immune responses. Besides, histopathological analysis suggested that vaccinated animals were protected against experimental L. intracellularis infection. This research constitutes a step forward to the generation of the first recombinant chimeric vaccine against L. intracellularis, representing a faster, easier and cost effective approach to counteract the porcine proliferative enteropathy. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Montesino, R.; Gutierrez, N.; Gonzalez, A.; Acosta, J.; Toledo, J. R.] Univ Concepcion, Sch Biol Sci, Pathophysiol Dept, Biotechnol & Biopharmaceut Lab, Victor Lamas 1290,POB 160C, Concepcion, Chile.
   [Camacho, F.; Sanchez, O.] Univ Concepcion, Sch Biol Sci, Pharmacol Dept, Victor Lamas 1290,POB 160C, Concepcion, Chile.
   [Farnos, O.] McGill Univ, Fac Engn, Dept Bioengn, 141 Ave President Kennedy, Montreal, PQ, Canada.
   [Andrades, S.; Ruiz, A.] Univ Concepcion, Sch Vet Sci, Pathol & Prevent Med Dept, Ave Vicente Mendez 595, Chillan, Chile.
   [Cortez-San Martin, M.] Univ Santiago Chile USACH, Fac Quim & Biol, Dept Biol, Mol Virol & Pathogen Control Lab, Alameda 3363,Correo 40,Casilla 33, Santiago 9170022, Chile.
RP Toledo, JR (reprint author), Univ Concepcion, Sch Biol Sci, Pathophysiol Dept, Biotechnol & Biopharmaceut Lab, Victor Lamas 1290,POB 160C, Concepcion, Chile.
EM rmontesino@udec.cl; jotoledo@udec.cl
OI Camacho, Frank/0000-0003-2247-7160; Sanchez,
   Oliberto/0000-0002-9744-8674
FU Chilean Government through Fondef Grant [ID14i10335]; Chilean Government
   through INNBIO Grant [VET007F]
FX The authors greatly appreciate the financial support provided by the
   Chilean Government through Fondef Grant: ID14i10335 and INNBIO Grant:
   VET007F.
CR Alexandersen S, 1996, ACTA VET SCAND, P89
   Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389
   Andreatta M, 2016, BIOINFORMATICS, V32, P511, DOI 10.1093/bioinformatics/btv639
   Biester HE, 1931, AM J PATHOL, V7, P175
   Christen M, 2005, J COMPUT CHEM, V26, P1719, DOI 10.1002/jcc.20303
   Dong BH, 1997, J BIOL CHEM, V272, P22236, DOI 10.1074/jbc.272.35.22236
   Duhamel GE, 1998, VET PATHOL, V35, P300, DOI 10.1177/030098589803500410
   GOGOLEWSKI RP, 1991, AUST VET J, V68, P406, DOI 10.1111/j.1751-0813.1991.tb03114.x
   Guedes RMC, 2002, J VET DIAGN INVEST, V14, P528, DOI 10.1177/104063870201400618
   Guzman E, 2008, ENFERM INFEC MICR CL, V26, P88, DOI 10.1157/13115544
   Hamza T, 2010, INT J MOL SCI, V11, P789, DOI 10.3390/ijms11030789
   Jacobson M, 2010, VET J, V184, P264, DOI 10.1016/j.tvjl.2009.05.010
   Jensen HM, 2006, ANIM BIOTECHNOL, V17, P189, DOI 10.1080/10495390600957142
   Kim DE, 2004, NUCLEIC ACIDS RES, V32, pW526, DOI 10.1093/nar/gkh468
   Kroll Jeremy J., 2005, Animal Health Research Reviews, V6, P173, DOI 10.1079/AHR2005109
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Lawson GHK, 2000, J COMP PATHOL, V122, P77, DOI 10.1053/jcpa.1999.0347
   Le Bon A, 2001, IMMUNITY, V14, P461, DOI 10.1016/S1074-7613(01)00126-1
   Li QM, 2011, INT J MOL SCI, V12, P1727, DOI 10.3390/ijms12031727
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Luna LG, 1968, MANUAL HISTOLOGIC ST
   MacIntyre N, 2003, VET PATHOL, V40, P421, DOI 10.1354/vp.40-4-421
   McCluskey J, 2002, INFECT IMMUN, V70, P2899, DOI 10.1128/IAI.70.6.2899-2907.2002
   McOrist S, 2005, VET J, V170, P8, DOI 10.1016/j.tvjl.2004.04.008
   MCORIST S, 1989, VET PATHOL, V26, P260, DOI 10.1177/030098588902600311
   Nielsen M, 2003, PROTEIN SCI, V12, P1007, DOI 10.1110/ps.0239403
   Palmer I, 2004, CURR PROT PROTEIN SC
   Riber U, 2015, VACCINE, V33, P156, DOI 10.1016/j.vaccine.2014.10.084
   Roerink F, 2018, VACCINE, V36, P1500, DOI 10.1016/j.vaccine.2017.12.049
   Saha S, 2004, LECT NOTES COMPUT SC, V3239, P197
   Saha S, 2006, PROTEINS, V65, P40, DOI 10.1002/prot.21078
   Sait M, 2013, GENOME ANNOUNC, P1
   Sanchez O, 2014, CLIN VACCINE IMMUNOL, V21, P1628, DOI 10.1128/CVI.00416-14
   Smith DGE, 2001, VET MICROBIOL, V82, P331, DOI 10.1016/S0378-1135(01)00397-2
   Suarez M, 2017, VACCINE, V35, P4437, DOI 10.1016/j.vaccine.2017.05.028
   Toledo JR, 2010, VACCINE, V28, P7907, DOI 10.1016/j.vaccine.2010.09.073
   Vannucci FA, 2012, J CLIN MICROBIOL, V50, P1070, DOI 10.1128/JCM.05976-11
   Vincent AL, 2017, VET MICROBIOL, V206, P35, DOI 10.1016/j.vetmic.2016.11.026
   Watson E, 2014, VET MICROBIOL, V174, P448, DOI 10.1016/j.vetmic.2014.10.002
   Watson E, 2011, CLIN VACCINE IMMUNOL, V18, P1282, DOI 10.1128/CVI.05073-11
   Wattanaphansak S, 2009, VET MICROBIOL, V134, P305, DOI 10.1016/j.vetmic.2008.08.007
   Williams NM, 1996, J VET DIAGN INVEST, V8, P254, DOI 10.1177/104063879600800220
   Wuersch K, 2006, J VET MED A, V53, P17, DOI 10.1111/j.1439-0442.2006.00776.x
   Yu HR, 2017, SCI REP-UK, V7, DOI 10.1038/srep41212
NR 44
TC 1
Z9 1
U1 1
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 28
PY 2019
VL 37
IS 10
BP 1340
EP 1349
DI 10.1016/j.vaccine.2019.01.029
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HO1ZU
UT WOS:000460712000012
PM 30711318
DA 2020-05-12
ER

PT J
AU Parker, AR
   Park, MA
   Harding, S
   Abraham, RS
AF Parker, Antony R.
   Park, Miguel A.
   Harding, Stephen
   Abraham, Roshini S.
TI The total IgM, IgA and IgG antibody responses to pneumococcal
   polysaccharide vaccination (Pneumovax (R) 23) in a healthy adult
   population and patients diagnosed with primary immunodeficiencies
SO VACCINE
LA English
DT Article
DE Pneumovax; Pneumococcal; PPV; Normal; IgA; 1gM; IgG
ID INFLUENZAE TYPE-B; CAPSULAR POLYSACCHARIDE; CHILDREN; AGE; PROTECTION;
   ASSAY
AB Background: Interpretation of the responses to the pneumococcal polysaccharide vaccine (Pneumovax (R) 23, PPV) has proven challenging. In addition, there are few studies documenting the longevity of these responses.
   Methods: The age-specific PPV IgM, IgA, IgG and IgG2 concentrations were determined pre, 4-6 weeks and 6 years post-vaccination in the serum of Prevnar (R)-naive adults using VaccZyme (TM) pneumococcal capsular polysaccharide ELISAs.
   Results: The median pre-vaccination concentrations were; PPV IgM 53 U/mL (5-95% CI: 16-169 U/mL), IgA 23 U/mL (6-103 U/mL), IgG 41 mg/L (10-184 U/mL) and IgG2 18 mg/L (3-95 U/mL). 4-6 weeks post-vaccination there was a median 6-fold (5-95% CI: 2-24) increase in PPV IgM (median 315 U/mL (5-95% CI: 60-1133 U/mL), 18-fold (4-74) increase in IgA (369 U/mL (78-1802 U/mL)), 9-fold (2-19) increase in IgG (375 mg/L (77-1238 mg/L)) and 8-fold (1-20) increase in IgG2 (141 mg/L (25-573 mg/ L)). This was significant for all isotypes in all age ranges (p < 0.0001). Six years post-vaccination median PPV concentrations were; IgM 54 U/mL (17-128), IgA 85 U/mL (19-279), IgG 148 mg/L (30-997) and IgG2 57 mg/L (9-437). The median concentrations for all ages 6 years post-vaccination were significantly elevated compared to the pre-vaccination titres for PPV IgA, IgG and IgG2 isotypes only. The PPV IgM and IgA responses were influenced by age. At 6 years post vaccination, in individuals with normal PPV IgG, 34 individuals had PPV IgM and/or IgA concentrations below the lower limit of the healthy adult ranges. We also used the healthy adult reference ranges developed in this study to assess a cohort of primary immunodeficiency (PID) patients.
   Conclusion: These ranges will help to provide a framework for assessment and definition of normal response to PPV, which will facilitate clinical interpretation of a deficient polysaccharide response in those suspected of antibody deficiency. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Parker, Antony R.; Harding, Stephen] Binding Site Grp Ltd, 8 Calthorpe Rd, Birmingham B15 1QT, W Midlands, England.
   [Park, Miguel A.] Mayo Clin, Dept Internal Med, Div Allerg Dis, Rochester, MN USA.
   [Abraham, Roshini S.] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA.
RP Harding, S (reprint author), Binding Site Grp Ltd, 8 Calthorpe Rd, Birmingham B15 1QT, W Midlands, England.
EM Stephen.Harding@Bindingsite.co.uk
CR Ademokun A, 2011, AGING CELL, V10, P922, DOI 10.1111/j.1474-9726.2011.00732.x
   Biagini RE, 2003, CLIN DIAGN LAB IMMUN, V10, P744, DOI 10.1128/CDLI.10.5.744-750.2003
   Bonilla FA, 2005, ANN ALLERG ASTHMA IM, V94, pS1, DOI 10.1016/S1081-1206(10)61142-8
   Cavaliere FM, 2013, J CLIN IMMUNOL, V33, P838, DOI 10.1007/s10875-012-9856-z
   Chua I, 2011, J ALLERGY CLIN IMMUN, V127, P1410, DOI 10.1016/j.jaci.2011.01.035
   Dziadzio M., 2017, J MOL IMMUNOL, V2, P108
   Echeverria de Carlos Ainara, 2017, J Immunoassay Immunochem, V38, P505, DOI 10.1080/15321819.2017.1337641
   Hanitsch L, 2014, J CLIN IMMUNOL, V34, pS407
   HAZLEWOOD M, 1993, CLIN EXP IMMUNOL, V93, P157
   Janssen WJM, 2015, VACCINE, V33, P6320, DOI 10.1016/j.vaccine.2015.09.041
   Janssen WJM, 2014, J CLIN IMMUNOL, V34, P3, DOI 10.1007/s10875-013-9925-y
   Marchese RD, 2006, CLIN VACCINE IMMUNOL, V13, P905, DOI 10.1128/CVI.00014-06
   Moschese V, 2016, J ALLERGY CLIN IMMUN, V137, P617, DOI 10.1016/j.jaci.2015.06.014
   Orange JS, 2012, J ALLERGY CLIN IMMUN, V130, pS1, DOI 10.1016/j.jaci.2012.07.002
   Paris K, 2007, ANN ALLERG ASTHMA IM, V99, P462, DOI 10.1016/S1081-1206(10)60572-8
   Park S, 2011, INFECT IMMUN, V79, P314, DOI 10.1128/IAI.00768-10
   Parker AR, 2016, PRACTICAL LAB MED, P1
   Pickering JW, 2007, AM J CLIN PATHOL, V128, P23, DOI 10.1309/781K5W6QH7JH2TMA
   Pickering JW, 2002, AM J CLIN PATHOL, V117, P589
   Plotkin SA, 2012, CLIN INFECT DIS, V54, P1615, DOI 10.1093/cid/cis238
   Rose MA, 2013, MED MICROBIOL IMMUN, V202, P285, DOI 10.1007/s00430-013-0292-3
   Schauer U, 2003, CLIN DIAGN LAB IMMUN, V10, P202, DOI 10.1128/CDLI.10.2.202-207.2003
   Schutz K, 2013, J CLIN IMMUNOL, V33, P288, DOI 10.1007/s10875-012-9792-y
   Smith PG, 2010, PROCEDIA VACCINOL, V2, P134, DOI 10.1016/j.provac.2010.07.005
   Sorensen RU, 1998, J ALLERGY CLIN IMMUN, V102, P215, DOI 10.1016/S0091-6749(98)70089-2
   Westerink MAJ, 2012, AGING DIS, V3, P51
NR 26
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 28
PY 2019
VL 37
IS 10
BP 1350
EP 1355
DI 10.1016/j.vaccine.2019.01.035
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HO1ZU
UT WOS:000460712000013
PM 30737041
OA Other Gold
DA 2020-05-12
ER

PT J
AU Ghorbani, A
   Ngunjiri, JM
   Xia, M
   Elaish, M
   Jang, H
   Mahesh, KC
   Abundo, MC
   Jiang, X
   Lee, CW
AF Ghorbani, Amir
   Ngunjiri, John M.
   Xia, Ming
   Elaish, Mohamed
   Jang, Hyesun
   Mahesh, K. C.
   Abundo, Michael C.
   Jiang, Xi
   Lee, Chang-Won
TI Heterosubtypic protection against avian influenza virus by live
   attenuated and chimeric norovirus P-particle-M2e vaccines in chickens
SO VACCINE
LA English
DT Article
DE Influenza viruses; Live attenuated influenza vaccine; Chimeric norovirus
   P particle containing M2e; Heterosubtypic protection
ID DEPENDENT CELLULAR CYTOTOXICITY; A H5N1 VIRUS; PHYLOGENETIC ANALYSIS;
   IMMUNE-RESPONSES; H9N2 INFLUENZA; FUSION PROTEIN; T-CELLS; ANTIBODY;
   VACCINATION; EFFICACY
AB Avian influenza in poultry continues to be a great concern worldwide, and the currently licensed inactivated influenza vaccines are not effective against the novel strains of influenza virus that continue to emerge in the field. This warrants the development of more broadly protective influenza vaccines or vaccination regimens. Live attenuated influenza vaccines (LAIVs) and subunit vaccines derived from viral peptides, such as the highly conserved ectodomain of influenza virus matrix protein 2 (M2e), can offer a more broadly reactive immune response. In chickens, we previously showed that a chimeric norovirus P particle containing M2e (M2eP) could provide partial but broad immunity, when administered as a standalone vaccine, and also enhanced the protective efficacy of inactivated vaccine when used in a combination regimen. We also demonstrated that a naturally-selected NS1-truncated H7N3 LAIV (pc4-LAIV) was highly efficacious against antigenically distant heterologous H7N2 low pathogenicity avian influenza virus challenge, especially when used as the priming vaccine in a prime-boost vaccination regimen. In this study, we investigated the cross-subtype protective efficacy of pc4-LAIV in conjunction with M2eP using single vaccination, combined treatment, and prime-boost approaches. Chickens vaccinated with pc4-LAIV showed significant reduction of tracheal shedding of a low pathogenicity H5N2 challenge virus. This cross-subtype protective efficacy was further enhanced, during the initial stages of challenge virus replication, in chickens that received a vaccination regimen consisting of priming with pc4-LAIV at 1 day of age and boosting with M2eP. Further, H5N2-specific serum IgG and pc4-LAIV-specific hemagglutination-inhibition antibody titers were enhanced in LAIV-primed and M2eP boostvaccinated chickens. Taken together, our data point to the need of further investigation into the benefits of combined and prime-boost vaccination schemes utilizing LAIV and epitope-based vaccines, to develop more broadly protective vaccination regimens. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Ghorbani, Amir; Ngunjiri, John M.; Elaish, Mohamed; Jang, Hyesun; Mahesh, K. C.; Abundo, Michael C.; Lee, Chang-Won] Ohio State Univ, Ohio Agr Res & Dev Ctr, Food Anim Hlth Res Program, Wooster, OH 44691 USA.
   [Ghorbani, Amir; Jang, Hyesun; Mahesh, K. C.; Abundo, Michael C.; Lee, Chang-Won] Ohio State Univ, Coll Vet Med, Dept Vet Prevent Med, Columbus, OH 43210 USA.
   [Xia, Ming; Jiang, Xi] Cincinnati Childrens Hosp Med Ctr, Div Infect Dis, Cincinnati, OH 45229 USA.
   [Elaish, Mohamed] Cairo Univ, Fac Vet Med, Poultry Dis Dept, Cairo, Egypt.
RP Lee, CW (reprint author), 1680 Madison Ave, Wooster, OH 44691 USA.
EM lee.2854@osu.edu
OI Ghorbani, Amir/0000-0001-8511-1727
FU Agriculture and Food Research Initiative Competitive Grant from the USDA
   National Institute of Food and Agriculture [2013-67015-20476]
FX The authors would like to acknowledge the professional and enthusiastic
   support from our animal care team, Dr. Juliette Hanson, Megan Strother,
   Rachelle Root (deceased), Sara Tallmadge, Ronna Wood, and Dennis
   Hartzler. We also thank Kara Taylor for editing the manuscript. This
   project was supported by Agriculture and Food Research Initiative
   Competitive Grant no. 2013-67015-20476 from the USDA National Institute
   of Food and Agriculture.
CR Ashkenazi S, 2006, PEDIATR INFECT DIS J, V25, P870, DOI 10.1097/01.inf.0000237829.66310.85
   Beyer WEP, 2002, VACCINE, V20, P1340, DOI 10.1016/S0264-410X(01)00471-6
   Brandtzaeg P., 2002, DEV BIOL, V115, P39
   Burton DR, 2002, NAT REV IMMUNOL, V2, P706, DOI 10.1038/nri891
   Chen SJ, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01086
   CLEMENTS ML, 1986, J CLIN MICROBIOL, V23, P66, DOI 10.1128/JCM.23.1.66-72.1986
   Dabaghian M, 2014, VET MICROBIOL, V174, P116, DOI 10.1016/j.vetmic.2014.09.009
   Ebrahimi SM, 2012, VIROLOGY, V430, P63, DOI 10.1016/j.virol.2012.04.015
   Elaish M, 2015, VACCINE, V33, P4901, DOI 10.1016/j.vaccine.2015.07.049
   Elaish M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171174
   Eliasson DG, 2018, MUCOSAL IMMUNOL, V11, P273, DOI 10.1038/mi.2017.14
   Fellah J. S., 2014, AVIAN IMMUNOLOGY, P45
   Delgado MF, 2009, NAT MED, V15, P34, DOI 10.1038/nm.1894
   Ghorbani A, 2016, VET ARHIV, V86, P95
   GORSE GJ, 1995, J INFECT DIS, V172, P1, DOI 10.1093/infdis/172.1.1
   Hoft DF, 2017, CLIN VACCINE IMMUNOL, V24, DOI [10.1128/CVI.00414-16, 10.1128/cvi.00414-16]
   Hoft DF, 2011, J INFECT DIS, V204, P845, DOI 10.1093/infdis/jir436
   Jang H, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195285
   Jang H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156603
   Jegaskanda S, 2016, J INFECT DIS, V214, P945, DOI 10.1093/infdis/jiw262
   Jegaskanda S, 2013, J IMMUNOL, V190, P1837, DOI 10.4049/jimmunol.1201574
   Krammer F, 2015, NAT REV DRUG DISCOV, V14, P167, DOI 10.1038/nrd4529
   Layton SL, 2009, POULTRY SCI, V88, P2244, DOI 10.3382/ps.2009-00251
   Lee CW, 2004, J VIROL, V78, P8372, DOI [10.1128/JVI.78.15.8372-8381.2004, 10.1128/jvi.78.15.8372-8381.2004]
   Lee CW, 2004, J VIROL METHODS, V119, P151, DOI 10.1016/j.jviromet.2004.03.014
   Lee YN, 2016, J IMMUNOL, V196, P2637, DOI 10.4049/jimmunol.1501637
   Marcus PI, 2010, J VIROL, V84, P10974, DOI 10.1128/JVI.00502-10
   MCMICHAEL AJ, 1983, NEW ENGL J MED, V309, P13, DOI 10.1056/NEJM198307073090103
   Mohn KGI, 2018, HUM VACC IMMUNOTHER, V14, P571, DOI 10.1080/21645515.2017.1377376
   Moosakhani F, 2010, AVIAN DIS, V54, P870, DOI 10.1637/9103-101309-Reg.1
   Neirynck S, 1999, NAT MED, V5, P1157
   Nguyen HH, 1999, VIROLOGY, V254, P50, DOI 10.1006/viro.1998.9521
   Pedersen Janice C., 2008, V436, P53, DOI 10.1007/978-1-59745-279-3_8
   Pica N, 2012, J VIROL, V86, P10293, DOI 10.1128/JVI.01131-12
   Pillai SPS, 2010, ARCH VIROL, V155, P1439, DOI 10.1007/s00705-010-0727-8
   Raj GD, 1996, VET IMMUNOL IMMUNOP, V53, P147, DOI 10.1016/0165-2427(95)05545-2
   Rowe T, 1999, J CLIN MICROBIOL, V37, P937, DOI 10.1128/JCM.37.4.937-943.1999
   Straight TM, 2008, VIROL J, V5, DOI 10.1186/1743-422X-5-44
   Swayne D. E., 2016, Animal influenza, P74
   Swayne D. E., 2016, Animal influenza, P378
   Tumpey TM, 2005, J CLIN MICROBIOL, V43, P676, DOI 10.1128/JCM.43.2.676-683.2005
   Tumpey TM, 2001, J VIROL, V75, P5141, DOI 10.1128/JVI.75.11.5141-5150.2001
   Wang L, 2008, VACCINE, V26, P3580, DOI 10.1016/j.vaccine.2008.05.001
   Xia M, 2011, VACCINE, V29, P7670, DOI 10.1016/j.vaccine.2011.07.139
NR 44
TC 2
Z9 2
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 28
PY 2019
VL 37
IS 10
BP 1356
EP 1364
DI 10.1016/j.vaccine.2019.01.037
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HO1ZU
UT WOS:000460712000014
PM 30691981
DA 2020-05-12
ER

PT J
AU Polkowska, A
   Skoczynska, A
   Paradowska-Stankiewicz, I
   Stefanoff, P
   Hryniewicz, W
   Kuch, A
   Lyytikainen, O
   Nuorti, JP
AF Polkowska, Aleksandra
   Skoczynska, Anna
   Paradowska-Stankiewicz, Iwona
   Stefanoff, Pawel
   Hryniewicz, Waleria
   Kuch, Alicja
   Lyytikainen, Outi
   Nuorti, J. Pekka
TI Pneumococcal meningitis before the introduction of 10-valent
   pneumococcal conjugate vaccine into the National Childhood Immunization
   Program in Poland
SO VACCINE
LA English
DT Article
DE Pneumococcal meningitis; Epidemiology; Pneumococcal conjugate
   vaccine,PCV10; Streptococcus pneumoniae
ID STREPTOCOCCUS-PNEUMONIAE; ANTIMICROBIAL RESISTANCE;
   BACTERIAL-MENINGITIS; CLINICAL-OUTCOMES; DISEASE; EPIDEMIOLOGY;
   SEROTYPES; CHILDREN; TRENDS; SURVEILLANCE
AB Background: Poland introduced the 10-valent conjugate pneumococcal vaccine (PCV10) into the childhood immunization program in January 2017. During previous decades, considerable changes had occurred in the surveillance system for invasive pneumococcal disease. Therefore, to provide baseline data on pneumococcal diseases before PCV10 introduction, we evaluated the epidemiology of pneumococcal meningitis (PM), the only syndrome monitored consistently since 1970.
   Methods: Based on laboratory-confirmed cases reported during 2005-2015, we calculated the reported rates, serotypes distribution and antimicrobial resistance of pneumococcal meningitis isolates. Data from the mandatory national surveillance system was linked with data on cerebrospinal fluid isolates submitted to the National Reference Centre for Bacterial Meningitis. We used negative binomial regression with Newey West method to test for trend in rates of pneumococcal meningitis notified during 2005-2015 and Chi-squared test to assess changes in the serotype distribution from 2008-2011 to 2012-2015.
   Results: From 2005 to 2015, the overall reported incidence of PM increased from 0.21 to 0.47 cases per 100,000 population, average yearly increase of 7% (rate ratio 1.07; 95% CI 1.06-1.08). The increase was primarily due to annual increase of 3% (1.02-1.05) among 15-49 years of age, 12% (95% CI: 1.10-1.13) among 50-64 years of age, 18% (95% CI: 1.16-1.19) among persons 65-74 years of age and 9% (95% CI 1.07-1.10) among persons >= 75 years of age. In children <5 years of age, serotypes included in PCV10 and PCV13 accounted for 75% and 80% of reported isolates, respectively. From 2008-2011 to 2012-2015, the proportion of PM cases caused by PCV10 serotypes decreased from 52% to 41% (p < 0.01). Overall, 28% of isolates were resistant to penicillin and 13% were non-susceptible to cefotaxime.
   Conclusions: The introduction of PCV10 into national immunization program may have considerable impact on disease burden, especially on number of cases caused by isolates non-susceptible to antimicrobials. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Polkowska, Aleksandra; Nuorti, J. Pekka] Univ Tampere, Fac Social Sci, Hlth Sci Unit, Tampere, Finland.
   [Skoczynska, Anna; Hryniewicz, Waleria; Kuch, Alicja] Natl Med Inst, NRCBM, Dept Epidemiol & Clin Microbiol, Warsaw, Poland.
   [Paradowska-Stankiewicz, Iwona; Stefanoff, Pawel] NIPH NIH, Dept Epidemiol Infect Dis & Surveillance, Warsaw, Poland.
   [Lyytikainen, Outi; Nuorti, J. Pekka] Natl Inst Hlth & Welf THL, Dept Hlth Secur, Helsinki, Finland.
RP Nuorti, JP (reprint author), Univ Tampere, Fac Social Sc, Epidemiol Hlth Sci Unit, FI-33014 Tampere, Finland.
EM Pekka.Nuorti@tuni.fl
OI Skoczynska, Anna/0000-0002-2247-830X
FU School of Health Sciences, University of Tampere; Ministry of Science
   and Higher Education (Mikrobank 2 Programme) in Poland; Ministry of
   Health in Poland
FX This study was supported by the School of Health Sciences, University of
   Tampere. The study was partially supported by the Ministry of Health
   within the framework of the National Programme of Antibiotic Protection
   (NPOA) and by the Ministry of Science and Higher Education (Mikrobank 2
   Programme) in Poland.
CR Alari A, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0755-7
   Albrecht P, 2011, REKOMENDACJE POSTEPO
   [Anonymous], 2014, ANT RES SURV EUR ANN, DOI [10.2900/39777, DOI 10.2900/39777]
   Bijlsma MW, 2016, LANCET INFECT DIS, V16, P339, DOI 10.1016/S1473-3099(15)00430-2
   Brouwer MC, 2010, CLIN MICROBIOL REV, V23, P467, DOI 10.1128/CMR.00070-09
   Castelblanco RL, 2014, LANCET INFECT DIS, V14, P813, DOI 10.1016/S1473-3099(14)70805-9
   Czarkowski MP, 2016, VACCINATIONS POLAND
   Dagan R, 2009, CLIN MICROBIOL INFEC, V15, P16, DOI 10.1111/j.1469-0691.2009.02726.x
   Edmond K, 2010, LANCET INFECT DIS, V10, P317, DOI 10.1016/S1473-3099(10)70048-7
   Engelen-Lee JY, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0297-4
   European Centre for Disease Prevention and Control, 2016, ANN REP EUR ANT RES
   European Committee on Antimicrobial Susceptibility Testing, 2015, BREAKP TABL INT MICS
   Gouveia EL, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-323
   Grabenstein JD, 2014, VACCINE, V32, P2399, DOI 10.1016/j.vaccine.2014.02.096
   Grzesiowski P, 2008, EUR J CLIN MICROBIOL, V27, P883, DOI 10.1007/s10096-008-0512-8
   Hanquet G, 2010, VACCINE, V28, P3920, DOI 10.1016/j.vaccine.2010.03.069
   Harboe ZB, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000081
   Hausdorff WP, 2005, LANCET INFECT DIS, V5, P83, DOI 10.1016/S1473-3099(05)01280-6
   Hausdorff WP, 2000, CLIN INFECT DIS, V30, P122, DOI 10.1086/313609
   Hausdorff WP, 2000, CLIN INFECT DIS, V30, P100, DOI 10.1086/313608
   Hausdorff WP, 2001, LANCET, V357, P950, DOI 10.1016/S0140-6736(00)04222-7
   Htar MTT, 2013, ADV THER, V30, P748, DOI 10.1007/s12325-013-0051-2
   Imohl M, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-0787-1
   Isturiz R, 2017, EXPERT REV VACCINES, V16, P1007, DOI 10.1080/14760584.2017.1362339
   Kim SH, 2012, ANTIMICROB AGENTS CH, V56, P1418, DOI 10.1128/AAC.05658-11
   Klemets P, 2008, SCAND J INFECT DIS, V40, P621, DOI 10.1080/00365540801938931
   Klemets P, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-96
   Levy C, 2014, PEDIATR INFECT DIS J, V33, P1216, DOI 10.1097/INF.0000000000000451
   Linares J, 2010, CLIN MICROBIOL INFEC, V16, P402, DOI 10.1111/j.1469-0691.2010.03182.x
   Miller E, 2000, ACTA PAEDIATR, V89, P11, DOI 10.1080/080352500300051477
   Mook-Kanamori BB, 2011, CLIN MICROBIOL REV, V24, P557, DOI 10.1128/CMR.00008-11
   O'Brien KL, 2009, LANCET, V374, P893, DOI 10.1016/S0140-6736(09)61204-6
   Polkowska A, 2017, BMJ OPEN, DOI [10.1136/brnjopen-2016-015080, DOI 10.1136/BRNJOPEN-2016-015080]
   Reinert RR, 2009, CLIN MICROBIOL INFEC, V15, P7, DOI 10.1111/j.1469-0691.2009.02724.x
   Rendi-Wagner P, 2004, J ANTIMICROB CHEMOTH, V53, P826, DOI 10.1093/jac/dkh211
   Richter SS, 2014, ANTIMICROB AGENTS CH, V58, P6484, DOI 10.1128/AAC.03344-14
   Schrag SJ, 2001, RESISTANT PNEUMOCOCC
   Sihvonen R, 2017, EUR J CLIN MICROBIOL, V36, P2109, DOI 10.1007/s10096-017-3033-5
   SIMPSON EH, 1949, NATURE, V163, P688, DOI 10.1038/163688a0
   Skoczynska A, 2015, EUR J CLIN MICROBIOL, V34, P779, DOI 10.1007/s10096-014-2283-8
   Skoczynska A, 2011, VACCINE, V29, P2199, DOI 10.1016/j.vaccine.2010.09.100
   Steens A, 2013, VACCINE, V31, P6232, DOI 10.1016/j.vaccine.2013.10.032
   Tsai CJ, 2008, CLIN INFECT DIS, V46, P1664, DOI 10.1086/587897
   Uber Neufeld F., 1902, Z HYG INFEKT KR, V40, P54
   van Selm S, 2003, INFECT IMMUN, V71, P6192, DOI 10.1128/IAI.71.11.6192-6198.2003
   Wagenvoort GHJ, 2016, VACCINE, V34, P1077, DOI 10.1016/j.vaccine.2015.12.066
NR 46
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 28
PY 2019
VL 37
IS 10
BP 1365
EP 1373
DI 10.1016/j.vaccine.2018.12.028
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA HO1ZU
UT WOS:000460712000015
PM 30638798
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Halilu, S
   Iliyasu, G
   Hamza, M
   Chippaux, JP
   Kuznik, A
   Habib, AG
AF Halilu, Sadiq
   Iliyasu, Garba
   Hamza, Muhammad
   Chippaux, Jean-Philippe
   Kuznik, Andreas
   Habib, Abdulrazaq G.
TI Snakebite burden in Sub-Saharan Africa: estimates from 41 countries
SO TOXICON
LA English
DT Article
DE Burden; Snakebite; Sub-Saharan Africa; Disability adjusted life years
ID POSTTRAUMATIC-STRESS-DISORDER
AB There is no reliable estimate of burden of snakebite-envenoming (SBE) in Sub-Saharan Africa (SSA). We derived from a meta-analysis the burden of SBE related deaths, amputations and Post-Traumatic Stress Disorder (PTSD) in 41 countries in SSA. The annual burden was estimated at 1.03 million DALYs (95% Confidence Interval: 0.80-1.28 million DALYs). This is similar to or higher than the burden of many Neglected Tropical Diseases (NTDs) and the finding advocates for a commensurate resources allocation towards control of SBE.
C1 [Halilu, Sadiq; Iliyasu, Garba; Hamza, Muhammad; Habib, Abdulrazaq G.] Bayero Univ, Aminu Kano Teaching Hosp, Infect & Trop Dis Unit, Kano, Nigeria.
   [Chippaux, Jean-Philippe] Inst Res Dev, Paris, France.
   [Kuznik, Andreas] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA.
RP Habib, AG (reprint author), Bayero Univ, Aminu Kano Teaching Hosp, Infect & Trop Dis Unit, Kano, Nigeria.
EM abdulrazaq_habib@yahoo.co.uk
CR Chippaux JP, 2011, TOXICON, V57, P586, DOI 10.1016/j.toxicon.2010.12.022
   Gampini S, 2016, J VENOM ANIM TOXINS, V22, DOI [10.1186/s40409-016-0066-7, 10.1186/S40409-016-0066-7]
   Gutierrez JM, 2017, NAT REV DIS PRIMERS, V3, DOI [10.1038/nrdp.2017.79, 10.1038/nrdp.2017.63]
   Habib AG, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004088
   Habib AG, 2013, TOXICON, V69, P82, DOI 10.1016/j.toxicon.2013.01.002
   Habib Zaharaddeen G., 2018, POSTTRAUMATIC UNPUB
   Hampson K., 2015, PLOS NEGLECT TROP D, V9, P4, DOI DOI 10.1371/J0URNAL.PNTD.0003709.E0003709
   Hay SI, 2017, LANCET, V390, P1260, DOI 10.1016/S0140-6736(17)32130-X
   Hotez PJ, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000412
   Husky MM, 2015, J TRAUMA STRESS, V28, P275, DOI 10.1002/jts.22020
   KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012
   Khosrojerdi H., 2013, ASIA PAC J MED TOXIC, V2, P140
   WHO, 2017, GLOB HLTH OBS COUNTR
   Wijesinghe CA, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003989
   Williams SS, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001255
   World Health Organization, 2013, WHOHISHSIGHE20134
   World Health Organization (WHO), GLOB BURD DIS 2004 U
   World Health Organization (WHO), 2016, GLOBAL HEALTH ESTIMA
NR 18
TC 2
Z9 2
U1 1
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD MAR 1
PY 2019
VL 159
BP 1
EP 4
DI 10.1016/j.toxicon.2018.12.002
PG 4
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HM3II
UT WOS:000459366600001
PM 30594637
DA 2020-05-12
ER

PT J
AU de Roodt, AR
   Lanari, LC
   Laskowicz, RD
   de Oliveira, VC
   Litwina, S
   Calderon, L
   Damin, CF
   Dokmetjian, JC
   Dolab, JA
   Lago, NR
   Lertora, E
AF de Roodt, Adolfo Rafael
   Lanari, Laura Cecilia
   Laskowicz, Rodrigo Daniel
   de Oliveira, Vanessa Costa
   Litwina, Silvana
   Calderon, Leandro
   Damin, Carlos Fabian
   Dokmetjian, Jose Christian
   Dolab, Jorge Adrian
   Lago, Nestor Ruben
   Lertora, Emiliano
TI Study on the obtaining of Tityus trivittatus venom in Argentina
SO TOXICON
LA English
DT Article
DE Tityus trivittatus; Venom; Milking; Telson homogenate; Toxicity;
   Antivenom
ID BUENOS-AIRES CITY; NEUTRALIZING CAPACITY; ANTIVENOM; SCORPIONS;
   ENVENOMATION; REACTIVITY; TOXICITY; CHILDREN; PEPTIDE
AB Envenomation by scorpions of the genus Tityus is an important public health problem in Argentina, involving near 8000 stings and 2 deaths each year. Treatment for envenomation is the use of specific antivenom and intensive hospital care. Antivenom is produced by the Ministry of Health and freely distributed throughout the country. For antivenom production it is necessary to collect scorpion venom, which is a difficult task because although scorpions can be found in Argentina, they are less abundant than in warmer latitudes. For this reason venom collection constitutes a bottleneck for antivenom production. Although in Argentina several species of Tityus can be found, most of the accidents are caused by Tityus trivittatus, and the venom of this scorpion has historically been the venom used for antivenom production. We analyzed retrospectively 26 pools of telson homogenates (6964 telsons) and 37 pools of milked venom obtained by electrical stimulation (equivalent to 6841 milkings). Lethal potencies of samples from different provinces were very similar, although venom from scorpions of Buenos Aires city showed the lowest potency. The venom obtained by milking (median LD50 12.3 mu g), provided batches containing LD(50)s more potent when compared with the venom obtained from telson homogenates (p < 0.0001). Many batches of telson homogenates (30%) showed lower potencies than acceptable for antivenom production and control. In addition to the study of the venom yield, the records of immunization of horses, the potency of the batches and the protein content of each batch of anti-scorpion antivenom produced were analyzed, comparing those produced using milked venom with those using telson homogenates as immunogens. Batches produced using milked venom required a shorter period of immunization (p < 0.0001), rendered higher neutralizing titers (p 0.0350) and possessed lower protein content (p 0.0092). Results clearly showed that the milking of scorpions is a more efficient tool to obtain venom for antivenom production in comparison to the use of telson homogenates.
C1 [de Roodt, Adolfo Rafael; Lanari, Laura Cecilia; Laskowicz, Rodrigo Daniel; Litwina, Silvana; Calderon, Leandro; Damin, Carlos Fabian; Dokmetjian, Jose Christian; Dolab, Jorge Adrian; Lertora, Emiliano] Adm Nacl Lab & Inst Salud Dr Carlos G Malbran, Minist Salud, Inst Nacl Prod Biol, Buenos Aires, DF, Argentina.
   [de Roodt, Adolfo Rafael; de Oliveira, Vanessa Costa; Lago, Nestor Ruben] Univ Buenos Aires, Fac Med, Ctr Patol Expt & Aplicada, Lab Toxinopatol, Buenos Aires, DF, Argentina.
   [de Roodt, Adolfo Rafael; de Oliveira, Vanessa Costa] Univ Buenos Aires, Fac Med, Primera Catedra Toxicol, Buenos Aires, DF, Argentina.
   [de Roodt, Adolfo Rafael] INPB ANLIS Dr Carlos G Malbran, Av Velez Sarsfield 563, RA-1281 CABA, Argentina.
RP de Roodt, AR (reprint author), INPB ANLIS Dr Carlos G Malbran, Av Velez Sarsfield 563, RA-1281 CABA, Argentina.
EM aderoodt@gmail.com
OI de Roodt, Adolfo/0000-0003-2607-8060
CR ACOSTA LE, 2005, [No title captured], P21
   AMARAL CFS, 1994, TOXICON, V32, P211, DOI 10.1016/0041-0101(94)90110-4
   Blanco G, 2016, ARCH ARGENT PEDIATR, V114, P77, DOI 10.5546/aap.2016.77
   Bochner R, 2013, J VENOM ANIM TOXINS, V19, DOI 10.1186/1678-9199-19-29
   Bordon C. F. K, 2015, SCORPION VENOM, P412
   Boyer LV, 2009, NEW ENGL J MED, V360, P2090, DOI 10.1056/NEJMoa0808455
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Candido D. M., 2004, J. Venom. Anim. Toxins incl. Trop. Dis, V10, P86, DOI 10.1590/S1678-91992004000100007
   Carmo AO, 2015, TOXICON, V97, P64, DOI 10.1016/j.toxicon.2015.02.007
   Casas N., 2013, REV ARGENT ZOONOSIS, V12, P22
   Casasola A, 2009, TOXICON, V53, P602, DOI 10.1016/j.toxicon.2009.01.011
   Chippaux JP, 2008, ACTA TROP, V107, P71, DOI 10.1016/j.actatropica.2008.05.021
   Chippaux J P, 2006, Med Trop (Mars), V66, P215
   CICARELLI R M B, 1983, Memorias do Instituto Butantan (Sao Paulo), V47-48, P45
   Coronas FIV, 2015, PEPTIDES, V68, P11, DOI 10.1016/j.peptides.2014.05.002
   da Silva WD, 2011, TOXICON, V57, P1109, DOI 10.1016/j.toxicon.2011.03.022
   de Roodt AR, 2014, CLIN TOXICOL, V52, P594, DOI 10.3109/15563650.2014.925561
   de Roodt A. R, 2009, THESIS, P228
   de Roodt A. R, 2007, B ASOCIACION TOXICOL, V21, P18
   de Roodt AR, 2012, TOXICON, V60, P183, DOI 10.1016/j.toxicon.2012.04.172
   de Roodt AR, 2010, TOXICON, V55, P307, DOI 10.1016/j.toxicon.2009.08.014
   de Roodt AR, 2009, TOXICON, V53, P1, DOI 10.1016/j.toxicon.2008.10.003
   de Roodt Adolfo Rafael, 2014, Acta toxicol. argent., V22, P5
   de Roodt AR, 2003, TOXICON, V41, P971, DOI 10.1016/S0041-0101(03)00066-7
   de Roodt AR, 2001, J NAT TOXINS, V10, P99
   De Roodt R, 2017, REV ECUATORIANA CIEN, P1
   DELORI P, 1981, TOXICON, V19, P393, DOI 10.1016/0041-0101(81)90044-1
   FREIREMAIA L, 1994, TOXICON, V32, P1009, DOI 10.1016/0041-0101(94)90382-4
   Garcia C, 2003, TOXICON, V41, P417, DOI 10.1016/S0041-0101(02)00337-9
   Instituto Geografico Militar, LIM SUP PUNT EXTR
   Kalapothakis E, 1997, TOXICON, V35, P1523, DOI 10.1016/S0041-0101(97)00017-2
   Khattabi A, 2011, T ROY SOC TROP MED H, V105, P364, DOI 10.1016/j.trstmh.2011.03.007
   Krifi M. N, 1999, J VENOM ANIM TOXINS, V5, P2
   MARTIN MF, 1986, TOXICON, V24, P1131, DOI 10.1016/0041-0101(86)90139-X
   Md Saude, 2001, MAN DIAGN TRAT AC AN
   Ministerio de Salud, 2011, GUIA PREV DIAGN TRAT
   Ministerio de Salud, 2011, GUIA CTR ANT REP ARG
   NISHIKAWA AK, 1994, TOXICON, V32, P989, DOI 10.1016/0041-0101(94)90377-8
   Ojanguren-Affilastro A. A., 2005, REV IBERICA ARACNOLO, V11, P75
   Oukkache N, 2013, J VENOM ANIM TOXINS, V19, DOI 10.1186/1678-9199-19-5
   Ozkan O, 2006, J VENOM ANIM TOXINS, V12, P297, DOI 10.1590/S1678-91992006000200011
   Ozkan O, 2008, TOXICON, V52, P375, DOI 10.1016/j.toxicon.2008.06.019
   Ozkan O, 2017, IRAN J PHARM RES, V16, P653
   Pucca MB, 2015, TOXICON, V108, P272, DOI 10.1016/j.toxicon.2015.10.015
   de Roodt AR, 2017, TOXICON, V130, P63, DOI 10.1016/j.toxicon.2017.02.029
   de Roodt AR, 2015, ACTA BIOQUIM CLIN L, V49, P55
   de Roodt AR, 2014, TOXINS, V6, P1434, DOI 10.3390/toxins6041434
   Rezende NA, 1998, TOXICON, V36, P1507, DOI 10.1016/S0041-0101(98)00141-X
   Rolim Rosa R, 1980, MEM I BUTANTAN SAO P, V44, P253
   THEAKSTON RDG, 1983, B WORLD HEALTH ORGAN, V61, P949
   Whittemore Jr. F. W, 1961, STUDIES SCORPION ANT, V1
   WHO, 2016, GUID PROD CONTR REG
   WHO, 2010, GUID PROD CONTR REG
   WHO, 1981, PROGR CHAR VEN STAND
   Yacioob R, 2016, PAK J ZOOL, V48, P265
NR 55
TC 0
Z9 1
U1 1
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD MAR 1
PY 2019
VL 159
BP 5
EP 13
DI 10.1016/j.toxicon.2018.12.004
PG 9
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HM3II
UT WOS:000459366600002
PM 30611824
DA 2020-05-12
ER

PT J
AU Qiao, Q
   Djediat, C
   Huet, H
   Duval, C
   Le Manach, S
   Bernard, C
   Edery, M
   Marie, B
AF Qiao, Qin
   Djediat, Chakib
   Huet, Helene
   Duval, Charlotte
   Le Manach, Severine
   Bernard, Cecile
   Edery, Marc
   Marie, Benjamin
TI Subcellular localization of microcystin in the liver and the gonads of
   medaka fish acutely exposed to microcystin-LR
SO TOXICON
LA English
DT Article
DE Microcystin; Reproductive cell; Immunogold electron microscopy; OATP;
   Reproductive toxicity
ID ZEBRAFISH DANIO-RERIO; IMMUNOHISTOCHEMICAL LOCALIZATION;
   PLANKTOTHRIX-AGARDHII; CELLULAR-RESPONSES; ORYZIAS-LATIPES; IN-VIVO;
   MECHANISMS; APOPTOSIS; TOXICITY; DAMAGE
AB Among the diverse toxic components produced by cyanobacteria, microcystins (MCs) are one of the most toxic and notorious cyanotoxin groups. Besides their potent hepatotoxicity, MCs have been revealed to induce potential reproductive toxicity in various animal studies. However, little is still known regarding the distribution of MCs in the reproductive organ, which could directly affect reproductive cells. In order to respond to this question, an acute study was conducted in adult medaka fish (model animal) gavaged with 10 mu g.g(-1) body weight of pure MC-LR. The histological and immunohistochemical examinations reveal an intense distribution of MC-LR within hepatocytes along with a severe liver lesion in the toxin-treated female and male fish. Besides being accumulated in the hepatocytes, MC-LR was also found in the connective tissue of the ovary and the testis, as well as in oocytes and degenerative spermatocyte-like structures but not spermatocytes. Both liver and gonad play important roles in the reproductive process of oviparous vertebrates. This observation constitutes the first observation of the presence of MC-LR in reproductive cells (female, oocytes) of a vertebrate model with in vivo study. Our results, which provide intracellular localization of MC-LR in the gonad, advance our understanding of the potential reproductive toxicity of MC-LR in fish.
C1 [Qiao, Qin; Djediat, Chakib; Huet, Helene; Duval, Charlotte; Le Manach, Severine; Bernard, Cecile; Edery, Marc; Marie, Benjamin] Museum Natl Hist & Nat, CNRS, Mol Commun & Adaptat Microorganismes, UMR 7245 MNHN, CP 39,12 Rue Buffon, F-75005 Paris, France.
   [Huet, Helene] Univ Paris Est, Ecole Natl Vet Alfort, BioPole Alfort, F-94700 Maisons Alfort, France.
RP Marie, B (reprint author), Museum Natl Hist & Nat, CNRS, Mol Commun & Adaptat Microorganismes, UMR 7245 MNHN, CP 39,12 Rue Buffon, F-75005 Paris, France.
EM bmarie@mnhn.fr
RI Marie, Benjamin/A-3930-2012
OI Marie, Benjamin/0000-0001-9880-5541; Bernard, Cecile/0000-0001-7032-3989
FU CNRS Defi ENVIROMICS "Toxcyfish" project; ATM "Cycles biologiques:
   evolution et adaptation" of the MNHN
FX This work was supported by grants from the CNRS Defi ENVIROMICS
   "Toxcyfish" project and from the ATM "Cycles biologiques: evolution et
   adaptation" of the MNHN to Dr. Benjamin Marie. Qin Qiao Ph.D. is founded
   by the China Scholarship Council. We thank the Amagen platform for
   providing medaka fish Cab strain, the microscopy platform of ENVA and
   MNHN for the histology and immunolocalization techniques. We also thank
   Marie-Claude Mercier for its administrative support.
CR Acuna S, 2012, TOXICON, V60, P1191, DOI 10.1016/j.toxicon.2012.08.004
   Campos A, 2010, INT J MOL SCI, V11, P268, DOI 10.3390/ijms11010268
   Chen J, 2009, SCI TOTAL ENVIRON, V407, P3317, DOI 10.1016/j.scitotenv.2009.02.005
   Chen YB, 2018, CELL MOL LIFE SCI, V75, P1117, DOI 10.1007/s00018-017-2687-6
   Dietrich D. R., 2009, HIST ANAL ENDOCRINE, P88
   Djediat C, 2011, TOXICON, V58, P112, DOI 10.1016/j.toxicon.2011.05.011
   Djediat C, 2010, TOXICON, V55, P531, DOI 10.1016/j.toxicon.2009.10.005
   Fischer A, 2010, TOXICOL APPL PHARM, V245, P9, DOI 10.1016/j.taap.2010.02.006
   Fischer WJ, 2005, TOXICOL APPL PHARM, V203, P257, DOI 10.1016/j.taap.2004.08.012
   Fischer WJ, 2000, TOXICOL APPL PHARM, V164, P73, DOI 10.1006/taap.1999.8861
   Fischer WJ, 2000, TOXICOL SCI, V54, P365, DOI 10.1093/toxsci/54.2.365
   Gurbuz F, 2009, SCI TOTAL ENVIRON, V407, P4038, DOI 10.1016/j.scitotenv.2009.02.039
   Guzman RE, 2002, VET PATHOL, V39, P17, DOI 10.1354/vp.39-1-17
   Hagenbuch B, 2013, MOL ASPECTS MED, V34, P396, DOI 10.1016/j.mam.2012.10.009
   Ho R. H., 2018, COMPREHENSIVE TOXICO, P574, DOI [10.1016/B978-0-12-801238-3.95625-3, DOI 10.1016/B978-0-12-801238-3.95625-3]
   Hou J, 2015, CHEMOSPHERE, V120, P729, DOI 10.1016/j.chemosphere.2014.09.079
   Lance E, 2010, AQUAT TOXICOL, V98, P211, DOI 10.1016/j.aquatox.2010.02.014
   Li Y, 2008, REPROD TOXICOL, V26, P239, DOI 10.1016/j.reprotox.2008.09.004
   MACKINTOSH C, 1990, FEBS LETT, V264, P187, DOI 10.1016/0014-5793(90)80245-E
   Marie B, 2012, AQUAT TOXICOL, V114, P39, DOI 10.1016/j.aquatox.2012.02.008
   Mattos LJ, 2014, TOXICON, V83, P43, DOI 10.1016/j.toxicon.2014.02.015
   Meier-Abt F, 2007, TOXICOL APPL PHARM, V218, P274, DOI 10.1016/j.taap.2006.11.015
   Mezhoud K, 2008, TOXICON, V51, P1431, DOI 10.1016/j.toxicon.2008.03.017
   Papadimitriou T, 2012, ECOTOXICOLOGY, V21, P1155, DOI 10.1007/s10646-012-0870-y
   Puddick J, 2014, MAR DRUGS, V12, P5372, DOI 10.3390/md12115372
   Qiao Q, 2016, ENVIRON POLLUT, V219, P119, DOI 10.1016/j.envpol.2016.10.029
   Qiao Q, 2016, SCI REP-UK, V6, DOI 10.1038/srep32459
   Qiao Q, 2013, AQUAT TOXICOL, V142, P272, DOI 10.1016/j.aquatox.2013.07.002
   SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cb.10.110194.000415
   Singo A, 2017, TOXICON, V134, P50, DOI 10.1016/j.toxicon.2017.05.017
   Spoof L, 2017, HDB CYANOBACTERIAL M, P526, DOI DOI 10.1002/9781119068761.APP3
   Steiner K, 2016, ARCH TOXICOL, V90, P1129, DOI 10.1007/s00204-015-1544-3
   Steiner K, 2014, TOXICOL APPL PHARM, V280, P534, DOI 10.1016/j.taap.2014.08.031
   Su YJ, 2016, AQUAT TOXICOL, V175, P205, DOI 10.1016/j.aquatox.2016.03.018
   Testai E., 2016, EFSA SUPPORT PUBL, V13, P1, DOI [10.2903/sp.efsa.2016.EN-998, DOI 10.2903/SP.EFSA.2016.EN-998]
   Pham TL, 2018, J ENVIRON MANAGE, V213, P520, DOI 10.1016/j.jenvman.2018.01.077
   Trinchet I, 2013, TOXICON, V71, P121, DOI 10.1016/j.toxicon.2013.05.019
   Trinchet I, 2011, REPROD TOXICOL, V32, P329, DOI 10.1016/j.reprotox.2011.07.006
   Wan HT, 2013, TRENDS MOL MED, V19, P396, DOI 10.1016/j.molmed.2013.03.006
   Wang LH, 2013, ECOTOXICOLOGY, V22, P1555, DOI 10.1007/s10646-013-1141-2
   Wang XT, 2013, FOOD CHEM TOXICOL, V60, P309, DOI 10.1016/j.fct.2013.07.039
   Yan RY, 2016, SCI REP-UK, V6, DOI 10.1038/srep20001
   Yoshida T, 1998, TOXICOL PATHOL, V26, P411, DOI 10.1177/019262339802600316
   Yoshida T., 2001, J TOXICOL PATHOL, V14, P205, DOI DOI 10.1293/T0X.14.205
   Zeck A, 2001, ANAL CHIM ACTA, V441, P1, DOI 10.1016/S0003-2670(01)01092-3
   Zhang HJ, 2013, AQUAT TOXICOL, V140, P11, DOI 10.1016/j.aquatox.2013.05.009
   Zhao SJ, 2012, PROTEOMICS, V12, P300, DOI 10.1002/pmic.201100214
   Zhou M, 2015, TOXICON, V101, P92, DOI 10.1016/j.toxicon.2015.05.005
   Zhou Y, 2013, J TOXICOL SCI, V38, P661
   Zhou Y, 2012, TOXICOL LETT, V212, P48, DOI 10.1016/j.toxlet.2012.05.001
NR 50
TC 2
Z9 2
U1 11
U2 32
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD MAR 1
PY 2019
VL 159
BP 14
EP 21
DI 10.1016/j.toxicon.2018.12.006
PG 8
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HM3II
UT WOS:000459366600003
PM 30629997
DA 2020-05-12
ER

PT J
AU Almeida, MC
   Santos, IC
   Paschoalin, T
   Travassos, LR
   Mauch, C
   Zigrino, P
   Pesquero, JB
   Pesquero, JL
   Higuchi, DA
AF Almeida, Meire C.
   Santos, Ivan C.
   Paschoalin, Thaysa
   Travassos, Luiz R.
   Mauch, Cornelia
   Zigrino, Paola
   Pesquero, Joao B.
   Pesquero, Jorge L.
   Higuchi, Debora A.
TI Leucurogin and melanoma therapy
SO TOXICON
LA English
DT Article
DE Disintegrins; Melanoma; Metastasis; Recombinant protein; Leucurogin
ID SNAKE-VENOM METALLOPROTEINASE; 3-DIMENSIONAL COLLAGEN LATTICES;
   BOTHROPS-JARARACA VENOM; CELL-MIGRATION; RECOMBINANT DISINTEGRIN;
   INTEGRIN ALPHA-2-BETA-1; MATRIX REORGANIZATION; PLATELET-AGGREGATION;
   MONOCLONAL-ANTIBODY; MALIGNANT-MELANOMA
AB Leucurogin is an ECD disintegrin-like protein, cloned from Bothrops leucurus venom gland. This new protein, encompassing the disintegrin region of a PIII metalloproteinase, is produced by recombinant technology and its biological and functional activity was partially characterized in this study. Biological activity was characterized in vitro using human fibroblasts. Functional activity of leucurogin was analysed in vitro and in vivo with murine B16F10 Nex-2 and human melanoma BLM cells. The results show that leucurogin inhibits cellular processes dependent on collagen type I. In a competition assay with collagen, leucurogin inhibits, in a dose-dependent manner, the adhesion of fibroblast to collagen. At 10 mu M leucurogin reduces adhesion (40%) and migration (70%) of hFb and inhibits migration (32%) and proliferation (65%) of BLM cells. At 2.5 mu M leucurogin inhibits 80% cell proliferation of B16F10 Nex-2 melanoma cells. At 4.8 mu M leucurogin inhibits, in vitro, the vascular structures formation by endothelial cells by 66%. Leucurogin, injected intraperitoneally, i.p. (5 mu g/animal, two-month old C57/B16 male mice) on alternate days for 15 days, inhibits lung metastasis of Bl6F10 Nex-2 cells by 70-75%. In the treatment of human melanoma, grafted intradermally in the nude mice flank, leucurogin (7.5 mu g/ kg in alternate days during 17 days) inhibits tumor growth by more than 40%. Leucurogin can be considered a promising agent for melanoma treatment.
C1 [Almeida, Meire C.] Proteobras Biotechnol Dev Ltd, Campinas, SP, Brazil.
   [Santos, Ivan C.] Univ Fed Sao Joao del Rei, Sao Joao Del Rei, MG, Brazil.
   [Paschoalin, Thaysa; Travassos, Luiz R.; Pesquero, Joao B.] Univ Fed Sao Paulo, Sao Paulo, Brazil.
   [Mauch, Cornelia; Zigrino, Paola] Univ Cologne, Dept Dermatol, Cologne, Germany.
   [Pesquero, Jorge L.] Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil.
   [Higuchi, Debora A.] Fed Inst Educ Sci & Technol Sao Paulo, Suzano, SP, Brazil.
RP Santos, IC (reprint author), Univ Fed Sao Joao del Rei, Dept Biosyst Engn, Pc Dom Helvecio 74, BR-36301160 Sao Joao Del Rei, MG, Brazil.
EM ivan@ufsj.edu.br
RI Travassos, Luiz/V-2467-2019
OI Zigrino, Paola/0000-0002-7470-0064; Almeida, Meire/0000-0001-7110-3953
FU DAAD - Deutscher Akademischer AustauschdienstDeutscher Akademischer
   Austausch Dienst (DAAD); CAPES - Coordination for the Improvement of
   Higher EducationCAPES; CNPq - National Council of Technological and
   Scientific DevelopmentNational Council for Scientific and Technological
   Development (CNPq); FAPESP - Sao Paulo Research FoundationFundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
FX This work was supported by DAAD - Deutscher Akademischer
   Austauschdienst, CAPES - Coordination for the Improvement of Higher
   Education, CNPq - National Council of Technological and Scientific
   Development, and FAPESP - Sao Paulo Research Foundation.
CR Abety AN, 2012, J INVEST DERMATOL, V132, P2451, DOI 10.1038/jid.2012.153
   ACS, 2013, CANC FACTS FIG 2013
   Arribas J, 2006, CANCER METAST REV, V25, P57, DOI 10.1007/s10555-006-7889-6
   Biselli-Chicote PM, 2012, J CANCER RES CLIN, V138, P363, DOI 10.1007/s00432-011-1073-2
   Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115
   BOYLE P, 2008, WORLD CANC REPORT
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Calvete J. J., 2012, TOXICON, V62, P40
   Calvete JJ, 2005, TOXICON, V45, P1063, DOI 10.1016/j.toxicon.2005.02.024
   CHAN BMC, 1991, SCIENCE, V251, P1600, DOI 10.1126/science.2011740
   Chavaroche A, 2014, ANAL BIOCHEM, V449, P68, DOI 10.1016/j.ab.2013.12.018
   Cominetti M, 2004, J BIOL CHEM, V279, P18247, DOI 10.1074/jbc.M311771200
   Cooper CR, 2003, CANCER, V97, P739, DOI 10.1002/cncr.11181
   Cross MJ, 2001, TRENDS PHARMACOL SCI, V22, P201, DOI 10.1016/S0165-6147(00)01676-X
   DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539
   Danen E.H.J., 2013, ISRN CELL BIOL, V2013, P1, DOI [DOI 10.1155/2013/135164, 10.1155/2013/135164.]
   David V, 2018, TOXINS, V10, DOI 10.3390/toxins10080321
   de Aguiar RB, 2016, CANCER LETT, V371, P151, DOI 10.1016/j.canlet.2015.11.030
   Deryugina EI, 2006, CANCER METAST REV, V25, P9, DOI 10.1007/s10555-006-7886-9
   Desch A, 2012, AM J PATHOL, V181, P693, DOI 10.1016/j.ajpath.2012.04.012
   Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748
   Docheva D, 2007, J CELL MOL MED, V11, P21, DOI 10.1111/j.1582-4934.2007.00001.x
   Eble JA, 2001, J BIOL CHEM, V276, P12274, DOI 10.1074/jbc.M009338200
   Eliceiri BP, 1999, J CLIN INVEST, V103, P1227, DOI 10.1172/JCI6869
   FILARDO EJ, 1995, J CELL BIOL, V130, P441, DOI 10.1083/jcb.130.2.441
   Fox JW, 2008, FEBS J, V275, P3016, DOI 10.1111/j.1742-4658.2008.06466.x
   Friedl P, 1997, CANCER RES, V57, P2061
   Gabriel LM, 2012, J VENOM ANIM TOXINS, V18, P24, DOI 10.1590/S1678-91992012000100004
   Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028
   Giebeler N, 2016, TOXINS, V8, DOI 10.3390/toxins8040122
   Goodman SL, 2012, TRENDS PHARMACOL SCI, V33, P405, DOI 10.1016/j.tips.2012.04.002
   Haddad T, 2017, CANCER CHEMOTH PHARM, V79, P1221, DOI 10.1007/s00280-017-3322-9
   Hielscher AC, 2012, CANCER RES, V72, P6089, DOI 10.1158/0008-5472.CAN-12-2773
   Higuchi DA, 2011, TOXICON, V58, P123, DOI 10.1016/j.toxicon.2011.05.013
   Holtke C, 2018, J MED CHEM, V61, P7471, DOI 10.1021/acs.jmedchem.8b01123
   Hsu MY, 1998, AM J PATHOL, V153, P1435, DOI 10.1016/S0002-9440(10)65730-6
   Huang Y, 2015, DEV COMP IMMUNOL, V52, P155, DOI 10.1016/j.dci.2015.05.005
   HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S
   Jahangiri A, 2014, CANCER RES, V74, P3, DOI 10.1158/0008-5472.CAN-13-1742
   Jain RK, 2007, NAT REV NEUROSCI, V8, P610, DOI 10.1038/nrn2175
   Kang IC, 1999, CANCER RES, V59, P3754
   Kang IC, 2000, BIOCHEM BIOPH RES CO, V275, P169, DOI 10.1006/bbrc.2000.3130
   KLEIN CE, 1991, J CELL BIOL, V115, P1427, DOI 10.1083/jcb.115.5.1427
   Korc M, 2009, CURR CANCER DRUG TAR, V9, P639, DOI 10.2174/156800909789057006
   Kuphal S, 2005, CANCER METAST REV, V24, P195, DOI 10.1007/s10555-005-1572-1
   Luttenberger T, 2000, LAB INVEST, V80, P47, DOI 10.1038/labinvest.3780007
   Maaser K, 1999, MOL BIOL CELL, V10, P3067, DOI 10.1091/mbc.10.10.3067
   Marcinkiewicz C, 1997, BLOOD, V90, P1565, DOI 10.1182/blood.V90.4.1565.1565_1565_1575
   Marcinkiewicz C, 2000, BIOCHEMISTRY-US, V39, P9859, DOI 10.1021/bi000428a
   Maria DA, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-446
   Minea R, 2012, TOXICON, V59, P472, DOI 10.1016/j.toxicon.2011.02.020
   Mitjans F, 2000, INT J CANCER, V87, P716, DOI 10.1002/1097-0215(20000901)87:5<716::AID-IJC14>3.3.CO;2-I
   Mizejewski GJ, 1999, P SOC EXP BIOL MED, V222, P124, DOI 10.1046/j.1525-1373.1999.d01-122.x
   Momic T, 2012, TOXINS, V4, P862, DOI 10.3390/toxins4100862
   NIEWIAROWSKI S, 1994, SEMIN HEMATOL, V31, P289
   PAINE MJI, 1992, J BIOL CHEM, V267, P22869
   Paschoalin T, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-44
   Raab-Westphal S, 2017, CANCERS, V9, DOI 10.3390/cancers9090110
   RAK JW, 1995, ANTI-CANCER DRUG, V6, P3, DOI 10.1097/00001813-199502000-00001
   Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053
   Santos IC, 2010, CANCER SCI, V101, P453, DOI 10.1111/j.1349-7006.2009.01403.x
   SCHWARTZ MA, 1993, CANCER RES, V53, P1503
   Soda Y, 2013, J MOL MED, V91, P439, DOI 10.1007/s00109-013-1019-z
   Souza DHF, 2000, ARCH BIOCHEM BIOPHYS, V384, P341, DOI 10.1006/abbi.2000.2120
   Spinella F, 2014, CARCINOGENESIS, V35, P840, DOI 10.1093/carcin/bgu018
   Suntravat M, 2016, TOXICON, V122, P43, DOI 10.1016/j.toxicon.2016.09.007
   Swenson S, 2005, PATHOPHYSIOL HAEMO T, V34, P169, DOI 10.1159/000092418
   Tabatabai G, 2010, TARGET ONCOL, V5, P175, DOI 10.1007/s11523-010-0156-3
   Tanjoni I, 2003, TOXICON, V42, P809, DOI 10.1016/j.toxicon.2003.10.011
   Tanjoni I, 2010, TOXICON, V55, P1093, DOI 10.1016/j.toxicon.2009.12.010
   Teixeira CDP, 2005, MEM I OSWALDO CRUZ, V100, P181, DOI 10.1590/S0074-02762005000900031
   Trochon-Joseph V, 2004, CANCER RES, V64, P2062, DOI 10.1158/0008-5472.CAN-03-3272
   USAMI Y, 1994, BIOCHEM BIOPH RES CO, V201, P331, DOI 10.1006/bbrc.1994.1706
   VANGRONINGEN JJM, 1995, CANCER RES, V55, P6237
   Walsh EM, 2012, NEURO-ONCOLOGY, V14, P890, DOI 10.1093/neuonc/nos119
   Yang RS, 2005, TOXICON, V45, P661, DOI 10.1016/j.toxicon.2005.01.013
   Zigrino P, 2001, EUR J CELL BIOL, V80, P68, DOI 10.1078/0171-9335-00134
   Zigrino P, 2007, J BIOL CHEM, V282, P30785, DOI 10.1074/jbc.M701658200
NR 78
TC 0
Z9 0
U1 1
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD MAR 1
PY 2019
VL 159
BP 22
EP 31
DI 10.1016/j.toxicon.2018.12.005
PG 10
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HM3II
UT WOS:000459366600004
PM 30611825
DA 2020-05-12
ER

PT J
AU Ujevic, I
   Roje-Busatto, R
   Ezgeta-Balic, D
AF Ujevic, Ivana
   Roje-Busatto, Romana
   Ezgeta-Balic, Dania
TI Comparison of amnesic, paralytic and lipophilic toxins profiles in
   cockle (Acanthocardia tuberculata) and smooth clam (Callista chione)
   from the central Adriatic Sea (Croatia)
SO TOXICON
LA English
DT Article
DE Acanthocardia tuberculata; Callista chione; Lipophilic toxins; PSP; ASP;
   Adriatic sea
ID SHELLFISH POISONING TOXINS; MYTILUS-GALLOPROVINCIALIS;
   LIQUID-CHROMATOGRAPHY; DOMOIC ACID; QUANTITATIVE-DETERMINATION; MDIQ
   BAY; BIVALVE; ACCUMULATION; DSP; PSP
AB Searching for Amnesic (ASP), Paralytic (PSP) and Lipophilic (LT) toxins in seafood is of great importance for consumer protection. Studies are usually focused on the most aquacultured species, the mussel. But, there are a number of potentially commercially important shellfish species as rough cockle Acanthocardia tuberculata (Linnaeus, 1758) and smooth clam Callista chione (Linnaeus, 1758) which are common in the Croatian Adriatic Sea. Investigation of marine biotoxins accumulation in these two species of shellfish from the Adriatic Sea has not been conducted up to now. In order to detect the potential marine biotoxin profile of A. tuberculata and C. chione wild populations, samples were taken monthly during one-year survey from the estuarine area in the central Adriatic Sea. HPLC-FLD with pre-column oxidation and HPLC-UV-DAD methods were employed for PSP and ASP toxins determination, respectively, while LTs were determined by LC-MS/MS. This research had revealed the differences in the accumulation of ASP, PSP and LT toxins between the two studied species, as Acanthocardia tuberculata showed more diverse profile with higher concentrations of analysed toxins. Both investigated shellfish species had shown levels of these biotoxins under the legal limits set by the European Commission.
C1 [Ujevic, Ivana; Roje-Busatto, Romana; Ezgeta-Balic, Dania] Inst Oceanog & Fisheries, Setaliste Ivana Mestrovica 63, Split 21000, Croatia.
RP Roje-Busatto, R (reprint author), Inst Oceanog & Fisheries, Setaliste Ivana Mestrovica 63, Split 21000, Croatia.
EM rroje@izor.hr
RI Balic, Daria Ezgeta/G-9440-2017
OI Balic, Daria Ezgeta/0000-0003-0763-3647; Roje-Busatto,
   Romana/0000-0002-9270-6646; Ujevic, Ivana/0000-0001-6686-1418
FU Ministry of Science and Education of the Republic of Croatia
FX This study was supported by the Ministry of Science and Education of the
   Republic of Croatia as a part of Multiannual Financing intended for
   institutions. Authors are grateful to Mario Zokic for help with sample
   collection.
CR Alexander J, 2009, EFSA J, V7, DOI 10.2903/j.efsa.2009.1019
   Arapov J., 2015, FRESEN ENVIRON BULL, V24, P4801
   Bire R, 2002, J NAT TOXINS, V11, P269
   Bosak S, 2009, ACTA BOT CROAT, V68, P351
   Caroppo C, 2005, J PLANKTON RES, V27, P763, DOI 10.1093/plankt/fbi050
   Charles F, 1999, J MAR BIOL ASSOC UK, V79, P577, DOI 10.1017/S0025315498000745
   Ciminiello P, 2006, TOXICON, V47, P597, DOI 10.1016/j.toxicon.2006.02.003
   Ciminiello P, 2010, TOXICON, V55, P280, DOI 10.1016/j.toxicon.2009.07.037
   Delgado M, 2016, ACTA ADRIAT, V57, P93
   EURLMB, 2015, EU HARM STAND OP PRO
   Garcia-Altares M, 2014, MAR DRUGS, V12, P3706, DOI 10.3390/md12063706
   Gladan ZN, 2011, MOLECULES, V16, P888, DOI 10.3390/molecules16010888
   James KJ, 2005, TOXICON, V46, P852, DOI 10.1016/j.toxicon.2005.02.009
   Lawrence JF, 2005, J AOAC INT, V88, P1714
   Leblad BR, 2013, ACTA BOT CROAT, V72, P35, DOI 10.2478/v10184-012-0004-x
   Marquez I., 1993, 3 REUN IB FIT TOX BI, P27
   Metaxatos A, 2004, J SEA RES, V52, P293, DOI 10.1016/j.seares.2004.03.001
   Peharda M, 2012, SCI MAR, V76, P59, DOI 10.3989/scimar.03257.21A
   Peharda M, 2010, ACTA ADRIAT, V51, P141
   QUILLIAM MA, 1995, J AOAC INT, V78, P543
   Rharrass A, 2016, SCI MAR, V80, P359, DOI 10.3989/scimar.04312.09A
   Roje-Busatto R, 2014, TOXICON, V79, P28, DOI 10.1016/j.toxicon.2013.12.014
   Sagou R, 2005, TOXICON, V46, P612, DOI 10.1016/j.toxicon.2005.06.020
   Takati N, 2007, TOXICON, V50, P311, DOI 10.1016/j.toxicon.2007.04.016
   Taleb H, 2001, TOXICON, V39, P1855, DOI 10.1016/S0041-0101(01)00167-2
   Ujevic I, 2015, MOLECULES, V20, P13031, DOI 10.3390/molecules200713031
   Ujevic I, 2012, FOOD CONTROL, V25, P285, DOI 10.1016/j.foodcont.2011.10.050
   Ujevic I, 2010, MOLECULES, V15, P6835, DOI 10.3390/molecules15106835
   Vale P, 2005, FOOD ADDIT CONTAM, V22, P838, DOI 10.1080/02652030500195247
   Vale P, 2002, TOXICON, V40, P511, DOI 10.1016/S0041-0101(01)00246-X
   Van Wagoner RM, 2011, TETRAHEDRON LETT, V52, P4243, DOI 10.1016/j.tetlet.2011.05.137
NR 31
TC 2
Z9 2
U1 5
U2 12
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD MAR 1
PY 2019
VL 159
BP 32
EP 37
DI 10.1016/j.toxicon.2018.12.008
PG 6
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HM3II
UT WOS:000459366600005
PM 30659862
DA 2020-05-12
ER

PT J
AU Barton, DJ
   Shao, S
   Marino, RT
   Reichmeider, A
   Yanta, JH
   Pizon, AF
AF Barton, David J.
   Shao, Shirley
   Marino, Ryan T.
   Reichmeider, Alex
   Yanta, Joseph H.
   Pizon, Anthony F.
TI Neurotoxic envenomation by the South African coral snake (Aspidelaps
   lubricus): A case report
SO TOXICON
LA English
DT Review
DE Aspidelaps lubricus; South African coral snake; Envenomation;
   Neurotoxicity; Snakebite
ID SHIELD; SCUTATUS; CENTERS; BITE
AB The South African coral snake (Aspidelaps lubricus, Elapidae) has not previously been reported to cause any neurotoxic envenomations in humans. We recently treated a 44-year-old man who was bitten twice, once in each hand, by a captive South African coral snake (Aspidelaps lubricus) while feeding the female snake who had recently laid eggs. Approximately one hour after receiving the bite, he developed vomiting, respiratory failure requiring mechanical ventilation, and paralysis of the bulbar and upper extremity muscles, with retention of voluntary motor control in the lower extremities. Supportive care was provided, and paralysis and respiratory failure resolved spontaneously 12 hours after onset. No antivenom for this species is available. To our knowledge, this is the first published case report of significant human envenomation by Aspidelaps lubricus. Physicians, first responders, and herpetologists should be aware of the potential for neurotoxicity in humans.
C1 [Barton, David J.; Reichmeider, Alex] Univ Pittsburgh, Sch Med, Dept Emergency Med, 230 McKee Pl,Suite 500, Pittsburgh, PA 15213 USA.
   [Shao, Shirley; Marino, Ryan T.; Yanta, Joseph H.; Pizon, Anthony F.] Univ Pittsburgh, Sch Med, Dept Emergency Med, Div Med Toxicol, Iroquois Bldg Suite 400,3600 Forbes Ave, Pittsburgh, PA 15213 USA.
RP Pizon, AF (reprint author), Univ Pittsburgh, Sch Med, Dept Emergency Med, Div Med Toxicol, Iroquois Bldg Suite 400,3600 Forbes Ave, Pittsburgh, PA 15213 USA.
EM pizonaf@upmc.edu
RI Marino, Ryan/AAM-8665-2020; Barton, David J./M-8850-2019
OI Barton, David J./0000-0003-0976-0383; Pizon, Anthony/0000-0002-1196-6930
CR Branch W.R., 1981, Journal of the Herpetological Association of Africa, P2
   Broadley Donald G., 2006, Herpetological Natural History, V9, P163
   Gold BS, 1996, ANN EMERG MED, V28, P87, DOI 10.1016/S0196-0644(96)70142-7
   Gummin DD, 2017, CLIN TOXICOL, V55, P1072, DOI 10.1080/15563650.2017.1388087
   JOUBERT FJ, 1988, INT J BIOCHEM, V20, P93, DOI 10.1016/0020-711X(88)90016-X
   Lubich C, 2007, EMERG MED J, V24, P796, DOI 10.1136/emj.2007.046292
   Ruha AM, 2017, J MED TOXICOL, V13, P309, DOI 10.1007/s13181-017-0633-5
   Slagboom J, 2018, TOXICON, V148, P213, DOI 10.1016/j.toxicon.2018.04.022
   VANEGMOND KC, 1984, S AFR MED J, V66, P714
   WATT G, 1986, NEW ENGL J MED, V315, P1444, DOI 10.1056/NEJM198612043152303
   Whiteley G, 2019, J PROTEOMICS, V198, P186, DOI 10.1016/j.jprot.2018.09.019
   Young HS, 2003, BIOPHYS J, V85, P943, DOI 10.1016/S0006-3495(03)74533-0
   ZALTZMAN M, 1984, S AFR MED J, V66, P111
NR 13
TC 0
Z9 0
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD MAR 1
PY 2019
VL 159
BP 38
EP 40
DI 10.1016/j.toxicon.2019.01.001
PG 3
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HM3II
UT WOS:000459366600006
PM 30660557
DA 2020-05-12
ER

PT J
AU Bellon, G
   Venturin, A
   Masiero, S
   Del Felice, A
AF Bellon, Giulia
   Venturin, Andrea
   Masiero, Stefano
   Del Felice, Alessandra
TI Intra-articular botulinum toxin injection in complex regional pain
   syndrome: Case report and review of the literature
SO TOXICON
LA English
DT Review
DE CRPS; Intra-articular injection; Botulinum toxin; Pain
ID TRPV1
AB Complex regional pain syndrome (CAPS) is characterized by hyperalgesia, autonomic and trophic alterations of bones, muscles and skin. It is supported by neurogenic inflammation and impairment of sympathetic nervous system. Botulinum Toxin (BTX) is an option for the management of pain, with level B evidence of efficacy in neuropathic, joint and myofascial pain syndrome. We report a case of CRPS treated with intra articular injection of BTX-A (IaBI). BTX-A 100 U in 2 cc Na Cl 0,9% was injected into the gleno-humeral joint. Visual analogue scale (VAS) pain score and McGill Pain Questionnaire (MPQ) were administered at T0 (baseline), T1 (one month after IaBI) and T2 (four months after IaBI). Autonomic and trophic skin disorders were clinically monitored. Pain decreased at T1, with a lasting effect at T2, associated with improvement of range of motion (ROM). No improvement in terms of autonomic and trophic skin disorders were reported neither at T1 nor T2. These findings support a possible antinociceptive role of BTX-A in the management of CRPS pain related to inhibition of pain neurotransmitters release. A literature revision of IaBI is provided.
C1 [Bellon, Giulia; Venturin, Andrea; Masiero, Stefano; Del Felice, Alessandra] Univ Padua, Dept Phys & Rehabil Med, Via Giustiniani 3, I-35128 Padua, Italy.
RP Bellon, G (reprint author), Univ Padua, Dept Neurosci, Via Giustiniani 3, I-35128 Padua, Italy.
EM giulia.bellon@studenti.unipd.it
OI Masiero, Stefano/0000-0002-0361-4898; Bellon, Giulia/0000-0001-5045-9184
CR Boon AJ, 2010, PM&R, V2, P268, DOI 10.1016/j.pmrj.2010.02.011
   Drummond PD, 2001, LANCET, V358, P168, DOI 10.1016/S0140-6736(01)05400-9
   Gouin O, 2017, PROTEIN CELL, V8, P644, DOI 10.1007/s13238-017-0395-5
   Harden RN, 2013, PAIN MED, V14, P180, DOI 10.1111/pme.12033
   Hsieh LF, 2016, PM&R, V8, P1127, DOI 10.1016/j.pmrj.2016.05.009
   Joo YJ, 2013, ANN REHABIL MED-ARM, V37, P208, DOI 10.5535/arm.2013.37.2.208
   Mahowald ML, 2006, NEUROTOX RES, V9, P179, DOI 10.1007/BF03033937
   Qerama E, 2010, CURR OPIN ANESTHESIO, V23, P602, DOI 10.1097/ACO.0b013e32833c3405
   Safarpour D, 2010, PAIN MED, V11, P1411, DOI 10.1111/j.1526-4637.2010.00897.x
   Schattschneider J, 2006, CLIN J PAIN, V22, P240, DOI 10.1097/01.ajp.0000169672.49438.67
   Shimizu T, 2012, NEUROBIOL DIS, V48, P367, DOI 10.1016/j.nbd.2012.07.010
   Singh JA, 2009, TRANSL RES, V153, P205, DOI 10.1016/j.trsl.2009.02.004
   Sun SF, 2014, J FOOT ANKLE RES, V7, DOI 10.1186/1757-1146-7-9
   Wheeler A, 2013, TOXICOLOGY, V306, P124, DOI 10.1016/j.tox.2013.02.006
NR 14
TC 1
Z9 1
U1 1
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD MAR 1
PY 2019
VL 159
BP 41
EP 44
DI 10.1016/j.toxicon.2019.01.002
PG 4
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HM3II
UT WOS:000459366600007
PM 30660558
DA 2020-05-12
ER

PT J
AU El-Asheer, OM
   Hammad, EEM
   Mohamad, IL
   Saad, K
   Aziz, NA
AF El-Asheer, Osama M.
   Hammad, Emad E. M.
   Mohamad, Ismail L.
   Saad, Khaled
   Aziz, Nancy A.
TI A randomized comparative study between intravenous and intramuscular
   scorpion antivenom regimens in children
SO TOXICON
LA English
DT Article
DE Intramuscular; Intravenous; Scorpion antivenom; Children
ID PHARMACOKINETICS; ENVENOMATION; F(AB')(2); VENOM; IGG
AB Background: Scorpion envenomation and its consequences represented a serious healthcare problem in Upper Egypt and considered to be an important cause of life-threatening emergency particularly in children.
   Methods: One hundred patients presented to the emergency department of Assiut University Children Hospital with a history of scorpion sting aged less than 18 years were included in our randomized comparative trial during 2016. Two groups of patients were randomly categorized according to the route of administration of scorpion antivenom; intramuscular and intravenous with 50 patients in each group. Full history, clinical examination, and routine baseline investigations were performed.
   Results: Myocarditis, encephalopathy, cardiogenic shock, ICU admission, need for mechanical ventilation, mean hospital stay and mortality were significantly lower in those received intravenous antivenom compared with those received intramuscular one.
   Conclusion: The results of the present study and other experimental and clinical trials confirmed that the administration of the scorpion antivenom by intravenous route has a lower incidence of systemic toxicity, a better outcome of fatal complication resulted from envenomation especially cardiogenic shock, decreased need for ICU facilities and mechanical ventilation, shorter hospital stay, and better overall outcome than the intramuscular route.
C1 [El-Asheer, Osama M.; Hammad, Emad E. M.; Mohamad, Ismail L.; Saad, Khaled; Aziz, Nancy A.] Assiut Univ, Fac Med, Pediat Dept, Assiut 71516, Egypt.
RP Saad, K (reprint author), Assiut Univ, Fac Med, Pediat Dept, Assiut 71516, Egypt.
EM ksaad8@yahoo.com
RI Mohamad, Ismail/AAJ-5900-2020; Saad, Khaled/G-9901-2012
OI Saad, Khaled/0000-0002-8473-6116
CR Abroug F, 1999, LANCET, V354, P906, DOI 10.1016/S0140-6736(98)12083-4
   Ahmed AE, 2015, THER ADV ENDOCRINOL, V6, P210, DOI 10.1177/2042018815593034
   Chippaux JP, 2012, DRUG DES DEV THER, V6, P165, DOI 10.2147/DDDT.S24754
   Ismail M, 2003, INT J ANTIMICROB AG, V21, P170, DOI 10.1016/S0924-8579(02)00289-3
   Ismail M, 1998, TOXICON, V36, P93, DOI 10.1016/S0041-0101(97)00062-7
   Ismail M, 1998, TOXICON, V36, P1523, DOI 10.1016/S0041-0101(98)00144-5
   Joshi Shashank R, 2007, J Assoc Physicians India, V55, P11
   Karnad Dilip R, 2009, J Assoc Physicians India, V57, P299
   Krifi M. N., 1999, Journal of Venomous Animals and Toxins, V5, P128
   Krifi M. N, 2005, TOXICON, V15, P429
   Meki ARAM, 2003, TOXICON, V41, P129, DOI 10.1016/S0041-0101(02)00155-1
   Mohamad IL, 2014, EUR J PEDIATR, V173, P815, DOI 10.1007/s00431-013-2244-8
   Pandi K, 2014, ARCH DIS CHILD, V99, P575, DOI 10.1136/archdischild-2013-305483
   PepinCovatta S, 1996, TOXICOL APPL PHARM, V141, P272, DOI 10.1016/S0041-008X(96)80033-0
   Saad K, 2017, J CHILD NEUROL, V32, P537, DOI 10.1177/0883073817690091
   Srinivasa K, 2014, INT J RECENT TRENDS, V10, P22
   Ulug M, 2012, TURKISH J PEDIATR, V54, P119
NR 17
TC 0
Z9 0
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD MAR 1
PY 2019
VL 159
BP 45
EP 49
DI 10.1016/j.toxicon.2019.01.004
PG 5
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HM3II
UT WOS:000459366600008
PM 30664882
DA 2020-05-12
ER

PT J
AU Rosa, JG
   de Albuquerque, CZ
   Mattaraia, VGD
   Santoro, ML
AF Rosa, Jaqueline Gomes
   de Albuquerque, Cynthia Zaccanini
   de Moura Mattaraia, Vania Gomes
   Santoro, Marcelo Larami
TI Comparative study of platelet aggregation and secretion induced by
   Bothrops jararaca snake venom and thrombin
SO TOXICON
LA English
DT Article
DE Bothrops; Agglutination; C-type lectin-like proteins; Hermansky-Pudlak
   syndrome; Envenoming; Bothropoides; Botrocetin; Rhodocytin; Glycoprotein
   Ib; Convulxin; Glycoprotein VI; ATP; CLEC-2; von Willebrand factor;
   Platelet factor 4
ID HERMANSKY-PUDLAK-SYNDROME; PATIENTS BITTEN; STRAIN DIFFERENCES;
   PURIFICATION; EXPRESSION; RELEASE; ENVENOMATION; RECEPTORS; COAGULANT;
   RESPONSES
AB Victims of Bothrops jararaca snakebites manifest bleedings, blood incoagulability, platelet dysfunction, and thrombocytopenia, and the latter has been directly implicated in the genesis of hemorrhagic diathesis. We addressed herein the direct effects of B. jararaca venom (BjV) on ex vivo platelet aggregation and granule secretion in washed human and mouse platelets. BjV directly aggregated platelets, but the extent of platelet aggregation was lower in human than mouse platelets. On the other hand, BjV (24.4 mu g/mL) and thrombin (0.1 U/mL) induced a similar extent of ATP and platelet factor 4 (PF4) secretion in both species. BjV-induced platelet aggregation was independent of the platelet dense body content, as in pearl mouse (Ap3b1(-/-))platelets, whose dense bodies are deficient in adenine nucleotides and serotonin, the extent of platelet aggregation was superior to that induced in BALB/c or C57BL/6 mice. BjV-induced beta-hexosaminidase secretion in human platelets was less intense than that evoked by thrombin, and the contrary was observed in mouse platelets. Irreversible inactivation of platelet cyclooxygenase 1 by acetylsalicylic acid did not reduce BjV-induced platelet aggregation. BjV exerted no cytotoxic activity in human and mouse platelets, as evaluated by lactate dehydrogenase loss. Eptifibatide, which inhibits the binding of fibrinogen to platelet glycoprotein complex GPIIb-IIIa, differently blocked BjV-induced platelet aggregation in mice and humans. BjV-induced platelet aggregation did not depend on snake venom serine proteinases nor metalloproteinases in mice, whilst serine proteinases were rather important for platelet aggregation in humans. Our results show that BjV induces direct activation, aggregation, and secretion in human and mouse platelets, but it exerts diverse responses in them, which should be considered in comparative studies to understand pathophysiological events during Bothrops envenomation.
C1 [Rosa, Jaqueline Gomes; Santoro, Marcelo Larami] Inst Butantan, Lab Fisiopatol, Av Dr Vital Brazil 1500, BR-05503900 Sao Paulo, SP, Brazil.
   [de Albuquerque, Cynthia Zaccanini; de Moura Mattaraia, Vania Gomes] Inst Butantan, Bioterio Cent, Av Dr Vital Brazil 1500, BR-05503900 Sao Paulo, SP, Brazil.
   [Rosa, Jaqueline Gomes; Santoro, Marcelo Larami] Univ Sao Paulo, Fac Med, Sao Paulo, SP, Brazil.
RP Santoro, ML (reprint author), Inst Butantan, Lab Fisiopatol, Av Dr Vital Brazil 1500, BR-05503900 Sao Paulo, SP, Brazil.
EM marcelo.santoro@butantan.gov.br
RI Santoro, Marcelo L./K-7064-2019; Santoro, Marcelo/H-3892-2012
OI Santoro, Marcelo L./0000-0001-6364-3757; 
FU Sao Paulo Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2013/25177-0, 2018/07819-9]; Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)National
   Council for Scientific and Technological Development (CNPq)
   [305245/2015-5]; Fundacao Butantan; CAPES (Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior)CAPES [001]
FX This work was supported by the Sao Paulo Research Foundation (FAPESP,
   grants #2013/25177-0, #2018/07819-9, www.fapesp.br), Conselho Nacional
   de Desenvolvimento Cientifico e Tecnologico (CNPq, grant #305245/2015-5,
   www.cnpq.br), and Fundacao Butantan. JGR was a recipient of CAPES
   (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior)
   fellowships (Finance Code 001).
CR Ambrosini A., 2016, PLATELETS, P1
   Antunes TC, 2010, TOXICON, V56, P1443, DOI 10.1016/j.toxicon.2010.08.011
   Arlinghaus FT, 2012, TOXICON, V60, P512, DOI 10.1016/j.toxicon.2012.03.001
   Arteaga-Vizcaino M, 2011, REV CIENT-FAC CIEN V, V21, P548
   Atkinson BT, 2001, EUR J BIOCHEM, V268, P5242, DOI 10.1046/j.0014-2956.2001.02448.x
   Sachetto ATA, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006774
   Berger M, 2008, TOXICON, V51, P488, DOI [10.1016/j.toxicon.2007.09.005, 10.1016/j.toxicon.2007-09.005]
   BOX GEP, 1964, J ROY STAT SOC B, V26, P211, DOI 10.1111/j.2517-6161.1964.tb00553.x
   CARDOSO JLC, 1993, Q J MED, V86, P315
   Cedro RCA, 2018, J VENOM ANIM TOXINS, V24, DOI 10.1186/s40409-018-0170-y
   DAVEY MG, 1965, NATURE, V207, P730, DOI 10.1038/207730a0
   DAVEY MG, 1967, NATURE, V216, P857, DOI 10.1038/216857a0
   Feng LJ, 1999, HUM MOL GENET, V8, P323, DOI 10.1093/hmg/8.2.323
   Fernandez JH, 2005, BIOCHEM BIOPH RES CO, V329, P457, DOI 10.1016/j.bbrc.2005.01.148
   Francischetti IMB, 1998, COMP BIOCHEM PHYS C, V119, P21, DOI 10.1016/S0742-8413(97)00163-1
   Fujimura Y, 1996, THROMB HAEMOSTASIS, V76, P633
   FUJIMURA Y, 1995, THROMB HAEMOSTASIS, V74, P743
   GEORGE JN, 1991, NEW ENGL J MED, V324, P27, DOI 10.1056/NEJM199101033240106
   Gitz E, 2014, BLOOD, V124, P2262, DOI 10.1182/blood-2014-05-572818
   Gutierrez JM, 2017, NAT REV DIS PRIMERS, V3, DOI [10.1038/nrdp.2017.79, 10.1038/nrdp.2017.63]
   Heijnen H, 2015, J THROMB HAEMOST, V13, P2141, DOI 10.1111/jth.13147
   Herrera C, 2013, TOXICON, V63, P19, DOI 10.1016/j.toxicon.2012.10.023
   HOLMSEN H, 1989, METHOD ENZYMOL, V169, P336
   Jirouskova M, 2007, J THROMB HAEMOST, V5, P661, DOI 10.1111/j.1538-7836.2007.02407.x
   Jonnalagadda D, 2012, BLOOD, V120, P5209, DOI 10.1182/blood-2012-07-445080
   Kahr WHA, 2013, BLOOD, V122, P3349, DOI 10.1182/blood-2013-04-499491
   Kamiguti AS, 2005, TOXICON, V45, P1041, DOI 10.1016/j.toxicon.2005.02.026
   Kamiguti AS, 1996, BIOCHEM J, V320, P635, DOI 10.1042/bj3200635
   Li TT, 2004, BLOOD, V103, P3396, DOI 10.1182/blood-2003-10-3721
   Liu J, 2004, J THROMB HAEMOST, V2, P2213, DOI 10.1111/j.1538-7836.2004.01023.x
   Lu QM, 2005, TOXICON, V45, P1089, DOI 10.1016/j.toxicon.2005.02.022
   MARSHALL LR, 1989, THROMB RES, V54, P269, DOI 10.1016/0049-3848(89)90085-6
   MARUYAMA M, 1990, THROMB HAEMOSTASIS, V63, P449
   Matsui T, 2005, TOXICON, V45, P1075, DOI 10.1016/j.toxicon.2005.02.023
   May F, 2009, BLOOD, V114, P3464, DOI 10.1182/blood-2009-05-222273
   Menezes MC, 2011, BIOCHIMIE, V93, P345, DOI 10.1016/j.biochi.2010.10.007
   Meng RH, 2015, BLOOD, V125, P1623, DOI 10.1182/blood-2014-07-586727
   Moss DW, 1999, TIETZ TXB CLIN CHEM, P617
   Murakami MT, 2003, BIOCHEM BIOPH RES CO, V310, P478, DOI 10.1016/j.bbrc.2003.09.032
   Nicolau CA, 2017, J PROTEOMICS, V151, P214, DOI 10.1016/j.jprot.2016.06.029
   NISHIDA S, 1994, BIOCHEMISTRY-US, V33, P1843, DOI 10.1021/bi00173a030
   NOVAK EK, 1984, BLOOD, V63, P536
   OVERBERGH L, 1991, J BIOL CHEM, V266, P16903
   PAIGEN B, 1987, ATHEROSCLEROSIS, V64, P181, DOI 10.1016/0021-9150(87)90245-0
   Przygodzki T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146346
   RENDU F, 1987, AM J HEMATOL, V25, P165, DOI 10.1002/ajh.2830250206
   Ribeiro W, 2003, TOXICON, V42, P173, DOI 10.1016/S0041-0101(03)00130-2
   Rucavado A, 2005, THROMB HAEMOSTASIS, V94, P123
   SanoMartins IS, 1997, THROMB RES, V87, P183, DOI 10.1016/S0049-3848(97)00118-7
   Santoro ML, 2008, TOXICON, V51, P1440, DOI 10.1016/j.toxicon.2008.03.018
   Santoro ML, 2009, TOXICON, V54, P499, DOI 10.1016/j.toxicon.2009.05.016
   Santoro ML, 2004, THROMB HAEMOSTASIS, V92, P369, DOI 10.1160/TH04-02-0120
   SANTORO ML, 1994, PLATELETS, V5, P162, DOI 10.3109/09537109409005530
   Santos BF, 2000, FEBS LETT, V477, P199, DOI 10.1016/S0014-5793(00)01803-2
   Sazima Ivan, 1992, P199
   SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1058
   Senise LV, 2015, EXP BIOL MED, V240, P1528, DOI 10.1177/1535370215590818
   SERRANO SMT, 1995, BIOCHEMISTRY-US, V34, P7186, DOI 10.1021/bi00021a033
   Serrano SMT, 1999, ARCH BIOCHEM BIOPHYS, V367, P26, DOI 10.1006/abbi.1999.1230
   Sharda A, 2015, BLOOD, V125, P1633, DOI 10.1182/blood-2014-08-597419
   Sudo T, 2006, THROMB HAEMOSTASIS, V95, P159, DOI 10.1160/TH05-05-0322
   Suzuki-Inoue K, 2011, J THROMB HAEMOST, V9, P44, DOI 10.1111/j.1538-7836.2011.04335.x
   Takeda S, 2012, BBA-PROTEINS PROTEOM, V1824, P164, DOI 10.1016/j.bbapap.2011.04.009
   Thomazini C. M, 2018, ENVOLVIMENTO FATOR W
   VLADUTIU GD, 1984, BIOCHIM BIOPHYS ACTA, V802, P435, DOI 10.1016/0304-4165(84)90361-1
   Xu XR, 2016, CRIT REV CL LAB SCI, V53, P409, DOI 10.1080/10408363.2016.1200008
   Yamashita KM, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002814
   Zeiler M, 2014, MOL CELL PROTEOMICS, V13, P3435, DOI 10.1074/mcp.M114.038513
   ZINGALI RB, 1993, BIOCHEMISTRY-US, V32, P10794, DOI 10.1021/bi00091a034
   ZINGALI RB, 1990, THROMB RES, V58, P303, DOI 10.1016/0049-3848(90)90100-Q
NR 70
TC 2
Z9 2
U1 2
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD MAR 1
PY 2019
VL 159
BP 50
EP 60
DI 10.1016/j.toxicon.2019.01.003
PG 11
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HM3II
UT WOS:000459366600009
PM 30677414
DA 2020-05-12
ER

PT J
AU Alger, J
   Boza-Oviedo, EE
   Mejia, RE
   Navas, F
   Simons-Morales, P
   Velazquez, RT
   Gutierrez, JM
AF Alger, Jackeline
   Enrique Boza-Oviedo, Eduardo
   Elena Mejia, Rosa
   Navas, Fanny
   Simons-Morales, Perla
   Teresa Velazquez, Reina
   Maria Gutierrez, Jose
TI A multi-sectorial approach for addressing the problem of snakebite
   envenoming in Honduras
SO TOXICON
LA English
DT Letter
C1 [Alger, Jackeline] Hosp Escuela Univ, Tegucigalpa, Honduras.
   [Alger, Jackeline; Simons-Morales, Perla] Univ Nacl Autonoma Honduras, Fac Ciencias Med, Unidad Invest Cient, Tegucigalpa, Honduras.
   [Enrique Boza-Oviedo, Eduardo] Proyecto Ixchel, Tegucigalpa, Honduras.
   [Elena Mejia, Rosa] Org Mundial Salud, Org Panamer Salud, Tegucigalpa, Honduras.
   [Navas, Fanny] Colegio Med Honduras, Secretaria Asuntos Educ & Culturales, Tegucigalpa, Honduras.
   [Teresa Velazquez, Reina] Secretaria Salud Honduras, Unidad Vigilancia Zoonosis & Enfermedades Infecci, Tegucigalpa, Honduras.
   [Maria Gutierrez, Jose] Univ Costa Rica, Fac Microbiol, Inst Clodomiro Picado, San Jose, Costa Rica.
RP Alger, J (reprint author), Univ Nacl Autonoma Honduras, Hosp Escuela Univ, Tegucigalpa, Honduras.; Velazquez, RT (reprint author), Secretaria Salud Honduras, Tegucigalpa, Honduras.
EM jackelinealger@gmail.com; zoonosishn@yahoo.com
OI Gutierrez, Jose Maria/0000-0001-8385-3081; Alger,
   Jackeline/0000-0001-9244-0668
CR Chippaux JP, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005662
   Gutierrez JM, 2017, NAT REV DIS PRIMERS, V3, DOI [10.1038/nrdp.2017.79, 10.1038/nrdp.2017.63]
   Gutierrez JM, 2014, J VENOM ANIM TOXINS, V20, DOI 10.1186/1678-9199-20-7
   McCranie J.R., 2011, SNAKES HONDURAS SYST
   Pinto L. J., 2019, AM J TROP MED HYG
   Republica de Honduras, 2018, B EP REP HOND 2017 2
   Seventy First World Health Assembly, 2018, ADDR BURD SNAK ENV
   Williams D. J., 2019, PLOS NEGLECTED TROP
NR 8
TC 1
Z9 1
U1 1
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD MAR 1
PY 2019
VL 159
BP 61
EP 62
DI 10.1016/j.toxicon.2019.01.005
PG 2
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA HM3II
UT WOS:000459366600010
PM 30677415
DA 2020-05-12
ER

PT J
AU Scalia, G
   Certo, F
   Malone, M
   Barbagallo, GMV
AF Scalia, Gianluca
   Certo, Francesco
   Malone, Massimiliano
   Barbagallo, Giuseppe M., V
TI Spinal Arachnoiditis Ossificans: Report of Quadruple-Triggered Case
SO WORLD NEUROSURGERY
LA English
DT Article
DE Ankylosing spondylitis; Arachnoid cysts; Arachnoiditis ossificans;
   Spinal surgery; Spinal trauma
ID ANKYLOSING-SPONDYLITIS; CALCIFICATION; SYRINGOMYELIA
AB BACKGROUND: Arachnoiditis ossificans (AO) is a rare condition often associated with previous spine surgery. Here we describe a unique case of a patient affected by ankylosing spondylitis (AS), presenting with progressive neurologic deterioration due to AO. We also review the literature on evaluation and management of patients suffering from AO.
   CASE DESCRIPTION: The 65-year-old patient had a history of previous spinal trauma and related thoracolumbar surgery. Magnetic resonance imaging revealed multiloculated intradural/extramedullary cysts on the posterior surface of the spinal cord at Th9-L1, with clustered nerve roots. Computed tomography, with 3-dimensional reconstruction, demonstrated a likely ossification of both the dura and arachnoid from Th9 to S1. Microsurgical debridement of scar tissue from previous surgery, drilling of posterior ossified plaques at Th11-Th12-L1, and marsupialization and drainage of arachnoid cysts at Th11-Th12 were performed.
   CONCLUSIONS: We submit that AS, spinal trauma, epidural hematoma, and related surgery may be synergistic and independent factors in the etiopatho-genesis of AO. This should be considered in patients with AS and/or a history of spinal surgery who present neurologic worsening.
C1 [Scalia, Gianluca; Certo, Francesco; Malone, Massimiliano; Barbagallo, Giuseppe M., V] Policlin G Rodolico Univ Hosp, Dept Neurol Surg, Catania, Italy.
RP Scalia, G (reprint author), Policlin G Rodolico Univ Hosp, Dept Neurol Surg, Catania, Italy.
EM gianluca.scalia@outlook.it
RI Certo, Francesco/AAC-1855-2019
OI Scalia, Gianluca/0000-0002-9465-2506; BARBAGALLO, Giuseppe Maria
   Vincenzo/0000-0002-7760-6700
CR BARTHELEMY CR, 1982, J COMPUT ASSIST TOMO, V6, P809, DOI 10.1097/00004728-198208000-00029
   Bilgen IG, 1999, NEURORADIOLOGY, V41, P508, DOI 10.1007/s002340050793
   BURTON C V, 1978, Spine, V3, P24, DOI 10.1097/00007632-197803000-00006
   Domenicucci M, 2004, NEUROSURGERY, V55, P985, DOI 10.1227/01.NEU.0000137281.65551.54
   Frizzell B, 2001, AM J ROENTGENOL, V177, P461, DOI 10.2214/ajr.177.2.1770461
   Hasturk AE, 2013, J BACK MUSCULOSKELET, V26, P479, DOI 10.3233/BMR-130407
   Joo KB, 2013, RHEUMATOL INT, V33, P1623, DOI 10.1007/s00296-011-2293-0
   KAUFMAN AB, 1971, NEUROLOGY, V21, P1243, DOI 10.1212/WNL.21.12.1243
   KITAGAWA H, 1990, SPINE, V15, P1236, DOI 10.1097/00007632-199011010-00028
   Liu LD, 2015, ORTHOPEDICS, V38, pE437, DOI 10.3928/01477447-20150504-91
   LYNCH C, 1983, NEUROSURGERY, V12, P321, DOI 10.1227/00006123-198303000-00013
   Papavlasopoulos F, 2007, J CLIN NEUROSCI, V14, P572, DOI 10.1016/j.jocn.2006.02.024
   Puusepp L, 1931, J NERV MENT DIS, V73, P1, DOI 10.1097/00005053-193101000-00001
   Revilla TY, 1999, CLIN IMAG, V23, P1, DOI 10.1016/S0899-7071(98)00085-0
   Singh H, 2011, WORLD NEUROSURG, V76, P478
   TORIBATAKI Y, 1995, PARAPLEGIA, V33, P224, DOI 10.1038/sc.1995.50
NR 16
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 1
EP 6
DI 10.1016/j.wneu.2018.11.203
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400097
PM 30521955
DA 2020-05-12
ER

PT J
AU Das, S
   Mitchell, P
   Ross, N
   Whitfield, PC
AF Das, Suparna
   Mitchell, Patrick
   Ross, Nicholas
   Whitfield, Peter C.
TI Decompressive Hemicraniectomy in the Treatment of Malignant Middle
   Cerebral Artery Infarction: A Meta-Analysis
SO WORLD NEUROSURGERY
LA English
DT Review
DE Decompressive hemicraniectomy; Infarction; Malignant MCA stroke; Middle
   cerebral artery
ID QUALITY-OF-LIFE; TERRITORY INFARCTION; CONTROLLED-TRIAL; CRANIECTOMY;
   STROKE; MULTICENTER; SURGERY; EDEMA; AGE
AB BACKGROUND: Malignant middle cerebral artery infarctions are large space-occupying infarctions involving massive edema, herniation, and frequently death. Survivors are disabled. Management involves medical treatment, with or without decompressive hemicraniectomy and later duraplasty. This meta-analysis aimed to determine whether surgery is worthwhile with particular regard to views on quality of life of professionals and patients.
   METHODS: A Medline search was performed with the search terms "decompressive surgery," "craniectomy," "hemicraniectomy," "decompressive hemicraniectomy," and " middle cerebral artery," "MCA," "infarct,*" "stroke,*" "embolus," "emboli," "thrombosis," "occlusion," "infarction," and "middle cerebral artery stroke," A second search was also done for views on postoperative quality of life. Studies retrieved were randomized controlled trials, observational studies, and reviews. We compared patients who received only medical treatment with those who had decompressive surgery. Participants were adult patients presenting with malignant middle cerebral artery infarction.
   RESULTS: 270 abstracts were reviewed. 40 articles were identified: 8 randomized controlled trials and 4 observational studies. There were a total of 692 patients: 268 surgical and 424 medical. The 2 groups were comparable, with similar demographics. In most trials, mortality was lower with surgery. However, morbidity tended to be higher, particularly in the elderly population. Morbidity was lower with medical treatment. Twelve articles on postoperative quality of life were reviewed; views differed between professionals, and survivors and caregivers. A patient-level comparison could not be made between all studies.
   CONCLUSIONS: Surgical decompression results in lowered mortality but high morbidity, especially in the elderly. There is an increase in Quality Adjusted Life Years but at high costs. Professionals think that surgery is not worth the high disability rate. However, patients and caregivers are satisfied with their postoperative quality of life. Survey data from healthy study participants who are not professionals in stroke care were not available. The decision to treat surgically needs to be decided on an individual basis.
C1 [Das, Suparna; Mitchell, Patrick; Ross, Nicholas] Royal Victoria Infirm, Newcastle Upon Tyne, Tyne & Wear, England.
   [Whitfield, Peter C.] Derriford Hosp, Plymouth, Devon, England.
RP Das, S (reprint author), Royal Victoria Infirm, Newcastle Upon Tyne, Tyne & Wear, England.
EM suparna.das1@nhs.net
OI Das, Suparna/0000-0002-2152-2719; Whitfield, Peter/0000-0003-0566-1820
CR Alexander P, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-014390
   Benejam B, 2009, J NEUROL, V256, P1126, DOI 10.1007/s00415-009-5083-9
   Broughton E, 2014, BRIT J NEUROSURG, V28, P34, DOI 10.3109/02688697.2013.815319
   Carter BS, 1997, NEUROSURGERY, V40, P1168, DOI 10.1097/00006123-199706000-00010
   Chua AE, 2015, ACTA MED PHILIPP, V49, P28
   Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077
   Dasenbrock HH, 2017, STROKE, V48, P704, DOI 10.1161/STROKEAHA.116.014727
   Demertzi A, 2011, J NEUROL, V258, P1058, DOI 10.1007/s00415-010-5882-z
   Erban P, 2006, CLIN NEUROL NEUROSUR, V108, P384, DOI 10.1016/j.clineuro.2005.06.008
   Foerch C, 2004, J NEUROSURG, V101, P248, DOI 10.3171/jns.2004.101.2.0248
   Frank JI, 2014, STROKE, V45, P781, DOI 10.1161/STROKEAHA.113.003200
   Gupta R, 2004, STROKE, V35, P539, DOI 10.1161/01.STR.0000109772.64650.18
   Hacke W, 1996, ARCH NEUROL-CHICAGO, V53, P309, DOI 10.1001/archneur.1996.00550040037012
   Hao ZL, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001039
   Harscher S, 2006, ACTA NEUROCHIR, V148, P31, DOI 10.1007/s00701-005-0617-0
   Hofmeijer J, 2013, J NEUROL, V260, P1396, DOI 10.1007/s00415-012-6810-1
   Hofmeijer J, 2009, LANCET NEUROL, V8, P326, DOI 10.1016/S1474-4422(09)70047-X
   Holtkamp M, 2001, J NEUROL NEUROSUR PS, V70, P226, DOI 10.1136/jnnp.70.2.226
   Hutchinson PJ, 2016, NEW ENGL J MED, V375, P1119, DOI 10.1056/NEJMoa1605215
   Juttler E, 2014, NEW ENGL J MED, V370, P1091, DOI 10.1056/NEJMoa1311367
   Juttler E, 2007, STROKE, V38, P2518, DOI 10.1161/STROKEAHA.107.485649
   Leonhardt G, 2002, J NEUROL, V249, P1433, DOI 10.1007/s00415-002-0875-1
   Lu XC, 2014, SCI REP-UK, V4, DOI 10.1038/srep07070
   Mayer SA, 2007, STROKE, V38, P2410, DOI 10.1161/STROKEAHA.107.494203
   Murthy JMK, 2012, NEUROL INDIA, V60, P565, DOI 10.4103/0028-3886.105186
   Rahme R, 2012, J NEUROSURG, V117, P749, DOI 10.3171/2012.6.JNS111140
   Rai VK, 2014, NEUROL INDIA, V62, P26, DOI 10.4103/0028-3886.128273
   Ronchetti G, 2014, BIOMED RES INT, DOI 10.1155/2014/624126
   ROPPER AH, 1984, ARCH NEUROL-CHICAGO, V41, P26, DOI 10.1001/archneur.1984.04050130032017
   Sahuquillo J, 2013, CURR OPIN CRIT CARE, V19, P101, DOI 10.1097/MCC.0b013e32835eba1a
   Schwab S, 1998, STROKE, V29, P1888, DOI 10.1161/01.STR.29.9.1888
   Slezins J, 2012, MEDICINA-LITHUANIA, V48, P521
   Staykov D, 2012, NEUROCRIT CARE, V17, P159, DOI 10.1007/s12028-012-9722-0
   Subramaniam S, 2009, NEUROLOGIST, V15, P178, DOI 10.1097/NRL.0b013e3181963d19
   Vahedi K, 2007, STROKE, V38, P2506, DOI 10.1161/STROKEAHA.107.485235
   Walz B, 2002, J NEUROL, V249, P1183, DOI 10.1007/s00415-002-0798-x
   Weil AG, 2011, CAN J NEUROL SCI, V38, P434, DOI 10.1017/S0317167100011835
   Woertgen C, 2004, ACTA NEUROCHIR, V146, P691, DOI 10.1007/s00701-004-0280-x
   Yang Xiao-feng, 2005, J Zhejiang Univ Sci B, V6, P644, DOI 10.1631/jzus.2005.B0644
   Zhao JW, 2012, NEUROCRIT CARE, V17, P161, DOI 10.1007/s12028-012-9703-3
NR 40
TC 5
Z9 5
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 8
EP 16
DI 10.1016/j.wneu.2018.11.176
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400098
PM 30500591
DA 2020-05-12
ER

PT J
AU Inoue, T
   Okada, Y
   Sato, S
   Ishikawa, T
   Kawamata, T
AF Inoue, Tatsuya
   Okada, Yoshikazu
   Sato, Shinsuke
   Ishikawa, Tatsuya
   Kawamata, Takakazu
TI Omnidirectional Malleable Ring Retractor: New Approach to Retraction
   During Carotid Endarterectomy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Carotid endarterectomy; Malleable metal; Omnidirectional retraction
   supporting ring; Tin alloy
ID SUPPORTING RING
AB OBJECTIVE: To resolve problems with retraction instruments in order to obtain shallow and flat operative field in procedures such as carotid endarterectomy, we developed a new malleable tin alloy omnidirectional retraction supporting (ORS) ring.
   METHODS: The new ORS ring has an ellipse-shaped (major axis: 275 mm; minor axis: 192 mm) bar frame (4 mm x 6 mm). The bar has 22 equidistant outward protrusions (length, 12 mm; diameter, 2.5 mm). The frame is made of tin alloy with approximately 1% silver, which provides sufficient malleability to fit different cervical surgical approaches. Rubber bands ending with hooks are attached around the protrusions. The new ORS ring can be placed closer to the skin surface, and skin incision edges are horizontally retracted by the hooks attached in the desired direction. The hooks are repositioned in a stepwise fashion at deeper layers of the surgical wound following dissection for carotid artery exposure.
   RESULTS: The tin alloy ORS ring was used in 30 carotid endarterectomies. As this ring could be closely positioned in all cases, the real depth of the operative fields (with all instruments in place) was reduced by the omnidirectional horizontal retraction without interference with surgical manipulations. Working on the distal internal carotid artery, such as putting a tacking suture in place and arteriotomy closure, could be easily performed.
   CONCLUSIONS: The newly developed malleable tin alloy ORS ring can be a valuable instrument for the easy performance of surgery for cervical carotid lesions. Considering its advantages, it is better than conventional retractors and existing stainless steel ORS rings.
C1 [Inoue, Tatsuya; Okada, Yoshikazu; Sato, Shinsuke] St Lukes Int Hosp, Dept Neurosurg, Tokyo, Japan.
   [Inoue, Tatsuya; Sato, Shinsuke; Ishikawa, Tatsuya; Kawamata, Takakazu] Tokyo Womens Med Univ, Tokyo, Japan.
RP Inoue, T (reprint author), St Lukes Int Hosp, Dept Neurosurg, Tokyo, Japan.; Inoue, T (reprint author), Tokyo Womens Med Univ, Tokyo, Japan.
EM inota@luke.ac.jp
OI Ishikawa, Tatsuya/0000-0003-3553-6510
CR Ganss C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123889
   Kamaleshwaran Koramadai Karuppusamy, 2015, World J Nucl Med, V14, P216, DOI 10.4103/1450-1147.161730
   Loftus CM., 2007, CAROTID ENDARTERECTO
   Moteki Y, 2018, WORLD NEUROSURG, V109, P110, DOI 10.1016/j.wneu.2017.09.085
   Rehman W, 2016, J PHOTOCH PHOTOBIO B, V164, P65, DOI 10.1016/j.jphotobiol.2016.09.018
   Ryu B, 2018, WORLD NEUROSURG, V120, P368, DOI 10.1016/j.wneu.2018.09.059
   Shima T, 1998, NEUROSURGERY, V42, P1182, DOI 10.1097/00006123-199805000-00146
   Sundt Jr TM, 1994, SUNDTS OCCLUSIVE CER, P198
   Yoneyama T, 2015, J NEUROSURG, V122, P148, DOI 10.3171/2014.9.JNS132856
NR 9
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 17
EP 22
DI 10.1016/j.wneu.2018.11.160
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400099
PM 30481633
DA 2020-05-12
ER

PT J
AU Bozkurt, G
   Turri-Zanoni, M
   Russo, F
   Elhassan, HA
   Castelnuovo, P
   Battaglia, P
AF Bozkurt, Gulpembe
   Turri-Zanoni, Mario
   Russo, Federico
   Elhassan, Hassan Ahmed
   Castelnuovo, Paolo
   Battaglia, Paolo
TI Ultrasonic Scalpel-Assisted Endoscopic Endonasal Surgery of
   Infratemporal Fossa: Our First Impressions
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endoscopic surgery; Hemostasis; Infratemporal fossa; Skull base;
   Transpterygoid approach; Ultrasonic scalpel
ID INJURY
AB BACKGROUND: The endoscopic endonasal transpterygoid approach is emerging as a valid option for treating selected tumors in the infratemporal fossa. Compared with traditional open approaches, the endoscopic endonasal approach presents more difficulty in controlling bleeding and less choice in surgical instruments for endoscopic tumor dissection, which is often performed with bipolar forceps or steel dissectors.
   CASE DESCRIPTION: We describe the use of an ultrasonic scalpel device for performing endoscopic endonasal resection of 2 rare infratemporal fossa tumors (mature teratoma and hemangiopericytoma), which has not been reported in the literature so far. We also review the literature on endoscopic ultrasonic scalpel use.
   CONCLUSIONS: The ultrasonically activated scalpel is a safe, effective and simple to use device, which achieved excellent hemostasis and did not damage adjacent neurovascular structures.
C1 [Bozkurt, Gulpembe; Turri-Zanoni, Mario; Russo, Federico; Castelnuovo, Paolo; Battaglia, Paolo] Univ Insubria, Head & Neck Surg & Forens Dissect Res Ctr, Dept Biotechnol & Life Sci, Div Otorhinolaryngol, Varese, Italy.
   [Elhassan, Hassan Ahmed] Lewisham Univ Hosp, Div Otorhinolaryngol, London, England.
RP Bozkurt, G (reprint author), Univ Insubria, Head & Neck Surg & Forens Dissect Res Ctr, Dept Biotechnol & Life Sci, Div Otorhinolaryngol, Varese, Italy.
EM pgtalayhan@gmail.com
OI Elhassan, Hassan/0000-0001-5378-8709; Turri-Zanoni,
   Mario/0000-0002-3678-9088; Bozkurt, Gulpembe/0000-0003-2100-023X
CR Amaral J F, 1994, Endosc Surg Allied Technol, V2, P181
   Battaglia P, 2016, HEAD NECK-J SCI SPEC, V38, P214
   Battaglia P, 2014, OTOLARYNG HEAD NECK, V150, P696, DOI 10.1177/0194599813520290
   Brucoli M, 2005, J CRANIOFAC SURG, V16, P1146, DOI 10.1097/01.scs.0000180006.52986.c2
   Carlander J, 2005, BRIT J SURG, V92, P772, DOI 10.1002/bjs.4948
   Castelnuovo P, 2013, OTOLARYNG HEAD NECK, V149, P424, DOI 10.1177/0194599813493073
   Dequanter D, 2016, MED DEVICES-EVID RES, V9, P139, DOI 10.2147/MDER.S104786
   Isolan GR, 2007, SKULL BASE-INTERD AP, V17, P285, DOI 10.1055/s-2007-985193
   Joo W, 2013, CLIN ANAT, V26, P455, DOI 10.1002/ca.22202
   Kassam Amin, 2005, Neurosurg Focus, V19, pE7
   Kirdak T, 2005, WORLD J SURG, V29, P771, DOI 10.1007/s00268-005-7788-y
   Lund V, 2011, RHINOLOGY, P1
   Schemmel M, 1997, FERTIL STERIL, V67, P382, DOI 10.1016/S0015-0282(97)81926-7
   Turri-Zanoni M, 2017, HEAD NECK-J SCI SPEC, V39, P754, DOI 10.1002/hed.24676
   Yu Q, 1998, ORAL SURG ORAL MED O, V85, P742, DOI 10.1016/S1079-2104(98)90045-2
NR 15
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 23
EP 28
DI 10.1016/j.wneu.2018.11.202
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400100
PM 30521958
DA 2020-05-12
ER

PT J
AU Lieng, Q
   Wan, Q
   Long, G
   Ma, WX
   Jin, WD
   Liu, LH
   Wu, YX
   Shi, JD
   Wang, ZL
AF Lieng, Qiang
   Wan, Qian
   Long, Guo
   Ma, Wenxin
   Jin, Weidong
   Liu, Liehua
   Wu, Yuexiang
   Shi, Jiandang
   Wang, Zili
TI Clinical Effectiveness of the Posterior Affected-Vertebrae Fixation
   Method in Posterior-Anterior Surgery to Treat Thoracic Spinal
   Tuberculosis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Affected-vertebrae fixation; Combined posterior-anterior approach;
   Short-segment fixation; Supporting bone grafts; Thoracic spinal
   tuberculosis
ID ADJACENT SEGMENT DISEASE; SURGICAL-TREATMENT; DEBRIDEMENT; LUMBAR;
   FUSION; INSTRUMENTATION
AB OBJECTIVE: The present retrospective comparative analysis was conducted to assess the effectiveness of affected-vertebrae fixation versus short-segment fixation to treat thoracic spinal tuberculosis.
   METHODS: The present study included 110 patients receiving treatment for thoracic spinal tuberculosis at our hospital from January 2006 to June 2013. All cases involved the use of posterior spinal correction, posterior lateral fusion, internal fixation, anterior decompression, radical debridement, and intervertebral supporting bone grafts. The cases were divided by the scope of posterior internal fixation into the affected-vertebrae fixation group (n = 62) and the short-segment fixation group (n = 48). Statistical analysis was used to compare the clinical effectiveness, laboratory test results, and imaging findings.
   RESULTS: The mean surgical blood loss, mean operating time, and mean inpatient expenditures were all significantly less in the affected-vertebrae fixation group than in the short-segment fixation group (P < 0.05). The affected-vertebrae fixation group had a lower mean graft fusion time (5.21 vs. 5.06 months), mean healing time (5.73 vs. 5.91 months), mean degree of correction of thoracic vertebrae kyphosis Cobb angle (16.9 degrees vs. 18.4 degrees), and mean loss of angle (2.6 degrees vs. 2.1 degrees) compared with the short-segment fixation group. However, these differences all lacked statistical significance. Postoperatively, neurological deficits and pain were effectively relieved in all patients, and the lesion had healed at the final follow-up evaluation (>= 5 years postoperatively).
   CONCLUSIONS: As long as the surgical indications are strictly observed, posterior affected-vertebrae fixation in posterior-anterior surgery for thoracic spinal tuberculosis is safe, effective, and feasible; entails minimal surgical trauma; and has a lower inpatient cost.
C1 [Lieng, Qiang; Ma, Wenxin; Jin, Weidong; Liu, Liehua; Shi, Jiandang; Wang, Zili] Ningxia Med Univ, Gen Hosp, Dept Spinal Surg, Yinchuan, Peoples R China.
   [Wan, Qian] Hillsborough Community Coll, Tampa, FL USA.
   [Long, Guo; Wang, Zili] Shanghai Guolong Hosp, Shanghai, Peoples R China.
   [Wu, Yuexiang] Ningxia Med Univ, Gen Hosp, Dept Outpatients, Yinchuan, Peoples R China.
RP Wang, ZL (reprint author), Ningxia Med Univ, Gen Hosp, Dept Spinal Surg, Yinchuan, Peoples R China.; Wang, ZL (reprint author), Shanghai Guolong Hosp, Shanghai, Peoples R China.
EM wangzinx@126.com
CR Christensen FB, 2001, SPINE, V26, P538, DOI 10.1097/00007632-200103010-00018
   Guzey FK, 2005, J NEUROSURG-SPINE, V3, P450, DOI 10.3171/spi.2005.3.6.0450
   Jin WD, 2014, SPINE J, V14, P964, DOI 10.1016/j.spinee.2013.07.466
   Liu Z, 2016, CLIN NEUROL NEUROSUR, V141, P111, DOI 10.1016/j.clineuro.2016.01.002
   Luo CK, 2016, SPINE J, V16, P154, DOI 10.1016/j.spinee.2013.11.014
   Park P, 2004, SPINE, V29, P1938, DOI 10.1097/01.brs.0000137069.88904.03
   Ramos RD, 2017, J NEUROSURG-SPINE, V26, P507, DOI 10.3171/2016.9.SPINE16174
   Ran B, 2016, J HUAZHONG U SCI-MED, V36, P541, DOI 10.1007/s11596-016-1622-7
   Saavedra-Pozo FM, 2014, OCHSNER J, V14, P78
   Shi J, 2017, EUR SPINE J, V26, P1
   Shi JD, 2014, ORTHOP SURG, V6, P259, DOI 10.1111/os.12140
   Virk SS, 2014, ORTHOPEDICS, V37, P547, DOI 10.3928/01477447-20140728-08
   Wang Q, 2015, J SPINAL SURG, V13, P1
   Wang ZL, 2013, EUR SPINE J, V22, P274, DOI 10.1007/s00586-012-2536-0
   Wu P, 2015, EUR J TRAUMA EMERG S, V41, P189, DOI 10.1007/s00068-014-0421-8
   [武启军 WU Qijun], 2010, [中国脊柱脊髓杂志, Chinese Journal of Spine and Spinal Cord], V20, P267
   Wu QJ, 2010, J NINGXIA MED U, V2, P194
   Wu WJ, 2018, WORLD NEUROSURG, V110, pE842, DOI 10.1016/j.wneu.2017.11.126
   Yao Y, 2017, WORLD NEUROSURG, V105, P327, DOI 10.1016/j.wneu.2017.05.167
   Yin XH, 2016, EUR SPINE J, V25, P1047, DOI 10.1007/s00586-015-4283-5
   Zhong WY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119759
   王自立, 2010, [中华骨科杂志, Chinese Journal of Orthopedics], V30, P717
NR 22
TC 2
Z9 3
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 29
EP 39
DI 10.1016/j.wneu.2018.11.199
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400101
PM 30503294
DA 2020-05-12
ER

PT J
AU Donnally, CJ
   Trapana, EJ
   Barnhill, SW
   Bondar, KJ
   Rivera, S
   Sheu, JI
   Wang, MY
AF Donnally, Chester J., III
   Trapana, Evan J.
   Barnhill, Spencer W.
   Bondar, Kevin J.
   Rivera, Sebastian
   Sheu, Jonathan I.
   Wang, Michael Y.
TI The Most Influential Publications in Odontoid Fracture Management
SO WORLD NEUROSURGERY
LA English
DT Review
DE Bibliometric study; Citation analysis; Elderly fracture management; Most
   influential; Odontoid; Odontoid fracture
ID CITED ARTICLES; IMPACT
AB OBJECTIVE: Management of odontoid fractures has improved and evolved due to advancing diagnostic guidelines and understanding of long-term outcomes. The aim of this study was to quantify the most frequently cited publications pertaining to odontoid fractures and determine their validity as a tool to practice evidence-based medicine.
   METHODS: A Clarivate Analytics Web of Science search was used to identify all articles related to odontoid fractures. The 50 most cited articles were reviewed. Criteria included the frequency of citation, year of publication, countries of origin, journal, levels of evidence (LOE), article types, and supporting authors and institutions.
   RESULTS: The top 3 most cited papers were " Radiological and anatomical evaluation of the atlantoaxial transarticular screw fixation technique" (Madawi 1997), " Atlantoaxial fixation using, plate and screw method: A report of 160 treated patients" (Goel 2002), and " The anatomical suitability of the C1-2 complex for transarticular screw fixation" (Paramore 1996). Spine (n = 13; 26%) was the most common journal, and the most frequent decade was 2000-2009 (n = 18; 36%). The United States was associated with the greatest number of publications, and the most common article type was clinical outcomes (n = 16; 32%). The most recurring LOE was IV (n = 20; 40%).
   CONCLUSIONS: This review provides a comprehensive understanding of the historical literature pertaining to odontoid fracture management. There is a paucity of high LOE publications regarding this topic, and clinicians should strive to provide more high-level studies. This article can help practitioners navigate the vast body of literature about this topic and identify high-impact publications.
C1 [Donnally, Chester J., III; Trapana, Evan J.; Barnhill, Spencer W.; Rivera, Sebastian] Univ Miami Hosp, Dept Orthopaed Surg, Miami, FL 33136 USA.
   [Bondar, Kevin J.; Sheu, Jonathan I.] Univ Miami, Miller Sch Med, Dept Educ, Miami, FL 33136 USA.
   [Wang, Michael Y.] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA.
RP Donnally, CJ (reprint author), Univ Miami Hosp, Dept Orthopaed Surg, Miami, FL 33136 USA.
EM chester.donnally@jhsmiami.org
OI Sheu, Jonathan/0000-0002-1916-0755; Donnally III,
   Chester/0000-0002-1701-0745
CR Alan N, 2017, J CRANIOVERTEBRAL JU, V8, P22, DOI 10.4103/0974-8237.199883
   BLOCKEY NJ, 1956, J BONE JOINT SURG BR, V38, P794
   Cheek J, 2006, QUAL HEALTH RES, V16, P423, DOI 10.1177/1049732305285701
   Dvorak MF, 2007, SPINE, V32, P2620, DOI 10.1097/BRS.0b013e318158ce16
   Ellegaard O, 2015, SCIENTOMETRICS, V105, P1809, DOI 10.1007/s11192-015-1645-z
   GARFIELD E, 1972, SCIENCE, V178, P471, DOI 10.1126/science.178.4060.471
   Garner RM, 2018, J NEUROINTERV SURG, V10, P102, DOI 10.1136/neurintsurg-2017-013265
   Goal A, 2002, NEUROSURGERY, V51, P1356
   Goel A, 2002, NEUROSURGERY, V51, P1351, DOI 10.1097/00006123-200212000-00004
   Howick J, 2011 OXFORD CEBM LEV
   Jones LB, 2018, J ORTHOP TRAUMA, V32, pe139, DOI 10.1097/BOT.0000000000001106
   Lee YC, 2017, INT J SPINE SURG, V11, DOI 10.14444/4019
   Lefaivre KA, 2011, CLIN ORTHOP RELAT R, V469, P1487, DOI 10.1007/s11999-010-1604-1
   Madawi AA, 1997, J NEUROSURG, V86, P961, DOI 10.3171/jns.1997.86.6.0961
   Paramore CG, 1996, J NEUROSURG, V85, P221, DOI 10.3171/jns.1996.85.2.0221
   Qiu J, 2001, INF STUD THEORY APPL, V24, P474
   Robinson AL, 2017, BIOMED RES INT, DOI 10.1155/2017/8321680
   Ruegsegger N, 2016, SPINE, V41, P538, DOI 10.1097/BRS.0000000000001261
   Sheikh HQ, 2018, SURG-J R COLL SURG E, V16, P297, DOI 10.1016/j.surge.2018.03.007
   Skovrlj B, 2016, GLOB SPINE J, V6, P69, DOI 10.1055/s-0035-1551652
   Smith HE, 2010, J SPINAL DISORD TECH, V23, P501, DOI 10.1097/BSD.0b013e3181cc43c7
NR 21
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 41
EP 48
DI 10.1016/j.wneu.2018.11.205
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400103
PM 30528529
DA 2020-05-12
ER

PT J
AU Deckey, DG
   Reid, DBC
   Mallozzi, S
   Daniels, AH
AF Deckey, David G.
   Reid, Daniel B. C.
   Mallozzi, Scott
   Daniels, Alan H.
TI Cutaneous Metastasis via Surgical Planes After Lumbar Spinal
   Reconstruction for Spinal Metastatic Disease
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cutaneous lesion; Lumbar metastasis; Pathologic fracture; Wound
   complications
ID SQUAMOUS-CELL CARCINOMA; CERVICAL-CANCER
AB BACKGROUND: Cervical squamous cell carcinoma is the second most common cancer in women worldwide and the third most common cause of female cancer mortality. It frequently metastasizes to the osseous spine and has been rarely reported to cause cutaneous metastases at gynecologic surgical scars.
   CASE DESCRIPTION: A 63-year-old woman with known metastatic cervical squamous cell carcinoma presented with a pathologic fracture of the L2 vertebra, unrelenting back pain, bilateral lower extremity weakness, and inability to ambulate. The patient elected to undergo an L2 corpectomy with intervertebral cage placement via the right-sided retroperitoneal approach followed by percutaneous L1-L4 pedicle screw instrumentation in the same operative setting. Her immediate postoperative course was uneventful. Eight weeks after surgery, both her flank and posterior incisions became painful and swollen. She underwent irrigation and debridement of the right flank incision due to elevated inflammatory markers and concern for surgical site infection. Multiple intraoperative cultures were obtained and were ultimately negative for bacterial or fungal growth. Several weeks later, the patient presented with worsening painful growths of her incisions. Excisional biopsy and debulking of the masses in the operating room revealed squamous cell carcinoma with areas of cystic change and tumor necrosis consistent with progression of the patient's metastatic cervical cancer.
   CONCLUSIONS: Cervical squamous cell carcinoma can metastasize regionally via surgical planes and manifest as cutaneous lesions. Local metastasis should be included in the differential in cases of postoperative wound complications.
C1 [Deckey, David G.] Tufts Univ, Sch Med, Boston, MA 02111 USA.
   [Reid, Daniel B. C.] Brown Univ, Alpert Med Sch, Dept Orthopaed, East Providence, RI USA.
   [Mallozzi, Scott] Univ Connecticut, Hlth Ctr, Farmington, CT USA.
   [Daniels, Alan H.] Brown Univ, Alpert Med Sch, Dept Orthopaed, Div Spine Surg, East Providence, RI 02912 USA.
RP Daniels, AH (reprint author), Brown Univ, Alpert Med Sch, Dept Orthopaed, Div Spine Surg, East Providence, RI 02912 USA.
EM alan_daniels@brown.edu
CR ABUGHAZALEH SZ, 1979, SURG GYNECOL OBSTET, V148, P728
   Agrawal A, 2010, J OBSTET GYNAECOL CA, V32, P467, DOI 10.1016/S1701-2163(16)34501-7
   Aoude A, 2014, CAN J SURG, V57, P188, DOI 10.1503/cjs.012013
   Basu B, 2013, J TURK-GER GYNECOL A, V14, P174, DOI 10.5152/jtgga.2013.62444
   Colombo N, 2012, ANN ONCOL, V23, P27, DOI 10.1093/annonc/mds268
   COPAS PR, 1995, GYNECOL ONCOL, V56, P102, DOI 10.1006/gyno.1995.1018
   Hongladaromp W, 2014, ASIAN PAC J CANCER P, V15, P887, DOI 10.7314/APJCP.2014.15.2.887
   Iavazzo C, 2015, IRISH J MED SCI, V184, P113, DOI 10.1007/s11845-014-1208-y
   Iavazzo C, 2008, INT J GYNECOL OBSTET, V101, P199, DOI 10.1016/j.ijgo.2007.11.016
   Nagura M, 2015, GYNECOL ONCOL, V136, P104, DOI 10.1016/j.ygyno.2014.11.075
   Schiffman M, 2007, LANCET, V370, P890, DOI 10.1016/S0140-6736(07)61416-0
   Sil Amit Kumar, 2012, J Indian Med Assoc, V110, P649
   Thanapprapasr D, 2010, INT J GYNECOL CANCER, V20, P373, DOI 10.1111/IGC.0b013e3181d4a0a1
   Tokuhashi Y, 2014, WORLD J ORTHOP, V5, P262, DOI 10.5312/wjo.v5.i3.262
NR 14
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 49
EP 53
DI 10.1016/j.wneu.2018.11.218
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400104
PM 30528523
DA 2020-05-12
ER

PT J
AU Koge, J
   Kato, S
   Hashimoto, T
   Nakamura, Y
   Kawajiri, M
   Yamada, T
AF Koge, Junpei
   Kato, Seiya
   Hashimoto, Tetsuya
   Nakamura, Yukihiko
   Kawajiri, Masakazu
   Yamada, Takeshi
TI Vessel Wall Injury After Stent Retriever Thrombectomy for Internal
   Carotid Artery Occlusion with Duplicated Middle Cerebral Artery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Arterial duplication; Autopsy; Ischemic stroke; Middle cerebral artery;
   Thrombectomy
ID ACUTE ISCHEMIC-STROKE; MECHANICAL THROMBECTOMY; PUSH
AB BACKGROUND: Experimental evidence that stent retriever thrombectomy (SRT) may cause arterial wall damage is increasing, although histopathologic findings focused on vessel wall injury after SRT have not fully been reported in humans.
   CASE DESCRIPTION: We describe an autopsy case of an 82-year-old woman who presented with acute left intracranial internal carotid artery occlusion and received SRT. When we attempted to catheterize the M1 segment of the normal middle cerebral artery (MCA), we were not aware of a duplicated MCA and advanced the microcatheter into the main MCA trunk with a smaller caliber than that of the normal M1 segment. A 6-mm Trevo thrombectomy device was deployed from the main MCA trunk but was insufficiently expanded in the MCA segment. Two passes with a Trevo resulted in failed recanalization. The patient died on postoperative day 4 because of extensive infarction. Autopsy revealed a duplicated MCA and subintimal arterial dissection in the proximal segment of the main MCA trunk. The supraclinoid internal carotid artery also revealed endothelial denudation and mural thrombus.
   CONCLUSIONS: We provide a histopathologic report of vessel wall injury after SRT that caused failed recanalization. Anatomic variations of the MCA should be considered when selecting suitable thrombectomy devices in order to avoid vessel wall injury.
C1 [Koge, Junpei; Hashimoto, Tetsuya; Kawajiri, Masakazu; Yamada, Takeshi] Saiseikai Fukuoka Gen Hosp, Div Neurol, Fukuoka, Fukuoka, Japan.
   [Kato, Seiya] Saiseikai Fukuoka Gen Hosp, Div Pathol, Fukuoka, Fukuoka, Japan.
   [Nakamura, Yukihiko] Saiseikai Fukuoka Gen Hosp, Div Neurosurg, Fukuoka, Fukuoka, Japan.
RP Koge, J (reprint author), Saiseikai Fukuoka Gen Hosp, Div Neurol, Fukuoka, Fukuoka, Japan.
EM j.kouge@gmail.com
OI Hashimoto, Tetsuya/0000-0002-8121-0215
CR Arai D, 2016, J NEUROINTERV SURG, V8, P992, DOI 10.1136/neurintsurg-2015-011968
   Gascou G, 2014, AM J NEURORADIOL, V35, P734, DOI 10.3174/ajnr.A3746
   Gory B, 2013, AM J NEURORADIOL, V34, P2192, DOI 10.3174/ajnr.A3531
   Goyal M, 2016, LANCET, V387, P1723, DOI 10.1016/S0140-6736(16)00163-X
   Gutierrez J, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00056
   Haussen DC, 2015, STROKE, V46, P2838, DOI 10.1161/STROKEAHA.115.010044
   Hwang YH, 2016, STROKE, V47, P1850, DOI 10.1161/STROKEAHA.116.013046
   Jovin TG, 2015, NEW ENGL J MED, V372, P2296, DOI 10.1056/NEJMoa1503780
   Kai Y, 2006, SURG NEUROL, V65, P190, DOI 10.1016/j.surneu.2005.05.032
   Komiyama M, 1998, AM J NEURORADIOL, V19, P45
   Mendez B, 2018, STROKE, V49, P2723, DOI 10.1161/STROKEAHA.118.021989
   Mourand I, 2018, J NEUROINTERV SURG, V10, P5, DOI 10.1136/neurintsurg-2017-013358
   Pereira VM, 2013, STROKE, V44, P2802, DOI 10.1161/STROKEAHA.113.001232
   Rai AT, 2013, J NEUROINTERV SURG, V5, P371, DOI 10.1136/neurintsurg-2012-010314
   Roth C, 2010, STROKE, V41, P2559, DOI 10.1161/STROKEAHA.110.592071
   Teng DY, 2015, STROKE, V46, P1099, DOI 10.1161/STROKEAHA.114.007494
   Tsai JP, 2018, STROKE, V49, P952, DOI 10.1161/STROKEAHA.117.018858
   Tsang COA, 2018, AM J NEURORADIOL, V39, P2070, DOI 10.3174/ajnr.A5825
   Uchiyama N, 2017, NEUROL MED-CHIR, V57, P261, DOI 10.2176/nmc.ra.2017-0043
   Wiesmann M, 2017, J NEUROINTERV SURG, V9, P253, DOI 10.1136/neurintsurg-2016-012322
   Yin NS, 2010, STROKE, V41, P938, DOI 10.1161/STROKEAHA.109.576793
NR 21
TC 3
Z9 3
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 54
EP 58
DI 10.1016/j.wneu.2018.11.223
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400105
PM 30529524
DA 2020-05-12
ER

PT J
AU Linzey, JR
   Sivakumar, W
   Johnson, JN
   Ivan, ME
   Haider, AS
   Philips, CA
   Than, KD
   Tomei, KL
   Muraszko, KM
   Nduom, EK
AF Linzey, Joseph R.
   Sivakumar, Walavan
   Johnson, Jeremiah N.
   Ivan, Michael E.
   Haider, Ali S.
   Philips, Chris Ann
   Than, Khoi D.
   Tomei, Krystal L.
   Muraszko, Karin M.
   Nduom, Edjah K.
TI Young Neurosurgeons Committee of the American Association of
   Neurological Surgeons: Training Ground for Future Leaders in Organized
   Neurosurgery in the United States of America
SO WORLD NEUROSURGERY
LA English
DT Review
DE Leadership; Organized neurosurgery; YNC; Young Neurosurgeons Committee
ID HISTORY
AB The Young Neurosurgeons Committee, founded in 1991 by Dr. Roberto C. Heros, has been a vital component of the American Association of Neurological Surgeons. It has grown from an opportunity for young neurosurgeons to network with senior neurosurgeons to becoming the major voice of young neurosurgeons and a training ground for the future leaders of organized neurosurgery. The present report has reviewed the leadership involvement of 168 previous Young Neurosurgeons Committee members and briefly highlighted the careers of 4 of these members who have attained leadership positions in neurosurgery.
C1 [Linzey, Joseph R.] Univ Michigan, Med Sch, Ann Arbor, MI 48109 USA.
   [Sivakumar, Walavan] John Wayne Canc Inst, Pacific Neurosci Inst, Santa Monica, CA USA.
   [Johnson, Jeremiah N.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA.
   [Ivan, Michael E.] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA.
   [Haider, Ali S.] Texas A&M Coll Med, College Stn, TX USA.
   [Philips, Chris Ann] Amer Assoc Neurol Surg, Member Serv, Rolling Meadows, IL USA.
   [Than, Khoi D.] Oregon Hlth & Sci Univ, Dept Neurol Surg, Portland, OR 97201 USA.
   [Tomei, Krystal L.] Case Western Reserve Univ, Univ Hosp Cleveland, Sch Med, Med Ctr,Dept Neurol Surg, Cleveland, OH 44106 USA.
   [Muraszko, Karin M.] Univ Michigan, Dept Neurosurg, Michigan Med, Ann Arbor, MI 48109 USA.
   [Nduom, Edjah K.] NINDS, Surg Neurol Branch, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.
RP Nduom, EK (reprint author), NINDS, Surg Neurol Branch, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.
EM edjah.nduom@nih.gov
OI Johnnson, Jeremiah/0000-0002-9920-5895; Haider, Ali/0000-0002-4368-871X;
   Ivan, Michael/0000-0002-4798-4989
FU Intramural NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [Z99 NS999999]
CR Boco T, 2010, NEUROSURGERY, V67, P1036, DOI 10.1227/NEU.0b013e3181eda3b1
   Boockvar JA, 2000, NEUROSURGERY, V46, P1223, DOI 10.1097/00006123-200005000-00040
   Brock M, 1997, ACT NEUR S, V69, P8
   Chalouhi N, 2013, NEUROSURGERY, V73, P709, DOI 10.1227/01.neu.0000430299.02714.46
   Engelhard HH, 1998, NEUROSURGERY, V43, P914, DOI 10.1097/00006123-199810000-00111
   House PA, 2010, NEUROSURGERY, V67, P781, DOI 10.1227/01.NEU.0000374766.52631.0C
   Jea A, 2007, NEUROSURGERY, V61, P612, DOI 10.1227/01.NEU.0000290910.32600.7E
   Lanzino G, 1998, NEUROSURGERY, V43, P133, DOI 10.1097/00006123-199807000-00085
   Mehta GU, 2010, WORLD NEUROSURG, V74, P49, DOI 10.1016/j.wneu.2010.05.027
   Nduom E, 2015, YOUNG NEUROSURGEONS, V5
   Nduom E., 2015, YOUNG NEUROSURGEONS, V3
   Piepmeier JM, 1996, NEUROSURGERY, V38, P146, DOI 10.1097/00006123-199601000-00034
   Schulz K, 2013, MED EDUC ONLINE, V18, DOI 10.3402/meo.v18i0.22440
   Than K, 2016, YOUNG NEUROSURGEONS, V5
NR 14
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 59
EP 63
DI 10.1016/j.wneu.2018.11.206
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400106
PM 30529528
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Inoue, Y
   Matsuzawa, K
AF Inoue, Yasuaki
   Matsuzawa, Kazuhito
TI Occipital Artery-to-Vertebral Artery Bypass to Stop Transient Ischemic
   Attacks Caused by Traumatic Vertebral Artery Dissection
SO WORLD NEUROSURGERY
LA English
DT Article
DE Bypass; Surgical treatment; Transient ischemic attack; Traumatic
   vertebral artery dissection
ID OCCLUSION; MANAGEMENT; ANEURYSM
AB BACKGROUND: Ischemic symptoms caused by traumatic vertebral artery dissection after cervical maneuvers are treated medically and surgically. This is a report of the infrequently documented occipital to vertebral artery bypass to stop the transient ischemic attacks following traumatic vertebral artery dissection.
   CASE DESCRIPTION: A 33-year-old man presented with a sudden right posterior neck pain following a sudden neck movement, accompanied by left lower quadrant anopsia and rotational vertigo. The neurologic symptoms had already been resolved on arrival. Magnetic resonance imaging and digital subtraction angiography revealed an extracranial vertebral artery dissection with no evidence of cerebral infarction. Although medical therapy was initiated, he repeatedly complained of ischemic symptoms. A bypass was performed from the occipital artery to the atlas loop of the vertebral artery with distal occlusion of the lesion. The patient was neurologically intact after the surgery, and magnetic resonance imaging showed no cerebral infarction.
   CONCLUSION: A bypass from the occipital artery to the atlas loop of the vertebral artery is an effective procedure for traumatic extracranial vertebral artery dissection with ischemic symptoms.
C1 [Inoue, Yasuaki; Matsuzawa, Kazuhito] Nadogaya Hosp, Dept Neurosurg, Kashiwa, Chiba, Japan.
RP Inoue, Y (reprint author), Nadogaya Hosp, Dept Neurosurg, Kashiwa, Chiba, Japan.
EM inoue.yasuaki@gmail.com
CR Arnold M, 2006, STROKE, V37, P2499, DOI 10.1161/01.STR.0000240493.88473.39
   Chiche L, 2005, ANN VASC SURG, V19, P5, DOI 10.1007/s10016-004-0149-8
   Cohen JE, 2016, J CLIN NEUROSCI, V32, P77, DOI 10.1016/j.jocn.2016.03.023
   Iida Y, 2018, WORLD NEUROSURG, V111, P367, DOI 10.1016/j.wneu.2017.12.167
   Inui Y, 2006, NEUROL MED-CHIR, V46, P32, DOI 10.2176/nmc.46.32
   Katsuki Masahito, 2018, Surg Neurol Int, V9, P82, DOI 10.4103/sni.sni_20_18
   Katsuno M, 2015, BRIT J NEUROSURG, V29, P401, DOI 10.3109/02688697.2015.1004300
   Kidani N, 2017, ACTA NEUROCHIR, V159, P1329, DOI 10.1007/s00701-017-3204-2
   Kieffer E, 2002, J VASC SURG, V36, P549, DOI 10.1067/mva.2002.126092
   Matsuyama T, 1997, NEUROSURGERY, V41, P1393, DOI 10.1097/00006123-199712000-00030
   Mohan IV, 2014, ANGIOLOGY, V65, P274, DOI 10.1177/0003319712475154
   Preul C, 2010, CLIN NEURORADIOL, V20, P255, DOI 10.1007/s00062-010-0021-x
   Reuter U, 2006, J NEUROL, V253, P724, DOI 10.1007/s00415-006-0099-x
   Schievink WI, 2001, NEW ENGL J MED, V344, P898, DOI 10.1056/NEJM200103223441206
   Sorteberg A, 2008, NEUROSURGERY, V63, P651, DOI 10.1227/01.NEU.0000325727.51405.D5
   Suzuki H, 2018, INTERNAL MED, V57, P3321, DOI 10.2169/internalmedicine.0608-17
NR 16
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 64
EP 66
DI 10.1016/j.wneu.2018.11.220
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400107
PM 30529517
DA 2020-05-12
ER

PT J
AU Hayenga, HN
   Bishop, AJ
   Wardak, Z
   Sen, C
   Mickey, B
AF Hayenga, Heather N.
   Bishop, Andrew J.
   Wardak, Zabi
   Sen, Chandra
   Mickey, Bruce
TI Intraspinal Dissemination and Local Recurrence of an Intracranial
   Hemangiopericytoma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain; Hemangiopericytoma; Intradural; Metastasis; Solitary fibrous
   tumor; Spine
ID CENTRAL-NERVOUS-SYSTEM; MENINGEAL HEMANGIOPERICYTOMA; MANAGEMENT;
   NEOPLASMS; TUMORS
AB BACKGROUND: Hemangiopericytomas (HPCs) are rare vascular tumors that resemble meningiomas on imaging and have a high rate of local recurrence and metastases. There remains a paucity of data to guide management decisions of intraspinal dissemination of HPCs in the literature, and none specifically related to anaplastic HPCs.
   CASE DESCRIPTION: We report a case of a 34-year-old woman with locally and distantly recurrent anaplastic HPC (World Health Organization grade III). She initially presented with tinnitus in her right ear. A well-circumscribed, contrast-enhancing lesion was identified in the right cerebellopontine angle. Treatment consisted of subtotal resection and postoperative radiation therapy (RT) to a dose of 60 Gy in 30 fractions. After a 3-year disease-free interval, 7 lesions recurred intra- and extracranially. The extracranial lesions were drop metastases of the original HPC through the cerebrospinal fluid into the spinal canal. Of note, fluorodeoxyglucose positron emission tomography (PET)/computed tomography scan was not sensitive enough to detect these new lesions. The intracranial recurrence was on the edge of the prior radiotherapy field, representing a marginal failure having received less than 50 Gy. The intracranial recurrences were treated with salvage gamma knife stereotactic radiosurgery (SRS) with local control. She underwent intradural extramedullary hemilaminectomy of a thoracic spine metastasis followed by fractionated proton beam therapy (PBT) with a boost to unresected lesions. Within a few months of PBT, she became pregnant. Pregnancy did not affect recurrence or ameliorate tumor growth.
   CONCLUSIONS: This case report discusses the role genetics, adjuvant RT, SRS, magnetic resonance imaging, and PET scan played in this unique clinical scenario of anaplastic HPC.
C1 [Hayenga, Heather N.] Univ Texas Dallas, Dept Bioengn, Richardson, TX 75083 USA.
   [Bishop, Andrew J.] MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX USA.
   [Wardak, Zabi] Univ Texas Southwestern Med Ctr Dallas, Dept Radiat Oncol, Dallas, TX 75390 USA.
   [Mickey, Bruce] Univ Texas Southwestern Med Ctr Dallas, Dept Neurosurg, Dallas, TX 75390 USA.
   [Sen, Chandra] NYU Langone Med Ctr, Dept Neurosurg, New York, NY USA.
RP Hayenga, HN (reprint author), Univ Texas Dallas, Dept Bioengn, Richardson, TX 75083 USA.
EM heather.hayenga@utdallas.edu
RI Hayenga, Heather/H-1053-2011
OI Hayenga, Heather/0000-0001-7581-8294; Bishop,
   Andrew/0000-0002-7737-8023; Sen, Chandranath/0000-0003-1603-2958
CR Ali Hosam Shata Mohanmed, 2016, Surg Neurol Int, V7, pS1016, DOI 10.4103/2152-7806.195585
   Chan WSW, 2010, BRIT J RADIOL, V83, pE172, DOI 10.1259/bjr/37923115
   Fritchie KJ, 2016, J NEUROPATH EXP NEUR, V75, P263, DOI 10.1093/jnen/nlv026
   Galanis E, 1998, CANCER-AM CANCER SOC, V82, P1915
   Ghia AJ, 2013, NEUROSURGERY, V73, P624, DOI 10.1227/NEU.0000000000000064
   Ghia AJ, 2013, NEUROSURGERY, V72, P203, DOI 10.1227/NEU.0b013e31827b9e68
   Jeon SH, 2018, J NEURO-ONCOL, V137, P567, DOI 10.1007/s11060-018-2746-3
   Kracht LW, 1999, J COMPUT ASSIST TOMO, V23, P365, DOI 10.1097/00004728-199905000-00008
   Lee A, 2018, CLIN NEUROL NEUROSUR, V167, P1, DOI 10.1016/j.clineuro.2018.02.004
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Ostrom QT, 2017, NEURO-ONCOLOGY, V19, pV1, DOI 10.1093/neuonc/nox158
   Park MS, 2010, CURR OPIN ONCOL, V22, P351, DOI 10.1097/CCO.0b013e32833aaad4
   Patel AR, 2017, J NEUROL SURG PART B, V78, P324, DOI 10.1055/s-0037-1599073
   Purandare NC, 2010, CANCER IMAGING, V10, P117, DOI 10.1102/1470-7330.2010.0017
   Rutkowski MJ, 2010, J NEUROSURG, V113, P333, DOI 10.3171/2010.3.JNS091882
   Schweizer L, 2013, ACTA NEUROPATHOL, V125, P651, DOI 10.1007/s00401-013-1117-6
   Sheehan J, 2002, NEUROSURGERY, V51, P905, DOI 10.1097/00006123-200210000-00008
   Soyuer S, 2004, CANCER-AM CANCER SOC, V100, P1491, DOI 10.1002/cncr.20109
   Stevenson CB, 2005, CLIN OBSTET GYNECOL, V48, P24, DOI 10.1097/01.grf.0000153209.70749.d0
   Stomeo F, 2004, EUR ARCH OTO-RHINO-L, V261, P555, DOI 10.1007/s00405-003-0726-4
   Stout AP, 1942, ANN SURG, V116, P26, DOI 10.1097/00000658-194207000-00004
   Wang K, 2012, J ENDOCRINOL, V212, P243, DOI 10.1530/JOE-11-0296
   Yalcin CE, 2016, ADV ANAT PATHOL, V23, P104, DOI 10.1097/PAP.0000000000000103
NR 23
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 68
EP 75
DI 10.1016/j.wneu.2018.11.173
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400109
PM 30503286
DA 2020-05-12
ER

PT J
AU Maki, Y
   Hattori, E
   Satow, T
   Komuro, T
   Miyamoto, S
AF Maki, Yoshinori
   Hattori, Etsuko
   Satow, Takeshi
   Komuro, Taro
   Miyamoto, Susumu
TI Carotid Artery Stenting for Symptomatic Internal Carotid Artery Stenosis
   Associated with Moyamoya Disease
SO WORLD NEUROSURGERY
LA English
DT Article
DE Carotid artery stenting; Hyperperfusion; Internal carotid stenosis;
   Moyamoya disease; Symptomatic
ID INTRACRANIAL HEMORRHAGE; CEREBRAL-ISCHEMIA; MO.MA ULTRA; ENDARTERECTOMY;
   BALLOON; FEATURES; PATIENT
AB BACKGROUND: Surgical intervention in a case of internal carotid artery stenosis with moyamoya vessels has not been well described. We present a case with detailed description of the surgical procedure and perioperative management.
   CASE DESCRIPTION: A 58-year-old man with symptomatic internal carotid artery stenosis had concurrent moyamoya vessels intracranially. He had motor weakness and numbness in the left upper extremity. Magnetic resonance imaging showed an ischemic lesion in the right frontal lobe and right chronic subdural hematoma. On day 18 after surgery for subdural hematoma, carotid artery stenting was performed under proximal balloon protection and distal filter protection. After carotid artery stenting, systolic blood pressure was maintained at <120 mm Hg. Hyperperfusion syndrome or hemorrhagic complication did not occur. The patient was discharged without any neurologic deficits.
   CONCLUSIONS: In our patient with internal carotid artery stenosis with moyamoya vessels, strict control of blood pressure likely contributed to prevention of hyperperfusion syndrome or hemorrhagic complications.
C1 [Maki, Yoshinori; Hattori, Etsuko; Satow, Takeshi; Komuro, Taro] Nagahama City Hosp, Dept Neurosurg, Nagahama, Japan.
   [Maki, Yoshinori; Hattori, Etsuko; Miyamoto, Susumu] Kyoto Univ, Dept Neurosurg, Grad Sch Med, Kyoto, Japan.
RP Maki, Y (reprint author), Nagahama City Hosp, Dept Neurosurg, Nagahama, Japan.; Maki, Y (reprint author), Kyoto Univ, Dept Neurosurg, Grad Sch Med, Kyoto, Japan.
EM maki0427@kuhp.kyoto-u-ac.jp
OI Satow, Takeshi/0000-0003-1764-4059
CR Abbott AL, 2015, STROKE, V46, P3288, DOI 10.1161/STROKEAHA.115.003390
   Asai K, 2014, J STROKE CEREBROVASC, V23, P1871, DOI 10.1016/j.jstrokecerebrovasdis.2014.02.021
   BARNETT HJM, 1991, STROKE, V22, P711, DOI 10.1161/01.STR.22.6.711
   Bates ER, 2007, J AM COLL CARDIOL, V49, P126, DOI 10.1016/j.jacc.2006.10.021
   Brott TG, 2010, NEW ENGL J MED, V363, P11, DOI 10.1056/NEJMoa0912321
   Casana R, 2012, MINERVA CARDIOANGIOL, V60, P643
   Chaer RA, 2006, J VASC SURG, V43, P946, DOI 10.1016/j.jvs.2006.01.007
   Eicker S, 2011, J NEUROINTERV SURG, V3, P160, DOI 10.1136/jnis.2010.003004
   Fujimura M, 2015, NEUROL MED-CHIR, V55, P189, DOI 10.2176/nmc.ra.2014-0307
   Hoshino H, 2012, NEUROL MED-CHIR, V52, P295, DOI 10.2176/nmc.52.295
   Kuriyama S, 2008, STROKE, V39, P42, DOI 10.1161/STROKEAHA.107.490714
   Moritz S, 2007, ANESTHESIOLOGY, V107, P563, DOI 10.1097/01.anes.0000281894.69422.ff
   Moteki Y, 2016, J STROKE CEREBROVASC, V25, P2627, DOI 10.1016/j.jstrokecerebrovasdis.2016.07.003
   Nagata Shun-ichi, 2005, Radiat Med, V23, P427
   Ogasawara K, 2007, J NEUROSURG, V107, P1130, DOI 10.3171/JNS-07/12/1130
   Ogata A, 2014, J NEUROINTERV SURG, V6, P517, DOI 10.1136/neurintsurg-2013-010873
   Rosenfield K, 2016, NEW ENGL J MED, V374, P1011, DOI [10.1056/NEJMoa1515706, 10.1016/j.jvs.2016.06.057]
   Spentzouris G, 2016, ANN VASC SURG, V34, DOI 10.1016/j.avsg.2015.11.035
   TAYLOR DW, 1991, NEW ENGL J MED, V325, P445
   Yoshida K, 2008, AM J NEURORADIOL, V29, P868, DOI 10.3174/ajnr.A1015
NR 20
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 76
EP 80
DI 10.1016/j.wneu.2018.11.204
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400110
PM 30528525
DA 2020-05-12
ER

PT J
AU Choi, KC
   Shim, HK
   Lee, DC
   Park, CK
AF Choi, Kyung-Chul
   Shim, Hyeong-Ki
   Lee, Dong Chan
   Park, Choon-Keun
TI Intraoperative Disc Prolapse During Percutaneous Endoscopic Lumbar
   Discectomy
SO WORLD NEUROSURGERY
LA English
DT Article
DE De novo disc prolapse; Discography; Inside-out PELD; Percutaneous
   endoscopic lumbar discectomy
AB BACKGROUND: Percutaneous endoscopic lumbar discectomy (PELD) is regarded as an alternative treatment for lumbar disc herniation. Although the indication for PELD has expanded with remarkable evolution of the technique, sometimes unexpected complications have occurred during PELD. We report 3 cases of de novo disc prolapse during PELD.
   CASE DESCRIPTION: In 3 patients who underwent PELD for lumbar disc herniation with local anesthesia, postoperative magnetic resonance imaging demonstrated newly developed up-migrated disc herniation. Compared with their preoperative states, these patients experienced decreased intensity of both leg and back pain. There were no neurologic deficits. PELD was repeated for L1-L2 disc herniation only to relieve compression of the conus medullaris.
   CONCLUSIONS: Although the incidence was very low (0.3%) and the lesions were nonsymptomatic, de novo disc prolapse may be associated with an inside-out PELD technique. Discography and insertion of the obturator should be handled gently. The possibility of de novo disc prolapse should be kept in mind when performing PELD.
C1 [Choi, Kyung-Chul; Shim, Hyeong-Ki; Lee, Dong Chan] Leon Wiltse Mem Hosp, Dept Neurosurg, Anyang, South Korea.
   [Park, Choon-Keun] Leon Wiltse Mem Hosp, Dept Neurosurg, Suwon, South Korea.
RP Choi, KC (reprint author), Leon Wiltse Mem Hosp, Dept Neurosurg, Anyang, South Korea.
EM chul5104@hanmail.net
CR Ahn Y, 2012, EXPERT REV MED DEVIC, V9, P361, DOI [10.1586/erd.12.23, 10.1586/ERD.12.23]
   Ahn Y, 2009, J NEUROSURG-SPINE, V10, P595, DOI 10.3171/2009.2.SPINE08227
   Choi G, 2013, J ORTHOP SURG RES, V8, DOI 10.1186/1749-799X-8-14
   Choi I, 2013, EUR SPINE J, V22, P2481, DOI 10.1007/s00586-013-2849-7
   Choi KC, 2017, WORLD NEUROSURG, V106, P484, DOI 10.1016/j.wneu.2017.07.035
   Choi KC, 2016, PAIN PHYSICIAN, V19, pE291
   Choi KC, 2015, NEUROSURGERY, V76, P372, DOI 10.1227/NEU.0000000000000628
   Lee HJ, 2017, WORLD NEUROSURG, V98, DOI 10.1016/j.wneu.2016.11.078
   Lee SH, 2014, SPINE, V39, pE473, DOI 10.1097/BRS.0000000000000239
   Lee SH, 2006, SPINE, V31, pE285, DOI 10.1097/01. brs.0000216446.13205.7a
   Ruetten S, 2008, SPINE, V33, P931, DOI 10.1097/BRS.0b013e31816c8af7
   Schubert Michael, 2005, Oper Orthop Traumatol, V17, P641, DOI 10.1007/s00064-005-1156-9
   Tsou Paul Moody, 2002, Spine J, V2, P41, DOI 10.1016/S1529-9430(01)00153-X
NR 13
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 81
EP 85
DI 10.1016/j.wneu.2018.11.216
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400111
PM 30529530
DA 2020-05-12
ER

PT J
AU Zhang, J
   Zhang, Z
   Zhang, JP
   Song, Y
   Han, J
AF Jun Zhang
   Xiao Zhang
   Jinping Zhang
   Yun Song
   Ju Han
TI Distal Thrombectomy for Acute Anterior Circulation Stroke with Chronic
   Large Vessel Occlusion
SO WORLD NEUROSURGERY
LA English
DT Article
DE Chronic occlusion; Distal occlusion; Ischemic stroke; Mechanical
   thrombectomy
AB BACKGROUND: Endovascular therapy has been increasingly recommended for the treatment of acute ischemic stroke with large vessel occlusion of the anterior circulation. However, occlusions of the distal cerebral artery are not uncommon and may cause clinical deficits, especially when combined with ipsilateral chronic large vessel occlusion. Therefore in this patient population, the recognition of chronic occlusion and recanalization of the distal occlusive artery might be of great value for flow compensation.
   CASE DESCRIPTION: A 59-year-old male with a history of stroke was transferred to the emergency department with a severe right hemiplegia and aphasia syndrome. Head computed tomography demonstrated an old infarction focus of the left basal ganglia, and digital subtraction angiography revealed an occlusion of the left middle cerebral artery (MCA). After careful attempts, the microguidewire could not pass through the left MCA. On consideration of the patient's previous stroke history and the angiographic neovascularization, the left MCA was recognized as a chronic occlusion and its territory was supposed to be partly compensated by the ipsilateral anterior cerebral artery (ACA). A super-selective angiography of the left ACA demonstrated an occlusion of the callosomarginal artery. After a mechanical thrombectomy with a stent retriever, an angiogram showed complete recanalization and good antegrade reperfusion of the ACA supplying the partial MCA territory. The patient had a positive prognosis.
   CONCLUSIONS: The recognition of chronic occlusion is crucial during acute mechanical thrombectomy, and distal thrombectomy may be beneficial after a careful full-scale assessment.
C1 [Jun Zhang; Xiao Zhang; Jinping Zhang; Yun Song; Ju Han] Shandong Univ, Shandong Prov Qianfoshan Hosp, Dept Neurol, Jinan, Shandong, Peoples R China.
RP Han, J (reprint author), Shandong Univ, Shandong Prov Qianfoshan Hosp, Dept Neurol, Jinan, Shandong, Peoples R China.
EM hanjujack@163.com
OI Zhang, Jun/0000-0002-5673-2193
CR Alonso A, 2012, J NEUROL, V259, P944, DOI 10.1007/s00415-011-6289-1
   Berkhemer OA, 2015, NEW ENGL J MED, V372, P11, DOI 10.1056/NEJMoa1411587
   Campbell BCV, 2015, NEW ENGL J MED, V372, P1009, DOI 10.1056/NEJMoa1414792
   Chalumeau V, 2018, J NEUROINTERV SURG, V10, P1057, DOI 10.1136/neurintsurg-2018-013793
   Goyal M, 2015, NEW ENGL J MED, V372, P1019, DOI 10.1056/NEJMoa1414905
   Grossberg JA, 2018, STROKE, V49, P1662, DOI 10.1161/STROKEAHA.118.020567
   Jovin TG, 2015, NEW ENGL J MED, V372, P2296, DOI 10.1056/NEJMoa1503780
   Pfaff J, 2016, AM J NEURORADIOL, V37, P673, DOI 10.3174/ajnr.A4594
   Saver JL, 2015, NEW ENGL J MED, V372, P2285, DOI 10.1056/NEJMoa1415061
NR 9
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 86
EP 88
DI 10.1016/j.wneu.2018.11.236
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400112
PM 30537546
DA 2020-05-12
ER

PT J
AU Zhang, XQ
   Ma, H
   Li, L
   Zou, JJ
   Jiao, YY
   Zhang, XW
   Yang, HY
AF Zhang, Xiaoqiang
   Ma, Hao
   Li, Lin
   Zou, Junjie
   Jiao, Yuanyong
   Zhang, Xiwei
   Yang, Hongyu
TI A Meta-Analysis of Transfemoral Endovascular Treatment of Common Carotid
   Artery Lesions
SO WORLD NEUROSURGERY
LA English
DT Review
DE Angioplasty; Carotid revascularization; Common carotid artery disease;
   Stenting
ID THROMBO-OBLITERATIVE DISEASE; AORTIC-ARCH; CEREBRAL PROTECTION;
   SUBCLAVIAN ARTERIES; ENDARTERECTOMY; OCCLUSION; INNOMINATE; ANGIOPLASTY;
   STENOSIS; DIAGNOSIS
AB OBJECTIVE: High-grade stenoses of the common carotid artery (CCA) are rare and represent a therapeutic dilemma for the treating physician. Endovascular treatment through antegrade access has been proposed as a less invasive treatment option. The aim of this study was to review the existing literature on such a procedure.
   METHODS: A meta-analysis of all studies reporting on endovascular treatment for the treatment of CCA was performed.
   RESULTS: Six studies, including 227 patients, were identified. Forty-nine percent of the patients were male, and 55% symptomatic. Lesions were located in CCA in 237 cases, in innominate artery in 4 cases, combined with internal carotid artery in 28 and subclavian artery in 5 cases. The reported technical success of the procedure was 97.9%. In the 234 successful endovascular treatments, a stent was implanted. Thirty-day mortality and stroke rate were 0.4% and 3.1%, respectively. During a mean follow-up of 8.4 to 31.7 months, 4 patients presented symptoms of cerebral ischemia and 18 died (none related to the procedure). Thirty-one patients developed restenosis of the CCA lesion; successful repercutaneous transluminal angioplasty was performed in 9 cases.
   CONCLUSIONS: This meta-analysis reported the largest collection of patients having undergone endovascular treatment of CCA stenosis or occlusion. Results from this study showed that 30-day mortality and stroke rate were 0.4% and 3.1%, respectively. The procedure is absolutely effective, and no significant change of stroke was found with or without an embolic protection device. In sum, balloon angioplasty with stenting of the component of this disease should be pursued to decrease the risk of stroke.
C1 [Zhang, Xiaoqiang; Ma, Hao; Li, Lin; Zou, Junjie; Jiao, Yuanyong; Zhang, Xiwei; Yang, Hongyu] Nanjing Med Univ, Div Vasc Surg, Dept Gen Surg, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China.
RP Yang, HY (reprint author), Nanjing Med Univ, Div Vasc Surg, Dept Gen Surg, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China.
EM rodgeryang1997@163.com
OI zhang, xiao qiang/0000-0002-8172-6684
CR BACHMAN DM, 1980, AM J ROENTGENOL, V135, P995, DOI 10.2214/ajr.135.5.995
   BELKIN M, 1993, J VASC SURG, V17, P1019, DOI 10.1016/0741-5214(93)90672-9
   Berguer R, 1998, J VASC SURG, V27, P34, DOI 10.1016/S0741-5214(98)70289-7
   Brott TG, 2010, NEW ENGL J MED, V363, P11, DOI 10.1056/NEJMoa0912321
   Cam A, 2012, EUROINTERVENTION, V7, P1210, DOI 10.4244/EIJV7I10A193
   Chio FL, 2003, AM J CARDIOL, V92, P1135, DOI 10.1016/j.amjcard.2003.07.014
   Clouse WD, 2015, J VASC SURG, V62, P1096, DOI 10.1016/j.jvs.2015.07.014
   CRAWFORD ES, 1962, J THORAC CARDIOV SUR, V43, P38
   CRAWFORD ES, 1983, SURGERY, V94, P781
   Cui LK, 2018, EUR J VASC ENDOVASC, V55, P614, DOI 10.1016/j.ejvs.2018.02.020
   DAVIS JB, 1956, ANN SURG, V144, P124, DOI 10.1097/00000658-195607000-00018
   DEBAKEY ME, 1958, JAMA-J AM MED ASSOC, V166, P998, DOI 10.1001/jama.1958.02990090006002
   DIETHRICH EB, 1967, AM J SURG, V114, P800, DOI 10.1016/0002-9610(67)90151-1
   Dumont TM, 2013, J NEUROINTERV SURG, V5, P539, DOI 10.1136/neurintsurg-2012-010523
   Eckstein HH, 2008, LANCET NEUROL, V7, P893, DOI 10.1016/S1474-4422(08)70196-0
   Ederle J, 2010, LANCET, V375, P985, DOI 10.1016/S0140-6736(10)60239-5
   Feldtman RW, 2006, AM J SURG, V192, P779, DOI 10.1016/j.amjsurg.2006.08.044
   FRY WR, 1992, J VASC SURG, V15, P83, DOI 10.1016/0741-5214(92)70016-E
   Gurm HS, 2008, NEW ENGL J MED, V358, P1572, DOI 10.1056/NEJMoa0708028
   Kadkhodayan Y, 2009, SURG NEUROL, V72, P451, DOI 10.1016/j.surneu.2009.05.017
   Klonaris C, 2013, EUR J VASC ENDOVASC, V46, P291, DOI 10.1016/j.ejvs.2013.06.006
   Lal BK, 2007, SEMIN VASC SURG, V20, P259, DOI 10.1053/j.semvascsurg.2007.10.009
   Mas J, 2006, NEW ENGL J MED, V355, P1660, DOI 10.1056/NEJMoa061752
   MATHIAS K, 1980, FORTSCHR RONTG NEUEN, V132, P346
   Monica AN, 2005, J DIAGN MED SONOG, V21, P502, DOI 10.1177/8756479305281346
   Moresoli P, 2017, STROKE, V48, P2150, DOI 10.1161/STROKEAHA.117.016824
   Paukovits TM, 2008, J VASC SURG, V48, P80, DOI 10.1016/j.jvs.2008.03.008
   Payne DA, 2006, BRIT J SURG, V93, P187, DOI 10.1002/bjs.5232
   Queral LA, 1996, J VASC SURG, V23, P368, DOI 10.1016/S0741-5214(96)70282-3
   Rosenfield K, 2016, NEW ENGL J MED, V374, P1011, DOI [10.1056/NEJMoa1515706, 10.1016/j.jvs.2016.06.057]
   Sfyroeras GS, 2011, J VASC SURG, V54, P534, DOI 10.1016/j.jvs.2011.04.022
   SHIMIZU K, 1951, J Neuropathol Clin Neurol, V1, P37
   Sullivan TM, 1998, J VASC SURG, V28, P1059, DOI 10.1016/S0741-5214(98)70032-1
   Tsuji K, 2016, NEUROSURGERY, V79, P598, DOI 10.1227/NEU.0000000000001312
   Tsutsumi M, 2007, NEUROL MED-CHIR, V47, P285, DOI 10.2176/nmc.47.285
   Usachev D Iu, 2013, Zh Vopr Neirokhir Im N N Burdenko, V77, P27
NR 36
TC 2
Z9 2
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 89
EP 94
DI 10.1016/j.wneu.2018.10.072
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400113
PM 30453085
DA 2020-05-12
ER

PT J
AU Shaikh, AT
   Farhan, SA
   Siddiqi, R
   Fatima, K
   Siddiqi, J
   Khosa, F
AF Shaikh, Ali Tariq
   Farhan, Syed Ali
   Siddiqi, Rabbia
   Fatima, Kaneez
   Siddiqi, Javed
   Khosa, Faisal
TI Disparity in Leadership in Neurosurgical Societies: A Global Breakdown
SO WORLD NEUROSURGERY
LA English
DT Article
DE Gender disparity; H-index; Neurosurgical societies; Women leaders
ID H-INDEX; PUBLICATION PRODUCTIVITY; GENDER-DIFFERENCES; SCHOLARLY IMPACT;
   WOMEN; FUTURE; DISCRIMINATION; PERSPECTIVES; POSITIONS; CHOICE
AB OBJECTIVE: Gender disparity in academic and organizational settings has been the topic of numerous studies and they have tried to extract its causes using H-index as the prime metric. The primary objective of our study was to assess gender disparity in leadership positions in neurosurgical societies worldwide. A second objective was to evaluate scholarly output among neurosurgeons in neurosurgical societies worldwide, utilizing H-index as a predominant metric.
   METHODS: The World Federation of Neurosurgeons database was used to gather details on the neurosurgical societies present worldwide. Online data present for leadership positions were extracted from each of the respective societies. Neurosurgeons holding leadership positions were arranged according to their academic and hierarchical ranks. The Scopus database was used to calculate H-index along with other bibliometric variables.
   RESULTS: H-index was statistically significant between both genders, with male neurosurgeons having significantly higher H-index than female neurosurgeons. A positive correlation was also found between H-index and academic ranks of neurosurgeons. However, no statistical significance was found between H-index and executive committee positions. Female neurosurgeons held 29% executive committee positions globally.
   CONCLUSIONS: A paucity of female neurosurgeons was seen in leadership positions in neurosurgical societies worldwide. Significant disparity present in research productivity between genders is a highlighted statistic further discussed in this study, considering variables such as H-index among others. The increase in female neurosurgeons to neurosurgical organizational echelons can be achieved by enhancing institutionalized support, setting up networking platforms, and identifying mentorship opportunities for prospective leaders.
C1 [Shaikh, Ali Tariq; Farhan, Syed Ali; Siddiqi, Rabbia; Fatima, Kaneez] Dow Univ Hlth Sci, Doctor Ruth KM Fau Civil Hosp, Karachi, Pakistan.
   [Siddiqi, Javed] Arrowhead Neurosurg Med Grp, Dept Neurosurg, Palm Springs, CA USA.
   [Khosa, Faisal] Vancouver Gen Hosp, Dept Radiol, Vancouver, BC, Canada.
RP Khosa, F (reprint author), Vancouver Gen Hosp, Dept Radiol, Vancouver, BC, Canada.
EM fkhosa@hotmail.com
CR Agarwal Nitin, 2013, World Neurosurg, V80, P738, DOI 10.1016/j.wneu.2013.09.020
   Ahmadi M, 2018, AM J NEURORADIOL, V39, P18, DOI 10.3174/ajnr.A5443
   American Association of Neurological Surgeons, 2016, BYL AM ASS NEUR SURG
   Amrein K, 2011, GENDER MED, V8, P378, DOI 10.1016/j.genm.2011.10.007
   Andrews NC, 2007, NEW ENGL J MED, V357, P1887, DOI 10.1056/NEJMp078198
   Association of American Medical Colleges, 2015, PERC ACT PHYS WHO AR
   Association of American Medical Colleges, 2018, US MED SCH APPL MATR, P2018
   Battaglia F, 2019, EMERG RADIOL, V26, P21, DOI 10.1007/s10140-018-1642-7
   Benzil DL, 2008, J NEUROSURG, V109, P378, DOI 10.3171/JNS/2008/109/9/0378
   Benzil DL, 2017, NEUROSURGERY, V80, pS59, DOI 10.1093/neuros/nyw150
   Bismark M, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-009384
   Carr PL, 2003, J WOMENS HEALTH, V12, P1009, DOI 10.1089/154099903322643938
   Challenges WIR, 2015, MORE WOMEN CHOOSE CA, V307, P18
   Chisholm-Burns MA, 2017, AM J HEALTH-SYST PH, V74, P312, DOI 10.2146/ajhp160930
   Congress of Neurological Surgeons, 2017, BYL C NEUR SURG
   Cydulka RK, 2000, ACAD EMERG MED, V7, P999
   Darvis B, 2015, NEUROSURG MARK WATCH, V5, P12
   De Groote SL, 2012, NURS OUTLOOK, V60, P391, DOI 10.1016/j.outlook.2012.04.007
   Downs JA, 2014, ACAD MED, V89, P1103, DOI 10.1097/ACM.0000000000000369
   Eloy JA, 2017, WORLD NEUROSURG, V103, P517, DOI 10.1016/j.wneu.2017.03.110
   Eloy JA, 2013, LARYNGOSCOPE, V123, P1865, DOI 10.1002/lary.24039
   ETZKOWITZ H, 1994, SCIENCE, V266, P51, DOI 10.1126/science.7939644
   Gasco J, 2014, MALAYS J MED SCI, V21, P1
   Hamidizadeh R, 2018, AM J ROENTGENOL, V211, P831, DOI 10.2214/AJR.18.19741
   Hirsch JE, 2007, P NATL ACAD SCI USA, V104, P19193, DOI 10.1073/pnas.0707962104
   Hirsch JE, 2005, P NATL ACAD SCI USA, V102, P16569, DOI 10.1073/pnas.0507655102
   Holliday EB, 2014, ACAD MED, V89, P767, DOI 10.1097/ACM.0000000000000229
   Jonasson O, 2002, SURGERY, V131, P672, DOI 10.1067/msy.2002.124880
   Kane-Berman J, 2003, SAMJ S AFR MED J, V93, P69
   Kelly CD, 2006, TRENDS ECOL EVOL, V21, P167, DOI 10.1016/j.tree.2006.01.005
   Khan NR, 2014, J NEUROSURG, V120, P746, DOI 10.3171/2013.11.JNS131708
   Khurshid K, 2018, AM J ROENTGENOL, V210, P2, DOI 10.2214/AJR.17.18303
   Lawton MT, 2007, NEUROSURGERY, V60, P934, DOI 10.1227/01.NEU.0000255445.51989.33
   Lee J, 2009, J NEUROSURG, V111, P387, DOI 10.3171/2008.10.JNS08978
   Lopez SA, 2014, J SURG EDUC, V71, P851, DOI 10.1016/j.jsurg.2014.03.015
   Mattei TA, 2014, NEUROSURG REV, V37, P357, DOI 10.1007/s10143-014-0540-z
   McClelland S, 2010, J CLIN NEUROSCI, V17, P287, DOI 10.1016/j.jocn.2009.07.098
   McLemore Elisabeth C, 2012, Perm J, V16, P54
   Monroe AK, 2015, J WOMENS HEALTH, V24, P837, DOI 10.1089/jwh.2014.5054
   Morton MJ, 2007, J NATL MED ASSOC, V99, P764
   Mueller C, 2017, BMC SURG, V17, DOI 10.1186/s12893-017-0211-4
   Nora LM, 2002, ACAD MED, V77, P1226, DOI 10.1097/00001888-200212000-00018
   Omerhodzic I, 2012, TURK NEUROSURG, V22, P286, DOI 10.5137/1019-5149.JTN.5133-11.0
   Paik AM, 2014, J SURG EDUC, V71, P593, DOI 10.1016/j.jsurg.2014.01.010
   Pashkova AA, 2013, ACTA ANAESTH SCAND, V57, P1058, DOI 10.1111/aas.12141
   Purvis A, 2006, TRENDS ECOL EVOL, V21, P422, DOI 10.1016/j.tree.2006.05.014
   Qamar SR, 2018, SKELETAL RADIOL, V47, P381, DOI 10.1007/s00256-017-2836-x
   Renfrow JJ, 2018, NEUROSURGERY, V82, P576, DOI 10.1093/neuros/nyx251
   Renfrow JJ, 2016, J NEUROSURG, V124, P834, DOI 10.3171/2015.3.JNS142313
   Rezai Ali R, 2014, Neurosurgery, V61 Suppl 1, P66, DOI 10.1227/NEU.0000000000000419
   SANDLER BR, 1996, CHILLY CLASSROOM CLI
   Satiani B, 2010, J VASC SURG, V51, p47S, DOI 10.1016/j.jvs.2009.09.063
   Serrano Karen, 2007, WMJ, V106, P260
   Shah A, 2018, INT J DERMATOL, V57, P171, DOI 10.1111/ijd.13875
   Sheikh MH, 2018, CUREUS, V10, DOI 10.7759/cureus.2514
   Spetzler Robert F, 2011, Asian J Neurosurg, V6, P6, DOI 10.4103/1793-5482.85627
   Steklacova A, 2017, WORLD NEUROSURG, V104, P48, DOI 10.1016/j.wneu.2017.04.094
   Wilkes FA, 2015, J NEUROSURG, V122, P948, DOI 10.3171/2014.11.JNS14856
   Woodrow SI, 2006, NEUROSURGERY, V59, P749, DOI 10.1227/01.NEU.0000232671.44297.DF
NR 59
TC 4
Z9 4
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 95
EP 102
DI 10.1016/j.wneu.2018.11.145
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400114
PM 30481634
DA 2020-05-12
ER

PT J
AU Meena, RK
   Doddamani, RS
   Sharma, R
AF Meena, Rajesh Kumar
   Doddamani, Ramesh S.
   Sharma, Ravi
TI Contiguous Diastematomyelia with Lipomyelomeningocele in Each
   Hemicord-an Exceptional Case of Spinal Dysraphism
SO WORLD NEUROSURGERY
LA English
DT Article
DE Diastematomyelia; Hemicord; Lipomyelomeningocele; Split cord
   malformation
ID SPLIT CORD MALFORMATION; TETHERED CORD; PROPOSAL
AB BACKGROUND: Split cord malformation (SCM) is a rare congenital anomaly of the spinal cord. Rarely, SCM coexists with a variety of dysraphic pathologies that occur at the same or different spinal level in a patient. Exceptionally rare is the occurrence of SCM type 1 and lipomeningomyelocele of each hemicord.
   CASE DESCRIPTION: A 15-month-old girl presented with gradually progressive, painless swelling in the lower back since birth. Spinal imaging showed the presence of type I SCM associated with lipomeningomyelocele of each hemicord. Surgical exploration and detethering was done.
   CONCLUSIONS: Management of such complex cases of spinal dysraphism is challenging. Delineating their embryologic basis, detailed radiologic assessment, and meticulous microneurosurgical techniques are the cornerstone for successful management.
C1 [Meena, Rajesh Kumar; Doddamani, Ramesh S.; Sharma, Ravi] All India Inst Med Sci, Dept Neurosurg, New Delhi, India.
RP Doddamani, RS (reprint author), All India Inst Med Sci, Dept Neurosurg, New Delhi, India.
EM drsdramesh@gmail.com
OI Meena, Rajesh/0000-0003-2977-4977
CR Ailawadhi P, 2011, PEDIATR NEUROSURG, V47, P372, DOI 10.1159/000336752
   Akay KM, 2002, PEDIATR NEUROSURG, V36, P225, DOI 10.1159/000058424
   Akay KM, 2000, ACTA NEUROCHIR, V142, P1111, DOI 10.1007/s007010070038
   Chandra PS, 1999, PEDIATR NEUROSURG, V31, P49, DOI 10.1159/000028831
   DUCKWORT.T, 1968, DEV MED CHILD NEUROL, VS, P69
   Ersahin Y, 1998, J NEUROSURG, V88, P57, DOI 10.3171/jns.1998.88.1.0057
   Ersahin Y, 2002, CHILD NERV SYST, V18, P111, DOI 10.1007/s00381-001-0543-2
   Ersahin Y, 1996, PEDIATR NEUROSURG, V24, P155, DOI 10.1159/000121033
   Gupta DK, 2006, PEDIATR NEUROSURG, V42, P341, DOI 10.1159/000095563
   Hanif H, 2013, J PEDIATR NEUROSCI, V8, P204, DOI 10.4103/1817-1745.123665
   Izci Y, 2007, J CLIN NEUROSCI, V14, P383, DOI 10.1016/j.jocn.2005.12.016
   Jans L, 2008, JBR-BTR, V91, P198
   Khandelwal A, 2011, J PEDIATR NEUROSCI, V6, P58, DOI 10.4103/1817-1745.84411
   Kumar R, 2002, PEDIATR NEUROSURG, V36, P119, DOI 10.1159/000048366
   Kumar R, 2004, J PEDIAT NEUROL, V2, P21
   Mahapatra AK, 2005, J NEUROSURG, V103, P531, DOI 10.3171/ped.2005.103.6.0531
   MCLONE DG, 1985, NEUROSURGERY, V16, P36, DOI 10.1227/00006123-198501000-00008
   McLone DG, 1983, CONCEPTS PEDIATRIC N, P170
   Merrow AC, 2010, PEDIATR RADIOL, V40, P168, DOI 10.1007/s00247-010-1734-3
   Murakami N, 2017, CHILD NERV SYST, V33, P993, DOI 10.1007/s00381-017-3350-0
   Muthukumar N, 2003, CHILD NERV SYST, V19, P46, DOI 10.1007/s00381-002-0669-x
   Pang D., 1995, NEUROSURG CLIN N AM, V3, P339
   PANG DL, 1992, NEUROSURGERY, V31, P481, DOI 10.1227/00006123-199209000-00011
   PANG DL, 1992, NEUROSURGERY, V31, P451, DOI 10.1227/00006123-199209000-00010
   Salunke P, 2012, J NEUROSURG-PEDIATR, V9, P627, DOI 10.3171/2012.2.PEDS11498
   Salunke P, 2011, CLIN NEUROL NEUROSUR, V113, P774, DOI 10.1016/j.clineuro.2011.07.023
   Schijman E, 2003, CHILD NERV SYST, V19, P96, DOI 10.1007/s00381-002-0675-z
   Singh PK, 2011, PEDIATR NEUROSURG, V47, P227, DOI 10.1159/000334278
   Solanki GA, 2003, CHILD NERV SYST, V19, P376, DOI 10.1007/s00381-003-0728-y
   Vaishya S, 2001, CHILD NERV SYST, V17, P528, DOI 10.1007/s003810100482
   Yamanaka T, 2001, PEDIATR NEUROSURG, V35, P253, DOI 10.1159/000050431
   Yigit H, 2013, EUR SPINE J, V22, pS487, DOI 10.1007/s00586-013-2655-2
NR 32
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 103
EP 107
DI 10.1016/j.wneu.2018.11.225
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400115
PM 30529523
DA 2020-05-12
ER

PT J
AU Mbadugha, T
   Ogiwara, T
   Nagm, A
   Hasegawa, T
   Kamiya, K
   Ohaegbulam, S
   Hongo, K
AF Mbadugha, Tobechi
   Ogiwara, Toshihiro
   Nagm, Alhusain
   Hasegawa, Takatoshi
   Kamiya, Keisuke
   Ohaegbulam, Samuel
   Hongo, Kazuhiro
TI Superficial Siderosis Associated with Craniopharyngioma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Craniopharyngioma; Endoscopic endonasal approach; Superficial siderosis
ID CENTRAL-NERVOUS-SYSTEM
AB BACKGROUND: Superficial siderosis (SS) associated with craniopharyngioma is an extremely rare occurrence. To our knowledge, only 3 cases have been reported in literature. Two of the cases occurred following resection of the tumor. Similar to the present case, 1 of the cases was discovered before surgical intervention, "pure tumor-related" SS. The clinical presentation, diagnosis, management, and outcome are discussed in this article.
   CASE DESCRIPTION: A 50-year-old man presented with an 11-month history of left-sided tinnitus, hearing impairment, and a 2-month history of visual disturbance. Cerebellar ataxia and gait disturbance were found on examination. Brain magnetic resonance imaging findings were consistent with SS. Cerebrospinal fluid (CSF) analysis before surgery revealed xanthochromia confirming an existing chronic sustainable subarachnoid hemorrhage. He underwent a tumor resection in endoscopic endonasal approach followed by stereotactic radiosurgery. On follow-up, the visual symptoms resulting from craniopharyngioma subsided, whereas hearing impairment, cerebellar ataxia, and gait disturbance associated with SS did not progress but were unchanged despite subsequent evidence of watery-clear CSF.
   CONCLUSIONS: In the present case, SS could be associated with craniopharyngioma on the basis of CSF findings and clinical symptoms. Detection and early treatment aimed at eliminating the bleeding source offer the best chance of halting the disease process.
C1 [Mbadugha, Tobechi; Ogiwara, Toshihiro; Nagm, Alhusain; Hasegawa, Takatoshi; Kamiya, Keisuke; Hongo, Kazuhiro] Shinshu Univ, Dept Neurosurg, Sch Med, Matsumoto, Nagano, Japan.
   [Mbadugha, Tobechi; Ohaegbulam, Samuel] Memfys Hosp Neurosurg, Unit Neurosurg, Enugu, Nigeria.
   [Nagm, Alhusain] Al Azhar Univ, Dept Neurosurg, Fac Med Nasr City, Cairo, Egypt.
RP Ogiwara, T (reprint author), Shinshu Univ, Dept Neurosurg, Sch Med, Matsumoto, Nagano, Japan.
EM togiwara@shinshu-u.ac.jp
RI Nagm, Alhusain/AAF-5478-2020
OI Nagm, Alhusain/0000-0003-0469-4970
CR FEARNLEY JM, 1995, BRAIN, V118, P1051, DOI 10.1093/brain/118.4.1051
   Kellermier H, 2009, NEUROPATHOLOGY, V29, P187, DOI 10.1111/j.1440-1789.2008.00943.x
   Koeppen AH, 2008, ACTA NEUROPATHOL, V116, P371, DOI 10.1007/s00401-008-0421-z
   Kumar N, 2006, NEUROLOGY, V66, P1144, DOI 10.1212/01.wnl.0000208510.76323.5b
   Leussink VI, 2003, ACTA NEUROL SCAND, V107, P54, DOI 10.1034/j.1600-0404.2003.02001.x
   Levy M, 2007, NAT CLIN PRACT NEURO, V3, P54, DOI 10.1038/ncpneuro0356
   Ogiwara T, 2019, NEUROSURG REV, V42, P683, DOI 10.1007/s10143-018-1006-5
   Tosaka M, 2015, NEUROL MED-CHIR, V55, P89, DOI 10.2176/nmc.cr.2012-0362
NR 8
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 108
EP 112
DI 10.1016/j.wneu.2018.11.222
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400116
PM 30529527
DA 2020-05-12
ER

PT J
AU Ravina, K
   Strickland, BA
   Buchanan, IA
   Rennert, RC
   Kim, PE
   Fredrickson, VL
   Russin, JJ
AF Ravina, Kristine
   Strickland, Ben A.
   Buchanan, Ian A.
   Rennert, Robert C.
   Kim, Paul E.
   Fredrickson, Vance L.
   Russin, Jonathan J.
TI Postoperative Antiplatelet Therapy in the Treatment of Complex Basilar
   Apex Aneurysms Implementing Hunterian Ligation and
   Extracranial-to-Intracranial Bypass: Review of the Literature with an
   Illustrative Case Report
SO WORLD NEUROSURGERY
LA English
DT Review
DE Aneurysm; Antiplatelet therapy; Basilar artery; Bypass; Hunterian
   ligation
ID VERTEBRAL ARTERY-OCCLUSION; CEREBRAL ANEURYSMS; MICROSURGICAL TREATMENT;
   ENDOVASCULAR TREATMENT; CIRCULATORY ARREST; SURGICAL-TREATMENT; FUSIFORM
   ANEURYSM; TRUNK ANEURYSMS; TIP ANEURYSM; FOLLOW-UP
AB Large broad-based basilar artery (BA) apex aneurysms involving multiple arterial origins are complex lesions commonly not amenable to direct clipping or endovascular management. BA proximal (Hunterian) occlusion with extracranial-to-intracranial bypass is a supported strategy if 1 or both posterior communicating arteries are small. Hunterian ligation risks sudden aneurysm thrombosis and thromboembolism in the perforator-rich BA apex. There currently exist no guidelines for antiplatelet and anticoagulant therapy after Hunterian ligation for complex BA apex aneurysm treatment. We present a literature review and an illustrative case of an 18-year-old man who presented with progressive headaches and was found to have a large unruptured BA apex aneurysm involving the origins of the bilateral superior cerebellar and posterior cerebral arteries. Given the small posterior communicating arteries and complexity of the aneurysm, proximal BA occlusion with unilateral superficial temporal artery-to-superior cerebellar artery bypass was recommended. Despite antiplatelet treatment with acetylsalicylic acid before and after operation, the patient experienced acute ischemia of the brainstem and cerebellum and an embolic left temporal lobe infarct. The patient received dual antiplatelet therapy starting on postoperative day 6, after which he experienced no new infarcts and made a significant neurologic recovery. The current evidence suggests that proximal BA occlusion in complex BA apex aneurysm cases is thrombogenic and can be especially dangerous if thrombosis occurs suddenly in aneurysms without pre-existing intraluminal thrombus. Dual antiplatelet therapy during the first postoperative week presents a possible strategy for reducing the risk of ischemia due to sudden aneurysm thrombosis.
C1 [Ravina, Kristine; Russin, Jonathan J.] Univ Southern Calif, Keck Sch Med, Neurorestorat Ctr, Los Angeles, CA 90033 USA.
   [Strickland, Ben A.; Buchanan, Ian A.; Fredrickson, Vance L.; Russin, Jonathan J.] Univ Southern Calif, Keck Sch Med, Dept Neurol Surg, Los Angeles, CA 90033 USA.
   [Kim, Paul E.] Univ Southern Calif, Keck Sch Med, Dept Radiol, Los Angeles, CA 90033 USA.
   [Rennert, Robert C.] Univ Calif San Diego, Dept Neurosurg, San Diego, CA 92103 USA.
RP Russin, JJ (reprint author), Univ Southern Calif, Keck Sch Med, Neurorestorat Ctr, Los Angeles, CA 90033 USA.; Russin, JJ (reprint author), Univ Southern Calif, Keck Sch Med, Dept Neurol Surg, Los Angeles, CA 90033 USA.
EM jonathan.russin@med.usc.edu
OI Ravina, Kristine/0000-0002-0927-5719
CR Anson JA, 1996, J NEUROSURG, V84, P185, DOI 10.3171/jns.1996.84.2.0185
   AUSMAN JI, 1990, J NEUROSURG, V72, P554, DOI 10.3171/jns.1990.72.4.0554
   Batjer HH, 2009, NEUROSURGERY, V65, P360, DOI 10.1227/01.NEU.0000345651.91532.6B
   Batjer HH, 2009, NEUROSURGERY, V65, P370
   DRAKE CG, 1975, J NEUROSURG, V43, P255, DOI 10.3171/jns.1975.43.3.0255
   ECHIVERRI HC, 1989, STROKE, V20, P1741, DOI 10.1161/01.STR.20.12.1741
   Elhammady MS, 2011, J NEUROSURG, V115, P316, DOI 10.3171/2010.11.JNS101607
   Evans JJ, 2004, NEUROSURGERY, V55, P1036, DOI 10.1227/01.NEU.0000140822.64362.C6
   Flemming KD, 2004, J NEUROSURG, V101, P82, DOI 10.3171/jns.2004.101.1.0082
   Friedman JA, 2003, AM J NEURORADIOL, V24, P526
   Hasan D, 2012, STROKE, V43, P1964, DOI 10.1161/STROKEAHA.112.655829
   Hasan DM, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.112.000019
   Heppner PA, 2007, ACTA NEUROCHIR, V149, P517, DOI 10.1007/s00701-007-1128-y
   HOPKINS LN, 1983, NEUROSURGERY, V13, P189, DOI 10.1227/00006123-198308000-00016
   Inoue T, 2012, ACTA NEUROCHIR, V154, P1455, DOI 10.1007/s00701-012-1398-x
   Kalani MYS, 2013, J CLIN NEUROSCI, V20, P887, DOI 10.1016/j.jocn.2012.09.007
   Kalani MYS, 2013, NEUROSURGERY, V72, P763, DOI 10.1227/NEU.0b013e3182870703
   Kawashima M, 2005, J NEUROSURG, V102, P132, DOI 10.3171/jns.2005.102.1.0132
   Kellner CP, 2011, J NEUROSURG, V115, P319, DOI 10.3171/2011.2.JNS10188
   Lawton MT, 2016, NEUROSURGERY, V79, P83, DOI 10.1227/NEU.0000000000001175
   Lawton MT, 2002, NEUROSURGERY, V50, P1
   Leibowitz R, 2003, AM J NEURORADIOL, V24, P902
   Lin YW, 2012, CLINICS PRACT, V2, P212, DOI 10.4081/cp.2012.e84
   Liu YL, 2018, WORLD NEUROSURG, V111, pE710, DOI 10.1016/j.wneu.2017.12.158
   Lozier AP, 2004, NEUROSURGERY, V54, P286, DOI 10.1227/01.NEU.0000103222.13642.00
   Mack WJ, 2007, NEUROSURGERY, V60, P815, DOI 10.1227/01.NEU.0000255452.20602.C9
   Mai JC, 2013, NEUROSURGERY, V72, P116, DOI 10.1227/NEU.0b013e31827bf2d8
   Matsukawa H, 2017, ACTA NEUROCHIR, V159, P1633, DOI 10.1007/s00701-017-3239-4
   Miyamoto S, 2011, J NEUROSURG, V114, P1028, DOI 10.3171/2010.9.JNS10448
   MOUNT LA, 1962, J NEUROSURG, V19, P167, DOI 10.3171/jns.1962.19.2.0167
   NISHIZAKI T, 1986, STROKE, V17, P1277, DOI 10.1161/01.STR.17.6.1277
   Oprea AD, 2013, BRIT J ANAESTH, V111, P3, DOI 10.1093/bja/aet402
   PELZ DM, 1984, J NEUROSURG, V60, P560, DOI 10.3171/jns.1984.60.3.0560
   Piotin M, 2010, STROKE, V41, P110, DOI 10.1161/STROKEAHA.109.558114
   Quinones-Hinojosa A, 2004, NEUROSURGERY, V54, P916, DOI 10.1227/01.NEU.0000114511.33035.AF
   Redekop G, 1999, NEUROSURGERY, V45, P1258, DOI 10.1097/00006123-199911000-00056
   Sorteberg A, 2014, AM J NEURORADIOL, V35, P862, DOI 10.3174/ajnr.A3852
   STEINBERG GK, 1993, J NEUROSURG, V79, P161, DOI 10.3171/jns.1993.79.2.0161
   Sullivan BJ, 1999, ACTA NEUROCHIR, V141, P1, DOI 10.1007/s007010050259
   Takahashi JC, 2007, J NEUROSURG, V106, P484, DOI 10.3171/jns.2007.106.3.484
   Than KD, 2012, J CLIN NEUROSCI, V19, P1316, DOI 10.1016/j.jocn.2011.12.018
   Thomas B, 2017, WORLD NEUROSURG, V103, P829, DOI 10.1016/j.wneu.2017.04.071
   TOGNETTI F, 1984, SURG NEUROL, V22, P33, DOI 10.1016/0090-3019(84)90224-6
   Uda K, 2001, J NEUROSURG, V95, P624, DOI 10.3171/jns.2001.95.4.0624
   Wenderoth JD, 2003, AM J NEURORADIOL, V24, P1226
   Xu DS, 2018, J NEUROSURG, V128, P560, DOI 10.3171/2016.10.JNS161041
NR 46
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 113
EP 122
DI 10.1016/j.wneu.2018.11.237
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400117
PM 30537547
DA 2020-05-12
ER

PT J
AU Fenlon, JB
   Khattab, MH
   Ferguson, DC
   Luo, GZ
   Keedy, VL
   Chambless, LB
   Kirschner, AN
AF Fenlon, Jordan B.
   Khattab, Mohamed H.
   Ferguson, Donna C.
   Luo, Guozhen
   Keedy, Vicki L.
   Chambless, Lola B.
   Kirschner, Austin N.
TI Linear Accelerator-Based Stereotactic Radiosurgery for Cranial
   Intraparenchymal Metastasis of a Malignant Peripheral Nerve Sheath
   Tumor: Case Report and Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Brain metastasis; Linear accelerator; Malignant peripheral nerve sheath
   tumor; Stereotactic radiosurgery; Unresected
ID MULTIPLE BRAIN METASTASES; PHASE-II; SCHWANNOMA; SURVIVAL
AB BACKGROUND: Malignant peripheral nerve sheath tumors (MPNSTs) are rare, aggressive soft tissue sarcomas. MPNST intracranial metastasis is exceedingly rare with only 22 documented cases in the literature and, to our knowledge, only 1 case with intraparenchymal brain metastasis. Most have been managed surgically; however, 2 documented cases were treated with Gamma Knife radiosurgery. Excluding this case report, there are no other documented cases of linear accelerator-based stereotactic radiosurgery (SRS) to treat MPNST brain metastasis.
   CASE DESCRIPTION: A 41-year-old man with MPNST of the lung initially underwent tumor resection. He developed multiple systemic metastases that were managed with directed radiation therapy. A parietal brain metastasis was treated with linear accelerator-based SRS. Following SRS therapy, the patient was treated with a tropomyosin receptor kinase inhibitor. Complete resolution of brain metastasis was seen on brain magnetic resonance imaging 5 months after treatment with SRS. At 11 months after SRS, there was no evidence of recurrence or progression of the intraparenchymal disease. The patient continued to have stable extracranial disease on his ninth cycle of systemic treatment.
   CONCLUSIONS: This report provides important insights into efficacy of linear accelerator-based SRS to treat MPNST brain metastases.
C1 [Fenlon, Jordan B.] Western Michigan Univ, Sch Med, Kalamazoo, MI 49008 USA.
   [Khattab, Mohamed H.; Luo, Guozhen; Kirschner, Austin N.] Vanderbilt Univ, Med Ctr, Dept Radiat Oncol, Nashville, TN 37235 USA.
   [Ferguson, Donna C.] Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA.
   [Keedy, Vicki L.] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA.
   [Chambless, Lola B.] Vanderbilt Univ, Med Ctr, Dept Neurol Surg, Nashville, TN USA.
RP Kirschner, AN (reprint author), Vanderbilt Univ, Med Ctr, Dept Radiat Oncol, Nashville, TN 37235 USA.
EM austin.kirschner@vumc.org
RI Kirschner, Austin/AAI-8383-2020
OI Kirschner, Austin/0000-0003-3807-6900
FU Translational Pathology Shared Resource - National Institutes of Health
   National Cancer Institute Cancer Center Support Grant [5P30 CA68485-19];
   Vanderbilt Mouse Metabolic Phenotyping Center Grant [2 U24 DK059637-16];
   National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [5K12CA090625-18]
FX This work was supported by the Translational Pathology Shared Resource,
   which is supported by the National Institutes of Health National Cancer
   Institute Cancer Center Support Grant No. 5P30 CA68485-19 and Vanderbilt
   Mouse Metabolic Phenotyping Center Grant No. 2 U24 DK059637-16, and the
   National Institutes of Health Grant No. 5K12CA090625-18 to A.N.
   Kirschner from the Vanderbilt Clinical Oncology Research Career
   Development Program.
CR Albritton KH, 2006, J CLIN ONCOL, V24, p524S
   Anghileri M, 2006, CANCER-AM CANCER SOC, V107, P1065, DOI 10.1002/cncr.22098
   Chugh R, 2009, J CLIN ONCOL, V27, P3148, DOI 10.1200/JCO.2008.20.5054
   CRAS P, 1990, CLIN NEUROPATHOL, V9, P290
   DAGOSTINO AM, 1963, CANCER, V16, P1015, DOI 10.1002/1097-0142(196308)16:8<1015::AID-CNCR2820160808>3.0.CO;2-I
   DANGELO V, 1991, NEUROSURGERY, V29, P906, DOI 10.1227/00006123-199112000-00018
   Dickson MA, 2016, ANN ONCOL, V27, P1855, DOI 10.1093/annonc/mdw281
   DUCATMAN BS, 1986, CANCER-AM CANCER SOC, V57, P2006, DOI 10.1002/1097-0142(19860515)57:10<2006::AID-CNCR2820571022>3.0.CO;2-6
   Evans DGR, 2002, J MED GENET, V39, P311, DOI 10.1136/jmg.39.5.311
   Farid M, 2014, ONCOLOGIST, V19, P193, DOI 10.1634/theoncologist.2013-0328
   FENZI F, 1995, ITAL J NEUROL SCI, V16, P495, DOI 10.1007/BF02229328
   Flannery T, 2010, INT J RADIAT ONCOL, V76, P513, DOI 10.1016/j.ijrobp.2009.02.007
   Gupta Gaurav, 2007, Neurosurg Focus, V22, pE12
   Haisa Toshihiko, 1996, Neurologia Medico-Chirurgica, V36, P462, DOI 10.2176/nmc.36.462
   HASEGAWA M, 1984, J LARYNGOL OTOL, V98, P1057, DOI 10.1017/S0022215100148017
   HIROSE T, 1989, AM J SURG PATHOL, V13, P613, DOI 10.1097/00000478-198907000-00010
   Huang Jason H, 2005, Expert Rev Neurother, V5, P515
   Kim AeRang, 2017, Sarcoma, V2017, P7429697, DOI 10.1155/2017/7429697
   MACAULAY RAA, 1978, J NEUROL NEUROSUR PS, V41, P474, DOI 10.1136/jnnp.41.5.474
   Maki RG, 2009, J CLIN ONCOL, V27, P3133, DOI 10.1200/JCO.2008.20.4495
   Maschke M, 1999, CLIN NEUROPATHOL, V18, P42
   Matyja E, 2004, FOLIA NEUROPATHOL, V42, P43
   Mrugala MM, 2005, CURR OPIN NEUROL, V18, P604, DOI 10.1097/01.wco.0000179507.51647.02
   Oishi H, 2000, NEUROL MED-CHIR, V40, P116, DOI 10.2176/nmc.40.116
   Park SK, 2007, SURG NEUROL, V68, P79, DOI 10.1016/j.surneu.2006.10.033
   Probst-Cousin Stefan, 1997, General and Diagnostic Pathology, V142, P357
   Puffer RC, 2016, WORLD NEUROSURG, V92, DOI 10.1016/j.wneu.2016.06.069
   Schuetze S, 2010, J CLIN ONCOL, V28
   Shweikeh Faris, 2014, Sarcoma, V2014, P475175, DOI 10.1155/2014/475175
   Tilgner J, 2007, BMC NEUROL, V7, DOI 10.1186/1471-2377-7-2
   VALDUEZA JM, 1991, NEUROSURG REV, V14, P283, DOI 10.1007/BF00383263
   Van Eck ATCJ, 2006, J NEUROSURG, V105, P238
   WHITE HR, 1971, CANCER, V27, P720, DOI 10.1002/1097-0142(197103)27:3<720::AID-CNCR2820270331>3.0.CO;2-D
   Widemann BC, 2009, CURR ONCOL REP, V11, P322, DOI 10.1007/s11912-009-0045-z
   Wiedemann F, 2013, J CLIN ONCOL, V31
   Wong WW, 1998, INT J RADIAT ONCOL, V42, P351, DOI 10.1016/S0360-3016(98)00223-5
   Xu Q, 2012, SPINE J, V12, pE7, DOI 10.1016/j.spinee.2012.03.030
NR 37
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 123
EP 127
DI 10.1016/j.wneu.2018.11.231
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400118
PM 30529515
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Weng, ST
   Wang, WQ
   Wei, QT
   Lan, HZ
   Su, J
   Xu, YM
AF Weng, Shaotao
   Wang, Wanqi
   Wei, Quantang
   Lan, Huanzhen
   Su, Jing
   Xu, Yimin
TI Effect of Tranexamic Acid in Patients with Traumatic Brain Injury: A
   Systematic Review and Meta-Analysis
SO WORLD NEUROSURGERY
LA English
DT Review
DE Antifibrinolytic agent; Brain hemorrhage; Tranexamic acid; Traumatic
   brain injury
ID HEMORRHAGE; PREVENTION; CARE
AB OBJECTIVE: Tranexamic acid (TXA) reduces hemorrhage volume and consequently the need for operative intervention. However, its effectiveness and safety in patients with traumatic brain injury (TBI) is unclear. We conducted this systematic review and meta-analysis to evaluate the safety and efficacy of TXA in patients with TBI.
   METHODS: In July 2018, a systematic search for studies including patients with TBI treated with TXA was conducted using PubMed, Embase, and the Cochrane Library databases. Only related randomized controlled trials were included. Main outcomes included hematoma expansion, surgery rate, death rate, neurologic outcome, and any thrombosis events.
   RESULTS: Of the identified 426 studies, 5 randomized controlled trials involving 917 patients met our inclusion criteria. For hematoma expansion, pooled results showed that TXA significantly decreased hemorrhage growth rate and total hemorrhage growth in patients with TBI. Regarding clinical outcomes, pooled results of surgery, mortality, and neurologic outcome showed no significant difference between the groups, and rate of thrombosis events was similar. Following sensitivity analysis, one study was excluded due to low quality. Then, results of TXA effect on mortality and neurologic outcomes became significant. We confirm that the earlier the TXA treatment is performed, the smaller the size of hematoma will be.
   CONCLUSIONS: TXA demonstrates significant effect in reducing the risk of hematoma expansion by lowering the mortality rate and improving favorable neurologic outcomes in patients with TBI while not affecting thrombosis event rates. In addition, early TXA treatment is more effective in decreasing hematomas.
C1 [Weng, Shaotao; Wei, Quantang; Lan, Huanzhen; Xu, Yimin] Shantou Univ, Med Coll, Affiliated Hosp 1, Dept Neurosurg, Shantou, Guangdong, Peoples R China.
   [Wang, Wanqi; Su, Jing] Shantou Univ, Med Coll, Sch Nursing, Shantou, Guangdong, Peoples R China.
RP Xu, YM (reprint author), Shantou Univ, Med Coll, Affiliated Hosp 1, Dept Neurosurg, Shantou, Guangdong, Peoples R China.
EM 447993193@qq.com
CR Chakroun-Walha O, 2019, EUR J TRAUMA EMERG S, V45, P719, DOI 10.1007/s00068-018-0974-z
   COATS T, 2004, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD004896
   Fakharian E, 2018, WORLD NEUROSURG, V109, pE748, DOI 10.1016/j.wneu.2017.10.075
   Gayet-Ageron A, 2018, LANCET, V391, P125, DOI 10.1016/S0140-6736(17)32455-8
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
   Jokar A, 2017, CHIN J TRAUMATOL, V20, P49, DOI 10.1016/j.cjtee.2016.02.005
   Lei J, 2015, CONTEMP CLIN TRIALS, V40, P9, DOI 10.1016/j.cct.2014.11.008
   Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X
   Mahmood A, 2016, BMJ-BRIT MED J, V354, P4814
   Narayan RK, 2008, J NEUROTRAUM, V25, P629, DOI 10.1089/neu.2007.0385
   Perel P, 2012, HEALTH TECHNOL ASSES, V16, P1, DOI 10.3310/hta16130
   Perel P, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007877.pub2
   Perel P, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-72
   Picot J, 2012, HLTH TECHNOLOGY ASSE, V16
   Roberts I, 2011, LANCET, V377, P1096, DOI 10.1016/S0140-6736(11)60278-X
   Rocchetti NS, 2018, REV NEUROLOGIA, V67, P121, DOI 10.33588/rn.6704.2018077
   Salman RAS, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005951.pub4
   Shakur H, 2017, LANCET, V389, P2105, DOI 10.1016/S0140-6736(17)30638-4
   Yutthakasemsunt S, 2013, BMC EMERG MED, V13, DOI 10.1186/1471-227X-13-20
   Zehtabchi S, 2014, AM J EMERG MED, V32, P1503, DOI 10.1016/j.ajem.2014.09.023
NR 21
TC 5
Z9 5
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 128
EP 135
DI 10.1016/j.wneu.2018.11.214
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400119
PM 30529516
DA 2020-05-12
ER

PT J
AU Izumi, M
   Higuchi, Y
   Yakufujiang, M
   Motoshima, T
   Horiguchi, K
   Aoyagi, K
   Nagano, O
   Serizawa, T
   Iwadate, Y
   Yamakami, I
AF Izumi, Masaki
   Higuchi, Yoshinori
   Yakufujiang, Maidinamu
   Motoshima, Takayuki
   Horiguchi, Kentaro
   Aoyagi, Kyoko
   Nagano, Osamu
   Serizawa, Toru
   Iwadate, Yasuo
   Yamakami, Iwao
TI The Tethered Effect of Vestibular Schwannoma Tumor Shrinkage Following
   Stereotactic Radiosurgery in Secondary Trigeminal Neuralgia
SO WORLD NEUROSURGERY
LA English
DT Article
DE Stereotactic radiosurgery; Tethered effect; Transient tumor expansion;
   Trigeminal neuralgia; Vestibular schwannoma
ID GAMMA-KNIFE SURGERY; EXPANSION
AB BACKGROUND: Compression of the trigeminal nerve by vessels and tumors causes trigeminal neuralgia. However, a tethering effect, provoking an abnormal root-stretching force, has been previously reported to play a role in trigeminal nerve hyperexcitability. We report 2 patients with vestibular schwannomas treated by stereotactic radiosurgery (SRS) who presented with typical manifestations of trigeminal neuralgia after tumor shrinkage. Furthermore, we discuss the mechanisms of trigeminal neuralgia.
   CASE DESCRIPTION: Two patients without a history of trigeminal dysfunction, including trigeminal neuralgia, underwent SRS for vestibular schwannomas. Both patients demonstrated tumor shrinkage after transient tumor expansion following SRS. Neither patient presented with facial pain or dysesthesia at the time of peak tumor volume. However, trigeminal neuralgia occurred after tumor shrinkage. One patient underwent surgery, as the neuralgia was refractory to medical treatment; although the trigeminal nerve was adhered and tethered to the tumor, no neurovascular conflict was identified between the tumor and the nerve. We removed the tumor partially, dissecting between the nerve and the tumor, and relieved the tethered effect. Trigeminal neuralgia was relieved without medication after surgery.
   CONCLUSIONS: The present cases demonstrate a tethered effect of tumor shrinkage after SRS, which was considered to play a role in trigeminal neuralgia. Surgical dissection surrounding the nerve root is effective for medically resistant neuralgia, even if the tumor shrinks. Partial tumor removal is adequate in such cases, as the tumor has been controlled by radiosurgery.
C1 [Izumi, Masaki; Higuchi, Yoshinori; Yakufujiang, Maidinamu; Motoshima, Takayuki; Horiguchi, Kentaro; Iwadate, Yasuo] Chiba Univ, Dept Neurol Surg, Grad Sch Med, Chiba, Japan.
   [Aoyagi, Kyoko; Nagano, Osamu] Chiba Cerebral & Cardiovasc Ctr, Dept Neurosurg, Ichihara, Chiba, Japan.
   [Serizawa, Toru] Tsukiji Neurol Clin, Gamma Unit Ctr, Tokyo, Japan.
   [Yamakami, Iwao] Seikei Kai Chiba Med Ctr, Dept Neurosurg, Chiba, Japan.
RP Higuchi, Y (reprint author), Chiba Univ, Dept Neurol Surg, Grad Sch Med, Chiba, Japan.
EM yhiguchi@faculty.chiba-u.jp
OI Higuchi, Yoshinori/0000-0001-5689-3416; Horiguchi,
   Kentaro/0000-0002-4400-3006
CR Chung WY, 2005, J NEUROSURG, V102, P87, DOI 10.3171/jns.2005.102.s_supplement.0087
   CRUCCU G, 1990, J NEUROL NEUROSUR PS, V53, P1034, DOI 10.1136/jnnp.53.12.1034
   DeSouza DD, 2016, FRONT NEUROANAT, V10, DOI 10.3389/finana.2016.0095
   Fowler JF, 2010, BRIT J RADIOL, V83, P554, DOI 10.1259/bjr/31372149
   Germano IM, 2018, NEUROSURGERY, V82, pE49, DOI 10.1093/neuros/nyx515
   Hasegawa T, 2006, NEUROSURGERY, V58, P1119, DOI 10.1227/01.NEU.0000215947.35646.DD
   Hempel JM, 2006, EUR ARCH OTO-RHINO-L, V263, P714, DOI 10.1007/s00405-006-0054-6
   Huang CW, 2018, J NEUROSURG, V128, P1380, DOI 10.3171/2016.12.JNS161530
   Ishikawa M, 2002, J CLIN NEUROSCI, V9, P200, DOI 10.1054/jocn.2001.0922
   Ishikawa M, 2017, INTERDISCIP NEUROSUR, V10, P126, DOI 10.1016/j.inat.2017.08.001
   Iwai Y, 2007, NEUROSURGERY, V60, P75, DOI 10.1227/01.NEU.0000249251.78794.45
   Jamjoom AB, 1996, NEUROSURG REV, V19, P237, DOI 10.1007/BF00314838
   Kobata H, 2002, NEUROSURGERY, V50, P276, DOI 10.1097/00006123-200202000-00008
   Love S, 2001, BRAIN, V124, P2347, DOI 10.1093/brain/124.12.2347
   Maarbjerg S, 2015, BRAIN, V138, P311, DOI 10.1093/brain/awu349
   Mindermann T, 2013, ACTA NEUROCHIR, V155, P71, DOI 10.1007/s00701-012-1553-4
   Nagano O, 2008, J NEUROSURG, V109, P811, DOI 10.3171/JNS/2008/109/11/0811
   Nagano O, 2010, J NEUROSURG, V113, P122, DOI 10.3171/2010.8.GKS10960
   Nakamura H, 2000, AM J NEURORADIOL, V21, P1540
   Otsuka S, 2011, INT J RADIAT ONCOL, V81, P1538, DOI 10.1016/j.ijrobp.2011.05.034
   Prasad D, 2000, J NEUROSURG, V92, P745, DOI 10.3171/jns.2000.92.5.0745
   Shulev Y, 2011, SKULL BASE-INTERD AP, V21, P287, DOI 10.1055/s-0031-1284218
   Shuto T, 2008, ACTA NEUROCHIR, V150, P229, DOI 10.1007/s00701-007-1486-5
   Zhao H, 2017, J CRANIOFAC SURG, V28, pE15, DOI 10.1097/SCS.0000000000003161
   Zhou XC, 2016, BRAZ J OTORHINOLAR, V82, P574, DOI 10.1016/j.bjorl.2015.11.006
NR 25
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 136
EP 141
DI 10.1016/j.wneu.2018.12.002
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400120
PM 30553070
DA 2020-05-12
ER

PT J
AU Viswanathan, VK
   Manoharan, SRR
   Subramanian, S
   Moon, A
AF Viswanathan, Vibhu Krishnan
   Manoharan, Sakthivel Rajan Rajaram
   Subramanian, Surabhi
   Moon, Andrew
TI Nanotechnology in Spine Surgery: A Current Update and Critical Review of
   the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Advances in spine surgery; Nanotechnology; Tissue engineering
ID IN-VITRO; DRUG-DELIVERY; NANOFIBRILLAR SURFACES; SILVER NANOPARTICLES;
   BARRIER PERMEABILITY; CONTROLLED-RELEASE; BONE REGENERATION; STEM-CELLS;
   CORD; BRAIN
AB OBJECTIVE: Nanotechnology is a promising field with numerous applications across various branches of medicine. The unique innate physical, chemical, and biological properties of nanoparticles enable them to serve as appropriate agents performing diverse functions at cellular and subcellular levels. Spinal pathologies constitute one major field where its applications are being explored.
   METHODS: A critical review of literature was performed to identify the current role of nanotechnology in spine surgery. A PubMed search was done using the following key words: "nanotechnology in neurosurgery," "nanotechnology in surgery," "nanotechnology in spine," "nanotechnology in spine surgery," "nanotechnology in disc regeneration," "nanotechnology in spinal injury," "nanotechnology in spinal cord regeneration," "nanotechnology in spine fusion," "nanotechnology in osteoporosis," "nanotechnology in spinal drug delivery," and "nanotechnology in spinal infection." Initial search revealed 347 articles. Articles were further screened. Duplicate articles, articles on non-nanotechnologic topics, nonspine articles, or articles with details not pertaining to the current field of interest and non-English language studies were excluded.
   RESULTS: A total of 76 articles were finally included. Nanotechnologic advancements in spine surgery include applications in spinal fusion, central nervous system drug delivery, neuronal regeneration, disk regeneration, spinal infection prophylaxis, management of osteoporosis, sutureless vascular anastomosis, molecular imaging, and theranostic medicine.
   CONCLUSIONS: Nanotechnology in spine surgery is still in its early stages. Eventually, we may see the implementation of nanotechnology as an alternative to existing treatment options. Concerns regarding safety of this technology need to be addressed through future research projects. Although promising, the exact role of nanotechnology in spine surgery remains to be seen.
C1 [Viswanathan, Vibhu Krishnan] IWK Hosp, Dept Surg, Halifax, NS, Canada.
   [Manoharan, Sakthivel Rajan Rajaram] Univ Alabama Birmingham, Dept Orthoped Surg, Birmingham, AL 35294 USA.
   [Subramanian, Surabhi] SRM Inst Med Sci, Dept Radiodiag, Chennai, Tamil Nadu, India.
   [Moon, Andrew] Tufts Univ, Sch Med, Boston, MA 02111 USA.
RP Manoharan, SRR (reprint author), Univ Alabama Birmingham, Dept Orthoped Surg, Birmingham, AL 35294 USA.
EM svrajanpgi@gmail.com
CR Abdel-Bar HM, 2014, INT J PHARM SCI RES, V5, P2936, DOI 10.13040/IJPSR.0975-8232.5(7).2936-46
   Ahmed I, 2006, J BIOMED MATER RES A, V76A, P851, DOI 10.1002/jbm.a.30587
   Ajeesh M, 2010, J MATER SCI-MATER M, V21, P1427, DOI 10.1007/s10856-010-4005-9
   Aksakal B, 2014, Eur J Orthop Surg Traumatol, V24, P813, DOI 10.1007/s00590-013-1236-8
   Alt V, 2004, BIOMATERIALS, V25, P4383, DOI 10.1016/j.biomaterials.2003.10.078
   Andrychowski J, 2013, FOLIA NEUROPATHOL, V51, P147, DOI 10.5114/fn.2013.35958
   Antunes JC, 2017, J MATER SCI-MATER M, V28, DOI 10.1007/s10856-016-5787-1
   Aryal M, 2015, PHYS MED BIOL, V60, P2511, DOI 10.1088/0031-9155/60/6/2511
   Aunoble S, 2006, J BIOMED MATER RES A, V78A, P416, DOI 10.1002/jbm.a.30749
   Barry M, 2016, CURR OSTEOPOROS REP, V14, P87, DOI 10.1007/s11914-016-0306-3
   Bazylinska U, 2014, COLLOID SURFACE A, V442, P42, DOI 10.1016/j.colsurfa.2013.02.023
   Bistolfi Alessandro, 2011, ISRN Orthop, V2011, P290851, DOI 10.5402/2011/290851
   Boger A, 2008, J BIOMED MATER RES B, V86B, P474, DOI 10.1002/jbm.b.31044
   Bogni S, 2011, ACTA NEUROCHIR SUPPL, V112, P45, DOI 10.1007/978-3-7091-0661-7_9
   Buchlak QD, 2016, CURR REV MUSCULOSKE, V9, P316, DOI 10.1007/s12178-016-9351-x
   Campbell SB, 2013, BIOMACROMOLECULES, V14, P644, DOI 10.1021/bm301703x
   Cao LY, 2014, BIOMATERIALS, V35, P2730, DOI 10.1016/j.biomaterials.2013.12.028
   Cao L, 2012, INT J NANOMED, V7, P5875, DOI 10.2147/IJN.S38288
   Caron WP, 2013, J PHARMACOL EXP THER, V347, P599, DOI 10.1124/jpet.113.208801
   Castro JB, 2015, J HISTOCHEM CYTOCHEM, V63, P897, DOI 10.1369/0022155415610169
   Chang Wesley C, 2007, Clin Neurosurg, V54, P137
   Chaudhary PM, 2009, J PHARM RES, V2, P1179
   Chen CL, 2008, PHARM RES-DORDR, V25, P39, DOI 10.1007/s11095-007-9484-0
   Chen S, 2007, LANGMUIR, V23, P12669, DOI 10.1021/la702049d
   Chew KK, 2011, J MECH BEHAV BIOMED, V4, P331, DOI 10.1016/j.jmbbm.2010.10.013
   Cho Y, 2008, SMALL, V4, P1676, DOI 10.1002/smll.200800838
   Clapham L M, 1999, Clin Perform Qual Health Care, V7, P167, DOI 10.1108/14664109910315587
   Collins MO, 2006, J NEUROCHEM, V97, P16, DOI 10.1111/j.1471-4159.2005.03507.x
   Das M, 2007, BIOMATERIALS, V28, P1918, DOI 10.1016/j.biomaterials.2006.11.036
   Daum N, 2012, WIRES NANOMED NANOBI, V4, P52, DOI 10.1002/wnan.165
   De Leonardis D, 1999, INT J ORAL MAXILOFAC, V14, P34
   Esposito G, 2012, J BIOL REG HOMEOS AG, V26, P447
   Fernandez-Fernandez A, 2011, APPL BIOCHEM BIOTECH, V165, P1628, DOI 10.1007/s12010-011-9383-z
   Fiorillo A, 2004, J NEURO-ONCOL, V66, P179, DOI 10.1023/B:NEON.0000013471.53015.52
   Frith JE, 2013, BIOMATERIALS, V34, P9430, DOI 10.1016/j.biomaterials.2013.08.072
   Gao CD, 2014, INT J MOL SCI, V15, P4714, DOI 10.3390/ijms15034714
   Gao CX, 2015, INT J NANOMED, V10, P5139, DOI 10.2147/IJN.S85037
   Gelain F, 2011, ACS NANO, V5, P227, DOI 10.1021/nn102461w
   Girasole G, 2013, INT J SPINE SURG, V7, DOI 10.1016/j.ijsp.2013.08.001
   Gittens RA, 2012, BIOMATERIALS, V33, P8986, DOI 10.1016/j.biomaterials.2012.08.059
   Glaser T, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00166
   Gomoll AH, 2008, ACTA ORTHOP, V79, P421, DOI 10.1080/17453670710015349
   Guo J, 2007, NANOMED-NANOTECHNOL, V3, P311, DOI 10.1016/j.nano.2007.09.003
   Hasegawa M, 2001, LASER SURG MED, V29, P62, DOI 10.1002/lsm.1087
   Hassim A, 2010, AIP CONF PROC, V1284, P195, DOI 10.1063/1.3515549
   Hazer DB, 2016, SPINE, V41, P323
   Heo DN, 2014, J MATER CHEM B, V2, P1584, DOI 10.1039/c3tb21246g
   Hesaraki S, 2009, J BIOMED MATER RES B, V91B, P651, DOI 10.1002/jbm.b.31441
   Iyer AK, 2006, DRUG DISCOV TODAY, V11, P812, DOI 10.1016/j.drudis.2006.07.005
   Jackson H, 2007, NEUROSURGERY, V60, P524, DOI 10.1227/01.NEU.0000255334.95532.DD
   Jain KK, 2007, NEURODEGENER DIS, V4, P287, DOI 10.1159/000101884
   Jain KK, 2012, NANOMEDICINE-UK, V7, P1225, DOI 10.2217/nnm.12.86
   Jing H, 2016, THERANOSTICS, V6, P862, DOI 10.7150/thno.12890
   Kim HH, 2014, INT J BIOL MACROMOL, V70, P516, DOI 10.1016/j.ijbiomac.2014.06.052
   Kim YT, 2009, BIOMATERIALS, V30, P2582, DOI 10.1016/j.biomaterials.2008.12.077
   Koh HS, 2008, BIOMATERIALS, V29, P3574, DOI 10.1016/j.biomaterials.2008.05.014
   Kolambkar YM, 2011, BIOMATERIALS, V32, P65, DOI 10.1016/j.biomaterials.2010.08.074
   La-Beck NM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00416
   Lee JY, 2009, BIOMATERIALS, V30, P4325, DOI 10.1016/j.biomaterials.2009.04.042
   Lee SY, 2013, BIOMATERIALS, V34, P552, DOI 10.1016/j.biomaterials.2012.09.065
   Lee SSS, 2015, ADV HEALTHC MATER, V4, DOI 10.1002/adhm.201400129
   Leucuta SE, 2010, CURR CLIN PHARMACOL, V5, P257, DOI 10.2174/157488410793352003
   Li K, 2012, ADV ENG MATER, V14, pB155, DOI 10.1002/adem.201080145
   Li W, 2014, J MATER SCI-MATER M, V25, P1435, DOI 10.1007/s10856-014-5190-8
   Liang CZ, 2012, J BIOMAT SCI-POLYM E, V23, P2287, DOI 10.1163/156856211X614789
   Lissarrague MH, 2014, J BIOMED NANOTECHNOL, V10, P3536, DOI 10.1166/jbn.2014.2045
   Liu HN, 2010, J BIOMED MATER RES A, V93A, P1180, DOI 10.1002/jbm.a.32614
   Liu T, 2012, TISSUE ENG PT A, V18, P1057, DOI [10.1089/ten.tea.2011.0430, 10.1089/ten.TEA.2011.0430]
   Liu X, 2010, J BIOMED MATER RES B, V94B, P72, DOI 10.1002/jbm.b.31625
   Liu Y, 2010, J DRUG TARGET, V18, P420, DOI 10.3109/10611860903434001
   Lu W, 2006, CANCER RES, V66, P11878, DOI 10.1158/0008-5472.CAN-06-2354
   Lubick N, 2008, ENVIRON SCI TECHNOL, V42, P8617, DOI 10.1021/es8026314
   Ma HY, 2016, J NANOMATER, DOI 10.1155/2016/4754190
   Ma R, 2012, J SOL-GEL SCI TECHN, V62, P52, DOI 10.1007/s10971-012-2682-1
   Markowska K, 2013, ACTA BIOCHIM POL, V60, P523
   Mattei TA, 2015, NEUROSURG REV, V38, P27, DOI 10.1007/s10143-014-0566-2
   McMahon RE, 2013, J BIOMED MATER RES B, V101B, P387, DOI 10.1002/jbm.b.32823
   Meiners S, 2007, POLYM INT, V56, P1340, DOI 10.1002/pi.2383
   Meirelles L, 2008, J BIOMED MATER RES A, V87A, P299, DOI 10.1002/jbm.a.31744
   Millon LE, 2009, J BIOMED MATER RES B, V90B, P922, DOI 10.1002/jbm.b.31364
   Moghimi SM, 2014, J CONTROL RELEASE, V190, P556, DOI 10.1016/j.jconrel.2014.03.051
   Mondal D, 2013, PROG NAT SCI-MATER, V23, P579, DOI 10.1016/j.pnsc.2013.11.009
   Moroder P, 2011, ACTA BIOMATER, V7, P944, DOI 10.1016/j.actbio.2010.10.013
   Mura S, 2012, ADV DRUG DELIVER REV, V64, P1394, DOI 10.1016/j.addr.2012.06.006
   Nair LS, 2008, J BONE JOINT SURG AM, V90A, P128, DOI 10.2106/JBJS.G.01520
   Narayanan D, 2013, MOL PHARMACEUT, V10, P4159, DOI 10.1021/mp400184v
   Nesti LJ, 2008, TISSUE ENG PT A, V14, P1527, DOI 10.1089/ten.tea.2008.0215
   Nguyen-Vu TDB, 2007, IEEE T BIO-MED ENG, V54, P1121, DOI 10.1109/TBME.2007.891169
   Nie SM, 2007, ANNU REV BIOMED ENG, V9, P257, DOI 10.1146/annurev.bioeng.9.060906.152025
   No YJ, 2014, NANOMEDICINE-UK, V9, P1745, DOI [10.2217/nnm.14.109, 10.2217/NNM.14.109]
   Oh S, 2009, P NATL ACAD SCI USA, V106, P2130, DOI 10.1073/pnas.0813200106
   Olivares-Navarrete R, 2013, SPINE J, V13, P1563, DOI 10.1016/j.spinee.2013.03.047
   Olivares-Navarrete R, 2012, SPINE J, V12, P265, DOI 10.1016/j.spinee.2012.02.002
   Ortega-Oller I, 2015, BIOMED RES INT, DOI 10.1155/2015/415289
   Ott B, 2004, LASER SURG MED, V35, P312, DOI 10.1002/lsm.20096
   Patil Mallanagouda, 2008, J Indian Soc Periodontol, V12, P34, DOI 10.4103/0972-124X.44088
   Peng Q, 2013, ACTA BIOMATER, V9, P5063, DOI 10.1016/j.actbio.2012.09.034
   Perni S, 2015, INT J NANOMED, V10, P6317, DOI 10.2147/IJN.S86440
   Petersen GH, 2016, J CONTROL RELEASE, V232, P255, DOI 10.1016/j.jconrel.2016.04.028
   Polini A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026211
   Puckett SD, 2010, BIOMATERIALS, V31, P706, DOI 10.1016/j.biomaterials.2009.09.081
   Qiu Y, 2010, BIOMATERIALS, V31, P7606, DOI 10.1016/j.biomaterials.2010.06.051
   Qu Y, 2017, INT J NANOMED, V12, P8459, DOI 10.2147/IJN.S143824
   RAE T, 1977, J BIOMED MATER RES, V11, P839, DOI 10.1002/jbm.820110604
   Raki L, 2010, MATERIALS, V3, P918, DOI 10.3390/ma3020918
   RAO CNR, 1995, MAT SCI ENG R, V15, P209, DOI 10.1016/S0927-796X(95)00181-6
   Rao RD, 2003, J BONE JOINT SURG AM, V85A, P2010, DOI 10.2106/00004623-200310000-00024
   Reddy NN, 2011, COLLOID SURFACE A, V385, P20, DOI 10.1016/j.colsurfa.2011.05.006
   Reukov V, 2011, BIOTECHNOL BIOENG, V108, P243, DOI 10.1002/bit.22958
   Richardson SM, 2016, METHODS, V99, P69, DOI 10.1016/j.ymeth.2015.09.015
   Ricker A, 2008, INT J NANOMED, V3, P125
   Rios-Doria J, 2015, NEOPLASIA, V17, P661, DOI 10.1016/j.neo.2015.08.004
   Rodriguez R, 2003, J BIOMED MATER RES A, V65A, P352, DOI 10.1002/jbm.a.10490
   Roman JA, 2011, J NEUROTRAUM, V28, P2349, DOI 10.1089/neu.2010.1409
   Roy S, 2001, NEUROSURGERY, V49, P779, DOI 10.1097/00006123-200110000-00003
   Sabnani MK, 2015, NANOMED-NANOTECHNOL, V11, P259, DOI 10.1016/j.nano.2014.08.010
   Santos T, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00180
   Schwartz Z, 2008, J BONE JOINT SURG AM, V90A, P2485, DOI 10.2106/JBJS.G.00499
   Sharma HS, 2010, ACTA NEUROCHIR SUPPL, V106, P359, DOI 10.1007/978-3-211-98811-4_65
   Shi YZ, 2010, NAT NANOTECHNOL, V5, P80, DOI [10.1038/NNANO.2009.303, 10.1038/nnano.2009.303]
   Shmeeda H, 2016, J DRUG TARGET, V24, P878, DOI 10.1080/1061186X.2016.1191081
   Silber J, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-14
   SIQUEIRA EB, 1983, SURG NEUROL, V19, P168, DOI 10.1016/0090-3019(83)90418-4
   Skeoch GD, 2017, GLOB SPINE J, V7, P272, DOI 10.1177/2192568217699189
   Slosar PJ, 2013, PROSPECTIVE STUDY UN
   Sorg BS, 2003, LASER SURG MED, V32, P215, DOI 10.1002/lsm.10156
   Stummer W, 2006, LANCET ONCOL, V7, P392, DOI 10.1016/S1470-2045(06)70665-9
   Su XH, 2013, WIRES NANOMED NANOBI, V5, P219, DOI 10.1002/wnan.1212
   Sun G, 2013, NANOMED-NANOTECHNOL, V9, P829, DOI 10.1016/j.nano.2012.12.003
   Triozon F, 2004, PHYS REV B, V69, DOI 10.1103/PhysRevB.69.121410
   Tyler JY, 2013, NANOSCALE, V5, P8821, DOI 10.1039/c3nr00957b
   Tysseling-Mattiace VM, 2008, J NEUROSCI, V28, P3814, DOI 10.1523/JNEUROSCI.0143-08.2008
   Tzeng SY, 2013, ADV HEALTHC MATER, V2, P468, DOI 10.1002/adhm.201200257
   Wahajuddin, 2012, INT J NANOMED, V7, P3445, DOI 10.2147/IJN.S30320
   Wang J, 2008, INT J CANCER, V122, P761, DOI 10.1002/ijc.23130
   Wang XP, 2007, J AM CERAM SOC, V90, P962, DOI 10.1111/j.1551-2916.2006.01460.x
   Wei D, 2016, CURR OSTEOPOROSIS RE, V14, P1
   Wei DL, 2016, CURR OSTEOPOROS REP, V14, P239, DOI 10.1007/s11914-016-0324-1
   White-Schenk D, 2015, INT J NANOMED, V10, P923, DOI 10.2147/IJN.S75686
   Wilhelm BG, 2014, SCIENCE, V344, P1023, DOI 10.1126/science.1252884
   Wu XM, 2012, INT J NANOMED, V7, P1215, DOI 10.2147/IJN.S28101
   Xie JW, 2009, ADV FUNCT MATER, V19, P2312, DOI 10.1002/adfm.200801904
   Xie JW, 2009, BIOMATERIALS, V30, P354, DOI 10.1016/j.biomaterials.2008.09.046
   Xin YC, 2009, ACS NANO, V3, P3228, DOI 10.1021/nn9007675
   Yiu G, 2006, NAT REV NEUROSCI, V7, P617, DOI 10.1038/nrn1956
   Yoshida J, 2004, HUM GENE THER, V15, P77, DOI 10.1089/10430340460732472
NR 146
TC 2
Z9 2
U1 7
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 142
EP 155
DI 10.1016/j.wneu.2018.11.035
PG 14
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400121
PM 30447449
DA 2020-05-12
ER

PT J
AU Gosal, JS
   Pandey, S
   Das, KK
   Khatri, D
   Rangari, K
   Jaiswal, AK
   Behari, S
AF Gosal, Jaskaran Singh
   Pandey, Satyadeo
   Das, Kuntal Kanti
   Khatri, Deepak
   Rangari, Kamlesh
   Jaiswal, Awadhesh Kumar
   Behari, Sanjay
TI Pathologic Laughter as an Early and Unusual Presenting Symptom of
   Petroclival Meningioma: a Case Report and Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Brainstem compression; Coordination center; Middle fossa approach;
   Pathologic laughter; Petroclival meningioma
ID TRIGEMINAL SCHWANNOMA; BRAIN-STEM
AB BACKGROUND: Pathologic laughter is inappropriate, involuntary, and unmotivated laughter episodes that may or may not be associated with mirth or amusement. Although associated with many diffuse brain pathologies, its association with intracranial focal mass lesions causing ventrolateral brainstem compression, like petroclival meningioma, is very rare. The exact pathophysiology of this interesting and unusual clinical symptom is unknown, but probably involves disinhibition and release of the so-called coordination center located in the upper brainstem due to compression by the tumor.
   CASE DESCRIPTION: A 26-year-old woman presented with recurrent episodes of inappropriate and involuntary laughter, which significantly affected her quality of life, for 2 years. These episodes did not resolve, and a magnetic resonance imaging of the brain showed a giant petroclival meningioma causing upper brainstem compression. Near-total excision of the tumor was done using an extended middle fossa approach. To our surprise, the pathologic laughter subsided immediately after surgery.
   CONCLUSIONS: Pathologic laughter may be the only symptom of a focal mass lesion causing ventrolateral upper brainstem compression, like petroclival meningioma, well before other neurological sign/symptoms appear. Tumors causing ventral brainstem compression must be ruled out before the patient is sent for a psychiatric evaluation.
C1 [Gosal, Jaskaran Singh; Pandey, Satyadeo; Das, Kuntal Kanti; Khatri, Deepak; Rangari, Kamlesh; Jaiswal, Awadhesh Kumar; Behari, Sanjay] Sanjay Gandhi Postgrad Inst Med Sci, Dept Neurosurg, Lucknow, Uttar Pradesh, India.
RP Das, KK (reprint author), Sanjay Gandhi Postgrad Inst Med Sci, Dept Neurosurg, Lucknow, Uttar Pradesh, India.
EM drkuntalkantidas@gmail.com
RI Khatri, Deepak/C-3554-2019
OI Khatri, Deepak/0000-0003-1902-9623
CR ACHARI AN, 1976, JAMA-J AM MED ASSOC, V235, P1469
   Adams RD, 1997, PRINCIPLES NEUROLOGY, P508
   Bhatjiwale MG, 2000, NEUROSURGERY, V47, P469, DOI 10.1097/00006123-200008000-00044
   CANTU RC, 1966, J NEUROSURG, V24, P1024, DOI 10.3171/jns.1966.24.6.1024
   CANTU RC, 1966, J NERV MENT DIS, V143, P508, DOI 10.1097/00005053-196612000-00006
   Cheng TJ, 2003, ACTA NEUROLOGICA TAI, V12, P187
   Gripp Daniel Andrade, 2014, Surg Neurol Int, V5, P18, DOI 10.4103/2152-7806.127257
   Jagetia A, 2006, NEUROSURG REV, V29, P348, DOI 10.1007/s10143-006-0038-4
   Machado AG, 2002, ARQ NEURO-PSIQUIAT, V60, P1000, DOI 10.1590/S0004-282X2002000600021
   MATSUOKA S, 1993, J NEUROSURG, V79, P428, DOI 10.3171/jns.1993.79.3.0428
   Muzumdar D, 2001, NEUROL MED-CHIR, V41, P505, DOI 10.2176/nmc.41.505
   Muzumdar DP, 2003, J CLIN NEUROSCI, V10, P384, DOI 10.1016/S0967-5868(03)00027-4
   Osumi Y, 1976, CLIN NEUROL, V16, P715
   POECK K, 1969, HDB CLIN NEUROLOGY, V3, P343
   Shafqat S, 1998, NEUROLOGY, V50, P1918, DOI 10.1212/WNL.50.6.1918
   STEVENSON GC, 1966, J NEUROSURG, V24, P544, DOI 10.3171/jns.1966.24.2.0544
   Tsutsumi S, 2000, NEUROL MED-CHIR, V40, P272, DOI 10.2176/nmc.40.272
   VALDUEZA JM, 1994, NEUROSURGERY, V34, P949, DOI 10.1227/00006123-199406000-00001
   Virani MJ, 2001, NEUROL INDIA, V49, P162
   WALI GM, 1993, J NEUROL NEUROSUR PS, V56, P209, DOI 10.1136/jnnp.56.2.209
   Wild B, 2003, BRAIN, V126, P2121, DOI 10.1093/brain/awg226
NR 21
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 161
EP 164
DI 10.1016/j.wneu.2018.11.240
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400125
PM 30554003
DA 2020-05-12
ER

PT J
AU Lim, MS
   Kaar, GF
AF Lim, Ming-Sheng
   Kaar, George F.
TI Spontaneous Fractures in the Setting of Extensive Craniocervical
   Pneumatization: Case Report and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Atlas; Craniocervical; Fracture; Occipital condyle; Pneumatization;
   Valsalva
ID EMPHYSEMA
AB BACKGROUND: Cranial pneumatization in humans is normally confined to the paranasal sinuses and the petrous and mastoid parts of the temporal bones.
   CASE DESCRIPTION: We present a case of left-sided fractures of the occipital condyle and lateral mass of the atlas in the setting of extensive craniocervical pneumatization but in the absence of trauma, with a resulting unilateral hypoglossal nerve palsy.
   CONCLUSIONS: We discussed the possible etiology of this rare disease, its management, and prognosis.
C1 [Lim, Ming-Sheng; Kaar, George F.] Cork Univ Hosp, Dept Neurosurg, Cork, Ireland.
RP Lim, MS (reprint author), Cork Univ Hosp, Dept Neurosurg, Cork, Ireland.
EM mingsheng.lim@gmail.com
CR Francies O, 2017, J RADIOL CASE REP, V11, P1, DOI 10.3941/jrcr.v11i11.3152
   Fussey JM, 2014, J LARYNGOL OTOL, P1
   GANS H, 1966, ARCHIV OTOLARYNGOL, V83, P343
   Germino JC, 2013, SPINE J, V13, pE47, DOI 10.1016/j.spinee.2013.06.033
   Kaiser R, 2014, EUR SPINE J, DOI [10.1007/s00586-014-3360-5, DOI 10.1007/S00586-014-3360-5]
   Quigley AJ, 2013, J RADIOL CASE REP, V7, P27, DOI 10.3941/jrcr.v7i8.1444
   Turowski B, 2001, AM J NEURORADIOL, V22, P1398
   VIRAPONGSE C, 1985, AM J ROENTGENOL, V145, P473, DOI 10.2214/ajr.145.3.473
NR 8
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 165
EP 167
DI 10.1016/j.wneu.2018.11.128
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400126
PM 30476663
DA 2020-05-12
ER

PT J
AU Li, ZX
   Chen, JG
   Qu, XL
   Duan, LW
   Huang, CG
   Zhang, DF
   Hou, LJ
AF Li, Zhenxing
   Chen, Jigang
   Qu, Xiaolin
   Duan, Liwei
   Huang, Chenguang
   Zhang, Danfeng
   Hou, Lijun
TI Management of a Steel Bar Injury Penetrating the Head and Neck: A Case
   Report and Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Non-missile penetrating injuries; Steel bar; Vascular injury
ID BRAIN-INJURY
AB BACKGROUND: Nonmissile penetrating injuries to the head and neck caused by a steel bar are rare, and a standard management strategy is lacking.
   CASE DESCRIPTION: A 42-year-old woman sustained a steel bar injury with penetration of the head and neck. Computed tomography and three-dimensional reconstruction were performed for preoperative evaluation. Digital subtraction angiography was performed to confirm potential vascular injury. The steel bar was successfully removed through an open surgical procedure by a multidisciplinary team.
   CONCLUSIONS: Relevant literature regarding nonmissile penetrating injuries involving a steel bar was reviewed to propose appropriate management strategies. Comprehensive imaging evaluation and prompt surgery by a multidisciplinary team contributed to the successful removal of the steel bar.
C1 [Li, Zhenxing; Chen, Jigang; Qu, Xiaolin; Huang, Chenguang; Zhang, Danfeng; Hou, Lijun] Second Mil Med Univ, Changzheng Hosp, Dept Neurosurg, Shanghai, Peoples R China.
   [Duan, Liwei] Second Mil Med Univ, Changzheng Hosp, Dept Emergency, Shanghai, Peoples R China.
RP Hou, LJ (reprint author), Second Mil Med Univ, Changzheng Hosp, Dept Neurosurg, Shanghai, Peoples R China.
EM shczsjwk11@126.com
CR Atay M, 2013, J NEUROIMAGING, V23, P314, DOI 10.1111/jon.12003
   Chen PY, 2014, ULUS TRAVMA ACIL CER, V20, P382, DOI 10.5505/tjtes.2014.39338
   Fehlings MG, 2017, GLOB SPINE J, V7, p203S, DOI 10.1177/2192568217703085
   Grossbach AJ, 2014, BRAIN INJURY, V28, P1617, DOI 10.3109/02699052.2014.934284
   Haut ER, 2010, J TRAUMA, V68, P115, DOI 10.1097/TA.0b013e3181c9ee58
   Hurlbert R John, 2015, Neurosurgery, V76 Suppl 1, pS71, DOI 10.1227/01.neu.0000462080.04196.f7
   Jacob JT, 2005, J NEUROSURG, V102, P350, DOI 10.3171/ped.2005.102.3.0350
   Lee DH, 2011, J CRANIOFAC SURG, V22, P1800, DOI 10.1097/SCS.0b013e31822e829f
   Li XS, 2017, WORLD NEUROSURG, V98, DOI 10.1016/j.wneu.2016.11.125
   Luo P, 2015, NEUROLOGY, V84, P1909, DOI 10.1212/WNL.0000000000001544
   Macht M, 2005, EUR J TRAUMA, V31, P503
   Mandavia DP, 2000, ANN EMERG MED, V35, P221, DOI 10.1016/S0196-0644(00)70071-0
   Mansour AM, 2009, BMJ CASE REP, V2009
   Maruya J, 2002, NEUROL MED-CHIR, V42, P143, DOI 10.2176/nmc.42.143
   Naito K, 2009, EUR J ORTHOP SURG TR, V19, P83, DOI 10.1007/s00590-008-0376-8
   Nunez DB, 2004, RADIOGRAPHICS, V24, P1087, DOI 10.1148/rg.244035035
   Oteir AO, 2015, INJURY, V46, P528, DOI 10.1016/j.injury.2014.12.032
   Pandey S, 2018, J CRANIOFAC SURG, V29, pE372, DOI 10.1097/SCS.0000000000004394
   Petersen K, 2011, EXPERT REV ANTI-INFE, V9, P81, DOI 10.1586/ERI.10.155
   Shahlaie K, 2006, J NEUROSURG-SPINE, V4, P400, DOI 10.3171/spi.2006.4.5.400
   Temple N, 2015, J MED RADIAT SCI, V62, P122, DOI 10.1002/jmrs.101
   Wang LT, 2009, DIS COLON RECTUM, V52, P346, DOI 10.1007/DCR.0b013e318199daed
   Wang YL, 2014, J CRANIOFAC SURG, V25, pE521, DOI 10.1097/SCS.0000000000000505
   Yamashita T, 2007, J NEURO-OPHTHALMOL, V27, P48, DOI 10.1097/WNO.0b013e3180325ef4
   Zhou ZJ, 2011, SPINE, V36, pE803, DOI 10.1097/BRS.0b013e3181fab574
NR 25
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 168
EP 173
DI 10.1016/j.wneu.2018.11.029
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400127
PM 30447445
DA 2020-05-12
ER

PT J
AU Sanchis-Gimeno, JA
   Llido, S
   Nalla, S
AF Sanchis-Gimeno, Juan A.
   Llido, Susanna
   Nalla, Shahed
TI The Retrotransverse Foramen of the Atlas Is not a Modern Anatomic
   Variation
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anatomy; Cervical atlas; Regional circulation; Spine; Variations
ID VERTEBRAL ARTERY; GROOVE; PREVALENCE
AB BACKGROUND: The retrotransverse foramen (RTF) is a nonmetric variant of the atlas vertebra that consists of an abnormal accessory foramen located on the posterior root of the transverse process and it extends from the posterior root of the transverse process to the root of the posterior arch. Its presence has been related to regional variations of the venous circulation. It is currently unknown whether the RTF is a modern or an ancient anatomic variation.
   CASE DESCRIPTION: We analyzed the skeletal remains from the late-ancient Roman necropolis (II-VI centuries AD) of La Boatella (Valencia, Spain) and we found a well-preserved individual skeleton that presented with a left retrotransverse foramen in C1.
   CONCLUSIONS: The RTF is not a modern anatomic variation. As a result, ancient individuals had the same modifications in the regional circulation as modern subjects present today.
C1 [Sanchis-Gimeno, Juan A.; Llido, Susanna] Univ Valencia, Fac Med, Dept Anat & Human Embryol, Valencia, Spain.
   [Nalla, Shahed] Univ Johannesburg, Fac Hlth Sci, Dept Human Anat & Physiol, Auckland Pk, South Africa.
RP Sanchis-Gimeno, JA (reprint author), Univ Valencia, Fac Med, Dept Anat & Human Embryol, Valencia, Spain.
EM Juan.sanchis@uv.es
RI Nalla, Shahed/U-2213-2017; Sanchis-Gimeno, Juan A./G-9976-2015
OI Nalla, Shahed/0000-0002-0957-1067; Sanchis-Gimeno, Juan
   A./0000-0002-2599-8474
FU Ministry of Economy, Industry and Competitiveness of Spain
   [CGL2015-63648-P]
FX This research is funded in part by the Ministry of Economy, Industry and
   Competitiveness of Spain (grant/award number: CGL2015-63648-P).
CR Bodon Gergely, 2016, Eur J Orthop Surg Traumatol, V26, P793, DOI 10.1007/s00590-016-1771-1
   Le Minor JM, 1997, ACTA ANAT, V160, P208
   Le Minor JM, 2004, AM J PHYS ANTHROPOL, V125, P16, DOI 10.1002/ajpa.10270
   Machancoses-Lopez M, 2016, AAC, V27, P183
   Paraskevas G, 2005, SURG RADIOL ANAT, V27, P129, DOI 10.1007/s00276-004-0300-9
   Pekala PA, 2017, J NEUROSURG-SPINE, V27, P276, DOI 10.3171/2017.1.SPINE161092
   Quiles-Guinau Laura, 2016, Italian Journal of Anatomy and Embryology, V121, P123, DOI 10.13128/IJAE-18485
   Sanchis-Gimeno JA, 2018, SPINE J, V18, P2102, DOI 10.1016/j.spinee.2018.06.352
   Sanchis-Gimeno JA, 2018, EUR SPINE J, V27, P1272, DOI 10.1007/s00586-017-5372-4
   Sanchis-Gimeno JA, 2018, WORLD NEUROSURG, V114, pE869, DOI 10.1016/j.wneu.2018.03.102
   Travan L, 2015, ANAT SCI INT, V90, P308, DOI 10.1007/s12565-014-0270-x
   VELEANU C, 1977, ACTA ANAT, V97, P400
NR 12
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 174
EP 176
DI 10.1016/j.wneu.2018.11.241
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400128
PM 30557656
DA 2020-05-12
ER

PT J
AU Dietz, N
   Sharma, M
   Alhourani, A
   Ugiliweneza, B
   Wang, DZ
   Nuno, MA
   Drazin, D
   Boakye, M
AF Dietz, Nicholas
   Sharma, Mayur
   Alhourani, Ahmad
   Ugiliweneza, Beatrice
   Wang, Dengzhi
   Nuno, Miriam A.
   Drazin, Doniel
   Boakye, Maxwell
TI Bundled Payment Models in Spine Surgery: Current Challenges and
   Opportunities, a Systematic Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Bundled payment; Cervical; Challenges; Cost variation; Degenerative
   spine surgery; Episodes of care; Lumbar; Opportunities; Payment
   variation; Spine surgery
ID CERVICAL SPONDYLOTIC MYELOPATHY; OUTCOMES DATABASE; QUALITY OUTCOMES;
   FUSION; COSTS; REIMBURSEMENT; COMPLICATIONS; ANTERIOR; TEXAS
AB BACKGROUND: Bundled payments offer a lump sum for management of particular conditions over a specified period that has the potential to reduce health care payments. In addition, bundled payments represent a shift toward patient-centered reimbursement, which has the upside of improved care coordination among providers and may lead to improved outcomes.
   OBJECTIVE: To review the challenges and sources of payment variation and opportunities for restructuring bundled payments plans in the context of spine surgery.
   METHODS: We reviewed episodes of care over the past 10 years. We completed a search using PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines and the PICOS (Participants, Intervention, Comparison, Outcomes, Study Design) model in PubMed and Ovid databases to identify studies that met our search criteria.
   RESULTS: Ten studies met the search criteria, which were retrospective in design. The primary recipient of reimbursement was the hospital associated with the index procedure (59.7%-77% of the bundled payment), followed by surgeon reimbursement (12.8%-14%) and post-acute care rehabilitation (3.6%-7.3%). On average, the index hospitalization was $32,467, ranging from $11,880 to $107,642, depending on number of levels fused, complications, and malignancy. Readmission was shown to increase the 90-day payment by 50%-200% for uncomplicated fusion.
   CONCLUSIONS: The implementation of spine surgery in bundled payment models offers opportunity for health care cost reduction. Patient heterogeneity, complications, and index hospitalization pricing are among factors that contribute to the challenge of payment variation. Development of standard care pathways, multidisciplinary coordination between inpatient and outpatient postoperative care, and empowerment of patients are also key elements of progress in the evolution of bundled payments in spine surgery. We anticipate more individualized risk-adjusted prediction models of payment for spine surgery, contributing to more manageable variation in payment and favorable models of bundled payments for payers and providers.
C1 [Dietz, Nicholas; Sharma, Mayur; Alhourani, Ahmad; Ugiliweneza, Beatrice; Wang, Dengzhi; Boakye, Maxwell] Univ Louisville, Dept Neurosurg, Louisville, KY 40292 USA.
   [Nuno, Miriam A.] Univ Calif Davis, Dept Publ Hlth Sci, Div Biostat, Davis, CA 95616 USA.
   [Drazin, Doniel] Evergreen Hosp, Neurosci Inst, Kirkland, WA USA.
RP Boakye, M (reprint author), Univ Louisville, Dept Neurosurg, Louisville, KY 40292 USA.
EM Maxwell.boakye@ulp.org
RI Sharma, Mayur/B-3228-2018
OI Sharma, Mayur/0000-0001-6481-7819; Dietz, Nicholas/0000-0001-5822-1680
CR Angeli C, 2012, SPINAL CORD, V50, P925, DOI 10.1038/sc.2012.93
   Bekelis K, 2014, SPINE J, V14, P1247, DOI 10.1016/j.spinee.2013.08.009
   Boakye M, 2008, NEUROSURGERY, V62, P455, DOI 10.1227/01.neu.0000316013.97926.4c
   Centers for Medicare and Medicaid Services, 2015, SMART SPEND HLTH PEO
   Chotai S, 2018, NEUROSURGERY, V83, P898, DOI 10.1093/neuros/nyy140
   Cooley DA, 2008, TEX HEART I J, V35, P235
   Culler SD, 2016, SPINE, V41, P1613, DOI 10.1097/BRS.0000000000001641
   Dummit LA, 2016, JAMA-J AM MED ASSOC, V316, P1267, DOI 10.1001/jama.2016.12717
   Gillis CC, 2015, CLIN NEUROL NEUROSUR, V139, P29, DOI 10.1016/j.clineuro.2015.08.024
   Jain N, 2018, CLIN SPINE SURG, V31, P120, DOI 10.1097/BSD.0000000000000550
   Jain N, 2018, CLIN SPINE SURG, V31, pE197, DOI 10.1097/BSD.0000000000000612
   Jain N, 2018, SPINE, V43, P193, DOI 10.1097/BRS.0000000000002283
   JOHNSON LL, 1994, ARTHROSCOPY, V10, P462, DOI 10.1016/S0749-8063(05)80200-2
   Jubelt LE, 2017, J AM ACAD ORTHOP SUR, V25, P654, DOI 10.5435/JAAOS-D-16-00626
   Kahn EN, 2018, J NEUROSURG-SPINE, V29, P214, DOI 10.3171/2017.12.SPINE17674
   Martin BI, 2018, SPINE, V43, P705, DOI 10.1097/BRS.0000000000002404
   McCarthy IM, 2014, SPINE J, V14, P2326, DOI 10.1016/j.spinee.2014.01.032
   McGirt MJ, 2017, J NEUROSURG-SPINE, V27, P357, DOI 10.3171/2016.11.SPINE16526
   Mok JM, 2016, INT J SPINE SURG, V10, DOI 10.14444/3019
   NANGLE M, 1995, TEX HEART I J, V22, P77
   Preston JS, 2018, J ARTHROPLASTY, V33, P2362, DOI 10.1016/j.arth.2018.03.007
   Ramkumar Prem N, 2015, Am J Orthop (Belle Mead NJ), V44, P397
   Schoenfeld AJ, 2014, SPINE J, V14, P2793, DOI 10.1016/j.spinee.2014.07.002
   Sharma M, 2018, WORLD NEUROSURG, V115, pE664, DOI 10.1016/j.wneu.2018.04.131
   Soegaard R, 2007, EUR SPINE J, V16, P657, DOI 10.1007/s00586-006-0179-8
   Sullivan R, 2017, CURR REV MUSCULOSKE, V10, P218, DOI 10.1007/s12178-017-9405-8
   Trahan J, 2011, WORLD NEUROSURG, V75, P145, DOI 10.1016/j.wneu.2010.09.015
   Ugiliweneza B, 2014, SPINE, V39, P1235, DOI 10.1097/BRS.0000000000000378
   VanLare JM, 2012, NEW ENGL J MED, V367, P292, DOI 10.1056/NEJMp1204939
   Virk SS, 2018, J NEUROSURG-SPINE, V28, P244, DOI 10.3171/2017.7.SPINE1714
   Wadhwa RK, 2017, J NEUROSURG-SPINE, V27, P131, DOI 10.3171/2016.12.SPINE16714
   Warren Daniel, 2011, Evid Based Spine Care J, V2, P57, DOI 10.1055/s-0030-1267113
   Wright DJ, 2016, SPINE, V41, P1747, DOI 10.1097/BRS.0000000000001649
   Yeramaneni S, 2018, SPINE J, V18, P1829, DOI 10.1016/j.spinee.2018.03.012
NR 34
TC 3
Z9 3
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 177
EP 183
DI 10.1016/j.wneu.2018.12.001
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400129
PM 30553071
DA 2020-05-12
ER

PT J
AU Griffin, AS
   Oppong, MD
   Hauck, EF
AF Griffin, Andrew S.
   Oppong, Marvin Darkwah
   Hauck, Erik F.
TI Infundibular Dilations and Subarachnoid Hemorrhage: to Treat or Not to
   Treat?
SO WORLD NEUROSURGERY
LA English
DT Review
DE Aneurysm; Infundibular dilation; Infundibulum; Subarachnoid hemorrhage
ID POSTERIOR COMMUNICATING ARTERY; JUNCTIONAL DILATATION; ANEURYSM
   FORMATION; RUPTURE; ENLARGEMENT; PROGRESSION; ORIGIN
AB BACKGROUND: Infundibular dilations are funnel-shaped widenings at the origin of a cerebral artery, most commonly the posterior communicating artery. Controversy exists as to whether an infundibulum represents a normal anatomic variant or a lesion with the potential for rupture and subarachnoid hemorrhage (SAH).
   METHODS: We reviewed all reported cases of infundibular dilations and SAH in the world literature and present an illustrative case.
   RESULTS: Most infundibula in the context of SAH were associated with an aneurysm either on or near an infundibulum. However, there have been 7 reports in which the infundibulum could have been the primary site of rupture and no associated aneurysm was identified. Close review reveals significant limitations of those 7 reports.
   CONCLUSIONS: The literature, and our own experience, do not support the treatment of infundibula, even in SAH patients. Treatment should be directed toward an associated aneurysm, not the infundibulum.
C1 [Griffin, Andrew S.; Oppong, Marvin Darkwah; Hauck, Erik F.] Duke Univ, Med Ctr, Dept Neurosurg, Durham, NC 27708 USA.
RP Griffin, AS (reprint author), Duke Univ, Med Ctr, Dept Neurosurg, Durham, NC 27708 USA.
EM Andrew.s.griffin@duke.edu
CR ARCHER CR, 1978, NEURORADIOLOGY, V15, P247, DOI 10.1007/BF00342917
   BJORKESTEN G, 1962, J NEUROSURG, V19, P583, DOI 10.3171/jns.1962.19.7.0583
   Coupe NJ, 2007, SURG NEUROL, V67, P204, DOI 10.1016/j.surneu.2006.05.066
   Cowan JA, 2004, J NEUROSURG, V101, P694, DOI 10.3171/jns.2004.101.4.0694
   EBINA K, 1986, NEURORADIOLOGY, V28, P23, DOI 10.1007/BF00341761
   ENDO S, 1995, J NEUROSURG, V83, P421, DOI 10.3171/jns.1995.83.3.0421
   EPSTEIN F, 1970, J NEUROSURG, V33, P529, DOI 10.3171/jns.1970.33.5.0529
   Fischer S, 2011, CLIN NEURORADIOL, V21, P87, DOI 10.1007/s00062-010-0038-1
   FOX JL, 1964, J NEUROSURG, V21, P135, DOI 10.3171/jns.1964.21.2.0135
   Glynn LE, 1940, J PATHOL BACTERIOL, V51, P213, DOI 10.1002/path.1700510206
   HASSLER OVE, 1959, ACTA PATHOL ET MICROBIOL SCAND, V46, P305
   ITAKURA T, 1983, J NEUROSURG, V58, P117, DOI 10.3171/jns.1983.58.1.0117
   Kameda-Smith MM, 2014, NEURORADIOLOGY, V56, P35, DOI 10.1007/s00234-013-1295-x
   KOIKE G, 1994, NEUROSURGERY, V34, P1075, DOI 10.1227/00006123-199406000-00020
   KUWAHARA K, 1980, Neurological Surgery, V8, P551
   Marshman LAG, 1998, NEUROSURGERY, V43, P1445, DOI 10.1097/00006123-199812000-00107
   Nashimoto Takeo, 2009, Brain and Nerve (Tokyo), V61, P1177
   Ohyama Takashiro, 1994, Neurologia Medico-Chirurgica, V34, P172, DOI 10.2176/nmc.34.172
   PATRICK D, 1983, BRIT J RADIOL, V56, P59, DOI 10.1259/0007-1285-56-661-59
   PUNT J, 1979, J NEUROSURG, V51, P151, DOI 10.3171/jns.1979.51.2.0151
   Radulovic D, 2006, NEUROCHIRURGIE, V52, P525, DOI 10.1016/S0028-3770(06)71360-1
   SALTZMAN GF, 1959, ACTA RADIOL, V51, P415, DOI 10.3109/00016925909171114
   Shi WY, 2011, SURG RADIOL ANAT, V33, P75, DOI 10.1007/s00276-010-0728-z
   Shojima M, 2018, NEUROSURGERY, V82, P864, DOI 10.1093/neuros/nyx307
   STUNTZ JT, 1970, J NEUROSURG, V33, P591, DOI 10.3171/jns.1970.33.5.0591
   Thung-Ming S, 1999, ACTA NEUROL TAIWAN, V8, P178
   TRASI S, 1981, AM J NEURORADIOL, V2, P368
   YOSHIDA M, 1981, NEUROSURGERY, V9, P718, DOI 10.1227/00006123-198112000-00018
   YOSHIMOTO T, 1974, J NEUROSURG, V41, P377, DOI 10.3171/jns.1974.41.3.0377
   YOUNG B, 1971, J NEUROSURG, V34, P814, DOI 10.3171/jns.1971.34.6.0814
   Yu JL, 2015, INT J CLIN EXP MED, V8, P17080
   Yu JL, 2010, CASE REP MED, DOI 10.1155/2010/210397
NR 32
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 188
EP 192
DI 10.1016/j.wneu.2018.12.007
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400131
PM 30576822
DA 2020-05-12
ER

PT J
AU Nakayama, Y
   Kamio, Y
   Kato, N
   Murayama, Y
AF Nakayama, Yosuke
   Kamio, Yoshinobu
   Kato, Naoki
   Murayama, Yuichi
TI Extracranial-Intracranial Bypass for Cerebral Vasculitis After
   Graft-Versus-Host Disease: Case Report and Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Cerebral vasculitis; Graft-versus-host disease; Superficial temporal
   artery-middle cerebral artery bypass
ID CONSENSUS DEVELOPMENT PROJECT; CLINICAL-TRIALS; CRITERIA; ANGIITIS
AB BACKGROUND: Cerebral vasculitis owing to chronic graft-versus-host disease (GVHD) is very rare. To our knowledge, only 2 cases have been reported. We describe the first case of superficial temporal artery-middle cerebral artery (STA-MCA) bypass for cerebral vasculitis owing to GVHD.
   CASE DESCRIPTION: A 59-year-old woman presented with right upper extremity weakness and dysarthria 33 months after undergoing matching allogenic bone marrow transplantation. The patient had STA-MCA bypass for MCA occlusion and resting cerebral blood flow in the left MCA area improved.
   CONCLUSIONS: Although the mechanism of cerebral vasculitis after chronic GVHD is not known, cerebral vasculitis that causes cerebrovascular disease long after bone marrow transplantation should be considered. In this case, an STA-MCA bypass was efficient for the repeated ischemic attacks owing to cerebral vasculitis. Moreover, it is important to select the optimal recipient vessels to area originated neurologic symptoms.
C1 [Nakayama, Yosuke; Kamio, Yoshinobu; Kato, Naoki; Murayama, Yuichi] Jikei Univ, Sch Med, Dept Neurosurg, Minato Ku, Tokyo, Japan.
RP Kamio, Y (reprint author), Jikei Univ, Sch Med, Dept Neurosurg, Minato Ku, Tokyo, Japan.
EM kyoshi429520@gmail.com
CR Al-Hashmi S, 2011, INT J CLIN EXP PATHO, V4, P596
   Campbell JN, 2005, AM J NEURORADIOL, V26, P654
   Cooke KR, 2017, BIOL BLOOD MARROW TR, V23, P211, DOI 10.1016/j.bbmt.2016.09.023
   Filipovich AH, 2005, BIOL BLOOD MARROW TR, V11, P945, DOI 10.1016/j.bbmt.2005.09.004
   Lee SJ, 2003, BIOL BLOOD MARROW TR, V9, P215, DOI 10.1053/bbmt.2003.50026
   Ma M, 2002, NEUROLOGY, V59, P1994, DOI 10.1212/01.WNL.0000038948.09158.A7
   Padovan CS, 1999, STROKE, V30, P1651, DOI 10.1161/01.STR.30.8.1651
   Padovan CS, 1998, ANN NEUROL, V43, P627, DOI 10.1002/ana.410430511
   Ruggiu M, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008303
   Stewart BL, 2004, BLOOD, V104, P3501, DOI 10.1182/blood-2004-01-0200
NR 10
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 193
EP 196
DI 10.1016/j.wneu.2018.11.256
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400132
PM 30576821
DA 2020-05-12
ER

PT J
AU Mugge, L
   Krafcik, B
   Pontasch, G
   Alnemari, A
   Neimat, J
   Gaudin, D
AF Mugge, Luke
   Krafcik, Brianna
   Pontasch, Gregory
   Alnemari, Ahmed
   Neimat, Joseph
   Gaudin, Daniel
TI A Review of Biomarkers Use in Parkinson with Deep Brain Stimulation: A
   Successful Past Promising a Bright Future
SO WORLD NEUROSURGERY
LA English
DT Review
DE Biomarkers; Deep brain stimulation; Parkinson disease
ID HIGH-FREQUENCY STIMULATION; LOCAL-FIELD POTENTIALS; SUBTHALAMIC NUCLEUS
   STIMULATION; INDUCED CELLULAR DEFECTS; DISEASE PATIENTS; BASAL GANGLIA;
   STRIATAL DOPAMINE; RAT STRIATUM; TEST-RETEST; RECEPTOR
AB BACKGROUND: Parkinson disease (PD) remains a common neurodegenerative disorder. Functional neurosurgery largely arose with the introduction of deep brain stimulation (DBS) as a potential option for PD unresponsive to medical management. Biomarkers are clinical and laboratory indicators of therapeutic success or failure.
   OBJECTIVE: To examine the current and published literature relating to the development and use of biomarkers in monitoring and determining the efficacy of DBS in PD.
   METHODS: The PubMed database was systematically searched using the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines for systemic reviews. Studies that examined current or potential biomarkers measurable after DBS were included. Articles from 1952 to date were examined.
   RESULTS: The initial search identified 49 articles. Thirty articles met the inclusion criteria. Articles were subdivided into those addressing biomarkers with proven clinical usefulness and potential biomarkers that have future application.
   CONCLUSIONS: Biomarkers have been identified that can help to determine the effect of DBS on patients with PD. Current studies show that there are measured differences in electrophysiologic oscillations, gene expression, neuropeptide levels, metabolic function, inflammatory activity, and others in the central nervous system after DBS in PD. Local field potential and beta-band analysis stand as the clinically proven biomarkers of choice for DBS in PD. Many of the identified changes noted could be implemented as clinically useful biomarkers through which DBS may be monitored. Future studies are needed to determine which noted physiologic changes are most appropriately used as biomarkers and in which contexts they are most helpful.
C1 [Mugge, Luke; Krafcik, Brianna; Pontasch, Gregory; Alnemari, Ahmed; Gaudin, Daniel] Univ Toledo, Med Ctr, Dept Neurosurg, 2801 W Bancroft St, Toledo, OH 43606 USA.
   [Neimat, Joseph] Univ Louisville Hosp, Dept Neurosurg, Louisville, KY USA.
RP Mugge, L (reprint author), Univ Toledo, Med Ctr, Dept Neurosurg, 2801 W Bancroft St, Toledo, OH 43606 USA.
EM luke.mugge@rockets.utoledo.edu
CR Abosch A, 2012, NEUROSURGERY, V71, P804, DOI 10.1227/NEU.0b013e3182676b91
   Aitio A, 1993, WHO INT PROGRAMME CH
   Anderson D, 2001, BIOMARKERS RISK ASSE
   Arroyo-Jimenez MD, 1999, J NEUROSCI, V19, P6475
   Asanuma K, 2006, BRAIN, V129, P2667, DOI 10.1093/brain/awl162
   Bacci JJ, 2004, EUR J NEUROSCI, V20, P3331, DOI 10.1111/j.1460-9568.2004.03792.x
   BAIK JH, 1995, NATURE, V377, P424, DOI 10.1038/377424a0
   Benabid A. L., 1988, STEREOT FUNCT NEUROS, V50, P344
   BENABID AL, 1991, LANCET, V337, P403, DOI 10.1016/0140-6736(91)91175-T
   Beudel Martijn, 2018, Prog Neurol Surg, V33, P230, DOI 10.1159/000481107
   Brioni J D, 1997, Adv Pharmacol, V37, P153
   Brown P, 2005, CLIN NEUROPHYSIOL, V116, P2510, DOI 10.1016/j.clinph.2005.05.009
   Bruet N, 2001, J NEUROPATH EXP NEUR, V60, P15, DOI 10.1093/jnen/60.1.15
   Calabresi P, 2006, LANCET NEUROL, V5, P974, DOI 10.1016/S1474-4422(06)70600-7
   Carcenac C, 2015, MOVEMENT DISORD, V30, P1739, DOI 10.1002/mds.26146
   Constantinescu R, 2011, ACTA NEUROL SCAND, V124, P206, DOI 10.1111/j.1600-0404.2010.01451.x
   Cousineau M, 2017, NEUROIMAGE-CLIN, V16, P222, DOI 10.1016/j.nicl.2017.07.020
   DELONG MR, 1990, TRENDS NEUROSCI, V13, P281, DOI 10.1016/0166-2236(90)90110-V
   Dickson DW, 2018, PARKINSONISM RELAT D, V46, pS30, DOI 10.1016/j.parkreldis.2017.07.033
   Eddy MC, 2014, LEARN MEMORY, V21, P334, DOI 10.1101/lm.034462.114
   Elsworth JD, 1997, EXP NEUROL, V144, P4, DOI 10.1006/exnr.1996.6379
   Fleming TR, 1996, ANN INTERN MED, V125, P605, DOI 10.7326/0003-4819-125-7-199610010-00011
   Graul AI, 2014, DRUG TODAY, V50, P641, DOI 10.1358/dot.2014.50.9.2229405
   Gubellini P, 2006, EUR J NEUROSCI, V24, P1802, DOI 10.1111/j.1460-9568.2006.05047.x
   Hesse S, 2008, J NEUROL, V255, P1059, DOI 10.1007/s00415-008-0849-z
   Hirano S, 2009, MOVEMENT DISORD, V24, pS725, DOI 10.1002/mds.22541
   Hirsch Etienne C, 2012, Parkinsonism Relat Disord, V18 Suppl 1, pS210, DOI 10.1016/S1353-8020(11)70065-7
   Hirshler Y, 2010, EXP NEUROL, V222, P42, DOI 10.1016/j.expneurol.2009.12.006
   Kalia LV, 2018, PARKINSONISM RELAT D, V46, pS19, DOI 10.1016/j.parkreldis.2017.07.023
   Kempuraj D, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00216
   Koprich JB, 2010, MOL NEURODEGENER, V5, DOI 10.1186/1750-1326-5-43
   Kronenbuerger M, 2015, MOVEMENT DISORD, V30, P1125, DOI 10.1002/mds.26247
   Kuhn AA, 2005, EXP NEUROL, V194, P212, DOI 10.1016/j.expneurol.2005.02.010
   Labarca C, 2001, P NATL ACAD SCI USA, V98, P2786, DOI 10.1073/pnas.041582598
   Lee KH, 2006, EUR J NEUROSCI, V23, P1005, DOI 10.1111/j.1460-9568.2006.04638.x
   Lefaucheur R, 2014, PARKINSONISM RELAT D, V20, P1304, DOI 10.1016/j.parkreldis.2014.08.018
   LEGATT AD, 1980, J NEUROSCI METH, V2, P203, DOI 10.1016/0165-0270(80)90061-8
   Lin HC, 2016, FRONT NEURAL CIRCUIT, V9, DOI 10.3389/fncir.2015.00087
   Little S, 2012, ANN NY ACAD SCI, V1265, P9, DOI 10.1111/j.1749-6632.2012.06650.x
   Lopez-Aguado L, 2002, J NEUROPHYSIOL, V88, P2809, DOI 10.1152/jn.00183.2002
   Ma YL, 2007, J CEREBR BLOOD F MET, V27, P597, DOI 10.1038/sj.jcbfm.9600358
   Martin-Vazquez G, 2016, CEREB CORTEX, V26, P4082, DOI 10.1093/cercor/bhv211
   Martin-Vazquez G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075499
   McIntyre CC, 2004, CLIN NEUROPHYSIOL, V115, P589, DOI 10.1016/j.clinph.2003.10.033
   Meissner W, 2001, NEUROSCI LETT, V303, P165, DOI 10.1016/S0304-3940(01)01758-X
   Michmizos KP, 2015, IEEE J BIOMED HEALTH, V19, P174, DOI 10.1109/JBHI.2014.2344102
   Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005
   Mole JP, 2016, EUR RADIOL, V26, P3327, DOI 10.1007/s00330-015-4178-1
   Mollazadeh H, 2019, CRIT REV FOOD SCI, V59, P89, DOI 10.1080/10408398.2017.1358139
   Morishita T, 2017, NEURAL REGEN RES, V12, P747, DOI 10.4103/1673-5374.206642
   Musacchio T, 2017, ANN NEUROL, V81, P825, DOI 10.1002/ana.24947
   Neumann WJ, 2016, MOVEMENT DISORD, V31, P1748, DOI 10.1002/mds.26759
   Oueslati A, 2007, J NEUROSCI, V27, P2377, DOI 10.1523/JNEUROSCI.2949-06.2007
   Pal GD, 2017, MOVEMENT DISORD, V32, P274, DOI 10.1002/mds.26882
   Poewe W, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.13
   Popovych OV, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173363
   Ramirez AI, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00214
   Rey NL, 2016, J EXP MED, V213, P1759, DOI 10.1084/jem.20160368
   Ross SA, 2000, J NEUROSCI, V20, P6431, DOI 10.1523/JNEUROSCI.20-17-06431.2000
   Sakai W, 2017, J PARKINSON DIS, V7, P247, DOI 10.3233/JPD-160948
   Salin P, 2002, J NEUROSCI, V22, P5137, DOI 10.1523/JNEUROSCI.22-12-05137.2002
   Sanabria DE, 2017, J NEUROPHYSIOL, V118, P2654, DOI 10.1152/jn.00388.2017
   Sankar Tejas, 2012, Surg Neurol Int, V3, pS26, DOI 10.4103/2152-7806.91607
   Son SJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep38070
   Soreq L, 2015, GENOM DATA, V3, P57, DOI 10.1016/j.gdata.2014.11.009
   Soreq L, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003517
   Stefani A, 2005, ANN NEUROL, V57, P448, DOI 10.1002/ana.20402
   Stefani A, 2006, J NEURAL TRANSM-SUPP, P401
   Strimbu K, 2010, CURR OPIN HIV AIDS, V5, P463, DOI 10.1097/COH.0b013e32833ed177
   Suthana N, 2014, NEUROIMAGE, V85, P996, DOI 10.1016/j.neuroimage.2013.07.066
   Tarakad A, 2017, SEMIN NEUROL, V37, P118, DOI 10.1055/s-0037-1601888
   Thompson JA, 2014, STEREOT FUNCT NEUROS, V92, P251, DOI 10.1159/000364913
   Tropea TF, 2018, PARKINSONISM RELAT D, V46, pS15, DOI 10.1016/j.parkreldis.2017.07.021
   Tufekci KU, 2012, ADV PROTEIN CHEM STR, V88, P69, DOI 10.1016/B978-0-12-398314-5.00004-0
   Vedam-Mai V, 2016, NEUROMODULATION, V19, P451, DOI 10.1111/ner.12406
   Wang CF, 2017, BRAIN STIMUL, V10, P672, DOI 10.1016/j.brs.2017.02.004
   Wang DD, 2016, NEUROBIOL DIS, V89, P213, DOI 10.1016/j.nbd.2016.02.015
   Youngerman BE, 2016, J NEUROSURG, V125, P461, DOI 10.3171/2015.7.JNS142599
NR 78
TC 1
Z9 1
U1 1
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 197
EP 207
DI 10.1016/j.wneu.2018.11.247
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400133
PM 30576816
DA 2020-05-12
ER

PT J
AU Onen, MR
   Varol, E
   Tosun, MI
   Naderi, S
AF Onen, Mehmet Resid
   Varol, Eyup
   Tosun, Muzaffer Ilkay
   Naderi, Sait
TI Nontraumatic Myositis Ossificans as an Uncommon Cause of Scoliosis: Case
   Report and Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Myositis ossificans; Nontraumatic ossificans; Scoliosis
ID TRAUMATICA; MUSCLE
AB BACKGROUND: A 5-year-old pediatric patient developed scoliosis associated with nontraumatic myositis ossificans in the lumbar region. Although there have been reports in literature of syndromes leading to widespread muscle ossifications resulting in shoulder deformities owing to impaired movement in the facet joints, to the best of our knowledge there has been no report of scoliosis associated with myositis ossificans.
   CASE DESCRIPTION: The case presented is of a 5-year-old girl who developed scoliosis associated with nontraumatic myositis ossificans in the lumbar region. On the thoracolumbar radiograph, a hyperintense lesion was seen at the right-side L2-L3 level and scoliosis with a Cobb angle of 16.2 degrees to the right side. The decision for surgery was made with the consideration of the existing scoliosis and that the complaints were associated with paravertebral calcified lesions adjacent to the facet joints. After surgery, the scoliosis improved.
   CONCLUSIONS: Nontraumatic, paravertebral myositis ossificans at an early age is a very rare pathology. Therefore, it must be recognized that spine deformities such as scoliosis and kyphosis can develop in neglected cases of paravertebral myositis ossificans. In addition, there is a high risk of confusion with malignant pathologies, such as osteosarcoma, in this area. Removal of the mass eliminates both the pain of myositis ossificans and prevents the development of scoliosis.
C1 [Onen, Mehmet Resid; Varol, Eyup; Naderi, Sait] Umraniye Teaching & Res Hosp, Dept Neurosurg, Istanbul, Turkey.
   [Tosun, Muzaffer Ilkay] Umraniye Teaching & Res Hosp, Dept Pathol, Istanbul, Turkey.
RP Onen, MR (reprint author), Umraniye Teaching & Res Hosp, Dept Neurosurg, Istanbul, Turkey.
EM mresid@gmail.com
OI onen, mehmet/0000-0003-4353-9068; Naderi, Sait/0000-0002-6784-4270
CR Abdallah A, 2014, AM J CASE REP, V15, P421, DOI 10.12659/AJCR.891151
   Bressner J, 2016, THE GROWING SPINE, P293
   Ferreira C, 2017, INT J SURG CASE REP, V37, P22, DOI 10.1016/j.ijscr.2017.06.004
   Galanis N, 2017, ORTHOP J SPORTS MED, V5, DOI 10.1177/2325967117718780
   Geschickter CF, 1938, J BONE JOINT SURG, V20, P661
   HAIT G, 1970, J TRAUM, V10, P405, DOI 10.1097/00005373-197005000-00005
   HANNA SL, 1990, RADIOGRAPHICS, V10, P945, DOI 10.1148/radiographics.10.5.2217980
   Hanquinet S, 1999, PEDIATR SURG INT, V15, P287, DOI 10.1007/s003830050580
   Jaimo AHN, 2003, J BONE JOINT SURG, V85, P667
   Lau J, 2012, J PEDIATR SURG, V47, P1763, DOI 10.1016/j.jpedsurg.2012.05.009
   Manzano Damian, 2007, Med Oral Patol Oral Cir Bucal, V12, pE277
   MICHELSSON JE, 1980, J BONE JOINT SURG AM, V62, P811, DOI 10.2106/00004623-198062050-00017
   Nakamura Y, 2009, SPINE J, V9, P809, DOI 10.1016/j.spinee.2009.06.017
   Parikh J, 2002, CLIN RADIOL, V57, P1058, DOI 10.1053/crad.2002.1120
   Pohlodek K, 2018, MOL CLIN ONCOL, V8, P749, DOI 10.3892/mco.2018.1609
   Reinke A, 2017, Z ORTHOP UNFALLCHIR, V155, P328, DOI 10.1055/s-0043-103412
   Rosa M, 2009, CAN J SURG, V52, pE31
   Rossettini G, 2018, J ORTHOP SPORT PHYS, V48, P420, DOI 10.2519/jospt.2018.7567
   Sariyilmaz K, 2017, J CRANIOVERTEBRAL JU, V8, P283, DOI 10.4103/jcvjs.JCVJS_133_16
   SHAH PB, 1994, J BONE JOINT SURG AM, V76A, P1442, DOI 10.2106/00004623-199410000-00002
   Sirvanci M, 2004, ACTA RADIOL, V45, P523, DOI 10.1080/02841850410005697
   Soultanis KC, 2007, SCOLIOSIS SPINAL DIS, V2, DOI 10.1186/1748-7161-2-15
   Ucar BY, 2013, SPINE, V2, P2
   Vanden Bossche L, 2005, J REHABIL MED, V37, P129, DOI 10.1080/16501970510027628
NR 24
TC 1
Z9 1
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 208
EP 211
DI 10.1016/j.wneu.2018.11.259
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400134
PM 30576826
DA 2020-05-12
ER

PT J
AU Lavorato, A
   Titolo, P
   Vincitorio, F
   Cofano, F
   Garbossa, D
AF Lavorato, Andrea
   Titolo, Paolo
   Vincitorio, Francesca
   Cofano, Fabio
   Garbossa, Diego
TI Intraneural Ewing Sarcoma of Fibular Nerve: Case Report, Radiologic
   Findings and Review of Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Diagnosis; Ewing sarcoma; Extraosseous Ewing sarcoma; Intraneural Ewing
   sarcoma; Nerve sheath tumor; Primitive neuroectodermal tumor; Treatment
AB BACKGROUND: Intraneural Ewing sarcoma (ES) was first described in 1918 by Stout in a tumor of the ulnar nerve. These tumors are in the category of ES family of tumors, together with ES of bone, extraosseous ES, and primitive neuroectodermal tumor. ES typically occurs in the second decade of life; only 20% of cases affect elder people. The most frequently involved sites are the craniospinal vault and cauda equina, while the peripheral nerve location is extremely rare (only 11 cases mentioned in the literature to date).
   CASE DESCRIPTION: This case report documents a rare case of a 46-year-old woman with an intraneural extraosseous ES and offers a complete radiologic documentation including contrast magnetic resonance imaging and microbubble contrast-enhanced ultrasonographic data. A review of the literature about diagnostic and treatment management is presented.
   CONCLUSIONS: The challenge of intraneural extraosseous ES consists of the right balance between the necessity to consider a potential malignant nature of the lesion and perform adequate surgical excision in a relatively brief time from the first clinical examination and the fact that these are extremely rare pathologic entities among most frequent cases of completely benign tumors, which could even have the same clinical and radiologic presentation. For this reason, a multidisciplinary setting with a team of neurosurgeons, orthopedic specialists, radiologists, pathologists, and oncologists should manage these cases as soon as a pathologic diagnosis is available. More attention should be focused on other therapies that effectively manage microscopic pathologic involvement, without increasing the risk of postoperative morbidity.
C1 [Lavorato, Andrea; Vincitorio, Francesca; Cofano, Fabio; Garbossa, Diego] Univ Turin, Dept Neurosci, Neurosurg Unit, Turin, Italy.
   [Titolo, Paolo] CTO Hosp, Dept Orthopaed & Traumatol, UOC Traumatol Reconstruct Microsurg, Turin, Italy.
RP Lavorato, A (reprint author), Univ Turin, Dept Neurosci, Neurosurg Unit, Turin, Italy.
EM andrea.lavorato@yahoo.it
RI Garbossa, Diego/AAC-8888-2019
CR Bacci G, 2007, CANCER, V109, P780, DOI 10.1002/cncr.22456
   Bang JS, 2018, WORLD NEUROSURG, V115, P89, DOI 10.1016/j.wneu.2018.04.045
   Burchill SA, 2003, J CLIN PATHOL, V56, P96, DOI 10.1136/jcp.56.2.96
   Dhua Anjan K, 2014, J Indian Assoc Pediatr Surg, V19, P230, DOI 10.4103/0971-9261.142016
   Galyfos G, 2016, INDIAN J SURG, V78, P49, DOI 10.1007/s12262-015-1399-0
   Kutty RK, 2017, WORLD NEUROSURG, V107, DOI 10.1016/j.wneu.2017.07.182
   Mitchell BD, 2010, J CLIN NEUROSCI, V17, P1317, DOI 10.1016/j.jocn.2010.02.010
   Mobley BC, 2006, HUM PATHOL, V37, P845, DOI 10.1016/j.humpath.2006.02.011
   Mohan AT, 2011, J PLAST RECONSTR AES, V64, pE153, DOI 10.1016/j.bjps.2011.01.010
   Saeedinia Saeed, 2012, Surg Neurol Int, V3, P55, DOI 10.4103/2152-7806.96154
   Stou AP, 1918, P NY PATHOL SOC, V18, P2
   Zagar TM, 2008, J CLIN ONCOL, V26, P4230, DOI 10.1200/JCO.2008.16.5308
NR 12
TC 2
Z9 2
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 212
EP 215
DI 10.1016/j.wneu.2018.12.043
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400135
PM 30579008
DA 2020-05-12
ER

PT J
AU Kolcun, JPG
   Richardson, AM
   Gernsback, JE
   Rosenberg, A
   Komotar, RJ
AF Kolcun, John Paul G.
   Richardson, Angela M.
   Gernsback, Joanna E.
   Rosenberg, Andrew
   Komotar, Ricardo J.
TI Frontal Sinus Osteoma Presenting with Meningitis and Epilepsy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Frontal sinus; Meningitis; Osteoma
ID INTRACRANIAL MUCOCELE; PARANASAL; PATTERNS; ABSCESS
AB BACKGROUND: Osteomas are benign lesions of bone, most frequently seen in the paranasal sinuses; however, they are typically asymptomatic and without complication. We report a rare case of large frontal sinus osteoma with intracranial extension, associated with meningitis and the development of seizures.
   CASE DESCRIPTION: The patient is a 38-year-old man with a prolonged history of headache and seizures, who was seen by multiple specialists previously, all of whom deferred treatment. After years of worsening seizure activity, he finally underwent surgical resection of the lesion at our institution in a joint operation with neurosurgery and otolaryngology. We examine his course, presentation, and management, and examine the literature for cases of complicated sinus osteomas.
   CONCLUSIONS: This represents the fourth reported case of frontal sinus osteoma associated with meningitis. We believe this case demonstrates the value of a robust differential and a multidisciplinary approach.
C1 [Kolcun, John Paul G.; Richardson, Angela M.; Gernsback, Joanna E.; Komotar, Ricardo J.] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA.
   [Rosenberg, Andrew] Univ Miami, Miller Sch Med, Dept Pathol, Miami, FL 33136 USA.
RP Kolcun, JPG (reprint author), Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA.
EM jpk73@med.miami.edu
CR Akay KM, 2004, NEUROL MED-CHIR, V44, P201, DOI 10.2176/nmc.44.201
   Alexander AAZ, 2007, ANN OTO RHINOL LARYN, V116, P658, DOI 10.1177/000348940711600906
   Arslan HH, 2017, J CRANIOFAC SURG, V28, P741, DOI 10.1097/SCS.0000000000003397
   BARTLETT JR, 1971, BRIT J SURG, V58, P607, DOI 10.1002/bjs.1800580818
   BRUNORI A, 1995, NEUROSURGERY, V36, P1237, DOI 10.1227/00006123-199506000-00042
   Elin D M, 1973, Zh Ushn Nos Gorl Bolezn, V33, P93
   Erdogan N, 2009, LARYNGOSCOPE, V119, P2355, DOI 10.1002/lary.20646
   Halawi AM, 2013, AM J RHINOL ALLERGY, V27, P128, DOI 10.2500/ajra.2013.27.3840
   Huneidi A H, 1989, Br J Neurosurg, V3, P389
   Koyuncu M, 2000, Auris Nasus Larynx, V27, P285, DOI 10.1016/S0385-8146(00)00063-8
   LOGUE J T, 1960, Mo Med, V57, P1011
   Sente M, 1999, Med Pregl, V52, P169
   SHADY JA, 1994, NEUROSURGERY, V34, P920, DOI 10.1227/00006123-199405000-00024
   SIEGLER J, 1964, J Laryngol Otol, V78, P226, DOI 10.1017/S0022215100062009
   Strek P, 2007, MED SCI MONITOR, V13, pCR244
   Summers LE, 2001, SURG NEUROL, V55, P235, DOI 10.1016/S0090-3019(01)00344-5
   Vazquez A, 2016, OTOLARYNG CLIN N AM, V49, P899, DOI 10.1016/j.otc.2016.03.014
NR 17
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 216
EP 220
DI 10.1016/j.wneu.2018.12.031
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400136
PM 30579023
DA 2020-05-12
ER

PT J
AU Matsuo, S
   Amano, T
   Kawauchi, S
   Nakamizo, A
AF Matsuo, Satoshi
   Amano, Toshiyuki
   Kawauchi, Shigeto
   Nakamizo, Akira
TI Multiple Brain Metastases from Pancreatic Adenocarcinoma Manifesting
   with Simultaneous Intratumoral Hemorrhages
SO WORLD NEUROSURGERY
LA English
DT Article
DE Intratumoral hemorrhage; Metastatic brain tumor; Pancreatic
   adenocarcinoma
ID LONG-TERM SURVIVAL
AB BACKGROUND: Pancreatic adenocarcinoma rarely metastasizes to the brain, and clinical features of brain metastasis in such cases remain elusive. To the best of our knowledge, only 21 cases of brain metastasis from pancreatic adenocarcinoma have been previously reported in the English language literature.
   CASE DESCRIPTION: A 61-year-old woman was diagnosed with pancreatic adenocarcinoma and began chemotherapy 1 year 4 months before the current admission. Three days before the current admission, she developed acute dysarthria. She was referred to a cancer center, where neuroradiologic examination showed multiple metastatic brain tumors, including a 30-mm-diameter tumor in the right cerebellar region. She was transferred to our institute. Three days after admission, she developed sudden-onset disturbance of consciousness and left hemiparesis. Computed tomography and magnetic resonance imaging of the head showed that the metastatic lesions had increased in size with development of intratumoral hemorrhage and obstructive hydrocephalus. She underwent urgent removal of the tumor in the cerebellum. Obstructive hydrocephalus was relieved, and her consciousness improved immediately after surgery. She was transferred to the palliative care unit of the cancer center and died under hospice care 3 weeks after surgery.
   CONCLUSIONS: This case demonstrates that brain metastases from pancreatic adenocarcinoma can enlarge suddenly and simultaneously with intratumoral hemorrhage even without coagulation disorders, resulting in neurologic deterioration in a short time. Surgical resection of metastatic brain lesions from pancreatic adenocarcinoma has an extremely limited role, but such treatment can remove neurologic symptoms and temporarily improve the patient's quality of life in selected cases.
C1 [Matsuo, Satoshi; Amano, Toshiyuki; Nakamizo, Akira] Natl Hosp Org Kyushu Med Ctr, Clin Res Inst, Dept Neurosurg, Fukuoka, Fukuoka, Japan.
   [Kawauchi, Shigeto] Natl Hosp Org Kyushu Med Ctr, Clin Res Inst, Dept Pathol, Fukuoka, Fukuoka, Japan.
RP Matsuo, S (reprint author), Natl Hosp Org Kyushu Med Ctr, Clin Res Inst, Dept Neurosurg, Fukuoka, Fukuoka, Japan.
EM smatsuo1979@gmail.com
RI Matsuo, Satoshi/AAE-3849-2020
OI Matsuo, Satoshi/0000-0002-2052-0471
CR Barajas RF, 2016, NEUROIMAG CLIN N AM, V26, P601, DOI 10.1016/j.nic.2016.06.008
   Caricato M, 2006, PANCREATOLOGY, V6, P306, DOI 10.1159/000092693
   Chiang KC, 2012, WORLD J SURG ONCOL, V10, DOI 10.1186/1477-7819-10-138
   El Kamar FG, 2004, DIGEST LIVER DIS, V36, P355, DOI 10.1016/j.dld.2003.10.019
   Go PH, 2011, CANCER-AM CANCER SOC, V117, P3630, DOI 10.1002/cncr.25940
   Hidalgo M, 2010, NEW ENGL J MED, V362, P1605, DOI 10.1056/NEJMra0901557
   Kumar Abhijeet, 2015, J Gastrointest Cancer, V46, P5, DOI 10.1007/s12029-014-9667-y
   KURATSU J-I, 1990, Neurologia Medico-Chirurgica, V30, P476, DOI 10.2176/nmc.30.476
   Lemke J, 2011, ANTICANCER RES, V31, P4599
   Lin XL, 2015, J CLIN ONCOL, V33, P3475, DOI 10.1200/JCO.2015.60.9503
   MarepaIly R, 2009, DIGEST DIS SCI, V54, P188, DOI 10.1007/s10620-008-0531-4
   Matsumoto Hiroaki, 2015, Asian J Neurosurg, V10, P35, DOI 10.4103/1793-5482.151507
   Park KS, 2003, J NEURO-ONCOL, V63, P313, DOI 10.1023/A:1024337020884
   Rajappa P, 2013, ANTICANCER RES, V33, P3899
   Rao Rohit, 2013, Gastrointest Cancer Res, V6, P90
   Sun HH, 2014, SCI REP-UK, V4, DOI 10.1038/srep06747
NR 16
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 221
EP 225
DI 10.1016/j.wneu.2018.12.036
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400137
PM 30579022
DA 2020-05-12
ER

PT J
AU Wang, M
   Luo, XJ
   Ye, YJ
   Zhang, Z
AF Wang, Miao
   Luo, Xiao Ji
   Ye, Yong Jie
   Zhang, Zhi
TI Does Concomitant Degenerative Spondylolisthesis Influence the Outcome of
   Decompression Alone in Degenerative Lumbar Spinal Stenosis? A
   Meta-Analysis of Comparative Studies
SO WORLD NEUROSURGERY
LA English
DT Review
DE Comparative study; Decompression; Degenerative spondylolisthesis; Lumbar
   spinal stenosis; Meta-analysis
ID MINIMALLY INVASIVE DECOMPRESSION; STUDY COMPARING DECOMPRESSION;
   BILATERAL DECOMPRESSION; SURGICAL-MANAGEMENT; UNILATERAL APPROACH;
   COST-EFFECTIVENESS; CLINICAL-OUTCOMES; FUSION; LAMINECTOMY;
   INSTRUMENTATION
AB OBJECTIVE: To investigate whether the preoperative presence of degenerative spondylolisthesis (DS) worsens the outcome of patients undergoing decompression alone for degenerative lumbar stenosis.
   METHODS: We conducted a comprehensive search in the PubMed, Embase, and Cochrane Library databases. All comparative studies were included in this meta-analysis. The literature search, data extraction, and quality assessment were conducted by 2 independent reviewers. The functional outcomes were clinical scores and reoperation rate. The radiologic outcomes were slippage rate and postoperative instability rate.
   RESULTS: A total of 11 studies with 1081 cases, including 469 cases of degenerative lumbar stenosis with DS (DS group) and 612 degenerative lumbar stenosis without spondylolisthesis (noDS group), were enrolled in our meta-analysis. There were no significant differences between the 2 groups for functional outcomes in terms of Japanese Orthopedic Association score, Japanese Orthopedic Association recovery rate, Oswestry Disability Index score, visual analog scale back/leg, and reoperation rate after decompression alone. For the radiologic outcomes, slippage rate was found not changed significantly before and after minimally invasive decompression alone in the DS group and the postoperative instability rate did not differ significantly between the 2 groups after decompression alone by a minimally invasive method.
   CONCLUSIONS: Our meta-analysis revealed that concomitant DS (Meyerding grade I-II) does not influence the outcome of decompression alone in degenerative lumbar spinal stenosis, especially when a minimally invasive procedure was performed and patients did not have predominant symptoms of mechanical back pain. The presence of DS should not be an indication for fusion surgery in degenerative lumbar spinal stenosis.
C1 [Wang, Miao; Ye, Yong Jie; Zhang, Zhi] Suining Cent Hosp, Dept Orthoped, Suining, Peoples R China.
   [Luo, Xiao Ji] Chongqing Med Univ, Affiliated Hosp 1, Dept Orthoped, Chongqing, Peoples R China.
RP Zhang, Z (reprint author), Suining Cent Hosp, Dept Orthoped, Suining, Peoples R China.
EM mrzhang1974@126.com
CR Ahmad S, 2017, EUR SPINE J, V26, P414, DOI 10.1007/s00586-016-4637-7
   Alimi M, 2015, J NEUROSURG-SPINE, V22, P339, DOI 10.3171/2014.11.SPINE13597
   Amundsen T, 2000, SPINE, V25, P1424, DOI 10.1097/00007632-200006010-00016
   Bae HW, 2013, SPINE, V38, P916, DOI 10.1097/BRS.0b013e3182833e7c
   BOXALL D, 1979, J BONE JOINT SURG AM, V61, P479, DOI 10.2106/00004623-197961040-00001
   BRIDWELL KH, 1993, J SPINAL DISORD, V6, P461, DOI 10.1097/00002517-199306060-00001
   Chang HS, 2014, SPINE, V39, P400, DOI 10.1097/BRS.0000000000000161
   Deyo RA, 2010, JAMA-J AM MED ASSOC, V303, P1259, DOI 10.1001/jama.2010.338
   Dijkerman ML, 2018, EUR SPINE J, V27, P1629, DOI 10.1007/s00586-017-5436-5
   Dohzono S, 2013, J NEUROSURG-SPINE, V18, P472, DOI 10.3171/2013.2.SPINE12633
   Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377
   Fischgrund JS, 1997, SPINE, V22, P2807, DOI 10.1097/00007632-199712150-00003
   Forsth P, 2016, NEW ENGL J MED, V374, P1413, DOI 10.1056/NEJMoa1513721
   Fox MW, 1996, J NEUROSURG, V85, P793, DOI 10.3171/jns.1996.85.5.0793
   Frazier DD, 1997, SPINE, V22, P2025, DOI 10.1097/00007632-199709010-00017
   Ghogawala Z, 2004, J NEUROSURG-SPINE, V1, P267, DOI 10.3171/spi.2004.1.3.0267
   Ghogawala Z, 2016, NEW ENGL J MED, V374, P1424, DOI 10.1056/NEJMoa1508788
   Harrop JS, 2014, SPINE, V39, pS75, DOI 10.1097/BRS.0000000000000545
   HERKOWITZ HN, 1991, J BONE JOINT SURG AM, V73A, P802, DOI 10.2106/00004623-199173060-00002
   Ishimoto Y, 2013, OSTEOARTHR CARTILAGE, V21, P783, DOI 10.1016/j.joca.2013.02.656
   JOHNSSON KE, 1986, SPINE, V11, P107, DOI 10.1097/00007632-198603000-00001
   Kato M, 2017, GLOB SPINE J, V7, P498, DOI 10.1177/2192568217699192
   Kelleher MO, 2010, SPINE, V35, pE981, DOI 10.1097/BRS.0b013e3181c46fb4
   Kepler CK, 2014, SPINE, V39, P1584, DOI 10.1097/BRS.0000000000000486
   Kornblum MB, 2004, SPINE, V29, P726, DOI 10.1097/01.BRS.0000119398.22620.92
   Kuntz KM, 2000, SPINE, V25, P1132, DOI 10.1097/00007632-200005010-00015
   LEE CK, 1983, SPINE, V8, P429, DOI 10.1097/00007632-198305000-00014
   LOMBARDI JS, 1985, SPINE, V10, P821, DOI 10.1097/00007632-198511000-00008
   Machado GC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122800
   Martin CR, 2007, SPINE, V32, P1791, DOI 10.1097/BRS.0b013e3180bc219e
   MATSUNAGA S, 1990, SPINE, V15, P1204, DOI 10.1097/00007632-199011010-00021
   Matz PG, 2016, SPINE J, V16, P439, DOI 10.1016/j.spinee.2015.11.055
   Minamide A, 2015, EUR SPINE J, V24, P396, DOI 10.1007/s00586-014-3599-x
   Nomura H, 2014, J NEUROSURG-SPINE, V21, P187, DOI 10.3171/2014.4.SPINE1373
   Pearson A, 2010, SPINE, V35, P298, DOI 10.1097/BRS.0b013e3181bdafd1
   Resnick DK, 2014, J NEUROSURG-SPINE, V21, P54, DOI 10.3171/2014.4.SPINE14274
   Sasai K, 2008, J NEUROSURG-SPINE, V9, P554, DOI 10.3171/SPI.2008.8.08122
   Shen JL, 2018, PAIN PHYSICIAN, V21, P1
   Simmonds AM, 2015, J NEUROSURG-SPINE, V23, P178, DOI 10.3171/2014.11.SPINE1426
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Sterne JAC, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4002
   Thomsen K, 1997, SPINE, V22, P2813, DOI 10.1097/00007632-199712150-00004
   Toyoda H, 2011, SPINE, V36, P410, DOI 10.1097/BRS.0b013e3181d25829
   TUITE GF, 1994, J NEUROSURG, V81, P699, DOI 10.3171/jns.1994.81.5.0699
   TUITE GF, 1994, J NEUROSURG, V81, P707, DOI 10.3171/jns.1994.81.5.0707
   Ulrich NH, 2018, WORLD NEUROSURG, V114, pE1275, DOI 10.1016/j.wneu.2018.03.196
   Vaccaro AR, 1997, SPINE, V22, P368, DOI 10.1097/00007632-199702150-00002
   Waldfahrer Frank, 2016, GMS Curr Top Otorhinolaryngol Head Neck Surg, V15, pDoc01, DOI 10.3205/cto000128
NR 48
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 226
EP 238
DI 10.1016/j.wneu.2018.11.246
PG 13
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400138
PM 30576810
DA 2020-05-12
ER

PT J
AU Murase, M
   Toda, M
   Ohara, K
   Ishihara, E
   Yoshida, K
AF Murase, Makoto
   Toda, Masahiro
   Ohara, Kentarou
   Ishihara, Eriko
   Yoshida, Kazunari
TI Endoscopic Endonasal Removal of Large Calcified Pituitary Adenoma: Case
   Report and Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Endonasal approach; Endoscopy; Pituitary stone
ID CHROMOPHOBE ADENOMA; STONE; HYPERPROLACTINEMIA; CALCIFICATIONS
AB BACKGROUND: Large calcified intrasellar masses, called pituitary stones, have been reported as calcified pituitary adenomas in the literature. Although relatively rare, calcified pituitary adenomas appear in various formations. Thus, whether the lesion is removable-and, if so, which approach is appropriate-mainly depends on its formation and quality.
   CASE DESCRIPTION: A 46-year-old woman presented with visual loss and amenorrhea. Although computed tomography showed a uniformly calcified sellar tumor, magnetic resonance imaging displayed heterogenous intensity on T2-weighted images and mild gadolinium enhancement, suggesting that the lesion was a mixture of pituitary adenoma and fine calcification. Thus, we undertook tumor resection via an endoscopic endonasal approach, which resulted in total removal. The pathological diagnosis was a pituitary adenoma with rich calcification.
   CONCLUSIONS: We report a rare case of a large pituitary stone that was successfully removed via an endoscopic endonasal approach. This could therefore be a feasible, effective technique for the removal of pituitary stones, although careful analysis of preoperative magnetic resonance imaging is required.
C1 [Murase, Makoto; Toda, Masahiro; Ishihara, Eriko; Yoshida, Kazunari] Keio Univ, Sch Med, Dept Neurosurg, Shinjuku Ku, Tokyo, Japan.
   [Ohara, Kentarou] Keio Univ, Sch Med, Dept Pathol, Shinjuku Ku, Tokyo, Japan.
RP Murase, M (reprint author), Keio Univ, Sch Med, Dept Neurosurg, Shinjuku Ku, Tokyo, Japan.
EM m.murase.ns@gmail.com
OI Toda, Masahiro/0000-0003-2700-1620; Murase, Makoto/0000-0002-3846-5714
CR CARAPELLA CM, 1983, J NEUROSURG, V59, P871, DOI 10.3171/jns.1983.59.5.0871
   CHAMBERS AA, 1976, J NEUROSURG, V44, P623, DOI 10.3171/jns.1976.44.5.0623
   Chentli F, 2015, INT J ENDOCRINOL MET, V13, DOI 10.5812/ijem.28383v2
   DICHIRO G, 1975, ANN INTERN MED, V83, P66, DOI 10.7326/0003-4819-83-1-66
   Garg M K, 2013, Indian J Endocrinol Metab, V17, pS703, DOI 10.4103/2230-8210.123573
   Gheorghiu ML, 2008, ACTA ENDOCRINOL-BUCH, V4, P203, DOI 10.4183/aeb.2008.203
   GUAY AT, 1978, FERTIL STERIL, V29, P585
   HIROTA S, 1995, J NEUROPATH EXP NEUR, V54, P698, DOI 10.1097/00005072-199509000-00012
   Horiuchi Tetsuyoshi, 1996, Neurologia Medico-Chirurgica, V36, P729, DOI 10.2176/nmc.36.729
   Ibrahim R, 2014, ENDOCRINOL DIAB META, DOI 10.1530/EDM-13-0079
   Kasliwal MK, 2008, TURK NEUROSURG, V18, P232
   KATO T, 1983, Neurologia Medico-Chirurgica, V23, P633, DOI 10.2176/nmc.23.633
   KEENE M, 1979, J LARYNGOL OTOL, V93, P613, DOI 10.1017/S0022215100087478
   Kertmen H, 2010, J CLIN NEUROSCI, V17, P956
   Korchi AM, 2012, CAN J NEUROL SCI, V39, P89, DOI 10.1017/S0317167100012762
   LEISHMAN AG, 1948, P ROY SOC MED, V41, P655, DOI 10.1177/003591574804101003
   RASMUSSEN C, 1990, NEURORADIOLOGY, V31, P507, DOI 10.1007/BF00340132
   RILLIET B, 1981, SURG NEUROL, V15, P249, DOI 10.1016/S0090-3019(81)80003-1
   Tamaki T, 2000, NEUROL MED-CHIR, V40, P383, DOI 10.2176/nmc.40.383
   Tanriover N, 2014, TURK NEUROSURG, V24, P967, DOI 10.5137/1019-5149.JTN.9688-13.0
   TAYLOR HC, 1979, JAMA-J AM MED ASSOC, V242, P751
   VONWESTARP C, 1980, AM J MED, V68, P949, DOI 10.1016/0002-9343(80)90229-6
   WEBSTER J, 1994, CLIN ENDOCRINOL, V40, P137, DOI 10.1111/j.1365-2265.1994.tb02456.x
   ZAHRA M, 1977, ACTA NEUROCHIR, V38, P279, DOI 10.1007/BF01401098
NR 24
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 239
EP 243
DI 10.1016/j.wneu.2018.11.255
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400139
PM 30576820
DA 2020-05-12
ER

PT J
AU Hanabusa, K
   Miyake, H
   Ukita, T
   Yamada, Y
   Masubuchi, T
   Ohmura, T
AF Hanabusa, Kenichiro
   Miyake, Hiroji
   Ukita, Toru
   Yamada, Yoshitaka
   Masubuchi, Takahiro
   Ohmura, Takehisa
TI Cervical Myelopathy Due to Direct Cord Compression by Posterior Inferior
   Cerebellar Artery Associated with Aberrant Vertebral Artery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aberrant vertebral artery; Cervical myelopathy; Cord compression;
   Microvascular decompression; Posterior inferior cerebellar artery
ID MICROVASCULAR DECOMPRESSION
AB BACKGROUND: The effectiveness of surgical microvascular decompression (MVD) of the vertebral artery (VA) for treating conditions such as trigeminal neuralgia or hemifacial spasm is well known. However, the use of MVD for a case in which the posterior inferior cerebellar artery (PICA) is directly compressing the high cervical cord has not been reported.
   CASE DESCRIPTION: A 48-year-old male was diagnosed with a rare case of myelopathy due to the PICA directly compressing the high cervical cord. The patient had a C-2 segmental type of VA that penetrated the intradural space at the C1 level. The VA-PICA portion was located just after where the intradural space was penetrated, and the branching PICA strongly and vertically compressed the high cervical cord.
   CONCLUSIONS: MVD of the PICA was performed, and the patient experienced rapid improvement of myelopathy. The patient immediately improved postoperative day 1 and was doing well at his 1-year follow-up. This is a rare case of the PICA directly compressing the cervical cord and causing myelopathy. MVD of the PICA resulted in good patient recovery.
C1 [Hanabusa, Kenichiro; Miyake, Hiroji; Ukita, Toru; Yamada, Yoshitaka; Masubuchi, Takahiro; Ohmura, Takehisa] Nishinomiya Kyoritsu Neurosurg Hosp, Dept Neurosurg, Koyukai Med Cooperat, Nishinomiya, Hyogo, Japan.
RP Hanabusa, K (reprint author), Nishinomiya Kyoritsu Neurosurg Hosp, Dept Neurosurg, Koyukai Med Cooperat, Nishinomiya, Hyogo, Japan.
EM hanabusa-nsu@umin.ac.jp
CR Ball Bret Gene, 2011, Surg Neurol Int, V2, P103, DOI 10.4103/2152-7806.83232
   Choudhri O, 2017, NEUROSURGERY, V81, P367, DOI 10.1093/neuros/nyx110
   Curylo LJ, 2000, SPINE, V25, P2860, DOI 10.1097/00007632-200011150-00004
   El-Ghandour NMF, 2010, NEUROSURGERY, V67, P330, DOI 10.1227/01.NEU.0000371978.86528.60
   Furumoto T, 1996, SPINE, V21, P2280, DOI 10.1097/00007632-199610010-00022
   Hage ZA, 2012, J NEUROSURG-SPINE, V17, P337, DOI 10.3171/2012.7.SPINE123
   Hayashi S, 2018, WORLD NEUROSURG, V110, P86, DOI 10.1016/j.wneu.2017.10.143
   HONGO K, 1993, J NEUROSURG, V79, P116, DOI 10.3171/jns.1993.79.1.0116
   Lee SH, 2016, J KOREAN NEUROSURG S, V59, P505, DOI 10.3340/jkns.2016.59.5.505
   SATOH S, 1993, J NEUROSURG, V79, P283, DOI 10.3171/jns.1993.79.2.0283
   Sellin JN, 2014, J NEUROSURG, V121, P919, DOI 10.3171/2014.5.JNS131825
   Takahashi Y, 2001, NEUROL MED-CHIR, V41, P322, DOI 10.2176/nmc.41.322
   Takei H, 2008, SPINE, V33, pE611, DOI 10.1097/BRS.0b013e31817c6c17
   Tandon A, 2013, NEUROSURG FOCUS, V35, DOI 10.3171/2013.6.FOCUS1339
   TOKUDA K, 1985, NEURORADIOLOGY, V27, P410, DOI 10.1007/BF00327604
NR 15
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 248
EP 250
DI 10.1016/j.wneu.2018.12.044
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400142
PM 30579018
DA 2020-05-12
ER

PT J
AU Zhang, N
   Guo, LH
   Kuang, HM
   Ji, YQ
   Zeng, XJ
AF Zhang, Ning
   Guo, Linghong
   Kuang, Hongmei
   Ji, Yuqiang
   Zeng, Xianjun
TI Primary Intracranial Fibrosarcoma: Case Report and Systematic Review of
   Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Diagnosis; Fibrosarcoma; Intracranial; Magnetic resonance imaging
ID SARCOMAS
AB Primary intracranial fibrosarcoma (PIF) is an exceedingly rare tumor. Only about 50 cases have been reported in the literature. Here, we present a case of a 20-year-old male who presented with a sudden-onset headache. Magnetic resonance imaging of the brain showed a hemorrhagic extra-axial space-occupying mass. The mass was surgically resected, and biopsy was consistent with PIF. The patient was lost to follow-up and presented with recurrence 3 months later. He expired from complications of the tumor. PIF is a diagnosis of exclusion: More common intracranial tumors should first be excluded. Biopsy is necessary to diagnose PIF.
C1 [Zhang, Ning; Guo, Linghong; Kuang, Hongmei; Ji, Yuqiang; Zeng, Xianjun] Nanchang Univ, Affiliated Hosp 1, Dept Radiol, Nanchang, Jiangxi, Peoples R China.
RP Zhang, N (reprint author), Nanchang Univ, Affiliated Hosp 1, Dept Radiol, Nanchang, Jiangxi, Peoples R China.
EM ningzhang@wustl.edu
CR Bisogno G, 2002, CHILD NERV SYST, V18, P648, DOI 10.1007/s00381-002-0628-6
   Cai N, 2004, J NEURO-ONCOL, V68, P161, DOI 10.1023/B:NEON.0000027740.70380.5c
   CHANG SM, 1995, NEUROSURGERY, V36, P685, DOI 10.1227/00006123-199504000-00007
   Chen Q, 2012, AM J NEURORADIOL, V33, P195, DOI 10.3174/ajnr.A2721
   Chopra R, 2010, RARE TUMORS, V2, P8, DOI 10.4081/rt.2010.e3
   Donnet A, 1999, J NEURO-ONCOL, V42, P79, DOI 10.1023/A:1006100119406
   FOLKMAN J, 1992, J BIOL CHEM, V267, P10931
   GASPAR LE, 1993, CANCER, V72, P3277, DOI 10.1002/1097-0142(19931201)72:11<3277::AID-CNCR2820721124>3.0.CO;2-C
   Giridhar P, 2016, J EGYPT NATL CANCER, V28, P111, DOI 10.1016/j.jnci.2015.07.002
   Kaminski JM, 2000, PEDIATR NEUROSURG, V33, P257, DOI 10.1159/000055965
   Lee Jong Gon, 2013, Brain Tumor Res Treat, V1, P91, DOI 10.14791/btrt.2013.1.2.91
   Mama N, 2014, J NEURORADIOLOGY, V41, P296, DOI 10.1016/j.neurad.2013.10.007
   McDonald P, 1997, J NEURO-ONCOL, V35, P133, DOI 10.1023/A:1005723013144
   MENA H, 1978, CANCER, V42, P1298, DOI 10.1002/1097-0142(197809)42:3<1298::AID-CNCR2820420340>3.0.CO;2-K
   Nichols P, 1971, J NEUROPATHOL EXP NE, V11, P215
   PAULUS W, 1991, HISTOPATHOLOGY, V18, P395, DOI 10.1111/j.1365-2559.1991.tb00869.x
   Rabinstein AA, 2002, NEUROLOGY, V58, P146, DOI 10.1212/WNL.58.1.146
   Russel DS, 1989, PATHOLOGY TUMORS NER
   Vinodh VP, 2017, J NEUROSCI RURAL PRA, V8, P111, DOI 10.4103/jnrp.jnrp_165_17
NR 19
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 251
EP 255
DI 10.1016/j.wneu.2018.12.005
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400143
PM 30579028
DA 2020-05-12
ER

PT J
AU Panagopoulos, D
   Themistocleous, M
   Sfakianos, G
AF Panagopoulos, Dimitrios
   Themistocleous, Marios
   Sfakianos, Georgios
TI Repair of a Transclival Meningocele Through a Transoral Approach: Case
   Report and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Airway obstruction; Transclival meningocele; Transoral repair
ID RARE BASIOCCIPITAL MENINGOCELE; CANALIS BASILARIS MEDIANUS; CSF
   RHINORRHEA; RECURRENT MENINGITIS; EMBRYOLOGY; MALFORMATIONS; ANATOMY
AB BACKGROUND: Transclival meningoceles and related primary spontaneous cerebrospinal fluid leaks at the clivus are extremely rare lesions, with only a few cases reported in the literature.
   CASE DESCRIPTION: An infant presented with nasal airway obstruction and meningitis secondary to cerebrospinal fluid leak from a transclival meningocele. The radiologic investigation and surgical repair of the lesion are reported, along with intraoperative findings. Basic anatomy, embryology, and development of the clivus are reviewed to clarify the relationship of anatomic variants with the formation of transclival meningoceles.
   CONCLUSIONS: Transclival meningocele should be considered in patients with spontaneous cerebrospinal fluid rhinorrhea. The existing classification of meningoencephaloceles based on the location of the defect in the cranium should probably be reconsidered, taking into consideration the described entity.
C1 [Panagopoulos, Dimitrios; Themistocleous, Marios; Sfakianos, Georgios] Agia Sophia Childrens Hosp, Neurosurg Dept, Athens, Greece.
RP Panagopoulos, D (reprint author), Agia Sophia Childrens Hosp, Neurosurg Dept, Athens, Greece.
EM dimpanayop@gmail.com
CR AARABI B, 1992, Ear Nose and Throat Journal, V71, P300
   Akyuz M, 2008, J NEUROIMAGING, V18, P191, DOI 10.1111/j.1552-6569.2007.00187.x
   AZIZKHAN RG, 1989, NEUROSURGERY, V25, P469, DOI 10.1227/00006123-198909000-00027
   CALCATERRA TC, 1980, ANN OTO RHINOL LARYN, V89, P108, DOI 10.1177/000348948008900202
   CURRARINO G, 1988, AM J NEURORADIOL, V9, P208
   Di Ieva A, 2014, CHILD NERV SYST, V30, P991, DOI 10.1007/s00381-014-2411-x
   Ingraham FD, 1943, NEW ENGL J MED, V228, P559, DOI 10.1056/NEJM194305062281801
   Jacquemin C, 2000, NEURORADIOLOGY, V42, P121, DOI 10.1007/s002340050029
   Johans SJ, 2018, J NEUROSURG-PEDIATR, V21, P498, DOI 10.3171/2017.11.PEDS17302
   Kirtane MV, 2014, PAK J OTOLARYNGOL, V30, P61
   Ko AL, 2010, J NEUROSURG-PEDIATR, V6, P188, DOI 10.3171/2010.5.PEDS09346
   KOOPMANN CF, 1981, OTOLARYNG HEAD NECK, V89, P545, DOI 10.1177/019459988108900407
   Lai SY, 2002, LARYNGOSCOPE, V112, P1800, DOI 10.1097/00005537-200210000-00018
   LOCKWOOD AH, 1980, J NEUROSURG, V53, P553, DOI 10.3171/jns.1980.53.4.0553
   NAGER GT, 1987, LARYNGOSCOPE, V97, P77
   Nayak S R, 2007, Rom J Morphol Embryol, V48, P427
   Pang D, 2011, CHILD NERV SYST, V27, P523, DOI 10.1007/s00381-010-1358-9
   Rai R, 2018, CHILD NERV SYST, V34, P1451, DOI 10.1007/s00381-018-3875-x
   Schick B, 2000, EUR ARCH OTO-RHINO-L, V257, P430, DOI 10.1007/s004050000235
   Schick B, 2003, EUR ARCH OTO-RHINO-L, V260, P518, DOI 10.1007/s00405-003-0620-0
   Sharma R, 2017, CHILD NERV SYST, V33, P369, DOI 10.1007/s00381-016-3256-2
   Tubbs RS, 2010, CHILD NERV SYST, V26, P1207, DOI 10.1007/s00381-010-1100-7
   Turanzas FS, 1996, ACTA NEUROCHIR, V138, P595, DOI 10.1007/BF01411183
   Van Zele T, 2013, ALLERGY RHINOL, V4, pE100, DOI 10.2500/ar.2013.4.0053
   Zdilla MJ, 2017, CHILD NERV SYST, V33, P1209, DOI 10.1007/s00381-017-3466-2
NR 25
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 259
EP 264
DI 10.1016/j.wneu.2018.12.025
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400145
PM 30579031
DA 2020-05-12
ER

PT J
AU Fahed, E
   Grelat, M
   Younes, P
   Madkouri, R
   Kreichati, G
   Kharrat, K
   Rizk, T
AF Fahed, Elie
   Grelat, Michael
   Younes, Philippe
   Madkouri, Rachid
   Kreichati, Gaby
   Kharrat, Khalil
   Rizk, Toni
TI Cervical Hyperextension Deformity After Sagittal Balance Correction in
   Patient with Congenital Limb-Girdle Myopathy: Surgical Technique and
   Review of Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Limb-girdle muscular dystrophy; Neuromonitoring; Posterior cervical
   release and fusion; Rigid neck hyperextension deformity
ID RIGID SPINE SYNDROME; MUSCULAR-DYSTROPHY; NECK HYPEREXTENSION; OSTEOTOMY
AB BACKGROUND: There is no gold standard surgical treatment for cervical hyperextension deformity, especially in case of muscular dystrophy. Special considerations and caution should be taken as they carry a high risk of early mortality and spinal cord injury. Only a few case reports are available in the literature.
   CASE DESCRIPTION: We report a case of surgical correction of an iatrogenic cervical hyperextension deformity following sagittal balance correction in a patient with congenital limb-girdle myopathy. The patient was successfully treated by posterior cervical release and fusion after verification of the range of motion, reducibility of the deformity, and absence of any positional spinal cord compression with dynamic radiographic examination and preoperative magnetic resonance imaging in the desired postoperative position.
   CONCLUSIONS: We suggest posterior cervical release and fusion in case of a radiologically and clinically reducible cervical hyperextension deformity under both motor and sensory spinal evoked potential monitoring. In cases of long-standing, rigid, nonreducible cervical hyperextension, laminectomy and concomitant duroplasty could be considered.
C1 [Fahed, Elie; Younes, Philippe; Rizk, Toni] Hotel Dieu France Hosp, Dept Neurosurg, Beirut, Lebanon.
   [Kreichati, Gaby; Kharrat, Khalil] Hotel Dieu France Hosp, Dept Orthoped, Beirut, Lebanon.
   [Grelat, Michael; Madkouri, Rachid] Univ Hosp, Dept Neurosurg, Dijon, France.
RP Rizk, T (reprint author), Hotel Dieu France Hosp, Dept Neurosurg, Beirut, Lebanon.
EM tony.rizk@hdf.usj.edu.lb
CR AKIYAMA Y, 1992, RESPIRATION, V59, P48
   Arkader A, 2005, SPINE, V30, pE623, DOI 10.1097/01.brs.0000182313.40748.d3
   BERTINI E, 1986, J NEUROL, V233, P248, DOI 10.1007/BF00314029
   BOACHIEADJEI O, 1991, J SPINAL DISORD, V4, P193, DOI 10.1097/00002517-199106000-00010
   Fadic R, 1997, MUSCLE NERVE, V20, P364, DOI 10.1002/(SICI)1097-4598(199703)20:3<364::AID-MUS16>3.0.CO;2-0
   Flanigan KM, 2000, ANN NEUROL, V47, P152, DOI 10.1002/1531-8249(200002)47:2<152::AID-ANA4>3.3.CO;2-L
   Giannini S, 2005, CLIN ORTHOP RELAT R, P151, DOI 10.1097/01.blo.0000150667.44293.e9
   GIANNINI S, 1988, NEUROPEDIATRICS, V19, P105, DOI 10.1055/s-2008-1052411
   Giannini S, 2006, SPINE, V31, P1805, DOI 10.1097/01.brs.0000225971.26117.bf
   Granata C, 1996, NEUROMUSCULAR DISORD, V6, P61, DOI 10.1016/0960-8966(95)00019-4
   Kose KC, 2014, SPINE, V39, pE1066, DOI 10.1097/BRS.0000000000000433
   MERLINI L, 1989, J CHILD NEUROL, V4, P274, DOI 10.1177/088307388900400405
   Pegoraro E, 2000, GENEREVIEWS
   Poulter GT, 2009, SPINE, V34, P378, DOI 10.1097/BRS.0b013e3181947ce4
   Sengupta DK, 2001, SPINE, V26, P1068, DOI 10.1097/00007632-200105010-00016
   SIMMONS EH, 1977, CLIN ORTHOP RELAT R, P65
   URIST MR, 1958, J BONE JOINT SURG AM, V40, P833, DOI 10.2106/00004623-195840040-00007
   VANMUNSTER ETL, 1986, J NEUROL NEUROSUR PS, V49, P1292, DOI 10.1136/jnnp.49.11.1292
   Yang MC, 2002, J FORMOS MED ASSOC, V101, P650
NR 19
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 265
EP 271
DI 10.1016/j.wneu.2018.10.211
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400146
PM 30415053
DA 2020-05-12
ER

PT J
AU Khatri, D
   Gosal, JS
   Bhaisora, KS
   Das, KK
   Srivastava, AK
   Behari, S
AF Khatri, Deepak
   Gosal, Jaskaran Singh
   Bhaisora, Kamlesh Singh
   Das, Kuntal Kanti
   Srivastava, Arun Kumar
   Behari, Sanjay
TI Orbital Hemangioma in Bean Syndrome: The Lure of the Red Herring
SO WORLD NEUROSURGERY
LA English
DT Article
DE Bean syndrome; Low-flow angiomatosis; Mucocutaneous lesions; Orbital
   hemangioma; Red herring; Refractory anemia; Sinus pericranii
ID BLEB NEVUS SYNDROME; DEVELOPMENTAL VENOUS ANOMALIES; SINUS PERICRANII;
   VASCULAR-LESIONS; MALFORMATIONS; INVOLVEMENT; HEMORRHAGE; PATIENT;
   ONSET; GALEN
AB BACKGROUND: Bean syndrome (BS) is a rare congenital low-flow angiomatosis affecting multiple organ systems. About 200 cases with heterogeneous clinical presentation have been reported worldwide. The exact etiopathology is still not known. Most reported cases have occurred sporadically, although autosomal dominant inheritance has been suggested. BS predominantly presents with characteristic multifocal mucocutaneous lesions and often leads to refractory anemia caused by occult blood loss from the alimentary tract. Apart from the mucocutaneous and gastrointestinal tract involvement, this syndrome may rarely affect the central nervous system in the form of multiple venous anomalies. Patients often approach a dermatologist or gastroenterologist for treatment and this entity is usually less known among neurosurgeons. To the best of our knowledge, only 3 cases of sinus pericranii and 12 cases with orbital hemangioma as a presenting feature in BS have been reported.
   CASE DESCRIPTION: Keeping neurosurgical management of this rare entity in mind, we discuss a case of a young female who presented with congenital naso-orbital swelling with a history of multiple-stage embolization and surgical excision of the orbital mass in her childhood. Now, she presented with recurrent swelling involving the right side of the forehead for cosmetic concerns and was subsequently diagnosed to have BS at 23 years of age.
   CONCLUSIONS: Blue rubber bleb nevus syndrome is a lesser known entity among neurosurgeons that requires a high index of clinical suspicion for diagnosis. Red herrings, such as in our case, must prompt a search for characteristic mucocutaneous lesions and other associated lesions of blue rubber bleb nevus syndrome. A timely diagnosis may improve the quality of life and help avoid life-threatening complications.
C1 [Khatri, Deepak; Gosal, Jaskaran Singh; Bhaisora, Kamlesh Singh; Das, Kuntal Kanti; Srivastava, Arun Kumar; Behari, Sanjay] Sanjay Gandhi Postgrad Inst Med Sci, Dept Neurosurg, Lucknow, Uttar Pradesh, India.
RP Bhaisora, KS (reprint author), Sanjay Gandhi Postgrad Inst Med Sci, Dept Neurosurg, Lucknow, Uttar Pradesh, India.
EM drkamleshbhaisora@gmail.com
RI Khatri, Deepak/C-3554-2019
OI Khatri, Deepak/0000-0003-1902-9623
CR Bahl A, 2013, TURK NEUROSURG, V23, P818, DOI 10.5137/1019-5149.JTN.6256-12.1
   BEAN WB, 1958, VASCULAR SPIDERS REL, P178
   Carvalho S, 2003, AM J NEURORADIOL, V24, P1916
   Chung JI, 2003, INTERV NEURORADIOL, V9, P169, DOI 10.1177/159101990300900206
   DCosta H, 1996, BRIT J RADIOL, V69, P502, DOI 10.1259/0007-1285-69-822-502
   Demir FT, 2017, CLIN EXP DERMATOL, V42, P210, DOI 10.1111/ced.13012
   den Heijer T, 2007, NEUROLOGY, V68, P1075, DOI 10.1212/01.wnl.0000258547.31946.a3
   DIECKMANN K, 1994, EUR J PEDIATR SURG, V4, P372, DOI 10.1055/s-2008-1066139
   Domini M, 2002, EUR J PEDIATR SURG, V12, P129, DOI 10.1055/s-2002-30172
   Eiris-Punal J, 2002, J CHILD NEUROL, V17, P219, DOI 10.1177/088307380201700313
   Ellis JA, 2016, J NEUROSURG-PEDIATR, V17, P129, DOI 10.3171/2015.6.PEDS15183
   Gabikian P, 2003, J NEUROSURG, V99, P409, DOI 10.3171/jns.2003.99.2.0409
   GALLIONE CJ, 1995, J MED GENET, V32, P197, DOI 10.1136/jmg.32.3.197
   GALLMANN T, 1987, KLIN PADIATR, V199, P382, DOI 10.1055/s-2008-1026825
   GASCOYEN GG, 1860, T PATHOL SOC LOND, V11
   Gildener-Leapman Juliana R, 2017, Ophthalmic Plast Reconstr Surg, V33, pS143, DOI 10.1097/IOP.0000000000000692
   HOFFMAN T, 1978, JOHNS HOPKINS MED J, V142, P91
   Huang W, 2012, PEDIATR DERMATOL, V29, P524, DOI 10.1111/j.1525-1470.2011.01555.x
   Kim SJ, 2000, PEDIATR NEUROL, V22, P410, DOI 10.1016/S0887-8994(00)00137-5
   KISU T, 1986, Gastroenterologia Japonica, V21, P262
   Kondziella D, 2010, J NEUROL NEUROSUR PS, V81, P1207, DOI 10.1136/jnnp.2009.194449
   Lin CH, 2018, DERMATOL SIN, V36, P153, DOI 10.1016/j.dsi.2018.01.002
   MUNKVAD M, 1983, DERMATOLOGICA, V167, P307, DOI 10.1159/000249805
   Ocampo-Garza J, 2016, PEDIATR DERMATOL, V33, pE29, DOI 10.1111/pde.12718
   Palleschi GM, 2005, J DERMATOL, V32, P589, DOI 10.1111/j.1346-8138.2005.tb00804.x
   Park CO, 2006, J DERMATOL, V33, P649, DOI 10.1111/j.1346-8138.2006.00153.x
   Pereira AR, 2015, INT J DERMATOL, V54, P1420, DOI 10.1111/ijd.12393
   Petek Bradley, 2014, GMS Ophthalmol Cases, V4, pDoc04, DOI 10.3205/oc000017
   RENNIE IG, 1982, BRIT J OPHTHALMOL, V66, P594, DOI 10.1136/bjo.66.9.594
   RICE JS, 1962, ARCH DERMATOL, V86, P503, DOI 10.1001/archderm.1962.01590100117021
   Rodrigues D, 2000, Rev Hosp Clin Fac Med Sao Paulo, V55, P29
   ROSENBLUM WI, 1978, HISTOPATHOLOGY, V2, P301, DOI 10.1111/j.1365-2559.1978.tb01722.x
   Saeed ID, 2014, BMJ CASE REP, V2014
   SATYAMURTI S, 1986, ARCH NEUROL-CHICAGO, V43, P1184, DOI 10.1001/archneur.1986.00520110070019
   Sedat J, 2008, NEURORADIOL J, V21, P327, DOI 10.1177/197140090802100306
   Shannon Jack, 2005, Australas J Dermatol, V46, P192, DOI 10.1111/j.1440-0960.2005.00178.x
   SHERRY RG, 1984, AM J NEURORADIOL, V5, P832
   Soblet J, 2017, J INVEST DERMATOL, V137, P207, DOI 10.1016/j.jid.2016.07.034
   Tomelleri G, 2010, NEUROL SCI, V31, P501, DOI 10.1007/s10072-010-0250-4
   Tzoufi MS, 2008, EUR J PEDIATR, V167, P897, DOI 10.1007/s00431-007-0615-8
   Vig EK, 2002, J GERIATR PSYCH NEUR, V15, P7, DOI 10.1177/089198870201500102
   WALSHE MM, 1966, BRIT MED J, V2, P931, DOI 10.1136/bmj.2.5519.931
   WAYBRIGHT EA, 1978, ANN NEUROL, V3, P464, DOI 10.1002/ana.410030522
   Wirf f, 1998, AM FAM PHYSICIAN, V57, P765
   Wong CH, 2003, J GASTROEN HEPATOL, V18, P1000, DOI 10.1046/j.1440-1746.2003.03083.x
   Wynford-Thomas Ray, 2014, Pract Neurol, V14, P360, DOI 10.1136/practneurol-2013-000725
NR 46
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 272
EP 280
DI 10.1016/j.wneu.2018.11.257
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400147
PM 30576827
DA 2020-05-12
ER

PT J
AU Su, XJ
   Li, Q
   Shen, HX
AF Su, Xin-Jin
   Li, Quan
   Shen, Hong-Xing
TI Arteriovenous Fistula Inside Cervical Spinal Canal Associated with
   Neurofibromatosis Type 1
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cervical spine arteriovenous fistula; Neurofibromatosis type 1; Spinal
   cord compression; Vascular embolization
AB BACKGROUND: Neurofibromatosis type 1 (NF-1) is an autosomal dominant disease caused by mutation on chromosome 17, which affects the skin, vascular system, nervous system, and skeleton system. Arteriovenous fistula (AVF) is one of the recognized complications of NF-1.
   CASE DESCRIPTION: We report a case of a 33-year-old woman with NF-1 with cervical spine AVF inside the cervical spinal canal who presented with progressive spinal cord compression which was abnormal. After sufficient preparation, the patient underwent vascular embolization, and then symptoms of spinal cord compression significantly improved.
   CONCLUSIONS: This report reminds readers of the possibility of AVF if there is a space-occupying lesion inside the cervical spinal canal and to do computed tomography angiography examination when necessary.
C1 [Su, Xin-Jin; Li, Quan; Shen, Hong-Xing] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Spine Surg, Shanghai, Peoples R China.
RP Shen, HX (reprint author), Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Spine Surg, Shanghai, Peoples R China.
EM jizhuwai@126.com
CR DEANS WR, 1982, RADIOLOGY, V144, P103, DOI 10.1148/radiology.144.1.6806851
   Gao P, 2013, TURK NEUROSURG, V23, P289, DOI 10.5137/1019-5149.JTN.4993-11.0
   Narayanamurthy H, 2017, BRIT J NEUROSURG, V31, P736, DOI 10.1080/02688697.2016.1226257
NR 3
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 283
EP 285
DI 10.1016/j.wneu.2018.12.045
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400149
PM 30580065
DA 2020-05-12
ER

PT J
AU Haddad, R
   Alkubaisi, A
   Al Bozom, I
   Haider, A
   Belkhair, S
AF Haddad, Rizq
   Alkubaisi, Aisha
   Al Bozom, Issam
   Haider, Abdulrazzaq
   Belkhair, Sirajeddin
TI Solitary Primary Central Nervous System Lymphoma Mimicking Third
   Ventricular Colloid Cyst-Case Report and Review of Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Colloid cyst; Endoscopic resection of third ventricular mass; Lymphoma
   mimicking colloid cyst; PCNSL
AB BACKGROUND: Primary central nervous system lymphoma is a rare malignant tumor of the central nervous system. It is associated with poor prognosis and accounts for 0.7%-0.9% of all lymphomas and only 0.3%-1.5% of intracranial tumors. Typically, these lesions are in the cerebral white matter near the corpus callosum, the central gray matter, the basal ganglia-thalamus-hypothalamic region, the posterior fossa and the periventricular region. Only 2 cases with pure third ventricular lymphoma have been reported in the literature.
   CASE DESCRIPTION: A 72-year-old female patient known to have type II diabetes mellitus treated with insulin, hypertension, chronic kidney disease, dyslipidemia, and obesity presented with a history of acute confusion and urinary incontinence. No headache was reported on admission, but previously she had intermittent mild headaches and generalized body aches. She had no history of visual symptoms. Her family said she was mildly confused and had memory difficulties that started acutely 2 days before presentation to the hospital. The patient had urgent computed tomography of the brain, which showed a hyperdense lesion in the region of the foramen of Monro. Pre-operative images diagnosed the case as colloid cyst, but post-operative histopathology proved the lesion to be primary CNS lymphoma.
   CONCLUSIONS: Eleven months after surgery, the patient is fully consciousness and oriented, with no memory issues or neurologic deficit. She is back to her baseline activities. We are reporting this case for the rarity of the disease and the unusual location of it.
C1 [Haddad, Rizq; Alkubaisi, Aisha; Al Bozom, Issam; Haider, Abdulrazzaq; Belkhair, Sirajeddin] Hamad Med Corp, Neurosurg, Doha, Qatar.
RP Haddad, R (reprint author), Hamad Med Corp, Neurosurg, Doha, Qatar.
EM Rmh001@gmail.com
OI Haddad, Rizq/0000-0001-6332-8861
CR Jaiswal AK, 2004, J CLIN NEUROSCI, V11, P328, DOI 10.1016/S0967-5868(03)00110-3
   Mappa S, 2013, HEMATOL ONCOL, V31, P143, DOI 10.1002/hon.2037
   Marcus R, 2009, GUIDELINES DIAGNOSIS
   Mendez Joe S, 2018, Am Soc Clin Oncol Educ Book, V38, P604, DOI 10.1200/EDBK_200829
   Nagle Sarah J, 2017, Int J Hematol Oncol, V6, P113, DOI 10.2217/ijh-2017-0020
   Nayak L, 2017, BLOOD, V129, P3071, DOI 10.1182/blood-2017-01-764209
   Nayak L, 2013, CURR TREAT OPTION ON, V14, P539, DOI 10.1007/s11864-013-0252-6
   Queiroz Rodolfo Mendes, 2017, Radiol Bras, V50, P413, DOI 10.1590/0100-3984.2016.0065
   Rubenstein J, 2008, LEUKEMIA LYMPHOMA, V49, P43, DOI 10.1080/10428190802311441
   Sasani Mehdi, 2011, J Med Case Rep, V5, P213, DOI 10.1186/1752-1947-5-213
   Slone HW, 2005, AM J ROENTGENOL, V184, P1679, DOI 10.2214/ajr.184.5.01841679
   Wang J, 2015, ONCOL LETT, V9, P1795, DOI 10.3892/ol.2015.2903
NR 12
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 286
EP 294
DI 10.1016/j.wneu.2018.12.026
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400150
PM 30579027
DA 2020-05-12
ER

PT J
AU Corley, J
   Lepard, J
   Barthelemy, E
   Ashby, JL
   Park, KB
AF Corley, Jacquelyn
   Lepard, Jacob
   Barthelemy, Ernest
   Ashby, Joanna L.
   Park, Kee B.
TI Essential Neurosurgical Workforce Needed to Address Neurotrauma in Low-
   and Middle-Income Countries
SO WORLD NEUROSURGERY
LA English
DT Article
DE Global neurosurgery; Low-and middle-income countries; Neurotrauma;
   Traumatic brain injury; Traumatic spinal injury
ID SURGICAL CARE; EMERGENCY NEUROSURGERY; MODELING STRATEGY; GENERAL
   SURGEONS; ACCESS; HEALTH
AB BACKGROUND: Among all trauma-related injuries globally, traumatic brain injury (TBI) and traumatic spine injury (TSI) account for the largest proportion of cases. Where previously data was lacking, recent efforts have been initiated to better quantify the extent of neurotrauma in low-and middle-income countries (LMICs). This information is vital to understand the current neurosurgical deficit so that resources and efforts can be focused on where they are needed most. The purpose of this study is to determine the minimum number of neurosurgeons to address the neurotrauma demand in LMICs and evaluate current evidence to support facility needs so that policy-based recommendations can be made to prioritize development initiatives to scale up neurosurgical services.
   METHODS: Using existing data regarding the incidence of TBI and TSI in LMICs and current neurosurgical workforce and estimates of case load capacity, the minimum number of neurosurgeons needed to address neurotrauma per population was calculated. Evidence was gathered regarding necessary hospital facilities and disbursement patterns based on time needed to intervene effectively for neurotrauma.
   RESULTS: There are 4,897,139 total operative cases of TBI and TSI combined in LMICs annually. At minimum, there needs to be 1 neurosurgeon only performing neurotrauma cases per approximately 212,000 people. Evidence suggests that patients should be within 4 hours of a neurosurgical facility at the very least.
   CONCLUSIONS: The development of neurotrauma systems is essential to address the large burden of neurotrauma in LMICs. The minimum requirements for neurosurgical workforce is 1 neurotrauma surgeon per 212,000 people.
C1 [Corley, Jacquelyn; Lepard, Jacob; Barthelemy, Ernest; Ashby, Joanna L.; Park, Kee B.] Harvard Med Sch, Global Neurosurg Initiat, Program Global Surg & Social Change, Boston, MA 02115 USA.
   [Corley, Jacquelyn] Duke Dept Neurosurg, Durham, NC 27704 USA.
   [Lepard, Jacob] Univ Alabama Birmingham, Dept Neurosurg, Birmingham, AL USA.
   [Lepard, Jacob] Boston Childrens Hosp, Boston, MA USA.
   [Barthelemy, Ernest] Icahn Sch Med Mt Sinai, Dept Neurosurg, New York, NY 10029 USA.
   [Ashby, Joanna L.] Univ Glasgow, Med Sch, Glasgow, Lanark, Scotland.
RP Corley, J (reprint author), Harvard Med Sch, Global Neurosurg Initiat, Program Global Surg & Social Change, Boston, MA 02115 USA.; Corley, J (reprint author), Duke Dept Neurosurg, Durham, NC 27704 USA.
EM jacorley21@gmail.com
CR Albutt K, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195986
   Alkire BC, 2015, LANCET GLOB HEALTH, V3, pE316, DOI 10.1016/S2214-109X(15)70115-4
   Bagan M, 2010, WORLD NEUROSURG, V73, P289, DOI 10.1016/j.wneu.2010.03.007
   Cairo SB, 2018, PEDIATR SURG INT, V34, P467, DOI 10.1007/s00383-018-4238-0
   Chao TE, 2015, WORLD J SURG, V39, P2140, DOI 10.1007/s00268-014-2905-4
   Dewan MC, 2019, J NEUROSURG, V130, P1055, DOI 10.3171/2017.11.JNS171500
   El Khamlichi Abdeslam, 2014, World Neurosurg, V81, P234, DOI 10.1016/j.wneu.2013.10.051
   Esquivel MM, 2016, JAMA SURG, V151, P1064, DOI 10.1001/jamasurg.2016.2303
   Haglund MM, 2011, WORLD J SURG, V35, P1175, DOI 10.1007/s00268-011-1080-0
   Kanyi JK, 2018, WORLD J SURG, V42, P40, DOI 10.1007/s00268-017-4143-z
   Kempthorne P, 2017, ANESTH ANALG, V125, P981, DOI 10.1213/ANE.0000000000002258
   Kumar R, 2018, WORLD NEUROSURG, V113, pE345, DOI 10.1016/j.wneu.2018.02.033
   Luck T, 2015, ANZ J SURG, V85, P610, DOI 10.1111/ans.13138
   Meara JG, 2015, LANCET, V386, P569, DOI 10.1016/S0140-6736(15)60160-X
   Muniz SA, 2017, J TRAUMA NURS, V24, P306, DOI 10.1097/JTN.0000000000000310
   Rose J, 2015, LANCET GLOB HEALTH, V3, pS13, DOI 10.1016/S2214-109X(15)70087-2
   Rubiano AM, 2015, NATURE, V527, pS193, DOI 10.1038/nature16035
   Santos MM, 2018, WORLD NEUROSURG, V113, P425, DOI 10.1016/j.wneu.2018.01.084
   Treacy PJ, 2005, ANZ J SURG, V75, P852, DOI 10.1111/j.1445-2197.2005.03549.x
   Weiser TG, 2008, LANCET, V372, P139, DOI 10.1016/S0140-6736(08)60878-8
   WHO, 2008, TASK SHIFT GLOB REC
NR 21
TC 10
Z9 10
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 295
EP 299
DI 10.1016/j.wneu.2018.12.042
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400151
PM 30579006
DA 2020-05-12
ER

PT J
AU Morinaga, Y
   Nii, K
   Sakamoto, K
   Inoue, R
   Mitsutake, T
   Hanada, H
AF Morinaga, Yusuke
   Nii, Kouhei
   Sakamoto, Kimiya
   Inoue, Ritsurou
   Mitsutake, Takafumi
   Hanada, Hayatsura
TI Stent-Assisted Coil Embolization for a Ruptured Posterior Communicating
   Artery Pseudoaneurysm After Endoscopic Transsphenoidal Surgery for
   Pituitary Adenoma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endoscopic trans-sphenoidal surgery; Pituitary adenoma; Posterior
   communicating artery; Pseudoaneurysm; Stent-assisted coil embolization
ID ANEURYSM; INJURY
AB BACKGROUND: Intracranial pseudoaneurysm is a rare complication of endoscopic endonasal surgery. Herein, we describe 2-staged stent-assisted coil embolization for posterior communicating artery pseudoaneurysm after endoscopic endonasal surgery for pituitary adenoma.
   CASE DESCRIPTION: A 68-year-old man had a history of severe adult growth hormone secretion deficiency, requiring growth hormone replacement therapy; secondary adrenocortical hypofunction; hyperthyroidism; hypertension; constipation; glaucoma; and hyperuricemia. Five years ago, after initial endoscopic transsphenoidal surgery for pituitary adenoma, he was hospitalized for reoperation. Posterior communicating artery injury was observed during second endoscopic transsphenoidal surgery, and pressure hemostasis was performed using a hemostatic preparation. Immediately post surgery, a localized subarachnoid hemorrhage was observed. Sudden-onset impaired consciousness and respiratory disturbances ensued on postoperative day 7, and computed tomography of the head was performed. Recurrent subarachnoid hemorrhage was confirmed, and acute hydrocephalus secondary to third ventricular blockage was identified. Cerebral angiography was performed after urgent bilateral cerebral ventricular drainage under general anesthesia. A pseudoaneurysm was identified in the left posterior communicating artery, and coil embolization was performed. Six weeks post surgery, a low-profile visualized intraluminal stent called an LVIS Jr. stent was placed in the posterior communicating artery. Recurrence of the aneurysm was not detected 6 months post surgery. He underwent lumboperitoneal shunting for secondary normal pressure hydrocephalus after dual antiplatelet therapy discontinuation and is being followed up as an outpatient with a modified Rankin scale score of 2 ten months post surgery.
   CONCLUSIONS: Two-staged stent-assisted coil embolization using a low-profile visualized intraluminal stent was effective for a posterior communicating artery pseudoaneurysm occurring after posterior communicating artery injury following endoscopic transsphenoidal surgery for follicle-stimulating hormone-producing pituitary adenoma.
C1 [Morinaga, Yusuke; Nii, Kouhei; Sakamoto, Kimiya; Inoue, Ritsurou; Mitsutake, Takafumi; Hanada, Hayatsura] Fukuoka Univ, Dept Neurosurg, Chikushi Hosp, Chikushino City, Japan.
RP Morinaga, Y (reprint author), Fukuoka Univ, Dept Neurosurg, Chikushi Hosp, Chikushino City, Japan.
EM yu_the_morio@yahoo.co.jp
CR Amirjamshidi A, 1996, J NEUROSURG, V84, P769, DOI 10.3171/jns.1996.84.5.0769
   CABEZUDO JM, 1981, J NEUROSURG, V54, P118, DOI 10.3171/jns.1981.54.1.0118
   Ciric I, 1997, NEUROSURGERY, V40, P225, DOI 10.1097/00006123-199702000-00001
   de Souza JM, 2003, ARQ NEURO-PSIQUIAT, V61, P459, DOI 10.1590/S0004-282X2003000300025
   Kai Y, 2001, NEUROL SURG TOKYO, V29, P241
   Karadag Ali, 2017, Acta Medica (Hradec Kralove), V60, P89, DOI 10.14712/18059694.2017.100
   Leung GKK, 2006, BRIT J NEUROSURG, V20, P55, DOI 10.1080/02688690600601382
   Tokunaga K, 2001, AM J NEURORADIOL, V22, P35
   WILSON CB, 1978, J NEUROSURG, V48, P13, DOI 10.3171/jns.1978.48.1.0013
NR 9
TC 1
Z9 1
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 301
EP 305
DI 10.1016/j.wneu.2018.12.047
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400153
PM 30583130
DA 2020-05-12
ER

PT J
AU Scala, M
   Vennarini, S
   Garre, ML
   Tortora, D
   Cianchetti, M
   Fellin, F
   Lorentini, S
   Pavanello, M
AF Scala, Marcello
   Vennarini, Sabina
   Garre, Maria Luisa
   Tortora, Domenico
   Cianchetti, Marco
   Fellin, Francesco
   Lorentini, Stefano
   Pavanello, Marco
TI Radiation-Induced Moyamoya Syndrome After Proton Therapy in Child with
   Clival Chordoma: Natural History and Surgical Treatment
SO WORLD NEUROSURGERY
LA English
DT Article
DE Chordoma; Moyamoya syndrome; Proton beam therapy; Surgical
   revascularization
ID PROGNOSTIC-FACTORS; CERVICAL-SPINE; SKULL BASE; SURVIVAL; PATTERNS;
   PATIENT; TUMORS
AB BACKGROUND: Proton therapy has proven to be effective and safe in the treatment of radioresistant skull base tumors such as chordomas. Thanks to the peculiar physical properties of the proton beam, radiation energy is delivered in a narrow space called the Bragg peak and the surrounding normal tissues receive a minimal amount of the radiation dose. This is important to lower the risk of radiation-induced damage, especially in children. However, local adverse effects in proximity to the target volume may occur. In particular, the development of moyamoya syndrome (MMS) has been rarely reported in children receiving proton beam therapy for brain tumors.
   CASE DESCRIPTION: We report on a child who developed rapidly progressive MMS after proton beam therapy for a clivus chordoma. A combined indirect revascularization procedure by encephalo-duro-arterio-synangiosis and encephalo-myo-synangiosis was performed with good neuroradiologic and clinical outcome.
   CONCLUSIONS: Regardless of the presence of known risk factors for MMS, strict neuroimaging surveillance is indicated in all patients treated with radiotherapy including those receiving proton beam therapy. We suggest that an early revascularization procedure should be considered in patients with worsening symptoms and/or sign of neuroradiologic progression of cerebral vasculopathy. This management of MMS could lower the risk of permanent neurologic deficits and improve patients' quality of life.
C1 [Scala, Marcello; Pavanello, Marco] IRCCS Ist Giannina Gaslini, Dept Neurosurg, Via Gerolamo Gaslini, Genoa, Italy.
   [Vennarini, Sabina; Cianchetti, Marco; Fellin, Francesco; Lorentini, Stefano] Hosp Trento, Proton Therapy Ctr, APSS, Trento, Italy.
   [Garre, Maria Luisa] IRCCS Ist Giannina Gaslini, Dept Neuroncol Unit, Via Gerolamo Gaslini, Genoa, Italy.
   [Tortora, Domenico] IRCCS Ist Giannina Gaslini, Dept Neuroradiol Unit, Via Gerolamo Gaslini, Genoa, Italy.
RP Scala, M (reprint author), IRCCS Ist Giannina Gaslini, Dept Neurosurg, Via Gerolamo Gaslini, Genoa, Italy.
EM marcelloscala87@gmail.com
RI Marco, Pavanello/K-2859-2019; Garre, Maria Luisa/K-4205-2018
OI Marco, Pavanello/0000-0001-7312-0204; Scala,
   Marcello/0000-0003-2194-7239; Garre, Maria Luisa/0000-0002-9055-3340
CR Amichetti M, 2009, NEUROSURG REV, V32, P403, DOI 10.1007/s10143-009-0194-4
   Currie S, 2011, PEDIATR NEUROL, V44, P401, DOI 10.1016/j.pediatrneurol.2011.02.007
   Fukui M, 1997, CLIN NEUROL NEUROSUR, V99, pS238
   Habrand JL, 2016, REP PRACT ONCOL RADI, V21, P412, DOI 10.1016/j.rpor.2016.04.003
   Hug EB, 2002, STRAHLENTHER ONKOL, V178, P10, DOI 10.1007/s00066-002-0874-2
   MATSUMOTO J, 1989, PEDIATR RADIOL, V20, P28, DOI 10.1007/BF02010629
   McMaster ML, 2001, CANCER CAUSE CONTROL, V12, P1, DOI 10.1023/A:1008947301735
   Munzenrider JE, 1999, STRAHLENTHER ONKOL, V175, P57, DOI 10.1007/BF03038890
   Noel G, 2005, ACTA ONCOL, V44, P700, DOI 10.1080/02841860500326257
   Noel G, 2003, STRAHLENTHER ONKOL, V179, P241, DOI 10.1007/s00066-003-1065-5
   Reynolds MR, 2016, PEDIATR NEUROSURG, V51, P297, DOI 10.1159/000446075
   SALISBURY JR, 1993, J PATHOL, V171, P59, DOI 10.1002/path.1711710112
   Smith ER, 2010, NEUROSURG CLIN N AM, V21, P543, DOI 10.1016/j.nec.2010.03.007
   Smoll NR, 2013, CANCER-AM CANCER SOC, V119, P2029, DOI 10.1002/cncr.28032
   Stacchiotti S, 2015, LANCET ONCOL, V16, pE71, DOI 10.1016/S1470-2045(14)71190-8
   Tsitouras V, 2016, J CLIN NEUROSCI, V34, P169, DOI 10.1016/j.jocn.2016.06.003
   Ullrich NJ, 2007, NEUROLOGY, V68, P932, DOI 10.1212/01.wnl.0000257095.33125.48
   Zou MX, 2018, WORLD NEUROSURG, V109, P307, DOI 10.1016/j.wneu.2017.10.010
   Zwagerman NT, 2014, PEDIATR BLOOD CANCER, V61, P1490, DOI 10.1002/pbc.24961
NR 19
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 306
EP 309
DI 10.1016/j.wneu.2018.12.048
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400154
PM 30583132
DA 2020-05-12
ER

PT J
AU Cho, N
   Alkins, R
   Khan, OH
   Ginsberg, H
   Cusimano, MD
AF Cho, Newton
   Alkins, Ryan
   Khan, Osaama H.
   Ginsberg, Howard
   Cusimano, Michael D.
TI Unilateral Lumbar Facet Dislocation: Case Report and Review of the
   Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Dislocation; Lumbar facet; Spine
ID LOCKED FACET; SPINE
AB BACKGROUND: Facet dislocations of the lumbar spine, particularly without neurologic injury, are rare occurrences after major trauma. Although there are documented cases of lumbosacral dislocation in the published literature, strictly lumbar unilateral facet dislocation is rare.
   CASE DESCRIPTION: We report a case of a unilateral facet dislocation at L4-L5 after a single vehicle motorcycle accident. This injury was treated with posterior open reduction and instrumented stabilization with good results.
   CONCLUSIONS: Given the rarity of this injury pattern, the management of this type of injury is not established. Careful imaging to make the diagnosis is crucial, and we recommend a surgical treatment in the form of an open reduction and instrumented stabilization. In our case, we achieved good outcomes with a posterior approach.
C1 [Cho, Newton; Alkins, Ryan; Khan, Osaama H.; Ginsberg, Howard; Cusimano, Michael D.] Univ Toronto, Dept Neurosurg, St Michaels Hosp, Toronto, ON, Canada.
   [Ginsberg, Howard; Cusimano, Michael D.] Univ Toronto, Injury Prevent Res Off, St Michaels Hosp, Toronto, ON, Canada.
RP Cho, N (reprint author), Univ Toronto, Dept Neurosurg, St Michaels Hosp, Toronto, ON, Canada.
EM newton.cho@mail.utoronto.ca
RI Cusimano, Michael/X-4059-2019
CR CONNOLLY PJ, 1992, SPINE, V17, P1244, DOI 10.1097/00007632-199210000-00020
   Im Sang-Hyuk, 2012, Korean J Spine, V9, P278, DOI 10.14245/kjs.2012.9.3.278
   MIZ GS, 1988, SPINE, V13, P956, DOI 10.1097/00007632-198808000-00022
   Mori K, 2002, EUR SPINE J, V11, P602, DOI 10.1007/s00586-002-0396-8
   Park HY, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000012483
   Ra IH, 2013, SPINE J, V13, P1705, DOI 10.1016/j.spinee.2013.07.477
   Reddy SJ, 2008, J NEUROSURG-SPINE, V9, P576, DOI 10.3171/SPI.2008.6.08301
   Rhea E, 2018, WORLD NEUROSURG, V119, P103, DOI 10.1016/j.wneu.2018.07.199
   Song KJ, 2005, J SPINAL DISORD TECH, V18, P462
   Stuart Ranald M, 2004, Australas Radiol, V48, P224, DOI 10.1111/j.1440-1673.2004.01303.x
   Tsirikos AI, 2004, SPINE, V29, pE164, DOI 10.1097/00007632-200404150-00026
   Zenonos GA, 2016, EUR SPINE J, V25, pS129, DOI 10.1007/s00586-015-4245-y
NR 12
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 310
EP 316
DI 10.1016/j.wneu.2018.12.006
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400155
PM 30576818
DA 2020-05-12
ER

PT J
AU Ding, YH
   Rong, HT
   Wang, Y
   Liu, T
   Zhang, JH
   Li, SP
   Wang, Z
   Wang, Y
   Zhu, T
AF Ding, Yuhui
   Rong, Hongtao
   Wang, Yi
   Liu, Tong
   Zhang, Jinhao
   Li, Sipeng
   Wang, Zhe
   Wang, Ya
   Zhu, Tao
TI Detection of Germline Mutations of the SMARCB1 Gene in a Chinese Family
   with Intraspinal Schwannomatosis
SO WORLD NEUROSURGERY
LA English
DT Article
DE INI1; Intraspinal; Multiple schwannomas; Schwannomatosis; SMARCB1 gene
ID TYPE-2
AB BACKGROUND: Schwannomatosis is the third subtype of neurofibromatosis. Because the tumor is multiple and prone to recurrence, it often brings challenges to clinical diagnosis and treatment. In the past decade, researchers have come to realize the relationship between the SMARCB1 gene and schwannomatosis, which is expected to improve the current level of diagnosis and treatment.
   CASE DESCRIPTION: We collected the clinical data of intraspinal schwannomatosis in the same family, which is rare, and carried out the genetic tests on 3 generations of family members (N = 25). We found that 8 family members had germline mutations of the SMARCB1 gene, manifested as mutation at the splice site between SMARCB1 gene exon 8 and 9 (c.1118 D 1G > A).
   CONCLUSIONS: The structural and functional abnormalities of proteins caused by the mutations of the SMARCB1 gene may be the molecular basis for the pathogenesis of schwannomatosis in this family. This study may provide clues for the study of schwannomatosis in the future.
C1 [Ding, Yuhui; Rong, Hongtao; Wang, Yi; Liu, Tong; Zhang, Jinhao; Li, Sipeng; Wang, Zhe; Wang, Ya; Zhu, Tao] Tianjin Med Univ Gen Hosp, Dept Neurosurg, Tianjin, Peoples R China.
RP Zhu, T (reprint author), Tianjin Med Univ Gen Hosp, Dept Neurosurg, Tianjin, Peoples R China.
EM zhutao5@126.com
CR Asai K, 2015, BRAIN TUMOR PATHOL, V32, P216, DOI 10.1007/s10014-015-0213-9
   Blakeley JO, 2016, NEURO-ONCOLOGY, V18, P624, DOI 10.1093/neuonc/nov200
   Ding YH, 2018, WORLD NEUROSURG, V119, P335, DOI 10.1016/j.wneu.2018.08.087
   Hulsebos TJM, 2010, CLIN GENET, V77, P86, DOI 10.1111/j.1399-0004.2009.01249.x
   Hulsebos TJM, 2007, AM J HUM GENET, V80, P805, DOI 10.1086/513207
   Jordan JT, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000009717
   Kehrer-Sawatzki H, 2017, HUM GENET, V136, P129, DOI 10.1007/s00439-016-1753-8
   Koontz NA, 2013, AM J ROENTGENOL, V200, pW646, DOI 10.2214/AJR.12.8577
   Landi A, 2011, INT J SURG CASE REP, V2, P36, DOI 10.1016/j.ijscr.2010.12.001
   Li P, 2016, J NEUROSURG-SPINE, V24, P145, DOI 10.3171/2015.3.SPINE141145
   Smith MJ, 2014, CANCER GENET-NY, V207, P373, DOI 10.1016/j.cancergen.2014.04.001
   Smith MJ, 2012, NEUROGENETICS, V13, P141, DOI 10.1007/s10048-012-0319-8
NR 12
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 318
EP 322
DI 10.1016/j.wneu.2018.11.254
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400156
PM 30576819
DA 2020-05-12
ER

PT J
AU Salem, MM
   Ascanio, LC
   Kicielinski, KP
   Cambria, RP
   Ogilvy, CS
   Alturki, AY
AF Salem, Mohamed M.
   Ascanio, Luis C.
   Kicielinski, Kimberly P.
   Cambria, Richard P.
   Ogilvy, Christopher S.
   Alturki, Abdulrahman Y.
TI Endovascular Trapping of Large Cervical Carotid Pseudoaneurysm in Marfan
   Syndrome Presenting with Progressive Respiratory Distress
SO WORLD NEUROSURGERY
LA English
DT Article
DE Carotid; Endovascular; Marfan syndrome; Pseudoaneurysm; Trapping
ID CLOSURE DEVICE FAILURE; ARTERY ANEURYSM; DANLOS-SYNDROME; MANAGEMENT
AB BACKGROUND: Isolated cervical pseudoaneurysms of the internal carotid artery (ICA) in patients with Marfan syndrome are extremely rare.
   CASE DESCRIPTION: A 73-year-old female with Marfan syndrome and history of multiple aortic aneurysms presented to an outside hospital with dysphagia, a mass in her neck, dizziness, nausea, and vomiting. A computed tomography angiogram showed bilateral cervical ICA pseudoaneurysms, more significant on the right side. A laryngoscopy demonstrated edematous vocal cords and a significant mass effect on the right side. She suffered from significant respiratory distress and aspiration, for which she had to be intubated and transferred to our institution for definitive care. The patient was taken for angiography for carotid artery test occlusion and endovascular trapping with coils and onyx embolization of the carotid pseudoaneurysm. The hospital course was complicated with femoral closure device failure, leading to groin hematoma, pneumonia, and respiratory failure requiring tracheostomy and percutaneous endoscopic gastrostomy. The patient was discharged to rehabilitation 34 days after admission. Stable exclusion of the large right pseudoaneurysm was observed at 3 months' follow-up with computed tomography angiography, as well as significant improvement in the last clinical follow-up obtained 6 months after the procedure.
   CONCLUSION: Pseudoaneurysms of the cervical ICA associated with Marfan syndrome are rare. Carotid test occlusion and endovascular permanent embolization are possible in a patient with life-threatening symptoms. Cautious use of vascular closure devices, especially collagen plug-based ones, are required in such patients, given their abnormal extracellular matrix structure.
C1 [Salem, Mohamed M.; Ascanio, Luis C.; Kicielinski, Kimberly P.; Ogilvy, Christopher S.; Alturki, Abdulrahman Y.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Neurosurg Serv, Boston, MA 02115 USA.
   [Alturki, Abdulrahman Y.] King Fahad Med City, Natl Neurosci Inst, Dept Neurosurg, Riyadh, Saudi Arabia.
   [Cambria, Richard P.] St Elizabeths Med Ctr, Div Vasc & Endovasc Surg, Brighton, MA USA.
RP Salem, MM (reprint author), Harvard Med Sch, Beth Israel Deaconess Med Ctr, Neurosurg Serv, Boston, MA 02115 USA.
EM msalem_123@yahoo.com
OI Ascanio, Luis/0000-0001-9914-1599
CR Bangalore S, 2009, CIRC-CARDIOVASC INTE, V2, P549, DOI 10.1161/CIRCINTERVENTIONS.109.877407
   Bergqvist D, 2013, ANN SURG, V258, P257, DOI 10.1097/SLA.0b013e31829c7a59
   Bouziane Z, 2013, VASA, V42, P457, DOI 10.1024/0301-1526/a000317
   DIETZ HC, 1991, NATURE, V352, P337, DOI 10.1038/352337a0
   Fankhauser GT, 2015, J VASC SURG, V61, P389, DOI 10.1016/j.jvs.2014.07.092
   Gupta K, 2004, CATHETER CARDIO INTE, V62, P64, DOI 10.1002/ccd.20006
   HARDIN CA, 1962, NEW ENGL J MED, V267, P141, DOI 10.1056/NEJM196207192670306
   Judge DP, 2005, LANCET, V366, P1965, DOI 10.1016/S0140-6736(05)67789-6
   LATTER DA, 1989, CAN J SURG, V32, P463
   Li Z, 2011, EUR J VASC ENDOVASC, V42, P419, DOI 10.1016/j.ejvs.2011.05.008
   Loeys BL, 2010, J MED GENET, V47, P476, DOI 10.1136/jmg.2009.072785
   Lum YW, 2012, ANN VASC SURG, V26, P25, DOI 10.1016/j.avsg.2011.05.028
   MURDOCH JL, 1972, NEW ENGL J MED, V286, P804, DOI 10.1056/NEJM197204132861502
   Ohta T, 2016, J NEUROENDOVASC THER, V10, P64
   Ohyama Takashiro, 1992, Neurologia Medico-Chirurgica, V32, P965, DOI 10.2176/nmc.32.965
   Pacini D, 2013, ANN THORAC SURG, V95, P737, DOI 10.1016/j.athoracsur.2012.09.059
   SCHIEVINK WI, 1994, STROKE, V25, P889, DOI 10.1161/01.STR.25.4.889
   Sponseller PD, 2010, J BONE JOINT SURG AM, V92A, P1868, DOI 10.2106/JBJS.I.00892
   Sztajzel R, 2001, CEREBROVASC DIS, V11, P346, DOI 10.1159/000047665
   Vidi VD, 2012, JACC-CARDIOVASC INTE, V5, P837, DOI 10.1016/j.jcin.2012.05.005
   Waterman AL, 2012, J VASC SURG, V55, P1234, DOI 10.1016/j.jvs.2011.11.089
   Welleweerd JC, 2015, EUR J VASC ENDOVASC, V50, P141, DOI 10.1016/j.ejvs.2015.05.002
   Wityk RJ, 2002, STROKE, V33, P680, DOI 10.1161/hs0302.103816
   Zhou W, 2006, J VASC SURG, V43, P493, DOI 10.1016/j.jvs.2005.11.023
NR 24
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 323
EP 327
DI 10.1016/j.wneu.2018.12.050
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400157
PM 30590218
DA 2020-05-12
ER

PT J
AU Pagano, A
   Novegno, F
   Ferlosio, A
   Lunardi, P
AF Pagano, Andrea
   Novegno, Federica
   Ferlosio, Amedeo
   Lunardi, Pierpaolo
TI Repeat Bleeding 18 Years After Hemorrhagic Pilocytic Astrocytoma:
   Prognostic Implications of Conservative Management-Case Report and
   Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Hemorrhage; Natural history; Pilocytic astrocytoma; Prognosis; Surgery
ID PILOMYXOID ASTROCYTOMA; SUBARACHNOID HEMORRHAGE; INTRAVENTRICULAR
   HEMORRHAGE; INTRACRANIAL HEMORRHAGE; INTRATUMORAL HEMORRHAGE; CEREBELLAR
   HEMORRHAGE; FATAL HEMORRHAGE; ADULT; BRAIN; TUMOR
AB BACKGROUND: Acute hemorrhagic occurrence of pilocytic astrocytomas is extremely rare but has become increasingly recognized and often presents in clinically emergent situations. The precise significance of hemorrhage in these tumors and its pathogenetic mechanisms have not yet been defined. Nothing is known about the natural history of bleeding pilocytic astrocytomas.
   CASE DESCRIPTION: A 21-year-old man presented with acute biventricular hydrocephalus for repeat bleeding of a midbrain lesion that had been diagnosed 18 years earlier after a similar acute hemorrhagic episode. The patient had been initially treated conservatively, considering the high risk of surgery. He underwent urgent biventricular external shunt surgery and, subsequently, total removal of the lesion. Histopathological analysis revealed pilocytic astrocytoma. Including the present case, 59 cases were analyzed and reviewed, including 5 cases with a pilomyxoid variant. Different pathogenetic mechanisms have been proposed, including histological characteristics, rupture of the bridging veins torn by the neoplastic mass, and vascular instability determined by overexpression of vascular endothelial growth factor.
   CONCLUSIONS: To the best of our knowledge, the presented case is completely unique owing to the long-term observational follow-up data available. The hemorrhagic potential did not decrease over time, representing a specific feature of this tumor. The occurrence of bleeding might not reflect either malignancy or aggressiveness. However, the worse prognosis is related to the clinical behavior, with life-threatening complications often associated. Surgery remains the standard treatment and will influence the final prognosis.
C1 [Pagano, Andrea; Novegno, Federica; Lunardi, Pierpaolo] Univ Roma Tor Vergata, Dept Neurosurg, Policlin Tor Vergata, Rome, Italy.
   [Ferlosio, Amedeo] Univ Roma Tor Vergata, Div Anat Pathol, Dept Biomed & Prevent, Policlin Tor Vergata, Rome, Italy.
RP Pagano, A (reprint author), Univ Roma Tor Vergata, Dept Neurosurg, Policlin Tor Vergata, Rome, Italy.
EM pagano.andrea1987@gmail.com
CR Bell D, 2004, BRIT J NEUROSURG, V18, P613, DOI 10.1080/02688690400022896
   Bosnjak R, 2005, J NEUROSURG, V103, P473, DOI 10.3171/jns.2005.103.3.0473
   Briet C, 2015, ENDOCR REV, V36, P622, DOI 10.1210/er.2015-1042
   Burkhard C, 2003, J NEUROSURG, V98, P1170, DOI 10.3171/jns.2003.98.6.1170
   BYARD RW, 1992, PEDIATR NEUROSURG, V17, P88, DOI 10.1159/000120573
   Carlson ML, 2017, LARYNGOSCOPE, V127, P1420, DOI 10.1002/lary.26193
   CHARLES NC, 1981, AM J OPHTHALMOL, V92, P691, DOI 10.1016/S0002-9394(14)74663-X
   Chourmouzi D, 2014, INSIGHTS IMAGING, V5, P387, DOI 10.1007/s13244-014-0328-2
   Devi BI, 2001, CHILD NERV SYST, V17, P567
   Donato J, 2015, BLOOD, V126, P494, DOI 10.1182/blood-2015-02-626788
   FOGELSON MH, 1980, NEUROLOGY, V30, P669, DOI 10.1212/WNL.30.6.669
   Frassanito P, 2009, CHILD NERV SYST, V25, P7, DOI 10.1007/s00381-008-0711-8
   Galgano MA, 2016, CUREUS, V8, DOI 10.7759/cureus.510
   Garg A, 2004, J NEUROSURG, V100, P525, DOI 10.3171/ped.2004.100.5.0525
   GLEW WB, 1977, ANN OPHTHALMOL, V9, P139
   Golash A, 1998, BRIT J NEUROSURG, V12, P59, DOI 10.1080/02688699845564
   Gottfried ON, 2003, J NEUROSURG, V99, P416, DOI 10.3171/jns.2003.99.2.0416
   Hamada H, 2008, J NEUROS-PEDIATR, V1, P244, DOI 10.3171/PED/2008/1/3/244
   He JT, 2018, CHILD NERV SYST, V34, P149, DOI 10.1007/s00381-017-3549-0
   Hill JD, 2012, CHILD NERV SYST, V28, P327, DOI 10.1007/s00381-011-1643-2
   Hwang SL, 1998, J FORMOS MED ASSOC, V97, P784
   Kapoor A, 2015, CHILD NERV SYST, V31, P1617, DOI 10.1007/s00381-015-2749-8
   Kato K, 2011, NEUROL MED-CHIR, V51, P82, DOI 10.2176/nmc.51.82
   Kim MS, 2011, J KOREAN NEUROSURG S, V49, P363, DOI 10.3340/jkns.2011.49.6.363
   Kleijwegt M, 2016, OTOL NEUROTOL, V37, P1411, DOI 10.1097/MAO.0000000000001169
   Kumar A, 2010, NEUROL INDIA, V58, P172, DOI 10.4103/0028-3886.73775
   Lee CS, 2009, CHILD NERV SYST, V25, P125, DOI 10.1007/s00381-008-0678-5
   Leung SY, 1997, AM J SURG PATHOL, V21, P941, DOI 10.1097/00000478-199708000-00009
   Li HM, 2008, J CHIN MED ASSOC, V71, P587, DOI 10.1016/S1726-4901(08)70175-8
   Lieu AS, 1999, J FORMOS MED ASSOC, V98, P365
   LONES MA, 1991, ACTA NEUROPATHOL, V81, P688, DOI 10.1007/BF00296382
   Lyons MK, 2007, CLIN NEUROL NEUROSUR, V109, P76, DOI 10.1016/j.clineuro.2006.03.002
   Matsumoto Katsumi, 1997, Neurologia Medico-Chirurgica, V37, P849, DOI 10.2176/nmc.37.849
   Matsumoto Y, 2018, WORLD NEUROSURG, V116, P155, DOI 10.1016/j.wneu.2018.05.107
   MAUERSBERGER W, 1977, NEUROPADIATRIE, V8, P443, DOI 10.1055/s-0028-1091539
   Mesiwala AH, 2001, PEDIATR NEUROSURG, V34, P235, DOI 10.1159/000056028
   Oka F, 2007, NEUROL MED-CHIR, V47, P219, DOI 10.2176/nmc.47.219
   Ostrom QT, 2015, NEURO-ONCOLOGY, V17, P1, DOI 10.1093/neuonc/nov189
   Prasad GL, 2019, NEUROSURG REV, V42, P97, DOI 10.1007/s10143-017-0915-z
   Ramdurg SR, 2016, J PEDIATR NEUROSCI, V11, P249, DOI 10.4103/1817-1745.193366
   Sekula RF, 2008, CLIN NEUROPATHOL, V27, P396
   Shibahara I, 2009, BRAIN TUMOR PATHOL, V26, P1, DOI 10.1007/s10014-008-0243-7
   Shibao S, 2012, BRAIN TUMOR PATHOL, V29, P96, DOI 10.1007/s10014-011-0068-7
   Sie M, 2010, NEUROPATH APPL NEURO, V36, P636, DOI 10.1111/j.1365-2990.2010.01113.x
   SORENSON EJ, 1995, J NEUROL NEUROSUR PS, V58, P761, DOI 10.1136/jnnp.58.6.761
   Tabouret E, 2013, B CANCER, V100, P57, DOI 10.1684/bdc.2012.1681
   Taraszewska A, 2005, FOLIA NEUROPATHOL, V43, P172
   Turel MK, 2016, J PEDIATR NEUROSCI, V11, P170, DOI 10.4103/1817-1745.193375
   van Ouwerkerk WJR, 1998, CHILD NERV SYST, V14, P742, DOI 10.1007/s003810050308
   VINCENT FM, 1980, NEUROLOGY, V30, P91, DOI 10.1212/WNL.30.1.91
   Wang Z, 2016, J CLIN NEUROSCI, V33, P217, DOI 10.1016/j.jocn.2016.03.033
   White JB, 2008, J NEUROSURG, V108, P223, DOI 10.3171/JNS/2008/108/2/0223
   Wilson MP, 2016, J NEUROSURG-PEDIATR, V17, P446, DOI 10.3171/2015.10.PEDS1580
NR 53
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 328
EP 338
DI 10.1016/j.wneu.2018.12.032
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400158
PM 30579034
DA 2020-05-12
ER

PT J
AU Katsuhiro, T
   Fujimaro, I
   Satoru, T
   Tomoyuki, K
   Shinichi, S
   Hidenori, S
AF Katsuhiro, Tanaka
   Fujimaro, Ishida
   Satoru, Tanioka
   Tomoyuki, Kishimoto
   Shinichi, Shimosaka
   Hidenori, Suzuki
TI Transient Aggravation of Hypopituitarism After Parent Artery Occlusion
   with Low-Flow Bypass for Unruptured Giant Cavernous Carotid Aneurysm
SO WORLD NEUROSURGERY
LA English
DT Article
DE Bypass surgery; Hormone replacement therapy; Hypopituitarism; Unruptured
   cavernous carotid aneurysm
ID INTRASELLAR ANEURYSM; PANHYPOPITUITARISM
AB BACKGROUND: Hypopituitarism is not well known after the treatment of a cavernous carotid aneurysm extending to the sellar region by the parent artery occlusion and bypass surgery.
   CASE DESCRIPTION: A 60-year-old female presented with a 2-year-old progressive visual disturbance. The patient had no pituitary hormone-related symptoms or signs, but elevated prolactin and decreased free thyroxin levels are shown on blood examination. Neuroimages revealed a right giant partially thrombosed cavernous carotid aneurysm compressing the sella turcica markedly. The aneurysm was treated by the right cervical internal carotid artery ligation with the right superficial temporal artery-middle cerebral artery double anastomoses. The patient had headache, general fatigue, chilling, and hypoactivity on postoperative day 6, when aneurysmal mass effects were transiently increased on neuroimages, associated with hypocortisolism and hyponatremia. Hydrocortisone administration improved the symptoms and was tapered off at 8 months post surgery, as the aneurysm shrank and pituitary hormone values were normalized except for prolactin.
   CONCLUSION: Hypopituitarism should be taken into consideration even after the parent artery occlusion with bypass surgery for a giant carotid aneurysm compressing the sella turcica.
C1 [Katsuhiro, Tanaka; Fujimaro, Ishida; Satoru, Tanioka; Shinichi, Shimosaka] Mie Univ, Grad Sch Med, Dept Neurosurg, Tsu, Mie, Japan.
   [Tomoyuki, Kishimoto; Hidenori, Suzuki] Mie Univ, Grad Sch Med, NHO Mie Chuo Med Ctr, Tsu, Mie, Japan.
RP Katsuhiro, T (reprint author), Mie Univ, Grad Sch Med, Dept Neurosurg, Tsu, Mie, Japan.
EM tk_0303_ns@yahoo.com
CR Ding D, 2014, BRIT J NEUROSURG, V28, P290, DOI 10.3109/02688697.2013.829559
   FERNANDEZREAL JM, 1994, CLIN INVESTIGATOR, V72, P302
   Gondim J, 2004, ARQ NEURO-PSIQUIAT, V62, P158, DOI 10.1590/S0004-282X2004000100029
   Gungor A, 2015, CASE REP MED, DOI 10.1155/2015/536191
   Hall J, 2015, BRIT J NEUROSURG, V29, P303, DOI 10.3109/02688697.2014.969681
   Heshmati HM, 2001, MAYO CLIN PROC, V76, P789
   Ono Hideaki, 2017, Surg Neurol Int, V8, P180, DOI 10.4103/sni.sni_178_17
   RIEDEL M, 1986, ACTA ENDOCRINOL-COP, V113, P196, DOI 10.1530/acta.0.1130196
   Sato K, 2014, J CEREBR BLOOD F MET, V34, P136, DOI 10.1038/jcbfm.2013.176
   Schneider HJ, 2007, LANCET, V369, P1461, DOI 10.1016/S0140-6736(07)60673-4
   Tan LA, 2014, BMJ CASE REP, V2014
   Tungaria A, 2011, ACTA NEUROCHIR, V153, P1129, DOI 10.1007/s00701-010-0931-z
   van Rooij WJ, 2005, AM J NEURORADIOL, V26, P175
   VERBALIS JG, 1982, NEUROSURGERY, V10, P604, DOI 10.1227/00006123-198205000-00011
NR 14
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 339
EP 342
DI 10.1016/j.wneu.2018.12.020
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400159
PM 30579016
DA 2020-05-12
ER

PT J
AU Golden, N
   Asih, MW
AF Golden, Nyoman
   Asih, Made Widhi
TI Traumatic Subacute Spinal Subdural Hematoma Concomitant with Symptomatic
   Cranial Subdural Hematoma: Possible Mechanism
SO WORLD NEUROSURGERY
LA English
DT Article
DE Concomitant; Cranial subdural hematoma; Gravity; Spinal decompression;
   Spinal subdural hematoma
ID SPACE; CONCURRENT; LUMBAR; ORIGIN
AB BACKGROUND: Spinal subdural hematoma (SDH) concomitant with cranial SDH is extremely rare. Although some theories have been proposed, the pathophysiology underlying this condition remains unclear. We present a case of traumatic subacute spinal SDH followed by symptomatic subacute cranial SDH.
   CASE DESCRIPTION: A 56-year-old woman was admitted with severe back pain 2 weeks after sustaining a minor head injury. The pain was worse with walking or standing and was relieved a little bit by sitting. There was no clinical evidence of back injury. There was no neurologic deficit. Magnetic resonance imaging of the spine showed subacute spinal SDH from T12 to S1. Owing to progressive worsening of back pain, bilateral laminectomy of L1-S1 and drainage of subacute spinal SDH were performed. The pain was completely relieved after surgery. On postoperative day 4, the patient was noted to be unconscious with Glasgow Coma Scale score of 10 (E2V3M5). Computed tomography scan of the head showed subacute bilateral cranial SDH. Burr hole drainage was performed. The patient experienced a complete recovery.
   CONCLUSIONS: This case suggests the possibility that spinal SDH can develop as a result of cranial SDH migration to the most dependent spinal subdural space. The physician should be aware of the possibility of symptomatic cranial SDH developing following spinal SDH evacuation.
C1 [Golden, Nyoman] Udayana Univ, Sanglah Gen Hosp, Kasih Ibu Gen Hosp, Dept Neurosurg,Sch Med, Bali, Indonesia.
   [Asih, Made Widhi] Udayana Univ, Sanglah Gen Hosp, Kasih Ibu Gen Hosp, Dept Radiol,Sch Med, Bali, Indonesia.
RP Golden, N (reprint author), Udayana Univ, Sanglah Gen Hosp, Kasih Ibu Gen Hosp, Dept Neurosurg,Sch Med, Bali, Indonesia.
EM nyoman_golden@yahoo.com
CR Bortolotti C, 2004, J NEUROSURG, V100, P372, DOI 10.3171/spi.2004.100.4.0372
   Hagihara N, 2010, NEUROL MED-CHIR, V50, P333, DOI 10.2176/nmc.50.333
   Ichinose D, 2018, NEUROL MED-CHIR, V58, P178, DOI 10.2176/nmc.cr.2017-0177
   Jain V, 2008, SINGAP MED J, V49, pE53
   Ji GY, 2013, J KOREAN NEUROSURG S, V54, P515, DOI 10.3340/jkns.2013.54.6.515
   Jibu KJ, 2012, J NEUROSCI RURAL PRA, V3, P97, DOI 10.4103/0976-3147.91977
   KHOSLA VK, 1985, J NEUROSURG, V63, P636, DOI 10.3171/jns.1985.63.4.0636
   Kim Hyun Gon, 2014, Korean J Neurotrauma, V10, P146, DOI 10.13004/kjnt.2014.10.2.146
   Kokubo R, 2014, J NEUROSURG-SPINE, V20, P157, DOI 10.3171/2013.10.SPINE13346
   Kwon O Ik, 2015, Korean J Spine, V12, P207, DOI 10.14245/kjs.2015.12.3.207
   Lin JC, 2014, J EMERG MED, V47, P552, DOI 10.1016/j.jemermed.2014.06.030
   Matsumoto H, 2016, WORLD NEUROSURG, V90, DOI 10.1016/j.wneu.2016.03.020
   Moon W, 2013, J KOREAN NEUROSURG S, V54, P68, DOI 10.3340/jkns.2013.54.1.68
   Nagashima H, 2010, BRIT J NEUROSURG, V24, P537, DOI 10.3109/02688691003656119
   Reina MA, 2002, ANESTH ANALG, V94, P991
   Sari A, 2006, J NEURORADIOLOGY, V33, P67, DOI 10.1016/S0150-9861(06)77231-5
   SMITH GB, 1984, ANAESTHESIA, V39, P355, DOI 10.1111/j.1365-2044.1984.tb07277.x
   Treister DS, 2014, J RADIOL CASE REP, V1, P1
   Wang US, 2012, J KOREAN NEUROSURG S, V51, P237, DOI 10.3340/jkns.2012.51.4.237
   Wong ST, 2009, SURG NEUROL, V71, P99, DOI 10.1016/j.surneu.2007.06.079
   Yamaguchi S, 2005, NEUROL MED-CHIR, V45, P645, DOI 10.2176/nmc.45.645
NR 21
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 343
EP 347
DI 10.1016/j.wneu.2018.12.053
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400160
PM 30590215
DA 2020-05-12
ER

PT J
AU Dayyani, M
   Zabihyan, S
AF Dayyani, Mojtaba
   Zabihyan, Samira
TI Giant Tarlov Cyst of Infancy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Abdominal cyst; Infancy; Perineural cyst; Tarlov cyst
ID PERINEURIAL; PREVALENCE
AB We report an 8-month-old female infant with complaints of irritability and recent inability to sit in a stable position. On physical examination, a palpable mass in the left upper quadrant of her abdomen was evident. Sonography and magnetic resonance imaging showed a giant cyst, consisting of 2 communicating compartments: dorsal and ventrolateral. The dorsal part compressed the conus medullaris, and the ventrolateral part compressed the left kidney.
   Partial cyst wall resection and imbrication for the dorsal pouch were done, and diagnosis of Tarlov cyst was confirmed via the visualization of the endocystic nerve root during surgery.
   Familiarizing physicians with this unusual presentation of Tarlov cyst may help them in early recognition of this lesion, and subsequent surgery might be considered to prevent clinical sequela. To our knowledge, a lumbar Tarlov cyst presenting as a giant abdominal cyst in an infant has not been reported in the English-language literature.
C1 [Dayyani, Mojtaba; Zabihyan, Samira] Mashhad Univ Med Sci, Fac Med, Dept Neurosurg, Ghaem Teaching Hosp, Mashhad, Razavi Khorasan, Iran.
   [Zabihyan, Samira] Mashhad Univ Med Sci, Metab Syndrome Res Ctr, Mashhad, Razavi Khorasan, Iran.
RP Zabihyan, S (reprint author), Mashhad Univ Med Sci, Fac Med, Dept Neurosurg, Ghaem Teaching Hosp, Mashhad, Razavi Khorasan, Iran.; Zabihyan, S (reprint author), Mashhad Univ Med Sci, Metab Syndrome Res Ctr, Mashhad, Razavi Khorasan, Iran.
EM zabihyan@yahoo.com
RI Dayyani, Mojtaba/AAB-1733-2019
OI Dayyani, Mojtaba/0000-0002-1802-0662; Zabihyan,
   Samira/0000-0003-0742-6664
CR Elsawaf A, 2016, EUR SPINE J, V25, P3385, DOI 10.1007/s00586-016-4584-3
   Klekamp J, 2017, NEUROSURGERY, V81, P29, DOI 10.1093/neuros/nyx049
   Kuhn FP, 2017, J NEURORADIOLOGY, V44, P38, DOI 10.1016/j.neurad.2016.09.006
   Lucantoni C, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11221
   PAULSEN RD, 1994, AM J NEURORADIOL, V15, P293
   Ramadorai Uma, 2014, Evid Based Spine Care J, V5, P95, DOI 10.1055/s-0034-1386753
   TARLOV IM, 1970, J NEUROL NEUROSUR PS, V33, P833, DOI 10.1136/jnnp.33.6.833
   Voyadzis JM, 2001, J NEUROSURG, V95, P25, DOI 10.3171/spi.2001.95.1.0025
   Wang BC, 2018, WORLD NEUROSURG, V110, P79, DOI 10.1016/j.wneu.2017.10.135
   Wootton-Gorges SL, 2005, PEDIATR RADIOL, V35, P1277, DOI 10.1007/s00247-005-1559-7
NR 10
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 348
EP 350
DI 10.1016/j.wneu.2018.12.009
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400161
PM 30576828
DA 2020-05-12
ER

PT J
AU Cuoco, JA
   Rogers, CM
   Busch, CM
   Benko, MJ
   Apfel, LS
   Elias, Z
AF Cuoco, Joshua A.
   Rogers, Cara M.
   Busch, Christopher M.
   Benko, Michael J.
   Apfel, Lisa S.
   Elias, Zev
TI Postexercise Death Due to Hemorrhagic Colloid Cyst of Third Ventricle:
   Case Report and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Colloid cyst; Endoscopy; Headache; Hydrocephalus; Sudden death; Third
   ventricle
ID 3RD VENTRICLE; ACUTE DETERIORATION; NATURAL-HISTORY; SUDDEN-DEATH
AB BACKGROUND: Colloid cysts of the third ventricle are rare, slow-growing lesions of neuroepithelial origin. Although histopathologically benign, third ventricular colloid cysts are a well-known cause of sudden, unexpected coma and death. Several theories have been proposed to describe the rare, sudden onset of severe symptomatology and rapid clinical decline due to colloid cysts. Moreover, there is currently no clear consensus regarding the most suitable neurosurgical technique or the most effective approach for resection, nor do guidelines or standardized clinical indications exist to recommend observation versus intervention and/or resection in the asymptomatic patient. To highlight this conundrum, we present a clinical case of a hemorrhagic colloid cyst that resulted in fatality and discuss the relevant literature.
   CASE DESCRIPTION: A 21-year-old male presented to an outside hospital with an acute onset of a severe headache, nausea, and vomiting, which started while jogging. A few hours later, he precipitously declined into a comatose state. Radiographic imaging demonstrated a hemorrhagic third ventricular colloid cyst causing acute obstructive hydrocephalus, severe increased intracranial pressure, and downward herniation. He was then transferred to our institution for neurosurgical intervention. Despite aggressive cerebrospinal fluid drainage and medical management, he was declared brain dead several days later.
   CONCLUSIONS: To our knowledge, this is the only case report to describe sudden-onset coma and death due to a hemorrhagic third ventricular colloid cyst occurring after exercising. We review the literature on fatal colloid cysts emphasizing the proposed mechanisms of sudden death and current neurosurgical management in both asymptomatic and symptomatic patients.
C1 [Cuoco, Joshua A.; Rogers, Cara M.; Busch, Christopher M.; Benko, Michael J.; Apfel, Lisa S.; Elias, Zev] Carilion Clin, Sect Neurosurg, Roanoke, VA 24013 USA.
   [Cuoco, Joshua A.; Rogers, Cara M.; Busch, Christopher M.; Benko, Michael J.; Apfel, Lisa S.; Elias, Zev] Virginia Tech, Carilion Sch Med, Roanoke, VA 23606 USA.
   [Cuoco, Joshua A.; Rogers, Cara M.; Busch, Christopher M.; Benko, Michael J.; Apfel, Lisa S.; Elias, Zev] Virginia Tech, Sch Neurosci, Blacksburg, VA 24061 USA.
   [Cuoco, Joshua A.; Rogers, Cara M.; Busch, Christopher M.; Benko, Michael J.; Apfel, Lisa S.; Elias, Zev] Edward Via Coll Osteopath Med, Blacksburg, VA 24060 USA.
RP Cuoco, JA (reprint author), Carilion Clin, Sect Neurosurg, Roanoke, VA 24013 USA.; Cuoco, JA (reprint author), Virginia Tech, Carilion Sch Med, Roanoke, VA 23606 USA.; Cuoco, JA (reprint author), Virginia Tech, Sch Neurosci, Blacksburg, VA 24061 USA.; Cuoco, JA (reprint author), Edward Via Coll Osteopath Med, Blacksburg, VA 24060 USA.
EM jacuoco@carilionclinic.org
CR Al-Hashel J, 2015, CASE REP NEUROL MED, DOI 10.1155/2015/180404
   Beaumont TL, 2016, J NEUROSURG, V125, P1420, DOI 10.3171/2015.11.JNS151396
   Buttner A, 1997, INT J LEGAL MED, V110, P260, DOI 10.1007/s004140050082
   Connolly ID, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00259
   Decq P, 2013, WORLD NEUROSURG, V80, P498, DOI 10.1016/j.wneu.2012.10.034
   DIMAIO SM, 1980, AM J FOREN MED PATH, V1, P29, DOI 10.1097/00000433-198003000-00007
   Diyora Batuk, 2013, Asian J Neurosurg, V8, P162, DOI 10.4103/1793-5482.121689
   Gaab MR, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2014.08.016
   Hadjipanayis CG, 2010, NEUROSURGERY, V67, P197, DOI 10.1227/01.NEU.0000370602.15820.E4
   Hamer PCD, 2002, J NEUROSURG, V96, P1041, DOI 10.3171/jns.2002.96.6.1041
   Hamlat A, 2004, MED HYPOTHESES, V63, P1014, DOI 10.1016/j.mehy.2004.04.020
   Lagman C, 2017, WORLD NEUROSURG, V107, P409, DOI 10.1016/j.wneu.2017.07.183
   LEESTMA JE, 1981, J FORENSIC SCI, V26, P486
   Mamourian AC, 1998, AM J NEURORADIOL, V19, P875
   NELSON ERLAND, 1957, JOUR AVIATION MED, V28, P356
   Pollock BE, 1999, J NEUROSURG, V91, P364, DOI 10.3171/jns.1999.91.3.0364
   Rahmouni K, 2016, HYPERTENSION, V67, P1064, DOI 10.1161/HYPERTENSIONAHA.115.06425
   RYDER JW, 1986, J NEUROSURG, V64, P216, DOI 10.3171/jns.1986.64.2.0216
   Shaktawat Sameer S, 2006, World J Surg Oncol, V4, P47, DOI 10.1186/1477-7819-4-47
   Sheikh AB, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2014.06.024
   Singh H, 2018, J CLIN NEUROSCI, V54, P88, DOI 10.1016/j.jocn.2018.06.006
   Sudha D, 2016, INT J MED RES HEALTH, V5, P8
   TORREY J, 1983, MED SCI LAW, V23, P114, DOI 10.1177/002580248302300211
   Turillazzi E, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-144
   Wallmann H, 1858, VIRCHOWS ARCH, V14, P385
NR 25
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 351
EP 356
DI 10.1016/j.wneu.2018.12.057
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400162
PM 30590211
DA 2020-05-12
ER

PT J
AU Richardson, AM
   Armstrong, VL
   Gernsback, JE
   Gultekin, SH
   Komotar, RJ
AF Richardson, Angela M.
   Armstrong, Valerie L.
   Gernsback, Joanna E.
   Gultekin, Sakir H.
   Komotar, Ricardo J.
TI Central Neurocytoma: Rare Presentation in Fourth Ventricle and Review of
   Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Case report; Central neurocytoma; Fourth ventricle; Neurocytoma;
   Neurosurgery
ID DIAGNOSIS; TUMORS
AB Central neurocytomas are rare tumors, typically found in the third ventricle. We present the unusual case of a fourth ventricular central neurocytoma in a 70-year-old female presenting with imbalance and headaches, with an enhancing fourth ventricular mass on imaging. We examine the details of her clinical presentation, imaging characteristics, histopathologic analysis, and post-operative course. We performed a critical literature review of fourth ventricular central neurocytoma, identifying 6 previously reported cases. In contrast to our patient, the majority of these cases were in young males. The 2 females with fourth ventricular neurocytoma developed it at a much later age (mean 63.5 years) than their male counterparts (mean 22.8 years; P = 0.005). Despite being a rare cause for a fourth ventricular lesion, given the appropriate clinical context and radiographic findings, this should remain part of the differential diagnosis.
C1 [Richardson, Angela M.; Gernsback, Joanna E.; Komotar, Ricardo J.] Univ Miami, Dept Neurosurg, Miami, FL 33146 USA.
   [Armstrong, Valerie L.] Univ Miami, Miller Sch Med, Miami, FL 33136 USA.
   [Gultekin, Sakir H.] Univ Miami, Dept Pathol, Miami, FL USA.
RP Richardson, AM (reprint author), Univ Miami, Dept Neurosurg, Miami, FL 33146 USA.
EM angmrichardson@gmail.com
CR Bonney PA, 2015, NEUROSURG CLIN N AM, V26, P21, DOI 10.1016/j.nec.2014.09.001
   Chen HH, 2012, J CLIN NEUROSCI, V19, P849, DOI 10.1016/j.jocn.2011.06.038
   Chen MC, 2011, STEREOT FUNCT NEUROS, V89, P185, DOI 10.1159/000326780
   Chiba K, 2014, CHILD NERV SYST, V30, P351, DOI 10.1007/s00381-013-2216-3
   Cook DJ, 2004, CAN J NEUROL SCI, V31, P558, DOI 10.1017/S0317167100003814
   Cultrera F, 2005, J Neurosurg Sci, V49, P125
   Dutta SW, 2018, J CLIN NEUROSCI, V53, P106, DOI 10.1016/j.jocn.2018.04.015
   Gallina P, 2005, ACTA NEUROCHIR, V147, P1193, DOI 10.1007/s00701-005-0585-4
   HASSOUN J, 1993, BRAIN PATHOL, V3, P297, DOI 10.1111/j.1750-3639.1993.tb00756.x
   Hsu PW, 2002, NEUROSURGERY, V50, P1365, DOI 10.1097/00006123-200206000-00031
   Jain D, 2012, CLIN NEUROL NEUROSUR, V114, P182, DOI 10.1016/j.clineuro.2011.10.008
   Kaur G, 2013, J CLIN NEUROSCI, V20, P89, DOI 10.1016/j.jocn.2012.05.025
   Koperek O, 2004, ACTA NEUROPATHOL, V108, P24, DOI 10.1007/s00401-004-0856-9
   KUBOTA T, 1991, ACTA NEUROPATHOL, V81, P418, DOI 10.1007/BF00293463
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Mozes P, 2014, PATHOL ONCOL RES, V20, P319, DOI 10.1007/s12253-013-9697-y
   Patel DM, 2013, J CLIN NEUROSCI, V20, P1193, DOI 10.1016/j.jocn.2013.01.001
   Shih RY, 2016, NEUROIMAG CLIN N AM, V26, P493, DOI 10.1016/j.nic.2016.06.003
   Sim FJ, 2006, J NEUROSCI, V26, P12544, DOI 10.1523/JNEUROSCI.0829-06.2006
   Soylemezoglu F, 1997, J NEUROPATH EXP NEUR, V56, P551
   Soylemezoglu F, 2003, PATHOL RES PRACT, V199, P463, DOI 10.1078/0344-0338-00446
   TOWNSEND JJ, 1986, ACTA NEUROPATHOL, V71, P167, DOI 10.1007/BF00687981
   Vasiljevic A, 2012, AM J SURG PATHOL, V36, P220, DOI 10.1097/PAS.0b013e31823b8232
   VINORES SA, 1984, ARCH PATHOL LAB MED, V108, P536
   Wang MM, 2018, WORLD NEUROSURG, V109, pE59, DOI 10.1016/j.wneu.2017.09.103
   Warmuth-Metz M, 1999, J NEUROSURG, V91, P506, DOI 10.3171/jns.1999.91.3.0506
   Wong J, 2006, BRIT J NEUROSURG, V20, P57, DOI 10.1080/02688690600598463
NR 27
TC 2
Z9 2
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 357
EP 361
DI 10.1016/j.wneu.2018.12.021
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400163
PM 30579012
DA 2020-05-12
ER

PT J
AU Aciduman, A
   Ilgili, O
   Askit, C
   Tuzcu, K
AF Aciduman, Ahmet
   Ilgili, Onder
   Askit, Cagatay
   Tuzcu, Kemal
TI Did Ibn Zuhr (Avenzoar) Postulate Before Vesalius That Liquid Collects
   in Ventricles in the Hydrocephalus?
SO WORLD NEUROSURGERY
LA English
DT Review
DE Al-TaysIr fI al-Muda wat wa al-TadbIr; Avenzoar; History of medicine;
   History of neurosurgery; Hydrocephalus; Ibn Zuhr; Liber Teisir
ID TRANSLATIONS; TREATISE
AB OBJECTIVE: This study aimed to present and evaluate the part of Avenzoar's Liber Teisir that pertains to hydrocephalus. Avenzoar was an Andalusian physician prominent in the history of medicine because of the broadness of his observations and original methods. His most important work is recognized to be the Al-Taysir fi al-Mudawat wa al-Tadbir (On Preventive Regimen and Treatment), and its Latin version, Alteisir scilicet regiminis et medelae, which was in use for centuries in Europe.
   METHODS: The Arabic (Rabat, Morocco, in 1991) and Latin (Venice, Italy, in 1530) versions of Avenzoar's work were perused, relevant sections were separately translated into English, and both translations were then compared. An English version was prepared and is given in our results.
   RESULTS: The location of liquid collection was described as the anterior ventricles of the brain and around the brain.
   CONCLUSIONS: Avenzoar might have noted one of the earliest records on the clinical state called idiopathic adult hydrocephalus and postulated liquid collection in the ventricles of the brain in hydrocephalus before Vesalius.
C1 [Aciduman, Ahmet] Ankara Univ, Fac Med, Dept Hist Med & Eth, Ankara, Turkey.
   [Askit, Cagatay] Ankara Univ, Fac Languages Hist & Geog, Dept Ancient Languages & Cultures, Subdept Latin Language & Literature, Ankara, Turkey.
   [Tuzcu, Kemal] Ankara Univ, Fac Languages Hist & Geog, Dept Eastern Languages & Literatures, Subdept Arab Language & Literature, Ankara, Turkey.
   [Ilgili, Onder] Hacettepe Univ, Fac Med, Dept Hist Med & Eth, Ankara, Turkey.
RP Aciduman, A (reprint author), Ankara Univ, Fac Med, Dept Hist Med & Eth, Ankara, Turkey.
EM aciduman@medicine.ankara.edu.tr
RI Ilgili, Onder/AAA-3316-2019
OI Ilgili, Onder/0000-0002-3239-5516
CR Abbas  Haly, 1492, LIBER MED QUI DICITU
   Abdel-Halim RE, 2007, SAUDI MED J, V28, P323
   Abdel-Halim RE, 2005, SAUDI MED J, V26, P1333
   Abinzoar  Abhomeron, 1530, COLLIGET AVER, p2r
   Acar F, 2005, NEUROSURGERY, V56, P861, DOI 10.1227/01.NEU.0000156791.97198.58
   Aciduman A., 2006, Cocuk Sagligi ve Hastaliklari Dergisi, V49, P169
   Aciduman A, 2007, J NEUROSURG, V106, P513, DOI 10.3171/ped.2007.106.6.513
   Aciduman A, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2013.07.077
   Aciduman A, 2009, J NEUROS-PEDIATR, V3, P161, DOI 10.3171/2008.12.PEDS08201
   Albright AL, 1994, PRINCIPLES NEUROSURG
   [Anonymous], 1608, AVICENNAE ARABUM MED
   Aschoff A, 1999, NEUROSURG REV, V22, P67, DOI 10.1007/s101430050035
   Averrois, 1530, COLLIGET AVER, p45r
   Baas JH, 1889, OUTLINES HIST MED ME
   Ben Rusd Abu Al-Walid, 2005, AL KULLIYAT FI AL TI
   Bostock J, 1835, SKETCH HIST MED ITS
   CASTIGLIONI A., 1958, HIST MED
   De Koning P, 1903, TROIS TRATIES ANATOM
   Doerner F, 1826, HYDROCEPHALO CHRONIC
   Elias EA, 1962, ELIAS MODERN DICT
   Galen, 1968, USEFULNESS PARTS BOD, VI
   Galen, 1976, AFFECTED PARTS
   Galen, 1956, ANATOMICAL PROCEDURE
   Galeni  Claudii, 1822, OPERA OMNIA, VIII
   Galeni  Claudii, 1824, OPERA OMNIA, VVIII
   Garrison FH, 1929, INTRO HIST MED MED C
   Gonzales M, 1986, COLLINS GEM DICT
   Grunert P, 2007, MINIM INVAS NEUROSUR, V50, P253, DOI 10.1055/s-2007-991178
   Hakim S, 1965, J Neurol Sci, V2, P307, DOI 10.1016/0022-510X(65)90016-X
   Hamilton W, 1831, HIST MED SURG ANATOM, V1
   Ibn Zuhr Anees MA., 2008, ENCY HIST SCI TECHNO, V1, P1125
   Lascaratos JG, 2004, NEUROSURGERY, V55, P214, DOI 10.1227/01.NEU.0000126883.25501.E3
   Maomethi Abubetri Rhazae, 1544, OB USUM EXPERI ENTIA
   Missios S, 2014, J NEUROSURG, V120, P244, DOI 10.3171/2013.8.JNS13550
   Missios Symeon, 2007, Neurosurg Focus, V23, pE11
   Missori P, 2010, BRAIN, V133, P1836, DOI 10.1093/brain/awq014
   Moir D.M., 1831, OUTLINES ANCIENT HIS
   NEUBURGER M, 1910, HIST MED, V1
   Park R, 1898, EPITOME HIST MED
   PORMANN PE, 2007, MEDIEVAL ISLAMIC MED
   RADBILL SX, 1971, AM J DIS CHILD, V122, P369, DOI 10.1001/archpedi.1971.02110050039001
   Rocca J, 1997, J Hist Neurosci, V6, P227
   Rocca Julius, 2003, Stud Anc Med, V26, P1
   Sina Abu Ali Ibn, 1593, KITAB AL QANUN FI AL
   Steinschneider M, 1900, JQR, V12, P602
   Temkin O., 1962, DUMBARTON OAKS PAPER, V16, P95
   Temkin O, 1962, DUMBARTON OAKS PAPER, V16, P97
   TORACK RM, 1982, ARCH NEUROL-CHICAGO, V39, P197, DOI 10.1001/archneur.1982.00510160003001
   Von Staden H., 1989, HEROPHILUS ART MED E
   Zuhr Abu Marwan Abd al-Malik Ibn, KITAB AL TAYSIR FI A
NR 50
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 363
EP 370
DI 10.1016/j.wneu.2018.11.103
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400164
PM 30472286
DA 2020-05-12
ER

PT J
AU Wen, R
   Shi, YF
   Gao, Y
   Xu, YY
   Xiong, BT
   Li, DH
   Gong, FL
   Wang, W
AF Wen, Rong
   Shi, Yifeng
   Gao, Yuan
   Xu, Yangyang
   Xiong, Botao
   Li, Denghui
   Gong, Feilong
   Wang, Wei
TI The Efficacy of Gamma Knife Radiosurgery for Cavernous Malformations: A
   Meta-Analysis and Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Cavernous malformations; CMs; Gamma knife radiosurgery; GKRS;
   Re-hemorrhage rate
ID BRAIN-STEM; STEREOTACTIC RADIOSURGERY; HEMORRHAGE RISK; MANAGEMENT;
   SURGERY; MICROSURGERY; EXPERIENCE; REDUCTION; HISTORY; SINUS
AB OBJECTIVE: This meta-analysis is to evaluate the clinical efficacy of gamma knife radiosurgery (GKRS) for treating cavernous malformations.
   METHODS: PubMed, Ovid Embase, and Ovid Medline electronic databases were searched. The primary outcome is hemorrhage rate and this meta-analysis is performed.
   RESULTS: Nine studies are included in this meta-analysis. The overall risk ratio (RR) of hemorrhage rate of pre-GKRS and post-GKRS is 6.08 (95% confidence interval [CI], 5.04-7.35). The overall RR is 3.03 (95% CI, 2.65-4.11) between the hemorrhage rate of pre-GKRS and the first 2 years postradiosurgery, and the overall RR is 12.13 (95% CI, 1.73-85.07) comparing pre-GKRS with 2 years after GKRS. There is no significant difference of the hemorrhage rate between the first 2 years postradiosurgery and 2 years after GKRS (RR [2.81; 95% CI, 0.20-13.42). The neurologic deficiency is the most common radiosurgery-related complication.
   CONCLUSIONS: Patients with cerebral cavernous malformations, especially ones that were deep seated and surgically inaccessible, seem to benefit from GKRS owing to a reduction of annual hemorrhage rate in the first 2 years and 2 years after, despite several cases that suffer from negative side effects of radiation.
C1 [Wen, Rong; Shi, Yifeng; Gao, Yuan; Xu, Yangyang; Xiong, Botao; Li, Denghui; Gong, Feilong; Wang, Wei] Sichuan Univ, Dept Neurosurg, West China Hosp, Chengdu, Sichuan, Peoples R China.
RP Wang, W (reprint author), Sichuan Univ, Dept Neurosurg, West China Hosp, Chengdu, Sichuan, Peoples R China.
EM wcnsww@163.com
CR Aboukais R, 2016, STEREOT FUNCT NEUROS, V94, P397, DOI 10.1159/000452844
   Almefty KK, 2015, WORLD NEUROSURG, V83, P317, DOI 10.1016/j.wneu.2014.03.019
   Amin-Hanjani S, 1998, NEUROSURGERY, V42, P1229, DOI 10.1097/00006123-199806000-00013
   Consales A, 2010, NEUROL SCI, V31, P117, DOI 10.1007/s10072-009-0157-0
   Cornelius JF, 2016, WORLD NEUROSURG, V95, P315, DOI 10.1016/j.wneu.2016.08.014
   Ding D, 2015, ACTA NEUROCHIR, V157, P49, DOI 10.1007/s00701-014-2262-y
   Ferroli P, 2005, NEUROSURGERY, V56, P1203, DOI 10.1227/01.NEU.0000159644.04757.45
   Frischer JM, 2014, WORLD NEUROSURG, V81, P520, DOI 10.1016/j.wneu.2014.01.004
   Gross BA, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.6.FOCUS10144
   Hasegawa T, 2002, NEUROSURGERY, V50, P1190, DOI 10.1097/00006123-200206000-00003
   Hugelshofer M, 2011, J NEUROSURG-PEDIATR, V8, P522, DOI 10.3171/2011.8.PEDS09164
   Karlsson B, 1998, J NEUROSURG, V88, P293, DOI 10.3171/jns.1998.88.2.0293
   Kida Yoshihisa, 2015, Surg Neurol Int, V6, pS249, DOI 10.4103/2152-7806.157071
   Kim BS, 2014, CLIN NEUROL NEUROSUR, V126, P110, DOI 10.1016/j.clineuro.2014.08.028
   KONDZIOLKA D, 1995, J NEUROSURG, V83, P825, DOI 10.3171/jns.1995.83.5.0825
   KONDZIOLKA D, 1995, J NEUROSURG, V83, P820, DOI 10.3171/jns.1995.83.5.0820
   Lanzino G, 2007, CAVERNOUS MALFORMATI, V75, P124
   Lee CC, 2012, J NEUROSURG, V117, P164, DOI 10.3171/2012.8.GKS121066
   Lee SH, 2014, ACTA NEUROCHIR, V156, P1937, DOI 10.1007/s00701-014-2155-0
   Li D, 2014, J NEUROSURG, V121, P32, DOI 10.3171/2014.3.JNS132537
   Liao CL, 2017, ACTA NEUROCHIR SUPPL, V124, P195, DOI 10.1007/978-3-319-39546-3_30
   Liscak R, 2000, MINIM INVAS NEUROSUR, V43, P201, DOI 10.1055/s-2000-11378
   Liu HB, 2016, CLIN NEUROL NEUROSUR, V151, P55, DOI 10.1016/j.clineuro.2016.09.018
   Lopez-Serrano R, 2017, STEREOT FUNCT NEUROS, V95, P369, DOI 10.1159/000480664
   Lunsford LD, 2010, J NEUROSURG, V113, P23, DOI 10.3171/2010.1.JNS081626
   Mitchell P, 2000, BRIT J NEUROSURG, V14, P96
   Monaco EA, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.7.FOCUS10151
   Nagy G, 2010, J NEUROSURG, V113, P691, DOI 10.3171/2010.3.JNS091156
   Nicola A, 2009, CAVERNOUS MALFORMATI, V45, P81
   Niranjan A, 2013, PROG NEUROL SURG, V27, P1, DOI 10.1159/000341608
   Nishimura F, 2018, WORLD NEUROSURG, V112, P1, DOI 10.1016/j.wneu.2018.01.016
   Park SH, 2013, WORLD NEUROSURG, V80, pE261, DOI 10.1016/j.wneu.2012.09.013
   Sawarkar DP, 2017, CHILD NERV SYST, V33, P1525, DOI 10.1007/s00381-017-3429-7
   Schwyzer L, 2017, NEUROCHIRURGIE, V63, P320, DOI 10.1016/j.neuchi.2017.05.001
   Sengoz M, 2017, TURK NEUROSURG
   Shah A, 2017, CLIN NEUROL NEUROSUR, V154, P49, DOI 10.1016/j.clineuro.2017.01.007
   Shin SS, 2015, J NEUROSURG, V123, P938, DOI 10.3171/2014.10.JNS14499
   Tian KB, 2017, J NEUROSURG, V127, P480, DOI 10.3171/2016.8.JNS16934
   Toprak MK, 2017, J NEUROL SCI, V381, P545, DOI 10.1016/j.jns.2017.08.3743
   Wadley J, 2017, BRIT J NEUROSURG, V31, P129
   WEIL S, 1990, J NEUROSURG, V72, pA336
   Yin YH, 2013, J CLIN NEUROSCI, V20, P128, DOI 10.1016/j.jocn.2012.01.050
NR 42
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 371
EP 377
DI 10.1016/j.wneu.2018.12.046
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400165
PM 30583131
DA 2020-05-12
ER

PT J
AU Attiah, M
   Tucker, AM
   Perez-Rosendahl, M
   Niu, TY
   Nagasawa, DT
   Kodrat, E
   Martin, NA
   Nelson, S
AF Attiah, Mark
   Tucker, Alexander M.
   Perez-Rosendahl, Mari
   Niu, Tianyi
   Nagasawa, Daniel T.
   Kodrat, Evelina
   Martin, Neil A.
   Nelson, Scott
TI Epithelioid Osteoblastoma of the Temporal Bone: A Case Report
SO WORLD NEUROSURGERY
LA English
DT Article
DE Epithelioid; Meningioma; Osteoblastoma; Skull tumor
ID AGGRESSIVE OSTEOBLASTOMA; BENIGN OSTEOBLASTOMA; OSTEOID OSTEOMA; TUMOR
AB BACKGROUND: Epithelioid osteoblastoma of the cranium is extremely rare and can mimic other etiologies on radiographic imaging, pathology, and symptomatology.
   CASE DESCRIPTION: An 18-year-old male patient had a 3-week history of a palpable left temporal mass. Magnetic resonance imaging revealed a large, extra-axial, hypervascular mass in the left temporal bone, with bony erosion and intracranial extension. The patient underwent surgical near gross-total resection of the mass. Initial frozen microscopic examination of the tumor was inconclusive. The postoperative course was uneventful, and the patient was discharged a few days later. Final pathology confirmed the diagnosis of epithelioid osteoblastoma.
   CONCLUSIONS: Epithelioid osteoblastoma of the skull base is exceedingly rare but should be included in the differential diagnoses of all extra axial tumors. Preoperative radiographic clues are limited, and final diagnosis relies solely on accurate pathologic examination. A diagnosis of epithelioid osteoblastoma should be considered for all cranial bone-based tumors, as an incorrect diagnosis of another radiographic and histologic mimic could lead to the patient receiving unnecessary and harmful neoadjuvant/adjuvant chemotherapy or radiotherapy.
C1 [Attiah, Mark; Tucker, Alexander M.; Niu, Tianyi; Nagasawa, Daniel T.; Martin, Neil A.] Univ Calif Los Angeles, Dept Neurosurg, Los Angeles, CA USA.
   [Perez-Rosendahl, Mari; Kodrat, Evelina; Nelson, Scott] Univ Calif Los Angeles, Dept Pathol, Los Angeles, CA 90024 USA.
RP Nelson, S (reprint author), Univ Calif Los Angeles, Dept Pathol, Los Angeles, CA 90024 USA.
EM sdnelson@mednet.ucla.edu
CR ADLER M, 1990, J OTOLARYNGOL, V19, P307
   Berberoglu S, 1997, MED PEDIATR ONCOL, V28, P304, DOI 10.1002/(SICI)1096-911X(199704)28:4<304::AID-MPO11>3.0.CO;2-C
   Boriani S, 2012, EUR SPINE J, V21, P2003, DOI 10.1007/s00586-012-2395-8
   CAMITTA B, 1991, CANCER-AM CANCER SOC, V68, P999, DOI 10.1002/1097-0142(19910901)68:5<999::AID-CNCR2820680515>3.0.CO;2-Z
   Dixit R, 2016, BRAZ J OTORHINOLAR, V84, P119
   Dorfman H D, 1984, Semin Diagn Pathol, V1, P215
   Filippi RZ, 2007, AM J SURG PATHOL, V31, P1265
   Jacques L, 2017, CUREUS, V9, DOI 10.7759/cureus.1733
   Jain M, 2013, INDIAN J PATHOL MICR, V56, P169, DOI 10.4103/0377-4929.118684
   KROON HM, 1990, RADIOLOGY, V175, P783, DOI 10.1148/radiology.175.3.2343130
   Kukwa W, 2010, ONCOL LETT, V1, P367, DOI 10.3892/ol_00000065
   LICHTENSTEIN L, 1956, CANCER, V9, P1044, DOI 10.1002/1097-0142(195609/10)9:5<1044::AID-CNCR2820090523>3.0.CO;2-O
   LOIZAGA JM, 1993, PATHOL RES PRACT, V189, P33, DOI 10.1016/S0344-0338(11)80114-7
   Lu ZH, 2013, CLIN IMAG, V37, P386, DOI 10.1016/j.clinimag.2012.05.017
   Lucas DR, 2010, ARCH PATHOL LAB MED, V134, P1460, DOI 10.1043/2010-0201-CR.1
   LUCAS DR, 1994, HUM PATHOL, V25, P117, DOI 10.1016/0046-8177(94)90267-4
   Lypka MA, 2008, INT J ORAL MAX SURG, V37, P675, DOI 10.1016/j.ijom.2008.01.013
   Meli GA, 2008, NEURORADIOL J, V21, P71, DOI 10.1177/197140090802100109
   MITCHELL ML, 1986, SKELETAL RADIOL, V15, P213, DOI 10.1007/BF00354063
   Mohanty S, 2014, J CRANIO MAXILL SURG, V42, P1207, DOI 10.1016/j.jcms.2014.02.010
   Pelargos PE, 2015, J CLIN NEUROSCI, V22, P445, DOI 10.1016/j.jocn.2014.10.002
   PITLYK PJ, 1981, SURG NEUROL, V15, P355, DOI 10.1016/0090-3019(81)90168-3
   POTTER C, 1983, AM J OTOL, V4, P318
   SUNDARESAN N, 1985, J NEUROSURG, V63, P562, DOI 10.3171/jns.1985.63.4.0562
   Vigneswaran N, 2001, PATHOL RES PRACT, V197, P569, DOI 10.1016/S0344-0338(04)70129-6
NR 25
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 378
EP 382
DI 10.1016/j.wneu.2018.11.209
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400166
PM 30521959
DA 2020-05-12
ER

PT J
AU Zhao, H
   Tang, DZ
   Zhu, J
   Zhang, X
   Tang, YD
   Li, ST
AF Zhao, Hua
   Tang, Ding-zhong
   Zhu, Jin
   Zhang, Xin
   Tang, Yin-da
   Li, Shi-ting
TI Diffuse Large B Cell Lymphoma Presented as Trigeminal Neuralgia: 2 Cases
   Reported and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Biopsy; Malignant lymphoma; Neuropathic pain
ID MALIGNANT-LYMPHOMA; REGION
AB BACKGROUND: Extraaxial lymphoma involving the trigeminal nerve, an uncommon condition that presents as a trigeminal schwannoma, resulted in misdiagnosis and a flawed surgical strategy. We report 2 cases: a primary lymphoma of the Meckel cave and a metastasis lymphoma in the prepontine cistern arising from the supraclavicular lymph node.
   CASE DESCRIPTION: The first patient presented with a 3-month history of persistent, sharp facial pain across the area innervated by the V2 nerve. She was misdiagnosed with primary trigeminal neuralgia and underwent microvascular decompression. Intraoperatively, the trigeminal nerve was swollen to a large extent and surrounded by red granuloma-like tissue. The second case was a 75-year-old woman; she had a history of a malignant lymphoma of the supraclavicular lymph node and presented with right facial pain. Magnetic resonance imaging revealed that the cisternal portion of the right trigeminal nerve was swollen. A specimen was taken from the 2 patients, and histopathologic examinations revealed a diffuse large B cell lymphoma.
   CONCLUSIONS: The diagnosis of a malignant lymphoma should be considered for lesions in the trigeminal region. Extracting a specimen for biopsy is the most suitable surgical strategy. Our report indicates that postoperative adjuvant chemotherapy for malignant lymphomas is essential.
C1 [Zhao, Hua; Zhu, Jin; Zhang, Xin; Tang, Yin-da; Li, Shi-ting] Shanghai Jiao Tong Univ, Dept Neurosurg, Xinhua Hosp, Sch Med, Shanghai, Peoples R China.
   [Tang, Ding-zhong] Shanghai Sixth Peoples Hosp, Dept Neurol, Jinshan Branch, Shanghai, Peoples R China.
RP Li, ST (reprint author), Shanghai Jiao Tong Univ, Dept Neurosurg, Xinhua Hosp, Sch Med, Shanghai, Peoples R China.
EM lishiting@xinhuamed.com.cn
CR Adhikari N, 2018, CHILD NERV SYST, V34, P1777, DOI 10.1007/s00381-018-3807-9
   Akaza Miho, 2009, Rinsho Shinkeigaku, V49, P432
   Ang JWJ, 2015, J CLIN NEUROSCI, V22, P1188, DOI 10.1016/j.jocn.2015.01.018
   Aziz KMA, 1999, NEUROSURGERY, V44, P859, DOI 10.1097/00006123-199904000-00096
   Bower K, 2018, CASE REP ONCOL MED, DOI 10.1155/2018/5869135
   Bulsara KR, 2005, J NEURO-ONCOL, V73, P279, DOI 10.1007/s11060-004-5951-1
   Chiavazza C, 2018, BIOMED RES INT, DOI 10.1155/2018/3606970
   DeAngelis LM, 2015, NAT REV NEUROL, V11, P314, DOI 10.1038/nrneurol.2015.64
   HAN MH, 1993, J COMPUT ASSIST TOMO, V17, P567, DOI 10.1097/00004728-199307000-00009
   Iplikcioglu AC, 2006, BRIT J NEUROSURG, V20, P103, DOI 10.1080/02688690600682630
   Jack AS, 2014, CAN J NEUROL SCI, V41, P103, DOI 10.1017/S0317167100016371
   Kinoshita M, 2003, SURG NEUROL, V60, P343, DOI 10.1016/S0090-3019(02)01046-7
   Nakatomi H, 1996, SURG NEUROL, V46, P272, DOI 10.1016/0090-3019(96)00159-0
   Ogiwara T, 2015, WORLD NEUROSURG, V84, DOI 10.1016/j.wneu.2015.03.019
   Perera C, 2014, BRIT J NEUROSURG, V28, P278, DOI 10.3109/02688697.2013.835374
   Tanaka T, 2014, NEUROL MED-CHIR, V54, P677, DOI 10.2176/nmc.cr2013-0095
NR 16
TC 2
Z9 2
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 383
EP 389
DI 10.1016/j.wneu.2018.11.217
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400167
PM 30528527
DA 2020-05-12
ER

PT J
AU Belykh, E
   Carotenuto, A
   Kalinin, AA
   Akshulakov, SK
   Kerimbayev, T
   Borisov, VE
   Allyev, MA
   Nakaji, P
   Preul, MC
   Byvaltsev, VA
AF Belykh, Evgenii
   Carotenuto, Alessandro
   Kalinin, Andrey A.
   Akshulakov, Serik K.
   Kerimbayev, Talgat
   Borisov, Vladislav E.
   Allyev, Marat A.
   Nakaji, Peter
   Preul, Mark C.
   Byvaltsev, Vadim A.
TI Surgical Protocol for Infections, Nonhealing Wound Prophylaxis, and
   Analgesia: Development and Implementation for Posterior Spinal Fusions
SO WORLD NEUROSURGERY
LA English
DT Article
DE Analgesia; Antibiotic prophylaxis; Complications; Lumbar spine; Spinal
   surgery; Surgical safety checklist; Surgical wound infections; World
   Health Organization
ID LOCAL VANCOMYCIN POWDER; STAPHYLOCOCCUS-AUREUS INFECTIONS;
   HEALTH-ORGANIZATION CHECKLIST; SAFETY CHECKLIST; SITE INFECTIONS;
   PRACTICE GUIDELINES; LUMBAR LAMINECTOMY; POSTOPERATIVE PAIN; DISEASES
   SOCIETY; SURGERY
AB OBJECTIVE: To analyze the effects of a surgical protocol for infections, nonhealing wound prophylaxis, and analgesia among patients who underwent posterior spinal fusion at a single tertiary-care neurosurgical center.
   METHODS: This prospective study was conducted in the neurosurgery department of a tertiary-care neurosurgical center and compared a control group of patients who had posterior spinal fusion within 3 months before implementation of a surgical protocol with a study group of patients enrolled within 1 year after protocol implementation. The protocol included a surgical safety checklist, control of modifiable risks associated with surgical site infection, administration of intrawound vancomycin and local analgesia, and standard closure. Postoperative pain, demand for analgesics, and postoperative surgical site infections were assessed among patients before and after the introduction of the protocol.
   RESULTS: The control group (n = 35; 30 women; median age, 40 years [interquartile range, 31-54 years]) experienced a higher-than-predicted rate of minor surgical infections and nonhealing wounds (12 patients; 34%). In the study group (n = 113; 74 women; median age, 45 years [interquartile range, 37-54 years]), 11 patients (10%) had minor surgical infections and nonhealing wounds. Introduction of the protocol was associated with a 24% absolute risk reduction for minor surgical site infection and a significant decrease in pain on postoperative days 1 and 2 (P < 0.01 for both). Interpersonal communication improved among specialists involved in patient management.
   CONCLUSIONS: The protocol was effective in reducing postoperative pain and the rate of surgical site infection among patients with posterior spinal surgeries.
C1 [Belykh, Evgenii; Kalinin, Andrey A.; Borisov, Vladislav E.; Allyev, Marat A.; Byvaltsev, Vadim A.] Irkutsk State Med Univ, Dept Neurosurg, Irkutsk, Russia.
   [Belykh, Evgenii; Carotenuto, Alessandro; Nakaji, Peter; Preul, Mark C.] St Josephs Hosp, Barrow Neurol Inst, Dept Neurosurg, Phoenix, AZ USA.
   [Akshulakov, Serik K.; Kerimbayev, Talgat; Byvaltsev, Vadim A.] Natl Ctr Neurosurg, Astana, Kazakhstan.
RP Byvaltsev, VA (reprint author), Irkutsk State Med Univ, Dept Neurosurg, Irkutsk, Russia.; Byvaltsev, VA (reprint author), Natl Ctr Neurosurg, Astana, Kazakhstan.
EM Neuropub@barrowneuro.org
RI Akshulakov, Serik/N-7474-2019; Kerimbayev, Talgat/Y-2409-2018; Belykh,
   Evgenii/O-8279-2017
OI Belykh, Evgenii/0000-0003-2060-5739; Kalinin, Andrei/0000-0002-6059-4344
CR Anderson DJ, 2014, INFECT CONT HOSP EP, V35, P605, DOI [10.1086/676022, 10.1017/S0899823X00193869]
   Aveling EL, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003039
   Bagnall N. M., 2009, SURGERY, V27, P426, DOI DOI 10.1016/J.MPSUR.2009.08.007
   Bergs J, 2014, BRIT J SURG, V101, P150, DOI 10.1002/bjs.9381
   Biskup N, 2016, ANN PLAS SURG, V76, P550, DOI 10.1097/SAP.0000000000000427
   Brown MD, 2004, SPINE, V29, P1066, DOI 10.1097/00007632-200405150-00003
   Byval'tsev VA, 2011, ZH NEVROL PSIKHIATR, V111, P51
   Cherian MN, 1997, SURG NEUROL, V47, P120, DOI 10.1016/S0090-3019(96)00255-8
   Cherian MN, 1997, SURG NEUROL, V47, P122
   Chiang HY, 2014, SPINE J, V14, P1367, DOI 10.1016/j.spinee.2014.02.002
   Chiang HY, 2014, SPINE J, V14, P397, DOI 10.1016/j.spinee.2013.10.012
   Chotai S, 2017, NEUROSURGERY, V80, P746, DOI 10.1093/neuros/nyw097
   Clifton R, 2008, INT ORTHOP, V32, P723, DOI 10.1007/s00264-007-0420-z
   de Lissovoy G, 2009, AM J INFECT CONTROL, V37, P387, DOI 10.1016/j.ajic.2008.12.010
   de Oliveira AC, 2007, REV LAT-AM ENFERM, V15, P992, DOI 10.1590/S0104-11692007000500017
   Ersayli DT, 2006, SPINE, V31, P2221, DOI 10.1097/01.brs.0000232801.19965.a0
   Fourcade A, 2012, BMJ QUAL SAF, V21, P191, DOI 10.1136/bmjqs-2011-000094
   Ghobrial GM, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.7.FOCUS15258
   Ghobrial GM, 2014, SPINE, V39, P550, DOI 10.1097/BRS.0000000000000241
   Godil SS, 2013, J NEUROSURG-SPINE, V19, P331, DOI 10.3171/2013.6.SPINE121105
   Greze J, 2017, EUR SPINE J, V26, P832, DOI 10.1007/s00586-016-4428-1
   Gurbet A, 2008, EUR SPINE J, V17, P1237, DOI 10.1007/s00586-008-0676-z
   Gurbet A, 2014, TURK NEUROSURG, V24, P48, DOI 10.5137/1019-5149.JTN.8431-13.0
   Haugen AS, 2015, ANN SURG, V261, P821, DOI 10.1097/SLA.0000000000000716
   Haynes AB, 2009, NEW ENGL J MED, V360, P491, DOI 10.1056/NEJMsa0810119
   Hey HWD, 2017, SPINE, V42, P267, DOI 10.1097/BRS.0000000000001710
   Hill BW, 2014, ACTA NEUROCHIR, V156, P749, DOI 10.1007/s00701-014-2022-z
   Hochberg J, 2009, SURG CLIN N AM, V89, P627, DOI 10.1016/j.suc.2009.03.001
   Ishii M, 2013, GLOB SPINE J, V3, P95, DOI 10.1055/s-0033-1343072
   Jirarattanaphochai K, 2007, SPINE, V32, P609, DOI 10.1097/01.brs.0000257541.91728.a1
   Jonnavithula Nirmala, 2015, Middle East J Anaesthesiol, V23, P193
   Kakimaru H, 2010, J ORTHOP SCI, V15, P305, DOI 10.1007/s00776-010-1464-2
   Kang DG, 2015, SPINE J, V15, P762, DOI 10.1016/j.spinee.2015.01.030
   Kawano T, 2014, J ANESTH, V28, P467, DOI 10.1007/s00540-013-1737-y
   Khan NR, 2014, J NEUROSURG-SPINE, V21, P974, DOI 10.3171/2014.8.SPINE1445
   Kivelev Juri, 2013, Surg Neurol Int, V4, P115, DOI 10.4103/2152-7806.118171
   Klevens RM, 2007, JAMA-J AM MED ASSOC, V298, P1763, DOI 10.1001/jama.298.15.1763
   Kurz A, 1996, NEW ENGL J MED, V334, P1209, DOI 10.1056/NEJM199605093341901
   Lepanluoma M, 2015, J NEUROSURG, V123, P145, DOI 10.3171/2014.12.JNS141077
   Lieber B, 2016, WORLD NEUROSURG, V89, P517, DOI 10.1016/j.wneu.2015.12.085
   Liu C, 2011, CLIN INFECT DIS, V52, P285, DOI 10.1093/cid/cir034
   Pereira PL, 2017, BRIT J NEUROSURG, V31, P10, DOI 10.1080/02688697.2016.1260687
   Martin JR, 2014, SPINE, V39, P177, DOI 10.1097/BRS.0000000000000071
   Moise PA, 2008, J ANTIMICROB CHEMOTH, V61, P85, DOI 10.1093/jac/dkm445
   Oak SN, 2015, J POSTGRAD MED, V61, P92, DOI 10.4103/0022-3859.150450
   Ozyilmaz K, 2012, J NEUROSURG ANESTH, V24, P331, DOI 10.1097/ANA.0b013e3182611a1d
   Pawar AY, 2016, ASIAN SPINE J, V10, P176, DOI 10.4184/asj.2016.10.1.176
   PONS VG, 1993, NEUROSURGERY, V33, P416
   Puffer RC, 2016, SPINE J, V16, P1305, DOI 10.1016/j.spinee.2016.06.013
   Radcliff KE, 2015, SPINE J, V15, P336, DOI 10.1016/j.spinee.2014.09.022
   Ragusa PS, 2016, ORTHOPEDICS, V39, pE307, DOI 10.3928/01477447-20160301-02
   Rahmanian A, 2016, NEUROSURG QUART, V26, P293, DOI [10.1097/WNQ.0000000000000185, DOI 10.1097/WNQ.0000000000000185]
   Roberts FJ, 1998, SPINE, V23, P366, DOI 10.1097/00007632-199802010-00016
   Russ SJ, 2015, ANN SURG, V261, P81, DOI 10.1097/SLA.0000000000000793
   Stevens DL, 2014, CLIN INFECT DIS, V59, pE10, DOI [10.1093/cid/ciu444, 10.1093/cid/ciu296]
   Strom RG, 2013, SPINE, V38, P991, DOI 10.1097/BRS.0b013e318285b219
   Sweet FA, 2011, SPINE, V36, P2084, DOI 10.1097/BRS.0b013e3181ff2cb1
   Swennen C, 2017, ORTHOP TRAUMATOL-SUR, V103, P291, DOI 10.1016/j.otsr.2016.11.012
   TAENZER P, 1986, PAIN, V24, P331, DOI 10.1016/0304-3959(86)90119-3
   Theologis AA, 2014, SPINE, V39, P1875, DOI 10.1097/BRS.0000000000000533
   Tubaki VR, 2013, SPINE, V38, P2149, DOI 10.1097/BRS.0000000000000015
   Wolff S, 2012, ORTHOP TRAUMATOL-SUR, V98, P879, DOI 10.1016/j.otsr.2012.06.016
   Xu B, 2017, EUR SPINE J, V26, P825, DOI 10.1007/s00586-015-3979-x
   Yeramaneni S, 2016, CURR REV MUSCULOSKE, V9, P327, DOI 10.1007/s12178-016-9352-9
NR 64
TC 2
Z9 2
U1 1
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 390
EP +
DI 10.1016/j.wneu.2018.11.135
PG 14
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400168
PM 30481624
DA 2020-05-12
ER

PT J
AU Tumialan, LM
   Madhavan, K
   Godzik, J
   Wang, MY
AF Tumialan, Luis M.
   Madhavan, Karthik
   Godzik, Jakub
   Wang, Michael Y.
TI The History of and Controversy over Kambin's Triangle: A Historical
   Analysis of the Lumbar Transforaminal Corridor for Endoscopic and
   Surgical Approaches
SO WORLD NEUROSURGERY
LA English
DT Review
DE Endoscopic; Fusion; History; Kambin's triangle; Lumbar; Minimally
   invasive; TLIF; Transforaminal
ID INTERBODY FUSION; DISKECTOMY
AB The transforaminal corridor in the lumbar spine allows access to the traversing and exiting nerve roots, the thecal sac, and the intervertebral disc space. Surgeons performing midline and minimally invasive approaches for lumbar interbody fusion access the disc space within the boundaries created by the exiting root of a segment and the traversing root after a complete facetectomy and removal of the pars interarticularis and lamina. Endoscopic surgeons and interventional pain management physicians approach the lumbar segment through a similar corridor, but with the bony anatomy intact. Although the boundaries of the corridor may seem the same, the angle of the trajectory and the bone work between the two differ.
   The overlap between these 2 distinct access corridors has led to an openhanded application of the term Kambin's triangle. Initially described for endoscopic approaches to the lumbar spine for microdiscectomy, this working triangle has been grafted into the transforaminal lumbar interbody fusion literature. Given the similarities between these corridors, it is understandable how the lines of this nomenclature have blurred. The result has been an interchangeable application of the term Kambin's triangle for a variety of procedures in the spine literature. The objective of the current work is to add clarity to the various lumbar transforaminal corridors. The term Kambin's triangle should be limited to percutaneous access to the disc space for endoscopic procedures in the intact spine and should not be applied to transforaminal lumbar interbody fusion after laminectomy and facetectomy. Instead, the term expanded transforaminal corridor should be applied.
C1 [Tumialan, Luis M.; Godzik, Jakub] St Josephs Hosp, Dept Neurosurg, Barrow Neurol Inst, Phoenix, AZ 85013 USA.
   [Madhavan, Karthik; Wang, Michael Y.] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA.
RP Tumialan, LM (reprint author), St Josephs Hosp, Dept Neurosurg, Barrow Neurol Inst, Phoenix, AZ 85013 USA.
EM neuropub@barrowneuro.org
CR Caspar W, 1977, NEW SURG PROCEDURE L
   Chang PY, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.2.FocusVid.1694
   Hardenbrook M, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2015.10.FOCUS15389
   HARMS J, 1982, Z ORTHOP GRENZGEB, V120, P343, DOI 10.1055/s-2008-1051624
   Harms J G, 1998, Oper Orthop Traumatol, V10, P90, DOI 10.1007/s00064-006-0112-7
   Hoshide R, 2016, CUREUS, V8, DOI 10.7759/cureus.475
   Hurday Y, 2017, EUR SPINE J, V26, P635, DOI 10.1007/s00586-016-4454-z
   Jacquot F, 2013, INT ORTHOP, V37, P1507, DOI 10.1007/s00264-013-1905-6
   KAMBIN P, 1989, CLIN ORTHOP RELAT R, P24
   KAMBIN P, 1986, CLIN ORTHOP RELAT R, P37
   KAMBIN P, 1987, CLIN ORTHOP RELAT R, P145
   KAMBIN P, 1989, JAMA-J AM MED ASSOC, V262, P1776
   KAMBIN P, 1991, MT SINAI J MED, V58, P159
   KAMBIN P, 1983, CLIN ORTHOP RELAT R, P127
   KAMBIN P, 1988, SPINE, V13, P671
   Kambin P., 1988, SURG ROUNDS ORTHOP, P31
   Kim CW, 2016, WORLD NEUROSURG, V90, P228, DOI 10.1016/j.wneu.2016.02.075
   Madhavan K, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2015.11.FOCUS15511
   Ozer AF, 2017, WORLD NEUROSURG, V100, P498, DOI 10.1016/j.wneu.2017.01.057
   Park JW, 2011, ANN REHABIL MED-ARM, V35, P833, DOI 10.5535/arm.2011.35.6.833
   Rhee JM, 2013, OPERATIVE TECHNIQUES
   SCHAFFER JL, 1991, J BONE JOINT SURG AM, V73A, P822, DOI 10.2106/00004623-199173060-00005
   Vogelsang JP, 2008, ZBL NEUROCHIR, V69, P35, DOI 10.1055/s-2007-992134
   WILLIAMS R W, 1978, Spine, V3, P175
   Yasargil M, 1977, MICROSURGICAL OPERAT
NR 25
TC 4
Z9 5
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 402
EP 408
DI 10.1016/j.wneu.2018.10.221
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400169
PM 30415041
DA 2020-05-12
ER

PT J
AU Bokhari, R
   You, E
   Zeiler, FA
   Bakhaidar, M
   Bajunaid, K
   Lasry, O
   Baeesa, S
   Marcoux, J
AF Bokhari, Rakan
   You, Eunice
   Zeiler, Frederick A.
   Bakhaidar, Mohamad
   Bajunaid, Khalid
   Lasry, Oliver
   Baeesa, Saleh
   Marcoux, Judith
TI Effect of Intrawound Vancomycin on Surgical Site Infections in Nonspinal
   Neurosurgical Procedures: A Systematic Review and Meta-Analysis
SO WORLD NEUROSURGERY
LA English
DT Review
DE Infection prevention; Intrawound vancomycin; Surgical site infection;
   Topical vancomycin; Vancomycin powder
ID STANDARDIZED PROTOCOL; SHUNT INFECTION; SIGNIFICANT REDUCTION; TOPICAL
   VANCOMYCIN; POWDER; CRANIOTOMY; PROPHYLAXIS; PREVENTION
AB BACKGROUND: Applying vancomycin into the surgical site has been well-described in spinal neurosurgery, with extensive institutional experience and systematic reviews describing its effectiveness in reducing surgical site infections (SSIs). Its use in nonspinal neurosurgical procedures is a logical extension of those findings; however, recent studies have described varying degrees of success. We have summarized the effect of local vancomycin application on SSIs in nonspinal neurosurgical procedures and describe the quality of the supporting evidence.
   METHODS: MEDLINE, Embase, and Google Scholar were searched through June 2018. Information on study design, demographic data, exposure, and outcomes was extracted. The estimates were combined using random-effects models.
   RESULTS: Our search retrieved 9 studies for quantitative analysis. They assessed vancomycin use in craniotomy, cranioplasty, deep brain stimulator-related procedures, and ventriculoperitoneal shunt surgery. Most of the studies had serious methodological shortcomings that introduced confounding. We found an overall beneficial effect on SSI incidence (odds ratio, 0.25; 95% confidence interval, 0.12-0.52), which was seen across all subspecialties, except for cranioplasty. The use of vancomycin did not result in the emergence of resistant infections or in a significant increase in the proportion of infections caused by gram-negative organisms.
   CONCLUSIONS: Vancomycin use in nonspinal neurosurgery is not supported by high-quality evidence, limiting the strength of the conclusions that can be drawn on the topic. Nonetheless, we found an overall favorable effect on SSIs (except in the context of cranioplasty), which should be reproduced in a randomized controlled fashion.
C1 [Bokhari, Rakan; Bakhaidar, Mohamad; Baeesa, Saleh] King Abdulaziz Univ, Div Neurosurg, Dept Surg, Fac Med, Jeddah, Saudi Arabia.
   [Bokhari, Rakan; Bakhaidar, Mohamad; Lasry, Oliver; Marcoux, Judith] McGill Univ, Dept Neurol & Neurosurg, Montreal Neurol Hosp & Inst, Montreal, PQ, Canada.
   [Bokhari, Rakan] Sir Mortimer B Davis Jewish Hosp, Orthopaed Res Lab, Lady Davis Inst Med Res, Montreal, PQ, Canada.
   [You, Eunice] McGill Univ, Montreal, PQ, Canada.
   [Zeiler, Frederick A.] Univ Manitoba, Dept Surg, Rady Fac Hlth Sci, Winnipeg, MB, Canada.
   [Zeiler, Frederick A.] Univ Manitoba, Clinician Investigator Program, Rady Fac Hlth Sci, Winnipeg, MB, Canada.
   [Zeiler, Frederick A.] Univ Cambridge, Div Anaesthesia, Addenbrookes Hosp, Cambridge, England.
   [Bajunaid, Khalid] Univ Jeddah, Div Neurosurg, Dept Surg, Fac Med, Jeddah, Saudi Arabia.
   [Lasry, Oliver] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada.
RP Bokhari, R (reprint author), King Abdulaziz Univ, Div Neurosurg, Dept Surg, Fac Med, Jeddah, Saudi Arabia.; Bokhari, R (reprint author), McGill Univ, Dept Neurol & Neurosurg, Montreal Neurol Hosp & Inst, Montreal, PQ, Canada.; Bokhari, R (reprint author), Sir Mortimer B Davis Jewish Hosp, Orthopaed Res Lab, Lady Davis Inst Med Res, Montreal, PQ, Canada.
EM rfbokhari@kau.edu.sa
RI Bajunaid, Khalid/P-8499-2019; Baeesa, Saleh Salem/G-5519-2011
OI Bajunaid, Khalid/0000-0002-7925-5959; Baeesa, Saleh
   Salem/0000-0002-3053-7912; You, Eunice/0000-0002-0860-3100
FU King Abdulaziz University; Saudi Arabian Cultural Bureau; Canadian
   Institutes of Health Research Vanier Canada Graduate ScholarshipCanadian
   Institutes of Health Research (CIHR)
FX R.B. was supported by a scholarship from King Abdulaziz University and
   the Saudi Arabian Cultural Bureau. O.L. was supported by a Canadian
   Institutes of Health Research Vanier Canada Graduate Scholarship to
   support his doctoral studies. The remaining authors declare that the
   article content was composed in the absence of any commercial or
   financial relationships that could be construed as a potential conflict
   of interest.
CR Abdullah KG, 2015, J NEUROSURG, V123, P1600, DOI 10.3171/2014.12.JNS142092
   Abdullah KG, 2015, J NEUROSURG, V123, pA531
   Abode-Iyamah KO, 2019, J NEUROSURG, V130, P629, DOI 10.3171/2017.9.JNS1780
   Abode-Iyamah KO, 2018, J NEUROSURG, V128, P1241, DOI 10.3171/2016.12.JNS161967
   Appelbaum PC, 2006, CLIN MICROBIOL INFEC, V12, P16, DOI 10.1111/j.1469-0691.2006.01344.x
   Bao Yun, 2016, Zhonghua Wei Zhong Bing Ji Jiu Yi Xue, V28, P169, DOI 10.3760/cma.j.issn.2095-4352.2016.02.016
   Beckman JM, 2015, J NEUROSURG-PEDIATR, V16, P719, DOI 10.3171/2015.4.PEDS14699
   Bennett-Guerrero E, 2010, NEW ENGL J MED, V363, P1038, DOI 10.1056/NEJMoa1000837
   Berrios SI, 2017, JAMA SURG, V152, P784, DOI 10.1001/jamasurg.2017.0904
   Chiang HY, 2014, J NEUROSURG, V120, P509, DOI 10.3171/2013.9.JNS13843
   Chiang HY, 2011, J NEUROSURG, V114, P1746, DOI 10.3171/2011.1.JNS10782
   Chotai S, 2017, NEUROSURGERY, V80, P746, DOI 10.1093/neuros/nyw097
   Desai VR, 2018, J NEUROSURG-PEDIATR, V21, P395, DOI 10.3171/2017.10.PEDS17248
   Eder C, 2016, EUR SPINE J, V25, P1021, DOI 10.1007/s00586-015-3943-9
   Emohare O, 2014, SPINE J, V14, P2710, DOI 10.1016/j.spinee.2014.03.011
   Fu RZ, 2017, BRIT J NEUROSURG, V31, P16, DOI 10.1080/02688697.2016.1229741
   Ghobrial GM, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.7.FOCUS15258
   Goldschmidt E, 2016, J NEUROSURG-SPINE, V25, P665, DOI 10.3171/2016.3.SPINE151491
   Hampl JA, 2003, INFECTION, V31, P109, DOI 10.1007/s15010-002-2113-2
   Higgins JP, 2011, COCHRANE COLLABORATI, DOI DOI 10.1002/9780470712184
   HORAN TC, 1992, INFECT CONT HOSP EP, V13, P606
   Jonokuchi AJ, 2018, CONTEMP CLIN TRIALS, V64, P195, DOI 10.1016/j.cct.2017.10.004
   Kestle JRW, 2016, J NEUROSURG-PEDIATR, V17, P391, DOI 10.3171/2015.8.PEDS15253
   Kestle JRW, 2011, J NEUROSURG-PEDIATR, V8, P22, DOI 10.3171/2011.4.PEDS10551
   Kochanski RB, 2018, OPER NEUROSURG, V15, P584, DOI 10.1093/ons/opx293
   Linzey JR, 2017, NEUROSURGERY, V81, P504, DOI 10.1093/neuros/nyx046
   Mallela AN, 2018, NEUROSURGERY, V83, P761, DOI 10.1093/neuros/nyx559
   Miller JP, 2009, J NEUROSURG, V110, P247, DOI 10.3171/2008.6.17605
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Moussa WMM, 2016, CLIN NEUROL NEUROSUR, V143, P144, DOI 10.1016/j.clineuro.2016.02.034
   O'Keeffe AB, 2012, BRIT J NEUROSURG, V26, P265, DOI 10.3109/02688697.2011.626878
   Pepper J, 2017, J NEUROSURG, V126, P1165, DOI 10.3171/2016.4.JNS152934
   Ragel BT, 2006, J NEUROSURG, V105, P242, DOI 10.3171/jns.2006.105.2.242
   Rasouli JJ, 2016, WORLD NEUROSURG, V95, P9, DOI 10.1016/j.wneu.2016.07.063
   Ravikumar V, 2017, NEUROSURGERY, V80, P754, DOI 10.1093/neuros/nyw127
   Ryan SL, 2014, J NEUROSURG-PEDIATR, V14, P259, DOI 10.3171/2014.5.PEDS1448
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Tennent DJ, 2016, J ORTHOP TRAUMA, V30, P531, DOI 10.1097/BOT.0000000000000617
   van Lindert EJ, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190249
   Wells GA, NEWCASTLE OTTAWA SCA
   Winkler EA, 2016, J NEURO-ONCOL, V130, P341, DOI 10.1007/s11060-016-2198-6
   Zimlichman E, 2013, JAMA INTERN MED, V173, P2039, DOI 10.1001/jamainternmed.2013.9763
NR 42
TC 1
Z9 1
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 409
EP +
DI 10.1016/j.wneu.2018.10.168
PG 16
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400170
PM 30391768
DA 2020-05-12
ER

PT J
AU Cho, SS
   Kim, SE
   Kim, HC
   Kim, WJ
   Jeon, JP
AF Cho, Steve S.
   Kim, Sung-Eun
   Kim, Heung Cheol
   Kim, Won Jin
   Jeon, Jin Pyeong
TI Clazosentan for Aneurysmal Subarachnoid Hemorrhage: An Updated
   Meta-Analysis with Trial Sequential Analysis
SO WORLD NEUROSURGERY
LA English
DT Review
DE Aneurysm; Clazosentan; Subarachnoid hemorrhage
ID CEREBRAL VASOSPASM; DOUBLE-BLIND; RECEPTOR ANTAGONIST; ENDOTHELIN;
   INFARCTION; PREVENTION; OUTCOMES; SURGERY; THERAPY; STROKE
AB OBJECTIVE: Clazosentan, an endothelin receptor antagonist, reduced vasospasm and delayed ischemic neurologic deficit (DIND) but did not improve outcome after subarachnoid hemorrhage (SAH) in clinical trials. However, a lack of dose-dependent analysis and potential overestimation of clazosentan's effect are concerning. We used stratified analysis and trial sequential analysis (TSA) of existing data to investigate the effects of clazosentan on SAH outcome.
   METHODS: Studies from PubMed, Embase, and Cochrane were reviewed for eligibility. Primary outcomes were DIND requiring rescue therapy, all-cause mortality, and vasospasm-related morbidity at 6 weeks. Secondary outcomes were moderate-to-severe angiographic vasospasm, new cerebral infarction, and poor clinical outcome at 3 months. TSA was performed to assess the required information size and the alpha-spending monitoring boundary effect of relative risk (RR) reduction. A stratified analysis of clazosentan dosage was performed.
   RESULTS: Five studies (N = 2317) were included. Clazosentan significantly reduced the risk of DIND requiring rescue therapy (RR, 0.625; 95% confidence interval [CI], 0.462-0.846) and vasospasm (RR, 0.543; 95% CI, 0.464-0.635), but did not significantly affect mortality or vasospasm-related morbidity (RR, 0.775; 95% CI, 0.578-1.039), new cerebral infarction (RR, 0.604; 95% CI, 0.383-0.952), or outcome (RR, 1.131; 95% CI, 0.959-1.334). TSA revealed that the studies were underpowered to evaluate the effects of clazosentan on mortality and vasospasm-associated morbidity. We found 10-15 mg/h of clazosentan administration was associated with lower rates of vasospasm and new cerebral infarctions compared with 5 mg/h.
   CONCLUSIONS: Clazosentan reduced the risk of DIND requiring rescue therapy and moderate-to-severe vasospasm. Further meta-analyses based on individual patient data with different clazosentan doses and more refined outcome measures are necessary to clarify clazosentan's efficacy in improving post-SAH outcome.
C1 [Cho, Steve S.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Kim, Sung-Eun] Seoul Emergency Operat Ctr, Dept Emergency Med, Seoul, South Korea.
   [Kim, Heung Cheol] Dongtan Sacred Heart Hosp, Dept Radiol, Chunchon, South Korea.
   [Kim, Won Jin] Dongtan Sacred Heart Hosp, Dept Anesthesiol & Pain Med, Chunchon, South Korea.
   [Jeon, Jin Pyeong] Hallym Univ, Inst New Frontier Res, Coll Med, Chunchon, South Korea.
   [Jeon, Jin Pyeong] Hallym Univ, Dept Neurosurg, Coll Med, Chunchon, South Korea.
RP Jeon, JP (reprint author), Hallym Univ, Inst New Frontier Res, Coll Med, Chunchon, South Korea.; Jeon, JP (reprint author), Hallym Univ, Dept Neurosurg, Coll Med, Chunchon, South Korea.
EM jjs6553@daum.net
FU Rural Development AdministrationRural Development Administration (RDA)
   [PJ01313901]; Hallym University Research Fund [HURF-2018-23]
FX This research was supported by a BioGreen21 (PJ01313901) grant from the
   Rural Development Administration and Hallym University Research Fund
   (HURF-2018-23).
CR ASANO T, 1989, BIOCHEM BIOPH RES CO, V159, P1345, DOI 10.1016/0006-291X(89)92258-4
   Bellapart J, 2014, NEUROCRIT CARE, V20, P77, DOI 10.1007/s12028-013-9887-1
   Cho YD, 2018, J KOREAN NEUROSURG S, V61, P458, DOI 10.3340/jkns.2017.0202.001
   Crowley RW, 2008, DRUG DISCOV TODAY, V13, P254, DOI 10.1016/j.drudis.2007.11.010
   Crowley RW, 2011, STROKE, V42, P919, DOI 10.1161/STROKEAHA.110.597005
   Dreier JP, 2006, BRAIN, V129, P3224, DOI 10.1093/brain/awl297
   Fergusen S, 2007, NEUROSURGERY, V60, P658, DOI 10.1227/01.NEU.0000255396.23280.31
   Fujii M, 2013, TRANSL STROKE RES, V4, P432, DOI 10.1007/s12975-013-0257-2
   Fujimura M, 2017, CEREBROVASC DIS, V44, P59, DOI 10.1159/000475824
   Guo J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008354.pub2
   Jeon JP, 2018, CHINESE MED J-PEKING, V131, P657, DOI 10.4103/0366-6999.226886
   Li ZQ, 2012, J INT MED RES, V40, P2145, DOI 10.1177/030006051204000612
   Ma JP, 2012, CRIT CARE, V16, DOI 10.1186/cc11686
   Macdonald RL, 2008, STROKE, V39, P3015, DOI 10.1161/STROKEAHA.108.519942
   Macdonald RL, 2007, NAT CLIN PRACT NEURO, V3, P256, DOI 10.1038/ncpneuro0490
   Macdonald RL, 2012, STROKE, V43, P1463, DOI 10.1161/STROKEAHA.111.648980
   Macdonald RL, 2011, LANCET NEUROL, V10, P618, DOI 10.1016/S1474-4422(11)70108-9
   Manoel ALD, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1193-9
   Phan K, 2016, J CLIN NEUROSCI, V30, P15, DOI 10.1016/j.jocn.2016.01.013
   Phan K, 2016, J CLIN NEUROSCI, V29, P38, DOI 10.1016/j.jocn.2015.12.025
   PICKARD JD, 1989, BRIT MED J, V298, P636, DOI 10.1136/bmj.298.6674.636
   Saver JL, 2009, NEUROLOGY, V72, P1310, DOI 10.1212/01.wnl.0000341308.73506.b7
   Shen J, 2013, J NEUROSURG, V119, P180, DOI 10.3171/2013.3.JNS121436
   Suhardja A, 2004, NAT CLIN PRACT CARD, V1, P110, DOI 10.1038/ncpcardio0046
   Thampatty BP, 2011, NEUROCRIT CARE, V15, P19, DOI 10.1007/s12028-011-9508-9
   Vajkoczy P, 2005, J NEUROSURG, V103, P9, DOI 10.3171/jns.2005.103.1.0009
   Vergouwen MDI, 2012, STROKE, V43, P2671, DOI 10.1161/STROKEAHA.112.666693
   Wang HF, 2015, J NEUROL NEUROSUR PS, V86, P135, DOI 10.1136/jnnp-2014-307659
   Wang XJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036663
   Wartenberg KE, 2006, CURR OPIN CRIT CARE, V12, P78, DOI 10.1097/01.ccx.0000216571.80944.65
   Wetterslev J, 2017, BMC MED RES METHODOL, V17, DOI 10.1186/s12874-017-0315-7
NR 31
TC 4
Z9 4
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 418
EP +
DI 10.1016/j.wneu.2018.10.213
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400171
PM 30508597
DA 2020-05-12
ER

PT J
AU Kerezoudis, P
   Watts, CR
   Bydon, M
   Dababneh, AS
   Deyo, CN
   Frye, JM
   Kelley, PC
   Kemp, AM
   Palraj, BV
   Pupillo, GT
AF Kerezoudis, Panagiotis
   Watts, Charles R.
   Bydon, Mohamad
   Dababneh, Ala S.
   Deyo, Christopher N.
   Frye, Judson M.
   Kelley, Parker C.
   Kemp, Anna M.
   Palraj, Bharath V.
   Pupillo, Gregory T.
TI Diagnosis and Treatment of Isolated Cerebral Mucormycosis: Patient-Level
   Data Meta-Analysis and Mayo Clinic Experience
SO WORLD NEUROSURGERY
LA English
DT Review
DE Cerebral mucormycosis; Fungal brain abscess; Fungal intracranial
   abscess; Intracranial mucormycosis; Isolated; Primary
ID CENTRAL-NERVOUS-SYSTEM; PHYCOMYCOSIS MUCORMYCOSIS; INTRACRANIAL
   MUCORMYCOSIS; BRAIN ABSCESSES; BASAL GANGLIA; ZYGOMYCOSIS; INFECTION;
   LEUKEMIA; ASPERGILLOSIS; MALIGNANCIES
AB BACKGROUND: Isolated cerebral mucormycosis is a rare and serious infection associated with intravenous drug abuse.
   METHODS: We performed a comprehensive meta-analysis of cases reported in studies and have included an unreported case from our institution. We searched PubMed/Medline, EMBASE, Scopus, Cochrane Databases, and our institution's electronic medical health records from inception through March 31, 2018. The cases were considered isolated (only affecting the cerebrum, cerebellum, or brainstem) if the absence of other primary sources of infection had been documented. Continuous variables were summarized using the median and interquartile range and categorical variables using frequencies and proportions. The relationships between variables were tested using the Wilcoxon rank sum and Pearson chi(2) tests.
   RESULTS: A total of 130 studies (141 patients) met the eligibility requirements and were screened; 68 patients were included. The median age was 28 years (interquartile range, 24-38); 57% were men. Most patients had a history of intravenous drug abuse (82%), and 20% had positive human immunodeficiency virus findings. The lesion location was mostly supratentorial (91%), especially in the basal ganglia (71.2%). The cultures were positive in 38%, with Rhizopus the most common organism (59%). The mortality rate was 65%. The survivors were significantly more likely to have received amphotericin B (92% vs. 43%; P < 0.001) or to have undergone stereotactic aspiration (58% vs. 25%; P < 0.01).
   CONCLUSIONS: Isolated cerebral mucormycosis has a pooled mortality rate of 65%. The presence of lesions in the basal ganglia, rapidly progressive symptoms, and a history of intravenous drug abuse should raise suspicion for the early initiation of amphotericin B and stereotactic aspiration.
C1 [Kerezoudis, Panagiotis; Watts, Charles R.; Bydon, Mohamad] Mayo Clin, Dept Neurol Surg, Rochester, MN 55905 USA.
   [Dababneh, Ala S.; Palraj, Bharath V.] Mayo Clin, Div Infect Dis, Rochester, MN USA.
   [Deyo, Christopher N.] Mayo Clin Hlth Syst, Franciscan Healthcare, Dept Hosp Med, La Crosse, WI USA.
   [Frye, Judson M.] Mayo Clin Hlth Syst, Franciscan Healthcare, Dept Radiol, La Crosse, WI USA.
   [Kelley, Parker C.] Mayo Clin Hlth Syst, Franciscan Healthcare, Dept Neurosurg, La Crosse, WI USA.
   [Kemp, Anna M.] Mayo Clin Hlth Syst, Franciscan Healthcare, Dept Pathol, La Crosse, WI USA.
   [Dababneh, Ala S.; Palraj, Bharath V.] Mayo Clin Hlth Syst, Franciscan Healthcare, Dept Infect Dis, La Crosse, WI USA.
   [Pupillo, Gregory T.] Mayo Clin Hlth Syst, Franciscan Healthcare, Dept Neurol, La Crosse, WI USA.
RP Watts, CR (reprint author), Mayo Clin, Dept Neurol Surg, Rochester, MN 55905 USA.
EM watts.charles@mayo.edu
RI Watts, Charles R./AAK-9849-2020
OI Watts, Charles R./0000-0002-5011-487X
FU Mayo Clinic Health Systeme-Franciscan Healthcare Foundation; Mayo
   Foundation of Mayo Clinic
FX Funding for the present study was provided in part through a grant from
   Mayo Clinic Health Systeme-Franciscan Healthcare Foundation and the Mayo
   Foundation of Mayo Clinic. This research did not receive any specific
   grant from funding agencies in the public, commercial, or not-for-profit
   sectors. Dr. Watts is a consultant for Medtronic Spine and Biologics.
CR ADELMAN LS, 1969, B NEW YORK ACAD MED, V45, P225
   ADLER CH, 1989, MOVEMENT DISORD, V4, P333, DOI 10.1002/mds.870040407
   Air Ellen L, 2010, Surg Neurol Int, V1, P81, DOI 10.4103/2152-7806.73800
   Al Barbarawi MM, 2014, PEDIATR NEUROSURG, V50, P165, DOI 10.1159/000381750
   BAKER RD, 1948, AM J PATHOL, V24, P716
   BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183
   BAUER H, 1955, AM J MED, V18, P822, DOI 10.1016/0002-9343(55)90194-7
   BELLOT SM, 1982, CLIN NEUROL NEUROSUR, V84, P59, DOI 10.1016/0303-8467(82)90111-1
   Bennett KD, 2015, SCIENCE, V349, DOI 10.1126/science.aab1886
   BERENGUER J, 1990, MED CLIN-BARCELONA, V94, P766
   BETTONI L, 1984, ITAL J NEUROL SCI, V5, P437, DOI 10.1007/BF02042629
   Bialek R, 2013, PATHOLOGE, V34, P511, DOI 10.1007/s00292-013-1831-9
   BICHILE L, 1985, J NEUROL NEUROSUR PS, V48, P1188, DOI 10.1136/jnnp.48.11.1188
   Birchall D, 1999, J NEUROL NEUROSUR PS, V66, P404, DOI 10.1136/jnnp.66.3.404
   Blazquez R, 1996, EUR J CLIN MICROBIOL, V15, P598, DOI 10.1007/BF01709370
   BORLAND DS, 1959, AMA J DIS CHILD, V97, P852, DOI 10.1001/archpedi.1959.02070010854013
   BURROW GN, 1963, JAMA-J AM MED ASSOC, V183, P370, DOI 10.1001/jama.1963.63700050034023a
   CARPENTER DF, 1968, NEUROLOGY, V18, P807, DOI 10.1212/WNL.18.8.807
   Carpenter M, 2007, CLIN INFECT DIS, V4, P1522
   CHMEL H, 1973, AM J MED SCI, V266, P225, DOI 10.1097/00000441-197309000-00009
   Clark D, 2011, NEUROLOGY, V76, pE1, DOI 10.1212/WNL.0b013e318203e92b
   COOK BA, 1989, AM J PEDIAT HEMATOL, V11, P330
   CUADRADO LM, 1988, ARCH NEUROL-CHICAGO, V45, P109, DOI 10.1001/archneur.1988.00520250119032
   Cuellar H, 2007, NEURORADIOL J, V20, P525, DOI 10.1177/197140090702000509
   DEAN DF, 1977, J NEUROSURG, V46, P97, DOI 10.3171/jns.1977.46.1.0097
   Deshpande D H, 1976, Neurol India, V24, P20
   DeWitt J, 2018, CRIT CARE MED, V46, P298, DOI 10.1097/01.ccm.0000528639.60023.b4
   Dhakar MB, 2015, AM J MED, V128, P1296, DOI 10.1016/j.amjmed.2015.08.033
   Dussaule C, 2012, NEUROLOGY, V78, pE93, DOI 10.1212/WNL.0b013e31824e8ed0
   EPSTEIN NE, 1991, SURG NEUROL, V35, P286, DOI 10.1016/0090-3019(91)90006-U
   Ermak D, 2014, J STROKE CEREBROVASC, V23, pE403, DOI 10.1016/j.jstrokecerebrovasdis.2014.02.024
   ESCOBAR A, 1990, J NEUROL NEUROSUR PS, V53, P431, DOI 10.1136/jnnp.53.5.431
   Farid S, 2017, BMJ CASE REP
   Farmakiotis D, 2016, INFECT DIS CLIN N AM, V30, P143, DOI 10.1016/j.idc.2015.10.011
   FONG KM, 1990, AUST NZ J MED, V20, P74, DOI 10.1111/j.1445-5994.1990.tb00377.x
   FOUSHEE S, 1956, N C Med J, V17, P26
   FRIEDMAN AD, 1981, J PEDIATR-US, V99, P413, DOI 10.1016/S0022-3476(81)80331-9
   GAING AA, 1992, MT SINAI J MED, V59, P69
   GALLO RC, 1983, SCIENCE, V220, P865, DOI 10.1126/science.6601823
   GINSBERG F, 1987, AM J NEURORADIOL, V8, P558
   GOLLARD R, 1994, NEUROSURGERY, V34, P174, DOI 10.1097/00006123-199401000-00026
   Grannan BL, 2014, J CLIN NEUROSCI, V21, P1819, DOI 10.1016/j.jocn.2014.01.008
   Greene S, 2005, J LA STATE MED SOC, V157, P140
   Greene Stacy, 2005, J La State Med Soc, V157, P135
   Gregory JE, 1943, B JOHNS HOPKINS HOSP, V73, P405
   GUNSON HH, 1955, ARCH PATHOL, V60, P440
   HAMEROFF SB, 1970, NEUROLOGY, V20, P261, DOI 10.1212/WNL.20.3.261
   Han SR, 2007, J KOREAN NEUROSURG S, V42, P400, DOI 10.3340/jkns.2007.42.5.400
   HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747
   HARRIS JS, 1955, PEDIATRICS, V16, P857
   HOPKINS RJ, 1994, CLIN INFECT DIS, V19, P1133, DOI 10.1093/clinids/19.6.1133
   Ibrahim AS, 2012, CLIN INFECT DIS, V54, pS16, DOI 10.1093/cid/cir865
   IGNELZI RJ, 1975, J NEUROSURG, V42, P593, DOI 10.3171/jns.1975.42.5.0593
   JACKSON J R, 1957, Can Med Assoc J, V76, P130
   Jaitly R, 2000, NEUROLOGIST, V6, P232, DOI 10.1097/00127893-200006040-00005
   JONES PG, 1981, JAMA-J AM MED ASSOC, V246, P2063
   KASANTIKUL V, 1987, SURG NEUROL, V28, P468, DOI 10.1016/0090-3019(87)90232-1
   KEYE JD, 1956, AM J CLIN PATHOL, V26, P1235
   KONTOYIANIS DP, 1994, CLIN INFECT DIS, V18, P925, DOI 10.1093/clinids/18.6.925
   KURREIN F, 1954, J CLIN PATHOL, V7, P141, DOI 10.1136/jcp.7.2.141
   Lackner M, 2014, FUTURE MICROBIOL, V9, P683, DOI 10.2217/fmb.14.23
   LANDAU JW, 1962, J PEDIATR-US, V61, P363, DOI 10.1016/S0022-3476(62)80368-0
   Lanternier F, 2012, CLIN INFECT DIS, V54, pS35, DOI 10.1093/cid/cir880
   Lass-Florl C, 2009, CLIN MICROBIOL INFEC, V15, P60, DOI 10.1111/j.1469-0691.2009.02999.x
   LECOMPTE PM, 1947, AM J PATHOL, V23, P673
   LIE-KIAN-JOE, 1959, AMER JOUR CLIN PATHOL, V32, P62
   Lin TP, 2013, NEUROLOGY, V80, pE73, DOI 10.1212/WNL.0b013e318281cd02
   LONG EL, 1959, AM J MED, V26, P625, DOI 10.1016/0002-9343(59)90283-9
   MAKE BJ, 1983, NEW ENGL J MED, V309, P1171, DOI 10.1056/NEJM198311103091909
   Malik Athar N, 2014, Clin Neurol Neurosurg, V124, P102, DOI 10.1016/j.clineuro.2014.06.022
   MARTIN FP, 1954, J PEDIATR-US, V44, P437, DOI 10.1016/S0022-3476(54)80218-6
   MASUCCI EF, 1982, ARCH NEUROL-CHICAGO, V39, P304, DOI 10.1001/archneur.1982.00510170046013
   MCCALL W, 1957, NEUROLOGY, V7, P290, DOI 10.1212/WNL.7.4.290
   MERRIAM JC, 1957, NEUROLOGY, V7, P510, DOI 10.1212/WNL.7.7.510
   Metellus P, 2008, SURG NEUROL, V69, P510, DOI 10.1016/j.surneu.2007.02.035
   MEYER RD, 1972, ANN INTERN MED, V77, P871, DOI 10.7326/0003-4819-77-6-871
   MICOZZI MS, 1985, J FORENSIC SCI, V30, P504
   MILLER NS, 1988, J CLIN PSYCHIAT, V49, P320
   MURESAN A, 1960, J CLIN PATHOL, V13, P34, DOI 10.1136/jcp.13.1.34
   OLIVERI S, 1988, EUR J EPIDEMIOL, V4, P284, DOI 10.1007/BF00148911
   Pandian JD, 2007, ARCH NEUROL-CHICAGO, V64, P134, DOI 10.1001/archneur.64.1.134
   PARFREY NA, 1986, MEDICINE, V65, P113, DOI 10.1097/00005792-198603000-00004
   Petrikkos G, 2012, CLIN INFECT DIS, V54, pS23, DOI 10.1093/cid/cir866
   PIERCE PF, 1982, JAMA-J AM MED ASSOC, V248, P2881, DOI 10.1001/jama.248.21.2881
   Platauf AP, 1885, VIRCHOWS ARCH PATHOL, V102, P543, DOI [10.1007/BF01932420, DOI 10.1007/BF01932420]
   Prabhu RM, 2004, CLIN MICROBIOL INFEC, V10, P31, DOI 10.1111/j.1470-9465.2004.00843.x
   PRICE DL, 1971, J NEUROL SCI, V14, P359, DOI 10.1016/0022-510X(71)90223-1
   PROCKOP LD, 1967, ARCH NEUROL-CHICAGO, V17, P379, DOI 10.1001/archneur.1967.00470280045005
   RAO VRK, 1978, NEURORADIOLOGY, V15, P291, DOI 10.1007/BF00342923
   REEVES DL, 1965, J NEUROSURG, V23, P82, DOI 10.3171/jns.1965.23.1.0082
   Ribes JA, 2000, CLIN MICROBIOL REV, V13, P236, DOI 10.1128/CMR.13.2.236-301.2000
   RIEFLER J, 1991, MIL MED, V156, P497
   Roden MM, 2005, CLIN INFECT DIS, V41, P634, DOI 10.1086/432579
   RODRIGUEZ E, 1971, NEW YORK STATE J MED, V71, P2879
   Rumboldt Z, 2002, AM J NEURORADIOL, V23, P932
   SANDHYAMANI S, 1981, SURG NEUROL, V15, P431, DOI 10.1016/S0090-3019(81)80030-4
   SHUANGSHOTI S, 1979, J MED ASSOC THAILAND, V62, P146
   SIDDIQI SU, 1994, SOUTHERN MED J, V87, P997, DOI 10.1097/00007611-199410000-00006
   Siegal JA, 2000, MAGN RESON IMAGING, V18, P915, DOI 10.1016/S0730-725X(00)00180-6
   Skiada A, 2013, HAEMATOLOGICA, V98, P492, DOI 10.3324/haematol.2012.065110
   SMITH HW, 1958, ARCHIV OTOLARYNGOL, V68, P715
   STAVE GM, 1989, AM J MED, V86, P115, DOI 10.1016/0002-9343(89)90242-8
   STEVENS KM, 1972, ARCHIV OTOLARYNGOL, V96, P250
   STRAATSMA BR, 1962, LAB INVEST, V11, P963
   STRATEMEIER WP, 1950, ARCH NEURO PSYCHIATR, V63, P179
   Sundaram C, 2005, MYCOSES, V48, P396, DOI 10.1111/j.1439-0507.2005.01167.x
   SWEENEY PJ, 1980, J NEUROSURG, V52, P270, DOI 10.3171/jns.1980.52.2.0270
   TANG LM, 1988, NEUROSURGERY, V23, P108, DOI 10.1097/00006123-198807000-00020
   TAY AGC, 1986, MED J AUSTRALIA, V144, P725, DOI 10.5694/j.1326-5377.1986.tb113716.x
   TERK MR, 1992, MAGN RESON IMAGING, V10, P81, DOI 10.1016/0730-725X(92)90376-B
   Uy Edilfavia Mae, 2011, Conn Med, V75, P273
   VENTURA GJ, 1986, CANCER, V58, P1534, DOI 10.1002/1097-0142(19861001)58:7<1534::AID-CNCR2820580725>3.0.CO;2-0
   Verma A, 2006, J NEUROL SCI, V240, P65, DOI 10.1016/j.jns.2005.09.010
   VONLANTHEN M, 1977, SCHWEIZ MED WSCHR, V107, P1784
   WASSERMAN A, 1961, SOUTHERN MED J, V54, P403, DOI 10.1097/00007611-196104000-00011
   WATSON DF, 1985, ARCH NEUROL-CHICAGO, V42, P922, DOI 10.1001/archneur.1985.04060080108024
   WETLI CV, 1984, J FORENSIC SCI, V29, P260
   WHALEN MJ, 1979, ANN INTERN MED, V91, P655, DOI 10.7326/0003-4819-91-4-655_1
   WILSON WB, 1979, ARCH NEUROL-CHICAGO, V36, P725, DOI 10.1001/archneur.1979.00500470095024
   WOLF A, 1949, J NEUROPATH EXP NEUR, V8, P107
   WOODS KF, 1986, AM J MED, V80, P126
   Zarei M, 2000, EUR J NEUROL, V7, P443, DOI 10.1046/j.1468-1331.2000.00089.x
NR 122
TC 3
Z9 3
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 425
EP +
DI 10.1016/j.wneu.2018.10.218
PG 15
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400172
PM 30415043
DA 2020-05-12
ER

PT J
AU Aguilar-Salinas, P
   Hayward, K
   Santos, R
   Agarwal, V
   Sauvageau, E
   Hanel, RA
   Aldana, PR
AF Aguilar-Salinas, Pedro
   Hayward, Kelsey
   Santos, Roberta
   Agarwal, Vibhuti
   Sauvageau, Eric
   Hanel, Ricardo A.
   Aldana, Philipp R.
TI Surgical Revascularization for Pediatric Patients with Sickle Cell
   Disease and Moyamoya Disease in the Prevention of Ischemic Strokes: A
   Single-Center Case Series and a Systematic Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Cerebral vasculopathy; Moyamoya; Revascularization; Sickle cell disease;
   Stroke
ID INDIVIDUAL PARTICIPANT DATA; TRANSFUSION THERAPY; IRON OVERLOAD;
   CHILDREN; ANEMIA; ENCEPHALODUROARTERIOSYNANGIOSIS; TRIAL; METAANALYSIS;
   VELOCITIES; SURGERY
AB BACKGROUND: This systematic review aims to identify and analyze the available evidence on the safety and efficacy of surgical revascularization for pediatric patients with sickle cell disease (SCD) and moyamoya disease (MMD).
   METHODS: A systematic review was conducted following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. The following databases were searched: PubMed, Ovid MEDLINE, and Scopus. Studies included in the review were original research articles in peer-reviewed journals in which individual participant data were available. The articles were thoroughly examined and compared on study design, outcomes, and results. The authors reviewed their institution's database to identify pediatric patients with SCD and MMD who underwent surgical revascularization and were included in the analysis.
   RESULTS: A total of 53 patients were included and 82 hemispheres were intervened with direct or indirect surgical revascularization. Encephaloduroarteriosynangiosis (EDAS) was the most common procedure performed (42/82; 51.2%) followed by pial synangiosis (31/82; 37.8%). There was 1 intraprocedural complication. The median clinical follow-up was 37 months (interquartile range, 24.1-73.5 months) and during this period, 3 of 52 patients (5.8%) had ischemic strokes. All ischemic strokes occurred within the first 30 days after the surgery and the rate of ischemic stroke-free survival was 94.3% (95% confidence interval, 83.3-98.1). The estimated incidence rate of ischemic stroke was 1.42 events/100 patient-years (95% confidence interval, 0.46-4.4).
   CONCLUSIONS: Our study suggests that surgical revascularization in pediatric patients with SCD and MMD is safe to perform and results in a low rate of future ischemic insults.
C1 [Aguilar-Salinas, Pedro; Santos, Roberta; Sauvageau, Eric; Hanel, Ricardo A.] Baptist Neurol Inst, Lyerly Neurosurg, Jacksonville, FL USA.
   [Hayward, Kelsey; Aldana, Philipp R.] Univ Florida Hlth Jacksonville, Div Pediat Neurosurg, Jacksonville, FL 32209 USA.
   [Agarwal, Vibhuti] Nemours Childrens Specialty Care, Dept Pediat Hematol Oncol, Pensacola, FL USA.
   [Aguilar-Salinas, Pedro] Univ Arizona, Div Neurosurg, Tucson, AZ USA.
RP Aldana, PR (reprint author), Univ Florida Hlth Jacksonville, Div Pediat Neurosurg, Jacksonville, FL 32209 USA.
EM Philipp.Aldana@jax.ufl.edu
RI Aguilar-Salinas, Pedro/AAJ-4444-2020
OI Aguilar-Salinas, Pedro/0000-0002-5268-6548; Santos,
   Roberta/0000-0002-6633-6792
FU Baptist Health Foundation of Jacksonville, Jacksonville, Florida, USA
FX Fund Name: Wolfson Children's Hospital Pediatric Neurovascular
   Endowment. Funder Name: Baptist Health Foundation of Jacksonville,
   Jacksonville, Florida, USA.
CR Adams RJ, 2005, NEW ENGL J MED, V353, P2769
   Adams RJ, 1998, NEW ENGL J MED, V339, P5, DOI 10.1056/NEJM199807023390102
   Alamri A, 2019, BRIT J NEUROSURG, V33, P161, DOI 10.1080/02688697.2017.1339227
   Ballas SK, 2001, SEMIN HEMATOL, V38, P30, DOI 10.1053/shem.2001.20142
   BRODERICK J, 1993, J CHILD NEUROL, V8, P250, DOI 10.1177/088307389300800308
   Castellino SM, 1999, BRIT J HAEMATOL, V104, P189, DOI 10.1046/j.1365-2141.1999.01127.x
   DeBaun MR, 2014, NEW ENGL J MED, V371, P699, DOI 10.1056/NEJMoa1401731
   Debray TPA, 2015, RES SYNTH METHODS, V6, P293, DOI 10.1002/jrsm.1160
   Dobson SR, 2002, BLOOD, V99, P3144, DOI 10.1182/blood.V99.9.3144
   Fryer RH, 2003, PEDIATR NEUROL, V29, P124, DOI 10.1016/S0887-8994(03)00047-X
   Fung LWE, 2005, CHILD NERV SYST, V21, P358, DOI 10.1007/s00381-004-1118-9
   Griessenauer CJ, 2015, J NEUROSURG-PEDIATR, V16, P64, DOI 10.3171/2014.12.PEDS14522
   Hall EM, 2016, PEDIATR BLOOD CANCER, V63, P1431, DOI 10.1002/pbc.26022
   Hankinson TC, 2008, J NEUROSURG-PEDIATR, V1, P211, DOI 10.3171/PED/2008/1/3/211
   Harmatz P, 2000, BLOOD, V96, P76, DOI 10.1182/blood.V96.1.76.013k22_76_79
   Helton KJ, 2014, BLOOD, V124, P891, DOI 10.1182/blood-2013-12-545186
   Houkin K, 2000, ACTA NEUROCHIR, V142, P269, DOI 10.1007/s007010050035
   Kennedy BC, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2013.10.FOCUS13405
   MATSUSHIMA Y, 1984, CHILD BRAIN, V11, P155
   MATSUSHIMA Y, 1981, SURG NEUROL, V15, P313, DOI 10.1016/S0090-3019(81)80017-1
   Ohene-Frempong K, 1998, BLOOD, V91, P288
   Ouzzani M, 2016, SYST REV-LONDON, V5, DOI 10.1186/s13643-016-0384-4
   ROSSE WF, 1990, BLOOD, V76, P1431
   Scothorn DJ, 2002, J PEDIATR-US, V140, P348, DOI 10.1067/mpd.2002.122498
   Smith ER, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.01.FOCUS08307
   Stewart LA, 2015, JAMA-J AM MED ASSOC, V313, P1657, DOI 10.1001/jama.2015.3656
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Strouse JJ, 2009, AM J HEMATOL, V84, P548, DOI 10.1002/ajh.21476
   Tierney JF, 2015, J CLIN EPIDEMIOL, V68, P1325, DOI 10.1016/j.jclinepi.2015.05.024
   Vernet O, 1996, PEDIATR NEUROL, V14, P226, DOI 10.1016/0887-8994(96)00045-8
   Ware RE, 2016, LANCET, V387, P661, DOI 10.1016/S0140-6736(15)01041-7
   Ware RE, 2012, BLOOD, V119, P3925, DOI 10.1182/blood-2011-11-392340
   Ware RE, 2011, PEDIATR BLOOD CANCER, V57, P1011, DOI 10.1002/pbc.23145
   Winstead M, 2017, PEDIATR HEMAT ONCOL, V34, P100, DOI 10.1080/08880018.2017.1313917
   Yang WY, 2017, J NEUROSURG-PEDIATR, V20, P232, DOI 10.3171/2017.1.PEDS16576
NR 35
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 435
EP +
DI 10.1016/j.wneu.2018.11.157
PG 16
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400173
PM 30496928
DA 2020-05-12
ER

PT J
AU Altinel, Y
   Alkhalfan, F
   Qiao, N
   Velimirovic, M
AF Altinel, Yuksel
   Alkhalfan, Fahad
   Qiao, Nidan
   Velimirovic, Marko
TI Outcomes in Lesion Surgery versus Deep Brain Stimulation in Patients
   with Tremor: A Systematic Review and Meta-Analysis
SO WORLD NEUROSURGERY
LA English
DT Review
DE Essential tremor; Multiple sclerosis; Parkinson disease; Radiosurgery
ID FOCUSED ULTRASOUND THALAMOTOMY; PARKINSONS-DISEASE; RANDOMIZED-TRIAL;
   MEDICAL THERAPY; UNILATERAL PALLIDOTOMY; NEUROSTIMULATION; NEUROSURGERY;
   POPULATION; PREVALENCE; DISABILITY
AB INTRODUCTION: Optimal surgical strategy for patients with tremor remains uncertain. We conducted a systematic review and meta-analysis evaluating randomized controlled trials of deep brain stimulation (DBS) and lesion surgery (LS) in the treatment of tremor.
   METHODS: We searched PubMed, Embase, and the Cochrane database to include randomized clinical trials with either LS, deep brain stimulation, or controls. The outcomes were the change in tremor score, quality of life, cognitive function, and neuropsychiatric function. We used standardized mean differences (SMDs) to pool the outcomes.
   RESULTS: Fifteen trials, including 1508 patients, met eligibility criteria. We observed no significant difference in change of tremor scale (SMD -0.07, 95% confidence interval [CI]: -0.38 to 0.24), quality of life (SMD -0.21, 95% CI: -0.69 to 0.27), cognitive function (SMD 0.06, 95% CI: -0.27 to 0.39), or neuropsychiatric function (SMD -0.15, 95% CI: -0.49 to 0.19) between LS and stimulation surgery. We observed heterogeneity across studies during indirect comparison of quality of life. We identified a possible effect modifier: improvement in quality of life correlated with duration of disease (P = 0.035). We found that focused-ultrasound LS was associated with a 0.70 SMD increase (P = 0.014) in quality of life versus DBS in an exploratory subgroup analysis by separating 2 studies with focused-ultrasound LS from other LS studies.
   CONCLUSIONS: Although the main analysis showed that LS and DBS were equally effective in the treatment of patients with tremor, an exploratory subgroup analysis indicated an improvement in quality of life with noninvasive focused-ultrasound surgery.
C1 [Altinel, Yuksel; Alkhalfan, Fahad; Qiao, Nidan] Harvard Med Sch, Med Sci Clin Invest, Boston, MA 02115 USA.
   [Qiao, Nidan] Fudan Univ, Huashan Hosp, Dept Neurosurg, Shanghai, Peoples R China.
   [Velimirovic, Marko] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
   [Velimirovic, Marko] Harvard Med Sch, Boston, MA 02115 USA.
RP Qiao, N (reprint author), Harvard Med Sch, Med Sci Clin Invest, Boston, MA 02115 USA.; Qiao, N (reprint author), Fudan Univ, Huashan Hosp, Dept Neurosurg, Shanghai, Peoples R China.
EM norikaisa@gmail.com
RI Altinel, Yuksel/AAL-9231-2020
OI Qiao, Nidan/0000-0001-5478-3555
FU Shanghai Committee of Science and Technology, ChinaShanghai Science &
   Technology Committee [17JC1402100]
FX N. Qiao is supported by a grant 17JC1402100 from the Shanghai Committee
   of Science and Technology, China.
CR Abrams KR, 2005, STAT MED, V24, P3823, DOI 10.1002/sim.2423
   Barbosa MT, 2013, MOVEMENT DISORD, V28, P640, DOI 10.1002/mds.25355
   Bond AE, 2017, JAMA NEUROL, V74, P1412, DOI 10.1001/jamaneurol.2017.3098
   de Bie RMA, 1999, LANCET, V354, P1665, DOI 10.1016/S0140-6736(99)03556-4
   Deuschl G, 2006, NEW ENGL J MED, V355, P896, DOI 10.1056/NEJMoa060281
   Deuschl G, 2015, MOVEMENT DISORD, V30, P1327, DOI 10.1002/mds.26265
   Edwards CA, 2017, MAYO CLIN PROC, V92, P1427, DOI 10.1016/j.mayocp.2017.05.005
   Elias WJ, 2016, NEW ENGL J MED, V375, P730, DOI 10.1056/NEJMoa1600159
   Esselink RAJ, 2004, NEUROLOGY, V62, P201, DOI 10.1212/01.WNL.0000103235.12621.C3
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
   Krishna V, 2018, JAMA NEUROL, V75, P246, DOI 10.1001/jamaneurol.2017.3129
   Louis ED, 2005, LANCET NEUROL, V4, P100, DOI 10.1016/S1474-4422(05)00991-9
   Mendonca MD, 2018, PARKINSONISM RELAT D, V47, P8, DOI 10.1016/j.parkreldis.2017.12.014
   Merello M, 2008, BRIT J NEUROSURG, V22, P415, DOI 10.1080/02688690801971667
   Merello M, 1999, MOVEMENT DISORD, V14, P50, DOI 10.1002/1531-8257(199901)14:1<50::AID-MDS1010>3.0.CO;2-6
   Mohammed N, 2018, NEUROSURG FOCUS, V44, DOI 10.3171/2017.11.FOCUS17628
   Murray AM, 2004, J GERONTOL A-BIOL, V59, P864
   Okun MS, 2012, LANCET NEUROL, V11, P140, DOI 10.1016/S1474-4422(11)70308-8
   Phibbs FT, 2014, PARKINSONISM RELAT D, V20, P1341, DOI 10.1016/j.parkreldis.2014.09.004
   Pittock SJ, 2004, MOVEMENT DISORD, V19, P1482, DOI 10.1002/mds.20227
   Ravikumar VK, 2017, MOVEMENT DISORD, V32, P1165, DOI 10.1002/mds.26997
   Schreglmann SR, 2018, J NEUROL NEUROSUR PS, V89, P717, DOI 10.1136/jnnp-2017-316302
   Schuepbach WMM, 2013, NEW ENGL J MED, V368, P610, DOI 10.1056/NEJMoa1205158
   Schupbach WMM, 2007, NEUROLOGY, V68, P267, DOI 10.1212/01.wnl.0000250253.03919.fb
   Schuurman PR, 2000, NEW ENGL J MED, V342, P461, DOI 10.1056/NEJM200002173420703
   Thawani SP, 2009, NEUROLOGY, V73, P621, DOI 10.1212/WNL.0b013e3181b389f1
   Thenganatt MA, 2014, JAMA NEUROL, V71, P499, DOI 10.1001/jamaneurol.2013.6233
   Tramontana MG, 2015, J PARKINSON DIS, V5, P151, DOI 10.3233/JPD-140448
   Vitek JL, 2003, ANN NEUROL, V53, P558, DOI 10.1002/ana.10517
   Wan X, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-135
   Weaver FM, 2009, JAMA-J AM MED ASSOC, V301, P63, DOI 10.1001/jama.2008.929
   Williams A, 2010, LANCET NEUROL, V9, P581, DOI 10.1016/S1474-4422(10)70093-4
NR 33
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 443
EP +
DI 10.1016/j.wneu.2018.11.175
PG 18
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400174
PM 30500587
DA 2020-05-12
ER

PT J
AU Groen, RJM
   Lukassen, JNM
   Boer, GJ
   Vergeer, RA
   Coppes, MH
   Drost, G
   Middel, B
AF Groen, Rob J. M.
   Lukassen, Jertske N. M.
   Boer, Gert Jan
   Vergeer, Rob A.
   Coppes, Maarten H.
   Drost, Gea
   Middel, Berrie
TI Anterior Thoracic Spinal Cord Herniation: Surgical Treatment and
   Postoperative Course. An Individual Participant Data Meta-Analysis of
   246 Cases
SO WORLD NEUROSURGERY
LA English
DT Review
DE Anterior dura patch; Anterior thoracic spinal cord herniation; IDP
   meta-analysis; Positive-result publication bias; Thoracic myelopathy;
   Widening dura defect
ID BROWN-SEQUARD-SYNDROME; INCREASINGLY RECOGNIZED CAUSE; TREATABLE CAUSE;
   TRANSDURAL HERNIATION; RARE CAUSE; DURAL DEFECT; TRANSPEDICULAR
   APPROACH; VENTRAL HERNIATION; VERTEBRAL BODY; FOLLOW-UP
AB BACKGROUND: Anterior thoracic spinal cord herniation (ATSCH) is a rare cause of progressive myelopathy. Early surgery is essential, but there is no agreement about the best surgical approach.
   OBJECTIVE: To identify factors that determine surgical results and to find evidence for the most favorable technique to correct ATSCH.
   METHODS: To find relevant literature, computed databases of PubMed, EMBASE, and ISI Web of Science were searched. The study comprised case reports published between 1974 and 2018, and the data set was completed with 12 cases treated in our own institute. Patient characteristics were analyzed following the principles of an individual participant data meta-analysis.
   RESULTS: Brown-Sequard-like neurologic deficit before surgery was associated with postoperative motor function improvement compared with patients with paraparesis (P = 0.04). In the univariate analysis, widening of the dura defect (WDD) was more prevalent among improved patients, whereas anterior dura patch and application of intraoperative neurophysiologic monitoring were not. In the multivariate analysis, the favorable association with WDD disappeared, which is explained by the dominant influence of a Brown-Sequard-like deficit on outcome.
   CONCLUSIONS: In general, postoperative results after surgery for ATSCH are favorable, with a high percentage of patients experiencing postoperative improvement. Postoperative motor function improvement is more likely to occur in patients with a Brown-Sequard-like neurologic deficit. The WDD should be favored above the application of a patch as the technique of choice in surgical treatment of ATSCH.
C1 [Groen, Rob J. M.; Lukassen, Jertske N. M.; Boer, Gert Jan; Vergeer, Rob A.; Coppes, Maarten H.; Drost, Gea] Univ Groningen, Univ Med Ctr Groningen, Dept Neurosurg, Groningen, Netherlands.
   [Middel, Berrie] Univ Groningen, Univ Med Ctr Groningen, Dept Hlth Sci & Oral Hlth & Clin Epidemiol, Groningen, Netherlands.
RP Groen, RJM (reprint author), Univ Groningen, Univ Med Ctr Groningen, Dept Neurosurg, Groningen, Netherlands.
EM r.j.m.groen@umcg.nl
OI Groen, Rob J.M./0000-0003-3067-763X
CR Abe M, 1999, J Orthop Sci, V4, P450, DOI 10.1007/s007760050129
   Adams RF, 2001, NEURORADIOLOGY, V43, P383, DOI 10.1007/s002340000469
   Aizawa T, 2001, Spine (Phila Pa 1976), V26, pE488, DOI 10.1097/00007632-200110150-00030
   Akaza M, 2007, INTERNAL MED, V46, P537, DOI 10.2169/internalmedicine.46.6370
   Akutsu H, 2012, NEUROL MED-CHIR, V52, P238, DOI 10.2176/nmc.52.238
   Alkan O, 2008, NEURORADIOL J, V21, P563, DOI 10.1177/197140090802100415
   Alkhamees A, 2016, INT J HEALTH SCI-IJH, V10, P592
   Amin M, 2015, AVICENNA J CLIN MICR, V2, P10, DOI DOI 10.17795/AJCMI-23233
   Ammar Kevin N, 2005, Neurosurgery, V57, pE1067, DOI 10.1227/01.NEU.0000180016.69507.e0
   Aquilina K, 2004, Ir Med J, V97, P115
   Arts MP, 2006, ACTA NEUROCHIR, V148, P1005, DOI 10.1007/s00701-006-0783-8
   Aydin AL, 2011, SPINE J, V11, pE9, DOI 10.1016/j.spinee.2011.07.003
   Bandai Hideki, 2006, Brain and Nerve (Tokyo), V58, P893
   Barbagallo GMV, 2002, J NEUROSURG, V97, P369, DOI 10.3171/spi.2002.97.3.0369
   Barrenechea IJ, 2006, J NEUROSURG-SPINE, V5, P294, DOI 10.3171/spi.2006.5.4.294
   Bartelme RP, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00101
   Bartels RHMA, 2018, WORLD NEUROSURG, V114, P30, DOI [10.1016/J.WNEU.2018.02.187, 10.1016/j.wneu.2018.02.187]
   Bartolomei J, 2000, NEUROSURGERY, V46, P1408, DOI 10.1097/00006123-200006000-00024
   Batzdorf U, 2012, J SPINAL DISORD TECH, V25, P157, DOI 10.1097/BSD.0b013e31823d79f6
   Baur A, 1997, EUR RADIOL, V7, P1259, DOI 10.1007/s003300050286
   Beltran M, 2016, Rev Med Brux, V37, P101
   Berbel A, 2001, REV NEUROLOGIA, V32, P54, DOI 10.33588/rn.3201.99600
   Berg-Johnsen J, 2014, J CENT NERV SYST DIS, V6, P85, DOI 10.4137/JCNSD.S16180
   Bode Michaela K, 2003, Duodecim, V119, P61
   Boncoraglio GB, 2012, J NEUROL SCI, V312, P170, DOI 10.1016/j.jns.2011.07.034
   BORGES LF, 1995, NEUROSURGERY, V36, P1028, DOI 10.1227/00006123-199505000-00023
   Brugieres P, 1999, AM J NEURORADIOL, V20, P935
   Brus-Ramer M, 2012, AM J NEURORADIOL, V33, P52, DOI 10.3174/ajnr.A2730
   Bustamante-Vidales JC, 2010, CIR CIR, V78, P251
   Carroll Liam S, 2015, Pract Neurol, V15, P482, DOI 10.1136/practneurol-2015-001159
   Carter BJ, 2015, SPINE J, V15, P1943, DOI 10.1016/j.spinee.2015.04.013
   Castelnovo G, 2014, NEUROLOGY, V82, P1290, DOI 10.1212/WNL.0000000000000286
   Cellerini M, 2002, ACTA NEUROCHIR, V144, P321, DOI 10.1007/s007010200044
   Chaichana KL, 2009, J SPINAL DISORD TECH, V22, P67, DOI 10.1097/BSD.0b013e318165fe2a
   Choradia M, 2012, NEUROL INDIA, V60, P342, DOI 10.4103/0028-3886.98535
   Corbetto M, 2014, NEUROLOGY, V82, P1476, DOI 10.1212/WNL.0000000000000334
   Darbar A, 2006, SPINE, V31, pE600, DOI 10.1097/01.brs.0000229247.69171.a1
   Delgado-Lopez PD, 2017, J NEUROSURG-SPINE, V26, P384, DOI 10.3171/2016.8.SPINE16318
   De Souza Rodrigo Becco, 2014, Surg Neurol Int, V5, pS564, DOI 10.4103/2152-7806.148042
   Dietemann JL, 2006, J RADIOL, V87, P706, DOI 10.1016/S0221-0363(06)74072-0
   Dix JE, 1998, AM J NEURORADIOL, V19, P1345
   Eguchi T, 2001, NEUROL MED-CHIR, V41, P508, DOI 10.2176/nmc.41.508
   Ellger T, 2006, CLIN NEUROL NEUROSUR, V108, P388, DOI 10.1016/j.clineuro.2004.07.005
   Ewald C, 2001, NERVENARZT, V72, P441, DOI 10.1007/s001150050776
   Fallah A, 2010, CAN J NEUROL SCI, V37, P271, DOI 10.1017/S0317167100010052
   Ferre JC, 2005, J NEURORADIOLOGY, V32, P125, DOI 10.1016/S0150-9861(05)83127-X
   Fonoff ET, 2016, NEUROLOGY, V87, pE34, DOI 10.1212/WNL.0000000000002886
   Francis D, 2006, J CLIN NEUROSCI, V13, P582, DOI 10.1016/j.jocn.2005.07.013
   Gao HX, 2015, SPINE J, V15, P552, DOI 10.1016/j.spinee.2014.10.024
   Garcia Moreno CM, 2005, AN RADIOL MEXICO, V4, P121
   Gaudino S, 2016, AM J NEURORADIOL, V37, P558, DOI 10.3174/ajnr.A4537
   Ghostine S, 2009, SURG NEUROL, V71, P362, DOI 10.1016/j.surneu.2007.08.022
   Gimena-Reyes B, 2005, REV NEUROLOGIA, V41, P757, DOI 10.33588/rn.4112.2005669
   Gkekas N, 2017, BRIT J NEUROSURG, V31, P615, DOI 10.1080/02688697.2016.1199785
   Goetti R, 2013, JAMA NEUROL, V70, P125, DOI 10.1001/jamaneurol.2013.586
   Groen RJM, 2009, NEUROSURGERY, V64, pS145, DOI 10.1227/01.NEU.0000327686.99072.E7
   Gwinn R, 2004, J NEUROSURG-SPINE, V1, P223, DOI 10.3171/spi.2004.1.2.0223
   Hamcan S, 2016, SPINE J, V16, pE701, DOI 10.1016/j.spinee.2016.03.038
   Haque A, 2010, ACTA NEUROCHIR, V152, P1985, DOI 10.1007/s00701-010-0767-6
   Hassler W, 2008, J NEUROSURG-SPINE, V9, P438, DOI 10.3171/SPI.2008.9.11.438
   Hausmann ON, 1996, NEURORADIOLOGY, V38, P503
   Hawasli AH, 2014, OPER NEUROSURG, V10, pE498, DOI 10.1227/NEU.0000000000000437
   Henry A, 1997, ARCH PHYS MED REHAB, V78, P530, DOI 10.1016/S0003-9993(97)90170-2
   Hussain A, 2008, INTERNET J NEUROL, V11, P1
   Imagama S, 2009, J NEUROSURG-SPINE, V11, P310, DOI 10.3171/2009.4.SPINE08691
   Imai T, 2015, NAGOYA J MED SCI, V77, P515
   Inoue T, 2003, J NEUROSURG, V98, P93, DOI 10.3171/spi.2003.98.1.0093
   Ishida M, 2008, J CLIN NEUROSCI, V15, P933, DOI 10.1016/j.jocn.2006.10.024
   ISU T, 1991, NEUROSURGERY, V29, P137, DOI 10.1227/00006123-199107000-00027
   Iyer RV, 2002, BRIT J NEUROSURG, V16, P507, DOI 10.1080/0268869021000030960
   Jeong Kyung-Ho, 2016, Korean J Spine, V13, P77, DOI 10.14245/kjs.2016.13.2.77
   Ju MW, 2015, J KOREAN NEUROSURG S, V58, P294, DOI 10.3340/jkns.2015.58.3.294
   Karadeniz-Bilgili MY, 2005, CLIN IMAG, V29, P288, DOI 10.1016/j.clinimag.2004.09.001
   Kasliwal MK, 2012, ASIAN SPINE J, V6, P55, DOI 10.4184/asj.2012.6.1.55
   Kenez J, 2002, ACTA CLIN CROAT S, V41, P23
   Kim JM, 2007, J CLIN NEUROL, V3, P204, DOI 10.3988/jcn.2007.3.4.204
   Kiran NAS, 2009, NEUROL INDIA, V57, P221, DOI 10.4103/0028-3886.51306
   Klimo P, 2014, J NEUROSURG, V120, P796, DOI 10.3171/2013.11.JNS13195
   Kotecha J, 2014, J SPINAL SURG, V1, P46
   Kothbauer K., 2002, NEUROPHYSIOLOGY NEUR, P73
   Krishnan P, 2013, NEUROL INDIA, V61, P453, DOI 10.4103/0028-3886.117610
   KUMAR R, 1995, J NEUROSURG, V82, P131, DOI 10.3171/jns.1995.82.1.0131
   Kuo J., 2000, IDIOPATHIC HERNIATIO, P1
   Kwong Y, 2010, J RADIOL CASE REP, V4, P1, DOI 10.3941/jrcr.v4i10.528
   Lambert PC, 2002, J CLIN EPIDEMIOL, V55, P86, DOI 10.1016/S0895-4356(01)00414-0
   Landino FM, 2012, CASE REV MALPOSITION
   Liu Z, 2011, EUR SPINE J, V20, pS222, DOI 10.1007/s00586-010-1592-6
   Lorente-Munoz A, 2013, NEUROCIRUGIA, V24, P216, DOI 10.1016/j.neucir.2012.12.002
   Lui J, 2018, OPER NEUROSURG, V14, P252, DOI 10.1093/ons/opx108
   Mahmood A, 2015, ANAESTH INTENS CARE, V43, P787
   Maira G, 2006, J NEUROSURG-SPINE, V4, P10, DOI 10.3171/spi.2006.4.1.10
   Manara R, 2011, NEURODEGENER DIS, V8, P381, DOI 10.1159/000323798
   Manda VVS, 2013, INT J RES MED SCI, V2, P1144
   Marshman LAG, 1999, NEUROSURGERY, V44, P1129, DOI 10.1097/00006123-199905000-00112
   Martinez-del-Campo E, 2015, NEUROSURGERY, V77, pE492, DOI 10.1227/NEU.0000000000000860
   Maruichi K, 2004, NEUROL SURG TOKYO, V32, P509
   Massicotte Eric M, 2002, Spine (Phila Pa 1976), V27, pE233, DOI 10.1097/00007632-200205010-00025
   MASUZAWA H, 1981, J NEUROSURG, V55, P983, DOI 10.3171/jns.1981.55.6.0983
   Matsumura T, 1996, Rinsho Shinkeigaku, V36, P566
   Mejdoubi M, 2009, J NEURORADIOLOGY, V36, P117, DOI 10.1016/j.neurad.2008.06.006
   Miura Y, 1996, NEURORADIOLOGY, V38, P155
   Miyaguchi M, 2001, SPINE, V26, P1090, DOI 10.1097/00007632-200105010-00022
   Miyake S, 1999, NEUROSURG FOCUS, V7, pE8
   Mohanty CB, 2016, J NEUROSURG IMAGING, V1, P12
   Morley S, 2006, Australas Radiol, V50, P168, DOI 10.1111/j.1440-1673.2006.01547.x
   Morokoff AP, 2001, J CLIN NEUROSCI, V8, P180, DOI 10.1054/jocn.2000.0819
   Naik S, 2016, NEUROL INDIA, V64, P831, DOI 10.4103/0028-3886.185363
   Najjar MW, 2004, SURG NEUROL, V62, P161, DOI 10.1016/j.surneu.2003.10.030
   Nakagawa H, 2003, J SPINAL DISORD TECH, V16, P299, DOI 10.1097/00024720-200306000-00013
   Nakamura M, 2011, J ORTHOP SCI, V16, P347, DOI 10.1007/s00776-011-0065-z
   NAKAZAWA H, 1993, SPINE, V18, P2138, DOI 10.1097/00007632-199310001-00036
   Newcombe RG, 1999, STAT MED, V18, P1293, DOI 10.1002/(SICI)1097-0258(19990530)18:10<1293::AID-SIM175>3.3.CO;2-Z
   Novak K, 2012, J NEUROSURG-SPINE, V16, P114, DOI 10.3171/2011.10.SPINE11109
   Oe T, 1990, Nihon Seikeigeka Gakkai Zasshi, V64, P43
   Parmar H, 2008, RADIOGRAPHICS, V28, P511, DOI 10.1148/rg.282075030
   Payer M, 2016, ACTA NEUROCHIR, V158, P1579, DOI 10.1007/s00701-016-2840-2
   Pereira P, 2001, ACTA NEUROCHIR, V143, P401, DOI 10.1007/s007010170096
   Porrino J, 2014, PM&R, V6, P1063, DOI 10.1016/j.pmrj.2014.06.004
   Prada F, 2012, ACTA NEUROCHIR, V154, P723, DOI 10.1007/s00701-011-1265-1
   Rajapakse D, 2016, BMJ CASE REP, V2016
   Reddy R, 2017, NEUROL INDIA, V65, P906, DOI 10.4103/neuroindia.NI_1064_16
   Rivas JJ, 2004, NEUROCIRUGIA, V15, P484
   Roland Th, 2006, JBR-BTR, V89, P101
   Sadek AR, 2018, BRIT J NEUROSURG, V32, P297, DOI 10.1080/02688697.2016.1265091
   Sagiuchi T, 2003, NEUROL MED-CHIR, V43, P364, DOI 10.2176/nmc.43.364
   SAHL H, 1995, ROFO FORTSCHR RONTG, V162, P350, DOI 10.1055/s-2007-1015897
   Saito A, 2006, MINIM INVAS NEUROSUR, V49, P120, DOI 10.1055/s-2006-932171
   Saito T, 2004, J ORTHOP SCI, V9, P94, DOI 10.1007/s00776-003-0730-y
   Alvarez ES, 2010, RADIOLOGIA-MADRID, V52, P353, DOI 10.1016/j.rx.2010.01.018
   Samuel N, 2015, J NEUROSURG-SPINE, V23, P306, DOI 10.3171/2014.12.SPINE14950
   Sasani M, 2009, J SPINAL CORD MED, V32, P86, DOI 10.1080/10790268.2009.11760757
   Sasaoka R, 2003, J SPINAL DISORD TECH, V16, P288, DOI 10.1097/00024720-200306000-00011
   Saur K, 2013, CESK SLOV NEUROL N, V76, P740
   Scazzeri F, 2001, RIV NEURORADIOL, V14, P339, DOI 10.1177/197140090101400315
   Selviaridis Panagiotis, 2009, Spine J, V9, pe17, DOI 10.1016/j.spinee.2008.03.013
   Senturk S, 2008, SPINE, V33, P474
   Shimizu S, 2019, EUR SPINE J, V28, P298, DOI 10.1007/s00586-017-5147-y
   Shin JH, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.3.FOCUS1089
   Singh P, 2011, ANN INDIAN ACAD NEUR, V14, P136, DOI 10.4103/0972-2327.82814
   Sioutos P, 1996, SPINE, V21, P1710, DOI 10.1097/00007632-199607150-00019
   Slavotinek JP, 1996, NEURORADIOLOGY, V38, P152
   Soriano Guillen AP, 2010, REHABILITACION, V44, P371
   Spissu A, 2004, NEUROL SCI, V25, P151, DOI 10.1007/s10072-004-0251-2
   Srinivasan A, 2004, NEUROLOGY, V63, P2187, DOI 10.1212/01.WNL.0000140620.32658.0B
   Staekenborg SS, 2016, TIJDSCHR NEUROL NEUR, V117, P36
   Sugimoto T, 2005, J SPINAL DISORD TECH, V18, P106, DOI 10.1097/01.bsd.0000123427.12852.ae
   Summers Johanne C, 2013, Asian J Neurosurg, V8, P97, DOI 10.4103/1793-5482.116386
   Szucs A, 2015, J NEUROL NEUROSCI, V6, P1, DOI [10.21767/2171-6625.S10012, DOI 10.21767/2171-6625.S10012]
   Taghipour M, 2004, NEUROSURG QUART, V14, P105, DOI 10.1097/01.wnq.0000126696.94879.8c
   Tandon AS, 2014, HONG KONG J RADIOL, V17, pE5, DOI 10.12809/hkjr1412144
   Taylor TR, 2012, BRIT J RADIOL, V85, pE123, DOI 10.1259/bjr/81458631
   Tekkok IH, 2000, NEUROSURGERY, V46, P485, DOI 10.1097/00006123-200002000-00044
   TRONNIER VM, 1991, NEUROSURGERY, V29, P916, DOI 10.1227/00006123-199112000-00021
   Turel MK, 2017, J CRANIOVERTEBRAL JU, V8, P288, DOI 10.4103/jcvjs.JCVJS_12_17
   Uchino A, 1997, EUR RADIOL, V7, P289, DOI 10.1007/s003300050153
   Uhl E, 2008, J NEUROL, V255, P125, DOI 10.1007/s00415-008-0553-z
   Ulivieri S, 2009, NEUROL NEUROCHIR POL, V43, P86
   Ulrich CT, 2018, ACTA NEUROCHIR, V160, P467, DOI 10.1007/s00701-018-3466-3
   Urbach H, 1996, NEURORADIOLOGY, V38, P157
   Vallee B, 1999, ACTA NEUROCHIR, V141, P907, DOI 10.1007/s007010050396
   van den Hauwe L, 2006, JBR-BTR, V89, P150
   Vergeer Rob A, 2012, Ned Tijdschr Geneeskd, V156, pA4824
   Verny C, 1999, NEUROCHIRURGIE, V45, P225
   Wada E, 2000, SPINE, V25, P1984, DOI 10.1097/00007632-200008010-00019
   Watanabe M, 2001, J NEUROSURG, V95, P169, DOI 10.3171/spi.2001.95.2.0169
   Watters MR, 1998, AM J NEURORADIOL, V19, P1337
   White BD, 2004, BRIT J NEUROSURG, V18, P246, DOI 10.1080/02688690410001732670
   WHITE BD, 1994, J NEUROL NEUROSUR PS, V57, P1433, DOI 10.1136/jnnp.57.11.1433
   WORTZMAN G, 1974, J NEUROSURG, V41, P631, DOI 10.3171/jns.1974.41.5.0631
   Yamamoto N, 2014, INT J SPINE SURG, V8, DOI 10.14444/1029
   Zairi F, 2010, ACTA NEUROCHIR, V152, P1991, DOI 10.1007/s00701-010-0773-8
NR 171
TC 1
Z9 1
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 453
EP +
DI 10.1016/j.wneu.2018.11.229
PG 26
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400175
PM 30529595
DA 2020-05-12
ER

PT J
AU Sato, S
   Shibahara, I
   Inoue, Y
   Hide, T
   Kumabe, T
AF Sato, Sumito
   Shibahara, Ichiyo
   Inoue, Yusuke
   Hide, Takuichiro
   Kumabe, Toshihiro
TI New Radiologic Findings of Hypertrophic Olivary Degeneration in 2
   Patients with Brainstem Lymphoma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Arterial spin-labeling; Brainstem lymphoma; Hypertrophic olivary
   degeneration; Oculopalatal tremor
ID TREMOR
AB BACKGROUND: Hypertrophic olivary degeneration (HOD) is a rare neurological condition of trans-synaptic degeneration caused by disruption of the dentatorubro-olivary pathway. We present new radiologic findings of HOD in 2 cases of brainstem lymphoma.
   CASE DESCRIPTION: A 35-year-old woman (Case 1) and a 69-year-old man (Case 2) presented with remarkably similar clinical courses. The primary lesion was located at the dorsal pons extending to the midbrain. Pathologic diagnosis of diffuse large B-cell lymphoma was obtained after surgical resection. Complete remission of the primary lesion was achieved by treatment with 3 courses of high-dose methotrexate and radiotherapy. Arterial spin-labeling and T-2-weighted imagings showed high signal intensity in the inferior olive (IO) at some time after the operation. Slight contrast enhancement in the IO was also found in Case 1. These radiologic findings nearly misled us into a diagnosis of recurrence of lymphoma. Signal intensity in the IO on arterial spin-labeling imaging changed with time. Normalized regional cerebral blood flow (rCBF) in the IO was defined as a percentage of rCBF to the global cerebral blood flow calculated using automated software. Chronologic change in normalized rCBF in the IO revealed a large peak in Case 1, but only a mild increase in Case 2. Neurological findings demonstrated severe oculopalatal tremor in Case 1 and mild palatal tremor in Case 2.
   CONCLUSIONS: Hyperperfusion and contrast enhancement in the IO were found in 2 patients with HOD. These findings may be confused with recurrence of malignant tumor.
C1 [Sato, Sumito; Shibahara, Ichiyo; Hide, Takuichiro; Kumabe, Toshihiro] Kitasato Univ, Sch Med, Dept Neurosurg, Sagamihara, Kanagawa, Japan.
   [Inoue, Yusuke] Kitasato Univ, Sch Med, Dept Diagnost Radiol, Sagamihara, Kanagawa, Japan.
RP Sato, S (reprint author), Kitasato Univ, Sch Med, Dept Neurosurg, Sagamihara, Kanagawa, Japan.
EM sumito@med.kitasato-u-ac.jp
CR Deibler AR, 2008, AM J NEURORADIOL, V29, P1428, DOI 10.3174/ajnr.A1034
   DUBINSKY RM, 1991, NEUROLOGY, V41, P557, DOI 10.1212/WNL.41.4.557
   GOTO N, 1981, ACTA NEUROPATHOL, V54, P275, DOI 10.1007/BF00697000
   Goyal M, 2000, AM J NEURORADIOL, V21, P1073
   Inoue Y, 2014, AM J NEURORADIOL, V35, P1111, DOI 10.3174/ajnr.A3815
   Korpela J, 2015, TREMOR OTHER HYPERK, V5, DOI 10.7916/D8PV6JMT
   Litkowski P, 2012, CLIN IMAG, V36, P371, DOI 10.1016/j.clinimag.2011.09.014
   Lozano-Ros A, 2016, NEUROLOGIST, V21, P83, DOI 10.1097/NRL.0000000000000089
   Marques J, 2013, BMJ CASE REP, V2013
   Mayo C, 2010, INT J RADIAT ONCOL, V76, pS36, DOI 10.1016/j.ijrobp.2009.08.078
   Nishie M, 2002, BRAIN, V125, P1348, DOI 10.1093/brain/awf126
   Onen MR, 2018, WORLD NEUROSURG, V112, pE763, DOI 10.1016/j.wneu.2018.01.150
   Shah R, 2010, AM J NEURORADIOL, V31, P1729, DOI 10.3174/ajnr.A1911
   Tanaka Y, 2018, CLIN IMAG, V52, P23, DOI 10.1016/j.clinimag.2018.02.016
   Tilikete C, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00302
NR 15
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP 464
EP +
DI 10.1016/j.wneu.2018.11.161
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400176
PM 30496930
DA 2020-05-12
ER

PT J
AU Abunimer, AM
   Abou-Al-Shaar, H
   Azab, MA
   Karsy, M
   Guan, J
   Kestle, JR
   Couldwell, WT
AF Abunimer, Abdullah M.
   Abou-Al-Shaar, Hussam
   Azab, Mohammed A.
   Karsy, Michael
   Guan, Jian
   Kestle, John R.
   Couldwell, William T.
TI Transsphenoidal Approaches for Microsurgical Resection of Pituitary
   Adenomas in Pediatric Patients
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endoscopy; Microscopy; Outcome; Pediatrics; Pituitary adenoma; Safety;
   Transsphenoidal approach
ID SKULL BASE SURGERY; SURGICAL-TREATMENT; CUSHINGS-DISEASE; TUMORS;
   CHILDHOOD; CRANIOPHARYNGIOMAS; EXPERIENCE; CHILDREN; MANAGEMENT;
   RECONSTRUCTION
AB OBJECTIVE: Pituitary adenomas are uncommon in the pediatric population. Although medical treatment can be effective in treating prolactinomas and some growth hormone-secreting tumors, resection is indicated in the setting of pituitary apoplexy, large or giant pituitary adenomas causing mass effect or visual loss, or when medical therapy becomes ineffective or intolerable. Modern microsurgical transsphenoidal approaches are potential avenues for resection in pediatric patients. We evaluated the outcomes and safety of this approach.
   METHODS: A retrospective cohort analysis was performed from February 2002 through May 2017 for patients younger than 19 years of age that underwent a transsphenoidal approach for pituitary adenoma resection.
   RESULTS: Among a total of 634 patients who underwent transsphenoidal approach for pituitary adenoma resection, 24 pediatric cases were identified. Prolactinomas (29.2%) and adrenocorticotropic hormone-secreting (20.8%) pituitary adenomas were the most commonly encountered histologies. Gross total resection was achieved in 75.0% of patients, and complete hormone function normalization was seen in 91.7% of patients. Eight patients (33.3%) required postoperative hormone replacement therapy. Twelve patients (50.0%) underwent fat/ fascia use and 1 patient (4.2%) underwent lumbar puncture perioperatively for management of cerebrospinal fluid leak. There were no tumor recurrences during a follow-up period of 24.7 +/- 32.1 months.
   CONCLUSIONS: A modern transsphenoidal microsurgical approach proved to be a safe, well-tolerated, and effective modality in the setting of pediatric pituitary adenomas.
C1 [Abunimer, Abdullah M.] Harvard Med Sch, Brigham & Womens Hosp, Dept Neurosurg, Boston, MA 02115 USA.
   [Abou-Al-Shaar, Hussam] Hofstra Northwell Sch Med, Dept Neurosurg, New York, NY USA.
   [Abou-Al-Shaar, Hussam; Azab, Mohammed A.; Karsy, Michael; Guan, Jian; Kestle, John R.; Couldwell, William T.] Univ Utah, Clin Neurosci Ctr, Dept Neurosurg, Salt Lake City, UT 84112 USA.
RP Couldwell, WT (reprint author), Univ Utah, Clin Neurosci Ctr, Dept Neurosurg, Salt Lake City, UT 84112 USA.
EM neuropub@hsc.utah.edu
RI Karsy, Michael/AAH-8583-2020
OI Karsy, Michael/0000-0002-0422-7937; Guan, Jian/0000-0002-4762-7113;
   Azab, Mohammed/0000-0002-3519-9035
CR Ahmet A, 2006, J PEDIATR ENDOCR MET, V19, P121
   Artese R, 1998, NEUROL RES, V20, P415
   Barzaghi LR, 2019, NEUROSURGERY, V85, P65, DOI 10.1093/neuros/nyy204
   Chivukula S, 2013, J NEUROSURG-PEDIATR, V11, P227, DOI 10.3171/2012.10.PEDS12160
   de Divitiis E, 2000, CHILD NERV SYST, V16, P692, DOI 10.1007/s003810000350
   Dhellemmes P, 2006, J PEDIATR ENDOCR MET, V19, P329
   Di Battista E, 2006, J PEDIATR ENDOCR MET, V19, P431
   Di Rocco C, 2006, J PEDIATR ENDOCR MET, V19, P355
   Duek I, 2018, J NEUROL SURG PART B, V79, P81, DOI 10.1055/s-0037-1615806
   DYER EH, 1994, NEUROSURGERY, V34, P207, DOI 10.1227/00006123-199402000-00001
   Fahlbusch R, 1999, J NEUROSURG, V90, P237, DOI 10.3171/jns.1999.90.2.0237
   Frazier J, 2008, CHILD NERV SYST, V24, P1469, DOI 10.1007/s00381-008-0710-9
   GRIFFITH HB, 1987, J NEUROSURG, V66, P140, DOI 10.3171/jns.1987.66.1.0140
   HADDAD SF, 1991, NEUROSURGERY, V29, P509, DOI 10.1227/00006123-199110000-00004
   Hirsch O, 1910, J AMER MED ASSOC, V55, P772, DOI 10.1001/jama.1910.04330090046014
   Jane JA, 2010, J NEUROSURG-PEDIATR, V5, P49, DOI 10.3171/2009.7.PEDS09252
   Jiao W, 2017, J CRANIOFAC SURG, V28, P1010, DOI 10.1097/SCS.0000000000003632
   Joshi SM, 2005, NEUROSURGERY, V57, P281, DOI 10.1227/01.NEU.0000166580.94215.53
   KANE LA, 1994, J CLIN ENDOCR METAB, V79, P1135, DOI 10.1210/jc.79.4.1135
   Karsy M, 2017, WORLD NEUROSURG, V105, P818, DOI 10.1016/j.wneu.2017.05.148
   Kassam A, 2007, J NEUROSURG, V106, P75, DOI 10.3171/ped.2007.106.2.75
   Kunwar S, 1999, J CLIN ENDOCR METAB, V84, P4385, DOI 10.1210/jc.84.12.4385
   LAWS ER, 1987, PROG EXP TUMOR RES, V30, P359
   LEINUNG MC, 1995, J CLIN ENDOCR METAB, V80, P2475, DOI 10.1210/jc.80.8.2475
   Locatelli D, 2010, INT J PEDIATR OTORHI, V74, P1298, DOI 10.1016/j.ijporl.2010.08.009
   Lonser RR, 2013, J CLIN ENDOCR METAB, V98, P892, DOI 10.1210/jc.2012-3604
   Massimi L, 2011, ACTA NEUROCHIR, V153, P843, DOI 10.1007/s00701-010-0929-6
   Mehrazin M, 2007, CHILD NERV SYST, V23, P391, DOI 10.1007/s00381-006-0259-4
   MINDERMANN T, 1995, NEUROSURGERY, V36, P259, DOI 10.1227/00006123-199502000-00004
   Ohmori K, 2007, PEDIATR NEUROSURG, V43, P265, DOI 10.1159/000103306
   Pandey P, 2005, J CLIN NEUROSCI, V12, P124, DOI 10.1016/j.jocn.2004.10.003
   PARTINGTON MD, 1994, J NEUROSURG, V80, P209, DOI 10.3171/jns.1994.80.2.0209
   Perry A, 2018, J NEUROL SURG PART B, V79, DOI 10.1055/s-0038-1625984
   RICHMOND IL, 1978, J NEUROSURG, V49, P163, DOI 10.3171/jns.1978.49.2.0163
   Rigante M, 2011, INT J PEDIATR OTORHI, V75, P1132, DOI 10.1016/j.ijporl.2011.06.004
   Shah NS, 2011, ENDOCR PRACT, V17, P369, DOI 10.4158/EP10143.OR
   Shah RN, 2009, LARYNGOSCOPE, V119, P1067, DOI 10.1002/lary.20216
   Steele CA, 2010, EUR J ENDOCRINOL, V163, P515, DOI 10.1530/EJE-10-0519
   Tamura T, 2000, ENDOCR J, V47, pS95, DOI 10.1507/endocrj.47.SupplMarch_S95
   Tan HKK, 2003, INT J PEDIATR OTORHI, V67, P1295, DOI 10.1016/j.ijporl.2003.07.012
   Tarapore PE, 2011, J NEUROSURG-PEDIATR, V7, P501, DOI 10.3171/2011.2.PEDS10278
   Taskapilioglu MO, 2014, PEDIATR NEUROSURG, V50, P128, DOI 10.1159/000381862
   Tatreau JR, 2010, LARYNGOSCOPE, V120, P1730, DOI 10.1002/lary.20964
   Webb C, 2008, ARCH PATHOL LAB MED, V132, P77, DOI 10.1043/1543-2165(2008)132[77:PPA]2.0.CO;2
   Zhan RC, 2015, J CRANIOFAC SURG, V26, P1818, DOI 10.1097/SCS.0000000000001946
   Zhan RC, 2015, ARCH DIS CHILD, V100, P774, DOI 10.1136/archdischild-2015-308365
   Zhang NN, 2017, CHILD NERV SYST, V33, P1961, DOI 10.1007/s00381-017-3538-3
NR 47
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E186
EP E193
DI 10.1016/j.wneu.2018.11.117
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400023
PM 30476659
DA 2020-05-12
ER

PT J
AU Adogwa, O
   Lilly, DT
   Khalid, S
   Desai, SA
   Vuong, VD
   Davison, MA
   Ouyang, B
   Bagley, CA
   Cheng, J
AF Adogwa, Owoicho
   Lilly, Daniel T.
   Khalid, Syed
   Desai, Shyam A.
   Vuong, Victoria D.
   Davison, Mark A.
   Ouyang, Bichun
   Bagley, Carlos A.
   Cheng, Joseph
TI Extended Length of Stay After Lumbar Spine Surgery: Sick Patients,
   Postoperative Complications, or Practice Style Differences Among
   Hospitals and Physicians?
SO WORLD NEUROSURGERY
LA English
DT Article
DE Enhanced recovery pathway; Length of stay; Lumbar fusion; Postoperative
   complications; Spine surgery
ID ENHANCED RECOVERY; OUTCOMES
AB BACKGROUND: The degree to which extended length of stay (LOS) after surgery represents patient illness or postoperative complications is unknown. The aim of this study was to investigate the influence of postoperative complications and patient comorbidities on variance in extended length of hospital stay after lumbar spine surgery.
   METHODS: Data from the American College of Surgeons National Surgical Quality Improvement Program were analyzed from January 1, 2008, through December 31, 2014. Study participants were 23,102 patients undergoing a 1-level or 2-level lumbar decompression and fusion procedure. Multivariable logistic regression analysis was used to determine the odds ratio for risk-adjusted extended length of hospital stay, defined as patients with a hospital stay greater than the 75th percentile (LOS > 5 days) for the cohort. The primary outcome was the extent to which extended LOS represented preoperative patient illness or postoperative complications.
   RESULTS: Of 23,102 participants, 3794 (16.42%) had extended LOS. Most patients (2849 patients; 75.10%) with extended LOS did not have a documented postoperative complication. Only a minority of patients with extended LOS had a history of comorbidities known to influence outcomes in patients undergoing spine surgery, including diabetes (24%), chronic obstructive pulmonary disease (7%), congestive heart failure (0.69%), myocardial infarction (0.20%), acute renal failure (0.26%), and stroke (2.23%).
   CONCLUSIONS: This study suggests that much of the variation in LOS after lumbar spine surgery is not attributable to baseline patient illness or complications and most likely represents differences in practice style or surgeon preference.
C1 [Adogwa, Owoicho; Lilly, Daniel T.; Khalid, Syed; Desai, Shyam A.; Vuong, Victoria D.; Davison, Mark A.; Ouyang, Bichun] Rush Univ, Med Ctr, Dept Neurosurg, Chicago, IL 60612 USA.
   [Bagley, Carlos A.] Univ Texas Southwestern Med Ctr Dallas, Dept Neurosurg, Dallas, TX 75390 USA.
   [Cheng, Joseph] Univ Cincinnati, Med Ctr, Dept Neurosurg, Cincinnati, OH 45267 USA.
RP Adogwa, O (reprint author), Rush Univ, Med Ctr, Dept Neurosurg, Chicago, IL 60612 USA.
EM owoicho.Adogwa@gmail.com
RI Khalid, Syed/U-4117-2019
OI Khalid, Syed/0000-0003-4710-1688
CR Dasenbrock HH, 2012, NEUROSURGERY, V70, P1353
   Dasenbrock HH, 2012, NEUROSURGERY, V70, P1346, DOI 10.1227/NEU.0b013e318251791a
   Epstein NE, 2011, SPINE, V36, P905, DOI 10.1097/BRS.0b013e3181e6c4d8
   Farjoodi P, 2011, SPINE, V36, P2069, DOI 10.1097/BRS.0b013e318202ac56
   Freburger JK, 2009, ARCH INTERN MED, V169, P251, DOI 10.1001/archinternmed.2008.543
   Gross TS, 2016, J PEDIATR SURG, V51, P1292, DOI 10.1016/j.jpedsurg.2016.01.016
   Gruskay JA, 2015, SPINE J, V15, P1188, DOI 10.1016/j.spinee.2013.10.022
   Krell RW, 2014, JAMA SURG, V149, P815, DOI 10.1001/jamasurg.2014.629
   Nandyala SV, 2014, SPINE, V39, P417, DOI 10.1097/BRS.0000000000000149
   Rawlinson A, 2011, ANN ROY COLL SURG, V93, P583, DOI 10.1308/147870811X605219
   Seicean A, 2014, SPINE, V39, P1605, DOI 10.1097/BRS.0000000000000489
   Simpson JC, 2015, BRIT J ANAESTH, V115, P560, DOI 10.1093/bja/aev105
   Styron JF, 2011, J ARTHROPLASTY, V26, P1418, DOI 10.1016/j.arth.2010.11.008
   Zheng FY, 2002, SPINE, V27, P818, DOI 10.1097/00007632-200204150-00008
   Zhuang CL, 2013, DIS COLON RECTUM, V56, P667, DOI 10.1097/DCR.0b013e3182812842
NR 15
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E734
EP E739
DI 10.1016/j.wneu.2018.12.016
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400087
PM 30579024
DA 2020-05-12
ER

PT J
AU Aghaebrahim, A
   Agnoletto, GJ
   Aguilar-Salinas, P
   Granja, MF
   Monteiro, A
   Siddiqui, AH
   Levy, EI
   Shallwani, H
   Kim, SJ
   Haussen, DC
   Nogueira, RG
   Lopes, D
   Saied, A
   Jovin, TG
   Jadhav, AP
   Limaye, K
   Turk, AS
   Spiotta, AM
   Chaudry, MI
   Turner, RD
   Brasiliense, LBC
   Dumont, TM
   Cherian, J
   Kan, P
   Sauvageau, E
   Hanel, RA
AF Aghaebrahim, Amin
   Agnoletto, Guilherme Jose
   Aguilar-Salinas, Pedro
   Granja, Manuel F.
   Monteiro, Andre
   Siddiqui, Adnan H.
   Levy, Elad, I
   Shallwani, Hussain
   Kim, Song J.
   Haussen, Diogo C.
   Nogueira, Raul G.
   Lopes, Demetrius
   Saied, Ahmed
   Jovin, Tudor G.
   Jadhav, Ashutosh P.
   Limaye, Kaustubh
   Turk, Aquilla S.
   Spiotta, Alejandro M.
   Chaudry, Mohammad, I
   Turner, Raymond D.
   Brasiliense, Leonardo B. C.
   Dumont, Travis M.
   Cherian, Jacob
   Kan, Peter
   Sauvageau, Eric
   Hanel, Ricardo A.
TI Endovascular Recanalization of Symptomatic Intracranial Arterial
   Stenosis Despite Aggressive Medical Management
SO WORLD NEUROSURGERY
LA English
DT Article
DE Angioplasty; Intracranial atherosclerosis; Stents; Stroke
ID THERAPY; WARFARIN; ASPIRIN; DISEASE
AB BACKGROUND: The optimal management of intracranial arterial stenosis is unclear, particularly in patients who have failed medical management. We report a multicenter real-world experience of endovascular recanalization of intracranial atherosclerotic stenosis refractory to aggressive medical therapy.
   METHODS: Retrospective multicenter case series of consecutive endovascularly treated patients presenting with symptomatic (transient ischemic attack [TIA] or stroke) intracranial stenosis who had failed medical therapy. Patients were divided into 2 groups: patients with recurrent TIA or stroke despite medical management (group 1) versus patients presenting with a stroke and worsening symptoms (progressive or crescendo stroke) despite medical management (group 2).
   RESULTS: A total of 101 patients were treated in 8 stroke centers from August 2009 to May 2017. Sixty-nine presented with recurrent TIA or stroke and 32 with stroke and worsening symptoms. Successful recanalization was achieved in 84% of patients. Periprocedural stroke occurred in 3 patients and 2 had a recurrent ischemic stroke at the 90-day follow-up. Symptomatic intraparenchymal hemorrhage secondary to reperfusion injury occurred in 3 patients and 1 had a hemorrhagic stroke after discharge. There were 2 periprocedural perforations that resulted in death. At 90 days, 86% of patients (64/74) did not have a recurrence of stroke and the 90-day cumulative ischemic stroke rate was 6.7% with 90-day mortality of 11.2%. The 90-day favorable outcome (modified Rankin Scale score, <= 2) rate was 77.5%.
   CONCLUSIONS: Endovascular recanalization of unstable intracranial atherosclerotic stenosis in patients who have failed medical therapy is feasible. Future randomized trials need to determine if recanalization is of any value for this population.
C1 [Aghaebrahim, Amin; Agnoletto, Guilherme Jose; Aguilar-Salinas, Pedro; Granja, Manuel F.; Monteiro, Andre; Sauvageau, Eric; Hanel, Ricardo A.] Baptist Neurol Inst, Lyerly Neurosurg Baptist Hlth, Jacksonville, FL 32207 USA.
   [Siddiqui, Adnan H.; Levy, Elad, I; Shallwani, Hussain] Univ Buffalo, Dept Neurosurg, Buffalo, NY USA.
   [Siddiqui, Adnan H.; Levy, Elad, I; Shallwani, Hussain] Univ Buffalo, Toshiba Stroke Res Ctr, Buffalo, NY USA.
   [Kim, Song J.; Haussen, Diogo C.; Nogueira, Raul G.] Emory Univ, Dept Neurol, Grady Mem Hosp, Sch Med, Atlanta, GA USA.
   [Lopes, Demetrius; Saied, Ahmed] Rush Univ, Dept Neurosurg, Med Ctr, Chicago, IL 60612 USA.
   [Jovin, Tudor G.; Jadhav, Ashutosh P.; Limaye, Kaustubh] Univ Pittsburgh, Dept Neurol, Med Ctr, Pittsburgh, PA 15260 USA.
   [Turk, Aquilla S.; Spiotta, Alejandro M.; Chaudry, Mohammad, I; Turner, Raymond D.] Med Univ South Carolina, Dept Neurosurg, Charleston, SC 29425 USA.
   [Brasiliense, Leonardo B. C.; Dumont, Travis M.] Univ Arizona, Div Neurosurg, Tucson, AZ USA.
   [Cherian, Jacob; Kan, Peter] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA.
RP Aghaebrahim, A (reprint author), Baptist Neurol Inst, Lyerly Neurosurg Baptist Hlth, Jacksonville, FL 32207 USA.
EM Amin.Aghaebrahim@bmcjax.com
RI Lopes, Demetrius/AAD-7334-2020; Aguilar-Salinas, Pedro/AAJ-4444-2020;
   Siddiqui, Adnan H./AAG-9781-2019
OI Lopes, Demetrius/0000-0002-6280-0113; Aguilar-Salinas,
   Pedro/0000-0002-5268-6548; Granja Santibanez, Manuel
   Felipe/0000-0002-9126-2932; Haussen, Diogo C./0000-0003-1884-2196;
   Limaye, Kaustubh/0000-0002-7280-7407
CR Boden WE, 2007, NEW ENGL J MED, V356, P1503, DOI 10.1056/NEJMoa070829
   Chimowitz MI, 2011, NEW ENGL J MED, V365, P993, DOI 10.1056/NEJMoa1105335
   Chimowitz MI, 2005, NEW ENGL J MED, V352, P1305, DOI 10.1056/NEJMoa043033
   Derdeyn CP, 2014, LANCET, V383, P333, DOI 10.1016/S0140-6736(13)62038-3
   Dumont TM, 2012, NEUROSURGERY, V71, P1103, DOI 10.1227/NEU.0b013e318271bcb8
   Gao P, 2016, AM J NEURORADIOL, V37, P1275, DOI 10.3174/ajnr.A4698
   Kasner SE, 2006, NEUROLOGY, V67, P1275, DOI 10.1212/01.wnl.0000238506.76873.2f
   Levine GN, 2016, J AM COLL CARDIOL, V67, P1235, DOI 10.1016/j.jacc.2015.10.005
   Samaniego EA, 2013, J NEUROINTERV SURG, V5, P302, DOI 10.1136/neurintsurg-2012-010321
   Sangha RS, 2017, STROKE, V48, P2158, DOI 10.1161/STROKEAHA.116.016254
   Stergiopoulos K, 2012, ARCH INTERN MED, V172, P312, DOI 10.1001/archinternmed.2011.1484
   Zaidat OO, 2015, JAMA-J AM MED ASSOC, V313, P1240, DOI 10.1001/jama.2015.1693
NR 12
TC 0
Z9 1
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E693
EP E699
DI 10.1016/j.wneu.2018.12.008
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400082
PM 30576811
DA 2020-05-12
ER

PT J
AU Ahn, A
   Phan, K
   Cheung, ZB
   White, SJW
   Kim, JS
   Cho, SKW
AF Ahn, Amy
   Phan, Kevin
   Cheung, Zoe B.
   White, Samuel J. W.
   Kim, Jun S.
   Cho, Samuel Kang-Wook
TI Predictors of Discharge Disposition Following Laminectomy for Intradural
   Extramedullary Spinal Tumors
SO WORLD NEUROSURGERY
LA English
DT Article
DE Discharge disposition; Laminectomy; NSQIP; Outcomes; Spinal tumor
ID QUALITY IMPROVEMENT PROGRAM; ELDERLY-PATIENTS; DESCRIPTIVE EPIDEMIOLOGY;
   PART I; CORD; SURGERY; MORTALITY; NEOPLASMS; RESECTION; OUTCOMES
AB OBJECTIVE: To identify independent risk factors for nonhome discharge in patients undergoing laminectomy for intradural extramedullary spinal tumors.
   METHODS: We performed a retrospective cohort analysis of data from the American College of Surgeons National Surgical Quality Improvement Program from 2011 to 2014. Adult patients who underwent laminectomy for the excision of intradural extramedullary spinal tumors were included and divided into 2 groups based on home or non-home discharge disposition. We compared baseline patient characteristics, comorbidities, and operative factors between the 2 groups, and then performed multivariate regression analyses to identify independent risk factors for non-home discharge.
   RESULTS: A total of 1232 patients were included, of whom 248 (20.1%) were discharged to a non-home facility. Univariate analysis demonstrated that patients discharged to a non-home facility were more frequently aged >= 65 years and American Society of Anesthesiologists classification >= 3 with obesity, diabetes, dyspnea, functional dependence, cardiac comorbidity, renal comorbidity, and anemia. Operative factors correlated with non-home discharge were operative time of >= 4 hours and tumor location in the cervical or thoracic spine. Multivariate regression analysis identified age >= 65 years (odds ratio [OR] 2.73; confidence interval [CI] 1.80-4.13; P < 0.001), American Society of Anesthesiologists classification >= 3 (OR 2.36; CI 1.53-3.65; P < 0.001), dependent functional status (OR 4.30; CI 1.95-9.48; P < 0.001), hospital-acquired conditions (OR 2.32; CI 1.15-4.68; P = 0.019), and prolonged length of stay (OR 4.05; CI 2.72-6.03; P < 0.001) as predictors of non-home discharge.
   CONCLUSIONS: Early identification of patients at risk for non-home discharge is important in order to implement comprehensive discharge planning protocols that reduce inpatient length of stay, as well as associated complications and costs.
C1 [Ahn, Amy; Cheung, Zoe B.; White, Samuel J. W.; Kim, Jun S.; Cho, Samuel Kang-Wook] Icahn Sch Med Mt Sinai, Dept Orthopaed Surg, New York, NY 10029 USA.
   [Phan, Kevin] Prince Wales Private Hosp, NeuroSpine Surg Res Grp NSURG, Sydney, NSW, Australia.
RP Cho, SKW (reprint author), Icahn Sch Med Mt Sinai, Dept Orthopaed Surg, New York, NY 10029 USA.
EM samuelkcho@gmail.com
RI Cheung, Zoe/AAG-4511-2020
OI Cheung, Zoe/0000-0002-0189-5390; Ahn, Amy/0000-0003-1374-8483
CR Abul-Kasim K, 2008, NEURORADIOLOGY, V50, P301, DOI 10.1007/s00234-007-0345-7
   Adams H, 2012, SPINE, V37, pE727, DOI 10.1097/BRS.0b013e31824584c0
   Aldebeyan S, 2016, SPINE, V41, P1535, DOI 10.1097/BRS.0000000000001575
   Aynardi M, 2013, J ARTHROPLASTY, V28, P517, DOI 10.1016/j.arth.2012.06.040
   Costantino ME, 2013, POPUL HEALTH MANAG, V16, P310, DOI 10.1089/pop.2012.0084
   Di Capua J, 2018, GLOB SPINE J, V8, P266, DOI 10.1177/2192568217717971
   Duong LM, 2012, CANCER-AM CANCER SOC, V118, P4220, DOI 10.1002/cncr.27390
   El-Mahdy W, 1999, BRIT J NEUROSURG, V13, P550, DOI 10.1080/02688699943042
   Fink AS, 2002, ANN SURG, V236, P344, DOI 10.1097/00000658-200209000-00011
   Gruskay JA, 2015, SPINE J, V15, P1188, DOI 10.1016/j.spinee.2013.10.022
   Hall BL, 2009, ANN SURG, V250, P363, DOI 10.1097/SLA.0b013e3181b4148f
   HELSETH A, 1989, J NEUROSURG, V71, P842, DOI 10.3171/jns.1989.71.6.0842
   Iacoangeli M, 2012, CLIN INTERV AGING, V7, P557, DOI 10.2147/CIA.S38923
   KENNEDY L, 1987, GERONTOLOGIST, V27, P577, DOI 10.1093/geront/27.5.577
   Legner VJ, 2009, ANN SURG, V249, P250, DOI 10.1097/SLA.0b013e318195e12f
   McGirt MJ, 2010, NEUROSURGERY, V66, P1005, DOI 10.1227/01.NEU.0000367721.73220.C9
   Molina CS, 2015, CLIN ORTHOP RELAT R, V473, P1574, DOI 10.1007/s11999-014-3597-7
   Morandi X, 2004, SPINE, V29, P2191, DOI 10.1097/01.brs.0000141173.79572.40
   NARAIN P, 1988, J AM GERIATR SOC, V36, P775, DOI 10.1111/j.1532-5415.1988.tb04259.x
   NAYLOR M, 1994, ANN INTERN MED, V120, P999, DOI 10.7326/0003-4819-120-12-199406150-00005
   Schellinger KA, 2008, J NEURO-ONCOL, V87, P173, DOI 10.1007/s11060-007-9507-z
   Schoenfeld AJ, 2013, SPINE J, V13, P1171, DOI 10.1016/j.spinee.2013.02.071
   Stuebe J, 2018, ANN THORAC SURG, V105, P1384, DOI 10.1016/j.athoracsur.2017.11.060
   Suskind AM, 2016, UROLOGY, V97, P25, DOI 10.1016/j.urology.2016.03.073
   Traul DE, 2007, LANCET ONCOL, V8, P35, DOI 10.1016/S1470-2045(06)71009-9
   Van Goethem JWM, 2004, EUR J RADIOL, V50, P159, DOI 10.1016/j.ejrad.2003.10.021
   Wachter RM, 2013, ANN INTERN MED, V158, P350, DOI 10.7326/0003-4819-158-5-201303050-00010
   Yeo DK, 2011, J KOREAN NEUROSURG S, V50, P195, DOI 10.3340/jkns.2011.50.3.195
   Yeom JS, 2008, SPINE, V33, pE543, DOI 10.1097/BRS.0b013e31817c6c9b
   Zuckerman SL, 2016, SPINE, V41, P1925, DOI 10.1097/BRS.0000000000001653
NR 30
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E427
EP E432
DI 10.1016/j.wneu.2018.11.183
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400049
PM 30500579
DA 2020-05-12
ER

PT J
AU Akiyama, O
   Kondo, A
   Arai, H
AF Akiyama, Osamu
   Kondo, Akihide
   Arai, Hajime
TI The Rhomboid Lip: Anatomy, Pathology, and Clinical Consideration in
   Neurosurgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Lateral recess; Lower cranial nerves; Microvascular decompression;
   Rhomboid lip
ID MICROVASCULAR DECOMPRESSION; HEMIFACIAL SPASM; MICROSURGICAL ANATOMY;
   4TH-VENTRICLE; SURGERY
AB OBJECTIVE: To describe microsurgical anatomy of the rhomboid lip (RL) and to consider its role by presenting histology and clinical cases.
   METHODS: We examined 10 (20 sides) formalin-fixed adult human cadaveric heads injected with colored silicone. A total of 20 RLs were examined posteriorly. We examined the expansion of the RL in the cerebellopontine cistern. We assessed the relationship between the RL and choroid plexus and the RL and cranial nerve IX and classified the RL. We also observed these relationships in clinical cases during surgeries and examined histologic assessments of the RL.
   RESULTS: The RL was divided into 3 types, non-extension type, lateral extension type, and jugular foramen type, according to the relationship between the RL and choroid plexus. There were many variations of the extension of the RL. The jugular foramen type was rare.
   CONCLUSIONS: Histologically, the RL is the remnant of the fourth ventricle covered with ependymal cells. Knowledge of the detailed anatomy and proper dissection of the RL may help surgeons to obtain good visualization of structures around the foramen of Luschka.
C1 [Akiyama, Osamu; Kondo, Akihide; Arai, Hajime] Juntendo Univ, Dept Neurosurg, Tokyo, Japan.
RP Kondo, A (reprint author), Juntendo Univ, Dept Neurosurg, Tokyo, Japan.
EM knd-aki@juntenclo.ac.jp
CR Akiyama O, 2018, J NEUROSURG, V129, P740, DOI 10.3171/2017.5.JNS17251
   Amagasaki Kenichi, 2017, Surg Neurol Int, V8, P67, DOI 10.4103/sni.sni_8_17
   Amagasaki K, 2015, BRIT J NEUROSURG, V29, P347, DOI 10.3109/02688697.2014.1003033
   Barany L, 2018, WORLD NEUROSURG, V112, pE288, DOI 10.1016/j.wneu.2018.01.037
   Barany L, 2017, ACTA NEUROCHIR, V159, P1539, DOI 10.1007/s00701-017-3234-9
   Cavusoglu H, 2015, ACTA NEUROCHIR, V157, P1999, DOI 10.1007/s00701-015-2563-9
   Funaki Takeshi, 2010, Surg Neurol Int, V1, P71, DOI 10.4103/2152-7806.72581
   Hitotsumatsu T, 2003, NEUROSURGERY, V53, P1436, DOI 10.1227/01.NEU.0000093431.43456.3B
   Huang S, 2009, P JPN ACAD B-PHYS, V85, P324, DOI 10.2183/pjab.85.324
   Matsumoto H, 2016, WORLD NEUROSURG, V86, DOI 10.1016/j.wneu.2015.10.019
   MATSUSHIMA T, 1982, NEUROSURGERY, V11, P631, DOI 10.1227/00006123-198211000-00008
   McLaughlin MR, 1999, J NEUROSURG, V90, P1, DOI 10.3171/jns.1999.90.1.0001
   Nakahara Y, 2013, J NEUROSURG, V119, P1038, DOI 10.3171/2013.4.JNS121546
   Silva J, 2012, WORLD NEUROSURG, V77, P731, DOI 10.1016/j.wneu.2011.08.019
   Tubbs RS, 2016, J CLIN NEUROSCI, V26, P79, DOI 10.1016/j.jocn.2015.10.006
NR 15
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E252
EP E258
DI 10.1016/j.wneu.2018.11.148
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400031
PM 30496925
DA 2020-05-12
ER

PT J
AU Anadani, M
   Ajinkya, S
   Alawieh, A
   Vargas, J
   Chatterjee, A
   Turk, A
   Spiotta, AM
AF Anadani, Mohammad
   Ajinkya, Shaun
   Alawieh, Ali
   Vargas, Jan
   Chatterjee, Arindam
   Turk, Aquilla
   Spiotta, Alejandro M.
TI Intra-Arterial Tissue Plasminogen Activator Is a Safe Rescue Therapy
   with Mechanical Thrombectomy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Hemorrhage; Stroke; Thrombectomy; Tissue plasminogen activator
ID ACUTE ISCHEMIC-STROKE; ENDOVASCULAR TREATMENT; THROMBOLYSIS; TRIAL;
   SELECTION; ALTEPLASE
AB INTRODUCTION: Intra-arterial tissue plasminogen activator (IA-tPA) has been widely used in conjunction with mechanical thrombectomy (MT) or as rescue therapy. Data on the safety of IA-tPA as a rescue therapy are scarce.
   OBJECTIVE: To report the safety outcome of IA-tPA during MT with respect to hemorrhage and functional outcome.
   METHODS: We reviewed our prospectively maintained data and identified patients who received mechanical thrombectomy between November 1, 2014, and January 30, 2018. Collected variables included demographics, comor-bidities, baseline National Institutes of Health Stroke Scale, procedural variables, and outcome variables, which were subjected to a matched and unmatched analysis. Hemorrhagic transformation was classified based on European Cooperative Acute Stroke Study criteria. Functional outcome was assessed based on modified Rankin Scale.
   RESULTS: A total of 486 patients were treated with MT during the study period, of whom 67 patients received IA tPA as a rescue therapy. IA tPA was used at the discretion of neuroendovascular surgeon if complete recanalization (modified Treatment in Cerebral Ischemia >= 2c) was not achieved with ADAPT (A Direct Aspiration First Pass Technique) or for distal occlusion that could not be reached with thrombectomy catheters. Both groups did not differ in baseline characteristics, comorbidities, or admission National Institutes of Health Stroke Scale. There was no significant difference in good outcome (modified Rankin Scale <= 2), death, any hemorrhage, or parenchymal hemorrhage type 2 between groups in matched and unmatched analyses.
   CONCLUSIONS: IA-tPA administration during MT was not associated with increased risk of hemorrhage in selected patients with incomplete recanalization after thrombectomy.
C1 [Anadani, Mohammad; Ajinkya, Shaun] Med Univ South Carolina, Dept Neurol, Charleston, SC 29425 USA.
   [Vargas, Jan; Turk, Aquilla; Spiotta, Alejandro M.] Med Univ South Carolina, Dept Neurosurg, Charleston, SC 29425 USA.
   [Chatterjee, Arindam] Med Univ South Carolina, Dept Radiol, Charleston, SC 29425 USA.
   [Alawieh, Ali] Med Univ South Carolina, Med Scientist Training Program, Charleston, SC 29425 USA.
RP Anadani, M (reprint author), Med Univ South Carolina, Dept Neurol, Charleston, SC 29425 USA.
EM anadani@musc.edu
RI Alawieh, Ali/AAM-1420-2020; Anadani, Mohammad/J-6012-2019
OI Anadani, Mohammad/0000-0002-7813-2949; Chatterjee,
   Arindam/0000-0002-6172-2010
CR Albers GW, 2018, NEW ENGL J MED, V378, P708, DOI 10.1056/NEJMoa1713973
   Anadani M, 2019, J NEUROINTERV SURG, V11, P641, DOI 10.1136/neurintsurg-2018-014294
   Berkhemer OA, 2015, NEW ENGL J MED, V372, P11, DOI 10.1056/NEJMoa1411587
   Christoforidis GA, 2010, INTERV NEURORADIOL, V16, P297, DOI 10.1177/159101991001600312
   Ciccone A, 2010, J NEUROINTERV SURG, V2, P74, DOI 10.1136/jnis.2009.001388
   Ding D, 2015, J STROKE, V17, P123, DOI 10.5853/jos.2015.17.2.123
   Goyal M, 2015, NEW ENGL J MED, V372, P1019, DOI 10.1056/NEJMoa1414905
   Goyal M, 2016, LANCET, V387, P1723, DOI 10.1016/S0140-6736(16)00163-X
   Hacke W, 1998, LANCET, V352, P1245, DOI 10.1016/S0140-6736(98)08020-9
   Heiferman DM, 2017, J STROKE CEREBROVASC, V26, P3004, DOI 10.1016/j.jstrokecerebrovasdis.2017.07.031
   Kidwell CS, 2013, NEW ENGL J MED, V368, P914, DOI 10.1056/NEJMoa1212793
   Kim BM, 2017, J STROKE, V19, P131, DOI 10.5853/jos.2017.00283
   Lewandowski CA, 1999, STROKE, V30, P2598, DOI 10.1161/01.STR.30.12.2598
   Ma QF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116120
   Mattle HP, 2008, STROKE, V39, P379, DOI 10.1161/STROKEAHA.107.492348
   Nogueira RG, 2018, NEW ENGL J MED, V378, P11, DOI 10.1056/NEJMoa1706442
   Sen S, 2009, NEUROCRIT CARE, V11, P76, DOI 10.1007/s12028-009-9204-1
   Turk AS, 2014, J NEUROINTERV SURG, V6, P260, DOI 10.1136/neurintsurg-2014-011125
   Wechsler LR, 2003, STROKE, V34, P1224, DOI 10.1161/01.STR.0000068782.15297.28
   Zhang B, 2010, CAN J NEUROL SCI, V37, P240, DOI 10.1017/S0317167100009999
NR 20
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E604
EP E608
DI 10.1016/j.wneu.2018.11.232
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400071
PM 30529522
DA 2020-05-12
ER

PT J
AU Ansaritoroghi, M
   Nagaraju, SP
   Nair, RP
   Kumar, V
   Kongwad, LI
   Attur, RP
   Ramachandran, GM
   Hegde, A
AF Ansaritoroghi, Marzieh
   Nagaraju, Shankar Prasad
   Nair, Rajesh Parameshwaran
   Kumar, Vinod
   Kongwad, Lakshman, I
   Attur, Ravindra Prabhu
   Ramachandran, Girish Menon
   Hegde, Ajay
TI Study on Acute Kidney Injury in Patients with Spontaneous Intracerebral
   Hemorrhage: an Overview from a Tertiary Care Hospital in South India
SO WORLD NEUROSURGERY
LA English
DT Article
DE Acute kidney injury; Estimated glomerular filtration rate; Glasgow Coma
   Scale; Spontaneous intracerebral hemorrhage
ID ACUTE-RENAL-FAILURE; ACUTE STROKE; EPIDEMIOLOGY; POPULATION; OUTCOMES;
   TERM
AB INTRODUCTION: Acute kidney injury (AKI) is an independent risk factor for adverse clinical outcomes in patients with hemorrhagic stroke. There is limited data regarding the occurrence and impact of AKI in the setting of spontaneous intracerebral hemorrhage (SICH). Considering this, we sought to determine the incidence and risk factors for AKI in patients with SICH and to determine the role of AKI on SICH mortality in our population.
   MATERIALS AND METHODS: This is a retrospective analysis of the data recorded in the stroke registry maintained by the Department of Neurosurgery, Kasturba Hospital, Kasturba Medical College, Manipal Academy of Higher Education after ethical committee clearance. Information regarding clinical features, demographics, laboratory data, prescribing patterns, and the use of contrast-mediated imaging were collected. AKI was defined according to the Kidney Disease: Improving Global Outcomes criteria. Logistic multivariate regression was used to determine predictors of AKI. Analysis of variance was used to measure the effect of AKI on SICH outcome.
   RESULTS: Of 316 patients with SICH admitted to the hospital, 20% of patients developed AKI. It was found that risk factors for AKI were lower baseline estimated glomerular filtration rate (odds ratio, 1.60; 95% confidence interval, 1.21 SICH 2.2; P < 0.001) and infectious complications (odds ratio, 3.37; 95% confidence interval, 1.9-5.7; P < 0.001). The incidence of 30 days' mortality was higher in the group with AKI (14% vs. 5.5%). There was a significant association between AKI severity and short-term mortality (P < 0.001). Patients with AKI had a lower Glasgow Coma Scale on admission (11.81 +/- 3.17 vs. 10.83 +/- 3.2) and discharge (12.44 +/- 3.44 vs. 10.38 +/- 3.2) compared to patients without AKI (P < 0.001). Greater severity of AKI was associated with worse neurologic outcome (P < 0.001).
   DISCUSSION: Various studies in literature have evaluated the incidence of AKI after a stroke episode. The incidence of AKI was ranging from 8%-21% in those studies. In our study, we found that 20% of SICH patients developed AKI. The incidence of AKI in our study falls along the spectrum described in these previous studies.
   CONCLUSIONS: AKI is a common complication of SICH. Lower estimated glomerular filtration rate at admission and infections were the significant risk factors. Patients with AKI had poor neurologic outcome and higher mortality and it increased with the severity of AKI.
C1 [Nair, Rajesh Parameshwaran; Kumar, Vinod; Kongwad, Lakshman, I; Ramachandran, Girish Menon; Hegde, Ajay] Manipal Acad Higher Educ, Kasturba Med Coll, Dept Neurosurg, Manipal, Karnataka, India.
   [Nagaraju, Shankar Prasad; Attur, Ravindra Prabhu] Manipal Acad Higher Educ, Kasturba Med Coll, Dept Nephrol, Manipal, Karnataka, India.
   [Ansaritoroghi, Marzieh] Manipal Acad Higher Educ, Manipal Coll Pharmaceut Sci, Manipal, Karnataka, India.
RP Nair, RP (reprint author), Manipal Acad Higher Educ, Kasturba Med Coll, Dept Neurosurg, Manipal, Karnataka, India.
EM rajeshnair39@yahoo.com
RI Prabhu, Ravindra/AAE-7064-2020; Hegde, Ajay/AAG-3703-2019
OI Hegde, Ajay/0000-0001-6970-2260; nagaraju, shankar
   prasad/0000-0003-1016-8280; Prabhu, Ravindra/0000-0002-5980-7197
CR Covic A, 2008, NEPHROL DIAL TRANSPL, V23, P2228, DOI 10.1093/ndt/gfm591
   Demel SL, 2017, STROKE, V48, P835, DOI 10.1161/STROKEAHA.116.014603
   Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8
   Goldfarb S, 2009, MAYO CLIN PROC, V84, P170, DOI 10.1016/S0025-6196(11)60825-2
   Khatri M, 2014, J STROKE CEREBROVASC, V23, P25, DOI 10.1016/j.jstrokecerebrovasdis.2012.06.005
   Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006
   Matsushita K, 2010, AM J KIDNEY DIS, V55, P648, DOI 10.1053/j.ajkd.2009.12.016
   Saeed F, 2015, J STROKE CEREBROVASC, V24, P789, DOI 10.1016/j.jstrokecerebrovasdis.2014.11.012
   Singbartl K, 2012, KIDNEY INT, V81, P819, DOI 10.1038/ki.2011.339
   TEASDALE G, 1974, LANCET, V2, P81
   Tsagalis G, 2009, NEPHROL DIAL TRANSPL, V24, P194, DOI 10.1093/ndt/gfn471
   Uchino S, 2005, JAMA-J AM MED ASSOC, V294, P813, DOI 10.1001/jama.294.7.813
   Waikar SS, 2008, CLIN J AM SOC NEPHRO, V3, P844, DOI 10.2215/CJN.05191107
   Wang CW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102326
   Wang DX, 2018, INTERN EMERG MED, V13, P17, DOI 10.1007/s11739-017-1703-z
   Zorrilla-Vaca A, 2018, CEREBROVASC DIS, V45, P1, DOI 10.1159/000479338
NR 16
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E740
EP E746
DI 10.1016/j.wneu.2018.12.018
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400088
PM 30579025
DA 2020-05-12
ER

PT J
AU Appel, S
   Biron, T
   Goldstein, K
   Ashkenazi, E
AF Appel, Shmuel
   Biron, Tali
   Goldstein, Kobi
   Ashkenazi, Ely
TI Effect of Intra- and Extraoperative Factors on the Efficacy of
   Intraoperative Neuromonitoring During Cervical Spine Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cervical spine surgery; Intraoperative neuromonitoring; Prognosis;
   Surgical outcome
ID PATIENT; CORD
AB INTRODUCTION: The purpose of the present study was to examine the effect of various extra- and intraoperative factors on the ability of neuromonitoring to predict neurological complications.
   METHODS: We reviewed the data from 592 patients who had undergone cervical spine surgery with neuromonitoring at Assuta Medical Center from 2006 to 2013. We compared the somatosensory evoked potentials, transcranial electric motor evoked potentials, and electromyographic signals collected throughout surgery with the patient surgical outcome measures, demographic data, preexisting pathological features found on neurological examination, and radiographic findings. Descriptive and inferential analyses were used to estimate the relative explanatory power contributed by these factors.
   RESULTS: We included 468 patients in the present study. Neuromonitoring changes occurred in 100 patients, and the appropriate clinical intervention was undertaken in all 100, with recovery of the signals in 69. A transient neuromonitoring change was not associated with a poor outcome (only 8 of 69 patients). However, a permanent neuromonitoring change was associated with a new neurological deficit (13 of 31 patients) Changes occurring during positioning or decompression were associated with better clinical outcomes than were changes occurring during the rest of the procedure. Extraoperative factors were not associated with an increased risk of neuromonitoring changes during surgery or poorer surgical outcomes.
   CONCLUSIONS: Permanent neuromonitoring changes predicted for new neurological deficits. However, transient changes were not associated with a new deficit. Neuromonitoring changes occurring during positioning and decompression had better clinical outcomes compared with those occurring during the rest of the procedure.
C1 [Appel, Shmuel] Ben Gurion Univ Negev, Barzilai Med Ctr Ashkelon, Dept Neurol, Joyce & Irving Goldman Sch Med, Negev, Israel.
   [Appel, Shmuel; Biron, Tali; Goldstein, Kobi] Surg Monitoring Serv LTD, Bet Shemesh, Israel.
   [Biron, Tali] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Dept Pediat Neurosurg, Sackler Sch Med, Tel Aviv, Israel.
   [Ashkenazi, Ely] Assuta Med Ctr, Israel Spine Ctr, Tel Aviv, Israel.
RP Appel, S (reprint author), Ben Gurion Univ Negev, Barzilai Med Ctr Ashkelon, Dept Neurol, Joyce & Irving Goldman Sch Med, Negev, Israel.; Appel, S (reprint author), Surg Monitoring Serv LTD, Bet Shemesh, Israel.
EM shmuela@barzi.health.gov.il
CR Cheng JS, 2014, J NEUROSURG-PEDIATR, V13, P591, DOI 10.3171/2014.2.PEDS1392
   Cole T, 2014, SPINE, V39, P1950, DOI 10.1097/BRS.0000000000000593
   Danto J, 2012, J NEUROSURG ANESTH, V24, P350, DOI 10.1097/ANA.0b013e3182622843
   Epstein Nancy E, 2013, Surg Neurol Int, V4, pS383, DOI 10.4103/2152-7806.120782
   EPSTEIN NE, 1993, SPINE, V18, P737, DOI 10.1097/00007632-199305000-00011
   Hamilton DK, 2011, SPINE, V36, P1218, DOI 10.1097/BRS.0b013e3181ec5fd9
   Holdefer RN, 2015, CLIN NEUROPHYSIOL, V126, P857, DOI 10.1016/j.clinph.2014.11.009
   Lall RR, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.9.FOCUS12235
   Lee JY, 2006, SPINE, V31, P1916, DOI 10.1097/01.brs.0000228724.01795.a2
   Bello JP, 2015, CLIN NEUROPHYSIOL, V126, P1264, DOI 10.1016/j.clinph.2014.09.020
   Quraishi NA, 2009, SPINE, V34, P1504, DOI 10.1097/BRS.0b013e3181a87b66
   Raynor BL, 2013, SPINE, V38, pE101, DOI 10.1097/BRS.0b013e31827aafb9
   Romstock J, 2000, J NEUROSURG, V93, P586, DOI 10.3171/jns.2000.93.4.0586
   Sala F, 2004, ADV TECH STAND NEUR, V29, P133
   Smith PN, 2007, SPINE J, V7, P83, DOI 10.1016/j.spinee.2006.04.008
   Tamkus AA, 2014, SPINE J, V14, P1440, DOI 10.1016/j.spinee.2013.08.037
   Vadivelu S, 2014, WORLD NEUROSURG, V81, P617, DOI 10.1016/j.wneu.2013.11.010
NR 17
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E646
EP E651
DI 10.1016/j.wneu.2018.11.244
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400076
PM 30576814
DA 2020-05-12
ER

PT J
AU Asmaro, K
   Arshad, M
   Massie, L
   Griffith, B
   Lee, I
AF Asmaro, Karam
   Arshad, Muzamil
   Massie, Lara
   Griffith, Brent
   Lee, Ian
TI Sellar Atypical Teratoid/Rhabdoid Tumor Presenting with Subarachnoid and
   Intraventricular Hemorrhage
SO WORLD NEUROSURGERY
LA English
DT Article
DE ATRT; Atypical teratoid/rhabdoid tumors; Intraventricular hemorrhage;
   Leptomeningeal carcinomatosis; Leptomeningeal spread; Sellar ATRT;
   Subarachnoid hemorrhage
ID TERATOID RHABDOID TUMOR; ADULT; CHILDREN; SURVIVAL; THERAPY; TURCICA;
   EXPERIENCE; MANAGEMENT; CHILDHOOD; PATIENT
AB BACKGROUND: Atypical teratoid/rhabdoid tumors (ATRT) are uncommon malignancies of the central nervous system and are often difficult to distinguish radiographically and pathologically from other common tumors. We present the first case of sellar ATRT presenting with subarachnoid hemorrhage (SAH) and intraventricular hemorrhage (IVH).
   CASE DESCRIPTION: A 62-year-old woman, who had presented with symptoms of headache, diabetes insipidus, hypothyroidism, and seizures, was found to have a sellar tumor with hemorrhagic transformation. Surgical resection was performed. The pathological examination findings were consistent with ATRT. Despite early surgical intervention, she later died before starting craniospinal radiotherapy and chemotherapy.
   CONCLUSION: To the best of our knowledge, although known to present with intratumoral hemorrhage, to date, no cases of sellar ATRT have presented with SAH or IVH have been reported. Considering our finding that ATRT can present with SAH and IVH, establishing the correct diagnosis using radiographic imaging, gender, pathological findings, and molecular markers is paramount for speedy treatment and management.
C1 [Asmaro, Karam; Arshad, Muzamil; Massie, Lara; Lee, Ian] Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI 48202 USA.
   [Griffith, Brent] Henry Ford Hlth Syst, Dept Radiol, Detroit, MI USA.
RP Asmaro, K (reprint author), Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI 48202 USA.
EM kasmaro2@hfhs.org
OI Asmaro, Karam/0000-0002-2084-4863; Massie, Lara/0000-0002-7427-5547
CR Almalki Mussa Hussain, 2017, J Clin Med Res, V9, P216, DOI 10.14740/jocmr2922w
   Arita K, 2008, ACTA NEUROCHIR, V150, P491, DOI 10.1007/s00701-008-1500-y
   Barresi V, 2018, NEUROPATHOLOGY, V38, P260, DOI 10.1111/neup.12440
   Biswas A, 2016, CANCER MANAG RES, V8, P115, DOI 10.2147/CMAR.S83472
   Biswas A, 2015, ACTA NEUROCHIR, V157, P589, DOI 10.1007/s00701-015-2355-2
   Biswas S, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00236
   Chi SN, 2009, J CLIN ONCOL, V27, P385, DOI 10.1200/JCO.2008.18.7724
   CRIST W, 1995, J CLIN ONCOL, V13, P610, DOI 10.1200/JCO.1995.13.3.610
   Dardis C, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00247
   Dufour C, 2012, CANCER-AM CANCER SOC, V118, P3812, DOI 10.1002/cncr.26684
   Fruhwald MC, 2016, NEURO-ONCOLOGY, V18, P764, DOI 10.1093/neuonc/nov264
   Ganaha Tsukasa, 2016, Surg Neurol Int, V7, pS459, DOI 10.4103/2152-7806.185775
   Geyer JR, 2005, J CLIN ONCOL, V23, P7621, DOI 10.1200/JCO.2005.09.095
   Han L, 2011, AM J NEURORADIOL, V32, P103, DOI 10.3174/ajnr.A2361
   Heras FL, 2010, PATHOL RES PRACT, V206, P788, DOI 10.1016/j.prp.2010.07.004
   Hilden JM, 2004, J CLIN ONCOL, V22, P2877, DOI 10.1200/jco.2004.07.073
   Kuge A, 2000, NEUROL SURG TOKYO, V28, P351
   Louis DN, 2016, WHO CLASSIFICATION T
   Meyers SP, 2006, AM J NEURORADIOL, V27, P962
   Moretti C, 2013, CLIN MED INSIGHT-CAS, V6, P177, DOI 10.4137/CCRep.S12834
   Nakata S, 2017, AM J SURG PATHOL, V41, P932, DOI 10.1097/PAS.0000000000000845
   Nishikawa A, 2018, J CLIN NEUROSCI, V49, P16, DOI 10.1016/j.jocn.2017.12.010
   Nobusawa S, 2016, VIRCHOWS ARCH, V469, P711, DOI 10.1007/s00428-016-2017-7
   Park Hae Gi, 2014, Brain Tumor Res Treat, V2, P108, DOI 10.14791/btrt.2014.2.2.108
   Raisanen J, 2005, BRAIN PATHOL, V15, P23
   RORKE LB, 1995, J NEURO-ONCOL, V24, P21, DOI 10.1007/BF01052653
   Schneiderhan TM, 2011, NEUROPATH APPL NEURO, V37, P326, DOI 10.1111/j.1365-2990.2010.01111.x
   Shitara Satoshi, 2014, Surg Neurol Int, V5, P75, DOI 10.4103/2152-7806.133105
   Singh TD, 2015, J NEUROSURG, V122, P1450, DOI 10.3171/2014.10.JNS141204
   Slavc I, 2014, CANCER MED-US, V3, P91, DOI 10.1002/cam4.161
   Sredni ST, 2015, PEDIATR DEVEL PATHOL, V18, P49, DOI 10.2350/14-07-1531-MISC.1
   Tekautz TM, 2005, J CLIN ONCOL, V23, P1491, DOI 10.1200/JCO.2005.05.187
   von Hoff K, 2011, PEDIATR BLOOD CANCER, V57, P978, DOI 10.1002/pbc.23236
   Woehrer A, 2010, CANCER-AM CANCER SOC, V116, P5725, DOI 10.1002/cncr.25540
NR 34
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E31
EP E38
DI 10.1016/j.wneu.2018.10.198
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400006
PM 30404057
DA 2020-05-12
ER

PT J
AU Cai, F
   Hong, Y
   Xu, JH
   Wu, Q
   Reis, C
   Yan, W
   Wang, W
   Zhang, JM
AF Cai, Feng
   Hong, Yuan
   Xu, Jinghong
   Wu, Qun
   Reis, Cesar
   Yan, Wei
   Wang, Wei
   Zhang, Jianmin
TI A Novel Mutation of Aryl Hydrocarbon Receptor Interacting Protein Gene
   Associated with Familial Isolated Pituitary Adenoma Mediates Tumor
   Invasion and Growth Hormone Hypersecretion
SO WORLD NEUROSURGERY
LA English
DT Article
DE AIP; Aryl hydrocarbon receptor interacting protein; Drug resistance;
   Familial isolated pituitary adenoma; FIPA; Hypersecretion; Mutation;
   Tumor invasiveness
ID SOMATOSTATIN ANALOGS; AIP GENE; SOMATOTROPH ADENOMAS; GERMLINE
   MUTATIONS; AHR; OCTREOTIDE; EXPRESSION; RESISTANT; FEATURES
AB BACKGROUND: Germline mutations in the aryl hydrocarbon receptor-interacting protein (AIP) gene were identified in nearly 20% of families with familial isolated pituitary adenoma. Some variants of AIP have been confirmed to induce tumor cell proliferation and invasiveness; however, the mechanism is still unclear.
   METHODS: A novel missense mutation (c.512C>T, p.T171I) was discovered in 3 patients from a Chinese family with familial isolated pituitary adenoma. In silico and multiplex ligation-dependent probe amplification analysis predicted the mutation to be pathogenic. GH3 and 293FT cell lines were used to verify the variant's effect on cell proliferation (Cell Counting Kit-8), invasiveness (Transwell) and growth hormone (GH) secretion (enzyme-linked immunosorbent assay) by transfection with different vectors: control, blank vector, wild-type AIP, p. T171I variant (experimental group), p. Q315* variant, and AIP small interfering RNA. Furthermore, Zac1, Sstr2, interleukin (IL)-6, and Stat3/phosphorylation-Stat3 expression (reverse transcription polymerase chain reaction, Western blot) in each group was also evaluated.
   RESULTS: The experimental group, p. Q315* variant group, and AIP small interfering RNA-overexpressing group promoted cell proliferation at 24 and 48 hours, respectively (compared with the control group; P < 0.01 for both). Similarly, the cells in the experimental group manifested more invasion and GH secretion compared with the control group (P < 0.01 and P < 0.05, respectively). Furthermore, the experimental group cells expressed less Sstr2 (a prerequisite for the responsiveness to somatostatin analogues) and Zac1 (tumor suppressor gene), but more IL-6 and phosphorylated-Stat3 (GH-secretion related).
   CONCLUSIONS: The novel AIP mutation c. 512C>T (p.T171I) is a pathogenic variant that promoted cell proliferation, invasiveness, and GH secretion through regulation of Sstr2, Zac1, and IL-6/phosphorylated-Stat3 expression.
C1 [Cai, Feng; Hong, Yuan; Wu, Qun; Yan, Wei; Wang, Wei; Zhang, Jianmin] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Neurosurg, Hangzhou, Zhejiang, Peoples R China.
   [Xu, Jinghong] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Pathol, Hangzhou, Zhejiang, Peoples R China.
   [Reis, Cesar] Loma Linda Univ, Sch Med, Dept Prevent Med, Loma Linda, CA USA.
   [Reis, Cesar] Loma Linda Univ, Sch Med, Dept Physiol & Pharmacol, Loma Linda, CA USA.
RP Zhang, JM (reprint author), Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Neurosurg, Hangzhou, Zhejiang, Peoples R China.
EM zjm135@zju.edu.cn
OI Yan, Wei/0000-0002-1123-0835
FU Medical and Health Research Project of Zhejiang Province [201482029];
   Natural Science Foundation of Zhejiang ProvinceNatural Science
   Foundation of Zhejiang Province [LQ15H070001, LY17H090012]; Natural
   Science Foundation of ChinaNational Natural Science Foundation of China
   [81502321]; Science and Technology Department of Zhejiang Province
   Project [2015C33192]; major science and technology project in medical
   and health of Zhejiang Province [WKJ-ZJ-1615(2016149634)]
FX This work was supported by Medical and Health Research Project of
   Zhejiang Province (Grant number: 201482029), Natural Science Foundation
   of Zhejiang Province (Grant number: LQ15H070001, LY17H090012), Natural
   Science Foundation of China (Grant number: 81502321), Science and
   Technology Department of Zhejiang Province Project (Grant number:
   2015C33192), and Grant WKJ-ZJ-1615(2016149634) from a major science and
   technology project in medical and health of Zhejiang Province
   (co-constructed project by the province and the ministry).
CR Beckers A, 2007, EUR J ENDOCRINOL, V157, P371, DOI 10.1530/EJE-07-0348
   Bell DR, 2000, J BIOL CHEM, V275, P36407, DOI 10.1074/jbc.M004236200
   Cai F, 2013, EUR J ENDOCRINOL, V169, P867, DOI 10.1530/EJE-13-0442
   Caimari F, 2016, CLIN CANCER RES, V22, P5030, DOI 10.1158/1078-0432.CCR-16-0452
   Cansu GB, 2016, HORM-INT J ENDOCRINO, V15, P441, DOI [10.14310/horm.2002.1686, 10.14310/horm.2002.1692]
   Chahal HS, 2012, J CLIN ENDOCR METAB, V97, pE1411, DOI 10.1210/jc.2012-1111
   Daly AF, 2010, J CLIN ENDOCR METAB, V95, pE373, DOI 10.1210/jc.2009-2556
   Daly AF, 2009, BEST PRACT RES CL EN, V23, P543, DOI 10.1016/j.beem.2009.05.008
   Fujii-Kuriyama Y, 2005, BIOCHEM BIOPH RES CO, V338, P311, DOI 10.1016/j.bbrc.2005.08.162
   Fukuda T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164131
   Gadelha MR, 2013, TRENDS ENDOCRIN MET, V24, P238, DOI 10.1016/j.tem.2012.11.007
   Guaraldi Federica, 2012, Pituitary, V15 Suppl 1, pS61, DOI 10.1007/s11102-012-0391-y
   Hernandez-Ramirez LC, 2015, J CLIN ENDOCR METAB, V100, pE1242, DOI 10.1210/jc.2015-1869
   Iacovazzo D, 2016, EUR J ENDOCRINOL, V174, P241, DOI 10.1530/EJE-15-0832
   Igreja S, 2010, HUM MUTAT, V31, P950, DOI 10.1002/humu.21292
   Iwata T, 2014, ENDOCR PATHOL, V25, P273, DOI 10.1007/s12022-014-9318-7
   Jaffrain-Rea ML, 2009, ENDOCR-RELAT CANCER, V16, P1029, DOI 10.1677/ERC-09-0094
   Kasuki L, 2012, ENDOCR-RELAT CANCER, V19, pL25, DOI 10.1530/ERC-12-0020
   Kazlauskas A, 2000, J BIOL CHEM, V275, P41317, DOI 10.1074/jbc.M007765200
   Leontiou CA, 2008, J CLIN ENDOCR METAB, V93, P2390, DOI 10.1210/jc.2007-2611
   Linnert M, 2012, BIOMOL NMR ASSIGN, V6, P209, DOI 10.1007/s12104-012-9359-0
   Morgan RML, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0053339
   Occhi G, 2010, J ENDOCRINOL INVEST, V33, P800, DOI [10.1007/BF03350345, 10.3275/6956]
   Oriola J, 2013, EUR J ENDOCRINOL, V168, P9, DOI 10.1530/EJE-12-0457
   Ozfirat Z, 2010, MOL CELL ENDOCRINOL, V326, P71, DOI 10.1016/j.mce.2010.05.001
   Ritvonen E, 2017, EUR J ENDOCRINOL, V176, P243, DOI 10.1530/EJE-16-0620
   Soares BS, 2005, J CLIN ENDOCR METAB, V90, P6580, DOI 10.1210/jc.2005-1478
   Theodoropoulou M, 2006, CANCER RES, V66, P1576, DOI 10.1158/0008-5472.CAN-05-1189
   Trivellin G, 2014, NEW ENGL J MED, V371, P2363, DOI 10.1056/NEJMoa1408028
   Trivellin G, 2011, J ENDOCRINOL, V210, P137, DOI 10.1530/JOE-11-0054
   Vargiolu M, 2009, J CLIN ENDOCR METAB, V94, P2571, DOI 10.1210/jc.2008-1980
   Vierimaa O, 2006, SCIENCE, V312, P1228, DOI 10.1126/science.1126100
   Zhou CQ, 2015, J CLIN INVEST, V125, P1692, DOI 10.1172/JCI78173
NR 33
TC 0
Z9 0
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E45
EP E59
DI 10.1016/j.wneu.2018.11.021
PG 15
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400008
PM 30447469
DA 2020-05-12
ER

PT J
AU Du, CN
   Yang, MF
   Zhang, Q
   Jin, XQ
   Yan, C
   Huang, YW
AF Chao-Nan Du
   Ming-Fei Yang
   Qiang Zhang
   Xiao-Qing Jin
   Chao Yan
   Yong-Wei Huang
TI Establishment and Verification of the Hematoma Expansion Prediction
   Score of Intracerebral Hemorrhage in the Qinghai-Tibetan Plateau
SO WORLD NEUROSURGERY
LA English
DT Article
DE CT; Hematoma expansion; Intracerebral hemorrhage; Nomogram model;
   Qinghai-Tibetan Plateau
ID BLACK-HOLE SIGN; IMAGING PREDICTOR; ISLAND SIGN; BLEND SIGN; GROWTH;
   DETERMINANTS; NOMOGRAM; RISK; CT
AB OBJECTIVE: The latest World Health Organization data showed that stroke was the highest mortality in China, accounting for 23.7% of the total mortality from 2000 to 2012. Intracerebral hemorrhage (ICH) was the most deadly and incurable type of stroke. In the Qinghai-Tibetan Plateau, the incidence of stroke was relatively higher. Several studies showed that the shape and heterogeneity of hematoma and image markers on brain computed tomography scan had predictive effects on hematoma expansion (HE). The study aimed to find relative factors and established a nomogram model to predict the HE of ICH.
   METHODS: All patients with ICH in Qinghai Provincial People's Hospital from January 1, 2012, to May 22, 2018, were continuously collected. A total of 402 patients were included in the study. This was a single-center retrospective study. Univariate and binary logistic regression analysis were performed to screen out the independent predictors that were significantly associated with HE.
   RESULTS: The total incidence of HE in ICH was 30.9%, whereas the incidence of HE in the basal ganglia and nonbasal ganglia was 36.4% and 17.2%, respectively. Diabetes, basal ganglia hemorrhage, time of onset to baseline computed tomography, island sign, blend sign, black hole sign, and swirl sign were independent predictors of HE. Based on these predictors, a nomogram model was established and the accuracy was 81.6%, the sensitivity was 91.1%, and the specificity was 70.5%.
   CONCLUSIONS: This model had a high accuracy of predicting HE in the Qinghai-Tibetan Plateau. Because this model is noninvasive, rapid, and low cost, it is easy to promote and has wide application prospects in clinical practice.
C1 [Chao-Nan Du; Xiao-Qing Jin; Chao Yan; Yong-Wei Huang] Qinghai Univ, Grad Sch, Xining, Qinghai, Peoples R China.
   [Ming-Fei Yang; Qiang Zhang] Qinghai Prov Peoples Hosp, Dept Neurosurg, Xining, Qinghai, Peoples R China.
RP Yang, MF (reprint author), Qinghai Prov Peoples Hosp, Dept Neurosurg, Xining, Qinghai, Peoples R China.
EM iloveyoucmu@163.com
CR [Anonymous], 2012, COUNTR STAT GLOB HLT
   Barras CD, 2009, STROKE, V40, P1325, DOI 10.1161/STROKEAHA.108.536888
   Broderick JP, 2007, STROKE, V38, P1072, DOI 10.1161/01.STR.0000258078.35316.30
   Brouwers HB, 2012, NEUROCRIT CARE, V17, P421, DOI 10.1007/s12028-012-9765-2
   Chang CH, 2010, DIABETIC MED, V27, P636, DOI 10.1111/j.1464-5491.2010.03007.x
   Dowlatshahi D, 2011, NEUROLOGY, V76, P1238, DOI 10.1212/WNL.0b013e3182143317
   Huang YW, 2018, BIOSCI TRENDS, V12, P193, DOI 10.5582/bst.2018.01061
   Huhtakangas J, 2013, STROKE, V44, P585, DOI 10.1161/STROKEAHA.112.671230
   Iasonos A, 2008, J CLIN ONCOL, V26, P1364, DOI 10.1200/JCO.2007.12.9791
   Li Q, 2017, STROKE, V48, P3019, DOI 10.1161/STROKEAHA.117.017985
   Li Q, 2016, STROKE, V47, P1777, DOI 10.1161/STROKEAHA.116.013186
   Li Q, 2015, STROKE, V46, P2119, DOI 10.1161/STROKEAHA.115.009185
   Li RL, 2017, BIOSCI TRENDS, V11, P682, DOI 10.5582/bst.2017.01283
   Ovesen C, 2014, STROKE, V45, P994, DOI 10.1161/STROKEAHA.113.003608
   Rost NS, 2008, STROKE, V39, P2166, DOI 10.1161/STROKEAHA.107.501650
   Sarwar N, 2010, LANCET, V375, P2215, DOI 10.1016/S0140-6736(10)60484-9
   Selariu E, 2012, LANCET NEUROL, V11, P307
   Selariu E, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-109
   Shimoda Y, 2017, CEREBROVASC DIS, V44, P105, DOI 10.1159/000477179
   Sun Banruo, 2014, Zhonghua Yi Xue Za Zhi, V94, P591
   Wang X, 2015, STROKE, V46, P376, DOI 10.1161/STROKEAHA.114.006910
   Wu ZS, 2001, CIRCULATION, V103, P462
   Yao XY, 2015, NEUROCRIT CARE, V23, P179, DOI 10.1007/s12028-015-0147-4
   Yu ZY, 2018, STROKE, V49, pE34, DOI 10.1161/STROKEAHA.117.019992
   Yuan RZ, 2016, WORLD NEUROSURG, V93, P6, DOI 10.1016/j.wneu.2016.05.064
   Zhang LF, 2003, STROKE, V34, P2091, DOI 10.1161/01.STR.0000087149.42294.8C
   Zheng Y, 2018, EUR J SURG ONCOL, V18
NR 27
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E465
EP E473
DI 10.1016/j.wneu.2018.11.189
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400054
PM 30500588
DA 2020-05-12
ER

PT J
AU Chen, CJ
   Ding, D
   Lronside, N
   Buell, TJ
   Southerland, AM
   Woo, D
   Worrall, BB
AF Chen, Ching-Jen
   Ding, Dale
   Lronside, Natasha
   Buell, Thomas J.
   Southerland, Andrew M.
   Woo, Daniel
   Worrall, Bradford B.
CA ERICH Investigators
TI Predictors of Surgical Intervention in Patients with Spontaneous
   Intracerebral Hemorrhage
SO WORLD NEUROSURGERY
LA English
DT Article
DE Evacuation; Intracerebral hemorrhage; Neurosurgery; Predictors; Surgery
ID MINIMALLY INVASIVE SURGERY; INITIAL CONSERVATIVE TREATMENT; CEREBELLAR
   HEMORRHAGE; MANAGEMENT; STROKE; METAANALYSIS; HEMATOMAS; BLACKS; TRIAL;
   STICH
AB OBJECTIVE: Despite no clear evidence from randomized trials, surgical intervention of spontaneous intracerebral hemorrhage (ICH) still occurs. We sought to describe the characteristics of patients undergoing surgical intervention in ICH.
   METHODS: Data from the ERICH (ERICH Ethnic/Racial Variations of Intracerebral Hemorrhage) study were analyzed, and patients with ICH were categorized into surgical intervention or nonoperative management groups. Patients with primary intraventricular hemorrhage and those without data regarding the use of surgical intervention were excluded.
   RESULTS: The study cohort comprised 2947 patients, and surgical intervention was performed in 289 (10%). Younger age (odds ratio [OR], 0.967; P < 0.001), lower baseline modified Rankin Scale score (OR, 0.728; P < 0.001), higher admission Glasgow Coma Scale score (OR, 1.059; P = 0.007), larger ICH volume (OR, 1.037; P < 0.001), infratentorial ICH location (OR, 5.966; P < 0.001), lobar ICH location (OR, 1.906; P = 0.001), lack of intraventricular hemorrhage (OR, 0.567; P = 0.001), intracranial pressure (ICP) monitoring (OR, 5.022; P < 0.001), and mannitol use (OR, 2.389; P < 0.001) were independent predictors of surgical intervention. Younger age (OR, 0.953; P < 0.001), lower baseline modified Rankin Scale score (OR, 0.713; P = 0.002), larger ICH volume (OR, 1.033; P < 0.001), lobar ICH location (OR, 2.467; P < 0.001), ICP monitoring (OR, 3.477; P < 0.001), and mannitol use (OR, 2.139; P < 0.001) were independent predictors of surgical interventions in supratentorial ICHs. Larger ICH volume (OR, 1.078; P < 0.001), ICP monitoring (OR, 6.099; P < 0.001), and mannitol use (OR, 2.952; P = 0.005) were independent predictors of surgical interventions in infratentorial ICHs.
   CONCLUSIONS: We identified multiple factors associated with surgical intervention for patients with ICH. Younger age, good neurologic function at baseline, large ICH volume on presentation, and lobar or infratentorial hematomas were independently associated with surgical intervention in patients with ICH .
C1 [Chen, Ching-Jen; Buell, Thomas J.] Univ Virginia, Dept Neurol Surg, Charlottesville, VA 22908 USA.
   [Ding, Dale] Univ Louisville, Dept Neurosurg, Louisville, KY USA.
   [Lronside, Natasha] Columbia Univ, Med Ctr, New York Presbyterian, Dept Neurosurg, New York, NY USA.
   [Southerland, Andrew M.; Worrall, Bradford B.] Univ Virginia, Dept Ncurol & Publ Hlth Sci, Charlottesville, VA USA.
   [Woo, Daniel] Univ Cincinnati, Dept Neurol & Rehabil Med, Cincinnati, OH USA.
RP Chen, CJ (reprint author), Univ Virginia, Dept Neurol Surg, Charlottesville, VA 22908 USA.
EM chenjared@gmail.com
RI Ding, Dale/AAN-3583-2020
FU National Institute of Neurological Disorders and Stroke (NINDS)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Neurological Disorders &
   Stroke (NINDS) [U-01-NS069763]; NIHUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [NS-069763,
   NS-36695, NS-30678]
FX This study was supported by a grant from the National Institute of
   Neurological Disorders and Stroke (NINDS: U-01-NS069763). C.J.C., D.D.,
   N.I., and T.J.B., no disclosures; A.M.S., nonestudy-related personal
   fees from Neurology Podcast, personal fees from Expert Legal Review,
   grants from American Heart Association eAmerican Stroke Association,
   grants from American Academy of Neurology, grants from American Board of
   Psychiatry and Neurology, and a pending patent on mobile telemedicine
   for rapid evaluation of acute stroke (serial number: 61/867,477); D.W.,
   NIH grant support, including NIH NS-069763, NS-36695, and NS-30678.; and
   B.W., NIH grant support, including NIH NS-069763, and is the Deputy
   Editor for the Journal of Neurology.
CR BRODERICK JP, 1992, NEW ENGL J MED, V326, P733, DOI 10.1056/NEJM199203123261103
   Da Pian R, 1984, Neurol Res, V6, P145
   DENNIS MS, 1993, STROKE, V24, P796, DOI 10.1161/01.STR.24.6.796
   Fiorella D, 2016, STROKE, V47, P1399, DOI 10.1161/STROKEAHA.115.011415
   FIRSCHING R, 1991, NEUROSURG REV, V14, P191, DOI 10.1007/BF00310656
   Fung C, 2012, STROKE, V43, P3207, DOI 10.1161/STROKEAHA.112.666537
   Gregson BA, 2003, STROKE, V34, P2593, DOI 10.1161/01.STR.0000097491.82104.F3
   Gregson BA, 2012, STROKE, V43, P1496, DOI 10.1161/STROKEAHA.111.640284
   Hanley DF, 2016, LANCET NEUROL, V15, P1226, DOI 10.1016/S1474-4422(16)30234-4
   Hayes SB, 2013, NEUROSURG FOCUS, V34, DOI 10.3171/2013.2.FOCUS12422
   Hemphill JC, 2015, STROKE, V46, P2032, DOI 10.1161/STR.0000000000000069
   Hemphill JC, 2001, STROKE, V32, P891, DOI 10.1161/01.STR.32.4.891
   Heuts SG, 2013, NEUROSURG FOCUS, V34, DOI 10.3171/2013.2.FOCUS1326
   Kleindorfer DO, 2010, STROKE, V41, P1326, DOI 10.1161/STROKEAHA.109.575043
   Mendelow AD, 2013, LANCET, V382, P397, DOI 10.1016/S0140-6736(13)60986-1
   Mendelow AD, 2005, LANCET, V365, P387
   Prasad K, 2008, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000200.pub2, 10.1002/14651858.CD002244.pub3]
   Rubin DB, 1987, WILEY SERIES PROBABI
   Sacco S, 2009, STROKE, V40, P394, DOI 10.1161/STROKEAHA.108.523209
   Takeuchi S, 2013, NEUROSURG FOCUS, V34, DOI 10.3171/2013.2.FOCUS12424
   van Asch CJJ, 2010, LANCET NEUROL, V9, P167, DOI 10.1016/S1474-4422(09)70340-0
   VANLOON J, 1993, ACTA NEUROCHIR, V122, P187, DOI 10.1007/BF01405527
   Vespa P, 2016, STROKE, V47, P2749, DOI 10.1161/STROKEAHA.116.013837
   Wang WZ, 2009, INT J STROKE, V4, P11, DOI 10.1111/j.1747-4949.2009.00239.x
   Woo D, 2013, STROKE, V44, pE120, DOI 10.1161/STROKEAHA.113.002332
   Zhou XY, 2012, STROKE, V43, P2923, DOI 10.1161/STROKEAHA.112.667535
NR 26
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E700
EP E708
DI 10.1016/j.wneu.2018.11.260
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400083
PM 30743036
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Cheung, ZB
   Chen, DH
   White, SJW
   Kim, JS
   Cho, SK
AF Cheung, Zoe B.
   Chen, Daniel H.
   White, Samuel J. W.
   Kim, Jun S.
   Cho, Samuel K.
TI Anterior Column Realignment in Adult Spinal Deformity: A Case Report and
   Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Adult spinal deformity; Anterior longitudinal ligament release; Anterior
   column realignment; Lateral lumber interbody fusion; Minimally invasive;
   Sagittal balance
ID RETROPERITONEAL TRANSPSOAS APPROACH; LONGITUDINAL LIGAMENT RELEASE;
   SAGITTAL BALANCE; OSTEOTOMIES; COMPLICATIONS; OUTCOMES
AB OBJECTIVE: Anterior column realignment (ACR) is a new emerging minimally invasive surgical technique for adult spinal deformity (ASD) that has the potential to provide similar corrective ability to traditional posterior approaches. This article reviews the current literature on the clinical efficacy and safety of ACR and illustrates an additional use of this technique in a case of sagittal imbalance after posterior spinal fusion with segmental instrumentation.
   METHODS: We performed a literature search of all published ACR reports using PubMed, including only clinical studies describing the ACR technique and reporting radiographic and/or clinical outcomes.
   RESULTS: Thirteen studies were included. Improvement in lumbar lordosis after ACR ranged from 12.7 degrees to 39 degrees, and increases in focal segmental lordosis at each ACR level ranged from 1 degrees to 34 degrees. Good clinical and functional outcomes have consistently been reported after ACR. The complication rate has been comparable to or lower than traditional posterior-based techniques. We also illustrate the use of ACR in a patient with sagittal imbalance after a prior posterior instrumented spinal fusion. ACR in combination with a posterior osteotomy allowed for the induction of lordosis by cantilevering of rods and compression of pedicle screws.
   CONCLUSIONS: Radiographic and clinical outcomes after ACR have been promising so far. In addition to primary ASD surgery, ACR can also be effectively used in cases with prior posterior instrumented spinal fusion to correct sagittal imbalance.
C1 [Cheung, Zoe B.; Chen, Daniel H.; White, Samuel J. W.; Kim, Jun S.; Cho, Samuel K.] Icahn Sch Med Mt Sinai, Dept Orthopaed Surg, New York, NY 10029 USA.
RP Cho, SK (reprint author), Icahn Sch Med Mt Sinai, Dept Orthopaed Surg, New York, NY 10029 USA.
EM samuel.cho@mountsinai.org
RI Cheung, Zoe/AAG-4511-2020
OI Cheung, Zoe/0000-0002-0189-5390
CR Agur AMR, 2012, GRANTS ATLAS ANATOMY
   Akbarnia BA, 2014, J SPINAL DISORD TECH, V27, P29, DOI 10.1097/BSD.0b013e318287bdc1
   Anand N, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2014.3.FOCUS13585
   Arslan M, 2011, NEUROSURGERY, V68, DOI 10.1227/NEU.0b013e318205e307
   Beckman JM, 2016, OPER NEUROSURG, V12, P214, DOI 10.1227/NEU.0000000000001203
   Berjano P, 2015, EUR SPINE J, V24, pS451, DOI 10.1007/s00586-015-3962-6
   Berjano P, 2015, EUR SPINE J, V24, pS433, DOI 10.1007/s00586-015-3930-1
   Berjano P, 2015, EUR SPINE J, V24, pS49, DOI 10.1007/s00586-014-3670-7
   Bianco K, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2014.2.FOCUS1422
   Bridwell KH, 2003, SPINE, V28, P2093, DOI 10.1097/01.BRS.0000090891.60232.70
   Deukmedjian AR, 2012, J NEUROSURG-SPINE, V16, P615, DOI 10.3171/2012.3.SPINE1210
   Deukmedjian AR, 2013, NEUROSURG FOCUS, V35, DOI 10.3171/2013.5.FOCUS13173
   Deukmedjian AR, 2012, SCI WORLD J, DOI 10.1100/2012/789698
   Deukmedjian AR, 2012, J NEUROSURG-SPINE, V17, P530, DOI 10.3171/2012.8.SPINE12432
   Dorward IG, 2014, SPINE, V39, P870, DOI 10.1097/BRS.0000000000000302
   Dorward IG, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2009.12.FOCUS09259
   Gill JB, 2008, J BONE JOINT SURG AM, V90A, P2509, DOI 10.2106/JBJS.H.00081
   Glassman SD, 2005, SPINE, V30, P2024, DOI 10.1097/01.brs.0000179086.30449.96
   Haque RM, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2014.3.FOCUS1424
   Hosseini P, 2017, NEUROSURG FOCUS, V43, DOI 10.3171/2017.8.FOCUS17423
   Kelly MP, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2014.2.FOCUS1419
   Leveque JC, 2017, NEUROSURG FOCUS, V43, DOI 10.3171/2017.5.FOCUS17195
   Manwaring JC, 2014, J NEUROSURG-SPINE, V20, P515, DOI 10.3171/2014.2.SPINE1347
   Mundis GM, 2017, WORLD NEUROSURG, V105, P249, DOI 10.1016/j.wneu.2017.05.122
   Murray G, 2015, EUR SPINE J, V24, pS397, DOI 10.1007/s00586-015-3894-1
   Ozgur Burak M, 2006, Spine J, V6, P435, DOI 10.1016/j.spinee.2005.08.012
   Pimenta Luiz, 2015, Eur J Orthop Surg Traumatol, V25 Suppl 1, pS29, DOI 10.1007/s00590-015-1642-1
   Sansur CA, 2011, SPINE, V36, pE593, DOI 10.1097/BRS.0b013e3182059bfd
   Smith JS, 2017, J NEUROSURG-SPINE, V27, P444, DOI 10.3171/2016.10.SPINE16849
   Smith JS, 2011, SPINE, V36, P958, DOI 10.1097/BRS.0b013e3181eabb26
   Turner JD, 2015, EUR SPINE J, V24, pS427, DOI 10.1007/s00586-015-3842-0
NR 31
TC 1
Z9 1
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E379
EP E386
DI 10.1016/j.wneu.2018.11.174
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400044
PM 30500589
DA 2020-05-12
ER

PT J
AU Cho, SM
   Park, DH
   Yoon, SH
AF Cho, Sung Min
   Park, Dong Ha
   Yoon, Soo Han
TI Continuous Intracranial Pressure Monitoring in 24 Microcephalic Children
   with Developmental Delay: A Significant Portion of Microcephalic
   Children with Developmental Delay Have High Intracranial Pressure
SO WORLD NEUROSURGERY
LA English
DT Article
DE Developmental delay; Head size; Intracranial pressure monitoring;
   Microcephaly
ID CRANIAL VAULT DISTRACTION; SLIT-VENTRICLE SYNDROME; CRANIOCEREBRAL
   DISPROPORTION; HEAD SIZE; CRANIOSYNOSTOSIS; SECONDARY; OSTEOGENESIS;
   BRAIN; INTELLIGENCE; ADVANCEMENT
AB OBJECTIVE: The new direct gradual cranial expansion surgical technique has been used to treat children with postshunt microcephaly and slit ventricle syndrome. To evaluate the feasibility of this new surgical treatment, we studied intracranial pressure (ICP) in microcephalic children with developmental delay.
   METHODS: Mean ICP, age, sex, head size, and developmental assessments were compared in 24 microcephalic children with developmental delay who had had continuous ICP monitoring.
   RESULTS: Children studied included 9 boys and 15 girls with a mean age of 4.9 +/- 2.0 years. Mean ICP was 18.7 +/- 8.6 mm Hg. Children with high ICP had significantly lower age and higher B wave ratios than children with low ICP. There were no statistically significant differences in developmental scores and head sizes between children with high ICP and children with low ICP. In multiple linear regression analysis, we observed significantly increased risk of mean ICP elevation by B wave ratio and developmental score and decreased risk of mean ICP elevation by age, but not significantly increased risk of mean ICP elevation by head circumferences (z score).
   CONCLUSIONS: Our findings suggest that a portion of microcephalic children with developmental delay have high ICP that cannot be expected from head sizes, and high ICP has decreasing tendency with age.
C1 [Cho, Sung Min] Yonsei Univ, Wonju Severance Christian Hosp, Dept Neurosurg, Wonju Coll Med, Wonju, South Korea.
   [Park, Dong Ha] Ajou Univ, Sch Med, Dept Plast & Reconstruct Surg, Suwon, South Korea.
   [Yoon, Soo Han] Ajou Univ, Sch Med, Dept Neurosurg, Suwon, South Korea.
RP Yoon, SH (reprint author), Ajou Univ, Sch Med, Dept Neurosurg, Suwon, South Korea.
EM ee802000@yahoo.co.kr
CR Auger N, 2018, ARCH DIS CHILD-FETAL, V103, pF167, DOI 10.1136/archdischild-2016-311199
   Bartholomeusz HH, 2002, NEUROPEDIATRICS, V33, P239, DOI 10.1055/s-2002-36735
   Baxter PS, 2009, PEDIATRICS, V124, P590, DOI 10.1542/peds.2008-2784
   Chung J, 2006, J CRANIOFAC SURG, V17, P557, DOI 10.1097/00001665-200605000-00029
   Davis C, 2008, J CRANIOFAC SURG, V19, P588, DOI 10.1097/SCS.0b013e31816aaa60
   de Lima MHN, 2013, PEDIATR NEUROSURG, V49, P187, DOI 10.1159/000358924
   Doorenbosch X, 2009, CHILD NERV SYST, V25, P871, DOI 10.1007/s00381-009-0842-6
   Engel M, 2012, J CRANIOFAC SURG, V23, P1407, DOI 10.1097/SCS.0b013e31825e4b18
   EPSTEIN F, 1988, PEDIATR NEUROSCI, V14, P5, DOI 10.1159/000120354
   EPSTEIN FJ, 1974, J NEUROSURG, V41, P29, DOI 10.3171/jns.1974.41.1.0029
   FAULHAUER K, 1978, ACTA NEUROCHIR, V45, P89, DOI 10.1007/BF01774384
   Feinsod M, 2003, NEUROSURGERY, V53, P723, DOI 10.1227/01.NEU.0000079627.28240.63
   Gale CR, 2006, PEDIATRICS, V118, P1486, DOI 10.1542/peds.2005-2629
   Hirabayashi S, 1998, J NEUROSURG, V89, P1058, DOI 10.3171/jns.1998.89.6.1058
   HOFFMAN HJ, 1976, J NEUROSURG, V45, P376, DOI 10.3171/jns.1976.45.4.0376
   Ijichi S, 2015, CHILD NERV SYST, V31, P1009, DOI 10.1007/s00381-015-2714-6
   Inagaki T, 2007, CHILD NERV SYST, V23, P1455, DOI 10.1007/s00381-007-0436-0
   INGRAHAM FD, 1948, SURGERY, V24, P518
   Ivanovic DM, 2004, NEUROPSYCHOLOGIA, V42, P1118, DOI 10.1016/j.neuropsychologia.2003.11.022
   Jane JA, 2007, J NEUROSURG, V107, P427, DOI 10.3171/PED-07/11/427
   Jimenez DF, 1998, J NEUROSURG, V88, P77, DOI 10.3171/jns.1998.88.1.0077
   KLOSS JL, 1968, AM J DIS CHILD, V116, P315, DOI 10.1001/archpedi.1968.02100020317015
   Lauritzen C, 1998, SCAND J PLAST RECONS, V32, P331, DOI 10.1080/02844319850158697
   Martinez-Lage JF, 2006, NEUROSURG REV, V29, P229, DOI 10.1007/s10143-006-0022-z
   Nilsson D, 2013, J NEUROSURG-PEDIATR, V12, P483, DOI 10.3171/2013.8.PEDS1370
   OPITZ JM, 1990, J CRAN GENET DEV BIO, V10, P175
   Park DH, 2017, WORLD NEUROSURG, V97, P701, DOI 10.1016/j.wneu.2016.09.093
   Park DH, 2009, PEDIATR NEUROSURG, V45, P437, DOI 10.1159/000277618
   Rekate HL, 2003, PEDIATR NEUROSURG, V38, P41, DOI 10.1159/000067562
   REKATE HL, 1993, PEDIATR NEUROSURG, V19, P15, DOI 10.1159/000120694
   Sandler AL, 2013, J NEUROSURG-PEDIATR, V11, P653, DOI 10.3171/2013.2.PEDS12404
   Shimoji T, 2004, CHILD NERV SYST, V20, P749, DOI 10.1007/s00381-004-0970-y
   Shimoji T, 2002, CHILD NERV SYST, V18, P215, DOI 10.1007/s00381-002-0568-1
   Tarrant A, 2009, PEDIATR RADIOL, V39, P772, DOI 10.1007/s00247-009-1266-x
   Uemura T, 2003, J CRANIOFAC SURG, V14, P29, DOI 10.1097/00001665-200301000-00005
   Undabeitia J, 2011, CHILD NERV SYST, V27, P1995, DOI 10.1007/s00381-011-1531-9
   Watemberg N, 2002, J CHILD NEUROL, V17, P117, DOI 10.1177/088307380201700205
   WEAVER DD, 1980, J PEDIATR-US, V96, P990, DOI 10.1016/S0022-3476(80)80623-8
   Weinzweig J, 2008, PLAST RECONSTR SURG, V122, P1171, DOI 10.1097/PRS.0b013e3181858c84
NR 39
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E760
EP E765
DI 10.1016/j.wneu.2018.12.027
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400091
PM 30579032
DA 2020-05-12
ER

PT J
AU Colby, GP
   Baharyandat, H
   Mowla, A
   Young, R
   Shwe, Y
   Jahan, R
   Tateshima, S
   Szeder, V
   Nour, M
   Vinuela, F
   Duckwiler, G
AF Colby, Geoffrey P.
   Baharyandat, Humain
   Mowla, Ashkan
   Young, Richard
   Shwe, Yamin
   Jahan, Reza
   Tateshima, Satoshi
   Szeder, Viktor
   Nour, May
   Vinuela, Fernando
   Duckwiler, Gary
TI Increased Success of Single-Pass Large Vessel Recanalization Using a
   Combined Stentriever and Aspiration Technique: A Single Institution
   Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aspiration; Large vessel occlusion; Mechanical thrombectomy;
   Recanalization; Solumbra; Stentrieval; Stent retriever
ID ACUTE ISCHEMIC-STROKE; STENT-RETRIEVER THROMBECTOMY; BALLOON GUIDE
   CATHETER; MECHANICAL THROMBECTOMY; ENDOVASCULAR TREATMENT; THERAPY;
   EFFICACY; SAFETY; TRIAL; ADAPT
AB BACKGROUND: Extensive evidence supports mechanical thrombectomy using stentrievers (SR) for acute large vessel occlusion (aLVO). Aspiration is also used as a first pass or adjunct technique during clot removal. Here we report technical results from mechanical thrombectomy cases using SR alone, aspiration alone (AD), or a combination of SR and aspiration (SA) as a first pass for aLVO.
   METHODS: An institutional stroke database was reviewed for patients presenting to a single academic institution with anterior circulation aLVO and who were treated with mechanical thrombectomy from 2011 to 2017. Patients managed with SR alone, AD, or a combination of these 2 techniques (SA) were identified. The rate of successful recanalization after the first thrombectomy attempt was compared between the 3 groups.
   RESULTS: A total of 353 patients were analyzed, including 215 in SR, 32 in AD, and 106 in SA groups. There was no significant difference for age and admission National Institutes of Health Stroke Scale between the groups. Successful recanalization rates after the first pass were 35.8% in the SR group, 34.4% in aspiration as a first pass technique, and 55.7% in SA, with a statistically significant higher rate of first pass success in the SA group (P = 0.002). Using balloon-guide catheter doubled the rate of successful first pass recanalization from 21.3% to 41.6% in the SR group (P = 0.005); however, the SA technique was more effective for first pass recanalization when compared with an SR and balloon-guide catheter combination (55.7% vs. 41.6%, P = 0.025).
   CONCLUSIONS: The combination of SR and catheter aspiration can increase the rate of single pass successful recanalization compared with these techniques individually.
C1 [Colby, Geoffrey P.; Baharyandat, Humain] Univ Calif Los Angeles, Dept Neurosurg, Los Angeles, CA 90095 USA.
   [Colby, Geoffrey P.; Mowla, Ashkan; Young, Richard; Shwe, Yamin; Jahan, Reza; Tateshima, Satoshi; Szeder, Viktor; Nour, May; Vinuela, Fernando] Univ Calif Los Angeles, Dept Radiol, Los Angeles, CA 90095 USA.
RP Colby, GP (reprint author), Univ Calif Los Angeles, Dept Neurosurg, Los Angeles, CA 90095 USA.; Colby, GP (reprint author), Univ Calif Los Angeles, Dept Radiol, Los Angeles, CA 90095 USA.
EM gcolby@mednet.ucla.edu
CR Almandoz JED, 2016, J NEUROINTERV SURG, V8, P1123, DOI 10.1136/neurintsurg-2015-012122
   Berkhemer OA, 2015, NEW ENGL J MED, V372, P11, DOI 10.1056/NEJMoa1411587
   Blanc R, 2017, STROKE, V48, P1588, DOI 10.1161/STROKEAHA.116.016149
   Bourcier R, 2018, J NEUROINTERV SURG, V10, P625, DOI 10.1136/neurintsurg-2017-013398
   Brinjikji W, 2018, J NEUROINTERV SURG, V10, P335, DOI 10.1136/neurintsurg-2017-013179
   Campbell BCV, 2015, NEW ENGL J MED, V372, P1009, DOI 10.1056/NEJMoa1414792
   Campbell BCV, 2016, STROKE, V47, P798, DOI 10.1161/STROKEAHA.115.012360
   Deshaies EM, 2013, J CLIN NEUROSCI, V20, P1303, DOI 10.1016/j.jocn.2012.10.037
   Goyal M, 2015, NEW ENGL J MED, V372, P1019, DOI 10.1056/NEJMoa1414905
   Goyal N, 2018, NEUROLOGY, V90, pE1274, DOI 10.1212/WNL.0000000000005299
   Hopf-Jensen S, 2016, CARDIOVASC INTER RAD, V39, P1620, DOI 10.1007/s00270-016-1404-4
   Humphries W, 2015, J NEUROINTERV SURG, V7, P90, DOI 10.1136/neurintsurg-2013-010986
   Jindal G, 2017, J NEUROINTERV SURG, V9, P944, DOI 10.1136/neurintsurg-2016-012581
   Jovin TG, 2015, NEW ENGL J MED, V372, P2296, DOI 10.1056/NEJMoa1503780
   Kang DH, 2017, J KOREAN NEUROSURG S, V60, P335, DOI 10.3340/jkns.2016.0809.005
   Lapergue B, 2017, JAMA-J AM MED ASSOC, V318, P443, DOI 10.1001/jama.2017.9644
   Lin LM, 2014, J NEUROINTERV SURG, V6, P301, DOI 10.1136/neurintsurg-2013-010772
   Massari F, 2016, INTERV NEURORADIOL, V22, P325, DOI 10.1177/1591019916632369
   Maus V, 2018, CLIN NEURORADIOL, V28, P327, DOI 10.1007/s00062-017-0566-z
   Oh JS, 2017, J KOREAN NEUROSURG S, V60, P155, DOI 10.3340/jkns.2016.0809.003
   Przybylowski Colin J, 2014, World J Clin Cases, V2, P614, DOI 10.12998/wjcc.v2.i11.614
   Saver JL, 2015, NEW ENGL J MED, V372, P2285, DOI 10.1056/NEJMoa1415061
   Smith WS, 2006, AM J NEURORADIOL, V27, P1177
   Stapleton CJ, 2018, J NEUROSURG, V128, P567, DOI 10.3171/2016.11.JNS161563
   Turk AS, 2018, J NEUROINTERV SURG, V10, P953, DOI 10.1136/neurintsurg-2017-013722
   Turk AS, 2014, J NEUROINTERV SURG, V6, P231, DOI 10.1136/neurintsurg-2013-010713
   Velasco A, 2016, RADIOLOGY, V280, P169, DOI 10.1148/radiol.2015150575
   Wei D, 2017, AM J NEURORADIOL, V38, P1978, DOI 10.3174/ajnr.A5309
NR 28
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E747
EP E752
DI 10.1016/j.wneu.2018.12.023
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400089
PM 30579014
DA 2020-05-12
ER

PT J
AU Corliss, BM
   Barkley, KF
   Polifka, AJ
   Hoh, BL
   Fox, WC
AF Corliss, Brian M.
   Barkley, Kaitlyn F.
   Polifka, Adam J.
   Hoh, Brian L.
   Fox, W. Chris
TI Single-Center Case Series of Temporary Stent Assistance for Coiling of
   Acutely Ruptured Aneurysms
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm; Balloon; Endovascular; Solitaire; Stent
ID INTRACRANIAL ANEURYSMS; EMBOLIZATION
AB BACKGROUND: Wide-necked intracranial aneurysms continue to pose a challenge for endovascular surgeons. Flow diversion and stent-assisted coiling are 2 techniques that have improved the ability to manage these lesions, but these require the use of dual antiplatelet therapy. In patients with aneurysmal subarachnoid hemorrhage, dual antiplatelet therapy is relatively contraindicated, and many surgeons prefer to use open techniques or balloon assistance for coiling, although at times the latter is not feasible. We describe temporary stent assistance using retrievable stents for coiling of ruptured intracranial aneurysms as an endovascular management option.
   METHODS: Surgeon case logs were retrospectively reviewed for cases of temporary stent assistance for aneurysm coiling. Cases were identified and compiled into a case series.
   RESULTS: Seven cases were identified, including 6 using the Solitaire FR device in an off-label manner as a temporary stent for assistance with coiling of wide-necked aneurysms. One patient experienced intraoperative aneurysm rupture (planned stent coiling; stent placement aborted after rupture), but otherwise no hemorrhagic complications were noted. Two patients experienced radiographic thromboembolic complications, with 1 patient requiring intervention during the index operation, but neither patient experienced demonstrable neurologic deficits postoperatively. After mean follow-up of 9 months, the average Glasgow Coma Scale score was 14, and the average modified Rankin Scale score was 1.2.
   CONCLUSIONS: Stents and stent retrievers can be temporarily used for technically challenging aneurysms as an alternative to balloon assistance for treatment of ruptured intracranial aneurysms without needing to use dual antiplatelet therapy.
C1 [Corliss, Brian M.; Barkley, Kaitlyn F.; Polifka, Adam J.; Hoh, Brian L.; Fox, W. Chris] Univ Florida, Dept Neurol Surg, Gainesville, FL 32611 USA.
RP Barkley, KF (reprint author), Univ Florida, Dept Neurol Surg, Gainesville, FL 32611 USA.
EM kaitlyn.barkley@neurosurgery.ufl.edu
OI Fox, W Christopher/0000-0002-7762-9902
CR Almekhlafi MA, 2013, J NEUROINTERV SURG, V5, pIII76, DOI 10.1136/neurintsurg-2013-010737
   Chalouhi N, 2013, STROKE, V44, P1348, DOI 10.1161/STROKEAHA.111.000641
   Clajus C, 2013, NEURORADIOLOGY, V55, P629, DOI 10.1007/s00234-013-1148-7
   Edwards NJ, 2017, J NEUROSURG, V127, P1326, DOI 10.3171/2016.9.JNS161340
   Gonzalez AV, 2018, NEURORADIOLOGY, V60, P1223, DOI 10.1007/s00234-018-2088-z
   Jeong Hae Woong, 2015, J Cerebrovasc Endovasc Neurosurg, V17, P301, DOI 10.7461/jcen.2015.17.4.301
   Mahaney KB, 2013, J NEUROSURG, V119, P937, DOI 10.3171/2013.5.JNS122494
   Molyneux AJ, 2005, LANCET, V366, P809, DOI 10.1016/S0140-6736(05)67214-5
   Muller M, 2017, AM J NEURORADIOL, V38, P1372, DOI 10.3174/ajnr.A5204
   Sanal B, 2016, VASC ENDOVASC SURG, V50, P84, DOI 10.1177/1538574416631644
   Zumofen DW, 2014, J CLIN NEUROSCI, V21, P852, DOI 10.1016/j.jocn.2013.10.009
NR 11
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E766
EP E772
DI 10.1016/j.wneu.2018.12.029
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400092
PM 30579035
DA 2020-05-12
ER

PT J
AU Deng, WJ
   Teng, JF
   Liebeskind, D
   Miao, W
   Du, R
AF Deng, Wenjing
   Teng, Junfang
   Liebeskind, David
   Miao, Wang
   Du, Ran
TI Predictors of Infarct Growth Measured by Apparent Diffusion Coefficient
   Quantification in Patients with Acute Ischemic Stroke
SO WORLD NEUROSURGERY
LA English
DT Article
DE Acute ischemic stroke; Endovascular treatment; Infarct growth; Predictor
ID ENDOVASCULAR THERAPY; CLINICAL-RESPONSE; LESION VOLUMES; REPERFUSION;
   THROMBECTOMY; RETRIEVER; TRIAL; FLOW
AB BACKGROUND: The infarct volume is associated with the clinical outcome after ischemic stroke. We investigated the factors associated with infarct growth and its effect on functional outcome in patients with acute ischemic stroke.
   METHODS: The present retrospective study included 158 patients with acute ischemic stroke receiving endovascular treatment at the University of California, Los Angeles, Medical Center from 2011 to 2016. The patients' clinical parameters were collected. Magnetic resonance imaging was performed before treatment and 24 hours after endovascular treatment to calculate the infarct volume. The infarct sizes were measured using apparent diffusion coefficient maps. The modified Rankin scale (mRS) scores at discharge and 90 days after discharge were used to evaluate the functional outcomes. An mRS score of 0-2 was defined as a good outcome. The predictors of infarct growth and mRS score at 90 days were analyzed using regression analysis.
   RESULTS: Patients with smaller infarct growth had significantly better clinical outcomes as measured by the mRS score at discharge and at 90 days and mortality at 90 days (P < 0.001). Infarct growth of 12.11 cm(2) was defined as the optimal cutoff to predict the clinical outcome using the receiver operating characteristic curve. The baseline Alberta Stroke Program Early CT (computed tomography) score (odds ratio [OR], 0.8; 95% confidence interval [CI], 0.665-0.962; P = 0.017) and modified thrombolysis in cerebral infarction score (OR, 0.259; 95% CI, 0.120-0.559; P = 0.001) were independent factors that predicted for infarct growth. Infarct growth (OR, 1.044; 95% CI, 1.024-1.064; P < 0.001) and baseline National Institutes of Health stroke scale score (OR, 1.070; 95% CI, 1.008-1.136; P = 0.027) were independent factors that predicted the mRS score at 90 days.
   CONCLUSIONS: Infarct growth was associated with the functional outcome. Smaller infarct growth correlated with better outcomes. A greater Alberta Stroke Program Early CT score and better perfusion predicted for smaller infarct growth.
C1 [Deng, Wenjing; Teng, Junfang; Miao, Wang; Du, Ran] Zhengzhou Univ, Neurointens Care Unit, Affiliated Hosp 1, Zhengzhou, Henan, Peoples R China.
   [Liebeskind, David] Univ Calif Los Angeles, Sch Med, Dept Neurol, Neurovasc Imaging Res Core, Los Angeles, CA 90024 USA.
RP Deng, WJ (reprint author), Zhengzhou Univ, Neurointens Care Unit, Affiliated Hosp 1, Zhengzhou, Henan, Peoples R China.
EM 1367695683@126.com
OI Deng, Wenjing/0000-0002-0437-3176
CR Albers GW, 2006, ANN NEUROL, V60, P508, DOI 10.1002/ana.20976
   Berkhemer OA, 2015, NEW ENGL J MED, V372, P11, DOI 10.1056/NEJMoa1411587
   Bratane BT, 2009, BRAIN RES, V1279, P182, DOI 10.1016/j.brainres.2009.05.002
   Campbell BCV, 2015, NEW ENGL J MED, V372, P1009, DOI 10.1056/NEJMoa1414792
   Campbell BCV, 2012, J CEREBR BLOOD F MET, V32, P50, DOI 10.1038/jcbfm.2011.102
   Chemmanam T, 2010, NEUROLOGY, V75, P1040, DOI 10.1212/WNL.0b013e3181f39ab6
   Goyal M, 2015, NEW ENGL J MED, V372, P1019, DOI 10.1056/NEJMoa1414905
   Haussen DC, 2016, J NEUROINTERV SURG, V8, P117, DOI 10.1136/neurintsurg-2014-011497
   Higashida RT, 2003, STROKE, V34, pE109, DOI 10.1161/01.STR.0000082721.62796.09
   Jovin TG, 2015, NEW ENGL J MED, V372, P2296, DOI 10.1056/NEJMoa1503780
   Lansberg MG, 2008, STROKE, V39, P2491, DOI 10.1161/STROKEAHA.107.508572
   Lansberg MG, 2007, STROKE, V38, P1826, DOI 10.1161/STROKEAHA.106.480145
   Lansberg MG, 2012, LANCET NEUROL, V11, P860, DOI 10.1016/S1474-4422(12)70203-X
   Lee SU, 2016, J STROKE, V18, P179, DOI 10.5853/jos.2015.01529
   Lin WL, 2003, STROKE, V34, P64, DOI 10.1161/01.STR.0000048151.28173.0D
   Man SM, 2015, J STROKE CEREBROVASC, V24, P401, DOI 10.1016/j.jstrokecerebrovasdis.2014.09.004
   Parsons MW, 2010, J CEREBR BLOOD F MET, V30, P1214, DOI 10.1038/jcbfm.2010.3
   Perkins NJ, 2006, AM J EPIDEMIOL, V163, P670, DOI 10.1093/aje/kwj063
   Purushotham A, 2015, INT J STROKE, V10, P348, DOI 10.1111/ijs.12068
   Sakamoto Y, 2013, INT J STROKE, V8, P321, DOI 10.1111/j.1747-4949.2012.00902.x
   Saver JL, 2015, NEW ENGL J MED, V372, P2285, DOI 10.1056/NEJMoa1415061
   Saver JL, 2012, LANCET, V380, P1241, DOI 10.1016/S0140-6736(12)61384-1
   Simonsen CZ, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00574
   Straka M, 2010, J MAGN RESON IMAGING, V32, P1024, DOI 10.1002/jmri.22338
   von Kummer R, 2015, STROKE, V46, P2981, DOI 10.1161/STROKEAHA.115.010049
   Yoo AJ, 2012, STROKE, V43, P1323, DOI 10.1161/STROKEAHA.111.639401
   Yoo AJ, 2011, NEUROIMAG CLIN N AM, V21, P51, DOI 10.1016/j.nic.2011.02.002
   Yoo AJ, 2010, STROKE, V41, P1728, DOI 10.1161/STROKEAHA.110.582874
NR 28
TC 1
Z9 1
U1 1
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E797
EP E802
DI 10.1016/j.wneu.2018.12.051
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400096
PM 30590217
DA 2020-05-12
ER

PT J
AU Devi, BI
   Shukla, DP
   Bhat, DI
   Tripathi, M
   Warren, A
   Shanbhag, NC
   Konar, SK
   Stake, AL
   Singhal, R
AF Devi, Bhagavatula Indira
   Shukla, Dhaval P.
   Bhat, Dhananjaya, I
   Tripathi, Manjul
   Warren, Amara
   Shanbhag, Nagesh C.
   Konar, Subhas K.
   Stake, Anne L.
   Singhal, Ruchika
TI Neurotrauma Care Delivery in a Limited Resource Setting-Lessons Learned
   From Referral and Patient Flow in a Tertiary Care Center
SO WORLD NEUROSURGERY
LA English
DT Article
DE Computed tomography; Lean Six Sigma approach; Referral; Tertiary care
   hospital; Traumatic brain injury; Triage
ID TRAUMA CARE; INDIA; SYSTEMS; NEUROSURGERY; DELAYS
AB BACKGROUND: With the increasing population, motorization, and road traffic accidents, neurotrauma has been increasing in India. Inadequate triage and underusage of locally available resources at all healthcare levels has led to nonuniform neurotrauma care delivery. We present our experience at a tertiary care hospital. We evaluated the referral pattern of mild traumatic brain injury (mTBI) cases to enable adequate care to patients with moderate and severely injured TBI.
   METHODS: All patients with head injury (n = 3891) referred to the emergency department of our institution during a 4-month period were evaluated. The demographic characteristics, ambulance usage, and time management during in-hospital patient flow were evaluated using the Lean Six Sigma approach. We have also provided solutions for optimal usage of available resources.
   RESULTS: Patients with mTBI comprised 77% of head injury referrals. Of all the patients referred from peripheral hospitals, 48% had normal head computed tomography (CT) scan findings. The CT waiting and lead (arrival-to-discharge) times were 35 +/- 44 minutes and 114 minutes, respectively. No clinical to radiological correlation was found between the head CT scan findings and a decision to refer a patient to our institute. Only 10% of the patients with abnormal head CT scans (41%) required neurosurgical intervention. The mean duration from CT imaging to the initiation of surgery was 192.7 +/- 172.1 minutes.
   CONCLUSIONS: Most of the patients with mTBI were referred to a tertiary care center, leading to secondary overtriage and overburdening of the existing resources at a specialized care hospital, possibly owing to ineffective triage at the primary and secondary healthcare centers. This would limit the adequate management of moderate to severe TBI cases in such a hospital.
C1 [Devi, Bhagavatula Indira; Shukla, Dhaval P.; Bhat, Dhananjaya, I; Tripathi, Manjul; Shanbhag, Nagesh C.; Konar, Subhas K.] Natl Inst Mental Hlth & Neurosci, Dept Neurosurg, Bangalore, Karnataka, India.
   [Warren, Amara; Singhal, Ruchika] Medtron Labs & Global Hlth, Fridley, MN USA.
   [Stake, Anne L.] Medtron Labs, Brooklyn, NY USA.
   [Tripathi, Manjul] Postgrad Inst Med Educ & Res, Dept Neurosurg, Chandigarh, Punjab, India.
RP Devi, BI (reprint author), Natl Inst Mental Hlth & Neurosci, Dept Neurosurg, Bangalore, Karnataka, India.
EM bidevidr@gmail.com
RI Tripathi, Manjul/AAE-7128-2019
OI Tripathi, Manjul/0000-0002-5679-3439
FU Medtronic, Inc.Medtronic [MIST/003/306/2014/00762]; Medtronic,
   Inc.Medtronic
FX The present study received funding from Medtronic, Inc., "Traumatic
   Brain Injury: Phase 1" (code no. MIST/003/306/2014/00762). Amara Warren,
   Anne L. Stake, and Ruchika Singhal received financial remuneration for
   working as assistants in this project from Medtronic, Inc.
CR Bishop CV, 2006, ANZ J SURG, V76, P53, DOI 10.1111/j.1445-2197.2006.03642.x
   Chokshi M, 2016, J PERINATOL, V36, pS9, DOI 10.1038/jp.2016.184
   Ganapathy K, 2015, NEUROL INDIA, V63, P142, DOI 10.4103/0028-3886.156274
   Ganapathy K, 2013, WORLD NEUROSURG, V79, P621, DOI 10.1016/j.wneu.2013.02.071
   Gururaj G, 2017, USITC PUBL, V138
   Gururaj G., 2017, USITC PUBL, V137
   Indian Public Health Standards (IPHS), GUID DISTR HOSP 101
   Joshipura M, 2006, WORLD J SURG, V30, P930, DOI 10.1007/s00268-005-0765-7
   Joshipura MK, 2003, INJURY, V34, P686, DOI 10.1016/S0020-1383(03)00163-3
   Luck T, 2015, ANZ J SURG, V85, P610, DOI 10.1111/ans.13138
   Marcoux J, 2016, J NEUROSURG, V125, P642, DOI 10.3171/2015.6.JNS15175
   Niemeijer GC, 2010, J TRAUMA, V69, P614, DOI 10.1097/TA.0b013e3181e70f90
   Oestern HJ, 2013, CLIN ORTHOP RELAT R, V471, P2869, DOI 10.1007/s11999-013-3035-2
   Parks JK, 2008, J TRAUMA, V65, P1098, DOI 10.1097/TA.0b013e318188e8ad
   Reddy KS, 2015, NEW ENGL J MED, V373, P1, DOI 10.1056/NEJMp1414214
   Strengthening of District Hospitals and the Creation of District Hospital Knowledge Centers (DHKCs), STRENGTH DISTR HOSP
   VANDENHEUVEL J, 2006, INT J 6 SIGMA COMPET, V2, P377
NR 17
TC 3
Z9 3
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E588
EP E596
DI 10.1016/j.wneu.2018.11.227
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400069
PM 30529521
DA 2020-05-12
ER

PT J
AU Divito, A
   Kerr, K
   Wilkerson, C
   Shepard, S
   Choi, A
   Kitagawa, RS
AF Divito, Anthony
   Kerr, Keith
   Wilkerson, Christopher
   Shepard, Scott
   Choi, Alex
   Kitagawa, Ryan S.
TI Use of Anticoagulation Agents After Traumatic Intracranial Hemorrhage
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anticoagulation; Intracranial hemorrhage; Traumatic brain injury
ID VENOUS THROMBOEMBOLISM; AMERICAN-COLLEGE; BRAIN-INJURY; 1602 EPISODES;
   THROMBOSIS; THERAPY; MANAGEMENT; STROKE
AB OBJECTIVE: Anticoagulant therapy (ACT) after traumatic intracranial hemorrhage may lead to progression of hemorrhage, but in the presence of thromboembolic events, the clinician must decide if the benefits outweigh the risks. Currently, no data exist to guide therapy in the acute setting.
   METHODS: We retrospectively identified all patients admitted to our institution with traumatic intracranial hemorrhage that received intravenous heparin, full-dose enoxaparin, or warfarin during their initial hospitalization over a 3-year period. We reviewed their demographics, hospital course, clinical indication and timing for initiation of ACT, and complications.
   RESULTS: A total of 112 patients were identified. The median age and Glasgow Coma Scale score of these patients was 50.5 years and 9.5, respectively. Twenty-two patients required neurosurgical procedures for their presenting injury, including intracranial pressure monitors and/ or open surgeries. Fifty-four patients had deep vein thrombosis or pulmonary embolism prior to initiation, and the remaining 20 patients had preexisting conditions or other indications for initiating ACT. The median time from injury to starting ACT was 8 days. Immediate complications occurred in 6 patients; however, none of these patients required a neurosurgical intervention. Delayed complications included progression of acute to chronic subdural hematoma that required intervention in 2 patients. One patient died from delayed hemorrhage.
   CONCLUSIONS: For this patient population, the risk of immediate and delayed intracranial hemorrhages from initiating ACT therapy in intracranial injury must be weighed against the morbidity of delaying treatment. Although further studies are needed, our review provides the first rates of complications for this patient population.
C1 [Divito, Anthony; Kerr, Keith; Wilkerson, Christopher; Shepard, Scott; Choi, Alex; Kitagawa, Ryan S.] Univ Texas Hlth Sci Ctr Houston, Vivian L Smith Dept Neurosurg, Houston, TX 77030 USA.
RP Kitagawa, RS (reprint author), Univ Texas Hlth Sci Ctr Houston, Vivian L Smith Dept Neurosurg, Houston, TX 77030 USA.
EM Ryan.S.Kitagawa@uth.tmc.edu
CR Albrecht JS, 2014, JAMA INTERN MED, V174, P1244, DOI 10.1001/jamainternmed.2014.2534
   Anderson JL, 2007, J AM COLL CARDIOL, V50, P652, DOI 10.1016/j.jacc.2007.02.028
   Brandt MM, 2007, AM J SURG, V193, P383
   Byrnes MC, 2012, WORLD J EMERG SURG, V7, DOI 10.1186/1749-7922-7-25
   Centers for Disease Control and Prevention (CDC), 2010, NAT HOSP DISCH SURV
   Cohen DB, 2006, J TRAUMA, V60, P553, DOI 10.1097/01.ta.0000196542.54344.05
   Denson K, 2007, AM J SURG, V193, P380, DOI 10.1016/j.amjsurg.2006.12.004
   Dunn AS, 2003, ARCH INTERN MED, V163, P901, DOI 10.1001/archinte.163.8.901
   Farooqui A, 2013, J NEUROSURG, V119, P1576, DOI 10.3171/2013.8.JNS13424
   Friberg L, 2012, EUR HEART J, V33, P1500, DOI 10.1093/eurheartj/ehr488
   GEERTS WH, 1994, NEW ENGL J MED, V331, P1601, DOI 10.1056/NEJM199412153312401
   Jansen S, 2015, AGE AGEING, V44, P598, DOI 10.1093/ageing/afv017
   Kearon C, 2014, BLOOD, V123, P1794, DOI 10.1182/blood-2013-12-512681
   Kearon C, 2012, CHEST, V141, pE419S, DOI 10.1378/chest.11-2301
   Kelly J, 2003, STROKE, V34, P2999, DOI 10.1161/01.STR.0000102561.86835.17
   Khaldi A, 2011, J NEUROSURG, V114, P40, DOI 10.3171/2010.8.JNS10332
   Knudson MM, 2004, ANN SURG, V240, P490, DOI 10.1097/01.sla.0000137138.40116.6c
   Ntaios G, 2013, NEUROLOGY, V80, P1009, DOI 10.1212/WNL.0b013e318287281b
   Phelan HA, 2012, J TRAUMA ACUTE CARE, V73, P1434, DOI 10.1097/TA.0b013e31825ac49e
   Romualdi E, 2009, THROMB HAEMOSTASIS, V101, P290, DOI 10.1160/TH08-07-0474
   Shackford SR, 2004, ANN SURG, V240, P496
   Singer DE, 2008, CHEST, V133, p546S, DOI 10.1378/chest.08-0678
   Wijdicks EFM, 1998, NEUROSURGERY, V42, P769, DOI 10.1097/00006123-199804000-00053
NR 23
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E25
EP E30
DI 10.1016/j.wneu.2018.10.173
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400005
PM 30528524
DA 2020-05-12
ER

PT J
AU Durand, WM
   Depasse, JM
   Bokshan, SL
   Eltorai, AE
   Daniels, AH
AF Durand, Wesley M.
   Depasse, J. Mason
   Bokshan, Steven L.
   Eltorai, Adam Em
   Daniels, Alan H.
TI Tobacco Use and Complications Following Spinal Fusion: A Comparison of
   the National Surgical Quality Improvement Program and National Inpatient
   Sample Datasets
SO WORLD NEUROSURGERY
LA English
DT Article
DE Complications; NIS; NSQIP; Smoking; Spinal fusion; Tobacco use
ID RISK-FACTORS; SITE INFECTIONS; SMOKING; OUTCOMES; SURGERY;
   COMORBIDITIES; LAMINECTOMY; ANTERIOR
AB BACKGROUND: Smoking is a known risk factor for inferior health outcomes. Retrospective analyses of large datasets may assesswhether such risk is manifested or mitigated in clinical practice. Although many risk factor analyses use the National Surgical Quality Improvement Program (NSQIP) and National (Nationwide) Inpatient Sample (NIS), such investigations have seldom been directly compared.
   METHODS: NIS and NSQIP datasets were used. Primary outcome measures were perioperative complications. NSQIP complications were stratified based on occurrence before versus after discharge. Multiple logistic regression was employed in adjusted analyses.
   RESULTS: Among NSQIP (N = 56,145) and NIS (N = 1,311,426) patients, 24.0% and 31.8% were identified as tobacco users, respectively. Before discharge, NSQIP smokers had increased odds of pneumonia (adjusted odds ratio [aOR] = 1.43), postoperative intubation (aOR = 1.40), and sepsis (aOR = 1.71) and decreased odds of pulmonary embolism (aOR = 0.57) (all P < 0.05). After discharge, NSQIP smokers exhibited increased odds of cardiac arrest (aOR = 2.53) and surgical site infection (aOR = 1.25) and decreased odds of urinary tract infection (aOR = 0.68) and deep venous thrombosis (aOR = 0.61) (all P < 0.05). In adjusted analysis of NIS data, tobacco users exhibited increased odds of inpatient pneumonia (aOR = 1.57), myocardial infarction (aOR = 1.29), and postoperative intubation (aOR = 1.15) and decreased odds of pulmonary embolism (aOR = 0.80) and deep venous thrombosis (aOR = 0.78) (all P < 0.05).
   CONCLUSIONS: Patients with a history of tobacco use undergoing spinal fusion were at increased risk of pneumonia and intubation but decreased risk of deep venous thrombosis and pulmonary embolism during the inpatient postoperative stay. After discharge, smokers exhibited increased odds of cardiac arrest and surgical site infection. NIS and NSQIP results were similar, with 9 of 12 outcomes exhibiting identical inpatient conclusions. Qualitative comparison of NIS and NSQIP yields results that offer increased validity over single-source studies.
C1 [Durand, Wesley M.; Depasse, J. Mason; Bokshan, Steven L.; Eltorai, Adam Em; Daniels, Alan H.] Brown Univ, Warren Alpert Med Sch, Dept Orthoped, Div Spine Surg, Providence, RI 02912 USA.
RP Durand, WM (reprint author), Brown Univ, Warren Alpert Med Sch, Dept Orthoped, Div Spine Surg, Providence, RI 02912 USA.
EM wesleymdurand@gmail.com
FU Alpha Omega Alpha Carolyn L. Kuckein Student Research Fellowship
FX A. E. M. Eltorai discloses partial ownership of a company producing a
   smoking cessation device and corresponding patent. W. M. Durand's work
   on this project was supported in part by an Alpha Omega Alpha Carolyn L.
   Kuckein Student Research Fellowship. The remaining authors have no
   conflicts to report.
CR Agaku IT, 2014, MMWR-MORBID MORTAL W, V63, P29
   Boakye M, 2008, J NEUROTRAUM, V25, P173, DOI 10.1089/neu.2007.0395
   Boffetta P, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3060
   Bohl DD, 2015, SPINE, V40, P1527, DOI 10.1097/BRS.0000000000001073
   Bohl DD, 2014, J BONE JOINT SURG AM, V96A, DOI 10.2106/JBJS.M.01490
   Bohl DD, 2014, CLIN ORTHOP RELAT R, V472, P1672, DOI 10.1007/s11999-014-3559-0
   Buckland AJ, 2017, SPINE, V42, P1248, DOI 10.1097/BRS.0000000000002064
   Cho SK, 2017, AAOS 2017 ANN M MARC
   Chughtai M, 2017, SURG TECHNOL INT, V30
   Fang A, 2005, SPINE, V30, P1460, DOI 10.1097/01.brs.0000166532.58227.4f
   Fineberg SJ, 2014, SPINE J, V14, P1680, DOI 10.1016/j.spinee.2013.10.015
   Fuchshuber Pascal R, 2012, Perm J, V16, P39
   Gajdos C, 2012, ANN SURG ONCOL, V19, P1430, DOI 10.1245/s10434-011-2128-y
   HALLSTROM AP, 1986, NEW ENGL J MED, V314, P271, DOI 10.1056/NEJM198601303140502
   Hatcher JL, 2016, HEAD NECK-J SCI SPEC, V38, P700, DOI 10.1002/hed.23944
   Hawn MT, 2011, ANN SURG, V254, P914, DOI 10.1097/SLA.0b013e31822d7f81
   Hodari A, 2013, J SURG RES, V183, P663, DOI 10.1016/j.jss.2013.01.031
   Jackson KL, 2016, GLOB SPINE J, V6, P695, DOI 10.1055/s-0036-1571285
   Kong LD, 2017, SURG INFECT, V18, P206, DOI 10.1089/sur.2016.209
   Kubasiak JC, 2017, SURG ENDOSC, V31, P2661, DOI 10.1007/s00464-016-5280-4
   Li G, 2008, SPINE, V33, P1250, DOI 10.1097/BRS.0b013e3181714a44
   Musallam KM, 2013, JAMA SURG, V148, P755, DOI 10.1001/jamasurg.2013.2360
   Patil CG, 2008, SPINE, V33, P1491, DOI 10.1097/BRS.0b013e318175d1bf
   Poorman GW, 2017, SPINE, V42, P1165, DOI 10.1097/BRS.0000000000002002
   Rajaee SS, 2014, BONE JOINT J, V96B, P807, DOI 10.1302/0301-620X.96B6.31149
   Schimmel JJP, 2010, EUR SPINE J, V19, P1711, DOI 10.1007/s00586-010-1421-y
   Schlussel AT, 2017, AM J SURG, V213, P723, DOI 10.1016/j.amjsurg.2016.08.009
   Shiloach M, 2010, J AM COLL SURGEONS, V210, P6, DOI 10.1016/j.jamcollsurg.2009.09.031
   Somani S, 2017, SPINE, V42, P565, DOI 10.1097/BRS.0000000000001850
   Teo KK, 2006, LANCET, V368, P647, DOI 10.1016/S0140-6736(06)69249-0
   US Department of Health and Human Services, 2014, HLTH CONSMOK 50 YE
   Veeravagu A, 2009, SPINE, V34, P1869, DOI 10.1097/BRS.0b013e3181adc989
   Warner DO, 2007, CURR OPIN ANESTHESIO, V20, P279, DOI 10.1097/ACO.0b013e3280c60c3b
   Weiss A, 2015, JAMA SURG, V150, P815, DOI 10.1001/jamasurg.2015.0962
   Wiley LK, 2013, J AM MED INFORM ASSN, V20, P652, DOI 10.1136/amiajnl-2012-001557
   Xing D, 2013, EUR SPINE J, V22, P605, DOI 10.1007/s00586-012-2514-6
NR 36
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E393
EP E407
DI 10.1016/j.wneu.2018.11.180
PG 15
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400046
PM 30500580
DA 2020-05-12
ER

PT J
AU Faffell, NF
   Kingdom, TT
   Getz, AE
   Lillehei, KO
   Youssef, AS
   Ramakrishnan, VR
AF Faffell, Nyssa Fox
   Kingdom, Todd T.
   Getz, Anne E.
   Lillehei, Kevin O.
   Youssef, A. Samy
   Ramakrishnan, Vijay R.
TI Development of Chronic Sphenoid Sinusitis After Sellar Reconstruction
   with Medpor Porous Polyethylene Implant
SO WORLD NEUROSURGERY
LA English
DT Article
DE CSF leak; Medpor; Pituitary adenoma; Porous polyethylene; Sellar
   reconstruction; Sphenoid sinusitis; Transsphenoidal surgery
ID BACTERIAL BIOFILM FORMATION; TRANSSPHENOIDAL SURGERY; FLOOR
   RECONSTRUCTION; COMPLICATIONS; CLOSURE; BRAIN; PLATE
AB OBJECTIVE: The Medpor porous polyethylene implant is reported to be safe and effective for sellar reconstruction after transsphenoidal surgery (TSS). However, we have observed several cases of delayed chronic sphenoid sinusitis related to the implant. The purpose of this study is to describe the presentation and management of implant-related sphenoid sinusitis after sellar reconstruction.
   METHODS: This is a retrospective study of patients who underwent endonasal TSS with Medpor sellar reconstruction between December 2008 and January 2013 at a tertiary care institution. Patient demographics, initial surgical management, sinonasal symptoms, postoperative imaging, sinusitis management, and resulting outcomes were analyzed.
   RESULTS: From 2008-2013, 139 patients underwent sellar reconstruction using Medpor. Five patients (3.6%) presented between 8 and 60 months after surgery with chronic sphenoid sinusitis that required surgical management. All 5 patients presented as outpatients for management of headaches and nasal drainage, 4 patients experienced chronic nasal congestion, and 3 patients noted recurrent sinusitis. At the time of revision surgery, all 5 patients were found to have mucosal inflammation and edema surrounding the implant, and 4 of the 5 had an exposed or partially extruded implant that was removed.
   CONCLUSIONS: Reconstruction of the sellar floor may be performed after TSS to prevent postoperative complications. Although porous polyethylene implants have previously been described as safe and effective for this purpose, surgeons should be aware of the risk of subsequent implant extrusion and chronic sphenoid sinusitis that can occur in a delayed manner.
C1 [Faffell, Nyssa Fox; Kingdom, Todd T.; Getz, Anne E.; Youssef, A. Samy; Ramakrishnan, Vijay R.] Univ Colorado, Sch Med, Dept Otolaryngol Head & Neck Surg, Aurora, CO 80045 USA.
   [Lillehei, Kevin O.; Youssef, A. Samy; Ramakrishnan, Vijay R.] Univ Colorado, Sch Med, Dept Neurosurg, Aurora, CO 80045 USA.
RP Ramakrishnan, VR (reprint author), Univ Colorado, Sch Med, Dept Otolaryngol Head & Neck Surg, Aurora, CO 80045 USA.; Ramakrishnan, VR (reprint author), Univ Colorado, Sch Med, Dept Neurosurg, Aurora, CO 80045 USA.
EM vijay.ramakrishnan@ucdenver.edu
FU NIDCD NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Deafness &
   Other Communication Disorders (NIDCD) [K23 DC014747]
CR Arita K, 1999, J NEUROSURG, V91, P1055, DOI 10.3171/jns.1999.91.6.1055
   BLACK PM, 1987, NEUROSURGERY, V20, P920, DOI 10.1227/00006123-198706000-00017
   Choi SY, 2017, INT J ORAL MAX SURG, V46, P582, DOI 10.1016/j.ijom.2017.01.007
   Ciric I, 1997, NEUROSURGERY, V40, P225, DOI 10.1097/00006123-199702000-00001
   Colletti G, 2018, J CRANIO MAXILL SURG, V46, P274, DOI 10.1016/j.jcms.2017.11.017
   Couldwell William T, 2006, Neurosurg Focus, V20, pE11, DOI 10.3171/foc.2006.20.3.12
   Dolecek TA, 2012, NEURO-ONCOLOGY, V14, pv1, DOI 10.1093/neuonc/nos218
   FREIDBERG SR, 1994, NEUROSURGERY, V35, P159, DOI 10.1227/00006123-199407000-00027
   Goljo E, 2018, AM J OTOLARYNG, V39, P253, DOI 10.1016/j.amjoto.2017.12.015
   Karnezis TT, 2016, INT FORUM ALLERGY RH, V6, P1117, DOI 10.1002/alr.21783
   KOBAYASHI S, 1981, SURG NEUROL, V15, P196, DOI 10.1016/0090-3019(81)90142-7
   KUBOTA T, 1991, SURG NEUROL, V36, P360, DOI 10.1016/0090-3019(91)90024-4
   Liebelt BD, 2015, WORLD NEUROSURG, V84, P240, DOI 10.1016/j.wneu.2015.02.025
   Liu JK, 2004, NEUROSURG FOCUS, V16, P1, DOI DOI 10.3171/F0C.2004.16.4.3
   Locatelli D, 2009, ACTA NEUROCHIR, V151, P1431, DOI 10.1007/s00701-009-0428-9
   Malaisrie SC, 1998, LARYNGOSCOPE, V108, P1733, DOI 10.1097/00005537-199811000-00026
   Naunheim MR, 2015, J NEUROL SURG PART B, V76, P390, DOI 10.1055/s-0035-1549308
   Park J, 2004, SURG NEUROL, V61, P488, DOI 10.1016/S0090-3019(03)00581-0
   Patel PN, 2018, OTOLARYNG HEAD NECK, V158, P952, DOI 10.1177/0194599818756272
   Ramakrishnan VR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0085507
   Ferreira ACRD, 2016, J CRANIOFAC SURG, V27, P425, DOI 10.1097/SCS.0000000000002325
   Ridwan-Pramana A, 2015, J CRANIO MAXILL SURG, V43, P1330, DOI 10.1016/j.jcms.2015.06.022
   Seda L, 2006, SURG NEUROL, V66, P46, DOI 10.1016/j.surneu.2005.10.021
   Surawicz TS, 1998, J NEURO-ONCOL, V40, P151, DOI 10.1023/A:1006091608586
   Tabaee A, 2009, J NEUROSURG, V111, P545, DOI 10.3171/2007.12.17635
   Walker TJ, 2016, JAMA FACIAL PLAST SU, V18, P299, DOI 10.1001/jamafacial.2016.0279
NR 26
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E781
EP E786
DI 10.1016/j.wneu.2018.12.034
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400094
PM 30579017
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Freyschlag, CF
   Boehme, C
   Bauer, M
   Kerschbaumer, J
   Pinggera, D
   Riedmann, M
   Unterhofer, C
   Grams, AE
   Knoflach, M
   Thome, C
AF Freyschlag, Christian F.
   Boehme, Christian
   Bauer, Marlies
   Kerschbaumer, Johannes
   Pinggera, Daniel
   Riedmann, Marina
   Unterhofer, Claudia
   Grams, Astrid E.
   Knoflach, Michael
   Thome, Claudius
TI The Volume of Ischemic Brain Predicts Poor Outcome in Patients with
   Surgically Treated Malignant Stroke
SO WORLD NEUROSURGERY
LA English
DT Article
DE Computed tomography; Decompressive hemicraniectomy; Outcome; Stroke;
   Volumetry
ID MIDDLE CEREBRAL-ARTERY; DECOMPRESSIVE SURGERY; INFARCTION;
   HEMICRANIECTOMY; MULTICENTER; TRIAL
AB BACKGROUND: Malignant middle cerebral artery stroke is a life-threatening condition. The outcomes of surgical treatments have presented strong evidence in favor of decompressive hemicraniectomy (DHC). A significant subpopulation of patients still experience very poor outcomes. In particular, indication for DHC is based on few objective parameters to facilitate decision making. We hypothesized that larger ischemic brain volume would have a large impact on the outcome.
   METHODS: A cohort study of 34 patients undergoing DHC was performed using a volumetric analysis of infarction volume (measured preoperatively and again on postoperative day [POD] 1 and POD 3). Outcomes were assessed using the modified Rankin Scale (mRS), and a favorable outcome was defined as modified Rankin Scale score <= 3.
   RESULTS: Median age of patients was 53.5 years (range, 25-72 years), the median time from onset of first symptoms to surgical intervention was 38 hours (range, 10-150 hours), and male-to-female ratio was 2:1. The median ischemic volume was 250 cm3 preoperatively, 315 cm(3) on POD1, and 349 cm(3) on POD3. Modified Rankin Scale score <= 3 after 6 months was attained in 7 (20%) patients. Within the first 24 hours after DHC, ischemic volume increased significantly (P = 0.0003) and was associated with a worse outcome (P < 0.0001) after exceeding a cutoff volume of 300 cm(3).
   CONCLUSIONS: Volumetric analysis of infarction can predict the outcome of patients. DHC should be reserved for patients with prognosticated good outcome, which was observed only in patients with a volume <301 cm(3).
C1 [Freyschlag, Christian F.; Bauer, Marlies; Kerschbaumer, Johannes; Pinggera, Daniel; Unterhofer, Claudia; Thome, Claudius] Med Univ Innsbruck, Dept Neurosurg, Innsbruck, Austria.
   [Boehme, Christian; Knoflach, Michael] Med Univ Innsbruck, Dept Neurol, Innsbruck, Austria.
   [Riedmann, Marina] Med Univ Innsbruck, Dept Med Stat Informat & Hlth Econ, Innsbruck, Austria.
   [Grams, Astrid E.] Med Univ Innsbruck, Dept Neuroradiol, Innsbruck, Austria.
RP Freyschlag, CF (reprint author), Med Univ Innsbruck, Dept Neurosurg, Innsbruck, Austria.
EM christian.freyschlag@i-med.ac.at
RI Grams, Astrid/AAH-6325-2019
OI Boehme, Christian/0000-0003-1369-418X; Knoflach,
   Michael/0000-0001-5576-6562; Kerschbaumer, Johannes/0000-0002-9997-4336
CR Goto Y, 2016, J STROKE CEREBROVASC, V25, P1389, DOI 10.1016/j.jstrokecerebrovasdis.2015.12.034
   Goyal M, 2016, LANCET, V387, P1723, DOI 10.1016/S0140-6736(16)00163-X
   Hofmeijer J, 2009, LANCET NEUROL, V8, P326, DOI 10.1016/S1474-4422(09)70047-X
   Juttler E, 2007, STROKE, V38, P2518, DOI 10.1161/STROKEAHA.107.485649
   Kondziella D, 2013, ACTA NEUROL SCAND, V127, P1, DOI 10.1111/j.1600-0404.2012.01702.x
   Lin K, 2011, J NEUROIMAGING, V21, P229, DOI 10.1111/j.1552-6569.2010.00487.x
   Mendis S, 2011, GLOBAL ATLAS CARDIOV
   Neugebauer H, 2016, CEREBROVASC DIS, V41, P283, DOI 10.1159/000443935
   Shi JJ, 2017, CURR NEUROVASC RES, V14, P141, DOI 10.2174/1567202614666170328095431
   Sporns PB, 2017, CLIN NEURORADIOL, V27, P193, DOI 10.1007/s00062-015-0478-8
   Vahedi K, 2007, STROKE, V38, P2506, DOI 10.1161/STROKEAHA.107.485235
   Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4
   Weil AG, 2011, CAN J NEUROL SCI, V38, P434, DOI 10.1017/S0317167100011835
   Willeit J, 2015, LANCET NEUROL, V14, P48, DOI 10.1016/S1474-4422(14)70286-8
NR 14
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E515
EP E519
DI 10.1016/j.wneu.2018.11.197
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400060
PM 30503289
DA 2020-05-12
ER

PT J
AU de Andoain, GBG
   Delgado-Fernandez, J
   Cuesta, JRP
   Gil-Simoes, R
   Frade-Porto, N
   Sanchez, MP
AF Garcia de Andoain, Guillermo Blasco
   Delgado-Fernandez, Juan
   Penanes Cuesta, Juan Ramcon
   Gil-Simoes, Ricardo
   Frade-Porto, Natalia
   Pedrosa Sanchez, Manuel
TI Meningiomas Originated at the Falcotentorial Region: Analysis of
   Topographic and Diagnostic Features Guiding an Optimal Surgical Planning
SO WORLD NEUROSURGERY
LA English
DT Article
DE Falcotentorial meningioma; Occipital transtentorial approach; Pineal
   region meningioma; Pineal region surgery; Supracerebellar infratentorial
   approach; Velum interpositum meningioma
ID PINEAL-REGION; JUNCTION; TUMORS; CRANIOTOMY; MANAGEMENT
AB BACKGROUND: Meningiomas arising at the pineal region are a rare entity and still represent a great neurosurgical challenge given their deep location and critical neuroanatomic relationships. The optimal surgical approach to treat these lesions is still under debate. Our objective is to review the topographic and diagnostic features of these lesions, which can help to guide an optimal surgical outcome.
   METHODS: We present 2 clinical cases of falcotentorial meningiomas successfully treated at our institution (2016-2017) with different surgical approaches. A literature review is performed, and a description of the classification, anatomic relationships, clinical features, diagnosis, and different surgical options and outcomes of these lesions is presented.
   RESULTS: The first patient was treated via a supracerebellar infratentorial approach, and the second patient was treated via a parieto-occipital interhemispheric approach. In both tumors, a gross total resection was achieved with no permanent neurologic deficits. In the literature review, gross total resection rates range from 33% to 100%, with no differences regarding the type of meningioma or the surgical approach performed. Permanent neurologic morbidity varies from 0% to 50%, and mortality rates range from 0% to 23%. The distortion and displacement of the vein of Galen and straight sinus represent the most important feature in the decision of optimal surgical approach.
   CONCLUSIONS: Pineal region meningiomas represent very infrequent, challenging lesions, and their description in the literature is scarce. The systematic topographic classification of these tumors and evaluation of the neuroanatomic structures involved are crucial to guide a safe and optimal surgical approach and achieve satisfactory outcomes.
C1 [Garcia de Andoain, Guillermo Blasco; Gil-Simoes, Ricardo; Frade-Porto, Natalia; Pedrosa Sanchez, Manuel] Univ Hosp Princesa, Dept Neurosurg, Dept Surg, Madrid, Spain.
   [Delgado-Fernandez, Juan] Natl Hosp Neurol & Neurosurg, Victor Horsley Dept Neurosurg, Queen Sq, London, England.
   [Penanes Cuesta, Juan Ramcon] Fdn Jimenez Diaz, Dept Neurosurg, Madrid, Spain.
RP de Andoain, GBG (reprint author), Univ Hosp Princesa, Dept Neurosurg, Dept Surg, Madrid, Spain.
EM guilleblasco20@gmail.com
RI Delgado-Fernandez, Juan/AAH-8667-2019
OI Delgado-Fernandez, Juan/0000-0002-4251-8356
CR [Anonymous], 2008, SURG RADIOL ANAT, V30, P131, DOI 10.1007/s00276-007-0293-2
   Araki C, 1937, ARCH JAP CHIR, V14, P1181
   ASARI S, 1995, J NEUROSURG, V82, P726, DOI 10.3171/jns.1995.82.5.0726
   Bassiouni H, 2008, SURG NEUROL, V69, P339, DOI 10.1016/j.surneu.2007.02.029
   Behari S, 2014, NEUROL INDIA, V62, P290, DOI 10.4103/0028-3886.136934
   Carey J P, 1975, Surg Neurol, V3, P41
   Goto T, 2006, J NEUROSURG, V104, P47, DOI 10.3171/jns.2006.104.1.47
   Guttmann E, 1930, Z GESAMTE NEUROL PSY, V123, P606, DOI 10.1007/BF02865520
   Hong CK, 2016, YONSEI MED J, V57, P1022, DOI 10.3349/ymj.2016.57.4.1022
   ITO J, 1981, NEURORADIOLOGY, V21, P207, DOI 10.1007/BF00367342
   Konovalov AN, 1996, J NEUROSURG, V85, P586, DOI 10.3171/jns.1996.85.4.0586
   Lozier Alan P, 2003, Neurosurg Focus, V15, pE11
   Matushita H, 2007, ARQ NEURO-PSIQUIAT, V65, P1000, DOI 10.1590/S0004-282X2007000600016
   NAZZARO JM, 1992, J NEUROSURG, V76, P746, DOI 10.3171/jns.1992.76.5.0746
   Nowak A, 2014, NEUROL NEUROCHIR POL, V48, P397, DOI 10.1016/j.pjnns.2014.09.009
   Okami N, 2001, J CLIN NEUROSCI, V8, P15, DOI 10.1054/jocn.2001.0870
   Oppenheim H, 1913, BERL KLIN WOCHENSCHR, V50, P2316
   Otani N, 2018, NEUROSURG FOCUS, V44, DOI 10.3171/2017.12.FOCUS17602
   PIATT JH, 1983, NEUROSURGERY, V12, P369, DOI 10.1227/00006123-198304000-00002
   POPPEN JL, 1968, J NEUROSURG, V28, P357, DOI 10.3171/jns.1968.28.4.0357
   Qiu B, 2014, INT J NEUROSCI, V124, P741, DOI 10.3109/00207454.2013.878341
   Quinones-Hinojosa Alfredo, 2003, Neurosurg Focus, V14, pe11
   Quinones-Hinojosa A, 2009, NEUROSURGERY, V64, P260, DOI 10.1227/01.NEU.0000344642.98597.A7
   Raco A, 2004, SURG NEUROL, V61, P157, DOI 10.1016/S0090-3019(03)00573-1
   Roberti F, 2001, SURG NEUROL, V56, P8, DOI 10.1016/S0090-3019(01)00479-7
   Samii M, 1996, J NEUROSURG, V84, P375, DOI 10.3171/jns.1996.84.3.0375
   SEKHAR LN, 1992, SURG NEUROL, V37, P197, DOI 10.1016/0090-3019(92)90230-K
   SUNG DI, 1978, RADIOLOGY, V128, P745, DOI 10.1148/128.3.745
   SUZUKI M, 1984, NEUROSURGERY, V15, P710, DOI 10.1227/00006123-198411000-00015
   Tandler J, 1920, CHIRURGISCHE ANATOMI
   Yasargil MG, 1996, MENINGIOMAS MICRONEU
NR 31
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E723
EP E733
DI 10.1016/j.wneu.2018.12.013
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400086
PM 30580064
DA 2020-05-12
ER

PT J
AU Han, XY
   Geng, X
   Li, ZZ
   Chen, Z
   Liu, YL
   Liu, PF
   Wang, QB
   Li, CL
   Ai, DD
   Li, ZF
AF Han, Xinyu
   Geng, Xin
   Li, Zhenzhu
   Chen, Zheng
   Liu, Yongliang
   Liu, Pengfei
   Wang, Qingbo
   Li, Chenglong
   Ai, Dingding
   Li, Zefu
TI The Relationship Between Phospho-p38, Matrix Metalloproteinase 9, and
   Major Histocompatibility Complex Class I Chain-Related Molecule A
   Expression in Pituitary Adenomas Demonstrates a New Mechanism of
   Pituitary Adenoma Immune Escape
SO WORLD NEUROSURGERY
LA English
DT Article
DE Immune escape; MICA; MMP-9; p38/MAPK; phospho-p38; Pituitary adenoma
ID P38 MAP KINASE; MICA EXPRESSION; GASTRIC-CANCER; NKG2D; MMP-9; PATHWAY;
   PROLIFERATION; DISINTEGRIN; ACTIVATION; LIGANDS
AB BACKGROUND: The major histocompatibility complex class I chain-related molecule A (MICA) is one of the natural killer group 2D ligands. Soluble major histocompatibility complex class I chain-related molecule A (sMICA) mediates tumor immune escape, but the mechanism is not fully understood. In this study, we examined the expression of phospho-p38, matrix metalloproteinase 9 (MMP-9), and MICA and their relationships among each other in pituitary adenoma tissues to provide a histologic basis for the mechanism of pituitary adenoma immune escape.
   METHODS: We applied immunohistochemistry, real-time quantitative reverse-transcriptase polymerase chain reaction, and Western blot to detect phospho-p38, MMP-9, and MICA expression at the mRNA and protein levels in pituitary adenoma tissues. Enzyme-linked immunosorbent assay was used to examine the expression levels of MMP-9 and sMICA in peripheral blood serum from patients with pituitary adenoma.
   RESULTS: We found that p38, MICA, and MMP-9 mRNA levels were greater in pituitary adenomas than in normal tissues. The phospho-p38, MMP-9, and MICA proteins were overexpressed in pituitary adenomas, and the expression of MMP-9 and MICA were positively correlated with the expression of phospho-p38. In addition, the serum levels of sMICA and MMP-9 proteins in pituitary adenoma patients were significantly greater than those in normal controls.
   CONCLUSIONS: These findings suggest that activation of the p38/mitogen-activated protein kinase pathway may increase MICA expression and induce MMP-9 expression. MMP-9 is involved in the shedding of sMICA from MICA to promote tumor immune escape. Furthermore, p38/mitogen-activated protein kinase could potentially represent a novel target for inhibiting pituitary adenoma immune escape.
C1 [Han, Xinyu; Li, Zhenzhu; Chen, Zheng; Liu, Yongliang; Liu, Pengfei; Wang, Qingbo; Li, Chenglong; Li, Zefu] Binzhou Med Univ, Affiliated Hosp, Dept Neurosurg, Binzhou, Peoples R China.
   [Geng, Xin] Binzhou Med Univ, Affiliated Hosp, Dept Pediat Surg, Binzhou, Peoples R China.
   [Ai, Dingding] Binzhou Med Univ, Affiliated Hosp, Dept Reprod Med, Binzhou, Peoples R China.
RP Li, ZF (reprint author), Binzhou Med Univ, Affiliated Hosp, Dept Neurosurg, Binzhou, Peoples R China.
EM lizefu163@163.com
FU Natural Science Foundation of Shandong ProvinceNatural Science
   Foundation of Shandong Province [ZR2018LH007]
FX This work was supported by the Natural Science Foundation of Shandong
   Province (ZR2018LH007).
CR Chauveau A, 2014, J INNATE IMMUN, V6, P89, DOI 10.1159/000351605
   Chen Z, 2015, NEUROSCI LETT, V597, P77, DOI 10.1016/j.neulet.2015.04.025
   Chitadze G, 2013, INT J CANCER, V133, P1557, DOI 10.1002/ijc.28174
   Czernek L, 2017, ARCH IMMUNOL THER EX, V65, P311, DOI 10.1007/s00005-016-0453-3
   Gasser S, 2005, NATURE, V436, P1186, DOI 10.1038/nature03884
   Gradiser M, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13030330
   Groh V, 2002, NATURE, V419, P734, DOI 10.1038/nature01112
   Koul Hari K, 2013, Genes Cancer, V4, P342, DOI 10.1177/1947601913507951
   Kumar B, 2010, CANCER RES, V70, P832, DOI 10.1158/0008-5472.CAN-09-2918
   Leifler KS, 2013, J IMMUNOL, V190, P4420, DOI 10.4049/jimmunol.1202610
   Li Y, 2018, NATL MED J CHINA, V98, P712
   Liu G, 2010, J IMMUNOL, V184, P3346, DOI 10.4049/jimmunol.0903789
   Lundholm M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108925
   Molinero LL, 2003, J LEUKOCYTE BIOL, V73, P815, DOI 10.1189/jlb.0602329
   [母义明 Mu Yiming], 2017, [解放军医学杂志, Medical Journal of Chinese People's Liberation Army], V42, P576
   New LG, 1998, TRENDS CARDIOVAS MED, V8, P220, DOI 10.1016/S1050-1738(98)00012-7
   Shiraishi K, 2016, J GASTROENTEROL, V51, P1101, DOI 10.1007/s00535-016-1197-x
   Simon C, 2001, EXP CELL RES, V271, P344, DOI 10.1006/excr.2001.5374
   Song H, 2006, CANCER RES, V66, P10487, DOI 10.1158/0008-5472.CAN-06-1461
   Soriani A, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2016.1264564
   Sun DH, 2011, CELL BIOL INT, V35, P569, DOI 10.1042/CBI20100431
   Wang DW, 2018, EUR REV MED PHARMACO, V22, P1241, DOI 10.26355/eurrev_201803_14464
   Xu XL, 2006, J CLIN ENDOCR METAB, V91, P2704, DOI 10.1210/jc.2006-0492
   Yao S, 2013, NAT REV DRUG DISCOV, V12, P130, DOI 10.1038/nrd3877
   Zhao SL, 2012, CANCER IMMUNOL IMMUN, V61, P1745, DOI 10.1007/s00262-012-1235-3
   Zou X, 2017, CANCER LETT, V384, P19, DOI 10.1016/j.canlet.2016.10.008
NR 26
TC 2
Z9 2
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E116
EP E124
DI 10.1016/j.wneu.2018.11.077
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400014
PM 30458325
DA 2020-05-12
ER

PT J
AU Harrichandparsad, R
   Nadvi, SS
   Moosa, MYS
   Van Dellen, JR
AF Harrichandparsad, Rohen
   Nadvi, Syed Sameer
   Moosa, Mahomed-Yunus Suleman
   Van Dellen, James Rikus
TI Outcome of Ventriculoperitoneal Shunt Surgery in Human Immunodeficiency
   Virus-Positive Patients on Combination Antiretroviral Therapy with
   Tuberculosis Meningitis and Hydrocephalus
SO WORLD NEUROSURGERY
LA English
DT Article
DE Human immunodeficiency virus; Hydrocephalus; Tuberculous meningitis
ID CEREBROSPINAL-FLUID; HIV-INFECTION; MANAGEMENT; DIAGNOSIS; PROFILE;
   UPDATE
AB BACKGROUND: In 2000, we advised against insertion of a ventriculoperitoneal shunt (VPS) in human immunodeficiency virus (HIV)-positive patients with tuberculous meningitis (TBM) complicated by hydrocephalus. However, this was in the era when combination antiretroviral therapy (ART) was not freely available in South Africa. In this subsequent preliminary report, we describe the outcome of ventriculoperitoneal shunting in patients with TBM and hydrocephalus who are HIV positive and receiving ART.
   METHODS: We compared a group of 15 HIV-positive patients with TBM and hydrocephalus on ART with a retrospective control group of 15 patients (demographically and clinically matched) but not on ART. All patients were otherwise managed similarly and evaluated at 1 month after VPS insertion.
   RESULTS: In historical controls, 10 patients died (66.7%) and no patient showed any improvement 1 month after shunting. In contrast, in the current group on ART, 4 patients died (26.7%), with 11 patients (73.3%) having a good outcome. Eight of 12 patients with grade 3 TBM had a good outcome, whereas all 3 with grade 1 TBM made a good recovery.
   CONCLUSIONS: The outcome of VP shunting in HIV-positive patients with TBM and hydrocephalus is markedly improved in patients on ART. Based on limited data from this study, we recommend that better grades of TBM (1 and 2) undergo immediate VPS surgery. Patients with grade 4 TBM should undergo a trial of external ventricular drainage and those who improve should undergo a definitive procedure. Further research is required for patients with grade 3 TBM to identify characteristics associated with better outcomes to allow for effective use of limited resources.
C1 [Harrichandparsad, Rohen; Nadvi, Syed Sameer] Univ KwaZulu Natal, Nelson R Mandela Sch Med, Dept Neurosurg, Durban, South Africa.
   [Moosa, Mahomed-Yunus Suleman] Univ KwaZulu Natal, Nelson R Mandela Sch Med, Dept Infect Dis, Durban, South Africa.
   [Van Dellen, James Rikus] Bupa Cromwell Hosp, London, England.
RP Harrichandparsad, R (reprint author), Univ KwaZulu Natal, Nelson R Mandela Sch Med, Dept Neurosurg, Durban, South Africa.
EM Harrichandparsad@ukzn.ac.za
CR [Anonymous], 2018, UNAIDS REGIONAL REPO
   BERENGUER J, 1992, NEW ENGL J MED, V326, P668, DOI 10.1056/NEJM199203053261004
   BULLOCK MRR, 1982, SURG NEUROL, V18, P274, DOI 10.1016/0090-3019(82)90344-5
   BULLOCK MRR, 1982, J NEUROL NEUROSUR PS, V45, P1098, DOI 10.1136/jnnp.45.12.1098
   Chan KH, 2003, QJM-INT J MED, V96, P643, DOI 10.1093/qjmed/hcg108
   Chaya S, 2016, INT J TUBERC LUNG D, V20, P1457, DOI 10.5588/ijtld.15.0845
   DECOCK KM, 1992, JAMA-J AM MED ASSOC, V268, P1581, DOI 10.1001/jama.1992.03490120095035
   DIPERRI G, 1991, NEW ENGL J MED, V325, P1882
   Garg RK, 2010, ACTA NEUROL SCAND, V122, P75, DOI 10.1111/j.1600-0404.2009.01316.x
   Henderson D, 2016, J NEUROSURG, V10, P1
   JENNETT B, 1975, LANCET, V1, P480
   Kalita J, 2007, EUR J NEUROL, V14, P33, DOI 10.1111/j.1468-1331.2006.01534.x
   Katrak SM, 2000, J NEUROL SCI, V181, P118, DOI 10.1016/S0022-510X(00)00440-8
   Lamprecht D, 2001, BRIT J NEUROSURG, V15, P119
   Marais S, 2010, TUBERCULOSIS, V90, P367, DOI 10.1016/j.tube.2010.08.006
   Mathe M, 2014, S AFR J HIV MED, V15, P121
   Mathew JM, 1998, J NEUROL NEUROSUR PS, V65, P115, DOI 10.1136/jnnp.65.1.115
   Misra UK, 2000, J NEUROL NEUROSUR PS, V68, P300, DOI 10.1136/jnnp.68.3.300
   NADVI SS, 1995, BRIT J NEUROSURG, V9, P519, DOI 10.1080/02688699550041160
   Nadvi SS, 2000, NEUROSURGERY, V47, P644, DOI 10.1097/00006123-200009000-00024
   NAROTAM PK, 1994, NEUROSURGERY, V34, P982, DOI 10.1227/00006123-199406000-00005
   Paes BF, 2009, PEDIATRICS, V123
   PALUR R, 1991, J NEUROSURG, V74, P64, DOI 10.3171/jns.1991.74.1.0064
   Rajshekhar V, 2015, ACTA NEUROCHIR, V157, P1665, DOI 10.1007/s00701-015-2501-x
   Raut T, 2013, J INFECTION, V66, P330, DOI 10.1016/j.jinf.2012.12.009
   Rizvi I, 2017, J NEUROL SCI, V375, P255, DOI 10.1016/j.jns.2017.02.008
   SanchezPortocarrero J, 1996, ARCH NEUROL-CHICAGO, V53, P671, DOI 10.1001/archneur.1996.00550070109018
   Schutte CM, 2001, INFECTION, V29, P213, DOI 10.1007/s15010-001-1198-3
   Sharma RM, 2015, J NEUROSURG, V122, P1087, DOI 10.3171/2014.12.JNS14257
   Srikantha U, 2009, J NEUROSURG-PEDIATR, V4, P176, DOI 10.3171/2009.3.PEDS08308
   Strazza M, 2011, BRAIN RES, V1399, P96, DOI 10.1016/j.brainres.2011.05.015
   Tandon V, 2011, CHILD NERV SYST, V27, P1699, DOI 10.1007/s00381-011-1482-1
   THEUER CP, 1990, J INFECT DIS, V162, P8, DOI 10.1093/infdis/162.1.8
   Thwaites G, 2000, J NEUROL NEUROSUR PS, V68, P289, DOI 10.1136/jnnp.68.3.289
   Thwaites GE, 2005, J INFECT DIS, V192, P2134, DOI 10.1086/498220
   Thwaites GE, 2009, CLIN CHEST MED, V30, P745, DOI 10.1016/j.ccm.2009.08.018
   Torok ME, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001772
   van der Weert EM, 2006, PEDIATR INFECT DIS J, V25, P65, DOI 10.1097/01.inf.0000183751.75880.f8
   van Toorn R, 2014, SEMIN PEDIATR NEUROL, V21, P12, DOI 10.1016/j.spen.2014.01.006
   Wolzak NK, 2012, J TROP PEDIATRICS, V58, P491, DOI 10.1093/tropej/fms031
   ZHANG YH, 1995, J CLIN INVEST, V95, P2324, DOI 10.1172/JCI117924
NR 41
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E574
EP E580
DI 10.1016/j.wneu.2018.11.221
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400067
PM 30529520
DA 2020-05-12
ER

PT J
AU Hayes, MJ
   TerMaath, SC
   Crook, TR
   Killeffer, JA
AF Hayes, Madeline J.
   TerMaath, Stephanie C.
   Crook, T. Russell
   Killeffer, James A.
TI A Review on the Effectiveness of Surgical Intervention for Symptomatic
   Intracranial Arachnoid Cysts in Adults
SO WORLD NEUROSURGERY
LA English
DT Review
DE Arachnoid cyst; Craniotomy; Endoscopic fenestration; Shunt
ID MIDDLE CRANIAL FOSSA; SENSORINEURAL HEARING-LOSS; 12TH NERVE PARESIS;
   TERM-FOLLOW-UP; POSTERIOR-FOSSA; ENDOSCOPIC TREATMENT; CEREBELLOPONTINE
   ANGLE; QUADRIGEMINAL CISTERN; INCIDENTAL FINDINGS;
   ELECTROCONVULSIVE-THERAPY
AB BACKGROUND: Intracranial arachnoid cysts are generally benign and can be asymptomatic or symptomatic. When symptoms are indicated, the effects of arachnoid cysts can be disabling to the patient. Quantitative assessment on the effectiveness of surgical intervention to relieve symptoms is inconsistently reported throughout the literature and is often contradictory. Due to this lack of direct evidence and disagreement among practitioners, nonsurgical treatment, such as pain management, is often prescribed. The objectives of this research were to evaluate the effectiveness of the 3 most common surgical treatments (craniotomy, endoscopic fenestration, and shunting) in relieving patient symptoms and to provide a resource of case study information for doctors and patients considering surgical intervention.
   METHODS: A worldwide literature review was performed using the PubMed database to collect reported data on case studies describing surgical intervention for intracranial arachnoid cysts. A meta-analytic review was performed on the viable data to investigate the overall surgical effectiveness for an adult population (aged 18 years or older). To increase the number of patient outcomes, some mixed data (case studies containing both adult and pediatric patients) were included in this study.
   RESULTS: The meta-analytic results show that, for the mixed adult and pediatric population, surgical treatment improves patient outcomes ((r) over bar = 0.828; P < 0.01), and the specific effects for craniotomy, shunting, and endoscopy are <(r)over bar> = 0.890, 0.738, and 0.892. For the adult-only population, the meta-analytic results show that surgical treatment also improves patient outcomes ((r) over bar = 0.667; P < 0.01), and the specific effects for craniotomy, shunting, and endoscopy are <(r)over bar> = 0.638, 0.684, and 0.727.
   CONCLUSIONS: The results indicate that surgical intervention is an effective approach to reduce or eliminate symptoms caused by intracranial arachnoid cysts.
C1 [Hayes, Madeline J.] Univ Tennessee, Dept Chem & Biomol Engn, Knoxville, TN 37996 USA.
   [TerMaath, Stephanie C.] Univ Tennessee, Dept Mech Aerosp & Biomed Engn, Knoxville, TN USA.
   [Crook, T. Russell] Univ Tennessee, Dept Management, Knoxville, TN 37996 USA.
   [Killeffer, James A.] Univ Tennessee, Grad Sch Med, Dept Surg, Div Neurosurg, Knoxville, TN 37996 USA.
RP Hayes, MJ (reprint author), Univ Tennessee, Dept Chem & Biomol Engn, Knoxville, TN 37996 USA.
EM madelinejhayes@gmail.com
RI TerMaath, Stephanie/AAB-9983-2019
FU Research and Instructional Strategies for Engineering Retention (RISER)
   at the University of Tennessee, Knoxville, Tennessee, USA; National
   Science Foundation (NSF) through the Science, Technology, Engineering,
   and Mathematics Talent Expansion Program (STEP) [1068103]
FX M.H. acknowledges the support of the Research and Instructional
   Strategies for Engineering Retention (RISER) at the University of
   Tennessee, Knoxville, Tennessee, USA. RISER is funded by the National
   Science Foundation (NSF) through the Science, Technology, Engineering,
   and Mathematics Talent Expansion Program (STEP) award number 1068103.
CR Abhinav K, 2012, BRIT J NEUROSURG, V26, P754, DOI 10.3109/02688697.2011.641617
   Acar O, 2003, CLIN NEUROL NEUROSUR, V105, P93, DOI 10.1016/S0303-8467(02)00111-7
   Achilli V, 2005, Acta Otorhinolaryngol Ital, V25, P296
   Aggouri M, 2010, NEUROSCIENCES, V15, P277
   Ahn SW, 2011, NEUROL INDIA, V59, P467, DOI 10.4103/0028-3886.82739
   Al-Holou WN, 2013, J NEUROSURG, V118, P222, DOI 10.3171/2012.10.JNS12548
   Al-Holou WN, 2010, J NEUROSURG-PEDIATR, V5, P578, DOI 10.3171/2010.2.PEDS09464
   Aleman J, 2001, NEUROSURGERY, V48, P1291, DOI 10.1097/00006123-200106000-00021
   Alfieri A, 1996, NEURORADIOLOGY, V38, P569
   Ali ZS, 2014, CHILD NERV SYST, V30, P461, DOI 10.1007/s00381-013-2306-2
   ALLEN R, 1986, J MED ENG TECHNOL, V10, P299, DOI 10.3109/03091908609022923
   ANDERSON FM, 1979, J NEUROSURG, V50, P333, DOI 10.3171/jns.1979.50.3.0333
   Anninos P., 2007, Journal of Integrative Neuroscience, V6, P227, DOI 10.1142/S0219635207001519
   Arai H, 1996, NEUROSURGERY, V39, P1108, DOI 10.1097/00006123-199612000-00007
   Arai H, 1996, NEUROSURGERY, V39, P1112
   ARTICO M, 1995, ACTA NEUROCHIR, V132, P75, DOI 10.1007/BF01404851
   Arunkumar MJ, 1999, BRIT J NEUROSURG, V13, P326
   Ashker L, 2008, J NEURO-OPHTHALMOL, V28, P192, DOI 10.1097/WNO.0b013e318183c57c
   AUER LM, 1981, J NEUROSURG, V54, P366, DOI 10.3171/jns.1981.54.3.0366
   Awaji M, 2007, NEURORADIOLOGY, V49, P721, DOI 10.1007/s00234-007-0248-7
   BABU R, 1991, NEUROSURGERY, V28, P886, DOI 10.1227/00006123-199106000-00018
   Bahuleyan B, 2007, J CLIN NEUROSCI, V14, P895, DOI 10.1016/j.jocn.2006.06.009
   Baldawa S, 2014, BRIT J NEUROSURG, V28, P799, DOI 10.3109/02688697.2014.913773
   BANNA M, 1976, AM J ROENTGENOL, V127, P979, DOI 10.2214/ajr.127.6.979
   Barker RA, 2005, AZ NEUROLOGICAL PRAC
   BARTH A, 1994, EUR NEUROL, V34, P51, DOI 10.1159/000117009
   Battal B, 2011, BRIT J RADIOL, V84, P758, DOI 10.1259/bjr/66206791
   Bechter K, 2010, PSYCHIAT RES-NEUROIM, V184, P196, DOI 10.1016/j.pscychresns.2010.03.009
   Berle M, 2010, FLUIDS BARRIERS CNS, V7, DOI 10.1186/1743-8454-7-8
   BLACKSHAW S, 1987, CAN J PSYCHIAT, V32, P688, DOI 10.1177/070674378703200809
   Bodani M, 2004, NEUROPSYCHIATRY BEHA
   Bonde V, 2008, SINGAP MED J, V49, pE281
   Boomkens HR, 2010, INT PSYCHOGERIATR, V22, P832, DOI 10.1017/S1041610210000670
   Borges G, 1999, ARQ NEURO-PSIQUIAT, V57, P377, DOI 10.1590/S0004-282X1999000300006
   Boutarbouch M, 2008, CLIN NEUROL NEUROSUR, V110, P1, DOI 10.1016/j.clineuro.2007.08.009
   Buongiorno G, 2003, J LARYNGOL OTOL, V117, P728, DOI 10.1258/002221503322334602
   Buxton N, 1999, BRIT J NEUROSURG, V13, P316
   CAEMAERT J, 1992, ACTA NEUROCHIR, V119, P68, DOI 10.1007/BF01541784
   Caldarelli M., 1993, INTRACRANIAL CYST LE, P113
   Cameron A, 2002, PROGR NEUROLOGY PSYC, V6, P23
   CARTWRIGHT MJ, 1991, CLIN NEUROL NEUROSUR, V93, P69, DOI 10.1016/0303-8467(91)90013-F
   Caruso R, 2006, ACTA NEUROCHIR, V148, P801, DOI 10.1007/s00701-006-0765-x
   CARUSO R, 1994, NEUROSURG REV, V17, P195, DOI 10.1007/BF00418430
   Charalampaki P, 2005, MINIM INVAS NEUROSUR, V48, P283, DOI 10.1055/s-2005-870953
   Chernov MF, 2004, SURG NEUROL, V61, P483, DOI 10.1016/S0090-3019(03)00574-3
   CHEUNG SW, 1995, AM J OTOL, V16, P690
   Choi JU, 1999, CHILD NERV SYST, V15, P285, DOI 10.1007/s003810050396
   CHOUX M, 1978, CHILD BRAIN, V4, P15
   CILLUFFO JM, 1983, ACTA NEUROCHIR, V67, P215, DOI 10.1007/BF01401423
   Cincu R, 2007, CLIN NEUROL NEUROSUR, V109, P837, DOI 10.1016/j.clineuro.2007.07.013
   CIRICILLO SF, 1991, J NEUROSURG, V74, P230, DOI 10.3171/jns.1991.74.2.0230
   Coumou AD, 2012, MOVEMENT DISORD, V27, P964, DOI 10.1002/mds.25039
   Crimmins DW, 2006, J NEUROSURG, V105, P107, DOI 10.3171/ped.2006.105.2.107
   CULLUM CM, 1994, ARCH CLIN NEUROPSYCH, V9, P371, DOI 10.1016/0887-6177(94)90001-9
   D'Angelo V, 1999, STEREOT FUNCT NEUROS, V72, P62, DOI 10.1159/000029672
   da Silva Joaquim Alves, 2007, Ann Gen Psychiatry, V6, P16, DOI 10.1186/1744-859X-6-16
   Dagain A, 2010, SURG RADIOL ANAT, V32, P389, DOI 10.1007/s00276-009-0579-7
   Das D, 2009, ORBIT, V28, P169, DOI 10.1080/01676830902765933
   Dawkins RL, 2016, WORLD NEUROSURG, V87, DOI 10.1016/j.wneu.2015.10.077
   Decq P, 1996, J NEUROSURG, V84, P696, DOI 10.3171/jns.1996.84.4.0696
   DEIANANG K, 1989, NEUROSURG REV, V12, P59, DOI 10.1007/BF01787131
   Desseilles M, 2009, J ECT, V25, P64, DOI 10.1097/YCT.0b013e3181729268
   Di Rocco C, 2003, SURG NEUROL, V60, P211, DOI 10.1016/S0090-3019(03)00064-8
   Di Rocco C, 2010, CHILD NERV SYST, V26, P173, DOI 10.1007/s00381-009-1041-1
   Dutt SN, 2002, OTOL NEUROTOL, V23, P84, DOI 10.1097/00129492-200201000-00019
   EBEL H, 1995, MINIM INVAS NEUROSUR, V38, P41, DOI 10.1055/s-2008-1053459
   Elhammady MSA, 2007, PEDIATR NEUROSURG, V43, P209, DOI 10.1159/000098833
   Erdincler P, 1999, BRIT J NEUROSURG, V13, P10, DOI 10.1080/02688699944122
   Ersahin Y, 2008, CHILD NERV SYST, V24, P1013, DOI 10.1007/s00381-008-0615-7
   Eskandary H, 2005, SURG NEUROL, V63, P550, DOI 10.1016/j.surneu.2004.07.049
   Feletti A, 2016, ACTA NEUROCHIR, V158, P655, DOI 10.1007/s00701-016-2734-3
   Fewel ME, 1996, PEDIATR NEUROSURG, V25, P165, DOI 10.1159/000121119
   Fitzpatrick MO, 2001, BRIT J NEUROSURG, V15, P234, DOI 10.1080/02688690120057745
   Fleck SK, 2011, NEUROSURGERY, V68, pE267, DOI 10.1227/NEU.0b013e3181ff1fb7
   Galassi E, 1988, Acta Neurochir Suppl (Wien), V42, P201
   GALASSI E, 1985, J NEUROSURG, V63, P210, DOI 10.3171/jns.1985.63.2.0210
   GALASSI E, 1982, SURG NEUROL, V17, P363, DOI 10.1016/0090-3019(82)90315-9
   Galassi E, 1993, INTRACRANIAL CYST LE, P53
   Gangemi M, 2007, BRIT J NEUROSURG, V21, P276, DOI 10.1080/02688690701339197
   Gangemi M, 2005, MINIM INVAS NEUROSUR, V48, P289, DOI 10.1055/s-2005-915604
   Gangemi M, 2001, MINIM INVAS NEUROSUR, V44, P21, DOI 10.1055/s-2001-13588
   Gangemi M, 2011, J NEUROSURG-PEDIATR, V8, P158, DOI 10.3171/2011.5.PEDS1152
   Gazioglu N, 2010, TURK NEUROSURG, V20, P512, DOI 10.5137/1019-5149.JTN.2493-09.1
   GEISSINGER JD, 1978, SURG NEUROL, V10, P27
   Gelabert-Gonzalez M, 2004, REV NEUROLOGIA, V39, P1161, DOI 10.33588/rn.3912.2004400
   Godano U, 2004, CHILD NERV SYST, V20, P839, DOI 10.1007/s00381-004-0940-4
   Goel A, 2007, NEUROL INDIA, V55, P388, DOI 10.4103/0028-3886.37097
   Graillon T, 2013, NEUROCHIRURGIE, V59, P218, DOI 10.1016/j.neuchi.2013.09.001
   Grover S, 2013, J ECT, V29, pE38, DOI 10.1097/YCT.0b013e31828b3546
   Gui SB, 2011, CHILD NERV SYST, V27, P1121, DOI 10.1007/s00381-011-1399-8
   Gunduz B, 2010, NEUROL INDIA, V58, P312, DOI 10.4103/0028-3886.63795
   Guzel A, 2007, TURK NEUROSURG, V17, P138
   Halani SH, 2013, J NEUROSURG-PEDIATR, V12, P62, DOI 10.3171/2013.4.PEDS12609
   HANIEH A, 1988, CHILD NERV SYST, V4, P92
   Hanretta AT, 2007, J ECT, V23, P126, DOI 10.1097/yct.0b013e318042b642
   HARSH GR, 1986, J NEUROSURG, V64, P835, DOI 10.3171/jns.1986.64.6.0835
   HASSOUNAH MI, 1994, J NEUROSURG, V81, P126, DOI 10.3171/jns.1994.81.1.0126
   Hayashi N, 1999, J NEUROSURG, V90, P1125, DOI 10.3171/jns.1999.90.6.1125
   HAYASHI T, 1980, SURG NEUROL, V14, P267
   Helland CA, 2007, J NEUROL NEUROSUR PS, V78, P1129, DOI 10.1136/jnnp.2006.107995
   Helland CA, 2006, J NEUROSURG, V105, P385, DOI 10.3171/ped.2006.105.5.385
   Helland CA, 2006, SURG NEUROL, V66, P56, DOI 10.1016/j.surneu.2005.12.032
   Helland CA, 2010, J NEUROSURG, V113, P934, DOI 10.3171/2009.11.JNS081663
   HOFFMAN HJ, 1982, J NEUROSURG, V57, P597, DOI 10.3171/jns.1982.57.5.0597
   Holst Anders Vedel, 2012, Acta Neurochir Suppl, V114, P267, DOI 10.1007/978-3-7091-0956-4_52
   Hopf NJ, 1998, NEUROSURGERY, V43, P1330, DOI 10.1097/00006123-199812000-00037
   Hou ZG, 2010, NEUROL INDIA, V58, P493, DOI 10.4103/0028-3886.65524
   Huang QB, 2007, SURG NEUROL, V68, P149, DOI 10.1016/j.surneu.2006.10.059
   Ide C, 1997, AM J NEURORADIOL, V18, P1407
   ILDAN F, 1994, NEUROSURG REV, V17, P229, DOI 10.1007/BF00418441
   Inamasu J, 2003, ACTA NEUROL SCAND, V107, P67, DOI 10.1034/j.1600-0404.2003.02044.x
   Isaksen E, 2013, ACTA NEUROCHIR, V155, P841, DOI 10.1007/s00701-013-1641-0
   Jallo GI, 1997, NEUROSURGERY, V40, P31, DOI 10.1097/00006123-199701000-00006
   Jayarao M, 2009, J NEUROSURG-PEDIATR, V4, P121, DOI 10.3171/2009.3.PEDS08416
   Johnson RD, 2011, J CLIN NEUROSCI, V18, P607, DOI 10.1016/j.jocn.2010.10.006
   Kaliaperumal C, 2013, WORLD NEUROSURG, V80, DOI 10.1016/j.wneu.2012.11.002
   Kandenwein JA, 2004, ACTA NEUROCHIR, V146, P1317, DOI 10.1007/s00701-004-0359-4
   Kang JK, 2000, CHILD NERV SYST, V16, P111, DOI 10.1007/s003810050024
   Karabagli H, 2012, CHILD NERV SYST, V28, P445, DOI 10.1007/s00381-011-1632-5
   Karabatsou K, 2007, J NEUROSURG, V106, P455, DOI 10.3171/ped.2007.106.6.455
   Karamanakos PN, 2009, ACTA NEUROL BELG, V109, P149
   Kastenholz KJ, 2014, J ECT, V30, pE53, DOI 10.1097/YCT.0000000000000182
   Katzman GL, 1999, JAMA-J AM MED ASSOC, V282, P36, DOI 10.1001/jama.282.1.36
   Khan IS, 2013, TURK NEUROSURG, V23, P138, DOI 10.5137/1019-5149.JTN.5592-11.1
   Killer HE, 2001, AM J OPHTHALMOL, V132, P589, DOI 10.1016/S0002-9394(01)01043-1
   Kim BS, 2002, AM J NEURORADIOL, V23, P1674
   Kim MH, 1999, J KOREAN MED SCI, V14, P443, DOI 10.3346/jkms.1999.14.4.443
   Kim MK, 2013, KOREAN J RADIOL, V14, P829, DOI 10.3348/kjr.2013.14.5.829
   Kirollos RW, 2001, CHILD NERV SYST, V17, P713, DOI 10.1007/s003810100494
   Kocaeli H, 2008, ACTA NEUROCHIR, V150, P407, DOI 10.1007/s00701-008-1553-6
   KOGA H, 1995, ACTA NEUROCHIR, V137, P113, DOI 10.1007/BF02188793
   Kondziolka D, 1997, MINIM INVAS NEUROSUR, V40, P55, DOI 10.1055/s-2008-1053416
   Kotil K, 2007, TURK NEUROSURG, V17, P147
   Kouyialis AT, 2008, J CLIN NEUROSCI, V15, P1409, DOI 10.1016/j.jocn.2006.10.027
   Kurabe S, 2011, ARCH NEUROL-CHICAGO, V68, P1606, DOI 10.1001/archneurol.2011.749
   Kurihara N, 2000, NEURORADIOLOGY, V42, P634, DOI 10.1007/s002340000330
   Kushen Medina C, 2007, Neurosurg Focus, V22, pE5
   Kutlay M, 1998, NEUROSURGERY, V43, P1215, DOI 10.1097/00006123-199811000-00117
   Laitt RD, 1999, NEURORADIOLOGY, V41, P117, DOI 10.1007/s002340050715
   Levy ML, 2003, NEUROSURGERY, V53, P1138, DOI 10.1227/01.NEU.0000089060.65702.03
   Li Z, 2010, ADV THEOR APPL MECH, V3, P139
   Lindvall P, 2012, ACTA NEUROCHIR, V154, P1417, DOI 10.1007/s00701-012-1401-6
   Maher CO, 2011, J NEUROSURG-PEDIATR, V7, P64, DOI 10.3171/2010.10.PEDS10356
   Maiuri F, 1997, SURG NEUROL, V48, P401, DOI 10.1016/S0090-3019(96)00550-2
   Maiuri F, 1999, MINIM INVAS NEUROSUR, V42, P83, DOI 10.1055/s-2008-1053376
   MAIXNER VJ, 1992, CHILD NERV SYST, V8, P207, DOI 10.1007/BF00262847
   Marin SA, 2010, CAN J NEUROL SCI, V37, P273, DOI 10.1017/S0317167100010064
   Marin-Sanabria EA, 2007, CHILD NERV SYST, V23, P535, DOI 10.1007/s00381-006-0284-3
   Martinez-Lage JF, 2007, NEUROCIRUGIA, V18, P227
   Martinez-Lage JF, 2006, CHILD NERV SYST, V22, P1091, DOI 10.1007/s00381-006-0043-5
   Martinez-Lage JF, 2011, CHILD NERV SYST, V27, P1643, DOI 10.1007/s00381-011-1481-2
   Martinoni M, 2014, OPER NEUROSURG, V10, pE374, DOI 10.1227/NEU.0000000000000335
   Mastronardi L, 2009, NEUROSURGERY, V65, P1205, DOI 10.1227/01.NEU.0000360155.18123.D1
   MAYR U, 1982, NEUROCHIRURGIA, V25, P51
   McBride LA, 2003, PEDIATR NEUROSURG, V39, P323, DOI 10.1159/000075261
   McDonald PJ, 1997, PEDIATR NEUROSURG, V26, P48, DOI 10.1159/000121161
   McLaughlin N, 2012, J NEUROSURG, V116, P728, DOI 10.3171/2011.12.JNS11399
   Millichap JG, 1997, NEUROLOGY, V48, P1435, DOI 10.1212/WNL.48.5.1435
   Mitsos AP, 2006, ACTA NEUROCHIR, V148, P93, DOI 10.1007/s00701-005-0640-1
   Miyamoto T, 1999, NEUROL MED-CHIR, V39, P941, DOI 10.2176/nmc.39.941
   Mottolese C, 2010, J NEUROSURG-PEDIATR, V5, P408, DOI 10.3171/2009.11.PEDS08435
   NAIDICH TP, 1986, PAEDIATRIC NEUROSCIE, V12, P10
   NAKANO H, 1995, J NEUROL NEUROSUR PS, V58, P264, DOI 10.1136/jnnp.58.2.264
   Naraghi M, 2002, AM J RHINOL, V16, P57, DOI 10.1177/194589240201600110
   Novak Z, 2006, Bratisl Lek Listy, V107, P435
   Nowoslawska E, 2006, CHILD NERV SYST, V22, P599, DOI 10.1007/s00381-006-0068-9
   O'Reilly RC, 2003, AM J OTOLARYNG, V24, P420, DOI 10.1016/S0196-0709(03)00097-8
   OBERBAUER RW, 1992, CHILD NERV SYST, V8, P281, DOI 10.1007/BF00300797
   Oertel JMK, 2010, NEUROSURGERY, V67, P824, DOI 10.1227/01.NEU.0000377852.75544.E4
   Oertel JMK, 2009, J NEUROSURG, V110, P792, DOI 10.3171/2008.7.JNS0841
   Ottaviani F, 2002, EUR ARCH OTO-RHINO-L, V259, P306, DOI 10.1007/s00405-002-0461-2
   Oyama K, 2014, NEUROSURG REV, V37, P261, DOI 10.1007/s10143-013-0496-4
   PAGNI CA, 1990, ACTA NEUROCHIR, V105, P147, DOI 10.1007/BF01669999
   Paladino J, 1998, MINIM INVAS NEUROSUR, V41, P137, DOI 10.1055/s-2008-1052029
   Park KJ, 2011, NEUROSURGERY, V68, pE258, DOI 10.1227/NEU.0b013e3181ff355c
   Park YS, 2009, CHILD NERV SYST, V25, P1071, DOI 10.1007/s00381-009-0872-0
   Parsch CS, 1997, NEUROSURGERY, V40, P483, DOI 10.1097/00006123-199703000-00010
   Perry CL, 2007, J ECT, V23, P36, DOI 10.1097/01.yct.0000264340.27072.e3
   Pierre-Kahn A, 2002, NEUROCHIRURGIE, V48, P327
   PIERREKAHN A, 1990, J NEUROSURG, V73, P355, DOI 10.3171/jns.1990.73.3.0355
   Pradilla Gustavo, 2007, Neurosurg Focus, V22, pE7
   Prezerakos GK, 2011, IRISH J MED SCI, V180, P769, DOI 10.1007/s11845-011-0681-9
   PUNZO A, 1992, NEUROCHIRURGIA, V35, P35
   Rabiei K, 2017, J NEUROSURG, P1
   RAFFEL C, 1988, NEUROSURGERY, V23, P338, DOI 10.1227/00006123-198809000-00009
   Rampini P, 1998, PEDIATR NEUROSURG, V29, P102, DOI 10.1159/000028698
   Ramtahal J, 2006, J Neurosurg Sci, V50, P79
   Rangel-Castilla L, 2009, J NEUROSURG-PEDIATR, V3, P225, DOI 10.3171/2008.11.PEDS08106
   Rao G, 2005, J NEUROSURG, V102, P314, DOI 10.3171/ped.2005.102.3.0314
   RAPPAPORT ZH, 1993, ACTA NEUROCHIR, V122, P71, DOI 10.1007/BF01446989
   RENGACHARY SS, 1981, J NEUROPATH EXP NEUR, V40, P61
   ROBERTSON SJ, 1989, AM J NEURORADIOL, V10, P1007
   Robinson RC, 1971, PROGR NEUROLOGICAL S, V4, P133
   Russo N, 2008, BRIT J NEUROSURG, V22, P626, DOI 10.1080/02688690802295652
   Sadowski B, 2006, NEURO-OPHTHALMOLOGY, V30, P33, DOI 10.1080/01658100600721683
   Sajko T, 2011, ACTA CLIN CROAT, V50, P589
   Samii M, 1999, SURG NEUROL, V51, P376, DOI 10.1016/S0090-3019(98)00095-0
   Santamarta D, 1995, MINIM INVAS NEUROSUR, V38, P133, DOI 10.1055/s-2008-1053473
   Schmidt F. L., 2014, METHODS METAANALYSIS
   Schroeder HWS, 1997, NEUROSURGERY, V40, P198, DOI 10.1097/00006123-199701000-00045
   Schroeder HWS, 1996, J NEUROSURG, V85, P293, DOI 10.3171/jns.1996.85.2.0293
   Seizeur R, 2007, ACTA NEUROCHIR, V149, P75, DOI 10.1007/s00701-006-1073-1
   Shiba M, 2010, NEUROL MED-CHIR, V50, P509, DOI 10.2176/nmc.50.509
   Shiga T, 2012, PSYCHIAT CLIN NEUROS, V66, P536, DOI 10.1111/j.1440-1819.2012.02371.x
   Shim KW, 2013, NEUROSURGERY, V72, P520, DOI 10.1227/NEU.0b013e318282a6e3
   Shim KW, 2009, CHILD NERV SYST, V25, P1459, DOI 10.1007/s00381-009-0930-7
   Singleton WGB, 2010, ACTA NEUROCHIR, V152, P881, DOI 10.1007/s00701-009-0516-x
   Sommer IEC, 1997, CHILD NERV SYST, V13, P8, DOI 10.1007/s003810050030
   Spacca B, 2010, CHILD NERV SYST, V26, P163, DOI 10.1007/s00381-009-0952-1
   Spansdahl T, 2007, ACTA NEUROCHIR, V149, P1025, DOI 10.1007/s00701-007-1272-4
   Sprung C, 1979, Acta Neurochir Suppl (Wien), V28, P619
   Strojnik T, 2006, WIEN KLIN WOCHENSCHR, V118, P85, DOI 10.1007/s00508-006-0540-2
   Sugimoto T, 2016, WORLD NEUROSURG, V85, DOI 10.1016/j.wneu.2015.08.061
   Suzuki M, 2009, NEUROL MED-CHIR, V49, P134, DOI 10.2176/nmc.49.134
   Szucs A, 2008, IDEGGYOGY SZEMLE, V61, P54
   Tahir MZ, 2012, CNS NEUROL DISORD-DR, V11, P127
   Takano S, 1998, NEUROL MED-CHIR, V38, P100, DOI 10.2176/nmc.38.100
   Takeuchi Totaro, 1996, Neurologia Medico-Chirurgica, V36, P396, DOI 10.2176/nmc.36.396
   Talamonti G, 2011, NEUROSURGERY, V68, P803
   Talamonti G, 2011, NEUROSURGERY, V68, P788, DOI 10.1227/NEU.0b013e318207ac91
   Tamburrini G, 2007, CHILD NERV SYST, V23, P645, DOI 10.1007/s00381-007-0327-4
   Tamburrini G, 2003, CHILD NERV SYST, V19, P159, DOI 10.1007/s00381-003-0724-2
   Tamburrini G, 2008, CHILD NERV SYST, V24, P593, DOI 10.1007/s00381-008-0585-9
   Tarantino R, 2014, BRIT J NEUROSURG, V28, P528, DOI 10.3109/02688697.2013.841851
   Thinakara-Rajan T, 2006, J LARYNGOL OTOL, V120, P979, DOI 10.1017/S0022215106002337
   Thomas BP, 2009, J NEUROS-PEDIATR, V3, P70, DOI 10.3171/2008.10.PEDS0869
   Thompson TP, 2000, NEUROSURGERY, V46, P1518, DOI 10.1097/00006123-200006000-00042
   Thorat JD, 2006, BRIT J NEUROSURG, V20, P94, DOI 10.1080/02688690600682515
   Topsakal C, 2002, NEUROL MED-CHIR, V42, P44, DOI 10.2176/nmc.42.44
   Tsurushima H, 2000, NEUROL MED-CHIR, V40, P339, DOI 10.2176/nmc.40.339
   Tucker A, 2006, NEUROL MED-CHIR, V46, P361, DOI 10.2176/nmc.46.361
   Ucar T, 2000, NEUROSURGERY, V47, P966, DOI 10.1097/00006123-200010000-00034
   Vakis AF, 2006, BRIT J NEUROSURG, V20, P156, DOI 10.1080/02688690600776986
   Valenca MM, 2002, ARQ NEURO-PSIQUIAT, V60, P542, DOI 10.1590/S0004-282X2002000400005
   Van Houten EEW, 2005, IEEE T MED IMAGING, V24, P311, DOI 10.1109/TMI.2004.842451
   VANBURKEN MMG, 1992, NEUROCHIRURGIA, V35, P199
   VANDERMECHE FGA, 1983, J NEUROL NEUROSUR PS, V46, P1102, DOI 10.1136/jnnp.46.12.1102
   Verghese J, 2012, J CLIN NEUROSCI, V19, P763, DOI 10.1016/j.jocn.2011.07.039
   Verhoeven S, 2012, B-ENT, V8, P289
   Vernooij MW, 2007, NEW ENGL J MED, V357, P1821, DOI 10.1056/NEJMoa070972
   VOORMOLEN JHC, 1992, CLIN NEUROL NEUROSUR, V94, pS176
   Wang C, 2013, NEUROL INDIA, V61, P60, DOI 10.4103/0028-3886.108013
   Wang JC, 2004, J NEUROSURG, V100, P418, DOI 10.3171/ped.2004.100.5.0418
   Wang X, 2012, J NEUROL SCI, V318, P125, DOI 10.1016/j.jns.2012.03.008
   Weber F, 2006, J NEUROL SCI, V240, P81, DOI 10.1016/j.jns.2005.09.008
   WEBER R, 1991, CHILD NERV SYST, V7, P414, DOI 10.1007/BF00304210
   Weil RJ, 2001, SOUTHERN MED J, V94, P1118, DOI 10.1097/00007611-200111000-00016
   WESTER K, 1995, J NEUROL NEUROSUR PS, V59, P293, DOI 10.1136/jnnp.59.3.293
   Wester K, 1996, SURG NEUROL, V45, P15, DOI 10.1016/0090-3019(95)00383-5
   Wester K, 1999, NEUROSURGERY, V45, P775, DOI 10.1097/00006123-199910000-00008
   Wester K, 2008, J NEUROL, V255, P1113, DOI 10.1007/s00415-008-0011-y
   WHITENER EM, 1990, J APPL PSYCHOL, V75, P315, DOI 10.1037/0021-9010.75.3.315
   WONG CW, 1993, NEUROSURGERY, V32, P841, DOI 10.1227/00006123-199305000-00020
   Yadav YR, 2010, NEUROL INDIA, V58, P280, DOI 10.4103/0028-3886.63772
   Yang SH, 2008, PEDIATR NEUROSURG, V44, P465, DOI 10.1159/000172969
   Yasuda K, 2005, NEUROL MED-CHIR, V45, P164, DOI 10.2176/nmc.45.164
   Yousaf I, 2005, BRIT J NEUROSURG, V19, P191, DOI 10.1080/02688690500145894
   Zada Gabriel, 2007, Neurosurg Focus, V22, pE1
   Zeng L, 2008, J HUAZHONG U SCI-MED, V28, P431, DOI 10.1007/s11596-008-0412-2
   Zhang J, 2006, SURG NEUROL, V66, P616, DOI 10.1016/j.surneu.2006.03.031
   Zheng J, 2013, CLIN NEUROL NEUROSUR, V115, P227, DOI 10.1016/j.clineuro.2012.05.004
NR 261
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E259
EP E272
DI 10.1016/j.wneu.2018.11.149
PG 14
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400032
PM 30496927
DA 2020-05-12
ER

PT J
AU Hu, BW
   Yang, X
   Hu, YJ
   Lyu, QN
   Liu, LM
   Zhu, C
   Zhou, CG
   Song, YM
AF Hu, Bowen
   Yang, Xi
   Hu, Yujie
   Lyu, Qiunan
   Liu, Limin
   Zhu, Ce
   Zhou, Chunguang
   Song, Yueming
TI The n-HA/PA66 Cage Versus the PEEK Cage in Anterior Cervical Fusion with
   Single-Level Discectomy During 7 Years of Follow-Up
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cage; Cervical spine; Discectomy; Fusion;
   Nano-hydroxyapatite/polyamide66 cage; Polyetheretherketone cage
ID COMPOSITE SCAFFOLDS; TITANIUM-CAGES; SUBSIDENCE; ALLOGRAFT
AB OBJECTIVE: The nano-hydroxyapatite/polyamide66 (nHA/PA66) cage is a novel biomimetic nonmetal cage, whereas the polyetheretherketone (PEEK) cage has been widely used for decades with excellent clinical outcomes. However, there has been no long-term comparison of these 2 cages in anterior cervical reconstruction.
   METHODS: This retrospective study included 98 patients who underwent single-level anterior cervical decompression and fusion (ACDF) from January 2009 to June 2011 with at least 7 years of follow-up; the PEEK cage was used in 51 patients (PEEK group), whereas the n-HA/PA66 cage was used in 47 (n-HA/PA66 group). The groups were compared regarding radiographic (cage subsidence, fusion status, cervical lordosis, and segmental sagittal alignment) and clinical (10-point visual analog scale and Japanese Orthopedic Association scores) parameters preoperatively, postoperatively, and at the final follow-up.
   RESULTS: The n-HA/PA66 and PEEK cages had similar fusion rates at the final follow-up (97.9% vs. 98.0%). The respective cage subsidence rates in the PEEK and n-HA/PA66 cage groups were 9.8% and 10.6%. There were no significant differences between the 2 groups in mean cervical lordosis, mean interbody height, segmental sagittal alignment, cervical lordosis, and 10-point visual analog scale and Japanese Orthopedic Association scores at the final follow-up. The n-HA/PA66 cages resulted in high fusion and low subsidence rates during long-term follow-up.
   CONCLUSIONS: After single-level ACDF, the n-HA/PA66 cage showed similar radiographic fusion, subsidence rate, and clinical results compared with the PEEK cage during 7 years of follow-up. These results suggest that the n-HA/PA66 cage could be comparable with the PEEK cage for ACDF.
C1 [Hu, Bowen; Yang, Xi; Hu, Yujie; Lyu, Qiunan; Liu, Limin; Zhu, Ce; Zhou, Chunguang; Song, Yueming] Sichuan Univ, West China Hosp, Dept Orthoped Surg, Chengdu, Sichuan, Peoples R China.
RP Song, YM (reprint author), Sichuan Univ, West China Hosp, Dept Orthoped Surg, Chengdu, Sichuan, Peoples R China.
EM sym_cd@163.com
FU China Nature Science Foundation [81501900]; Projects of the Science &
   Technology Department of Sichuan Province [2015SZ0026]
FX We are grateful to China Nature Science Foundation: No. 81501900 and
   Projects of the Science & Technology Department of Sichuan Province: No.
   2015SZ0026.
CR BRANTIGAN JW, 1993, SPINE, V18, P2106, DOI 10.1097/00007632-199310001-00030
   Cabraja M, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471-2474-13-172
   Chen Y, 2013, EUR SPINE J, V22, P1539, DOI 10.1007/s00586-013-2772-y
   Chou YC, 2008, J CLIN NEUROSCI, V15, P1240, DOI 10.1016/j.jocn.2007.05.016
   Kersten RFMR, 2015, SPINE J, V15, P1446, DOI 10.1016/j.spinee.2013.08.030
   Kim CH, 2015, J SPINAL DISORD TECH, V28, pE17, DOI 10.1097/BSD.0000000000000137
   Le TV, 2012, SPINE, V37, P1268, DOI 10.1097/BRS.0b013e3182458b2f
   Lee YS, 2014, SPINE, V39, P1280, DOI 10.1097/BRS.0000000000000400
   Niu CC, 2010, J SPINAL DISORD TECH, V23, P310, DOI 10.1097/BSD.0b013e3181af3a84
   Noiset O, 1999, J BIOMAT SCI-POLYM E, V10, P657, DOI 10.1163/156856299X00865
   Oliveira TP, 2018, INT J FATIGUE, V108, P1, DOI 10.1016/j.ijfatigue.2017.10.016
   Pelletier M, 2012, CLIN SPINE SURG, V29, pE208
   Samartzis D, 2004, SPINE J, V4, pS72
   SMITH GW, 1958, J BONE JOINT SURG AM, V40, P607, DOI 10.2106/00004623-195840030-00009
   Stein IC, 2015, EUR SPINE J, V24, pS555, DOI 10.1007/s00586-014-3704-1
   Wang HN, 2007, BIOMATERIALS, V28, P3338, DOI 10.1016/j.biomaterials.2007.04.014
   Wang XJ, 2002, BIOMATERIALS, V23, P4787, DOI 10.1016/S0142-9612(02)00229-6
   Wei GB, 2004, BIOMATERIALS, V25, P4749, DOI 10.1016/j.biomaterials.2003.12.005
   Xu Q, 2013, J BIOMED MATER RES B, V101B, P893, DOI 10.1002/jbm.b.32894
   Yang X, 2014, INDIAN J ORTHOP, V48, P152, DOI 10.4103/0019-5413.128753
   Yang X, 2013, INT ORTHOP, V37, P2421, DOI 10.1007/s00264-013-2101-4
   Yson SC, 2017, J CLIN NEUROSCI, V38, P118, DOI 10.1016/j.jocn.2016.12.037
   Yue WM, 2005, SPINE, V30, P2138, DOI 10.1097/01.brs.0000180479.63092.17
   Zhang Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096265
   Zhao ZH, 2012, J CLIN NEUROSCI, V19, P536, DOI 10.1016/j.jocn.2011.05.043
NR 25
TC 0
Z9 0
U1 2
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E678
EP E684
DI 10.1016/j.wneu.2018.11.251
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400080
PM 30576825
DA 2020-05-12
ER

PT J
AU Huang, YF
   Liu, JJ
   Guo, L
   Meng, YB
   Hao, DJ
   Du, JP
AF Huang, Yunfei
   Liu, Jijun
   Guo, Lei
   Meng, Yibin
   Hao, Dingjun
   Du, Jinpeng
TI "Temporary" Short Segment Fixation in Treating Adolescent Lumbar
   Spondylolysis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Isthmic bone graft; Lumbar isthmic spondylolysis; Short segment
   fixation; Temporary
ID PEDICLE SCREW; REPAIR; SPONDYLOLISTHESIS
AB BACKGROUND: We have introduced a new operation for isthmic spondylolysis in adolescents and evaluated its clinical efficacy.
   METHODS: A total of 30 adolescent patients with isthmic spondylolysis and chronic low back pain underwent "temporary" short-segmental pedicle screw combined with transverse device fixation and isthmic bone graft repair treatment. Radiograph and computed tomography images were evaluated during regular follow-up examinations to confirm successful bone graft fusion, after which the fixation was removed. Lumbar magnetic resonance imaging was performed before and 1 year after fixation surgery and 1 year after fixation removal. Modic and Pfirrmann grading standards were used to observe the effect of " temporary" fixation on the corresponding vertebral endplate and intervertebral disc.
   RESULTS: All 30 patients had complete follow-up data available at 2 years postoperatively. The low back pain symptoms had disappeared completely, and radiographs and computed tomography showed that the isthmus in all patients had achieved bony fusion. With removal of the internal fixation, motion of the fixed segment recovered. "Temporary" rigid internal fixation did not increase the corresponding vertebral endplate or intervertebral disc degeneration.
   CONCLUSIONS: "Temporary" short-segmental pedicle screw combined with transverse device fixation is a simple and effective method for adolescent isthmic spondylolysis with rigid internal fixation and accelerated bone graft fusion.
C1 [Huang, Yunfei; Liu, Jijun; Guo, Lei; Meng, Yibin; Hao, Dingjun; Du, Jinpeng] Xi An Jiao Tong Univ, Hong Hui Hosp, Dept Spine Surg, Coll Med, Xian, Shaanxi, Peoples R China.
RP Huang, YF (reprint author), Xi An Jiao Tong Univ, Hong Hui Hosp, Dept Spine Surg, Coll Med, Xian, Shaanxi, Peoples R China.
EM 304921241@qq.com
OI Hao, Dingjun/0000-0002-0946-6080
CR Buck JE, 1970, BONE JOINT J, V52, P432, DOI DOI 10.1302/0301-620X.52B3.432
   Chuang WH, 2012, SPINE, V37, pE1488, DOI 10.1097/BRS.0b013e31826cdd93
   Chung CH, 2007, J SPINAL DISORD TECH, V20, P399, DOI 10.1097/01.bsd.0000211253.67576.90
   Debnath UK, 2003, J BONE JOINT SURG BR, V85B, P244, DOI 10.1302/0301-620X.85B2.13074
   KIMURA M, 1968, ORTHOP SURG, V19, P285
   Krodel A, 2008, EUR SPINE J, V17, P1481, DOI 10.1007/s00586-008-0810-y
   MODIC MT, 1988, RADIOLOGY, V166, P193, DOI 10.1148/radiology.166.1.3336678
   Moller H, 2000, SPINE, V25, P1711, DOI 10.1097/00007632-200007010-00016
   NICOL RO, 1986, SPINE, V11, P1027, DOI 10.1097/00007632-198612000-00011
   Pfirrmann CWA, 2001, SPINE, V26, P1873, DOI 10.1097/00007632-200109010-00011
   Reitman CA, 2002, SPINE, V27, pE174, DOI 10.1097/00007632-200203150-00022
   SALIB RM, 1993, SPINE, V18, P440
   Soler T, 2000, AM J SPORT MED, V28, P57, DOI 10.1177/03635465000280012101
   Xu X., 1994, CHIN ORTHOP SURG J, V1, P103
   Zhu T., 1999, ORTHOPEDIC SURG
NR 15
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E77
EP E84
DI 10.1016/j.wneu.2018.11.046
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400011
PM 30448583
DA 2020-05-12
ER

PT J
AU Hwang, K
   Kim, DG
   Paek, SH
   Kim, CY
   Yun, CH
   Oh, CW
   Juh, R
   Han, JH
AF Hwang, Kihwan
   Kim, Dong Gyu
   Paek, Sun Ha
   kim, Chae-Yong
   Yun, Chang-Ho
   Oh, Chang Wan
   Juh, Rahyeong
   Han, Jung Ho
TI Seizures After Stereotactic Radiosurgery for Benign Supratentorial
   Meningiomas: An Uncontrollable Type of Seizure?
SO WORLD NEUROSURGERY
LA English
DT Article
DE Meningioma; Peritumoral edema; Radiation toxicity; Radiosurgery; Seizure
ID GAMMA-KNIFE RADIOSURGERY; INTRACRANIAL MENINGIOMAS; PERITUMORAL EDEMA;
   COMPLICATIONS
AB OBJECTIVE: We investigated seizure outcomes of patients with supratentorial meningiomas (ST-MNGs) treated with stereotactic radiosurgery (SRS).
   METHODS: One hundred and thirty-three patients with a total of 144 ST-MNGs, who were treated with SRS between 2009 and 2016, were included in this study. The mean age was 59.0 +/- 11.9 years (range, 13-87 years). The mean follow-up duration was 49.8 +/- 24.5 months (range, 9-96 months). The median tumor volume was 2.60 cm(3) (range, 0.06-32.40 cm(3)), and the median marginal dose was 14.0 Gy (range, 11.0-20.0 Gy). Postradiosurgery peritumoral edema (PRPTE) was developed in 43 lesions (29.9%).
   RESULTS: New seizure attacks developed in 16 patients (12.0%) after SRS (first seizure attack in 14 [87.5%]; seizure aggravation in 2 [12.5%]). In 15 patients with new seizure attacks (93.8%), PRPTE was proved on magnetic resonance imaging. The mean interval between SRS and new seizure attack was 6.6 +/- 7.1 (range, 0.23-28.8) months. Simple partial seizure was the most common type of seizure (n = 9 [56.3%]). Five patients (31.3%) were seizure-free with antiepileptic drug (AED) medication (3 [18.8%] withdrew AEDs during the follow-up period); however, the remaining 11 patients (68.7%) did not achieve seizure-free outcomes even with AED medication. Moreover, seizures became intractable in 8 patients (50.0%). From multivariate analysis, the significant predictors of post-SRS seizure attack were PRPTE (odds ratio, 53.99; 95% confidence interval, 5.214-559.1; P = 0.001) and brain-tumor contact-surface index (odds ratio, 2.466; 95% confidence interval, 1.183-5.138; P = 0.016).
   CONCLUSIONS: The clinical outcomes of seizures after SRS for ST-MNGs fall short of our expectation, and seizures seem to be uncontrollable and even intractable.
C1 [Hwang, Kihwan; kim, Chae-Yong; Oh, Chang Wan; Juh, Rahyeong; Han, Jung Ho] Seoul Natl Univ, Bundang Hosp, Dept Neurosurg, Seongnam Si, South Korea.
   [Kim, Dong Gyu; Paek, Sun Ha] Seoul Natl Univ Hosp, Dept Neurosurg, Seoul, South Korea.
   [Yun, Chang-Ho] Seoul Natl Univ, Bundang Hosp, Dept Neurol, Seongnam Si, South Korea.
   [Kim, Dong Gyu; Paek, Sun Ha; kim, Chae-Yong; Oh, Chang Wan] Seoul Natl Univ, Dept Neurosurg, Coll Med, Seoul, South Korea.
RP Han, JH (reprint author), Seoul Natl Univ, Bundang Hosp, Dept Neurosurg, Seongnam Si, South Korea.
EM nstaus29@snu.ac.kr
OI KIM, CHAE-YONG/0000-0001-9773-5553
FU Seoul National University Bundang Hospital Research Fund [02-2011-006]
FX We thank all colleagues who contributed to the study. This study was
   supported by a grant (number 02-2011-006 to J.H.H.) from the Seoul
   National University Bundang Hospital Research Fund.
CR Cai RS, 2010, NEUROSURGERY, V66, P513, DOI 10.1227/01.NEU.0000365366.53337.88
   Chang JH, 2003, J NEUROL NEUROSUR PS, V74, P226, DOI 10.1136/jnnp.74.2.226
   Chung HT, 2009, INT J RADIAT ONCOL, V74, P1027, DOI 10.1016/j.ijrobp.2008.09.007
   Conti A, 2016, CUREUS, V8, DOI 10.7759/cureus.605
   DEVRIES J, 1993, ACTA NEUROCHIR, V125, P34, DOI 10.1007/BF01401825
   Ding DL, 2017, J NEUROSURG, V127, P117, DOI 10.3171/2013.6.JNS13110
   Han JH, 2008, INT J RADIAT ONCOL, V72, P1324, DOI 10.1016/j.ijrobp.2008.03.028
   Hasegawa T, 2011, J NEUROSURG, V114, P1392, DOI 10.3171/2010.11.JNS10112
   Kan P, 2007, J NEURO-ONCOL, V83, P33, DOI 10.1007/s11060-006-9294-y
   Kim JW, 2017, STEREOT FUNCT NEUROS, V95, P209, DOI 10.1159/000475763
   Kwan P, 2010, EPILEPSIA, V51, P1069, DOI 10.1111/j.1528-1167.2009.02397.x
   Marcus HJ, 2008, BRIT J NEUROSURG, V22, P520, DOI 10.1080/02688690802308687
   Novotny J, 2006, J NEUROSURG, V105, P120
   Osawa T, 2013, J NEURO-ONCOL, V111, P49, DOI 10.1007/s11060-012-0989-y
   Patibandla MR, 2017, WORLD NEUROSURG, V108, P176, DOI 10.1016/j.wneu.2017.08.166
   Patil CG, 2008, NEUROSURGERY, V63, P435, DOI 10.1227/01.NEU.0000325257.58684.92
   Pinzi V, 2017, CRIT REV ONCOL HEMAT, V113, P122, DOI 10.1016/j.critrevonc.2017.03.005
   Pollock BE, 2012, INT J RADIAT ONCOL, V83, P1414, DOI 10.1016/j.ijrobp.2011.10.033
   ROGERS L, 2007, [No title captured], V23, pE4, DOI DOI 10.3171/FOC-07/10/E4
   Sheehan JP, 2015, J NEUROSURG, V123, P1287, DOI 10.3171/2014.12.JNS142159
   SIMPSON D, 1957, J NEUROL NEUROSUR PS, V20, P22, DOI 10.1136/jnnp.20.1.22
   Takeguchi Takashi, 2003, Magn Reson Med Sci, V2, P171, DOI 10.2463/mrms.2.171
NR 22
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E549
EP E556
DI 10.1016/j.wneu.2018.11.211
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400064
PM 30528526
DA 2020-05-12
ER

PT J
AU Ishida, W
   Ramhmdani, S
   Xia, YX
   Kosztowski, TA
   Xu, RS
   Choi, J
   Ramos, RD
   Elder, BD
   Theodore, N
   Gokaslan, ZL
   Sciubba, DM
   Witham, TF
   Bydon, A
   Wolinsky, JP
   Lo, SFL
AF Ishida, Wataru
   Ramhmdani, Seba
   Xia, Yuanxuan
   Kosztowski, Thomas A.
   Xu, Risheng
   Choi, John
   Ramos, Rafael De la Garza
   Elder, Benjamin D.
   Theodore, Nicholas
   Gokaslan, Ziya L.
   Sciubba, Daniel M.
   Witham, Timothy F.
   Bydon, Ali
   Wolinsky, Jean-Paul
   Lo, Sheng-Fu L.
TI Use of Recombinant Human Bone Morphogenetic Protein-2 at the C1-C2
   Lateral Articulation without Posterior Structural Bone Graft in
   Posterior Atlantoaxial Fusion in Adult Patients
SO WORLD NEUROSURGERY
LA English
DT Article
DE Atlantoaxial fusion; C1-C2 fusion; Pseudoarthrosis; rhBMP-2
ID TRANSARTICULAR SCREW FIXATION; LUMBAR INTERBODY FUSION; NERVE ROOT
   TRANSECTION; ILIAC CREST; PEDICLE SCREWS; ROD CONSTRUCTS; SPINE SURGERY;
   RHBMP-2 USE; COMPLICATIONS; ALLOGRAFT
AB BACKGROUND: Posterior atlantoaxial fusion is an important armamentarium for neurosurgeons to treat several pathologies involving the craniovertebral junction. Although the potential advantages of recombinant human bone morphogenetic protein-2 (rhBMP-2) are well documented in the lumbar spine, its indication for C1-C2 fusion has not been well characterized. In our institution, we apply rhBMP-2 to the C1-C2 joint either alone or with hydroxyapatite, locally harvested autograft chips, and/or morselized allogenic bone graft for selected cases-without conventional posterior structural bone graft. We report the clinical outcomes of the surgical technique to elucidate its feasibility.
   METHODS: We performed a single-center, retrospective review of data from 2008 to 2016 and identified 69 patients who had undergone posterior atlantoaxial fusion with rhBMP-2. The clinical records of these patients were reviewed, and the baseline characteristics, operative data, and postoperative complications were collected and statistically analyzed.
   RESULTS: The average age of the 69 patients was 60.8 +/- 4.5 years, and 55.1% were women. With an average follow-up period of 21.1 +/- 4.2 months, the C1-C2 fusion rate was 94.3% (65 of 69), and the average time to fusion was 11.4 +/- 2.6 months (range, 5-23). The overall reoperation rate was 10.1% (7 of 69), with instrumentation failure in 7 patients (10.1%), adjacent segment disease in 2 (2.9%), and postoperative dysphagia and dyspnea in 2 patients (2.9%). No ectopic bone formation or soft tissue edema developed.
   CONCLUSIONS: Although retrospective and from a single center, our study has shown that rhBMP-2 usage at the C1-C2 joint without posterior structural bone grafting is a safe and reasonable surgical option.
C1 [Ishida, Wataru; Ramhmdani, Seba; Xia, Yuanxuan; Xu, Risheng; Choi, John; Theodore, Nicholas; Sciubba, Daniel M.; Witham, Timothy F.; Bydon, Ali; Lo, Sheng-Fu L.] Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA.
   [Kosztowski, Thomas A.; Gokaslan, Ziya L.] Brown Univ, Sch Med, Dept Neurosurg, Providence, RI 02912 USA.
   [Ramos, Rafael De la Garza] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Neurol Surg, Bronx, NY 10467 USA.
   [Elder, Benjamin D.] Mayo Clin, Dept Neurosurg, Rochester, MN USA.
   [Wolinsky, Jean-Paul] Northwestern Univ, Dept Neurol Surg, Chicago, IL 60611 USA.
RP Lo, SFL (reprint author), Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA.
EM larrylo@jhmi.edu
OI Ishida, Wataru/0000-0001-7015-3027
CR Aryan HE, 2008, J NEUROSURG-SPINE, V8, P222, DOI 10.3171/SPI/2008/8/3/222
   Baldus C, 2017, SPINE, V42, P1785, DOI 10.1097/BRS.0000000000002232
   Bannwarth M, 2016, ORTHOP TRAUMATOL-SUR, V102, P255, DOI 10.1016/j.otsr.2015.11.013
   Bess S, 2014, SPINE, V39, P233, DOI 10.1097/BRS.0000000000000104
   Cahill KS, 2015, J NEUROSURG-SPINE, V23, P86, DOI 10.3171/2014.10.SPINE14338
   Calori GM, 2014, INJURY, V45, pS116, DOI 10.1016/j.injury.2014.10.034
   Couture J, 2013, SPINE, V38, P558, DOI 10.1097/BRS.0b013e3182761109
   Dewan MC, 2014, NEUROSURGERY, V74, P475, DOI 10.1227/NEU.0000000000000306
   Dimar JR, 2009, J BONE JOINT SURG AM, V91A, P1377, DOI 10.2106/JBJS.H.00200
   Eleraky MA, 1998, J NEUROSURG, V89, P8, DOI 10.3171/jns.1998.89.1.0008
   Elias E, 2018, WORLD NEUROSURG, V111, P55, DOI 10.1016/j.wneu.2017.11.182
   Elliott RE, 2014, J SPINAL DISORD TECH, V27, P11, DOI 10.1097/BSD.0b013e318277da19
   Elliott RE, 2012, J NEUROSURG-SPINE, V17, P577, DOI 10.3171/2012.9.SPINE111021
   Elliott RE, 2012, WORLD NEUROSURG, V78, P326, DOI 10.1016/j.wneu.2011.12.083
   ElSaghir H, 2005, NEUROSURG REV, V28, P59, DOI 10.1007/s10143-004-0358-1
   Finn MA, 2010, NEUROSURGERY, V66, pA184, DOI 10.1227/01.NEU.0000365798.53288.A3
   France JC, 2015, GLOB SPINE J, V5, P195, DOI 10.1055/s-0035-1552985
   Goal A, 2002, NEUROSURGERY, V51, P1356
   Goel A, 2002, NEUROSURGERY, V51, P1351, DOI 10.1097/00006123-200212000-00004
   Hood B, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2013.01.083
   Huang DG, 2017, CLIN NEUROL NEUROSUR, V162, P95, DOI 10.1016/j.clineuro.2017.10.002
   Huang DG, 2015, SPINE J, V15, P2271, DOI 10.1016/j.spinee.2015.07.008
   Izeki M, 2014, EUR SPINE J, V23, P328, DOI 10.1007/s00586-013-2963-6
   Jakoi A M, 2015, Musculoskelet Surg, V99, P171, DOI 10.1007/s12306-015-0351-6
   Kang MM, 2012, WORLD NEUROSURG, V78, DOI 10.1016/j.wneu.2011.07.010
   Khan TR, 2018, SPINE J, V18, P439, DOI 10.1016/j.spinee.2017.08.230
   Liu JW, 2018, EUR SPINE J, V27, P1209, DOI 10.1007/s00586-017-5311-4
   Lord EL, 2017, GLOB SPINE J, V7, P603, DOI 10.1177/2192568217699207
   Lubelski D, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2013.02.077
   Malham GM, 2015, SPINE, V40, P1737, DOI 10.1097/BRS.0000000000001184
   Rajinda P, 2017, EUR SPINE J, V26, P1064, DOI 10.1007/s00586-016-4829-1
   Reintjes SL, 2016, J NEUROSURG-PEDIATR, V17, P187, DOI 10.3171/2015.6.PEDS1562
   Sayama C, 2015, J NEUROSURG-PEDIATR, V16, P14, DOI 10.3171/2015.2.PEDS14533
   Sheshadri V, 2017, J CLIN NEUROSCI, V39, P124, DOI 10.1016/j.jocn.2016.12.036
   Siemionow K, 2017, J NEUROL SURG PART A, V78, P113, DOI 10.1055/s-0036-1584905
   SIMONDS RJ, 1992, NEW ENGL J MED, V326, P726, DOI 10.1056/NEJM199203123261102
   Singh K, 2013, SPINE J, V13, P1118, DOI 10.1016/j.spinee.2013.07.028
   Sorimachi Y, 2011, EUR SPINE J, V20, P798, DOI 10.1007/s00586-010-1611-7
   Tannoury CA, 2014, SPINE J, V14, P552, DOI 10.1016/j.spinee.2013.08.060
   Tian W, 2017, CLIN SPINE SURG, V30, pE1306, DOI 10.1097/BSD.0000000000000493
   Vavken J, 2016, EUR SPINE J, V25, P3979, DOI 10.1007/s00586-015-3870-9
   Wang C, 2007, SPINE, V32, P643, DOI 10.1097/01.brs.0000257539.75693.cc
   Wang MY, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.7.FOCUS15180
   Weidner A, 2000, SPINE, V25, P2668, DOI 10.1097/00007632-200010150-00020
   Yan L, 2014, ORTHOPEDICS, V37, pE51, DOI 10.3928/01477447-20131219-17
   Yeom JS, 2013, SPINE J, V13, P786, DOI 10.1016/j.spinee.2013.04.006
   Yoshida M, 2006, SPINE, V31, pE513, DOI 10.1097/01.brs.0000224516.29747.52
   Zadegan SA, 2017, WORLD NEUROSURG, V104, P752, DOI 10.1016/j.wneu.2017.02.098
   Zhang YH, 2017, WORLD NEUROSURG, V105, P549, DOI 10.1016/j.wneu.2017.06.048
NR 49
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E69
EP E76
DI 10.1016/j.wneu.2018.11.037
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400010
PM 30448576
DA 2020-05-12
ER

PT J
AU Jiang, XC
   Wang, H
   Song, YC
   Wang, XG
   Li, FT
   Dong, Y
   Wang, JS
   Chen, HM
   Yuan, ZY
AF Jiang, Xuechao
   Wang, Hui
   Song, Yongchun
   Wang, Xiaoguang
   Li, Fengtong
   Dong, Yang
   Wang, Jingsheng
   Chen, Huaming
   Yuan, Zhiyong
TI A Second Course of Stereotactic Image-Guided Robotic Radiosurgery for
   Patients with Cerebral Metastasis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain metastases; CyberKnife; Salvage radiotherapy; Stereotactic
   radiosurgery
ID WHOLE-BRAIN RADIATION; THERAPY; IRRADIATION; JLGK0901; SURVIVAL; SRS
AB OBJECTIVES: The purpose of this research was to study the outcome of brain metastases in a cohort of patients undergoing a second course of stereotactic image-guided robotic radiosurgery and to identify predictors corelated with survival.
   METHODS: A total of 63 patients with primary malignancies underwent a second course of CyberKnife radiosurgery for intracranial progression, including recurrence and new metastases after initial stereotactic radiosurgery (SRS). Overall survival (OS) and control rate were calculated by the Kaplan-Meier method. A Cox proportional hazards model was used to analyze predictive factors for survival.
   RESULTS: With a median follow-up duration of 12 months after second SRS, the median OS of the second course of radiosurgery was 18 months. On multivariate analysis, the sum of total planned target volume (hazard ratio, 2.112; 95% confidence interval, 1.069-4.173) and minimum dose (hazard ratio, 1.990, 95% confidence interval, 1.017-3.892) were significantly associated with OS. Median intracranial progression-free survival was 23 months. The 6-month and 12-month local control rates of the targets were 97.0% and 94.4%, respectively. Univariate analysis showed that only tumor number significantly influenced intracranial progression-free survival (P = 0.012). Nine patients (14.2%) developed brain necrosis. Median time to brain necrosis in regions in which brain necrosis occurred after a single course of SRS was not reached, compared with 16 months for those treated with repeat SRS (P = 0.041).
   CONCLUSIONS: A second course of CyberKnife radiosurgery seems to be an effective salvage option for brain progression after initial SRS. The total planned target volume shows prediction for OS. Tumor volume of initial SRS may influence selection of the potential population that may benefit from salvage radiosurgery.
C1 [Jiang, Xuechao; Wang, Hui; Song, Yongchun; Wang, Xiaoguang; Li, Fengtong; Dong, Yang; Wang, Jingsheng; Chen, Huaming; Yuan, Zhiyong] Tianjin Med Univ, Canc Inst & Hosp, Dept Radiat Oncol, Tianjin, Peoples R China.
   [Jiang, Xuechao; Wang, Hui; Song, Yongchun; Wang, Xiaoguang; Li, Fengtong; Dong, Yang; Wang, Jingsheng; Chen, Huaming; Yuan, Zhiyong] Natl Clin Res Ctr Canc, Tianjin, Peoples R China.
   [Jiang, Xuechao; Wang, Hui; Song, Yongchun; Wang, Xiaoguang; Li, Fengtong; Dong, Yang; Wang, Jingsheng; Chen, Huaming; Yuan, Zhiyong] Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China.
   [Jiang, Xuechao; Wang, Hui; Song, Yongchun; Wang, Xiaoguang; Li, Fengtong; Dong, Yang; Wang, Jingsheng; Chen, Huaming; Yuan, Zhiyong] Tianjins Clin Res Ctr Canc, Tianjin, Peoples R China.
   [Jiang, Xuechao] Binzhou Ctr Hosp, Dept Radiat Oncol, Binzhou, Shandong, Peoples R China.
RP Yuan, ZY (reprint author), Tianjin Med Univ, Canc Inst & Hosp, Dept Radiat Oncol, Tianjin, Peoples R China.; Yuan, ZY (reprint author), Natl Clin Res Ctr Canc, Tianjin, Peoples R China.; Yuan, ZY (reprint author), Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China.; Yuan, ZY (reprint author), Tianjins Clin Res Ctr Canc, Tianjin, Peoples R China.
EM zyuan@tmu.edu.cn
CR Andrews DW, 2004, LANCET, V363, P1665, DOI 10.1016/S0140-6736(04)16250-8
   Aoyama H, 2006, JAMA-J AM MED ASSOC, V295, P2483, DOI 10.1001/jama.295.21.2483
   Baschnagel AM, 2013, J NEUROSURG, V119, P1139, DOI 10.3171/2013.7.JNS13431
   Bhatnagar AK, 2006, INT J RADIAT ONCOL, V64, P898, DOI 10.1016/j.ijrobp.2005.08.035
   Chang EL, 2009, LANCET ONCOL, V10, P1037, DOI 10.1016/S1470-2045(09)70263-3
   Chidel MA, 2000, INT J RADIAT ONCOL, V47, P993, DOI 10.1016/S0360-3016(00)00527-7
   Gerosa M, 2004, ANN ONCOL, V15, P113, DOI 10.1093/annonc/mdh914
   Jayachandran P, 2014, INT J RADIAT ONCOL, V90, pS320, DOI 10.1016/j.ijrobp.2014.05.1063
   Kim DH, 2013, J NEURO-ONCOL, V115, P37, DOI 10.1007/s11060-013-1191-6
   Kondziolka D, 2011, J NEUROSURG, V114, P792, DOI 10.3171/2010.8.JNS10461
   Kotecha R, 2017, NEUROSURGERY, V80, P871, DOI 10.1093/neuros/nyw147
   Kwon KY, 2007, CLIN NEUROL NEUROSUR, V109, P132, DOI 10.1016/j.clineuro.2006.06.007
   Likhacheva A, 2013, INT J RADIAT ONCOL, V85, P656, DOI 10.1016/j.ijrobp.2012.05.047
   Mckay WH, 2017, J NEUROSURG, V127, P148, DOI 10.3171/2016.5.JNS153051
   Meisner J, 2010, STRAHLENTHER ONKOL, V186, P76, DOI 10.1007/s00066-010-2036-2
   Na A, 2014, ASIA-PAC J CLIN ONCO, V10, P11, DOI 10.1111/ajco.12124
   Pontoriero A, 2016, NEUROSURG REV, V39, P495, DOI 10.1007/s10143-016-0718-7
   Romano KD, 2017, WORLD NEUROSURG, V98, P761, DOI 10.1016/j.wneu.2016.11.038
   Sahgal A, 2015, INT J RADIAT ONCOL, V91, P710, DOI 10.1016/j.ijrobp.2014.10.024
   Shaw E, 2000, INT J RADIAT ONCOL, V47, P291, DOI 10.1016/S0360-3016(99)00507-6
   Shen CJ, 2016, PRACT RADIAT ONCOL, V6, P409, DOI 10.1016/j.prro.2016.04.004
   Shin SM, 2016, J NEURO-ONCOL, V126, P483, DOI 10.1007/s11060-015-1986-8
   Shultz DB, 2015, INT J RADIAT ONCOL, V92, P993, DOI 10.1016/j.ijrobp.2015.04.036
   Shuto T, 2004, ACTA NEUROCHIR, V146, P989, DOI 10.1007/s00701-004-0306-4
   Sun A, 2011, J CLIN ONCOL, V29, P279, DOI 10.1200/JCO.2010.29.6053
   Wowra B, 2002, J NEUROSURG, V97, P785, DOI 10.3171/jns.2002.97.4.0785
   Yamamoto M, 2017, INT J RADIAT ONCOL, V99, P31, DOI 10.1016/j.ijrobp.2017.04.037
   Yamamoto M, 2014, LANCET ONCOL, V15, P387, DOI 10.1016/S1470-2045(14)70061-0
NR 28
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E621
EP E628
DI 10.1016/j.wneu.2018.11.238
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400073
PM 30553069
DA 2020-05-12
ER

PT J
AU Johnson, PB
   Monterroso, MI
   Yang, F
   Bossart, E
   Keyvanloo, A
   Mellon, EA
AF Johnson, Perry B.
   Monterroso, Maria, I
   Yang, Fei
   Bossart, Elizabeth
   Keyvanloo, Amir
   Mellon, Eric A.
TI Clinical Evaluation of Shot-Within-Shot Optimization for Gamma Knife
   Radiosurgery Planning and Delivery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Gamma Knife; Gradient index; Metastases; Optimization; Radiosurgery;
   Shot-within-shot technique
ID 3 BRAIN METASTASES; STEREOTACTIC RADIOSURGERY; RADIATION NECROSIS;
   ISODOSE; VOLUME
AB OBJECTIVE: Shot-within-shot (SWS) optimization is a new planning technique that relies on various combinations of shot weighting and prescription isodose line (IDL) to reduce beam-on time. The method differs from other planning techniques that incorporate mixed collimation, multiple stereotactic coordinates, and traditionally low prescription IDLs (<60%). In this work, we evaluate the percentage of brain metastasis for which the method can be applied, the magnitude of the resultant time savings, and the possible tradeoffs in plan quality.
   METHODS: A retrospective analysis was performed on 75 patients treated for 241 metastatic lesions in the brain. For each lesion, the original planning metrics related to target coverage, conformity, gradient, and beam-on time were recorded. A subset of lesions were selected for replanning using the SWS technique based on size, shape, and proximity to critical structures. Two replans were done, a reference plan was prescribed at the 50% IDL, and an optimized plan was prescribed at an IDL typically >50%. Planning metrics were then compared among the original plan and the 2 replans.
   RESULTS: More than a third (39%) of the brain metastases were eligible for the SWS technique. For these lesions, the differences between the original plan and reference SWS plan were as follows: Delta V-12Gy < 0.5 cc in 93% of cases, Delta V-12Gy < 0.5 cc in 100% of cases, Delta selectivity < 0.1 in 79% of cases. Negligible differences were seen between the 2 replans in terms of Delta selectivity and Delta V-12Gy; Delta GI < 5% in 99% of cases. After optimization, beam-on time was reduced by 25% -30% in approximately 40% -50% of eligible lesions when compared with the reference SWS plan (Delta T-max = 42%). In comparison with the original plan, beam-on time was reduced even further, Delta T > 50% in 20% of cases (Delta T-max = 70%).
   CONCLUSIONS: This work demonstrates clinically that optimization using the shot-within-shot technique can reduce beam-on time without degrading treatment plan quality.
C1 [Johnson, Perry B.; Bossart, Elizabeth] Univ Miami, Radiat Oncol Biomed Engn, Miami, FL 33146 USA.
   [Monterroso, Maria, I; Yang, Fei; Keyvanloo, Amir; Mellon, Eric A.] Univ Miami, Radiat Oncol, Miami, FL 33146 USA.
RP Johnson, PB (reprint author), Univ Miami, Radiat Oncol Biomed Engn, Miami, FL 33146 USA.
EM p.johnson41@med.miami.edu
CR Andrews DW, 2004, LANCET, V363, P1665, DOI 10.1016/S0140-6736(04)16250-8
   Flickinger JC, 1997, INT J RADIAT ONCOL, V38, P485, DOI 10.1016/S0360-3016(97)89481-3
   Jani A, 2015, NEUROSURGERY, V77, P119, DOI 10.1227/NEU.0000000000000750
   Johnson P. B., 2017, RADIAT ONCOL, V12, P1
   Korytko T, 2006, INT J RADIAT ONCOL, V64, P419, DOI 10.1016/j.ijrobp.2005.07.980
   Lawrence YR, 2010, INT J RADIAT ONCOL, V76, pS20, DOI 10.1016/j.ijrobp.2009.02.091
   Meeks SL, 1998, INT J RADIAT ONCOL, V41, P183, DOI 10.1016/S0360-3016(98)00044-3
   Nakamura JL, 2003, INT J RAD BIOL PHYS, V81, P115
   Romano KD, 2017, WORLD NEUROSURG, V98, P761, DOI 10.1016/j.wneu.2016.11.038
   Sharma M, 2017, CANCER MED-US, V6, P2076, DOI 10.1002/cam4.1149
   Shiue K, 2014, NEUROSURGERY, V74, P360, DOI 10.1227/NEU.0000000000000289
   Sio TT, 2014, J APPL CLIN MED PHYS, V15, P14, DOI 10.1120/jacmp.v15i1.4095
NR 12
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E218
EP E227
DI 10.1016/j.wneu.2018.11.140
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400027
PM 30481630
DA 2020-05-12
ER

PT J
AU Karhadel, AV
   Shah, AA
   Lin, KY
   Ogink, PT
   Shah, KC
   Nelson, SB
   Schwab, JH
AF Karhadel, Aditya, V
   Shah, Akash A.
   Lin, Kuan-Yu
   Ogink, Paul T.
   Shah, Kush C.
   Nelson, Sandra B.
   Schwab, Joseph H.
TI Albumin and Spinal Epidural Abscess: Derivation and Validation in Two
   Independent Data Sets
SO WORLD NEUROSURGERY
LA English
DT Article
DE Albumin; Nutritional status; Prognosis; Spinal epidural abscess
ID PROGNOSTIC-FACTORS; SERUM-ALBUMIN; MORTALITY; HYPOALBUMINEMIA; RISK;
   COMPLICATION; MANAGEMENT
AB BACKGROUND: None of the existing prognostic scoring systems for spinal epidural abscess (SEA) include albumin despite albumin's established role in inflammation, nutrition, lipid peroxidation, and regulation of apoptosis. The purpose of the present study was to determine the prognostic value of albumin in SEA.
   METHODS: We performed a retrospective, case-control study of 2 independent data sets: patients with SEA in an institutional population and patients in the National Surgical Quality Improvement Program (NSQIP). Bivariate analyses and multivariate analyses were used to determine whether albumin is an independent prognostic factor for survival in both data sets.
   RESULTS: For the 1053 patients with SEA in the institutional cohort, the 90-day postdischarge mortality was 134 (12.7%). Overall, 633 (60.1%) underwent surgery in the initial admission, with a 30-day postoperative mortality rate of 5.5% (n = 35). For the 1154 patients with SEA in the NSQIP database, the 30-day postoperative mortality rate was 3.6% (n = 42). The rate of 90-day postdischarge mortality in the institutional cohort for patients with albumin <2.3 g/dL was 25.1%. In contrast, the rate for patients with albumin >3.3 g/dL was 4.5%. On multivariate analysis of the NSQIP database, hypoalbuminemia was an independent prognostic factor for 30-day postoperative mortality. On multivariate analysis of the institutional cohort, hypoalbuminemia remained a prognostic factor for 90-day postdischarge mortality.
   CONCLUSION: Albumin was validated as an independent prognostic factor in patients with SEA. The lack of this marker in existing scoring systems underscores the need for updated models to optimize risk stratification and shared decision-making before surgery.
C1 [Karhadel, Aditya, V; Lin, Kuan-Yu; Ogink, Paul T.; Shah, Kush C.; Schwab, Joseph H.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Orthopaed Surg, Boston, MA 02115 USA.
   [Nelson, Sandra B.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Infect Dis, Boston, MA 02115 USA.
   [Shah, Akash A.] Univ Calif Los Angeles, Sch Med, Dept Orthopaed Surg, Los Angeles, CA USA.
RP Schwab, JH (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Orthopaed Surg, Boston, MA 02115 USA.
EM jhschwab@mgh.harvard.edu
OI Shah, Kush/0000-0003-0468-4684
CR Adogwa O, 2014, SPINE, V39, P1513, DOI 10.1097/BRS.0000000000000450
   Adogwa O, 2014, J NEUROSURG-SPINE, V20, P344, DOI 10.3171/2013.11.SPINE13527
   Chen HJ, 2010, SPINE, V35, pE1339, DOI [10.1155/2010/174528, 10.1097/BRS.0b013e3181e574f5]
   Collins GS, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.g7594
   Dasenbrock HH, 2017, J NEUROSURG, V126, P677, DOI 10.3171/2016.2.JNS152345
   Foley RN, 1996, J AM SOC NEPHROL, V7, P728
   Gatta A, 2012, INTERN EMERG MED, V7, pS193, DOI 10.1007/s11739-012-0802-0
   HLAVIN ML, 1990, NEUROSURGERY, V27, P177, DOI 10.1227/00006123-199008000-00001
   Hui AY, 2002, J CLIN GASTROENTEROL, V34, P569, DOI 10.1097/00004836-200205000-00018
   Karhade AV, 2018, NEUROSURGERY, V83, P333, DOI 10.1093/neuros/nyx408
   Karikari IO, 2009, NEUROSURGERY, V65, P919, DOI 10.1227/01.NEU.0000356972.97356.C5
   KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619
   Lohr M, 2005, ACTA NEUROCHIR, V147, P159, DOI 10.1007/s00701-004-0414-1
   Lopez-Raton M, 2014, J STAT SOFTW, V61, P1
   Ondeck NT, 2018, SPINE J, V18, P2009, DOI 10.1016/j.spinee.2018.04.001
   Patel AR, 2014, SPINE J, V14, P326, DOI 10.1016/j.spinee.2013.10.046
   Rady MY, 1997, JPEN-PARENTER ENTER, V21, P81, DOI 10.1177/014860719702100281
   Schoenfeld AJ, 2016, SPINE J, V16, P482, DOI 10.1016/j.spinee.2015.09.043
   Schoenfeld AJ, 2015, SPINE J, V15, P249, DOI 10.1016/j.spinee.2014.09.003
   Shah AA, 2018, J BONE JOINT SURG AM, V100, P1030, DOI 10.2106/JBJS.17.00630
   Soehle M, 2002, NEUROSURGERY, V51, P79, DOI 10.1097/00006123-200207000-00013
   Stekhoven DJ, 2012, BIOINFORMATICS, V28, P112, DOI 10.1093/bioinformatics/btr597
   Vincent JL, 2003, ANN SURG, V237, P319, DOI 10.1097/00000658-200303000-00005
   von Elm E, 2014, INT J SURG, V12, P1495, DOI 10.1016/j.ijsu.2014.07.013
NR 24
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E416
EP E426
DI 10.1016/j.wneu.2018.11.182
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400048
PM 30500590
DA 2020-05-12
ER

PT J
AU Karsy, M
   Watkins, R
   Jensen, MR
   Guan, J
   Brock, AA
   Mahan, MA
AF Karsy, Michael
   Watkins, Ryan
   Jensen, Michael R.
   Guan, Jian
   Brock, Andrea A.
   Mahan, Mark A.
TI Trends and Cost Analysis of Upper Extremity Nerve Injury Using the
   National (Nationwide) Inpatient Sample
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cost analysis; National Impatient Sample; NIS; Upper extremity injury
ID BRACHIAL-PLEXUS INJURY; ULNAR NERVES; EPIDEMIOLOGY; DISABILITY;
   PATTERNS; LIFE
AB OBJECTIVE: Epidemiology in upper extremity peripheral nerve injury (PNI) has not been comprehensively evaluated. The aim of this study was to calculate updated incidence of upper extremity PNIs in the United States and examine clinical trends and costs using a national database.
   METHODS: The National (Nationwide) Inpatient Sample was used to evaluate patients with upper extremity PNI (International Classification of Diseases, Ninth Revision, Clinical Modification 9534, 9550-9559) in 2001-2013.
   RESULTS: A weighted total of 170,579 patients experienced upper extremity PNI, representing a mean incidence of 43.8/1 million people annually. Mean (+/- SEM) age of patients was 38.1 +/- 0.05 years, 74.3% of patients were male, and 49.0% were Caucasian. PNIs occurred to the ulnar (17.8%), radial (15.1%), digital (18.0%), median (13.0%), multiple (11.5%), and other (10.1%) nerves and brachial plexus (14.5%). The number of upper extremity PNIs decreased overall. Average care charge was $ 47,004 +/- $ 185, with an average increase of $ 4623/year and compound annual growth rate of 9.59%. Although surgical nerve repair and home disposition were common with isolated PNIs, patients with brachial plexus PNIs did not have nerve surgery and were more likely to be discharged to skilled nursing facilities. Multivariate analysis showed that length of stay (beta = 0.677, P = 0.0001) and number of procedures (beta = 0.188, P = 0.0001) most affected total patient charges.
   CONCLUSIONS: These results suggest an overall decrease in number of PNIs, suggesting lower incidence or frequency of detection; however, the cost of care has increased. Despite advances in nerve repair techniques, nerve surgery rates have not increased, especially for brachial plexus injuries, which may be undertreated.
C1 [Karsy, Michael; Watkins, Ryan; Guan, Jian; Brock, Andrea A.; Mahan, Mark A.] Univ Utah, Dept Neurosurg, Clin Neurosci Ctr, Salt Lake City, UT 84112 USA.
   [Jensen, Michael R.] Stanford Neurosci Hlth Ctr, Dept Neurosurg, Palo Alto, CA USA.
RP Mahan, MA (reprint author), Univ Utah, Dept Neurosurg, Clin Neurosci Ctr, Salt Lake City, UT 84112 USA.
EM mark.mahan@hsu.utah.edu
RI Karsy, Michael/AAH-8583-2020
OI Karsy, Michael/0000-0002-0422-7937; jensen, michael/0000-0002-4517-822X;
   Guan, Jian/0000-0002-4762-7113
CR Andreisek G, 2006, RADIOGRAPHICS, V26, P1267, DOI 10.1148/rg.265055712
   Belzberg AJ, 2004, J NEUROSURG, V101, P365, DOI 10.3171/jns.2004.101.3.0365
   Castelli A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133545
   Centers for Disease Control and Prevention, 2015, C TRAUM BRAIN INJ US
   Ciaramitaro P, 2010, J PERIPHER NERV SYST, V15, P120, DOI 10.1111/j.1529-8027.2010.00260.x
   Dubuisson AS, 2002, NEUROSURGERY, V51, P673, DOI 10.1097/00006123-200209000-00011
   Eser F, 2009, NEUROL INDIA, V57, P434, DOI 10.4103/0028-3886.55614
   Guan J, 2018, NEUROSURGERY, V83, P726, DOI 10.1093/neuros/nyx471
   Haagsma JA, 2016, INJURY PREV, V22, P3, DOI 10.1136/injuryprev-2015-041616
   Houchens R., 2014, HCUP METHODS SERIES
   Karsy M, 2017, WORLD NEUROSURG, V105, P818, DOI 10.1016/j.wneu.2017.05.148
   Kestle JRW, 2015, J NEUROSURG, V122, P441, DOI 10.3171/2014.4.JNS14689
   Kouyoumdjian JA, 2006, MUSCLE NERVE, V34, P785, DOI 10.1002/mus.20624
   Krishnan AV, 2008, J PERIPHER NERV SYST, V13, P7, DOI 10.1111/j.1529-8027.2008.00155.x
   Krishnan KG, 2008, NEUROSURGERY, V62, P873, DOI 10.1227/01.neu.0000318173.28461.32
   Lad SP, 2010, NEUROSURGERY, V66, P953, DOI 10.1227/01.NEU.0000368545.83463.91
   Maniker A, 2003, J NEUROSURG, V98, P1159, DOI 10.3171/jns.2003.98.6.1159
   McAllister RMR, 1996, J HAND SURG-BRIT EUR, V21B, P4, DOI 10.1016/S0266-7681(96)80004-0
   McCutcheon BA, 2015, J NEUROSURG, V123, P406, DOI 10.3171/2015.3.JNS131356
   McLaughlin N, 2014, J NEUROSURG, V121, P700, DOI 10.3171/2014.5.JNS131996
   Midha R, 1997, NEUROSURGERY, V40, P1182, DOI 10.1097/00006123-199706000-00014
   Missios S, 2014, J NEUROSURG-PEDIATR, V14, P688, DOI 10.3171/2014.8.PEDS14112
   Murovic JA, 2009, NEUROSURGERY, V65, pA11
   National Spinal Cord Injury Statistical Center, 2016, FACTS FIG GLANC
   Noble J, 1998, J TRAUMA, V45, P116, DOI 10.1097/00005373-199807000-00025
   Novak CB, 2011, J BONE JOINT SURG AM, V93A, P929, DOI 10.2106/JBJS.J.00110
   Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22
   Saadat S, 2011, ULUS TRAVMA ACIL CER, V17, P539, DOI 10.5505/tjtes.2011.75735
   Stock Gregory N, 2011, J Health Organ Manag, V25, P142
   Szylejko A., 2015, Progress in Health Sciences, V5, P130
   Taha A, 1998, J TRAUMA, V45, P335, DOI 10.1097/00005373-199808000-00021
   Taylor CA, 2008, AM J PHYS MED REHAB, V87, P381, DOI 10.1097/PHM.0b013e31815e6370
   Thatte Mukund R, 2011, Indian J Plast Surg, V44, P380, DOI 10.4103/0970-0358.90805
   Torres Ruben Y, 2015, Bol Asoc Med P R, V107, P79
NR 34
TC 1
Z9 2
U1 1
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E488
EP E500
DI 10.1016/j.wneu.2018.11.192
PG 13
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400057
PM 30502477
DA 2020-05-12
ER

PT J
AU Kerezoudis, P
   Alvi, MA
   Spinner, RJ
   Meyer, FB
   Habermann, EB
   Bydon, M
AF Kerezoudis, Panagiotis
   Alvi, Mohammed Ali
   Spinner, Robert J.
   Meyer, Fredric B.
   Habermann, Elizabeth B.
   Bydon, Mohamad
TI Predictors of Unplanned Returns to the Operating Room within 30 Days in
   Neurosurgery: Insights from a National Surgical Registry
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cranial; National Surgical Quality Improvement Program; Peripheral
   nerve; Reoperation; Return to the operating room; Spinal; Unplanned
ID UNRUPTURED INTRACRANIAL ANEURYSM; AMERICAN-COLLEGE; QUALITY;
   REOPERATION; SURGERY; READMISSION; INDICATOR; COMPLICATIONS; MORTALITY;
   INFECTION
AB BACKGROUND: In the modern, increasingly pay-for-performance era, unplanned return to the operating room (ROR) is gaining attention as a surgical quality metric. However, large-scale data on the appropriateness and usefulness of this measure in neurosurgery are scarce.
   OBJECTIVE: To provide a comprehensive description of all RORs after neurosurgical procedures in a national surgical registry and identify factors associated with ROR.
   METHODS: We queried the American College of Surgeons National Surgical Quality Improvement Program multicenter database for patients undergoing neurosurgical procedures during 2012-2016. Multivariable logistic regression was conducted to identify factors associated with 30-day unplanned ROR after the 3 most common inpatient cranial and spinal operations: craniotomy for intra-axial neoplasm, convexity/falx meningioma, or skull base tumors; anterior cervical discectomy and fusion; and posterior lumbar decompression and posterior lumbar fusion.
   RESULTS: A total of 193,459 cases were identified, of which 7067 (3.7%) had at least 1 unplanned ROR within 30 days after the index procedure (inpatient, 4.3%; outpatient, 1.5%). Overall, the most common reasons were wound complication/surgical site infection (0.7%), hematoma evacuation (0.6%), and repeat surgery (0.5%). On multivariable analysis, the relative amount of variation in reoperation risk was found to be 1%-24% for demographics, 1% -19% for comorbidities, 1%-6% for preoperative laboratory values, and 4%-58% for operative characteristics.
   CONCLUSIONS: These findings may inform stakeholders on the optimal parameters that need to be taken into account when crafting, endorsing, and implementing quality metrics for neurosurgery that aim to assess surgical performance and reward or penalize hospitals and providers.
C1 [Kerezoudis, Panagiotis; Alvi, Mohammed Ali; Bydon, Mohamad] Mayo Clin, Neuroinformat Lab, Mayo Clin Coll Med & Sci, Rochester, MN 55905 USA.
   [Kerezoudis, Panagiotis; Alvi, Mohammed Ali; Spinner, Robert J.; Meyer, Fredric B.] Mayo Clin, Dept Neurol Surg, Rochester, MN USA.
   [Habermann, Elizabeth B.] Mayo Clin, Surg Outcomes Program, Robert D & Patricia E Kern Ctr Sci Hlth Care Deli, Rochester, MN USA.
RP Bydon, M (reprint author), Mayo Clin, Neuroinformat Lab, Mayo Clin Coll Med & Sci, Rochester, MN 55905 USA.
EM bydon.mohamad@mayo.edu
RI Alvi, Mohammed Ali/AAE-1490-2019
OI Alvi, Mohammed Ali/0000-0002-7131-079X; Habermann,
   Elizabeth/0000-0002-1140-003X
FU Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of
   Health Care Delivery; CTSA Grant from the National Center for Advancing
   Translational Sciences (NCATS), a component of the National Institutes
   of Health (NIH)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS) [UL1 TR002377]
FX This publication was made possible by funding from the Mayo Clinic
   Robert D. and Patricia E. Kern Center for the Science of Health Care
   Delivery and by CTSA Grant Number UL1 TR002377 from the National Center
   for Advancing Translational Sciences (NCATS), a component of the
   National Institutes of Health (NIH). Its contents are solely the
   responsibility of the authors and do not necessarily represent the
   official view of NIH.
CR Abraham M, 2012, CPT 2013 CURRENT PRO
   Agostini P, 2010, THORAX, V65, P815, DOI 10.1136/thx.2009.123083
   Biffl WL, 2015, PATIENT SAF SURG, V9, DOI 10.1186/s13037-014-0056-z
   Birkmeyer JD, 2001, ARCH SURG-CHICAGO, V136, P405, DOI 10.1001/archsurg.136.4.405
   Dasenbrock HH, 2018, J NEUROSURG, V128, P756, DOI 10.3171/2016.10.JNS161810
   Dasenbrock HH, 2017, NEUROSURGERY, V81, P761, DOI 10.1093/neuros/nyx089
   Etzioni DA, 2018, ANN SURG, V267, P81, DOI 10.1097/SLA.0000000000002041
   Harrell Jr FE, 2015, SPRINGER SER STAT, DOI DOI 10.1007/978-3-319-19425-7
   Hechenbleikner EM, 2013, J AM COLL SURGEONS, V216, P1150, DOI 10.1016/j.jamcollsurg.2013.01.057
   Hornor MA, 2018, ANN SURG, V267, P231, DOI 10.1097/SLA.0000000000002437
   Karkouti K, 2009, CIRCULATION, V119, P495, DOI 10.1161/CIRCULATIONAHA.108.786913
   Kerezoudis P, 2016, CLIN NEUROL NEUROSUR, V149, P75, DOI 10.1016/j.clineuro.2016.07.027
   Kirchhoff P, 2010, PATIENT SAF SURG, V4, DOI 10.1186/1754-9493-4-5
   Kizer K W, 2001, MedGenMed, V3, P10
   Kroon HM, 2007, AM J MED QUAL, V22, P198, DOI 10.1177/1062860607300652
   Lawson EH, 2012, ANN SURG, V256, P973, DOI 10.1097/SLA.0b013e31826b4c4f
   Lepanluoma M, 2015, J NEUROSURG, V123, P145, DOI 10.3171/2014.12.JNS141077
   Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006
   Livingston EH, 2006, J AM COLL SURGEONS, V203, P625, DOI 10.1016/j.jamcollsurg.2006.07.006
   McCutcheon BA, 2016, WORLD NEUROSURG, V91, P272, DOI [10.1016/j.wneu.2016.04.039, 10.1016/J.WNEU.2016.04.039]
   McGirt MJ, 2013, NEUROSURG FOCUS, V34, DOI 10.3171/2012.10.FOCUS12297
   McLaughlin N, 2015, J NEUROSURG, V123, P198, DOI 10.3171/2014.9.JNS14666
   Merkow RP, 2013, ANN SURG, V257, P483, DOI 10.1097/SLA.0b013e318273bf17
   Merkow RP, 2009, J AM COLL SURGEONS, V209, P557, DOI 10.1016/j.jamcollsurg.2009.07.003
   Moucha Calin S, 2011, Instr Course Lect, V60, P557
   Mukerji N, 2012, J NEUROSURG-PEDIATR, V9, P665, DOI 10.3171/2012.2.PEDS11305
   Murphy ME, 2017, NEUROSURGERY, V81, P638, DOI 10.1093/neuros/nyx057
   Pitt HA, 2009, HPB, V11, P405, DOI 10.1111/j.1477-2574.2009.00074.x
   Ploeg AJ, 2008, VASC ENDOVASC SURG, V42, P19, DOI 10.1177/1538574407306793
   Scoggins JF, 2010, J NATL CANCER I, V102, P1371, DOI 10.1093/jnci/djq291
   Sellers MM, 2013, J AM COLL SURGEONS, V216, P420, DOI 10.1016/j.jamcollsurg.2012.11.013
   Shiloach M, 2010, J AM COLL SURGEONS, V210, P6, DOI 10.1016/j.jamcollsurg.2009.09.031
   Theodosopoulos PV, 2012, J NEUROSURG, V117, P947, DOI 10.3171/2012.7.JNS111622
   Trick WE, 2000, J THORAC CARDIOV SUR, V119, P108, DOI 10.1016/S0022-5223(00)70224-8
   van Westreenen HL, 2011, DIS COLON RECTUM, V54, P1438, DOI 10.1097/DCR.0b013e31822c64f1
NR 35
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E348
EP E370
DI 10.1016/j.wneu.2018.11.171
PG 23
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400042
PM 30500576
DA 2020-05-12
ER

PT J
AU Khan, A
   Meyers, JE
   Yavorek, S
   Oconnor, TE
   Siasios, I
   Mullin, JP
   Pollina, J
AF Khan, Asham
   Meyers, Joshua E.
   Yavorek, Samantha
   Oconnor, Timothy E.
   Siasios, Ioannis
   Mullin, Jeffrey P.
   Pollina, John
TI Comparing Next-Generation Robotic Technology with 3-Dimensional Computed
   Tomography Navigation Technology for the Insertion of Posterior Pedicle
   Screws
SO WORLD NEUROSURGERY
LA English
DT Article
DE 3D-CT navigation; Mazor X; O-arm; Pedicle screws; Robotic guidance;
   Spinal stabilization
ID SPINE SURGERY; PERCUTANEOUS PLACEMENT; CLINICAL ACCURACY; FREE-HAND;
   LUMBAR; FLUOROSCOPY; GUIDANCE
AB OBJECTIVE: To study the differences between robot-guided (Mazor X, Mazor Robotics Ltd., Caesarea, Israel) and 3-dimensional (3D) computed tomography (CT) navigation (O-arm Surgical Imaging System, Medtronic, Minneapolis, Minnesota, USA) for the insertion of pedicle screws.
   METHODS: We reviewed the charts of 50 patients who underwent robot-guided pedicle screw insertion (between May 2017-October 2017), and 49 patients who underwent 3D-CT navigation pedicle screw insertion (between September 2015-August 2016). Variables included were age, sex, body mass index, blood loss, length of stay, lumbar level(s), operation time, fluoroscopy time, radiation dose, accuracy, and time-per-screw placement.
   RESULTS: Mean ages were 59.3 years in the robotic group and 58.2 years in the 3D-CT navigation group. Mean was 30.7 kg/m(2) in the robotic group and 32.1 kg/m(2) in the 3D-CT navigation group. Mean time-per-screw placement was 3.7 minutes for the robotic group and 6.8 minutes for the 3D-CT navigation group, P < 0.001. In the robotic group, 189 of 190 screws were placed with Ravi grade I accuracy, and 1 was grade II. In the 3D-CT navigation group, 157 of 165 screws were Ravi grade I, and 8 were grade II (P = 0.11). Fluoroscopy time (P < 0.001), time-per-screw placement (P < 0.001), and length of stay (P < 0.001) were significantly lower in the robotic group.
   CONCLUSIONS: Both technologies are safe and accurate. Robotic technology exposed patients to less fluoroscopy time, decreased time-per-screw placement and shorter hospital stay than 3D-CT navigation. Further studies are warranted to verify our results.
C1 [Khan, Asham; Meyers, Joshua E.; Oconnor, Timothy E.; Mullin, Jeffrey P.; Pollina, John] Univ Buffalo, Dept Neurosurg, Buffalo, NY 14260 USA.
   [Yavorek, Samantha] Univ Buffalo, Jacobs Sch Med & Biomed Sci, Buffalo, NY USA.
   [Khan, Asham; Meyers, Joshua E.; Oconnor, Timothy E.; Mullin, Jeffrey P.; Pollina, John] Kaleida Hlth, Dept Neurosurg, Buffalo Gen Med Ctr, New York, NY 14210 USA.
   [Siasios, Ioannis] Papageorgiou Gen Hosp, Dept Neurosurg, Thessaloniki, Greece.
RP Pollina, J (reprint author), Univ Buffalo, Dept Neurosurg, Buffalo, NY 14260 USA.; Pollina, J (reprint author), Kaleida Hlth, Dept Neurosurg, Buffalo Gen Med Ctr, New York, NY 14210 USA.
EM jpollina@ubns.com
RI Siasios, Ioannis/A-2224-2017
OI Siasios, Ioannis/0000-0001-7945-9604
CR Aoude AA, 2015, EUR SPINE J, V24, P990, DOI 10.1007/s00586-015-3853-x
   Best Natalie M, 2009, Am J Orthop (Belle Mead NJ), V38, P387
   Castro WHM, 1996, SPINE, V21, P1320, DOI 10.1097/00007632-199606010-00008
   Devito DP, 2010, SPINE, V35, P2109, DOI 10.1097/BRS.0b013e3181d323ab
   Faraj A A, 1997, Eur Spine J, V6, P324, DOI 10.1007/BF01142678
   Gelalis ID, 2012, EUR SPINE J, V21, P247, DOI 10.1007/s00586-011-2011-3
   GERTZBEIN SD, 1990, SPINE, V15, P11, DOI 10.1097/00007632-199001000-00004
   Hu XB, 2013, EUR SPINE J, V22, P661, DOI 10.1007/s00586-012-2499-1
   Hyun SJ, 2017, SPINE, V42, P353, DOI 10.1097/BRS.0000000000001778
   Kantelhardt S, 2011, EUR SPINE J, V20, P860, DOI 10.1007/s00586-011-1729-2
   Keric N, 2017, NEUROSURG FOCUS, V42, DOI 10.3171/2017.2.FOCUS16552
   Khan A, 2019, OPER NEUROSURG, V17, P61, DOI 10.1093/ons/opy280
   Khanna AR, 2016, J CLIN NEUROSCI, V32, P72, DOI 10.1016/j.jocn.2016.02.033
   Kim HJ, 2017, INT J MED ROBOT COMP, V13, DOI 10.1002/rcs.1779
   Kosmopoulos V, 2007, SPINE, V32, pE111, DOI 10.1097/01.brs.0000254048.79024.8b
   Laudato PA, 2018, SPINE, V43, pE373, DOI 10.1097/BRS.0000000000002449
   Lieberman IH, 2006, NEUROSURGERY, V59, P641, DOI 10.1227/01.NEU.0000229055.00829.5B
   Lonjon N, 2016, EUR SPINE J, V25, P947, DOI 10.1007/s00586-015-3758-8
   Miekisiak G, 2015, J SPINAL DISORD TECH, V28, pE194, DOI 10.1097/BSD.0000000000000243
   Mirza SK, 2003, SPINE, V28, P402, DOI 10.1097/00007632-200302150-00018
   Nasser R, 2010, J NEUROSURG-SPINE, V13, P144, DOI 10.3171/2010.3.SPINE09369
   Onen MR, 2014, TURK NEUROSURG, V24, P512, DOI 10.5137/1019-5149.JTN.8951-13.1
   Pechlivanis I, 2009, SPINE, V34, P392, DOI 10.1097/BRS.0b013e318191ed32
   Rampersaud YR, 2005, SPINE, V30, pE183, DOI 10.1097/01.brs.0000157490.65706.38
   Ravi B, 2011, SPINE, V36, P84, DOI 10.1097/BRS.0b013e3181cbfd09
   Ringel F, 2012, SPINE, V37, pE496, DOI 10.1097/BRS.0b013e31824b7767
   Rivkin MA, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2014.1.FOCUS13499
   Roser F, 2013, NEUROSURGERY, V72, pA12, DOI 10.1227/NEU.0b013e318270d02c
   Saklad M., GRADING PATIENTS SUR
   Schroder ML, 2017, NEUROSURG FOCUS, V42, DOI 10.3171/2017.3.FOCUS16534
   Schulze CJ, 1998, SPINE, V23, P2215, DOI 10.1097/00007632-199810150-00014
   Shin MH, 2012, J KOREAN NEUROSURG S, V52, P204, DOI 10.3340/jkns.2012.52.3.204
   Siasios Ioannis D, 2017, J Spine Surg, V3, P657, DOI 10.21037/jss.2017.12.05
   Silbermann J, 2011, EUR SPINE J, V20, P875, DOI 10.1007/s00586-010-1683-4
   Solomiichuk V, 2017, NEUROSURG FOCUS, V42, DOI 10.3171/2017.3.FOCUS1710
   Staartjes VE, 2018, WORLD NEUROSURG, V116, P433, DOI 10.1016/j.wneu.2018.05.159
   Urakov TM, 2017, NEUROSURG FOCUS, V42, DOI 10.3171/2017.2.FOCUS175
   Verma R, 2010, EUR SPINE J, V19, P370, DOI 10.1007/s00586-009-1258-4
   Xiao R, 2017, J NEUROSURG-SPINE, V26, P628, DOI 10.3171/2016.10.SPINE16373
NR 39
TC 5
Z9 5
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E474
EP E481
DI 10.1016/j.wneu.2018.11.190
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400055
PM 30500593
DA 2020-05-12
ER

PT J
AU Kogias, E
   Schmeiser, B
   Doostkam, S
   Brande, A
   Hammen, T
   Zentner, J
   Ramantani, G
AF Kogias, Evangelos
   Schmeiser, Barbara
   Doostkam, Soroush
   Brande, Armin
   Hammen, Thilo
   Zentner, Josef
   Ramantani, Georgia
TI Multilobar Resections for 3T MRI-Negative Epilepsy: Worth the Trouble?
SO WORLD NEUROSURGERY
LA English
DT Article
DE 3T MRI-negative; Cortical dysplasia; Epilepsy surgery; Malformation of
   cortical development; Multilobar; Seizure freedom
ID FOCAL CORTICAL DYSPLASIA; PRESURGICAL EVALUATION; EXTRATEMPORAL
   EPILEPSY; SURGICAL OUTCOMES; CONSENSUS CLASSIFICATION; REFRACTORY
   EPILEPSY; DIAGNOSTIC METHODS; POSTERIOR CORTEX; TASK-FORCE; FDG-PET
AB OBJECTIVE: Multilobar resection in magnetic resonance imaging (MRI)-negative drug-resistant epilepsy warrants attention because they account for up to one third of MRI-negative epilepsy surgery. Despite their high prevalence, data are sparse, and the risk/benefit ratio continues to be debated. The present study investigated the postoperative seizure outcomes in this especially challenging subgroup.
   METHODS: We retrospectively analyzed the data of 4 consecutive patients with 3T MRI-negative findings and drug-resistant focal epilepsy who had undergone multi-lobar epilepsy surgery at our institution.
   RESULTS: The mean age at first surgery was 28.5 years (range, 14-48); 1 patient required 2 consecutive reoperations. The final resection was in the frontotemporal and temporo-parieto-occipital regions in 2 patients each. Histopathological examination revealed mild malformations of cortical development in 2 patients and focal cortical dysplasia type Ia and type IIa in 1 patient each. At the last follow-up examination (median, 3.3 years; range, 1-11), 2 patients were completely seizure free (Engel class Ia), 1 patient had experienced some disabling seizures after surgery but had been free of disabling seizures for 2 years at the last follow-up examination (Engel class Ic), and 1 patient had experienced worthwhile improvement (Engel class IIb) and had been seizure free for 1 year at the last follow-up examination. No surgical complications developed.
   CONCLUSIONS: Our results have demonstrated that multilobar epilepsy surgery is effective for lasting seizure control for selected 3T MRI-negative candidates, leading to favorable outcomes for all 4 of our patients. Comprehensive multimodal preoperative evaluation is a prerequisite for postoperative success. Reevaluation should be considered for patients with seizure recurrence, because reoperation could be especially beneficial for selected patients who have not responded to an initially limited resection.
C1 [Kogias, Evangelos; Schmeiser, Barbara; Zentner, Josef] Univ Freiburg, Med Ctr, Dept Neurosurg, Freiburg, Germany.
   [Doostkam, Soroush] Univ Freiburg, Inst Neuropathol, Freiburg, Germany.
   [Brande, Armin; Hammen, Thilo; Ramantani, Georgia] Univ Freiburg, Epilepsy Ctr, Dept Neurosurg, Freiburg, Germany.
   [Ramantani, Georgia] Univ Childrens Hosp Zurich, Dept Neuropediat, Zurich, Switzerland.
RP Ramantani, G (reprint author), Univ Freiburg, Epilepsy Ctr, Dept Neurosurg, Freiburg, Germany.; Ramantani, G (reprint author), Univ Childrens Hosp Zurich, Dept Neuropediat, Zurich, Switzerland.
EM georgia.ramantani@kispi.uzh.ch
OI Ramantani, Georgia/0000-0002-7931-2327
CR Alarcon G, 2006, J NEUROL NEUROSUR PS, V77, P474, DOI 10.1136/jnnp.2005.077289
   Arya R, 2016, SEIZURE-EUR J EPILEP, V41, P56, DOI 10.1016/j.seizure.2016.07.004
   Bast T, 2005, NEUROIMAGE, V25, P1232, DOI 10.1016/j.neuroimage.2004.12.059
   Bien CG, 2013, J NEUROL NEUROSUR PS, V84, P54, DOI 10.1136/jnnp-2011-301763
   Bien CG, 2009, ARCH NEUROL-CHICAGO, V66, P1491, DOI 10.1001/archneurol.2009.283
   Blumcke I, 2013, EPILEPSIA, V54, P1315, DOI 10.1111/epi.12220
   Blumcke I, 2011, EPILEPSIA, V52, P158, DOI 10.1111/j.1528-1167.2010.02777.x
   Chapman K, 2005, J NEUROL NEUROSUR PS, V76, P710, DOI 10.1136/jnnp.2003.026757
   Chassoux F, 2010, NEUROLOGY, V75, P2168, DOI 10.1212/WNL.0b013e31820203a9
   Cho EB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136565
   Cukiert A, 2001, EPILEPSIA, V42, P889, DOI 10.1046/j.1528-1157.2001.00201.x
   Elsharkawy AE, 2009, J NEUROL NEUROSUR PS, V80, P773, DOI 10.1136/jnnp.2008.164145
   Engel Jr J., 1993, SURG TREATMENT EPILE, P609
   Englot DJ, 2012, NEUROLOGY, V78, P1200, DOI 10.1212/WNL.0b013e318250d7ea
   Fedele T, 2017, CLIN NEUROPHYSIOL, V128, P1220, DOI 10.1016/j.clinph.2017.03.038
   Guerrini R, 2015, EPILEPSIA, V56, P1669, DOI 10.1111/epi.13200
   Harvey S, 2008, EPILEPSIA, V49, P146, DOI 10.1111/j.1528-1167.2007.01421.x
   Hemb M, 2010, NEUROLOGY, V74, P1768, DOI 10.1212/WNL.0b013e3181e0f17a
   Hong KS, 2002, SEIZURE-EUR J EPILEP, V11, P184, DOI 10.1053/seiz.2001.0616
   Iimura Y, 2017, CLIN NEUROPHYSIOL, V128, P1197, DOI 10.1016/j.clinph.2017.03.031
   Isler C, 2017, WORLD NEUROSURG, V106, P638, DOI 10.1016/j.wneu.2017.07.046
   Jacobs J, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00335
   Jacobs J, 2014, NEUROIMAGE, V88, P282, DOI 10.1016/j.neuroimage.2013.10.018
   Jager V, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140537
   Jayakar P, 2008, EPILEPSIA, V49, P758, DOI 10.1111/j.1528-1167.2007.01428.x
   Jobst BC, 2017, EPILEPSIA, V58, P1005, DOI 10.1111/epi.13739
   Jung J, 2013, BRAIN, V136, P3176, DOI 10.1093/brain/awt213
   Kadish NE, 2019, NEUROSURGERY, V84, pE368, DOI 10.1093/neuros/nyy376
   Kim YH, 2011, ACTA NEUROCHIR, V153, P1739, DOI 10.1007/s00701-011-1074-6
   Kogias E, 2018, J CLIN NEUROSCI, V47, P273, DOI 10.1016/j.jocn.2017.10.012
   Kogias E, 2017, CLIN NEUROL NEUROSUR, V163, P116, DOI 10.1016/j.clineuro.2017.10.038
   Krsek P, 2009, NEUROLOGY, V72, P217, DOI 10.1212/01.wnl.0000334365.22854.d3
   Krsek P, 2008, ANN NEUROL, V63, P758, DOI 10.1002/ana.21398
   Krsek P, 2013, EPILEPSIA, V54, P351, DOI 10.1111/epi.12059
   Kudr M, 2013, EPILEPTIC DISORD, V15, P3, DOI 10.1684/epd.2013.0560
   Kwon HE, 2016, NEUROLOGY, V87, P945, DOI 10.1212/WNL.0000000000003042
   Lee SK, 2005, ANN NEUROL, V58, P525, DOI 10.1002/ana.20569
   Liava A, 2014, EPILEPTIC DISORD, V16, P141, DOI 10.1684/epd.2014.0648
   Liava A, 2012, EPILEPSY BEHAV, V25, P68, DOI 10.1016/j.yebeh.2012.05.008
   Mani J, 2006, NEUROLOGY, V66, P1038, DOI 10.1212/01.wnl.0000204236.96232.1c
   Nilsson DT, 2016, ACTA NEUROCHIR, V158, P1151, DOI 10.1007/s00701-016-2807-3
   O'Brien TJ, 2004, EPILEPSIA, V45, P367, DOI 10.1111/j.0013-9580.2004.54703.x
   Park SA, 2002, EPILEPSY RES, V48, P199, DOI 10.1016/S0920-1211(02)00006-2
   Ramantani G, 2006, J CLIN NEUROPHYSIOL, V23, P498, DOI 10.1097/01.wnp.0000240873.69759.cc
   Ramantani G, 2018, NEUROSURGERY, V83, P93, DOI 10.1093/neuros/nyx340
   Ramantani G, 2017, EPILEPSIA, V58, P412, DOI 10.1111/epi.13654
   Ramantani G, 2014, NEUROSURGERY, V74, P648, DOI 10.1227/NEU.0000000000000327
   Ramantani G, 2014, EPILEPSIA, V55, P278, DOI 10.1111/epi.12512
   Ramantani G, 2013, NEUROSURGERY, V73, P695, DOI 10.1227/NEU.0000000000000081
   Ramantani G, 2013, EUR J PAEDIATR NEURO, V17, P498, DOI 10.1016/j.ejpn.2013.03.009
   Ramantani G, 2013, EPILEPSIA, V54, P1046, DOI 10.1111/epi.12140
   Ramantani G, 2013, CLIN NEUROPHYSIOL, V124, P481, DOI 10.1016/j.clinph.2012.09.001
   Rikir E, 2014, EPILEPSIA, V55, P918, DOI 10.1111/epi.12591
   Rolston JD, 2018, NEUROSURGERY, V82, P613, DOI 10.1093/neuros/nyx311
   Ryvlin P, 2014, LANCET NEUROL, V13, P1114, DOI 10.1016/S1474-4422(14)70156-5
   Sarkis RA, 2012, EPILEPSIA, V53, P44, DOI 10.1111/j.1528-1167.2011.03274.x
   Shi JG, 2017, EPILEPSY RES, V133, P103, DOI 10.1016/j.eplepsyres.2017.04.010
   Siegel AM, 2001, EPILEPSIA, V42, P883, DOI 10.1046/j.1528-1157.2001.042007883.x
   Tellez-Zenteno JF, 2010, EPILEPSY RES, V89, P310, DOI 10.1016/j.eplepsyres.2010.02.007
   Urbach H, 2015, CLIN NEURORADIOL, V25, P151, DOI 10.1007/s00062-015-0387-x
NR 60
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E338
EP E347
DI 10.1016/j.wneu.2018.11.170
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400041
PM 30502474
DA 2020-05-12
ER

PT J
AU Lang, CD
   Huang, ZF
   Sui, WY
   Di, MP
   He, SF
   Fan, HW
   Deng, YL
   Yang, JL
AF Lang, Chuandong
   Huang, Zifang
   Sui, Wenyuan
   Di, Muping
   He, Shaofu
   Fan, Hengwei
   Deng, Yaolong
   Yang, Junlin
TI Factors That Influence In-Brace Correction in Patients with Adolescent
   Idiopathic Scoliosis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adolescent idiopathic scoliosis; Coronal balance; In-brace correction;
   Lumbar pelvic relationship; Major curve Cobb angle; Sagittal balance
ID SUCCESS; PROGRESSION; CAD/CAM
AB OBJECTIVE: To identify the factors affecting in-brace correction in patients with adolescent idiopathic scoliosis (AIS).
   METHODS: We performed a retrospective analysis of patients with AIS receiving Gensingen brace treatment in our scoliosis center from July 2015 to October 2017 was performed. The selection of patients was in accordance with the Scoliosis Research Society inclusion criteria for a bracing study. Some radiographic and clinical parameters, including the Cobb angle, rib-vertebra angle difference, coronal and sagittal balance, lumbar-pelvic relationship (LPR), Risser sign, curve type, age, gender, height, weight, body mass index, and menstrual status were collected. The correlation and difference analyses were performed to identify the factors influencing in-brace correction.
   RESULTS: A cohort of 112 patients with AIS (94 girls and 18 boys) were included in the present study. The mean in-brace correction was 59.29% +/- 22.33% (range, 16.22%-100.00%). In-brace correction showed a significantly negative correlation with the major curve Cobb angle, minor curve Cobb angle, total curve Cobb angle, and LPR (P < 0.05 for all). Sagittal and coronal imbalance could reduce the curve correction (P < 0.001 and P = 0.008, respectively). The remaining parameters were not related to in-brace correction.
   CONCLUSIONS: In-brace correction in the present study was 59.29% +/- 22.33% (range, 16.22%-100.00%). Some factors, including the Cobb angle, sagittal and coronal balance, and LPR, have an effect on in-brace correction. The results from the present study can provide some useful information for brace design and fabrication.
C1 [Lang, Chuandong; Huang, Zifang] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Spine Surg, Guangzhou, Guangdong, Peoples R China.
   [He, Shaofu] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Radiol, Guangzhou, Guangdong, Peoples R China.
   [Sui, Wenyuan] Sun Yat Sen Univ, Dept Spine Surg, Affiliated Hosp 7, Shenzhen, Guangdong, Peoples R China.
   [Di, Muping] Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Canc Ctr, Guangzhou, Guangdong, Peoples R China.
   [Fan, Hengwei; Deng, Yaolong; Yang, Junlin] Shanghai Jiao Tong Univ, Spine Ctr, Sch Med, Xinhua Hosp, Shanghai, Peoples R China.
RP Yang, JL (reprint author), Shanghai Jiao Tong Univ, Spine Ctr, Sch Med, Xinhua Hosp, Shanghai, Peoples R China.
EM yjunlin@126.com
FU National Key Research and Development Program [2018YFC0116500];
   Guangdong Science and Technology Planning Project [2014B02021202];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [31771330]
FX The publication of this article was supported by funding from
   2018YFC0116500, National Key Research and Development Program,
   2014B02021202, Guangdong Science and Technology Planning Project, and
   31771330, National Natural Science Foundation of China.
CR Adobor RD, 2011, SCOLIOSIS SPINAL DIS, V6, DOI 10.1186/1748-7161-6-23
   Bullmann V, 2004, Z ORTHOP GRENZGEB, V142, P403, DOI 10.1055/s-2004-822843
   CARR WA, 1980, J BONE JOINT SURG AM, V62, P599, DOI 10.2106/00004623-198062040-00015
   Castro Frank P Jr, 2003, Spine J, V3, P180, DOI 10.1016/S1529-9430(02)00557-0
   Cheung JPY, 2018, SPINE, V43, P971, DOI 10.1097/BRS.0000000000002503
   Cheung KMC, 2007, INT ORTHOP, V31, P507, DOI 10.1007/s00264-006-0209-5
   Clin J, 2010, SPINE, V35, P1706, DOI 10.1097/BRS.0b013e3181cb46f6
   EMANS JB, 1986, SPINE, V11, P792, DOI 10.1097/00007632-198610000-00009
   Gepstein R, 2002, J PEDIATR ORTHOPED, V22, P84, DOI 10.1097/00004694-200201000-00018
   Goodbody CM, 2016, J CHILD ORTHOP, V10, P395, DOI 10.1007/s11832-016-0763-3
   Karol LA, 2016, J BONE JOINT SURG AM, V98, P1253, DOI 10.2106/JBJS.15.01313
   Karol LA, 2016, J BONE JOINT SURG AM, V98, P9, DOI 10.2106/JBJS.O.00359
   Katz DE, 2001, SPINE, V26, P2354, DOI 10.1097/00007632-200111010-00012
   Kuroki H, 2015, SCOLIOSIS SPINAL DIS, V10, DOI 10.1186/s13013-015-0038-7
   Landauer Franz, 2003, Pediatr Rehabil, V6, P201
   Lateur G, 2017, ORTHOP TRAUMATOL-SUR, V103, P275, DOI 10.1016/j.otsr.2016.10.022
   Negrini S, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006850.pub3
   Ohrt-Nissen S, 2016, SPINE, V41, P1724, DOI 10.1097/BRS.0000000000001634
   Ohrt-Nissen S, 2016, SPINE, V41, P798, DOI 10.1097/BRS.0000000000001519
   OLAFSSON Y, 1995, J PEDIATR ORTHOPED, V15, P524, DOI 10.1097/01241398-199507000-00023
   Richards BS, 2005, SPINE, V30, P2068, DOI 10.1097/01.brs.0000178819.90239.d0
   Richards BS, 2005, SPINE, V30, P76
   Sankar WN, 2007, J CHILD ORTHOP, V1, P345, DOI 10.1007/s11832-007-0066-9
   Sun WX, 2017, EUR SPINE J, V26, P1665, DOI 10.1007/s00586-016-4839-z
   Thompson RM, 2017, J BONE JOINT SURG AM, V99, P923, DOI 10.2106/JBJS.16.01050
   Weinstein SL, 2013, NEW ENGL J MED, V369, P1512, DOI 10.1056/NEJMoa1307337
   Weiss HR, 2007, SCOLIOSIS SPINAL DIS, V2, DOI 10.1186/1748-7161-2-2
   Weiss Hans-Rudolf, 2005, Pediatr Rehabil, V8, P199
   Weiss Hans-Rudolf, 2017, Open Orthop J, V11, P1558, DOI 10.2174/1874325001711011558
   Weiss HR, 2010, SCOLIOSIS SPINAL DIS, V5, DOI 10.1186/1748-7161-5-22
   Weiss HR, 2010, SCOLIOSIS SPINAL DIS, V5, DOI 10.1186/1748-7161-5-19
   Wong MS, 2005, PROSTHET ORTHOT INT, V29, P105, DOI 10.1080/17461550500069547
   Xu LL, 2017, CLIN SPINE SURG, V30, pE475, DOI 10.1097/BSD.0000000000000343
NR 33
TC 4
Z9 4
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E597
EP E603
DI 10.1016/j.wneu.2018.11.228
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400070
PM 30529518
DA 2020-05-12
ER

PT J
AU Le Blanc, M
   Maus, V
   Kabbasch, C
   Dorn, F
   Chang, DH
   Liebig, T
   Mpotsaris, A
   Borggrefe, J
AF Le Blanc, Markus
   Maus, Volker
   Kabbasch, Christoph
   Dorn, Franziska
   Chang, De-Hua
   Liebig, Thomas
   Mpotsaris, Anastasios
   Borggrefe, Jan
TI Effects of Intermediate Catheter Evolution on Technical Outcome of
   Mechanical Thrombectomy-A Comparison of the Performance of Two Distal
   Access Catheters in Mechanical Thrombectomy of Acute Ischemic Stroke
SO WORLD NEUROSURGERY
LA English
DT Article
DE Acute ischemic stroke; Distal aspiration; Mechanical thrombectomy
ID TISSUE-PLASMINOGEN ACTIVATOR; 1ST PASS TECHNIQUE; ENDOVASCULAR
   TREATMENT; EMBOLUS REMOVAL; STENT-RETRIEVER; ADAPT TECHNIQUE;
   ASPIRATION; REVASCULARIZATION; EXPERIENCE; SAFETY
AB OBJECTIVE: Fast and secure access to intracranial vessel occlusion is essential for mechanical thrombectomy (MT) in the treatment of acute ischemic stroke. We compared 2 intermediate distal access catheters (DAC: Distal Access Catheter [C1] and SOFIA: Soft torquable catheter Optimized For Intracranial Access [C2]) for procedural speed and safety of MTas well as clinical outcome at discharge and after 90 days.
   METHODS: This is a retrospective study of all 398 consecutive patients receiving MT with C1 or C2 for the treatment of acute ischemic stroke between September 2010 and June 2016, using a propensity score matched cohort. Baseline characteristics, clinical outcome, and procedural factors such as the number of retrieval attempts or duration of procedure were analyzed.
   RESULTS: A total of 282 patients (70.9%) underwent MT with C1 and 116 patients (29.1%) with C2. MT with C2 was faster with an average duration of 69.8 +/- 51 minutes (mean +/- standard deviation) compared with 80.6 +/- 54 minutes with C1 (P < 0.05). The average number of necessary stent-retriever maneuvers was significantly lower with C2 (1.8 +/- 1.7 vs. 3.2 +/- 2.5, P < 0.0001). Successful MT with aspiration only yielded higher modified Thrombolysis in Cerebral Infarction rates (mTIC 2b/3 69.9% vs. 31.5%, P < 0.0001) with C2. Modified Rankin Scale at discharge was significantly lower with C2 (3.5 +/- 1.9) versus C1 (3.9 +/- 1.7, P < 0.05). No significant differences of modified Rankin Scale 90 were observed.
   CONCLUSIONS: The use of C2 resulted in reduced procedural times with less stent-retriever maneuvers. Clinical outcome at discharge was better for C2 catheters, whereas no significant difference of outcome was apparent after 90 days.
C1 [Le Blanc, Markus; Maus, Volker; Kabbasch, Christoph; Chang, De-Hua; Borggrefe, Jan] Univ Hosp Cologne, Dept Neuroradiol, Cologne, Germany.
   [Dorn, Franziska] Ludwig Maximilians Univ Munchen, Munich, Germany.
   [Liebig, Thomas] Charite Univ Med Berlin, Berlin, Germany.
   [Mpotsaris, Anastasios] Univ Hosp Aachen, Aachen, Germany.
RP Le Blanc, M (reprint author), Univ Hosp Cologne, Dept Neuroradiol, Cologne, Germany.
EM markus.le-blanc@uk-koeln.de
RI Dorn, Franziska/AAA-7754-2020; Borggrefe, Jan/N-6549-2018; Mpotsaris,
   Anastasios/O-2247-2016
OI Dorn, Franziska/0000-0001-9093-8307; Borggrefe, Jan/0000-0003-2908-7560;
   Mpotsaris, Anastasios/0000-0002-1275-8164; Maus,
   Volker/0000-0001-5097-2631
CR Almandoz JED, 2016, J NEUROINTERV SURG, V8, P1123, DOI 10.1136/neurintsurg-2015-012122
   Berkhemer OA, 2015, NEW ENGL J MED, V372, P11, DOI 10.1056/NEJMoa1411587
   Campbell BCV, 2015, NEW ENGL J MED, V372, P1009, DOI 10.1056/NEJMoa1414792
   Costalat V, 2012, EUR J RADIOL, V81, P4075, DOI 10.1016/j.ejrad.2012.07.012
   Gobin YP, 2004, STROKE, V35, P2848, DOI 10.1161/01.STR.0000147718.12954.60
   Goyal M, 2015, NEW ENGL J MED, V372, P1019, DOI 10.1056/NEJMoa1414905
   Hacke W, 2004, LANCET, V363, P768
   Hacke W, 2008, NEW ENGL J MED, V359, P1317, DOI 10.1056/NEJMoa0804656
   Han HC, 2012, J VASC RES, V49, P185, DOI 10.1159/000335123
   Hu YC, 2016, J NEUROINTERV SURG, V8, P244, DOI 10.1136/neurintsurg-2014-011563
   Jovin TG, 2015, NEW ENGL J MED, V372, P2296, DOI 10.1056/NEJMoa1503780
   Kabbasch C, 2016, INTERV NEURORADIOL, V22, P333, DOI 10.1177/1591019916632370
   Kang DH, 2011, AM J NEURORADIOL, V32, P283, DOI 10.3174/ajnr.A2299
   Kaymaz ZO, 2017, INTERV NEURORADIOL, V23, DOI 10.1177/1591019917729364
   Kowoll A, 2016, J NEUROINTERV SURG, V8, P230, DOI 10.1136/neurintsurg-2014-011520
   Lapergue B, 2017, JAMA-J AM MED ASSOC, V318, P443, DOI 10.1001/jama.2017.9644
   MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401
   Marler JR, 2000, NEUROLOGY, V55, P1649, DOI 10.1212/WNL.55.11.1649
   Maus V, 2018, CLIN NEURORADIOL, V28, P327, DOI 10.1007/s00062-017-0566-z
   Mohlenbruch MA, 2017, J NEUROINTERV SURG, V9, P1223, DOI 10.1136/neurintsurg-2016-012812
   Rosso C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120230
   Saver JL, 2015, NEW ENGL J MED, V372, P2285, DOI 10.1056/NEJMoa1415061
   Seker F, 2017, AM J NEURORADIOL, V38, P1368, DOI 10.3174/ajnr.A5212
   Shallwani H, 2018, NEUROSURGERY, V82, P312, DOI 10.1093/neuros/nyx169
   Smith WS, 2008, STROKE, V39, P1205, DOI 10.1161/STROKEAHA.107.497115
   Smith WS, 2006, AM J NEURORADIOL, V27, P1177
   Tan IYL, 2009, AM J NEURORADIOL, V30, P525, DOI 10.3174/ajnr.A1408
   Tomsick T, 2008, AM J NEURORADIOL, V29, P582, DOI 10.3174/ajnr.A0843
   Tomsick TA, 2015, J NEUROINTERV SURG, V7, P795, DOI 10.1136/neurintsurg-2014-011318
   Turk AS, 2014, J NEUROINTERV SURG, V6, P260, DOI 10.1136/neurintsurg-2014-011125
   Turk AS, 2014, J NEUROINTERV SURG, V6, P231, DOI 10.1136/neurintsurg-2013-010713
   Wong JHY, 2017, J NEUROINTERV SURG, V9, P1103, DOI 10.1136/neurintsurg-2016-012750
   Zaidat OO, 2013, STROKE, V44, P2650, DOI 10.1161/STROKEAHA.113.001972
NR 33
TC 0
Z9 0
U1 4
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E433
EP E439
DI 10.1016/j.wneu.2018.11.185
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400050
PM 30500582
DA 2020-05-12
ER

PT J
AU Lee, JB
   Kim, IS
   Kwon, JY
   Lee, JJ
   Park, JH
   Cho, CB
   Yang, SH
   Sung, JH
   Hong, JT
AF Lee, Jong Beom
   Kim, Il Sup
   Kwon, Jae Yoel
   Lee, Jung Jae
   Park, Jong-Hyeok
   Cho, Chul Bum
   Yang, Seung Ho
   Sung, Jae Hoon
   Hong, Jae Taek
TI Difference of Dynamic Morphometric Changes Between in Patients with
   Ossification of Posterior Longitudinal Ligament and Patients with
   Cervical Spondylosis: Assessment by Cervical Dynamic Magnetic Resonance
   Imaging
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cervical degenerative spondylosis; Dynamic morphometric changes; Dynamic
   MRI; Muhle's classification; Ossification of the posterior longitudinal
   ligament
ID MYELOPATHY; EXTENSION; FLEXION; FLAVUM; MRI
AB PURPOSE: To evaluate differences between thicknesses of the ligamentum flavum (LF) and diameter of the spinal canal in different neck positions in patients with ossification of the posterior longitudinal ligament (OPLL) and patients with cervical degenerative spondylosis (CDS) using cervical dynamic magnetic resonance imaging (MRI).
   METHODS: Eighty-eight patients (66 CDS and 22 OPLL) who underwent neutral and dynamic MRI at our institute from February 2014 to July 2017 were the subjects of this retrospective study. Canal diameters and LF thicknesses were measured and Muhle's grades were determined in neutral and dynamic MRI from C2-C3 to C7-T1. Patients with CDS and OPLL were compared with respect to changes in morphometric parameters. Statistical analysis was performed using SPSS software and statistical significance was accepted for P values < 0.05.
   RESULTS: Mean ages in the CDS and OPLL groups were 68.2 +/- 12.27 and 63.1 +/- 9.36 years, respectively. Mean canal diameters were smaller in extension than in neutral at all measured levels, especially between C3-C4 and C6-C7 in patients with CDS. LF thickness in extension was significantly greater than in neutral and flexion positions in the CDS group, but not in the OPLL group. In addition, positional changes in Muhle's grades in the CDS group were significantly greater than in the OPLL group (P = 0.042).
   CONCLUSIONS: Dynamic morphometric changes were found to be significantly greater in the CDS group than in the OPLL group. The study shows dynamic MRI may provide additional information in CDS patients.
C1 [Lee, Jong Beom; Kim, Il Sup; Park, Jong-Hyeok; Cho, Chul Bum; Yang, Seung Ho; Sung, Jae Hoon] Catholic Univ Korea, St Vincents Hosp, Dept Neurosurg, Suwon, South Korea.
   [Kwon, Jae Yoel] St Marys Will Hosp, Dept Neurosurg, Sungnam, South Korea.
   [Lee, Jung Jae] Gangneung Asan Hosp, Asan Med Ctr, Dept Neurosurg, Kangnung, South Korea.
   [Hong, Jae Taek] Eunpyeong St Marys Hosp, Dept Neurosurg, Seoul, South Korea.
RP Hong, JT (reprint author), Eunpyeong St Marys Hosp, Dept Neurosurg, Seoul, South Korea.
EM jatagi@daum.net
OI Sung, Jae Hoon/0000-0003-3738-6413
CR Agundez M, 2015, NEUROLOGIA, V30, P502, DOI 10.1016/j.nrl.2013.05.005
   Azuma Y, 2010, J SPINAL DISORD TECH, V23, P166, DOI 10.1097/BSD.0b013e31819e9066
   Dalbayrak S, 2015, TURK NEUROSURG, V25, P36, DOI 10.5137/1019-5149.JTN.9082-13.1
   Evans Linton T, 2015, Case Rep Radiol, V2015, P275623, DOI 10.1155/2015/275623
   Fujimori T, 2012, J NEUROSURG-SPINE, V16, P289, DOI 10.3171/2011.11.SPINE11502
   Gu R, 2006, J SPINAL DISORD TECH, V19, P187, DOI 10.1097/01.bsd.0000190816.28682.83
   Guppy KH, 2009, J NEUROSURG-SPINE, V10, P366, DOI 10.3171/2009.1.SPINE08567
   Harada T, 2010, MAGN RESON IMAGING, V28, P820, DOI 10.1016/j.mri.2010.03.038
   Hong JT, 2008, SPINE, V33, P1739, DOI 10.1097/BRS.0b013e31817d2aa2
   Hong JT, 2016, SPINE J, V16, P1055, DOI 10.1016/j.spinee.2016.04.019
   Kim IS, 2018, WORLD NEUROSURG, V111, P361, DOI 10.1016/j.wneu.2018.01.018
   Kim IS, 2011, J CLIN NEUROSCI, V18, P481, DOI 10.1016/j.jocn.2010.07.114
   Kitagawa T, 2004, SPINE, V29, P2821, DOI 10.1097/01.brs.0000147741.11273.1c
   Kolcun JP, 2017, ASIAN SPINE J, V11, P1008, DOI 10.4184/asj.2017.11.6.1008
   Kuklo TR, 2006, SPINE, V31, P1240, DOI 10.1097/01.brs.0000217774.13433.a7
   Mackenzie WG, 2013, J PEDIATR ORTHOPED, V33, P91, DOI 10.1097/BPO.0b013e318279c51f
   Matsunaga S, 2008, SPINE, V33, P2648, DOI 10.1097/BRS.0b013e31817f988c
   Muhle C, 1998, AM J NEURORADIOL, V19, P1763
   Nagata K, 2014, SPINE J, V14, P2811, DOI 10.1016/j.spinee.2014.03.051
   Nigro Lorenzo, 2017, J Spine Surg, V3, P212, DOI 10.21037/jss.2017.06.01
   Nouri A, 2015, SPINE, V40, pE675, DOI 10.1097/BRS.0000000000000913
   Sayit E, 2013, GLOB SPINE J, V3, P69, DOI 10.1055/s-0033-1337121
   Suleiman LI, 2014, SEMIN SPINE SURG, V26, P68, DOI DOI 10.1053/J.SEMSS.2014.05.003
   Tykocki T, 2018, ACTA NEUROCHIR, V160, P1251, DOI 10.1007/s00701-018-3540-x
   Tykocki T, 2018, WORLD NEUROSURG, V114, pE317, DOI 10.1016/j.wneu.2018.02.179
   Zeitoun D, 2015, SPINE J, V15, P668, DOI 10.1016/j.spinee.2014.12.001
   Zhong GB, 2015, SPINE J, V15, P2216, DOI 10.1016/j.spinee.2015.06.048
NR 27
TC 1
Z9 1
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E566
EP E573
DI 10.1016/j.wneu.2018.11.213
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400066
PM 30528528
DA 2020-05-12
ER

PT J
AU Lee, WH
   Park, CK
   Park, HP
   Kim, SM
   Oh, BM
   Kim, K
   Choi, YD
   Seo, HG
AF Lee, Woo Hyung
   Park, Chul-Kee
   Park, Hee-Pyoung
   Kim, Sung-Min
   Oh, Byung-Mo
   Kim, Keewon
   Choi, Young-Doo
   Seo, Han Gil
TI Effect of Dexmedetomidine Combined Anesthesia on Motor evoked Potentials
   During Brain Tumor Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain tumor; Dexmedetomidine; Intraoperative monitoring; Motor evoked
   potentials; Somatosensory evoked potentials
ID INTRAOPERATIVE MOTOR; RESECTION; INFUSION
AB BACKGROUND: Dexmedetomidine (DEX) is used as an adjunct to total intravenous anesthesia. However, its effect on intraoperative neurophysiologic monitoring (IOM) during brain tumor surgery remains controversial. The aim of this study was to explore the effect of DEX on IOM during brain tumor surgery.
   METHODS: Seventy-eight consecutive patients (DEX group, n = 40; control group, n = 38), who underwent brain tumor surgery with IOM, were retrospectively reviewed. The outcomes included the predictability, laterality of alterations, and stimulation parameters of transcranial motor evoked potentials (tcMEPs) and somatosensory evoked potentials (SSEPs).
   RESULTS: The predictability of tcMEPs for postoperative motor outcomes showed a higher false-positive rate in the DEX group than in the control group (27.5% vs. 5.3%, P = 0.047). Bilateral alterations were observed only in the DEX group (31.3%; P = 0.053). Compared with the control group, the DEX group required significantly higher intensity (377.5 +/- 48.0 vs. 347.1 +/- 30.0 mV; P = 0.001) and repetition rate (6.0 +/- 0.2 vs. 5.7 +/- 0.5 pulse/train; P = 0.001) of transcranial electric stimulation to evoke adequate tcMEPs. The SSEP results were comparable between both groups. In the DEX group, false-positive tcMEPs changes occurred 222.2 +/- 70.5 minutes (range, 95-342 minutes) after the induction of anesthesia. In addition, the patients who were administered DEX under bispectral index monitoring (n = 12) showed a significantly higher false-positive rate than shown by the control group (50.5% vs. 5.3%; P = 0.003).
   CONCLUSIONS: This study showed that DEX had significant effects on tcMEPs during IOM in brain tumor surgery. Because the high false-positive rate could decrease the accuracy of IOM, outcomes after using DEX should be cautiously interpreted.
C1 [Lee, Woo Hyung; Oh, Byung-Mo; Kim, Keewon; Seo, Han Gil] Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Dept Rehabil Med, Seoul, South Korea.
   [Park, Chul-Kee; Choi, Young-Doo] Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Dept Neurosurg, Seoul, South Korea.
   [Park, Hee-Pyoung] Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Dept Anesthesiol & Pain Med, Seoul, South Korea.
   [Kim, Sung-Min] Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Dept Neurol, Seoul, South Korea.
   [Lee, Woo Hyung] Seoul Natl Univ, Dept Biomed Engn, Coll Med, Seoul, South Korea.
RP Seo, HG (reprint author), Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Dept Rehabil Med, Seoul, South Korea.
EM hgseo80@gmail.com
OI Oh, Byung-Mo/0000-0001-9353-7541; Park, Hee-Pyoung/0000-0002-4772-0780;
   Seo, Han Gil/0000-0001-6904-7542
CR Akpinar H, 2016, SCI REP-UK, V6, DOI 10.1038/srep37196
   Bala E, 2008, ANESTHESIOLOGY, V109, P417, DOI 10.1097/ALN.0b013e318182a467
   Bloom M, 2001, J NEUROSURG ANESTH, V13, P320, DOI 10.1097/00008506-200110000-00007
   Calderon P, 2017, NEUROPHYSIOL CLIN, V48, P93
   Hans P, 2006, CURR OPIN ANESTHESIO, V19, P498, DOI 10.1097/01.aco.0000245274.69292.ad
   Hervey-Jumper SL, 2015, J NEUROSURG, V123, P325, DOI 10.3171/2014.10.JNS141520
   Kim E, 2017, NEUROSCI LETT, V649, P20, DOI 10.1016/j.neulet.2017.04.011
   Kim SM, 2013, J KOREAN MED SCI, V28, P1261, DOI 10.3346/jkms.2013.28.9.1261
   Krieg SM, 2013, J NEUROSURG, V118, P1269, DOI 10.3171/2013.2.JNS121752
   Krieg SM, 2012, NEUROSURGERY, V70, P1060, DOI 10.1227/NEU.0b013e31823f5ade
   Laundre BJ, 2005, AM J NEURORADIOL, V26, P791
   Lee JJ, 2014, J KOREAN NEUROSURG S, V56, P98, DOI 10.3340/jkns.2014.56.2.98
   Li BH, 2003, ANESTH ANALG, V96, P1155, DOI 10.1213/01.ANE.0000053239.62623.32
   Li Y, 2015, BMC ANESTHESIOL, V16, P51
   Lin S, 2014, EXP THER MED, V7, P1383, DOI 10.3892/etm.2014.1555
   MacDonald DB, 2013, CLIN NEUROPHYSIOL, V124, P2291, DOI 10.1016/j.clinph.2013.07.025
   MACDONALD DR, 1990, J CLIN ONCOL, V8, P1277, DOI 10.1200/JCO.1990.8.7.1277
   Mahmoud M, 2007, ANESTHESIOLOGY, V106, P393, DOI 10.1097/00000542-200702000-00027
   Mahmoud M, 2010, ANESTHESIOLOGY, V112, P1364, DOI 10.1097/ALN.0b013e3181d74f55
   McGirt MJ, 2008, NEUROSURGERY, V63, P700, DOI 10.1227/01.NEU.0000325729.41085.73
   Neuloh G, 2004, ADV TECH STAND NEUR, V29, P171
   Neuloh G, 2004, NEUROSURGERY, V54, P1061, DOI 10.1227/01.NEU.0000119326.15032.00
   Purdon PL, 2015, ANESTHESIOLOGY, V123, P937, DOI 10.1097/ALN.0000000000000841
   Sloan TB, 2002, J CLIN NEUROPHYSIOL, V19, P430, DOI 10.1097/00004691-200210000-00006
   Thornton C, 1999, BRIT J ANAESTH, V83, P381
   Tobias JD, 2008, PEDIATR ANESTH, V18, P1082, DOI 10.1111/j.1460-9592.2008.02733.x
   Tomio R, 2017, J NEUROSURG, V127, P543, DOI 10.3171/2016.7.JNS152759
   Yamamoto Y, 2007, ANESTH ANALG, V104, P1488, DOI 10.1213/01.ane.0000261518.62873.91
   Zheng W, 2015, TRANSL PERIOPER PAIN, V18, P1067
   Zhou HH, 2001, NEUROSURGERY, V48, P1075, DOI 10.1097/00006123-200105000-00021
   Zhuang QY, 2014, SPINE, V39, pE1425, DOI 10.1097/BRS.0000000000000589
NR 31
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E280
EP E287
DI 10.1016/j.wneu.2018.11.152
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400034
PM 30496923
DA 2020-05-12
ER

PT J
AU Lenski, M
   Biczok, A
   Tonn, JC
   Kreth, FW
AF Lenski, Markus
   Biczok, Annemariea
   Tonn, Joerg-Christian
   Kreth, Friedrich-Wilhelm
TI Stereotactic Internal Shunt Placement in Congenital Intracranial Cysts
SO WORLD NEUROSURGERY
LA English
DT Article
DE Arachnoid cysts; Congenital intracranial cysts; Eloquent intracranial
   cysts; Internal shunt; Stereotactic surgery
ID FOSSA ARACHNOID CYSTS; PINEAL CYSTS; ENDOSCOPIC MANAGEMENT; CHILDREN;
   SURGERY; MICRONEUROSURGERY; HYDROCEPHALUS; FENESTRATION; EXPERIENCE;
   DIAGNOSIS
AB INTRODUCTION: Treatment of symptomatic intracranial cysts remains a controversial issue. We present a risk/benefit profile of a minimally invasive, not yet described, stereotactic internal shunt implantation technique. The provided data might serve as a reference against which other treatment modalities could be compared.
   METHODS: From our prospective database, we identified a consecutive series of patients with symptomatic, untreated cysts who had undergone internal shunting from 2009 to 2017. We estimated the rates of clinical symptom improvement (RCSI), cyst reduction, total complications, and long-term complications. A minimal follow-up of 6 months was required. The prognostic factors were obtained from logistic regression models. Cyst recurrencefree survival was calculated using the Kaplan-Meier method. The outcomes data were compared with those from reported alternative treatment strategies using chi(2) statistics.
   RESULTS: We included 38 patients. The cyst locations differed greatly and included the cerebellum (n = 2), brainstem (n= 5), and pineal area (n = 4). Cyst-associated hydrocephalus (n = 6) resolved after treatment. The 2-year cyst recurrence-free survival rate was 97%. The RCSI and rate of cyst reduction, total complications, and long-term complications was 91%, 97%, 11%, and 2.6%, respectively. We did not find any risk factors associated with the rate of total complications. The RCSI and rate of total and long-term complications compared favorably (P < 0.01) with the corresponding estimates of alternative treatments (P < 0.01).
   CONCLUSIONS: The described stereotactic internal shunt implantation technique is safe and can be successfully applied for treatment of cystic formations in any location in the brain.
C1 [Lenski, Markus; Biczok, Annemariea; Tonn, Joerg-Christian; Kreth, Friedrich-Wilhelm] Klinikum Univ Munchen, Dept Neurosurg, Campus Grosshadern, Munich, Germany.
RP Lenski, M (reprint author), Klinikum Univ Munchen, Dept Neurosurg, Campus Grosshadern, Munich, Germany.
EM markus.lenski@med.uni-muenchen.de
CR Ali M, 2015, J NEUROSURG-PEDIATR, V16, P275, DOI 10.3171/2015.2.PEDS14612
   Arai H, 1996, NEUROSURGERY, V39, P1108, DOI 10.1097/00006123-199612000-00007
   Arai H, 1996, NEUROSURGERY, V39, P1112
   Azab WA, 2017, ACTA NEUROCHIR, V159, P2313, DOI 10.1007/s00701-017-3320-z
   BEHRENS P, 1992, NERVENARZT, V63, P725
   BEHRENS P, 1993, ACTA NEUROCHIR, V123, P141, DOI 10.1007/BF01401870
   Berhouma M, 2013, ACTA NEUROCHIR, V155, P1901, DOI 10.1007/s00701-013-1849-z
   Chen CC, 2013, WORLD NEUROSURG, V79, DOI 10.1016/j.wneu.2011.02.025
   Chen Y, 2016, WORLD NEUROSURG, V92, P480, DOI 10.1016/j.wneu.2016.06.046
   D'Angelo V, 1999, STEREOT FUNCT NEUROS, V72, P62, DOI 10.1159/000029672
   DASTUV DK, 1968, J NEUROL SCI, V6, P575, DOI 10.1016/0022-510X(68)90036-1
   Di Rocco F, 2010, CHILD NERV SYST, V26, P155, DOI 10.1007/s00381-009-0977-5
   DONAUER E, 1986, ACTA NEUROCHIR, V83, P12, DOI 10.1007/BF01420502
   EBEL H, 1995, MINIM INVAS NEUROSUR, V38, P41, DOI 10.1055/s-2008-1053459
   Ebel H, 1994, Zentralbl Neurochir, V55, P54
   El-Ghandour NMF, 2012, J NEUROSURG-PEDIATR, V9, P231, DOI 10.3171/2011.12.PEDS11298
   Epelman M, 2006, RADIOGRAPHICS, V26, P173, DOI 10.1148/rg.261055033
   Molina GF, 2013, WORLD NEUROSURG, V79, DOI 10.1016/j.wneu.2012.02.012
   Gangemi M, 2007, BRIT J NEUROSURG, V21, P276, DOI 10.1080/02688690701339197
   Gangemi M, 2001, MINIM INVAS NEUROSUR, V44, P21, DOI 10.1055/s-2001-13588
   Gangemi M, 2011, J NEUROSURG-PEDIATR, V8, P158, DOI 10.3171/2011.5.PEDS1152
   Gazioglu N, 2010, TURK NEUROSURG, V20, P512, DOI 10.5137/1019-5149.JTN.2493-09.1
   Godano U, 2004, CHILD NERV SYST, V20, P839, DOI 10.1007/s00381-004-0940-4
   Gui SB, 2011, CHILD NERV SYST, V27, P1121, DOI 10.1007/s00381-011-1399-8
   Hopf NJ, 1998, NEUROSURGERY, V43, P1330, DOI 10.1097/00006123-199812000-00037
   Kang JK, 2000, CHILD NERV SYST, V16, P111, DOI 10.1007/s003810050024
   Karabagli H, 2012, CHILD NERV SYST, V28, P445, DOI 10.1007/s00381-011-1632-5
   Karabatsou K, 2007, J NEUROSURG, V106, P455, DOI 10.3171/ped.2007.106.6.455
   Levy ML, 2003, NEUROSURGERY, V53, P1138, DOI 10.1227/01.NEU.0000089060.65702.03
   Li LS, 2013, CLIN NEUROL NEUROSUR, V115, P411, DOI 10.1016/j.clineuro.2012.06.021
   Majovsky M, 2016, ACTA NEUROCHIR, V158, P663, DOI 10.1007/s00701-016-2726-3
   Mattox A, 2010, SURG INNOV, V17, P206, DOI 10.1177/1553350610377212
   Michielsen G, 2002, ACTA NEUROCHIR, V144, P233, DOI 10.1007/s007010200031
   OBERBAUER RW, 1992, CHILD NERV SYST, V8, P281, DOI 10.1007/BF00300797
   Oertel J, 2017, WORLD NEUROSURG, V108, P817, DOI 10.1016/j.wneu.2017.09.045
   Okano A, 2016, CHILD NERV SYST, V32, P153, DOI 10.1007/s00381-015-2908-y
   Osborn AG, 2006, RADIOLOGY, V239, P650, DOI 10.1148/radiol.2393050823
   Pradilla Gustavo, 2007, Neurosurg Focus, V22, pE7
   Rabiei K, 2018, J NEUROSURG, V128, P250, DOI 10.3171/2016.9.JNS161139
   Rabiei K, 2016, CHILD NERV SYST, V32, P1257, DOI 10.1007/s00381-016-3064-8
   Schulz M, 2015, WORLD NEUROSURG, V84, P327, DOI 10.1016/j.wneu.2015.03.026
   Spacca B, 2010, CHILD NERV SYST, V26, P163, DOI 10.1007/s00381-009-0952-1
   Takeuchi Totaro, 1996, Neurologia Medico-Chirurgica, V36, P396, DOI 10.2176/nmc.36.396
   Tamura Y, 2013, NEUROL MED-CHIR, V53, P625
   Turhan T, 2012, CHILD NERV SYST, V28, P229, DOI 10.1007/s00381-011-1487-9
   Wester K, 1996, SURG NEUROL, V45, P15, DOI 10.1016/0090-3019(95)00383-5
NR 46
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E670
EP E677
DI 10.1016/j.wneu.2018.11.250
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400079
PM 30576829
DA 2020-05-12
ER

PT J
AU Li, CH
   Gao, BL
   Wang, JW
   Liu, JF
   Li, H
   Yang, ST
AF Li, Cong-Hui
   Gao, Bu-Lang
   Wang, Ji-Wei
   Liu, Jian-Feng
   Li, Hui
   Yang, Song-Tao
TI Construction of Aneurysmal Models on a Curved Vascular Segment of a
   Carotid Siphon Model for Testing Endovascular Devices
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm model; Canine common carotid artery; Curved vessels;
   Endovascular device; Human carotid siphon segment
ID EMBOLIZATION DEVICE; CREATION
AB OBJECTIVE: To investigate construction of an aneurysm on a curved vascular segment of a carotid siphon model for testing endovascular devices.
   METHODS: Preshaped carotid siphon models of polytetrafluoroethylene were constructed from a human cadaver for confining canine common carotid artery (CCA). The canine right external jugular vein was isolated and harvested to make a venous pouch by suturing 1 end. The right CCA was isolated, and the venous pouch was sutured onto the right CCA to make an aneurysm. The right CCA segment containing the aneurysm was excised and guided through the preshaped polytetrafluoroethylene carotid siphon model using a guidewire with the aneurysm adjusted to protrude out of the round window of the siphon model. The siphon model together with the aneurysm was sutured end-to-end onto the left CCA to form a carotid siphon model in vivo.
   RESULTS: Five canine models were successfully constructed; the average construction time was 120 minutes. All aneurysms and siphon models remained patent 7 days and 2 weeks later. Five covered stents for intracranial use were tested for flexibility and apposition to the vascular wall in the curved segment of the carotid siphon model in vivo. All the covered stents passed the tortuous siphon model without much difficulty and were deployed successfully to cover the aneurysm orifice without endoleak.
   CONCLUSIONS: The carotid siphon model in vivo can simulate well the geometry of the human carotid siphon segment and can be used to test endovascular devices for interventions.
C1 [Li, Cong-Hui; Gao, Bu-Lang; Wang, Ji-Wei; Liu, Jian-Feng; Li, Hui; Yang, Song-Tao] Hebei Med Univ, Shijiazhuang Hosp 1, Dept Neurosurg, Shijiazhuang, Hebei, Peoples R China.
   [Gao, Bu-Lang] Hebei Med Univ, Shijiazhuang Hosp 1, Dept Med Res, Shijiazhuang, Hebei, Peoples R China.
RP Li, CH (reprint author), Hebei Med Univ, Shijiazhuang Hosp 1, Dept Neurosurg, Shijiazhuang, Hebei, Peoples R China.
EM 13363880072@163.com
RI Gao, Bu-Lang/N-3669-2015
OI Gao, Bu-Lang/0000-0003-4668-0737
FU Hebei Provincial Plan for 100 Overseas Talents [E2014100010]; National
   Natural Scientific Fund of ChinaNational Natural Science Foundation of
   China [81271575]
FX This study was supported by the Hebei Provincial Plan for 100 Overseas
   Talents (Grant No. E2014100010) and National Natural Scientific Fund of
   China (Grant No. 81271575).
CR Arends J, 2008, J INVEST SURG, V21, P39, DOI 10.1080/08941930701834189
   Cawley CM, 1996, AM J NEURORADIOL, V17, P1761
   Georganos SA, 2004, NEUROSURGERY, V54, P1239, DOI 10.1227/01.NEU.0000119759.56437.F5
   Juszkat R, 2016, INTERV NEURORADIOL, V22, P129, DOI 10.1177/1591019915622164
   Kallmes DF, 1999, NEURORADIOLOGY, V41, P338, DOI 10.1007/s002340050760
   KASSELL NF, 1990, J NEUROSURG, V73, P18, DOI 10.3171/jns.1990.73.1.0018
   Leung GKK, 2012, CLIN NEURORADIOL, V22, P295, DOI 10.1007/s00062-012-0178-6
   Linn FHH, 1996, STROKE, V27, P625, DOI 10.1161/01.STR.27.4.625
   Rhoton AL, 2002, NEUROSURGERY, V51, pS121, DOI 10.1227/01.NEU.0000028227.73143.A7
   Sfyroeras GS, 2012, J VASC SURG, V56, P839, DOI 10.1016/j.jvs.2012.04.020
   Shin YS, 2005, AM J NEURORADIOL, V26, P1764
   Talamonti G, 2016, WORLD NEUROSURG, V85, P215, DOI 10.1016/j.wneu.2015.08.082
   Withers K, 2013, APPL HEALTH ECON HEA, V11, P5, DOI 10.1007/s40258-012-0005-x
   Xie J, 2009, AM J NEURORADIOL, V30, P1041, DOI 10.3174/ajnr.A1479
   Yoshino Y, 2004, J NEUROSURG, V101, P996, DOI 10.3171/jns.2004.101.6.0996
NR 15
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E581
EP E587
DI 10.1016/j.wneu.2018.11.224
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400068
PM 30529529
DA 2020-05-12
ER

PT J
AU Li, J
   Wang, WK
   Zuo, R
   Zhou, Y
AF Li, Jie
   Wang, Wenkai
   Zuo, Rui
   Zhou, Yue
TI Biomechanical Stability Before and After Graft Fusion with Unilateral
   and Bilateral Pedicle Screw Fixation: Finite Element Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Biomechanical stability; Finite element analysis; Minimally invasive
   transformational lumbar interbody fusion; Pedicle screw fixation; Stress
   distribution
ID LUMBAR INTERBODY FUSION; OUTCOMES
AB BACKGROUND: Minimally invasive transformational lumbar interbody fusion (MI-TLIF) with unilateral pedicle screw (UPS) fixation was controversial. The aim of this study was to compare the stability between UPS and bilateral pedicle screw (BPS) fixation before and after graft fusion.
   METHODS: An L3-L5 finite element model was modified to simulate L4/5 MI-TLIF. Five different statuses of posterior instrumentation were simulated: UPS fixation or BPS fixation before and after graft fusion and removal of posterior instrumentation after graft fusion. Range of motion and Von Mises stress were evaluated for intact and instrumentation models in all loading planes.
   RESULTS: Range of motion of the L4/5 segment with UPS fixation was 2.1, 1.3, and 1.7 times greater than those with BPS fixation before fusion in flexion-extension, lateral bending, and axial rotation, respectively, while it was 1.3, 1.1, and 1.4 times greater after fusion. The peak Von Mises stresses on posterior instrumentations with UPS fixation ranged from 1.0 to 1.7 times greater than those in BPS fixation before fusion, while it ranged from 1.0 to 1.4 times greater after fusion. The peak Von Mises stresses on intervertebral graft with UPS fixation ranged from 1.9 to 3.5 times greater than those with BPS fixation before fusion, while it ranged from 0.9 to 1.2 times greater after fusion.
   CONCLUSIONS: Fusion of graft improved the fixation effect of posterior instrumentation system. Unilateral pedicle screw fixation could provide similar biomechanical stability to bilateral pedicle screw fixation in 1-level MI-TLIF after fusion.
C1 [Li, Jie; Wang, Wenkai; Zuo, Rui; Zhou, Yue] Army Mil Univ, Xinqiao Hosp, Dept Orthopaed, Chongqing, Peoples R China.
RP Zhou, Y (reprint author), Army Mil Univ, Xinqiao Hosp, Dept Orthopaed, Chongqing, Peoples R China.
EM xqzhoue@163.com
FU Clinical Research Project of Xinqiao Hospital of Army Military
   University [2015YLC22]
FX This work was supported by the Clinical Research Project of Xinqiao
   Hospital of Army Military University (2015YLC22).
CR Ambati DV, 2015, SPINE J, V15, P1812, DOI 10.1016/j.spinee.2014.06.015
   Chen SH, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471-2474-13-72
   Kang MS, 2014, BIOMED RES INT, DOI 10.1155/2014/919248
   Kim HJ, 2014, YONSEI MED J, V55, P1386, DOI 10.3349/ymj.2014.55.5.1386
   Li J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144637
   Liu Z, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111979
   Park P, 2004, SPINE, V29, P1938, DOI 10.1097/01.brs.0000137069.88904.03
   Razak HRBA, 2017, ASIAN SPINE J, V11, P204, DOI 10.4184/asj.2017.11.2.204
   Seng CS, 2013, SPINE, V38, P2049, DOI 10.1097/BRS.0b013e3182a8212d
   Shen XL, 2014, J CLIN NEUROSCI, V21, P1612, DOI 10.1016/j.jocn.2013.11.055
   Tian NF, 2013, EUR SPINE J, V22, P1741, DOI 10.1007/s00586-013-2747-z
   Wang L, 2014, BMC SURG, V14, DOI 10.1186/1471-2482-14-87
   Xie L, 2016, CHINESE MED J-PEKING, V129, P1969, DOI 10.4103/0366-6999.187847
   Xie QS, 2018, BMC MUSCULOSKEL DIS, V19, DOI 10.1186/s12891-018-1937-6
   Xue HM, 2012, SPINE J, V12, P209, DOI 10.1016/j.spinee.2012.01.010
   Yucesoy K, 2008, J NEUROSURG-SPINE, V8, P44, DOI 10.3171/SPI-08/01/044
NR 16
TC 1
Z9 2
U1 2
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E228
EP E234
DI 10.1016/j.wneu.2018.11.141
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400028
PM 30481621
DA 2020-05-12
ER

PT J
AU Li, L
   Zhang, XX
   Feng, ZZ
   Zhao, R
   Hong, B
   Xu, Y
   Huang, QH
   Liu, JM
AF Li, Li
   Zhang, Xiaoxi
   Feng, Zhengzhe
   Zhao, Rui
   Hong, Bo
   Xu, Yi
   Huang, Qinghai
   Liu, Jianmin
TI Risk Factors for Intraprocedural Rupture in the Endovascular Treatment
   of Unruptured Intracranial Aneurysms: A Single-Center Experience with
   1232 Procedures
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endovascular treatment; Intraprocedural rupture; Unruptured intracranial
   aneurysms
ID COIL EMBOLIZATION; CEREBRAL ANEURYSMS; MANAGEMENT; OUTCOMES; THERAPY
AB BACKGROUND: Intraprocedural rupture (IPR) is a rare complication that can occur during endovascular treatment (EVT) of unruptured intracranial aneurysms (UIAs). However, it universally leads to poor outcomes if not properly managed. In the present study, we sought to illuminate the risk factors for IPR during EVT of UIAs.
   METHODS: The data from patients with UIAs who had undergone EVT in our center from January 2010 to March 2017 were retrospectively collected and reviewed. Univariate analysis and multivariate logistic analysis were performed to analyze the risk factors for IPR.
   RESULTS: A total of 1232 patients with 1312 unruptured aneurysms were included in the present study. IPR occurred in 11 patients (0.9%). Univariate analysis showed that cardiac comorbidities, irregular morphology, and location at the anterior communicating artery (AcomA) were significantly associated with the development of IPR (P < 0.05). In addition, stent placement was related to a lower risk of IPR compared with no stent placement (P = 0.024). The multivariate analysis showed that cardiac comorbidities (odds ratio [OR], 6.320; P = 0.016), irregular morphology (OR, 9.562; P = 0.001), and location on the AcomA (OR, 6.971; P = 0.006) were independent risk factors for IPR.
   CONCLUSIONS: The occurrence rate of IPR was relatively low. Cardiac comorbidities, irregular morphology, and location on the AcomA are independent risk factors for IPR. Stents and flow diverters are safe and feasible in treating UIA, with a significantly low risk of IPR.
C1 [Li, Li; Zhang, Xiaoxi; Feng, Zhengzhe; Zhao, Rui; Hong, Bo; Xu, Yi; Huang, Qinghai; Liu, Jianmin] Naval Med Univ, Changhai Hosp, Dept Neurosurg, Shanghai, Peoples R China.
RP Liu, JM (reprint author), Naval Med Univ, Changhai Hosp, Dept Neurosurg, Shanghai, Peoples R China.
EM chstroke@163.com
FU National Key R&D Program of China [2016YFC1300700]; project on research
   and application of effective intervention techniques for high risk
   population of stroke from the National Health and Family Planning
   Commission in China [GN-2016R0012]
FX The present study was supported by the National Key R&D Program of China
   (grant 2016YFC1300700) and the project on research and application of
   effective intervention techniques for high risk population of stroke
   from the National Health and Family Planning Commission in China (grant
   GN-2016R0012).
CR Brown RD, 2014, LANCET NEUROL, V13, P393, DOI 10.1016/S1474-4422(14)70015-8
   Cho SH, 2017, WORLD NEUROSURG, V105, P177, DOI 10.1016/j.wneu.2017.05.147
   Fan LH, 2017, J NEUROINTERV SURG, V9, P370, DOI 10.1136/neurintsurg-2016-012335
   Fang S, 2014, AM J NEURORADIOL, V35, P943, DOI 10.3174/ajnr.A3802
   Frontera JA, 2014, J NEUROINTERV SURG, V6, P65, DOI 10.1136/neurintsurg-2012-010544
   Gonzalez N, 2008, STROKE, V39, P2776, DOI 10.1161/STROKEAHA.107.505222
   Im SH, 2009, AM J NEURORADIOL, V30, P79, DOI 10.3174/ajnr.A1290
   Kawabata S, 2018, J NEUROINTERV SURG, V10, P362, DOI 10.1136/neurintsurg-2017-013156
   Kleinloog R, 2018, NEUROSURGERY, V82, P431, DOI 10.1093/neuros/nyx238
   Kunz M, 2013, J NEUROL, V260, P1304, DOI 10.1007/s00415-012-6795-9
   Liu J, 2014, J NEUROINTERV SURG, V6, P658, DOI 10.1136/neurintsurg-2013-010946
   Meng H, 2005, NEUROL RES, V27, P459, DOI 10.1179/016164105X25171
   Mitchell PJ, 2013, J STROKE CEREBROVASC, V22, P1298, DOI 10.1016/j.jstrokecerebrovasdis.2012.10.017
   Morita A, 2012, NEW ENGL J MED, V366, P2474, DOI 10.1056/NEJMoa1113260
   Oishi H, 2012, AM J NEURORADIOL, V33, P958, DOI 10.3174/ajnr.A2858
   Oishi H, 2015, J NEUROINTERV SURG, V7, P660, DOI 10.1136/neurintsurg-2014-011305
   Pierot L, 2008, STROKE, V39, P2497, DOI 10.1161/STROKEAHA.107.512756
   Sanchez M, 2014, AM J NEURORADIOL, V35, P1765, DOI 10.3174/ajnr.A3949
   Sanchez M, 2013, ANN BIOMED ENG, V41, P28, DOI 10.1007/s10439-012-0632-2
   Santillan A, 2012, AM J NEURORADIOL, V33, P2017, DOI 10.3174/ajnr.A3061
   Shigematsu T, 2013, STROKE, V44, P2735, DOI 10.1161/STROKEAHA.111.000609
   Stapleton CJ, 2015, J NEUROSURG, V122, P128, DOI 10.3171/2014.9.JNS14616
   Thompson BG, 2015, STROKE, V46, P2368, DOI 10.1161/STR.0000000000000070
   Yamaki VN, 2016, AM J NEURORADIOL, V37, P862, DOI 10.3174/ajnr.A4651
   Zang PZ, 2011, NEUROL INDIA, V59, P369, DOI 10.4103/0028-3886.82736
   Zheng YT, 2016, J NEUROINTERV SURG, V8, P152, DOI 10.1136/neurintsurg-2014-011459
NR 26
TC 0
Z9 1
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E9
EP E14
DI 10.1016/j.wneu.2018.09.164
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400003
PM 30278291
DA 2020-05-12
ER

PT J
AU Li, XS
   Fan, HW
   Huang, ZF
   Deng, YL
   Chen, BL
   Li, ZZ
   Yang, JL
AF Li, Xue-Shi
   Fan, Heng-Wei
   Huang, Zi-Fang
   Deng, Yao-Long
   Chen, Bai-Ling
   Li, Zhi-Zhong
   Yang, Jun-Lin
TI Predictive Value of Spinal Cord Function Classification and Sagittal
   Deformity Angular Ratio for Neurologic Risk Stratification in Patients
   with Severe and Stiff Kyphoscoliosis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Deformity angular ratio; Kyphoscoliosis; Neurologic deficit; Risk
   stratification; Spinal cord function classification
ID VERTEBRAL COLUMN RESECTION; SCOLIOSIS; COMPLICATIONS; OSTEOTOMIES;
   KYPHOSIS; FUSION
AB BACKGROUND: Three-column osteotomies were developed to treat severe spinal deformities but result in high neurologic complications and require further risk stratification. The present study investigated whether the combination of spinal cord function classification (SCFC) and deformity angular ratio (DAR) could further stratify the neurologic risks in the surgical correction of severe and stiff kyphoscoliosis.
   METHODS: The patients with kyphoscoliosis who had undergone posterior 3-column osteotomies at the spinal cord level were reviewed. Using our SCFC system, the preoperative neurologic function (type A, B, or C) was classified. The sagittal DAR (S-DAR), coronal, and total DARs were calculated. Intraoperative monitoring events and new neurologic deficits (NNDs) postoperatively were documented and analyzed using the SCFC and DAR or both combined.
   RESULTS: The NND rates increased significantly from type A to C (P = 0.000) and increased exponentially with an increase in S-DAR in types B and C but not type A. They also increased exponentially with aggravation of the SCFC in the medium and high but not low S-DAR group. All NNDs had recovered at 3 months for type A and most had recovered at 6 months for type B or C.
   CONCLUSIONS: The NNDs in type A SCFC usually experienced better recovery even with high S-DARs. Type B SCFC with an S-DAR >20 degrees and type C SCFC with any S-DAR resulted in significantly greater intra- and postoperative neurologic risks. The combination of SCFC and S-DAR can further stratify the intra- and postoperative neurologic risks with these procedures.
C1 [Li, Xue-Shi; Li, Zhi-Zhong; Yang, Jun-Lin] Jinan Univ, Dept Orthopaed Surg, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China.
   [Fan, Heng-Wei; Deng, Yao-Long; Yang, Jun-Lin] Shanghai Jiao Tong Univ, Ctr Spinal Surg, Dept Pediat Orthoped, Affiliated Xinhua Hosp, Shanghai, Peoples R China.
   [Huang, Zi-Fang; Chen, Bai-Ling; Yang, Jun-Lin] Sun Yat Sen Univ, Dept Orthopaed Surg, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China.
RP Yang, JL (reprint author), Jinan Univ, Dept Orthopaed Surg, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China.; Yang, JL (reprint author), Shanghai Jiao Tong Univ, Ctr Spinal Surg, Dept Pediat Orthoped, Affiliated Xinhua Hosp, Shanghai, Peoples R China.; Yang, JL (reprint author), Sun Yat Sen Univ, Dept Orthopaed Surg, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China.
EM yjunlin@126.com
CR Bradford DS, 1997, SPINE, V22, P1590, DOI 10.1097/00007632-199707150-00013
   Charles YP, 2014, EUR SPINE J, V23, P708, DOI 10.1007/s00586-014-3225-y
   Coe JD, 2006, SPINE, V31, P345, DOI 10.1097/01.brs.0000197188.76369.13
   CRAWFORD AH, 1989, CLIN ORTHOP RELAT R, P29
   Fan HW, 2017, SPINE, V42, pE1371, DOI 10.1097/BRS.0000000000002210
   Hamzaoglu A, 2011, SPINE, V36, pE340, DOI 10.1097/BRS.0b013e3182015712
   Huang JH, 2015, SPINE, V40, pE1103, DOI 10.1097/BRS.0000000000001035
   Jarvis JG, 2013, SPINE, V38, pE493, DOI 10.1097/BRS.0b013e3182880378
   Kokubun S, 2011, J NEUROSURG-SPINE, V15, P21, DOI 10.3171/2011.2.SPINE10114
   Lenke LG, 2013, SPINE, V38, P119, DOI 10.1097/BRS.0b013e318269fab1
   Lenke LG, 2009, SPINE, V34, P2213, DOI 10.1097/BRS.0b013e3181b53cba
   Lenke LGN, 2014, SCOL RES SOC 49 ANN
   Lewis NDH, 2015, SPINE, V40, pE879, DOI 10.1097/BRS.0000000000000984
   Li XS, 2017, SPINE, V42, P1050, DOI 10.1097/BRS.0000000000002117
   MacLennan A, 1922, BRIT MED J, V2, P864
   MCMASTER MJ, 1976, J BONE JOINT SURG BR, V58, P305
   Qiu Y, 2008, SPINE, V33, P519, DOI 10.1097/BRS.0b013e3181657d93
   Schwab F, 2014, NEUROSURGERY, V74, P112, DOI 10.1227/NEU.0000000000000182o
   Shen JX, 2016, J BONE JOINT SURG AM, V98, P926, DOI 10.2106/JBJS.15.00882
   Suk S, 2002, SPINE, V27, P2374, DOI 10.1097/00007632-200211010-00012
   Suk SI, 2005, SPINE, V30, P1682, DOI 10.1097/01.brs.0000170590.21071.c1
   Wang SR, 2017, EUR SPINE J, V26, P1817, DOI 10.1007/s00586-015-4344-9
   Wang XB, 2016, SPINE, V41, P1447, DOI 10.1097/BRS.0000000000001547
   Wang Y, 2011, EUR SPINE J, V20, P1703, DOI 10.1007/s00586-011-1771-0
   Xie JM, 2012, J NEUROSURG-SPINE, V17, P540, DOI 10.3171/2012.9.SPINE111026
   Yang JL, 2016, EUR SPINE J, V25, P1821, DOI 10.1007/s00586-015-4367-2
   Zeng Y, 2013, J SPINAL DISORD TECH, V26, P367, DOI 10.1097/BSD.0b013e3182499237
   Zhang ZF, 2016, EUR SPINE J, V25, P1897, DOI 10.1007/s00586-015-4051-6
NR 28
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E787
EP E796
DI 10.1016/j.wneu.2018.12.041
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400095
PM 30579019
DA 2020-05-12
ER

PT J
AU Li, ZX
   Chen, JG
   Zhang, DF
   Lv, LQ
   Hou, LJ
AF Li, Zhenxing
   Chen, Jigang
   Zhang, Danfeng
   Lv, Liquan
   Hou, Lijun
TI Tracheostomy as a Risk Factor for Paroxysmal Sympathetic Hyperactivity
   in Severe Traumatic Brain Injury
SO WORLD NEUROSURGERY
LA English
DT Article
DE Paroxysmal sympathetic hyperactivity; Severe traumatic brain injury;
   Tracheostomy
ID MANAGEMENT; TRACHEOTOMY
AB BACKGROUND: Paroxysmal sympathetic hyperactivity (PSH) is an uncommon complication of severe traumatic brain injury (sTBI). The clinical risk factors for PSH have not been fully characterized, especially regarding tracheostomy, which has usually been recommended for patients with sTBI to facilitate treatment. We examined the effects of tracheostomy on PSH incidence in patients with sTBI.
   METHODS: The present single-center, retrospective study included consecutive patients with sTBI who had been admitted to the Shanghai Changzheng Hospital from January 1, 2013 to March 31, 2018. The potential risk factors related to the occurrence of PSH was explored by univariate analysis. Multivariate logistic regression analysis was conducted to determine the independence of the factors associated with PSH development.
   RESULTS: Of the 120 patients with sTBI, 17 with PSH were identified (14.16%). We found 3 risk factors were significantly associated with PSH on univariate and multivariate analyses: 1) tracheostomy (odds ratio [OR], 5.368; 95% confidence interval [CI], 1.102-26.151; P = 0.038); 2) age (OR, 0.916; 95% CI, 0.874-0.960; P < 0.001); and 3) hydrocephalus (OR, 6.715; 95% CI, 1.708-26.408; P = 0.006).
   CONCLUSIONS: Our results suggest that tracheostomy is independently associated with an increased incidence of PSH.
C1 [Li, Zhenxing; Chen, Jigang; Zhang, Danfeng; Lv, Liquan; Hou, Lijun] Second Mil Med Univ, Changzheng Hosp, Dept Neurosurg, Shanghai, Peoples R China.
RP Hou, LJ (reprint author), Second Mil Med Univ, Changzheng Hosp, Dept Neurosurg, Shanghai, Peoples R China.
EM schzsjkw11@126.com
FU Natural Science Foundation of ChinaNational Natural Science Foundation
   of China [81671206]
FX The present study was funded by the Natural Science Foundation of China
   (grant 81271350) to Liquan Lv and the Natural Science Foundation of
   China (grant 81671206) to Lijun Hou.
CR Alali Aziz S, 2014, J Trauma Acute Care Surg, V76, P70, DOI 10.1097/TA.0b013e3182a8fd6a
   Vieira RDA, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00178
   Baguley IJ, 2008, MED HYPOTHESES, V70, P26, DOI 10.1016/j.mehy.2007.04.037
   Baguley IJ, 2014, J NEUROTRAUM, V31, P1515, DOI 10.1089/neu.2013.3301
   Bouderka MA, 2004, J TRAUMA, V57, P251, DOI 10.1097/01.TA.0000087646.68382.9A
   Boynton JH, 2004, CRIT CARE, V8, pR261, DOI 10.1186/cc2885
   Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432
   Cheung NH, 2014, RESP CARE, V59, P895, DOI 10.4187/respcare.02971
   De Leyn P, 2007, EUR J CARDIO-THORAC, V32, P412, DOI 10.1016/j.ejcts.2007.05.018
   DOLCE G, 2008, [No title captured], V25, P1079, DOI DOI 10.1089/NEU.2008.0536
   Fernandez-Ortega JF, 2006, J TRAUMA, V61, P1129, DOI 10.1097/01.ta.0000197634.83217.80
   Fernandez-Ortega JF, 2012, J NEUROTRAUM, V29, P1364, DOI 10.1089/neu.2011.2033
   Heffner JE, 2008, CRIT CARE, V12, DOI 10.1186/cc6833
   Hinson HE, 2017, J HEAD TRAUMA REHAB, V32, pE50, DOI 10.1097/HTR.0000000000000271
   Hinson HE, 2015, BRAIN INJURY, V29, P455, DOI 10.3109/02699052.2014.995229
   Hsu CL, 2005, CRIT CARE, V9, pR46, DOI 10.1186/cc3018
   Ireton Joanna, 2007, Paediatr Nurs, V19, P14
   Khalili H, 2017, WORLD NEUROSURG, V103, P88, DOI 10.1016/j.wneu.2017.02.060
   Laxe S, 2013, BRAIN INJURY, V27, P1383, DOI 10.3109/02699052.2013.823648
   Lewarski Joseph S, 2005, Respir Care, V50, P534
   Lv LQ, 2011, ARCH PHYS MED REHAB, V92, P1515, DOI 10.1016/j.apmr.2011.01.014
   Lv LQ, 2010, J NEUROTRAUM, V27, P1945, DOI 10.1089/neu.2010.1391
   Mathew MJ, 2016, ACTA NEUROCHIR, V158, P2047, DOI 10.1007/s00701-016-2934-x
   Meyfroidt G, 2017, LANCET NEUROL, V16, P721, DOI 10.1016/S1474-4422(17)30259-4
   Perkes I, 2010, ANN NEUROL, V68, P126, DOI 10.1002/ana.22066
   Pucks-Faes E, 2018, BRAIN BEHAV, V8, DOI 10.1002/brb3.1124
   Ringrose H, 2018, NEUROREHABILITATION, V42, P207, DOI 10.3233/NRE-172276
   Scales DC, 2010, JAMA-J AM MED ASSOC, V303, P1537, DOI 10.1001/jama.2010.462
   Sheriff FG, 2015, SEMIN NEUROL, V35, P42, DOI 10.1055/s-0035-1544238
   Siddiqui Usman Tariq, 2015, Surg Neurol Int, V6, P65, DOI 10.4103/2152-7806.155757
   Zhou ZW, 2007, J NEUROSURG, V106, P687, DOI 10.3171/jns.2007.106.4.687
NR 31
TC 1
Z9 2
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E156
EP E161
DI 10.1016/j.wneu.2018.11.101
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400019
PM 30471448
DA 2020-05-12
ER

PT J
AU Liu, LX
   Zhang, CW
   Xie, XD
   Wang, CH
AF Liu, Lun-Xin
   Zhang, Chang-Wei
   Xie, Xiao-Dong
   Wang, Chao-Hua
TI Application of the Willis Covered Stent in the Treatment of Blood
   Blister-Like Aneurysms: A Single-Center Experience and Systematic
   Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE BBA; Endovascular; Intracranial aneurysm; Review; Willis covered stent
ID INTERNAL CAROTID-ARTERY; ENDOVASCULAR TREATMENT; INTRACRANIAL ANEURYSMS;
   CLINICAL ANALYSIS; MANAGEMENT; PSEUDOANEURYSMS; TERRITORIES
AB OBJECTIVE: The purpose of the present study was to introduce our initial experience with the use and feasibility of the Willis covered stent (WCS) in the treatment of blood blister-like aneurysms (BBAs) and to present a systematic review of the reported data on the treatment of BBAs with covered stents.
   METHODS: Fourteen consecutive patients with BBAs had been treated with WCSs at West China Hospital from January 2015 to August 2017. The patient medical records, angiographic findings, and endovascular treatment reports were reviewed by interventional neuroradiologists and neurosurgeons to obtain relevant clinical and angiographic information. We conducted a systematic review of all reports of BBAs treated with covered stents. We searched the reported data using PubMed, Embase, China National Knowledge Infrastructure, and Wanfang databases and commercial Internet search engines. We included BBAs located at nonbranching portions of the internal carotid artery (ICA).
   RESULTS: The present study included 9 men and 5 women, with a mean age of 54.5 years (range, 30-79). All patients had complete occlusion found on immediate postoperative angiography. The ophthalmic artery was occluded in 2 patients (14.3%). No mortality or morbidity had occurred during the procedure. Two patients (14.3%) experienced a mild recurrence. One patient (7.1%) had developed mild in-stent stenosis. The clinical follow-up period was 6e15 months for all the patients. Of the 14 patients, 11 (78.6%) had a modified Rankin scale score of 0, and 1 (7.1%) had a modified Rankin scale score of 1 during the follow-up period. One patient (7.1%) experienced sub-arachnoid hemorrhage at 7 days postoperatively and had died 10 days after surgery. None of the patients experienced visual defects. Of our 14 patients, 13 (92.9%) survived, as determined by outpatient department visits or telephone interviews. A total of 8 reports, including 38 patients, met our criteria. Of these 38 patients, 37 (97.3%) had successful delivery to the diseased ICA, and 34 (89.5%) had experienced complete occlusion during follow-up. The overall rate of complete occlusion was 83.0% (95% confidence interval, 68%-91%).
   CONCLUSIONS: Patients with ruptured BBAs treated with WCSs can achieve satisfactory clinical results. Therefore, for BBAs, the implementation of the WCS could be safe and feasible. This strategy could be a promising option for this type of high-risk aneurysm. However, patients with tortuous ICAs or aneurysms close to essential branch arteries should be carefully evaluated before the WCS is used.
C1 [Liu, Lun-Xin; Zhang, Chang-Wei; Xie, Xiao-Dong; Wang, Chao-Hua] Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu, Sichuan, Peoples R China.
RP Wang, CH (reprint author), Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu, Sichuan, Peoples R China.
EM wangchaohuaHX@163.com
FU Scientific Research Foundation of the Scientific and Technology
   Department of Sichuan Province [2016FZ0073, 2017ZR0169]; National
   Natural Scientific Fund of ChinaNational Natural Science Foundation of
   China [81372446]
FX This work was supported by the Scientific Research Foundation of the
   Scientific and Technology Department of Sichuan Province (grants
   2016FZ0073 and 2017ZR0169) and the National Natural Scientific Fund of
   China (grant 81372446).
CR Almandoz JED, 2014, J NEUROINTERV SURG, V6, P767, DOI 10.1136/neurintsurg-2013-010976
   Andaluz N, 2008, SKULL BASE-INTERD AP, V18, P265, DOI 10.1055/s-2008-1058367
   Charbel FT, 1999, NEUROSURGERY, V45, P643, DOI 10.1097/00006123-199909000-00043
   Cinar C, 2013, NEURORADIOLOGY, V55, P441, DOI 10.1007/s00234-013-1136-y
   Drake RL, 2009, ANAT SCI EDUC, V2, P253, DOI 10.1002/ase.117
   Fang C, 2017, J NEUROINTERV SURG, V9, P963, DOI 10.1136/neurintsurg-2016-012662
   Feekes JA, 2005, ANN NEUROL, V58, P18, DOI 10.1002/ana.20505
   Fiorella D, 2006, NEUROSURGERY, V59, P34, DOI 10.1227/01.NEU.0000219853.56553.71
   Ghica J, 1990, ARCH NEUROL-CHICAGO, V47, P1097
   Gonzalez AM, 2014, EUR J RADIOL, V83, P197, DOI 10.1016/j.ejrad.2013.09.017
   Hamoir XL, 2004, EUR RADIOL, V14, P417, DOI 10.1007/s00330-003-2220-1
   Ishikawa T, 1997, NEUROSURGERY, V40, P403, DOI 10.1097/00006123-199702000-00038
   Kazumata K, 2013, OPER NEUROSURG, V10, P66
   Kim BC, 2014, NEURORADIOLOGY, V56, P211, DOI 10.1007/s00234-014-1317-3
   Kipshidze N, 2004, J AM COLL CARDIOL, V44, P733, DOI 10.1016/j.jacc.2004.04.048
   LASJAUNIAS P, 1975, NEURORADIOLOGY, V9, P87, DOI 10.1007/BF00341426
   Lee BH, 2009, J NEUROSURG, V110, P431, DOI 10.3171/2008.7.JNS08257
   Lee JW, 2009, ACTA NEUROCHIR, V151, P125, DOI 10.1007/s00701-008-0165-5
   Li MH, 2008, AM J NEURORADIOL, V29, P1395, DOI 10.3174/ajnr.A1096
   Li MH, 2007, AM J NEURORADIOL, V28, P1579, DOI 10.3174/ajnr.A0668
   Li MH, 2009, RADIOLOGY, V253, P470, DOI 10.1148/radiol.2532090037
   [刘学政 Liu Xuezheng], 2016, [临床放射学杂志, Journal of Clinical Radiology], V35, P279
   Meling TR, 2008, J NEUROSURG, V108, P662, DOI 10.3171/JNS/2008/108/4/0662
   Perrini P, 2007, J NEUROSURG, V106, P142, DOI 10.3171/jns.2007.106.1.142
   Piotin M, 2012, NEURORADIOLOGY, V54, P345, DOI 10.1007/s00234-011-0870-2
   Prabhakaran S, 2008, AM J NEURORADIOL, V29, P281, DOI 10.3174/ajnr.A0818
   Qingfeng Z, 2017, J SHANXI MED COLL, P20
   Rasskazoff S, 2010, INTERV NEURORADIOL, V16, P255, DOI 10.1177/159101991001600304
   Regelsberger J, 2011, NEUROSURG REV, V34, P409, DOI 10.1007/s10143-011-0313-x
   Ren YM, 2018, WORLD NEUROSURG, V109, pE615, DOI 10.1016/j.wneu.2017.10.048
   Shi WY, 2014, VASCULAR, V22, P432, DOI 10.1177/1708538113519443
   Tan HQ, 2011, CEREBROVASC DIS, V31, P154, DOI 10.1159/000321735
   Tanoue S, 2004, J NEUROSURG, V101, P159, DOI 10.3171/jns.2004.101.1.0159
   Tatu L, 1998, NEUROLOGY, V50, P1699, DOI 10.1212/WNL.50.6.1699
   Wang Gang, 2016, Nan Fang Yi Ke Da Xue Xue Bao, V36, P1165
   Yanaka K, 2002, NEUROSURGERY, V50, P218, DOI 10.1097/00006123-200201000-00037
   Yu JL, 2015, INT J CLIN EXP MED, V8, P21786
   Zhang YX, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00639
   Zhenhui L, 2017, IMAGING DIAGNOSIS IN, P367
   Zhu YQ, 2013, EUR RADIOL, V23, P287, DOI 10.1007/s00330-012-2581-4
NR 40
TC 3
Z9 3
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E652
EP E660
DI 10.1016/j.wneu.2018.11.245
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400077
PM 30576815
DA 2020-05-12
ER

PT J
AU Liu, YJ
   Zheng, YT
   An, QZ
   Song, YB
   Leng, B
AF Liu, Yingjun
   Zheng, Yongtao
   An, Qingzhu
   Song, Yanbing
   Leng, Bing
TI Optical Coherence Tomography for Intracranial Aneurysms: A New Method
   for Assessing the Aneurysm Structure
SO WORLD NEUROSURGERY
LA English
DT Article
DE Intracranial aneurysm; Optical coherence tomography; Pathology
ID INDUCED CEREBRAL ANEURYSMS; SUBARACHNOID HEMORRHAGE; RUPTURE; RISK; AGE;
   PREVALENCE; SEX
AB BACKGROUND: There is a lack of precise methods for predicting the risk of aneurysm rupture. Therefore, prophylactic treatment is used, which leads to unnecessary potential complications. A new modality enabling a more accurate risk assessment is needed. Optical coherence tomography (OCT) is a new-generation imaging technology that has astonishing resolution for vascular imaging. In this study, OCT was used for the evaluation of intracranial aneurysms.
   METHODS: In vivo OCT imaging was performed for aneurysms induced in 6 rabbits and in 9 intracranial aneurysm patients. Catheters were cut short to prevent any extra length from damaging aneurysms and tissues. Images of both the parent artery and the aneurysm at multiple viewing angles were obtained using rotational OCT scanning.
   RESULTS: The OCT images of rabbits correlated well with histologic sections. The 3-layered architecture of the parent arteries was explicitly shown. Ruptured intracranial aneurysms manifested complete breakdown of the wall structure; however, this was not observed in any unruptured aneurysms. The OCT images of unruptured intracranial aneurysms demonstrated a trend of degradation by showing the gradual disappearance of the demarcation between the layers or incomplete apoptosis in layer structures.
   CONCLUSION: OCT is the most precise imaging modality because it provides detailed information regarding the aneurysm structures, thus enabling more distinct insight into the vascular construction of intracranial aneurysms.
C1 [Liu, Yingjun; Zheng, Yongtao; An, Qingzhu; Song, Yanbing; Leng, Bing] Fudan Univ, Huashan Hosp, Dept Neurosurg, Shanghai, Peoples R China.
RP Leng, B (reprint author), Fudan Univ, Huashan Hosp, Dept Neurosurg, Shanghai, Peoples R China.
EM lengbing99999@126.com
FU Ministry of Science and Technology of the People's Republic of
   ChinaMinistry of Science and Technology, China [2016YFC0906003]
FX This project was sponsored by the Ministry of Science and Technology of
   the People's Republic of China (grant 2016YFC0906003).
CR Alfonso F, 2014, J AM COLL CARDIOL, V63, P2659, DOI 10.1016/j.jacc.2014.02.545
   Attizzani GF, 2013, J VASC SURG, V58, P201, DOI 10.1016/j.jvs.2012.11.038
   Elsharkawy A, 2013, NEUROSURGERY, V73, P825, DOI 10.1227/NEU.0000000000000116
   Frosen J, 2004, STROKE, V35, P2287, DOI 10.1161/01.STR.0000140636.30204.da
   Fujimoto JG, 1999, HEART, V82, P128, DOI 10.1136/hrt.82.2.128
   Greving JP, 2014, LANCET NEUROL, V13, P59, DOI 10.1016/S1474-4422(13)70263-1
   HAZAMA F, 1986, AM J PATHOL, V124, P399
   Hoffmann T, 2016, INT J COMPUT ASS RAD, V11, P231, DOI 10.1007/s11548-015-1275-1
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Ingall T, 2000, STROKE, V31, P1054, DOI 10.1161/01.STR.31.5.1054
   Jang IK, 2002, J AM COLL CARDIOL, V39, P604, DOI 10.1016/S0735-1097(01)01799-5
   Kataoka K, 1999, STROKE, V30, P1396, DOI 10.1161/01.STR.30.7.1396
   Keedy Alexander, 2006, Mcgill J Med, V9, P141
   KIM C, 1988, STROKE, V19, P507, DOI 10.1161/01.STR.19.4.507
   Kyle R A, 1981, JAMA, V246, P880, DOI 10.1001/jama.246.8.880
   Lopes DK, 2012, J NEUROINTERV SURG, V4, P291, DOI 10.1136/neurintsurg-2011-010102
   Malmivaara K, 2012, EUR J NEUROL, V19, P1455, DOI 10.1111/j.1468-1331.2012.03744.x
   Mathews MS, 2011, NEUROSURGERY, V69, P430, DOI 10.1227/NEU.0b013e318212bcb4
   Nieuwkamp DJ, 2013, INT J STROKE, V8, P90, DOI 10.1111/ijs.12006
   Nieuwkamp DJ, 2009, LANCET NEUROL, V8, P635, DOI 10.1016/S1474-4422(09)70126-7
   Rinkel GJE, 1998, STROKE, V29, P251, DOI 10.1161/01.STR.29.1.251
   SCANARINI M, 1978, ACTA NEUROCHIR, V43, P171, DOI 10.1007/BF01587953
   Tearney GJ, 2012, J AM COLL CARDIOL, V59, P1058, DOI 10.1016/j.jacc.2011.09.079
   Thorell WE, 2005, J NEUROSURG, V102, P348, DOI 10.3171/jns.2005.102.2.0348
   Viswanathan GN, 2014, JACC-CARDIOVASC INTE, V7, P336, DOI 10.1016/j.jcin.2013.06.022
   Vlak MHM, 2011, LANCET NEUROL, V10, P626, DOI 10.1016/S1474-4422(11)70109-0
   Wiebers D, 2003, LANCET, V362, P103, DOI 10.1016/S0140-6736(03)13860-3
   Yabushita H, 2002, CIRCULATION, V106, P1640, DOI 10.1161/01.CIR.0000029927.92825.F6
NR 28
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E194
EP E201
DI 10.1016/j.wneu.2018.11.123
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400024
PM 30476668
DA 2020-05-12
ER

PT J
AU Liu, YY
   Zhu, GY
   Jian, Y
   Wang, X
   Chen, YC
   Meng, FG
   Zhang, K
   Yang, AC
   Liu, HG
   Zhan, X
   Zhang, JG
AF Liu, Yuye
   Zhu, Guanyu
   Jian, Yin
   Wang, Xiu
   Chen, Yingchuan
   Meng, Fangang
   Zhang, Kai
   Yang, Anchao
   Liu, Huanguang
   Zhan, Xin
   Zhang, Jianguo
TI Comparison of Short-Term Stimulation of the Globus Pallidus Interna and
   Subthalamic Nucleus for Treatment of Primary Dystonia
SO WORLD NEUROSURGERY
LA English
DT Article
DE Deep brain stimulation (DBS); Globus pallidus internus (GPi); Primary
   dystonia; Subthalamic nucleus (STN)
ID DEEP-BRAIN-STIMULATION; FOLLOW-UP; PARKINSONS-DISEASE; BASAL GANGLIA;
   MULTICENTER
AB OBJECTIVE: To compare the efficacy and side effects of bilateral globus pallidus internus (GPi) and subthalamic nucleus (STN) deep brain stimulation (DBS) in the same patient with primary dystonia.
   METHODS: Patients with primary dystonia from the department of functional neurosurgery in Beijing Tiantan Hospital were recruited for the study. Four electrodes were bilaterally implanted in the GPi and STN. A trial stimulation was applied to determine the preliminary therapeutic effects. Five evaluations were conducted: preoperative, postoperative (before stimulation), after sham stimulation, and after stimulation for 24 hours of GPi and STN using optimal parameters, judged by the Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS).
   RESULTS: The BFMDRS movement score decreased after both short-term GPi stimulation (from 15.3 +/- 6.9 to 7.6 +/- 4.2, P < 0.05) and short-term STN stimulation (from 15.3 +/- 6.9 to 8.6 +/- 5.0, P < 0.05). There were significant reductions in facial (eyes and mouth) movement scores after short-term GPi and STN DBS compared with baseline (P < 0.05), but not in cervical symptoms (P > 0.05). The cervical symptoms of tonic dystonia had an improvement after long-term DBS treatment (P < 0.05). There were more adverse events with STN DBS; however, most side effects could be ameliorated by adjusting stimulation parameters.
   CONCLUSIONS: Both short-term GPi and STN stimulation improved the motor symptoms of dystonia, but there was no significant difference between GPi DBS and STN DBS. There were more side effects associated with STN stimulation.
C1 [Liu, Yuye; Zhu, Guanyu; Wang, Xiu; Chen, Yingchuan; Meng, Fangang; Zhang, Kai; Yang, Anchao; Liu, Huanguang; Zhang, Jianguo] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing, Peoples R China.
   [Jian, Yin; Meng, Fangang; Zhan, Xin; Zhang, Jianguo] Capital Med Univ, Dept Funct Neurosurg, Beijing Neurosurg Inst, Beijing, Peoples R China.
   [Zhang, Jianguo] Beijing Key Lab Neurostimulat, Beijing, Peoples R China.
RP Zhang, JG (reprint author), Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing, Peoples R China.; Zhang, JG (reprint author), Capital Med Univ, Dept Funct Neurosurg, Beijing Neurosurg Inst, Beijing, Peoples R China.; Zhang, JG (reprint author), Beijing Key Lab Neurostimulat, Beijing, Peoples R China.
EM zjguo73@126.com
FU National Key Technology R&D Program of ChinaNational Key Technology R&D
   Program [2016YFC0105902]; Beijing Municipal Administration of Hospitals'
   Ascent Plan [DFL20150503]; Beijing Municipal Science and Technology
   CommissionBeijing Municipal Science & Technology Commission
   [Z161100000216130]; National Natural Science Foundation of ChinaNational
   Natural Science Foundation of China [81671104]
FX This study was supported by the National Key Technology R&D Program of
   China (2016YFC0105902), Beijing Municipal Administration of Hospitals'
   Ascent Plan (DFL20150503), Beijing Municipal Science and Technology
   Commission (Z161100000216130), and National Natural Science Foundation
   of China (81671104).
CR ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041
   Cao CY, 2013, MOVEMENT DISORD, V28, P1877, DOI 10.1002/mds.25586
   Charlesworth G, 2013, CURR OPIN NEUROL, V26, P406, DOI 10.1097/WCO.0b013e3283633696
   Comella CL, 2018, PARKINSONISM RELAT D, V46, pS66, DOI 10.1016/j.parkreldis.2017.06.025
   Hariz MI, 2008, MOVEMENT DISORD, V23, P416, DOI 10.1002/mds.21888
   Jahanshahi M, 2011, MOVEMENT DISORD, V26, pS68, DOI 10.1002/mds.23511
   Kiss ZHT, 2007, BRAIN, V130, P2879, DOI 10.1093/brain/awm229
   LeDoux MS, 2009, PARKINSONISM RELAT D, V15, P483, DOI 10.1016/j.parkreldis.2009.04.006
   Mahlknecht P, 2017, MOVEMENT DISORD, V32, P1174, DOI 10.1002/mds.27042
   Moro E, 2017, EUR J NEUROL, V24, P552, DOI 10.1111/ene.13255
   MUNDINGER F, 1977, MED KLIN, V72, P1982
   Okun MS, 2009, ANN NEUROL, V65, P586, DOI 10.1002/ana.21596
   Ostrem JL, 2017, NEUROLOGY, V88, P25, DOI 10.1212/WNL.0000000000003451
   Roubertie A, 2012, EUR J NEUROL, V19, P1292, DOI 10.1111/j.1468-1331.2011.03649.x
   Schjerling L, 2013, J NEUROSURG, V119, P1537, DOI 10.3171/2013.8.JNS13844
   Sudhyadhom A, 2007, CURR NEUROL NEUROSCI, V7, P278, DOI 10.1007/s11910-007-0043-1
   Tolosa E, 1988, Adv Neurol, V49, P73
   Vercueil L, 2001, J NEUROL, V248, P695, DOI 10.1007/s004150170116
   Vidailhet M, 2005, NEW ENGL J MED, V352, P459, DOI 10.1056/NEJMoa042187
   Vidailhet M, 2007, LANCET NEUROL, V6, P223, DOI 10.1016/S1474-4422(07)70035-2
   Volkmann J, 2012, LANCET NEUROL, V11, P1029, DOI 10.1016/S1474-4422(12)70257-0
   Wang X, 2016, NEUROMODULATION, V19, P818, DOI 10.1111/ner.12345
   Wichmann T, 2016, NEUROTHERAPEUTICS, V13, P264, DOI 10.1007/s13311-016-0426-6
   Yelnik J, 2002, MOVEMENT DISORD, V17, pS15, DOI 10.1002/mds.10138
   Zhang JG, 2006, CHINESE MED J-PEKING, V119, P2069, DOI 10.1097/00029330-200612020-00008
   Zhao XM, 2017, J CRYST GROWTH, V470, P1, DOI 10.1016/j.jcrysgro.2017.03.051
NR 26
TC 3
Z9 3
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E211
EP E217
DI 10.1016/j.wneu.2018.11.137
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400026
PM 30481618
DA 2020-05-12
ER

PT J
AU Ma, J
   Bao, L
   Xia, XH
   Feng, QP
   Zhou, Y
   Wang, YX
   Cao, Z
AF Ma, Jin
   Bao, Lei
   Xia, Xiaohua
   Feng, Qiupeng
   Zhou, Yan
   Wang, Yingxin
   Cao, Zhen
TI miR-128b Promotes Cerebral Infarction by Regulating the Expressions of
   BCL-2 and CAPASE 3
SO WORLD NEUROSURGERY
LA English
DT Article
DE Apoptosis; BCL-2; CAPASE 3; Cerebral infarction; miR-128b
ID APOPTOSIS; BRAIN; MODEL; RATS
AB OBJECTIVE: To investigate the effect of miR-128b on apoptosis and BCL-2 and CAPASE 3 expression in a rat middle cerebral artery occlusion (MCAO) model.
   METHODS: The MCAO model was established by the thread embolism method. miR-128b agomir and antagomir were injected into the ventricle of MCAO rats by stereotaxic intracerebral injection. Then the rats were divided into a sham group, model group, miR-128b agomir group, and miR-128b antagomir group. Zea Longa was used to score the modeling rats. The area of cerebral infarction was assessed by 2,3,5-triphenyltetrazolium chloride staining. Apoptosis was detected by terminal deoxynucleotidyl transferase dUTP nick end labeling assay. The miR-128b relative expression was detected by real-time polymerase chain reaction. The expressions of BCL-2 and CAPASE 3 were detected by immunohistochemistry and Western blotting.
   RESULTS: The MCAO model was constructed successfully. The expressions of miR-128b in the MCAO groups were higher than that of the sham group (P < 0.05). Compared with the model group, the cerebral infarction area in the miR-128b agomir group was significantly bigger and that of the miR-128b antagomir group was smaller (P < 0.05). The number of apoptotic cells in the miR-128b agomir group was more and that of miR-128b antagomir group was less (P < 0.05 vs. model group). The BCL-2 expression reduced and CAPASE 3 expression increased in the MCAO groups (P < 0.05 vs. sham group). Compared with the model group, the Bcl-2 expression decreased and Caspase 3 expression increased in the miR-128b agomir group, and those in the miR-128b antagomir group were opposite.
   CONCLUSIONS: miR-128b promoted cerebral infarction in MCAO rats by regulating Bcl-2 and Caspase 3 expression.
C1 [Ma, Jin; Bao, Lei; Xia, Xiaohua; Feng, Qiupeng; Zhou, Yan; Wang, Yingxin; Cao, Zhen] First Peoples Hosp Kunshan, Dept Emergency Med, Kunshan City, Jiangsu, Peoples R China.
RP Cao, Z (reprint author), First Peoples Hosp Kunshan, Dept Emergency Med, Kunshan City, Jiangsu, Peoples R China.
EM caozhen256@163.com
CR Bai X, 2017, CHINESE J PHARM TOXI, V31, P985
   Chen J, 2012, CNS NEUROSCI THER, V18, P847, DOI 10.1111/j.1755-5949.2012.00382.x
   Cheng CY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155748
   Gao J, 2017, J BINZHOU MED U, V40, P33
   GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493
   Guidi M, 2010, BMC MOL BIOL, V11, DOI 10.1186/1471-2199-11-95
   Homi HM, 2010, J THORAC CARDIOV SUR, V140, P660, DOI 10.1016/j.jtcvs.2009.10.063
   Hu PF, 2018, MOL MED REP, V17, P6194, DOI 10.3892/mmr.2018.8631
   Jeyaseelan K, 2008, STROKE, V39, P959, DOI 10.1161/STROKEAHA.107.500736
   Khaksari M, 2012, J MOL NEUROSCI, V48, P201, DOI 10.1007/s12031-012-9808-3
   Nguyen MA, 2018, ARTERIOSCL THROM VAS, V38, P49, DOI 10.1161/ATVBAHA.117.309795
   Peng J, 2017, J APOPLEXY NERVOUS D, V34, P217
   Peng JH, 2017, J HENAN U SCI TECHNO, V35, P85
   Song Y, 2018, EUR REV MED PHARMACO, V22, P250, DOI 10.26355/eurrev_201801_14126
   Springer JE, 2000, J NEUROSCI, V20, P7246
   Sun DW, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0229-7
   Sun YH, 2015, EXP THER MED, V10, P133, DOI 10.3892/etm.2015.2462
   Sun YuJie, 2018, Journal of Hainan Medical University, V24, P5
   Wang J, 2018, EXP THER MED, V15, P1263, DOI 10.3892/etm.2017.5577
   Wang P, 2015, BIOCHEM BIOPH RES CO, V467, P798, DOI 10.1016/j.bbrc.2015.10.062
   Wang XP, 2013, PRACTICAL J CLIN MED, V10, P53
   Wu N, 2011, ACTA PHARMACOL SIN, V32, P345, DOI 10.1038/aps.2010.220
   Yin J, 2017, EXP THER MED, V14, P2751, DOI 10.3892/etm.2017.4886
   Zhang H, 2017, J MODERN CLIN MED, V43, P413
   Zhang Z, 2014, EXPRESSION CHANGES P
   Zhao WJ, 2017, MOL MED REP, V16, P5434, DOI 10.3892/mmr.2017.7230
   Zhou L, 2017, INT J IMMUNOPATH PH, V30, P123, DOI 10.1177/0394632017703274
NR 27
TC 1
Z9 1
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E245
EP E251
DI 10.1016/j.wneu.2018.11.144
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400030
PM 30481625
DA 2020-05-12
ER

PT J
AU Malik, AT
   Yu, E
   Kim, J
   Khan, SN
AF Malik, Azeem Tariq
   Yu, Elizabeth
   Kim, Jeffery
   Khan, Safdar N.
TI Discharge to Inpatient Care Facility Following Revision Posterior Lumbar
   Fusions-Risk Factors and Postdischarge Outcomes
SO WORLD NEUROSURGERY
LA English
DT Article
DE Discharge destination; NSQIP; Revision posterior lumbar fusions;
   Revision spine
ID TOTAL KNEE ARTHROPLASTY; SPINAL-FUSION; DESTINATION; MORBIDITY;
   COMPLICATIONS; MORTALITY
AB BACKGROUND: Recent literature has denoted care in an inpatient facility after discharge to be linked with worse outcomes after elective primary lumbar and cervical fusions. No study has explored the risk factors and associated postdischarge outcomes after discharge to inpatient facility after revision posterior lumbar fusion.
   METHODS: The 2012-2016 American College of Surgeons-National Surgical Quality Improvement Program were queried using Current Procedural Terminology codes for posterior lumbar fusions (22630, 22633, 22614) combined with Current Procedural Terminology codes for revision-22830 (exploration of spinal fusion), 22849 (reinsertion of spinal fixation device), 22850 (removal of posterior nonsegmental instrumentation), and 22852 (removal of posterior segmental instrumentation).
   RESULTS: Of 1170 patients who underwent revision posterior lumbar fusion, 253 (21.6%) were discharged to an inpatient care facility and 917 (78.4%) were discharged to home. Significant risk factors associated with discharge to inpatient care facility were age 60-69 years (odds ratio [OR] 3.62), age >= 70 years (OR 7.46), female gender (OR 1.61), partially dependent functional health status before surgery (OR 2.94), history of chronic obstructive pulmonary disease (OR 1.92), a length of stay >3 days (OR 3.13), and the occurrence of any predischarge complication (OR 4.10). Discharge to inpatient care facilities versus home was associated with a higher risk of experiencing any postdischarge complication (8.3% vs. 3.2%; OR 2.2).
   CONCLUSIONS: Providers should understand the need of construction of care pathways and reducing discharge to inpatient facilities to mitigate the risks of experiencing adverse outcomes and consequently reduce the financial burden on the health care system.
C1 [Malik, Azeem Tariq; Yu, Elizabeth; Kim, Jeffery; Khan, Safdar N.] Ohio State Univ, Dept Orthopaed, Wexner Med Ctr, Columbus, OH 43210 USA.
RP Khan, SN (reprint author), Ohio State Univ, Dept Orthopaed, Wexner Med Ctr, Columbus, OH 43210 USA.
EM Safdar.Khan@osumc.edu
CR ACS NSQIP, 2016, PART US FIL PUF US G
   Aldebeyan S, 2016, SPINE, V41, P1535, DOI 10.1097/BRS.0000000000001575
   Ali R, 2016, J NEUROSURG-SPINE, V25, P537, DOI 10.3171/2015.10.SPINE14582
   Basques BA, 2017, CLIN SPINE SURG, V30, pE770, DOI 10.1097/BSD.0000000000000391
   Culler SD, 2016, SPINE, V41, P1613, DOI 10.1097/BRS.0000000000001641
   Fu MC, 2017, J ARTHROPLASTY, V32, pS144, DOI 10.1016/j.arth.2017.03.044
   Halawi MJ, 2015, J ARTHROPLASTY, V30, P539, DOI 10.1016/j.arth.2014.10.031
   Hernandez VH, 2015, J ARTHROPLASTY, V30, P34, DOI 10.1016/j.arth.2015.06.008
   Kalakoti P, 2016, WORLD NEUROSURG, V85, P114, DOI 10.1016/j.wneu.2015.08.020
   Kapella MC, 2011, MED SCI SPORT EXER, V43, P218, DOI 10.1249/MSS.0b013e3181eb6024
   Kimball CC, 2018, J ARTHROPLASTY, V33, P3130, DOI 10.1016/j.arth.2018.06.020
   Ma Y, 2010, SPINE J, V10, P881, DOI 10.1016/j.spinee.2010.07.391
   Malik AT, 2018, CLIN SPINE SURG, V31, pE453, DOI 10.1097/BSD.0000000000000700
   Malik Azeem Tariq, 2018, J Spine Surg, V4, P264, DOI 10.21037/jss.2018.05.25
   McLawhorn AS, 2017, J ARTHROPLASTY, V32, pS113, DOI 10.1016/j.arth.2017.01.039
   Rajaee SS, 2014, BONE JOINT J, V96B, P807, DOI 10.1302/0301-620X.96B6.31149
   Schwarzkopf R, 2016, GERIATR ORTHOP SURG, V7, P95, DOI 10.1177/2151458516645635
NR 17
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E482
EP E487
DI 10.1016/j.wneu.2018.11.191
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400056
PM 30500577
DA 2020-05-12
ER

PT J
AU Mao, CL
   Chen, FL
   Li, YW
   Jiang, XM
   Liu, SC
   Guo, HG
   Huang, L
   Wei, XJ
   Liang, ZL
   Li, WY
   Tang, K
AF Mao, Chengliang
   Chen, Feili
   Li, Yanwen
   Jiang, Xinmiao
   Liu, Sichu
   Guo, Hanguo
   Huang, Ling
   Wei, Xiaojuan
   Liang, Zhanli
   Li, Wenyu
   Tang, Kai
TI Characteristics and Outcomes of Primary Central Nervous System Lymphoma:
   A Retrospective Study of 91 Cases in a Chinese Population
SO WORLD NEUROSURGERY
LA English
DT Article
DE Chemotherapy; Craniotomy; Primary central nervous system lymphoma;
   Radiotherapy
ID PRIMARY CNS LYMPHOMA; STEM-CELL TRANSPLANTATION; HIGH-DOSE METHOTREXATE;
   INTERNATIONAL EXTRANODAL LYMPHOMA; WHOLE-BRAIN RADIOTHERAPY; 1ST-LINE
   TREATMENT; RADIATION-THERAPY; SINGLE-CENTER; TEMOZOLOMIDE; RITUXIMAB
AB BACKGROUND: Primary central nervous system lymphoma (PCNSL) is a rare disease affecting the brain, leptomeninges, spinal cord, cerebrospinal fluid, or vitreoretinal compartment, without evidence of systemic disease. Prognosis is still poor after intensive methotrexate-based chemotherapy.
   METHODS: Clinical data of 91 patients treated in a tertiary referral center during a 13-year period were retrospectively reviewed.
   RESULTS: The estimated median progression-free survival and overall survival (OS) for the entire cohort were 39.1 months (95% confidence interval [CI], 14.1-64.0 months) and 54.5 months (95% CI, 28.9-80.1 months), respectively. Estimated 5-year progression-free survival and OS were 37.0% +/- 6.5% and 47.5% +/- 7.5%. Survival was associated with cycles of methotrexate only in multivariate analysis. Seventy-four patients received methotrexate-based chemotherapy after diagnosis. Thirty-nine patients experienced disease progression. Patients with relapsed/refractory disease had a poor survival, with median second OS (calculated from the date of first disease progression to the time of death from any cause) being 7.2 months (95% CI, 2.5-12.00 months). Three patients responded to ibrutinib after disease progression and incurred no fungal infection.
   CONCLUSIONS: The outcomes of patients with PCNSL treated in our cohort are still poor. Relapse or refractory PCNSL and those not tolerating aggressive chemotherapy urgently require new approaches to improve their still dismal prognosis. Novel agents such as ibrutinib have shown promising clinical activity. Future studies should focus on the predictive biomarkers for the treatment of PCNSL with novel agents to provide precision medicine for PCNSL.
C1 [Mao, Chengliang; Li, Yanwen; Wei, Xiaojuan; Tang, Kai] Guangdong Acad Med Sci, Guangdong Gen Hosp, Div Neurosurg, Guangzhou, Guangdong, Peoples R China.
   [Chen, Feili; Jiang, Xinmiao; Liu, Sichu; Guo, Hanguo; Huang, Ling; Liang, Zhanli; Li, Wenyu] Guangdong Acad Med Sci, Guangdong Gen Hosp, Div Lymphoma, Guangzhou, Guangdong, Peoples R China.
RP Tang, K (reprint author), Guangdong Acad Med Sci, Guangdong Gen Hosp, Div Neurosurg, Guangzhou, Guangdong, Peoples R China.
EM neurosurgery80411@163.com
FU Guangdong Provincial Department of Science and Technology Fund Project
   [2016A050502028]
FX This article was supported by Guangdong Provincial Department of Science
   and Technology Fund Project (to W.L., grant number 2016A050502028).
CR Abramson JS, 2017, NEW ENGL J MED, V377, P783, DOI 10.1056/NEJMc1704610
   Bellinzona M, 2005, EJSO, V31, P100, DOI 10.1016/j.ejso.2004.10.002
   Carnevale J, 2016, HEMATOL ONCOL CLIN N, V30, P1293, DOI 10.1016/j.hoc.2016.07.013
   Chamoun K, 2017, NEUROLOGY, V88, P101, DOI 10.1212/WNL.0000000000003420
   Correa DD, 2012, NEURO-ONCOLOGY, V14, P101, DOI 10.1093/neuonc/nor186
   DAVIES KG, 1994, BRIT J NEUROSURG, V8, P487, DOI 10.3109/02688699408995120
   Dolecek TA, 2012, NEURO-ONCOLOGY, V14, pv1, DOI 10.1093/neuonc/nos218
   Evers G, 2017, WORLD NEUROSURG, V98, P375, DOI 10.1016/j.wneu.2016.11.011
   Ferreri AJM, 2003, J CLIN ONCOL, V21, P266, DOI 10.1200/JCO.2003.09.139
   Ferreri AJM, 2017, LANCET HAEMATOL, V4, pE510, DOI 10.1016/S2352-3026(17)30174-6
   Ferreri AJM, 2016, LANCET HAEMATOL, V3, pE217, DOI 10.1016/S2352-3026(16)00036-3
   Ferreri AJM, 2009, LANCET, V374, P1512, DOI 10.1016/S0140-6736(09)61416-1
   Ferreri AJM, 2017, HEMATOL-AM SOC HEMAT, P565, DOI 10.1182/asheducation-2017.1.565
   Fritsch K, 2011, ANN ONCOL, V22, P2080, DOI 10.1093/annonc/mdq712
   Glass J, 2016, J CLIN ONCOL, V34, P1620, DOI 10.1200/JCO.2015.64.8634
   Grommes C, 2017, CANCER DISCOV, V7, P1018, DOI 10.1158/2159-8290.CD-17-0613
   Grommes C, 2017, CANCER CELL, V31, P731, DOI 10.1016/j.ccell.2017.05.004
   Herrlinger U, 2002, NEUROLOGY, V58, P1573, DOI 10.1212/WNL.58.10.1573
   Holdhoff M, 2014, NEUROLOGY, V83, P235, DOI 10.1212/WNL.0000000000000593
   Houillier C, 2017, J NEURO-ONCOL, V133, P315, DOI 10.1007/s11060-017-2435-7
   Houillier C, 2015, NEUROLOGY, V84, P325, DOI 10.1212/WNL.0000000000001158
   Illerhaus G, 2006, J CLIN ONCOL, V24, P3865, DOI 10.1200/JCO.2006.06.2117
   Jelicic J, 2016, BRIT J NEUROSURG, V30, P80, DOI 10.3109/02688697.2015.1071328
   Kansara R, 2015, AM J HEMATOL, V90, P1149, DOI 10.1002/ajh.24204
   Kasenda B, 2012, ANN ONCOL, V23, P2670, DOI 10.1093/annonc/mds059
   Kiefer T, 2012, ANN ONCOL, V23, P1809, DOI 10.1093/annonc/mdr553
   Korfel A, 2015, NEUROLOGY, V84, P1242, DOI 10.1212/WNL.0000000000001395
   Kurzwelly D, 2010, J NEURO-ONCOL, V97, P389, DOI 10.1007/s11060-009-0032-0
   Lakshmanan A, 2017, CANCER DISCOV, V7, P940, DOI 10.1158/2159-8290.CD-17-0714
   Liu BL, 2009, ONCOL REP, V22, P439, DOI 10.3892/or_00000455
   Madle M, 2015, ANN HEMATOL, V94, P1853, DOI 10.1007/s00277-015-2470-4
   Nayak L, 2017, BLOOD, V129, P3071, DOI 10.1182/blood-2017-01-764209
   Omuro A, 2015, LANCET HAEMATOL, V2, pE251, DOI 10.1016/S2352-3026(15)00074-5
   Omuro AMP, 2007, J NEURO-ONCOL, V85, P207, DOI 10.1007/s11060-007-9397-0
   Pulczynski EJ, 2015, HAEMATOLOGICA, V100, P534, DOI 10.3324/haematol.2014.108472
   Rae AI, 2019, NEUROSURGERY, V84, P935, DOI 10.1093/neuros/nyy096
   Reni M, 2000, J NATL CANCER I, V92, P575, DOI 10.1093/jnci/92.7.575
   Rubenstein JL, 2018, BLOOD ADV, V2, P1595, DOI 10.1182/bloodadvances.2017014845
   Rubenstein JL, 2013, J CLIN ONCOL, V31, P3061, DOI 10.1200/JCO.2012.46.9957
   Rubenstein JL, 2005, HEMATOL ONCOL CLIN N, V19, P705, DOI 10.1016/j.hoc.2005.05.012
   Salamoon M, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0690-9
   Schultz C, 1996, J CLIN ONCOL, V14, P556, DOI 10.1200/JCO.1996.14.2.556
   Siegal T, 2014, J CLIN NEUROSCI, V21, P709, DOI 10.1016/j.jocn.2014.02.002
   Wang XX, 2014, LEUKEMIA LYMPHOMA, V55, P2497, DOI 10.3109/10428194.2014.889823
   Weller M, 2012, NEURO-ONCOLOGY, V14, P1481, DOI 10.1093/neuonc/nos159
   Wong SF, 2012, J CLIN NEUROSCI, V19, P1501, DOI 10.1016/j.jocn.2012.04.001
NR 46
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E15
EP E24
DI 10.1016/j.wneu.2018.10.034
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400004
PM 30326304
DA 2020-05-12
ER

PT J
AU Meng, XL
   Zhou, SY
   Wan, JH
AF Meng, Xiaoli
   Zhou, Shengyu
   Wan, Jinghai
TI Primary Lymphoma of the Skull Base in the Chinese: Clinical,
   Radiological, Pathological, and Therapeutic Experience in a Series of 8
   Patients
SO WORLD NEUROSURGERY
LA English
DT Article
DE Chemotherapy; Diagnosis; Lymphoma; Non-Hodgkin; Radiotherapy; Skull base
   neoplasm
ID NON-HODGKINS-LYMPHOMA; NERVOUS-SYSTEM LYMPHOMA; B-CELL LYMPHOMA;
   MALIGNANT-LYMPHOMA; RESPONSE CRITERIA; MIMICKING; CLIVUS; MR
AB BACKGROUND: Primary lymphoma of the skull base (PLSB) is an extremely rare neoplasm and not much is known regarding the clinical features of, treatment strategies for, and prognoses of these lesions. We investigated the manifestations and clinical outcomes of Chinese patients with PLSB.
   METHODS: We retrospectively reviewed the data from 8 consecutive patients with PLSB who had been treated at our center from October 2008 to December 2016 and analyzed their clinical features, treatment strategies, and prognoses.
   RESULTS: Of the 8 patients, 3 were men and 5 were women, with a male/female ratio of 0.6. The median age was 53.5 years. In most instances, the onset was characterized by headache, followed by dysfunction of the cranial nerves. The most frequently affected region was the cavernous sinus. On magnetic resonance imaging, the main characteristic was that the internal carotid artery was encased by the tumor without an obvious tendency to be deformed, dislocated, or narrowed. All patients underwent surgical biopsy via a transsphenoidal or sublabiale-transmaxillary approach. The pathological diagnosis was non-Hodgkin lymphoma for all 8 patients, with diffuse large B-cell lymphoma in 7 patients. The patients underwent chemotherapy and involved-field radiotherapy. The median overall survival was 52 months, and the 1-year progression-free survival rate was 87.5%.
   CONCLUSIONS: PLSB is a rare disease and a diagnostic challenge, with most cases in the Chinese due to diffuse large B-cell lymphoma. We found that the incidence peaked in middle and old age, and the cavernous sinus was usually affected. Multidisciplinary treatment involving surgical biopsy, chemotherapy, and radiotherapy was an effective therapeutic strategy.
C1 [Meng, Xiaoli; Wan, Jinghai] Chinese Acad Med Sci, Natl Canc Ctr, Natl Clin Res Ctr Canc, Dept Neurosurg,Canc Hosp, Beijing, Peoples R China.
   [Zhou, Shengyu] Chinese Acad Med Sci, Natl Canc Ctr, Natl Clin Res Ctr Canc, Dept Med Oncol,Canc Hosp, Beijing, Peoples R China.
   [Meng, Xiaoli; Wan, Jinghai] Peking Union Med Coll, Dept Neurosurg, Beijing, Peoples R China.
   [Zhou, Shengyu] Peking Union Med Coll, Dept Med Oncol, Beijing, Peoples R China.
RP Wan, JH (reprint author), Chinese Acad Med Sci, Natl Canc Ctr, Natl Clin Res Ctr Canc, Dept Neurosurg,Canc Hosp, Beijing, Peoples R China.; Wan, JH (reprint author), Peking Union Med Coll, Dept Neurosurg, Beijing, Peoples R China.
EM Wanjinghai@sina.com
FU Beijing Hope Run Special Fund of Cancer Foundation of China [LC2015L15,
   LC2014B16]
FX The present study was supported by the Beijing Hope Run Special Fund of
   Cancer Foundation of China (grants LC2015L15 and LC2014B16).
CR Abramson JS, 2013, J NATL COMPR CANC NE, V11, P671, DOI 10.6004/jnccn.2013.0198
   Abrey LE, 2005, J CLIN ONCOL, V23, P5034, DOI 10.1200/JCO.2005.13.524
   Ang JWJ, 2015, J CLIN NEUROSCI, V22, P1188, DOI 10.1016/j.jocn.2015.01.018
   CEYHAN M, 1994, PEDIATR NEUROL, V10, P67, DOI 10.1016/0887-8994(94)90071-X
   Chen SM, 2008, J CLIN NEUROSCI, V15, P1148, DOI 10.1016/j.jocn.2007.08.021
   Cheson BD, 2007, J CLIN ONCOL, V25, P579, DOI 10.1200/JCO.2006.09.2403
   Choi HK, 2008, PEDIATR RADIOL, V38, P863, DOI 10.1007/s00247-008-0912-z
   Dare AO, 2001, SKULL BASE-INTERD AP, V11, P129, DOI 10.1055/s-2001-14433
   Erlich RB, 1996, LEUKEMIA LYMPHOMA, V23, P395, DOI 10.3109/10428199609054844
   Ferreri AJM, 2002, NEUROLOGY, V58, P1513, DOI 10.1212/WNL.58.10.1513
   Ferreri AJM, 2017, LANCET HAEMATOL, V4, pE510, DOI 10.1016/S2352-3026(17)30174-6
   Grau S, 2010, WORLD NEUROSURG, V74, P513, DOI 10.1016/j.wneu.2010.06.020
   HAN MH, 1993, J COMPUT ASSIST TOMO, V17, P567, DOI 10.1097/00004728-199307000-00009
   Hans FJ, 2005, NEURORADIOLOGY, V47, P539, DOI 10.1007/s00234-005-1394-4
   Hirschmann JV, 1997, CLIN INFECT DIS, V24, P291, DOI 10.1093/clinids/24.3.291
   Jaiswal A K, 2000, J Neurosurg Sci, V44, P145
   Jamshidi Pouya, 2013, Surg Neurol Int, V4, P57, DOI 10.4103/2152-7806.110656
   Jiayu L, 2016, ZHONG GUO WEI QIN XI, P458
   Jung CS, 2004, ACTA NEUROCHIR, V146, P533, DOI 10.1007/s00701-004-0244-1
   Kanumuri VV, 2014, AM J OTOLARYNG, V35, P154, DOI 10.1016/j.amjoto.2013.09.003
   LISTER TA, 1989, J CLIN ONCOL, V7, P1630, DOI 10.1200/JCO.1989.7.11.1630
   Marinelli JP, 2018, OTOLARYNG HEAD NECK, V159, P643, DOI 10.1177/0194599818773994
   Nakamura A, 2009, J NEUROIMAGING, V19, P295, DOI 10.1111/j.1552-6569.2008.00264.x
   Nakatomi H, 1996, SURG NEUROL, V46, P272, DOI 10.1016/0090-3019(96)00159-0
   OYAMA H, 1992, JPN J CLIN ONCOL, V22, P131
   Perera C, 2014, BRIT J NEUROSURG, V28, P278, DOI 10.3109/02688697.2013.835374
   Pesce A, 2017, J NEUROL SURG PART A, V78, P60, DOI 10.1055/s-0035-1571160
   Pine RR, 2013, ORBIT, V32, P45, DOI 10.3109/01676830.2012.736603
   Roman-Goldstein SM, 1998, NEUROSURGERY, V43, P613, DOI 10.1097/00006123-199809000-00119
   Sehn LH, 2012, CANCER J, V18, P421, DOI 10.1097/PPO.0b013e31826c5907
   Tsai VW, 2002, SURG NEUROL, V58, P246, DOI 10.1016/S0090-3019(02)00845-5
   von Elm E, 2008, J CLIN EPIDEMIOL, V61, P344, DOI 10.1016/j.jclinepi.2007.11.008
   Wang L, 2013, CLIN NEUROL NEUROSUR, V115, P237, DOI 10.1016/j.clineuro.2012.05.014
   [王亮 Wang Liang], 2010, [中华神经外科杂志, Chinese Journal of Neurosurgery], V26, P980
   Yang L, 2015, INT J CLIN EXP MED, V8, P10091
   Yao Bo, 2006, Zhonghua Zhongliu Zazhi, V28, P58
   Zhang Hua, 2009, Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, V23, P216
NR 37
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E171
EP E179
DI 10.1016/j.wneu.2018.11.109
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400021
PM 30476664
DA 2020-05-12
ER

PT J
AU Omran, K
   Abdel-Fattah, AS
AF Omran, Khaled
   Abdel-Fattah, Ahmed S.
TI Posterior Extensive Circumferential Decompressive Reconstructive
   Technique in Surgical Treatment of Upper Thoracic Spine Compressive
   Lesions
SO WORLD NEUROSURGERY
LA English
DT Article
DE PECDR; Posterior extensive circumferential decompressive reconstructive;
   UTSCL; Upper thoracic spine compressive lesions
ID TUBERCULOSIS; INSTRUMENTATION; CHEMOTHERAPY; MANAGEMENT
AB BACKGROUND: Complexity in ventral surgical exposure and presence of scapula and large parascapular musculature during posterior surgery are the main obstacles in operative treatment of upper thoracic spine compressive lesions (UTSCLs), such as trauma, tuberculosis, and neoplasm. Recently, the advantages of combined ventrodorsal surgery could be successfully gained using a 1-stage posterior salvage technique with enough accessibility to all 3 spinal columns. This was a retrospective evaluation of 35 patients with UTSCLs treated by the posterior extensive circumferential decompressive reconstructive (PECDR) procedure.
   METHODS: Traumatic, tuberculosis, and neoplastic lesions were involved between 2009 and 2012. All patients were examined pre- and postoperatively and during follow-up clinically (pain by visual analog scale), neurologically (sensory and motor deficit by American Spinal Injury Association grading), functionally (Oswestry Disability Index), radiologically (kyphosis correction, loss of correction, and fusion time), and with laboratory investigations in patients with tuberculosis. Two authors plus an independent observer performed the final clinical, neurologic, and radiologic examination. Operative time, hospital stay, blood loss, and complications were documented.
   RESULTS: The mean follow-up period was 36 +/- 5.5 months. Local symptoms, deformity correction, and neurologic recovery significantly improved postoperatively. Solid fusion was evident in 32 cases. No major complications were reported. Three patients developed wound infection and 3 had intercostal neuralgia; both complications were resolved uneventfully and did not influence the outcomes.
   CONCLUSIONS: Because of difficult ventral exposure, the PECDR technique is a feasible tool for maintained deformity correction, bony fusion, thecal decompression, and functional improvement in surgical treatment of UTSCLs. However, tuberculosis had better satisfactory results than traumatic and neoplastic lesions.
C1 [Omran, Khaled] Minia Univ Hosp, Dept Orthoped Surg & Traumatol, El Minia, Egypt.
   Menia Univ, Spine Unit, Fac Med, Minia Univ Hosp, El Minia, Egypt.
RP Omran, K (reprint author), Minia Univ Hosp, Dept Orthoped Surg & Traumatol, El Minia, Egypt.
EM khaled.omran@mu.edu.eg
OI omran, khaled/0000-0002-5024-8165
CR Barcelos ACES, 2013, J NEUROSURG-SPINE, V18, P194, DOI 10.3171/2012.10.SPINE12582
   CAPENER N, 1954, J BONE JOINT SURG BR, V36, P173
   CAUCHOIX J, 1957, Ann R Coll Surg Engl, V21, P234
   Dai LY, 2010, WORLD NEUROSURG, V73, P560, DOI 10.1016/j.wneu.2010.02.023
   He B, 2012, ARCH ORTHOP TRAUM SU, V132, P1407, DOI 10.1007/s00402-012-1565-9
   Jandial Rahul, 2012, Surg Neurol Int, V3, P136, DOI 10.4103/2152-7806.103643
   KONSTAM PG, 1962, BRIT J SURG, V50, P26, DOI 10.1002/bjs.18005021908
   Liu Z, 2016, CLIN NEUROL NEUROSUR, V141, P111, DOI 10.1016/j.clineuro.2016.01.002
   McAfee PC, 1999, J BONE JOINT SURG AM, V81A, P859, DOI 10.2106/00004623-199906000-00014
   Mirnard V, 1894, ORTHOPEDIC REV, V5, P47
   Omran K, 2017, CLIN SPINE SURG, V30, pE1211, DOI 10.1097/BSD.0000000000000485
   Peto HM, 2009, CLIN INFECT DIS, V49, P1350, DOI 10.1086/605559
   SUNDARESAN N, 1984, J NEUROSURG, V61, P686, DOI 10.3171/jns.1984.61.4.0686
   Upadhyay SS, 1996, SPINE, V21, P1898, DOI 10.1097/00007632-199608150-00014
   Xiao ZM, 2007, EUR SPINE J, V16, P439, DOI 10.1007/s00586-006-0239-0
   [肖增明 Xiao Zengming], 2006, [中华骨科杂志, Chinese Journal of Orthopedics], V26, P183
   Xu R, 2000, Am J Orthop (Belle Mead NJ), V29, P37
NR 17
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E501
EP E508
DI 10.1016/j.wneu.2018.11.194
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400058
PM 30521957
DA 2020-05-12
ER

PT J
AU Park, CY
   Hwang, SE
   Jung, NY
   Chang, WS
   Jung, YH
   Chang, JW
AF Park, Chang Kyu
   Hwang, Su Jeong
   Jung, Na Young
   Chang, Won Seok
   Jung, Hyun Ho
   Chang, Jin Woo
TI Magnetoencephalography as a Prognostic Tool in Patients with Medically
   Intractable Temporal Lobe Epilepsy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior temporal lobectomy; Magnetoencephalography; Prognosis; Temporal
   lobe epilepsy
ID BAND ACTIVITY; EEG; MEG; LOCALIZATION; OSCILLATIONS; DISCHARGES
AB BACKGROUND: Most surgical treatments for medically intractable temporal lobe epilepsy are helpful. When a patient has persistent symptoms after surgery, there are no tests that accurately predict whether a patient will have remnant epileptic foci. The aim of this study was to evaluate the usefulness of magnetoencephalography (MEG) as a prognostic tool in patients with temporal lobe epilepsy.
   METHODS: From July 2012 to July 2016, 21 patients underwent preoperative and postoperative MEG at our center. Postoperative MEG was performed within 2 weeks after surgery. We analyzed MEG by estimating the time-frequency component of the signal to define gamma oscillations (GOs), which are an indicator of epileptogenic foci. We analyzed the relationship between GOs on MEG and surgical outcomes.
   RESULTS: Mean follow-up period was 28.3 months (range, 13-44 months). At the last follow-up visit, patients were divided into 2 groups according to surgical outcome. All patients showed spike waves and GOs on preoperative electroencephalography and MEG. In the seizure control group (16 patients), spike waves (2 patients) and GOs (2 patients) were seen postoperatively despite absence of symptoms. In the recurrent seizure group (5 patients), whereas 3 patients showed spike waves, all 5 patients showed GOs on MEG postoperatively. There was a significant association between presence of GOs on postoperative MEG and surgical outcome (P = 0.01).
   CONCLUSIONS: MEG can provide valuable postsurgical information on epileptic foci in patients with recurrent symptoms; GOs on postoperative MEG were especially correlated with epileptic recurrence. Our data show that GOs on postoperative MEG may have prognostic value.
C1 [Park, Chang Kyu] Kyung Hee Univ, Dept Neurosurg, Coll Med, Seoul, South Korea.
   [Hwang, Su Jeong; Jung, Na Young; Chang, Won Seok; Jung, Hyun Ho; Chang, Jin Woo] Yonsei Univ, Severance Hosp, Brain Inst, Seoul, South Korea.
   [Jung, Na Young; Chang, Won Seok; Jung, Hyun Ho; Chang, Jin Woo] Yonsei Univ, Dept Neurosurg, Coll Med, Seoul, South Korea.
RP Chang, JW (reprint author), Yonsei Univ, Severance Hosp, Brain Inst, Seoul, South Korea.; Chang, JW (reprint author), Yonsei Univ, Dept Neurosurg, Coll Med, Seoul, South Korea.
EM jchang@yuhs.ac
OI Chang, Won Seok/0000-0003-3145-4016; Park, Chang Kyu/0000-0002-5935-8264
FU Korea Research Council of Fundamental Science and Technology through a
   Basic Research Project; grant entitled 'Association study between
   biomarkers of the brain degeneration based on functional connectivity
   imaging' from the Korea Institute of Oriental Medicine [K18172]
FX This work was supported by the Korea Research Council of Fundamental
   Science and Technology through a Basic Research Project managed by the
   Korea Research Institute of Standards and Science. This study was
   supported by a grant entitled 'Association study between biomarkers of
   the brain degeneration based on functional connectivity imaging' (No.
   K18172) awarded from the Korea Institute of Oriental Medicine.
CR Assaf BA, 2004, CLIN NEUROPHYSIOL, V115, P2066, DOI 10.1016/j.clinph.2004.04.020
   Barkley GL, 2003, J CLIN NEUROPHYSIOL, V20, P163, DOI 10.1097/00004691-200305000-00002
   BAUMGARTNER C, 1994, ACTA NEUROL SCAND, V89, P91, DOI 10.1111/j.1600-0404.1994.tb05194.x
   Bosnyakova D, 2006, J NEUROSCI METH, V154, P80, DOI 10.1016/j.jneumeth.2005.12.006
   Dalal SS, 2007, P ANN INT IEEE EMBS, P4941, DOI 10.1109/IEMBS.2007.4353449
   Doesburg SM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054943
   Ebersole JS, 1997, EPILEPSIA, V38, pS1, DOI 10.1111/j.1528-1157.1997.tb04533.x
   ENGEL J, 1993, NEUROLOGY, V43, P1612, DOI 10.1212/WNL.43.8.1612
   Fisher RS, 2014, ADV EXP MED BIOL, V813, P3, DOI 10.1007/978-94-017-8914-1_1
   Galicia E, 2009, BRAIN DEV-JPN, V31, P569, DOI 10.1016/j.braindev.2008.08.011
   Gorji A, 2009, CLIN EEG NEUROSCI, V40, P230, DOI 10.1177/155005940904000404
   GUY CN, 1993, PHYSIOL MEAS, V14, pA99, DOI 10.1088/0967-3334/14/4A/018
   Heers M, 2014, EPILEPSY RES, V108, P1195, DOI 10.1016/j.eplepsyres.2014.05.003
   Papanicolaou AC, 2004, J NEUROSURG, V100, P867, DOI 10.3171/jns.2004.100.5.0867
   Perry G, 2014, EPILEPSY RES, V108, P1076, DOI 10.1016/j.eplepsyres.2014.04.012
   Ramey WL, 2013, CLIN NEUROL NEUROSUR, V115, P2411, DOI 10.1016/j.clineuro.2013.09.035
   Rampp S, 2010, EPILEPSIA, V51, P1638, DOI 10.1111/j.1528-1167.2010.02579.x
   Schneider TR, 2008, NEUROIMAGE, V42, P1244, DOI 10.1016/j.neuroimage.2008.05.033
   Srejic LR, 2013, J NEUROSURG, V118, P1098, DOI 10.3171/2013.1.JNS121059
   Sueda K, 2010, EPILEPSY RES, V88, P100, DOI 10.1016/j.eplepsyres.2009.10.002
   Takanashi Y, 1997, Nihon Rinsho, V55 Suppl 1, P389
   Takusa Yuichi, 1999, No To Hattatsu, V31, P48
   Tallon-Baudry C, 1999, TRENDS COGN SCI, V3, P151, DOI 10.1016/S1364-6613(99)01299-1
   Uhlhaas PJ, 2011, PROG BIOPHYS MOL BIO, V105, P14, DOI 10.1016/j.pbiomolbio.2010.10.004
   von Ellenrieder N, 2016, BRAIN TOPOGR, V29, P218, DOI 10.1007/s10548-016-0471-9
   West S, 2016, EPILEPTIC DISORD, V18, P113, DOI 10.1684/epd.2016.0825
   Yoshinaga H, 2008, PEDIATR NEUROL, V39, P48, DOI 10.1016/j.pediatrneurol.2008.03.010
   Zhang Ning, 2007, Zhonghua Nei Ke Za Zhi, V46, P370
   Zhigalov A, 2015, J NEUROSCI, V35, P5385, DOI 10.1523/JNEUROSCI.4880-14.2015
NR 29
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E753
EP E759
DI 10.1016/j.wneu.2018.12.024
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400090
PM 30579026
DA 2020-05-12
ER

PT J
AU Peng, XQ
   Sun, CG
   Fei, ZG
   Zhou, QJ
AF Peng, Xiao-Qiang
   Sun, Chun-Guang
   Fei, Zheng-Guo
   Zhou, Qi-Jia
TI Risk Factors for Surgical Site Infection After Spinal Surgery: A
   Systematic Review and Meta-Analysis Based on Twenty-Seven Studies
SO WORLD NEUROSURGERY
LA English
DT Review
DE Meta-analysis; Risk factor; Spinal surgery; Surgical site infection
ID WOUND-INFECTION; PROSPECTIVE MULTICENTER; FUSION; INSTRUMENTATION;
   SURVEILLANCE; INDEX; RATES
AB BACKGROUND: The present meta-analysis was conducted to explore and identify the risk factors for surgical site infection (SSI) after spinal surgery based on qualified studies and to gain insight into the management of SSI among patients undergoing spinal surgery.
   METHODS: We searched the following electronic data-bases, PubMed, the Cochrane Library, and the Embase database, updated to May 2018, to identify eligible studies according to the index words with associated publications. The odds ratios and 95% confidence intervals were used to analyze the main outcomes.
   RESULTS: We found 27 studies with a total of 2175 patients in the SSI group and 41,536 patients in the control group for the present meta-analysis. The pooled results revealed that the risk factors for SSI included diabetes, obesity, hypertension, >= 3 hours operative time, and transfusion. In addition, no significant association was found between SSI and the following risk factors: female gender, age >60 years, smoking habit, bone autograft, bone allograft, prophylactic antibiotics, and steroid therapy.
   CONCLUSIONS: Our findings provide evidence that diabetes, obesity (body mass index >30 kg/m(2)), hypertension, >= 3 hours operative time, and transfusion have a strong association with a remarkable increase in the risk of SSI after spinal surgery. In conclusion, more high-quality trials with larger sample sizes and long-term randomized controlled trials are warranted to confirm the risk factors for SSI among patients undergoing spinal surgery.
C1 [Peng, Xiao-Qiang; Sun, Chun-Guang; Fei, Zheng-Guo; Zhou, Qi-Jia] Funing Peoples Hosp, Dept Orthopaed, Yancheng City, Funing County, Peoples R China.
RP Zhou, QJ (reprint author), Funing Peoples Hosp, Dept Orthopaed, Yancheng City, Funing County, Peoples R China.
EM dr_sj@126.com
CR ABBEY DM, 1995, J SPINAL DISORD, V8, P278, DOI 10.1097/00002517-199508040-00003
   Apisarnthanarak A, 2003, INFECT CONT HOSP EP, V24, P31, DOI 10.1086/502112
   Blam OG, 2003, SPINE, V28, P1475, DOI 10.1097/00007632-200307010-00022
   Chen KW, 2011, J SPINAL DISORD TECH, V24, P230, DOI 10.1097/BSD.0b013e3181ea478a
   Chen S, 2009, CLIN ORTHOP RELAT R, V467, P1670, DOI 10.1007/s11999-009-0740-y
   Cizik AM, 2012, J BONE JOINT SURG AM, V94A, P335, DOI 10.2106/JBJS.J.01084
   Ee WWG, 2014, CLIN ORTHOP RELAT R, V472, P1718, DOI 10.1007/s11999-013-3158-5
   Fang A, 2005, SPINE, V30, P1460, DOI 10.1097/01.brs.0000166532.58227.4f
   Fei Q, 2016, WORLD NEUROSURG, V95, P507, DOI 10.1016/j.wneu.2015.05.059
   Gaynes RP, 2001, CLIN INFECT DIS, V33, pS69, DOI 10.1086/321860
   Glassman SD, 1996, SPINE, V21, P2163, DOI 10.1097/00007632-199609150-00021
   Gu WF, 2018, AM J INFECT CONTROL, V46, P8, DOI 10.1016/j.ajic.2017.09.025
   Keller R B, 1972, Orthop Clin North Am, V3, P99
   Klekamp J, 1999, J SPINAL DISORD, V12, P187
   Kong LD, 2017, SURG INFECT, V18, P206, DOI 10.1089/sur.2016.209
   Koutsoumbelis S, 2011, J BONE JOINT SURG AM, V93A, P1627, DOI 10.2106/JBJS.J.00039
   Lee SE, 2010, J KOREAN NEUROSURG S, V47, P265, DOI 10.3340/jkns.2010.47.4.265
   Liu JM, 2018, SPINE, V43, P732, DOI 10.1097/BRS.0000000000002419
   Lonjon G, 2012, ORTHOP TRAUMATOL-SUR, V98, P788, DOI 10.1016/j.otsr.2012.07.006
   Maragakis LL, 2009, ANESTHESIOLOGY, V110, P556, DOI 10.1097/ALN.0b013e3181974be7
   MASSIE JB, 1992, CLIN ORTHOP RELAT R, P99
   Mehta AI, 2012, SPINE, V37, P1652, DOI 10.1097/BRS.0b013e318241b186
   Meng F, 2015, CHILD NERV SYST, V31, P521, DOI 10.1007/s00381-015-2659-9
   Nota SPFT, 2015, CLIN ORTHOP RELAT R, V473, P1612, DOI 10.1007/s11999-014-3933-y
   Ogihara S, 2015, J ORTHOP SCI, V20, P71, DOI 10.1007/s00776-014-0669-1
   Olsen MA, 2003, J NEUROSURG, V98, P149, DOI 10.3171/spi.2003.98.2.0149
   Olsen MA, 2008, J BONE JOINT SURG AM, V90A, P62, DOI 10.2106/JBJS.F.01515
   Picada R, 2000, J SPINAL DISORD, V13, P42, DOI 10.1097/00002517-200002000-00009
   Rao SB, 2011, CLIN INFECT DIS, V53, P686, DOI 10.1093/cid/cir506
   Salvetti David J, 2015, Surg Neurol Int, V6, pS500, DOI 10.4103/2152-7806.166893
   Satake K, 2013, EUR SPINE J, V22, P1854, DOI 10.1007/s00586-013-2783-8
   Schimmel JJP, 2010, EUR SPINE J, V19, P1711, DOI 10.1007/s00586-010-1421-y
   Schwarzkopf R, 2010, SPINE, V35, P340, DOI 10.1097/BRS.0b013e3181b86eda
   TENNEY JH, 1985, J NEUROSURG, V62, P243, DOI 10.3171/jns.1985.62.2.0243
   ter Gunne AFP, 2009, SPINE, V34, P1422, DOI 10.1097/BRS.0b013e3181a03013
   Veeravagu A, 2009, SPINE, V34, P1869, DOI 10.1097/BRS.0b013e3181adc989
   Watanabe M, 2010, J NEUROSURG-SPINE, V12, P540, DOI 10.3171/2009.11.SPINE09308
   Weinstein MA, 2000, J SPINAL DISORD, V13, P422, DOI 10.1097/00002517-200010000-00009
NR 38
TC 1
Z9 1
U1 1
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E318
EP E329
DI 10.1016/j.wneu.2018.11.158
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400039
PM 30496932
DA 2020-05-12
ER

PT J
AU Pessina, F
   Navarria, P
   Clerici, E
   Soffietti, R
   Nibali, MC
   Ruda, R
   Riva, M
   Scorsetti, M
   Bello, L
AF Pessina, Federico
   Navarria, Pierina
   Clerici, Elena
   Soffietti, Riccardo
   Nibali, Marco Conti
   Ruda, Roberta
   Riva, Marco
   Scorsetti, Marta
   Bello, Lorenzo
TI Intracranial Meningiomas: A Systematic Analysis of Prognostic Factors
   for Recurrence in a Large Single Institution Surgical Series
SO WORLD NEUROSURGERY
LA English
DT Article
DE Grade I-II; Intracranial meningioma; Prognostic factors
ID GROSS-TOTAL RESECTION; QUALITY-OF-LIFE; ADJUVANT RADIOTHERAPY; ATYPICAL
   MENINGIOMAS; GRADE I; SURVIVAL; EPIDEMIOLOGY; RADIATION; OUTCOMES;
   THERAPY
AB BACKGROUND: Meningioma is the most common primary intracranial tumor. Surgical resection is the first choice of treatment, whereas the role of adjuvant radiotherapy (RT) is still unclear. Aim of the study was to evaluate prognostic factors influencing the local recurrence rate.
   METHODS: Patients who had grade I-II meningiomas and underwent surgery were included in the present study. The extent of surgical resection was defined according to Simpson criteria, and were dichotomized as gross total and subtotal resection (STR). Adjuvant RT was considered in case of STR. Clinical outcome was evaluated by neurological examination and brain magnetic resonance imaging, which was performed every 6 months for the first year and yearly thereafter.
   RESULTS: From January 2000 to December 2015, 296 patients were analyzed. Most were women (65.9%), with a Karnofsky performance status >= 80 (94.6%), grade I meningioma (79.4%), and symptoms at diagnosis (91.5%). STR was performed in 58%, followed by adjuvant RT in 10%. Improvement or stability of neurological status was obtained in 90.4% of patients. The median follow-up time was 79 months (range, 24-214 months). Local recurrence occurred in 87 (29.4%) patients, at a median time of 56 months (range, 6-214 months). No patients, who underwent surgery plus adjuvant RT, had local relapse. The median, 2-, 5-, 10-year progression-free survival were 172 months, 91.1%, 80.7%, and 67.2%, respectively. On univariate and multivariate analysis factors impacting on progression-free survival were grade, extent of surgical resection, and adjuvant RT in case of STR, regardless of meningioma grade.
   CONCLUSIONS: Overall, our findings suggest that recurrence rates are influenced by grade, extent of surgical resection, and use of adjuvant RT in not completely resected meningioma, regardless of tumor grade.
C1 [Pessina, Federico; Nibali, Marco Conti; Riva, Marco; Bello, Lorenzo] Humanitas Univ, Dept Neurosurg Oncol, Rozzano, Italy.
   [Navarria, Pierina; Clerici, Elena; Scorsetti, Marta] Humanitas Univ, Dept Radiotherapy & Radiosurg, Rozzano, Italy.
   [Scorsetti, Marta] Humanitas Univ, Dept Biomed Sci, Rozzano, Italy.
   [Soffietti, Riccardo; Ruda, Roberta] Humanitas Canc Ctr & Res Hosp, Neurosurg Oncol, Rozzano, Italy.
RP Pessina, F (reprint author), Humanitas Univ, Dept Neurosurg Oncol, Rozzano, Italy.
EM federico.pessina@humanitas.it
RI Riva, Marco/AAC-1357-2019; Navarria, Pierina/AAB-2595-2019; Pessina,
   Federico/K-7198-2016
OI Riva, Marco/0000-0003-4643-6451; Conti Nibali,
   Marco/0000-0003-2611-5685; Pessina, Federico/0000-0002-8717-4999
CR Aghi MK, 2009, NEUROSURGERY, V64, P56, DOI 10.1227/01.NEU.0000330399.55586.63
   Aizer AA, 2014, NEURO-ONCOLOGY, V16, P1547, DOI 10.1093/neuonc/nou098
   Alvernia JE, 2011, J NEUROSURG, V115, P491, DOI 10.3171/2011.4.JNS101922
   Bagshaw HP, 2017, J NEUROSURG, V126, P1822, DOI 10.3171/2016.5.JNS152809
   Cheung VLS, 2018, J NEURO-ONCOL, V136, P351, DOI 10.1007/s11060-017-2659-6
   Claus EB, 2005, NEUROSURGERY, V57, P1088, DOI 10.1227/01.NEU.0000188281.91351.B9
   Endo T, 2016, ACTA NEUROCHIR, V158, P1661, DOI 10.1007/s00701-016-2900-7
   Goldbrunner R, 2016, LANCET ONCOL, V17, pE383, DOI 10.1016/S1470-2045(16)30321-7
   GOLDSMITH BJ, 1994, J NEUROSURG, V80, P195, DOI 10.3171/jns.1994.80.2.0195
   Goyal LK, 2000, INT J RADIAT ONCOL, V46, P57, DOI 10.1016/S0360-3016(99)00349-1
   Hammouche S, 2014, ACTA NEUROCHIR, V156, P1475, DOI 10.1007/s00701-014-2156-z
   Hardesty DA, 2013, J NEUROSURG, V119, P475, DOI 10.3171/2012.12.JNS12414
   Jakola AS, 2012, J NEURO-ONCOL, V110, P137, DOI 10.1007/s11060-012-0947-8
   Jenkinson MD, 2016, J CLIN NEUROSCI, V28, P87, DOI 10.1016/j.jocn.2015.09.021
   Jenkinson MD, 2015, TRIALS, V16, DOI 10.1186/s13063-015-1040-3
   Kalkanis SN, 2000, J NEURO-ONCOL, V48, P233, DOI 10.1023/A:1006476604338
   Kaur G, 2014, NEURO-ONCOLOGY, V16, P628, DOI 10.1093/neuonc/nou025
   Komotar RJ, 2012, J NEUROSURG, V117, P679, DOI 10.3171/2012.7.JNS112113
   Lee KD, 2013, NEUROSURG FOCUS, V35, DOI 10.3171/2013.9.FOCUS13325
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Ma J, 2014, WORLD NEUROSURG, V82, P757, DOI 10.1016/j.wneu.2014.05.026
   Mair R, 2011, J NEUROSURG, V115, P811, DOI 10.3171/2011.5.JNS11112
   Mansouri A, 2016, J NEUROSURG, V125, P431, DOI 10.3171/2015.7.JNS15546
   Miao YF, 2010, J CLIN NEUROSCI, V17, P446, DOI 10.1016/j.jocn.2009.07.111
   Nanda A, 2016, CLIN NEUROL NEUROSUR, V142, P31, DOI 10.1016/j.clineuro.2016.01.005
   Ohba S, 2011, J NEUROSURG, V114, P1278, DOI 10.3171/2010.11.JNS10701
   Park HJ, 2013, J NEURO-ONCOL, V115, P241, DOI 10.1007/s11060-013-1219-y
   Pasquier D, 2008, INT J RADIAT ONCOL, V71, P1388, DOI 10.1016/j.ijrobp.2007.12.020
   Perry A, 2007, WHO CLASSIFICATION T, P164
   Rogers L, 2015, ASTRO 57 ANN M
   ROHRINGER M, 1989, J NEUROSURG, V71, P665, DOI 10.3171/jns.1989.71.5.0665
   Saraf S, 2011, ONCOLOGIST, V16, P1604, DOI 10.1634/theoncologist.2011-0193
   SIMPSON D, 1957, J NEUROL NEUROSUR PS, V20, P22, DOI 10.1136/jnnp.20.1.22
   Stessin AM, 2012, J NEUROSURG, V117, P669, DOI 10.3171/2012.7.JNS111439
   Sughrue ME, 2010, J NEUROSURG, V113, P1029, DOI 10.3171/2010.3.JNS091971
   Tanzler E, 2011, INT J RADIAT ONCOL, V79, P508, DOI 10.1016/j.ijrobp.2009.11.032
   van der Vossen S, 2014, J REHABIL MED, V46, P430, DOI 10.2340/16501977-1795
   Wang CY, 2017, NEURO-ONCOLOGY, V19, P1263, DOI 10.1093/neuonc/nox007
   Wong Ricky H, 2013, Surg Neurol Int, V4, P71, DOI 10.4103/2152-7806.112617
   Yoon H, 2015, J CANCER RES THER, V11, P59, DOI 10.4103/0973-1482.148708
   Zaher A, 2013, WORLD NEUROSURG, V80, P549, DOI 10.1016/j.wneu.2013.07.001
NR 41
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E273
EP E279
DI 10.1016/j.wneu.2018.11.150
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400033
PM 30496926
DA 2020-05-12
ER

PT J
AU Pishnamaz, M
   Curfs, I
   Uhing, D
   Herren, C
   van Santbrink, H
   Mueller, CA
   Scholz, M
   Lichti, P
   Rijkers, K
   Boselie, TF
   Hildebrand, F
   Willems, PC
   Kobbel, P
AF Pishnamaz, Miguel
   Curfs, Inez
   Uhing, Daniel
   Herren, Christian
   van Santbrink, Henk
   Mueller, Christian A.
   Scholz, Matti
   Lichti, Philipp
   Rijkers, Kim
   Boselie, Toon F.
   Hildebrand, Frank
   Willems, Paul C.
   Kobbel, Philipp
TI Two-Nation Comparison of Classification and Treatment of Subaxial
   Cervical Spine Fractures: An Internet-Based Multicenter Study Among
   Spine Surgeons
SO WORLD NEUROSURGERY
LA English
DT Article
DE AO spine classification; International; Interobserver; Multicenter;
   Spine trauma; Subaxial cervical spine
ID INJURIES; REPRODUCIBILITY; AGREEMENT; ANTERIOR; CARE
AB BACKGROUND: To date, no evidence-based treatment algorithm is available for fractures of the subaxial spine. The aim of the present study was to assess and compare the management strategy for traumatic subaxial fractures among German and Dutch spine surgeons.
   METHODS: In our web-based multicenter study, German and Dutch spine surgeons evaluated the computed tomography data of traumatic subaxial fractures (C3-C7). Supplementary case-specific information was provided. The fractures were classified using the AO spine classification. Next, 9 questions concerning the treatment algorithm were evaluated. Data were analyzed using SPSS. Statistical significance was defined as P < 0.05.
   RESULTS: Ten surgeons (5/country) evaluated 31 cases (310 votes). The fractures were classified as AO type A in 37% (114 votes), type B in 50% (155 votes), and type C in 13% (41 votes). German spine surgeons had a lower threshold concerning the indication for surgical treatment (German, 94.2% vs. Netherlands, 58.1%; P < 0.05). A consensus was present for operative stabilization for type B and C injuries, but a discrepancy was found in the therapeutic algorithm for type A fractures. The most significant difference was seen in the treatment of type A2 and A3 fractures (surgery for type A2/A3 fracture: German, 92.9% vs. Netherlands, 5.3%; P < 0.05).
   CONCLUSION: We found a consensus for the stabilization of AO type B and C fractures but country-specific differences in the treatment of type A fractures, especially for A2 and A3 fractures. Further evidence is necessary to ensure more consistent international treatment strategies.
C1 [Pishnamaz, Miguel; Uhing, Daniel; Herren, Christian; Lichti, Philipp; Hildebrand, Frank; Kobbel, Philipp] Univ Aachen, Med Ctr, Dept Orthopaed Trauma, Aachen, Germany.
   [Mueller, Christian A.] Univ Aachen, Med Ctr, Dept Neurosurg, Aachen, Germany.
   [Curfs, Inez; Willems, Paul C.] Maastricht Univ, Med Ctr, Spine Ctr, Dept Orthopaed, Maastricht, Netherlands.
   [van Santbrink, Henk; Rijkers, Kim; Boselie, Toon F.] Maastricht Univ, Med Ctr, Dept Neurosurg, Maastricht, Netherlands.
   [Scholz, Matti] Berufsgenossenschaftl Unfallklin Frankfurt, Ctr Spinal Surg & Neurotraumatol, Frankfurt, Germany.
RP Pishnamaz, M (reprint author), Univ Aachen, Med Ctr, Dept Orthopaed Trauma, Aachen, Germany.
EM mpishnamaz@ukaachen.de
CR Aebi M, 2010, EUR SPINE J, V19, P33, DOI 10.1007/s00586-009-1120-8
   Amorosa Louis F, 2014, Instr Course Lect, V63, P255
   Bagley LJ, 2006, RADIOL CLIN N AM, V44, P1, DOI 10.1016/j.rcl.2005.08.004
   Bono CM, 2011, SPINE, V36, P1374, DOI 10.1097/BRS.0b013e318221e169
   Brodke DS, 2003, J SPINAL DISORD TECH, V16, P229, DOI 10.1097/00024720-200306000-00001
   Del Curto D, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008129.pub2
   Dvorak MF, 2007, SPINE, V32, P2620, DOI 10.1097/BRS.0b013e318158ce16
   Feuchtbaum E, 2016, CURR REV MUSCULOSKE, V9, P496, DOI 10.1007/s12178-016-9377-0
   Holla M, 2016, EUR SPINE J, V25, P2023, DOI 10.1007/s00586-016-4379-6
   Kadam A, 2016, INT J SPINE SURG, V10, DOI 10.14444/3033
   Kwon BK, 2007, J NEUROSURG-SPINE, V7, P1, DOI 10.3171/SPI-07/07/001
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Lenehan B, 2010, SPINE, V35, pS174, DOI 10.1097/BRS.0b013e3181f32c82
   Mesman R, 2018, J HEALTH SERV RES PO, V23, P185, DOI 10.1177/1355819618766392
   PANJABI MM, 1980, NEUROSURGERY, V7, P76, DOI 10.1227/00006123-198007000-00014
   Pishnamaz M, 2015, SPINE, V40, P1749, DOI 10.1097/BRS.0000000000001143
   Pizones J, 2013, SPINE, V38, P745, DOI 10.1097/BRS.0b013e31827934e4
   Sadiqi S, 2017, EUR SPINE J, V26, P1483, DOI 10.1007/s00586-016-4716-9
   Schleicher P, 2017, Z ORTHOP UNFALLCHIR, V155, P556, DOI 10.1055/s-0043-110855
   Schnake KJ, 2017, J ORTHOP TRAUMA, V31, pS14, DOI 10.1097/BOT.0000000000000947
   Schut FT, 2017, HEALTH POLICY, V121, P126, DOI 10.1016/j.healthpol.2016.11.002
   Stone Addison T, 2010, Evid Based Spine Care J, V1, P19, DOI 10.1055/s-0030-1267064
   Urrutia J, 2017, SPINE, V42, P298, DOI 10.1097/BRS.0000000000001302
   Urrutia J, 2015, SPINE, V40, pE54, DOI 10.1097/BRS.0000000000000656
   Vaccaro AR, 2016, EUR SPINE J, V25, P2173, DOI 10.1007/s00586-015-3831-3
   WHITE AA, 1977, CLIN ORTHOP RELAT R, P8
NR 26
TC 0
Z9 0
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E125
EP E132
DI 10.1016/j.wneu.2018.11.078
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400015
PM 30465953
DA 2020-05-12
ER

PT J
AU Pitskhelauri, DI
   Konovalov, AN
   Abramov, IT
   Danilov, GV
   Pronin, IN
   Alexandrova, EV
   Serova, NK
   Sanikidze, AZ
AF Pitskhelauri, David, I
   Konovalov, Alexander N.
   Abramov, Irakliy T.
   Danilov, Gleb, V
   Pronin, Igor N.
   Alexandrova, Evgeniya, V
   Serova, Nataliya K.
   Sanikidze, Alexander Z.
TI Pineal Cyst-Related Aqueductal Stenosis as Cause of Intractable
   Headaches in Nonhydrocephalic Patients
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebral aqueduct; Headache; Neurosurgery; Magnetic resonance imaging;
   Pineal cyst
ID SYMPTOMATIC GLIAL CYSTS; NATURAL-HISTORY; CASE SERIES; MANAGEMENT;
   PREVALENCE; DEATH; GLAND
AB BACKGROUND: Pineal cysts (PCs) are histologically benign lesions of the pineal gland. Although the majority of PCs are asymptomatic, some cases are ambiguous and accompanied by nonspecific symptoms of variable severity. We suggested that disabling headache in non-hydrocephalic patients with PCs is associated with cerebral aqueduct (CAq) stenosis.
   METHODS: A retrospective analysis was conducted in patients with PCs suffering from headache without secondary hydrocephalus who underwent surgical resection at Burdenko Neurosurgery Center between 1995 and 2016. All available medical records and radiographic images were retrospectively assessed in these patients. The comparison groups included 22 patients with nonoperated PCs and 25 healthy individuals. Specific magnetic resonance imaging measures were selected to assess the morphometry of the CAq and degree of the stenosis.
   RESULTS: In 25 patients (82%) we observed clinical improvement after surgery in a follow-up period. Among those with improvement, 10 of them (40%) experienced total relief and 15 of them (60%) had marked headache diminishment. In 5 patients the headache remained persistent. The preoperative rostral CAq diameter appeared to be significantly narrower (P = 0.0011045), and the preoperative rostral/caudal diameter ratio (Rd/Cd) was found to be lower (P = 0.004391) in patients who recovered from headache versus those who did not.
   CONCLUSION: The results indicate a statistically significant relationship between the changes in the CAq morphometrics and the clinical outcome in postoperative period. Surgical removal of symptomatic pineal cysts in patients without hydrocephalus can be considered as an effective treatment. However, a thorough preoperative examination and patient selection should be conducted in every case.
C1 [Pitskhelauri, David, I; Konovalov, Alexander N.; Abramov, Irakliy T.; Danilov, Gleb, V; Sanikidze, Alexander Z.] Burdenko Natl Med Res Ctr Neurosurg, Dept Neurooncol, Moscow, Russia.
   [Pronin, Igor N.] Burdenko Natl Med Res Ctr Neurosurg, Dept Neuroradiol, Moscow, Russia.
   [Alexandrova, Evgeniya, V] Burdenko Natl Med Res Ctr Neurosurg, Dept Neurol, Moscow, Russia.
   [Serova, Nataliya K.] Burdenko Natl Med Res Ctr Neurosurg, Dept Neuroopththalmol, Moscow, Russia.
RP Abramov, IT (reprint author), Burdenko Natl Med Res Ctr Neurosurg, Dept Neurooncol, Moscow, Russia.
EM irakliyabramov@gmail.com
RI Danilov, Gleb/P-6080-2016
OI Danilov, Gleb/0000-0003-1442-5993
CR Abramov I T, 2017, Zh Vopr Neirokhir Im N N Burdenko, V81, P113, DOI 10.17116/neiro2017814113-120
   Al-Holou WN, 2011, J NEUROSURG, V115, P1106, DOI 10.3171/2011.6.JNS11506
   Al-Holou WN, 2009, J NEUROSURG-PEDIATR, V4, P230, DOI 10.3171/2009.4.PEDS0951
   Barboriak DP, 2001, AM J ROENTGENOL, V176, P737, DOI 10.2214/ajr.176.3.1760737
   Berhouma M, 2015, NEUROCHIRURGIE, V61, P201, DOI 10.1016/j.neuchi.2013.08.010
   Carr JL, 1944, J NERV MENT DIS, V99, P552, DOI 10.1097/00005053-194405000-00010
   Eide PK, 2016, J NEUROL SCI, V363, P207, DOI 10.1016/j.jns.2016.02.038
   Eide PK, 2016, ACTA NEUROCHIR, V159, P349
   Eskandary H, 2005, SURG NEUROL, V63, P550, DOI 10.1016/j.surneu.2004.07.049
   Evans RW, 2010, HEADACHE, V50, P666, DOI 10.1111/j.1526-4610.2010.01652.x
   Kalani MYS, 2015, J NEUROSURG, V123, P352, DOI 10.3171/2014.9.JNS141081
   KLEIN P, 1989, J NEUROL NEUROSUR PS, V52, P991, DOI 10.1136/jnnp.52.8.991
   Kosinski M, 2003, QUAL LIFE RES, V12, P963, DOI 10.1023/A:1026119331193
   Majovsky M, 2017, WORLD NEUROSURG, V105, P199, DOI 10.1016/j.wneu.2017.05.155
   Majovsky M, 2016, ACTA NEUROCHIR, V158, P663, DOI 10.1007/s00701-016-2726-3
   Matys T, 2013, NEUROSURGERY, V73, P132, DOI 10.1227/01.neu.0000430286.08552.ca
   Mena H, 1997, Ann Diagn Pathol, V1, P11, DOI 10.1016/S1092-9134(97)80004-4
   Milroy CM, 1996, J CLIN PATHOL, V49, P267, DOI 10.1136/jcp.49.3.267
   Morgan JT, 2008, PEDIATR NEUROSURG, V44, P234, DOI 10.1159/000121382
   Na JY, 2014, AM J FOREN MED PATH, V35, P186, DOI 10.1097/PAF.0000000000000107
   Nevins EJ, 2016, WORLD NEUROSURG, V90, P96, DOI 10.1016/j.wneu.2016.02.092
   Osborn AG, 2006, RADIOLOGY, V239, P650, DOI 10.1148/radiol.2393050823
   Peres MFP, 2004, HEADACHE, V44, P929, DOI 10.1111/j.1526-4610.2004.04178_2.x
   Sarikaya-Seiwert S, 2009, J NEUROSURG-PEDIATR, V4, P130, DOI 10.3171/2009.4.PEDS08309
   Seifert CL, 2007, HEADACHE, V48, P448
   VAQUERO J, 1988, SURG NEUROL, V30, P468, DOI 10.1016/0090-3019(88)90033-X
   WISOFF JH, 1992, J NEUROSURG, V77, P896, DOI 10.3171/jns.1992.77.6.0896
NR 27
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E147
EP E155
DI 10.1016/j.wneu.2018.11.096
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400018
PM 30468924
DA 2020-05-12
ER

PT J
AU Raj, R
   Rautio, R
   Pekkola, J
   Rahi, M
   Sillanpaa, M
   Numminen, J
AF Raj, Rahul
   Rautio, Riitta
   Pekkola, Johanna
   Rahi, Melissa
   Sillanpaa, Mikko
   Numminen, Jussi
TI Treatment of Ruptured Intracranial Aneurysms Using the Woven EndoBridge
   Device: A Two-Center Experience
SO WORLD NEUROSURGERY
LA English
DT Article
DE Intracranial aneurysm; Stroke; Subarachnoid hemorrhage; WEB; Woven
   EndoBridge device
ID INTRASACCULAR FLOW-DISRUPTION; CEREBRAL ANEURYSMS; WEB TREATMENT;
   ENDOVASCULAR TREATMENT; COIL EMBOLIZATION; TRIAL; COMPLICATIONS;
   FEASIBILITY; RETREATMENT; COHORT
AB BACKGROUND: The Woven EndoBridge (WEB) device is a new treatment modality developed for broad-necked unruptured intracranial aneurysms (IAs) but shows potential for the treatment of ruptured IAs as well. Our aim was to describe 6-month aneurysm obliteration rates, clinical outcomes, and procedure-related complications after WEB treatment for ruptured IAs from 2 academic centers.
   METHODS: We conducted a retrospective observational study, including all consecutive patients treated with the WEB device (WEB single layer and single-layer sphere) for a ruptured IA causing acute subarachnoid hemorrhage between 2014 (start of use) and 2017. Primary outcome was angiographic aneurysm obliteration (Beaujon Occlusion Scale Score) rate. Secondary outcomes were early re-bleedings, complications, and patient outcome (death and modified Rankin Scale).
   RESULTS: A total of 33 patients with ruptured IAs were treated 0-4 days from IA rupture. Of 27 survivors, 6-month angiographic follow-up was available for 26 patients, of whom 81% showed complete occlusion. Of the 27 survivors, 24 patients (89%) had a favorable neurologic outcome at 6 months after subarachnoid hemorrhage. Two aneurysms were retreated (8% of all). There was 1 fatal procedure-related complication. No early aneurysm re-bleedings were noted.
   CONCLUSIONS: For anatomically suitable ruptured IAs, WEB device treatment seems to be safe and results in acceptable occlusion rates. Still, larger studies with long-term results are needed before recommendations can be made.
C1 [Raj, Rahul] Univ Helsinki, Dept Neurosurg, Helsinki, Finland.
   [Raj, Rahul; Pekkola, Johanna; Sillanpaa, Mikko; Numminen, Jussi] Helsinki Univ Hosp, Helsinki, Finland.
   [Pekkola, Johanna; Sillanpaa, Mikko; Numminen, Jussi] Univ Helsinki, Dept Radiol, Helsinki, Finland.
   [Rautio, Riitta] Turku Univ Hosp, Dept Radiol, Turku, Finland.
   [Rahi, Melissa] Turku Univ Hosp, Dept Neurosurg, Turku, Finland.
RP Raj, R (reprint author), Univ Helsinki, Dept Neurosurg, Helsinki, Finland.; Raj, R (reprint author), Helsinki Univ Hosp, Helsinki, Finland.
EM rahul.raj@hus.fi
RI Raj, Rahul/K-7693-2012
OI Raj, Rahul/0000-0003-4243-9591
CR Andaluz N, 2008, J NEUROSURG, V108, P1163, DOI 10.3171/JNS/2008/108/6/1163
   Ansari SA, 2019, J NEUROINTERV SURG, V11, P80, DOI 10.1136/neurintsurg-2018-014189
   Banks JL, 2007, STROKE, V38, P1091, DOI 10.1161/01.STR.0000258355.23810.c6
   Bechan RS, 2016, AM J NEURORADIOL, V37, P502, DOI 10.3174/ajnr.A4542
   Campi A, 2007, STROKE, V38, P1538, DOI 10.1161/STROKEAHA.106.466987
   Caroff J, 2015, AM J NEURORADIOL, V36, P1942, DOI 10.3174/ajnr.A4369
   Caroff J, 2017, J NEUROINTERV SURG, V9, pE11, DOI 10.1136/neurintsurg-2015-011862
   Caroff J, 2014, NEURORADIOLOGY, V56, P755, DOI 10.1007/s00234-014-1390-7
   Ding YH, 2011, AM J NEURORADIOL, V32, P607, DOI 10.3174/ajnr.A2399
   Fiorella D, 2017, J NEUROINTERV SURG, V9, P1191, DOI 10.1136/neurintsurg-2016-012841
   Johnston SC, 2006, STROKE, V37, P1437, DOI 10.1161/01.STR.0000221331.01830.ce
   Liebig T, 2015, AM J NEURORADIOL, V36, P1721, DOI 10.3174/ajnr.A4347
   Lin N, 2012, J NEUROINTERV SURG, V4, P182, DOI 10.1136/jnis.2011.004978
   Mehta RI, 2010, MODERN PATHOL, V23, P921, DOI 10.1038/modpathol.2010.74
   Molyneux A, 2002, LANCET, V360, P1267, DOI 10.1016/S0140-6736(02)11314-6
   Molyneux AJ, 2005, LANCET, V366, P809, DOI 10.1016/S0140-6736(05)67214-5
   Molyneux AJ, 2015, LANCET, V385, P691, DOI 10.1016/S0140-6736(14)60975-2
   Pierot L, 2017, J NEURORADIOLOGY, V44, P203, DOI 10.1016/j.neurad.2016.12.011
   Pierot L, 2016, AM J NEURORADIOL, V37, P655, DOI 10.3174/ajnr.A4578
   Pierot L, 2015, AM J NEURORADIOL, V36, P922, DOI 10.3174/ajnr.A4230
   Pierot L, 2012, AM J NEURORADIOL, V33, P1232, DOI 10.3174/ajnr.A3191
   Pierot L, 2018, J NEUROINTERV SURG, V10, P553, DOI 10.1136/neurintsurg-2017-013448
   Pierot L, 2016, J NEUROSURG, V124, P1250, DOI 10.3171/2015.2.JNS142634
   Popielski J, 2018, AM J NEURORADIOL, V39, P111, DOI 10.3174/ajnr.A5413
   Qureshi AI, 2011, J NEUROSURG, V114, P834, DOI 10.3171/2010.6.JNS091486
   Raymond J, 2003, STROKE, V34, P1398, DOI 10.1161/01.STR.0000073841.88563.E9
   Renowden SA, 2008, AM J NEURORADIOL, V29, P1401, DOI 10.3174/ajnr.A1098
   Rosenwasser Robert H, 2014, Neurosurgery, V61 Suppl 1, P121, DOI 10.1227/NEU.0000000000000377
   Ryu CW, 2015, AM J NEURORADIOL, V36, P1682, DOI 10.3174/ajnr.A4365
   Tikka J, 2018, LEGAL MED-TOKYO, V35, P66, DOI 10.1016/j.legalmed.2018.09.015
   van Rooij SBT, 2017, AM J NEURORADIOL, V38, P2282, DOI 10.3174/ajnr.A5371
   van Rooij WJ, 2016, AM J NEURORADIOL, V37, P1679, DOI 10.3174/ajnr.A4811
   VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604
   Zhao B, 2017, J NEUROINTERV SURG, V9, P165, DOI 10.1136/neurintsurg-2016-012259
NR 34
TC 8
Z9 7
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E709
EP E716
DI 10.1016/j.wneu.2018.12.010
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400084
PM 30576812
OA Green Published
DA 2020-05-12
ER

PT J
AU Ramayya, AG
   Glauser, G
   Mcshane, B
   Branche, M
   Sinha, S
   Kvint, S
   Buch, V
   Abdullah, KG
   Kung, D
   Chen, HI
   Malhotra, NR
   Ozturk, A
AF Ramayya, Ashwin G.
   Glauser, Gregory
   Mcshane, Brendan
   Branche, Marc
   Sinha, Saurabh
   Kvint, Svetlana
   Buch, Vivek
   Abdullah, Kalil G.
   Kung, David
   Chen, H. Isaac
   Malhotra, Neil R.
   Ozturk, Ali
TI Factors Predicting Ventriculostomy Revision at a Large Academic Medical
   Center
SO WORLD NEUROSURGERY
LA English
DT Article
DE Blocked drain; External ventricular drain (EVD) placement; Hemorrhage;
   Revision; Third ventricle; Ventriculostomy
ID DRAIN PLACEMENT; RISK-FACTORS; HEMORRHAGE; ACCURACY; INSERTION;
   INFECTION; SAFETY; RATES
AB BACKGROUND: Freehand bedside ventriculostomy placement can result in catheter malfunction requiring a revision procedure and cause significant patient morbidity. We performed a single-center retrospective review to assess factors related to this complication.
   METHODS: Using an administrative database and chart review, we identified 101 first-time external ventricular drain placements performed at the bedside. We collected data regarding demographics, medical comorbidities, complications, and catheter tip location. We performed univariate and multivariate statistical analyses using MATLAB. We corrected for multiple comparisons using the false discovery rate (FDR) procedure.
   RESULTS: Multivariate regression analyses revealed that revision procedures were more likely to occur after drain blockage (odds ratio [OR] 17.9) and hemorrhage (OR 10.3, FDR-corrected P values < 0.01, 0.05, respectively). Drain blockage was less frequent after placement in an "optimal location" (ipsilateral ventricle or near foramen of Monroe; OR 0.09, P = 0.009, FDR-corrected P < 0.03) but was more likely to occur after placement in third ventricle (post-hoc P values < 0.015). Primary diagnoses included subarachnoid hemorrhage (n = 30, 29.7%), intraparenchymal hemorrhage with intraventricular extravasation (n = 24, 23.7%), tumor (n = 20, 19.8%), and trauma (n = 17, 16.8%). Most common complications included drain blockage (n = 12, 11.8%) and hemorrhage (n = 8, 7.9%). In total, 16 patients underwent at least 1 revision procedure (15.8%).
   CONCLUSIONS: Bedside external ventricular drain placement is associated with a 15% rate of revision, that typically occurred after drain blockage and postprocedure hemorrhage. Optimal placement within the ipsilateral frontal horn or foramen of Monroe was associated with a reduced rate of drain blockage.
C1 [Ramayya, Ashwin G.; Glauser, Gregory; Mcshane, Brendan; Branche, Marc; Sinha, Saurabh; Kvint, Svetlana; Buch, Vivek; Abdullah, Kalil G.; Kung, David; Chen, H. Isaac; Malhotra, Neil R.; Ozturk, Ali] Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA.
RP Ramayya, AG (reprint author), Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA.
EM ashwinramayya@gmail.com
CR AlAzri A, 2017, ACTA NEUROCHIR, V159, P1399, DOI 10.1007/s00701-017-3201-5
   Baum GR, 2017, J NEUROSURG, V127, P1190, DOI 10.3171/2016.9.JNS16367
   Cagnazzo Federico, 2020, Neurosurg Rev, V43, P397, DOI 10.1007/s10143-018-0999-0
   Coulson NK, 2015, J NEUROSURG-PEDIATR, V16, P393, DOI 10.3171/2015.2.PEDS14387
   Dey M, 2015, NEUROSURGERY, V76, P291, DOI 10.1227/NEU.0000000000000624
   Enriquez-Marulanda A, 2018, NEUROCRIT CARE, V29, P435, DOI 10.1007/s12028-018-0556-2
   Gardner PA, 2009, J NEUROSURG, V110, P1021, DOI 10.3171/2008.9.JNS17661
   Hsieh CT, 2011, ACTA NEUROL BELG, V111, P22
   Hudson JS, 2019, NEUROSURGERY, V84, P479, DOI 10.1093/neuros/nyy127
   Kakarla UK, 2008, NEUROSURGERY, V63, P162, DOI 10.1227/01.NEU.0000312390.83127.7F
   Kohli G, 2018, WORLD NEUROSURG, V110, pE135, DOI 10.1016/j.wneu.2017.10.129
   Manfield JH, 2017, NEUROSURG FOCUS, V43, DOI 10.3171/2017.7.FOCUS17148
   Miller C, 2017, J NEUROSURG, V126, P289, DOI 10.3171/2015.12.JNS152341
   Muller A, 2018, NEUROCRIT CARE, V29, P23, DOI 10.1007/s12028-017-0492-6
   Park YG, 2011, J KOREAN NEUROSURG S, V50, P317, DOI 10.3340/jkns.2011.50.4.317
   Patil V, 2013, ACTA NEUROCHIR, V155, P1773, DOI 10.1007/s00701-013-1769-y
   Phillips SB, 2014, WORLD NEUROSURG, V82, P739, DOI 10.1016/j.wneu.2013.08.030
   Raabe C, 2018, J NEUROSURG, V128, P1250, DOI 10.3171/2016.11.JNS161765
   Rosenbaum BP, 2013, CLIN NEUROL NEUROSUR, V115, P1514, DOI 10.1016/j.clineuro.2012.12.008
   Rowe AS, 2018, BMC NEUROL, V18, DOI 10.1186/s12883-018-1030-7
   Schuss P, 2016, WORLD NEUROSURG, V85, P125, DOI 10.1016/j.wneu.2015.08.046
   Sussman ES, 2014, J NEUROSURG, V120, P931, DOI 10.3171/2013.12.JNS131685
   Toma AK, 2009, NEUROSURGERY, V65, P1197, DOI 10.1227/01.NEU.0000356973.39913.0B
   Wan KR, 2011, J CLIN NEUROSCI, V18, P485, DOI 10.1016/j.jocn.2010.06.018
   Wilson MP, 2019, J NEUROSURG, V130, P2048, DOI 10.3171/2018.1.JNS172839
   Yuen J, 2018, ANN ROY COLL SURG, V100, P221, DOI 10.1308/rcsann.2017.0221
NR 26
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E509
EP E514
DI 10.1016/j.wneu.2018.11.196
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400059
PM 30503293
DA 2020-05-12
ER

PT J
AU Razek, AAKA
   El-Serougy, L
   Abdelsalam, M
   Gabeha, G
   Talaat, M
AF Razek, Ahmed Abdel Khalek Abdel
   El-Serougy, Lamiaa
   Abdelsalam, Mohamed
   Gabeha, Gada
   Talaat, Mona
TI Differentiation of Primary Central Nervous System Lymphoma From
   Glioblastoma: Quantitative Analysis Using Arterial Spin Labeling and
   Diffusion Tensor Imaging
SO WORLD NEUROSURGERY
LA English
DT Article
DE Arterial spin labeling; Diffusion tensor; Glioblastoma; Lymphoma
ID PRIMARY CEREBRAL LYMPHOMA; MR; GRADE; MULTIFORME; PERFUSION; GLIOMAS;
   HEAD
AB OBJECTIVE: Differentiation of primary central nervous system lymphoma (PCNSL) from glioblastoma using arterial spin labeling perfusion and diffusion tensor imaging (DTI).
   METHODS: We performed a prospective study of 31 patients with a provisional diagnosis of PCNSL and glioblastoma who underwent conventional magnetic resonance imaging, DTI, and arterial spin labeling of the brain. The tumor blood flow (TBF), mean diffusivity (MD) plus fractional anisotropy (FA) of the mass were measured. The final diagnosis was confirmed by pathological examination.
   RESULTS: The TBF of PCNSL (26.41 +/- 4.03 mL/100 g/minute) was significantly lower than that of glioblastoma (51.08 +/- 3.9 mL/100 g/minute; P = 0.001). The TBF cutoff (35.73 mL/100 g/minute) used for differentiation showed area under the curve (AUC) of 0.93, accuracy of 95.2%, sensitivity of 91.7%, and specificity of 100%. The MD of PCNSL (0.87 +/- 0.2X 10(-3) mm(2)/second) was significantly lower than that of glioblastoma (0.87 +/- 0.2 3 10(-3) mm(2)/second; P = 0.01). The MD cutoff (0.935 3 10(-3) mm(2)/second) used for differentiation showed an AUC of 0.73 and accuracy of 66.7% and a sensitivity of 75% and specificity of 55.6%. The FA of PCNSL (0.253 +/- 0.05) was significantly greater than that of glioblastoma (0.135 +/- 0.06; P = 0.001). The FA cutoff (0.185) used for differentiation revealed an AUC of 0.944 and accuracy of 85.7% and a sensitivity of 83.3% and specificity of 88.9%. The combined TBF, MD, and FA cutoffs revealed an AUC of 0.96 and accuracy of 95.5% and a sensitivity of 83.3% and specificity of 100%.
   CONCLUSION: The noninvasive imaging parameters using TBF and DTI might help in differentiating PCNSL from glioblastoma.
C1 [Razek, Ahmed Abdel Khalek Abdel; El-Serougy, Lamiaa; Gabeha, Gada] Mansoura Fac Med, Dept Diagnost Radiol, Mansoura, Egypt.
   [Abdelsalam, Mohamed] Mansoura Fac Med, Dept Neurol, Mansoura, Egypt.
   [Talaat, Mona] Kafr Elsheak Fac Med, Dept Diagnost Radiol, Kafr Elsheak, Egypt.
RP Razek, AAKA (reprint author), Mansoura Fac Med, Dept Diagnost Radiol, Mansoura, Egypt.
EM arazek@mans.edu.eg
RI Abdel Razek, Ahmed/J-6737-2016
OI Abdel Razek, Ahmed/0000-0002-9613-5932
CR Barrantes-Freer A, 2018, BRAIN PATHOL, V28, P225, DOI 10.1111/bpa.12496
   Choi YS, 2017, EUR RADIOL, V27, P1344, DOI 10.1007/s00330-016-4484-2
   El-Serougy L, 2016, NEURORADIOL J, V29, P400, DOI 10.1177/1971400916665382
   Villalonga JF, 2018, ARQ NEURO-PSIQUIAT, V76, P139, DOI [10.1590/0004-282x20180002, 10.1590/0004-282X20180002]
   Furtner J, 2014, EUR J RADIOL, V83, P806, DOI 10.1016/j.ejrad.2014.01.017
   Grommes C, 2017, J CLIN ONCOL, V35, P2410, DOI 10.1200/JCO.2017.72.7602
   Han Catherine H, 2017, Continuum (Minneap Minn), V23, P1601, DOI 10.1212/CON.0000000000000539
   Han CH, 2017, CANCER-AM CANCER SOC, V123, P4314, DOI 10.1002/cncr.30965
   de la Pena MDJ, 2017, CURR PROBL DIAGN RAD, V46, P136, DOI 10.1067/j.cpradiol.2016.04.004
   Kang D, 2018, NEURO-ONCOLOGY, V20, P1251, DOI 10.1093/neuonc/noy021
   Kickingereder P, 2014, RADIOLOGY, V272, P843, DOI 10.1148/radiol.14132740
   Koeller KK, 2016, RADIOL CLIN N AM, V54, P649, DOI 10.1016/j.rcl.2016.03.003
   Lin X, 2017, AM J NEURORADIOL, V38, P485, DOI 10.3174/ajnr.A5023
   Low S, 2018, SEMIN NEUROL, V38, P86, DOI 10.1055/s-0038-1627470
   Lu SS, 2017, J COMPUT ASSIST TOMO, V41, P898, DOI 10.1097/RCT.0000000000000622
   Makino K, 2018, WORLD NEUROSURG, V112, pE1, DOI 10.1016/j.wneu.2017.10.141
   Nabavizadeh SA, 2016, HEMATOL ONCOL CLIN N, V30, P799, DOI 10.1016/j.hoc.2016.03.005
   Nagashima H, 2018, J NEURO-ONCOL, V136, P317, DOI 10.1007/s11060-017-2655-x
   Partovi S, 2014, BRIT J RADIOL, V87, DOI 10.1259/bjr.20130684
   Razek AAKA, 2018, J LARYNGOL OTOL, V132, P923, DOI 10.1017/S0022215118001743
   Razek AAKA, 2018, MAGN RESON IMAGING, V54, P84, DOI 10.1016/j.mri.2018.08.009
   Razek AAKA, 2018, NEURORADIOLOGY, V60, P1159, DOI 10.1007/s00234-018-2078-1
   Razek AAKA, 2018, DENTOMAXILLOFAC RAD, V47, DOI 10.1259/dmfr.20170343
   Razek AAKA, 2018, NEUROIMAG CLIN N AM, V28, P303, DOI 10.1016/j.nic.2018.01.009
   Razek AAKA, 2018, NEUROIMAG CLIN N AM, V28, P245, DOI 10.1016/j.nic.2018.01.010
   Razek AAKA, 2018, EUR ARCH OTO-RHINO-L, V275, P1301, DOI 10.1007/s00405-018-4950-3
   Razek AAKA, 2018, NEURORADIOLOGY, V60, P169, DOI 10.1007/s00234-017-1955-3
   Razek AAKA, 2017, CLIN RHEUMATOL, V36, P2319, DOI 10.1007/s10067-016-3463-y
   Razek AAKA, 2016, NMR BIOMED, V29, P483, DOI 10.1002/nbm.3472
   Razek AAKA, 2013, EUR J RADIOL, V82, P1885, DOI 10.1016/j.ejrad.2013.07.007
   Razek AAKA, 2011, MAGN RESON IMAGING, V29, P167, DOI 10.1016/j.mri.2010.08.002
   Suh HB, 2018, EUR RADIOL, V28, P3832, DOI 10.1007/s00330-018-5368-4
   Toh CH, 2008, AM J NEURORADIOL, V29, P471, DOI 10.3174/ajnr.A0872
   Wen JB, 2017, J COMPUT ASSIST TOMO, V41, P904, DOI 10.1097/RCT.0000000000000636
   Xu WL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173430
   Yamashita K, 2013, NEURORADIOLOGY, V55, P135, DOI 10.1007/s00234-012-1089-6
   Yoo RE, 2013, J MAGN RESON IMAGING, V38, P852, DOI 10.1002/jmri.24026
   You SH, 2018, EUR RADIOL, V28, P3801, DOI 10.1007/s00330-018-5359-5
NR 38
TC 13
Z9 13
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E303
EP E309
DI 10.1016/j.wneu.2018.11.155
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400037
PM 30502475
HC Y
HP N
DA 2020-05-12
ER

PT J
AU Roh, H
   Kim, J
   Kim, JH
   Chong, K
   Yoon, WK
   Kwon, TH
   Kim, JH
AF Roh, Haewon
   Kim, Junwon
   Kim, Jang Hun
   Chong, Kyuha
   Yoon, Won Ki
   Kwon, Taek-Hyun
   Kim, Jong Hyun
TI Analysis of Complications After Cranioplasty with a Customized
   Three-Dimensional Titanium Mesh Plate
SO WORLD NEUROSURGERY
LA English
DT Article
DE Complication; Cranioplasty; Customized 3D titanium; Extrusion; Mesh;
   Titanium; Ventriculoperitoneal shunt
ID DECOMPRESSIVE CRANIECTOMY; RETROSPECTIVE ANALYSIS; AUTOLOGOUS BONE;
   POLYMETHYLMETHACRYLATE; EXPERIENCE; DEFECTS
AB OBJECTIVE: To report outcomes of cranioplasty (CP) with a customized three-dimensional (3D) titanium mesh plate and identify the relationship between various clinical variables and complications after CP.
   METHODS: Twenty patients who underwent surgery with customized 3D titanium mesh plates and had followup for > 6 months from January 2015 to December 2017 were enrolled. Complications related to CP were retrospectively reviewed. Patients were divided into 2 groups (no complication group and complication group), and clinical variables related to complications were compared between the 2 groups. Correlation analysis was performed to identify the clinical variable significantly correlated with complications after CP with a customized 3D titanium mesh plate.
   RESULTS: Of 20 patients, 11 developed complications, including extrusion, intracranial infection, severe operative site pain, and wound dehiscence. Among the clinical variables, only the presence of a ventriculoperitoneal shunt was significantly correlated with the overall complication rate (odds ratio = 18.66; 95% confidence interval, 1.56-222.92; P = 0.021).
   CONCLUSIONS: A customized 3D titanium mesh plate is associated with a lower risk of intracranial infection, but the rate of postoperative complications, mainly cosmetic problems, such as forehead mesh extrusion and dehiscence, was high at 55%. A ventriculoperitoneal shunt was significantly correlated with the overall complication rate after CP with a customized 3D titanium mesh plate.
C1 [Roh, Haewon; Kim, Junwon; Chong, Kyuha; Yoon, Won Ki; Kwon, Taek-Hyun; Kim, Jong Hyun] Korea Univ, Gum Hosp, Dept Neurosurg, Coll Med, Seoul, South Korea.
   [Roh, Haewon] Korea Univ, Guro Hosp, Focused Training Ctr Trauma, Coll Med, Seoul, South Korea.
   [Kim, Jang Hun] Armed Forces Yang Ju Hosp, Dept Neurosurg, Gyeonggi Do, South Korea.
RP Kim, JH (reprint author), Korea Univ, Gum Hosp, Dept Neurosurg, Coll Med, Seoul, South Korea.
EM jhkimns@gmail.com
CR Bobinski L, 2013, CLIN NEUROL NEUROSUR, V115, P1788, DOI 10.1016/j.clineuro.2013.04.013
   Cabraja M, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS091
   Frodel JL, 2008, FACIAL PLAST SURG, V24, P22, DOI [10.1055/s-2007-1021459, 10.1016/j.fsc.2007.11.013]
   Grant GA, 2004, J NEUROSURG, V100, P163, DOI 10.3171/ped.2004.100.2.0163
   Hill CS, 2012, BRIT J NEUROSURG, V26, P832, DOI 10.3109/02688697.2012.692839
   Honeybul S, 2017, J NEUROSURG, V126, P81, DOI 10.3171/2015.12.JNS152004
   Kim JH, 2018, WORLD NEUROSURG, V115, pE111, DOI 10.1016/j.wneu.2018.03.197
   Kriegel RJ, 2007, ZBL NEUROCHIR, V68, P182, DOI 10.1055/s-2007-985857
   Lai JB, 2011, J ORAL MAXIL SURG, V69, P1175, DOI 10.1016/j.joms.2010.05.034
   Lam S, 2015, CRANIOMAX TRAUM REC, V8, P159, DOI 10.1055/s-0034-1395880
   Lee L, 2013, BRIT J NEUROSURG, V27, P629, DOI 10.3109/02688697.2013.815313
   Liao CC, 2002, J CLIN NEUROSCI, V9, P553, DOI 10.1054/jocn.2002.1116
   Mukherjee S, 2014, ACTA NEUROCHIR, V156, P989, DOI 10.1007/s00701-014-2024-x
   Schuss P, 2012, J NEUROTRAUM, V29, P1090, DOI 10.1089/neu.2011.2176
   Stieglitz LH, 2015, ACTA NEUROCHIR, V157, P275, DOI 10.1007/s00701-014-2310-7
   Thien A, 2015, WORLD NEUROSURG, V83, P176, DOI 10.1016/j.wneu.2014.06.003
   Tsang ACO, 2015, J CLIN NEUROSCI, V22, P834, DOI 10.1016/j.jocn.2014.11.021
   Wiggins A, 2013, NEUROSURGERY, V72, P248, DOI 10.1227/NEU.0b013e31827b98f3
   Zanaty M, 2015, J NEUROSURG, V123, P182, DOI 10.3171/2014.9.JNS14405
NR 19
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E39
EP E44
DI 10.1016/j.wneu.2018.10.227
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400007
PM 30415044
DA 2020-05-12
ER

PT J
AU Roy, AK
   Philipp, LR
   Howard, BM
   Cawley, CM
   Grossberg, JA
   Barrow, DL
AF Roy, Anil K.
   Philipp, Lucas R.
   Howard, Brian M.
   Cawley, C. Michael, III
   Grossberg, Jonathan A.
   Barrow, Daniel L.
TI Microsurgical Treatment of Cerebral Aneurysms After Previous
   Endovascular Therapy: Single-Center Series and Systematic Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Microsurgical clipping; Recurrent cerebral aneurysm
ID RUPTURED INTRACRANIAL ANEURYSMS; PREVIOUSLY COILED ANEURYSMS; GUGLIELMI
   DETACHABLE COIL; NEUROSURGICAL MANAGEMENT; SURGICAL-MANAGEMENT;
   RECURRENT ANEURYSMS; ARTERY ANEURYSM; EMBOLIZATION; SURGERY;
   UNSUCCESSFUL
AB BACKGROUND: Since its introduction in the early 1990s, endovascular treatment of cerebral aneurysms has had a steady upward trend and is the primary mode of treatment for most intracranial aneurysms. Concurrently, the need for retreatment of aneurysms after previous endovascular treatment has continued to increase, some of which can only be treated with microsurgical techniques. The factors that dictate outcomes in this group of patients are incompletely understood.
   OBJECTIVE: To study factors contributing to patient outcomes after microsurgical treatment of aneurysms with previous endovascular treatment.
   METHODS: The records of the senior author (D.L.B.) since 2002 were retrospectively reviewed for aneurysms treated after previous endovascular treatment. Demographics, treatment details, and imaging were reviewed for all patients. A systematic review of the literature on microsurgical treatment of aneurysms previously treated by endovascular therapy was also conducted.
   RESULTS: A total of 91 patients were identified from the retrospective review. Mean age at the time of initial treatment was 49 +/- 12.68 years. Most patients initially presented with subarachnoid hemorrhage before initial endovascular treatment, with only 11 patients (12%) presenting with incidentally discovered lesions. Modified Rankin Scale score at discharge after initial treatment was good (0-3) in 81.4% of cases. Functional outcomes at the last known follow-up showed a modified Rankin Scale score of 0-3 in 77 patients (84.6%). Only aneurysm neck size was found to be a significant predictor of surgical complications (Wald chi(2) = 10.79; P = 0.0010) with an odds ratio of 2.32 (95% confidence interval, 1.40-3.83) for a 2-mm increase in neck size. Systematic review identified 37 studies who were used to pool data on 370 patients. Although type of surgery was identified as a predictor of poor outcomes, this was significantly confounded by Hunt and Hess grade in the systematic review.
   CONCLUSIONS: Favorable outcomes can be obtained even for highly complex cerebral aneurysms that have failed endovascular treatment at high-volume cerebrovascular centers. Initial presentation grade and aneurysm size are important predictors of final patient outcomes.
C1 [Roy, Anil K.; Philipp, Lucas R.; Howard, Brian M.; Cawley, C. Michael, III; Grossberg, Jonathan A.; Barrow, Daniel L.] Emory Univ, Sch Med, Dept Neurosurg, Atlanta, GA 30322 USA.
RP Grossberg, JA (reprint author), Emory Univ, Sch Med, Dept Neurosurg, Atlanta, GA 30322 USA.
EM jonathan.a.grossberg@emory.edu
RI Philipp, Lucas/AAK-7896-2020
CR Al-Schameri AR, 2016, INTERV NEURORADIOL, V22, P49, DOI 10.1177/1591019915617313
   Aoun SG, 2013, J CLIN NEUROSCI, V20, P1299, DOI 10.1016/j.jocn.2012.10.040
   Arnaout OM, 2015, WORLD NEUROSURG, V84, P246, DOI 10.1016/j.wneu.2015.02.027
   Asgari S, 2002, J NEUROSURG, V97, P843, DOI 10.3171/jns.2002.97.4.0843
   Rubino PA, 2014, WORLD NEUROSURG, V82, pE203, DOI 10.1016/j.wneu.2013.09.016
   Birchall D, 2001, BRIT J NEUROSURG, V15, P269, DOI 10.1080/026886901750353746
   Boet R, 2001, ACTA NEUROCHIR, V143, P1093, DOI 10.1007/s007010100001
   Bowers CA, 2015, ACTA NEUROCHIR, V157, P2071, DOI 10.1007/s00701-015-2593-3
   Byrne JV, 1999, J NEUROSURG, V90, P656, DOI 10.3171/jns.1999.90.4.0656
   Chung J, 2010, NEURORADIOLOGY, V52, P1143, DOI 10.1007/s00234-010-0695-4
   Civit T, 1996, NEUROSURGERY, V38, P955, DOI 10.1097/00006123-199605000-00021
   Conrad MD, 2002, ACTA NEUROCHIR, V144, P419, DOI 10.1007/s007010200062
   Daou B, 2016, J NEUROSURG, V125, P1337, DOI 10.3171/2015.10.JNS151544
   Deinsberger W, 2003, BRIT J NEUROSURG, V17, P149, DOI 10.1080/0268869031000108882
   Deshmukh VR, 2006, MINIM INVAS NEUROSUR, V49, P70, DOI 10.1055/s-2006-932187
   Ding Dale, 2014, J Cerebrovasc Endovasc Neurosurg, V16, P26, DOI 10.7461/jcen.2014.16.1.26
   Dorfer C, 2012, NEUROSURGERY, V70, P537, DOI 10.1227/NEU.0b013e3182350da5
   Gallas S, 2005, AM J NEURORADIOL, V26, P1723
   Gallas S, 2009, AM J NEURORADIOL, V30, P1986, DOI 10.3174/ajnr.A1744
   Grasso G, 2009, MED SCI MONITOR, V15, pCS63
   GURIAN JH, 1995, J NEUROSURG, V83, P843, DOI 10.3171/jns.1995.83.5.0843
   Hodgson TJ, 1998, AM J NEURORADIOL, V19, P1939
   Horowitz M, 1999, NEUROSURGERY, V44, P712, DOI 10.1097/00006123-199904000-00013
   Izumo T, 2015, WORLD NEUROSURG, V83, P211, DOI 10.1016/j.wneu.2014.08.013
   Johnston SC, 2008, STROKE, V39, P120, DOI 10.1161/STROKEAHA.107.495747
   Johnston SC, 2006, STROKE, V37, P1437, DOI 10.1161/01.STR.0000221331.01830.ce
   Kang HS, 2006, NEUROSURGERY, V58, P60, DOI 10.1227/01.NEU.0000194188.51731.13
   Kim YB, 2009, ACTA NEUROCHIR, V151, P1609, DOI 10.1007/s00701-009-0437-8
   Klein O, 2008, NEUROSURG REV, V31, P403, DOI 10.1007/s10143-008-0151-7
   Konig RW, 2007, ZBL NEUROCHIR, V68, P8, DOI 10.1055/s-2007-968164
   Kumar R, 2010, NEUROL INDIA, V58, P292, DOI 10.4103/0028-3886.63791
   LADOUCEUR DL, 1993, STROKE, V24, P1087, DOI 10.1161/01.STR.24.7.1087
   Lejeune JP, 2008, NEUROSURGERY, V63, P684, DOI 10.1227/01.NEU.0000325499.82876.6D
   Makoui AS, 2000, J NEUROSURG, V92, P355, DOI 10.3171/jns.2000.92.2.0355
   Minh T, 2006, BRIT J NEUROSURG, V20, P306, DOI 10.1080/02688690601000014
   Molyneux A, 2002, LANCET, V360, P1267, DOI 10.1016/S0140-6736(02)11314-6
   Nakamura M, 2013, CLIN NEUROL NEUROSUR, V115, P1343, DOI 10.1016/j.clineuro.2012.12.030
   Nomura M, 2000, INTERV NEURORADIOL, V6, P49, DOI 10.1177/15910199000060S105
   Petr O, 2015, ACTA NEUROCHIR, V157, P1623, DOI 10.1007/s00701-015-2500-y
   Pillai Promod, 2007, J Med Case Rep, V1, P168, DOI 10.1186/1752-1947-1-168
   Raftopoulos C, 2007, ACTA NEUROCHIR, V149, P11, DOI 10.1007/s00701-006-1046-4
   Romani R, 2011, NEUROSURGERY, V68, P140, DOI 10.1227/NEU.0b013e3181fd860e
   Spetzler RF, 2013, J NEUROSURG, V119, P146, DOI 10.3171/2013.3.JNS12683
   Thomas J Alex, 2008, Neurosurgery, V63, pE817, DOI 10.1227/01.NEU.0000325489.65932.AB
   Thornton J, 2000, SURG NEUROL, V54, P352, DOI 10.1016/S0090-3019(00)00337-2
   Tirakotai W, 2007, CLIN NEUROL NEUROSUR, V109, P744, DOI 10.1016/j.clineuro.2007.05.024
   Toyota S, 2015, NEUROL MED-CHIR, V55, P838, DOI 10.2176/nmc.oa.2015-0037
   Veznedaroglu E, 2008, NEUROSURGERY, V62, P1532, DOI [10.1227/01.NEU.0000103223.90054.C2, 10.1227/01.neu.0000333817.87401.74]
   Waldron JS, 2009, NEUROSURGERY, V64, P301, DOI 10.1227/01.NEU.0000335178.15274.B4
   Wang HW, 2017, BRIT J NEUROSURG, V31, P96, DOI 10.1080/02688697.2016.1226255
   Yoshida K, 2005, NEUROL MED-CHIR, V45, P356, DOI 10.2176/nmc.45.356
   Zhang YJ, 2003, NEUROSURGERY, V52, P283, DOI 10.1227/01.NEU.0000043643.93767.86
NR 52
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E103
EP E115
DI 10.1016/j.wneu.2018.11.065
PG 13
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400013
PM 30465952
DA 2020-05-12
ER

PT J
AU Rychen, J
   Stricker, S
   Mariani, L
   Schaeren, S
   Jost, GF
AF Rychen, Jonathan
   Stricker, Sarah
   Mariani, Luigi
   Schaeren, Stefan
   Jost, Gregory F.
TI Outcome of Spinal Surgery in Patients Older Than Age 90 Years
SO WORLD NEUROSURGERY
LA English
DT Article
DE 90 years; Complications; Elderly; Spinal surgery; Mortality;
   Nonagenarians; Outcome
ID HIP FRACTURE; ELDERLY-PATIENTS; MORTALITY; DECOMPRESSION; COMPLICATIONS;
   MORBIDITY; INTERVENTION; EFFICACY; STENOSIS
AB BACKGROUND: Increased life expectancy has led to indications for spine surgery in patients older than 90 years, but data on associated risks and outcome are lacking.
   METHODS: Indication, type of surgery, complications, functional outcome, and mortality were retrospectively collected from all patients aged 90 years or older operated between 2006 and 2016 at the University Hospital Basel, Switzerland.
   RESULTS: Sixty-nine patients were included, of which 55% had degenerative, 36% traumatic, and 9% other pathologies. Most surgeries (84%) were performed electively and 16% as emergencies. More than a third (36%) of elective and 58% of emergency surgeries required stabilization. The complication rate was 54% in the elective surgery group (ELSG) and 125% in the emergency surgery group (EMSG). Stabilization (P = 0.006) and emergency surgeries (P = 0.032) were significant risk factors for experiencing complications. Six weeks after surgery, 80% of the patients reported symptomatic improvement. More than half (58%) of the patients in the ELSG reached their specific median life expectancy, compared with 38% in the EMSG. Seventeen percent of patients in the EMSG versus 0% in the ELSG died in the first 3 months after surgery. In the nonstabilized group, 67% of the patients reached their median life expectancy, compared with 38% of the stabilized group.
   CONCLUSIONS: Elective spinal surgery in patients older than 90 years of age does not reduce life expectancy and has a good functional outcome for well-selected patients, whereas emergency surgery and stabilization surgery in this age group are associated with a high rate of complications and higher mortality.
C1 [Rychen, Jonathan; Stricker, Sarah; Schaeren, Stefan; Jost, Gregory F.] Univ Hosp Basel, Spine Surg, Basel, Switzerland.
   [Rychen, Jonathan; Stricker, Sarah; Mariani, Luigi] Univ Hosp Basel, Dept Neurosurg, Basel, Switzerland.
RP Jost, GF (reprint author), Univ Hosp Basel, Spine Surg, Basel, Switzerland.
EM gregory.jost@usb.ch
RI Mariani, Luigi/AAB-9464-2019
CR Acosta FL, 2011, J NEUROSURG-SPINE, V15, P667, DOI 10.3171/2011.7.SPINE10640
   Arinzon ZH, 2003, ARCH GERONTOL GERIAT, V36, P273, DOI 10.1016/S0167-4943(02)00172-3
   Bouloussa H, 2017, INT ORTHOP, V41, P2091, DOI 10.1007/s00264-017-3555-6
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Chen JW, 2015, CLIN NEUROL NEUROSUR, V132, P47, DOI 10.1016/j.clineuro.2015.02.012
   Federal Statistical Office of Switzerland, LIF EXP
   Fehlings MG, 2015, NEUROSURGERY, V77, pS1, DOI 10.1227/NEU.0000000000000953
   Fredman B, 2002, EUR SPINE J, V11, P571, DOI 10.1007/s00586-002-0409-7
   Grigoryan KV, 2014, J ORTHOP TRAUMA, V28, pE49, DOI 10.1097/BOT.0b013e3182a5a045
   Hagino T, 2006, J Orthop Surg (Hong Kong), V14, P122
   Hapuarachchi KS, 2014, J ORTHOP TRAUMATOL, V15, P13, DOI 10.1007/s10195-013-0248-9
   Intiso D, 2009, AGE AGEING, V38, P619, DOI 10.1093/ageing/afp126
   Kadowaki M, 2012, ARCH GERONTOL GERIAT, V54, pE113, DOI 10.1016/j.archger.2011.10.003
   KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868
   Khashan M, 2016, WORLD NEUROSURG, V89, P337, DOI 10.1016/j.wneu.2016.02.018
   Manoli A, 2017, J BONE JOINT SURG AM, V99, DOI 10.2106/JBJS.16.00697
   Prestmo A, 2015, LANCET, V385, P1623, DOI 10.1016/S0140-6736(14)62409-0
   Puvanesarajah V, 2016, SPINE, V41, pE1298, DOI 10.1097/BRS.0000000000001618
   Raffo CS, 2006, SPINE, V31, P99, DOI 10.1097/01.brs.0000192678.25586.e5
   Riley JC, 2005, POPUL DEV REV, V31, P537, DOI 10.1111/j.1728-4457.2005.00083.x
   Rosen DS, 2007, NEUROSURGERY, V60, P503, DOI 10.1227/01.NEU.0000255332.87909.58
   Vidan M, 2005, J AM GERIATR SOC, V53, P1476, DOI 10.1111/j.1532-5415.2005.53466.x
   Wang Michael Y, 2003, Neurosurg Focus, V14, pe7
   Wang MY, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.7.FOCUS15180
   Winkler EA, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.7.FOCUS15270
NR 25
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E457
EP E464
DI 10.1016/j.wneu.2018.11.188
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400053
PM 30500575
DA 2020-05-12
ER

PT J
AU Saglam, N
   Dogan, S
   Ozcan, C
   Turkmen, I
AF Saglam, Necdet
   Dogan, Selman
   Ozcan, Cagri
   Turkmen, Ismail
TI Comparison of Four Different Posterior Screw Fixation Techniques for the
   Treatment of Thoracolumbar Junction Fractures
SO WORLD NEUROSURGERY
LA English
DT Article
DE Fracture; Posterior stabilization; Short segment instrumentation;
   Thoracolumbar junction
ID BURST FRACTURES; SHORT-SEGMENT; INTERMEDIATE SCREWS; PEDICLE SCREWS;
   MANAGEMENT; ANTERIOR; INSTRUMENTATION; VERTEBRA; SURGERY; LEVEL
AB OBJECTIVE: The purpose of this study was to compare clinical and radiologic outcomes of patients who under- went short-segment posterior instrumentation with screw augmentation at the fracture level and long-segment instrumentation for thoracolumbar junction fractures.
   METHODS: Sixty-three patients were retrospectively evaluated by being divided into the following 4 groups: Groups A, B, C, and D included patients who had undergone 4-level instrumentation without insertion of screws at the fracture level, 3-level instrumentation by insertion of screws at the fracture level, 4-level instrumentation by insertion of screws at the fracture level, and 5-level instrumentation by insertion of screws at the fracture level, respectively.
   RESULTS: No significant difference was observed in preoperative local kyphosis angle (LKA) (P > 0.05), whereas there was a significant decrease in early postoperative LKA in Group C compared with the other groups (P < 0.05). However, there was no significant difference of LKA in the 4 groups measured on radiographs obtained at the final follow-up (P > 0.05). Anterior corpus height loss, Cobb angle of the fractured vertebra, and sagittal index, measured pre- and postoperatively and at the final follow-up, showed no significant difference (P > 0.05). There was no statistically significant difference between clinical scores of the 4 groups (P > 0.05).
   CONCLUSIONS: Short-segment posterior instrumentation with screw augmentation at the fracture level provides at least as much mechanical stability as long-segment instrumentation. Moreover, there is no difference between short-segment instrumentation with screw augmentation at the fracture level and long-segment instrumentation in terms of clinical outcomes.
C1 [Saglam, Necdet; Ozcan, Cagri; Turkmen, Ismail] SBU Umraniye Training & Res Hosp, Dept Orthopaed, Istanbul, Turkey.
   [Saglam, Necdet; Ozcan, Cagri; Turkmen, Ismail] SBU Umraniye Training & Res Hosp, Dept Traumatol, Istanbul, Turkey.
   [Dogan, Selman] SBU Sanliurfa Mehmet Akif Inan Training & Res Hos, Istanbul, Turkey.
RP Ozcan, C (reprint author), SBU Umraniye Training & Res Hosp, Dept Orthopaed, Istanbul, Turkey.; Ozcan, C (reprint author), SBU Umraniye Training & Res Hosp, Dept Traumatol, Istanbul, Turkey.
EM cagriozcann@gmail.com
RI Ozcan, Cagri/AAC-4040-2020
CR Aly TA, 2017, ASIAN SPINE J, V11, P150, DOI 10.4184/asj.2017.11.1.150
   Ankomah F, 2018, WORLD NEUROSURG, V118, DOI 10.1016/j.wneu.2018.07.022
   Assunção Filho Carlos Alberto, 2016, Coluna/Columna, V15, P78, DOI 10.1590/S1808-185120161501154925
   Bolesta MJ, 2012, INT J SPINE SURG, V6, P200, DOI 10.1016/j.ijsp.2012.09.002
   Canbek Umut, 2014, Eur J Orthop Surg Traumatol, V24, P459, DOI 10.1007/s00590-013-1326-7
   CARL AL, 1992, SPINE, V17, pS317
   Cheng LM, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009073.pub2
   Curfs Inez, 2016, Open Orthop J, V10, P135, DOI 10.2174/1874325001610010135
   DEKUTOSKI MB, 1993, J BONE JOINT SURG AM, V75A, P168, DOI 10.2106/00004623-199302000-00003
   DICK JC, 1994, J SPINAL DISORD, V7, P402
   Dobran M, 2016, ACTA NEUROCHIR, V158, P1883, DOI 10.1007/s00701-016-2907-0
   GERTZBEIN SD, 1988, SPINE, V13, P641
   Kanna RM, 2015, SPINE J, V15, P256, DOI 10.1016/j.spinee.2014.09.004
   Kim GW, 2014, J KOREAN NEUROSURG S, V56, P230, DOI 10.3340/jkns.2014.56.3.230
   Kong WQ, 2010, J SPINAL DISORD TECH, V23, P302, DOI 10.1097/BSD.0b013e3181b4adcd
   Kumar A, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064-015-0960-4
   Lee JK, 2013, ACTA NEUROCHIR, V155, P2305, DOI 10.1007/s00701-013-1859-x
   Li KP, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004574
   Ozdemir B, 2017, WORLD NEUROSURG, V99, P409, DOI 10.1016/j.wneu.2016.11.133
   Pishnamaz M, 2018, WORLD NEUROSURG, V115, pE695, DOI 10.1016/j.wneu.2018.04.138
   Sapkas George, 2010, Open Orthop J, V4, P7, DOI 10.2174/1874325001004010007
   Sasso RC, 2006, J SPINAL DISORD TECH, V19, P242, DOI 10.1097/01.bsd.0000211298.59884.24
   Serin E, 2004, EUR J ORTHOP SURG TR, V14, P1, DOI DOI 10.1007/S00590-003-0110-5
   Tong MJ, 2018, WORLD NEUROSURG, V110, pE271, DOI 10.1016/j.wneu.2017.10.157
   Uzumcugil Onat, 2010, Kobe J Med Sci, V56, pE67
   Verlaan JJ, 2013, SPINE J, V13, P1733, DOI 10.1016/j.spinee.2013.07.029
   Wang HW, 2017, CLIN SPINE SURG, V30, pE239, DOI 10.1097/BSD.0000000000000135
   Wang L, 2014, INT J CLIN EXP MED, V7, P657
NR 28
TC 1
Z9 2
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E773
EP E780
DI 10.1016/j.wneu.2018.12.030
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400093
PM 30579033
DA 2020-05-12
ER

PT J
AU Salunke, P
   Sahoo, SK
AF Salunke, Pravin
   Sahoo, Sushanta K.
TI Irreducible Posterior C1-2 Dislocation with Retrolisthesis of Dens:
   Hindsight from 10 Cases
SO WORLD NEUROSURGERY
LA English
DT Article
DE C1-2 realignment; Odontoid fracture; Os odontoideum; Posterior
   atlantoaxial dislocation; Retrolisthesis
ID ODONTOID FRACTURE; REDUCTION
AB OBJECTIVE: Posterior C1-2 dislocation secondary to fracture of the dens or os odontoideum is uncommon. Little is known about posterior dislocations in which close reduction fails, requiring intraoperative maneuvers. The objective of this retrospective study was to analyze clinical presentations, factors causing irreducibility, and nuances in the achievement of intraoperative reduction.
   METHODS: The clinicoradiological features of 10 patients with irreducible posterior C1-2 dislocation were studied. Six were posttraumatic, with odontoid fractures, and 4 had os odontoideum. The radiologic images were studied to analyze the cause of irreducibility, and the operative management of these cases was discussed.
   RESULTS: The patients with traumatic dislocation had persistent neck pain (n = 6) and early onset (n = 1) or delayed onset (n = 4) myelopathy. The fracture line was oblique, extending anterosuperiorly to posteroinferiorly in all except 1 patient, with fracture fragments distracted in 4 and interlocked in 2. There was associated lateral translation in 2. All patients had facet locking. Intraoperative reduction was achieved in all by unlocking the facets, intrafracture reduction, or both. All 4 patients with congenital posterior dislocations had retrolisthesis of dens with lateral translation. They presented with neck tilt (n = 4) and severe myelopathy (n = 3). They were easier to reduce intraoperatively, but the improvement lesser in comparison with the traumatic fractures.
   CONCLUSIONS: The posterior C1-2 dislocation associated with fracture of the dens or os-odontoideum is a distinct entity. Lateral translation is often seen with retrolisthesis of the os odontoideum and occasionally in traumatic posterior dislocations. It is necessary to address the cause of irreducibility and achieve multiplanar realignment for a good outcome.
C1 [Salunke, Pravin; Sahoo, Sushanta K.] PGIMER, Dept Neurosurg, Chandigarh, India.
RP Sahoo, SK (reprint author), PGIMER, Dept Neurosurg, Chandigarh, India.
EM drsushantasahoo@gmail.com
CR Behari S, 2010, INDIAN J ORTHOP, V44, P417, DOI 10.4103/0019-5413.69316
   Goel A, 2018, WORLD NEUROSURG, V110, P558, DOI 10.1016/j.wneu.2017.08.192
   Grauer Jonathan N, 2005, Spine J, V5, P123, DOI 10.1016/j.spinee.2004.09.014
   Meng H, 2014, SKELETAL RADIOL, V43, P1001, DOI 10.1007/s00256-013-1809-y
   Prasad PK, 2017, J CRANIOVERTEBRAL JU, V8, P354, DOI 10.4103/jcvjs.JCVJS_109_17
   Salunke P, 2016, WORLD NEUROSURG, V95, P156, DOI 10.1016/j.wneu.2016.07.097
   Salunke P, 2016, PEDIATR NEUROSURG, V51, P218, DOI 10.1159/000444939
   Salunke P, 2015, BRIT J NEUROSURG, V29, P513, DOI 10.3109/02688697.2015.1019421
   Salunke P, 2015, J NEUROSURG-SPINE, V23, P294, DOI 10.3171/2014.12.SPINE14310
   Salunke P, 2015, CLIN NEUROL NEUROSUR, V131, P47, DOI 10.1016/j.clineuro.2015.01.025
   Salunke P, 2014, NEUROL INDIA, V62, P310, DOI 10.4103/0028-3886.136993
   Salunke P, 2014, J NEUROSURG-SPINE, V20, P722, DOI 10.3171/2014.3.SPINE13806
NR 12
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E202
EP E210
DI 10.1016/j.wneu.2018.11.124
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400025
PM 30476658
DA 2020-05-12
ER

PT J
AU Schreiber, A
   Bertazzoni, G
   Ferrari, M
   Rampinelli, V
   Verri, P
   Mattavelli, D
   Fontanella, M
   Nicolai, P
   Doglietto, F
AF Schreiber, Alberto
   Bertazzoni, Giacomo
   Ferrari, Marco
   Rampinelli, Vittorio
   Verri, Paolo
   Mattavelli, Davide
   Fontanella, Marco
   Nicolai, Piero
   Doglietto, Francesco
TI Nasal Morbidity and Quality of Life After Endoscopic Transsphenoidal
   Surgery: A Single-Center Prospective Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endoscopic surgery; Nasal morbidity; Olfaction; Pituitary; Quality of
   life; Transsphenoidal approach
ID SKULL-BASE SURGERY; SEPTAL FLAP RECONSTRUCTION; ENDONASAL APPROACH;
   OLFACTORY OUTCOMES; SINONASAL OUTCOMES; PITUITARY SURGERY; VALIDATION;
   IMPACT; PRESERVATION; MANAGEMENT
AB OBJECTIVE: The aim of this study was to assess nasal morbidity of endoscopic transsphenoidal approaches (ETAs) for treatment of sellar and parasellar diseases through evaluation of quality of life (QoL) and nasal function. The impact of different ETAs, according to extent and reconstruction technique, was also studied.
   METHODS: Patients undergoing ETA for treatment of sellar or parasellar lesions were prospectively recruited and examined preoperatively and at 6 months after surgery according to the following workup: nasal endoscopy, rhinomanometry, acoustic rhinometry, University of Pennsylvania Smell Identification Test, Anterior Skull Base Nasal Inventory-12, Sino-nasal Outcome Test-22, and Short-Form Health Survey-36 (SF-36).
   RESULTS: Of 34 patients initially recruited, 29 completed follow-up examinations. Seven patients (24.14%) developed turbinoseptal synechiae; anterior septal perforations were observed in 3 patients (10.35%). More extended surgical dissection was associated with the presence of postoperative septal perforation and synechiae. No significant difference was noted between preoperative and postoperative results on the University of Pennsylvania Smell Identification Test, acoustic rhinometry, Sino-nasal Outcome Test-22, or Anterior Skull Base Nasal Inventory-12. There was a significant increase in nasal airflow after surgery and improvement of the Short-Form Health Survey-36 score in 4 of 8 domains.
   CONCLUSIONS: The modular ETA technique is associated with minimal morbidity and preserves nasal patency, airflow, and olfactory function. Quality of life is not affected and although small septal perforations and synechiae can be observed, nasal physiology is not compromised. Nonetheless, careful manipulation of sinonasal structures is recommended to minimize postoperative sequelae.
C1 [Schreiber, Alberto; Bertazzoni, Giacomo; Ferrari, Marco; Rampinelli, Vittorio; Mattavelli, Davide; Nicolai, Piero] Univ Brescia, Unit Otorhinolaryngol Head & Neck Surg, Brescia, Italy.
   [Verri, Paolo] Univ Brescia, Brescia, Italy.
   [Fontanella, Marco; Doglietto, Francesco] Univ Brescia, Unit Neurosurg, Brescia, Italy.
RP Bertazzoni, G (reprint author), Univ Brescia, Unit Otorhinolaryngol Head & Neck Surg, Brescia, Italy.
EM ilbertaz@gmail.com
RI Schreiber, Alberto/AAB-6722-2020; rampinelli, vittorio/AAF-5514-2019;
   Ferrari, Marco/AAC-7179-2019; Mattavelli, Davide/AAC-1548-2019
OI Ferrari, Marco/0000-0002-4023-0121; Mattavelli,
   Davide/0000-0001-7023-6746; Bertazzoni, Giacomo/0000-0002-9553-1757;
   Schreiber, Alberto/0000-0002-1580-3928
CR Almutairi RD, 2018, ACTA NEUROCHIR, V160, P1005, DOI 10.1007/s00701-017-3438-z
   Alobid I, 2013, AM J RHINOL ALLERGY, V27, P426, DOI 10.2500/ajra.2013.27.3932
   Alobid I, 2013, NEUROSURGERY, V72, P540, DOI 10.1227/NEU.0b013e318282a535
   Apolone G, 1998, J CLIN EPIDEMIOL, V51, P1025, DOI 10.1016/S0895-4356(98)00094-8
   Awad AJ, 2015, CLIN NEUROL NEUROSUR, V130, P162, DOI 10.1016/j.clineuro.2015.01.004
   Balaker AE, 2010, SKULL BASE-INTERD AP, V20, P245, DOI 10.1055/s-0030-1249248
   Batra PS, 2005, AM J RHINOL, V19, P185, DOI 10.1177/194589240501900212
   Belotti F, 2018, WORLD NEUROSURG, V109, pE281, DOI 10.1016/j.wneu.2017.09.165
   Chaaban MR, 2015, AM J RHINOL ALLERGY, V29, P365, DOI 10.2500/ajra.2015.29.4206
   Charalampaki P, 2009, J CLIN NEUROSCI, V16, P786, DOI 10.1016/j.jocn.2008.09.002
   Cheng Y, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006614
   Cote DJ, 2017, J AM COLL SURGEONS, V224, P971, DOI 10.1016/j.jamcollsurg.2017.02.015
   Davies BM, 2017, J NEUROL SURG PART B, V78, P266, DOI 10.1055/s-0036-1597814
   de Almeida JR, 2011, HEAD NECK-J SCI SPEC, V33, P547, DOI 10.1002/hed.21483
   De Los Reyes KM, 2015, J CLIN NEUROSCI, V22, P116, DOI 10.1016/j.jocn.2014.07.004
   Esposito F, 2007, NEUROSURGERY, V60, P295, DOI 10.1227/01.NEU.0000255354.64077.66
   Frank G, 2006, NEUROENDOCRINOLOGY, V83, P240, DOI 10.1159/000095534
   Garcia HG, 2016, J NEUROL SURG PART B, V77, P479, DOI 10.1055/s-0036-1584077
   Gondim JA, 2011, PITUITARY, V14, P174, DOI 10.1007/s11102-010-0280-1
   Greig SR, 2016, INT FORUM ALLERGY RH, V6, P1040, DOI 10.1002/alr.21760
   Griffiths CF, 2014, ACTA NEUROCHIR, V156, P1393, DOI 10.1007/s00701-014-2107-8
   Hadad G, 2006, LARYNGOSCOPE, V116, P1882, DOI 10.1097/01.mlg.0000234933.37779.e4
   Hanson M, 2015, J LARYNGOL OTOL, V129, pS41, DOI 10.1017/S002221511500047X
   Hong SD, 2016, WORLD NEUROSURG, V87, P162, DOI 10.1016/j.wneu.2015.12.050
   Jalessi Maryam, 2016, Med J Islam Repub Iran, V30, P379
   Jalessi M, 2016, EUR ARCH OTO-RHINO-L, V273, P1199, DOI 10.1007/s00405-015-3729-z
   Johnson Michelle D, 2003, Pituitary, V6, P81, DOI 10.1023/B:PITU.0000004798.27230.ed
   Kassam Amin, 2005, Neurosurg Focus, V19, pE3
   Kim SW, 2013, LARYNGOSCOPE, V123, P1602, DOI 10.1002/lary.24107
   Kirkman MA, 2014, J NEUROL SURG PART B, V75, P73, DOI 10.1055/s-0033-1359303
   Leng LZ, 2008, NEUROSURGERY, V62, P342, DOI [10.1227/01.NEU.0000312720.93685.17, 10.1227/01.neu.0000326017.84315.1f]
   Little AS, 2013, J NEUROSURG, V119, P1068, DOI 10.3171/2013.3.JNS122032
   McCoul ED, 2015, INT FORUM ALLERGY RH, V5, P1124, DOI 10.1002/alr.21602
   McCoul ED, 2012, J NEUROSURG, V117, P498, DOI 10.3171/2012.6.JNS111066
   McCoul ED, 2012, INT FORUM ALLERGY RH, V2, P174, DOI 10.1002/alr.21008
   McLaughlin N, 2013, J NEUROSURG, V118, P613, DOI 10.3171/2012.11.JNS112020
   Moreland DB, 2000, MINIM INVAS NEUROSUR, V43, P57, DOI 10.1055/s-2000-12259
   Mozzanica F, 2017, EUR ARCH OTO-RHINO-L, V274, P887, DOI 10.1007/s00405-016-4313-x
   Nyquist GG, 2010, SKULL BASE-INTERD AP, V20, P343, DOI 10.1055/s-0030-1253582
   Pallanch J, 2015, CUMMINGS OTOLARYNGOL, P644
   Pant H, 2010, SKULL BASE-INTERD AP, V20, P35, DOI 10.1055/s-0029-1242983
   Picillo M, 2014, CLIN OTOLARYNGOL, V39, P53, DOI 10.1111/coa.12212
   Pledger CL, 2016, J NEUROSURG, V125, P323, DOI 10.3171/2015.6.JNS142695
   Rioja E, 2016, EUR ARCH OTO-RHINO-L, V273, P1809, DOI 10.1007/s00405-015-3853-9
   Rivera-Serrano CM, 2011, LARYNGOSCOPE, V121, P990, DOI 10.1002/lary.21419
   Rotenberg BW, 2011, LARYNGOSCOPE, V121, P1611, DOI 10.1002/lary.21890
   Schwartz TH, 2008, NEUROSURGERY, V62, P991, DOI [10.1227/01.NEU.0000313231.81129.66, 10.1227/01.neu.0000325861.06832.06]
   Sowerby LJ, 2013, INT FORUM ALLERGY RH, V3, P217, DOI 10.1002/alr.21103
   Suberman TA, 2011, INT FORUM ALLERGY RH, V1, P161, DOI 10.1002/alr.20029
   Tam S, 2013, INT FORUM ALLERGY RH, V3, P62, DOI 10.1002/alr.21069
   Tewfik MA, 2014, J NEUROL SURG PART B, V75, P415, DOI 10.1055/s-0034-1383855
   Thompson CF, 2014, J NEUROL SURG PART B, V75, P65, DOI 10.1055/s-0033-1356492
   Thompson CF, 2012, ORL J OTO-RHINO-LARY, V74, P315, DOI 10.1159/000345500
   van der Klaauw AA, 2008, CLIN ENDOCRINOL, V69, P775, DOI 10.1111/j.1365-2265.2008.03288.x
   Wang SS, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000465
   Wu V, 2018, AM J RHINOL ALLERGY, V32, P52, DOI 10.2500/ajra.2018.32.4499
   Zimmer LA, 2014, J NEUROL SURG PART B, V75, P288, DOI 10.1055/s-0034-1372464
NR 57
TC 3
Z9 3
U1 4
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E557
EP E565
DI 10.1016/j.wneu.2018.11.212
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400065
PM 30528530
DA 2020-05-12
ER

PT J
AU Solari, D
   Zenga, F
   Angileri, FF
   Barbanera, A
   Berlucchi, S
   Bemucci, C
   Carapella, C
   Catapano, D
   Catapano, G
   Cavallo, LM
   D'Arrigo, C
   de Angelis, M
   Denaro, L
   Desogus, N
   Ferroli, P
   Fontanella, MM
   Galzio, RJ
   Gianfreda, CD
   Iacoangeli, M
   Lauretti, L
   Locatelli, D
   Locatelli, M
   Luglietto, D
   Mazzatenta, D
   Menniti, A
   Milani, D
   Nasi, MT
   Romano, A
   Ruggeri, AG
   Saladino, A
   Santonocito, O
   Schwarz, A
   Skrap, M
   Stefini, R
   Volpin, L
   Wembagher, GC
   Zoia, C
   Zona, G
   Cappabianca, P
AF Solari, Domenico
   Zenga, Francesco
   Angileri, Filippo F.
   Barbanera, Andrea
   Berlucchi, Silvia
   Bemucci, Claudio
   Carapella, Carmine
   Catapano, Domenico
   Catapano, Giuseppe
   Cavallo, Luigi M.
   D'Arrigo, Corrado
   de Angelis, Michelangelo
   Denaro, Luca
   Desogus, Nicola
   Ferroli, Paolo
   Fontanella, Marco M.
   Galzio, Renato J.
   Gianfreda, Cosimo D.
   Iacoangeli, Maurizio
   Lauretti, Liverana
   Locatelli, Davide
   Locatelli, Marco
   Luglietto, Davide
   Mazzatenta, Diego
   Menniti, Agazio
   Milani, Davide
   Nasi, Maria Teresa
   Romano, Antonio
   Ruggeri, Andrea G.
   Saladino, Andrea
   Santonocito, Orazio
   Schwarz, Andreas
   Skrap, Miran
   Stefini, Roberto
   Volpin, Lorenzo
   Wembagher, Giulio C.
   Zoia, Cesare
   Zona, Gianluigi
   Cappabianca, Paolo
TI A Survey on Pituitary Surgery in Italy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Craniopharyngiomas; Endoscopic endonasal surgery; Multidisciplinary
   team; Pituitary adenomas; Pituitary/hypothalamus; Pituitary surgery;
   Transsphenoidal surgery
ID ENDOSCOPIC ENDONASAL APPROACH; SKULL BASE SURGERY; OPEN TRANSCRANIAL
   RESECTION; OF-THE-LITERATURE; TRANSSPHENOIDAL APPROACH; ADENOMAS;
   MANAGEMENT; CHORDOMAS; CRANIOPHARYNGIOMAS; PREVALENCE
AB BACKGROUND: Pituitary tumors are a heterogeneous group of lesions that are usually benign. Therefore, a proper understanding of the anatomy, physiology, and pathology is mandatory to achieve favorable outcomes. Accordingly, diagnostic tests and treatment guidelines should be determined and implemented. Thus, we decided to perform a multicenter study among Italian neurosurgical centers performing pituitary surgery to provide an actual depiction from the neurosurgical standpoint.
   METHODS: On behalf of the SINch (Societa Italiana di Neurochirurgia), a survey was undertaken with the participants to explore the activities in the field of pituitary surgery within 41 public institutions.
   RESULTS: Of the 41 centers, 37 participated in the present study. The total number of neurosurgical procedures performed in 2016 was 1479. Most of the procedures were performed using the transsphenoidal approach (1320 transsphenoidal [1204 endoscopic, 53 microscopic, 53 endoscope-assisted microscopic] vs. 159 transcranial). A multidisciplinary tumor board is convened regularly in 32 of 37 centers, and a research laboratory is present in 18 centers.
   CONCLUSIONS: Diagnosing pituitary/hypothalamus disorders and treating them is the result of teamwork, composed of several diverse experts. Regarding neurosurgery, our findings have confirmed the central role of the transsphenoidal approach, with preference toward the endoscopic technique. Better outcomes can be expected at centers with a multidisciplinary team and a full, or part of a, residency program, with a greater surgical caseload.
C1 [Solari, Domenico; Cavallo, Luigi M.; Cappabianca, Paolo] Univ Napoli Federico II, Div Neurosurg, Naples, Italy.
   [Zenga, Francesco] Univ Torino, Div Neurosurg, Citte Salute & Sci, Turin, Italy.
   [Angileri, Filippo F.] Univ Messina, Div Neurosurg, Policlin G Martino, Messina, Italy.
   [Barbanera, Andrea] AO SS Antonio & Biagio & Cesare Arrigo, Div Neurosurg, Alessandria, Italy.
   [Berlucchi, Silvia] AOU Osped Civile Baggiovara, Div Neurosurg, Modena, Italy.
   [Bemucci, Claudio] ASST Papa Giovanni XXIII, Div Neurosurg, Bergamo, Italy.
   [Carapella, Carmine] IRCCS Ist Nazl Tumori Regina Elena, Div Neurosurg, Rome, Italy.
   [Catapano, Domenico] IRCCS Casa Sollievo Sofferenza, Div Neurosurg, San Giovanni Rotondo, Italy.
   [Catapano, Giuseppe] AO G Rummo, Div Neurosurg, Benevento, Italy.
   [D'Arrigo, Corrado] AO Cannizraro, Div Neurosurg, Catania, Italy.
   [de Angelis, Michelangelo] IRCCS Neuromed, Div Neurosurg, Pozzilli, Italy.
   [Denaro, Luca] Univ Padua, Div Neurosurg, Padua, Italy.
   [Desogus, Nicola] AO G Brotzu, Div Neurosurg, Cagliari, Italy.
   [Ferroli, Paolo] Fdn IRCCS Ist Neurol Carlo Besta, Div Neurosurg NCH 2, Milan, Italy.
   [Fontanella, Marco M.] Univ Brescia, Spedali Civili, Div Neurosurg, Brescia, Italy.
   [Galzio, Renato J.] Univ Osped Civile T Salvatore, Div Neurosurg, Laquila, Italy.
   [Galzio, Renato J.; Zoia, Cesare] Univ Pavia, Fdn IRCCS Policlin S Mateo, Div Neurosurg, Pavia, Italy.
   [Gianfreda, Cosimo D.] Presidio Osped V Fazzi, Div Neurosurg, Lecce, Italy.
   [Iacoangeli, Maurizio] Univ Politecn Marche, Osped Riuniti Torrette, Div Neurosurg, Ancona, Italy.
   [Lauretti, Liverana] Univ Cattolica Sacro Cuore, Policlin A Gemelli, Div Neurosurg, Rome, Italy.
   [Locatelli, Davide] Univ Insubria, Osped Circolo & Fdn Macchi, Div Neurosurg, Varese, Italy.
   [Locatelli, Marco] Fdn IRCCS Ca Grande, Osped Maggiore Policlin, Div Neurosurg, Milan, Italy.
   [Luglietto, Davide] AOU Senese Le Scotte, Div Neurosurg, Siena, Italy.
   [Mazzatenta, Diego] Osped Bellaria, IRCCS Ist Sci Neurol, Div Neurosurg, Bologna, Italy.
   [Menniti, Agazio] AO San Camillo Forlanini, Div Neurosurg, Rome, Italy.
   [Milani, Davide] Humanitas Res Hosp, Div Neurosurg, Rozzano, Italy.
   [Nasi, Maria Teresa] AO M Bufalini, Div Neurosurg, Cesena, Italy.
   [Romano, Antonio] AOU Parma Reggio Emilia, Div Neurosurg, Parma, Italy.
   [Ruggeri, Andrea G.] Univ Roma La Sapienza, Div Neurosurg, Rome, Italy.
   [Saladino, Andrea] Fdn IRCCS Ist Neurol Carlo Besta, Div Neurosurg NCH 1, Milan, Italy.
   [Santonocito, Orazio] USL Toscana Nord Ovest, Spedali Riuniti Livorno, Div Neurosurg, Livorno, Italy.
   [Schwarz, Andreas] Osped Bolzano, Div Neurosurg, Bolzano, Italy.
   [Skrap, Miran] AOU Udine, Div Neurosurg, Udine, Italy.
   [Stefini, Roberto] AO Osped Civile Legnano, Div Neurosurg, Legnano, Italy.
   [Volpin, Lorenzo] Osped San Bortolo, Div Neurosurg, Vicenza, Italy.
   [Wembagher, Giulio C.] AOU Careggi, Div Neurosurg, Florence, Italy.
   [Zona, Gianluigi] Univ Genoa, Div Neurosurg, Osped San Martino, Genoa, Italy.
RP Solari, D (reprint author), Univ Napoli Federico II, Div Neurosurg, Naples, Italy.
EM domenico.solari@unina.it
RI ; Angileri, Filippo/J-3533-2012; Zoia, Cesare/B-8463-2015
OI LOCATELLI, DAVIDE/0000-0003-1163-9611; catapano,
   domenico/0000-0002-4301-9137; Angileri, Filippo/0000-0002-1107-4115;
   SOLARI, Domenico/0000-0003-1535-8737; Luglietto,
   Davide/0000-0001-9744-3171; Zoia, Cesare/0000-0001-7304-6120
CR AlMefty O, 1997, J NEUROSURG, V86, P182, DOI 10.3171/jns.1997.86.2.0182
   Asa SL, 2017, ENDOCR-RELAT CANCER, V24, pC5, DOI 10.1530/ERC-17-0004
   Asa SL, 2018, HISTOPATHOLOGY, V72, P133, DOI 10.1111/his.13295
   Baldeweg SE, 2016, ENDOCR CONNECT, V5, pG12, DOI 10.1530/EC-16-0057
   Bander ED, 2018, J NEUROSURG, V128, P40, DOI 10.3171/2016.9.JNS16823
   Barajas MA, 2002, J NEUROSURG, V97, P607, DOI 10.3171/jns.2002.97.supplement_5.0607
   Barkhoudarian G, 2013, NEUROSURGERY, V73, P74, DOI 10.1227/NEU.0b013e31828ba962
   Benveniste RJ, 2005, J NEUROSURG, V102, P1004, DOI 10.3171/jns.2005.102.6.1004
   Birkmeyer JD, 2003, NEW ENGL J MED, V349, P2117, DOI 10.1056/NEJMsa035205
   Capatina C, 2015, EUR J ENDOCRINOL, V172, pR179, DOI 10.1530/EJE-14-0794
   Cappabianca P, 2004, NEUROSURGERY, V54, P1043, DOI 10.1227/01.NEU.0000119325.14116.9C
   Cappabianca P, 2002, J NEUROSURG, V97, P293, DOI 10.3171/jns.2002.97.2.0293
   Cappabianca P, 2008, ADV TECHNICAL STANDA, P152
   Cappabianca P, 2010, ENDOCRINOLOGY, P358
   Cappabianca P, 2008, PITUITARY, V11, P385, DOI 10.1007/s11102-008-0087-5
   Cappabianca P, 2007, SURG NEUROL, V67, P496, DOI 10.1016/j.surneu.2006.09.039
   Cappabianca P, 2014, WORLD NEUROSURG, V82, pS3, DOI 10.1016/j.wneu.2014.07.019
   Cappabianca P, 2014, ACTA NEUROCHIR, V156, P2217, DOI 10.1007/s00701-014-2213-7
   Casanueva FF, 2017, PITUITARY, V20, P489, DOI 10.1007/s11102-017-0838-2
   Cavallo LM, 2013, WORLD NEUROSURG, V80, P342, DOI 10.1016/j.wneu.2012.10.008
   Cavallo LM, 2009, J NEUROSURG, V111, P578, DOI 10.3171/2009.2.JNS081026
   Cavallo LM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147524
   Cavallo LM, 2014, J NEUROSURG, V121, P100, DOI 10.3171/2014.3.JNS131521
   Cavallo LM, 2013, NEUROSURG REV, V36, P27, DOI 10.1007/s10143-012-0403-4
   Chang EF, 2010, PITUITARY, V13, P223, DOI 10.1007/s11102-010-0221-z
   Chibbaro S, 2014, NEUROSURG REV, V37, P224
   Chibbaro S, 2014, NEUROSURG REV, V37, P217, DOI 10.1007/s10143-013-0503-9
   Ciric I, 1997, NEUROSURGERY, V40, P225, DOI 10.1097/00006123-199702000-00001
   Clayton RN, 1999, BEST PRACT RES CL EN, V13, P451, DOI 10.1053/beem.1999.0036
   Daly A F, 2005, J Endocrinol Invest, V28, P67
   Daly AF, 2006, J CLIN ENDOCR METAB, V91, P4769, DOI 10.1210/jc.2006-1668
   de Divitiis E, 2002, NEUROSURGERY, V51, P699, DOI 10.1097/00006123-200209000-00016
   de Divitiis E, 2002, NEUROSURGERY, V51, P705
   De Divitiis E, 2007, NEUROSURGERY, V61, P219, DOI 10.1227/01.neu.0000303220.55393.73
   de Divitiis E, 2007, NEUROSURGERY, V60, P46, DOI 10.1227/01.NEU.0000249211.89096.25
   de Divitiis E, 2006, NEUROSURGERY, V59, P512, DOI 10.1227/01.NEU.0000227475.69682.77
   de Notaris M, 2014, LARYNGOSCOPE, V124, P2231, DOI 10.1002/lary.24693
   Dhandapani S, 2017, J NEUROSURG, V126, P418, DOI 10.3171/2016.1.JNS152238
   Dusick JR, 2005, J NEUROSURG, V102, P832, DOI 10.3171/jns.2005.102.5.0832
   Ellegala DB, 2002, NEUROSURGERY, V51, P513, DOI 10.1097/00006123-200208000-00041
   Esposito F., 2016, J NEUROSURG SCI
   Esposito F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151533
   Ezzat S, 2004, CANCER, V101, P613, DOI 10.1002/cncr.20412
   Fernandez A, 2010, CLIN ENDOCRINOL, V72, P377, DOI 10.1111/j.1365-2265.2009.03667.x
   Frank G, 2006, NEUROSURGERY, V59, P75, DOI 10.1227/01.NEU.0000219897.98238.A3
   Frank G, 2006, NEUROSURGERY, V59, P50, DOI 10.1227/01.NEU.0000219914.17221.55
   Fraser JF, 2009, MINIM INVAS NEUROSUR, V52, P25, DOI 10.1055/s-0028-1104567
   Fraser JF, 2010, J NEUROSURG, V112, P1061, DOI 10.3171/2009.7.JNS081504
   Gardner PA, 2008, NEUROSURGERY, V63, P36, DOI 10.1227/01.NEU.0000335069.30319.1E
   Gardner PA, 2008, J NEUROSURG, V109, P6, DOI 10.3171/JNS/2008/109/7/0006
   Gardner PA, 2008, J NEUROSURG, V108, P1043, DOI 10.3171/JNS/2008/108/5/1043
   Golden SH, 2009, J CLIN ENDOCR METAB, V94, P1853, DOI 10.1210/jc.2008-2291
   Gondim JA, 2014, WORLD NEUROSURG, V82, pE281, DOI 10.1016/j.wneu.2013.08.028
   HARDY J, 1971, J NEUROSURG, V34, P582, DOI 10.3171/jns.1971.34.4.0582
   Jane JA, 2002, NEUROSURGERY, V51, P435, DOI 10.1097/00006123-200208000-00025
   Jeswani S, 2016, J NEUROSURG, V124, P627, DOI 10.3171/2015.3.JNS142254
   Kari E, 2012, INT FORUM ALLERGY RH, V2, P2, DOI 10.1002/alr.20036
   Kassam A, 2007, J NEUROSURG, V106, P75, DOI 10.3171/ped.2007.106.2.75
   Kassam Amin, 2005, Neurosurg Focus, V19, pE4
   Kassam Amin, 2005, Neurosurg Focus, V19, pE3
   Kassam Amin B, 2005, Neurosurg Focus, V19, pE6
   Kassam AB, 2011, J NEUROSURG, V114, P1544, DOI 10.3171/2010.10.JNS09406
   Kassam AB, 2009, NEUROSURGERY, V64, pS71, DOI 10.1227/01.NEU.0000335162.36862.54
   Komotar RJ, 2012, PITUITARY, V15, P150, DOI 10.1007/s11102-011-0359-3
   Komotar RJ, 2012, WORLD NEUROSURG, V77, P329, DOI 10.1016/j.wneu.2011.07.011
   Komotar RJ, 2011, WORLD NEUROSURG, V76, P318, DOI 10.1016/j.wneu.2011.02.026
   Koutourousiou M, 2013, J NEUROSURG, V119, P1194, DOI 10.3171/2013.6.JNS122259
   Koutourousiou M, 2013, J NEUROSURG, V118, P621, DOI 10.3171/2012.11.JNS121190
   Koutourousiou M, 2012, NEUROSURGERY, V71, P614, DOI 10.1227/NEU.0b013e31825ea3e0
   Laufer I, 2007, J NEUROSURG, V106, P400, DOI 10.3171/jns.2007.106.3.400
   Laws E R, 2001, Clin Neurosurg, V48, P306
   Laws Edward R. Jr., 1993, P679
   Laws ER, 1999, ENDOCRIN METAB CLIN, V28, P119, DOI 10.1016/S0889-8529(05)70059-1
   Laws ER, 2010, TRANSSPHENOIDAL SURG
   Leng LZ, 2012, NEUROSURGERY, V70, P110, DOI 10.1227/NEU.0b013e31822e8ffc
   Liu JK, 2001, J NEUROSURG, V95, P1083, DOI 10.3171/jns.2001.95.6.1083
   Maira G, 1996, J NEUROSURG, V85, P784, DOI 10.3171/jns.1996.85.5.0784
   Manojlovic-Gacic E, 2018, PITUITARY, V21, P119, DOI 10.1007/s11102-017-0855-1
   McLaughlin N, 2013, J NEUROSURG, V118, P613, DOI 10.3171/2012.11.JNS112020
   McLaughlin N, 2012, NEUROSURGERY, V71, P916, DOI 10.1227/NEU.0b013e31826d5d06
   Molitch ME, 2017, JAMA-J AM MED ASSOC, V317, P516, DOI 10.1001/jama.2016.19699
   Moussazadeh N, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.9.FOCUS16299
   Nishioka H, 2015, ENDOCR PATHOL, V26, P349, DOI 10.1007/s12022-015-9398-z
   O'Malley BW, 2007, ARCH OTOLARYNGOL, V133, P1215, DOI 10.1001/archotol.133.12.1215
   O'Malley BW, 2007, INT J RADIAT ONCOL, V69, pS125, DOI 10.1016/j.ijrobp.2007.06.028
   O'Malley BW, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.12.E10
   Osamura RY, 2017, WHO CLASSIFICATION T, P14
   Pratheesh R, 2013, PITUITARY, V16, P419, DOI 10.1007/s11102-012-0439-z
   Prevedello Daniel M, 2007, Neurosurgery, V60, pE401, DOI 10.1227/01.NEU.0000255359.94571.91
   Prevedello DM, 2012, SCHMIDECK SWEET OPER, P303
   Rudnik A, 2006, MINIM INVAS NEUROSUR, V49, P10, DOI 10.1055/s-2006-932126
   Samii A, 2007, J NEUROSURG, V107, P319, DOI 10.3171/JNS-07/08/0319
   Semple PL, 2008, J NEUROSURG, V108, P909, DOI 10.3171/JNS/2008/108/5/0909
   Semple PL, 2007, NEUROSURGERY, V61, P956, DOI 10.1227/01.neu.0000303191.57178.2a
   Semple PL, 2005, NEUROSURGERY, V56, P65, DOI 10.1227/01.NEU.0000144840.55247.38
   Shahlaie K, 2010, CURR OPIN ENDOCRINOL, V17, P369, DOI 10.1097/MED.0b013e32833abcba
   Snyderman C, 2007, LARYNGOSCOPE, V117, P699, DOI 10.1097/mlg.0b013e318031c817
   Solari D, 2014, HAND CLINIC, V124, P291, DOI 10.1016/B978-0-444-59602-4.00019-8
   Spencer WR, 1999, LARYNGOSCOPE, V109, P791, DOI 10.1097/00005537-199905000-00020
   Stippler M, 2009, NEUROSURGERY, V64, P268, DOI 10.1227/01.NEU.0000338071.01241.E2
   Tabaee A, 2009, J NEUROSURG, V111, P545, DOI 10.3171/2007.12.17635
   Thapar K, 2001, BRAIN TUMORS, P804
   Trevillot V, 2013, EUR ANN OTORHINOLARY, V130, P201, DOI 10.1016/j.anorl.2012.03.010
   Villwock JA, 2014, INT FORUM ALLERGY RH, V4, P767, DOI 10.1002/alr.21356
   Wang SQ, 2017, WORLD NEUROSURG, V101, P1, DOI 10.1016/j.wneu.2017.01.075
   Wang YY, 2012, CLIN ENDOCRINOL, V76, P399, DOI 10.1111/j.1365-2265.2011.04193.x
   Wannemuehler TJ, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.9.FOCUS16314
   Yildirim AE, 2013, TURK NEUROSURG, V23, P226, DOI 10.5137/1019-5149.JTN.6828-12.1
   Zada G, 2003, J NEUROSURG, V98, P350, DOI 10.3171/jns.2003.98.2.0350
   Zada G, 2011, J NEUROSURG, V114, P286, DOI 10.3171/2010.8.JNS10520
   Zoli M, 2017, WORLD NEUROSURG, V106, P331, DOI [10.1016/J.WNEU.2017.06.117, 10.1016/j.wneu.2017.06.117]
NR 111
TC 4
Z9 4
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E440
EP E449
DI 10.1016/j.wneu.2018.11.186
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400051
PM 30500583
DA 2020-05-12
ER

PT J
AU Song, J
   Xue, YQ
   Wang, YJ
   Xu, P
   Sun, DK
   Chen, W
AF Song, Jie
   Xue, Yue-Qin
   Wang, Yan-Ju
   Xu, Peng
   Sun, De-Ke
   Chen, Wei
TI An Update on the Efficacy and Safety Profile of Clazosentan in Cerebral
   Vasospasm After Aneurysmal Subarachnoid Hemorrhage: A Meta-Analysis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm; Clazosentan; Meta-analysis; Subarachnoid hemorrhage; Vasospasm
ID DOUBLE-BLIND; RECEPTOR ANTAGONIST; ENDOTHELIN; MANAGEMENT
AB OBJECTIVE: The present meta-analysis was conducted to provide an update on the efficacy and safety profile of clazosentan with different doses in aneurysmal subarachnoid hemorrhage (aSAH).
   METHODS: We performed a comprehensive and electronic search updated to September 2018 of The Cochrane Library, Embase, and PubMed to identify relevant clinical trials. Trials of the effectiveness of clazosentan in treating cerebral vasospasm after aSAH were studied. The main outcomes included new cerebral infarction (NCI), delayed ischemic neurologic deficit (DIND), vasospasm associated with morbidity/mortality, angiographic vasospasm, rescue therapy, and adverse events. We applied RevMan 5.3 software for this meta-analysis to analyze the combined pooled odds ratios (ORs) with 95% confidence intervals (CIs) using a fixed-or random-effects model on the basis of heterogeneity.
   RESULTS: A total of 5 randomized placebo-controlled trials were included in this meta-analysis. Beneficial outcome was found in patients who received higher doses of clazosentan (> 5mg/h) after aSAH based on decreased incidence of DINDs (OR, 1.76; 95% CI, 1.16-2.69; P = 0.008), NCIs (OR, 2.31; 95% CI, 1.34-3.95; P = 0.002), and angiographic vasospasms (OR, 1.85; 95% CI, 1.19-2.89; P = 0.007). Meanwhile, other parameters, such as vasospasm-related morbidity/mortality, rescue therapy, and adverse events, showed no statistical significance (P > 0.05) between high and low doses of clazosentan.
   CONCLUSIONS: The significant beneficial outcomes of high-dose clazosentan have been proven in preventing cerebral vasospasm and subsequent cerebral infarction compared with low-dose clazosentan, with a manageable safety profile. However, high doses of clazosentan had no significant effect on rescue therapy and vasospasm-related morbidity/mortality.
C1 [Song, Jie; Wang, Yan-Ju; Xu, Peng; Sun, De-Ke; Chen, Wei] Linyi Cent Hosp, Dept Neurosurg, Linyi, Shandong, Peoples R China.
   [Xue, Yue-Qin] Linyi Cent Hosp, Dept Pharm, Linyi, Shandong, Peoples R China.
RP Chen, W (reprint author), Linyi Cent Hosp, Dept Neurosurg, Linyi, Shandong, Peoples R China.
EM dr_sj@126.com
CR Barth M, 2007, ACTA NEUROCHIR, V149, P911, DOI 10.1007/s00701-007-1249-3
   Cahill J, 2009, STROKE, V40, pS86, DOI 10.1161/STROKEAHA.108.533315
   Connolly ES, 2012, STROKE, V43, P1711, DOI 10.1161/STR.0b013e3182587839
   Crowley RW, 2008, DRUG DISCOV TODAY, V13, P254, DOI 10.1016/j.drudis.2007.11.010
   de Oliveira JG, 2007, NEUROSURG REV, V30, P22, DOI 10.1007/s10143-006-0045-5
   Dorhout Mees SM, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000277.pub3
   Fujimura M, 2017, CEREBROVASC DIS, V44, P59, DOI 10.1159/000475824
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
   Hop JW, 1997, STROKE, V28, P660, DOI 10.1161/01.STR.28.3.660
   Kramer A, 2009, STROKE, V40, P3403, DOI 10.1161/STROKEAHA.109.560243
   Macdonald RL, 2008, STROKE, V39, P3015, DOI 10.1161/STROKEAHA.108.519942
   Macdonald RL, 2007, NAT CLIN PRACT NEURO, V3, P256, DOI 10.1038/ncpneuro0490
   Macdonald RL, 2012, STROKE, V43, P1463, DOI 10.1161/STROKEAHA.111.648980
   Macdonald RL, 2011, LANCET NEUROL, V10, P618, DOI 10.1016/S1474-4422(11)70108-9
   Mayer S A, 2001, Curr Neurol Neurosci Rep, V1, P566, DOI 10.1007/s11910-001-0063-1
   QUANDT CM, 1982, DRUG INTEL CLIN PHAR, V16, P909, DOI 10.1177/106002808201601202
   Rabinstein AA, 2010, LANCET NEUROL, V9, P504, DOI 10.1016/S1474-4422(10)70087-9
   Suzuki H, 2015, JPN J NEUROSURG, V24, P232
   The Japanese Stroke Society, 2015, JAP GUID MAN STROK 2
   Vajkoczy P, 2005, J NEUROSURG, V103, P9, DOI 10.3171/jns.2005.103.1.0009
   Zimmermann M, 2004, CLIN AUTON RES, V14, P143, DOI 10.1007/s10286-004-0186-y
NR 23
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E235
EP E244
DI 10.1016/j.wneu.2018.11.143
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400029
PM 30496924
DA 2020-05-12
ER

PT J
AU Suzuki, Y
   Enatsu, R
   Kanno, A
   Yokoyama, R
   Suzuki, H
   Tachibana, S
   Akiyama, Y
   Mikami, T
   Ochi, S
   Yamakage, M
   Mikuni, N
AF Suzuki, Yuto
   Enatsu, Rei
   Kanno, Aya
   Yokoyama, Rintaro
   Suzuki, Hime
   Tachibana, Shunsuke
   Akiyama, Yukinori
   Mikami, Takeshi
   Ochi, Satoko
   Yamakage, Michiaki
   Mikuni, Nobuhiro
TI The Influence of Anesthesia on Corticocortical Evoked Potential
   Monitoring Network Between Frontal and Temporoparietal Cortices
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anesthesia; Awake surgery; Corticocortical evoked potential; Electric
   cortical stimulation
ID LANGUAGE FUNCTION; STIMULATION; PROPOFOL; AREA
AB BACKGROUND: Previous studies have reported the usefulness of intraoperative corticocortical evoked potentials (CCEPs) for preserving language function during brain surgery.
   OBJECTIVE: This study aimed to assess the influence of depth of anesthesia on CCEP to establish its clinical utility.
   METHODS: Twenty patients with brain tumors or epilepsy who underwent awake craniotomy were included in this study. Before resection, the electrode plates were placed on the frontal and temporoparietal cortices, and 1-Hz alternating electrical stimuli were delivered to the pars opercularis/pars triangularis in a bipolar fashion. Electrocorticograms from the temporoparietal cortices time-locked to stimuli were averaged to obtain CCEP responses from a state of deep anesthesia until the awake state. The correlation between CCEP waveforms and bispectral index (BIS) was evaluated.
   RESULTS: CCEP amplitude increased with the increase in the BIS level. CCEP latency decreased in 5 patients and increased in 15 patients under anesthesia compared with the awake state. CCEP amplitudes decreased by 11.3% to 75.2% (median 31.3%) under anesthesia with <65 BIS level. These differences were statistically significant (P < 0.01, Wilcoxon signed-rank test). With respect to CCEP latencies, there was no significant difference between the awake and anesthetic states.
   CONCLUSIONS: CCEP amplitudes were correlated with depth of anesthesia, whereas CCEP latencies were not affected by anesthesia. The influence of anesthesia should be considered when applying this technique to intraoperative monitoring.
C1 [Suzuki, Yuto; Enatsu, Rei; Kanno, Aya; Yokoyama, Rintaro; Suzuki, Hime; Akiyama, Yukinori; Mikami, Takeshi; Ochi, Satoko; Mikuni, Nobuhiro] Sapporo Med Univ, Dept Neurosurg, Sapporo, Hokkaido, Japan.
   [Tachibana, Shunsuke; Yamakage, Michiaki] Sapporo Med Univ, Dept Anesthesiol, Sapporo, Hokkaido, Japan.
RP Mikuni, N (reprint author), Sapporo Med Univ, Dept Neurosurg, Sapporo, Hokkaido, Japan.
EM mikunin@sapmed.ac.jp
OI Mikami, Takeshi/0000-0002-8608-1037
FU KAKENHIMinistry of Education, Culture, Sports, Science and Technology,
   Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for
   Scientific Research (KAKENHI) [16K10795]; Japan Ministry of Education,
   Culture, Sports, Science and Technology (MEXT)Ministry of Education,
   Culture, Sports, Science and Technology, Japan (MEXT)
FX This study was partly supported by KAKENHI 16K10795 from the Japan
   Ministry of Education, Culture, Sports, Science and Technology (MEXT).
CR Enatsu R, 2013, CORTEX, V49, P2080, DOI 10.1016/j.cortex.2012.08.026
   Jones SE, 2014, BRAIN CONNECT, V4, P286, DOI 10.1089/brain.2014.0225
   Kakinohana M, 2000, Masui, V49, P596
   Kammer T, 2002, ANESTHESIOLOGY, V97, P1416, DOI 10.1097/00000542-200212000-00013
   Kanno A, 2015, NEUROL MED-CHIR, V55, P367, DOI 10.2176/nmc.ra.2014-0395
   Keller CJ, 2011, P NATL ACAD SCI USA, V108, P10308, DOI 10.1073/pnas.1019750108
   Kikuchi T, 2012, CLIN NEUROPHYSIOL, V123, P324, DOI 10.1016/j.clinph.2011.06.011
   Matsumoto R, 2004, BRAIN, V127, P2316, DOI 10.1093/brain/awh246
   Matsuzaki N, 2013, CLIN NEUROPHYSIOL, V124, P1290, DOI 10.1016/j.clinph.2013.02.007
   Ohtaki S, 2017, J NEUROSURG, V126, P260, DOI 10.3171/2015.11.JNS151291
   Ookawa S, 2017, WORLD NEUROSURG, V107, P239, DOI [10.1016/j.wneu.2017.07.166, 10.1016/J.WNEU.2017.07.166]
   ORSER BA, 1994, J NEUROSCI, V14, P7747
   Saito T, 2014, J NEUROSURG, V121, P827, DOI 10.3171/2014.4.JNS131195
   Sebel PS, 1997, ANESTH ANALG, V84, P891, DOI 10.1097/00000539-199704000-00035
   SIGL JC, 1994, J CLIN MONITOR, V10, P392, DOI 10.1007/BF01618421
   Tamura Y, 2016, J NEUROSURG, V125, P1580, DOI 10.3171/2015.4.JNS15193
   Yamao Y, 2014, HUM BRAIN MAPP, V35, P4345, DOI 10.1002/hbm.22479
NR 17
TC 0
Z9 0
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E685
EP E692
DI 10.1016/j.wneu.2018.11.253
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400081
PM 30576824
DA 2020-05-12
ER

PT J
AU Ulgen, E
   Bektasoglu, PK
   Sav, MA
   Can, O
   Danyeli, AE
   Hizal, DB
   Pamir, MN
   Ozduman, K
AF Ulgen, Ege
   Bektasoglu, Pinar Kuru
   Sav, M. Aydin
   Can, Ozge
   Danyeli, Ayca Ersen
   Hizal, Deniz Baycin
   Pamir, M. Necmettin
   Ozduman, Koray
TI Meningiomas Display a Specific Immunoexpression Pattern in a
   Rostrocaudal Gradient: An Analysis of 366 Patients
SO WORLD NEUROSURGERY
LA English
DT Article
DE Immunohistochemistry; Meningioma; Survival
ID TUMOR-LOCALIZATION; PROGNOSTIC VALUE; MUTATIONS; DIAGNOSIS;
   CLASSIFICATION; PROLIFERATION; PROGRESSION; EXPRESSION; SYSTEM; TRAF7
AB BACKGROUND: Meningiomas are heterogeneous, with differences in anatomical, histopathological, and clinical characteristics. Such spatial variability in meningioma biology is thought to result from differences in the expression of critical developmental regulators. We hypothesized that the variability in meningioma biology would follow gradients such as in embryology and tested a cohort of 366 meningiomas for histopathological and immunohistochemical gradients.
   METHODS: The medical records from 366 patients treated for meningiomas from 2003 to 2016 were retrospectively analyzed for age, gender, anatomical localization, recurrence-free survival, overall survival, histopathological diagnosis, and immunohistochemistry findings for 6 markers: epithelial membrane antigen (EMA), progesterone receptor (PR), CD34, S100, p53, and Ki-67 labeling index.
   RESULTS: EMA, PR, S100, p53, and CD34 were expressed in 94%, 73%, 49%, 26%, and 23% of the tumors, respectively. p53 expression correlated positively with Ki-67 and World Health Organization (WHO) grade (r(tau) = 0.31 and r(tau) = 0.4, respectively). PR positivity correlated inversely with S100, p53, Ki-67, and WHO grade (r(tau) = -0.19, r(tau) = -0.14, r(tau) = -0.15, and r(tau) = -0.16, respectively). All secretory meningiomas were positive for EMA and PR and negative for S100, and this pattern exhibited a rostrocaudal gradient. The overall proportion of EMA(+)PR(+)S100(-) cases was significantly lower in the cranial vault (30.3%) than in the skull base (45.89%; P = 0.021). The proportion of WHO grade II-III tumors was greater in cranial vault than in skull base meningiomas.
   CONCLUSIONS: Unsupervised methods detected an association between the anatomical location and tumor biology in meningiomas. Unlike the categorical associations that former studies had indicated, the present study revealed a rostrocaudal gradient in both the cranial vault and the skull base, correlating with human developmental biology.
C1 [Ulgen, Ege] Acibadem Mehmet Ali Aydinlar Univ, Fac Engn, Dept Biostat & Mod Informat, Sch Med, Istanbul, Turkey.
   [Sav, M. Aydin; Danyeli, Ayca Ersen] Acibadem Mehmet Ali Aydinlar Univ, Fac Engn, Dept Pathol, Sch Med, Istanbul, Turkey.
   [Pamir, M. Necmettin; Ozduman, Koray] Acibadem Mehmet Ali Aydinlar Univ, Fac Engn, Dept Neurosurg, Sch Med, Istanbul, Turkey.
   [Can, Ozge] Acibadem Mehmet Ali Aydinlar Univ, Fac Engn, Dept Med Engn, Istanbul, Turkey.
   [Bektasoglu, Pinar Kuru] Univ Hlth Sci, Fatih Sultan Mehmet Educ & Res Hosp, Dept Neurosurg, Turkish Minist Hlth, Istanbul, Turkey.
   [Bektasoglu, Pinar Kuru] Marmara Univ, Dept Physiol, Sch Med, Istanbul, Turkey.
   [Hizal, Deniz Baycin] Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD USA.
   [Hizal, Deniz Baycin] Turgut Biopharmaceut, Biotechnol Dept, Istanbul, Turkey.
RP Ozduman, K (reprint author), Acibadem Mehmet Ali Aydinlar Univ, Fac Engn, Dept Neurosurg, Sch Med, Istanbul, Turkey.
EM koray.ozduman@icloud.com
RI Ulgen, Ege/I-7803-2015; Danyeli, Ayca Ersen/X-3384-2018; Can,
   Ozge/G-9355-2015; Ozduman, Koray/D-7007-2015
OI Ulgen, Ege/0000-0003-2090-3621; Danyeli, Ayca Ersen/0000-0001-8015-9916;
   Ozduman, Koray/0000-0002-3543-0401; Kuru Bektasoglu,
   Pinar/0000-0001-9889-9955
CR Bailey P, 1948, INTRACRANIAL TUMORS
   Barresi V, 2012, PATHOL RES PRACT, V208, P567, DOI 10.1016/j.prp.2012.07.002
   Baxter DS, 2014, J CLIN NEUROSCI, V21, P421, DOI 10.1016/j.jocn.2013.06.008
   Bi WL, 2016, FRONT SURG, V3, DOI 10.3389/fsurg.2016.00040
   Boulagnon-Rombi C, 2017, J NEUROPATH EXP NEUR, V76, P289, DOI 10.1093/jnen/nlx008
   Bronner ME, 2016, CURR TOP DEV BIOL, V116, P115, DOI 10.1016/bs.ctdb.2015.12.003
   Clark VE, 2013, SCIENCE, V339, P1077, DOI 10.1126/science.1233009
   Clarke VE, 2016, NAT GENET, V48, P1253, DOI 10.1038/ng.3651
   Cushing H, 1938, MENINGIOMAS THEIR CL
   Donato R, 2013, CURR MOL MED, V13, P24, DOI 10.2174/156652413804486214
   Eisenhardt L, 1930, AM J PATHOL, V6, P541
   Hansson CM, 2007, BMC GENOMICS, V8, P1, DOI 10.1186/1471-2164-8-16
   Harmanci AS, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14433
   Jazaeri AA, 2001, ONCOGENE, V20, P6965, DOI 10.1038/sj.onc.1204809
   Ketter R, 2008, NEUROSURGERY, V62, P61, DOI 10.1227/01.NEU.0000311062.72626.D6
   Kilic T, 2002, NEUROSURGERY, V51, P183, DOI 10.1227/01.NEU.0000017466.25827.18
   Kros J, 2001, J PATHOL, V194, P367, DOI 10.1002/path.909
   Linda W, 2016, NEUROSURG CLIN N AM, V27, P167, DOI 10.1016/j.nec.2015.11.009
   Ling C, 2016, J NEUROPATH EXP NEUR, V75, P1160, DOI 10.1093/jnen/nlw095
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Loussouarn D, 2006, HUM PATHOL, V37, P415, DOI 10.1016/j.humpath.2005.12.020
   Ng J, 2015, APPL IMMUNOHISTO M M, V23, P215, DOI 10.1097/PAI.0000000000000072
   Pham MH, 2011, NEUROSURG FOCUS, V30, DOI 10.3171/2011.2.FOCUS1117
   R Core Team, 2014, R LANG ENV STAT COMP
   Reuss DE, 2013, ACTA NEUROPATHOL, V125, P351, DOI 10.1007/s00401-013-1093-x
   Roser F, 2004, J CLIN PATHOL, V57, P1033, DOI 10.1136/jcp.2004.018333
   Roser F, 2004, ACTA NEUROCHIR, V146, P37, DOI 10.1007/s00701-003-0173-4
   Sahm F, 2017, LANCET ONCOL, V18, P682, DOI 10.1016/S1470-2045(17)30155-9
   Takami H, 2015, BRAIN PATHOL, V25, P256, DOI 10.1111/bpa.12173
   Yamashima T., 2009, MENINGIOMAS, P15
NR 30
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E520
EP E535
DI 10.1016/j.wneu.2018.11.201
PG 16
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400061
PM 30503291
DA 2020-05-12
ER

PT J
AU van de Vijfeijken, SECM
   Munker, TJAG
   De Jager, N
   Vandertop, WP
   Becking, AG
   Kleverlaan, CJ
AF van de Vijfeijken, Sophie E. C. M.
   Munker, Tijmen J. A. G.
   De Jager, Niek
   Vandertop, William P.
   Becking, Alfred G.
   Kleverlaan, Cornelis J.
CA CranioSafe Grp
TI Properties of an In Vivo Fractured Poly(Methyl Methacrylate)
   Cranioplasty After 15 Years
SO WORLD NEUROSURGERY
LA English
DT Article
DE Acrylic; Decompressive craniectomy; Fracture; Implant; Skull
ID ACRYLIC BONE CEMENTS; IMPLANTS; HEAD; COMPLICATIONS; EXPERIENCE; DESIGN
AB BACKGROUND: In 2001, a 27-year-old man was diagnosed with a meningioma with skull bone involvement. A craniectomy was performed and a CMW-3 poly(methyl methacrylate) cranioplasty was manually manufactured to reconstruct the remaining cranial defect. In 2016, he complained about progressive neurologic impairment. A computed tomography scan revealed that the cranioplasty had fractured into 4 dislocated pieces. Removal was indicated, and during the same operation a polyetheretherketone patient-specific implant was inserted.
   METHODS: The fractured cranioplasty was compared with freshly prepared CMW-3 specimens to determine whether the material properties had changed during 15 years in vivo. Gel permeation chromatography, microcomputed tomography, and flexural strength tests were performed. The fracture itself was analyzed using finite element analysis.
   RESULTS: The polydispersity index and molecular weight were not significantly different for the fractured cranioplasty and CMW-3. The fractured cranioplasty contained a total porosity of 10.7%, fresh CMW-3 cured at atmospheric pressure contained 4.1%, and 0.06% when cured at 2.2 bar. The flexural strength of the CMW-3 cured at 2.2 bar was significantly higher than both the fractured cranioplasty and CMW-3 cured at atmospheric pressure. Finite element analysis showed stress of 12.2 MPa under a load of 100 N on a weak spot.
   CONCLUSIONS: This ex vivo study shows that CMW-3 after 15 years in vivo was not influenced in molecular weight or flexural strength. However, the design of the implant and the handling of the poly(methyl methacrylate) seem to be important factors to improve mechanical properties of cranial reconstructions.
C1 [van de Vijfeijken, Sophie E. C. M.; Becking, Alfred G.] Univ Amsterdam, Med Ctr, Dept Oral & Maxillofacial Surg, Amsterdam, Netherlands.
   [Vandertop, William P.] Univ Amsterdam, Med Ctr, Neurosurg Ctr Amsterdam, Acad Med Ctr, Amsterdam, Netherlands.
   [Munker, Tijmen J. A. G.; De Jager, Niek; Kleverlaan, Cornelis J.] Acad Ctr Dent Amsterdam, Dept Dent Mat Sci, Amsterdam, Netherlands.
   [Vandertop, William P.] Univ Amsterdam, VU Univ Med Ctr, Neurosurg Ctr Amsterdam, Med Ctr, Amsterdam, Netherlands.
RP van de Vijfeijken, SECM (reprint author), Univ Amsterdam, Med Ctr, Dept Oral & Maxillofacial Surg, Amsterdam, Netherlands.
EM s.e.vandevijfeijken@amc.uva.nl
OI Milstein, Dan/0000-0003-1335-5516
FU Dutch Technology Foundation STW part of The Netherlands Organisation for
   Scientific Research [14326]; Ministry of Economic Affairs
FX This research is supported by the Dutch Technology Foundation STW
   (project number 14326; CranioSafe), which is part of The Netherlands
   Organisation for Scientific Research, and which is partly funded by the
   Ministry of Economic Affairs.
CR ANDREWS EH, 1959, J APPL PHYS, V30, P740, DOI 10.1063/1.1735224
   Arora M, 2013, WORLD J ORTHOP, V4, P67, DOI 10.5312/wjo.v4.i2.67
   CHARNLEY J, 1960, J BONE JOINT SURG BR, V42, P28
   Cheng CH, 2018, CLIN NEUROL NEUROSUR, V168, P118, DOI 10.1016/j.clineuro.2018.03.004
   Dujovny M, 1997, SURG NEUROL, V47, P238, DOI 10.1016/S0090-3019(96)00013-4
   FOX JL, 1973, J NEUROL NEUROSUR PS, V36, P302, DOI 10.1136/jnnp.36.2.302
   Goiato MC, 2015, ADV CLIN EXP MED, V24, P679, DOI 10.17219/acem/33009
   GOLDSTEIN JP, 1986, EVALUATION REV, V10, P355, DOI 10.1177/0193841X8601000306
   Guerrini F, 2017, WORLD NEUROSURG, V107, DOI 10.1016/j.wneu.2017.08.111
   HAIBARA T, 1986, J LIGHTWAVE TECHNOL, V4, P1434, DOI 10.1109/JLT.1986.1074902
   Hay JA, 2017, WORLD NEUROSURG, V105, P971, DOI 10.1016/j.wneu.2017.05.007
   Honeybul S, 2012, PLAST RECONSTR SURG, V130, P1110, DOI 10.1097/PRS.0b013e318267d4de
   Hughes KF, 2003, J BIOMED MATER RES A, V65A, P126, DOI 10.1002/jbm.a.10373
   Jiang Y, 2016, INT J SURG CASE REP, V24, P50, DOI 10.1016/j.ijscr.2016.04.039
   Kim BJ, 2012, J KOREAN NEUROSURG S, V52, P541, DOI 10.3340/jkns.2012.52.6.541
   KLEINSCHMIDT O, 1941, CHIRURGIE, V13, P273
   Ko AL, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2013.09.025
   Kuhn KD., 2014, PMMA CEMENTS
   Lethaus B, 2014, J CRANIO MAXILL SURG, V42, P1948, DOI 10.1016/j.jcms.2014.08.006
   Lu Y, 2012, BRIT J NEUROSURG, V26, P216, DOI 10.3109/02688697.2011.629699
   Marchac D, 2008, J PLAST RECONSTR AES, V61, P744, DOI 10.1016/j.bjps.2007.10.055
   Mracek J, 2015, ACTA NEUROCHIR, V157, P501, DOI 10.1007/s00701-014-2333-0
   Nottrott M, 2010, ACTA ORTHOP, V81, P1, DOI 10.3109/17453674.2010.487929
   Oonishi Hiroyuki, 2011, Acta Orthop, V82, P553, DOI 10.3109/17453674.2011.625538
   Staffa G, 2007, ACTA NEUROCHIR, V149, P161, DOI 10.1007/s00701-006-1078-9
   Stefini Roberto, 2013, Surg Neurol Int, V4, P12, DOI 10.4103/2152-7806.106290
   Sundseth J, 2014, ACTA NEUROCHIR, V156, P805, DOI 10.1007/s00701-013-1992-6
   van de Vijfeijken SECM, 2018, WORLD NEUROSURG, V117, P443, DOI 10.1016/j.wneu.2018.05.193
   Zanotti B, 2016, J CRANIOFAC SURG, V27, P2061, DOI 10.1097/SCS.0000000000003025
NR 29
TC 2
Z9 2
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E60
EP E68
DI 10.1016/j.wneu.2018.11.026
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400009
PM 30447447
DA 2020-05-12
ER

PT J
AU Vanaclocha, V
   Vanaclocha-Saiz, A
   Rivera-Paz, M
   Atienza-Vicente, C
   Ortiz-Criado, JM
   Belloch, V
   Santabarbara-Gomez, JM
   Gomez, A
   Vanaclocha, L
AF Vanaclocha, Vicente
   Vanaclocha-Saiz, Amparo
   Rivera-Paz, Marlon
   Atienza-Vicente, Carlos
   Ortiz-Criado, Jose Maria
   Belloch, Vicente
   Santabarbara-Gomez, Jose Manuel
   Gomez, Amelia
   Vanaclocha, Leyre
TI S-1 Pedicle Subtraction Osteotomy in Sagittal Balance Correction. A
   Feasibility Study on Human Cadaveric Specimens
SO WORLD NEUROSURGERY
LA English
DT Article
DE Finite element analysis; S-1 pedicle subtraction osteotomy; Sagittal
   profile; Spinal balance; Spinopelvic alignment; Spinopelvic parameters
ID ADULT SPINAL DEFORMITY; VERTEBRAL COLUMN RESECTION; LUMBAR INTERBODY
   FUSION; SURGICAL-TECHNIQUE; DECISION-MAKING; THORACOLUMBAR KYPHOSIS;
   SPINOPELVIC PARAMETERS; NORMATIVE-VALUES; ILIAC FIXATION; POSTERIOR
AB BACKGROUND: A cadaveric feasibility study was carried out. Osteotomies to correct fixed sagittal imbalance are usually performed at L-3/L-4.
   OBJECTIVE: To investigate the feasibility of S-1 pedicle subtraction osteotomy to correct spinal deformity and spinopelvic parameters, achieving better results with more limited exposure. The data obtained will allow a fixation construct specific for this osteotomy to be designed.
   METHODS: S-1 pedicle subtraction osteotomy was performed on 12 cadaveric specimens. Baseline and post-procedural computed tomography and biomechanical studies were performed. Data were analyzed with a fixation system SolidWorks model, and the redesigned fixation construct was described and analyzed with an ANSYS model.
   RESULTS: S-1 pedicle subtraction osteotomy is technically feasible. The fixation can be achieved with L-4, L-5, and iliac screws connected with bars. The system can be reinforced with a polyetheretherketone cage placed anteriorly in the S-1 body osteotomy site, a cross-connecting bar, a double iliac screw, or an anterior interbody cage placed at the L-5-S-1 disc. The fixation strength is improved by angulating the iliac rod channel 10 degrees, adding a semi-sphere to the locking screw contact surface and 2 fins to its saddle. The redesigned construct showed suitable stress and deformation levels, achieving the expected biomechanical requirements.
   DISCUSSION: Compared with surgery on higher levels, S-1 pedicle subtraction osteotomy allows greater correction with shorter fixation, because the osteotomy is performed at a more caudal level, modifying the spinopelvic parameters.
   CONCLUSIONS: S-1 pedicle subtraction osteotomy is technically feasible. Finite element analysis results indicate that it has appropriate biomechanical properties.
C1 [Vanaclocha, Vicente; Rivera-Paz, Marlon] Hosp Gen Univ Valencia, Valencia, Spain.
   [Vanaclocha-Saiz, Amparo; Atienza-Vicente, Carlos] Inst Biomecan, Valencia, Spain.
   [Belloch, Vicente; Santabarbara-Gomez, Jose Manuel; Gomez, Amelia] ERESA, Valencia, Spain.
   [Ortiz-Criado, Jose Maria] Inst Med Legal Valencia, Valencia, Spain.
   [Vanaclocha, Leyre] UCL, Med Sch, London, England.
RP Vanaclocha, V (reprint author), Hosp Gen Univ Valencia, Valencia, Spain.
EM vanaclo@hotmail.com
OI Vanaclocha, Vicente/0000-0002-4909-5886; Vanaclocha-Saiz,
   Leyre/0000-0002-7215-2105
CR Abulizi YF, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000007614
   AENOR, F171715 AENOR ASTM
   Akbar M, 2011, ORTHOPADE, V40, P661, DOI 10.1007/s00132-011-1814-6
   Alzakri A, 2018, EUR SPINE J, V27, P644, DOI 10.1007/s00586-017-5403-1
   Angevine PD, 2006, NEUROSURG CLIN N AM, V17, P353, DOI 10.1016/j.nec.2006.04.005
   Anwar HA, 2015, SPINE J, V15, P2518, DOI 10.1016/j.spinee.2015.09.021
   Banno T, 2016, EUR SPINE J, V25, P3687, DOI 10.1007/s00586-016-4411-x
   Bao HD, 2015, SPINE, V40, pE293, DOI 10.1097/BRS.0000000000000744
   Barrey Cedric, 2014, Eur J Orthop Surg Traumatol, V24 Suppl 1, pS21, DOI 10.1007/s00590-014-1470-8
   Been E, 2010, CLIN ORTHOP RELAT R, V468, P1822, DOI 10.1007/s11999-009-1153-7
   Boachie-Adjei O, 2006, SPINE, V31, P485, DOI 10.1097/01.brs.0000199893.71141.59
   BOACHIEADJEI O, 1991, J SPINAL DISORD, V4, P193, DOI 10.1097/00002517-199106000-00010
   Boissiere L, 2013, EUR SPINE J, V22, P1339, DOI 10.1007/s00586-013-2711-y
   Bridwell KH, 2006, SPINE, V31, pS171, DOI 10.1097/01.brs.0000231963.72810.38
   Bridwell KH, 2003, SPINE, V28, P2093, DOI 10.1097/01.BRS.0000090891.60232.70
   Bridwell KH, 2004, J BONE JOINT SURG AM, V86A, P1587, DOI 10.2106/00004623-200407000-00033
   Buchowski JM, 2007, SPINE, V32, P2245, DOI 10.1097/BRS.0b013e31814b2d52
   Burns Camden B, 2016, Spine Deform, V4, P10, DOI 10.1016/j.jspd.2015.07.008
   Chang KW, 2011, SPINE, V36, pE186, DOI 10.1097/BRS.0b013e3181ef6828
   Chang TL, 2009, SPINE, V34, P436, DOI 10.1097/BRS.0b013e318194128c
   Charosky S, 2014, EUR SPINE J, V23, P2340, DOI 10.1007/s00586-014-3295-x
   Chen I H, 2001, Spine (Phila Pa 1976), V26, pE354, DOI 10.1097/00007632-200108150-00010
   Cho KJ, 2013, SPINE, V38, pE1561, DOI 10.1097/BRS.0b013e3182a63c29
   Cho SK, 2012, SPINE, V37, P489, DOI 10.1097/BRS.0b013e3182217ab5
   Dahl BT, 2017, EUR SPINE J, V26, P2773, DOI 10.1007/s00586-017-5222-4
   Demirkiran G, 2016, CLIN SPINE SURG, V29, P141, DOI 10.1097/BSD.0000000000000377
   Deviren V, 2012, GLOB SPINE J, V2, P213, DOI 10.1055/s-0032-1331460
   Dick JC, 2001, SPINE, V26, P1668, DOI 10.1097/00007632-200108010-00008
   Diebo BG, 2015, EUR SPINE J, V24, pS3, DOI 10.1007/s00586-014-3653-8
   Dubousset J, 2011, J PEDIATR ORTHOPED, V31, pS1, DOI 10.1097/BPO.0b013e3181f73beb
   Fleischer GD, 2012, SPINE, V37, pE163, DOI 10.1097/BRS.0b013e31822ce9a7
   Garbossa D, 2014, EUR SPINE J, V23, pS616, DOI 10.1007/s00586-014-3558-6
   Geck MJ, 2007, J SPINAL DISORD TECH, V20, P586, DOI 10.1097/BSD.0b013e31803d3b16
   Glassman SD, 2005, SPINE, V30, P2024, DOI 10.1097/01.brs.0000179086.30449.96
   Ha Y, 2013, J NEUROSURG-SPINE, V19, P360, DOI 10.3171/2013.5.SPINE12737
   Hallager DW, 2016, SPINE, V41, pE388, DOI 10.1097/BRS.0000000000001282
   Hamilton DK, 2016, EUR SPINE J, V25, P2605, DOI 10.1007/s00586-016-4443-2
   Heary RF, 2008, NEUROSURGERY, V63, pA69, DOI 10.1227/01.NEU.0000320426.59061.79
   Hyun SJ, 2014, SPINE, V39, P1899, DOI 10.1097/BRS.0000000000000556
   Jager Zachary S, 2016, Spine Deform, V4, P3, DOI 10.1016/j.jspd.2015.06.005
   Januszewski Jacob, 2017, Surg Neurol Int, V8, P207, DOI 10.4103/sni.sni_44_17
   Kiapour A, 2012, J ORTHOP RES, V30, P1577, DOI 10.1002/jor.22119
   Kim KT, 2009, ASIAN SPINE J, V3, P113, DOI 10.4184/asj.2009.3.2.113
   Kim YJ, 2007, SPINE, V32, P2189, DOI 10.1097/BRS.0b013e31814b8371
   Kim YJ, 2016, J KOREAN NEUROSURG S, V59, P327, DOI 10.3340/jkns.2016.59.4.327
   Kirby KN, 2013, BEHAV RES METHODS, V45, P905, DOI 10.3758/s13428-013-0330-5
   Lafage V, 2011, J NEUROSURG-SPINE, V14, P184, DOI 10.3171/2010.9.SPINE10129
   Lafage V, 2009, SPINE, V34, pE599, DOI 10.1097/BRS.0b013e3181aad219
   Le Huec J C, 2011, Eur Spine J, V20 Suppl 5, P669, DOI 10.1007/s00586-011-1935-y
   Le Huec J C, 2011, Eur Spine J, V20 Suppl 5, P558, DOI 10.1007/s00586-011-1939-7
   Le Huec JC, 2016, EUR SPINE J, V25, P3630, DOI 10.1007/s00586-016-4485-5
   Lee CS, 2016, ASIAN SPINE J, V10, P1023, DOI 10.4184/asj.2016.10.6.1023
   Lehman RA, 2015, SPINE J, V15, P1629, DOI 10.1016/j.spinee.2015.03.010
   Luca A, 2014, EUR SPINE J, V23, pS610, DOI 10.1007/s00586-014-3555-9
   Luca A, 2017, EUR SPINE J, V26, P764, DOI 10.1007/s00586-016-4859-8
   Nguyen TQ, 2011, P I MECH ENG H, V225, P194, DOI 10.1243/09544119JEIM763
   Noshchenko A, 2017, CLIN SPINE SURG, V30, P392, DOI 10.1097/BSD.0000000000000533
   Oskouian RJ, 2006, NEUROSURG CLIN N AM, V17, P299, DOI 10.1016/j.nec.2006.05.002
   Ponte A, 2018, SPINE DEFORM, V6, P2
   Popa I, 2016, INT ORTHOP, V40, P1219, DOI 10.1007/s00264-016-3126-2
   Qian BP, 2012, SPINE, V37, P1415, DOI 10.1097/BRS.0b013e318250dc95
   Sanchez C, 2012, APUNTES BREVE INTROD
   Scheer JK, 2011, NEUROSURGERY, V69, P164, DOI 10.1227/NEU.0b013e31820f362a
   Schwab F, 2010, SPINE, V35, P2224, DOI 10.1097/BRS.0b013e3181ee6bd4
   Smith JS, 2014, J NEUROSURG-SPINE, V21, P994, DOI 10.3171/2014.9.SPINE131176
   Smith JS, 2012, J NEUROSURG-SPINE, V17, P300, DOI 10.3171/2012.6.SPINE1250
   Smith JS, 2011, SPINE, V36, P817, DOI 10.1097/BRS.0b013e3181e21783
   Smith-Petersen M N, 1969, Clin Orthop Relat Res, V66, P6
   Sterling AJ, 2016, DATA BRIEF, V6, P970, DOI 10.1016/j.dib.2016.01.059
   Sugrue PA, 2013, SPINE, V38, P484, DOI 10.1097/BRS.0b013e318273a1c0
   Tang JA, 2013, NEUROSURGERY, V72, P276, DOI 10.1227/NEU.0b013e31827ba066
   Trobisch PD, 2016, EUR SPINE J, V25, P2629, DOI 10.1007/s00586-015-4278-2
   van Royen BJ, 2007, EUR SPINE J, V16, P1445, DOI 10.1007/s00586-007-0371-5
   Vos T, 2012, LANCET, V380, P2163, DOI 10.1016/S0140-6736(12)61729-2
   Voyadzis JM, 2008, NEUROSURGERY, V63, pA204, DOI 10.1227/01.NEU.0000320430.37577.B7
   Wang MY, 2014, WORLD NEUROSURG, V81, DOI 10.1016/j.wneu.2012.10.002
   Yagi Mitsuru, 2013, Spine Deform, V1, P123, DOI 10.1016/j.jspd.2013.01.003
   Yang BP, 2006, J NEUROSURG-SPINE, V5, P9, DOI 10.3171/spi.2006.5.1.9
   Yao ZM, 2016, SPINE, V41, P591, DOI 10.1097/BRS.0000000000001278
   Yu BS, 2010, EUR SPINE J, V19, P1121, DOI 10.1007/s00586-010-1343-8
   Yukawa Y, 2018, EUR SPINE J, V27, P426, DOI 10.1007/s00586-016-4807-7
NR 81
TC 0
Z9 0
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E85
EP E102
DI 10.1016/j.wneu.2018.11.052
PG 18
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400012
PM 30465963
DA 2020-05-12
ER

PT J
AU Vazan, M
   Ryang, VM
   Barz, M
   Torok, E
   Gempt, J
   Meyer, B
AF Vazan, Martin
   Ryang, Vu-Mi
   Barz, Melanie
   Torok, Elisabeth
   Gempt, Jens
   Meyer, Bernhard
TI Ankylosing Spinal Disease-Diagnosis and Treatment of Spine Fractures
SO WORLD NEUROSURGERY
LA English
DT Article
DE Ankylosing spondylitis; AS; Diffuse idiopathic skeletal hyperostosis;
   DISH; Spine fracture; Spinal fusion
ID IDIOPATHIC SKELETAL HYPEROSTOSIS; OF-THE-LITERATURE; THORACOLUMBAR
   SPINE; NEUROLOGICAL-STATUS; SCREW PLACEMENT; CERVICAL-SPINE; PREVALENCE;
   SPONDYLITIS; INJURIES; FIXATION
AB BACKGROUND: In patients with ankylosing spinal disease, including ankylosing spondylitis and diffuse idiopathic skeletal hyperostosis, even low-impact trauma can lead to complex injuries. The injuries seem to be highly unstable and associated with greater mortality rates compared with the general spine trauma population.
   METHODS: We reviewed the medical records of a consecutive series of 41 patients (34 men, 7 women) with ankylosing spinal disease and unstable traumatic spine injuries who were admitted to our department from 2007 to 2016.
   RESULTS: The mean patient age was 73.4 +/- 12.7 years. Of the 41 patients, 24 (58.5%) had ankylosing spondylitis and 17 (41.5%) had diffuse idiopathic skeletal hyperostosis. Low-velocity accidents were documented in 38 patients (92.7%). The most frequent injuries were type B spine fractures (61.0%). Accompanying spinal epidural hematoma was detected using magnetic resonance imaging in 12 patients (29.3%) but was not found by radiography or computed tomography. Of the 41 patients, 24 (58.5%) presented with American Spinal Injury Association impairment scale (AIS) grade E, 6 (14.6%) with grade D, and 8 (19.6%) with grade C or worse. All the patients had undergone internal fixation. All but 1 (97.6%) had received posterior fixation. In 25 (61%), a combined approach was performed. Five patients died of early complications. Of the 36 discharged patients, 11 died during the follow-up period and 1 was lost to follow-up. The surviving 24 patients had a median follow-up of 733 +/- 576 days; 21 had AIS grade E, 2 had AIS grade D, and 1 had AIS grade C.
   CONCLUSIONS: A thorough diagnostic evaluation with multislice computed tomography and magnetic resonance imaging can reveal injuries that would remain undetected on conventional radiographs. A combined approach or posterior-only fixation seems safe.
C1 [Vazan, Martin; Ryang, Vu-Mi; Barz, Melanie; Torok, Elisabeth; Gempt, Jens; Meyer, Bernhard] Tech Univ Munich, Dept Neurosurg, Klinikum Rechts Isar, Munich, Germany.
   [Vazan, Martin] Tech Univ Dresden, Acad Teaching Hosp, Municipal Hosp Dresden, Dept Orthopaed, Dresden, Germany.
RP Vazan, M (reprint author), Tech Univ Munich, Dept Neurosurg, Klinikum Rechts Isar, Munich, Germany.; Vazan, M (reprint author), Tech Univ Dresden, Acad Teaching Hosp, Municipal Hosp Dresden, Dept Orthopaed, Dresden, Germany.
EM martin.vazan@gmail.com
RI Meyer, Bernhard/AAH-3329-2019; Ryang, Yu-Mi/Q-8373-2016
OI Ryang, Yu-Mi/0000-0002-9045-5038
CR Anwar F, 2011, EUR SPINE J, V20, P403, DOI 10.1007/s00586-010-1628-y
   Aoki Y, 2013, MOD RHEUMATOL, V23, P1008, DOI [10.3109/s10165-012-0726-6, 10.1007/s10165-012-0726-6]
   Balling H, 2015, SPINE, V40, pE61, DOI 10.1097/BRS.0000000000000676
   Braun J, 2007, LANCET, V369, P1379, DOI 10.1016/S0140-6736(07)60635-7
   BROOM MJ, 1988, SPINE, V13, P763, DOI 10.1097/00007632-198807000-00009
   Caron T, 2010, SPINE, V35, pE458, DOI 10.1097/BRS.0b013e3181cc764f
   Chaudhary Saad B, 2011, ISRN Rheumatol, V2011, P150484, DOI 10.5402/2011/150484
   Domenicucci M, 2011, EUR SPINE J, V20, pS314, DOI 10.1007/s00586-011-1732-7
   Einsiedel T, 2006, J NEUROSURG-SPINE, V5, P33, DOI 10.3171/spi.2006.5.1.33
   FAZL M, 1981, NEUROSURGERY, V8, P732, DOI 10.1227/00006123-198106000-00019
   GERTZBEIN SD, 1990, SPINE, V15, P11, DOI 10.1097/00007632-199001000-00004
   Harrop JS, 2005, SPINE, V30, pE417, DOI 10.1097/01.brs.0000170594.45021.67
   HISSA E, 1986, CLIN ORTHOP RELAT R, P225
   HUNTER T, 1978, ANN INTERN MED, V88, P546, DOI 10.7326/0003-4819-88-4-546
   Jaiswal Ashish, 2007, Indian J Orthop, V41, P312, DOI 10.4103/0019-5413.36993
   Janssen I, 2017, SPINE J, V17, P837, DOI 10.1016/j.spinee.2017.01.009
   Johnson MG, 2004, SPINE, V29, P2815, DOI 10.1097/01.brs.0000151088.80797.bd
   Kagotani R, 2015, J BONE MINER METAB, V33, P221, DOI 10.1007/s00774-014-0583-9
   Kanter AS, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/1/E11
   Kim SK, 2004, J RHEUMATOL, V31, P2032
   Kiss C, 2002, RHEUMATOLOGY, V41, P27, DOI 10.1093/rheumatology/41.1.27
   Kruger A, 2014, SPINE J, V14, P2897, DOI 10.1016/j.spinee.2014.04.018
   Malham GM, 2009, SPINE, V34, P2754, DOI 10.1097/BRS.0b013e3181b6170b
   Rajan VV, 2010, INDIAN J ORTHOP, V44, P163, DOI 10.4103/0019-5413.62083
   Sapkas G, 2009, BMC MUSCULOSKEL DIS, V10, DOI 10.1186/1471-2474-10-96
   Sedney CL, 2016, INT J SPINE SURG, V10, DOI 10.14444/3023
   Taggard DA, 2000, SPINE, V25, P2035, DOI 10.1097/00007632-200008150-00006
   Vaccaro AR, 2013, SPINE, V38, P2028, DOI 10.1097/BRS.0b013e3182a8a381
   Van de Straete S, 1997, J Belge Radiol, V80, P109
   Verlaan JJ, 2004, SPINE, V29, P803, DOI 10.1097/01.BRS.0000116990.31984.A9
   Waldman SK, 2013, J EMERG MED, V44, pE315, DOI 10.1016/j.jemermed.2012.11.002
   Weinfeld RM, 1997, SKELETAL RADIOL, V26, P222, DOI 10.1007/s002560050225
   Westerveld LA, 2014, SPINE J, V14, P729, DOI 10.1016/j.spinee.2013.06.038
   Westerveld LA, 2009, EUR SPINE J, V18, P145, DOI 10.1007/s00586-008-0764-0
   Westerveld LA, 2008, J RHEUMATOL, V35, P1635
   Yeoh D, 2014, INJURY, V45, P1534, DOI 10.1016/j.injury.2014.03.020
NR 36
TC 3
Z9 3
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E162
EP E170
DI 10.1016/j.wneu.2018.11.108
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400020
PM 30476662
DA 2020-05-12
ER

PT J
AU Vigo, V
   Donesl, F
   Di Bonaventura, R
   Barakat, D
   Mcdermott, MW
   Abla, AA
   Rubio, RR
AF Vigo, Vera
   Donesl, Flavia
   Di Bonaventura, Rine
   Barakat, Dania
   Mcdermott, Michael W.
   Abla, Adib A.
   Rubio, Roberto Rodriguez
TI Middle Meningeal Artery to Premeatal Anterior Inferior Cerebellar Artery
   Bypass via Anterior Petrosectomy: An Anatomic Feasibility Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior inferior cerebellar artery; Anterior petrosectomy; End-to-end
   anastomosis; Middle meningeal artery; Posterior circulation
   revascularization
ID ENDONASAL TRANSCLIVAL APPROACH; SUPERFICIAL TEMPORAL ARTERY; INTERNAL
   CAROTID-ARTERY; OCCIPITAL ARTERY; CEREBRAL REVASCULARIZATION;
   TRANSPETROSAL APPROACH; VERTEBRAL ARTERY; VEIN GRAFT; ANEURYSMS;
   MANAGEMENT
AB BACKGROUND: Anterior inferior cerebellar artery (AICA) aneurysms are rare with no optimal consensus on management strategies. When treatment requires parent artery occlusion, postoperative ischemic or neuropathic complications can occur. This study evaluated the feasibility of direct revascularization of premeatal AICA using the middle meningeal artery (MMA) as the donor through an anterior petrosectomy window.
   METHODS: Ten specimens were used for surgical simulation of MMA-AICA bypass. MMA was harvested from the dura down to the foramen spinosum. An anterior petrosectomy approach was performed on each specimen, and AICA was exposed up to its origin from the basilar artery. The lateral pontine (A2) segment was mobilized laterally, and the end-to-end anastomosis was completed. Measurements of the required length of the AICA, MMA, and their calibers at the anastomotic site were recorded.
   RESULTS: MMA-AICA bypass was feasible in all specimens. The mean length of AICA from the origin at the anastomotic site was 7.3 +/- 1.7 mm, and mean length of MMA from the foramen spinosum was 34.6 +/- 5.1 mm. Mean calibers of MMA were 2.1 +/- 0.2 mm at the foramen spinosum and 1.7 +/- 0.2 mm at the anastomosis. A2 caliber was 1.6 +/- 0.3 mm with average lateral mobilization of 7.6 +/- 2.7 mm.
   CONCLUSIONS: This study establishes the feasibility of MMA-AICA bypass via a middle fossa approach. The matching caliber of the 2 arteries makes end-to-end anastomosis easy to achieve. The MMA is a suitable donor artery that avoids the use of an interposition graft and the complications of extracranial-intracranial bypass.
C1 [Vigo, Vera; Donesl, Flavia; Di Bonaventura, Rine; Barakat, Dania; Abla, Adib A.; Rubio, Roberto Rodriguez] Univ Calif San Francisco, Skull Base & Cerebrovasc Lab, San Francisco, CA 94143 USA.
   [Mcdermott, Michael W.; Abla, Adib A.; Rubio, Roberto Rodriguez] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.
RP Rubio, RR (reprint author), Univ Calif San Francisco, Skull Base & Cerebrovasc Lab, San Francisco, CA 94143 USA.; Rubio, RR (reprint author), Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.
EM neurodriguez@gmail.com
OI Rodriguez-Rubio, Roberto/0000-0002-7206-309X
CR AMARENCO P, 1994, STROKE, V25, P105, DOI 10.1161/01.STR.25.1.105
   AUSMAN JI, 1990, J NEUROSURG, V72, P554, DOI 10.3171/jns.1990.72.4.0554
   Bambakidis NC, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.1.FOCUS0915
   BARNETT HJM, 1985, NEW ENGL J MED, V313, P1191, DOI 10.1056/nejm198511073131904
   Benet A, 2017, OPER NEUROSURG, V13, P159, DOI 10.1227/NEU.0000000000001159
   Benet A, 2014, J NEUROSURG, V120, P1229, DOI 10.3171/2014.1.JNS131857
   Binning M, 2017, OPER NEUROSURG, V13, P641, DOI 10.1093/ons/opw030
   CANTORE GP, 1982, SURG NEUROL, V18, P76, DOI 10.1016/0090-3019(82)90025-8
   Chang SW, 2009, NEUROSURGERY, V64, pS44, DOI 10.1227/01.NEU.0000334410.24984.DD
   CROCKARD HA, 1991, J NEUROSURG, V75, P483, DOI 10.3171/jns.1991.75.3.0483
   da Silva TH, 2013, J NEUROL SURG PART B, V74, P108, DOI 10.1055/s-0033-1333615
   DALLEY RW, 1986, J COMPUT ASSIST TOMO, V10, P881, DOI 10.1097/00004728-198609000-00038
   DIAZ FG, 1985, NEUROSURGERY, V17, P271, DOI 10.1227/00006123-198508000-00004
   Doan V, 2016, J NEUROL SURG PART B, V77, P207, DOI 10.1055/s-0035-1564055
   Evans JJ, 2004, NEUROSURGERY, V55, P1036, DOI 10.1227/01.NEU.0000140822.64362.C6
   Feng XQ, 2017, OPER NEUROSURG, V13, P246, DOI 10.1093/ons/opw006
   Fujimura M, 2012, NEUROL MED-CHIR, V52, P435, DOI 10.2176/nmc.52.435
   Gonzalez L Fernando, 2005, Neurosurg Focus, V19, pE3
   Gonzalez LF, 2004, NEUROSURGERY, V55, P1025, DOI 10.1227/01.NEU.0000141083.00866.82
   HANSEN CC, 1970, ANN OTO RHINOL LARYN, V79, P269
   Hori S, 2015, ACTA NEUROCHIR, V157, P29, DOI 10.1007/s00701-014-2282-7
   KAMANO S, 1986, NEUROCHIRURGIA, V29, P28
   Kanamori F, 2016, NAGOYA J MED SCI, V78, P517, DOI 10.18999/nagjms.78.4.517
   KAWASE T, 1985, J NEUROSURG, V63, P857, DOI 10.3171/jns.1985.63.6.0857
   Lawton MT, 1997, NEUROSURGERY, V41, P513, DOI 10.1097/00006123-199709000-00001
   Lee BS, 2018, OPER NEUROSURG, V15, P418, DOI 10.1093/ons/opx275
   Li X, 2012, NEUROSURG REV, V35, P111, DOI 10.1007/s10143-011-0338-1
   Lv XL, 2016, INTERV NEURORADIOL, V22, P643, DOI 10.1177/1591019916656474
   MILLER CF, 1979, J NEUROSURG, V50, P802, DOI 10.3171/jns.1979.50.6.0802
   Mizushima H, 1999, SURG NEUROL, V52, P137, DOI 10.1016/S0090-3019(99)00042-7
   Niknejad HR, 2018, OPER NEUROSURG, V15, P89, DOI 10.1093/ons/opx200
   Ogilvy CS, 1996, NEUROSURGERY, V39, P736, DOI 10.1097/00006123-199610000-00018
   Oikawa S, 1996, J NEUROSURG, V84, P297, DOI 10.3171/jns.1996.84.2.0297
   Pasler D, 2011, J NEUROSURG, V114, P1057, DOI 10.3171/2010.9.JNS10491
   Peluso JPP, 2007, AM J NEURORADIOL, V28, P1573, DOI 10.3174/ajnr.A0607
   Plummer III SC, 1896, ANN SURG, V23, P540
   Quinones-Hinojosa A, 2005, SKULL BASE-INTERD AP, V15, P119, DOI 10.1055/s-2005-870598
   Rhoton AL, 2000, NEUROSURGERY, V47, pS29, DOI 10.1097/00006123-200009001-00010
   Rhoton AL., 2007, RHOTONS CRANIAL ANAT
   Rodriguez-Hernandez A, 2011, J NEUROSURG, V115, P387, DOI 10.3171/2011.3.JNS101413
   Sanmillan JL, 2016, WORLD NEUROSURG, V89, P368, DOI 10.1016/j.wneu.2016.01.081
   Santillan Alejandro, 2011, Surg Neurol Int, V2, P95, DOI 10.4103/2152-7806.82577
   Seifert V, 1996, J NEUROSURG, V85, P373, DOI 10.3171/jns.1996.85.3.0373
   Sekhar LN, 1999, NEUROSURGERY, V44, P1207, DOI 10.1097/00006123-199906000-00028
   Sekhar LN, 1999, NEUROSURGERY, V44, P1223
   SEN C, 1992, NEUROSURGERY, V30, P732
   Suh SH, 2011, AM J NEURORADIOL, V32, P159, DOI 10.3174/ajnr.A2360
   Suzuki K, 1999, SURG NEUROL, V51, P509, DOI 10.1016/S0090-3019(97)00462-X
   Tabani H, 2018, OPER NEUROSURG, V15, P101, DOI 10.1093/ons/opx257
   Taussky P, 2011, CENT EUR NEUROSURG, V72, P108, DOI 10.1055/s-0030-1268498
   TOUHO H, 1993, SURG NEUROL, V40, P164, DOI 10.1016/0090-3019(93)90130-S
   Tummala Ramachandra P, 2005, Neurosurg Focus, V19, pE6
   Umekawa M, 2018, WORLD NEUROSURG, V116, P209, DOI 10.1016/j.wneu.2018.04.161
   Ustun ME, 2004, SKULL BASE-INTERD AP, V14, P153, DOI 10.1055/s-2004-832258
   Ustun ME, 2006, SKULL BASE-INTERD AP, V16, P39, DOI 10.1055/s-2006-931622
   Youssef AS, 2009, SKULL BASE-INTERD AP, V19, P183, DOI 10.1055/s-0028-1096196
   Yu JL, 2016, INT J MED SCI, V13, P790, DOI 10.7150/ijms.16489
   Yu ZT, 2017, J ULTRAS MED, V36, P439, DOI 10.7863/ultra.16.02011
   Zotta DC, 2011, J CLIN NEUROSCI, V18, P561, DOI 10.1016/j.jocn.2010.06.019
NR 59
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E536
EP E542
DI 10.1016/j.wneu.2018.11.207
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400062
PM 30521956
DA 2020-05-12
ER

PT J
AU Wallace, AN
   Almandoz, JED
   Kayan, Y
   Fease, JL
   Scholz, JM
   Milner, AM
   Thomas, M
AF Wallace, Adam N.
   Almandoz, Josser E. Delgado
   Kayan, Yasha
   Fease, Jennifer L.
   Scholz, Jill M.
   Milner, Anna M.
   Thomas, Mary
TI Pipeline Treatment of Intracranial Aneurysms Is Safe and Effective in
   Patients with Cutaneous Metal Allergy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm; Flow diverter; Hemorrhage; Pipeline; Stroke
ID EMBOLIZATION DEVICE; RESTENOSIS; PREDICTORS; EFFICACY
AB BACKGROUND: The Pipeline embolization device (PED) has expanded the range of aneurysms amenable to endovascular treatment, including some that were previously untreatable. The PED contains several metals, including nickel, cobalt, chromium, platinum, and tungsten. The safety of PED implantation in patients with cutaneous metal allergy is unknown. The aim of this study was to assess clinical and angiographic outcomes of PED treatment in patients with cutaneous metal allergy.
   METHODS: A single-institution neurointerventional database was retrospectively reviewed for patients with documented cutaneous metal allergy who were treated with the PED. Patient, aneurysm, and procedural data were collected, including perioperative and delayed complications. Posttreatment angiograms were reviewed for in-Pipeline stenosis and aneurysm occlusion.
   RESULTS: Twenty patients with metal allergy underwent 23 PED treatments for 26 aneurysms. The cohort was 95% (19/20) female; mean age was 55.7 years. Aneurysms were primarily anterior circulation (92%, 24/26) and saccular (92%; 24/26); mean size was 8.8 mm (range, 2-32 mm). One PED was implanted in 70% (14/20) of patients, 25% (5/20) had 2 devices placed, and 1 patient had 3 devices. One major procedural complication occurred (4.3%, 1/23) in which a stroke was caused by perioperative PED thrombosis. Angiographic follow-up was available for all patients (mean duration 15.7 months; range, 6- 64 months),which demonstrated a complete aneurysm occlusion rate of 88% (23/26). Asymptomatic in-Pipeline stenosis occurred in 2 cases, resulting in 65% and 50% parent artery stenosis, respectively.
   CONCLUSIONS: Preliminary results suggest that PED implantation in patients with cutaneous metal allergy is safe and effective.
C1 [Wallace, Adam N.; Almandoz, Josser E. Delgado; Kayan, Yasha; Fease, Jennifer L.; Scholz, Jill M.; Milner, Anna M.; Thomas, Mary] Abbott NW Hosp, Neurosci Inst, Div Neurointervent Radiol, Minneapolis, MN 55407 USA.
   [Wallace, Adam N.] Univ Iowa Hosp & Clin, Dept Radiol, Iowa City, IA 52242 USA.
RP Wallace, AN (reprint author), Abbott NW Hosp, Neurosci Inst, Div Neurointervent Radiol, Minneapolis, MN 55407 USA.; Wallace, AN (reprint author), Univ Iowa Hosp & Clin, Dept Radiol, Iowa City, IA 52242 USA.
EM adam.wallace@crlmed.com
CR Almandoz JED, 2017, NEURORADIOLOGY, V59, P1291, DOI 10.1007/s00234-017-1930-z
   Becske T, 2013, RADIOLOGY, V267, P858, DOI 10.1148/radiol.13120099
   Brinjikji W, 2015, AM J NEURORADIOL, V36, P2308, DOI 10.3174/ajnr.A4443
   Chalouhi N, 2015, NEUROSURGERY, V77, P875, DOI 10.1227/NEU.0000000000000908
   Chalouhi N, 2015, J NEUROSURG, V122, P1498, DOI 10.3171/2014.12.JNS14411
   Farb A, 1999, CIRCULATION, V99, P44, DOI 10.1161/01.CIR.99.1.44
   Farb A, 2002, CIRCULATION, V105, P2974, DOI 10.1161/01.CIR.0000019071.72887.BD
   GAWKRODGER DJ, 1993, CONTACT DERMATITIS, V28, P257, DOI 10.1111/j.1600-0536.1993.tb03427.x
   Gilbert J, 2004, DIABETES CARE, V27, P990, DOI 10.2337/diacare.27.4.990
   Gimenez-Arnau A, 2000, CONTACT DERMATITIS, V43, P35, DOI 10.1034/j.1600-0536.2000.043001035.x
   Griessenauer CJ, 2019, J NEUROSURG, V130, P923, DOI 10.3171/2017.9.JNS171376
   Griessenauer CJ, 2017, NEUROSURGERY, V80, P579, DOI 10.1227/NEU.0000000000001377
   Hillen U, 2002, CONTACT DERMATITIS, V47, P353, DOI 10.1034/j.1600-0536.2002.470607.x
   Kallmes DF, 2015, AM J NEURORADIOL, V36, P108, DOI 10.3174/ajnr.A4111
   Kallmes DF, 2016, INTERV NEUROL, V5, P89, DOI 10.1159/000446503
   Kayan Y, 2017, J NEUROINTERV SURG, V9, P792, DOI 10.1136/neurintsurg-2016-012409
   Keane FN, 2001, LANCET, V357, P1205, DOI 10.1016/S0140-6736(00)04350-6
   KING L, 1993, NEW ENGL J MED, V329, P1583, DOI 10.1056/NEJM199311183292121
   Koster R, 2000, LANCET, V356, P1895, DOI 10.1016/S0140-6736(00)03262-1
   Lin Li-Mei, 2013, Surg Neurol Int, V4, P114, DOI 10.4103/2152-7806.117711
   Lin N, 2016, NEUROSURGERY, V79, P14, DOI 10.1227/NEU.0000000000001117
   Lylyk P, 2009, NEUROSURGERY, V64, P632, DOI 10.1227/01.NEU.0000339109.98070.65
   McAuliffe W, 2012, AM J NEURORADIOL, V33, P487, DOI 10.3174/ajnr.A2797
   Saatci I, 2012, AM J NEURORADIOL, V33, P1436, DOI 10.3174/ajnr.A3246
   Snellman E, 2000, BRIT J DERMATOL, V142, P1056, DOI 10.1046/j.1365-2133.2000.03502.x
   Thyssen JP, 2010, CHEM RES TOXICOL, V23, P309, DOI 10.1021/tx9002726
   Tonetti DA, 2018, WORLD NEUROSURG, V120, P349, DOI 10.1016/j.wneu.2018.09.041
   Wallace AN, 2018, NEUROSURGERY, V83, P790, DOI 10.1093/neuros/nyx561
   Yu SCH, 2012, RADIOLOGY, V265, P893, DOI 10.1148/radiol.12120422
NR 29
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E180
EP E185
DI 10.1016/j.wneu.2018.11.115
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400022
PM 30476671
DA 2020-05-12
ER

PT J
AU Wang, HB
   Sun, JC
   Tan, Y
   Li, P
   Xu, XM
   Wang, Y
   Kong, QJ
   Wang, YJ
   Zhang, B
   Guo, YF
   Shi, GD
   Shi, JG
   Tan, L
AF Wang, Haibo
   Sun, Jingchuan
   Tan, Ying
   Li, Peng
   Xu, Ximing
   Wang, Yuan
   Kong, Qingjie
   Wang, Yingjie
   Zhang, Bin
   Guo, Yongfei
   Shi, Guodong
   Shi, Jiangang
   Tan, Lei
TI Anterior Controllable Antedisplacement and Fusion as Revision Surgery
   After Posterior Decompression Surgery in Patients with Ossification of
   the Posterior Longitudinal Ligament
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior controllable antedisplacement and fusion; Cervical;
   Ossification of the posterior longitudinal ligament; Reoperation
ID MULTILEVEL SEVERE OSSIFICATION; LATE NEUROLOGIC DETERIORATION; CERVICAL
   OSSIFICATION; SURGICAL STRATEGY; RISK-FACTORS; MYELOPATHY; LAMINOPLASTY;
   CORPECTOMY; COMPLICATIONS; MANAGEMENT
AB OBJECTIVE: The aim of the present study was to evaluate the surgical outcomes of anterior controllable ante-displacement and fusion (ACAF) as a revision surgery after posterior decompression surgery (PDS) in patients with ossification of the posterior longitudinal ligament (OPLL).
   METHODS: From June 2016 to May 2017, 15 patients (7 men; 8 women) had undergone ACAF as revision after PDS. The Japanese Orthopaedic Association (JOA) score was used to evaluate the pre-and postoperative neurological function. The kappa line and complications were also evaluated.
   RESULTS: The 15 patients were followed up for 15.1 +/- 1.8 months (range, 12-18). The mean interval between the initial PDS and revision ACAF was 40.3 +/- 11.3 months (range, 24-62). The JOA score improved from 8.9 +/- 1.6 (range, 5-11) before revision ACAF to 13.9 +/- 1.6 (range, 11-16) at the final follow-up evaluation (P < 0.05). The JOA recovery rate was 61.9% +/- 15.8% (range, 37.5%-90.9%). The kappa line of 7 patients improved from negative values to positive values after ACAF. Five complications (33.3%) developed in 5 patients. No instrument failure or neurological deterioration was observed during the follow-up period.
   CONCLUSION: In the present study, the outcomes of ACAF for revision surgery for OPLL were satisfactory. ACAF could improve neurological function significantly and is an alternative surgical procedure for revision of PDS for OPLL.
C1 [Wang, Haibo; Tan, Ying; Li, Peng; Tan, Lei] Weifang Tradit Chinese Med Hosp, Dept Spine Surg, Weifang, Peoples R China.
   [Wang, Haibo; Sun, Jingchuan; Xu, Ximing; Wang, Yuan; Kong, Qingjie; Wang, Yingjie; Zhang, Bin; Guo, Yongfei; Shi, Guodong; Shi, Jiangang] Second Mil Med Univ, Changzheng Hosp, Spine Ctr, Dept Orthoped Surg, Shanghai, Peoples R China.
RP Tan, L (reprint author), Weifang Tradit Chinese Med Hosp, Dept Spine Surg, Weifang, Peoples R China.
EM zaiyuanfang111@163.com
FU Shanghai Science and Technology Commission Technology [15441904700];
   Shanghai Municipal Commission of Health and Family Planning [201640262];
   Shanghai Committee of Science and Technology, ChinaShanghai Science &
   Technology Committee [18441905800]
FX The present study was supported by grants from the Shanghai Science and
   Technology Commission Technology support project (grant 15441904700),
   Shanghai Municipal Commission of Health and Family Planning (grant
   201640262), and Shanghai Committee of Science and Technology, China
   (grant 18441905800). Our report does not contain information about
   medical devices or drugs.
CR Chang SW, 2010, NEUROSURGERY, V66, P639, DOI 10.1227/01.NEU.0000367449.60796.94
   Chen Y, 2011, J SPINAL DISORD TECH, V24, P24, DOI 10.1097/BSD.0b013e3181c7e91e
   Chen Y, 2009, EUR SPINE J, V18, P1541, DOI 10.1007/s00586-009-1029-2
   Chen Y, 2009, INT ORTHOP, V33, P477, DOI 10.1007/s00264-008-0542-y
   Cho WS, 2008, J KOREAN NEUROSURG S, V43, P259, DOI 10.3340/jkns.2008.43.6.259
   Epstein N, 2002, SURG NEUROL, V58, P194, DOI 10.1016/S0090-3019(02)00819-4
   Epstein Nancy E, 2013, Surg Neurol Int, V4, pS301, DOI 10.4103/2152-7806.111427
   Fargen KM, 2012, J NEUROSURG-SPINE, V17, P512, DOI 10.3171/2012.9.SPINE12548
   Iwasaki M, 2007, SPINE, V32, P647, DOI 10.1097/01.brs.0000257560.91147.86
   Jain SK, 2005, NEUROL INDIA, V53, P283
   Kaminsky S B, 2004, Iowa Orthop J, V24, P95
   Kawaguchi Y, 2014, SPINE J, V14, P955, DOI 10.1016/j.spinee.2013.07.457
   KIMURA I, 1995, J BONE JOINT SURG BR, V77B, P956
   Kishiya Masaki, 2009, J Spinal Disord Tech, V22, P361, DOI 10.1097/BSD.0b013e31817eee55
   Koda M, 2016, EUR SPINE J, V25, P2294, DOI 10.1007/s00586-016-4555-8
   Lee DH, 2017, J NEUROSURG-SPINE, V26, P325, DOI 10.3171/2016.8.SPINE16542
   Li H, 2011, SPINE J, V11, P1049, DOI 10.1016/j.spinee.2011.09.008
   Li ZH, 2014, EUR SPINE J, V23, P1472, DOI 10.1007/s00586-014-3208-z
   Liu T, 2011, EUR SPINE J, V20, P224, DOI 10.1007/s00586-010-1486-7
   Matsunaga S, 2001, SPINE, V26, P494, DOI 10.1097/00007632-200103010-00012
   Miao JH, 2018, WORLD NEUROSURG, V113, P212, DOI 10.1016/j.wneu.2018.02.076
   Odate S, 2017, J NEUROSURG-SPINE, V26, P466, DOI 10.3171/2016.9.SPINE16430
   Park Y, 2010, SPINE J, V10, P193, DOI 10.1016/j.spinee.2009.09.006
   Sakaura H, 2016, GLOB SPINE J, V6, P53, DOI 10.1055/s-0035-1556583
   Shin JH, 2011, NEUROSURG FOCUS, V30, DOI 10.3171/2010.12.FOCUS10270
   Shousha M, 2012, EUR SPINE J, V21, P2512, DOI 10.1007/s00586-012-2307-y
   Sun JC, 2018, WORLD NEUROSURG, V113, pE101, DOI 10.1016/j.wneu.2018.01.181
   Sun JC, 2018, WORLD NEUROSURG, V116, pE118, DOI 10.1016/j.wneu.2018.04.128
   Sun JC, 2018, EUR SPINE J, V27, P1469, DOI 10.1007/s00586-017-5437-4
   Wu JC, 2011, NEUROSURG FOCUS, V30, DOI 10.3171/2010.12.FOCUS10268
   Yang HS, 2018, WORLD NEUROSURG, V115, pE428, DOI 10.1016/j.wneu.2018.04.065
   Yang HS, 2015, EUR SPINE J, V24, P1673, DOI 10.1007/s00586-014-3539-9
   Yilmaz M, 2017, CLIN SPINE SURG, V30, pE152, DOI 10.1097/BSD.0b013e318268d30a
NR 33
TC 0
Z9 0
U1 1
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E310
EP E317
DI 10.1016/j.wneu.2018.11.156
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400038
PM 30496921
DA 2020-05-12
ER

PT J
AU Wang, JW
   Zhao, K
   Han, L
   Jiao, LW
   Liu, WH
   Xu, Y
   Niu, HQ
   Ke, CS
   Shu, K
   Lei, T
AF Wang, Junwen
   Zhao, Kai
   Han, Lin
   Jiao, Liwu
   Liu, Weihua
   Xu, Yu
   Niu, Hongquan
   Ke, Changshu
   Shu, Kai
   Lei, Ting
TI Solitary Fibrous Tumor/Hemangiopericytoma of Spinal Cord: A
   Retrospective Single-Center Study of 16 Cases
SO WORLD NEUROSURGERY
LA English
DT Article
DE Radiotherapy; Recurrence; Solitary fibrous tumor/hemangiopericytoma;
   Spinal cord; Surgery; WHO grade
ID CENTRAL-NERVOUS-SYSTEM; TUMOR; FEATURES; THERAPY
AB OBJECTIVE: In this study, we retrospectively reviewed our experience in the surgical management of solitary fibrous tumor (SFT)/hemangiopericytomas (HPCs) of the spinal cord.
   METHODS: Sixteen patients with SFT/HPCs of the spinal cord were enrolled in this study. Data on clinical presentation, radiologic findings, histopathologic features, surgical treatment, adjuvant therapy, and prognosis were retrospectively reviewed. Kaplan-Meier curves and log-rank tests were used to identify the prognostic factors for recurrence and overall survival (OS).
   RESULTS: Our series included 6 men and 10 women, with a male/female ratio of 1:1.7. Magnetic resonance imaging (MRI) showed slightly hyperintense lesions on T2-weighted images for all 16 patients. All tumors showed positive immunohistochemical staining for signal transducer and activator of transcription 6. Statistical analysis of clinical data showed that age, gender, tumor location, tumor size, medullary compartment location, and Ki-67 index were not associated with recurrence and OS (P > 0.05). However, World Health Organization grade III was significantly associated with recurrence (P < 0.01). Gross total resection (GTR) and postoperative radiotherapy significantly reduced recurrence (P < 0.01 and P < 0.05), but only GTR showed remarkable benefits to improve OS (P < 0.05).
   CONCLUSIONS: SFT/HPCs of spinal cord are rare neoplasms with a propensity to recur. Hyperintensity on T2-weighted magnetic resonance imaging combined with positive immunohistochemical staining for signal transducer and activator of transcription 6 are important clues for classification and differentiation of these tumors. The extent of resection, World Health Organization grade, and postoperative radiotherapy might be predictive factors for recurrence. Complete tumor resection should be sought whenever possible, and adjuvant radiotherapy is recommended after surgical resection. Moreover, regular and long-term follow-up is mandatory to monitor recurrence.
C1 [Wang, Junwen; Zhao, Kai; Han, Lin; Jiao, Liwu; Liu, Weihua; Xu, Yu; Niu, Hongquan; Shu, Kai; Lei, Ting] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Neurosurg, Wuhan, Hubei, Peoples R China.
   [Ke, Changshu] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Pathol, Wuhan, Hubei, Peoples R China.
RP Shu, K (reprint author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Neurosurg, Wuhan, Hubei, Peoples R China.
EM kshu@tjh.tjmu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81702478, 81602204]; Natural Science Foundation of
   Hubei ProvinceNatural Science Foundation of Hubei Province [2017CFB643]
FX This work was supported by National Natural Science Foundation of China
   (grant number 81702478 and 81602204) and Natural Science Foundation of
   Hubei Province (grant number 2017CFB643). The authors want to thank Eric
   Adams and Jorg W. Bartsch for proofreading of the manuscript.
CR Ahmad Z, 2018, NEUROL INDIA, V66, P1419, DOI 10.4103/0028-3886.241365
   Albert GW, 2017, J NEUROSURG-PEDIATR, V19, P339, DOI 10.3171/2016.10.PEDS16279
   Basaran R, 2015, CASE REP NEUROL MED, DOI 10.1155/2015/708472
   Bisceglia M, 2011, INT J SURG PATHOL, V19, P476, DOI 10.1177/1066896911405655
   Bisceglia M, 2011, ADV ANAT PATHOL, V18, P356, DOI 10.1097/PAP.0b013e318229c004
   Bishop AJ, 2018, AM J CLIN ONCOL-CANC, V41, P81, DOI 10.1097/COC.0000000000000218
   Brigui M, 2013, J CLIN NEUROSCI, V20, P311, DOI 10.1016/j.jocn.2012.02.031
   Carlos R, 2016, OR SURG OR MED OR PA, V121, P390, DOI 10.1016/j.oooo.2015.11.001
   Carneiro SS, 1996, AM J CLIN PATHOL, V106, P217, DOI 10.1093/ajcp/106.2.217
   Chen H, 2012, ACTA NEUROCHIR, V154, P237, DOI 10.1007/s00701-011-1160-9
   Ciappetta P, 2010, NEUROPATHOLOGY, V30, P273, DOI 10.1111/j.1440-1789.2009.01056.x
   Diebold M, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0693-8
   Flores-Justa A, 2018, NEUROCIRUGIA, V29, P309, DOI 10.1016/j.neucir.2018.01.005
   Ge W, 2016, ONCOL LETT, V12, P2475, DOI 10.3892/ol.2016.4967
   Hwang US, 2014, J KOREAN NEUROSURG S, V56, P265, DOI 10.3340/jkns.2014.56.3.265
   Hyodo R, 2015, NAGOYA J MED SCI, V77, P167
   Jallo George I, 2005, Neurosurgery, V57, pE195, DOI 10.1227/01.NEU.0000163420.33635.9F
   Jia Q, 2018, EUR SPINE J, V27, P891, DOI 10.1007/s00586-017-5376-0
   Klemperer P, 1992, Am J Ind Med, V22, P1
   Kobayashi K, 2014, NAGOYA J MED SCI, V76, P217
   Lavrador JP, 2015, NEUROCHIRURGIE, V61, P287, DOI 10.1016/j.neuchi.2015.03.006
   Mariniello G, 2012, NEURORADIOL J, V25, P610, DOI 10.1177/197140091202500516
   Meroni S, 2012, HIPPOKRATIA, V16, P269
   Olson NJ, 2018, ARCH PATHOL LAB MED, V142, P761, DOI 10.5858/arpa.2016-0570-RS
   Pakasa NM, 2005, VIRCHOWS ARCH, V447, P81, DOI 10.1007/s00428-005-1220-8
   Pizzolitto Stefano, 2004, Ann Diagn Pathol, V8, P268, DOI 10.1016/j.anndiagpath.2004.07.002
   Rana N, 2018, CUREUS, V10, DOI 10.7759/cureus.2656
   Robert T, 2014, NEUROL NEUROCHIR POL, V48, P144, DOI 10.1016/j.pjnns.2013.09.006
   Sahai Puja, 2016, Asian J Neurosurg, V11, P449
   Schuetze SM, 2017, CANCER-AM CANCER SOC, V123, P90, DOI 10.1002/cncr.30379
   Song ZQ, 2018, ONCOTARGETS THER, V11, P5227, DOI 10.2147/OTT.S168045
   Spagnuolo RD, 2016, ONCOTARGET, V7, P45015, DOI 10.18632/oncotarget.7523
   Tihan T, 2003, ARCH PATHOL LAB MED, V127, P432
   Walker CT, 2015, J NEUROSURG-SPINE, V23, P438, DOI 10.3171/2015.1.SPINE13915
   Wen Patrick Y, 2017, Continuum (Minneap Minn), V23, P1531, DOI 10.1212/CON.0000000000000536
   Yi XP, 2017, WORLD NEUROSURG, V104, P318, DOI 10.1016/j.wneu.2017.05.016
   Zeng LC, 2017, J NEURO-ONCOL, V131, P153, DOI 10.1007/s11060-016-2282-y
NR 37
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E629
EP E638
DI 10.1016/j.wneu.2018.12.004
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400074
PM 30554000
DA 2020-05-12
ER

PT J
AU Wang, TH
   Cai, ZH
   Zhao, YF
   Wang, W
   Zheng, GQ
   Wan, Z
   Wang, Y
AF Wang, Tianhao
   Cai, Zhihua
   Zhao, Yongfei
   Wang, Wei
   Zheng, Guoquan
   Wan, Zheng
   Wang, Yan
TI The Influence of Cross-Links on Long-Segment Instrumentation Following
   Spinal Osteotomy: A Finite Element Analysis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Biomechanics; Cross-link; Finite element analysis; Osteotomy; Pedicle
   screw instrumentation
ID PEDICLE SCREW FIXATION; TRANSVERSE CONNECTORS; STABILITY; SCOLIOSIS;
   FUSION; COMPLICATIONS; BIOMECHANICS
AB OBJECTIVE: To develop finite element models of spine following osteotomy and evaluate the effect of number and location of cross-links (CLs) on long-segment instrumentation.
   METHODS: A finite element model of instrumented spine following osteotomy was created from computed tomography images of a postoperative male patient with thoracolumbar kyphotic deformity. Five fixation models were established to simulate different number and location of CLs. Four loading conditions (flexion, extension, lateral bending, and axial rotation) were applied on the models. Range of motion (ROM), maximum value and distribution of stress on implants, and stress on vertebrae were compared between models.
   RESULTS: With increased number of CLs, average ROM of instrumented segments was reduced by 2.37%, 1.89%, and 2.49% in flexion, extension, and lateral bending. ROM was reduced by 21.98% in loading axial rotation condition. With increased number of CLs, ROM tended to be limited. Peak stresses were located on rods during axial rotation, on proximal pedicle screws during flexion, and on the osteotomy site during extension and lateral bending. CLs had an effect of dispersing stress concentration.
   CONCLUSIONS: The application of CLs enhanced the rigidity of the construct. With increased number of CLs, ROM of the construct was decreased, especially in axial rotation. CLs can also disperse the stress concentration. After comparing various CL configurations in different motion conditions, we believe that the optimal method is to place 2 CLs at the osteotomy site and the proximal segment.
C1 [Wang, Tianhao] Third Mil Med Univ, Southwest Hosp, Dept Orthopaed, Chongqing, Peoples R China.
   [Wang, Tianhao; Zhao, Yongfei; Zheng, Guoquan; Wan, Zheng; Wang, Yan] Gen Hosp Chinese Peoples Liberat Army, Dept Orthopaed, Beijing, Peoples R China.
   [Cai, Zhihua; Wang, Wei] Hunan Univ Sci & Technol, Sch Electromech Engn, Xiangtan, Peoples R China.
RP Wang, Y (reprint author), Gen Hosp Chinese Peoples Liberat Army, Dept Orthopaed, Beijing, Peoples R China.
EM yanwang_301@126.com
FU Clinical Support Foundation of General Hospital of Chinese People's
   Liberation Army [2016FC-CXYY-1004]; Science and Technology Stars Project
   of Beijing Academy of Science and Technology [Z171100001117109]
FX This study was supported by the Clinical Support Foundation of General
   Hospital of Chinese People's Liberation Army (Grant Number
   2016FC-CXYY-1004) and Science and Technology Stars Project of Beijing
   Academy of Science and Technology (Grant Number Z171100001117109).
CR Alizadeh M, 2013, J ORTHOP RES, V31, P1447, DOI 10.1002/jor.22376
   Bridwell KH, 2003, SPINE, V28, P2093, DOI 10.1097/01.BRS.0000090891.60232.70
   Brodke D S, 2001, Spine J, V1, P373, DOI 10.1016/S1529-9430(01)00116-4
   Burney MU, 2005, J SPINAL DISORD TECH, V18, P364, DOI 10.1097/01.bsd.0000167754.89778.8e
   Chen CS, 2005, MED ENG PHYS, V27, P487, DOI 10.1016/j.medengphy.2004.12.007
   Choi J, 2016, J KOREAN NEUROSURG S, V59, P91, DOI 10.3340/jkns.2016.59.2.91
   Dahl BT, 2017, EUR SPINE J, V26, P2773, DOI 10.1007/s00586-017-5222-4
   Dhawale AA, 2013, SPINE J, V13, P1485, DOI 10.1016/j.spinee.2013.05.022
   Garg Sumeet, 2015, Spine Deform, V3, P338, DOI 10.1016/j.jspd.2014.12.002
   GOEL VK, 1995, SPINE, V20, P1719, DOI 10.1097/00007632-199508000-00014
   Gzik M, 2008, ACTA BIOENG BIOMECH, V10, P49
   Holzapfel GA, 2005, BIOMECH MODEL MECHAN, V3, P125, DOI 10.1007/s10237-004-0053-8
   JOHNSTON CE, 1990, SPINE, V15, P908, DOI 10.1097/00007632-199009000-00013
   Jones AC, 2008, MED ENG PHYS, V30, P1287, DOI 10.1016/j.medengphy.2008.09.006
   Kim SS, 2012, ASIAN SPINE J, V6, P257, DOI 10.4184/asj.2012.6.4.257
   Kuklo TR, 2008, SPINE, V33, pE482, DOI 10.1097/BRS.0b013e31817c64d5
   Lehman RA, 2015, SPINE J, V15, P1629, DOI 10.1016/j.spinee.2015.03.010
   Liao JC, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891-017-1623-0
   Lim TH, 1996, SPINE, V21, P2224, DOI 10.1097/00007632-199610010-00009
   Lynn G, 1997, SPINE, V22, P1568, DOI 10.1097/00007632-199707150-00007
   MORAN JM, 1989, J ORTHOPAED RES, V7, P107, DOI 10.1002/jor.1100070115
   Schwab Frank, 2015, Neurosurgery, V76 Suppl 1, pS33, DOI 10.1227/01.neu.0000462076.73701.09
   Serhan H, 2013, J SPINAL DISORD TECH, V26, pE70, DOI 10.1097/BSD.0b013e31826a0f19
   SHIRAZIADL SA, 1984, SPINE, V9, P120, DOI 10.1097/00007632-198403000-00003
   Valdevit Antonio, 2005, Spine J, V5, P441, DOI 10.1016/j.spinee.2005.03.010
   Wang Y, 2011, EUR SPINE J, V20, P1703, DOI 10.1007/s00586-011-1771-0
   Wilke H J, 1998, Eur Spine J, V7, P148, DOI 10.1007/s005860050045
   Wood KB, 2000, SPINE, V25, P1893, DOI 10.1097/00007632-200008010-00006
   YAMAMOTO I, 1989, SPINE, V14, P1256, DOI 10.1097/00007632-198911000-00020
   Yoganandan N, 2001, CLIN BIOMECH, V16, P1, DOI 10.1016/S0268-0033(00)00074-7
   Zhang ZJ, 2018, WORLD NEUROSURG, V114, pE1120, DOI 10.1016/j.wneu.2018.03.158
   Zhao X, 2018, WORLD NEUROSURG, V114, pE114, DOI 10.1016/j.wneu.2018.02.073
NR 32
TC 1
Z9 1
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E294
EP E302
DI 10.1016/j.wneu.2018.11.154
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400036
PM 30496922
DA 2020-05-12
ER

PT J
AU Wei, D
   Nistal, DA
   Sobotka, S
   Martini, M
   Hawks, C
   Jenkins, AL
AF Wei, Daniel
   Nistal, Dominic A.
   Sobotka, Stanislaw
   Martini, Michael
   Hawks, Charlotte
   Jenkins, Arthur L., III
TI New Predictive Index for Survival in Symptomatic Spinal Metastases
SO WORLD NEUROSURGERY
LA English
DT Article
DE Neurosurgery; Spine; Survival index
ID TOKUHASHI SCORE; CORD COMPRESSION; TOMITA; PROGNOSIS; VALIDATION;
   SURGERY; CANCER; SYSTEM
AB OBJECTIVE: Patients with spinal metastases have broad variability in morbidity, mortality, and survival. Existing prognostic scoring systems have limited predictive value. Our aim is, given recent advances in surgical and medical care for patients with cancer and spinal metastases, to develop a new survival index with superior prognostic value.
   METHODS: We completed a retrospective analysis on 77 patients who received surgery for metastatic tumors to the spine, of patient factors like pathologic subtype, age, neurologic examination, type of surgical procedure, Hauser Ambulation Index, and a novel scoring system for degree of tumor burden in several organ systems, among others. A survival index will be derived from the patient factors that, when measured preintervention, best predicted survival post intervention.
   RESULTS: Although primary organ or pathologic type was not predictive of survival for patients with metastatic disease in this population, the degree of lung tumor burden (LTB) and preoperative Hauser Ambulation Index were predictive of survival. After a multivariable analysis of >20 different patient factors, the Jenkins Survival Index (JSI, a 0-21 scale) was constructed using a machine-learning system as the sum of the HAI (0-9 scale) and LTB score (0-3 scale) multiplied by 4 (JSI = HAI + 4 . LTB, Rho = -0.588, P < 0.0001). The JSI had a positive predictive value of 92% compared with 54.1% and 56.9% for Tokuhashi and Tomita scales, respectively.
   CONCLUSIONS: The JSI predicts in a meaningful way survival outcomes for patients symptomatic from spinal metastases, which will be of value to oncologists and other clinicians treating patients with metastatic disease.
C1 [Wei, Daniel; Nistal, Dominic A.; Sobotka, Stanislaw; Martini, Michael; Jenkins, Arthur L., III] Icahn Sch Med Mt Sinai, Mt Sinai Hosp, Dept Neurosurg, New York, NY 10029 USA.
   [Jenkins, Arthur L., III] Icahn Sch Med Mt Sinai, Mt Sinai Hosp, Dept Orthoped, New York, NY 10029 USA.
   [Hawks, Charlotte] Jenkins NeuroSpine, New York, NY USA.
RP Sobotka, S (reprint author), Icahn Sch Med Mt Sinai, Mt Sinai Hosp, Dept Neurosurg, New York, NY 10029 USA.
EM stanislaw.sobotka@mountsinai.org
OI Wei, Daniel/0000-0002-3786-1192; Martini, Michael/0000-0001-8169-7679;
   Jenkins, Arthur/0000-0003-0837-0420; Nistal, Dominic/0000-0001-9713-5873
CR Anderson DC, 2012, ANN INTERN MED, V156, DOI 10.7326/0003-4819-156-6-201203200-02006
   Aoude A, 2014, CAN J SURG, V57, P188, DOI 10.1503/cjs.012013
   Bhatt AD, 2013, CANCER TREAT REV, V39, P142, DOI 10.1016/j.ctrv.2012.08.002
   CHARLSON M, 1994, J CLIN EPIDEMIOL, V47, P1245, DOI 10.1016/0895-4356(94)90129-5
   Chen HJ, 2010, SPINE, V35, pE1339, DOI [10.1155/2010/174528, 10.1097/BRS.0b013e3181e574f5]
   Eap C, 2015, ORTHOP TRAUMATOL-SUR, V101, P483, DOI 10.1016/j.otsr.2015.03.007
   Enkaoua EA, 1997, SPINE, V22, P2293, DOI 10.1097/00007632-199710010-00020
   Fehlings MG, 2016, SPINE, V16, P317
   Katagiri H, 1998, INT J RADIAT ONCOL, V42, P1127, DOI 10.1016/S0360-3016(98)00288-0
   Kim JY, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477-7819-12-245
   Laufer I, 2013, ONCOLOGIST, V18, P744, DOI 10.1634/theoncologist.2012-0293
   Lei MX, 2016, SPINE, V41, P1469, DOI 10.1097/BRS.0000000000001538
   Mazenko GF, 2000, PHYS REV E, V62, P5967, DOI 10.1103/PhysRevE.62.5967
   Pereira NRP, 2016, J BONE JOINT SURG AM, V98, P1767, DOI 10.2106/JBJS.15.00975
   Putz C, 2008, SPINE, V33, P2669, DOI 10.1097/BRS.0b013e318188b98f
   Singh B, 1997, LARYNGOSCOPE, V107, P1469, DOI 10.1097/00005537-199711000-00009
   Smith HG, 2016, BRIT J SURG, V103, P1487, DOI 10.1002/bjs.10227
   TOKUHASHI Y, 1990, SPINE, V15, P1110, DOI 10.1097/00007632-199011010-00005
   Tokuhashi Y, 2014, WORLD J ORTHOP, V5, P262, DOI 10.5312/wjo.v5.i3.262
   Tomita K, 2001, SPINE, V26, P298, DOI 10.1097/00007632-200102010-00016
   Ulmar B, 2005, SPINE, V30, P2222, DOI 10.1097/01.brs.0000181055.10977.5b
   Ulmar B, 2007, ONKOLOGIE, V30, P414, DOI 10.1159/000104491
   Ulmar B, 2007, ANN SURG ONCOL, V14, P998, DOI 10.1245/s10434-006-9000-5
   Zheng BY, 2000, STAT MED, V19, P1771, DOI 10.1002/1097-0258(20000715)19:13<1771::AID-SIM485>3.3.CO;2-G
   Zou KH, 2007, CIRCULATION, V115, P654, DOI 10.1161/CIRCULATIONAHA.105.594929
NR 25
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E133
EP E140
DI 10.1016/j.wneu.2018.11.088
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400016
PM 30468921
DA 2020-05-12
ER

PT J
AU Xiao, L
   Xu, Z
   Liu, C
   Zhao, QL
   Zhang, Y
   Xu, HG
AF Xiao, Liang
   Xu, Ziang
   Liu, Chen
   Zhao, Quanlai
   Zhang, Yu
   Xu, Hongguang
TI Anatomic Relationship Between Ureter and Oblique Lateral Interbody
   Fusion Access: Analysis Based on Contrast-Enhanced Computed Tomographic
   Urography
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anatomy; Contrast-enhanced computed tomographic urography; Oblique
   lateral interbody fusion; Ureter injury
ID SURGERY; COMPLICATIONS; COMPRESSION; MULTICENTER
AB OBJECTIVE: To investigate the anatomic relationship between ureter and oblique lateral interbody fusion access by using contrast-enhanced computed tomographic urography.
   METHODS: Contrast-enhanced computed tomographic urography data of 234 patients were retrospectively analyzed. The angle of inclination (angle alpha) of bilateral ureters, the angle between bilateral surgical accesses (angle beta), the insertion angle of surgical access (angle gamma), and the angle between ureter and outer margin of ipsilateral surgical access (angle epsilon) at L2/3, L3/4, and L4/5 levels were measured and analyzed.
   RESULTS: angle alpha gradually increased from L2/3 to L4/5. angle beta gradually decreased from L2/3 to L4/5, and at each level the left-sided angle beta was larger than right-sided angle beta. angle epsilon were positive at L2/3 and left-sided L3/4. The right-sided angle epsilon at L3/4 and the bilateral sided angle epsilon at L4/5 were negative, and the right-sided angle epsilon at L4/5 had the largest absolute value.
   CONCLUSIONS: The bilateral ureters gradually descents from the lateral margin to the anteromedial margin on the surface of psoas major muscle. The range of bilateral surgical accesses for oblique lateral interbody fusion gradually decreases from L2/3 to L4/5, and the left-sided access is larger than the right-sided when at the same level. Ureters at the right-sided L3/4 level and bilateral L4/5 levels are at high risk of being injured. In particular, the right ureter at the L4/5 level is most likely to be injured.
C1 [Xiao, Liang; Xu, Ziang; Liu, Chen; Zhao, Quanlai; Zhang, Yu; Xu, Hongguang] Wannan Med Coll, Affiliated Hosp 1, Yijishan Hosp, Res Ctr Spine Surg,Dept Orthoped Surg, Wuhu, Anhui, Peoples R China.
RP Xu, HG (reprint author), Wannan Med Coll, Affiliated Hosp 1, Yijishan Hosp, Res Ctr Spine Surg,Dept Orthoped Surg, Wuhu, Anhui, Peoples R China.
EM pumchxuhg@126.com
OI XIAO, Liang/0000-0002-5779-6092
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81572185]; Natural Science Foundation of Anhui
   Province of ChinaNatural Science Foundation of Anhui Province
   [1708085MH185]; Natural Science Foundation for Young Scientists of Anhui
   Province of China [1808085QH275]; Foreign Cooperation and Technology
   Foundation of Anhui Province of China [1704e1002229]
FX This study was supported by a grant from the National Natural Science
   Foundation of China (grant no. 81572185), the Natural Science Foundation
   of Anhui Province of China (grant no. 1708085MH185), the Natural Science
   Foundation for Young Scientists of Anhui Province of China (grant no.
   1808085QH275) and the Foreign Cooperation and Technology Foundation of
   Anhui Province of China (grant no. 1704e1002229).
CR Abe K, 2017, SPINE, V42, P55, DOI 10.1097/BRS.0000000000001650
   Benglis DM, 2009, J NEUROSURG-SPINE, V10, P139, DOI 10.3171/2008.10.SPI08479
   Christensen FB, 1997, INT ORTHOP, V21, P176, DOI 10.1007/s002640050145
   Fujibayashi S, 2017, J ORTHOP SCI, V22, P420, DOI 10.1016/j.jos.2017.01.009
   Fujibayashi S, 2015, SPINE, V40, pE175, DOI 10.1097/BRS.0000000000000703
   Karikari IO, 2011, J SPINAL DISORD TECH, V24, P368, DOI 10.1097/BSD.0b013e3181ffefd2
   Kubota Go, 2017, BMC Res Notes, V10, P193, DOI 10.1186/s13104-017-2509-9
   Lee HJ, 2017, WORLD NEUROSURG, V102, DOI 10.1016/j.wneu.2017.04.038
   Louie PK, 2017, SPINE, V42, pE1386, DOI 10.1097/BRS.0000000000002303
   Molinares DM, 2016, J NEUROSURG-SPINE, V24, P248, DOI 10.3171/2015.3.SPINE13976
   Mundis GM, 2010, SPINE, V35, pS312, DOI 10.1097/BRS.0b013e318202495f
   Ohtori S, 2015, ASIAN SPINE J, V9, P565, DOI 10.4184/asj.2015.9.4.565
   Papanastassiou ID, 2011, J CLIN NEUROSCI, V18, P149, DOI 10.1016/j.jocn.2010.07.109
   Regan JJ, 1997, CLIN ORTHOP RELAT R, P122
   Regan JJ, 1999, SPINE, V24, P402, DOI 10.1097/00007632-199902150-00023
   Silvestre C, 2012, ASIAN SPINE J, V6, P89, DOI 10.4184/asj.2012.6.2.89
   Wakita Hiromasa, 2015, BMC Res Notes, V8, P126, DOI 10.1186/s13104-015-1087-y
NR 17
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E717
EP E722
DI 10.1016/j.wneu.2018.12.011
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400085
PM 30576813
DA 2020-05-12
ER

PT J
AU Yang, K
   Chen, J
   Xiang, J
   Liu, HY
   Zou, YJ
   Kan, WW
   Liu, Y
   Li, LX
AF Yang, Kun
   Chen, Jiu
   Xiang, Jing
   Liu, Hongyi
   Zou, Yuanjie
   Kan, Wenwu
   Liu, Yong
   Li, Lixin
TI Histopathologic and Clinical Correlation of Aberrant Neuromagnetic
   Activities with Low to High Frequency of Gliomas
SO WORLD NEUROSURGERY
LA English
DT Article
DE Accumulated source imaging; Brain activities; Glioma;
   Magnetoencephalography; Multiple frequency analysis
ID BRAIN ACTIVITY; LOCALIZATION; OSCILLATIONS; EPILEPSY;
   MAGNETOENCEPHALOGRAPHY; ZONES; MEG
AB OBJECTIVE: To quantify the low- to high-frequency range of abnormal brain activities and assess the histopathologic and clinical correlation in patients with glioma.
   METHODS: Twenty-five patients with glioma and 20 healthy controls were examined with a magnetoencephalography (MEG) system. MEG data collected in 6 frequency bands, including 1-4 Hz, 4-8 Hz, 8-12 Hz, 12-30 Hz, 30-45 Hz, and 55-75 Hz, were analyzed by neuropathology to assess neuromagnetic signatures of glioma grade.
   RESULTS: Compared with controls, patients with glioma showed greatly altered brain activities in 4-8 Hz, 8-12 Hz, and 55-75 Hz. Magnetic source power of brain activities in 4-8 Hz and 55-75 Hz in patients with high-grade gliomas significantly differed from that in patients with low-grade gliomas. The magnitude of source power of brain activities in 4-8 Hz and 55-75 Hz had marked correlation with the grading of gliomas in histopathological analyses.
   CONCLUSIONS: The degree of neuromagnetic source abnormality is a potential biomarker for noninvasive assessment of glioma grade. Because MEG tests can be performed noninvasively and preoperatively, MEG may play an important role in clinical biopsies and surgical planning for patients with brain gliomas in the future.
C1 [Yang, Kun; Liu, Hongyi; Zou, Yuanjie; Kan, Wenwu; Liu, Yong] Nanjing Med Univ, Affiliated Brain Hosp, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China.
   [Chen, Jiu] Nanjing Med Univ, Clin Coll 4, Inst Neuropsychiat, Affiliated Brain Hosp, Nanjing, Jiangsu, Peoples R China.
   [Xiang, Jing] Cincinnati Childrens Hosp Med Ctr, MEG Ctr, Dept Neurol, Cincinnati, OH 45229 USA.
   [Li, Lixin] Nanjing Med Univ, Dept Neurosurg, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China.
RP Li, LX (reprint author), Nanjing Med Univ, Dept Neurosurg, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China.
EM lilixin2@hotmail.com
RI Xiang, Jing/AAA-5326-2020
OI Xiang, Jing/0000-0003-0242-5590
FU Jiangsu Government Scholarship for Overseas Studies [JS-2014-294];
   clinical sci-tech project of National Health and Family Planning
   Commission of the People's Republic of China [W201308]; Nanjing
   Commission of Health and Family Planning [H201540]; medical sci-tech
   development project of Nanjing [YKK12137, ZKX14044]
FX This study was supported by Jiangsu Government Scholarship for Overseas
   Studies (No. JS-2014-294), a grant from the clinical sci-tech project of
   National Health and Family Planning Commission of the People's Republic
   of China (No. W201308), the Nanjing Commission of Health and Family
   Planning (No. H201540), and a grant from the medical sci-tech
   development project of Nanjing (No. YKK12137 and ZKX14044).
CR Amo C, 2003, SEIZURE-EUR J EPILEP, V12, P19, DOI 10.1016/S1059131102001486
   Baayen JC, 2003, BRAIN TOPOGR, V16, P85, DOI 10.1023/B:BRAT.0000006332.71345.b7
   Birk Harjus S, 2017, CNS Oncol, V6, P61, DOI 10.2217/cns-2016-0013
   Bosma I, 2008, NEURO-ONCOLOGY, V10, P734, DOI 10.1215/15228517-2008-034
   Brookes MJ, 2007, NEUROIMAGE, V34, P1454, DOI 10.1016/j.neuroimage.2006.11.012
   Carbo EWS, 2017, SCI REP-UK, V7, DOI 10.1038/srep42117
   Chang W, 2013, ACTA NEUROCHIR, V155, P1449, DOI 10.1007/s00701-013-1781-2
   de Jongh A, 2003, NEUROIMAGE, V20, P2291, DOI 10.1016/j.neuroimage.2003.07.030
   Douw L, 2013, NEUROIMAGE, V75, P195, DOI 10.1016/j.neuroimage.2013.02.067
   Fischer MJM, 2008, EPILEPSY RES, V82, P238, DOI 10.1016/j.eplepsyres.2008.07.019
   Ganslandt O, 2004, CLIN NEUROL NEUROSUR, V107, P20, DOI 10.1016/j.clineuro.2004.02.027
   HAGLUND MM, 1992, J NEUROSURG, V77, P209, DOI 10.3171/jns.1992.77.2.0209
   Kerkhof M, 2013, EPILEPSIA, V54, P12, DOI 10.1111/epi.12437
   Kotecha R, 2009, INT J PSYCHOPHYSIOL, V72, P102, DOI 10.1016/j.ijpsycho.2008.10.009
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Louis DN, 2007, WHO CLASSIFICATION T
   Miao AL, 2014, NEUROSCI LETT, V566, P21, DOI 10.1016/j.neulet.2014.02.038
   Mizuno T, 2011, CHILD NERV SYST, V27, P479, DOI 10.1007/s00381-010-1286-8
   Osorio Joseph A, 2014, CNS Oncol, V3, P359, DOI 10.2217/cns.14.36
   Rampp S, 2007, EXPERT REV MED DEVIC, V4, P335, DOI 10.1586/17434440.4.3.335
   Sohal VS, 2012, BIOL PSYCHIAT, V71, P1039, DOI 10.1016/j.biopsych.2012.01.024
   Tenney JR, 2014, ANN NEUROL, V76, P558, DOI 10.1002/ana.24231
   van Dellen E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050122
   Wilson TW, 2012, NEURO-ONCOLOGY, V14, P624, DOI 10.1093/neuonc/nos064
   Xiang J, 2015, J NEUROSCI METH, V239, P114, DOI 10.1016/j.jneumeth.2014.10.007
   Xiang J, 2014, FRONT NEUROINFORM, V8, DOI 10.3389/fninf.2014.00057
   Xiang J, 2010, J NEUROS-PEDIATR, V5, P113, DOI 10.3171/2009.8.PEDS09345
   Xiao Z, 2006, PEDIATR RADIOL, V36, P16, DOI 10.1007/s00247-005-0013-1
NR 28
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E609
EP E620
DI 10.1016/j.wneu.2018.11.235
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400072
PM 30529596
DA 2020-05-12
ER

PT J
AU Yasid, H
   Hoff, HJ
   Bluemcke, I
   Simon, M
AF Yasid, Hamzah
   Hoff, Hans-Joachim
   Bluemcke, Ingmar
   Simon, Matthias
TI Experience with 102 Frameless Stereotactic Biopsies Using the neuromate
   Robotic Device
SO WORLD NEUROSURGERY
LA English
DT Article
DE Frameless stereotaxy; Robot-assisted biopsy; Robotic device;
   Stereotactic biopsy
ID ELECTRODES; EFFICACY; SAFETY
AB OBJECTIVE: Stereotactic biopsy is a standard procedure in neurosurgery. In addition to or even replacing frame-based stereotaxy, some centers also use frameless imaging-based techniques and more recently robotic systems. Here we report a retrospective analysis of our experience with 102 consecutive biopsies performed in our institution using the neuromate robotic device.
   METHODS: Between March 2013 and April 2018, 102 robot-assisted frameless biopsies were performed in 100 consecutive patients (median age/range: 66/7-86 years, male: 64). Target lesions were deep-seated (insula, basal ganglia, thalamus, midbrain, cerebellar peduncle) in 29 (28.4%) and/or small (<15 mm) in 24 (23.5%) cases. We retrospectively analyzed the histopathologic results as well as complications and the duration of the procedures.
   RESULTS: A definite histologic diagnosis could be established in 94 of 102 procedures (92.2%; 94/100 patients = 94.0%), including 67 glial and glioneuronal tumors, 16 central nervous system lymphomas, 7 metastases, 1 primitive neuroectodermal tumor, and 5 cases with inflammatory or infectious disorders. There were no infectious complications. A total of 13 cases (12.7%) suffered from biopsy-related hemorrhages >10 mm; however, persistent surgery-related neurologic worsening was seen in only 3 (2.9%). The average operating time was 10 minutes for placement of the localizing device under local anesthesia and 30 minutes for the actual biopsy procedure.
   CONCLUSIONS: Robot-assisted fameless stereotactic biopsies using the neuromate robot are an alternative to frame-based stereotaxy with a similar diagnostic yield and comparable complication rates.
C1 [Yasid, Hamzah; Hoff, Hans-Joachim; Simon, Matthias] Bethel Clin, Dept Neurosurg, Bielefeld, Germany.
   [Bluemcke, Ingmar] Univ Hosp Erlangen, Inst Neuropathol, Erlangen, Germany.
RP Simon, M (reprint author), Bethel Clin, Dept Neurosurg, Bielefeld, Germany.
EM Matthias.Simon@evkb.de
CR Abel TJ, 2018, J NEUROSURG-PEDIATR, V22, P37, DOI 10.3171/2018.1.PEDS17435
   Abhinav K, 2013, BRIT J NEUROSURG, V27, P704, DOI 10.3109/02688697.2013.798859
   Air EL, 2009, J NEUROSURG, V111, P820, DOI 10.3171/2009.3.JNS081695
   Barua NU, 2013, ACTA NEUROCHIR, V155, P1459, DOI 10.1007/s00701-013-1700-6
   Bekelis K, 2012, J NEUROSURG, V116, P1002, DOI 10.3171/2012.1.JNS111746
   Carai A, 2017, WORLD NEUROSURG, V101, P584, DOI 10.1016/j.wneu.2017.02.088
   De Benedictis A, 2017, NEUROSURG FOCUS, V42, DOI 10.3171/2017.2.FOCUS16579
   Eibach S, 2014, STEREOT FUNCT NEUROS, V92, P80, DOI 10.1159/000355904
   Grimm F, 2015, J NEUROSURG, V123, P737, DOI 10.3171/2014.12.JNS141781
   Grossman R, 2005, ACTA NEUROCHIR, V147, P627, DOI 10.1007/s00701-005-0495-5
   Haegelen C, 2010, NEUROCHIRURGIE, V56, P363, DOI 10.1016/j.neuchi.2010.05.006
   Harrisson SE, 2012, NEUROSURGERY, V70, DOI 10.1227/NEU.0b013e31822d75af
   Lefranc M, 2017, WORLD NEUROSURG, V106, P602, DOI 10.1016/j.wneu.2017.07.047
   Lefranc M, 2015, J NEUROSURG, V122, P342, DOI 10.3171/2014.9.JNS14107
   Li Qing Hang, 2002, Comput Aided Surg, V7, P90, DOI 10.3109/10929080209146020
   Minchev G, 2017, J NEUROSURG, V126, P985, DOI 10.3171/2016.1.JNS152005
   Ollivier I, 2017, NEUROCHIRURGIE, V63, P286, DOI 10.1016/j.neuchi.2017.03.002
   Owen CM, 2009, J NEURO-ONCOL, V93, P139, DOI 10.1007/s11060-009-9871-y
   Shooman D, 2010, J NEUROSURG, V113, P170, DOI 10.3171/2009.12.JNS09573
   Smith JS, 2005, J NEURO-ONCOL, V73, P173, DOI 10.1007/s11060-004-4208-3
   Varma TRK, 2003, STEREOT FUNCT NEUROS, V80, P132, DOI 10.1159/000075173
   Verploegh ISC, 2015, ACTA NEUROCHIR, V157, P2011, DOI 10.1007/s00701-015-2543-0
   von Langsdorff D, 2015, J NEUROSURG, V122, P191, DOI 10.3171/2014.9.JNS14256
   Willems PWA, 2003, ACTA NEUROCHIR, V145, P889, DOI 10.1007/s00701-003-0112-4
   Woodworth GF, 2006, J NEUROSURG, V104, P233, DOI 10.3171/jns.2006.104.2.233
   Yuen J, 2014, STEREOT FUNCT NEUROS, V92, P160, DOI 10.1159/000360862
NR 26
TC 0
Z9 0
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E450
EP E456
DI 10.1016/j.wneu.2018.11.187
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400052
PM 30500594
DA 2020-05-12
ER

PT J
AU Ye, I
   Tang, R
   White, SJ
   Cheung, ZB
   Cho, SK
AF Ye, Ivan
   Tang, Ray
   White, Samuel J.
   Cheung, Zoe B.
   Cho, Samuel K.
TI Predictors of 30-Day Postoperative Pulmonary Complications After Open
   Reduction and Internal Fixation of Vertebral Fractures
SO WORLD NEUROSURGERY
LA English
DT Article
DE Complications; NSQIP; Surgical outcome; Vertebral fracture
ID THORACOLUMBAR BURST FRACTURE; POSTERIOR LUMBAR FUSION; AMERICAN-COLLEGE;
   RISK-FACTORS; NONCARDIOTHORACIC SURGERY; DIABETES-MELLITUS; SPINE
   FUSION; DECOMPRESSION; TRANSFUSION; STRATEGIES
AB OBJECTIVE: The purpose of this study was to identify predictors of 30-day postoperative pulmonary complications after open reduction and internal fixation (ORIF) of vertebral fractures.
   METHODS: We performed a retrospective study using the American College of Surgeons National Surgical Quality Improvement Program database from 2010 to 2014. Adult patients who underwent ORIF of vertebral fractures were included and divided into 2 groups based on the occurrence of 30-day postoperative pulmonary complications. Baseline patient and operative characteristics were compared between the 2 groups. Multivariate regression (MVR) analysis was performed to identify independent risk factors for pulmonary complications.
   RESULTS: A total of 900 patients were included in our cohort. The overall 30-day pulmonary complication rate was 5.67%. Patients who had a pulmonary complication after vertebral ORIF were more often men and more often had diabetes, functional dependence, American Society of Anesthesiologists score classification of 3 or higher, pulmonary comorbidity, renal comorbidity, and preoperative anemia. The pulmonary complication group also had a higher incidence of 30-day mortality, prolonged hospitalization, pneumonia, cardiac complications, urinary tract infection, blood transfusion, and sepsis. The MVR analysis found that pulmonary comorbidity (odds ratio [OR], 5.3; 95% confidence interval [CI], 2.5-11.5; P < 0.001), diabetes (OR, 2.1; 95% CI, 1.0-4.2; P = 0.037), partial or dependent functional status (OR, 4.7; 95% CI, 2.2-10.2; P < 0.001), and cervical spine involvement (OR, 3.6; 95% CI, 1.7-8.0; P = 0.001) were independent predictors of pulmonary complications.
   CONCLUSIONS: Early identification of risk factors for postoperative pulmonary complications is important in the evaluation of patients with vertebral fractures for surgical decision-making, preoperative optimization, and subsequent postoperative care to improve patient outcomes and minimize morbidity.
C1 [Ye, Ivan; Tang, Ray; White, Samuel J.; Cheung, Zoe B.; Cho, Samuel K.] Icahn Sch Med Mt Sinai, Dept Orthopaed Surg, New York, NY 10029 USA.
RP Cho, SK (reprint author), Icahn Sch Med Mt Sinai, Dept Orthopaed Surg, New York, NY 10029 USA.
EM samuel.cho@mountsinai.org
RI Cheung, Zoe/AAG-4511-2020
OI Cheung, Zoe/0000-0002-0189-5390
CR Aarabi B, 2012, J NEUROSURG-SPINE, V17, P38, DOI 10.3171/2012.4.AOSPINE1295
   Aoude A, 2017, ASIAN SPINE J, V11, P880, DOI 10.4184/asj.2017.11.6.880
   Ardigo Diego, 2004, Current Drug Targets - Inflammation and Allergy, V3, P455, DOI 10.2174/1568010042634488
   Arozullah A, 2002, OBSTET GYNECOL SURV, V57, P283
   Arozullah AM, 2000, ANN SURG, V232, P242, DOI 10.1097/00000658-200008000-00015
   Bazzocchi A, 2016, SEMIN MUSCULOSKEL R, V20, P317, DOI 10.1055/s-0036-1592435
   Bohl DD, 2016, SPINE, V41, P1058, DOI 10.1097/BRS.0000000000001389
   Bohl DD, 2016, SPINE J, V16, P335, DOI 10.1016/j.spinee.2015.11.021
   Boulbou MS, 2003, MED PRIN PRACT, V12, P87, DOI 10.1159/000069118
   Bronsard N, 2013, ORTHOP TRAUMATOL-SUR, V99, P162, DOI 10.1016/j.otsr.2012.12.012
   CALDER I, 1995, ANAESTHESIA, V50, P756, DOI 10.1111/j.1365-2044.1995.tb06135.x
   Carabini LM, 2014, J NEUROSURG ANESTH, V26, P205, DOI 10.1097/ANA.0000000000000014
   Carreon LY, 2003, J BONE JOINT SURG AM, V85A, P2089, DOI 10.2106/00004623-200311000-00004
   Charles YP, 2015, ORTHOP TRAUMATOL-SUR, V101, pS31, DOI 10.1016/j.otsr.2014.06.024
   Chughtai Morad, 2017, J Clin Med Res, V9, P466, DOI 10.14740/jocmr3002w
   Diaz-Fuentes G, 2016, HEALTH SERV INSIGHTS, V9, P9, DOI 10.4137/HSI.S40541
   Gabel BC, 2016, GLOB SPINE J, V6, P296, DOI 10.1055/s-0036-1582232
   Ghobrial GM, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.4.FOCUS1467
   Goldman M, 2005, TRANSFUS MED REV, V19, P2, DOI 10.1016/j.tmrv.2004.10.001
   Imposti Felix, 2010, Evid Based Spine Care J, V1, P26, DOI 10.1055/s-0028-1100911
   Jackson SA, 2000, OSTEOPOROSIS INT, V11, P680, DOI 10.1007/s001980070066
   Kalanithi PS, 2009, SPINE, V34, P1963, DOI 10.1097/BRS.0b013e3181ae2243
   Khakban A, 2017, AM J RESP CRIT CARE, V195, P287, DOI 10.1164/rccm.201606-1162PP
   KOZIEL H, 1995, INFECT DIS CLIN N AM, V9, P65
   Memtsoudis SG, 2010, REGION ANESTH PAIN M, V35, P417, DOI 10.1097/AAP.0b013e3181e85a07
   Memtsoudis SG, 2011, SPINE, V36, P1867, DOI 10.1097/BRS.0b013e3181c7decc
   Minhas SV, 2017, BONE JOINT J, V99B, P824, DOI 10.1302/0301-620X.99B6.BJJ-2016-1149.R1
   Patil PG, 2005, NEUROSURGERY, V57, P753, DOI 10.1227/01.NEU.0000175729.79119.1d
   Pumberger M, 2012, J BONE JOINT SURG BR, V94B, P359, DOI 10.1302/0301-620X.94B3.27825
   Qaseem A, 2006, ANN INTERN MED, V144, P575, DOI 10.7326/0003-4819-144-8-200604180-00008
   Sanderson PL, 1999, EUR SPINE J, V8, P495, DOI 10.1007/s005860050212
   Schousboe JT, 2018, CURR OSTEOPOROS REP, V16, P573, DOI 10.1007/s11914-018-0472-6
   Smetana GW, 2006, ANN INTERN MED, V144, P581, DOI 10.7326/0003-4819-144-8-200604180-00009
   Stadhouder A, 2008, SPINE, V33, P1006, DOI 10.1097/BRS.0b013e31816c8b32
   Stundner O, 2012, WORLD J ORTHOP, V3, P156, DOI 10.5312/wjo.v3.i10.156
   Tezeren G, 2005, J SPINAL DISORD TECH, V18, P485, DOI 10.1097/01.bsd.0000149874.61397.38
   Tezeren G, 2009, J BACK MUSCULOSKELET, V22, P107, DOI 10.3233/BMR-2009-0224
   Vaidya R, 2009, SPINE, V34, P495, DOI 10.1097/BRS.0b013e318198c5f2
   Waterloo S, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471-2474-13-3
   Weinberg DS, 2017, SPINE J, V17, P1449, DOI 10.1016/j.spinee.2017.05.008
   Winslow C, 2002, CHEST, V121, P1548, DOI 10.1378/chest.121.5.1548
NR 41
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E288
EP E293
DI 10.1016/j.wneu.2018.11.153
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400035
PM 30496929
DA 2020-05-12
ER

PT J
AU Yoon, JW
   Wanderman, NR
   Kerezoudis, P
   Alvi, MA
   De Biase, G
   Akinduro, OO
   Berbari, EF
   Bydon, M
   Freedman, BA
AF Yoon, Jang W.
   Wanderman, Nathan R.
   Kerezoudis, Panagiotis
   Alvi, Mohammed Ali
   De Biase, Gaetano
   Akinduro, Oluwaseun O.
   Berbari, Elie F.
   Bydon, Mohamad
   Freedman, Brett A.
TI Enterobacter Infection after Spine Surgery: An Institutional Experience
SO WORLD NEUROSURGERY
LA English
DT Article
DE Antibiotics; Enterobacter; Infection; Multi-drug resistant; Spine
   surgery
ID SURGICAL-SITE INFECTIONS; RISK-FACTORS; MANAGEMENT
AB BACKGROUND: Gram-negative surgical site infections (SSI) following spine surgery are becoming increasingly more common owing to a broad perioperative antibiotic usage targeting gram-positive organisms. Enterobacter species have been reported to be the most common gram-negative bacteria following spine surgery.
   METHODS: We queried our institutional database for Enterobacter SSIs after spine surgery at a single institution from 2009-2016. Relevant demographic, clinical, and operative variables were collected. We compared this cohort to patients who had non-Enterobacter SSI during the same period.
   RESULTS: Enterobacter species were isolated in 16 patients (9 males) diagnosed with SSI after undergoing spine surgery. This group represented 0.2% of all spine cases and 14.5% of all spinal SSIs. Seven patients (43.8%) required multiple irrigations and debridements (I&Ds) (range: 2-8), whereas only 17 of 94 patients (18.1%) with non-Enterobacter SSI required multiple I&Ds (range: 2-5, P = 0.043). Those infected with Enterobacter were associated with higher BMI (37.6 +/- 12.7 vs. 31.7 +/- 8, P = 0.036), earlier wound dehiscence (14.8 vs. 24.6 days, P = 0.01), polymicrobial infections (37.5% vs. 10.6%, P = 0.012), and longer length of stay (18 days [9.5-31.5] vs. 5 days [3-8], P = 0.01) when compared to non-Enterobacter SSI cohort. At an average of 24.2 months follow-up, all 15 surviving patients were infection free with no further revision surgeries needed.
   CONCLUSIONS: Enterobacter SSI cases were associated with higher BMI, earlier wound breakdown, polymicrobial infection and longer length of stay. Nevertheless, with vigilant surveillance and timely I&Ds, these challenging infections can be treated successfully with original implant retention in almost all cases.
C1 [Yoon, Jang W.; Kerezoudis, Panagiotis; Alvi, Mohammed Ali; Bydon, Mohamad] Mayo Clin, Mayo Clin Neuroinformat Lab, Coll Med & Sci, Rochester, MN 55905 USA.
   [Wanderman, Nathan R.; Freedman, Brett A.] Mayo Clin, Dept Orthoped Surg, Rochester, MN USA.
   [Kerezoudis, Panagiotis; Alvi, Mohammed Ali; Bydon, Mohamad] Mayo Clin, Dept Neurol Surg, Rochester, MN 55905 USA.
   [Berbari, Elie F.] Mayo Clin, Div Infect Dis, Rochester, MN USA.
   [Yoon, Jang W.; De Biase, Gaetano; Akinduro, Oluwaseun O.] Mayo Clin, Dept Neurol Surg, Jacksonville, FL 32224 USA.
RP Bydon, M (reprint author), Mayo Clin, Mayo Clin Neuroinformat Lab, Coll Med & Sci, Rochester, MN 55905 USA.
EM bydon.mohamad@mayo.edu
RI Alvi, Mohammed Ali/AAE-1490-2019
OI Alvi, Mohammed Ali/0000-0002-7131-079X
CR Abdul-Jabbar A, 2013, SPINE, V38, pE1425, DOI 10.1097/BRS.0b013e3182a42a68
   Beiner John M, 2003, Neurosurg Focus, V15, pE14
   Berven S, 2007, SPINE, V32, pS33, DOI 10.1097/BRS.0b013e318053d537
   Brook Itzhak, 2002, Pediatr Rehabil, V5, P171, DOI 10.1080/1363849021000054022
   Dubee V, 2012, CLIN INFECT DIS, V55, P1481, DOI 10.1093/cid/cis769
   Ghobrial GM, 2014, SPINE, V39, P550, DOI 10.1097/BRS.0000000000000241
   Kowalski TJ, 2007, CLIN INFECT DIS, V44, P913, DOI 10.1086/512194
   O'Neill KR, 2011, SPINE J, V11, P641, DOI 10.1016/j.spinee.2011.04.025
   Olsen MA, 2003, J NEUROSURG, V98, P149, DOI 10.3171/spi.2003.98.2.0149
   Olsen MA, 2008, J BONE JOINT SURG AM, V90A, P62, DOI 10.2106/JBJS.F.01515
   Prokuski L, 2008, J AM ACAD ORTHOP SUR, V16, P283, DOI 10.5435/00124635-200805000-00007
   Sponseller PD, 2000, SPINE, V25, P2461, DOI 10.1097/00007632-200010010-00007
   Tali ET, 2015, NEUROIMAG CLIN N AM, V25, pXV, DOI 10.1016/j.nic.2015.02.001
   ter Gunne AFP, 2009, SPINE, V34, P1422, DOI 10.1097/BRS.0b013e3181a03013
   Turnidge JD, 2011, CLIN INFECT DIS, V52, P917, DOI 10.1093/cid/cir031
   Whitehouse JD, 2002, INFECT CONT HOSP EP, V23, P183, DOI 10.1086/502033
NR 16
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E330
EP E337
DI 10.1016/j.wneu.2018.11.169
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400040
PM 30500574
DA 2020-05-12
ER

PT J
AU Yoshida, K
   Fukumitsu, R
   Kurosaki, Y
   Negata, M
   Tao, Y
   Suzuki, M
   Yamamoto, Y
   Funaki, T
   Kikuchi, T
   Ishii, A
   Miyamoto, S
AF Yoshida, Kazumichi
   Fukumitsu, Ryu
   Kurosaki, Yoshitaka
   Negata, Manabu
   Tao, Yang
   Suzuki, Megumu
   Yamamoto, Yu
   Funaki, Takeshi
   Kikuchi, Takayuki
   Ishii, Akira
   Miyamoto, Susumu
TI Carotid Endarterectomy for Medical Therapy-Resistant Symptomatic
   Low-Grade Stenosis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Carotid endarterectomy; Expansive remodeling; Low-grade stenosis;
   Vulnerable plaque
ID INTRAPLAQUE HEMORRHAGE; ARTERY; PLAQUE; STROKE; RISK; ASSOCIATION;
   MODERATE; MRI
AB BACKGROUND: Plaque characteristics play pivotal roles in ischemic events, but stenosis severity does not accurately reflect carotid plaque volume due to expansive remodeling in some patients with low-grade stenosis (LGS). This study aimed to assess the safety, efficacy, and durability of carotid endarterectomy (CEA) for symptomatic LGS.
   METHODS: Study participants comprised 61 consecutive patients who underwent CEA for symptomatic carotid stenosis. Patients were divided into an LGS group (<50%, n = 17) and a non-LGS group (>= 50%, n = 44). Patient characteristics and short-term (within 30 days of CEA) and long-term outcomes were compared between groups for selective usage of internal shunt and known complications of CEA.
   RESULTS: Magnetic resonance imaging-detected intraplaque hemorrhage was more significant in LGS than in non-LGS (P = 0.04). For short-term outcomes, no symptomatic infarcts, hyperperfusion syndrome, or acute myocardial infarction was confirmed in either group. Internal shunts were used in 4 LGS (23.5%) and 6 non-LGS (13.6%). Asymptomatic diffusion-weighted imaging-positive lesions were confirmed in 2 LGS patients (11.8%) and 5 non-LGS patients (11.4%), neck hematoma in 1 LGS patient, and transient cranial nerve palsy in 1 LGS patient and 2 non-LGS patients, with no significant differences apparent between groups. For long-term outcomes, 5 non-LGS patients showed restenosis (P = 0.17). Hemorrhagic stroke was not observed in either group. No significant differences were seen for infarct in the ipsilateral carotid territory, any ischemic stroke, AMI, or mortality.
   CONCLUSIONS: CEA represents a safe and feasible therapeutic option for a subset of patients with symptomatic LGS.
C1 [Yoshida, Kazumichi; Fukumitsu, Ryu; Negata, Manabu; Tao, Yang; Suzuki, Megumu; Yamamoto, Yu; Funaki, Takeshi; Kikuchi, Takayuki; Ishii, Akira; Miyamoto, Susumu] Kyoto Univ, Dept Neurosurg, Grad Sch Med, Kyoto, Japan.
   [Kurosaki, Yoshitaka] Kurashiki Cent Hosp, Dept Neurosurg, Okayama, Japan.
RP Yoshida, K (reprint author), Kyoto Univ, Dept Neurosurg, Grad Sch Med, Kyoto, Japan.
EM kazuy@kuhp.kyoto-u.ac.jp
CR Altaf N, 2008, J VASC SURG, V47, P337, DOI 10.1016/j.jvs.2007.09.064
   Altaf N, 2013, ANN VASC SURG, V27, P655, DOI 10.1016/j.avsg.2012.10.011
   Ballotta E, 2014, J VASC SURG, V59, P25, DOI 10.1016/j.jvs.2013.06.079
   Barnett HJM, 1998, NEW ENGL J MED, V339, P1415, DOI 10.1056/NEJM199811123392002
   Bonati LH, 2015, LANCET, V385, P529, DOI 10.1016/S0140-6736(14)61184-3
   Brinjikji W, 2016, J NEUROSURG, V124, P27, DOI 10.3171/2015.1.JNS142452
   Brott TG, 2011, CIRCULATION, V124, P489, DOI 10.1161/CIR.0b013e31820d8d78
   Brott TG, 2010, NEW ENGL J MED, V363, P11, DOI 10.1056/NEJMoa0912321
   Esposito-Bauer L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067927
   Farrell B, 1998, LANCET, V351, P1379, DOI 10.1016/s0140-6736(97)09292-1
   Gupta A, 2013, STROKE, V44, P3071, DOI 10.1161/STROKEAHA.113.002551
   Halliday A, 2004, LANCET, V363, P1491
   Howard G, 2016, LANCET, V387, P1305, DOI 10.1016/S0140-6736(15)01309-4
   Lechtman E, 2018, BRIT J RADIOL, V91
   Marnane M, 2014, STROKE, V45, P801, DOI 10.1161/STROKEAHA.113.003657
   Mossa-Basha M, 2016, NEUROIMAG CLIN N AM, V26, P129, DOI 10.1016/j.nic.2015.09.010
   Naylor AR, 2018, STROKE VASC NEUROL, V3, P101, DOI 10.1136/svn-2018-000146
   Rantner B, 2013, J VASC SURG, V57, P619, DOI 10.1016/j.jvs.2012.08.107
   Saam T, 2016, J CARDIOVASC MAGN R, V18, DOI 10.1186/s12968-016-0229-2
   Saito A, 2012, NEURORADIOLOGY, V54, P1187, DOI 10.1007/s00234-012-1025-9
   Shallwani Hussain, 2014, J Vasc Interv Neurol, V7, P43
   Tendera M, 2011, EUR HEART J, V32, P2851, DOI 10.1093/eurheartj/ehr211
   Toma N, 2003, J NEUROSURG, V98, P199, DOI 10.3171/jns.2003.98.1.0199
   WALKER MD, 1995, JAMA-J AM MED ASSOC, V273, P1421, DOI 10.1001/jama.1995.03520420037035
   Yadav JS, 2004, NEW ENGL J MED, V351, P1493, DOI 10.1056/NEJMoa040127
   Yoshida K, 2008, AM J NEURORADIOL, V29, P868, DOI 10.3174/ajnr.A1015
   Yoshida K, 2015, J NEUROSURG, V123, P434, DOI 10.3171/2014.12.JNS14185
   Yoshida K, 2012, NEUROSURGERY, V70, P1143, DOI 10.1227/NEU.0b013e31823fe50b
NR 28
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2019
VL 123
BP E543
EP E548
DI 10.1016/j.wneu.2018.11.208
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR2II
UT WOS:000462958400063
PM 30521960
DA 2020-05-12
ER

EF